﻿FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Shailasree, S
   Venkataramana, M
   Niranjana, SR
   Prakash, HS
AF Shailasree, S.
   Venkataramana, M.
   Niranjana, S. R.
   Prakash, H. S.
TI Cytotoxic Effect of p-Coumaric Acid on Neuroblastoma, N2a Cell via
   Generation of Reactive Oxygen Species Leading to Dysfunction of
   Mitochondria Inducing Apoptosis and Autophagy
SO MOLECULAR NEUROBIOLOGY
LA English
DT Article
DE p-Coumaric acid; Neuroblastoma N2a cells; Apoptosis; p53; Caspase-8;
   Autophagy; LC3-II
ID COLON-CANCER CELLS; IN-VITRO; ANTIOXIDANT ACTIONS; OXIDATIVE STRESS;
   DEATH; PATHWAYS; ACTIVATION; CASPASE-8; THERAPY; VIVO
AB p-Coumaric acid (p-CA), an ubiquitous plant phenolic acid, has been proven to render protection against pathological conditions. In the present study, p-CA was evaluated for its capacity to induce cytotoxic effect to neuroblastoma N2a cells and we report here the possible mechanism of its action. p-CA at a concentration of 150 mu mol/L, upon exposure for 72 h, stimulated 81.23 % of cells to apoptosis, as evidenced by flow cytometer studies mediated through elevated levels of ROS (7.5-fold over control). Excess ROS production activated structural injury to mitochondrial membrane, observed as dissipation of its membrane potential and followed by the release of cytochrome c (8.73-fold). Enhanced generation of intracellular ROS correlated well with the decreased levels (similar to 60 %) of intracellular GSH. Sensitizing neuroblastoma cells for induction of apoptosis by p-CA identified p53-mediated upregulated accumulation of caspase-8 messenger RNA (2.8-fold). Our data report on autophagy, representing an additional mechanism of p-CA to induce growth arrest, detected by immunoblotting and fluorescence, correlated with accumulation of elevated levels (1.2-fold) of the LC3-II protein and acridine orange-stained autophagosomes, both autophagy markers. The present study indicates p-CA was effective in production of ROS-dependent mitochondrial damage-induced cytotoxicity in N2a cells.
C1 [Shailasree, S.] Univ Mysore, Inst Excellence, Mysore 570006, Karnataka, India.
   [Niranjana, S. R.; Prakash, H. S.] Univ Mysore, Dept Studies Biotechnol, Mysore 570006, Karnataka, India.
   [Venkataramana, M.] Bharathiar Univ, Def Res Dev Org, Coimbatore, Tamil Nadu, India.
RP Prakash, HS (corresponding author), Univ Mysore, Dept Studies Biotechnol, Mysore 570006, Karnataka, India.
EM shailasree_s@yahoo.co.uk; srn@appbot.uni-mysore.ac.in;
   hsprakash55@yahoo.in
OI H S, Dr. Prakash/0000-0002-9973-7939
FU Ministry of Human Resource Development, Govt. of India through UGC
   [UOM/IOE/RESEARCH/1/2010-11]
FX The authors acknowledge the recognition of the University of Mysore as
   an Institution of Excellence and financial support from the Ministry of
   Human Resource Development, Govt. of India through UGC under
   UOM/IOE/RESEARCH/1/2010-11, dt 22-04-2010 project.
CR Abdel-Wahab MH, 2003, PHARMACOL RES, V48, P461, DOI 10.1016/S1043-6618(03)00214-7
   Amelio I, 2011, BIOCHEM BIOPH RES CO, V414, P277, DOI 10.1016/j.bbrc.2011.09.080
   Armstrong JS, 2002, CELL DEATH DIFFER, V9, P252, DOI 10.1038/sj.cdd.4400959
   Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305
   Azad MB, 2009, ANTIOXID REDOX SIGN, V11, P777, DOI 10.1089/ARS.2008.2270
   Blagosklonny MV, 2002, INT J CANCER, V98, P161, DOI 10.1002/ijc.10158
   Chaabane W, 2013, ARCH IMMUNOL THER EX, V61, P43, DOI 10.1007/s00005-012-0205-y
   Chen Q, 2003, J BIOL CHEM, V278, P36027, DOI 10.1074/jbc.M304854200
   Cho YS, 2010, MOL CELLS, V29, P327, DOI 10.1007/s10059-010-0066-3
   de Barros MP, 2008, J ETHNOPHARMACOL, V120, P372, DOI 10.1016/j.jep.2008.09.015
   Dore S, 2005, NEUROSIGNALS, V14, P61, DOI 10.1159/000085386
   Dragsted LO, 2003, INT J VITAM NUTR RES, V73, P112, DOI 10.1024/0300-9831.73.2.112
   Ehrhardt H, 2008, ONCOGENE, V27, P783, DOI 10.1038/sj.onc.1210666
   Ehrhardt H, 2011, CLIN CANCER RES, V17, P7605, DOI 10.1158/1078-0432.CCR-11-0513
   Ferguson LR, 2005, MOL NUTR FOOD RES, V49, P585, DOI 10.1002/mnfr.200500014
   Fulda S, 2006, ONCOGENE, V25, P4798, DOI 10.1038/sj.onc.1209608
   Fuster JJ, 2007, TRENDS MOL MED, V13, P192, DOI 10.1016/j.molmed.2007.03.002
   Gao M, 2008, CANCER RES, V68, P9348, DOI 10.1158/0008-5472.CAN-08-1642
   Grever MCB, 2001, CANC DRUG DISCOVERY, P328
   Gurney J., 1999, NIH PUB, P149
   Han WD, 2009, APOPTOSIS, V14, P674, DOI 10.1007/s10495-009-0334-x
   HUG H, 1994, FEBS LETT, V351, P311, DOI 10.1016/0014-5793(94)00852-3
   Jaganathan SK, 2013, WORLD J GASTROENTERO, V19, P7726, DOI 10.3748/wjg.v19.i43.7726
   Janicke B, 2005, J AGR FOOD CHEM, V53, P6658, DOI 10.1021/jf050489l
   KERR JFR, 1994, CANCER-AM CANCER SOC, V73, P2013, DOI 10.1002/1097-0142(19940415)73:8<2013::AID-CNCR2820730802>3.0.CO;2-J
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   Langer C, 1996, EXP CELL RES, V222, P117, DOI 10.1006/excr.1996.0015
   Larrosa M, 2008, FREE RADICAL RES, V42, P903, DOI 10.1080/10715760802510077
   Li PF, 1999, EMBO J, V18, P6027, DOI 10.1093/emboj/18.21.6027
   Ling LU, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.12
   Luceri C, 2007, BRIT J NUTR, V97, P458, DOI 10.1017/S0007114507657882
   Mehta SL, 2007, BRAIN RES REV, V54, P34, DOI 10.1016/j.brainresrev.2006.11.003
   Nakamura H, 1997, ANNU REV IMMUNOL, V15, P351, DOI 10.1146/annurev.immunol.15.1.351
   Ouyang L, 2012, CELL PROLIFERAT, V45, P487, DOI 10.1111/j.1365-2184.2012.00845.x
   Ozben T, 2007, J PHARM SCI-US, V96, P2181, DOI 10.1002/jps.20874
   Periyasamy-Thandavan S, 2009, AM J PHYSIOL-RENAL, V297, pF244, DOI 10.1152/ajprenal.00033.2009
   Petrosillo G, 2009, FREE RADICAL BIO MED, V46, P88, DOI 10.1016/j.freeradbiomed.2008.09.031
   Pingoud-Meier C, 2003, CLIN CANCER RES, V9, P6401
   Radio NM, 2008, NEUROTOXICOLOGY, V29, P361, DOI 10.1016/j.neuro.2008.02.011
   Rubinsztein DC, 2007, NAT REV DRUG DISCOV, V6, P304, DOI 10.1038/nrd2272
   Sang SM, 2005, ANTIOXID REDOX SIGN, V7, P1704, DOI 10.1089/ars.2005.7.1704
   Sareen D, 2006, INVEST OPHTH VIS SCI, V47, P3708, DOI 10.1167/iovs.06-0119
   Sena LA, 2012, MOL CELL, V48, P158, DOI 10.1016/j.molcel.2012.09.025
   Seo YK, 2011, CLIN EXP DERMATOL, V36, P260, DOI 10.1111/j.1365-2230.2010.03983.x
   Shailasree S, 2004, PLANT SCI, V167, P1227, DOI 10.1016/j.plantsci.2004.06.012
   Shastry P, 2001, INT J NEUROSCI, V108, P109, DOI 10.3109/00207450108986509
   Smith RAJ, 2003, P NATL ACAD SCI USA, V100, P5407, DOI 10.1073/pnas.0931245100
   Surh YJ, 2001, MUTAT RES-FUND MOL M, V480, P243, DOI 10.1016/S0027-5107(01)00183-X
   Tanida Isei, 2008, V445, P77, DOI 10.1007/978-1-59745-157-4_4
   Turrens JF, 2003, J PHYSIOL-LONDON, V552, P335, DOI 10.1113/jphysiol.2003.049478
   Vauzour D, 2010, ARCH BIOCHEM BIOPHYS, V501, P106, DOI 10.1016/j.abb.2010.03.016
   von Harsdorf R, 1999, CIRCULATION, V99, P2934, DOI 10.1161/01.CIR.99.22.2934
   Xie CM, 2011, FREE RADICAL BIO MED, V51, P1365, DOI 10.1016/j.freeradbiomed.2011.06.016
   Yang C, 2008, AM J PHYSIOL-RENAL, V294, pF777, DOI 10.1152/ajprenal.00590.2007
   Zhang YLMCQ, 2005, TOXICOL SCI, V88, P545, DOI 10.1093/toxsci/kfi333
NR 55
TC 49
Z9 52
U1 0
U2 26
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0893-7648
EI 1559-1182
J9 MOL NEUROBIOL
JI Mol. Neurobiol.
PD FEB
PY 2015
VL 51
IS 1
BP 119
EP 130
DI 10.1007/s12035-014-8700-2
PG 12
WC Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA CA6FT
UT WOS:000349006200010
PM 24760364
DA 2022-04-25
ER

PT J
AU Ji, CX
   Ju, S
   Qiang, JW
AF Ji, Changxue
   Ju, Shuai
   Qiang, Jinwei
TI miR-212 and mTOR Form a Regulation Loop to Modulate Autophagy in
   Colorecta Adenoma HT-29 Cells
SO DISCOVERY MEDICINE
LA English
DT Article
ID INHIBITOR NVP-BEZ235; CANCER CELLS; IN-VIVO; PATHWAY; EXPRESSION;
   RAPAMYCIN; PROLIFERATION; TUMORIGENESIS; BIOGENESIS; MICRORNA
AB Autophagy is a conserved lysosomal degradation pathway that regulates cell survival and death in order to maintain cellular homeostasis. Dysfunctional autophagy is associated with different types of cancer, making it an attractive therapeutic target. Mammalian target of rapamycin (mTOR) signaling negatively regulates autophagy and suppresses the efficacy of certain cancer therapeutic agents. NVP-BEZ235 is a dual inhibitor of the P13K/mTOR signaling pathway and exhibits anticancer activities; it also induced autophagy and inhibited proliferation in colorectal adenoma HT-29 cells. Colorectal adenoma and colorectal cancer have been recently shown to have elevated levels of miR-212. In the current study, we examined the role of miR-212 in NVP-BEZ235-induced autophagy in HT-29 cells. NVP-BEZ235 at the concentration as low as of 1 nM effectively induced autophagy and dose-dependently inhibited the expression of microRNA-212 (miR-212) whereas mTOR activator MHY1485 elevated the milt-212 expression. Transfection of mi R-212 mimics inhibited autophagy whereas miR-212 inhibitors promoted autophagy as assessed by the LC3B-1 conversion to LC3B-II and the expression levels of beclin-1. Furthermore, miR-212 mimics activated mTOR whereas miR-212 inhibitors suppressed mTOR activation as shown by the levels of phospho-mTOR. miR-212 mimics further enhanced the effect of NVP-BEZ235 in reducing the viability of HT-29 cells. Our data support that miR-212 is a target of mTOR signaling as well as an activator of mTOR to negatively regulate autophagy. Thus, miR-212 and mTOR signalings may form a positive regulation loop in maintaining cellular homeostasis. This study warrants further investigation of miR-212 as an effective target of autophagy-based cancer therapeutic strategies.
C1 [Qiang, Jinwei] Fudan Univ, Jinshan Hosp, Dept Radiol, Shanghai 201508, Peoples R China.
   Fudan Univ, Shanghai Med Coll, Shanghai 201508, Peoples R China.
RP Qiang, JW (corresponding author), Fudan Univ, Jinshan Hosp, Dept Radiol, Shanghai 201508, Peoples R China.
EM dr.jinweiqiang@163.com
RI Ju, Shuai/AAE-5635-2019
CR Alemu EA, 2012, J BIOL CHEM, V287, DOI 10.1074/jbc.M112.378109
   Bahrami A, 2018, J CELL BIOCHEM, V119, P2460, DOI 10.1002/jcb.25950
   Bornachea O, 2012, SCI REP-UK, V2, DOI 10.1038/srep00434
   Dunlop EA, 2014, SEMIN CELL DEV BIOL, V36, P121, DOI 10.1016/j.semcdb.2014.08.006
   Ganley IG, 2009, J BIOL CHEM, V284, P12297, DOI 10.1074/jbc.M900573200
   Go YM, 2015, AM J PHYSIOL-REG I, V308, pR62, DOI 10.1152/ajpregu.00278.2014
   Gomes LR, 2016, PHARMACOL RES, V107, P300, DOI 10.1016/j.phrs.2016.03.031
   Gozuacik D, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00065
   Huang ZQ, 2017, J CELL MOL MED, V21, P467, DOI 10.1111/jcmm.12990
   Hudder A, 2008, TOXICOL SCI, V103, P228, DOI 10.1093/toxsci/kfn033
   Ji YH, 2015, CLIN LAB, V61, P1043, DOI 10.7754/Clin.Lab.2015.150144
   Laplante M, 2009, J CELL SCI, V122, P3589, DOI 10.1242/jcs.051011
   Lee IH, 2008, P NATL ACAD SCI USA, V105, P3374, DOI 10.1073/pnas.0712145105
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257
   Lin F, 2017, CLIN CANCER RES, V23, P1286, DOI 10.1158/1078-0432.CCR-16-1276
   Liu J, 2016, ADV CANCER RES, V130, P1, DOI 10.1016/bs.acr.2016.01.005
   LoPiccolo J, 2008, DRUG RESIST UPDATE, V11, P32, DOI 10.1016/j.drup.2007.11.003
   Maejima Y, 2016, J MOL CELL CARDIOL, V95, P19, DOI 10.1016/j.yjmcc.2015.10.032
   Meng X, 2013, GASTROENTEROLOGY, V145
   Mizushima N, 2011, ANNU REV CELL DEV BI, V27, P107, DOI 10.1146/annurev-cellbio-092910-154005
   Mizushima N, 2010, CURR OPIN CELL BIOL, V22, P132, DOI 10.1016/j.ceb.2009.12.004
   Park JK, 2011, BIOCHEM BIOPH RES CO, V406, P518, DOI 10.1016/j.bbrc.2011.02.065
   Ramalinga M, 2015, ONCOTARGET, V6, P34446, DOI 10.18632/oncotarget.5920
   Shukla U, 2013, DRUG METAB DISPOS, V41, P1769, DOI 10.1124/dmd.113.052860
   Smith PY, 2015, HUM MOL GENET, V24, P6721, DOI 10.1093/hmg/ddv377
   Song LL, 2016, TUMOR BIOL, V37, P12161, DOI 10.1007/s13277-016-5073-3
   Totary-Jain H, 2013, J BIOL CHEM, V288, P6034, DOI 10.1074/jbc.M112.416446
   Ucar A, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2090
   Wada R, 2010, INT J CANCER, V127, P1106, DOI 10.1002/ijc.25126
   Wanet A, 2012, NUCLEIC ACIDS RES, V40, P4742, DOI 10.1093/nar/gks151
   Wang C, 2016, PHARMACOL RES, V105, P164, DOI 10.1016/j.phrs.2016.01.028
   Weidberg H, 2011, DEV CELL, V20, P444, DOI 10.1016/j.devcel.2011.02.006
   Wu ZR, 2017, CANCER BIOMARK, V18, P35, DOI 10.3233/CBM-160671
   Xie GF, 2017, CANCER LETT, V388, P12, DOI 10.1016/j.canlet.2016.11.024
   Yang XY, 2016, ONCOL LETT, V12, P102, DOI 10.3892/ol.2016.4590
   Ye PY, 2015, MOL CELL, V57, P708, DOI 10.1016/j.molcel.2014.12.034
   Yin Y, 2016, GENE, V578, P177, DOI 10.1016/j.gene.2015.12.015
   Zhai HY, 2013, CELL CYCLE, V12, P246, DOI 10.4161/cc.23273
   Zhang LD, 2016, INT J ONCOL, V49, P657, DOI 10.3892/ijo.2016.3557
   Zhang YJ, 2017, CELL MOL LIFE SCI, V74, P2613, DOI 10.1007/s00018-017-2485-1
NR 41
TC 4
Z9 4
U1 0
U2 4
PU DISCOVERY MEDICINE
PI TIMONIUM
PA 10 GERARD AVE, STE 201, TIMONIUM, MD 21093 USA
SN 1539-6509
EI 1944-7930
J9 DISCOV MED
JI Discov. Med.
PD JUN
PY 2018
VL 25
IS 140
BP 265
EP 275
PG 11
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA GS4FN
UT WOS:000443593800001
PM 30021100
DA 2022-04-25
ER

PT J
AU Malarz, K
   Zych, D
   Gawecki, R
   Kuczak, M
   Musiol, R
   Mrozek-Wilczkiewicz, A
AF Malarz, Katarzyna
   Zych, Dawid
   Gawecki, Robert
   Kuczak, Michal
   Musiol, Robert
   Mrozek-Wilczkiewicz, Anna
TI New derivatives of 4 '-phenyl-2,2 ':6 ',2 ''-terpyridine as promising
   anticancer agents
SO EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
DE Terpyridine; Anticancer activity; Metal chelators; Reactive oxygen
   species
ID CELL-PROLIFERATION; HEME OXYGENASE-1; ANTIPROLIFERATIVE ACTIVITY;
   TERPYRIDINE DERIVATIVES; POLYPYRIDYL COMPLEXES; CONFERS RESISTANCE;
   NUCLEASE ACTIVITY; METAL-COMPLEXES; CANCER-CELLS; DNA
AB Terpyridine derivatives are known from their broad application including anticancer properties. In this work we present the newly synthesized 4'-phenyl-2,2':6',2 ''-terpyridine group with high anti-proliferative activity. We suggest that these compounds influence cellular redox homeostasis. Cancer cells are particularly susceptible to any changes in the redox balance because of their handicapped and inefficient antioxidant cellular systems. The antiproliferative activity of the studied compounds was tested on five different cell lines that represent several types of tumours; glioblastoma, leukemia, breast, pancreatic and colon. Additionally, we also tested their selectivity towards normal cells. We performed molecular biology studies in order to detect the response of a cell to its treatment with the compounds that were tested. We looked at the in-depth changes in the proteins and cellular pathways that lead to cell cycle inhibition (G0/G1 and S), and consequently, death on the apoptosis and autophagy pathways. We proved that the studied compounds targeted DNA as well. Special attention was paid to the targets connected with ROS generation. (C) 2020 Elsevier Masson SAS. All rights reserved.
C1 [Malarz, Katarzyna; Gawecki, Robert; Kuczak, Michal; Mrozek-Wilczkiewicz, Anna] Univ Silesia Katowice, A Chelkowski Inst Phys, 75 Pulku Piechoty 1a, PL-41500 Chorzow, Poland.
   [Malarz, Katarzyna; Gawecki, Robert; Kuczak, Michal; Mrozek-Wilczkiewicz, Anna] Univ Silesia Katowice, Silesian Ctr Educ & Interdisciplinary Res, 75 Pulku Piechoty 1a, PL-41500 Chorzow, Poland.
   [Zych, Dawid] Wroclaw Sch Informat Technol, Ks M Lutra 4, PL-54239 Wroclaw, Poland.
   [Kuczak, Michal; Musiol, Robert] Univ Silesia Katowice, Inst Chem, Szkolna 9, PL-40006 Katowice, Poland.
RP Malarz, K; Mrozek-Wilczkiewicz, A (corresponding author), Univ Silesia Katowice, A Chelkowski Inst Phys, 75 Pulku Piechoty 1a, PL-41500 Chorzow, Poland.; Malarz, K; Mrozek-Wilczkiewicz, A (corresponding author), Univ Silesia Katowice, Silesian Ctr Educ & Interdisciplinary Res, 75 Pulku Piechoty 1a, PL-41500 Chorzow, Poland.
EM katarzyna.malarz@us.edu.pl; anna.mrozek-wilczkiewicz@us.edu.pl
RI Gawecki, Robert/ABF-8021-2021; Zych, Dawid/Q-7629-2017
OI Zych, Dawid/0000-0002-7757-7321; Gawecki, Robert/0000-0002-7752-000X;
   Malarz, Katarzyna/0000-0003-4283-3126
FU National Science CentreNational Science Centre, Poland
   [2016/23/N/NZ7/00351, 2018/31/B/NZ7/02122]
FX The financial support of the National Science Centre grants;
   2016/23/N/NZ7/00351 (K.M.) and 2018/31/B/NZ7/02122 (R.M.) is greatly
   appreciated.
CR Berberat PO, 2005, CLIN CANCER RES, V11, P3790, DOI 10.1158/1078-0432.CCR-04-2159
   Budnikova YH, 2018, INORGANICS, V6, DOI 10.3390/inorganics6010018
   Chaitanya GV, 2010, CELL COMMUN SIGNAL, V8, DOI 10.1186/1478-811X-8-31
   Chen WM, 2009, MOL CELL, V34, P663, DOI 10.1016/j.molcel.2009.04.029
   Chenard E, 2016, J PHYS CHEM C, V120, P8461, DOI 10.1021/acs.jpcc.6b00858
   Corral E, 2009, J BIOL INORG CHEM, V14, P439, DOI 10.1007/s00775-008-0460-x
   Czaplinska B, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-50734-8
   Dedoussis GVZ, 2001, EUR J CELL BIOL, V80, P608, DOI 10.1078/0171-9335-00193
   Deka B, 2017, DALTON T, V46, P396, DOI 10.1039/c6dt03660k
   Donadelli M, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.36
   Durand N, 2017, EXPERT REV ANTICANC, V17, P19, DOI 10.1080/14737140.2017.1261017
   Erkkila KE, 1999, CHEM REV, V99, P2777, DOI 10.1021/cr9804341
   Fu D., 2021, BLOOD, V110
   Gama S, 2016, J INORG BIOCHEM, V160, P275, DOI 10.1016/j.jinorgbio.2016.04.002
   Ghosh D, 2013, J BIOMOL STRUCT DYN, V31, P331, DOI 10.1080/07391102.2012.698190
   Gottschaldt M, 2009, CHEM-EUR J, V15, P1548, DOI 10.1002/chem.200802013
   Gurzov EN, 2006, NEUROL RES, V28, P493, DOI 10.1179/016164106X115143
   Hannon MJ, 2006, CHEM-EUR J, V12, P8000, DOI 10.1002/chem.200501012
   Inguaggiato P, 2001, KIDNEY INT, V60, P2181, DOI 10.1046/j.1523-1755.2001.00046.x
   Jiang Q, 2009, BIOMETALS, V22, P297, DOI 10.1007/s10534-008-9166-3
   Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720
   Karges J, 2019, J INORG BIOCHEM, V198, DOI 10.1016/j.jinorgbio.2019.110752
   Kerins MJ, 2018, ANTIOXID REDOX SIGN, V29, P1756, DOI 10.1089/ars.2017.7176
   Kim SY, 2012, BIOL PHARM BULL, V35, P2160, DOI 10.1248/bpb.b12-00507
   Lau A, 2008, PHARMACOL RES, V58, P262, DOI 10.1016/j.phrs.2008.09.003
   Li CY, 2020, FRONT CHEM, V8, DOI 10.3389/fchem.2020.00210
   Lister A, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-37
   Liu HX, 2014, INT J MOL SCI, V15, P9945, DOI 10.3390/ijms15069945
   Liu L, 2019, CELL COMMUN SIGNAL, V17, DOI 10.1186/s12964-018-0313-3
   Liu ZM, 2004, ONCOGENE, V23, P503, DOI 10.1038/sj.onc.1207173
   Luo X, 2012, GENE DEV, V26, P417, DOI 10.1101/gad.183509.111
   Ma Z, 2016, DALTON T, V45, P5339, DOI 10.1039/c5dt02744f
   Mahendiran D, 2017, MAT SCI ENG C-MATER, V76, P601, DOI 10.1016/j.msec.2017.03.085
   Mahendiran D, 2016, DALTON T, V45, P7794, DOI 10.1039/c5dt03831f
   Malarz K, 2020, EUR J MED CHEM, V189, DOI 10.1016/j.ejmech.2020.112039
   Malarz Katarzyna, 2018, Oncotarget, V9, P17689, DOI 10.18632/oncotarget.24844
   Mazumder S, 2004, CURR CANCER DRUG TAR, V4, P65, DOI 10.2174/1568009043481669
   Mendo AS, 2015, J BIOL INORG CHEM, V20, P935, DOI 10.1007/s00775-015-1277-z
   Morel E, 2019, MOLECULES, V24, DOI 10.3390/molecules24030404
   Morel E, 2016, INORG CHIM ACTA, V452, P152, DOI 10.1016/j.ica.2016.02.033
   Moussa RS, 2018, BBA-GEN SUBJECTS, V1862, P761, DOI 10.1016/j.bbagen.2017.10.009
   Moussa RS, 2015, ONCOTARGET, V6, P29694, DOI 10.18632/oncotarget.5088
   Mrozek-Wilczkiewicz A, 2019, EUR J MED CHEM, V177, P338, DOI 10.1016/j.ejmech.2019.05.061
   Mrozek-Wilczkiewicz A, 2019, EUR J MED CHEM, V171, P180, DOI 10.1016/j.ejmech.2019.03.027
   Munoz-Gomez JA, 2009, AUTOPHAGY, V5, P61, DOI 10.4161/auto.5.1.7272
   Notaro A, 2017, CHEM SOC REV, V46, P7317, DOI 10.1039/c7cs00356k
   Pardo R, 2010, PANCREATOLOGY, V10, P19, DOI 10.1159/000264680
   Prokop A, 2016, EUR J INORG CHEM, P3480, DOI 10.1002/ejic.201600325
   Pruchnik F P, 1996, Met Based Drugs, V3, P185, DOI 10.1155/MBD.1996.185
   Qin QP, 2018, MEDCHEMCOMM, V9, P525, DOI 10.1039/c7md00532f
   Ramu V, 2015, CHEM-EUR J, V21, P9185, DOI 10.1002/chem.201500561
   Saccone D, 2016, MATERIALS, V9, DOI 10.3390/ma9030137
   Schreiber V, 2006, NAT REV MOL CELL BIO, V7, P517, DOI 10.1038/nrm1963
   Serda M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110291
   Smith KA, 2017, REDOX BIOL, V13, P228, DOI 10.1016/j.redox.2017.05.020
   Sosna J, 2014, CELL MOL LIFE SCI, V71, P331, DOI 10.1007/s00018-013-1381-6
   Suntharalingam K, 2012, CHEM-EUR J, V18, P15133, DOI 10.1002/chem.201202482
   Trachootham D, 2009, NAT REV DRUG DISCOV, V8, P579, DOI 10.1038/nrd2803
   Wang K, 2019, ANGEW CHEM INT EDIT, V58, P4638, DOI 10.1002/anie.201900387
   Winter A, 2020, CHEMCATCHEM, V12, P2890, DOI 10.1002/cctc.201902290
   Winter A, 2012, CURR TOP MED CHEM, V12, P158, DOI 10.2174/156802612799078919
   Yang PS, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19092502
   Yang YZ, 2019, J BIOL CHEM, V294, P772, DOI 10.1074/jbc.RA118.005166
   Yuan L, 2014, J AGR FOOD CHEM, V62, P5390, DOI 10.1021/jf500903g
   Zhao LX, 2001, BIOORG MED CHEM LETT, V11, P2659, DOI 10.1016/S0960-894X(01)00531-5
   Zhu JH, 2018, BIOTECHNOL APPL BIOC, V65, P665, DOI 10.1002/bab.1657
   Zhu QY, 2020, ONCOTARGETS THER, V13, P2807, DOI 10.2147/OTT.S240803
   Zych D, 2019, RSC ADV, V9, P16554, DOI 10.1039/c9ra02655j
   Zych D, 2018, CHEMISTRYSELECT, V3, P7009, DOI 10.1002/slct.201801204
NR 69
TC 7
Z9 7
U1 5
U2 9
PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY-LES-MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE
SN 0223-5234
EI 1768-3254
J9 EUR J MED CHEM
JI Eur. J. Med. Chem.
PD FEB 15
PY 2021
VL 212
AR 113032
DI 10.1016/j.ejmech.2020.113032
EA FEB 2021
PG 14
WC Chemistry, Medicinal
WE Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC)
SC Pharmacology & Pharmacy
GA QX8WC
UT WOS:000629622800008
PM 33261897
DA 2022-04-25
ER

PT J
AU Maiese, K
   Chong, ZZ
   Shang, YC
   Wang, SH
AF Maiese, Kenneth
   Chong, Zhao Zhong
   Shang, Yan Chen
   Wang, Shaohui
TI Targeting disease through novel pathways of apoptosis and autophagy
SO EXPERT OPINION ON THERAPEUTIC TARGETS
LA English
DT Review
DE beta-catenin; Akt; Alzheimer's disease; apoptosis; autophagy; Beclin 1;
   cancer; cardiovascular disease; caspase; CCN family; diabetes mellitus;
   erythropoietin; forkhead transcription factors; FoxO; glycogen synthase
   kinase-3 beta; mammalian target of rapamycin; neurodegenerative disease;
   oxidative stress; Parkinson's disease; phosphoinositide 3-kinase;
   programmed cell death; Wnt1-inducible signaling pathway protein 1
ID FOCAL CEREBRAL-ISCHEMIA; HUMAN COLORECTAL-CANCER; WNT SIGNALING PATHWAY;
   BETA-CATENIN LEVELS; OXIDATIVE STRESS; ALZHEIMERS-DISEASE;
   CELL-SURVIVAL; PARKINSONS-DISEASE; MOUSE MODEL; CASPASE 3
AB Introduction: Apoptosis and autophagy impact cell death in multiple systems of the body. Development of new therapeutic strategies that target these processes must address their complex role during developmental cell growth as well as during the modulation of toxic cellular environments.
   Areas covered: Novel signaling pathways involving Wnt1-inducible signaling pathway protein 1 (WISP1), phosphoinositide 3-kinase (PI3K), protein kinase B (Akt), beta-catenin and mammalian target of rapamycin (mTOR) govern apoptotic and autophagic pathways during oxidant stress that affect the course of a broad spectrum of disease entities including Alzheimer's disease, Parkinson's disease, myocardial injury, skeletal system trauma, immune system dysfunction and cancer progression. Implications of potential biological and clinical outcome for these signaling pathways are presented.
   Expert opinion: The CCN family member WISP1 and its intimate relationship with canonical and non-canonical wingless signaling pathways of PI3K, Akt1, beta-catenin and mTOR offer an exciting approach for governing the pathways of apoptosis and autophagy especially in clinical disorders that are currently without effective treatments. Future studies that can elucidate the intricate role of these cytoprotective pathways during apoptosis and autophagy can further the successful translation and development of these cellular targets into robust and safe clinical therapeutic strategies.
C1 [Maiese, Kenneth; Chong, Zhao Zhong; Shang, Yan Chen; Wang, Shaohui] New Jersey Hlth Sci Univ, Canc Inst New Jersey, Lab Cellular & Mol Signaling, Newark, NJ 07101 USA.
RP Maiese, K (corresponding author), New Jersey Hlth Sci Univ, Canc Inst New Jersey, Lab Cellular & Mol Signaling, F 1220,205 S Orange Ave, Newark, NJ 07101 USA.
EM wntin75@yahoo.com
RI Wang, Shaohui/G-7247-2012
FU American Diabetes AssociationAmerican Diabetes Association; American
   Heart Association (National)American Heart Association; Bugher
   Foundation AwardAmerican Heart Association; Janssen Neuroscience
   AwardJohnson & JohnsonJohnson & Johnson USAJanssen Biotech Inc; LEARN
   Foundation Award; NIH NIEHSUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Environmental Health Sciences (NIEHS); NIH NIAUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute on Aging (NIA); NIH NINDSUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Neurological Disorders & Stroke (NINDS);
   NIH ARRAUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [NS059346-04, NS059346-03S1]; NATIONAL
   INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department
   of Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Neurological Disorders & Stroke (NINDS)
   [R01NS053946] Funding Source: NIH RePORTER
FX This research was supported by the following grants to K Maiese:
   American Diabetes Association, American Heart Association (National),
   Bugher Foundation Award, Janssen Neuroscience Award, LEARN Foundation
   Award, NIH NIEHS, NIH NIA, NIH NINDS and NIH ARRA (NS059346-04 and
   NS059346-03S1). The authors state no other conflicts of interest.
CR Aksu U, 2011, CONTRIB NEPHROL, V174, P119, DOI 10.1159/000329249
   Baba H, 2009, J VASC SURG, V50, P381, DOI 10.1016/j.jvs.2009.03.042
   Bailey TJ, 2010, EXP EYE RES, V91, P601, DOI 10.1016/j.exer.2010.07.017
   Balan V, 2008, J BIOL CHEM, V283, P27810, DOI 10.1074/jbc.M804681200
   Baryawno N, 2010, CANCER RES, V70, P266, DOI 10.1158/0008-5472.CAN-09-0578
   Benjamin D, 2011, NAT REV DRUG DISCOV, V10, P868, DOI 10.1038/nrd3531
   Bhaskar K, 2009, MOL NEURODEGENER, V4, DOI 10.1186/1750-1326-4-14
   Broe M, 2001, ACTA NEUROPATHOL, V101, P616
   Canu N, 2005, J NEUROCHEM, V92, P1228, DOI 10.1111/j.1471-4159.2004.02956.x
   Carayol N, 2010, P NATL ACAD SCI USA, V107, P12469, DOI 10.1073/pnas.1005114107
   Case N, 2008, J BIOL CHEM, V283, P29196, DOI 10.1074/jbc.M801907200
   Cechetti F, 2012, NEUROBIOL LEARN MEM, V97, P90, DOI 10.1016/j.nlm.2011.09.008
   Chen JR, 2010, J BONE MINER RES, V25, P1117, DOI 10.1002/jbmr.7
   Chen L, 2010, LAB INVEST, V90, P762, DOI 10.1038/labinvest.2010.36
   Choi KC, 2010, J NEUROCHEM, V112, P366, DOI 10.1111/j.1471-4159.2009.06463.x
   Chong ZZ, 2007, HISTOL HISTOPATHOL, V22, P1251, DOI 10.14670/HH-22.1251
   Chong ZZ, 2007, CURR NEUROVASC RES, V4, P194
   Chong ZZ, 2007, CELL SIGNAL, V19, P1150, DOI 10.1016/j.cellsig.2006.12.009
   Chong ZZ, 2007, INT J MOL MED, V19, P263
   Chong ZZ, 2006, CURR NEUROVASC RES, V3, P25, DOI 10.2174/156720206775541741
   Chong ZZ, 2012, CARDIOVASC DIABETOL, V11, DOI 10.1186/1475-2840-11-45
   Chong ZZ, 2011, TRENDS CARDIOVAS MED, V21, P151, DOI 10.1016/j.tcm.2012.04.005
   Chong ZZ, 2012, EXPERT OPIN THER TAR, V16, P167, DOI 10.1517/14728222.2012.648926
   Chong ZZ, 2011, CURR NEUROVASC RES, V8, P103
   Chong ZZ, 2010, OXID MED CELL LONGEV, V3, P374, DOI 10.4161/oxim.3.6.14787
   Chong ZZ, 2010, OXID MED CELL LONGEV, V3, P153, DOI 10.4161/oxim.3.2.11758
   Chong ZZ, 2005, CURR NEUROVASC RES, V2, P197, DOI 10.2174/1567202054368317
   Chong ZZ, 2005, PROG NEUROBIOL, V75, P207, DOI 10.1016/j.pneurobio.2005.02.004
   Chong ZZ, 2003, J NEUROSCI RES, V71, P659, DOI 10.1002/jnr.10528
   Chung CY, 2012, DIGEST DIS SCI, V57, P371, DOI 10.1007/s10620-011-1892-7
   CLARK SL, 1957, J BIOPHYS BIOCHEM CY, V3, P349, DOI 10.1083/jcb.3.3.349
   Colston JT, 2007, AM J PHYSIOL-HEART C, V293, pH1839, DOI 10.1152/ajpheart.00428.2007
   Davies SR, 2010, INT J ONCOL, V36, P1129, DOI 10.3892/ijo_00000595
   Deretic V, 2012, TRENDS CELL BIOL, V22, P397, DOI 10.1016/j.tcb.2012.04.008
   Desnoyers L, 2001, J BIOL CHEM, V276, P47599, DOI 10.1074/jbc.M108339200
   Pastor MD, 2009, J BIOL CHEM, V284, P22067, DOI 10.1074/jbc.M109.033100
   Dormond O, 2007, J BIOL CHEM, V282, P23679, DOI 10.1074/jbc.M700563200
   Fokas E, 2012, RADIAT ONCOL, V7, DOI 10.1186/1748-717X-7-48
   French DM, 2004, AM J PATHOL, V165, P855, DOI 10.1016/S0002-9440(10)63348-2
   Grammas P, 2011, INT J CLIN EXP PATHO, V4, P616
   Gumy LF, 2010, EXP NEUROL, V223, P28, DOI 10.1016/j.expneurol.2009.06.004
   Heise RL, 2011, J BIOL CHEM, V286, P17435, DOI 10.1074/jbc.M110.137273
   Hernandez G, 2011, EXP CELL RES, V317, P2938, DOI 10.1016/j.yexcr.2011.09.011
   Hou JL, 2010, MOL CELL ENDOCRINOL, V321, P194, DOI 10.1016/j.mce.2010.02.037
   Hou JL, 2010, CURR NEUROVASC RES, V7, P95, DOI 10.2174/156720210791184899
   Hwang SK, 2011, BMB REP, V44, P506, DOI 10.5483/BMBRep.2011.44.8.506
   Jaber N, 2012, P NATL ACAD SCI USA, V109, P2003, DOI 10.1073/pnas.1112848109
   Janku F, 2012, J CLIN ONCOL, V30, P777, DOI 10.1200/JCO.2011.36.1196
   Jeong JK, 2012, NEUROSCI RES, V73, P99, DOI 10.1016/j.neures.2012.03.005
   Jiang YL, 2011, INT J MOL MED, V28, P153, DOI 10.3892/ijmm.2011.696
   Jourde-Chiche N, 2011, SEMIN DIALYSIS, V24, P327, DOI 10.1111/j.1525-139X.2011.00925.x
   Kapoor V, 2012, CANCER LETT, V319, P39, DOI 10.1016/j.canlet.2011.12.032
   KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33
   KERR JFR, 1965, J PATHOL BACTERIOL, V90, P419, DOI 10.1002/path.1700900210
   Kim J, 2012, J CELL BIOCHEM, V113, P220, DOI 10.1002/jcb.23347
   Koh PO, 2012, J VET MED SCI, V74, P377, DOI 10.1292/jvms.11-0392
   Kook YH, 2011, BIOCHEM BIOPH RES CO, V411, P370, DOI 10.1016/j.bbrc.2011.06.151
   L'Episcopo F, 2011, NEUROBIOL DIS, V41, P508, DOI 10.1016/j.nbd.2010.10.023
   L'Episcopo F, 2012, J NEUROSCI, V32, P2062, DOI 10.1523/JNEUROSCI.5259-11.2012
   Lafay-Chebassier C, 2006, J NEUROSCI RES, V84, P1323, DOI 10.1002/jnr.21039
   Le XF, 2010, CANCER-AM CANCER SOC, V116, P4980, DOI 10.1002/cncr.25426
   Lee G, 2010, GASTROENTEROLOGY, V139
   Li F, 2006, HISTOL HISTOPATHOL, V21, P103, DOI 10.14670/HH-21.103
   Li F, 2006, CURR NEUROVASC RES, V3, P187, DOI 10.2174/156720206778018758
   Liu YL, 2011, CURR CANCER DRUG TAR, V11, P1098, DOI 10.2174/156800911798073041
   Liu ZG, 2012, J ENDOCRINOL, V213, P143, DOI 10.1530/JOE-11-0328
   Louneva N, 2008, AM J PATHOL, V173, P1488, DOI 10.2353/ajpath.2008.080434
   Luo S, 2010, CELL DEATH DIFFER, V17, P268, DOI 10.1038/cdd.2009.121
   Macsai CE, 2012, BONE, V50, P1081, DOI 10.1016/j.bone.2012.02.013
   Maiese K., 2012, CURR NEUROVASC RES, V9, P1
   Maiese K, 2008, EXPERT OPIN THER TAR, V12, P905, DOI 10.1517/14728222.12.7.905 
   Maiese K, 2008, PHARMACOL THERAPEUT, V118, P58, DOI 10.1016/j.pharmthera.2008.01.004
   Maiese K, 2007, CURR NEUROVASC RES, V4, P295, DOI 10.2174/156720207782446306
   Maiese K, 2011, J CLIN PHARMACOL, V51, P128, DOI 10.1177/0091270010362904
   Maiese K, 2009, MOLECULES, V14, P3446, DOI 10.3390/molecules14093446
   Marchand A, 2011, AGING CELL, V10, P220, DOI 10.1111/j.1474-9726.2010.00661.x
   Fernandez-Martos CM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027000
   McPhee CK, 2010, NATURE, V465, P1093, DOI 10.1038/nature09127
   Narula J, 2001, NAT MED, V7, P1347, DOI 10.1038/nm1201-1347
   Nascimento EBM, 2010, CELL SIGNAL, V22, P961, DOI 10.1016/j.cellsig.2010.02.002
   Nerurkar PV, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-64
   Nguyen TMB, 2009, J CELL MOL MED, V13, P3687, DOI 10.1111/j.1582-4934.2009.00722.x
   Noguti J, 2012, ANTICANCER RES, V32, P873
   Nopparat C, 2010, J PINEAL RES, V49, P382, DOI 10.1111/j.1600-079X.2010.00805.x
   NOVIKOFF ALEX B., 1956, JOUR BIOPHYS AND BIOCHEM CYTOL, V2, P179, DOI 10.1083/jcb.2.4.179
   Ogura Y, 2011, BIOCHEM BIOPH RES CO, V414, P756, DOI 10.1016/j.bbrc.2011.09.152
   Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002
   Pearl R., 1928, RATE LIVING
   Poulose SM, 2011, RADIAT RES, V176, P761, DOI 10.1667/RR2605.1
   Qin AP, 2010, AUTOPHAGY, V6, P738, DOI 10.4161/auto.6.6.12573
   Raza SS, 2011, J NEUROL SCI, V309, P45, DOI 10.1016/j.jns.2011.07.035
   Reddy VS, 2011, J CELL PHYSIOL, V226, P3303, DOI 10.1002/jcp.22676
   Salvesen GS, 2008, ADV EXP MED BIOL, V615, P13, DOI 10.1007/978-1-4020-6554-5_2
   Schips TG, 2011, CARDIOVASC RES, V91, P587, DOI 10.1093/cvr/cvr144
   Shang YC, 2012, AGING-US, V4, P187, DOI 10.18632/aging.100440
   Shang YC, 2011, CURR NEUROVASC RES, V8, P270
   Shang YC, 2010, CELL SIGNAL, V22, P1317, DOI 10.1016/j.cellsig.2010.04.009
   Shang YC, 2009, CURR NEUROVASC RES, V6, P223, DOI 10.2174/156720209789630302
   Shang YC, 2009, CURR NEUROVASC RES, V6, P20, DOI 10.2174/156720209787466064
   Shanmugam P, 2011, J MOL CELL CARDIOL, V50, P928, DOI 10.1016/j.yjmcc.2011.02.012
   Silva DFF, 2011, CURR ALZHEIMER RES, V8, P563
   Sinha SS, 2008, AM HEART J, V155, DOI 10.1016/j.ahj.2008.02.004
   Spencer B, 2009, J NEUROSCI, V29, P13578, DOI 10.1523/JNEUROSCI.4390-09.2009
   Spilman P, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009979
   Su F, 2002, GENE DEV, V16, P46, DOI 10.1101/gad.942902
   Suzen S, 2012, CHEM BIOL DRUG DES, V79, P76, DOI 10.1111/j.1747-0285.2011.01216.x
   Tanno M, 2010, J BIOL CHEM, V285, P8375, DOI 10.1074/jbc.M109.090266
   Tatton NA, 2000, EXP NEUROL, V166, P29, DOI 10.1006/exnr.2000.7489
   Thedieck K, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001217
   Troy CM, 2011, PROG MOL BIOL TRANSL, V99, P265, DOI 10.1016/S1877-1173(11)99007-3
   Tupe RS, 2011, BRIT J NUTR, V105, P1741, DOI 10.1017/S0007114510005520
   Ullah N, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027093
   Vendelbo MH, 2011, BBA-MOL CELL RES, V1813, P634, DOI 10.1016/j.bbamcr.2011.01.029
   Venkatesan B, 2010, CELL SIGNAL, V22, P809, DOI 10.1016/j.cellsig.2010.01.005
   Wang JY, 2011, J NEUROPATH EXP NEUR, V70, P314, DOI 10.1097/NEN.0b013e31821352bd
   Wang RH, 2011, J CLIN INVEST, V121, P4477, DOI 10.1172/JCI46243
   Wang S, 2012, CURR NEUROVASC RES, V9, P89
   Wang SH, 2012, CURR NEUROVASC RES, V9, P20, DOI 10.2174/156720212799297137
   Wang YS, 2012, AM J TRANSL RES, V4, P44
   Wexler EM, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2002282
   Wu XH, 2004, J BIOL CHEM, V279, P9167, DOI 10.1074/jbc.M312397200
   Xilouri M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005515
   Xue LZ, 1999, MOL CELL NEUROSCI, V14, P180, DOI 10.1006/mcne.1999.0780
   Yamada E, 2012, DIABETES, V61, P272, DOI 10.2337/db11-1199
   Yeo W, 2004, DEV BIOL, V274, P233, DOI 10.1016/j.ydbio.2004.07.026
   Yu L, 2010, NATURE, V465, P942, DOI 10.1038/nature09076
   Yu Y, 2012, NEUROCHEM RES, V37, P503, DOI 10.1007/s11064-011-0636-6
   Yuan HM, 2012, PHARMACOL RES, V65, P328, DOI 10.1016/j.phrs.2011.11.014
   Zengi A, 2011, EXP CLIN ENDOCR DIAB, V119, P467, DOI 10.1055/s-0031-1275289
   Zhang DH, 2010, J CLIN INVEST, V120, P2805, DOI 10.1172/JCI43008
   Zhang YQ, 2011, CELL PHYSIOL BIOCHEM, V27, P503, DOI 10.1159/000329952
   Zhou XP, 2011, IMMUNOPHARM IMMUNOT, V33, P594, DOI 10.3109/08923973.2010.549135
NR 132
TC 102
Z9 110
U1 0
U2 48
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1472-8222
EI 1744-7631
J9 EXPERT OPIN THER TAR
JI Expert Opin. Ther. Targets
PD DEC
PY 2012
VL 16
IS 12
BP 1203
EP 1214
DI 10.1517/14728222.2012.719499
PG 12
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 039HM
UT WOS:000311235400006
PM 22924465
OA Green Accepted
DA 2022-04-25
ER

PT J
AU Shahzad, MMK
   Felder, M
   Ludwig, K
   Van Gelder, HR
   Anderson, ML
   Kim, J
   Cook, ME
   Kapur, AK
   Patankar, MS
AF Shahzad, Mian M. K.
   Felder, Mildred
   Ludwig, Kai
   Van Gelder, Hannah R.
   Anderson, Matthew L.
   Kim, Jong
   Cook, Mark E.
   Kapur, Arvinder K.
   Patankar, Manish S.
TI Trans10, cis12 conjugated linoleic acid inhibits proliferation and
   migration of ovarian cancer cells by inducing ER stress, autophagy, and
   modulation of Src
SO PLOS ONE
LA English
DT Article
ID UNFOLDED-PROTEIN RESPONSE; COLON; APOPTOSIS; ISOMERS; KINASE;
   EXPRESSION; BREAST; DEPHOSPHORYLATION; ANTICARCINOGENS; DERIVATIVES
AB The goal of this study was to investigate the anti-cancer effects of Trans10, cis12 conjugated linoleic acid (t10, c12 CLA). MTT assays and QCM T chemotaxis 96-wells were used to test the effect of t10, c12 CLA on the proliferation and migration and invasion of cancer cells. qPCR and Western Blotting were used to determine the expression of specific factors. RNA sequencing was conducted using the Illumina platform and apoptosis was measured using a flow cytometry assay. t10, c12 CLA (IC50, 7 mu M) inhibited proliferation of ovarian cancer cell lines SKOV-3 and A2780. c9, t11 CLA did not attenuate the proliferation of these cells. Transcription of 165 genes was significantly repressed and 28 genes were elevated. Genes related to ER stress, ATF4, CHOP, and GADD34 were overexpressed whereas EDEM2 and Hsp90, genes required for proteasomal degradation of misfolded proteins, were downregulated upon treatment. While apoptosis was not detected, t10, c12 CLA treatment led to 9-fold increase in autophagolysosomes and higher levels of LC3-II. G1 cell cycle arrest in treated cells was correlated with phosphorylation of GSK3 beta and loss of beta-catenin. microRNA miR184 and miR215 were upregulated. miR184 likely contributed to G1 arrest by downregulating E2F1. miR215 upregulation was correlated with increased expression of p27/Kip-1. t10, c12 CLA-mediated inhibition of invasion and migration correlated with decreased expression of PTP1b and decreased Src activation by inhibiting phosphorylation at Tyr 416. Due to its ability to inhibit proliferation and migration, t10, c12 CLA should be considered for treatment of ovarian cancer.
C1 [Shahzad, Mian M. K.; Felder, Mildred; Ludwig, Kai; Van Gelder, Hannah R.; Kapur, Arvinder K.; Patankar, Manish S.] Univ Wisconsin, Dept Obstet & Gynecol, Div Gynecol Oncol, Sch Med & Publ Hlth, Madison, WI 53706 USA.
   [Shahzad, Mian M. K.] H Lee Moffitt Canc Ctr & Res Inst, Dept Obstet & Gynecol, Tampa, FL USA.
   [Anderson, Matthew L.; Kim, Jong] Baylor Coll Med, Dept Obstet & Gynecol, Div Gynecol Oncol, Dan L Duncan Canc Ctr, Houston, TX 77030 USA.
   [Cook, Mark E.] Univ Wisconsin Sch Madison, Dept Anim Sci, Madison, WI USA.
RP Kapur, AK; Patankar, MS (corresponding author), Univ Wisconsin, Dept Obstet & Gynecol, Div Gynecol Oncol, Sch Med & Publ Hlth, Madison, WI 53706 USA.
EM akapur@wisc.edu; patankar@wisc.edu
RI ; Anderson, Matthew/C-4755-2019
OI Ludwig, Kai/0000-0001-9867-9346; Anderson, Matthew/0000-0002-2081-4672;
   Patankar, Manish/0000-0002-8205-6432
FU Department of Obstetrics and Gynecology at UW-Madison; NCI (T32 training
   grant) [CA 009614]; Cancer Prevention and Research Institute of Texas
   [RP11035]; Partnership for Baylor College of Medicine; Ovarian Cancer
   Research Fund; Young Texans Against Cancer; Cancer Fighters of Houston;
   Alkek Foundation; NATIONAL CANCER INSTITUTEUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Cancer Institute (NCI) [T32CA009614, T32CA009206] Funding
   Source: NIH RePORTER
FX This research was supported by an intramural grant from the Department
   of Obstetrics and Gynecology (MS, AK, and MSP) at UW-Madison, and a
   grant from the NCI (T32 training grant CA 009614) to MS. Additional
   support was provided by RP11035 from the Cancer Prevention and Research
   Institute of Texas (MLA), Partnership for Baylor College of Medicine
   (MLA), Ovarian Cancer Research Fund (MLA), Young Texans Against Cancer
   (MLA), Cancer Fighters of Houston (MLA) and the Alkek Foundation (MLA).
   The funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.; We thank Dr.
   Bilal Hafeez for providing helpful discussions. Author contributions:
   M.M.S., A. K.K., and M.S.P. designed the study. M.M.S., A.K.K., K.L.,
   and H.R.V.G. performed all experiments, analyzed data, and helped
   prepare the manuscript. M.L.A., J.K. prepared small RNA sequencing
   libraries and performed small RNA sequencing. M.F. helped with flow
   cytometry and cell culture assays, K.L. and H.R.V.G helped with MTT
   assays,. M.E.C. provided expert and essential advice on CLA biochemistry
   and the CLA literature and M.S.P. designed and edited the manuscript.
   This research was supported by an intramural grants from the Department
   of Obstetrics and Gynecology (MS, AK, and MSP) at UW-Madison, and a
   grant from the NCI (T32 training grant CA 009614) to MS. Additional
   support was provided by RP11035 from the Cancer Prevention and Research
   Institute of Texas (MLA), Partnership for Baylor College of Medicine
   (MLA), Ovarian Cancer Research Fund (MLA), Young Texans Against Cancer
   (MLA), Cancer Fighters of Houston (MLA) and the Alkek Foundation (MLA).
CR Beppu F, 2006, J NUTR BIOCHEM, V17, P830, DOI 10.1016/j.jnutbio.2006.01.007
   Bertolotti A, 2000, NAT CELL BIOL, V2, P326, DOI 10.1038/35014014
   Boni V, 2010, MOL CANCER THER, V9, P2265, DOI 10.1158/1535-7163.MCT-10-0061
   Cho HJ, 2006, J NUTR, V136, P893, DOI 10.1093/jn/136.4.893
   Creighton CJ, 2009, BRIEF BIOINFORM, V10, P490, DOI 10.1093/bib/bbp019
   Degner SC, 2006, J NUTR, V136, P421, DOI 10.1093/jn/136.2.421
   Flowers M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005342
   Gehrke S, 2010, NATURE, V466, P637, DOI 10.1038/nature09191
   Gildea JJ, 2000, BIOTECHNIQUES, V29, P81, DOI 10.2144/00291st02
   Gubbels JAA, 2010, J OVARIAN RES, V3, DOI 10.1186/1757-2215-3-8
   HA YL, 1987, CARCINOGENESIS, V8, P1881, DOI 10.1093/carcin/8.12.1881
   Halder J, 2005, CLIN CANCER RES, V11, P8829, DOI 10.1158/1078-0432.CCR-05-1728
   Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729
   Harding HP, 2000, MOL CELL, V5, P897, DOI 10.1016/S1097-2765(00)80330-5
   Hsu YC, 2011, CELL SIGNAL, V23, P2013, DOI 10.1016/j.cellsig.2011.07.015
   Ip C, 2002, NUTR CANCER, V43, P52, DOI 10.1207/S15327914NC431_6
   Ip MM, 2007, CARCINOGENESIS, V28, P1269, DOI 10.1093/carcin/bgm018
   JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0
   Jones LJ, 2001, J IMMUNOL METHODS, V254, P85, DOI 10.1016/S0022-1759(01)00404-5
   Kelley NS, 2007, J NUTR, V137, P2599, DOI 10.1093/jn/137.12.2599
   Kuniyasu H, 2006, INT J CANCER, V118, P571, DOI 10.1002/ijc.21368
   Lau DSY, 2010, NUTR CANCER, V62, P116, DOI 10.1080/01635580903191536
   Lim DY, 2005, J CELL PHYSIOL, V205, P107, DOI 10.1002/jcp.20380
   Liu Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0053178
   Maattanen P, 2010, SEMIN CELL DEV BIOL, V21, P500, DOI 10.1016/j.semcdb.2010.03.006
   Marcu MG, 2002, MOL CELL BIOL, V22, P8506, DOI 10.1128/MCB.22.24.8506-8513.2002
   Miller A, 2001, LIPIDS, V36, P1161, DOI 10.1007/s11745-001-0827-0
   Mosley EE, 2006, J NUTR, V136, P2297, DOI 10.1093/jn/136.9.2297
   Ni M, 2007, FEBS LETT, V581, P3641, DOI 10.1016/j.febslet.2007.04.045
   Novoa I, 2001, J CELL BIOL, V153, P1011, DOI 10.1083/jcb.153.5.1011
   Oda Y, 2003, SCIENCE, V299, P1394, DOI 10.1126/science.1079181
   Ou LH, 2008, J LIPID RES, V49, P985, DOI 10.1194/jlr.M700465-JLR200
   PARIZA MW, 1990, MED ONCOL TUMOR PHAR, V7, P169
   QIN XQ, 1995, MOL CELL BIOL, V15, P742
   Roskoski R, 2005, BIOCHEM BIOPH RES CO, V331, P1, DOI 10.1016/j.bbrc.2005.03.012
   Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023
   Shahzad MMK, 2011, NEOPLASIA, V13, P309, DOI 10.1593/neo.101372
   Shen JS, 2002, DEV CELL, V3, P99, DOI 10.1016/S1534-5807(02)00203-4
   Soel SM, 2007, J NUTR BIOCHEM, V18, P650, DOI 10.1016/j.jnutbio.2006.10.011
   Wang LS, 2006, ANTICANCER RES, V26, P889
   Yamasaki M, 2002, CANCER LETT, V188, P171, DOI 10.1016/S0304-3835(02)00459-7
NR 41
TC 10
Z9 13
U1 4
U2 11
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 11
PY 2018
VL 13
IS 1
AR e0189524
DI 10.1371/journal.pone.0189524
PG 19
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA FS7BJ
UT WOS:000419952400009
PM 29324748
OA gold, Green Submitted, Green Published
DA 2022-04-25
ER

PT J
AU Lan, L
   Liu, JJ
   Xing, ML
   Smith, AR
   Wang, JA
   Wu, XQ
   Appelman, C
   Li, K
   Roy, A
   Gowthaman, R
   Karanicolas, J
   Somoza, AD
   Wang, CCC
   Miao, YL
   De Guzman, R
   Oakley, BR
   Neufeld, KL
   Xu, L
AF Lan, Lan
   Liu, Jiajun
   Xing, Minli
   Smith, Amber R.
   Wang, Jinan
   Wu, Xiaoqing
   Appelman, Carl
   Li, Ke
   Roy, Anuradha
   Gowthaman, Ragul
   Karanicolas, John
   Somoza, Amber D.
   Wang, Clay C. C.
   Miao, Yinglong
   De Guzman, Roberto
   Oakley, Berl R.
   Neufeld, Kristi L.
   Xu, Liang
TI Identification and Validation of anAspergillus nidulansSecondary
   Metabolite Derivative as an Inhibitor of the Musashi-RNA Interaction
SO CANCERS
LA English
DT Article
DE RNA-binding proteins; Musashi; drug discovery; Notch signaling; Wnt
   signaling; cancer therapy; fungi secondary metabolite derivative
ID BINDING PROTEIN MUSASHI1; SMALL-MOLECULE INHIBITORS; STEM-CELLS;
   THERAPEUTIC TARGET; MYELOID-LEUKEMIA; PROSTATE-CANCER; FAMILY; MARKER;
   EXPRESSION; SCLEROTIORIN
AB RNA-binding protein Musashi-1 (MSI1) is a key regulator of several stem cell populations. MSI1 is involved in tumor proliferation and maintenance, and it regulates target mRNAs at the translational level. The known mRNA targets of MSI1 includeNumb,APC, andP21(WAF-1), key regulators of Notch/Wnt signaling and cell cycle progression, respectively. In this study, we aim to identify small molecule inhibitors of MSI1-mRNA interactions, which could block the growth of cancer cells with high levels of MSI1. Using a fluorescence polarization (FP) assay, we screened small molecules from several chemical libraries for those that disrupt the binding of MSI1 to its consensus RNA. One cluster of hit compounds is the derivatives of secondary metabolites fromAspergillus nidulans. One of the top hits, Aza-9, from this cluster was further validated by surface plasmon resonance and nuclear magnetic resonance spectroscopy, which demonstrated that Aza-9 binds directly to MSI1, and the binding is at the RNA binding pocket. We also show that Aza-9 binds to Musashi-2 (MSI2) as well. To test whether Aza-9 has anti-cancer potential, we used liposomes to facilitate Aza-9 cellular uptake. Aza-9-liposome inhibits proliferation, induces apoptosis and autophagy, and down-regulates Notch and Wnt signaling in colon cancer cell lines. In conclusion, we identified a series of potential lead compounds for inhibiting MSI1/2 function, while establishing a framework for identifying small molecule inhibitors of RNA binding proteins using FP-based screening methodology.
C1 [Lan, Lan; Liu, Jiajun; Smith, Amber R.; Wu, Xiaoqing; Appelman, Carl; Li, Ke; De Guzman, Roberto; Oakley, Berl R.; Neufeld, Kristi L.; Xu, Liang] Univ Kansas, Dept Mol Biosci, Lawrence, KS 66045 USA.
   [Xing, Minli] Univ Kansas, Bio NMR Core Facil, Lawrence, KS 66045 USA.
   [Wang, Jinan; Gowthaman, Ragul; Miao, Yinglong] Univ Kansas, Ctr Computat Biol, Lawrence, KS 66045 USA.
   [Roy, Anuradha] Univ Kansas, High Throughput Screening Lab, Lawrence, KS 66045 USA.
   [Karanicolas, John] Fox Chase Canc Ctr, Program Mol Therapeut, 7701 Burholme Ave, Philadelphia, PA 19111 USA.
   [Somoza, Amber D.; Wang, Clay C. C.] Univ Southern Calif, Dept Chem, Los Angeles, CA 90007 USA.
   [Wang, Clay C. C.] Univ Southern Calif, Sch Pharm, Dept Pharmacol & Pharmaceut Sci, Los Angeles, CA 90007 USA.
   [Neufeld, Kristi L.] Univ Kansas, Ctr Canc, Dept Canc Biol, Kansas City, KS 66160 USA.
   [Xu, Liang] Univ Kansas, Ctr Canc, Dept Radiat Oncol, Kansas City, KS 66160 USA.
RP Xu, L (corresponding author), Univ Kansas, Dept Mol Biosci, Lawrence, KS 66045 USA.; Xu, L (corresponding author), Univ Kansas, Ctr Canc, Dept Radiat Oncol, Kansas City, KS 66160 USA.
EM lan@ku.edu; gajun988@gmail.com; mlxing@umich.edu; arsmith1@stanford.edu;
   jawang@ku.edu; wuxq@ku.edu; carltonapps@gmail.com; lk_jzs@xiyi.edu.cn;
   anuroy@ku.edu; ragul@umd.edu; John.Karanicolas@fccc.edu;
   amber.somoza@gmail.com; clayw@usc.edu; miao@ku.edu; rdguzman@ku.edu;
   boakley@ku.edu; klneuf@ku.edu; xul@ku.edu
RI Wang, Clay/ABG-9056-2021
OI Neufeld, Kristi/0000-0003-3653-9385; LAN, LAN/0000-0002-8045-7654;
   Gowthaman, Ragul/0000-0002-0008-6401
FU National Institutes of Health from the National Institute of General
   Medical Science [R01 CA178831, CA191785, P01GM084077]; University of
   Kansas Bold Aspiration Strategic Initiative Award [P30 CA168524];
   National Cancer Institute Cancer Center Support GrantUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Cancer Institute (NCI) [P30 CA168524]; Kansas
   Bioscience Authority Rising Star Award; NIHUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USA
   [AI074856]; NIH COBRE at KU CCET Pilot Project [P30 RR030926]; Irving S.
   Johnson Fund of the University of Kansas Endowment
FX This study was supported in part by National Institutes of Health grants
   R01 CA178831 and CA191785, P01GM084077 from the National Institute of
   General Medical Science (to B.R.O. and C.C.C.W.); the University of
   Kansas Bold Aspiration Strategic Initiative Award and National Cancer
   Institute Cancer Center Support Grant P30 CA168524 (to L.X., K.N.);
   Kansas Bioscience Authority Rising Star Award (to L.X.); NIH grant
   AI074856 (to R.N.D.); NIH COBRE at KU CCET Pilot Project (P30 RR030926
   to K.N.) and the Irving S. Johnson Fund of the University of Kansas
   Endowment (to B.R.O.).
CR [Anonymous], **NON-TRADITIONAL**
   Aviv T, 2003, NAT STRUCT BIOL, V10, P614, DOI 10.1038/nsb956
   Battelli C, 2006, MOL CELL NEUROSCI, V31, P85, DOI 10.1016/j.mcn.2005.09.003
   Chan TA, 2002, P NATL ACAD SCI USA, V99, P8265, DOI 10.1073/pnas.082240999
   Charlesworth A, 2006, EMBO J, V25, P2792, DOI 10.1038/sj.emboj.7601159
   Chidananda C, 2006, BIOTECHNOL LETT, V28, P1633, DOI 10.1007/s10529-006-9133-4
   Curtin TP, 1940, BIOCHEM J, V34, P1419
   Estrada DF, 2009, J BIOL CHEM, V284, P8645, DOI 10.1074/jbc.M808081200
   Fan LF, 2010, INT J COLORECTAL DIS, V25, P17, DOI 10.1007/s00384-009-0791-2
   Fox RG, 2015, ANNU REV CELL DEV BI, V31, P249, DOI 10.1146/annurev-cellbio-100814-125446
   Giridharan P, 2012, INDIAN J EXP BIOL, V50, P464
   Glazer RI, 2012, FRONT BIOSCI-LANDMRK, V17, P54, DOI 10.2741/3915
   Gowthaman R, 2013, J CHEM INF MODEL, V53, P2073, DOI 10.1021/ci4002316
   Griner LN, 2010, CANCER BIOL THER, V10, P979, DOI 10.4161/cbt.10.10.14010
   Hong S, 2017, J CANCER PREV, V22, P203, DOI 10.15430/JCP.2017.22.4.203
   Imai T, 2001, MOL CELL BIOL, V21, P3888, DOI 10.1128/MCB.21.12.3888-3900.2001
   Ito T, 2010, NATURE, V466, P765, DOI 10.1038/nature09171
   Kaneko Y, 2000, DEV NEUROSCI-BASEL, V22, P139, DOI 10.1159/000017435
   Kaur K, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175471
   Kharas MG, 2017, TRENDS CANCER, V3, P347, DOI 10.1016/j.trecan.2017.03.007
   Kharas MG, 2010, NAT MED, V16, P903, DOI 10.1038/nm.2187
   Kudinov AE, 2017, CLIN CANCER RES, V23, P2143, DOI 10.1158/1078-0432.CCR-16-2728
   Kudinov AE, 2016, P NATL ACAD SCI USA, V113, P6955, DOI 10.1073/pnas.1513616113
   Kuwako K, 2010, NEURON, V67, P407, DOI 10.1016/j.neuron.2010.07.005
   Lan L, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4704-z
   Lan L, 2017, ONCOTARGET, V8, P106587, DOI 10.18632/oncotarget.22540
   Lan L, 2015, MOL ONCOL, V9, P1406, DOI 10.1016/j.molonc.2015.03.014
   Li L, 2014, GASTROENTEROLOGY, V146, P1108, DOI 10.1053/j.gastro.2013.12.035
   Li L, 2013, CLIN CANCER RES, V19, P6703, DOI 10.1158/1078-0432.CCR-13-0621
   Li N, 2015, CELL REP, V13, P2440, DOI 10.1016/j.celrep.2015.11.022
   Lian J, 2011, CELL DEATH DIFFER, V18, P60, DOI 10.1038/cdd.2010.74
   Mei HY, 1997, BIOORGAN MED CHEM, V5, P1173, DOI 10.1016/S0968-0896(97)00064-3
   Meng Y, 2008, MOL CANCER THER, V7, P2192, DOI 10.1158/1535-7163.MCT-08-0333
   Minuesa G, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10523-3
   Minuesa G, 2014, COMB CHEM HIGH T SCR, V17, P596, DOI 10.2174/1386207317666140609122714
   NAKAMURA M, 1994, NEURON, V13, P67, DOI 10.1016/0896-6273(94)90460-X
   Nero TL, 2014, NAT REV CANCER, V14, P248, DOI 10.1038/nrc3690
   Ohyama T, 2012, NUCLEIC ACIDS RES, V40, P3218, DOI 10.1093/nar/gkr1139
   Osmanova N, 2010, PHYTOCHEM REV, V9, P315, DOI 10.1007/s11101-010-9171-3
   Ozoline ON, 2019, FEMS MICROBIOL LETT, V366, DOI 10.1093/femsle/fny281
   Pagano JM, 2011, RNA, V17, P14, DOI 10.1261/rna.2428111
   Potten CS, 2003, DIFFERENTIATION, V71, P28, DOI 10.1046/j.1432-0436.2003.700603.x
   Rezza A, 2010, J CELL SCI, V123, P3256, DOI 10.1242/jcs.065284
   Sakakibara S, 2002, P NATL ACAD SCI USA, V99, P15194, DOI 10.1073/pnas.232087499
   Sakakibara S, 1996, DEV BIOL, V176, P230, DOI 10.1006/dbio.1996.0130
   Somoza AD, 2012, ORG LETT, V14, P972, DOI 10.1021/ol203094k
   Spears E, 2011, J BIOL CHEM, V286, P4946, DOI 10.1074/jbc.C110.205922
   Sugiyama-Nakagiri Y, 2006, AM J PATHOL, V168, P80, DOI 10.2353/ajpath.2006.050469
   Sureban SM, 2008, GASTROENTEROLOGY, V134, P1448, DOI 10.1053/j.gastro.2008.02.057
   Sutherland JM, 2013, ADV EXP MED BIOL, V786, P233, DOI 10.1007/978-94-007-6621-1_13
   Takahashi T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053540
   Toda M, 2001, GLIA, V34, P1, DOI 10.1002/glia.1034
   Vo DT, 2012, MOL CANCER RES, V10, P143, DOI 10.1158/1541-7786.MCR-11-0208
   Wang S, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7517
   Wang XY, 2013, ONCOTARGET, V4, P739, DOI 10.18632/oncotarget.1034
   Wang XY, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-221
   Warui DM, 2012, J MED CHEM, V55, P4132, DOI 10.1021/jm2007694
   Wu XQ, 2015, ACS CHEM BIOL, V10, P1476, DOI 10.1021/cb500851u
   Wu XQ, 2010, BIOORGAN MED CHEM, V18, P3812, DOI 10.1016/j.bmc.2010.04.046
   Yang J, 2006, J BIOL CHEM, V281, P17751, DOI 10.1074/jbc.M600831200
   Ye F, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-108
   ZAPP ML, 1993, CELL, V74, P969, DOI 10.1016/0092-8674(93)90720-B
   Zhang JH, 1999, J BIOMOL SCREEN, V4, P67, DOI 10.1177/108705719900400206
NR 63
TC 2
Z9 2
U1 4
U2 14
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2072-6694
J9 CANCERS
JI Cancers
PD AUG
PY 2020
VL 12
IS 8
AR 2221
DI 10.3390/cancers12082221
PG 18
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA OC1KT
UT WOS:000578922100001
PM 32784494
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Liu, YS
   Chang, YC
   Kuo, WW
   Chen, MC
   Hsu, HH
   Tu, CC
   Yeh, YL
   Viswanadha, VP
   Liao, PH
   Huang, CY
AF Liu, Yi-Sheng
   Chang, Yu-Chun
   Kuo, Wei-Wen
   Chen, Ming-Cheng
   Hsu, Hsi-Hsien
   Tu, Chuan-Chou
   Yeh, Yu-Lan
   Viswanadha, Vijaya Padma
   Liao, Po-Hsiang
   Huang, Chih-Yang
TI Inhibition of Protein Phosphatase 1 Stimulates Noncanonical ER Stress
   eIF2 alpha Activation to Enhance Fisetin-induced Chemosensitivity in
   HDAC Inhibitor-resistant Hepatocellular Carcinoma Cells
SO CANCERS
LA English
DT Article
DE hepatocellular carcinoma; fisetin; protein phosphatase 1; eIF2 alpha;
   chemosensitivity
ID HISTONE DEACETYLASE INHIBITORS; COLON-CANCER CELLS;
   ENDOPLASMIC-RETICULUM; SIGNALING PATHWAY; INDUCED APOPTOSIS; EXPRESSION;
   DEPHOSPHORYLATION; MIGRATION; TRANSCRIPTION; AUTOPHAGY
AB Hepatocellular carcinoma (HCC) is a common fatal type of malignant tumor that has highly metastatic and recurrent properties. Fisetin is a natural flavonoid found in various vegetables and fruits which exhibits anti-cancer and anti-inflammatory properties, as well as other effects. Thus, we hypothesized that fisetin can act as an adjuvant therapy in cancer or drug-resistant cancer cells, and further investigated the molecular mechanisms underlying the development of drug-resistance in HCC cells. We found that fisetin effectively inhibited the cell viability of not only parental cells but also histone deacetylase inhibitors-resistant (HDACis-R) cells and enhanced the chemosensitivity of HCC cells. Interestingly, fisetin did not induce cell apoptosis through the activation of the endoplasmic reticulum (ER) stress sensor of protein kinase R (PKR)-like endoplasmic reticulum kinase, but rather through the non-canonical pathway of the protein phosphatase 1 (PP1)-mediated suppression of eIF2 alpha phosphorylation. Moreover, fisetin-induced cell apoptosis was reversed by treatment with PP1 activator or eIF2 alpha siRNA in HCC cells. Based on these observations, we suggest that PP1-eIF2 alpha pathways are significantly involved in the effect of fisetin on HCC apoptosis. Thus, fisetin may act as a novel anticancer drug and new chemotherapy adjuvant which can improve the efficacy of chemotherapeutic agents and diminish their side-effects.
C1 [Liu, Yi-Sheng] China Med Univ, Program Aging, Taichung 404, Taiwan.
   [Liu, Yi-Sheng] Kaohsiung Armed Forces Gen Hosp, Dept Med, Div Hematol & Oncol, Kaohsiung 802, Taiwan.
   [Chang, Yu-Chun] Natl Pingtung Univ Sci & Technol, Grad Dept Biol Sci & Technol, Pingtung 912, Taiwan.
   [Chang, Yu-Chun] China Med Univ, Sch Chinese Med, Taichung 404, Taiwan.
   [Kuo, Wei-Wen] China Med Univ, Dept Biol Sci & Technol, Taichung 404, Taiwan.
   [Chen, Ming-Cheng] Taichung Vet Gen Hosp, Dept Surg, Div Colorectal Surg, Taichung 407, Taiwan.
   [Chen, Ming-Cheng] Natl Yang Ming Univ, Fac Med, Taipei 112, Taiwan.
   [Hsu, Hsi-Hsien] MacKay Mem Hosp, Div Colorectal Surg, Taipei 104, Taiwan.
   [Hsu, Hsi-Hsien] MacKay Med Nursing & Management Coll, Taipei 112, Taiwan.
   [Tu, Chuan-Chou] Armed Force Taichung Gen Hosp, Dept Internal Med, Div Chest Med, Taichung 411, Taiwan.
   [Yeh, Yu-Lan] Changhua Christian Hosp, Dept Pathol, Changhua 500, Taiwan.
   [Yeh, Yu-Lan] Jen Teh Jr Coll Med Nursing & Management, Dept Med Technol, Miaoli 356, Taiwan.
   [Viswanadha, Vijaya Padma] Bharathiar Univ, Dept Biotechnol, Coimbatore 641046, Tamil Nadu, India.
   [Liao, Po-Hsiang] China Med Univ, Grad Inst Basic Med Sci, Taichung 404, Taiwan.
   [Liao, Po-Hsiang; Huang, Chih-Yang] Hualien Tzu Chi Hosp, Cardiovasc Res Ctr, Hualien 970, Taiwan.
   [Liao, Po-Hsiang; Huang, Chih-Yang] Tzu Chi Univ Sci & Technol, Buddhist Tzu Chi Med Fdn, Ctr Gen Educ, Hualien 970, Taiwan.
   [Huang, Chih-Yang] China Med Univ, China Med Univ Hosp, Dept Med Res, Taichung 404, Taiwan.
   [Huang, Chih-Yang] Asia Univ, Dept Biotechnol, Taichung 413, Taiwan.
RP Liao, PH (corresponding author), China Med Univ, Grad Inst Basic Med Sci, Taichung 404, Taiwan.; Liao, PH; Huang, CY (corresponding author), Hualien Tzu Chi Hosp, Cardiovasc Res Ctr, Hualien 970, Taiwan.; Liao, PH; Huang, CY (corresponding author), Tzu Chi Univ Sci & Technol, Buddhist Tzu Chi Med Fdn, Ctr Gen Educ, Hualien 970, Taiwan.; Huang, CY (corresponding author), China Med Univ, China Med Univ Hosp, Dept Med Res, Taichung 404, Taiwan.; Huang, CY (corresponding author), Asia Univ, Dept Biotechnol, Taichung 413, Taiwan.
EM robert750927@hotmail.com; cyhuang@mail.cmu.edu.tw
RI Viswanadha, Vijaya Padma/ABG-4936-2020
OI Viswanadha, Vijaya Padma/0000-0001-9154-027X; Huang,
   Chih-Yang/0000-0003-2347-0411
FU Asia University, Taichung, Taiwan [ASIA-104-CMUH-08]; China Medical
   University Hospital, Taichung, Taiwan [DMR-108-169]
FX This work was supported by the Asia University, Taichung, Taiwan,
   Grant/Award Number: ASIA-104-CMUH-08 and China Medical University
   Hospital, Taichung, Taiwan, Grant/Award Number: DMR-108-169.
CR Asadi-Samani M, 2018, BIOMEDICINE-TAIWAN, V8, P16, DOI 10.1051/bmdcn/2018080208
   Brower V, 1998, NAT BIOTECHNOL, V16, P728, DOI 10.1038/nbt0898-728
   Brush MH, 2003, MOL CELL BIOL, V23, P1292, DOI 10.1128/MCB.23.4.1292-1303.2003
   Chalfant CE, 1999, J BIOL CHEM, V274, P20313, DOI 10.1074/jbc.274.29.20313
   Cheng X, 2013, BLOOD CANCER J, V3, DOI 10.1038/bcj.2013.42
   Chou HL, 2019, CANCERS, V11, DOI 10.3390/cancers11030370
   Chou RH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071983
   Fan CH, 2017, NEUROSCI LETT, V651, P198, DOI 10.1016/j.neulet.2017.03.006
   Fan LL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062627
   GRUNICKE H, 1994, ANN HEMATOL, V69, pS1, DOI 10.1007/BF01757347
   Gyawali B, 2017, NAT REV CLIN ONCOL, V14, P521, DOI 10.1038/nrclinonc.2017.72
   Higa S, 2003, J ALLERGY CLIN IMMUN, V111, P1299, DOI 10.1067/mai.2003.1456
   Hsieh CH, 2017, MOL CARCINOGEN, V56, P1055, DOI 10.1002/mc.22570
   Hsieh CH, 2013, BIOSCI BIOTECH BIOCH, V77, P2397, DOI 10.1271/bbb.130503
   Hsu HH, 2017, ENVIRON TOXICOL, V32, P2021, DOI 10.1002/tox.22379
   Hsu HH, 2017, WORLD J GASTROENTERO, V23, P1171, DOI 10.3748/wjg.v23.i7.1171
   Hsu HH, 2014, TUMOR BIOL, V35, P303, DOI 10.1007/s13277-013-1041-3
   Huang CY, 2017, BIOMEDICINE-TAIWAN, V7, P12, DOI 10.1051/bmdcn/2017070423
   Huang WSW, 2017, INT J MED SCI, V14, P136, DOI 10.7150/ijms.17754
   Jin ZS, 2014, MOL MED REP, V10, P3099, DOI 10.3892/mmr.2014.2664
   Kamiya T, 2013, J CLIN BIOCHEM NUTR, V52, P101, DOI 10.3164/jcbn.12-46
   Kang KA, 2016, TUMOR BIOL, V37, P9615, DOI 10.1007/s13277-016-4864-x
   Khan N, 2008, CARCINOGENESIS, V29, P1049, DOI 10.1093/carcin/bgn078
   Kim JY, 2017, J ENDODONT, V43, P417, DOI 10.1016/j.joen.2016.10.013
   Lee Jaeryun, 2017, Dev Reprod, V21, P139, DOI 10.12717/DR.2017.21.2.139
   Li DWC, 2006, ONCOGENE, V25, P3006, DOI 10.1038/sj.onc.1209334
   Liao PH, 2017, ONCOGENE, V36, P1978, DOI 10.1038/onc.2016.357
   Liu KY, 2018, CANCERS, V10, DOI 10.3390/cancers10010008
   Luo W, 2018, ONCOGENE, V37, P798, DOI 10.1038/onc.2017.378
   Luqmani YA, 2005, MED PRIN PRACT, V14, P35, DOI 10.1159/000086183
   Marks PA, 2001, CURR OPIN ONCOL, V13, P477, DOI 10.1097/00001622-200111000-00010
   Novoa I, 2001, J CELL BIOL, V153, P1011, DOI 10.1083/jcb.153.5.1011
   Pierce JP, 2007, JAMA-J AM MED ASSOC, V298, P289, DOI 10.1001/jama.298.3.289
   Santos CXC, 2016, EMBO J, V35, P319, DOI 10.15252/embj.201592394
   Serper M, 2017, GASTROENTEROLOGY, V152, P1954, DOI 10.1053/j.gastro.2017.02.040
   Shi YG, 2009, CELL, V139, P468, DOI 10.1016/j.cell.2009.10.006
   STARZL TE, 1963, SURG GYNECOL OBSTET, V117, P659
   Steelman LS, 2011, LEUKEMIA, V25, P1080, DOI 10.1038/leu.2011.66
   Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000
   Su CH, 2017, ENVIRON TOXICOL, V32, P1725, DOI 10.1002/tox.22396
   Syed DN, 2014, ARCH BIOCHEM BIOPHYS, V563, P108, DOI 10.1016/j.abb.2014.06.034
   Tang Y, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-11526-0
   Tsilimigras DI, 2018, SURG ONCOL, V27, P611, DOI 10.1016/j.suronc.2018.07.015
   Tu CC, 2013, CHINESE J PHYSIOL, V56, P326, DOI 10.4077/CJP.2013.BAB158
   Urruticoechea A, 2010, CURR PHARM DESIGN, V16, P3, DOI 10.2174/138161210789941847
   Veeresham C, 2012, J ADV PHARM TECHNOL, V3, P200, DOI 10.4103/2231-4040.104709
   Wang HD, 2016, LANCET, V388, P1459, DOI 10.1016/S0140-6736(16)31012-1
   Wang RH, 2001, ONCOGENE, V20, P6111, DOI 10.1038/sj.onc.1204829
   Wickremasinghe RG, 1999, BLOOD, V93, P3587, DOI 10.1182/blood.V93.11.3587.411k46_3587_3600
   Xiao L, 2010, CELL DEATH DIFFER, V17, P1448, DOI 10.1038/cdd.2010.16
   Zhang YF, 2015, CENT EUR J IMMUNOL, V40, P411, DOI 10.5114/ceji.2015.56961
NR 51
TC 12
Z9 12
U1 0
U2 7
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2072-6694
J9 CANCERS
JI Cancers
PD JUN 26
PY 2019
VL 11
IS 7
AR 918
DI 10.3390/cancers11070918
PG 20
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA IO4AV
UT WOS:000479322800029
PM 31261976
OA Green Submitted, Green Published, gold
DA 2022-04-25
ER

PT J
AU Wu, SP
   Zhang, YG
   Lu, R
   Xia, YL
   Zhou, D
   Petrof, EO
   Claud, EC
   Chen, D
   Chang, EB
   Carmeliet, G
   Sun, J
AF Wu, Shaoping
   Zhang, Yong-guo
   Lu, Rong
   Xia, Yinglin
   Zhou, David
   Petrof, Elaine O.
   Claud, Erika C.
   Chen, Di
   Chang, Eugene B.
   Carmeliet, Geert
   Sun, Jun
TI Intestinal epithelial vitamin D receptor deletion leads to defective
   autophagy in colitis
SO GUT
LA English
DT Article
ID INFLAMMATORY-BOWEL-DISEASE; KAPPA-B ACTIVITY; COLON-CANCER CELLS;
   CROHNS-DISEASE; PANETH CELLS; 1,25-DIHYDROXYVITAMIN D-3;
   ULCERATIVE-COLITIS; GENE POLYMORPHISM; INNATE IMMUNITY; KNOCKOUT MICE
AB Objective Vitamin D and the vitamin D receptor (VDR) appear to be important immunological regulators of inflammatory bowel diseases (IBD). Defective autophagy has also been implicated in IBD, where interestingly, polymorphisms of genes such as ATG16L1 have been associated with increased risk. Although vitamin D, the microbiome and autophagy are all involved in pathogenesis of IBD, it remains unclear whether these processes are related or function independently.
   Design We investigated the effects and mechanisms of intestinal epithelial VDR in healthy and inflamed states using cell culture models, a conditional VDR knockout mouse model (VDR Delta IEC), colitis models and human samples.
   Results Absence of intestinal epithelial VDR affects microbial assemblage and increases susceptibility to dextran sulfate sodium-induced colitis. Intestinal epithelial VDR downregulates expressions of ATG16L1 and lysozyme, and impairs antimicrobial function of Paneth cells. Gain and loss-of-function assays showed that VDR levels regulate ATG16L1 and lysozyme at the transcriptional and translational levels. Moreover, low levels of intestinal epithelial VDR correlated with reduced ATG16L1 and representation by intestinal Bacteroides in patients with IBD. Administration of the butyrate (a fermentation product of gut microbes) increases intestinal VDR expression and suppresses inflammation in a colitis model.
   Conclusions Our study demonstrates fundamental relationship between VDR, autophagy and gut microbial assemblage that is essential for maintaining intestinal homeostasis, but also in contributing to the pathophysiology of IBD. These insights can be leveraged to define therapeutic targets for restoring VDR expression and function.
C1 [Wu, Shaoping; Zhang, Yong-guo; Lu, Rong; Chen, Di; Sun, Jun] Rush Univ, Dept Biochem, Chicago, IL 60612 USA.
   [Xia, Yinglin] Univ Rochester, Dept Biostat & Computat Biol, Rochester, NY USA.
   [Zhou, David] Univ Rochester, Dept Pathol, Rochester, NY 14627 USA.
   [Petrof, Elaine O.] Queens Univ, Dept Med, GI Dis Res Unit, Kingston, ON K7L 3N6, Canada.
   [Petrof, Elaine O.] Queens Univ, Div Infect Dis, Kingston, ON, Canada.
   [Claud, Erika C.] Univ Chicago, Med Ctr, Dept Pediat, Chicago, IL 60637 USA.
   [Claud, Erika C.; Chang, Eugene B.] Univ Chicago, Med Ctr, Dept Med, Chicago, IL 60637 USA.
   [Carmeliet, Geert] Katholieke Univ Leuven, Lab Expt Med & Endocrinol, Leuven, Belgium.
RP Sun, J (corresponding author), Rush Univ, Dept Biochem, Cohn Res Bldg,1735 W Harrison St,506, Chicago, IL 60612 USA.
EM jun_sun@rush.edu
RI Chen, Di/AAJ-3665-2021; Sun, Jun/S-7440-2019
OI Sun, Jun/0000-0001-7465-3133
FU NIDDKUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Diabetes &
   Digestive & Kidney Diseases (NIDDK) [KO1 DK075386, 1R03DK089010-01];
   American Cancer SocietyAmerican Cancer Society [RSG-09-075-01-MBC]; Swim
   Across America Cancer Research Award; NATIONAL CENTER FOR ADVANCING
   TRANSLATIONAL SCIENCESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Center for
   Advancing Translational Sciences (NCATS) [UL1TR000430] Funding Source:
   NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND
   SKIN DISEASESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Arthritis &
   Musculoskeletal & Skin Diseases (NIAMS) [R01AR055915, R01AR054465]
   Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND
   DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Diabetes & Digestive & Kidney Diseases (NIDDK) [R37DK047722,
   R01DK047722, R01DK097268, K01DK075386, R03DK089010, P30DK042086] Funding
   Source: NIH RePORTER
FX We thank Liesbet Lieben for technical assistance with VDR.IEC mice. This
   work was supported by the NIDDK (KO1 DK075386 and 1R03DK089010-01), the
   American Cancer Society (RSG-09-075-01-MBC) and Swim Across America
   Cancer Research Award to JS. NIDDK DK42086 (DDRCC), DK097268 and DK47722
   to EBC.
CR Abreu MT, 2004, GUT, V53, P1129, DOI 10.1136/gut.2003.036657
   Adams JS, 2008, NAT CLIN PRACT ENDOC, V4, P80, DOI 10.1038/ncpendmet0716
   Adolph TE, 2013, NATURE, V503, P272, DOI 10.1038/nature12599
   Adorini L, 2008, NAT CLIN PRACT RHEUM, V4, P404, DOI 10.1038/ncprheum0855
   Ananthakrishnan AN, 2012, GASTROENTEROLOGY, V142, P482, DOI 10.1053/j.gastro.2011.11.040
   Aranow C, 2011, J INVEST MED, V59, P881, DOI 10.2310/JIM.0b013e31821b8755
   Barrett JC, 2008, NAT GENET, V40, P955, DOI 10.1038/ng.175
   Basset C, 2004, DIGEST DIS SCI, V49, P1425, DOI 10.1023/B:DDAS.0000042241.13489.88
   Bevins CL, 2011, NAT REV MICROBIOL, V9, P356, DOI 10.1038/nrmicro2546
   Blaney GP, 2009, ANN NY ACAD SCI, V1173, P384, DOI 10.1111/j.1749-6632.2009.04875.x
   Bloom SM, 2011, CELL HOST MICROBE, V9, P390, DOI 10.1016/j.chom.2011.04.009
   Bouillon R, 2008, ENDOCR REV, V29, P726, DOI 10.1210/er.2008-0004
   Cadwell K, 2008, NATURE, V456, P259, DOI 10.1038/nature07416
   Cadwell K, 2010, GASTROENTEROLOGY, V139, P1448, DOI 10.1053/j.gastro.2010.09.023
   Campbell FC, 2009, BIOCHEM PHARMACOL, V79, P1
   Campbell GR, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002689
   Cannell J, 2008, EXPERT OPIN PHARMACO, V9, P107, DOI 10.1517/14656566.9.1.107
   Carlberg C, 2009, ANTICANCER RES, V29, P3485
   Chan AT, 2010, GASTROENTEROLOGY, V138, P2029, DOI 10.1053/j.gastro.2010.01.057
   Couturier-Maillard A, 2013, J CLIN INVEST, V123, P700, DOI 10.1172/JCI62236
   Demay MB, 2006, ANN NY ACAD SCI, V1068, P204, DOI 10.1196/annals.1346.026
   Deretic V, 2008, DEV CELL, V15, P641, DOI 10.1016/j.devcel.2008.10.009
   Devkota S, 2012, NATURE, V487, P104, DOI 10.1038/nature11225
   Dresner-Pollak R, 2004, GENET TEST, V8, P417, DOI 10.1089/gte.2004.8.417
   Eloranta JJ, 2011, PHARMACOGENET GENOM, V21, P559, DOI 10.1097/FPC.0b013e328348f70c
   Fan YJ, 2010, J BIOL CHEM, V285, P7324, DOI 10.1074/jbc.M109.035584
   Fichera A, 2007, J SURG RES, V142, P239, DOI 10.1016/j.jss.2007.02.038
   Franks AH, 1998, APPL ENVIRON MICROB, V64, P3336
   Froicu M, 2006, IMMUNOLOGY, V117, P310, DOI 10.1111/j.1365-2567.2005.02290.x
   Gocek E, 2009, CRIT REV CL LAB SCI, V46, P190, DOI 10.1080/10408360902982128
   Gombart AF, 2005, FASEB J, V19, P1067, DOI 10.1096/fj.04-3284com
   Grau MV, 2003, J NATL CANCER I, V95, P1765, DOI 10.1093/jnci/djg110
   Hamamoto N, 1999, CLIN EXP IMMUNOL, V117, P462
   Hampe J, 2007, NAT GENET, V39, P207, DOI 10.1038/ng1954
   Haussler MR, 1998, J BONE MINER RES, V13, P325, DOI 10.1359/jbmr.1998.13.3.325
   Heaney RP, 2008, CLIN J AM SOC NEPHRO, V3, P1535, DOI 10.2215/CJN.01160308
   Herfarth HH, 1996, GUT, V39, P836, DOI 10.1136/gut.39.6.836
   Hughes DJ, 2011, EUR J GASTROEN HEPAT, V23, P807, DOI 10.1097/MEG.0b013e328349283e
   Hwang S, 2012, CELL HOST MICROBE, V11, P397, DOI 10.1016/j.chom.2012.03.002
   Kabi A, 2012, INFLAMM BOWEL DIS, V18, P782, DOI 10.1002/ibd.21868
   Kaler P, 2009, ONCOGENE, V28, P3892, DOI 10.1038/onc.2009.247
   Kanneganti TD, 2007, IMMUNITY, V27, P549, DOI 10.1016/j.immuni.2007.10.002
   Kaser A, 2008, CELL, V134, P743, DOI 10.1016/j.cell.2008.07.021
   Kato S, 2000, J BIOCHEM, V127, P717, DOI 10.1093/oxfordjournals.jbchem.a022662
   Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717
   Kochl R, 2006, TRAFFIC, V7, P129, DOI 10.1111/j.1600-0854.2005.00368.x
   Komatsu M, 2007, CELL, V131, P1149, DOI 10.1016/j.cell.2007.10.035
   Kong J, 2008, AM J PHYSIOL-GASTR L, V294, pG208, DOI 10.1152/ajpgi.00398.2007
   Koslowski MJ, 2010, INT J MED MICROBIOL, V300, P34, DOI 10.1016/j.ijmm.2009.08.011
   Lagishetty V, 2010, ENDOCRINOLOGY, V151, P2423, DOI 10.1210/en.2010-0089
   Lau KS, 2012, PLOS BIOL, V10, DOI 10.1371/journal.pbio.1001393
   Levine B, 2011, NATURE, V469, P323, DOI 10.1038/nature09782
   Li XY, 1999, MOL ENDOCRINOL, V13, P1686, DOI 10.1210/me.13.10.1686
   Lim WC, 2005, NAT CLIN PRACT GASTR, V2, P308, DOI 10.1038/ncpgasthep0215
   Liu PT, 2006, SCIENCE, V311, P1770, DOI 10.1126/science.1123933
   Liu WC, 2013, J CLIN INVEST, V123, P3983, DOI 10.1172/JCI65842
   Lozupone C, 2005, APPL ENVIRON MICROB, V71, P8228, DOI 10.1128/AEM.71.12.8228-8235.2005
   Lu R, 2012, CURR COLORECT CANC R, V8, P57, DOI 10.1007/s11888-011-0114-1
   Lu R, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010505
   Machiels Kathleen, 2014, Gut, V63, P1275, DOI 10.1136/gutjnl-2013-304833
   Masuyama R, 2006, J CLIN INVEST, V116, P3150, DOI 10.1172/JCI29463
   Menard S, 2008, J EXP MED, V205, P183, DOI 10.1084/jem.20071022
   Moscat J, 2009, CELL, V137, P1001, DOI 10.1016/j.cell.2009.05.023
   Mouli VP, 2014, ALIMENT PHARM THER, V39, P125, DOI 10.1111/apt.12553
   Murillo G, 2005, J STEROID BIOCHEM, V97, P129, DOI 10.1016/j.jsbmb.2005.06.008
   Nagpal S, 2001, CURR MED CHEM, V8, P1661, DOI 10.2174/0929867013371950
   Ouellette AJ, 2011, CELL MOL LIFE SCI, V68, P2215, DOI 10.1007/s00018-011-0714-6
   Palmer HG, 2003, CANCER RES, V63, P7799
   Parkes M, 2012, DIGEST DIS, V30, P330, DOI 10.1159/000338119
   Phan TG, 2009, NAT IMMUNOL, V10, P786, DOI 10.1038/ni.1745
   Prindiville TP, 2000, EMERG INFECT DIS, V6, P171, DOI 10.3201/eid0602.000210
   Protiva P, 2009, CANCER PREV RES, V2, P43, DOI 10.1158/1940-6207.CAPR-08-0103
   Randall-Demllo S, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00301
   Robizadeh S, 2007, INFLAMM BOWEL DIS, V13, P1475, DOI 10.1002/ibd.20265
   Saitoh T, 2008, NATURE, V456, P264, DOI 10.1038/nature07383
   Salzman NH, 2010, NAT IMMUNOL, V11, P76, DOI 10.1038/ni.1825
   Schauber J, 2003, GUT, V52, P735, DOI 10.1136/gut.52.5.735
   Segaert S, 2008, J INVEST DERMATOL, V128, P773, DOI 10.1038/jid.2008.35
   Sellon RK, 1998, INFECT IMMUN, V66, P5224, DOI 10.1128/IAI.66.11.5224-5231.1998
   Sentongo TA, 2002, AM J CLIN NUTR, V76, P1077, DOI 10.1093/ajcn/76.5.1077
   Simmons JD, 2000, GUT, V47, P211, DOI 10.1136/gut.47.2.211
   Stamatiou R, 2009, EUR RESPIR J, V34, P721, DOI 10.1183/09031936.00089407
   Stio M, 2006, INT IMMUNOPHARMACOL, V6, P1083, DOI 10.1016/j.intimp.2006.01.018
   Sun J, 2008, J STEROID BIOCHEM, V111, P37, DOI 10.1016/j.jsbmb.2008.01.003
   Sun J, 2006, AM J PHYSIOL-ENDOC M, V291, pE315, DOI 10.1152/ajpendo.00590.2005
   Takahashi N, 2008, J EXP MED, V205, P1755, DOI 10.1084/jem.20080588
   Thachil E, 2012, GASTROENTEROLOGY, V142, P1097, DOI 10.1053/j.gastro.2012.01.031
   Travassos LH, 2010, NAT IMMUNOL, V11, P55, DOI 10.1038/ni.1823
   Trowbridge R, 2013, CANCER EPIDEM BIOMAR, V22, P1007, DOI 10.1158/1055-9965.EPI-13-0085
   TSOUKAS CD, 1984, SCIENCE, V224, P1438, DOI 10.1126/science.6427926
   Vaishnava S, 2008, P NATL ACAD SCI USA, V105, P20858, DOI 10.1073/pnas.0808723105
   Van Cromphaut SJ, 2001, P NATL ACAD SCI USA, V98, P13324, DOI 10.1073/pnas.231474698
   Verway M, 2010, EXPERT REV CLIN IMMU, V6, P505, DOI [10.1586/eci.10.31, 10.1586/ECI.10.31]
   Virgin HW, 2009, NAT IMMUNOL, V10, P461, DOI 10.1038/ni.1726
   Wada K, 2009, ONCOL REP, V22, P1021, DOI 10.3892/or_00000530
   Wang DH, 2011, P NATL ACAD SCI USA, V108, P10272, DOI 10.1073/pnas.1017668108
   Wang TT, 2004, J IMMUNOL, V173, P2909, DOI 10.4049/jimmunol.173.5.2909
   Wang YJ, 2010, ARCH BIOCHEM BIOPHYS, V494, P166, DOI 10.1016/j.abb.2009.11.029
   Wang YW, 2009, ISME J, V3, P944, DOI 10.1038/ismej.2009.37
   Wehkamp J, 2007, J IMMUNOL, V179, P3109, DOI 10.4049/jimmunol.179.5.3109
   Wu SP, 2011, DISCOV MED, V11, P325
   Wu SP, 2010, AM J PATHOL, V177, P686, DOI 10.2353/ajpath.2010.090998
   Wu SP, 2010, INT J BIOCHEM CELL B, V42, P329, DOI 10.1016/j.biocel.2009.11.012
   Xu ZQ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041137
   Yu SH, 2008, P NATL ACAD SCI USA, V105, P20834, DOI 10.1073/pnas.0808700106
   Yuk JM, 2009, CELL HOST MICROBE, V6, P231, DOI 10.1016/j.chom.2009.08.004
   Zeeuwen PLJM, 2013, CURR OPIN ALLERGY CL, V13, P514, DOI 10.1097/ACI.0b013e328364ebeb
   Zhang XQ, 2010, CANCER GENE THER, V17, P579, DOI 10.1038/cgt.2010.14
NR 108
TC 183
Z9 186
U1 10
U2 71
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0017-5749
EI 1468-3288
J9 GUT
JI Gut
PD JUL
PY 2015
VL 64
IS 7
BP 1082
EP 1094
DI 10.1136/gutjnl-2014-307436
PG 13
WC Gastroenterology & Hepatology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Gastroenterology & Hepatology
GA CK2EF
UT WOS:000356022700012
PM 25080448
OA Green Accepted
HC Y
HP N
DA 2022-04-25
ER

PT J
AU Yu, C
   Li, WB
   Liu, JB
   Lu, JW
   Feng, JF
AF Yu, Chen
   Li, Wei-bing
   Liu, Jun-bao
   Lu, Jian-wei
   Feng, Ji-feng
TI Autophagy: novel applications of nonsteroidal anti-inflammatory drugs
   for primary cancer
SO CANCER MEDICINE
LA English
DT Review
DE Autophagy; nonsteroidal anti-inflammatory drugs; programmed cell death
ID ENDOPLASMIC-RETICULUM STRESS; COLORECTAL-CANCER; CELL-DEATH;
   HEPATOCELLULAR-CARCINOMA; CARDIOVASCULAR-DISEASE; REGULATES AUTOPHAGY;
   INHIBITOR CELECOXIB; MEDIATED CLEAVAGE; INDUCED APOPTOSIS; MAMMALIAN
   TARGET
AB In eukaryotic cells, autophagy is a process associated with programmed cell death. During this process, cytoplasmic proteins and organelles are engulfed by double-membrane autophagosomes, which then fuse with lysosomes to form autolysosomes. These autolysosomes then degrade their contents to recycle the cellular components. Autophagy has been implicated in a wide variety of physiological and pathological processes that are closely related to tumorigenesis. In recent years, an increasing number of studies have indicated that nonsteroidal anti-inflammatory drugs, such as celecoxib, meloxicam, sulindac, aspirin, sildenafil, rofecoxib, and sodium salicylate, have diverse effects in cancer that are mediated by the autophagy pathway. These nonsteroidal anti-inflammatory drugs can modulate tumor autophagy through the PI3K/Akt/mTOR, MAPK/ERK1/2, P53/DRAM, AMPK/mTOR, Bip/GRP78, CHOP/ GADD153, and HGF/MET signaling pathways and inhibit lysosome function, leading to p53-dependent G1 cell-cycle arrest. In this review, we summarize the research progress in autophagy induced by nonsteroidal anti-inflammatory drugs and the molecular mechanisms of autophagy in cancer cells to provide a reference for the potential benefits of nonsteroidal anti-inflammatory drugs in cancer chemotherapy.
C1 [Yu, Chen; Li, Wei-bing] Nanjing Med Univ, Affiliated Canc Hosp, Jiangsu Inst Canc Res, Dept Integrated TCM & Western Med,Jiangsu Canc Ho, Nanjing 210000, Jiangsu, Peoples R China.
   [Liu, Jun-bao] Henan Prov Peoples Hosp, Dept Tradit Chinese Med, Zhengzhou, Henan, Peoples R China.
   [Lu, Jian-wei; Feng, Ji-feng] Nanjing Med Univ, Affiliated Canc Hosp, Jiangsu Inst Canc Res, Dept Med,Jiangsu Canc Hosp, Nanjing 210000, Jiangsu, Peoples R China.
RP Lu, JW; Feng, JF (corresponding author), Nanjing Med Univ, Affiliated Canc Hosp, Jiangsu Inst Canc Res, Dept Med,Jiangsu Canc Hosp, Nanjing 210000, Jiangsu, Peoples R China.
EM lujw@medmail.com.cn; jifeng_feng@163.com
FU Jiangsu Cadre Health Care Research Project [BJ15028]; National Natural
   Science Foundation of ChinaNational Natural Science Foundation of China
   (NSFC) [81503528]
FX This study was funded by grants from Jiangsu Cadre Health Care Research
   Project (BJ15028) and the National Natural Science Foundation of China
   (81503528).
CR Abedin MJ, 2007, CELL DEATH DIFFER, V14, P500, DOI 10.1038/sj.cdd.4402039
   Amaravadi RK, 2007, CLIN CANCER RES, V13, P7271, DOI 10.1158/1078-0432.CCR-07-1595
   Baron JA, 2009, RECENT RESULTS CANC, V181, P223
   Bauvy C, 2001, EXP CELL RES, V268, P139, DOI 10.1006/excr.2001.5285
   Bibbins-Domingo K, 2016, ANN INTERN MED, V164, P836, DOI 10.7326/M16-0577
   Booth L, 2015, J CELL PHYSIOL, V230, P1115, DOI 10.1002/jcp.24843
   Cao Y, 2016, JAMA ONCOL, V2, P762, DOI 10.1001/jamaoncol.2015.6396
   Chapuis N, 2010, LEUKEMIA, V24, P1686, DOI 10.1038/leu.2010.170
   Chen J, 2014, CLIN THER, V36, P1253, DOI 10.1016/j.clinthera.2014.06.015
   Cheng Y, 2011, CANCER RES, V71, P2654, DOI 10.1158/0008-5472.CAN-10-2889
   Chiarugi P, 2008, BIOCHEM PHARMACOL, V76, P1352, DOI 10.1016/j.bcp.2008.07.023
   Chresta CM, 2010, CANCER RES, V70, P288, DOI 10.1158/0008-5472.CAN-09-1751
   Crighton D, 2006, CELL, V126, P121, DOI 10.1016/j.cell.2006.05.034
   Din FVN, 2012, GASTROENTEROLOGY, V142, P1504, DOI 10.1053/j.gastro.2012.02.050
   Djavaheri-Mergny M, 2010, ONCOGENE, V29, P1717, DOI 10.1038/onc.2009.519
   Dong XF, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092864
   Dulai PS, 2016, BMJ-BRIT MED J, V355, DOI 10.1136/bmj.i6188
   Duran A, 2008, CANCER CELL, V13, P343, DOI 10.1016/j.ccr.2008.02.001
   Feng ZH, 2005, P NATL ACAD SCI USA, V102, P8204, DOI 10.1073/pnas.0502857102
   Fosslien E, 2000, ANN CLIN LAB SCI, V30, P3
   Gao M, 2008, CANCER RES, V68, P9348, DOI 10.1158/0008-5472.CAN-08-1642
   Ghavami S, 2014, BBA-MOL CELL RES, V1843, P1259, DOI 10.1016/j.bbamcr.2014.03.006
   Gwinn DM, 2008, MOL CELL, V30, P214, DOI 10.1016/j.molcel.2008.03.003
   Han HY, 2014, ASIAN PAC J CANCER P, V15, P6939, DOI 10.7314/APJCP.2014.15.16.6939
   Hour TC, 2000, ANTICANCER RES, V20, P3221
   Hoyer-Hansen M., 2007, MOL CELL, V19, P3
   Hua X., 2017, J CLIN ONCOL, V15
   Huang KH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082034
   Huang SB, 2010, AUTOPHAGY, V6, P256, DOI 10.4161/auto.6.2.11124
   Ito H, 2005, INT J ONCOL, V26, P1401
   Jin SK, 2007, AUTOPHAGY, V3, P28, DOI 10.4161/auto.3269
   Johnson AJ, 2002, BIOCHEM J, V366, P831, DOI 10.1042/BJ20020279
   Jorgensen HG, 2007, BLOOD, V109, P4016, DOI 10.1182/blood-2006-11-057521
   Jung CH, 2010, FEBS LETT, V584, P1287, DOI 10.1016/j.febslet.2010.01.017
   Kaneko S, 2013, INT J CLIN ONCOL, V18, P116, DOI 10.1007/s10147-011-0354-8
   Kang KB, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-66
   Kang R, 2011, CELL DEATH DIFFER, V18, P571, DOI 10.1038/cdd.2010.191
   Kanzawa T, 2005, ONCOGENE, V24, P980, DOI 10.1038/sj.onc.1208095
   Kanzawa T, 2004, CELL DEATH DIFFER, V11, P448, DOI 10.1038/sj.cdd.4401359
   Kim KW, 2006, J BIOL CHEM, V281, P36883, DOI 10.1074/jbc.M607094200
   Kim YC, 2015, J CLIN INVEST, V125, P25, DOI 10.1172/JCI73939
   Kimple RJ, 2010, AM J CLIN ONCOL-CANC, V33, P265, DOI 10.1097/COC.0b013e3181a76a24
   Konno H, 2002, CLIN EXP METASTAS, V19, P527, DOI 10.1023/A:1020392309715
   Kroemer G, 2010, MOL CELL, V40, P280, DOI 10.1016/j.molcel.2010.09.023
   Lee AS, 2007, CANCER RES, V67, P3496, DOI 10.1158/0008-5472.CAN-07-0325
   Lee HJ, 2017, J CLIN BIOCHEM NUTR, V60, P55, DOI 10.3164/jcbn.16-69
   Liang JY, 2007, NAT CELL BIOL, V9, P218, DOI 10.1038/ncb1537
   Lim SC, 2008, ONCOL REP, V19, P1165
   Liu J, 2011, TUMOR BIOL, V32, P1113, DOI 10.1007/s13277-011-0211-4
   Liu M, 2014, INT J MOL MED, V33, P1451, DOI 10.3892/ijmm.2014.1713
   Lotrionte M, 2016, PROG CARDIOVASC DIS, V58, P495, DOI 10.1016/j.pcad.2016.02.001
   Lu Y, 2016, BIOMED PHARMACOTHER, V84, P1551, DOI 10.1016/j.biopha.2016.11.026
   Lu Y, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-1012-8
   Lu Z, 2008, J CLIN INVEST, V118, P3917, DOI 10.1172/JCI35512
   Luo S, 2007, CELL DEATH DIFFER, V14, P1247, DOI 10.1038/sj.cdd.4402149
   Ma L, 2005, CELL, V121, P179, DOI 10.1016/j.cell.2005.02.031
   Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239
   Maiuri MC, 2007, EMBO J, V26, P2527, DOI 10.1038/sj.emboj.7601689
   Mathew R, 2009, CELL, V137, P1062, DOI 10.1016/j.cell.2009.03.048
   Matsushita M, 2007, J BIOL CHEM, V282, P6763, DOI 10.1074/jbc.M609876200
   Mazzanti R, 2009, BIOCHEM PHARMACOL, V78, P21, DOI 10.1016/j.bcp.2009.03.013
   Moscat J, 2009, CELL, V137, P1001, DOI 10.1016/j.cell.2009.05.023
   Movahedi M, 2015, J CLIN ONCOL, V33, P3591, DOI 10.1200/JCO.2014.58.9952
   NEWCOMB EW, 1993, BRAIN PATHOL, V3, P229, DOI 10.1111/j.1750-3639.1993.tb00749.x
   Norbury CJ, 2004, ONCOGENE, V23, P2797, DOI 10.1038/sj.onc.1207532
   Oyadomari S, 2004, CELL DEATH DIFFER, V11, P381, DOI 10.1038/sj.cdd.4401373
   Pattingre S, 2003, J BIOL CHEM, V278, P16667, DOI 10.1074/jbc.M210998200
   Pellicano R, 2014, Minerva Gastroenterol Dietol, V60, P255
   Pyrko P, 2007, MOL CANCER THER, V6, P1262, DOI 10.1158/1535-7163.MCT-06-0629
   Sahni S, 2014, J CLIN PATHOL, V67, P656, DOI 10.1136/jclinpath-2014-202356
   Sato K, 2007, CANCER RES, V67, P9677, DOI 10.1158/0008-5472.CAN-07-1462
   Schaaf MBE, 2013, RADIOTHER ONCOL, V108, P529, DOI 10.1016/j.radonc.2013.06.015
   Schonthal Axel H, 2012, Front Biosci (Schol Ed), V4, P412
   Scott RC, 2007, CURR BIOL, V17, P1, DOI 10.1016/j.cub.2006.10.053
   Silva J, 2017, ANTICANCER RES, V37, P1737, DOI 10.21873/anticanres.11506
   Sinha S, 2008, ONCOGENE, V27, pS137, DOI 10.1038/onc.2009.51
   Su J, 2015, ONCOL REP, V34, P235, DOI 10.3892/or.2015.3944
   Suzuki K, 2013, NEURO-ONCOLOGY, V15, P1186, DOI 10.1093/neuonc/not062
   Tabas I, 2011, NAT CELL BIOL, V13, P184, DOI 10.1038/ncb0311-184
   Thomas S, 2012, CANCER LETT, V325, P63, DOI 10.1016/j.canlet.2012.05.030
   Wang LT, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079814
   White E, 2009, CLIN CANCER RES, V15, P5308, DOI 10.1158/1078-0432.CCR-07-5023
   Yang CS, 2014, AUTOPHAGY, V10, P785, DOI 10.4161/auto.28072
   Yang PM, 2010, CANCER RES, V70, P7699, DOI 10.1158/0008-5472.CAN-10-1626
   Yousefi S, 2006, NAT CELL BIOL, V8, P1124, DOI 10.1038/ncb1482
   Yu Hong-Jeng, 1992, Journal of the Formosan Medical Association, V91, P608
   Yu H, 2011, EUR J CANCER, V47, P1585, DOI 10.1016/j.ejca.2011.01.019
   Zeng XH, 2007, CLIN CANCER RES, V13, P1315, DOI 10.1158/1078-0432.CCR-06-1517
   Zhang C, 2015, J CELL MOL MED, V19, P408, DOI 10.1111/jcmm.12461
   Zhao QQ, 2016, ONCOL LETT, V12, P2804, DOI 10.3892/ol.2016.5017
   Zhong JT, 2015, CELL PROLIFERAT, V48, P691, DOI 10.1111/cpr.12221
   Zhu JX, 2004, CANCER RES, V64, P4309, DOI 10.1158/0008-5472.CAN-03-4063
   Zhu X, 2017, EXP THER MED, V13, P2348, DOI 10.3892/etm.2017.4287
NR 93
TC 33
Z9 34
U1 5
U2 15
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2045-7634
J9 CANCER MED-US
JI Cancer Med.
PD FEB
PY 2018
VL 7
IS 2
BP 471
EP 484
DI 10.1002/cam4.1287
PG 14
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA FV6TE
UT WOS:000424713800019
PM 29282893
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Zhao, H
   Yang, MP
   Zhao, B
AF Zhao, Hong
   Yang, Maopeng
   Zhao, Bin
TI Beclin 1 and LC3 as predictive biomarkers for metastatic colorectal
   carcinoma
SO ONCOTARGET
LA English
DT Article
DE colorectal carcinoma; beclin 1; LC3; metastasis; biomarker
ID AUTOPHAGY; CANCER; EXPRESSION; PROGNOSIS; SURVIVAL; SYSTEM; SENESCENCE;
   PROTEIN; GROWTH; CELLS
AB Autophagy is a highly conserved self-destructive process that disassembles dysfunctional or unnecessary cellular components. It plays an important role in cancer metastasis, which is of particular interest considering metastatic disease is the major cause of colorectal carcinoma (CRC) related mortality. Here, we investigated the immunohistochemical expression of autophagy-related protein Beclin 1 and Microtubule-associated protein 1A/1B-light chain 3 (LC3) within surgical CRC specimens, first in a training cohort (205 patients), then in an inner validation cohort (160 patients) and an independent cohort (161 patients). The expressions of Beclin 1 and LC3 were lower in metastatic CRC compared with non-metastatic CRC. Furthermore, we developed an autophagy-based classifier for metastatic prediction. This classifier, including Beclin 1, LC3 and carcinoembryonic antigen (CEA) level, resulted in 82.9% sensitivity and 89.8% specificity for metastatic detection in the training cohort. In the independent cohort, it achieved 77.9% sensitivity and 90.3% specificity in predicting the metastasis of CRC. These results suggested that low expression of Beclin 1 and LC3 contributed to a more aggressive cancer cell phenotype, and our autophagy-based classifier was a reliable tool for metastatic prediction in CRC.
C1 [Zhao, Hong] Harbin Med Univ, Daqing, Heilongjiang, Peoples R China.
   [Zhao, Hong; Yang, Maopeng] Harbin Med Univ, Affiliated Hosp 3, Dept Med Oncol, Harbin, Heilongjiang, Peoples R China.
   [Zhao, Bin] Wenzhou Med Univ, Affiliated Hosp 2, Wenzhou, Peoples R China.
   [Zhao, Bin] Wenzhou Med Univ, Yuying Childrens Hosp, Wenzhou, Peoples R China.
RP Zhao, H (corresponding author), Harbin Med Univ, Daqing, Heilongjiang, Peoples R China.; Zhao, H (corresponding author), Harbin Med Univ, Affiliated Hosp 3, Dept Med Oncol, Harbin, Heilongjiang, Peoples R China.; Zhao, B (corresponding author), Wenzhou Med Univ, Affiliated Hosp 2, Wenzhou, Peoples R China.; Zhao, B (corresponding author), Wenzhou Med Univ, Yuying Childrens Hosp, Wenzhou, Peoples R China.
EM doctorhongzhao@126.com; doctorbinzhao@126.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [31571417, 81502478]; Natural Science
   Foundation of Heilongjiang ProvinceNatural Science Foundation of
   Heilongjiang Province [H2016023]; Haiyan Foundation of The third
   Affiliated Hospital of Harbin Medical University [JJMS2014-06]
FX This work was funded by National Natural Science Foundation of China
   (No. 31571417 and No. 81502478), Natural Science Foundation of
   Heilongjiang Province (No. H2016023) and Haiyan Foundation of The third
   Affiliated Hospital of Harbin Medical University (No. JJMS2014-06).
CR Adachi Y, 1999, DIS COLON RECTUM, V42, P1053, DOI 10.1007/BF02236702
   Ahn CH, 2007, APMIS, V115, P1344, DOI 10.1111/j.1600-0463.2007.00858.x
   Apetoh L, 2007, NAT MED, V13, P1050, DOI 10.1038/nm1622
   Barozzi C, 2002, CANCER-AM CANCER SOC, V94, P647, DOI 10.1002/cncr.10278
   Boya P, 2013, NAT CELL BIOL, V15, P713, DOI 10.1038/ncb2788
   Burada F, 2015, WORLD J GASTRO ONCOL, V7, P271, DOI 10.4251/wjgo.v7.i11.271
   Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865
   Choi AMK, 2013, NEW ENGL J MED, V368, P651, DOI [10.1056/NEJMra1205406, 10.1056/NEJMc1303158]
   Cunningham D, 2010, LANCET, V375, P1030, DOI 10.1016/S0140-6736(10)60353-4
   DeNardo DG, 2008, CANCER METAST REV, V27, P11, DOI 10.1007/s10555-007-9100-0
   Gallagher DJ, 2010, ONCOLOGY-BASEL, V78, P237, DOI 10.1159/000315730
   Guo GF, 2011, WORLD J GASTROENTERO, V17, P4779, DOI 10.3748/wjg.v17.i43.4779
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Hu H, 2009, CLIN CANCER RES, V15, P5485, DOI 10.1158/1078-0432.CCR-08-2491
   Kenific CM, 2010, CURR OPIN CELL BIOL, V22, P241, DOI 10.1016/j.ceb.2009.10.008
   Klionsky DJ, 2007, AUTOPHAGY, V3, P181, DOI 10.4161/auto.3678
   Koukourakis MI, 2010, BRIT J CANCER, V103, P1209, DOI 10.1038/sj.bjc.6605904
   Krizhanovsky V, 2008, COLD SH Q B, V73, P513, DOI 10.1101/sqb.2008.73.048
   Lai K, 2014, J CLIN PATHOL, V67, P854, DOI 10.1136/jclinpath-2014-202529
   Li BX, 2009, AUTOPHAGY, V5, P303, DOI 10.4161/auto.5.3.7491
   Liang XH, 2001, CANCER RES, V61, P3443
   Mukhopadhyay S, 2014, APOPTOSIS, V19, P555, DOI 10.1007/s10495-014-0967-2
   Nanashima A, 1999, J GASTROEN HEPATOL, V14, P1004, DOI 10.1046/j.1440-1746.1999.01991.x
   Ohji Y, 2007, ONCOL REP, V17, P525
   Park JM, 2013, CANCER BIOL THER, V14, P100, DOI 10.4161/cbt.22954
   Pavlides S, 2012, ANTIOXID REDOX SIGN, V16, P1264, DOI 10.1089/ars.2011.4243
   Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI [10.3322/caac.21254, 10.3322/caac.21208, 10.1001/jamaoto.2014.2530, 10.1136/bmj.g1502]
   Tanida I, 2004, INT J BIOCHEM CELL B, V36, P2503, DOI 10.1016/j.biocel.2004.05.009
   Wild P, 2014, J CELL SCI, V127, P3, DOI 10.1242/jcs.140426
   Wong SKC, 2008, DIS COLON RECTUM, V51, P1331, DOI 10.1007/s10350-008-9274-8
   Yang MP, 2015, ONCOTARGET, V6, P7084, DOI 10.18632/oncotarget.3054
   Young ARJ, 2009, GENE DEV, V23, P798, DOI 10.1101/gad.519709
   Zhang J, 2013, INT J BIOCHEM CELL B, V45, P745, DOI 10.1016/j.biocel.2012.11.001
   Zhang MY, 2014, INT J MOL SCI, V15, P14372, DOI 10.3390/ijms150814372
   Zhao HL, 2015, ONCOTARGET, V6, P5022, DOI 10.18632/oncotarget.3217
   Zhou WH, 2012, AUTOPHAGY, V8, P389, DOI 10.4161/auto.18641
   Zlobec I, 2007, J CLIN PATHOL, V60, P1112, DOI 10.1136/jcp.2006.044537
NR 37
TC 11
Z9 14
U1 0
U2 4
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD AUG 29
PY 2017
VL 8
IS 35
BP 59058
EP 59067
DI 10.18632/oncotarget.19939
PG 10
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA FF4RD
UT WOS:000408941900093
PM 28938618
OA Green Published, gold, Green Submitted
DA 2022-04-25
ER

PT J
AU Sim, KH
   Shu, MS
   Kim, S
   Kim, JY
   Choi, BH
   Lee, YJ
AF Sim, Kyeong Hwa
   Shu, Mi-Sun
   Kim, Soyoung
   Kim, Jong-Yeon
   Choi, Bo-Hyun
   Lee, Youn Ju
TI Cilostazol Induces Apoptosis and Inhibits Proliferation of
   Hepatocellular Carcinoma Cells by Activating AMPK
SO BIOTECHNOLOGY AND BIOPROCESS ENGINEERING
LA English
DT Article
DE cilostazol; hepatocellular carcinoma; apoptosis; AMPK; ERK; AKT
ID LIVER-REGENERATION; SIGNALING PATHWAY; PROTEIN-KINASE; CANCER;
   MANAGEMENT; EXPRESSION; METASTASES; AUTOPHAGY; RESECTION; GROWTH
AB Hepatocellular carcinoma (HCC) is the most common primary liver cancer and one of the leading causes of cancer-related death. Cilostazol, an antiplatelet drug, elicits anticancer effects on human squamous cell carcinoma and colon cancer cells. We previously reported that cilostazol protects normal mature hepatocytes from alcohol-induced apoptotic cell death. In addition, cilostazol stimulates liver regeneration after hepatectomy. Therefore, this study evaluated whether cilostazol elicits pro- or anti-proliferative effects on HCC using Hep3B and SK-Hep1 cells. Cilostazol inhibited proliferation of HCC cells by inducing apoptosis. Additionally, cilostazol induced G(0)/G(1) cell cycle arrest and decreased expression of cyclin D1 and proliferating cell nuclear antigen. Activation of AMP-activated protein kinase (AMPK) and inhibition of extracellular signal-regulated kinase (ERK) and AKT signaling were associated with the anti-proliferative effect of cilostazol. LY294002 and PD98059, inhibitors of AKT and ERK, respectively, enhanced the anti-proliferative effect of cilostazol. By contrast, inhibition of AMPK using compound C or AMPK-targeting siRNA abolished the anti-proliferative effect of cilostazol. Moreover, AMPK inhibition reversed the down-regulation of AKT/EKR induced by cilostazol, indicating negative cross-talk between AMPK and AKT/ERK. These findings provide evidence that cilostazol exerts anti-tumor activity in HCC by counter-regulating AMPK and AKT/ERK signaling. Taken together, our findings suggest that cilostazol may provide clinical benefits in HCC patients by selectively targeting HCC cells without interfering with liver function.
C1 [Sim, Kyeong Hwa; Choi, Bo-Hyun; Lee, Youn Ju] Catholic Univ Daegu, Sch Med, Dept Pharmacol, Daegu 42472, South Korea.
   [Shu, Mi-Sun; Kim, Jong-Yeon] Yeungnam Univ, Sch Med, Dept Physiol, Daegu 42415, South Korea.
   [Kim, Soyoung] Dongguk Univ, Sch Med, Dept Pharmacol, Gyeongju 38066, South Korea.
RP Lee, YJ (corresponding author), Catholic Univ Daegu, Sch Med, Dept Pharmacol, Daegu 42472, South Korea.
EM whrytn4337@cu.ac.kr
CR Akula SM, 2019, EXPERT OPIN THER TAR, DOI 10.1080/14728222.2019.1685501
   Cao W, 2019, BREAST CANCER RES, V21, DOI 10.1186/s13058-019-1107-2
   Chan KM, 2017, LIVER INT, V37, P434, DOI 10.1111/liv.13280
   Cheng JD, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093256
   Chiang PC, 2010, BIOCHEM PHARMACOL, V79, P162, DOI 10.1016/j.bcp.2009.08.022
   Cordero MD, 2018, TRENDS ENDOCRIN MET, V29, P8, DOI 10.1016/j.tem.2017.10.009
   Ferretti AC, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-39556-w
   Fujii T, 2017, J SURG RES, V213, P207, DOI 10.1016/j.jss.2017.02.020
   Gomez D, 2007, BRIT J SURG, V94, P1395, DOI 10.1002/bjs.5820
   Grabinski N, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-85
   He C, 2018, BIOCHEM BIOPH RES CO, V503, P3093, DOI 10.1016/j.bbrc.2018.08.098
   Hoffmann K, 2011, ANTICANCER RES, V31, P3883
   Huang J, 2018, MOL MED REP, V17, P5390, DOI 10.3892/mmr.2018.8522
   Ishii H, 2016, J CARDIOL, V67, P199, DOI 10.1016/j.jjcc.2015.05.003
   Ito Y, 1998, HEPATOLOGY, V27, P951, DOI 10.1002/hep.510270409
   Jeon BH, 2015, METABOLISM, V64, P1444, DOI 10.1016/j.metabol.2015.07.014
   Jiang X, 2019, CANCERS, V11, DOI 10.3390/cancers11050647
   Jiao P, 2013, MOL CELL BIOCHEM, V382, P217, DOI 10.1007/s11010-013-1737-0
   Kabil SL, 2018, CLIN EXP PHARMACOL P, V45, P1341, DOI 10.1111/1440-1681.13004
   Kangawa Y, 2017, FOOD CHEM TOXICOL, V100, P103, DOI 10.1016/j.fct.2016.12.018
   Kawaguchi T, 2015, INT J ONCOL, V46, P2216, DOI 10.3892/ijo.2015.2928
   Kwon HY, 2018, ARCH TOXICOL, V92, P241, DOI 10.1007/s00204-017-2021-y
   Lee CH, 2017, AM J PHYSIOL-RENAL, V312, pF398, DOI 10.1152/ajprenal.00258.2016
   Lee YJ, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0211415
   Liu L, 2006, CANCER RES, V66, P11851, DOI 10.1158/0008-5472.CAN-06-1377
   Matter MS, 2014, J HEPATOL, V60, P855, DOI 10.1016/j.jhep.2013.11.031
   Merlen G, 2014, J HEPATOL, V60, P152, DOI 10.1016/j.jhep.2013.08.025
   Mihaylova MM, 2011, NAT CELL BIOL, V13, P1016, DOI 10.1038/ncb2329
   Nordlinger B, 2008, LANCET, V371, P1007, DOI 10.1016/S0140-6736(08)60455-9
   Park SY, 2016, ONCOL REP, V35, P1566, DOI 10.3892/or.2015.4519
   Poon RTP, 2002, J AM COLL SURGEONS, V195, P311, DOI 10.1016/S1072-7515(02)01226-7
   Ratchford EV, 2017, J VASC SURG, V66, P275, DOI 10.1016/j.jvs.2017.02.040
   Ruderman NB, 2013, J CLIN INVEST, V123, P2764, DOI 10.1172/JCI67227
   Schulte L, 2019, LIVER INT, V39, P714, DOI 10.1111/liv.14048
   Seo YS, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000003527
   Shi JH, 2014, WORLD J GASTROENTERO, V20, P16167, DOI 10.3748/wjg.v20.i43.16167
   Strowitzki MJ, 2014, CLIN EXP METASTAS, V31, P795, DOI 10.1007/s10585-014-9669-y
   Tabrizian P, 2014, WORLD J GASTROENTERO, V20, P10223, DOI 10.3748/wjg.v20.i30.10223
   Tejeda-Maldonado J, 2015, WORLD J HEPATOL, V7, P362, DOI 10.4254/wjh.v7.i3.362
   Umezawa S, 2017, CURR PHARM DESIGN, V23, P3629, DOI 10.2174/0929867324666170713150440
   Uzawa K, 2013, CANCER MED-US, V2, P40, DOI 10.1002/cam4.56
   von Heesen M, 2015, LIVER TRANSPLANT, V21, P792, DOI 10.1002/lt.24114
   Wang JC, 2019, J CELL PHYSIOL, V234, P6908, DOI 10.1002/jcp.27449
   Wang SSS, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.18
   Xie XH, 2018, CELL STRESS CHAPERON, V23, P203, DOI 10.1007/s12192-017-0828-3
   Yang SF, 2017, ONCOL LETT, V13, P1041, DOI 10.3892/ol.2017.5557
   Yoo AR, 2010, J ATHEROSCLER THROMB, V17, P1009, DOI 10.5551/jat.4309
   Zheng LY, 2013, CLIN CANCER RES, V19, P5372, DOI 10.1158/1078-0432.CCR-13-0203
NR 48
TC 0
Z9 0
U1 1
U2 1
PU KOREAN SOC BIOTECHNOLOGY & BIOENGINEERING
PI SEOUL
PA KOREAN SCIENCE TECHNOLOGY CENTER, #704 YEOGSAM-DONG, KANGNAM-KU, SEOUL
   135-703, SOUTH KOREA
SN 1226-8372
EI 1976-3816
J9 BIOTECHNOL BIOPROC E
JI Biotechnol. Bioprocess Eng.
PD OCT
PY 2021
VL 26
IS 5
BP 776
EP 785
DI 10.1007/s12257-021-0002-8
PG 10
WC Biotechnology & Applied Microbiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology
GA WT4KR
UT WOS:000715835300008
DA 2022-04-25
ER

PT J
AU Chen, Z
   Gao, SH
   Wang, DY
   Song, DF
   Feng, Y
AF Chen, Zhi
   Gao, Shuohui
   Wang, Dayv
   Song, Defeng
   Feng, Ye
TI Colorectal cancer cells are resistant to anti-EGFR monoclonal antibody
   through adapted autophagy
SO AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH
LA English
DT Article
DE Colorectal carcinoma (CRC); aEGFR; autophagy; Beclin-1; miR-216b
ID PROSTATE-CANCER; HEPATOCELLULAR-CARCINOMA; SIGNALING PATHWAY; INHIBITS
   GROWTH; MIR-216B; ACTIVATION; CRC; PATHOGENESIS; PROGRESSION; BIOMARKERS
AB The epidermal growth factor receptor (EGFR) signaling plays a key role in the initiation, progression, growth and metastases of colorectal carcinoma (CRC). Monoclonal antibody against EGFR (aEGFR; Cetuximab) has been used in treating CRC but some CRCs appeared to be resistant to aEGFR therapy, with undetermined mechanisms. Here, we studied the effects of aEGFR on CRC cells in vitro. We found that aEGFR dose-dependently activated Beclin-1 in 2 CRC cell lines, HT29 and SW480. Inhibition of autophagy significantly increased the aEGFR-induced CRC cell death in an CCK-8 assay. Moreover, microRNA (miR)-216b levels were significantly downregulated in aEGFR-treated CRC cells. Bioinformatics study showed that miR-216b targeted the 3'-UTR of Beclin-1 mRNA to inhibit its translation, which was confirmed by luciferase reporter assay. Together, these data suggest that aEGFR may decrease miR-216b levels in CRC cells, which subsequently upregulates Beclin-1 to increase CRC cell autophagy to antagonize aEGFR-induced cell death. Strategies that increase miR-216b levels or inhibit cell autophagy may improve the outcome of aEGFR treatment in CRC therapy.
C1 [Chen, Zhi] Jilin Univ, Hosp 1, Dept Nephrol, Changchun 130021, Peoples R China.
   [Gao, Shuohui; Wang, Dayv; Song, Defeng; Feng, Ye] Jilin Univ, China Japan Union Hosp, Dept Gastrointestinal Colorectal & Anal Surg, 126 Xiantai St, Changchun 130033, Peoples R China.
RP Feng, Y (corresponding author), Jilin Univ, China Japan Union Hosp, Dept Gastrointestinal Colorectal & Anal Surg, 126 Xiantai St, Changchun 130033, Peoples R China.
EM Fengye0431@163.com
FU Jilin province Natural Science Foundation of China [20160-101115JC];
   provincal funds for health service of Jilin
FX This study was supported by Jilin province Natural Science Foundation of
   China 20160-101115JC, and the provincal funds for health service of
   Jilin.
CR Chen J, 2015, AM J TRANSL RES, V7, P1510
   Chen YC, 2015, AM J TRANSL RES, V7, P1574
   Coronnello C, 2013, NUCLEIC ACIDS RES, V41, pW159, DOI 10.1093/nar/gkt379
   Dahabreh IJ, 2011, ANN INTERN MED, V154, P37, DOI 10.7326/0003-4819-154-1-201101040-00006
   Dasari A, 2010, CLIN CANCER RES, V16, P3811, DOI 10.1158/1078-0432.CCR-09-2283
   Deng M, 2011, J CELL SCI, V124, P2997, DOI 10.1242/jcs.085050
   Di Leva G, 2013, CURR OPIN GENET DEV, V23, P3, DOI 10.1016/j.gde.2013.01.004
   East JE, 2013, NAT REV GASTRO HEPAT, V10, P69, DOI 10.1038/nrgastro.2012.245
   Farrow JM, 2014, NAT REV UROL, V11, P508, DOI 10.1038/nrurol.2014.196
   Garza-Trevino EN, 2015, CANCER CELL INT, V15, DOI 10.1186/s12935-015-0163-7
   Green DR, 2014, CELL, V157, P65, DOI 10.1016/j.cell.2014.02.049
   Guo JY, 2013, CELL, V155, P1216, DOI 10.1016/j.cell.2013.11.019
   Huang CY, 2015, SCI REP-UK, V5, DOI 10.1038/srep14045
   Jean GW, 2008, PHARMACOTHERAPY, V28, P742, DOI 10.1592/phco.28.6.742
   Jones C, 2013, HPB, V15, P11, DOI 10.1111/j.1477-2574.2012.00591.x
   Kim SY, 2012, BIOCHEM BIOPH RES CO, V429, P173, DOI 10.1016/j.bbrc.2012.10.117
   Labianca R, 2005, ANN ONCOL, V16, P37, DOI 10.1093/annonc/mdi906
   LEIBOVITZ A, 1976, CANCER RES, V36, P4562
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Liu FY, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.46
   Liu G, 2014, TUMOR BIOL, V35, P9801, DOI 10.1007/s13277-014-2273-6
   Mei Q, 2014, CANCER SCI, V105, P755, DOI 10.1111/cas.12436
   Nandi SS, 2015, AM J TRANSL RES, V7, P683
   Patel DK, 2008, PHARMACOTHERAPY, V28, p31S, DOI 10.1592/phco.28.11-supp.31S
   Pereira DM, 2013, DRUG DISCOV TODAY, V18, P282, DOI 10.1016/j.drudis.2012.10.002
   Shi Y, 2013, MOL ENDOCRINOL, V27, P280, DOI 10.1210/me.2012-1260
   Van Schaeybroeck S, 2011, NAT REV CLIN ONCOL, V8, P222, DOI 10.1038/nrclinonc.2011.15
   von Kleist S, 1975, J Natl Cancer Inst, V55, P555
   Wang F, 2014, TUMOR BIOL, V35, P8653, DOI 10.1007/s13277-014-2131-6
   Wang F, 2015, ONCOTARGET, V6, P7899, DOI 10.18632/oncotarget.3219
   White E, 2012, NAT REV CANCER, V12, P401, DOI 10.1038/nrc3262
NR 31
TC 26
Z9 28
U1 0
U2 3
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1943-8141
J9 AM J TRANSL RES
JI Am. J. Transl. Res.
PY 2016
VL 8
IS 2
BP 1190
EP 1196
PG 7
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Research & Experimental Medicine
GA DJ1DR
UT WOS:000373944000082
PM 27158405
DA 2022-04-25
ER

PT J
AU Ren, LW
   Yi, J
   Li, W
   Zheng, XJ
   Liu, JY
   Wang, JH
   Du, GH
AF Ren, Liwen
   Yi, Jie
   Li, Wan
   Zheng, Xiangjin
   Liu, Jinyi
   Wang, Jinhua
   Du, Guanhua
TI Apolipoproteins and cancer
SO CANCER MEDICINE
LA English
DT Review
DE apolipoprotein; autophagy; cancer; drug resistance; oxidative stress
ID INHIBIT TUMOR-DEVELOPMENT; A-I; HEPATOCELLULAR-CARCINOMA; CLUSTERIN
   EXPRESSION; PROSTATE-CANCER; BREAST-CANCER; CLINICAL-SIGNIFICANCE;
   COLORECTAL-CANCER; POOR-PROGNOSIS; OVARIAN-CANCER
AB The role of apolipoproteins in cardiovascular disease has been well investigated, but their participation in cancer has only been explored in a few published studies which showed a close link with certain kinds of cancer. In this review, we focused on the function of different kinds of apolipoproteins in cancers, autophagy, oxidative stress, and drug resistance. The potential application of apolipoproteins as biomarkers for cancer diagnosis and prognosis was highlighted, together with an investigation of their potential as drug targets for cancer treatment. Many important roles of apolipoproteins and their mechanisms in cancers were reviewed in detail and future perspectives of apolipoprotein research were discussed.
C1 [Ren, Liwen; Li, Wan; Zheng, Xiangjin; Liu, Jinyi; Wang, Jinhua; Du, Guanhua] State Key Lab Bioact Subst & Funct Nat Med, Beijing, Peoples R China.
   [Ren, Liwen; Li, Wan; Zheng, Xiangjin; Liu, Jinyi; Wang, Jinhua; Du, Guanhua] Chinese Acad Med Sci, Key Lab Drug Target Res & Drug Screen, Inst Mat Med, Beijing, Peoples R China.
   [Ren, Liwen; Li, Wan; Zheng, Xiangjin; Liu, Jinyi; Wang, Jinhua; Du, Guanhua] Peking Union Med Coll, Beijing, Peoples R China.
   [Yi, Jie] Peking Union Med Coll Hosp, Dept Clin Lab, Beijing, Peoples R China.
RP Wang, JH; Du, GH (corresponding author), Peking Union Med Coll, Beijing, Peoples R China.; Wang, JH; Du, GH (corresponding author), Chinese Acad Med Sci, Inst Mat Med, Beijing, Peoples R China.
EM wjh@imm.ac.cn; dugh@imm.ac.cn
FU Beijing Natural Science FoundationBeijing Natural Science Foundation
   [7172142]; National Natural Science Foundation of ChinaNational Natural
   Science Foundation of China (NSFC) [81573454]; Technology Major Projects
   for "Major New Drugs Innovation and Development"
   [2018ZX09711001-005-025]; CAMS Innovation Fund for Medical Sciences
   [2016-I2M-3-007]
FX Beijing Natural Science Foundation, Grant/Award Number: 7172142;
   National Natural Science Foundation of China, Grant/Award Number:
   81573454; Technology Major Projects for "Major New Drugs Innovation and
   Development", Grant/Award Number: 2018ZX09711001-005-025; CAMS
   Innovation Fund for Medical Sciences, Grant/Award Number: 2016-I2M-3-007
CR Albert JM, 2007, CANCER EPIDEM BIOMAR, V16, P1845, DOI 10.1158/1055-9965.EPI-07-0146
   Bajo-Graneras R, 2013, INT J COLORECTAL DIS, V28, P751, DOI 10.1007/s00384-012-1616-2
   Bertuzzi M, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1058-7
   Bharali D, 2018, INDIAN J MED RES, V147, P361, DOI 10.4103/ijmr.IJMR_1358_16
   BORCHMAN D, 1995, CLIN EXP IMMUNOL, V102, P373
   Calle EE, 2004, ONCOGENE, V23, P6365, DOI 10.1038/sj.onc.1207751
   Cedo L, 2019, J CLIN MED, V8, DOI 10.3390/jcm8060853
   Cedo L, 2016, SCI REP-UK, V6, DOI 10.1038/srep36387
   Chan DC, 2006, QJM-INT J MED, V99, P277, DOI 10.1093/qjmed/hcl027
   Chang SJ, 2007, CLIN CHEM LAB MED, V45, P1219, DOI 10.1515/CCLM.2007.263
   Chen J, 2013, MED ONCOL, V30, DOI 10.1007/s12032-013-0583-y
   Chen QF, 2011, WORLD J SURG ONCOL, V9, DOI 10.1186/1477-7819-9-59
   Chen YC, 2005, CANCER RES, V65, P331
   Chi KN, 2005, J NATL CANCER I, V97, P1287, DOI 10.1093/jnci/dji252
   Chidiac M, 2016, PATHOL RES PRACT, V212, P631, DOI 10.1016/j.prp.2016.04.004
   Christian P, 2013, BBA-MOL CELL BIOL L, V1831, P819, DOI 10.1016/j.bbalip.2012.12.009
   Chu JF, 2018, ONCOL LETT, V16, P2091, DOI 10.3892/ol.2018.8904
   Chun YJ, 2014, J TOXICOL ENV HEAL A, V77, P1443, DOI 10.1080/15287394.2014.951760
   Conlon DM, 2016, J CLIN INVEST, V126, P3852, DOI 10.1172/JCI86028
   Cruz IN, 2017, CANCER GENOM PROTEOM, V14, P35, DOI 10.21873/cgp.20017
   de Bont JM, 2006, CLIN CHEM, V52, P1501, DOI 10.1373/clinchem.2006.069294
   Di Angelantonio E, 2009, JAMA-J AM MED ASSOC, V302, P1993, DOI 10.1001/jama.2009.1619
   Dieplinger H, 2009, CANCER EPIDEM BIOMAR, V18, P1127, DOI 10.1158/1055-9965.EPI-08-0653
   DIEZITZA I, 1994, AM J PATHOL, V144, P310
   Engwegen JYMN, 2008, BIOMARK INSIGHTS, V3, P375
   Fan YX, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-79
   Fulda S, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00128
   Galaris D, 2008, CANCER LETT, V266, P21, DOI 10.1016/j.canlet.2008.02.038
   Ginsberg HN, 2009, J LIPID RES, V50, pS162, DOI 10.1194/jlr.R800090-JLR200
   Gkouskou KK, 2016, ONCOGENE, V35, P2496, DOI 10.1038/onc.2015.307
   Gleave ME, 2001, UROLOGY, V58, P39, DOI 10.1016/S0090-4295(01)01241-9
   Gunawardana CG, 2009, J PROTEOME RES, V8, P4705, DOI 10.1021/pr900411g
   Guo SJ, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000003147
   HACHEM H, 1987, J CLIN CHEM CLIN BIO, V25, P675
   Hall RE, 2004, PROSTATE, V58, P103, DOI 10.1002/pros.10343
   Honda K, 2015, SCI REP-UK, V5, DOI 10.1038/srep15921
   Hu YW, 2015, APOPTOSIS, V20, P1321, DOI 10.1007/s10495-015-1153-x
   Huebbe P, 2017, AGEING RES REV, V37, P146, DOI 10.1016/j.arr.2017.06.002
   Humphries JM, 2014, BBA-PROTEINS PROTEOM, V1844, P1051, DOI 10.1016/j.bbapap.2014.01.018
   Hunter S, 2002, J NEUROPATH EXP NEUR, V61, P275, DOI 10.1093/jnen/61.3.275
   Jiang JT, 2011, ACTA HISTOCHEM, V113, P53, DOI 10.1016/j.acthis.2009.08.005
   Jin JS, 2012, WORLD J SURG ONCOL, V10, DOI 10.1186/1477-7819-10-146
   Jing X, 2010, J CANCER RES CLIN, V136, P1671, DOI 10.1007/s00432-010-0825-8
   Johanneson B, 2010, HUM MOL GENET, V19, P3852, DOI 10.1093/hmg/ddq283
   Kang YK, 2004, HUM PATHOL, V35, P1340, DOI 10.1016/j.humpath.2004.07.021
   Kastelein JJP, 2008, CIRCULATION, V117, P3002, DOI 10.1161/CIRCULATIONAHA.107.713438
   Kim BK, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2247
   Kim YW, 2012, ONCOL REP, V28, P585, DOI 10.3892/or.2012.1829
   Klee EW, 2012, CLIN CHEM, V58, P599, DOI 10.1373/clinchem.2011.171637
   Ko HL, 2014, THORAC CANCER, V5, P500, DOI 10.1111/1759-7714.12117
   Kususda Y, 2012, BRIT J CANCER, V106, P1945, DOI 10.1038/bjc.2012.209
   Lee CH, 2002, UROLOGY, V60, P516, DOI 10.1016/S0090-4295(02)01806-X
   Lee G, 2018, EXP MOL MED, V50, DOI 10.1038/s12276-018-0174-2
   Lee SW, 2012, ELECTROPHORESIS, V33, P1863, DOI 10.1002/elps.201200047
   Levy JMM, 2017, NAT REV CANCER, V17, P528, DOI 10.1038/nrc.2017.53
   Li CY, 2014, BIOCHEM BIOPH RES CO, V446, P1047, DOI 10.1016/j.bbrc.2014.03.053
   Li J, 2012, J INT MED RES, V40, P545, DOI 10.1177/147323001204000216
   Lin XR, 2017, DISCOV MED, V23, P247
   Linden M, 2013, BJU INT, V112, P407, DOI 10.1111/j.1464-410X.2012.11653.x
   Liu M, 2016, MOL CANCER THER, V15, P2955, DOI 10.1158/1535-7163.MCT-15-0961
   Liu Y, 2014, AM J CLIN PATHOL, V141, P52, DOI 10.1309/AJCPBLFBNAP6N2UN
   Liu ZH, 2005, MOL CANCER RES, V3, P21
   Lourda M, 2007, INT J CANCER, V120, P611, DOI 10.1002/ijc.22327
   Luo GH, 2010, LIPIDS HEALTH DIS, V9, DOI 10.1186/1476-511X-9-102
   Luo JM, 2016, TUMOR BIOL, V37, P10715, DOI 10.1007/s13277-016-4975-4
   Luo XL, 2015, ONCOTARGET, V6, P44037, DOI 10.18632/oncotarget.5823
   Lyu NN, 2018, J CANCER RES THER, V14, pS444, DOI 10.4103/0973-1482.181178
   Ma XL, 2016, ONCOTARGET, V7, P70654, DOI 10.18632/oncotarget.12203
   MAHLEY RW, 1984, J LIPID RES, V25, P1277
   Malik G, 2005, CLIN CANCER RES, V11, P1073
   Mandili G, 2018, BIOMARKERS, V23, P123, DOI 10.1080/1354750X.2016.1269132
   Marcil VR, 2002, AM J PHYSIOL-GASTR L, V283, pG340, DOI 10.1152/ajpgi.00440.2001
   Martin P, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-887
   Mathew R, 2007, NAT REV CANCER, V7, P961, DOI 10.1038/nrc2254
   Miranda E, 2003, J SURG ONCOL, V83, P99, DOI 10.1002/jso.10245
   Miyake H, 2002, J UROLOGY, V167, P703, DOI 10.1016/S0022-5347(01)69130-4
   Miyake H, 2006, UROLOGY, V68, P609, DOI 10.1016/j.urology.2006.03.017
   Morry J, 2017, REDOX BIOL, V11, P240, DOI 10.1016/j.redox.2016.12.011
   Mowers EE, 2017, ONCOGENE, V36, P1619, DOI 10.1038/onc.2016.333
   Muramaki M, 2009, BJU INT, V103, P384, DOI 10.1111/j.1464-410X.2008.08098.x
   Nicoll JAR, 2003, NEUROREPORT, V14, P1923, DOI 10.1097/00001756-200310270-00008
   Ogawa K, 2005, INT J ONCOL, V27, P417
   Oue N, 2004, CANCER RES, V64, P2397, DOI 10.1158/0008-5472.CAN-03-3514
   Pan MH, 2008, P NATL ACAD SCI USA, V105, P5862, DOI 10.1073/pnas.0707460104
   Pani G, 2010, CANCER METAST REV, V29, P351, DOI 10.1007/s10555-010-9225-4
   Parcon PA, 2018, ALZHEIMERS DEMENT, V14, P230, DOI 10.1016/j.jalz.2017.07.754
   Park DC, 2006, GYNECOL ONCOL, V103, P996, DOI 10.1016/j.ygyno.2006.06.037
   Pencheva N, 2012, CELL, V151, P1068, DOI 10.1016/j.cell.2012.10.028
   Peng MY, 2017, ONCOTARGET, V8, P99693, DOI 10.18632/oncotarget.21157
   Pucci S, 2004, ONCOGENE, V23, P2298, DOI 10.1038/sj.onc.1207404
   Quan Q, 2017, TRANSL ONCOL, V10, P288, DOI 10.1016/j.tranon.2017.01.006
   Quan Q, 2016, ONCOTARGETS THER, V9, P1281, DOI 10.2147/OTT.S96549
   Radziwon-Balicka A, 2014, CARCINOGENESIS, V35, P324, DOI 10.1093/carcin/bgt332
   Rassart E, 2000, BBA-PROTEIN STRUCT M, V1482, P185, DOI 10.1016/S0167-4838(00)00162-X
   Reddy ST, 2014, CURR OPIN LIPIDOL, V25, P304, DOI 10.1097/MOL.0000000000000092
   Redondo M, 2000, AM J PATHOL, V157, P393, DOI 10.1016/S0002-9440(10)64552-X
   Redondo M, 2010, HISTOPATHOLOGY, V56, P932, DOI 10.1111/j.1365-2559.2010.03565.x
   Ren H, 2019, CANCER MANAG RES, V11, P4917, DOI 10.2147/CMAR.S192529
   Saad F, 2011, CLIN CANCER RES, V17, P5765, DOI 10.1158/1078-0432.CCR-11-0859
   Sakashita K, 2008, ONCOL REP, V20, P1313, DOI 10.3892/or_00000146
   Sandim V, 2016, UROLOGIC ONCOLOGY, V34
   Shang ZH, 2018, CANCER MANAG RES, V10, P1177, DOI 10.2147/CMAR.S165213
   Shapiro B, 2015, ONCOTARGET, V6, P34389, DOI 10.18632/oncotarget.5360
   Shi H, 2018, ONCOTARGETS THER, V11, P6995, DOI 10.2147/OTT.S170227
   Shi J, 2016, YONSEI MED J, V57, P549, DOI 10.3349/ymj.2016.57.3.549
   Soiland H, 2009, ACTA ONCOL, V48, P514, DOI 10.1080/02841860802620613
   Song DJ, 2016, CANCER BIOL THER, V17, P635, DOI 10.1080/15384047.2016.1156262
   Su F, 2012, MOL CANCER THER, V11, P1311, DOI 10.1158/1535-7163.MCT-11-0905
   Su F, 2010, P NATL ACAD SCI USA, V107, P19997, DOI 10.1073/pnas.1009010107
   Su F, 2007, BIOMARK INSIGHTS, V2, P369
   Sui X, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.350
   Sung H, 2019, CA-CANCER J CLIN, V69, P88, DOI 10.3322/caac.21499
   Takano S, 2008, ONCOGENE, V27, P2810, DOI 10.1038/sj.onc.1210951
   Tang Y, 2012, J EXP CLIN CANC RES, V31, DOI 10.1186/1756-9966-31-73
   Tavazoie MF, 2018, CELL, V172, P825, DOI 10.1016/j.cell.2017.12.026
   Tellez T, 2016, CURR MED CHEM, V23, P4297, DOI 10.2174/0929867323666161024150540
   Trost Z, 2008, ARCH MED RES, V39, P663, DOI 10.1016/j.arcmed.2008.06.009
   Trougakos IP, 2002, INT J BIOCHEM CELL B, V34, P1430, DOI 10.1016/S1357-2725(02)00041-9
   Trougakos IP, 2004, CANCER RES, V64, P1834, DOI 10.1158/0008-5472.CAN-03-2664
   Urquidi V, 2012, J UROLOGY, V188, P2377, DOI 10.1016/j.juro.2012.07.094
   Utsunomiya T, 2005, INT J CANCER, V116, P105, DOI 10.1002/ijc.20986
   Van Hemelrijck M, 2011, CANCER CAUSE CONTROL, V22, P1011, DOI 10.1007/s10552-011-9774-z
   Vange P, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0184514
   Vanhollebeke B, 2006, CELL MOL LIFE SCI, V63, P1937, DOI 10.1007/s00018-006-6091-x
   Vazquez J, 2000, GYNECOL ONCOL, V76, P340, DOI 10.1006/gyno.1999.5678
   Venanzoni MC, 2003, INT J ONCOL, V22, P779
   von Zychlinski A, 2014, J PROTEOMICS, V106, P181, DOI 10.1016/j.jprot.2014.04.030
   Wan GH, 2008, J BIOL CHEM, V283, P21540, DOI 10.1074/jbc.M800214200
   Wang BL, 2014, J PHARM SCI-US, V103, P3994, DOI 10.1002/jps.24216
   Wang C, 2012, INT J BIOCHEM CELL B, V44, P2308, DOI 10.1016/j.biocel.2012.09.012
   Wang XS, 2014, UROL INT, V92, P95, DOI 10.1159/000351923
   Wang Y, 2012, J CHEMOTHERAPY, V24, P348, DOI 10.1179/1973947812Y.0000000049
   Xie D, 2005, WORLD J GASTROENTERO, V11, P3285, DOI 10.3748/wjg.v11.i21.3285
   Xiu P, 2014, DIGEST DIS SCI, V59, P1798, DOI 10.1007/s10620-014-3111-9
   Xu XD, 2016, TUMOR BIOL, V37, P15959, DOI 10.1007/s13277-016-5453-8
   Xue A, 2012, BRIT J CANCER, V107, P1883, DOI 10.1038/bjc.2012.458
   Yang GFF, 2009, INT J GYNECOL CANCER, V19, P1342, DOI 10.1111/IGC.0b013e3181a83ed9
   Yang XJ, 2018, LEUKEMIA, V32, P1587, DOI 10.1038/s41375-018-0010-7
   Yang Y, 2009, TECHNOL CANCER RES T, V8, P455, DOI 10.1177/153303460900800607
   Yiu CCP, 2010, EXPERT OPIN INV DRUG, V19, pS79, DOI 10.1517/13543781003701011
   Yokoyama Y, 2006, INT J ONCOL, V28, P625
   Yom CK, 2009, ANTICANCER RES, V29, P3909
   Zamanian-Daryoush M, 2013, J BIOL CHEM, V288, P21237, DOI 10.1074/jbc.M113.468967
   Zellweger T, 2002, CLIN CANCER RES, V8, P3276
   Zhang JJ, 2014, INT J MOL SCI, V15, P16186, DOI 10.3390/ijms150916186
   Zhaorigetu S, 2011, J BIOL CHEM, V286, P27389, DOI 10.1074/jbc.M110.210245
   Zhu YF, 2018, BIOCHEM BIOPH RES CO, V501, P520, DOI 10.1016/j.bbrc.2018.05.029
NR 147
TC 37
Z9 37
U1 3
U2 12
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2045-7634
J9 CANCER MED-US
JI Cancer Med.
PD NOV
PY 2019
VL 8
IS 16
BP 7032
EP 7043
DI 10.1002/cam4.2587
EA OCT 2019
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA JM3TJ
UT WOS:000488691500001
PM 31573738
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Itabashi, M
   Tsukamoto, C
   Kurosaka, A
   Krishnamurthy, P
   Shin, TS
   Yang, SH
   Son, E
   Chung, G
AF Itabashi, Mei
   Tsukamoto, Chigen
   Kurosaka, Ayaka
   Krishnamurthy, Panneerselvam
   Shin, Tai-Sun
   Yang, Seung Hwan
   Son, Eunho
   Chung, Gyuhwa
TI Efficient method for large-scale preparation of two components H and I
   of Sg-6 saponins from whole seeds of wild soybean (Glycine soja Sieb.
   and Zucc.)
SO JOURNAL OF LIQUID CHROMATOGRAPHY & RELATED TECHNOLOGIES
LA English
DT Article
DE Purification; saponins; separation; soybean; triterpene glycosides; wild
   soybean (Glycine soja)
ID COLON-CANCER CELLS; STRUCTURAL ELUCIDATION; SOYASAPONINS;
   MACROAUTOPHAGY; POLYMORPHISM; INHIBITION; INDUCTION; MICE; BB; AB
AB New saponin components, Sg-6 saponins, have been recently reported from the seeds of wild soybean (Glycine soja) which may have specific health benefits. To evaluate the possible health benefits, a large amount of Sg-6 saponins are needed, but general group A acetyl saponins and new Sg-6 saponins are eluted in overlapping peaks by ordinal preparative high-performance liquid chromatography and/or open column methods. A new method is proposed in this report. This method includes (1) deacetylation of group A acetyl saponins in alkali condition with KOH, (2) precipitation of Sg-6 saponins in acid condition with HCl, (3) recovery of Sg-6 saponins with aqueous methanol from the precipitate, and (4) elution of Sg-6 saponins by preparative reverse-phase open column. With this method, from 450g of wild soybean whole seed powder, about 1g of Sg-6 saponins (mixture of six components) was clearly separated from other saponins with 61% recovery.
   [GRAPHICS]
   .
C1 [Itabashi, Mei; Kurosaka, Ayaka; Chung, Gyuhwa] Chonnam Natl Univ, Dept Biomed & Elect Engn, Yeosu 59626, Chonnam, South Korea.
   [Itabashi, Mei; Tsukamoto, Chigen; Kurosaka, Ayaka] Iwate Univ, Fac Agr, Morioka, Iwate, Japan.
   [Krishnamurthy, Panneerselvam] Natl Inst Agrobiol Sci, Soybean Appl Genom Res Unit, Tsukuba, Ibaraki, Japan.
   [Shin, Tai-Sun] Chonnam Natl Univ, Div Food & Nutr, Gwangju, South Korea.
   [Yang, Seung Hwan] Chonnam Natl Univ, Dept Biotechnol, Yeosu, Chonnam, South Korea.
   [Son, Eunho] RDA, Natl Inst Agr Sci, Natl Agrobiodivers Ctr, Jeonju, South Korea.
RP Chung, G (corresponding author), Chonnam Natl Univ, Dept Biomed & Elect Engn, Yeosu 59626, Chonnam, South Korea.
EM chung@chonnam.ac.kr
OI Krishnamurthy, Panneerselvam/0000-0002-9045-430X
FU National Research Foundation of Korea (NRF) - Ministry of Education
   [NRF-2015R1D1A1A09060925]; Revitalization Project for the Creation of
   Fisheries Research and Education Center in Sanriku under Ministry of
   Education, Culture, Sports, Science and Technology of Japan
FX This research was supported by Basic Science Research Program through
   the National Research Foundation of Korea (NRF) funded by the Ministry
   of Education (NRF-2015R1D1A1A09060925) and was partly supported by the
   grant of the Revitalization Project for the Creation of Fisheries
   Research and Education Center in Sanriku under the aegis of the Ministry
   of Education, Culture, Sports, Science and Technology of Japan.
CR Berhow MA, 2000, MUTAT RES-FUND MOL M, V448, P11, DOI 10.1016/S0027-5107(99)00225-0
   Chitisankul WT, 2015, LWT-FOOD SCI TECHNOL, V64, P197, DOI 10.1016/j.lwt.2015.05.023
   Ellington AA, 2006, CARCINOGENESIS, V27, P298, DOI 10.1093/carcin/bgi214
   Ellington AA, 2005, CARCINOGENESIS, V26, P159, DOI 10.1093/carcin/bgh297
   Hirakawa T, 2000, CHEM PHARM BULL, V48, P286, DOI 10.1248/cpb.48.286
   Honda N, 2009, P WORLD SOYB RES C 8
   Hong SW, 2014, J AGR FOOD CHEM, V62, P2062, DOI 10.1021/jf4046528
   Katano H, 2015, ANAL SCI, V31, P85, DOI 10.2116/analsci.31.85
   Krishnamurthy P, 2014, BIOSCI BIOTECH BIOCH, V78, P1988, DOI 10.1080/09168451.2014.946389
   Krishnamurthy P, 2014, GENET RESOUR CROP EV, V61, P1121, DOI 10.1007/s10722-014-0095-4
   Krishnamurthy P, 2014, EUPHYTICA, V198, P413, DOI 10.1007/s10681-014-1118-0
   KUDOU S, 1992, BIOSCI BIOTECH BIOCH, V56, P142, DOI 10.1271/bbb.56.142
   KUDOU S, 1993, BIOSCI BIOTECH BIOCH, V57, P546, DOI 10.1271/bbb.57.546
   OKUBO K, 1992, BIOSCI BIOTECH BIOCH, V56, P99, DOI 10.1271/bbb.56.99
   TAKESHITA T, 1991, CHEM PHARM BULL, V39, P1908, DOI 10.1248/cpb.39.1908
   TSUKAMOTO C, 1993, PHYTOCHEMISTRY, V34, P1351, DOI 10.1016/0031-9422(91)80028-Y
   Tsukamoto C., 2005, SOY HLTH DIS PREVENT
   Wang P, 2016, CHEM RES TOXICOL, V29, P406, DOI 10.1021/acs.chemrestox.5b00516
   Yang SH, 2015, PHYTOTHER RES, V29, P281, DOI 10.1002/ptr.5252
   YOSHIKI Y, 1995, BIOSCI BIOTECH BIOCH, V59, P1556, DOI 10.1271/bbb.59.1556
NR 20
TC 2
Z9 3
U1 0
U2 1
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1082-6076
EI 1520-572X
J9 J LIQ CHROMATOGR R T
JI J. Liq. Chromatogr. Relat. Technol.
PY 2016
VL 39
IS 14
BP 640
EP 646
DI 10.1080/10826076.2016.1227991
PG 7
WC Biochemical Research Methods; Chemistry, Analytical
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA EA8NH
UT WOS:000386891700002
DA 2022-04-25
ER

PT J
AU Ono, A
   Sano, O
   Kazetani, K
   Muraki, T
   Imamura, K
   Sumi, H
   Matsui, J
   Iwata, H
AF Ono, Akito
   Sano, Osamu
   Kazetani, Ken-ichi
   Muraki, Takamichi
   Imamura, Keisuke
   Sumi, Hiroyuki
   Matsui, Junji
   Iwata, Hidehisa
TI Feedback activation of AMPK-mediated autophagy acceleration is a key
   resistance mechanism against SCD1 inhibitor-induced cell growth
   inhibition
SO PLOS ONE
LA English
DT Article
ID COA DESATURASE 1; IN-VITRO; HETEROGENEITY; CARBOXYLASE; LIPOGENESIS;
   EVOLUTION; DISCOVERY; CARCINOMA; TARGET; TUMORS
AB Elucidating the bioactive compound modes of action is crucial for increasing success rates in drug development. For anticancer drugs, defining effective drug combinations that overcome resistance improves therapeutic efficacy. Herein, by using a biologically annotated compound library, we performed a large-scale combination screening with Stearoyl-CoA desaturase-1 (SCD1) inhibitor, T-3764518, which partially inhibits colorectal cancer cell proliferation. T-3764518 induced phosphorylation and activation of AMPK in HCT-116 cells, which led to blockade of downstream fatty acid synthesis and acceleration of autophagy. Attenuation of fatty acid synthesis by small molecules suppressed the growth inhibitory effect of T-3764518. In contrast, combination of T-3764518 with autophagy flux inhibitors synergistically inhibited cellular proliferation. Experiments using SCD1 knock-out cells validated the results obtained with T-3764518. The results of our study indicated that activation of autophagy serves as a survival signal when SCD1 is inhibited in HCT-116 cells. Furthermore, these findings suggest that combining SCD1 inhibitor with autophagy inhibitors is a promising anticancer therapy.
C1 [Ono, Akito; Sano, Osamu; Kazetani, Ken-ichi; Muraki, Takamichi; Matsui, Junji; Iwata, Hidehisa] Takeda Pharmaceut Co Ltd, Pharmaceut Res Div, Biomol Res Labs, Fujisawa, Kanagawa, Japan.
   [Imamura, Keisuke; Sumi, Hiroyuki] Takeda Pharmaceut Co Ltd, Pharmaceut Res Div, Oncol Drug Discovery Unit, Fujisawa, Kanagawa, Japan.
   [Sumi, Hiroyuki] Celgene KK, Med Affairs, Med Sci, Tokyo, Japan.
RP Iwata, H (corresponding author), Takeda Pharmaceut Co Ltd, Pharmaceut Res Div, Biomol Res Labs, Fujisawa, Kanagawa, Japan.
EM hidehisa.iwata@takeda.com
RI Iwata, Hidehisa/K-7493-2019
OI Iwata, Hidehisa/0000-0002-0950-6388
FU Takeda Pharmaceutical Company LimitedTakeda Pharmaceutical Company Ltd
FX This study was financially supported by Takeda Pharmaceutical Company
   Limited. Employees of Takeda played roles in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Barth S, 2010, J PATHOL, V221, P117, DOI 10.1002/path.2694
   Baselga J, 2015, CLIN CANCER RES, V21, pS1, DOI 10.1158/1078-0432.CCR-15-1846
   Burrell RA, 2014, MOL ONCOL, V8, P1095, DOI 10.1016/j.molonc.2014.06.005
   Cassidy S, 2016, NAT REV DRUG DISCOV, V15, P527, DOI 10.1038/nrd.2016.140
   Cong L, 2013, SCIENCE, V339, P819, DOI 10.1126/science.1231143
   Deans RM, 2016, NAT CHEM BIOL, V12, P361, DOI [10.1038/NCHEMBIO.2050, 10.1038/nchembio.2050]
   Dobrzyn P, 2004, P NATL ACAD SCI USA, V101, P6409, DOI 10.1073/pnas.0401627101
   Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107
   Fong PC, 2009, NEW ENGL J MED, V361, P123, DOI 10.1056/NEJMoa0900212
   Fukuda Y, 2016, BMC BIOCHEM, V17, DOI 10.1186/s12858-016-0066-9
   Garrido-Laguna I, 2011, NAT REV CLIN ONCOL, V8, P562, DOI 10.1038/nrclinonc.2011.113
   Gerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205
   Griner LAM, 2014, P NATL ACAD SCI USA, V111, P2349, DOI 10.1073/pnas.1311846111
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Hess D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011394
   Huang GM, 2015, CANCER LETT, V358, P180, DOI 10.1016/j.canlet.2014.12.036
   Hutchinson L, 2011, NAT REV CLIN ONCOL, V8, P189, DOI [10.1038/nrclinonc.2011.34, 10.1038/nrclinonc.2010.204]
   Imamura K, 2017, BIOORGAN MED CHEM, V25, P3768, DOI 10.1016/j.bmc.2017.05.016
   Jones LH, 2017, NAT REV DRUG DISCOV
   Kamata M, 2012, BIOORG MED CHEM LETT, V22, P3643, DOI 10.1016/j.bmcl.2012.04.047
   Kim E, 2011, EUR J PHARMACOL, V672, P38, DOI 10.1016/j.ejphar.2011.09.172
   Kim J, 2011, NAT CELL BIOL, V13, P132, DOI 10.1038/ncb2152
   Liu J, 2013, P NATL ACAD SCI USA, V110, P18832, DOI 10.1073/pnas.1309469110
   Liu Y, 2014, MOL BIOSYST, V10, P251, DOI 10.1039/c3mb70413k
   Luyimbazi D, 2010, MOL CANCER THER, V9, P2770, DOI 10.1158/1535-7163.MCT-09-0980
   Martinez-Outschoorn UE, 2017, NAT REV CLIN ONCOL, V14, P11, DOI 10.1038/nrclinonc.2016.60
   Mason P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033823
   Mounier C, 2014, INT J ONCOL, V45, P485, DOI 10.3892/ijo.2014.2441
   Nijman SMB, 2015, NAT CHEM BIOL, V11, P942, DOI 10.1038/nchembio.1963
   Nijman SMB, 2013, SCIENCE, V342, P809, DOI 10.1126/science.1244669
   Nishizawa S, 2017, EUR J PHARMACOL, V807, P21, DOI 10.1016/j.ejphar.2017.03.064
   Ogasawara Y, 2014, J BIOL CHEM, V289, P23938, DOI 10.1074/jbc.M114.591065
   Paddison PJ, 2002, GENE DEV, V16, P948, DOI 10.1101/gad.981002
   Polyakov VR, 2014, J CHEM INF MODEL, V54, P377, DOI 10.1021/ci400245c
   Rangwala R, 2014, AUTOPHAGY, V10, P1391, DOI 10.4161/auto.29119
   Sano O, 2017, FEBS OPEN BIO
   Sano O, 2016, FEBS LETT, V590, P1576, DOI 10.1002/1873-3468.12195
   Scaglia N, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006812
   Severyn B, 2011, ACS CHEM BIOL, V6, P1391, DOI 10.1021/cb2003225
   Tan SH, 2014, AUTOPHAGY, V10, P226, DOI 10.4161/auto.27003
   Uitdehaag JCM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125021
   von Roemeling CA, 2015, J CLIN ENDOCR METAB, V100, pE697, DOI 10.1210/jc.2014-2764
   von Roemeling CA, 2013, CLIN CANCER RES, V19, P2368, DOI 10.1158/1078-0432.CCR-12-3249
   Wallin JJ, 2012, CLIN CANCER RES, V18, P3901, DOI 10.1158/1078-0432.CCR-11-2088
   Wassermann AM, 2014, FRONT PHARMACOL, V5, DOI 10.3389/fphar.2014.00164
   Zhao W, 2014, J BIOMOL SCREEN, V19, P817, DOI 10.1177/1087057114521867
NR 46
TC 7
Z9 7
U1 1
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 13
PY 2017
VL 12
IS 7
AR e0181243
DI 10.1371/journal.pone.0181243
PG 17
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA FA7TL
UT WOS:000405649700115
PM 28704514
OA Green Published, Green Submitted, gold
DA 2022-04-25
ER

PT J
AU Yu, XF
   Shi, WN
   Zhang, YH
   Wang, XH
   Sun, SY
   Song, ZY
   Liu, M
   Zeng, Q
   Cui, SX
   Qu, XJ
AF Yu, Xinfeng
   Shi, Wenna
   Zhang, Yuhang
   Wang, Xiaohui
   Sun, Shiyue
   Song, Zhiyu
   Liu, Man
   Zeng, Qiao
   Cui, Shuxiang
   Qu, Xianjun
TI CXCL12/CXCR4 axis induced miR-125b promotes invasion and confers
   5-fluorouracil resistance through enhancing autophagy in colorectal
   cancer
SO SCIENTIFIC REPORTS
LA English
DT Article
ID EPITHELIAL-MESENCHYMAL TRANSITION; STEM-CELLS; BREAST-CANCER; CHEMOKINE
   RECEPTORS; TUMOR-SUPPRESSOR; BAK1 EXPRESSION; MICRORNAS; METASTASIS;
   CXCR4; CARCINOMA
AB The activation of CXCL12/CXCR4 axis is associated with potential progression of cancer, such as invasion, metastasis and chemoresistance. However, the underlying mechanisms of CXCL12/CXCR4 axis and cancer progression have been poorly explored. We hypothesized that miRNAs might be critical downstream mediators of CXCL12/CXCR4 axis involved in cancer invasion and chemoresistance in CRC. In human CRC cells, we found that the activation of CXCL12/CXCR4 axis promoted epithelialmesenchymal transition (EMT) and concurrent upregulation of miR-125b. Overexpression of miR-125b robustly triggered EMT and cancer invasion, which in turn enhanced the expression of CXCR4. Importantly, the reciprocal positive feedback loop between CXCR4 and miR-125b further activated the Wnt/beta-catenin signaling by targeting Adenomatous polyposis coli (APC) gene. There was a negative correlation of the expression of miR-125b with APC mRNA in paired human colorectal tissue specimens. Further experiments indicated a role of miR-125b in conferring 5-fluorouracil (5-FU) resistance in CRC probably through increasing autophagy both in vitro and in vivo. MiR-125b functions as an important downstream mediator upon the activation of CXCL12/CXCR4 axis that involved in EMT, invasion and 5-FU resistance of CRC. These findings shed a new insight into the role of miR-125b and provide a potential therapeutic target in CRC.
C1 [Yu, Xinfeng; Shi, Wenna; Zhang, Yuhang; Sun, Shiyue; Song, Zhiyu; Liu, Man; Zeng, Qiao; Qu, Xianjun] Capital Med Univ, Sch Basic Med Sci, Dept Pharmacol, Beijing, Peoples R China.
   [Wang, Xiaohui] Capital Med Univ, Xuan Wu Hosp, Dept Gen Surg, Beijing, Peoples R China.
   [Cui, Shuxiang] Capital Med Univ, Sch Publ Hlth, Dept Toxicol & Sanit Chem, Beijing Key Lab Environm Toxicol, Beijing, Peoples R China.
RP Qu, XJ (corresponding author), Capital Med Univ, Sch Basic Med Sci, Dept Pharmacol, Beijing, Peoples R China.
EM quxj@ccmu.edu.cn
OI Wang, Xiaohui/0000-0002-2299-3977
FU National Natural Science FoundationNational Natural Science Foundation
   of China (NSFC) [81201731, 81373435/6, 91229113]; Beijing Natural
   Science FoundationBeijing Natural Science Foundation [7162024, 7142017];
   Basic and Clinical grants of Capital Medical University [16JL56]
FX This study was supported by grants from the National Natural Science
   Foundation (81201731, 81373435/6 and 91229113), Beijing Natural Science
   Foundation (7162024, 7142017) and Basic and Clinical grants of Capital
   Medical University (16JL56). We thank Shandong Tumor Hospital for
   providing human colonic cancer tissues.
CR Amir S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061064
   Baek D, 2008, NATURE, V455, P64, DOI 10.1038/nature07242
   Brabletz T, 2005, CELLS TISSUES ORGANS, V179, P56, DOI 10.1159/000084509
   Bracken CP, 2009, CELL MOL LIFE SCI, V66, P1682, DOI 10.1007/s00018-009-8750-1
   Chen Y, 2013, J CLIN INVEST, V123, P2395, DOI 10.1172/JCI66553
   Chi YD, 2016, J EXP CLIN CANC RES, V35, DOI 10.1186/s13046-016-0320-4
   Cojoc Monica, 2013, Onco Targets Ther, V6, P1347, DOI 10.2147/OTT.S36109
   Croker AK, 2008, J CELL MOL MED, V12, P374, DOI 10.1111/j.1582-4934.2007.00211.x
   Gao J, 2015, ONCOGENE, V34, P4142, DOI 10.1038/onc.2014.348
   Gargalionis AN, 2014, CURR PHARM BIOTECHNO, V15, P468, DOI 10.2174/1389201015666140519123609
   Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010
   Jiang FZ, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-425
   Le MTN, 2009, GENE DEV, V23, P862, DOI 10.1101/gad.1767609
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Longley DB, 2003, NAT REV CANCER, V3, P330, DOI 10.1038/nrc1074
   Manfe V, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059390
   Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027
   Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016
   Nishida N, 2011, INT J ONCOL, V38, P1437, DOI 10.3892/ijo.2011.969
   Nordlinger B, 2002, J CLIN ONCOL, V20, P1442, DOI 10.1200/JCO.2002.20.6.1442
   Polakis P, 2000, GENE DEV, V14, P1837
   Ramsey DM, 2013, BIOORG MED CHEM LETT, V23, P20, DOI 10.1016/j.bmcl.2012.10.138
   Rhodes LV, 2011, EXP CELL RES, V317, P2573, DOI 10.1016/j.yexcr.2011.08.016
   Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384
   Scheel C, 2012, SEMIN CANCER BIOL, V22, P396, DOI 10.1016/j.semcancer.2012.04.001
   Schimanski CC, 2005, CLIN CANCER RES, V11, P1743, DOI 10.1158/1078-0432.CCR-04-1195
   Shi XB, 2007, P NATL ACAD SCI USA, V104, P19983, DOI 10.1073/pnas.0706641104
   Sun XQ, 2010, CANCER METAST REV, V29, P709, DOI 10.1007/s10555-010-9256-x
   Svoronos AA, 2016, CANCER RES, V76, P3666, DOI 10.1158/0008-5472.CAN-16-0359
   Tang F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035435
   Vermeulen L, 2014, NAT REV CANCER, V14, P468, DOI 10.1038/nrc3744
   Vermeulen L, 2010, NAT CELL BIOL, V12, P468, DOI 10.1038/ncb2048
   Vilquin P, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0515-1
   Wu SB, 2013, BIOCHEM BIOPH RES CO, V434, P898, DOI 10.1016/j.bbrc.2013.04.053
   Xia HF, 2009, CELL PHYSIOL BIOCHEM, V23, P347, DOI 10.1159/000218181
   Yang HZ, 2015, CANCER LETT, V361, P128, DOI 10.1016/j.canlet.2015.02.045
   Ye JJ, 2014, WORLD J GASTROENTERO, V20, P4288, DOI 10.3748/wjg.v20.i15.4288
   Zeelenberg IS, 2003, CANCER RES, V63, P3833
   Zhou M, 2010, J BIOL CHEM, V285, P21496, DOI 10.1074/jbc.M109.083337
NR 39
TC 69
Z9 72
U1 2
U2 18
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD FEB 8
PY 2017
VL 7
AR 42226
DI 10.1038/srep42226
PG 13
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA EJ9VN
UT WOS:000393575300001
PM 28176874
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Pagliero, RJ
   D'Astolfo, DS
   Lelieveld, D
   Pratiwi, RD
   Aits, S
   Jaattela, M
   Martin, NI
   Klumperman, J
   Egan, DA
AF Pagliero, Romina J.
   D'Astolfo, Diego S.
   Lelieveld, Daphne
   Pratiwi, Riyona D.
   Aits, Sonja
   Jaattela, Marja
   Martin, Nathaniel I.
   Klumperman, Judith
   Egan, David A.
TI Discovery of Small Molecules That Induce Lysosomal Cell Death in Cancer
   Cell Lines Using an Image-Based Screening Platform
SO ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES
LA English
DT Article
DE lysosomal cell dead; galectin-3 reporter; LMP phenotypic assay; high
   throughput screening
ID ACID SPHINGOMYELINASE; MEMBRANE PERMEABILIZATION; FUNCTIONAL INHIBITORS;
   CYSTEINE CATHEPSINS; OXIDATIVE STRESS; BREAST-CANCER; COLON-CANCER;
   LUNG-CANCER; APOPTOSIS; AUTOPHAGY
AB The lysosomal cell death (LCD) pathway is a caspase 3-independent cell death pathway that has been suggested as a possible target for cancer therapy, making the development of sensitive and specific high-throughput (HT) assays to identify LCD inducers highly desirable. In this study, we report a two-step HT screening platform to reliably identify such molecules. First, using a robust HT primary screen based on propidium iodide uptake, we identified compounds that kill through nonapoptotic pathways. A phenotypic image-based assay using a galectin-3 (Gal-3) reporter was then used to further classify hits based on lysosomal permeabilization, a hallmark of LCD. The identification of permeabilized lysosomes in our image-based assay is not affected by changes in the lysosomal pH, thus resolving an important limitation in currently used methods. We have validated our platform in a screen by identifying 24 LCD inducers, some previously known to induce LCD. Although most LCD inducers were cationic amphiphilic drugs (CADs), we have also identified a non-CAD LCD inducer, which is of great interest in the field. Our data also gave new insights into the biology of LCD, suggesting that lysosomal accumulation and acid sphingomyelinase inhibition are not sufficient or necessary for the induction of LCD. Overall, our results demonstrate a robust HT platform to identify novel LCD inducers that will also be very useful for gaining deeper insights into the molecular mechanism of LCD induction.
C1 [Pagliero, Romina J.; D'Astolfo, Diego S.; Lelieveld, Daphne; Pratiwi, Riyona D.; Klumperman, Judith; Egan, David A.] UMCU, Dept Cell Biol, Heidelberglaan 100,Room H02-313, NL-3584 CX Utrecht, Netherlands.
   [D'Astolfo, Diego S.] KNAW Hubrecht Inst, Utrecht, Netherlands.
   [Aits, Sonja; Jaattela, Marja] Danish Canc Soc, Res Ctr, Ctr Autophagy Recycling & Dis, Cell Death & Metab Unit, Copenhagen, Denmark.
   [Martin, Nathaniel I.] Univ Utrecht, UIPS, Dept Chem Biol & Drug Discovery, Utrecht, Netherlands.
   [Pagliero, Romina J.] Genmab BV, Utrecht, Netherlands.
RP Egan, DA (corresponding author), UMCU, Dept Cell Biol, Heidelberglaan 100,Room H02-313, NL-3584 CX Utrecht, Netherlands.
EM d.a.egan@umcutrecht.nl
RI Jäättelä, Marja/AAT-7932-2021; Aits, Sonja/D-1496-2011
OI Jäättelä, Marja/0000-0001-5950-7111; Aits, Sonja/0000-0002-1321-0678;
   Pratiwi, Riyona Desvy/0000-0003-3313-9909
FU UMCU; European Research CouncilEuropean Research Council (ERC)European
   Commission [AdG340751]; Danish National Research FoundationDanmarks
   Grundforskningsfond [DNRF125]; Danish Cancer SocietyDanish Cancer
   Society; Swedish Research CouncilSwedish Research CouncilEuropean
   Commission; The Danish Cancer SocietyDanish Cancer Society [R90-A5783]
   Funding Source: researchfish
FX The authors thank Dr. Harald Wodrich (Laboratoire de Microbiologie
   Fondamentale et Pathogenicite, Bordeaux, France) for kindly providing
   the U2OS-mCherry-Gal3 cells. This work was funded in part by the UMCU,
   the European Research Council (AdG340751), the Danish National Research
   Foundation (DNRF125), the Danish Cancer Society, the Swedish Research
   Council.
CR Aits S, 2015, AUTOPHAGY, V11, P1408, DOI 10.1080/15548627.2015.1063871
   Aits S, 2015, METHOD CELL BIOL, V126, P261, DOI 10.1016/bs.mcb.2014.10.032
   Aits S, 2013, J CELL SCI, V126, P1905, DOI 10.1242/jcs.091181
   Antunes F, 2001, BIOCHEM J, V356, P549, DOI 10.1042/0264-6021:3560549
   Appelqvist H, 2013, J MOL CELL BIOL, V5, P214, DOI 10.1093/jmcb/mjt022
   Brown JM, 2005, NAT REV CANCER, V5, P231, DOI 10.1038/nrc1560
   Buenz EJ, 2007, CYTOM PART A, V71A, P170, DOI 10.1002/cyto.a.20376
   Carpenter AE, 2007, NAT CHEM BIOL, V3, P461, DOI 10.1038/nchembio.2007.15
   Cesen MH, 2012, EXP CELL RES, V318, P1245, DOI 10.1016/j.yexcr.2012.03.005
   D'Anneo A, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.415
   D'Astolfo DS, 2015, CELL, V161, P674, DOI 10.1016/j.cell.2015.03.028
   DEDUVE C, 1983, EUR J BIOCHEM, V137, P391, DOI 10.1111/j.1432-1033.1983.tb07841.x
   DeStafanis D, 1997, CELL TISSUE RES, V289, P109
   Edwards B. S., 2007, CURR PROTOC CYTOM, V9, P24
   Ellegaard AM, 2013, MOL CANCER THER, V12, P2018, DOI 10.1158/1535-7163.MCT-13-0084
   Fehrenbacher N, 2005, CANCER RES, V65, P2993, DOI 10.1158/0008-5472.CAN-05-0476
   Fehrenbacher N, 2004, CANCER RES, V64, P5301, DOI 10.1158/0008-5472.CAN-04-1427
   Fehrenbacher N, 2008, CANCER RES, V68, P6623, DOI 10.1158/0008-5472.CAN-08-0463
   Feng J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111809
   Feng Y, 2009, NAT REV DRUG DISCOV, V8, P567, DOI 10.1038/nrd2876
   Freeman D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062143
   Ghantous A, 2010, DRUG DISCOV TODAY, V15, P668, DOI 10.1016/j.drudis.2010.06.002
   Groth-Pedersen L, 2007, CANCER RES, V67, P2217, DOI 10.1158/0008-5472.CAN-06-3520
   Groth-Pedersen L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045381
   Groth-Pedersen L, 2013, CANCER LETT, V332, P265, DOI 10.1016/j.canlet.2010.05.021
   Guicciardi ME, 2004, ONCOGENE, V23, P2881, DOI 10.1038/sj.onc.1207512
   Hwang JJ, 2010, BIOMETALS, V23, P997, DOI 10.1007/s10534-010-9346-9
   Jaattela M, 2004, ONCOGENE, V23, P2746, DOI 10.1038/sj.onc.1207513
   Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357
   Kallunki T, 2013, ONCOGENE, V32, P1995, DOI 10.1038/onc.2012.292
   Kim LA, 2014, INVEST OPHTH VIS SCI, V55, P4747, DOI 10.1167/iovs.13-13662
   Kim SL, 2015, ONCOL LETT, V9, P2135, DOI 10.3892/ol.2015.3017
   Kirkegaard T, 2009, BBA-MOL CELL RES, V1793, P746, DOI 10.1016/j.bbamcr.2008.09.008
   Kornhuber J, 2008, J MED CHEM, V51, P219, DOI 10.1021/jm070524a
   Kornhuber J, 2010, CELL PHYSIOL BIOCHEM, V26, P9, DOI 10.1159/000315101
   Kroemer G, 2005, NAT REV CANCER, V5, P886, DOI 10.1038/nrc1738
   Lemieux B, 2004, ANAL BIOCHEM, V327, P247, DOI 10.1016/j.ab.2004.01.010
   Luzio JP, 2007, NAT REV MOL CELL BIO, V8, P622, DOI 10.1038/nrm2217
   Maejima I, 2013, EMBO J, V32, P2336, DOI 10.1038/emboj.2013.171
   Maier O, 2012, J VIROL, V86, P10821, DOI 10.1128/JVI.01428-12
   Mohamed MM, 2006, NAT REV CANCER, V6, P764, DOI 10.1038/nrc1949
   MORIYAMA Y, 1982, J BIOCHEM-TOKYO, V92, P1333, DOI 10.1093/oxfordjournals.jbchem.a134053
   Mrschtik M, 2015, FEBS J, V282, P1858, DOI 10.1111/febs.13253
   Nadanaciva S, 2011, TOXICOL IN VITRO, V25, P715, DOI 10.1016/j.tiv.2010.12.010
   Kreuger MRO, 2012, ANTI-CANCER DRUG, V23, P883, DOI 10.1097/CAD.0b013e328356cad9
   Ostenfeld MS, 2008, AUTOPHAGY, V4, P487, DOI 10.4161/auto.5774
   Ostenfeld MS, 2005, CANCER RES, V65, P8975, DOI 10.1158/0008-5472.CAN-05-0269
   Paz I, 2010, CELL MICROBIOL, V12, P530, DOI 10.1111/j.1462-5822.2009.01415.x
   PERREGAARD J, 1995, J MED CHEM, V38, P1998, DOI 10.1021/jm00011a019
   Petersen NHT, 2013, CANCER CELL, V24, P379, DOI 10.1016/j.ccr.2013.08.003
   Reinheckel T, 2001, BIOL CHEM, V382, P735, DOI 10.1515/BC.2001.089
   Sommer M, 2004, US patent, Patent No. [WO 2004/026855 A1, 2004026855]
   Stoka V, 2007, BIOL CHEM, V388, P555, DOI 10.1515/BC.2007.064
   Sukhai MA, 2013, J CLIN INVEST, V123, P315, DOI 10.1172/JCI64180
   Thurston TLM, 2012, NATURE, V482, P414, DOI 10.1038/nature10744
   Tiuman TS, 2005, ANTIMICROB AGENTS CH, V49, P176, DOI 10.1128/AAC.49.11.176-182.2005
   Varma H, 2013, EXP CELL RES, V319, P1759, DOI 10.1016/j.yexcr.2013.03.019
   Wyrebska A, 2014, MINI-REV MED CHEM, V14, P222, DOI 10.2174/1389557514666140219113509
   Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129
   Zhang JH, 1999, J BIOMOL SCREEN, V4, P67, DOI 10.1177/108705719900400206
   Zong D, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.56
   Zong D, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.62
NR 62
TC 10
Z9 12
U1 1
U2 13
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1540-658X
EI 1557-8127
J9 ASSAY DRUG DEV TECHN
JI ASSAY DRUG DEV. TECHNOL.
PD OCT
PY 2016
VL 14
IS 8
SI SI
BP 489
EP 510
DI 10.1089/adt.2016.727
PG 22
WC Biochemical Research Methods; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
GA DZ8MX
UT WOS:000386125600006
PM 27732064
OA Green Accepted
DA 2022-04-25
ER

PT J
AU Zhang, FF
   Yang, QX
   Meng, FJ
   Shi, HJ
   Li, H
   Liang, YJ
   Han, AJ
AF Zhang, Fenfen
   Yang, Qingxu
   Meng, Fengjiao
   Shi, Huijuan
   Li, Hui
   Liang, Yingjie
   Han, Anjia
TI Astrocyte Elevated Gene-1 Interacts With beta-Catenin and Increases
   Migration and Invasion of Colorectal Carcinoma
SO MOLECULAR CARCINOGENESIS
LA English
DT Article
DE astrocyte elevated gene-1; -catenin; colorectal carcinoma; migration;
   invasion
ID X-RECEPTOR-ALPHA; PROTECTIVE AUTOPHAGY; CANCER PROGRESSION; TUMOR
   PROGRESSION; BREAST-CANCER; METASTASIS; AEG-1; TRANSCRIPTION;
   PATHOGENESIS; SUPPRESSION
AB To investigate the astrocyte elevated gene-1 (AEG-1) expression and its relationship with the clinicopathological features of colorectal carcinoma (CRC) and -catenin signaling pathway. Real-time PCR, Western blot, immunohistochemistry, and immunofluorescence staining were performed to detect AEG-1 expression in CRC cell lines, 8 pairs of fresh CRC and adjacent nontumor tissues (ANT), 120 pairs of paraffin-embedded CRC specimens and ANT tissues, and 60 samples of lymph node metastatic CRC tissues. Scratch wound assay and transwell matrix penetration assay were performed to determine migration and invasion of SW480 cell lines with stable AEG-1 overexpression or SW620 cell lines with AEG-1 knockdown. AEG-1 expression was upregulated in CRC cell lines and tissues compared with ANT. Furthermore, AEG-1 expression level significantly correlated with UICC stage, and the N classification. AEG-1 overexpression significantly enhanced migration and invasion of SW480 cell lines. However, AEG-1 knockdown suppressed migration and invasion of SW620 cell lines. Meanwhile, there was a positive correlation between AEG-1 high expression and -catenin nuclear expression in CRC. AEG-1 overexpression increased nuclear -catenin accumulation in CRC cell lines. AEG-1 knockdown decreased nuclear -catenin accumulation in CRC cell lines. Moreover, we firstly found that AEG-1 interacted with -catenin in SW480 cell lines. Our results for the first time showed that AEG-1 interacted with -catenin in CRC cells and AEG-1 expression was closely associated with progression of CRC. AEG-1 might be a potential therapeutic target in CRC. (c) 2012 Wiley Periodicals, Inc.
C1 [Zhang, Fenfen; Meng, Fengjiao; Shi, Huijuan; Li, Hui; Liang, Yingjie; Han, Anjia] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Pathol, Guangzhou 510080, Guangdong, Peoples R China.
   [Zhang, Fenfen; Meng, Fengjiao; Shi, Huijuan; Li, Hui; Liang, Yingjie; Han, Anjia] Sun Yat Sen Univ, Zhongshan Sch Med, Guangzhou 510080, Guangdong, Peoples R China.
   [Yang, Qingxu] Huizhou Municipal Cent Hosp, Dept Pathol, Huizhou, Peoples R China.
RP Han, AJ (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 1, Dept Pathol, 58,Zhongshan Rd 2, Guangzhou 510080, Guangdong, Peoples R China.
FU Guangdong Province Natural Science FoundationNational Natural Science
   Foundation of Guangdong Province [8151008901000125, S2011010004853]
FX We would like to thank Dr. Mengfeng Li, Jun Li, and Jueheng Wu for
   technical and reagent assistance. This study was supported by Guangdong
   Province Natural Science Foundation (8151008901000125; S2011010004853).
CR Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0
   Bhutia SK, 2011, AUTOPHAGY, V7, P547, DOI 10.4161/auto.7.5.15078
   Bhutia SK, 2010, P NATL ACAD SCI USA, V107, P22243, DOI 10.1073/pnas.1009479107
   Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018
   Emdad L, 2006, CANCER RES, V66, P1509, DOI 10.1158/0008-5472.CAN-05-3029
   Emdad L, 2007, PHARMACOL THERAPEUT, V114, P155, DOI 10.1016/j.pharmthera.2007.01.010
   Emdad L, 2009, P NATL ACAD SCI USA, V106, P21300, DOI 10.1073/pnas.0910936106
   Han AJ, 2008, CANCER BIOL THER, V7, P454, DOI 10.4161/cbt.7.3.5455
   Hu GH, 2009, CLIN CANCER RES, V15, P5615, DOI 10.1158/1078-0432.CCR-09-0049
   Kang DC, 2005, GENE, V353, P8, DOI [10.1016/j.gene.2005.04.006, 10.1016/j.gene.2005.04.005]
   Kang DW, 2011, CANCER RES, V71, P293, DOI 10.1158/0008-5472.CAN-10-2463
   Kang DW, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012109
   Kikuno N, 2007, ONCOGENE, V26, P7647, DOI 10.1038/sj.onc.1210572
   Lee SG, 2008, ONCOGENE, V27, P1114, DOI 10.1038/sj.onc.1210713
   Lee SG, 2009, ONCOGENE, V28, P2476, DOI 10.1038/onc.2009.93
   Li J, 2009, ONCOGENE, V28, P3188, DOI 10.1038/onc.2009.171
   Li J, 2008, CLIN CANCER RES, V14, P3319, DOI 10.1158/1078-0432.CCR-07-4054
   Liu LP, 2010, CANCER RES, V70, P3750, DOI 10.1158/0008-5472.CAN-09-3838
   Maruyama K, 2000, ONCOLOGY-BASEL, V59, P302, DOI 10.1159/000012187
   Sarkar D, 2008, CANCER RES, V68, P1478, DOI 10.1158/0008-5472.CAN-07-6164
   Song HT, 2010, INT J COLORECTAL DIS, V25, P1201, DOI 10.1007/s00384-010-1009-3
   Song LB, 2009, J PATHOL, V219, P317, DOI 10.1002/path.2595
   Wong NACS, 2002, AM J PATHOL, V160, P389, DOI 10.1016/S0002-9440(10)64856-0
   Xia ZB, 2010, CLIN NEUROL NEUROSUR, V112, P413, DOI 10.1016/j.clineuro.2010.02.007
   Xu JB, 2011, MED ONCOL, V28, P455, DOI 10.1007/s12032-010-9475-6
   Ying Z, 2011, CELL BIOSCI, V1, DOI 10.1186/2045-3701-1-36
   Yoo BK, 2009, J CLIN INVEST, V119, P465, DOI 10.1172/JCI36460
   You SY, 2011, TUMOR BIOL, V32, P623, DOI 10.1007/s13277-011-0161-x
   Yu CP, 2009, CARCINOGENESIS, V30, P894, DOI 10.1093/carcin/bgp064
   Zhang FF, 2011, EUR J CANCER, V47, P2060, DOI 10.1016/j.ejca.2011.04.010
NR 30
TC 27
Z9 29
U1 0
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0899-1987
EI 1098-2744
J9 MOL CARCINOGEN
JI Mol. Carcinog.
PD AUG
PY 2013
VL 52
IS 8
BP 603
EP 610
DI 10.1002/mc.21894
PG 8
WC Biochemistry & Molecular Biology; Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology
GA 181LM
UT WOS:000321669100003
PM 22431469
DA 2022-04-25
ER

PT J
AU Huang, FC
AF Huang, Fu-Chen
TI The Role of Sphingolipids on Innate Immunity to Intestinal Salmonella
   Infection
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Review
DE sphingolipids; Salmonella; intestine epithelia; innate immunity
ID ENTERICA SEROVAR TYPHIMURIUM; NADPH PHAGOCYTE OXIDASE; RICH MEMBRANE
   RAFTS; COLON-CANCER CELLS; PROTEIN-KINASE-B; EPITHELIAL-CELLS;
   PSEUDOMONAS-AERUGINOSA; INTRACELLULAR TRAFFICKING; ANTIMICROBIAL
   ACTIONS; DIETARY GANGLIOSIDES
AB Salmonella spp. remains a major public health problem for the whole world. To reduce the use of antimicrobial agents and drug-resistant Salmonella, a better strategy is to explore alternative therapy rather than to discover another antibiotic. Sphingolipid- and cholesterol-enriched lipid microdomains attract signaling proteins and orchestrate them toward cell signaling and membrane trafficking pathways. Recent studies have highlighted the crucial role of sphingolipids in the innate immunity against infecting pathogens. It is therefore mandatory to exploit the role of the membrane sphingolipids in the innate immunity of intestinal epithelia infected by this pathogen. In the present review, we focus on the role of sphingolipids in the innate immunity of intestinal epithelia against Salmonella infection, including adhesion, autophagy, bactericidal effect, barrier function, membrane trafficking, cytokine and antimicrobial peptide expression. The intervention of sphingolipid-enhanced foods to make our life healthy or pharmacological agents regulating sphingolipids is provided at the end.
C1 [Huang, Fu-Chen] Kaohsiung Chang Gung Mem Hosp, Dept Pediat, Kaohsiung 833, Taiwan.
   [Huang, Fu-Chen] Chang Gung Univ, Coll Med, Kaohsiung 833, Taiwan.
RP Huang, FC (corresponding author), Kaohsiung Chang Gung Mem Hosp, Dept Pediat, Kaohsiung 833, Taiwan.; Huang, FC (corresponding author), Chang Gung Univ, Coll Med, Kaohsiung 833, Taiwan.
EM huang817@cgmh.org.tw
OI Huang, Fu-Chen/0000-0003-3702-6856
FU Ministry of Science and Technology [MOST 104-2314-B-182-057]
FX This work was supported, in part, by the Ministry of Science and
   Technology grant MOST 104-2314-B-182-057.
CR Abraham C, 2011, GASTROENTEROLOGY, V140, P1729, DOI 10.1053/j.gastro.2011.02.012
   Aldhous MC, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006285
   Barnich N, 2005, J CELL BIOL, V170, P21, DOI 10.1083/jcb.200502153
   BIBEL DJ, 1992, J INVEST DERMATOL, V98, P269, DOI 10.1111/1523-1747.ep12497842
   Bionda T, 2016, AUTOPHAGY, V12, P1683, DOI 10.1080/15548627.2016.1203490
   Birecki CJ, 2006, J PEDIATR GASTR NUTR, V42, P59, DOI 10.1097/01.mpg.0000187567.79633.a7
   Bock J, 2007, WORLD J GASTROENTERO, V13, P5217, DOI 10.3748/wjg.v13.i39.5217
   Bouhet S, 2004, TOXICOL SCI, V77, P165, DOI 10.1093/toxsci/kfh006
   Brandstaetter H, 2012, J CELL SCI, V125, P1991, DOI 10.1242/jcs.097212
   Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200
   Brumell JH, 2002, INFECT IMMUN, V70, P3264, DOI 10.1128/IAI.70.6.3264-3270.2002
   Cazzolli R, 2001, DIABETES, V50, P2210, DOI 10.2337/diabetes.50.10.2210
   Chapman H, 2005, J CELL SCI, V118, P5325, DOI 10.1242/jcs.02635
   Cheng ZJ, 2006, MOL BIOL CELL, V17, P3197, DOI 10.1091/mbc.E05-12-1101
   Cornell TT, 2009, AM J PHYSIOL-LUNG C, V296, pL849, DOI 10.1152/ajplung.90516.2008
   Cukkemane N, 2015, EUR J ORAL SCI, V123, P221, DOI 10.1111/eos.12200
   Cuschieri Joseph, 2007, Surg Infect (Larchmt), V8, P91, DOI 10.1089/sur.2006.050
   Daniel C, 2007, J IMMUNOL, V178, P2458, DOI 10.4049/jimmunol.178.4.2458
   Danielsen EM, 2006, MOL MEMBR BIOL, V23, P71, DOI 10.1080/09687860500445604
   Dobierzewska A, 2011, J BIOL CHEM, V286, P32064, DOI 10.1074/jbc.M111.238030
   Duan RD, 2011, J DIGEST DIS, V12, P60, DOI 10.1111/j.1751-2980.2011.00481.x
   Duan RD, 2009, PROG LIPID RES, V48, P62, DOI 10.1016/j.plipres.2008.04.003
   Ellington AA, 2006, CARCINOGENESIS, V27, P298, DOI 10.1093/carcin/bgi214
   Feng D, 2010, DIGEST DIS SCI, V55, P3377, DOI 10.1007/s10620-010-1202-9
   Fischer CL, 2012, ANTIMICROB AGENTS CH, V56, P1157, DOI 10.1128/AAC.05151-11
   Fischer H, 2007, CELL MICROBIOL, V9, P1239, DOI 10.1111/j.1462-5822.2006.00867.x
   Fiskin E, 2016, MOL CELL, V62, P967, DOI 10.1016/j.molcel.2016.04.015
   Fleckenstein JM, 2001, J CLIN INVEST, V107, P27, DOI 10.1172/JCI11792
   Garner MJ, 2002, CELL MICROBIOL, V4, P153, DOI 10.1046/j.1462-5822.2002.00181.x
   Ghosh N, 2007, ENDOCRINOLOGY, V148, P1359, DOI 10.1210/en.2006-0750
   Grassme H, 2003, NAT MED, V9, P322, DOI 10.1038/nm823
   Gulbins E, 2004, J MOL MED, V82, P357, DOI 10.1007/s00109-004-0539-y
   Gulbins E, 2003, ONCOGENE, V22, P7070, DOI 10.1038/sj.onc.1207146
   Hanada K, 2005, JPN J INFECT DIS, V58, P131
   Hannun YA, 2001, BIOCHEMISTRY-US, V40, P4893, DOI 10.1021/bi002836k
   Hannun YA, 2008, NAT REV MOL CELL BIO, V9, P139, DOI 10.1038/nrm2329
   Head BP, 2014, BBA-BIOMEMBRANES, V1838, P532, DOI 10.1016/j.bbamem.2013.07.018
   Helms JB, 2004, TRAFFIC, V5, P247, DOI 10.1111/j.1600-0854.2004.0181.x
   Homer CR, 2010, GASTROENTEROLOGY, V139, P1630, DOI 10.1053/j.gastro.2010.07.006
   Huang FC, 2005, FEMS MICROBIOL LETT, V243, P265, DOI 10.1016/j.femsle.2004.12.013
   Huang FC, 2016, GUT PATHOG, V8, DOI 10.1186/s13099-016-0088-2
   Huang FC, 2014, INT J MOL SCI, V15, P12558, DOI 10.3390/ijms150712558
   Huang FC, 2011, CELL IMMUNOL, V271, P480, DOI 10.1016/j.cellimm.2011.08.018
   Huang GTJ, 2002, HUM GENE THER, V13, P2017, DOI 10.1089/10430340260395875
   IDOTA T, 1995, BIOSCI BIOTECH BIOCH, V59, P417, DOI 10.1271/bbb.59.417
   Jess T, 2011, GUT, V60, P318, DOI 10.1136/gut.2010.223396
   Jiang WH, 2014, BBA-MOL CELL BIOL L, V1841, P783, DOI 10.1016/j.bbalip.2013.09.005
   Kanazawa T, 2004, J BIOL CHEM, V279, P8452, DOI 10.1074/jbc.M306337200
   Kim YI, 2014, MOL CELL BIOL, V34, P4368, DOI 10.1128/MCB.00599-14
   Kuballa P, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003391
   Kurek K, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/908907
   Lapaquette P, 2010, J CLIN GASTROENTEROL, V44, pS26, DOI 10.1097/MCG.0b013e3181dd4fa5
   Lasserre R, 2008, NAT CHEM BIOL, V4, P538, DOI 10.1038/nchembio.103
   Li DD, 2009, ONCOGENE, V28, P886, DOI 10.1038/onc.2008.441
   Liu Y, 2012, J PHARMACOL SCI, V118, P423, DOI 10.1254/jphs.11181FP
   Lu DY, 2012, INFECT IMMUN, V80, P1823, DOI 10.1128/IAI.05856-11
   Maceyka M, 2014, NATURE, V510, P58, DOI 10.1038/nature13475
   MAN MQ, 1993, J INVEST DERMATOL, V101, P185, DOI 10.1111/1523-1747.ep12363729
   Manes S, 2003, NAT REV IMMUNOL, V3, P557, DOI 10.1038/nri1129
   Marcus SL, 2002, CELL MICROBIOL, V4, P435, DOI 10.1046/j.1462-5822.2002.00202.x
   Margalit M, 2002, POSTGRAD MED J, V78, P564, DOI 10.1136/pmj.78.923.564
   Mastroeni P, 2000, J EXP MED, V192, P237, DOI 10.1084/jem.192.2.237
   McCollister BD, 2007, INFECT IMMUN, V75, P5346, DOI 10.1128/IAI.00689-07
   Miklavcic JJ, 2012, J NUTR METAB, V2012, DOI 10.1155/2012/280286
   Misselwitz B, 2011, MOL SYST BIOL, V7, DOI 10.1038/msb.2011.7
   Narayanan LA, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00558
   Nilsson A, 2006, J LIPID RES, V47, P154, DOI 10.1194/jlr.M500357-JLR200
   Nixon GF, 2009, BRIT J PHARMACOL, V158, P982, DOI 10.1111/j.1476-5381.2009.00281.x
   Ogier-Denis E, 2000, J BIOL CHEM, V275, P39090, DOI 10.1074/jbc.M006198200
   Oswald IP, 2003, APPL ENVIRON MICROB, V69, P5870, DOI 10.1128/AEM.69.10.5870-5874.2003
   Owen KA, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004159
   Park JW, 2014, BBA-MOL CELL BIOL L, V1841, P671, DOI 10.1016/j.bbalip.2013.08.019
   Park K, 2013, BIOMOL THER, V21, P251, DOI 10.4062/biomolther.2013.058
   Pewzner-Jung Y, 2014, EMBO MOL MED, V6, P1205, DOI 10.15252/emmm.201404075
   Pralhada Rao R., 2013, J LIPIDS, V2013, DOI DOI 10.1155/2013/17891023984075
   Radin NS, 2006, MICROBES INFECT, V8, P938, DOI 10.1016/j.micinf.2005.09.005
   Rouabhia M, 2011, MED MYCOL, V49, P458, DOI 10.3109/13693786.2010.535031
   Rueda R, 2007, BRIT J NUTR, V98, pS68, DOI 10.1017/S0007114507832946
   Sakata A, 2007, CELL IMMUNOL, V245, P24, DOI 10.1016/j.cellimm.2007.03.005
   Sanjuan MA, 2009, IMMUNOL REV, V227, P203, DOI 10.1111/j.1600-065X.2008.00732.x
   Scarlatti F, 2004, J BIOL CHEM, V279, P18384, DOI 10.1074/jbc.M313561200
   Schengrund CL, 2003, BIOCHEM PHARMACOL, V65, P699, DOI 10.1016/S0006-2952(02)01553-8
   Schwan C, 2011, J BIOL CHEM, V286, P29356, DOI 10.1074/jbc.M111.261925
   Simons K, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a004697
   Simons K, 2010, NAT REV MOL CELL BIO, V11, P688, DOI 10.1038/nrm2977
   Sims K, 2010, J BIOL CHEM, V285, P38568, DOI 10.1074/jbc.M110.170621
   Sprong RC, 2001, ANTIMICROB AGENTS CH, V45, P1298, DOI 10.1128/AAC.45.4.1298-1301.2001
   Steele-Mortimer O, 2000, J BIOL CHEM, V275, P37718, DOI 10.1074/jbc.M008187200
   Sun T, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-161
   Tabazavareh ST, 2016, CELL PHYSIOL BIOCHEM, V38, P2094, DOI 10.1159/000445567
   Tafazoli F, 2003, INFECT IMMUN, V71, P872, DOI 10.1128/IAI.71.2.872-881.2003
   Tattoli I, 2012, CELL HOST MICROBE, V11, P563, DOI 10.1016/j.chom.2012.04.012
   Vazquez-Torres A, 2000, J EXP MED, V192, P227, DOI 10.1084/jem.192.2.227
   Voss E, 2006, J BIOL CHEM, V281, P2005, DOI 10.1074/jbc.M511044200
   Walton KA, 2006, J LIPID RES, V47, P1967, DOI 10.1194/jlr.M600060-JLR200
   Yamagata M, 2011, BIOCHEM BIOPH RES CO, V410, P786, DOI 10.1016/j.bbrc.2011.06.061
   Young MM, 2013, J LIPID RES, V54, P5, DOI 10.1194/jlr.R031278
   Yu H, 2009, AM J RESP CELL MOL, V41, P367, DOI 10.1165/rcmb.2008-0295OC
   Zilbauer M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015389
NR 99
TC 8
Z9 9
U1 0
U2 3
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD AUG
PY 2017
VL 18
IS 8
AR 1720
DI 10.3390/ijms18081720
PG 13
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA FF4HB
UT WOS:000408897400121
PM 28783107
OA Green Submitted, Green Published, gold
DA 2022-04-25
ER

PT J
AU Chuffa, LGD
   Carvalho, RF
   Justulin, LA
   Cury, SS
   Seiva, FRF
   Jardim-Perassi, BV
   Zuccari, DAPD
   Reiter, RJ
AF Chuffa, Luiz Gustavo de Almeida
   Carvalho, Robson Francisco
   Justulin, Luis Antonio
   Cury, Sarah Santiloni
   Seiva, Fabio Rodrigues Ferreira
   Jardim-Perassi, Bruna Victorasso
   Zuccari, Debora Aparecida Pires de Campos
   Reiter, Russel J.
TI A meta-analysis of microRNA networks regulated by melatonin in cancer:
   Portrait of potential candidates for breast cancer treatment
SO JOURNAL OF PINEAL RESEARCH
LA English
DT Review
DE cancer; melatonin; microRNA; miRNA regulatory network; target genes
ID EXPRESSION ANALYSIS; UP-REGULATION; TOOL; PROLIFERATION; TRANSCRIPTOME;
   ENVIRONMENT; INHIBITION; REPRESSION; RECEPTOR; HEALTH
AB Melatonin is a ubiquitous molecule with a broad spectrum of functions including widespread anti-cancer activities. Identifying how melatonin intervenes in complex molecular signaling at the gene level is essential to guide proper therapies. Using meta-analysis approach, herein we examined the role of melatonin in regulating the expression of 46 microRNAs (miRNAs) and their target genes in breast, oral, gastric, colorectal, and prostate cancers, and glioblastoma. The deregulated miRNA-associated target genes revealed their involvement in the regulation of cellular proliferation, differentiation, apoptosis, senescence, and autophagy. Melatonin changes the expression of miRNA-associated genes in breast, gastric, and oral cancers. These genes are associated with cellular senescence, the hedgehog signaling pathway, cell proliferation, p53 signaling, and the hippo signaling pathway. Conversely, colorectal and prostate cancers as well as glioblastoma and oral carcinoma present a clear pattern of less pronounced changes in the expression of miRNA-associated genes. Most notably, colorectal cancer displayed a unique molecular change in response to melatonin. Considering breast cancer network complexity, we compared the genes found during the meta-analysis with RNA-Seq data from breast cancer-bearing mice treated with melatonin. Mechanistically, melatonin upregulated genes associated with immune responses and apoptotic processes, whereas it downregulated genes involved in cellular aggressiveness/metastasis (eg, mitosis, telomerase activity, and angiogenesis). We further characterized the expression profile of our gene subsets with human breast cancer and found eight upregulated genes and 16 downregulated genes that were appositively correlated with melatonin. Our results pose a multi-dimension network of tumor-associated genes regulated by miRNAs potentially targeted by melatonin.
C1 [Chuffa, Luiz Gustavo de Almeida; Carvalho, Robson Francisco; Justulin, Luis Antonio; Cury, Sarah Santiloni] UNESP Sao Paulo State Univ, Inst Biosci, Dept Struct & Funct Biol, Botucatu, SP, Brazil.
   [Seiva, Fabio Rodrigues Ferreira] UENP CLM Univ Estadual Norte Parana, Dept Biol & Technol, Bandeirantes, Brazil.
   [Jardim-Perassi, Bruna Victorasso; Zuccari, Debora Aparecida Pires de Campos] Fac Med Sao Jose Do Rio Preto, Sao Jose Do Rio Preto, Brazil.
   [Reiter, Russel J.] UT Hlth, Dept Cell Syst & Anat, San Antonio, TX USA.
RP Chuffa, LGD (corresponding author), UNESP Sao Paulo State Univ, Inst Biosci Botucatu, Dept Struct & Funct Biol, POB 18618-689,Rubiao Jr S-N, BR-510 Botucatu, SP, Brazil.
EM guchuffa@yahoo.com.br
RI Seiva, Fábio R.F./I-5452-2013; de Campos Zuccari, Debora Aparecida
   Pires/M-3560-2014; Justulin, Luis A/ABH-5494-2020; Chuffa, Luiz
   Gustavo/ABC-2781-2020; Justulin, Luis A/AAC-4000-2021; Carvalho, Robson
   Francisco/E-1161-2012
OI Seiva, Fábio R.F./0000-0002-7461-8773; de Campos Zuccari, Debora
   Aparecida Pires/0000-0002-0146-9041; Justulin, Luis
   A/0000-0001-6142-3515; Chuffa, Luiz Gustavo/0000-0002-0199-3396;
   Justulin, Luis A/0000-0001-6142-3515; Reis,
   AlessanRSS/0000-0001-8486-7469; Cury, Sarah/0000-0002-4803-0933;
   Carvalho, Robson Francisco/0000-0002-4901-7714
FU National Council for Scientific and Technological DevelopmentConselho
   Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ) [CNPq
   401040/2016-0, 311530/2019-2, 870415/1997-2]; Sao Paulo Research
   Foundation (FAPESP)Fundacao de Amparo a Pesquisa do Estado de Sao Paulo
   (FAPESP) [2019/00906-6]
FX The following grants supported the development of this study: National
   Council for Scientific and Technological Development (CNPq
   401040/2016-0, 311530/2019-2 to RFC and scholarship #870415/1997-2 to
   SSC) and Sao Paulo Research Foundation (FAPESP grants #2019/00906-6).
CR Acuna-Castroviejo D, 2014, CELL MOL LIFE SCI, V71, P2997, DOI 10.1007/s00018-014-1579-2
   Agarwal V, 2015, ELIFE, V4, DOI 10.7554/eLife.05005
   Bardou P, 2014, BMC BIOINFORMATICS, V15, DOI 10.1186/1471-2105-15-293
   Ben-Moshe Z, 2014, NUCLEIC ACIDS RES, V42, P3750, DOI 10.1093/nar/gkt1359
   Bondy SC, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19082205
   Chen EY, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-128
   Chou CH, 2016, NUCLEIC ACIDS RES, V44, pD239, DOI 10.1093/nar/gkv1258
   Chuffa L.G.A., 2019, MELATONIN RES, V2, P133, DOI [10.32794/mr11250026, DOI 10.32794/MR11250026]
   de Castro TB, 2018, ANTI-CANCER AGENT ME, V18, P2110, DOI 10.2174/1871520618666181025125532
   Dubocovich ML, 2003, FRONT BIOSCI-LANDMRK, V8, pD1093, DOI 10.2741/1089
   Dweep H, 2011, J BIOMED INFORM, V44, P839, DOI 10.1016/j.jbi.2011.05.002
   Fabbri M, 2012, P NATL ACAD SCI USA, V109, pE2110, DOI 10.1073/pnas.1209414109
   Ferreira LC, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0228062
   Gu JY, 2017, BIOMED PHARMACOTHER, V93, P969, DOI 10.1016/j.biopha.2017.07.010
   Hardeland R, 2017, MINI REV RECENT MELA, P109
   Hardeland R., 2018, BIOCH MOL BIOL J, V4, P7, DOI DOI 10.21767/2471-8084.100056
   Hardeland Ruediger, 2018, Central Nervous System Agents in Medicinal Chemistry, V18, P102, DOI 10.2174/1871524918666180531083944
   Hardeland R, 2014, INT J MOL SCI, V15, P18221, DOI 10.3390/ijms151018221
   Hardeland R, 2012, J PINEAL RES, V52, P139, DOI 10.1111/j.1600-079X.2011.00934.x
   He S, 2013, BLOOD, V121, P4663, DOI 10.1182/blood-2012-07-441360
   Hsieh MJ, 2020, MOL THER-NUCL ACIDS, V19, P877, DOI 10.1016/j.omtn.2019.12.022
   Hunsaker M, 2019, DENT J-BASEL, V7, DOI 10.3390/dj7020048
   Huo XK, 2017, J PINEAL RES, V62, DOI 10.1111/jpi.12390
   Jardim-Perassi BV, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-37413-w
   Jardim-Perassi BV, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085311
   Jung JH, 2019, CANCERS, V11, DOI 10.3390/cancers11111684
   Jung-Hynes B, 2010, J PINEAL RES, V48, P9, DOI 10.1111/j.1600-079X.2009.00729.x
   Jung-Hynes B, 2009, FASEB J, V23, P2803, DOI 10.1096/fj.09-129148
   Jung-Hynes B, 2009, CELL CYCLE, V8, P1478, DOI 10.4161/cc.8.10.8408
   Kuleshov MV, 2016, NUCLEIC ACIDS RES, V44, pW90, DOI 10.1093/nar/gkw377
   Lacerda Jessica Zani, 2019, Microrna, V8, P237, DOI 10.2174/2211536608666190219095426
   Lai JG, 2019, AGING-US, V11, P7525, DOI 10.18632/aging.102268
   Lee SE, 2011, J PINEAL RES, V51, P345, DOI 10.1111/j.1600-079X.2011.00896.x
   Liberati A, 2009, ANN INTERN MED, V151, pW65, DOI [10.7326/0003-4819-151-4-200908180-00136, 10.1371/journal.pmed.1000100]
   Marques JHM, 2018, LIFE SCI, V208, P131, DOI 10.1016/j.lfs.2018.07.012
   Menendez-Menendez J, 2019, CANCERS, V11, DOI 10.3390/cancers11071011
   Metsalu T, 2015, NUCLEIC ACIDS RES, V43, pW566, DOI 10.1093/nar/gkv468
   Mi HY, 2017, NUCLEIC ACIDS RES, V45, pD183, DOI 10.1093/nar/gkw1138
   Mitchell PS, 2008, P NATL ACAD SCI USA, V105, P10513, DOI 10.1073/pnas.0804549105
   Mori F, 2016, ONCOTARGET, V7, P20532, DOI 10.18632/oncotarget.7978
   Peng Y, 2016, SIGNAL TRANSDUCT TAR, V1, DOI 10.1038/sigtrans.2015.4
   Qiu JT, 2019, J PINEAL RES, V66, DOI 10.1111/jpi.12552
   Reiter RJ, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18040843
   Reiter Russel J., 2007, Critical Reviews in Oncogenesis, V13, P303
   Robinson MD, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-3-r25
   Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616
   Sakatani A, 2019, CARCINOGENESIS, V40, P422, DOI 10.1093/carcin/bgy186
   Saunders MA, 2009, RNA BIOL, V6, P324, DOI 10.4161/rna.6.3.8871
   Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303
   Slominski AT, 2016, BIOESSAYS, V38, P1193, DOI 10.1002/bies.201600204
   Slominski AT, 2014, FASEB J, V28, P2775, DOI 10.1096/fj.13-242040
   Sohn EJ, 2015, J CANCER, V6, P19, DOI 10.7150/jca.9591
   Starruy J, 2014, BIOINFORMATICS, V30, P1331, DOI 10.1093/bioinformatics/btt772
   Stevens RG, 2009, MUTAT RES-REV MUTAT, V682, P1, DOI 10.1016/j.mrrev.2009.01.003
   Su SC, 2018, TRENDS ENDOCRIN MET, V29, P435, DOI 10.1016/j.tem.2018.03.008
   Su SC, 2017, J PINEAL RES, V62, DOI 10.1111/jpi.12370
   Szklarczyk D, 2019, NUCLEIC ACIDS RES, V47, pD607, DOI 10.1093/nar/gky1131
   Talib WH, 2018, MOLECULES, V23, DOI 10.3390/molecules23030518
   Tomczak Katarzyna, 2015, Contemp Oncol (Pozn), V19, pA68, DOI 10.5114/wo.2014.47136
   Torre D, 2018, CELL SYST, V7, P556, DOI 10.1016/j.cels.2018.10.007
   Vasudevan S, 2007, SCIENCE, V318, P1931, DOI 10.1126/science.1149460
   Wang TH, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19092687
   Wang X, 2015, CURR MED CHEM, V22, P1582, DOI 10.2174/0929867322666150227155009
   Xia JG, 2015, NAT PROTOC, V10, P823, DOI 10.1038/nprot.2015.052
   Xia JG, 2013, BIOINFORMATICS, V29, P3232, DOI 10.1093/bioinformatics/btt562
   Xia YY, 2019, J PINEAL RES, V66, DOI 10.1111/jpi.12547
   Xiang SL, 2019, J PINEAL RES, V67, DOI 10.1111/jpi.12586
   Zhou GY, 2019, NUCLEIC ACIDS RES, V47, pW234, DOI 10.1093/nar/gkz240
   Zhu CY, 2018, DNA CELL BIOL, V37, P244, DOI 10.1089/dna.2017.4040
NR 69
TC 15
Z9 16
U1 2
U2 13
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0742-3098
EI 1600-079X
J9 J PINEAL RES
JI J. Pineal Res.
PD NOV
PY 2020
VL 69
IS 4
AR e12693
DI 10.1111/jpi.12693
EA SEP 2020
PG 19
WC Endocrinology & Metabolism; Neurosciences; Physiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Endocrinology & Metabolism; Neurosciences & Neurology; Physiology
GA OI6LU
UT WOS:000570878100001
PM 32910542
OA Bronze
DA 2022-04-25
ER

PT J
AU Ragimbeau, R
   El Kebriti, L
   Sebti, S
   Fourgous, E
   Boulahtouf, A
   Arena, G
   Espert, L
   Turtoi, A
   Gongora, C
   Houede, N
   Pattingre, S
AF Ragimbeau, Romain
   El Kebriti, Leila
   Sebti, Salwa
   Fourgous, Elise
   Boulahtouf, Abdelhay
   Arena, Giuseppe
   Espert, Lucile
   Turtoi, Andrei
   Gongora, Celine
   Houede, Nadine
   Pattingre, Sophie
TI BAG6 promotes PINK1 signaling pathway and is essential for mitophagy
SO FASEB JOURNAL
LA English
DT Article
DE BAG6; mitophagy; receptor; signaling
ID QUALITY-CONTROL; PROTEIN; MITOCHONDRIA; PARKIN; DEGRADATION;
   ELIMINATION; APOPTOSIS; UBIQUITIN; RESOURCE; HUB
AB Bcl-2-associated athanogen-6 (BAG6) is a nucleocytoplasmic shuttling protein involved in protein quality control. We previously demonstrated that BAG6 is essential for autophagy by regulating the intracellular localization of the acetyltransferase EP300, and thus, modifying accessibility to its substrates (TP53 in the nucleus and autophagy-related proteins in the cytoplasm). Here, we investigated BAG6 localization and function in the cytoplasm. First, we demonstrated that BAG6 is localized in the mitochondria. Specifically, BAG6 is expressed in the mitochondrial matrix under basal conditions, and translocates to the outer mitochondrial membrane after mitochondrial depolarization with carbonyl cyanide m-chlorophenyl hydrazine, a mitochondrial uncoupler that induces mitophagy. In SW480 cells, the deletion of BAG6 expression abrogates its ability to induce mitophagy and PINK1 accumulation. On the reverse, its ectopic expression in LoVo colon cancer cells, which do not express endogenous BAG6, reduces the size of the mitochondria, induces mitophagy, leads to the activation of the PINK1/PARKIN pathway and to the phospho-ubiquitination of mitochondrial proteins. Finally, BAG6 contains two LIR (LC3-interacting Region) domains specifically found in receptors for selective autophagy and responsible for the interaction with LC3 and for autophagosome selectivity. Site-directed mutagenesis showed that BAG6 requires wild-type LIRs domains for its ability to stimulate mitophagy. In conclusion, we propose that BAG6 is a novel mitophagy receptor or adaptor that induces PINK1/PARKIN signaling and mitophagy in a LIR-dependent manner.
C1 [Ragimbeau, Romain; El Kebriti, Leila; Fourgous, Elise; Boulahtouf, Abdelhay; Turtoi, Andrei; Gongora, Celine; Houede, Nadine; Pattingre, Sophie] Univ Montpellier, IRCM, Inst Reg Canc Montpellier, INSERM,U1194, F-34298 Montpellier, France.
   [El Kebriti, Leila; Houede, Nadine] CHU Nimes, Nimes, France.
   [Sebti, Salwa] Univ Texas Southwestern Med Ctr Dallas, Ctr Autophagy Res, Dallas, TX 75390 USA.
   [Sebti, Salwa] Univ Texas Southwestern Med Ctr Dallas, Dept Internal Med, Dallas, TX USA.
   [Arena, Giuseppe] Univ Luxembourg, Luxembourg Ctr Syst Biomed LCSB, Belvaux, Luxembourg.
   [Espert, Lucile] Univ Montpellier, IRIM, UMR 9004, CNRS, Montpellier, France.
RP Pattingre, S (corresponding author), Univ Montpellier, IRCM, Inst Reg Canc Montpellier, INSERM,U1194, F-34298 Montpellier, France.
EM sophie.pattingre@inserm.fr
RI Sebti, Salwa/AAB-3188-2020; Espert, Lucile/ABF-5614-2021; Arena,
   Giuseppe/ABE-8093-2021; Turtoi, Andrei/ABD-1271-2021
OI Arena, Giuseppe/0000-0003-2398-5503; Turtoi, Andrei/0000-0003-3813-6635;
   Sebti, Salwa/0000-0003-4327-1129; FOURGOUS, Elise/0000-0002-3626-250X
CR Bhujabal Z, 2017, EMBO REP, V18, P947, DOI 10.15252/embr.201643147
   Che XQ, 2013, BIOCHEM BIOPH RES CO, V441, P488, DOI 10.1016/j.bbrc.2013.10.086
   Chu CT, 2013, NAT CELL BIOL, V15, P1197, DOI 10.1038/ncb2837
   Claessen JHL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028542
   De Snoo ML, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-2132-x
   Desmots F, 2005, MOL CELL BIOL, V25, P10329, DOI 10.1128/MCB.25.23.10329-10337.2005
   Frezza C, 2007, NAT PROTOC, V2, P287, DOI 10.1038/nprot.2006.478
   Gomes LC, 2013, BBA-MOL CELL RES, V1833, P205, DOI 10.1016/j.bbamcr.2012.02.012
   Gomes LC, 2011, NAT CELL BIOL, V13, P589, DOI 10.1038/ncb2220
   Hanna RA, 2012, J BIOL CHEM, V287, P19094, DOI 10.1074/jbc.M111.322933
   Harbauer AB, 2014, CELL METAB, V19, P357, DOI 10.1016/j.cmet.2014.01.010
   Hayashishita M, 2019, FEBS OPEN BIO, V9, P1281, DOI 10.1002/2211-5463.12677
   Kalvari I, 2014, AUTOPHAGY, V10, P913, DOI 10.4161/auto.28260
   Kawahara H, 2013, J BIOCHEM, V153, P147, DOI 10.1093/jb/mvs149
   Kazlauskaite A, 2014, BIOCHEM J, V460, P127, DOI 10.1042/BJ20140334
   Klionsky DJ, 2012, AUTOPHAGY, V8, P445, DOI 10.4161/auto.19496
   Koyano F, 2014, NATURE, V510, P162, DOI 10.1038/nature13392
   Lee JG, 2013, BIOESSAYS, V35, P377, DOI 10.1002/bies.201200159
   Liu L, 2012, NAT CELL BIOL, V14, P177, DOI 10.1038/ncb2422
   Montava-Garriga L, 2020, J MOL BIOL, V432, P206, DOI 10.1016/j.jmb.2019.06.032
   Morita M, 2017, MOL CELL, V67, P922, DOI 10.1016/j.molcel.2017.08.013
   Murakawa T, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8527
   Novak I, 2010, EMBO REP, V11, P45, DOI 10.1038/embor.2009.256
   Okamoto K, 2009, DEV CELL, V17, P87, DOI 10.1016/j.devcel.2009.06.013
   Qu DB, 2015, J BIOL CHEM, V290, P30441, DOI 10.1074/jbc.M115.677815
   Rambold AS, 2011, CELL CYCLE, V10, P4032, DOI 10.4161/cc.10.23.18384
   Saita S, 2016, GENES CELLS, V21, P408, DOI 10.1111/gtc.12351
   Sebti S, 2014, AUTOPHAGY, V10, P1341, DOI 10.4161/auto.28979
   Sebti S, 2014, P NATL ACAD SCI USA, V111, P4115, DOI 10.1073/pnas.1313618111
   Stelzl U, 2005, CELL, V122, P957, DOI 10.1016/j.cell.2005.08.029
   Tahrir FG, 2017, J CELL PHYSIOL, V232, P797, DOI 10.1002/jcp.25476
   Twig G, 2008, EMBO J, V27, P433, DOI 10.1038/sj.emboj.7601963
   Verma M, 2020, J BIOL CHEM, V295, P7865, DOI 10.1074/jbc.RA119.010474
   Wai T, 2016, EMBO REP, V17, P1844, DOI 10.15252/embr.201642698
   Wang XJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086276
   Wei YJ, 2017, CELL, V168, P224, DOI 10.1016/j.cell.2016.11.042
   Wu W, 2012, J CELL SCI, V125, P4219, DOI 10.1242/jcs.086553
   Yoshii SR, 2011, J BIOL CHEM, V286, P19630, DOI 10.1074/jbc.M110.209338
   Zhu YY, 2013, J BIOL CHEM, V288, P1099, DOI 10.1074/jbc.M112.399345
NR 39
TC 6
Z9 6
U1 2
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0892-6638
EI 1530-6860
J9 FASEB J
JI Faseb J.
PD FEB
PY 2021
VL 35
IS 2
AR e21361
DI 10.1096/fj.202000930R
PG 14
WC Biochemistry & Molecular Biology; Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics; Cell Biology
GA RY3BC
UT WOS:000647789600111
PM 33522017
OA Green Submitted
DA 2022-04-25
ER

PT J
AU Zhou, W
   Yang, WL
   Yang, J
   Zhu, HJ
   Duan, LL
   Wang, XQ
   Li, YD
   Niu, LR
   Xiao, S
   Zhang, R
   Yang, JJ
   Hong, L
AF Zhou, Wei
   Yang, Wanli
   Yang, Jing
   Zhu, Haijun
   Duan, Lili
   Wang, Xiaoqian
   Li, Yiding
   Niu, Liaoran
   Xiao, Shuao
   Zhang, Rui
   Yang, Jianjun
   Hong, Liu
TI miR-483 promotes the development of colorectal cancer by inhibiting the
   expression level of EI24
SO MOLECULAR MEDICINE REPORTS
LA English
DT Article
DE colorectal cancer; miR-483; EI24; proliferation; migration; invasion
ID METASTASIS; INVASION; ANGIOGENESIS; PROGRESSION; RESISTANCE; MICRORNAS;
   CARCINOMA; TARGETS; GROWTH
AB MicroRNAs (miRs) serve an important role in cell differentiation, proliferation and apoptosis by negatively regulating gene expression at the transcriptional or post-transcriptional level. EI24 autophagy associated transmembrane protein (EI24) is a tumor suppressor gene that serves an important role in the occurrence and development of digestive system tumors. However, little is known regarding the relationship between EI24 and the prognosis of patients with colorectal cancer (CRC). Our previous study confirmed EI24 as the target molecule of miR-483, using reporter gene detection. Thus, the aim of the present study was to elucidate the effect of the abnormal expression of miR-483 on the malignant phenotype of CRC through a series of cell function experiments and nude mice tumorigenicity experiments, and to determine the expression level of EI24, a downstream target gene of miR-483, in CRC and its relationship with patient prognosis. In CRC tissues and cells, the expression level of miR-483 was upregulated, while the expression level of EI24 was downregulated. Cell function tests such as MTT assay, cell cycle assay, colony formation assay, Migration and invasion assays and nude mice tumorigenicity experiments demonstrated that the overexpression of miR-483 promoted the proliferation, invasion and metastasis of CRC. Moreover, the reverse transcription-quantitative PCR results indicated that overexpression of miR-483 inhibited the expression level of EI24. The relationship between the clinical data and immunohistochemical results from 183 patients with CRC and survival was examined. It was found that the expression level of EI24 was positively associated with the prognosis of patients. As a cancer-promoting factor, miR-483 enhances the proliferation, migration and invasion of CRC cells by reducing the expression level of EI24.
C1 [Zhou, Wei; Yang, Wanli; Duan, Lili; Wang, Xiaoqian; Li, Yiding; Niu, Liaoran; Xiao, Shuao; Zhang, Rui; Yang, Jianjun; Hong, Liu] Fourth Mil Med Univ, Xijing Hosp Digest Dis, Dept Gastrointestinal Surg, 127 Changle West Rd, Xian 710032, Shaanxi, Peoples R China.
   [Yang, Jing] Fourth Mil Med Univ, Xijing Hosp, Dept Emergency, Xian 710032, Shaanxi, Peoples R China.
   [Zhu, Haijun] Xian Cent Hosp, Dept Gen Surg, Xian 710003, Shaanxi, Peoples R China.
RP Hong, L (corresponding author), Fourth Mil Med Univ, Xijing Hosp Digest Dis, Dept Gastrointestinal Surg, 127 Changle West Rd, Xian 710032, Shaanxi, Peoples R China.
EM hongliu1@fmmu.edu.cn
CR Allgayer H, 2020, SEMIN CANCER BIOL, V60, P1, DOI 10.1016/j.semcancer.2019.07.018
   Brenner H, 2014, LANCET, V383, P1490, DOI 10.1016/S0140-6736(13)61649-9
   Chen X, 2018, J TRANSL MED, V16, DOI 10.1186/s12967-018-1722-1
   Chi SW, 2009, NATURE, V460, P479, DOI 10.1038/nature08170
   Choi JM, 2015, LUNG CANCER, V90, P175, DOI 10.1016/j.lungcan.2015.08.019
   Choi JM, 2013, ONCOTARGET, V4, P2383, DOI 10.18632/oncotarget.1434
   Clark JAM, 2020, ANIM MODEL EXP MED, V3, P103, DOI 10.1002/ame2.12111
   Cui HM, 2016, ONCOTARGET, V7, P48456, DOI 10.18632/oncotarget.10309
   Dekker E, 2019, LANCET, V394, P1467, DOI 10.1016/S0140-6736(19)32319-0
   Duan LL, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.01570
   Ferland-McCollough D, 2012, CELL DEATH DIFFER, V19, P1003, DOI 10.1038/cdd.2011.183
   Haase G, 2016, CANCERS, V8, DOI 10.3390/cancers8050048
   Huang DD, 2018, CANCER METAST REV, V37, P173, DOI 10.1007/s10555-017-9726-5
   Huang SL, 2018, J CANCER, V9, P3867, DOI 10.7150/jca.28588
   Kawaguchi Y, 2019, CLIN CANCER RES, V25, P5843, DOI 10.1158/1078-0432.CCR-19-0863
   Leber MF, 2009, INT J ONCOL, V34, P881, DOI 10.3892/ijo_00000214
   Li ZS, 2017, ONCOTARGET, V8, P19455, DOI 10.18632/oncotarget.14307
   Liu X, 2015, FUTURE ONCOL, V11, P2911, DOI 10.2217/fon.15.235
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Loes IM, 2016, INT J CANCER, V139, P647, DOI 10.1002/ijc.30089
   Ma JJ, 2016, CELL BIOL INT, V40, P448, DOI 10.1002/cbin.10585
   Ma JJ, 2014, DIGEST DIS SCI, V59, P716, DOI 10.1007/s10620-013-2939-8
   Malki A, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22010130
   Mazumder D, 2011, INT J CANCER, V129, P1859, DOI 10.1002/ijc.25849
   Mentz RJ, 2016, CIRCULATION, V133, P872, DOI 10.1161/CIRCULATIONAHA.115.019902
   Nam TW, 2019, BIOCHEM BIOPH RES CO, V514, P1087, DOI 10.1016/j.bbrc.2019.04.186
   Niu LR, 2021, MOL THER-NUCL ACIDS, V23, P42, DOI 10.1016/j.omtn.2020.10.030
   Patterson EE, 2011, CANCER-AM CANCER SOC, V117, P1630, DOI 10.1002/cncr.25724
   Qiao Y, 2011, FEBS LETT, V585, P3095, DOI 10.1016/j.febslet.2011.08.039
   Shi L, 2015, REPROD BIOMED ONLINE, V31, P565, DOI 10.1016/j.rbmo.2015.06.023
   Si YR, 2017, CELL PHYSIOL BIOCHEM, V42, P1670, DOI 10.1159/000479412
   Song QC, 2014, CANCER RES, V74, P3031, DOI 10.1158/0008-5472.CAN-13-2193
   Vu T, 2017, CANCERS, V9, DOI 10.3390/cancers9120171
   Wang CR, 2015, ONCOTARGET, V6, P36231, DOI 10.18632/oncotarget.4740
   Wang H, 2017, MOL THER, V25, P715, DOI 10.1016/j.ymthe.2016.12.020
   Weidle UH, 2015, CLIN EXP METASTAS, V32, P623, DOI 10.1007/s10585-015-9732-3
   Xiao Y, 2019, MOL MED REP, V20, P4558, DOI 10.3892/mmr.2019.10700
   Xue LY, 2017, CANCER BIOMARK, V19, P193, DOI 10.3233/CBM-160506
   Yang QQ, 2017, ONCOL LETT, V13, P1958, DOI 10.3892/ol.2017.5608
   Yu X, 2016, TUMOR BIOL, V37, P1445, DOI 10.1007/s13277-015-4514-8
   Zang Y, 2018, GASTROENT RES PRACT, V2018, DOI [10.1155/2018/2626545, 10.1080/00207543.2018.1471238]
   Zhou W., 2016, J PREV MED CARE, V1, P9, DOI [10.14302/issn.2474-3585.jpmc-15-757, DOI 10.14302/ISSN.2474-3585.JPMC-15-757]
   Zhou W, 2018, J CANCER, V9, P407, DOI 10.7150/jca.21394
   Zhou Y, 2013, GENET TEST MOL BIOMA, V17, P470, DOI 10.1089/gtmb.2012.0518
NR 44
TC 0
Z9 0
U1 0
U2 5
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1791-2997
EI 1791-3004
J9 MOL MED REP
JI Mol. Med. Rep.
PD AUG
PY 2021
VL 24
IS 2
AR 567
DI 10.3892/mmr.2021.12206
PG 10
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Research & Experimental Medicine
GA SS1SK
UT WOS:000661521400001
PM 34109432
DA 2022-04-25
ER

PT J
AU Huang, RH
   Quan, YJ
   Chen, JH
   Wang, T
   Xu, M
   Ye, M
   Yuan, H
   Zhang, CJ
   Liu, XJ
   Min, ZJ
AF Huang, Ren-hong
   Quan, Ying-jun
   Chen, Jin-hong
   Wang, Ting-feng
   Xu, Ming
   Ye, Min
   Yuan, Hao
   Zhang, Chong-jie
   Liu, Xiao-jian
   Min, Zhi-jun
TI Osteopontin Promotes Cell Migration and Invasion, and Inhibits Apoptosis
   and Autophagy in Colorectal Cancer by activating the p38 MAPK Signaling
   Pathway
SO CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
LA English
DT Article
DE Osteopontin; Autophagy; Proliferation; Migration; Invasion; Apoptosis;
   Colorectal cancer; P38 MAPK pathway
ID BREAST-CANCER; CARCINOMA-CELLS; INTEGRIN; METASTASIS; GROWTH;
   PI3K/AKT/MTOR; PROGRESSION; RESISTANCE; EXPRESSION; BLOCKADE
AB Background: Osteopontin (OPN) is highly expressed in colorectal cancer (CRC) and is associated with disease progression in vivo. High levels of OPN have been demonstrated to predict low survival rates in CRC. Autophagy is a process of self-digestion, which is thought to autophagy have not been elucidated. Therefore, we aimed to investigate possible mechanisms Methods: HCT116 cell proliferation, apoptosis, and wound healing assay, and transwell chamber invasion assay, respectively. The ratios of proteins LC3-II/LC3-I, P62, and Atg7 were analyzed by Western-blot. Expressions of Beclin-1, Atg4b, Bnip3, and Vps34, both in transcriptional and translational levels, were analyzed and compared to investigate the formation of autophagosomes. Results: The results showed that OPN can promote cell proliferation, migration, and invasion, as well as inhibit cell apoptosis. It was also demonstrated that OPN could inhibit cell autophagy. Further experiments revealed that the inhibitory effect of OPN on autophagy could be reversed by blocking the p38 MAPK pathway in HCT116 cells. Conclusion: OPN is involved in HCT116 cell progression and is capable of inhibiting cell autophagy possibly by activating the p38 MAPK signaling pathway, implying that OPN could be a potential novel molecular therapeutic biomarker in patients with CRC. (C) 2017 The Author(s) Published by S. Karger AG, Basel.
C1 [Huang, Ren-hong; Quan, Ying-jun; Wang, Ting-feng; Xu, Ming; Ye, Min; Yuan, Hao; Zhang, Chong-jie; Min, Zhi-jun] Fudan Univ, Pudong Med Ctr, Shanghai Pudong Hosp, Dept Gastroenterol Surg, 2800 Gongwei Rd, Shanghai 201399, Peoples R China.
   [Chen, Jin-hong] Fudan Univ, Huashan Hosp, Dept Gen Surg, Shanghai, Peoples R China.
   [Liu, Xiao-jian] Fudan Univ, Shanghai Canc Ctr, Dept Med Oncol, Shanghai 200032, Peoples R China.
RP Min, ZJ (corresponding author), Fudan Univ, Pudong Med Ctr, Shanghai Pudong Hosp, Dept Gastroenterol Surg, 2800 Gongwei Rd, Shanghai 201399, Peoples R China.; Liu, XJ (corresponding author), Fudan Univ, Shanghai Canc Ctr, Dept Med Oncol, Shanghai 200032, Peoples R China.
EM lxj068@hotmail.com; minzhijun@126.com
FU Shanghai municipal Bureau of Health Fund [20134242]; Shanghai Committee
   of Science and Technology FundShanghai Science & Technology Committee
   [15ZR1437500]
FX This work were supported by Shanghai municipal Bureau of Health Fund
   (No. 20134242), Shanghai Committee of Science and Technology Fund (No.
   15ZR1437500).
CR Anborgh PH, 2010, J CELL MOL MED, V14, P2037, DOI 10.1111/j.1582-4934.2010.01115.x
   Burada F, 2015, WORLD J GASTRO ONCOL, V7, P271, DOI 10.4251/wjgo.v7.i11.271
   Chang SH, 2012, J RADIAT RES, V53, P422, DOI 10.1269/jrr.11148
   Chen YJ, 2009, J CELL PHYSIOL, V221, P98, DOI 10.1002/jcp.21835
   Ramos BRD, 2016, CELL STRESS CHAPERON, V21, P755, DOI 10.1007/s12192-016-0715-3
   Di Girolamo N, 2006, INVEST OPHTH VIS SCI, V47, P2430, DOI 10.1167/iovs.05-1130
   Fok TC, 2014, OR SURG OR MED OR PA, V118, P320, DOI 10.1016/j.oooo.2014.05.004
   Grossi V, 2014, WORLD J GASTROENTERO, V20, P9744, DOI 10.3748/wjg.v20.i29.9744
   Guo CX, 2015, INT J NANOMED, V10, P1463, DOI 10.2147/IJN.S76114
   Huang CL, 2013, DIABETES, V62, P2923, DOI 10.2337/db13-0135
   Kurisetty VV, 2008, ONCOGENE, V27, P7139, DOI 10.1038/onc.2008.325
   Li YH, 2015, CELL PHYSIOL BIOCHEM, V37, P1503, DOI 10.1159/000438518
   Liu GK, 2016, CANCER LETT, V383, P171, DOI 10.1016/j.canlet.2016.09.033
   Luo DH, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-203
   Luo M, 2017, J CELL MOL MED, V21, P46, DOI 10.1111/jcmm.12937
   Ma YY, 2016, INT J ONCOL, V48, P2349, DOI 10.3892/ijo.2016.3464
   McNair AGK, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1002071
   Mi ZY, 2009, MOL THER, V17, P153, DOI 10.1038/mt.2008.235
   Mony VK, 2016, AUTOPHAGY, V12, P619, DOI 10.1080/15548627.2016.1147671
   Ng L, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126219
   Ntsapi C, 2016, EXP GERONTOL, V83, P97, DOI 10.1016/j.exger.2016.07.014
   Pizzute T, 2016, TISSUE ENG PT A, V22, P1036, DOI [10.1089/ten.tea.2016.0102, 10.1089/ten.TEA.2016.0102]
   Rodrigues LR, 2007, CANCER EPIDEM BIOMAR, V16, P1087, DOI 10.1158/1055-9965.EPI-06-1008
   Ryter SW, 2012, ANNU REV PHYSIOL, V74, P377, DOI 10.1146/annurev-physiol-020911-153348
   Schurpf T, 2012, FASEB J, V26, P3412, DOI 10.1096/fj.11-202036
   Sharon Y, 2015, CANCER RES, V75, P963, DOI 10.1158/0008-5472.CAN-14-1990
   Shi Y, 2016, ONCOTARGET, V7, P48027, DOI 10.18632/oncotarget.10338
   Siracusano G, 2016, SCI REP-UK, V6, DOI 10.1038/srep31302
   Sun CC, 2016, AM J THER, V23, pE198, DOI 10.1097/MJT.0000000000000053
   Sun SJ, 2016, ONCOTARGET, V7, P55572, DOI 10.18632/oncotarget.10865
   Thorsen SB, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-253
   Tsuprykov O, 2015, CELL PHYSIOL BIOCHEM, V37, P1474, DOI 10.1159/000438516
   vom Dahl S, 2003, J BIOL CHEM, V278, P27088, DOI 10.1074/jbc.M210699200
   Wang LK, 2010, J GASTROINTEST SURG, V14, P74, DOI 10.1007/s11605-009-1035-z
   Wang QR, 2016, PHARMACOL RES, V111, P357, DOI 10.1016/j.phrs.2016.06.024
   Wild N, 2010, CLIN CANCER RES, V16, P6111, DOI 10.1158/1078-0432.CCR-10-0119
   Yatsuoka Toshimasa, 2013, Gan To Kagaku Ryoho, V40, P2041
   Zhang H, 2014, CELL PHYSIOL BIOCHEM, V33, P991, DOI 10.1159/000358670
   Zhang HY, 2015, CELL PHYSIOL BIOCHEM, V37, P548, DOI 10.1159/000430376
   Zhang R, 2015, CELL PHYSIOL BIOCHEM, V35, P175, DOI 10.1159/000369685
   Zheng YH, 2012, J CELL PHYSIOL, V227, P127, DOI 10.1002/jcp.22709
   Zhu YA, 2015, CELL PHYSIOL BIOCHEM, V37, P1983, DOI 10.1159/000438559
NR 42
TC 36
Z9 38
U1 0
U2 11
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 1015-8987
EI 1421-9778
J9 CELL PHYSIOL BIOCHEM
JI Cell. Physiol. Biochem.
PY 2017
VL 41
IS 5
BP 1851
EP 1864
DI 10.1159/000471933
PG 14
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Physiology
GA EY7LW
UT WOS:000404173800011
PM 28376477
OA gold
DA 2022-04-25
ER

PT J
AU Molinari, F
   Pin, F
   Gorini, S
   Chiandotto, S
   Pontecorvo, L
   Penna, F
   Rizzuto, E
   Pisu, S
   Musaro, A
   Costelli, P
   Rosano, G
   Ferraro, E
AF Molinari, Francesca
   Pin, Fabrizio
   Gorini, Stefania
   Chiandotto, Sergio
   Pontecorvo, Laura
   Penna, Fabio
   Rizzuto, Emanuele
   Pisu, Simona
   Musaro, Antonio
   Costelli, Paola
   Rosano, Giuseppe
   Ferraro, Elisabetta
TI The mitochondrial metabolic reprogramming agent trimetazidine as an
   'exercise mimetic' in cachectic C26-bearing mice
SO JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE
LA English
DT Article
DE Cachexia; Atrophy; Metabolism; Mitochondria; Rehabilitation
ID FATTY-ACID OXIDATION; KINASE SIGNAL-TRANSDUCTION; SKELETAL-MUSCLE
   ATROPHY; COENZYME-A THIOLASE; CANCER CACHEXIA; TRANSCRIPTIONAL
   COACTIVATOR; HEART-FAILURE; FIBER-TYPE; MODULATOR TRIMETAZIDINE;
   GLUCOSE-OXIDATION
AB Background Cancer cachexia is characterized by muscle depletion and exercise intolerance caused by an imbalance between protein synthesis and degradation and by impaired myogenesis. Myofibre metabolic efficiency is crucial so as to assure optimal muscle function. Some drugs are able to reprogram cell metabolism and, in some cases, to enhance metabolic efficiency. Based on these premises, we chose to investigate the ability of the metabolic modulator trimetazidine (TMZ) to counteract skeletal muscle dysfunctions and wasting occurring in cancer cachexia.
   Methods For this purpose, we used mice bearing the C26 colon carcinoma as a model of cancer cachexia. Mice received 5 mg/kg TMZ (i.p.) once a day for 12 consecutive days. A forelimb grip strength test was performed and tibialis anterior, and gastrocnemius muscles were excised for analysis. Ex vivo measurement of skeletal muscle contractile properties was also performed.
   Results Our data showed that TMZ induces some effects typically achieved through exercise, among which is grip strength increase, an enhanced fast-to slow myofibre phenotype shift, reduced glycaemia, PGC1 alpha up-regulation, oxidative metabolism, and mitochondrial biogenesis. TMZ also partially restores the myofibre cross-sectional area in C26-bearing mice, while modulation of autophagy and apoptosis were excluded as mediators of TMZ effects.
   Conclusions In conclusion, our data show that TMZ acts like an 'exercise mimetic' and is able to enhance some mechanisms of adaptation to stress in cancer cachexia. This makes the modulation of the metabolism, and in particular TMZ, a suitable candidate for a therapeutic rehabilitative protocol design, particularly considering that TMZ has already been approved for clinical use.
C1 [Molinari, Francesca; Gorini, Stefania; Pontecorvo, Laura; Rosano, Giuseppe; Ferraro, Elisabetta] IRCCS San Raffaele Pisana, Lab Pathophysiol Cachexia & Metab Skeletal Muscle, Via Val Cannuta, I-00166 Rome, Italy.
   [Pin, Fabrizio; Penna, Fabio; Costelli, Paola] Univ Turin, Dept Clin & Biol Sci, IIM, I-10125 Turin, Italy.
   [Chiandotto, Sergio] Sapienza Univ Rome, DMCM, Dept Surg Pietro Valdoni, Via Scarpa, I-00161 Rome, Italy.
   [Rizzuto, Emanuele] Sapienza Univ Rome, Dept Mech & Aerosp Engn, Via Eudossiana, I-00184 Rome, Italy.
   [Pisu, Simona; Musaro, Antonio] Sapienza Univ Rome, Inst Pasteur Cenci Bolognetti, DAHFMO Unit Histol & Med Embryol, IIM, Via Scarpa, I-00161 Rome, Italy.
   [Musaro, Antonio] Ist Italiano Tecnol, Ctr Life Nano Sci Sapienza, Viale Regina Elena, I-00161 Rome, Italy.
   [Rosano, Giuseppe] St Georges Univ London, Cardiovasc & Cell Sci Inst, Cranmer Terrace, London SW17, England.
RP Ferraro, E (corresponding author), IRCCS San Raffaele Pisana, Lab Pathophysiol Cachexia & Metab Skeletal Muscle, Via Val Cannuta 247, I-00166 Rome, Italy.; Rosano, G (corresponding author), IRCCS San Raffaele, Ctr Vasc Physiol, 106 Harley St, London W1G 7JQ, England.
EM giuseppe.rosano@gmail.com; elisabetta.ferraro@sanraffaele.it
RI Musarò, Antonio/K-9598-2016; gorini, stefania/ABI-6853-2020; ferraro,
   elisabetta/K-3904-2016; Ferraro, Elisabetta/AAS-4975-2020; molinari,
   francesca/K-3862-2016; Musaro, Antonio/P-2953-2019; Rosano, Giuseppe M.
   C./K-8718-2018; Penna, Fabio/K-5090-2016
OI Musarò, Antonio/0000-0002-2944-9739; ferraro,
   elisabetta/0000-0002-9596-4624; molinari, francesca/0000-0003-0570-7438;
   Musaro, Antonio/0000-0002-2944-9739; Rosano, Giuseppe M.
   C./0000-0003-4023-2263; Pisu, Simona/0000-0002-8216-9090; Penna,
   Fabio/0000-0002-2774-6027
FU Italian Ministry of Health for Institutional ResearchMinistry of Health,
   Italy; grant Ricerca Finalizzata (RF) [2010-2318508]
FX This work was supported by the Italian Ministry of Health for
   Institutional Research and grant Ricerca Finalizzata (RF) 2010-2318508
   to Elisabetta Ferraro.
CR Acharyya S, 2007, CLIN CANCER RES, V13, P1356, DOI 10.1158/1078-0432.CCR-06-2307
   Anker SD, 2015, J CACHEXIA SARCOPENI, V6, P269, DOI 10.1002/jcsm.12088
   Baar K, 2002, FASEB J, V16, P1879, DOI 10.1096/fj.02-0367com
   Baar K, 2010, ACTA PHYSIOL, V199, P477, DOI 10.1111/j.1748-1716.2010.02121.x
   BARANY M, 1967, J GEN PHYSIOL, V50, P197, DOI 10.1085/jgp.50.6.197
   Booth FW, 2008, BRIT J SPORT MED, V42, P950, DOI 10.1136/bjsm.2008.052589
   Bowen TS, 2015, J CACHEXIA SARCOPENI, V6, P197, DOI 10.1002/jcsm.12043
   BROOKS SV, 1988, J PHYSIOL-LONDON, V404, P71, DOI 10.1113/jphysiol.1988.sp017279
   Calabria E, 2009, P NATL ACAD SCI USA, V106, P13335, DOI 10.1073/pnas.0812911106
   Cervelli M, 2009, INT J BIOCHEM CELL B, V41, P934, DOI 10.1016/j.biocel.2008.09.009
   Chinsomboon J, 2009, P NATL ACAD SCI USA, V106, P21401, DOI 10.1073/pnas.0909131106
   Coats AJS, 2012, J CACHEXIA SARCOPENI, V3, P219, DOI 10.1007/s13539-012-0090-6
   CONDON K, 1990, DEV BIOL, V138, P256, DOI 10.1016/0012-1606(90)90196-P
   De Zio D, 2015, CELL MOL LIFE SCI, V72, P4173, DOI 10.1007/s00018-015-1927-x
   Del Prete Z, 2008, ANN BIOMED ENG, V36, P1281, DOI 10.1007/s10439-008-9496-x
   Drescher C, 2015, J CACHEXIA SARCOPENI, V6, P303, DOI 10.1002/jcsm.12082
   Edelmann F, 2015, ESC HEART FAIL, V2, P41, DOI 10.1002/ehf2.12037
   Egan B, 2013, CELL METAB, V17, P162, DOI 10.1016/j.cmet.2012.12.012
   Evans WJ, 2008, CLIN NUTR, V27, P793, DOI 10.1016/j.clnu.2008.06.013
   Ferraro E, 2007, ARCH BIOCHEM BIOPHYS, V462, P210, DOI 10.1016/j.abb.2007.02.006
   Ferraro E, 2016, J CACHEXIA SARCOPENI, V7, P449, DOI 10.1002/jcsm.12097
   Ferraro E, 2014, ANTIOXID REDOX SIGN, V21, P154, DOI 10.1089/ars.2013.5773
   Ferraro E, 2013, FEBS J, V280, P5094, DOI 10.1111/febs.12484
   Ferraro E, 2011, J CELL SCI, V124, P3450, DOI 10.1242/jcs.086298
   Fragasso G, 2003, AM HEART J, V146, DOI 10.1016/S0002-8703(03)00415-0
   Fragasso G, 2013, INT J CARDIOL, V163, P320, DOI 10.1016/j.ijcard.2012.09.123
   Fukawa T, 2016, NAT MED, V22, P666, DOI 10.1038/nm.4093
   Gaffney CJ, 2016, J CACHEXIA SARCOPENI, V7, P181, DOI 10.1002/jcsm.12040
   Grande AJ, 2015, J CACHEXIA SARCOPENI, V6, P208, DOI 10.1002/jcsm.12055
   Gundersen K, 2011, BIOL REV, V86, P564, DOI 10.1111/j.1469-185X.2010.00161.x
   Guttridge DC, 2000, SCIENCE, V289, P2363, DOI 10.1126/science.289.5488.2363
   Hawley JA, 2016, NAT REV ENDOCRINOL, V12, P7, DOI 10.1038/nrendo.2015.201
   Heymsfield SB, 2014, J CACHEXIA SARCOPENI, V5, P9, DOI 10.1007/s13539-014-0130-5
   Irrcher I, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003614
   Irwin MH, 2013, INT J BIOCHEM CELL B, V45, P34, DOI 10.1016/j.biocel.2012.08.009
   Iwata Y, 2016, J CACHEXIA SARCOPENI, V7, P366, DOI 10.1002/jcsm.12067
   Jahnke VE, 2012, SKELET MUSCLE, V2, DOI 10.1186/2044-5040-2-16
   Jaswal JS, 2011, BBA-MOL CELL RES, V1813, P1333, DOI 10.1016/j.bbamcr.2011.01.015
   Kantor PF, 2000, CIRC RES, V86, P580, DOI 10.1161/01.RES.86.5.580
   Khodabukus A, 2015, J CELL PHYSIOL, V230, P1750, DOI 10.1002/jcp.24848
   Komajda M, 2015, EUR J HEART FAIL, V17, P1294, DOI 10.1002/ejhf.347
   Lecker SH, 2004, FASEB J, V18, P39, DOI 10.1096/fj.03-0610com
   Lenk K, 2010, J CACHEXIA SARCOPENI, V1, P9, DOI 10.1007/s13539-010-0007-1
   Lerner L, 2016, J CACHEXIA SARCOPENI, V7, P467, DOI 10.1002/jcsm.12077
   Lin J, 2002, NATURE, V418, P797, DOI 10.1038/nature00904
   Lira VA, 2010, AM J PHYSIOL-ENDOC M, V299, pE145, DOI 10.1152/ajpendo.00755.2009
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lodka D, 2016, J CACHEXIA SARCOPENI, V7, P165, DOI 10.1002/jcsm.12057
   Long YC, 2004, P NUTR SOC, V63, P227, DOI 10.1079/PNS2004346
   Lopaschuk GD, 2003, CIRC RES, V93, pE33, DOI 10.1161/01.RES.0000086964.07404.A5
   Lopatin YM, 2016, INT J CARDIOL, V203, P909, DOI 10.1016/j.ijcard.2015.11.060
   Mammucari C, 2007, CELL METAB, V6, P458, DOI 10.1016/j.cmet.2007.11.001
   Marazzi G, 2009, ADV THER, V26, P455, DOI 10.1007/s12325-009-0024-7
   Marino FE, 2015, J CACHEXIA SARCOPENI, V6, P365, DOI 10.1002/jcsm.12031
   Milone M, 2013, MOL GENET METAB, V110, P35, DOI 10.1016/j.ymgme.2013.07.007
   Molinari F, 2016, INT J CARDIOL, V219, P105, DOI 10.1016/j.ijcard.2016.05.071
   Montagna C, 2014, ANTIOXID REDOX SIGN, V21, P570, DOI 10.1089/ars.2013.5696
   Moreno S, 2006, APOPTOSIS, V11, P1595, DOI 10.1007/s10495-006-9081-4
   Narkar VA, 2008, CELL, V134, P405, DOI 10.1016/j.cell.2008.06.051
   Palus S, 2014, J CACHEXIA SARCOPENI, V5, P193, DOI 10.1007/s13539-014-0157-7
   Penna F, 2013, AM J PATHOL, V182, P1367, DOI 10.1016/j.ajpath.2012.12.023
   Penna F, 2010, INT J CANCER, V127, P1706, DOI 10.1002/ijc.25146
   Pilegaard H, 2003, J PHYSIOL-LONDON, V546, P851, DOI 10.1113/jphysiol.2002.034850
   Pin F, 2015, ONCOTARGET, V6, P43202, DOI 10.18632/oncotarget.6439
   Proud CG, 2009, BIOCHEM SOC T, V37, P227, DOI 10.1042/BST0370227
   Puigserver P, 2003, ENDOCR REV, V24, P78, DOI 10.1210/er.2002-0012
   Rosano GMC, 2003, CARDIOVASC DIABETOL, V2, DOI 10.1186/1475-2840-2-16
   Ruas JL, 2012, CELL, V151, P1319, DOI 10.1016/j.cell.2012.10.050
   Ryder JW, 2000, J BIOL CHEM, V275, P1457, DOI 10.1074/jbc.275.2.1457
   Sanders KJC, 2016, J CACHEXIA SARCOPENI, V7, P5, DOI 10.1002/jcsm.12062
   Sandri M, 2010, FEBS LETT, V584, P1411, DOI 10.1016/j.febslet.2010.01.056
   Schiaffino S, 2010, ACTA PHYSIOL, V199, P451, DOI 10.1111/j.1748-1716.2010.02130.x
   Schiaffino S, 1996, PHYSIOL REV, V76, P371, DOI 10.1152/physrev.1996.76.2.371
   Schiaffino S, 2011, SKELET MUSCLE, V1, DOI 10.1186/2044-5040-1-4
   Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089
   Talbert E, 2014, J CACHEXIA SARCOPENI, V5, P321, DOI 10.1007/s13539-014-0141-2
   Tan BHL, 2008, CURR OPIN CLIN NUTR, V11, P400, DOI 10.1097/MCO.0b013e328300ecc1
   Tanaka T, 2003, P NATL ACAD SCI USA, V100, P15924, DOI 10.1073/pnas.0306981100
   Tocchetti CG, 2014, EUR J HEART FAIL, V16, P358, DOI 10.1002/ejhf.50
   Vitale C, 2011, PHARMACOL RES, V63, P278, DOI 10.1016/j.phrs.2011.01.003
   von Haehling S, 2016, J CACHEXIA SARCOPENI, V7, P507, DOI 10.1002/jcsm.12167
   von Haehling S, 2015, J CACHEXIA SARCOPENI, V6, P315, DOI 10.1002/jcsm.12089
   von Haehling S, 2015, INT J CARDIOL, V184, P736, DOI 10.1016/j.ijcard.2014.10.026
   Wang YC, 2013, CURR OPIN CLIN NUTR, V16, P243, DOI 10.1097/MCO.0b013e328360272d
   Widegren U, 2001, ACTA PHYSIOL SCAND, V172, P227, DOI 10.1046/j.1365-201x.2001.00855.x
   Zierath JR, 2002, J APPL PHYSIOL, V93, P773, DOI 10.1152/japplphysiol.00126.2002
NR 86
TC 43
Z9 45
U1 1
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2190-6009
J9 J CACHEXIA SARCOPENI
JI J. Caxhexia Sarcopenia Muscle
PD DEC
PY 2017
VL 8
IS 6
BP 954
EP 973
DI 10.1002/jcsm.12226
PG 20
WC Geriatrics & Gerontology; Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology; General & Internal Medicine
GA FU4MP
UT WOS:000423827500009
PM 29130633
OA Green Published, Green Accepted, gold
DA 2022-04-25
ER

PT J
AU Wei, R
   Xiao, YH
   Song, Y
   Yuan, HP
   Luo, J
   Xu, W
AF Wei, Ran
   Xiao, Yuhong
   Song, Yi
   Yuan, Huiping
   Luo, Jun
   Xu, Wei
TI FAT4 regulates the EMT and autophagy in colorectal cancer cells in part
   via the PI3K-AKT signaling axis
SO JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
LA English
DT Article
DE Colorectal cancer; FAT4; PI3K; AKT; EMT; Proliferation; Autophagy
ID MESENCHYMAL TRANSITION; BETA-CATENIN; PATHWAY; PHOSPHORYLATION; COMPLEX;
   LC3; INHIBITION; EXPRESSION; GSK-3-BETA; INVASION
AB BackgroundFAT4 functions as a tumor suppressor, and previous findings have demonstrated that FAT4 can inhibit the epithelial-to-mesenchymal transition (EMT) and the proliferation of gastric cancer cells. However, few studies have investigated the role of FAT4 in the development of colorectal cancer (CRC). The current study aimed to detect the role of FAT4 in the invasion, migration, proliferation and autophagy of CRC and elucidate the probable molecular mechanisms through which FAT4 interacts with these processes.MethodsTranswell invasion assays, MTT assays, transmission electron microscopy, immunohistochemistry and western blotting were performed to evaluate the migration, invasion, proliferation and autophagy abilities of CRC cells, and the levels of active molecules involved in PI3K/AKT signaling were examined through a western blotting analysis. In addition, the function of FAT4 in vivo was assessed using a tumor xenograft model.ResultsFAT4 expression in CRC tissues was weaker than that in nonmalignant tissues and could inhibit cell invasion, migration, and proliferation by promoting autophagy in vitro. Furthermore, the regulatory effects of FAT4 on autophagy and the EMT were partially attributed to the PI3K-AKT signaling pathway. The results in vivo also showed that FAT4 modulated CRC tumorigenesis.ConclusionFAT4 can regulate the activity of PI3K to promote autophagy and inhibit the EMT in part through the PI3K/AKT/mTOR and PI3K/AKT/GSK-3 signaling pathways.
C1 [Xiao, Yuhong; Luo, Jun] Nanchang Univ, Affiliated Hosp 2, Dept Rehabil Med, Nanchang 330006, Jiangxi, Peoples R China.
   [Song, Yi; Yuan, Huiping; Xu, Wei] Nanchang Univ, Affiliated Hosp 2, Dept Gen Surg, Nanchang 330006, Jiangxi, Peoples R China.
   [Wei, Ran] Nanchang Univ, Clin Med Coll 1, Nanchang 330006, Jiangxi, Peoples R China.
RP Luo, J (corresponding author), Nanchang Univ, Affiliated Hosp 2, Dept Rehabil Med, Nanchang 330006, Jiangxi, Peoples R China.; Xu, W (corresponding author), Nanchang Univ, Affiliated Hosp 2, Dept Gen Surg, Nanchang 330006, Jiangxi, Peoples R China.
EM luojun1786@163.com; xu_wei111@126.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81560365, 81760408, 81860435]
FX This work was supported by grants from the National Natural Science
   Foundation of China (Grant numbers 81560365, 81760408, and 81860435).
CR Alers S, 2012, MOL CELL BIOL, V32, P2, DOI 10.1128/MCB.06159-11
   Bodine SC, 2001, NAT CELL BIOL, V3, P1014, DOI 10.1038/ncb1101-1014
   Burk U, 2008, EMBO REP, V9, P582, DOI 10.1038/embor.2008.74
   Byers LA, 2013, CLIN CANCER RES, V19, P279, DOI 10.1158/1078-0432.CCR-12-1558
   Cheong H, 2011, P NATL ACAD SCI USA, V108, P11121, DOI 10.1073/pnas.1107969108
   Choi AMK, 2013, NEW ENGL J MED, V368, P651, DOI [10.1056/NEJMra1205406, 10.1056/NEJMc1303158]
   Czech MP, 2000, CELL, V100, P603, DOI 10.1016/S0092-8674(00)80696-0
   Debnath J, 2005, AUTOPHAGY, V1, P66, DOI 10.4161/auto.1.2.1738
   Di Bartolomeo S, 2010, TRAFFIC, V11, P1280, DOI 10.1111/j.1600-0854.2010.01103.x
   Egan DF, 2015, MOL CELL, V59, P285, DOI 10.1016/j.molcel.2015.05.031
   Egan DF, 2011, AUTOPHAGY, V7, P645, DOI 10.4161/auto.7.6.15123
   Egan DF, 2011, SCIENCE, V331, P456, DOI 10.1126/science.1196371
   Fujita N, 2008, MOL BIOL CELL, V19, P2092, DOI 10.1091/mbc.E07-12-1257
   Gao N, 2004, AM J PHYSIOL-CELL PH, V287, pC281, DOI 10.1152/ajpcell.00422.2003
   Gozuacik D, 2004, ONCOGENE, V23, P2891, DOI 10.1038/sj.onc.1207521
   Gravdal K, 2007, CLIN CANCER RES, V13, P7003, DOI 10.1158/1078-0432.CCR-07-1263
   Gugnoni M, 2017, ONCOGENE, V36, P667, DOI 10.1038/onc.2016.237
   Haraguchi K, 2008, ONCOGENE, V27, P274, DOI 10.1038/sj.onc.1210644
   Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371
   Ishiuchi T, 2009, J CELL BIOL, V185, P959, DOI 10.1083/jcb.200811030
   Ito H, 2005, INT J ONCOL, V26, P1401
   Karantza-Wadsworth V, 2007, GENE DEV, V21, P1621, DOI 10.1101/gad.1565707
   Katoh Y, 2006, INT J MOL MED, V18, P523
   Kim J, 2011, NAT CELL BIOL, V13, P132, DOI 10.1038/ncb2152
   Komatsu M, 2007, CELL, V131, P1149, DOI 10.1016/j.cell.2007.10.035
   Komatsu M, 2010, NAT CELL BIOL, V12, P213, DOI 10.1038/ncb2021
   Kroemer G, 2010, MOL CELL, V40, P280, DOI 10.1016/j.molcel.2010.09.023
   Lee YJ, 2010, AM J PHYSIOL-RENAL, V298, pF1263, DOI 10.1152/ajprenal.00475.2009
   Levine B, 2007, NATURE, V446, P745, DOI 10.1038/446745a
   Li J, 2013, CARCINOGENESIS, V34, P1343, DOI 10.1093/carcin/bgt063
   Mathew R, 2009, ASSESSING METABOLIC
   Mathew R, 2007, NAT REV CANCER, V7, P961, DOI 10.1038/nrc2254
   Mizushima N, 2010, CURR OPIN CELL BIOL, V22, P132, DOI 10.1016/j.ceb.2009.12.004
   Pankiv S., 2007, AIP ADV
   Qian Y, 2004, AM J PHYSIOL-CELL PH, V286, pC153, DOI 10.1152/ajpcell.00142.2003
   Qiang L, 2014, AUTOPHAGY, V10, P1864, DOI 10.4161/auto.32171
   Qiang L, 2014, P NATL ACAD SCI USA, V111, P9241, DOI 10.1073/pnas.1322913111
   Saiki S, 2011, AUTOPHAGY, V7, P176, DOI 10.4161/auto.7.2.14074
   Shamir ER, 2014, J CELL BIOL, V204, P839, DOI 10.1083/jcb.201306088
   Shang LB, 2011, AUTOPHAGY, V7, P924, DOI 10.4161/auto.7.8.15860
   Siegel RL, 2017, CA-CANCER J CLIN, V67, P177, DOI 10.3322/caac.21395
   Tanida I, 2004, INT J BIOCHEM CELL B, V36, P2503, DOI 10.1016/j.biocel.2004.05.009
   Van Rheenen J, 2007, J CELL BIOL, V179, P1247, DOI 10.1083/jcb.200706206
   Vuoriluoto K, 2011, ONCOGENE, V30, P1436, DOI 10.1038/onc.2010.509
   Xiao JA, 2011, INT J CARDIOL, V148, P110, DOI 10.1016/j.ijcard.2011.01.029
   Xie QY, 2015, INT J CLIN EXP MED, V8, P12498
   Xu W, 2015, CANCER LETT, V356, P613, DOI 10.1016/j.canlet.2014.10.008
   Yang W, 2007, J BIOL CHEM, V282, P3799, DOI 10.1074/jbc.M610185200
   Yuan TL, 2008, ONCOGENE, V27, P5497, DOI 10.1038/onc.2008.245
   Zhou DH, 2016, EXP MOL MED, V48, DOI 10.1038/emm.2016.37
   Zhu HT, 2014, ONCOL REP, V32, P935, DOI 10.3892/or.2014.3298
NR 51
TC 46
Z9 49
U1 2
U2 4
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1756-9966
J9 J EXP CLIN CANC RES
JI J. Exp. Clin. Cancer Res.
PD MAR 4
PY 2019
VL 38
AR 112
DI 10.1186/s13046-019-1043-0
PG 14
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA HO0LK
UT WOS:000460594700001
PM 30832706
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Han, YH
   Mun, JG
   Jeon, HD
   Kee, JY
   Hong, SH
AF Han, Yo-Han
   Mun, Jeong-Geon
   Jeon, Hee Dong
   Kee, Ji-Ye
   Hong, Seung-Heon
TI Betulin Inhibits Lung Metastasis by Inducing Cell Cycle Arrest,
   Autophagy, and Apoptosis of Metastatic Colorectal Cancer Cells
SO NUTRIENTS
LA English
DT Article
DE betulin; colorectal metastasis; apoptosis; autophagy; cell cycle arrest
ID AMPK; INDUCTION; CARCINOMA; PATHWAYS; EXTRACT; INJURY; DEATH
AB Background: Colorectal cancer (CRC) is one of the diseases with high prevalence and mortality worldwide. In particular, metastatic CRC shows low probability of surgery and lacks proper treatment. In this study, we conducted experiments to investigate the inhibitory effect of betulin against metastatic CRC and related mechanisms. Methods: Water-soluble tetrazolium assay was used to determine the effect of betulin on metastatic CRC cell viability. Flow cytometry and TUNEL assay were performed to confirm whether betulin can induce apoptosis, autophagy, and cell cycle arrest. A lung metastasis mouse model was employed to estimate the anti-metastatic effect of betulin. Results: betulin decreased viability of metastatic CRC cells, including CT26, HCT116, and SW620 cell lines. Through PI3K/Akt/mTOR inactivation, betulin induced AMPK-mediated G0/G1 phase arrest and autophagy of CT26 and HCT116 cells. In addition, betulin occurred caspase-dependent apoptosis via the mitogen-activated protein kinase signaling pathway in metastatic CRC cells. Moreover, orally administered betulin significantly inhibited metastasis of CT26 cells to the lung. Conclusion: Our results demonstrate the anti-metastatic effect and therapeutic potential of betulin in metastatic CRC treatment.
C1 [Han, Yo-Han; Mun, Jeong-Geon; Jeon, Hee Dong; Kee, Ji-Ye; Hong, Seung-Heon] Wonkwang Univ, Wonkwang Oriental Med Res Inst, Coll Pharm, Dept Oriental Pharm, 460 Iksandae Ro, Iksan 54538, Jeonbuk, South Korea.
RP Kee, JY; Hong, SH (corresponding author), Wonkwang Univ, Wonkwang Oriental Med Res Inst, Coll Pharm, Dept Oriental Pharm, 460 Iksandae Ro, Iksan 54538, Jeonbuk, South Korea.
EM dygks1867@hanmail.net; wjdrjs92@daum.net; alen0707@naver.com;
   keejy@wku.ac.kr; jooklim@wku.ac.kr
OI Kee, Ji-Ye/0000-0002-9836-2127
FU Wonkwang University
FX This study was supported by Wonkwang University in 2017.
CR Acquaviva R, 2016, ONCOL REP, V36, P2298, DOI 10.3892/or.2016.5035
   Arnold M, 2017, GUT, V66, P683, DOI 10.1136/gutjnl-2015-310912
   Bai T, 2016, PHARMACOL RES, V105, P1, DOI 10.1016/j.phrs.2015.12.022
   BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812
   Boulares AH, 1999, J BIOL CHEM, V274, P22932, DOI 10.1074/jbc.274.33.22932
   Cho N, 2016, BIOSCI BIOTECH BIOCH, V80, P166, DOI 10.1080/09168451.2015.1072460
   Ci XX, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.39
   Cicenas J, 2018, CANCERS, V10, DOI 10.3390/cancers10010001
   Elmore S, 2007, TOXICOL PATHOL, V35, P495, DOI 10.1080/01926230701320337
   He CC, 2009, ANNU REV GENET, V43, P67, DOI 10.1146/annurev-genet-102808-114910
   Jager S, 2008, MOLECULES, V13, P3224, DOI 10.3390/molecules13123224
   Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682
   Kee JY, 2018, J ETHNOPHARMACOL, V220, P177, DOI 10.1016/j.jep.2018.03.036
   KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33
   Kim J, 2011, NAT CELL BIOL, V13, P132, DOI 10.1038/ncb2152
   Kim KJ, 2018, J CLIN MED, V7, DOI 10.3390/jcm7060154
   Krol SK, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/584189
   Law BYK, 2016, ONCOTARGET, V7, P8090, DOI 10.18632/oncotarget.6980
   Li WD, 2015, ONCOTARGET, V6, P7365, DOI 10.18632/oncotarget.3629
   Li Y, 2016, ARCH PHARM RES, V39, P1257, DOI 10.1007/s12272-016-0761-5
   Li Y, 2010, MOL CARCINOGEN, V49, P630, DOI 10.1002/mc.20638
   Lin SR, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18071412
   Ma CH, 2017, BIOMED PHARMACOTHER, V85, P679, DOI 10.1016/j.biopha.2016.11.079
   Malfa GA, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20112723
   Manning BD, 2017, CELL, V169, P381, DOI 10.1016/j.cell.2017.04.001
   Mathew R, 2007, NAT REV CANCER, V7, P961, DOI 10.1038/nrc2254
   Mogavero A, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-16149-z
   Sikka A, 2012, CELL CYCLE, V11, P1374, DOI 10.4161/cc.19798
   Tsuchiya T, 2008, HEPATO-GASTROENTEROL, V55, P930
   Wada T, 2004, ONCOGENE, V23, P2838, DOI 10.1038/sj.onc.1207556
   Wang Y, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0731-5
   Yan XN, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0255-5
   Yim NH, 2015, ONCOL REP, V34, P1058, DOI 10.3892/or.2015.4045
   Zhao HY, 2016, LIFE SCI, V144, P185, DOI 10.1016/j.lfs.2015.12.003
   Zhou YQ, 2017, ACTA PHARMACOL SIN, V38, P201, DOI 10.1038/aps.2016.102
   Zhou ZY, 2018, ONCOL LETT, V15, P7319, DOI 10.3892/ol.2018.8183
   Zhuang Yongxian, 2008, J Mol Signal, V3, P18, DOI 10.1186/1750-2187-3-18
   Zhuo ZJ, 2018, ONCOL LETT, V15, P2097, DOI 10.3892/ol.2017.7575
NR 38
TC 16
Z9 16
U1 1
U2 8
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2072-6643
J9 NUTRIENTS
JI Nutrients
PD JAN
PY 2020
VL 12
IS 1
AR 66
DI 10.3390/nu12010066
PG 13
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA KQ3KN
UT WOS:000516825500066
PM 31887988
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Salgado-Garcia, R
   Coronel-Hernandez, J
   Delgado-Waldo, I
   de Leon, DC
   Garcia-Castillo, V
   Lopez-Urrutia, E
   Gutierrez-Ruiz, MC
   Perez-Plasencia, C
   Jacobo-Herrera, N
AF Salgado-Garcia, Rebeca
   Coronel-Hernandez, Jossimar
   Delgado-Waldo, Izamary
   Cantu de Leon, David
   Garcia-Castillo, Veronica
   Lopez-Urrutia, Eduardo
   Gutierrez-Ruiz, Ma. Concepcion
   Perez-Plasencia, Carlos
   Jacobo-Herrera, Nadia
TI Negative Regulation of ULK1 by microRNA-106a in Autophagy Induced by a
   Triple Drug Combination in Colorectal Cancer Cells In Vitro
SO GENES
LA English
DT Article
DE autophagy; miR-106a; ULK1; colorectal cancer; HCT116; SW480; metformin;
   doxorubicin; sodium oxamate
AB Colorectal cancer (CRC) is among the top three most deadly cancers worldwide. The survival rate for this disease has not been reduced despite the treatments, the reason why the search for therapeutic alternatives continues to be a priority issue in oncology. In this research work, we tested our successful pharmacological combination of three drugs, metformin, doxorubicin, and sodium oxamate (triple therapy, or TT), as an autophagy inducer. Firstly, we employed western blot (WB) assays, where we observed that after 8 h of stimulation with TT, the proteins Unc-51 like autophagy activating kinase 1(ULK1), becline-1, autophagy related 1 protein (Atg4), and LC3 increased in the CRC cell lines HCT116 and SW480 in contrast to monotherapy with doxorubicin. The overexpression of these proteins indicated the beginning of autophagy flow through the activation of ULK1 and the hyperlipidation of LC3 at the beginning of this process. Moreover, we confirm that ULK1 is a bona fide target of hsa-miR-106a-5p (referred to from here on as miR-106a) in HCT116. We also observed through the GFP-LC3 fusion protein that in the presence of miR-106a, the accumulation of autophagy vesicles in cells stimulated with TT is inhibited. These results show that the TT triggered autophagy to modulate miR-106a/ULK1 expression, probably affecting different cellular pathways involved in cellular proliferation, survivance, metabolic maintenance, and cell death. Therefore, considering the importance of autophagy in cancer biology, the study of miRNAs that regulate autophagy in cancer will allow a better understanding of malignant tumors and lead to the development of new disease markers and therapeutic strategies.
C1 [Salgado-Garcia, Rebeca] Autonomous Metropolitan Univ Iztapalapa, Postgrad Expt Biol, DCBS, Mexico City 09340, DF, Mexico.
   [Salgado-Garcia, Rebeca; Coronel-Hernandez, Jossimar; Delgado-Waldo, Izamary; Perez-Plasencia, Carlos] Natl Canc Inst, Genom Lab, Mexico City 14080, DF, Mexico.
   [Coronel-Hernandez, Jossimar; Garcia-Castillo, Veronica; Lopez-Urrutia, Eduardo; Perez-Plasencia, Carlos] UNAM, Funct Genom Lab, Biomed Unit, FES IZTACALA, Tlalnepantla 54090, Mexico.
   [Cantu de Leon, David] Natl Canc Inst, Canc Biomed Res Unit, Genom Lab, Mexico City 14080, DF, Mexico.
   [Gutierrez-Ruiz, Ma. Concepcion] UNAM Natl Inst Cardiol Ignacio Chavez, Inst Biomed Res, Translat Med Unit, Expt Med Lab, Mexico City 14080, DF, Mexico.
   [Gutierrez-Ruiz, Ma. Concepcion] Autonomous Metropolitan Univ Iztapalapa, Dept Hlth Sci, Mexico City 09340, DF, Mexico.
   [Jacobo-Herrera, Nadia] Inst Med Sci & Nutr, Biochem Unit, Mexico City, DF 14080, Mexico.
RP Perez-Plasencia, C (corresponding author), Natl Canc Inst, Genom Lab, Mexico City 14080, DF, Mexico.; Perez-Plasencia, C (corresponding author), UNAM, Funct Genom Lab, Biomed Unit, FES IZTACALA, Tlalnepantla 54090, Mexico.; Jacobo-Herrera, N (corresponding author), Inst Med Sci & Nutr, Biochem Unit, Mexico City, DF 14080, Mexico.
EM rebe_zoid92@hotmail.com; jossi_thunders@hotmail.com;
   izz.waldo11@gmail.com; dfcantu@gmail.com; garciaver@gmail.com;
   e_urrutia@unam.mx; mcgr@xanum.uam.mx; carlos.pplas@gmail.com;
   nadia.jacoboh@incmnsz.mx
RI Jacobo-Herrera, Nadia/AGG-8009-2022
OI Jacobo-Herrera, Nadia/0000-0002-1026-3774; Delgado-Waldo,
   Izamary/0000-0002-3688-9775; Salgado, Rebeca/0000-0002-1289-1213;
   Lopez-Urrutia, Eduardo/0000-0002-5307-2003; Gutierrez-Ruiz, Maria
   Concepcion/0000-0003-0501-7226
FU Consejo Nacional de Ciencia y Tecnologia (CONACYT), MexicoConsejo
   Nacional de Ciencia y Tecnologia (CONACyT) [285884]; UNAMUniversidad
   Nacional Autonoma de Mexico [PAPIIT-IN231420]
FX This research was funded by the Consejo Nacional de Ciencia y Tecnologia
   (CONACYT), Mexico (grant number 285884); UNAM PAPIIT-IN231420.
CR Agarwal V, 2015, ELIFE, V4, DOI 10.7554/eLife.05005
   Ahmed D, 2013, ONCOGENESIS, V2, DOI 10.1038/oncsis.2013.35
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
   Carrington JC, 2003, SCIENCE, V301, P336, DOI 10.1126/science.1085242
   Chen Y, 2015, SCI REP-UK, V5, DOI 10.1038/srep11035
   Clarke AJ, 2019, NAT REV IMMUNOL, V19, P170, DOI 10.1038/s41577-018-0095-2
   Cristofani R, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0866-5
   Dehal A, 2018, J GASTROINTEST SURG, V22, P242, DOI 10.1007/s11605-017-3566-z
   Figueroa-Gonzalez G, 2016, J CANCER, V7, P1632, DOI 10.7150/jca.13123
   Garcia-Castillo V, 2017, J CANCER, V8, P178, DOI 10.7150/jca.16387
   Gelibter AJ, 2019, SURG ONCOL, V30, P100, DOI 10.1016/j.suronc.2019.06.003
   Gozuacik D, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00065
   Griffiths-Jones S, 2008, NUCLEIC ACIDS RES, V36, pD154, DOI 10.1093/nar/gkm952
   Hao HB, 2017, MED MOL MORPHOL, V50, P76, DOI 10.1007/s00795-016-0150-7
   Horakova O, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-42531-0
   Huang YP, 2011, CELL CYCLE, V10, P3938, DOI 10.4161/cc.10.22.18107
   Huo TY, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0188697
   Jing L, 2019, MOL MED REP, V19, P3393, DOI 10.3892/mmr.2019.10000
   Jing Z, 2015, CANCER LETT, V356, P332, DOI 10.1016/j.canlet.2014.09.039
   Kleivi K, 2004, CANCER GENET CYTOGEN, V155, P119, DOI 10.1016/j.cancergencyto.2004.03.014
   Kroemer G, 2010, MOL CELL, V40, P280, DOI 10.1016/j.molcel.2010.09.023
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Li B, 2020, INT J BIOL SCI, V16, P74, DOI 10.7150/ijbs.33787
   Li JH, 2014, NUCLEIC ACIDS RES, V42, pD92, DOI 10.1093/nar/gkt1248
   Li N, 2013, BIOCHEM BIOPH RES CO, V439, P187, DOI 10.1016/j.bbrc.2013.08.065
   Mens MMJ, 2018, STEM CELL REV REP, V14, P309, DOI 10.1007/s12015-018-9808-y
   Meyers BM, 2017, CLIN ONCOL-UK, V29, P459, DOI 10.1016/j.clon.2017.03.001
   Mitrakas AG, 2018, CANCER BIOL MED, V15, P260, DOI 10.20892/j.issn.2095-3941.2017.0173
   Peng QL, 2020, BMC CANCER, V20, DOI 10.1186/s12885-020-06863-9
   Pourhanifeh MH, 2020, CELL COMMUN SIGNAL, V18, DOI 10.1186/s12964-020-00587-w
   Qadir MA, 2008, BREAST CANCER RES TR, V112, P389, DOI 10.1007/s10549-007-9873-4
   Rothschild SI, 2017, LUNG CANCER, V107, P73, DOI 10.1016/j.lungcan.2016.06.004
   Rusmini P, 2019, AUTOPHAGY, V15, P631, DOI 10.1080/15548627.2018.1535292
   Samaddar JS, 2008, MOL CANCER THER, V7, P2977, DOI 10.1158/1535-7163.MCT-08-0447
   Seliger C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078935
   Sesen J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123721
   Skarkova V, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8030234
   Tacar O, 2013, J PHARM PHARMACOL, V65, P1577, DOI 10.1111/jphp.12144
   Tormo E, 2015, J CELL BIOCHEM, V116, P2061, DOI 10.1002/jcb.25162
   Tschan MP, 2010, BLOOD, V116, P223
   Valvona CJ, 2018, BRAIN SCI, V8, DOI 10.3390/brainsci8040056
   Ventura A, 2009, CELL, V136, P586, DOI 10.1016/j.cell.2009.02.005
   Wang ZC, 2019, INT J BIOCHEM CELL B, V111, P63, DOI 10.1016/j.biocel.2019.01.020
   Wang ZY, 2014, ONCOTARGET, V5, P7013, DOI 10.18632/oncotarget.2192
   Wu H, 2012, CELL SIGNAL, V24, P2179, DOI 10.1016/j.cellsig.2012.07.001
   Yang Y, 2014, ONCOTARGET, V5, P11886, DOI 10.18632/oncotarget.2620
   Yazdani HO, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8020091
   Yu JH, 2018, ONCOL REP, V40, P1959, DOI 10.3892/or.2018.6632
   Zachari M, 2017, ESSAYS BIOCHEM, V61, P585, DOI 10.1042/EBC20170021
   Zhang CM, 2018, PERS MED, V15, P167, DOI 10.2217/pme-2017-0071
   Zhang GJ, 2015, J EXP CLIN CANC RES, V34, DOI 10.1186/s13046-015-0189-7
   Zhang YJ, 2017, CELL MOL LIFE SCI, V74, P2613, DOI 10.1007/s00018-017-2485-1
   Zhao YY, 2019, BIOFACTORS, V45, P844, DOI 10.1002/biof.1555
   Zhao Z, 2015, CANCER LETT, V358, P17, DOI 10.1016/j.canlet.2014.11.046
   Zhu QW, 2021, AUTOPHAGY, V17, P1667, DOI 10.1080/15548627.2020.1781368
NR 56
TC 3
Z9 3
U1 1
U2 2
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2073-4425
J9 GENES-BASEL
JI Genes
PD FEB
PY 2021
VL 12
IS 2
AR 245
DI 10.3390/genes12020245
PG 14
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA QN6SC
UT WOS:000622585600001
PM 33572255
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Zhang, CD
   Wang, YL
   Zhou, DM
   Zhu, MY
   Lv, Y
   Hao, XQ
   Qu, CF
   Chen, Y
   Gu, WZ
   Wu, BQ
   Chen, PC
   Zhao, ZY
AF Zhang, Chu-di
   Wang, Yi-long
   Zhou, Dong-ming
   Zhu, Meng-ying
   Lv, Yao
   Hao, Xiao-qiang
   Qu, Chu-fan
   Chen, Yi
   Gu, Wei-zhong
   Wu, Ben-qing
   Chen, Pei-chun
   Zhao, Zheng-yan
TI A recombinant Chinese measles virus vaccine strain rMV-Hu191 inhibits
   human colorectal cancer growth through inducing autophagy and apoptosis
   regulating by PI3K/AKT pathway
SO TRANSLATIONAL ONCOLOGY
LA English
DT Article
DE Colorectal cancer; Oncolytic measles virotherapy; Apoptosis; Autophagy;
   PI3K; AKT signaling pathway
ID ONCOLYTIC VIRUSES; UP-REGULATION; STEM-CELLS; RECEPTOR; THERAPY; MODEL;
   SLAM; AXIS
AB The potential therapeutic effects of oncolytic measles virotherapy have been verified against plenty of malig-nancies. However, the oncolytic effects and underlying mechanisms of the recombinant Chinese measles virus vaccine strain Hu191 (rMV-Hu191) against human colorectal cancer (CRC) remain elusive. In this study, the anti-tumor effects of rMV-Hu191 were evaluated in CRC both in vitro and in vivo. From our data, rMV-Hu191 induced remarkably caspase-dependent apoptosis and complete autophagy in vitro . In mice bearing CRC xenografts, tumor volume was remarkably suppressed and median survival was prolonged significantly with intratumoral treatment of rMV-Hu191. To gain further insight into the relationship of rMV-Hu191-induced apoptosis and autophagy, we utilized Rapa and shATG7 to regulate autophagy. Our data suggested that autophagy was served as a protective role in rMV-Hu191-induced apoptosis in CRC. PI3K/AKT signaling pathway as one of the common upstream pathways of apoptosis and autophagy was activated in CRC after treatment with rMV-Hu191. And inhibition of PI3K/AKT pathway using LY294002 was accompanied by enhanced apoptosis and decreased autophagy which suggested that PI3K/AKT pathway promoted rMV-Hu191-induced autophagy and inhibited rMV-Hu191-induced apoptosis. This is the first study to demonstrate that rMV-Hu191 could be used as a potentially effective ther-apeutic agent in CRC treatment. As part of the underlying cellular mechanisms, apoptosis and autophagy were involved in the oncolytic effects generated by rMV-Hu191. And the cross-talk between these two processes and the PI3K/AKT signaling pathway was well identified.
C1 [Zhang, Chu-di; Wang, Yi-long; Zhou, Dong-ming; Zhu, Meng-ying; Lv, Yao; Hao, Xiao-qiang; Qu, Chu-fan; Chen, Yi; Gu, Wei-zhong; Zhao, Zheng-yan] Zhejiang Univ, Sch Med, Childrens Hosp, Hangzhou 310052, Zhejiang, Peoples R China.
   [Zhang, Chu-di; Zhu, Meng-ying; Qu, Chu-fan; Chen, Yi; Zhao, Zheng-yan] Zhejiang Univ, Sch Med, Hangzhou 310000, Zhejiang, Peoples R China.
   [Wu, Ben-qing; Chen, Pei-chun] Univ Chinese Acad Sci, Shenzhen Hosp, Shenzhen 518000, Peoples R China.
RP Zhao, ZY (corresponding author), Zhejiang Univ, Sch Med, Childrens Hosp, Hangzhou 310052, Zhejiang, Peoples R China.; Zhao, ZY (corresponding author), Zhejiang Univ, Sch Med, Hangzhou 310000, Zhejiang, Peoples R China.
EM 21718442@zju.edu.cn; 11418155@zju.edu.cn; 21318243@zju.edu.cn;
   11618182@zju.edu.cn; 21418068@zju.edu.cn; 11718196@zju.edu.cn;
   21818469@zju.edu.cn; 21918473@zju.edu.cn; 6195013@zju.edu.cn;
   wubenqing783@126.com; 674870541@qq.com; zhaozy@zju.edu.cn
OI Wang, Yilong/0000-0002-7833-9990
FU Zhejiang Provincial Science technology research program [2017C33047]
FX This work was supported by the Zhejiang Provincial Science technology
   research program (2017C33047).
CR Amaravadi R, 2016, GENE DEV, V30, P1913, DOI 10.1101/gad.287524.116
   Andtbacka RHI, 2015, J CLIN ONCOL, V33, P2780, DOI 10.1200/JCO.2014.58.3377
   Aref S, 2016, VIRUSES-BASEL, V8, DOI 10.3390/v8100294
   Bah ES, 2020, MOL CANCER THER, V19, P2057, DOI 10.1158/1535-7163.MCT-20-0134
   Bhutia SK, 2013, ADV CANCER RES, V118, P61, DOI 10.1016/B978-0-12-407173-5.00003-0
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
   Brody H, 2015, NATURE, V521, pS1, DOI 10.1038/521S1a
   Cecconi F, 2008, DEV CELL, V15, P344, DOI 10.1016/j.devcel.2008.08.012
   Cifuentes-Munoz N, 2020, ADV VIRUS RES, V108, P85, DOI 10.1016/bs.aivir.2020.09.002
   Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7
   Dekker E, 2019, LANCET, V394, P1467, DOI 10.1016/S0140-6736(19)32319-0
   Dhiman N, 2004, REV MED VIROL, V14, P217, DOI 10.1002/rmv.430
   Dikic I, 2018, NAT REV MOL CELL BIO, V19, P349, DOI 10.1038/s41580-018-0003-4
   Dispenzieri A, 2017, LEUKEMIA, V31, P2791, DOI 10.1038/leu.2017.120
   DORIG RE, 1993, CELL, V75, P295, DOI 10.1016/0092-8674(93)80071-L
   Dou QH, 2016, CANCER RES, V76, P4457, DOI 10.1158/0008-5472.CAN-15-2887
   Downs-Canner S, 2016, MOL THER, V24, P1492, DOI 10.1038/mt.2016.101
   Eskelinen EL, 2019, INT J BIOCHEM CELL B, V111, P1, DOI 10.1016/j.biocel.2019.03.010
   Galanis E, 2015, CANCER RES, V75, P22, DOI 10.1158/0008-5472.CAN-14-2533
   Garber K, 2006, J NATL CANCER I, V98, P298, DOI 10.1093/jnci/djj111
   Goradel NH, 2019, J CELL PHYSIOL, V234, P8636, DOI 10.1002/jcp.27850
   Gump JM, 2014, NAT CELL BIOL, V16, P47, DOI 10.1038/ncb2886
   Huang F, 2016, WORLD J GASTROENTERO, V22, P7999, DOI 10.3748/wjg.v22.i35.7999
   Kang DW, 2017, CLIN CANCER RES, V23, P7340, DOI 10.1158/1078-0432.CCR-17-0749
   Kim YC, 2015, J CLIN INVEST, V125, P25, DOI 10.1172/JCI73939
   Klionsky DJ, 2005, J CELL SCI, V118, P7, DOI 10.1242/jcs.01620
   Lal S, 2018, NEURO-ONCOLOGY, V20, P1606, DOI 10.1093/neuonc/noy089
   Lalaoui N, 2015, SEMIN CELL DEV BIOL, V39, P63, DOI 10.1016/j.semcdb.2015.02.003
   Lamb CA, 2013, NAT REV MOL CELL BIO, V14, P759, DOI 10.1038/nrm3696
   Liu B, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0994-x
   Liu XQ, 2018, DRUG DELIV, V25, P1950, DOI 10.1080/10717544.2018.1534895
   Lv Y, 2019, CANCER LETT, V460, P108, DOI 10.1016/j.canlet.2019.06.010
   Mader EK, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-20
   Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239
   Meng X, 2010, MOL THER, V18, P544, DOI 10.1038/mt.2009.296
   Noyce RS, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002240
   Ong HT, 2013, J HEPATOL, V59, P999, DOI 10.1016/j.jhep.2013.07.010
   Sahani MH, 2014, AUTOPHAGY, V10, P431, DOI 10.4161/auto.27344
   Tatsuo H, 2000, NATURE, V406, P893, DOI 10.1038/35022579
   Ungerechts G, 2007, MOL THER, V15, P1991, DOI 10.1038/sj.mt.6300291
   Wang YL, 2018, VIROLOGY, V518, P210, DOI 10.1016/j.virol.2018.02.022
   Zeyaullah M, 2012, PATHOL ONCOL RES, V18, P771, DOI 10.1007/s12253-012-9548-2
   Zhou D, 2019, WORLD J PEDIATR, V15, P499, DOI 10.1007/s12519-019-00286-8
   Zhou D, 2019, WORLD J PEDIATR, V15, P511, DOI 10.1007/s12519-019-00287-7
NR 44
TC 1
Z9 1
U1 6
U2 11
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1936-5233
J9 TRANSL ONCOL
JI Transl. Oncol.
PD JUL
PY 2021
VL 14
IS 7
AR 101091
DI 10.1016/j.tranon.2021.101091
EA APR 2021
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA SJ5PX
UT WOS:000655587700005
PM 33848808
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Huang, GN
   Liu, ZM
   He, LZ
   Luk, KH
   Cheung, ST
   Wong, KH
   Chen, TF
AF Huang, Guanning
   Liu, Zumei
   He, Lizhen
   Luk, Kar-Him
   Cheung, Siu-To
   Wong, Ka-Hing
   Chen, Tianfeng
TI Autophagy is an important action mode for functionalized selenium
   nanoparticles to exhibit anti-colorectal cancer activity
SO BIOMATERIALS SCIENCE
LA English
DT Article
ID REGULATES AUTOPHAGY; SURFACE DECORATION; PROTEIN COMPLEXES; CARCINOMA
   CELLS; CELLULAR UPTAKE; APOPTOSIS; INDUCTION; POLYSACCHARIDES;
   NANOTECHNOLOGY; EFFICACY
AB Selenium nanoparticles (SeNPs) have attracted much interest as potential anticancer nanodrugs. Our previous studies also demonstrated that SeNPs could be developed as carriers of clinically used anticancer drugs to achieve synergistic efficacy. Here, we describe the synthesis of Pleurotus tuber-regium (PTR)-conjugated SeNPs (PTR-SeNPs) and their application in the treatment of colorectal cancer (CRC), which is one of the principal causes of cancer morbidity and mortality in the world. PTR-SeNPs were absorbed by cancer cells via clathrin-mediated endocytosis into lysosomes and caveolae-mediated endocytosis into the Golgi apparatus. Internalized PTR-SeNPs trigger intracellular dose- and time-dependent G2/M phase arrest and apoptosis. Moreover, as shown by using a pEGFP-LC3 plasmid transfection model, PTR-SeNPs activate autophagy to promote the death of cancer cells via upregulation of beclin 1-related signaling pathways. In summary, this study demonstrates the high efficacy of functionalized SeNPs for therapy of colorectal cancer and reveals the important role of autophagy in promoting apoptosis and cell cycle arrest to induce cell death.
C1 [Huang, Guanning; He, Lizhen; Chen, Tianfeng] Jinan Univ, Affiliated Hosp 1, Guangzhou 510632, Guangdong, Peoples R China.
   [Huang, Guanning; He, Lizhen; Chen, Tianfeng] Jinan Univ, Dept Chem, Guangzhou 510632, Guangdong, Peoples R China.
   [Liu, Zumei; Luk, Kar-Him; Cheung, Siu-To; Wong, Ka-Hing] Hong Kong Polytech Univ, Dept Appl Biol & Chem Technol, Hong Kong, Hong Kong, Peoples R China.
RP Chen, TF (corresponding author), Jinan Univ, Affiliated Hosp 1, Guangzhou 510632, Guangdong, Peoples R China.; Chen, TF (corresponding author), Jinan Univ, Dept Chem, Guangzhou 510632, Guangdong, Peoples R China.; Wong, KH (corresponding author), Hong Kong Polytech Univ, Dept Appl Biol & Chem Technol, Hong Kong, Hong Kong, Peoples R China.
EM kahing.wong@polyu.edu.hk; tchentf@jnu.edu.cn
RI Chen, Tianfeng/AAG-6123-2019; WONG, Ka Hing/AFW-2400-2022
OI WONG, Ka Hing/0000-0003-0286-4921
FU National High-level personnel of special support program [W02070191];
   YangFan Innovative & Entrepreneurial Research Team Project [201312H05];
   Fundamental Research Funds for the Central UniversitiesFundamental
   Research Funds for the Central Universities; GRF/ECS 2017/18; Natural
   Science Foundation of ChinaNational Natural Science Foundation of China
   (NSFC) [21701051]; Natural Science Foundation of Guangdong
   ProvinceNational Natural Science Foundation of Guangdong Province
   [2017A030313051]; China Postdoctoral Science FoundationChina
   Postdoctoral Science Foundation [2016M600705, 2018T110922]
FX This study was supported by the National High-level personnel of special
   support program (W02070191), YangFan Innovative & Entrepreneurial
   Research Team Project (201312H05), Fundamental Research Funds for the
   Central Universities, Internal Grant for Eligible PIs Whose Proposal
   Rated 3.5 in GRF/ECS 2017/18, Natural Science Foundation of China
   (21701051), Natural Science Foundation of Guangdong Province
   (2017A030313051), and China Postdoctoral Science Foundation
   (2016M600705, 2018T110922).
CR Bjorkoy G, 2009, METHOD ENZYMOL, V452, P181, DOI 10.1016/S0076-6879(08)03612-4
   Brown NE, 2012, CANCER RES, V72, P6477, DOI 10.1158/0008-5472.CAN-11-4139
   Canton I, 2012, CHEM SOC REV, V41, P2718, DOI 10.1039/c2cs15309b
   Carew JS, 2007, BLOOD, V110, P313, DOI 10.1182/blood-2006-10-050260
   Chan SL, 2006, LIFE SCI, V78, P2463, DOI 10.1016/j.lfs.2005.10.011
   Chang YZ, 2017, ACS NANO, V11, P4848, DOI 10.1021/acsnano.7b01346
   Decuypere Jean-Paul, 2012, Cells, V1, P284, DOI 10.3390/cells1030284
   Farrell D, 2010, ACS NANO, V4, P589, DOI 10.1021/nn100073g
   Feng YX, 2014, DALTON T, V43, P1854, DOI 10.1039/c3dt52468j
   Guo WJ, 2013, AUTOPHAGY, V9, P996, DOI 10.4161/auto.24407
   He LZ, 2014, ANGEW CHEM INT EDIT, V53, P12532, DOI 10.1002/anie.201407143
   Heath JR, 2008, ANNU REV MED, V59, P251, DOI 10.1146/annurev.med.59.061506.185523
   Huang H, 2018, BIOMATERIALS, V171, P12, DOI 10.1016/j.biomaterials.2018.04.022
   Huang W, 2017, ADV FUNCT MATER, V27, DOI 10.1002/adfm.201701388
   Huang YY, 2013, BIOMATERIALS, V34, P7106, DOI 10.1016/j.biomaterials.2013.04.067
   Lefranc F, 2007, ONCOLOGIST, V12, P1395, DOI 10.1634/theoncologist.12-12-1395
   Li YH, 2013, J MATER CHEM B, V1, P6365, DOI 10.1039/c3tb21168a
   Liu T, 2015, NANOMED-NANOTECHNOL, V11, P947, DOI 10.1016/j.nano.2015.01.009
   Liu W, 2012, ACS NANO, V6, P6578, DOI 10.1021/nn202452c
   Ma XW, 2011, ACS NANO, V5, P8629, DOI 10.1021/nn202155y
   Ma YT, 2016, J MOL MED, V94, P497, DOI 10.1007/s00109-016-1401-8
   Maiuri MC, 2007, AUTOPHAGY, V3, P374, DOI 10.4161/auto.4237
   Marchesi N, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/4956080
   Mi FL, 2005, BIOMACROMOLECULES, V6, P975, DOI 10.1021/bm049335p
   Musgrove EA, 2011, NAT REV CANCER, V11, P558, DOI 10.1038/nrc3090
   Park SH, 2012, TOXICOL LETT, V212, P252, DOI 10.1016/j.toxlet.2012.06.007
   Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002
   Peer D, 2007, NAT NANOTECHNOL, V2, P751, DOI 10.1038/nnano.2007.387
   Pimkina J, 2009, AUTOPHAGY, V5, P397, DOI 10.4161/auto.5.3.7782
   Qu XP, 2007, CELL, V128, P931, DOI 10.1016/j.cell.2006.12.044
   Schwarz-Schilling M, 2018, NANO LETT, V18, P2650, DOI 10.1021/acs.nanolett.8b00526
   Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387
   Spyratou E, 2012, CANCER LETT, V327, P111, DOI 10.1016/j.canlet.2011.12.039
   Wang JR, 2009, J BIOL CHEM, V284, P21412, DOI 10.1074/jbc.M109.026013
   Wu HL, 2013, J AGR FOOD CHEM, V61, P9859, DOI 10.1021/jf403564s
   Wu HL, 2012, J MATER CHEM, V22, P9602, DOI 10.1039/c2jm16828f
   Yu B, 2015, J MATER CHEM B, V3, P2497, DOI 10.1039/c4tb02146k
   Zeng HW, 2009, MOLECULES, V14, P1263, DOI 10.3390/molecules14031263
   Zhang M, 2001, J AGR FOOD CHEM, V49, P5059, DOI 10.1021/jf010228l
   Zhang WJ, 2011, COLLOID SURFACE B, V88, P196, DOI 10.1016/j.colsurfb.2011.06.031
NR 40
TC 31
Z9 35
U1 5
U2 84
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2047-4830
EI 2047-4849
J9 BIOMATER SCI-UK
JI Biomater. Sci.
PD SEP 1
PY 2018
VL 6
IS 9
BP 2508
EP 2517
DI 10.1039/c8bm00670a
PG 10
WC Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Materials Science
GA GS1GR
UT WOS:000443267300020
PM 30091749
DA 2022-04-25
ER

PT J
AU Mo, RH
   Zaro, JL
   Ou, JHJ
   Shen, WC
AF Mo, Robert H.
   Zaro, Jennica L.
   Ou, Jing-Hsiung James
   Shen, Wei-Chiang
TI Effects of Lipofectamine 2000/siRNA Complexes on Autophagy in Hepatoma
   Cells
SO MOLECULAR BIOTECHNOLOGY
LA English
DT Article
DE Autophagy; siRNA; Lipofectamine 2000; GFP-LC3; Autophagosomes; siRNA
   delivery
ID SMALL INTERFERING RNA; COLON-CANCER CELLS; MAMMALIAN-CELLS; PROTEASOME
   INHIBITOR; SIRNA DELIVERY; FLOW-CYTOMETRY; INDUCTION; LC3; NEURONS;
   PATHWAY
AB Lipofectamine 2000 is commonly used for siRNA transfections. However, few studies have examined cellular responses to this delivery system. The purpose of this study is to evaluate the effect of siRNA transfection using Lipofectamine 2000 on cellular autophagy. Huh7.5 cells, stably transfected to express GFP-LC3, were treated with Lipofectamine 2000/negative control siRNA (NC siRNA) complexes. At different time points after treatment, cells were lysed and analyzed by immunoblotting and fluorescence spectroscopy. Cells were also observed using confocal microscopy. An increase of endogenous LC3 lipidation, GFP-LC3 fluorescence, and autophagosomal puncta was observed in cells treated with Lipofectamine 2000/NC siRNA complexes. The kinetics of the increase of GFP-LC3 fluorescence correlated with the concentration of NC siRNA transfected, where 50, 100, and 200 nM NC siRNA caused a significant increase at 72, 48, and 24 h, respectively, after transfection. A similar effect on the GFP-LC3 signal was also observed for cells treated with Lipofectamine 2000 complexed with two other NC siRNAs. The effects were also confirmed in another hepatoma cell line, H4IIE, by immunoblotting. Lipofectamine 2000-mediated transport of NC siRNAs led to an increase of autophagosomes in a dose- and time-dependent manner. Thus, this effect on cells should be taken into consideration when using this approach for intracellular delivery of siRNA.
C1 [Mo, Robert H.; Zaro, Jennica L.; Shen, Wei-Chiang] Univ So Calif, Sch Pharm, Dept Pharmacol & Pharmaceut Sci, Los Angeles, CA 90033 USA.
   [Ou, Jing-Hsiung James] Univ So Calif, Keck Sch Med, Dept Mol Microbiol & Immunol, Los Angeles, CA 90033 USA.
RP Shen, WC (corresponding author), Univ So Calif, Sch Pharm, Dept Pharmacol & Pharmaceut Sci, 1985 Zonal Ave,PSC 404B, Los Angeles, CA 90033 USA.
EM rmo@usc.edu; zaro@usc.edu; jamesou@hsc.usc.edu; weishen@usc.edu
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [GM070777, AI083025]; American
   Foundation for Pharmaceutical Education; NATIONAL INSTITUTE OF ALLERGY
   AND INFECTIOUS DISEASESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [U19AI083025] Funding Source:
   NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY
   DISEASESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Diabetes &
   Digestive & Kidney Diseases (NIDDK) [P30DK048522] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of General Medical Sciences (NIGMS)
   [R01GM070777] Funding Source: NIH RePORTER
FX This research was supported in part by NIH GM070777 (W. C. S.) and
   AI083025 (J.J.O.). We thank Dr. Charles M. Rice, Rockefeller University,
   for providing us with the Huh7.5 cells. We also thank Cheng-Fu Kuo for
   his help with confocal microscopy and Michelle MacVeigh of the Confocal
   Microscopy Sub-Core at the USC Center for Liver Diseases (NIH P30
   DK48522) for her assistance. R. H. M. is a recipient of the American
   Foundation for Pharmaceutical Education pre-doctoral fellowship.
CR Aagaard L, 2007, ADV DRUG DELIVER REV, V59, P75, DOI 10.1016/j.addr.2007.03.005
   Bjorkoy G, 2005, J CELL BIOL, V171, P603, DOI 10.1083/jcb.200507002
   Chiu YL, 2003, RNA, V9, P1034, DOI 10.1261/rna.5103703
   Chiu YL, 2002, MOL CELL, V10, P549, DOI 10.1016/S1097-2765(02)00652-4
   Dalby B, 2004, METHODS, V33, P95, DOI 10.1016/j.ymeth.2003.11.023
   Egami Y, 2005, BIOCHEM BIOPH RES CO, V337, P1206, DOI 10.1016/j.bbrc.2005.09.171
   Elbashir SM, 2002, METHODS, V26, P199, DOI 10.1016/S1046-2023(02)00023-3
   Eng KE, 2010, AUTOPHAGY, V6, P634, DOI 10.4161/auto.6.5.12112
   Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888
   Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720
   Klionsky DJ, 2008, AUTOPHAGY, V4, P151, DOI 10.4161/auto.5338
   Kobayashi S, 2010, AUTOPHAGY, V6, P36, DOI 10.4161/auto.6.1.10324
   Kumar P, 2007, NATURE, V448, P39, DOI 10.1038/nature05901
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Man N, 2010, AUTOPHAGY, V6, P449, DOI 10.4161/auto.6.4.11612
   Meade BR, 2007, ADV DRUG DELIVER REV, V59, P134, DOI 10.1016/j.addr.2007.03.004
   Mizushima N, 2007, AUTOPHAGY, V3, P542, DOI 10.4161/auto.4600
   Mizushima N, 2010, CELL, V140, P313, DOI 10.1016/j.cell.2010.01.028
   Pascual G, 2005, NATURE, V437, P759, DOI 10.1038/nature03988
   Ravikumar B, 2002, HUM MOL GENET, V11, P1107, DOI 10.1093/hmg/11.9.1107
   Seleverstov O, 2006, NANO LETT, V6, P2826, DOI 10.1021/nl0619711
   Shintani T, 2010, BIOCHEM BIOPH RES CO, V391, P1775, DOI 10.1016/j.bbrc.2009.12.154
   Shvets E, 2008, AUTOPHAGY, V4, P621, DOI 10.4161/auto.5939
   Sir D, 2008, HEPATOLOGY, V48, P1054, DOI 10.1002/hep.22464
   Tannous P, 2008, CIRCULATION, V117, P3070, DOI 10.1161/CIRCULATIONAHA.107.763870
   Wu WKK, 2008, BIOCHEM BIOPH RES CO, V374, P258, DOI 10.1016/j.bbrc.2008.07.031
   Wu WKK, 2009, BIOCHEM BIOPH RES CO, V386, P598, DOI 10.1016/j.bbrc.2009.06.080
   Xie FY, 2006, DRUG DISCOV TODAY, V11, P67, DOI 10.1016/S1359-6446(05)03668-8
   Xie ZP, 2007, NAT CELL BIOL, V9, P1102, DOI 10.1038/ncb1007-1102
   Zabirnyk O, 2007, AUTOPHAGY, V3, P278, DOI 10.4161/auto.3916
NR 30
TC 26
Z9 28
U1 6
U2 29
PU HUMANA PRESS INC
PI TOTOWA
PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA
SN 1073-6085
EI 1559-0305
J9 MOL BIOTECHNOL
JI Mol. Biotechnol.
PD MAY
PY 2012
VL 51
IS 1
BP 1
EP 8
DI 10.1007/s12033-011-9422-6
PG 8
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology
GA 920CW
UT WOS:000302380500001
PM 21660602
OA Green Accepted
DA 2022-04-25
ER

PT J
AU Sumbul, AT
   Gogebakan, B
   Ergun, S
   Yengil, E
   Batmaci, CY
   Tonyali, O
   Yaldiz, M
AF Sumbul, Ahmet Taner
   Gogebakan, Bulent
   Ergun, Sercan
   Yengil, Erhan
   Batmaci, Celal Yucel
   Tonyali, Onder
   Yaldiz, Mehmet
TI miR-204-5p expression in colorectal cancer: an autophagy-associated gene
SO TUMOR BIOLOGY
LA English
DT Article
DE Colorectal cancer; miR-204-5p; LC3B-II; Bcl2; Clinicopathological
   factors
ID POOR-PROGNOSIS; MICRORNA; CELLS; OVEREXPRESSION; BIOGENESIS; TUMORS
AB MicroRNAs (miRNAs) are important factors during tumorigenesis by affecting posttranscriptional gene expression. miRNA 204 (miR-204) is a miRNA frequently investigated in different types of cancers. According to literature, autophagy has dual roles in cancer, acting as both a tumor suppressor and cell survival agent. Also, the current data suggests that autophagy is activated in human colorectal cancer cells and enhances the aggressiveness of human colorectal cancer cells. So, our aim is to investigate potential effect of miR-204-5p on colorectal cancer by associating its expression with autophagy-related targets of miR-204-5p. This is the first miRNA study conducted on patients with colorectal cancer and healthy subjects and also to search the relation of miR-204-5p with clinicopathological factors and survival. Sixty-six patients with colorectal cancer and healthy subjects without any known chronic disease were enrolled into our study. Total miRNA was isolated from paraffin-embedded tissues of all patients' cancerous and normal tissues, and healthy subjects. cDNAs were obtained from this miRNAs by reverse transcriptase method, and miR-204-5p relative expression levels were detected by qRT-PCR method. Patients were divided into two groups according to median relative expression levels of miR-204-5p, as low-and high-expression group. Relation of miR-204-5p with clinicopathological factors and overall survival was also investigated. Medians of miR-204-5p relative expression levels in cancerous and normal tissues of patients were found as 0.00235 and 0.00376, respectively. The difference between two groups was not statistically significant (p=0.11). Nonetheless, median of miR-204-5p relative expression levels in healthy subjects were found as 0.00135, and the difference between patient with cancer and healthy subjects and between normal tissues of patients and healthy subjects were statistically significant (p=0.021 and p=0.0005, respectively). There were 32 patients (48.5 %) showing high expression and 34 patients (51.5 %) showing low expression according to miR-204-5p relative expression levels. There were no statistically significant relation between clinicopathologic features and miR-2045p relative expression levels. We also investigated the relation between miR-204-5p relative expression levels and overall survival, and no statistically significant relation was found between them (p=0.462). The absence of any significant difference between tumor and non-tumor samples, low sample size, and performance at just one center are the limitations of our study. In opposition to literature, miR-204-5p is overexpressed in colorectal cancer patients as compared with healthy subjects and this situation is not associated with clinicopathological factors and overall survival. This may be explained by the fact that miR-204-5p increases in colorectal cancer cases in order to inhibit increased activity of LC3B-II in autophagy and Bcl2 against apoptosis posttranscriptionally and to take role as tumor suppressor.
C1 [Sumbul, Ahmet Taner; Tonyali, Onder] Mustafa Kemal Univ, Fac Med, Dept Med Oncol, Antakya, Turkey.
   [Gogebakan, Bulent] Mustafa Kemal Univ, Fac Med, Dept Med Biol & Genet, Antakya, Turkey.
   [Ergun, Sercan] Gaziantep Univ, Fac Med, Dept Med Biol, Antakya, Turkey.
   [Yengil, Erhan] Mustafa Kemal Univ, Fac Med, Dept Family Med, Antakya, Turkey.
   [Batmaci, Celal Yucel] Mustafa Kemal Univ, Fac Med, Dept Internal Med, Antakya, Turkey.
   [Yaldiz, Mehmet] Mustafa Kemal Univ, Fac Med, Dept Pathol, Antakya, Turkey.
RP Sumbul, AT (corresponding author), Mustafa Kemal Univ, Fac Med, Dept Med Oncol, Antakya, Turkey.
EM drtanersu@yahoo.com
RI Sumbul, Ahmet T/D-4793-2014; Ergün, Sercan/I-8798-2019
OI Sumbul, Ahmet T/0000-0002-5573-906X; Ergün, Sercan/0000-0002-6733-9848
FU Turkish Medical Oncology Society
FX This study was performed with a grant taken from the Turkish Medical
   Oncology Society.
CR Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5
   Brennecke J, 2003, CELL, V113, P25, DOI 10.1016/S0092-8674(03)00231-9
   Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997
   Chao-Jie W, 2009, DIS MARKERS, V26, P27
   Chen ZY, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-105
   Chung TKH, 2012, INT J CANCER, V130, P1036, DOI 10.1002/ijc.26060
   Cui RR, 2012, CARDIOVASC RES, V96, P320, DOI 10.1093/cvr/cvs258
   De Craene B, 2013, NAT REV CANCER, V13, P97, DOI 10.1038/nrc3447
   Drullion C, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.111
   Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840
   Gong M, 2012, NEURO-ONCOLOGY, V14, P1007, DOI 10.1093/neuonc/nos124
   He L, 2005, NATURE, V435, P828, DOI 10.1038/nature03552
   Johnson SM, 2005, CELL, V120, P635, DOI 10.1016/j.cell.2005.01.014
   Lee Y, 2010, PLOS COMPUT BIOL, V6, DOI 10.1371/journal.pcbi.1000730
   Li GR, 2011, INVEST OPHTH VIS SCI, V52, P2999, DOI 10.1167/iovs.10-6708
   Liu H, 2013, INT J COLORECTAL DIS, V28, P697, DOI 10.1007/s00384-013-1674-0
   Mathew R, 2009, CELL, V137, P1062, DOI 10.1016/j.cell.2009.03.048
   Mikhaylova O, 2012, CANCER CELL, V21, P532, DOI 10.1016/j.ccr.2012.02.019
   Poy MN, 2004, NATURE, V432, P226, DOI 10.1038/nature03076
   Saadi JI, 2012, PLOS ONE, V7
   Sacconi A, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.160
   Sato K, 2007, CANCER RES, V67, P9677, DOI 10.1158/0008-5472.CAN-07-1462
   Schetter AJ, 2008, JAMA-J AM MED ASSOC, V299, P425, DOI 10.1001/jama.299.4.425
   Shibutani ST, 2014, CELL RES, V24, P58, DOI 10.1038/cr.2013.159
   Thai TH, 2007, SCIENCE, V316, P604, DOI 10.1126/science.1141229
   Toiyama Y, 2013, ANN SURG
   Voorhoeve PM, 2006, CELL, V124, P1169, DOI 10.1016/j.cell.2006.02.037
   Waldman SA, 2007, JAMA-J AM MED ASSOC, V297, P1923, DOI 10.1001/jama.297.17.1923
   Wang XQ, 2012, MED ONCOL, V29, P919, DOI 10.1007/s12032-011-9880-5
   Xu D, 2013, ACTA GASTRO-ENT BELG, V76, P372
   Ying Z, 2013, CANCER RES, V73, P990, DOI 10.1158/0008-5472.CAN-12-2895
   Yoshimori T, 2004, BIOCHEM BIOPH RES CO, V313, P453, DOI 10.1016/j.bbrc.2003.07.023
   Yu H, 2013, INT J CLIN EXP PATHO, V6, P2904
   Zhang GJ, 2012, MED ONCOL, V29, P3108, DOI 10.1007/s12032-012-0233-9
   Zheng Hai-yang, 2012, Cancer Biology Medicine, V9, P105, DOI 10.3969/j.issn.2095-3941.2012.02.004
   Zhou T, 2014, EUR J GASTROENTEROL, V26
   Zhou T, 2013, INT J COLORECTAL DIS, V28, P19, DOI 10.1007/s00384-012-1528-1
NR 37
TC 37
Z9 40
U1 1
U2 17
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD DEC
PY 2014
VL 35
IS 12
BP 12713
EP 12719
DI 10.1007/s13277-014-2596-3
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA AX3UI
UT WOS:000346863700120
PM 25209181
DA 2022-04-25
ER

PT J
AU Zhao, HB
   Huang, CZ
   Luo, YW
   Yao, XY
   Hu, Y
   Wang, MQ
   Chen, X
   Zeng, J
   Hu, WX
   Wang, JJ
   Li, RJ
   Yao, XQ
AF Zhao, Haibi
   Huang, Chengzhi
   Luo, Yuwen
   Yao, Xiaoya
   Hu, Yong
   Wang, Muqing
   Chen, Xin
   Zeng, Jun
   Hu, Weixian
   Wang, Junjiang
   Li, Rongjiang
   Yao, Xueqing
TI A Correlation Study of Prognostic Risk Prediction for Colorectal Cancer
   Based on Autophagy Signature Genes
SO FRONTIERS IN ONCOLOGY
LA English
DT Article
DE ARGs; prognostic indicator; CRC; nomogram; risk model
ID CELL-DEATH; PROMOTES; INFLAMMATION; INHIBITION; VALIDATION; ACTIVATION;
   RESISTANCE
AB Autophagy plays a complex role in tumors, sometimes promoting cancer cell survival and sometimes inducing apoptosis, and its role in the colorectal tumor microenvironment is controversial. The purpose of this study was to investigate the prognostic value of autophagy-related genes (ARGs) in colorectal cancer. We identified 37 differentially expressed autophagy-related genes by collecting TCGA colorectal tumor transcriptome data. A single-factor COX regression equation was used to identify 11 key prognostic genes, and a prognostic risk prediction model was constructed based on multifactor COX analysis. We classified patients into high and low risk groups according to prognostic risk parameters (p <0.001) and determined the prognostic value they possessed by survival analysis and the receiver operating characteristic (ROC) curve in the training and test sets of internal tests. In a multifactorial independent prognostic analysis, this risk value could be used as an independent prognostic indicator (HR=1.167, 95% CI=1.078-1.264, P<0.001) and was a robust predictor without any staging interference. To make it more applicable to clinical procedures, we constructed nomogram based on risk parameters and parameters of key clinical characteristics. The area under ROC curve for 3-year and 5-year survival rates were 0.735 and 0.718, respectively. These will better enable us to monitor patient prognosis, thus improve patient outcomes.
C1 [Zhao, Haibi; Yao, Xiaoya; Hu, Yong; Yao, Xueqing] South China Univ Technol, Sch Biol & Biol Engn, Guangzhou, Peoples R China.
   [Zhao, Haibi; Huang, Chengzhi; Luo, Yuwen; Yao, Xiaoya; Hu, Yong; Wang, Muqing; Chen, Xin; Hu, Weixian; Wang, Junjiang; Yao, Xueqing] Guangdong Acad Med Sci, Dept Gastrointestinal Surg, Guangdong Prov Peoples Hosp, Guangzhou, Peoples R China.
   [Zhao, Haibi; Huang, Chengzhi; Luo, Yuwen; Yao, Xiaoya; Hu, Yong; Wang, Muqing; Chen, Xin; Yao, Xueqing] Guangdong Prov Peoples Hosp, Ganzhou Hosp, Ganzhou Municipal Hosp, Ganzhou, Peoples R China.
   [Huang, Chengzhi; Wang, Muqing; Wang, Junjiang; Yao, Xueqing] South China Univ Technol, Sch Med, Guangzhou, Peoples R China.
   [Luo, Yuwen; Wang, Junjiang; Yao, Xueqing] Southern Med Univ, Sch Clin Med 2, Guangzhou, Peoples R China.
   [Chen, Xin; Yao, Xueqing] Shantou Univ, Coll Med, Shantou, Peoples R China.
   [Zeng, Jun; Li, Rongjiang] Shen Zhen Univ, Affiliated Hosp 1, Baoan Cent Hosp, Dept Gen Surg, Shenzhen, Peoples R China.
RP Yao, XQ (corresponding author), South China Univ Technol, Sch Biol & Biol Engn, Guangzhou, Peoples R China.; Yao, XQ (corresponding author), Guangdong Acad Med Sci, Dept Gastrointestinal Surg, Guangdong Prov Peoples Hosp, Guangzhou, Peoples R China.; Yao, XQ (corresponding author), Guangdong Prov Peoples Hosp, Ganzhou Hosp, Ganzhou Municipal Hosp, Ganzhou, Peoples R China.; Yao, XQ (corresponding author), South China Univ Technol, Sch Med, Guangzhou, Peoples R China.; Yao, XQ (corresponding author), Southern Med Univ, Sch Clin Med 2, Guangzhou, Peoples R China.; Yao, XQ (corresponding author), Shantou Univ, Coll Med, Shantou, Peoples R China.; Li, RJ (corresponding author), Shen Zhen Univ, Affiliated Hosp 1, Baoan Cent Hosp, Dept Gen Surg, Shenzhen, Peoples R China.
EM lirongjiang@163.com; syyaoxueqing@scut.edu.cn
OI CHEN, Xin/0000-0003-3561-2691
FU Science and Technology Planning Project of Guangdong Province, China
   [2017A030223006, 2016A020215128]; Science and Technology Planning
   Project of Guangzhou, China [201704020077]; Second Batch of Scientific
   Research Projects of Dengfeng Plan [DFJH201913]; Research Fund of
   CSCO-Roche Oncology [Y-2019Roche-190]; Research Fund of CSCO-Hansoh
   Oncology [Y-HS2019/2-050]; Research Fund of Guangdong General Hospital
   [y012015338]; Yuexiu Science and Information Center of Guangzhou
   Scientific Foundation [2012-GX-046]
FX This work was supported by grants from the Science and Technology
   Planning Project of Guangdong Province, China (No. 2017A030223006,
   2016A020215128), the Science and Technology Planning Project of
   Guangzhou, China (No. 201704020077), the Second Batch of Scientific
   Research Projects of Dengfeng Plan (NO. DFJH201913), the Research Fund
   of CSCO-Roche Oncology (NO. Y-2019Roche-190) and the Research Fund of
   CSCO-Hansoh Oncology (NO. Y-HS2019/2-050), the Research Fund of
   Guangdong General Hospital (No. y012015338), the Yuexiu Science and
   Information Center of Guangzhou Scientific Foundation (No. 2012-GX-046).
CR Agarwal S, 2020, CANCERS, V12, DOI 10.3390/cancers12040772
   Bae HR, 2020, J AUTOIMMUN, V111, DOI 10.1016/j.jaut.2020.102436
   Barutcu SA, 2018, AUTOPHAGY, V14, P1586, DOI 10.1080/15548627.2018.1466013
   Braden CR, 2016, FEBS J, V283, P3889, DOI 10.1111/febs.13906
   Brown M, 2016, J CELL SCI, V129, P2317, DOI 10.1242/jcs.179127
   Goruppi S, 2017, CELL REP, V20, P2468, DOI 10.1016/j.celrep.2017.08.048
   Ishaq M, 2020, SEMIN CANCER BIOL, V66, P171, DOI 10.1016/j.semcancer.2020.03.010
   Jiang YY, 2020, GASTROENTEROLOGY, V159, P1311, DOI 10.1053/j.gastro.2020.06.050
   Jin P, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1844-2
   Levy JMM, 2017, NAT REV CANCER, V17, P528, DOI 10.1038/nrc.2017.53
   Li YJ, 2017, CHIN J CANCER, V52, DOI 10.1186/s40880-017-0219-2
   Liu M, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12573-z
   Lu XH, 2020, INT J BIOL SCI, V16, P1427, DOI 10.7150/ijbs.42962
   Mao Z, 2019, INT J BIOL SCI, V15, P1310, DOI 10.7150/ijbs.32987
   Matsuda Y, 2015, CANCER LETT, V357, P602, DOI 10.1016/j.canlet.2014.12.030
   Perez-Hernandez M, 2019, CANCERS, V11, DOI 10.3390/cancers11101599
   Polimeno L, 2020, MICROORGANISMS, V8, DOI 10.3390/microorganisms8040469
   Qiu HD, 2020, FRONT GENET, V11, DOI 10.3389/fgene.2020.00012
   Shi Y, 2020, ONCOTARGETS THER, V13, P2127, DOI 10.2147/OTT.S229913
   Wang WJ, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1054-x
   Wang ZH, 2019, AGING-US, V11, P12246, DOI 10.18632/aging.102566
   Xie YH, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0116-z
   Yeh SJ, 2020, FRONT GENET, V11, DOI 10.3389/fgene.2020.00117
   Yi M, 2020, CELL MOL LIFE SCI, V77, P4325, DOI 10.1007/s00018-020-03539-2
   Yun CW, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113466
   Zhang ZOA, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1336-3
   Zhao C, 2020, CANCER LETT, V481, P15, DOI 10.1016/j.canlet.2020.03.010
NR 27
TC 4
Z9 4
U1 2
U2 5
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2234-943X
J9 FRONT ONCOL
JI Front. Oncol.
PD MAY 25
PY 2021
VL 11
AR 595099
DI 10.3389/fonc.2021.595099
PG 13
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA SW0VJ
UT WOS:000664235200001
PM 34168974
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Shiratori, H
   Kawai, K
   Hata, K
   Tanaka, T
   Nishikawa, T
   Otani, K
   Sasaki, K
   Kaneko, M
   Murono, K
   Emoto, S
   Sonoda, H
   Nozawa, H
AF Shiratori, Hiroshi
   Kawai, Kazushige
   Hata, Keisuke
   Tanaka, Toshiaki
   Nishikawa, Takeshi
   Otani, Kensuke
   Sasaki, Kazuhito
   Kaneko, Manabu
   Murono, Koji
   Emoto, Shigenobu
   Sonoda, Hirofumi
   Nozawa, Hiroaki
TI The combination of temsirolimus and chloroquine increases
   radiosensitivity in colorectal cancer cells
SO ONCOLOGY REPORTS
LA English
DT Article
DE colorectal cancer; radiosensitivity; mTOR; autophagy; temsirolimus;
   chloroquine
ID AUTOPHAGY INHIBITION; OVERCOMES RESISTANCE; MAMMALIAN TARGET;
   CARCINOMA-CELLS; RAPAMYCIN; APOPTOSIS; MTOR; PATHWAY;
   HYDROXYCHLOROQUINE; RADIORESISTANCE
AB The PI3K/AKT/mTOR pathway and autophagy are known to play important roles in cancer radioresistance. The aim of the present study was to investigate whether the combination of temsirolimus (TEM), an mTOR inhibitor, and chloroquine (CQ), an autophagy inhibitor, can increase radiosensitivity in colorectal cancer (CRC) cells. The efficacies of TEM and/or CQ as radiosensitizers were examined using clonogenic assays in CRC cell lines SW480 and HT-29. The expression levels of the phosphorylated isoforms of S6 and 4E-BP1, downstream proteins of mTOR, as well as the expression levels of p62 and LC3, autophagy-related proteins, were assessed by western blot analysis. The formation of acidic organelles was detected in acridine orange-stained cells. Apoptosis and caspase activity were assessed using flow cytometry. The results revealed that ionizing radiation (IR) activated the downstream proteins of mTOR and induced autophagy. In the clonogenic assays, neither TEM nor CQ influenced the efficacy of IR, whereas their combination significantly increased the dose-dependent efficacy of IR. TEM inhibited phosphorylation of the downstream proteins of mTOR and induced autophagy. CQ inhibited autophagy in the late phase and did not influence the downstream proteins of mTOR. TEM and CQ inhibited both the phosphorylation of downstream proteins of mTOR and autophagy. Cell death analysis revealed that the combination of TEM and CQ strongly induced apoptosis in cells exposed to IR. In conclusion, the combination of TEM and CQ increased radiosensitivity in CRC cells through co-inhibition of mTOR and autophagy.
C1 [Shiratori, Hiroshi; Kawai, Kazushige; Hata, Keisuke; Tanaka, Toshiaki; Nishikawa, Takeshi; Otani, Kensuke; Sasaki, Kazuhito; Kaneko, Manabu; Murono, Koji; Emoto, Shigenobu; Sonoda, Hirofumi; Nozawa, Hiroaki] Univ Tokyo, Fac Med, Dept Surg, Div Surg Oncol, Tokyo 1138655, Japan.
RP Shiratori, H (corresponding author), Univ Tokyo, Fac Med, Dept Surg, Div Surg Oncol,Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.
EM tori.shior@gmail.com
RI Murono, Koji/AAC-3958-2020; Kawai, Kazushige/AAF-4334-2020
OI Kawai, Kazushige/0000-0002-5881-0036; Shiratori,
   Hiroshi/0000-0001-7404-7926; Sonoda, Hirofumi/0000-0003-3353-1783
FU Japan Society for the Promotion of ScienceMinistry of Education,
   Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for
   the Promotion of Science [16K07143, 16K07161, 17K10620, 17K10621,
   17K10623, 18K07194]; Project for Cancer Research and Therapeutic
   Evolution (P-CREATE) from the Japan Agency for Medical Research and
   Development (AMED)Japan Agency for Medical Research and Development
   (AMED) [18cm0106502h0003]
FX The present study was supported by Grants-in-Aid for Scientific Research
   (grant nos. 16K07143, 16K07161, 17K10620, 17K10621, 17K10623 and
   18K07194) from the Japan Society for the Promotion of Science. This
   research was also supported by the Project for Cancer Research and
   Therapeutic Evolution (P-CREATE; grant no. 18cm0106502h0003) from the
   Japan Agency for Medical Research and Development (AMED).
CR Al-Bari MAA, 2015, J ANTIMICROB CHEMOTH, V70, P1608, DOI 10.1093/jac/dkv018
   Albert JM, 2006, MOL CANCER THER, V5, P1183, DOI 10.1158/1535-7163.MCT-05-0400
   Apel A, 2008, CANCER RES, V68, P1485, DOI 10.1158/0008-5472.CAN-07-0562
   Boya P, 2003, ONCOGENE, V22, P3927, DOI 10.1038/sj.onc.1206622
   Bristol ML, 2013, J PHARMACOL EXP THER, V344, P544, DOI 10.1124/jpet.112.199802
   Buijsen J, 2015, RADIOTHER ONCOL, V116, P214, DOI 10.1016/j.radonc.2015.07.039
   Cao C, 2006, CANCER RES, V66, P10040, DOI 10.1158/0008-5472.CAN-06-0802
   Chaurasia M, 2016, FREE RADICAL RES, V50, P273, DOI 10.3109/10715762.2015.1129534
   Chen HH, 2011, RADIAT RES, V175, P214, DOI 10.1667/RR2323.1
   Choo AY, 2008, P NATL ACAD SCI USA, V105, P17414, DOI 10.1073/pnas.0809136105
   Edwards E, 2002, CANCER RES, V62, P4671
   Enzenmuller S, 2013, ANTI-CANCER DRUG, V24, P14, DOI 10.1097/CAD.0b013e32835a36db
   Fingar DC, 2004, MOL CELL BIOL, V24, P200, DOI 10.1128/MCB.24.1.200-216.2004
   Hu LL, 2016, INT J ONCOL, V49, P2217, DOI 10.3892/ijo.2016.3719
   Kaneko M, 2014, J CANCER RES CLIN, V140, P769, DOI 10.1007/s00432-014-1628-0
   Lakhter AJ, 2013, J INVEST DERMATOL, V133, P2247, DOI 10.1038/jid.2013.56
   Lomonaco SL, 2009, INT J CANCER, V125, P717, DOI 10.1002/ijc.24402
   Manegold PC, 2008, CLIN CANCER RES, V14, P892, DOI 10.1158/1078-0432.CCR-07-0955
   Martin ST, 2012, BRIT J SURG, V99, P918, DOI 10.1002/bjs.8702
   Miyasaka A, 2015, GYNECOL ONCOL, V138, P174, DOI 10.1016/j.ygyno.2015.04.015
   Mo N, 2014, ONCOL REP, V32, P1905, DOI 10.3892/or.2014.3427
   Nishikawa T, 2010, ANN SURG ONCOL, V17, P592, DOI 10.1245/s10434-009-0696-x
   Okuno T, 2018, ANTICANCER RES, V38, P3323, DOI 10.21873/anticanres.12598
   Rangwala R, 2014, AUTOPHAGY, V10, P1391, DOI 10.4161/auto.29119
   Rodel C, 2012, LANCET ONCOL, V13, P679, DOI 10.1016/S1470-2045(12)70187-0
   Rosich L, 2012, CLIN CANCER RES, V18, P5278, DOI 10.1158/1078-0432.CCR-12-0351
   Sasaki K, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-370
   Saxton RA, 2017, CELL, V168, P960, DOI [10.1016/j.cell.2017.02.004, 10.1016/j.cell.2017.03.035]
   Seitz C, 2013, INT J CANCER, V132, P2682, DOI 10.1002/ijc.27935
   Shi TT, 2017, CANCER CHEMOTH PHARM, V79, P287, DOI 10.1007/s00280-016-3197-1
   Sun QQ, 2015, INT J CANCER, V136, P1003, DOI 10.1002/ijc.29065
   Yan C, 2016, ONCOTARGET, V7, P45112, DOI 10.18632/oncotarget.8972
NR 32
TC 11
Z9 11
U1 4
U2 13
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1021-335X
EI 1791-2431
J9 ONCOL REP
JI Oncol. Rep.
PD JUL
PY 2019
VL 42
IS 1
BP 377
EP 385
DI 10.3892/or.2019.7134
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA IH9EF
UT WOS:000474808700034
PM 31059051
OA Bronze
DA 2022-04-25
ER

PT J
AU Xia, D
   Zhang, YT
   Xu, GP
   Yan, WW
   Pan, XR
   Tong, JH
AF Xia, Di
   Zhang, Ying-Ting
   Xu, Gui-Ping
   Yan, Wei-Wei
   Pan, Xiao-Rong
   Tong, Jian-Hua
TI Sertraline exerts its antitumor functions through both apoptosis and
   autophagy pathways in acute myeloid leukemia cells
SO LEUKEMIA & LYMPHOMA
LA English
DT Article
DE Sertraline; apoptosis; autophagy; acute myeloid leukemia
ID SEROTONIN REUPTAKE INHIBITORS; TUMOR REVERSION; ANTIDEPRESSANT
   SERTRALINE; COLORECTAL-CANCER; LSD1 INHIBITORS; IN-VITRO; PHASE 1B;
   TARGET; BEVACIZUMAB; COMBINATION
AB It has been found that sertraline, a widely used antidepressant drug, possessed antitumor roles in a variety of cancers including liver cancer, colorectal cancer and lymphoma. In this study, we provided evidences that sertraline had potent antiproliferative activity not only in acute myeloid leukemia (AML) cell lines but also in the fresh leukemia cells from AML patients, and could induce cell death through both apoptosis and autophagy pathways. Moreover, we found that inhibiting autophagy pathway could partially attenuate sertraline-induced apoptosis and cell growth inhibition, indicating that sertraline-induced autophagy process could facilitate AML cell apoptosis to some degree. However, blocking apoptosis pathway seemed no obvious effects on sertraline-caused autophagy as well as cell growth inhibition. Our results suggested a potential application value of sertraline in the treatment of AML patients, furnishing some perspectives for novel therapeutic strategies in leukemia.
C1 Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, State Key Lab Med Genom, Shanghai, Peoples R China.
   Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Fac Med Lab Sci, Shanghai, Peoples R China.
RP Pan, XR; Tong, JH (corresponding author), Ruijin Hosp, 197 Ruijin Er Rd, Shanghai 200025, Peoples R China.
EM xrpan@126.com; jh_tong@126.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81470317, 81170508]; Shanghai Municipal
   Human Resources and Social Security Bureau
FX This work was supported in part by National Natural Science Foundation
   of China [81470317 and 81170508]; Leading Talent Program of Shanghai
   Municipal Human Resources and Social Security Bureau.
CR Acunzo J, 2014, CANCER TREAT REV, V40, P760, DOI 10.1016/j.ctrv.2014.02.007
   Amit B, 2009, EUR NEUROPSYCHOPHARM, V19, P726, DOI 10.1016/j.euroneuro.2009.06.003
   Amson R, 2013, CURR OPIN ONCOL, V25, P59, DOI 10.1097/CCO.0b013e32835b7d21
   Baig S, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2015.275
   Barbey JT, 1998, J CLIN PSYCHIAT, V59, P42
   Brown LF, 2010, PSYCHO-ONCOLOGY, V19, P734, DOI 10.1002/pon.1627
   Chen S, 2014, TOXICOL SCI, V137, P404, DOI 10.1093/toxsci/kft254
   Fuchs Y, 2011, CELL, V147, P742, DOI 10.1016/j.cell.2011.10.033
   Fulda S, 2015, ONCOGENE, V34, P5105, DOI 10.1038/onc.2014.458
   Fulda S, 2015, SEMIN CANCER BIOL, V31, P84, DOI 10.1016/j.semcancer.2014.05.002
   Gil-Ad I, 2008, INT J ONCOL, V33, P277, DOI 10.3892/ijo_00000007
   Granata S, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17050735
   Kaplan C, 2012, J MENT HEALTH POLICY, V15, P171
   KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33
   Kim ES, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118190
   Lin CJ, 2010, CANCER RES, V70, P3199, DOI 10.1158/0008-5472.CAN-09-4072
   Lockshin RA, 2016, CELL DEATH DIFFER, V23, P10, DOI 10.1038/cdd.2015.126
   Maes T, 2015, CURR OPIN PHARMACOL, V23, P52, DOI 10.1016/j.coph.2015.05.009
   Mandrioli R, 2013, EXPERT OPIN DRUG MET, V9, P1495, DOI 10.1517/17425255.2013.816675
   Marino G, 2014, NAT REV MOL CELL BIO, V15, P81, DOI 10.1038/nrm3735
   Mizushima N, 2010, CELL, V140, P313, DOI 10.1016/j.cell.2010.01.028
   Mohammad HP, 2015, CANCER CELL, V28, P57, DOI 10.1016/j.ccell.2015.06.002
   Ohsumi Y, 2014, CELL RES, V24, P9, DOI 10.1038/cr.2013.169
   Rebecca VW, 2016, ONCOGENE, V35, P1, DOI 10.1038/onc.2015.99
   SALETU B, 1986, J NEURAL TRANSM, V67, P241, DOI 10.1007/BF01243351
   Sanchez C, 2014, INT CLIN PSYCHOPHARM, V29, P185, DOI 10.1097/YIC.0000000000000023
   Saran U, 2015, CLIN SCI, V129, P895, DOI 10.1042/CS20150149
   Schenk T, 2012, NAT MED, V18, P605, DOI 10.1038/nm.2661
   Soria JC, 2010, J CLIN ONCOL, V28, P1527, DOI 10.1200/JCO.2009.25.4847
   Telerman A, 2009, NAT REV CANCER, V9, P206, DOI 10.1038/nrc2589
   Tuynder M, 2004, P NATL ACAD SCI USA, V101, P15364, DOI 10.1073/pnas.0406776101
   Tzadok S, 2010, INT J ONCOL, V37, P1043, DOI 10.3892/ijo_00000756
   Wainberg ZA, 2013, CLIN COLORECTAL CANC, V12, P248, DOI 10.1016/j.clcc.2013.06.002
   Zheng YC, 2016, CURR TOP MED CHEM, V16, P2179, DOI 10.2174/1568026616666160216154042
NR 34
TC 17
Z9 17
U1 3
U2 8
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1042-8194
EI 1029-2403
J9 LEUKEMIA LYMPHOMA
JI Leuk. Lymphoma
PY 2017
VL 58
IS 9
BP 2208
EP 2217
DI 10.1080/10428194.2017.1287358
PG 10
WC Oncology; Hematology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Hematology
GA EY4FU
UT WOS:000403933700022
PM 28278721
DA 2022-04-25
ER

PT J
AU Nam, Y
   Ryu, KD
   Jang, C
   Moon, YH
   Kim, M
   Ko, D
   Chung, KS
   Gandini, MA
   Lee, KT
   Zamponi, GW
   Lee, JY
AF Nam, Yunchan
   Ryu, Ki Deok
   Jang, Changyoung
   Moon, Yoon Hyoung
   Kim, Misong
   Ko, Dohyeong
   Chung, Kyung-Sook
   Gandini, Maria A.
   Lee, Kyung-Tae
   Zamponi, Gerald W.
   Lee, Jae Yeol
TI Synthesis and cytotoxic effects of 2-thio-3,4-dihydroquinazoline
   derivatives as novel T-type calcium channel blockers
SO BIOORGANIC & MEDICINAL CHEMISTRY
LA English
DT Article
DE T-type calcium channel; 2-thio-3,4-dihydroquinazoline; Current
   inhibition; Cytotoxicity
ID CANCER-CELLS; A549 CELLS; APOPTOSIS; INHIBITION; EXPRESSION; AUTOPHAGY;
   ARREST; GROWTH
AB In our previous work, a series of 2-amino-3,4-dihydroquinazoline derivatives using an electron acceptor group was reported to be potent T-type calcium channel blockers and exhibit strong cytotoxic effects against various cancerous cell lines. To investigate the role of the guanidine moiety in the 2-amino-3,4-dihydroquinazoline scaffold as a pharmacophore for dual biological activity, a new series of 2-thio-3,4-dihydroquniazoline derivatives using an electron donor group at the C2-position was synthesized and evaluated for T-type calcium channel blocking activity and cytotoxic effects against two human cancerous cell lines (lung cancer A549 and colon cancer HCT-116). Among them, compound 6g showed potent inhibition of Ca(v)3.2 currents (83% inhibition) at 10 mu M concentrations. The compound also exhibited IC50 values of 5.0 and 6.4 mu M against A549 and HCT-116 cell lines, respectively, which are comparable to the parental lead compound KYS05090. These results indicate that the isothiourea moiety similar to the guanidine moiety of 2-amino-3,4-dihydroquinazoline derivatives may be an essential pharmacophore for the desired biological activities. Therefore, our preliminary work can provide the opportunity to expand a chemical repertoire to improve affinity and selectivity for T-type calcium channels.
C1 [Nam, Yunchan; Ryu, Ki Deok; Jang, Changyoung; Moon, Yoon Hyoung; Kim, Misong; Ko, Dohyeong; Lee, Jae Yeol] Kyung Hee Univ, Coll Sci, Res Inst Basic Sci, Seoul 02447, South Korea.
   [Nam, Yunchan; Ryu, Ki Deok; Jang, Changyoung; Moon, Yoon Hyoung; Kim, Misong; Ko, Dohyeong; Lee, Jae Yeol] Kyung Hee Univ, Coll Sci, Dept Chem, Seoul 02447, South Korea.
   [Chung, Kyung-Sook; Lee, Kyung-Tae] Kyung Hee Univ, Dept Life & Nanopharmaceut Sci, Coll Pharm, Seoul 02447, South Korea.
   [Gandini, Maria A.; Zamponi, Gerald W.] Univ Calgary, Cumming Sch Med, Hotchkiss Brain Inst, Dept Physiol & Pharmacol, Calgary, AB T2N 4N1, Canada.
   [Gandini, Maria A.; Zamponi, Gerald W.] Univ Calgary, Cumming Sch Med, Alberta Childrens Hosp Res Inst, Calgary, AB T2N 4N1, Canada.
   [Lee, Jae Yeol] Kyung Hee Univ, KHU KIST Dept Converging Sci & Technol, Seoul 02447, South Korea.
RP Lee, KT; Zamponi, GW; Lee, JY (corresponding author), Kyung Hee Univ, Coll Sci, Res Inst Basic Sci, Seoul 02447, South Korea.; Lee, KT; Zamponi, GW; Lee, JY (corresponding author), Kyung Hee Univ, Coll Sci, Dept Chem, Seoul 02447, South Korea.
EM ktlee@khu.ac.kr; zamponi@ucalgary.ca; ljy@khu.ac.kr
FU National Research Foundation (NRF) - Korea government MISIT
   [2016R1D1A1B03936197]; National Research Foundation (NRF) grant - Korea
   government MIE [2019R1F1A1059332]; Canadian Institutes for Health
   Research (CIHR)Canadian Institutes of Health Research (CIHR); Alberta
   Innovates; CIHR FellowshipCanadian Institutes of Health Research (CIHR)
FX This work was supported by the National Research Foundation (NRF) grant
   funded by the Korea government MISIT (No. 2016R1D1A1B03936197) and MIE
   (No. 2019R1F1A1059332)/ The Canadian Institutes for Health Research
   (CIHR) and Alberta Innovates. GWZ is a Canada Research Chair. MAG holds
   a CIHR Fellowship.
CR Akl H, 2013, BBA-REV CANCER, V1835, P180, DOI 10.1016/j.bbcan.2012.12.001
   Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155
   Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035
   Bertolesi GE, 2002, MOL PHARMACOL, V62, P210, DOI 10.1124/mol.62.2.210
   Busselberg D, 2017, CANCERS, V9, DOI 10.3390/cancers9050048
   Byun JS, 2016, BIOORG MED CHEM LETT, V26, P1073, DOI 10.1016/j.bmcl.2015.12.010
   Chen YF, 2013, J BIOMED SCI, V20, DOI 10.1186/1423-0127-20-23
   Choi DL, 2014, BIOORG MED CHEM LETT, V24, P1565, DOI 10.1016/j.bmcl.2014.01.071
   Clapham DE, 2007, CELL, V131, P1047, DOI 10.1016/j.cell.2007.11.028
   Das A, 2013, PIGM CELL MELANOMA R, V26, DOI 10.1111/pcmr.12155
   Dziegielewska B, 2014, MOL CANCER RES, V12, P348, DOI 10.1158/1541-7786.MCR-13-0485
   Dziegielewska B, 2014, PFLUG ARCH EUR J PHY, V466, P801, DOI 10.1007/s00424-014-1444-z
   Garcia-Caballero A, 2014, NEURON, V83, P1144, DOI 10.1016/j.neuron.2014.07.036
   GarciaCaballero A, 2019, MOL BRAIN, V12, P98
   Gunaratna MJ, 2019, ARKIVOC, P22, DOI 10.24820/ark.5550190.p010.752
   Hirooka K, 2002, J NEUROPHYSIOL, V88, P196, DOI 10.1152/jn.2002.88.1.196
   Iftinca MC, 2009, TRENDS PHARMACOL SCI, V30, P32, DOI 10.1016/j.tips.2008.10.004
   Jang SJ, 2013, BIOORG MED CHEM LETT, V23, P6656, DOI 10.1016/j.bmcl.2013.10.049
   Kang HB, 2012, BIOORG MED CHEM LETT, V22, P1198, DOI 10.1016/j.bmcl.2011.11.083
   Lastraioli E, 2015, BBA-BIOMEMBRANES, V1848, P2685, DOI 10.1016/j.bbamem.2014.12.016
   Latour I, 2004, GLIA, V48, P112, DOI 10.1002/glia.20063
   Lu FM, 2008, CELL CALCIUM, V43, P49, DOI 10.1016/j.ceca.2007.03.006
   Monteith GR, 2007, NAT REV CANCER, V7, P519, DOI 10.1038/nrc2171
   Monteith GR, 2017, NAT REV CANCER, V17, P367, DOI 10.1038/nrc.2017.18
   Monteith GR, 2012, J BIOL CHEM, V287, P31666, DOI 10.1074/jbc.R112.343061
   Munch H, 2008, TETRAHEDRON LETT, V49, P3117, DOI 10.1016/j.tetlet.2008.03.045
   Paetzold E, 2000, J MOL CATAL A-CHEM, V152, P69, DOI 10.1016/S1381-1169(99)00286-1
   Park SJ, 2006, BIOORGAN MED CHEM, V14, P3502, DOI 10.1016/j.bmc.2006.01.005
   Parkash J, 2010, LIFE SCI, V87, P587, DOI 10.1016/j.lfs.2010.09.013
   Pillaiyar T, 2011, CHEM PHARM BULL, V59, P1285
   Regina GL, 2009, J HETEROCYCLIC CHEM, V46, P10
   Rim HK, 2014, MOLECULES, V19, P9864, DOI 10.3390/molecules19079864
   Rim HK, 2012, BIOORG MED CHEM LETT, V22, P7123, DOI 10.1016/j.bmcl.2012.09.076
   RUBINSTEIN LV, 1990, J NATL CANCER I, V82, P1113, DOI 10.1093/jnci/82.13.1113
   Sairaman A, 2018, BIOORGAN MED CHEM, V26, P3046, DOI 10.1016/j.bmc.2018.03.031
   Sallan MC, 2018, CANCER RES, V78, P603, DOI 10.1158/0008-5472.CAN-17-3061
   Schreiber R, 2005, J MEMBRANE BIOL, V205, P129, DOI 10.1007/s00232-005-0778-z
   Seo HN, 2007, BIOORG MED CHEM LETT, V17, P5740, DOI 10.1016/j.bmcl.2007.08.070
   Snutch TP, 2018, BRIT J PHARMACOL, V175, P2375, DOI 10.1111/bph.13906
   Stewart TA, 2015, BBA-BIOMEMBRANES, V1848, P2502, DOI 10.1016/j.bbamem.2014.08.016
   Suo A, 2018, ONCOTARGET, V9, P8573
   Teleb M, 2019, BIOORG CHEM, V88, DOI 10.1016/j.bioorg.2019.04.009
   Teleb M, 2019, BIOORG CHEM, V83, P354, DOI 10.1016/j.bioorg.2018.10.054
   Wang D, 2018, MAR DRUGS, V16, DOI 10.3390/md16120475
   Weiss N, 2019, J MED GENET
   Weiss N, 2019, INT J BIOCHEM CELL B, V108, P34, DOI 10.1016/j.biocel.2019.01.008
   White E, 2015, CLIN CANCER RES, V21, P5037, DOI 10.1158/1078-0432.CCR-15-0490
   Zamponi GW, 2016, NAT REV DRUG DISCOV, V15, P19, DOI 10.1038/nrd.2015.5
   Zamponi GW, 2015, PHARMACOL REV, V67, P821, DOI 10.1124/pr.114.009654
NR 49
TC 3
Z9 3
U1 0
U2 7
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0968-0896
EI 1464-3391
J9 BIOORGAN MED CHEM
JI Bioorg. Med. Chem.
PD JUN 1
PY 2020
VL 28
IS 11
AR 115491
DI 10.1016/j.bmc.2020.115491
PG 9
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Chemistry,
   Organic
WE Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Chemistry
GA LR6NF
UT WOS:000535808700014
PM 32327350
DA 2022-04-25
ER

PT J
AU Mbaveng, AT
   Ndontsa, BL
   Kuete, V
   Nguekeu, YMM
   Celik, I
   Mbouangouere, R
   Tane, P
   Efferth, T
AF Mbaveng, Armelle T.
   Ndontsa, Blanche L.
   Kuete, Victor
   Nguekeu, Yves M. M.
   Celik, Ilhami
   Mbouangouere, Roukayatou
   Tane, Pierre
   Efferth, Thomas
TI A naturally occuring triterpene saponin ardisiacrispin B displayed
   cytotoxic effects in multi-factorial drug resistant cancer cells via
   ferroptotic and apoptotic cell death
SO PHYTOMEDICINE
LA English
DT Article
DE Ardisiacrispin B; Cell cycle distribution; Cytotoxicity; Ferroptosis;
   Mitochondrial membrane potential; Saponin
ID LEUKEMIA-CELLS; BREAST-CANCER; TUMOR-CELLS; MODES; TRANSPORTER;
   FLAVONOIDS; AUTOPHAGY; PUSILLA; LINES
AB Introduction: Multidrug resistance of cancer cells constitutes a serious problem in chemotherapy and a challenging issue in the discovery of new cytotoxic drugs. Many saponins are known to display anti-cancer effects. In this study, the cytotoxicity and the modes of action of a naturally occuring oleanane-type tritepene saponin, ardisiacrispin B isolated from the fruit of Ardisia kivuensis Talon (Myrsinaceae) was evaluated on a panel of 9 cancer cell lines including various sensitive and drug-resistant phenotypes.
   Methods: Resazurin reduction assay was used to evaluate cytotoxicity and ferroptotic cell death of samples; caspase-Glo assay was used to detect the activation of caspases in CCRF-CEM leukemia cells. Flow cytometry was used for cell cycle analysis and detection of apoptotic cells by annexin V/PI staining, analysis of mitochondrial membrane potential (MMP) and measurement of reactive oxygen species (ROS).
   Results: Ardisiacrispin B displayed significant cytotoxic effects in the 9 tested cancer cell lines with IC 50 values below 10 mu M. The IC50 values ranges were 1.20 mu M (towards leukemia CCRF-CEM cells) to 6.76 mu M [against heptocarcinoma HepG2 cells] for ardisiacrispin B and 0.02 mu M (against CCRF-CEM cells) to 122.96 mu M (against resistant CEM/ADR5000 leukemia cells) for doxorubicin. Collateral sensitivity of resistant HCT116p53(-/-) colon adenocarcinoma cells to ardisiacripsin B was observed. Ardisiacrispin B induced apoptosis in CCRF-CEM cells via activation of inititator caspases 8 and 9 and effector caspase 3/7, alteration of MMP and increase in ROS production. Ferroptosis also contributed to the cytotoxicity of ardisiacrispin B.
   Conclusions: The studied oleanane-type triterpene saponin is a good cytotoxic molecule that deserve more detailed exploration in the future, to develop novel cytotoxic drugs to combat both sensitive and drug-resistant cancers.
C1 [Mbaveng, Armelle T.; Kuete, Victor; Efferth, Thomas] Johannes Gutenberg Univ Mainz, Inst Pharm & Biochem, Dept Pharmaceut Biol, Staudinger Weg 5, D-55128 Mainz, Germany.
   [Mbaveng, Armelle T.; Kuete, Victor] Univ Dschang, Dept Biochem, Fac Sci, Dschang, Cameroon.
   [Ndontsa, Blanche L.; Nguekeu, Yves M. M.; Mbouangouere, Roukayatou; Tane, Pierre] Univ Yaounde I, Dept Organ Chem, Fac Sci, Yaounde, Cameroon.
   [Celik, Ilhami] Anadolu Univ, Fac Sci, Dept Chem, TR-26470 Tepebasi, Eskisehir, Turkey.
RP Efferth, T (corresponding author), Johannes Gutenberg Univ Mainz, Inst Pharm & Biochem, Dept Pharmaceut Biol, Staudinger Weg 5, D-55128 Mainz, Germany.
EM efferth@uni-mainz.de
RI Çelik, Ilhami/P-6075-2019
OI Çelik, Ilhami/0000-0002-5384-4755; Mbaveng, Armelle/0000-0003-4178-4967;
   Nguekeu Mba, Yves Martial/0000-0001-6543-2734; Efferth,
   Thomas/0000-0002-3096-3292
FU Alexander von Humboldt FoundationAlexander von Humboldt Foundation;
   International Foundation for Science (IFS)International Foundation for
   Science [F5543]; Organization for the Prohibition of Chemical Weapons
   (OPCW); Scientific Research Projects Commission of Anadolu University,
   Eskisehir, Turkey [1306F110]
FX ATM is thankful to Alexander von Humboldt Foundation for an 18 months
   fellowship in Prof. Dr. Thomas Efferth's laboratory in Mainz, Germany
   through the "Georg Foster Research Fellowship for Experienced
   Researcher'' program. VK is very grateful to the Alexander von Humboldt
   Foundation for the funding through the Linkage program (2015-2018). BLN
   grant (F5543) thanks the International Foundation for Science (IFS) and
   Organization for the Prohibition of Chemical Weapons (OPCW) for their
   financial supports. IC would like to thank the Scientific Research
   Projects Commission of Anadolu University, Eskisehir, Turkey for the
   funding grant (1306F110). Authors are also thankful to the Institute of
   Molecular Biology gGmbH (IMB) (Mainz, Germany) where the flow cytometry
   experiments were performed.
CR Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3
   BASS DA, 1983, J IMMUNOL, V130, P1910
   Boik J., 2001, NATURAL COMPOUNDS CA
   Brahemi G, 2010, J MED CHEM, V53, P2757, DOI 10.1021/jm901757t
   Chen X, 2016, PHYTOMEDICINE, V23, P1555, DOI 10.1016/j.phymed.2016.09.002
   Cossarizza A, 2009, NAT PROTOC, V4, P1790, DOI 10.1038/nprot.2009.189
   Dai LM, 2017, PHYTOCHEMISTRY, V136, P165, DOI 10.1016/j.phytochem.2017.01.021
   Dejean LM, 2006, CELL DEATH DIFFER, V13, P1387, DOI 10.1038/sj.cdd.4401949
   Dixon SJ, 2014, ELIFE, V3, DOI 10.7554/eLife.02523
   Dixon SJ, 2014, NAT CHEM BIOL, V10, P9, DOI 10.1038/nchembio.1416
   Dixon SJ, 2012, CELL, V149, P1060, DOI 10.1016/j.cell.2012.03.042
   Doyle LA, 1998, P NATL ACAD SCI USA, V95, P15665, DOI 10.1073/pnas.95.26.15665
   Dzoyem JP, 2012, PLANTA MED, V78, P787, DOI 10.1055/s-0031-1298431
   Efferth T, 2003, MOL PHARMACOL, V64, P382, DOI 10.1124/mol.64.2.382
   Gerwirtz D. A., 2005, CURR OPIN INVEST DR, V6, P1199
   Gillet JP, 2004, CANCER RES, V64, P8987, DOI 10.1158/0008-5472.CAN-04-1978
   Gottesman Michael M, 2006, Discov Med, V6, P18
   Haridas V, 2001, P NATL ACAD SCI USA, V98, P5821, DOI 10.1073/pnas.101619098
   Howley B, 2008, J CELL MOL MED, V12, P1502, DOI 10.1111/j.1582-4934.2008.00292.x
   Hsieh MJ, 2016, PHYTOMEDICINE, V23, P1545, DOI 10.1016/j.phymed.2016.09.004
   JIA ZH, 1994, PHYTOCHEMISTRY, V37, P1389, DOI 10.1016/S0031-9422(00)90418-7
   Jiang SS, 2016, PHYTOMEDICINE, V23, P243, DOI 10.1016/j.phymed.2016.01.010
   KIMMIG A, 1990, CANCER RES, V50, P6793
   Kuete V., 2013, PHARM CHEM
   Kuete V, 2017, PHYTOMEDICINE, V33, P62, DOI 10.1016/j.phymed.2017.07.010
   Kuete V, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/914813
   Kuete V, 2014, INVEST NEW DRUG, V32, P1053, DOI 10.1007/s10637-014-0137-y
   Kuete V, 2014, J ETHNOPHARMACOL, V153, P207, DOI 10.1016/j.jep.2014.02.025
   Kuete V, 2014, PHYTOMEDICINE, V21, P315, DOI 10.1016/j.phymed.2013.08.018
   Kuete V, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/285903
   Kuete V, 2013, J ETHNOPHARMACOL, V149, P245, DOI 10.1016/j.jep.2013.06.029
   Kuete V, 2013, PHYTOMEDICINE, V20, P528, DOI 10.1016/j.phymed.2013.02.003
   Kuete V, 2011, PLANTA MED, V77, P1984, DOI 10.1055/s-0031-1280023
   Kuete V, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021762
   Li M, 2008, J ASIAN NAT PROD RES, V10, P729, DOI 10.1080/10286020802016198
   Man SL, 2010, FITOTERAPIA, V81, P703, DOI 10.1016/j.fitote.2010.06.004
   Mbaveng AT, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00343
   O'Brien J, 2000, EUR J BIOCHEM, V267, P5421, DOI 10.1046/j.1432-1327.2000.01606.x
   Samarghandian S, 2011, CLINICS, V66, P1073, DOI 10.1590/S1807-59322011000600026
   Shin DY, 2009, BIOMED PHARMACOTHER, V63, P86, DOI 10.1016/j.biopha.2008.08.001
   Sparg SG, 2004, J ETHNOPHARMACOL, V94, P219, DOI 10.1016/j.jep.2004.05.016
   Tang HF, 2009, CHEM BIODIVERS, V6, P1443, DOI 10.1002/cbdv.200800233
   Tian Y, 2009, PLANTA MED, V75, P70, DOI 10.1055/s-0028-1088369
   Volm M., 2015, RESISTANCE TARGETED, P1
   Zhang GX, 2016, PHYTOMEDICINE, V23, P1329, DOI 10.1016/j.phymed.2016.07.003
NR 45
TC 43
Z9 45
U1 7
U2 36
PU ELSEVIER GMBH, URBAN & FISCHER VERLAG
PI JENA
PA OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY
SN 0944-7113
J9 PHYTOMEDICINE
JI Phytomedicine
PD APR 1
PY 2018
VL 43
BP 78
EP 85
DI 10.1016/j.phymed.2018.03.035
PG 8
WC Plant Sciences; Chemistry, Medicinal; Integrative & Complementary
   Medicine; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary
   Medicine
GA GG5GD
UT WOS:000432722700010
PM 29747757
DA 2022-04-25
ER

PT J
AU Skrypek, N
   Vasseur, R
   Vincent, A
   Duchene, B
   Van Seuningen, I
   Jonckheere, N
AF Skrypek, Nicolas
   Vasseur, Romain
   Vincent, Audrey
   Duchene, Belinda
   Van Seuningen, Isabelle
   Jonckheere, Nicolas
TI The oncogenic receptor ErbB2 modulates gemcitabine and irinotecan/SN-38
   chemoresistance of human pancreatic cancer cells via hCNT1 transporter
   and multidrug-resistance associated protein MRP-2
SO ONCOTARGET
LA English
DT Article
DE ErbB2; pancreatic cancer; gemcitabine; FOLFIRINOX; chemoresistance
ID TOPOISOMERASE-I INHIBITORS; MUCIN GENE; AUTOPHAGY; OVEREXPRESSION;
   COLON; HER2; ADENOCARCINOMA; CYTOTOXICITY; COMBINATION; ACTIVATION
AB Pancreatic adenocarcinoma (PDAC) is one of the most deadly cancers because of a lack of early diagnotic markers and efficient therapeutics. The fluorinated analog of deoxycytidine, gemcitabine and emerging FOLFIRINOX protocol (5-fluorouracil (5-FU), irinotecan/SN-38, oxaliplatin and leucovorin) are the main chemotherapies to treat PDAC. The ErbB2/HER2 oncogenic receptor is commonly overexpressed in PDAC. In this context, we aimed to decipher the ErbB2-mediated mechanisms of chemoresistance to the two main chemotherapy protocols used to treat PDAC.
   ErbB2 knocking down (KD) in CAPAN-1 and CAPAN-2 cells led to an increased sensitivity to gemcitabine and an increased resistance to irinotecan/SN-38 both in vitro and in vivo (subcuteanous xenografts) This was correlated to an increase of hCNT1 and hCNT3 transporters and ABCG2, MRP1 and MRP2 ATP-binding cassette transporters expression and resistance to cell death. We also show that MRP2 is repressed following activation of JNK, Erk1/2 and NF-kappa B pathways by ErbB2. Finally, in datasets of human PDAC samples, ErbB2 and MRP2 expression was conversely correlated. Altogether, we propose that ErbB2 mediates several intracellular mechanisms linked to PDAC cell chemoresistance that may represent potential targets in order to ameliorate chemotherapy response and allow stratification of patients eligible for either gemcitabine or FOLFIRINOX treatment.
C1 [Skrypek, Nicolas; Vasseur, Romain; Vincent, Audrey; Duchene, Belinda; Van Seuningen, Isabelle; Jonckheere, Nicolas] INSERM, UMR S1172, Jean Pierre Aubert Res Ctr, Team Mucins Epithelial Differentiat & Carcinogene, F-59045 Lille, France.
   [Skrypek, Nicolas; Vasseur, Romain; Vincent, Audrey; Duchene, Belinda; Van Seuningen, Isabelle; Jonckheere, Nicolas] Univ Lille Nord France, F-59000 Lille, France.
   [Skrypek, Nicolas; Vasseur, Romain; Vincent, Audrey; Duchene, Belinda; Van Seuningen, Isabelle; Jonckheere, Nicolas] CHRU Lille, F-59037 Lille, France.
RP Jonckheere, N (corresponding author), INSERM, UMR S1172, Jean Pierre Aubert Res Ctr, Team Mucins Epithelial Differentiat & Carcinogene, F-59045 Lille, France.
EM nicolas.jonckheere@inserm.fr
RI Jonckheere, Nicolas/J-6028-2013; Vincent, Audrey/I-2934-2016; VAN
   SEUNINGEN, Isabelle/N-6176-2016
OI Jonckheere, Nicolas/0000-0002-0496-0661; Vincent,
   Audrey/0000-0003-0058-2058; VAN SEUNINGEN, Isabelle/0000-0002-3131-2694;
   Vasseur, Romain/0000-0003-4179-9800; Duchene,
   Belinda/0000-0002-4810-4680
FU Centre Hospitalier Regional et Universitaire (CHRU) de Lille/region
   Nord-Pas de CalaisRegion Hauts-de-France; Universite de Lille 2;
   Fondation ARC; Region Nord-Pas de CalaisRegion Hauts-de-FranceEuropean
   Commission; la Ligue Nationale Contre le Cancer (Equipe Labellisee
   Ligue); SIRIC ONCOLille; Grant INCaDGOS-Inserm [6041]; "Contrat de Plan
   Etat Region" CPER Cancer
FX We thank MH Gevaert and R Siminsky (Department of Histology, Faculty of
   Medicine, University of Lille 2) for their technical help, the
   IFR114/IMPRT confocal microscopy platform (M. Tardivel), and animal
   facility (D. Taillieu). Nicolas Skrypek is the recipient of a PhD
   fellowship from the Centre Hospitalier Regional et Universitaire (CHRU)
   de Lille/region Nord-Pas de Calais. Romain Vasseur is a recipient of a
   PhD fellowship from the Universite de Lille 2. Audrey Vincent is the
   recipient of a postdoctoral fellowship from the Fondation ARC and Region
   Nord-Pas de Calais. Isabelle Van Seuningen. is the recipient of a
   "Contrat Hospitalier de Recherche Translationnelle"/CHRT 2010, AVIESAN.
   This work is supported by grants from la Ligue Nationale Contre le
   Cancer (Equipe Labellisee Ligue 2010, IVS), from SIRIC ONCOLille, Grant
   INCaDGOS-Inserm 6041 (IVS, NJ) and from "Contrat de Plan Etat Region"
   CPER Cancer 2007-2013 (IVS). The funders had no role in study design,
   data collection and interpretations, decision to publish, or preparation
   of the manuscript.
CR Candeil L, 2004, INT J CANCER, V109, P848, DOI 10.1002/ijc.20032
   Catley L, 2004, CANCER RES, V64, P8746, DOI 10.1158/0008-5472.CAN-04-2894
   Conroy T, 2011, NEW ENGL J MED, V364, P1817, DOI 10.1056/NEJMoa1011923
   Davies BR, 2007, MOL CANCER THER, V6, P2209, DOI 10.1158/1535-7163.MCT-07-0231
   Diamandis EP, 2010, J NATL CANCER I, V102, P1462, DOI 10.1093/jnci/djq306
   Fiorini C, 2015, BBA-MOL CELL RES, V1853, P89, DOI 10.1016/j.bbamcr.2014.10.003
   Fiorini C, 2013, APOPTOSIS, V18, P337, DOI 10.1007/s10495-012-0790-6
   Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]
   Jonckheere N, 2004, ONCOGENE, V23, P5729, DOI 10.1038/sj.onc.1207769
   Jonckheere N, 2009, BRIT J CANCER, V101, P637, DOI 10.1038/sj.bjc.6605190
   Jonckheere N, 2014, CLIN RES HEPATOL GAS, V38, P423, DOI 10.1016/j.clinre.2014.04.009
   Jonckheere N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032232
   Kim HS, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/527534
   Komoto M, 2009, CANCER SCI, V100, P1243, DOI 10.1111/j.1349-7006.2009.01176.x
   LaBonte MJ, 2009, INT J CANCER, V125, P2957, DOI 10.1002/ijc.24658
   Lee SH, 2012, PATHOL INT, V62, P167, DOI 10.1111/j.1440-1827.2011.02772.x
   Lozy F, 2014, AUTOPHAGY, V10, P662, DOI 10.4161/auto.27867
   Lu CR, 2006, MOL CELL, V23, P121, DOI 10.1016/j.molcel.2006.05.023
   Maciejczyk A, 2012, PATHOL ONCOL RES, V18, P331, DOI 10.1007/s12253-011-9449-9
   Mazard T, 2013, MOL CANCER THER, V12, P2121, DOI 10.1158/1535-7163.MCT-12-0966
   Mishra Alok, 2010, Cancers (Basel), V2, P190, DOI 10.3390/cancers2010190
   Moasser MM, 2007, ONCOGENE, V26, P6469, DOI 10.1038/sj.onc.1210477
   Mohelnikova-Duchonova B, 2013, PANCREAS, V42, P707, DOI 10.1097/MPA.0b013e318279b861
   O'Reilly Eileen M, 2009, Gastrointest Cancer Res, V3, pS11
   Piessen G, 2007, BIOCHEM J, V402, P81, DOI 10.1042/BJ20061461
   Pommier Y, 2006, NAT REV CANCER, V6, P789, DOI 10.1038/nrc1977
   Pommier Y, 2009, CHEM REV, V109, P2894, DOI 10.1021/cr900097c
   Rahib L, 2014, CANCER RES, V74, P2913, DOI 10.1158/0008-5472.CAN-14-0155
   Rosenfeldt MT, 2013, NATURE, V504, P296, DOI 10.1038/nature12865
   Rosner GL, 2008, CLIN PHARMACOL THER, V84, P393, DOI 10.1038/clpt.2008.63
   Sharom FJ, 2008, PHARMACOGENOMICS, V9, P105, DOI 10.2217/14622416.9.1.105
   Skrypek N, 2013, ONCOGENE, V32, P1714, DOI 10.1038/onc.2012.179
   Stoecklein NH, 2004, J CLIN ONCOL, V22, P4737, DOI 10.1200/JCO.2004.05.142
   Szakacs G, 2006, NAT REV DRUG DISCOV, V5, P219, DOI 10.1038/nrd1984
   Torrisani J, 2009, HUM GENE THER, V20, P831, DOI 10.1089/hum.2008.134
   van der Sluis M, 2004, BIOCHEM BIOPH RES CO, V325, P952, DOI 10.1016/j.bbrc.2004.10.108
   Van Seuningen I, 2000, BIOCHEM J, V348, P675
   Vannini I, 2009, ANTI-CANCER DRUG, V20, P918, DOI 10.1097/CAD.0b013e32833179bf
   Vincent A, 2011, LANCET, V378, P607, DOI 10.1016/S0140-6736(10)62307-0
   Wagner EF, 2009, NAT REV CANCER, V9, P537, DOI 10.1038/nrc2694
   Yamade M, 2012, ANTICANCER RES, V32, P105
   Yu H, 2012, CANCER RES TREAT, V44, P195, DOI 10.4143/crt.2012.44.3.195
   Zhang L, 2009, CANCER LETT, V285, P58, DOI 10.1016/j.canlet.2009.04.041
NR 43
TC 29
Z9 32
U1 0
U2 9
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD MAY 10
PY 2015
VL 6
IS 13
BP 10853
EP 10867
DI 10.18632/oncotarget.3414
PG 15
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA CO2SH
UT WOS:000359006400016
PM 25890497
OA Green Submitted, gold, Green Published
DA 2022-04-25
ER

PT J
AU Kranz, P
   Sanger, C
   Wolf, A
   Baumann, J
   Metzen, E
   Baumann, M
   Gopelt, K
   Brockmeier, U
AF Kranz, Philip
   Saenger, Christopher
   Wolf, Alexandra
   Baumann, Jennifer
   Metzen, Eric
   Baumann, Melanie
   Goepelt, Kirsten
   Brockmeier, Ulf
TI Tumor cells rely on the thiol oxidoreductase PDI for PERK signaling in
   order to survive ER stress
SO SCIENTIFIC REPORTS
LA English
DT Article
ID PROTEIN DISULFIDE-ISOMERASE; ENDOPLASMIC-RETICULUM STRESS; INHIBITOR;
   DISCOVERY; RADIATION; AUTOPHAGY; KINASE; FAMILY; DEATH
AB Upon ER stress cells activate the unfolded protein response through PERK, IRE1 and ATF6. Remarkable effort has been made to delineate the downstream signaling of these three ER stress sensors after activation, but upstream regulation at the ER luminal site still remains mostly undefined. Here we report that the thiol oxidoreductase PDI is mandatory for activation of the PERK pathway in HEK293T as well as in human pancreatic, lung and colon cancer cells. Under ER stress, depletion of PDI selectively abrogated eIF2 alpha phosphorylation, induction of ATF4, CHOP and even BiP. Furthermore, we could demonstrate that PDI prevented degradation of activated PERK by the 26S proteasome and therefore contributes to maintained PERK signaling. As a result of decreased PERK activity, PDI depleted cells showed an increased vulnerability to ER stress induced by chemicals or ionizing radiation in 2D as well as in 3D culture models. We conclude that PDI is an obligatory regulator of the PERK pathway with future therapy implications.
C1 [Kranz, Philip; Saenger, Christopher; Wolf, Alexandra; Baumann, Jennifer; Metzen, Eric; Baumann, Melanie; Goepelt, Kirsten; Brockmeier, Ulf] Univ Duisburg Essen, Inst Physiol, Duisburg, Germany.
   [Brockmeier, Ulf] Univ Duisburg Essen, Univ Hosp Essen, Dept Neurol, Duisburg, Germany.
RP Brockmeier, U (corresponding author), Univ Duisburg Essen, Inst Physiol, Duisburg, Germany.; Brockmeier, U (corresponding author), Univ Duisburg Essen, Univ Hosp Essen, Dept Neurol, Duisburg, Germany.
EM ulf.brockmeier@uni-due.de
FU IFORES program of the Universitatsklinik Essen; research training group
   GRK1739 of the Deutsche ForschungsgemeinschaftGerman Research Foundation
   (DFG)
FX This study was funded by the IFORES program of the Universitatsklinik
   Essen and the research training group GRK1739 of the Deutsche
   Forschungsgemeinschaft. We are indebted to George Iliakis, Institut fur
   Strahlenbiologie, Universitat Duisburg-Essen, for providing radiation
   equipment.
CR Atkins C, 2013, CANCER RES, V73, P1993, DOI 10.1158/0008-5472.CAN-12-3109
   Avci D, 2015, TRENDS CELL BIOL, V25, P611, DOI 10.1016/j.tcb.2015.07.003
   Avivar-Valderas A, 2011, MOL CELL BIOL, V31, P3616, DOI 10.1128/MCB.05164-11
   Axten JM, 2013, ACS MED CHEM LETT, V4, P964, DOI 10.1021/ml400228e
   Bobrovnikova-Marjon E, 2010, ONCOGENE, V29, P3881, DOI 10.1038/onc.2010.153
   Bobrovnikova-Marjon E, 2008, P NATL ACAD SCI USA, V105, P16314, DOI 10.1073/pnas.0808517105
   Carrara M, 2013, INT J MOL SCI, V14, P6454, DOI 10.3390/ijms14036454
   Cole KS, 2018, BIOCHEMISTRY-US, V57, P2035, DOI 10.1021/acs.biochem.8b00178
   Eletto D, 2016, FASEB J, V30, P653, DOI 10.1096/fj.15-275883
   Eletto D, 2014, MOL CELL, V53, P562, DOI 10.1016/j.molcel.2014.01.004
   Ellgaard L, 2005, EMBO REP, V6, P28, DOI 10.1038/sj.embor.7400311
   Ellgaard L, 2016, TRAFFIC, V17, P615, DOI 10.1111/tra.12392
   Feng YX, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01052-y
   Gao Y, 2012, MOL CELL BIOL, V32, P5129, DOI 10.1128/MCB.01009-12
   Guzman C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092444
   Han J, 2016, J LIPID RES, V57, P1329, DOI 10.1194/jlr.R067595
   Hatahet F, 2009, ANTIOXID REDOX SIGN, V11, P2807, DOI 10.1089/ARS.2009.2466
   Hetz C, 2018, MOL CELL, V69, P169, DOI 10.1016/j.molcel.2017.06.017
   Higa A, 2014, MOL CELL BIOL, V34, P1839, DOI 10.1128/MCB.01484-13
   Hong F, 2017, NAT STRUCT MOL BIOL, V24, P834, DOI 10.1038/nsmb.3458
   Hussmann M, 2015, ONCOTARGET, V6, P39247, DOI 10.18632/oncotarget.5746
   Ivanov DP, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103817
   Kaplan A, 2015, P NATL ACAD SCI USA, V112, pE2245, DOI 10.1073/pnas.1500439112
   Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211
   Khan HA, 2014, FRONT CHEM, V2, DOI 10.3389/fchem.2014.00070
   Kim KW, 2010, ONCOGENE, V29, P3241, DOI 10.1038/onc.2010.74
   Kim K, 2013, BLOOD, V122, P1052, DOI 10.1182/blood-2013-03-492504
   Kranz P, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.369
   Krossa S, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-19429-4
   Kyani A, 2018, CHEMMEDCHEM, V13, P164, DOI 10.1002/cmdc.201700629
   Lehman SL, 2015, SCI REP-UK, V5, DOI 10.1038/srep11781
   Liu HT, 2008, BMC BIOTECHNOL, V8, DOI 10.1186/1472-6750-8-91
   Liu Z, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.183
   Nadanaka S, 2007, MOL CELL BIOL, V27, P1027, DOI 10.1128/MCB.00408-06
   Pytel D, 2016, ONCOGENE, V35, P1207, DOI 10.1038/onc.2015.178
   Rouschop KM, 2013, P NATL ACAD SCI USA, V110, P4622, DOI 10.1073/pnas.1210633110
   Rutkevich LA, 2010, MOL BIOL CELL, V21, P3093, DOI 10.1091/mbc.E10-04-0356
   Salaroglio IC, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0657-0
   Vatolin S, 2016, CANCER RES, V76, P3340, DOI 10.1158/0008-5472.CAN-15-3099
   Wang M, 2014, NAT REV CANCER, V14, P581, DOI 10.1038/nrc3800
   Weiswald LB, 2015, NEOPLASIA, V17, P1, DOI 10.1016/j.neo.2014.12.004
   Won JK, 2017, HEPATOLOGY, V66, P855, DOI 10.1002/hep.29237
   Xu SL, 2012, P NATL ACAD SCI USA, V109, P16348, DOI 10.1073/pnas.1205226109
   Yu QJ, 2015, P NATL ACAD SCI USA, V112, P15420, DOI 10.1073/pnas.1516362112
   Zhang M., 2018, CANC MED
   Zhang Z., 2018, REDOX BIOL
   Zhou X, 2018, HUM MOL GENET, V27, P1545, DOI 10.1093/hmg/ddy061
NR 47
TC 1
Z9 1
U1 0
U2 2
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD SEP 17
PY 2020
VL 10
IS 1
AR 15299
DI 10.1038/s41598-020-72259-1
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA NU6NF
UT WOS:000573758500043
PM 32943707
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Nasef, NA
   Mehta, S
   Ferguson, LR
AF Nasef, Noha Ahmed
   Mehta, Sunali
   Ferguson, Lynnette R.
TI Dietary interactions with the bacterial sensing machinery in the
   intestine: the plant polyphenol case
SO FRONTIERS IN GENETICS
LA English
DT Review
ID CATECHOL-O-METHYLTRANSFERASE; VITAMIN-E SUPPLEMENTATION;
   CORONARY-HEART-DISEASE; TOLL-LIKE RECEPTORS; COLON-CANCER CELLS;
   NF-KAPPA-B; BETA-CAROTENE; IN-VITRO; PHYTOCHEMICAL VARIATION;
   CARDIOVASCULAR EVENTS
AB There are millions of microbes that live in the human gut. These are important in digestion as well as defense. The host immune system needs to be able to distinguish between the harmless bacteria and pathogens. The initial interaction between bacteria and the host happen through the pattern recognition receptors (PRRs). As these receptors are in direct contact with the external environment, this makes them important candidates for regulation by dietary components and therefore potential targets for therapy. In this review, we introduce some of the main PRRs including a cellular process known as autophagy, and how they function. Additionally we review dietary phytochemicals from plants which are believed to be beneficial for humans. The purpose of this review was to give a better understanding of how these components work in order to create better awareness on how they could be explored in the future.
C1 [Nasef, Noha Ahmed; Mehta, Sunali; Ferguson, Lynnette R.] Univ Auckland, Dept Nutr, Fac Med & Hlth Sci, Auckland 1023, New Zealand.
RP Ferguson, LR (corresponding author), Univ Auckland, Dept Nutr, Fac Med & Hlth Sci, 85 Pk Rd, Auckland 1023, New Zealand.
EM l.ferguson@auckland.ac.nz
RI Mehta, Sunali/O-8459-2019
OI Mehta, Sunali/0000-0002-1777-1245
CR Abbas AK, 2012, CELLULAR MOL IMMUNOL
   Abreu MT, 2010, NAT REV IMMUNOL, V10, P131, DOI 10.1038/nri2707
   Aharoni A, 2005, TRENDS PLANT SCI, V10, P594, DOI 10.1016/j.tplants.2005.10.005
   Aherne SA, 2002, NUTRITION, V18, P75, DOI 10.1016/S0899-9007(01)00695-5
   Albert A, 2009, OECOLOGIA, V160, P1, DOI 10.1007/s00442-009-1277-1
   Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560
   Ban H, 2004, INT J MOL MED, V13, P537
   Bernales S, 2006, PLOS BIOL, V4, P2311, DOI 10.1371/journal.pbio.0040423
   Beutler B, 2009, IMMUNOL REV, V227, P248, DOI 10.1111/j.1600-065X.2008.00733.x
   Bielig H, 2010, CHEMMEDCHEM, V5, P2065, DOI 10.1002/cmdc.201000320
   Binns SE, 2002, J AGR FOOD CHEM, V50, P3673, DOI 10.1021/jf011439t
   Birt DF, 2001, PHARMACOL THERAPEUT, V90, P157, DOI 10.1016/S0163-7258(01)00137-1
   Biswas SK, 2007, INT J BIOCHEM CELL B, V39, P1582, DOI 10.1016/j.biocel.2007.04.021
   Bjelakovic G, 2012, COCHRANE DB SYST REV, DOI [10.1590/1516-3180.20151332T1, 10.1002/14651858.CD007176.pub2]
   BLOCK G, 1992, NUTR CANCER, V18, P1, DOI 10.1080/01635589209514201
   Bolca S, 2013, CURR OPIN BIOTECH, V24, P220, DOI 10.1016/j.copbio.2012.09.009
   BOUDIKOVA B, 1990, CLIN PHARMACOL THER, V48, P381, DOI 10.1038/clpt.1990.166
   Bravo L, 1998, NUTR REV, V56, P317, DOI 10.1111/j.1753-4887.1998.tb01670.x
   Cario E, 2007, GASTROENTEROLOGY, V132, P1359, DOI 10.1053/j.gastro.2007.02.056
   Chen G, 2009, ANNU REV PATHOL-MECH, V4, P365, DOI 10.1146/annurev.pathol.4.110807.092239
   Correa RG, 2012, BIOSCIENCE REP, V32, P597, DOI 10.1042/BSR20120055
   Covert MW, 2005, SCIENCE, V309, P1854, DOI 10.1126/science.1112304
   Crespy V, 2003, AM J PHYSIOL-GASTR L, V284, pG980, DOI 10.1152/ajpgi.00223.2002
   Cuervo AM, 2012, MOL ASPECTS MED, V33, P2, DOI 10.1016/j.mam.2011.09.001
   De Cruz P, 2012, INFLAMM BOWEL DIS, V18, P372, DOI 10.1002/ibd.21751
   Del Rio D, 2010, NUTR METAB CARDIOVAS, V20, P1, DOI 10.1016/j.numecd.2009.05.015
   Deretic V, 2011, IMMUNOL REV, V240, P92, DOI 10.1111/j.1600-065X.2010.00995.x
   Deretic V, 2010, CURR OPIN CELL BIOL, V22, P252, DOI 10.1016/j.ceb.2009.12.009
   Diebold SS, 2004, SCIENCE, V303, P1529, DOI 10.1126/science.1093616
   Doyle SL, 2006, BIOCHEM PHARMACOL, V72, P1102, DOI 10.1016/j.bcp.2006.07.010
   DUTTON GJ, 1978, ANNU REV PHARMACOL, V18, P17, DOI 10.1146/annurev.pa.18.040178.000313
   Eberhardt MV, 2000, NATURE, V405, P903, DOI 10.1038/35016148
   Ellett S., 2013, NUTRIGENOMICS NUTRIG, P269
   Ellington AA, 2005, CARCINOGENESIS, V26, P159, DOI 10.1093/carcin/bgh297
   Faurobert M, 2007, PLANT PHYSIOL, V143, P1327, DOI 10.1104/pp.106.092817
   Fukata M, 2009, SEMIN IMMUNOL, V21, P242, DOI 10.1016/j.smim.2009.06.005
   Gershenzon J., 1984, Phytochemical Adaptations to Stress, P273
   Gewirtz AT, 2001, J IMMUNOL, V167, P1882, DOI 10.4049/jimmunol.167.4.1882
   Girardin SE, 2003, J BIOL CHEM, V278, P8869, DOI 10.1074/jbc.C200651200
   Girardin SE, 2003, SCIENCE, V300, P1584, DOI 10.1126/science.1084677
   Goberdhan DCI, 2009, BIOCHEM SOC T, V37, P248, DOI 10.1042/BST0370248
   Gonzalez R, 2011, CRIT REV FOOD SCI, V51, P331, DOI 10.1080/10408390903584094
   GREENBERG ER, 1990, NEW ENGL J MED, V323, P789, DOI 10.1056/NEJM199009203231204
   Heil F, 2004, SCIENCE, V303, P1526, DOI 10.1126/science.1093620
   Hennekens CH, 1996, NEW ENGL J MED, V334, P1145, DOI 10.1056/NEJM199605023341801
   HERTOG MGL, 1993, NUTR CANCER, V20, P21, DOI 10.1080/01635589309514267
   HERTOG MGL, 1995, ARCH INTERN MED, V155, P381, DOI 10.1001/archinte.155.4.381
   HERTOG MGL, 1993, LANCET, V342, P1007, DOI 10.1016/0140-6736(93)92876-U
   Hodgson JM, 2006, J SCI FOOD AGR, V86, P2492, DOI 10.1002/jsfa.2675
   Hooper L, 2008, AM J CLIN NUTR, V88, P38, DOI 10.1093/ajcn/88.1.38
   Hooper LV, 2012, SCIENCE, V336, P1268, DOI 10.1126/science.1223490
   Inohara N, 1999, J BIOL CHEM, V274, P14560, DOI 10.1074/jbc.274.21.14560
   Itoh T, 2008, MOL BIOL CELL, V19, P2916, DOI 10.1091/mbc.E07-12-1231
   Iwata J, 2006, J BIOL CHEM, V281, P4035, DOI 10.1074/jbc.M512283200
   Izukawa T, 2009, DRUG METAB DISPOS, V37, P1759, DOI 10.1124/dmd.109.027227
   Jancova P, 2010, BIOMED PAP, V154, P103, DOI 10.5507/bp.2010.017
   JEFFERY DR, 1984, J NEUROCHEM, V42, P826, DOI 10.1111/j.1471-4159.1984.tb02755.x
   Jensen GS, 2008, J AGR FOOD CHEM, V56, P8326, DOI 10.1021/jf8016157
   Jensen GS, 2011, J MED FOOD, V14, P702, DOI 10.1089/jmf.2010.0150
   Jeong EJ, 2005, CURR DRUG METAB, V6, P455, DOI 10.2174/138920005774330657
   Jialal I, 2000, NEW ENGL J MED, V342, P1917
   Jiang H, 1998, NEUROREPORT, V9, P2861, DOI 10.1097/00001756-199808240-00033
   Jiang M, 2010, AUTOPHAGY, V6, P175, DOI 10.4161/auto.6.1.10700
   Kadian SS, 2012, INT J PHARM SCI RES, V3, P42, DOI 10.13040/IJPSR.0975-8232.3(1).42-48
   Kim JG, 2004, INFECT IMMUN, V72, P1487, DOI 10.1128/IAI.72.3.1487-1495.2004
   Kosinska A, 2013, FOOD RES INT, V54, P951, DOI 10.1016/j.foodres.2012.12.038
   Kroemer G, 2010, MOL CELL, V40, P280, DOI 10.1016/j.molcel.2010.09.023
   Kuriyama S, 2006, JAMA-J AM MED ASSOC, V296, P1255, DOI 10.1001/jama.296.10.1255
   Kusano Y, 2008, BIOCHEMISTRY-US, V47, P6169, DOI 10.1021/bi800199z
   Lambert JD, 2007, MOL PHARMACEUT, V4, P819, DOI 10.1021/mp700075m
   Lapaquette P, 2012, J MOL MED, V90, P987, DOI 10.1007/s00109-012-0934-8
   Levine B, 2011, NATURE, V469, P323, DOI 10.1038/nature09782
   Ley RE, 2006, CELL, V124, P837, DOI 10.1016/j.cell.2006.02.017
   Lien E, 1999, J BIOL CHEM, V274, P33419, DOI 10.1074/jbc.274.47.33419
   LING WH, 1995, LIFE SCI, V57, P195, DOI 10.1016/0024-3205(95)00263-6
   Lipinski CA, 1997, ADV DRUG DELIVER REV, V23, P3, DOI 10.1016/S0169-409X(96)00423-1
   Liu R. H., 2012, NUTR HLTH STRATEGIES, DOI DOI 10.1007/978-1-61779-894-8_13
   Liu RH, 2005, J AGR FOOD CHEM, V53, P2341, DOI 10.1021/jf058010c
   Manach C, 2005, AM J CLIN NUTR, V81, p230S, DOI [10.1093/ajcn/81.1.230S, 10.1093/ajcn/81.1.243S]
   Mansfield JL, 1999, AM J BOT, V86, P1154, DOI 10.2307/2656979
   Marion-Letellier R, 2009, GUT, V58, P586, DOI 10.1136/gut.2008.162859
   Marion-Letellier R, 2013, INFLAMM BOWEL DIS, V19, P205, DOI [10.1002/ibd.23001, 10.1097/MIB.0b013e3182810122]
   Martinez FO, 2009, ANNU REV IMMUNOL, V27, P451, DOI 10.1146/annurev.immunol.021908.132532
   Martinon F, 2007, SEMIN IMMUNOPATHOL, V29, P213, DOI 10.1007/s00281-007-0079-y
   Medzhitov R, 2010, CELL, V140, P771, DOI 10.1016/j.cell.2010.03.006
   Mithen R., 2008, PLANT SECONDARY META, P25, DOI DOI 10.1002/9780470988558.CH2
   Mizel SB, 2002, J BIOL CHEM, V277, P22414, DOI 10.1074/jbc.M201762200
   Mizushima N, 2003, J CELL SCI, V116, P1679, DOI 10.1242/jcs.00381
   Moreira LO, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00328
   Mori S, 2007, WORLD J GASTROENTERO, V13, P6512, DOI 10.3748/wjg.13.6512
   Mulder TPJ, 2001, J CHROMATOGR B, V760, P271, DOI 10.1016/S0378-4347(01)00285-7
   Nakajima A, 2007, J PHARMACOL SCI, V105, P122, DOI 10.1254/jphs.SC0070155
   Natsume Y, 2005, CYTOTECHNOLOGY, V47, P79, DOI 10.1007/s10616-005-3753-8
   Neilson A., 2012, NUTR PREVENTION TREA
   Neilson AP, 2009, J AGR FOOD CHEM, V57, P9418, DOI 10.1021/jf902919k
   NISSINEN E, 1988, LIFE SCI, V42, P2609, DOI 10.1016/0024-3205(88)90330-X
   Ogura Y, 2001, J BIOL CHEM, V276, P4812, DOI 10.1074/jbc.M008072200
   Okamoto K, 2009, DEV CELL, V17, P87, DOI 10.1016/j.devcel.2009.06.013
   Omenn GS, 1996, NEW ENGL J MED, V334, P1150, DOI 10.1056/NEJM199605023341802
   Opitz B, 2005, CIRC RES, V96, P319, DOI 10.1161/01.RES.0000155721.83594.2c
   Ozinsky A, 2000, P NATL ACAD SCI USA, V97, P13766, DOI 10.1073/pnas.250476497
   PACIFICI GM, 1991, DEV PHARMACOL THERAP, V17, P16, DOI 10.1159/000457495
   Piccinini AM, 2010, MEDIAT INFLAMM, V2010, DOI 10.1155/2010/672395
   Planas JM, 2012, ARCH BIOCHEM BIOPHYS, V527, P67, DOI 10.1016/j.abb.2012.06.004
   PRICE PW, 1989, J CHEM ECOL, V15, P1117, DOI 10.1007/BF01014816
   Priego S, 2008, MOL CANCER THER, V7, P3330, DOI 10.1158/1535-7163.MCT-08-0363
   Psahoulia FH, 2007, CARCINOGENESIS, V28, P1021, DOI 10.1093/carcin/bgl232
   Ramos HC, 2004, TRENDS MICROBIOL, V12, P509, DOI 10.1016/j.tim.2004.09.002
   Rein MJ, 2013, BRIT J CLIN PHARMACO, V75, P588, DOI 10.1111/j.1365-2125.2012.04425.x
   Rhoads JM, 2009, AMINO ACIDS, V37, P111, DOI 10.1007/s00726-008-0225-4
   RICEEVANS CA, 1995, FREE RADICAL RES, V22, P375, DOI 10.3109/10715769509145649
   Riches Z, 2009, DRUG METAB DISPOS, V37, P2255, DOI 10.1124/dmd.109.028399
   Rubinsztein DC, 2006, NATURE, V443, P780, DOI 10.1038/nature05291
   Sakiyama T, 2009, GASTROENTEROLOGY, V136, P924, DOI 10.1053/j.gastro.2008.12.002
   Satsu H, 2008, J AGR FOOD CHEM, V56, P5366, DOI 10.1021/jf073350e
   Satsu H, 2009, J NUTR SCI VITAMINOL, V55, P442, DOI 10.3177/jnsv.55.442
   SAVAGE DC, 1977, ANNU REV MICROBIOL, V31, P107, DOI 10.1146/annurev.mi.31.100177.000543
   Scalbert A, 2002, BIOMED PHARMACOTHER, V56, P276, DOI 10.1016/S0753-3322(02)00205-6
   Scalbert A, 2005, CRIT REV FOOD SCI, V45, P287, DOI 10.1080/1040869059096
   Schenk M, 2009, IMMUNITY, V31, P847, DOI 10.1016/j.immuni.2009.11.008
   SCHLEIFER KH, 1972, BACTERIOL REV, V36, P407, DOI 10.1128/MMBR.36.4.407-477.1972
   Schuier M, 2005, J NUTR, V135, P2320, DOI 10.1093/jn/135.10.2320
   Shahidi F., 1995, FOOD PHENOLICS SOURC
   Shan JH, 2009, INT IMMUNOPHARMACOL, V9, P1042, DOI 10.1016/j.intimp.2009.04.011
   Shapiro H, 2007, GUT, V56, P426, DOI 10.1136/gut.2006.094599
   Shimizu M, 2010, BIOSCI BIOTECH BIOCH, V74, P232, DOI 10.1271/bbb.90730
   Shin JE, 2005, PLANTA MED, V71, P197, DOI 10.1055/s-2005-837816
   Sies H, 2010, ARCH BIOCHEM BIOPHYS, V501, P2, DOI 10.1016/j.abb.2010.04.006
   Singletary K, 2008, CANCER EPIDEM BIOMAR, V17, P1596, DOI 10.1158/1055-9965.EPI-07-2917
   Smoak KA, 2010, CELL METAB, V11, P493, DOI 10.1016/j.cmet.2010.04.006
   Spencer JPE, 1999, FEBS LETT, V458, P224, DOI 10.1016/S0014-5793(99)01160-6
   Stephens NG, 1996, LANCET, V347, P781, DOI 10.1016/S0140-6736(96)90866-1
   Strassburg CP, 2000, J BIOL CHEM, V275, P36164, DOI 10.1074/jbc.M002180200
   Suzuki T, 2011, J NUTR, V141, P87, DOI 10.3945/jn.110.125633
   Tanida I, 2011, MICROBIOL IMMUNOL, V55, P1, DOI 10.1111/j.1348-0421.2010.00271.x
   Tsao R, 2010, NUTRIENTS, V2, P1231, DOI 10.3390/nu2121231
   Vaidyanathan JB, 2003, J PHARMACOL EXP THER, V307, P745, DOI 10.1124/jpet.103.054296
   van Duynhoven J, 2011, P NATL ACAD SCI USA, V108, P4531, DOI 10.1073/pnas.1000098107
   Wakabayashi K, 2006, DRUG METAB REV, V38, P371, DOI 10.1080/03602530600727947
   Whalen R, 1998, SEMIN LIVER DIS, V18, P345, DOI 10.1055/s-2007-1007169
   Windmill KF, 2000, TOXICOL SCI, V54, P19, DOI 10.1093/toxsci/54.1.19
   Wink M, 1998, ALKALOIDS, P11
   Yamamoto M, 2003, SCIENCE, V301, P640, DOI 10.1126/science.1087262
   Yang CS, 2008, MOL NUTR FOOD RES, V52, pS139, DOI 10.1002/mnfr.200700234
   Yang J, 2009, J AGR FOOD CHEM, V57, P8581, DOI 10.1021/jf8039796
   Yang YM, 2010, MOLECULES, V15, P6332, DOI 10.3390/molecules15096332
   Yang ZF, 2010, CURR OPIN CELL BIOL, V22, P124, DOI 10.1016/j.ceb.2009.11.014
   Yoshikawa M, 1997, CHEM PHARM BULL, V45, P1671, DOI 10.1248/cpb.45.1671
   Yuk JM, 2009, CELL HOST MICROBE, V6, P231, DOI 10.1016/j.chom.2009.08.004
   Yusuf S, 2000, NEW ENGL J MED, V342, P154, DOI 10.1056/NEJM200001203420302
   Zhao ZH, 2008, J AGR FOOD CHEM, V56, P3863, DOI 10.1021/jf073168d
NR 151
TC 18
Z9 18
U1 0
U2 7
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 1664-8021
J9 FRONT GENET
JI Front. Genet.
PD APR 4
PY 2014
VL 5
AR 64
DI 10.3389/fgene.2014.00064
PG 14
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA AX6LP
UT WOS:000347034100001
PM 24772116
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Zhu, B
   Li, SX
   Yu, L
   Hu, W
   Sheng, DD
   Hou, J
   Zhao, NP
   Hou, XJ
   Wu, YC
   Han, ZP
   Wei, LX
   Zhang, L
AF Zhu, Bing
   Li, Shanxin
   Yu, Lei
   Hu, Wei
   Sheng, Dandan
   Hou, Jing
   Zhao, Naping
   Hou, Xiaojuan
   Wu, Yechen
   Han, Zhipeng
   Wei, Lixin
   Zhang, Li
TI Inhibition of Autophagy with Chloroquine Enhanced Sinoporphyrin Sodium
   Mediated Photodynamic Therapy-induced Apoptosis in Human Colorectal
   Cancer Cells
SO INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES
LA English
DT Article
DE sinoporphyin sodium; photodynamic therapy; colorectal cancer; apoptosis;
   autophagy; chloroquine
ID BREAST-CANCER; IN-VITRO; SENSITIZER; STATISTICS; RESISTANCE;
   MITOCHONDRIAL; RESPONSES
AB To evaluate the antitumor effect of sinoporphyrin sodium mediated photodynamic therapy (DVDMS-PDT) against human colorectal cancer (CRC) and to investigate the role of autophagy in its effect.
   Shrunken cells, condensed nuclei and increased levels of cleaved caspase-3 and Bax were observed in DVDMS-PDT treated HCT116 cells, reminiscent of apoptosis. DVDMS-PDT showed better antitumor efficiency in HCT116 cells than Photofrin mediated photodynamic therapy (PF-PDT) both in vitro and in vivo. And DVDMS-PDT caused autophagic characteristics: double membrane autophagosome structures and changes in autophagy-related protein expression (ATG7, P62, Bcl-2 and LC3-II). In addition, inhibition of autophagy by chloroquine (CQ) promoted apoptosis, suggesting a possible protective role of autophagy in DVDMS-PDT-treated HCT116 cells, which was proved by flow cytometry and western blotting. The results of xenograft mouse model showed markedly increased apoptosis and significantly reduced tumor size in DVDMS-PDT treated group than Control, and DVDMS-PDT exhibited better antitumor efficiency than PF-PDT. Further, no visible tumor was observed in the CQ+DVDMS-PDT group at the end of the xenograft mouse experiment, which confirmed the hypothesis that autophagy was protective to DVDMS-PDT treated HCT116 cells.
   Our findings suggest that DVDMS is a promising photosensitizer and the combined use of autophagy inhibitor can remarkably enhance the DVDMS-PDT mediated anti-cancer efficiency in HCT116 cells both in vitro and in vivo.
C1 [Zhu, Bing; Li, Shanxin; Zhao, Naping; Zhang, Li] Second Mil Med Univ, Changhai Hosp, Dept Pharm, Shanghai, Peoples R China.
   [Sheng, Dandan; Hou, Xiaojuan; Wu, Yechen; Han, Zhipeng; Wei, Lixin] Second Mil Med Univ, Eastern Hepatobiliary Surg Hosp, Tumor Immunol & Gene Therapy Ctr, Shanghai, Peoples R China.
   [Yu, Lei] Second Mil Med Univ, Changzheng Hosp, Dept Informat, Shanghai, Peoples R China.
   [Hu, Wei; Zhang, Li] Anhui Med Univ, Dept Pharm, Hosp 2, Hefei, Anhui, Peoples R China.
   [Hou, Jing] Shanghai Jiao Tong Univ, Sch Med, Xinhua Hosp, GCP Off, Shanghai, Peoples R China.
RP Zhang, L (corresponding author), Second Mil Med Univ, Changhai Hosp, Dept Pharm, Shanghai, Peoples R China.; Wei, LX (corresponding author), Second Mil Med Univ, Eastern Hepatobiliary Surg Hosp, Tumor Immunol & Gene Therapy Ctr, Shanghai, Peoples R China.; Zhang, L (corresponding author), Anhui Med Univ, Dept Pharm, Hosp 2, Hefei, Anhui, Peoples R China.
EM weilixin_smmu@163.com; chyyzhl@163.com
RI cai, yuanyuan/C-6301-2014
FU National Key Research and Development Program of China [2018YFA0107503];
   National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81472846]; Fundamental Research Funds for
   the Central UniversitiesFundamental Research Funds for the Central
   Universities [GK201502009]
FX This research was supported by the National Key Research and Development
   Program of China (2018YFA0107503), the National Natural Science
   Foundation of China (No. 81472846) and the Fundamental Research Funds
   for the Central Universities (GK201502009). The authors thank department
   of biophysics (College of Basic Medical Sciences, Second Military
   Medical University) for performing the TEM imaging. The authors thank
   Qinglong Hi-tech Co., Ltd for providing the novel sensitizer DVDMS.
CR Andrzejak M, 2011, AUTOPHAGY, V7, P979, DOI 10.4161/auto.7.9.15865
   Benov Ludmil, 2015, Med Princ Pract, V24 Suppl 1, P14, DOI 10.1159/000362416
   Ch'ng JH, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.265
   Chen KL, 2011, CLIN EXP METASTAS, V28, P751, DOI 10.1007/s10585-011-9407-7
   [陈克力 CHEN Ke-li], 2009, [解放军医学杂志, Medical Journal of Chinese People's Liberation Army], V34, P1292
   Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338
   Chilakamarthi U, 2017, CHEM REC, V17, P775, DOI 10.1002/tcr.201600121
   Dewaele M, 2011, J CELL MOL MED, V15, P1402, DOI 10.1111/j.1582-4934.2010.01118.x
   Fang Q, 2012, Patent No. [2009101791165, ZL 200910179116. 5]
   Huang Q, 2016, APOPTOSIS, V21, P749, DOI 10.1007/s10495-016-1243-4
   [姜智换 Jiang Zhihuan], 2013, [癌变·畸变·突变, Carcinogenesis, Teratogenesis and Mutagenesis], V25, P163
   Kessel D, 2007, PHOTOCH PHOTOBIO SCI, V6, P1290, DOI 10.1039/b707953b
   Kessel D, 2007, PHOTOCHEM PHOTOBIOL, V83, P1024, DOI 10.1111/j.1751-1097.2007.00088.x
   Kimmelman AC, 2011, GENE DEV, V25, P1999, DOI 10.1101/gad.17558811
   Lin N, 2015, PHOTOCH PHOTOBIO SCI, V14, P815, DOI 10.1039/c4pp00463a
   Mulsow J, 2011, BRIT J SURG, V98, P1785, DOI 10.1002/bjs.7653
   Nakamura T, 2003, GASTROINTEST ENDOSC, V57, P266, DOI 10.1067/mge.2003.57
   Ning ST, 2016, ACS APPL MATER INTER, V8, P17793, DOI 10.1021/acsami.6b04403
   Reiners JJ, 2010, AUTOPHAGY, V6, P7, DOI 10.4161/auto.6.1.10220
   Shi R, 2017, MOLECULES, V22, DOI 10.3390/molecules22010112
   Siegel RL, 2019, CA-CANCER J CLIN, V69, P7, DOI 10.3322/caac.21551
   Siegel RL, 2017, CA-CANCER J CLIN, V67, P177, DOI 10.3322/caac.21395
   Solomon VR, 2009, EUR J PHARMACOL, V625, P220, DOI 10.1016/j.ejphar.2009.06.063
   van Straten D, 2017, CANCERS, V9, DOI 10.3390/cancers9020019
   Wang HP, 2015, INT J BIOL SCI, V11, P1401, DOI 10.7150/ijbs.12802
   Wang HP, 2014, INT J NANOMED, V9, P3077, DOI 10.2147/IJN.S59302
   Wang XB, 2015, THERANOSTICS, V5, P772, DOI 10.7150/thno.10853
   Wei MF, 2014, AUTOPHAGY, V10, P1179, DOI 10.4161/auto.28679
   Wu LJ, 2016, PHOTODIAGN PHOTODYN, V13, P58, DOI 10.1016/j.pdpdt.2015.12.008
   Xiong L, 2017, ONCOTARGET, V8, P6419, DOI 10.18632/oncotarget.14117
   Xiong WL, 2016, J PHOTOCH PHOTOBIO B, V160, P299, DOI 10.1016/j.jphotobiol.2016.04.024
   Xue LY, 2010, AUTOPHAGY, V6, P248, DOI 10.4161/auto.6.2.11077
   Yano S, 2011, J PHOTOCH PHOTOBIO C, V12, P46, DOI 10.1016/j.jphotochemrev.2011.06.001
NR 33
TC 18
Z9 19
U1 6
U2 19
PU IVYSPRING INT PUBL
PI LAKE HAVEN
PA PO BOX 4546, LAKE HAVEN, NSW 2263, AUSTRALIA
SN 1449-2288
J9 INT J BIOL SCI
JI Int. J. Biol. Sci.
PY 2019
VL 15
IS 1
BP 12
EP 23
DI 10.7150/ijbs.27156
PG 12
WC Biochemistry & Molecular Biology; Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics
GA HE3LU
UT WOS:000453258300002
PM 30662343
OA Green Published, gold, Green Submitted
DA 2022-04-25
ER

PT J
AU Dalla Pozza, M
   Orvain, C
   Brustolin, L
   Pettenuzzo, N
   Nardon, C
   Gaiddon, C
   Fregona, D
AF Dalla Pozza, Maria
   Orvain, Christophe
   Brustolin, Leonardo
   Pettenuzzo, Nicolo
   Nardon, Chiara
   Gaiddon, Christian
   Fregona, Dolores
TI Gold(III) to Ruthenium(III) Metal Exchange in Dithiocarbamato Complexes
   Tunes Their Biological Mode of Action for Cytotoxicity in Cancer Cells
SO MOLECULES
LA English
DT Article
DE gastric cancer; metal complexes; chemotherapy; dithiocarbamates; drug
   mechanism of action; ER stress; p53; autophagy
ID CURRENT CLINICAL-USES; ANTICANCER AGENTS; MTT ASSAY; PLATINUM;
   APOPTOSIS; THERAPY; LOCALIZATION; PERSPECTIVES; MECHANISMS; EXPRESSION
AB Malignant tumors have affected the human being since the pharaoh period, but in the last century the incidence of this disease has increased due to a large number of risk factors, including deleterious lifestyle habits (i.e., smoking) and the higher longevity. Many efforts have been spent in the last decades on achieving an early stage diagnosis of cancer, and more effective cures, leading to a decline in age-standardized cancer mortality rates. In the last years, our research groups have developed new metal-based complexes, with the aim to obtain a better selectivity for cancer cells and less side effects than the clinically established reference drug cisplatin. This work is focused on four novel Au(III) and Ru(III) complexes that share the piperidine dithiocarbamato (pipe-DTC) as the ligand, in a different molar ratio. The compounds [AuCl2(pipeDTC)], [Au(pipeDTC)(2)]Cl, [Ru(pipeDTC)(3)] and beta-[Ru-2(pipeDTC)(5)] have been synthesized and fully characterized by several chemical analyses. We have then investigated their biological properties in two different cell lines, namely, AGS (gastric adenocarcinoma) and HCT116 (colon carcinomas), showing significant differences among the four compounds. First, the two gold-based compounds and beta-[Ru-2(pipeDTC)(5)] display IC50 in the mu M range, significantly lower than cisplatin. Second, we showed that [AuCl2(pipeDTC)] and beta-[Ru-2(pipeDTC)(5)]Cl drive different molecular mechanisms. The first was able to induce the protein level of the DNA damage response factor p53 and the autophagy protein p62, in contrast to the second that induced the ATF4 protein level, but repressed p62 expression. This study highlights that the biological activity of different complexes bringing the same organic ligand depends on the electronic and structural properties of the metal, which are able to fine tune the biological properties, giving us precious information that can help to design more selective anticancer drugs.
C1 [Dalla Pozza, Maria; Brustolin, Leonardo; Pettenuzzo, Nicolo; Nardon, Chiara; Fregona, Dolores] Univ Padua, Dept Chem Sci, Via F Marzolo 1, I-35131 Padua, Italy.
   [Orvain, Christophe; Gaiddon, Christian] Univ Strasbourg, INSERM, UMR S 1113, Interface Rech Fondamentale Cancerol, 3 Av Moliere, F-67200 Strasbourg, France.
RP Fregona, D (corresponding author), Univ Padua, Dept Chem Sci, Via F Marzolo 1, I-35131 Padua, Italy.; Gaiddon, C (corresponding author), Univ Strasbourg, INSERM, UMR S 1113, Interface Rech Fondamentale Cancerol, 3 Av Moliere, F-67200 Strasbourg, France.
EM maria.dalla-pozza@chimieparistech.psl.eu; orvain@unistra.fr;
   leo.brus90@gmail.com; nicolo.pettenuzzo.np@gmail.com;
   chiara.nardon@unipd.it; Gaiddon@unistra.fr; dolores.fregona@unipd.it
RI Gaiddon, Christian/F-7321-2012
OI Gaiddon, Christian/0000-0003-4315-3851
FU Ligue contre le CancerLigue nationale contre le cancer; IDEX from
   Strasbourg University; Interdisciplinary Thematic Institute InnoVec
FX This research was funded by Ligue contre le Cancer, IDEX from Strasbourg
   University, Interdisciplinary Thematic Institute InnoVec.
CR Allardyce CS, 2001, PLATIN MET REV, V45, P62
   Bergamo A, 2012, J INORG BIOCHEM, V106, P90, DOI 10.1016/j.jinorgbio.2011.09.030
   Blanchet A, 2021, CANCERS, V13, DOI 10.3390/cancers13040916
   BONATI F, 1967, J ORGANOMET CHEM, V10, P257, DOI 10.1016/S0022-328X(00)93085-7
   BORCH RF, 1979, P NATL ACAD SCI USA, V76, P6611, DOI 10.1073/pnas.76.12.6611
   Boscutti G, 2013, CHEM-EUR J, V19, P13428, DOI 10.1002/chem.201302550
   Brustolin L, 2020, J INORG BIOCHEM, V213, DOI 10.1016/j.jinorgbio.2020.111259
   Carcas Lauren Peirce, 2014, J Carcinog, V13, P14, DOI 10.4103/1477-3163.146506
   Cepeda V, 2007, ANTI-CANCER AGENT ME, V7, P3, DOI 10.2174/187152007779314044
   Chow MJ, 2018, MOL PHARMACEUT, V15, P3020, DOI 10.1021/acs.molpharmaceut.8b00003
   Chow MJ, 2017, CHEM SCI, V8, P3641, DOI 10.1039/c7sc00497d
   Chow MJ, 2016, MOL PHARMACEUT, V13, P2543, DOI 10.1021/acs.molpharmaceut.6b00348
   Costa EC, 2016, BIOTECHNOL ADV, V34, P1427, DOI 10.1016/j.biotechadv.2016.11.002
   Dilruba S, 2016, CANCER CHEMOTH PHARM, V77, P1103, DOI 10.1007/s00280-016-2976-z
   Edmondson R, 2014, ASSAY DRUG DEV TECHN, V12, P207, DOI 10.1089/adt.2014.573
   FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5
   Galluzzi L, 2012, ONCOGENE, V31, P1869, DOI 10.1038/onc.2011.384
   Giovagnini L, 2008, DALTON T, P6699, DOI 10.1039/b806341a
   Graf N, 2012, ADV DRUG DELIVER REV, V64, P993, DOI 10.1016/j.addr.2012.01.007
   Hogarth G, 2012, MINI-REV MED CHEM, V12, P1202, DOI 10.2174/138955712802762095
   Kelland LR, 2000, DRUGS, V59, P1, DOI 10.2165/00003495-200059004-00001
   Klajner M, 2014, INORG CHEM, V53, P5150, DOI 10.1021/ic500250e
   KRATZ F, 1993, J INORG BIOCHEM, V49, P79, DOI 10.1016/0162-0134(93)85017-3
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   Lazarevic T, 2017, EUR J MED CHEM, V142, P8, DOI 10.1016/j.ejmech.2017.04.007
   Lee S. H., 2010, MOL CELLS, V29, P311, DOI DOI 10.1007/s10059-010-0053-8
   Lee SY, 2020, DRUG DES DEV THER, V14, P5375, DOI 10.2147/DDDT.S275007
   Li S, 2015, CURR TOP MED CHEM, V15, P720, DOI 10.2174/1568026615666150302105343
   Licona C, 2020, INORG CHEM FRONT, V7, P678, DOI 10.1039/c9qi01148j
   Licona C, 2017, ONCOTARGET, V8, P2568, DOI 10.18632/oncotarget.13711
   Liu ZQ, 2014, N AM J MED SCI, V6, P160, DOI 10.4103/1947-2714.128482
   Nagy EM, 2012, CHEM-EUR J, V18, P14464, DOI 10.1002/chem.201202171
   Nardon C, 2017, EUR J INORG CHEM, P1737, DOI 10.1002/ejic.201601215
   Nardon C, 2016, FUTURE MED CHEM, V8, P211, DOI 10.4155/fmc.15.175
   Nardon C, 2016, CURR TOP MED CHEM, V16, P360, DOI 10.2174/1568026615666150827094500
   Ndagi U, 2017, DRUG DES DEV THER, V11, P599, DOI 10.2147/DDDT.S119488
   Notaro A, 2017, CHEM SOC REV, V46, P7317, DOI 10.1039/c7cs00356k
   O'Donovan N, 2003, CLIN CANCER RES, V9, P738
   Oun R., 2013, ENCY METALLOPROTEINS
   Ozaki Toshinori, 2011, Cancers (Basel), V3, P994, DOI 10.3390/cancers3010994
   Pan YC, 2014, ELECTROPHORESIS, V35, P2078, DOI 10.1002/elps.201300500
   Pricker SP, 1996, GOLD BULL, V29, P53, DOI DOI 10.1007/BF03215464
   Reddy TS, 2020, INORG CHEM, V59, P5662, DOI 10.1021/acs.inorgchem.0c00423
   Rivlin Noa, 2011, Genes Cancer, V2, P466, DOI 10.1177/1947601911408889
   Ronconi L, 2009, DALTON T, P10670, DOI 10.1039/b913597a
   Rozpedek W, 2016, CURR MOL MED, V16, P533, DOI 10.2174/1566524016666160523143937
   Shi YA, 2013, INORG CHEM COMMUN, V30, P178, DOI 10.1016/j.inoche.2013.02.010
   Shintani M., 2013, NAT REV CANCER, V7, P961, DOI [10.5772/55315, DOI 10.5772/55315, 10.5772/55315.]
   Singleton DC, 2012, EXPERT OPIN THER TAR, V16, P1189, DOI 10.1517/14728222.2012.728207
   Stepanenko AA, 2015, GENE, V574, P193, DOI 10.1016/j.gene.2015.08.009
   Stockert JC, 2012, ACTA HISTOCHEM, V114, P785, DOI 10.1016/j.acthis.2012.01.006
   Stoytcheva M., 2012, PESTICIDES MODERN WO
   Tormanen-Napankangas U, 2001, INT J CANCER, V93, P192, DOI 10.1002/ijc.1315
   Verfaillie T., 2010, INT J CELL BIOL, V2010, P930509, DOI [DOI 10.1155/2010/930509, 10.1155/2010/930509]
   Walton MI, 2005, MOL CANCER THER, V4, P1369, DOI 10.1158/1535-7163.MCT-04-0341
   Weiswald LB, 2015, NEOPLASIA, V17, P1, DOI 10.1016/j.neo.2014.12.004
   Younger ST, 2017, NUCLEIC ACIDS RES, V45, P9889, DOI 10.1093/nar/gkx577
   Zhang M, 2016, EUR REV MED PHARMACO, V20, P3152
NR 58
TC 1
Z9 1
U1 5
U2 7
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1420-3049
J9 MOLECULES
JI Molecules
PD JUL
PY 2021
VL 26
IS 13
AR 4073
DI 10.3390/molecules26134073
PG 17
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA TG0AN
UT WOS:000671075700001
PM 34279414
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Issman-Zecharya, N
   Schuldiner, O
AF Issman-Zecharya, Noa
   Schuldiner, Oren
TI The PI3K Class III Complex Promotes Axon Pruning by Downregulating a
   Ptc-Derived Signal via Endosome-Lysosomal Degradation
SO DEVELOPMENTAL CELL
LA English
DT Article
ID MICROSATELLITE INSTABILITY; COLON-CANCER; DROSOPHILA; UVRAG; EXPRESSION;
   AUTOPHAGY; RECEPTOR; PROTEIN; TRAFFICKING; HEDGEHOG
AB Developmental axon pruning is essential for wiring the mature nervous system, but its regulation remains poorly understood. Here we show that the endosomal-lysosomal pathway regulates developmental pruning of Drosophila mushroom body gamma neurons. We demonstrate that the UV radiation resistance-associated gene (UVRAG) functions together with all core components of the phosphatidylinositol 3-kinase class Ill (PI3K-cIII) complex to promote pruning via the endocytic pathway. By studying several PI(3)P binding proteins, we found that Hrs, a subunit of the ESCRT-0 complex, required for multivesicular body (MVB) maturation, is essential for normal pruning progression. Thus, we hypothesized the existence of an inhibitory signal that needs to be downregulated. Finally, our data suggest that the Hedgehog receptor, Patched, is the source of this inhibitory signal likely functioning in a Smo-independent manner. Taken together, our in vivo study demonstrates that the PI3K-cIII complex is essential for downregulating Patched via the endosomal-lysosomal pathway to execute axon pruning.
C1 [Issman-Zecharya, Noa; Schuldiner, Oren] Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel.
RP Schuldiner, O (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel.
EM oren.schuldiner@weizmann.ac.il
RI Schuldiner, Oren/K-1353-2012
OI Schuldiner, Oren/0000-0002-7350-9380
FU Israeli Cancer Research Fund (ICRF) [11-711-RCDA]; Minerva foundation
FX We thank E. Arama, E.H. Baehrecke, H. Bellen, Y. Chou, J. Chung, S.
   Eaton, F.B. Gao, L. Gilboa, M. Gonzalez-Gaitan, I. Guerrero, H. Kramer,
   T. Neufeld, A. Rodal, J. Rubin, F. Tina, F. Tokunaga, F. Yu, and the
   Bloomington Stock Center for reagents; E.H. Baehrecke for providing
   reagents prior to publication; F. Yu and S. Zhu for discussing
   experiments prior to publication; Ron Rotkopf for statistical analyses;
   and E.H Baehrecke, A. Yaron, M. Schuldiner, S.P. Yaniv, and members of
   the O.S. lab for discussions and critical readings of the manuscript.
   The Fasll (1D4) and EcR-B1 (AD4.4) monoclonal antibodies were obtained
   from the Developmental Studies Hybridoma Bank developed under the
   auspices of the NICHD and maintained by the University of Iowa. This
   work was supported by the Israeli Cancer Research Fund (ICRF) grant
   #11-711-RCDA and the Minerva foundation. The Zeiss LSM710 microscope was
   purchased with the help of the Adelis foundation. O.S. is the incumbent
   of the Rothstein Career Development Chair of Genetic Diseases.
CR Boulanger A, 2011, NAT NEUROSCI, V14, P37, DOI 10.1038/nn.2700
   Briscoe J, 2013, NAT REV MOL CELL BIO, V14, P416, DOI 10.1038/nrm3598
   Burman C, 2010, FEBS LETT, V584, P1302, DOI 10.1016/j.febslet.2010.01.011
   Callejo A, 2008, P NATL ACAD SCI USA, V105, P912, DOI 10.1073/pnas.0705603105
   Funderburk SF, 2010, TRENDS CELL BIOL, V20, P355, DOI 10.1016/j.tcb.2010.03.002
   Gillooly DJ, 2000, EMBO J, V19, P4577, DOI 10.1093/emboj/19.17.4577
   Guichet A, 2002, EMBO J, V21, P1661, DOI 10.1093/emboj/21.7.1661
   He SS, 2014, AUTOPHAGY, V10, P180, DOI 10.4161/auto.26917
   Incardona JP, 2002, CURR BIOL, V12, P983, DOI 10.1016/S0960-9822(02)00895-3
   Ionov Y, 2004, ONCOGENE, V23, P639, DOI 10.1038/sj.onc.1207178
   Itakura E, 2009, AUTOPHAGY, V5, P534, DOI 10.4161/auto.5.4.8062
   Jaber N, 2012, P NATL ACAD SCI USA, V109, P2003, DOI 10.1073/pnas.1112848109
   Juhasz G, 2008, J CELL BIOL, V181, P655, DOI 10.1083/jcb.200712051
   Kim MS, 2008, HUM PATHOL, V39, P1059, DOI 10.1016/j.humpath.2007.11.013
   Kitamoto T, 2001, J NEUROBIOL, V47, P81, DOI 10.1002/neu.1018
   Knaevelsrud H, 2010, AUTOPHAGY, V6, P863, DOI 10.4161/auto.6.7.13033
   Kutateladze TG, 2010, NAT CHEM BIOL, V6, P507, DOI [10.1038/NCHEMBIO.390, 10.1038/nchembio.390]
   Lee G, 2011, DEV BIOL, V356, P588, DOI 10.1016/j.ydbio.2011.06.024
   Lee T, 1999, DEVELOPMENT, V126, P4065
   Lee T, 2000, NEURON, V28, P807, DOI 10.1016/S0896-6273(00)00155-0
   Liang C, 2006, NAT CELL BIOL, V8, P688, DOI 10.1038/ncb1426
   Low LK, 2006, PHILOS T R SOC B, V361, P1531, DOI 10.1098/rstb.2006.1883
   Luo LQ, 2005, ANNU REV NEUROSCI, V28, P127, DOI 10.1146/annurev.neuro.28.061604.135632
   Peplowska K, 2008, NAT CELL BIOL, V10, P759, DOI 10.1038/ncb0708-759
   Perelman B, 1997, GENOMICS, V41, P397, DOI 10.1006/geno.1997.4623
   Pfeiffer BD, 2012, P NATL ACAD SCI USA, V109, P6626, DOI 10.1073/pnas.1204520109
   Portera-Cailliau C, 2005, PLOS BIOL, V3, P1473, DOI 10.1371/journal.pbio.0030272
   Robbins DJ, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002906
   Rodal AA, 2011, J CELL BIOL, V193, P201, DOI 10.1083/jcb.201009052
   Schuldiner O, 2008, DEV CELL, V14, P227, DOI 10.1016/j.devcel.2007.11.001
   Shravage BV, 2013, DEVELOPMENT, V140, P1321, DOI 10.1242/dev.089490
   Thoresen SB, 2010, EXP CELL RES, V316, P3368, DOI 10.1016/j.yexcr.2010.07.008
   Tsukazaki T, 1998, CELL, V95, P779, DOI 10.1016/S0092-8674(00)81701-8
   Watts RJ, 2003, NEURON, V38, P871, DOI 10.1016/S0896-6273(03)00295-2
   Watts RJ, 2004, CURR BIOL, V14, P678, DOI 10.1016/j.cub.2004.03.035
   Yaniv SP, 2012, CURR BIOL, V22, P1774, DOI 10.1016/j.cub.2012.07.044
   Yu XMM, 2013, NEURON, V78, P456, DOI 10.1016/j.neuron.2013.03.004
   Zhang H, 2014, DEV CELL, V30, P463, DOI 10.1016/j.devcel.2014.06.014
   Zheng XY, 2003, CELL, V112, P303, DOI 10.1016/S0092-8674(03)00072-2
   Zhou X, 2010, P NATL ACAD SCI USA, V107, P9424, DOI 10.1073/pnas.0914725107
NR 40
TC 35
Z9 36
U1 1
U2 7
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1534-5807
EI 1878-1551
J9 DEV CELL
JI Dev. Cell
PD NOV 24
PY 2014
VL 31
IS 4
BP 461
EP 473
DI 10.1016/j.devcel.2014.10.013
PG 13
WC Cell Biology; Developmental Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Developmental Biology
GA AU3UZ
UT WOS:000345540200011
PM 25458013
OA Bronze
DA 2022-04-25
ER

PT J
AU Liu, Z
   Xiong, L
   Ouyang, GQ
   Ma, L
   Sahi, S
   Wang, KP
   Lin, LW
   Huang, H
   Miao, XY
   Chen, W
   Wen, Y
AF Liu, Zhipeng
   Xiong, Li
   Ouyang, Guoqing
   Ma, Lun
   Sahi, Sunil
   Wang, Kunpeng
   Lin, Liangwu
   Huang, He
   Miao, Xiongying
   Chen, Wei
   Wen, Yu
TI Investigation of Copper Cysteamine Nanoparticles as a New Type of
   Radiosensitiers for Colorectal Carcinoma Treatment
SO SCIENTIFIC REPORTS
LA English
DT Article
ID PHOTODYNAMIC THERAPY; SINGLET OXYGEN; CANCER; RADIOTHERAPY; CELLS;
   SENSITIZERS; RADIATION
AB Copper Cysteamine (Cu-Cy) is a new photosensitizer and a novel radiosensitizer that can be activated by light, X-ray and microwave to produce singlet oxygen for cancer treatment. However, the killing mechanism of Cu-Cy nanoparticles on cancer cells is not clear yet and Cu-Cy nanoparticles as novel radiosensitizers have never been tested on colorectal cancers. Here, for the first time, we investigate the treatment efficiency of Cu-Cy nanoparticles on SW620 colorectal cells and elucidate the underlying mechanisms of the effects. The results show that X-ray activated Cu-Cy nanoparticles may kill SW620 cancerscells is in a dose-dependent manner. The JC-1 staining shows the mitochondrial membrane potential is decreased after the treatment. The observations confirm that Cu-Cy nanoparticles may improve X-ray radiotherapy on cancer treatment and X-ray activated Cu-Cy nanoparticles can be efficiently destroy colorectal cancer cells by inducing apoptosis as well as autophagy. As a new type of radiosensitizers and photosensitizers, Cu-Cy nanoparticles have a good potential for colorectal cancer treatment and the discovery of autophagy induced by X-ray irradiated Cu-Cy nanoparticles sheds a good insight to the mechanism of Cu-Cy for cancer treatment as a new radiosensitizers.
C1 [Liu, Zhipeng; Xiong, Li; Ouyang, Guoqing; Wang, Kunpeng; Miao, Xiongying; Wen, Yu] Cent South Univ Changsha, Xiangya Hosp 2, Dept Gen Surg, Changsha 410011, Hunan, Peoples R China.
   [Ma, Lun; Sahi, Sunil; Chen, Wei] Univ Texas Arlington, Dept Phys, Arlington, TX 76019 USA.
   [Ma, Lun; Sahi, Sunil; Chen, Wei] Univ Texas Arlington, SAVANT Ctr, Arlington, TX 76019 USA.
   [Lin, Liangwu] Cent South Univ, State Key Lab Powder Met, Changsha 410083, Hunan, Peoples R China.
   [Huang, He] Cent South Univ, Xiangya Sch Med, Dept Histol & Embryol, Changsha 410078, Hunan, Peoples R China.
RP Wen, Y (corresponding author), Cent South Univ Changsha, Xiangya Hosp 2, Dept Gen Surg, Changsha 410011, Hunan, Peoples R China.; Chen, W (corresponding author), Univ Texas Arlington, Dept Phys, Arlington, TX 76019 USA.; Chen, W (corresponding author), Univ Texas Arlington, SAVANT Ctr, Arlington, TX 76019 USA.
EM weichen@uta.edu; 1850129046@qq.com
FU Development and Reform Commission of Hunan the Fundamental Research
   Funds for the Central South University [201583, 2016zzts537]; Furong
   Scholarship from Central South University; U.S. Army Medical Research
   Acquisition Activity (USAMRAA) [W81XWH-10-1-0279, W81XWH-10-1-0234];
   Science and Technology Department of Nanning [20151266]
FX This work was supported by the Development and Reform Commission of
   Hunan (Grant 201583) the Fundamental Research Funds for the Central
   South University (grant 2016zzts537), the Furong Scholarship from
   Central South University as well as the support from the U.S. Army
   Medical Research Acquisition Activity (USAMRAA) under Contracts of
   W81XWH-10-1-0279 and W81XWH-10-1-0234, and a grant from the Science and
   Technology Department of Nanning (grant no. 20151266).
CR ACS, 2014, CANC FACTS FIG AM CA
   Babaei M, 2014, BIOIMPACTS, V4, P15, DOI 10.5681/bi.2014.003
   Bancirova M, 2011, LUMINESCENCE, V26, P685, DOI 10.1002/bio.1296
   Chen W, 2006, J NANOSCI NANOTECHNO, V6, P1159, DOI 10.1166/jnn.2006.327
   Chen W, 2008, J BIOMED NANOTECHNOL, V4, P369, DOI 10.1166/jbn.2008.001
   Codogno P, 2005, CELL DEATH DIFFER, V12, P1509, DOI 10.1038/sj.cdd.4401751
   Cohen L., 1996, CANCER RES, V26, P1769
   De Rosa FS, 2000, PHARM RES-DORDR, V17, P1447, DOI 10.1023/A:1007612905378
   Delaney G, 2005, CANCER-AM CANCER SOC, V104, P1129, DOI 10.1002/cncr.21324
   Hainfeld JF, 2008, J PHARM PHARMACOL, V60, P977, DOI 10.1211/jpp.60.8.0005
   Jain S, 2014, RADIOTHER ONCOL, V110, P342, DOI 10.1016/j.radonc.2013.12.013
   Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]
   Jeynes JCG, 2014, PHYS MED BIOL, V59, P6431, DOI 10.1088/0031-9155/59/21/6431
   Kessel D, 1999, CELL DEATH DIFFER, V6, P28, DOI 10.1038/sj.cdd.4400446
   Kessel D, 2007, PHOTOCH PHOTOBIO SCI, V6, P1290, DOI 10.1039/b707953b
   KRALJIC I, 1978, PHOTOCHEM PHOTOBIOL, V28, P577, DOI 10.1111/j.1751-1097.1978.tb06972.x
   Krishnan S, 2006, AM J CLIN ONCOL-CANC, V29, P562, DOI 10.1097/01.coc.0000236210.41199.91
   Kroemer G, 2008, NAT REV MOL CELL BIO, V9, P1004, DOI 10.1038/nrm2529
   Luksiene Z, 2006, CANCER LETT, V235, P40, DOI 10.1016/j.canlet.2005.03.041
   Luksiene Z, 1999, J PHOTOCH PHOTOBIO B, V52, P35, DOI 10.1016/S1011-1344(99)00098-6
   Ma L, 2014, J MATER CHEM C, V2, P4239, DOI 10.1039/c4tc00114a
   Ma L, 2014, J BIOMED NANOTECHNOL, V10, P1501, DOI 10.1166/jbn.2014.1954
   Maggiorella L, 2012, FUTURE ONCOL, V8, P1167, DOI [10.2217/fon.12.96, 10.2217/FON.12.96]
   MOAN J, 1981, INT J RADIAT BIOL, V40, P107, DOI 10.1080/713858230
   Mornex F, 2006, INT J RADIAT ONCOL, V66, P1152, DOI 10.1016/j.ijrobp.2006.06.015
   Mroz Pawel, 2011, Cancers (Basel), V3, P2516, DOI 10.3390/cancers3022516
   Mulsow J, 2011, BRIT J SURG, V98, P1785, DOI 10.1002/bjs.7653
   Ni J, 2008, J NANOPART RES, V10, P643, DOI 10.1007/s11051-007-9295-6
   Oleinick NL, 2002, PHOTOCH PHOTOBIO SCI, V1, P1, DOI 10.1039/b108586g
   Paganelli G, 2006, NEUROL RES, V28, P518, DOI 10.1179/016164106X116782
   Takahashi J, 2009, RADIAT PHYS CHEM, V78, P889, DOI 10.1016/j.radphyschem.2009.06.036
   Thissen MR, 2002, J INVEST DERMATOL, V118, P239, DOI 10.1046/j.0022-202x.2001.01571.x
   Timmerman RD, 2009, CA-CANCER J CLIN, V59, P145, DOI 10.3322/caac.20013
   Wardman P, 2007, CLIN ONCOL-UK, V19, P397, DOI 10.1016/j.clon.2007.03.010
   Xue LY, 2010, AUTOPHAGY, V6, P248, DOI 10.4161/auto.6.2.11077
   Yao MY, 2016, J BIOMED NANOTECHNOL, V12, P1835, DOI 10.1166/jbn.2016.2322
   Zou XJ, 2014, NANOMEDICINE-UK, V9, P2339, DOI [10.2217/NNM.13.198, 10.2217/nnm.13.198]
NR 37
TC 31
Z9 31
U1 6
U2 32
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD AUG 24
PY 2017
VL 7
AR 9290
DI 10.1038/s41598-017-09375-y
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA FE8FS
UT WOS:000408441600014
PM 28839163
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Kukcinaviciute, E
   Sasnauskiene, A
   Dabkeviciene, D
   Kirveliene, V
   Jonusiene, V
AF Kukcinaviciute, E.
   Sasnauskiene, A.
   Dabkeviciene, D.
   Kirveliene, V.
   Jonusiene, V.
TI Effect of mTHPC-mediated photodynamic therapy on 5-fluorouracil
   resistant human colorectal cancer cells
SO PHOTOCHEMICAL & PHOTOBIOLOGICAL SCIENCES
LA English
DT Article
ID APOPTOSIS; ACTIVATION; AUTOPHAGY; MCF-7; DEATH
AB The primary or acquired cancer chemoresistance is a major problem in the treatment of cancer patients. It could be overcome by non-overlapping treatment regimens such as photodynamic therapy (PDT). PDT is based on the oxidation of cellular components which occurs when a light-excited photosensitizer generates reactive oxygen species (ROS). In this study the effect of mTHPC mediated PDT (mTHPC-PDT) on 5-FU resistant colorectal cancer (CRC) cells HCT116 was investigated. The results show that mTHPC-PDT overcomes 5-FU resistance and is effective against chemoresistant colorectal carcinoma cells.
C1 [Kukcinaviciute, E.; Sasnauskiene, A.; Dabkeviciene, D.; Kirveliene, V.; Jonusiene, V.] Vilnius Univ, Life Sci Ctr, Inst Biosci, Vilnius, Lithuania.
RP Jonusiene, V (corresponding author), Vilnius Univ, Life Sci Ctr, Inst Biosci, Vilnius, Lithuania.
EM violeta.jonusiene@gf.vu.lt
FU EEA grant of the Norwegian financial mechanism [2004-LT0057-IP-1NOR]
FX This project was supported by the EEA grant of the Norwegian financial
   mechanism, No. 2004-LT0057-IP-1NOR.
CR Celli JP, 2011, LASER SURG MED, V43, P565, DOI 10.1002/lsm.21093
   Chiu SM, 2005, APOPTOSIS, V10, P1357, DOI 10.1007/s10495-005-2217-0
   Dallas NA, 2009, CANCER RES, V69, P1951, DOI 10.1158/0008-5472.CAN-08-2023
   Ferlay J, 2012, CANC INCIDENCE MORTA
   Francois A, 2011, INT J ONCOL, V39, P1537, DOI 10.3892/ijo.2011.1174
   Goler-Baron V, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035487
   Holohan C, 2013, NAT REV CANCER, V13, P714, DOI 10.1038/nrc3599
   ITO M, 1984, J INTERFERON RES, V4, P603, DOI 10.1089/jir.1984.4.603
   Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720
   Kessel D, 2016, PHOTOCHEM PHOTOBIOL, V92, P620, DOI 10.1111/php.12592
   Kessel D, 2015, AUTOPHAGY, V11, P1941, DOI 10.1080/15548627.2015.1078960
   Kulbacka J, 2010, EXP BIOL MED, V235, P98, DOI 10.1258/ebm.2009.009162
   Longley DB, 2003, NAT REV CANCER, V3, P330, DOI 10.1038/nrc1074
   Marchal S, 2007, BRIT J CANCER, V96, P944, DOI 10.1038/sj.bjc.6603631
   Oleinick NL, 2002, PHOTOCH PHOTOBIO SCI, V1, P1, DOI 10.1039/b108586g
   Saif MW, 2010, CANCER J, V16, P196, DOI 10.1097/PPO.0b013e3181e076af
   Sasnauskiene A, 2009, APOPTOSIS, V14, P276, DOI 10.1007/s10495-008-0292-8
   Senge MO, 2011, PHOTOCHEM PHOTOBIOL, V87, P1240, DOI 10.1111/j.1751-1097.2011.00986.x
   Spring BQ, 2015, PHOTOCH PHOTOBIO SCI, V14, P1476, DOI 10.1039/c4pp00495g
   Tsai T, 2004, LASER SURG MED, V34, P62, DOI 10.1002/lsm.10246
   Weyergang A, 2015, PHOTOCH PHOTOBIO SCI, V14, P1465, DOI 10.1039/c5pp00029g
   White E, 2012, NAT REV CANCER, V12, P401, DOI 10.1038/nrc3262
   Yao CW, 2017, BIOMOL THER, V25, P315, DOI 10.4062/biomolther.2016.069
   Yu CS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099368
   Zuluaga MF, 2008, CURR MED CHEM, V15, P1655, DOI 10.2174/092986708784872401
NR 25
TC 5
Z9 6
U1 0
U2 10
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 1474-905X
EI 1474-9092
J9 PHOTOCH PHOTOBIO SCI
JI Photochem. Photobiol. Sci.
PD JUL 1
PY 2017
VL 16
IS 7
BP 1063
EP 1070
DI 10.1039/c7pp00014f
PG 8
WC Biochemistry & Molecular Biology; Biophysics; Chemistry, Physical
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics; Chemistry
GA FA4RV
UT WOS:000405431800006
PM 28509917
DA 2022-04-25
ER

PT J
AU Wang, ZY
   Wang, N
   Wang, Q
   Peng, C
   Zhang, J
   Liu, PX
   Ou, AH
   Zhong, SW
   Cordero, MD
   Lin, Y
AF Wang Zhiyu
   Wang, Neng
   Wang, Qi
   Peng, Cheng
   Zhang, Jin
   Liu, Pengxi
   Ou, Aihua
   Zhong, Shaowen
   Cordero, Mario D.
   Lin, Yi
TI The inflammasome: an emerging therapeutic oncotarget for cancer
   prevention
SO ONCOTARGET
LA English
DT Review
DE inflammasome; nod-like receptors; inflammation; cancer prevention; IL-1
   beta/IL-18
ID NF-KAPPA-B; NLRP3 INFLAMMASOME; NALP3 INFLAMMASOME; CASPASE-1
   ACTIVATION; OXIDATIVE STRESS; INNATE IMMUNITY; LISTERIA-MONOCYTOGENES;
   FRANCISELLA-TULARENSIS; COLON INFLAMMATION; AIM2 INFLAMMASOME
AB Deregulated inflammation is considered to be one of the hallmarks of cancer initiation and development regulation. Emerging evidence indicates that the inflammasome plays a central role in regulating immune cells and cytokines related to cancer. The inflammasome is a multimeric complex consisting of Nod-like receptors (NLRs) and responds to a variety of endogenous (damage-associated molecular patterns) and exogenous (pathogen-associated molecular patterns) stimuli. Several lines of evidence suggests that in cancer the inflammasome is positively associated with characteristics such as elevated levels of IL-1 beta and IL-18, activation of NF-kappa B signaling, enhanced mitochondrial oxidative stress, and activation of autophagic process. A number of NLRs, such as NLRP3 and NLRC4 are also highlighted in carcinogenesis and closely correlate to chemoresponse and prognosis. Although conflicting evidence suggested the duplex role of inflammasome in cancer development, the phenomenon might be attributed to NLRs difference, cell and tissue type, cancer stage, and specific experimental conditions. Given the promising role of inflammasome in mediating cancer development, precise elucidation of its signaling network and pathological significance may lead to novel therapeutic options for malignancy therapy and prevention.
C1 [Wang Zhiyu; Liu, Pengxi; Ou, Aihua; Zhong, Shaowen; Lin, Yi] Guangdong Prov Hosp Chinese Med, Dept Mammary Dis, Guangzhou, Guangdong, Peoples R China.
   [Wang, Neng] Sun Yat Sen Univ, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med, Dept Breast Oncol,Canc Ctr, Guangzhou, Guangdong, Peoples R China.
   [Wang, Qi] Inst Clin Pharmacol, Guangzhou, Guangdong, Peoples R China.
   [Peng, Cheng] Chengdu Univ Tradit Chinese Med, State Key Lab Breeding Base Systemat Res Dev & Ut, Coll Pharm, Chengdu, Peoples R China.
   [Zhang, Jin] Guangzhou Univ Chinese Med, Coll Basic Med, Guangzhou, Guangdong, Peoples R China.
   [Cordero, Mario D.] Univ Seville, Dept Oral Med, Res Lab, Seville, Spain.
RP Wang, ZY (corresponding author), Guangdong Prov Hosp Chinese Med, Dept Mammary Dis, Guangzhou, Guangdong, Peoples R China.
EM wangzhiyu976@126.com
RI wang, zhiyu/K-5255-2016
OI wang, zhiyu/0000-0002-5299-8410
FU National Natural science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81402173, 81573651]; Pearl River S&T Nova
   Program of Guangzhou [201506010098]; Combined Scientific Project -
   Guangdong Provincial Science and Technology Agency; Guangdong Provincial
   Academy of Traditional Chinese Medicine [2014A020221047]
FX This work was supported by the National Natural science Foundation of
   China (81402173, 81573651), Pearl River S&T Nova Program of Guangzhou
   (201506010098) and Combined Scientific Project Funded by Guangdong
   Provincial Science and Technology Agency and Guangdong Provincial
   Academy of Traditional Chinese Medicine (2014A020221047).
CR Allen IC, 2012, IMMUNITY, V36, P742, DOI 10.1016/j.immuni.2012.03.012
   Allen IC, 2009, IMMUNITY, V30, P556, DOI 10.1016/j.immuni.2009.02.005
   [Anonymous], 1863, R V DIEKR GESCHW
   Apetoh L, 2007, NAT MED, V13, P1050, DOI 10.1038/nm1622
   Arthur JC, 2010, J IMMUNOL, V185, P4515, DOI 10.4049/jimmunol.1002227
   Balkwill F, 2001, LANCET, V357, P539, DOI 10.1016/S0140-6736(00)04046-0
   Bartsch H, 2006, LANGENBECK ARCH SURG, V391, P499, DOI 10.1007/s00423-006-0073-1
   Bergsbaken T, 2009, NAT REV MICROBIOL, V7, P99, DOI 10.1038/nrmicro2070
   Borghini S, 2011, ARTHRITIS RHEUM-US, V63, P830, DOI 10.1002/art.30170
   Bruchard M, 2013, NAT MED, V19, P57, DOI 10.1038/nm.2999
   Bruey JM, 2007, CELL, V129, P45, DOI 10.1016/j.cell.2007.01.045
   Bryan NB, 2009, J IMMUNOL, V182, P3173, DOI 10.4049/jimmunol.0802367
   Cassel SL, 2008, P NATL ACAD SCI USA, V105, P9035, DOI 10.1073/pnas.0803933105
   Chen GY, 2011, J IMMUNOL, V186, P7187, DOI 10.4049/jimmunol.1100412
   Chow MT, 2012, CANCER RES, V72, P5721, DOI 10.1158/0008-5472.CAN-12-0509
   Coffelt SB, 2014, NATURE, V507, P48, DOI 10.1038/nature13062
   Cohen EN, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132710
   Cook GP, 2010, EUR J IMMUNOL, V40, P631, DOI 10.1002/eji.200940162
   Crisan TO, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018666
   de Alba E, 2009, J BIOL CHEM, V284, P32932, DOI 10.1074/jbc.M109.024273
   Detjen KM, 2001, GUT, V49, P251, DOI 10.1136/gut.49.2.251
   Dickensheets HL, 1997, J IMMUNOL, V159, P6226
   DiDonato JA, 2012, IMMUNOL REV, V246, P379, DOI 10.1111/j.1600-065X.2012.01099.x
   Dostert C, 2008, SCIENCE, V320, P674, DOI 10.1126/science.1156995
   Dostert C, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006510
   Dowds TA, 2004, J BIOL CHEM, V279, P21924, DOI 10.1074/jbc.M401178200
   Duncan JA, 2009, J IMMUNOL, V182, P6460, DOI 10.4049/jimmunol.0802696
   Dupaul-Chicoine J, 2010, IMMUNITY, V32, P367, DOI 10.1016/j.immuni.2010.02.012
   Dupont N, 2011, EMBO J, V30, P4701, DOI 10.1038/emboj.2011.398
   Eisenbarth SC, 2008, NATURE, V453, P1122, DOI 10.1038/nature06939
   Elinav E, 2011, CELL, V145, P745, DOI 10.1016/j.cell.2011.04.022
   Fabbi M, 2015, J LEUKOCYTE BIOL, V97, P665, DOI 10.1189/jlb.5RU0714-360RR
   Fan YH, 2013, PROTEIN CELL, V4, P176, DOI 10.1007/s13238-013-2084-3
   Faustin B, 2009, P NATL ACAD SCI USA, V106, P3935, DOI 10.1073/pnas.0809414106
   Fernandes-Alnemri T, 2010, NAT IMMUNOL, V11, P385, DOI 10.1038/ni.1859
   Franchi L, 2009, IMMUNOL REV, V227, P106, DOI 10.1111/j.1600-065X.2008.00734.x
   Ghiringhelli F, 2009, NAT MED, V15, P1170, DOI 10.1038/nm.2028
   Gross O, 2011, IMMUNOL REV, V243, P136, DOI 10.1111/j.1600-065X.2011.01046.x
   Guarda G, 2011, IMMUNITY, V34, P213, DOI 10.1016/j.immuni.2011.02.006
   Guarda G, 2009, NATURE, V460, P269, DOI 10.1038/nature08100
   Gurung P, 2015, AM J PATHOL, V185, P17, DOI 10.1016/j.ajpath.2014.08.025
   Halle A, 2008, NAT IMMUNOL, V9, P857, DOI 10.1038/ni.1636
   Harris J, 2011, J BIOL CHEM, V286, P9587, DOI 10.1074/jbc.M110.202911
   Hawkins CJ, 1996, P NATL ACAD SCI USA, V93, P13786, DOI 10.1073/pnas.93.24.13786
   Henry T, 2007, J EXP MED, V204, P987, DOI 10.1084/jem.20062665
   Hise AG, 2009, CELL HOST MICROBE, V5, P487, DOI 10.1016/j.chom.2009.05.002
   Hoesel B, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-86
   Hoffman HM, 2011, J BIOL CHEM, V286, P10889, DOI 10.1074/jbc.R110.135491
   Hornung V, 2008, NAT IMMUNOL, V9, P847, DOI 10.1038/ni.1631
   Hu B, 2011, CELL CYCLE, V10, P1936, DOI 10.4161/cc.10.12.16008
   Hu B, 2010, P NATL ACAD SCI USA, V107, P21635, DOI 10.1073/pnas.1016814108
   Hussain SP, 2007, INT J CANCER, V121, P2373, DOI 10.1002/ijc.23173
   Huysamen C, 2009, FEMS MICROBIOL LETT, V290, P121, DOI 10.1111/j.1574-6968.2008.01418.x
   Ippagunta SK, 2011, NAT IMMUNOL, V12, P1010, DOI 10.1038/ni.2095
   Jeru I, 2008, P NATL ACAD SCI USA, V105, P1614, DOI 10.1073/pnas.0708616105
   Jiang XJ, 2015, J CLIN INVEST, V125, P47, DOI 10.1172/JCI73942
   Jones JW, 2010, P NATL ACAD SCI USA, V107, P9771, DOI 10.1073/pnas.1003738107
   Kanneganti TD, 2007, IMMUNITY, V26, P433, DOI 10.1016/j.immuni.2007.03.008
   Kanneganti TD, 2010, NAT REV IMMUNOL, V10, P688, DOI 10.1038/nri2851
   Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870
   Kayagaki N, 2011, NATURE, V479, P117, DOI 10.1038/nature10558
   Kazama H, 2008, IMMUNITY, V29, P21, DOI 10.1016/j.immuni.2008.05.013
   Khansari N, 2009, RECENT PATENTS INFLA, V3, P73, DOI 10.2174/187221309787158371
   Kim JW, 2013, CANCER RES TREAT, V45, P325, DOI 10.4143/crt.2013.45.4.325
   Kim S, 2010, EUR J IMMUNOL, V40, P1545, DOI 10.1002/eji.201040425
   Kono H, 2008, NAT REV IMMUNOL, V8, P279, DOI 10.1038/nri2215
   Labbe K, 2011, IMMUNITY, V35, P897, DOI 10.1016/j.immuni.2011.10.016
   Lamkanfi M, 2011, IMMUNOL REV, V243, P163, DOI 10.1111/j.1600-065X.2011.01042.x
   Lechtenberg BC, 2014, CURR OPIN STRUC BIOL, V29, P17, DOI 10.1016/j.sbi.2014.08.011
   Lee GS, 2012, NATURE, V492, P123, DOI 10.1038/nature11588
   Li J, 2004, HUM MOL GENET, V13, P1715, DOI 10.1093/hmg/ddh182
   Li JN, 2015, J IMMUNOL, V195, P5732, DOI 10.4049/jimmunol.1501606
   Li QX, 2008, INT J CANCER, V123, P493, DOI 10.1002/ijc.23692
   Li Q, 2015, TOXICOL APPL PHARM, V289, P133, DOI 10.1016/j.taap.2015.09.025
   Liu MH, 2015, INT J CARDIOL, V185, P320, DOI 10.1016/j.ijcard.2015.03.165
   Malhotra S, 2015, BRAIN, V138, P644, DOI 10.1093/brain/awu388
   Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205
   Mariathasan S, 2006, NATURE, V440, P228, DOI 10.1038/nature04515
   Martinon F, 2002, MOL CELL, V10, P417, DOI 10.1016/S1097-2765(02)00599-3
   Martins JD, 2015, DNA CELL BIOL, V34, P274, DOI 10.1089/dna.2014.2752
   Masters SL, 2012, IMMUNITY, V37, P1009, DOI 10.1016/j.immuni.2012.08.027
   Masters SL, 2010, EMBO REP, V11, P640, DOI 10.1038/embor.2010.93
   Masters SL, 2009, ANNU REV IMMUNOL, V27, P621, DOI 10.1146/annurev.immunol.25.022106.141627
   Meixenberger K, 2010, J IMMUNOL, V184, P922, DOI 10.4049/jimmunol.0901346
   Miao EA, 2010, NAT IMMUNOL, V11, P1136, DOI 10.1038/ni.1960
   Munoz-Planillo R, 2009, J IMMUNOL, V183, P3942, DOI 10.4049/jimmunol.0900729
   Murakami T, 2012, P NATL ACAD SCI USA, V109, P11282, DOI 10.1073/pnas.1117765109
   Nakahira K, 2011, NAT IMMUNOL, V12, P222, DOI 10.1038/ni.1980
   Normand S, 2011, P NATL ACAD SCI USA, V108, P9601, DOI 10.1073/pnas.1100981108
   Pan H., 2016, ONCOTARGET
   Piccini A, 2008, P NATL ACAD SCI USA, V105, P8067, DOI 10.1073/pnas.0709684105
   Prasad S, 2010, MOL CELL BIOCHEM, V336, P25, DOI 10.1007/s11010-009-0267-2
   Qiao Y, 2012, FEBS LETT, V586, P1022, DOI 10.1016/j.febslet.2012.02.045
   Rathinam VAK, 2012, NAT IMMUNOL, V13, P333, DOI 10.1038/ni.2237
   Rebecca VW, 2016, ONCOGENE, V35, P1, DOI 10.1038/onc.2015.99
   Reuter S, 2010, FREE RADICAL BIO MED, V49, P1603, DOI 10.1016/j.freeradbiomed.2010.09.006
   Rossol M, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2339
   Sadasivam S, 2005, ONCOGENE, V24, P627, DOI 10.1038/sj.onc.1208201
   Saitoh T, 2008, NATURE, V456, P264, DOI 10.1038/nature07383
   Shalapour S, 2015, J CLIN INVEST, V125, P3347, DOI 10.1172/JCI80007
   Shaw PJ, 2010, J IMMUNOL, V184, P4610, DOI 10.4049/jimmunol.1000217
   Shin S, 2015, SEMIN IMMUNOL, V27, P102, DOI 10.1016/j.smim.2015.03.006
   Siegel RM, 2006, NAT REV IMMUNOL, V6, P308, DOI 10.1038/nri1809
   Suarez R, 2015, INVEST CLIN, V56, P74
   Sutterwala FS, 2014, ANN NY ACAD SCI, V1319, P82, DOI 10.1111/nyas.12458
   Takeda K, 2005, INT IMMUNOL, V17, P1, DOI 10.1093/intimm/dxh186
   Tas F, 2015, BIOMED PHARMACOTHER, V70, P19, DOI 10.1016/j.biopha.2014.12.040
   van Deventer HW, 2010, CANCER RES, V70, P10161, DOI 10.1158/0008-5472.CAN-10-1921
   Verma D, 2012, PIGM CELL MELANOMA R, V25, P506, DOI 10.1111/j.1755-148X.2012.01008.x
   Villani AC, 2009, NAT GENET, V41, P71, DOI 10.1038/ng.285
   Vince JE, 2012, IMMUNITY, V36, P215, DOI 10.1016/j.immuni.2012.01.012
   Wei Q, 2014, LAB INVEST, V94, P52, DOI 10.1038/labinvest.2013.126
   Willingham SB, 2009, J IMMUNOL, V183, P2008, DOI 10.4049/jimmunol.0900138
   Wree A, 2014, HEPATOLOGY, V59, P898, DOI 10.1002/hep.26592
   Xiang PJ, 2015, INFLAMM RES, V64, P799, DOI 10.1007/s00011-015-0863-4
   Xu YF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077955
   Yang L, 2010, CANCER METAST REV, V29, P263, DOI 10.1007/s10555-010-9226-3
   Yoneyama M, 2007, CYTOKINE GROWTH F R, V18, P545, DOI 10.1016/j.cytogfr.2007.06.023
   Zaki MH, 2011, CANCER CELL, V20, P649, DOI 10.1016/j.ccr.2011.10.022
   Zaki MH, 2010, IMMUNITY, V32, P379, DOI 10.1016/j.immuni.2010.03.003
   Zaki MH, 2010, J IMMUNOL, V185, P4912, DOI 10.4049/jimmunol.1002046
   Zhong ZY, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2608
   Zhou RB, 2011, NATURE, V469, P221, DOI 10.1038/nature09663
   Zitvogel L, 2012, NAT IMMUNOL, V13, P343, DOI 10.1038/ni.2224
NR 124
TC 26
Z9 27
U1 0
U2 14
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD AUG 2
PY 2016
VL 7
IS 31
BP 50766
EP 50780
DI 10.18632/oncotarget.9391
PG 15
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA DY8ZS
UT WOS:000385422000148
PM 27206676
OA Green Published, Green Submitted, gold
DA 2022-04-25
ER

PT J
AU Ma, Z
   Lou, SP
   Jiang, Z
AF Ma, Zhan
   Lou, Shuping
   Jiang, Zheng
TI PHLDA2 regulates EMT and autophagy in colorectal cancer via the PI3K/AKT
   signaling pathway
SO AGING-US
LA English
DT Article
DE PHLDA2; colorectal cancer; autophagy; apoptosis; tumorigenesis
ID EPITHELIAL-MESENCHYMAL TRANSITION; DOWN-REGULATION; PROSTATE-CANCER;
   GENE; CELLS; EXPRESSION; MODULATION; APOPTOSIS
AB High levels of the imprinted gene pleckstrin homology like domain family A member 2 (PHLDA2) correlate with tumor progression in several malignancies. Here, we investigated the effects of PHDLDA2 expression in CRC through assays of cellular proliferation, invasion, migration, and apoptosis. We also screened for possible mechanisms of action. Our results show that PHLDA2 was upregulated in CRC tissues. Knockdown of PHLDA2 inhibited cellular proliferation, invasion, migration, and epithelial-mesenchymal transition (EMT) in vitro. Knockout of PHLDA2 promoted cellular apoptosis, in part by activating autophagy. PHLDA2 knockout also inhibited tumorigenesis and expression of KI67 protein in vivo. The effects of PHLDA2 on autophagy and EMT were mediated in part via the PI3K/AKT signaling pathway. Taken together, these results suggest that downregulation of PHLDA2 inhibits tumor growth and PI3K, thereby promoting autophagy and inhibiting EMT, in part through the PI3K/AKT/mTOR and PI3K/AKT/GSK-3 beta signaling pathways.
C1 [Ma, Zhan; Jiang, Zheng] Chongqing Med Univ, Dept Gastroenterol, Affiliated Hosp 1, Chongqing 400016, Peoples R China.
   [Lou, Shuping] Huazhong Univ Sci & Technol, Sch Publ Hlth, Dept Maternal & Child Hlth, Tongji Med Coll, Wuhan 430030, Peoples R China.
RP Jiang, Z (corresponding author), Chongqing Med Univ, Dept Gastroenterol, Affiliated Hosp 1, Chongqing 400016, Peoples R China.
EM jiangz1753@163.com
CR Baran Y, 2015, GENOME RES, V25, P927, DOI 10.1101/gr.192278.115
   Bianchini F, 2002, LANCET ONCOL, V3, P565, DOI 10.1016/S1470-2045(02)00849-5
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
   Cohen JH, 2000, JNCI-J NATL CANCER I, V92, P61, DOI 10.1093/jnci/92.1.61
   Ding XF, 2017, AM J HYPERTENS, V30, P1211, DOI 10.1093/ajh/hpx117
   Durbas M, 2016, INT J ONCOL, V49, P823, DOI 10.3892/ijo.2016.3572
   FRIEDRICHS K, 1993, CANCER, V72, P3641, DOI 10.1002/1097-0142(19931215)72:12<3641::AID-CNCR2820721215>3.0.CO;2-8
   GOLDGAR DE, 1994, J NATL CANCER I, V86, P1600, DOI 10.1093/jnci/86.21.1600
   Heras-Sandoval D, 2014, CELL SIGNAL, V26, P2694, DOI 10.1016/j.cellsig.2014.08.019
   Huber MA, 2005, CURR OPIN CELL BIOL, V17, P548, DOI 10.1016/j.ceb.2005.08.001
   Idichi T, 2018, CANCER SCI, V109, P2013, DOI 10.1111/cas.13610
   Jiang JY, 2019, ONCOL REP, V41, P3281, DOI 10.3892/or.2019.7126
   Jung CH, 2010, FEBS LETT, V584, P1287, DOI 10.1016/j.febslet.2010.01.017
   Kim YC, 2015, J CLIN INVEST, V125, P25, DOI 10.1172/JCI73939
   Kolonel LN, 2004, NAT REV CANCER, V4, P519, DOI 10.1038/nrc1389
   Kroemer G, 2010, MOL CELL, V40, P280, DOI 10.1016/j.molcel.2010.09.023
   Kwon YJ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151598
   Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Li YJ, 2017, CHIN J CANCER, V52, DOI 10.1186/s40880-017-0219-2
   Liu GB, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18020367
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lu Z, 2008, J CLIN INVEST, V118, P3917, DOI 10.1172/JCI35512
   Lv YF, 2016, CANCER LETT, V373, P164, DOI 10.1016/j.canlet.2016.01.046
   Lv YF, 2015, SCI REP-UK, V5, DOI 10.1038/srep12999
   Meng Y, 2008, MOL CANCER THER, V7, P2192, DOI 10.1158/1535-7163.MCT-08-0333
   Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639
   Moad AIH, 2013, CELL BIOCHEM BIOPHYS, V66, P567, DOI 10.1007/s12013-012-9504-5
   Mohindra V, 2014, J BIOSCIENCES, V39, P433, DOI 10.1007/s12038-014-9426-z
   Moon HG, 2015, BREAST CANCER RES TR, V154, P13, DOI 10.1007/s10549-015-3585-y
   Osaki M, 2004, APOPTOSIS, V9, P667, DOI 10.1023/B:APPT.0000045801.15585.dd
   Simon K, 2016, CLIN INTERV AGING, V11, DOI 10.2147/CIA.S109285
   Takao T, 2012, J BIOL CHEM, V287, P42685, DOI 10.1074/jbc.M112.388777
   Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262
   Vara JAF, 2004, CANCER TREAT REV, V30, P193, DOI 10.1016/j.ctrv.2003.07.007
   Wei R, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1043-0
   White E, 2009, CLIN CANCER RES, V15, P5308, DOI 10.1158/1078-0432.CCR-07-5023
   Xiong Y, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/4909103
   Yang J, 2008, DEV CELL, V14, P818, DOI 10.1016/j.devcel.2008.05.009
   Yang W, 2007, J BIOL CHEM, V282, P3799, DOI 10.1074/jbc.M610185200
   Ying L, 2013, MOL BIOSYST, V9, P407, DOI 10.1039/c2mb25386k
   Zhao GS, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0856-6
   Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032
   Zhu L, 2016, J CELL BIOCHEM, V117, P1187, DOI 10.1002/jcb.25402
NR 44
TC 13
Z9 13
U1 2
U2 12
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
SN 1945-4589
J9 AGING-US
JI Aging-US
PD MAY 15
PY 2020
VL 12
IS 9
BP 7985
EP 8000
DI 10.18632/aging.103117
PG 16
WC Cell Biology; Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Geriatrics & Gerontology
GA LN7ZB
UT WOS:000533150800025
PM 32385195
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Bahrami, A
   Bianconi, V
   Pirro, M
   Orafai, HM
   Sahebkar, A
AF Bahrami, Afsane
   Bianconi, Vanessa
   Pirro, Matteo
   Orafai, Hossein M.
   Sahebkar, Amirhossein
TI The role of TFEB in tumor cell autophagy: Diagnostic and therapeutic
   opportunities
SO LIFE SCIENCES
LA English
DT Review
DE TFEB; CLEAR network; MALAT1; MiT family; Traslocation renal cell
   carcinoma
ID TRANSCRIPTION FACTOR GENE; LYSOSOMAL BIOGENESIS; COLORECTAL-CANCER;
   CLINICOPATHOLOGICAL FEATURES; TRANSLOCATION CARCINOMA; REGULATES
   AUTOPHAGY; PHYTOSOMAL CURCUMIN; SUPPRESSOR GENE; RENAL TUMOR; FACTOR EB
AB Autophagy is a conserved "self-eating" recycling process which removes aggregated or misfolded proteins, or defective organelles, to maintain cellular hemostasis. In the autophagy-lysosome pathway (ALP), clearance of unwanted debris and materials occurs through the generation of the autophagosome, a complex of double-membrane bounded vesicles that form around cytosolic cargos and catabolize their contents by fusion to lysosomes. In tumors, autophagy has dichotomous functions via preventing tumor initiation but promoting tumor progression. The basic helix-loop-helix leucine zipper transcription factor EB (TFEB) activates the promoters of genes encoding for proteins, which participate in this cellular degradative system by regulating lysosomal biogenesis, lysosomal acidification, lysosomal exocytosis and autophagy. In humans, disturbances of ALP are related to various pathological conditions. Recently, TFEB dysregulation was found to have a crucial pathogenic role in different tumors by modulating tumor cell autophagy. Notably, in renal cell carcinomas, different TFEB gene fusions were reported to promote oncogenic features. In this review, we discuss the role of TFEB in human cancers with a special focus on potential diagnostic and therapeutic implications.
C1 [Bahrami, Afsane] Birjand Univ Med Sci, Cellular & Mol Res Ctr, Birjand, Iran.
   [Bianconi, Vanessa; Pirro, Matteo] Univ Perugia, Dept Med, Unit Internal Med, Perugia, Italy.
   [Orafai, Hossein M.] Univ Ahl Al Bayt, Fac Pharm, Dept Pharmaceut, Karbala, Iraq.
   [Orafai, Hossein M.] Al Zahraa Univ, Fac Pharm, Dept Pharmaceut, Karbala, Iraq.
   [Sahebkar, Amirhossein] FDA, Halal Res Ctr IRI, Tehran, Iran.
   [Sahebkar, Amirhossein] Mashhad Univ Med Sci, Biotechnol Res Ctr, Pharmaceut Technol Inst, Mashhad, Razavi Khorasan, Iran.
   [Sahebkar, Amirhossein] Mashhad Univ Med Sci, Neurogen Inflammat Res Ctr, Mashhad, Razavi Khorasan, Iran.
RP Sahebkar, A (corresponding author), Mashhad Univ Med Sci, Sch Med, Dept Med Biotechnol, POB 91779-48564, Mashhad, Razavi Khorasan, Iran.
EM sahebkara@mums.ac.ir
RI Pirro, Matteo/AAC-2318-2022; Sahebkar, Amirhossein/B-5124-2018
FU Cancer Research Center of Cancer Institute of Iran (Shams cancer
   charity) [37312-202-01-97, 960206]; Biotechnology Development Council of
   the Islamic Republic of Iran
FX This study has been conducted by a grant from Cancer Research Center of
   Cancer Institute of Iran (Shams cancer charity, Grant No:
   37312-202-01-97). This study was also financially supported by grant No.
   960206 of the Biotechnology Development Council of the Islamic Republic
   of Iran.
CR Abdollahi E, 2018, J CELL PHYSIOL, V233, P830, DOI 10.1002/jcp.25778
   AHLBERG J, 1985, EXP MOL PATHOL, V42, P78, DOI 10.1016/0014-4800(85)90020-6
   Aita VM, 1999, GENOMICS, V59, P59, DOI 10.1006/geno.1999.5851
   Amin MB, 2002, AM J SURG PATHOL, V26, P281, DOI 10.1097/00000478-200203000-00001
   Argani P, 2005, AM J SURG PATHOL, V29, P230, DOI 10.1097/01.pas.0000146007.54092.37
   Argani P, 2006, J CLIN ONCOL, V24, P1529, DOI 10.1200/JCO.2005.04.4693
   Argani P, 2003, ONCOGENE, V22, P5374, DOI 10.1038/sj.onc.1206686
   Argani P, 2003, AM J SURG PATHOL, V27, P750, DOI 10.1097/00000478-200306000-00005
   Argani P, 2001, AM J PATHOL, V158, P2089, DOI 10.1016/S0002-9440(10)64680-9
   Argani P, 2016, AM J SURG PATHOL, V40, P1484, DOI 10.1097/PAS.0000000000000720
   Bahrami A, 2018, PHARMACOL RES, V137, P159, DOI 10.1016/j.phrs.2018.10.009
   Bahrami A, 2018, J CELL PHYSIOL, V233, P2928, DOI 10.1002/jcp.26041
   Bahrami A, 2018, J CELL BIOCHEM, V119, P111, DOI 10.1002/jcb.26183
   Balderhaar HJK, 2013, J CELL SCI, V126, P1307, DOI 10.1242/jcs.107805
   Ballabio A, 2009, BBA-MOL CELL RES, V1793, P684, DOI 10.1016/j.bbamcr.2008.12.001
   Bronisz A, 2006, MOL BIOL CELL, V17, P3897, DOI 10.1091/mbc.E06-05-0470
   Cardili L, 2017, PATHOL INT, V67, P208, DOI 10.1111/pin.12517
   CHIANG HL, 1989, SCIENCE, V246, P382, DOI 10.1126/science.2799391
   Chung MC, 2001, BIOCHEMISTRY-US, V40, P8887, DOI 10.1021/bi002847d
   Cuervo AM, 1996, SCIENCE, V273, P501, DOI 10.1126/science.273.5274.501
   DALCIN P, 1991, CANCER GENET CYTOGEN, V57, P137, DOI 10.1016/0165-4608(91)90199-5
   Davis IJ, 2003, P NATL ACAD SCI USA, V100, P6051, DOI 10.1073/pnas.0931430100
   Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001
   Ellis CL, 2014, MODERN PATHOL, V27, P875, DOI 10.1038/modpathol.2013.208
   Enzenmuller S, 2013, CANCER LETT, V329, P27, DOI 10.1016/j.canlet.2012.09.007
   Eskelinen Eeva-Liisa, 2006, Molecular Aspects of Medicine, V27, P495, DOI 10.1016/j.mam.2006.08.005
   Eskelinen EL, 2009, BBA-MOL CELL RES, V1793, P664, DOI 10.1016/j.bbamcr.2008.07.014
   Fang LM, 2017, ACTA PHARMACOL SIN, V38, P1305, DOI 10.1038/aps.2017.25
   Fang L, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2017.1312042
   Ferron M, 2013, GENE DEV, V27, P955, DOI 10.1101/gad.213827.113
   FISHER DE, 1991, GENE DEV, V5, P2342, DOI 10.1101/gad.5.12a.2342
   Galluzzi L, 2015, EMBO J, V34, P856, DOI 10.15252/embj.201490784
   Garraway LA, 2005, NATURE, V436, P117, DOI 10.1038/nature03664
   Giatromanolaki Alexandra, 2017, Clin Breast Cancer, V17, pe119, DOI 10.1016/j.clbc.2016.11.006
   Giatromanolaki A, 2015, LUNG CANCER, V90, P98, DOI 10.1016/j.lungcan.2015.07.008
   Griffiths J R, 2001, Novartis Found Symp, V240, P46
   Gunawan B, 2003, CANCER RES, V63, P6200
   Gupta S, 2017, MODERN PATHOL, V30, P998, DOI 10.1038/modpathol.2017.24
   Haq R, 2011, J CLIN ONCOL, V29, P3474, DOI 10.1200/JCO.2010.32.6223
   Hashimoto D, 2014, EUR J CANCER, V50, P1382, DOI 10.1016/j.ejca.2014.01.011
   HEMESATH TJ, 1994, GENE DEV, V8, P2770, DOI 10.1101/gad.8.22.2770
   Hershey CL, 2004, BONE, V34, P689, DOI 10.1016/j.bone.2003.08.014
   Hu JL, 2018, ONCOGENESIS, V7, DOI 10.1038/s41389-018-0028-8
   Inamura K, 2012, AM J SURG PATHOL, V36, P35, DOI 10.1097/PAS.0b013e3182293ec3
   Jin J, 2004, CURR BIOL, V14, P1436, DOI 10.1016/j.cub.2004.07.051
   Katayama M, 2007, CELL DEATH DIFFER, V14, P548, DOI 10.1038/sj.cdd.4402030
   Kauffman EC, 2014, NAT REV UROL, V11, P465, DOI 10.1038/nrurol.2014.162
   Kirkegaard T, 2009, BBA-MOL CELL RES, V1793, P746, DOI 10.1016/j.bbamcr.2008.09.008
   Klein K, 2016, INT J ONCOL, V49, P164, DOI 10.3892/ijo.2016.3505
   Klionsky DJ, 2016, AUTOPHAGY, V12, P1, DOI 10.1080/15548627.2015.1100356
   Klionsky DJ, 2005, J CELL SCI, V118, P7, DOI 10.1242/jcs.01620
   Komai Y, 2009, CLIN CANCER RES, V15, P1170, DOI 10.1158/1078-0432.CCR-08-1183
   Kuiper RP, 2004, NUCLEIC ACIDS RES, V32, P2315, DOI 10.1093/nar/gkh571
   Kuiper RP, 2003, HUM MOL GENET, V12, P1661, DOI 10.1093/hmg/ddg178
   Ladanyi M, 2001, ONCOGENE, V20, P48, DOI 10.1038/sj.onc.1204074
   Papademetrio DL, 2014, TARGET ONCOL, V9, P123, DOI 10.1007/s11523-013-0278-5
   Li WW, 2012, CELL MOL LIFE SCI, V69, P1125, DOI 10.1007/s00018-011-0865-5
   Liang J, 2018, ONCOTARGETS THER, V11, P8089, DOI 10.2147/OTT.S180112
   Linehan WM, 2016, NEW ENGL J MED, V374, P135, DOI 10.1056/NEJMoa1505917
   Lippai M, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/832704
   Liu K, 2015, AUTOPHAGY, V11, P271, DOI 10.1080/15548627.2015.1009787
   Liu Y, 2015, CELL DEATH DIFFER, V22, P367, DOI 10.1038/cdd.2014.143
   Lu Z, 2008, J CLIN INVEST, V118, P3917, DOI 10.1172/JCI35512
   Lubke T, 2009, BBA-MOL CELL RES, V1793, P625, DOI 10.1016/j.bbamcr.2008.09.018
   Luzio JP, 2007, NAT REV MOL CELL BIO, V8, P622, DOI 10.1038/nrm2217
   Lystad AH, 2014, EMBO REP, V15, P557, DOI 10.1002/embr.201338003
   Marjaneh RM, 2018, J CELL PHYSIOL, V233, P6785, DOI 10.1002/jcp.26538
   Martina JA, 2016, EMBO J, V35, P479, DOI 10.15252/embj.201593428
   Martina JA, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2004754
   Martina JA, 2013, J CELL BIOL, V200, P475, DOI 10.1083/jcb.201209135
   Martina JA, 2012, AUTOPHAGY, V8, P903, DOI 10.4161/auto.19653
   MARZELLA L, 1981, VIRCHOWS ARCH B, V36, P219, DOI 10.1007/BF02912068
   Mazure NM, 2010, CURR OPIN CELL BIOL, V22, P177, DOI 10.1016/j.ceb.2009.11.015
   Medina DL, 2015, NAT CELL BIOL, V17, P288, DOI 10.1038/ncb3114
   Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639
   Mizushima N, 2007, GENE DEV, V21, P2861, DOI 10.1101/gad.1599207
   Mizushima N, 2011, ANNU REV CELL DEV BI, V27, P107, DOI 10.1146/annurev-cellbio-092910-154005
   Nagamura-Inoue T, 2001, Int Rev Immunol, V20, P83, DOI 10.3109/08830180109056724
   Nakagawa I, 2004, SCIENCE, V306, P1037, DOI 10.1126/science.1103966
   Neoptolemos JP, 2010, JAMA-J AM MED ASSOC, V304, P1073, DOI 10.1001/jama.2010.1275
   Palmieri M, 2011, HUM MOL GENET, V20, P3852, DOI 10.1093/hmg/ddr306
   Panahi Y, 2017, DRUG RES, V67, P244, DOI 10.1055/s-0043-100019
   Parsamanesh N, 2018, PHARMACOL RES, V136, P181, DOI 10.1016/j.phrs.2018.09.012
   Perera R, 2015, NATURE, V524, P361, DOI 10.1038/nature14587
   Petersson F, 2012, HUM PATHOL, V43, P726, DOI 10.1016/j.humpath.2011.07.001
   Ploper D, 2015, P NATL ACAD SCI USA, V112, pE420, DOI 10.1073/pnas.1424576112
   Price ER, 2001, NEURON, V30, P15, DOI 10.1016/S0896-6273(01)00259-8
   Ramphal R, 2006, AM J CLIN PATHOL, V126, P349, DOI 10.1309/98YE9E442ARLX2X
   Rao Q, 2012, AM J SURG PATHOL, V36, P1327, DOI 10.1097/PAS.0b013e31825aafb5
   Rao Qiu, 2010, Chinese Journal of Pathology, V39, P582, DOI 10.3760/cma.j.issn.0529-5807.2010.09.002
   Raposo G, 2007, NAT REV MOL CELL BIO, V8, P786, DOI 10.1038/nrm2258
   Rehli M, 1999, J IMMUNOL, V162, P1559
   Rehli M, 1999, GENOMICS, V56, P111, DOI 10.1006/geno.1998.5588
   Rezaee R, 2017, PHARMACOL RES, V117, P218, DOI 10.1016/j.phrs.2016.12.037
   Ricciuti B, 2019, SEMIN CANCER BIOL, V56, P87, DOI 10.1016/j.semcancer.2017.11.005
   Roczniak-Ferguson A, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002790
   Saftig P, 2009, NAT REV MOL CELL BIO, V10, P623, DOI 10.1038/nrm2745
   Sahu R, 2011, DEV CELL, V20, P131, DOI 10.1016/j.devcel.2010.12.003
   Sakamoto H, 2018, ORAL DIS, V24, P741, DOI 10.1111/odi.12826
   Sardiello M, 2009, SCIENCE, V325, P473, DOI 10.1126/science.1174447
   Sato M, 2019, J PHARMACOL SCI, V140, P201, DOI 10.1016/j.jphs.2019.05.007
   Sato S, 1997, ONCOGENE, V14, P3083, DOI 10.1038/sj.onc.1201298
   Schilling JD, 2013, J IMMUNOL, V190, P1285, DOI 10.4049/jimmunol.1202208
   Settembre C, 2013, NAT CELL BIOL, V15, P647, DOI 10.1038/ncb2718
   Settembre C, 2013, NAT REV MOL CELL BIO, V14, P283, DOI 10.1038/nrm3565
   Settembre C, 2012, EMBO J, V31, P1095, DOI 10.1038/emboj.2012.32
   Settembre C, 2011, SCIENCE, V332, P1429, DOI 10.1126/science.1204592
   Shen Y, 2008, AUTOPHAGY, V4, P1067, DOI 10.4161/auto.6827
   Sica A, 2012, J CLIN INVEST, V122, P787, DOI 10.1172/JCI59643
   Sivridis E, 2011, AUTOPHAGY, V7, P74, DOI 10.4161/auto.7.1.13947
   Slade L, 2017, MOL CANCER RES, V15, P1637, DOI 10.1158/1541-7786.MCR-17-0320
   STEINGRIMSSON E, 1994, NAT GENET, V8, P256, DOI 10.1038/ng1194-256
   Suarez-Vilela D, 2011, INT J SURG PATHOL, V19, P506, DOI 10.1177/1066896909340531
   Takamura A, 2011, GENE DEV, V25, P795, DOI 10.1101/gad.2016211
   Tanaka M, 2017, CANCER RES, V77, P897, DOI 10.1158/0008-5472.CAN-16-2486
   Tanida I, 2011, ANTIOXID REDOX SIGN, V14, P2201, DOI 10.1089/ars.2010.3482
   Taniguchi M, 2015, CELL STRUCT FUNCT, V40, P13, DOI 10.1247/csf.14015
   Tekirdag K, 2018, J BIOL CHEM, V293, P5414, DOI 10.1074/jbc.R117.818237
   Verastegui C, 2000, MOL ENDOCRINOL, V14, P449, DOI 10.1210/me.14.3.449
   Verastegui C, 2000, J BIOL CHEM, V275, P30757, DOI 10.1074/jbc.C000445200
   Weterman MAJ, 2001, ONCOGENE, V20, P1414, DOI 10.1038/sj.onc.1204213
   White E, 2012, NAT REV CANCER, V12, P401, DOI 10.1038/nrc3262
   Widlund HR, 2003, ONCOGENE, V22, P3035, DOI 10.1038/sj.onc.1206443
   Wolpin BM, 2014, ONCOLOGIST, V19, P637, DOI 10.1634/theoncologist.2014-0086
   Xie L, 2019, ASIAN J UROL, V6, P312, DOI 10.1016/j.ajur.2019.04.003
   Xie YC, 2015, AUTOPHAGY, V11, P28, DOI 10.4161/15548627.2014.984267
   Yamamoto A, 1998, CELL STRUCT FUNCT, V23, P33, DOI 10.1247/csf.23.33
   Yang A, 2014, AUTOPHAGY, V10, P1683, DOI 10.4161/auto.29961
   Yasumoto K, 2002, EMBO J, V21, P2703, DOI 10.1093/emboj/21.11.2703
   Yu TC, 2017, CELL, V170, P548, DOI 10.1016/j.cell.2017.07.008
   Zeng CJ, 2016, GASTROENTEROLOGY, V150, P1633, DOI 10.1053/j.gastro.2016.02.076
   Zhan HQ, 2010, J CLIN ONCOL, V28, pE709, DOI 10.1200/JCO.2010.30.3172
   Zhang JB, 2016, ONCOTARGET, V7, P75659, DOI 10.18632/oncotarget.12318
   Zhang ZL, 2017, BIOMED PHARMACOTHER, V89, P1055, DOI 10.1016/j.biopha.2017.02.103
   ZHAO GQ, 1993, MOL CELL BIOL, V13, P4505, DOI 10.1128/MCB.13.8.4505
   Zhitomirsky B, 2015, ONCOTARGET, V6, P1143, DOI 10.18632/oncotarget.2732
   Zhong MH, 2012, AM J SURG PATHOL, V36, P654, DOI 10.1097/PAS.0b013e31824f24a6
   Zoncu R, 2011, SCIENCE, V334, P678, DOI 10.1126/science.1207056
NR 138
TC 10
Z9 11
U1 6
U2 15
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0024-3205
EI 1879-0631
J9 LIFE SCI
JI Life Sci.
PD MAR 1
PY 2020
VL 244
AR 117341
DI 10.1016/j.lfs.2020.117341
PG 12
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA KK8OT
UT WOS:000512996400024
PM 31972208
DA 2022-04-25
ER

PT J
AU Zhang, RJ
   Yu, QY
   Lu, WQ
   Shen, J
   Zhou, DQ
   Wang, YJ
   Gao, SR
   Wang, ZJ
AF Zhang, Ruijuan
   Yu, Qianyun
   Lu, Wenqiang
   Shen, Jun
   Zhou, Dongqing
   Wang, Yingjue
   Gao, Shurong
   Wang, Zhijun
TI Grape seed procyanidin B2 promotes the autophagy and apoptosis in
   colorectal cancer cells via regulating PI3K/Akt signaling pathway
SO ONCOTARGETS AND THERAPY
LA English
DT Article
DE colorectal cancer; grape seed procyanidin extract; autophagy; apoptosis;
   PI3K/Akt/mTOR dsignaling pathway
ID ENDOPLASMIC-RETICULUM STRESS; INHIBITION; EXTRACT
AB Aim: Colorectal cancer (CRC) is a major malignancy in China, which is the critical risk of people health. Many natural herbs extracts have been found to exhibit good therapeutic effect on CRC. Our previous study found that grape seed procyanidins B2 (PB2) would induce CRC cell death. However, the molecular mechanism underlying its anti-tumor effect on CRC remains unclear. Thereby, this study aimed to investigate the anti-tumor mechanism of PB2 on CRC.
   Methods: CCK-8, western blotting, flow cytometry, qRT-PCR and animal study were used in the current study.
   Results: The in vitro and in vivo data demonstrated that PB2 could promote the apoptosis of CRC cells in a dose-dependent manner, which was significantly reversed by caspase 3 inhibitor. Meanwhile, PB2 dose-dependently induced autophagy in CRC cells, which was markedly attenuated by autophagy inhibitor 3-MA. In addition, PB2 dose-dependently inhibited the expressions of p-PI3K, p-Akt and p-mTOR in the cells.
   Conclusion: PB2 dose-dependently induced apoptosis and autophagy in CRC cells via downregulation of PI3K/Akt pathway. This study provided the experimental basis for further development of PB2 as a new effective anticancer drug for the patients with CRC.
C1 [Zhang, Ruijuan; Lu, Wenqiang; Shen, Jun; Zhou, Dongqing; Wang, Yingjue; Gao, Shurong; Wang, Zhijun] Shanghai Putuo Dist Peoples Hosp, Dept TCM, 1291 Jiangning Rd, Shanghai 200060, Peoples R China.
   [Yu, Qianyun] Shanghai Huangpu Dist Wuliqiao Community Hlth Ctr, Dept TCM, Shanghai 200023, Peoples R China.
RP Gao, SR; Wang, ZJ (corresponding author), Shanghai Putuo Dist Peoples Hosp, Dept TCM, 1291 Jiangning Rd, Shanghai 200060, Peoples R China.
EM shuronggao@yandex.com; zhijunwang90@126.com
FU independent innovation research fund of Shanghai Putuo District health
   system [KW15204]
FX This work was supported by Project supported by independent innovation
   research fund of Shanghai Putuo District health system (No. KW15204).
CR Afrin S, 2020, BIOTECHNOL ADV, V38, DOI 10.1016/j.biotechadv.2018.11.011
   Chang TC, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0210274
   Chen XH, 2018, J CANCER, V9, P1207, DOI 10.7150/jca.20964
   Chen ZH, 2013, DIGEST DIS SCI, V58, P2887, DOI 10.1007/s10620-013-2732-8
   Cheng X, 2018, CANCER LETT, V431, P105, DOI 10.1016/j.canlet.2018.05.046
   Choi AMK, 2013, NEW ENGL J MED, V368, P1845, DOI 10.1056/NEJMc1303158
   Derry MM, 2014, CURR CANCER DRUG TAR, V14, P323, DOI 10.2174/1568009614666140411101942
   Fan XJ, 2016, ONCOL REP, V36, P3559, DOI 10.3892/or.2016.5138
   Fang SC, 2019, ONCOTARGETS THER, V12, P985, DOI 10.2147/OTT.S189984
   Feng HR, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-1054-3
   Fiandalo M. V., 2012, Experimental Oncology, V34, P165
   Hussey S, 2008, J PEDIATR GASTR NUTR, V46, P496, DOI 10.1097/MPG.0b013e3181617895
   Kumar D, 2014, CANCER LETT, V343, P179, DOI 10.1016/j.canlet.2013.10.003
   Li T, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000014182
   Lu MJ, 2016, INT J ONCOL, V49, P603, DOI 10.3892/ijo.2016.3565
   Miura K, 2015, EXPERT OPIN DRUG DIS, V10, P411, DOI 10.1517/17460441.2015.1018174
   Ohsumi Y, 2014, CELL RES, V24, P9, DOI 10.1038/cr.2013.169
   Ouyang L, 2012, CELL PROLIFERAT, V45, P487, DOI 10.1111/j.1365-2184.2012.00845.x
   Pan P, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00997
   Pan ST, 2015, DRUG DES DEV THER, V9, P1601, DOI 10.2147/DDDT.S76057
   Qian HR, 2017, ONCOTARGET, V8, P62759, DOI 10.18632/oncotarget.18663
   Rossi M, 2010, CANCER CAUSE CONTROL, V21, P243, DOI 10.1007/s10552-009-9455-3
   Roy B, 2014, CHEM-BIOL INTERACT, V210, P96, DOI 10.1016/j.cbi.2014.01.003
   Saif MW, 2010, CANCER J, V16, P196, DOI 10.1097/PPO.0b013e3181e076af
   Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387
   Tsai DH, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-35780-y
   Yang L, 2016, ONCOL LETT, V12, P3771, DOI 10.3892/ol.2016.5213
   Yin WB, 2015, J CARDIOVASC PHARM, V65, P13, DOI 10.1097/FJC.0000000000000157
   Zhang JX, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/4350965
   Zhang Z, 2013, BBA-MOL BASIS DIS, V1832, P805, DOI 10.1016/j.bbadis.2013.02.022
   Zhu J, 2018, MED SCI MONITOR, V24, P7035, DOI 10.12659/MSM.910650
NR 31
TC 17
Z9 17
U1 3
U2 6
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-6930
J9 ONCOTARGETS THER
JI OncoTargets Ther.
PY 2019
VL 12
BP 4109
EP 4118
DI 10.2147/OTT.S195615
PG 10
WC Biotechnology & Applied Microbiology; Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Oncology
GA HZ8ZM
UT WOS:000469145400003
PM 31213831
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Ge, J
   Liu, Y
   Li, Q
   Guo, X
   Gu, L
   Ma, ZG
   Zhu, YP
AF Ge Jiao
   Liu Yan
   Li Qiang
   Guo Xia
   Gu Ling
   Ma Zhi Gui
   Zhu Yi Ping
TI Resveratrol Induces Apoptosis and Autophagy in T-cell Acute
   Lymphoblastic Leukemia Cells by Inhibiting Akt/mTOR and Activating
   p38-MAPK
SO BIOMEDICAL AND ENVIRONMENTAL SCIENCES
LA English
DT Article
DE Resveratrol; Apoptosis; Autophagy; T-cell acute lymphoblastic leukemia;
   Akt/mTOR; p38-MAPK
ID PI3K/AKT/MTOR PATHWAY; MULTITARGETED AGENT; COLON-CANCER; CYCLE ARREST;
   IN-VITRO; CROSSTALK; BECLIN-1; TARGET; MCF-7
AB Objective To explore the effects of resveratrol-induced apoptosis and autophagy in T-cell acute lymphoblastic leukemia (T-ALL) cells and potential molecular mechanisms.
   Methods The anti-proliferation effect of resveratrol-induced, apoptosis and autophagy on T-ALL cells were detected by using MU test, immunofluorescence, electronic microscope, and flow cytometry, respectively. Western blotting was performed for detecting changes of apoptosis-associated proteins, cell cycle regulatory proteins and state of activation of Akt, mTOR, p70S6K, 4E-BP1, and p38-MAPK.
   Results Resveratrol inhibited the proliferation and induced apoptosis and autophagy in T-ALL cells in a dose and time-dependent manner. It also induced cell cycle arrest at G0/G1 phase via up regulating cyclin-dependent kinase (CDK) inhibitors p21 and p27 and down regulating cyclin A and cyclin D1. Western blotting revealed that resveratrol significantly decreased the expression of antiapoptotic proteins (Mcl-1 and Bcl-2) and increased the expression of proapoptotic proteins (Bax, Bim, and Bad), and induced cleaved-caspase-3 in a time-dependent manner. Significant increase in ratio of LC3-II/LC3-1 and Beclin 1 was also detected. Furthermore, resveratrol induced significant dephosphorylation of Akt, mTOR, p70S6K, and 4E-BP1, but enhanced specific phosphorylation of p38-MAPK which could be blocked by SB203580. When autophagy was suppressed by 3-MA, apoptosis in T-ALL cells induced by resveratrol was enhanced.
   Conclusion Our findings have suggested that resveratrol induces cell cycle arrest, apoptosis, and autophagy in T-ALL cells through inhibiting Akt/mTOR/p70S6K/4E-BP1 and activating p38-MAPK signaling pathways. Autophagy might play a role as a self-defense mechanism in T-ALL cells treated by resveratrol. Therefore, the reasonable inhibition of autophagy in T-ALL cells may serve as a promising strategy for resveratrol induced apoptosis and can be used as adjuvant chemotherapy for T-ALL.
C1 [Ge Jiao; Liu Yan; Li Qiang; Guo Xia; Gu Ling; Ma Zhi Gui; Zhu Yi Ping] Sichuan Univ, West China Univ Hosp 2, Dept Pediat Hematol Oncol, Chengdu 610041, Sichuan, Peoples R China.
RP Li, Q (corresponding author), Sichuan Univ, West China Univ Hosp 2, Dept Pediat Hematol Oncol, Chengdu 610041, Sichuan, Peoples R China.
EM lqcm2000@yahoo.com.cn
OI Gu, Ling/0000-0002-2410-1696
FU Department of Science and Technology of Sichuan Province, China
   [2008JY0029-1, 07FG002-024]; Program for Changjiang Scholars and
   Innovative-Research Team in UniversityProgram for Changjiang Scholars &
   Innovative Research Team in University (PCSIRT) [IRT0935]
FX This study was supported by grants from the Department of Science and
   Technology of Sichuan Province, China (No. 2008JY0029-1 and No.
   07FG002-024) and research funds from the Program for Changjiang Scholars
   and Innovative-Research Team in University (No. IRT0935).
CR Abedin MJ, 2007, CELL DEATH DIFFER, V14, P500, DOI 10.1038/sj.cdd.4402039
   Bai Y, 2010, CANCER SCI, V101, P488, DOI 10.1111/j.1349-7006.2009.01415.x
   Benitez DA, 2007, J ANDROL, V28, P282, DOI 10.2164/jandrol.106.000968
   Cecchinato V, 2007, BIOCHEM PHARMACOL, V74, P1568, DOI 10.1016/j.bcp.2007.08.001
   Cheng GZ, 2008, CURR CANCER DRUG TAR, V8, P2
   Ciechomska IA, 2009, ONCOGENE, V28, P2128, DOI 10.1038/onc.2009.60
   Cully M, 2006, NAT REV CANCER, V6, P184, DOI 10.1038/nrc1819
   Dorrie J, 2001, CANCER RES, V61, P4731
   Filomeni G, 2007, GENES NUTR, V2, P295, DOI 10.1007/s12263-007-0059-9
   Furuya N, 2005, AUTOPHAGY, V1, P46, DOI 10.4161/auto.1.1.1542
   Gatouillat G, 2010, J CELL BIOCHEM, V110, P893, DOI 10.1002/jcb.22601
   Germain M, 2011, AUTOPHAGY, V7, P549, DOI 10.4161/auto.7.5.15098
   Gordy C, 2012, PROTEIN CELL, V3, P17, DOI 10.1007/s13238-011-1127-x
   Gu L, 2010, J EXP CLIN CANC RES, V29, DOI 10.1186/1756-9966-29-150
   Harikumar KB, 2008, CELL CYCLE, V7, P1020, DOI 10.4161/cc.7.8.5740
   Harikumar KB, 2010, INT J CANCER, V127, P257, DOI 10.1002/ijc.25041
   Jang MS, 1997, SCIENCE, V275, P218, DOI 10.1126/science.275.5297.218
   Jung CH, 2010, FEBS LETT, V584, P1287, DOI 10.1016/j.febslet.2010.01.017
   Lockshin RA, 2004, INT J BIOCHEM CELL B, V36, P2405, DOI 10.1016/j.biocel.2004.04.011
   LoPiccolo J, 2008, DRUG RESIST UPDATE, V11, P32, DOI 10.1016/j.drup.2007.11.003
   Lv XC, 2012, CAN J PHYSIOL PHARM, V90, P655, DOI [10.1139/Y2012-051, 10.1139/y2012-051]
   Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239
   Miki H, 2012, INT J ONCOL, V40, P1020, DOI 10.3892/ijo.2012.1325
   Morgensztern D, 2005, ANTI-CANCER DRUG, V16, P797, DOI 10.1097/01.cad.0000173476.67239.3b
   Munafo DB, 2001, J CELL SCI, V114, P3619
   Parekh P, 2011, EXP TOXICOL PATHOL, V63, P167, DOI 10.1016/j.etp.2009.11.005
   Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002
   Saiki S, 2011, AUTOPHAGY, V7, P176, DOI 10.4161/auto.7.2.14074
   Sinha S, 2008, ONCOGENE, V27, pS137, DOI 10.1038/onc.2009.51
   Tang FY, 2008, MOL NUTR FOOD RES, V52, P683, DOI 10.1002/mnfr.200700325
   Tanida I, 2011, ANTIOXID REDOX SIGN, V14, P2201, DOI 10.1089/ars.2010.3482
   Tanida I, 2010, METHODS MOL BIOL, V648, P193, DOI 10.1007/978-1-60761-756-3_13
   Thyagarajan A, 2010, NUTR CANCER, V62, P630, DOI 10.1080/01635580903532390
   van Grotel M, 2008, LEUKEMIA, V22, P124, DOI 10.1038/sj.leu.2404957
   White E, 2009, CLIN CANCER RES, V15, P5308, DOI 10.1158/1078-0432.CCR-07-5023
   Yang ZNJ, 2011, MOL CANCER THER, V10, P1533, DOI 10.1158/1535-7163.MCT-11-0047
   Zhang X, 2012, CELL PROLIFERAT, DOI 10.111141365-2184.2012.00833.x
   Zhang Ya-hong, 2011, Yaoxue Xuebao, V46, P1332
NR 38
TC 84
Z9 99
U1 0
U2 21
PU CHINESE CENTER DISEASE CONTROL & PREVENTION
PI BEIJING
PA 155 CHANGBAI RD, CHANGPING DISTRICT, BEIJING, 102206, PEOPLES R CHINA
SN 0895-3988
J9 BIOMED ENVIRON SCI
JI Biomed. Environ. Sci.
PD NOV
PY 2013
VL 26
IS 11
BP 902
EP 911
DI 10.3967/bes2013.019
PG 10
WC Environmental Sciences; Public, Environmental & Occupational Health
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
   Health
GA AA2HW
UT WOS:000330916700005
PM 24331535
DA 2022-04-25
ER

PT J
AU McMahon, KM
   Volpato, M
   Chi, HY
   Musiwaro, P
   Poterlowicz, K
   Peng, Y
   Scally, AJ
   Patterson, LH
   Phillips, RM
   Sutton, CW
AF McMahon, K. M.
   Volpato, M.
   Chi, H. Y.
   Musiwaro, P.
   Poterlowicz, K.
   Peng, Y.
   Scally, A. J.
   Patterson, L. H.
   Phillips, R. M.
   Sutton, C. W.
TI Characterization of Changes in the Proteome in Different Regions of 3D
   Multicell Tumor Spheroids
SO JOURNAL OF PROTEOME RESEARCH
LA English
DT Article
DE cancer; spheroids; proteomics; autophagy; necrosis; hypoxia; metabolic
   processes; lipid metabolism
ID CYCLE INHIBITOR P27(KIP1); BIOREDUCTIVE DRUGS; CELL-CULTURE; EXPRESSION;
   HYPOXIA; MONOLAYER; CARCINOMA; NECROSIS; GLUCOSE; MODELS
AB Three dimensional multicell tumor spheroids (MCTS) provide an experimental model where the influence of microenvironmental conditions on protein expression can be determined. Sequential trypsin digestion of HT29 colon carcinoma MCTS enabled segregation into four populations comprising proliferating cells from the surface (SL), an intermediate region (IR), nonproliferating hypoxic cells from the perinecrotic region (PN), and a necrotic core (NC). Total protein was extracted from each population and subjected to iTRAQ-based quantitative proteomics analysis. From a total of 887 proteins identified, 209 were observed to be up-regulated and 114 were down-regulated in the PN and NC regions relative to the SL. Among the up-regulated proteins, components of glycolysis, TCA cycle, lipid metabolism, and steroid biosynthesis increased progressively toward the PN and NC regions. Western blotting, immunohistochemistry, and enzyme assays confirmed that significant changes in the expression of proteins involved in cellular metabolism occur in the nonproliferating fraction of cells within the viable rim. The presence of full length, functional proteins within the NC was unexpected, and further analysis demonstrated that this region contains cells that are undergoing autophagy. This study has identified possible targets that may be suitable for therapeutic intervention, and further studies to validate these are required.
C1 [McMahon, K. M.; Volpato, M.; Chi, H. Y.; Musiwaro, P.; Patterson, L. H.; Phillips, R. M.; Sutton, C. W.] Univ Bradford, Inst Canc Therapeut, Bradford BD7 1DP, W Yorkshire, England.
   [Poterlowicz, K.; Peng, Y.] Univ Bradford, Dept Comp, Bradford BD7 1DP, W Yorkshire, England.
   [Scally, A. J.] Univ Bradford, Sch Hlth Studies, Bradford BD7 1DP, W Yorkshire, England.
RP Phillips, RM (corresponding author), Univ Bradford, Inst Canc Therapeut, Bradford BD7 1DP, W Yorkshire, England.
EM r.m.phillips@Bradford.ac.uk; c.w.sutton@bradford.ac.uk
RI Poterlowicz, Krzysztof/AAS-2395-2020; Peng, Yonghong/A-5778-2013;
   Phillips, Roger M/I-5803-2017; Peng, Yonghong/ABD-5633-2021
OI Poterlowicz, Krzysztof/0000-0001-6173-5674; Peng,
   Yonghong/0000-0002-8806-2075; Phillips, Roger M/0000-0003-3504-177X;
   Sutton, Chris/0000-0002-1548-5093; Scally, Andy/0000-0002-6189-2247
FU Agilent Technologies UK; EPSRCUK Research & Innovation (UKRI)Engineering
   & Physical Sciences Research Council (EPSRC); Yorkshire Cancer Research
FX We thank Sham Naal and Agilent Technologies UK for their cosponsorship,
   with the EPSRC grant awarding body, for the support of KM. and Yorkshire
   Cancer Research for the support of C.S. Thanks to Tavga Mohammed, Hajer
   Omar, Asma Omar and Rafiqul Fysal for their technical support.
CR Altmann Brigitte, 2009, World J Stem Cells, V1, P43, DOI 10.4252/wjsc.v1.i1.43
   Benita Y, 2009, NUCLEIC ACIDS RES, V37, P4587, DOI 10.1093/nar/gkp425
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   Buzzai M, 2005, ONCOGENE, V24, P4165, DOI 10.1038/sj.onc.1208622
   Catzavelos C, 1999, CANCER RES, V59, P684
   DAMSKY CH, 1994, DEVELOPMENT, V120, P3657
   Dice JF, 2007, AUTOPHAGY, V3, P295, DOI 10.4161/auto.4144
   DURAND RE, 1992, INT J RADIAT ONCOL, V22, P689, DOI 10.1016/0360-3016(92)90504-B
   Espina V., 2011, PLOS ONE, V5
   ESSAND M, 1995, INT J CANCER, V63, P387, DOI 10.1002/ijc.2910630315
   Fang DD, 2010, BRIT J CANCER, V102, P1265, DOI 10.1038/sj.bjc.6605610
   FREYER JP, 1986, CANCER RES, V46, P3504
   Friedrich J, 2007, INT J RADIAT BIOL, V83, P849, DOI 10.1080/09553000701727531
   Gaedtke L, 2007, J PROTEOME RES, V6, P4111, DOI 10.1021/pr0700596
   Groebe K, 1996, INT J RADIAT ONCOL, V34, P395, DOI 10.1016/0360-3016(95)02065-9
   Grun B, 2009, CELL PROLIFERAT, V42, P219, DOI 10.1111/j.1365-2184.2008.00579.x
   Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704
   Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809
   Hirschhaeuser F, 2010, J BIOTECHNOL, V148, P3, DOI 10.1016/j.jbiotec.2010.01.012
   Knowles HJ, 2001, ANTICANCER RES, V21, P2305
   Kumar HR, 2008, PEDIATR SURG INT, V24, P1229, DOI 10.1007/s00383-008-2245-2
   Lin Ruei-Zhen, 2008, Biotechnology Journal, V3, P1172, DOI 10.1002/biot.200700228
   McKeown SR, 2007, CLIN ONCOL-UK, V19, P427, DOI 10.1016/j.clon.2007.03.006
   MEDES G, 1953, CANCER RES, V13, P27
   Mees G, 2009, EUR J NUCL MED MOL I, V36, P1674, DOI 10.1007/s00259-009-1195-9
   Menchon C, 2011, CELL CYCLE, V10, P1435, DOI 10.4161/cc.10.9.15421
   Milotti E, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013942
   Mizushima N, 2002, CELL STRUCT FUNCT, V27, P421, DOI 10.1247/csf.27.421
   MuellerKlieser W, 1996, INT J HYPERTHER, V12, P501, DOI 10.3109/02656739609023527
   PHILLIPS RM, 1994, CANCER RES, V54, P3766
   Pietsch J, 2011, PROTEOMICS, V11, P2095, DOI 10.1002/pmic.201000817
   Poland J, 2002, ELECTROPHORESIS, V23, P1174, DOI 10.1002/1522-2683(200204)23:7/8<1174::AID-ELPS1174>3.0.CO;2-O
   Pozzi A, 2000, P NATL ACAD SCI USA, V97, P2202, DOI 10.1073/pnas.040378497
   Rathinam R, 2010, CANCER METAST REV, V29, P223, DOI 10.1007/s10555-010-9211-x
   Romero FJ, 1997, AM J PHYSIOL-CELL PH, V272, pC1507, DOI 10.1152/ajpcell.1997.272.5.C1507
   Singh R, 2009, NATURE, V458, P1131, DOI 10.1038/nature07976
   STEIN I, 1995, MOL CELL BIOL, V15, P5363
   Trebinska A, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-76
   Vaupel P, 2004, SEMIN RADIAT ONCOL, V14, P198, DOI 10.1016/j.semradonc.2004.04.008
   Vuoristo M, 2007, MELANOMA RES, V17, P215, DOI 10.1097/CMR.0b013e328270b935
NR 40
TC 49
Z9 50
U1 1
U2 22
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1535-3893
EI 1535-3907
J9 J PROTEOME RES
JI J. Proteome Res.
PD MAY
PY 2012
VL 11
IS 5
BP 2863
EP 2875
DI 10.1021/pr2012472
PG 13
WC Biochemical Research Methods
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 935BM
UT WOS:000303492100020
PM 22416669
DA 2022-04-25
ER

PT J
AU Wang, HY
   Wang, X
   Zhang, HY
   Deng, T
   Liu, R
   Liu, Y
   Li, HL
   Bai, M
   Ning, T
   Wang, JY
   Ge, SH
   Ba, Y
AF Wang, Huiya
   Wang, Xia
   Zhang, Haiyang
   Deng, Ting
   Liu, Rui
   Liu, Ying
   Li, Hongli
   Bai, Ming
   Ning, Tao
   Wang, Junyi
   Ge, Shaohua
   Ba, Yi
TI The HSF1/miR-135b-5p axis induces protective autophagy to promote
   oxaliplatin resistance through the MUL1/ULK1 pathway in colorectal
   cancer
SO ONCOGENE
LA English
DT Article
ID ADJUVANT CHEMOTHERAPY; OPEN-LABEL; CELLS; CHEMORESISTANCE; MIR-135B-5P;
   MICRORNAS; TUMORIGENESIS; FLUOROURACIL; LEUCOVORIN; MECHANISM
AB Oxaliplatin (oxa) is widely used in the treatment of colorectal cancer (CRC), but the development of oxaliplatin resistance is a major obstacle to the therapeutic efficacy in patients. MicroRNAs (miRNAs), endogenous noncoding RNAs measuring between 22 and 24 nucleotides, have been shown to be involved in the development of CRC drug resistance. However, the mechanism by which differentially expressed miRNAs induce chemotherapy resistance in CRC has not been fully elucidated to date. Here, we showed the differentially expressed miRNAs in oxaliplatin-sensitive and oxaliplatin-resistant CRC cells through miRNA microarray technology and found that miR-135b-5p was significantly increased in oxaliplatin-resistant cells. And miR-135b-5p was increased in the serum of colorectal cancer patients. More importantly, the miR-135b-5p level in the serum of oxaliplatin-resistant patients was further increased compared to that of oxaliplatin-sensitive patients. Recent studies have shown that protective autophagy is an important mechanism that promotes drug resistance in tumors. The potential role of miR-135b-5p in inducing protective autophagy and promoting oxaliplatin resistance was evaluated in two stable oxaliplatin-resistant CRC cell lines and their parental cells. We further identified MUL1 as a direct downstream target of miR-135b-5p and showed that MUL1 could degrade the key molecule of autophagy, ULK1, through ubiquitination. Mouse xenograft models were adopted to evaluate the correlation between miR-135b-5p and oxaliplatin-induced autophagy in vivo. Furthermore, we also investigated the regulatory factors for the upregulation of miR-135b-5p in CRC cells under oxaliplatin chemotoxicity. These results indicated that miR-135b-5p upregulation in colorectal cancer could induce protective autophagy through the MUL1/ULK1 signaling pathway and promote oxaliplatin resistance. Targeting miR-135b-5p may provide a new treatment strategy for reversing oxaliplatin resistance in CRC.
C1 [Wang, Huiya; Wang, Xia; Zhang, Haiyang; Deng, Ting; Liu, Rui; Liu, Ying; Li, Hongli; Bai, Ming; Ning, Tao; Wang, Junyi; Ge, Shaohua; Ba, Yi] Tianjin Med Univ Canc Inst & Hosp, Natl Clin Res Ctr Canc, Key Lab Canc Prevent & Therapy, Tianjins Clin Res Ctr Canc, Tianjin, Peoples R China.
RP Ba, Y (corresponding author), Tianjin Med Univ Canc Inst & Hosp, Natl Clin Res Ctr Canc, Key Lab Canc Prevent & Therapy, Tianjins Clin Res Ctr Canc, Tianjin, Peoples R China.
EM bayi@tjmuch.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [82072664, 81772629, 81802363, 81702431,
   81772843, 81974374]; Demonstrative Research Platform of Clinical
   Evaluation Technology for New Anticancer Drugs [2018ZX09201015]; Tianjin
   Science FoundationNatural Science Foundation of Tianjin [18JCQNJC81900,
   18JCYBJC92000, 18JCYBJC25400, 18JCYBJC92900, 20JCYBJC00100]; Science &
   Technology Development Fund of the Tianjin Education Commission for
   Higher Education [2018KJ046, 2017KJ227]
FX This work was supported by grants from the National Natural Science
   Foundation of China (Nos. 82072664, 81772629, 81802363, 81702431,
   81772843, 81974374) and the Demonstrative Research Platform of Clinical
   Evaluation Technology for New Anticancer Drugs (No. 2018ZX09201015).
   This work was also supported by the Tianjin Science Foundation (Nos.
   18JCQNJC81900, 18JCYBJC92000, 18JCYBJC25400, 18JCYBJC92900,
   20JCYBJC00100) and the Science & Technology Development Fund of the
   Tianjin Education Commission for Higher Education (2018KJ046,
   2017KJ227). The funders had no role in the study design, the data
   collection and analysis, the interpretation of the data, the writing of
   the report, and the decision to submit this article for publication.
CR Andre T, 2018, J CLIN ONCOL, V36, P1469, DOI 10.1200/JCO.2017.76.0355
   Bai M, 2019, MOL THER, V27, P1772, DOI 10.1016/j.ymthe.2019.06.018
   Bertoli G, 2015, THERANOSTICS, V5, P1122, DOI 10.7150/thno.11543
   Chen H, 2019, ONCOTARGETS THER, V12, P3869, DOI 10.2147/OTT.S207938
   Dikic I, 2018, NAT REV MOL CELL BIO, V19, P349, DOI 10.1038/s41580-018-0003-4
   Filipowicz W, 2008, NAT REV GENET, V9, P102, DOI 10.1038/nrg2290
   Glick D, 2010, J PATHOL, V221, P3, DOI 10.1002/path.2697
   Goldberg RM, 2004, J CLIN ONCOL, V22, P23, DOI 10.1200/JCO.2004.09.046
   Hong YS, 2014, LANCET ONCOL, V15, P1245, DOI 10.1016/S1470-2045(14)70377-8
   Iqbal MA, 2019, MOL ASPECTS MED, V70, P3, DOI 10.1016/j.mam.2018.07.003
   Lee YS, 2009, ANNU REV PATHOL-MECH, V4, P199, DOI 10.1146/annurev.pathol.4.110807.092222
   Levy JMM, 2017, NAT REV CANCER, V17, P528, DOI 10.1038/nrc.2017.53
   Li J, 2015, AUTOPHAGY, V11, P1216, DOI 10.1080/15548627.2015.1017180
   Li W, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001487
   Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257
   Liu B, 2017, MOL CARCINOGEN, V56, P2669, DOI 10.1002/mc.22710
   Liu T, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0981-7
   Lorente J, 2018, BIOL REV, V93, P152, DOI 10.1111/brv.12337
   Lv ZD, 2019, J CELL PHYSIOL, V234, P10819, DOI 10.1002/jcp.27906
   Magalhaes L, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4980-7
   Miller KD, 2019, CA-CANCER J CLIN, V69, P363, DOI 10.3322/caac.21565
   Mishra S, 2016, CRIT REV ONCOL HEMAT, V98, P12, DOI 10.1016/j.critrevonc.2015.10.003
   Mizushima N, 2011, CELL, V147, P728, DOI 10.1016/j.cell.2011.10.026
   Neuspiel M, 2008, CURR BIOL, V18, P102, DOI 10.1016/j.cub.2007.12.038
   Pan XF, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1660-8
   Poultsides GA, 2009, J CLIN ONCOL, V27, P3379, DOI 10.1200/JCO.2008.20.9817
   Puri R, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11636-5
   Rupaimoole R, 2017, NAT REV DRUG DISCOV, V16, P203, DOI 10.1038/nrd.2016.246
   Seo HA, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9010029
   Shao LL, 2019, FASEB J, V33, P264, DOI 10.1096/fj.201701456RR
   SLATER AFG, 1993, PHARMACOL THERAPEUT, V57, P203, DOI 10.1016/0163-7258(93)90056-J
   Su WM, 2016, BIOMED PHARMACOTHER, V84, P123, DOI 10.1016/j.biopha.2016.09.027
   Sun W, 2020, THERANOSTICS, V10, P1981, DOI 10.7150/thno.37621
   Umezu T, 2014, BLOOD, V124, P3748, DOI 10.1182/blood-2014-05-576116
   Vihervaara A, 2014, J CELL SCI, V127, P261, DOI 10.1242/jcs.132605
   Wang N, 2016, ONCOL LETT, V11, P543, DOI 10.3892/ol.2015.3970
   Wang Q, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00308
   Yang ZF, 2010, CURR OPIN CELL BIOL, V22, P124, DOI 10.1016/j.ceb.2009.11.014
   Yu L, 2018, AUTOPHAGY, V14, P207, DOI 10.1080/15548627.2017.1378838
   Yu TC, 2017, CELL, V170, P548, DOI 10.1016/j.cell.2017.07.008
   Zachari M, 2017, ESSAYS BIOCHEM, V61, P585, DOI 10.1042/EBC20170021
   Zhang BC, 2008, CELL RES, V18, P900, DOI 10.1038/cr.2008.75
   Zhang Y, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1024-3
   Zhang ZL, 2017, BIOMED PHARMACOTHER, V96, P1341, DOI 10.1016/j.biopha.2017.11.074
   Zhou CF, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01237-y
NR 45
TC 3
Z9 3
U1 6
U2 7
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 0950-9232
EI 1476-5594
J9 ONCOGENE
JI Oncogene
PD JUL 15
PY 2021
VL 40
IS 28
BP 4695
EP 4708
DI 10.1038/s41388-021-01898-z
EA JUN 2021
PG 14
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
GA TK8LG
UT WOS:000662838900005
PM 34140641
DA 2022-04-25
ER

PT J
AU Feng, J
   Li, Z
   Li, L
   Xie, HB
   Lu, QC
   He, XZ
AF Feng, Jin
   Li, Zhong
   Li, Ling
   Xie, Haibin
   Lu, Qicheng
   He, Xiaozhou
TI Hypoxia-induced circCCDC66 promotes the tumorigenesis of colorectal
   cancer via the miR-3140/autophagy pathway
SO INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
LA English
DT Article
DE colorectal cancer; circCCDC66; microRNA-3140; autophagy; hypoxia
ID GENE-EXPRESSION; PROGRESSION; INVASION; PROLIFERATION; MIGRATION;
   MIRNAS; GROWTH
AB Circular RNAs (circRNAs) have been reported to be involved in the progression of colorectal cancer (CRC). However, the biological role of circCCDC66 in CRC remains unclear. Therefore, the present study aimed to elucidate the mechanisms through which circCCDC66 affects the hypoxia-induced progression of CRC. It was found that hypoxia promoted the progression of CRC and upregulated the expression of circCCDC66. Furthermore, circCCDC66-knockdown reduced viability, migration and invasion, and enhanced the apoptosis of hypoxia-exposed CRC cells. Using the starBase database, it was identified that circCCDC66 may bind to miR-3140. Subsequently, it was confirmed that circCCDC66 serves as a sponge of miR-3140 and the depletion of miR-3140 partly abolished the effects of circCCDC66 on the phenotype of hypoxia-exposed CRC cells. In addition, miR-3140 was validated to inhibit the autophagy pathway. The use of an autophagy inducer partially reversed the miR-3140 overexpression-induced inhibition of the viability and invasion, and the promotion of the apoptosis of hypoxia-exposed CRC cells. In summary, the findings of the present study demonstrated that circCCDC66 facilitates the development of CRC cells under hypoxic conditions via regulation of miR-3140/autophagy. These findings may provide a novel therapeutic option for patients with CRC.
C1 [Feng, Jin; Li, Zhong; Li, Ling; Xie, Haibin; Lu, Qicheng] First Peoples Hosp Changzhou, Dept Gastrointestinal Surg, 185 Juqian St, Changzhou 213029, Jiangsu, Peoples R China.
   [He, Xiaozhou] First Peoples Hosp Changzhou, Dept Urol Surg, 185 Juqian St, Changzhou 213029, Jiangsu, Peoples R China.
RP Lu, QC (corresponding author), First Peoples Hosp Changzhou, Dept Gastrointestinal Surg, 185 Juqian St, Changzhou 213029, Jiangsu, Peoples R China.; He, XZ (corresponding author), First Peoples Hosp Changzhou, Dept Urol Surg, 185 Juqian St, Changzhou 213029, Jiangsu, Peoples R China.
EM qichenglu666@126.com; xiaozhouhe59@163.com
FU Applied Basic Research Project of Changzhou Science and Technology
   Bureau [J20180070]; Changzhou High-Level Medical Talents Training
   Project [2016-CZBJ046]
FX This work was supported by the Applied Basic Research Project of
   Changzhou Science and Technology Bureau (no.C J20180070) and Changzhou
   High-Level Medical Talents Training Project (no. 2016-CZBJ046).
CR Barrett SP, 2015, ELIFE, V4, DOI 10.7554/eLife.07540
   Bian LJ, 2018, BIOCHEM BIOPH RES CO, V505, P346, DOI 10.1016/j.bbrc.2018.09.073
   Brenner H, 2014, LANCET, V383, P1490, DOI 10.1016/S0140-6736(13)61649-9
   Bruera G, 2010, LANCET ONCOL, V11, P845, DOI [10.1016/S1470-2045(10)70175-3, DOI 10.1016/S1470-2045(10)70175-3]
   Bruera G, 2011, EXPERT OPIN BIOL TH, V11, P821, DOI 10.1517/14712598.2011.582462
   Che J, 2019, MOL CARCINOGEN, V58, P1234, DOI 10.1002/mc.23006
   Choi BJ, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-15139-5
   Dong YP, 2017, J HEMATOL ONCOL, V10, DOI 10.1186/s13045-016-0370-2
   Fang QY, 2020, EUR REV MED PHARMACO, V24, P2548, DOI 10.26355/eurrev_202003_20522
   Guo JU, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0409-z
   Hansen TB, 2013, NATURE, V495, P384, DOI 10.1038/nature11993
   He JH, 2020, FRONT GENET, V11, DOI 10.3389/fgene.2020.00009
   Hsiao KY, 2017, CANCER RES, V77, P2339, DOI 10.1158/0008-5472.CAN-16-1883
   Hu KF, 2020, MOL CELL PROBE, V52, DOI 10.1016/j.mcp.2020.101562
   Kim CW, 2018, CANCER LETT, V416, P31, DOI 10.1016/j.canlet.2017.12.018
   Li HB, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-6017-2
   Liang HT, 2020, BIOSCIENCE REP, V40, DOI 10.1042/BSR20193484
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Luan WK, 2018, BIOCHEM BIOPH RES CO, V502, P22, DOI 10.1016/j.bbrc.2018.05.114
   Meng SJ, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0663-2
   Ouyang L, 2012, CELL PROLIFERAT, V45, P487, DOI 10.1111/j.1365-2184.2012.00845.x
   Petrelli F, 2013, ANN ONCOL, V24, P186, DOI 10.1093/annonc/mds289
   Qureshi-Baig K, 2020, AUTOPHAGY, V16, P1436, DOI 10.1080/15548627.2019.1687213
   Ren SS, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1398-2
   Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI [10.3322/caac.21254, 10.3322/caac.21208, 10.1001/jamaoto.2014.2530, 10.1136/bmj.g1502]
   Sumazin P, 2011, CELL, V147, P370, DOI 10.1016/j.cell.2011.09.041
   Sun NH, 2020, CELL MOL BIOL LETT, V25, DOI 10.1186/s11658-020-00210-3
   Thomou T, 2017, NATURE, V542, P450, DOI 10.1038/nature21365
   Tonouchi E, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-22767-y
   Tu FL, 2020, AM J TRANSL RES, V12, P281
   Turchinovich A, 2012, TRENDS BIOCHEM SCI, V37, P460, DOI 10.1016/j.tibs.2012.08.003
   Ulimann P, 2019, CANCER LETT, V450, P32, DOI 10.1016/j.canlet.2019.02.030
   Wei SL, 2019, EBIOMEDICINE, V44, P182, DOI 10.1016/j.ebiom.2019.05.032
   Wei YS, 2019, AM J TRANSL RES, V11, P6838
   Zeng KX, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0454-8
   Zeng WH, 2020, CANCER CELL INT, V20, DOI 10.1186/s12935-020-1160-z
   Zhang L, 2019, INT J BIOL SCI, V15, P1091, DOI 10.7150/ijbs.31533
   Zheng HT, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/5958272
NR 38
TC 11
Z9 11
U1 4
U2 5
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1107-3756
EI 1791-244X
J9 INT J MOL MED
JI Int. J. Mol. Med.
PD DEC
PY 2020
VL 46
IS 6
BP 1973
EP 1982
DI 10.3892/ijmm.2020.4747
PG 10
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA OU2PZ
UT WOS:000591376800004
PM 33125087
OA hybrid, Green Published
DA 2022-04-25
ER

PT J
AU Usman, RM
   Razzaq, F
   Akbar, A
   Farooqui, AA
   Iftikhar, A
   Latif, A
   Hassan, H
   Zhao, JJ
   Carew, JS
   Nawrocki, ST
   Anwer, F
AF Usman, Rana Muhammad
   Razzaq, Faryal
   Akbar, Arshia
   Farooqui, Arafat Ali
   Iftikhar, Ahmad
   Latif, Azka
   Hassan, Hamza
   Zhao, Jianjun
   Carew, Jennifer S.
   Nawrocki, Steffan T.
   Anwer, Faiz
TI Role and mechanism of autophagy-regulating factors in tumorigenesis and
   drug resistance
SO ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Review
DE Autophagy-related genes; autophagy; drug resistance; hydroxychloroquine;
   tumorigenesis
ID MIGRATION INHIBITORY FACTOR; OVARIAN-CANCER CELLS; BREAST-CANCER; FACTOR
   MIF; THERAPEUTIC TARGET; SIGNALING PATHWAY; INDUCED APOPTOSIS;
   TUMOR-SUPPRESSOR; OVER-EXPRESSION; POOR-PROGNOSIS
AB A hallmark feature of tumorigenesis is uncontrolled cell division. Autophagy is regulated by more than 30 genes and it is one of several mechanisms by which cells maintain homeostasis. Autophagy promotes cancer progression and drug resistance. Several genes play important roles in autophagy-induced tumorigenesis and drug resistance includingBeclin-1, MIF, HMGB1, p53, PTEN, p62, RAC3, SRC3, NF-2, MEG3, LAPTM4B, mTOR, BRAFandc-MYC. These genes alter cell growth, cellular microenvironment and cell division. Mechanisms involved in tumorigenesis and drug resistance include microdeletions, genetic mutations, loss of heterozygosity, hypermethylation, microsatellite instability and translational modifications at a molecular level. Disrupted or altered autophagy has been reported in hematological malignancies like lymphoma, leukemia and myeloma as well as multiple solid organ tumors like colorectal, hepatocellular, gall bladder, pancreatic, gastric and cholangiocarcinoma among many other malignancies. In addition, defects in autophagy also play a role in drug resistance in cancers like osteosarcoma, ovarian and lung carcinomas following treatment with drugs such as doxorubicin, paclitaxel, cisplatin, gemcitabine and etoposide. Therapeutic approaches that modulate autophagy are a novel future direction for cancer drug development that may help to prevent issues with disease progression and overcome drug resistance.
C1 [Usman, Rana Muhammad] Univ Tennessee, Dept Med, Hlth Sci Ctr, Memphis, TN USA.
   [Razzaq, Faryal] Fdn Univ Med Coll, Islamabad, Pakistan.
   [Akbar, Arshia] Holy Family Hosp, Dept Med Intens Care, Rawalpindi, Pakistan.
   [Farooqui, Arafat Ali] King Edward Med Univ, Dept Med, Lahore, Pakistan.
   [Iftikhar, Ahmad; Carew, Jennifer S.; Nawrocki, Steffan T.] Univ Arizona, Dept Med, Tucson, AZ USA.
   [Latif, Azka] Crieghton Univ, Dept Med, Omaha, NE USA.
   [Hassan, Hamza] Boston Univ, Med Ctr, Dept Hematol & Med Oncol, Boston, MA USA.
   [Zhao, Jianjun; Anwer, Faiz] Cleveland Clin, Taussig Canc Ctr, Cleveland, OH 44106 USA.
RP Anwer, F (corresponding author), Cleveland Clin, Taussig Canc Ctr, Multiple Myeloma Program, Hematol,Oncol,Stem Cell Transplantat, Cleveland, OH 44195 USA.
EM ANWERF@ccf.org
OI Zhao, Jianjun/0000-0003-3008-3655
CR Alahari SV, 2016, INT REV CEL MOL BIO, V324, P229, DOI 10.1016/bs.ircmb.2016.01.004
   Amaravadi RK, 2012, AUTOPHAGY, V8, P1383, DOI 10.4161/auto.20958
   Anbarasu K, 2017, J RECEPT SIG TRANSD, V37, P51, DOI 10.3109/10799893.2016.1155069
   Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965
   Asare Y, 2013, THROMB HAEMOSTASIS, V109, P391, DOI 10.1160/TH12-11-0831
   Bach JP, 2008, ONCOLOGY-BASEL, V75, P127, DOI 10.1159/000155223
   Bacher M, 2003, AM J PATHOL, V162, P11, DOI 10.1016/S0002-9440(10)63793-5
   Barras D, 2015, BIOMARK CANC, V7, pS9
   Beltrami S, 2013, ANTICANCER RES, V33, P1
   Blakeley J, 2012, CURR OPIN OTOLARYNGO, V20, P372, DOI 10.1097/MOO.0b013e328357d2ee
   Bollag G, 2012, NAT REV DRUG DISCOV, V11, P873, DOI 10.1038/nrd3847
   Brezniceanu ML, 2003, FASEB J, V17, P1295, DOI 10.1096/fj.02-0621fje
   BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0
   Bucala R, 2007, IMMUNITY, V26, P281, DOI 10.1016/j.immuni.2007.03.005
   Cai D, 2010, CANCER RES, V70, P6477, DOI 10.1158/0008-5472.CAN-10-0005
   Cairns J, 2019, BREAST CANCER RES, V21, DOI 10.1186/s13058-019-1130-3
   Cebrian MJG, 2016, ANTICANCER RES, V36, P4381, DOI 10.21873/anticanres.10981
   Chen JH, 2018, MOL MED REP, V17, P6859, DOI 10.3892/mmr.2018.8686
   Chen J, 2012, J CELL PHYSIOL, V227, P3629, DOI 10.1002/jcp.24069
   Chen Q, 2012, HEPATOLOGY, V55, P1820, DOI 10.1002/hep.25549
   Cheng XJ, 2008, ANN ONCOL, V19, P527, DOI 10.1093/annonc/mdm469
   Cheng Y, 2013, PHARMACOL REV, V65, P1162, DOI 10.1124/pr.112.007120
   Choudhary S, 2013, CARCINOGENESIS, V34, P2891, DOI 10.1093/carcin/bgt239
   Chude CI, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18061279
   Citi V, 2018, CANCER CHEMOTH PHARM, V81, P745, DOI 10.1007/s00280-018-3543-6
   Colo GP, 2008, ONCOGENE, V27, P2430, DOI 10.1038/sj.onc.1210900
   Corcoran RB, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2001148
   Dessein AF, 2010, CANCER RES, V70, P4644, DOI 10.1158/0008-5472.CAN-09-3828
   Dihge L, 2008, BREAST CANCER RES TR, V109, P255, DOI 10.1007/s10549-007-9645-1
   Donohue E, 2013, J CANCER, V4, P585, DOI 10.7150/jca.7030
   Ebert C, 1999, AM J PATHOL, V155, P627, DOI 10.1016/S0002-9440(10)65158-9
   Emery CM, 2009, P NATL ACAD SCI USA, V106, P20411, DOI 10.1073/pnas.0905833106
   Eum KH, 2011, MOL CELLS, V31, P231, DOI 10.1007/s10059-011-0034-6
   Faivre S, 2016, PREDICTIVE BIOMARKER, P217
   Feng Y, 2016, ONCOTARGET, V7, P81402, DOI 10.18632/oncotarget.13233
   Feng YQ, 2017, ARCH BIOCHEM BIOPHYS, V623, P20, DOI 10.1016/j.abb.2017.05.001
   Rubio MF, 2017, CANCER CELL INT, V17, DOI 10.1186/s12935-017-0483-x
   Fu LL, 2013, INT J BIOCHEM CELL B, V45, P921, DOI 10.1016/j.biocel.2013.02.007
   Galluzzi L, 2017, EMBO J, V36, P1811, DOI 10.15252/embj.201796697
   Gasparri ML, 2017, GEBURTSH FRAUENHEILK, V77, P1095, DOI 10.1055/s-0043-118907
   Giamas G, 2011, NAT MED, V17, P715, DOI 10.1038/nm.2351
   Hamurcu Z, 2018, J CANCER RES CLIN, V144, P415, DOI 10.1007/s00432-017-2557-5
   Han I, 2008, CLIN ORTHOP RELAT R, V466, P2107, DOI 10.1007/s11999-008-0333-1
   Han WD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018691
   He H, 2003, J BIOL CHEM, V278, P29278, DOI 10.1074/jbc.M303800200
   Henson E, 2017, CANCERS, V9, DOI 10.3390/cancers9040027
   Henson ES, 2006, CELL SIGNAL, V18, P2089, DOI 10.1016/j.cellsig.2006.05.015
   Hospital SNUB, 2019, AZD8186 PACL ADV GAS
   Hu YM, 2017, BIOMED PHARMACOTHER, V88, P562, DOI 10.1016/j.biopha.2017.01.110
   Huang J, 2012, CANCER RES, V72, P230, DOI 10.1158/0008-5472.CAN-11-2001
   Institute NC, 2011, Z END HYDR TREAT PAT
   Institute NC, 2015, HER2 NEG BREAST CANC
   Jancik S, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/150960
   Janes MR, 2018, CELL, V172, P578, DOI 10.1016/j.cell.2018.01.006
   Jiang LL, 2014, ONCOL REP, V32, P1931, DOI 10.3892/or.2014.3432
   Jiang LX, 2016, ONCOL LETT, V11, P2699, DOI 10.3892/ol.2016.4298
   Kaur J, 2015, NAT REV MOL CELL BIO, V16, P461, DOI 10.1038/nrm4024
   Kawakami H, 2016, MOL CANCER THER, V15, P3015, DOI 10.1158/1535-7163.MCT-16-0017
   Kent OA, 2018, HEPATOBIL SURG NUTR, V7, P403, DOI 10.21037/hbsn.2018.07.03
   Kessler D, 2019, P NATL ACAD SCI USA, V116, P15823, DOI 10.1073/pnas.1904529116
   Kong BY, 2016, MELANOMA MANAG, V3, P33, DOI 10.2217/mmt.15.38
   Li L, 2010, ONCOGENE, V29, P5785, DOI 10.1038/onc.2010.303
   Li X, 2020, MOL CANCER, V19, DOI 10.1186/s12943-019-1085-0
   Li Y, 2007, ONCOL REP, V17, P377
   Li Y, 2010, NAT MED, V16, P214, DOI 10.1038/nm.2090
   Li ZY, 2018, BIOMED PHARMACOTHER, V104, P181, DOI 10.1016/j.biopha.2018.05.047
   Lim D, 2016, HIGH NRF2 P62 COEXPR
   Liu XR, 2009, CANCER SCI, V100, P2335, DOI 10.1111/j.1349-7006.2009.01346.x
   Liu Y, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.300
   Luo G, 2015, CELL PHYSIOL BIOCHEM, V37, P2209, DOI 10.1159/000438577
   Marino G, 2007, J BIOL CHEM, V282, P18573, DOI 10.1074/jbc.M701194200
   Marquez RT, 2012, AM J CANCER RES, V2, P214
   Meng Y, 2016, ONCOGENE, V35, P6359, DOI 10.1038/onc.2016.189
   Meyer A, 2008, LEUKEMIA LYMPHOMA, V49, P1184, DOI 10.1080/10428190802064909
   Meyer-Siegler KL, 2002, CANCER-AM CANCER SOC, V94, P1449, DOI 10.1002/cncr.10354
   Mitchell RA, 2004, CELL SIGNAL, V16, P13, DOI 10.1016/j.cellsig.2003.07.002
   Mitra A, 2015, J INVEST DERMATOL, V135, P2873, DOI 10.1038/jid.2015.252
   Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639
   Mizushima N, 2007, GENE DEV, V21, P2861, DOI 10.1101/gad.1599207
   Mizushima N, 2007, ANNU REV NUTR, V27, P19, DOI 10.1146/annurev.nutr.27.061406.093749
   Modali SD, 2015, MOL ENDOCRINOL, V29, P224, DOI 10.1210/me.2014-1304
   Molina JR, 2012, ONCOGENE, V31, P1264, DOI 10.1038/onc.2011.324
   Madeira MFM, 2012, MICROBES INFECT, V14, P198, DOI 10.1016/j.micinf.2011.09.005
   Nishihira J, 2000, J INTERF CYTOK RES, V20, P751, DOI 10.1089/10799900050151012
   Normanno N, 2005, CURR DRUG TARGETS, V6, P243, DOI 10.2174/1389450053765879
   Ohta S, 2012, J CELL SCI, V125, P3210, DOI 10.1242/jcs.102210
   Osborne CK, 2003, J NATL CANCER I, V95, P353, DOI 10.1093/jnci/95.5.353
   Pan BZ, 2015, ONCOTARGET, V6, P317, DOI 10.18632/oncotarget.2787
   Pan BZ, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-165
   Park JM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100819
   Pellegrini P, 2014, AUTOPHAGY, V10, P562, DOI 10.4161/auto.27901
   Petrilli AM, 2016, ONCOGENE, V35, P537, DOI 10.1038/onc.2015.125
   Pietrocola F, 2016, AUTOPHAGY, V12, P1962, DOI 10.1080/15548627.2016.1214778
   Plotkin SR, 2009, J NEURO-ONCOL, V93, P61, DOI 10.1007/s11060-009-9867-7
   Populo H, 2012, INT J MOL SCI, V13, P1886, DOI 10.3390/ijms13021886
   Porru M, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0719-1
   Qin R, 2013, NEOPLASMA, V60, P486, DOI 10.4149/neo_2013_063
   Roy M, 2016, THERANOSTICS, V6, P2209, DOI 10.7150/thno.15584
   Schroeder RD, 2014, ONCOTARGET, V5, P67, DOI 10.18632/oncotarget.1557
   Selvendiran K, 2007, J BIOL CHEM, V282, P28609, DOI 10.1074/jbc.M703796200
   Shi Y, 2018, ONCOL LETT, V15, P1917, DOI 10.3892/ol.2017.7463
   Simpson L, 2001, EXP CELL RES, V264, P29, DOI 10.1006/excr.2000.5130
   SITHANANDAM G, 1990, ONCOGENE, V5, P1775
   Stebbing J, 2013, ONCOGENE, V32, P3371, DOI 10.1038/onc.2012.343
   Stebbing J, 2018, ONCOGENE, V37, P3113, DOI 10.1038/s41388-018-0197-0
   Steele AJ, 2008, BLOOD, V112, P3827, DOI 10.1182/blood-2008-05-156380
   Sun Y, 2010, CANCER LETT, V294, P204, DOI 10.1016/j.canlet.2010.02.001
   Suren D, 2014, MED SCI MONITOR, V20, P530, DOI 10.12659/MSM.890531
   Takahashi Hideo, 2016, Nihon Rinsho, V74, P703
   Takamura A, 2011, GENE DEV, V25, P795, DOI 10.1101/gad.2016211
   Tang DL, 2010, J CELL BIOL, V190, P881, DOI 10.1083/jcb.200911078
   Tao H, 2017, MOL MED REP, V16, P1701, DOI 10.3892/mmr.2017.6828
   Tian T, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20030755
   Toton E, 2014, J PHYSIOL PHARMACOL, V65, P459
   Tsuboyama K, 2016, SCIENCE, V354, P1036, DOI 10.1126/science.aaf6136
   Utermark T, 2005, BRAIN PATHOL, V15, P17
   van Rensburg HJJ, 2017, J THORAC DIS, V9, P3533, DOI 10.21037/jtd.2017.09.34
   Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839
   Wajapeyee N, 2008, CELL, V132, P363, DOI 10.1016/j.cell.2007.12.032
   Wang L, 2016, EBIOMEDICINE, V7, P50, DOI 10.1016/j.ebiom.2016.03.022
   Wang L, 2015, ONCOL REP, V34, P2969, DOI 10.3892/or.2015.4278
   Wieduwilt MJ, 2008, CELL MOL LIFE SCI, V65, P1566, DOI 10.1007/s00018-008-7440-8
   Wu D, 2008, J PATHOL, V216, P167, DOI 10.1002/path.2391
   Wu Hui-Juan, 2007, Zhonghua Fu Chan Ke Za Zhi, V42, P612
   Wu JF, 2019, ONCOTARGETS THER, V12, P495, DOI 10.2147/OTT.S183940
   Wu MY, 2012, CELL RES, V22, P1003, DOI 10.1038/cr.2012.44
   Wu T, 2012, MOL MED REP, V5, P305, DOI 10.3892/mmr.2011.634
   Wu ZR, 2019, J ENDOCRINOL, V240, P1, DOI 10.1530/JOE-18-0203
   Xie ZP, 2007, NAT CELL BIOL, V9, P1102, DOI 10.1038/ncb1007-1102
   Xu JH, 2018, BIOCHEM BIOPH RES CO, V504, P123, DOI 10.1016/j.bbrc.2018.08.142
   Xu JM, 2009, NAT REV CANCER, V9, P615, DOI 10.1038/nrc2695
   Xu TW, 2019, ONCOTARGETS THER, V12, P365, DOI 10.2147/OTT.S185876
   Xu Y, 2010, ONCOGENE, V29, P3386, DOI 10.1038/onc.2010.90
   Xu Y, 2012, JPN J CLIN ONCOL, V42, P413, DOI 10.1093/jjco/hys026
   Yan XJ, 2006, GYNECOL ONCOL, V102, P348, DOI 10.1016/j.ygyno.2005.12.033
   Yang L, 2003, WORLD J GASTROENTERO, V9, P35, DOI 10.3748/wjg.v9.i1.35
   Yang X, 2017, CELL PHYSIOL BIOCHEM, V43, P1126, DOI 10.1159/000481754
   Ying HC, 2015, ONCOL LETT, V9, P1759, DOI 10.3892/ol.2015.2950
   Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100
   Zhang CY, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317701311
   Zhang LY, 2017, 2017 4TH INTERNATIONAL CONFERENCE ON TRANSPORTATION INFORMATION AND SAFETY (ICTIS), P12, DOI 10.1109/ICTIS.2017.8047734
   Zhang LF, 2014, PLOS ONE, V9, DOI [10.1371/journal.pone.0084950, 10.1371/journal.pone.0099946]
   Zheng H, 2016, DNA CELL BIOL, V35, P622, DOI 10.1089/dna.2016.3360
   Zhou HJ, 2005, CANCER RES, V65, P7976, DOI 10.1158/0008-5472.CAN-04-4076
   Zhou L, 2008, CANCER LETT, V264, P209, DOI 10.1016/j.canlet.2008.01.025
   Zhou L, 2010, AM J SURG, V199, P515, DOI 10.1016/j.amjsurg.2009.03.031
   Zhu JL, 2017, MOL THER-NUCL ACIDS, V7, P299, DOI 10.1016/j.omtn.2017.04.012
NR 147
TC 15
Z9 16
U1 12
U2 22
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1743-7555
EI 1743-7563
J9 ASIA-PAC J CLIN ONCO
JI Asia-Pac. J. Clin. Oncol.
PD JUN
PY 2021
VL 17
IS 3
BP 193
EP 208
DI 10.1111/ajco.13449
EA SEP 2020
PG 16
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA SU2TE
UT WOS:000572260000001
PM 32970929
OA Bronze
DA 2022-04-25
ER

PT J
AU Goder, A
   Nagel, G
   Kraus, A
   Dorsam, B
   Seiwert, N
   Kaina, B
   Fahrer, J
AF Goeder, Anja
   Nagel, Georg
   Kraus, Alexander
   Doersam, Bastian
   Seiwert, Nina
   Kaina, Bernd
   Fahrer, Jorg
TI Lipoic acid inhibits the DNA repair protein O-6-methylguanine-DNA
   methyltransferase (MGMT) and triggers its depletion in colorectal cancer
   cells with concomitant autophagy induction
SO CARCINOGENESIS
LA English
DT Article
ID BASE-EXCISION-REPAIR; AGE-RELATED LOSS; TUMOR-CELLS;
   O-6-ALKYLGUANINE-DNA ALKYLTRANSFERASE; ALKYLATING-AGENTS; INDUCED
   APOPTOSIS; OXIDATIVE STRESS; KAPPA-B; ALPHA; P53
AB Alkylating agents are present in food and tobacco smoke, but are also used in cancer chemotherapy, inducing the DNA lesion O-6-methylguanine. This critical adduct is repaired by O-6-methylguanine-DNA methyltransferase (MGMT), resulting in MGMT inactivation and degradation. In the present study, we analyzed the effects of the natural disulfide compound lipoic acid (LA) on MGMT in vitro and in colorectal cancer cells. We show that LA, but not its reduced form dihydrolipoic acid, potently inhibits the activity of recombinant MGMT by interfering with its catalytic Cys-145 residue, which was partially reversible by N-acetyl cysteine. Incubation of HCT116 colorectal cancer cells with LA altered their glutathione pool and caused a decline in MGMT activity. This was mirrored by LA-induced depletion of MGMT protein, which was not attributable to changes in MGMT messenger RNA levels. Loss of MGMT protein coincided with LA-induced autophagy, a process resulting in lysosomal degradation of proteins, including presumably MGMT. LA-stimulated autophagy in a p53-independent manner as revealed by the response of isogenic HCT116 cell lines. Knockdown of the crucial autophagy component beclin-1 and chemical inhibitors blocked LA-induced autophagy, but did not abrogate LA-triggered MGMT degradation. Concomitant with MGMT depletion, LA pretreatment resulted in enhanced O-6-methylguanine levels in DNA. It also increased the cytotoxicity of the alkylating anticancer drug temozolomide in temozolomide-resistant colorectal cancer cells. Taken together, our study showed that the natural compound LA inhibits MGMT and induces autophagy. Furthermore, LA enhanced the cytotoxic effects of temozolomide, which makes it a candidate for a supplement in cancer therapy.
C1 [Goeder, Anja; Nagel, Georg; Kraus, Alexander; Doersam, Bastian; Seiwert, Nina; Kaina, Bernd; Fahrer, Jorg] Univ Med Ctr Mainz, Dept Toxicol, D-55131 Mainz, Germany.
RP Fahrer, J (corresponding author), Univ Med Ctr Mainz, Dept Toxicol, Obere Zahlbacher Str 67, D-55131 Mainz, Germany.
EM fahrer@uni-mainz.de
RI Seiwert, Nina/ABD-2627-2020; Kaina, Bernd/AAE-4692-2020
OI Seiwert, Nina/0000-0003-2169-3670; Goder, Anja/0000-0001-9743-1656
FU University of Mainz (Stufe I) [973 8549]; University Medical Center
   Mainz (MAIFOR) [972 8716]; German Research FoundationGerman Research
   Foundation (DFG) [DFG-FA1034, DFG-KA724]
FX University of Mainz (Stufe I, grant # 973 8549), University Medical
   Center Mainz (MAIFOR, grant # 972 8716), and the German Research
   Foundation (DFG-FA1034 and DFG-KA724).
CR BERANEK DT, 1990, MUTAT RES, V231, P11, DOI 10.1016/0027-5107(90)90173-2
   Berkers CR, 2013, CELL METAB, V18, P617, DOI 10.1016/j.cmet.2013.06.019
   BRANCH P, 1995, CANCER RES, V55, P2304
   Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863
   Carlson DA, 2007, ALTERN MED REV, V12, P343
   Christmann M, 2013, NUCLEIC ACIDS RES, V41, P8403, DOI 10.1093/nar/gkt635
   Christmann M, 2011, BBA-REV CANCER, V1816, P179, DOI 10.1016/j.bbcan.2011.06.002
   Daniels DS, 2000, EMBO J, V19, P1719, DOI 10.1093/emboj/19.7.1719
   Dorsam B., 2014, ARCH TOXICOL
   Dorsam B., 2014, ARCH TOXICOL
   Dozio E, 2010, EUR J PHARMACOL, V641, P29, DOI 10.1016/j.ejphar.2010.05.009
   Fahrer J, 2014, DNA REPAIR, V18, P31, DOI 10.1016/j.dnarep.2014.03.002
   Fahrer J, 2013, CARCINOGENESIS, V34, P2435, DOI 10.1093/carcin/bgt275
   Fahrer J, 2013, BIOCONJUGATE CHEM, V24, P595, DOI 10.1021/bc300563c
   Fleming A, 2011, NAT CHEM BIOL, V7, P9, DOI 10.1038/NCHEMBIO.500
   Guertin DA, 2009, CANCER CELL, V15, P148, DOI 10.1016/j.ccr.2008.12.017
   Hahm JR, 2014, LIFE SCI, V100, P125, DOI 10.1016/j.lfs.2014.02.001
   Han D, 1997, BIOFACTORS, V6, P321, DOI 10.1002/biof.5520060303
   HANDELMAN GJ, 1994, BIOCHEM PHARMACOL, V47, P1725, DOI 10.1016/0006-2952(94)90298-4
   Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870
   Hiratsuka T, 2013, ONCOL REP, V29, P2140, DOI 10.3892/or.2013.2394
   Huber WW, 2003, MUTAT RES-FUND MOL M, V522, P57, DOI 10.1016/S0027-5107(02)00264-6
   Jones W, 2002, FREE RADICAL BIO MED, V33, P83, DOI 10.1016/S0891-5849(02)00862-6
   Kaina B, 2007, DNA REPAIR, V6, P1079, DOI 10.1016/j.dnarep.2007.03.008
   Kaina B, 2010, CELL MOL LIFE SCI, V67, P3663, DOI 10.1007/s00018-010-0491-7
   Kim HJ, 2006, FREE RADICAL BIO MED, V40, P1483, DOI 10.1016/j.freeradbiomed.2005.10.066
   Knizhnik AV, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055665
   Kuo CC, 2007, INT J CANCER, V121, P2293, DOI 10.1002/ijc.22927
   Lamark T, 2010, CURR OPIN CELL BIOL, V22, P192, DOI 10.1016/j.ceb.2009.11.002
   Levine B, 2009, CELL DEATH DIFFER, V16, P1, DOI 10.1038/cdd.2008.139
   Lips J, 2001, MUTAT RES-DNA REPAIR, V487, P59, DOI 10.1016/S0921-8777(01)00105-7
   Liu LL, 2002, CLIN CANCER RES, V8, P2985
   Liu LP, 2002, CANCER RES, V62, P3037
   Liu Y, 2006, P NATL ACAD SCI USA, V103, P976, DOI 10.1073/pnas.0510146103
   Michikoshi H, 2013, CANCER LETT, V335, P472, DOI 10.1016/j.canlet.2013.03.008
   Mojas N, 2007, GENE DEV, V21, P3342, DOI 10.1101/gad.455407
   Mosbech A, 2013, J BIOL CHEM, V288, P16579, DOI 10.1074/jbc.M113.459917
   Moungjaroen J, 2006, J PHARMACOL EXP THER, V319, P1062, DOI 10.1124/jpet.106.110965
   Naumann SC, 2009, BRIT J CANCER, V100, P322, DOI 10.1038/sj.bjc.6604856
   Niture SK, 2007, CARCINOGENESIS, V28, P378, DOI 10.1093/carcin/bgl155
   Paranjpe A, 2014, CARCINOGENESIS, V35, P692, DOI 10.1093/carcin/bgt366
   Paranjpe A, 2013, CARCINOGENESIS, V34, P990, DOI 10.1093/carcin/bgt032
   Park KG, 2008, HEPATOLOGY, V48, P1477, DOI 10.1002/hep.22496
   PEGG AE, 1991, CARCINOGENESIS, V12, P1679, DOI 10.1093/carcin/12.9.1679
   Pegg AE, 2011, CHEM RES TOXICOL, V24, P618, DOI 10.1021/tx200031q
   PREUSS I, 1995, INT J CANCER, V61, P321, DOI 10.1002/ijc.2910610308
   Rochette L, 2013, MOL NUTR FOOD RES, V57, P114, DOI 10.1002/mnfr.201200608
   Roos WP, 2009, DNA REPAIR, V8, P72, DOI 10.1016/j.dnarep.2008.09.003
   Rubinsztein DC, 2009, AUTOPHAGY, V5, P585, DOI 10.4161/auto.5.5.8823
   Shang F, 2011, FREE RADICAL BIO MED, V51, P5, DOI 10.1016/j.freeradbiomed.2011.03.031
   Shay KP, 2009, BBA-GEN SUBJECTS, V1790, P1149, DOI 10.1016/j.bbagen.2009.07.026
   Siggens L, 2012, FASEB J, V26, P2117, DOI 10.1096/fj.11-197525
   Simbula G, 2007, APOPTOSIS, V12, P113, DOI 10.1007/s10495-006-0487-9
   Simonsen A, 2009, J CELL BIOL, V186, P773, DOI 10.1083/jcb.200907014
   Smith AR, 2004, CURR MED CHEM, V11, P1135, DOI 10.2174/0929867043365387
   Srivenugopal KS, 1996, BIOCHEMISTRY-US, V35, P1328, DOI 10.1021/bi9518205
   Suh JH, 2004, ARCH BIOCHEM BIOPHYS, V423, P126, DOI 10.1016/j.abb.2003.12.020
   Suh JH, 2004, P NATL ACAD SCI USA, V101, P3381, DOI 10.1073/pnas.0400282101
   Takaishi N, 2007, J AGR FOOD CHEM, V55, P5253, DOI 10.1021/jf063624i
   Underwood BR, 2010, HUM MOL GENET, V19, P3413, DOI 10.1093/hmg/ddq253
   Vessoni AT, 2013, CELL DEATH DIFFER, V20, P1444, DOI 10.1038/cdd.2013.103
   Wollin SD, 2003, J NUTR, V133, P3327
   Xu Y, 2013, FASEB J, V27, P4799, DOI 10.1096/fj.13-235127
   Xu-Welliver M, 2002, CARCINOGENESIS, V23, P823, DOI 10.1093/carcin/23.5.823
   Yang J, 2010, J CELL SCI, V123, P861, DOI 10.1242/jcs.060475
   Zhang WJ, 2007, P NATL ACAD SCI USA, V104, P4077, DOI 10.1073/pnas.0700305104
NR 66
TC 27
Z9 30
U1 1
U2 25
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0143-3334
EI 1460-2180
J9 CARCINOGENESIS
JI Carcinogenesis
PD AUG
PY 2015
VL 36
IS 8
BP 817
EP 831
DI 10.1093/carcin/bgv070
PG 15
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA CO7CH
UT WOS:000359314600002
PM 25998848
OA Bronze
DA 2022-04-25
ER

PT J
AU Jin, L
   Chen, YH
   Cheng, D
   He, ZK
   Shi, XY
   Du, BY
   Xi, XY
   Gao, YJ
   Guo, Y
AF Jin, Lan
   Chen, Yunhe
   Cheng, Dan
   He, Zhikai
   Shi, Xinyi
   Du, Boyu
   Xi, Xueyan
   Gao, Yujing
   Guo, Yang
TI YAP inhibits autophagy and promotes progression of colorectal cancer via
   upregulating Bcl-2 expression
SO CELL DEATH & DISEASE
LA English
DT Article
ID YES-ASSOCIATED PROTEIN; CELL-DEATH; HIPPO PATHWAY; PROLIFERATION;
   GROWTH; CHEMORESISTANCE; BIOLOGY
AB Colorectal cancer (CRC) is one of the most aggressive and lethal cancers. The role of autophagy in the pathobiology of CRC is intricate, with opposing functions manifested in different cellular contexts. The Yes-associated protein (YAP), a transcriptional coactivator inactivated by the Hippo tumor-suppressor pathway, functions as an oncoprotein in a variety of cancers. In this study, we found that YAP could negatively regulate autophagy in CRC cells, and consequently, promote tumor progression of CRC in vitro and in vivo. Mechanistically, YAP interacts with TEAD forming a complex to upregulate the transcription of the apoptosis-inhibitory protein Bcl-2, which may subsequently facilitate cell survival by suppressing autophagy-related cell death; silencing Bcl-2 expression could alleviate YAP-induced autophagy inhibition without affecting YAP expression. Collectively, our data provide evidence for YAP/Bcl-2 as a potential therapeutic target for drug exploration against CRC.
C1 [Jin, Lan; Chen, Yunhe; Cheng, Dan; He, Zhikai; Du, Boyu; Xi, Xueyan; Guo, Yang] Hubei Univ Med, Sch Basic Med Sci, Dept Immunol, Shiyan 442000, Hubei, Peoples R China.
   [Jin, Lan; Chen, Yunhe; Guo, Yang] Hubei Univ Med, Hubei Key Lab Embryon Stem Cell Res, Shiyan 442000, Hubei, Peoples R China.
   [Shi, Xinyi; Gao, Yujing] Ningxia Med Univ, Sch Basic Med Sci, Dept Biochem & Mol Biol, Key Lab Fertil Preservat & Maintenance,Minist Edu, Yinchuan, Ningxia, Peoples R China.
RP Guo, Y (corresponding author), Hubei Univ Med, Sch Basic Med Sci, Dept Immunol, Shiyan 442000, Hubei, Peoples R China.; Guo, Y (corresponding author), Hubei Univ Med, Hubei Key Lab Embryon Stem Cell Res, Shiyan 442000, Hubei, Peoples R China.; Gao, YJ (corresponding author), Ningxia Med Univ, Sch Basic Med Sci, Dept Biochem & Mol Biol, Key Lab Fertil Preservat & Maintenance,Minist Edu, Yinchuan, Ningxia, Peoples R China.
EM gaoyujing2004@126.com; guoyang_hbmu@foxmail.com
OI Gao, yujing/0000-0003-0718-4992; Guo, Yang/0000-0002-4763-0072
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81702930, 81872395, 81660486]; Hubei
   Provincial Natural Science Foundation [2019CFB424]; Biomedical Research
   Foundation, Hubei University of Medicine [PI201804]
FX This study was supported by the National Natural Science Foundation of
   China (81702930, 81872395, 81660486), Hubei Provincial Natural Science
   Foundation (2019CFB424), and the Biomedical Research Foundation, Hubei
   University of Medicine (PI201804).
CR Akar U, 2008, AUTOPHAGY, V4, P669, DOI 10.4161/auto.6083
   Berry DL, 2008, AUTOPHAGY, V4, P359, DOI 10.4161/auto.5575
   Buchholz TA, 2005, CLIN CANCER RES, V11, P8398, DOI 10.1158/1078-0432.CCR-05-0885
   Hall CA, 2010, CANCER RES, V70, P8517, DOI 10.1158/0008-5472.CAN-10-1242
   Harvey KF, 2003, CELL, V114, P457, DOI 10.1016/S0092-8674(03)00557-9
   Ito H, 2006, JNCI-J NATL CANCER I, V98, P625, DOI 10.1093/jnci/djj161
   Kang W, 2011, CLIN CANCER RES, V17, P2130, DOI 10.1158/1078-0432.CCR-10-2467
   Kroemer G, 2008, NAT REV MOL CELL BIO, V9, P1004, DOI 10.1038/nrm2529
   Lee KW, 2015, CLIN CANCER RES, V21, P357, DOI 10.1158/1078-0432.CCR-14-1374
   Liu ZM, 2017, AM J TRANSL RES, V9, P3212
   Liu-Chittenden Y, 2012, GENE DEV, V26, P1300, DOI 10.1101/gad.192856.112
   Marti P, 2015, HEPATOLOGY, V62, P1497, DOI 10.1002/hep.27992
   Mo JS, 2014, EMBO REP, V15, P642, DOI 10.15252/embr.201438638
   Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002
   Piccolo S, 2014, PHYSIOL REV, V94, P1287, DOI 10.1152/physrev.00005.2014
   Saeki K, 2000, CELL DEATH DIFFER, V7, P1263, DOI 10.1038/sj.cdd.4400759
   Sakanashi F, 2019, PATHOL RES PRACT, V215, DOI 10.1016/j.prp.2019.04.017
   Siegel RL, 2017, CA-CANCER J CLIN, V67, P177, DOI 10.3322/caac.21395
   Steinhardt AA, 2008, HUM PATHOL, V39, P1582, DOI 10.1016/j.humpath.2008.04.012
   Wang C, 2015, MOL MED REP, V11, P4101, DOI 10.3892/mmr.2015.3257
   Wei R, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1043-0
   Yin ZY, 2016, MICROB CELL, V3, P457, DOI 10.15698/mic2016.12.546
   Yu L, 2004, SCIENCE, V304, P1500, DOI 10.1126/science.1096645
   Yu TC, 2017, CELL, V170, P548, DOI 10.1016/j.cell.2017.07.008
   Zhao B, 2008, GENE DEV, V22, P1962, DOI 10.1101/gad.1664408
   Zhao B, 2007, GENE DEV, V21, P2747, DOI 10.1101/gad.1602907
   Zhou Y, 2019, CANCER CELL INT, V19, DOI 10.1186/s12935-019-0898-7
NR 27
TC 4
Z9 4
U1 2
U2 4
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 2041-4889
J9 CELL DEATH DIS
JI Cell Death Dis.
PD MAY 7
PY 2021
VL 12
IS 5
AR 457
DI 10.1038/s41419-021-03722-8
PG 10
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA SK5LQ
UT WOS:000656257100003
PM 33963173
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Tsai, WL
   Wang, CY
   Lee, YC
   Tang, WC
   Anuraga, G
   Ta, HDK
   Wu, YF
   Lee, KH
AF Tsai, Wei-Lun
   Wang, Chih-Yang
   Lee, Yu-Cheng
   Tang, Wan-Chun
   Anuraga, Gangga
   Ta, Hoang Dang Khoa
   Wu, Yung-Fu
   Lee, Kuen-Haur
TI A New Light on Potential Therapeutic Targets for Colorectal Cancer
   Treatment
SO BIOMEDICINES
LA English
DT Article
DE colorectal cancer; CRNDE; MiR-29b-3p; ANGPTL4; autophagy; lipid
   metabolism
ID NONCODING RNA CRNDE; EPITHELIAL-MESENCHYMAL TRANSITION;
   ANGIOPOIETIN-LIKE 4; LIPID-ACCUMULATION; AUTOPHAGY; EXPRESSION; AMPK;
   CELLS; AXIS; PROLIFERATION
AB The development and progression of colorectal cancer (CRC) involve changes in genetic and epigenetic levels of oncogenes and/or tumor suppressors. In spite of advances in understanding of the molecular mechanisms involved in CRC, the overall survival rate of CRC still remains relatively low. Thus, more research is needed to discover and investigate effective biomarkers and targets for diagnosing and treating CRC. The roles of long non-coding RNAs (lncRNAs) participating in various aspects of cell biology have been investigated and potentially contribute to tumor development. Our recent study also showed that CRNDE was among the top 20 upregulated genes in CRC clinical tissues compared to normal colorectal tissues by analyzing a Gene Expression Omnibus (GEO) dataset (GSE21815). Although CRNDE is widely reported to be associated with different types of cancer, most studies of CRNDE were limited to examining regulation of its transcription levels, and in-depth mechanistic research is lacking. In the present study, CRNDE was found to be significantly upregulated in CRC patients at an advanced TNM stage, and its high expression was correlated with poor outcomes of CRC patients. In addition, we found that knocking down CRNDE could reduce lipid accumulation through the miR-29b-3p/ANGPTL4 axis and consequently induce autophagy of CRC cells.</p>
C1 [Tsai, Wei-Lun; Anuraga, Gangga; Ta, Hoang Dang Khoa] Taipei Med Univ, Coll Med Sci & Technol, PhD Program Canc Mol Biol & Drug Discovery, Taipei 11031, Taiwan.
   [Tsai, Wei-Lun; Anuraga, Gangga; Ta, Hoang Dang Khoa] Acad Sinica, Taipei 11031, Taiwan.
   [Wang, Chih-Yang; Tang, Wan-Chun; Lee, Kuen-Haur] Taipei Med Univ, Coll Med Sci & Technol, PhD Program Canc Mol Biol & Drug Discovery, Taipei 11031, Taiwan.
   [Wang, Chih-Yang; Tang, Wan-Chun; Anuraga, Gangga; Ta, Hoang Dang Khoa; Lee, Kuen-Haur] Taipei Med Univ, Coll Med Sci & Technol, Grad Inst Canc Biol & Drug Discovery, Taipei 11031, Taiwan.
   [Lee, Yu-Cheng] Taipei Med Univ, Coll Med, Grad Inst Med Sci, Taipei 11031, Taiwan.
   [Anuraga, Gangga] Univ PGRI Adi Buana, Fac Sci & Technol, Dept Stat, Surabaya 60234, East Java, Indonesia.
   [Wu, Yung-Fu] Triserv Gen Hosp, Sch Med, Dept Med Res, Natl Def Med Ctr, Taipei 11490, Taiwan.
   [Lee, Kuen-Haur] Taipei Med Univ, Wan Fang Hosp, Canc Ctr, Taipei 11031, Taiwan.
RP Lee, KH (corresponding author), Taipei Med Univ, Coll Med Sci & Technol, PhD Program Canc Mol Biol & Drug Discovery, Taipei 11031, Taiwan.; Lee, KH (corresponding author), Taipei Med Univ, Coll Med Sci & Technol, Grad Inst Canc Biol & Drug Discovery, Taipei 11031, Taiwan.; Lee, KH (corresponding author), Taipei Med Univ, Wan Fang Hosp, Canc Ctr, Taipei 11031, Taiwan.
EM mebar1995@gmail.com; chihyang@tmu.edu.tw; yclee0212@tmu.edu.tw;
   yeas0310@hotmail.com; g.anuraga@unipasby.ac.id; d621109004@tmu.edu.tw;
   qrince@yahoo.com.tw; khlee@tmu.edu.tw
RI Anuraga, Gangga/AAE-8623-2021; Anuraga, Gangga/ABE-1220-2021
OI Anuraga, Gangga/0000-0002-0902-3968; Lee, Kuen-Haur/0000-0002-6354-3315;
   , Khoa/0000-0001-8809-239X
FU Health and Welfare Surcharge of Tobacco Product of Taiwan (Wan-Fang
   Hospital) [MOHW110-TDU-B-212-144020]; Health and Welfare Surcharge of
   Tobacco Product of Taiwan (Chi-Mei Medical Center)
   [MOHW110-TDU-B-212-144020]; Health and Welfare Surcharge of Tobacco
   Product of Taiwan (Hualien Tzu-Chi Hospital Joint Cancer Center
   Grant-Focus on Colon Cancer Research) [MOHW110-TDU-B-212-144020];
   Ministry of Education of TaiwanMinistry of Education, Taiwan
   [DP2-110-21121-03-C-03-03]; Chi-Mei Medical Center [110CM-TMU-16]; "TMU
   Research Center of Cancer Translational Medicine" from The Featured
   Areas Research Center Program within the Ministry of Education (MOE) in
   Taiwan
FX This research was funded by the Health and Welfare Surcharge of Tobacco
   Products of Taiwan (Wan-Fang Hospital, Chi-Mei Medical Center, and
   Hualien Tzu-Chi Hospital Joint Cancer Center Grant-Focus on Colon Cancer
   Research; grant no.: MOHW110-TDU-B-212-144020, awarded to K-H.L.),
   Ministry of Education of Taiwan (grant no.: DP2-110-21121-03-C-03-03),
   Chi-Mei Medical Center (grant no.: 110CM-TMU-16 to K.-H.L.), and the
   "TMU Research Center of Cancer Translational Medicine" from The Featured
   Areas Research Center Program within the framework of the Higher
   Education Sprout Project by the Ministry of Education (MOE) in Taiwan.
CR Altman BJ, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a008763
   Aryal B, 2019, TRENDS MOL MED, V25, P723, DOI 10.1016/j.molmed.2019.05.010
   Beermann J, 2016, PHYSIOL REV, V96, P1297, DOI 10.1152/physrev.00041.2015
   Bjorkoy G, 2005, J CELL BIOL, V171, P603, DOI 10.1083/jcb.200507002
   Brunner AL, 2012, GENOME BIOL, V13, DOI 10.1186/gb-2012-13-8-r75
   Canto C, 2011, PHYSIOLOGY, V26, P214, DOI 10.1152/physiol.00010.2011
   Chen SY, 2020, CANCER MANAG RES, V12, P10521, DOI 10.2147/CMAR.S272230
   Cirone M, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1275-z
   DeBerardinis RJ, 2016, SCI ADV, V2, DOI 10.1126/sciadv.1600200
   Dekker E, 2019, LANCET, V394, P1467, DOI 10.1016/S0140-6736(19)32319-0
   Ding CG, 2018, J CELL BIOCHEM, V119, P10406, DOI 10.1002/jcb.27389
   Ding DY, 2018, MOL CELLS, V41, P423, DOI 10.14348/molcells.2018.2258
   Frith MC, 2005, EUR J HUM GENET, V13, P894, DOI 10.1038/sj.ejhg.5201459
   Graham Lloyd D, 2011, Genes Cancer, V2, P829, DOI 10.1177/1947601911431081
   Gutschner T, 2012, RNA BIOL, V9, P703, DOI 10.4161/rna.20481
   Hardie DG, 2012, NAT REV MOL CELL BIO, V13, P251, DOI 10.1038/nrm3311
   Hovelson DH, 2015, J CLIN ONCOL, V33
   Hu CE, 2017, CELL PHYSIOL BIOCHEM, V42, P13, DOI 10.1159/000477107
   Huang HY, 2020, NUCLEIC ACIDS RES, V48, pD148, DOI 10.1093/nar/gkz896
   Huang YM, 2019, BIOMOLECULES, V9, DOI 10.3390/biom9110688
   Jia R, 2020, CANCER MANAG RES, V12, P2559, DOI 10.2147/CMAR.S246625
   Jiang HJ, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.258
   Jing SY, 2016, EUR REV MED PHARMACO, V20, P3992
   Kim YM, 1997, J BIOL CHEM, V272, P31138, DOI 10.1074/jbc.272.49.31138
   Kung JTY, 2013, GENETICS, V193, P651, DOI 10.1534/genetics.112.146704
   Kwon JJ, 2019, MOL THER-ONCOLYTICS, V12, P173, DOI 10.1016/j.omto.2018.12.011
   La Paglia L, 2017, PPAR RES, V2017, DOI 10.1155/2017/8187235
   Lan G, 2016, BIOCHEM BIOPH RES CO, V472, P410, DOI 10.1016/j.bbrc.2015.10.158
   Lee YF, 2018, DATABASE-OXFORD, DOI 10.1093/database/bax101
   Leone RD, 2013, TRENDS ENDOCRIN MET, V24, P209, DOI 10.1016/j.tem.2013.01.008
   Li HL, 2014, BBA-MOL BASIS DIS, V1842, P1844, DOI 10.1016/j.bbadis.2014.07.002
   Liberzon A, 2015, CELL SYST, V1, P417, DOI 10.1016/j.cels.2015.12.004
   Liu T, 2016, ONCOTARGETS THER, V9, P1437, DOI 10.2147/OTT.S98268
   Lopez-Urrutia E, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00669
   Lu Y, 2020, CANCER CELL INT, V20, DOI 10.1186/s12935-020-01246-3
   Lv MX, 2017, BBA-MOL CELL RES, V1864, P1887, DOI 10.1016/j.bbamcr.2017.08.001
   Maiese K, 2012, EXPERT OPIN THER TAR, V16, P1203, DOI 10.1517/14728222.2012.719499
   Mandard S, 2006, J BIOL CHEM, V281, P934, DOI 10.1074/jbc.M506519200
   Meng YY, 2018, BIOL CHEM, V399, P93, DOI 10.1515/hsz-2017-0199
   Mercer TR, 2009, NAT REV GENET, V10, P155, DOI 10.1038/nrg2521
   Migliore L, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/792362
   Mihaylova MM, 2011, NAT CELL BIOL, V13, P1016, DOI 10.1038/ncb2329
   Nakayama T, 2011, ONCOL REP, V25, P929, DOI 10.3892/or.2011.1176
   Obernosterer G, 2007, NAT PROTOC, V2, P1508, DOI 10.1038/nprot.2007.153
   Ponting CP, 2009, CELL, V136, P629, DOI 10.1016/j.cell.2009.02.006
   Siegel RL, 2020, CA-CANCER J CLIN, V70, P145, DOI 10.3322/caac.21601
   Siegel RL, 2019, CA-CANCER J CLIN, V69, P7, DOI 10.3322/caac.21551
   Statello L, 2021, NAT REV MOL CELL BIO, V22, P96, DOI 10.1038/s41580-020-00315-9
   Su YH, 2015, BBA-MOL CELL RES, V1853, P2261, DOI 10.1016/j.bbamcr.2015.05.012
   Sun K, 2013, CELL BIOSCI, V3, DOI 10.1186/2045-3701-3-35
   Sun YP, 2019, CANCER BIOL THER, V20, P729, DOI 10.1080/15384047.2018.1529121
   Szafron LM, 2015, ONCOTARGET, V6, P43897, DOI 10.18632/oncotarget.6016
   Tang ZF, 2017, NUCLEIC ACIDS RES, V45, pW98, DOI 10.1093/nar/gkx247
   Tariq K, 2016, CANCER BIOL MED, V13, P120, DOI 10.28092/j.issn.2095-3941.2015.0103
   Tsuchihara K, 2009, CANCER LETT, V278, P130, DOI 10.1016/j.canlet.2008.09.040
   Wang LY, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20225758
   Yang ZNJ, 2011, MOL CANCER THER, V10, P1533, DOI 10.1158/1535-7163.MCT-11-0047
   Zhang B, 2019, BIOL RES, V52, DOI 10.1186/s40659-019-0245-4
   Zhu HZ, 2019, PATHOL RES PRACT, V215, P256, DOI 10.1016/j.prp.2018.11.008
NR 59
TC 0
Z9 0
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2227-9059
J9 BIOMEDICINES
JI Biomedicines
PD OCT
PY 2021
VL 9
IS 10
AR 1438
DI 10.3390/biomedicines9101438
PG 20
WC Biochemistry & Molecular Biology; Medicine, Research & Experimental;
   Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Research & Experimental Medicine;
   Pharmacology & Pharmacy
GA WO7NW
UT WOS:000712637500001
PM 34680556
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Li, HY
   Gao, CD
   Liu, C
   Liu, LJ
   Zhuang, J
   Yang, J
   Zhou, C
   Feng, FB
   Sun, CG
   Wu, JB
AF Li, Huayao
   Gao, Chundi
   Liu, Cun
   Liu, Lijuan
   Zhuang, Jing
   Yang, Jing
   Zhou, Chao
   Feng, Fubin
   Sun, Changgang
   Wu, Jibiao
TI A review of the biological activity and pharmacology of
   cryptotanshinone, an important active constituent in Danshen
SO BIOMEDICINE & PHARMACOTHERAPY
LA English
DT Review
DE Cryptotanshinone; Biological activity; Pharmacological; Anti-cancer;
   Anti-inflammatory
ID SALVIA-MILTIORRHIZA; CANCER-CELLS; IN-VITRO; COLON-CANCER; LUNG-CANCER;
   APOPTOSIS; GROWTH; INHIBITION; EXPRESSION; ANTITUMOR
AB Cryptotanshinone (IUPAC name: (R)-1,2,6,7,8,9-hexahydro-1,6,6-trimethyl-phenanthro(1,2-b)furan-10,11dione), a biologically active constituent extracted from the roots and rhizomes of the plant Salvia miltiorrhiza, has been studied in depth as a medicinally active compound and shown to have efficacy in the treatment of numerous diseases and disorders. In this review, we describe in detail the current status of cryptotanshinone research, including findings relating to the structure, pharmacokinetics, pharmacological activity, and derivatives of this compound. Cryptotanshinoneh as a diverse range of pharmacological effects, including anticancer, anti-inflammatory, immune regulatory, neuroprotective, and anti-fibrosis activities. Studies on the molecular mechanisms underlying the activities of cryptotanshinone have established that the JAK2/STAT3, PI3K/AKT, NF-kappa B, AMPK, and cell cycle pathways are involved in the inhibitory and pro-apoptotic effects of cryptotanshinone on different tumor cell lines, these molecular pathways interact in a coordinated manner to inhibit cell proliferation, migration and invasion,and induce transformation, autophagy, necrosis, and cellular immunity. The anti-inflammatory mechanisms of cryptotanshinone have been found to be associated with the TLR4MyD88/PI3K/Nrf2 and TLR4-MyD88/NF-kappa B/MAPK pathways, whereasthe Hedgehog, NF-kappa B, and Nrf-2/HO-1 pathways are regulated by cryptotanshinone to reduce organ fibrosis, and its inhibitory effects on the PI3K/ AKT-eNOS pathway have been linked to neuroprotective effects. Given the potential medicinal utility of cryptotanshinone, further research is needed to verify the efficacy and safety of this compound in clinical use, evaluate its pharmacological activity, and identify molecular targets.
C1 [Li, Huayao; Wu, Jibiao] Shandong Univ Tradit Chinese Med, Coll Chinese Med, Jinan 250014, Shandong, Peoples R China.
   [Gao, Chundi; Liu, Cun; Zhou, Chao] Shandong Univ Tradit Chinese Med, Coll Clin Med 1, Jinan 250014, Shandong, Peoples R China.
   [Liu, Lijuan; Zhuang, Jing; Yang, Jing; Zhou, Chao; Feng, Fubin; Sun, Changgang] Weifang Tradit Chinese Hosp, Dept Oncol, Weifang 261041, Shandong, Peoples R China.
   [Zhuang, Jing] Shandong Univ Chinese Med, Qingdao Acad Chinese Med Sci, Qingdao 266112, Shandong, Peoples R China.
   [Liu, Cun; Feng, Fubin] Qingdao Univ, Dept Basic Med Sci, Qingdao 266071, Peoples R China.
   [Sun, Changgang] Shandong Univ Tradit Chinese Med, Chinese Med Innovat Inst, Jinan 250014, Shandong, Peoples R China.
RP Sun, CG; Wu, JB (corresponding author), 4655 Univ Rd,Univ Sci Pk, Jinan 250355, Shandong, Peoples R China.
EM lhy126913@163.com; gaochundi2017@163.com; 18763678002@163.com;
   hxdhxd19852003@163.com; 13963676719@163.com; xyjf63@163.com;
   285758078@163.com; wfffb0618@163.com; scgdoctor@126.com;
   wujibiao1963@163.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81673799, 81973677, 81703915]
FX This work is supported by the grants from National Natural Science
   Foundation of China (81673799, 81973677, 81703915) .
CR Ahmad Z, 2016, J PHYSIOL SCI, V66, P213, DOI 10.1007/s12576-015-0410-7
   Breitfeld PP, 2005, ONCOLOGIST, V10, P518, DOI 10.1634/theoncologist.10-7-518
   Buyanravjikh S, 2018, MOL MED REP, V18, P1095, DOI 10.3892/mmr.2018.9042
   Cao SG, 2018, MICROB PATHOGENESIS, V116, P313, DOI 10.1016/j.micpath.2017.12.027
   Cha JD, 2014, EVID-BASED COMPL ALT, V2014, DOI 10.1155/2014/450572
   Chen WX, 2017, BMC CANCER, V17, DOI 10.1186/s12885-016-3038-y
   Chen WX, 2013, ANTI-CANCER AGENT ME, V13, P979, DOI 10.2174/18715206113139990115
   Dai HX, 2008, J PHARMACEUT BIOMED, V48, P885, DOI 10.1016/j.jpba.2008.07.011
   Dong BW, 2018, SCI CHINA LIFE SCI, V61, P999, DOI 10.1007/s11427-018-9324-y
   Esch S, 2019, PLANTA MED, V85, P552, DOI 10.1055/a-0660-0441
   Ge YQ, 2015, LEUKEMIA LYMPHOMA, V56, P730, DOI 10.3109/10428194.2014.928934
   Ge YQ, 2012, MOL CELL BIOCHEM, V368, P17, DOI 10.1007/s11010-012-1338-3
   Guan WJ, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00547-2020
   Han Z, 2019, CANCER IMMUNOL IMMUN, V68, P1073, DOI 10.1007/s00262-019-02338-4
   Hao WH, 2016, ANTI-CANCER AGENT ME, V16, P593, DOI 10.2174/1871520615666150907093036
   He WN, 2017, APPL MICROBIOL BIOT, V101, P6365, DOI 10.1007/s00253-017-8351-0
   Imran KM, 2017, BBA-MOL CELL BIOL L, V1862, P1110, DOI 10.1016/j.bbalip.2017.08.001
   Ji QB, 2018, MOL THER-NUCL ACIDS, V11, P170, DOI 10.1016/j.omtn.2018.02.001
   Jia QQ, 2019, PHYTOMEDICINE, V58, DOI 10.1016/j.phymed.2019.152871
   Jiang GQ, 2017, J ETHNOPHARMACOL, V205, P33, DOI 10.1016/j.jep.2017.04.026
   Jiang YF, 2019, EVID-BASED COMPL ALT, V2019, DOI 10.1155/2019/1908416
   Jiao XL, 2012, BIOINFORMATICS, V28, P1805, DOI 10.1093/bioinformatics/bts251
   Kim EJ, 2017, TOXICOL APPL PHARM, V330, P84, DOI 10.1016/j.taap.2017.07.007
   Kim SA, 2018, INT J MOL SCI, V19, DOI [10.3390/ijms19092739, 10.15818/ihss.2018.19.1.1]
   Kwon H, 2020, FOOD CHEM TOXICOL, V136, DOI 10.1016/j.fct.2019.111011
   Lee HJ, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/390957
   Li L, 2020, AGING-US, V12, P9585, DOI 10.18632/aging.103228
   Li XX, 2020, CHIN MED-UK, V15, DOI 10.1186/s13020-020-00303-3
   Li Y, 2016, BIOMED PHARMACOTHER, V80, P80, DOI 10.1016/j.biopha.2016.03.006
   Li ZH, 2018, ASIAN J PHARM SCI, V13, P310, DOI 10.1016/j.ajps.2018.02.009
   Lien EC, 2017, CURR OPIN CELL BIOL, V45, P62, DOI 10.1016/j.ceb.2017.02.007
   Liu S, 2019, CANCER IMMUNOL IMMUN, V68, P1059, DOI 10.1007/s00262-019-02326-8
   Liu YD, 2020, J CANCER, V11, P488, DOI 10.7150/jca.31422
   Lo SH, 2017, PHYTOTHER RES, V31, P638, DOI 10.1002/ptr.5777
   Lu L, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.174
   Maione F, 2018, PHARMACOL RES, V129, P482, DOI 10.1016/j.phrs.2017.11.018
   Man YH, 2016, ONCOL LETT, V12, P4094, DOI 10.3892/ol.2016.5123
   Papa A, 2019, BIOMOLECULES, V9, DOI 10.3390/biom9040153
   Phillipson JD, 2007, PHYTOCHEMISTRY, V68, P2960, DOI 10.1016/j.phytochem.2007.06.028
   Qi PF, 2019, INT J BIOL SCI, V15, P1072, DOI 10.7150/ijbs.31277
   Qin WJ, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-49480-8
   Rahman N, 2016, PHYTOMEDICINE, V23, P58, DOI 10.1016/j.phymed.2015.12.004
   Ran XL, 2016, KOREAN J PHYSIOL PHA, V20, P347, DOI 10.4196/kjpp.2016.20.4.347
   Ru JL, 2014, J CHEMINFORMATICS, V6, DOI 10.1186/1758-2946-6-13
   Shen L, 2017, BMC COMPLEM ALTERN M, V17, DOI 10.1186/s12906-016-1548-4
   Shin DS, 2009, CANCER RES, V69, P193, DOI 10.1158/0008-5472.CAN-08-2575
   Tang LP, 2018, EXP DERMATOL, V27, P268, DOI 10.1111/exd.13511
   Wang CY, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01338
   Wang HJ, 2019, ONCOL LETT, V18, P2554, DOI 10.3892/ol.2019.10580
   Wang JY, 2017, J INT MED RES, V45, P220, DOI 10.1177/0300060516685513
   Wang LL, 2017, CURR PHARM DESIGN, V23, P1077, DOI 10.2174/1381612822666161010105242
   Wang W, 2018, BASIC CLIN PHARMACOL, V123, P714, DOI 10.1111/bcpt.13091
   Wang WZ, 2019, J CELL BIOCHEM, V120, P7333, DOI 10.1002/jcb.28008
   Wang YL, 2017, NUCLEIC ACIDS RES, V45, pD955, DOI 10.1093/nar/gkw1118
   Wang Y, 2017, BIOMED PHARMACOTHER, V95, P1388, DOI 10.1016/j.biopha.2017.09.062
   Wang Y, 2017, BIOCHEM PHARMACOL, V138, P119, DOI 10.1016/j.bcp.2017.05.006
   Wu CF, 2016, ARCH TOXICOL, V90, P2275, DOI 10.1007/s00204-015-1616-4
   Wu YH, 2020, FITOTERAPIA, V145, DOI 10.1016/j.fitote.2020.104633
   Xia C, 2015, CELL PHYSIOL BIOCHEM, V37, P816, DOI 10.1159/000430398
   Xia YQ, 2017, AM J TRANSL RES, V9, P2447
   Xu X, 2012, INT J MOL SCI, V13, P6964, DOI 10.3390/ijms13066964
   Xu ZY, 2017, CHEM-BIOL INTERACT, V273, P48, DOI 10.1016/j.cbi.2017.06.003
   Yang YF, 2018, CANCER MED-US, V7, P4610, DOI 10.1002/cam4.1691
   Ye TH, 2016, BIOMED PHARMACOTHER, V82, P319, DOI 10.1016/j.biopha.2016.05.015
   Yen JH, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-018-1008-8
   Zeng J, 2018, ACTA PHARMACOL SIN, V39, P1393, DOI 10.1038/aps.2017.144
   Zhang J, 2006, J PHARMACOL EXP THER, V317, P1285, DOI 10.1124/jpet.105.100701
   Zhang JT, 2018, ONCOL REP, V40, P2926, DOI 10.3892/or.2018.6638
   Zhang L, 2018, INT IMMUNOPHARMACOL, V65, P429, DOI 10.1016/j.intimp.2018.10.035
   Zhang QY, 2020, PHYTOTHER RES, V34, P2685, DOI 10.1002/ptr.6699
   Zhang WD, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-1139-z
   Zhang YT, 2019, PHARMACOL RES, V147, DOI 10.1016/j.phrs.2019.104307
   Zhao HY, 2019, FRONT NEUROL, V10, DOI 10.3389/fneur.2019.00381
   Zhou Y, 2019, FRONT NEUROSCI-SWITZ, V13, DOI 10.3389/fnins.2019.00852
   Zhu WX, 2017, MOL MED REP, V16, P9361, DOI 10.3892/mmr.2017.7824
   Zhu ZJ, 2016, MOL CARCINOGEN, V55, P1399, DOI 10.1002/mc.22383
   Zuo T, 2016, ACS OMEGA, V1, P1326, DOI 10.1021/acsomega.6b00232
NR 77
TC 9
Z9 9
U1 11
U2 24
PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY-LES-MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE
SN 0753-3322
EI 1950-6007
J9 BIOMED PHARMACOTHER
JI Biomed. Pharmacother.
PD MAY
PY 2021
VL 137
AR 111332
DI 10.1016/j.biopha.2021.111332
EA FEB 2021
PG 12
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA RC2UF
UT WOS:000632659500001
PM 33548911
OA gold
DA 2022-04-25
ER

PT J
AU Olszewski, U
   Deally, A
   Tacke, M
   Hamilton, G
AF Olszewski, Ulrike
   Deally, Anthony
   Tacke, Matthias
   Hamilton, Gerhard
TI Alterations of Phosphoproteins in NCI-H526 Small Cell Lung Cancer Cells
   Involved in Cytotoxicity of Cisplatin and Titanocene Y
SO NEOPLASIA
LA English
DT Article
ID N-TERMINAL KINASE; CASPASE-DEPENDENT APOPTOSIS; OVARIAN-CANCER;
   ANTITUMOR-ACTIVITY; ANTICANCER DRUGS; IN-VITRO; ACTIVATION; RESISTANCE;
   INHIBITION; PATHWAY
AB First-line treatment of small cell lung cancer (SCLC) with combination chemotherapy consisting of cis-diamminedichloroplatinum(II) (cisplatin) and etoposide is frequently followed by early relapses and a dismal prognosis. Survival of a fraction of tumor cells and development of chemoresistance may be influenced by an initial cellular stress response against the administered xenobiotics. Therefore, we compared the short-term effects of cisplatin and non-cross-resistant bis-[(p-methoxybenzyl) cyclopentadienyl] titanium(IV) dichloride (Titanocene Y) on phosphorylation of 46 sites of a total of 38 signaling proteins in tumor suppressor protein 53 (p53)-wild-type NCI-H526 SCLC cells. The functional significance of selected kinases for the cytotoxicity of both drugs was tested using specific inhibitors and an activator. The cisplatin-induced cellular stress response involved activation of p38 alpha mitogen-activated protein kinase, whereas Titanocene Y-triggered signaling affected c-Jun N-terminal kinase. Phosphorylation of adenosine monophosphate (AMP)-activated protein kinase alpha 1 (AMPK alpha 1) was increased by both drugs, which promoted cell survival, as indicated by results obtained using AMPK inhibitor compound C and AMPK activator 5-aminoimidazole-4-carboxamide 1-beta-D-ribofuranoside. This is in good agreement with previous reports, where AMPK alpha 1 was demonstrated to represent an important factor for the sensitivity to cisplatin in colon and ovarian cancers, most likely by induction of autophagy. Thus, AMPK alpha 1 constitutes a potential target to be exploited for chemotherapeutic treatment of SCLC to circumvent resistance to metal-based compounds. Neoplasia (2012) 14, 813-822
C1 [Olszewski, Ulrike; Hamilton, Gerhard] Ludwig Boltzmann Soc, Vienna, Austria.
   [Deally, Anthony; Tacke, Matthias] Univ Coll Dublin, Sch Chem & Chem Biol, Dublin 2, Ireland.
   [Hamilton, Gerhard] Med Univ Vienna, Dept Surg, Vienna, Austria.
RP Olszewski, U (corresponding author), Ludwig Boltzmann Cluster Translat Oncol, Balderichgasse 26A-7-8, A-1170 Vienna, Austria.
EM ulrike.olszewski@toc.lbg.ac.at
OI Tacke, Matthias/0000-0002-8903-3137
FU Higher Education Authority (HEA) [PRTLI4]; Medical Scientific Fund of
   the Mayor of the City of Vienna [11016]
FX This project was funded in part (in Ireland) by the Higher Education
   Authority (HEA) through a PRTLI4 grant and the Medical Scientific Fund
   of the Mayor of the City of Vienna (No. 11016). The authors declare that
   they have no conflict of interest.
CR Alexander A, 2011, FEBS LETT, V585, P952, DOI 10.1016/j.febslet.2011.03.010
   Andjilani M, 2006, INT J ONCOL, V28, P535
   Bannon JH, 2007, BRIT J CANCER, V97, P1234, DOI 10.1038/sj.bjc.6604021
   Belyanskaya LL, 2005, INT J CANCER, V117, P755, DOI 10.1002/ijc.21242
   Benhar M, 2002, EMBO REP, V3, P420, DOI 10.1093/embo-reports/kvf094
   Benhar M, 2001, MOL CELL BIOL, V21, P6913, DOI 10.1128/MCB.21.20.6913-6926.2001
   Bragado P, 2007, APOPTOSIS, V12, P1733, DOI 10.1007/s10495-007-0082-8
   Brozovic A, 2007, CANCER LETT, V251, P1, DOI 10.1016/j.canlet.2006.10.007
   Cai GQ, 2007, INT J ONCOL, V31, P657
   Califano R, 2012, DRUGS, V72, P471, DOI 10.2165/11597640-000000000-00000
   Ceppi P, 2009, MOL CANCER THER, V8, P3066, DOI 10.1158/1535-7163.MCT-09-0151
   Chavain N, 2010, CURR MED CHEM, V17, P2729, DOI 10.2174/092986710791859306
   Chen Helen H. W., 2010, Metal-Based Drugs, P430939, DOI 10.1155/2010/430939
   Choi CH, 2012, BIOCHEM BIOPH RES CO, V418, P759, DOI 10.1016/j.bbrc.2012.01.095
   Cubero Francisco Javier, 2011, Hepatology, V54, P1470, DOI 10.1002/hep.24532
   Erxleben A, 2010, J INORG BIOCHEM, V104, P390, DOI 10.1016/j.jinorgbio.2009.11.010
   Fichtner I, 2006, ANTI-CANCER DRUG, V17, P333, DOI 10.1097/00001813-200603000-00012
   Florea Ana-Maria, 2011, Cancers (Basel), V3, P1351, DOI 10.3390/cancers3011351
   Garbutcheon-Singh KB, 2011, CURR TOP MED CHEM, V11, P521
   Garrido C, 2006, CELL CYCLE, V5, P2592, DOI 10.4161/cc.5.22.3448
   Go RS, 1999, J CLIN ONCOL, V17, P409, DOI 10.1200/JCO.1999.17.1.409
   Gotlieb WH, 2008, GYNECOL ONCOL, V110, P246, DOI 10.1016/j.ygyno.2008.04.008
   Harhaji-Trajkovic L, 2009, J CELL MOL MED, V13, P3644, DOI 10.1111/j.1582-4934.2009.00663.x
   Hogan Megan, 2008, Metal-Based Drugs, P754358, DOI 10.1155/2008/754358
   Hublarova P, 2010, CELL MOL BIOL LETT, V15, P473, DOI 10.2478/s11658-010-0021-5
   Itamochi H, 2011, GYNECOL ONCOL, V122, P641, DOI 10.1016/j.ygyno.2011.05.003
   Jungwirth U, 2011, ANTIOXID REDOX SIGN, V15, P1085, DOI 10.1089/ars.2010.3663
   Kelland L, 2007, NAT REV CANCER, V7, P573, DOI 10.1038/nrc2167
   Kemp MG, 2011, J BIOL CHEM, V286, P19237, DOI 10.1074/jbc.M111.235036
   Kim HS, 2008, J BIOL CHEM, V283, P3731, DOI 10.1074/jbc.M704432200
   Kim RK, 2010, BIOCHEM BIOPH RES CO, V402, P631, DOI 10.1016/j.bbrc.2010.10.072
   Korfel A, 1998, CLIN CANCER RES, V4, P2701
   Levresse V, 2002, MOL PHARMACOL, V62, P689, DOI 10.1124/mol.62.3.689
   Liu J, 2005, CELL RES, V15, P36, DOI 10.1038/sj.cr.7290262
   Losa JH, 2003, ONCOGENE, V22, P3998, DOI 10.1038/sj.onc.1206608
   Olszewski U, 2011, INVEST NEW DRUG, V29, P607, DOI 10.1007/s10637-010-9395-5
   Olszewski U, 2010, ANTI-CANCER AGENT ME, V10, P302, DOI 10.2174/187152010791162261
   Peng DJ, 2010, BIOCHEM BIOPH RES CO, V394, P600, DOI 10.1016/j.bbrc.2010.03.029
   Rattan R, 2011, NEOPLASIA, V13, P483, DOI 10.1593/neo.11148
   Shi MJ, 2006, MOL CANCER RES, V4, P39, DOI 10.1158/1541-7786.MCR-05-0202
   Siddik ZH, 2003, ONCOGENE, V22, P7265, DOI 10.1038/sj.onc.1206933
   Suzuki K, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/978312
   Tripathi R, 2011, MOL CANCER THER, V10, P255, DOI 10.1158/1535-7163.MCT-10-0606
   Wang D, 2005, NAT REV DRUG DISCOV, V4, P307, DOI 10.1038/nrd1691
   Yamamoto K, 2001, CANCER LETT, V168, P173, DOI 10.1016/S0304-3835(01)00532-8
   Yano T, 2007, APOPTOSIS, V12, P1901, DOI 10.1007/s10495-007-0110-8
   Yuan ZQ, 2003, J BIOL CHEM, V278, P23432, DOI 10.1074/jbc.M302674200
   Yun H, 2009, CARCINOGENESIS, V30, P529, DOI 10.1093/carcin/bgn259
   Zhu Q, 2010, MOL CELL BIOCHEM, V340, P275, DOI 10.1007/s11010-010-0428-3
NR 49
TC 18
Z9 21
U1 1
U2 16
PU NEOPLASIA PRESS
PI ANN ARBOR
PA 1150 W MEDICAL CENTER DR, MSRB III, RM 9303, ANN ARBOR, MI 48109-0648
   USA
SN 1522-8002
J9 NEOPLASIA
JI Neoplasia
PD SEP
PY 2012
VL 14
IS 9
BP 813
EP 822
DI 10.1593/neo.12962
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 068DR
UT WOS:000313345200005
PM 23019413
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Wang, KL
   Chen, Q
   Shao, YY
   Yin, SS
   Liu, CY
   Liu, YM
   Wang, R
   Wang, T
   Qiu, YL
   Yu, HY
AF Wang, Kailong
   Chen, Qian
   Shao, Yingying
   Yin, Shuangshuang
   Liu, Caiyan
   Liu, Yiman
   Wang, Rui
   Wang, Tao
   Qiu, Yuling
   Yu, Haiyang
TI Anticancer activities of TCM and their active components against tumor
   metastasis
SO BIOMEDICINE & PHARMACOTHERAPY
LA English
DT Review
DE Cancer metastasis; Traditional Chinese medicine (TCM); TCM prescription;
   Chinese patent medicine; TCM monomer compound
ID EPITHELIAL-MESENCHYMAL TRANSITION; LUNG-CANCER CELLS; TRADITIONAL
   CHINESE MEDICINE; NF-KAPPA-B; HUMAN HEPATOCELLULAR-CARCINOMA; HUMAN
   GASTRIC ADENOCARCINOMA; BREAST-CANCER; IN-VITRO; COLORECTAL-CANCER;
   INHIBITS METASTASIS
AB Traditional Chinese Medicine (TCM) has the characteristics of multiple targets, slight side effects and good therapeutic effects. Good anti-tumor effects are shown by Traditional Chinese Medicine prescription, Chinese patent medicine, single Traditional Chinese Medicine and Traditional Chinese medicine monomer compound. Clinically, TCM prolonged the survival time of patients and improved the life quality of patients, due to less side effects. Cancer metastasis is a complex process involving numerous steps, multiple genes and their products. During the process of tumor metastasis, firstly, cancer cell increases its proliferative capacity by reducing autophagy and apoptosis, and then the cancer cell capacity is stimulated by increasing the ability of tumors to absorb nutrients from the outside through angiogenesis. Both of the two steps can increase tumor migration and invasion. Finally, the purpose of tumor metastasis is achieved. By inhibiting autophagy and apoptosis of tumor cells, angiogenesis and EMT outside the tumor can inhibit the invasion and migration of cancer, and consequently achieve the purpose of inhibiting tumor metastasis. This review explores the research achievements of Traditional Chinese Medicine on breast cancer, lung cancer, hepatic carcinoma, colorectal cancer, gastric cancer and other cancer metastasis in the past five years, summarizes the development direction of TCM on cancer metastasis research in the past five years and makes a prospect for the future.
C1 [Wang, Kailong; Chen, Qian; Shao, Yingying; Yin, Shuangshuang; Liu, Caiyan; Liu, Yiman; Wang, Rui; Wang, Tao; Yu, Haiyang] Tianjin Univ Tradit Chinese Med, State Key Lab Component Based Modern Chinese Med, Tianjin 301617, Peoples R China.
   [Qiu, Yuling] Tianjin Med Univ, Sch Pharm, Tianjin 300070, Peoples R China.
RP Yu, HY (corresponding author), Tianjin Univ Tradit Chinese Med, State Key Lab Component Based Modern Chinese Med, Tianjin 301617, Peoples R China.; Qiu, YL (corresponding author), Tianjin Med Univ, Sch Pharm, Tianjin 300070, Peoples R China.
EM qiuyuling@tmu.edu.cn; hyyu@tjutcm.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81873089, 81603253, 81973570]; Important
   Drug Development Fund, Ministry of Science and Technology of China
   [2018ZX09735-002, 2018ZX092011]
FX This work was supported by grants from National Natural Science
   Foundation of China (Nos. 81873089 and 81603253 to H. Yu, No. 81973570
   to Y. Qiu), Important Drug Development Fund, Ministry of Science and
   Technology of China (2018ZX09735-002 to T. Wang, No. 2018ZX092011 to Z.
   Li).
CR Acikgoz E, 2020, J CELL BIOCHEM, V121, P3313, DOI 10.1002/jcb.29602
   Akram M, 2017, BIOL RES, V50, DOI 10.1186/s40659-017-0140-9
   Bai CF, 2020, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01646
   Bhagya N, 2018, BIOMED PHARMACOTHER, V97, P624, DOI 10.1016/j.biopha.2017.10.116
   Camargo MC, 2019, HELICOBACTER, V24, DOI 10.1111/hel.12642
   Cao HH, 2016, SCI REP-UK, V6, DOI 10.1038/srep21731
   Casey SC, 2015, SEMIN CANCER BIOL, V35, pS199, DOI 10.1016/j.semcancer.2015.02.007
   Chai FN, 2018, BIOMED PHARMACOTHER, V103, P1002, DOI 10.1016/j.biopha.2018.04.052
   Chang CY, 2012, EVID-BASED COMPL ALT, V2012, DOI [10.1155/2012/952504, 10.1155/2012/125247]
   Chapelle N, 2018, DIGEST LIVER DIS, V50, P220, DOI 10.1016/j.dld.2017.12.004
   Chen C, 2019, MOLECULES, V24, DOI 10.3390/molecules24203725
   Chen CY, 2018, INT J MOL SCI, V19
   Chen P., 2019, BIOSCIENCE REP, V39
   Chen Y, 2018, BIOMED PHARMACOTHER, V101, P311, DOI 10.1016/j.biopha.2018.02.028
   Cheng Y, 2019, CANCER MANAG RES, V11, P5883, DOI 10.2147/CMAR.S194795
   Chu ZW, 2019, MOLECULES, V24, DOI 10.3390/molecules24193513
   Cui HX, 2015, ONCOL REP, V33, P1284, DOI 10.3892/or.2014.3682
   D'Agostino VG, 2015, SCI REP-UK, V5, DOI 10.1038/srep16478
   Dai L, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/6242103
   Dang HL, 2019, PHYTOMEDICINE, V64, DOI 10.1016/j.phymed.2019.153072
   Deng Y, 2017, 2017 4TH INTERNATIONAL CONFERENCE ON INFORMATION, CYBERNETICS AND COMPUTATIONAL SOCIAL SYSTEMS (ICCSS), P668, DOI 10.1109/ICCSS.2017.8091498
   Desreux JAC, 2018, EUR J OBSTET GYN R B, V230, P208, DOI 10.1016/j.ejogrb.2018.05.018
   Ding Y, 2019, INT J ONCOL, V54, P1995, DOI 10.3892/ijo.2019.4777
   Dou JW, 2019, BMC COMPLEM ALTERN M, V19, DOI 10.1186/s12906-019-2708-0
   Dragoj M, 2017, CELL ONCOL, V40, P47, DOI 10.1007/s13402-016-0304-6
   Du MT, 2017, BIOL RES, V50, DOI 10.1186/s40659-017-0141-8
   Du Q, 2013, FITOTERAPIA, V91, P68, DOI 10.1016/j.fitote.2013.08.008
   Elshaer M, 2018, LIFE SCI, V207, P340, DOI 10.1016/j.lfs.2018.06.028
   Fan L, 2015, PHYTOTHER RES, V29, P1366, DOI 10.1002/ptr.5389
   Fan L, 2018, BIOSCIENCE REP, V38, DOI 10.1042/BSR20180738
   Fan ZR, 2018, CELL PHYSIOL BIOCHEM, V47, P1977, DOI 10.1159/000491466
   Fang M, 2018, J ETHNOPHARMACOL, V213, P359, DOI 10.1016/j.jep.2017.11.025
   Feng YL, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1426434
   Ferlay J, 2019, INT J CANCER, V144, P1941, DOI 10.1002/ijc.31937
   Fu HY, 2016, AM J CHINESE MED, V44, P1491, DOI 10.1142/S0192415X1650083X
   Fu JJ, 2016, ONCOL REP, V35, P117, DOI 10.3892/or.2015.4394
   Fu XQ, 2018, EXP DERMATOL, V27, P201, DOI 10.1111/exd.13454
   Fu ZH, 2019, MED SCI MONITOR, V25, P6836, DOI 10.12659/MSM.915146
   Gai JQ, 2016, INT J ONCOL, V48, P338, DOI 10.3892/ijo.2015.3250
   Gao L, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-18325-7
   Gao YF, 2019, FREE RADICAL RES, V53, P324, DOI 10.1080/10715762.2019.1575512
   Guo CJ, 2019, PHARMACOL RES, V149, DOI 10.1016/j.phrs.2019.104463
   Guo D, 2019, INT J MOL SCI, V20
   Han B, 2018, PHYTOMEDICINE, V48, P152, DOI 10.1016/j.phymed.2017.12.027
   Han FY, 2018, STEROIDS, V140, P125, DOI 10.1016/j.steroids.2018.09.014
   Han Y, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20040925
   He XR, 2017, J ETHNOPHARMACOL, V204, P45, DOI 10.1016/j.jep.2017.04.008
   Hill A, 2019, CANCER TREAT RES, V178, P3, DOI 10.1007/978-3-030-16391-4_1
   Hu B, 2019, BMC COMPLEM ALTERN M, V19, DOI 10.1186/s12906-019-2477-9
   Hu B, 2018, BMC COMPLEM ALTERN M, V18, DOI 10.1186/s12906-018-2083-2
   Hu Q, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01150
   Huang C., 2018, J CELL PHYSL, V234, P11679
   Huang MN, 2018, LIFE SCI, V192, P55, DOI 10.1016/j.lfs.2017.11.024
   Huang WH, 2020, PHYTOMEDICINE, V76, DOI 10.1016/j.phymed.2020.153253
   Huang YX, 2017, CELL ONCOL, V40, P537, DOI 10.1007/s13402-017-0342-8
   Ji Q, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1119-y
   Jiang K, 2017, INT IMMUNOPHARMACOL, V42, P195, DOI 10.1016/j.intimp.2016.10.001
   Jiang M, 2019, THORAC CANCER, V10, P1319, DOI 10.1111/1759-7714.13019
   Jiang WG, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0639-1
   Jiang ZD, 2017, ANN NY ACAD SCI, V1403, P59, DOI 10.1111/nyas.13466
   Jieensinue S, 2018, BMC CELL BIOL, V19, DOI 10.1186/s12860-018-0174-z
   Jin LT, 2018, CANCER BIOL THER, V19, P858, DOI 10.1080/15384047.2018.1456599
   Jin YY, 2017, EXP THER MED, V14, P5527, DOI 10.3892/etm.2017.5242
   Karlsson MC, 2017, MOL ONCOL, V11, P781, DOI 10.1002/1878-0261.12092
   Kim BH, 2011, BRIT J PHARMACOL, V164, P106, DOI 10.1111/j.1476-5381.2011.01353.x
   Kong LY, 2019, BIOSCIENCE REP, V39, DOI 10.1042/BSR20190850
   Kumar KJS, 2018, PHYTOMEDICINE, V50, P223, DOI 10.1016/j.phymed.2018.04.010
   Lai YJ, 2016, MOLECULES, V21, DOI 10.3390/molecules21050553
   Lei CJ, 2019, CANCER MANAG RES, V11, P8635, DOI 10.2147/CMAR.S209861
   Li CJ, 2012, CANCER LETT, V319, P203, DOI 10.1016/j.canlet.2012.01.006
   Li CY, 2019, EUR J PHARMACOL, V858, DOI 10.1016/j.ejphar.2019.172463
   Li CY, 2018, ONCOL LETT, V16, P2289, DOI 10.3892/ol.2018.8943
   Li DD, 2019, ENVIRON TOXICOL PHAR, V66, P109, DOI 10.1016/j.etap.2018.12.005
   Li DM, 2020, BIOMED PHARMACOTHER, V123, DOI 10.1016/j.biopha.2019.109616
   Li HQ, 2019, INT J BIOL MACROMOL, V131, P886, DOI 10.1016/j.ijbiomac.2019.03.053
   Li JJ, 2019, PHARMACOL RES, V146, DOI 10.1016/j.phrs.2019.104313
   Li L, 2016, MOL MED REP, V13, P5276, DOI 10.3892/mmr.2016.5171
   Li LM, 2017, MOL MED REP, V16, P2461, DOI 10.3892/mmr.2017.6905
   Li YW, 2012, BRAZ J MED BIOL RES, V45, P1052, DOI [10.1590/S0100-879X2012001100009, 10.1590/S0100-879X2012007500125]
   Li ZH, 2018, ONCOTARGETS THER, V11, P2937, DOI 10.2147/OTT.S157949
   Liang LL, 2018, BASIC CLIN PHARMACOL, V123, P692, DOI 10.1111/bcpt.13090
   Liang SF, 2018, EVID-BASED COMPL ALT, V2018, DOI 10.1155/2018/5629304
   Liang YC, 2016, TUMOR BIOL, V37, P9837, DOI 10.1007/s13277-015-4748-5
   Lin FX, 2017, CHIN J INTEGR MED, V23, P648, DOI 10.1007/s11655-016-2581-3
   Lin HJ, 2015, BMC COMPLEM ALTERN M, V15, DOI 10.1186/s12906-015-0870-6
   Lin WF, 2016, EXP THER MED, V12, P3369, DOI 10.3892/etm.2016.3793
   Lin XL, 2020, PHYTOMEDICINE, V66, DOI 10.1016/j.phymed.2019.153112
   Lin X, 2016, J ETHNOPHARMACOL, V187, P187, DOI 10.1016/j.jep.2016.04.050
   Lin ZW, 2019, LIFE SCI, V218, P197, DOI 10.1016/j.lfs.2018.12.038
   Liu JY, 2016, CHIN MED-UK, V11, DOI 10.1186/s13020-016-0075-z
   Liu K, 2019, J CELL MOL MED, V23, P3040, DOI 10.1111/jcmm.14169
   Liu Q, 2019, ONCOL RES, V27, P1043, DOI 10.3727/096504019X15560124931900
   Liu XN, 2018, BMC COMPLEM ALTERN M, V18, DOI 10.1186/s12906-018-2123-y
   Liu XX, 2017, BIOMED PHARMACOTHER, V92, P429, DOI 10.1016/j.biopha.2017.05.102
   Liu X, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123478
   Liu YM, 2018, CANCER MED-US, V7, P5704, DOI 10.1002/cam4.1827
   Liu YT, 2019, BMC COMPLEM ALTERN M, V19, DOI 10.1186/s12906-019-2630-5
   Liu YX, 2018, BIOCHEM BIOPH RES CO, V498, P246, DOI 10.1016/j.bbrc.2018.01.091
   Liu ZM, 2020, J CELL BIOCHEM, V121, P2467, DOI 10.1002/jcb.29469
   Lou CH, 2017, ONCOL REP, V37, P179, DOI 10.3892/or.2016.5269
   Lu WL, 2019, J ETHNOPHARMACOL, V234, P204, DOI 10.1016/j.jep.2018.11.044
   Lu X, 2007, J MAMMARY GLAND BIOL, V12, P153, DOI 10.1007/s10911-007-9047-3
   Lyu ZK, 2017, MOL MED REP, V16, P7513, DOI 10.3892/mmr.2017.7576
   Ma M., 2016, SCI REP, V6
   Ma WN, 2017, PHYTOMEDICINE, V25, P45, DOI 10.1016/j.phymed.2016.12.013
   Ma Z, 2019, INT J NANOMED, V14, P2029, DOI 10.2147/IJN.S197889
   Machlowska J, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19061658
   Martinson HA, 2020, CANCERS, V12, DOI 10.3390/cancers12010198
   Mattar RE, 2016, WORLD J GASTROENTERO, V22, P567, DOI 10.3748/wjg.v22.i2.567
   Mierke CT, 2019, REP PROG PHYS, V82, DOI 10.1088/1361-6633/ab1628
   Millar FR, 2017, EUR RESPIR REV, V26, DOI 10.1183/16000617.0069-2016
   Nasim F, 2019, MED CLIN N AM, V103, P463, DOI 10.1016/j.mcna.2018.12.006
   Ni TY, 2019, BIOMED PHARMACOTHER, V118, DOI 10.1016/j.biopha.2019.109241
   Nourmohammadi S, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00314
   Orcutt ST, 2018, CANCER CONTROL, V25, DOI 10.1177/1073274817744621
   Osipov A, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0667-0
   Pan JL, 2017, BMC COMPLEM ALTERN M, V17, DOI 10.1186/s12906-017-2006-7
   Pang LN, 2017, INT J ONCOL, V51, P25, DOI 10.3892/ijo.2017.4014
   Paul CD, 2017, NAT REV CANCER, V17, P131, DOI 10.1038/nrc.2016.123
   Pei Z, 2017, BIOCHEM BIOPH RES CO, V493, P455, DOI 10.1016/j.bbrc.2017.08.170
   Peng F, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08422-y
   Peng WJ, 2018, J ETHNOPHARMACOL, V224, P140, DOI 10.1016/j.jep.2018.05.039
   Ping T.Z., 2017, SCUTELLARIN SUPPRESS, V9, P5094
   Qi YX, 2019, EXP MOL PATHOL, V107, P23, DOI 10.1016/j.yexmp.2019.01.008
   Qian YY, 2019, CHIN J INTEGR MED, V25, P334, DOI 10.1007/s11655-018-2562-9
   Qian YY, 2018, ONCOL LETT, V15, P243, DOI 10.3892/ol.2017.7341
   Rashid HU, 2019, EUR J MED CHEM, V161, P205, DOI 10.1016/j.ejmech.2018.10.037
   Reno TA, 2015, ANN THORAC SURG, V100, P1817, DOI 10.1016/j.athoracsur.2015.05.074
   Ribatti D, 2020, TRANSL ONCOL, V13, DOI 10.1016/j.tranon.2020.100773
   Ruan SM, 2018, J CANCER, V9, P3382, DOI 10.7150/jca.25136
   Salmani JMM, 2017, CHIN J NAT MEDICINES, V15, P321, DOI 10.1016/S1875-5364(17)30052-3
   Sekar V, 2016, BIOFACTORS, V42, P623, DOI 10.1002/biof.1298
   Sharma R, 2017, CELL ONCOL, V40, P199, DOI 10.1007/s13402-017-0324-x
   Shen JL, 2018, ONCOL LETT, V15, P4557, DOI 10.3892/ol.2018.7851
   Shen Lin, 2013, Lancet Oncol, V14, pe535, DOI 10.1016/S1470-2045(13)70436-4
   Shi J, 2016, J ETHNOPHARMACOL, V189, P230, DOI 10.1016/j.jep.2016.05.043
   Shi QT, 2018, MOL MED REP, V18, P131, DOI 10.3892/mmr.2018.8976
   Si LL, 2018, ONCOL REP, V39, P2160, DOI 10.3892/or.2018.6329
   Siegel RL, 2019, CA-CANCER J CLIN, V69, P7, DOI 10.3322/caac.21551
   Simula L, 2017, SEMIN CANCER BIOL, V47, P29, DOI 10.1016/j.semcancer.2017.06.007
   Song J, 2017, MOL CARCINOGEN, V56, P36, DOI 10.1002/mc.22471
   Song MY, 2020, CHEM-BIOL INTERACT, V317, DOI 10.1016/j.cbi.2020.108939
   Sun C, 2019, PHYTOMEDICINE, V61, DOI 10.1016/j.phymed.2019.152848
   Sun CL, 2019, CANCER BIOTHER RADIO, V34, P634, DOI 10.1089/cbr.2019.2874
   Sun XH, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/9241769
   Sun XW, 2015, ANTI-CANCER DRUG, V26, P641, DOI 10.1097/CAD.0000000000000229
   Sun Z, 2018, MED SCI MONITOR, V24, P2878, DOI 10.12659/MSM.909748
   Tan XL, 2016, BIOMED PHARMACOTHER, V83, P526, DOI 10.1016/j.biopha.2016.06.049
   Tan ZB, 2019, J ETHNOPHARMACOL, V232, P62, DOI 10.1016/j.jep.2018.12.019
   Tao FF, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0168892
   Tian ML, 2018, BRAZ J MED BIOL RES, V51, DOI [10.1590/1414-431X20187151, 10.1590/1414-431x20187151]
   Tian Y, 2017, PANCREAS, V46, P1076, DOI 10.1097/MPA.0000000000000895
   Tong JF, 2019, BIOSCIENCE REP, V39, DOI 10.1042/BSR20190452
   Tong NN, 2012, ONCOL LETT, V3, P1263, DOI 10.3892/ol.2012.644
   Tsuboki J, 2016, SCI REP-UK, V6, DOI 10.1038/srep29588
   Tsui KH, 2019, THERANOSTICS, V9, P6631, DOI 10.7150/thno.33353
   Wan LF, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-38391-9
   Wang C, 2016, J COSMOL ASTROPART P, DOI 10.1088/1475-7516/2016/06/006
   Wang J, 2015, APOPTOSIS, V20, P399, DOI 10.1007/s10495-014-1071-3
   Wang J, 2020, ACTA PHARMACOL SIN, V41, P82, DOI 10.1038/s41401-019-0271-3
   Wang J, 2016, ONCOL REP, V36, P1269, DOI 10.3892/or.2016.4954
   Wang JX, 2018, CHINESE J CANCER RES, V30, P112, DOI 10.21147/j.issn.1000-9604.2018.01.12
   Wang PW, 2016, SCI REP-UK, V6, DOI 10.1038/srep33709
   Wang R, 2019, MOL CANCER RES, V17, P2469, DOI 10.1158/1541-7786.MCR-19-0553
   Wang TL, 2018, BIOMED PHARMACOTHER, V106, P821, DOI 10.1016/j.biopha.2018.07.009
   Wang WD, 2019, ACTA PHARMACOL SIN, V40, P1219, DOI 10.1038/s41401-019-0240-x
   Wang Y, 2019, ARCH MED SCI, V15, P1017, DOI 10.5114/aoms.2018.77068
   Wang Y, 2020, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.01487
   Wang YZ, 2020, ONCOL LETT, V19, P3059, DOI 10.3892/ol.2020.11437
   Wang YC, 2019, MED SCI MONITOR, V25, P7538, DOI 10.12659/MSM.917115
   Wang YW, 2018, MOL MED REP, V18, P911, DOI 10.3892/mmr.2018.9023
   Wei CL, 2019, PHARMACOL RES, V144, P79, DOI 10.1016/j.phrs.2019.03.011
   Wen SY, 2019, PHYTOMEDICINE, V57, P352, DOI 10.1016/j.phymed.2018.12.033
   Wu C, 2017, ANTI-CANCER AGENT ME, V17, P1624, DOI 10.2174/1871520615666150930112631
   Wu CY, 2019, J ETHNOPHARMACOL, V235, P206, DOI 10.1016/j.jep.2019.02.004
   Wu CY, 2018, J ETHNOPHARMACOL, V211, P89, DOI 10.1016/j.jep.2017.09.033
   Wu J, 2018, ONCOTARGETS THER, V11, P2685, DOI 10.2147/OTT.S157129
   Wu LC, 2016, BIOORG MED CHEM LETT, V26, P4267, DOI 10.1016/j.bmcl.2016.07.045
   Wu Q, 2015, CHIN J NAT MEDICINES, V13, P925, DOI 10.1016/S1875-5364(15)30098-4
   Wu SZ, 2019, PHYTOMEDICINE, V59, DOI 10.1016/j.phymed.2019.152895
   Wu XW, 2018, ONCOTARGETS THER, V11, P6437, DOI 10.2147/OTT.S172048
   Xia C, 2015, CELL PHYSIOL BIOCHEM, V37, P816, DOI 10.1159/000430398
   Xia JF, 2018, BIOMED PHARMACOTHER, V99, P921, DOI 10.1016/j.biopha.2018.01.163
   Xue JL, 2019, MED SCI MONITOR, V25, P4793, DOI 10.12659/MSM.914446
   Yan XH, 2017, CELL BIOSCI, V7, DOI 10.1186/s13578-017-0179-x
   Yan YQ, 2018, EXP BIOL MED, V243, P645, DOI 10.1177/1535370218762514
   Yang J, 2017, ONCOTARGETS THER, V10, P5209, DOI 10.2147/OTT.S149609
   Yang YM, 2019, SEMIN LIVER DIS, V39, P26, DOI 10.1055/s-0038-1676806
   Ye L, 2015, ONCOL LETT, V10, P1240, DOI 10.3892/ol.2015.3459
   Ye RF, 2018, BIOMED PHARMACOTHER, V105, P962, DOI 10.1016/j.biopha.2018.06.065
   Ye TH, 2016, BIOMED PHARMACOTHER, V82, P319, DOI 10.1016/j.biopha.2016.05.015
   Yousefi M, 2017, CELL ONCOL, V40, P419, DOI 10.1007/s13402-017-0345-5
   Yu SB, 2018, BMC COMPLEM ALTERN M, V18, DOI 10.1186/s12906-018-2108-x
   Yu Y, 2009, CANCER-AM CANCER SOC, V115, P5132, DOI 10.1002/cncr.24567
   Yuan L, 2019, MOL MED REP, V20, P2783, DOI 10.3892/mmr.2019.10528
   Yuan L, 2019, EVID-BASED COMPL ALT, V2019, DOI 10.1155/2019/1431726
   Yuan ZG, 2017, BIOMED PHARMACOTHER, V89, P227, DOI 10.1016/j.biopha.2017.02.038
   Yue ZQ, 2015, MOL CELL BIOCHEM, V410, P143, DOI 10.1007/s11010-015-2546-4
   Zeng AQ, 2019, BIOORGAN MED CHEM, V27, P2546, DOI 10.1016/j.bmc.2019.03.033
   Zhang EY, 2017, ONCOL REP, V38, P359, DOI 10.3892/or.2017.5652
   Zhang J, 2020, N-S ARCH PHARMACOL, V393, P469, DOI 10.1007/s00210-019-01746-8
   Zhang JY, 2019, BIOCHEM BIOPH RES CO, V515, P57, DOI 10.1016/j.bbrc.2019.04.063
   Zhang K, 2018, EVID-BASED COMPL ALT, V2018, DOI 10.1155/2018/1495768
   Zhang LF, 2019, ONCOL REP, V42, P1843, DOI 10.3892/or.2019.7278
   Zhang L, 2015, IUBMB LIFE, V67, P778, DOI 10.1002/iub.1435
   Zhang L, 2019, ONCOL LETT, V18, P3274, DOI 10.3892/ol.2019.10604
   Zhang N, 2020, INT J BIOL SCI, V16, P147, DOI 10.7150/ijbs.36955
   Zhang W, 2018, PHYTOMEDICINE, V48, P51, DOI 10.1016/j.phymed.2018.04.058
   Zhang XR, 2018, MOL MED REP, V18, P3429, DOI 10.3892/mmr.2018.9318
   Zhang Y, 2017, BIOCHEM BIOPH RES CO, V488, P679, DOI 10.1016/j.bbrc.2017.04.086
   Zhang Z, 2017, ONCOL REP, V38, P1172, DOI 10.3892/or.2017.5760
   Zhang ZW, 2018, MED SCI MONITOR, V24, P6405, DOI 10.12659/MSM.912227
   Zhao L, 2015, INT J MOL MED, V36, P645, DOI 10.3892/ijmm.2015.2268
   Zhao X, 2018, J ETHNOPHARMACOL, V222, P261, DOI 10.1016/j.jep.2018.01.013
   Zhao Y, 2015, MOL CARCINOGEN, V54, pE81, DOI 10.1002/mc.22182
   Zhao YW, 2017, BIOMED PHARMACOTHER, V95, P18, DOI 10.1016/j.biopha.2017.08.045
   Zheng YF, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/8781690
   Zhou GN, 2019, AM J TRANSL RES, V11, P6290
   Zhou Y, 2019, J CELL PHYSIOL, V234, P17876, DOI 10.1002/jcp.28418
   Zhou ZL, 2019, EXP THER MED, V18, P2917, DOI 10.3892/etm.2019.7912
   Zhu YD, 2015, INTEGR CANCER THER, V14, P271, DOI 10.1177/1534735415572880
   Zhuang YW, 2018, BIOCHEM BIOPH RES CO, V505, P485, DOI 10.1016/j.bbrc.2018.09.094
NR 222
TC 18
Z9 19
U1 43
U2 67
PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY-LES-MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE
SN 0753-3322
EI 1950-6007
J9 BIOMED PHARMACOTHER
JI Biomed. Pharmacother.
PD JAN
PY 2021
VL 133
AR 111044
DI 10.1016/j.biopha.2020.111044
PG 17
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA PN6JO
UT WOS:000604583500002
PM 33378952
OA gold
HC Y
HP N
DA 2022-04-25
ER

PT J
AU Yang, B
   Zang, J
   Yuan, WL
   Jiang, XJ
   Zhang, F
AF Yang, Bo
   Zang, Jian
   Yuan, Weili
   Jiang, Xuejun
   Zhang, Fang
TI The miR-136-5p/ROCK1 axis suppresses invasion and migration, and
   enhances cisplatin sensitivity in head and neck cancer cells
SO EXPERIMENTAL AND THERAPEUTIC MEDICINE
LA English
DT Article
DE cell invasion; cell migration; cisplatin sensitivity; laryngeal squamous
   cell carcinoma; hypopharyngeal squamous cell carcinoma; microRNA-136-5p;
   Rho-associated coiled-coil containing protein kinase 1
ID PROTEIN-KINASE; COLON-CANCER; RHO; MIR-136; PROLIFERATION; METASTASIS;
   EXPRESSION; ROCK; RESISTANCE; CARCINOMA
AB Laryngeal squamous cell carcinoma (LSCC) and hypopharyngeal squamous cell carcinoma (HPSCC) are two types of head and neck cancers with high incidence rates and relatively poor prognoses. The aim of the present study was to determine the effects of microRNA (miR/miRNA)-136-5p and its downstream target, Rho-associated coiled-coil containing protein kinase 1 (ROCK1), on LSCC and HPSCC progression and cisplatin sensitivity. The miRNA and protein expression levels in head and neck cancer cell lines were evaluated using reverse transcription-quantitative PCR and western blotting, respectively. MTT, wound healing assays, transwell assays and flow cytometry analysis were performed to measure cell properties. The binding between miR-136-5p and ROCK1 was detected using a dual-luciferase reporter assay. Autophagy double-labeled adenoviral infection assays were used to assess cell autophagy. The results showed that miR-136-5p was expressed in LSCC and HPSCC cells. Functional experiments showed that the expression of miR-136-5p in LSCC and HPSCC cells was negatively correlated with cell viability, invasion and migration. Additionally, miR-136-5p overexpression inhibited epithelial-mesenchymal transition, whereas miR-136-5p knockdown had the opposite effect. Dual-luciferase reporter assays confirmed the targeting relationship between miR-136-5p and ROCK1. miR-136-5p overexpression increased the cisplatin sensitivity of LSCC and HPSCC cells by reducing cell viability, as well as promoting cell apoptosis and autophagy. miR-136-5p overexpression decreased the expression levels of its downstream target ROCK1 and attenuated activity of the Akt/mTOR signaling pathway in cisplatin-treated LSCC and HPSCC cells. Conversely, miR-136-5p knockdown increased ROCK1 levels and decreased cisplatin sensitivity of the LSCC and HPSCC cells by increasing cell viability and inhibiting cell apoptosis, which was reversed by ROCK1 inhibition using the ROCK1 inhibitor, Y27632. Taken together, the results showed that the miR-136-5p/ROCK1 axis inhibits cell invasion and migration, and increases the sensitivity of LSCC and HPSCC cells to cisplatin.
C1 [Yang, Bo; Zang, Jian; Jiang, Xuejun] China Med Univ, Hosp 1, Dept Otorhinolaryngol Head & Neck Surg, Shenyang 110001, Liaoning, Peoples R China.
   [Yuan, Weili] China Med Univ, Affiliated Hosp 4, Dept Oral & Maxillofacial Surg, Shenyang 110032, Liaoning, Peoples R China.
   [Zhang, Fang] China Med Univ, Affiliated Hosp 4, Dept Otorhinolaryngol Head & Neck Surg, 4 East Chongshan Rd, Shenyang 110032, Liaoning, Peoples R China.
RP Zhang, F (corresponding author), China Med Univ, Affiliated Hosp 4, Dept Otorhinolaryngol Head & Neck Surg, 4 East Chongshan Rd, Shenyang 110032, Liaoning, Peoples R China.
EM zhangfang_cmu4h@163.com
CR Amable L, 2016, PHARMACOL RES, V106, P27, DOI 10.1016/j.phrs.2016.01.001
   Azoulay-Alfaguter I, 2015, ONCOGENE, V34, P4613, DOI 10.1038/onc.2014.390
   Bhowmick NA, 2001, MOL BIOL CELL, V12, P27, DOI 10.1091/mbc.12.1.27
   Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241
   Bjorkoy G, 2005, J CELL BIOL, V171, P603, DOI 10.1083/jcb.200507002
   Bushati N, 2007, ANNU REV CELL DEV BI, V23, P175, DOI 10.1146/annurev.cellbio.23.090506.123406
   Carlsson L, 2017, CURR TREAT OPTION ON, V18, DOI 10.1007/s11864-017-0482-0
   Chaffer CL, 2016, CANCER METAST REV, V35, P645, DOI 10.1007/s10555-016-9648-7
   Chaffer CL, 2011, SCIENCE, V331, P1559, DOI 10.1126/science.1203543
   Chan JYK, 2019, SEMIN CANCER BIOL, V55, P1, DOI 10.1016/j.semcancer.2018.07.008
   Chen WH, 2014, J NEURO-ONCOL, V120, P43, DOI 10.1007/s11060-014-1535-x
   Chipuk JE, 2010, MOL CELL, V37, P299, DOI 10.1016/j.molcel.2010.01.025
   Cho ES, 2019, ARCH PHARM RES, V42, P14, DOI 10.1007/s12272-018-01108-7
   Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001
   Cristina V, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20215399
   Dasari S, 2014, EUR J PHARMACOL, V740, P364, DOI 10.1016/j.ejphar.2014.07.025
   del Peso L, 1997, ONCOGENE, V15, P3047
   Du WW, 2019, RESP RES, V20, DOI 10.1186/s12931-019-1184-x
   Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210
   Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516
   Fong PY, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0224665
   Glick D, 2010, J PATHOL, V221, P3, DOI 10.1002/path.2697
   Gong H, 2019, MED SCI MONITOR, V25, P3090, DOI 10.12659/MSM.912098
   Gregoire V, 2010, ANN ONCOL, V21, pv184, DOI 10.1093/annonc/mdq185
   Hu CP, 2019, INT J ONCOL, V55, P833, DOI 10.3892/ijo.2019.4864
   Imamura F, 2000, JPN J CANCER RES, V91, P811, DOI 10.1111/j.1349-7006.2000.tb01018.x
   Ishizaki T, 1997, FEBS LETT, V404, P118, DOI 10.1016/S0014-5793(97)00107-5
   Ishizaki T, 1996, EMBO J, V15, P1885, DOI 10.1002/j.1460-2075.1996.tb00539.x
   Janku F, 2011, NAT REV CLIN ONCOL, V8, P384, DOI 10.1038/nrclinonc.2011.82
   Kang WT, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-03240-z
   Lee YS, 2009, ANNU REV PATHOL-MECH, V4, P199, DOI 10.1146/annurev.pathol.4.110807.092222
   Liang HL, 2019, J CELL PHYSIOL, V234, P7266, DOI 10.1002/jcp.27484
   LIBBUS BL, 1988, CYTOGENET CELL GENET, V47, P181, DOI 10.1159/000132544
   Liu SJ, 2009, CANCER RES, V69, P8742, DOI 10.1158/0008-5472.CAN-09-1541
   Liu Y, 2017, MOL MED REP, V16, P7154, DOI 10.3892/mmr.2017.7460
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Mathew R, 2009, CELL, V137, P1062, DOI 10.1016/j.cell.2009.03.048
   Morgan-Fisher M, 2013, J HISTOCHEM CYTOCHEM, V61, P185, DOI 10.1369/0022155412470834
   Narumiya S, 2009, CANCER METAST REV, V28, P65, DOI 10.1007/s10555-008-9170-7
   Nowicka Z, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20194799
   Ohta T, 2012, CANCER BIOL THER, V13, P25, DOI 10.4161/cbt.13.1.18440
   Ren HP, 2018, ONCOTARGETS THER, V11, P67, DOI 10.2147/OTT.S113359
   Riento K, 2003, NAT REV MOL CELL BIO, V4, P446, DOI 10.1038/nrm1128
   Solomon B, 2018, SEMIN CANCER BIOL, V52, P228, DOI 10.1016/j.semcancer.2018.01.008
   Tanida I, 2004, INT J BIOCHEM CELL B, V36, P2503, DOI 10.1016/j.biocel.2004.05.009
   Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822
   Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262
   Wang ZX, 2020, BIOMED PHARMACOTHER, V125, DOI 10.1016/j.biopha.2020.109874
   Wong CCL, 2009, HEPATOLOGY, V49, P1583, DOI 10.1002/hep.22836
   Wu T, 2015, DRUG DES DEV THER, V9, DOI 10.2147/DDDT.S95606
   Xu ZR, 2020, APPL MICROBIOL BIOT, V104, P575, DOI 10.1007/s00253-019-10257-8
   Yan MS, 2016, ONCOL REP, V36, P65, DOI 10.3892/or.2016.4767
   Yao Q, 2011, TUMOR BIOL, V32, P1163, DOI 10.1007/s13277-011-0219-9
   YOUNG FE, 1990, TRANSFUSION, V30, P4, DOI 10.1046/j.1537-2995.1990.30190117628.x
   Yu L, 2018, EUR REV MED PHARMACO, V22, P7251, DOI 10.26355/eurrev_201811_16259
   Yuan QG, 2017, GENE, V628, P48, DOI 10.1016/j.gene.2017.07.031
   Zhang JB, 2015, INT J CLIN EXP PATHO, V8, P244
   Zhang WJ, 2020, J CELL PHYSIOL, V235, P5962, DOI 10.1002/jcp.29521
   Zhang YW, 2019, BIOMED PHARMACOTHER, V113, DOI 10.1016/j.biopha.2019.108686
   Zhao HN, 2015, ONCOL REP, V33, P591, DOI 10.3892/or.2014.3640
   Zheng JY, 2017, TUMOR BIOL, V39, P1, DOI 10.1177/1010428317706207
   Zhong Y, 2019, CANCER GENE THER, V26, P234, DOI 10.1038/s41417-018-0067-5
NR 62
TC 3
Z9 3
U1 0
U2 2
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792-0981
EI 1792-1015
J9 EXP THER MED
JI Exp. Ther. Med.
PD APR
PY 2021
VL 21
IS 4
AR 317
DI 10.3892/etm.2021.9748
PG 10
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA QI4EW
UT WOS:000618933600001
PM 33717260
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Smith, EL
   Schuchman, EH
AF Smith, Eric L.
   Schuchman, Edward H.
TI Acid sphingomyelinase overexpression enhances the antineoplastic effects
   of irradiation in vitro and in vivo
SO MOLECULAR THERAPY
LA English
DT Article
ID NIEMANN-PICK-DISEASE; RENAL-CELL CARCINOMA; RADIATION-INDUCED APOPTOSIS;
   HUMAN COLON-CANCER; PROSTATE-CANCER; GLUCOSYLCERAMIDE SYNTHASE;
   ADRIAMYCIN RESISTANCE; GLIOMA-CELLS; HUMAN-TUMORS; CERAMIDE
AB Exposure of cells or animals to stress frequently induces acid sphingomyelinase (ASM)-mediated ceramide production that leads to cell death. Consistent with this, overexpression of ASM in subcutaneous B16-F10 mouse melanomas, in combination with irradiation, resulted in tumors that were up to 12-fold smaller than irradiated control melanomas. Similarly, when irradiated melanomas were pretreated with a single, peritumoral injection of recombinant ASM (rhASM), the tumors were up to threefold smaller. The in vivo effect of ASM was likely due to enhanced cell death of the tumor cells themselves, as well as the surrounding microvascular endothelial cells. In vitro, rhASM had little or no effect on the growth of tumor cells, even in combination with irradiation. However, when the culture media was acidified to mimic the acidic microenvironment of solid tumors, rhASM-mediated cell death was markedly enhanced when combined with irradiation. Microscopic analysis suggested that this was associated with an increase in autophagy. rhASM has been produced for the treatment of the lysosomal storage disorder, type B Niemann-Pick disease, and is currently being evaluated in a phase-1 clinical trial. Based on the data presented in this article, we propose that further investigation of this protein and gene as antineoplastic agents also is warranted.
C1 [Smith, Eric L.; Schuchman, Edward H.] Mt Sinai Sch Med, Dept Genet & Genom Sci, New York, NY 10029 USA.
RP Schuchman, EH (corresponding author), Mt Sinai Sch Med, Dept Genet & Genom Sci, 1425 Madison Ave,Room 14-20A, New York, NY 10029 USA.
EM edward.schuchman@mssm.edu
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [2 R01 HD28607, 5 T32 GM007280]; EUNICE
   KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN
   DEVELOPMENTUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National
   Institute of Child Health & Human Development (NICHD) [R01HD028607]
   Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL
   SCIENCESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of General
   Medical Sciences (NIGMS) [T32GM007280] Funding Source: NIH RePORTER
FX We thank Xingxuan He and Chien-Ling Huang for help with the ceramide
   quantification assay, and Yu Zhou for help with bioluminescent imaging.
   We also thank John Martignetti and Goutham Narla for careful reading of
   the manuscript. This research was supported by a grant from the NIH (2
   R01 HD28607) to E. H. S. E. L. S. was supported, in part, by a Medical
   Scientist Training Program Grant from the NIH (5 T32 GM007280).
CR Alphonse G, 2002, INT J RADIAT BIOL, V78, P821, DOI 10.1080/09553000210153943
   Bionda C, 2007, FREE RADICAL BIO MED, V43, P681, DOI 10.1016/j.freeradbiomed.2007.04.031
   Bollinger CR, 2005, BBA-MOL CELL RES, V1746, P284, DOI 10.1016/j.bbamcr.2005.09.001
   Daido S, 2004, CANCER RES, V64, P4286, DOI 10.1158/0008-5472.CAN-03-3084
   Dimanche-Boitrel MT, 2005, DRUG RESIST UPDATE, V8, P5, DOI 10.1016/j.drup.2005.02.003
   Elojeimy S, 2007, MOL THER, V15, P1259, DOI 10.1038/sj.mt.6300167
   Garcia-Barros M, 2003, SCIENCE, V300, P1155, DOI 10.1126/science.1082504
   Grammatikos G, 2007, ANTIOXID REDOX SIGN, V9, P1449, DOI 10.1089/ars.2007.1673
   Grassme H, 2001, J BIOL CHEM, V276, P20589, DOI 10.1074/jbc.M101207200
   Gulbins E, 2003, ONCOGENE, V22, P7070, DOI 10.1038/sj.onc.1207146
   Gulbins Erich, 2002, Subcell Biochem, V36, P229
   Gumz ML, 2007, CLIN CANCER RES, V13, P4740, DOI 10.1158/1078-0432.CCR-07-0143
   He XX, 1999, BBA-PROTEIN STRUCT M, V1432, P251, DOI 10.1016/S0167-4838(99)00069-2
   He XX, 2003, ANAL BIOCHEM, V314, P116, DOI 10.1016/S0003-2697(02)00629-2
   He XX, 2001, ANAL BIOCHEM, V293, P204, DOI 10.1006/abio.2001.5108
   Higgins JPT, 2003, AM J PATHOL, V162, P925, DOI 10.1016/S0002-9440(10)63887-4
   Ivanchuk SM, 2001, J NEURO-ONCOL, V51, P219, DOI 10.1023/A:1010632309113
   Lacour S, 2004, CANCER RES, V64, P3593, DOI 10.1158/0008-5472.CAN-03-2787
   Lenburg ME, 2003, BMC CANCER, V3, DOI 10.1186/1471-2407-3-31
   Liu YY, 2000, J BIOL CHEM, V275, P7138, DOI 10.1074/jbc.275.10.7138
   Liu YY, 1999, J BIOL CHEM, V274, P1140, DOI 10.1074/jbc.274.2.1140
   Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239
   Melnikova VO, 2004, ONCOGENE, V23, P2347, DOI 10.1038/sj.onc.1207405
   Mikami T, 2002, J NEUROL SCI, V199, P39, DOI 10.1016/S0022-510X(02)00106-5
   Miranda SRP, 2000, FASEB J, V14, P1988, DOI 10.1096/fj.00-0014com
   Morita Y, 2000, NAT MED, V6, P1109, DOI 10.1038/80442
   Ogretmen B, 2004, NAT REV CANCER, V4, P604, DOI 10.1038/nrc1411
   Oh JE, 2006, ARCH PHARM RES, V29, P1140, DOI 10.1007/BF02969305
   Paris F, 2001, SCIENCE, V293, P293, DOI 10.1126/science.1060191
   Patschan S, 2008, AM J PHYSIOL-HEART C, V294, pH1119, DOI 10.1152/ajpheart.00713.2007
   Peng PL, 2008, INT J RADIAT ONCOL, V70, P529, DOI 10.1016/j.ijrobp.2007.08.034
   Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2
   Riboni L, 2002, GLIA, V39, P105, DOI 10.1002/glia.10087
   Rylova SN, 1998, BIOCHEMISTRY-MOSCOW+, V63, P1057
   Saad AF, 2007, CANCER BIOL THER, V6, P1455
   Santana P, 1996, CELL, V86, P189, DOI 10.1016/S0092-8674(00)80091-4
   Scarlatti F, 2004, J BIOL CHEM, V279, P18384, DOI 10.1074/jbc.M313561200
   Schissel SL, 1998, J BIOL CHEM, V273, P2738, DOI 10.1074/jbc.273.5.2738
   Seelan RS, 2000, GENE CHROMOSOME CANC, V29, P137, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1018>3.0.CO;2-E
   Selzner M, 2001, CANCER RES, V61, P1233
   SPENCE MW, 1989, J BIOL CHEM, V264, P5358
   Srikanth K. N., 2005, Sarcoma, V9, P33, DOI 10.1080/13577140500090030
   SUCHI M, 1992, P NATL ACAD SCI USA, V89, P3227, DOI 10.1073/pnas.89.8.3227
   THISTLETHWAITE AJ, 1985, INT J RADIAT ONCOL, V11, P1647, DOI 10.1016/0360-3016(85)90217-2
   VAUPEL P, 1989, CANCER RES, V49, P6449
   Yang C, 2008, AM J PHYSIOL-RENAL, V294, pF777, DOI 10.1152/ajprenal.00590.2007
   Zeidan YH, 2007, J BIOL CHEM, V282, P11549, DOI 10.1074/jbc.M609424200
NR 47
TC 32
Z9 35
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA
SN 1525-0016
J9 MOL THER
JI Mol. Ther.
PD SEP
PY 2008
VL 16
IS 9
BP 1565
EP 1571
DI 10.1038/mt.2008.145
PG 7
WC Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine,
   Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Genetics & Heredity; Research &
   Experimental Medicine
GA 342KG
UT WOS:000258782400009
PM 18628757
OA hybrid
DA 2022-04-25
ER

PT J
AU Mathieu, V
   Le Mercier, M
   De Neve, N
   Sauvage, S
   Gras, T
   Roland, I
   Lefranc, F
   Kiss, R
AF Mathieu, Veronique
   Le Mercier, Marie
   De Neve, Nancy
   Sauvage, Sebastien
   Gras, Thierry
   Roland, Isabelle
   Lefranc, Florence
   Kiss, Robert
TI Galectin-1 knockdown increases sensitivity to temozolomide in a B16F10
   mouse metastatic melanoma model
SO JOURNAL OF INVESTIGATIVE DERMATOLOGY
LA English
DT Article
ID LYSOSOMAL MEMBRANE PERMEABILIZATION; MALIGNANT GLIOMA-CELLS; INDUCED
   CYTOTOXICITY; TUMOR ANGIOGENESIS; FUTURE-ISSUES; CANCER-CELLS;
   COLON-CANCER; IN-VITRO; APOPTOSIS; RESISTANCE
AB The rapid increase in the incidence of malignant melanomas has not been associated with improved therapeutic options over the years. Indeed melanomas have proven resistant to apoptosis ( type I programmed cell death ( PCD)) and consequently to most chemotherapy and immunotherapy. It is believed that this resistance can be partly overcome by proautophagic drugs inducing type II ( autophagy) PCD. Change at the genomic, transcriptional, and post- translational level of G- proteins and protein kinases, including Ras, plays an important role in the ability of melanomas to resist apoptosis. Ras transformation itself requires membrane anchorage and the overexpression of galectin- 1 increases membrane- associated Ras. In this study, it has been found that decreasing galectin- 1 expression in B16F10 mouse melanoma cells in vitro by means of an antigalectin-1 small interfering RNA approach does not modify their sensitivity to type I and type II PCD. However, it does induce heat shock protein 70- mediated lysosomal membrane permeabilization, a process associated with cathepsin B release into the cytosol, which in turn is believed to sensitize the cells to the proautophagic effects of temozolomide when grafted in vivo. Furthermore, temozolomide when compared to the proapoptotic drug cisplatin, significantly increased the survival times of mice in the B16F10 melanoma model.
C1 Free Univ Brussels, Inst Pharm, Toxicol Lab, B-1050 Brussels, Belgium.
   Unibioscreen SA, Brussels, Belgium.
   Univ Libre Bruxelles, Erasmus Univ Hosp, Dept Neurosurg, Brussels, Belgium.
RP Kiss, R (corresponding author), Free Univ Brussels, Inst Pharm, Toxicol Lab, Campus Plaine,CP205-1,Blvd Triomphe, B-1050 Brussels, Belgium.
EM rkiss@ulb.ac.be
CR Atallah Ehab, 2005, Curr Treat Options Oncol, V6, P185
   Branle F, 2002, CANCER-AM CANCER SOC, V95, P641, DOI 10.1002/cncr.10710
   Camby I, 2002, J NEUROPATH EXP NEUR, V61, P585, DOI 10.1093/jnen/61.7.585
   Camby I, 2006, GLYCOBIOLOGY, V16, p137R, DOI 10.1093/glycob/cwl025
   Cheng Z, 2005, CANCER RES, V65, P4979, DOI 10.1158/0008-5472.CAN-03-3093
   Danguy A, 2002, BBA-GEN SUBJECTS, V1572, P285, DOI 10.1016/S0304-4165(02)00315-X
   Darro F, 2005, INT J ONCOL, V27, P607
   Debeir O, 2005, IEEE T MED IMAGING, V24, P697, DOI 10.1109/TMI.2005.846851
   Decaestecker C, 2007, MED RES REV, V27, P149, DOI 10.1002/med.20078
   DELBELLO B, ONCOGENE
   Douma S, 2004, NATURE, V430, P1034, DOI 10.1038/nature02765
   Eskelinen Eeva-Liisa, 2006, Molecular Aspects of Medicine, V27, P495, DOI 10.1016/j.mam.2006.08.005
   Fehrenbacher N, 2005, CANCER RES, V65, P2993, DOI 10.1158/0008-5472.CAN-05-0476
   Glinsky GV, 1996, CANCER LETT, V101, P43, DOI 10.1016/0304-3835(96)04112-2
   He SJ, 2005, MOL CANCER THER, V4, P996, DOI 10.1158/1535-7163.MCT-04-0252
   Hersey P, 2006, CURR OPIN ONCOL, V18, P189, DOI 10.1097/01.cco.0000208794.24228.9f
   Ingrassia L, 2006, CURR MED CHEM, V13, P3513, DOI 10.2174/092986706779026219
   Ivanov VN, 2003, ONCOGENE, V22, P3152, DOI 10.1038/sj.onc.1206456
   Kageshita T, 2002, INT J CANCER, V99, P809, DOI 10.1002/ijc.10436
   Kanzawa T, 2004, CELL DEATH DIFFER, V11, P448, DOI 10.1038/sj.cdd.4401359
   Kondo Y, 2005, NAT REV CANCER, V5, P726, DOI 10.1038/nrc1692
   Kroemer G, 2005, NAT REV CANCER, V5, P886, DOI 10.1038/nrc1738
   Kuwada SK, 2005, J BIOL CHEM, V280, P19027, DOI 10.1074/jbc.M410540200
   Lefranc F, 2005, J CLIN ONCOL, V23, P2411, DOI 10.1200/JCO.2005.03.089
   Lefranc F, 2004, CLIN CANCER RES, V10, P8250, DOI 10.1158/1078-0432.CCR-04-0343
   Lefranc F, 2006, EXPERT REV ANTICANC, V6, P719, DOI 10.1586/14737140.6.5.719
   Liu FT, 2005, NAT REV CANCER, V5, P29, DOI 10.1038/nrc1527
   Maecker HL, 2000, CANCER RES, V60, P4638
   Mathieu A, 2005, MODERN PATHOL, V18, P1264, DOI 10.1038/modpathol.3800416
   Mathieu V, 2005, NEOPLASIA, V7, P930, DOI 10.1593/neo.05379
   Mijatovic T, 2006, NEOPLASIA, V8, P402, DOI 10.1593/neo.05850
   Miller AJ, 2006, NEW ENGL J MED, V355, P51, DOI 10.1056/NEJMra052166
   Na KY, 2003, J AM SOC NEPHROL, V14, P283, DOI 10.1097/01.ASN.0000045050.19544.B2
   Nylandsted J, 2004, J EXP MED, V200, P425, DOI 10.1084/jem.20040531
   Ozawa K, 2001, CANCER RES, V61, P4206
   Pattingre S, 2006, CANCER RES, V66, P2885, DOI 10.1158/0008-5472.CAN-05-4412
   Paz A, 2001, ONCOGENE, V20, P7486, DOI 10.1038/sj.onc.1204950
   PERILLO NL, 1995, NATURE, V378, P736, DOI 10.1038/378736a0
   Roos WP, 2007, ONCOGENE, V26, P186, DOI 10.1038/sj.onc.1209785
   Rubinstein N, 2004, CANCER CELL, V5, P241, DOI 10.1016/S1535-6108(04)00024-8
   Schmitt E, 2006, CANCER RES, V66, P4191, DOI 10.1158/0008-5472.CAN-05-3778
   Schmitt E, 2003, CANCER RES, V63, P8233
   Smalley KSM, 2006, MOL CANCER THER, V5, P1136, DOI 10.1158/1535-7163.MCT-06-0084
   Stillman BN, 2006, J IMMUNOL, V176, P778, DOI 10.4049/jimmunol.176.2.778
   Stillman BN, 2005, BRAIN PATHOL, V15, P124
   Tas F, 2005, MELANOMA RES, V15, P543, DOI 10.1097/00008390-200512000-00010
   Thijssen VLJL, 2006, P NATL ACAD SCI USA, V103, P15975, DOI 10.1073/pnas.0603883103
   Tinari N, 2001, INT J CANCER, V91, P167, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1022>3.3.CO;2-Q
   Toker A, 2006, CANCER RES, V66, P3963, DOI 10.1158/0008-5472.CAN-06-0743
   Walzel H, 2002, CELL SIGNAL, V14, P861, DOI 10.1016/S0898-6568(02)00035-9
   Zubieta MR, 2006, AM J PATHOL, V168, P1666, DOI 10.2353/ajpath.2006.050971
NR 51
TC 80
Z9 82
U1 1
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0022-202X
EI 1523-1747
J9 J INVEST DERMATOL
JI J. Invest. Dermatol.
PD OCT
PY 2007
VL 127
IS 10
BP 2399
EP 2410
DI 10.1038/sj.jid.5700869
PG 12
WC Dermatology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Dermatology
GA 217FF
UT WOS:000249933100018
PM 17495956
OA Bronze
DA 2022-04-25
ER

PT J
AU Divya, D
   Nagarajaprakash, R
   Vidhyapriya, P
   Sakthivel, N
   Manimaran, B
AF Divya, Dhanaraj
   Nagarajaprakash, Ramamurthy
   Vidhyapriya, Pitchavel
   Sakthivel, Natarajan
   Manimaran, Bala
TI Single-Pot Self-Assembly of Heteroleptic Mn(I)-Based
   Aminoquinonato-Bridged Ester/Amide-Functionalized Dinuclear
   Metallastirrups: Potential Anticancer and Visible-Light-Triggered CORMs
SO ACS OMEGA
LA English
DT Article
ID CO-RELEASING MOLECULES; MANGANESE(I) TRICARBONYL COMPLEX;
   CARBON-MONOXIDE RELEASE; STRUCTURAL-CHARACTERIZATION; METAL
   COORDINATION; EXCITED-STATE; RECTANGLES; RHENIUM(I); LIGAND; PHOTOCORMS
AB Multicomponent self-assembly of Mn-2(CO)(10), a bis-chelating aminoquinonato (ON boolean AND ON) bridge (L), and an ester/amide-functionalized flexible neutral ditopic linker (L') has resulted into the formation of M2LL'-type manganese(I)-based dinuclear metallastirrups of general formula [{(CO)(3)Mn(mu-eta(4)-L) Mn(CO)(3)}(mu-L')] (1-10). Compounds 1-10 were accomplished via orthogonal bonding of the aminoquinone ligand (2,5-bis(n-butylamino)-1,4-benzoquinone/2,5-bis(phenethylamino)-1,4-benzoquinone) and ditopic pyridyl ligand to manganese carbonyl. The resultant metal-lastirrups were characterized using elemental analyses and IR, UV-vis, H-1 NMR, and electrospray ionization-mass spectroscopic techniques. The molecular structure of 6 was confirmed by single-crystal X-ray diffraction methods. Furthermore, molecular recognition capabilities of 1, 5, 7, and 9 were evaluated with aromatic compounds containing hydroxy/amine functionalities. Anticancer activities of compounds 1-3, 5-7, 9, and 10 were investigated against three cancer cell lines, that is, lung (A549), colon (HCT-15), and cervical (HeLa) as well as on normal cells (HEK 293). Compound 9 showed a broad-spectrum inhibition toward these cancer cells upon exposure to visible light. The myoglobin assay was performed using UV-vis absorption spectroscopy to investigate the visible-light-triggered CO release from 5 and 9 that could be related to their ability to effectively inhibit cancer cells. In addition, morphological studies confirmed the induction of autophagy due to the treatment of cancer cells using compound 9.
C1 [Divya, Dhanaraj; Manimaran, Bala] Pondicherry Univ, Dept Chem, Pondicherry 605014, India.
   [Vidhyapriya, Pitchavel; Sakthivel, Natarajan] Pondicherry Univ, Dept Biotechnol, Pondicherry 605014, India.
   [Nagarajaprakash, Ramamurthy] Lovely Profess Univ, Div Res & Dev, Chem Sci Res Grp, Phagwara 144411, Punjab, India.
RP Manimaran, B (corresponding author), Pondicherry Univ, Dept Chem, Pondicherry 605014, India.; Sakthivel, N (corresponding author), Pondicherry Univ, Dept Biotechnol, Pondicherry 605014, India.
EM manimaran.che@pondiuni.edu.in
OI Manimaran, Bala./0000-0002-2974-4949; D, Divya/0000-0002-8127-2678
FU Department of Science and Technology, Government of IndiaDepartment of
   Science & Technology (India); Council of Scientific and Industrial
   Research, Government of IndiaCouncil of Scientific & Industrial Research
   (CSIR) - India; CSIR, Government of IndiaCouncil of Scientific &
   Industrial Research (CSIR) - India; DBTDepartment of Biotechnology (DBT)
   India; DST-FIST ProgramDepartment of Science & Technology (India);
   UGC-SAPUniversity Grants Commission, India
FX We thank the Department of Science and Technology, Government of India,
   and Council of Scientific and Industrial Research, Government of India,
   for financial support. D. D. gratefully acknowledges CSIR, Government of
   India, for the award of Senior Research Fellowship and financial
   assistance. P. V. gratefully acknowledges DBT for the award of Senior
   Research Fellowship. We are grateful to the Central Instrumentation
   Facility, Pondicherry University, for providing spectral data. We are
   also thankful to the DST-FIST Program sponsored ESI-MS facility at the
   Department of Chemistry, Pondicherry University, and UGC-SAP-funded cell
   culture facility at the Department of Biotechnology, Pondicherry
   University. The authors thank the SAIF, IIT-Madras, Chennai, for
   providing single-crystal X-ray diffraction data.
CR ALSALIH T, 1993, J CHEM SOC DALTON, P3015, DOI 10.1039/dt9930003015
   Armarego WLF, 2009, PURIFICATION OF LABORATORY CHEMICALS, 6TH EDITION, P1
   Askes SHC, 2017, J AM CHEM SOC, V139, P15292, DOI 10.1021/jacs.7b07427
   Barba V, 2011, J ORGANOMET CHEM, V696, P1949, DOI 10.1016/j.jorganchem.2010.10.040
   Bayen S, 2007, DYES PIGMENTS, V75, P770, DOI 10.1016/j.dyepig.2006.07.033
   Beckmann U, 2003, INORG CHEM, V42, P1045, DOI 10.1021/ic020518z
   Benkstein KD, 1998, INORG CHEM, V37, P5404, DOI 10.1021/ic980513v
   Benkstein KD, 1998, J AM CHEM SOC, V120, P12982, DOI 10.1021/ja982363t
   Berends HM, 2012, INORG CHIM ACTA, V380, P141, DOI 10.1016/j.ica.2011.10.047
   Braunstein P, 2009, INORG CHEM, V48, P2534, DOI 10.1021/ic802042w
   Burchell TJ, 2004, INORG CHEM, V43, P5550, DOI 10.1021/ic049500+
   Carrington SJ, 2015, DALTON T, V44, P13828, DOI 10.1039/c5dt01007a
   Carrington SJ, 2013, CHEM COMMUN, V49, P11254, DOI 10.1039/c3cc46558f
   Chakraborty I, 2003, DALTON T, P134, DOI 10.1039/b208338h
   Chakraborty I, 2014, ACCOUNTS CHEM RES, V47, P2603, DOI 10.1021/ar500172f
   Chatterjee B, 2004, J AM CHEM SOC, V126, P10645, DOI 10.1021/ja0388919
   Das HS, 2009, CHEM COMMUN, P4387, DOI 10.1039/b907710c
   Deibel N, 2014, ORGANOMETALLICS, V33, P4756, DOI 10.1021/om500035c
   Dinolfo PH, 2004, J AM CHEM SOC, V126, P16814, DOI 10.1021/ja045457d
   Dordelmann G, 2012, CHEM COMMUN, V48, P11528, DOI 10.1039/c2cc36491c
   Dordelmann G, 2011, INORG CHEM, V50, P4362, DOI 10.1021/ic1024197
   EDWARDS DA, 1977, J ORGANOMET CHEM, V131, P73, DOI 10.1016/S0022-328X(00)91360-3
   ENGELKING PC, 1979, J AM CHEM SOC, V101, P5569, DOI 10.1021/ja00513a019
   Farrugia, 1997, J APPL CRYSTALLOGR, V30, P565, DOI [DOI 10.1107/S0021889897003117, 10.1107/S0021889897003117]
   Frantz S, 2004, CHEM-EUR J, V10, P149, DOI 10.1002/chem.200305369
   GEORGE MW, 1993, J CHEM SOC DALTON, P2977, DOI 10.1039/dt9930002977
   Ghisolfi A, 2014, INORG CHEM, V53, P5515, DOI 10.1021/ic500194y
   GIORDANO PJ, 1979, J AM CHEM SOC, V101, P2888, DOI 10.1021/ja00505a016
   Gonzalez MA, 2012, INORG CHEM, V51, P601, DOI 10.1021/ic2021287
   Govender P, 2013, INORG CHEM, V52, P5470, DOI 10.1021/ic400377k
   Govindarajan R, 2015, INORG CHEM, V54, P10686, DOI 10.1021/acs.inorgchem.5b01543
   Govindarajan R, 2018, CHEMISTRYSELECT, V3, P3742, DOI 10.1002/slct.201800296
   HOUK LW, 1966, INORG CHEM, V5, P2119, DOI 10.1021/ic50046a008
   Hu WJ, 2013, INORG CHEM, V52, P9309, DOI 10.1021/ic400751n
   Jiang XJ, 2017, INORG CHIM ACTA, V464, P125, DOI 10.1016/j.ica.2017.04.053
   Jimenez J, 2018, INORG CHEM, V57, P1766, DOI 10.1021/acs.inorgchem.7b02480
   Jimenez J, 2016, DALTON T, V45, P13204, DOI 10.1039/c6dt01358a
   Jo JH, 2017, INORG CHEM, V56, P8430, DOI 10.1021/acs.inorgchem.7b01101
   Karthikeyan M, 2018, J ORGANOMET CHEM, V866, P27, DOI 10.1016/j.jorganchem.2018.04.002
   Karthikeyan M., 2017, CHEMISTRYSELECT, V2, P3362, DOI DOI 10.1002/SLCT.201700646
   Karthikeyan S, 2015, DALTON T, V44, P17389, DOI 10.1039/c5dt01866h
   Kautz AC, 2016, DALTON T, V45, P18045, DOI 10.1039/c6dt03515a
   Kennedy RK, 2015, APOPTOSIS, V20, P858, DOI 10.1007/s10495-015-1118-0
   Kottelat E, 2016, DALTON T, V45, P6920, DOI 10.1039/c6dt00858e
   Kottelat E, 2017, INORGANICS, V5, DOI 10.3390/inorganics5020024
   Kubeil M, 2017, INORG CHEM, V56, P5941, DOI 10.1021/acs.inorgchem.7b00599
   Kubicka A, 2018, J PHOTOCH PHOTOBIO A, V351, P115, DOI 10.1016/j.jphotochem.2017.10.012
   Kumar CA, 2017, J ORGANOMET CHEM, V846, P152, DOI 10.1016/j.jorganchem.2017.06.003
   Kumar CA, 2016, INORG CHEM COMMUN, V64, P39, DOI 10.1016/j.inoche.2015.12.011
   Kumar U, 2019, ACS OMEGA, V4, P1923, DOI 10.1021/acsomega.8b03177
   Lalitha P, 2016, APOPTOSIS, V21, P566, DOI 10.1007/s10495-016-1221-x
   Lee CC, 2009, INORG CHEM, V48, P6329, DOI 10.1021/ic900040a
   Lee SJ, 2011, AM J RESP CELL MOL, V45, P867, DOI 10.1165/rcmb.2010-0352OC
   Leonidova A, 2014, DALTON T, V43, P4287, DOI 10.1039/c3dt51817e
   Manes TA, 2016, INORG CHEM, V55, P5127, DOI 10.1021/acs.inorgchem.5b02737
   Manimaran B, 2014, ORGANOMETALLICS, V33, P465, DOI 10.1021/om400673f
   Mansour AM, 2018, INORG CHIM ACTA, V480, P159, DOI 10.1016/j.ica.2018.05.009
   Mansour AM, 2017, APPL ORGANOMET CHEM, V31, DOI 10.1002/aoc.3564
   Marin-Garcia M, 2018, DALTON T, V47, P14293, DOI 10.1039/c8dt01584h
   MATONDO SOC, 1995, J CHEM SOC CHEM COMM, P161, DOI 10.1039/c39950000161
   MEYER TJ, 1986, PURE APPL CHEM, V58, P1193, DOI 10.1351/pac198658091193
   Mishra A, 2012, ORGANOMETALLICS, V31, P3519, DOI 10.1021/om2012826
   Motterlini R, 2002, CIRC RES, V90, pE17, DOI 10.1161/hh0202.104530
   Mullen GED, 2000, INORG CHEM, V39, P4093, DOI 10.1021/ic991240m
   Nagarajaprakash R, 2014, ORGANOMETALLICS, V33, P1367, DOI 10.1021/om400776m
   Niesel J, 2008, CHEM COMMUN, P1798, DOI 10.1039/b719075a
   Palao E, 2016, J AM CHEM SOC, V138, P126, DOI 10.1021/jacs.5b10800
   Paretzki A, 2010, CHEM COMMUN, V46, P1497, DOI 10.1039/b921731b
   Patra M, 2015, CHEM SCI, V6, P214, DOI 10.1039/c4sc02709d
   Peng P, 2013, ORG BIOMOL CHEM, V11, P6671, DOI 10.1039/c3ob41385c
   Pfeiffer H, 2009, DALTON T, P4292, DOI 10.1039/b819091g
   Pokharel UR, 2013, DALTON T, V42, P14064, DOI 10.1039/c3dt52208c
   Popova M, 2017, RSC ADV, V7, P21997, DOI 10.1039/c7ra02653f
   Rajakannu P, 2013, DALTON T, V42, P11359, DOI 10.1039/c3dt51096d
   Ramakrishna B, 2015, EUR J INORG CHEM, P5839, DOI 10.1002/ejic.201500962
   Reddy GU, 2017, CHEM SCI, V8, P6555, DOI 10.1039/c7sc01692a
   Rimmer RD, 2012, COORDIN CHEM REV, V256, P1509, DOI 10.1016/j.ccr.2011.12.009
   Rimmer RD, 2010, INORG CHEM, V49, P1180, DOI 10.1021/ic902147n
   Schatzschneider U, 2011, INORG CHIM ACTA, V374, P19, DOI 10.1016/j.ica.2011.02.068
   Schweinfurth D, 2013, INORG CHEM, V52, P10332, DOI 10.1021/ic400955c
   Schweinfurth D, 2011, INORG CHEM, V50, P1150, DOI 10.1021/ic101972u
   Sengupta S, 2003, EUR J INORG CHEM, P1157
   Sheldrick G M, 1997, SHELX 97 PROGRAM CRY
   Sheldrick GM, 2008, ACTA CRYSTALLOGR A, V64, P112, DOI 10.1107/S0108767307043930
   Simpson PV, 2015, J ORGANOMET CHEM, V782, P116, DOI 10.1016/j.jorganchem.2014.12.034
   Sommer MG, 2013, ORGANOMETALLICS, V32, P2069, DOI 10.1021/om300939x
   STEBLER M, 1987, INORG CHEM, V26, P1449, DOI 10.1021/ic00256a025
   Thanasekaran P, 2005, COORDIN CHEM REV, V249, P1085, DOI 10.1016/j.ccr.2004.11.006
   Ustun E, 2017, TRANSIT METAL CHEM, V42, P331, DOI 10.1007/s11243-017-0136-x
   Wahler K, 2014, EUR J INORG CHEM, V2014, P807
   Woessner SM, 1998, INORG CHEM, V37, P5406, DOI 10.1021/ic9805168
   Wu JY, 2008, ORGANOMETALLICS, V27, P2141, DOI 10.1021/om700873x
   Yang QZ, 2005, CHEM-EUR J, V11, P7237, DOI 10.1002/chem.200500704
   Yang SH, 2016, DALTON T, V45, P3727, DOI 10.1039/c5dt04479k
   Zeng Q, 2014, ORGANOMETALLICS, V33, P5002, DOI 10.1021/om500389y
   Zobi F, 2012, DALTON T, V41, P370, DOI 10.1039/c1dt10649j
   Zobi F, 2011, DALTON T, V40, P4994, DOI 10.1039/c1dt10110b
   Zobi F, 2010, INORG CHEM, V49, P7313, DOI 10.1021/ic100458j
   Zobi F, 2009, INORG CHEM, V48, P8965, DOI 10.1021/ic901031x
NR 99
TC 7
Z9 7
U1 2
U2 10
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 2470-1343
J9 ACS OMEGA
JI ACS Omega
PD JUL
PY 2019
VL 4
IS 7
BP 12790
EP 12802
DI 10.1021/acsomega.9b01438
PG 13
WC Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry
GA IS5FB
UT WOS:000482176800170
PM 31460403
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Zhang, X
   Huang, QB
   Wang, XH
   Xu, YY
   Xu, R
   Han, MZ
   Huang, B
   Chen, AJ
   Qiu, C
   Sun, T
   Wang, F
   Li, XG
   Wang, J
   Zhao, P
   Wang, XY
AF Zhang, Xin
   Huang, Qibing
   Wang, Xuehai
   Xu, Yangyang
   Xu, Ran
   Han, Mingzhi
   Huang, Bin
   Chen, Anjing
   Qiu, Chen
   Sun, Tao
   Wang, Feng
   Li, Xingang
   Wang, Jian
   Zhao, Peng
   Wang, Xinyu
TI Bufalin enhances radiosensitivity of glioblastoma by suppressing
   mitochondrial function and DNA damage repair
SO BIOMEDICINE & PHARMACOTHERAPY
LA English
DT Article
DE Bufalin; Glioblastoma; Mitochondria; RAD51; Radiosensitivity
ID LUNG-CANCER CELLS; PHASE-II; RADIATION; AUTOPHAGY; INHIBITION; RAD51;
   RADIOTHERAPY; ACTIVATION; INDUCTION; APOPTOSIS
AB Bufalin, a cardiotonic steroid found in the venom of the Chinese toad Bufo gargarizan, has been shown to inhibit the growth of human cancers, such as colon and bladder. Here, we investigated the response of U251 and U87MG glioblastoma (GBM) cell lines to bufalin in vitro and found that bufalin impaired several biological processes. First, in both U251 and U87 MG, bufalin reduced cell proliferation and induced a G2/M cell cycle arrest (similar to 10% vs similar to 30%, untreated vs treated cells, respectively). Second, bufalin disrupted the mitochondrial membrane potential, leading to reduced oxygen consumption and ATP production. Third, homologous recombination (HR) efficiency was reduced by similar to 40% in both cell lines in the presence of bufalin. At the molecular level, bufalin led to decreased RAD51 protein, a central player in HR, and increased gamma-H2AX, a marker for the presence of DNA double strand breaks. Finally, bufalin was additive with radiation in the treatment of GBM cells in vitro. Cell death increased significantly under combination treatment compared to radiation treatment alone. Our findings indicated that bufalin led to reduced mitochondrial and DNA repair function and therefore, might be a promising therapeutic drug to increase the sensitivity of GBM cells to radiotherapy. (C) 2017 Published by Elsevier Masson SAS.
C1 [Zhang, Xin; Xu, Yangyang; Xu, Ran; Han, Mingzhi; Huang, Bin; Chen, Anjing; Li, Xingang; Wang, Jian; Zhao, Peng; Wang, Xinyu] Shandong Univ, Qilu Hosp, Dept Neurosurg, Jinan 250012, Shandong, Peoples R China.
   [Zhang, Xin; Xu, Yangyang; Xu, Ran; Han, Mingzhi; Huang, Bin; Chen, Anjing; Li, Xingang; Wang, Jian; Zhao, Peng; Wang, Xinyu] Shandong Univ, Brain Sci Res Inst, Jinan 250012, Shandong, Peoples R China.
   [Huang, Qibing] Shandong Univ, Qilu Hosp, Dept Emergency Surg, Jinan 250012, Shandong, Peoples R China.
   [Wang, Xuehai] Weihai Municipal Hosp, Dept Otolaryngol, Weihai 264200, Shandong, Peoples R China.
   [Qiu, Chen] Shandong Univ, Qilu Hosp, Dept Radiat Oncol, Jinan 250012, Shandong, Peoples R China.
   [Sun, Tao; Wang, Feng] Ningxia Med Univ, Incubat Base Natl Key Lab, Ningxia Key Lab Craniocerebral Dis, Yinchuan 750004, Peoples R China.
   [Wang, Jian] Univ Bergen, Dept Biomed, N-5009 Bergen, Norway.
RP Zhao, P; Wang, XY (corresponding author), Shandong Univ, Qilu Hosp, Dept Neurosurg, Jinan 250012, Shandong, Peoples R China.; Zhao, P; Wang, XY (corresponding author), Shandong Univ, Brain Sci Res Inst, Jinan 250012, Shandong, Peoples R China.
EM zhaopengqilu@163.com; sjwwxy@126.com
RI Huang, Bin/AAT-4514-2021
OI Han, Mingzhi/0000-0001-8357-5974
FU Natural Science Foundation of ChinaNational Natural Science Foundation
   of China (NSFC) [81572487, 81402060]; Special Foundation for Taishan
   Scholars [tshw201502056]; Department of Science & Technology of Shandong
   Province [2015ZDXX0801A01, 2014kjhm0101]; Shandong Provincial
   Outstanding Medical Academic Professional Program; Fundamental Research
   Funds of Shandong University [2016JC019]; Stiftelsen Kristian Gerhard
   Jebsen; Norwegian Cancer SocietyNorwegian Cancer Society; Norwegian
   Research CouncilResearch Council of NorwayEuropean Commission; Norwegian
   Centre for International Cooperation in Education (SIU)
   [UTF-2014/10047]; Helse-Vest; Haukeland Hospital
FX This work was supported by the Natural Science Foundation of China Grant
   (81572487 and 81402060), the Special Foundation for Taishan Scholars
   (No. tshw201502056), the Department of Science & Technology of Shandong
   Province (2015ZDXX0801A01 and 2014kjhm0101), the Shandong Provincial
   Outstanding Medical Academic Professional Program, Fundamental Research
   Funds of Shandong University (2016JC019), Stiftelsen Kristian Gerhard
   Jebsen, Helse-Vest, Haukeland Hospital, the Norwegian Cancer Society,
   the Norwegian Research Council and the Norwegian Centre for
   International Cooperation in Education (SIU) (UTF-2014/10047).
CR Azzam EI, 2012, CANCER LETT, V327, P48, DOI 10.1016/j.canlet.2011.12.012
   Bao YH, 2007, CURR OPIN GENET DEV, V17, P126, DOI 10.1016/j.gde.2007.02.010
   Branzei D, 2008, NAT REV MOL CELL BIO, V9, P297, DOI 10.1038/nrm2351
   Carruthers R, 2015, MOL ONCOL, V9, P192, DOI 10.1016/j.molonc.2014.08.003
   de Laat WL, 1999, GENE DEV, V13, P768, DOI 10.1101/gad.13.7.768
   Desjardins A, 2007, J NEURO-ONCOL, V83, P53, DOI 10.1007/s11060-006-9302-2
   Feng TT, 2015, BIOMED PHARMACOTHER, V69, P260, DOI 10.1016/j.biopha.2014.11.021
   Goetze K, 2013, STRAHLENTHER ONKOL, V189, P782, DOI 10.1007/s00066-013-0371-9
   Gu W, 2014, ONCOL REP, V31, P216, DOI 10.3892/or.2013.2817
   Hou Lewis C, 2006, Neurosurg Focus, V20, pE5
   Hsui CM, 2013, INT J ONCOL, V43, P338, DOI 10.3892/ijo.2013.1942
   Lai TH, 2016, CLIN CANCER RES, V22, P3537, DOI 10.1158/1078-0432.CCR-15-1063
   LAWRENCE TS, 1988, INT J RADIAT ONCOL, V15, P953, DOI 10.1016/0360-3016(88)90132-0
   Lynam-Lennon N, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100738
   Rodriguez-Vargas JM, 2012, CELL RES, V22, P1181, DOI 10.1038/cr.2012.70
   Miao Q, 2013, INT J MOL SCI, V14, P1370, DOI 10.3390/ijms14011370
   Parplys AC, 2015, CELL CYCLE, V14, P3190, DOI 10.1080/15384101.2015.1055996
   Pastor N, 2003, DNA REPAIR, V2, P1353, DOI 10.1016/j.dnarep.2003.08.001
   Pawlik TM, 2004, INT J RADIAT ONCOL, V59, P928, DOI 10.1016/j.ijrobp.2004.03.005
   Qi FH, 2011, CANCER SCI, V102, P951, DOI 10.1111/j.1349-7006.2011.01900.x
   Richardson C, 2005, CANCER LETT, V218, P127, DOI 10.1016/j.canlet.2004.08.009
   Richardson RB, 2016, ONCOTARGET, V7, P21469, DOI 10.18632/oncotarget.7412
   Solaini G, 2010, BBA-BIOENERGETICS, V1797, P1171, DOI 10.1016/j.bbabio.2010.02.011
   Taylor MRG, 2015, CELL, V162, P271, DOI 10.1016/j.cell.2015.06.015
   Vredenburgh JJ, 2007, CLIN CANCER RES, V13, P1253, DOI 10.1158/1078-0432.CCR-06-2309
   Wang L, 2011, ANTICANCER RES, V31, P2141
   Wu SH, 2014, AM J CHINESE MED, V42, P729, DOI 10.1142/S0192415X14500475
   Xie CM, 2011, FREE RADICAL BIO MED, V51, P1365, DOI 10.1016/j.freeradbiomed.2011.06.016
   Yu CH, 2008, CANCER SCI, V99, P2467, DOI 10.1111/j.1349-7006.2008.00966.x
   Zhang D, 2015, CANCER BIOL THER, V16, P1005, DOI 10.1080/15384047.2015.1046022
   Zhou HJ, 2014, BIOMATERIALS, V35, P1597, DOI 10.1016/j.biomaterials.2013.11.020
NR 31
TC 9
Z9 10
U1 2
U2 9
PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI PARIS
PA 23 RUE LINOIS, 75724 PARIS, FRANCE
SN 0753-3322
EI 1950-6007
J9 BIOMED PHARMACOTHER
JI Biomed. Pharmacother.
PD OCT
PY 2017
VL 94
BP 627
EP 635
DI 10.1016/j.biopha.2017.07.136
PG 9
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA FP6MU
UT WOS:000417741000069
PM 28787697
DA 2022-04-25
ER

PT J
AU Masuelli, L
   Benvenuto, M
   Izzi, V
   Zago, E
   Mattera, R
   Cerbelli, B
   Potenza, V
   Fazi, S
   Ciuffa, S
   Tresoldi, I
   Lucarelli, E
   Modesti, A
   Bei, R
AF Masuelli, Laura
   Benvenuto, Monica
   Izzi, Valerio
   Zago, Erika
   Mattera, Rosanna
   Cerbelli, Bruna
   Potenza, Vito
   Fazi, Sara
   Ciuffa, Sara
   Tresoldi, Ilaria
   Lucarelli, Enrico
   Modesti, Andrea
   Bei, Roberto
TI In vivo and in vitro inhibition of osteosarcoma growth by the pan Bcl-2
   inhibitor AT-101
SO INVESTIGATIONAL NEW DRUGS
LA English
DT Article
DE AT-101; Bcl-2 inhibitor; Osteosarcoma; Apoptosis; Polyphenol
ID HIGH-GRADE OSTEOSARCOMA; CARCINOMA CELL-LINES; PHASE-II TRIAL; INDUCED
   APOPTOSIS; BREAST-CANCER; BECLIN 1; AUTOPHAGY; GOSSYPOL; CURCUMIN;
   CISPLATIN
AB Osteosarcoma (OS) is the most common primary malignant bone tumor and mainly affects children and adolescents. The OS five-year survival rate remains very low. Thus, novel therapeutic protocols for the treatment of OS are needed. Several approaches targeting deregulated signaling pathways have been proposed. The antitumoral effects of polyphenols, which are naturally occurring compounds with potent antioxidant and anti-inflammatory activity, have been investigated in different tumors. Gossypol, which is a natural polyphenolic aldehyde isolated from the seeds of the cotton plant, has been shown to exert antitumoral activity in leukemia and lymphoma and in breast, head and neck, colon and prostate cancers. Therefore, in this study, we evaluated the effect of AT-101, which is the (-) enantiomer and more active form of gossypol, on the growth of human and murine OS cells in vitro and in vivo. Several clinical trials employing AT-101 have been performed, and some clinical trials are ongoing. Our results showed for the first time that AT-101 significantly inhibits OS cell growth in a dose- and time-dependent manner, inducing apoptosis and necrosis and partially activating autophagy. Our results demonstrated that AT-101 inhibits prosurvival signaling pathways depending on Akt, p38 MAPK and JNK. In addition, treatment with AT-101 increases the survival of OS-bearing mice. Overall, these results suggest that AT-101 is a candidate chemo-supportive molecule for the development of novel chemotherapeutic protocols for the treatment of OS.
C1 [Masuelli, Laura; Zago, Erika; Fazi, Sara] Univ Rome Sapienza, Dept Expt Med, I-00164 Rome, Italy.
   [Benvenuto, Monica; Mattera, Rosanna; Potenza, Vito; Ciuffa, Sara; Tresoldi, Ilaria; Modesti, Andrea; Bei, Roberto] Univ Roma Tor Vergata, Dept Clin Sci & Translat Med, I-00133 Rome, Italy.
   [Izzi, Valerio] Univ Oulu, Oulu Ctr Cell Matrix Res, FIN-90014 Oulu, Finland.
   [Cerbelli, Bruna] Polo Pontino Sapienza Univ, Dept Medicosurg Sci & Biotechnol, I-04100 Latina, Italy.
   [Lucarelli, Enrico] IRCCS, Ist Ortoped Rizzoli, Osteoarticolar Regenerat Lab, I-40136 Bologna, Italy.
RP Masuelli, L (corresponding author), Univ Rome Sapienza, Dept Expt Med, I-00164 Rome, Italy.
EM laura.masuelli@uniromal.it
RI Bei, Roberto/W-8023-2019; Enrico, Lucarelli/G-3588-2015; Masuelli,
   Laura/AGW-4259-2022; Benvenuto, Monica/K-2685-2016
OI Enrico, Lucarelli/0000-0002-6681-6374; Benvenuto,
   Monica/0000-0002-2520-1306; MASUELLI, Laura/0000-0001-8174-8034; Izzi,
   Valerio/0000-0002-9960-4917
CR Abdullah LN, 2013, CLIN TRANSL MED, V2, DOI 10.1186/2001-1326-2-3
   AbdulSalam SF, 2016, BIOCHEMISTRY-US, V55, P5341, DOI 10.1021/acs.biochem.6b00703
   Anderson JL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133610
   Angulo P, 2017, J HEMATOL ONCOL, V10, DOI 10.1186/s13045-016-0373-z
   Baggstrom MQ, 2011, J THORAC ONCOL, V6, P1757, DOI 10.1097/JTO.0b013e31822e2941
   Balakrishnan K, 2009, BLOOD, V113, P149, DOI 10.1182/blood-2008-02-138560
   Benvenuto M, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01269
   Benvenuto M, 2017, INT J FOOD SCI NUTR, V68, P298, DOI 10.1080/09637486.2016.1236077
   Benvenuto M, 2016, ONCOTARGET, V7, P9250, DOI 10.18632/oncotarget.7062
   Benvenuto M, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0455-7
   Benvenuto M, 2013, FRONT BIOSCI-LANDMRK, V18, P1291, DOI 10.2741/4180
   Beristain AG, 2012, J CELL SCI, V125, P943, DOI 10.1242/jcs.094029
   Billard C, 2013, MOL CANCER THER, V12, P1691, DOI 10.1158/1535-7163.MCT-13-0058
   Bishop MW, 2016, CURR OPIN PEDIATR, V28, P26, DOI 10.1097/MOP.0000000000000298
   Chandhanayingyong Chandhanarat, 2012, Sarcoma, V2012, P404810, DOI 10.1155/2012/404810
   Checquolo S, 2010, ONCOGENE, V29, P1463, DOI 10.1038/onc.2009.446
   Cialfi S, 2014, CELL CYCLE, V13, P2046, DOI 10.4161/cc.29079
   ClinicalTrials.gov, 2019, CLINICALTRIALS GOV I
   Coutinho EM, 2002, CONTRACEPTION, V65, P259, DOI 10.1016/S0010-7824(02)00294-9
   De Amicis A, 2015, MUTAT RES-GEN TOX EN, V793, P150, DOI 10.1016/j.mrgentox.2015.06.003
   Filomeni G, 2015, CELL DEATH DIFFER, V22, P377, DOI 10.1038/cdd.2014.150
   Focaccetti C, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20071714
   Fridman JS, 2003, ONCOGENE, V22, P9030, DOI 10.1038/sj.onc.1207116
   Gobeil S, 2001, CELL DEATH DIFFER, V8, P588, DOI 10.1038/sj.cdd.4400851
   Goncalves C, 2015, LIFE SCI, V130, P47, DOI 10.1016/j.lfs.2015.03.009
   Gonzalez-Polo RA, 2005, J CELL SCI, V118, P3091, DOI 10.1242/jcs.02447
   Grignani G, 2012, ANN ONCOL, V23, P508, DOI 10.1093/annonc/mdr151
   Grignani G, 2015, LANCET ONCOL, V16, P98, DOI 10.1016/S1470-2045(14)71136-2
   Gupte A, 2015, CLIN CANCER RES, V21, P3216, DOI 10.1158/1078-0432.CCR-14-3026
   Hayden JB, 2006, ORTHOP CLIN N AM, V37, P1, DOI 10.1016/j.ocl.2005.06.004
   Heist RS, 2010, J THORAC ONCOL, V5, P1637, DOI 10.1097/JTO.0b013e3181e8f4dc
   Hong AM, 2013, ANN ONCOL, V24, P2676, DOI 10.1093/annonc/mdt252
   Kang MA, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2011.134
   Kang R, 2011, CELL DEATH DIFFER, V18, P571, DOI 10.1038/cdd.2010.191
   Keshmiri-Neghab H, 2014, PHARM BIOL, V52, P124, DOI 10.3109/13880209.2013.832776
   Konopleva M, 2006, CANCER CELL, V10, P375, DOI 10.1016/j.ccr.2006.10.006
   Koul Hari K, 2013, Genes Cancer, V4, P342, DOI 10.1177/1947601913507951
   La Sala D, 2003, ONCOGENE, V22, P3518, DOI 10.1038/sj.onc.1206487
   Li HY, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2014.543
   Li TS, 2010, STEM CELLS, V28, P1178, DOI 10.1002/stem.438
   Lin L, 2015, MOL CELL ONCOL, V2, DOI 10.4161/23723556.2014.985913
   Liu G, 2009, CLIN CANCER RES, V15, P3172, DOI 10.1158/1078-0432.CCR-08-2985
   Lussier DM, 2015, J IMMUNOTHER CANCER, V3, DOI 10.1186/s40425-015-0067-z
   Mancini M, 2017, MICROCIRCULATION, V24, DOI 10.1111/micc.12298
   Mason NJ, 2016, CLIN CANCER RES, V22, P4380, DOI 10.1158/1078-0432.CCR-16-0088
   Masood A, 2012, BRIT J HAEMATOL, V157, P59, DOI 10.1111/j.1365-2141.2011.08984.x
   Masuelli L, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2017.1356151
   Masuelli L, 2017, ONCOTARGET, V8, P34405, DOI 10.18632/oncotarget.14907
   Masuelli L, 2016, TUMOR BIOL, V37, P3705, DOI 10.1007/s13277-015-4207-3
   Masuelli L, 2014, ONCOTARGET, V5, P10745, DOI 10.18632/oncotarget.2534
   Masuelli L, 2012, FRONT BIOSCI-LANDMRK, V17, P498, DOI 10.2741/3940
   Masuelli L, 2010, CANCER IMMUNOL IMMUN, V59, P1247, DOI 10.1007/s00262-010-0850-0
   McCubrey JA, 2007, BBA-MOL CELL RES, V1773, P1263, DOI 10.1016/j.bbamcr.2006.10.001
   Miller Benjamin J, 2013, J Bone Joint Surg Am, V95, pe89, DOI 10.2106/JBJS.L.01189
   Mirabello L, 2009, INT J CANCER, V125, P229, DOI 10.1002/ijc.24320
   Misaghi A, 2018, SICOT-J, V4, DOI 10.1051/sicotj/2017028
   Mohammad RM, 2015, SEMIN CANCER BIOL, V35, pS78, DOI 10.1016/j.semcancer.2015.03.001
   Opydo-Chanek M, 2017, BIOCHEM PHARMACOL, V136, P12, DOI 10.1016/j.bcp.2017.03.006
   Prieto-Vila M, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18122574
   Ready N, 2011, J THORAC ONCOL, V6, P781, DOI 10.1097/JTO.0b013e31820a0ea6
   Reed JC, 2018, CELL DEATH DIFFER, V25, P3, DOI 10.1038/cdd.2017.188
   Ren T, 2015, DRUG DES DEV THER, V9, P2887, DOI 10.2147/DDDT.S82724
   Rivas S, 2018, BIOMEDICINES, V6, DOI 10.3390/biomedicines6010029
   Schelman WR, 2014, INVEST NEW DRUG, V32, P295, DOI 10.1007/s10637-013-9999-7
   Shamas-Din A, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a008714
   Sinha S, 2008, ONCOGENE, V27, pS137, DOI 10.1038/onc.2009.51
   Sonpavde G, 2012, ANN ONCOL, V23, P1803, DOI 10.1093/annonc/mdr555
   Strober Warren, 2015, Curr Protoc Immunol, V111, DOI 10.1002/0471142735.ima03bs111
   Tian X, 2016, SCI CHINA LIFE SCI, V59, P122, DOI 10.1007/s11427-016-5003-z
   Tournier Cathy, 2013, Genes Cancer, V4, P397, DOI 10.1177/1947601913486349
   Touzeau C, 2018, LEUKEMIA, V32, P1899, DOI 10.1038/s41375-018-0223-9
   Tseng SC, 2017, J AGR FOOD CHEM, V65, P2670, DOI 10.1021/acs.jafc.6b04800
   Van Poznak C, 2001, BREAST CANCER RES TR, V66, P239, DOI 10.1023/A:1010686204736
   Vandenberg CJ, 2013, BLOOD, V121, P2285, DOI 10.1182/blood-2013-01-475855
   Wang GP, 2006, J MED CHEM, V49, P6139, DOI 10.1021/jm060460o
   Woessmann W, 2002, CANCER CHEMOTH PHARM, V50, P397, DOI 10.1007/s00280-002-0502-y
   Zhang YW, 2017, EXP THER MED, V14, P593, DOI 10.3892/etm.2017.4529
   Zhu J, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.488
   Zuch D, 2012, J CELL BIOCHEM, V113, P1282, DOI 10.1002/jcb.24002
NR 79
TC 5
Z9 5
U1 3
U2 7
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0167-6997
EI 1573-0646
J9 INVEST NEW DRUG
JI Invest. New Drugs
PD JUN
PY 2020
VL 38
IS 3
BP 675
EP 689
DI 10.1007/s10637-019-00827-y
PG 15
WC Oncology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Pharmacology & Pharmacy
GA LK9XS
UT WOS:000531213000011
PM 31264066
DA 2022-04-25
ER

PT J
AU Nguyen, CB
   Kotturi, H
   Waris, G
   Mohammed, A
   Chandrakesan, P
   May, R
   Sureban, S
   Weygant, N
   Qu, DF
   Rao, CV
   Dhanasekaran, DN
   Bronze, MS
   Houchen, CW
   Ali, N
AF Nguyen, Charles B.
   Kotturi, Hari
   Waris, Gulam
   Mohammed, Altaf
   Chandrakesan, Parthasarathy
   May, Randal
   Sureban, Sripathi
   Weygant, Nathaniel
   Qu, Dongfeng
   Rao, Chinthalapally V.
   Dhanasekaran, Danny N.
   Bronze, Michael S.
   Houchen, Courtney W.
   Ali, Naushad
TI (Z)-3,5,4'-Trimethoxystilbene Limits Hepatitis C and Cancer
   Pathophysiology by Blocking Microtubule Dynamics and Cell-Cycle
   Progression
SO CANCER RESEARCH
LA English
DT Article
ID DOUBLECORTIN-LIKE KINASE; RESVERATROL ANALOG
   (Z)-3,5,4'-TRIMETHOXYSTILBENE; ADVANCED HEPATOCELLULAR-CARCINOMA;
   GENOTYPE 1 INFECTION; MESENCHYMAL TRANSITION; STEM-CELLS; TUMOR; GROWTH;
   INHIBITION; MECHANISM
AB Hepatocellular carcinoma (HCC) is the third most common cause of cancer-related deaths worldwide. Chronic hepatitis C virus (HCV) infection causes induction of several tumors/cancer stem cell (CSC) markers and is known to be a major risk factor for development of HCC. Therefore, drugs that simultaneously target viral replication and CSC properties are needed for a risk-free treatment of advanced stage liver diseases, including HCC. Here, we demonstrated that (Z)-3,5,4'-trimethoxystilbene (Z-TMS) exhibits potent antitumor and anti-HCV activities without exhibiting cytotoxicity to human hepatocytes in vitro or in mice livers. Diethylnitrosamine (DEN)/carbon tetrachloride (CCl4) extensively induced expression of DCLK1 (a CSC marker) in the livers of C57BL/6 mice following hepatic injury. Z-TMS exhibited hepatoprotective effects against DEN/CCl4-induced injury by reducing DCLK1 expression and improving histologic outcomes. The drug caused bundling of DCLK1 with microtubules and blocked cell-cycle progression at G(2)-M phase in hepatoma cells via downregulation of CDK1, induction of p21(cip1/waf1) expression, and inhibition of Akt (Ser(473)) phosphorylation. Z-TMS also inhibited proliferation of erlotinib-resistant lung adenocarcinoma cells (H1975) bearing the T790M EGFR mutation, most likely by promoting autophagy and nuclear fragmentation. In conclusion, Z-TMS appears to be a unique therapeutic agent targeting HCV and concurrently eliminating cells with neoplastic potential during chronic liver diseases, including HCC. It may also be a valuable drug for targeting drug-resistant carcinomas and cancers of the lungs, pancreas, colon, and intestine, in which DCLK1 is involved in tumorigenesis. (C) 2016 AACR.
C1 [Nguyen, Charles B.; Mohammed, Altaf; Rao, Chinthalapally V.] Univ Oklahoma, Hlth Sci Ctr, Coll Med, Oklahoma City, OK 73190 USA.
   [Kotturi, Hari] Univ Cent Oklahoma, Dept Biol, Edmond, OK USA.
   [Waris, Gulam] Rosalind Franklin Univ Med & Sci, Dept Microbiol & Immunol, N Chicago, IL USA.
   [Mohammed, Altaf; Chandrakesan, Parthasarathy; Sureban, Sripathi; Rao, Chinthalapally V.; Dhanasekaran, Danny N.; Houchen, Courtney W.; Ali, Naushad] Univ Oklahoma, Hlth Sci Ctr, Peggy & Charles Stephenson Canc Ctr, Oklahoma City, OK 73190 USA.
   [Mohammed, Altaf; Rao, Chinthalapally V.] Univ Oklahoma, Hlth Sci Ctr, Ctr Canc Prevent & Drug Dev, Hematol Oncol Sect, Oklahoma City, OK USA.
   [Chandrakesan, Parthasarathy; May, Randal; Sureban, Sripathi; Weygant, Nathaniel; Qu, Dongfeng; Bronze, Michael S.; Houchen, Courtney W.; Ali, Naushad] Univ Oklahoma, Hlth Sci Ctr, Dept Med, Sect Digest Dis & Nutr, Oklahoma City, OK 73190 USA.
   [Chandrakesan, Parthasarathy; May, Randal; Sureban, Sripathi; Qu, Dongfeng; Houchen, Courtney W.; Ali, Naushad] Dept Vet Affairs Med Ctr, Oklahoma City, OK 73104 USA.
   [Dhanasekaran, Danny N.] Univ Oklahoma, Hlth Sci Ctr, Dept Cell Biol, Oklahoma City, OK USA.
RP Houchen, CW (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Peggy & Charles Stephenson Canc Ctr, Oklahoma City, OK 73190 USA.; Houchen, CW (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Med, Sect Digest Dis & Nutr, Oklahoma City, OK 73190 USA.; Houchen, CW (corresponding author), Dept Vet Affairs Med Ctr, Oklahoma City, OK 73104 USA.; Ali, N (corresponding author), Univ Oklahoma, Hlth Sci Ctr, 975 NE 10th St BRC1266, Oklahoma City, OK 73104 USA.
EM Courtney-houchen@ouhsc.edu; naushad-ali@ouhsc.edu
RI Sureban, Sripathi/Q-8232-2019; Chandrakesan, Parthasarathy/AAB-9136-2020
OI Weygant, Nathaniel/0000-0001-7861-6532; Sureban,
   Sripathi/0000-0001-5476-9593
FU NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department
   of Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of General Medical Sciences (NIGMS) [P20GM103639]
   Funding Source: NIH RePORTER; NIGMS NIH HHSUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of General Medical Sciences (NIGMS) [P20 GM103639]
   Funding Source: Medline
CR Afdhal N, 2014, NEW ENGL J MED, V370, P1889, DOI 10.1056/NEJMoa1402454
   Afdhal N, 2014, NEW ENGL J MED, V370, P1483, DOI 10.1056/NEJMoa1316366
   Ali N, 2015, ONCOTARGET, V6, P20327, DOI 10.18632/oncotarget.3972
   Ali N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080304
   Ali N, 2011, J VIROL, V85, P12292, DOI 10.1128/JVI.05920-11
   Bartosch B, 2009, J HEPATOL, V51, P810, DOI 10.1016/j.jhep.2009.05.008
   Baur JA, 2006, NATURE, V444, P337, DOI 10.1038/nature05354
   Bertino G, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/203693
   Borriello A, 2014, CANCER TREAT RES, V159, P167, DOI 10.1007/978-3-642-38007-5_10
   Caviglia Jorge Matias, 2015, Methods Mol Biol, V1267, P165, DOI 10.1007/978-1-4939-2297-0_8
   Chabert P, 2006, BIOFACTORS, V27, P37, DOI 10.1002/biof.5520270104
   Chen KF, 2011, J PHARMACOL EXP THER, V337, P155, DOI 10.1124/jpet.110.175786
   Chow AKM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078675
   Dapito DH, 2012, CANCER CELL, V21, P504, DOI 10.1016/j.ccr.2012.02.007
   Diao JY, 2012, J VIROL, V86, P10935, DOI 10.1128/JVI.00750-12
   El-Serag HB, 2012, GASTROENTEROLOGY, V142, P1264, DOI 10.1053/j.gastro.2011.12.061
   Gauthier A, 2013, HEPATOL RES, V43, P147, DOI 10.1111/j.1872-034X.2012.01113.x
   Guo JT, 2001, J VIROL, V75, P8516, DOI 10.1128/JVI.75.18.8516-8523.2001
   Iqbal J, 2013, J BIOL CHEM, V288, P36994, DOI 10.1074/jbc.M113.492314
   Jung Y, 2015, ARCH PHARM RES, V38, P414, DOI 10.1007/s12272-015-0570-2
   Kandel ES, 2002, MOL CELL BIOL, V22, P7831, DOI 10.1128/MCB.22.22.7831-7841.2002
   Kao CL, 2009, INT J RADIAT ONCOL, V74, P219, DOI 10.1016/j.ijrobp.2008.12.035
   Kasai T, 2014, J STEM CELLS REGEN, V10, pP2
   Kavallaris M, 2010, NAT REV CANCER, V10, P194, DOI 10.1038/nrc2803
   Kim MH, 2003, NAT STRUCT BIOL, V10, P324, DOI 10.1038/nsb918
   Lai CK, 2008, J VIROL, V82, P8838, DOI 10.1128/JVI.00398-08
   Li JP, 2014, MOL MED REP, V10, P1717, DOI 10.3892/mmr.2014.2417
   Lin HS, 2010, J PHARMACEUT BIOMED, V53, P693, DOI 10.1016/j.jpba.2010.03.028
   Lin PT, 2000, J NEUROSCI, V20, P9152
   Liu B, 2014, MOL MED REP, V10, P1697, DOI 10.3892/mmr.2014.2406
   Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857
   Lupberger J, 2011, NAT MED, V17, P589, DOI 10.1038/nm.2341
   MACRAE WD, 1984, J ETHNOPHARMACOL, V12, P75, DOI 10.1016/0378-8741(84)90088-6
   Majumdar A, 2012, NAT REV GASTRO HEPAT, V9, P530, DOI 10.1038/nrgastro.2012.114
   Nelson HB, 2006, J VIROL, V80, P1181, DOI 10.1128/JVI.80.3.1181-1190.2006
   Novelle MG, 2015, AGEING RES REV, V21, P1, DOI 10.1016/j.arr.2015.01.002
   Padhya KT, 2013, CURR OPIN GASTROEN, V29, P285, DOI 10.1097/MOG.0b013e32835ff1cf
   Schneider Y, 2003, INT J CANCER, V107, P189, DOI 10.1002/ijc.11344
   Singh CK, 2013, ANN NY ACAD SCI, V1290, P113, DOI 10.1111/nyas.12160
   Souza GR, 2010, NAT NANOTECHNOL, V5, P291, DOI 10.1038/nnano.2010.23
   Sureban SM, 2015, ONCOTARGET, V6, P37200, DOI 10.18632/oncotarget.5808
   Tresguerres IF, 2014, REJUV RES, V17, P439, DOI 10.1089/rej.2014.1551
   Uehara T, 2013, TOXICOL SCI, V132, P53, DOI 10.1093/toxsci/kfs342
   Weygant N, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-103
   Yamashita T, 2013, J CLIN INVEST, V123, P1911, DOI 10.1172/JCI66024
   Yang HL, 2010, J BIOL CHEM, V285, P32242, DOI 10.1074/jbc.M110.160820
   Yang JD, 2010, NAT REV GASTRO HEPAT, V7, P448, DOI 10.1038/nrgastro.2010.100
   Zhou BBS, 2009, NAT REV DRUG DISCOV, V8, P806, DOI 10.1038/nrd2137
NR 48
TC 15
Z9 15
U1 1
U2 6
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD AUG 15
PY 2016
VL 76
IS 16
BP 4887
EP 4896
DI 10.1158/0008-5472.CAN-15-2722
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA DU6BI
UT WOS:000382297700029
PM 27287718
OA Green Accepted, hybrid
DA 2022-04-25
ER

PT J
AU Khan, MZI
   Tam, SY
   Law, HKW
AF Khan, Md Zahirul Islam
   Tam, Shing Yau
   Law, Helen Ka Wai
TI Autophagy-Modulating Long Non-coding RNAs (LncRNAs) and Their Molecular
   Events in Cancer
SO FRONTIERS IN GENETICS
LA English
DT Review
DE autophagy; long non-coding RNAs; cancer; therapy; biomarkers
ID PROMOTES CELL-PROLIFERATION; HEPATOCELLULAR-CARCINOMA; GASTRIC-CANCER;
   ACTIVATES AUTOPHAGY; COLORECTAL-CANCER; PANCREATIC-CANCER;
   TUMOR-SUPPRESSOR; PROSTATE-CANCER; CISPLATIN SENSITIVITY; GROWTH ARREST
AB Cancer is a global threat of health. Cancer incidence and death is also increasing continuously because of poor understanding of diseases. Although, traditional treatments (surgery, radiotherapy, and chemotherapy) are effective against primary tumors, death rate is increasing because of metastasis development where traditional treatments have failed. Autophagy is a conserved regulatory process of eliminating proteins and damaged organelles. Numerous research revealed that autophagy has dual sword mechanisms including cancer progressions and suppressions. In most of the cases, it maintains homeostasis of cancer microenvironment by providing nutritional supplement under starvation and hypoxic conditions. Over the past few decades, stunning research evidence disclosed significant roles of long non-coding RNAs (lncRNAs) in the regulation of autophagy. LncRNAs are RNA containing more than 200 nucleotides, which have no protein-coding ability but they are found to be expressed in most of the cancers. It is also proved that, autophagy-modulating lncRNAs have significant impacts on pro-survival or pro-death roles in cancers. In this review, we highlighted the recently identified autophagy-modulating lncRNAs, their signaling transduction in cancer and mechanism in cancer. This review will explore newly emerging knowledge of cancer genetics and it may provide novel targets for cancer therapy.
C1 [Khan, Md Zahirul Islam; Tam, Shing Yau; Law, Helen Ka Wai] Hong Kong Polytech Univ, Fac Hlth & Social Sci, Dept Hlth Technol & Informat, Hong Kong, Peoples R China.
RP Law, HKW (corresponding author), Hong Kong Polytech Univ, Fac Hlth & Social Sci, Dept Hlth Technol & Informat, Hong Kong, Peoples R China.
EM hthelen@polyu.edu.hk
RI Tam, Shing Yau/AAZ-1345-2020; Tam, Shing Yau/AAN-4109-2020; Khan,
   Zahirul Islam/AAV-4254-2020
OI Tam, Shing Yau/0000-0002-5899-1041; Islam Khan, Md
   Zahirul/0000-0001-7048-2613
FU Hong Kong Polytechnic UniversityHong Kong Polytechnic University
FX This work was supported by Departmental Start-up and Seed Funding for
   HL, and Departmental Postgraduate Funds for MK and ST, The Hong Kong
   Polytechnic University.
CR Amaravadi R, 2016, GENE DEV, V30, P1913, DOI 10.1101/gad.287524.116
   Avalos Y, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/603980
   Bao X, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.31
   Blessing AM, 2017, AUTOPHAGY, V13, P506, DOI 10.1080/15548627.2016.1268300
   Bogenrieder T, 2003, ONCOGENE, V22, P6524, DOI 10.1038/sj.onc.1206757
   Botti G, 2017, CURR DRUG TARGETS, V18, P27, DOI 10.2174/1389450117666151209122950
   BRANNAN CI, 1990, MOL CELL BIOL, V10, P28, DOI 10.1128/MCB.10.1.28
   Chen CL, 2015, BIOMATERIALS, V44, P71, DOI 10.1016/j.biomaterials.2014.12.023
   Chen S, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.486
   Chen SS, 2017, ONCOTARGET, V8, P110685, DOI 10.18632/oncotarget.22161
   Chen T, 2016, MINERVA MED, V107, P251
   Chen X, 2017, CELL PHYSIOL BIOCHEM, V41, P1424, DOI 10.1159/000468005
   Chen YM, 2016, ONCOTARGET, V7, P59604, DOI 10.18632/oncotarget.10730
   Cicchini M, 2015, CLIN CANCER RES, V21, P498, DOI 10.1158/1078-0432.CCR-13-2438
   Cui HM, 2002, CANCER RES, V62, P6442
   Cui M, 2016, BIOCHEM BIOPH RES CO, V471, P10, DOI 10.1016/j.bbrc.2015.12.101
   Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210
   Forouzanfar MH, 2016, LANCET, V388, P1659, DOI 10.1016/S0140-6736(16)31679-8
   Fu ZQ, 2017, BIOCHEM BIOPH RES CO, V492, P480, DOI 10.1016/j.bbrc.2017.08.070
   Gao D, 2017, J CELL BIOCHEM, V118, P3341, DOI 10.1002/jcb.25987
   Gao QJ, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00814
   Gong X, 2017, CANCER GENE THER, V24, P381, DOI 10.1038/cgt.2017.32
   Gu J, 2018, CELL PHYSIOL BIOCHEM, V48, P194, DOI 10.1159/000491718
   Guo D, 2018, EXP CELL RES, V362, P172, DOI 10.1016/j.yexcr.2017.11.014
   Gutschner T, 2013, J MOL MED, V91, P791, DOI 10.1007/s00109-013-1028-y
   He JH, 2016, TUMOR BIOL, V37, P16163, DOI 10.1007/s13277-016-5450-y
   He YQ, 2017, ONCOTARGET, V8, P73282, DOI 10.18632/oncotarget.19931
   Hou ZH, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317718135
   Hu MC, 2016, INT J CLIN EXP PATHO, V9, P5015
   Hu XW, 2018, CURR OPIN GENET DEV, V48, P8, DOI 10.1016/j.gde.2017.10.004
   Hu YR, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0743-3
   Huang FT, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0845-6
   Huang J, 2018, J CELL BIOCHEM, V119, P3853, DOI 10.1002/jcb.26464
   Huang XX, 2017, J HEMATOL ONCOL, V10, DOI 10.1186/s13045-017-0428-9
   Huo JF, 2019, J CELL BIOCHEM, V120, P6127, DOI 10.1002/jcb.27900
   Isin M, 2015, FRONT GENET, V6, DOI 10.3389/fgene.2015.00168
   Ji P, 2003, ONCOGENE, V22, P8031, DOI 10.1038/sj.onc.1206928
   Jiang CM, 2018, BIOMED PHARMACOTHER, V97, P844, DOI 10.1016/j.biopha.2017.10.146
   Kim KH, 2014, NAT REV ENDOCRINOL, V10, P322, DOI 10.1038/nrendo.2014.35
   Ktistakis NT, 2016, TRENDS CELL BIOL, V26, P624, DOI 10.1016/j.tcb.2016.03.006
   Kung CP, 2011, CRIT REV EUKAR GENE, V21, P71, DOI 10.1615/CritRevEukarGeneExpr.v21.i1.50
   Li CG, 2016, CANCER CHEMOTH PHARM, V78, P1199, DOI 10.1007/s00280-016-3178-4
   Li H, 2017, MED SCI MONITOR, V23, P919, DOI 10.12659/MSM.903462
   Li HL, 2018, BIOCHEM BIOPH RES CO, V495, P2350, DOI 10.1016/j.bbrc.2017.12.114
   Li J, 2018, BIOSCIENCE REP, V38, DOI 10.1042/BSR20171150
   Li L, 2016, MOL CANCER THER, V15, P2232, DOI 10.1158/1535-7163.MCT-16-0008
   Li MW, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0128-y
   Li S, 2018, J CELL PHYSIOL, V233, P6679, DOI 10.1002/jcp.26325
   Li XJ, 2017, ONCOL REP, V38, P465, DOI 10.3892/or.2017.5650
   Li YH, 2017, DIGEST DIS SCI, V62, P3426, DOI 10.1007/s10620-017-4831-4
   Li YH, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317705790
   Li ZG, 2016, BEHAV BRAIN RES, V305, P265, DOI 10.1016/j.bbr.2016.03.023
   Li ZH, 2017, CELL PHYSIOL BIOCHEM, V42, P1407, DOI 10.1159/000479205
   Lin CP, 2017, ANNU REV CANC BIOL, V1, P163, DOI 10.1146/annurev-cancerbio-050216-034443
   Liu ZQ, 2016, BIOCHEM BIOPH RES CO, V473, P1268, DOI 10.1016/j.bbrc.2016.04.054
   Loewen G, 2014, J HEMATOL ONCOL, V7, DOI 10.1186/s13045-014-0090-4
   Loewer S, 2010, NAT GENET, V42, P1113, DOI 10.1038/ng.710
   Lu DP, 2017, CLIN CHIM ACTA, V474, P1, DOI 10.1016/j.cca.2017.08.038
   Luo J, 2017, ONCOTARGET, V8, P22187, DOI 10.18632/oncotarget.14728
   Ma BB, 2017, MOL MED REP, V16, P2946, DOI 10.3892/mmr.2017.6897
   Ma BB, 2017, BBA-MOL CELL RES, V1864, P1393, DOI 10.1016/j.bbamcr.2017.05.008
   Ma CH, 2016, TUMOR BIOL, V37, P1437, DOI 10.1007/s13277-015-4521-9
   Ma L, 2018, ONCOL REP, V39, P1132, DOI 10.3892/or.2018.6178
   Ma YW, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317694326
   Ma ZH, 2017, ONCOTARGETS THER, V10, P4711, DOI 10.2147/OTT.S136915
   Matouk IJ, 2016, ONCOTARGET, V7, P3748, DOI 10.18632/oncotarget.6387
   Miao ZM, 2016, MINERVA MED, V107, P392
   Miyoshi N, 2000, GENES CELLS, V5, P211, DOI 10.1046/j.1365-2443.2000.00320.x
   Mizushima N, 2007, GENE DEV, V21, P2861, DOI 10.1101/gad.1599207
   Mizushima N, 2011, CELL, V147, P728, DOI 10.1016/j.cell.2011.10.026
   Mowers EE, 2017, ONCOGENE, V36, P1619, DOI 10.1038/onc.2016.333
   Pan Y, 2016, CELL PHYSIOL BIOCHEM, V40, P219, DOI 10.1159/000452539
   Panzitt K, 2007, GASTROENTEROLOGY, V132, P330, DOI 10.1053/j.gastro.2006.08.026
   Peng WX, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0727-3
   Pickard MR, 2015, GENES-BASEL, V6, P484, DOI 10.3390/genes6030484
   Popa I, 2007, MODERN PATHOL, V20, P1121, DOI 10.1038/modpathol.3800963
   Qi P, 2016, MOL CANCER, V15, DOI 10.1186/s12943-016-0524-4
   Rinn JL, 2007, CELL, V129, P1311, DOI 10.1016/j.cell.2007.05.022
   Sankaranarayanan R, 2014, BMC MED, V12, DOI 10.1186/1741-7015-12-3
   Santana-Codina N, 2017, ANNU REV CANC BIOL, V1, P19, DOI 10.1146/annurev-cancerbio-041816-122338
   SCHNEIDER C, 1988, CELL, V54, P787, DOI 10.1016/S0092-8674(88)91065-3
   Shaker OG, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-16500-4
   Shan TD, 2016, ONCOTARGET, V7, P961, DOI 10.18632/oncotarget.5830
   Shen YM, 2017, EXP CELL RES, V358, P188, DOI 10.1016/j.yexcr.2017.06.016
   Song J, 2014, J ORTHOP RES, V32, P1628, DOI 10.1002/jor.22718
   Sun MY, 2017, BIOTECHNOL LETT, V39, P1477, DOI 10.1007/s10529-017-2392-4
   Sun T, 2018, PHARMACOL RES, V129, P151, DOI 10.1016/j.phrs.2017.11.009
   Takahashi K, 2014, FEBS OPEN BIO, V4, P458, DOI 10.1016/j.fob.2014.04.007
   Wang P, 2017, ONCOTARGETS THER, V10, P5137, DOI 10.2147/OTT.S146423
   Wang S, 2016, CELL REPROGRAM, V18, P319, DOI 10.1089/cell.2016.0001
   Wang Y, 2014, ONCOL LETT, V8, P1947, DOI 10.3892/ol.2014.2487
   Wang YH, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08890-2
   Wang Z, 2016, CANC TRANSL MED, V2, P147, DOI DOI 10.4103/2395-3977.192932
   Wang ZG, 2017, ONCOTARGET, V8, P31465, DOI 10.18632/oncotarget.16356
   Wei GH, 2017, EUR REV MED PHARMACO, V21, P3850
   White E, 2015, J CLIN INVEST, V125, P42, DOI 10.1172/JCI73941
   World Health Organization, 2018, CANCER
   Xiong H, 2017, ONCOGENE, V36, P3528, DOI 10.1038/onc.2016.521
   Xiong YB, 2018, ONCOL REP, V39, P967, DOI 10.3892/or.2018.6204
   Xiu YL, 2017, ONCOTARGET, V8, P31727, DOI 10.18632/oncotarget.15955
   Xu ZJ, 2017, ONCOL REP, V37, P1359, DOI 10.3892/or.2017.5416
   Yang L, 2016, MOL BIOSYST, V12, P2605, DOI 10.1039/c6mb00114a
   Yang LX, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.464
   Ying L, 2013, MOL BIOSYST, V9, P407, DOI 10.1039/c2mb25386k
   Yu X, 2018, CANCER BIOL MED, V15, P228, DOI 10.20892/j.issn.2095-3941.2017.0150
   Yu X, 2017, J CELL MOL MED, V21, P410, DOI 10.1111/jcmm.12956
   Yuan P, 2016, BIOCHEM BIOPH RES CO, V478, P1067, DOI 10.1016/j.bbrc.2016.08.065
   ZEIDLER R, 1994, GENE CHROMOSOME CANC, V9, P282, DOI 10.1002/gcc.2870090408
   Zhan HX, 2016, CANCER LETT, V374, P261, DOI 10.1016/j.canlet.2016.02.018
   Zhang CY, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317701311
   Zhang J, 2017, AUTOPHAGY, V13, P1004, DOI 10.1080/15548627.2017.1312041
   Zhang N, 2016, EUR REV MED PHARMACO, V20, P2271
   Zhang XW, 2017, EXP THER MED, V14, P1789, DOI 10.3892/etm.2017.4650
   Zhao Y, 2014, ONCOL REP, V31, P358, DOI 10.3892/or.2013.2850
   Zhao ZS, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7212
   Zhou DD, 2017, CELL PROLIFERAT, V50, DOI 10.1111/cpr.12398
   Zhou XL, 2014, ACTA BIOCH BIOPH SIN, V46, P1011, DOI 10.1093/abbs/gmu104
   Zuo YG, 2017, BIOMED PHARMACOTHER, V95, P922, DOI 10.1016/j.biopha.2017.09.005
NR 118
TC 24
Z9 25
U1 2
U2 6
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 1664-8021
J9 FRONT GENET
JI Front. Genet.
PD JAN 14
PY 2019
VL 9
AR 750
DI 10.3389/fgene.2018.00750
PG 11
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA HH4DN
UT WOS:000455671000001
PM 30693021
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Buzzai, M
   Jones, RG
   Amaravadi, RK
   Lum, JJ
   DeBerardinis, RJ
   Zhao, FP
   Viollet, B
   Thompson, CB
AF Buzzai, Monica
   Jones, Russell G.
   Amaravadi, Ravi K.
   Lum, Julian J.
   DeBerardinis, Ralph J.
   Zhao, Fangping
   Viollet, Benoit
   Thompson, Craig B.
TI Systemic treatment with the antidiabetic drug metformin selectively
   impairs p53-deficient tumor cell growth
SO CANCER RESEARCH
LA English
DT Article
ID ACTIVATED PROTEIN-KINASE; CREB COACTIVATOR TORC2; AUTOPHAGY; APOPTOSIS;
   METABOLISM; MECHANISM; SURVIVAL; RESPIRATION; REGULATOR; PATHWAYS
AB The effect of the antidiabetic drug metformin on tumor growth was investigated using the paired isogenic colon cancer cell lines HCT116 p53(+/+) and HCT116 p53(-/-) . Treatment with metformin selectively suppressed the tumor growth of HCT116 p53(-/-) xenografts. Following treatment with metformin, we detected increased apoptosis in p53(-/-) tumor sections and an enhanced susceptibility of p53(-/-) cells to undergo apoptosis in vitro when subject to nutrient deprivation. Metformin is proposed to function in diabetes treatment as an indirect activator of AIMP-activated protein kinase (AMPK). Treatment with AICAR, another AMPK activator, also showed a selective ability to inhibit p53(-/-) tumor growth in vivo. In the presence of either of the two drugs, HCT116 P53(+/+) cells, but not HCT116 p53(-/-) cells, activated autophagy. A similar p53-dependent induction of autophagy was observed when nontransformed mouse embryo fibroblasts were treated. Treatment with either metformin or AICAR also led to enhanced fatty acid beta-oxidation in p53(+/+) MEFs but not in p53(-/-) MEFs. However, the magnitude of induction was significantly lower in metformin-treated cells, as metformin treatment also suppressed mitochondrial electron transport. Metformin-treated cells compensated for this suppression of oxidative phosphorylation by increasing their rate of glycolysis in a p53-dependent manner. Together, these data suggest that metformin treatment forces a metabolic conversion that p53(-/-) cells are unable to execute. Thus, metformin is selectively toxic to p53-deficient cells and provides a potential mechanism for the reduced incidence of tumors observed in patients being treated with metformin.
C1 Univ Penn, Dept Canc Biol, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA.
   Univ Penn, Dept Med, Div Hematol Oncol, Philadelphia, PA 19104 USA.
   Childrens Hosp Philadelphia, Div Child Dev Rehabil Med & Metab Dis, Philadelphia, PA 19104 USA.
   Univ Paris 05, Inst Cochin Genet Mol, CNRS, UMR 8104, Paris, France.
   INSERM, U567, Paris, France.
RP Thompson, CB (corresponding author), Univ Penn, Dept Canc Biol, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA.
EM craig@mail.med.upenn.edu
RI Jones, Russell Graham/ABD-5261-2021; Viollet, Benoit/O-6927-2017;
   Viollet, Benoit/N-2397-2019; Jones, Russell/AAC-2861-2022
OI Jones, Russell Graham/0000-0003-2250-4675; Viollet,
   Benoit/0000-0002-0121-0224; Viollet, Benoit/0000-0002-0121-0224; Lum,
   Julian/0000-0002-5624-3541
CR Amaravadi RK, 2007, J CLIN INVEST, V117, P326, DOI 10.1172/JCI28833
   Bensaad K, 2006, CELL, V126, P107, DOI 10.1016/j.cell.2006.05.036
   Bowker SL, 2006, DIABETES CARE, V29, P254, DOI 10.2337/diacare.29.02.06.dc05-1558
   Buzzai M, 2005, ONCOGENE, V24, P4165, DOI 10.1038/sj.onc.1208622
   Carling D, 2004, TRENDS BIOCHEM SCI, V29, P18, DOI 10.1016/j.tibs.2003.11.005
   Crighton D, 2006, CELL, V126, P121, DOI 10.1016/j.cell.2006.05.034
   DeBerardinis RJ, 2006, J BIOL CHEM, V281, P37372, DOI 10.1074/jbc.M608372200
   Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001
   El-Mir MY, 2000, J BIOL CHEM, V275, P223, DOI 10.1074/jbc.275.1.223
   Evans JMM, 2005, BMJ-BRIT MED J, V330, P1304, DOI 10.1136/bmj.38415.708634.F7
   Fang YM, 2001, SCIENCE, V294, P1942, DOI 10.1126/science.1066015
   Feng ZH, 2005, P NATL ACAD SCI USA, V102, P8204, DOI 10.1073/pnas.0502857102
   Fryer LGD, 2002, J BIOL CHEM, V277, P25226, DOI 10.1074/jbc.M202489200
   Hawley SA, 2002, DIABETES, V51, P2420, DOI 10.2337/diabetes.51.8.2420
   HUNDAL HS, 1992, ENDOCRINOLOGY, V131, P1165, DOI 10.1210/en.131.3.1165
   James F, 1996, BIOCHEM J, V320, P283, DOI 10.1042/bj3200283
   Jones RG, 2005, MOL CELL, V18, P283, DOI 10.1016/j.molcel.2005.03.027
   Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720
   Kahn BB, 2005, CELL METAB, V1, P15, DOI 10.1016/j.cmet.2004.12.003
   Koo SH, 2005, NATURE, V437, P1109, DOI 10.1038/nature03967
   Laderoute KR, 2006, MOL CELL BIOL, V26, P5336, DOI 10.1128/MCB.00166-06
   Lam E, 2004, NAT REV MOL CELL BIO, V5, P305, DOI 10.1038/nrm1358
   LILLY K, 1992, BIOCHEM PHARMACOL, V43, P353, DOI 10.1016/0006-2952(92)90298-W
   Lum JJ, 2005, CELL, V120, P237, DOI 10.1016/j.cell.2004.11.046
   Matoba S, 2006, SCIENCE, V312, P1650, DOI 10.1126/science.1126863
   Melendez A, 2003, SCIENCE, V301, P1387, DOI 10.1126/science.1087782
   Mizushima N, 2004, INT J BIOCHEM CELL B, V36, P2491, DOI 10.1016/j.biocel.2004.02.005
   SCHAFER G, 1983, DIABETES METAB, V9, P148
   SCHUMACKER PT, 1993, AM J PHYSIOL, V265, P395
   Screaton RA, 2004, CELL, V119, P61, DOI 10.1016/j.cell.2004.09.015
   Shaw RJ, 2005, SCIENCE, V310, P1642, DOI 10.1126/science.1120781
   STUMVOLL M, 1995, NEW ENGL J MED, V333, P550, DOI 10.1056/NEJM199508313330903
   Warburg O., 1924, BIOCHEM Z, V152, P319
   Witters LA, 2001, J CLIN INVEST, V108, P1105, DOI 10.1172/JCI14178
   Zhou GC, 2001, J CLIN INVEST, V108, P1167, DOI 10.1172/JCI200113505
NR 35
TC 726
Z9 752
U1 1
U2 93
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
J9 CANCER RES
JI Cancer Res.
PD JUL 15
PY 2007
VL 67
IS 14
BP 6745
EP 6752
DI 10.1158/0008-5472.CAN-06-4447
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 194BN
UT WOS:000248319000028
PM 17638885
DA 2022-04-25
ER

PT J
AU Hao, M
   Kong, CF
   Jiang, CW
   Hou, RZ
   Zhao, XM
   Li, J
   Wang, YQ
   Gao, YY
   Zhang, H
   Yang, B
   Jiang, JL
AF Hao, Miao
   Kong, Chenfei
   Jiang, Chengwei
   Hou, Ruizhi
   Zhao, Xiaoming
   Li, Jing
   Wang, Yuqian
   Gao, Yiyao
   Zhang, Hao
   Yang, Bai
   Jiang, Jinlan
TI Polydopamine-coated Au-Ag nanoparticle-guided photothermal colorectal
   cancer therapy through multiple cell death pathways
SO ACTA BIOMATERIALIA
LA English
DT Article
DE Photothermal therapy; Nanoparticles; Lysosomal membrane permeability;
   Autophagy; Caspase-independent apoptosis
ID LYSOSOMAL MEMBRANE PERMEABILIZATION; HEAT-SHOCK PROTEINS; NANOMEDICINE;
   EXPRESSION; APOPTOSIS
AB Nanoparticles are emerging as a new therapeutic modality due to their high stability, precise targeting, and high biocompatibility. Branched Au-Ag nanoparticles with polydopamine coating (Au-Ag@PDA) have strong near-infrared absorbance and no cytotoxicity but high photothermal conversion efficiency. However, the photothermal activity of Au-Ag@PDA in vivo and in vitro has not been reported yet, and the mechanism underlying the effects of photothermal nanomaterials is not clear. Therefore, in this study, the colorectal cancer cell line HCT-116 and nude mice xenografts were used to observe the photothermal effects of Au-Ag@PDA in vivo and in vitro. The results suggest that Au-Ag@PDA NPs significantly inhibited cell proliferation and induced apoptosis in colorectal cancer cells. Moreover, Au-Ag@PDA NP mediated photothermal therapy inhibited the growth of tumors at doses of 50 and 100 mu g in vivo. The mechanisms through which Au-Ag@PDA NPs induced colorectal cancer cell death involved multiple pathways, including caspase-dependent and -independent apoptosis, mitochondrial damage, lysosomal membrane permeability, and autophagy. Thus, our findings suggest that Au-Ag@PDA NPs could be used as potential antitumor agents for photothermal ablation of colorectal cancer cells. (C) 2018 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.
C1 [Hao, Miao; Kong, Chenfei; Zhao, Xiaoming; Li, Jing; Wang, Yuqian; Gao, Yiyao; Jiang, Jinlan] Jilin Univ, China Japan Union Hosp, Sci Res Ctr, Changchun 130033, Jilin, Peoples R China.
   [Jiang, Chengwei] Jilin Univ, China Japan Union Hosp, Dept Pathol, Changchun 130033, Jilin, Peoples R China.
   [Hou, Ruizhi] Jilin Univ, China Japan Union Hosp, Gastrointestinal Colorectal & Anal Surg, Changchun 130033, Jilin, Peoples R China.
   [Zhang, Hao; Yang, Bai] Jilin Univ, Coll Chem, State Key Lab Supramol Struct & Mat, Changchun 130000, Jilin, Peoples R China.
RP Jiang, JL (corresponding author), Jilin Univ, China Japan Union Hosp, Sci Res Ctr, Changchun 130033, Jilin, Peoples R China.
EM jiangjinlan@jlu.edu.cn
RI guo, min/AAI-2966-2021; Yang, Bai/F-6483-2012
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81401966]; Bethune plan of Jilin University
   [2015332]; Jilin Provincial Health Project [sczsy201614, sczsy201716];
   Jilin Province Health Service Capacity Improvement Project [2017F014]
FX This work was supported by the National Natural Science Foundation of
   China (Grant No. 81401966), the research project of Bethune plan of
   Jilin University (No. 2015332), Jilin Provincial Health Project (No.
   sczsy201614 and sczsy201716) and Jilin Province Health Service Capacity
   Improvement Project (No. 2017F014). We would like to thank Peize
   Optoelectronics Technology Co., Ltd (Nanjing, China) for technical
   service, and Editage [www.editage.cn] for English language editing.
CR Aftab S, 2018, INT J PHARMACEUT, V540, P132, DOI 10.1016/j.ijpharm.2018.02.007
   Ahmad R, 2016, J NANOSCI NANOTECHNO, V16, P67, DOI 10.1166/jnn.2016.10770
   Ali MRK, 2017, P NATL ACAD SCI USA, V114, pE5655, DOI 10.1073/pnas.1703151114
   Allen RT, 1997, J PHARMACOL TOX MET, V37, P215, DOI 10.1016/S1056-8719(97)00033-6
   Brenner H, 2014, LANCET, V383, P1490, DOI 10.1016/S0140-6736(13)61649-9
   Brody H, 2015, NATURE, V521, pS1, DOI 10.1038/521S1a
   Calderwood SK, 2016, TRENDS BIOCHEM SCI, V41, P311, DOI 10.1016/j.tibs.2016.01.003
   Carabineiro SAC, 2017, MOLECULES, V22, DOI 10.3390/molecules22050857
   Dixon SJ, 2012, CELL, V149, P1060, DOI 10.1016/j.cell.2012.03.042
   Erdal H, 2005, P NATL ACAD SCI USA, V102, P192, DOI 10.1073/pnas.0408592102
   Gao CY, 2016, ACS APPL MATER INTER, V8, P34252, DOI 10.1021/acsami.6b12865
   Gharatape A, 2017, EUR J MED CHEM, V138, P221, DOI 10.1016/j.ejmech.2017.06.034
   Haine AT, 2017, CHEM PHARM BULL, V65, P625, DOI 10.1248/cpb.c17-00102
   Hao M, 2015, HUM PATHOL, V46, P1815, DOI 10.1016/j.humpath.2015.07.020
   HORNBACK NB, 1989, RADIOL CLIN N AM, V27, P481
   Hou M., 2018, ACTA BIOMATER, V51742-7061, P30280
   Jin HB, 2018, MOL MED REP, V17, P7274, DOI 10.3892/mmr.2018.8763
   Li H, 2018, ADV COLLOID INTERFAC, V252, P1, DOI 10.1016/j.cis.2018.01.001
   Li J, 2015, ACS APPL MATER INTER, V7, P11613, DOI 10.1021/acsami.5b02666
   Liu Y, 2015, THERANOSTICS, V5, P946, DOI 10.7150/thno.11974
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Loro LL, 2003, J ORAL PATHOL MED, V32, P125, DOI 10.1034/j.1600-0714.2003.00052.x
   Lou JS, 2017, ONCOTARGET, V8, P93131, DOI 10.18632/oncotarget.21862
   Luo D, 2017, EVID-BASED COMPL ALT, V2017, DOI 10.1155/2017/8268736
   Mu XP, 2017, INT J NANOMED, V12, P2899, DOI 10.2147/IJN.S131418
   Nikfarjam M, 2005, ANTICANCER RES, V25, P1413
   Oberle C, 2010, CELL DEATH DIFFER, V17, P1167, DOI 10.1038/cdd.2009.214
   Sauvage F, 2017, J CONTROL RELEASE, V248, P133, DOI 10.1016/j.jconrel.2017.01.013
   Spyratou E, 2017, CANCERS, V9, DOI 10.3390/cancers9120173
   Sun X, 2015, ONCOGENE, V34, P5617, DOI 10.1038/onc.2015.32
   Trincheri NF, 2007, CARCINOGENESIS, V28, P922, DOI 10.1093/carcin/bgl223
   Wang M, 2009, ACS NANO, V3, P1580, DOI 10.1021/nn900491j
   Wang S, 2016, ACS APPL MATER INTER, V8, P3736, DOI 10.1021/acsami.5b08087
   Wang SM, 2014, EUR J RADIOL, V83, P117, DOI 10.1016/j.ejrad.2013.09.010
   Wang YY, 2015, CARBOHYD POLYM, V127, P215, DOI 10.1016/j.carbpol.2015.03.070
   Yang QH, 2017, CELL PHYSIOL BIOCHEM, V42, P2182, DOI 10.1159/000479993
   Zhang BF, 2015, BIOMATERIALS, V61, P178, DOI 10.1016/j.biomaterials.2015.05.027
   Zhang WB, 2018, ROY SOC OPEN SCI, V5, DOI 10.1098/rsos.172310
NR 38
TC 38
Z9 38
U1 20
U2 196
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1742-7061
EI 1878-7568
J9 ACTA BIOMATER
JI Acta Biomater.
PD JAN 1
PY 2019
VL 83
BP 414
EP 424
DI 10.1016/j.actbio.2018.10.032
PG 11
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Engineering; Materials Science
GA HG6CP
UT WOS:000455068900036
PM 30366131
DA 2022-04-25
ER

PT J
AU Jalota-Badhwar, A
   Bhatia, DR
   Boreddy, S
   Joshi, A
   Venkatraman, M
   Desai, N
   Chaudhari, S
   Bose, J
   Kolla, LS
   Deore, V
   Yewalkar, N
   Kumar, S
   Sharma, R
   Damre, A
   More, A
   Sharma, S
   Agarwal, VR
AF Jalota-Badhwar, Archana
   Bhatia, Dimple R.
   Boreddy, Srinivas
   Joshi, Asavari
   Venkatraman, Magesh
   Desai, Nikesh
   Chaudhari, Sarika
   Bose, Julie
   Kolla, Lakshmi S.
   Deore, Vijaykumar
   Yewalkar, Nilambari
   Kumar, Sanjay
   Sharma, Rajiv
   Damre, Anagha
   More, Avinash
   Sharma, Somesh
   Agarwal, Veena R.
TI P7170: A Novel Molecule with Unique Profile of mTORC1/C2 and Activin
   Receptor-like Kinase 1 Inhibition Leading to Antitumor and
   Antiangiogenic Activity
SO MOLECULAR CANCER THERAPEUTICS
LA English
DT Article
ID MONOCLONAL-ANTIBODY; CELL-PROLIFERATION; TARGET; CANCER; RAPAMYCIN;
   PATHWAY; GROWTH; ACTIVATION; NVP-BEZ235; GENERATION
AB The mTOR pathway is often upregulated in cancer and thus intensively pursued as a target to design novel anticancer therapies. Approved and emerging drugs targeting the mTOR pathway have positively affected the clinical landscape. Recently, activin receptor-like kinase 1 (ALK1), belonging to the TGF beta receptor family, has been reported as an emerging target for antiangiogenic cancer therapy. Here, we describe a novel orally efficacious compound, P7170, that inhibits mTORC1/mTORC2/ALK1 activity with a potent cell growth inhibition. In cell-based assays, P7170 strongly inhibited (IC50 < 10 nmol/L) the phosphorylation of p70S6K (T389) and pAKT (S473). In many cancer cell lines, such as prostate, ovarian, colon, and renal, P7170 treatment resulted in marked cell growth inhibition. Furthermore, it induced G(1)-S cell-cycle arrest and autophagy. In vitro HUVEC tube formation, in vivo Matrigel plug, and rat aorta ring assays demonstrated that P7170 exhibited significant antiangiogenic activity. In addition, ALK1 knockdown studies in HUVEC confirmed that the antiangiogenic activity of P7170 was primarily due to ALK1 inhibition. Strong inhibition of ALK1 in addition to mTORC1/mTORC2 differentiates P7170 in its mechanism of action in comparison with existing inhibitors. In vivo mouse xenograft studies revealed P7170 to exhibit a significant dose-dependent tumor growth inhibition in a broad range of human tumor types when administered orally at 10 to 20 mg/kg doses. The distinctive pharmacological profile with favorable pharmacokinetic parameters and in vivo efficacy makes P7170 an attractive candidate for clinical development. It is currently being tested in phase I clinical studies. (C) 2015 AACR.
C1 [Jalota-Badhwar, Archana; Bhatia, Dimple R.; Boreddy, Srinivas; Joshi, Asavari; Venkatraman, Magesh; Desai, Nikesh; Chaudhari, Sarika; Bose, Julie; Kolla, Lakshmi S.; Sharma, Somesh; Agarwal, Veena R.] Piramal Enterprises Ltd, Dept Pharmacol, Bombay 400063, Maharashtra, India.
   [Deore, Vijaykumar; Yewalkar, Nilambari; Kumar, Sanjay; Sharma, Rajiv] Piramal Enterprises Ltd, Dept Med Chem, Bombay 400063, Maharashtra, India.
   [Damre, Anagha; More, Avinash] Piramal Enterprises Ltd, Dept Pharmacokinet & Drug Metab, Bombay 400063, Maharashtra, India.
RP Agarwal, VR (corresponding author), Piramal Enterprises Ltd, 1-Nirlon Complex,Western Express Highway, Bombay 400063, Maharashtra, India.
EM Veena_828@yahoo.com
OI Joshi, Asavari/0000-0001-7329-997X
CR Alain T, 2012, ONCOTARGET, V3, P1491
   Astanehe A, 2008, J CELL SCI, V121, P664, DOI 10.1242/jcs.013029
   Benjamin D, 2011, NAT REV DRUG DISCOV, V10, P868, DOI 10.1038/nrd3531
   Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240
   Montero JC, 2012, MOL CANCER THER, V11, P1342, DOI 10.1158/1535-7163.MCT-11-0723
   Chien CY, 2013, OTOLARYNG HEAD NECK, V148, P965, DOI 10.1177/0194599813479556
   Chresta CM, 2010, CANCER RES, V70, P288, DOI 10.1158/0008-5472.CAN-09-1751
   Cunha SI, 2011, BLOOD, V117, P6999, DOI 10.1182/blood-2011-01-330142
   Cunha SI, 2010, J EXP MED, V207, P85, DOI 10.1084/jem.20091309
   Fabian MA, 2005, NAT BIOTECHNOL, V23, P329, DOI 10.1038/nbt1068
   Fruman DA, 2014, NAT REV DRUG DISCOV, V13, P140, DOI 10.1038/nrd4204
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Hawinkels LJAC, 2013, EXPERT OPIN INV DRUG, V22, P1371, DOI 10.1517/13543784.2013.837884
   Hennessy BT, 2005, NAT REV DRUG DISCOV, V4, P988, DOI 10.1038/nrd1902
   Hu-Lowe DD, 2011, CANCER RES, V71, P1362, DOI 10.1158/0008-5472.CAN-10-1451
   Huang JX, 2008, MOL CELL BIOL, V28, P4104, DOI 10.1128/MCB.00289-08
   Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839
   Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017
   Lebrin F, 2004, EMBO J, V23, P4018, DOI 10.1038/sj.emboj.7600386
   Luu KT, 2012, J PHARMACOL EXP THER, V341, P702, DOI 10.1124/jpet.112.191999
   Maira SM, 2008, MOL CANCER THER, V7, P1851, DOI 10.1158/1535-7163.MCT-08-0017
   Markman B, 2010, ONCOTARGET, V1, P530, DOI 10.18632/oncotarget.188
   Nazio F, 2013, NAT CELL BIOL, V15, P406, DOI 10.1038/ncb2708
   Necchi A, 2014, INVEST NEW DRUG, V32, P555, DOI 10.1007/s10637-014-0074-9
   NICOSIA RF, 1990, LAB INVEST, V63, P115
   Oh SP, 2000, P NATL ACAD SCI USA, V97, P2626, DOI 10.1073/pnas.97.6.2626
   Sansal I, 2004, J CLIN ONCOL, V22, P2954, DOI 10.1200/jco.2004.02.141
   Sarbassov DD, 2006, MOL CELL, V22, P159, DOI 10.1016/j.molcel.2006.03.029
   Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148
   Shah OJ, 2004, CURR BIOL, V14, P1650, DOI 10.1016/j.cub.2004.08.026
   Sini P, 2010, AUTOPHAGY, V6, P553, DOI 10.4161/auto.6.4.11671
   Sujobert P, 2005, BLOOD, V106, P1063, DOI 10.1182/blood-2004-08-3225
   Takano T, 2001, MOL CELL BIOL, V21, P5050, DOI 10.1128/MCB.21.15.5050-5062.2001
   Tamburini J, 2009, BLOOD, V114, P1618, DOI 10.1182/blood-2008-10-184515
   Tanida Isei, 2008, V445, P77, DOI 10.1007/978-1-59745-157-4_4
   Thompson JE, 2004, J CLIN ONCOL, V22, P4217, DOI 10.1200/jco.2004.01.103
   Wander SA, 2011, J CLIN INVEST, V121, P1231, DOI 10.1172/JCI44145
   Wang WJ, 2013, ACTA PHARMACOL SIN, V34, P681, DOI 10.1038/aps.2013.22
   Wrighton KH, 2013, NAT REV MOL CELL BIO, V14, P191, DOI 10.1038/nrm3549
   Yap TA, 2008, CURR OPIN PHARMACOL, V8, P393, DOI 10.1016/j.coph.2008.08.004
   Yoshimatsu Y, 2013, P NATL ACAD SCI USA, V110, P18940, DOI 10.1073/pnas.1310479110
   Zhou HY, 2011, CURR PROTEIN PEPT SC, V12, P30
NR 42
TC 9
Z9 9
U1 0
U2 7
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1535-7163
EI 1538-8514
J9 MOL CANCER THER
JI Mol. Cancer Ther.
PD MAY
PY 2015
VL 14
IS 5
BP 1095
EP 1106
DI 10.1158/1535-7163.MCT-14-0486
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA CM9TX
UT WOS:000358053000002
PM 25700704
DA 2022-04-25
ER

PT J
AU Mishra, SK
   Gao, YG
   Zou, XQ
   Stephenson, DJ
   Malinina, L
   Hinchcliffe, EH
   Chalfant, CE
   Brown, RE
AF Mishra, Shrawan K.
   Gao, Yong-Guang
   Zou, Xianqiong
   Stephenson, Daniel J.
   Malinina, Lucy
   Hinchcliffe, Edward H.
   Chalfant, Charles E.
   Brown, Rhoderick E.
TI Emerging roles for human glycolipid transfer protein superfamily members
   in the regulation of autophagy, inflammation, and cell death
SO PROGRESS IN LIPID RESEARCH
LA English
DT Review
DE Glycolipid transfer protein superfamily; Sphingolipid homeostasis;
   Autophagy; Inflammasomes; Necroptosis; Eicosanoids; Cytokines;
   Sphingolipid rheostat; Phosphoglyceride regulatory binding
ID MEMBRANE CONTACT SITES; CERAMIDE-1-PHOSPHATE TRANSFER PROTEIN; CERAMIDE
   1-PHOSPHATE; STRUCTURAL BASIS; NONVESICULAR TRAFFICKING; SPHINGOLIPID
   METABOLISM; PLASMA-MEMBRANE; GD3 GANGLIOSIDE; TRYPTOPHAN FLUORESCENCE;
   MEDIATED TRANSFER
AB Glycolipid transfer proteins (GLTPs) were first identified over three decades ago as similar to 24kDa, soluble, amphitropic proteins that specifically accelerate the intermembrane transfer of glycolipids. Upon discovery that GLTPs use a unique, all-alpha-helical, two-layer 'sandwich' architecture (GLTP-fold) to bind glycosphingolipids (GSLs), a new protein superfamily was born. Structure/function studies have provided exquisite insights defining features responsible for lipid headgroup selectivity and hydrophobic 'pocket' adaptability for accommodating hydrocarbon chains of differing length and unsaturation. In humans, evolutionarily-modified GLTP-folds have been identified with altered sphingolipid specificity, e. g. ceramide-1-phosphate transfer protein (CPTP), phosphatidylinositol 4-phosphate adaptor protein-2 (FAPP2) which harbors a GLTP-domain and GLTPD2. Despite the wealth of structural data (> 40 Protein Data Bank deposits), insights into the in vivo functional roles of GLTP superfamily members have emerged slowly. In this review, recent advances are presented and discussed implicating human GLTP superfamily members as important regulators of: i) pro-inflammatory eicosanoid production associated with Group-IV cytoplasmic phospholipase A(2); ii) autophagy and inflammasome assembly that drive surveillance cell release of interleukin-1 beta and interleukin-18 inflammatory cytokines; iii) cell cycle arrest and necroptosis induction in certain colon cancer cell lines. The effects exerted by GLTP superfamily members appear linked to their ability to regulate sphingolipid homeostasis by acting in either transporter and/or sensor capacities. These timely findings are opening new avenues for future cross-disciplinary, translational medical research involving GLTP-fold proteins in human health and disease. Such avenues include targeted regulation of specific GLTP superfamily members to alter sphingolipid levels as a therapeutic means for combating viral infection, neurodegenerative conditions and circumventing chemo-resistance during cancer treatment.
C1 [Mishra, Shrawan K.; Gao, Yong-Guang; Zou, Xianqiong; Malinina, Lucy; Hinchcliffe, Edward H.; Brown, Rhoderick E.] Univ Minnesota, Hormel Inst, 801 16th Ave NE, Austin, MN 55912 USA.
   [Stephenson, Daniel J.] Virginia Commonwealth Univ, Med Ctr, Dept Biochem & Mol Biol, Med Coll Virginia Campus, Richmond, VA 23298 USA.
   [Stephenson, Daniel J.; Chalfant, Charles E.] Univ S Florida, Dept Cell Biol Microbiol & Mol Biol, Tampa, FL 33620 USA.
   [Chalfant, Charles E.] James A Haley Vet Hosp, Res Serv, Tampa, FL 33612 USA.
   [Chalfant, Charles E.] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33620 USA.
   [Mishra, Shrawan K.] WuXi AppTec Inc, 2540 Execut Dr, St Paul, MN 55120 USA.
   [Zou, Xianqiong] Guilin Med Univ, Coll Biotechnol, Guilin 541100, Guangxi, Peoples R China.
RP Brown, RE (corresponding author), UMN Hormel Inst, 801 16th Ave NE, Austin, MN 55912 USA.
EM reb@umn.edu
RI Mishra, Shrawan K/J-7972-2013; Gao, Yongguang/B-8546-2012
OI Gao, Yongguang/0000-0002-9359-4252; Brown, Rhoderick/0000-0002-7337-3604
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [RO1-GM45928]; Southern Minnesota
   Paint-the-Town-Pink Grant Awards; Hormel Foundation;  [RO1-CA121493]; 
   [RO1-HL125353]
FX We are grateful to Xin Lin, Taeowan Chung, and Helen Pike for their
   pioneering molecular biological and cell biological studies of GLTP and
   CPTP as members of the REB lab. Our studies also benefited from
   collaborative research on the plant CPTP orthologue, ACD11, with the
   John Mundy lab via Nikolaj Petersen, Daniel Hofius, and David Munch. We
   are thankful for biophysical studies carried out by Xiuhong Zhai,
   Dhirendra Simanshu, Ivan Boldyrev, Ravi-Kanth Kamlekar, Roop Kenoth,
   Margarita Malakhova, Chetan Rao, Xin-Min Li, and Peter Mattjus as well
   as to other long-standing collaborators (Julian G. Molotkovsky and
   Dinshaw J. Patel) who played key roles in elucidating GLTP-fold
   structure/function relationships. We especially appreciate the long-term
   interest and support of GLTP superfamily research by Dr. Jean Chin while
   administering NIH RO1-GM45928 and also are grateful for support received
   from RO1-CA121493, RO1-HL125353, Southern Minnesota Paint-the-Town-Pink
   Grant Awards, and the Hormel Foundation.
CR ABE A, 1982, BIOCHEM BIOPH RES CO, V104, P1386, DOI 10.1016/0006-291X(82)91403-6
   ABE A, 1985, J BIOL CHEM, V260, P1231
   Ahrens I, 2011, BASIC RES CARDIOL, V106, P879, DOI 10.1007/s00395-011-0191-y
   Airenne TT, 2006, J MOL BIOL, V355, P224, DOI 10.1016/j.jmb.2005.10.031
   Andersen JP, 2016, FRONT PHYSIOL, V7, DOI 10.3389/fphys.2016.00275
   Annunziata I, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0025-4
   Backman APE, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0209230
   Bergsbaken T, 2009, NAT REV MICROBIOL, V7, P99, DOI 10.1038/nrmicro2070
   Berna A, 2008, INT J BIOCHEM CELL B, V40, P170, DOI 10.1016/j.biocel.2007.02.004
   Boath A, 2008, J BIOL CHEM, V283, P8517, DOI 10.1074/jbc.M707107200
   Boggs JM, 2010, FEBS LETT, V584, P1771, DOI 10.1016/j.febslet.2009.11.074
   Bornancin F, 2011, CELL SIGNAL, V23, P999, DOI 10.1016/j.cellsig.2010.11.012
   Bourquin F, 2010, STRUCTURE, V18, P1054, DOI 10.1016/j.str.2010.05.011
   Brodersen P, 2002, GENE DEV, V16, P490, DOI 10.1101/gad.218202
   BROWN RE, 1990, BIOCHIM BIOPHYS ACTA, V1044, P77, DOI 10.1016/0005-2760(90)90221-I
   BROWN RE, 1985, CHEM PHYS LIPIDS, V38, P79, DOI 10.1016/0009-3084(85)90059-3
   Brown RE, 2007, BBA-MOL CELL BIOL L, V1771, P746, DOI 10.1016/j.bbalip.2007.01.011
   Cao XW, 2009, P NATL ACAD SCI USA, V106, P21121, DOI 10.1073/pnas.0911789106
   Casares D, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20092167
   CHANNON JY, 1990, J BIOL CHEM, V265, P5409
   Choi ME, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.128834
   CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E
   Crespo PM, 2004, J BIOL CHEM, V279, P47610, DOI 10.1074/jbc.M407181200
   Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0
   D'Angelo CS, 2010, AM J MED GENET A, V152A, P102, DOI 10.1002/ajmg.a.33160
   D'Angelo G, 2007, NATURE, V449, P62, DOI 10.1038/nature06097
   D'Angelo G, 2013, NATURE, V501, DOI 10.1038/nature12423
   D'Angelo G, 2012, BBA-MOL CELL BIOL L, V1821, P1089, DOI 10.1016/j.bbalip.2012.01.003
   de Vasconcelos NM, 2020, CSH PERSPECT BIOL, V12, DOI 10.1101/cshperspect.a036392
   DeMaria R, 1997, SCIENCE, V277, P1652, DOI 10.1126/science.277.5332.1652
   Dowler S, 2000, BIOCHEM J, V351, P19, DOI 10.1042/0264-6021:3510019
   Espaillat MP, 2015, TRANSL CANCER RES, V4, P484, DOI 10.3978/j.issn.2218-676X.2015.10.01
   Fairn GD, 2011, J CELL BIOL, V194, P257, DOI 10.1083/jcb.201012028
   Frank D, 2019, CELL DEATH DIFFER, V26, P99, DOI 10.1038/s41418-018-0212-6
   GAMMON CM, 1987, BIOCHEMISTRY-US, V26, P6239, DOI 10.1021/bi00393a043
   GAMMON CM, 1985, J NEUROCHEM, V44, P979, DOI 10.1111/j.1471-4159.1985.tb12912.x
   Gao Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019990
   Godi A, 2004, NAT CELL BIOL, V6, P393, DOI 10.1038/ncb1119
   Gomez-Munoz A, 2006, BBA-BIOMEMBRANES, V1758, P2049, DOI 10.1016/j.bbamem.2006.05.011
   Gomez-Munoz A, 2018, ADV CANCER RES, V140, P217, DOI 10.1016/bs.acr.2018.04.012
   Gomez-Munoz A, 2016, PROG LIPID RES, V61, P51, DOI 10.1016/j.plipres.2015.09.002
   Gong YT, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1029-8
   Halter D, 2007, J CELL BIOL, V179, P101, DOI 10.1083/jcb.200704091
   Hanada K, 2003, NATURE, V426, P803, DOI 10.1038/nature02188
   Hanada K, 2018, J LIPID RES, V59, P1341, DOI 10.1194/jlr.R085324
   Hannun YA, 2018, NAT REV MOL CELL BIO, V19, P175, DOI 10.1038/nrm.2017.107
   Harizi H, 2008, TRENDS MOL MED, V14, P461, DOI 10.1016/j.molmed.2008.08.005
   He SD, 2009, CELL, V137, P1100, DOI 10.1016/j.cell.2009.05.021
   Hiraizumi M, 2019, SCIENCE, V365, P1149, DOI 10.1126/science.aay3353
   Hirsch AKH, 2007, ANGEW CHEM INT EDIT, V46, P338, DOI 10.1002/anie.200603420
   Hoeferlin L Alexis, 2013, Handb Exp Pharmacol, P153, DOI 10.1007/978-3-7091-1368-4_8
   Holthuis JCM, 2014, NATURE, V510, P48, DOI 10.1038/nature13474
   Huang MH, 2019, ACTA PHARMACOL SIN B, V9, P769, DOI 10.1016/j.apsb.2019.01.013
   Jain A, 2017, BBA-MOL CELL RES, V1864, P1450, DOI 10.1016/j.bbamcr.2017.05.017
   Jung K, 2015, INT J SURG, V23, P28, DOI 10.1016/j.ijsu.2015.09.049
   Kaiser SE, 2005, STRUCTURE, V13, P1035, DOI 10.1016/j.str.2005.04.010
   Kamlekar RK, 2013, BBA-MOL CELL BIOL L, V1831, P417, DOI 10.1016/j.bbalip.2012.10.010
   Kamlekar RK, 2010, BIOPHYS J, V99, P2626, DOI 10.1016/j.bpj.2010.08.038
   Kenoth R, 2010, J BIOL CHEM, V285, P13066, DOI 10.1074/jbc.M109.093203
   Khan I, 2014, J VIROL, V88, P12276, DOI 10.1128/JVI.00970-14
   Kitatani K, 2008, CELL SIGNAL, V20, P1010, DOI 10.1016/j.cellsig.2007.12.006
   Kjellberg MA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097263
   Kjellberg MA, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0070283, 10.1371/annotation/712bb339-6073-4e62-9f68-b285caedd913]
   Kudo N, 2008, P NATL ACAD SCI USA, V105, P488, DOI 10.1073/pnas.0709191105
   Kumari S, 2015, BIOCHEM BIOPH RES CO, V456, P312, DOI 10.1016/j.bbrc.2014.11.077
   Kurji KH, 2010, INVEST OPHTH VIS SCI, V51, P1151, DOI 10.1167/iovs.09-3622
   Kurz J, 2019, TRENDS MOL MED, V25, P20, DOI 10.1016/j.molmed.2018.10.009
   Lamb CA, 2013, NAT REV MOL CELL BIO, V14, P759, DOI 10.1038/nrm3696
   Lauria I, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059871
   Ledeen R, 2011, J NEUROCHEM, V116, P714, DOI 10.1111/j.1471-4159.2010.07115.x
   Ledeen RW, 2008, J LIPID RES, V49, P1176, DOI 10.1194/jlr.R800009-JLR200
   Lenoir M, 2010, EMBO REP, V11, P279, DOI 10.1038/embor.2010.28
   Leventis PA, 2010, ANNU REV BIOPHYS, V39, P407, DOI 10.1146/annurev.biophys.093008.131234
   Lewis AC, 2018, CELL DEATH DISCOV, V4, DOI 10.1038/s41420-018-0075-0
   Li XM, 2004, BIOCHEMISTRY-US, V43, P10285, DOI 10.1021/bi0495432
   Liao J, 2019, J MOL CELL BIOL, V11, P107, DOI 10.1093/jmcb/mjy030
   Lin X, 2000, J BIOL CHEM, V275, P5104, DOI 10.1074/jbc.275.7.5104
   Locher KP, 2016, NAT STRUCT MOL BIOL, V23, P487, DOI 10.1038/nsmb.3216
   Loewen CJR, 2003, EMBO J, V22, P2025, DOI 10.1093/emboj/cdg201
   LUECKE H, 1990, NATURE, V347, P402, DOI 10.1038/347402a0
   Luo J, 2019, TRENDS BIOCHEM SCI, V44, P273, DOI 10.1016/j.tibs.2018.10.001
   Malakhova ML, 2005, J BIOL CHEM, V280, P26312, DOI 10.1074/jbc.M500481200
   Malinina L, 2004, NATURE, V430, P1048, DOI 10.1038/nature02856
   Malinina L, 2006, PLOS BIOL, V4, P1996, DOI 10.1371/journal.pbio.0040362
   Malinina L, 2017, ANNU REV BIOCHEM, V86, P609, DOI 10.1146/annurev-biochem-061516-044445
   Malinina L, 2015, Q REV BIOPHYS, V48, P281, DOI 10.1017/S003358351400016X
   Marcus J, 2002, BBA-GEN SUBJECTS, V1573, P406, DOI 10.1016/S0304-4165(02)00410-5
   Matarrese P, 2014, AUTOPHAGY, V10, P750, DOI 10.4161/auto.27959
   Mattjus P, 2002, BIOCHEMISTRY-US, V41, P266, DOI 10.1021/bi015718l
   Mattjus P, 1999, ANAL BIOCHEM, V268, P297, DOI 10.1006/abio.1998.3065
   Mattjus P, 2000, BIOCHEMISTRY-US, V39, P1067, DOI 10.1021/bi991810u
   Mattjus P, 2016, CHEM PHYS LIPIDS, V194, P72, DOI 10.1016/j.chemphyslip.2015.07.018
   Mattjus P, 2009, BBA-BIOMEMBRANES, V1788, P267, DOI 10.1016/j.bbamem.2008.10.003
   Mayinger P, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a005314
   METZ RJ, 1982, J BIOL CHEM, V257, P2901
   METZ RJ, 1980, J BIOL CHEM, V255, P4463
   Mikitova V, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030455
   Mishra SK, 2017, CANCER RES, V77, DOI 10.1158/1538-7445.AM2017-1123
   Mishra SK, 2019, BBA-MOL CELL BIOL L, V1864, P158, DOI 10.1016/j.bbalip.2018.11.002
   Mishra SK, 2018, AUTOPHAGY, V14, P862, DOI 10.1080/15548627.2017.1393129
   Morgan MJ, 2015, BMB REP, V48, P303, DOI 10.5483/BMBRep.2015.48.6.068
   Muallem S, 2017, EMBO REP, V18, P1893, DOI 10.15252/embr.201744331
   Mullen TD, 2012, ANTI-CANCER AGENT ME, V12, P340, DOI 10.2174/187152012800228661
   Neumann J, 2017, BBA-BIOMEMBRANES, V1859, P605, DOI 10.1016/j.bbamem.2016.09.023
   Newton J, 2015, EXP CELL RES, V333, P195, DOI 10.1016/j.yexcr.2015.02.025
   Nganga R, 2019, J BIOL CHEM, V294, P502, DOI 10.1074/jbc.RA118.005865
   Nylund M, 2005, BBA-BIOMEMBRANES, V1669, P87, DOI 10.1016/j.bbamem.2004.12.014
   Nylund M, 2007, LANGMUIR, V23, P11726, DOI 10.1021/la701927u
   Nylund M, 2006, BBA-BIOMEMBRANES, V1758, P807, DOI 10.1016/j.bbamem.2006.04.023
   Ochoa-Lizarralde B, 2018, J BIOL CHEM, V293, P16709, DOI 10.1074/jbc.RA117.000733
   Ogretmen B, 2018, NAT REV CANCER, V18, P33, DOI 10.1038/nrc.2017.96
   Ohvo-Rekila H, 2011, BBA-BIOMEMBRANES, V1808, P47, DOI 10.1016/j.bbamem.2010.08.018
   Petersen NHT, 2008, FEBS J, V275, P4378, DOI 10.1111/j.1742-4658.2008.06584.x
   Pettus BJ, 2003, J BIOL CHEM, V278, P38206, DOI 10.1074/jbc.M304816200
   Pettus BJ, 2004, J BIOL CHEM, V279, P11320, DOI 10.1074/jbc.M309262200
   Prashek J, 2017, J BIOL CHEM, V292, P14217, DOI 10.1074/jbc.M117.780007
   Prashek J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079590
   Prinz WA, 2014, J CELL BIOL, V205, P759, DOI 10.1083/jcb.201401126
   Qian HW, 2017, CELL, V169, P1228, DOI 10.1016/j.cell.2017.05.020
   Rao CS, 2005, BIOPHYS J, V89, P4017, DOI 10.1529/biophysj.105.070631
   Rao CS, 2004, BIOCHEMISTRY-US, V43, P13805, DOI 10.1021/bi0492197
   Rippo MR, 2000, FASEB J, V14, P2047, DOI 10.1096/fj.99-1028com
   Ros U, 2017, CELL REP, V19, P175, DOI 10.1016/j.celrep.2017.03.024
   Roy A, 2010, NAT PROTOC, V5, P725, DOI 10.1038/nprot.2010.5
   Samaha D, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20143554
   Samygina VR, 2013, ACTA CRYSTALLOGR D, V69, P603, DOI 10.1107/S0907444913000024
   Samygina VR, 2011, STRUCTURE, V19, P1644, DOI 10.1016/j.str.2011.09.011
   Sano R, 2009, MOL CELL, V36, P500, DOI 10.1016/j.molcel.2009.10.021
   Sentelle RD, 2012, NAT CHEM BIOL, V8, P831, DOI 10.1038/NCHEMBIO.1059
   Shan B, 2018, GENE DEV, V32, P327, DOI 10.1101/gad.312561.118
   Sharma K, 2015, NAT NEUROSCI, V18, P1819, DOI 10.1038/nn.4160
   Simanshu DK, 2014, CELL REP, V6, P388, DOI 10.1016/j.celrep.2013.12.023
   Simanshu DK, 2013, NATURE, V500, P463, DOI 10.1038/nature12332
   Stahelin RV, 2007, J BIOL CHEM, V282, P20467, DOI 10.1074/jbc.M701396200
   Su Z, 2016, CELL DEATH DIFFER, V23, P748, DOI 10.1038/cdd.2016.8
   Tabassum R, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11954-8
   Takada N, 2018, EMBO J, V37, DOI 10.15252/embj.201797705
   Takahashi Y, 2011, AUTOPHAGY, V7, P61, DOI 10.4161/auto.7.1.14015
   Taniguchi M, 2012, J BIOL CHEM, V287, DOI 10.1074/jbc.M112.416552
   Theorin L, 2019, BIOCHEM J, V476, P783, DOI 10.1042/BCJ20180891
   Thorsell AG, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019521
   Trayssac M, 2018, J CLIN INVEST, V128, P2702, DOI 10.1172/JCI97949
   Tritz R, 2009, BIOCHEM BIOPH RES CO, V383, P167, DOI 10.1016/j.bbrc.2009.03.126
   Tummers B, 2017, IMMUNOL REV, V277, P76, DOI 10.1111/imr.12541
   Tuuf J, 2007, BBA-MOL CELL BIOL L, V1771, P1353, DOI 10.1016/j.bbalip.2007.09.001
   Tuuf J, 2014, CHEM PHYS LIPIDS, V178, P27, DOI 10.1016/j.chemphyslip.2013.10.013
   Tuuf J, 2009, BIOCHEM BIOPH RES CO, V388, P395, DOI 10.1016/j.bbrc.2009.08.023
   van Meer G, 2008, NAT REV MOL CELL BIO, V9, P112, DOI 10.1038/nrm2330
   Wang J, 2017, CLIN RES HEPATOL GAS, V41, P86, DOI 10.1016/j.clinre.2016.08.003
   Ward KE, 2013, J LIPID RES, V54, P636, DOI 10.1194/jlr.M031088
   WARNOCK DE, 1994, P NATL ACAD SCI USA, V91, P2708, DOI 10.1073/pnas.91.7.2708
   West G, 2008, FEBS J, V275, P3421, DOI 10.1111/j.1742-4658.2008.06498.x
   West G, 2006, BBA-BIOMEMBRANES, V1758, P1732, DOI 10.1016/j.bbamem.2006.06.020
   Wijesinghe DS, 2009, J LIPID RES, V50, P1986, DOI 10.1194/jlr.M800367-JLR200
   Wong LH, 2019, NAT REV MOL CELL BIO, V20, P85, DOI 10.1038/s41580-018-0071-5
   Wong LH, 2017, TRENDS BIOCHEM SCI, V42, P516, DOI 10.1016/j.tibs.2017.05.001
   WONG M, 1984, BIOCHEMISTRY-US, V23, P6498, DOI 10.1021/bi00321a035
   YAMADA K, 1985, J BIOL CHEM, V260, P4615
   Yamaji T, 2015, TRAFFIC, V16, P101, DOI 10.1111/tra.12239
   Yang F, 2019, MOL BRAIN, V12, DOI 10.1186/s13041-019-0440-9
   Yellajoshyula D, 2017, DEV CELL, V42, P52, DOI 10.1016/j.devcel.2017.06.009
   Young MM, 2018, ADV CANCER RES, V140, P27, DOI 10.1016/bs.acr.2018.04.008
   Young MM, 2013, J LIPID RES, V54, P5, DOI 10.1194/jlr.R031278
   Yui N, 2009, AM J PHYSIOL-CELL PH, V297, pC1389, DOI 10.1152/ajpcell.00098.2009
   Zhai XH, 2017, BIOPHYS J, V112, p229A, DOI 10.1016/j.bpj.2016.11.1259
   Zhai XH, 2017, J BIOL CHEM, V292, P2531, DOI 10.1074/jbc.M116.760256
   Zhai XH, 2009, J BIOL CHEM, V284, P13620, DOI 10.1074/jbc.M809089200
   Zou XQ, 2011, J BIOL CHEM, V286, P1301, DOI 10.1074/jbc.M110.127837
   Zou XQ, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-72
NR 169
TC 7
Z9 7
U1 0
U2 10
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0163-7827
EI 1873-2194
J9 PROG LIPID RES
JI Prog. Lipid Res.
PD APR
PY 2020
VL 78
AR 101031
DI 10.1016/j.plipres.2020.101031
PG 18
WC Biochemistry & Molecular Biology; Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Nutrition & Dietetics
GA LO3CZ
UT WOS:000533508000005
PM 32339554
OA Green Accepted
DA 2022-04-25
ER

PT J
AU Sorokina, IV
   Denisenko, TV
   Imreh, G
   Tyurin-Kuzmin, PA
   Kaminskyy, VO
   Gogvadze, V
   Zhivotovsky, B
AF Sorokina, Irina V.
   Denisenko, Tatiana V.
   Imreh, Gabriela
   Tyurin-Kuzmin, Pyotr A.
   Kaminskyy, Vitaliy O.
   Gogvadze, Vladimir
   Zhivotovsky, Boris
TI Involvement of autophagy in the outcome of mitotic catastrophe
SO SCIENTIFIC REPORTS
LA English
DT Article
ID CELL-CYCLE CHECKPOINT; DNA-DAMAGE; IMMUNE-RESPONSES; DEATH; CANCER;
   APOPTOSIS; 14-3-3-SIGMA; MITOCHONDRIA; DISRUPTION; ACTIVATION
AB Evading cell death is a major driving force for tumor progression that is one of the main problems in current cancer research. Mitotic catastrophe (MC) represents attractive platform compromising tumor resistance to current therapeutic modalities. MC appeared as onco-suppressive mechanism and is defined as a stage driving the cell to an irreversible destiny, i.e. cell death via apoptosis or necrosis. Our study highlights that MC induction in colorectal carcinoma cell lines ultimately leads to the autophagy followed by apoptosis. We show that autophagy suppression in Atg 13 knockout non-small cell lung carcinoma cells lead to the dramatic decrease of MC rate. Furthermore, mitochondria-linked antiapoptotic proteins Mcl-1 and Bcl-xL play a crucial role in the duration of MC and a cross-talk between autophagy and apoptosis. Thus, the suppression of apoptosis by overexpression of Mcl-1 or Bcl-xL affected MC and lead to a significant induction of autophagy in HCT116 wt and HCT116 14-3-3 sigma(-/-)cells. Our data demonstrate that MC induction is a critical stage, in which a cell decides how to die, while mitochondria are responsible for the maintaining the balance between MC - autophagy - apoptosis.
C1 [Sorokina, Irina V.; Denisenko, Tatiana V.; Tyurin-Kuzmin, Pyotr A.; Gogvadze, Vladimir; Zhivotovsky, Boris] Moscow MV Lomonosov State Univ, Fac Fundamental Med, Moscow 119992, Russia.
   [Imreh, Gabriela; Kaminskyy, Vitaliy O.; Gogvadze, Vladimir; Zhivotovsky, Boris] Karolinska Inst, Inst Environm Med, Div Toxicol, Box 210, S-17177 Stockholm, Sweden.
   [Imreh, Gabriela] Karolinska Inst, Dept Biosci & Nutr, S-17177 Stockholm, Sweden.
RP Zhivotovsky, B (corresponding author), Moscow MV Lomonosov State Univ, Fac Fundamental Med, Moscow 119992, Russia.; Zhivotovsky, B (corresponding author), Karolinska Inst, Inst Environm Med, Div Toxicol, Box 210, S-17177 Stockholm, Sweden.
EM Boris.Zhivotovsky@ki.se
RI Tyurin-Kuzmin, Pyotr A./A-8193-2014; Gogvadze, Vladimir/A-4392-2014;
   Zhivotovsky, Boris/A-4346-2014; Denisenko, Tatyana/U-9986-2018
OI Tyurin-Kuzmin, Pyotr A./0000-0002-1901-1637; Zhivotovsky,
   Boris/0000-0002-2238-3482; Kaminskyy, Vitaliy/0000-0002-8151-5270
FU Russian Science FoundationRussian Science Foundation (RSF)
   [14-25-00056]; Stockholm Cancer Society [161292]; Swedish Cancer
   SocietySwedish Cancer Society [160733]; Swedish Childhood Cancer
   FoundationEuropean Commission [PR2016-0090]; Swedish Research
   CouncilSwedish Research CouncilEuropean Commission [521-2014-2258]; 
   [NSH-7082.2016]; Russian Science FoundationRussian Science Foundation
   (RSF) [17-25-00012] Funding Source: Russian Science Foundation
FX We thank Prof. Bert Vogelstein for HCT116 cells, Prof. Fazoil
   Ataullakhanov and Dr. Pyotr Makhov for plasmid containing LC3-GFP. This
   work was supported by Russian Science Foundation (grant number
   14-25-00056). The work in the authors' laboratories is being supported
   from Russian President Fund (grant number NSH-7082.2016), as well as the
   Stockholm (grant number 161292) and Swedish (grant number 160733) Cancer
   Societies, the Swedish Childhood Cancer Foundation (grant number
   PR2016-0090), the Swedish Research Council (grant number 521-2014-2258).
CR Abedin MJ, 2007, CELL DEATH DIFFER, V14, P500, DOI 10.1038/sj.cdd.4402039
   Allavena G, 2016, AUTOPHAGY, V12, P2085, DOI 10.1080/15548627.2016.1226733
   Castedo M, 2004, ONCOGENE, V23, P4353, DOI 10.1038/sj.onc.1207573
   Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188
   Chopra P, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014305
   Cook K. L., 2014, CELL BIOSCI, V4
   Corazzari M, 2015, CELL DEATH DIFFER, V22, P946, DOI 10.1038/cdd.2014.183
   Denisenko TV, 2016, DRUG RESIST UPDATE, V24, P1, DOI 10.1016/j.drup.2015.11.002
   Galluzzi L, 2012, CELL DEATH DIFFER, V19, P107, DOI 10.1038/cdd.2011.96
   Germain M, 2011, AUTOPHAGY, V7, P549, DOI 10.4161/auto.7.5.15098
   Gogvadze V, 2014, MITOCHONDRION, V19, P1, DOI 10.1016/j.mito.2014.10.002
   Huertas D, 2012, ONCOGENE, V31, P1408, DOI 10.1038/onc.2011.335
   Ichim G, 2015, MOL CELL, V57, P860, DOI 10.1016/j.molcel.2015.01.018
   Kaminskyy VO, 2012, AUTOPHAGY, V8, P1032, DOI 10.4161/auto.20123
   Kanzawa T, 2004, CELL DEATH DIFFER, V11, P448, DOI 10.1038/sj.cdd.4401359
   Laane E, 2009, CELL DEATH DIFFER, V16, P1018, DOI 10.1038/cdd.2009.46
   Ladoire S, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2016.1174801
   Lanz HL, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.2
   Lee HK, 2010, IMMUNITY, V32, P227, DOI 10.1016/j.immuni.2009.12.006
   Lodygin D, 2005, CELL RES, V15, P237, DOI 10.1038/sj.cr.7290292
   Ma YT, 2013, IMMUNITY, V39, P211, DOI 10.1016/j.immuni.2013.07.017
   Michaud M, 2011, SCIENCE, V334, P1573, DOI 10.1126/science.1208347
   Niewerth D, 2015, DRUG RESIST UPDATE, V18, P18, DOI 10.1016/j.drup.2014.12.001
   Nomura M, 2003, J BIOL CHEM, V278, P2058, DOI 10.1074/jbc.M207880200
   Roninson IB, 2001, DRUG RESIST UPDATE, V4, P303, DOI 10.1054/drup.2001.0213
   Rubinsztein DC, 2012, NAT REV DRUG DISCOV, V11, P709, DOI 10.1038/nrd3802
   Sablina AA, 1999, CELL BIOL INT, V23, P323, DOI 10.1006/cbir.1999.0362
   Sablina AA, 2001, ONCOGENE, V20, P899, DOI 10.1038/sj.onc.1204156
   Schmitt MW, 2015, NAT METHODS, V12, P423, DOI [10.1038/nmeth.3351, 10.1038/NMETH.3351]
   Suzuki T, 2007, PLOS PATHOG, V3, P1082, DOI 10.1371/journal.ppat.0030111
   Vakifahmetoglu H, 2008, CELL DEATH DIFFER, V15, P1153, DOI 10.1038/cdd.2008.47
   Viola G, 2012, BIOCHEM PHARMACOL, V83, P16, DOI 10.1016/j.bcp.2011.09.017
   Vitale I, 2011, NAT REV MOL CELL BIO, V12, P384, DOI 10.1038/nrm3115
   Yamamoto A, 1998, CELL STRUCT FUNCT, V23, P33, DOI 10.1247/csf.23.33
   Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3
   Zong WX, 2016, MOL CELL, V61, P667, DOI 10.1016/j.molcel.2016.02.011
NR 36
TC 22
Z9 22
U1 1
U2 5
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD NOV 6
PY 2017
VL 7
AR 14571
DI 10.1038/s41598-017-14901-z
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA FL7GN
UT WOS:000414415000071
PM 29109414
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Gerada, C
   Ryan, KM
AF Gerada, Chelsea
   Ryan, Kevin M.
TI Autophagy, the innate immune response and cancer
SO MOLECULAR ONCOLOGY
LA English
DT Review
DE autophagy; cancer; immunotherapy; innate immune response; tumour
   microenvironment
ID INFLAMMATORY-BOWEL-DISEASE; LYMPH-NODE METASTASIS; TUMOR-CELLS;
   HEPATOCELLULAR-CARCINOMA; COLORECTAL-CANCER; NK CELLS; SUSCEPTIBILITY;
   INHIBITION; SENESCENCE; INVASION
AB Autophagy is a cellular degradation and recycling system, which can interact with components of innate immune signalling pathways to enhance pathogen clearance, in both immune and nonimmune cells. Whilst this interaction is often beneficial for pathogen clearance, it can have varying outcomes in regard to tumorigenesis. Autophagy and the innate immune response can have both pro- and antitumorigenic effects at different stages of tumorigenesis due to the plastic nature of the tumour microenvironment (TME). Although both of these components have been studied in isolation as potential therapeutic targets, there has been less research concerning the interaction between autophagy and the innate immune response within the TME. As the innate immune response is critical for the formation of an effective antitumour adaptive immune response, targeting autophagy pathways in both tumour cells and innate immune cells could enhance tumour clearance. Within tumour cells, autophagy pathways are intertwined with pattern recognition receptor (PRR), inflammatory and cell death pathways, and therefore can alter the immunogenicity of the TME and development of the antitumour immune response. In innate immune cells, autophagy components can have autophagy-independent roles in functional pathways, and therefore could be valuable targets for enhancing immune cell function in the TME and immunotherapy. This review highlights the individual importance of autophagy and the innate immune response to tumorigenesis, and also explains the complex interactions between these pathways in the TME.
C1 [Gerada, Chelsea; Ryan, Kevin M.] Canc Res UK Beatson Inst, Switchback Rd, Glasgow G61 1BD, Lanark, Scotland.
   [Ryan, Kevin M.] Univ Glasgow, Inst Canc Sci, Glasgow, Lanark, Scotland.
RP Ryan, KM (corresponding author), Canc Res UK Beatson Inst, Switchback Rd, Glasgow G61 1BD, Lanark, Scotland.
EM k.ryan@beatson.gla.ac.uk
RI Gerada, Chelsea/AAD-7063-2021
OI Ryan, Kevin M./0000-0002-1059-9681; Gerada, Chelsea/0000-0001-8491-2506
FU Cancer Research UKCancer Research UK [A22903, A17196]
FX Work in the Tumour Cell Death Laboratory is supported by grants from
   Cancer Research UK (A22903 and A17196). Thanks to Dr. Victoria Wang for
   reading and providing suggestions for the manuscript.
CR Alissafi T, 2018, J CLIN INVEST, V128, P3840, DOI 10.1172/JCI120888
   Allen IC, 2012, IMMUNITY, V36, P742, DOI 10.1016/j.immuni.2012.03.012
   Aspord C, 2013, CANCER IMMUNOL RES, V1, P402, DOI 10.1158/2326-6066.CIR-13-0114-T
   Baghdadi M, 2013, IMMUNITY, V39, P1070, DOI 10.1016/j.immuni.2013.09.014
   Baginska J, 2013, P NATL ACAD SCI USA, V110, P17450, DOI 10.1073/pnas.1304790110
   Bal SM, 2020, NAT REV IMMUNOL, V20, P552, DOI 10.1038/s41577-020-0282-9
   Belderbos RA, 2019, MOL THER-ONCOLYTICS, V13, P67, DOI 10.1016/j.omto.2019.03.007
   Bie QL, 2014, J IMMUNOL RES, V2014, DOI 10.1155/2014/923135
   Bojesen RD, 2017, CLIN GASTROENTEROL H, V15, P1900, DOI 10.1016/j.cgh.2017.06.051
   Bottazzi B, 2018, SEMIN IMMUNOL, V40, P74, DOI 10.1016/j.smim.2018.10.011
   Bronte V, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12150
   Cadwell K, 2016, NAT REV IMMUNOL, V16, P661, DOI 10.1038/nri.2016.100
   Canli O, 2017, CANCER CELL, V32, P869, DOI 10.1016/j.ccell.2017.11.004
   Cardoso AP, 2014, ONCOGENE, V33, P2123, DOI 10.1038/onc.2013.154
   Cassetta L, 2019, CANCER CELL, V35, P588, DOI 10.1016/j.ccell.2019.02.009
   Chiossone L, 2018, NAT REV IMMUNOL, V18, P671, DOI 10.1038/s41577-018-0061-z
   Choi CHR, 2017, NAT REV GASTRO HEPAT, V14, P218, DOI 10.1038/nrgastro.2017.1
   Chollat-Namy M, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1950-1
   Clappaert EJ, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02250
   Cunha LD, 2018, CELL, V175, P429, DOI 10.1016/j.cell.2018.08.061
   Dadi S, 2016, CELL, V164, P365, DOI 10.1016/j.cell.2016.01.002
   Dapito DH, 2012, CANCER CELL, V21, P504, DOI 10.1016/j.ccr.2012.02.007
   Delconte RB, 2016, NAT IMMUNOL, V17, P816, DOI 10.1038/ni.3470
   DeNardo DG, 2019, NAT REV IMMUNOL, V19, P369, DOI 10.1038/s41577-019-0127-6
   Dikic I, 2018, NAT REV MOL CELL BIO, V19, P349, DOI 10.1038/s41580-018-0003-4
   Eckl J, 2012, J MOL MED, V90, P55, DOI 10.1007/s00109-011-0806-7
   Fan DP, 2018, J IMMUNOL, V200
   Fehniger TA, 2016, TRENDS IMMUNOL, V37, P877, DOI 10.1016/j.it.2016.09.005
   Fucikova J, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02393
   Galle-Treger L, 2020, J ALLERGY CLIN IMMUN, V145, P502, DOI 10.1016/j.jaci.2019.10.035
   Gao YL, 2017, NAT IMMUNOL, V18, P1004, DOI 10.1038/ni.3800
   Germic N, 2019, CELL DEATH DIFFER, V26, P715, DOI 10.1038/s41418-019-0297-6
   Goodall ML, 2016, DEV CELL, V37, P337, DOI 10.1016/j.devcel.2016.04.018
   Greten FR, 2019, IMMUNITY, V51, P27, DOI 10.1016/j.immuni.2019.06.025
   Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025
   Gui X, 2019, NATURE, V567, P262, DOI 10.1038/s41586-019-1006-9
   Haas L, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02746
   Ham SW, 2019, CELL DEATH DIFFER, V26, P409, DOI 10.1038/s41418-018-0126-3
   He SJ, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0626-6
   Hegde S, 2020, CANCER CELL, V37, P289, DOI 10.1016/j.ccell.2020.02.008
   Ikutani M, 2012, J IMMUNOL, V188, P703, DOI 10.4049/jimmunol.1101270
   Irshad S, 2017, CANCER RES, V77, P1083, DOI 10.1158/0008-5472.CAN-16-0598
   Jeon HY, 2019, CELL DEATH DIFFER, V26, P2139, DOI 10.1038/s41418-019-0282-0
   Johnson DE, 2018, NAT REV CLIN ONCOL, V15, P234, DOI 10.1038/nrclinonc.2018.8
   Jovanovic IP, 2014, INT J CANCER, V134, P1669, DOI 10.1002/ijc.28481
   Kang R, 2010, CELL DEATH DIFFER, V17, P666, DOI 10.1038/cdd.2009.149
   Kaushik S, 2018, NAT REV MOL CELL BIO, V19, P365, DOI 10.1038/s41580-018-0001-6
   Khoo LT, 2018, EMBO REP, V19, DOI 10.15252/embr.201846935
   Kim J, 2019, CLIN NUTR, pS0261
   Kirchberger S, 2013, J EXP MED, V210, P917, DOI 10.1084/jem.20122308
   Klein JC, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14600
   Ko A, 2014, CELL DEATH DIFFER, V21, P92, DOI 10.1038/cdd.2013.124
   Kon M, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3003182
   Kong E, 2020, CELL DEATH DIFFER, V27, P2517, DOI 10.1038/s41418-020-0519-y
   Kortlever RM, 2017, CELL, V171, P1301, DOI 10.1016/j.cell.2017.11.013
   Krysko DV, 2012, NAT REV CANCER, V12, P860, DOI 10.1038/nrc3380
   Lee S, 2019, NAT CELL BIOL, V21, P94, DOI 10.1038/s41556-018-0249-2
   Leidal AM, 2020, NAT CELL BIOL, V22, P187, DOI 10.1038/s41556-019-0450-y
   Levy J, 2015, NAT CELL BIOL, V17, P1062, DOI 10.1038/ncb3206
   Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257
   Lim J, 2019, ELIFE, V8, DOI 10.7554/eLife.44452
   Lin H, 2013, HEPATOLOGY, V57, P171, DOI 10.1002/hep.25991
   Liu D, 2019, CELL DEATH DIFFER, V26, P1735, DOI 10.1038/s41418-018-0251-z
   Loi M, 2016, CELL REP, V15, P1076, DOI 10.1016/j.celrep.2016.04.002
   Lytle NK, 2018, NAT REV CANCER, V18, P669, DOI 10.1038/s41568-018-0056-x
   Mah LY, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a008821
   Maiuri MC, 2009, CELL DEATH DIFFER, V16, P87, DOI 10.1038/cdd.2008.131
   Mantovani A, 2017, NAT REV CLIN ONCOL, V14, P399, DOI 10.1038/nrclinonc.2016.217
   Mantovani F, 2019, CELL DEATH DIFFER, V26, P199, DOI 10.1038/s41418-018-0246-9
   Martinez J, 2015, NAT CELL BIOL, V17, P893, DOI 10.1038/ncb3192
   Martins I, 2014, CELL DEATH DIFFER, V21, P79, DOI 10.1038/cdd.2013.75
   Mgrditchian T, 2017, P NATL ACAD SCI USA, V114, pE9271, DOI 10.1073/pnas.1703921114
   Moral JA, 2020, NATURE, V579, P130, DOI 10.1038/s41586-020-2015-4
   Mowers EE, 2018, FEBS J, V285, P1751, DOI 10.1111/febs.14388
   Nassour J, 2019, NATURE, V565, P659, DOI 10.1038/s41586-019-0885-0
   Netea-Maier RT, 2016, AUTOPHAGY, V12, P245, DOI 10.1080/15548627.2015.1071759
   O'Sullivan TE, 2015, IMMUNITY, V43, P331, DOI 10.1016/j.immuni.2015.07.012
   Oh DS, 2019, AUTOPHAGY, V15, P2091, DOI 10.1080/15548627.2019.1596493
   Parekh VV, 2017, P NATL ACAD SCI USA, V114, pE6371, DOI 10.1073/pnas.1706504114
   Pekow J, 2019, J CROHNS COLITIS, V13, P884, DOI 10.1093/ecco-jcc/jjz014
   Platonova S, 2011, CANCER RES, V71, P5412, DOI 10.1158/0008-5472.CAN-10-4179
   Pradere JP, 2014, ONCOGENE, V33, P3485, DOI 10.1038/onc.2013.302
   Quach C, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-13475-w
   Robles AI, 2016, GASTROENTEROLOGY, V150, P931, DOI 10.1053/j.gastro.2015.12.036
   Rosenfeldt MT, 2017, CELL DEATH DIFFER, V24, P1303, DOI 10.1038/cdd.2016.120
   Rosenfeldt MT, 2013, NATURE, V504, P296, DOI 10.1038/nature12865
   Saitoh T, 2008, NATURE, V456, P264, DOI 10.1038/nature07383
   Saitoh T, 2009, P NATL ACAD SCI USA, V106, P20842, DOI 10.1073/pnas.0911267106
   Samie M, 2018, NAT IMMUNOL, V19, P246, DOI 10.1038/s41590-017-0042-6
   Santana-Codina N, 2017, ANNU REV CANC BIOL, V1, P19, DOI 10.1146/annurev-cancerbio-041816-122338
   Saxena M, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00327
   Schwitalla S, 2013, CANCER CELL, V23, P93, DOI 10.1016/j.ccr.2012.11.014
   Simoni Y, 2017, IMMUNITY, V46, P148, DOI 10.1016/j.immuni.2016.11.005
   Singh SS, 2018, ONCOGENE, V37, P1142, DOI 10.1038/s41388-017-0046-6
   Slobodnyuk K, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1607-0
   Snyder AG, 2019, SCI IMMUNOL, V4, DOI 10.1126/sciimmunol.aaw2004
   Song S, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2304-8
   Strohecker AM, 2013, CANCER DISCOV, V3, P1272, DOI 10.1158/2159-8290.CD-13-0397
   Su T, 2020, FRONT PLANT SCI, V11, DOI 10.3389/fpls.2020.00164
   Takamura A, 2011, GENE DEV, V25, P795, DOI 10.1101/gad.2016211
   Takeuchi O, 2010, CELL, V140, P805, DOI 10.1016/j.cell.2010.01.022
   Tan HY, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.271
   Tekirdag K, 2018, J BIOL CHEM, V293, P5414, DOI 10.1074/jbc.R117.818237
   Thorburn J, 2009, CELL DEATH DIFFER, V16, P175, DOI 10.1038/cdd.2008.143
   Verzella D, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2399-y
   Vivier E, 2005, NAT IMMUNOL, V6, P17, DOI 10.1038/ni1153
   Wang TY, 2019, ONCOGENE, V38, P4932, DOI 10.1038/s41388-019-0763-0
   Yamamoto K, 2020, NATURE, V581, P100, DOI 10.1038/s41586-020-2229-5
   Young ARJ, 2009, GENE DEV, V23, P798, DOI 10.1101/gad.519709
   Yu J, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3248-y
   Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100
   Zhan ZZ, 2014, AUTOPHAGY, V10, P257, DOI 10.4161/auto.27162
   Zhang Q, 2018, NAT IMMUNOL, V19, P723, DOI 10.1038/s41590-018-0132-0
   Zhong FL, 2016, CELL, V167, P187, DOI 10.1016/j.cell.2016.09.001
   Zhong ZY, 2016, CELL, V164, P896, DOI 10.1016/j.cell.2015.12.057
   Zhu H, 2017, CELL MOL IMMUNOL, V14, P403, DOI 10.1038/cmi.2017.14
   Zitvogel L, 2017, NAT IMMUNOL, V18, P843, DOI 10.1038/ni.3754
NR 117
TC 19
Z9 19
U1 2
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1574-7891
EI 1878-0261
J9 MOL ONCOL
JI Mol. Oncol.
PD SEP
PY 2020
VL 14
IS 9
BP 1913
EP 1929
DI 10.1002/1878-0261.12774
EA AUG 2020
PG 17
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA NH8GM
UT WOS:000563745600001
PM 32745353
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Fu, ZQ
   Luo, WZ
   Wang, JT
   Peng, T
   Sun, GF
   Shi, JY
   Li, ZH
   Zhang, BA
AF Fu, Zhenqiang
   Luo, Wenzheng
   Wang, Jingtao
   Peng, Tao
   Sun, Guifang
   Shi, Jingyu
   Li, Zhihong
   Zhang, Boai
TI Malatl activates autophagy and promotes cell proliferation by sponging
   miR-101 and upregulating STMN1, RAB5A and ATG4D expression in glioma
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Glioma; The long noncoding RNA Malat1; Autophagy; Proliferation; miR-101
ID HEPATOCELLULAR-CARCINOMA CELLS; INHIBITS AUTOPHAGY; COLORECTAL-CANCER;
   POOR-PROGNOSIS; TUMOR-GROWTH; METASTASIS; OSTEOSARCOMA; APOPTOSIS
AB The long noncoding RNA Malati has been reported to be an oncogene that promotes tumor progress and correlates with prognosis in glioma. Growing evidence shows that autophagy plays a very important role in tumorigenesis and tumor cell survival, but whether Malatl regulates autophagy in glioma is still unclear. In this study, we found that Malatl expression and autophagy activity were significantly increased in glioma tissues compared with adjacent normal tissues. Additionally, Malatl level was positively correlated with the expression of LC3-II (autophagy marker) mRNA in vivo. In vitro assays revealed that Malatl significantly promoted autophagy activation and cell proliferation in glioma cells. More importantly, inhibition of autophagy by 3-MA relieved Malatl-induced cell proliferation. These data demonstrated that Malatl activates autophagy and increases cell proliferation in glioma. We further investigated the molecular mechanisms whereby Malatl functioned on glioma cell autophagy and proliferation. We found that Malati served as an endogenous sponge to reduce miR-101 expression by directly binding to miR-101. Moreover, Malati abolished the suppression effects of miR-101 on glioma cell autophagy and proliferation, which involved in upregulating the expression of miR-101 targets STMN1, RAB5A and ATG4D. Overall, our study elucidated a novel Malatl-miR-101-STMN1/RAB5A/ATG4D regulatory network that Malatl activates autophagy and promotes cell proliferation by sponging miR101 and upregulating STMN1, RAB5A and ATG4D expression in glioma cells. (C) 2017 Elsevier Inc. All rights reserved.
C1 [Fu, Zhenqiang; Wang, Jingtao; Peng, Tao; Sun, Guifang; Zhang, Boai] Zhengzhou Univ, Affiliated Hosp 1, Dept Neurol, Jianshe Dong Rd 1, Zhengzhou 450000, Henan, Peoples R China.
   [Luo, Wenzheng] Zhengzhou Univ, Affiliated Hosp 1, Dept Neurosurg, Zhengzhou, Henan, Peoples R China.
   [Shi, Jingyu] Luoyang Cent Hosp, Dept Neurol, Luoyang, Peoples R China.
   [Li, Zhihong] Zhengzhou Cent Hosp, Dept Neurol, Zhengzhou, Henan, Peoples R China.
RP Zhang, BA (corresponding author), Zhengzhou Univ, Affiliated Hosp 1, Dept Neurol, Jianshe Dong Rd 1, Zhengzhou 450000, Henan, Peoples R China.
EM zbadoctor@163.com
CR Betin VMS, 2009, AUTOPHAGY, V5, P1057, DOI 10.4161/auto.5.7.9684
   Chang Y, 2012, GASTROENTEROLOGY, V143, P177, DOI 10.1053/j.gastro.2012.04.009
   Chang Z., 2014, SCI WORLD J
   Dong YQ, 2015, TUMOR BIOL, V36, P1477, DOI 10.1007/s13277-014-2631-4
   Fan Y, 2014, CLIN CANCER RES, V20, P1531, DOI 10.1158/1078-0432.CCR-13-1455
   Frankel LB, 2011, EMBO J, V30, P4628, DOI 10.1038/emboj.2011.331
   Hu YL, 2012, CANCER RES, V72, P1773, DOI 10.1158/0008-5472.CAN-11-3831
   Ji Q, 2014, BRIT J CANCER, V111, P736, DOI 10.1038/bjc.2014.383
   Kyostila K, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005169
   Li H, 2014, ONCOTARGET, V5, P2318, DOI 10.18632/oncotarget.1913
   Li J, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-215
   Li L, 2016, MOL CANCER THER, V15, P2232, DOI 10.1158/1535-7163.MCT-16-0008
   Li YJ, 2013, AUTOPHAGY, V9, P150, DOI 10.4161/auto.22742
   Lu YY, 2014, AUTOPHAGY, V10, P1895, DOI 10.4161/auto.32200
   Ma KX, 2015, TUMOR BIOL, V36, P3355, DOI 10.1007/s13277-014-2969-7
   Ostrom QT, 2014, NEURO-ONCOLOGY, V16, P1, DOI 10.1093/neuonc/nou223
   Pennati M, 2014, BIOCHEM PHARMACOL, V87, P579, DOI 10.1016/j.bcp.2013.12.009
   Smits M, 2010, ONCOTARGET, V1, P710, DOI 10.18632/oncotarget.205
   Wang YW, 2014, BIOCHEM PHARMACOL, V88, P322, DOI 10.1016/j.bcp.2014.01.041
   Wang Z., 1899, ONCOL LETT, V13, P3465
   Wu H, 2006, CANCER RES, V66, P3015, DOI 10.1158/0008-5472.CAN-05-1554
   Xu T, 2015, AM J TRANSL RES, V7, P1172
   Xu YH, 2013, ONCOL REP, V29, P2019, DOI 10.3892/or.2013.2338
   Yao YL, 2015, CNS NEUROSCI THER, V21, P40, DOI 10.1111/cns.12321
   Yuan P, 2016, BIOCHEM BIOPH RES CO, V478, P1067, DOI 10.1016/j.bbrc.2016.08.065
   Zhang HH, 2015, CANCER LETT, V356, P781, DOI 10.1016/j.canlet.2014.10.029
   Zhao HX, 2016, AM J TRANSL RES, V8, P3503
NR 27
TC 64
Z9 66
U1 1
U2 16
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD OCT 21
PY 2017
VL 492
IS 3
BP 480
EP 486
DI 10.1016/j.bbrc.2017.08.070
PG 7
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA FH8EJ
UT WOS:000411424300031
PM 28834690
DA 2022-04-25
ER

PT J
AU Paillas, S
   Boudousq, V
   Piron, B
   Kersual, N
   Bardies, M
   Chouin, N
   Bascoul-Mollevi, C
   Arnaud, FX
   Pelegrin, A
   Navarro-Teulon, I
   Pouget, JP
AF Paillas, Salome
   Boudousq, Vincent
   Piron, Berengere
   Kersual, Nathalie
   Bardies, Manuel
   Chouin, Nicolas
   Bascoul-Mollevi, Caroline
   Arnaud, Francois-Xavier
   Pelegrin, Andre
   Navarro-Teulon, Isabelle
   Pouget, Jean-Pierre
TI Apoptosis and p53 are not involved in the anti-tumor efficacy of
   I-125-labeled monoclonal antibodies targeting the cell membrane
SO NUCLEAR MEDICINE AND BIOLOGY
LA English
DT Article
DE Radioimmunotherapy; Auger electrons; p53; Apoptosis; I-125-mAbs
ID MAMMALIAN-CELLS; COLON-CANCER; RADIOIMMUNOTHERAPY; DEATH; RADIOTOXICITY;
   THERAPY; LINES; DNA
AB Introduction: I-125-labeled monoclonal antibodies (I-125-mAbs) can efficiently treat small solid tumors. Here, we investigated the role of apoptosis, autophagy and mitotic catastrophe in I-125-mAb toxicity in p53(-/-) and p53(+/+) cancer cells.
   Methods: We exposed p53(-/-) and p53(+/+) HCT116 cells to increasing activities of internalizing (cytoplasmic location) anti-HER1 I-125-mAbs, or non-internalizing (cell surface location) anti-CEA I-125-mAbs. For each targeting model we established the relationship between survival and mean nucleus absorbed dose using the MIRD formalism.
   Results: In both p53(-/-) and p53(+/+) HCT116 cells, anti-CEA I-125-mAbs were more cytotoxic per Gy than anti-HER1 I-125-mAbs. Sensitivity to anti-CEA I-125-mAbs was p53-independent, while sensitivity to anti-HER1 I-125-mAbs was higher in p53(-/-) HCT116 cells, suggesting that they act through different signaling pathways. Apoptosis was only induced in p53(+/+) HCT116 cells and could not explain cell membrane radiation sensitivity. Inhibition of autophagy did not modify the cell response to I-125-mAbs. By contrast, mitotic death was similarly induced in both p53(-/-) and p53(+/+) HCT116 cells by the two types of I-125-mAbs. We also showed using medium transfer experiments that gamma-H2AX foci were produced in bystander cells.
   Conclusion: Cell membrane sensitivity to I-125-mAbs is not mediated by apoptosis and is p53-independent. Bystander effects-mediated mitotic death could be involved in the efficacy of I-125-mAbs binding cell surface receptors. (C) 2013 Elsevier Inc. All rights reserved.
C1 [Paillas, Salome; Boudousq, Vincent; Piron, Berengere; Kersual, Nathalie; Pelegrin, Andre; Navarro-Teulon, Isabelle; Pouget, Jean-Pierre] Inst Rech Cancerol Montpellier, IRCM, F-34298 Montpellier, France.
   [Paillas, Salome; Boudousq, Vincent; Piron, Berengere; Kersual, Nathalie; Pelegrin, Andre; Navarro-Teulon, Isabelle; Pouget, Jean-Pierre] INSERM, U896, F-34298 Montpellier, France.
   [Paillas, Salome; Boudousq, Vincent; Piron, Berengere; Kersual, Nathalie; Pelegrin, Andre; Navarro-Teulon, Isabelle; Pouget, Jean-Pierre] Univ Montpellier I, F-34298 Montpellier, France.
   [Paillas, Salome; Boudousq, Vincent; Piron, Berengere; Kersual, Nathalie; Bascoul-Mollevi, Caroline; Pelegrin, Andre; Navarro-Teulon, Isabelle; Pouget, Jean-Pierre] CRLC Val dAurelle Paul Lamarque, F-34298 Montpellier, France.
   [Bardies, Manuel] INSERM UPS, UMR 1037, Toulouse, France.
   [Chouin, Nicolas] LUNAM Univ, Oniris, AMaROC, F-44307 Nantes, France.
   [Arnaud, Francois-Xavier] Univ Toulouse, Lab Laplace, UMR 5213, F-31400 Toulouse, France.
RP Pouget, JP (corresponding author), CRLC Val dAurelle, Inst Rech Cancerol Montpellier, F-34298 Montpellier 5, France.
EM jean-pierre.pouget@inserm.fr
RI Pèlegrin, André/J-3167-2016; Chouin, Nicolas/M-7914-2016; Mollevi,
   Caroline/AAA-6839-2019; Bardies, Manuel/L-3136-2014
OI Chouin, Nicolas/0000-0003-1489-4351; Mollevi,
   Caroline/0000-0003-4827-3684; Bardies, Manuel/0000-0002-1766-727X;
   POUGET, Jean-Pierre/0000-0001-8551-2029; Pelegrin,
   Andre/0000-0001-9254-2648
FU Institut National du CancerInstitut National du Cancer (INCA) France
   [R09080FF/RPT09005FFA]
FX The authors would like to thank Dr Jean-Marc Brondello, Dr Maguy Del Rio
   and Dr Celine Gongora for helpful discussions. This work was supported
   by the Institut National du Cancer, grant R09080FF/RPT09005FFA.
CR Balagurumoorthy P., 2012, INT J RAD BIOL
   Boudousq V, 2010, J NUCL MED, V51, P1748, DOI 10.2967/jnumed.110.080226
   Buchegger F, 2006, EUR J NUCL MED MOL I, V33, P1352, DOI 10.1007/s00259-006-0187-2
   Cornelissen Bart, 2010, Curr Drug Discov Technol, V7, P263, DOI 10.2174/157016310793360657
   Eriksson D, 2010, TUMOR BIOL, V31, P363, DOI 10.1007/s13277-010-0042-8
   Feinendegen LE, 2012, INT J RAD BIOL
   Goddu SM., 1997, MIRD CELLULAR S VALU
   Golden EB, 2012, FRONT ONCOL, V2, P1, DOI [10.3389/fonc.2012.00088, 10.3389/fonc.2012.00153]
   HAIMOVITZFRIEDMAN A, 1994, J EXP MED, V180, P525, DOI 10.1084/jem.180.2.525
   HAMMARSTROM S, 1989, CANCER RES, V49, P4852
   Howell RW, 2008, INT J RADIAT BIOL, V84, P959, DOI 10.1080/09553000802395527
   KASSIS AI, 1989, RADIAT RES, V118, P283, DOI 10.2307/3577443
   KASSIS AI, 1987, RADIAT RES, V111, P305, DOI 10.2307/3576987
   Kassis Amin I, 2005, Expert Opin Drug Deliv, V2, P981, DOI 10.1517/17425247.2.6.981
   KOHLER G, 1976, EUR J IMMUNOL, V6, P292, DOI 10.1002/eji.1830060411
   Li LN, 2010, J NEUROSURG, V113, P192, DOI 10.3171/2010.2.JNS091211
   Paillas S, 2012, AUTOPHAGY, P8
   Palanca-Wessels MCA, 2010, CANCER-AM CANCER SOC, V116, P1126, DOI 10.1002/cncr.24801
   POMPLUN E, 1987, RADIAT RES, V111, P533, DOI 10.2307/3576938
   Pomplun E, 2000, ACTA ONCOL, V39, P673, DOI 10.1080/028418600750063712
   Pouget JP, 2008, RADIAT RES, V170, P192, DOI 10.1667/RR1359.1
   Pouget JP, 2011, NAT REV CLIN ONCOL, V8, P720, DOI 10.1038/nrclinonc.2011.160
   Prise KM, 2005, LANCET ONCOL, V6, P520, DOI 10.1016/S1470-2045(05)70246-1
   Quang TS, 2004, INT J RADIAT ONCOL, V58, P972, DOI 10.1016/j.ijrobp.2003.09.096
   Santoro L, 2009, J NUCL MED, V50, P2033, DOI 10.2967/jnumed.109.066993
   Seidl C, 2007, MOL CANCER THER, V6, P2346, DOI 10.1158/1535-7163.MCT-07-0132
   Vaidyanathan G, 2002, NUCL MED BIOL, V29, P1, DOI 10.1016/S0969-8051(01)00277-3
   WELT S, 1990, J CLIN ONCOL, V8, P1894, DOI 10.1200/JCO.1990.8.11.1894
   Welt S, 1996, J CLIN ONCOL, V14, P1787, DOI 10.1200/JCO.1996.14.6.1787
   Wu WKK, 2012, ONCOGENE, V31, P939, DOI 10.1038/onc.2011.295
   YAGINUMA Y, 1992, CANCER RES, V52, P4196
   Yasui LS, 2012, INT J RAD BIOL
NR 32
TC 17
Z9 17
U1 0
U2 14
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0969-8051
EI 1872-9614
J9 NUCL MED BIOL
JI Nucl. Med. Biol.
PD MAY
PY 2013
VL 40
IS 4
BP 471
EP 480
DI 10.1016/j.nucmedbio.2013.02.001
PG 10
WC Radiology, Nuclear Medicine & Medical Imaging
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Radiology, Nuclear Medicine & Medical Imaging
GA 237BI
UT WOS:000325842800007
PM 23522976
OA Green Submitted
DA 2022-04-25
ER

PT J
AU Zhu, Y
   Cheng, J
   Min, ZL
   Yin, TZ
   Zhang, R
   Zhang, W
   Hu, L
   Cui, ZW
   Gao, CZ
   Xu, SQ
   Zhang, CX
   Hu, XM
AF Zhu, Yue
   Cheng, Jing
   Min, Zhenli
   Yin, Tingzi
   Zhang, Rong
   Zhang, Wei
   Hu, Ling
   Cui, Zhiwen
   Gao, Chengzhi
   Xu, Shiqiang
   Zhang, Chunxiang
   Hu, Xiamin
TI Effects of fucoxanthin on autophagy and apoptosis in SGC-7901cells and
   the mechanism
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Article
DE apoptosis; autophagy; fucoxanthin; SGC-7901 cells
ID CANCER-CELLS; PI3K/AKT/MTOR PATHWAY; SIGNALING PATHWAYS;
   COLORECTAL-CANCER; BECLIN 1; MACROAUTOPHAGY; INHIBITION; INDUCTION;
   INVASION; DISEASE
AB Autophagy and apoptosis are involved in the development of a variety of cancers. Fucoxanthin is a natural compound known to have antitumor effects, so we aimed to explore its effects on autophagy and apoptosis in gastric cancer SGC7901 cells. Specifically, we performed methyl thiazolyl tetrazolium assay, transmission electron microscopy, real-time polymerase chain reaction, Western blot analysis, immunofluorescence assay, and cell apoptosis analysis to clarify the role of fucoxanthin in SGC-7901 cells. Our results indicate that fucoxanthin significantly inhibits the viability of SGC-7901 cells, effectively inducing both autophagy and apoptosis by up-regulating the expressions of beclin-1, LC3, and cleaved caspase-3 (CC3), and by down regulating Bcl-2. Fucoxanthin-induced autophagy also seems to occur before, and may promote apoptosis.
C1 [Zhu, Yue; Cheng, Jing; Min, Zhenli; Yin, Tingzi; Zhang, Rong; Hu, Ling; Cui, Zhiwen; Gao, Chengzhi; Xu, Shiqiang; Zhang, Chunxiang; Hu, Xiamin] Wuhan Univ Sci & Technol, Hubei Prov Key Lab Occupat Hazard Identificat & C, Wuhan 430065, Hubei, Peoples R China.
   [Zhu, Yue; Cheng, Jing; Min, Zhenli; Yin, Tingzi; Zhang, Rong; Hu, Ling; Cui, Zhiwen; Gao, Chengzhi; Zhang, Chunxiang] Univ Alabama Birmingham, Dept Biomed Engn, Sch Med, Birmingham, AL 35294 USA.
   [Zhu, Yue; Cheng, Jing; Min, Zhenli; Yin, Tingzi; Zhang, Rong; Hu, Ling; Cui, Zhiwen; Gao, Chengzhi; Zhang, Chunxiang] Univ Alabama Birmingham, Dept Biomed Engn, Sch Engn, Birmingham, AL 35294 USA.
   [Zhang, Wei] China Resources & WISCO Gen Hosp, Dept Rehabil Med, Wuhan, Hubei, Peoples R China.
   [Hu, Xiamin] Shanghai Univ Med & Hlth Sci, Dept Pharm, Shanghai, Peoples R China.
RP Hu, XM (corresponding author), Wuhan Univ Sci & Technol, Hubei Prov Key Lab Occupat Hazard Identificat & C, Wuhan 430065, Hubei, Peoples R China.
EM huxm@sumhs.edu.cn
CR Antoine F, 2013, SAGE OPEN MED, V1, DOI 10.1177/2050312113488104
   Brech A, 2009, MOL ONCOL, V3, P366, DOI 10.1016/j.molonc.2009.05.007
   Campbell Frederick C, 2005, Future Oncol, V1, P405, DOI 10.1517/14796694.1.3.405
   Che JB, 2017, CARDIOVASC PATHOL, V31, P57, DOI 10.1016/j.carpath.2017.08.001
   Ciechomska IA, 2009, ONCOGENE, V28, P2128, DOI 10.1038/onc.2009.60
   Djavaheri-Mergny M, 2010, ONCOGENE, V29, P1717, DOI 10.1038/onc.2009.519
   Geng JF, 2008, EMBO REP, V9, P859, DOI 10.1038/embor.2008.163
   Hara T, 2006, NATURE, V441, P885, DOI 10.1038/nature04724
   Hayashi-Nishino M, 2009, NAT CELL BIOL, V11, P1433, DOI 10.1038/ncb1991
   He CC, 2009, ANNU REV GENET, V43, P67, DOI 10.1146/annurev-genet-102808-114910
   Hou LL, 2013, ACTA PHARMACOL SIN, V34, P1403, DOI 10.1038/aps.2013.90
   Huang ZQ, 2015, MOL MED REP, V11, P4678, DOI 10.3892/mmr.2015.3322
   Kang R, 2011, CELL DEATH DIFFER, V18, P571, DOI 10.1038/cdd.2010.191
   Kuma A, 2004, NATURE, V432, P1032, DOI 10.1038/nature03029
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257
   Liu YG, 2016, NEUROCHEM RES, V41, P2728, DOI 10.1007/s11064-016-1989-7
   Luo C, 2017, FRONT CELL NEUROSCI, V11, DOI 10.3389/fncel.2017.00197
   Miracco C, 2007, INT J ONCOL, V30, P429
   Nakatogawa H, 2009, NAT REV MOL CELL BIO, V10, P458, DOI 10.1038/nrm2708
   O'Sullivan-Coyne G, 2009, BRIT J CANCER, V101, P1585, DOI 10.1038/sj.bjc.6605308
   Pattingre S, 2008, BIOCHIMIE, V90, P313, DOI 10.1016/j.biochi.2007.08.014
   Ravikumar B, 2010, PHYSIOL REV, V90, P1383, DOI 10.1152/physrev.00030.2009
   Rubinsztein DC, 2010, EMBO REP, V11, P3, DOI 10.1038/embor.2009.253
   Ryan KM, 2011, EUR J CANCER, V47, P44, DOI 10.1016/j.ejca.2010.10.020
   Shinojima N, 2007, AUTOPHAGY, V3, P635, DOI 10.4161/auto.4916
   Su JN, 2016, AM J CANCER RES, V6, P1949
   Wang J, 2012, MAR DRUGS, V10, P2055, DOI 10.3390/md10092055
   Yang ZF, 2009, CURR TOP MICROBIOL, V335, P1, DOI 10.1007/978-3-642-00302-8_1
   Ye GL, 2014, TUMOR BIOL, V35, P11261, DOI 10.1007/s13277-014-2337-7
   Yu RX, 2011, EUR J PHARMACOL, V657, P10, DOI 10.1016/j.ejphar.2010.12.006
   Yuan Q, 2016, CAN J PHYSIOL PHARM, V94, P929, DOI 10.1139/cjpp-2015-0530
   Zhang JQ, 2011, ONCOL REP, V26, P115, DOI 10.3892/or.2011.1277
   Zhang LL, 2017, EUR J PHARMACOL, V797, P1, DOI 10.1016/j.ejphar.2017.01.008
NR 34
TC 19
Z9 19
U1 4
U2 18
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0730-2312
EI 1097-4644
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD SEP
PY 2018
VL 119
IS 9
BP 7274
EP 7284
DI 10.1002/jcb.27022
PG 11
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA GU3OB
UT WOS:000445187800016
PM 29761894
DA 2022-04-25
ER

PT J
AU Zheng, NN
   Wang, K
   He, JJ
   Qiu, YP
   Xie, GX
   Su, MM
   Jia, W
   Li, HK
AF Zheng, Ningning
   Wang, Ke
   He, Jiaojiao
   Qiu, Yunping
   Xie, Guoxiang
   Su, Mingming
   Jia, Wei
   Li, Houkai
TI Effects of ADMA on gene expression and metabolism in serum-starved LoVo
   cells
SO SCIENTIFIC REPORTS
LA English
DT Article
ID STARVATION-INDUCED APOPTOSIS; ASYMMETRIC DIMETHYLARGININE; AUTOPHAGY;
   PROTEIN; DAMAGE; GROWTH; HOMOCYSTEINE; DEPRIVATION; P62/SQSTM1;
   CARCINOMA
AB Serum starvation is a typical way for inducing tumor cell apoptosis and stress. Asymmetric dimethylarginine (ADMA) is an endogenous metabolite. Our previous study reveals the plasma ADMA level is elevated in colon cancer patients, which can attenuate serum starvation-induced apoptosis in LoVo cells. In current study, we evaluated the effects of ADMA on gene expression and metabolism in serum-starved LoVo cells with gene microarray and metabolomic approaches. Our results indicated that 96 h serum starvation induced comprehensive alterations at transcriptional level, and most of them were restored by ADMA. The main signaling pathways induced by serum starvation included cancers-related pathways, pathways in cell death, apoptosis, and cell cycle etc. Meanwhile, the metabolomic data showed serum-starved cells were clearly separated with control cells, but not with ADMA-treated cells in PCA model. The identified differential metabolites indicated serum starvation significantly suppressed TCA cycle, altered glucose and fatty acids metabolism, as well as nucleic acids metabolism. However, very few differential metabolites were identified between ADMA and serum-starved cells. In summary, our current results indicated serum starvation profoundly altered the gene expression and metabolism of LoVo cells, whereas ADMA could restore most of the changes at transcriptional level, but not at metabolic level.
C1 [Zheng, Ningning; He, Jiaojiao; Jia, Wei; Li, Houkai] Shanghai Univ Tradit Chinese Med, Ctr Chinese Med Therapy & Syst Biol, Shanghai 201203, Peoples R China.
   [Wang, Ke] Shanghai Univ Tradit Chinese Med, Shuguang Hosp, Lab Integrat Med Surg, Shanghai 201203, Peoples R China.
   [Qiu, Yunping] Albert Einstein Coll Med, Ctr Diabet, Stable Isotope & Metabol Core Facil, 1300 Morris Part Ave, Bronx, NY 10461 USA.
   [Xie, Guoxiang; Su, Mingming; Jia, Wei] Univ Hawaii, Ctr Canc, Cancer Epidemiol Program, Honolulu, HI 96813 USA.
   [Jia, Wei] Shanghai Jiao Tong Univ, Affiliated Peoples Hosp 6, Ctr Translat Med, Shanghai 200233, Peoples R China.
   [Jia, Wei] Shanghai Jiao Tong Univ, Affiliated Peoples Hosp 6, Dept Endocrinol & Metab, Shanghai Key Lab Diabet Mellitus, Shanghai 200233, Peoples R China.
RP Li, HK (corresponding author), Shanghai Univ Tradit Chinese Med, Ctr Chinese Med Therapy & Syst Biol, Shanghai 201203, Peoples R China.
EM houkai1976@126.com
RI Qiu, Yunping/AAO-5200-2021; li, houkai/S-6785-2019; Xie,
   Guoxiang/F-3022-2016; Jia, Wei/AAN-5102-2020
OI li, houkai/0000-0003-2846-7895; Xie, Guoxiang/0000-0002-0951-4150; Jia,
   Wei/0000-0002-3739-8994; Qiu, Yunping/0000-0003-1039-5264
FU Shanghai Municipal Education CommissionShanghai Municipal Education
   Commission (SHMEC); Shanghai Pujiang Program from the Science and
   Technology Commission of Shanghai Municipality [14PJD031]; Shanghai
   Creative Research Fund of Higher Education [ZYX-CXYJ-017]; NATIONAL
   CANCER INSTITUTEUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Cancer
   Institute (NCI) [P30CA071789] Funding Source: NIH RePORTER
FX This work was financially supported by The Program for Professor of
   Special Appointment (Eastern Scholar) at Shanghai Institutions of Higher
   Learning from Shanghai Municipal Education Commission, Shanghai Pujiang
   Program (14PJD031) from the Science and Technology Commission of
   Shanghai Municipality, and the Shanghai Creative Research Fund
   (ZYX-CXYJ-017) of Higher Education.
CR Alexandre S, 2000, EXP CELL RES, V255, P30, DOI 10.1006/excr.1999.4759
   Arango D, 2001, CANCER RES, V61, P4910
   Bedford MT, 2009, MOL CELL, V33, P1, DOI 10.1016/j.molcel.2008.12.013
   Bjorkoy G, 2005, J CELL BIOL, V171, P603, DOI 10.1083/jcb.200507002
   Bonuccelli G, 2010, CELL CYCLE, V9, P3506, DOI 10.4161/cc.9.17.12731
   Caricchio R, 1998, J IMMUNOL, V161, P241
   Cheng Y, 2012, J PROTEOME RES, V11, P1354, DOI 10.1021/pr201001a
   Dirican A, 2014, MED ONCOL, V31, DOI 10.1007/s12032-014-0905-8
   Enervald E, 2013, J EXP MED, V210, P2503, DOI 10.1084/jem.20130168
   Esteve JM, 1999, FASEB J, V13, P1055, DOI 10.1096/fasebj.13.9.1055
   Ganguly P, 2015, NUTR J, V14, DOI 10.1186/1475-2891-14-6
   Gary JD, 1998, PROG NUCLEIC ACID RE, V61, P65, DOI 10.1016/S0079-6603(08)60825-9
   Harfouche R, 2002, MICROVASC RES, V64, P135, DOI 10.1006/mvre.2002.2421
   Hsu CP, 2012, ATHEROSCLEROSIS, V225, P504, DOI 10.1016/j.atherosclerosis.2012.09.040
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27
   Kilic M, 2002, CELL DEATH DIFFER, V9, P125, DOI 10.1038/sj.cdd.4400968
   Komatsu M, 2012, PHARMACOL RES, V66, P457, DOI 10.1016/j.phrs.2012.07.004
   Li H, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.345
   Mathews EH, 2014, NUTRITION, V30, P218, DOI 10.1016/j.nut.2013.07.024
   McCully KS, 2009, ANN CLIN LAB SCI, V39, P219
   Moscat J, 2009, CELL, V137, P1001, DOI 10.1016/j.cell.2009.05.023
   Peng XJ, 1998, ENDOCR J, V45, P247, DOI 10.1507/endocrj.45.247
   Pirkmajer S, 2011, AM J PHYSIOL-CELL PH, V301, pC272, DOI 10.1152/ajpcell.00091.2011
   Pirouzpanah S, 2014, NUTR CANCER, V66, P1097, DOI 10.1080/01635581.2014.948213
   Qiu YP, 2009, J PROTEOME RES, V8, P4844, DOI 10.1021/pr9004162
   Romero-Garcia S, 2011, CANCER BIOL THER, V12, P939, DOI 10.4161/cbt.12.11.18140
   Rosenfeldt MT, 2011, CARCINOGENESIS, V32, P955, DOI 10.1093/carcin/bgr031
   Sahani MH, 2014, AUTOPHAGY, V10, P431, DOI 10.4161/auto.27344
   Schamberger CJ, 2005, EXP CELL RES, V302, P115, DOI 10.1016/j.yexcr.2004.08.026
   Serg M, 2011, BLOOD PRESSURE, V20, P111, DOI 10.3109/08037051.2010.533821
   Siegel RM, 2000, NAT IMMUNOL, V1, P469, DOI 10.1038/82712
   SIMM A, 1994, J CELL PHYSIOL, V160, P295, DOI 10.1002/jcp.1041600211
   Smith CL, 2005, PLOS MED, V2, P1031, DOI 10.1371/journal.pmed.0020264
   Stefanis L, 1996, J BIOL CHEM, V271, P30663, DOI 10.1074/jbc.271.48.30663
   Sudo H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058806
   Surget S, 2014, ONCOTARGETS THER, V7, P57, DOI 10.2147/OTT.S53876
   Tamura RE, 2012, CURR MOL MED, V12, P634
   Tan XJ, 2015, CELL, V160, P145, DOI 10.1016/j.cell.2014.12.006
   Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498
   Xie GX, 2015, J PROTEOME RES, V14, P3336, DOI 10.1021/acs.jproteome.5b00388
   Yoshimatsu M, 2011, INT J CANCER, V128, P562, DOI 10.1002/ijc.25366
   Zairis MN, 2012, HEART, V98, P860, DOI 10.1136/heartjnl-2011-301372
   Zhang XY, 2014, J CANCER RES THER, V10, pC108, DOI 10.4103/0973-1482.145811
   Zhang YB, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.77
   Zhou MM, 2012, J PROTEOME RES, V11, P4961, DOI 10.1021/pr3004826
   Zoccali C, 2002, BLOOD PURIFICAT, V20, P469, DOI 10.1159/000063550
NR 47
TC 13
Z9 14
U1 2
U2 14
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD MAY 16
PY 2016
VL 6
AR 25892
DI 10.1038/srep25892
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA DL8OM
UT WOS:000375901300001
PM 27180883
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Janicke, P
   Lennicke, C
   Meister, A
   Seliger, B
   Wessjohann, LA
   Kaluderovic, GN
AF Jaenicke, Paul
   Lennicke, Claudia
   Meister, Annette
   Seliger, Barbara
   Wessjohann, Ludger A.
   Kaluderovic, Goran N.
TI Fluorescent spherical mesoporous silica nanoparticles loaded with
   emodin: Synthesis, cellular uptake and anticancer activity
SO MATERIALS SCIENCE & ENGINEERING C-MATERIALS FOR BIOLOGICAL APPLICATIONS
LA English
DT Article
DE Emodin; Spherical mesoporous silica; Apoptosis; Anticancer drugs; Drug
   targeting; Tumor cells; Autophagy
ID POROUS SILICON; DRUG-DELIVERY; ALOE EMODIN; CONTROLLED-RELEASE; CANCER
   CELLS; GROWTH; PATHWAY; SBA-15; DIFFERENTIATION; APOPTOSIS
AB The natural product emodin (EO) exhibits anti-inflammatory, antiangiogenesis and antineoplastic properties in vitro and in vivo. Due to its biological properties as well as its fluorescence, EO can be useful in pharmacology and pharmacokinetics. To enhance its selectivity to cancer cells, EO was loaded into non-fluorescent and novel fluorescent spherical mesoporous nanoparticles bearing N-methyl isatoic anhydride (SNM similar to M) or lissamine rhodamine B sulfonyl moieties (SNM similar to L). The propylamine functionalized mesoporous silica nanomaterial (SNM) were characterized by powder X-ray diffraction (XRD), nitrogen gas sorption, scanning electron microscopy (SEM), transmission electron microscopy (TEM), fluorescence spectroscopy, thermogravimetric analysis (TGA) and UV spectroscopy. The cytotoxicity of EO-loaded nanoparticles was tested against the human colon carcinoma cell line HT-29. Non-loaded SNM did not affect cell proliferation, whereas those loaded with EO were at least as efficient as EO alone. It could be shown by fluorescence microscopy that the uptake of silica nano material by the tumor cells occurred within 2 h and the release of EO occurred within 48 h of treatment. Flow cytometry and Western blot analysis showed that SNM containing EO induced apoptosis in HT-29 cells.
C1 [Jaenicke, Paul; Wessjohann, Ludger A.; Kaluderovic, Goran N.] Leibniz Inst Plant Biochem, Dept Bioorgan Chem, Weinberg 3, D-06120 Halle, Saale, Germany.
   [Lennicke, Claudia; Seliger, Barbara] Martin Luther Univ Halle Wittenberg, Inst Med Immunol, Magdeburger Str 2, D-06112 Halle, Saale, Germany.
   [Meister, Annette] Martin Luther Univ Halle Wittenberg, Inst Chem Phys & Theoret Chem, D-06099 Halle, Saale, Germany.
   [Kaluderovic, Goran N.] Univ Appl Sci Merseburg, Dept Engn & Nat Sci, Eberhard Leibnitz Str 2, D-06217 Merseburg, Germany.
RP Kaluderovic, GN (corresponding author), Univ Appl Sci Merseburg, Dept Engn & Nat Sci, Eberhard Leibnitz Str 2, D-06217 Merseburg, Germany.
EM goran.kaluderovic@hs-merseburg.de
RI Wessjohann, Ludger/AAZ-3838-2021; Kaluderovic, Goran/AAR-7347-2021
OI Kaluderovic, Goran/0000-0001-5168-1000; Wessjohann, Ludger
   A./0000-0003-2060-8235
CR Ahn HJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086173
   Amann T, 2010, ONCOL REP, V23, P1669, DOI 10.3892/or_00000810
   Anglin EJ, 2008, ADV DRUG DELIVER REV, V60, P1266, DOI 10.1016/j.addr.2008.03.017
   Bulatovic MZ, 2014, ANGEW CHEM INT EDIT, V53, P5982, DOI 10.1002/anie.201400763
   CANHAM LT, 1994, ADV MATER, V6, P865, DOI 10.1002/adma.19940061115
   Cao Y.-Y., 2012, J TRADIT CHIN MED, V9, P81
   Chang CH, 1996, AM J CHINESE MED, V24, P139, DOI 10.1142/S0192415X96000189
   Chen M, 2017, PROSTATE, V77, P489, DOI 10.1002/pros.23287
   Chipuk JE, 2006, CELL DEATH DIFFER, V13, P1396, DOI 10.1038/sj.cdd.4401963
   CORY AH, 1991, CANCER COMMUN, V3, P207, DOI 10.3727/095535491820873191
   Coti KK, 2009, NANOSCALE, V1, P16, DOI 10.1039/b9nr00162j
   CRABTREE EV, 1978, J ORG CHEM, V43, P268, DOI 10.1021/jo00396a019
   Crawford ED, 2011, ANNU REV BIOCHEM, V80, P1055, DOI 10.1146/annurev-biochem-061809-121639
   Crowell JA, 2005, EUR J CANCER, V41, P1889, DOI 10.1016/j.ejca.2005.04.016
   Deng G., 2015, MOL MED REPORTS
   Dong MH, 2014, BIOMED REP, V2, P250, DOI 10.3892/br.2014.226
   Drury LJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012895
   Duronio V, 2008, BIOCHEM J, V415, P333, DOI 10.1042/BJ20081056
   Dutta D, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2055-1
   Edeler D., 2014, THESIS
   Edeler D, 2019, MAT SCI ENG C-MATER, V100, P315, DOI 10.1016/j.msec.2019.03.010
   Feng Y, 2010, BRIT J PHARMACOL, V161, P113, DOI 10.1111/j.1476-5381.2010.00826.x
   FERRARI M, 1990, J IMMUNOL METHODS, V131, P165, DOI 10.1016/0022-1759(90)90187-Z
   Foraker AB, 2003, PHARMACEUT RES, V20, P110, DOI 10.1023/A:1022211127890
   Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8
   Fruman DA, 2014, NAT REV DRUG DISCOV, V13, P140, DOI 10.1038/nrd4204
   Hamanaka RB, 2009, ONCOGENE, V28, P910, DOI 10.1038/onc.2008.428
   Heo SK, 2008, J CELL BIOCHEM, V105, P70, DOI 10.1002/jcb.21805
   HUANG HC, 1992, EUR J PHARMACOL, V211, P359, DOI 10.1016/0014-2999(92)90393-I
   Huang Q, 2007, MED RES REV, V27, P609, DOI 10.1002/med.20094
   Iyer AK, 2006, DRUG DISCOV TODAY, V11, P812, DOI 10.1016/j.drudis.2006.07.005
   Josse C., AM J PHYSL GASTROINT, V306
   KAWAI K, 1984, TOXICOL LETT, V20, P155, DOI 10.1016/0378-4274(84)90141-3
   Klarner T, 2014, BIOSYST BIOROBOT, V7, P479, DOI 10.1007/978-3-319-08072-7_71
   Ko JC, 2010, BIOCHEM PHARMACOL, V79, P655, DOI 10.1016/j.bcp.2009.09.024
   Krajnovic T, 2018, NANOMATERIALS-BASEL, V8, DOI 10.3390/nano8050322
   Kumar R, 2008, ACS NANO, V2, P449, DOI 10.1021/nn700370b
   KUPCHAN SM, 1976, LLOYDIA, V39, P223
   KUROBANE I, 1979, J ANTIBIOT, V32, P1256, DOI 10.7164/antibiotics.32.1256
   Lee CH, 2009, ADV FUNCT MATER, V19, P215, DOI 10.1002/adfm.200800753
   Lee HZ, 2001, BRIT J PHARMACOL, V134, P11, DOI 10.1038/sj.bjp.0704205
   Lien GS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104891
   Lindqvist LM, 2014, P NATL ACAD SCI USA, V111, P8512, DOI 10.1073/pnas.1406425111
   Liong M, 2008, ACS NANO, V2, P889, DOI 10.1021/nn800072t
   Liu A, 2011, ONCOL REP, V26, P81, DOI 10.3892/or.2011.1257
   Luna-Vargas MPA, 2016, FEBS J, V283, P2676, DOI 10.1111/febs.13624
   Ma L, 2014, EXP THER MED, V8, P1225, DOI 10.3892/etm.2014.1900
   Maksimovic-Ivanic D, 2019, J BIOL INORG CHEM, V24, P223, DOI 10.1007/s00775-019-01640-x
   Malinowsky K, 2014, BRIT J CANCER, V110, P2081, DOI 10.1038/bjc.2014.100
   Mellaerts R, 2007, CHEM COMMUN, P1375, DOI 10.1039/b616746b
   Meng HA, 2010, J AM CHEM SOC, V132, P12690, DOI 10.1021/ja104501a
   Mijatovic S, 2005, CELL MOL LIFE SCI, V62, P589, DOI 10.1007/s00018-005-4425-8
   Mishra BB, 2011, EUR J MED CHEM, V46, P4769, DOI 10.1016/j.ejmech.2011.07.057
   Mombeini M, 2018, MEDICINA-LITHUANIA, V54, DOI 10.3390/medicina54010001
   Murai S, 2017, ANTICANCER RES, V37, P436, DOI 10.21873/anticanres.11335
   Nuvoli B, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-69
   Parish C. R., 2001, CURRENT PROTOCOLS IM
   Perez-Quintanilla D, 2009, CHEM-EUR J, V15, P5588, DOI 10.1002/chem.200900151
   Qian Z.J., 2011, EVID BASED COMPLEMEN, V2011
   Ranganathan AC, 2008, CANCER RES, V68, P3260, DOI 10.1158/0008-5472.CAN-07-6215
   Salonen J, 2005, J CONTROL RELEASE, V108, P362, DOI 10.1016/j.jconrel.2005.08.017
   Sandholt IS, 2009, ANTI-CANCER DRUG, V20, P238, DOI 10.1097/CAD.0b013e328326472e
   Saunders IT, 2019, CANCER CELL INT, V19, DOI 10.1186/s12935-019-0820-3
   SLADOWSKI D, 1993, J IMMUNOL METHODS, V157, P203, DOI 10.1016/0022-1759(93)90088-O
   Srinivas G, 2007, MED RES REV, V27, P591, DOI 10.1002/med.20095
   Steven A, 2016, ONCOTARGET, V7, P35454, DOI 10.18632/oncotarget.7721
   Tao JJ, 2011, ADV MATER RES-SWITZ, V236-238, P1873, DOI 10.4028/www.scientific.net/AMR.236-238.1873
   Trewyn BG, 2007, CHEM COMMUN, P3236, DOI 10.1039/b701744h
   Tripathi D.N., 2013, PNAS, P2951
   Van Speybroeck M, 2009, J PHARM SCI-US, V98, P2648, DOI 10.1002/jps.21638
   VANDELOOSDRECHT AA, 1994, J IMMUNOL METHODS, V174, P311, DOI 10.1016/0022-1759(94)90034-5
   Wang HH, 1997, CURR MICROBIOL, V35, P262, DOI 10.1007/s002849900250
   Woo SW, 2002, PHARMACOL TOXICOL, V90, P193, DOI 10.1034/j.1600-0773.2002.900404.x
   Wu YQ, 2019, ONCOL LETT, V17, P3439, DOI 10.3892/ol.2019.9999
   Xiao ZM, 2015, BIOTECHNOL APPL BIOC, V62, P401, DOI 10.1002/bab.1193
   Yuenyongsawad S., 2014, Songklanakarin Journal of Science and Technology, V36, P189
   ZHANG LS, 1995, CANCER RES, V55, P3890
NR 77
TC 4
Z9 4
U1 5
U2 38
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0928-4931
EI 1873-0191
J9 MAT SCI ENG C-MATER
JI Mater. Sci. Eng. C-Mater. Biol. Appl.
PD FEB
PY 2021
VL 119
AR 111619
DI 10.1016/j.msec.2020.111619
PG 10
WC Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Materials Science
GA PI1PP
UT WOS:000600871200006
PM 33321661
DA 2022-04-25
ER

PT J
AU Schmitz, KJ
   Ademi, C
   Bertram, S
   Schmid, KW
   Baba, HA
AF Schmitz, Klaus Juergen
   Ademi, Ceflije
   Bertram, Stefanie
   Schmid, Kurt Werner
   Baba, Hideo Andreas
TI Prognostic relevance of autophagy-related markers LC3, p62/sequestosome
   1, Beclin-1 and ULK1 in colorectal cancer patients with respect to KRAS
   mutational status
SO WORLD JOURNAL OF SURGICAL ONCOLOGY
LA English
DT Article
DE Colorectal cancer; Autophagy; p62; Beclin-1; LC3; ULK1
ID PROTEIN EXPRESSION; POOR-PROGNOSIS; P62; HYDROXYCHLOROQUINE; MTOR;
   PHOSPHORYLATION; TEMOZOLOMIDE; INHIBITION; P62/SQSTM1; KINASE
AB Background: Autophagy is a cellular pathway that regulates transportation of cytoplasmic macromolecules and organelles to lysosomes for degradation. Autophagy is involved in both tumorigenesis and tumour suppression. Here we investigated the potential prognostic value of the autophagy-related proteins Beclin-1, p62, LC3 and uncoordinated (UNC) 51-like kinase 1 (ULK1) in a cohort of colorectal cancer (CRC) specimens.
   Methods: In this study, we analysed the immunoexpression of the autophagy-related proteins p62, LC3, Beclin-1 and ULK1 in 127 CRC patients with known KRAS mutational status and detailed clinical follow-up.
   Results: Survival analysis of p62 staining showed a significant correlation of cytoplasmic (not nuclear) p62 expression with a favourable tumour-specific overall survival (OS). The prognostic power of cytoplasmic p62 was found in the KRAS-mutated subgroup but was lost in the KRAS wildtype subgroup. Survival analysis of Beclin-1 staining did not show an association with OS in the complete cohort. LC3 overexpression demonstrated a slight, though not significant, association with decreased OS. Upon stratifying cases by KRAS mutational status, nuclear (not cytoplasmic) Beclin-1 staining was associated with a significantly decreased OS in the KRAS-mutated subgroup but not in the KRAS wildtype CRCs. In addition, LC3 overexpression was significantly associated with decreased OS in the KRAS-mutated CRC subgroup. ULK1 expression was not correlated to survival.
   Conclusions: Immunohistochemical analyses of LC3, p62 and Beclin-1 may constitute promising novel prognostic markers in CRC, especially in KRAS-mutated CRCs. This strategy might help in identifying high-risk patients who would benefit from autophagy-related anticancer drugs.
C1 [Schmitz, Klaus Juergen] Inst Pathol, Muhlenstr 31, D-45659 Recklinghausen, Germany.
   [Schmitz, Klaus Juergen; Bertram, Stefanie; Schmid, Kurt Werner; Baba, Hideo Andreas] Univ Duisburg Essen, Univ Hosp Essen, Inst Pathol, Hufelandstr 55, D-45147 Essen, Germany.
   [Ademi, Ceflije] Prosper Hosp Recklinghausen, Dept Senol, Muhlenstr 27, D-45659 Recklinghausen, Germany.
RP Schmitz, KJ (corresponding author), Inst Pathol, Muhlenstr 31, D-45659 Recklinghausen, Germany.; Schmitz, KJ (corresponding author), Univ Duisburg Essen, Univ Hosp Essen, Inst Pathol, Hufelandstr 55, D-45147 Essen, Germany.
EM kjschmitz@pathologie-re.de
CR Adams O, 2016, ONCOTARGET, V7, P39241, DOI 10.18632/oncotarget.9649
   Avalos Y, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/603980
   Carew JS, 2007, BLOOD, V110, P313, DOI 10.1182/blood-2006-10-050260
   Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095
   Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001
   Dong LW, 2011, AUTOPHAGY, V7, P1222, DOI 10.4161/auto.7.10.16610
   Duffy A, 2015, CANCER CHEMOTH PHARM, V75, P439, DOI 10.1007/s00280-014-2637-z
   Duran A, 2008, CANCER CELL, V13, P343, DOI 10.1016/j.ccr.2008.02.001
   Egan DF, 2011, AUTOPHAGY, V7, P645, DOI 10.4161/auto.7.6.15123
   Fei BY, 2016, ONCOL LETT, V11, P2271, DOI 10.3892/ol.2016.4183
   Fullgrabe J, 2014, NAT REV MOL CELL BIO, V15, P65, DOI 10.1038/nrm3716
   Gao C, 2010, NAT CELL BIOL, V12, P781, DOI 10.1038/ncb2082
   Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088
   Guo JY, 2011, GENE DEV, V25, P460, DOI 10.1101/gad.2016311
   Han J, 2008, J BIOL CHEM, V283, P19665, DOI 10.1074/jbc.M710169200
   Huang SB, 2011, J BIOL CHEM, V286, P40002, DOI 10.1074/jbc.M111.297432
   Inoue D, 2012, CANCER SCI, V103, P760, DOI 10.1111/j.1349-7006.2012.02216.x
   Inui T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074398
   Jin ZY, 2009, CELL, V137, P721, DOI 10.1016/j.cell.2009.03.015
   Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720
   Kim HS, 2011, PATHOL RES PRACT, V207, P247, DOI 10.1016/j.prp.2011.02.007
   Klionsky DJ, 2008, AUTOPHAGY, V4, P740, DOI 10.4161/auto.6398
   Klionsky DJ, 2012, AUTOPHAGY, V8, P445, DOI 10.4161/auto.19496
   Ko YH, 2013, PANCREAS, V42, P829, DOI 10.1097/MPA.0b013e318279d0dc
   Koukourakis MI, 2010, BRIT J CANCER, V103, P1209, DOI 10.1038/sj.bjc.6605904
   Laddha SV, 2014, MOL CANCER RES, V12, P485, DOI 10.1158/1541-7786.MCR-13-0614
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Linares JF, 2011, MOL CELL BIOL, V31, P105, DOI 10.1128/MCB.00620-10
   Liu JL, 2014, BRIT J CANCER, V111, P944, DOI 10.1038/bjc.2014.355
   Lock R, 2011, MOL BIOL CELL, V22, P165, DOI 10.1091/mbc.E10-06-0500
   Luo Rong-Zhen, 2013, Onco Targets Ther, V6, P883, DOI 10.2147/OTT.S46222
   Mahalingam D, 2014, AUTOPHAGY, V10, P1403, DOI 10.4161/auto.29231
   Masuda G, 2016, ANTICANCER RES, V36, P129
   Mohamed A, 2015, FRONT ONCOL, V5, DOI [10.3389/fonc.2015.00070, 10.1158/1541-7786.MCR-06-0182]
   Moscat J, 2012, TRENDS BIOCHEM SCI, V37, P230, DOI 10.1016/j.tibs.2012.02.008
   Park JM, 2013, CANCER BIOL THER, V14, P100, DOI 10.4161/cbt.22954
   Pattingre S, 2008, BIOCHIMIE, V90, P313, DOI 10.1016/j.biochi.2007.08.014
   Rabinowitz JD, 2010, SCIENCE, V330, P1344, DOI 10.1126/science.1193497
   Rangwala R, 2014, AUTOPHAGY, V10, P1369, DOI 10.4161/auto.29118
   Rosenfeld MR, 2014, AUTOPHAGY, V10, P1359, DOI 10.4161/auto.28984
   Sahni S, 2014, J CLIN PATHOL, V67, P656, DOI 10.1136/jclinpath-2014-202356
   Schlafli AM, 2015, EUR J HISTOCHEM, V59, P137, DOI 10.4081/ejh.2015.2481
   Schmitz KJ, 2007, VIRCHOWS ARCH, V450, P151, DOI 10.1007/s00428-006-0342-y
   Wu SH, 2015, INT J CLIN EXP PATHO, V8, P3882
   Yuan N, 2015, HAEMATOLOGICA, V100, P345, DOI 10.3324/haematol.2014.113324
   Zou YF, 2015, ONCOL LETT, V10, P1583, DOI 10.3892/ol.2015.3417
NR 46
TC 65
Z9 71
U1 1
U2 5
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1477-7819
J9 WORLD J SURG ONCOL
JI World J. Surg. Oncol.
PD JUL 22
PY 2016
VL 14
AR 189
DI 10.1186/s12957-016-0946-x
PG 13
WC Oncology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Surgery
GA DR9SB
UT WOS:000380235300001
PM 27444698
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Yang, XY
   Niu, BX
   Wang, LB
   Chen, ML
   Kang, XC
   Wang, LN
   Ji, YH
   Zhong, JT
AF Yang, Xiaoyu
   Niu, Bingxuan
   Wang, Libo
   Chen, Meiling
   Kang, Xiaochun
   Wang, Luonan
   Ji, Yinghua
   Zhong, Jiateng
TI Autophagy inhibition enhances colorectal cancer apoptosis induced by
   dual phosphatidylinositol 3-kinase/mammalian target of rapamycin
   inhibitor NVP-BEZ235
SO ONCOLOGY LETTERS
LA English
DT Article
DE NVP-BEZ235; autophagy; apoptosis; colorectal cancer;
   phosphatidylinositol 3-kinase/mammalian target of rapamycin
ID PI3K/MTOR INHIBITOR; BREAST-CANCER; CELL-LINES; PATHWAY; GROWTH;
   ANTICANCER; ACTIVATION; MECHANISM; THERAPY; STRESS
AB Phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) signaling pathway performs a central role in tumorigenesis and is constitutively activated in many malignancies. As a novel dual PI3K/mTOR inhibitor currently undergoing evaluation in a phase I/II clinical trial, NVP-BEZ235 indicates a significant antitumor efficacy in diverse solid tumors, including colorectal cancer (CRC). Autophagy is a catabolic process that maintains cellular homeostasis and reduces diverse stresses through lysosomal recycling of the unnecessary and damaged cell components. This process is also observed to antagonize the antitumor efficacy of PI3K/mTOR inhibitor agents such as NVP-BEZ235, via apoptosis inhibition. In the present study, we investigated anti-proliferative and apoptosis-inducing ability of NVP-BEZ235 in SW480 cells and the crosstalk between autophagy and apoptosis in SW480 cells treated with NVP-BEZ235 in combination with an autophagy inhibitor. The results revealed that, NVP-BEZ235 effectively inhibit the growth of SW480 cells by targeting the PI3K/mTOR signaling pathway and induced apoptosis. The inhibition of autophagy with 3-methyladenine or chloroquine inhibitors in combination with NVP-BEZ235 in SW480 cells enhanced the apoptotic rate as componets to NVP-BEZ235 alone. In conclusion, the findings provide a rationale for chemotherapy targeting the PI3K/mTOR signaling pathway presenting a potential therapeutic strategy to enhance the efficacy of dual PI3K/mTOR inhibitor NVP-BEZ235 in combination with an autophagy inhibitor in CRC treatment and treatment of other tumors.
C1 [Yang, Xiaoyu; Zhong, Jiateng] Xinxiang Med Univ, Dept Pathol, 96 Xinfei St, Xinxiang 453003, Henan, Peoples R China.
   [Niu, Bingxuan] Xinxiang Med Univ, Coll Pharm, Xinxiang 453003, Henan, Peoples R China.
   [Wang, Libo] Jilin Univ, Affiliated Hosp 1, Dept Gastroenterol, Changchun 130021, Jilin, Peoples R China.
   [Chen, Meiling; Kang, Xiaochun; Wang, Luonan; Ji, Yinghua] Xinxiang Med Univ, Affiliated Hosp 1, Dept Oncol, Xinxiang 453100, Henan, Peoples R China.
RP Zhong, JT (corresponding author), Xinxiang Med Univ, Dept Pathol, 96 Xinfei St, Xinxiang 453003, Henan, Peoples R China.
EM si148w@163.com
CR Atkin WS, 2010, LANCET, V375, P1624, DOI 10.1016/S0140-6736(10)60551-X
   Brachmann SM, 2009, P NATL ACAD SCI USA, V106, P22299, DOI 10.1073/pnas.0905152106
   Carpten JD, 2007, NATURE, V448, P439, DOI 10.1038/nature05933
   Carracedo A, 2008, J CLIN INVEST, V118, P3065, DOI [10.1172/jCI34739, 10.1172/JCI34739]
   Cerniglia GJ, 2012, MOL PHARMACOL, V82, P1230, DOI 10.1124/mol.112.080408
   Chen HY, 2011, CANCER PREV RES, V4, P973, DOI 10.1158/1940-6207.CAPR-10-0387
   Denton D, 2012, CELL DEATH DIFFER, V19, P87, DOI 10.1038/cdd.2011.146
   Eisenberg-Lerner A, 2009, CELL DEATH DIFFER, V16, P966, DOI 10.1038/cdd.2009.33
   Engelman JA, 2006, NAT REV GENET, V7, P606, DOI 10.1038/nrg1879
   Fan QW, 2006, CANCER CELL, V9, P341, DOI 10.1016/j.ccr.2006.03.029
   Filomeni G, 2015, CELL DEATH DIFFER, V22, P377, DOI 10.1038/cdd.2014.150
   Fujiwara K, 2007, INT J ONCOL, V31, P753
   Generali D, 2008, CLIN CANCER RES, V14, P2673, DOI 10.1158/1078-0432.CCR-07-1046
   Ghadimi MP, 2012, MOL CANCER THER, V11, P1758, DOI 10.1158/1535-7163.MCT-12-0015
   Herrera VA, 2011, ANTICANCER RES, V31, P849
   Janku F, 2011, NAT REV CLIN ONCOL, V8, P528, DOI 10.1038/nrclinonc.2011.71
   Kurtz JE, 2012, ANTICANCER RES, V32, P2463
   Lao VV, 2011, NAT REV GASTRO HEPAT, V8, P686, DOI 10.1038/nrgastro.2011.173
   Li MX, 2014, INT J CANCER, V134, P2403, DOI 10.1002/ijc.28536
   Li QG, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-277
   Liu TJ, 2009, MOL CANCER THER, V8, P2204, DOI 10.1158/1535-7163.MCT-09-0160
   Maira SM, 2008, MOL CANCER THER, V7, P1851, DOI 10.1158/1535-7163.MCT-08-0017
   Markman B, 2010, ONCOTARGET, V1, P530, DOI 10.18632/oncotarget.188
   Masuda M, 2011, ONCOL REP, V26, P1273, DOI 10.3892/or.2011.1370
   Mathur A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098515
   McMillin DW, 2009, CANCER RES, V69, P5835, DOI 10.1158/0008-5472.CAN-08-4285
   Mirzoeva OK, 2011, J MOL MED, V89, P877, DOI 10.1007/s00109-011-0774-y
   Murrow L, 2013, ANNU REV PATHOL-MECH, V8, P105, DOI 10.1146/annurev-pathol-020712-163918
   Ogino S, 2008, J MOL DIAGN, V10, P13, DOI 10.2353/jmoldx.2008.070082
   Potter DS, 2014, NEOPLASIA, V16, P147, DOI 10.1593/neo.131376
   Prevo R, 2008, CANCER RES, V68, P5915, DOI 10.1158/0008-5472.CAN-08-0757
   Rubinsztein DC, 2012, NAT REV DRUG DISCOV, V11, P709, DOI 10.1038/nrd3802
   Samuels Y, 2005, CANCER CELL, V7, P561, DOI 10.1016/j.ccr.2005.05.014
   Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502
   Scarlatti F, 2009, CELL DEATH DIFFER, V16, P12, DOI 10.1038/cdd.2008.101
   Wan X, 2007, ONCOGENE, V26, P1932, DOI 10.1038/sj.onc.1209990
   Xu CX, 2011, CANCER BIOL THER, V12, P549, DOI 10.4161/cbt.12.6.16397
   Yang F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059879
   Yang SJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026343
   Yang Y, 2010, BIOCHEM BIOPH RES CO, V395, P190, DOI 10.1016/j.bbrc.2010.03.155
   Zimonin F S, 1973, Veterinariia, V8, P69
   Zoncu R, 2011, NAT REV MOL CELL BIO, V12, P21, DOI 10.1038/nrm3025
NR 42
TC 19
Z9 21
U1 0
U2 5
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792-1074
EI 1792-1082
J9 ONCOL LETT
JI Oncol. Lett.
PD JUL
PY 2016
VL 12
IS 1
BP 102
EP 106
DI 10.3892/ol.2016.4590
PG 5
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA DR5RN
UT WOS:000379960200018
PM 27347108
OA Green Published, gold, Green Submitted
DA 2022-04-25
ER

PT J
AU He, C
   Fu, Y
   Chen, Y
   Li, XQ
AF He, Chi
   Fu, Yi
   Chen, Yan
   Li, Xiquan
TI Long non-coding RNA SNHG8 promotes autophagy as a ceRNA to upregulate
   ATG7 by sponging microRNA-588 in colorectal cancer
SO ONCOLOGY LETTERS
LA English
DT Article
DE SNHG8; autophagy; CRC; ATG7; microRNA-588
ID CELL-PROLIFERATION; LUNG-CANCER; MIGRATION; INVASION; PROGRESSION;
   METASTASIS; STATISTICS; APOPTOSIS
AB Colorectal cancer (CRC) is the third most common cancer worldwide. Long non-coding RNA (lncRNA) small nucleolar RNA host gene 8 (SNHG8) acts as an oncogene in different types of cancer, including prostate, breast and ovarian cancer. SNHG8 promotes the tumorigenesis of CRC; however, its underlying molecular mechanism remains unclear. The present study aimed to explore the mechanism of SNHG8 on CRC development via various assays, including western blot, pull-down, PCR and immunofluorescence assays. The results of the present study demonstrated that SNHG8 expression was substantially upregulated in primary tumor tissues from The Cancer Genome Atlas dataset. Western blot and immunofluorescence analyses demonstrated that SNHG8 facilitated cell proliferation and autophagy in CRC cells. Notably, the function of SNHG8 in enhancing autophagy was dependent on autophagy-related gene 7 (ATG7). In addition, western blot analysis indicated that the effect of SNHG8 on autophagy in CRC cells was dependent on the miR-588/ATG7 axis. Taken together, the results of the present study suggest that SNHG8 promotes autophagy in CRC cells.
C1 [He, Chi; Li, Xiquan] Shenyang Anorectal Hosp, Dept Gen Surg, 9 Nanjingbei St, Shenyang 110054, Liaoning, Peoples R China.
   [Fu, Yi] Dalian Med Univ, Dept Gen Surg, Hosp 2, Dalian 116000, Liaoning, Peoples R China.
   [Chen, Yan] Daqing Oilfield Gen Hosp, Dept Gen Surg, Daqing 163000, Heilongjiang, Peoples R China.
RP Li, XQ (corresponding author), Shenyang Anorectal Hosp, Dept Gen Surg, 9 Nanjingbei St, Shenyang 110054, Liaoning, Peoples R China.
EM shenyang_xiquan@126.com
CR Amaravadi R, 2016, GENE DEV, V30, P1913, DOI 10.1101/gad.287524.116
   Cao QH, 2016, AM J TRANSL RES, V8, P3831
   Dikic I, 2018, NAT REV MOL CELL BIO, V19, P349, DOI 10.1038/s41580-018-0003-4
   Fan D, 2020, EUR REV MED PHARMACO, V24, P11639, DOI 10.26355/eurrev_202011_23808
   Guo CT, 2020, ONCOL LETT, V20, DOI 10.3892/ol.2020.12139
   Jin KT, 2021, BIOMED PHARMACOTHER, V134, DOI 10.1016/j.biopha.2020.110932
   Kang Y, 2019, ONCOTARGETS THER, V12, P10787, DOI 10.2147/OTT.S226044
   Kohlhapp FJ, 2015, ONCOGENE, V34, P5857, DOI 10.1038/onc.2015.89
   Kroemer G, 2015, J CLIN INVEST, V125, P1, DOI 10.1172/JCI78652
   Li CF, 2018, CELL PHYSIOL BIOCHEM, V50, P196, DOI 10.1159/000493968
   Li C, 2015, AM J TRANSL RES, V7, P1747
   Li HR, 2004, CANCER RES, V64, P4760, DOI 10.1158/0008-5472.CAN-04-0975
   Li XM, 2020, ONCOL LETT, V20, DOI 10.3892/ol.2020.12219
   Li XY, 2019, BIOMED PHARMACOTHER, V119, DOI 10.1016/j.biopha.2019.109415
   Lin LQ, 2021, J CELL MOL MED, V25, P61, DOI 10.1111/jcmm.15759
   Liu AH, 2019, AM J TRANSL RES, V11, P5240
   Liu JY, 2019, BIOMED PHARMACOTHER, V114, DOI 10.1016/j.biopha.2019.108847
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Luo M, 2013, CANCER LETT, V333, P213, DOI 10.1016/j.canlet.2013.01.033
   Ma HB, 2018, J CELL BIOCHEM, V119, P8325, DOI 10.1002/jcb.26883
   Masters JR, 2001, P NATL ACAD SCI USA, V98, P8012, DOI 10.1073/pnas.121616198
   Miao Wei, 2020, Cancer Biomark, V28, P459, DOI 10.3233/CBM-190640
   Mukhopadhyay S, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2021475118
   Qian L, 2016, MOL MED REP, V14, P3021, DOI 10.3892/mmr.2016.5643
   Qu XH, 2020, J CELL BIOCHEM, V121, P4120, DOI 10.1002/jcb.29646
   Shi ZF, 2021, J GENE MED, V23, DOI 10.1002/jgm.3309
   Shukla Girish C, 2011, Mol Cell Pharmacol, V3, P83
   Si YR, 2019, CELL MOL BIOL LETT, V24, DOI 10.1186/s11658-019-0175-8
   Siegel RL, 2017, CA-CANCER J CLIN, V67, P177, DOI 10.3322/caac.21395
   Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387
   Tang B, 2019, GENE, V686, P56, DOI 10.1016/j.gene.2018.10.059
   Xu JL, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.621428
   Yan XH, 2015, CANCER CELL, V28, P529, DOI 10.1016/j.ccell.2015.09.006
   Yang L, 2019, GENE, V697, P94, DOI 10.1016/j.gene.2019.02.036
   Ying SY, 2008, MOL BIOTECHNOL, V38, P257, DOI 10.1007/s12033-007-9013-8
   Yu M, 2017, MED SCI MONITOR, V23, P5690, DOI 10.12659/MSM.905126
   Yu XZ, 2020, ONCOTARGETS THER, V13, P11645, DOI 10.2147/OTT.S271955
   Yun CW, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22010179
   Zhang PG, 2020, HUM CELL, V33, P123, DOI 10.1007/s13577-019-00290-0
NR 39
TC 2
Z9 2
U1 2
U2 7
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792-1074
EI 1792-1082
J9 ONCOL LETT
JI Oncol. Lett.
PD AUG
PY 2021
VL 22
IS 2
AR 577
DI 10.3892/ol.2021.12838
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA SP6VU
UT WOS:000659805500001
PM 34122628
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Noble, CL
   Abbas, AR
   Lees, CW
   Cornelius, J
   Toy, K
   Modrusan, Z
   Clark, HF
   Arnott, ID
   Penman, ID
   Satsangi, J
   Diehl, L
AF Noble, Colin L.
   Abbas, Alexander R.
   Lees, Charles W.
   Cornelius, Jennine
   Toy, Karen
   Modrusan, Zora
   Clark, Hilary F.
   Arnott, Ian D.
   Penman, Ian D.
   Satsangi, Jack
   Diehl, Lauri
TI Characterization of Intestinal Gene Expression Profiles in Crohn's
   Disease by Genome-wide Microarray Analysis
SO INFLAMMATORY BOWEL DISEASES
LA English
DT Article
DE genome-wide microarray analysis; Crohn's disease; gene expression; Th17
   signalling; autophagy
ID INFLAMMATORY-BOWEL-DISEASE; COLONIC EPITHELIAL-CELLS;
   ULCERATIVE-COLITIS; SUSCEPTIBILITY; ASSOCIATION; CHEMOKINES; CANCERS;
   FAT10; HOMEOSTASIS; CYTOKINES
AB Background: Genome-wide microarray expression analysis creates a comprehensive picture of gene expression at the cellular level. The aim of this study was to investigate differential intestinal gene expression in patients with Crohn's disease (CD) and controls with subanalysis of confirmed CD susceptibility genes, associated pathways, and cell lineage.
   Methods: In all, 172 biopsies from 53 CD and 31 control subjects were studied. Paired endoscopic biopsies were taken at ileo-colonoscopy from five specific anatomical locations including the terminal ileum (TI) for RNA extraction and histology. The 41,058 expression sequence tags were analyzed using the Agilent platform.
   Results: Analysis of all CD biopsies versus controls showed 259 sequences were upregulated and 87 sequences were downregulated. Upregulated genes in CD included SAA1 (fold change [FC] +7.5, P = 1.47 x 10(-41)) and REGL (FC +7.3, P = 2.3 x 10(-16)), whereas cellular detoxification genes including-SLC14A2 (FC-2.49, P = 0.00002) were downregulated. In the CD TI biopsies diubiquitin (FC+11.3, P < 1 x 10(-45)), MMP3 (FC+7.4, P = 1.3 x 10(-11)), and IRTA1 (FC-11.4, P = 4.7 x 10(-12)) were differentially expressed compared to controls. In the colon SAA1 (FC+6.3, P = 5.3 x 10(-8)) was upregulated and thymic stromal lymphopoietin (TSLP) (FC-2.3, P = 2.7 x 10(-6)) was downregulated comparing noninflamed CD and control biopsies, and the colonic inflammatory CD signature was characterized by downregulation of the organic solute carriers-SLC38A4, SLC26A2, and OST alpha. Of CD susceptibility genes identified by genome-wide association scan IL-23A, JAK2, and STAT3 were upregulated in the CD group, confirming the dysregulation of Th17 signaling.
   Conclusions: These data characterize the dysregulation of a series of specific inflammatory pathways highlighting potential pathogenic mechanisms as well as areas for translation to therapeutic targets.
C1 [Noble, Colin L.] Univ Edinburgh, Western Gen Hosp, Gastrointestinal Unit, Mol Med Ctr,MRCP, Edinburgh EH4 2XU, Midlothian, Scotland.
   [Noble, Colin L.; Cornelius, Jennine; Diehl, Lauri] Genentech Inc, Dept Pathol, San Francisco, CA 94080 USA.
   [Abbas, Alexander R.; Clark, Hilary F.] Genentech Inc, Dept Bioinformat, San Francisco, CA 94080 USA.
   [Toy, Karen; Modrusan, Zora] Genentech Inc, Microarray Dept, San Francisco, CA 94080 USA.
RP Noble, CL (corresponding author), Univ Edinburgh, Western Gen Hosp, Gastrointestinal Unit, Mol Med Ctr,MRCP, Edinburgh EH4 2XU, Midlothian, Scotland.
EM noblecolin@hotmail.com
OI Lees, Charlie/0000-0002-0732-8215
FU Medical Research CouncilUK Research & Innovation (UKRI)Medical Research
   Council UK (MRC)European Commission [G0800675, G0600329, G0800759]
   Funding Source: Medline; Chief Scientist Office [CZB/4/540] Funding
   Source: Medline; MRCUK Research & Innovation (UKRI)Medical Research
   Council UK (MRC) [G0600329, G0800759, G0800675] Funding Source: UKRI
CR Al-Shami A, 2005, J EXP MED, V202, P829, DOI 10.1084/jem.20050199
   Aldhous MC, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006285
   Banks C, 2003, J PATHOL, V199, P28, DOI 10.1002/path.1245
   Barrett JC, 2008, NAT GENET, V40, P955, DOI 10.1038/ng.175
   Burton PR, 2007, NATURE, V447, P661, DOI 10.1038/nature05911
   Cho JH, 2007, GASTROENTEROLOGY, V133, P1327, DOI 10.1053/j.gastro.2007.08.032
   Costello CM, 2005, PLOS MED, V2, P771, DOI 10.1371/journal.pmed.0020199
   Duerr RH, 2006, SCIENCE, V314, P1461, DOI 10.1126/science.1135245
   Dwinell MB, 2001, GASTROENTEROLOGY, V120, P49, DOI 10.1053/gast.2001.20914
   Fan WF, 1996, IMMUNOGENETICS, V44, P97, DOI 10.1007/BF02660056
   Gaya DR, 2006, LANCET, V367, P1271, DOI 10.1016/S0140-6736(06)68345-1
   Gutfeld O, 2006, J HISTOCHEM CYTOCHEM, V54, P63, DOI 10.1369/jhc.5A6645.2005
   Hugot JP, 2001, NATURE, V411, P599, DOI 10.1038/35079107
   Kwon JH, 2002, GUT, V51, P818, DOI 10.1136/gut.51.6.818
   Lawrance IC, 2001, HUM MOL GENET, V10, P445, DOI 10.1093/hmg/10.5.445
   Lee CGL, 2003, ONCOGENE, V22, P2592, DOI 10.1038/sj.onc.1206337
   Lee JW, 2008, J IMMUNOL, V181, P6536, DOI 10.4049/jimmunol.181.9.6536
   LEES CW, 2009, INFLAMM BOWEL DIS MO, V9
   LENNARDJONES JE, 1989, SCAND J GASTROENTERO, V24, P2, DOI 10.3109/00365528909091339
   Lukasiak S, 2008, ONCOGENE, V27, P6068, DOI 10.1038/onc.2008.201
   Madsen L, 2007, BMC BIOCHEM, V8, DOI 10.1186/1471-2091-8-S1-S1
   Maloy KJ, 2008, MUCOSAL IMMUNOL, V1, P339, DOI 10.1038/mi.2008.28
   Noble CL, 2008, GUT, V57, P1398, DOI 10.1136/gut.2008.148395
   Ogura Y, 2001, NATURE, V411, P603, DOI 10.1038/35079114
   Puleston J, 2005, ALIMENT PHARM THER, V21, P109, DOI 10.1111/j.1365-2036.2004.02262.x
   Ren JW, 2006, J BIOL CHEM, V281, P11413, DOI 10.1074/jbc.M507218200
   Sandborn WJ, 2008, GASTROENTEROLOGY, V135, P1130, DOI 10.1053/j.gastro.2008.07.014
   Sanjuan MA, 2007, NATURE, V450, P1253, DOI 10.1038/nature06421
   Simms LA, 2008, GUT, V57, P903, DOI 10.1136/gut.2007.142588
   Storey JD, 2003, P NATL ACAD SCI USA, V100, P9440, DOI 10.1073/pnas.1530509100
   Strober W, 2007, J CLIN INVEST, V117, P514, DOI 10.1172/JCI30587
   Travassos LH, 2010, NAT IMMUNOL, V11, P55, DOI 10.1038/ni.1823
   Wehkamp J, 2005, P NATL ACAD SCI USA, V102, P18129, DOI 10.1073/pnas.0505256102
   Yang SK, 1997, GASTROENTEROLOGY, V113, P1214, DOI 10.1053/gast.1997.v113.pm9322516
   Zaph C, 2007, NATURE, V446, P552, DOI 10.1038/nature05590
   Zhang DW, 2006, ONCOGENE, V25, P2318, DOI 10.1038/sj.onc.1209220
NR 36
TC 60
Z9 60
U1 0
U2 2
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1078-0998
EI 1536-4844
J9 INFLAMM BOWEL DIS
JI Inflamm. Bowel Dis.
PD OCT
PY 2010
VL 16
IS 10
BP 1717
EP 1728
DI 10.1002/ibd.21263
PG 12
WC Gastroenterology & Hepatology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Gastroenterology & Hepatology
GA 660EV
UT WOS:000282623700016
PM 20848455
DA 2022-04-25
ER

PT J
AU Yan, SY
   Yuan, DD
   Li, QQ
   Li, S
   Zhang, F
AF Yan, Siyuan
   Yuan, Dongdong
   Li, Qianqian
   Li, Shi
   Zhang, Fan
TI AICAR enhances the cytotoxicity of PFKFB3 inhibitor in an AMPK
   signaling-independent manner in colorectal cancer cells
SO MEDICAL ONCOLOGY
LA English
DT Article
DE PFKFB3; Cell viability; AICAR; AMPK signaling; Colorectal cancer
ID UBIQUITIN-PROTEASOME SYSTEM; AUTOPHAGIC DEGRADATION; PROTEIN-KINASE;
   PHOSPHORYLATION; AKT; COORDINATE; PATHWAY; DEATH; ULK1
AB Numerous studies have shown that 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase isoform 3 (PFKFB3), a pivotal enzyme in modulating glycolysis, plays vital roles in various physiological processes. PFKFB3 activity could be regulated by several factors, such as hypoxia and AMPK signaling; however, it could also function as upstream of AMPK signaling. Here, we showed that PFKFB3 inhibitor PFK-15 induced cell viability loss and apoptosis. Deprivation of PFKFB3 inhibited autophagy, while enhanced the ubiquitin-proteasome degradation pathway. Furthermore, PFK-15 reduced both the AMPK and AKT-mTORC1 signaling pathways, as the attenuated phosphorylation level of kinases themselves and their substrates. The addition of AICAR rescued the AMPK activity and autophagy, but enhanced PFK-15-induced cell viability loss. In fact, AICAR promoted the cytotoxicity of PFK-15 even in the AMPK alpha 1/2-silenced cells, indicating AICAR might function in an AMPK-independent manner. Nevertheless, AICAR further reduced the AKT-mTORC1 activity down-regulated by PFK-15. Moreover, it failed to enhance PFK-15's cytotoxicity in the AKT1/2-silenced cells, indicating AKT-mTORC1 participated during these processes. Collectively, the presented data demonstrated that PFK-15 inhibited cell viability, AMPK, and AKT-mTORC1 signaling, and AICAR probably enhanced the cell viability loss aroused by PFK-15 in an AKT-dependent and AMPK-independent manner, thereby revealing a more intimate relationship among PFKFB3, AMPK, and AKT-mTORC1 signaling pathways.
C1 [Yan, Siyuan; Li, Qianqian; Li, Shi] Jining Med Univ, Key Lab Precis Oncol Univ Shandong, Inst Precis Med, Jining 272067, Peoples R China.
   [Yuan, Dongdong] Shandong Acad Pharmaceut Sci, Jinan 250101, Peoples R China.
   [Zhang, Fan] Zhengzhou Univ, Dept Bone & Soft Tissue Oncol, Affiliated Canc Hosp, Zhengzhou 450008, Peoples R China.
RP Yan, SY (corresponding author), Jining Med Univ, Key Lab Precis Oncol Univ Shandong, Inst Precis Med, Jining 272067, Peoples R China.; Zhang, F (corresponding author), Zhengzhou Univ, Dept Bone & Soft Tissue Oncol, Affiliated Canc Hosp, Zhengzhou 450008, Peoples R China.
EM yansy@mail.jnmc.edu.cn; zhangfan_1109@163.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [31801169]; Miaopu Funds from Henan Cancer
   Hospital; Jining Medical University; Teacher Research Support Foundation
   in Jining Medical University [JYFC2018KJ065]
FX This work was supported by Grants from the National Natural Science
   Foundation of China (31801169), the Miaopu Funds from Henan Cancer
   Hospital (to Fan Zhang), the Faculty Start-up Funds from Jining Medical
   University (to Yan S.), and the Teacher Research Support Foundation in
   Jining Medical University (JYFC2018KJ065).
CR Chen XG, 2010, MOL CARCINOGEN, V49, P603, DOI 10.1002/mc.20628
   Cohen-Kaplan V, 2016, P NATL ACAD SCI USA, V113, pE7490, DOI 10.1073/pnas.1615455113
   Dikic I, 2017, ANNU REV BIOCHEM, V86, P193, DOI 10.1146/annurev-biochem-061516-044908
   Egan DF, 2011, SCIENCE, V331, P456, DOI 10.1126/science.1196371
   Feng ZH, 2005, P NATL ACAD SCI USA, V102, P8204, DOI 10.1073/pnas.0502857102
   Ge PF, 2009, ACTA PHARMACOL SIN, V30, P1046, DOI 10.1038/aps.2009.71
   Gwinn DM, 2008, MOL CELL, V30, P214, DOI 10.1016/j.molcel.2008.03.003
   Hardie DG, 2011, EMBO J, V30, P634, DOI 10.1038/emboj.2011.12
   Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2
   Ji CH, 2017, MOL CELLS, V40, P441, DOI 10.14348/molcells.2017.0115
   Jose C, 2011, BBA-BIOENERGETICS, V1807, P707, DOI 10.1016/j.bbabio.2010.12.002
   Juenemann K, 2013, J BIOL CHEM, V288, P27068, DOI 10.1074/jbc.M113.486076
   Kim J, 2011, NAT CELL BIOL, V13, P132, DOI 10.1038/ncb2152
   Klarer AC, 2014, CANCER METAB, V2, DOI 10.1186/2049-3002-2-2
   Klionsky DJ, 2016, AUTOPHAGY, V12, P1, DOI 10.1080/15548627.2015.1100356
   Kocaturk NM, 2018, FRONT CELL DEV BIOL, V6, DOI 10.3389/fcell.2018.00128
   Leclerc Gilles M, 2010, J Mol Signal, V5, P15, DOI 10.1186/1750-2187-5-15
   Lee KC, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18112363
   Levy JMM, 2017, NAT REV CANCER, V17, P528, DOI 10.1038/nrc.2017.53
   Li FL, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-02950-5
   Li J, 2010, EUR J CANCER, V46, P1900, DOI 10.1016/j.ejca.2010.02.021
   Liu TY, 2016, DIABETES, V65, P3262, DOI 10.2337/db16-0356
   Lu Q, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.344
   Marshall RS, 2015, MOL CELL, V58, P1053, DOI 10.1016/j.molcel.2015.04.023
   Mathew R, 2007, GENE DEV, V21, P1367, DOI 10.1101/gad.1545107
   Mondal S, 2019, INT J CANCER, V144, P178, DOI 10.1002/ijc.31868
   Okamura N, 1998, BIOSCI BIOTECH BIOCH, V62, P2039, DOI 10.1271/bbb.62.2039
   Park HS, 2011, BIOCHEM PHARMACOL, V82, P1110, DOI 10.1016/j.bcp.2011.07.085
   Pohl C, 2019, SCIENCE, V366, P818, DOI 10.1126/science.aax3769
   Ros S, 2013, CANCER METAB, V1, DOI 10.1186/2049-3002-1-8
   Shang LB, 2011, AUTOPHAGY, V7, P924, DOI 10.4161/auto.7.8.15860
   Shi WK, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0435-y
   Simon-Molas H, 2016, FEBS LETT, V590, P2915, DOI 10.1002/1873-3468.12338
   Suraweera A, 2012, MOL CELL, V48, P242, DOI 10.1016/j.molcel.2012.08.003
   Vucicevic L, 2011, AUTOPHAGY, V7, P40, DOI 10.4161/auto.7.1.13883
   Wang CH, 2018, INT J MOL MED, V42, P359, DOI 10.3892/ijmm.2018.3599
   Wang XR, 2008, CANCER RES, V68, P7409, DOI 10.1158/0008-5472.CAN-08-1522
   Xiao YN, 2021, ONCOGENE, V40, P1409, DOI 10.1038/s41388-020-01621-4
   Yan SY, 2021, AM J CANCER RES, V11, P2062
   Yan SY, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20215415
   Yan SY, 2017, ONCOTARGET, V8, P80909, DOI 10.18632/oncotarget.20757
   Yang Z, 2013, J EXP MED, V210, P2119, DOI 10.1084/jem.20130252
   Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100
   Zhu W, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0163768
NR 44
TC 0
Z9 0
U1 7
U2 7
PU HUMANA PRESS INC
PI TOTOWA
PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA
SN 1357-0560
EI 1559-131X
J9 MED ONCOL
JI Med. Oncol.
PD JAN
PY 2022
VL 39
IS 1
AR 10
DI 10.1007/s12032-021-01601-y
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA WV0QY
UT WOS:000716943200004
PM 34761330
DA 2022-04-25
ER

PT J
AU Lee, YC
   Lee, CH
   Tsai, HP
   An, HW
   Lee, CM
   Wu, JC
   Chen, CS
   Huang, SH
   Hwang, J
   Cheng, KT
   Leiw, PL
   Chen, CL
   Lin, CM
AF Lee, Yu-Chieh
   Lee, Chii-Hong
   Tsai, Hsiang-Ping
   An, Herng-Wei
   Lee, Chi-Ming
   Wu, Jen-Chine
   Chen, Chien-Shu
   Huang, Shih-Hao
   Hwang, Jaulang
   Cheng, Kur-Ta
   Leiw, Phui-Ly
   Chen, Chi-Long
   Lin, Chun-Mao
TI Targeting of Topoisomerase I for Prognoses and Therapeutics of
   Camptothecin-Resistant Ovarian Cancer
SO PLOS ONE
LA English
DT Article
ID CYCLIN D1; COLORECTAL-CANCER; CARCINOMA-CELLS; EVODIAMINE; APOPTOSIS;
   INHIBITION; TUMORS; EXPRESSION; AUTOPHAGY; VITRO
AB DNA topoisomerase I (TOP1) levels of several human neoplasms are higher than those of normal tissues. TOP1 inhibitors are widely used in treating conventional therapy-resistant ovarian cancers. However, patients may develop resistance to TOP1 inhibitors, hampering chemotherapy success. In this study, we examined the mechanisms associated with the development of camptothecin (CPT) resistance in ovarian cancers and identified evodiamine (EVO), a natural product with TOP1 inhibiting activity that overcomes the resistance. The correlations among TOP1 levels, cancer staging, and overall survival (OS) were analyzed. The effect of EVO on CPT-resistant ovarian cancer was evaluated in vitro and in vivo. TOP1 was associated with poor prognosis in ovarian cancers (p = 0.024). EVO induced apoptosis that was detected using flow cytometry and terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay. The tumor size decreased significantly in the EVO treatment group compared with the control group (p < 0.01) in a xenograft mouse model. Effects of drugs targeting TOP1 for prognosis and therapy in CPT-resistant ovarian cancer are anticipated. EVO with TOP1 can be developed as an antiproliferative agent for overcoming CPT resistance in ovarian cancers.
C1 [Lee, Yu-Chieh; An, Herng-Wei; Lee, Chi-Ming] Taipei Med Univ, Grad Inst Med Sci, Coll Med, Taipei, Taiwan.
   [Lee, Chii-Hong; Leiw, Phui-Ly] Taipei Med Univ, Shuang Ho Hosp, Dept Pathol, New Taipei City, Taiwan.
   [Tsai, Hsiang-Ping; Hwang, Jaulang; Cheng, Kur-Ta; Lin, Chun-Mao] Taipei Med Univ, Sch Med, Dept Biochem, Taipei, Taiwan.
   [Wu, Jen-Chine] Chang Gung Mem Hosp, Ctr Stem Cells & Translat Canc Res, Gueishan, Taoyuan County, Taiwan.
   [Chen, Chien-Shu] China Med Univ, Sch Pharm, Taichung, Taiwan.
   [Huang, Shih-Hao] Taipei Coll Maritime Technol, Dept Food & Beverage Management, Taipei, Taiwan.
   [Chen, Chi-Long] Taipei Med Univ, Dept Pathol, Coll Med, Taipei, Taiwan.
   [Chen, Chi-Long] Taipei Med Univ Hosp, Dept Pathol, Taipei, Taiwan.
RP Lin, CM (corresponding author), Taipei Med Univ, Sch Med, Dept Biochem, Taipei, Taiwan.
EM cmlin@tmu.edu.tw
OI Lin, Chun-Mao/0000-0002-8366-4026
FU National Science Council, TaiwanMinistry of Science and Technology,
   Taiwan [NSC101-2320-B-038-023]; Ministry of Health Welfare
   [MOHW104-TDU-B-212-113001]; Taipei Medical University-Shuang Ho Hospital
   [101TMU-SHH-10]
FX This study was supported by grants from the National Science Council,
   Taiwan (NSC101-2320-B-038-023), the Ministry of Health & Welfare
   (MOHW104-TDU-B-212-113001), and Taipei Medical University-Shuang Ho
   Hospital (101TMU-SHH-10).
CR Al Sawah E, 2015, J CANCER RES CLIN, V141, P237, DOI 10.1007/s00432-014-1797-x
   Barbieri F, 1999, CLIN CANCER RES, V5, P1837
   Batey MA, 2013, MOL CANCER THER, V12, P959, DOI 10.1158/1535-7163.MCT-12-0707
   Bhutia SK, 2010, P NATL ACAD SCI USA, V107, P22243, DOI 10.1073/pnas.1009479107
   Bonneau C, 2015, GYNECOL ONCOL, V136, P112, DOI 10.1016/j.ygyno.2014.10.024
   Chan KKL, 2011, ANN ONCOL, V22, P2241, DOI 10.1093/annonc/mdq749
   Chen Y, 2014, ASIAN PAC J CANCER P, V15, P10351, DOI 10.7314/APJCP.2014.15.23.10351
   Chiou JF, 2011, EVID-BASED COMPL ALT, V2011, P1, DOI 10.1093/ecam/nep228
   Dai JP, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042706
   Day CP, 2009, PIGM CELL MELANOMA R, V22, P283, DOI 10.1111/j.1755-148X.2009.00545.x
   Dong GQ, 2012, J MED CHEM, V55, P7593, DOI 10.1021/jm300605m
   Dou J, 2011, CELL BIOL INT, V35, P227, DOI 10.1042/CBI20100347
   Du J, 2013, ONCOL REP, V30, P685, DOI 10.3892/or.2013.2498
   Hunakova L, 2014, TOXICOL LETT, V230, P479, DOI 10.1016/j.toxlet.2014.08.018
   Ikeguchi M, 2011, SURG TODAY, V41, P1196, DOI 10.1007/s00595-011-4546-7
   Jiao J, 2013, ONCOTARGETS THER, V6, P667, DOI 10.2147/OTT.S44177
   Kim HS, 2012, APOPTOSIS, V17, P938, DOI 10.1007/s10495-012-0719-0
   Lee JC, 2015, CANCER LETT, V360, P310, DOI 10.1016/j.canlet.2015.02.034
   Li DD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045058
   Li J, 2009, ONCOL REP, V21, P1605, DOI 10.3892/or_00000394
   Liang Xiaobing, 2011, Chemother Res Pract, V2011, P715469, DOI 10.1155/2011/715469
   Matrone A, 2010, INT J GYNECOL CANCER, V20, P203, DOI 10.1111/IGC.0b013e3181c8ca12
   McAuliffe SM, 2012, P NATL ACAD SCI USA, V109, pE2939, DOI 10.1073/pnas.1206400109
   Nguyen HG, 2014, ONCOGENE, V33, P4521, DOI 10.1038/onc.2014.25
   Olszewski U, 2012, NEOPLASIA, V14, P813, DOI 10.1593/neo.12962
   Ozols RF, 2004, CANCER CELL, V5, P19, DOI 10.1016/S1535-6108(04)00002-9
   Pan XB, 2012, PHYTOMEDICINE, V19, P618, DOI 10.1016/j.phymed.2012.02.003
   Perego P, 2012, BIOCHEM PHARMACOL, V83, P27, DOI 10.1016/j.bcp.2011.09.021
   Proszek J, 2014, SENSORS-BASEL, V14, P1195, DOI 10.3390/s140101195
   Rasul A, 2012, ONCOL REP, V27, P1481, DOI 10.3892/or.2012.1694
   Ryan D, 2010, PIGM CELL MELANOMA R, V23, P542, DOI 10.1111/j.1755-148X.2010.00720.x
   Sereno M, 2012, INT J ONCOL, V40, P2104, DOI 10.3892/ijo.2012.1378
   Siu WY, 2004, MOL CANCER THER, V3, P621
   Surowiak P, 2006, HISTOL HISTOPATHOL, V21, P713, DOI 10.14670/HH-21.713
   Tsai HP, 2010, J BIOMED SCI, V17, DOI 10.1186/1423-0127-17-49
   Tsunetoh S, 2010, CANCER BIOL THER, V10, P1138, DOI 10.4161/cbt.10.11.13443
   Wang KL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067297
   Wang LF, 1997, CANCER RES, V57, P1516
   Worsley SD, 1997, GYNECOL ONCOL, V64, P189, DOI 10.1006/gyno.1996.4569
   Wu SY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112220
   Yang J, 2008, FREE RADICAL RES, V42, P492, DOI 10.1080/10715760802112791
   Yang J, 2013, CANCER LETT, V328, P243, DOI 10.1016/j.canlet.2012.09.019
   Yang L, 2014, MOL MED REP, V9, P1147, DOI 10.3892/mmr.2014.1924
   Yu H, 2013, MOLECULES, V18, P1826, DOI 10.3390/molecules18021826
   Yu SH, 2011, PLANTA MED, V77, P907, DOI 10.1055/s-0030-1250682
   Yue GF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065164
   Zhang JW, 2014, BIOCHEM PHARMACOL, V90, P265, DOI 10.1016/j.bcp.2014.05.009
   Zhang Y, 2004, J ASIAN NAT PROD RES, V6, P19, DOI 10.1080/1028602031000119772
   Zhang YX, 2011, CANCER LETT, V304, P21, DOI 10.1016/j.canlet.2011.01.022
NR 49
TC 20
Z9 22
U1 1
U2 26
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 24
PY 2015
VL 10
IS 7
AR e0132579
DI 10.1371/journal.pone.0132579
PG 19
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA CN7NT
UT WOS:000358622000033
PM 26207989
OA Green Submitted, Green Published, gold
DA 2022-04-25
ER

PT J
AU Foerster, EG
   Mukherjee, T
   Cabral-Fernandes, L
   Rocha, JDB
   Girardin, SE
   Philpott, DJ
AF Foerster, Elisabeth G.
   Mukherjee, Tapas
   Cabral-Fernandes, Liliane
   Rocha, Juliana D. B.
   Girardin, Stephen E.
   Philpott, Dana J.
TI How autophagy controls the intestinal epithelial barrier
SO AUTOPHAGY
LA English
DT Review
DE Autophagy; Crohn disease; IBD; intestinal epithelium; intestinal stem
   cells; MTOR
ID INFLAMMATORY-BOWEL-DISEASE; GENOME-WIDE ASSOCIATION; CROHNS-DISEASE; ER
   STRESS; COLORECTAL-CANCER; GENE ATG16L1; SUSCEPTIBILITY LOCI; PANETH
   CELLS; STEM-CELLS; SELECTIVE AUTOPHAGY
AB Macroautophagy/autophagy is a cellular catabolic process that results in lysosome-mediated recycling of organelles and protein aggregates, as well as the destruction of intracellular pathogens. Its role in the maintenance of the intestinal epithelium is of particular interest, as several autophagy-related genes have been associated with intestinal disease. Autophagy and its regulatory mechanisms are involved in both homeostasis and repair of the intestine, supporting intestinal barrier function in response to cellular stress through tight junction regulation and protection from cell death. Furthermore, a clear role has emerged for autophagy not only in secretory cells but also in intestinal stem cells, where it affects their metabolism, as well as their proliferative and regenerative capacity. Here, we review the physiological role of autophagy in the context of intestinal epithelial maintenance and how genetic mutations affecting autophagy contribute to the development of intestinal disease.
C1 [Foerster, Elisabeth G.; Mukherjee, Tapas; Rocha, Juliana D. B.; Girardin, Stephen E.; Philpott, Dana J.] Univ Toronto, Dept Immunol, Toronto, ON, Canada.
   [Mukherjee, Tapas; Cabral-Fernandes, Liliane; Girardin, Stephen E.] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada.
RP Philpott, DJ (corresponding author), Univ Toronto, Dept Immunol, Toronto, ON, Canada.
EM dana.philpott@utoronto.ca
OI Foerster, Elisabeth/0000-0002-3271-0782
FU Canadian Institutes of Health ResearchCanadian Institutes of Health
   Research (CIHR) [FDN-14333]; Natural Sciences and Engineering
   CouncilNatural Sciences and Engineering Research Council of Canada
   (NSERC) [RGPIN-201]
FX This work was supported by the Canadian Institutes of Health Research
   [MOP-12353]; Canadian Institutes of Health Research [FDN-14333]; Natural
   Sciences and Engineering Council [RGPIN-201].
CR Aden K, 2018, J EXP MED, V215, P2868, DOI 10.1084/jem.20171029
   Adolph TE, 2013, NATURE, V503, P272, DOI 10.1038/nature12599
   Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871
   Asano J, 2017, CELL REP, V20, P1050, DOI 10.1016/j.celrep.2017.07.019
   Barker N, 2007, NATURE, V449, P1003, DOI 10.1038/nature06196
   Barrett JC, 2008, NAT GENET, V40, P955, DOI 10.1038/ng.175
   Barron L, 2017, CELL MOL GASTROENTER, V3, P231, DOI 10.1016/j.jcmgh.2016.10.006
   Bel S, 2017, SCIENCE, V357, P1047, DOI 10.1126/science.aal4677
   Benjamin JL, 2013, CELL HOST MICROBE, V13, P723, DOI 10.1016/j.chom.2013.05.004
   Berger E, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13171
   BLOMMAART EFC, 1995, J BIOL CHEM, V270, P2320, DOI 10.1074/jbc.270.5.2320
   Boya P, 2013, NAT CELL BIOL, V15, P713, DOI 10.1038/ncb2788
   Buckley A, 2018, CSH PERSPECT BIOL, V10, DOI 10.1101/cshperspect.a029314
   Burger E, 2018, CELL HOST MICROBE, V23, P177, DOI 10.1016/j.chom.2018.01.001
   Cabrera S, 2013, AUTOPHAGY, V9, P1188, DOI 10.4161/auto.24797
   Cadwell K, 2008, NATURE, V456, P259, DOI 10.1038/nature07416
   Cadwell K, 2010, CELL, V141, P1135, DOI 10.1016/j.cell.2010.05.009
   Cadwell K, 2009, AUTOPHAGY, V5, P250, DOI 10.4161/auto.5.2.7560
   Castro AF, 2003, J BIOL CHEM, V278, P32493, DOI 10.1074/jbc.C300226200
   Chang SW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054564
   Conway KL, 2013, GASTROENTEROLOGY, V145, P1347, DOI 10.1053/j.gastro.2013.08.035
   Cosin-Roger J, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00213-3
   De Stefano D, 2014, AUTOPHAGY, V10, P2053, DOI 10.4161/15548627.2014.973737
   Deuring JJ, 2014, GUT, V63, P1081, DOI 10.1136/gutjnl-2012-303527
   Diamanti MA, 2017, J EXP MED, V214, P423, DOI 10.1084/jem.20161867
   Doherty J, 2018, NAT CELL BIOL, V20, P1110, DOI 10.1038/s41556-018-0201-5
   Egan DF, 2011, SCIENCE, V331, P456, DOI 10.1126/science.1196371
   Fan XL, 2015, ONCOTARGET, V6, P35274, DOI 10.18632/oncotarget.5895
   Franke A, 2010, NAT GENET, V42, P1118, DOI 10.1038/ng.717
   Frankel LB, 2012, CARCINOGENESIS, V33, P2018, DOI 10.1093/carcin/bgs266
   Gehart H, 2019, NAT REV GASTRO HEPAT, V16, P19, DOI 10.1038/s41575-018-0081-y
   Grimm WA, 2016, GUT, V65, P456, DOI 10.1136/gutjnl-2014-308735
   Guan YT, 2015, J IMMUNOL, V195, P339, DOI 10.4049/jimmunol.1303356
   Guo T, 2019, J BIOL CHEM, V294, P5666, DOI 10.1074/jbc.RA118.006069
   Gutierrez-Martinez IZ, 2019, TRANSL ONCOL, V12, P24, DOI 10.1016/j.tranon.2018.08.016
   Hampe J, 2007, NAT GENET, V39, P207, DOI 10.1038/ng1954
   Nguyen HTT, 2014, GASTROENTEROLOGY, V146, P508, DOI 10.1053/j.gastro.2013.10.021
   Haq S, 2019, J BIOMED SCI, V26, DOI 10.1186/s12929-019-0512-2
   Hara K, 2002, CELL, V110, P177, DOI 10.1016/S0092-8674(02)00833-4
   He D, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13911-x
   Heijmans J, 2013, CELL REP, V3, P1128, DOI 10.1016/j.celrep.2013.02.031
   Henckaerts L, 2011, INFLAMM BOWEL DIS, V17, P1392, DOI 10.1002/ibd.21486
   Hu CAA, 2015, ANIM NUTR, V1, P123, DOI 10.1016/j.aninu.2015.08.014
   Huang LQ, 2019, INFLAMM RES, V68, P677, DOI 10.1007/s00011-019-01251-x
   Hugot JP, 2001, NATURE, V411, P599, DOI 10.1038/35079107
   Hui KY, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aai7795
   Huo HZ, 2014, BIOCHEM BIOPH RES CO, V443, P406, DOI 10.1016/j.bbrc.2013.11.099
   Ibrahim IM, 2019, LIFE SCI, V226, P156, DOI 10.1016/j.lfs.2019.04.022
   Ichimura Y, 2000, NATURE, V408, P488, DOI 10.1038/35044114
   Igarashi M, 2016, CELL, V166, P436, DOI 10.1016/j.cell.2016.05.044
   Inoki K, 2003, GENE DEV, V17, P1829, DOI 10.1101/gad.1110003
   Inoue J, 2012, ARCH BIOCHEM BIOPHYS, V521, P95, DOI 10.1016/j.abb.2012.03.019
   Itakura E, 2010, AUTOPHAGY, V6, P764, DOI 10.4161/auto.6.6.12709
   Jostins L, 2012, NATURE, V491, P119, DOI 10.1038/nature11582
   Jung H, 2019, AUTOPHAGY, V15, P1990, DOI 10.1080/15548627.2019.1596495
   Kabat AM, 2016, FRONT IMMUNOL, V7, P1, DOI 10.3389/fimmu.2016.00240
   Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720
   Kaser A, 2008, CELL, V134, P743, DOI 10.1016/j.cell.2008.07.021
   Khaloian S., 2020, GUT, P1
   Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5
   Kim J, 2011, NAT CELL BIOL, V13, P132, DOI 10.1038/ncb2152
   Kim SW, 2017, MOL BIOL CELL, V28, P3043, DOI 10.1091/mbc.E17-01-0021
   Kim S, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8010077
   Kishi-Itakura C, 2014, J CELL SCI, V127, P4089, DOI 10.1242/jcs.156034
   Koustas E, 2017, CANCER LETT, V396, P94, DOI 10.1016/j.canlet.2017.03.023
   Kuma A, 2004, NATURE, V432, P1032, DOI 10.1038/nature03029
   Lapaquette P, 2010, CELL MICROBIOL, V12, P99, DOI 10.1111/j.1462-5822.2009.01381.x
   Larabi A, 2020, AUTOPHAGY, V16, P38, DOI 10.1080/15548627.2019.1635384
   Lassen KG, 2018, AUTOPHAGY, V14, P216, DOI 10.1080/15548627.2017.1389358
   Lassen KG, 2014, P NATL ACAD SCI USA, V111, P7741, DOI 10.1073/pnas.1407001111
   Levine B, 2019, CELL, V176, P11, DOI 10.1016/j.cell.2018.09.048
   Levy A, 2020, P NATL ACAD SCI USA, V117, P1994, DOI 10.1073/pnas.1902788117
   Levy J, 2015, NAT CELL BIOL, V17, P1062, DOI 10.1038/ncb3206
   Lin SC, 2018, CELL METAB, V27, P299, DOI 10.1016/j.cmet.2017.10.009
   Liu B, 2013, AM J PHYSIOL-GASTR L, V305, pG573, DOI 10.1152/ajpgi.00071.2013
   Liu JZ, 2015, NAT GENET, V47, P979, DOI 10.1038/ng.3359
   Liu TC, 2018, J CLIN INVEST, V128, P5110, DOI 10.1172/JCI120453
   Liu TC., 2017, JCI INSIGHT, V2, P1
   Liu X, 2016, INT IMMUNOPHARMACOL, V40, P351, DOI 10.1016/j.intimp.2016.09.017
   Lucas C, 2020, GASTROENTEROLOGY, V158, P1373, DOI 10.1053/j.gastro.2019.12.026
   Mak WY, 2020, J GASTROEN HEPATOL, V35, P380, DOI 10.1111/jgh.14872
   Manzoni C, 2016, SCI REP-UK, V6, DOI 10.1038/srep35106
   Marchiando AM, 2013, CELL HOST MICROBE, V14, P216, DOI 10.1016/j.chom.2013.07.013
   Martin PK, 2018, NAT MICROBIOL, V3, P1131, DOI 10.1038/s41564-018-0229-0
   Martina JA, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2004754
   Matsuzawa-Ishimoto Y, 2017, J EXP MED, V214, P3687, DOI 10.1084/jem.20170558
   McCarroll SA, 2008, NAT GENET, V40, P1107, DOI 10.1038/ng.215
   Meijer AJ, 2009, CRIT REV CL LAB SCI, V46, P210, DOI 10.1080/10408360903044068
   Mihaylova MM, 2018, CELL STEM CELL, V22, P769, DOI 10.1016/j.stem.2018.04.001
   Mizushima N, 1998, NATURE, V395, P395, DOI 10.1038/26506
   Mizushima N, 2018, NAT CELL BIOL, V20, P521, DOI 10.1038/s41556-018-0092-5
   Mizushima N, 2011, ANNU REV CELL DEV BI, V27, P107, DOI 10.1146/annurev-cellbio-092910-154005
   Mizushima N, 2010, NAT CELL BIOL, V12, P823, DOI 10.1038/ncb0910-823
   Mokarram P, 2017, AUTOPHAGY, V13, P781, DOI 10.1080/15548627.2017.1290751
   Murthy A, 2014, NATURE, V506, P456, DOI 10.1038/nature13044
   Na HJ, 2018, BIOCHEM BIOPH RES CO, V498, P18, DOI 10.1016/j.bbrc.2018.02.191
   Nagy P, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-23065-3
   Ng SC, 2012, INFLAMM BOWEL DIS, V18, P1164, DOI 10.1002/ibd.21845
   Nicoli ER, 2014, ROM J MORPHOL EMBRYO, V55, P57
   Niederreiter L, 2013, J EXP MED, V210, P2041, DOI 10.1084/jem.20122341
   Nighot PK, 2015, J BIOL CHEM, V290, P7234, DOI 10.1074/jbc.M114.597492
   O'Brien LE, 2011, CELL, V147, P603, DOI 10.1016/j.cell.2011.08.048
   Ogura Y, 2001, NATURE, V411, P603, DOI 10.1038/35079114
   Okou DT, 2017, GASTROENTEROLOGY, V152, P2083, DOI 10.1053/j.gastro.2017.05.006
   Palmieri M, 2011, HUM MOL GENET, V20, P3852, DOI 10.1093/hmg/ddr306
   Parkes M, 2007, NAT GENET, V39, P830, DOI 10.1038/ng2061
   Patel KK, 2013, EMBO J, V32, P3130, DOI 10.1038/emboj.2013.233
   Paulus GLC, 2017, SCI REP-UK, V7, P1
   Peterson LW, 2014, NAT REV IMMUNOL, V14, P141, DOI 10.1038/nri3608
   Pickles S, 2018, CURR BIOL, V28, pR170, DOI 10.1016/j.cub.2018.01.004
   Pott J, 2018, CELL HOST MICROBE, V23, P191, DOI 10.1016/j.chom.2017.12.017
   Prescott NJ, 2007, GASTROENTEROLOGY, V132, P1665, DOI 10.1053/j.gastro.2007.03.034
   Puertollano R, 2018, EMBO J, V37, DOI 10.15252/embj.201798804
   Ravanan P, 2017, LIFE SCI, V188, P53, DOI 10.1016/j.lfs.2017.08.029
   Ravikumar B, 2004, NAT GENET, V36, P585, DOI 10.1038/ng1362
   Ravikumar B, 2010, PHYSIOL REV, V90, P1383, DOI 10.1152/physrev.00030.2009
   Ravindran R, 2016, NATURE, V531, P523, DOI 10.1038/nature17186
   Rawla P, 2019, GASTROENTEROL REV, V14, P89, DOI 10.5114/pg.2018.81072
   Rioux JD, 2007, NAT GENET, V39, P596, DOI 10.1038/ng2032
   Rivas MA., 2018, PLOS GENET, V14, P1
   Rodriguez-Colman MJ, 2017, NATURE, V543, P424, DOI 10.1038/nature21673
   Rodriguez-Fernandez IA, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08982-9
   Rogala AR., 2018, DIS MODEL MECH, V11, P1
   Rubinsztein DC, 2012, NAT REV DRUG DISCOV, V11, P709, DOI 10.1038/nrd3802
   Rufini S, 2015, DIGEST LIVER DIS, V47, P744, DOI 10.1016/j.dld.2015.05.012
   Saitoh T, 2008, NATURE, V456, P264, DOI 10.1038/nature07383
   Samie M, 2018, NAT IMMUNOL, V19, P246, DOI 10.1038/s41590-017-0042-6
   Sampson LL, 2016, FASEB J, V30, P1263, DOI 10.1096/fj.15-278606
   Sarbassov DD, 2004, CURR BIOL, V14, P1296, DOI 10.1016/j.cub.2004.06.054
   Sardiello M, 2009, SCIENCE, V325, P473, DOI 10.1126/science.1174447
   Sato T, 2011, NATURE, V469, P415, DOI 10.1038/nature09637
   Saxton RA, 2017, CELL, V168, P960, DOI [10.1016/j.cell.2017.02.004, 10.1016/j.cell.2017.03.035]
   Settembre C, 2011, AUTOPHAGY, V7, P1379, DOI 10.4161/auto.7.11.17166
   Settembre C, 2011, SCIENCE, V332, P1429, DOI 10.1126/science.1204592
   Sharma V, 2018, FRONT CELL DEV BIOL, V6, DOI 10.3389/fcell.2018.00147
   Sorbara MT, 2018, CELL HOST MICROBE, V23, P644, DOI 10.1016/j.chom.2018.04.008
   Sorbara MT, 2013, IMMUNITY, V39, P858, DOI 10.1016/j.immuni.2013.10.013
   Strisciuglio C, 2013, J CROHNS COLITIS, V7, P534, DOI 10.1016/j.crohns.2012.08.009
   Sun Q, 2017, MOL MED, V23, P188, DOI 10.2119/molmed.2017.00077
   Suzuki K, 2007, GENES CELLS, V12, P209, DOI 10.1111/j.1365-2443.2007.01050.x
   TAKESHIGE K, 1992, J CELL BIOL, V119, P301, DOI 10.1083/jcb.119.2.301
   Tang DL, 2010, J CELL BIOL, V190, P881, DOI 10.1083/jcb.200911078
   Tang HW, 2013, DEV CELL, V27, P489, DOI 10.1016/j.devcel.2013.10.017
   Tee AR, 2003, CURR BIOL, V13, P1259, DOI 10.1016/S0960-9822(03)00506-2
   Torchinsky MB, 2009, NATURE, V458, P78, DOI 10.1038/nature07781
   Torres J, 2017, LANCET, V389, P1741, DOI 10.1016/S0140-6736(16)31711-1
   Travassos LH, 2010, AUTOPHAGY, V6, P409, DOI 10.4161/auto.6.3.11305
   Travassos LH, 2010, NAT IMMUNOL, V11, P55, DOI 10.1038/ni.1823
   Trentesaux C., 2020, P NATL ACAD SCI USA, V117, P1
   Tschurtschenthaler M, 2017, J EXP MED, V214, P401, DOI 10.1084/jem.20160791
   Vermeire S, 2004, BEST PRACT RES CL GA, V18, P569, DOI 10.1016/j.bpg.2003.12.008
   Villella VR., 2019, CELL DEATH DIS, V10, P1
   Wang CH, 2012, P NATL ACAD SCI USA, V109, P11008, DOI 10.1073/pnas.1203952109
   Wang L, 2015, CANCER BIOL THER, V16, P383, DOI 10.1080/15384047.2014.1002331
   Wen JK, 2017, ELIFE, V6, DOI 10.7554/eLife.29338
   Wittkopf N, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/278059
   Wlodarska M, 2014, CELL, V156, P1045, DOI 10.1016/j.cell.2014.01.026
   Wong M, 2019, AM J PHYSIOL-CELL PH, V316, pC753, DOI 10.1152/ajpcell.00246.2018
   Wu SP, 2015, GUT, V64, P1082, DOI 10.1136/gutjnl-2014-307436
   Wu YP, 2019, J CELL PHYSIOL, V234, P19406, DOI 10.1002/jcp.28722
   Xie YD, 2020, J CLIN INVEST, V130, P2111, DOI 10.1172/JCI133264
   Yilmaz OH, 2012, NATURE, V486, P490, DOI 10.1038/nature11163
   Yu XL, 2015, AUTOPHAGY, V11, P1711, DOI 10.1080/15548627.2015.1043076
   Zachari M, 2017, ESSAYS BIOCHEM, V61, P585, DOI 10.1042/EBC20170021
   Zhang C, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18010157
   Zhang P, 2019, DEV CELL, V49, P574, DOI 10.1016/j.devcel.2019.03.029
   Zhang Q, 2015, NAT IMMUNOL, V16, P918, DOI 10.1038/ni.3233
   Zhou MX, 2018, EBIOMEDICINE, V35, P345, DOI 10.1016/j.ebiom.2018.08.035
   Zhu XR, 2015, J CLIN INVEST, V125, P1098, DOI 10.1172/JCI76344
NR 169
TC 6
Z9 6
U1 19
U2 46
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1554-8627
EI 1554-8635
J9 AUTOPHAGY
JI Autophagy
PD JAN 2
PY 2022
VL 18
IS 1
BP 86
EP 103
DI 10.1080/15548627.2021.1909406
EA APR 2021
PG 18
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA ZC9DA
UT WOS:000648149000001
PM 33906557
DA 2022-04-25
ER

PT J
AU Liu, XH
   Xu, YJ
   Li, Y
   Pan, YC
   Sun, ZH
   Zhao, SL
   Hou, YY
AF Liu, Xinghan
   Xu, Yujun
   Li, Yi
   Pan, Yuchen
   Sun, Zhiheng
   Zhao, Shuli
   Hou, Yayi
TI Ganoderma lucidum fruiting body extracts inhibit colorectal cancer by
   inducing apoptosis, autophagy, and G0/G1 phase cell cycle arrest in
   vitro and in vivo
SO AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH
LA English
DT Article
DE Ganoderma lucidum fruiting body extracts; colorectal cancer; apoptosis;
   autophagy
ID POLYSACCHARIDES
AB Although previous studies have found that Ganoderma lucidum extracts have the ability to directly resist tumor proliferation and reduce metastasis and invasion, the effect of the extracts of Ganoderma lucidum fruiting body (GLE) on cancer is not clarified. This study intends to investigate the anticancer role of GLE on HCT116 colorectal cancer cells in vitro and in vivo. The effects of GLE on the proliferation, apoptosis, autophagy and cell cycle arrest of HCT116 cells were detected by cell counting kit-8 (CCK-8), flow cytometry, electron microscope, quantitative reverse transcription-polymerase chain reaction (RT-PCR) and Western blot assay. Xenografted mouse models were used to evaluate the tumor growth inhibition effect of GLE in vivo. GLE could significantly inhibit the viability of four tumor cell lines (A549, SW1990, SKOV3 and HCT116) and HCT116 cells were more sensitive to GLE treatment with a half inhibitory concentration of 106 mu g/mL. GLE treatment induced apoptosis of HCT116 cells by downregulating of the ratio of Bcl-2 to Bax and increasing cleaved caspase-3 and poly ADP-ribose polymerase (PARP) protein expression. Autophagy of HCT116 cells also increased after GLE treatment, as shown by observation of autophagosomes formation and altered protein expressions in the mTOR pathway. In addition, GLE treatment led to G0/G1 cell cycle arrest as evidenced by flow cytometry analysis and changes in cell-cycle-related gene expressions at the mRNA levels. Of note, in vivo evaluation indicated that GLE significantly inhibited tumor weight and tumor volume and decreased Ki67 expression. In summary, GLE has potential to be developed as an anticancer agent against colorectal cancer, and further evaluation is needed.
C1 [Liu, Xinghan; Xu, Yujun; Li, Yi; Pan, Yuchen; Sun, Zhiheng; Hou, Yayi] Nanjing Univ, Med Sch, Div Immunol, State Key Lab Pharmaceut Biotechnol, Nanjing 210093, Peoples R China.
   [Zhao, Shuli] Nanjing Med Univ, Nanjing Hosp 1, Gen Clin Res Ctr, Nanjing 210006, Peoples R China.
   [Hou, Yayi] Nanjing Univ, Jiangsu Key Lab Mol Med, Nanjing 210093, Peoples R China.
RP Hou, YY (corresponding author), Nanjing Univ, Med Sch, Div Immunol, State Key Lab Pharmaceut Biotechnol, Nanjing 210093, Peoples R China.; Zhao, SL (corresponding author), Nanjing Med Univ, Nanjing Hosp 1, Gen Clin Res Ctr, Nanjing 210006, Peoples R China.
EM shulizhao79@163.com; yayihou@nju.edu.cn
FU special fund for Provincial Key Research and Development of Jiangsu
   Province [BE2019617]; National Natural Science Foundation of
   ChinaNational Natural Science Foundation of China (NSFC) [81572557,
   81872114]
FX This work was supported by a special fund for Provincial Key Research
   and Development of Jiangsu Province (grant number: BE2019617) and the
   National Natural Science Foundation of China (grant number: 81572557,
   81872114).
CR Agrawal B, 2019, CLIN TRANSL MED, V8, DOI 10.1186/s40169-019-0241-x
   Amaravadi RK, 2019, CANCER DISCOV, V9, P1167, DOI 10.1158/2159-8290.CD-19-0292
   Barbieri A, 2017, NUTRIENTS, V9, DOI 10.3390/nu9030210
   Bhat P, 2018, BIOCHEM PHARMACOL, V147, P170, DOI 10.1016/j.bcp.2017.11.021
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
   Chen P, 2019, INTEGR CANCER THER, V18, DOI 10.1177/1534735419828824
   Chen ZW, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1058-3
   Guler I, 2019, EXPERT REV GASTROENT, V13, P919, DOI 10.1080/17474124.2019.1663174
   Hernandez JB, 2015, NAT COMMUN, V6, DOI [10.1038/ncomms8216, 10.1038/ncomms8489]
   Hsu SC, 2009, CANCER LETT, V281, P108, DOI 10.1016/j.canlet.2009.02.032
   Huang SC, 2017, STEM CELL REP, V8, P84, DOI 10.1016/j.stemcr.2016.12.007
   Kottschade LA, 2019, SEMIN ONCOL NURS, V35, DOI [10.1016/j.soacn.2019.08.013, 10.1016/j.soncn.2019.08.013]
   Liang CY, 2019, EUR J MED CHEM, V174, P130, DOI 10.1016/j.ejmech.2019.04.039
   Miller KD, 2019, CA-CANCER J CLIN, V69, P363, DOI 10.3322/caac.21565
   Pistritto G, 2016, AGING-US, V8, P603, DOI 10.18632/aging.100934
   Sanchez-Martinez C, 2019, BIOORG MED CHEM LETT, V29, DOI 10.1016/j.bmcl.2019.126637
   Sohretoglu D, 2018, ANTI-CANCER AGENT ME, V18, P667, DOI 10.2174/1871520617666171113121246
   Stintzing S, 2017, EUR J CANCER, V84, P69, DOI 10.1016/j.ejca.2017.07.016
   Suprasert P, 2014, ASIAN PAC J CANCER P, V15, P4193, DOI 10.7314/APJCP.2014.15.10.4193
   Unlu A, 2016, J BUON, V21, P792
   Zhang WY, 2004, INT IMMUNOPHARMACOL, V4, P461, DOI 10.1016/j.intimp.2004.01.014
   Zhao H, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/809614
   Zhong LD, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00703
   Zuo K, 2019, CANCER METAST REV, V38, P507, DOI 10.1007/s10555-019-09802-8
NR 24
TC 1
Z9 1
U1 0
U2 3
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1943-8141
J9 AM J TRANSL RES
JI Am. J. Transl. Res.
PY 2020
VL 12
IS 6
BP 2675
EP 2684
PG 10
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Research & Experimental Medicine
GA MJ7DE
UT WOS:000548246400006
PM 32655799
DA 2022-04-25
ER

PT J
AU Zheng, HC
   Zhao, S
   Xue, H
   Zhao, EH
   Jiang, HM
   Hao, CL
AF Zheng, Hua-chuan
   Zhao, Shuang
   Xue, Hang
   Zhao, En-hong
   Jiang, Hua-mao
   Hao, Chang-lai
TI The Roles of Beclin 1 Expression in Gastric Cancer: A Marker for
   Carcinogenesis, Aggressive Behaviors and Favorable Prognosis, and a
   Target of Gene Therapy
SO FRONTIERS IN ONCOLOGY
LA English
DT Article
DE Beclin 1; gastric cancer; gene therapy; carcinogenesis; aggressive
   behaviors; prognosis
ID EPITHELIAL-MESENCHYMAL TRANSITION; COLORECTAL-CANCER; INDUCED APOPTOSIS;
   POOR-PROGNOSIS; AUTOPHAGY; PROMOTES; INVASION; BECN1; TUMORIGENESIS;
   SENSITIVITY
AB Beclin 1 is encoded by Becn1, and plays a role in tumorigenesis, neurodegeneration, apoptosis and autophagy. Here, the aggressive phenotypes and relevant proteins were examined after Beclin 1 expression was altered in gastric cancer cells. We also observed the effects of Beclin 1 on gastric carcinogenesis using Becn1 knockout mice. Finally, clinicopathological significances of Beclin 1 expression were analyzed using meta- and bioinformatics analyses. Becn1 overexpression was found to inhibit proliferation, glucose metabolism, migration and invasion of gastric cancer cells, whereas its knockdown caused the opposite effects. Beclin 1 suppressed the tumor growth by decreasing proliferation and increasing apoptosis. The heterozygous abrogation of Becn1 in gastric pit, parietal and chief cells could not cause any epithelial lesion. Beclin 1-mediated chemoresistance was closely linked to the autophagy, Bax underexpression, and the overexpression of Bcl-2, LRP1, MDR1, and ING5. Bioinformatics analysis showed higher Becn1 mRNA expression in intestinal- than diffuse-type carcinomas (P<0.05), and in male than female gastric cancer patients (P<0.05). Becn1 hyperexpression was positively associated with both overall and progression-free survival rates of the cancer patients (P<0.05). Meta-analysis showed that down-regulated Beclin 1 expression in gastric cancer was positively with lymph node metastasis, TNM staging, dedifferentiation and poor prognosis (P<0.05). Becn1-related signal pathways in gastric cancer included prostate, lung, renal, colorectal, endometrial and thyroid cancers, glioma, and leukemia, the metabolism of amino acid, lipid and sugar, and some signal pathways of insulin, MAPK, TRL, VEGF, JAK-STAT, chemokine, p53, lysosome, peroxidome and ubiquitin-mediated protein degradation (P<0.05). These suggested that Beclin 1 might be considered as a potential marker of gastric carcinogenesis, aggressiveness and prognostic prediction, and as a target of gene therapy in gastric cancer.
C1 [Zheng, Hua-chuan; Zhao, Shuang; Xue, Hang] Chengde Med Univ, Affiliated Hosp, Dept Oncol, Chengde, Peoples R China.
   [Zheng, Hua-chuan; Zhao, Shuang; Xue, Hang] Chengde Med Univ, Affiliated Hosp, Expt Ctr, Chengde, Peoples R China.
   [Zhao, En-hong] Chengde Med Univ, Affiliated Hosp, Dept Surg, Chengde, Peoples R China.
   [Jiang, Hua-mao] Jinzhou Med Univ, Affiliated Hosp 1, Dept Urol, Jinzhou, Peoples R China.
   [Hao, Chang-lai] Chengde Med Univ, Affiliated Hosp, Dept Hematol, Chengde, Peoples R China.
RP Hao, CL (corresponding author), Chengde Med Univ, Affiliated Hosp, Dept Hematol, Chengde, Peoples R China.
EM haochanglai882@163.com
FU Award for Liaoning Distinguished Professor; National Natural Scientific
   Foundation of ChinaNational Natural Science Foundation of China (NSFC)
   [81672700]
FX This study was supported by Award for Liaoning Distinguished Professor,
   and National Natural Scientific Foundation of China (81672700).
CR Bi C, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-5429-3
   Cao QH, 2016, AM J TRANSL RES, V8, P3831
   Catalano M, 2015, MOL ONCOL, V9, P1612, DOI 10.1016/j.molonc.2015.04.016
   Chen YG, 2014, WSPOLCZESNA ONKOL, V18, P171, DOI 10.5114/wo.2014.41395
   Chen YB, 2012, J SURG ONCOL, V105, P542, DOI 10.1002/jso.22151
   Chen YS, 2021, J MATERN-FETAL NEO M, V34, P1297, DOI 10.1080/14767058.2019.1635582
   Cheng ZJ, 2019, CELL ADHES MIGR, V13, P249, DOI 10.1080/19336918.2019.1638690
   den Hoed Caroline M, 2016, Curr Gastroenterol Rep, V18, P34, DOI 10.1007/s11894-016-0506-0
   Ding XQ, 2017, ONCOTARGET, V8, P81953, DOI 10.18632/oncotarget.17918
   Fei BY, 2016, ONCOL LETT, V11, P2271, DOI 10.3892/ol.2016.4183
   Fujiwara N, 2016, J BIOL CHEM, V291, P10858, DOI 10.1074/jbc.M115.704908
   Furuya D, 2005, EXP CELL RES, V307, P26, DOI 10.1016/j.yexcr.2005.02.023
   Gao P, 2019, INT J CLIN EXP PATHO, V12, P885
   Geng QR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045968
   Gu Y, 2017, ONCOTARGET, V8, P52156, DOI 10.18632/oncotarget.11044
   Guo CQ, 2010, J ZHENGZHOU U MED SC, V45, P463
   Han LL, 2019, MOL CANCER RES, V17, P2267, DOI 10.1158/1541-7786.MCR-19-0321
   Hasan A, 2020, LIFE SCI, V256, DOI 10.1016/j.lfs.2020.118000
   Hill SM, 2019, CELL DEATH DIFFER, V26, P617, DOI 10.1038/s41418-018-0254-9
   Hu FQ, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2467-3
   Hu YF, 2017, MODERN ONCOL, V25, P1093
   Huang JM, 2016, IMPLEMENTATION EMERG, V31, pe4888, DOI 10.7759/cureus.4888
   Jin SH, 2016, EMBO J, V35, P866, DOI 10.15252/embj.201593596
   Jung G, 2015, ACTA HAEMATOL-BASEL, V134, P17, DOI 10.1159/000368848
   Kang R, 2011, CELL DEATH DIFFER, V18, P571, DOI 10.1038/cdd.2010.191
   Katagiri H, 2015, INT J ONCOL, V47, P2037, DOI 10.3892/ijo.2015.3191
   Li S, 2016, ONCOTARGET, V7, P70364, DOI 10.18632/oncotarget.12217
   Li XB, 2016, CELL RES, V26, P838, DOI 10.1038/cr.2016.47
   Liu H, 2017, AUTOPHAGY, V13, P900, DOI 10.1080/15548627.2017.1291479
   Liu H, 2015, AUTOPHAGY, V11, P2323, DOI 10.1080/15548627.2015.1074372
   Liu KJ, 2020, AUTOPHAGY, V16, P975, DOI 10.1080/15548627.2019.1647944
   Liu L, 2016, GENET MOL RES, V15, DOI 10.4238/gmr.15027704
   Liu T, 2017, AM J PHYSIOL-LUNG C, V313, pL27, DOI 10.1152/ajplung.00510.2016
   Minamoto T, 2018, ONCOL LETT, V15, P1170, DOI 10.3892/ol.2017.7379
   Moon SY, 2014, NEPHRON EXP NEPHROL, V126, P127, DOI 10.1159/000362457
   Morikawa A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125762
   Ouyang F, 2016, INT J MOL MED, V37, P679, DOI 10.3892/ijmm.2016.2474
   Pang M, 2016, INT J BIOCHEM CELL B, V76, P123, DOI 10.1016/j.biocel.2016.05.010
   Park SE, 2016, ONCOTARGET, V7, P39796, DOI 10.18632/oncotarget.9290
   Peng Y, 2016, AUTOPHAGY, V12, P2167, DOI 10.1080/15548627.2016.1217380
   Pickford F, 2008, J CLIN INVEST, V118, P2190, DOI 10.1172/JCI33585
   Qin WJ, 2015, ONCOTARGET, V6, P39839, DOI 10.18632/oncotarget.5674
   Qin ZQ, 2018, WORLD J SURG ONCOL, V16, DOI 10.1186/s12957-018-1465-8
   Qiu GL, 2016, DIS MARKERS, V2016, DOI 10.1155/2016/6869415
   Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039
   Sahni S, 2014, J CLIN PATHOL, V67, P656, DOI 10.1136/jclinpath-2014-202356
   Shu CW, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160586
   Siddiqui MA, 2015, INT J MOL SCI, V16, P17611, DOI 10.3390/ijms160817611
   Song SS, 2017, ONCOL LETT, V14, P7849, DOI 10.3892/ol.2017.7218
   Sun T, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0167-4
   Sun T, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8215
   Tang H, 2015, EBIOMEDICINE, V2, P255, DOI 10.1016/j.ebiom.2015.01.008
   Tang YF, 2020, J CELL MOL MED, V24, P954, DOI 10.1111/jcmm.14806
   Venerito M, 2016, HELICOBACTER, V21, P39, DOI 10.1111/hel.12339
   Wang MC, 2015, INT J CLIN EXP MED, V8, P7049
   Wang WY, 2016, MOL MED REP, V14, P355, DOI 10.3892/mmr.2016.5219
   Weh KM, 2016, MOL CARCINOGEN, V55, P1876, DOI 10.1002/mc.22432
   Won KY, 2015, PATHOL RES PRACT, V211, P308, DOI 10.1016/j.prp.2014.11.005
   Wu JC, 2018, CANCER MED-US, V7, P4554, DOI 10.1002/cam4.1634
   Wu T, 2012, MOL MED REP, V5, P305, DOI 10.3892/mmr.2011.634
   Yu M, 2013, TUMOR BIOL, V34, P1071, DOI 10.1007/s13277-013-0648-8
   Yu SJ, 2016, TUMOR BIOL, V37, P15007, DOI 10.1007/s13277-016-5383-5
   Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100
   Zhang J, 2019, J CELL PHYSIOL, V234, P12800, DOI 10.1002/jcp.27914
   Zhang MY, 2019, ONCOL LETT, V17, P2441, DOI 10.3892/ol.2018.9817
   Zhang MY, 2014, INT J MOL SCI, V15, P14372, DOI 10.3390/ijms150814372
   Zhang YX, 2016, ONCOL LETT, V11, P4089, DOI 10.3892/ol.2016.4542
   Zhao S, 2017, ONCOTARGET, V8, P56558, DOI 10.18632/oncotarget.17802
   Zhao S, 2016, ONCOTARGET, V7, P54596, DOI 10.18632/oncotarget.10519
   Zhao Y, 2014, TUMOR BIOL, V35, P1955, DOI 10.1007/s13277-013-1261-6
   Zhao Z, 2015, CANCER LETT, V358, P17, DOI 10.1016/j.canlet.2014.11.046
   Zheng HC, 2017, ONCOTARGET, V8, P103449, DOI 10.18632/oncotarget.21968
   Zheng HC, 2017, ONCOTARGET, V8, P59950, DOI 10.18632/oncotarget.19048
   Zheng TL, 2018, ONCOTARGETS THER, V11, P4167, DOI 10.2147/OTT.S164987
   Zhou WH, 2012, AUTOPHAGY, V8, P389, DOI 10.4161/auto.18641
   Zhu HT, 2014, ONCOL REP, V32, P935, DOI 10.3892/or.2014.3298
   Zhu YS, 2010, PROTEIN CELL, V1, P468, DOI 10.1007/s13238-010-0048-4
NR 77
TC 5
Z9 5
U1 7
U2 10
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2234-943X
J9 FRONT ONCOL
JI Front. Oncol.
PD DEC 23
PY 2020
VL 10
AR 613679
DI 10.3389/fonc.2020.613679
PG 13
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA PP6HX
UT WOS:000605962600001
PM 33425768
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Xie, B
   Nie, SL
   Hu, G
   Xiong, L
   Hu, F
   Li, M
   Peng, TS
   Nie, J
   He, YH
AF Xie, Biao
   Nie, Shaolin
   Hu, Gui
   Xiong, Li
   Hu, Fan
   Li, Mei
   Peng, Tianshu
   Nie, Jing
   He, Yongheng
TI The Involvement of NF-kappa B/Klotho Signaling in Colorectal Cancer Cell
   Survival and Invasion
SO PATHOLOGY & ONCOLOGY RESEARCH
LA English
DT Article
DE LPS; NF-kappa B; Colorectal cancer; Klotho
ID EXPRESSION INDUCES APOPTOSIS; TUMOR-SUPPRESSOR; KLOTHO; INFLAMMATION;
   RESTORATION; AUTOPHAGY
AB Lipopolysaccharide significantly increased invasion, cell proliferation, and phospho-NF-kappa B p65 and phospho-IGF-1R protein, but decreased klotho protein expression, cell apoptosis, and the percentage of sub G0/G1 cells in SW480 and HT29 colorectal cancer cells. In contrast, NF-kappa B inhibitor exhibited a counteract effect of lipopolysaccharide. Transfection of Toll-like receptor 4 shRNA significantly decreased phospho-NF-kappa B p65 and phospho-IGF-1R protein levels, invasion, but significantly increased klotho protein expression, cell apoptosis, and the percentage of sub G0/G1 in SW480 and HT29 cells. In conclusion, inflammation inhibits klotho gene expression in colorectal cancer cells through activation of Toll-like receptor 4 /NF-kappa B signal pathway.
C1 [Xie, Biao; Hu, Fan; Li, Mei; He, Yongheng] Hunan Univ Chinese Med, Affiliated Hosp 2, Dept Anorectal Surg 1, 139 Renmin Rd, Changsha 410005, Hunan, Peoples R China.
   [Nie, Shaolin] Hunan Prov Tumor Hosp, Dept Colorectal Surg, Changsha 410013, Hunan, Peoples R China.
   [Hu, Gui] Cent S Univ, Xiangya Hosp 3, Dept Gastrointestinal Surg, Changsha 410013, Hunan, Peoples R China.
   [Xiong, Li] Cent S Univ, Xiangya Hosp 2, Dept Hepatobiliary Surg, Changsha 410008, Hunan, Peoples R China.
   [Peng, Tianshu] Hunan Slack King Lab Anim Co Ltd, Changsha 4100125, Hunan, Peoples R China.
   [Nie, Jing] Hunan Univ Chinese Med, Affiliated Hosp 2, Dept Anorectal Surg 4, Changsha 410005, Hunan, Peoples R China.
RP He, YH (corresponding author), Hunan Univ Chinese Med, Affiliated Hosp 2, Dept Anorectal Surg 1, 139 Renmin Rd, Changsha 410005, Hunan, Peoples R China.
EM heyongheng1964@163.com
FU Postdoctoral Science Foundation of ChinaChina Postdoctoral Science
   Foundation [2016 M602416]; National Natural Science Foundation of
   ChinaNational Natural Science Foundation of China (NSFC) [81704089];
   Postdoctoral Science Fund Special Grant of China [2017 T100603]; 2016
   Postdoctoral Researcher Daily Funding of Hunan Province [49]; Department
   of Education Key Project of Hunan Province [15A024]; Changsha City's
   Outstanding Innovation Youth Training Program [kq 1707012]
FX This study was supported by the Postdoctoral Science Foundation of China
   (2016 M602416), National Natural Science Foundation of China (81704089),
   Postdoctoral Science Fund Special Grant of China (2017 T100603), 2016
   Postdoctoral Researcher Daily Funding of Hunan Province (49), the
   Department of Education Key Project of Hunan Province (15A024), and
   Changsha City's Outstanding Innovation Youth Training Program (kq
   1707012).
CR American Cancer Society (ACS), 2014, COL CANC FACTS FIG 2
   [Anonymous], 2017, CA-CANCER J CLIN, DOI DOI 10.3322/CAAC.21395
   Liu BD, 2015, CANCER CELL, V27, P370, DOI 10.1016/j.ccell.2015.02.004
   Roy A, 2016, INT IMMUNOPHARMACOL, V40, P79, DOI 10.1016/j.intimp.2016.08.026
   Shu GS, 2013, CELL ONCOL, V36, P121, DOI 10.1007/s13402-012-0118-0
   Sims GP, 2010, ANNU REV IMMUNOL, V28, P367, DOI 10.1146/annurev.immunol.021908.132603
   Tang XW, 2016, LAB INVEST, V96, P197, DOI 10.1038/labinvest.2015.86
   Terzic J, 2010, GASTROENTEROLOGY, V138, P2101, DOI 10.1053/j.gastro.2010.01.058
   Viennois Emilie, 2013, Transl Gastrointest Cancer, V2, P21
   Wang LJ, 2011, AM J CANCER RES, V1, P111
   Wu C, 2015, MOL CELL ENDOCRINOL, V417, P84, DOI 10.1016/j.mce.2015.09.024
   Xie B, 2013, PATHOL ONCOL RES, V19, P611, DOI 10.1007/s12253-013-9663-8
   Xie BA, 2013, HUM PATHOL, V44, P795, DOI 10.1016/j.humpath.2012.07.023
   Xie B, 2013, CANCER CELL INT, V13, DOI 10.1186/1475-2867-13-18
   Zhang GL, 2000, J ENDOTOXIN RES, V6, P453, DOI 10.1179/096805100101532414
   Zhou XX, 2015, J CANCER RES CLIN, V141, P961, DOI 10.1007/s00432-014-1788-y
   Zhu QC, 2013, ASIAN PAC J CANCER P, V14, P2689, DOI 10.7314/APJCP.2013.14.5.2689
NR 17
TC 5
Z9 5
U1 2
U2 4
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1219-4956
EI 1532-2807
J9 PATHOL ONCOL RES
JI Pathol. Oncol. Res.
PD OCT
PY 2019
VL 25
IS 4
BP 1553
EP 1565
DI 10.1007/s12253-018-0493-6
PG 13
WC Oncology; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Pathology
GA JH3JE
UT WOS:000492663100032
PM 30612312
DA 2022-04-25
ER

PT J
AU Fujii, S
   Mitsunaga, S
   Yamazaki, M
   Hasebe, T
   Ishii, G
   Kojima, M
   Kinoshita, T
   Ueno, T
   Esumi, H
   Ochiai, A
AF Fujii, Satoshi
   Mitsunaga, Shuichi
   Yamazaki, Manabu
   Hasebe, Takahiro
   Ishii, Genichiro
   Kojima, Motohiro
   Kinoshita, Taira
   Ueno, Takashi
   Esumi, Hiroyasu
   Ochiai, Atsushi
TI Autophagy is activated in pancreatic cancer cells and correlates with
   poor patient outcome
SO CANCER SCIENCE
LA English
DT Article
ID PROGNOSTIC-FACTORS; DUCTAL CARCINOMA; ADENOCARCINOMA; HYPOXIA;
   RESECTION; TOLERANCE; SURVIVAL; GROWTH; TUMORS
AB Because autonomous proliferating cancer cells are often exposed to hypoxic conditions, there must be an alternative metabolic pathway, such as autophagy, that allows them to obtain energy when both oxygen and glucose are depleted. We previously reported finding that autophagy actually contributes to cancer cell survival in colorectal cancers both in vitro and in vivo. Pancreatic cancer remains a devastating and poorly understood malignancy, and hypoxia in pancreatic cancers is known to increase their malignant potential. In the present study archival pancreatic cancer tissue was retrieved from 71 cases treated by curative pancreaticoduodenectomy. Autophagy was evaluated by immunohistochemical staining with anti-LC3 antibody, as LC3 is a key component of autophagy and has been used as a marker of autophagy. The results showed that strong LC3 expression in the peripheral area of pancreatic cancer tissue was correlated with a poor outcome (P = 0.0170) and short disease-free period (P = 0.0118). Two of the most significant correlations among the clinicopathological factors tested were found between the peripheral intensity level of LC3 expression and tumor size (P = 0.0098) or tumor necrosis (P = 0.0127). Activated autophagy is associated with pancreatic cancer cells, and autophagy is thought to be a response to factors in the cancer microenvironment, such as hypoxia and poor nutrient supply. This is the first study to report the clinicopathological significance of autophagy in pancreatic cancer.
C1 [Fujii, Satoshi; Yamazaki, Manabu; Ishii, Genichiro; Kojima, Motohiro; Ochiai, Atsushi] Natl Canc Ctr Hosp E, Res Ctr Innovat Oncol, Div Pathol, Chiba 2778577, Japan.
   [Mitsunaga, Shuichi] Natl Canc Ctr Hosp E, Div Hepatobiliary & Pancreat Oncol, Chiba 2778577, Japan.
   [Hasebe, Takahiro] Natl Canc Ctr, Ctr Canc Control & Informat Serv, Clin Trials & Practice Support Div, Off Pathol Consultat & Serv,Chuo Ku, Tokyo 1040045, Japan.
   [Kinoshita, Taira] Natl Canc Ctr Hosp E, Dept Hepatobiliary Pancreat Surg, Chiba 2778577, Japan.
   [Ueno, Takashi] Juntendo Univ, Dept Biochem, Sch Med, Bunkyo Ku, Tokyo 1138421, Japan.
   [Esumi, Hiroyasu] Natl Canc Ctr Hosp E, Res Ctr Innovat Oncol, Canc Physiol Project, Chiba 2778577, Japan.
RP Ochiai, A (corresponding author), Natl Canc Ctr Hosp E, Res Ctr Innovat Oncol, Div Pathol, 6-5-1 Kashiwanoha, Chiba 2778577, Japan.
EM aochiai@east.ncc.go.jp
RI Yamazaki, Manabu/AAV-1263-2020; Ishii, Genichiro/E-2913-2012
OI Yamazaki, Manabu/0000-0002-7156-1820; 
FU Ministry of Health, Labour, and WelfareMinistry of Health, Labour and
   Welfare, Japan
FX This work was supported by a grant from the Ministry of Health, Labour,
   and Welfare for the Third-Term Comprehensive 10-year Strategy for Cancer
   Control. We wish to thank Miss Mai Okumoto for her excellent technical
   assistance.
CR Buchler P, 2004, J SURG RES, V120, P295, DOI 10.1016/j.jss.2004.02.014
   Esumi H, 2002, J BIOL CHEM, V277, P32791, DOI 10.1074/jbc.M112270200
   GEER RJ, 1993, AM J SURG, V165, P68, DOI 10.1016/S0002-9610(05)80406-4
   Hamilton R, 2000, WHO CLASSIFICATION T
   Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704
   Izuishi K, 2000, CANCER RES, V60, P6201
   Jager S, 2004, J CELL SCI, V117, P4837, DOI 10.1242/jcs.01370
   Jain RK, 2003, NAT MED, V9, P685, DOI 10.1038/nm0603-685
   *JAP PANCR SOC, 1996, CLASSIFICATION PANCR
   Kirkegaard K, 2004, NAT REV MICROBIOL, V2, P301, DOI 10.1038/nrmicro865
   Kitano M, 2004, GUT, V53, P854, DOI 10.1136/gut.2003.029934
   Kivela AJ, 2000, HISTOCHEM CELL BIOL, V114, P197
   Klionsky DJ, 2008, AUTOPHAGY, V4, P151, DOI 10.4161/auto.5338
   Kondo Y, 2005, NAT REV CANCER, V5, P726, DOI 10.1038/nrc1692
   Koong AC, 2000, INT J RADIAT ONCOL, V48, P919, DOI 10.1016/S0360-3016(00)00803-8
   Kuhlmann KFCD, 2004, EUR J CANCER, V40, P549, DOI 10.1016/j.ejca.2003.10.026
   KUMAR V, 1992, ROBBINS PATHOLOGIC B
   Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1
   Levine B, 2007, NATURE, V446, P745, DOI 10.1038/446745a
   Lim JE, 2003, ANN SURG, V237, P74, DOI 10.1097/00000658-200301000-00011
   Luttges J, 2000, J PATHOL, V191, P154
   Mitsunaga S, 2005, CANCER SCI, V96, P858, DOI 10.1111/j.1349-7006.2005.00128.x
   Sato K, 2007, CANCER RES, V67, P9677, DOI 10.1158/0008-5472.CAN-07-1462
   SENER SF, 1985, J AM COLL SURGEONS, V189, P1
   Shibaji T, 2003, ANTICANCER RES, V23, P4721
   Sipos B, 2002, INT J CANCER, V102, P592, DOI 10.1002/ijc.10753
   Sobin H, 2002, TNM CLASSIFICATION M
   Sohn TA, 2000, J GASTROINTEST SURG, V4, P567, DOI 10.1016/S1091-255X(00)80105-5
   Takahashi S, 2001, ANTICANCER RES, V21, P1407
   Takai S, 2003, PANCREAS, V26, P243, DOI 10.1097/00006676-200304000-00007
   Tanida I, 2005, AUTOPHAGY, V1, P84, DOI 10.4161/auto.1.2.1697
   Vaupel P, 2001, MED ONCOL, V18, P243, DOI 10.1385/MO:18:4:243
NR 32
TC 194
Z9 206
U1 0
U2 6
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1347-9032
EI 1349-7006
J9 CANCER SCI
JI Cancer Sci.
PD SEP
PY 2008
VL 99
IS 9
BP 1813
EP 1819
DI 10.1111/j.1349-7006.2008.00893.x
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 339VE
UT WOS:000258604600017
PM 18616529
OA Bronze
DA 2022-04-25
ER

PT J
AU Zhang, W
   Yeo, MC
   Tang, FY
   Popovich, DG
AF Zhang, Wei
   Yeo, Mei Ching
   Tang, Fang Yin
   Popovich, David G.
TI Bioactive responses of Hep-G2 cells to soyasaponin extracts differs with
   respect to extraction conditions
SO FOOD AND CHEMICAL TOXICOLOGY
LA English
DT Article
DE Oleanane triterpenoids; Soyasaponins; Differentiation; Hep-G2
ID COLON-CANCER CELLS; LIQUID-CHROMATOGRAPHY; TRITERPENOID SAPONINS; SIALIC
   ACIDS; HELA-CELLS; PROLIFERATION; APOPTOSIS; SURFACE; MACROAUTOPHAGY;
   EXPRESSION
AB Soyasaponins are bioactive oleanane triterpenoids found in soy and other legumes. The effect of two methanolic extractions of soy flour, room temperature (RT) and reflux (RE) extractions on composition and bioactive properties in hepatocarcinoma cells (Hep-G2) were investigated. A greater amount of 2,3-dihydro-2,5-dihydroxy-6-methyl-4H-pyran-4-one (DDMP) conjugated soyasaponins beta g was measured in RT and a greater amount of the structurally related non-DDMP soyasaponins I and III were detected in RE. MTT cell viability yielded an LC50 of 0.926 +/- 0.08 mg/mL for RT and 0.546 +/- 0.06 mg/mL for RE. Via-Count viability assay showed similar results for RE as the MTT assay however, RT treatment produced no difference compared with the control. Analysis using TUNEL and cell cycle analysis revealed that RE treatment induced apoptosis and flow cytometry forward side scatter and morphological assessment of RT showed evidence of Hep-G2 differentiation after 72 h. Differences in the bioactivities may be attributed to the different concentration of DDMP conjugated soyasaponin beta g recovered in RT and RE extracts. (C) 2009 Elsevier Ltd. All rights reserved.
C1 [Zhang, Wei; Yeo, Mei Ching; Tang, Fang Yin; Popovich, David G.] Natl Univ Singapore, Dept Chem, Singapore 117543, Singapore.
RP Popovich, DG (corresponding author), Natl Univ Singapore, Dept Chem, Sci Dr 4, Singapore 117543, Singapore.
EM chmpdg@nus.edu.sg
RI Zhang, Wei/G-8229-2016
OI Zhang, Wei/0000-0003-2691-2721; Popovich, David/0000-0002-8630-320X
FU National University of Singapore (NUS)National University of Singapore;
   Singapore Ministry of EducationMinistry of Education, Singapore
   [R-143-050-287-133/101]
FX The authors acknowledge the National University of Singapore (NUS) and
   the Singapore Ministry of Education (Grants R-143-050-287-133/101) for
   financial support and graduate scholarship (WZ).
CR Bernas T, 2002, CYTOMETRY, V47, P236, DOI 10.1002/cyto.10080
   Chang WW, 2006, BIOCHEM BIOPH RES CO, V341, P614, DOI 10.1016/j.bbrc.2005.12.216
   DAVEBY YD, 1998, J SCI FOOD AGR, V14, P1
   Ellington AA, 2006, CARCINOGENESIS, V27, P298, DOI 10.1093/carcin/bgi214
   Ellington AA, 2005, CARCINOGENESIS, V26, P159, DOI 10.1093/carcin/bgh297
   Fournier DB, 1998, CANCER EPIDEM BIOMAR, V7, P1055
   Gurfinkel DM, 2005, INT J FOOD SCI NUTR, V56, P501, DOI 10.1080/09637480500460601
   Gurfinkel DM, 2003, NUTR CANCER, V47, P24, DOI 10.1207/s15327914nc4701_3
   Hsu CC, 2005, GYNECOL ONCOL, V96, P415, DOI 10.1016/j.ygyno.2004.10.010
   Hu J, 2002, J AGR FOOD CHEM, V50, P2587, DOI 10.1021/jf0114740
   KUDOU S, 1993, BIOSCI BIOTECH BIOCH, V57, P546, DOI 10.1271/bbb.57.546
   Leu YL, 2008, J MED CHEM, V51, P1740, DOI 10.1021/jm701151c
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4
   OAKENFULL D, 1990, EUR J CLIN NUTR, V44, P79
   PILATTE Y, 1993, GLYCOBIOLOGY, V3, P201, DOI 10.1093/glycob/3.3.201
   Popovich DG, 2004, PHYTOCHEMISTRY, V65, P337, DOI 10.1016/j.phytochem.2003.11.020
   SHIRAIWA M, 1991, AGR BIOL CHEM TOKYO, V55, P911, DOI 10.1080/00021369.1991.10870686
   WARREN L, 1972, P NATL ACAD SCI USA, V69, P1838, DOI 10.1073/pnas.69.7.1838
   Xiao JX, 2007, EXP TOXICOL PATHOL, V59, P35, DOI 10.1016/j.etp.2007.02.004
   Xiao JX, 2007, TOXICOL IN VITRO, V21, P820, DOI 10.1016/j.tiv.2007.01.025
   Yamamoto H, 2008, ANN HEMATOL, V87, P87, DOI 10.1007/s00277-007-0381-8
   Yoshiki Y, 1998, BIOSCI BIOTECH BIOCH, V62, P2291, DOI 10.1271/bbb.62.2291
   Zhang W, 2008, J AGR FOOD CHEM, V56, P2603, DOI 10.1021/jf0731550
   Zhang XW, 2000, ACTA PHARMACOL SIN, V21, P364
   [No title captured]
NR 25
TC 15
Z9 17
U1 0
U2 12
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0278-6915
EI 1873-6351
J9 FOOD CHEM TOXICOL
JI Food Chem. Toxicol.
PD SEP
PY 2009
VL 47
IS 9
BP 2202
EP 2208
DI 10.1016/j.fct.2009.06.006
PG 7
WC Food Science & Technology; Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Food Science & Technology; Toxicology
GA 489PF
UT WOS:000269432000007
PM 19520140
DA 2022-04-25
ER

PT J
AU Pin, F
   Minero, VG
   Penna, F
   Muscaritoli, M
   De Tullio, R
   Baccino, FM
   Costelli, P
AF Pin, Fabrizio
   Minero, Valerio G.
   Penna, Fabio
   Muscaritoli, Maurizio
   De Tullio, Roberta
   Baccino, Francesco M.
   Costelli, Paola
TI Interference with Ca2+-Dependent Proteolysis Does Not Alter the Course
   of Muscle Wasting in Experimental Cancer Cachexia
SO FRONTIERS IN PHYSIOLOGY
LA English
DT Article
DE muscle protein turnover; calpains; calpastatin; muscle atrophy;
   proteostasis
ID TUMOR-BEARING RATS; ENDOPLASMIC-RETICULUM STRESS; SKELETAL-MUSCLE;
   CALPAIN ACTIVATION; CALPASTATIN; DEGRADATION; PATHWAY; ATROPHY; SYSTEM;
   MICE
AB Protein hypercatabolism significantly contributes to the onset and progression of muscle wasting in cancer cachexia. In this regard, a major role is played by the ATP-ubiquitin-proteasome-dependent pathway and by autophagy. However, little is known about the relevance of the Ca2+-dependent proteolytic system. Since previous results suggested that this pathway is activated in the skeletal muscle of tumor hosts, the present study was aimed to investigate whether inhibition of Ca2+-dependent proteases (calpains) may improve cancer-induced muscle wasting. Two experimental models of cancer cachexia were used, namely the AH-130 Yoshida hepatoma and the C26 colon carcinoma. The Ca2+-dependent proteolytic system was inhibited by treating the animals with dantrolene or by overexpressing in the muscle calpastatin, the physiologic inhibitor of Ca2+-dependent proteases. The results confirm that calpain-1 is overexpressed and calpastatin is reduced in the muscle of rats implanted with the AH-130 hepatoma, and show for the first time that the Ca2+-dependent proteolytic system is overactivated also in the C26-bearing mice. Yet, administration of dantrolene, an inhibitor of the Ca2+-dependent proteases, did not modify tumor-induced body weight loss and muscle wasting in the AH-130 hosts. Dantrolene was also unable to reduce the enhancement of protein degradation rates occurring in rats bearing the AH-130 hepatoma. Similarly, overexpression of calpastatin in the tibialis muscle of the C26 hosts did not improve muscle wasting at all. These observations suggest that inhibiting a single proteolytic system is not a good strategy to contrast cancer-induced muscle wasting. In this regard, a more general and integrated approach aimed at targeting the catabolic stimuli rather than the proteolytic activity of a single pathway would likely be the most appropriate therapeutic intervention.
C1 [Pin, Fabrizio; Minero, Valerio G.; Penna, Fabio; Baccino, Francesco M.; Costelli, Paola] Univ Turin, Dept Clin & Biol Sci, Turin, Italy.
   [Muscaritoli, Maurizio] Sapienza Univ, Dept Clin Med, Rome, Italy.
   [De Tullio, Roberta] Univ Genoa, Dept Expt Med, Genoa, Italy.
RP Costelli, P (corresponding author), Univ Turin, Dept Clin & Biol Sci, Turin, Italy.
EM paola.costelli@unito.it
RI Penna, Fabio/K-5090-2016
OI Penna, Fabio/0000-0002-2774-6027
FU Associazione Italiana per la Ricerca sul Cancro, Milano (PRIN)
   [AIRC-IG9153]; Ministero per I'Universita e la Ricerca, Roma (PRIN);
   University of Torino; Regione PiemonteRegione Piemonte
FX The work was supported by Associazione Italiana per la Ricerca sul
   Cancro (AIRC-IG9153), Milano, Ministero per I'Universita e la Ricerca,
   Roma (PRIN projects), University of Torino (ex-60% funds), and Regione
   Piemonte.
CR Argiles JM, 2014, NAT REV CANCER, V14, P754, DOI 10.1038/nrc3829
   Assi M, 2016, FREE RADICAL BIO MED, V91, P204, DOI 10.1016/j.freeradbiomed.2015.12.019
   BARACOS VE, 1995, AM J PHYSIOL-ENDOC M, V268, pE996, DOI 10.1152/ajpendo.1995.268.5.E996
   Bohnert KR, 2016, FASEB J, V30, P3053, DOI 10.1096/fj.201600250RR
   Bonetto A, 2009, CURR CANCER DRUG TAR, V9, P608, DOI 10.2174/156800909789057015
   Borges F H, 2014, Pathophysiology, V21, P257, DOI 10.1016/j.pathophys.2014.05.003
   Busquets S, 2000, BBA-GEN SUBJECTS, V1475, P5, DOI 10.1016/S0304-4165(00)00050-7
   Chacon-Cabrera A, 2014, J CELL PHYSIOL, V229, P1660, DOI 10.1002/jcp.24611
   COSTELLI P, 1993, J CLIN INVEST, V92, P2783, DOI 10.1172/JCI116897
   Costelli P, 2002, CYTOKINE, V19, P1, DOI 10.1006/cyto.2002.1036
   Costelli P, 2001, BRIT J CANCER, V84, P946, DOI 10.1054/bjoc.2001.1696
   Dargelos E, 2010, EXP CELL RES, V316, P115, DOI 10.1016/j.yexcr.2009.07.025
   De Tullio R, 1999, BIOCHEM J, V343, P467
   De Tullio R, 2000, FEBS LETT, V475, P17, DOI 10.1016/S0014-5793(00)01613-6
   De Tullio R, 2014, BBA-MOL CELL RES, V1843, P2583, DOI 10.1016/j.bbamcr.2014.07.002
   De Tullio R, 2009, BBA-GEN SUBJECTS, V1790, P182, DOI 10.1016/j.bbagen.2008.11.002
   Fermoselle C, 2013, EXP PHYSIOL, V98, P1349, DOI 10.1113/expphysiol.2013.072496
   Goll DE, 2003, PHYSIOL REV, V83, P731, DOI 10.1152/physrev.00029.2002
   Huang JR, 2016, PHYSIOL RES, V65, P547, DOI 10.33549/physiolres.933087
   Isaac ST, 2016, CURR DRUG TARGETS, V17, P1140, DOI 10.2174/1389450116666150416115721
   Langou K, 2010, J NEUROCHEM, V114, P795, DOI 10.1111/j.1471-4159.2010.06806.x
   Lee J. D, 1982, STATISTICAL NUMERICA, V1, P185
   LLOVERA M, 1995, INT J CANCER, V61, P138, DOI 10.1002/ijc.2910610123
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   Malvestio LM, 2017, PARASITOL RES, V116, P429, DOI 10.1007/s00436-016-5281-1
   Mastrocola R, 2008, FREE RADICAL BIO MED, V44, P584, DOI 10.1016/j.freeradbiomed.2007.10.047
   Melloni E, 2006, J BIOL CHEM, V281, P24945, DOI 10.1074/jbc.M601449200
   Muruganandan S, 2006, TOXICOL SCI, V94, P118, DOI 10.1093/toxsci/kfl084
   NIH, 1996, PUBL HLTH SERV POL H
   Ono Y, 2016, NAT REV DRUG DISCOV, V15, P854, DOI 10.1038/nrd.2016.212
   Penna F, 2016, J CACHEXIA SARCOPENI, V7, P345, DOI 10.1002/jcsm.12050
   Penna F, 2013, AM J PATHOL, V182, P1367, DOI 10.1016/j.ajpath.2012.12.023
   Penna F, 2010, INT J CANCER, V127, P1706, DOI 10.1002/ijc.25146
   Perry SW, 2010, J NEUROSCI, V30, P14153, DOI 10.1523/JNEUROSCI.1042-10.2010
   Pigna E, 2016, SCI REP-UK, V6, DOI 10.1038/srep26991
   PONTREMOLI S, 1991, ARCH BIOCHEM BIOPHYS, V288, P646, DOI 10.1016/0003-9861(91)90247-G
   SALAMINO F, 1992, ARCH BIOCHEM BIOPHYS, V298, P287, DOI 10.1016/0003-9861(92)90125-G
   Smith IJ, 2011, MUSCLE NERVE, V43, P410, DOI 10.1002/mus.21893
   Smuder AJ, 2010, FREE RADICAL BIO MED, V49, P1152, DOI 10.1016/j.freeradbiomed.2010.06.025
   Stifanese R, 2008, ARCH BIOCHEM BIOPHYS, V479, P145, DOI 10.1016/j.abb.2008.09.002
   Tardif N, 2013, AM J CLIN NUTR, V98, P1485, DOI 10.3945/ajcn.113.063859
   TEMPARIS S, 1994, CANCER RES, V54, P5568
   TESSITORE L, 1994, BIOCHEM J, V299, P71, DOI 10.1042/bj2990071
   Toledo M, 2016, J CACHEXIA SARCOPENI, V7, P48, DOI 10.1002/jcsm.12035
   Wing SS, 2016, INT J BIOCHEM CELL B, V79, P462, DOI 10.1016/j.biocel.2016.07.028
   Yamaguchi O, 2012, CARDIOVASC RES, V96, P46, DOI 10.1093/cvr/cvs236
NR 46
TC 16
Z9 16
U1 0
U2 2
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015,
   SWITZERLAND
SN 1664-042X
J9 FRONT PHYSIOL
JI Front. Physiol.
PD APR 19
PY 2017
VL 8
AR 213
DI 10.3389/fphys.2017.00213
PG 9
WC Physiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Physiology
GA EW9TZ
UT WOS:000402863600001
PM 28469577
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Wang, L
   Zhang, HP
   Sun, M
   Yin, ZH
   Qian, JH
AF Wang, Li
   Zhang, Huiping
   Sun, Min
   Yin, Zhanghua
   Qian, Jihong
TI High mobility group box 1-mediated autophagy promotes neuroblastoma cell
   chemoresistance
SO ONCOLOGY REPORTS
LA English
DT Article
DE HMGB1; autophagy; Beclin-1; proliferation; invasion; chemoresistance
ID IN-VITRO; REGULATES AUTOPHAGY; COLORECTAL-CANCER; INDUCED APOPTOSIS;
   DRUG-RESISTANCE; 1 HMGB1; EXPRESSION; OSTEOSARCOMA; CARCINOMA; PROTEIN
AB Neuroblastoma (NB) is one of the most common tumors in childhood. Unfortunately, the survival outcomes remain unsatisfactory since NB commonly develops multidrug resistance. Recent studies have demonstrated that the high mobility group box 1 (HMGB1)-mediated autophagy promotes chemoresistance in osteosarcoma, lung adenocarcinoma and ovarian cancer, but the exact molecular mechanism underlying HMGB1-mediated autophagy in NB has not been clearly defined. In the present study, we investigated the role of HMGB1 in the development of resistance to anticancer agents in NB. Anticancer agents including doxorubicin, cisplatin and etoposide each induced HMGB1 upregulation, promoted cytosolic HMGB1 translocation and the elevation of autophagic activity in human NB cells. RNA interference-mediated knockdown of HMGB1 restored the chemosensitivity of NB cells. Furthermore, mechanistic investigation revealed that HMGB1 promoted the proliferative activity and invasive potential of NB cells. HMGB1 enhanced drug resistance by inducing Beclin-l-mediated autophagy, an intracellular self-defense mechanism known to confer drug resistance. In addition, we found that HMGB1 facilitated autophagic progression and reduced oxidative stress induced by doxorubicin. Therefore, through its role as a regulator of autophagy, HMGB1 is a critical factor in the development of chemoresistance and tumorigenesis, and it may be a novel target for improving the efficacy of NB therapy.
C1 [Wang, Li; Zhang, Huiping; Sun, Min; Yin, Zhanghua; Qian, Jihong] Shanghai Jiao Tong Univ, Sch Med, Xinhua Hosp, Dept Neonatol, Shanghai 200092, Peoples R China.
RP Qian, JH (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Xinhua Hosp, Dept Neonatol, 1665 Kongjiang Rd, Shanghai 200092, Peoples R China.
EM qianjh668@163.com
CR BIEDLER JL, 1994, CANCER RES, V54, P666
   Brezniceanu ML, 2003, FASEB J, V17, P1295, DOI 10.1096/fj.02-0621fje
   Chen J, 2012, J CELL PHYSIOL, V227, P3629, DOI 10.1002/jcp.24069
   Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001
   Faraco G, 2007, J NEUROCHEM, V103, P590, DOI 10.1111/j.1471-4159.2007.04788.x
   Fu LL, 2013, INT J BIOCHEM CELL B, V45, P921, DOI 10.1016/j.biocel.2013.02.007
   Furfaro AL, 2014, BBA-MOL BASIS DIS, V1842, P613, DOI 10.1016/j.bbadis.2013.12.008
   Guazzi S, 2003, GENE EXPR PATTERNS, V3, P29, DOI 10.1016/S1567-133X(02)00093-5
   Huang J, 2012, CANCER RES, V72, P230, DOI 10.1158/0008-5472.CAN-11-2001
   Lanvers-Kaminsky C, 2005, ONCOL REP, V14, P751
   Lockshin RA, 2004, INT J BIOCHEM CELL B, V36, P2405, DOI 10.1016/j.biocel.2004.04.011
   Meyer A, 2008, LEUKEMIA LYMPHOMA, V49, P1184, DOI 10.1080/10428190802064909
   Michaelis M, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-80
   Mohan N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078958
   Moreira AC, 2014, BBA-MOL BASIS DIS, V1842, P2468, DOI 10.1016/j.bbadis.2014.09.015
   Murai T, 2001, J BIOL CHEM, V276, P6797, DOI 10.1074/jbc.M009355200
   Pan BZ, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-165
   Pedrazzi M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044518
   Petiot A, 2000, J BIOL CHEM, V275, P992, DOI 10.1074/jbc.275.2.992
   Reismann M, 2009, EUR J PEDIATR SURG, V19, P224, DOI 10.1055/s-0029-1202778
   Shokoohinia Y, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/156848
   Singla Shivani, 2014, Toxicol Int, V21, P191, DOI 10.4103/0971-6580.139808
   Suren D, 2014, MED SCI MONITOR, V20, P530, DOI 10.12659/MSM.890531
   Tang D, 2010, ONCOGENE, V29, P5299, DOI 10.1038/onc.2010.261
   Tang DL, 2011, CELL METAB, V13, P701, DOI 10.1016/j.cmet.2011.04.008
   Tang DL, 2010, J CELL BIOL, V190, P881, DOI 10.1083/jcb.200911078
   Tonini GP, 2006, CURR PHARM DESIGN, V12, P2303, DOI 10.2174/138161206777585193
   Ueda M, 2014, ANTICANCER RES, V34, P5357
   Wang L, 2014, BIOCHEM BIOPH RES CO, V448, P448, DOI 10.1016/j.bbrc.2014.04.120
   Wittig JC, 2002, AM FAM PHYSICIAN, V65, P1123
   Wu D, 2008, J PATHOL, V216, P167, DOI 10.1002/path.2391
   Yang S, 2014, J LEUKOCYTE BIOL, V95, P563, DOI 10.1189/jlb.0713412
   Yang YH, 2014, FREE RADICAL BIO MED, V77, P10, DOI 10.1016/j.freeradbiomed.2014.08.028
   Yang YH, 2013, APOPTOSIS, V18, P1363, DOI 10.1007/s10495-013-0867-x
   Zhang L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110626
   Zhang Y, 2012, ONCOGENE, V31, P1055, DOI 10.1038/onc.2011.290
   Zhao ZF, 2014, INT J MOL MED, V33, P271, DOI 10.3892/ijmm.2013.1578
   Zhou Y, 2014, SCI REP-UK, V4, DOI 10.1038/srep05382
NR 38
TC 26
Z9 28
U1 0
U2 9
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1021-335X
EI 1791-2431
J9 ONCOL REP
JI Oncol. Rep.
PD DEC
PY 2015
VL 34
IS 6
BP 2969
EP 2976
DI 10.3892/or.2015.4278
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA CV9OR
UT WOS:000364617000019
PM 26397184
OA Bronze
DA 2022-04-25
ER

PT J
AU Gao, H
   Shi, XF
   Chen, QQ
   Che, BC
   Yin, HJ
   Li, YX
AF Gao, Hao
   Shi, Xiafei
   Chen, Qianqian
   Che, Bochen
   Yin, Huijuan
   Li, Yingxin
TI Deep proteome profiling of SW837 cells treated by photodynamic therapy
   (PDT) reveals the underlying mechanisms of metronomic and acute PDTs
SO PHOTODIAGNOSIS AND PHOTODYNAMIC THERAPY
LA English
DT Article
DE Metronomic photodynamic therapy; Acute photodynamic therapy; Colorectal
   cancer; Proteome; SWATH-MS; Differentially expressed protein
ID COLORECTAL-CANCER TREATMENT; OF-THE-ART; A431 CELLS; DEATH; CARCINOMA;
   APOPTOSIS; PATHWAYS; DESFERRIOXAMINE; PHOTOFRIN; AUTOPHAGY
AB Aim: Metronomic photodynamic therapy (mPDT) with a longer irradiation time and lower energy compared with acute (or classic) photodynamic therapy (aPDT) is a more effective treatment than aPDT for tumor cells, especially colorectal cancer. However, the underlying mechanisms of the superior effects of mPDT are unknown.
   Methods: we used SWATH-MS (sequential window acquisition of all theoretical mass spectra) to identify differentially expressed proteins (DEPs) specific to aPDT (conventional fluence rate, 20 mW/cm(2), 4 min 10 s), mPDT (metronomic fluence rate, 0.4 mW/cm(2), 3.5 h), and control groups of SW837 cells. The photosensitizer used in both PDT methods was aminolevulinic acid which were incubated with the cells before irradiation.
   Results: A total of 6805 proteins were identified in the three groups of SW837 cells. aPDT induced 333 DEPs and mPDT induced 1716 DEPs compared with the control. We identified 185 common DEPs in the two PDT groups, 148 different DEPs in the aPDT group, and 1531 different DEPs in the mPDT group. Most of the 185 common DEPs were involved in the extracellular component, participated in the processes of vesicle transport and secretion, binding, and hydrolase/catalytic activity. They were also involved in PI3K-Akt, cGMP-PKG, RAS, and aAMP signaling pathways. In addition, the 1531 different DEPs in the mPDT group participated in similar processes and molecular functions, but in a more complex manner than those in the aPDT group.
   Conclusion: our proteome data suggest that mPDT has a complex tumor destruction mechanism with more involved proteins compared with aPDT, which may explain the better tumor killing effect of mPDT.
C1 [Gao, Hao] Tianjin Peoples Hosp, Dept Colorectal Surg, Tianjin Union Med Ctr, 190 Jieyuan Rd, Tianjin 300121, Peoples R China.
   [Shi, Xiafei; Chen, Qianqian; Che, Bochen; Yin, Huijuan; Li, Yingxin] Chinese Acad Med Sci & Peking Union Med Coll, Lab Laser Med, Inst Biomed Engn, 236 Baidi Rd, Tianjin 300192, Peoples R China.
RP Yin, HJ (corresponding author), Chinese Acad Med Sci & Peking Union Med Coll, Lab Laser Med, Inst Biomed Engn, 236 Baidi Rd, Tianjin 300192, Peoples R China.
EM yinzi490@163.com
FU Fund Program "CAMS Initiative for Innovative Medicine" [2018-I2M-AI-011]
FX We thank the Fund Program "CAMS Initiative for Innovative Medicine to
   H.Y. (2018-I2M-AI-011)" for support.
CR Agostinis P, 2011, CA-CANCER J CLIN, V61, P250, DOI 10.3322/caac.20114
   Bisland SK, 2004, PHOTOCHEM PHOTOBIOL, V80, P22, DOI 10.1562/2004-03-05-RA-100.1
   Busch TM, 2006, LASER SURG MED, V38, P494, DOI 10.1002/lsm.20355
   Buytaert E, 2007, BBA-REV CANCER, V1776, P86, DOI 10.1016/j.bbcan.2007.07.001
   Cao H, 2015, PATHOL RES PRACT, V211, P557, DOI 10.1016/j.prp.2015.05.010
   Castano AP, 2006, NAT REV CANCER, V6, P535, DOI 10.1038/nrc1894
   Dolmans DEJGJ, 2003, NAT REV CANCER, V3, P380, DOI 10.1038/nrc1071
   Gao H, 2016, J PHOTOCH PHOTOBIO B, V163, P162, DOI 10.1016/j.jphotobiol.2016.08.038
   HANANIA J, 1992, CANCER LETT, V65, P127, DOI 10.1016/0304-3835(92)90156-P
   HE XY, 1994, PHOTOCHEM PHOTOBIOL, V59, P468, DOI 10.1111/j.1751-1097.1994.tb05066.x
   Hsieh YJ, 2010, J CELL BIOCHEM, V111, P821, DOI 10.1002/jcb.22767
   Hsieh YJ, 2003, J CELL PHYSIOL, V194, P363, DOI 10.1002/jcp.10273
   Karczmarski J, 2014, CLIN PROTEOM, V11, DOI 10.1186/1559-0275-11-24
   Kawczyk-Krupka A, 2016, PHOTODIAGN PHOTODYN, V13, P158, DOI 10.1016/j.pdpdt.2015.07.175
   Kawczyk-Krupka A, 2015, PHOTODIAGN PHOTODYN, V12, P545, DOI 10.1016/j.pdpdt.2015.04.004
   LOH CS, 1994, ENDOSCOPY, V26, P243, DOI 10.1055/s-2007-1008952
   Luo Y, 1997, PHOTOCHEM PHOTOBIOL, V66, P479, DOI 10.1111/j.1751-1097.1997.tb03176.x
   Magi B, 2004, CELL DEATH DIFFER, V11, P842, DOI 10.1038/sj.cdd.4401427
   Moor ACE, 2000, J PHOTOCH PHOTOBIO B, V57, P1, DOI 10.1016/S1011-1344(00)00065-8
   Nakamura T, 2003, GASTROINTEST ENDOSC, V57, P266, DOI 10.1067/mge.2003.57
   Noodt BB, 1996, BRIT J CANCER, V74, P22, DOI 10.1038/bjc.1996.310
   Peng LY, 2018, MOL OMICS, V14, P405, DOI 10.1039/c8mo00126j
   Pye A, 2007, PHOTOCHEM PHOTOBIOL, V83, P766, DOI 10.1562/2006-05-30-RA-906
   de Souza ALR, 2016, BRIT J CANCER, V115, P805, DOI 10.1038/bjc.2016.267
   Rosenberger G, 2014, SCI DATA, V1, DOI 10.1038/sdata.2014.31
   Sakharov DV, 2005, FEBS LETT, V579, P1255, DOI 10.1016/j.febslet.2005.01.024
   Schubert OT, 2015, NAT PROTOC, V10, DOI 10.1038/nprot.2015.015
   Shen HX, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-34904-8
   Shi XF, 2018, J PHOTOCH PHOTOBIO B, V181, P143, DOI 10.1016/j.jphotobiol.2018.03.012
   Shi XF, 2019, J PHOTOCH PHOTOBIO B, V198, DOI 10.1016/j.jphotobiol.2019.111586
   Singh G, 2010, METHODS MOL BIOL, V635, P65, DOI 10.1007/978-1-60761-697-9_5
   Tu PH, 2016, ONCOL REP, V35, P3209, DOI 10.3892/or.2016.4703
   Uzdensky A, 2015, MOL NEUROBIOL, V52, P811, DOI 10.1007/s12035-015-9237-8
   Woods JA, 2004, PHOTOCHEM PHOTOBIOL, V79, P105, DOI 10.1562/0031-8655(2004)79<105:TEOPOD>2.0.CO;2
   Xie JJ, 2019, J PHOTOCH PHOTOBIO B, V194, P46, DOI 10.1016/j.jphotobiol.2019.03.012
   Yamagishi K, 2019, NAT BIOMED ENG, V3, P27, DOI 10.1038/s41551-018-0261-7
   Ye YB, 2013, PROTEOM CLIN APPL, V7, P403, DOI 10.1002/prca.201100103
   Zhou ZW, 2015, DRUG DES DEV THER, V9, P1511, DOI 10.2147/DDDT.S75976
NR 38
TC 0
Z9 0
U1 1
U2 5
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1572-1000
EI 1873-1597
J9 PHOTODIAGN PHOTODYN
JI Photodiagnosis Photodyn. Ther.
PD SEP
PY 2020
VL 31
AR 101809
DI 10.1016/j.pdpdt.2020.101809
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA NZ2QQ
UT WOS:000576941600004
PM 32437970
DA 2022-04-25
ER

PT J
AU Levy, J
   Cacheux, W
   Bara, MA
   L'Hermitte, A
   Lepage, P
   Fraudeau, M
   Trentesaux, C
   Lemarchand, J
   Durand, A
   Crain, AM
   Marchiol, C
   Renault, G
   Dumont, F
   Letourneur, F
   Delacres, M
   Schmitt, A
   Terris, B
   Perret, C
   Chamaillard, M
   Couty, JP
   Romagnolo, B
AF Levy, Jonathan
   Cacheux, Walfran
   Bara, Medhi Ait
   L'Hermitte, Antoine
   Lepage, Patricia
   Fraudeau, Marie
   Trentesaux, Coralie
   Lemarchand, Julie
   Durand, Aurelie
   Crain, Anne-Marie
   Marchiol, Carmen
   Renault, Gilles
   Dumont, Florent
   Letourneur, Franck
   Delacres, Myriam
   Schmitt, Alain
   Terris, Benoit
   Perret, Christine
   Chamaillard, Mathias
   Couty, Jean-Pierre
   Romagnolo, Beatrice
TI Intestinal inhibition of Atg7 prevents tumour initiation through a
   microbiome-influenced immune response and suppresses tumour growth
SO NATURE CELL BIOLOGY
LA English
DT Article
ID AUTOPHAGY GENE ATG16L1; REGULATORY T-CELLS; TUMORIGENESIS; CANCER; MICE;
   INFLAMMATION; MOUSE; PROGRESSION; ACTIVATION; EXPRESSION
AB Here, we show that autophagy is activated in the intestinal epithelium in murine and human colorectal cancer and that the conditional inactivation of Atg7 in intestinal epithelial cells inhibits the formation of pre-cancerous lesions in Apc(+/-) mice by enhancing anti-tumour responses. The antibody-mediated depletion of CD8(+) T cells showed that these cells are essential for the anti-tumoral responses mediated by the inhibition of autophagy. We show that Atg7 deficiency leads to intestinal dysbiosis and that the microbiota is required for anticancer responses. In addition, Atg7 deficiency resulted in a stress response accompanied by metabolic defects, AMPK activation and p53-mediated cell-cycle arrest in tumour cells but not in normal tissue. This study reveals that the inhibition of autophagy within the epithelium may prevent the development and progression of colorectal cancer in genetically predisposed patients.
C1 [Levy, Jonathan; Cacheux, Walfran; Bara, Medhi Ait; L'Hermitte, Antoine; Fraudeau, Marie; Trentesaux, Coralie; Lemarchand, Julie; Durand, Aurelie; Crain, Anne-Marie; Marchiol, Carmen; Renault, Gilles; Dumont, Florent; Letourneur, Franck; Schmitt, Alain; Terris, Benoit; Perret, Christine; Couty, Jean-Pierre; Romagnolo, Beatrice] Univ Paris 05, CNRS, Inst Cochin, UMR8104, F-75014 Paris, France.
   [Levy, Jonathan; Cacheux, Walfran; Bara, Medhi Ait; L'Hermitte, Antoine; Fraudeau, Marie; Trentesaux, Coralie; Lemarchand, Julie; Durand, Aurelie; Crain, Anne-Marie; Marchiol, Carmen; Renault, Gilles; Dumont, Florent; Letourneur, Franck; Schmitt, Alain; Terris, Benoit; Perret, Christine; Couty, Jean-Pierre; Romagnolo, Beatrice] Inst Natl Sante & Rech Med INSFRM, U1016, F-75014 Paris, France.
   [Cacheux, Walfran] Inst Curie, Dept Med Oncol, F-75248 Paris 05, France.
   [Cacheux, Walfran] Inst Curie, Dept Genet, Pharmacogen Unit, F-75248 Paris 05, France.
   [Lepage, Patricia] INRA, Micalis UMR1319, F-78352 Jouy En Josas, France.
   [Lepage, Patricia] AgroParis Tech, Micalis UMR1319, F-78350 Jouy En Josas, France.
   [Crain, Anne-Marie; Couty, Jean-Pierre] Univ Paris Diderot, Sorbonne Paris Cite, UFR Sci Vivant, F-75013 Paris, France.
   [Delacres, Myriam; Chamaillard, Mathias] Univ Lille Nord France, F-59000 Lille, France.
   [Delacres, Myriam; Chamaillard, Mathias] Ctr Infect & Immun Lille, Inst Pasteur Lille, F-59800 Lille, France.
   [Delacres, Myriam; Chamaillard, Mathias] CNRS, Unite Mixle Rech, F-59046 Lille, France.
   [Delacres, Myriam; Chamaillard, Mathias] Inst Nat Sante & Rech Med, F-59045 Lille, France.
   [Terris, Benoit] Univ Paris 05, Hop Cochin, AP HP, Serv Anat & Cytol Pathol, F-75014 Paris, France.
RP Romagnolo, B (corresponding author), Univ Paris 05, CNRS, Inst Cochin, UMR8104, F-75014 Paris, France.
EM beatrice.romagnolo@inserm.fr
RI Romagnolo, Béatrice/D-5017-2017; Lepage, Patricia/D-4362-2014;
   Chamaillard, Mathias/L-6542-2013; Couty, Jean-Pierre/P-5268-2017;
   Terris, Benoit/P-1497-2017; Perret-Mayeux, Christine/L-3297-2017
OI Romagnolo, Béatrice/0000-0001-8772-3604; Lepage,
   Patricia/0000-0002-9501-6771; Chamaillard, Mathias/0000-0002-0243-9717;
   Marchiol, Carmen/0000-0002-9666-7939; Renault,
   Gilles/0000-0003-2273-1229; COUTY, Jean-Pierre/0000-0003-3492-9136;
   Trentesaux, Coralie/0000-0003-3387-4890; perret,
   christine/0000-0003-4710-7051
FU Institut National du CancerInstitut National du Cancer (INCA) France;
   Comite de Paris de la Ligue Contre le Cancer; Cancer Research
   Personalized Medicine (CARPEM); Poste d'acceuil INSERM; Ministere de la
   Recherche et de la Technologie; la Fondation Arc; InsermInstitut
   National de la Sante et de la Recherche Medicale (Inserm)European
   Commission; Fondation pour la Recherche Medicale ('Equipe FRM')Fondation
   pour la Recherche Medicale
FX We thank M. Komatsu (Niigata University, Japan) and S. Robine (Institut
   Curie, France) for a generous supply of mutant mice, S. Pham, P.
   Mariani, Y. Bieche, S. Vacher, B. Violet, M. Foretz, B. Radenen-Bussiere
   and V. Maillet for technical help and for helpful discussions. We are
   grateful to the staff of Cochin's animal housing facility and in
   particular to F. Lager and I. Lagoutte. This work was supported by
   Institut National du Cancer, the Comite de Paris de la Ligue Contre le
   Cancer, la Fondation Arc, and by the Cancer Research Personalized
   Medicine (CARPEM). W.C. was supported by Poste d'acceuil INSERM, M.F.
   and F.D. by CARPEM, and J.L. held a fellowship from the Ministere de la
   Recherche et de la Technologie and was also financially supported by la
   Fondation Arc. This work was also supported by funds from Inserm and by
   grants from the Fondation pour la Recherche Medicale ('Equipe FRM 2013'
   to M.C.).
CR Andreu P, 2005, DEVELOPMENT, V132, P1443, DOI 10.1242/dev.01700
   Benjamin JL, 2013, CELL HOST MICROBE, V13, P723, DOI 10.1016/j.chom.2013.05.004
   Berg DJ, 1996, J CLIN INVEST, V98, P1010, DOI 10.1172/JCI118861
   Berkers CR, 2013, CELL METAB, V18, P617, DOI 10.1016/j.cmet.2013.06.019
   Cadwell K, 2008, NATURE, V456, P259, DOI 10.1038/nature07416
   Cadwell K, 2009, CURR TOP MICROBIOL, V335, P141, DOI 10.1007/978-3-642-00302-8_7
   Caporaso JG, 2010, NAT METHODS, V7, P335, DOI 10.1038/nmeth.f.303
   Castellino F, 2006, ANNU REV IMMUNOL, V24, P519, DOI 10.1146/annurev.immunol.23.021704.115825
   Cerovic V, 2014, TRENDS IMMUNOL, V35, P270, DOI 10.1016/j.it.2014.04.003
   Cole JR, 2009, NUCLEIC ACIDS RES, V37, pD141, DOI 10.1093/nar/gkn879
   Colnot S, 2004, LAB INVEST, V84, P1619, DOI 10.1038/labinvest.3700180
   Conway KL, 2013, GASTROENTEROLOGY, V145, P1347, DOI 10.1053/j.gastro.2013.08.035
   Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001
   Dunn GP, 2006, NAT REV IMMUNOL, V6, P836, DOI 10.1038/nri1961
   Fujishita T, 2008, P NATL ACAD SCI USA, V105, P13544, DOI 10.1073/pnas.0800041105
   Gao Q, 2007, J CLIN ONCOL, V25, P2586, DOI 10.1200/JCO.2006.09.4565
   Ghiringhelli F, 2009, NAT MED, V15, P1170, DOI 10.1038/nm.2028
   Grimm WA, GUT
   Guo JY, 2013, GENE DEV, V27, P1447, DOI 10.1101/gad.219642.113
   Hu B, 2013, P NATL ACAD SCI USA, V110, P9862, DOI 10.1073/pnas.1307575110
   Iida N, 2013, SCIENCE, V342, P967, DOI 10.1126/science.1240527
   Komatsu M, 2005, J CELL BIOL, V169, P425, DOI 10.1083/jcb.200412022
   Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784
   Lepage P, 2005, INFLAMM BOWEL DIS, V11, P473, DOI 10.1097/01.MIB.0000159662.62651.06
   Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257
   Loddenkemper C, 2006, J TRANSL MED, V4, DOI 10.1186/1479-5876-4-52
   Marchiando AM, 2013, CELL HOST MICROBE, V14, P216, DOI 10.1016/j.chom.2013.07.013
   Mathew R, 2007, NAT REV CANCER, V7, P961, DOI 10.1038/nrc2254
   Mathew R, 2009, CELL, V137, P1062, DOI 10.1016/j.cell.2009.03.048
   Michaud M, 2011, SCIENCE, V334, P1573, DOI 10.1126/science.1208347
   Mlecnik B, 2010, GASTROENTEROLOGY, V138, P1429, DOI 10.1053/j.gastro.2009.10.057
   Murai M, 2009, NAT IMMUNOL, V10, P1178, DOI 10.1038/ni.1791
   Pages F, 2005, NEW ENGL J MED, V353, P2654, DOI 10.1056/NEJMoa051424
   Patel KK, 2013, EMBO J, V32, P3130, DOI 10.1038/emboj.2013.233
   Paulos CM, 2007, J CLIN INVEST, V117, P2197, DOI 10.1172/JCI32205
   Peignon G, 2011, GUT, V60, P166, DOI 10.1136/gut.2009.204719
   Petherick KJ, 2013, EMBO J, V32, P1903, DOI 10.1038/emboj.2013.123
   Rao S, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4056
   Rosenfeldt MT, 2013, NATURE, V504, P296, DOI 10.1038/nature12865
   Ruffell B, 2014, CANCER CELL, V26, P623, DOI 10.1016/j.ccell.2014.09.006
   Sansom OJ, 2004, GENE DEV, V18, P1385, DOI 10.1101/gad.287404
   Sato E, 2005, P NATL ACAD SCI USA, V102, P18538, DOI 10.1073/pnas.0509182102
   Segata N, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-6-r60
   Seksik P, 2003, GUT, V52, P237, DOI 10.1136/gut.52.2.237
   Serebrennikova OB, 2012, P NATL ACAD SCI USA, V109, pE1082, DOI 10.1073/pnas.1115098109
   Strohecker AM, 2013, CANCER DISCOV, V3, P1272, DOI 10.1158/2159-8290.CD-13-0397
   Tjalsma H, 2012, NAT REV MICROBIOL, V10, P575, DOI 10.1038/nrmicro2819
   Toes REM, 1999, J EXP MED, V189, P753, DOI 10.1084/jem.189.5.753
   Tosolini M, 2011, CANCER RES, V71, P1263, DOI 10.1158/0008-5472.CAN-10-2907
   Viaud S, 2013, SCIENCE, V342, P971, DOI 10.1126/science.1240537
   Wei HJ, 2011, GENE DEV, V25, P1510, DOI 10.1101/gad.2051011
   Weigmann B, 2007, NAT PROTOC, V2, P2307, DOI 10.1038/nprot.2007.315
   Xiao H, 2010, GASTROENTEROLOGY, V139, P574, DOI 10.1053/j.gastro.2010.04.043
   Yang A, 2014, CANCER DISCOV, V4, P905, DOI 10.1158/2159-8290.CD-14-0362
   Yang SH, 2011, GENE DEV, V25, P717, DOI 10.1101/gad.2016111
   Zeineldin M, 2013, BBA-REV CANCER, V1836, P80, DOI 10.1016/j.bbcan.2013.01.001
   Zhan Y, 2013, CANCER RES, V73, P7199, DOI 10.1158/0008-5472.CAN-13-0827
   Zhou GC, 2001, J CLIN INVEST, V108, P1167, DOI 10.1172/JCI200113505
NR 58
TC 104
Z9 107
U1 1
U2 50
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1465-7392
EI 1476-4679
J9 NAT CELL BIOL
JI Nat. Cell Biol.
PD AUG
PY 2015
VL 17
IS 8
BP 1062
EP U440
DI 10.1038/ncb3206
PG 24
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA CO0NE
UT WOS:000358847700013
PM 26214133
DA 2022-04-25
ER

PT J
AU Kim, D
   Choi, BH
   Ryoo, IG
   Kwak, MK
AF Kim, Donghyeok
   Choi, Bo-hyun
   Ryoo, In-geun
   Kwak, Mi-Kyoung
TI High NRF2 level mediates cancer stem cell-like properties of aldehyde
   dehydrogenase (ALDH)-high ovarian cancer cells: inhibitory role of
   all-trans retinoic acid in ALDH/NRF2 signaling
SO CELL DEATH & DISEASE
LA English
DT Article
ID TRANSCRIPTION FACTOR NRF2; INITIATING CELLS; RESISTANCE; AUTOPHAGY;
   ACTIVATION; THERAPY; IDENTIFICATION; CHEMOTHERAPY; EXPRESSION; PATHWAY
AB Aldehyde dehydrogenase 1A1 (ALDH1A1) is one of cancer stem cell (CSC) markers, and high ALDH1 expression has been related to drug resistance and facilitated tumor growth. In this study, we investigated the potential involvement of nuclear factor erythroid 2-like 2 (NFE2L2/NRF2) in CSC-like properties of ALDH-high ovarian CSCs. Our experimental system, ALDH1A1-high (ALDH-H) subpopulation, was isolated and stabilized using doxorubicin-resistant ovarian cancer A2780 cells. ALDH-H exerted CSC-like properties such as drug resistance, colony/sphere formation, and enhanced tumor growth along with high levels of CSCs markers compared to ALDH1A1-low (ALDH-L). Levels of NRF2 and subsequent target genes substantially increased in ALDH-H cells, and the increase in ALDH1A1 and p62 was associated with NRF2 upregulation. ALDH1A1-silencing blocked increases in NRF2, drug efflux transporters, and p62, along with CSC markers in ALDH-H cells. The inhibition of p62, which was elevated in ALDH-H, suppressed NRF2 activation. High NRF2 level was confirmed in the ALDH1-high subpopulation from colon cancer HCT116 cells. The functional implication of NRF2 activation in ovarian CSCs was verified by two experimental approaches. First, CSC-like properties such as high CSC markers, chemoresistance, colony/sphere formation, and tumor growth were significantly inhibited by NRF2-silencing in ALDH-H cells. Second, all-trans retinoic acid (ATRA) suppressed ALDH1 expression, inhibiting NRF2 activation, which led to the attenuation of CSC-like properties in ALDH-H cells but not in ALDH-L cells. These results provide insight into the molecular basis of the ALDH1A1-mediated development of CSC-like properties such as stress/treatment resistance, and further suggest the therapeutic potential of ATRA in ALDH-high ovarian CSCs.
C1 [Kim, Donghyeok; Choi, Bo-hyun; Kwak, Mi-Kyoung] Catholic Univ Korea, Grad Sch, Dept Pharm, 43 Jibong Ro, Bucheon 14662, Gyeonggi Do, South Korea.
   [Ryoo, In-geun; Kwak, Mi-Kyoung] Catholic Univ Korea, Integrated Res Inst Pharmaceut Sci, 43 Jibong Ro, Bucheon 14662, Gyeonggi Do, South Korea.
   [Kwak, Mi-Kyoung] Catholic Univ Korea, Coll Pharm, 43 Jibong Ro, Bucheon 14662, Gyeonggi Do, South Korea.
RP Kwak, MK (corresponding author), Catholic Univ Korea, Grad Sch, Dept Pharm, 43 Jibong Ro, Bucheon 14662, Gyeonggi Do, South Korea.; Kwak, MK (corresponding author), Catholic Univ Korea, Integrated Res Inst Pharmaceut Sci, 43 Jibong Ro, Bucheon 14662, Gyeonggi Do, South Korea.
EM mkwak@catholic.ac.kr
FU National Research Foundation of Korea (NRF) - Korea government (MSIP)
   [NRF-2015R1A2A1A10054384, NRF-2013M3A9B5075839]; BK21Plus grant of NRF -
   Korean government [22A20130012250]
FX This study was financially supported by a grant from the National
   Research Foundation of Korea (NRF) funded by the Korea government (MSIP;
   NRF-2015R1A2A1A10054384, NRF-2013M3A9B5075839). This study was also
   supported by the BK21Plus grant of NRF funded by Korean government
   (22A20130012250).
CR Achuthan S, 2011, J BIOL CHEM, V286, P37813, DOI 10.1074/jbc.M110.200675
   Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100
   Alison MR, 2010, J CELL SCI, V123, P2357, DOI 10.1242/jcs.054296
   Armstrong L, 2004, STEM CELLS, V22, P1142, DOI 10.1634/stemcells.2004-0170
   Ayub TH, 2015, ONCOTARGET, V6, P16437, DOI 10.18632/oncotarget.4103
   Bae SH, 2013, CELL METAB, V17, P73, DOI 10.1016/j.cmet.2012.12.002
   Bertolini G, 2009, P NATL ACAD SCI USA, V106, P16281, DOI 10.1073/pnas.0905653106
   Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730
   Chang B, 2009, MODERN PATHOL, V22, P817, DOI 10.1038/modpathol.2009.35
   Cojoc M, 2015, SEMIN CANCER BIOL, V31, P16, DOI 10.1016/j.semcancer.2014.06.004
   Condello S, 2015, ONCOGENE, V34, P2297, DOI 10.1038/onc.2014.178
   Crowe DL, 1998, CANCER RES, V58, P142
   Dragnev KH, 2003, CANCER BIOL THER, V2, pS150
   Duong HQ, 2012, INT J ONCOL, V41, P855, DOI 10.3892/ijo.2012.1516
   Emmink BL, 2013, J PROTEOMICS, V91, P84, DOI 10.1016/j.jprot.2013.06.027
   Frank NY, 2010, J CLIN INVEST, V120, P41, DOI 10.1172/JCI41004
   Galavotti S, 2013, ONCOGENE, V32, P699, DOI 10.1038/onc.2012.111
   Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014
   Gong C, 2013, ONCOGENE, V32, P2261, DOI 10.1038/onc.2012.252
   Guan JL, 2013, AUTOPHAGY, V9, P830, DOI 10.4161/auto.24132
   Hayes JD, 2009, TRENDS BIOCHEM SCI, V34, P176, DOI 10.1016/j.tibs.2008.12.008
   Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943
   Januchowski R, 2016, INT J BIOCHEM CELL B, V78, P248, DOI 10.1016/j.biocel.2016.07.017
   Jaramillo MC, 2013, GENE DEV, V27, P2179, DOI 10.1101/gad.225680.113
   Jiang F, 2009, MOL CANCER RES, V7, P330, DOI 10.1158/1541-7786.MCR-08-0393
   Jung KA, 2015, MOL PHARMACOL, V87, P465, DOI 10.1124/mol.114.096065
   Komatsu M, 2010, NAT CELL BIOL, V12, P213, DOI 10.1038/ncb2021
   Kulsum S, 2017, MOL CARCINOGEN, V56, P694, DOI 10.1002/mc.22526
   Landen CN, 2010, MOL CANCER THER, V9, P3186, DOI 10.1158/1535-7163.MCT-10-0563
   Lau A, 2010, MOL CELL BIOL, V30, P3275, DOI 10.1128/MCB.00248-10
   Le Magnen C, 2013, CLIN CANCER RES, V19, P5361, DOI 10.1158/1078-0432.CCR-12-2857
   Liu SY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081050
   Magni M, 1996, BLOOD, V87, P1097, DOI 10.1182/blood.V87.3.1097.bloodjournal8731097
   Mirza N, 2006, CANCER RES, V66, P9299, DOI 10.1158/0008-5472.CAN-06-1690
   Moreb JS, 2017, CANCER CHEMOTH PHARM, V79, P295, DOI 10.1007/s00280-016-3213-5
   Moreb JS, 2005, J PHARMACOL EXP THER, V312, P339, DOI 10.1124/jpet.104.072496
   Pattabiraman DR, 2014, NAT REV DRUG DISCOV, V13, P497, DOI 10.1038/nrd4253
   Ponti D, 2005, CANCER RES, V65, P5506, DOI 10.1158/0008-5472.CAN-05-0626
   Raha D, 2014, CANCER RES, V74, P3579, DOI 10.1158/0008-5472.CAN-13-3456
   Rao R, 2012, MOL CANCER THER, V11, P973, DOI 10.1158/1535-7163.MCT-11-0979
   Rausch V, 2012, J PATHOL, V227, P325, DOI 10.1002/path.3994
   Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384
   Roy M, 2018, HUM PATHOL, V73, P1, DOI 10.1016/j.humpath.2017.06.025
   Ryoo IG, 2018, REDOX BIOL, V17, P246, DOI 10.1016/j.redox.2018.04.015
   Ryoo IG, 2016, BIOMOL THER, V24, P482, DOI 10.4062/biomolther.2016.145
   Ryoo IG, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/2428153
   Ryoo IG, 2015, ONCOTARGET, V6, P8167, DOI 10.18632/oncotarget.3047
   Shim GS, 2009, FREE RADICAL BIO MED, V47, P1619, DOI 10.1016/j.freeradbiomed.2009.09.006
   Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128
   Singh S, 2013, FREE RADICAL BIO MED, V56, P89, DOI 10.1016/j.freeradbiomed.2012.11.010
   Tallman MS, 1997, NEW ENGL J MED, V337, P1021, DOI 10.1056/NEJM199710093371501
   Umemura A, 2016, CANCER CELL, V29, P935, DOI 10.1016/j.ccell.2016.04.006
   van den Hoogen C, 2010, CANCER RES, V70, P5163, DOI 10.1158/0008-5472.CAN-09-3806
   Wang XJ, 2007, P NATL ACAD SCI USA, V104, P19589, DOI 10.1073/pnas.0709483104
   Wang YC, 2012, AM J PATHOL, V180, P1159, DOI 10.1016/j.ajpath.2011.11.015
   Whitworth JM, 2012, GYNECOL ONCOL, V125, P226, DOI 10.1016/j.ygyno.2011.12.425
   Wu SB, 2013, BIOCHEM BIOPH RES CO, V434, P898, DOI 10.1016/j.bbrc.2013.04.053
   Wu TD, 2015, MOL CARCINOGEN, V54, P1494, DOI 10.1002/mc.22202
   Xu LZ, 2017, ONCOGENE, V36, P304, DOI 10.1038/onc.2016.202
   Ying M, 2011, ONCOGENE, V30, P3454, DOI 10.1038/onc.2011.58
   Young MJ, 2015, CARCINOGENESIS, V36, P498, DOI 10.1093/carcin/bgv018
   Zhu JH, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-380
NR 62
TC 47
Z9 48
U1 1
U2 7
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-4889
J9 CELL DEATH DIS
JI Cell Death Dis.
PD AUG 30
PY 2018
VL 9
AR 896
DI 10.1038/s41419-018-0903-4
PG 17
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA GT8YO
UT WOS:000444826200011
PM 30166520
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Kim, HS
   Quon, MJ
   Kim, JA
AF Kim, Hae-Suk
   Quon, Michael J.
   Kim, Jeong-a
TI New insights into the mechanisms of polyphenols beyond antioxidant
   properties; lessons from the green tea polyphenol, epigallocatechin
   3-gallate
SO REDOX BIOLOGY
LA English
DT Review
DE Polyphenol; EGCG; Anti-oxidant; Pro-oxidant
ID COLON-CANCER CELLS; 67-KDA LAMININ RECEPTOR; NITRIC-OXIDE SYNTHASE;
   ACTIVATED PROTEIN-KINASE; GROWTH-FACTOR RECEPTOR; FACTOR-BETA-RECEPTOR;
   SMOOTH-MUSCLE-CELLS; HIGH-FAT DIET; (-)-EPIGALLOCATECHIN GALLATE;
   INSULIN-RESISTANCE
AB Green tea is rich in polyphenol flavonoids including catechins. Epigallocatechin 3-gallate (EGCG) is the most abundant and potent green tea catechin. EGCG has been extensively studied for its beneficial health effects as a nutriceutical agent. Based upon its chemical structure, EGCG is often classified as an antioxidant However, treatment of cells with EGCG results in production of hydrogen peroxide and hydroxyl radicals in the presence of Fe (III). Thus, EGCG functions as a pro-oxidant in some cellular contexts. Recent investigations have revealed many other direct actions of EGCG that are independent from anti-oxidative mechanisms. In this review, we discuss these novel molecular mechanisms of action for EGCG. In particular, EGCG directly interacts with proteins and phospholipids in the plasma membrane and regulates signal transduction pathways, transcription factors, DNA methylation, mitochonclrial function, and autophagy to exert many of its beneficial biological actions. (C) 2014 The Authors. Published by Elsevier B.V. All rights reserved.
C1 [Kim, Hae-Suk; Kim, Jeong-a] Univ Alabama Birmingham, Div Endocrinol Diabet & Metab, Dept Med, UAB Comprehens Diabet Ctr, Birmingham, AL 35294 USA.
   [Kim, Jeong-a] Univ Alabama Birmingham, UAB Comprehens Diabet Ctr, Dept Cell Dev & Integrat Biol, Birmingham, AL 35294 USA.
   [Quon, Michael J.] Univ Maryland, Sch Med, Dept Med, Div Endocrinol Diabet & Nutr, Baltimore, MD 21201 USA.
RP Kim, JA (corresponding author), Univ Alabama Birmingham, Div Endocrinol Diabet & Metab, Dept Med, UAB Comprehens Diabet Ctr, Birmingham, AL 35294 USA.
EM jakim@uab.edu
OI QUON, MICHAEL/0000-0002-5289-3707; Quon, Michael/0000-0002-9601-9915
FU American Diabetes AssociationAmerican Diabetes Association [1-09-JF-33,
   1-12-BS-99, 1-13-BS-150]; American Heart AssociationAmerican Heart
   Association [13GRNT17220057]; UAB diabetes research center - National
   Institutes of Health [P60 DK-079626]; NATIONAL INSTITUTE OF DIABETES AND
   DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Diabetes & Digestive & Kidney Diseases (NIDDK) [P30DK079637,
   P30DK072488, P60DK079626, P30DK079626] Funding Source: NIH RePORTER
FX This study was supported by the American Diabetes Association
   (1-09-JF-33; 1-12-BS-99 to J.K; 1-13-BS-150 to M.J.Q), American Heart
   Association (13GRNT17220057 to J.K), and UAB diabetes research center
   sponsored pilot and feasibility program supported by the National
   Institutes of Health (P60 DK-079626).
CR Ahn HY, 1999, MOL BIOL CELL, V10, P1093, DOI 10.1091/mbc.10.4.1093
   Aktas O, 2004, J IMMUNOL, V173, P5794, DOI 10.4049/jimmunol.173.9.5794
   Alvarez E, 2006, BRIT J PHARMACOL, V147, P269, DOI 10.1038/sj.bjp.0706507
   Aneja R, 2004, MOL MED, V10, P55, DOI 10.2119/2004-00032.Aneja
   Babich H, 2007, TOXICOL LETT, V171, P171, DOI 10.1016/j.toxlet.2007.05.125
   Bae YS, 2009, CIRC RES, V104, P210, DOI 10.1161/CIRCRESAHA.108.181040
   Basu A, 2010, J AM COLL NUTR, V29, P31, DOI 10.1080/07315724.2010.10719814
   Bose M, 2007, J AGR FOOD CHEM, V55, P7695, DOI 10.1021/jf071004r
   Byun EH, 2010, J IMMUNOL, V185, P33, DOI 10.4049/jimmunol.0903742
   Chen AP, 2003, J BIOL CHEM, V278, P23381, DOI 10.1074/jbc.M212042200
   Chen D, 2012, BIOORGAN MED CHEM, V20, P3031, DOI 10.1016/j.bmc.2012.03.002
   Chen L., 2013, J SCI FOOD AGR
   Chen N, 2009, NUTR RES, V29, P784, DOI 10.1016/j.nutres.2009.10.003
   Chou CW, 2007, SYNAPSE, V61, P889, DOI 10.1002/syn.20444
   Chyu KY, 2004, CIRCULATION, V109, P2448, DOI 10.1161/01.CIR.0000128034.70732.C2
   Collins QF, 2007, J BIOL CHEM, V282, P30143, DOI 10.1074/jbc.M702390200
   Corcoran Michael P., 2012, Journal of Nutrition in Gerontology and Geriatrics, V31, P176, DOI 10.1080/21551197.2012.698219
   Cuervo AM, 2004, TRENDS CELL BIOL, V14, P70, DOI 10.1016/j.tcb.2003.12.002
   Cuervo AM, 2005, AUTOPHAGY, V1, P131, DOI 10.4161/auto.1.3.2017
   de Boer VCJ, 2006, MECH AGEING DEV, V127, P618, DOI 10.1016/j.mad.2006.02.007
   Devika PT, 2008, PHARMACOL RES, V57, P351, DOI 10.1016/j.phrs.2008.03.008
   Dong ZG, 1997, CANCER RES, V57, P4414
   Elbling L, 2005, FASEB J, V19, P807, DOI 10.1096/fj.04-2915fje
   Elbling L, 2010, FREE RADICAL BIO MED, V49, P1444, DOI 10.1016/j.freeradbiomed.2010.08.008
   Ermakova S, 2005, J BIOL CHEM, V280, P16882, DOI 10.1074/jbc.M414185200
   Fang MZ, 2007, J NUTR, V137, p223S, DOI 10.1093/jn/137.1.223S
   Fang MZ, 2003, CANCER RES, V63, P7563
   Feng W, 2010, BIOCHEM PHARMACOL, V80, P512, DOI 10.1016/j.bcp.2010.05.004
   Fujimura Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037942
   Fung ST, 2013, BRIT J NUTR, V109, P2199, DOI 10.1017/S0007114512004370
   Giunta B, 2010, NEUROSCI LETT, V471, P134, DOI 10.1016/j.neulet.2010.01.026
   Hashimoto K, 2008, ANTICANCER RES, V28, P1713
   Hellermann GR, 1997, J BIOL CHEM, V272, P12030, DOI 10.1074/jbc.272.18.12030
   Hong J, 2002, CANCER RES, V62, P7241
   Hotta Y, 2006, EUR J PHARMACOL, V552, P123, DOI 10.1016/j.ejphar.2006.09.017
   Hou Z, 2005, CANCER RES, V65, P8049, DOI 10.1158/0008-5472.CAN-05-0480
   Hsu Chung-Hua, 2011, Altern Med Rev, V16, P157
   Hwang JT, 2007, CANCER LETT, V247, P115, DOI 10.1016/j.canlet.2006.03.030
   Ikeda I, 2005, J NUTR, V135, P155, DOI 10.1093/jn/135.2.155
   Ikeda I, 2008, ASIA PAC J CLIN NUTR, V17, P273
   Jang HJ, 2013, AM J PHYSIOL-ENDOC M, V305, pE1444, DOI 10.1152/ajpendo.00434.2013
   Jimenez-Lopez JM, 2004, FREE RADICAL BIO MED, V36, P359, DOI 10.1016/j.freeradbiomed.2003.11.016
   Kargacin ME, 2011, J MUSCLE RES CELL M, V32, P89, DOI 10.1007/s10974-011-9256-7
   Katiyar SK, 2001, CARCINOGENESIS, V22, P287, DOI 10.1093/carcin/22.2.287
   Kim HS, 2013, J BIOL CHEM, V288, P22693, DOI 10.1074/jbc.M113.477505
   Kim H, 2012, CELL BIOL INT, V36, P147, DOI 10.1042/CBI20110047
   Kim H, 2010, CYTOTECHNOLOGY, V62, P245, DOI 10.1007/s10616-010-9285-x
   Kim JA, 2007, J BIOL CHEM, V282, P13736, DOI 10.1074/jbc.M609725200
   Kim Jeong-A., 2008, Endocrine Metabolic & Immune Disorders-Drug Targets, V8, P82, DOI 10.2174/187153008784534349
   Kim SY, 2004, EUR J BIOCHEM, V271, P3470, DOI 10.1111/j.0014-2956.2004.04242.x
   Kishimoto Y, 2013, EUR J CLIN NUTR, V67, P532, DOI 10.1038/ejcn.2013.29
   Klaus S, 2005, INT J OBESITY, V29, P615, DOI 10.1038/sj.ijo.0802926
   Kondo T, 2002, CANCER LETT, V180, P139, DOI 10.1016/S0304-3835(02)00007-1
   Kumazoe M, 2013, FEBS LETT, V587, P3052, DOI 10.1016/j.febslet.2013.07.041
   Kumazoe M, 2013, J CLIN INVEST, V123, P787, DOI 10.1172/JCI64768
   Kuriyama S, 2006, JAMA-J AM MED ASSOC, V296, P1255, DOI 10.1001/jama.296.10.1255
   Lambert JD, 2006, DRUG METAB DISPOS, V34, P8, DOI 10.1124/dmd.104.003434
   Lee H, 2013, J NUTR BIOCHEM, V24, P1232, DOI 10.1016/j.jnutbio.2012.09.007
   Lee IT, 2013, J NUTR BIOCHEM, V24, P124, DOI 10.1016/j.jnutbio.2012.03.009
   Lee MS, 2009, ANN NUTR METAB, V54, P151, DOI 10.1159/000214834
   LEE MJ, 1995, CANCER EPIDEM BIOMAR, V4, P393
   Lee MJ, 2002, CANCER EPIDEM BIOMAR, V11, P1025
   Li CP, 2013, BIOCHEM BIOPH RES CO, V438, P739, DOI 10.1016/j.bbrc.2013.07.097
   Li GY, 2010, PROCEEDINGS OF THE 4TH INTERNATIONAL YELLOW RIVER FORUM ON ECOLOGICAL CIVILIZATION AND RIVER ETHICS, VOL I, P3
   Li W, 2011, BIOCHEM PHARMACOL, V81, P1152, DOI 10.1016/j.bcp.2011.02.015
   Li Y, 2011, DIABETES RES CLIN PR, V93, P205, DOI 10.1016/j.diabres.2011.03.036
   Liang YC, 1997, J CELL BIOCHEM, V67, P55, DOI 10.1002/(SICI)1097-4644(19971001)67:1<55::AID-JCB6>3.0.CO;2-V
   Lorenz M, 2004, J BIOL CHEM, V279, P6190, DOI 10.1074/jbc.M309114200
   Massey AC, 2006, AUTOPHAGY, V2, P325, DOI 10.4161/auto.3090
   Matsuo N, 1996, IN VITRO CELL DEV-AN, V32, P340
   Menard S, 1997, J CELL BIOCHEM, V67, P155, DOI 10.1002/(SICI)1097-4644(19971101)67:2<155::AID-JCB1>3.0.CO;2-W
   Meng QY, 2008, REJUV RES, V11, P649, DOI 10.1089/rej.2007.0645
   Michel JB, 1997, J BIOL CHEM, V272, P15583, DOI 10.1074/jbc.272.25.15583
   Moon HS, 2007, OBESITY, V15, P2571, DOI 10.1038/oby.2007.309
   Murase T, 2009, BIOCHEM PHARMACOL, V78, P78, DOI 10.1016/j.bcp.2009.03.021
   Mythri RB, 2012, CURR PHARM DESIGN, V18, P91, DOI 10.2174/138161212798918995
   Nakagawa H, 2004, CARCINOGENESIS, V25, P1567, DOI 10.1093/carcin/bgh168
   Nakagawa H, 2002, BIOCHEM BIOPH RES CO, V292, P94, DOI 10.1006/bbrc.2002.6622
   O'Neill LAJ, 2013, NATURE, V493, P346, DOI 10.1038/nature11862
   Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194
   Oh CJ, 2008, ARCH PHARM RES, V31, P34, DOI 10.1007/s12272-008-1117-6
   Ok WJ, 2012, J ATHEROSCLER THROMB, V19, P337, DOI 10.5551/jat.10363
   Orsolic N., 2013, MUTAT RES
   Pallauf K, 2013, AGEING RES REV, V12, P237, DOI 10.1016/j.arr.2012.03.008
   Park IJ, 2009, ANN NY ACAD SCI, V1171, P538, DOI 10.1111/j.1749-6632.2009.04698.x
   Picchi A, 2006, CIRC RES, V99, P69, DOI 10.1161/01.RES.0000229685.37402.80
   Potenza MA, 2007, AM J PHYSIOL-ENDOC M, V292, pE1378, DOI 10.1152/ajpendo.00698.2006
   Pullikotil P, 2012, J NUTR BIOCHEM, V23, P1134, DOI 10.1016/j.jnutbio.2011.06.007
   Qanungo S, 2005, CARCINOGENESIS, V26, P958, DOI 10.1093/carcin/bgi040
   Reiter CEN, 2010, ENDOCRINOLOGY, V151, P103, DOI 10.1210/en.2009-0997
   Ren FG, 2000, ONCOGENE, V19, P1924, DOI 10.1038/sj.onc.1203511
   Rizvi SI, 2005, CLIN CHIM ACTA, V354, P59, DOI 10.1016/j.cccn.2004.11.008
   Rodriguez SK, 2006, INT J CANCER, V118, P1635, DOI 10.1002/ijc.21545
   Ruderman NB, 2013, J CLIN INVEST, V123, P2764, DOI 10.1172/JCI67227
   Sachinidis A, 2002, FASEB J, V16, P893, DOI 10.1096/fj.01-0799fje
   Sah JF, 2004, J BIOL CHEM, V279, P12755, DOI 10.1074/jbc.M312333200
   Sakagami H, 2001, ANTICANCER RES, V21, P2633
   Sakurai N, 2009, NUTRITION, V25, P1047, DOI 10.1016/j.nut.2009.02.012
   Satoh M, 2013, CANCER CELL INT, V13, DOI 10.1186/1475-2867-13-19
   Schroeder EK, 2009, ANTIOXID REDOX SIGN, V11, P469, DOI [10.1089/ars.2008.2215, 10.1089/ARS.2008.2215]
   Shanafelt TD, 2009, J CLIN ONCOL, V27, P3808, DOI 10.1200/JCO.2008.21.1284
   Shimizu M, 2005, BIOCHEM BIOPH RES CO, V334, P947, DOI 10.1016/j.bbrc.2005.06.182
   Soler F, 2012, J BIOENERG BIOMEMBR, V44, P597, DOI 10.1007/s10863-012-9462-z
   Stephanou A, 2004, J CELL MOL MED, V8, P519, DOI 10.1111/j.1582-4934.2004.tb00476.x
   Tian WX, 2006, CURR MED CHEM, V13, P967, DOI 10.2174/092986706776361012
   Tomas-Barberan FA, 2012, J AGR FOOD CHEM, V60, P8773, DOI 10.1021/jf300671j
   Toniolo A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056683
   Towler MC, 2007, CIRC RES, V100, P328, DOI 10.1161/01.RES.0000256090.42690.05
   Townsend PA, 2004, FASEB J, V18, P1612, DOI 10.1096/fj.04-1716fje
   Valenti D, 2013, BBA-MOL BASIS DIS, V1832, P2085, DOI 10.1016/j.bbadis.2013.07.014
   Valenti D, 2013, BBA-MOL BASIS DIS, V1832, P542, DOI 10.1016/j.bbadis.2012.12.011
   Van Amelsvoort JMM, 2001, XENOBIOTICA, V31, P891, DOI 10.1080/00498250110079149
   Waltner-Law ME, 2002, J BIOL CHEM, V277, P34933, DOI 10.1074/jbc.M204672200
   Weber AA, 2004, FASEB J, V18, P128, DOI 10.1096/fj.03-0007fje
   Wu CC, 2006, LIFE SCI, V78, P2889, DOI 10.1016/j.lfs.2005.11.013
   Wu HT, 2009, FREE RADICAL BIO MED, V47, P1028, DOI 10.1016/j.freeradbiomed.2009.07.011
   Yamamoto T, 2004, J PHARMACOL EXP THER, V308, P317, DOI 10.1124/jpet.103.058891
   Yan JQ, 2012, FREE RADICAL BIO MED, V52, P1648, DOI 10.1016/j.freeradbiomed.2012.01.033
   Yang CS, 2013, J CLIN INVEST, V123, P556, DOI 10.1172/JCI67589
   Yang FJ, 1998, J NUTR, V128, P2334, DOI 10.1093/jn/128.12.2334
   Yang GY, 2000, CARCINOGENESIS, V21, P2035, DOI 10.1093/carcin/21.11.2035
   Yu W, 2012, J CELL BIOCHEM, V113, P752, DOI 10.1002/jcb.23431
   Zgheib A, 2013, J BIOL CHEM, V288, P13378, DOI 10.1074/jbc.M113.456533
   Zhang Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046749
NR 124
TC 436
Z9 463
U1 31
U2 248
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 2213-2317
J9 REDOX BIOL
JI Redox Biol.
PY 2014
VL 2
BP 187
EP 195
DI 10.1016/j.redox.2013.12.022
PG 9
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA CD0MY
UT WOS:000350769600024
PM 24494192
OA Green Published, gold
HC Y
HP N
DA 2022-04-25
ER

PT J
AU Han, J
   Zhang, J
   Zhang, CL
AF Han, Jun
   Zhang, Jing
   Zhang, Chengliang
TI Irinotecan-Induced Steatohepatitis: Current Insights
SO FRONTIERS IN ONCOLOGY
LA English
DT Review
DE irinotecan; chemotherapy; hepatotoxicity; hepatic steatosis;
   steatohepatitis
ID CHEMOTHERAPY-ASSOCIATED HEPATOTOXICITY; METASTATIC COLORECTAL-CANCER;
   PREOPERATIVE CHEMOTHERAPY; MITOCHONDRIAL DYSFUNCTION; PREDICTS
   STEATOHEPATITIS; LIVER METASTASES; ADIPOSE-TISSUE; PHASE-II; MECHANISMS;
   AUTOPHAGY
AB The hepatotoxicity of irinotecan is drawing wide concern nowadays due to the widespread use of this chemotherapeutic against various solid tumors, particularly metastatic colorectal cancer. Irinotecan-induced hepatotoxicity mainly manifests as transaminase increase and steatosis with or without transaminase increase, and is accompanied by vacuolization, and lobular inflammation. Irinotecan-induced steatohepatitis (IIS) increases the risk of morbidity and mortality in patients with colorectal cancer liver metastasis (CRCLM). The major risks and predisposing factors for IIS include high body mass index (BMI) or obesity, diabetes, and high-fat diet. Mitochondrial dysfunction and autophagy impairment may be involved in the pathogenesis of IIS. However, there is currently no effective preventive or therapeutic treatment for this condition. Thus, the precise mechanisms underlying the pathogenesis of IIS should be deciphered for the development of therapeutic drugs. This review summarizes the current knowledge and research progress on IIS.
C1 [Han, Jun; Zhang, Chengliang] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Wuhan, Peoples R China.
   [Han, Jun] Jianghan Univ, Dept Pharm, Affiliated Hosp, Wuhan, Peoples R China.
   [Zhang, Jing] Wuhan Red Cross Hosp, Wuhan, Peoples R China.
RP Zhang, CL (corresponding author), Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Wuhan, Peoples R China.
EM cfzhang@tjh.tjmu.edu.cn
FU scientific research project of Wuhan NO.6 hospital [LX19013]
FX This work was supported by grants from the scientific research project
   of Wuhan NO.6 hospital (No. LX19013 to JH).
CR Abdelgalil Ahmed A, 2019, Profiles Drug Subst Excip Relat Methodol, V44, P239, DOI 10.1016/bs.podrm.2018.11.003
   Andrade RJ, 2019, J HEPATOL, V70, P1222, DOI 10.1016/j.jhep.2019.02.014
   Assis EM, 2017, TOXICOL APPL PHARM, V327, P71, DOI 10.1016/j.taap.2017.04.023
   Bailly C, 2019, PHARMACOL RES, V148, DOI 10.1016/j.phrs.2019.104398
   Bao X, 2019, J CLIN PHARMACOL, V59, P20, DOI 10.1002/jcph.1275
   Begriche K, 2011, J HEPATOL, V54, P773, DOI 10.1016/j.jhep.2010.11.006
   Bower M, 2013, AM J SURG, V205, P685, DOI 10.1016/j.amjsurg.2012.07.034
   Cai ZQ, 2014, J BUON, V19, P350
   Celik S, 2015, CHIRURGIA-BUCHAREST, V110, P49
   Choti MA, 2002, ANN SURG, V235, P759, DOI 10.1097/00000658-200206000-00002
   Chun YS, 2009, LANCET ONCOL, V10, P278, DOI 10.1016/S1470-2045(09)70064-6
   Chung MJ, 2011, CHEMOTHERAPY, V57, P236, DOI 10.1159/000328021
   Corcelle E, 2007, AUTOPHAGY, V3, P57, DOI 10.4161/auto.3424
   Esposti DD, 2012, BIOCHEM RES INT, V2012, DOI 10.1155/2012/387626
   Fernandez FG, 2005, J AM COLL SURGEONS, V200, P845, DOI 10.1016/j.jamcollsurg.2005.01.024
   Fernandez FG, 2004, ANN SURG, V240, P438, DOI 10.1097/01.sla.0000138076.72547.b1
   Fiorini RN, 2004, CLIN TRANSPLANT, V18, P700, DOI 10.1111/j.1399-0012.2004.00282.x
   Fromenty B, 2004, DIABETES METAB, V30, P121, DOI 10.1016/S1262-3636(07)70098-8
   Ghiasian M, 2021, J BIOCHEM MOL TOXIC, V35, DOI 10.1002/jbt.22800
   Gomez-Ramirez J, 2010, CIR ESPAN, V88, P404, DOI 10.1016/j.ciresp.2010.09.005
   Hasegawa Y, 2006, ANN NY ACAD SCI, V1086, P223, DOI 10.1196/annals.1377.020
   Kciuk M, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21144919
   Khawar MB, 2019, ADV EXP MED BIOL, V1206, P359, DOI 10.1007/978-981-15-0602-4_17
   Labbe G, 2008, FUND CLIN PHARMACOL, V22, P335, DOI 10.1111/j.1472-8206.2008.00608.x
   Laplante M, 2006, DIABETES, V55, P2771, DOI 10.2337/db06-0551
   Leclercq IA, 2007, LAB INVEST, V87, P56, DOI 10.1038/labinvest.3700489
   Lephart Edwin D, 2004, Nutr Metab (Lond), V1, P16, DOI 10.1186/1743-7075-1-16
   Levy JR, 2004, HEPATOLOGY, V39, P608, DOI 10.1002/hep.20093
   Li FZ, 2017, AM J CANCER RES, V7, P2350
   Liu LF, 2000, ANN NY ACAD SCI, V922, P1
   Luntz Steffen P, 2005, BMC Surg, V5, P18, DOI 10.1186/1471-2482-5-18
   Mahli A, 2018, GUT, V67, P746, DOI 10.1136/gutjnl-2016-312485
   Mallick P, 2018, CHEM-BIOL INTERACT, V291, P87, DOI 10.1016/j.cbi.2018.06.018
   Mallick P, 2015, LIFE SCI, V139, P132, DOI 10.1016/j.lfs.2015.08.017
   Mathijssen RHJ, 2002, CURR CANCER DRUG TAR, V2, P103, DOI 10.2174/1568009023333890
   McWhirter D, 2013, CRIT REV ONCOL HEMAT, V88, P404, DOI 10.1016/j.critrevonc.2013.05.011
   Meunier L, 2020, ANN HEPATOL, V19, P597, DOI 10.1016/j.aohep.2019.11.012
   Mikalauskas S, 2011, AMINO ACIDS, V40, P1139, DOI 10.1007/s00726-010-0737-6
   Morris-Stiff G, 2008, EJSO-EUR J SURG ONC, V34, P609, DOI 10.1016/j.ejso.2007.07.007
   Okusaka T, 2014, CANCER SCI, V105, P1321, DOI 10.1111/cas.12501
   Pathak S, 2010, EJSO-EUR J SURG ONC, V36, P52, DOI 10.1016/j.ejso.2009.09.004
   Pawlik TM, 2007, J GASTROINTEST SURG, V11, P860, DOI 10.1007/s11605-007-0149-4
   Pessaux P, 2010, J VISC SURG, V147, pE193, DOI 10.1016/j.jviscsurg.2010.06.004
   Robinson SM, 2012, ANN SURG ONCOL, V19, P4287, DOI 10.1245/s10434-012-2438-8
   Ryan P, 2010, AM J SURG PATHOL, V34, P784, DOI 10.1097/PAS.0b013e3181dc242c
   Saito T, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08829-3
   Schumacher JD, 2015, TOXICOL APPL PHARM, V289, P40, DOI 10.1016/j.taap.2015.08.022
   Torre-Villalvazo I, 2008, J NUTR, V138, P462, DOI 10.1093/jn/138.3.462
   Tvrdy V, 2021, MED RES REV, V41, P2195, DOI 10.1002/med.21791
   Vauthey JN, 2006, J CLIN ONCOL, V24, P2065, DOI 10.1200/JCO.2005.05.3074
   Wolf PS, 2013, J AM COLL SURGEONS, V216, P41, DOI 10.1016/j.jamcollsurg.2012.08.030
   Wu DF, 2013, REDOX BIOL, V1, P552, DOI 10.1016/j.redox.2013.10.008
   Zhong Z, 2003, CURR OPIN CLIN NUTR, V6, P229, DOI 10.1097/00075197-200303000-00013
   Zorzi D, 2007, BRIT J SURG, V94, P274, DOI 10.1002/bjs.5719
NR 54
TC 0
Z9 0
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2234-943X
J9 FRONT ONCOL
JI Front. Oncol.
PD OCT 11
PY 2021
VL 11
AR 754891
DI 10.3389/fonc.2021.754891
PG 6
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA WU7EA
UT WOS:000716703200001
PM 34707997
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Zhou, JM
   Wang, M
   Mao, AR
   Zhao, YM
   Wang, LR
   Xu, Y
   Jia, H
   Wang, L
AF Zhou, Jiamin
   Wang, Miao
   Mao, Anrong
   Zhao, Yiming
   Wang, Longrong
   Xu, Ye
   Jia, Hao
   Wang, Lu
TI Long noncoding RNA MALAT1 sponging miR-26a-5p to modulate Smad1
   contributes to colorectal cancer progression by regulating autophagy
SO CARCINOGENESIS
LA English
DT Article
ID EPITHELIAL-MESENCHYMAL TRANSITION; TUMOR SUPPRESSION; PROMOTES;
   MIGRATION; INVASION; NETWORK; CELLS
AB Accumulating evidences have suggested that bone morphogenetic protein (BMP)-Smad have a functional role in regulating autophagy in the development of human colorectal cancer (CRC). However, the regulatory mechanisms controlling this process remain unclear. Here, we showed that Smad1, the key effector of BMP2-Smad signaling, induces autophagy by upregulating autophagy-related gene 5 (ATG5) expression, and Smad1 binds to the proximal promoter to induce its expression. Moreover, BMP2 induces autophagy in CRC. Overexpression of Smad1 promotes tumorigenesis and migration of CRC cells, and knockdown of ATG5 is able to rescue the Smad1-induced promotion of CRC proliferation and migration partially. Mechanistically, metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) may act as a competing endogenous RNA by binding with miR-26a-5p competitively and thus modulating the de-repression of downstream target Smad1. Furthermore, clinical analysis results show that Smad1 is positively correlated with MALAT1 and negatively correlated with miR-26a-5p in CRC samples. In conclusion, our results demonstrated that Smad1 may serve as an oncogene in CRC through autophagy.
   [GRAPHICS]
   .
C1 [Zhou, Jiamin; Wang, Miao; Mao, Anrong; Zhao, Yiming; Wang, Longrong; Wang, Lu] Fudan Univ, Shanghai Canc Ctr, Dept Hepat Surg, Shanghai 200032, Peoples R China.
   [Zhou, Jiamin; Wang, Miao; Mao, Anrong; Zhao, Yiming; Wang, Longrong; Xu, Ye; Wang, Lu] Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai 200032, Peoples R China.
   [Xu, Ye] Fudan Univ, Shanghai Canc Ctr, Dept Colorectal Surg, Shanghai 200032, Peoples R China.
   [Jia, Hao] Shanghai Jiao Tong Univ, Sch Med, Fac Basic Med, Shanghai 200025, Peoples R China.
RP Wang, L (corresponding author), Fudan Univ, Shanghai Canc Ctr, Dept Hepat Surg, Shanghai 200032, Peoples R China.; Xu, Y; Wang, L (corresponding author), Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai 200032, Peoples R China.; Xu, Y (corresponding author), Fudan Univ, Shanghai Canc Ctr, Dept Colorectal Surg, Shanghai 200032, Peoples R China.; Jia, H (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Fac Basic Med, Shanghai 200025, Peoples R China.
EM fonney@sjtu.edu.cn; wang.lu99@hotmail.com
OI Jia, Hao/0000-0003-1856-6013
FU National Science Foundation of ChinaNational Natural Science Foundation
   of China (NSFC) [31970679, 81902438]; Shanghai Rising-Star Program
   [19QA1405000]
FX This work was supported by the National Science Foundation of China
   (31970679, 81902438), Shanghai Rising-Star Program (19QA1405000).
CR Bermudez M, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.01008
   Canalis E, 2003, ENDOCR REV, V24, P218, DOI 10.1210/er.2002-0023
   Chen B, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-443
   Cho DH, 2012, ANTICANCER RES, V32, P4091
   Das S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098965
   Devenport SN, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8111349
   Fan B, 2019, EUR REV MED PHARMACO, V23, P217, DOI 10.26355/eurrev_201901_16767
   Fu X, 2014, ONCOGENE, V33, P4296, DOI 10.1038/onc.2013.385
   Hu B, 2020, CLIN TRANSL MED, V10, DOI 10.1002/ctm2.233
   Ji P, 2003, ONCOGENE, V22, P8031, DOI 10.1038/sj.onc.1206928
   Jia H, 2015, ONCOGENE, V34, P3568, DOI 10.1038/onc.2014.287
   Jia H, 2021, EMBO REP, V22, DOI 10.15252/embr.202051780
   Jin FF, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.461
   Jin J, 2019, NEUROSCIENCE, V413, P123, DOI 10.1016/j.neuroscience.2019.06.008
   Levy J, 2015, NAT CELL BIOL, V17, P1062, DOI 10.1038/ncb3206
   Li ML, 2019, EUR REV MED PHARMACO, V23, P10708, DOI 10.26355/eurrev_201912_19771
   Li P, 2020, AUTOPHAGY, V16, P1186, DOI 10.1080/15548627.2019.1659614
   Li Y, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.281
   Li YR, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0882-5
   Lien SC, 2013, BBA-MOL CELL RES, V1833, P3124, DOI 10.1016/j.bbamcr.2013.08.023
   Liu L, 2019, MOL THER-NUCL ACIDS, V17, P644, DOI 10.1016/j.omtn.2019.06.009
   Liu ML, 2018, WORLD J GASTROENTERO, V24, P1004, DOI 10.3748/wjg.v24.i9.1004
   Luzi E, 2012, NUCLEIC ACID THER, V22, P103, DOI 10.1089/nat.2012.0344
   Niklaus M, 2017, ONCOTARGET, V8, P54604, DOI 10.18632/oncotarget.17554
   Pang M, 2016, INT J BIOCHEM CELL B, V76, P123, DOI 10.1016/j.biocel.2016.05.010
   Qian K, 2018, INT J ONCOL, V53, P1083, DOI 10.3892/ijo.2018.4443
   Salmena L, 2011, CELL, V146, P353, DOI 10.1016/j.cell.2011.07.014
   Sharma T, 2021, ENDOCR METAB IMMUNE, V21, P56, DOI 10.2174/1871530320666200519075908
   Si YR, 2019, CELL MOL BIOL LETT, V24, DOI 10.1186/s11658-019-0175-8
   Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138
   Siegel RL, 2020, CA-CANCER J CLIN, V70, P145, DOI 10.3322/caac.21601
   Su X, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.221
   Sun ZQ, 2019, ONCOGENE, V38, P2627, DOI 10.1038/s41388-018-0628-y
   Tang DX, 2019, J CELL PHYSIOL, V234, P20816, DOI 10.1002/jcp.28687
   Tong H, 2019, J CELL BIOCHEM, V120, P5118, DOI 10.1002/jcb.27788
   Wang M, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-1187-4
   Wang M, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0338-y
   Wang XK, 2019, CANCER CELL INT, V19, DOI 10.1186/s12935-019-0951-6
   Wu CQ, 2018, MOL CARCINOGEN, V57, P1421, DOI 10.1002/mc.22868
   Wu Q, 2018, J CELL PHYSIOL, V233, P6750, DOI 10.1002/jcp.26383
   Xu JC, 2020, J EXP CLIN CANC RES, V39, DOI 10.1186/s13046-020-01562-6
   Xu M, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-018-0690-5
   Yang DM, 2017, ONCOTARGET, V8, P110415, DOI 10.18632/oncotarget.22780
   Zeitels LR, 2014, GENE DEV, V28, P2585, DOI 10.1101/gad.250951.114
   Zhang BS, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1203-2
   Zhang MY, 2019, ONCOTARGETS THER, V12, P3349, DOI 10.2147/OTT.S197433
   Zhu X, 2019, CANCER CELL INT, V19, DOI 10.1186/s12935-019-0794-1
   Zhuang M, 2019, EBIOMEDICINE, V41, P286, DOI 10.1016/j.ebiom.2018.12.049
NR 48
TC 2
Z9 2
U1 1
U2 1
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0143-3334
EI 1460-2180
J9 CARCINOGENESIS
JI Carcinogenesis
PD NOV
PY 2021
VL 42
IS 11
BP 1370
EP 1379
DI 10.1093/carcin/bgab069
EA JUL 2021
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA XL4ZA
UT WOS:000728152300007
PM 34313719
DA 2022-04-25
ER

PT J
AU Edeler, D
   Kaluderovic, MR
   Dojcinovic, B
   Schmidt, H
   Kaluderovic, GN
AF Edeler, David
   Kaluderovic, Milena R.
   Dojcinovic, Biljana
   Schmidt, Harry
   Kaluderovic, Goran N.
TI SBA-15 mesoporous silica particles loaded with cisplatin induce
   senescence in B16F10 cells
SO RSC ADVANCES
LA English
DT Article
ID DRUG-DELIVERY SYSTEMS; ANTICANCER ACTIVITY; CANCER-CELLS; CO-DELIVERY;
   NANOPARTICLES; COMPLEXES; AUTOPHAGY; STRATEGY; CYTOTOXICITY;
   CHEMOTHERAPY
AB The anticancer drug cisplatin (CP) is loaded into SBA-15 mesoporous silica (SBA-15 vertical bar CP) and its release from the nanomaterial is studied. The CP-loaded SBA-15 is tested against four tumor cell lines: mouse malignant melanoma B16F10, human adenocarcinoma HeLa, colon HT-29 and prostate PC3. Most importantly, the superiority of this novel material in comparison to CP arises from the fact that the CP-grafted nanomaterial SBA-15 (-> SBA-15 vertical bar CP) is enhancing cessation of proliferation along with induction of senescence in B16F10 in approximately 3.5 times lower concentration. The control material loaded with therapeutically inactive K-2[PtCl4] (-> SBA-15 vertical bar TC) showed no antitumor activity. To a large extent, SBA15| CP-induced senescence might present a safe approach in tumor treatment. Such cells can be cleared by immune cells resulting in efficient tumor regression. So far only apoptotic agents are being exploited in clinics, thus an understanding of the chemotherapeutic-induced senescence will allow oncologists to explore this essential tumor suppressor mechanism.
C1 [Edeler, David; Kaluderovic, Goran N.] Leibniz Inst Plant Biochem, Dept Bioorgan Chem, Weinberg 3, D-06120 Halle, Saale, Germany.
   [Edeler, David; Schmidt, Harry] Martin Luther Univ Halle Wittenberg, Inst Chem, Kurt Mothes Str 2, D-06120 Halle, Germany.
   [Kaluderovic, Milena R.] Univ Hosp Leipzig, Dept Oral Maxillary Facial & Reconstruct Plast Su, Liebigstr 12, D-04103 Leipzig, Germany.
   [Dojcinovic, Biljana] Univ Belgrade, Inst Chem Technol & Met, Dept Chem, Studentski Trg 12-14, Belgrade 11000, Serbia.
RP Kaluderovic, GN (corresponding author), Leibniz Inst Plant Biochem, Dept Bioorgan Chem, Weinberg 3, D-06120 Halle, Saale, Germany.
EM goran.kaluderovic@ipb-halle.de
RI Kaluderovic, Goran/AAR-7347-2021
OI Kaluderovic, Goran/0000-0001-5168-1000; Dojcinovic,
   Biljana/0000-0003-1479-8060
CR Ahn B, 2013, J MATER CHEM B, V1, P2829, DOI 10.1039/c3tb20319k
   Arnesano F, 2009, COORDIN CHEM REV, V253, P2070, DOI 10.1016/j.ccr.2009.01.028
   Azimov F., 2012, J U CHEM TECHNOL MET, V47, P333
   Braun K, 2016, J COLLOID INTERF SCI, V475, P161, DOI 10.1016/j.jcis.2016.05.002
   Bu XX, 2008, CANCER BIOL THER, V7, P392, DOI 10.4161/cbt.7.3.5366
   Bulatovic M, 2015, EUR J PHARMACOL, V760, P136, DOI 10.1016/j.ejphar.2015.04.012
   Bulatovic MZ, 2014, ANGEW CHEM INT EDIT, V53, P5982, DOI 10.1002/anie.201400763
   Campisi J, 2007, AGING CELL, V6, P261, DOI 10.1111/j.1474-9726.2007.00292.x
   Ceresa C, 2013, CURR MED CHEM, V20, P2589, DOI 10.2174/0929867311320200007
   Ciarimboli G, 2014, ANTICANCER RES, V34, P547
   Collado M, 2010, NAT REV CANCER, V10, P51, DOI 10.1038/nrc2772
   de la Torre C, 2015, CHEM-EUR J, V21, P15506, DOI 10.1002/chem.201502413
   Diaz A, 2013, NANOSCALE, V5, P11456, DOI 10.1039/c3nr02206d
   Fang Y, 2014, ANGEW CHEM INT EDIT, V53, P5366, DOI 10.1002/anie.201402002
   Flor AC, 2016, CELL DEATH DISCOV, V2, DOI 10.1038/cddiscovery.2016.45
   Florea Ana-Maria, 2011, Cancers (Basel), V3, P1351, DOI 10.3390/cancers3011351
   Focaccetti C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0115686
   FORRESTER AR, 1992, J CHEM SOC DALTON, P2615, DOI 10.1039/dt9920002615
   Galluzzi L, 2016, TRENDS CELL BIOL, V26, P1, DOI 10.1016/j.tcb.2015.11.001
   Garcia-Penas A, 2012, J INORG BIOCHEM, V106, P100, DOI 10.1016/j.jinorgbio.2011.09.033
   Gewirtz DA, 2008, BIOCHEM PHARMACOL, V76, P947, DOI 10.1016/j.bcp.2008.06.024
   Gewirtz DA, 2013, AUTOPHAGY, V9, P808, DOI 10.4161/auto.23922
   Goehe RW, 2012, J PHARMACOL EXP THER, V343, P763, DOI 10.1124/jpet.112.197590
   Gomez-Ruiz S, 2012, BIOINORG CHEM APPL, V2012, DOI 10.1155/2012/140284
   Gu JL, 2013, LANGMUIR, V29, P403, DOI 10.1021/la3036264
   Hu JJ, 2016, SMALL, V12, P3344, DOI 10.1002/smll.201600325
   Huang YH, 2016, ONCOL LETT, V12, P11, DOI 10.3892/ol.2016.4596
   Jaganathan H, 2012, ADV DRUG DELIVER REV, V64, P1800, DOI 10.1016/j.addr.2012.05.008
   Johnstone TC, 2016, CHEM REV, V116, P3436, DOI 10.1021/acs.chemrev.5b00597
   Kaluderovic GN, 2011, CURR MED CHEM, V18, P4738
   Kaluderovic GN, 2005, J INORG BIOCHEM, V99, P488, DOI 10.1016/j.jinorgbio.2004.10.025
   Kaluderovic GN, 2010, DALTON T, V39, P2597, DOI 10.1039/b920051g
   Kaluderovic GN, 2010, J MATER CHEM, V20, P806, DOI 10.1039/b919269g
   Kaluderovic MR, 2016, ANTI-CANCER AGENT ME, V16, P359, DOI 10.2174/1871520615666151007160319
   Kieler-Ferguson HM, 2013, WIRES NANOMED NANOBI, V5, P130, DOI 10.1002/wnan.1209
   Knezevic NZ, 2015, NANOSCALE, V7, P2199, DOI 10.1039/c4nr06114d
   Kostova Irena, 2006, Anti-Cancer Agents in Medicinal Chemistry, V6, P19, DOI 10.2174/187152006774755500
   Krizhanovsky V, 2008, CELL, V134, P657, DOI 10.1016/j.cell.2008.06.049
   Kuilman T, 2010, GENE DEV, V24, P2463, DOI 10.1101/gad.1971610
   Kung ML, 2016, PHYS CHEM CHEM PHYS, V18, P7124, DOI 10.1039/c5cp07971c
   Lin CH, 2012, INT J PHARMACEUT, V429, P138, DOI 10.1016/j.ijpharm.2012.03.026
   Lippert B, 1999, COORDIN CHEM REV, V182, P263, DOI 10.1016/S0010-8545(98)00192-1
   Ludwig G, 2014, CHEMMEDCHEM, V9, P1586, DOI 10.1002/cmdc.201300479
   Maccio A, 2013, EXPERT OPIN PHARMACO, V14, P1839, DOI 10.1517/14656566.2013.813934
   Manzano M, 2010, J MATER CHEM, V20, P5593, DOI 10.1039/b922651f
   Mari C, 2015, CHIMIA, V69, P176, DOI 10.2533/chimia.2015.176
   Mohapatra S, 2014, DALTON T, V43, P15841, DOI 10.1039/c4dt02144d
   Morelli C, 2011, NANOSCALE, V3, P3198, DOI 10.1039/c1nr10253b
   Muhammad N, 2014, CURR OPIN CHEM BIOL, V19, P144, DOI 10.1016/j.cbpa.2014.02.003
   Munaweera I, 2015, J INORG BIOCHEM, V153, P23, DOI 10.1016/j.jinorgbio.2015.09.002
   Munteanu CR, 2015, DALTON T, V44, P13796, DOI 10.1039/c5dt02101d
   Napierska D, 2010, PART FIBRE TOXICOL, V7, DOI 10.1186/1743-8977-7-39
   Pantelic N, 2015, EUR J MED CHEM, V90, P766, DOI 10.1016/j.ejmech.2014.12.019
   Perez-Quintanilla D, 2009, CHEM-EUR J, V15, P5588, DOI 10.1002/chem.200900151
   Shrikhande SS, 2015, SAUDI PHARM J, V23, P341, DOI 10.1016/j.jsps.2014.08.004
   Siefker J, 2014, EXPERT OPIN DRUG DEL, V11, P1781, DOI 10.1517/17425247.2014.938636
   SING KSW, 1985, PURE APPL CHEM, V57, P603, DOI 10.1351/pac198557040603
   Srinivas D, 2007, MICROPOR MESOPOR MAT, V105, P170, DOI 10.1016/j.micromeso.2007.05.024
   Strohfeldt K, 2008, CHEM SOC REV, V37, P1174, DOI 10.1039/b707310k
   Sweeney Sean K, 2016, Cancer Nanotechnol, V7, P3, DOI 10.1186/s12645-016-0015-8
   Tao ZM, 2010, LANGMUIR, V26, P8914, DOI 10.1021/la904695a
   Tao ZM, 2010, ACS NANO, V4, P789, DOI 10.1021/nn9015345
   Taratula O, 2011, J DRUG TARGET, V19, P900, DOI 10.3109/1061186X.2011.622404
   van Rijt SH, 2015, ACS NANO, V9, P2377, DOI 10.1021/nn5070343
   Vicencio JM, 2008, GERONTOLOGY, V54, P92, DOI 10.1159/000129697
   Vivero-Escoto JL, 2015, NANOMATERIALS-BASEL, V5, P2302, DOI 10.3390/nano5042302
   Wan XJ, 2011, MACROMOL RAPID COMM, V32, P1082, DOI 10.1002/marc.201100198
   White E, 2009, GENE DEV, V23, P784, DOI 10.1101/gad.1795309
   Wu W, 2016, INT J PHARMACEUT, V511, P65, DOI 10.1016/j.ijpharm.2016.06.133
   Xie WL, 2015, IND ENG CHEM RES, V54, P1505, DOI 10.1021/ie5045007
   Xie WL, 2014, CHEM ENG J, V239, P60, DOI 10.1016/j.cej.2013.11.009
   Yingchoncharoen P, 2016, PHARMACOL REV, V68, P701, DOI 10.1124/pr.115.012070
   Yuan ZM, 2016, NANOTECHNOLOGY, V27, DOI 10.1088/0957-4484/27/24/245101
   Zhao DY, 1998, J AM CHEM SOC, V120, P6024, DOI 10.1021/ja974025i
NR 74
TC 17
Z9 17
U1 0
U2 13
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
EI 2046-2069
J9 RSC ADV
JI RSC Adv.
PY 2016
VL 6
IS 112
BP 111031
EP 111040
DI 10.1039/c6ra22596a
PG 10
WC Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry
GA EE3CD
UT WOS:000389463600062
OA Green Published
DA 2022-04-25
ER

PT J
AU Deng, YC
   Wu, L
   Ding, QS
   Yu, HG
AF Deng, Yunchao
   Wu, Lu
   Ding, Qianshan
   Yu, Honggang
TI AGXT2L1 is downregulated in carcinomas of the digestive system
SO ONCOLOGY LETTERS
LA English
DT Article
DE alanine-glyoxylate aminotransferase 2-like 1; digestive cancer;
   pathology; autophagy
ID AUTOPHAGY; EXPRESSION; CANCER; PHOSPHATIDYLCHOLINE; IDENTIFICATION;
   METABOLISM; HEALTH
AB Alanine-glyoxylate aminotransferase 2-like 1 (AGXT2L1) is a modulator of phospholipid metabolism, and its role in tumor biology is obscure. Previously, significant downregulation of AGXT2L1 has been observed in hepatocellular carcinoma. The aim of the present study was to investigate AGXT2L1 expression and its association with the clinical characteristics of common carcinomas of the digestive system. In the present study, the expression levels of AGXT2L1 were detected by immunohistochemical staining in colorectal cancer (CRC), gastric cancer and pancreatic cancer tissues. The associations between AGXT2L1 expression and clinicopathological features were analyzed using public gene expression datasets. Small interfering RNA was transfected into SW480 and HCT116 cells to explore the role of AGXT2L1 in CRC cells. AGXT2L1 expression was significantly decreased in cancerous tissues compared with in normal tissues, and low AGXT2L1 expression was associated with an unfavorable prognosis in patients. Furthermore, it was revealed that AGXT2L1 may regulate phosphatidylinositol and phosphatidylserine metabolism in cancerous tissues, and that decreased AGXT2L1 expression could induce autophagy in CRC cells. Overall, the present study provides a basis for further understanding of the role of AGXT2L1 and its association with autophagy in cancer.
C1 [Deng, Yunchao; Wu, Lu; Ding, Qianshan; Yu, Honggang] Wuhan Univ, Dept Gastroenterol, Renmin Hosp, 238 Jiefang Rd, Wuhan 430060, Hubei, Peoples R China.
   [Deng, Yunchao; Wu, Lu; Ding, Qianshan; Yu, Honggang] Wuhan Univ, Hubei Key Lab Digest Syst, Renmin Hosp, Wuhan 430060, Hubei, Peoples R China.
RP Ding, QS; Yu, HG (corresponding author), Wuhan Univ, Dept Gastroenterol, Renmin Hosp, 238 Jiefang Rd, Wuhan 430060, Hubei, Peoples R China.
EM iamdqs@163.com; yuhonggang1968@163.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81672387, 81703030]
FX The present study was supported by National Natural Science Foundation
   of China (grant nos. 81672387 and 81703030).
CR Cui JA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017819
   Cui JA, 2011, NUCLEIC ACIDS RES, V39, P1197, DOI 10.1093/nar/gkq960
   Ding QS, 2016, J CLIN PATHOL, V69, P215, DOI 10.1136/jclinpath-2015-203042
   Fotheringham J, 2000, BBA-MOL CELL BIOL L, V1485, P1, DOI 10.1016/S1388-1981(00)00025-1
   Garcia H, 2011, ONCOTARGET, V2, P783
   Giatromanolaki A, 2010, J CLIN PATHOL, V63, P867, DOI 10.1136/jcp.2010.079525
   Gual P, 2017, AM J PHYSIOL-CELL PH, V312, pC263, DOI 10.1152/ajpcell.00295.2016
   Hurley JH, 2017, ANNU REV BIOCHEM, V86, P225, DOI 10.1146/annurev-biochem-061516-044820
   Keckesova Z, 2017, NATURE, V543, P681, DOI 10.1038/nature21408
   Kowalik MA, 2016, ONCOTARGET, V7, P5788, DOI 10.18632/oncotarget.6810
   Lai K, 2014, J CLIN PATHOL, V67, P854, DOI 10.1136/jclinpath-2014-202529
   Lamb CA, 2013, NAT REV MOL CELL BIO, V14, P759, DOI 10.1038/nrm3696
   Li ZY, 2006, CELL METAB, V3, P321, DOI 10.1016/j.cmet.2006.03.007
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Pavlovic Z, 2013, INT J MOL SCI, V14, P2529, DOI 10.3390/ijms14022529
   Qiu Y, 2017, PROTEIN SCI, V26, P1674, DOI 10.1002/pro.3186
   Ravikumar B, 2010, PHYSIOL REV, V90, P1383, DOI 10.1152/physrev.00030.2009
   Rockenfeller P, 2015, CELL DEATH DIFFER, V22, P499, DOI 10.1038/cdd.2014.219
   Saha S, 2018, BIOMED PHARMACOTHER, V104, P485, DOI 10.1016/j.biopha.2018.05.007
   Schiroli D, 2013, IUBMB LIFE, V65, P645, DOI 10.1002/iub.1178
   Shao L, 2008, BIOL PSYCHIAT, V64, P89, DOI 10.1016/j.biopsych.2007.11.010
   Smith JJ, 2010, GASTROENTEROLOGY, V138, P958, DOI 10.1053/j.gastro.2009.11.005
   Sui XB, 2011, AUTOPHAGY, V7, P565, DOI 10.4161/auto.7.6.14073
   Tooze SA, 2013, ESSAYS BIOCHEM, V55, P29, DOI [10.1042/BSE0550029, 10.1042/bse0550029]
   Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262
   van der Veen JN, 2017, BBA-BIOMEMBRANES, V1859, P1558, DOI 10.1016/j.bbamem.2017.04.006
   Veiga-da-Cunha M, 2012, J BIOL CHEM, V287, P7246, DOI 10.1074/jbc.M111.323485
   Wu Y, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aax7525
   Zaffagnini G, 2016, J MOL BIOL, V428, P1714, DOI 10.1016/j.jmb.2016.02.004
   Zhang XX, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138820
NR 30
TC 0
Z9 0
U1 1
U2 2
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792-1074
EI 1792-1082
J9 ONCOL LETT
JI Oncol. Lett.
PD AUG
PY 2020
VL 20
IS 2
BP 1318
EP 1326
DI 10.3892/ol.2020.11645
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA NG2RJ
UT WOS:000563832100037
PM 32724374
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Liu, BW
   Yan, XF
   Hou, ZJ
   Zhang, L
   Zhang, DW
AF Liu, Bingwu
   Yan, Xinfeng
   Hou, Zuojia
   Zhang, Lei
   Zhang, Duwen
TI Impact of Bupivacaine on malignant proliferation, apoptosis and
   autophagy o f human colorectal cancer SW480 cells through regulating
   NF-kappa B signaling path
SO BIOENGINEERED
LA English
DT Article
DE Bupivacaine; colorectal cancer; nf-kappa B; apoptosis; autophagy
ID LOCAL-ANESTHETIC BUPIVACAINE; EFFICACY; SURGERY; DEATH
AB To probe into the impact of Bupivacaine on colorectal cancer (CRC) proliferation, apoptosis, and autophagy through regulating the NE-KB signaling pathway. Our work treated CRC cells with Bupivacaine, detected cell vitality through MTT assay, apoptosis through flow cytometry, cell migration through wound healing assay, NF-KB activity through immunofluorescence, inflammatory factor level, including TNF-alpha, IL-1 beta as well as IL-6 through ESLIA, apoptosis factor mRNA expression, including Bcl-2, Bax and caspase-3q through qRT-PCR, and protein expression linking with NF-KB signaling pathway as well as autophagy-related proteins via western blot. In in vivo experiments, we explored the impact of Bupivacaine on tumor volume, tumor and NF-kappa B expression. The results showed that 1 mM Bupivacaine was available to signally inhibit CRC cell vitality, promoted apoptosis rate and apoptosis gene expression, like Bax, and caspase-3, inhibited Bcl-2 expression, inhibited cancer cell migration, promoted autophagy-related protein LC3B II/LC3B I ratio and beclin-1 expression, and inhibited p62 expression. Additionally, it could elevate inflammatory factor level and induce IKK and I kappa B phosphorylation as well as NE-kappa B proteins. In in vivo experiments, Bupivacaine inhibited tumor volume and tumor, as well as NF-kappa B expression. In short, bupivacaine is available to inhibit CRC proliferation through regulating NE-kappa B signaling pathway, promote apoptosis and autophagy, and can be used as a potential drug to treat CRC in the future.
   [GRAPHICS]
   .
C1 [Liu, Bingwu; Yan, Xinfeng] Second Children & Womens Healthcare Jinan City, Dept Anesthesiol, Jinan, Shandong, Peoples R China.
   [Hou, Zuojia] Laiwu Peoples Hosp Jinan City, Dept Anesthesiol, Jinan, Shandong, Peoples R China.
   [Zhang, Lei] Laiwu Iron & Steel Grp Laiwu Min Co Ltd, Dept Anesthesiol, Staff Hosp, Jinan, Shandong, Peoples R China.
   [Zhang, Duwen] Guizhou Prov Peoples Hosp, Dept Anesthesiol, 83 East Zhongshan Rd, Guiyang 550002, Guizhou, Peoples R China.
RP Zhang, DW (corresponding author), Guizhou Prov Peoples Hosp, Dept Anesthesiol, 83 East Zhongshan Rd, Guiyang 550002, Guizhou, Peoples R China.
EM zhangdw_3@hotmail.com
CR Cheng L, 2021, J BIOENERG BIOMEMBR, V53, P415, DOI 10.1007/s10863-021-09901-8
   Dan JP, 2018, BIOMED PHARMACOTHER, V103, P823, DOI 10.1016/j.biopha.2018.04.106
   de Ridder I, 2021, BBA-MOL CELL RES, V1868, DOI 10.1016/j.bbamcr.2021.118983
   Eden C, 2018, SURG ONCOL, V27, P266, DOI 10.1016/j.suronc.2018.05.001
   Exadaktylos AK, 2006, ANESTHESIOLOGY, V105, P660, DOI 10.1097/00000542-200610000-00008
   Fan LH, 2019, EUR J PHARMACOL, V850, P43, DOI 10.1016/j.ejphar.2019.01.025
   Fares KM, 2015, PAIN MED, V16, P1186, DOI 10.1111/pme.12687
   Guo D, 2016, FUND CLIN PHARMACOL, V30, P307, DOI 10.1111/fcp.12197
   Hauseman ZJ, 2020, MOL CELL, V79, P68, DOI 10.1016/j.molcel.2020.05.029
   Kanemitsu Y, 2021, J CLIN ONCOL, V39, P1098, DOI 10.1200/JCO.20.02447
   Kim B, 2015, SURG ENDOSC, V29, P714, DOI 10.1007/s00464-014-3730-4
   Li R, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4576-2
   Li TC, 2019, J ANESTH, V33, P17, DOI 10.1007/s00540-018-2577-6
   Li Y., 2021, ARCH BIOCHEM BIOPHYS
   Marshall RS, 2019, FRONT MOL BIOSCI, V6, DOI 10.3389/fmolb.2019.00040
   Onorati AV, 2018, CANCER-AM CANCER SOC, V124, P3307, DOI 10.1002/cncr.31335
   Patel M, 2018, TRANSL RES, V197, P43, DOI 10.1016/j.trsl.2018.02.002
   Piawah S, 2019, CANCER-AM CANCER SOC, V125, P4139, DOI 10.1002/cncr.32163
   Provenzale D, 2018, J NATL COMPR CANC NE, V16, P939, DOI 10.6004/jnccn.2018.0067
   Rawla P, 2019, GASTROENTEROL REV, V14, P89, DOI 10.5114/pg.2018.81072
   Vega-Rubin-de-Celis S, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21239210
   Wang T, 2021, CELL CYCLE, V20, P1181, DOI 10.1080/15384101.2021.1930357
   Wang X, 2021, BIOENGINEERED, V12, P44, DOI 10.1080/21655979.2020.1857120
   Wong RSY, 2011, J EXP CLIN CANC RES, V30, DOI 10.1186/1756-9966-30-87
   Xia F, 2021, MED RES REV, V41, P1644, DOI 10.1002/med.21772
   Xuan W, 2016, SCI REP-UK, V6, DOI 10.1038/srep26277
   Ye F, 2017, MED GAS RES, V7, P204, DOI 10.4103/2045-9912.215751
   Yu L, 2017, BLOOD REV, V31, P77, DOI 10.1016/j.blre.2016.10.001
   Zhang JL, 2017, EXP THER MED, V13, P1074, DOI 10.3892/etm.2017.4058
NR 29
TC 3
Z9 3
U1 3
U2 7
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 2165-5979
EI 2165-5987
J9 BIOENGINEERED
JI Bioengineered
PD JAN 1
PY 2021
VL 12
IS 1
BP 2723
EP 2733
DI 10.1080/21655979.2021.1937911
PG 11
WC Biotechnology & Applied Microbiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology
GA SV7PA
UT WOS:000664010000001
PM 34151717
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Li, B
   Wang, Z
   Xie, JM
   Wang, G
   Qian, LQ
   Guan, XM
   Shen, XP
   Qin, ZH
   Shen, GH
   Li, XQ
   Gao, QG
AF Li, Bin
   Wang, Zhong
   Xie, Jia-ming
   Wang, Gang
   Qian, Li-qiang
   Guan, Xue-mei
   Shen, Xue-ping
   Qin, Zheng-hong
   Shen, Gen-hai
   Li, Xiao-qiang
   Gao, Quan-gen
TI TIGAR knockdown enhanced the anticancer effect of aescin via regulating
   autophagy and apoptosis in colorectal cancer cells
SO ACTA PHARMACOLOGICA SINICA
LA English
DT Article
DE TIGAR; aescin; apoptosis; autophagy; colorectal cancer
ID FACTOR-KAPPA-B; BETA-ESCIN; TP53-INDUCED GLYCOLYSIS;
   HEPATOCELLULAR-CARCINOMA; GLIOMA-CELLS; IDENTIFICATION; INHIBITION;
   STATISTICS; RESISTANCE; PATHWAY
AB Our previous study showed that TP53-induced glycolysis and apoptosis regulator (TIGAR) regulated ROS, autophagy, and apoptosis in response to hypoxia and chemotherapeutic drugs. Aescin, a triterpene saponin, exerts anticancer effects and increases ROS levels. The ROS is a key upstream signaling to activate autophagy. Whether there is a crosstalk between TIGAR and aescin in regulating ROS, autophagy, and apoptosis is unknown. In this study, we found that aescin inhibited cell viability and colony formation, and induced DNA damage, cell cycle arrest, and apoptosis in cancer cell lines HCT-116 and HCT-8 cells. Concurrently, aescin increased the expression of TIGAR, ROS levels, and autophagy activation. Knockdown of TIGAR enhanced the anticancer effects of aescin in vitro and in vivo, whereas overexpression of TIGAR or replenishing TIGAR downstream products, NADPH and ribose, attenuated aescin-induced apoptosis. Furthermore, aescin-induced ROS elevation and autophagy activation were further strengthened by TIGAR knockdown in HCT-116 cells. However, autophagy inhibition by knockdown of autophagy-related gene ATGS or 3-methyladenine (3-MA) exaggerated aescin-induced apoptosis when TIGAR was knocked down. In conclusion, TIGAR plays a dual role in determining cancer cell fate via inhibiting both apoptosis and autophagy in response to aescin, which indicated that inhibition of TIGAR and/or autophagy may be a junctional therapeutic target in treatment of cancers with aescin.
C1 [Li, Bin; Li, Xiao-qiang] Soochow Univ, Affiliated Hosp 2, Dept Vasc Surg, Suzhou 215007, Peoples R China.
   [Li, Bin; Wang, Gang; Qian, Li-qiang; Guan, Xue-mei; Shen, Xue-ping; Shen, Gen-hai; Gao, Quan-gen] First Peoples Hosp Wu Jiang, Dept Gen Surg, Suzhou 215200, Peoples R China.
   [Li, Bin; Qin, Zheng-hong] Soochow Univ, Jiangsu Key Lab Prevent & Translat Med Geriatr Di, Jiangsu Key Lab Translat Res & Therapy Neuropsyco, Coll Pharmaceut Sci,Dept Pharmacol, Suzhou 215123, Peoples R China.
   [Li, Bin; Qin, Zheng-hong] Soochow Univ, Jiangsu Key Lab Prevent & Translat Med Geriatr Di, Jiangsu Key Lab Translat Res & Therapy Neuropsyco, Coll Pharmaceut Sci,Lab Aging & Nervous Dis, Suzhou 215123, Peoples R China.
   [Wang, Zhong; Xie, Jia-ming] Soochow Univ, Affiliated Hosp 2, Dept Gen Surg, Suzhou 215007, Peoples R China.
RP Li, XQ (corresponding author), Soochow Univ, Affiliated Hosp 2, Dept Vasc Surg, Suzhou 215007, Peoples R China.; Shen, GH; Gao, QG (corresponding author), First Peoples Hosp Wu Jiang, Dept Gen Surg, Suzhou 215200, Peoples R China.
EM wjsgh3026@sina.com; flytsg@126.com; wjyygqg@sohu.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81770483, 81602613]; Jiangsu Provincial
   Commission of Health and Family Planning [YG201402, YG201503]; Jiangsu
   Provincial Medical Youth Talent [QNRC2016249]; Jiangsu Provincial
   Science and Technology office [BL2014043]; Suzhou Science and Technology
   Bureau [SYSD2013041, SYSD2016044, SYSD2017041, SYS201788]; Suzhou Health
   and Family Planning Commission Program [LCZX201504]; Wujiang District
   Science and Technology Bureau [WS201301]; Wujiang District Commission of
   Health and Family Planning [WWK201607, WWK201609]
FX This work was supported by grants from National Natural Science
   Foundation of China (No. 81770483 and 81602613), Jiangsu Provincial
   Commission of Health and Family Planning (No. YG201402 and YG201503),
   Jiangsu Provincial Medical Youth Talent (No. QNRC2016249), Jiangsu
   Provincial Science and Technology office (No. BL2014043), Suzhou Science
   and Technology Bureau (No. SYSD2013041, SYSD2016044, SYSD2017041, and
   SYS201788), Suzhou Health and Family Planning Commission Program (No.
   LCZX201504), Wujiang District Science and Technology Bureau (No.
   WS201301), and Wujiang District Commission of Health and Family Planning
   (No. WWK201607 and WWK201609).
CR Al-Khayal K, 2016, ONCOL REP, V35, P1281, DOI 10.3892/or.2015.4494
   Bensaad K, 2006, CELL, V126, P107, DOI 10.1016/j.cell.2006.05.036
   Bensaad K, 2009, EMBO J, V28, P3015, DOI 10.1038/emboj.2009.242
   Brenner H, 2014, LANCET, V383, P1490, DOI 10.1016/S0140-6736(13)61649-9
   Cheung EC, 2013, DEV CELL, V25, P463, DOI 10.1016/j.devcel.2013.05.001
   Cheung EC, 2012, P NATL ACAD SCI USA, V109, P20491, DOI 10.1073/pnas.1206530109
   Fang LM, 2017, ACTA PHARMACOL SIN, V38, P1305, DOI 10.1038/aps.2017.25
   Fearon ER, 2011, ANNU REV PATHOL-MECH, V6, P479, DOI 10.1146/annurev-pathol-011110-130235
   Harikumar KB, 2010, MOL PHARMACOL, V77, P818, DOI 10.1124/mol.109.062760
   Holohan C, 2013, NAT REV CANCER, V13, P714, DOI 10.1038/nrc3599
   Huang GL, 2015, WORLD J GASTROENTERO, V21, P1148, DOI 10.3748/wjg.v21.i4.1148
   Jackson SP, 2009, NATURE, V461, P1071, DOI 10.1038/nature08467
   Ji DB, 2011, MOL CARCINOGEN, V50, P945, DOI 10.1002/mc.20762
   Kroemer G, 2010, MOL CELL, V40, P280, DOI 10.1016/j.molcel.2010.09.023
   Lee HS, 2014, NUTR CANCER, V66, P938, DOI 10.1080/01635581.2014.922202
   Lee P, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.205
   Markowitz SD, 2009, NEW ENGL J MED, V361, P2449, DOI 10.1056/NEJMra0804588
   Ming ZJ, 2010, PHYTOMEDICINE, V17, P575, DOI 10.1016/j.phymed.2009.12.009
   Mizushima N, 2011, CELL, V147, P728, DOI 10.1016/j.cell.2011.10.026
   Mojzisova G, 2016, ACTA BIOCHIM POL, V63, P79, DOI 10.18388/abp.2015_1013
   Patiolla JMR, 2006, MOL CANCER THER, V5, P1459, DOI 10.1158/1535-7163.MCT-05-0495
   Qian LQ, 2015, CANCER LETT, V368, P126, DOI 10.1016/j.canlet.2015.07.035
   Qian SX, 2016, J HEMATOL ONCOL, V9, DOI 10.1186/s13045-016-0360-4
   Roos WP, 2006, TRENDS MOL MED, V12, P440, DOI 10.1016/j.molmed.2006.07.007
   SEGLEN PO, 1982, P NATL ACAD SCI-BIOL, V79, P1889, DOI 10.1073/pnas.79.6.1889
   Siegel RL, 2017, CA-CANCER J CLIN, V67, P177, DOI 10.3322/caac.21395
   Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387
   Tan SML, 2010, J PHARMACOL EXP THER, V334, P285, DOI 10.1124/jpet.110.165498
   Wang YW, 2012, J CANCER RES CLIN, V138, P785, DOI 10.1007/s00432-012-1152-z
   Wang YH, 2016, ONCOTARGET, V7, P23684, DOI 10.18632/oncotarget.8152
   Wanka C, 2012, J BIOL CHEM, V287, P33436, DOI 10.1074/jbc.M112.384578
   White E, 2012, NAT REV CANCER, V12, P401, DOI 10.1038/nrc3262
   Won KY, 2012, HUM PATHOL, V43, P221, DOI 10.1016/j.humpath.2011.04.021
   Wong EYL, 2015, ONCOL LETT, V9, P569, DOI 10.3892/ol.2014.2797
   Xie JM, 2014, CANCER RES, V74, P5127, DOI 10.1158/0008-5472.CAN-13-3517
   Yu HP, 2015, SCI REP-UK, V5, DOI 10.1038/srep09853
   Zhang HW, 2014, FREE RADICAL BIO MED, V69, P239, DOI 10.1016/j.freeradbiomed.2014.01.034
   Zhang L, 2015, FREE RADICAL BIO MED, V89, P452, DOI 10.1016/j.freeradbiomed.2015.08.030
NR 38
TC 11
Z9 11
U1 3
U2 13
PU ACTA PHARMACOLOGICA SINICA
PI SHANGHAI
PA 294 TAI-YUAN RD, SHANGHAI, 200031, PEOPLES R CHINA
SN 1671-4083
EI 1745-7254
J9 ACTA PHARMACOL SIN
JI Acta Pharmacol. Sin.
PD JAN
PY 2019
VL 40
IS 1
BP 111
EP 121
DI 10.1038/s41401-018-0001-2
PG 11
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry; Pharmacology & Pharmacy
GA HG2EA
UT WOS:000454774700012
PM 29769743
OA Green Published, Bronze
DA 2022-04-25
ER

PT J
AU Wang, YX
   Lin, C
   Cui, LJ
   Yang, WH
   Li, QM
   Liu, ZJ
   Miao, XP
AF Wang, Yu-Xuan
   Lin, Cheng
   Cui, Lu-Jia
   Yang, Wan-He
   Li, Qiu-Min
   Liu, Zhan-Ju
   Miao, Xin-Pu
TI Rauwolfia vomitoria Extract Represses Colorectal Cancer Cell Autophagy
   and Promotes Apoptosis
SO PHARMACOLOGY
LA English
DT Article
DE Colorectal cancer; Rauwolfia vomitoria extract; Autophagy; Apoptosis;
   Digestive tract tumors
ID ANTITUMOR ACTIVITIES; POTENTIATION; METASTASIS; THERAPY; DRUGS; DEATH
AB Background: Colorectal cancer (CRC) is one of the most frequent digestive tract tumors in the world with an increasing incidence. Currently, surgical resection and chemotherapy are the main therapeutic options; however, their effects are limited by various adverse reactions. Rauwolfia vomitoria extract (Rau) has been shown to repress the progression of multiple human cancers; however, whether Rau plays a role in CRC remains undetermined. Methods: Influences of Rau treatment on HCT-116 and LoVo cells were estimated via MTT and colony formation experiments. Flow cytometry analysis was adopted to evaluate the apoptosis rate of HCT-116 and LoVo cells. Apoptosis-related proteins (Bcl-2, Bax, and caspase-3) and autophagy-related proteins (LC3 and P62) were assessed by Western blotting. Effects of Rau on autophagy of HCT-116 and LoVo cell were evaluated through GFP-LC3 analysis. In vivo xenograft tumor assay was conducted to further examine the role of Rau in CRC tumor growth. Results: Rau remarkably repressed HCT-116 and LoVo cell viability and promoted HCT-116 and LoVo cell apoptosis in vitro in a dose-dependent manner. Rau increased the expression of caspase-3 and Bax and decreased the expression of Bcl-2 in HCT-116 and LoVo cells. Moreover, Rau was demonstrated to decrease the LC3||/LC3| ratio and increase the level of P62 in HCT-116 and LoVo cells. In addition, we found that Rau repressed xenograft tumor growth and also repressed autophagy in vivo. Conclusion: Our findings revealed that Rau repressed CRC cell viability and autophagy in vitro and in vivo, suggesting that Rau might be a potent therapeutic agent of CRC.
C1 [Wang, Yu-Xuan; Lin, Cheng; Cui, Lu-Jia; Yang, Wan-He; Li, Qiu-Min; Miao, Xin-Pu] Hainan Gen Hosp, Dept Gastroenterol, Haikou, Hainan, Peoples R China.
   [Liu, Zhan-Ju] Tongji Univ, Dept Gastroenterol, Shanghai Peoples Hosp 10, Shanghai, Peoples R China.
RP Miao, XP (corresponding author), Hainan Gen Hosp, Dept Gastroenterol, Haikou, Hainan, Peoples R China.
EM maoxinpu@163.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81360603]; Natural Science Foundation of
   Hainan Province [813215]
FX This work was supported by the National Natural Science Foundation of
   China (Grant No. 81360603) and Natural Science Foundation of Hainan
   Province (Grant No. 813215).
CR Al Bandar MH, 2017, ONCOL REP, V37, P2553, DOI 10.3892/or.2017.5531
   Amin A, 2015, INT J MOL SCI, V16, P1544, DOI 10.3390/ijms16011544
   BELJANSKI M, 1986, ONCOLOGY, V43, P198, DOI 10.1159/000226363
   Bemis DL, 2006, INT J ONCOL, V29, P1065
   Brody H, 2015, NATURE, V521, pS1, DOI 10.1038/521S1a
   Chen Q, 2005, INT J CANCER, V114, P675, DOI 10.1002/ijc.20703
   Connell LC, 2017, CURR TREAT OPTION ON, V18, DOI 10.1007/s11864-017-0463-3
   Cottone L, 2015, INT J CANCER, V136, P1381, DOI 10.1002/ijc.29125
   Dong RC, 2018, ONCOL REP, V40, P3144, DOI 10.3892/or.2018.6713
   Du L B, 2017, Zhonghua Zhong Liu Za Zhi, V39, P701, DOI 10.3760/cma.j.issn.0253-3766.2017.09.012
   Filfan M, 2017, ROM J MORPHOL EMBRYO, V58, P27
   Gbolade A, 2012, J ETHNOPHARMACOL, V144, P1, DOI 10.1016/j.jep.2012.07.018
   Geng F, 2017, CANCER BIOTHER RADIO, V32, P149, DOI 10.1089/cbr.2017.2210
   Golonko A, 2019, EUR J MED CHEM, V181, DOI 10.1016/j.ejmech.2019.07.015
   Hu T, 2015, PHYTOMEDICINE, V22, P536, DOI 10.1016/j.phymed.2015.03.010
   Huang F, 2018, WORLD J GASTROENTERO, V24, P4643, DOI 10.3748/wjg.v24.i41.4643
   Huang RH, 2017, CELL PHYSIOL BIOCHEM, V41, P1851, DOI 10.1159/000471933
   Jacob JA, 2017, CLIN CHIM ACTA, V468, P85, DOI 10.1016/j.cca.2017.01.028
   Li YJ, 2017, CHIN J CANCER, V52, DOI 10.1186/s40880-017-0219-2
   Lobay Douglas, 2015, Integr Med (Encinitas), V14, P40
   Mahar AL, 2017, J SURG ONCOL, V116, P969, DOI 10.1002/jso.24774
   Mokarram P, 2017, AUTOPHAGY, V13, P781, DOI 10.1080/15548627.2017.1290751
   Nagar R, 2017, INDIAN J DERMATOL VE, V83, P290, DOI 10.4103/0378-6323.196320
   Pesewu GA, 2008, J ETHNOPHARMACOL, V116, P102, DOI 10.1016/j.jep.2007.11.005
   Qian HR, 2017, ONCOTARGET, V8, P62759, DOI 10.18632/oncotarget.18663
   Racanelli AC, 2018, AUTOPHAGY, V14, P221, DOI 10.1080/15548627.2017.1389823
   Ravanan P, 2017, LIFE SCI, V188, P53, DOI 10.1016/j.lfs.2017.08.029
   Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993
   Tay KC, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00820
   Woods D, 2013, CANCER BIOL THER, V14, P379, DOI 10.4161/cbt.23761
   Xiong HY, 2010, CANCER LETT, V288, P68, DOI 10.1016/j.canlet.2009.06.039
   Yu J, 2014, INTEGR CANCER THER, V13, P217, DOI 10.1177/1534735414532010
   Yu Jun, 2013, Curr Ther Res Clin Exp, V75, P8, DOI 10.1016/j.curtheres.2013.04.001
   Zhang Yue, 2015, Zhonghua Liu Xing Bing Xue Za Zhi, V36, P709
   Zhao S, 2017, ONCOTARGET, V8, P7502, DOI 10.18632/oncotarget.10649
NR 35
TC 0
Z9 0
U1 3
U2 3
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0031-7012
EI 1423-0313
J9 PHARMACOLOGY
JI Pharmacology
PD SEP
PY 2021
VL 106
IS 9-10
BP 488
EP 497
DI 10.1159/000512614
EA JUL 2021
PG 10
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA UT8JV
UT WOS:000673910500001
PM 34237728
DA 2022-04-25
ER

PT J
AU Kwon, Y
   Kim, M
   Jung, HS
   Kim, Y
   Jeoung, D
AF Kwon, Yoojung
   Kim, Misun
   Jung, Hyun Suk
   Kim, Youngmi
   Jeoung, Dooil
TI Targeting Autophagy for Overcoming Resistance to Anti-EGFR Treatments
SO CANCERS
LA English
DT Review
DE anti-EGFR treatments; autophagy; EGFR signaling; co-targeting
ID GROWTH-FACTOR RECEPTOR; CELL LUNG-CANCER; TYROSINE KINASE INHIBITORS;
   ACQUIRED-RESISTANCE; EXTRACELLULAR VESICLES; TUMOR PROGRESSION;
   COLORECTAL-CANCER; CARCINOMA-CELLS; DRUG-RESISTANCE; MTOR-INHIBITOR
AB Epidermal growth factor receptor (EGFR) plays critical roles in cell proliferation, tumorigenesis, and anti-cancer drug resistance. Overexpression and somatic mutations of EGFR result in enhanced cancer cell survival. Therefore, EGFR can be a target for the development of anti-cancer therapy. Patients with cancers, including non-small cell lung cancers (NSCLC), have been shown to response to EGFR-tyrosine kinase inhibitors (EGFR-TKIs) and anti-EGFR antibodies. However, resistance to these anti-EGFR treatments has developed. Autophagy has emerged as a potential mechanism involved in the acquired resistance to anti-EGFR treatments. Anti-EGFR treatments can induce autophagy and result in resistance to anti-EGFR treatments. Autophagy is a programmed catabolic process stimulated by various stimuli. It promotes cellular survival under these stress conditions. Under normal conditions, EGFR-activated phosphoinositide 3-kinase (PI3K)/AKT serine/threonine kinase (AKT)/mammalian target of rapamycin (mTOR) signaling inhibits autophagy while EGFR/rat sarcoma viral oncogene homolog (RAS)/mitogen-activated protein kinase kinase (MEK)/mitogen-activated protein kinase (MAPK) signaling promotes autophagy. Thus, targeting autophagy may overcome resistance to anti-EGFR treatments. Inhibitors targeting autophagy and EGFR signaling have been under development. In this review, we discuss crosstalk between EGFR signaling and autophagy. We also assess whether autophagy inhibition, along with anti-EGFR treatments, might represent a promising approach to overcome resistance to anti-EGFR treatments in various cancers. In addition, we discuss new developments concerning anti-autophagy therapeutics for overcoming resistance to anti-EGFR treatments in various cancers.
C1 [Kwon, Yoojung; Kim, Misun; Jung, Hyun Suk; Jeoung, Dooil] Kangwon Natl Univ, Coll Nat Sci, Dept Biochem, Chunchon 24341, South Korea.
   [Kim, Youngmi] Hallym Univ, Coll Med, Inst New Frontier Res, Chunchon 24251, South Korea.
RP Jeoung, D (corresponding author), Kangwon Natl Univ, Coll Nat Sci, Dept Biochem, Chunchon 24341, South Korea.
EM kkwon89@kangwon.ac.kr; misunjtl@naver.com; hsjung@kangwon.ac.kr;
   kym8389@hanmail.net; jeoungd@kangwon.ac.kr
FU National Research Foundation [2017R1A2A2A05001029, 2017M3A9G7072417,
   2018R1D1A1B07043498]; BK21 plus Program
FX This work was supported by National Research Foundation Grants
   (2017R1A2A2A05001029, 2017M3A9G7072417, 2018R1D1A1B07043498), a grant
   from the BK21 plus Program.
CR Aita VM, 1999, GENOMICS, V59, P59, DOI 10.1006/geno.1999.5851
   Alam KJ, 2017, INT J CANCER, V141, P1614, DOI 10.1002/ijc.30861
   Anisuzzaman AM, 2017, MOL CANCER THER, V16, P729, DOI 10.1158/1535-7163.MCT-16-0683
   Aveic S, 2018, CANCER CELL INT, V18, DOI 10.1186/s12935-018-0557-4
   Aveic S, 2016, CANCER CELL INT, V16, DOI 10.1186/s12935-016-0341-2
   Azad MB, 2009, ANTIOXID REDOX SIGN, V11, P777, DOI 10.1089/ARS.2008.2270
   Bai WD, 2014, INT J CANCER, V135, P1356, DOI 10.1002/ijc.28782
   Balak MN, 2006, CLIN CANCER RES, V12, P6494, DOI 10.1158/1078-0432.CCR-06-1570
   Barlesi F, 2016, LANCET, V387, P1415, DOI 10.1016/S0140-6736(16)00004-0
   Bartolomeo R, 2017, J CLIN INVEST, V127, P3717, DOI 10.1172/JCI94130
   Belounis A, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2906-9
   Booth LA, 2014, CELL SIGNAL, V26, P549, DOI 10.1016/j.cellsig.2013.11.028
   Chan SK, 2006, EUR J CANCER, V42, P17, DOI 10.1016/j.ejca.2005.07.031
   Chen S, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0950-x
   Chen X, 2015, SCI REP-UK, V5, DOI 10.1038/srep17031
   Chen Z, 2016, AM J TRANSL RES, V8, P1190
   Chou TY, 2005, CLIN CANCER RES, V11, P3750, DOI 10.1158/1078-0432.CCR-04-1981
   Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001
   Demuth C, 2017, ONCOTARGET, V8, P68221, DOI 10.18632/oncotarget.19920
   Dong QJ, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-42245-3
   Dower CM, 2018, MOL CANCER THER, V17, P2365, DOI 10.1158/1535-7163.MCT-18-0176
   Du J, 2019, J PHARM PHARMACOL, V71, P196, DOI 10.1111/jphp.12941
   Dyczynski M, 2018, CANCER LETT, V435, P32, DOI 10.1016/j.canlet.2018.07.028
   Eimer S, 2011, CANCER BIOL THER, V11, P1017, DOI 10.4161/cbt.11.12.15693
   Fujishita T, 2017, ONCOGENE, V36, P6480, DOI 10.1038/onc.2017.242
   Fung C, 2012, CANCER BIOL THER, V13, P1417, DOI 10.4161/cbt.22002
   Gavali S, 2019, BBA-MOL CELL RES, V1866, P1498, DOI 10.1016/j.bbamcr.2019.06.014
   Gilmer TM, 2008, CANCER RES, V68, P571, DOI 10.1158/0008-5472.CAN-07-2404
   Gomes SE, 2016, ONCOTARGET, V7, P9369, DOI 10.18632/oncotarget.7010
   Greulich H, 2005, PLOS MED, V2, P1167, DOI 10.1371/journal.pmed.0020313
   Guo GF, 2011, WORLD J GASTROENTERO, V17, P4779, DOI 10.3748/wjg.v17.i43.4779
   Han WD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018691
   Han ZJ, 2017, ONCOL REP, V38, P3064, DOI 10.3892/or.2017.5938
   Hara T, 2008, J CELL BIOL, V181, P497, DOI 10.1083/jcb.200712064
   He YY, 2019, J INVEST DERMATOL, V139, P124, DOI 10.1016/j.jid.2018.07.020
   Henson ES, 2006, CELL SIGNAL, V18, P2089, DOI 10.1016/j.cellsig.2006.05.015
   Herr R, 2018, ONCOGENE, V37, P1576, DOI 10.1038/s41388-017-0063-5
   Hooper KM, 2019, INFLAMM BOWEL DIS, V25, P661, DOI 10.1093/ibd/izy380
   Hsu TI, 2016, ONCOTARGET, V7, P20840, DOI 10.18632/oncotarget.7894
   Hu Shousen, 2018, Cell Physiol Biochem, V51, P2509, DOI 10.1159/000495921
   Hu XX, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-04258-8
   Hu YL, 2012, CANCER RES, V72, P4294, DOI 10.1158/0008-5472.CAN-12-1076
   Huang CC, 2016, SCI REP-UK, V6, DOI 10.1038/srep29256
   Huang Q, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00461
   Huang W, 2019, BIOCHEM BIOPH RES CO, V514, P64, DOI 10.1016/j.bbrc.2019.04.111
   Inal C, 2015, EXPERT OPIN EMERG DR, V20, P597, DOI 10.1517/14728214.2015.1058778
   Jin HO, 2015, TOXICOL APPL PHARM, V287, P17, DOI 10.1016/j.taap.2015.05.001
   Jin SD, 2018, THORAC CANCER, V9, P1262, DOI 10.1111/1759-7714.12830
   Jorissen RN, 2003, EXP CELL RES, V284, P31, DOI 10.1016/S0014-4827(02)00098-8
   Juric D, 2018, J CLIN ONCOL, V36, P1291, DOI 10.1200/JCO.2017.72.7107
   Jutten B, 2014, CELL CYCLE, V13, P42, DOI 10.4161/cc.27518
   Kang M, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18020321
   Karantza-Wadsworth V, 2007, GENE DEV, V21, P1621, DOI 10.1101/gad.1565707
   Kim ES, 2001, CURR OPIN ONCOL, V13, P506, DOI 10.1097/00001622-200111000-00014
   Kim H, 2017, MOL CELLS, V40, P54, DOI 10.14348/molcells.2017.2258
   Kim H, 2016, MOL CELLS, V39, P229, DOI 10.14348/molcells.2016.2244
   Kim JS, 2017, J CANCER, V8, P2713, DOI 10.7150/jca.19458
   Kim KY, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18051088
   Kim Y, 2017, ONCOTARGET, V8, P13632, DOI 10.18632/oncotarget.14621
   Kim Y, 2016, ONCOTARGET, V7, P10297, DOI 10.18632/oncotarget.7185
   Kinsey CG, 2019, NAT MED, V25, P861, DOI 10.1038/s41591-019-0433-3
   Klionsky DJ, 2016, AUTOPHAGY, V12, P1, DOI 10.1080/15548627.2015.1100356
   Ko JC, 2009, MOL CANCER RES, V7, P1378, DOI 10.1158/1541-7786.MCR-09-0051
   Kobayashi S, 2005, NEW ENGL J MED, V352, P786, DOI 10.1056/NEJMoa044238
   Kol A, 2017, ONCOTARGET, V8, P45432, DOI 10.18632/oncotarget.17139
   Kotani T, 2018, P NATL ACAD SCI USA, V115, P10363, DOI 10.1073/pnas.1806727115
   Kris MG, 2014, JAMA-J AM MED ASSOC, V311, P1998, DOI 10.1001/jama.2014.3741
   Kumar A, 2008, J CLIN ONCOL, V26, P1742, DOI 10.1200/JCO.2007.12.1178
   Lee DS, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19061608
   Lei Y, 2016, ONCOGENE, V35, P4698, DOI 10.1038/onc.2016.11
   Lemmon MA, 2010, CELL, V141, P1117, DOI 10.1016/j.cell.2010.06.011
   Lewis KM, 2015, LUNG CANCER, V90, P182, DOI 10.1016/j.lungcan.2015.09.014
   Li L, 2019, CANCER LETT, V452, P191, DOI 10.1016/j.canlet.2019.03.027
   Li L, 2014, CLIN CANCER RES, V20, P2714, DOI 10.1158/1078-0432.CCR-13-2613
   Li XQ, 2016, ONCOTARGET, V7, P24585, DOI 10.18632/oncotarget.8358
   Li XQ, 2010, AUTOPHAGY, V6, P1066, DOI 10.4161/auto.6.8.13366
   Li YY, 2013, LUNG CANCER, V81, P354, DOI 10.1016/j.lungcan.2013.05.012
   Liang KH, 2018, CANCER LETT, V433, P165, DOI 10.1016/j.canlet.2018.06.040
   Liao WT, 2019, FREE RADICAL RES, V53, P800, DOI 10.1080/10715762.2019.1635251
   Lin L, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1362-2
   Liu HH, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0216759
   Liu JT, 2015, CLIN LUNG CANCER, V16, pE55, DOI 10.1016/j.cllc.2015.03.006
   Liu JL, 2011, CELL, V147, P223, DOI 10.1016/j.cell.2011.08.037
   Liu LM, 2018, BIOCHEM BIOPH RES CO, V498, P559, DOI 10.1016/j.bbrc.2018.03.019
   Liu XH, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00387
   Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938
   Ma XH, 2014, J CLIN INVEST, V124, P1406, DOI 10.1172/JCI70454
   Martin P, 2016, CLIN LUNG CANCER, V17, P375, DOI 10.1016/j.cllc.2016.01.002
   Martina JA, 2012, AUTOPHAGY, V8, P903, DOI 10.4161/auto.19653
   Meng F, 2016, FRONT GENET, V7, DOI 10.3389/fgene.2016.00197
   Migliore C, 2018, EMBO MOL MED, V10, DOI 10.15252/emmm.201708746
   Mijaljica D, 2011, AUTOPHAGY, V7, P673, DOI 10.4161/auto.7.7.14733
   Misale S, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9305
   Mizushima N, 2002, CELL STRUCT FUNCT, V27, P421, DOI 10.1247/csf.27.421
   Montermini L, 2015, J BIOL CHEM, V290, P24534, DOI 10.1074/jbc.M115.679217
   Moreira-Leite FF, 2010, J THORAC ONCOL, V5, P765, DOI 10.1097/JTO.0b013e3181d95d93
   Muniz-Feliciano L, 2017, AUTOPHAGY, V13, P2072, DOI 10.1080/15548627.2017.1380124
   Mussnich P, 2015, EXPERT OPIN THER TAR, V19, P1017, DOI 10.1517/14728222.2015.1057569
   Nagano T, 2019, DRUG TODAY, V55, P231, DOI 10.1358/dot.2019.55.4.2965337
   Nagaria TS, 2017, ONCOTARGET, V8, P80804, DOI 10.18632/oncotarget.20534
   Nakamura S, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08729-6
   Nathanson DA, 2014, SCIENCE, V343, P72, DOI 10.1126/science.1241328
   Nguyen KSH, 2009, CLIN LUNG CANCER, V10, P281, DOI 10.3816/CLC.2009.n.039
   Nihira K, 2014, J PATHOL, V234, P277, DOI 10.1002/path.4354
   Ouyang L, 2018, J MED CHEM, V61, P2776, DOI 10.1021/acs.jmedchem.7b01575
   Overdijk MB, 2011, J IMMUNOL, V187, P3383, DOI 10.4049/jimmunol.1003926
   Ozawa H, 2017, CLIN CANCER RES, V23, P5162, DOI 10.1158/1078-0432.CCR-16-1686
   Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314
   Pahl JHW, 2012, CLIN CANCER RES, V18, P432, DOI 10.1158/1078-0432.CCR-11-2277
   Pao W, 2005, PLOS MED, V2, P225, DOI 10.1371/journal.pmed.0020073
   Pao W, 2004, P NATL ACAD SCI USA, V101, P13306, DOI 10.1073/pnas.0405220101
   Park HJ, 2018, BIOCHEM BIOPH RES CO, V505, P194, DOI 10.1016/j.bbrc.2018.09.085
   Park SY, 2018, BIOCHEM BIOPH RES CO, V506, P641, DOI 10.1016/j.bbrc.2018.10.145
   Paulitti A, 2018, ONCOGENE, V37, P3399, DOI 10.1038/s41388-017-0107-x
   Prasetyanti PR, 2015, ONCOTARGET, V6, P16902, DOI 10.18632/oncotarget.4642
   Queralt B, 2016, ONCOTARGET, V7, P82185, DOI 10.18632/oncotarget.11985
   Rachiglio AM, 2019, CANCERS, V11, DOI 10.3390/cancers11030341
   Redell MS, 2011, BLOOD, V117, P5701, DOI 10.1182/blood-2010-04-280123
   Regales L, 2009, J CLIN INVEST, V119, P3000, DOI 10.1172/JCI38746
   Rouschop KMA, 2010, J CLIN INVEST, V120, P127, DOI 10.1172/JCI40027
   Russell RC, 2013, NAT CELL BIOL, V15, P741, DOI 10.1038/ncb2757
   Saint-Martin A, 2019, CANCERS, V11, DOI 10.3390/cancers11060755
   Sakurada A, 2006, CLIN LUNG CANCER, V7, pS138, DOI 10.3816/CLC.2006.s.005
   Schreier B, 2016, BBA-MOL CELL RES, V1863, P1519, DOI 10.1016/j.bbamcr.2016.03.017
   Senoo H, 2019, NAT CELL BIOL, V21, P867, DOI 10.1038/s41556-019-0348-8
   Shen J, 2013, BRIT J CANCER, V109, P164, DOI 10.1038/bjc.2013.306
   Shen S, 2011, ONCOGENE, V30, P4544, DOI 10.1038/onc.2011.168
   Shi K, 2018, J CONTROL RELEASE, V279, P53, DOI 10.1016/j.jconrel.2018.04.023
   Siano M, 2018, ORAL ONCOL, V82, P144, DOI 10.1016/j.oraloncology.2018.05.013
   Sobhakumari A, 2013, TOXICOL APPL PHARM, V272, P736, DOI 10.1016/j.taap.2013.07.013
   Srivastava RM, 2013, CLIN CANCER RES, V19, P1858, DOI 10.1158/1078-0432.CCR-12-2426
   Stahlhut C, 2015, CELL CYCLE, V14, P2171, DOI 10.1080/15384101.2014.1003008
   Sui X, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.350
   Suto T, 2015, CARCINOGENESIS, V36, P338, DOI 10.1093/carcin/bgu242
   Sutton MN, 2019, CANCERS, V11, DOI 10.3390/cancers11040557
   Ta NL, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-30804-z
   Takahashi Y, 2013, BLOOD, V121, P1622, DOI 10.1182/blood-2012-10-459826
   Tan Q, 2017, CANCER CHEMOTH PHARM, V79, P959, DOI 10.1007/s00280-017-3298-5
   Tan XJ, 2016, TRENDS CELL BIOL, V26, P352, DOI 10.1016/j.tcb.2015.12.006
   Tan XJ, 2015, CELL, V160, P145, DOI 10.1016/j.cell.2014.12.006
   Tang ZH, 2018, CANCER LETT, V412, P1, DOI 10.1016/j.canlet.2017.10.001
   Tang ZH, 2017, TOXICOL APPL PHARM, V321, P18, DOI 10.1016/j.taap.2017.02.017
   Thorburn A, 2014, MOL PHARMACOL, V85, P830, DOI 10.1124/mol.114.091850
   Tracy S, 2004, CANCER RES, V64, P7241, DOI 10.1158/0008-5472.CAN-04-1905
   Tung CL, 2017, EXP CELL RES, V357, P59, DOI 10.1016/j.yexcr.2017.04.026
   van Dommelen SM, 2016, NANOMEDICINE-UK, V11, P881, DOI 10.2217/nnm-2015-0009
   Voigt M, 2012, NEOPLASIA, V14, P1023, DOI 10.1593/neo.121242
   Wang H, 2019, CANCER LETT, V455, P48, DOI 10.1016/j.canlet.2019.04.027
   Wang R, 2019, INT J CANCER, V144, P200, DOI 10.1002/ijc.31907
   Wang ZL, 2016, INT J ONCOL, V48, P2558, DOI 10.3892/ijo.2016.3468
   Ward CW, 2001, BMC BIOINFORMATICS, V2, DOI 10.1186/1471-2105-2-4
   Wei YJ, 2013, CELL, V154, P1269, DOI 10.1016/j.cell.2013.08.015
   Wieduwilt MJ, 2008, CELL MOL LIFE SCI, V65, P1566, DOI 10.1007/s00018-008-7440-8
   Wu QW, 2018, BIOMED PHARMACOTHER, V99, P278, DOI 10.1016/j.biopha.2018.01.055
   Wykosky Jill, 2011, Chin J Cancer, V30, P5
   Xilouri M, 2016, AGEING RES REV, V32, P13, DOI 10.1016/j.arr.2016.07.001
   Yang Y, 2013, ONCOL RES, V21, P345, DOI 10.3727/096504014X14024160459285
   Yang ZNJ, 2011, MOL CANCER THER, V10, P1533, DOI 10.1158/1535-7163.MCT-11-0047
   Yang ZY, 2015, CURR CANCER DRUG TAR, V15, P215, DOI 10.2174/1568009615666150126161939
   Yao S, 2019, CELL SIGNAL, V61, P10, DOI 10.1016/j.cellsig.2019.05.004
   Ye J, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00676
   Ye MT, 2017, J CANCER, V8, P3774, DOI 10.7150/jca.21035
   Yeon M, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00599
   Yochum ZA, 2019, ONCOGENE, V38, P656, DOI 10.1038/s41388-018-0482-y
   Yu XJ, 2017, MOL IMMUNOL, V87, P300, DOI 10.1016/j.molimm.2017.05.010
   Yue JN, 2018, ONCOGENE, V37, P4300, DOI 10.1038/s41388-018-0276-2
   Yun CH, 2007, CANCER CELL, V11, P217, DOI 10.1016/j.ccr.2006.12.017
   Zhang NS, 2019, LAB INVEST, V99, P568, DOI 10.1038/s41374-018-0164-y
   Zhang PH, 2017, AUTOPHAGY, V13, P1093, DOI 10.1080/15548627.2017.1319039
   Zhang W, 2018, INT J ONCOL, V53, P527, DOI 10.3892/ijo.2018.4412
   Zhang XW, 2006, CELL, V125, P1137, DOI 10.1016/j.cell.2006.05.013
   Zhang Y, 2012, J BIOL CHEM, V287, P21926, DOI 10.1074/jbc.M112.340398
   Zhao J, 2017, LUNG CANCER, V108, P96, DOI 10.1016/j.lungcan.2017.02.020
   Zheng D, 2017, ONCOTARGET, V8, P49671, DOI 10.18632/oncotarget.17913
   Zhou ZJ, 2018, BIOCHEM BIOPH RES CO, V500, P411, DOI 10.1016/j.bbrc.2018.04.089
   Zhuang HQ, 2016, ONCOTARGET, V7, P84688, DOI 10.18632/oncotarget.12423
   Zou YY, 2013, J THORAC ONCOL, V8, P693, DOI 10.1097/JTO.0b013e31828c7210
   Zou ZZ, 2012, AUTOPHAGY, V8, P1798, DOI 10.4161/auto.22110
NR 178
TC 36
Z9 37
U1 3
U2 13
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2072-6694
J9 CANCERS
JI Cancers
PD SEP
PY 2019
VL 11
IS 9
AR 1374
DI 10.3390/cancers11091374
PG 24
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA JD1EW
UT WOS:000489719000159
PM 31527477
OA Green Submitted, Green Published, gold
DA 2022-04-25
ER

PT J
AU Hinze, L
   Labrosse, R
   Degar, J
   Han, T
   Schatoff, EM
   Schreek, S
   Karim, S
   McGuckin, C
   Sacher, JR
   Wagner, F
   Stanulla, M
   Yuan, C
   Sicinska, E
   Giannakis, M
   Ng, K
   Dow, LE
   Gutierrez, A
AF Hinze, Laura
   Labrosse, Roxane
   Degar, James
   Han, Teng
   Schatoff, Emma M.
   Schreek, Sabine
   Karim, Salmaan
   McGuckin, Connor
   Sacher, Joshua R.
   Wagner, Florence
   Stanulla, Martin
   Yuan, Chen
   Sicinska, Ewa
   Giannakis, Marios
   Ng, Kimmie
   Dow, Lukas E.
   Gutierrez, Alejandro
TI Exploiting the Therapeutic Interaction of WNT Pathway Activation and
   Asparaginase for Colorectal Cancer Therapy
SO CANCER DISCOVERY
LA English
DT Article
ID GENETIC ALTERATIONS; PROTEIN; MUTATIONS; RNF43; DIFFERENTIATION;
   GSK-3-ALPHA; HOMEOSTASIS; AUTOPHAGY; SURVIVAL; HOMOLOG
AB Colorectal cancer is driven by mutations that activate canonical WNT/beta-catenin signaling, but inhibiting WNT has significant on-target toxicity, and there are no approved therapies targeting dominant oncogenic drivers. We recently found that activating a beta-catenin-independent branch of WNT signaling that inhibits GSK3-dependent protein degradation induces asparaginase sensitivity in drug-resistant leukemias. To test predictions from our model, we turned to colorectal cancer because these cancers can have WNT-activating mutations that function either upstream (i.e., R-spondin fusions) or downstream (APC or beta-catenin mutations) of GSK3, thus allowing WNT/beta-catenin and WNT-induced asparaginase sensitivity to be unlinked genetically. We found that asparaginase had little efficacy in APC or beta-catenin-mutant colorectal cancer, but was profoundly toxic in the setting of R-spondin fusions. Pharmacologic GSK3 alpha inhibition was sufficient for asparaginase sensitization in APC or beta-catenin-mutant colorectal cancer, but not in normal intestinal progenitors. Our findings demonstrate that WNT-induced therapeutic vulnerabilities can be exploited for colorectal cancer therapy.
   SIGNIFICANCE Solid tumors are thought to be asparaginase-resistant via de novo asparagine synthesis. In leukemia, GSK3 alpha-dependent protein degradation, a catabolic amino acid source, mediates asparaginase resistance. We found that asparaginase is profoundly toxic to colorectal cancers with WNT-activating mutations that inhibit GSK3. Aberrant WNT activation can provide a therapeutic vulnerability in colorectal cancer.
C1 [Hinze, Laura; Labrosse, Roxane; Degar, James; Karim, Salmaan; McGuckin, Connor; Gutierrez, Alejandro] Harvard Med Sch, Boston Childrens Hosp, Div Hematol Oncol, Boston, MA 02115 USA.
   [Hinze, Laura; Schreek, Sabine; Stanulla, Martin] Hannover Med Sch, Dept Pediat Hematol & Oncol, Hannover, Germany.
   [Han, Teng; Schatoff, Emma M.] Weill Cornell Med, Sandra & Edward Meyer Canc Ctr, New York, NY USA.
   [Han, Teng; Schatoff, Emma M.; Dow, Lukas E.] Weill Cornell Med, Veil Cornell Grad Sch Med Sci, New York, NY USA.
   [Schatoff, Emma M.] Weill Cornell Rockefeller Sloan Kettering Triins, New York, NY USA.
   [Sacher, Joshua R.; Wagner, Florence] Broad Inst MIT & Harvard, Stanley Ctr Psychiat Res, Cambridge, MA 02142 USA.
   [Yuan, Chen; Giannakis, Marios; Ng, Kimmie] Harvard Med Sch, Dept Med Oncol, Dana Farber Canc Inst, Boston, MA 02115 USA.
   [Sicinska, Ewa] Dana Farber Canc Inst, Dept Oncol Pathol, Boston, MA 02115 USA.
   [Giannakis, Marios] Broad Inst MIT & Harvard, Cambridge, MA 02142 USA.
   [Dow, Lukas E.] Weill Cornell Med, Dept Med, New York, NY USA.
   [Dow, Lukas E.] Weill Cornell Med, Dept Biochem, New York, NY USA.
   [Gutierrez, Alejandro] Harvard Med Sch, Dept Pediat Oncol, Dana Farber Canc Inst, Boston, MA 02115 USA.
RP Gutierrez, A (corresponding author), Boston Childrens Hosp, Div Hematol Oncol, 300 Longwood Ave, Boston, MA 02115 USA.
EM alejandro.gutierrez@childrens.harvard.edu
RI ; Sacher, Joshua/M-7463-2016
OI Degar, James/0000-0002-5387-9069; Sacher, Joshua/0000-0003-4381-3979;
   McGuckin, Connor/0000-0001-8860-9926
FU NIH/NCIUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R01
   CA193651]; Boston Children's Hospital Translational Investigator
   Service; Dana-Farber Cancer Institute Medical Oncology Translational
   Grant Award; ERA-NET Transcan/European Commission under the 7th
   Framework Programme (FP7); German National Academic Foundation;
   Biomedical Education Program; Conquer Cancer Foundation of ASCO Career
   Development Award; Project P-Fund; Cancer Research UKCancer Research UK
   [C10674/A27140]; Stand Up To Cancer Colorectal Cancer Dream Team
   Translational Research Grant [SU2C-AACRDT22-17]; American Association
   for Cancer Research; Medical Scientist Training Program grant from the
   National Institute of General Medical Sciences of the NIH [T32GM07739];
   NCI/NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [1
   F31 CA224800-01]; NIHUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [R01 CA205406];
   DODUnited States Department of Defense [CA160344]; CHPA Investigatorship
   at Boston Children's Hospital
FX We thank Kimberly Stegmaier, Daniel Bauer, Alex Kentsis, Scott
   Armstrong, Gabriela Zurek, Nikolaus Kuehn-Velten, Mark Kellogg, Timothy
   Hagan, Otari Chipashvili, and Sung-Yun Pai for advice and discussion,
   and Meaghan McGuinness and Casey O'Brien for experimental assistance.
   This work was supported by NIH/NCI R01 CA193651, the Boston Children's
   Hospital Translational Investigator Service, a Dana-Farber Cancer
   Institute Medical Oncology Translational Grant Award, and the ERA-NET
   Transcan/European Commission under the 7th Framework Programme (FP7). L.
   Hinze was supported by the German National Academic Foundation and the
   Biomedical Education Program. M. Giannakis was supported by a Conquer
   Cancer Foundation of ASCO Career Development Award, the Project P-Fund,
   the Cancer Research UK C10674/A27140 Grand Challenge Award, and a Stand
   Up To Cancer Colorectal Cancer Dream Team Translational Research Grant
   (grant number: SU2C-AACRDT22-17). Stand Up To Cancer (SU2C) is a
   division of the Entertainment Industry Foundation, and research grants
   are administered by the American Association for Cancer Research, the
   scientific partner of SU2C. E.M. Schatoff was supported by a Medical
   Scientist Training Program grant from the National Institute of General
   Medical Sciences of the NIH under award number T32GM07739 to the Weill
   Cornell/Rockefeller/Sloan-Kettering Tri-Institutional MD/PhD Program,
   and an F31 Award from the NCI/NIH under grant number 1 F31 CA224800-01.
   K. Ng was supported by NIH R01 CA205406 and DOD CA160344. A. Gutierrez
   was supported by a CHPA Investigatorship at Boston Children's Hospital.
CR Acebron SP, 2014, MOL CELL, V54, P663, DOI 10.1016/j.molcel.2014.04.014
   Banerji V, 2012, J CLIN INVEST, V122, P935, DOI 10.1172/JCI46465
   Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003
   Bennett CN, 2002, J BIOL CHEM, V277, P30998, DOI 10.1074/jbc.M204527200
   Bryant KL, 2019, NAT MED, V25, P628, DOI 10.1038/s41591-019-0368-8
   Bullman S, 2017, SCIENCE, V358, P1443, DOI 10.1126/science.aal5240
   Burns MA, 2018, LEUKEMIA, V32, P2126, DOI 10.1038/s41375-018-0097-x
   Carugo A, 2019, CANCER CELL, V35, P204, DOI 10.1016/j.ccell.2019.01.006
   Chartier C, 2016, CANCER RES, V76, P713, DOI 10.1158/0008-5472.CAN-15-0561
   Cheung AF, 2010, ONCOGENE, V29, P1857, DOI 10.1038/onc.2009.457
   Choi WH, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10963
   CLARKSON B, 1970, CANCER, V25, P1237, DOI 10.1002/1097-0142(197006)25:6<1237::AID-CNCR2820250602>3.0.CO;2-7
   Commisso C, 2013, NATURE, V497, P633, DOI 10.1038/nature12138
   Crighton D, 2006, CELL, V126, P121, DOI 10.1016/j.cell.2006.05.034
   de Lau W, 2011, NATURE, V476, P293, DOI 10.1038/nature10337
   Doble BW, 2007, DEV CELL, V12, P957, DOI 10.1016/j.devcel.2007.04.001
   Dow LE, 2015, CELL, V161, P1539, DOI 10.1016/j.cell.2015.05.033
   Dow LE, 2015, NAT BIOTECHNOL, V33, P390, DOI 10.1038/nbt.3155
   Dubey R, 2020, ELIFE, V9, DOI 10.7554/eLife.54469
   Fahiminiya S, 2013, J MED GENET, V50, P345, DOI 10.1136/jmedgenet-2013-101567
   Gao H, 2015, NAT MED, V21, P1318, DOI 10.1038/nm.3954
   Gayet J, 2001, ONCOGENE, V20, P5025, DOI 10.1038/sj.onc.1204611
   Giannakis M, 2014, NAT GENET, V46, P1264, DOI 10.1038/ng.3127
   Guezguez B, 2016, CANCER CELL, V29, P61, DOI 10.1016/j.ccell.2015.11.012
   Han T, 2017, NAT COMMUN, V8, P1, DOI 10.1038/ncomms15945
   Hao HX, 2012, NATURE, V485, P195, DOI 10.1038/nature11019
   Hinze L, 2019, CANCER CELL, V35, P664, DOI 10.1016/j.ccell.2019.03.004
   Hoeflich KP, 2000, NATURE, V406, P86, DOI 10.1038/35017574
   Huang YL, 2015, P NATL ACAD SCI USA, V112, P5732, DOI 10.1073/pnas.1423533112
   Jiang XM, 2013, P NATL ACAD SCI USA, V110, P12649, DOI 10.1073/pnas.1307218110
   Kandasamy P, 2018, TRENDS BIOCHEM SCI, V43, P752, DOI 10.1016/j.tibs.2018.05.003
   Kato S, 2020, CANCER DISCOV, V10, P980, DOI 10.1158/2159-8290.CD-19-0532
   Klionsky DJ, 2016, AUTOPHAGY, V12, P1, DOI 10.1080/15548627.2015.1100356
   Koepp DM, 2001, SCIENCE, V294, P173, DOI 10.1126/science.1065203
   Koo BK, 2012, NATURE, V488, P665, DOI 10.1038/nature11308
   Liu Y, 2018, CANCER CELL, V33, P721, DOI 10.1016/j.ccell.2018.03.010
   Lochhead PA, 2006, MOL CELL, V24, P627, DOI 10.1016/j.molcel.2006.10.009
   MacAulay K, 2007, CELL METAB, V6, P329, DOI 10.1016/j.cmet.2007.08.013
   Narta UK, 2007, CRIT REV ONCOL HEMAT, V61, P208, DOI 10.1016/j.critrevonc.2006.07.009
   Nusse R, 2017, CELL, V169, P985, DOI 10.1016/j.cell.2017.05.016
   O'Rourke Kevin P, 2016, Bio Protoc, V6
   O'Rourke KP, 2017, NAT BIOTECHNOL, V35, P577, DOI 10.1038/nbt.3837
   OHNUMA T, 1970, CANCER RES, V30, P2297
   Palm W, 2015, CELL, V162, P259, DOI 10.1016/j.cell.2015.06.017
   Poppenborg SM, 2016, EUR J PHARM SCI, V91, P122, DOI 10.1016/j.ejps.2016.06.007
   Riihimaki M, 2016, SCI REP-UK, V6, DOI 10.1038/srep29765
   Rizzari C, 2013, CURR OPIN ONCOL, V25, pS1, DOI 10.1097/CCO.0b013e32835d7d85
   Sanchez-Rivera FJ, 2014, NATURE, V516, P428, DOI 10.1038/nature13906
   Schatoff EM, 2019, CANCER DISCOV, V9, P1358, DOI 10.1158/2159-8290.CD-19-0289
   Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089
   Seshagiri S, 2012, NATURE, V488, P660, DOI 10.1038/nature11282
   Sholl LM, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.87062
   Siegel RL, 2020, CA-CANCER J CLIN, V70, P145, DOI 10.3322/caac.21601
   Siegel RL, 2019, CA-CANCER J CLIN, V69, P7, DOI 10.3322/caac.21551
   SIEGFRIED E, 1992, CELL, V71, P1167, DOI 10.1016/S0092-8674(05)80065-0
   Soares Kevin C, 2014, J Vis Exp, P51677, DOI 10.3791/51677
   Stamos JL, 2014, ELIFE, V3, DOI 10.7554/eLife.01998
   Stock W, 2011, LEUKEMIA LYMPHOMA, V52, P2237, DOI 10.3109/10428194.2011.596963
   Storm EE, 2016, NATURE, V529, P97, DOI 10.1038/nature16466
   SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108
   Suraweera A, 2012, MOL CELL, V48, P242, DOI 10.1016/j.molcel.2012.08.003
   Taelman VF, 2010, CELL, V143, P1136, DOI 10.1016/j.cell.2010.11.034
   Tan D, 2018, ANN ONCOL S9, V29, pix23
   Thompson AA., 1985, J TISSUE CULTURE MET, V9, P117, DOI [10.1007/BF01797782, DOI 10.1007/BF01797782]
   Vabulas RM, 2005, SCIENCE, V310, P1960, DOI 10.1126/science.1121925
   van der Geest LGM, 2015, CLIN EXP METASTAS, V32, P457, DOI 10.1007/s10585-015-9719-0
   Wagner FF, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aam8460
   Wang JG, 2017, NAT PROTOC, V12, P279, DOI 10.1038/nprot.2016.160
   WEST MA, 1989, J CELL BIOL, V109, P2731, DOI 10.1083/jcb.109.6.2731
   WILSON WL, 1975, ONCOLOGY, V32, P109, DOI 10.1159/000225057
   Wu J, 2011, P NATL ACAD SCI USA, V108, P21188, DOI 10.1073/pnas.1118046108
   Yaeger R, 2018, CANCER CELL, V33, P125, DOI 10.1016/j.ccell.2017.12.004
   Zheng HF, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002745
NR 73
TC 14
Z9 14
U1 1
U2 8
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 2159-8274
EI 2159-8290
J9 CANCER DISCOV
JI Cancer Discov.
PD NOV
PY 2020
VL 10
IS 11
BP 1690
EP 1705
DI 10.1158/2159-8290.CD-19-1472
PG 16
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA OJ1OE
UT WOS:000583736200024
PM 32703769
OA Bronze, Green Accepted
DA 2022-04-25
ER

PT J
AU Jing, XM
   Yang, FM
   Shao, CC
   Wei, K
   Xie, MY
   Shen, H
   Shu, YQ
AF Jing, Xinming
   Yang, Fengming
   Shao, Chuchu
   Wei, Ke
   Xie, Mengyan
   Shen, Hua
   Shu, Yongqian
TI Role of hypoxia in cancer therapy by regulating the tumor
   microenvironment
SO MOLECULAR CANCER
LA English
DT Review
DE Cancer therapy; Chemotherapy; Drug resistance; Hypoxia; Tumor
   microenvironment
ID INDUCIBLE FACTORS; DNA-DAMAGE; COLORECTAL-CANCER; INDUCED RESISTANCE;
   ESOPHAGEAL CANCER; INDUCED APOPTOSIS; DRUG-RESISTANCE; CARCINOMA-CELLS;
   GLYOXALASE I; AUTOPHAGY
AB Aim Clinical resistance is a complex phenomenon in major human cancers involving multifactorial mechanisms, and hypoxia is one of the key components that affect the cellular expression program and lead to therapy resistance. The present study aimed to summarize the role of hypoxia in cancer therapy by regulating the tumor microenvironment (TME) and to highlight the potential of hypoxia-targeted therapy. Methods Relevant published studies were retrieved from PubMed, Web of Science, and Embase using keywords such as hypoxia, cancer therapy, resistance, TME, cancer, apoptosis, DNA damage, autophagy, p53, and other similar terms. Results Recent studies have shown that hypoxia is associated with poor prognosis in patients by regulating the TME. It confers resistance to conventional therapies through a number of signaling pathways in apoptosis, autophagy, DNA damage, mitochondrial activity, p53, and drug efflux. Conclusion Hypoxia targeting might be relevant to overcome hypoxia-associated resistance in cancer treatment.
C1 [Jing, Xinming; Yang, Fengming; Shao, Chuchu; Xie, Mengyan; Shen, Hua; Shu, Yongqian] Nanjing Med Univ, Affiliated Sir Run Run Hosp, Dept Oncol, Nanjing, Jiangsu, Peoples R China.
   [Jing, Xinming; Yang, Fengming; Shao, Chuchu; Xie, Mengyan; Shen, Hua; Shu, Yongqian] Nanjing Med Univ, Affiliated Hosp 1, Dept Oncol, Nanjing, Jiangsu, Peoples R China.
   [Wei, Ke] Nanjing Med Univ, Affiliated Hosp 1, Dept Thorac Surg, Nanjing, Jiangsu, Peoples R China.
RP Shen, H; Shu, YQ (corresponding author), Nanjing Med Univ, Affiliated Sir Run Run Hosp, Dept Oncol, Nanjing, Jiangsu, Peoples R China.
EM medshenhua@126.com; shuyongqian1998@163.com
RI Shu, Yongqian/ABD-5698-2021
FU Natural Science Foundation of Jiangsu ProvinceNatural Science Foundation
   of Jiangsu Province [BK20171484]; Project of Invigorating Health Care
   through Science, Technology, and Education (Jiangsu Provincial Medical
   Youth Talent) [QNRC2016856]; National Natural Science Foundation of
   ChinaNational Natural Science Foundation of China (NSFC) [81672896];
   Summit of the Six Top Talents Program of Jiangsu Province
   [2017-WSN-179]; Postgraduate Research & Practice Innovation Program of
   Jiangsu Province [KYCX18_1483, KYCX18_1482]; Priority Academic Program
   Development of Jiangsu Higher Education Institutions [JX10231801];
   Natural Science Foundation of ChinaNational Natural Science Foundation
   of China (NSFC) [81874230]; Jiangsu Social Development Project
   [BE2018726]
FX This study was supported by grants from the Natural Science Foundation
   of Jiangsu Province (Grants No BK20171484), the Project of Invigorating
   Health Care through Science, Technology, and Education (Jiangsu
   Provincial Medical Youth Talent QNRC2016856), the National Natural
   Science Foundation of China (No. 81672896), the Summit of the Six Top
   Talents Program of Jiangsu Province (2017-WSN-179), the Postgraduate
   Research & Practice Innovation Program of Jiangsu Province
   (KYCX18_1483), the Priority Academic Program Development of Jiangsu
   Higher Education Institutions (JX10231801), Postgraduate Research &
   Practice Innovation Program of Jiangsu Province (No. KYCX18_1482), The
   Natural Science Foundation of China (81874230) and the Jiangsu Social
   Development Project (BE2018726).
CR Achison M, 2003, ONCOGENE, V22, P3431, DOI 10.1038/sj.onc.1206434
   An Y, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.123
   Barsoum IB, 2014, CANCER RES, V74, P665, DOI 10.1158/0008-5472.CAN-13-0992
   Birner P, 2000, CANCER RES, V60, P4693
   Bridge G, 2014, CANCERS, V6, P1597, DOI 10.3390/cancers6031597
   Bristow RG, 2008, NAT REV CANCER, V8, P180, DOI 10.1038/nrc2344
   Brown JM, 1998, CANCER RES, V58, P1408
   Chen A, 2018, ONCOGENE, V37, P4214, DOI 10.1038/s41388-018-0259-3
   Chen F, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0278-7
   Chen JQ, 2014, PLOS ONE, V9, DOI [10.1371/journal.pone.0085161, 10.1371/journal.pone.0101277]
   Chen SN, 2010, BBA-REV CANCER, V1806, P220, DOI 10.1016/j.bbcan.2010.07.003
   Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338
   Corzo CA, 2010, J EXP MED, V207, P2439, DOI 10.1084/jem.20100587
   Cui XY, 2016, J THROMB HAEMOST, V14, P387, DOI 10.1111/jth.13206
   Daponte A, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-335
   Dean M, 2005, ANNU REV GENOM HUM G, V6, P123, DOI 10.1146/annurev.genom.6.080604.162122
   Denny W A, 2000, Lancet Oncol, V1, P25, DOI 10.1016/S1470-2045(00)00006-1
   Deschoemaeker S, 2015, EMBO MOL MED, V7, P1350, DOI 10.15252/emmm.201505492
   Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112
   Erler JT, 2004, MOL CELL BIOL, V24, P2875, DOI 10.1128/MCB.24.7.2875-2889.2004
   Fan TT, 2014, CELL BIOSCI, V4, DOI 10.1186/2045-3701-4-49
   Federici C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088193
   Flamant L, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-391
   Fukuda R, 2007, CELL, V129, P111, DOI 10.1016/j.cell.2007.01.047
   Fulda S, 2010, NAT REV DRUG DISCOV, V9, P447, DOI 10.1038/nrd3137
   Gaggioli C, 2007, NAT CELL BIOL, V9, P1392, DOI 10.1038/ncb1658
   Gatti L, 2005, METH MOLEC MED, V111, P127
   Gillet JP, 2007, BBA-REV CANCER, V1775, P237, DOI 10.1016/j.bbcan.2007.05.002
   Gottesman MM, 2002, ANNU REV MED, V53, P615, DOI 10.1146/annurev.med.53.082901.103929
   Greijer AE, 2004, J CLIN PATHOL, V57, P1009, DOI 10.1136/jcp.2003.015032
   Guzy RD, 2005, CELL METAB, V1, P401, DOI 10.1016/j.cmet.2005.05.001
   Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704
   He JM, 2017, J CANCER, V8, P1187, DOI 10.7150/jca.18171
   Hoffmann AC, 2008, NEOPLASIA, V10, P674, DOI 10.1593/neo.08292
   Hu T, 2015, PHYTOMEDICINE, V22, P536, DOI 10.1016/j.phymed.2015.03.010
   Huang YQ, 2017, SCI CHINA LIFE SCI, V60, P1114, DOI 10.1007/s11427-017-9178-y
   Hunter FW, 2015, CANCER RES, V75, P4211, DOI 10.1158/0008-5472.CAN-15-1107
   Jain RK, 2014, CANCER CELL, V26, P605, DOI 10.1016/j.ccell.2014.10.006
   Kandoth C, 2013, NATURE, V502, P333, DOI 10.1038/nature12634
   Kim CY, 1997, CANCER RES, V57, P4200
   Kim J, 2011, NAT CELL BIOL, V13, P132, DOI 10.1038/ncb2152
   Koshikawa N, 2006, ONCOGENE, V25, P917, DOI 10.1038/sj.onc.1209128
   Koukourakis MI, 2001, CANCER RES, V61, P1830
   Kozlova N, 2017, ONCOTARGET, V8, P9885, DOI 10.18632/oncotarget.14241
   Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994
   Lee YY, 2015, ONCOTARGET, V6, P35040, DOI 10.18632/oncotarget.5319
   Li CJ, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18071566
   Li F, 2005, MOL CELL BIOL, V25, P6225, DOI 10.1128/MCB.25.14.6225-6234.2005
   Li HH, 2017, GASTROENTEROLOGY, V153, P505, DOI 10.1053/j.gastro.2017.04.017
   Li Y, 2017, CHIN J CANC, P36
   Li Yuan, 2015, Zhongguo Yi Xue Ke Xue Yuan Xue Bao, V37, P75, DOI 10.3881/j.issn.1000-503X.2015.01.014
   Lin SH, 2018, JNCI-J NATL CANCER I, V110, DOI 10.1093/jnci/djx163
   Lin WM, 2015, GENET MOL RES, V14, P16905, DOI 10.4238/2015.December.14.18
   Liu XW, 2010, PHARMACOL RES, V62, P416, DOI 10.1016/j.phrs.2010.07.002
   Loges S, 2009, CANCER CELL, V15, P167, DOI 10.1016/j.ccr.2009.02.007
   Madan E, 2012, BIOCHEM J, V443, P811, DOI 10.1042/BJ20111627
   Maddika S, 2007, DRUG RESIST UPDATE, V10, P13, DOI 10.1016/j.drup.2007.01.003
   Maeda H, 2000, J CONTROL RELEASE, V65, P271, DOI 10.1016/S0168-3659(99)00248-5
   Majmundar AJ, 2010, MOL CELL, V40, P294, DOI 10.1016/j.molcel.2010.09.022
   Mantovani A, 2002, TRENDS IMMUNOL, V23, P549, DOI 10.1016/S1471-4906(02)02302-5
   Maranchie JK, 2002, CANCER CELL, V1, P247, DOI 10.1016/S1535-6108(02)00044-2
   Mayer A, 2008, CANCER RES, V68, P4719, DOI 10.1158/0008-5472.CAN-07-6339
   McKeown SR, 2014, BRIT J RADIOL, V87, DOI 10.1259/bjr.20130676
   Minchinton AI, 2006, NAT REV CANCER, V6, P583, DOI 10.1038/nrc1893
   Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639
   Mow BMF, 2001, CURR OPIN ONCOL, V13, P453, DOI 10.1097/00001622-200111000-00007
   Nardinocchi L, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-1
   Nelson DA, 2004, GENE DEV, V18, P2095, DOI 10.1101/gad.1204904
   Nita Malgorzata, 2016, Oxid Med Cell Longev, V2016, P3164734, DOI 10.1155/2016/3164734
   Noman MZ, 2014, J EXP MED, V211, P781, DOI 10.1084/jem.20131916
   O'Donovan TR, 2011, AUTOPHAGY, V7, P509, DOI 10.4161/auto.7.5.15066
   Olcina M, 2010, CLIN CANCER RES, V16, P5624, DOI 10.1158/1078-0432.CCR-10-0286
   Pan BZ, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-165
   Papandreou I, 2006, CELL METAB, V3, P187, DOI 10.1016/j.cmet.2006.01.012
   Pastorek J, 2015, SEMIN CANCER BIOL, V31, P52, DOI 10.1016/j.semcancer.2014.08.002
   Phillips RM, 2013, BRIT J PHARMACOL, V168, P11, DOI 10.1111/j.1476-5381.2012.01996.x
   Pilon-Thomas S, 2016, CANCER RES, V76, P1381, DOI 10.1158/0008-5472.CAN-15-1743
   Rohwer N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012038
   Roma-Rodrigues C, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20040840
   Rouschop KMA, 2010, J CLIN INVEST, V120, P127, DOI 10.1172/JCI40027
   Saggar JK, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00154
   Sakamoto H, 2000, BLOOD, V95, P3214, DOI 10.1182/blood.V95.10.3214
   Sakamoto H, 2001, CLIN CANCER RES, V7, P2513
   Sasabe E, 2005, CANCER SCI, V96, P394, DOI 10.1111/j.1349-7006.2005.00065.x
   Semenza GL, 2010, ONCOGENE, V29, P625, DOI 10.1038/onc.2009.441
   Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187
   Semenza GL, 2014, ANNU REV PATHOL-MECH, V9, P47, DOI 10.1146/annurev-pathol-012513-104720
   Semenza GL, 2010, CURR OPIN GENET DEV, V20, P51, DOI 10.1016/j.gde.2009.10.009
   Sendoel A, 2010, NATURE, V465, P577, DOI 10.1038/nature09141
   Sermeus A, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.48
   Sgarbi G, 2018, CELLS-BASEL, V7, DOI 10.3390/cells7070064
   Shao CC, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0869-y
   Shen Y, 2015, EXP CELL RES, V334, P207, DOI 10.1016/j.yexcr.2015.04.010
   Shukla SK, 2017, CANCER CELL, V32, P392, DOI 10.1016/j.ccell.2017.08.008
   Siegel RM, 1998, J CELL BIOL, V141, P1243, DOI 10.1083/jcb.141.5.1243
   Silva VL, 2017, J CONTROL RELEASE, V253, P82, DOI 10.1016/j.jconrel.2017.03.013
   Simiantonaki N, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-320
   Smith J, 2010, ADV CANCER RES, V108, P73, DOI 10.1016/S0065.230X(10)08002.4
   Soussi T, 2015, CELL DEATH DIFFER, V22, P1239, DOI 10.1038/cdd.2015.53
   Sullivan R, 2008, MOL CANCER THER, V7, P1961, DOI 10.1158/1535-7163.MCT-08-0198
   Sun HC, 2007, INT J ONCOL, V30, P1359
   Sun Y, 2016, CANCER LETT, V380, P205, DOI 10.1016/j.canlet.2015.07.044
   Syu JP, 2016, ONCOTARGET, V7, P14659, DOI 10.18632/oncotarget.7406
   TEICHER BA, 1987, CANCER RES, V47, P513
   Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007
   THORNALLEY PJ, 1990, BIOCHEM J, V269, P1
   Tosatto A, 2016, EMBO MOL MED, V8, P569, DOI 10.15252/emmm.201606255
   Triner D, 2016, J CLIN INVEST, V126, P3689, DOI 10.1172/JCI84430
   Ueda S, 2017, CLIN CANCER RES, V23, P5769, DOI 10.1158/1078-0432.CCR-17-0874
   Unruh A, 2003, ONCOGENE, V22, P3213, DOI 10.1038/sj.onc.1206385
   van Loo G, 2002, CELL DEATH DIFFER, V9, P1031, DOI 10.1038/sj.cdd.4401088
   Wang M, 2014, HORTIC RES-ENGLAND, V1, DOI 10.1038/hortres.2014.16
   Whatcott CJ, 2015, CANCER J, V21, P299, DOI 10.1097/PPO.0000000000000140
   Wiesener MS, 2002, FASEB J, V16, P271, DOI 10.1096/fj.02-0445fje
   Wigerup C, 2016, PHARMACOL THERAPEUT, V164, P152, DOI 10.1016/j.pharmthera.2016.04.009
   Wilson WR, 2011, NAT REV CANCER, V11, P393, DOI 10.1038/nrc3064
   Wirthner R, 2008, CARCINOGENESIS, V29, P2306, DOI 10.1093/carcin/bgn231
   Wohlkoenig C, 2011, CANCER LETT, V308, P134, DOI 10.1016/j.canlet.2011.03.014
   WOZNIAK AJ, 1984, CANCER RES, V44, P626
   Wu HM, 2016, LUNG, V194, P959, DOI 10.1007/s00408-016-9936-6
   Wu T, 2017, CANCER LETT, V387, P61, DOI 10.1016/j.canlet.2016.01.043
   Xia Shu, 2005, J Huazhong Univ Sci Technolog Med Sci, V25, P279
   Xiong GF, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06893-9
   Xu RH, 2005, CANCER RES, V65, P613
   Yan YL, 2016, J EXP CLIN CANC RES, V35, DOI 10.1186/s13046-016-0303-5
   Yang MH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097242
   Zeller KI, 2006, P NATL ACAD SCI USA, V103, P17834, DOI 10.1073/pnas.0604129103
   Zhang JJ, 2010, WORLD J GASTROENTERO, V16, P2881, DOI 10.3748/wjg.v16.i23.2881
   Zhitomirsky B, 2016, DRUG RESIST UPDATE, V24, P23, DOI 10.1016/j.drup.2015.11.004
   Zhu X, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.313
   Zub KA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119857
   Zunino F, 1997, PHARMACOL THERAPEUT, V76, P177, DOI 10.1016/S0163-7258(97)00086-7
NR 132
TC 341
Z9 351
U1 111
U2 178
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1476-4598
J9 MOL CANCER
JI Mol. Cancer
PD NOV 11
PY 2019
VL 18
IS 1
AR 157
DI 10.1186/s12943-019-1089-9
PG 15
WC Biochemistry & Molecular Biology; Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology
GA JM8BE
UT WOS:000496432800001
PM 31711497
OA Green Published, gold
HC Y
HP N
DA 2022-04-25
ER

PT J
AU Zeng, XF
   Liu, Q
   Yang, YH
   Jia, WK
   Li, SP
   He, DS
   Ma, RD
AF Zeng, Xiaofei
   Liu, Qing
   Yang, Yanhui
   Jia, Weikun
   Li, Shuping
   He, Dongsheng
   Ma, Ruidong
TI Placenta-specific protein 8 promotes the proliferation of lung
   adenocarcinoma PC-9 cells and their tolerance to an epidermal growth
   factor receptor tyrosine kinase inhibitor by activating the ERK
   signaling pathway
SO ONCOLOGY LETTERS
LA English
DT Article
DE lung adenocarcinoma; placenta-specific protein 8; proliferation; Erk1/2;
   epidermal growth factor receptor tyrosine kinase inhibitor
ID CANCER; PLAC8; RESISTANCE; REACTIVATION; CONTRIBUTES; METASTASIS;
   EXPRESSION; SYNERGIZES; MUTATIONS; REGULATOR
AB Placenta-specific protein 8 (PLAC8) is a conserved protein with a molecular weight of 12.5 kDa. The specific function of this protein has not been fully elucidated, however, PLAC8 has been found to play an important tumor regulatory role in certain types of cancer, including colon, pancreatic and liver cancer. PLAC8 also participates in the regulation of the cell cycle, autophagy, epithelial-mesenchymal transition and other cellular functions, indicating its potential as a molecular target worth further investigation. The present study investigated the effect of PLAC8 on the proliferation of lung adenocarcinoma PC-9 cells and their sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI). It was found that the inhibition of PLAC8 expression in PC-9 cells resulted in significantly decreased proliferation, whereas overexpression of PLAC8 significantly increased the proliferation (P<0.05) of PC-9 cells. Furthermore, inhibition of PLAC8 expression resulted in decreased activity of the ERK signaling pathway, while PLAC8 overexpression increased activity of this pathway. Inhibition of the ERK signaling pathway with U0126 reversed the effects induced by inhibiting or overexpressing PLAC8 on cell proliferation. In addition, overexpression of PLAC8 significantly decreased the sensitivity of PC-9 cells to gefitinib, and this effect was reversed by U0126. Overall, these results suggest that PLAC8 is involved in the regulation of proliferation of lung adenocarcinoma PC-9 cells and impacts their sensitivity to an EGFR-TKI. Thus, PLAC8 is a potential novel target in lung adenocarcinoma for future studies.
C1 [Zeng, Xiaofei; Jia, Weikun; Li, Shuping; He, Dongsheng; Ma, Ruidong] Chengdu Med Coll, Affiliated Hosp 1, Dept Cardiothorac Surg, 278 Middle Sect Baoguang Ave, Chengdu 610500, Sichuan, Peoples R China.
   [Liu, Qing] Chengdu Fifth Peoples Hosp, Dept Cardiothorac Surg, Chengdu 611130, Sichuan, Peoples R China.
   [Yang, Yanhui] First Peoples Hosp Neijiang, Dept Cardiothorac Surg, Neijiang 641000, Sichuan, Peoples R China.
RP Ma, RD (corresponding author), Chengdu Med Coll, Affiliated Hosp 1, Dept Cardiothorac Surg, 278 Middle Sect Baoguang Ave, Chengdu 610500, Sichuan, Peoples R China.
EM ma-ruidong@163.com
FU Scientific Research Topics of Sichuan Education Department [18ZA0165]
FX This study was supported by the Scientific Research Topics of Sichuan
   Education Department (grant no. 18ZA0165).
CR Cao MM, 2019, THORAC CANCER, V10, P3, DOI 10.1111/1759-7714.12916
   Chang WL, 2018, DEVELOPMENT, V145, DOI 10.1242/dev.148932
   Chen J, 2019, MOL THER-NUCL ACIDS, V14, P567, DOI 10.1016/j.omtn.2019.01.005
   CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915
   Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338
   Cong ZZ, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1361-3
   Corcoran RB, 2012, CANCER DISCOV, V2, P227, DOI 10.1158/2159-8290.CD-11-0341
   Dai B, 2019, EUR REV MED PHARMACO, V23, P1125, DOI 10.26355/eurrev_201902_17003
   Galaviz-Hernandez C, 2003, GENE, V309, P81, DOI 10.1016/S0378-1119(03)00508-0
   Gao X, 2017, MOL ONCOL, V11, P628, DOI 10.1002/1878-0261.12055
   Garces S, 2019, MODERN PATHOL, V32, P16, DOI 10.1038/s41379-018-0152-1
   Gong C, 2017, ONCOTARGET, V8, P52527, DOI 10.18632/oncotarget.17283
   Imielinski M, 2012, CELL, V150, P1107, DOI 10.1016/j.cell.2012.08.029
   Ito Y, 1998, HEPATOLOGY, V27, P951, DOI 10.1002/hep.510270409
   Jia YL, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0580-3
   Jin Z, 2018, BIOCHEM BIOPH RES CO, V499, P538, DOI 10.1016/j.bbrc.2018.03.185
   Kaistha BP, 2016, CANCER RES, V76, P96, DOI 10.1158/0008-5472.CAN-15-0216
   Kato Y, 2019, J THORAC DIS, V11, P2350, DOI 10.21037/jtd.2019.06.03
   Kinsey C, 2014, CELL REP, V7, P1143, DOI 10.1016/j.celrep.2014.03.061
   LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079
   Li CX, 2014, J CLIN INVEST, V124, P2172, DOI 10.1172/JCI71103
   Liu C, 2019, MED SCI MONITOR, V25, P5143, DOI 10.12659/MSM.913308
   Marks JL, 2008, CANCER RES, V68, P5524, DOI 10.1158/0008-5472.CAN-08-0099
   Mourtada-Maarabouni M, 2013, CURR CANCER DRUG TAR, V13, P80, DOI 10.2174/156800913804486584
   Ochi N, 2014, EXP CELL RES, V322, P168, DOI 10.1016/j.yexcr.2014.01.007
   Samatar AA, 2014, NAT REV DRUG DISCOV, V13, P928, DOI 10.1038/nrd4281
   Segawa S, 2018, J IMMUNOL, V201, P3534, DOI 10.4049/jimmunol.1800667
   Shigematsu H, 2005, JNCI-J NATL CANCER I, V97, P339, DOI 10.1093/jnci/dji055
   Shu YQ, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-00520-1
   Song J, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-5885-9
   Tanimoto A, 2017, CLIN CANCER RES, V23, P3139, DOI 10.1158/1078-0432.CCR-16-2271
   Tanimura S, 2017, J BIOCHEM, V162, P145, DOI 10.1093/jb/mvx048
   Verma N, 2017, CANCER RES, V77, P86, DOI 10.1158/0008-5472.CAN-16-1797
   Wang GJ, 2017, J CELL BIOCHEM, V118, P4444, DOI 10.1002/jcb.26100
   Wang LF, 2015, MOL NEUROBIOL, V52, P478, DOI 10.1007/s12035-014-8848-9
   Wu SF, 2010, LEUKEMIA, V24, P544, DOI 10.1038/leu.2009.280
   Zhang YQ, 2018, CELL PHYSIOL BIOCHEM, V48, P1099, DOI 10.1159/000491976
   Zhao L, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.563
   Zou ZQ, 2012, MOL MED REP, V5, P503, DOI 10.3892/mmr.2011.682
NR 39
TC 4
Z9 5
U1 0
U2 2
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792-1074
EI 1792-1082
J9 ONCOL LETT
JI Oncol. Lett.
PD NOV
PY 2019
VL 18
IS 5
BP 5621
EP 5627
DI 10.3892/ol.2019.10911
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA JW7HS
UT WOS:000503219600132
PM 31620204
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Marcucci, F
   Rumio, C
AF Marcucci, Fabrizio
   Rumio, Cristiano
TI Glycolysis-induced drug resistance in tumors-A response to danger
   signals?
SO NEOPLASIA
LA English
DT Review
DE Glycolysis; Tumors; Drug resistance; EMT; Danger; Apoptosis
ID PYRUVATE-KINASE M2; COLON-CANCER CELLS; EPITHELIAL-MESENCHYMAL
   TRANSITION; OVERCOMES SORAFENIB RESISTANCE; CYTOCHROME-C RELEASE;
   BREAST-CANCER; GLUCOSE-METABOLISM; CARCINOMA-CELLS; GASTRIC-CANCER;
   LACTATE-DEHYDROGENASE
AB Tumor cells often switch from mitochondrial oxidative metabolism to glycolytic metabolism even under aerobic conditions. Tumor cell glycolysis is accompanied by several nonenzymatic activities among which induction of drug resistance has important therapeutic implications. In this article, we review the main aspects of glycolysis-induced drug resistance. We discuss the classes of antitumor drugs that are affected and the components of the glycolytic pathway (transporters, enzymes, metabolites) that are involved in the induction of drug resistance. Glycolysis-associated drug resistance occurs in response to stimuli, either cell-autonomous (e.g., oncoproteins) or deriving from the tumor microenvironment (e.g., hypoxia or pseudohypoxia, mechanical cues, etc.). Several mechanisms mediate the induction of drug resistance in response to glycolytic metabolism: inhibition of apoptosis, induction of epithelial-mesenchymal transition, induction of autophagy, inhibition of drug influx and increase of drug efflux. We suggest that drug resistance in response to glycolysis comes into play in presence of qualitative (e.g., expression of embryonic enzyme isoforms, post-translational enzyme modifications) or quantitative (e.g., overexpression of enzymes or overproduction of metabolites) alterations of glycolytic metabolism. We also discern similarities between changes occurring in tumor cells in response to stimuli inducing glycolysis-associated drug resistance and those occurring in cells of the innate immune system in response to danger signals and that have been referred to as danger-associated metabolic modifications. Eventually, we briefly address that also mitochondrial oxidative metabolism may induce drug resistance and discuss the therapeutic implications deriving from the fact that the main energy-generating metabolic pathways may be both at the origin of antitumor drug resistance.
C1 [Marcucci, Fabrizio; Rumio, Cristiano] Univ Milan, Dept Pharmacol & Biomol Sci, Milan, Italy.
RP Marcucci, F (corresponding author), Univ Milan, Dept Pharmacol & Biomol Sci, Milan, Italy.
EM fabmarcu@gmail.com
CR Allen E, 2016, CELL REP, V15, P1144, DOI 10.1016/j.celrep.2016.04.029
   Apel A, 2008, CANCER RES, V68, P1485, DOI 10.1158/0008-5472.CAN-07-0562
   Apicella M, 2018, CELL METAB, V28, P848, DOI 10.1016/j.cmet.2018.08.006
   Baenke F, 2016, MOL ONCOL, V10, P73, DOI 10.1016/j.molonc.2015.08.003
   Bhatt AN, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1368-9
   Bouzier AK, 1998, DEV NEUROSCI-BASEL, V20, P331, DOI 10.1159/000017328
   Breedveld P, 2007, MOL PHARMACOL, V71, P240, DOI 10.1124/mol.106.028167
   Cai Q, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1016-0
   Cao XT, 2016, NAT REV IMMUNOL, V16, P35, DOI 10.1038/nri.2015.8
   Cardoso HJ, 2019, LIFE SCI, V218, P274, DOI 10.1016/j.lfs.2018.12.055
   Cesi G, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0667-y
   Chakraborty PK, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14634
   Chang YC, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2387-2
   Checa J, 2020, J INFLAMM RES, V13, P1057, DOI 10.2147/JIR.S275595
   Chen L, 2020, ARCH BIOCHEM BIOPHYS, V680, DOI 10.1016/j.abb.2019.108244
   Chen R, 2020, J CELL MOL MED, V24, P2123, DOI 10.1111/jcmm.14763
   Cheng CY, 2018, BIOMED PHARMACOTHER, V108, P194, DOI 10.1016/j.biopha.2018.09.031
   Christofk HR, 2008, NATURE, V452, P230, DOI 10.1038/nature06734
   Christofk HR, 2008, NATURE, V452, P181, DOI 10.1038/nature06667
   Colell A, 2007, CELL, V129, P983, DOI 10.1016/j.cell.2007.03.045
   Corazao-Rozas P, 2013, ONCOTARGET, V4, P1986, DOI 10.18632/oncotarget.1420
   Corbet C, 2017, NAT REV CANCER, V17, P577, DOI 10.1038/nrc.2017.77
   Dai J, 2017, TOXICOL APPL PHARM, V331, P164, DOI 10.1016/j.taap.2017.06.014
   Daneshmandi S, 2019, CANCERS, V11, DOI 10.3390/cancers11040450
   Das CK, 2019, BBA-MOL CELL RES, V1866, P1004, DOI 10.1016/j.bbamcr.2019.03.004
   Dongre A, 2019, NAT REV MOL CELL BIO, V20, P69, DOI 10.1038/s41580-018-0080-4
   Drame M, 2020, INT IMMUNOL, V32, P475, DOI 10.1093/intimm/dxaa035
   Efimova EV, 2016, MOL CANCER RES, V14, P173, DOI 10.1158/1541-7786.MCR-15-0263
   Eriksson JA, 2018, J NEUROCHEM, V144, P421, DOI 10.1111/jnc.14264
   Faes S, 2016, MOL CANCER, V15, DOI 10.1186/s12943-016-0562-y
   Fanciulli M, 2000, CLIN CANCER RES, V6, P1590
   Feng J, 2020, J EXP CLIN CANC RES, V39, DOI 10.1186/s13046-020-1528-x
   Feng MY, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0947-4
   Fitzwalter BE, 2018, DEV CELL, V44, P555, DOI 10.1016/j.devcel.2018.02.014
   Frenzel J, 2005, GLIA, V52, P276, DOI 10.1002/glia.20244
   Fu JX, 2016, MOL MED REP, V14, P995, DOI 10.3892/mmr.2016.5290
   Gatenby RA, 2004, NAT REV CANCER, V4, P891, DOI 10.1038/nrc1478
   Ge X, 2016, CELL MOL BIOL, V62, P119, DOI 10.14715/cmb/2016.62.6.22
   Gong T, 2020, NAT REV IMMUNOL, V20, P95, DOI 10.1038/s41577-019-0215-7
   Gottesman MM, 2002, NAT REV CANCER, V2, P48, DOI 10.1038/nrc706
   Greijer AE, 2005, CELL ONCOL, V27, P43
   Gustafsson NMS, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06287-x
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   He JX, 2014, CELL BIOCHEM BIOPHYS, V70, P1343, DOI 10.1007/s12013-014-0062-x
   He Y, 2019, AM J CANCER RES, V9, P2280
   Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809
   Holohan C, 2013, NAT REV CANCER, V13, P714, DOI 10.1038/nrc3599
   Hou GX, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0159-4
   Hua GJ, 2014, ONCOL REP, V31, P2727, DOI 10.3892/or.2014.3156
   Huang CY, 2017, J PHYSIOL-LONDON, V595, P505, DOI 10.1113/JP272208
   Hulleman E, 2009, BLOOD, V113, P2014, DOI 10.1182/blood-2008-05-157842
   Hur H, 2013, INT J ONCOL, V42, P44, DOI 10.3892/ijo.2012.1687
   Icard P, 2018, DRUG RESIST UPDATE, V38, P1, DOI 10.1016/j.drup.2018.03.001
   Jia DY, 2019, P NATL ACAD SCI USA, V116, P3909, DOI 10.1073/pnas.1816391116
   Jiang JX, 2014, MOL MED REP, V10, P995, DOI 10.3892/mmr.2014.2271
   Jin Y, 2016, ONCOTARGET, V7, P25113, DOI 10.18632/oncotarget.7159
   Kim J, 2017, ONCOGENE, V36, P6472, DOI 10.1038/onc.2017.265
   Klawitter J, 2009, BRIT J PHARMACOL, V158, P588, DOI 10.1111/j.1476-5381.2009.00345.x
   Koukourakis M, 2017, BIOCHEM BIOPH RES CO, V491, P932, DOI 10.1016/j.bbrc.2017.07.138
   Kroger C, 2019, P NATL ACAD SCI USA, V116, P7353, DOI 10.1073/pnas.1812876116
   Kwon OH, 2012, BIOCHEM BIOPH RES CO, V423, P38, DOI 10.1016/j.bbrc.2012.05.063
   Le Calve B, 2010, NEOPLASIA, V12, P727, DOI 10.1593/neo.10526
   Lee HJ, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10374-y
   LEE JS, 2020, CELLS-BASEL, V9, DOI DOI 10.3390/CELLS9092013
   Lee SY, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/1027453
   Li FL, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-02950-5
   Li L, 2018, ONCOL RES, V26, P547, DOI 10.3727/096504017X15016337254605
   Li N, 2020, P NATL ACAD SCI USA, V117, P20159, DOI 10.1073/pnas.1918986117
   Li QJ, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15308-7
   Li SN, 2017, INT J CANCER, V141, P2571, DOI 10.1002/ijc.31022
   LI WC, 2020, FRONT ONCOL, V10, DOI DOI 10.3389/FONC.2020.00176.
   Li XY, 2015, MOL MED REP, V11, P577, DOI 10.3892/mmr.2014.2726
   Liang Y, 2019, J CANCER, V10, P6037, DOI 10.7150/jca.34650
   Liao YX, 2019, INT J ONCOL, V55, P1213, DOI 10.3892/ijo.2019.4902
   Liberti MV, 2016, TRENDS BIOCHEM SCI, V41, P211, DOI 10.1016/j.tibs.2015.12.001
   Lin YZ, 2019, CANCER CELL INT, V19, DOI 10.1186/s12935-019-0845-7
   Liu CC, 2018, CELL PHYSIOL BIOCHEM, V46, P1525, DOI 10.1159/000489196
   Liu XC, 2019, MOL CELL PROTEOMICS, V18, P2273, DOI 10.1074/mcp.RA119.001576
   Lorito N, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9030668
   Lu HQ, 2013, MOL CANCER THER, V12, P2187, DOI 10.1158/1535-7163.MCT-12-1245
   Lu WQ, 2017, ONCOTARGET, V8, P44171, DOI 10.18632/oncotarget.17396
   Lypova N, 2019, J BIOL CHEM, V294, P10530, DOI 10.1074/jbc.RA119.007784
   Ma D, 2019, ONCOTARGETS THER, V12, P6711, DOI 10.2147/OTT.S205334
   Ma LY, 2020, CANCER SCI, V111, P2028, DOI 10.1111/cas.14412
   Maiso P, 2015, CANCER RES, V75, P2071, DOI 10.1158/0008-5472.CAN-14-3400
   Mangan MSJ, 2018, NAT REV DRUG DISCOV, V17, P588, DOI [10.1038/nrd.2018.97, 10.1038/nrd.2018.149]
   Marcucci F, 2020, TRENDS PHARMACOL SCI, V41, P162, DOI 10.1016/j.tips.2020.01.003
   Marcucci F, 2017, BBA-REV CANCER, V1868, P571, DOI 10.1016/j.bbcan.2017.10.006
   Marcucci F, 2017, MOL CANCER, V16, DOI 10.1186/s12943-016-0573-8
   Marcucci F, 2016, NAT REV DRUG DISCOV, V15, P311, DOI 10.1038/nrd.2015.13
   Marcucci F, 2014, INT J CANCER, V135, P1265, DOI 10.1002/ijc.28572
   Martin SP, 2020, J EXP CLIN CANC RES, V39, DOI 10.1186/s13046-020-01605-y
   Martinez-Outschoorn UE, 2011, CANCER BIOL THER, V12, P924, DOI 10.4161/cbt.12.10.17780
   Masamha CP, 2018, J CELL BIOCHEM, V119, P6136, DOI 10.1002/jcb.26814
   MATZINGER P, 1994, ANNU REV IMMUNOL, V12, P991, DOI 10.1146/annurev.immunol.12.1.991
   Meynet O, 2012, LEUKEMIA, V26, P1145, DOI 10.1038/leu.2011.327
   Morrot A, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00081
   Nakajima EC, 2013, MOL CARCINOGEN, V52, P329, DOI 10.1002/mc.21863
   Nakano A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027222
   Papaevangelou E, 2018, INT J CANCER, V143, P992, DOI 10.1002/ijc.31392
   Park GB, 2020, CARCINOGENESIS, V41, P1329, DOI 10.1093/carcin/bgaa074
   Park JS, 2020, NATURE, V578, P621, DOI 10.1038/s41586-020-1998-1
   Pastorino JG, 2002, J BIOL CHEM, V277, P7610, DOI 10.1074/jbc.M109950200
   Pastushenko I, 2018, NATURE, V556, P463, DOI 10.1038/s41586-018-0040-3
   Pavlides S, 2009, CELL CYCLE, V8, P3984, DOI 10.4161/cc.8.23.10238
   Pilon-Thomas S, 2016, CANCER RES, V76, P1381, DOI 10.1158/0008-5472.CAN-15-1743
   Qian XL, 2017, ONCOTARGET, V8, P47691, DOI 10.18632/oncotarget.17868
   Qian YJ, 2018, ANTI-CANCER DRUG, V29, P616, DOI 10.1097/CAD.0000000000000624
   Qin WJ, 2015, ONCOTARGET, V6, P39839, DOI 10.18632/oncotarget.5674
   Rajamaki K, 2013, J BIOL CHEM, V288, P13410, DOI 10.1074/jbc.M112.426254
   Roos WP, 2016, NAT REV CANCER, V16, P20, DOI 10.1038/nrc.2015.2
   Ruprecht B, 2017, CANCER RES, V77, P1842, DOI 10.1158/0008-5472.CAN-16-2976
   Ryu MJ, 2019, ONCOL REP, V42, P2149, DOI 10.3892/or.2019.7308
   Sattler UGA, 2009, INT J RADIAT BIOL, V85, P963, DOI 10.3109/09553000903258889
   Shang DP, 2017, INT J ONCOL, V50, P1848, DOI 10.3892/ijo.2017.3950
   Shao M, 2020, CANCER CELL INT, V20, DOI 10.1186/s12935-020-01275-y
   Shen YC, 2013, BRIT J CANCER, V108, P72, DOI 10.1038/bjc.2012.559
   Shi LL, 2017, SIGNAL TRANSDUCT TAR, V2, DOI 10.1038/sigtrans.2017.44
   Shi TG, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1549-6
   Singh L, 2018, DRUG DISCOV TODAY, V23, P1873, DOI 10.1016/j.drudis.2018.05.016
   Song K, 2016, ONCOL LETT, V12, P334, DOI 10.3892/ol.2016.4600
   Sonveaux P, 2008, J CLIN INVEST, V118, P3930, DOI 10.1172/JCI36843
   Sradhanjali S, 2018, CURR TOP MED CHEM, V18, P444, DOI 10.2174/1568026618666180523105756
   Sui X, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.350
   Sullivan E, 2014, CANCER CHEMOTH PHARM, V73, P417, DOI 10.1007/s00280-013-2366-8
   Sun L, 2019, EUR J PHARMACOL, V845, P8, DOI 10.1016/j.ejphar.2018.12.035
   Sun RL, 2019, TOXICOL IN VITRO, V55, P18, DOI 10.1016/j.tiv.2018.11.005
   Tan TZ, 2014, EMBO MOL MED, V6, P1279, DOI 10.15252/emmm.201404208
   Tavares-Valente D, 2013, J BIOENERG BIOMEMBR, V45, P467, DOI 10.1007/s10863-013-9519-7
   Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007
   Van Wilpe S, 2020, ONCOIMMUNOLOGY, V9, DOI 10.1080/2162402X.2020.1731942
   Vazquez-Martin A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006251
   VIDAL RS, 2018, FRONT ONCOL, V8, DOI DOI 10.3389/FONC.2018.00090.
   Vukovic V, 1997, BRIT J CANCER, V75, P1167, DOI 10.1038/bjc.1997.201
   Wagner W, 2017, J PHYSIOL PHARMACOL, V68, P555
   Wagner W, 2015, CELL COMMUN SIGNAL, V13, DOI 10.1186/s12964-015-0114-x
   Wang G, 2019, J CELL PHYSIOL, V234, P348, DOI 10.1002/jcp.26917
   Wang L, 2019, AM J TRANSL RES, V11, P4470
   Wang T, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4123-1
   Wang X, 2017, SCI REP-UK, V7, DOI 10.1038/srep45983
   Wang XY, 2020, MOL ONCOL, V14, P539, DOI 10.1002/1878-0261.12629
   Wang YL, 2018, CANCER SCI, V109, P2423, DOI 10.1111/cas.13662
   Wang Y, 2020, ONCOTARGETS THER, V13, P3607, DOI 10.2147/OTT.S242929
   Wangpaichitr M, 2017, ONCOTARGET, V8, P49275, DOI 10.18632/oncotarget.17568
   WARBURG O, 1956, SCIENCE, V124, P269
   WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309
   Wartenberg M, 2010, J CELL BIOCHEM, V109, P434, DOI 10.1002/jcb.22422
   Webb BA, 2011, NAT REV CANCER, V11, P671, DOI 10.1038/nrc3110
   Wei CY, 2017, EUR J MED CHEM, V139, P573, DOI 10.1016/j.ejmech.2017.08.029
   Xi Y, 2020, CANCER LETT, V479, P112, DOI 10.1016/j.canlet.2020.03.015
   Xie M, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13280
   Xu M, 2018, CELL PHYSIOL BIOCHEM, V47, P151, DOI 10.1159/000489759
   Xuan Y, 2014, EXP CELL RES, V321, P219, DOI 10.1016/j.yexcr.2013.12.009
   Yan XL, 2017, J CELL BIOCHEM, V118, P4792, DOI 10.1002/jcb.26148
   Yang TT, 2018, ONCOGENE, V37, P5997, DOI 10.1038/s41388-018-0386-x
   Yang YC, 2016, ONCOGENE, V35, P3387, DOI 10.1038/onc.2015.397
   Yu T, 2017, ONCOGENE, V36, P2131, DOI 10.1038/onc.2016.370
   Yu X, 2017, ONCOGENE, V36, P2629, DOI 10.1038/onc.2016.410
   Yu XX, 2020, ONCOTARGETS THER, V13, P1545, DOI 10.2147/OTT.S233031
   Zaal EA, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00500
   Zahra K, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00159
   Zechner D, 2017, J CANCER, V8, P1744, DOI 10.7150/jca.17972
   Zhang J, 2016, ONCOGENE, V35, P1926, DOI 10.1038/onc.2015.256
   Zhang JN, 2020, J CELL MOL MED, V24, P5707, DOI 10.1111/jcmm.15233
   Zhang L, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aau1167
   Zhang XY, 2018, LIFE SCI, V215, P1, DOI 10.1016/j.lfs.2018.10.050
   Zhao YH, 2011, CANCER RES, V71, P4585, DOI 10.1158/0008-5472.CAN-11-0127
   Zhou JW, 2019, MOL MED, V25, DOI 10.1186/s10020-019-0079-0
   Zhou YF, 2012, CANCER RES, V72, P304, DOI 10.1158/0008-5472.CAN-11-1674
   Zong S, 2020, BIOSCIENCE REP, DOI [10. 1042/BSR20201302., DOI 10.1042/BSR20201302.]
NR 170
TC 5
Z9 5
U1 8
U2 10
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1476-5586
J9 NEOPLASIA
JI Neoplasia
PY 2021
VL 23
IS 2
BP 234
EP 245
DI 10.1016/j.neo.2020.12.009
EA JAN 2021
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA PX2HA
UT WOS:000611180900006
PM 33418276
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Zhao, Y
   Wu, HN
   Xing, XY
   Ma, YQ
   Ji, SP
   Xu, XY
   Zhao, X
   Wang, SS
   Jiang, WY
   Fang, CY
   Zhang, L
   Yan, F
   Wang, XJ
AF Zhao, Yan
   Wu, Huina
   Xing, Xiaoyan
   Ma, Yuqian
   Ji, Shengping
   Xu, Xinyue
   Zhao, Xin
   Wang, Sensen
   Jiang, Wenyan
   Fang, Chunyan
   Zhang, Lei
   Yan, Fang
   Wang, Xuejian
TI CD13 Induces Autophagy to Promote Hepatocellular Carcinoma Cell
   Chemoresistance Through the P38/Hsp27/CREB/ATG7 Pathway
SO JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
LA English
DT Article
ID LIVER-CANCER; AMINOPEPTIDASE-N; TRANSCRIPTIONAL REGULATION;
   COLORECTAL-CANCER; DRUG-RESISTANCE; DOWN-REGULATION; P38 MAPK; PROTEIN;
   APOPTOSIS; CREB
AB The chemoresistance of hepatocellular carcinoma (HCC) is a serious problem that directly hinders the effect of chemotherapeutic agents. We previously reported that Aminopeptidase N (CD13) inhibition can enhance the cytotoxic efficacy of chemotherapy agents. In the present study, we use liver cancer cells to explore the molecular mechanism accounting for the relationship between CD13 and chemoresistance. We demonstrate that CD13 overexpression activates the P38/heat shock protein 27/cAMP response element-binding protein (CREB) signaling pathway to limit the efficacy of cytotoxic agents. Moreover, blockade of P38 or CREB sensitizes HCC cells to 5-fluorouracil. Then we reveal that CREB binds to the autophagy related 7 (ATG7) promoter to induce autophagy and promote HCC cell chemoresistance. CD13 inhibition also downregulates the expression of ATG7, autophagy, and tumor cell growth in vivo. Overall, the combination a CD13 inhibitor and chemotherapeutic agents may be a potential strategy for overcoming drug resistance in HCC.
   SIGNIFICANCE STATEMENT
   Our study demonstrates that Aminopeptidase N (CD13) promotes hepatocellular carcinoma (HCC) cell chemoresistance via the P38/heat shock protein 27/cAMP response element-binding protein (CREB) pathway. CREB regulates autophagy related 7 transcription and expression to induce autophagy. Our results collectively suggest that CD13 may serve as a potential target for overcoming HCC resistance.
C1 [Zhao, Yan; Wu, Huina; Xing, Xiaoyan; Ma, Yuqian; Ji, Shengping; Xu, Xinyue; Zhao, Xin; Wang, Sensen; Jiang, Wenyan; Fang, Chunyan; Zhang, Lei; Yan, Fang; Wang, Xuejian] Weifang Med Univ, Sch Pharm, 7166 Baotong West Rd, Weifang 261053, Shandong, Peoples R China.
   [Wu, Huina] Southwestern Lu Hosp, Dept Pharm, Liaocheng, Shandong, Peoples R China.
RP Yan, F; Wang, XJ (corresponding author), Weifang Med Univ, Sch Pharm, 7166 Baotong West Rd, Weifang 261053, Shandong, Peoples R China.
EM yanfang303@wfmc.edu.cn; wxj2901@126.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81503108]; Qing Chuang science and
   technology plan of colleges and universities in Shandong Province
   [2019KJM001]; Project of Shandong Province Higher Educational Science
   and Technology Program [J17KA255]; University Students Science and
   Technology Innovation Fund Project [201910438027X, KX2019025]
FX This work was supported by the National Natural Science Foundation of
   China [Grant 81503108]; Qing Chuang science and technology plan of
   colleges and universities in Shandong Province [Grant 2019KJM001];
   Project of Shandong Province Higher Educational Science and Technology
   Program [Grant J17KA255]; and University Students Science and Technology
   Innovation Fund Project [Grants 201910438027X and KX2019025].
CR Arts HJG, 1999, INT J CANCER, V84, P234, DOI 10.1002/(SICI)1097-0215(19990621)84:3<234::AID-IJC6>3.0.CO;2-9
   Chen R, 2011, FOLIA BIOL-PRAGUE, V57, P87
   Desai S, 2013, J BIOL CHEM, V288, P9165, DOI 10.1074/jbc.M112.422071
   Dou CH, 2017, INT J ONCOL, V51, P1775, DOI 10.3892/ijo.2017.4159
   El-Serag HB, 1999, NEW ENGL J MED, V340, P745, DOI 10.1056/NEJM199903113401001
   Feng JT, 2005, PROTEOMICS, V5, P4581, DOI 10.1002/pmic.200401309
   Fu XT, 2018, ONCOL LETT, V16, P346, DOI 10.3892/ol.2018.8667
   Golembieski WA, 2008, GLIA, V56, P1061, DOI 10.1002/glia.20679
   Guay J, 1997, J CELL SCI, V110, P357
   Guo JY, 2011, GENE DEV, V25, P460, DOI 10.1101/gad.2016311
   Guo Q, 2017, ONCOTARGET, V8, P72652, DOI 10.18632/oncotarget.20194
   Haraguchi N, 2010, J CLIN INVEST, V120, P3326, DOI 10.1172/JCI42550
   Hashida H, 2002, GASTROENTEROLOGY, V122, P376, DOI 10.1053/gast.2002.31095
   He J, 2012, CANCER RES, V72, P6393, DOI 10.1158/0008-5472.CAN-12-2664
   Hu Y, 2019, NANOSCALE, V11, P11789, DOI 10.1039/c8nr08442d
   Huang F, 2018, WORLD J GASTROENTERO, V24, P4643, DOI 10.3748/wjg.v24.i41.4643
   Hui KY, 2014, CANCER LETT, V354, P189, DOI 10.1016/j.canlet.2014.08.009
   Ishii K, 2001, INT J CANCER, V92, P49, DOI 10.1002/1097-0215(200102)9999:9999<::AID-IJC1161>3.3.CO;2-J
   Kang SH, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-286
   King KL, 2000, CANCER, V88, P2464, DOI 10.1002/1097-0142(20000601)88:11<2464::AID-CNCR6>3.0.CO;2-W
   Lamprecht R, 1999, CELL MOL LIFE SCI, V55, P554, DOI 10.1007/s000180050314
   Levy JMM, 2017, NAT REV CANCER, V17, P528, DOI 10.1038/nrc.2017.53
   Luo T, 2016, AUTOPHAGY, V12, P1355, DOI 10.1080/15548627.2015.1034405
   Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068
   Mina-Osorio P, 2008, TRENDS MOL MED, V14, P361, DOI 10.1016/j.molmed.2008.06.003
   Mlynarsky L, 2015, WORLD J HEPATOL, V7, P566, DOI 10.4254/wjh.v7.i3.566
   Nagano H, 2012, J HEPATO-BIL-PAN SCI, V19, P600, DOI 10.1007/s00534-012-0543-5
   O'Donovan TR, 2011, AUTOPHAGY, V7, P509, DOI 10.4161/auto.7.5.15066
   Paillas S, 2012, AUTOPHAGY, V8, P1098, DOI 10.4161/auto.20268
   Pan HM, 2014, SCI REP-UK, V4, DOI 10.1038/srep06683
   Pandey SC, 2005, ALCOHOL CLIN EXP RES, V29, P176, DOI 10.1097/01.ALC.0000153550.31168.1D
   Pandey SC, 2003, TRENDS PHARMACOL SCI, V24, P456, DOI 10.1016/S0165-6147(03)00226-8
   Raza A, 2014, WORLD J GASTROENTERO, V20, P4115, DOI 10.3748/wjg.v20.i15.4115
   Rincon M, 2009, IMMUNOL REV, V228, P212, DOI 10.1111/j.1600-065X.2008.00744.x
   Sato Y, 2003, ENDOTHELIUM-J ENDOTH, V10, P287, DOI 10.1080/10623320390272334
   Sun ZP, 2015, BIOMED PHARMACOTHER, V76, P65, DOI 10.1016/j.biopha.2015.10.023
   Takamura A, 2011, GENE DEV, V25, P795, DOI 10.1101/gad.2016211
   Wang P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065661
   Wang Y, 2013, AUTOPHAGY, V9, P2069, DOI 10.4161/auto.26447
   Wei KR, 2014, CHIN J CANCER, V33, P388, DOI 10.5732/cjc.014.10088
   Xu N, 2012, BIOCHEM BIOPH RES CO, V423, P826, DOI 10.1016/j.bbrc.2012.06.048
   Xu YM, 2013, CELL SIGNAL, V25, P1176, DOI 10.1016/j.cellsig.2013.01.017
   Yamashita M, 2016, INT J ONCOL, V49, P89, DOI 10.3892/ijo.2016.3496
   Yang F, 2010, HEPATOLOGY, V51, P1614, DOI 10.1002/hep.23566
   Yu L, 2014, ONCOGENE, V33, P690, DOI 10.1038/onc.2013.20
   Zhang J, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01042
   Zhang W, 2015, MED ONCOL, V32, DOI 10.1007/s12032-015-0549-3
   Zhang XQ, 2005, P NATL ACAD SCI USA, V102, P892, DOI 10.1073/pnas.0408936102
   Zhou S, 2019, AM J CANCER RES, V9, P511
   Zhu JL, 2019, ADV SCI, V6, DOI 10.1002/advs.201801927
NR 50
TC 2
Z9 3
U1 1
U2 4
PU AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA
SN 0022-3565
EI 1521-0103
J9 J PHARMACOL EXP THER
JI J. Pharmacol. Exp. Ther.
PD SEP 1
PY 2020
VL 374
IS 3
BP 512
EP 520
DI 10.1124/jpet.120.265637
PG 9
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA NR9XB
UT WOS:000571914300016
PM 32571958
OA Bronze
DA 2022-04-25
ER

PT J
AU Heuvel, JPV
   Thompson, JT
   Albrecht, P
   Mandetta, D
   Kamerow, H
   Ford, JP
AF Heuvel, John P. Vanden
   Thompson, Jerry T.
   Albrecht, Prajakta
   Mandetta, Donald
   Kamerow, Harry
   Ford, John P.
TI Differential nucleobase protection against 5-fluorouracil toxicity for
   squamous and columnar cells: implication for tissue function and
   oncogenesis
SO INVESTIGATIONAL NEW DRUGS
LA English
DT Article
DE 5-fluorouracil; Cancer chemotherapy; Pyrimidine salvage; Toxicity
   prevention; Preclinical studies; Oncogenesis
ID SUBSTRATE-SPECIFICITY; GENE-EXPRESSION; AUTOPHAGY; METABOLISM;
   MECHANISMS; DISEASE; S-1; PHOSPHORIBOSYLTRANSFERASE; PATHWAY; PROTEIN
AB Purpose The goal of these studies was to test if local excess of a normal nucleobase substrate prevents the toxicity of protracted 5FU exposure used in human cancer treatment. Methods Messenger RNA expression studies were performed of 5FU activating enzymes in human colon cancer cells lines (CaCo-2, HT-29), primary human gingival cells (HEGP), and normal esophageal and gastric clinical tissue samples. Excess nucleobase was then used in vitro to protect cells from 5FU toxicity. Results Pyrimidine salvage pathways predominate in squamous cells of the gingiva (HEGP) and esophageal tissue. Excess salvage nucleobase uracil but not adenine prevented 5FU toxicity in HEGP cells. Pyrimidine de novo synthesis predominates in columnar Caco-2, HT-29 and gastric tissue. Excess nucleobase adenine but not uracil prevented 5FU toxicity to Caco-2 and HT-29 cells. Conclusion The directed application of the normal nucleobase uracil to the squamous cells of the oral mucosa and palms and soles together with the delivery of the normal nucleobase adenine to the columnar cells of the GI tract may enable the safe delivery of higher 5FU dose intensity. These results also suggest a feature of tissue function where squamous cells grow largely by recycling overlying tissue cell components. Columnar cells use absorbed surface nutrients for de novo growth. A disruption of this tissue function can result in growth derived from an underlying nutrient source. That change would also cause the loss of the region of cell turnover at the tissue surface. Subsequent cell proliferation with limiting nutrient availability could promote oncogenesis in such initiated tissue.
C1 [Heuvel, John P. Vanden; Thompson, Jerry T.] Penn State Univ, Dept Vet & Biomed Sci, University Pk, PA 16802 USA.
   [Heuvel, John P. Vanden; Thompson, Jerry T.] Penn State Univ, Ctr Mol Toxicol & Carcinogenesis, University Pk, PA 16802 USA.
   [Heuvel, John P. Vanden; Albrecht, Prajakta] INDIGO Biosci Inc, State Coll, PA 16801 USA.
   [Mandetta, Donald; Kamerow, Harry; Ford, John P.] Mt Nittany Med Ctr, State Coll, PA 16803 USA.
   [Ford, John P.] Asymmetr Therapeut LLC, Unadilla, NY 13849 USA.
RP Ford, JP (corresponding author), Mt Nittany Med Ctr, 1850 East Pk Ave, State Coll, PA 16803 USA.
EM jpfordmd@hotmail.com
CR Baldwin SA, 2004, PFLUG ARCH EUR J PHY, V447, P735, DOI 10.1007/s00424-003-1103-2
   Berry DL, 2007, CELL, V131, P1137, DOI 10.1016/j.cell.2007.10.048
   Buhrdel P, 1985, Acta Paediatr Hung, V26, P327
   Chakilam S, 2013, AM J PATHOL, V182, P1005, DOI 10.1016/j.ajpath.2012.11.026
   Chen NX, 2006, NEPHROL DIAL TRANSPL, V21, P3435, DOI 10.1093/ndt/gfl429
   Choi AMK, 2013, NEW ENGL J MED, V368, P651, DOI [10.1056/NEJMra1205406, 10.1056/NEJMc1303158]
   Fenoglio-Preiser CM, 1989, GASTROINTESTINAL PAT
   Ford JP, 2012, US Patent, Patent No. [7,816,366, 7816366]
   Gillies PJ, 2012, J LIPID RES, V53, P1679, DOI 10.1194/jlr.M022657
   GUTENSOHN W, 1984, KLIN WOCHENSCHR, V62, P953, DOI 10.1007/BF01728425
   Hoff PM, 2000, INVEST NEW DRUG, V18, P331, DOI 10.1023/A:1006445214741
   Ichikawa W, 2006, CLIN CANCER RES, V12, P3928, DOI 10.1158/1078-0432.CCR-05-2665
   Jeung HC, 2011, ANTI-CANCER DRUG, V22, P801, DOI 10.1097/CAD.0b013e328345c9ae
   Karam Sherif M., 1999, Frontiers in Bioscience, V4, pD286, DOI 10.2741/Karam
   Kobayashi Y, 2005, J PHARM PHARMACOL, V57, P573, DOI 10.1211/0022357055966
   Kosinski C, 2007, P NATL ACAD SCI USA, V104, P15418, DOI 10.1073/pnas.0707210104
   Lee Y, 2009, J NUTR, V139, P1861, DOI 10.3945/jn.108.100461
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Ling FC, 2009, DIS ESOPHAGUS, V22, P694, DOI 10.1111/j.1442-2050.2009.00957.x
   Longley DB, 2003, NAT REV CANCER, V3, P330, DOI 10.1038/nrc1074
   Lorenzi PL, 2006, DRUG METAB DISPOS, V34, P1070, DOI 10.1124/dmd.105.009209
   Ma TA, 2013, EXP CELL RES, V319, P779, DOI 10.1016/j.yexcr.2013.01.018
   Malet-Martino M, 2002, ONCOLOGIST, V7, P288, DOI 10.1634/theoncologist.7-4-288
   Maring JG, 2005, PHARMACOGENOMICS J, V5, P226, DOI 10.1038/sj.tpj.6500320
   Muhale FA, 2011, PHARMACOGENOMICS, V12, P341, DOI [10.2217/pgs.10.188, 10.2217/PGS.10.188]
   Odze RD, 2005, AM J GASTROENTEROL, V100, P1853, DOI 10.1111/j.1572-0241.2005.50096.x
   Pasquale EB, 2008, CELL, V133, P38, DOI 10.1016/j.cell.2008.03.011
   Rektorschek M, 1998, GASTROENTEROLOGY, V115, P628, DOI 10.1016/S0016-5085(98)70142-8
   REYES P, 1975, J BIOL CHEM, V250, P5097
   Roesly HB, 2012, AM J PHYSIOL-GASTR L, V302, pG864, DOI 10.1152/ajpgi.00340.2011
   Squier C, 2011, HUMAN ORAL MUCOSA: DEVELOPMENT, STRUCTURE, AND FUNCTION, P1
   Vermeulen L, 2013, SCIENCE, V342, P995, DOI 10.1126/science.1243148
   Zhang J, 2010, MOL NUTR FOOD RES, V54, pS83, DOI 10.1002/mnfr.200900244
NR 33
TC 0
Z9 0
U1 0
U2 1
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0167-6997
EI 1573-0646
J9 INVEST NEW DRUG
JI Invest. New Drugs
PD OCT
PY 2015
VL 33
IS 5
BP 1003
EP 1011
DI 10.1007/s10637-015-0259-x
PG 9
WC Oncology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Pharmacology & Pharmacy
GA CW4PD
UT WOS:000364972700001
PM 26123924
OA hybrid, Green Published
DA 2022-04-25
ER

PT J
AU Focaccetti, C
   Bruno, A
   Magnani, E
   Bartolini, D
   Principi, E
   Dallaglio, K
   Bucci, EO
   Finzi, G
   Sessa, F
   Noonan, DM
   Albini, A
AF Focaccetti, Chiara
   Bruno, Antonino
   Magnani, Elena
   Bartolini, Desiree
   Principi, Elisa
   Dallaglio, Katiuscia
   Bucci, Eraldo O.
   Finzi, Giovanna
   Sessa, Fausto
   Noonan, Douglas M.
   Albini, Adriana
TI Effects of 5-Fluorouracil on Morphology, Cell Cycle, Proliferation,
   Apoptosis, Autophagy and ROS Production in Endothelial Cells and
   Cardiomyocytes
SO PLOS ONE
LA English
DT Article
ID CANCER-PATIENTS; BREAST-CANCER; IN-VITRO; MOLECULAR-MECHANISMS;
   GROWTH-FACTOR; ANTICANCER DRUGS; CARDIO-ONCOLOGY; FOLINIC ACID; HUMAN
   LIVER; CARDIOTOXICITY
AB Antimetabolites are a class of effective anticancer drugs interfering in essential biochemical processes. 5-Fluorouracil (5-FU) and its prodrug Capecitabine are widely used in the treatment of several solid tumors (gastro-intestinal, gynecological, head and neck, breast carcinomas). Therapy with fluoropyrimidines is associated with a wide range of adverse effects, including diarrhea, dehydration, abdominal pain, nausea, stomatitis, and hand-foot syndrome. Among the 5-FU side effects, increasing attention is given to cardiovascular toxicities induced at different levels and intensities. Since the mechanisms related to 5-FU-induced cardiotoxicity are still unclear, we examined the effects of 5-FU on primary cell cultures of human cardiomyocytes and endothelial cells, which represent two key components of the cardiovascular system. We analyzed at the cellular and molecular level 5-FU effects on cell proliferation, cell cycle, survival and induction of apoptosis, in an experimental cardioncology approach. We observed autophagic features at the ultrastructural and molecular levels, in particular in 5-FU exposed cardiomyocytes. Reactive oxygen species (ROS) elevation characterized the endothelial response. These responses were prevented by a ROS scavenger. We found induction of a senescent phenotype on both cell types treated with 5-FU. In vivo, in a xenograft model of colon cancer, we showed that 5-FU treatment induced ultrastructural changes in the endothelium of various organs. Taken together, our data suggest that 5-FU can affect, both at the cellular and molecular levels, two key cell types of the cardiovascular system, potentially explaining some manifestations of 5-FU-induced cardiovascular toxicity.
C1 [Focaccetti, Chiara; Bruno, Antonino; Bartolini, Desiree; Principi, Elisa; Noonan, Douglas M.] IRCCS MultiMed, Ctr Sci & Technol, Milan, Italy.
   [Magnani, Elena; Dallaglio, Katiuscia; Albini, Adriana] IRCCS Arcispedale Santa Maria Nuova, Dept Res & Stat, Reggio Emilia, Italy.
   [Bucci, Eraldo O.] IRCCS MultiMed, Oncol Unit, Castellanza, VA, Italy.
   [Finzi, Giovanna; Sessa, Fausto] Osped Circolo Varese, Dept Pathol, Varese, Italy.
   [Sessa, Fausto] Univ Insubria, Dept Surg & Morphol Sci, Varese, Italy.
   [Noonan, Douglas M.] Univ Insubria, Dept Biotechnol & Life Sci, Varese, Italy.
RP Albini, A (corresponding author), IRCCS Arcispedale Santa Maria Nuova, Dept Res & Stat, Reggio Emilia, Italy.
EM albini.adriana@gmail.com
RI Principi, Elisa/O-2424-2015; Noonan, Douglas M/A-8620-2010; Focaccetti,
   Chiara/AAD-9378-2019; Bartolini, Desirée/K-5319-2016; Bruno,
   Antonino/J-7066-2016
OI Noonan, Douglas M/0000-0001-8058-0719; Focaccetti,
   Chiara/0000-0002-7334-3966; Bartolini, Desirée/0000-0003-3849-757X;
   Bruno, Antonino/0000-0002-4790-0861; Principi,
   Elisa/0000-0003-3747-1167; Albini, Adriana/0000-0002-9624-5103
FU Ministero Italiano della Salute, Grande Progetto Strategico (GPS);
   Ministero dell'Istruzione dell'Universita e della Ricerca, PRIN
   (Programmi di Ricerca Scientifica di Rilevante Interesse Nazionale)
   [2010NECHBX 003]; AIRC (Associazione Italiana per la Ricerca sul
   Cancro)Fondazione AIRC per la ricerca sul cancro [IG10228]
FX These studies were supported by the Ministero Italiano della Salute,
   Grande Progetto Strategico (GPS), by the Ministero dell'Istruzione
   dell'Universita e della Ricerca, PRIN (Programmi di Ricerca Scientifica
   di Rilevante Interesse Nazionale) 2010NECHBX 003, AIRC (Associazione
   Italiana per la Ricerca sul Cancro) (IG10228). AB is a FIRC (Fondazione
   Italiana per la Ricerca sul Cancro) fellow. KD is a Fondazione Veronesi
   fellow. The authors thank Paola Corradino for assistance and
   bibliography and Alessandra Panvini Rosati for secretarial help. The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Albini A, 2012, INTERN EMERG MED, V7, P399, DOI 10.1007/s11739-012-0845-2
   Albini A, 2011, FUTUR CARDIOL, V7, P693, DOI [10.2217/FCA.11.54, 10.2217/fca.11.54]
   Albini A, 2011, JNCI-J NATL CANCER I, V103, P608, DOI 10.1093/jnci/djr034
   Albini A, 2010, JNCI-J NATL CANCER I, V102, P14, DOI 10.1093/jnci/djp440
   Alili L, 2014, DRUG INDUCED ACCELER
   Amstutz U, 2008, J EXP CLIN CANC RES, V27, DOI 10.1186/1756-9966-27-54
   Becker K, 1999, DRUGS, V57, P475, DOI 10.2165/00003495-199957040-00003
   Bijnsdorp IV, 2010, INT J CANCER, V126, P2457, DOI 10.1002/ijc.24943
   Boisen L, 2010, EXP GERONTOL, V45, P779, DOI 10.1016/j.exger.2010.06.003
   Bronckaers A, 2009, MED RES REV, V29, P903, DOI 10.1002/med.20159
   Brower V, 2013, JNCI-J NATL CANCER I, V105, P835, DOI 10.1093/jnci/djt161
   Bu XX, 2008, CANCER BIOL THER, V7, P392, DOI 10.4161/cbt.7.3.5366
   Buchel B, 2013, BIOMED CHROMATOGR, V27, P7, DOI 10.1002/bmc.2741
   Cardinale D, 2013, SEMIN ONCOL, V40, P186, DOI 10.1053/j.seminoncol.2013.01.008
   Casale F, 2004, PHARMACOL RES, V50, P173, DOI 10.1016/j.phrs.2004.01.006
   Coleman PR, 2013, AGING-US, V5, P913, DOI 10.18632/aging.100622
   CORONEL B, 1988, INTENS CARE MED, V14, P429, DOI 10.1007/BF00262901
   Cwikiel M, 1996, ANN ONCOL, V7, P731
   CWIKIEL M, 1995, ACTA ONCOL, V34, P83, DOI 10.3109/02841869509093643
   CWIKIEL M, 1995, SCANNING MICROSCOPY, V9, P561
   Dai Dao-Fu, 2014, Longev Healthspan, V3, P6, DOI 10.1186/2046-2395-3-6
   Durak I, 2000, J TOXICOL ENV HEAL A, V59, P585
   Erusalimsky JD, 2009, J APPL PHYSIOL, V106, P326, DOI 10.1152/japplphysiol.91353.2008
   Eskandari MR, 2014, XENOBIOTICA, P1
   Ewer MS, 2010, NAT REV CARDIOL, V7, P564, DOI 10.1038/nrcardio.2010.121
   Filgueiras MD, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063177
   Force T, 2007, NAT REV CANCER, V7, P332, DOI 10.1038/nrc2106
   FOX SB, 1995, J PATHOL, V176, P183, DOI 10.1002/path.1711760212
   FRAILE RJ, 1980, CANCER RES, V40, P2223
   Gajalakshmi P, 2013, TOXICOL APPL PHARM, V269, P121, DOI 10.1016/j.taap.2013.03.011
   Gates PE, 2009, EXP PHYSIOL, V94, P311, DOI 10.1113/expphysiol.2008.043349
   Gemma C., 2007, OXIDATIVE STRESS AGI
   Gewirtz DA, 2008, BIOCHEM PHARMACOL, V76, P947, DOI 10.1016/j.bcp.2008.06.024
   Ghoshal K, 1997, BIOCHEM PHARMACOL, V53, P1569, DOI 10.1016/S0006-2952(97)00040-3
   Gozuacik D, 2004, ONCOGENE, V23, P2891, DOI 10.1038/sj.onc.1207521
   Grem JL, 1997, SEMIN RADIAT ONCOL, V7, P249, DOI 10.1016/S1053-4296(97)80023-9
   Gressett Sarah M, 2006, J Oncol Pharm Pract, V12, P131, DOI 10.1177/1078155206069242
   Grover S, 2013, INT J CARDIOL, V168, P5465, DOI 10.1016/j.ijcard.2013.07.246
   Hemalatha T, 2010, BIOCHEM CELL BIOL, V88, P491, DOI [10.1139/O09-165, 10.1139/o09-165]
   Ignatescu MC, 1999, ARTERIOSCL THROM VAS, V19, P2340, DOI 10.1161/01.ATV.19.10.2340
   Ijichi K, 2014, ANTICANCER RES, V34, P2907
   ISHIKAWA F, 1989, NATURE, V338, P557, DOI 10.1038/338557a0
   Jensen SA, 2006, CANCER CHEMOTH PHARM, V58, P487, DOI 10.1007/s00280-005-0178-1
   Kleiman N S, 1987, Am J Med, V82, P566, DOI 10.1016/0002-9343(87)90465-7
   Kosmas C, 2008, J CANCER RES CLIN, V134, P75, DOI 10.1007/s00432-007-0250-9
   L'Ecuyer T, 2001, MOL GENET METAB, V74, P370, DOI 10.1006/mgme.2001.3243
   Lamberti M, 2014, TOXICOL LETT, V227, P151, DOI 10.1016/j.toxlet.2014.03.018
   Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1
   Li J, 2010, EUR J CANCER, V46, P1900, DOI 10.1016/j.ejca.2010.02.021
   Li J, 2009, ANN SURG ONCOL, V16, P761, DOI 10.1245/s10434-008-0260-0
   Maseri A, 2001, AM J MED, V111, P326, DOI 10.1016/S0002-9343(01)00930-5
   Menna P, 2008, CHEM RES TOXICOL, V21, P978, DOI 10.1021/tx800002r
   METZKURSCHEL U, 1990, RENAL FAILURE, V12, P93, DOI 10.3109/08860229009087124
   Meyer CC, 1997, PHARMACOTHERAPY, V17, P729
   MISSET B, 1990, INTENS CARE MED, V16, P210, DOI 10.1007/BF01724805
   Miwa M, 1998, EUR J CANCER, V34, P1274, DOI 10.1016/S0959-8049(98)00058-6
   Molteni LP, 2010, BREAST J, V16, pS45, DOI 10.1111/j.1524-4741.2010.01004.x
   MOSSERI M, 1993, CANCER RES, V53, P3028
   Muneoka Katsuki, 2005, Int J Clin Oncol, V10, P441, DOI 10.1007/s10147-005-0516-7
   Nelson G, 2012, AGING CELL, V11, P345, DOI 10.1111/j.1474-9726.2012.00795.x
   Polk A, 2014, BMC PHARMACOL TOXICO, V15, DOI 10.1186/2050-6511-15-47
   Polk A, 2013, CANCER TREAT REV, V39, P974, DOI 10.1016/j.ctrv.2013.03.005
   Russo G, 2012, INTERN EMERG MED, V7, P439, DOI 10.1007/s11739-012-0794-9
   Saif MW, 2009, EXPERT OPIN DRUG SAF, V8, P191, DOI [10.1517/14740330902733961, 10.1517/14740330902733961 ]
   SCHOBER C, 1993, CANCER, V72, P2242, DOI 10.1002/1097-0142(19931001)72:7<2242::AID-CNCR2820720730>3.0.CO;2-E
   Schumacker PT, 2006, CANCER CELL, V10, P175, DOI 10.1016/j.ccr.2006.08.015
   Sereno M, 2008, CLIN TRANSL ONCOL, V10, P35, DOI 10.1007/s12094-008-0150-8
   Shimizu S, 2004, NAT CELL BIOL, V6, P1221, DOI 10.1038/ncb1192
   Sikora E, 2013, CURR VASC PHARM
   Sorrentino MF, 2012, CARDIOL J, V19, P453, DOI 10.5603/CJ.2012.0084
   Spasojevic I, 2009, MOLECULES, V14, P53, DOI 10.3390/molecules14010053
   Swystun LL, 2009, J THROMB HAEMOST, V7, P619, DOI 10.1111/j.1538-7836.2009.03300.x
   Tabata T, 2004, DRUG METAB DISPOS, V32, P762, DOI 10.1124/dmd.32.7.762
   te Poele RH, 2002, CANCER RES, V62, P1876
   Tokalov SV, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-57
   Tsibiribi P, 2006, HUM EXP TOXICOL, V25, P305, DOI 10.1191/0960327106ht628oa
   Tsibiribi Panayota, 2006, Bull Cancer, V93, pE27
   VANGROENINGEN CJ, 1988, CANCER RES, V48, P6956
   Vene R, 2007, MOL CANCER THER, V6, P286, DOI 10.1158/1535-7163.MCT-06-0346
   Wada H, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-361
   Walko CM, 2005, CLIN THER, V27, P23, DOI 10.1016/j.clinthera.2005.01.005
   WEIDMANN B, 1994, CANCER, V73, P2001, DOI 10.1002/1097-0142(19940401)73:7<2001::AID-CNCR2820730736>3.0.CO;2-S
   Yeh ETH, 2009, J AM COLL CARDIOL, V53, P2231, DOI 10.1016/j.jacc.2009.02.050
   Yousefi S, 2006, NAT CELL BIOL, V8, P1124, DOI 10.1038/ncb1482
   Zafarullah M, 2003, CELL MOL LIFE SCI, V60, P6, DOI 10.1007/s000180300001
NR 85
TC 158
Z9 159
U1 9
U2 46
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 11
PY 2015
VL 10
IS 2
AR e0115686
DI 10.1371/journal.pone.0115686
PG 25
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA CB3RF
UT WOS:000349545300012
PM 25671635
OA Green Published, gold, Green Submitted
DA 2022-04-25
ER

PT J
AU Cui, XM
   Shen, WB
   Wang, GH
   Huang, ZY
   Wen, DP
   Yang, YL
   Liu, Y
   Cui, L
AF Cui, Ximao
   Shen, Wenbin
   Wang, Guanghui
   Huang, Zhenyu
   Wen, Dongpeng
   Yang, Yili
   Liu, Yun
   Cui, Long
TI Ring finger protein 152 inhibits colorectal cancer cell growth and is a
   novel prognostic biomarker
SO AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH
LA English
DT Article
DE Colorectal cancer; RNF152; prognosis; proliferation; E3 ligase
ID TOTAL MESORECTAL EXCISION; UBIQUITIN LIGASE; RNF152; DOMAIN
AB Colorectal cancer (CRC) is the third most commonly diagnosed cancer in the world. RING finger-related E3 ubiquitin ligases play a role in tumorigenesis and can function either as oncogenes or tumor suppressors based on their target proteins. Here, we show that the expression of RNF152, a ring finger protein, in CRC tissues was significantly reduced compared with adjacent non-cancerous tissues. High expression levels of RNF152 correlated with better prognosis in patients with colorectal cancer. Low expression of RNF152 correlated with lymphatic metastasis. Overexpression of RNF152 inhibited CRC cell proliferation both in vitro and in vivo by inactivating the mechanistic target of rapamycin complex 1 (mTORC1) and inducing autophagy and apoptotic cell death. This strong inhibition was dependent on the E3 ligase activity of RNF152. Ectopic expression of the RNF152-CS-mutant, which lacks E3 ligase activity, significantly restored the proliferation ability of CRC cells. Our findings showed that RNF152 inhibits colorectal cancer growth and may be a novel prognostic biomarker for the treatment of CRC.
C1 [Cui, Ximao; Shen, Wenbin; Wang, Guanghui; Huang, Zhenyu; Wen, Dongpeng; Liu, Yun; Cui, Long] Shanghai Jiao Tong Univ, Dept Colorectal & Anal Surg, Xinhua Hosp, Sch Med, 1665 Kongjiang Rd, Shanghai, Peoples R China.
   [Wang, Guanghui] Guizhou Prov Peoples Hosp, Guiyang, Guizhou, Peoples R China.
   [Yang, Yili] Chinese Acad Med Sci, Suzhou Inst Syst Med, Ctr Syst Med, Suzhou, Jiangsu, Peoples R China.
RP Liu, Y; Cui, L (corresponding author), Shanghai Jiao Tong Univ, Dept Colorectal & Anal Surg, Xinhua Hosp, Sch Med, 1665 Kongjiang Rd, Shanghai, Peoples R China.
EM yunliudr@126.com; cuilong@xinhua-med.com.cn
FU National High Technology Research and Development Program of China (863
   Program)National High Technology Research and Development Program of
   China [SQ2014SFOZD00314]; National Natural Science Foundation of
   ChinaNational Natural Science Foundation of China (NSFC) [81372636,
   81572378, 81302089]; Natural Science Foundation of Shanghai Municipal
   Commission of Health and Family Planning [201740122, 2015-4Y0203]
FX This study was funded by the National High Technology Research and
   Development Pro-gram of China (863 Program; Grant No. SQ2014SFOZD00314),
   the National Natural Science Foundation of China (Grant Nos. 81372636,
   81572378, and 81302089) and the Natural Science Foundation of Shanghai
   Municipal Commission of Health and Family Planning (Grant Nos. 201740122
   and 2015-4Y0203). We are very grateful to Dr. Lu Deng and Prof. Ping
   Wang for their help.SS
CR Borden KLB, 1996, CURR OPIN STRUC BIOL, V6, P395, DOI 10.1016/S0959-440X(96)80060-1
   Cui XM, 2017, BIOCHEM BIOPH RES CO, V483, P609, DOI 10.1016/j.bbrc.2016.12.095
   Cui XM, 2016, ONCOL LETT, V12, P1529, DOI 10.3892/ol.2016.4789
   Deng L, 2015, MOL CELL, V58, P804, DOI 10.1016/j.molcel.2015.03.033
   Deshaies RJ, 2009, ANNU REV BIOCHEM, V78, P399, DOI 10.1146/annurev.biochem.78.101807.093809
   Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945
   Fu JH, 2012, BMC SYST BIOL, V6, DOI 10.1186/1752-0509-6-68
   Geng R, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.400
   HEALD RJ, 1986, LANCET, V1, P1479
   Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5
   Kim J, 2011, NAT CELL BIOL, V13, P132, DOI 10.1038/ncb2152
   Lee JP, 2010, MOL CANCER RES, V8, P93, DOI 10.1158/1541-7786.MCR-08-0491
   Lipkowitz S, 2011, NAT REV CANCER, V11, P629, DOI 10.1038/nrc3120
   Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364
   Marine JC, 2010, CELL DEATH DIFFER, V17, P93, DOI 10.1038/cdd.2009.68
   Planas-Paz L, 2016, NAT CELL BIOL, V18, P467, DOI 10.1038/ncb3337
   Sankaranarayanan R, 2010, LANCET ONCOL, V11, P165, DOI 10.1016/S1470-2045(09)70335-3
   Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138
   van Gijn W, 2011, LANCET ONCOL, V12, P575, DOI 10.1016/S1470-2045(11)70097-3
   Wang GH, 2017, J CANCER RES CLIN, V143, P971, DOI 10.1007/s00432-017-2362-1
   Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563
   Welcsh PL, 2001, HUM MOL GENET, V10, P705, DOI 10.1093/hmg/10.7.705
   Wiederschain D, 2009, CELL CYCLE, V8, P498, DOI 10.4161/cc.8.3.7701
   Yamamoto F, 2007, ELECTROPHORESIS, V28, P1882, DOI 10.1002/elps.200700093
   Zhang SL, 2010, PROTEIN CELL, V1, P656, DOI 10.1007/s13238-010-0083-1
NR 25
TC 4
Z9 6
U1 2
U2 6
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1943-8141
J9 AM J TRANSL RES
JI Am. J. Transl. Res.
PY 2018
VL 10
IS 11
BP 3701
EP 3712
PG 12
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Research & Experimental Medicine
GA HC2VM
UT WOS:000451660000034
PM 30662620
DA 2022-04-25
ER

PT J
AU Wang, SS
   Li, MY
   Liu, Y
   Vlantis, AC
   Chan, JYK
   Xue, LB
   Hu, BG
   Yang, SC
   Chen, MX
   Zhou, SM
   Guo, W
   Zeng, XH
   Qiu, SQ
   van Hasselt, CA
   Tong, MCF
   Chen, GG
AF Wang, Shanshan
   Li, Ming-Yue
   Liu, Yi
   Vlantis, Alexander C.
   Chan, Jason Y. K.
   Xue, Lingbin
   Hu, Bao-Guang
   Yang, Shucai
   Chen, Mo-Xian
   Zhou, Shaoming
   Guo, Wei
   Zeng, Xianhai
   Qiu, Shuqi
   van Hasselt, C. Andrew
   Tong, Michael C. F.
   Chen, George G.
TI The role of microRNA in cisplatin resistance or sensitivity
SO EXPERT OPINION ON THERAPEUTIC TARGETS
LA English
DT Review
DE Cisplatin; miRNA; resistance; sensitivity; cancer
ID CELL LUNG-CANCER; EPITHELIAL-MESENCHYMAL TRANSITION; HUMAN
   NASOPHARYNGEAL CARCINOMA; OVARIAN-CANCER; STEM-CELLS; GASTRIC-CANCER;
   OSTEOSARCOMA CELLS; COLORECTAL-CANCER; MITOCHONDRIAL FISSION;
   MULTIDRUG-RESISTANCE
AB Introduction Cisplatin is a chemotherapy drug that has been used to treat a number of cancers for decades, and is still one of the most commonly used anti-cancer agents. However, some patients do not respond to cisplatin while other patients who were originally sensitive to cisplatin eventually develop chemoresistance, leading to treatment failure or/and tumor recurrence. Areas Covered Different mechanisms contribute to cisplatin resistance or sensitivity, involving multiple pathways or/and processes such as DNA repair, DNA damage response, drug transport, and apoptosis. Among the various mechanisms, it appears that microRNAs play an important role in determining the resistance or sensitivity. In this article, we analyzed and summarized recent findings in this area, with the aim that these data can aid further research and understanding, leading to the eventual reduction of cisplatin resistance. Expert Commentary microRNAs can positively or negatively regulate cisplatin resistance by acting on molecules or/and pathways related to apoptosis, autophagy, hypoxia, cancer stem cells, NF-kappa B, and Notch1. It appears that the modulation of relevant microRNAs can effectively re-sensitize cancer cells to cisplatin regimen in certain types of cancers including breast, colorectal, gastric, liver, lung, ovarian, prostate, testicular, and thyroid cancers.
C1 [Wang, Shanshan] Pharmaceut Univ, Sch Life Sci & Biopharmaceut, Guangzhou, Guangdong, Peoples R China.
   [Wang, Shanshan; Vlantis, Alexander C.; Chan, Jason Y. K.; Xue, Lingbin; van Hasselt, C. Andrew; Tong, Michael C. F.; Chen, George G.] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Otorhinolaryngol Head & Neck Surg, Shatin, Hong Kong, Peoples R China.
   [Li, Ming-Yue; Liu, Yi] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Surg, Hong Kong, Peoples R China.
   [Zeng, Xianhai; Qiu, Shuqi] Inst ENT, DShenzhen Key Lab ENT, Shenzhen, Shandong, Peoples R China.
   [Zeng, Xianhai; Qiu, Shuqi] Longgang ENT Hosp, Shenzhen, Shandong, Peoples R China.
   [Vlantis, Alexander C.; Chan, Jason Y. K.; Zeng, Xianhai; Qiu, Shuqi; van Hasselt, C. Andrew; Tong, Michael C. F.; Chen, George G.] Chinese Univ Hong Kong, Longgang ENT Hosp, Shenzhen Ear Nose & Throat Joint Res Ctr, Shenzhen, Peoples R China.
   [Hu, Bao-Guang] Binzhou Med Univ, Affiliated Hosp, Dept Gastrointestinal Surg, Shenzhen, Peoples R China.
   [Yang, Shucai] Pingshan Dist Peoples Hosp Shenzhen, Dept Clin Lab, Shenzhen, Guangdong, Peoples R China.
   [Chen, Mo-Xian; Zhou, Shaoming] Shenzhen Childrens Hosp, Div Gastroenterol, Shenzhen, Peoples R China.
   [Guo, Wei] Shenzhen Ritzcon Biol Technol Co LTD, Shenzhen, Guangdong, Peoples R China.
RP Tong, MCF; Chen, GG (corresponding author), Chinese Univ Hong Kong, Prince Wales Hosp, Dept Otorhinolaryngol Head & Neck Surg, Shatin, Hong Kong, Peoples R China.
EM mtong@ent.cuhk.edu.hk; gchen@cuhk.edu.hk
RI yang, shucai/AAZ-4319-2021; Chan, Jason/H-4049-2017
OI Chan, Jason/0000-0002-9480-4637; shucai, YANG/0000-0002-9694-828X; Zeng,
   Xianhai/0000-0002-9519-0112; Tong, Michael CF/0000-0002-9418-5223
FU Research Grants Council of the Hong Kong Special Administrative
   RegionHong Kong Research Grants Council [14109716]
FX This study was supported by grants from the Research Grants Council of
   the Hong Kong Special Administrative Region (No. 14109716).
CR Cao LQ, 2018, BMB REP, V51, P456, DOI 10.5483/BMBRep.2018.51.9.104
   Chang HP, 2018, INT J ONCOL, V52, P1504, DOI 10.3892/ijo.2018.4298
   Chen C, 2014, J BONE MINER RES, V29, P338, DOI 10.1002/jbmr.2032
   Chen HHW, 2012, LUNG CANCER, V75, P228, DOI 10.1016/j.lungcan.2011.06.011
   Chen Y, 2015, CELL PHYSIOL BIOCHEM, V37, P1869, DOI 10.1159/000438548
   Cheng QL, 2018, CELL PHYSIOL BIOCHEM, V47, P279, DOI 10.1159/000489806
   Chu DK, 2011, CLIN CANCER RES, V17, P5686, DOI 10.1158/1078-0432.CCR-10-3196
   Dong SW, 2019, ONCOTARGETS THER, V12, P10089, DOI 10.2147/OTT.S219977
   Dong Z, 2014, CANCER LETT, V343, P249, DOI 10.1016/j.canlet.2013.09.034
   Drayton RM, 2012, BIOCHEM SOC T, V40, P821, DOI 10.1042/BST20120055
   Fadejeva I, 2017, ONCOTARGET, V8, P115754, DOI 10.18632/oncotarget.22975
   Fan S, 2015, CANCER LETT, V362, P183, DOI 10.1016/j.canlet.2015.03.045
   Feng CZ, 2018, CELL CYCLE, V17, P448, DOI 10.1080/15384101.2017.1395533
   Ferreira JA, 2016, DRUG RESIST UPDATE, V24, P34, DOI 10.1016/j.drup.2015.11.003
   Fukusumi T, 2018, CLIN CANCER RES, V24, P619, DOI 10.1158/1078-0432.CCR-17-1366
   Ghasabi M, 2019, J CELL PHYSIOL, V234, P22581, DOI 10.1002/jcp.28823
   Gibalova L, 2012, TOXICOL IN VITRO, V26, P435, DOI 10.1016/j.tiv.2012.01.014
   Gu L, 2017, CLIN CANCER RES, V23, P7312, DOI 10.1158/1078-0432.CCR-16-2186
   He C, 2019, ANTICANCER RES, V39, P1711, DOI 10.21873/anticanres.13277
   Hess AK, 2017, EUR J CANCER, V77, P3, DOI 10.1016/j.ejca.2017.02.018
   Hua L, 2018, CELL BIOL INT, V42, P1240, DOI 10.1002/cbin.10995
   Huang RS, 2018, BIOMED PHARMACOTHER, V98, P538, DOI 10.1016/j.biopha.2017.12.092
   Islam SS, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1360-3
   Ito T, 2017, HUM CELL, V30, P1, DOI 10.1007/s13577-016-0149-3
   Jin C, 2017, ONCOTARGET, V8, P56174, DOI 10.18632/oncotarget.17045
   Jung KH, 2016, HEPATOLOGY, V63, P864, DOI 10.1002/hep.28367
   Kastrati I, 2015, ONCOGENE, V34, P2309, DOI 10.1038/onc.2014.180
   Khalil MA, 2012, NEOPLASMA, V59, P737, DOI 10.4149/neo_2012_093
   Kilari D, 2014, J CLIN ONCOL, V32, DOI 10.1200/jco.2014.32.15_suppl.e15516
   Dang K, 2015, INT J MOL SCI, V16, P6353, DOI 10.3390/ijms16036353
   Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758
   Li B, 2019, J CANCER, V10, P2628, DOI 10.7150/jca.33117
   Li BW, 2017, CANCER LETT, V410, P212, DOI 10.1016/j.canlet.2017.09.035
   Li DW, 2016, ONCOL LETT, V12, P1569, DOI 10.3892/ol.2016.4749
   Li HH, 2017, GASTROENTEROLOGY, V153, P505, DOI 10.1053/j.gastro.2017.04.017
   Li J, 2019, INT J MOL MED, V43, P517, DOI 10.3892/ijmm.2018.3940
   Li SJ, 2018, J CELL PHYSIOL, V233, P9416, DOI 10.1002/jcp.26815
   Li SJ, 2020, FRONT GENET, V10, DOI 10.3389/fgene.2019.01278
   Li XD, 2019, BIOCHEM PHARMACOL, V161, P98, DOI 10.1016/j.bcp.2019.01.009
   Li XD, 2017, BRIT J CANCER, V116, P66, DOI 10.1038/bjc.2016.379
   Li YH, 2019, SIGNAL TRANSDUCT TAR, V4, DOI 10.1038/s41392-019-0084-3
   Lin Z, 2018, REPROD SCI, V11, p1933719118805865
   Liu JG, 2018, ONCOL REP, V39, P1631, DOI 10.3892/or.2018.6268
   Liu J, 2019, ONCOL LETT, V17, P1453, DOI 10.3892/ol.2018.9745
   Liu J, 2018, ONCOL LETT, V15, P1021, DOI 10.3892/ol.2017.7398
   Liu QX, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/9870693
   Liu Y, 2016, AM J TRANSL RES, V8, P2681
   Lv YQ, 2015, ONCOTARGETS THER, V8, DOI 10.2147/OTT.S82835
   Ma YX, 2015, MOL MED REP, V11, P625, DOI 10.3892/mmr.2014.2688
   Ma Z, 2017, BIOCHEM BIOPH RES CO, V490, P309, DOI 10.1016/j.bbrc.2017.06.041
   Mittal V, 2018, ANNU REV PATHOL-MECH, V13, P395, DOI 10.1146/annurev-pathol-020117-043854
   Muz B, 2017, LEUKEMIA LYMPHOMA, V58, P2916, DOI 10.1080/10428194.2017.1319052
   Nunez-Hernandez DM, 2018, CHEMOSPHERE, V190, P253, DOI 10.1016/j.chemosphere.2017.09.131
   O'Brien SJ, 2018, INT J CANCER, V142, P2501, DOI 10.1002/ijc.31282
   Onorati AV, 2018, CANCER-AM CANCER SOC, V124, P3307, DOI 10.1002/cncr.31335
   Pan YY, 2018, ONCOL LETT, V15, P31, DOI 10.3892/ol.2017.7294
   Qin DW, 2018, MOL MED REP, V18, P3242, DOI 10.3892/mmr.2018.9316
   Shao QQ, 2018, GENE, V652, P48, DOI 10.1016/j.gene.2018.02.003
   Shen XW, 2020, EXP THER MED, V19, P375, DOI 10.3892/etm.2019.8191
   Si LH, 2019, ARCH BIOCHEM BIOPHYS, V668, P9, DOI 10.1016/j.abb.2019.04.009
   Song YD, 2017, CELL MOL BIOL, V63, P75, DOI 10.14715/cmb/2017.63.9.14
   Steele TM, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20061285
   Stordal B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040717
   Su J, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/234370
   Suzuki M, 2016, J CLIN INVEST, V126, P254, DOI 10.1172/JCI79775
   Tao PP, 2018, EXP THER MED, V15, P562, DOI 10.3892/etm.2017.5392
   Tian Y, 2018, CANCER BIOL MED, V15, P157, DOI 10.20892/j.issn.2095-3941.2017.0182
   Tong ZG, 2015, BIOMED PHARMACOTHER, V75, P129, DOI 10.1016/j.biopha.2015.07.036
   Vahabi M, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1119-x
   Valdes M, 2016, CURR ONCOL, V23, P386, DOI 10.3747/co.23.3191
   Wang LH, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.409
   Wang SS, 2018, MOL THER, V26, P2295, DOI 10.1016/j.ymthe.2018.06.015
   Wu D, 2018, ARCH GYNECOL OBSTET, V297, P699, DOI 10.1007/s00404-018-4649-0
   Wu DM, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1591-4
   Wu JJ, 2019, BIOMED PHARMACOTHER, V115, DOI 10.1016/j.biopha.2019.108869
   Xu XF, 2018, CANCER BIOL THER, V19, P427, DOI 10.1080/15384047.2018.1423925
   Xu Y, 2019, AGING ALBANY NY
   Xu Y, 2018, EXP CELL RES, V363, P160, DOI 10.1016/j.yexcr.2017.12.029
   Yang LW, 2018, MOL CARCINOGEN, V57, P419, DOI 10.1002/mc.22765
   Yang L, 2018, J MOL NEUROSCI, V66, P369, DOI 10.1007/s12031-018-1177-0
   Yang LY, 2012, ONCOL REP, V28, P592, DOI 10.3892/or.2012.1823
   Ye J, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00631
   Yin HY, 2018, TOXICOL APPL PHARM, V343, P16, DOI 10.1016/j.taap.2018.02.007
   Yu X, 2017, AM J CANCER RES, V7, P1769
   Zang HJ, 2017, J CANCER, V8, P3856, DOI 10.7150/jca.21267
   Zeng LP, 2016, J CELL MOL MED, V20, P559, DOI 10.1111/jcmm.12760
   Zhang GL, 2012, MUTAT RES-GEN TOX EN, V746, P66, DOI 10.1016/j.mrgentox.2012.03.004
   Zhang GH, 2019, HUM GENOMICS, V13, DOI 10.1186/s40246-019-0230-6
   Zhang JX, 2013, CANCER LETT, V329, P91, DOI 10.1016/j.canlet.2012.10.033
   Zhang LH, 2017, CELL CYCLE, V16, P999, DOI 10.1080/15384101.2017.1312237
   Zhang LY, 2018, CELL PHYSIOL BIOCHEM, V47, P1432, DOI 10.1159/000490834
   Zhang MN, 2019, CANCER LETT, V459, P168, DOI 10.1016/j.canlet.2019.05.039
   Zhang X, 2015, MOL CELLS, V38, P638, DOI 10.14348/molcells.2015.0037
   Zhang XY, 2018, ONCOTARGET, V9, P2105, DOI 10.18632/oncotarget.23249
   Zhang Y, 2014, BIOCHEM PHARMACOL, V87, P562, DOI 10.1016/j.bcp.2013.12.004
   Zhao Y, 2018, INT J ONCOL, V53, P644, DOI 10.3892/ijo.2018.4409
   Zheng H, 2020, WORLD J GASTROENTERO, V26, P499, DOI 10.3748/wjg.v26.i5.499
   Zhou DY, 2018, J CELL BIOCHEM, V119, P6997, DOI 10.1002/jcb.26908
   Zhou N, 2014, MOL MED REP, V10, P2495, DOI 10.3892/mmr.2014.2483
   Zhou Wen, 2015, Asian Pac J Cancer Prev, V16, P2425
   Zhou Y, 2017, NEURO-ONCOLOGY, V19, P8
   Zou SH, 2018, EUR REV MED PHARMACO, V22, P928, DOI 10.26355/eurrev_201802_14372
   Zuo Y, 2020, NEOPLASMA, V67, P93, DOI 10.4149/neo_2019_190202N106
NR 103
TC 12
Z9 12
U1 4
U2 20
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1472-8222
EI 1744-7631
J9 EXPERT OPIN THER TAR
JI Expert Opin. Ther. Targets
PD SEP 1
PY 2020
VL 24
IS 9
BP 885
EP 897
DI 10.1080/14728222.2020.1785431
EA JUL 2020
PG 13
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA OC5BH
UT WOS:000547434000001
PM 32559147
DA 2022-04-25
ER

PT J
AU Songyang, YY
   Song, TB
   Shi, Z
   Li, W
   Yang, SYS
   Li, DJ
AF Songyang, Yiyan
   Song, Tianbao
   Shi, Zhan
   Li, Wen
   Yang, Songyisha
   Li, Dejia
TI Effect of vitamin D on malignant behavior of non-small cell lung cancer
   cells
SO GENE
LA English
DT Article
DE Vitamin D; Lung cancer; PI3K/AKT/mTOR
ID NF-KAPPA-B; 1,25-DIHYDROXYVITAMIN D-3; SIDE-POPULATION; COLON-CANCER;
   CISPLATIN; GEMCITABINE; INHIBITION; AUTOPHAGY; PROTEINS; GROWTH
AB Objective: To investigate the effects of vitamin D on the malignant behavior of A549 and NCI-H1975 tumor cells (proliferation, apoptosis, invasion, metastasis and drug resistance-related proteins) and the activation of the PI3K/AKT/mTOR signaling pathway, in order to evaluate the effect of vitamin D on the therapeutic action of cisplatin.
   Method: In vitro cell experiments, CCK-8, flow cytometry, transwell, scratches, MTT and Western blot were used to reveal the effect of vitamin D on non-small cell lung cancer (NSCLC), and the expression of PI3K/AKT/mTOR signaling pathway was also detected. In vivo animal experiments, the nude mice were divided into four groups: control group, vitamin D treatment group, cisplatin treatment group and vitamin D + cisplatin combined treatment group. After tumor formation in vitro, tumor volume changes were calculated and tumor growth curves were drawn, collected tumor tissues for pathological sections. Western blot was used to detect the expression changes of drug-resistance related proteins in tumor tissues. Meanwhile, protein expression changes of PI3K/AKT/mTOR signaling pathway in tumor tissues were detected.
   Result: In vitro experiments confirm Vitamin D can inhibit the proliferation, invasion and metastasis of non-small cell lung cancer cells A549 and NCI-H1975, promoting cell apoptosis, up-regulate the sensitivity of chemotherapy drugs. These effects of vitamin D may be correlated with the PI3K/AKT/mTOR signaling pathway. In vivo animal experiments, the changes in tumor volume, tumor inflammatory infiltration range, expression of drug-resistant related proteins and signaling pathway related proteins in mice were as follows: The vitamin D and cisplatin combined treatment group was significantly smaller than the control group.
   Conclusion: Vitamin D can inhibit the proliferation, invasion and metastasis of non-small cell lung cancer (NSCLC) cells A549 and NCI-H1975 and promote apoptosis, up-regulate the sensitivity of chemotherapy drugs. The effect of vitamin D on NSCLC cells A549 and NCI-H1975 was correlated with the PI3K/AKT/mTOR signaling pathway. Vitamin D also promotes the therapeutic effect of CDDP.
C1 [Songyang, Yiyan] Wuhan Univ, Dept Pharm, Renmin Hosp, Wuhan, Peoples R China.
   [Li, Dejia] Wuhan Univ, Sch Publ Hlth, Dept Occupat & Environm Hlth, Wuhan, Peoples R China.
   [Song, Tianbao] Wuhan Univ, Sch Basic Med Sci, Dept Immunol, Wuhan, Peoples R China.
   [Shi, Zhan] Univ Toronto, Human Biol Program, Toronto, ON M5S 3J6, Canada.
   [Li, Wen] Wuhan Univ, Dept Emergency, Renmin Hosp, Wuhan, Peoples R China.
   [Yang, Songyisha] Hubei Univ Chinese Med, Coll Pharm, Wuhan, Peoples R China.
RP Li, DJ (corresponding author), Wuhan Univ, Sch Publ Hlth, Dept Occupat & Environm Hlth, Wuhan, Peoples R China.
EM lidj123123@126.com
CR Aranda F, 2015, ONCOGENE, V34, P3053, DOI 10.1038/onc.2014.234
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
   Chaudhry M, 2001, CANCER CHEMOTH PHARM, V47, P429, DOI 10.1007/s002800000251
   D'Orsi B, 2017, NEUROCHEM INT, V109, P162, DOI 10.1016/j.neuint.2017.03.010
   Ding Guo-Fang, 2011, Chinese Journal of Natural Medicines, V9, P151, DOI 10.3724/SP.J.1009.2011.00151
   Galanski M, 2006, RECENT PAT ANTI-CANC, V1, P285, DOI 10.2174/157489206777442287
   Galluzzi L, 2012, ONCOGENE, V31, P1869, DOI 10.1038/onc.2011.384
   Getzenberg RH, 1997, UROLOGY, V50, P999, DOI 10.1016/S0090-4295(97)00408-1
   Ghosh J, 2016, J CLIN INVEST, V126, P2621, DOI 10.1172/JCI84565
   Giovannucci E, 2005, CANCER CAUSE CONTROL, V16, P83, DOI 10.1007/s10552-004-1661-4
   Hershberger PA, 2002, MOL CANCER THER, V1, P821
   Huang CF, 2017, EXP THER MED, V14, P4174, DOI 10.3892/etm.2017.5097
   Jongbloet PH, 2006, INT J EPIDEMIOL, V35, P1359, DOI 10.1093/ije/dyl206
   Joyce H, 2015, EXPERT OPIN DRUG MET, V11, P795, DOI 10.1517/17425255.2015.1028356
   Keysar SB, 2017, JNCI-J NATL CANCER I, V109, DOI 10.1093/jnci/djw189
   Koshizuka K, 1999, BREAST CANCER RES TR, V53, P113, DOI 10.1023/A:1006123819675
   Liu GM, 2010, INT J CANCER, V126, P631, DOI 10.1002/ijc.24762
   LOINTIER P, 1987, ANTICANCER RES, V7, P817
   Ma YY, 2010, CANCER-AM CANCER SOC, V116, P3294, DOI 10.1002/cncr.25059
   Mu GG, 2015, DIGEST DIS SCI, V60, P1067, DOI 10.1007/s10620-014-3394-x
   PRESTAYKO AW, 1979, CANCER TREAT REV, V6, P17, DOI 10.1016/S0305-7372(79)80057-2
   Rai V, 2017, ANTICANCER RES, V37, P3991, DOI 10.21873/anticanres.11784
   Ravid A, 1999, CANCER RES, V59, P862
   Reck M, 2013, LANCET, V382, P709, DOI 10.1016/S0140-6736(13)61502-0
   Ren LQ, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/9396512
   Saracci R, 2008, LANCET, V372, P291, DOI 10.1016/S0140-6736(08)61109-5
   Sharma K, 2014, AUTOPHAGY, V10, P2346, DOI 10.4161/15548627.2014.993283
   Shi RX, 2007, MOL CANCER THER, V6, P1338, DOI 10.1158/1535-7163.MCT-06-0638
   Shin MH, 2002, JNCI-J NATL CANCER I, V94, P1301, DOI 10.1093/jnci/94.17.1301
   Singh S, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-73
   Singletary K, 2008, CANCER EPIDEM BIOMAR, V17, P1596, DOI 10.1158/1055-9965.EPI-07-2917
   SKOWRONSKI RJ, 1993, ENDOCRINOLOGY, V132, P1952, DOI 10.1210/en.132.5.1952
   Su C, 2010, J BIOL REG HOMEOS AG, V24, P19
   Sun CC, 2015, J BIOL CHEM, V290, P17784, DOI 10.1074/jbc.M115.655019
   Tavera-Mendoza L, 2006, EMBO REP, V7, P180, DOI 10.1038/sj.embor.7400594
   VINKVANWIJNGAARDEN T, 1994, CANCER RES, V54, P5711
   Wang Q, 2000, CANCER RES, V60, P2040
   Xu M, 2013, CANCER LETT, V333, P152, DOI 10.1016/j.canlet.2013.01.002
   Ylikomi T, 2002, VITAM HORM, V64, P357, DOI 10.1016/S0083-6729(02)64010-5
   Zhao JM, 2020, J ETHNOPHARMACOL, V250, DOI 10.1016/j.jep.2019.112492
   Zhou S, 2001, NAT MED, V7, P1028, DOI 10.1038/nm0901-1028
NR 41
TC 2
Z9 2
U1 4
U2 20
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0378-1119
EI 1879-0038
J9 GENE
JI Gene
PD FEB 5
PY 2021
VL 768
AR 145309
DI 10.1016/j.gene.2020.145309
EA JAN 2021
PG 10
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA PS9JT
UT WOS:000608238700008
PM 33197518
DA 2022-04-25
ER

PT J
AU Dastghaib, S
   Mokarram, P
   Erfani, M
   Ghavami, S
   Hosseini, SV
   Zamani, M
AF Dastghaib, Sanaz
   Mokarram, Pooneh
   Erfani, Mehran
   Ghavami, Saeid
   Hosseini, Seyed Vahid
   Zamani, Mozhdeh
TI Endoplasmic reticulum Metallo protease 1, a triggering factor for
   unfolded protein response and promising target in colorectal cancer
SO BIOLOGIA
LA English
DT Article
DE ERMP1; Unfolded protein response; Endoplasmic reticulum stress;
   Colorectal cancer
ID CELL-DEATH; ER STRESS; PATHWAY; ACTIVATION; UPR; OVEREXPRESSION;
   MECHANISM; AUTOPHAGY
AB Unfolded protein response (UPR) pathway is a promising target for cancer treatment because of its over-activation in different cancers and its role in tumorigenesis and chemotherapeutic drug resistance. Endoplasmic Reticulum Metallo Protease 1 (ERMP1) is overexpressed in cancers such as colorectal cancer. The ERMP1 role in UPR activation was previously reported in breast cancer. We aimed to investigate the ERMP1 role in the UPR activation in colorectal cancer. In this regard, ERMP1 gene was silenced in colorectal cancer HCT116 cell line using specific small hairpin RNA (shRNA). Then, UPR associated protein markers including inositol requiring enzyme 1 (IRE1 alpha), activating transcription factor 6 (ATF-6), eukaryotic initiation factor 2 alpha (eIF2 alpha) and phosphorylated eIF2 alpha (P- eIF2 alpha) were evaluated using western blot. We found that ERMP1 gene expression and all of the above UPR associated protein markers were significantly decreased after ERMP1 gene silencing. Therefore, it seems that ERMP1 plays an important role in UPR activation. Since the overexpression of ERMP1 as a potential oncogene can highly activate the UPR pathway in colorectal cancer, it can be considered as a promising target for colorectal cancer treatment. However, further investigations are required to confirm these findings.
C1 [Dastghaib, Sanaz] Shiraz Univ Med Sci, Endocrinol & Metab Res Ctr, Shiraz, Iran.
   [Mokarram, Pooneh; Zamani, Mozhdeh] Shiraz Univ Med Sci, Autophagy Res Ctr, Shiraz, Iran.
   [Mokarram, Pooneh; Erfani, Mehran] Shiraz Univ Med Sci, Fac Med, Dept Biochem, Shiraz, Iran.
   [Erfani, Mehran] Islamic Azad Univ, Arak Branch, Dept Med Lab Sci, Fac Med Sci, Arak, Iran.
   [Ghavami, Saeid] Univ Manitoba, Max Rady Fac Hlth Sci, Dept Human Anat & Cell Sci, Rady Coll Med, Winnipeg, MB, Canada.
   [Hosseini, Seyed Vahid; Zamani, Mozhdeh] Shiraz Univ Med Sci, Colorectal Res Ctr, Shiraz 71936355899, Iran.
RP Zamani, M (corresponding author), Shiraz Univ Med Sci, Autophagy Res Ctr, Shiraz, Iran.; Zamani, M (corresponding author), Shiraz Univ Med Sci, Colorectal Res Ctr, Shiraz 71936355899, Iran.
EM mozhdeh.zamani63@gmail.com
RI Erfani, Mehran/AAR-9705-2021; Dastghaib, Sanaz/ABD-5899-2021; Zamani,
   Mozhdeh/N-9607-2016
OI Erfani, Mehran/0000-0001-9593-5383; Dastghaib,
   Sanaz/0000-0001-8553-9221; Zamani, Mozhdeh/0000-0001-7856-6029
FU Shiraz University of Medical Sciences [16117]
FX This work was financially supported by Shiraz University of Medical
   Sciences (Grant No.16117).
CR Ahmed D, 2013, ONCOGENESIS, V2, DOI 10.1038/oncsis.2013.35
   Akbari-Birgani S, 2016, DRUG DISCOV TODAY, V21, P836, DOI 10.1016/j.drudis.2016.03.004
   Bernards R, 2008, NATURE, V455, P479, DOI 10.1038/455479a
   Bhat TA, 2017, BBA-REV CANCER, V1867, P58, DOI 10.1016/j.bbcan.2016.12.002
   Blais JD, 2006, MOL CELL BIOL, V26, P9517, DOI 10.1128/MCB.01145-06
   Coleman OI, 2018, GASTROENTEROLOGY, V155, P1539, DOI 10.1053/j.gastro.2018.07.028
   Corazzari M, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00078
   Cybulsky AV, 2017, NAT REV NEPHROL, V13, P681, DOI 10.1038/nrneph.2017.129
   Davenport EL, 2008, CELL CYCLE, V7, P865, DOI 10.4161/cc.7.7.5615
   Dikic I, 2018, NAT REV MOL CELL BIO, V19, P349, DOI 10.1038/s41580-018-0003-4
   Fujimoto T, 2007, ANTICANCER RES, V27, P127
   Garcia-Rudaz C, 2007, DEVELOPMENT, V134, P945, DOI 10.1242/dev.02795
   Ghavami S, 2010, BBA-MOL CELL RES, V1803, P452, DOI 10.1016/j.bbamcr.2009.12.005
   Ghavami S, 2009, BBA-MOL CELL RES, V1793, P546, DOI 10.1016/j.bbamcr.2009.01.002
   Glembotski CC, 2008, J MOL CELL CARDIOL, V44, P453, DOI 10.1016/j.yjmcc.2007.10.017
   Grandi A, 2016, ONCOTARGET, V7, P63596, DOI 10.18632/oncotarget.11550
   Grootjans J, 2016, NAT REV IMMUNOL, V16, P469, DOI 10.1038/nri.2016.62
   Gupta SS, 2016, ONCOTARGET, V7, P78516, DOI 10.18632/oncotarget.12392
   Hetz C, 2013, NAT REV DRUG DISCOV, V12, P703, DOI 10.1038/nrd3976
   Hetz C, 2012, NAT REV MOL CELL BIO, V13, P89, DOI 10.1038/nrm3270
   Jin C, 2016, BIOCHEM BIOPH RES CO, V470, P75, DOI 10.1016/j.bbrc.2015.12.119
   Kavousipour S, 2017, BIOTECHNOL LETT, V39, P785, DOI 10.1007/s10529-017-2303-8
   Kim Y, 2017, FRONT CELL NEUROSCI, V11, DOI 10.3389/fncel.2017.00030
   Kroeger H, 2019, FEBS J, V286, P399, DOI 10.1111/febs.14522
   Kumar R, 2003, J CEREBR BLOOD F MET, V23, P462, DOI 10.1097/01.WCB.0000056064.25434.CA
   Kuroda H, 2009, J VIROL METHODS, V157, P113, DOI 10.1016/j.jviromet.2008.11.021
   Lee J, 2014, J BIOL CHEM, V289, P1203, DOI 10.1074/jbc.R113.534743
   Levy JMM, 2017, NAT REV CANCER, V17, P528, DOI 10.1038/nrc.2017.53
   Likus W, 2016, DRUG RESIST UPDATE, V25, P13, DOI 10.1016/j.drup.2016.02.001
   Lindholm D, 2017, FRONT CELL DEV BIOL, V5, DOI 10.3389/fcell.2017.00048
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   Niederreiter L, 2013, J EXP MED, V210, P2041, DOI 10.1084/jem.20122341
   Osorio F, 2013, SEMIN IMMUNOPATHOL, V35, P293, DOI 10.1007/s00281-013-0368-6
   Qu JF, 2019, ONCOL RES, V27, P81, DOI 10.3727/096504018X15202988139874
   Roller C, 2013, FRONT PHARMACOL, V4, DOI 10.3389/fphar.2013.00010
   Ron D, 2007, NAT REV MOL CELL BIO, V8, P519, DOI 10.1038/nrm2199
   Rouschop KM, 2013, P NATL ACAD SCI USA, V110, P4622, DOI 10.1073/pnas.1210633110
   Saito S, 2009, CANCER RES, V69, P4225, DOI 10.1158/0008-5472.CAN-08-2689
   Scheper W, 2015, ACTA NEUROPATHOL, V130, P315, DOI 10.1007/s00401-015-1462-8
   Schwarz DS, 2016, CELL MOL LIFE SCI, V73, P79, DOI 10.1007/s00018-015-2052-6
   Shapiro DJ, 2016, TRENDS ENDOCRIN MET, V27, P731, DOI 10.1016/j.tem.2016.06.002
   Shirazi F, 2020, P NATL ACAD SCI USA, V117, P20004, DOI 10.1073/pnas.2005052117
   Spaan CN, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1729-4
   Suh DH, 2012, ANN NY ACAD SCI, V1271, P20, DOI 10.1111/j.1749-6632.2012.06739.x
   Walczak A, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/5729710
   Walter P, 2011, SCIENCE, V334, P1081, DOI 10.1126/science.1209038
   Wu J, 2012, ONCOGENE, V31, P333, DOI 10.1038/onc.2011.227
   Xing XM, 2006, CLIN CHIM ACTA, V364, P308, DOI 10.1016/j.cca.2005.07.016
   Yang YZ, 2016, ONCOTARGET, V7, P54010, DOI 10.18632/oncotarget.9833
   Zheng XB, 2016, STEROIDS, V114, P2, DOI 10.1016/j.steroids.2016.03.014
   Zhou AX, 2013, SEMIN IMMUNOPATHOL, V35, P321, DOI 10.1007/s00281-013-0372-x
NR 51
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0006-3088
EI 1336-9563
J9 BIOLOGIA
JI Biologia
PD AUG
PY 2021
VL 76
IS 8
BP 2403
EP 2411
DI 10.1007/s11756-021-00769-y
EA MAY 2021
PG 9
WC Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Life Sciences & Biomedicine - Other Topics
GA UC8NN
UT WOS:000649224200001
DA 2022-04-25
ER

PT J
AU Das, K
   Datta, A
   Frontera, A
   Wen, YS
   Roma-Rodrigues, C
   Raposo, LR
   Fernandes, AR
   Hung, CH
AF Das, Kuheli
   Datta, Amitabha
   Frontera, Antonio
   Wen, Yuh-Sheng
   Roma-Rodrigues, Catarina
   Raposo, Luis R.
   Fernandes, Alexandra R.
   Hung, Chen-Hsiung
TI Zn(II) and Co(II) derivatives anchored with scorpionate precursor:
   Antiproliferative evaluation in human cancer cell lines
SO JOURNAL OF INORGANIC BIOCHEMISTRY
LA English
DT Article
DE Zn(II); Co(II); Antiproliferative; Cancer cell lines; Autophagy, ROS
ID SPIN-RESONANCE-SPECTRA; COORDINATION CHEMISTRY; PLATINUM COMPLEXES;
   METAL-COMPLEXES; LIGANDS; SPECTROSCOPY; COBALT(II); IRON(III); COPPER;
   BLOOD
AB A 'scorpionate' type precursor [bdtbpza = bis(3,5-di-t-butylpyrazol-1-yl)acetate] has been employed to synthesize two mononuclear Zn-II and Co-II derivatives, namely [Zn(bdtbpza)(2) (H2O)(2)]center dot 2.5CH(3)OH center dot 2[(CH3)(3)C-C3H2N2-(CH3)(3)] (1) and lCo(bdtbpza)(2)(CH3OH)(4)] (2) in good yield. Single crystal X-ray diffraction analysis reveals that in 1, the Zn-II atom is tetrahedrally surrounded by a pair of O-acetate atoms of two bis(pyrazol-1-yl)acetate units and two water molecules; while in 2, the Co-II atom shows an octahedral environment coordinating a pair of O-acetate atoms of two bis(pyrazol-1-yl)acetate units along with four methanol molecules. The EPR spectra of 2 recorded at 77 and 298 K confirmed the tetragonal symmetry of the high spin Co(II). The DFT (Density functional theory) computation is in good agreement with the geometry proposed for compounds 1 and 2. Both the compounds display a high antiproliferative activity against HCT116 (colorectal carcinoma) and A2780 (ovarian carcinoma) cell lines compared to human normal dermal fibroblasts. In the case of A2780 cells, compounds 1 and 2 exhibit IC50 values that are similar to those described for cisplatin, a widely used chemotherapeutic drug. Exposure of A2780 cells to the IC50 concentration of each compound led to an increase of the number of apoptotic and autophagic cells. In the case of compound 1, the accumulation of intracellular ROS (Reactive oxygen species) is responsible for triggering A2780 cell death.
C1 [Das, Kuheli; Datta, Amitabha; Wen, Yuh-Sheng; Hung, Chen-Hsiung] Acad Sinica, Inst Chem, Taipei 115, Taiwan.
   [Frontera, Antonio] Univ Illes Balears, Dept Quim, Crta Valldemossa Km 7-5, Palma De Mallorca 07122, Baleares, Spain.
   [Roma-Rodrigues, Catarina; Raposo, Luis R.; Fernandes, Alexandra R.] Univ Nova Lisboa, Fac Ciencias & Tecnol, DCV, UCIBIO, Campus Caparica, P-2829516 Caparica, Portugal.
RP Datta, A; Hung, CH (corresponding author), Acad Sinica, Inst Chem, Taipei 115, Taiwan.; Fernandes, AR (corresponding author), Univ Nova Lisboa, Fac Ciencias & Tecnol, DCV, UCIBIO, Campus Caparica, P-2829516 Caparica, Portugal.
EM amitd_ju@yahoo.co.in; ma.fernandes@fct.unl.pt; chhung@gate.sinica.edu.tw
RI Hung, Chen-Hsiung/B-6638-2013; Roma-Rodrigues, Catarina/S-6144-2016;
   Frontera, Antonio/G-4517-2010; Fernandes, Alexandra R/C-7465-2011;
   Raposo, Luís/AAX-1610-2021; Roma-Rodrigues, Catarina/AAT-5658-2021;
   Raposo, Luís R/T-3754-2017
OI Hung, Chen-Hsiung/0000-0002-8060-348X; Roma-Rodrigues,
   Catarina/0000-0002-8676-6562; Frontera, Antonio/0000-0001-7840-2139;
   Fernandes, Alexandra R/0000-0003-2054-4438; Raposo,
   Luís/0000-0002-8637-346X; Roma-Rodrigues, Catarina/0000-0002-8676-6562;
   Raposo, Luís R/0000-0002-8637-346X
FU Ministry of Science and Technology, TaiwanMinistry of Science and
   Technology, Taiwan; Applied Molecular Biosciences Unit-UCIBIO from
   FCT/MCTES, Portugal [UID/Multi/04378/2019]
FX AD and CHH would like to express their appreciation to the Ministry of
   Science and Technology, Taiwan for financial assistance. This work is
   also supported by the Applied Molecular Biosciences Unit-UCIBIO which is
   financed by national funds from FCT/MCTES (UID/Multi/04378/2019),
   Portugal. The authors acknowledge A. Silva for preliminary biological
   assays. Our sincere thanks to Prof. Chiara Massera for her valuable
   suggestion in crystallographic description.
CR Abragam A., 1951, P ROY SOC LOND A MAT, P173
   Allardyce CS, 2016, DALTON T, V45, P3201, DOI 10.1039/c5dt03919c
   Altomare A, 1999, J APPL CRYSTALLOGR, V32, P115, DOI 10.1107/S0021889898007717
   Arman P, 1958, ANN APPL BIOL, V46, P366, DOI 10.1111/j.1744-7348.1958.tb02217.x
   Beck A, 2003, INORG CHEM, V42, P7182, DOI 10.1021/ic034097c
   Beck A, 2001, EUR J INORG CHEM, P521
   BENCINI A, 1980, INORG CHEM, V19, P1301, DOI 10.1021/ic50207a038
   BOYS SF, 1970, MOL PHYS, V19, P553, DOI 10.1080/00268977000101561
   Contreras-Garcia J, 2011, J CHEM THEORY COMPUT, V7, P625, DOI 10.1021/ct100641a
   Das K, 2018, NEW J CHEM, V42, P9126, DOI 10.1039/c8nj01033a
   Farrugia L.J., 1999, J APPL CRYSTALLOGR, V32, P837, DOI [10.1107/S0021889812029111, 10.1107/S0021889899006020, DOI 10.1107/S0021889899006020]
   Frezza M, 2010, CURR PHARM DESIGN, V16, P1813, DOI 10.2174/138161210791209009
   Frisch M.J., 2013, GAUSSIAN 09 REVISION
   Galanski M, 2003, CURR PHARM DESIGN, V9, P2078, DOI 10.2174/1381612033454180
   Gasser G, 2011, J MED CHEM, V54, P3, DOI 10.1021/jm100020w
   Grimme S, 2010, J CHEM PHYS, V132, DOI 10.1063/1.3382344
   HILL JM, 1982, ANTICANCER RES, V2, P173
   HORSFALL JG, 1956, PRINCIPLES FUNGICIDA
   KOJIMA K, 1987, B CHEM SOC JPN, V60, P3213, DOI 10.1246/bcsj.60.3213
   Kozlevcar B, 2015, EUR J INORG CHEM, P3688, DOI 10.1002/ejic.201500368
   Lenis-Rojas OA, 2017, INORG CHEM, V56, P7127, DOI 10.1021/acs.inorgchem.7b00790
   Lever A.B.P., 1984, INORGANIC ELECT SPEC
   Marchi S., 2012, J SIGNAL TRANSDUCT
   Maron A, 2018, DALTON T, V47, P6444, DOI 10.1039/c8dt00558c
   Mendes R, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-11491-8
   Min KS, 2004, DALTON T, P178, DOI 10.1039/b311385j
   Mjos KD, 2014, CHEM REV, V114, P4540, DOI 10.1021/cr400460s
   Muhammad N, 2014, CURR OPIN CHEM BIOL, V19, P144, DOI 10.1016/j.cbpa.2014.02.003
   Nakamoto K., 1997, INFRARED RAMAN SPECT
   Nardelli M, 1996, J APPL CRYSTALLOGR, V29, P296, DOI 10.1107/S0021889896000672
   Pettinari C., 2008, SCORPIONATES CHELATI
   Qin JL, 2017, SCI REP-UK, V7, DOI 10.1038/srep46056
   Qiu KQ, 2019, COORDIN CHEM REV, V378, P66, DOI 10.1016/j.ccr.2017.10.022
   Rizzi AC, 2003, INORG CHEM, V42, P4409, DOI 10.1021/ic026111b
   ROSENBERG B, 1969, NATURE, V222, P385, DOI 10.1038/222385a0
   ROSENBERG B, 1978, INTERDISCIPL SCI REV, V3, P134, DOI 10.1179/030801878791926119
   Rosenberg B, 1977, Adv Exp Med Biol, V91, P129
   Sanna D, 2017, DALTON T, V46, P8950, DOI 10.1039/c7dt00943g
   Sanna D, 2012, J INORG BIOCHEM, V115, P87, DOI 10.1016/j.jinorgbio.2012.04.020
   Santini C, 2014, CHEM REV, V114, P815, DOI 10.1021/cr400135x
   Shaver A., 1976, J ORGANOMET CHEM LIB, V4, P157
   Sheldrick G.M., 2004, SADABS V2 03 AREA DE
   Sheldrick GM, 2008, ACTA CRYSTALLOGR A, V64, P112, DOI 10.1107/S0108767307043930
   Silva TFS, 2014, CHEM-ASIAN J, V9, P1132, DOI 10.1002/asia.201301331
   Svahn N, 2018, CHEM-EUR J, V24, P14654, DOI 10.1002/chem.201802547
   THUERY P, 1986, INORG CHEM, V25, P2001, DOI 10.1021/ic00232a020
   TROFIMENKO S, 1986, PROG INORG CHEM, V34, P115, DOI 10.1002/9780470166352.ch3
   Trofimenko S., 1999, SCORPIONATES COORDIN
   Venkatachalam H, 2017, INDIAN J PHARM SCI, V79, P838, DOI 10.4172/pharmaceutical-sciences.1000299
   World Health Organization, CANCER
NR 50
TC 2
Z9 2
U1 0
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0162-0134
EI 1873-3344
J9 J INORG BIOCHEM
JI J. Inorg. Biochem.
PD JAN
PY 2020
VL 202
AR 110881
DI 10.1016/j.jinorgbio.2019.110881
PG 11
WC Biochemistry & Molecular Biology; Chemistry, Inorganic & Nuclear
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA JV9NK
UT WOS:000502686300012
PM 31698185
DA 2022-04-25
ER

PT J
AU Wei, L
   Chen, ZH
   Cheng, N
   Li, X
   Chen, J
   Wu, DH
   Dong, M
   Wu, XY
AF Wei, Li
   Chen, Zhanhong
   Cheng, Na
   Li, Xing
   Chen, Jie
   Wu, Donghao
   Dong, Min
   Wu, Xiangyuan
TI MicroRNA-126 Inhibit Viability of Colorectal Cancer Cell by Repressing
   mTOR Induced Apoptosis and Autophagy
SO ONCOTARGETS AND THERAPY
LA English
DT Article
DE CRC; miR-126; mTOR; apoptosis; autophagy
ID TUMOR-SUPPRESSOR; MIR-126; EXPRESSION; PATHWAY; GROWTH; PROLIFERATION;
   INFLAMMATION; INVASION
AB Objective: Colorectal cancer (CRC) is a fatal disease, and tumor development is a complex cellular event involving a multistep cascade process involving proliferation, invasion, and migration. In recent years, it has been shown that microRNA-126 (miR-126) plays a key role in the tumorigenesis of CRC, but further studies are required to investigate the regulatory mechanisms through which this miRNA affects cell viability, autophagy, and apoptosis in CRC. We aimed to study the effect of miR-126 in gene regulation in CRC HCT116 cells.
   Methods: CRC biopsy samples and normal colorectal tissue samples were used for miRNA profiling. Real-time quantitative PCR and WB were utilized to detect RNA and protein levels. MTT and colony formation assays were performed to examine cell viability. Furthermore, an immunofluorescence assay and Annexin V/PI flow cytometry were performed to detect autophagy and apoptosis, respectively.
   Results: The expression of miR-126 was downregulated in CRC biopsies and cell lines compared with that in normal cells and tissues. The upregulation of miR-126 resulted in impaired viability and growth of CRC cells. Furthermore, with the overexpression of miR-126, cell autophagy was increased, as evidenced by LC3-I/II transformation and p62 degradation. Meanwhile, apoptosis induction was also observed because of the increased miR-126 levels. The autophagy inhibitor Bafilomycin A1 (BafA1) repressed both autophagy and apoptosis, indicating that miR-126 induced autophagy was responsible for the induction of apoptosis. A dual-luciferase reporter assay (DLRA) and bioinformatics prediction revealed that miR-126 silenced the mTOR gene by targeting the 3'-UTR. mTOR mRNA levels in CRC biopsy tissues and cell lines were upregulated to a greater extent than that in normal cells and tissues. Furthermore, HCT116 cells transfected with an miR-126 mimic showed a decreased expression of mTOR. In addition, the overexpression of mTOR counteracted miR-126 on autophagy and apoptosis.
   Conclusion: Our study demonstrated that miR-126-induced can regulate the activity of CRC cells via autophagy and apoptosis and suggested a new mechanism of miR-126-mTOR interaction in CRC pathogenesis.
C1 [Wei, Li; Chen, Zhanhong; Li, Xing; Chen, Jie; Wu, Donghao; Dong, Min; Wu, Xiangyuan] Sun Yat Sen Univ, Affiliated Hosp 3, Med Oncol, 600 Tianhe Rd, Guangzhou 510630, Guangdong, Peoples R China.
   [Cheng, Na] Sun Yat Sen Univ, Affiliated Hosp 3, Pathol, Guangzhou 510630, Guangdong, Peoples R China.
RP Dong, M; Wu, XY (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 3, Med Oncol, 600 Tianhe Rd, Guangzhou 510630, Guangdong, Peoples R China.
EM dongmin@mail.sysu.edu.cn; xiangyunwu100@163.com
CR Banerjee N, 2013, CARCINOGENESIS, V34, P2814, DOI 10.1093/carcin/bgt295
   Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5
   Chen HX, 2014, ONCOTARGET, V5, P11873, DOI 10.18632/oncotarget.2662
   Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338
   Din FVN, 2012, GASTROENTEROLOGY, V142, P1504, DOI 10.1053/j.gastro.2012.02.050
   Feng RH, 2010, CANCER LETT, V298, P50, DOI 10.1016/j.canlet.2010.06.004
   Francipane MG, 2014, ONCOTARGET, V5, P49, DOI 10.18632/oncotarget.1548
   Guo CG, 2008, GENE CHROMOSOME CANC, V47, P939, DOI 10.1002/gcc.20596
   Heras-Sandoval D, 2014, CELL SIGNAL, V26, P2694, DOI 10.1016/j.cellsig.2014.08.019
   Kim H, 2017, MOL CARCINOGEN, V56, P197, DOI 10.1002/mc.22484
   Li N, 2013, MOL CELL BIOCHEM, V380, P107, DOI 10.1007/s11010-013-1664-0
   Li XF, 2009, ONCOGENE, V28, P3937, DOI 10.1038/onc.2009.245
   Li Z, 2013, MOL CELL BIOCHEM, V381, P233, DOI 10.1007/s11010-013-1707-6
   Liu B, 2009, LUNG CANCER, V66, P169, DOI 10.1016/j.lungcan.2009.01.010
   Liu YL, 2014, GENE CHROMOSOME CANC, V53, P358, DOI 10.1002/gcc.22146
   Liu YL, 2014, INT J ONCOL, V44, P203, DOI 10.3892/ijo.2013.2168
   Long GW, 2012, INT J BIOL SCI, V8, P811, DOI 10.7150/ijbs.4439
   Manfredi S, 2006, ANN SURG, V244, P254, DOI 10.1097/01.sla.0000217629.94941.cf
   Meister J, 2010, THESCIENTIFICWORLDJO, V10, P2090, DOI 10.1100/tsw.2010.198
   Saito Y, 2009, BIOCHEM BIOPH RES CO, V379, P726, DOI 10.1016/j.bbrc.2008.12.098
   Wang F, 2015, INT J IMMUNOPATH PH, V28, P362, DOI 10.1177/0394632015598849
   Wang SS, 2008, DEV CELL, V15, P261, DOI 10.1016/j.devcel.2008.07.002
   Wu XD, 2017, MOL MED REP, V16, P7112, DOI 10.3892/mmr.2017.7459
   Wu XL, 2018, J CELL BIOCHEM, V119, P2356, DOI 10.1002/jcb.26399
   Yin J, 2014, CHINESE J CANCER RES, V26, P95, DOI 10.3978/j.issn.1000-9604.2014.02.07
   Zhang J, 2008, BIOCHEM BIOPH RES CO, V377, P136, DOI 10.1016/j.bbrc.2008.09.089
   Zhang Q, 2015, BIOCHEM BIOPH RES CO, V465, P64, DOI 10.1016/j.bbrc.2015.07.130
   Zhang T, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/761617
   Zou WJ, 2018, BIOCHEM BIOPH RES CO, V503, P3212, DOI 10.1016/j.bbrc.2018.08.127
NR 30
TC 14
Z9 15
U1 0
U2 5
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-6930
J9 ONCOTARGETS THER
JI OncoTargets Ther.
PY 2020
VL 13
BP 2459
EP 2468
DI 10.2147/OTT.S238348
PG 10
WC Biotechnology & Applied Microbiology; Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Oncology
GA KX0ZS
UT WOS:000521613100001
PM 32273718
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Shen, T
   Cai, LD
   Liu, YH
   Li, S
   Gan, WJ
   Li, XM
   Wang, JR
   Guo, PD
   Zhou, Q
   Lu, XX
   Sun, LN
   Li, JM
AF Shen, Tong
   Cai, Ling-Dong
   Liu, Yu-Hong
   Li, Shi
   Gan, Wen-Juan
   Li, Xiu-Ming
   Wang, Jing-Ru
   Guo, Peng-Da
   Zhou, Qun
   Lu, Xing-Xing
   Sun, Li-Na
   Li, Jian-Ming
TI Ube2v1-mediated ubiquitination and degradation of Sirt1 promotes
   metastasis of colorectal cancer by epigenetically suppressing autophagy
SO JOURNAL OF HEMATOLOGY & ONCOLOGY
LA English
DT Article
DE Ubiquitin-conjugating E2 enzyme; Autophagy; Epithelial mesenchymal
   transition; Metastasis; Colorectal cancer
ID EPITHELIAL-MESENCHYMAL TRANSITION; HUMAN BREAST-CANCER; SELECTIVE
   AUTOPHAGY; CONJUGATING ENZYME; ACTIVATION; PROTEIN; TUMORIGENESIS;
   CELLS; KINASE; INHIBITION
AB Background: Ubiquitination is a basic post-translational modification for cellular homeostasis, and members of the conjugating enzyme (E2) family are the key components of the ubiquitin-proteasome system. However, the role of E2 family in colorectal cancer (CRC) is largely unknown. Our study aimed to investigate the role of Ube2v1, one of the ubiquitin-conjugating E2 enzyme variant proteins (Ube2v) but without the conserved cysteine residue required for the catalytic activity of E2s, in CRC.
   Methods: Immunohistochemistry and real-time RT-PCR were used to study the expressions of Ube2v1 at protein and mRNA levels in CRC, respectively. Western blotting and immunofluorescence, transmission electron microscopy, and in vivo rescue experiments were used to study the functional effects of Ube2v1 on autophagy and EMT program. Quantitative mass spectrometry, immunoprecipitation, ubiquitination assay, western blotting, and real-time RT-PCR were used to analyze the effects of Ube2v1 on histone H4 lysine 16 acetylation, interaction with Sirt1, ubiquitination of Sirt1, and autophagy-related gene expression.
   Results: Ube2v1 was elevated in CRC samples, and its increased expression was correlated with poorer survival of CRC patients. Ube2v1 promoted migration and invasion of CRC cells in vitro and tumor growth and metastasis of CRC cells in vivo. Interestingly, Ube2v1suppressed autophagy program and promoted epithelial mesenchymal transition (EMT) and metastasis of CRC cells in an autophagy-dependent pattern in vitro and in vivo. Moreover, both rapamycin and trehalose attenuated the enhanced Ube2v1-mediated lung metastasis by inducing the autophagy pathway in an orthotropic mouse xenograft model of lung metastasis. Mechanistically, Ube2v1 promoted Ubc13-mediated ubiquitination and degradation of Sirt1 and inhibited histone H4 lysine 16 acetylation, and finally epigenetically suppressed autophagy gene expression in CRC.
   Conclusions: Our study functionally links Ube2v1, an E2 member in the ubiquitin-proteasome system, to autophagy program, thereby shedding light on developing Ube2v1 targeted therapy for CRC patients.
C1 [Shen, Tong; Cai, Ling-Dong; Li, Shi; Gan, Wen-Juan; Li, Xiu-Ming; Wang, Jing-Ru; Guo, Peng-Da; Zhou, Qun; Lu, Xing-Xing; Sun, Li-Na; Li, Jian-Ming] Soochow Univ, Med Sch, Dept Pathol, Suzhou 215123, Peoples R China.
   [Liu, Yu-Hong] Southern Med Univ, Baoan Hosp, Dept Pathol, Shenzhen 518101, Peoples R China.
RP Li, JM (corresponding author), Soochow Univ, Med Sch, Dept Pathol, Suzhou 215123, Peoples R China.
EM jianmingli@suda.edu.cn
FU National Nature Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81525020, 81502033, 81272300, 31570753];
   Postdoctoral Science Foundation of Jiangsu ProvinceChina Postdoctoral
   Science Foundation [1302029B]; Science and Technology Foundation of
   Suzhou [SYS201412]
FX This work was supported by the National Nature Science Foundation of
   China (Grants81525020, 81502033, 81272300, and 31570753), the
   Postdoctoral Science Foundation (1302029B) of Jiangsu Province, and
   Science and Technology Foundation of Suzhou (SYS201412).
CR Bronsert P, 2014, J PATHOL, V234, P410, DOI 10.1002/path.4416
   Burger AM, 2004, EUR J CANCER, V40, P2217, DOI 10.1016/j.ejca.2004.07.006
   Catalano M, 2015, MOL ONCOL, V9, P1612, DOI 10.1016/j.molonc.2015.04.016
   Cicchini M, 2014, AUTOPHAGY, V10, P2036, DOI 10.4161/auto.34398
   Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001
   Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4
   Edinger AL, 2003, CANCER CELL, V4, P422, DOI 10.1016/S1535-6108(03)00306-4
   Fullgrabe J, 2013, AUTOPHAGY, V9, P1621, DOI 10.4161/auto.25803
   Fullgrabe J, 2013, NATURE, V500, P468, DOI 10.1038/nature12313
   Galluzzi L, 2015, EMBO J, V34, P856, DOI 10.15252/embj.201490784
   Grassi G, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.249
   Grimm WA, 2016, GUT, V65, P456, DOI 10.1136/gutjnl-2014-308735
   Guo JY, 2013, CELL, V155, P1216, DOI 10.1016/j.cell.2013.11.019
   He CC, 2009, ANNU REV GENET, V43, P67, DOI 10.1146/annurev-genet-102808-114910
   HERSHKO A, 1983, J BIOL CHEM, V258, P8206
   Hur K, 2013, GUT, V62, P1315, DOI 10.1136/gutjnl-2011-301846
   Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104
   Kirkin V, 2009, MOL CELL, V34, P259, DOI 10.1016/j.molcel.2009.04.026
   Kraft C, 2010, NAT CELL BIOL, V12, P836, DOI 10.1038/ncb0910-836
   Lamothe B, 2007, J BIOL CHEM, V282, P4102, DOI 10.1074/jbc.M609503200
   Li JP, 2015, DRUG DES DEV THER, V9, P1027, DOI 10.2147/DDDT.S74412
   Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257
   Liu H, 2014, AUTOPHAGY, V10, P372, DOI 10.4161/auto.27163
   Liu ZZ, 2014, CANCER CELL, V26, P106, DOI 10.1016/j.ccr.2014.05.015
   Lu KF, 2014, AUTOPHAGY, V10, P2381, DOI 10.4161/15548627.2014.981919
   Lv Q, 2012, AUTOPHAGY, V8, P1675, DOI 10.4161/auto.21438
   Lv Q, 2012, CANCER RES, V72, P3238, DOI 10.1158/0008-5472.CAN-11-3832
   Ma L, 1998, ONCOGENE, V17, P1321, DOI 10.1038/sj.onc.1202058
   Mathew R, 2007, NAT REV CANCER, V7, P961, DOI 10.1038/nrc2254
   Mathew R, 2009, CELL, V137, P1062, DOI 10.1016/j.cell.2009.03.048
   Moscat J, 2009, CELL, V137, P1001, DOI 10.1016/j.cell.2009.05.023
   Perera R, 2015, NATURE, V524, P361, DOI 10.1038/nature14587
   Petroski MD, 2007, J BIOL CHEM, V282, P29936, DOI 10.1074/jbc.M703911200
   Pulvino M, 2012, BLOOD, V120, P1668, DOI 10.1182/blood-2012-02-406074
   Qi JJ, 2016, GUT, V65, P1690, DOI 10.1136/gutjnl-2014-307900
   Qiang L, 2014, AUTOPHAGY, V10, P1864, DOI 10.4161/auto.32171
   Rogov V, 2014, MOL CELL, V53, P167, DOI 10.1016/j.molcel.2013.12.014
   Rothofsky ML, 1997, GENE, V195, P141, DOI 10.1016/S0378-1119(97)00097-8
   Ryall JG, 2015, CELL STEM CELL, V16, P171, DOI 10.1016/j.stem.2014.12.004
   Sheen JH, 2011, CANCER CELL, V19, P613, DOI 10.1016/j.ccr.2011.03.012
   Sun LN, 2013, JNCI-J NATL CANCER I, V105, P887, DOI 10.1093/jnci/djt118
   Sun LJ, 2004, MOL CELL, V14, P289, DOI 10.1016/S1097-2765(04)00236-9
   Thomson TM, 1998, FEBS LETT, V423, P49, DOI 10.1016/S0014-5793(98)00060-X
   Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597
   White E, 2015, J CLIN INVEST, V125, P42, DOI 10.1172/JCI73941
   White E, 2012, NAT REV CANCER, V12, P401, DOI 10.1038/nrc3262
   White E, 2010, CURR OPIN CELL BIOL, V22, P212, DOI 10.1016/j.ceb.2009.12.008
   Wiener R, 2012, NATURE, V483, P618, DOI 10.1038/nature10911
   Wu ZJ, 2014, BREAST CANCER RES, V16, DOI 10.1186/bcr3692
   Xia ZP, 2009, NATURE, V461, P114, DOI 10.1038/nature08247
   Yang SH, 2011, GENE DEV, V25, P717, DOI 10.1101/gad.2016111
NR 51
TC 27
Z9 28
U1 2
U2 9
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1756-8722
J9 J HEMATOL ONCOL
JI J. Hematol. Oncol.
PD JUL 17
PY 2018
VL 11
AR 95
DI 10.1186/s13045-018-0638-9
PG 16
WC Oncology; Hematology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Hematology
GA GN6YE
UT WOS:000439249700001
PM 30016968
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Kritikou, I
   Giannopoulou, E
   Koutras, AK
   Labropoulou, VT
   Kalofonos, HP
AF Kritikou, Ismini
   Giannopoulou, Efstathia
   Koutras, Angelos K.
   Labropoulou, Vassiliki T.
   Kalofonos, Haralabos P.
TI The combination of antitumor drugs, exemestane and erlotinib, induced
   resistance mechanism in H358 and A549 non-small cell lung cancer (NSCLC)
   cell lines
SO PHARMACEUTICAL BIOLOGY
LA English
DT Article
DE Beclin-1; EGFR; migration; mitochondria
ID GROWTH-FACTOR RECEPTOR; COLON-CANCER; ESTROGEN-RECEPTOR; EGF RECEPTOR;
   INHIBITORS; THERAPY; GEFITINIB; REPLACEMENT; CARCINOMA; AROMATASE
AB Context: Estrogens in non-small-cell lung cancer (NSCLC) are important, and their interaction with epidermal growth factor receptor (EGFR) might be crucial.
   Objective: This study investigates the effect of exemestane, an aromatase inhibitor, and erlotinib, an EGFR inhibitor, on human NSCLC cell lines; H23, H358 and A549.
   Materials and methods: A cell proliferation assay was used for measuring cell number, apoptosis assay for detecting apoptosis and necrosis and immunoblotting for beclin-1 and Bcl-2 proteins detection. An immunofluorescence assay was used for EGFR localization. A migration assay and zymography were used for cell motility and metalloproteinases (MMPs) expression, respectively.
   Results: Exemestane, erlotinib or their combination decreased cell proliferation and increased apoptosis. Exemestane's half maximal inhibitory concentration (IC50) was 50 mu M for H23 and H358 cells and 20 mu M for A549. The IC50 of erlotinib was 25 mM for all cell lines. Apoptosis increase induced by exemestane was 58.0 (H23), 186.3 (H358) and 34.7% (A549) and by erlotinib was 16.7 (H23), 65.3 (H358) and 66.3% (A549). A synergy effect was observed only in H23 cells. Noteworthy, the combination of exemestane and erlotinib decreased beclin-1 protein levels (32.3 +/- 19.2%), an indicator of autophagy, in H23 cells. The combination of exemestane and erlotinib partially reversed the EGFR translocation to mitochondria and decreased MMP levels and migration.
   Discussion and conclusions: The benefit from a dual targeting of aromatase and EGFR seems to be regulated by NSCLC cell content. The diverse responses of cells to agents might be influenced by the dominance of certain molecular pathways.
C1 [Kritikou, Ismini; Giannopoulou, Efstathia; Koutras, Angelos K.; Labropoulou, Vassiliki T.; Kalofonos, Haralabos P.] Univ Hosp Patras, Patras Med Sch, Clin Oncol Lab, Rion 26504, Greece.
   [Koutras, Angelos K.; Labropoulou, Vassiliki T.; Kalofonos, Haralabos P.] Univ Hosp Patras, Dept Med, Div Oncol, Rion 26504, Greece.
RP Kalofonos, HP (corresponding author), Univ Hosp Patras, Patras Med Sch, Dept Med, Div Oncol, Rion 26504, Greece.
EM kalofonos@upatras.gr
OI Kalofonos, Haralabos/0000-0002-3286-778X
FU EOGE Oncological Research Fund
FX We would like to thank the Medical School, University of Patras, Greece,
   for providing us the Advanced Light Microscopy facility, EOGE
   Oncological Research Fund for financial support and Gregoris Iconomou,
   PhD, Quality of life Unit, Division of Oncology, University Hospital of
   Patras, Greece for linguistic editing.
CR Ben Sahra I, 2010, CANCER RES, V70, P2465, DOI 10.1158/0008-5472.CAN-09-2782
   Chlebowski RT, 2010, JNCI-J NATL CANCER I, V102, P1413, DOI 10.1093/jnci/djq285
   Feld R, 2006, J THORAC ONCOL, V1, P367, DOI 10.1097/01243894-200605000-00018
   Fischel JL, 2005, BRIT J CANCER, V92, P1063, DOI 10.1038/sj.bjc.6602428
   Garon EB, 2013, J THORAC ONCOL, V8, P270, DOI 10.1097/JTO.0b013e31827d525c
   Giannopoulou E, 2009, ANTICANCER RES, V29, P5077
   Giannopoulou E, 2009, CANCER CHEMOTH PHARM, V63, P973, DOI 10.1007/s00280-008-0820-9
   Hede K, 2007, J NATL CANCER I, V99, P1830, DOI 10.1093/jnci/djm284
   Johnston SRD, 2009, CLIN BREAST CANCER, V9, pS28, DOI 10.3816/CBC.2009.s.003
   Koutras A, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-109
   Kuwada SK, 2004, INT J CANCER, V109, P291, DOI 10.1002/ijc.11686
   Lefranc F, 2007, ONCOLOGIST, V12, P1395, DOI 10.1634/theoncologist.12-12-1395
   Lin SY, 2001, NAT CELL BIOL, V3, P802, DOI 10.1038/ncb0901-802
   Mase K, 2002, LUNG CANCER-J IASLC, V36, P271, DOI 10.1016/S0169-5002(02)00004-1
   Meng XN, 2009, BRIT J CANCER, V101, P327, DOI 10.1038/sj.bjc.6605154
   Niikawa H, 2008, CLIN CANCER RES, V14, P4417, DOI 10.1158/1078-0432.CCR-07-1950
   Osborne CK, 2001, CLIN CANCER RES, V7, p4338S
   Osborne CK, 2001, CLIN CANCER RES, V7, p4411s
   Pietras RJ, 2005, STEROIDS, V70, P372, DOI 10.1016/j.steroids.2005.02.017
   Scaltriti M, 2006, CLIN CANCER RES, V12, P5268, DOI 10.1158/1078-0432.CCR-05-1554
   Siegfried JM, 2009, SEMIN ONCOL, V36, P524, DOI 10.1053/j.seminoncol.2009.10.004
   Slatore CG, 2010, J CLIN ONCOL, V28, P1540, DOI 10.1200/JCO.2009.25.9739
   Stabile Laura P, 2004, Curr Oncol Rep, V6, P259, DOI 10.1007/s11912-004-0033-2
   Stabile LP, 2005, CANCER RES, V65, P1459, DOI 10.1158/0008-5472.CAN-04-1872
   Takeuchi K, 2010, FEBS J, V277, P316, DOI 10.1111/j.1742-4658.2009.07450.x
   Verma MK, 2011, STEROIDS, V76, P759, DOI 10.1016/j.steroids.2011.02.020
   Wang PH, 2009, JPN J CLIN ONCOL, V39, P829, DOI 10.1093/jjco/hyp096
   Wang YC, 2008, CANCER RES, V68, P2820, DOI 10.1158/0008-5472.CAN-07-1336
   Weinberg OK, 2005, CANCER RES, V65, P11287, DOI 10.1158/0008-5472.CAN-05-2737
   Yoon YK, 2010, MOL CARCINOGEN, V49, P353, DOI 10.1002/mc.20607
   Yue XJ, 2008, AUTOPHAGY, V4, P641, DOI 10.4161/auto.5971
NR 31
TC 6
Z9 6
U1 0
U2 11
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 1388-0209
EI 1744-5116
J9 PHARM BIOL
JI Pharm. Biol.
PD APR
PY 2014
VL 52
IS 4
BP 444
EP 452
DI 10.3109/13880209.2013.841718
PG 9
WC Plant Sciences; Medical Laboratory Technology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Plant Sciences; Medical Laboratory Technology; Pharmacology & Pharmacy
GA AF2BX
UT WOS:000334518700006
DA 2022-04-25
ER

PT J
AU Lenis-Rojas, OA
   Carvalho, B
   Cabral, R
   Silva, M
   Friaes, S
   Roma-Rodrigues, C
   Meireles, MSH
   Gomes, CSB
   Fernandez, JAA
   Vila, SF
   Rubiolo, JA
   Sanchez, L
   Baptista, PV
   Fernandes, AR
   Royo, B
AF Lenis-Rojas, Oscar A.
   Carvalho, Beatriz
   Cabral, Rui
   Silva, Margarida
   Friaes, Sofia
   Roma-Rodrigues, Catarina
   Meireles, Marta S. H.
   Gomes, Clara S. B.
   Fernandez, Jhonathan A. A.
   Vila, Sabela F.
   Rubiolo, Juan A.
   Sanchez, Laura
   Baptista, Pedro, V
   Fernandes, Alexandra R.
   Royo, Beatriz
TI Manganese(I) tricarbonyl complexes as potential anticancer agents
SO JOURNAL OF BIOLOGICAL INORGANIC CHEMISTRY
LA English
DT Article
DE Mn(I) complexes; Antiproliferative activity; Cancer; In vivo models;
   A2780 tumor cells
ID CO-RELEASING PROPERTIES; CARBON-MONOXIDE; DINUCLEAR METALLACYCLES; GOLD
   NANOPARTICLES; CANCER-THERAPY; IN-VITRO; CYTOTOXICITY; DELIVERY; CELLS;
   MODULATION
AB The antiproliferative activity of [Mn(CO)(3)((NN)-N-boolean AND)Br] ((NN)-N-boolean AND = phendione 1, bipy 3) and of the two newly synthesized Mn complexes [Mn(CO)(3)(acridine)(phendione)]OTf (2) and [Mn(CO)(3)(di-triazole)Br] (4) has been evaluated by MTS against three tumor cell lines A2780 (ovarian carcinoma), HCT116 (colorectal carcinoma), HCT116doxR (colorectal carcinoma resistant to doxorubicin), and in human dermal fibroblasts. The antiproliferative assay showed a dose-dependent effect higher in complex 1 and 2 with a selectivity toward ovarian carcinoma cell line 21 times higher than in human fibroblasts. Exposure of A2780 cells to IC50 concentrations of complex 1 and 2 led to an increase of reactive oxygen species that led to the activation of cell death mechanisms, namely via intrinsic apoptosis for 2 and autophagy and extrinsic apoptosis for 1. Both complexes do not target DNA or interfere with cell cycle progression but are able to potentiate cell migration and neovascularization (for 2) an indicative that their application might be directed for initial tumor stages to avoid tumor invasion and metastization and opening a new avenue for complex 2 application in regenerative medicine. Interestingly, both complexes do not show toxicity in both in vivo models (CAM and zebrafish).
C1 [Lenis-Rojas, Oscar A.; Friaes, Sofia; Meireles, Marta S. H.; Royo, Beatriz] Inst Tecnol Quim & Biol Antonio Xavier, ITQB NOVA, Av Republ, P-2780157 Oeiras, Portugal.
   [Carvalho, Beatriz; Cabral, Rui; Silva, Margarida; Roma-Rodrigues, Catarina; Baptista, Pedro, V; Fernandes, Alexandra R.] NOVA Univ Lisbon, NOVA Sch Sci & Technol, Dept Life Sci, UCIBIO Appl Mol Biosci Unit, P-2819516 Caparica, Portugal.
   [Carvalho, Beatriz; Cabral, Rui; Silva, Margarida; Roma-Rodrigues, Catarina; Gomes, Clara S. B.; Baptista, Pedro, V; Fernandes, Alexandra R.] NOVA Univ Lisbon, NOVA Sch Sci & Technol, Associate Lab I4HB Inst Hlth & Bioecon, P-2819516 Caparica, Portugal.
   [Silva, Margarida] Univ Lisbon, Fac Farm, Imed, Av Prof Gama Pinto, P-1649003 Lisbon, Portugal.
   [Gomes, Clara S. B.] NOVA Sch Sci & Technol, Dept Quim, LAQV REQUIMTE, P-2829516 Caparica, Portugal.
   [Gomes, Clara S. B.] NOVA Sch Sci & Technol, Dept Quim, UCIBIO, P-2829516 Caparica, Portugal.
   [Fernandez, Jhonathan A. A.] Univ Campinas UNICAMP, Lab Zebrafish, Dept Med Genet & Genom Med, Sch Med Sci, Campinas, SP, Brazil.
   [Vila, Sabela F.; Rubiolo, Juan A.; Sanchez, Laura] Univ Santiago de Compostela, Fac Vet, Dept Zool Genet & Antropol Fis, Lugo 27002, Spain.
   [Sanchez, Laura] Hlth Res Inst Santiago Compostela IDIS, Preclin Anim Models Grp, Santiago De Compostela 15706, Spain.
RP Lenis-Rojas, OA; Royo, B (corresponding author), Inst Tecnol Quim & Biol Antonio Xavier, ITQB NOVA, Av Republ, P-2780157 Oeiras, Portugal.; Fernandes, AR (corresponding author), NOVA Univ Lisbon, NOVA Sch Sci & Technol, Dept Life Sci, UCIBIO Appl Mol Biosci Unit, P-2819516 Caparica, Portugal.; Fernandes, AR (corresponding author), NOVA Univ Lisbon, NOVA Sch Sci & Technol, Associate Lab I4HB Inst Hlth & Bioecon, P-2819516 Caparica, Portugal.
EM oscar.rojas@itqb.unl.pt; ma.fernandes@fct.unl.pt; broyo@itqb.unl.pt
RI Roma-Rodrigues, Catarina/S-6144-2016; Baptista, Pedro/A-1237-2009;
   Rojas, Oscar/ABE-2206-2021; Gomes, Clara S. B./H-7759-2012; Sanchez
   Pinon, Laura/L-2411-2014; Ferreira-Silva, Margarida/T-5012-2017
OI Roma-Rodrigues, Catarina/0000-0002-8676-6562; Rojas,
   Oscar/0000-0002-5914-5787; Gomes, Clara S. B./0000-0003-3672-0045;
   Sanchez Pinon, Laura/0000-0001-7927-5303; Ferreira-Silva,
   Margarida/0000-0002-5724-2823
FU FCT-FundacAo para a Ciencia e a Tecnologia, I.P., Project
   MOSTMICRO-ITQBPortuguese Foundation for Science and Technology
   [UIDB/04612/2020, UIDP/04612/2020]; FEDER through COMPETE; POCIEuropean
   Commission; PORL; FCT through PIDDACPortuguese Foundation for Science
   and Technology; FCT-FundacAo para a Ciencia e a Tecnologia, I.P. of the
   Research Unit on Applied Molecular Biosciences-UCIBIOPortuguese
   Foundation for Science and Technology [UIDP/04378/2020,
   UIDB/04378/2020]; Associate Laboratory Institute for Health and
   Bioeconomy-i4HB [LA/P/0140/2020]; FEDER funds through
   COMPETE2020-Programa Operacional Competitividade e InternacionalizacAo
   (POCI) [LISBOA-01-0145-FEDER-007660]; FCTPortuguese Foundation for
   Science and TechnologyEuropean Commission; POPH-Programa Operacional
   Potencial Humano; FSE (European Social Fund)European Social Fund (ESF);
   CoordenacAo de Aperfeicoamento de Pessoal de Nivel Superior-Brasil
   (CAPES)Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior
   (CAPES); program CAPES/PRINT [88887.470075/2019-00]; ACUIGEN from the
   Universidad de Santiago de Compostela [GI-1251]; Xunta de GaliciaXunta
   de GaliciaEuropean Commission [ED431C 2018/28]; FundacAo para a Ciencia
   e a TecnologiaPortuguese Foundation for Science and TechnologyEuropean
   Commission [UIDB/50006/2020, UIDP/50006/2020]; FCT-MCTESPortuguese
   Foundation for Science and TechnologyEuropean Commission
   [RECI/BBB-BEP/0124/2012];  [022161]
FX This work was funded by national funds through FCT-FundacAo para a
   Ciencia e a Tecnologia, I.P., Project MOSTMICRO-ITQB with refs
   UIDB/04612/2020 and UIDP/04612/2020. The NMR spectrometers at CERMAX are
   integrated in the National NMR, Network (PTNMR) and are partially
   supported by Infrastructure Project No. 022161 (co-financed by FEDER
   through COMPETE 2020, POCI and PORL and FCT through PIDDAC). This work
   is financed by national funds from FCT-FundacAo para a Ciencia e a
   Tecnologia, I.P., in the scope of the project UIDP/04378/2020 and
   UIDB/04378/2020 of the Research Unit on Applied Molecular
   Biosciences-UCIBIO and the project LA/P/0140/2020 of the Associate
   Laboratory Institute for Health and Bioeconomy-i4HB. Oscar A.
   Lenis-Rojas acknowledges Project LISBOA-01-0145-FEDER-007660
   (Microbiologia Molecular, Estrutural e Celular) funded by FEDER funds
   through COMPETE2020-Programa Operacional Competitividade e
   InternacionalizacAo (POCI) and by national funds through FCT,
   POPH-Programa Operacional Potencial Humano, and FSE (European Social
   Fund) for the CEEC 2017 Initiative. Jhonathan A.A Fernandez acknowledges
   CoordenacAo de Aperfeicoamento de Pessoal de Nivel Superior-Brasil
   (CAPES) and the program CAPES/PRINT Proc. 88887.470075/2019-00 for the
   financial support. Sabela F Vila, Juan A. Rubiolo, and Laura Sanchez
   acknowledge ACUIGEN (GI-1251) from the Universidad de Santiago de
   Compostela and Xunta de Galicia proyect ED431C 2018/28 for the financial
   support. Clara S. B. Gomes acknowledges the Associate Laboratory for
   Green Chemistry-LAQV and the Applied Molecular Biosciences Unit-UCIBIO.
   LAQV is financed by national funds from FundacAo para a Ciencia e a
   Tecnologia (UIDB/50006/2020, UIDP/50006/2020). X-ray infrastructure
   financed by FCT-MCTES through project RECI/BBB-BEP/0124/2012. The
   authors acknowledge M. Baleia and I. Goncalves for pDNA, gDNA, and
   preliminary BAX/BCL-2 data, respectively.
CR Abbas Z., 2018, NEOPLASMA, V1, P139, DOI [DOI 10.5772/INTECHOPEN.76558, 10.5772/intechopen.76558]
   [Anonymous], 2013, OECD GUIDELINES TEST
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
   Chakraborty I, 2017, INORG CHEM, V56, P1534, DOI 10.1021/acs.inorgchem.6b02623
   Chen S, 2008, WORLD J GASTROENTERO, V14, P2174, DOI 10.3748/wjg.14.2174
   Dasari S, 2014, EUR J PHARMACOL, V740, P364, DOI 10.1016/j.ejphar.2014.07.025
   Farrugia LJ, 2012, J APPL CRYSTALLOGR, V45, P849, DOI 10.1107/S0021889812029111
   Groom CR, 2016, ACTA CRYSTALLOGR B, V72, P171, DOI 10.1107/S2052520616003954
   Gutierrez-Lovera C, 2019, TOXICOL MECH METHOD, V29, P478, DOI 10.1080/15376516.2019.1611980
   Hohloch S, 2015, DALTON T, V44, P686, DOI 10.1039/c4dt02879a
   Howe K, 2013, NATURE, V496, P498, DOI 10.1038/nature12111
   Hu MX, 2019, RSC ADV, V9, P20505, DOI 10.1039/c9ra01370a
   Hubschle CB, 2011, J APPL CRYSTALLOGR, V44, P1281, DOI 10.1107/S0021889811043202
   Jimenez J, 2019, INORG CHIM ACTA, V485, P112, DOI 10.1016/j.ica.2018.09.088
   Jimenez J, 2018, INORG CHEM, V57, P1766, DOI 10.1021/acs.inorgchem.7b02480
   Katiyar SK, 2005, MOL CANCER THER, V4, P207
   Kawahara B, 2020, CHEM SCI, V11, P467, DOI 10.1039/c9sc03166a
   Kostova I, 2006, CURR MED CHEM, V13, P1085, DOI 10.2174/092986706776360941
   Krause L, 2015, J APPL CRYSTALLOGR, V48, P3, DOI 10.1107/S1600576714022985
   Kroemer G, 2009, CELL DEATH DIFFER, V16, P3, DOI 10.1038/cdd.2008.150
   Kumar CA, 2017, J ORGANOMET CHEM, V846, P152, DOI 10.1016/j.jorganchem.2017.06.003
   Kumar CA, 2016, INORG CHEM COMMUN, V64, P39, DOI 10.1016/j.inoche.2015.12.011
   Kumar U, 2019, NEW J CHEM, V43, P7520, DOI 10.1039/c8nj06271d
   Kumar U, 2019, ACS OMEGA, V4, P1923, DOI 10.1021/acsomega.8b03177
   Lenis-Rojas OA, 2016, DALTON T, V45, P19127, DOI 10.1039/c6dt03591d
   Lenis-Rojas OA, 2021, INORG CHEM, V60, P8011, DOI 10.1021/acs.inorgchem.1c00527
   Lenis-Rojas OA, 2018, INORG CHEM, V57, P13150, DOI 10.1021/acs.inorgchem.8b01270
   Lenis-Rojas OA, 2017, INORG CHEM, V56, P7127, DOI 10.1021/acs.inorgchem.7b00790
   Liu J, 2015, INT J MOL MED, V35, P607, DOI 10.3892/ijmm.2015.2073
   Luis DV, 2014, J BIOL INORG CHEM, V19, P787, DOI 10.1007/s00775-014-1110-0
   Makovec T, 2019, RADIOL ONCOL, V53, P148, DOI 10.2478/raon-2019-0018
   Mizushima N, 2010, CELL, V140, P313, DOI 10.1016/j.cell.2010.01.028
   Mjos KD, 2014, CHEM REV, V114, P4540, DOI 10.1021/cr400460s
   Morais TS, 2018, DALTON T, V47, P7819, DOI 10.1039/c8dt01653d
   Musib D, 2019, POLYHEDRON, V172, P125, DOI 10.1016/j.poly.2019.04.008
   Ndagi U, 2017, DRUG DES DEV THER, V11, P599, DOI 10.2147/DDDT.S119488
   Niesel J, 2008, CHEM COMMUN, P1798, DOI 10.1039/b719075a
   Oyarzo J, 2019, DALTON T, V48, P1023, DOI 10.1039/c8dt03265c
   Pedrosa P, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-29870-0
   Pierroz V, 2012, J AM CHEM SOC, V134, P20376, DOI 10.1021/ja307288s
   Pinto MN, 2019, INORG CHEM, V58, P14522, DOI 10.1021/acs.inorgchem.9b02121
   Reigosa-Chamorro F, 2021, INORG CHEM, V60, P3939, DOI 10.1021/acs.inorgchem.0c03763
   Riahi R, 2012, JALA-J LAB AUTOM, V17, P59, DOI 10.1177/2211068211426550
   Roma-Rodrigues C, 2016, INT J NANOMED, V11, P2633, DOI 10.2147/IJN.S108661
   Russell WMS, 1959, PRINCIPLES HUMANE EX
   Sheldrick GM, 2015, ACTA CRYSTALLOGR C, V71, P3, DOI 10.1107/S2053229614024218
   STAAL LH, 1979, J ORGANOMET CHEM, V170, P235, DOI 10.1016/S0022-328X(00)81088-8
   Stanbury M, 2017, ELECTROCHIM ACTA, V240, P288, DOI 10.1016/j.electacta.2017.04.080
   Svahn N, 2018, CHEM-EUR J, V24, P14654, DOI 10.1002/chem.201802547
   Tan CP, 2010, J MED CHEM, V53, P7613, DOI 10.1021/jm1009296
   Tarushi A, 2018, NEW J CHEM, V42, P6955, DOI 10.1039/c8nj01182f
   Ustun E, 2016, J COORD CHEM, V69, P3384, DOI 10.1080/00958972.2016.1231921
   Vidhyapriya P, 2018, J PHOTOCH PHOTOBIO B, V188, P28, DOI 10.1016/j.jphotobiol.2018.08.021
   Vinhas R, 2017, MOL THER-NUCL ACIDS, V7, P408, DOI 10.1016/j.omtn.2017.05.003
NR 54
TC 1
Z9 1
U1 6
U2 6
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0949-8257
EI 1432-1327
J9 J BIOL INORG CHEM
JI J. Biol. Inorg. Chem.
PD FEB
PY 2022
VL 27
IS 1
BP 49
EP 64
DI 10.1007/s00775-021-01910-7
EA OCT 2021
PG 16
WC Biochemistry & Molecular Biology; Chemistry, Inorganic & Nuclear
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA YX8VK
UT WOS:000712210400001
PM 34713347
DA 2022-04-25
ER

PT J
AU Bach, DH
   Kim, SH
   Hong, JY
   Park, HJ
   Oh, DC
   Lee, SK
AF Bach, Duc-Hiep
   Kim, Seong-Hwan
   Hong, Ji-Young
   Park, Hyen Joo
   Oh, Dong-Chan
   Lee, Sang Kook
TI Salternamide A Suppresses Hypoxia-Induced Accumulation of HIF-1 alpha
   and Induces Apoptosis in Human Colorectal Cancer Cells
SO MARINE DRUGS
LA English
DT Article
DE salternamide A (SA); HIF-1; PI3K; Akt; mTOR; p42; p44 MAPK; STAT3; cell
   death
ID INDUCIBLE FACTOR 1-ALPHA; GENE-EXPRESSION; PROTEIN-KINASES; BINDING;
   STAT3; CARCINOMA; AUTOPHAGY; GROWTH; HIF-1; FACTOR-1-ALPHA
AB Hypoxia inducible factor-1 (HIF-1) is an essential regulator of the cellular response to low oxygen concentrations, activating a broad range of genes that provide adaptive responses to oxygen deprivation. HIF-1 is overexpressed in various cancers and therefore represents a considerable chemotherapeutic target. Salternamide A (SA), a novel small molecule that is isolated from a halophilic Streptomyces sp., is a potent cytotoxic agent against a variety of human cancer cell lines. However, the mechanisms by which SA inhibits tumor growth remain to be elucidated. In the present study, we demonstrate that SA efficiently inhibits the hypoxia-induced accumulation of HIF-1 in a time- and concentration-dependent manner in various human cancer cells. In addition, SA suppresses the upstream signaling of HIF-1, such as PI3K/Akt/mTOR, p42/p44 MAPK, and STAT3 signaling under hypoxic conditions. Furthermore, we found that SA induces cell death by stimulating G2/M cell cycle arrest and apoptosis in human colorectal cancer cells. Taken together, SA was identified as a novel small molecule HIF-1 inhibitor from marine natural products and is potentially a leading candidate in the development of anticancer agents.
C1 [Bach, Duc-Hiep; Kim, Seong-Hwan; Hong, Ji-Young; Park, Hyen Joo; Oh, Dong-Chan; Lee, Sang Kook] Seoul Natl Univ, Coll Pharm, Seoul 151742, South Korea.
RP Lee, SK (corresponding author), Seoul Natl Univ, Coll Pharm, Seoul 151742, South Korea.
EM bdhiep90@snu.ac.kr; yanberk@snu.ac.kr; jyhong7876@daum.net;
   phj00@snu.ac.kr; dongchanoh@snu.ac.kr; sklee61@snu.ac.kr
RI Bach, Duc-Hiep/V-5276-2017
OI Bach, Duc-Hiep/0000-0002-9826-3137
FU National Research Foundation (NRF) - Korean government (MEST) (NRF)
   [2009-0083533]; MarineBio Research Program of the NRF (NRF)
   [2012-0006712]
FX This work was supported by a National Research Foundation (NRF) grant
   funded by the Korean government (MEST) (NRF No. 2009-0083533) and a
   grant from the MarineBio Research Program of the NRF (NRF No.
   2012-0006712).
CR [Anonymous], 2006, NOVART FDN SYMP, V272, P8, DOI [10.1002/9780470035009.ch2, DOI 10.1002/9780470035009.CH2]
   Chen CH, 2001, J BIOL CHEM, V276, P9519, DOI 10.1074/jbc.M010144200
   Creighton-Gutteridge M, 2007, CLIN CANCER RES, V13, P1010, DOI 10.1158/1078-0432.CCR-06-2301
   Dai Y, 2010, CLIN CANCER RES, V16, P376, DOI 10.1158/1078-0432.CCR-09-1029
   Dasari S, 2014, EUR J PHARMACOL, V740, P364, DOI 10.1016/j.ejphar.2014.07.025
   DOREE M, 1994, FASEB J, V8, P1114, DOI 10.1096/fasebj.8.14.7958616
   Feldser D, 1999, CANCER RES, V59, P3915
   Gump JM, 2011, TRENDS CELL BIOL, V21, P387, DOI 10.1016/j.tcb.2011.03.007
   Hansson LO, 2002, P NATL ACAD SCI USA, V99, P10305, DOI 10.1073/pnas.122347199
   Huang WW, 2011, INT J ONCOL, V38, P1067, DOI 10.3892/ijo.2011.922
   Jung JE, 2005, FASEB J, V19, P1296, DOI 10.1096/fj.04-3099fje
   Jung JE, 2008, EXP MOL MED, V40, P479, DOI 10.3858/emm.2008.40.5.479
   Kim SH, 2015, J NAT PROD, V78, P836, DOI 10.1021/acs.jnatprod.5b00002
   Koh MY, 2008, TRENDS BIOCHEM SCI, V33, P526, DOI 10.1016/j.tibs.2008.08.002
   Krishnamachary B, 2003, CANCER RES, V63, P1138
   Liu YV, 2007, MOL CELL, V25, P207, DOI 10.1016/j.molcel.2007.01.001
   Livesey KM, 2012, CANCER RES, V72, P1996, DOI 10.1158/0008-5472.CAN-11-2291
   Mack FA, 2003, CANCER CELL, V3, P75, DOI 10.1016/S1535-6108(02)00240-4
   Maranchie JK, 2002, CANCER CELL, V1, P247, DOI 10.1016/S1535-6108(02)00044-2
   Niu GL, 2008, MOL CANCER RES, V6, P1099, DOI 10.1158/1541-7786.MCR-07-2177
   Noman MZ, 2009, J IMMUNOL, V182, P3510, DOI 10.4049/jimmunol.0800854
   Pawlus MR, 2014, ONCOGENE, V33, P1670, DOI 10.1038/onc.2013.115
   Pawlus MR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072358
   Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501
   Pugh CW, 2003, NAT MED, V9, P677, DOI 10.1038/nm0603-677
   Richard DE, 1999, J BIOL CHEM, V274, P32631, DOI 10.1074/jbc.274.46.32631
   Safarzadeh E, 2014, ADV PHARM BULL, V4, P421, DOI 10.5681/apb.2014.062
   Sang NL, 2003, J BIOL CHEM, V278, P14013, DOI 10.1074/jbc.M209702200
   Semenza GL, 2000, GENE DEV, V14, P1983
   Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187
   Shrivastava A, 2011, MOL CANCER THER, V10, P1161, DOI 10.1158/1535-7163.MCT-10-1100
   Talks KL, 2000, AM J PATHOL, V157, P411, DOI 10.1016/S0002-9440(10)64554-3
   van den Beucken T, 2006, CANCER BIOL THER, V5, P749, DOI 10.4161/cbt.5.7.2972
   Zhong H, 1999, CANCER RES, V59, P5830
   Zhong H, 2000, CANCER RES, V60, P1541
   Zundel W, 2000, GENE DEV, V14, P391
NR 36
TC 24
Z9 24
U1 1
U2 18
PU MDPI AG
PI BASEL
PA POSTFACH, CH-4005 BASEL, SWITZERLAND
SN 1660-3397
J9 MAR DRUGS
JI Mar. Drugs
PD NOV
PY 2015
VL 13
IS 11
BP 6962
EP 6976
DI 10.3390/md13116962
PG 15
WC Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA CX4CI
UT WOS:000365645400021
PM 26610526
OA Green Published, gold, Green Submitted
DA 2022-04-25
ER

PT J
AU Klose, J
   Kattner, S
   Borgstrom, B
   Volz, C
   Schmidt, T
   Schneider, M
   Oredsson, S
   Strand, D
   Ulrich, A
AF Klose, Johannes
   Kattner, Sarah
   Borgstrom, Bjorn
   Volz, Claudia
   Schmidt, Thomas
   Schneider, Martin
   Oredsson, Stina
   Strand, Daniel
   Ulrich, Alexis
TI Semi-synthetic salinomycin analogs exert cytotoxic activity against
   human colorectal cancer stem cells
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Salinomycin; Salinomycin analogs; Colorectal cancer; Apoptosis; Cancer
   stem cells
ID SELECTIVITY; AUTOPHAGY; GROWTH
AB Salinomycin, a polyether antibiotic, is a well-known inhibitor of human cancer stem cells. Chemical modification of the allylic C20 hydroxyl of salinomycin has enabled access to synthetic analogs that display increased cytotoxic activity compared to the native structure. The aim of this study was to investigate the activity of a cohort of C20-O-acyl analogs of salinomycin on human colorectal cancer cell lines in vitro. Two human colorectal cancer cell lines (SW480 and SW620) were exposed to three C20-O-acylated analogs and salinomycin. The impact of salinomycin and its analogs on tumor cell number, migration, cell death, and cancer stem cell specifity was analyzed. Exposure of human colorectal cancer cells to the C20-O-acylated analogs of salinomycin resulted in reduced tumor cell number and impaired tumor cell migration at lower concentrations than salinomycin. When used at higher (micromolar) concentrations, these effects were accompanied by induction of apoptotic cell death. Salinomycin analogs further expose improved activity against cancer stem cells compared to salinomycin. (C) 2017 Elsevier Inc. All rights reserved.
C1 [Klose, Johannes; Kattner, Sarah; Volz, Claudia; Schmidt, Thomas; Schneider, Martin; Ulrich, Alexis] Heidelberg Univ, Dept Gen Visceral & Transplantat Surg, Neuenheimer Feld 110, D-69120 Heidelberg, Germany.
   [Borgstrom, Bjorn; Strand, Daniel] Lund Univ, Ctr Anal & Synth, Dept Chem, Lund, Sweden.
   [Oredsson, Stina] Lund Univ, Dept Biol, Lund, Sweden.
RP Klose, J (corresponding author), Heidelberg Univ, Dept Gen Visceral & Transplantat Surg, Neuenheimer Feld 110, D-69120 Heidelberg, Germany.
EM Johannes.Klose@med.uni-heidelberg.de; sarahkatt@web.de;
   bjom.borgstrom@chem.lu.se; Claudia.Volz@med.uni-heidelberg.de;
   Thomas1.Schmidt@med.uni.heidelberg.de; m.schneider@uni-heidelberg.de;
   stina.oredsson@biol.lu.se; daniel.strand@chem.lu.se;
   Alexis.Ulrich@med.uni-heidelberg.de
RI Schmidt, Thomas/Y-8431-2019
OI Schmidt, Thomas/0000-0002-7166-3675; Strand, Daniel/0000-0002-6113-4657
FU Heidelberger Stiftung Chirurgie; Swedish Cancer foundation
FX This study was supported by Heidelberger Stiftung Chirurgie to JK and
   the Swedish Cancer foundation.
CR Borgstrom B, 2016, ACS MED CHEM LETT, V7, P635, DOI 10.1021/acsmedchemlett.6b00079
   Borgstrom B, 2013, CHEM COMMUN, V49, P9944, DOI 10.1039/c3cc45983g
   Melo FDE, 2017, NATURE, V543, P676, DOI 10.1038/nature21713
   Dewangan J, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317695035
   Dong TT, 2011, ANN SURG ONCOL, V18, P1797, DOI 10.1245/s10434-011-1561-2
   Grubor-Bauk B, 2016, GENE THER, V23, P26, DOI 10.1038/gt.2015.86
   Gupta PB, 2009, CELL, V138, P645, DOI 10.1016/j.cell.2009.06.034
   Huang EH, 2009, CANCER RES, V69, P3382, DOI 10.1158/0008-5472.CAN-08-4418
   Huang XL, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2142-3
   Huang XL, 2014, ACS CHEM BIOL, V9, P1587, DOI 10.1021/cb5002153
   Ketola K, 2012, BRIT J CANCER, V106, P99, DOI 10.1038/bjc.2011.530
   Klose J, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2879-8
   Klose J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095970
   Lieke T, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-466
   Lobo NA, 2007, ANNU REV CELL DEV BI, V23, P675, DOI 10.1146/annurev.cellbio.22.010305.104154
   Mao J, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2013.515
   Mizushima N, 2010, CELL, V140, P313, DOI 10.1016/j.cell.2010.01.028
   PLUMLEE KH, 1995, J VET DIAGN INVEST, V7, P419, DOI 10.1177/104063879500700327
   Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089
   Story Phillipa, 2004, N Z Med J, V117, pU799
   Verdoodt B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044132
   Xipell E, 2016, ONCOTARGET, V7, P30626, DOI [10.16632/oncotarget.8905, 10.18632/oncotarget.8905]
   Zhang GN, 2011, CANCER LETT, V313, P137, DOI 10.1016/j.canlet.2011.05.030
   Zhou J, 2013, TOXICOL LETT, V222, P139, DOI 10.1016/j.toxlet.2013.07.022
NR 24
TC 7
Z9 7
U1 1
U2 8
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD JAN 1
PY 2018
VL 495
IS 1
BP 53
EP 59
DI 10.1016/j.bbrc.2017.10.147
PG 7
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA FU5MM
UT WOS:000423897600009
PM 29107689
DA 2022-04-25
ER

PT J
AU Singh, A
   Patel, P
   Jageshwar
   Patel, VK
   Jain, DK
   Kamal, M
   Rajak, H
AF Singh, Avineesh
   Patel, Preeti
   Jageshwar
   Patel, Vijay Kumar
   Jain, Deepak Kumar
   Kamal, M.
   Rajak, Harish
TI The Safety, Efficacy and Therapeutic Potential of Histone Deacetylase
   Inhibitors with Special Reference to Panobinostat in Gastrointestinal
   Tumors: A Review of Preclinical and Clinical Studies
SO CURRENT CANCER DRUG TARGETS
LA English
DT Review
DE HDAC; HDACi; panobinostat; combination therapy; GI tumors; preclinical
   and clinical studies
ID GROWTH-FACTOR-BETA; PANCREATIC-CANCER CELLS; VIRUS-X PROTEIN;
   SUBEROYLANILIDE HYDROXAMIC ACID; EPITHELIAL-MESENCHYMAL TRANSITION;
   HEPATOCELLULAR-CARCINOMA CELLS; HUMAN COLORECTAL-CANCER; NF-KAPPA-B;
   GASTRIC-CANCER; HEPATOMA-CELLS
AB Histone deacetylase inhibitors (HDACi) have been demonstrated as an emerging class of anticancer drugs involved in regulation of gene expression and chromatin remodeling thus indicating valid targets for different types of cancer therapeutics. The pan-deacetylase inhibitor panobinostat (Farydac (R), LBH589) is developed by Novartis Pharmaceuticals and a newly US FDA approved drug for the multiple myeloma. It is under clinical investigation for a range of hematological and solid tumors worldwide in both oral and intravenous formulations. Panobinostat inhibits tumor cell growth by interacting with acetylation of histones and nonhistone proteins as well as various apoptotic, autophagy-mediated targets and various tumorigenesis pathways involved in the development of cancer. The current article summarizes the status of panobinostat in gastrointestinal cancers. Preclinical and clinical data suggest that panobinostat has potential inhibitory activity in hepatocellular, pancreatic, colorectal, gastric and gastrointestinal stromal tumors. Clinical evaluations of panobinostat are currently underway. Herein, we have also reviewed the rationale behind the combination therapy under the trials and possible future prospective for the treatment of GI tumors.
C1 [Singh, Avineesh; Patel, Preeti; Jageshwar; Patel, Vijay Kumar; Jain, Deepak Kumar; Rajak, Harish] Guru Ghasidas Univ, Inst Pharmaceut Sci, Med Chem Res Lab, Bilaspur 495009, CG, India.
   [Kamal, M.] Prince Sattam Bin Abdulaziz Univ, Coll Pharm, Dept Pharmaceut Chem, Al Kharj 11942, Saudi Arabia.
RP Rajak, H (corresponding author), Guru Ghasidas Univ, Inst Pharmaceut Sci, Bilaspur, India.
EM harishdops@yahoo.co.in
RI Patel, Preeti/AAD-2040-2021; Kamal, Mehnaz/AAE-7681-2019; Rajak,
   Harish/AAP-5981-2021
OI Patel, Preeti/0000-0003-1606-2241; Kamal, Mehnaz/0000-0002-3585-0828;
   PATEL, VIJAY KUMAR/0000-0002-0392-3308; Rajak,
   Harish/0000-0003-2008-2827
FU Council of Scientific & Industrial Research (CSIR), New DelhiCouncil of
   Scientific & Industrial Research (CSIR) - India; Science & Engineering
   Research Board - Department of Science & Technology (SERB-DST), New
   DelhiDepartment of Science & Technology (India)Science Engineering
   Research Board (SERB), India; All India Council for Technical Education
   (AICTE), New DelhiAll India Council for Technical Education (AICTE)
FX One of the authors, Avineesh Singh is thankful to the Council of
   Scientific & Industrial Research (CSIR), New Delhi for awarding Senior
   Research Fellowship and financial assistance. One of the authors, Harish
   Rajak is grateful to Science & Engineering Research Board - Department
   of Science & Technology (SERB-DST), New Delhi, and All India Council for
   Technical Education (AICTE), New Delhi for providing financial
   assistance in the form of a Research Project and CAYT scheme,
   respectively.
CR Aghdassi A, 2012, GUT, V61, P439, DOI 10.1136/gutjnl-2011-300060
   [Anonymous], 2014, US FDA APPROVES BELE
   [Anonymous], 2014, CA CANC J CLIN, V64, P9
   Arlt A, 2013, CANCER LETT, V332, P346, DOI 10.1016/j.canlet.2010.10.015
   Armeanu S, 2005, J HEPATOL, V42, P210, DOI 10.1016/j.jhep.2004.10.020
   Arumugam T, 2009, CANCER RES, V69, P5820, DOI 10.1158/0008-5472.CAN-08-2819
   Bauer S, 2014, BRIT J CANCER, V110, P1155, DOI 10.1038/bjc.2013.826
   Bhaskara S, 2008, MOL CELL, V30, P61, DOI 10.1016/j.molcel.2008.02.030
   Bolden JE, 2006, NAT REV DRUG DISCOV, V5, P769, DOI 10.1038/nrd2133
   Carlisi D, 2009, EUR J CANCER, V45, P2425, DOI 10.1016/j.ejca.2009.06.024
   Cha EJ, 2009, CLIN CANCER RES, V15, P4453, DOI 10.1158/1078-0432.CCR-08-3329
   Chen J, 2011, CANCER RES, V71, P4138, DOI 10.1158/0008-5472.CAN-10-4274
   Chien WW, 2014, MOL CARCINOGEN, V53, P722, DOI 10.1002/mc.22024
   Chou CW, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018087
   Claerhout S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024662
   Cougot D, 2007, J BIOL CHEM, V282, P4277, DOI 10.1074/jbc.M606774200
   Dell'Aversana C, 2012, EXP CELL RES, V318, P1229, DOI 10.1016/j.yexcr.2012.01.025
   Deroanne CF, 2002, ONCOGENE, V21, P427, DOI 10.1038/sj.onc.1205108
   Di Fazio P, 2012, EXP CELL RES, V318, P1832, DOI 10.1016/j.yexcr.2012.04.018
   Di Fazio P, 2010, CELL ONCOL, V32, P285, DOI 10.3233/CLO-2010-0511
   Donadelli M, 2007, BBA-MOL CELL RES, V1773, P1095, DOI 10.1016/j.bbamcr.2007.05.002
   Duong FHT, 2010, HEPATOLOGY, V51, P741, DOI 10.1002/hep.23388
   Dzieran J, 2008, CANCER SCI, V99, P1685, DOI 10.1111/j.1349-7006.2008.00868.x
   Ellis L, 2009, CANCER LETT, V280, P145, DOI 10.1016/j.canlet.2008.11.012
   Emanuele S, 2007, APOPTOSIS, V12, P1327, DOI 10.1007/s10495-007-0063-y
   Farrell JJ, 2013, GASTROENTEROLOGY, V144, P1303, DOI 10.1053/j.gastro.2013.01.073
   Feng LF, 2013, J MOL MED, V91, P49, DOI 10.1007/s00109-012-0932-x
   Fernandez AF, 2010, ONCOGENE, V29, P1405, DOI 10.1038/onc.2009.517
   Floris G, 2009, CLIN CANCER RES, V15, P4066, DOI 10.1158/1078-0432.CCR-08-2588
   Fritsche P, 2009, GUT, V58, P1399, DOI 10.1136/gut.2009.180711
   Gahr S, 2008, ONCOL REP, V20, P1249, DOI 10.3892/or_00000137
   Gahr S, 2012, J CANCER, V3, P158, DOI 10.7150/jca.4211
   Galuppo R, 2014, DIGEST DIS SCI, V59, P1688, DOI 10.1007/s10620-014-3058-x
   Gandesiri M., 2010, CANCER RES, V70, P3649
   Gandesiri M, 2012, APOPTOSIS, V17, P1300, DOI 10.1007/s10495-012-0757-7
   Garcia-Morales P, 2005, MOL CANCER THER, V4, P1222, DOI 10.1158/1535-7163.MCT-04-0186
   Gauthier A, 2013, HEPATOL RES, V43, P147, DOI 10.1111/j.1872-034X.2012.01113.x
   Giardina C, 2015, CANCER PREV RES, V8, P387, DOI 10.1158/1940-6207.CAPR-14-0371
   Giles F, 2006, CLIN CANCER RES, V12, P4628, DOI 10.1158/1078-0432.CCR-06-0511
   Goggins M, 1998, CANCER RES, V58, P5329
   Gold PJ, 2012, J CLIN ONCOL, V30, DOI 10.1200/jco.2012.30.4_suppl.582
   Gryder BE, 2012, FUTURE MED CHEM, V4, P505, DOI [10.4155/FMC.12.3, 10.4155/fmc.12.3]
   Haefner M, 2008, WORLD J GASTROENTERO, V14, P3681, DOI 10.3748/wjg.14.3681
   Han RF, 2014, MOL MED REP, V10, P3211, DOI 10.3892/mmr.2014.2594
   He P, 2015, INT J CLIN EXP MED, V8, P6510
   Henrici A, 2015, MOL CARCINOGEN, V54, P585, DOI 10.1002/mc.22122
   Herceg Z, 2011, MUTAT RES-REV MUTAT, V727, P55, DOI 10.1016/j.mrrev.2011.04.001
   Herceg Z, 2009, J HEPATOL, V50, P252, DOI 10.1016/j.jhep.2008.11.013
   Herold C, 2002, J HEPATOL, V36, P233, DOI 10.1016/S0168-8278(01)00257-4
   Hideshima T, 2008, CONTEMP HEMATOL, P379
   Horikawa I, 2003, CARCINOGENESIS, V24, P1167, DOI 10.1093/carcin/bgg085
   Huang J, 2009, SCI CHINA SER C, V52, P31, DOI 10.1007/s11427-009-0014-7
   Huang WQ, 2005, J BIOL CHEM, V280, P10047, DOI 10.1074/jbc.M408680200
   Hung SY, 2014, INT J CLIN EXP PATHO, V7, P2496
   Iwatsuki M, 2010, CANCER SCI, V101, P293, DOI 10.1111/j.1349-7006.2009.01419.x
   Jiang JH, 2015, BBA-REV CANCER, V1855, P43, DOI 10.1016/j.bbcan.2014.11.004
   Jin JS, 2012, PATHOL ONCOL RES, V18, P713, DOI 10.1007/s12253-012-9499-7
   Jones Suzanne F, 2011, Clin Adv Hematol Oncol, V9, P225
   Kaler P, 2008, EXP CELL RES, V314, P1507, DOI 10.1016/j.yexcr.2008.01.010
   Kang Y, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.422
   Kanno K, 2012, ONCOL REP, V28, P867, DOI 10.3892/or.2012.1898
   Kauh J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010376
   Khan A., 2014, THESIS, P342
   Kim JK, 2013, HEPATOLOGY, V57, P1055, DOI 10.1002/hep.26101
   Kim JH, 2004, J GASTROEN HEPATOL, V19, P218, DOI 10.1111/j.1440-1746.2004.03336.x
   Kim R., PANOBINOSTAT SORAFEN
   Kumagai T, 2007, INT J CANCER, V121, P656, DOI 10.1002/ijc.22558
   LaBonte MJ, 2011, CANCER RES, V71, P3635, DOI 10.1158/0008-5472.CAN-10-2430
   Lachenmayer A, 2012, J HEPATOL, V56, P1343, DOI 10.1016/j.jhep.2012.01.009
   Lee JH, 2010, MOL CELLS, V30, P107, DOI 10.1007/s10059-010-0094-z
   Lee SC, 2011, ANTICANCER RES, V31, P3385
   LIU C, 2014, BIOMED RES INT, V2014, DOI DOI 10.1155/2014/871263
   Liu T, 2006, CANCER TREAT REV, V32, P157, DOI 10.1016/j.ctrv.2005.12.006
   Liu YQ, 2013, LIVER INT, V33, P504, DOI 10.1111/liv.12034
   Lv L, 2014, MED ONCOL, V31, DOI 10.1007/s12032-014-0965-9
   Ma XJ, 2009, DRUGS, V69, P1911, DOI 10.2165/11315680-000000000-00000
   Ma YN, 2015, AM J CANCER RES, V5, P663
   Maier Harald J, 2010, Cancers (Basel), V2, P2058, DOI 10.3390/cancers2042058
   Marks PA, 2009, J CELL BIOCHEM, V107, P600, DOI 10.1002/jcb.22185
   Mehdi O, 2012, PANCREATOLOGY, V12, P466, DOI 10.1016/j.pan.2012.10.001
   Meng J, 2012, ONCOL REP, V28, P384, DOI 10.3892/or.2012.1793
   Michaelis M, 2004, MOL PHARMACOL, V65, P520, DOI 10.1124/mol.65.3.520
   Mitani Y, 2005, J PATHOL, V205, P65, DOI 10.1002/path.1684
   Mitsiades N, 2003, BLOOD, V101, P4055, DOI 10.1182/blood-2002-11-3514
   Miura K, 2008, HEPATOLOGY, V48, P1420, DOI 10.1002/hep.22486
   Miyo M, 2015, BRIT J CANCER, V113, P492, DOI 10.1038/bjc.2015.226
   Montalbano R, 2013, TRANSL ONCOL, V6, P143, DOI 10.1593/tlo.12271
   Moore PS, 2004, BBA-MOL CELL RES, V1693, P167, DOI 10.1016/j.bbamcr.2004.07.001
   Mottet D, 2007, CIRC RES, V101, P1237, DOI 10.1161/CIRCRESAHA.107.149377
   Mutze K, 2010, ANN SURG ONCOL, V17, P3336, DOI 10.1245/s10434-010-1182-1
   Nakagawa M, 2007, ONCOL REP, V18, P769
   Natoni F, 2005, BBA-MOL CELL RES, V1745, P318, DOI 10.1016/j.bbamcr.2005.07.003
   Newbold A, 2008, MOL CANCER THER, V7, P1066, DOI 10.1158/1535-7163.MCT-07-2256
   Noguchi A, 2014, CANCER MED-US, V3, P1553, DOI 10.1002/cam4.310
   Noh JH, 2013, CANCER LETT, V335, P455, DOI 10.1016/j.canlet.2013.03.003
   Noh JH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028103
   Ocker M, 2005, J CANCER RES CLIN, V131, P385, DOI 10.1007/s00432-004-0664-6
   Ocker M, 2007, INT J BIOCHEM CELL B, V39, P1367, DOI 10.1016/j.biocel.2007.03.001
   Ouaissi M, 2008, ANN SURG ONCOL, V15, P2318, DOI 10.1245/s10434-008-9940-z
   Pal-Bhadra M, 2007, LIFE SCI, V81, P979, DOI 10.1016/j.lfs.2007.07.030
   Pan LN, 2010, FEBS J, V277, P989, DOI 10.1111/j.1742-4658.2009.07542.x
   Park IY, 2007, GASTROENTEROLOGY, V132, P1476, DOI 10.1053/j.gastro.2007.01.034
   Park JH, 2008, BIOCHEM BIOPH RES CO, V368, P318, DOI 10.1016/j.bbrc.2008.01.056
   Pathil A, 2006, HEPATOLOGY, V43, P425, DOI 10.1002/hep.21054
   Pollicino T, 2007, HEPATOLOGY, V45, P277, DOI 10.1002/hep.21529
   Portanova P, 2008, INT J ONCOL, V33, P325, DOI 10.3892/ijo_00000012
   Qian DZ, 2006, CLIN CANCER RES, V12, P634, DOI 10.1158/1078-0432.CCR-05-1132
   Qiao ZX, 2013, BIOCHEM BIOPH RES CO, V434, P95, DOI 10.1016/j.bbrc.2013.03.059
   Quint K, 2011, VIRCHOWS ARCH, V459, P129, DOI 10.1007/s00428-011-1103-0
   Rajak H, 2013, CURR MED CHEM, V20, P1887
   Regel I, 2012, GASTROENTEROLOGY, V143, P99, DOI 10.1053/j.gastro.2012.03.035
   Rikimaru T, 2007, ONCOLOGY-BASEL, V72, P69, DOI 10.1159/000111106
   Rossig L, 2002, CIRC RES, V91, P837, DOI 10.1161/01.RES.0000037983.07158.B1
   Ryu JK, 2006, CANCER LETT, V237, P143, DOI 10.1016/j.canlet.2005.05.040
   Schafer C, 2017, CELL SIGNAL, V29, P218, DOI 10.1016/j.cellsig.2016.11.002
   Schneider G, 2010, ONCOGENE, V29, P2795, DOI 10.1038/onc.2010.46
   Schneider Gunter, 2011, J Gastrointest Cancer, V42, P85, DOI 10.1007/s12029-011-9257-1
   Schuchmann M, 2006, ONCOL REP, V15, P227
   Schuler S, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-80
   Shin H, 2012, ONCOL REP, V27, P1111, DOI 10.3892/or.2011.1585
   Shin JW, 2013, WORLD J GASTROENTERO, V19, P6144, DOI 10.3748/wjg.v19.i37.6144
   Shona JK, 2009, VIRUS RES, V139, P14, DOI 10.1016/j.virusres.2008.09.006
   Siegel R., 2014, CANC STAT
   Song X, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-114
   Sonnemann J, 2014, BRIT J CANCER, V110, P656, DOI 10.1038/bjc.2013.742
   Spratlin JL, 2011, ANTICANCER RES, V31, P1093
   Stewart B. W., 2014, WHO
   Strobel D., SORAFENIB LBH589 HEP
   Stypula-Cyrus Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064600
   Sung V, 2011, CANCER SCI, V102, P1201, DOI 10.1111/j.1349-7006.2011.01921.x
   Suzuki T, 2000, INT J CANCER, V88, P992, DOI 10.1002/1097-0215(20001215)88:6<992::AID-IJC24>3.0.CO;2-9
   Torre L. A., 2012, GLOBAL CANC STAT
   Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262
   Truty MJ, 2009, J BIOL CHEM, V284, P6291, DOI 10.1074/jbc.M807791200
   Ungerstedt J, 2012, FREE RADICAL BIO MED, V53, P2002, DOI 10.1016/j.freeradbiomed.2012.09.019
   Ungerstedt JS, 2005, P NATL ACAD SCI USA, V102, P673, DOI 10.1073/pnas.0408732102
   van Roy F, 2008, CELL MOL LIFE SCI, V65, P3756, DOI 10.1007/s00018-008-8281-1
   Venkannagari S, 2012, ONCOTARGET, V3, P1416
   Venkatasubbarao K, 1998, GENE CHROMOSOME CANC, V22, P138, DOI 10.1002/(SICI)1098-2264(199806)22:2<138::AID-GCC8>3.0.CO;2-Y
   Venkatasubbarao K, 2000, ANTICANCER RES, V20, P43
   von Burstin J, 2009, GASTROENTEROLOGY, V137, P361, DOI 10.1053/j.gastro.2009.04.004
   Wang B, 2013, BIOCHEM BIOPH RES CO, V437, P1, DOI 10.1016/j.bbrc.2013.05.090
   Wang G, 2012, CANCER RES, V72, DOI 10.1158/1538-7445.AM2012-1830
   Wang G, 2015, CANCER LETT, V356, P656, DOI 10.1016/j.canlet.2014.10.015
   Wang GY, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0039700, 10.1371/journal.pone.0051764, 10.1371/journal.pone.0047051]
   Wang HB, 2012, ANTICANCER RES, V32, P1027
   Wang SS, 2008, P NATL ACAD SCI USA, V105, P7738, DOI 10.1073/pnas.0802857105
   Wang XX, 2015, BIOCHEM BIOPH RES CO, V456, P320, DOI 10.1016/j.bbrc.2014.11.079
   Wang Y., 2008, CANCER RES
   Weichert W, 2008, CLIN CANCER RES, V14, P1669, DOI 10.1158/1078-0432.CCR-07-0990
   Weichert W, 2008, LANCET ONCOL, V9, P139, DOI 10.1016/S1470-2045(08)70004-4
   Wilson PM, 2013, INVEST NEW DRUG, V31, P845, DOI 10.1007/s10637-012-9914-7
   Witt O, 2009, CANCER LETT, V277, P8, DOI 10.1016/j.canlet.2008.08.016
   Wu J, 2013, DIGEST DIS SCI, V58, P3545, DOI 10.1007/s10620-013-2867-7
   Wu LM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014460
   Xie HJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034265
   Yang H, 2010, EXP BIOL MED, V235, P32, DOI 10.1258/ebm.2009.009252
   Yasui W, 2003, ANN NY ACAD SCI, V983, P220, DOI 10.1111/j.1749-6632.2003.tb05977.x
   Yoo YG, 2008, ONCOGENE, V27, P3405, DOI 10.1038/sj.onc.1211000
   Yu HY, 2014, CLIN CANCER RES, V20, P3434, DOI 10.1158/1078-0432.CCR-13-2952
   Yuan JH, 2011, HEPATOLOGY, V54, P2025, DOI 10.1002/hep.24606
   Zeng JP, 2010, GASTROENTEROLOGY, V138, P981, DOI 10.1053/j.gastro.2009.10.004
   Zhang CZ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039870
   Zhang XZ, 2015, INT J CLIN EXP MED, V8, P809
   Zhang XT, 2006, ONCOL REP, V16, P563
   Zhao SJ, 2003, CANCER RES, V63, P2624
   Zhao X, 2011, TUMOR BIOL, V32, P335, DOI 10.1007/s13277-010-0126-5
   Zheng DL, 2009, J HEPATOL, V50, P377, DOI 10.1016/j.jhep.2008.10.019
   Zopf S, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-386
   Zou Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069992
NR 170
TC 7
Z9 9
U1 1
U2 9
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1568-0096
EI 1873-5576
J9 CURR CANCER DRUG TAR
JI Curr. Cancer Drug Targets
PY 2018
VL 18
IS 8
BP 720
EP 736
DI 10.2174/1568009617666170630124643
PG 17
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA GU9NG
UT WOS:000445673000001
PM 28669336
DA 2022-04-25
ER

PT J
AU Zhang, LZ
   Qi, WH
   Zhao, G
   Liu, LX
   Xue, H
   Hu, WX
   Wang, QQ
   Li, CS
AF Zhang, Li-ze
   Qi, Wen-hai
   Zhao, Gang
   Liu, Lin-xun
   Xue, Hui
   Hu, Wen-xiu
   Wang, Qian-qian
   Li, Chun-sheng
TI Correlation between PTEN and P62 gene expression in rat colorectal
   cancer cell
SO SAUDI JOURNAL OF BIOLOGICAL SCIENCES
LA English
DT Article
DE Autophagy; PTEN gene; p62; Colorectal cancer; pEGFP-N1-PTEN plasmid;
   Regulation
ID SIGNALING PATHWAY; LARYNGEAL-CANCER; UBIQUITINATION; GROWTH
AB Objective: Autophagy is a cellular pathway that regulates the transportation and degradation of cytoplasmic macromolecules and organelles towards lysosome, which is often related to the tumorigenesis and tumor suppression. Here, we investigate the regulating effect of PTEN gene on autophagy-related protein P62 in rat colorectal cancer (CRC) cells and explore the application value of PTEN gene in clinic.
   Methods: Rat colorectal cancer was induced by intraperitoneal injection of 1,2-dimethyl hydrazine in male ACI rats. A total of 20 rats were randomly selected from those successfully induced with CRC as the experimental group, while 10 healthy rats as control. The rat CRC cells were isolated and cultured. After transfecting the rat CRC cells with pEGFP-N1-PTEN plasmid, RT-PCR was adopted to examine that gene expression of p62 and PTEN, while Western blotting was used to detect the protein expression of p62 and PTEN. Also, the proliferation of CRC cells was measured by MTT assay.
   Results: The expression of PTEN gene in the experimental group was significantly inhibited as compared with the control group, while the expression of P62 gene was significantly increased (p < 0.05). Western blotting demonstrated that the PTEN protein in the experimental group was lower, while the expression of P62 protein was higher. When the CRC cells were transfected with pEGFP-N1-PTEN plasmid, the PTEN expressions were elevated, while p62 was down-regulated. Also, the proliferation of CRC cells was inhibited.
   Conclusion: The expression of PTEN gene is negatively correlated with the expression of P62 gene in rat CRC cells. And the expression of PTEN gene can inhibit the occurrence and development of colorectal cancer, thus providing theoretical basis for future clinical treatment. (C) 2019 Production and hosting by Elsevier B.V. on behalf of King Saud University.
C1 [Zhang, Li-ze; Zhao, Gang] Qingdao Univ, Dept Anorectal, Affiliated Hosp, Qingdao 266555, Shandong, Peoples R China.
   [Qi, Wen-hai] Yanan Univ, Dept Anorectal Surg, Affiliated Hosp, Yanan 716000, Peoples R China.
   [Liu, Lin-xun] Qinghai Prov Peoples Hosp, Dept Gen Surg, Xining 410035, Qinghai, Peoples R China.
   [Xue, Hui] Qingdao Hiser Hosp, Dept Gynecol, Qingdao 266000, Shandong, Peoples R China.
   [Hu, Wen-xiu] Inner Mongolia Med Univ, Dept Gen Surg, Affiliated Hosp, Hohhot 010050, Peoples R China.
   [Wang, Qian-qian] Qingdao Univ, Dept Anorectal, Songshan Hosp, Qingdao 266042, Shandong, Peoples R China.
   [Li, Chun-sheng] Jilin Univ, Gastrointestinal Colorectal & Anal Surg, China Japan Union Hosp, Changchun 130033, Jilin, Peoples R China.
RP Li, CS (corresponding author), Jilin Univ, Gastrointestinal Colorectal & Anal Surg, China Japan Union Hosp, Changchun 130033, Jilin, Peoples R China.
EM orf046@163.com
RI Zong, Guangdeng/AAA-3896-2020
OI Lize, Zhang/0000-0002-7241-2683
CR Chatenoud L, 2016, INT J CANCER, V138, P833, DOI 10.1002/ijc.29833
   Cheng MR, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-166
   Falchetti A, 2005, ARTHRITIS RES THER, V7, pR1289, DOI 10.1186/ar1828
   Forastiere AA, 2018, J CLIN ONCOL, V36, P1143, DOI 10.1200/JCO.2017.75.7385
   Haapaniemi A, 2016, HEAD NECK-J SCI SPEC, V38, P36, DOI 10.1002/hed.23834
   Korn T, 2007, NATURE, V448, P484, DOI 10.1038/nature05970
   Lague MN, 2008, CARCINOGENESIS, V29, P2062, DOI 10.1093/carcin/bgn186
   Lipkowitz S, 2003, BREAST CANCER RES, V5, P8, DOI 10.1186/bcr541
   McCabe Nuala, 2016, Oncoscience, V3, P54
   Ortega-Molina A, 2013, TRENDS ENDOCRIN MET, V24, P184, DOI 10.1016/j.tem.2012.11.002
   Slattery ML, 2010, CARCINOGENESIS, V31, P1604, DOI 10.1093/carcin/bgq142
   Steuer CE, 2017, CA-CANCER J CLIN, V67, P32, DOI 10.3322/caac.21386
   Xiao J, 2015, GENE DEV, V29, P184, DOI 10.1101/gad.252528.114
   Zhang YX, 2018, ONCOTARGETS THER, V11, P2037, DOI 10.2147/OTT.S147855
   Zhao D, 2017, NATURE, V542, P484, DOI 10.1038/nature21357
   Zhu JJ, 2012, ONCOL REP, V28, P2290, DOI 10.3892/or.2012.2065
NR 16
TC 3
Z9 3
U1 0
U2 1
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1319-562X
J9 SAUDI J BIOL SCI
JI Saudi J. Biol. Sci.
PD DEC
PY 2019
VL 26
IS 8
BP 1986
EP 1990
DI 10.1016/j.sjbs.2019.08.006
PG 5
WC Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Life Sciences & Biomedicine - Other Topics
GA JV3YY
UT WOS:000502303000013
PM 31885487
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Anwar, MA
   Abou Kheir, W
   Eid, S
   Fares, J
   Liu, XQ
   Eid, AH
   Eid, AA
AF Anwar, M. Akhtar
   Abou Kheir, Wassim
   Eid, Stephanie
   Fares, Joanna
   Liu, Xiaoqi
   Eid, Ali H.
   Eid, Assaad A.
TI Colorectal and Prostate Cancer Risk in Diabetes: Metformin, an Actor
   behind the Scene
SO JOURNAL OF CANCER
LA English
DT Review
DE Diabetes; Colorectal Cancer; Prostate Cancer; Metformin; AMPK; mTOR
ID ACTIVATED PROTEIN-KINASE; COENZYME-A REDUCTASE; ABERRANT CRYPT FOCI;
   IN-VITRO; AMPK; INHIBITION; PHOSPHORYLATION; MELLITUS; EPIGENETICS;
   APOPTOSIS
AB Both diabetes and cancer are prevalent diseases whose incidence rates are increasing worldwide, especially in countries that are undergoing rapid industrialization changes. Apparently, lifestyle risk factors including diet, physical inactivity and obesity play pivotal, yet preventable, roles in the etiology of both diseases. Epidemiological studies provide strong evidence that subjects with diabetes are at significantly higher risk of developing many forms of cancer and especially solid tumors. In addition to pancreatic and breast cancer, the incidence of colorectal cancer and prostate cancer is increased in type 2 diabetes. While diabetes (type 2) and cancer share many risk factors, the biological links between the two diseases are poorly characterized. In this review, we highlight the mechanistic pathways that link diabetes to colorectal and prostate cancer and the use of Metformin, a diabetes drug, to prevent and/or treat colorectal and prostate cancer. We review the role of AMPK activation in autophagy, oxidative stress, inflammation, apoptosis, and cell cycle progression.
C1 [Anwar, M. Akhtar; Eid, Ali H.] Qatar Univ, Dept Biol & Environm Sci, Coll Arts & Sci, Doha, Qatar.
   [Abou Kheir, Wassim; Eid, Stephanie; Fares, Joanna; Eid, Assaad A.] Amer Univ Beirut, Dept Anat Cell Biol & Physiol, Fac Med, Beirut 11072020, Lebanon.
   [Liu, Xiaoqi] Purdue Univ, Dept Biochem, W Lafayette, IN 47907 USA.
RP Eid, AA (corresponding author), Amer Univ Beirut, Dept Anat Cell Biol & Physiol, Fac Med, Bliss St 11-0236, Beirut 11072020, Lebanon.
EM ali.eid@qu.edu.qa; ae49@aub.edu.lb
RI Eid, Ali Hussein/ABD-6291-2021; Abou-Kheir, Wassim/AAP-2587-2020
OI Eid, Ali Hussein/0000-0003-3004-5675; Abou-Kheir,
   Wassim/0000-0001-9719-9324; Eid, Stephanie/0000-0003-3775-7544
FU Qatar National Research Fund (a member of Qatar Foundation) [NPRP
   5-409-3-112]
FX This publication was made possible by grant # NPRP 5-409-3-112 from the
   Qatar National Research Fund (a member of Qatar Foundation). The
   Statements made herein are solely the responsibility of the authors.
CR Rojas LBA, 2013, DIABETOL METAB SYNDR, V5, DOI 10.1186/1758-5996-5-6
   Aleksandrova Krasimira, 2013, Curr Nutr Rep, V2, P1
   Algire C, 2010, ENDOCR-RELAT CANCER, V17, P351, DOI 10.1677/ERC-09-0252
   Anisimov VN, 2005, EXP GERONTOL, V40, P685, DOI 10.1016/j.exger.2005.07.007
   Ashokkumar N., 2006, Archives of Physiology and Biochemistry, V112, P174, DOI 10.1080/13813450600935339
   Bailey CJ, 1996, NEW ENGL J MED, V334, P574, DOI 10.1056/NEJM199602293340906
   Batandier C, 2006, J BIOENERG BIOMEMBR, V38, P33, DOI 10.1007/s10863-006-9003-8
   Ben Sahra I, 2008, ONCOGENE, V27, P3576, DOI 10.1038/sj.onc.1211024
   Block K, 2012, NAT REV CANCER, V12, P627, DOI 10.1038/nrc3339
   Bowker SL, 2006, DIABETES CARE, V29, P254, DOI 10.2337/diacare.29.02.06.dc05-1558
   Brusselmans K, 2005, CANCER RES, V65, P6719, DOI 10.1158/0008-5472.CAN-05-0571
   Caballero AE, 2004, J CLIN ENDOCR METAB, V89, P3943, DOI 10.1210/jc.2004-0019
   Chen LG, 2010, J PHARMACOL EXP THER, V335, P42, DOI 10.1124/jpet.110.170159
   Chen L, 2010, LAB INVEST, V90, P762, DOI 10.1038/labinvest.2010.36
   CLARKE PR, 1990, EMBO J, V9, P2439, DOI 10.1002/j.1460-2075.1990.tb07420.x
   Crea F, 2011, DRUG RESIST UPDATE, V14, P280, DOI 10.1016/j.drup.2011.08.001
   Deng LY, 2012, DIGEST DIS SCI, V57, P1576, DOI 10.1007/s10620-012-2055-1
   Egan DF, 2011, SCIENCE, V331, P456, DOI 10.1126/science.1196371
   El-Mir MY, 2000, J BIOL CHEM, V275, P223, DOI 10.1074/jbc.275.1.223
   ENDO A, 1976, FEBS LETT, V72, P323, DOI 10.1016/0014-5793(76)80996-9
   Esposito K, 2012, DIABETES CARE, V35, P2402, DOI 10.2337/dc12-0336
   Evans JMM, 2005, BMJ-BRIT MED J, V330, P1304, DOI 10.1136/bmj.38415.708634.F7
   Goetz ME, 2008, CANCER LETT, V266, P73, DOI 10.1016/j.canlet.2008.02.035
   Goldstein JL, 2006, CELL, V124, P35, DOI 10.1016/j.cell.2005.12.022
   Graham GG, 2011, CLIN PHARMACOKINET, V50, P81, DOI 10.2165/11534750-000000000-00000
   Greer EL, 2007, J BIOL CHEM, V282, P30107, DOI 10.1074/jbc.M705325200
   Gwinn DM, 2008, MOL CELL, V30, P214, DOI 10.1016/j.molcel.2008.03.003
   Harborne LR, 2005, J CLIN ENDOCR METAB, V90, P4593, DOI 10.1210/jc.2004-2283
   Hardie DG, 2013, BMC BIOL, V11, DOI 10.1186/1741-7007-11-36
   Hardie DG, 2002, BIOCHEM SOC T, V30, P1064, DOI 10.1042/BST0301064
   Hosono K, 2010, CANCER PREV RES, V3, P1077, DOI 10.1158/1940-6207.CAPR-10-0186
   Hosono K, 2010, MOL CARCINOGEN, V49, P662, DOI 10.1002/mc.20637
   Hou XG, 2010, BIOCHEM BIOPH RES CO, V396, P199, DOI 10.1016/j.bbrc.2010.04.017
   Igata M, 2005, CIRC RES, V97, P837, DOI 10.1161/01.RES.0000185823.73556.06
   Inzucchi SE, 2002, JAMA-J AM MED ASSOC, V287, P360, DOI 10.1001/jama.287.3.360
   Istvan ES, 2001, SCIENCE, V292, P1160, DOI 10.1126/science.1059344
   Jeon SM, 2012, NATURE, V485, P661, DOI 10.1038/nature11066
   Kalender A, 2010, CELL METAB, V11, P390, DOI 10.1016/j.cmet.2010.03.014
   Kasper JS, 2009, INT J CANCER, V124, P1398, DOI 10.1002/ijc.24044
   Kim J, 2011, NAT CELL BIOL, V13, P132, DOI 10.1038/ncb2152
   Kim SA, 2012, BIOCHEM BIOPH RES CO, V425, P866, DOI 10.1016/j.bbrc.2012.07.165
   Kim YI, 1998, NUTR REV, V56, P275
   Kita Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043056
   Lambert MP, 2008, MOL ONCOL, V2, P33, DOI 10.1016/j.molonc.2008.03.005
   Larsson SC, 2005, JNCI-J NATL CANCER I, V97, P1679, DOI 10.1093/jnci/dji375
   Lee EK, 2012, NEPHRON EXP NEPHROL, V121, pE38, DOI 10.1159/000342802
   Lee JH, 2012, INT J CANCER, V131, P752, DOI 10.1002/ijc.26421
   Li XN, 2009, DIABETES, V58, P2246, DOI 10.2337/db08-1512
   Liang JY, 2007, NAT CELL BIOL, V9, P218, DOI 10.1038/ncb1537
   Liang JY, 2013, CANCER RES, V73, P2929, DOI 10.1158/0008-5472.CAN-12-3876
   MIYASHITA T, 1995, CELL, V80, P293
   Nelson WG, 2007, FRONT BIOSCI-LANDMRK, V12, P4254, DOI 10.2741/2385
   Notarnicola M, 2004, ANTICANCER RES, V24, P3837
   Noto H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033411
   Ouyang JY, 2011, J BIOL CHEM, V286, P1, DOI 10.1074/jbc.M110.121806
   Owen MR, 2000, BIOCHEM J, V348, P607, DOI 10.1042/0264-6021:3480607
   Peyton KJ, 2012, J PHARMACOL EXP THER, V342, P827, DOI 10.1124/jpet.112.194712
   Piwkowska A, 2010, BIOCHEM BIOPH RES CO, V393, P268, DOI 10.1016/j.bbrc.2010.01.119
   Ruiter R, 2012, DIABETES CARE, V35, P119, DOI 10.2337/dc11-0857
   Saenz A, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002966.pub3
   Schwabedissen HEMZ, 2010, AM J PHYSIOL-RENAL, V298, pF997, DOI 10.1152/ajprenal.00431.2009
   Sena CM, 2011, BRIT J PHARMACOL, V163, P424, DOI 10.1111/j.1476-5381.2011.01230.x
   Shaw RJ, 2009, ACTA PHYSIOL, V196, P65, DOI 10.1111/j.1748-1716.2009.01972.x
   Shu Y, 2007, J CLIN INVEST, V117, P1422, DOI 10.1172/JCI30558
   Song P, 2012, FREE RADICAL BIO MED, V52, P1607, DOI 10.1016/j.freeradbiomed.2012.01.025
   Soraya H, 2012, IRAN J BASIC MED SCI, V15, P1202
   Stocker SL, 2013, CLIN PHARMACOL THER, V93, P186, DOI 10.1038/clpt.2012.210
   Takane H, 2008, PHARMACOGENOMICS, V9, P415, DOI 10.2217/14622416.9.4.415
   Viollet B, 2012, CLIN SCI, V122, P253, DOI 10.1042/CS20110386
   Waters KM, 2009, AM J EPIDEMIOL, V169, P937, DOI 10.1093/aje/kwp003
   Witters LA, 2001, J CLIN INVEST, V108, P1105, DOI 10.1172/JCI14178
   Wright JL, 2009, CANCER CAUSE CONTROL, V20, P1617, DOI 10.1007/s10552-009-9407-y
   Xiang XQ, 2004, BIOCHEM BIOPH RES CO, V321, P161, DOI 10.1016/j.bbrc.2004.06.133
   Zakikhani M, 2008, CANCER PREV RES, V1, P369, DOI 10.1158/1940-6207.CAPR-08-0081
   Zhou GC, 2001, J CLIN INVEST, V108, P1167, DOI 10.1172/JCI200113505
   Zhou MY, 2007, DRUG METAB DISPOS, V35, P1956, DOI 10.1124/dmd.107.015495
   Zhuang Yongxian, 2008, J Mol Signal, V3, P18, DOI 10.1186/1750-2187-3-18
NR 77
TC 23
Z9 23
U1 1
U2 11
PU IVYSPRING INT PUBL
PI LAKE HAVEN
PA PO BOX 4546, LAKE HAVEN, NSW 2263, AUSTRALIA
SN 1837-9664
J9 J CANCER
JI J. Cancer
PY 2014
VL 5
IS 9
BP 736
EP 744
DI 10.7150/jca.9726
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA AY4OF
UT WOS:000347557400003
PM 25368673
OA Green Published, Green Submitted, gold
DA 2022-04-25
ER

PT J
AU Liu, SP
   Fei, WQ
   Shi, QL
   Li, Q
   Kuang, YY
   Wang, C
   He, C
   Hu, XT
AF Liu, Shuiping
   Fei, Weiqiang
   Shi, Qinglan
   Li, Qiang
   Kuang, Yeye
   Wang, Chan
   He, Chao
   Hu, Xiaotong
TI CHAC2, downregulated in gastric and colorectal cancers, acted as a tumor
   suppressor inducing apoptosis and autophagy through unfolded protein
   response
SO CELL DEATH & DISEASE
LA English
DT Article
ID MESSENGER-RNA; CELL-DEATH; ER STRESS; TRANSCRIPTION; ATF6; GENE; XBP1;
   MITOCHONDRIA; GLUTATHIONE; EXPRESSION
AB Tumor suppressor genes play a key role in cancer pathogenesis. Through massive expression profiling we identified CHAC2 as a frequently downregulated gene in gastric and colorectal cancers. Immunohistochemistry and western blot revealed that CHAC2 was downregulated in most tumor tissues, and 3-year survival rate of patients with high CHAC2 expression was significantly higher than that of patients with low CHAC2 expression (P<0.001 and P=0.001, respectively). The data of univariate analysis and multivariate analysis suggested that CHAC2 could serve as an independent prognostic marker. Our results showed for the first time that CHAC2 was degraded by the ubiquitin-proteasome pathway and CHAC2 expression inhibited tumor cell growth, proliferation, migration in vitro and in vivo. Mechanistic study showed that CHAC2 induced mitochondrial apoptosis and autophagy through unfolded protein response. So in gastric and colorectal cancer CHAC2 acted as a tumor suppressor and might have therapeutic implication for patients.
C1 [Liu, Shuiping; Fei, Weiqiang; Shi, Qinglan; Li, Qiang; Kuang, Yeye; Wang, Chan; He, Chao; Hu, Xiaotong] Zhejiang Univ, Sir Run Run Shaw Hosp, Biomed Res Ctr, Hangzhou 310016, Zhejiang, Peoples R China.
   [Liu, Shuiping; Fei, Weiqiang; Shi, Qinglan; Li, Qiang; Kuang, Yeye; Wang, Chan; He, Chao; Hu, Xiaotong] Zhejiang Univ, Sir Run Run Shaw Hosp, Key Lab Biotherapy Zhejiang Prov, Hangzhou 310016, Zhejiang, Peoples R China.
RP Hu, XT (corresponding author), Zhejiang Univ, Sir Run Run Shaw Hosp, Biomed Res Ctr, Hangzhou 310016, Zhejiang, Peoples R China.; Hu, XT (corresponding author), Zhejiang Univ, Sir Run Run Shaw Hosp, Key Lab Biotherapy Zhejiang Prov, Hangzhou 310016, Zhejiang, Peoples R China.
EM huxt@srrsh.com
RI Hu, Xiao-tong/K-5820-2019
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81071651, 81372622, 81672362]; Natural
   Science Foundation of Zhejiang ProvinceNatural Science Foundation of
   Zhejiang Province [LQ17H160009]
FX This study was supported by National Natural Science Foundation of China
   (81071651, 81372622 and 81672362) and Natural Science Foundation of
   Zhejiang Province (LQ17H160009).
CR Acosta-Alvear D, 2007, MOL CELL, V27, P53, DOI 10.1016/j.molcel.2007.06.011
   Ameri K, 2008, INT J BIOCHEM CELL B, V40, P14, DOI 10.1016/j.biocel.2007.01.020
   Anandasabapathy N, 2003, IMMUNITY, V18, P535, DOI 10.1016/S1074-7613(03)00084-0
   Avalos Y, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/603980
   Bito Virginie, 2015, Cold Spring Harb Protoc, V2015, P392, DOI 10.1101/pdb.prot076950
   Calfon M, 2002, NATURE, V415, P92, DOI 10.1038/415092a
   Crawford RR, 2015, J BIOL CHEM, V290, P15878, DOI 10.1074/jbc.M114.635144
   Dong Z, 1998, AM J PATHOL, V152, P231
   Franco R, 2009, CELL DEATH DIFFER, V16, P1303, DOI 10.1038/cdd.2009.107
   Fujiwara S, 2016, J BIOL CHEM, V291, P6813, DOI 10.1074/jbc.M115.678953
   Goebel G, 2012, BRIT J CANCER, V106, P189, DOI 10.1038/bjc.2011.510
   Guais A, 2006, GENE, V374, P112, DOI 10.1016/j.gene.2006.01.028
   Haze K, 1999, MOL BIOL CELL, V10, P3787, DOI 10.1091/mbc.10.11.3787
   Hu XT, 2013, J PATHOL, V229, P62, DOI 10.1002/path.4093
   Jiang PD, 2014, CELL RES, V24, P69, DOI 10.1038/cr.2013.161
   Kim I, 2008, NAT REV DRUG DISCOV, V7, P1013, DOI 10.1038/nrd2755
   Kroemer G, 2007, PHYSIOL REV, V87, P99, DOI 10.1152/physrev.00013.2006
   Kumar A, 2012, EMBO REP, V13, P1095, DOI 10.1038/embor.2012.156
   Lee AH, 2003, MOL CELL BIOL, V23, P7448, DOI 10.1128/MCB.23.21.7448-7459.2003
   Lee K, 2002, GENE DEV, V16, P452, DOI 10.1101/gad.964702
   Liu YQ, 2013, GENET MOL RES, V12, P4060, DOI 10.4238/2013.September.27.7
   Liu Yang, 2014, ScientificWorldJournal, V2014, P476219, DOI 10.1155/2014/476219
   Motloch LJ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148359
   Mungrue IN, 2009, J IMMUNOL, V182, P466, DOI 10.4049/jimmunol.182.1.466
   Nian H, 2008, CELL RES, V18, P800, DOI 10.1038/cr.2008.73
   Ogata M, 2006, MOL CELL BIOL, V26, P9220, DOI 10.1128/MCB.01453-06
   Oh-hashi K, 2013, MOL CELL BIOCHEM, V380, P97, DOI 10.1007/s11010-013-1663-1
   Panani AD, 2008, CANCER LETT, V266, P99, DOI 10.1016/j.canlet.2008.02.053
   Ron D, 2007, NAT REV MOL CELL BIO, V8, P519, DOI 10.1038/nrm2199
   Sako A, 2004, CANCER RES, V64, P3624, DOI 10.1158/0008-5472.CAN-04-0304
   Sankari SL, 2012, ASIAN PAC J CANCER P, V13, P4873, DOI 10.7314/APJCP.2012.13.10.4873
   Schroder M, 2005, ANNU REV BIOCHEM, V74, P739, DOI 10.1146/annurev.biochem.73.011303.074134
   Senft D, 2015, TRENDS BIOCHEM SCI, V40, P141, DOI 10.1016/j.tibs.2015.01.002
   Sui XB, 2014, CANCER LETT, V344, P174, DOI 10.1016/j.canlet.2013.11.019
   Tabas I, 2011, NAT CELL BIOL, V13, P184, DOI 10.1038/ncb0311-184
   Tait SWG, 2010, NAT REV MOL CELL BIO, V11, P621, DOI 10.1038/nrm2952
   Trafford AW, 1999, PFLUG ARCH EUR J PHY, V437, P501, DOI 10.1007/s004240050808
   Woehlbier U, 2011, TRENDS BIOCHEM SCI, V36, P329, DOI 10.1016/j.tibs.2011.03.001
   Yamamoto K, 2007, DEV CELL, V13, P365, DOI 10.1016/j.devcel.2007.07.018
   Yoshida H, 2001, CELL, V107, P881, DOI 10.1016/S0092-8674(01)00611-0
   Zhao J, 2012, J BIOL CHEM, V287, P19105, DOI 10.1074/jbc.M112.339507
   Zhu MT, 2008, TOXICOLOGY, V247, P102, DOI 10.1016/j.tox.2008.02.011
   Zoratto F, 2014, TUMOR BIOL, V35, P6195, DOI 10.1007/s13277-014-1845-9
NR 43
TC 8
Z9 8
U1 1
U2 14
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-4889
J9 CELL DEATH DIS
JI Cell Death Dis.
PD AUG
PY 2017
VL 8
AR e3009
DI 10.1038/cddis.2017.405
PG 13
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA FG1JB
UT WOS:000409550500047
PM 28837156
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Ghavami, S
   Asoodeh, A
   Klonisch, T
   Halayko, AJ
   Kadkhoda, K
   Kroczak, TJ
   Gibson, SB
   Booy, EP
   Naderi-Manesh, H
   Los, M
AF Ghavami, Saeid
   Asoodeh, Ahmad
   Klonisch, Thomas
   Halayko, Andrew J.
   Kadkhoda, Kamran
   Kroczak, Tadeusz J.
   Gibson, Spencer B.
   Booy, Evan P.
   Naderi-Manesh, Hossein
   Los, Marek
TI Brevinin-2R(1) semi-selectively kills cancer cells by a distinct
   mechanism, which involves the lysosomal-mitochondrial death pathway
SO JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
LA English
DT Article
DE antibacterial peptide; defensin; Brevinin-2R; cell death; caspase
   activation; lysosomotrophic agent; late and early endosome; ROS;
   mitochondrial pathway; targetted cancer therapy
ID KAPPA-B ACTIVATION; ANTIMICROBIAL PEPTIDES; RANA-ESCULENTA; INDUCED
   APOPTOSIS; OXIDATIVE STRESS; CYTOCHROME-C; SOLID TUMORS; CATHEPSIN-D;
   BH3 DOMAIN; EXPRESSION
AB Brevinin-2R is a novel non-hemolytic defensin that was isolated from the skin of the frog Rana ridibunda. It exhibits preferential cytotoxicity towards malignant cells, including Jurkat (T-cell leukemia), BJAB (B-cell lymphoma), HT29/219, SW742 (colon carcinomas), L929 (fibrosarcoma), MCF-7 (breast adenocarcinoma), A549 (lung carcinoma), as compared to primary cells including peripheral blood mononuclear cells (PBMC), T cells and human lung fibroblasts. Jurkat and MCF-7 cells overexpressing Bcl2, and L929 and MCF-7 over-expressing a dominant-negative mutant of a pro-apoptotic BNIP3 (Delta TM-BNIP3) were largely resistant towards Brevinin-2R treatment. The decrease in mitochondrial membrane potential (Delta Psi m), or total cellular ATP levels, and increased reactive oxygen species (ROS) production, but not caspase activation or the release of apoptosis-inducing factor (AIF) or endonuclease G (Endo G), were early indicators of Brevinin-2R-triggered death. Brevinin-2R interacts with both early and late endosomes. Lysosomal membrane permeabilization inhibitors and inhibitors of cathepsin-B and cathepsin-L prevented Brevinin-2R-induced cell death. Autophagosomes have been detected upon Brevinin-2R treatment. Our results show that Brevinin-2R activates the lysosomalmitochondrial death pathway, and involves autophagy-like cell death.
C1 [Los, Marek] BioApplicat Enterprises, Winnipeg, MB R2V 2N6, Canada.
   [Ghavami, Saeid; Kadkhoda, Kamran; Kroczak, Tadeusz J.; Gibson, Spencer B.; Booy, Evan P.] Manitoba Inst Cell Biol, Dept Biochem & Med Genet, Winnipeg, MB R3E 0V9, Canada.
   [Asoodeh, Ahmad; Naderi-Manesh, Hossein] Tarbiat Modares Univ, Fac Basic Sci, Dept Biophys & Biochem, Tehran, Iran.
   [Asoodeh, Ahmad] Ferdowsi Univ Mashhad, Fac Sci, Dept Chem, Mashhad, Iran.
   [Klonisch, Thomas] Univ Manitoba, Fac Med, Dept Human Anat & Cell Sci, Winnipeg, MB, Canada.
   [Halayko, Andrew J.] Univ Manitoba, Dept Physiol, Winnipeg, MB, Canada.
RP Los, M (corresponding author), BioApplicat Enterprises, 34 Vanier Dr, Winnipeg, MB R2V 2N6, Canada.
EM bioappl@gmail.com
RI Asoodeh, Ahmad/H-1484-2011; Ghavami, Saeid/Q-8918-2016; Klonisch,
   Thomas/W-9923-2019
OI Asoodeh, Ahmad/0000-0002-1406-0595; Naderi-Manesh,
   Hossein/0000-0002-4227-171X; Los, Marek/0000-0001-9518-1411; Ghavami,
   Saeid/0000-0001-5948-508X; Gibson, Spencer/0000-0003-0119-732X
CR BAKER MA, 1993, CANCER RES, V53, P3052
   Banerji S, 2006, CANCER BIOL THER, V5, P965, DOI 10.4161/cbt.5.8.3274
   Barczyk K, 2005, INT J CANCER, V116, P167, DOI 10.1002/ijc.21037
   BOMAN HG, 1995, ANNU REV IMMUNOL, V13, P61, DOI 10.1146/annurev.iy.13.040195.000425
   Borner C, 1999, CELL DEATH DIFFER, V6, P497, DOI 10.1038/sj.cdd.4400525
   Broker LE, 2004, CANCER RES, V64, P27, DOI 10.1158/0008-5472.CAN-03-3060
   Brotz H, 2000, J ANTIMICROB CHEMOTH, V46, P1, DOI 10.1093/jac/46.1.1
   Brunk UT, 1999, REDOX REP, V4, P3, DOI 10.1179/135100099101534675
   Bursch W, 2001, CELL DEATH DIFFER, V8, P569, DOI 10.1038/sj.cdd.4400852
   Chan SC, 1998, ANTICANCER RES, V18, P4467
   Chen HM, 1997, BBA-GEN SUBJECTS, V1336, P171, DOI 10.1016/S0304-4165(97)00024-X
   Conlon JM, 2004, COMP BIOCHEM PHYS C, V137, P191, DOI 10.1016/j.cca.2004.01.003
   Conlon JM, 2004, REGUL PEPTIDES, V118, P135, DOI 10.1016/j.regpep.2003.12.003
   Conlon JM, 2004, BBA-PROTEINS PROTEOM, V1696, P1, DOI 10.1016/j.bbapap.2003.09.004
   CONNOR J, 1989, P NATL ACAD SCI USA, V86, P3184, DOI 10.1073/pnas.86.9.3184
   CRUCIANI RA, 1991, P NATL ACAD SCI USA, V88, P3792, DOI 10.1073/pnas.88.9.3792
   Dathe M, 2001, FEBS LETT, V501, P146, DOI 10.1016/S0014-5793(01)02648-5
   Dimarcq JL, 1998, BIOPOLYMERS, V47, P465, DOI 10.1002/(SICI)1097-0282(1998)47:6<465::AID-BIP5>3.0.CO;2-#
   Duda TF, 2002, MOL BIOL EVOL, V19, P858, DOI 10.1093/oxfordjournals.molbev.a004143
   DUELLMAN W, 2004, COMP BIOCH PHYSL C, V137, P191
   Epand R, 2003, BIOPOLYMERS, V71, P2, DOI 10.1002/bip.10372
   Foghsgaard L, 2001, J CELL BIOL, V153, P999, DOI 10.1083/jcb.153.5.999
   Ganz T, 1998, CURR OPIN IMMUNOL, V10, P41, DOI 10.1016/S0952-7915(98)80029-0
   Ganz T, 2004, CR BIOL, V327, P539, DOI 10.1016/j.crvi.2003.12.007
   Ghavami S, 2005, MED SCI MONITOR, V11, pRA337
   Ghavami Saeid, 2005, P323, DOI 10.1007/0-387-23695-3_15
   Goraya J, 2000, EUR J BIOCHEM, V267, P894, DOI 10.1046/j.1432-1327.2000.01074.x
   Guicciardi ME, 2000, J CLIN INVEST, V106, P1127, DOI 10.1172/JCI9914
   Hancock REW, 2002, FEMS MICROBIOL LETT, V206, P143, DOI 10.1016/S0378-1097(01)00480-3
   Hancock REW, 2000, TRENDS MICROBIOL, V8, P402, DOI 10.1016/S0966-842X(00)01823-0
   Hashemi M, 2005, CELL PROLIFERAT, V38, P269, DOI 10.1111/j.1365-2184.2005.00349.x
   Hashemi M, 2007, EUR J PHARMACOL, V557, P9, DOI 10.1016/j.ejphar.2006.11.010
   Hill Michelle M, 2003, Mol Interv, V3, P19, DOI 10.1124/mi.3.1.19
   Hinton M, 2006, AM J PHYSIOL-LUNG C, V290, pL375, DOI 10.1152/ajplung.00307.2005
   Izyumov DS, 2004, BBA-BIOENERGETICS, V1658, P141, DOI 10.1016/j.bbabio.2004.05.007
   Jaattela M, 2003, NAT IMMUNOL, V4, P416, DOI 10.1038/ni0503-416
   Johansson J, 1998, J BIOL CHEM, V273, P3718, DOI 10.1074/jbc.273.6.3718
   Jones B, 1998, AM J PHYSIOL-GASTR L, V275, pG723, DOI 10.1152/ajpgi.1998.275.4.G723
   Kitanaka C, 2002, J NATL CANCER I, V94, P358
   KOGEL D, 2003, CASPASES THEIR ROLE, P237
   Kougias P, 2005, J CELL MOL MED, V9, P3, DOI 10.1111/j.1582-4934.2005.tb00332.x
   Krzemieniecki K, 2006, CENT EUR J BIOL, V1, P167, DOI 10.2478/s11535-006-0014-6
   Kwon MY, 1998, BBA-PROTEIN STRUCT M, V1387, P239, DOI 10.1016/S0167-4838(98)00123-X
   Leist M, 1997, J EXP MED, V185, P1481, DOI 10.1084/jem.185.8.1481
   Li LY, 2001, NATURE, V412, P95, DOI 10.1038/35083620
   LICHTENSTEIN A, 1986, BLOOD, V68, P1407
   Los M, 1999, IMMUNITY, V10, P629, DOI 10.1016/S1074-7613(00)80062-X
   Los M, 2002, MOL BIOL CELL, V13, P978, DOI 10.1091/mbc.01-05-0272
   LOS M, 1995, EMBO J, V14, P3731, DOI 10.1002/j.1460-2075.1995.tb00043.x
   Maddika S, 2006, CANCER BIOL THER, V5, P10, DOI 10.4161/cbt.5.1.2400
   Maddika S, 2005, J CELL SCI, V118, P4485, DOI 10.1242/jcs.02580
   Mai JC, 2001, CANCER RES, V61, P7709
   Mangoni ML, 2003, PEPTIDES, V24, P1771, DOI 10.1016/j.peptides.2003.07.029
   Marsden VS, 2003, ANNU REV IMMUNOL, V21, P71, DOI 10.1146/annurev.immunol.21.120601.141029
   Matsuzaki K, 2001, BIOCHEM SOC T, V29, P598, DOI 10.1042/BST0290598
   Mellman I, 1996, CURR OPIN CELL BIOL, V8, P497, DOI 10.1016/S0955-0674(96)80026-3
   Menestrina G, 2003, FEBS LETT, V552, P54, DOI 10.1016/S0014-5793(03)00850-0
   Minn I, 1998, BBA-MOL BASIS DIS, V1407, P31, DOI 10.1016/S0925-4439(98)00023-4
   Mukherjee S, 1997, PHYSIOL REV, V77, P759, DOI 10.1152/physrev.1997.77.3.759
   NICOLAS P, 1995, ANNU REV MICROBIOL, V49, P277, DOI 10.1146/annurev.mi.49.100195.001425
   Papo N, 2005, CELL MOL LIFE SCI, V62, P784, DOI 10.1007/s00018-005-4560-2
   Papo N, 2003, PEPTIDES, V24, P1693, DOI 10.1016/j.peptides.2003.09.013
   Papo N, 2003, J BIOL CHEM, V278, P21018, DOI 10.1074/jbc.M211204200
   Popescu LM, 2005, J CELL MOL MED, V9, P2, DOI 10.1111/j.1582-4934.2005.tb00331.x
   Ray R, 2000, J BIOL CHEM, V275, P1439, DOI 10.1074/jbc.275.2.1439
   Rich T, 2000, NATURE, V407, P777, DOI 10.1038/35037717
   Roberg K, 2002, AM J PATHOL, V161, P89, DOI 10.1016/S0002-9440(10)64160-0
   Roberg K, 2001, LAB INVEST, V81, P149, DOI 10.1038/labinvest.3780222
   Sanderson MJ, 2000, SYST BIOL, V49, P671, DOI 10.1080/106351500750049761
   Sarin A, 1997, IMMUNITY, V6, P209, DOI 10.1016/S1074-7613(00)80427-6
   SIMMACO M, 1990, BIOCHIM BIOPHYS ACTA, V1033, P318, DOI 10.1016/0304-4165(90)90140-R
   Skulachev VP, 2002, ANN NY ACAD SCI, V959, P214, DOI 10.1111/j.1749-6632.2002.tb02095.x
   Susin SA, 2000, J EXP MED, V192, P571, DOI 10.1084/jem.192.4.571
   Szalai G, 1999, EMBO J, V18, P6349, DOI 10.1093/emboj/18.22.6349
   THENNARASU S, 1995, INT J PEPT PROT RES, V46, P480
   Thorburn A, 2004, CELL SIGNAL, V16, P139, DOI 10.1016/j.cellsig.2003.08.007
   Tossi A, 2000, BIOPOLYMERS, V55, P4
   UTSUGI T, 1991, CANCER RES, V51, P3062
   Van De Water TR, 2004, OTOL NEUROTOL, V25, P627, DOI 10.1097/00129492-200407000-00035
   Wong BR, 1998, J BIOL CHEM, V273, P28355, DOI 10.1074/jbc.273.43.28355
   Xue L, 2001, CURR BIOL, V11, P361, DOI 10.1016/S0960-9822(01)00100-2
   Yasuda M, 1998, J BIOL CHEM, V273, P12415, DOI 10.1074/jbc.273.20.12415
   Yuan XM, 2002, P NATL ACAD SCI USA, V99, P6286, DOI 10.1073/pnas.092135599
   Zasloff M, 2002, NEW ENGL J MED, V347, P1199, DOI 10.1056/NEJMe020106
   ZELEZETSKY I, 2005, PEPTIDES
   Zuse A, 2007, EUR J PHARMACOL, V575, P34, DOI 10.1016/j.ejphar.2007.07.050
   Zwaal RFA, 1997, BLOOD, V89, P1121, DOI 10.1182/blood.V89.4.1121
NR 87
TC 123
Z9 130
U1 1
U2 30
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1582-1838
EI 1582-4934
J9 J CELL MOL MED
JI J. Cell. Mol. Med.
PD JUN
PY 2008
VL 12
IS 3
BP 1005
EP 1022
DI 10.1111/j.1582-4934.2008.00129.x
PG 18
WC Cell Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA 304JG
UT WOS:000256105200020
PM 18494941
OA Green Published
DA 2022-04-25
ER

PT J
AU Yan, JH
   Dou, XY
   Zhou, J
   Xiong, YF
   Mo, L
   Li, LH
   Lei, YL
AF Yan, Jianghong
   Dou, Xiaoyun
   Zhou, Jing
   Xiong, Yuanfeng
   Mo, Ling
   Li, Longhao
   Lei, Yunlong
TI Tubeimoside-I sensitizes colorectal cancer cells to chemotherapy by
   inducing ROS-mediated impaired autophagolysosomes accumulation
SO JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
LA English
DT Article
DE Tubeimoside-I; Autophagy; ROS; AMPK; Chemosensitivity
ID MITOCHONDRIAL DYSFUNCTION; CYTOCHROME-C; PHASE ARREST; AUTOPHAGY;
   APOPTOSIS; CYTOTOXICITY; STATISTICS; GROWTH; AMPK
AB Background Tubeimoside-I (TBM), a plant-derived bioactive compound, shows antitumor activity in different tumors and can enhance the efficacy of chemotherapeutic agents. However, the detail mechanism underlying remains to be elucidated. Methods The cytotoxic potential of TBM towards CRC cells was examined by CCK8 assay, colony formation, LDH release assay, flow cytometry method and Western blots. The ROS levels, autophagy, apoptosis, chemosensitivity to 5-FU or DOX, etc. were determined between control and TBM-treated CRC cells. Results In this study, we found that TBM could inhibit proliferation and induce apoptosis in colorectal cancer (CRC) cells. Intriguingly, TBM treatment could either promote autophagy initiation by ROS-induced AMPK activation, or block autophagy flux through inhibiting lysosomal hydrolytic enzymes, which leaded to massive impaired autophagylysosomes accumulation. Administration of autophagy initiation inhibitor (3-MA or selective ablation of autophagy related proteins) relieves TBM-induced CRC suppression, while combination use of autophagy flux inhibitor chloroquine (CQ) slightly augments TBM-induced cell death, suggesting that impaired autophagylysosomes accumulation contributes to TBM-induced growth inhibition in CRC cells. Notably, as an autophagy flux inhibitor, TBM works synergistically with 5-fluorouracil (5-FU) or doxorubicin (DOX) in CRC suppression. Conclusion Together, our study provides new insights regarding the anti-tumor activity of TBM against CRC, and established potential applications of TBM for CRC combination therapies in clinic.
C1 [Yan, Jianghong; Dou, Xiaoyun] Chongqing Med Univ, Inst Life Sci, Chongqing 400016, Peoples R China.
   [Yan, Jianghong; Xiong, Yuanfeng; Mo, Ling] Chongqing Med Univ, Dept Med Lab Technol, Chongqing 400016, Peoples R China.
   [Li, Longhao] Chongqing Med Univ, Dept Oncol, Affiliated Hosp 1, Chongqing 400016, Peoples R China.
   [Zhou, Jing; Lei, Yunlong] Chongqing Med Univ, Dept Biochem & Mol Biol & Mol Med, Chongqing 400016, Peoples R China.
   [Zhou, Jing; Lei, Yunlong] Chongqing Med Univ, Canc Res Ctr, Chongqing 400016, Peoples R China.
RP Li, LH (corresponding author), Chongqing Med Univ, Dept Oncol, Affiliated Hosp 1, Chongqing 400016, Peoples R China.; Lei, YL (corresponding author), Chongqing Med Univ, Dept Biochem & Mol Biol & Mol Med, Chongqing 400016, Peoples R China.; Lei, YL (corresponding author), Chongqing Med Univ, Canc Res Ctr, Chongqing 400016, Peoples R China.
EM llh@hospital.cqmu.edu.cn; leiyunglong@cqmu.edu.cn
OI Lei, Yunlong/0000-0002-7918-0221
FU Chinese NSFCNational Natural Science Foundation of China (NSFC)
   [31400999, 81872014]; Scientific and Technological Research Program of
   Chongqing Municipal Education Commission [KJQN201800417, KJQN201800429]
FX This work was supported by grants from the Chinese NSFC (31400999,
   81872014), and Scientific and Technological Research Program of
   Chongqing Municipal Education Commission (Grant No. KJQN201800417,
   KJQN201800429).
CR Bian Q, 2015, INT J CLIN EXP PATHO, V8, P12517
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
   Brenner H, 2014, LANCET, V383, P1490, DOI 10.1016/S0140-6736(13)61649-9
   Chen D, 2016, J TRADIT CHIN MED, V36, P113, DOI 10.11772/j.issn.1001-9081.2016.01.0113
   Chen WJ, 2012, INT J ONCOL, V40, P535, DOI 10.3892/ijo.2011.1218
   Fang LM, 2017, ACTA PHARMACOL SIN, V38, P1305, DOI 10.1038/aps.2017.25
   Feng XP, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-1151-3
   Gewirtz DA, 2014, CANCER RES, V74, P647, DOI 10.1158/0008-5472.CAN-13-2966
   Hao WL, 2015, INT J CLIN EXP PATHO, V8, P12075
   Hardie DG, 2011, GENE DEV, V25, P1895, DOI 10.1101/gad.17420111
   Huang P, 2011, INT J MOL MED, V28, P579, DOI 10.3892/ijmm.2011.727
   Islam MS, 2019, EUR J MED CHEM, V162, P109, DOI 10.1016/j.ejmech.2018.11.001
   Jia G, 2015, ONCOTARGETS THER, V8, P303, DOI 10.2147/OTT.S76063
   Jiang S-L, 2018, ACTA PHARM SIN
   Kim J, 2011, NAT CELL BIOL, V13, P132, DOI 10.1038/ncb2152
   Klionsky DJ, 2016, AUTOPHAGY, V12, P1, DOI 10.1080/15548627.2015.1100356
   Lei YY, 2017, CANCER LETT, V393, P33, DOI 10.1016/j.canlet.2017.02.012
   Lei YL, 2015, MED RES REV, V35, P306, DOI 10.1002/med.21330
   Levy JMM, 2017, NAT REV CANCER, V17, P528, DOI 10.1038/nrc.2017.53
   Li J, 2010, EUR J CANCER, V46, P1900, DOI 10.1016/j.ejca.2010.02.021
   Liu HZ, 2011, MOL MED REP, V4, P985, DOI 10.3892/mmr.2011.513
   Miller KD, 2016, CA-CANCER J CLIN, V66, P271, DOI 10.3322/caac.21349
   Sasaki K, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-370
   SCHIMANSKI CC, 2011, J CLIN ONCOL S, V29, P1
   Siegel RL, 2017, CA-CANCER J CLIN, V67, P177, DOI 10.3322/caac.21395
   Sui X, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.350
   Wang F, 2006, CANCER CHEMOTH PHARM, V57, P389, DOI 10.1007/s00280-005-0047-y
   Wang K, 2019, TRENDS BIOCHEM SCI, V44, P401, DOI 10.1016/j.tibs.2019.01.001
   Wang S, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.485
   White E, 2015, J CLIN INVEST, V125, P42, DOI 10.1172/JCI73941
   Xie N, 2016, AUTOPHAGY, V12, P1507, DOI 10.1080/15548627.2016.1191857
   Xu Y, 2011, J PROTEOMICS, V75, P491, DOI 10.1016/j.jprot.2011.08.014
   Xu Y, 2009, J PROTEOME RES, V8, P1585, DOI 10.1021/pr801001j
   Yang JB, 2016, ACTA PHARMACOL SIN, V37, P950, DOI 10.1038/aps.2016.34
   YU LJ, 1994, PLANTA MED, V60, P204, DOI 10.1055/s-2006-959459
   Zhang L, 2015, FREE RADICAL BIO MED, V89, P452, DOI 10.1016/j.freeradbiomed.2015.08.030
   Zhao BZ, 2016, GENES DIS, V3, P82, DOI 10.1016/j.gendis.2015.12.002
   Zhou J, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0883-4
NR 38
TC 12
Z9 15
U1 3
U2 8
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1756-9966
J9 J EXP CLIN CANC RES
JI J. Exp. Clin. Cancer Res.
PD AUG 14
PY 2019
VL 38
IS 1
AR 353
DI 10.1186/s13046-019-1355-0
PG 13
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA IQ4WY
UT WOS:000480753500002
PM 31412953
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Ahn, JH
   Jang, GH
   Lee, M
AF Ahn, Jun-Ho
   Jang, Gun-Hee
   Lee, Michael
TI Defective autophagy in multidrug resistant cells may lead to growth
   inhibition by BH3-mimetic gossypol
SO JOURNAL OF CELLULAR PHYSIOLOGY
LA English
DT Article
ID BREAST-CANCER CELLS; COLON-CARCINOMA; GENE-EXPRESSION; MITOTIC ARREST;
   TUNEL ASSAY; APOPTOSIS; DEATH; (-)-GOSSYPOL; MECHANISM; INSIGHTS
AB The clinical efficacy of many chemotherapeutic agents has been reduced due to the development of drug resistance. In this article, we aimed to validate gossypol, a natural BH3 mimetic found in cottonseeds, as a potential therapeutic to overcome multidrug resistance (MDR). Gossypol was found to retain its efficacy in v-Ha-ras-transformed NIH 3T3 cells that overexpressed P-glycoprotein (Ras-NIH 3T3/Mdr), which was similar to the efficacy observed in their parental counterparts (Ras-NIH 3T3). A rhodamine assay revealed that the alteration of MDR activity did not contribute to the cytotoxic effect of gossypol. Gossypol caused a G2/M arrest by the induction of p21Cip1 and the down-regulation of p27Kip1 expression in Ras-NIH 3T3 cells, whereas no significant G2/M arrest was exhibited in Ras-NIH 3T3/Mdr cells. Surprisingly, a 48-h treatment with gossypol induced apoptotic cell death in Ras-NIH 3T3 cells; however, gossypol induced both apoptosis and necrosis in Ras-NIH 3T3/Mdr cells, as determined with flow cytometry analysis. More notably, gossypol preferentially induced autophagy in Ras-NIH 3T3 cells but not in Ras-NIH 3T3/Mdr cells. Coimmunoprecipitation and flow cytometric analysis revealed that gossypol-induced autophagy is independent of the dissociation of Beclin 1 from Bcl-2 in Ras-NIH 3T3 cells. Taken together, these results suggest that the antiproliferative activity of gossypol appears to be due to cell-cycle arrest at the G2/M phase, with the induction of apoptosis in Ras-NIH 3T3 cells. In addition, defective autophagy might contribute to apoptotic and necrotic cell death in response to gossypol in Ras-NIH 3T3/Mdr cells. J. Cell. Physiol. 228: 14961505, 2013. (c) 2012 Wiley Periodicals, Inc.
C1 [Ahn, Jun-Ho; Jang, Gun-Hee; Lee, Michael] Univ Incheon, Div Life Sci, Coll Life Sci & Bioengn, Inchon 406772, South Korea.
RP Lee, M (corresponding author), Univ Incheon, Div Life Sci, Coll Life Sci & Bioengn, 12-1 Songdo Dong, Inchon 406772, South Korea.
EM mikelee@incheon.ac.kr
FU Basic Science Research Program through the National Research Foundation
   of Korea (NRF); Ministry of Education, Science and TechnologyMinistry of
   Education, Science and Technology, Republic of Korea [2010-0022172]
FX This research was supported by Basic Science Research Program through
   the National Research Foundation of Korea (NRF) funded by the Ministry
   of Education, Science and Technology (2010-0022172).
CR Ahn J-H, 2002, BIOCHEM BIOPH RES CO, V417, P857
   Ahn JH, 2011, CANCER LETT, V310, P188, DOI 10.1016/j.canlet.2011.06.034
   Ahn JH, 2011, BIOMOL THER, V19, P174, DOI 10.4062/biomolther.2011.19.2.174
   Balakrishnan K, 2008, BLOOD, V112, P1971, DOI 10.1182/blood-2007-12-126946
   Balci A, 1999, TOHOKU J EXP MED, V189, P51, DOI 10.1620/tjem.189.51
   BENZ CC, 1990, MOL PHARMACOL, V37, P840
   Blagosklonny MV, 2007, CELL CYCLE, V6, P70, DOI 10.4161/cc.6.1.3682
   Chen SN, 2010, BBA-REV CANCER, V1806, P220, DOI 10.1016/j.bbcan.2010.07.003
   de Grouw EPLM, 2006, LEUKEMIA, V20, P750, DOI 10.1038/sj.leu.2404131
   Debnath J, 2005, AUTOPHAGY, V1, P66, DOI 10.4161/auto.1.2.1738
   Eisenberg-Lerner A, 2009, CELL DEATH DIFFER, V16, P966, DOI 10.1038/cdd.2009.33
   Etxebarria A, 2008, BIOCHEM PHARMACOL, V76, P1563, DOI 10.1016/j.bcp.2008.08.003
   Filippi-Chiela EC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020849
   Franken NAP, 2006, NAT PROTOC, V1, P2315, DOI 10.1038/nprot.2006.339
   Gao P, 2010, J BIOL CHEM, V285, P25570, DOI 10.1074/jbc.M110.118125
   Gartel AL, 2002, MOL CANCER THER, V1, P639
   GRASLKRAUPP B, 1995, HEPATOLOGY, V21, P1465, DOI 10.1016/0270-9139(95)90071-3
   Han J, 2012, ONCOL REP, V27, P517, DOI 10.3892/or.2011.1511
   JAROSZEWSKI JW, 1990, CANCER RES, V50, P6936
   Kim YK, 2012, BIOMOL THER, V20, P393, DOI 10.4062/biomolther.2012.20.4.393
   Kondo Y, 2005, NAT REV CANCER, V5, P726, DOI 10.1038/nrc1692
   Kong DJ, 2012, BIOMED PHARMACOTHER, V66, P271, DOI 10.1016/j.biopha.2011.12.002
   Lee M, 2009, CANCER RES TREAT, V41, P93, DOI 10.4143/crt.2009.41.2.93
   Lei XB, 2006, FASEB J, V20, P2147, DOI 10.1096/fj.05-5665fje
   Levine B, 2005, J CLIN INVEST, V115, P2679, DOI 10.1172/JCI26390
   Lian J, 2011, CELL DEATH DIFFER, V18, P60, DOI 10.1038/cdd.2010.74
   LIU G-Z, 1981, Reproduccion, V5, P189
   Liu SL, 2002, ANTICANCER RES, V22, P33
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Marcus AI, 2005, J BIOL CHEM, V280, P11569, DOI 10.1074/jbc.M413471200
   Meijer AJ, 2009, CRIT REV CL LAB SCI, V46, P210, DOI 10.1080/10408360903044068
   Meric-Bernstam F, 2009, J CLIN ONCOL, V27, P2278, DOI 10.1200/JCO.2008.20.0766
   Moretti L, 2007, DRUG RESIST UPDATE, V10, P135, DOI 10.1016/j.drup.2007.05.001
   Oliver CL, 2005, MOL CANCER THER, V4, P23
   Oliver CL, 2004, CLIN CANCER RES, V10, P7757, DOI 10.1158/1078-0432.CCR-04-0551
   Patel MP, 2009, CURR OPIN ONCOL, V21, P516, DOI 10.1097/CCO.0b013e328331a7a4
   Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002
   Priyadarshi A, 2010, BIOCHEM BIOPH RES CO, V394, P515, DOI 10.1016/j.bbrc.2010.03.002
   Shepu X, 1980, Sci Sin, V23, P642
   Shidaifat F, 1997, ANTICANCER RES, V17, P1003
   Stahelin BJ, 1998, J CLIN PATHOL-MOL PA, V51, P204
   TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8
   TUSZYNSKI GP, 1984, CANCER RES, V44, P768
   Xu L, 2005, MOL CANCER THER, V4, P197
   Ye WP, 2007, ANTICANCER RES, V27, P107
   Zhang MC, 2007, CLIN EXP PHARMACOL P, V34, P230, DOI 10.1111/j.1440-1681.2007.04577.x
   Zhang MC, 2003, BIOCHEM PHARMACOL, V66, P93, DOI 10.1016/S0006-2952(03)00248-X
NR 47
TC 12
Z9 12
U1 0
U2 54
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0021-9541
EI 1097-4652
J9 J CELL PHYSIOL
JI J. Cell. Physiol.
PD JUL
PY 2013
VL 228
IS 7
BP 1496
EP 1505
DI 10.1002/jcp.24305
PG 10
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Physiology
GA 113PX
UT WOS:000316681100016
PM 23254564
DA 2022-04-25
ER

PT J
AU Tuli, HS
   Mittal, S
   Aggarwal, D
   Parashar, G
   Parashar, NC
   Upadhyay, SK
   Barwal, TS
   Jain, A
   Kaur, G
   Savla, R
   Sak, K
   Kumar, M
   Varol, M
   Iqubal, A
   Sharma, AK
AF Tuli, Hardeep Singh
   Mittal, Sonam
   Aggarwal, Diwakar
   Parashar, Gaurav
   Parashar, Nidarshana Chaturvedi
   Upadhyay, Sushil Kumar
   Barwal, Tushar Singh
   Jain, Aklank
   Kaur, Ginpreet
   Savla, Raj
   Sak, Katrin
   Kumar, Manoj
   Varol, Mehmet
   Iqubal, Ashif
   Sharma, Anil Kumar
TI Path of Silibinin from diet to medicine: A dietary polyphenolic
   flavonoid having potential anti-cancer therapeutic significance
SO SEMINARS IN CANCER BIOLOGY
LA English
DT Article
DE Silibinin; Flavonolignans; Apoptosis; Cell cycle arrest;
   Anti-angiogenesis; Anti-metastasis; Clinical studies
ID CELL-CYCLE ARREST; INDUCED GROWTH-INHIBITION; SILYBUM-MARIANUM L.; LONG
   NONCODING RNAS; INDUCED AUTOPHAGIC DEATH; COLORECTAL-CANCER CELLS;
   PROSTATE TUMOR-GROWTH; CARCINOMA DU145 CELLS; NF-KAPPA-B; BREAST-CANCER
AB In the last few decades, targeting cancer by the use of dietary phytochemicals has gained enormous attention. The plausible reason and believe or mind set behind this fact is attributed to either lesser or no side effects of natural compounds as compared to the modern chemotherapeutics, or due to their conventional use as dietary components by mankind for thousands of years. Silibinin is a naturally derived polyphenol (a flavonolignans), possess following biochemical features; molecular formula C25H22O10, Molar mass: 482.44 g/mol, Boiling point 793 degrees C, with strikingly high antioxidant and anti-tumorigenic properties. The anti-cancer properties of Silibinin are determined by a variety of cellular pathways which include induction of apoptosis, cell cycle arrest, inhibition of angiogenesis and metastasis. In addition, Silibinin controls modulation of the expression of aberrant miRNAs, inflammatory response, and synergism with existing anti-cancer drugs. Therefore, modulation of a vast array of cellular responses and homeostatic aspects makes Silibinin an attractive chemotherapeutic agent. However, like other polyphenols, the major hurdle to declare Silibinin a translational chemotherapeutic agent, is its lesser bioavailability. After summarizing the chemistry and metabolic aspects of Silibinin, this extensive review focuses on functional aspects governed by Silibinin in chemoprevention with an ultimate goal of summarizing the evidence supporting the chemopreventive potential of Silibinin and clinical trials that are currently ongoing, at a single platform.
C1 [Tuli, Hardeep Singh; Aggarwal, Diwakar; Parashar, Gaurav; Parashar, Nidarshana Chaturvedi; Upadhyay, Sushil Kumar; Sharma, Anil Kumar] Maharishi Markandeshwar Deemed be Univ, Dept Biotechnol, Mullana Ambala 133207, Haryana, India.
   [Mittal, Sonam] Jawaharlal Nehru Univ, Sch Biotechnol, New Delhi, India.
   [Barwal, Tushar Singh; Jain, Aklank] Cent Univ Punjab, Dept Zool, Bathinda 151001, Punjab, India.
   [Kaur, Ginpreet; Savla, Raj] Shobhaben Pratapbhai Patel Sch Pharm & Technol Ma, Dept Pharmacol, SVKMs, NMIMS, Mumbai 400056, Maharashtra, India.
   [Sak, Katrin] NGO Praeventio, EE-50407 Tartu, Estonia.
   [Kumar, Manoj] Maharishi Markandeshwar Univ, Dept Chem, Sadopur, India.
   [Varol, Mehmet] Mugla Sitki Kocman Univ, Dept Mol Biol & Genet, Fac Sci, TR-48000 Mugla, Turkey.
   [Iqubal, Ashif] Jamia Hamdard Deemed be Univ, Sch Pharmaceut Educ & Res, Dept Pharmacol, Delhi, India.
RP Sharma, AK (corresponding author), Maharishi Markandeshwar Deemed be Univ, Dept Biotechnol, Mullana Ambala 133207, Haryana, India.
EM anibiotech18@gmail.com
RI VAROL, Mehmet/AES-2638-2022; Aggarwal, Diwakar/AAA-8306-2020; Tuli,
   Hardeep Singh/ABA-9917-2021; Upadhyay, Sushil Kumar/K-4640-2019;
   Chaturvedi Parashar, Dr. Nidarshana/ABF-7477-2021; Sak,
   Katrin/C-5517-2016
OI VAROL, Mehmet/0000-0003-2565-453X; Aggarwal,
   Diwakar/0000-0001-6920-4341; Tuli, Hardeep Singh/0000-0003-1155-0094;
   Upadhyay, Sushil Kumar/0000-0002-1229-4275; Sak,
   Katrin/0000-0003-0736-2525; Sharma, Anil/0000-0002-9768-1644; barwal,
   tushar singh/0000-0002-9989-4790; Iqubal, Ashif/0000-0003-4694-4851;
   Kumar, Manoj/0000-0002-2062-9602; Jain, Aklank/0000-0001-5539-3225
CR Agarwal C, 2003, ONCOGENE, V22, P8271, DOI 10.1038/sj.onc.1207158
   Alipour M, 2020, J BIOMED MATER RES A, V108, P458, DOI 10.1002/jbm.a.36827
   Althagafy HS, 2013, J ORG CHEM, V78, P7594, DOI 10.1021/jo4011377
   Amawi H, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00498
   Amiri Boshra, 2016, Asian Pac J Cancer Prev, V17, P3835
   Amirsaadat S, 2017, ARTIF CELL NANOMED B, V45, P1649, DOI 10.1080/21691401.2016.1276922
   Anestopoulos I, 2017, MOLECULES, V22, DOI 10.3390/molecules22010062
   Anwar S, 2018, INDIAN J PHARMACOL, V50, P108, DOI 10.4103/ijp.IJP_660_16
   Baghbahadorani Fahimeh Kaveh, 2017, Electron Physician, V9, P5098, DOI 10.19082/5098
   Bai ZL, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/6165192
   Vue B, 2016, EUR J MED CHEM, V109, P36, DOI 10.1016/j.ejmech.2015.12.041
   Barros TMB, 2020, ENVIRON MOL MUTAGEN, V61, P445, DOI 10.1002/em.22363
   Becker-Schiebe M, 2011, STRAHLENTHER ONKOL, V187, P485, DOI 10.1007/s00066-011-2204-z
   Belli V, 2017, ONCOTARGET, V8, P68305, DOI 10.18632/oncotarget.20054
   Biedermann D, 2014, NAT PROD REP, V31, P1138, DOI 10.1039/c3np70122k
   Bijak M, 2017, NUTRIENTS, V9
   Bijak M, 2017, MOLECULES, V22, DOI 10.3390/molecules22111942
   Binienda A., 2019, ANTICANCER AGENTS ME
   Byun HJ, 2017, ONCOL REP, V37, P3270, DOI 10.3892/or.2017.5588
   Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025
   Catanzaro D, 2018, FITOTERAPIA, V124, P42, DOI 10.1016/j.fitote.2017.10.007
   Chakrabarti M, 2016, APOPTOSIS, V21, P312, DOI 10.1007/s10495-015-1198-x
   Chakrabarti M, 2015, BRAIN RES, V1629, P85, DOI 10.1016/j.brainres.2015.10.010
   Chang HR, 2011, MOL CARCINOGEN, V50, P812, DOI 10.1002/mc.20756
   Chang YC, 2015, ONCOTARGET, V6, P24002, DOI 10.18632/oncotarget.4365
   Chatran M, 2018, DRUG RES, V68, P710, DOI 10.1055/a-0631-8046
   Chavoshi Hadi, 2017, Asian Pac J Cancer Prev, V18, P2243, DOI 10.22034/APJCP.2017.18.8.2243
   Cheung CWY, 2010, ANTI-CANCER AGENT ME, V10, P186
   Choi ES, 2017, CELL ONCOL, V40, P235, DOI 10.1007/s13402-017-0318-8
   Chu C, 2018, ARCH PHARM RES, V41, P785, DOI 10.1007/s12272-018-1047-x
   Comelli MC, 2007, INTEGR CANCER THER, V6, P120, DOI 10.1177/1534735407302349
   Cufii S, 2013, SCI REP-UK, V3, P1, DOI 10.1038/srep02459
   Dang CV, 1999, MOL CELL BIOL, V19, P1
   de Oliveira DT, 2017, J BIOSCIENCES, V42, P91, DOI 10.1007/s12038-016-9654-5
   De Talhouet S, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-63759-1
   Deep G, 2017, MOL CARCINOGEN, V56, P833, DOI 10.1002/mc.22537
   Deep G, 2014, MUTAT RES-FUND MOL M, V768, P35, DOI 10.1016/j.mrfmmm.2014.05.002
   Deep G, 2010, CANCER METAST REV, V29, P447, DOI 10.1007/s10555-010-9237-0
   Delmas D, 2020, MOLECULES, V25
   Desai UN, 2015, J CANCER RES THER, V11, P352, DOI 10.4103/0973-1482.157330
   Dhanalakshmi S, 2003, INT J CANCER, V106, P699, DOI 10.1002/ijc.11299
   Dheeraj A, 2017, PHOTOCHEM PHOTOBIOL, V93, P999, DOI 10.1111/php.12727
   Dong XY, 2017, ACTA PHARMACOL SIN, V38, P1655, DOI 10.1038/aps.2017.74
   Duan WJ, 2011, J ASIAN NAT PROD RES, V13, P27, DOI 10.1080/10286020.2010.540757
   Duan WJ, 2011, BIOL PHARM BULL, V34, P47, DOI 10.1248/bpb.34.47
   Duan WJ, 2010, J PHARMACOL SCI, V113, P48, DOI 10.1254/jphs.09315FP
   Elyasi S, 2017, PHYTOTHER RES, V31, P1323, DOI 10.1002/ptr.5857
   Elyasi S, 2016, PHYTOTHER RES, V30, P1879, DOI 10.1002/ptr.5704
   Fan SM, 2012, FREE RADICAL RES, V46, P1082, DOI 10.3109/10715762.2012.688964
   Fan SM, 2012, FREE RADICAL RES, V46, P310, DOI 10.3109/10715762.2012.655244
   Fan YZ, 2020, INT J MOL MED, V45, P1341, DOI 10.3892/ijmm.2020.4521
   Fazio E, 2015, J MATER CHEM B, V3, P9023, DOI 10.1039/c5tb01076d
   Feng W, 2015, BIOMED PHARMACOTHER, V74, P257, DOI 10.1016/j.biopha.2015.08.017
   Feng XL, 2014, CANCER LETT, V344, P166, DOI 10.1016/j.canlet.2013.11.004
   Flaig TW, 2007, INVEST NEW DRUG, V25, P139, DOI 10.1007/s10637-006-9019-2
   Forghani P, 2014, CANCER MED-US, V3, P215, DOI 10.1002/cam4.186
   Gandara L, 2014, J PHOTOCH PHOTOBIO B, V133, P55, DOI 10.1016/j.jphotobiol.2014.03.006
   Gasparini G, 2003, LANCET ONCOL, V4, P605, DOI 10.1016/S1470-2045(03)01220-8
   Gazak R, 2007, CURR MED CHEM, V14, P315, DOI 10.2174/092986707779941159
   Gazak R, 2009, FREE RADICAL BIO MED, V46, P745, DOI 10.1016/j.freeradbiomed.2008.11.016
   Ge YK, 2011, INT J MOL SCI, V12, P4861, DOI 10.3390/ijms12084861
   Gholami M, 2016, AVICENNA J PHYTOMEDI, V6, P542
   Gohulkumar M, 2014, MAT SCI ENG C-MATER, V41, P274, DOI 10.1016/j.msec.2014.04.056
   Gu M, 2007, CANCER RES, V67, P3483, DOI 10.1158/0008-5472.CAN-06-3955
   Ham J, 2018, J CELL PHYSIOL, V233, P1638, DOI 10.1002/jcp.26069
   Han YH, 2004, J PHARMACEUT BIOMED, V34, P1071, DOI 10.1016/j.jpba.2003.12.002
   Hawke RL, 2010, J CLIN PHARMACOL, V50, P434, DOI 10.1177/0091270009347475
   He Haiyang, 2017, Zhongguo Fei Ai Za Zhi, V20, P293, DOI 10.3779/j.issn.1009-3419.2017.05.01
   Hogan FS, 2007, J SURG RES, V143, P58, DOI 10.1016/j.jss.2007.03.080
   Hoh C, 2006, CLIN CANCER RES, V12, P2944, DOI 10.1158/1078-0432.CCR-05-2724
   Hossainzadeh S, 2019, J CELL PHYSIOL, V234, P22285, DOI 10.1002/jcp.28795
   Hou XY, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00021
   Huo MR, 2020, J CONTROL RELEASE, V321, P198, DOI 10.1016/j.jconrel.2020.02.017
   Huseini HF, 2006, PHYTOTHER RES, V20, P1036, DOI 10.1002/ptr.1988
   Ikejima T, 2017, AUTOPHAGY: CANCER, OTHER PATHOLOGIES, INFLAMMATION, IMMUNITY, INFECTION, AND AGING, VOL 12, P401, DOI 10.1016/B978-0-12-812146-7.00020-2
   Imai-Sumida M, 2017, ONCOTARGET, V8, P92032, DOI 10.18632/oncotarget.20734
   INVERNIZZI R, 1993, HAEMATOLOGICA, V78, P340
   Iqbal MA, 2021, FEBS J, V288, P471, DOI 10.1111/febs.15353
   Jahanafrooz Z, 2018, LIFE SCI, V213, P236, DOI 10.1016/j.lfs.2018.10.009
   Jain D, 2016, INT J PHARM RES ALLI, V5, P136
   Jalali S, 2012, BIOL DIRECT, V7, DOI 10.1186/1745-6150-7-25
   Jancova P, 2007, DRUG METAB DISPOS, V35, P2035, DOI 10.1124/dmd.107.016410
   Jarroux J, 2017, ADV EXP MED BIOL, V1008, P1, DOI 10.1007/978-981-10-5203-3_1
   Javan Maasomi Zahra, 2017, Asian Pac J Cancer Prev, V18, P1283
   Javed S, 2011, ALTERN MED REV, V16, P239
   Jia LJ, 2010, COLLOID SURFACE B, V80, P213, DOI 10.1016/j.colsurfb.2010.06.008
   Jiang CH, 2016, ONCOTARGETS THER, V9, P6609, DOI 10.2147/OTT.S107101
   Jiang K, 2015, ONCOL REP, V33, P2711, DOI 10.3892/or.2015.3915
   Jiang M, 2020, INT J PHARMACEUT, V581, DOI 10.1016/j.ijpharm.2020.119239
   Jiang YY, 2011, EUR J PHARMACOL, V659, P7, DOI 10.1016/j.ejphar.2010.12.043
   Jin Bilian, 2011, Genes Cancer, V2, P607, DOI 10.1177/1947601910393957
   Karbasforooshan H, 2019, PHYTOTHER RES, V33, P379, DOI 10.1002/ptr.6231
   Karimi Maryam, 2017, Iran J Pathol, V12, P135
   Kashyap D, 2021, SEMIN CANCER BIOL, V69, P5, DOI 10.1016/j.semcancer.2019.08.014
   Kashyap D, 2017, LIFE SCI, V169, P27, DOI 10.1016/j.lfs.2016.11.013
   Kashyap D, 2016, TUMOR BIOL, V37, P12915, DOI 10.1007/s13277-016-5194-8
   Kauntz H, 2013, ONCOL LETT, V5, P1273, DOI 10.3892/ol.2013.1190
   Kauntz H, 2012, APOPTOSIS, V17, P797, DOI 10.1007/s10495-012-0731-4
   Kaur M, 2009, NUTRITIONAL COSMETICS: BEAUTY FROM WITHIN, P501, DOI 10.1016/B978-0-8155-2029-0.50032-6
   Kaur M, 2009, MOL CANCER THER, V8, P2366, DOI 10.1158/1535-7163.MCT-09-0304
   Kavitha CV, 2014, MOL CARCINOGEN, V53, P169, DOI 10.1002/mc.21959
   Khandelwal A, 2020, CANCER SCI, V111, P826, DOI 10.1111/cas.14199
   Khandelwal A, 2017, BIOCHIMIE, V132, P152, DOI 10.1016/j.biochi.2016.11.007
   Khandelwal A, 2015, MOL CARCINOGEN, V54, P1235, DOI 10.1002/mc.22362
   Kidd P, 2005, ALTERN MED REV, V10, P193
   Kim SH, 2015, BIOCHEM BIOPH RES CO, V468, P151, DOI 10.1016/j.bbrc.2015.10.143
   Kim S, 2011, ANTICANCER RES, V31, P3767
   Ko JW, 2017, FOOD CHEM TOXICOL, V106, P424, DOI 10.1016/j.fct.2017.06.016
   Kren Vladimir, 2005, Biomedical Papers (Olomouc), V149, P29
   Kuen CY, 2017, NANOMATERIALS-BASEL, V7, DOI 10.3390/nano7110379
   Kumar G, 2016, LIFE SCI, V148, P313, DOI 10.1016/j.lfs.2016.02.022
   Kumar G, 2015, TUMOR BIOL, V36, P4005, DOI 10.1007/s13277-015-3391-5
   Kumar R., 2015, CURR PHARM REP, V1
   Kumar Rahul, 2015, Curr Pharmacol Rep, V1, P206
   Ladas EJ, 2010, CANCER-AM CANCER SOC, V116, P506, DOI 10.1002/cncr.24723
   Lazzeroni M, 2016, CANCER PREV RES, V9, P89, DOI 10.1158/1940-6207.CAPR-15-0123
   Lee DYW, 2003, J NAT PROD, V66, P1171, DOI 10.1021/np030163b
   Leena RS, 2017, COLLOID SURFACE B, V158, P308, DOI 10.1016/j.colsurfb.2017.06.048
   Li F, 2015, INT J MOL SCI, V16, P8415, DOI 10.3390/ijms16048415
   Li J, 2016, EXPERT OPIN THER TAR, V20, P7, DOI 10.1517/14728222.2016.1121236
   Li L, 2016, ADV EXP MED BIOL, V927, P49, DOI 10.1007/978-981-10-1498-7_2
   Li RF, 2017, J BUON, V22, P1148
   Li WG, 2016, J BUON, V21, P917
   Li YM, 2017, ONCOL LETT, V14, P8035, DOI 10.3892/ol.2017.7246
   Liang L, 2012, ONCOL REP, V28, P999, DOI 10.3892/or.2012.1874
   Lin C C, 2017, Zhonghua Zhong Liu Za Zhi, V39, P650, DOI 10.3760/cma.j.issn.0253-3766.2017.09.003
   Lin CM, 2012, J AGR FOOD CHEM, V60, P12451, DOI 10.1021/jf300964f
   Liu BB, 2011, FREE RADICAL RES, V45, P835, DOI 10.3109/10715762.2011.580343
   Liu T, 2019, J CELL PHYSIOL, V234, P5496, DOI 10.1002/jcp.27342
   Liu WW, 2020, ARCH BIOCHEM BIOPHYS, V689, DOI 10.1016/j.abb.2020.108458
   Liu YY, 2019, INT J BIOL MACROMOL, V124, P667, DOI 10.1016/j.ijbiomac.2018.11.258
   Liu Y, 2020, J NANOBIOTECHNOL, V18, DOI 10.1186/s12951-020-00638-x
   Lou S, 2018, ACS OMEGA, V3, P9210, DOI 10.1021/acsomega.8b00949
   Ma ZK, 2015, ONCOL REP, V34, P2461, DOI 10.3892/or.2015.4224
   Madisch A, 2001, Z GASTROENTEROL, V39, P511, DOI 10.1055/s-2001-16142
   Mahira S, 2019, BIOMED PHARMACOTHER, V110, P803, DOI 10.1016/j.biopha.2018.11.145
   Malhotra A, 2019, BIOCHIMIE, V156, P148, DOI 10.1016/j.biochi.2018.10.006
   Malhotra A, 2017, ONCOTARGET, V8, P110671, DOI 10.18632/oncotarget.22577
   Manouchehri JM, 2017, ANTICANCER RES, V37, P6593, DOI 10.21873/anticanres.12116
   Mao J, 2018, EUR J PHARMACOL, V832, P39, DOI 10.1016/j.ejphar.2018.05.027
   Marchiori MCL, 2017, AAPS PHARMSCITECH, V18, P3236, DOI 10.1208/s12249-017-0810-5
   Marrazzo G, 2011, NEUROSCI LETT, V504, P252, DOI 10.1016/j.neulet.2011.09.041
   Mateen S, 2013, NUTR CANCER, V65, P3, DOI 10.1080/01635581.2013.785004
   Mateen S, 2013, J PHARMACOL EXP THER, V345, P206, DOI 10.1124/jpet.113.203471
   Mateen S, 2012, EPIGENETICS-US, V7, P1161, DOI 10.4161/epi.22070
   Meeran SM, 2006, MOL CANCER THER, V5, P1660, DOI 10.1158/1535-7163.MCT-06-0095
   Miethe C, 2017, NUTR CANCER, V69, P1272, DOI 10.1080/01635581.2017.1367935
   Min K, 2007, ARCH PHARM RES, V30, P1265, DOI 10.1007/BF02980267
   Mizushima N, 2005, CELL DEATH DIFFER, V12, P1535, DOI 10.1038/sj.cdd.4401728
   Mizushima N, 2007, GENE DEV, V21, P2861, DOI 10.1101/gad.1599207
   Molavi O, 2017, PHARM BIOL, V55, P729, DOI 10.1080/13880209.2016.1270972
   Molavi O, 2016, LEUKEMIA LYMPHOMA, V57, P1154, DOI 10.3109/10428194.2015.1068306
   Mongelli A, 2019, FRONT PHYSIOL, V10, DOI 10.3389/fphys.2019.00369
   Nafees S, 2018, ARCH MED RES, V49, P226, DOI 10.1016/j.arcmed.2018.09.008
   Nambiar D, 2013, CANCER LETT, V334, P109, DOI 10.1016/j.canlet.2012.09.004
   Napolitano JG, 2013, J ORG CHEM, V78, P2827, DOI 10.1021/jo302720h
   National Toxicology Program, 2011, Natl Toxicol Program Tech Rep Ser, P1
   Noh EM, 2011, J BREAST CANCER, V14, P8, DOI 10.4048/jbc.2011.14.1.8
   O'Brien J, 2018, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00402
   Ochi MM, 2016, CELL J, V18
   Park Ju Young, 2014, Brain Tumor Res Treat, V2, P1, DOI 10.14791/btrt.2014.2.1.1
   Pashaei-Asl F, 2018, ARTIF CELL NANOMED B, V46, P1483, DOI 10.1080/21691401.2017.1374281
   Patel S, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-35069-0
   Piazzini V, 2019, CURR DRUG DELIV, V16, P142, DOI 10.2174/1567201815666181008153602
   Polachi N, 2016, EUR J MED CHEM, V123, P577, DOI 10.1016/j.ejmech.2016.07.070
   Pooja D, 2014, INT J BIOL MACROMOL, V69, P267, DOI 10.1016/j.ijbiomac.2014.05.035
   Raina K, 2008, CANCER RES, V68, P6822, DOI 10.1158/0008-5472.CAN-08-1332
   Raina K, 2007, ACTA PHARMACOL SIN, V28, P1466, DOI 10.1111/j.1745-7254.2007.00691.x
   Raina K, 2016, J BIOMED RES, V30, P452, DOI 10.7555/JBR.30.20150111
   Raina K, 2013, AUTOPHAGY, V9, P697, DOI 10.4161/auto.23960
   Raina K, 2013, MOL CARCINOGEN, V52, P195, DOI 10.1002/mc.21843
   Rainone F, 2005, AM FAM PHYSICIAN, V72, P1285
   Rajamanickam S, 2010, CANCER RES, V70, P2368, DOI 10.1158/0008-5472.CAN-09-3249
   Razavi BM, 2016, IRAN J BASIC MED SCI, V19, P916
   RICKLING B, 1995, J CHROMATOGR B, V670, P267, DOI 10.1016/0378-4347(95)00168-9
   Rigby C, 2019, MOL CARCINOGEN, V58, P1260, DOI 10.1002/mc.23008
   Robertson KD, 2005, NAT REV GENET, V6, P597, DOI 10.1038/nrg1655
   Romanucci V, 2019, MOLECULES, V24, DOI 10.3390/molecules24010108
   Rouholamini SEY, 2018, ARTIF CELL NANOMED B, V46, P524, DOI 10.1080/21691401.2017.1326928
   Sahibzada MUK, 2017, DRUG DES DEV THER, V11, P1453, DOI 10.2147/DDDT.S133806
   Saller R, 2001, DRUGS, V61, P2035, DOI 10.2165/00003495-200161140-00003
   Salminen A, 2013, INT J MOL SCI, V14, P3834, DOI 10.3390/ijms14023834
   Sarkar Rashmi, 2014, Indian Dermatol Online J, V5, P426, DOI 10.4103/2229-5178.142484
   Schroder FH, 2005, EUR UROL, V48, P922, DOI 10.1016/j.eururo.2005.08.005
   Sharma U, 2020, TRANSL ONCOL, V13, DOI 10.1016/j.tranon.2020.100774
   Shen Y, 2019, ARTIF CELL NANOMED B, V47, P4059, DOI 10.1080/21691401.2019.1671430
   Shi ZZ, 2019, LIFE SCI, V217, P70, DOI 10.1016/j.lfs.2018.11.037
   Shukla SK, 2015, ONCOTARGET, V6, P41146, DOI 10.18632/oncotarget.5843
   Si LL, 2020, MOL CELL BIOCHEM, V463, P189, DOI 10.1007/s11010-019-03640-6
   Si LL, 2019, ARCH BIOCHEM BIOPHYS, V671, P42, DOI 10.1016/j.abb.2019.05.009
   Siegel AB, 2014, INTEGR CANCER THER, V13, P46, DOI 10.1177/1534735413490798
   Singh RP, 2008, CANCER RES, V68, P2043, DOI 10.1158/0008-5472.CAN-07-6247
   Singh RP, 2007, CARCINOGENESIS, V28, P2567, DOI 10.1093/carcin/bgm218
   Singh RP, 2008, CLIN CANCER RES, V14, P7773, DOI 10.1158/1078-0432.CCR-08-1309
   Singh RP, 2003, CANCER EPIDEM BIOMAR, V12, P933
   Singh RP, 2002, CANCER RES, V62, P3063
   Singh RP, 2004, MUTAT RES-FUND MOL M, V555, P21, DOI 10.1016/j.mrfmmm.2004.05.017
   Singh RP, 2004, CURR CANCER DRUG TAR, V4, P1, DOI 10.2174/1568009043481605
   Soleimani V, 2019, PHYTOTHER RES, V33, P1627, DOI 10.1002/ptr.6361
   Son YG, 2007, CANCER RES, V67, P8274, DOI 10.1158/0008-5472.CAN-07-0407
   Strickland GT, 2005, DIGEST LIVER DIS, V37, P542, DOI 10.1016/j.dld.2005.03.001
   Strotbek M, 2017, INT J CANCER, V140, P2310, DOI 10.1002/ijc.30661
   Sun TH, 2018, MOL CARCINOGEN, V57, P262, DOI 10.1002/mc.22753
   Surai PF, 2015, ANTIOXIDANTS-BASEL, V4, P204, DOI 10.3390/antiox4010204
   Takke A, 2019, NANOMED-NANOTECHNOL, V21, DOI 10.1016/j.nano.2019.102057
   Tamang S, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00901
   Tamayo C, 2007, INTEGR CANCER THER, V6, P146, DOI 10.1177/1534735407301942
   Tan JM, 2016, CHEM CENT J, V10, DOI 10.1186/s13065-016-0228-2
   Tang H, 2019, J CELL MOL MED, V23
   Tehrani FK, 2020, IRAN J BASIC MED SCI, V23, P469, DOI [10.22038/ijbms.2020.39427.9349, 10.22038/IJBMS.2020.39427.9349]
   Ting H, 2013, AAPS J, V15, P707, DOI 10.1208/s12248-013-9486-2
   Ting HJ, 2015, MOL CARCINOGEN, V54, P730, DOI 10.1002/mc.22135
   Tiwari P, 2011, CANCER INVEST, V29, P12, DOI 10.3109/07357907.2010.535053
   Tong WW, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-21674-6
   Torres CC, 2016, MAT SCI ENG C-MATER, V65, P164, DOI 10.1016/j.msec.2016.03.104
   Trappoliere M, 2009, J HEPATOL, V50, P1102, DOI 10.1016/j.jhep.2009.02.023
   Tuli HS, 2015, LIFE SCI, V143, P71, DOI 10.1016/j.lfs.2015.10.021
   Tyagi A, 2004, CARCINOGENESIS, V25, P1711, DOI 10.1093/carcin/bgh180
   Tyagi A., 2016, INFLAMMATION OXIDATI, P422
   Tyagi AK, 2002, CLIN CANCER RES, V8, P3512
   Tyagi A, 2006, CARCINOGENESIS, V27, P2269, DOI 10.1093/carcin/bgl098
   Vaknin Y, 2008, INT J FOOD SCI NUTR, V59, P339, DOI 10.1080/09637480701554095
   Velmurugan B, 2010, PHARM RES-DORDR, V27, P2085, DOI 10.1007/s11095-010-0207-6
   Vidlar A, 2010, BIOMED PAP, V154, P239, DOI 10.5507/bp.2010.036
   Vigano MA, 1998, MOL CELL BIOL, V18, P6201, DOI 10.1128/MCB.18.11.6201
   Wang HJ, 2010, FREE RADICAL RES, V44, P577, DOI 10.3109/10715761003692495
   Wang YC, 2012, J BIOMED NANOTECHNOL, V8, P760, DOI 10.1166/jbn.2012.1444
   Wang YC, 2010, NANOTECHNOLOGY, V21, DOI 10.1088/0957-4484/21/15/155104
   Wang YX, 2014, ASIAN PAC J CANCER P, V15, P6791, DOI 10.7314/APJCP.2014.15.16.6791
   Wu J, 2019, ZHONGHUA XUE YE XUE, V40
   Xie Y, 2019, MOLECULES, V24
   Yi T, 2017, EUR J PHARM SCI, V96, P420, DOI 10.1016/j.ejps.2016.08.047
   You YT, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00271
   Yu Y, 2012, FREE RADICAL RES, V46, P1346, DOI 10.3109/10715762.2012.715369
   Yuan ZW, 2018, PHARMACOL RES, V128, P153, DOI 10.1016/j.phrs.2017.09.019
   Zadeh MM, 2016, J BREAST CANCER, V19, P45, DOI 10.4048/jbc.2016.19.1.45
   Zadeh MM, 2015, IRAN J BASIC MED SCI, V18, P1209
   Zappavigna S, 2019, INT J MOL SCI, V20
   Zarrelli A, 2015, HELV CHIM ACTA, V98, P399, DOI 10.1002/hlca.201400282
   Zeng J, 2011, MOL CANCER THER, V10, P104, DOI 10.1158/1535-7163.MCT-10-0577
   Zhang S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083699
   Zhang XK, 2019, PATHOL RES PRACT, V215, DOI 10.1016/j.prp.2019.152530
   Zhang XK, 2018, ONCOL LETT, V15, P9868, DOI 10.3892/ol.2018.8541
   Zhang Y, 2012, CELL BIOCHEM FUNCT, V30, P243, DOI 10.1002/cbf.1842
   Zhang Y, 2018, MOL MED REP, V18
   Zhang YX, 2013, PHYTOTHER RES, V27, P397, DOI 10.1002/ptr.4733
   Zhao JF, 1999, MOL CARCINOGEN, V26, P321, DOI 10.1002/(SICI)1098-2744(199912)26:4<321::AID-MC11>3.3.CO;2-0
   Zhao JJ, 2015, CANCER CELL INT, V15, DOI 10.1186/s12935-015-0259-0
   Zhao TJ, 2016, CHEM PHYS LIPIDS, V196, P81, DOI 10.1016/j.chemphyslip.2016.02.008
   Zheng DD, 2011, CANCER LETT, V307, P158, DOI 10.1016/j.canlet.2011.03.028
   Zheng N, 2017, ACTA PHARMACOL SIN, V38, P277, DOI 10.1038/aps.2016.117
   Zheng N, 2016, ARCH BIOCHEM BIOPHYS, V591, P141, DOI 10.1016/j.abb.2016.01.002
   Zheng N, 2015, J PHARMACOL SCI, V128, P97, DOI 10.1016/j.jphs.2015.05.001
   Zheng RJ, 2018, MEDIAT INFLAMM, V2018, DOI 10.1155/2018/1562010
   Zhu XX, 2016, EXPERT REV CLIN PHAR, V9, P1323, DOI 10.1080/17512433.2016.1208563
   Zi XL, 1997, BIOCHEM BIOPH RES CO, V239, P334, DOI 10.1006/bbrc.1997.7375
   Zou H, 2017, ONCOTARGET, V8, P89307, DOI 10.18632/oncotarget.19153
NR 257
TC 4
Z9 5
U1 4
U2 6
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 1044-579X
EI 1096-3650
J9 SEMIN CANCER BIOL
JI Semin. Cancer Biol.
PD AUG
PY 2021
VL 73
SI SI
BP 196
EP 218
DI 10.1016/j.semcancer.2020.09.014
EA JUN 2021
PG 23
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA SR7TI
UT WOS:000661248600015
PM 33130037
DA 2022-04-25
ER

PT J
AU Li, YY
   Zhang, L
   Zhou, J
   Luo, SH
   Huang, R
   Zhao, CC
   Diao, AP
AF Li, Yuyin
   Zhang, Li
   Zhou, Jie
   Luo, Shenheng
   Huang, Rui
   Zhao, Changcai
   Diao, Aipo
TI Nedd4 E3 ubiquitin ligase promotes cell proliferation and autophagy
SO CELL PROLIFERATION
LA English
DT Article
ID MEMBRANE PERMEABILIZATION; CYTOCHROME-C; PATHWAY; GROWTH; CANCER;
   ASSOCIATION; DEGRADATION; RELOCATION; STABILITY; RELEASE
AB ObjectivesNedd4 (neural precursor cell expressed developmentally down-regulated protein 4) is a member of the HECT E3 ubiquitin ligases, and is elevated in prostate, bladder and colorectal cancers, and promotes colonic cell population expansion. Up to now, molecular mechanisms of how Nedd4 functions, have not been well understood.
   Materials and methodsIn this study, shRNA was used to reduce expression of Nedd4 in the human prostate carcinoma cell line DU145. To analyse effects of Nedd4 on cell proliferation, MTT and colony formation assays were performed. DAPI staining and FACS analysis were used to investigate outcomes of Nedd4 activity, on apoptosis. Results of Nedd4 expression on lysosomal membrane permeabilization and autophagy were further investigated using acridine orange (AO) staining, immunofluorescence and western blot analysis.
   ResultsWe found that in HeLa cells, expression of Nedd4 promoted cell proliferation, whereas its knockdown inhibited colony formation and induced apoptosis in DU145 cells. Furthermore, down-regulation of Nedd4 in DU145 cells promoted lysosomal membrane permeabilization. We also found that down-regulation of Nedd4 inhibited autophagy in both DU145 and A549 cells. Investigation into mechanisms involved revealed that knockdown of endogenous Nedd4 expression notably increased activated mTOR (p-mTOR) levels, which suggests that mTOR signalling was involved in the Nedd4-mediated autophagy.
   ConclusionsOur results indicate that expression of Nedd4 promoted cell proliferation and colony formation but prevented apoptosis. Moreover, Nedd4 promoted autophagy and was associated with the mTOR signalling pathway.
C1 [Li, Yuyin; Zhang, Li; Zhou, Jie; Luo, Shenheng; Huang, Rui; Zhao, Changcai; Diao, Aipo] Tianjin Univ Sci & Technol, Sch Biotechnol, Key Lab Ind Fermentat Microbiol, Minist Educ, Tianjin 300457, Peoples R China.
RP Diao, AP (corresponding author), Tianjin Univ Sci & Technol, Sch Biotechnol, Tianjin Econ & Technol Dev Area TEDA, 29,13th Ave, Tianjin 300457, Peoples R China.
EM diaoaipo@tust.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81402952]; program for Changjiang University
   Scholars and Innovative Research Team [IRT1166]; Tianjin Natural Science
   Foundation grant [10JCZDJC16800]
FX We are grateful to Dr. Edward McKenzie (University of Manchester, UK)
   for critical reading of the manuscript. This research is supported by
   the National Natural Science Foundation of China (81402952), program for
   Changjiang University Scholars and Innovative Research Team (IRT1166)
   and a Tianjin Natural Science Foundation grant (10JCZDJC16800).
CR Bernassola F, 2008, CANCER CELL, V14, P10, DOI 10.1016/j.ccr.2008.06.001
   Bidere N, 2003, J BIOL CHEM, V278, P31401, DOI 10.1074/jbc.M301911200
   Blot V, 2004, J CELL SCI, V117, P2357, DOI 10.1242/jcs.01095
   Boya P, 2003, ONCOGENE, V22, P3927, DOI 10.1038/sj.onc.1206622
   Boya P, 2003, J EXP MED, V197, P1323, DOI 10.1084/jem.20021952
   Cao XR, 2008, SCI SIGNAL, V1, DOI 10.1126/scisignal.1160940
   Chen C, 2007, CANCER METAST REV, V26, P587, DOI 10.1007/s10555-007-9091-x
   Eide PW, 2013, CELL SIGNAL, V25, P12, DOI 10.1016/j.cellsig.2012.08.012
   Fehrenbacher N, 2005, CANCER RES, V65, P2993, DOI 10.1158/0008-5472.CAN-05-0476
   Foghsgaard L, 2001, J CELL BIOL, V153, P999, DOI 10.1083/jcb.153.5.999
   Fouladkou F, 2008, P NATL ACAD SCI USA, V105, P8585, DOI 10.1073/pnas.0803233105
   Ganley IG, 2009, J BIOL CHEM, V284, P12297, DOI 10.1074/jbc.M900573200
   Guardavaccaro D, 2004, ONCOGENE, V23, P2037, DOI 10.1038/sj.onc.1207413
   Guicciardi ME, 2004, ONCOGENE, V23, P2881, DOI 10.1038/sj.onc.1207512
   Hosokawa N, 2009, MOL BIOL CELL, V20, P1981, DOI 10.1091/mbc.E08-12-1248
   Huang Z, 2015, ONCOGENE, V34, P1105, DOI 10.1038/onc.2014.56
   Jung CH, 2010, FEBS LETT, V584, P1287, DOI 10.1016/j.febslet.2010.01.017
   Jung CH, 2009, MOL BIOL CELL, V20, P1992, DOI 10.1091/mbc.E08-12-1249
   Laplante M, 2013, J CELL SCI, V126, P1713, DOI 10.1242/jcs.125773
   Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017
   Laplante M, 2009, J CELL SCI, V122, P3589, DOI 10.1242/jcs.051011
   Liu J, 2014, ONCOTARGET, V5, P1026, DOI 10.18632/oncotarget.1675
   Liu N, 2003, EMBO J, V22, P5313, DOI 10.1093/emboj/cdg510
   Nazio F, 2013, NAT CELL BIOL, V15, P406, DOI 10.1038/ncb2708
   Onodera J, 2005, J BIOL CHEM, V280, P31582, DOI 10.1074/jbc.M506736200
   Persaud A, 2011, EMBO J, V30, P3259, DOI 10.1038/emboj.2011.234
   Pham N, 2001, J BIOL CHEM, V276, P46995, DOI 10.1074/jbc.M108373200
   Pickart CM, 2004, CURR OPIN CHEM BIOL, V8, P610, DOI 10.1016/j.cbpa.2004.09.009
   Rabinowitz JD, 2010, SCIENCE, V330, P1344, DOI 10.1126/science.1193497
   Roberg K, 1999, FREE RADICAL BIO MED, V27, P1228, DOI 10.1016/S0891-5849(99)00146-X
   Schwartz AL, 1999, ANNU REV MED, V50, P57
   Thoreen CC, 2009, J BIOL CHEM, V284, P8023, DOI 10.1074/jbc.M900301200
   Trotman LC, 2007, CELL, V128, P141, DOI 10.1016/j.cell.2006.11.040
   Wang XJ, 2007, CELL, V128, P129, DOI 10.1016/j.cell.2006.11.039
   White E, 2009, CLIN CANCER RES, V15, P5308, DOI 10.1158/1078-0432.CCR-07-5023
   Zeng FH, 2009, FASEB J, V23, P1935, DOI 10.1096/fj.08-121947
   Zhao M, 2003, EUR J BIOCHEM, V270, P3778, DOI 10.1046/j.1432-1033.2003.03765.x
NR 37
TC 31
Z9 31
U1 2
U2 23
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0960-7722
EI 1365-2184
J9 CELL PROLIFERAT
JI Cell Prolif.
PD JUN
PY 2015
VL 48
IS 3
BP 338
EP 347
DI 10.1111/cpr.12184
PG 10
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA CH7JL
UT WOS:000354212100009
PM 25809873
OA Green Published
DA 2022-04-25
ER

PT J
AU Thongnuanjan, P
   Soodvilai, S
   Fongsupa, S
   Thipboonchoo, N
   Chabang, N
   Munyoo, B
   Tuchinda, P
   Soodvilai, S
AF Thongnuanjan, Penjai
   Soodvilai, Sirima
   Fongsupa, Somsak
   Thipboonchoo, Natechanok
   Chabang, Napason
   Munyoo, Bamroong
   Tuchinda, Patoomratana
   Soodvilai, Sunhapas
TI Panduratin A Derivative Protects against Cisplatin-Induced Apoptosis of
   Renal Proximal Tubular Cells and Kidney Injury in Mice
SO MOLECULES
LA English
DT Article
DE apoptosis; chemotherapy; cyclohexanyl chalcone; kidney; oxidative stress
ID MITOCHONDRIAL DYSFUNCTION; INDUCED NEPHROTOXICITY; KAEMPFERIA-PANDURATA;
   MECHANISMS; TOXICITIES; AMIFOSTINE; AUTOPHAGY; TRANSPORT; KINASE; ALPHA
AB Background: Panduratin A is a bioactive cyclohexanyl chalcone exhibiting several pharmacological activities, such as anti-inflammatory, anti-oxidative, and anti-cancer activities. Recently, the nephroprotective effect of panduratin A in cisplatin (CDDP) treatment was revealed. The present study examined the potential of certain compounds derived from panduratin A to protect against CDDP-induced nephrotoxicity. Methods: Three derivatives of panduratin A (DD-217, DD-218, and DD-219) were semi-synthesized from panduratin A. We investigated the effects and corresponding mechanisms of the derivatives of panduratin A for preventing nephrotoxicity of CDDP in both immortalized human renal proximal tubular cells (RPTEC/TERT1 cells) and mice. Results: Treating the cell with 10 mu M panduratin A significantly reduced the viability of RPTEC/TERT1 cells compared to control (panduratin A: 72% & PLUSMN; 4.85%). Interestingly, DD-217, DD-218, and DD-219 at the same concentration did not significantly affect cell viability (92% & PLUSMN; 8.44%, 90% & PLUSMN; 7.50%, and 87 & PLUSMN; 5.2%, respectively). Among those derivatives, DD-218 exhibited the most protective effect against CDDP-induced renal proximal tubular cell apoptosis (control: 57% & PLUSMN; 1.23%; DD-218: 19% & PLUSMN; 10.14%; DD-219: 33% & PLUSMN; 14.06%). The cytoprotective effect of DD-218 was mediated via decreases in CDDP-induced mitochondria dysfunction, intracellular reactive oxygen species (ROS) generation, activation of ERK1/2, and cleaved-caspase 3 and 7. In addition, DD-218 attenuated CDDP-induced nephrotoxicity by a decrease in renal injury and improved in renal dysfunction in C57BL/6 mice. Importantly, DD-218 did not attenuate the anti-cancer efficacy of CDDP in non-small-cell lung cancer cells or colon cancer cells. Conclusions: This finding suggests that DD-218, a derivative of panduratin A, holds promise as an adjuvant therapy in patients receiving CDDP.
C1 [Thongnuanjan, Penjai; Soodvilai, Sunhapas] Mahidol Univ, Fac Sci, Multidisciplinary Unit, Toxicol Grad Program, Rama VI Rd, Bangkok 10400, Thailand.
   [Thongnuanjan, Penjai; Thipboonchoo, Natechanok; Soodvilai, Sunhapas] Mahidol Univ, Fac Sci, Res Ctr Transport Prot Med Innovat, Dept Physiol, Rama VI Rd, Bangkok 10400, Thailand.
   [Soodvilai, Sirima] Rangsit Univ, Coll Pharm, Dept Pharmaceut Technol, Pathum Thani 12000, Thailand.
   [Fongsupa, Somsak] Thammasat Univ, Fac Allied Hlth Sci, Dept Med Technol, Pathum Thani 12121, Thailand.
   [Chabang, Napason] Mahidol Univ, Fac Sci, Sch Bioinnovat & Biobased Prod Intelligence, Rama VI Rd, Bangkok 10400, Thailand.
   [Munyoo, Bamroong; Tuchinda, Patoomratana; Soodvilai, Sunhapas] Mahidol Univ, Excellent Ctr Drug Discovery, Rama VI Rd, Bangkok 10400, Thailand.
RP Soodvilai, S (corresponding author), Mahidol Univ, Fac Sci, Multidisciplinary Unit, Toxicol Grad Program, Rama VI Rd, Bangkok 10400, Thailand.; Soodvilai, S (corresponding author), Mahidol Univ, Fac Sci, Res Ctr Transport Prot Med Innovat, Dept Physiol, Rama VI Rd, Bangkok 10400, Thailand.; Soodvilai, S (corresponding author), Mahidol Univ, Excellent Ctr Drug Discovery, Rama VI Rd, Bangkok 10400, Thailand.
EM penjai.tho@gmail.com; sirima.s@rsu.ac.th; fongsupa.mu@gmail.com;
   Joy_nate@hotmail.com; Napason.cha@mahidol.ac.th; Br_411@hotmail.com;
   scptcster@gmail.com; sunhapas.soo@mahidol.ac.th
FU Thailand Science Research and Innovation [RSA6280082]; Mahidol
   University; International Research Network (IRN), Thailand Research
   Funds [IRN5804PHDW02]
FX This work was supported by the Thailand Science Research and Innovation
   (Grant No. RSA6280082 to Sunhapas Soodvilai) and Mahidol University.
   Pe.T. was supported by the International Research Network (IRN),
   Thailand Research Funds (Grant No. IRN5804PHDW02).
CR Aziiz Mardanarian Rosdianto, 2020, Journal of Applied Pharmaceutical Science, V10, P116, DOI 10.7324/JAPS.2020.10715
   Cagnol S, 2010, FEBS J, V277, P2, DOI 10.1111/j.1742-4658.2009.07366.x
   Cassidy Hilary, 2012, J Signal Transduct, V2012, P463617, DOI 10.1155/2012/463617
   Chirino YI, 2009, EXP TOXICOL PATHOL, V61, P223, DOI 10.1016/j.etp.2008.09.003
   Choi YM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135083
   Choi Y, 2012, INFLAMMATION, V35, P1904, DOI 10.1007/s10753-012-9513-y
   Ciarimboli G, 2012, SCIENTIFICA, V2012, DOI 10.6064/2012/473829
   Ciarimboli G, 2010, AM J PATHOL, V176, P1169, DOI 10.2353/ajpath.2010.090610
   Clark JS, 2010, CANCER LETT, V297, P165, DOI 10.1016/j.canlet.2010.05.007
   Eng-Chong T, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/473637
   Filipski KK, 2009, CLIN PHARMACOL THER, V86, P396, DOI 10.1038/clpt.2009.139
   Filipski KK, 2008, CLIN CANCER RES, V14, P3875, DOI 10.1158/1078-0432.CCR-07-4793
   Florea AM, 2006, BIOMETALS, V19, P419, DOI 10.1007/s10534-005-4451-x
   Francescato HDC, 2009, LIFE SCI, V84, P590, DOI 10.1016/j.lfs.2009.02.004
   dos Santos NAG, 2012, ARCH TOXICOL, V86, P1233, DOI 10.1007/s00204-012-0821-7
   Jiang M, 2006, ONCOGENE, V25, P4056, DOI 10.1038/sj.onc.1209440
   Kemp G, 1996, J CLIN ONCOL, V14, P2101, DOI 10.1200/JCO.1996.14.7.2101
   Kim D, 2011, DIABETES OBES METAB, V13, P584, DOI 10.1111/j.1463-1326.2011.01379.x
   Kim DY, 2012, INT J MOL SCI, V13, P994, DOI 10.3390/ijms13010994
   Kirana C, 2007, J NAT MED-TOKYO, V61, P131, DOI 10.1007/s11418-006-0100-0
   Kruidering M, 1997, J PHARMACOL EXP THER, V280, P638
   Lai SL, 2018, PHYTOMEDICINE, V42, P144, DOI 10.1016/j.phymed.2018.03.027
   Liu QM, 2018, BIOMOL THER, V26, P328, DOI 10.4062/biomolther.2017.042
   McSweeney KR, 2021, CANCERS, V13, DOI 10.3390/cancers13071572
   Mebratu Y, 2009, CELL CYCLE, V8, P1168, DOI 10.4161/cc.8.8.8147
   Miller RP, 2010, TOXINS, V2, P2490, DOI 10.3390/toxins2112490
   MIURA K, 1987, TOXICOLOGY, V44, P147, DOI 10.1016/0300-483X(87)90145-4
   Nowak G, 2002, J BIOL CHEM, V277, P43377, DOI 10.1074/jbc.M206373200
   Ongwisespaiboon Oranun, 2017, Pharmacogn Rev, V11, P27, DOI 10.4103/phrev.phrev_50_16
   Pabla N, 2008, KIDNEY INT, V73, P994, DOI 10.1038/sj.ki.5002786
   Pabla N, 2009, AM J PHYSIOL-RENAL, V296, pF505, DOI 10.1152/ajprenal.90545.2008
   Park KM, 2005, FOOD SCI BIOTECHNOL, V14, P286
   Praetorius NP, 2008, J PHARM PHARMACOL, V60, P809, DOI 10.1211/jpp.60.7.0001
   Rukayadi Y, 2009, ANTIMICROB AGENTS CH, V53, P4529, DOI 10.1128/AAC.00624-09
   Rybak LP, 2009, TOHOKU J EXP MED, V219, P177, DOI 10.1620/tjem.219.177
   Salama SM, 2013, BMC COMPLEM ALTERN M, V13, DOI 10.1186/1472-6882-13-279
   Sprowl JA, 2013, CLIN PHARMACOL THER, V94, P585, DOI 10.1038/clpt.2013.145
   Thongnuanjan P, 2021, BIOL PHARM BULL, V44, P830, DOI 10.1248/bpb.b21-00036
   Tsang RY, 2009, DRUG SAFETY, V32, P1109, DOI 10.2165/11316640-000000000-00000
   Tuchinda P, 2002, PHYTOCHEMISTRY, V59, P169, DOI 10.1016/S0031-9422(01)00451-4
   TUNTIWACHWUTTIKUL P, 1984, AUST J CHEM, V37, P449, DOI 10.1071/CH9840449
   Wei Shu-qin, 2004, Chinese Medical Sciences Journal, V19, P125
   Wongwan T, 2017, PFLUG ARCH EUR J PHY, V469, P1471, DOI 10.1007/s00424-017-2033-8
   Yang C, 2007, AM J PHYSIOL-RENAL, V292, pF1710, DOI 10.1152/ajprenal.00505.2006
   Yun JM, 2006, CARCINOGENESIS, V27, P1454, DOI 10.1093/carcin/bgi348
NR 45
TC 0
Z9 0
U1 2
U2 2
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1420-3049
J9 MOLECULES
JI Molecules
PD NOV
PY 2021
VL 26
IS 21
AR 6642
DI 10.3390/molecules26216642
PG 16
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA WZ5XZ
UT WOS:000720041000001
PM 34771049
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Chen, JD
   Sun, SX
   Zha, DS
   Wu, JG
   Mao, LM
   Deng, H
   Chu, XW
   Luo, HJ
   Zha, LY
AF Chen, Jiading
   Sun, Suxia
   Zha, Dingsheng
   Wu, Jiguo
   Mao, Limei
   Deng, Hong
   Chu, Xinwei
   Luo, Haiji
   Zha, Longying
TI Soyasaponins Prevent H2O2-Induced Inhibition of Gap Junctional
   Intercellular Communication by Scavenging Reactive Oxygen Species in Rat
   Liver Cells
SO NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL
LA English
DT Article
ID SOYBEAN SAPONINS; HELA-CELLS; COLON; CANCER; PROLIFERATION;
   PHYTOCHEMICALS; MACROAUTOPHAGY; ACTIVATION; INDUCTION; PRESSURE
AB It appears to be more practical and effective to prevent carcinogenesis by targeting the tumor promotion stage. Gap junctional intercellular communication (GJIC) is strongly involved in carcinogenesis, especially the tumor promotion stage. Considerable interest has been focused on the chemoprevention activities of soyasaponin (SS), which are major phytochemicals found in soybeans and soy products. However, less is known about the preventive effects of SS (especially SS with different chemical structures) against tumor promoter-induced inhibition of GJIC. We investigated the protective effects of SS-A(1), SS-A(2), and SS-I against hydrogen peroxide (H2O2)-induced GJIC inhibition and reactive oxygen species (ROS) production in Buffalo rat liver (BRL) cells. The present results clearly show for the first time that SS-A(1), SS-A(2), and SS-I prevent the H2O2-induced GJIC inhibition by scavenging ROS in BRL cells in a dose-dependent manner at the concentration range of from 25 to 100 mu g/mL. Soyasaponins attenuated the H2O2-induced ROS through potentiating the activities of superoxide dismutase and glutathione peroxidase. This may be an important mechanism by which SS protects against tumor promotion. In addition, various chemical structures of SS appear to exhibit different protective abilities against GJIC inhibition. This may partly attribute to their differences in ROS-scavenging activities.
C1 [Chen, Jiading; Sun, Suxia; Mao, Limei; Deng, Hong; Chu, Xinwei; Luo, Haiji; Zha, Longying] Southern Med Univ, Sch Publ Hlth & Trop Med, Dept Nutr & Food Hyg, Guangzhou 510515, Guangdong, Peoples R China.
   [Zha, Dingsheng] Jinan Univ, Affiliated Hosp 1, Dept Orthoped Surg, Guangzhou, Guangdong, Peoples R China.
   [Wu, Jiguo] Southern Med Univ, Sch Publ Hlth & Trop Med, Dept Environm Hlth Sci, Guangzhou 510515, Guangdong, Peoples R China.
RP Zha, LY (corresponding author), Southern Med Univ, Sch Publ Hlth & Trop Med, Dept Nutr & Food Hyg, 1838 Guangzhou Ave North, Guangzhou 510515, Guangdong, Peoples R China.
EM lyzhasmu@126.com
OI Sun, Suxia/0000-0002-1159-6191
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81102130, 81202204]; Medical Scientific
   Research Foundation of Guangdong Province [A2011357]; Fundamental
   Research Funds for the Central Universities, ChinaFundamental Research
   Funds for the Central Universities [21612303]; Medical Scientific
   Research Foundation of Guangdong Province, China
   [WSTJJ20111125340822197903142037]; Scientific Research Training
   Foundation of the First Affiliated Hospital of Jinan University, China
   [2012-1]
FX This work was financially supported by National Natural Science
   Foundation of China (No. 81102130), Medical Scientific Research
   Foundation of Guangdong Province (A2011357) and partly by the
   Fundamental Research Funds for the Central Universities, China (No.
   21612303), Medical Scientific Research Foundation of Guangdong Province,
   China (No. WSTJJ20111125340822197903142037), the Youth Project of
   Scientific Research Training Foundation of the First Affiliated Hospital
   of Jinan University, China (No. 2012-1) and National Natural Science
   Foundation of China (No. 81202204). Jiading Chen and Suxia Sun
   contributed equally to this work.
CR Bhattacharyya J, 2004, CURR MED CHEM, V11, P359, DOI 10.2174/0929867043456098
   Cho JH, 2002, CARCINOGENESIS, V23, P1163, DOI 10.1093/carcin/23.7.1163
   ELFOULY MH, 1987, EXP CELL RES, V168, P422, DOI 10.1016/0014-4827(87)90014-0
   Ellington AA, 2006, CARCINOGENESIS, V27, P298, DOI 10.1093/carcin/bgi214
   Ellington AA, 2005, CARCINOGENESIS, V26, P159, DOI 10.1093/carcin/bgh297
   Guclu-Ustundag O, 2007, CRIT REV FOOD SCI, V47, P231, DOI 10.1080/10408390600698197
   Gurfinkel DM, 2005, INT J FOOD SCI NUTR, V56, P501, DOI 10.1080/09637480500460601
   Gurfinkel DM, 2003, NUTR CANCER, V47, P24, DOI 10.1207/s15327914nc4701_3
   HASLER CM, 1990, TOXICOL APPL PHARM, V103, P389, DOI 10.1016/0041-008X(90)90312-I
   Hsu CC, 2005, GYNECOL ONCOL, V96, P415, DOI 10.1016/j.ygyno.2004.10.010
   Hu J, 2004, J NUTR, V134, P1867, DOI 10.1093/jn/134.8.1867
   Huang RP, 2001, MOL CARCINOGEN, V30, P209, DOI 10.1002/mc.1030
   Jeon BH, 2000, ACTA PHARMACOL SIN, V21, P1095
   Johnson IT, 2007, P NUTR SOC, V66, P207, DOI 10.1017/S0029665107005459
   Kang KS, 2000, CANCER LETT, V152, P97, DOI 10.1016/S0304-3835(99)00438-3
   Kiefer D, 2003, AM FAM PHYSICIAN, V68, P1539
   Koratkar R, 1997, NUTR CANCER, V27, P206, DOI 10.1080/01635589709514526
   Lee DE, 2010, J NUTR BIOCHEM, V21, P680, DOI 10.1016/j.jnutbio.2009.03.014
   Lee IA, 2010, J AGR FOOD CHEM, V58, P10929, DOI 10.1021/jf102296y
   Lee KW, 2006, BIOFACTORS, V26, P105, DOI 10.1002/biof.5520260202
   Lee KW, 2005, J AGR FOOD CHEM, V53, P1990, DOI 10.1021/jf0486040
   Liu RH, 2007, J CEREAL SCI, V46, P207, DOI 10.1016/j.jcs.2007.06.010
   LOEWENSTEIN WR, 1979, BIOCHIM BIOPHYS ACTA, V560, P1, DOI 10.1016/0304-419X(79)90002-7
   MacDonald RS, 2007, FASEB J, V21, pA1101
   Mesnil M, 2005, BBA-BIOMEMBRANES, V1719, P125, DOI 10.1016/j.bbamem.2005.11.004
   Morris EJ, 1999, BIOTECHNIQUES, V26, P282, DOI 10.2144/99262st02
   Nielsen M, 2000, BIOCHEM BIOPH RES CO, V275, P804, DOI 10.1006/bbrc.2000.3378
   Oda K, 2003, VACCINE, V21, P2145, DOI 10.1016/S0264-410X(02)00739-9
   Oh YJ, 2001, NUTR CANCER, V39, P132, DOI 10.1207/S15327914nc391_18
   PIGEOLET E, 1990, MECH AGEING DEV, V51, P283, DOI 10.1016/0047-6374(90)90078-T
   SUNG MK, 1995, FOOD CHEM TOXICOL, V33, P357, DOI 10.1016/0278-6915(95)00007-O
   Trosko JE, 2005, MUTAGENESIS, V20, P81, DOI 10.1093/mutage/gei017
   Trosko JE, 2000, BIOFACTORS, V12, P259, DOI 10.1002/biof.5520120139
   Upham BL, 2009, ANTIOXID REDOX SIGN, V11, P297, DOI 10.1089/ars.2008.2146
   Vinken M, 2006, CELL SIGNAL, V18, P592, DOI 10.1016/j.cellsig.2005.08.012
   Xiao JX, 2007, EXP TOXICOL PATHOL, V59, P35, DOI 10.1016/j.etp.2007.02.004
   Xiao JX, 2007, TOXICOL IN VITRO, V21, P820, DOI 10.1016/j.tiv.2007.01.025
   YOSHIKI Y, 1995, BIOSCI BIOTECH BIOCH, V59, P1556, DOI 10.1271/bbb.59.1556
   Yoshiki Y, 2001, BIOSCI BIOTECH BIOCH, V65, P2162, DOI 10.1271/bbb.65.2162
   Zha LY, 2011, BIOORG MED CHEM LETT, V21, P2415, DOI 10.1016/j.bmcl.2011.02.071
   Zhang W, 2008, J AGR FOOD CHEM, V56, P2603, DOI 10.1021/jf0731550
NR 41
TC 9
Z9 10
U1 4
U2 18
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 0163-5581
EI 1532-7914
J9 NUTR CANCER
JI Nutr. Cancer
PD NOV 17
PY 2014
VL 66
IS 8
BP 1342
EP 1351
DI 10.1080/01635581.2014.956245
PG 10
WC Oncology; Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Nutrition & Dietetics
GA AT3WI
UT WOS:000344863600009
PM 25268883
DA 2022-04-25
ER

PT J
AU Takada, Y
   Sayama, T
   Kikuchi, A
   Kato, S
   Tatsuzaki, N
   Nakamoto, Y
   Suzuki, A
   Tsukamoto, C
   Ishimoto, M
AF Takada, Yoshitake
   Sayama, Takashi
   Kikuchi, Akio
   Kato, Shin
   Tatsuzaki, Nana
   Nakamoto, Yumi
   Suzuki, Ayako
   Tsukamoto, Chigen
   Ishimoto, Masao
TI Genetic analysis of variation in sugar chain composition at the C-22
   position of group A saponins in soybean, Glycine max (L.) Merrill
SO BREEDING SCIENCE
LA English
DT Article
DE genetic analysis; Glycine max (L.) Merrill; Glycine soja Sieb. et Zucc.;
   group A saponin; sugar chain composition; mapping
ID COLON-CANCER CELLS; LINKAGE MAP; SOYASAPOGENOL-A; STRUCTURAL
   ELUCIDATION; SEEDS; SOYASAPONINS; MARKERS; MACROAUTOPHAGY;
   BISDESMOSIDES; INHERITANCE
AB Saponins are a diverse group of secondary metabolites widely distributed in plants. Some saponins in soybean seeds have medicinal properties, but the terminal acetylated sugar at the C-22 position of group A saponins in seed hypocotyls causes a bitter and astringent taste. We used cultivated and wild soybean accessions classified into four different group A saponin phenotypes, including non-acetylated A0-alpha g and deacetyl-Af, as parents to obtain four F-2 populations and a population of recombinant inbred lines to test their genetic relationship. The gene controlling the phenotype of the group A saponins in each line was mapped near the simple sequence repeat marker Satt336 on soybean chromosome 7 (linkage group M). An allelism test of the A0-alpha g and deacetyl-Af variants revealed no segregation of Aa and Ab phenotypes in the progeny, although the genes controlling the two phenotypes have been assigned to two different loci, Sg-1 and Sg-2. These results suggest that the four group A saponin phenotypes are controlled by multiple alleles at the single locus Sg-1.
C1 [Takada, Yoshitake] Natl Agr Res Ctr Western Reg, Kagawa 7658508, Japan.
   [Sayama, Takashi; Nakamoto, Yumi; Suzuki, Ayako; Ishimoto, Masao] Natl Agr Res Ctr Hokkaido Reg, Sapporo, Hokkaido 0628555, Japan.
   [Kikuchi, Akio; Kato, Shin] Natl Agr Res Ctr Tohoku Reg, Akita 0192112, Japan.
   [Tatsuzaki, Nana; Tsukamoto, Chigen] Iwate Univ, Grad Sch Agr, Morioka, Iwate 0208550, Japan.
RP Takada, Y (corresponding author), Natl Agr Res Ctr Western Reg, 1-3-1 Senyuu, Kagawa 7658508, Japan.
EM yottake@affrc.go.jp
FU Ministry of Agriculture, Forestry and Fisheries of JapanMinistry of
   Agriculture Forestry & Fisheries - Japan [18063]
FX This work was supported by the Ministry of Agriculture, Forestry and
   Fisheries of Japan (Research Project for Utilizing Advanced Technologies
   in Agriculture, Forestry and Fisheries, 18063).
CR BURROWS JC, 1987, PHYTOCHEMISTRY, V26, P1214, DOI 10.1016/S0031-9422(00)82387-0
   Cregan PB, 1999, CROP SCI, V39, P1464, DOI 10.2135/cropsci1999.3951464x
   Ellington AA, 2006, CARCINOGENESIS, V27, P298, DOI 10.1093/carcin/bgi214
   Ellington AA, 2005, CARCINOGENESIS, V26, P159, DOI 10.1093/carcin/bgh297
   Hisano H, 2007, DNA RES, V14, P271, DOI 10.1093/dnares/dsm025
   Hwang TY, 2009, DNA RES, V16, P213, DOI 10.1093/dnares/dsp010
   Ishii Y, 2006, BIOL PHARM BULL, V29, P1759, DOI 10.1248/bpb.29.1759
   Kato S., 2007, Bulletin of the National Agricultural Research Center for Tohoku Region, P29
   Kikuchi A, 1999, BREEDING SCI, V49, P167, DOI 10.1270/jsbbs.49.167
   KITAGAWA I, 1988, CHEM PHARM BULL, V36, P2819
   KITAGAWA I, 1982, CHEM PHARM BULL, V30, P2294
   Kosambi DD, 1943, ANN EUGENIC, V12, P172, DOI 10.1111/j.1469-1809.1943.tb02321.x
   KUDOU S, 1992, BIOSCI BIOTECH BIOCH, V56, P142, DOI 10.1271/bbb.56.142
   KUDOU S, 1993, BIOSCI BIOTECH BIOCH, V57, P546, DOI 10.1271/bbb.57.546
   OKUBO K, 1992, BIOSCI BIOTECH BIOCH, V56, P99, DOI 10.1271/bbb.56.99
   SHIMOYAMADA M, 1990, AGR BIOL CHEM TOKYO, V54, P77, DOI 10.1080/00021369.1990.10869887
   SHIRAIWA M, 1990, AGR BIOL CHEM TOKYO, V54, P1347, DOI 10.1080/00021369.1990.10870134
   SHIRAIWA M, 1991, AGR BIOL CHEM TOKYO, V55, P911, DOI 10.1080/00021369.1991.10870686
   SHIRAIWA M, 1991, AGR BIOL CHEM TOKYO, V55, P315, DOI 10.1080/00021369.1991.10870574
   Song QJ, 2004, THEOR APPL GENET, V109, P122, DOI 10.1007/s00122-004-1602-3
   TANIYAMA T, 1988, CHEM PHARM BULL, V36, P2829
   TOPPING DL, 1980, AM J CLIN NUTR, V33, P783, DOI 10.1093/ajcn/33.4.783
   TSUKAMOTO C, 1992, PHYTOCHEMISTRY, V31, P4139, DOI 10.1016/0031-9422(92)80429-I
   TSUKAMOTO C, 1993, PHYTOCHEMISTRY, V34, P1351, DOI 10.1016/0031-9422(91)80028-Y
   Voorrips RE, 2002, J HERED, V93, P77, DOI 10.1093/jhered/93.1.77
   Xia Z, 2007, DNA RES, V14, P257, DOI 10.1093/dnares/dsm027
NR 26
TC 25
Z9 28
U1 1
U2 13
PU JAPANESE SOC BREEDING
PI TOKYO
PA UNIV TOKYO, GRADUATE SCHOOL AGRICULTURAL LIFE SCIENCES, BUNKYO-KU,
   TOKYO, 113-8657, JAPAN
SN 1344-7610
EI 1347-3735
J9 BREEDING SCI
JI Breed. Sci.
PD MAR
PY 2010
VL 60
IS 1
BP 3
EP 8
DI 10.1270/jsbbs.60.3
PG 6
WC Agronomy; Plant Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Agriculture; Plant Sciences
GA 590IS
UT WOS:000277219600002
OA Bronze
DA 2022-04-25
ER

PT J
AU Wu, SH
   Sun, CB
   Tian, D
   Li, YY
   Gao, XQ
   He, S
   Li, TY
AF Wu, Shuhua
   Sun, Chenbo
   Tian, Dong
   Li, Yangyang
   Gao, Xiangqian
   He, Shuang
   Li, Tangyue
TI Expression and clinical significances of Beclin1, LC3 and mTOR in
   colorectal cancer
SO INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY
LA English
DT Article
DE Colorectal cancer; Beclin1; LC3; mTOR; prognosis
ID DECREASED EXPRESSION; AUTOPHAGY; TUMORIGENESIS; PROGRESSION; PATTERNS;
   GABARAP; MARKER
AB Autophagy is related to cancer and other diseases, and compromised autophagy could promote chromosome instability associated with carcinogenesis and tumor progression. The role of autophagy in the growth and metastasis of colorectal cancer (CRC) remains poorly understood. Beclin1 mediates autophagic initiation, and LC3 is a specific marker for autophagy. Inactivation of mTOR caused by cellular hypoxia or energy deficiency induces autophagic activity. This study aims to examine the expression and clinical significance of these proteins in CRC. Immunohistochemistry results showed that the positive expression rates of Beclin1, LC3, and mTOR in cancer tissues were 90.50%, 87.19%, and 46.28%, respectively, which were higher than those in adjacent tissues (P < 0.05). Differentiation degree and lymph node metastasis were associated with LC3 overexpression (P < 0.05) but not with Beclin1 (P > 0.05). Lymph node metastasis was also related to mTOR. Spearman analysis results showed that LC3 expression was positively correlated with Beclin1 but negatively correlated with mTOR (r = 0.593 and -0.165, respectively; P < 0.01). Beclin1 expression was also not associated with mTOR (P > 0.05). Survival analysis further indicated that LC3, mTOR, and lymph node metastasis were independent prognostic factors in CRC. Real-time PCR results and Western blot indicated that Beclin1, LC3, and mTOR expression in CRC was significantly higher than that in adjacent tissues (P < 0.01). The aberrant protein expression may be associated with the development and progression of CRC. The LC3 and mTOR genes must be simultaneously detected to evaluate progression and prognosis of CRC.
C1 [Wu, Shuhua; Sun, Chenbo] Binzhou Med Univ Hosp, Dept Pathol, Binzhou 256603, Shandong, Peoples R China.
   [Tian, Dong; Li, Yangyang; Gao, Xiangqian; He, Shuang; Li, Tangyue] Binzhou Med Univ, Dept Pathol, Binzhou, Shandong, Peoples R China.
RP Wu, SH (corresponding author), Binzhou Med Univ Hosp, Dept Pathol, Binzhou 256603, Shandong, Peoples R China.
EM wsh6108@126.com; dongtianbz@163.com
FU Technology Development Project of Shandong Province [2010GSF10259]
FX This work was supported by Technology Development Project of Shandong
   Province (2010GSF10259). The authors thank Yuhong Zhu for technical
   assistance.
CR Bignell GR, 2010, NATURE, V463, P893, DOI 10.1038/nature08768
   Choi AMK, 2013, NEW ENGL J MED, V368, P651, DOI [10.1056/NEJMra1205406, 10.1056/NEJMc1303158]
   Edge SB, 2010, ANN SURG ONCOL, V17, P1471, DOI 10.1245/s10434-010-0985-4
   Giatromanolaki A, 2010, J CLIN PATHOL, V63, P867, DOI 10.1136/jcp.2010.079525
   Gimenez-Xavier P, 2008, INT J MOL MED, V22, P781, DOI 10.3892/ijmm_00000085
   Jiang ZF, 2012, MOL BIOL REP, V39, P259, DOI 10.1007/s11033-011-0734-1
   Johnson SM, 2010, J AM COLL SURGEONS, V210, P767, DOI 10.1016/j.jamcollsurg.2009.12.008
   Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720
   Kabeya Y, 2004, J CELL SCI, V117, P2805, DOI 10.1242/jcs.01131
   Kim J, 2011, NAT CELL BIOL, V13, P132, DOI 10.1038/ncb2152
   Klionsky DJ, 2008, AUTOPHAGY, V4, P740, DOI 10.4161/auto.6398
   Kremer CL, 2006, PROSTATE, V66, P1203, DOI 10.1002/pros.20410
   Kristensen AR, 2008, MOL CELL PROTEOMICS, V7, P2419, DOI 10.1074/mcp.M800184-MCP200
   Lee JW, 2007, APMIS, V115, P750, DOI 10.1111/j.1600-0463.2007.apm_640.x
   Levine B, 2008, AUTOPHAGY, V4, P600, DOI 10.4161/auto.6260
   Levine B, 2007, NATURE, V446, P745, DOI 10.1038/446745a
   Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257
   Marino G, 2007, J BIOL CHEM, V282, P18573, DOI 10.1074/jbc.M701194200
   Miracco C, 2010, HUM PATHOL, V41, P503, DOI 10.1016/j.humpath.2009.09.004
   Roesly HB, 2012, AM J PHYSIOL-GASTR L, V302, pG864, DOI 10.1152/ajpgi.00340.2011
   Sahin F, 2004, CLIN CANCER RES, V10, P8421, DOI 10.1158/1078-0432.CCR-04-0941
   Shen Y, 2008, AUTOPHAGY, V4, P1067, DOI 10.4161/auto.6827
   Sou Y, 2006, J BIOL CHEM, V281, P3017, DOI 10.1074/jbc.M505888200
   Sun ZJ, 2012, CLIN CANCER RES, V18, P5304, DOI 10.1158/1078-0432.CCR-12-1371
   Tanida I, 2005, AUTOPHAGY, V1, P84, DOI 10.4161/auto.1.2.1697
   Won KY, 2010, HUM PATHOL, V41, P107, DOI 10.1016/j.humpath.2009.07.006
   Wullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016
   Yoshioka A, 2008, INT J ONCOL, V33, P461, DOI 10.3892/ijo_00000028
NR 28
TC 54
Z9 61
U1 0
U2 6
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1936-2625
J9 INT J CLIN EXP PATHO
JI Int. J. Clin. Exp. Pathol.
PY 2015
VL 8
IS 4
BP 3882
EP 3891
PG 10
WC Oncology; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Pathology
GA CM5OP
UT WOS:000357737900046
PM 26097572
DA 2022-04-25
ER

PT J
AU Scott, AJ
   Arcaroli, JJ
   Bagby, SM
   Yahn, R
   Huber, KM
   Serkova, NJ
   Nguyen, A
   Kim, J
   Thorburn, A
   Vogel, J
   Quackenbush, KS
   Capasso, A
   Schreiber, A
   Blatchford, P
   Klauck, PJ
   Pitts, TM
   Eckhardt, SG
   Messersmith, WA
AF Scott, Aaron J.
   Arcaroli, John J.
   Bagby, Stacey M.
   Yahn, Rachel
   Huber, Kendra M.
   Serkova, Natalie J.
   Nguyen, Anna
   Kim, Jihye
   Thorburn, Andrew
   Vogel, Jon
   Quackenbush, Kevin S.
   Capasso, Anna
   Schreiber, Anna
   Blatchford, Patrick
   Klauck, Peter J.
   Pitts, Todd M.
   Eckhardt, S. Gail
   Messersmith, Wells A.
TI Cabozantinib Exhibits Potent Antitumor Activity in Colorectal Cancer
   Patient-Derived Tumor Xenograft Models via Autophagy and Signaling
   Mechanisms
SO MOLECULAR CANCER THERAPEUTICS
LA English
DT Article
ID HEPATOCYTE GROWTH-FACTOR; CONTRAST-ENHANCED MRI; C-MET; INHIBITION;
   METASTASIS; PATHWAYS; INVASION; THERAPY; KINASE; TARGET
AB Antiangiogenic therapy used in treatment of metastatic colorectal cancer (mCRC) inevitably succumbs to treatment resistance. Upregulation of MET may play an essential role to acquired anti-VEGF resistance. We previously reported that cabozantinib (XL184), an inhibitor of receptor tyrosine kinases (RTK) including MET, AXL, and VEGFR2, had potent antitumor effects in mCRC patient-derived tumor explant models. In this study, we examined the mechanisms of cabozantinib sensitivity, using regorafenib as a control. The tumor growth inhibition index (TGII) was used to compare treatment effects of cabozantinib 30 mg/kg daily versus regorafenib 10 mg/kg daily for a maximum of 28 days in 10 PDX mouse models. In vivo angiogenesis and glucose uptake were assessed using dynamic contrast-enhanced (DCE)-MRI and [F-18]-FDG-PET imaging, respectively. RNA-Seq, RTK assay, and immunoblotting analysis were used to evaluate gene pathway regulation in vivo and in vitro. Analysis of TGII demonstrated significant antitumor effects with cabozantinib compared with regorafenib (average TGII 3.202 vs. 48.48, respectively; P = 0.007). Cabozantinib significantly reduced vascularity and glucose uptake compared with baseline. Gene pathway analysis showed that cabozantinib significantly decreased protein activity involved in glycolysis and upregulated proteins involved in autophagy compared with control, whereas regorafenib did not. The combination of two separate anti-autophagy agents, SBI-0206965 and chloroquine, plus cabozantinib increased apoptosis in vitro. Cabozantinib demonstrated significant antitumor activity, reduction in tumor vascularity, increased autophagy, and altered cell metabolism compared with regorafenib. Our findings support further evaluation of cabozantinib and combinational approaches targeting autophagy in colorectal cancer. (C) 2018 AACR.
C1 [Scott, Aaron J.] Banner Univ Arizona, Canc Ctr, Div Hematol & Oncol, Tucson, AZ USA.
   [Arcaroli, John J.; Bagby, Stacey M.; Yahn, Rachel; Nguyen, Anna; Kim, Jihye; Quackenbush, Kevin S.; Capasso, Anna; Schreiber, Anna; Blatchford, Patrick; Klauck, Peter J.; Pitts, Todd M.; Messersmith, Wells A.] Univ Colorado, Div Med Oncol, Anschutz Med Campus, Aurora, CO USA.
   [Arcaroli, John J.; Bagby, Stacey M.; Yahn, Rachel; Huber, Kendra M.; Serkova, Natalie J.; Nguyen, Anna; Kim, Jihye; Thorburn, Andrew; Vogel, Jon; Quackenbush, Kevin S.; Capasso, Anna; Schreiber, Anna; Blatchford, Patrick; Klauck, Peter J.; Pitts, Todd M.; Messersmith, Wells A.] Univ Colorado, Canc Ctr, Aurora, CO USA.
   [Huber, Kendra M.; Serkova, Natalie J.] Univ Colorado, Dept Anesthesia, Anschutz Med Campus, Aurora, CO USA.
   [Thorburn, Andrew] Univ Colorado, Dept Pharmacol, Anschutz Med Campus, Aurora, CO USA.
   [Vogel, Jon] Univ Colorado, Dept Surg, Anschutz Med Campus, Aurora, CO USA.
   [Eckhardt, S. Gail] Univ Texas Austin, Div Med Oncol, Austin, TX 78712 USA.
   [Eckhardt, S. Gail] Univ Texas Austin, Dell Med Sch, Dept Oncol, Austin, TX 78712 USA.
   [Eckhardt, S. Gail] Univ Texas Austin, Dell Med Sch, Canc Programs, Austin, TX 78712 USA.
RP Scott, AJ (corresponding author), Banner Univ Arizona, Ctr Canc, 1501 N Campbell Ave,Rm 1916, Tucson, AZ 85724 USA.
EM ajscott@email.arizona.edu
OI Yahn, Rachel/0000-0001-8848-3593
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [1R01CA152303-01]; University of
   Colorado Cancer Center Shared Resource [P30CA046934]; NATIONAL CANCER
   INSTITUTEUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)
   [R01CA152303, P30CA046934] Funding Source: NIH RePORTER
FX This work was supported by the NIH (1R01CA152303-01; to W.A.
   Messersmith) and the University of Colorado Cancer Center Shared
   Resource (P30CA046934; to W.A. Messersmith). Support was also received
   by Exelixis (to T.M. Pitts). We also thank the patients who consented to
   allow their tumor tissue to be used in these experiments.
CR Abounader R, 2005, NEURO-ONCOLOGY, V7, P436, DOI 10.1215/S1152851705000050
   Bentzien F, 2013, THYROID, V23, P1569, DOI 10.1089/thy.2013.0137
   Birchmeier C, 2003, NAT REV MOL CELL BIO, V4, P915, DOI 10.1038/nrm1261
   BLADT F, 1995, NATURE, V376, P768, DOI 10.1038/376768a0
   Bottaro DP, 2003, NATURE, V423, P593, DOI 10.1038/423593a
   BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629
   Chan LLY, 2012, AUTOPHAGY, V8, P1371, DOI 10.4161/auto.21028
   Choueiri TK, 2015, NEW ENGL J MED, V373, P1814, DOI 10.1056/NEJMoa1510016
   Dandekar M, 2007, J NUCL MED, V48, P602, DOI 10.2967/jnumed.106.036608
   Daudigeos-Dubus E, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142612
   Denko NC, 2008, NAT REV CANCER, V8, P705, DOI 10.1038/nrc2468
   Din FVN, 2012, GASTROENTEROLOGY, V142, P1504, DOI 10.1053/j.gastro.2012.02.050
   Ebos JML, 2009, CLIN CANCER RES, V15, P5020, DOI 10.1158/1078-0432.CCR-09-0095
   Ebos JML, 2009, CANCER CELL, V15, P232, DOI 10.1016/j.ccr.2009.01.021
   Egan DF, 2015, MOL CELL, V59, P285, DOI 10.1016/j.molcel.2015.05.031
   Elisei R, 2013, J CLIN ONCOL, V31, P3639, DOI 10.1200/JCO.2012.48.4659
   Feng YC, 2014, CELL RES, V24, P24, DOI 10.1038/cr.2013.168
   Ferrara N, 2005, EXP SUPPL, V94, P209
   Gerritsen ME, 2003, BRIT J PHARMACOL, V140, P595, DOI 10.1038/sj.bjp.0705494
   Gherardi E, 2012, NAT REV CANCER, V12, P89, DOI 10.1038/nrc3205
   Graham TJ, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju033
   GRANT DS, 1993, P NATL ACAD SCI USA, V90, P1937, DOI 10.1073/pnas.90.5.1937
   Grothey A, 2013, LANCET, V381, P303, DOI 10.1016/S0140-6736(12)61900-X
   Hurwitz Herbert, 2004, Clin Colorectal Cancer, V4 Suppl 2, pS62, DOI 10.3816/CCC.2004.s.010
   Huynh H, 2015, J EXP CLIN CANC RES, V34, DOI 10.1186/s13046-015-0243-5
   Jiang XJ, 2015, J CLIN INVEST, V125, P47, DOI 10.1172/JCI73942
   Jung CH, 2010, FEBS LETT, V584, P1287, DOI 10.1016/j.febslet.2010.01.017
   Kanehisa M, 2017, NUCLEIC ACIDS RES, V45, pD353, DOI 10.1093/nar/gkw1092
   Kim KW, 2006, J BIOL CHEM, V281, P36883, DOI 10.1074/jbc.M607094200
   Kim SS, 2016, PLOS ONE, V11, DOI [10.1371/journal.pone.0164800, 10.1371/journal.pone.0147745]
   Kim YC, 2015, J CLIN INVEST, V125, P25, DOI 10.1172/JCI73939
   Kroemer G, 2010, MOL CELL, V40, P280, DOI 10.1016/j.molcel.2010.09.023
   Lai AZ, 2009, TRENDS CELL BIOL, V19, P542, DOI 10.1016/j.tcb.2009.07.002
   Longo DL, 2015, MAGN RESON IMAGING, V33, P725, DOI 10.1016/j.mri.2015.03.005
   Ma L, 2017, MAGN RESON IMAGING, V37, P27, DOI 10.1016/j.mri.2016.11.004
   Mayer RJ, 2015, NEW ENGL J MED, V372, P1909, DOI 10.1056/NEJMoa1414325
   Mosesson Y, 2008, NAT REV CANCER, V8, P835, DOI 10.1038/nrc2521
   Nguyen HD, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055336
   Paez-Ribes M, 2009, CANCER CELL, V15, P220, DOI 10.1016/j.ccr.2009.01.027
   Pennacchietti S, 2003, CANCER CELL, V3, P347, DOI 10.1016/S1535-6108(03)00085-0
   Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68
   Sennino B, 2012, CANCER DISCOV, V2, P270, DOI 10.1158/2159-8290.CD-11-0240
   Serkova NJ, 2009, RECENT PAT ANTI-CANC, V4, P36, DOI 10.2174/157489209787002434
   Shojaei F, 2012, CANCER LETT, V320, P48, DOI 10.1016/j.canlet.2012.01.026
   Song EK, 2015, INT J CANCER, V136, P1967, DOI 10.1002/ijc.29225
   Sulpice E, 2009, BIOL CELL, V101, P525, DOI 10.1042/BC20080221
   Takeuchi H, 2003, CLIN CANCER RES, V9, P1480
   Tentler JJ, 2012, NAT REV CLIN ONCOL, V9, P338, DOI 10.1038/nrclinonc.2012.61
   Thorburn A, 2014, PLOS BIOL, V12, DOI 10.1371/journal.pbio.1001967
   Thorburn A, 2014, MOL PHARMACOL, V85, P830, DOI 10.1124/mol.114.091850
   Trusolino L, 2010, NAT REV MOL CELL BIO, V11, P834, DOI 10.1038/nrm3012
   US Cancer Statistics Working Group, 2015, US CANC STAT 1999 20
   Wilhelm SM, 2011, INT J CANCER, V129, P245, DOI 10.1002/ijc.25864
   Yang XY, 2016, ONCOL LETT, V12, P102, DOI 10.3892/ol.2016.4590
   Yeo DM, 2015, J MAGN RESON IMAGING, V41, P474, DOI 10.1002/jmri.24541
NR 55
TC 18
Z9 21
U1 1
U2 13
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1535-7163
EI 1538-8514
J9 MOL CANCER THER
JI Mol. Cancer Ther.
PD OCT
PY 2018
VL 17
IS 10
BP 2112
EP 2122
DI 10.1158/1535-7163.MCT-17-0131
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA HI0QA
UT WOS:000456145700004
PM 30026382
OA Green Accepted
DA 2022-04-25
ER

PT J
AU Chen, PJ
   Luo, XY
   Nie, PP
   Wu, BY
   Xu, W
   Shi, XP
   Chang, HC
   Li, B
   Yu, XR
   Zou, ZZ
AF Chen, Pinjia
   Luo, Xiaoyong
   Nie, Peipei
   Wu, Baoyan
   Xu, Wei
   Shi, Xinpeng
   Chang, Haocai
   Li, Bing
   Yu, Xiurong
   Zou, Zhengzhi
TI CQ synergistically sensitizes human colorectal cancer cells to
   SN-38/CPT-11 through lysosomal and mitochondrial apoptotic pathway via
   p53-ROS cross-talk
SO FREE RADICAL BIOLOGY AND MEDICINE
LA English
DT Article
DE Chloroquine; SN-38; P53; ROS; Apoptosis; Colorectal cancer
ID ROS-MEDIATED MECHANISMS; PHASE-II TRIAL; OXIDATIVE STRESS; MEMBRANE
   PERMEABILIZATION; ANTIOXIDANT FUNCTION; P53 MUTATIONS; INHIBITION;
   AUTOPHAGY; IRINOTECAN; CHLOROQUINE
AB Autophagy plays a key role in supporting cell survival against chemotherapy-induced apoptosis. In this study, we found the chemotherapy agent SN-38 induced autophagy in colorectal cancer (CRC) cells. However, inhibition of autophagy using a small molecular inhibitor 3-methyladenine (3-MA) and ATG5 siRNA did not increase SN-38induced cytotoxicity in CRC cells. Notably, another autophagy inhibitor chloroquine (CQ) synergistically enhanced the anti-tumor activity of SN-38 in CRC cells with wild type (WT) p53. Subsequently, we identified a potential mechanism of this cooperative interaction by showing that CQ and SN-38 acted together to trigger reactive oxygen species (ROS) burst, upregulate p53 expression, elicit the loss of lysosomal membrane potential (LMP) and mitochondrial membrane potential (Aym). In addition, ROS induced by CQ plus SN-38 upregulated p53 levels by activating p38, conversely, p53 stimulated ROS. These results suggested that ROS and p53 reciprocally promoted each other's production and cooperated to induce CRC cell death. Moreover, we showed induction of ROS and p53 by the two agents provoked the loss of LMP and AWm. Altogether, all results suggested that CQ synergistically sensitized human CRC cells with WT p53 to SN-38 through lysosomal and mitochondrial apoptotic pathway via p53-ROS cross-talk. Lastly, we showed that CQ could enhance CRC cells response to CPT 11 (a prodrug of SN-38) in xenograft models. Thus the combined treatment might represent an attractive therapeutic strategy for the treatment of CRC.
C1 [Chen, Pinjia; Luo, Xiaoyong; Shi, Xinpeng; Li, Bing; Yu, Xiurong] Zhengzhou Univ, Dept Oncol, Affiliated Luoyang Cent Hosp, Luoyang, Peoples R China.
   [Nie, Peipei; Xu, Wei] Guangzhou Med Univ, KingMed Diagnost & KingMed Sch Lab Med, Guangzhou, Guangdong, Peoples R China.
   [Wu, Baoyan; Chang, Haocai; Zou, Zhengzhi] South China Normal Univ, MOE Key Lab Laser Life Sci, Joint Lab Laser Oncol, Canc Ctr,Sun Yat Sen Univ,Coll Biophoton, 55 Zhongshan Rd West, Guangzhou, Guangdong, Peoples R China.
   [Wu, Baoyan; Chang, Haocai; Zou, Zhengzhi] South China Normal Univ, Inst Laser Life Sci, Joint Lab Laser Oncol, Canc Ctr,Sun Yat Sen Univ,Coll Biophoton, 55 Zhongshan Rd West, Guangzhou, Guangdong, Peoples R China.
RP Zou, ZZ (corresponding author), South China Normal Univ, MOE Key Lab Laser Life Sci, Joint Lab Laser Oncol, Canc Ctr,Sun Yat Sen Univ,Coll Biophoton, 55 Zhongshan Rd West, Guangzhou, Guangdong, Peoples R China.; Zou, ZZ (corresponding author), South China Normal Univ, Inst Laser Life Sci, Joint Lab Laser Oncol, Canc Ctr,Sun Yat Sen Univ,Coll Biophoton, 55 Zhongshan Rd West, Guangzhou, Guangdong, Peoples R China.
EM zouzhengzhi@m.scnu.edu.cn
RI bin, li/AAK-6880-2020
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81402187, 81371646]; Ph.D Start-up Fund of
   Natural Science Foundation of Guangdong Province [2014A030310505];
   Foundation for Distinguished Young Talents in Higher Education of
   Guangdong [C1085229]
FX This study was supported by grants from the National Natural Science
   Foundation of China (Nos. 81402187 and 81371646), the Ph.D Start-up Fund
   of Natural Science Foundation of Guangdong Province (No. 2014A030310505
   to Z. Zou), the Foundation for Distinguished Young Talents in Higher
   Education of Guangdong (No. C1085229 to Z. Zou).
CR Amaravadi RK, 2007, J CLIN INVEST, V117, P326, DOI 10.1172/JCI28833
   Boya P, 2008, ONCOGENE, V27, P6434, DOI 10.1038/onc.2008.310
   Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845
   Carlisi D, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.94
   Ch'ng JH, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.265
   Choi AMK, 2013, NEW ENGL J MED, V368, P651, DOI [10.1056/NEJMra1205406, 10.1056/NEJMc1303158]
   CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4
   Denamur S, 2011, FREE RADICAL BIO MED, V51, P1656, DOI 10.1016/j.freeradbiomed.2011.07.015
   Pons DG, 2015, FREE RADICAL BIO MED, V86, P67, DOI 10.1016/j.freeradbiomed.2015.04.032
   Goto K, 2016, LANCET ONCOL, V17, P1147, DOI 10.1016/S1470-2045(16)30104-8
   Hasanain M, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.219
   Hu WW, 2010, P NATL ACAD SCI USA, V107, P7455, DOI 10.1073/pnas.1001006107
   Jiang SH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132880
   John S, 2013, ANTI-CANCER AGENT ME, V13, P811, DOI 10.2174/1871520611313050015
   Kalyanaraman B, 2012, FREE RADICAL BIO MED, V52, P1, DOI 10.1016/j.freeradbiomed.2011.09.030
   Kang MY, 2013, CELL DEATH DIFFER, V20, P117, DOI 10.1038/cdd.2012.102
   KASTRINAKIS WV, 1995, ONCOGENE, V11, P647
   Kimura T, 2013, CANCER RES, V73, P3, DOI 10.1158/0008-5472.CAN-12-2464
   Kishida O, 2005, CANCER CHEMOTH PHARM, V55, P393, DOI 10.1007/s00280-004-0904-0
   Liu B, 2008, FREE RADICAL BIO MED, V44, P1529, DOI 10.1016/j.freeradbiomed.2008.01.011
   Liu Y, 2006, P NATL ACAD SCI USA, V103, P976, DOI 10.1073/pnas.0510146103
   Lou YF, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097719
   Luo XY, 2016, ONCOTARGET, V7, P26480, DOI 10.18632/oncotarget.8419
   Maes H, 2014, AUTOPHAGY, V10, P2082, DOI 10.4161/auto.36259
   Maycotte P, 2012, AUTOPHAGY, V8, P200, DOI 10.4161/auto.8.2.18554
   Mi YJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120426
   Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639
   Muller PAJ, 2014, CANCER CELL, V25, P304, DOI 10.1016/j.ccr.2014.01.021
   Nie PP, 2015, CELL PHYSIOL BIOCHEM, V35, P2255, DOI 10.1159/000374030
   Ocean AJ, 2014, INVEST NEW DRUG, V32, P542, DOI 10.1007/s10637-014-0070-0
   Pettersen K, 2016, FREE RADICAL BIO MED, V90, P158, DOI 10.1016/j.freeradbiomed.2015.11.018
   Poston GJ, 2008, J CLIN ONCOL, V26, P4828, DOI 10.1200/JCO.2008.17.6453
   Rivory LP, 1996, BIOCHEM PHARMACOL, V52, P1103, DOI 10.1016/0006-2952(96)00457-1
   Sablina AA, 2005, NAT MED, V11, P1306, DOI 10.1038/nm1320
   Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X
   Shigeta K, 2016, INT J CANCER, V139, P946, DOI 10.1002/ijc.30127
   Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993
   Smyth EC, 2015, J CLIN ONCOL, V33, P2409, DOI 10.1200/JCO.2014.59.7088
   Trachootham D, 2009, NAT REV DRUG DISCOV, V8, P579, DOI 10.1038/nrd2803
   Wang S., 2003, P NATL ACAD SCI US, V100, P15095
   Wang XY, 2015, CANCER RES, V75, P5001, DOI 10.1158/0008-5472.CAN-15-0563
   Xu Y, 2016, FREE RADICAL BIO MED, V96, P67, DOI 10.1016/j.freeradbiomed.2016.04.016
   Yang JC, 2011, FREE RADICAL BIO MED, V51, P641, DOI 10.1016/j.freeradbiomed.2011.05.012
   Zou Z.Z., 2015, ONCOTARGET
   Zou ZZ, 2016, BIOCHEM BIOPH RES CO, V478, P227, DOI 10.1016/j.bbrc.2016.07.063
   Zou ZZ, 2012, AUTOPHAGY, V8, P1798, DOI 10.4161/auto.22110
   Zuco V, 2015, ONCOTARGET, V6, P8736, DOI 10.18632/oncotarget.3538
NR 47
TC 46
Z9 48
U1 3
U2 18
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0891-5849
EI 1873-4596
J9 FREE RADICAL BIO MED
JI Free Radic. Biol. Med.
PD MAR
PY 2017
VL 104
BP 280
EP 297
DI 10.1016/j.freeradbiomed.2017.01.033
PG 18
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA EN4HJ
UT WOS:000395968300023
PM 28131902
DA 2022-04-25
ER

PT J
AU Shyu, RY
   Wang, CH
   Wu, CC
   Chen, ML
   Lee, MC
   Wang, LK
   Jiang, SY
   Tsai, FM
AF Shyu, Rong-Yaun
   Wang, Chun-Hua
   Wu, Chang-Chieh
   Chen, Mao-Liang
   Lee, Ming-Cheng
   Wang, Lu-Kai
   Jiang, Shun-Yuan
   Tsai, Fu-Ming
TI Tazarotene-Induced Gene 1 Enhanced Cervical Cell Autophagy through
   Transmembrane Protein 192
SO MOLECULES AND CELLS
LA English
DT Article
DE all-trans retinoic acid; autophagy; Beclin-1; LC3B; tazarotene-induced
   gene 1; transmembrane protein 192
ID RETINOID RESPONSE GENE; ACID RECEPTOR-BETA; NASOPHARYNGEAL CARCINOMA;
   TUMOR-SUPPRESSOR; PROMOTER HYPERMETHYLATION; LYSOSOMAL MEMBRANE; DNA
   METHYLATION; TIG1; DIFFERENTIATION; BECLIN-1
AB Tazarotene-induced gene 1 (TIG1) is a retinoic acid-inducible protein that is considered a putative tumor suppressor. The expression of TIG1 is decreased in malignant prostate carcinoma or poorly differentiated colorectal adenocarcinoma, but TIG1 is present in benign or well-differentiated tumors. Ectopic TIG1 expression led to suppression of growth in cancer cells. However, the function of TIG1 in cell differentiation is still unknown. Using a yeast two-hybrid system, we found that transmembrane protein 192 (TMEM192) interacted with TIG1. We also found that both TIG1A and TIG1B isoforms interacted and co-localized with TMEM192 in HtTA cervical cancer cells. The expression of TIG1 induced the expression of autophagy-related proteins, including Beclin-1 and LC-3B. The silencing of TMEM192 reduced the TIG1-mediated upregulation of autophagic activity. Furthermore, silencing of either TIG1 or TMEM192 led to alleviation of the upregulation of autophagy induced by all-trans retinoic acid. Our results demonstrate that the expression of TIG1 leads to cell autophagy through TMEM192. Our study also suggests that TIG1 and TMEM192 play an important role in the all-trans retinoic acid-mediated upregulation of autophagic activity.
C1 [Shyu, Rong-Yaun] Buddhist Tzuchi Med Fdn, Taipei Tzuchi Hosp, Dept Internal Med, New Taipei 231, Taiwan.
   [Wang, Chun-Hua] Buddhist Tzuchi Med Fdn, Taipei Tzuchi Hosp, Dept Dermatol, New Taipei 231, Taiwan.
   [Wu, Chang-Chieh] Natl Def Med Ctr, Triserv Gen Hosp, Dept Surg, Taipei 114, Taiwan.
   [Chen, Mao-Liang; Lee, Ming-Cheng; Jiang, Shun-Yuan; Tsai, Fu-Ming] Buddhist Tzuchi Med Fdn, Taipei Tzuchi Hosp, Dept Res, New Taipei 231, Taiwan.
   [Wang, Lu-Kai] Chang Gung Univ, Chang Gung Mem Hosp, Inst Radiol Res, Radiat Biol Core Lab, Taoyuan 333, Taiwan.
RP Jiang, SY; Tsai, FM (corresponding author), Buddhist Tzuchi Med Fdn, Taipei Tzuchi Hosp, Dept Res, New Taipei 231, Taiwan.
EM jiang.shunyuan@gmail.com; afu2215@gmail.com
RI Chen, Mao-Liang/AAH-1283-2019
OI Tsai, Fu-Ming/0000-0002-4563-0458
FU Taipei Tzuchi Hospital through Buddhist Tzuchi Medical Foundation,
   Taipei, Taiwan [TCRD-TPE-105-17]; Core Laboratory of the Buddhist Tzuchi
   General Hospital
FX This work was supported by a grant (TCRD-TPE-105-17) from the Taipei
   Tzuchi Hospital through the Buddhist Tzuchi Medical Foundation, Taipei,
   Taiwan. The authors thank the Core Laboratory of the Buddhist Tzuchi
   General Hospital for support.
CR Aagaard A, 2005, STRUCTURE, V13, P309, DOI 10.1016/j.str.2004.12.013
   Aita VM, 1999, GENOMICS, V59, P59, DOI 10.1006/geno.1999.5851
   Anguiano J, 2013, NAT CHEM BIOL, V9, P374, DOI 10.1038/nchembio.1230
   Bernard M, 2014, AUTOPHAGY, V10, P2193, DOI 10.4161/15548627.2014.981786
   Chen X., 2014, J APPL MATH, V2014, P1, DOI DOI 10.1061/(ASCE)MT.1943-5533.0000778
   Choi AMK, 2013, NEW ENGL J MED, V368, P651, DOI [10.1056/NEJMra1205406, 10.1056/NEJMc1303158]
   Dooley HC, 2014, MOL CELL, V55, P238, DOI 10.1016/j.molcel.2014.05.021
   Guo JY, 2011, GENE DEV, V25, P460, DOI 10.1101/gad.2016311
   Hanada T, 2007, J BIOL CHEM, V282, P37298, DOI 10.1074/jbc.C700195200
   Hara T, 2008, J CELL BIOL, V181, P497, DOI 10.1083/jcb.200712064
   Jing C, 2002, JNCI-J NATL CANCER I, V94, P482
   Kadowaki M, 2009, METHOD ENZYMOL, V452, P199, DOI 10.1016/S0076-6879(08)03613-6
   Kang R, 2011, CELL DEATH DIFFER, V18, P571, DOI 10.1038/cdd.2010.191
   Kobayashi S, 2015, BIOL PHARM BULL, V38, P1098, DOI 10.1248/bpb.b15-00096
   Kwok WK, 2009, CANCER GENET CYTOGEN, V194, P58, DOI 10.1016/j.cancergencyto.2009.06.005
   Kwong J, 2005, INT J CANCER, V113, P386, DOI 10.1002/ijc.20593
   Lamb CA, 2013, NAT REV MOL CELL BIO, V14, P759, DOI 10.1038/nrm3696
   Lee IH, 2008, P NATL ACAD SCI USA, V105, P3374, DOI 10.1073/pnas.0712145105
   Lee J, 2012, BIOCHEM J, V441, P523, DOI 10.1042/BJ20111451
   Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257
   Liang Y, 2007, NAT GENET, V39, P178, DOI 10.1038/ng1938
   Liu Z, 2012, ONCOL REP, V28, P985, DOI 10.3892/or.2012.1881
   Lock R, 2014, CANCER DISCOV, V4, P466, DOI 10.1158/2159-8290.CD-13-0841
   Lock R, 2011, MOL BIOL CELL, V22, P165, DOI 10.1091/mbc.E10-06-0500
   Mizuiri H, 2005, CANCER SCI, V96, P571, DOI 10.1111/j.1349-7006.2005.00082.x
   Mizushima N, 2011, CELL, V147, P728, DOI 10.1016/j.cell.2011.10.026
   Mizushima N, 2011, ANNU REV CELL DEV BI, V27, P107, DOI 10.1146/annurev-cellbio-092910-154005
   Nagpal S, 1996, J INVEST DERMATOL, V106, P269, DOI 10.1111/1523-1747.ep12340668
   Orfali N, 2015, EXP HEMATOL, V43, P781, DOI 10.1016/j.exphem.2015.04.012
   Peng ZG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036891
   Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039
   Rajawat Y, 2010, AUTOPHAGY, V6, P1224, DOI 10.4161/auto.6.8.13793
   Russell RC, 2013, NAT CELL BIOL, V15, P741, DOI 10.1038/ncb2757
   Schroder B, 2010, BIOL CHEM, V391, P695, DOI 10.1515/BC.2010.062
   Shutoh M, 2005, CANCER-AM CANCER SOC, V104, P1609, DOI 10.1002/cncr.21392
   Simon HU, 2012, CIRC RES, V110, P524, DOI 10.1161/CIRCRESAHA.112.265157
   Takamura A, 2011, GENE DEV, V25, P795, DOI 10.1101/gad.2016211
   Tsai FM, 2011, J BIOMED SCI, V18, DOI 10.1186/1423-0127-18-88
   Vessoni AT, 2012, STEM CELLS DEV, V21, P513, DOI 10.1089/scd.2011.0526
   Wang Z., 2011, INFORM RES, V2011, P1, DOI DOI 10.1111/J.1365-313X.2011.04659.X
   White E, 2015, J CLIN INVEST, V125, P42, DOI 10.1172/JCI73941
   Wu CC, 2006, EUR J CANCER, V42, P557, DOI 10.1016/j.ejca.2005.11.015
   Wu CC, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-175
   Yanatatsaneejit P, 2008, ORAL ONCOL, V44, P400, DOI 10.1016/j.oraloncology.2007.05.008
   Yang SH, 2011, GENE DEV, V25, P717, DOI 10.1101/gad.2016111
   Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100
   Zhang JM, 2004, ONCOGENE, V23, P2241, DOI 10.1038/sj.onc.1207328
   Zhuang WZ, 2011, INT J CANCER, V129, P2720, DOI 10.1002/ijc.25975
NR 48
TC 8
Z9 8
U1 0
U2 18
PU KOREAN SOC MOLECULAR & CELLULAR  BIOLOGY
PI SEOUL
PA 635-4, YUCKSAM-DONG, GANGNAM-GU, SEOUL 135-703, SOUTH KOREA
SN 1016-8478
EI 0219-1032
J9 MOL CELLS
JI Mol. Cells
PD DEC 31
PY 2016
VL 39
IS 12
BP 877
EP 887
DI 10.14348/molcells.2016.0161
PG 11
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA EJ4IE
UT WOS:000393179300006
PM 27989102
OA Green Published, Green Submitted, hybrid
DA 2022-04-25
ER

PT J
AU Abdel-Aziz, AK
   Azab, SSE
   Youssef, SS
   El-Sayed, AM
   El-Demerdash, E
   Shouman, S
AF Abdel-Aziz, Amal Kamal
   Azab, Samar Saad Eldeen
   Youssef, Samar Samir
   El-Sayed, Abeer Mostafa
   El-Demerdash, Ebtehal
   Shouman, Samia
TI Modulation of Imatinib Cytotoxicity by Selenite in HCT116 Colorectal
   Cancer Cells
SO BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY
LA English
DT Article
ID GASTROINTESTINAL STROMAL TUMOR; KINASE INHIBITOR STI571; CHRONIC
   MYELOGENOUS LEUKEMIA; CHRONIC MYELOID-LEUKEMIA; SODIUM SELENITE;
   AUTOPHAGY INHIBITION; GROWTH-INHIBITION; APOPTOSIS; ACTIVATION;
   MECHANISMS
AB Imatinib is a principal therapeutic agent for targeting colorectal tumours. However, mono-targeting by imatinib does not always achieve complete cancer eradication. Selenite, a well-known chemopreventive agent, is commonly used in cancer patients. In this study, we aimed to explore whether selenite can modulate imatinib cytotoxicity in colorectal cancer cells. HCT116 cells were treated with different concentrations of imatinib and/or selenite for 24, 48 and 72hr. Imatinib-selenite interaction was analysed using isobologram equation. As indicators of apoptosis, DNA fragmentation, caspase-3 activity, Bcl-2 expression were explored. Autophagic machinery was also checked by visualizing acidic vesicular organelles and measuring Beclin-1 expression. Furthermore, reactive oxygen and nitrogen species were also examined. This study demonstrated that selenite synergistically augmented imatinib cytotoxicity in HCT116 cells as demonstrated by combination and dose reduction indices. Supranutritional dose of selenite when combined with imatinib induced apoptotic machinery by decreasing Bcl-2 expression, increasing caspase-3 activity and subsequently fragmenting DNA and blunted cytoprotective autophagy by decreasing Beclin-1 expression and autophagosomes formation. Moreover, their combination induced cell cycle S-phase block, increased total thiol content and reduced nitric oxide levels. In conclusion, selenite synergizes imatinib cytotoxicity through multi-barrelled molecular targeting, providing a novel therapeutic approach for colorectal cancer.
C1 [Abdel-Aziz, Amal Kamal; Azab, Samar Saad Eldeen; El-Demerdash, Ebtehal] Ain Shams Univ, Pharmacol & Toxicol Dept, Fac Pharm, Cairo, Egypt.
   [Youssef, Samar Samir] Natl Res Ctr, Microbial Biotechnol Dept, Cairo, Egypt.
   [El-Sayed, Abeer Mostafa] Cairo Univ, Natl Canc Inst, Dept Pathol, Tissue Culture & Cytogenet Unit, Cairo 11796, Egypt.
   [Shouman, Samia] Cairo Univ, Natl Canc Inst, Dept Canc Biol, Cairo 11796, Egypt.
RP Shouman, S (corresponding author), Cairo Univ, Natl Canc Inst, Dept Canc Biol, Kasr Alani St, Cairo 11796, Egypt.
EM samiasshouman@yahoo.com
RI Abdel-Aziz, Amal Kamal/AAA-1360-2021; El-Demerdash,
   Ebtehal/ABE-6729-2020; Abdel-Aziz, Amal Kamal/AAB-9050-2019; Elsayed,
   Abeer Mostafa/I-5973-2019; shouman, samia/F-5395-2018
OI Abdel-Aziz, Amal Kamal/0000-0003-1709-1183; Elsayed, Abeer
   Mostafa/0000-0002-8135-8025; shouman, samia/0000-0002-2883-8775;
   Youssef, Samar/0000-0001-7114-4325; Azab, Samar/0000-0002-0253-8280
CR Arthur CR, 2007, BIOCHEM PHARMACOL, V74, P981, DOI 10.1016/j.bcp.2007.07.003
   Attoub S, 2002, CANCER RES, V62, P4879
   Blagosklonny MV, 2005, CELL CYCLE, V4, P269, DOI 10.4161/cc.4.2.1493
   Brozmanova J, 2010, ARCH TOXICOL, V84, P919, DOI 10.1007/s00204-010-0595-8
   Cao TM, 2006, ANN HEMATOL, V85, P434, DOI 10.1007/s00277-005-0046-4
   Chou TC, 2006, PHARMACOL REV, V58, P621, DOI 10.1124/pr.58.3.10
   Cianchi F, 2004, CLIN CANCER RES, V10, P2694, DOI 10.1158/1078-0432.CCR-03-0192
   Connelly-Frost A, 2009, NUTR CANCER, V61, P165, DOI 10.1080/01635580802404188
   Crowley LC, 2013, ONCOL REP, V29, P2261, DOI 10.3892/or.2013.2377
   ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6
   Ertmer A, 2007, LEUKEMIA, V21, P936, DOI 10.1038/sj.leu.2404606
   Fang WF, 2010, INT J CANCER, V127, P32, DOI 10.1002/ijc.25029
   Gajiwala KS, 2009, P NATL ACAD SCI USA, V106, P1542, DOI 10.1073/pnas.0812413106
   Gallegos A, 1997, CANCER RES, V57, P4965
   Gottesman MM, 2002, ANNU REV MED, V53, P615, DOI 10.1146/annurev.med.53.082901.103929
   Gupta A, 2010, P NATL ACAD SCI USA, V107, P14333, DOI 10.1073/pnas.1000248107
   Guruswamy S, 2008, GENE REGUL SYST BIO, V2, P163
   Hamai A, 2006, ONCOGENE, V25, P7618, DOI 10.1038/sj.onc.1209738
   Huang F, 2009, FREE RADICAL BIO MED, V46, P1186, DOI 10.1016/j.freeradbiomed.2009.01.026
   Huguet F, 2008, MOL CANCER THER, V7, P398, DOI 10.1158/1535-7163.MCT-07-2023
   Hwang YY, 2009, AM J HEMATOL, V84, P302, DOI 10.1002/ajh.21383
   Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]
   Jiang Q, 2012, BMB REP, V45, P194, DOI 10.5483/BMBRep.2012.45.3.194
   Joensuu H, 2001, NEW ENGL J MED, V344, P1052, DOI 10.1056/NEJM200104053441404
   Karsa LV, 2010, BEST PRACT RES CL GA, V24, P381, DOI 10.1016/j.bpg.2010.06.004
   KiremidjianSchumacher L, 1996, BIOL TRACE ELEM RES, V52, P227, DOI 10.1007/BF02789164
   Koukourakis MI, 2010, BRIT J CANCER, V103, P1209, DOI 10.1038/sj.bjc.6605904
   Kralova V, 2012, TOXICOL IN VITRO, V26, P258, DOI 10.1016/j.tiv.2011.12.010
   Kralova V, 2009, TOXICOL IN VITRO, V23, P1497, DOI 10.1016/j.tiv.2009.07.012
   Kwee JK, 2008, ANTI-CANCER DRUG, V19, P975, DOI 10.1097/CAD.0b013e3283140c6f
   Luo HY, 2012, COLLOID SURFACE B, V94, P304, DOI 10.1016/j.colsurfb.2012.02.006
   Luo H, 2012, CANCER LETT, V315, P78, DOI 10.1016/j.canlet.2011.10.014
   Mahon FX, 2000, BLOOD, V96, P1070, DOI 10.1182/blood.V96.3.1070.015k17_1070_1079
   Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239
   Miranda KM, 2001, NITRIC OXIDE-BIOL CH, V5, P62, DOI 10.1006/niox.2000.0319
   NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0
   Okano M, 2014, J PEDIAT HEMATOL ONC, V36, P200, DOI 10.1097/MPH.0000000000000038
   Pagmantidis V, 2008, AM J CLIN NUTR, V87, P181, DOI 10.1093/ajcn/87.1.181
   Park J, 2005, BIOCHEM BIOPH RES CO, V336, P942, DOI 10.1016/j.bbrc.2005.08.201
   Park SH, 2012, TOXICOL LETT, V212, P252, DOI 10.1016/j.toxlet.2012.06.007
   Ren Y, 2009, BMB REP, V42, P599, DOI 10.5483/BMBRep.2009.42.9.599
   Rikiishi H, 2007, J BIOENERG BIOMEMBR, V39, P91, DOI 10.1007/s10863-006-9065-7
   Rubin BP, 2010, AUTOPHAGY, V6, P1190, DOI 10.4161/auto.6.8.13430
   Rumjanek VM, 2013, BIOSCIENCE REP, V33, P875, DOI 10.1042/BSR20130067
   Schroeder CP, 2004, BIOL TRACE ELEM RES, V99, P17, DOI 10.1385/BTER:99:1-3:017
   Sharma PS, 2009, CURR PHARM DESIGN, V15, P758, DOI 10.2174/138161209787582219
   SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107
   Tsuchihara K, 2009, CANCER LETT, V278, P130, DOI 10.1016/j.canlet.2008.09.040
   Tsujimoto Y, 2005, CELL DEATH DIFFER, V12, P1528, DOI 10.1038/sj.cdd.4401777
   Wang WL, 2000, ONCOGENE, V19, P3521, DOI 10.1038/sj.onc.1203698
NR 50
TC 13
Z9 13
U1 0
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1742-7835
EI 1742-7843
J9 BASIC CLIN PHARMACOL
JI Basic Clin. Pharmacol. Toxicol.
PD JAN
PY 2015
VL 116
IS 1
BP 37
EP 46
DI 10.1111/bcpt.12281
PG 10
WC Pharmacology & Pharmacy; Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy; Toxicology
GA AX4OH
UT WOS:000346911100007
PM 24930392
DA 2022-04-25
ER

PT J
AU Zhu, RZ
   Yang, G
   Cao, Z
   Shen, KX
   Zheng, LF
   Xiao, JC
   You, L
   Zhang, TP
AF Zhu, Ruizhe
   Yang, Gang
   Cao, Zhe
   Shen, Kexin
   Zheng, Lianfang
   Xiao, Jianchun
   You, Lei
   Zhang, Taiping
TI The prospect of serum and glucocorticoid-inducible kinase 1 (SGK1) in
   cancer therapy: a rising star
SO THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
LA English
DT Review
DE autophagy; calcium signaling; chemoresistance; immunoregulation; PI3K
   signaling; SGK1; therapeutic target
ID REGULATORY T-CELLS; PROTEIN-KINASE; BREAST-CANCER; PRECLINICAL MODEL;
   DOWN-REGULATION; POOR-PROGNOSIS; OVARIAN-CANCER; LUNG-CANCER; ER STRESS;
   INHIBITOR
AB Serum and glucocorticoid-inducible kinase 1 (SGK1) is an AGC kinase that has been reported to be involved in a variety of physiological and pathological processes. Recent evidence has accumulated that SGK1 acts as an essential Akt-independent mediator of phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) signaling pathway in cancer. SGK1 is overexpressed in several tumors, including prostate cancer, colorectal carcinoma, glioblastoma, breast cancer, and endometrial cancer. The functions of SGK1 include regulating tumor growth, survival, metastasis, autophagy, immunoregulation, calcium (Ca2+) signaling, cancer stem cells, cell cycle, and therapeutic resistance. In this review, we introduce the pleiotropic role of SGK1 in the development and progression of tumors, summarize its downstream targets, and integrate the knowledge provided by preclinical studies that the prospect of SGK1 inhibition as a potential therapeutic approach.
C1 [Zhu, Ruizhe; Yang, Gang; Cao, Zhe; Shen, Kexin; Xiao, Jianchun; You, Lei; Zhang, Taiping] Chinese Acad Med Sci & Peking Union Med Coll, Dept Gen Surg, Peking Union Med Coll Hosp, 1 Shuaifuyuan, Beijing 100730, Peoples R China.
   [Zheng, Lianfang] Chinese Acad Med Sci & Peking Union Med Coll, Dept Nucl Med, Peking Union Med Coll Hosp, Beijing, Peoples R China.
RP Zhang, TP (corresponding author), Chinese Acad Med Sci & Peking Union Med Coll, Dept Gen Surg, Peking Union Med Coll Hosp, 1 Shuaifuyuan, Beijing 100730, Peoples R China.
EM tpingzhang@yahoo.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81772639, 81802475, 81972258, 81974376];
   Natural Science Foundation of BeijingBeijing Natural Science Foundation
   [7192157]; CAMS Innovation Fund for Medical Sciences (CIFMS)
   [2016-I2M-1-001]; China Postdoctoral Science FoundationChina
   Postdoctoral Science Foundation [198831]; National Key R&D Program of
   China [2018YFE0118600]; Non-profit Central Research Institute Fund of
   Chinese Academy of Medical Sciences [2019XK320001]
FX The authors disclosed receipt of the following financial support for the
   research, authorship, and/or publication of this article: This study was
   supported by grants from the National Natural Science Foundation of
   China (No. 81772639; 81802475; 81972258; 81974376); Natural Science
   Foundation of Beijing (No. 7192157); CAMS Innovation Fund for Medical
   Sciences (CIFMS) (No.2016-I2M-1-001); China Postdoctoral Science
   Foundation (No.198831); National Key R&D Program of China
   (2018YFE0118600); Non-profit Central Research Institute Fund of Chinese
   Academy of Medical Sciences (2019XK320001).
CR Abbruzzese C, 2019, J CELL PHYSIOL, V234, P22529, DOI 10.1002/jcp.28816
   Abbruzzese C, 2017, ONCOTARGET, V8, P110743, DOI 10.18632/oncotarget.22500
   Ackermann TF, 2011, CELL PHYSIOL BIOCHEM, V28, P137, DOI 10.1159/000331722
   Aggarwal S, 2003, J BIOL CHEM, V278, P1910, DOI 10.1074/jbc.M207577200
   Ahmad G, 2017, EXPERT OPIN DRUG DEL, V14, P997, DOI 10.1080/17425247.2017.1263615
   Alkarain A, 2004, J MAMMARY GLAND BIOL, V9, P67, DOI 10.1023/B:JOMG.0000023589.00994.5e
   Amato R, 2013, ONCOGENE, V32, P4572, DOI 10.1038/onc.2012.470
   Amato R, 2007, J MOL MED, V85, P707, DOI 10.1007/s00109-007-0205-2
   Amato R, 2009, J MOL MED, V87, P1221, DOI 10.1007/s00109-009-0525-5
   Anacker C, 2013, P NATL ACAD SCI USA, V110, P8708, DOI 10.1073/pnas.1300886110
   Asadzadeh Z, 2017, CELL IMMUNOL, V322, P15, DOI 10.1016/j.cellimm.2017.10.015
   Batlle E, 2017, NAT MED, V23, P1124, DOI 10.1038/nm.4409
   Berdel HO, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113795
   Bruhn Maressa A, 2013, Cancer Manag Res, V5, P281, DOI 10.2147/CMAR.S35178
   Brunet A, 2001, MOL CELL BIOL, V21, P952, DOI 10.1128/MCB.21.3.952-965.2001
   Burgon J, 2014, J IMMUNOL, V192, P1796, DOI 10.4049/jimmunol.1300087
   Buse P, 1999, J BIOL CHEM, V274, P7253, DOI 10.1074/jbc.274.11.7253
   Castel P, 2016, CANCER CELL, V30, P229, DOI 10.1016/j.ccell.2016.06.004
   Catalogna G, 2017, CELL PHYSIOL BIOCHEM, V43, P108, DOI 10.1159/000480328
   Chai DD, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-5410-1
   Chen F, 2019, J MOL MED, V97, P1169, DOI 10.1007/s00109-019-01807-8
   Chu I, 2007, CELL, V128, P281, DOI 10.1016/j.cell.2006.11.049
   Chua MS, 2007, MODERN PATHOL, V20, P76, DOI 10.1038/modpathol.3800711
   Conza D, 2017, J CELL PHYSIOL, V232, P3735, DOI 10.1002/jcp.25850
   D'Antona L, 2019, TRANSL ONCOL, V12, P1045, DOI 10.1016/j.tranon.2019.05.008
   D'Antona L, 2015, CELL PHYSIOL BIOCHEM, V35, P2006, DOI 10.1159/000374008
   Dattilo V, 2017, SCI REP-UK, V7, DOI 10.1038/srep45361
   Derler I, 2016, AM J PHYSIOL-CELL PH, V310, pC643, DOI 10.1152/ajpcell.00007.2016
   Di Cristofano A, 2017, CURR TOP DEV BIOL, V123, P49, DOI 10.1016/bs.ctdb.2016.11.006
   Eylenstein A, 2011, FASEB J, V25, P2012, DOI 10.1096/fj.10-178210
   Fagerli UM, 2011, ONCOGENE, V30, P3198, DOI 10.1038/onc.2011.79
   Feng ZH, 2012, P NATL ACAD SCI USA, V109, P7013, DOI 10.1073/pnas.1203930109
   Francipane MG, 2013, ONCOTARGET, V4, P1948, DOI 10.18632/oncotarget.1310
   Fruman DA, 2017, CELL, V170, P605, DOI 10.1016/j.cell.2017.07.029
   Godbole M, 2018, J BIOL CHEM, V293, P19263, DOI 10.1074/jbc.RA118.002894
   Greenawalt EJ, 2019, MOL CANCER RES, V17, P289, DOI 10.1158/1541-7786.MCR-18-0364
   Hall BA, 2012, BREAST CANCER RES TR, V135, P469, DOI 10.1007/s10549-012-2161-y
   Halland N, 2015, ACS MED CHEM LETT, V6, P73, DOI 10.1021/ml5003376
   Hasna J, 2018, CELL DEATH DIFFER, V25, P691, DOI 10.1038/s41418-017-0007-1
   Heikamp EB, 2014, NAT IMMUNOL, V15, P457, DOI 10.1038/ni.2867
   Hong F, 2008, MOL CELL, V30, P701, DOI 10.1016/j.molcel.2008.04.027
   Inoue K, 2016, J NEUROCHEM, V138, P354, DOI 10.1111/jnc.13650
   Isikbay M, 2014, HORM CANCER-US, V5, P72, DOI 10.1007/s12672-014-0173-2
   Joshi NS, 2015, IMMUNITY, V43, P579, DOI 10.1016/j.immuni.2015.08.006
   Kim MJ, 2007, EMBO J, V26, P3075, DOI 10.1038/sj.emboj.7601755
   Knutson KL, 2005, CANCER IMMUNOL IMMUN, V54, P721, DOI 10.1007/s00262-004-0653-2
   Kouroku Y, 2007, CELL DEATH DIFFER, V14, P230, DOI 10.1038/sj.cdd.4401984
   Kulkarni S, 2018, MOL CANCER RES, V16, P103, DOI 10.1158/1541-7786.MCR-17-0146
   Lang F, 2006, PHYSIOL REV, V86, P1151, DOI 10.1152/physrev.00050.2005
   Lang F, 2018, CELL CALCIUM, V74, P29, DOI 10.1016/j.ceca.2018.05.001
   Lang F, 2013, HORM-INT J ENDOCRINO, V12, P160, DOI 10.14310/horm.2002.1401
   Lang F, 2013, FASEB J, V27, P3, DOI 10.1096/fj.12-218230
   Lang F, 2012, CELL CALCIUM, V52, P347, DOI 10.1016/j.ceca.2012.05.005
   Lang F, 2010, INT J BIOCHEM CELL B, V42, P1571, DOI 10.1016/j.biocel.2010.05.016
   Lang F, 2010, EXPERT OPIN THER PAT, V20, P129, DOI 10.1517/13543770903365209
   Lang F, 2009, EXPERT OPIN THER TAR, V13, P1303, DOI 10.1517/14728220903260807
   Lee LYW, 2019, CLIN CANCER RES, V25, P629, DOI 10.1158/1078-0432.CCR-18-1033
   Leroux AE, 2018, SEMIN CANCER BIOL, V48, P1, DOI 10.1016/j.semcancer.2017.05.011
   Liang XC, 2017, J CANCER, V8, P2256, DOI 10.7150/jca.19566
   Liu GL, 2015, CANCER BIOL THER, V16, P52, DOI 10.4161/15384047.2014.986982
   Liu WW, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0743-1
   Liu WW, 2017, BRIT J CANCER, V117, P1139, DOI 10.1038/bjc.2017.293
   Loffing J, 2006, ANNU REV PHYSIOL, V68, P461, DOI 10.1146/annurev.physiol.68.040104.131654
   Lou YY, 2017, FASEB J, V31, P447, DOI 10.1096/fj.201600760R
   Mason JA, 2016, CELL DEATH DIFFER, V23, P1271, DOI 10.1038/cdd.2016.15
   Matschke J, 2016, RADIAT ONCOL, V11, DOI 10.1186/s13014-016-0647-1
   Matteoni S, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1212-1
   Melhem A, 2009, CLIN CANCER RES, V15, P3196, DOI 10.1158/1078-0432.CCR-08-2131
   Mizuno H, 2001, GENES CELLS, V6, P261, DOI 10.1046/j.1365-2443.2001.00418.x
   Mo JS, 2011, J CELL SCI, V124, P100, DOI 10.1242/jcs.073924
   Murray JT, 2004, BIOCHEM J, V384, P477, DOI 10.1042/BJ20041057
   Narendra BL, 2013, INFLAMM RES, V62, P823, DOI 10.1007/s00011-013-0645-9
   Nishikawa H, 2014, CURR OPIN IMMUNOL, V27, P1, DOI 10.1016/j.coi.2013.12.005
   Nishimura T, 1999, J EXP MED, V190, P617, DOI 10.1084/jem.190.5.617
   Norton M, 2014, NAT IMMUNOL, V15, P411, DOI 10.1038/ni.2875
   Orlacchio A, 2017, CANCER RES, V77, P6914, DOI 10.1158/0008-5472.CAN-17-2105
   Ortuso F, 2014, J CHEM INF MODEL, V54, P1828, DOI 10.1021/ci500235f
   Parekh AB, 2005, PHYSIOL REV, V85, P757, DOI 10.1152/physrev.00057.2003
   Park KC, 2018, BBA-MOL BASIS DIS, V1864, P2644, DOI 10.1016/j.bbadis.2018.04.011
   Parkash J, 2010, LIFE SCI, V87, P587, DOI 10.1016/j.lfs.2010.09.013
   Pasham V, 2013, KIDNEY BLOOD PRESS R, V37, P48, DOI 10.1159/000343401
   Pearce LR, 2010, NAT REV MOL CELL BIO, V11, P9, DOI 10.1038/nrm2822
   Prevarskaya N, 2014, PHILOS T R SOC B, V369, DOI 10.1098/rstb.2013.0097
   Prevarskaya N, 2011, NAT REV CANCER, V11, P609, DOI 10.1038/nrc3105
   Putzer BM, 2017, ADV DRUG DELIVER REV, V120, P89, DOI 10.1016/j.addr.2017.07.013
   Putney JW, 2005, J CELL BIOL, V169, P381, DOI 10.1083/jcb.200503161
   Qui B, 2011, CELL CALCIUM, V50, P261, DOI 10.1016/j.ceca.2011.05.015
   Rensen WM, 2009, ONCOGENE, V28, P1748, DOI 10.1038/onc.2009.24
   Roderick HL, 2008, NAT REV CANCER, V8, P361, DOI 10.1038/nrc2374
   Salis O, 2016, TUMOR BIOL, V37, P3017, DOI 10.1007/s13277-015-4119-2
   Schmid E, 2017, CELL PHYSIOL BIOCHEM, V43, P1301, DOI 10.1159/000481842
   Schmid E, 2014, CELL PHYSIOL BIOCHEM, V34, P943, DOI 10.1159/000366311
   Schmidt EM, 2012, FEBS J, V279, P1231, DOI 10.1111/j.1742-4658.2012.08515.x
   Shaffer PL, 2004, P NATL ACAD SCI USA, V101, P4758, DOI 10.1073/pnas.0401123101
   Shanmugam I, 2007, CELL DEATH DIFFER, V14, P2085, DOI 10.1038/sj.cdd.4402227
   Shelly C, 2002, J CELL SCI, V115, P1985
   Sherk AB, 2008, CANCER RES, V68, P7475, DOI 10.1158/0008-5472.CAN-08-1047
   Skor MN, 2013, CLIN CANCER RES, V19, P6163, DOI 10.1158/1078-0432.CCR-12-3826
   Snyder PM, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.279pe41
   Sommer EM, 2013, BIOCHEM J, V452, P499, DOI 10.1042/BJ20130342
   Spagnuolo R, 2018, INFLAMM BOWEL DIS, V24, P1967, DOI 10.1093/ibd/izy158
   Sui X, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.350
   Sukkar B, 2018, CELL PHYSIOL BIOCHEM, V51, P278, DOI 10.1159/000495229
   Tai DJC, 2009, J BIOL CHEM, V284, P4073, DOI 10.1074/jbc.M805055200
   Talarico C, 2016, ONCOTARGET, V7, DOI 10.18632/oncotarget.7520
   Talarico C, 2016, CELL PHYSIOL BIOCHEM, V39, P1863, DOI 10.1159/000447885
   Talarico C, 2015, ONCOTARGET, V6, P37520, DOI 10.18632/oncotarget.5527
   Tanaka A, 2017, CELL RES, V27, P109, DOI 10.1038/cr.2016.151
   Tang C, 2011, CELL PHYSIOL BIOCHEM, V27, P757, DOI 10.1159/000330084
   Tang ZY, 2018, ONCOL REP, V39, P1505, DOI 10.3892/or.2018.6181
   Towhid ST, 2013, CELL PHYSIOL BIOCHEM, V32, P838, DOI 10.1159/000354486
   Wang M, 2019, REDOX BIOL, V24, DOI 10.1016/j.redox.2019.101225
   Weiler M, 2014, P NATL ACAD SCI USA, V111, P409, DOI 10.1073/pnas.1314469111
   Wolf D, 2015, J CELL PHYSIOL, V230, P2598, DOI 10.1002/jcp.25016
   Wu C, 2018, CELL REP, V22, P653, DOI 10.1016/j.celrep.2017.12.068
   Wu C, 2013, NATURE, V496, P513, DOI 10.1038/nature11984
   Wulff P, 2002, J CLIN INVEST, V110, P1263, DOI 10.1172/JCI200215696
   Yan Lijun, 2008, Biochem J, V416, pe19, DOI 10.1042/BJ20082202
   Yemelyanov A, 2012, CELL CYCLE, V11, P395, DOI 10.4161/cc.11.2.18945
   You H, 2004, P NATL ACAD SCI USA, V101, P14057, DOI 10.1073/pnas.0406286101
   Zhang LP, 2005, CANCER RES, V65, P457
   Zhu J, 2018, CELL PHYSIOL BIOCHEM, V51, P113, DOI 10.1159/000495168
NR 122
TC 10
Z9 10
U1 8
U2 13
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1758-8340
EI 1758-8359
J9 THER ADV MED ONCOL
JI Ther. Adv. Med. Oncol.
PD JUL
PY 2020
VL 12
AR 1758835920940946
DI 10.1177/1758835920940946
PG 14
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA MR7XR
UT WOS:000553805200001
PM 32728395
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Wang, H
   Maurer, BJ
   Liu, YY
   Wang, E
   Allegood, JC
   Kelly, S
   Symolon, H
   Liu, Y
   Merrill, AH
   Gouaze-Andersson, V
   Yu, JY
   Giuliano, AE
   Cabot, MC
AF Wang, Hongtao
   Maurer, Barry J.
   Liu, Yong-Yu
   Wang, Elaine
   Allegood, Jeremy C.
   Kelly, Samuel
   Symolon, Holly
   Liu, Ying
   Merrill, Alfred H., Jr.
   Gouaze-Andersson, Valerie
   Yu, Jing Yuan
   Giuliano, Armando E.
   Cabot, Myles C.
TI N-(4-hydroxyphenyl)retinamide increases dihydroceramide and synergizes
   with dimethylsphingosine to enhance cancer cell
SO MOLECULAR CANCER THERAPEUTICS
LA English
DT Article
ID FENRETINIDE-INDUCED APOPTOSIS; PHASE-I TRIAL; MULTIDRUG-RESISTANCE;
   SPHINGOID BASES; FUMONISIN B-1; CERAMIDE; LINES; AUTOPHAGY;
   NEUROBLASTOMA; CYTOTOXICITY
AB Fenretinide [N-(4-hydroxyphenyl)retinamide (4-HPR)] is cytotoxic in many cancer cell types. Studies have shown that elevation of ceramide species plays a role in 4-HPR cytotoxicity. To determine 4-HPR activity in a multidrug-resistant cancer cell line as well as to study ceramide metabolism, MCF-7/AdrR cells (redesignated NCI/ADR-RES) were treated with 4-HPR and sphingolipids were analyzed. TLC analysis of cells radiolabeled with [(3) H]palmitic acid showed that 4-HPR elicited a dose-responsive increase in radioactivity migrating in the ceramide region of the chromatogram and a decrease in cell viability. Results from liquid chromatography/electrospray tandem mass spectrometry revealed large elevations in dihydroceramides (N-acylsphinganines), but not desaturated ceramides, and large increases in complex dihydrosphingolipids (dihydrosphingomyelins, monohexosyldihydroceramides), sphinganine, and sphinganine 1-phosphate. To test the hypothesis that elevation of sphinganine participates in the cytotoxicity of 4-HPR, cells were treated with the sphingosine kinase inhibitor D-erythro-N,N-dimethylsphingosine (DMS), with and without 4-HPR. After 24 h, the 4-HPR/DMS combination caused a 9-fold increase in sphinganine that was sustained through + 48 hours, decreased sphinganine 1-phosphate, and increased cytotoxicity. Increased dihydrosphingolipids and sphinganine were also found in HL-60 leukemia cells and HT-29 colon cancer cells treated with 4-HPR. The 4-HPR/DMS combination elicited increased apoptosis in all three cell lines. We propose that a mechanism of 4-HPR-induced cytotoxicity involves increases in dihydrosphingolipids, and that the synergy between 4-HPR and DMS is associated with large increases in cellular sphinganine. These studies suggest that enhanced clinical efficacy of 4-HPR may be realized through regimens containing agents that modulate sphingoid base metabolism.
C1 [Wang, Hongtao; Maurer, Barry J.] Univ So Calif, Keck Sch Med, Childrens Hosp Los Angeles, Los Angeles, CA USA.
   [Liu, Yong-Yu] Univ Louisiana Monroe, Coll Pharm, Monroe, LA USA.
   [Wang, Elaine; Allegood, Jeremy C.; Kelly, Samuel; Symolon, Holly; Liu, Ying; Merrill, Alfred H., Jr.] Georgia Inst Technol, Sch Biol, Atlanta, GA 30332 USA.
   [Wang, Elaine; Allegood, Jeremy C.; Kelly, Samuel; Symolon, Holly; Liu, Ying; Merrill, Alfred H., Jr.] Georgia Inst Technol, Petit Inst Bioengn & Biosci, Atlanta, GA 30332 USA.
   [Gouaze-Andersson, Valerie; Yu, Jing Yuan; Giuliano, Armando E.; Cabot, Myles C.] St Johns Hlth Ctr, John Wayne Canc Inst, Gonda Goldschmied Res Labs, Santa Monica, CA USA.
RP Merrill, AH (corresponding author), Georgia Tech Res Inst, Sch Biol, Atlanta, GA 30332 USA.
EM al.merrill@biology.gatech.edu; cabot@jwci.org
RI Liu, Yong-Yu/H-8593-2014; Gouaze-Andersson, Valerie/O-9180-2014
OI Gouaze-Andersson, Valerie/0000-0002-1797-515X; Merrill,
   Alfred/0000-0002-6673-968X; Liu, Yong-Yu/0000-0002-7968-0162
FU USPHSUnited States Department of Health & Human ServicesUnited States
   Public Health Service [GM77391, CA95339, CA87525, GM69338]; Department
   of the Army DAMD [17-99-1-9228, 04-1-0491]; Susan G. Komen Breast Cancer
   FoundationSusan G. Komen Breast Cancer Foundation [BCTR0402450]; Ben B.
   and Joyce E. Eisenberg Foundation (Los Angeles, CA); Fashion Footwear
   Association of New York Charitable Foundation (New York, NY); Avon
   Foundation (New York, NY); Association for Breast and Prostate Cancer
   Studies (Santa Monica, CA); Sandra Krause and William Fitzgerald (Los
   Angeles, CA); NATIONAL CANCER INSTITUTEUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Cancer Institute (NCI) [R21CA095339, U19CA087525] Funding
   Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL
   SCIENCESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of General
   Medical Sciences (NIGMS) [R01GM077391, U54GM069338] Funding Source: NIH
   RePORTER
FX USPHS Grants GM77391, CA95339, CA87525 and GM69338 (LIPID MAPS);
   Department of the Army DAMD 17-99-1-9228 (Postdoctoral Traineeship in
   Breast Cancer Research, to H.W.); Department of the Army DAMD 04-1-0491
   (Postdoctoral Traineeship in Breast Cancer Research, to VG-A); The Susan
   G. Komen Breast Cancer Foundation, grant number BCTR0402450, and by
   funding from the Ben B. and Joyce E. Eisenberg Foundation (Los Angeles,
   CA), the Fashion Footwear Association of New York Charitable Foundation
   (New York, NY), Avon Foundation (New York, NY), the Association for
   Breast and Prostate Cancer Studies (Santa Monica, CA), Sandra Krause and
   William Fitzgerald (Los Angeles, CA).
CR BIELAWSKA A, 1993, J BIOL CHEM, V268, P26226
   BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911
   di Bartolomeo S, 2001, BIOCHEM BIOPH RES CO, V288, P269, DOI 10.1006/bbrc.2001.5748
   Fox TE, 2006, CELL MOL LIFE SCI, V63, P1017, DOI 10.1007/s00018-005-5543-z
   Garaventa A, 2003, CLIN CANCER RES, V9, P2032
   GarciaRuiz C, 1997, J BIOL CHEM, V272, P11369
   Gouaze-Andersson V, 2007, BBA-MOL CELL BIOL L, V1771, P1407, DOI 10.1016/j.bbalip.2007.09.005
   Gouaze-Andersson V, 2006, BBA-BIOMEMBRANES, V1758, P2096, DOI 10.1016/j.bbamem.2006.08.012
   Hail N, 2006, APOPTOSIS, V11, P1677, DOI 10.1007/s10495-006-9289-3
   Hait NC, 2006, BBA-BIOMEMBRANES, V1758, P2016, DOI 10.1016/j.bbamem.2006.08.007
   Hannun YA, 1997, ADV EXP MED BIOL, V407, P145
   Hu W, 2003, LANCET ONCOL, V4, P721, DOI 10.1016/S1470-2045(03)01277-4
   Kalli KR, 2003, MOL PHARMACOL, V64, P1434, DOI 10.1124/mol.64.6.1434
   Kolesnick R, 2002, J CLIN INVEST, V110, P3, DOI 10.1172/JCI200216127
   Kondo Y, 2005, NAT REV CANCER, V5, P726, DOI 10.1038/nrc1692
   Kong G, 2008, LEUKEMIA, V22, P1258, DOI 10.1038/sj.leu.2405023
   Kraveka JM, 2007, J BIOL CHEM, V282, P16718, DOI 10.1074/jbc.M700647200
   Lavie Y, 1996, J BIOL CHEM, V271, P19530, DOI 10.1074/jbc.271.32.19530
   Lavieu G, 2006, J BIOL CHEM, V281, P8518, DOI 10.1074/jbc.M506182200
   Lavieu G, 2007, AUTOPHAGY, V3, P45, DOI 10.4161/auto.3416
   Liscovitch M, 2007, CANCER LETT, V245, P350, DOI 10.1016/j.canlet.2006.01.013
   Liu YY, 2001, FASEB J, V15, P719, DOI 10.1096/fj.00-0223com
   Lopez-Marure R, 2002, BIOCHEM BIOPH RES CO, V293, P1028, DOI 10.1016/S0006-291X(02)00315-7
   Makin G, 2001, TRENDS CELL BIOL, V11, pS22, DOI 10.1016/S0962-8924(01)02124-9
   Maurer BJ, 2000, JNCI-J NATL CANCER I, V92, P1897, DOI 10.1093/jnci/92.23.1897
   Maurer BJ, 1999, JNCI-J NATL CANCER I, V91, P1138, DOI 10.1093/jnci/91.13.1138
   Merrill AH, 2005, METHODS, V36, P207, DOI 10.1016/j.ymeth.2005.01.009
   MOHRBACHER A, 2007, AM SOC HEM M
   Ogretmen B, 2004, NAT REV CANCER, V4, P604, DOI 10.1038/nrc1411
   Ogretmen B, 2002, J BIOL CHEM, V277, P12960, DOI 10.1074/jbc.M110699200
   Ogretmen B, 2001, DRUG RESIST UPDATE, V4, P368, DOI 10.1054/drup.2001.0225
   Perry David K, 2003, Cancer Treat Res, V115, P345
   Rehman F, 2004, BRIT J CANCER, V91, P1821, DOI 10.1038/sj.bjc.6602212
   REYNOLDS CP, 2007, P ASCO, pS287
   ROTMENSZ N, 1991, EUR J CANCER, V27, P1127, DOI 10.1016/0277-5379(91)90309-2
   Sanchenkov A, 2001, JNCI-J NATL CANCER I, V93, P347, DOI 10.1093/jnci/93.5.347
   Scarlatti F, 2004, J BIOL CHEM, V279, P18384, DOI 10.1074/jbc.M313561200
   Schmelz EM, 1998, TOXICOL APPL PHARM, V148, P252, DOI 10.1006/taap.1997.8356
   Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993
   Sietsma H, 2001, J MEMBRANE BIOL, V181, P153, DOI 10.1007/s00232-001-0033-1
   STEVENS VL, 1990, CANCER RES, V50, P222
   STEVENS VL, 1990, BIOCHIM BIOPHYS ACTA, V1051, P37, DOI 10.1016/0167-4889(90)90171-9
   Triola G, 2004, MOL PHARMACOL, V66, P1671, DOI 10.1124/mol.104.003681
   Van Brocklyn JR, 1998, J CELL BIOL, V142, P229, DOI 10.1083/jcb.142.1.229
   Veldman RJ, 2002, FASEB J, V16, P1111, DOI 10.1096/fj.01-0863fje
   Villablanca JG, 2006, J CLIN ONCOL, V24, P3423, DOI 10.1200/JCO.2005.03.9271
   Wang HT, 2003, UROLOGY, V61, P1047, DOI 10.1016/S0090-4295(02)02511-6
   Wang HT, 2001, CANCER RES, V61, P5102
   Yu CH, 2001, ARCH PHARM RES, V24, P136, DOI 10.1007/BF02976481
   Zheng W, 2006, BBA-BIOMEMBRANES, V1758, P1864, DOI 10.1016/j.bbamem.2006.08.009
NR 50
TC 81
Z9 83
U1 0
U2 1
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1535-7163
EI 1538-8514
J9 MOL CANCER THER
JI Mol. Cancer Ther.
PD SEP
PY 2008
VL 7
IS 9
BP 2967
EP 2976
DI 10.1158/1535-7163.MCT-08-0549
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 350XP
UT WOS:000259387300038
PM 18790777
DA 2022-04-25
ER

PT J
AU Nishio, T
   Kurabe, N
   Goto-Inoue, N
   Nakamura, T
   Sugimura, H
   Setou, M
   Maekawa, M
AF Nishio, Tomohisa
   Kurabe, Nobuya
   Goto-Inoue, Naoko
   Nakamura, Toshio
   Sugimura, Haruhiko
   Setou, Mitsutoshi
   Maekawa, Masato
TI Immunohistochemical expression analysis of leucine-rich
   PPR-motif-containing protein (LRPPRC), a candidate colorectal cancer
   biomarker identified by shotgun proteomics using iTRAQ
SO CLINICA CHIMICA ACTA
LA English
DT Article
DE Colorectal cancer; iTRAQ; LRPPRC; Immunohistochemistry; Differentiation
ID BREAST-CANCER; APOPTOSIS; AUTOPHAGY; CELLS; TAGS
AB Background: Colorectal cancer (CRC) is the fourth most frequent cause of cancer deaths in the world. Novel biomarkers for the diagnosis, prognosis, and treatment of CRC are required to improve the clinical strategy.
   Methods: We applied shotgun proteomics using isobaric tags for relative and absolute quantitation (iTRAQ) to identify novel biomarkers of CRC, and then we detected leucine-rich PPR-motif-containing protein (LRPPRC) expression in 83 normal colorectal tissues and 133 CRC tissues by immunohistochemistry.
   Results: A total of 570 proteins were identified using iTRAQ. We validated the expression of LRPPRC protein by immunohistochemical analysis of the 77 proteins that showed expression changes in the cancer tissues > 1.5 fold the levels in the normal tissues. The expression levels of LRPPRC were significantly higher in CRC tissues than those in normal colorectal tissues, and the expression levels were related with tumor differentiation and especially high in moderately differentiated CRC tissues.
   Conclusion: We identified a novel, differentially expressed protein, LRPPRC, which has the potential to serve as a molecular target for diagnosis and/or prognosis of CRC.
C1 [Nishio, Tomohisa; Maekawa, Masato] Hamamatsu Univ Sch Med, Dept Lab Med, Higashi Ku, 1-20-1 Handayama, Hamamatsu, Shizuoka 4313192, Japan.
   [Nishio, Tomohisa; Goto-Inoue, Naoko; Setou, Mitsutoshi] Hamamatsu Univ Sch Med, Dept Cell Biol & Anat, Higashi Ku, 1-20-1 Handayama, Hamamatsu, Shizuoka 4313192, Japan.
   [Nishio, Tomohisa] Sekisui Med Co Ltd, Tsukuba Res Inst, 3-3-1 Kouyoudai, Ryugasaki 3010852, Japan.
   [Kurabe, Nobuya; Sugimura, Haruhiko] Hamamatsu Univ Sch Med, Dept Tumor Pathol, Higashi Ku, 1-20-1 Handayama, Hamamatsu, Shizuoka 4313192, Japan.
   [Nakamura, Toshio] Hamamatsu Univ Sch Med, Dept Surg 2, Higashi Ku, 1-20-1 Handayama, Hamamatsu, Shizuoka 4313192, Japan.
   [Nakamura, Toshio] Fujieda Municipal Gen Hosp, Dept Surg, 4-1-11 Surugadai, Fujieda, Shizuoka 4268677, Japan.
RP Maekawa, M (corresponding author), Hamamatsu Univ Sch Med, Dept Lab Med, Hamamatsu, Shizuoka 4313192, Japan.
EM mmaekawa@hama-med.ac.jp
OI Maekawa, Masato/0000-0001-9710-5324
FU Ministry of Education, Science, Sports, Culture and Technology (MEXT) of
   JapanMinistry of Education, Culture, Sports, Science and Technology,
   Japan (MEXT) [23659295]; Ministry of Health, Labour and Welfare,
   JapanMinistry of Health, Labour and Welfare, Japan [19-19,10103838];
   MEXTMinistry of Education, Culture, Sports, Science and Technology,
   Japan (MEXT) [S-001]; MEXT/JSPS KAKENHIMinistry of Education, Culture,
   Sports, Science and Technology, Japan (MEXT)Japan Society for the
   Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)
   [JP15H05898B1]; National Cancer Center Research and Development
   FundNational Cancer Center - Japan [28A-1]; Center of Innovation Program
   of JST; MEXTMinistry of Education, Culture, Sports, Science and
   Technology, Japan (MEXT); Smoking Research Foundation; Grants-in-Aid for
   Scientific ResearchMinistry of Education, Culture, Sports, Science and
   Technology, Japan (MEXT)Japan Society for the Promotion of
   ScienceGrants-in-Aid for Scientific Research (KAKENHI) [15H05898,
   15H05897] Funding Source: KAKEN
FX This work was supported in part by a Grant-in-Aid for Challenging
   Exploratory Research (No. 23659295) from the Ministry of Education,
   Science, Sports, Culture and Technology (MEXT) of Japan and grants from
   the Ministry of Health, Labour and Welfare, Japan (19-19,10103838), MEXT
   (S-001), MEXT/JSPS KAKENHI (JP15H05898B1), the National Cancer Center
   Research and Development Fund (28A-1), the Center of Innovation Program
   of JST, MEXT, and the Smoking Research Foundation.
CR Aggarwal Kunal, 2006, Briefings in Functional Genomics & Proteomics, V5, P112, DOI 10.1093/bfgp/ell018
   Ajiki W, 2004, JPN J CLIN ONCOL, V34, P50, DOI 10.1093/jjco/hyh003
   Alessandro Riccardo, 2005, Clin Colorectal Cancer, V4, P396, DOI 10.3816/CCC.2005.n.012
   Bouchal P, 2009, J PROTEOME RES, V8, P362, DOI 10.1021/pr800622b
   Celis JE, 2003, CANCER CELL, V3, P9, DOI 10.1016/S1535-6108(02)00242-8
   Gohil VM, 2010, J BIOL CHEM, V285, P13742, DOI 10.1074/jbc.M109.098400
   HOU JZ, 1994, IN VITRO CELL DEV-AN, V30A, P111
   Jiang XH, 2014, CANCER-AM CANCER SOC, V120, P1228, DOI 10.1002/cncr.28551
   Kronborg O, 1996, LANCET, V348, P1467, DOI 10.1016/S0140-6736(96)03430-7
   Michaud M, 2011, INT J ONCOL, V38, P169, DOI 10.3892/ijo_00000836
   Mili S, 2003, MOL CELL BIOL, V23, P4972, DOI 10.1128/MCB.23.14.4972-4982.2003
   Mootha VK, 2003, P NATL ACAD SCI USA, V100, P605, DOI 10.1073/pnas.242716699
   Pollak M, 2013, CANCER CELL, V23, P263, DOI 10.1016/j.ccr.2013.02.015
   REMMELE W, 1987, PATHOLOGE, V8, P138
   Rho JH, 2008, J PROTEOME RES, V7, P2959, DOI 10.1021/pr8000892
   Ross PL, 2004, MOL CELL PROTEOMICS, V3, P1154, DOI 10.1074/mcp.M400129-MCP200
   Sugimura H, 2008, CARCINOGENESIS, V29, P681, DOI 10.1093/carcin/bgn046
   Tian T, 2012, EUR J CANCER, V48, P2462, DOI 10.1016/j.ejca.2012.01.018
   Tomonaga T, 2004, CLIN CANCER RES, V10, P2007, DOI 10.1158/1078-0432.CCR-03-0321
   Tsuchiya N, 2004, BIOCHEM BIOPH RES CO, V317, P736, DOI 10.1016/j.bbrc.2004.03.103
   Walsh J.M., 2003, JAMA-J AM MED ASSOC, V12, P1297
   Weitz J, 2005, LANCET, V365, P153, DOI 10.1016/S0140-6736(05)17706-X
   Zou J, 2013, BIOCHEM J, V454, P447, DOI 10.1042/BJ20130306
NR 23
TC 6
Z9 8
U1 1
U2 11
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0009-8981
EI 1873-3492
J9 CLIN CHIM ACTA
JI Clin. Chim. Acta
PD AUG
PY 2017
VL 471
BP 276
EP 282
DI 10.1016/j.cca.2017.06.011
PG 7
WC Medical Laboratory Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Medical Laboratory Technology
GA FD2ZK
UT WOS:000407403100045
PM 28622966
OA Green Submitted
DA 2022-04-25
ER

PT J
AU Wang, LP
   Yun, L
   Wang, XJ
   Sha, LY
   Wang, LN
   Sui, YY
   Zhang, H
AF Wang, Luping
   Yun, Lu
   Wang, Xiaojun
   Sha, Liying
   Wang, Luning
   Sui, Yingying
   Zhang, Hui
TI RETRACTED: Endoplasmic reticulum stress triggered by Soyasapogenol B
   promotes apoptosis and autophagy in colorectal cancer (Retracted
   article. See vol. 254, 2020)
SO LIFE SCIENCES
LA English
DT Article; Retracted Publication
DE Soy B; Colorectal cancer; Endoplasmic reticulum stress; Apoptosis;
   Autophagy
ID SOYASAPONINS; CELLS; PREVENTION; IV
AB Aim: Colorectal cancer (CRC) is a common human malignancy which accounts for 600,000 deaths annually at the global level. Soyasapogenol B (Soy B), an ingredient of soybean, has been found to exert anti-proliferative activities in vitro in human breast cancer cells. The current study aimed to evaluate the efficacy of Soy B in suppressing CRC.
   Methods and materials: The effect of Soy B on cell viability was assessed using the Cell Counting Kit-8 (CCK-8) assay. The effect of Soy B on cell proliferation was determined using colony formation assay. The percentage of apoptotic cells was determined by the TUNEL assay and flow cytometry following Annexin V-FITC/Propidium Iodide (PI) double staining. JC-1 staining was performed to examine the change in mitochondrial membrane potential. Autophagy was examined by acridine orange staining and mRFP-GFP-LC3 adenovirus transfection. Caspase-12 activities were determined by ELISA kit. Western blotting was used to determine the expression of relevant proteins. To investigate the role of autophagy in the pro-death and pro-apoptotic activities of Soy B, autophagy inhibitors Bafilomycin A1 (Baf-A1) and Atg5 siRNA were utilized. TUDCA and CHOP shRNA were utilized to block ER stress. Moreover, a CRC xenograft murine model was used to analyze the therapeutic efficacy of Soy B in vivo.
   Key findings: Soy B treatment decreased the number of viable cells and colonies formed in CRC cell lines. Moreover, Soy B treatment promoted the apoptotic cell death via the intrinsic pathway and autophagy which positively contributed to cell death and apoptosis. In addition, our results showed that ER stress, triggered by Soy B, mediated apoptosis and autophagy. In vivo results revealed that Soy B could suppress tumor growth, which was associated with increased ER stress, accompanied with apoptosis and autophagy induction.
   Significance: Soy B was able to promote cell death in vitro and in vivo. Our findings highlight the possibility of utilizing Soy B as a chemotherapeutic agent to prevent and treat CRC.
C1 [Wang, Luping; Wang, Xiaojun; Sha, Liying; Wang, Luning; Sui, Yingying; Zhang, Hui] Qingdao Univ, Affiliated Hosp, Qingdao, Shandong, Peoples R China.
   [Yun, Lu] Qingdao Cent Hosp, Qingdao, Shandong, Peoples R China.
RP Zhang, H (corresponding author), 16 Jiangsu Rd, Qingdao 266003, Peoples R China.
EM huizhangqyfu@163.com
CR Amin Hala A., 2018, Biotechnology Reports, V17, P55, DOI 10.1016/j.btre.2017.12.007
   Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338
   Cheng SY, 2018, APOPTOSIS, V23, P314, DOI 10.1007/s10495-018-1456-9
   Gao H, 2017, ACTA PHARMACOL SIN, V38, P1618, DOI 10.1038/aps.2017.154
   Han M., 2018, ACTA PHARM SIN
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Healy SJM, 2009, EUR J PHARMACOL, V625, P234, DOI 10.1016/j.ejphar.2009.06.064
   Iwamoto K, 2018, BIOCHEM BIOPHYS REP, V16, P44, DOI 10.1016/j.bbrep.2018.09.006
   Janji B, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00887
   Kamo S, 2014, NUTRITION, V30, P596, DOI 10.1016/j.nut.2013.10.017
   Kerwin S. M., 2004, Current Medicinal Chemistry - Anti-Cancer Agents, V4, P263, DOI 10.2174/1568011043352993
   Kinjo J, 1998, PLANTA MED, V64, P233, DOI 10.1055/s-2006-957416
   Lee IA, 2010, J AGR FOOD CHEM, V58, P10929, DOI 10.1021/jf102296y
   Lee SO, 2005, EXP BIOL MED, V230, P472
   Li L, 2014, ONCOTARGETS THER, V7, P1817, DOI 10.2147/OTT.S48409
   Liu Y, 2017, APOPTOSIS, V22, P544, DOI 10.1007/s10495-016-1334-2
   Lv SX, 2018, BIOCHEM BIOPH RES CO, V496, P1047, DOI 10.1016/j.bbrc.2018.01.111
   Marley AR, 2016, INT J MOL EPIDEMIOL, V7, P105
   MESSINA M, 1995, J NUTR, V125, pS567, DOI 10.1093/jn/125.3_Suppl.567S
   Philbrick DJ, 2003, KIDNEY INT, V63, P1230, DOI 10.1046/j.1523-1755.2003.00869.x
   Rowlands JC, 2002, FOOD CHEM TOXICOL, V40, P1767, DOI 10.1016/S0278-6915(02)00181-3
   Sasaki K, 2005, BIOORGAN MED CHEM, V13, P4900, DOI 10.1016/j.bmc.2005.04.074
   Shen SY, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.441
   Smith M, 2017, ESSAYS BIOCHEM, V61, P625, DOI 10.1042/EBC20170092
   Su ZY, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0321-5
   Sung JJY, 2015, GUT, V64, P121, DOI 10.1136/gutjnl-2013-306503
   Takahashi S, 2008, BIOSCI BIOTECH BIOCH, V72, P3232, DOI 10.1271/bbb.80495
   Wu KR, 2015, BIOCHEM BIOPH RES CO, V466, P369, DOI 10.1016/j.bbrc.2015.09.030
   Yanamandra N, 2003, CLIN EXP METASTAS, V20, P375, DOI 10.1023/A:1024043104803
   Yoshikoshi M, 1996, PLANTA MED, V62, P252, DOI 10.1055/s-2006-957871
   Zhang W, 2008, J AGR FOOD CHEM, V56, P2603, DOI 10.1021/jf0731550
   Zhao HY, 2017, BIOL OPEN, V6, P1416, DOI 10.1242/bio.026344
   Zheng YF, 2018, CANCER LETT, V431, P31, DOI 10.1016/j.canlet.2018.05.026
NR 33
TC 8
Z9 8
U1 0
U2 24
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0024-3205
EI 1879-0631
J9 LIFE SCI
JI Life Sci.
PD FEB 1
PY 2019
VL 218
BP 16
EP 24
DI 10.1016/j.lfs.2018.12.023
PG 9
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA HH4WO
UT WOS:000455727100003
PM 30553871
DA 2022-04-25
ER

PT J
AU Ouyang, HC
   Li, Q
   Zhong, JK
   Xia, FF
   Zheng, SL
   Lu, JH
   Deng, YY
   Hu, YZ
AF Ouyang, Haichun
   Li, Qian
   Zhong, Jiankai
   Xia, Fengfan
   Zheng, Sulin
   Lu, Jianhua
   Deng, Yuanyan
   Hu, Yunzhao
TI Combination of melatonin and irisin ameliorates
   lipopolysaccharide-induced cardiac dysfunction through suppressing the
   Mst1-JNK pathways
SO JOURNAL OF CELLULAR PHYSIOLOGY
LA English
DT Article
DE ATP; cardiomyocyte; irisin; LPS; melatonin; mitochondria
ID COLON-CANCER CELLS; CARDIOMYOCYTE APOPTOSIS; HEART-FAILURE; AUTOPHAGY;
   STRESS; INJURY; INHIBITION; INFLAMMATION; HYPERTROPHY; NECROPTOSIS
AB Despite significant advances in therapies in past decades, the mortality rate of septic cardiomyopathy remains high. The aim of this study is to explore the therapeutic effects of combined treatment using melatonin and irisin in a mouse model of lipopolysaccharide (LPS)-mediated septic cardiomyopathy. Our data found that melatonin and irisin could further attenuate LPS-induced myocardial depression. Molecular investigation illustrated that melatonin and irisin cotreatment sustained cardiomyocyte viability and improved mitochondrial function under LPS stress. Pathway analysis demonstrated that macrophage-stimulating 1 (Mst1), which was significantly activated by LPS, was drastically inhibited by melatonin/irisin cotreatment. Mechanically, Mst1 activated c-Jun N-terminal kinase (JNK) pathway and the latter induced oxidative stress, adenosine triphosphate metabolism disorder, mitochondrial membrane potential reduction, and cardiomyocyte death activation. Melatonin and irisin cotreatment effectively inhibited the Mst1-JNK pathway and, thus, promoted cardiomyocyte survival and mitochondrial homeostasis. Interestingly, Mst1 overexpression abolished the beneficial effects of melatonin and irisin in vivo and in vitro. Altogether, our results confirmed that melatonin and irisin combination treatment could protect heart against sepsis-induced myocardial depression via modulating the Mst1-JNK pathways.
C1 [Ouyang, Haichun; Zhong, Jiankai; Xia, Fengfan; Zheng, Sulin; Lu, Jianhua; Hu, Yunzhao] Southern Med Univ, Shunde Hosp, Dept Cardiol, Peoples Hosp Shunde Foshan 1, Foshan 528300, Guangdong, Peoples R China.
   [Li, Qian] Southern Med Univ, Nanfang Hosp, Dept Emergency Med, Guangzhou, Peoples R China.
   [Deng, Yuanyan] Southern Med Univ, Integrated Hosp Tradit Chinese Med, Dept Cardiol, Guangzhou 510315, Peoples R China.
RP Hu, YZ (corresponding author), Southern Med Univ, Shunde Hosp, Dept Cardiol, Peoples Hosp Shunde Foshan 1, Foshan 528300, Guangdong, Peoples R China.; Deng, YY (corresponding author), Southern Med Univ, Integrated Hosp Tradit Chinese Med, Dept Cardiol, Guangzhou 510315, Peoples R China.
EM dengyuanyan@126.com; sdhuyz@163.com
FU Natural Science Foundation of Guangdong Province of ChinaNational
   Natural Science Foundation of Guangdong Province [2018A030313067];
   Science and Technology Innovation Project from Foshan, Guangdong
   [FS0AA-KJ218-1301-0006, FS0AA-KJ218-1301-0010]; Key Specialist
   Department Training Project of Foshan City, Guangdong Province of China
   [Fspy 3-2015034]
FX Natural Science Foundation of Guangdong Province of China, Grant/Award
   Number: 2018A030313067; Science and Technology Innovation Project from
   Foshan, Guangdong, Grant/Award Numbers: FS0AA-KJ218-1301-0006,
   FS0AA-KJ218-1301-0010; Key Specialist Department Training Project of
   Foshan City, Guangdong Province of China, Grant/Award Number: Fspy
   3-2015034
CR Abeysuriya RG, 2018, J PINEAL RES, V64, DOI 10.1111/jpi.12474
   Abukar Y, 2018, BASIC RES CARDIOL, V113, DOI 10.1007/s00395-018-0695-9
   Afonso CB, 2019, REDOX BIOL, V23, DOI 10.1016/j.redox.2018.101066
   Afonso MB, 2018, CELL DEATH DIFFER, V25, P857, DOI 10.1038/s41418-017-0019-x
   Alvarez-Fernandez M, 2018, CELL DEATH DIFFER, V25, P828, DOI 10.1038/s41418-017-0024-0
   Angelova PR, 2018, REDOX BIOL, V14, P474, DOI 10.1016/j.redox.2017.10.016
   Armartmuntree N, 2018, REDOX BIOL, V14, P637, DOI 10.1016/j.redox.2017.11.011
   Ba XQ, 2018, REDOX BIOL, V14, P669, DOI 10.1016/j.redox.2017.11.008
   Baines CP, 2005, J MOL CELL CARDIOL, V38, P47, DOI 10.1016/j.yjmcc.2004.11.004
   Battelli MG, 2019, REDOX BIOL, V21, DOI 10.1016/j.redox.2018.101070
   Bellomo C, 2018, CELL DEATH DIFFER, V25, P885, DOI 10.1038/s41418-017-0021-3
   Bellot GL, 2019, REDOX BIOL, V20, P307, DOI 10.1016/j.redox.2018.10.014
   Biernacki M, 2018, REDOX BIOL, V15, P41, DOI 10.1016/j.redox.2017.11.022
   Botker HE, 2018, BASIC RES CARDIOL, V113, DOI 10.1007/s00395-018-0696-8
   Bramasole L, 2019, REDOX BIOL, V20, P533, DOI 10.1016/j.redox.2018.11.010
   Cameron AR, 2018, REDOX BIOL, V14, P187, DOI 10.1016/j.redox.2017.08.018
   Care A, 2018, CELL DEATH DIFFER, V25, P477, DOI 10.1038/s41418-017-0051-x
   Chandrasekharan A, 2019, REDOX BIOL, V20, P379, DOI 10.1016/j.redox.2018.10.013
   Chen HB, 2018, CELL DEATH DIFFER, V25, P646, DOI 10.1038/s41418-018-0060-4
   Chen L, 2016, APOPTOSIS, V21, P1291, DOI 10.1007/s10495-016-1287-5
   Cheng Z, 2019, J CELL MOL MED, V23, P543, DOI 10.1111/jcmm.13958
   Cheng Z, 2018, J MOL CELL CARDIOL, V125, P117, DOI 10.1016/j.yjmcc.2018.08.028
   Chiong M, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.130
   Corbalan JJ, 2016, BASIC RES CARDIOL, V111, DOI 10.1007/s00395-016-0549-2
   Davidson SM, 2018, BASIC RES CARDIOL, V113, DOI 10.1007/s00395-018-0704-z
   Dehdashtian E, 2018, LIFE SCI, V193, P20, DOI 10.1016/j.lfs.2017.12.001
   DeLeon-Pennell KY, 2018, BASIC RES CARDIOL, V113, DOI 10.1007/s00395-018-0699-5
   Deussen A, 2018, BASIC RES CARDIOL, V113, DOI 10.1007/s00395-018-0693-y
   Ding MG, 2018, J PINEAL RES, V64, DOI 10.1111/jpi.12447
   Edwards KS, 2018, BASIC RES CARDIOL, V113, DOI 10.1007/s00395-018-0707-9
   Feng H, 2016, INT J CARDIOL, V203, P145, DOI 10.1016/j.ijcard.2015.10.109
   Gandarillas A, 2018, CELL DEATH DIFFER, V25, P471, DOI 10.1038/s41418-017-0040-0
   Gao GY, 2018, BIOMED PHARMACOTHER, V108, P1208, DOI 10.1016/j.biopha.2018.06.172
   Goiran T, 2018, CELL DEATH DIFFER, V25, P873, DOI 10.1038/s41418-017-0016-0
   Gong HJ, 2018, CELL DEATH DIFFER, V25, P1063, DOI 10.1038/s41418-018-0085-8
   Gonzalez A, 2003, CARDIOVASC RES, V59, P549, DOI 10.1016/S0008-6363(03)00498-X
   Hasna J, 2018, CELL DEATH DIFFER, V25, P691, DOI 10.1038/s41418-017-0007-1
   Hay J. M., 2017, J MOL SIGNALING, V12, P12
   Heusch G, 2019, BASIC RES CARDIOL, V114, DOI 10.1007/s00395-019-0756-8
   Honda T, 2019, BASIC RES CARDIOL, V114, DOI 10.1007/s00395-019-0724-3
   Jiang Q, 2019, BASIC RES CARDIOL, V114, DOI 10.1007/s00395-019-0723-4
   Jung M, 2019, BASIC RES CARDIOL, V114, DOI 10.1007/s00395-018-0712-z
   Kazakov A, 2018, BASIC RES CARDIOL, V113, DOI 10.1007/s00395-018-0700-3
   Kiel AM, 2018, BASIC RES CARDIOL, V113, DOI 10.1007/s00395-018-0691-0
   Kim JE, 2019, FRONT CELL NEUROSCI, V13, DOI 10.3389/fncel.2019.00179
   Kohlhauer M, 2019, BASIC RES CARDIOL, V114, DOI 10.1007/s00395-019-0727-0
   Kraft L, 2019, BASIC RES CARDIOL, V114, DOI 10.1007/s00395-019-0719-0
   Lee Y, 2009, APOPTOSIS, V14, P536, DOI 10.1007/s10495-008-0302-x
   Li J, 2018, BASIC RES CARDIOL, V113, DOI 10.1007/s00395-018-0694-x
   Li RL, 2018, J MOL CELL CARDIOL, V121, P242, DOI 10.1016/j.yjmcc.2018.07.250
   Liang QR, 2003, J MOL CELL CARDIOL, V35, P1385, DOI 10.1016/j.yjmcc.2003.10.001
   Merz J, 2018, BASIC RES CARDIOL, V113, DOI 10.1007/s00395-018-0702-1
   Molkentin JD, 2004, CARDIOVASC RES, V63, P467, DOI 10.1016/j.cardiores.2004.01.021
   Ndongson-Dongmo B, 2019, BASIC RES CARDIOL, V114, DOI 10.1007/s00395-019-0734-1
   Petrich BG, 2004, TRENDS CARDIOVAS MED, V14, P50, DOI 10.1016/j.tcm.2003.11.002
   Ryan WK, 2019, CELL DEATH DIFFER, V26, P548, DOI 10.1038/s41418-018-0167-7
   Saito Y, 2019, CELL DEATH DIFFER, V26, P470, DOI 10.1038/s41418-018-0131-6
   Schreiber T, 2019, BASIC RES CARDIOL, V114, DOI 10.1007/s00395-019-0725-2
   Seidel T, 2019, BASIC RES CARDIOL, V114, DOI 10.1007/s00395-019-0758-6
   Shang XL, 2019, J MOL HISTOL, V50, P91, DOI 10.1007/s10735-018-09809-5
   Sharma BR, 2019, CELL DEATH DIFFER, V26, P741, DOI 10.1038/s41418-018-0159-7
   Sheng Y, 2018, CELL DEATH DIFFER, V25, P918, DOI 10.1038/s41418-017-0023-1
   Shi C, 2018, REDOX BIOL, V14, P59, DOI 10.1016/j.redox.2017.08.013
   Silverblatt JA, 2019, BASIC RES CARDIOL, V114, DOI 10.1007/s00395-019-0754-x
   Tan Y, 2019, CELL STRESS CHAPERON, V24, P595, DOI 10.1007/s12192-019-00992-2
   Trieb M, 2019, BASIC RES CARDIOL, V114, DOI 10.1007/s00395-019-0735-0
   Trindade F, 2019, BASIC RES CARDIOL, V114, DOI 10.1007/s00395-019-0716-3
   Vial J, 2019, CELL DEATH DIFFER, V26, P443, DOI 10.1038/s41418-018-0128-1
   Wang Z, 2018, J CARDIOVASC PHARM, V72, P259, DOI 10.1097/FJC.0000000000000608
   Wang Z, 2018, TRANSL STROKE RES, V9, P74, DOI 10.1007/s12975-017-0559-x
   Yao LD, 2019, CELL DEATH DIFFER, V26, P943, DOI 10.1038/s41418-018-0175-7
   Yao YW, 2017, BIOCHEM BIOPH RES CO, V493, P1288, DOI 10.1016/j.bbrc.2017.09.153
   Yu WC, 2019, J PHYSIOL SCI, V69, P113, DOI 10.1007/s12576-018-0627-3
   Zhang HF, 2019, BASIC RES CARDIOL, V114, DOI 10.1007/s00395-019-0752-z
   Zhang N, 2019, CELL DEATH DIFFER, V26, P843, DOI 10.1038/s41418-018-0158-8
   Zhang YH, 2019, CELL DEATH DIFFER, V26, P565, DOI 10.1038/s41418-018-0147-y
   Zhao J, 2019, BASIC RES CARDIOL, V114, DOI 10.1007/s00395-019-0721-6
   Zhong JK, 2019, REDOX BIOL, V26, DOI 10.1016/j.redox.2019.101287
   Zhou H, 2019, J CELL PHYSIOL, V234, P5056, DOI 10.1002/jcp.27308
   Zhou H, 2018, J PINEAL RES, V65, DOI 10.1111/jpi.12503
   Zhou H, 2018, ANGIOGENESIS, V21, P599, DOI 10.1007/s10456-018-9611-z
   Zhou H, 2018, CELL SIGNAL, V47, P88, DOI 10.1016/j.cellsig.2018.03.012
   Zhou H, 2018, REDOX BIOL, V15, P335, DOI 10.1016/j.redox.2017.12.019
   Zhou H, 2017, 2016 INTERNATIONAL CONFERENCE ON INTELLIGENT TRANSPORTATION, BIG DATA & SMART CITY (ICITBS), P1, DOI 10.1109/ICITBS.2016.27
   Zhou T, 2019, REDOX BIOL, V21, DOI 10.1016/j.redox.2019.101120
   Zhu PJ, 2018, REDOX BIOL, V16, P157, DOI 10.1016/j.redox.2018.02.019
   Zhu YM, 2019, CELL DEATH DIFFER, V26, P958, DOI 10.1038/s41418-018-0177-5
NR 87
TC 10
Z9 10
U1 3
U2 16
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0021-9541
EI 1097-4652
J9 J CELL PHYSIOL
JI J. Cell. Physiol.
PD OCT
PY 2020
VL 235
IS 10
BP 6647
EP 6659
DI 10.1002/jcp.29561
EA JAN 2020
PG 13
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Physiology
GA MZ8KE
UT WOS:000508956600001
PM 31976559
DA 2022-04-25
ER

PT J
AU Koustas, E
   Sarantis, P
   Theoharis, S
   Saetta, AA
   Chatziandreou, I
   Kyriakopoulou, G
   Giannopoulou, I
   Michelli, M
   Schizas, D
   Papavassiliou, AG
   Karamouzis, MV
AF Koustas, Evangelos
   Sarantis, Panagiotis
   Theoharis, Stamatios
   Saetta, Angelica A.
   Chatziandreou, Ilenia
   Kyriakopoulou, Georgia
   Giannopoulou, Ioanna
   Michelli, Maria
   Schizas, Dimitrios
   Papavassiliou, Athanasios G.
   Karamouzis, Michalis V.
TI Autophagy-related Proteins as a Prognostic Factor of Patients With
   Colorectal Cancer
SO AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
LA English
DT Article
DE autophagy; Beclin-1; chemotherapy; colorectal cancer
ID BECLIN 1; PROGRESSION; EXPRESSION; MATURATION; INTERPLAY; TUMORS; CELLS;
   P53
AB Objectives: Autophagy plays a dual role in tumorigenesis. In the initial stages, it promotes cell survival and suppresses carcinogenesis, whereas in cancer development, it induces cancer cell survival. In this study, we investigate the role of autophagy as a protective or tumor suppressor mechanism in colorectal cancer (CRC) cell lines and evaluate its role as a potential biomarker in human tumor samples. Materials and Methods: The data of 68 patients with CRC treated at our Department from January 1 to December 31, 2016 were analyzed. Immunohistochemistry evaluation of p62, LC3B, Beclin-1, and Rab-7 in formalin-fixed paraffin-embedded tissue samples was performed and their expression was correlated with clinicopathologic characteristics, mutation status, and therapeutic approach. The chi(2) was used to test an association among categorical variables. Survival curves were estimated using the Kaplan-Meier method and differences were assessed using the log-rank test. Colo-205, HT29, SW-480, and Caco-2 cell lines were also used so as to test the autophagy markers with oxaliplatin, irinotecan, hydroxychloroquine, and 3-methyladenine. Results: Overexpression of Beclin-1 is associated with poor survival (P=0.001) in patients with CRC treated with chemotherapy, irrespective of the stage and mutational status. Rab-7 is also correlated with progression-free survival (PFS) (P=0.088). Oxaliplatin (10 and 20 mu M) and irinotecan (10 and 20 mu M) inhibit autophagy in microsatellite stable (MSS) CRC cell lines. The inhibition of autophagy in MSS CRC cell lines after treatment with oxaliplatin and irinotecan is further identified through monodancylcadaverine staining. Moreover, inhibition of autophagy with molecules such as hydroxychloroquine (20 mu M) and 3-methyladenine (5 mM) was identified by the accumulation of p62 and LC3B. Conclusions: Beclin-1 is an independent prognostic factor of overall survival and PFS. Also, Rab-7 is identified as an independent prognostic factor of PFS. Besides, several chemotherapeutic drugs such as oxaliplatin and irinotecan inhibit autophagy in MSS CRC cell lines in a similar way like hydroxychloroquine and 3-methyladenine. Thus, in MSS patients who develop chemoresistance, a combination of other therapies that include an autophagy inhibitor could be more beneficial. Further clinical trials are needed to investigate these therapeutic strategies.
C1 [Koustas, Evangelos; Sarantis, Panagiotis; Kyriakopoulou, Georgia; Papavassiliou, Athanasios G.] Univ Athens, Sch Med, Laiko Hosp, Mol Oncol Unit,Dept Biol Chem, Athens, Greece.
   [Theoharis, Stamatios; Saetta, Angelica A.; Chatziandreou, Ilenia; Giannopoulou, Ioanna; Michelli, Maria] Univ Athens, Sch Med, Laiko Hosp, Dept Pathol, Athens, Greece.
   [Schizas, Dimitrios] Univ Athens, Sch Med, Laiko Hosp, Dept Surg 1, Athens, Greece.
   [Karamouzis, Michalis V.] Univ Athens, Sch Med, Laiko Hosp, Dept Internal Med 1, Athens, Greece.
RP Karamouzis, MV (corresponding author), Univ Athens, Dept Biol Chem, Sch Med, 75 M Asias St, Athens 11527, Greece.
EM mkaramouz@med.uoa.gr
RI Koustas, Evangelos/ABE-9336-2020; Sarantis, Panagiotis/AAF-4774-2021;
   Karamouzis, Michalis/AAD-2860-2020
OI Sarantis, Panagiotis/0000-0001-5848-7905; Saetta, Angelica
   A./0000-0002-4862-3413; CHATZIANDREOU, ILENIA/0000-0002-4940-5581
CR Aredia Francesca, 2012, Cells, V1, P520, DOI 10.3390/cells1030520
   Arnold M, 2017, GUT, V66, P683, DOI 10.1136/gutjnl-2015-310912
   Burada F, 2015, WORLD J GASTRO ONCOL, V7, P271, DOI 10.4251/wjgo.v7.i11.271
   Chude CI, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18061279
   Cianfanelli V, 2015, CELL CYCLE, V14, P959, DOI 10.1080/15384101.2015.1021526
   Colella B, 2019, CANCERS, V11, DOI 10.3390/cancers11030312
   Goulielmaki M, 2016, ONCOTARGET, V7, P9188, DOI 10.18632/oncotarget.6942
   Guerra F, 2016, CELLS-BASEL, V5, DOI 10.3390/cells5030034
   Huijbers A, 2012, ENDOCR-RELAT CANCER, V19, pL15, DOI 10.1530/ERC-11-0302
   Hyttinen JMT, 2013, BBA-MOL CELL RES, V1833, P503, DOI 10.1016/j.bbamcr.2012.11.018
   Jin SK, 2007, AUTOPHAGY, V3, P28, DOI 10.4161/auto.3269
   Kihara A, 2001, J CELL BIOL, V152, P519, DOI 10.1083/jcb.152.3.519
   Kim EK, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171280
   Koustas E, 2019, CANCERS, V11, DOI 10.3390/cancers11040533
   Koustas E, 2018, WORLD J GASTRO ONCOL, V10, P367, DOI 10.4251/wjgo.v10.i11.367
   Koustas E, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0207227
   Lamb CA, 2013, BIOESSAYS, V35, P34, DOI 10.1002/bies.201200130
   Lee JW, 2006, PATHOLOGY, V38, P312, DOI 10.1080/00313020600820880
   Liu JC, 2014, EMBO MOL MED, V6, P1542, DOI 10.15252/emmm.201404402
   Liu WJ, 2016, CELL MOL BIOL LETT, V21, DOI 10.1186/s11658-016-0031-z
   Ma KG, 2013, OSTEOARTHR CARTILAGE, V21, P2030, DOI 10.1016/j.joca.2013.10.002
   Manic G, 2014, MOL CELL ONCOL, V1, DOI 10.4161/mco.29911
   Marinkovic M, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/8023821
   Marino G, 2007, J BIOL CHEM, V282, P18573, DOI 10.1074/jbc.M701194200
   Mellor HR, 2007, CANCER METAST REV, V26, P553, DOI 10.1007/s10555-007-9080-0
   Mizushima N, 2002, CELL STRUCT FUNCT, V27, P421, DOI 10.1247/csf.27.421
   Mizushima N, 2011, ANNU REV CELL DEV BI, V27, P107, DOI 10.1146/annurev-cellbio-092910-154005
   Park JM, 2013, CANCER BIOL THER, V14, P100, DOI 10.4161/cbt.22954
   Pasquier B, 2016, CELL MOL LIFE SCI, V73, P985, DOI 10.1007/s00018-015-2104-y
   Perera R, 2015, NATURE, V524, P361, DOI 10.1038/nature14587
   Qian HR, 2017, ONCOTARGET, V8, P62759, DOI 10.18632/oncotarget.18663
   Qiu MZ, 2015, ONCOTARGET, V6, P38658, DOI 10.18632/oncotarget.6130
   Rangwala R, 2014, AUTOPHAGY, V10, P1369, DOI 10.4161/auto.29118
   Reggiori F, 2017, J MOL BIOL, V429, P486, DOI 10.1016/j.jmb.2017.01.002
   Riihimaki M, 2016, SCI REP-UK, V6, DOI 10.1038/srep29765
   Sakellariou S, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2213-5
   Schaaf MB, 2019, CELL DEATH DIFFER, V26, P665, DOI 10.1038/s41418-019-0287-8
   Schmitz KJ, 2016, WORLD J SURG ONCOL, V14, DOI 10.1186/s12957-016-0946-x
   Shpilka T, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-7-226
   Takahashi Y, 2008, BIF BECN1, V9, P1
   Thunnissen E, 2018, ARCH PATHOL LAB MED, V142, P408, DOI 10.5858/arpa.2017-0106-SA
   Tsikalakis S, 2018, PATHOL RES PRACT, V214, P826, DOI 10.1016/j.prp.2018.04.019
   Xu YH, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00234
   Yang A, 2014, CANCER DISCOV, V4, P905, DOI 10.1158/2159-8290.CD-14-0362
   Yang X, 2015, CELL BIOSCI, V5, DOI 10.1186/s13578-015-0005-2
   Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100
   Yun CW, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113466
   Zhou Y, 2015, INT J CLIN EXP PATHO, V8, P9428
NR 48
TC 10
Z9 10
U1 1
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0277-3732
EI 1537-453X
J9 AM J CLIN ONCOL-CANC
JI Am. J. Clin. Oncol.-Cancer Clin. Trials
PD OCT
PY 2019
VL 42
IS 10
BP 767
EP 776
DI 10.1097/COC.0000000000000592
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA JC9PI
UT WOS:000489607600006
PM 31517637
OA Green Published, hybrid
DA 2022-04-25
ER

PT J
AU Stoll, G
   Enot, D
   Mlecnik, B
   Galon, J
   Zitvogel, L
   Kroemer, G
AF Stoll, Gautier
   Enot, David
   Mlecnik, Bernhard
   Galon, Jerome
   Zitvogel, Laurence
   Kroemer, Guido
TI Immune-related gene signatures predict the outcome of neoadjuvant
   chemotherapy
SO ONCOIMMUNOLOGY
LA English
DT Article
DE autophagy; breast cancer; colorectal cancer; endoplasmic stress;
   immunogenic cell death; tumor-infiltrating lymphocytes
ID TUMOR-INFILTRATING LYMPHOCYTES; CALRETICULIN EXPOSURE; CELLULAR
   CLEARANCE; CANCER; AUTOPHAGY; STRESS; CELLS; EXPRESSION; DOXORUBICIN;
   METASTASIS
AB There is ample evidence that neoadjuvant chemotherapy of breast carcinoma is particularly efficient if the tumor presents signs of either a pre-existent or therapy-induced anticancer immune response. Antineoplastic chemotherapies are particularly beneficial if they succeed in inducing immunogenic cell death, hence converting the tumor into its own therapeutic vaccine. Immunogenic cell death is characterized by a pre-mortem stress response including endoplasmic reticulum stress and autophagy. Based on these premises, we attempted to identify metagenes that reflect an intratumoral immune response or local stress responses in the transcriptomes of breast cancer patients. No consistent correlations between immune-and stress-related metagenes could be identified across several cohorts of patients, representing a total of 1045 mammary carcinomas. Moreover, few if any, of the stress-relevant metagenes influenced the probability of pathological complete response to chemotherapy. In contrast, several immune-relevant metagenes had a significant positive impact on response rates. This applies in particular to a CXCL 13-centered, highly reproducible metagene signature reflecting the intratumoral presence of interferon-gamma-producing T cells.
C1 [Stoll, Gautier; Mlecnik, Bernhard; Galon, Jerome; Kroemer, Guido] Univ Paris 05, Paris, France.
   [Stoll, Gautier; Kroemer, Guido] INSERM, U1138, Cordeliers Res Ctr, Equipe Labellisee Ligue Natl Canc 11, Paris, France.
   [Enot, David; Kroemer, Guido] Metabol Platform, Villejuif, France.
   [Enot, David; Kroemer, Guido] Cell Biol Platform, Villejuif, France.
   INSERM, U1138, Lab Integrat Canc Immunol, Paris, France.
   [Mlecnik, Bernhard; Galon, Jerome] Univ Paris 06, Cordeliers Res Ctr, Paris, France.
   [Mlecnik, Bernhard; Galon, Jerome] INSERM, U1015, Villejuif, France.
   [Zitvogel, Laurence] Univ Paris 11, Fac Med, Le Kremlin Bicetre, France.
   [Zitvogel, Laurence] Ctr Clin Invest Biotherapies Canc CICBT 507, Villejuif, France.
   [Zitvogel, Laurence; Kroemer, Guido] INSERM, U848, Villejuif, France.
   [Kroemer, Guido] Hop Europeen Georges Pompidou, AP HP, Pole Biol, Paris, France.
RP Kroemer, G (corresponding author), Univ Paris 05, Paris, France.
EM kroemer@orange.fr
RI Kroemer, Guido/AAY-9859-2020; mlecnik, bernhard/AAT-7467-2021; KROEMER,
   Guido/B-4263-2013; Galon, Jerome/G-9838-2019
OI KROEMER, Guido/0000-0002-9334-4405; Galon, Jerome/0000-0001-9635-1339;
   Stoll, Gautier/0000-0002-0862-4139
FU Ligue contre le Cancer (equipe labelisee)Ligue nationale contre le
   cancer; Agence National de la Recherche (ANR)French National Research
   Agency (ANR); Association pour la recherche sur le cancer (ARC)Fondation
   ARC pour la Recherche sur le Cancer; Canceropole Ile-de-FranceRegion
   Ile-de-France; Institut National du Cancer (INCa)Institut National du
   Cancer (INCA) France; Fondation Bettencourt-Schueller; Fondation de
   FranceFondation de France; Fondation pour la Recherche Medicale
   (FRM)Fondation pour la Recherche Medicale; European Commission
   (ArtForce)European CommissionEuropean Commission Joint Research Centre;
   European Research Council (ERC)European Research Council (ERC)European
   Commission; LabEx Immuno-Oncology; SIRIC Stratified Oncology Cell DNA
   Repair and Tumor Immune Elimination (SOCRATE); SIRIC Cancer Research and
   Personalized Medicine (CARPEM); Paris Alliance of Cancer Research
   Institutes (PACRI)
FX G.K. is supported by the Ligue contre le Cancer (equipe labelisee);
   Agence National de la Recherche (ANR); Association pour la recherche sur
   le cancer (ARC); Canceropole Ile-de-France; Institut National du Cancer
   (INCa); Fondation Bettencourt-Schueller; Fondation de France; Fondation
   pour la Recherche Medicale (FRM); the European Commission (ArtForce);
   the European Research Council (ERC); the LabEx Immuno-Oncology; the
   SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination
   (SOCRATE); the SIRIC Cancer Research and Personalized Medicine (CARPEM);
   and the Paris Alliance of Cancer Research Institutes (PACRI). We thank
   also TCGA Research Network for generating TCGA data sets.
CR Angel H, 2013, CURR OPIN IMMUNOL, V25, P261, DOI 10.1016/j.coi.2013.03.004
   Ascierto ML, 2012, BREAST CANCER RES TR, V131, P871, DOI 10.1007/s10549-011-1470-x
   Bates GJ, 2006, J CLIN ONCOL, V24, P5373, DOI 10.1200/JCO.2006.05.9584
   Bindea G, 2013, IMMUNITY, V39, P782, DOI 10.1016/j.immuni.2013.10.003
   Bonnefoi Herve, 2007, Lancet Oncol, V8, P1071, DOI 10.1016/S1470-2045(07)70345-5
   Demaria S, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.23127
   DeNardo DG, 2011, CANCER DISCOV, V1, P54, DOI 10.1158/2159-8274.CD-10-0028
   Denkert C, 2010, J CLIN ONCOL, V28, P105, DOI 10.1200/JCO.2009.23.7370
   Desmedt C, 2008, CLIN CANCER RES, V14, P5158, DOI 10.1158/1078-0432.CCR-07-4756
   Dombroski BA, 2010, AM J HUM GENET, V86, P719, DOI 10.1016/j.ajhg.2010.03.017
   Freeman TJ, 2012, GASTROENTEROLOGY, V142, p[562, e2]
   Fridman WH, 2012, NAT REV CANCER, V12, P298, DOI 10.1038/nrc3245
   Galon J, 2006, SCIENCE, V313, P1960, DOI 10.1126/science.1129139
   Galon J, 2007, CANCER RES, V67, P1883, DOI 10.1158/0008-5472.CAN-06-4806
   Galon J, 2013, IMMUNITY, V39, P11, DOI 10.1016/j.immuni.2013.07.008
   Gobert M, 2009, CANCER RES, V69, P2000, DOI 10.1158/0008-5472.CAN-08-2360
   Grone J, 2011, INT J COLORECTAL DIS, V26, P847, DOI 10.1007/s00384-011-1176-x
   Guirnalda P, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.25752
   Harding HP, 2003, MOL CELL, V11, P619, DOI 10.1016/S1097-2765(03)00105-9
   Hatzis C, 2011, JAMA-J AM MED ASSOC, V305, P1873, DOI 10.1001/jama.2011.593
   Huang E, 2003, LANCET, V361, P1590, DOI 10.1016/S0140-6736(03)13308-9
   Ignatiadis M, 2012, J CLIN ONCOL, V30, P1996, DOI 10.1200/JCO.2011.39.5624
   Karthaus N, 2012, AM J PATHOL, V181, P733, DOI 10.1016/j.ajpath.2012.05.012
   KENNEDY BP, 1991, J BIOL CHEM, V266, P8511
   Kim R, 2006, APOPTOSIS, V11, P5, DOI 10.1007/s10495-005-3088-0
   Kroemer G, 2013, ANNU REV IMMUNOL, V31, P51, DOI 10.1146/annurev-immunol-032712-100008
   Kroemer G, 2010, MOL CELL, V40, P280, DOI 10.1016/j.molcel.2010.09.023
   Ladoire S, 2012, AUTOPHAGY, V8, P1175, DOI 10.4161/auto.20353
   Ladoire S, 2011, J PATHOL, V224, P389, DOI 10.1002/path.2866
   Lesokhin AM, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.22764
   Li M, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.25474
   Li QY, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-474
   Lim C Ming, 2013, ONCOIMMUNOLOGY, V2
   Lindenberg JJ, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.23837
   Loi S, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.24720
   Loi S, 2013, J CLIN ONCOL, V31, P860, DOI 10.1200/JCO.2011.41.0902
   Lorvik KB, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.24383
   Ma YT, 2013, IMMUNITY, V39, P211, DOI 10.1016/j.immuni.2013.07.017
   Mahmoud S, 2012, ONCOIMMUNOLOGY, V1, P363, DOI 10.4161/onci.18614
   Mahmoud SMA, 2011, J CLIN ONCOL, V29, P1949, DOI 10.1200/JCO.2010.30.5037
   Martins I, 2014, CELL DEATH DIFFER, V21, P79, DOI 10.1038/cdd.2013.75
   Menger L, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003807
   Michaud M, 2011, SCIENCE, V334, P1573, DOI 10.1126/science.1208347
   Mlecnik B, 2011, J CLIN ONCOL, V29, P610, DOI 10.1200/JCO.2010.30.5425
   Mlecnik B, 2010, GASTROENTEROLOGY, V138, P1429, DOI 10.1053/j.gastro.2009.10.057
   Obeid M, 2007, NAT MED, V13, P54, DOI 10.1038/nm1523
   Palmieri M, 2011, HUM MOL GENET, V20, P3852, DOI 10.1093/hmg/ddr306
   Panaretakis T, 2009, EMBO J, V28, P578, DOI 10.1038/emboj.2009.1
   Pietrocola F, 2013, SEMIN CANCER BIOL, V23, P310, DOI 10.1016/j.semcancer.2013.05.008
   R Core Team, 2015, R LANG ENV STAT COMP
   Rickman DS, 2008, ONCOGENE, V27, P6607, DOI 10.1038/onc.2008.251
   Schreiber RD, 2011, SCIENCE, V331, P1565, DOI 10.1126/science.1203486
   Senovilla L, 2012, SCIENCE, V337, P1678, DOI 10.1126/science.1224922
   Settembre C, 2013, NAT REV MOL CELL BIO, V14, P283, DOI 10.1038/nrm3565
   Smith JJ, 2010, GASTROENTEROLOGY, V138, P958, DOI 10.1053/j.gastro.2009.11.005
   Sung WW, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.25854
   Tabchy A, 2010, CLIN CANCER RES, V16, P5351, DOI 10.1158/1078-0432.CCR-10-1265
   Trapani JA, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.24185
   Vacca P, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.23638
   Velasco-Velazquez M, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.23660
   Vesely MD, 2011, ANNU REV IMMUNOL, V29, P235, DOI 10.1146/annurev-immunol-031210-101324
   Wang JH, 2006, J BIOL CHEM, V281, P34457, DOI 10.1074/jbc.M608019200
   Wang Y, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.25988
   West NR, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3072
   Wong JL, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.26245
   Yau C, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2753
   Zitvogel L, 2013, IMMUNITY, V39, P74, DOI 10.1016/j.immuni.2013.06.014
   Zitvogel L, 2011, NAT REV CLIN ONCOL, V8, P151, DOI 10.1038/nrclinonc.2010.223
NR 68
TC 60
Z9 60
U1 0
U2 9
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 2162-402X
J9 ONCOIMMUNOLOGY
JI OncoImmunology
PD FEB
PY 2014
VL 3
IS 2
AR e27884
DI 10.4161/onci.27884
PG 12
WC Oncology; Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Immunology
GA AM6DX
UT WOS:000339953700009
PM 24790795
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Zhang, NY
   Zhang, XX
   Xu, WB
   Zhang, XX
   Mu, ZP
AF Zhang, Nanyang
   Zhang, Xianxiang
   Xu, Wenbing
   Zhang, Xiaoxiao
   Mu, Zepeng
TI CircRNA_103948 inhibits autophagy in colorectal cancer in a ceRNA manner
SO ANNALS OF THE NEW YORK ACADEMY OF SCIENCES
LA English
DT Article
DE circRNA_103948; miR-1236-3p; TPT1; autophagy; CRC
ID TUMOR PROTEIN; CIRCULAR RNA; MIR-1236-3P; STATISTICS; TCTP
AB Circular RNA (circRNA) is implicated in many types of cancer; however, the expression and role of circRNAs in colorectal cancer (CRC) remains poorly understood. In this study, a circRNA microarray assay was performed to detect abnormally expressed circRNAs in CRC, and tissue arrays were used to determine the prognosis for CRC patients. Cell counting kit-8, clone formation, wound healing, and transwell assays were used to evaluate cell functions in vitro, and a mouse subcutaneous tumor model was designed for in vivo analysis. Autophagy was observed using confocal laser scanning and transmission electron microscopy. The expression of circRNA, miRNA, and mRNA was detected using qPCR; western blot, RNA pull-down assay, RNA immunoprecipitation, and dual luciferase assessment were applied for mechanistic studies. We found that circRNA_103948 expression is upregulated in CRC tissues, compared with adjacent normal tissues, and associated with poor prognosis. Knockdown of circRNA_103948 suppressed CRC both in vitro and in vivo. Mechanistically, circRNA_103948 could directly bind to miR-1236-3p and relieve suppression of the target TPT1. Furthermore, circRNA_103948 inhibited autophagy of CRC cells. Taken together, circRNA_103948 knockdown inhibited CRC cell growth by targeting miR-1236-3p/TPT1 axis-mediated autophagy. Thus, the circRNA_103948/miR-1236-3p/TPT1 axis affects CRC progression via modulation of autophagy.
C1 [Zhang, Nanyang; Xu, Wenbing; Zhang, Xiaoxiao; Mu, Zepeng] Qingdao Univ, Med Res Ctr, Affiliated Hosp, 1677 Wutaishan Rd, Qingdao 266500, Shandong, Peoples R China.
   [Zhang, Xianxiang] Qingdao Univ, Dept Gastrointestinal Surg, Affiliated Hosp, Qingdao, Shandong, Peoples R China.
   [Xu, Wenbing] Qingdao Univ, Dept Reprod Med, Affiliated Hosp, Qingdao, Shandong, Peoples R China.
RP Zhang, NY (corresponding author), Qingdao Univ, Med Res Ctr, Affiliated Hosp, 1677 Wutaishan Rd, Qingdao 266500, Shandong, Peoples R China.
EM nanyang.zhang@outlook.com
RI Zhang, Nanyang/AAU-7575-2021
OI Zhang, Nanyang/0000-0001-5765-6770
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81802473]; Qingdao Science and Technology
   Plan on Application and Basic Research, Youth Special Program
   [19-91-78-jch]; 2018 QingdaoWest Coast New Area Distinct Special Program
   on Science [SPST-1832041]; Youth Program of Research Foundation of The
   Affiliated Hospital of Qingdao University
FX This study was funded by the National Natural Science Foundation of
   China (81802473), 2019 Qingdao Science and Technology Plan on
   Application and Basic Research, Youth Special Program 19-91-78-jch, 2018
   QingdaoWest Coast New Area Distinct Special Program on Science
   (SPST-1832041),and the Youth Program of Research Foundation of The
   Affiliated Hospital of Qingdao University. We thank Dr. Meng Zhang for
   writing and revising the manuscript.
CR Abdelmohsen K, 2017, RNA BIOL, V14, P361, DOI 10.1080/15476286.2017.1279788
   Amaravadi R, 2016, GENE DEV, V30, P1913, DOI 10.1101/gad.287524.116
   Amson R, 2013, TRENDS CELL BIOL, V23, P37, DOI 10.1016/j.tcb.2012.10.002
   An JX, 2019, CANCER BIOMARK, V25, P127, DOI 10.3233/CBM-171026
   Arcuri F, 2004, PROSTATE, V60, P130, DOI 10.1002/pros.20054
   Bae SY, 2017, AUTOPHAGY, V13, P820, DOI 10.1080/15548627.2017.1287650
   Bai L, 2021, J PHARMACOL SCI, V147, P104, DOI 10.1016/j.jphs.2021.06.002
   Banerjee A, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-08211-9
   Cao MM, 2020, CANCER COMMUN, V40, P205, DOI 10.1002/cac2.12025
   Chan THM, 2012, HEPATOLOGY, V55, P491, DOI 10.1002/hep.24709
   Du WW, 2017, CELL DEATH DIFFER, V24, P357, DOI 10.1038/cdd.2016.133
   Feng WM, 2019, MOL THER-NUCL ACIDS, V18, P375, DOI 10.1016/j.omtn.2019.08.024
   Ferlay J, 2018, EUR J CANCER, V103, P356, DOI 10.1016/j.ejca.2018.07.005
   Hangai S, 2021, NAT IMMUNOL, V22, P947, DOI 10.1038/s41590-021-00967-5
   Hansen TB, 2013, CANCER RES, V73, P5609, DOI 10.1158/0008-5472.CAN-13-1568
   Hansen TB, 2013, NATURE, V495, P384, DOI 10.1038/nature11993
   Jian M, 2019, J ENDOCRINOL INVEST, V42, P639, DOI 10.1007/s40618-018-0963-4
   Jung J, 2011, ONCOGENE, V30, P2264, DOI 10.1038/onc.2010.604
   Li QH, 2019, BIOMED PHARMACOTHER, V114, DOI 10.1016/j.biopha.2019.108832
   Li SS, 2019, BRIEF BIOINFORM, V20, P1420, DOI 10.1093/bib/bby006
   Mokarram P, 2017, AUTOPHAGY, V13, P781, DOI 10.1080/15548627.2017.1290751
   Niederhuber J. E., 2020, ABELOFFS CLIN ONCOLO, V6th
   Patop IL, 2018, CURR OPIN GENET DEV, V48, P121, DOI 10.1016/j.gde.2017.11.007
   Siegel RL, 2016, CA-CANCER J CLIN, V66, P7, DOI 10.3322/caac.21332
   Sung HH, 2022, CLIN EXP HYPERTENS, V44, P146, DOI 10.1080/10641963.2021.2007943
   Towers CG, 2016, EBIOMEDICINE, V14, P15, DOI 10.1016/j.ebiom.2016.10.034
   Wilusz JE, 2013, SCIENCE, V340, P440, DOI 10.1126/science.1238522
   Yang YB, 2018, JNCI-J NATL CANCER I, V110, DOI 10.1093/jnci/djx166
   Yu TC, 2017, CELL, V170, P548, DOI 10.1016/j.cell.2017.07.008
   Yu ZJ, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419-021-03601-2
   Zhang DW, 2020, INT J ONCOL, V57, P478, DOI 10.3892/ijo.2020.5066
   Zhang J, 2020, INT J BIOL SCI, V16, P2612, DOI 10.7150/ijbs.46822
   Zhang L, 2018, BIOCHEM BIOPH RES CO, V503, P1484, DOI 10.1016/j.bbrc.2018.07.067
   Zhang QS, 2018, AM J TRANSL RES, V10, P731
NR 34
TC 3
Z9 3
U1 2
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0077-8923
EI 1749-6632
J9 ANN NY ACAD SCI
JI Ann. N.Y. Acad. Sci.
PD NOV
PY 2021
VL 1503
IS 1
SI SI
BP 88
EP 101
DI 10.1111/nyas.14679
EA SEP 2021
PG 14
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA XA5JQ
UT WOS:000692735800001
PM 34480353
DA 2022-04-25
ER

PT J
AU Shen, LD
   Qi, WH
   Bai, JJ
   Zuo, CY
   Bai, DL
   Gao, WD
   Zong, XL
   Hao, TT
   Ma, Y
   Cao, GC
AF Shen, Lian-Dong
   Qi, Wen-Hai
   Bai, Jiang-Jiang
   Zuo, Chun-Yi
   Bai, Dong-Lin
   Gao, Wei-Dong
   Zong, Xin-Ling
   Hao, Ting-Ting
   Ma, Yan
   Cao, Guang-Cai
TI Resibufogenin inhibited colorectal cancer cell growth and tumorigenesis
   through triggering ferroptosis and ROS production mediated by GPX4
   inactivation
SO ANATOMICAL RECORD-ADVANCES IN INTEGRATIVE ANATOMY AND EVOLUTIONARY
   BIOLOGY
LA English
DT Article
DE colorectal cancer; ferroptosis; GPX4; oxidative stress; resibufogenin
ID GLUTATHIONE-PEROXIDASE 4; DEATH
AB Resibufogenin (RB) has been used for cancer treatment, but the underlying mechanisms are still unclear. This study aimed to investigate the effects of RB treatment on colorectal cancer (CRC) cells, and to determine the underlying mechanisms. The cell counting kit-8 assay was used to determine cell viability. Cell morphology was observed under light microscopy, and terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling assay was employed to detect cell apoptosis. Intracellular ferrous iron (Fe2+), malondialdehyde (MDA), glutathione (GSH), and reactive oxygen species levels were detected by using commercial iron assay kit, MDA assay kit, GSH assay kit, and 2,7-dichlorodihydrofluorescein diacetate probes, respectively. The protein expressions were determined by Western blot and immunohistochemistry. RB inhibited cell viability in the CRC cell lines (HT29 and SW480) in a dose- and time-dependent manner, and caused cytotoxicity to the normal colonic epithelial cell line (NCM460) at high dose. Similarly, RB induced morphological changes in CRC cells from normal to round shape, and promoted cell death. Of note, RB triggered oxidative stress and ferroptotic cell death in CRC cells, and only ferroptosis inhibitors (deferoxamine and ferrostatin-1), instead of inhibitors for other types of cell death (apoptosis, autophagy, and necroptosis), reversed the inhibitory effects of RB on CRC cell proliferation. Furthermore, glutathione peroxidase 4 (GPX4) was inactivated by RB treatment, and overexpression of GPX4 alleviated RB-induced oxidative cell death in CRC cells. Consistently, the in vivo experiments validated that RB also triggered oxidative stress, and inhibited CRC cells growth and tumorigenicity in mice models. RB can inhibit CRC cells growth and tumorigenesis by triggering ferroptotic cell death in a GPX4 inactivation-dependent manner.
C1 [Shen, Lian-Dong; Qi, Wen-Hai; Bai, Jiang-Jiang; Zuo, Chun-Yi; Bai, Dong-Lin; Gao, Wei-Dong; Zong, Xin-Ling; Hao, Ting-Ting; Cao, Guang-Cai] Yanan Univ, Dept Anorectal Surg, Affiliated Hosp, 43 North St, Yanan 716000, Shaanxi, Peoples R China.
   [Ma, Yan] Yanan Peoples Hosp, Dept Med Cardiovasc, Yanan, Shaanxi, Peoples R China.
RP Cao, GC (corresponding author), Yanan Univ, Dept Anorectal Surg, Affiliated Hosp, 43 North St, Yanan 716000, Shaanxi, Peoples R China.
EM 38741819@qq.com
CR Ali SM, 2018, ANN SURG ONCOL, V25, P32, DOI 10.1245/s10434-016-5745-7
   An PJ, 2019, ACS APPL MATER INTER, V11, P42988, DOI 10.1021/acsami.9b16124
   Angius A, 2019, INT J MED SCI, V16, P1480, DOI 10.7150/ijms.35269
   Belavgeni A, 2019, P NATL ACAD SCI USA, V116, P22269, DOI 10.1073/pnas.1912700116
   Carbone M, 2019, CANCER RES, V79, P5149, DOI 10.1158/0008-5472.CAN-19-2453
   Chen XH, 2019, ACS CHEM NEUROSCI, V10, P4824, DOI 10.1021/acschemneuro.9b00539
   Hambright WS, 2017, REDOX BIOL, V12, P8, DOI 10.1016/j.redox.2017.01.021
   Han QR, 2018, J TRANSL MED, V16, DOI 10.1186/s12967-018-1580-x
   Hasakova K, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0224396
   Imai H, 2017, CURR TOP MICROBIOL, V403, P143, DOI 10.1007/82_2016_508
   Khoshinani HM, 2017, JPN J RADIOL, V35, P664, DOI 10.1007/s11604-017-0679-y
   Kim JH, 2015, WORLD J GASTROENTERO, V21, P5158, DOI 10.3748/wjg.v21.i17.5158
   Kinowaki Y, 2018, LAB INVEST, V98, P609, DOI 10.1038/s41374-017-0008-1
   Li Q, 2019, N-S ARCH PHARMACOL, V392, P1477, DOI 10.1007/s00210-019-01687-2
   Li S, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.01080
   Lu Z, 2018, ONCOL LETT, V16, P3297, DOI 10.3892/ol.2018.8979
   Ma B, 2017, FUTURE ONCOL, V13, P2489, DOI 10.2217/fon-2017-0310
   Ning J, 2015, DRUG METAB DISPOS, V43, P299, DOI 10.1124/dmd.114.060996
   Park S, 2018, ANIM CELLS SYST, V22, P334, DOI 10.1080/19768354.2018.1512521
   Peng GQ, 2019, ONCOL REP, V41, P1264, DOI 10.3892/or.2018.6905
   Sui XB, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01371
   Tang HX, 2019, INT J PHARMACEUT, V572, DOI 10.1016/j.ijpharm.2019.118782
   Uddin MN, 2012, HYPERTENS PREGNANCY, V31, P70, DOI 10.3109/10641955.2010.525275
   Wang GX, 2017, CELL REP, V21, P2926, DOI 10.1016/j.celrep.2017.11.030
   Wang Y, 2019, MOL MED REP, V20, P4081, DOI 10.3892/mmr.2019.10660
   Wu CH, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-18935-1
   Yin Y, 2017, CLIN CANCER RES, V23, P7375, DOI 10.1158/1078-0432.CCR-17-1283
   Zhang X., 2019, J CELLULAR PHYSL, V235, P3425
   Zou Y, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09277-9
NR 29
TC 17
Z9 17
U1 4
U2 31
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1932-8486
EI 1932-8494
J9 ANAT REC
JI Anat. Rec.
PD FEB
PY 2021
VL 304
IS 2
BP 313
EP 322
DI 10.1002/ar.24378
EA FEB 2020
PG 10
WC Anatomy & Morphology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Anatomy & Morphology
GA PT4TA
UT WOS:000511455800001
PM 31961485
DA 2022-04-25
ER

PT J
AU Janssen, K
   Horn, S
   Niemann, MT
   Daniel, PT
   Schulze-Osthoff, K
   Fischer, U
AF Janssen, Katja
   Horn, Sibylle
   Niemann, Mathis T.
   Daniel, Peter T.
   Schulze-Osthoff, Klaus
   Fischer, Ute
TI Inhibition of the ER Ca2+ pump forces multidrug-resistant cells
   deficient in Bak and Bax into necrosis
SO JOURNAL OF CELL SCIENCE
LA English
DT Article
DE ER stress; PARP; SERCA; Bak; Bax; Necrosis; Multidrug resistance; UPR;
   Autophagy; Ire1
ID ENDOPLASMIC-RETICULUM STRESS; UNFOLDED PROTEIN RESPONSE; MITOCHONDRIAL
   PERMEABILITY TRANSITION; INDUCED APOPTOSIS; POLY(ADP-RIBOSE) POLYMERASE;
   HEMATOPOIETIC MALIGNANCIES; MEMBRANE PERMEABILIZATION; MUTATIONAL
   INACTIVATION; PROAPOPTOTIC BAX; PROSTATE-CANCER
AB Tumor cells deficient in the proapoptotic proteins Bak and Bax are resistant to chemotherapeutic drugs. Here, we demonstrate that murine embryonic fibroblasts deficient for both Bak and Bax are, however, efficiently killed by thapsigargin, a specific inhibitor of ER Ca2+ pumps that induces ER stress by depleting ER Ca2+ stores. In the presence of Bak and Bax, thapsigargin eliminates cells by release of mitochondrial cytochrome c and subsequent caspase activation, which leads to the proteolytic inactivation of the molecular necrosis switch PARP-1 and results in apoptosis. By contrast, in the absence of Bak and Bax, a failure to activate caspases results in PARP-1-mediated ATP depletion. The subsequent necrosis is not prevented by autophagy as an alternative energy source. Moreover, in cells deficient for both Bak and Bax, thapsigargin induces permanent mitochondrial damage by Ca2+ overload, permeability transition and membrane rupture. Thus, even though deficiency in Bak and Bax protects these cells against apoptosis, it does not compromise necrosis induced by SERCA inhibitors. Importantly, thapsigargin induces caspase-independent cell death also in colon and prostate carcinoma cells deficient in Bak and Bax expression. Therefore, targeted application of ER stressors such as thapsigargin might be a promising approach for the treatment of Bak- and Bax-deficient, drug-resistant tumors.
C1 [Janssen, Katja; Horn, Sibylle; Niemann, Mathis T.; Schulze-Osthoff, Klaus; Fischer, Ute] Univ Tubingen, Interfac Inst Biochem, D-72076 Tubingen, Germany.
   [Janssen, Katja; Horn, Sibylle; Niemann, Mathis T.; Schulze-Osthoff, Klaus; Fischer, Ute] Univ Dusseldorf, Inst Mol Med, D-40225 Dusseldorf, Germany.
   [Daniel, Peter T.] Univ Med Ctr Charite, Dept Hematol Oncol & Tumor Immunol, D-13125 Berlin, Germany.
RP Fischer, U (corresponding author), Univ Tubingen, Interfac Inst Biochem, D-72076 Tubingen, Germany.
EM ute.fischer@uni-tuebingen.de
RI Schulze-Osthoff, Klaus/N-9025-2013
OI Schulze-Osthoff, Klaus/0000-0003-1443-2720
FU Deutsche ForschungsgemeinschaftGerman Research Foundation (DFG) [SFB773,
   GRK 1302]; Deutsche Krebshilfe, the Comprehensive Cancer Centre
   TubingenDeutsche Krebshilfe; Medical Faculty of the University
   Dusseldorf
FX The authors wish to thank Marion Nissen for electron microscopy, Reza
   Ahmadian, Hidenori Ichijo, Randal J. Kaufman, Stanley J. Korsmeyer,
   Heinz Mehlhorn, Roland Piekorz, Ingo Schmitz, Hans- Uwe Simon, Andreas
   Strasser, Andreas Villunger, Bert Vogelstein and Erwin F. Wagner for
   valuable materials and helpful discussion. This work was supported by
   the Deutsche Forschungsgemeinschaft (SFB773, GRK 1302), the Deutsche
   Krebshilfe, the Comprehensive Cancer Centre Tubingen, and a grant of the
   Medical Faculty of the University Dusseldorf.
CR Baines CP, 2005, NATURE, V434, P658, DOI 10.1038/nature03434
   Bell CW, 2006, AM J PHYSIOL-CELL PH, V291, pC1318, DOI 10.1152/ajpcell.00616.2005
   Boyce M, 2006, CELL DEATH DIFFER, V13, P363, DOI 10.1038/sj.cdd.4401817
   Brimmell M, 1998, ONCOGENE, V16, P1803, DOI 10.1038/sj.onc.1201704
   Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3
   Chipuk JE, 2008, TRENDS CELL BIOL, V18, P157, DOI 10.1016/j.tcb.2008.01.007
   Denmeade SR, 2005, CANCER BIOL THER, V4, P14
   Denmeade SR, 2003, J NATL CANCER I, V95, P990, DOI 10.1093/jnci/95.13.990
   Ditsworth D, 2007, J BIOL CHEM, V282, P17845, DOI 10.1074/jbc.M701465200
   Dong Z, 2006, ANNU REV PATHOL-MECH, V1, P405, DOI 10.1146/annurev.pathol.1.110304.100218
   Efferth T, 2006, CURR DRUG TARGETS, V7, P407, DOI 10.2174/138945006776359412
   Ferrari D, 1998, J EXP MED, V188, P979, DOI 10.1084/jem.188.5.979
   Fischer U, 2005, ONCOGENE, V24, P1231, DOI 10.1038/sj.onc.1208290
   Fischer U, 2007, BIODRUGS, V21, P273, DOI 10.2165/00063030-200721050-00001
   Friess H, 1998, GUT, V43, P414, DOI 10.1136/gut.43.3.414
   Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309
   Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320
   Gutierrez MI, 1999, CANCER RES, V59, P696
   Ha HC, 1999, P NATL ACAD SCI USA, V96, P13978, DOI 10.1073/pnas.96.24.13978
   Hemmati PG, 2006, ONCOGENE, V25, P6582, DOI 10.1038/sj.onc.1209668
   Herceg Z, 2001, MUTAT RES-FUND MOL M, V477, P97, DOI 10.1016/S0027-5107(01)00111-7
   Hetz C, 2006, SCIENCE, V312, P572, DOI 10.1126/science.1123480
   Hoyer-Hansen M, 2007, CELL DEATH DIFFER, V14, P1576, DOI 10.1038/sj.cdd.4402200
   Hsu YT, 1998, J BIOL CHEM, V273, P10777, DOI 10.1074/jbc.273.17.10777
   Ionov Y, 2000, P NATL ACAD SCI USA, V97, P10872, DOI 10.1073/pnas.190210897
   Janssen K, 2007, BLOOD, V110, P3662, DOI 10.1182/blood-2007-02-073213
   Karbowski M, 2006, NATURE, V443, P658, DOI 10.1038/nature05111
   Kieran D, 2007, P NATL ACAD SCI USA, V104, P20606, DOI 10.1073/pnas.0707906105
   Kondo S, 2000, CANCER RES, V60, P4328
   Kroemer G, 2007, PHYSIOL REV, V87, P99, DOI 10.1152/physrev.00013.2006
   LeBlanc H, 2002, NAT MED, V8, P274, DOI 10.1038/nm0302-274
   Leist M, 1997, J EXP MED, V185, P1481, DOI 10.1084/jem.185.8.1481
   Levine B, 2005, J CLIN INVEST, V115, P2679, DOI 10.1172/JCI26390
   Lindsten T, 2006, CELL DEATH DIFFER, V13, P1272, DOI 10.1038/sj.cdd.4401953
   Los M, 2002, MOL BIOL CELL, V13, P978, DOI 10.1091/mbc.01-05-0272
   Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239
   Martinou I, 1999, J CELL BIOL, V144, P883, DOI 10.1083/jcb.144.5.883
   McCullough KD, 2001, MOL CELL BIOL, V21, P1249, DOI 10.1128/MCB.21.4.1249-1259.2001
   Meijerink JPP, 1998, BLOOD, V91, P2991, DOI 10.1182/blood.V91.8.2991.2991_2991_2997
   Nakagawa T, 2005, NATURE, V434, P652, DOI 10.1038/nature03317
   NAKASE I, 2009, CANC LETT, V18, P290
   NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O
   Nishitoh H, 1998, MOL CELL, V2, P389, DOI 10.1016/S1097-2765(00)80283-X
   Pinton P, 2008, ONCOGENE, V27, P6407, DOI 10.1038/onc.2008.308
   Pinton P, 2000, J CELL BIOL, V148, P857, DOI 10.1083/jcb.148.5.857
   Puthalakath H, 2007, CELL, V129, P1337, DOI 10.1016/j.cell.2007.04.027
   Ricci JE, 2004, CELL, V117, P773, DOI 10.1016/j.cell.2004.05.008
   Rong Y, 2008, ANNU REV PHYSIOL, V70, P73, DOI 10.1146/annurev.physiol.70.021507.105852
   Scaffidi P, 2002, NATURE, V418, P191, DOI 10.1038/nature00858
   Schroder M, 2005, ANNU REV BIOCHEM, V74, P739, DOI 10.1146/annurev.biochem.73.011303.074134
   Scorrano L, 2003, SCIENCE, V300, P135, DOI 10.1126/science.1081208
   Sturm I, 1999, J CLIN ONCOL, V17, P1364, DOI 10.1200/JCO.1999.17.5.1364
   Suzuki M, 2000, CELL, V103, P645, DOI 10.1016/S0092-8674(00)00167-7
   Szalai G, 2000, J BIOL CHEM, V275, P15305, DOI 10.1074/jbc.275.20.15305
   Szegezdi E, 2006, EMBO REP, V7, P880, DOI 10.1038/sj.embor.7400779
   Uhlemann AC, 2005, NAT STRUCT MOL BIOL, V12, P628, DOI 10.1038/nsmb947
   Viemann D, 2007, BLOOD, V109, P2453, DOI 10.1182/blood-2006-08-040444
   Wang GQ, 2001, J BIOL CHEM, V276, P34307, DOI 10.1074/jbc.M103526200
   Wang HG, 1999, SCIENCE, V284, P339, DOI 10.1126/science.284.5412.339
   Waterhouse NJ, 2003, CELL DEATH DIFFER, V10, P853, DOI 10.1038/sj.cdd.4401263
   Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108
   Wu J, 2007, DEV CELL, V13, P351, DOI 10.1016/j.devcel.2007.07.005
   Xu CY, 2008, J BIOL CHEM, V283, P11477, DOI 10.1074/jbc.M708385200
   Xu CY, 2005, J CLIN INVEST, V115, P2656, DOI 10.1172/JCI26373
   Yamamoto K, 2007, DEV CELL, V13, P365, DOI 10.1016/j.devcel.2007.07.018
   Youle RJ, 2008, NAT REV MOL CELL BIO, V9, P47, DOI 10.1038/nrm2308
   Zhou LY, 2008, J CELL SCI, V121, P2186, DOI 10.1242/jcs.024703
NR 67
TC 39
Z9 40
U1 0
U2 2
PU COMPANY OF BIOLOGISTS LTD
PI CAMBRIDGE
PA BIDDER BUILDING CAMBRIDGE COMMERCIAL PARK COWLEY RD, CAMBRIDGE CB4 4DL,
   CAMBS, ENGLAND
SN 0021-9533
J9 J CELL SCI
JI J. Cell Sci.
PD DEC 15
PY 2009
VL 122
IS 24
BP 4481
EP 4491
DI 10.1242/jcs.055772
PG 11
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA 526XM
UT WOS:000272329300009
PM 19920074
OA Bronze
DA 2022-04-25
ER

PT J
AU Fu, SJ
   Wang, YH
   Li, H
   Chen, LL
   Liu, QZ
AF Fu, Shijian
   Wang, Yanhong
   Li, Hang
   Chen, Leilei
   Liu, Quanzhong
TI Regulatory Networks of LncRNA MALAT-1 in Cancer
SO CANCER MANAGEMENT AND RESEARCH
LA English
DT Review
DE long noncoding RNA; tumorigenesis; metastasis-associated lung
   adenocarcinoma transcript 1; regulatory cascade; oncogene; tumor
   suppressor
ID LONG NONCODING RNA; SQUAMOUS-CELL CARCINOMA; ADENOCARCINOMA TRANSCRIPT
   1; EPITHELIAL-MESENCHYMAL TRANSITION; HEPATOCELLULAR-CARCINOMA; LUNG
   ADENOCARCINOMA; GASTRIC-CANCER; PROMOTES PROLIFERATION;
   COLORECTAL-CANCER; DOWN-REGULATION
AB Long noncoding (lnc)RNAs are a group of RNAs with a length greater than 200 nt that do not encode a protein but play an essential role in regulating the expression of target genes in normal biological contexts as well as pathologic processes including tumorigenesis. The lncRNA metastasis-associated lung adenocarcinoma transcript (MALAT)-1 has been widely studied in cancer. In this review, we describe the known functions of MALAT-1; its mechanisms of action; and associated signaling pathways and their clinical significance in different cancers. In most malignancies, including lung, colorectal, thyroid, and other cancers, MALAT-1 functions as an oncogene and is upregulated in tumors and tumor cell lines. MALAT-1 has a distinct mechanism of action in each cancer type and is thus at the center of large gene regulatory networks. Dysregulation of MALAT-1 affects cellular processes such as alternative splicing, epithelial mesenchymal transition, apoptosis, and autophagy, which ultimately results in the abnormal cell proliferation, invasion, and migration that characterize cancers. In other malignancies, such as glioma and endometrial carcinoma, MALAT-1 functions as a tumor suppressor and thus forms additional regulatory networks. The current evidence indicates that MALAT-1 and its associated signaling pathways can serve as diagnostic or prognostic biomarker or therapeutic target in the treatment of many cancers.
C1 [Fu, Shijian; Li, Hang] Harbin Med Univ, Affiliated Hosp 1, Harbin 150081, Peoples R China.
   [Wang, Yanhong] Shantou Univ, Affiliated Hosp, Yuebei Peoples Hosp Shaoguan, Dept Lab Med, Shaoguan 512025, Peoples R China.
   [Chen, Leilei] Capital Med Univ, Beijing Anzhen Hosp, Beijing Inst Heart Lung & Blood Vessel Dis, Dept Cardiol, Beijing 100029, Peoples R China.
   [Liu, Quanzhong] Harbin Med Univ, Dept Med Genet, Harbin 150081, Peoples R China.
RP Liu, QZ (corresponding author), Harbin Med Univ, Dept Med Genet, Harbin 150081, Peoples R China.
EM JaneHeather@outlook.com
CR Amodio N, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-018-0606-4
   An Y, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.123
   Arun G, 2016, GENE DEV, V30, P34, DOI 10.1101/gad.270959.115
   Bai L, 2018, EXP CELL RES, V366, P161, DOI 10.1016/j.yexcr.2018.03.014
   Bamodu OA, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2108-5
   Bayoumi AS, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17030356
   Bolos V, 2007, ENDOCR REV, V28, P339, DOI 10.1210/er.2006-0046
   Bu PC, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7879
   Cai JJ, 2016, ONCOL REP, V35, P284, DOI 10.3892/or.2015.4355
   Cao SZ, 2016, AM J CANCER RES, V6, P2561
   Cao XG, 2015, CANCER BIOMARK, V15, P717, DOI 10.3233/CBM-150513
   Chakrabarti R, 1998, GENE CHROMOSOME CANC, V22, P130, DOI 10.1002/(SICI)1098-2264(199806)22:2<130::AID-GCC7>3.0.CO;2-Y
   Chan JJ, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19051310
   Chang SM, 2018, J CELL PHYSIOL, V233, P3384, DOI 10.1002/jcp.26185
   Chen J, 2019, MOL THER-NUCL ACIDS, V14, P567, DOI 10.1016/j.omtn.2019.01.005
   Chen LS, 2017, J CELL BIOCHEM, V118, P4836, DOI 10.1002/jcb.26158
   Chen MJ, 2018, ANTI-CANCER DRUG, V29, P767, DOI 10.1097/CAD.0000000000000645
   Chen QJ, 2016, ONCOL LETT, V12, P1361, DOI 10.3892/ol.2016.4800
   Chen RB, 2017, NUCLEIC ACIDS RES, V45, P9947, DOI 10.1093/nar/gkx600
   Chen TK, 2019, EUR J MED CHEM, V161, P378, DOI 10.1016/j.ejmech.2018.10.044
   Chen W, 2017, ONCOTARGET, V8, P22783, DOI 10.18632/oncotarget.15199
   Chen Y, 2018, CELL PHYSIOL BIOCHEM, V51, P1313, DOI 10.1159/000495550
   Chou JJ, 2016, BIOCHEM BIOPH RES CO, V472, P262, DOI 10.1016/j.bbrc.2016.02.102
   Chua HL, 2007, ONCOGENE, V26, P711, DOI 10.1038/sj.onc.1209808
   Cittelly DM, 2012, MOL CANCER THER, V11, P2556, DOI 10.1158/1535-7163.MCT-12-0463
   Claverie JM, 2005, SCIENCE, V309, P1529, DOI 10.1126/science.1116800
   Core LJ, 2008, SCIENCE, V322, P1845, DOI 10.1126/science.1162228
   Cui Y, 2018, ONCOL LETT, V16, P4821, DOI 10.3892/ol.2018.9293
   Dinescu S, 2019, GENES, V10, P1
   Dong YQ, 2015, TUMOR BIOL, V36, P1477, DOI 10.1007/s13277-014-2631-4
   Eastlack SC, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0198945
   Fan Y, 2014, CLIN CANCER RES, V20, P1531, DOI 10.1158/1078-0432.CCR-13-1455
   Fang DF, 2015, BIOCHEM BIOPH RES CO, V457, P500, DOI 10.1016/j.bbrc.2014.12.114
   Fang ZY, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2735-x
   Fang ZX, 2018, BIOMED PHARMACOTHER, V101, P536, DOI 10.1016/j.biopha.2018.02.130
   Fu ZQ, 2017, BIOCHEM BIOPH RES CO, V492, P480, DOI 10.1016/j.bbrc.2017.08.070
   Furuta M, 2010, CARCINOGENESIS, V31, P766, DOI 10.1093/carcin/bgp250
   Gai D, 2015, AM J MED GENET A, V167, P174, DOI 10.1002/ajmg.a.36710
   Gao D, 2017, J CELL BIOCHEM, V118, P3341, DOI 10.1002/jcb.25987
   Gordon MA, 2019, MOL CARCINOGEN, V58, P196, DOI 10.1002/mc.22919
   Gou LS, 2019, CANCER BIOL THER, V20, P1355, DOI 10.1080/15384047.2019.1617567
   Graham RP, 2017, MODERN PATHOL, V30, P1443, DOI 10.1038/modpathol.2017.68
   Guerrieri F, 2015, WORLD J HEPATOL, V7, P1971, DOI 10.4254/wjh.v7.i16.1971
   Gutschner T, 2013, J MOL MED, V91, P791, DOI 10.1007/s00109-013-1028-y
   Gutschner T, 2013, CANCER RES, V73, P1180, DOI 10.1158/0008-5472.CAN-12-2850
   Han X, 2019, ARCH MED SCI, V15, P992, DOI 10.5114/aoms.2018.73343
   Han Y, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2015.407
   Han Y, 2016, CELL MOL NEUROBIOL, V36, P1097, DOI 10.1007/s10571-015-0303-6
   Herranz N, 2008, MOL CELL BIOL, V28, P4772, DOI 10.1128/MCB.00323-08
   Hockel M, 2001, JNCI-J NATL CANCER I, V93, P266, DOI 10.1093/jnci/93.4.266
   Hoshino A, 2015, NATURE, V527, P329, DOI 10.1038/nature15756
   Hou ZH, 2020, AM J PHYSIOL-CELL PH, V318, pC649, DOI 10.1152/ajpcell.00510.2018
   Hou ZH, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317718135
   Hu L, 2018, ONCOL LETT, V16, P294, DOI 10.3892/ol.2018.8637
   Hu QY, 2017, MOL MED REP, V15, P1335, DOI 10.3892/mmr.2017.6115
   Hu YR, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0743-3
   Hu ZY, 2016, ONCOTARGET, V7, P11733, DOI 10.18632/oncotarget.7367
   Huang JK, 2017, J CELL BIOCHEM, V118, P4821, DOI 10.1002/jcb.26153
   Huang JK, 2016, BIOMED PHARMACOTHER, V83, P1, DOI 10.1016/j.biopha.2016.05.039
   Huang JF, 2013, HEPATOLOGY, V57, P1882, DOI 10.1002/hep.26195
   Huang MY, 2019, ONCOIMMUNOLOGY, V8, DOI 10.1080/2162402X.2018.1518628
   Huang XJ, 2018, ONCOL REP, V40, P2683, DOI 10.3892/or.2018.6705
   Huang ZL, 2015, ONCOL REP, V34, P2403, DOI 10.3892/or.2015.4259
   Huo YQ, 2017, ONCOTARGET, V8, P46993, DOI 10.18632/oncotarget.16551
   Husmann K, 2015, BIOCHEM BIOPH RES CO, V464, P1222, DOI 10.1016/j.bbrc.2015.07.108
   Jen JY, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0674-z
   Ji DG, 2018, BIOCHEM BIOPH RES CO, V501, P33, DOI 10.1016/j.bbrc.2018.04.116
   Ji P, 2003, ONCOGENE, V22, P8031, DOI 10.1038/sj.onc.1206928
   Ji Q, 2014, BRIT J CANCER, V111, P736, DOI 10.1038/bjc.2014.383
   Ji Q, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078700
   Jin C, 2016, TUMOR BIOL, V37, P4025, DOI 10.1007/s13277-015-4227-z
   Jin Y, 2017, EUR REV MED PHARMACO, V21, P3176
   Kan JY, 2015, J CELL PHYSIOL, V230, P1883, DOI 10.1002/jcp.24918
   Kim SS, 2018, NUCLEIC ACIDS RES, V46, P1424, DOI 10.1093/nar/gkx1221
   Kim SH, 2017, ONCOTARGET, V8, P56546, DOI 10.18632/oncotarget.17798
   Kim YK, 2005, CELL, V120, P195, DOI 10.1016/j.cell.2004.11.050
   King H, 2014, INT REV CEL MOL BIO, V309, P347, DOI 10.1016/B978-0-12-800255-1.00007-7
   Konishi H, 2016, CANCER SCI, V107, P149, DOI 10.1111/cas.12854
   Lai MC, 2012, MED ONCOL, V29, P1810, DOI 10.1007/s12032-011-0004-z
   Lee HW, 2015, CLIN EXP METASTAS, V32, P593, DOI 10.1007/s10585-015-9730-5
   Lee NK, 2017, BMC CANCER, V17, DOI 10.1186/s12885-016-2988-4
   Lei RL, 2017, ONCOTARGETS THER, V10, P35, DOI 10.2147/OTT.S112686
   Leong KG, 2006, BLOOD, V107, P2223, DOI 10.1182/blood-2005-08-3329
   Li C, 2017, CLIN GENITOURIN CANC, V15, P570, DOI 10.1016/j.clgc.2017.05.001
   Li C, 2017, ONCOTARGET, V8, P28683, DOI 10.18632/oncotarget.15640
   Li HW, 2017, CELL PHYSIOL BIOCHEM, V42, P1192, DOI 10.1159/000478917
   Li HY, 2019, ARTIF CELL NANOMED B, V47, P3163, DOI 10.1080/21691401.2019.1642903
   Li JJ, 2017, CANCER CELL INT, V17, DOI 10.1186/s12935-017-0408-8
   Li JP, 2016, AM J CANCER RES, V6, P1099
   Li L, 2017, CELL PHYSIOL BIOCHEM, V42, P2194, DOI 10.1159/000479994
   Li PL, 2017, MOL CANCER THER, V16, P739, DOI 10.1158/1535-7163.MCT-16-0591
   Li QL, 2016, CANCER LETT, V383, P28, DOI 10.1016/j.canlet.2016.09.019
   Li S, 2018, J CELL PHYSIOL, V233, P6679, DOI 10.1002/jcp.26325
   Li SF, 2018, CANCER SCI, V109, P1346, DOI 10.1111/cas.13587
   Li SF, 2015, J CANCER RES CLIN, V141, P1909, DOI 10.1007/s00432-015-1951-0
   Li XJ, 2017, J CELL BIOCHEM, V118, P2780, DOI 10.1002/jcb.25927
   Li ZJ, 2017, J NEURO-ONCOL, V134, P19, DOI 10.1007/s11060-017-2498-5
   Li ZX, 2018, CANCER MANAG RES, V10, P6757, DOI 10.2147/CMAR.S169406
   Li ZJ, 2017, J ORAL PATHOL MED, V46, P583, DOI 10.1111/jop.12538
   Liao KM, 2019, MOL THER-NUCL ACIDS, V18, P388, DOI 10.1016/j.omtn.2019.09.005
   Lin QB, 2018, ONCOL REP, V39, P2644, DOI 10.3892/or.2018.6384
   Liu DL, 2018, J CELL BIOCHEM, V119, P1368, DOI 10.1002/jcb.26297
   Liu K, 2017, CELL CYCLE, V16, P578, DOI 10.1080/15384101.2017.1288324
   Liu PH, 2019, ACTA BIOCH BIOPH SIN, V51, P1148, DOI 10.1093/abbs/gmz112
   Liu SH, 2019, J CANCER, V10, P6649, DOI 10.7150/jca.29213
   Liu SP, 2016, ONCOL LETT, V11, P3686, DOI 10.3892/ol.2016.4435
   Liu Z, 2010, CLIN CANCER RES, V16, P6009, DOI 10.1158/1078-0432.CCR-10-1627
   Lu ZM, 2019, OPEN BIOL, V9, DOI 10.1098/rsob.190095
   Luan WK, 2016, ONCOTARGET, V7, P63901, DOI 10.18632/oncotarget.11564
   Luo F, 2016, ONCOTARGET, V7, P5769, DOI 10.18632/oncotarget.6806
   Luo W, 2016, ONCOTARGET, V7, P54733, DOI 10.18632/oncotarget.10752
   Ma J, 2018, CANCER BIOMARK, V22, P63, DOI 10.3233/CBM-170917
   Ma KX, 2015, TUMOR BIOL, V36, P3355, DOI 10.1007/s13277-014-2969-7
   Malakar P, 2017, CANCER RES, V77, P1155, DOI 10.1158/0008-5472.CAN-16-1508
   Malik B, 2016, ASIAN J ANDROL, V18, P568, DOI 10.4103/1008-682X.177123
   Marampon F, 2017, CANCER LETT, V397, P1, DOI 10.1016/j.canlet.2017.03.028
   Meissner M, 2000, J CELL BIOCHEM, V76, P559, DOI 10.1002/(SICI)1097-4644(20000315)76:4<559::AID-JCB4>3.0.CO;2-U
   Nishikawa Ken, 2017, Biophys Rev, V9, P73, DOI 10.1007/s12551-017-0259-5
   Noritake J, 2005, J CELL SCI, V118, P2085, DOI 10.1242/jcs.02379
   Okugawa Y, 2014, CARCINOGENESIS, V35, P2731, DOI 10.1093/carcin/bgu200
   Pan YJ, 2018, CELL PHYSIOL BIOCHEM, V50, P108, DOI 10.1159/000493962
   Park SJ, 2013, BIOCHEM BIOPH RES CO, V434, P722, DOI 10.1016/j.bbrc.2013.03.091
   PATTON JG, 1991, GENE DEV, V5, P1237, DOI 10.1101/gad.5.7.1237
   Peng H, 2016, LIFE SCI, V151, P235, DOI 10.1016/j.lfs.2016.03.002
   Pennathur A, 2013, LANCET, V381, P400, DOI 10.1016/S0140-6736(12)60643-6
   Ponting CP, 2009, CELL, V136, P629, DOI 10.1016/j.cell.2009.02.006
   Prabhu KS, 2020, CANCERS, V12, DOI 10.3390/cancers12020351
   Qi Y, 2016, ONCOTARGET, V7, P12693, DOI 10.18632/oncotarget.7281
   Qin W, 2014, INT J ONCOL, V45, P1225, DOI 10.3892/ijo.2014.2506
   Qiu G, 2016, ONCOL LETT, V12, P5036, DOI 10.3892/ol.2016.5312
   Qiu MT, 2013, TUMOR BIOL, V34, P613, DOI 10.1007/s13277-013-0658-6
   Qu Y, 2019, ONCOTARGETS THER, V12, P2495, DOI 10.2147/OTT.S191155
   Rao AKDM, 2017, MOL BIOL REP, V44, P203, DOI 10.1007/s11033-017-4103-6
   Raychaudhuri P, 2011, CANCER RES, V71, P4329, DOI 10.1158/0008-5472.CAN-11-0640
   Ren SC, 2013, J UROLOGY, V190, P2278, DOI 10.1016/j.juro.2013.07.001
   Ribeiro DM, 2018, NUCLEIC ACIDS RES, V46, P917, DOI 10.1093/nar/gkx1169
   Shi BY, 2017, CANCER BIOL THER, V18, P792, DOI 10.1080/15384047.2017.1373214
   Shi M, 2014, CLIN CANCER RES, V20, P4370, DOI 10.1158/1078-0432.CCR-14-0186
   Smolle MA, 2015, INT J MOL SCI, V16, P26463, DOI 10.3390/ijms161125962
   Sun LC, 2018, AM J TRANSL RES, V10, P545
   Sun Q, 2019, ONCOTARGETS THER, V12, P6297, DOI 10.2147/OTT.S214689
   Sun YX, 2018, CANCER MED-US, V7, P4584, DOI 10.1002/cam4.1677
   Sun ZQ, 2019, ONCOGENE, V38, P2627, DOI 10.1038/s41388-018-0628-y
   Sun ZY, 2019, MED SCI MONITOR, V25, P1410, DOI 10.12659/MSM.912703
   Tan XY, 2017, J CELL BIOCHEM, V118, P3643, DOI 10.1002/jcb.25862
   Tang DX, 2019, J CELL PHYSIOL, V234, P20816, DOI 10.1002/jcp.28687
   Tang DX, 2019, CELL SIGNAL, V57, P21, DOI 10.1016/j.cellsig.2019.01.013
   Tano K, 2010, FEBS LETT, V584, P4575, DOI 10.1016/j.febslet.2010.10.008
   Tee AE, 2016, ONCOTARGET, V7, P8663, DOI 10.18632/oncotarget.6675
   Tesfaigzi Johannes, 1999, Cell Biochemistry and Biophysics, V30, P243, DOI 10.1007/BF02738069
   Tian YJ, 2014, MELANOMA RES, V24, P335, DOI 10.1097/CMR.0000000000000080
   Tripathi V, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003368
   Tripathi V, 2010, MOL CELL, V39, P925, DOI 10.1016/j.molcel.2010.08.011
   Vassallo I, 2016, ONCOGENE, V35, P12, DOI 10.1038/onc.2015.61
   Wang HF, 2017, CELL PHYSIOL BIOCHEM, V44, P1051, DOI 10.1159/000485405
   Wang Huaqi, 2018, Oncotarget, V9, P7501, DOI 10.18632/oncotarget.23483
   Wang JY, 2014, CELL SIGNAL, V26, P1048, DOI 10.1016/j.cellsig.2014.01.022
   Wang KC, 2011, MOL CELL, V43, P904, DOI 10.1016/j.molcel.2011.08.018
   Wang P, 2017, CHEM RES TOXICOL, V30, P1396, DOI 10.1021/acs.chemrestox.7b00049
   Wang W, 2016, ONCOTARGET, V7, P25668, DOI 10.18632/oncotarget.8257
   Wang XC, 2012, J RADIAT RES, V53, P72, DOI 10.1269/jrr.11090
   Wang XY, 2015, J BIOL CHEM, V290, P3925, DOI 10.1074/jbc.M114.596866
   Wang Y, 2017, ONCOTARGET, V8, P59417, DOI 10.18632/oncotarget.19727
   Wang Y, 2018, CANCER LETT, V436, P52, DOI 10.1016/j.canlet.2018.08.009
   Wang YZ, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317690998
   Wang ZW, 2018, BREAST CANCER RES TR, V171, P261, DOI 10.1007/s10549-018-4839-2
   Wei SQ, 2019, INT J IMMUNOPATH PH, V33, DOI 10.1177/2058738419859699
   Wu CQ, 2018, MOL CARCINOGEN, V57, P1421, DOI 10.1002/mc.22868
   Wu GQ, 2016, ONCOTARGET, V7, P26535, DOI 10.18632/oncotarget.8532
   Wu JS, 2018, ANTI-CANCER DRUG, V29, P628, DOI 10.1097/CAD.0000000000000626
   Wu MY, 2016, SCI REP-UK, V6, DOI 10.1038/srep36045
   Wu Q, 2018, J CELL PHYSIOL, V233, P6750, DOI 10.1002/jcp.26383
   Wu SS, 2019, CANCER RES, V79, P5432, DOI 10.1158/0008-5472.CAN-19-0773
   XI Y, 2018, ONCOL RES, V28, P124, DOI DOI 10.1007/S00330-017-4925-6
   Xia HW, 2016, ONCOTARGET, V7, P56209, DOI 10.18632/oncotarget.10941
   Xie HB, 2017, J CANCER, V8, P3803, DOI 10.7150/jca.21228
   Xiong ZY, 2018, J CELL MOL MED, V22, P3929, DOI 10.1111/jcmm.13667
   Xu CA, 2011, INT J ONCOL, V39, P169, DOI 10.3892/ijo.2011.1007
   Xu FQ, 2016, ONCOTARGETS THER, V9, P2143, DOI 10.2147/OTT.S100003
   Xu SP, 2015, INT J CLIN EXP PATHO, V8, P4881
   Xu Y, 2019, ONCOL REP, V1
   Xu YL, 2018, MOL MED, V24, DOI 10.1186/s10020-018-0050-5
   Yang SZ, 2015, WORLD J GASTROENTERO, V21, P8418, DOI 10.3748/wjg.v21.i27.8418
   Yao WJ, 2016, TUMOR BIOL, V37, P4305, DOI 10.1007/s13277-015-4223-3
   Ying L, 2012, MOL BIOSYST, V8, P2289, DOI 10.1039/c2mb25070e
   Yoon JH, 2012, MOL CELL, V47, P648, DOI 10.1016/j.molcel.2012.06.027
   Yuan LT, 2019, J CLIN MED, V8, DOI 10.3390/jcm8091406
   Yuan P, 2016, BIOCHEM BIOPH RES CO, V478, P1067, DOI 10.1016/j.bbrc.2016.08.065
   Zeng LH, 2018, ONCOL LETT, V15, P2117, DOI 10.3892/ol.2017.7557
   Zhang P, 2018, ONCOTARGETS THER, V11, P291, DOI 10.2147/OTT.S155134
   Zhang R, 2017, BIOCHEM BIOPH RES CO, V490, P406, DOI 10.1016/j.bbrc.2017.06.055
   Zhang TH, 2017, ONCOL REP, V37, P2087, DOI 10.3892/or.2017.5445
   Zhang XQ, 2017, BIOMED PHARMACOTHER, V93, P1065, DOI 10.1016/j.biopha.2017.07.005
   Zhang Y, 2017, BIOMED PHARMACOTHER, V85, P264, DOI 10.1016/j.biopha.2016.11.014
   Zhang ZC, 2017, INT J BIOL SCI, V13, P1398, DOI 10.7150/ijbs.22249
   Zhao KX, 2018, CANCER MANAG RES, V10, P6257, DOI 10.2147/CMAR.S177244
   Zhao Y, 2014, CANCER RES, V74, P5103, DOI 10.1158/0008-5472.CAN-14-0427
   Zhao ZB, 2019, YONSEI MED J, V60, P727, DOI 10.3349/ymj.2019.60.8.727
   Zhao ZY, 2014, BIOCHEM BIOPH RES CO, V445, P388, DOI 10.1016/j.bbrc.2014.02.006
   Zhou DB, 2017, CELL SIGNAL, V35, P197, DOI 10.1016/j.cellsig.2017.04.009
   ZHOU X, 2015, SCI REP-UK, V5, DOI DOI 10.1038/SREP15972
   Zhou YQ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155250
   Zhu KX, 2019, ONCOL LETT, V17, P5335, DOI 10.3892/ol.2019.10253
   Zhu MH, 2019, ONCOTARGETS THER, V12, P1365, DOI 10.2147/OTT.S192069
NR 204
TC 16
Z9 16
U1 1
U2 9
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1179-1322
J9 CANCER MANAG RES
JI Cancer Manag. Res.
PY 2020
VL 12
BP 10181
EP 10198
DI 10.2147/CMAR.S276022
PG 18
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA NZ9CC
UT WOS:000577396400026
PM 33116873
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Pantelic, ND
   Zmejkovski, BB
   Bozic, B
   Dojcinovic, B
   Banjac, NR
   Wessjohann, LA
   Kaluderovic, GN
AF Pantelic, Nebojsa D.
   Zmejkovski, Bojana B.
   Bozic, Bojan
   Dojcinovic, Biljana
   Banjac, Nebojsa R.
   Wessjohann, Ludger A.
   Kaluderovic, Goran N.
TI Synthesis, characterization and in vitro biological evaluation of novel
   organotin(IV) compounds with derivatives of
   2-(5-arylidene-2,4-dioxothiazolidin-3-yl)propanoic acid
SO JOURNAL OF INORGANIC BIOCHEMISTRY
LA English
DT Article
DE Tin(IV); In vitro; Prostate cancer; Apoptosis; Autophagy; NO
ID ANTITUMOR-ACTIVITY; METAL-COMPLEXES; CARBOXYLATE COMPLEXES; CYTOTOXIC
   ACTIVITY; ANTICANCER; TITANOCENE; PLATINUM; INHIBITION; REACTIVITY;
   DICHLORIDE
AB Two novel triphenyltin(IV) compounds, [Ph(3)SnL1] (L1 = 2-(5-(4- fluorobenzylidene)-2,4-dioxotetrahydrothiazole-3-yl)propanoate (1)) and [Ph(3)SnL2] (L2 = 2-(5-(5-methyl-2-furfurylidene)-2,4-dioxotetrahydrothiazole-3-yl)propanoate (2)) were synthesized and characterized by FT-IR, (H-1 and C-13) NMR spectroscopy, mass spectrometry, and elemental microanalysis. The in vitro anticancer activity of the synthesized organotin(IV) compounds was determined against four tumor cell lines: PC-3 (prostate), HT-29 (colon), MCF-7 (breast), and HepG2 (hepatic) using MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-12 diphenyltetrazolium bromide) and CV (crystal violet) assays. The IC50 values are found to be in the range from 0.11 to 0.50 mu M. Compound 1 exhibits the highest activity toward PC-3 cells (IC50 = 0.115 +/- 0.009 mu M; CV assay). The tin and platinum uptake in PC-3 cells showed a threefold lower uptake of tin in comparison to platinum (as cisplatin). Together with its higher activity this indicates a much higher cell inhibition potential of the tin compounds (calculated to ca. 50 to 100 times). Morphological analysis suggested that the compounds induce apoptosis in PC-3 cells, and flow cytometry analysis revealed that 1 and 2 induce autophagy as well as NO (nitric oxide) production.
C1 [Pantelic, Nebojsa D.; Kaluderovic, Goran N.] Univ Appl Sci Merseburg, Dept Engn & Nat Sci, Eberhard Leibnitz Str 2, D-06217 Merseburg, Germany.
   [Pantelic, Nebojsa D.; Banjac, Nebojsa R.] Univ Belgrade, Fac Agr, Dept Chem & Biochem, Nemanjina 6, Belgrade, Serbia.
   [Pantelic, Nebojsa D.; Wessjohann, Ludger A.; Kaluderovic, Goran N.] Leibniz Inst Plant Biochem, Dept Bioorgan Chem, Weinberg 3, D-06120 Halle, Saale, Germany.
   [Zmejkovski, Bojana B.; Dojcinovic, Biljana] Univ Belgrade, Inst Chem Technol & Met, Dept Chem, Studentski Trg 14, Belgrade 11000, Serbia.
   [Bozic, Bojan] Univ Belgrade, Fac Biol, Inst Physiol & Biochem, Studentski Trg 14, Belgrade 11000, Serbia.
RP Kaluderovic, GN (corresponding author), Univ Appl Sci Merseburg, Dept Engn & Nat Sci, Eberhard Leibnitz Str 2, D-06217 Merseburg, Germany.
EM goran.kaluderovic@hs-merseburg.de
RI Wessjohann, Ludger/AAZ-3838-2021; Bozic, Bojan/ABA-3278-2020;
   Kaluderovic, Goran/AAR-7347-2021
OI Kaluderovic, Goran/0000-0001-5168-1000; Wessjohann, Ludger
   A./0000-0003-2060-8235; Pantelic, Nebojsa D./0000-0003-1843-9890; Bozic,
   Bojan/0000-0001-9910-2741
FU Ministry of Education, Science and Technological Development of the
   Republic of Serbia [172035, 175033]; National Scholarship for
   Postdoctoral Studies of the Republic of Serbia; German Academic Exchange
   Service (DAAD)Deutscher Akademischer Austausch Dienst (DAAD) [57448219]
FX This research was supported by the Ministry of Education, Science and
   Technological Development of the Republic of Serbia, [grant numbers:
   172035 and 175033] and National Scholarship for Postdoctoral Studies of
   the Republic of Serbia (N. D. Pantelic). The authors acknowledge
   financial support from the German Academic Exchange Service (DAAD)
   [grant number: 57448219].
CR Abeysinghe PM, 2007, DALTON T, P3474, DOI 10.1039/b707440a
   ARAKAWA Y, 2000, BIOMED RES TRACE ELE, V11, P259
   Balas VI, 2011, EUR J MED CHEM, V46, P2835, DOI 10.1016/j.ejmech.2011.04.005
   Banada N.K., 1996, APOPTOSIS, V1, P69
   Barbieri F, 2002, ANTI-CANCER DRUG, V13, P599, DOI 10.1097/00001813-200207000-00006
   Baul TSB, 2006, J ORGANOMET CHEM, V691, P4850, DOI 10.1016/j.jorganchem.2006.08.005
   Bedard K, 2007, PHYSIOL REV, V87, P245, DOI 10.1152/physrev.00044.2005
   Bozdag-Dundar O, 2008, BIOORGAN MED CHEM, V16, P6747, DOI 10.1016/j.bmc.2008.05.059
   Bozic B, 2017, ARAB J CHEM, V10, pS2637, DOI 10.1016/j.arabjc.2013.10.002
   Bruijnincx PCA, 2008, CURR OPIN CHEM BIOL, V12, P197, DOI 10.1016/j.cbpa.2007.11.013
   Bruijnincx PCA, 2009, ADV INORG CHEM, V61, P1, DOI 10.1016/S0898-8838(09)00201-3
   Casas JS, 2004, INORG CHEM, V43, P1957, DOI 10.1021/ic0351141
   Ceballos-Torres J, 2012, J ORGANOMET CHEM, V716, P201, DOI 10.1016/j.jorganchem.2012.06.028
   Ceriello A, 2008, DIABETES-METAB RES, V24, P14, DOI 10.1002/dmrr.790
   Cristofani R, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0866-5
   Crowe AJ., 1994, ANTITUMOUR ACTIVITY, P147
   de Vos Dick, 1998, Metal-Based Drugs, V5, P179, DOI 10.1155/MBD.1998.179
   DEACON GB, 1980, COORDIN CHEM REV, V33, P227, DOI 10.1016/S0010-8545(00)80455-5
   Falcioni ML, 2008, MUTAT RES-GEN TOX EN, V653, P57, DOI 10.1016/j.mrgentox.2008.03.010
   Finkel T, 2005, NAT REV MOL CELL BIO, V6, P971, DOI 10.1038/nrm1763
   Gielen M, 1996, COORDIN CHEM REV, V151, P41, DOI 10.1016/S0010-8545(96)90193-9
   Gielen M, 1997, NATO ASI 2, V26, P445
   Gielen M., 2005, METALLOTHERAPEUTIC D, DOI [DOI 10.1002/0470864052, 10.1002/0470864052]
   Gomez-Ruiz S, 2008, J INORG BIOCHEM, V102, P1558, DOI 10.1016/j.jinorgbio.2008.02.001
   Gomez-Ruiz S, 2007, INORG CHEM COMMUN, V10, P748, DOI 10.1016/j.inoche.2007.03.016
   Gomez-Ruiz S, 2010, POLYHEDRON, V29, P354, DOI 10.1016/j.poly.2009.05.068
   Gomez-Ruiz S, 2010, POLYHEDRON, V29, P16, DOI 10.1016/j.poly.2009.05.056
   Gomez-Ruiz S, 2008, J INORG BIOCHEM, V102, P2087, DOI 10.1016/j.jinorgbio.2008.07.009
   Gust R, 2004, J MED CHEM, V47, P5837, DOI 10.1021/jm040763n
   Hadjikakou SK, 2009, COORDIN CHEM REV, V253, P235, DOI 10.1016/j.ccr.2007.12.026
   Han GY, 2002, J INORG BIOCHEM, V91, P230, DOI 10.1016/S0162-0134(02)00369-0
   Hartinger CG, 2009, CHEM SOC REV, V38, P391, DOI 10.1039/b707077m
   Hoti N, 2003, J BIOCHEM, V134, P521, DOI 10.1093/jb/mvg169
   Jakupec MA, 2008, DALTON T, P183, DOI 10.1039/b712656p
   Kaluderovic GN, 2015, J INORG BIOCHEM, V153, P315, DOI 10.1016/j.jinorgbio.2015.09.006
   Kaluderovic GN, 2010, J ORGANOMET CHEM, V695, P1883, DOI 10.1016/j.jorganchem.2010.04.029
   Kaluderovic GN, 2010, METALLOMICS, V2, P419, DOI 10.1039/c0mt00007h
   Kaluderovic GN, 2010, DALTON T, V39, P2597, DOI 10.1039/b920051g
   Kaluderovic GN, 2010, J MATER CHEM, V20, P806, DOI 10.1039/b919269g
   Kaluderovic MR, 2017, COATINGS, V7, DOI 10.3390/coatings7070102
   Kaluderovic MR, 2010, EUR J MED CHEM, V45, P519, DOI 10.1016/j.ejmech.2009.10.038
   Kelly ME, 2008, ORGANOMETALLICS, V27, P4917, DOI 10.1021/om800323z
   Kim J, 2016, EXP MOL MED, V48, DOI 10.1038/emm.2016.119
   Kntayya SB, 2018, NUTRIENTS, V10, DOI 10.3390/nu10060718
   Krajnovic T, 2016, PHARMACOL RES, V105, P62, DOI 10.1016/j.phrs.2016.01.011
   Lanas A, 2009, AM J MED SCI, V338, P96, DOI 10.1097/MAJ.0b013e3181ad8cd3
   Li QS, 1996, J INORG BIOCHEM, V64, P181, DOI 10.1016/0162-0134(96)00039-6
   Molter A, 2012, J ORGANOMET CHEM, V701, P80, DOI 10.1016/j.jorganchem.2011.12.027
   Mueller CFH, 2005, ARTERIOSCL THROM VAS, V25, P274, DOI 10.1161/01.ATV.0000149143.04821.eb
   Mujoo K, 2011, FREE RADICAL BIO MED, V51, P2150, DOI 10.1016/j.freeradbiomed.2011.09.037
   Nath M, 2001, COORDIN CHEM REV, V215, P99, DOI 10.1016/S0010-8545(00)00404-5
   Nikolini M., 1988, PLATINUM OTHER COORD
   Ott I, 2007, ARCH PHARM, V340, P117, DOI 10.1002/ardp.200600151
   Pantelic N, 2017, J INORG BIOCHEM, V172, P55, DOI 10.1016/j.jinorgbio.2017.04.001
   Pantelic ND, 2019, J SERB CHEM SOC, V84, P1119, DOI 10.2298/JSC190322032P
   Pantelic ND, 2019, J CHEM-NY, V2019, DOI 10.1155/2019/2905840
   Pellerito L, 2002, COORDIN CHEM REV, V224, P111, DOI 10.1016/S0010-8545(01)00399-X
   Perez-Quintanilla D, 2009, CHEM-EUR J, V15, P5588, DOI 10.1002/chem.200900151
   Pettinari C, 1999, MAIN GROUP MET CHEM, V22, P661
   Ray PD, 2012, CELL SIGNAL, V24, P981, DOI 10.1016/j.cellsig.2012.01.008
   Rocamora-Reverte L, 2012, CHEMMEDCHEM, V7, P301, DOI 10.1002/cmdc.201100432
   ROSENBERG B, 1965, NATURE, V205, P698, DOI 10.1038/205698a0
   Salamone S, 2012, EUR J MED CHEM, V51, P206, DOI 10.1016/j.ejmech.2012.02.044
   SAXENA AK, 1989, COORDIN CHEM REV, V95, P109, DOI 10.1016/0010-8545(89)80003-7
   Seibert H, 2004, CELL BIOL TOXICOL, V20, P273, DOI 10.1007/s10565-004-3859-3
   SLADOWSKI D, 1993, J IMMUNOL METHODS, V157, P203, DOI 10.1016/0022-1759(93)90088-O
   Spitz D.R., 2004, CANC METASTASIS REV, V23
   Strohfeldt K, 2008, CHEM SOC REV, V37, P1174, DOI 10.1039/b707310k
   Susperregui J, 1999, EUR J MED CHEM, V34, P617, DOI 10.1016/S0223-5234(00)80030-6
   Syng-Ai C, 2001, J Environ Pathol Toxicol Oncol, V20, P333
   Tian LJ, 2005, J INORG BIOCHEM, V99, P1646, DOI 10.1016/j.jinorgbio.2005.05.006
   Yan YK, 2005, CHEM COMMUN, P4764, DOI 10.1039/b508531b
   Yang P, 1999, COORDIN CHEM REV, V185-6, P189, DOI 10.1016/S0010-8545(98)00268-9
   Zheng Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078476
NR 74
TC 5
Z9 5
U1 1
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0162-0134
EI 1873-3344
J9 J INORG BIOCHEM
JI J. Inorg. Biochem.
PD OCT
PY 2020
VL 211
AR 111207
DI 10.1016/j.jinorgbio.2020.111207
PG 8
WC Biochemistry & Molecular Biology; Chemistry, Inorganic & Nuclear
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA NJ9DO
UT WOS:000566344500012
PM 32801055
DA 2022-04-25
ER

PT J
AU Ngaffo, CMN
   Tchangna, RSV
   Mbaveng, AT
   Kamga, J
   Harvey, FM
   Ngadjui, BT
   Bochet, CG
   Kuete, V
AF Ngaffo, Carine M. N.
   Tchangna, Rodrigue S., V
   Mbaveng, Armelle T.
   Kamga, Justin
   Harvey, Freya M.
   Ngadjui, Bonaventure T.
   Bochet, Christian G.
   Kuete, Victor
TI Botanicals from the leaves of Acacia sieberiana had better cytotoxic
   effects than isolated phytochemicals towards MDR cancer cells lines
SO HELIYON
LA English
DT Article
DE Acacia sieberiana; Apoptosis; Cytotoxicity; Fabaceae; Multi-drug
   resistance; Phytochemicals; Metabolite; Pharmaceutical science; Cancer
   research; Toxicology; Pharmacology
ID CAMEROONIAN MEDICINAL-PLANTS; MULTIDRUG-RESISTANCE; BREAST-CANCER;
   MODES; INHIBITION; FLAVONOIDS; AUTOPHAGY; TRANSPORTER; CARCINOMA;
   APOPTOSIS
AB The efficiency of cancer chemotherapy is seriously hampered by the development of resistance of neoplastic cells cytotoxic agents. In the present investigation, the cytotoxicity of the dichloromethane-methanol (1:1) extract of Acacia sieberiana (ASL), fractions (ASLa-c) from the leaves and isolated compounds: chrysoeriol-7-O-rutinoside (1), luteolin-7-O-rutinoside (2), chrysoeriol-7-O-beta-D-glucopyranoside (3), Apigenin-7-O-beta-D-glucopyranoside (4), luteolin-30,40-dimethoxylether-7-O-beta-D-glucoside (5) and luteolin (6) was investigated. The study was extended to assessment of the mode of induction of apoptosis by ASL. The resazurin reduction assay (RRA) was used for cytotoxicity studies. Assessments of cell cycle distribution, apoptosis, and reactive oxygen species (ROS) were performed by flow cytometry. A caspase-Glo assay was used to evaluate caspase activities. Botanicals ASL, ASLb and ASLc as well as doxorubicin displayed observable IC50 values towards the nine tested cancer cell lines while ASLa and compounds 1-7 had selective activities. The IC50 values ranged from 13.45 mu g/mL (in CCRF-CEM leukemia cells) to 33.20 mu g/mL (against MDA-MB-231-BCRP breast adenocarcinoma cells) for ASL, from 16.42 mu g/mL (in CCRF-CEM cells) to 29.64 mu g/mL (against MDA-MB-231-pcDNA cells) for ASLc, and from 22.94 mu g/mL MDA-MB-231-BCRP cells) to 40.19 mu g/mL (against HCT116 (p53-/-) colon adenocarcinoma cells) for ASLb (Table 1), and from 0.02 mu M (against CCRF-CEM cells) to 122.96 mu M (against CEM/ADR5000 cells) for doxorubicin. ASL induced apoptosis in CCRF-CEM cells, mediated by ROS production. Acacia sieberiana is a good cytotoxic plant and should be further explored to develop an anticancer phytomedicine to combat both sensitive and drug resistant phenotypes.
C1 [Ngaffo, Carine M. N.; Mbaveng, Armelle T.; Kuete, Victor] Univ Dschang, Fac Sci, Dept Biochem, Dschang, Cameroon.
   [Tchangna, Rodrigue S., V; Kamga, Justin; Ngadjui, Bonaventure T.] Univ Yaounde I, Fac Sci, Dept Chem, Yaounde, Cameroon.
   [Kamga, Justin; Harvey, Freya M.; Bochet, Christian G.] Univ Fribourg, Fac Sci & Med, Dept Chem, Chemin Musee 9, CH-1700 Fribourg, Switzerland.
RP Kuete, V (corresponding author), Univ Dschang, Fac Sci, Dept Biochem, Dschang, Cameroon.
EM kuetevictor@yahoo.fr
OI KAMGA, Justin/0000-0003-4822-8293; Kuete, Victor/0000-0002-1070-1236;
   Harvey, Freya/0000-0002-9877-4041; Bochet, Christian/0000-0003-4267-0523
FU Alexander von Humboldt (AvH) foundationAlexander von Humboldt Foundation
   [CMR 1163890]; Swiss Government Excellence Scholarship [2017.1063]
FX This work was supported by the Alexander von Humboldt (AvH) foundation
   (Grant no.: CMR 1163890 GF-E to ATM) and the Swiss Government Excellence
   Scholarship (Grant no.: 2017.1063 to JK).
CR Abdelhady M.I.S., 2013, ORG CHEM INDIAN J, V9, P236
   Aboul-Enein AM, 2014, BMC COMPLEM ALTERN M, V14, DOI 10.1186/1472-6882-14-397
   Adem FA, 2019, PHYTOMEDICINE, V58, DOI 10.1016/j.phymed.2019.152853
   BASS DA, 1983, J IMMUNOL, V130, P1910
   Boik J., 2001, NATURAL COMPOUNDS CA
   Brahemi G, 2010, J MED CHEM, V53, P2757, DOI 10.1021/jm901757t
   Cao ZJ, 2017, CELL PHYSIOL BIOCHEM, V43, P1803, DOI 10.1159/000484066
   Cirla A, 2003, NAT PROD REP, V20, P558, DOI 10.1039/b306797c
   Collett NP, 2010, SEMIN ONCOL, V37, P258, DOI 10.1053/j.seminoncol.2010.06.014
   CORDELL GA, 1991, J ETHNOPHARMACOL, V32, P117, DOI 10.1016/0378-8741(91)90110-Y
   Cossarizza A, 2009, NAT PROTOC, V4, P1790, DOI 10.1038/nprot.2009.189
   Doyle LA, 1998, P NATL ACAD SCI USA, V95, P15665, DOI 10.1073/pnas.95.26.15665
   Efferth T, 2003, MOL PHARMACOL, V64, P382, DOI 10.1124/mol.64.2.382
   Efferth T, 2008, CLIN CANCER RES, V14, P2405, DOI 10.1158/1078-0432.CCR-07-4525
   Gillet JP, 2004, CANCER RES, V64, P8987, DOI 10.1158/0008-5472.CAN-04-1978
   Hegazy MEF, 2019, PHYTOMEDICINE, V59, DOI 10.1016/j.phymed.2018.11.031
   KIMMIG A, 1990, CANCER RES, V50, P6793
   Kuete V, 2017, PHYTOMEDICINE, V33, P62, DOI 10.1016/j.phymed.2017.07.010
   Kuete V, 2016, SPRINGERPLUS, V5, DOI 10.1186/s40064-016-3361-4
   Kuete V, 2016, BMC COMPLEM ALTERN M, V16, DOI 10.1186/s12906-016-1253-3
   Kuete V, 2016, PHYTOMEDICINE, V23, P856, DOI 10.1016/j.phymed.2016.04.007
   Kuete V, 2016, J ETHNOPHARMACOL, V186, P196, DOI 10.1016/j.jep.2016.04.001
   Kuete V, 2015, PHYTOMEDICINE, V22, P1096, DOI 10.1016/j.phymed.2015.07.006
   Kuete V, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/914813
   Kuete V, 2014, PHYTOMEDICINE, V21, P1651, DOI 10.1016/j.phymed.2014.08.001
   Kuete V, 2014, INVEST NEW DRUG, V32, P1053, DOI 10.1007/s10637-014-0137-y
   Kuete V, 2014, J ETHNOPHARMACOL, V153, P207, DOI 10.1016/j.jep.2014.02.025
   Kuete V, 2013, J ETHNOPHARMACOL, V149, P245, DOI 10.1016/j.jep.2013.06.029
   Kuete V, 2013, PHYTOMEDICINE, V20, P528, DOI 10.1016/j.phymed.2013.02.003
   Kuete V, 2011, PLANTA MED, V77, P1984, DOI 10.1055/s-0031-1280023
   Kuete V, 2011, J ETHNOPHARMACOL, V134, P803, DOI 10.1016/j.jep.2011.01.035
   Liu G, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166823
   Luduena RF, 1998, INT REV CYTOL, V178, P207
   Mbaveng AT, 2020, PHYTOMEDICINE, V76, DOI 10.1016/j.phymed.2020.153261
   Mbaveng AT, 2019, EVID-BASED COMPL ALT, V2019, DOI 10.1155/2019/8450158
   Mbaveng AT, 2019, PHYTOMEDICINE, V60, DOI 10.1016/j.phymed.2019.152832
   Mbaveng AT, 2019, J ETHNOPHARMACOL, V235, P28, DOI 10.1016/j.jep.2019.01.031
   Mbaveng AT, 2018, PHYTOMEDICINE, V48, P112, DOI 10.1016/j.phymed.2017.12.016
   Mbaveng AT, 2018, PHYTOMEDICINE, V43, P78, DOI 10.1016/j.phymed.2018.03.035
   Mbaveng AT, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00343
   O'Brien J, 2000, EUR J BIOCHEM, V267, P5421, DOI 10.1046/j.1432-1327.2000.01606.x
   ORWA C, 2003, AGROFORESTREE DATABA
   Popoca J, 1998, J ETHNOPHARMACOL, V59, P173, DOI 10.1016/S0378-8741(97)00110-4
   Wei W, 2019, J BUON, V24, P936
   Yang JL, 2018, BIOMED PHARMACOTHER, V103, P699, DOI 10.1016/j.biopha.2018.04.072
   Yao X, 2019, FOOD FUNCT, V10, P703, DOI 10.1039/c8fo02013b
   Zhang ZF, 2007, STROKE, V38, P1606, DOI 10.1161/STROKEAHA.106.475129
NR 47
TC 2
Z9 2
U1 1
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
EI 2405-8440
J9 HELIYON
JI Heliyon
PD NOV
PY 2020
VL 6
IS 11
AR e05412
DI 10.1016/j.heliyon.2020.e05412
PG 9
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA PC1YA
UT WOS:000596803700008
PM 33163682
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Mazewski, C
   Kim, MS
   de Mejia, EG
AF Mazewski, Candice
   Kim, Morgan Sanha
   de Mejia, Elvira Gonzalez
TI Anthocyanins, delphinidin-3-O-glucoside and cyanidin-3-O-glucoside,
   inhibit immune checkpoints in human colorectal cancer cells in vitro and
   in silico
SO SCIENTIFIC REPORTS
LA English
DT Article
ID COLON-CANCER; PROLIFERATION; EXTRACTS; BIOAVAILABILITY; ACTIVATION;
   STABILITY; AUTOPHAGY; PURPLE; GRAPE
AB The objective was to assess anti-progression and stimulatory immune response effects among anthocyanins (ANC) and their metabolites on human colorectal cancer cells in vitro and in silico. Pure phenolics including delphinidin-3-O-glucoside (D3G) and its metabolites, delphinidin (DC) and gallic acid (GA), were tested alone or in combination, on HCT-116 and HT-29 human colorectal cancer cells (100-600 mu g/mL). HCT-116 and HT-29 50% inhibition concentrations (mu g/mL) were 396 +/- 23 and 329 +/- 17 for D3G; 242 +/- 16 and > 600 for DC; and 154 +/- 5 and 81 +/- 5 for GA, respectively. Using molecular docking, cyanidin-3-O-glucoside (C3G) showed the highest potential to inhibit immune checkpoints: programmed cell death protein-1 (PD-1) (-6.8 kcal/mol) and programmed death-ligand-1 (PD-L1) (-9.6 kcal/mol). C3G, D3G, DC, GA, and D3G-rich extracts decreased PD-L1 protein expression in HCT-116 cells. C3G decreased PD-L1 fluorescence intensity by 39%. ANC decreased PD-1 expression in peripheral blood mononuclear cells in monoculture by 41% and 55%, and co-culture with HCT-116 and HT-29 cells by 39% and 26% (C3G) and 50% and 51% (D3G), respectively. D3G and C3G, abundant in plant foods, showed potential for binding with and inhibiting immune checkpoints, PD-1 and PD-L1, which can activate immune response in the tumor microenvironment and induce cancer cell death.
C1 [Mazewski, Candice; de Mejia, Elvira Gonzalez] Univ Illinois, Dept Food Sci & Human Nutr, Urbana, IL 61801 USA.
   [Kim, Morgan Sanha] Univ Illinois, Dept Chem & Biomol Engn, Urbana, IL 61801 USA.
RP de Mejia, EG (corresponding author), Univ Illinois, Dept Food Sci & Human Nutr, Urbana, IL 61801 USA.
EM edemejia@illinois.edu
OI DE MEJIA, ELVIRA/0000-0001-7426-9035
FU USDA National Institute of Food and Agriculture Hatch project [1014457]
FX This work was partially supported by USDA National Institute of Food and
   Agriculture Hatch project 1014457.
CR Ahmed D, 2013, ONCOGENESIS, V2, DOI 10.1038/oncsis.2013.35
   American Institute for Cancer Research, 2018, LEARN COL CANC
   Hernandez-Herrero JA, 2011, INT J FOOD SCI TECH, V46, P2550, DOI 10.1111/j.1365-2621.2011.02780.x
   Anwar S, 2016, MOL MED REP, V14, P1397, DOI 10.3892/mmr.2016.5397
   Azevedo MI, 2013, MOL PAIN, V9, DOI 10.1186/1744-8069-9-53
   Banerjee N, 2013, CARCINOGENESIS, V34, P2814, DOI 10.1093/carcin/bgt295
   Boland CR, 2010, GASTROENTEROLOGY, V138, P2073, DOI [10.1053/j.gastro.2009.12.064, 10.1053/j.gastro.2010.04.024]
   Cao L., 2016, PLOS ONE, V11, P1
   Charepalli V, 2016, CANCERS, V8, DOI 10.3390/cancers8030029
   Chen DS, 2017, NATURE, V541, P321, DOI 10.1038/nature21349
   Choe YJ, 2012, ONCOL REP, V28, P2049, DOI 10.3892/or.2012.2034
   Choi YJ, 2017, GUT LIVER, V11, P243, DOI 10.5009/gnl16068
   Dia VP, 2011, MOL NUTR FOOD RES, V55, P623, DOI 10.1002/mnfr.201000419
   Fan MJ, 2017, EXP THER MED, V14, P59, DOI 10.3892/etm.2017.4467
   Fernandes I, 2014, J FUNCT FOODS, V7, P54, DOI 10.1016/j.jff.2013.05.010
   Fernandez J, 2018, GENES-BASEL, V9, DOI 10.3390/genes9030133
   Forester SC, 2014, MOL CARCINOGEN, V53, P432, DOI 10.1002/mc.21974
   Greaves M, 2018, BMC BIOL, V16, DOI 10.1186/s12915-018-0493-8
   Jing P, 2015, FOOD CHEM, V172, P183, DOI 10.1016/j.foodchem.2014.08.100
   Kausar H, 2012, CANCER LETT, V325, P54, DOI 10.1016/j.canlet.2012.05.029
   Khoo HE, 2017, FOOD NUTR RES, V61, P1, DOI 10.1080/16546628.2017.1361779
   Kubow S, 2017, NUTRIENTS, V9, DOI 10.3390/nu9090953
   Li N, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100314
   Li Q, 2017, FOOD CHEM, V231, P332, DOI 10.1016/j.foodchem.2017.03.146
   Li YL, 2016, CANCER BIOL MED, V13, P206, DOI 10.20892/j.issn.2095-3941.2015.0070
   de Las Hazas MCL, 2017, J AGR FOOD CHEM, V65, P6477, DOI 10.1021/acs.jafc.6b04096
   Luna-Vital D., 2018, PROTECTION COLOR CHE, DOI [10.1016/j.foodres.2017.11.009, DOI 10.1016/J.FOODRES.2017.11.009]
   Lynch D, 2016, ANN TRANSL MED, V4, DOI 10.21037/atm.2016.08.29
   Mazewski C., 2018, ADV PLANT PHENOLICS, DOI [10.1021/bk-2018-1286.ch0019, DOI 10.1021/BK-2018-1286.CH0019]
   Mazewski C, 2018, FOOD CHEM, V242, P378, DOI 10.1016/j.foodchem.2017.09.086
   Mazewski C, 2017, J FUNCT FOODS, V34, P254, DOI 10.1016/j.jff.2017.04.038
   Mckee AS, 2010, BMC BIOL, V8, DOI 10.1186/1741-7007-8-37
   Mojica L, 2017, FOOD CHEM, V229, P628, DOI 10.1016/j.foodchem.2017.02.124
   Moosavi MA, 2018, CANCER LETT, V424, P46, DOI 10.1016/j.canlet.2018.02.030
   National Cancer Institute, 2018, COMB IMM DRUGS APPR
   National Institutes of Health, 2019, COL CANC CANC STAT F
   Passardi A, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18061324
   PDQ Adult Treatment Editorial Board, 2002, COL CANC TREATM PDQ
   Pei RS, 2019, MOL NUTR FOOD RES, V63, DOI 10.1002/mnfr.201800985
   Peiffer DS, 2016, CANCER IMMUNOL RES, V4, P72, DOI 10.1158/2326-6066.CIR-15-0091
   Stalmach A, 2013, FOOD FUNCT, V4, P52, DOI 10.1039/c2fo30151b
   Steinert RE, 2008, J AGR FOOD CHEM, V56, P4995, DOI 10.1021/jf703670h
   Timbrell J, 2009, PRINCIPLES BIOCH TOX, DOI [10.3109/9781420007084, DOI 10.3109/9781420007084]
   Venancio VP, 2017, FOOD FUNCT, V8, P307, DOI [10.1039/c6fo01498d, 10.1039/C6FO01498D]
   Walsh TP, 1997, PROTEIN ENG, V10, P389, DOI 10.1093/protein/10.4.389
   Wang LS, 2008, CANCER LETT, V269, P281, DOI 10.1016/j.canlet.2008.05.020
   Wang N, 2012, BREAST CANCER RES TR, V134, P943, DOI 10.1007/s10549-012-1977-9
   Xie LY, 2016, FOOD CHEM, V211, P860, DOI 10.1016/j.foodchem.2016.05.122
   Zak KM, 2015, STRUCTURE, V23, P2341, DOI 10.1016/j.str.2015.09.010
   Zhou LP, 2018, BIOMED PHARMACOTHER, V104, P520, DOI 10.1016/j.biopha.2018.05.057
NR 50
TC 20
Z9 20
U1 3
U2 10
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD AUG 9
PY 2019
VL 9
AR 11560
DI 10.1038/s41598-019-47903-0
PG 15
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA IP7ND
UT WOS:000480233800012
PM 31399602
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Zou, YF
   Chen, ZX
   He, XW
   He, XS
   Wu, XR
   Chen, YF
   Wu, XJ
   Wang, JP
   Lan, P
AF Zou, Yifeng
   Chen, Zexian
   He, Xiaowen
   He, Xiaosheng
   Wu, Xianrui
   Chen, Yufeng
   Wu, Xiaojian
   Wang, Jianping
   Lan, Ping
TI High expression levels of unc-51-like kinase 1 as a predictor of poor
   prognosis in colorectal cancer
SO ONCOLOGY LETTERS
LA English
DT Article
DE ULK1; prognosis; colorectal cancer
ID AMERICAN JOINT COMMITTEE; ADJUVANT CHEMOTHERAPY; AUTOPHAGY; BIOMARKER;
   PHOSPHORYLATION; THERAPY; EDITION; AMPK
AB Colorectal cancer (CRC) is one of the most common and lethal cancers worldwide. Unc-51-like kinase 1 (ULK1) plays an important role in autophagy, which is widely involved in human CRC. The aim of the present study was to investigate the clinical and prognostic significance of the expression of ULK1 in human CRC. Expression of ULK1 in 339 CRC specimens (tumor-node-metastasis stages I-IV) was assessed by immunohistochemistry. The optimal cutpoint of the expression of ULK1 was assessed by the X-tile program, and the patients were divided into 2 groups of high or low expression levels of ULK1, accordingly. Correlation analysis between the expression of ULK1 and the clinicopathological variables in CRC demonstrated that the expression of ULK1 was significantly associated with gender and tumor differentiation. Univariate Cox regression analysis indicated that high expression levels of ULK1 were a risk factor for overall and disease-free survival. Therefore, the high expression levels of ULK1 may be a useful independent biomarker for predicting a poor prognosis in patients with CRC.
C1 [Zou, Yifeng; Chen, Zexian; He, Xiaowen; He, Xiaosheng; Wu, Xianrui; Chen, Yufeng; Wu, Xiaojian; Wang, Jianping; Lan, Ping] Sun Yat Sen Univ, Affiliated Hosp 6, Dept Colorectal & Anal Surg, Guangzhou 510655, Guangdong, Peoples R China.
RP Lan, P (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 6, Dept Colorectal & Anal Surg, 26 Yuancun Erheng Rd, Guangzhou 510655, Guangdong, Peoples R China.
EM sumslp@163.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81300367]; Natural Science Foundation of
   Guangdong ProvinceNational Natural Science Foundation of Guangdong
   Province [S2013010014186]
FX The current work was supported by the National Natural Science
   Foundation of China (No. 81300367) and the Natural Science Foundation of
   Guangdong Province (No. S2013010014186).
CR Brezden-Masley C, 2014, SURG ONCOL CLIN N AM, V23, P49, DOI 10.1016/j.soc.2013.09.009
   Cai MY, 2011, MOL MED, V17, P12, DOI 10.2119/molmed.2010.00103
   CAMP RL, 2004, CLIN CANCER RES, V10, P7252, DOI DOI 10.1158/1078-0432.CCR-04-0713
   Edge SB, 2010, ANN SURG ONCOL, V17, P1471, DOI 10.1245/s10434-010-0985-4
   Graziano F, 2003, ANN ONCOL, V14, P1026, DOI 10.1093/annonc/mdg284
   Honscheid P, 2014, INT J RADIAT BIOL, V90, P628, DOI 10.3109/09553002.2014.907932
   Hosokawa N, 2009, MOL BIOL CELL, V20, P1981, DOI 10.1091/mbc.E08-12-1248
   Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]
   Jiang S, 2011, CANCER SCI, V102, P1568, DOI 10.1111/j.1349-7006.2011.01964.x
   Jung CH, 2009, MOL BIOL CELL, V20, P1992, DOI 10.1091/mbc.E08-12-1249
   Kim J, 2011, NAT CELL BIOL, V13, P132, DOI 10.1038/ncb2152
   Kim KH, 2011, COLORECTAL DIS, V13, pE220, DOI 10.1111/j.1463-1318.2011.02625.x
   Lee JW, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015394
   Mathonnet M, 2014, WORLD J GASTROENTERO, V20, P4189, DOI 10.3748/wjg.v20.i15.4189
   Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639
   Mizushima N, 2010, CURR OPIN CELL BIOL, V22, P132, DOI 10.1016/j.ceb.2009.12.004
   Nagtegaal ID, 2010, J CLIN ONCOL, V28, pE397, DOI 10.1200/JCO.2010.28.5726
   O'Connell JB, 2004, JNCI-J NATL CANCER I, V96, P1420, DOI 10.1093/jnci/djh275
   Oh Ho-Suk, 2007, Cancer Res Treat, V39, P61, DOI 10.4143/crt.2007.39.2.61
   RAESIDE DE, 1976, PHYS MED BIOL, V21, P181, DOI 10.1088/0031-9155/21/2/001
   Rizzo S, 2010, CANCER TREAT REV, V36, pS56, DOI 10.1016/S0305-7372(10)70021-9
   Ross JS, 2011, BIOMARK MED, V5, P319, DOI [10.2217/bmm.11.38, 10.2217/BMM.11.38]
   Schmukler E, 2014, ONCOTARGET, V5, P577, DOI 10.18632/oncotarget.1775
   Siegel R, 2011, CA-CANCER J CLIN, V61, P212, DOI 10.3322/caac.20121
   Tang J, 2012, BREAST CANCER RES TR, V134, P549, DOI 10.1007/s10549-012-2080-y
   Wong PM, 2013, AUTOPHAGY, V9, P124, DOI 10.4161/auto.23323
   Yokota T, 2012, ANTI-CANCER AGENT ME, V12, P163, DOI 10.2174/187152012799014968
   Zhao MT, 2011, CELL METAB, V13, P119, DOI 10.1016/j.cmet.2011.01.009
NR 28
TC 16
Z9 16
U1 2
U2 6
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792-1074
EI 1792-1082
J9 ONCOL LETT
JI Oncol. Lett.
PD SEP
PY 2015
VL 10
IS 3
BP 1583
EP 1588
DI 10.3892/ol.2015.3417
PG 6
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA CQ9GZ
UT WOS:000360923000060
PM 26622714
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Duangkumpha, K
   Stoll, T
   Phetcharaburanin, J
   Yongvanit, P
   Thanan, R
   Techasen, A
   Namwat, N
   Khuntikeo, N
   Chamadol, N
   Roytrakul, S
   Mulvenna, J
   Mohamed, A
   Shah, AK
   Hill, MM
   Loilome, W
AF Duangkumpha, Kassaporn
   Stoll, Thomas
   Phetcharaburanin, Jutarop
   Yongvanit, Puangrat
   Thanan, Raynoo
   Techasen, Anchalee
   Namwat, Nisana
   Khuntikeo, Narong
   Chamadol, Nittaya
   Roytrakul, Sittiruk
   Mulvenna, Jason
   Mohamed, Ahmed
   Shah, Alok K.
   Hill, Michelle M.
   Loilome, Watcharin
TI Urine proteomics study reveals potential biomarkers for the differential
   diagnosis of cholangiocarcinoma and periductal fibrosis
SO PLOS ONE
LA English
DT Article
ID LYSOSOMAL MEMBRANE-GLYCOPROTEINS; EXPRESSION; CANCER; LAMP-1;
   OPISTHORCHIASIS; BIOGENESIS; AUTOPHAGY; PROTEINS; DAMAGE; COLON
AB Cholangiocarcinoma (CCA) is a primary malignant tumor of the epithelial lining of biliary track associated with endemic Opisthorchis viverrini (0v) infection in northeastern Thailand. Ov-associated periductal fibrosis (PDF) is the precancerous lesion for CCA, and can be detected by ultrasonography (US) to facilitate early detection. However, US cannot be used to distinguish PDF from cancer. Therefore, the objective of this study was to discover and qualify potential urine biomarkers for CCA detection in at-risk population. Biomarker discovery was conducted on pooled urine samples, 42 patients per group, with PDF or normal bile duct confirmed by ultrasound. After depletion of high abundance proteins, 338 urinary proteins were identified from the 3 samples (normal-US, PDF-US, CCA). Based on fold change and literature review, 70 candidate proteins were selected for qualification by multiple reaction monitoring mass spectrometry (MRM-MS) in 90 individual urine samples, 30 per group. An orthogonal signal correction projection to latent structures discriminant analysis (O-PLS-DA) multivariate model constructed from the 70 candidate biomarkers significantly discriminated CCA from normal and PDF groups (P = 0.003). As an independent validation, the expression of 3 candidate proteins was confirmed by immunohistochemistry in CCA tissues: Lysosome associated membrane glycoprotein 1 (LAMP1), lysosome associated membrane glycoprotein 2 (LAMP2) and cadherin-related family member 2 (CDHR2). Further evaluation of these candidate biomarkers in a larger cohort is needed to support their applicability in a clinical setting for screening and monitoring early CCA and for CCA surveillance.
C1 [Duangkumpha, Kassaporn; Phetcharaburanin, Jutarop; Thanan, Raynoo; Namwat, Nisana; Loilome, Watcharin] Khon Kaen Univ, Dept Biochem, Fac Med, Khon Kaen, Thailand.
   [Duangkumpha, Kassaporn; Phetcharaburanin, Jutarop; Yongvanit, Puangrat; Techasen, Anchalee; Namwat, Nisana; Khuntikeo, Narong; Chamadol, Nittaya; Loilome, Watcharin] Khon Kaen Univ, Cholangiocarcinoma Res Inst, Khon Kaen, Thailand.
   [Stoll, Thomas; Mulvenna, Jason; Mohamed, Ahmed; Shah, Alok K.; Hill, Michelle M.] QIMR Berghofer Med Res Inst, Brisbane, Qld, Australia.
   [Techasen, Anchalee] Khon Kaen Univ, Fac Associated Med Sci, Khon Kaen, Thailand.
   [Khuntikeo, Narong] Khon Kaen Univ, Dept Surg, Fac Med, Khon Kaen, Thailand.
   [Chamadol, Nittaya] Khon Kaen Univ, Dept Radiol, Fac Med, Khon Kaen, Thailand.
   [Roytrakul, Sittiruk] Natl Sci & Technol Dev Agcy, Natl Ctr Genet Engn & Biotechnol, Genome Inst, Prote Res Lab, Pathum Thani, Thailand.
RP Loilome, W (corresponding author), Khon Kaen Univ, Dept Biochem, Fac Med, Khon Kaen, Thailand.; Loilome, W (corresponding author), Khon Kaen Univ, Cholangiocarcinoma Res Inst, Khon Kaen, Thailand.; Hill, MM (corresponding author), QIMR Berghofer Med Res Inst, Brisbane, Qld, Australia.
EM michelle.hill@qimrberghofer.edu.au; watloi@yahoo.com
RI Hill, Michelle Mei Chih/G-4417-2010; Shah, Alok/AAB-6629-2019; Mohamed,
   Ahmed/L-4998-2016; Loilome, Watcharin/AAW-6203-2021
OI Hill, Michelle Mei Chih/0000-0003-1134-0951; Shah,
   Alok/0000-0002-2687-1168; Mohamed, Ahmed/0000-0001-6507-5300; Roytrakul,
   Sittiruk/0000-0003-3696-8390; Stoll, Thomas/0000-0002-6275-3433
FU Thailand Research Fund through Royal Golden Jubilee Ph.D. Program
   [PHD/0145/2556]; Cholangiocarcinoma Screening and Care Program (CASCAP);
   Faculty of Medicine [IN 59340]; Thailand Research FundThailand Research
   Fund (TRF) [RSA5980013]
FX This work was supported by Thailand Research Fund through Royal Golden
   Jubilee Ph.D. Program (Grant No. PHD/0145/2556) to W.L. and K.D., a
   grant from Cholangiocarcinoma Screening and Care Program (CASCAP) to
   W.L., the grant of Faculty of Medicine to K.D. (Grant No. IN 59340), a
   grant from the Thailand Research Fund (Grant No. RSA5980013) allocated
   to W.L.
CR Anderson NL, 2002, MOL CELL PROTEOMICS, V1, P845, DOI 10.1074/mcp.R200007-MCP200
   Bonney GK, 2008, LANCET ONCOL, V9, P149, DOI 10.1016/S1470-2045(08)70027-5
   Buhimschi IA, 2008, AM J OBSTET GYNECOL, V199, DOI 10.1016/j.ajog.2008.07.006
   Celis JE, 2004, PHARMACOGENOMICS, V5, P381, DOI 10.1517/14622416.5.4.381
   Chamadol N, 2014, J HEPATO-BIL-PAN SCI, V21, P316, DOI 10.1002/jhbp.64
   Choi KS, 2012, EXP MOL MED, V44, P109, DOI 10.3858/emm.2012.44.2.033
   Cox J, 2014, MOL CELL PROTEOMICS, V13, P2513, DOI 10.1074/mcp.M113.031591
   Cox J, 2011, J PROTEOME RES, V10, P1794, DOI 10.1021/pr101065j
   Cox J, 2008, NAT BIOTECHNOL, V26, P1367, DOI 10.1038/nbt.1511
   Dave KA, 2014, MOL CELL PROTEOMICS, V13, P3250, DOI 10.1074/mcp.M114.041129
   Eskelinen Eeva-Liisa, 2006, Molecular Aspects of Medicine, V27, P495, DOI 10.1016/j.mam.2006.08.005
   Furuta K, 2001, AM J PATHOL, V159, P449, DOI 10.1016/S0002-9440(10)61716-6
   Hughes T, 2017, INT J GEN MED, V10, P227, DOI 10.2147/IJGM.S133292
   Jensen SS, 2013, INT J CLIN EXP PATHO, V6, P1294
   Kaiser T, 2004, BLOOD, V104, P340, DOI 10.1182/blood-2004-02-0518
   Khuntikeo N, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1475-7
   KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411
   Kunzli BM, 2002, CANCER-AM CANCER SOC, V94, P228, DOI 10.1002/cncr.10162
   MacLean B, 2010, BIOINFORMATICS, V26, P966, DOI 10.1093/bioinformatics/btq054
   Metzger J, 2013, GUT, V62, P122, DOI 10.1136/gutjnl-2012-302047
   Mischak H, 2004, CLIN SCI, V107, P485, DOI 10.1042/CS20040103
   Namwat N, 2011, J GASTROENTEROL, V46, P664, DOI 10.1007/s00535-010-0345-y
   Nguyen MT, 2005, AM J NEPHROL, V25, P318, DOI 10.1159/000086476
   Okazaki N, 2002, CARCINOGENESIS, V23, P1139, DOI 10.1093/carcin/23.7.1139
   Petrick JL, 2018, BRIT J CANCER, V118, P1005, DOI 10.1038/s41416-018-0007-z
   SAITOH O, 1992, J BIOL CHEM, V267, P5700
   SAWADA R, 1993, J BIOL CHEM, V268, P9014
   Shao C, 2011, MOL CELL PROTEOMICS, V10, DOI 10.1074/mcp.M111.010975
   Sripa B, 2008, CURR OPIN GASTROEN, V24, P349, DOI 10.1097/MOG.0b013e3282fbf9b3
   Sripa B, 2009, HEPATOLOGY, V50, P1273, DOI 10.1002/hep.23134
   Taneja S, 2009, PROTEOME SCI, V7, DOI 10.1186/1477-5956-7-39
   Tantipaiboonwong P, 2005, PROTEOMICS, V5, P1140, DOI 10.1002/pmic.200401143
   Thongchot S, 2014, ASIAN PAC J CANCER P, V15, P5873, DOI 10.7314/APJCP.2014.15.14.5873
   Ward DG, 2008, PROTEOME SCI, V6, DOI 10.1186/1477-5956-6-19
   Ye B, 2006, CLIN CANCER RES, V12, P432, DOI 10.1158/1078-0432.CCR-05-0461
   Yongvanit P, 2014, J HEPATO-BIL-PAN SCI, V21, P309, DOI 10.1002/jhbp.63
   Yongvanit P, 2012, PARASITOL INT, V61, P130, DOI 10.1016/j.parint.2011.06.011
   Zimmerli LU, 2008, MOL CELL PROTEOMICS, V7, P290, DOI 10.1074/mcp.M700394-MCP200
NR 38
TC 12
Z9 12
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 19
PY 2019
VL 14
IS 8
AR e0221024
DI 10.1371/journal.pone.0221024
PG 17
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA IW5MK
UT WOS:000485022400022
PM 31425520
OA Green Published, Green Submitted, gold
DA 2022-04-25
ER

PT J
AU Xiong, Y
   Xiong, YJ
   Liu, DY
   Shen, RR
AF Xiong, Yong
   Xiong, Yi-Jia
   Liu, Dong-Yang
   Shen, Rong-Rong
TI Pancratistatin Inhibits the Growth of Colorectal Cancer Cells by
   Inducing Apoptosis, Autophagy, and G2/M Cell Cycle Arrest
SO MEDICAL SCIENCE MONITOR
LA English
DT Article
DE Apoptosis; Autophagy; Cell Cycle
ID NATURAL-PRODUCTS; MITOCHONDRIA
AB Background: Worldwide, colorectal cancer is ranked as the third most prevalent cancer. The natural compound, pancratistatin, extracted from the spider lily, has previously been shown to target apoptosis in cancer cells lines. This study aimed to investigate the effects of pancratistatin in human colorectal cancer cells in vitro.
   Material/Methods: Human colorectal cancer cell lines, including HTC-15 cells, were compared with a normal human colonic fibro- blast cell line, CDD-18Co. Cells were treated with increasing doses of pancratistatin. The MTT assay was used to assess cell viability. Fluorescence microscopy using DAPI and Annexin-V/propidium iodide (PI) was used to detect cell apoptosis. Cell autophagy was detected by electron microscopy. Cell migration was evaluated using a wound healing assay, and Western blot determined the expression levels of cell cycle proteins.
   Results: Pancratistatin inhibited the growth of the colorectal cancer cells with an IC50 ranging from 15-25 mu M, but had a limited effect in normal CCD-18Co cells, with an IC50 of >100 mu M. Pancratistatin reduced HCT-15 cell migration. Growth inhibition due to pancratistatin was associated with morphological changes of HCT-15 cells and included autophagy and apoptosis, and increased expression the autophagic proteins, LC3II, beclin-1, and Bax. Pancratistatin induced arrest of HCT-15 cells at G2/M of the cell cycle and inhibited phosphorylation of cdc2/cyclin-dependent kinase 1 (CDK1) and Cdc25c and the expression of cyclin B1.
   Conclusions: Pancratistatin inhibited the growth of colorectal cancer cells in vitro by inducing apoptosis, autophagy, and G2/M cell cycle arrest.
C1 [Xiong, Yong; Liu, Dong-Yang; Shen, Rong-Rong] Shanghai Unvi Med & Hlth Sci, Shanghai Peoples Hosp East 6, Dept Gen Surg, Shanghai, Peoples R China.
   [Xiong, Yi-Jia] Shanghai Sixth Peoples Hosp, Dept Radiol, Shanghai, Peoples R China.
RP Shen, RR (corresponding author), Shanghai Unvi Med & Hlth Sci, Shanghai Peoples Hosp East 6, Dept Gen Surg, Shanghai, Peoples R China.
EM RichieWattsfdv@yahoo.com
CR Aran V, 2016, CLIN COLORECTAL CANC, V15, P195, DOI 10.1016/j.clcc.2016.02.008
   Arnold M, 2016, GUT, V2, P2
   Griffin C, 2011, INT J ONCOL, V38, P1549, DOI 10.3892/ijo.2011.977
   Griffin C, 2011, MOL CANCER THER, V10, P57, DOI 10.1158/1535-7163.MCT-10-0735
   Guinney J, 2015, NAT MED, V21, P1350, DOI 10.1038/nm.3967
   Harvey AL, 2015, NAT REV DRUG DISCOV, V14, P111, DOI 10.1038/nrd4510
   Kekre N, 2005, CANCER CHEMOTH PHARM, V56, P29, DOI 10.1007/s00280-004-0941-8
   Kondo Y, 2005, NAT REV CANCER, V5, P726, DOI 10.1038/nrc1692
   McLachlan A, 2005, APOPTOSIS, V10, P619, DOI 10.1007/s10495-005-1896-x
   Mutsuga M, 2002, BIOL PHARM BULL, V25, P223, DOI 10.1248/bpb.25.223
   Newman DJ, 2016, J NAT PROD, V79, P629, DOI 10.1021/acs.jnatprod.5b01055
   Pandey S, 2005, ARTIF CELL BLOOD SUB, V33, P279, DOI 10.1081/BIO-200066621
   Patridge E, 2016, DRUG DISCOV TODAY, V21, P204, DOI 10.1016/j.drudis.2015.01.009
   PETTIT GR, 1984, J CHEM SOC CHEM COMM, P1693, DOI 10.1039/c39840001693
   Rinner U., 2004, ANGEW CHEM, V116, P5456
   Siegel R, 2014, CA-CANCER J CLIN, V64, P104, DOI 10.3322/caac.21220
   Van Cutsem E, 2016, ANN ONCOL, V27, P1386, DOI 10.1093/annonc/mdw235
NR 17
TC 2
Z9 2
U1 2
U2 12
PU INT SCIENTIFIC INFORMATION, INC
PI MELVILLE
PA 150 BROADHOLLOW RD, STE 114, MELVILLE, NY 11747 USA
SN 1643-3750
J9 MED SCI MONITOR
JI Med. Sci. Monitor
PD AUG 12
PY 2019
VL 25
BP 6015
EP 6022
DI 10.12659/MSM.916116
PG 8
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA IQ0DX
UT WOS:000480422100003
PM 31404056
OA Green Submitted, Green Published
DA 2022-04-25
ER

PT J
AU Wu, H
   Lu, XX
   Wang, JR
   Yang, TY
   Li, XM
   He, XS
   Li, Y
   Ye, WL
   Wu, Y
   Gan, WJ
   Guo, PD
   Li, JM
AF Wu, Hua
   Lu, Xing-Xing
   Wang, Jing-Ru
   Yang, Tian-Yu
   Li, Xiu-Ming
   He, Xiao-Shun
   Li, Yi
   Ye, Wen-Long
   Wu, Yong
   Gan, Wen-Juan
   Guo, Peng-Da
   Li, Jian-Ming
TI TRAF6 inhibits colorectal cancer metastasis through regulating selective
   autophagic CTNNB1/beta-catenin degradation and is targeted for
   GSK3B/GSK3 beta-mediated phosphorylation and degradation
SO AUTOPHAGY
LA English
DT Article
DE Autophagy; colorectal cancer; CTNNB1; GSK3B; metastasis; TRAF6
ID TUMORIGENESIS; IMPAIRMENT; PROTEIN; CD40
AB Aberrant CTNNB1 signaling is one of the fundamental processes in cancers, especially colorectal cancer (CRC). Here, we reported that TRAF6, an E3 ubiquitin ligase important for inflammatory signaling, inhibited epithelial-mesenchymal transition (EMT) and CRC metastasis through driving a selective autophagic CTNNB1 degradation machinery. Mechanistically, TRAF6 interacted with MAP1LC3B/LC3B through its LC3-interacting region 'YxxL' and catalyzed K63-linked polyubiquitination of LC3B. The K63-linked ubiquitination of LC3B promoted the formation of the LC3B-ATG7 complex and was critical to the subsequent recognition of CTNNB1 by LC3B for the selective autophagic degradation. However, TRAF6 was phosphorylated at Thr266 by GSK3B in most clinical CRC, which triggered K48-linked polyubiquitination and degradation of TRAF6 and thereby attenuated its inhibitory activity towards the autophagy-dependent CTNNB1 signaling. Clinically, decreased expression of TRAF6 was associated with elevated GSK3B protein levels and activity and reduced overall survival in CRC patients. Pharmacological inhibition of GSK3B activity stabilized the TRAF6 protein, promoted CTNNB1 degradation, and effectively suppressed EMT and CRC metastasis. Thus, targeting TRAF6 and its pathway may be meaningful for treating advanced CRC.
C1 [Wu, Hua; Li, Jian-Ming] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Pathol, Guangzhou 510120, Guangdong, Peoples R China.
   [Wu, Hua; Lu, Xing-Xing; Yang, Tian-Yu; Li, Xiu-Ming; Li, Yi; Ye, Wen-Long; Guo, Peng-Da; Li, Jian-Ming] Soochow Univ, Dept Pathol, Suzhou, Peoples R China.
   [Wang, Jing-Ru; He, Xiao-Shun; Gan, Wen-Juan] Soochow Univ, Dept Pathol, Affiliated Hosp 1, Suzhou, Peoples R China.
   [Wu, Yong] Soochow Univ, Affiliated Hosp 2, Dept Gen Surg, Suzhou, Peoples R China.
RP Li, JM (corresponding author), Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Pathol, Guangzhou 510120, Guangdong, Peoples R China.
EM lijming3@mail.sysu.edu.cn
RI Wu, Hua/W-4204-2019
CR Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7
   Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0
   Chen HZ, 2012, GUT, V61, P714, DOI 10.1136/gutjnl-2011-300783
   Dower CM, 2017, CANCER RES, V77, P646, DOI 10.1158/0008-5472.CAN-15-3458
   Feng LJ, 2017, AUTOPHAGY, V13, P686, DOI 10.1080/15548627.2017.1280207
   Guo PD, 2016, CANCER RES, V76, P3813, DOI 10.1158/0008-5472.CAN-15-2882
   Huang R, 2015, MOL CELL, V57, P456, DOI 10.1016/j.molcel.2014.12.013
   Ishida T, 1996, J BIOL CHEM, V271, P28745, DOI 10.1074/jbc.271.46.28745
   Jin SH, 2018, AUTOPHAGY, V14, P171, DOI 10.1080/15548627.2017.1393590
   Klionsky DJ, 2016, AUTOPHAGY, V12, P1, DOI 10.1080/15548627.2015.1100356
   Lamothe B, 2007, J BIOL CHEM, V282, P4102, DOI 10.1074/jbc.M609503200
   Li YZ, 2017, AUTOPHAGY, V13, P1145, DOI 10.1080/15548627.2017.1320467
   Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257
   Lomaga MA, 1999, GENE DEV, V13, P1015, DOI 10.1101/gad.13.8.1015
   Mizushima N, 2007, ANNU REV NUTR, V27, P19, DOI 10.1146/annurev.nutr.27.061406.093749
   Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252
   Nazio F, 2013, NAT CELL BIOL, V15, P406, DOI 10.1038/ncb2708
   Noda NN, 2010, FEBS LETT, V584, P1379, DOI 10.1016/j.febslet.2010.01.018
   Petherick KJ, 2013, EMBO J, V32, P1903, DOI 10.1038/emboj.2013.123
   Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039
   Rogov V, 2014, MOL CELL, V53, P167, DOI 10.1016/j.molcel.2013.12.014
   Rong YF, 2014, MED ONCOL, V31, DOI 10.1007/s12032-014-0260-9
   Sanchez-Tillo E, 2011, P NATL ACAD SCI USA, V108, P19204, DOI 10.1073/pnas.1108977108
   Shi CS, 2010, AUTOPHAGY, V6, P986, DOI 10.4161/auto.6.7.13288
   Starczynowski DT, 2011, J CLIN INVEST, V121, P4095, DOI 10.1172/JCI58818
   Sun H, 2013, CANCER RES, V73, P4950, DOI 10.1158/0008-5472.CAN-13-0370
   Tai HR, 2017, AUTOPHAGY, V13, P99, DOI 10.1080/15548627.2016.1247143
   Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007
   White E, 2012, NAT REV CANCER, V12, P401, DOI 10.1038/nrc3262
   Wu H, 2016, J PATHOL, V238, P457, DOI 10.1002/path.4670
   Xing C, 2016, CANCER RES, V76, P83, DOI 10.1158/0008-5472.CAN-14-3595
NR 31
TC 25
Z9 27
U1 5
U2 40
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1554-8627
EI 1554-8635
J9 AUTOPHAGY
JI Autophagy
PD SEP 2
PY 2019
VL 15
IS 9
BP 1506
EP 1522
DI 10.1080/15548627.2019.1586250
PG 17
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA IQ3DE
UT WOS:000480630300003
PM 30806153
OA Green Published, Bronze
DA 2022-04-25
ER

PT J
AU Hossain, KFB
   Rahman, MM
   Sikder, MT
   Saito, T
   Hosokawa, T
   Kurasaki, M
AF Hossain, Kaniz Fatima Binte
   Rahman, Md. Mostafizur
   Sikder, Md. Tajuddin
   Saito, Takeshi
   Hosokawa, Toshiyuki
   Kurasaki, Masaaki
TI Inhibitory effects of selenium on cadmium-induced cytotoxicity in PC12
   cells via regulating oxidative stress and apoptosis
SO FOOD AND CHEMICAL TOXICOLOGY
LA English
DT Article
DE Glutathione; Glutathione peroxidase; Cytochrome c; Oxidative stress;
   Autophagy; Apoptosis
ID ACTIVATED PROTEIN-KINASE; COLORECTAL-CANCER CELLS; LEUKEMIA NB4 CELLS;
   SODIUM SELENITE; GLUTATHIONE-PEROXIDASE; SIGNALING PATHWAY; HUMAN
   HEALTH; DEATH; MECHANISM; TOXICITY
AB Purpose of this study is to investigate mechanism/s of cyto-protection by selenium (Na2SeO3; Se4+) against cadmium (CdCL2; Cd2+)-induced cytotoxicity using PCl2 cells. In addition, Se (5, 10, 20 and 40 mu M) and Cd (2.5, 5 and 10 mu M) -induced cytotoxicity is determined. Cytotoxicity assays and western blot analyses confirmed that Se (>= 10 mu M) promotes autophagic cell death via inhibition of mTOR activation and p62 accumulation due to increase of cellular oxidative stress. On the other hand, co-presence of non-toxic Se (5 mu M) and toxic Cd (5 mu M) showed to increase cell viability, glutathione and glutathione peroxidase 1 (GPx1) levels, and to decrease DNA fragmentation and lactate dehydrogenase (LDH) activity compared to Cd-treated (5 mu M) cells alone. Furthermore, western blot analyses of cytochrome c and ERK1 indicated that Cd-induced apoptotic cell death in PC12 cells. However, the co-exposure of Se with Cd significantly decreases the release of cytochrome c into cytosol from mitochondria, and up-regulates ERK1 protein to inhibit Cd-induced apoptosis. In conclusion, Se (>= 10 mu M) possess cytotoxicity in PC12 cells; however, co-presence of Se (5 mu M) with Cd (5 mu M) protects against Cd-induced apoptosis in PC12 cells due to inhibition of Cd-induced oxidative stress and subsequently suppression of mitochondrial apoptosis pathway.
C1 [Hossain, Kaniz Fatima Binte; Rahman, Md. Mostafizur; Kurasaki, Masaaki] Hokkaido Univ, Grad Sch Environm Sci, Sapporo, Hokkaido 0600810, Japan.
   [Sikder, Md. Tajuddin; Saito, Takeshi] Hokkaido Univ, Lab Environm Hlth Sci, Fac Hlth Sci, Sapporo, Hokkaido 0600812, Japan.
   [Sikder, Md. Tajuddin; Kurasaki, Masaaki] Hokkaido Univ, Fac Environm Earth Sci, Grp Environm Adaptat Sci, Sapporo, Hokkaido 0600810, Japan.
   [Sikder, Md. Tajuddin] Jahangirnagar Univ, Dept Publ Hlth & Informat, Dhaka 1342, Bangladesh.
   [Hosokawa, Toshiyuki] Hokkaido Univ, Inst Adv Higher Educ, Res Div Higher Educ, Sapporo, Hokkaido 0600817, Japan.
RP Kurasaki, M (corresponding author), Hokkaido Univ, Fac Environm Earth Sci, Grp Environm Adaptat Sci, Kita Ku, Kita 10,Nishi 5, Sapporo, Hokkaido 0600810, Japan.
EM kura@ees.hokudai.ac.jp
RI , 細川敏幸/A-3851-2012; Sikder, Tajuddin/AAK-4868-2020; Kurasaki,
   Masaaki/B-8207-2012; Rahman, Mostafizur/X-7420-2019; Hossain, Kaniz
   Fatima Binte/AAD-7902-2019; SAITO, TAKESHI/E-5950-2012
OI , 細川敏幸/0000-0002-4818-8968; Sikder, Tajuddin/0000-0002-5717-2263;
   Kurasaki, Masaaki/0000-0003-2125-095X; Rahman,
   Mostafizur/0000-0002-5290-3821; Hossain, Kaniz Fatima
   Binte/0000-0003-2922-9813; 
CR Abdulah R, 2011, INT J ONCOL, V39, P301, DOI 10.3892/ijo.2011.1035
   Armstrong JS, 2002, CELL DEATH DIFFER, V9, P252, DOI 10.1038/sj.cdd.4400959
   Battin EE, 2009, CELL BIOCHEM BIOPHYS, V55, P1, DOI 10.1007/s12013-009-9054-7
   Brozmanova J, 2010, ARCH TOXICOL, V84, P919, DOI 10.1007/s00204-010-0595-8
   Chatterjee A, 2013, NUTRIENTS, V5, P525, DOI 10.3390/nu5020525
   Chen JJ, 2007, BIOFACTORS, V31, P55, DOI 10.1002/biof.5520310106
   Chen L, 2008, FREE RADICAL BIO MED, V45, P1035, DOI 10.1016/j.freeradbiomed.2008.07.011
   Chen L, 2008, J NEUROCHEM, V105, P251, DOI 10.1111/j.1471-4159.2007.05133.x
   Chen X, 2012, MOLECULES, V17, P14565, DOI 10.3390/molecules171214565
   Cheng Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035104
   Cummings Brian S, 2012, Curr Protoc Pharmacol, VChapter 12, DOI 10.1002/0471141755.ph1208s56
   Cuypers A, 2010, BIOMETALS, V23, P927, DOI 10.1007/s10534-010-9329-x
   Duran A, 2011, MOL CELL, V44, P134, DOI 10.1016/j.molcel.2011.06.038
   El-Demerdash FM, 2001, J ENVIRON SCI HEAL B, V36, P489, DOI 10.1081/PFC-100104191
   El-Sharaky AS, 2007, TOXICOLOGY, V235, P185, DOI 10.1016/j.tox.2007.03.014
   El-Shenawy SMA, 2008, PHARMACOL REP, V60, P199
   Elmore S, 2007, TOXICOL PATHOL, V35, P495, DOI 10.1080/01926230701320337
   Fan TJ, 2005, ACTA BIOCH BIOPH SIN, V37, P719, DOI 10.1111/j.1745-7270.2005.00108.x
   Finley JW, 2006, NUTR REV, V64, P146, DOI 10.1111/j.1753-4887.2006.tb00198.x
   Fordyce F. M., 2013, ESSENTIALS MED GEOLO, P375
   Gan L, 2002, BIOL TRACE ELEM RES, V89, P165, DOI 10.1385/BTER:89:2:165
   Guan LY, 2009, APOPTOSIS, V14, P218, DOI 10.1007/s10495-008-0295-5
   Hatfield DL, 2011, SELENIUM ITS MOL BIO
   Higuchi Y, 2003, BIOCHEM PHARMACOL, V66, P1527, DOI 10.1016/S0006-2952(03)00508-2
   Huang F, 2009, FREE RADICAL BIO MED, V46, P1186, DOI 10.1016/j.freeradbiomed.2009.01.026
   Ivanina AV, 2008, J EXP BIOL, V211, P577, DOI 10.1242/jeb.011262
   Jiang CY, 2014, BIOL TRACE ELEM RES, V158, P249, DOI 10.1007/s12011-014-9918-6
   Jung CH, 2010, FEBS LETT, V584, P1287, DOI 10.1016/j.febslet.2010.01.017
   Kawakami M, 2008, FOOD CHEM TOXICOL, V46, P2157, DOI 10.1016/j.fct.2008.02.014
   Kihara Y, 2014, ENVIRON TOXICOL, V29, P916, DOI 10.1002/tox.21819
   Kim EH, 2007, CANCER RES, V67, P6314, DOI 10.1158/0008-5472.CAN-06-4217
   Lau ATY, 2006, TOXICOL APPL PHARM, V215, P1, DOI 10.1016/j.taap.2006.01.011
   Li J, 2003, J TRACE ELEM MED BIO, V17, P19, DOI 10.1016/S0946-672X(03)80041-X
   Li JL, 2010, BIOMETALS, V23, P695, DOI 10.1007/s10534-010-9334-0
   Li Z, 2013, EUR REV MED PHARMACO, V17, P2166
   Liu Y, 2007, TOXICOL IN VITRO, V21, P677, DOI 10.1016/j.tiv.2007.01.015
   Luo H, 2012, CANCER LETT, V315, P78, DOI 10.1016/j.canlet.2011.10.014
   Magalingam Kasthuri Bai, 2014, BMC Res Notes, V7, P49, DOI 10.1186/1756-0500-7-49
   Mizushima N, 2005, CELL DEATH DIFFER, V12, P1535, DOI 10.1038/sj.cdd.4401728
   Nair AR, 2013, INT J MOL SCI, V14, P6116, DOI 10.3390/ijms14036116
   Newairy AA, 2007, TOXICOLOGY, V242, P23, DOI 10.1016/j.tox.2007.09.001
   Nishina A, 2007, BIOCHEM BIOPH RES CO, V352, P360, DOI 10.1016/j.bbrc.2006.11.025
   Pankiv S, 2007, J BIOL CHEM, V282, P24131, DOI 10.1074/jbc.M702824200
   Puissant A, 2010, CANCER RES, V70, P1042, DOI 10.1158/0008-5472.CAN-09-3537
   Rahman MM, 2018, CHEMOSPHERE, V196, P453, DOI 10.1016/j.chemosphere.2017.12.149
   Rahman MM, 2017, CHEM-BIOL INTERACT, V269, P41, DOI 10.1016/j.cbi.2017.04.003
   Rayman MP, 2012, LANCET, V379, P1256, DOI 10.1016/S0140-6736(11)61452-9
   Rayman MP, 2000, LANCET, V356, P233, DOI 10.1016/S0140-6736(00)02490-9
   Reeves MA, 2009, CELL MOL LIFE SCI, V66, P2457, DOI 10.1007/s00018-009-0032-4
   Roy R, 2014, TOXICOL LETT, V227, P29, DOI 10.1016/j.toxlet.2014.02.024
   Schnabel R, 2008, AM HEART J, V156, P1201, DOI 10.1016/j.ahj.2008.09.004
   Spanier G, 2009, J PHYSIOL PHARMACOL, V60, P111
   [U.S. Department of health & human services National Institutes of Health. USDA], 2012, NAT NUTR HLTH USDA N
   Wallenberg M, 2014, J CELL MOL MED, V18, P671, DOI 10.1111/jcmm.12214
   Wang S, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2014.563
   Wang Y, 2017, ENVIRON SCI POLLUT R, V24, P13405, DOI 10.1007/s11356-017-8785-z
   Yu L, 2006, P NATL ACAD SCI USA, V103, P4952, DOI 10.1073/pnas.0511288103
   Zeng HW, 2009, MOLECULES, V14, P1263, DOI 10.3390/molecules14031263
   Zhang JY, 2017, ENVIRON TOXICOL PHAR, V51, P30, DOI 10.1016/j.etap.2017.02.022
   Zhou N, 2003, J BIOL CHEM, V278, P29532, DOI 10.1074/jbc.M301877200
   Zhou YJ, 2009, TOXICOL IN VITRO, V23, P288, DOI 10.1016/j.tiv.2008.12.009
   Zitka O, 2012, ONCOL LETT, V4, P1247, DOI 10.3892/ol.2012.931
   Zuo L, 2004, ANN HEMATOL, V83, P751, DOI 10.1007/s00277-004-0920-5
NR 63
TC 31
Z9 31
U1 10
U2 43
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0278-6915
EI 1873-6351
J9 FOOD CHEM TOXICOL
JI Food Chem. Toxicol.
PD APR
PY 2018
VL 114
BP 180
EP 189
DI 10.1016/j.fct.2018.02.034
PG 10
WC Food Science & Technology; Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Food Science & Technology; Toxicology
GA GC4MH
UT WOS:000429758100020
PM 29454865
DA 2022-04-25
ER

PT J
AU Mira, A
   Morello, V
   Cespedes, MV
   Perera, T
   Comoglio, PM
   Mangues, R
   Michieli, P
AF Mira, Alessia
   Morello, Virginia
   Virtudes Cespedes, Maria
   Perera, Timothy
   Comoglio, Paolo M.
   Mangues, Ramon
   Michieli, Paolo
TI Stroma-derived HGF drives metabolic adaptation of colorectal cancer to
   angiogenesis inhibitors
SO ONCOTARGET
LA English
DT Article
DE colorectal cancer; HGF; anti-angiogenic therapy; resistance; tumor
   metabolism
ID HEPATOCYTE GROWTH-FACTOR; C-MET; GENE-EXPRESSION; GLUCOSE-UPTAKE; CELLS;
   MICROENVIRONMENT; XENOGRAFTS; RESISTANCE; THERAPIES; AUTOPHAGY
AB The role of paracrine Hepatocyte Growth Factor (HGF) in the resistance to angiogenesis inhibitors (AIs) is hidden in xenograft models because mouse HGF fails to fully activate human MET. To uncover it, we compared the efficacy of AIs in wild-type and human HGF knock-in SCID mice bearing orthotopic human colorectal tumors. Species-specific HGF/MET signaling dramatically impaired the response to anti-angiogenic agents and boosted metastatic dissemination. In cell-based assays mimicking the consequences of anti-angiogenic therapy, colorectal cancer cells were completely resistant to hypoxia but extremely sensitive to nutrient deprivation. Starvation-induced apoptosis could be prevented by HGF, which promoted GLUT1-mediated glucose uptake, sustained glycolysis and activated autophagy. Pharmacological inhibition of GLUT1 in the presence of glucose killed tumor cells as effectively as glucose deprivation, and this effect was antagonized by HGF. Concomitant targeting of GLUT1 and HGF potently suppressed growth and dissemination of AI-resistant human tumors in human HGF knock-in SCID mice without exacerbating tumor hypoxia. These data suggest that stroma-derived HGF protects CRC cells against glucose starvation-induced apoptosis, promoting resistance to both AIs and anti-glycolytic agents. Combined inhibition of glucose metabolism and HGF/MET signaling ('anti-METabolic therapy') may represent a more effective CRC treatment compared to utterly blocking tumor blood supply.
C1 [Mira, Alessia; Morello, Virginia; Comoglio, Paolo M.; Michieli, Paolo] IRCCS, FPO, Candiolo Canc Inst, Turin, Italy.
   [Morello, Virginia; Michieli, Paolo] Univ Turin, Med Sch, Dept Oncol, Turin, Italy.
   [Virtudes Cespedes, Maria; Mangues, Ramon] Hosp Santa Creu & Sant Pau, Biomed Res Inst St Pau, Barcelona, Spain.
   [Virtudes Cespedes, Maria; Mangues, Ramon] Ctr Invest Biomed Red Bioingn Biomat & Nanomed, Barcelona, Spain.
   [Perera, Timothy] OCTIMET Oncol Ltd, Oxford, England.
RP Michieli, P (corresponding author), IRCCS, FPO, Candiolo Canc Inst, Turin, Italy.; Michieli, P (corresponding author), Univ Turin, Med Sch, Dept Oncol, Turin, Italy.
EM paolo.michieli@ircc.it
RI Michieli, Paolo/A-2588-2011; Mangues, Ramon/J-6396-2014
OI Michieli, Paolo/0000-0002-3093-8871; Mangues, Ramon/0000-0003-2661-9525;
   Comoglio, Paolo/0000-0002-7056-5328; Morello,
   Virginia/0000-0002-3001-0993; Mira, Alessia/0000-0002-8456-8159
FU Associazione Italiana per la Ricerca sul Cancro (AIRC)Fondazione AIRC
   per la ricerca sul cancro [9970, 12798, 17489]; Instituto de Salud
   Carlos IIIInstituto de Salud Carlos IIIEuropean Commission;
   FEDEREuropean Commission [PI12/01861]; CIBER-BBN; Fondazione Umberto
   Veronesi FellowshipFondazione Umberto Veronesi
FX This work has been supported in part by the Associazione Italiana per la
   Ricerca sul Cancro (AIRC; 2010 Special Program in Molecular Clinical
   Oncology 5% #9970 to P.M. and P.M.C., 2012 IG #12798 and 2015 IG #17489
   to P.M.), the Instituto de Salud Carlos III (co-funding from FEDER;
   grant PI12/01861 to R.M.), and CIBER-BBN (Intramural Grant Nanomets to
   R.M.). A.M. was supported by a Fondazione Umberto Veronesi Fellowship.
CR Allen E, 2016, CELL REP, V15, P1144, DOI 10.1016/j.celrep.2016.04.029
   Basilico C, 2014, J CLIN INVEST, V124, P3172, DOI 10.1172/JCI72316
   Basilico C, 2013, CLIN CANCER RES, V19, P2381, DOI 10.1158/1078-0432.CCR-12-3459
   Bertola A, 2007, J BIOL CHEM, V282, P10325, DOI 10.1074/jbc.M611770200
   Brauer HA, 2013, CLIN CANCER RES, V19, P571, DOI 10.1158/1078-0432.CCR-12-2123
   Cecchi F, 2015, CLIN EXP METASTAS, V32, P659, DOI 10.1007/s10585-015-9735-0
   Cowey CL, 2013, DRUG DES DEV THER, V7, P519, DOI 10.2147/DDDT.S31442
   Dalva-Aydemir S, 2015, CLIN CANCER RES, V21, P1161, DOI 10.1158/1078-0432.CCR-14-1088
   Dienstmann R, 2015, J CLIN ONCOL, V33, P1787, DOI 10.1200/JCO.2014.60.0213
   Fakih MG, 2015, J CLIN ONCOL, V33, P1809, DOI 10.1200/JCO.2014.59.7633
   Gherardi E, 2012, NAT REV CANCER, V12, P89, DOI 10.1038/nrc3205
   Goos JACM, 2016, ANN SURG, V263, P138, DOI 10.1097/SLA.0000000000001109
   Grothey A, 2013, LANCET, V381, P303, DOI 10.1016/S0140-6736(12)61900-X
   Heijmen L, 2014, CONTRAST MEDIA MOL I, V9, P237, DOI 10.1002/cmmi.1564
   Ikebuchi F, 2013, CELL BIOCHEM FUNCT, V31, P298, DOI 10.1002/cbf.2898
   Jahangiri A, 2013, CLIN CANCER RES, V19, P1773, DOI 10.1158/1078-0432.CCR-12-1281
   Jimenez-Valerio G, 2016, CELL REP, V15, P1134, DOI 10.1016/j.celrep.2016.04.015
   Liu Y, 2012, MOL CANCER THER, V11, P1672, DOI 10.1158/1535-7163.MCT-12-0131
   Luraghi P, 2014, CANCER RES, V74, P1857, DOI 10.1158/0008-5472.CAN-13-2340-T
   Nardo G, 2011, CANCER RES, V71, P4214, DOI 10.1158/0008-5472.CAN-11-0242
   Patel SR, 2014, J GASTROINTEST ONCOL, V5, P99, DOI 10.3978/j.issn.2078-6891.2014.002
   Pennacchietti S, 2003, CANCER CELL, V3, P347, DOI 10.1016/S1535-6108(03)00085-0
   Pennacchietti S, 2014, CANCER RES, V74, P6598, DOI 10.1158/0008-5472.CAN-14-0761
   Perdomo G, 2008, J BIOL CHEM, V283, P13700, DOI 10.1074/jbc.M707551200
   Pisarsky L, 2016, CELL REP, V15, P1161, DOI 10.1016/j.celrep.2016.04.028
   Rapisarda A, 2009, DRUG RESIST UPDATE, V12, P74, DOI 10.1016/j.drup.2009.03.002
   Saigusa S, 2012, SURG TODAY, V42, P460, DOI 10.1007/s00595-011-0027-2
   Perez-Vargas JCS, 2013, INT J MOL SCI, V14, P18056, DOI 10.3390/ijms140918056
   Scheepers A, 2004, JPEN-PARENTER ENTER, V28, P364, DOI 10.1177/0148607104028005364
   Selvakumaran M, 2013, CLIN CANCER RES, V19, P2995, DOI 10.1158/1078-0432.CCR-12-1542
   Sennino B, 2012, CANCER DISCOV, V2, P270, DOI 10.1158/2159-8290.CD-11-0240
   Shen YM, 2011, INT J BIOL MARKER, V26, P166, DOI 10.5301/JBM.2011.8550
   Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI [10.3322/caac.21254, 10.3322/caac.21208, 10.1001/jamaoto.2014.2530, 10.1136/bmj.g1502]
   Stein U, 2009, NAT MED, V15, P59, DOI 10.1038/nm.1889
   Strickler JH, 2012, ONCOLOGIST, V17, P513, DOI 10.1634/theoncologist.2012-0003
   Tabernero J, 2014, CLIN CANCER RES, V20, P2793, DOI 10.1158/1078-0432.CCR-13-1837
   Trusolino L, 2010, NAT REV MOL CELL BIO, V11, P834, DOI 10.1038/nrm3012
   Ulivi P, 2016, ONCOTARGET, V7, P46678, DOI 10.18632/oncotarget.8712
   Van Cutsem E, 2016, NAT REV CLIN ONCOL, V13, P69, DOI 10.1038/nrclinonc.2015.217
   Van Cutsem E, 2011, J CLIN ONCOL, V29, P2004, DOI 10.1200/JCO.2010.29.5436
   Vander Heiden MG, 2011, NAT REV DRUG DISCOV, V10, P671, DOI 10.1038/nrd3504
   Vermeulen L, 2010, NAT CELL BIOL, V12, P468, DOI 10.1038/ncb2048
   Wang C, 2016, PHARMACOL RES, V105, P164, DOI 10.1016/j.phrs.2016.01.028
   Zhang YW, 2005, ONCOGENE, V24, P101, DOI 10.1038/sj.onc.1208181
NR 44
TC 15
Z9 15
U1 0
U2 6
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD JUN 13
PY 2017
VL 8
IS 24
BP 38193
EP 38213
DI 10.18632/oncotarget.16942
PG 21
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA EX5VX
UT WOS:000403311900015
PM 28445144
OA Green Published, gold, Green Submitted
DA 2022-04-25
ER

PT J
AU Tan, YY
   Ci, YP
   Dai, XP
   Wu, F
   Guo, JP
   Liu, DL
   North, BJ
   Huo, JR
   Zhang, JF
AF Tan, Yuyong
   Ci, Yanpeng
   Dai, Xiangpeng
   Wu, Fei
   Guo, Jianping
   Liu, Deliang
   North, Brian J.
   Huo, Jirong
   Zhang, Jinfang
TI Cullin 3(SPOP) ubiquitin E3 ligase promotes the poly-ubiquitination and
   degradation of HDAC6
SO ONCOTARGET
LA English
DT Article
DE HDAC6; SPOP; Cullin 3; ubiquitination; tumorigenesis
ID HISTONE DEACETYLASE 6; EPITHELIAL-MESENCHYMAL TRANSITION;
   CANCER-ASSOCIATED MUTANTS; TUMOR-SUPPRESSOR SPOP; PROSTATE-CANCER;
   ANDROGEN RECEPTOR; PROTEIN-TURNOVER; ACETYLATION; ACTIVATION; INHIBITOR
AB The histone deacetylase 6 (HDAC6) plays critical roles in human tumorigenesis and metastasis. As such, HDAC6-selective inhibitors have entered clinical trials for cancer therapy. However, the upstream regulator(s), especially ubiquitin E3 ligase(s), responsible for controlling the protein stability of HDAC6 remains largely undefined. Here, we report that Cullin 3(SPOP) earmarks HDAC6 for poly-ubiquitination and degradation. We found that the proteasome inhibitor MG132, or the Cullin-based E3 ligases inhibitor MLN4924, but not the autophagosome-lysosome inhibitor bafilomycin A1, stabilized endogenous HDAC6 protein in multiple cancer cell lines. Furthermore, we demonstrated that Cullin 3-based ubiquitin E3 ligase(s) primarily reduced the stability of HDAC6. Importantly, we identified SPOP, an adaptor protein of Cullin 3 family E3 ligases, specifically interacted with HDAC6, and promoted its poly-ubiquitination and subsequent degradation in cells. Notably, cancer-derived SPOP mutants disrupted their binding with HDAC6 and thereby failed to promote HDAC6 degradation. More importantly, increased cellular proliferation and migration in SPOP-depleted HCT116 colon cancer cells could be partly reversed by additional depletion of HDAC6, suggesting that HDAC6 is a key downstream effector for SPOP tumor suppressor function. Together, our data identify the tumor suppressor SPOP as an upstream negative regulator for HDAC6 stability, and SPOP loss-of-function mutations might lead to elevated levels of the HDAC6 oncoprotein to facilitate tumorigenesis and metastasis in various human cancers.
C1 [Tan, Yuyong; Liu, Deliang; Huo, Jirong] Cent S Univ, Dept Gastroenterol, Xiangya Hosp 2, Changsha 410011, Hunan, Peoples R China.
   [Tan, Yuyong; Ci, Yanpeng; Dai, Xiangpeng; Wu, Fei; Guo, Jianping; North, Brian J.; Zhang, Jinfang] Harvard Med Sch, Dept Pathol, Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
   [Ci, Yanpeng] Harbin Inst Technol, Sch Life Sci & Technol, Harbin 150001, Peoples R China.
   [Wu, Fei] Fudan Univ, Huashan Hosp, Dept Urol, Shanghai 200040, Peoples R China.
RP Huo, JR (corresponding author), Cent S Univ, Dept Gastroenterol, Xiangya Hosp 2, Changsha 410011, Hunan, Peoples R China.; North, BJ; Zhang, JF (corresponding author), Harvard Med Sch, Dept Pathol, Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
EM bnorth@bidmc.harvard.edu; hjr198@hotmail.com; jzhang17@bidmc.harvard.edu
RI Wu, Fei/AAP-5721-2021
OI Wu, Fei/0000-0001-6689-6135
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [AG052627]; Chinese National Key
   Disciplines [(2012)650]; Development and Reform Commission of Hunan
   Province [XFGTZ2014713]; NATIONAL INSTITUTE ON AGINGUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute on Aging (NIA) [K01AG052627] Funding Source:
   NIH RePORTER
FX We thank Dr. Wenyi Wei and Dr. Wenjian Gan for critical discussion and
   reading of the manuscript. B.J.N. was supported in part by NIH K01 grant
   AG052627. This work was partly supported by the Chinese National Key
   Disciplines [(2012)650] and Development and Reform Commission of Hunan
   Province (XFGTZ2014713 to D.L.).
CR Aldana-Masangkay GI, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/875824
   An J, 2015, MOL CELL, V59, P904, DOI 10.1016/j.molcel.2015.07.025
   An J, 2014, CELL REP, V6, P657, DOI 10.1016/j.celrep.2014.01.013
   Nieto MA, 2016, CELL, V166, P21, DOI 10.1016/j.cell.2016.06.028
   Barbieri CE, 2012, NAT GENET, V44, P685, DOI 10.1038/ng.2279
   Batchu SN, 2016, CLIN SCI, V130, P987, DOI 10.1042/CS20160084
   Berger MF, 2011, NATURE, V470, P214, DOI 10.1038/nature09744
   Cook C, 2012, HUM MOL GENET, V21, P2936, DOI 10.1093/hmg/dds125
   Duda DM, 2008, CELL, V134, P995, DOI 10.1016/j.cell.2008.07.022
   Gan WJ, 2015, MOL CELL, V59, P917, DOI 10.1016/j.molcel.2015.07.026
   Ganai SA, 2017, CURR DRUG TARGETS
   Geng C, 2014, CANCER RES, V74, P5631, DOI 10.1158/0008-5472.CAN-14-0476
   Geng C, 2013, P NATL ACAD SCI USA, V110, P6997, DOI 10.1073/pnas.1304502110
   Genschik P, 2013, EMBO J, V32, P2307, DOI 10.1038/emboj.2013.173
   Glozak MA, 2007, ONCOGENE, V26, P5420, DOI 10.1038/sj.onc.1210610
   Gu SC, 2016, J BIOL CHEM, V291, P5396, DOI 10.1074/jbc.M115.713123
   Han Y, 2009, BIOCHEM BIOPH RES CO, V383, P88, DOI 10.1016/j.bbrc.2009.03.147
   Hernadez-Munoz I, 2005, P NATL ACAD SCI USA, V102, P7635, DOI 10.1073/pnas.0408918102
   Hsieh TH, 2012, TOXICOL SCI, V128, P365, DOI 10.1093/toxsci/kfs163
   Huang PY, 2017, ONCOTARGET, V8, P2694, DOI 10.18632/oncotarget.13738
   Hubbert C, 2002, NATURE, V417, P455, DOI 10.1038/417455a
   Jung SH, 2016, ONCOTARGET, V7, P69638, DOI 10.18632/oncotarget.11922
   Kim MS, 2013, APMIS, V121, P626, DOI 10.1111/apm.12030
   Klionsky DJ, 2008, AUTOPHAGY, V4, P849, DOI 10.4161/auto.6845
   Kovacs JJ, 2005, MOL CELL, V18, P601, DOI 10.1016/j.molcel.2005.04.021
   Kwon JE, 2006, J BIOL CHEM, V281, P12664, DOI 10.1074/jbc.M600204200
   Lee DH, 1998, TRENDS CELL BIOL, V8, P397, DOI 10.1016/S0962-8924(98)01346-4
   Li GQ, 2014, CANCER CELL, V25, P455, DOI 10.1016/j.ccr.2014.02.007
   Li Y, 2016, HDACS HDACS HDAC INH, V6
   Mobley RJ, 2017, CELL REP, V18, P2387, DOI 10.1016/j.celrep.2017.02.030
   Petroski MD, 2005, NAT REV MOL CELL BIO, V6, P9, DOI 10.1038/nrm1547
   Pugacheva EN, 2007, CELL, V129, P1351, DOI 10.1016/j.cell.2007.04.035
   Ryu HW, 2017, CANCER LETT, V391, P162, DOI 10.1016/j.canlet.2017.01.033
   Santo L, 2012, BLOOD, V119, P2579, DOI 10.1182/blood-2011-10-387365
   Seidel C, 2015, EPIGENOMICS-UK, V7, P103, DOI [10.2217/EPI.14.69, 10.2217/epi.14.69]
   Shan B, 2008, J BIOL CHEM, V283, P21065, DOI 10.1074/jbc.M802786200
   Soucy TA, 2009, NATURE, V458, P732, DOI 10.1038/nature07884
   Theurillat JPP, 2014, SCIENCE, V346, P85, DOI 10.1126/science.1250255
   Wang ZW, 2014, NAT REV CANCER, V14, P233, DOI 10.1038/nrc3700
   Williams KA, 2013, J BIOL CHEM, V288, P33156, DOI 10.1074/jbc.M113.472506
   Wu F, 2017, CANCER LETT, V385, P207, DOI 10.1016/j.canlet.2016.10.021
   Yang PH, 2013, DRUG DISCOV THER, V7, P233, DOI 10.5582/ddt.2013.v7.6.233
   YOSHIMORI T, 1991, J BIOL CHEM, V266, P17707
   Zhang LL, 2017, CANCER LETT, V390, P11, DOI 10.1016/j.canlet.2017.01.003
   Zhang P, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.47
   Zhang Q, 2006, DEV CELL, V10, P719, DOI 10.1016/j.devcel.2006.05.004
   Zhang XH, 2007, MOL CELL, V27, P197, DOI 10.1016/j.molcel.2007.05.033
   Zhuang M, 2009, MOL CELL, V36, P39, DOI 10.1016/j.molcel.2009.09.022
NR 48
TC 22
Z9 27
U1 1
U2 8
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD JUL 18
PY 2017
VL 8
IS 29
BP 47890
EP 47901
DI 10.18632/oncotarget.18141
PG 12
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA FA8KD
UT WOS:000405694000097
PM 28599312
OA Green Published, Green Submitted, gold
DA 2022-04-25
ER

PT J
AU Zheng, TL
   Li, DP
   Zhang, K
   Guo, HZ
   Cui, GH
   Zhao, S
AF Zheng, Tianliang
   Li, Deping
   Zhang, Kai
   Guo, Haizhou
   Cui, Guanghui
   Zhao, Song
TI Prognostic value of autophagy marker LC3 in esophageal cancer: a
   meta-analysis
SO INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE
LA English
DT Article
DE Esophageal cancer; autophagy; microtubule-associated protein 1 light
   chain 3; prognosis; meta-analysis
ID SQUAMOUS-CELL CARCINOMA; PREDICTS POOR-PROGNOSIS; UNC-51-LIKE KINASE 1;
   COLORECTAL-CANCER; PROTEINS LC3; EXPRESSION; SURVIVAL; BECLIN-1;
   STATISTICS; APOPTOSIS
AB Objective: Autophagy played an important role in the carcinogenesis of esophageal cancer, and LC3 was a popular marker of autophagy. However, the association between LC3 and prognosis of esophageal cancer was controversial. We conducted this meta-analysis to systemically assess the prognostic value of LC3 in esophageal cancer. Materials and methods: Literature searches were performed in Embase and PubMed databases for eligible studies before June 30, 2016. Hazard ratio (HR) was pooled to assess the association of LC3 with overall survival (OS). Odds ratio (OR) was pooled to evaluate the correlation between LC3 and clinicopathological characteristics. Results: A total of six studies involving 775 patients were included for meta-analysis. The pooled result showed that the high LC3 level was significantly correlated with worse OS of esophageal cancer (HR=1.33, 95% CI 1.05-1.68; P=0.018). There was no correlation between LC3 and tumor grade (OR=0.96, 95% CI 0.68-1.36; P=0.822), lymph node involvement (OR=0.99, 95% CI 0.71-1.38; P=0.959) or TNM stage (OR=0.70, 95% CI 0.43-1.13; P=0.142). Conclusion: High LC3 level was correlated with worse prognosis of esophageal cancer, and LC3 might act as a promising autophagy-related prognostic marker of esophageal cancer.
C1 [Zheng, Tianliang; Guo, Haizhou; Cui, Guanghui; Zhao, Song] Zhengzhou Univ, Affiliated Hosp 1, Dept Thorac Surg, Zhengzhou 450000, Peoples R China.
   [Zhang, Kai] Zhengzhou Univ, Affiliated Hosp 2, Dept Resp Med, Zhengzhou 450000, Peoples R China.
   [Li, Deping] Zhengzhou Hosp Tradit Chinese Med, Dept Pain Management, Zhengzhou 450000, Peoples R China.
RP Zhao, S (corresponding author), Zhengzhou Univ, Affiliated Hosp 1, Dept Thorac Surg, Zhengzhou 450000, Peoples R China.
EM zzuzhaosong@yahoo.com
FU Youth Innovation Fund Project of the First Affiliated Hospital of
   Zhengzhou University
FX This study was supported by the Youth Innovation Fund Project of the
   First Affiliated Hospital of Zhengzhou University.
CR Adams O, 2016, ONCOTARGET, V7, P39241, DOI 10.18632/oncotarget.9649
   Birkenmeier K, 2016, ONCOTARGET
   Chen HI, 2016, PATHOL ONCOL RES, V22, P699, DOI 10.1007/s12253-016-0051-z
   Chen YS, 2013, PATHOL RES PRACT, V209, P562, DOI 10.1016/j.prp.2013.06.006
   Chen YS, 2009, PATHOL ONCOL RES, V15, P487, DOI 10.1007/s12253-008-9143-8
   Chen ZW, 2015, CANCER BIOMARK, V15, P467, DOI 10.3233/CBM-150474
   Cho TJ, 2014, ARCH ORAL BIOL, V59, P370, DOI 10.1016/j.archoralbio.2014.01.001
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Guo GF, 2011, WORLD J GASTROENTERO, V17, P4779, DOI 10.3748/wjg.v17.i43.4779
   Han Y., 2014, J ADV SIGNAL PROCESS, V2014, P1, DOI DOI 10.1097/PAT.0000000000000125
   Hao CL, 2014, INT J CLIN EXP PATHO, V7, P4213
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Jiang L, 2014, INT J CLIN EXP MED, V7, P1349
   Jiang S, 2011, CANCER SCI, V102, P1568, DOI 10.1111/j.1349-7006.2011.01964.x
   Jiang ZF, 2012, MOL BIOL REP, V39, P259, DOI 10.1007/s11033-011-0734-1
   Jung G, 2015, ACTA HAEMATOL-BASEL, V134, P17, DOI 10.1159/000368848
   Koukourakis MI, 2010, BRIT J CANCER, V103, P1209, DOI 10.1038/sj.bjc.6605904
   Liu H, 2014, AUTOPHAGY, V10, P372, DOI 10.4161/auto.27163
   Masuda G, 2016, ANTICANCER RES, V36, P129
   Parmar MKB, 1998, STAT MED, V17, P2815, DOI 10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8
   Stang A, 2010, EUR J EPIDEMIOL, V25, P603, DOI 10.1007/s10654-010-9491-z
   Sun WL, 2011, AUTOPHAGY, V7, P1035, DOI 10.4161/auto.7.9.16521
   Tang JY, 2013, HUM PATHOL, V44, P2558, DOI 10.1016/j.humpath.2013.06.017
   Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262
   Wang X, 2015, PROCEEDINGS OF 2015 INTERNATIONAL CONFERENCE ON ESTIMATION, DETECTION AND INFORMATION FUSION ICEDIF 2015, P8, DOI 10.1109/ICEDIF.2015.7280148
   Wang ZB, 2013, MOL MED REP, V8, P41, DOI 10.3892/mmr.2013.1451
   Wong WWL, 2009, J MOL CELL BIOL, V1, P80, DOI 10.1093/jmcb/mjp019
   Wu SH, 2015, INT J CLIN EXP PATHO, V8, P3882
   Yoshioka A, 2008, INT J ONCOL, V33, P461, DOI 10.3892/ijo_00000028
   Zhu WP, 2012, TUMOR BIOL, V33, P1653, DOI 10.1007/s13277-012-0421-4
   Zou YF, 2015, ONCOL LETT, V10, P1583, DOI 10.3892/ol.2015.3417
NR 31
TC 0
Z9 0
U1 0
U2 3
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1940-5901
J9 INT J CLIN EXP MED
JI Int. J. Clin. Exp. Med.
PY 2016
VL 9
IS 11
BP 21535
EP 21541
PG 7
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA EG7UD
UT WOS:000391260800114
DA 2022-04-25
ER

PT J
AU Xian, ZY
   Hu, B
   Wang, T
   Zeng, JY
   Cai, JL
   Zou, Q
   Zhu, PX
AF Xian, Zhenyu
   Hu, Bang
   Wang, Ting
   Zeng, Junyi
   Cai, Jinlin
   Zou, Qi
   Zhu, Peixuan
TI lncRNA UCA1 Contributes to 5-Fluorouracil Resistance of Colorectal
   Cancer Cells Through miR-23b-3p/ZNF281 Axis
SO ONCOTARGETS AND THERAPY
LA English
DT Article
DE colorectal cancer; 5-FU; UCA1; miR-23b-3p; ZNF281; autophagy; apoptosis
ID LONG NONCODING RNA; HEPATOCELLULAR-CARCINOMA; POOR-PROGNOSIS; APOPTOSIS;
   AUTOPHAGY; PROLIFERATION; MICRORNA-23B; PROGRESSION; ACTIVATION;
   INVASION
AB Purpose: The chemoresistance of 5-fluorouracil (5-FU) limited the application of chemotherapy in colorectal cancer (CRC) treatment. Herein, we aimed to uncover the potential mechanism behind the 5-FU resistance of CRC cells.
   Methods: The abundance of long noncoding RNA urothelial carcinoma associated 1 (lncRNA UCA1), microRNA-23b-3p (miR-23b-3p) and zinc finger protein 281 (ZNF281) was measured by quantitative real-time polymerase chain reaction (qRT-PCR) in CRC tissues and cells. Western blot was conducted to examine autophagy-related proteins, apoptosis-associated proteins and ZNF281 in CRC tissues and cells. Cell counting kit-8 (CCK8) assay was performed to detect the viability and inhibitory concentration 50% (IC50) value of 5-FU of CRC cells. The apoptosis of CRC cells was measured by flow cytometry. The binding sites between miR-23b-3p and UCA1 or ZNF281 were predicted by miRcode and Starbase software, respectively, and the combination was confirmed by dual-luciferase reporter assay and RIP assay. Murine xenograft model was established to verify the role of UCA1 on the 5-FU resistance of CRC in vivo.
   Results: The 5-FU resistance of CRC was positively related to the level of UCA1 and autophagy. UCA1 accelerated the 5-FU resistance of CRC cells through facilitating autophagy and suppressing apoptosis. MiR-23b-3p was a target of UCA1 in 293T and CRC cells. The knockdown of miR-23b-3p reversed the inhibitory effects of UCA1 interference on the 5-FU resistance and autophagy and the promoting impact on the apoptosis of CRC cells. ZNF281 could bind to miR-23b-3p in 293T cells. MiR-23b-3p elevated the 5-FU sensitivity through down-regulating ZNF281 in CRC cells. UCA1 interference enhanced the 5-FU sensitivity of CRC through miR-23b-3p/ZNF281 axis in vivo.
   Conclusion: UCA1 mediated 5-FU resistance of CRC cells through facilitating autophagy and inhibiting apoptosis via miR-23b-3p/ZNF281 axis in vivo and in vitro.
C1 [Xian, Zhenyu; Wang, Ting; Zeng, Junyi; Cai, Jinlin] Sun Yat Sen Univ, Affiliated Hosp 6, Graceland Med Ctr, Guangzhou, Guangdong, Peoples R China.
   [Hu, Bang; Zou, Qi] Sun Yat Sen Univ, Affiliated Hosp 6, Dept Colorectal Surg, Gastrointestinal & Anal Hosp, Guangzhou, Guangdong, Peoples R China.
   [Zhu, Peixuan] Guangzhou Gen Hosp Foresea Life Insurance, Int Med Ctr, 703 Xinchengdadao, Guangzhou 511300, Guangdong, Peoples R China.
RP Zhu, PX (corresponding author), Guangzhou Gen Hosp Foresea Life Insurance, Int Med Ctr, 703 Xinchengdadao, Guangzhou 511300, Guangdong, Peoples R China.
EM zhupx@gzqhrsyy.com
CR Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5
   Bian ZH, 2016, SCI REP-UK, V6, DOI 10.1038/srep23892
   Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997
   Cesana M, 2011, CELL, V147, P358, DOI 10.1016/j.cell.2011.09.028
   Croce CM, 2005, CELL, V122, P6, DOI 10.1016/j.cell.2005.06.036
   Campos-Viguri GE, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-60143-x
   Fang Q, 2016, MED SCI MONITOR, V22, DOI 10.12659/MSM.900688
   Hahn S, 2013, EMBO J, V32, P3079, DOI 10.1038/emboj.2013.236
   Han Y, 2014, PATHOLOGY, V46, P396, DOI 10.1097/PAT.0000000000000125
   Hu YR, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0743-3
   Huang J, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2013.541
   Jonker FHW, 2015, DIS COLON RECTUM, V58, P931, DOI 10.1097/DCR.0000000000000432
   Kallen AN, 2013, MOL CELL, V52, P101, DOI 10.1016/j.molcel.2013.08.027
   Kou CH, 2016, ONCOL LETT, V12, P4838, DOI 10.3892/ol.2016.5265
   Li JY, 2014, INT J CLIN EXP PATHO, V7, P7938
   Li WP, 2014, FEBS LETT, V588, P1608, DOI 10.1016/j.febslet.2014.02.055
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Loftus JC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039818
   PENG BH, 2019, J IMMUNOTHER CANCER, V8, DOI DOI 10.1186/S40425-019-0701-2
   Qian Y, 2017, DIGEST DIS SCI, V62, P2011, DOI 10.1007/s10620-017-4611-1
   Qin Chang-Jiang, 2019, Cell Physiol Biochem, V52, P1503, DOI 10.33594/000000104
   Salvi A, 2009, FEBS J, V276, P2966, DOI 10.1111/j.1742-4658.2009.07014.x
   Sun FF, 2019, MOL MED REP, V20, P3583, DOI 10.3892/mmr.2019.10588
   Wang F, 2008, FEBS LETT, V582, P1919, DOI 10.1016/j.febslet.2008.05.012
   Wang F, 2015, ONCOTARGET, V6, P7899, DOI 10.18632/oncotarget.3219
   Wang HH, 2017, ONCOTARGET, V8, P64638, DOI 10.18632/oncotarget.18344
   Wang K, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4596
   Wang M, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-1187-4
   Wang XS, 2006, CLIN CANCER RES, V12, P4851, DOI 10.1158/1078-0432.CCR-06-0134
   Wang ZX, 2008, STEM CELLS, V26, P2791, DOI 10.1634/stemcells.2008-0443
   Wei HM, 2019, INT IMMUNOPHARMACOL, V73, P72, DOI 10.1016/j.intimp.2019.04.049
   Xue YB, 2019, THORAC CANCER, V10, P1692, DOI 10.1111/1759-7714.13131
   Yang T, 2018, GENE, V670, P114, DOI 10.1016/j.gene.2018.05.061
   Yu XF, 2017, SCI REP-UK, V7, DOI 10.1038/srep42226
   Zhang HH, 2015, CANCER LETT, V356, P781, DOI 10.1016/j.canlet.2014.10.029
   Zhang L, 2017, BIOMED PHARMACOTHER, V96, P884, DOI 10.1016/j.biopha.2017.10.056
   Zhang Y, 2018, J CELL BIOCHEM, V119, P6296, DOI 10.1002/jcb.26899
NR 38
TC 11
Z9 12
U1 2
U2 6
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-6930
J9 ONCOTARGETS THER
JI OncoTargets Ther.
PY 2020
VL 13
BP 7571
EP 7583
DI 10.2147/OTT.S258727
PG 13
WC Biotechnology & Applied Microbiology; Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Oncology
GA MT3ZE
UT WOS:000554906400001
PM 32801774
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Liu, C
   Ji, L
   Song, X
AF Liu, Chao
   Ji, Le
   Song, Xue
TI Long non coding RNA UCA1 contributes to the autophagy and survival of
   colorectal cancer cells via sponging miR-185-5p to up-regulate the
   WISP2/beta-catenin pathway
SO RSC ADVANCES
LA English
DT Article
ID WNT/BETA-CATENIN PATHWAY; HEPATOCELLULAR-CARCINOMA; PREDICTIVE
   BIOMARKER; PANCREATIC-CANCER; POOR-PROGNOSIS; NONCODING RNAS;
   LUNG-CANCER; PROLIFERATION; MICRORNA-185; INHIBITION
AB The estimated number of new cases of colorectal cancer (CRC) will increase to 140250 in 2018 worldwide. The long non-coding RNA (lncRNA) urothelial carcinoma-associated 1 (UCA1) has recently been shown to be dysregulated in CRC, which plays an important role in the progression of CRC. However, the biological role and the underling mechanism of UCA1 in the carcinogenesis of CRC remain unclear. Herein, we found that UCA1 was aberrantly upregulated in two CRC cell lines (SW620 and HT29) compared to colorectal cell CCD-18Co. UCA1 knockdown inhibited the apoptosis, growth and autophagy of CRC cell lines in vitro. Furthermore, UCA1 could act as an endogenous sponge by directly interacting with miR-185-5p and downregulation miR-185-5p expression. In addition, UCA1 could reverse the inhibitory effect of miR-185-5p on the growth and autophagy of CRC cells, which might be involved in the derepression of member 1 (WNT1)-inducible signaling pathway protein 2 (WISP2, a target gene of miR-185-5p) expression and the activation of the WISP2/beta-catenin signaling pathway. In vivo, the present study elucidates a novel UCA1-miR-185-5p-WISP2-Wnt/beta-catenin axis in CRC, which may help us to understand the pathogenesis and the feasibility of lncRNA-directed diagnosis and therapy of CRC.
C1 [Liu, Chao; Ji, Le; Song, Xue] Yanan Univ, Affiliated Hosp, Dept Gastroenterol, 43 North St, Yanan 716000, Shaanxi, Peoples R China.
RP Song, X (corresponding author), Yanan Univ, Affiliated Hosp, Dept Gastroenterol, 43 North St, Yanan 716000, Shaanxi, Peoples R China.
EM songxuedoctor@outlook.com
CR Ashworth C, 2018, NAT REV MATER, V3, DOI 10.1038/natrevmats.2017.92
   Barreto SC, 2016, J BUON, V21, P1359
   Bian ZH, 2016, SCI REP-UK, V6, DOI 10.1038/srep23892
   Boehler M, 2011, J CANCER EDUC, V26, P147, DOI 10.1007/s13187-010-0161-3
   Dai ZM, 2014, J NEUROSCI, V34, P8467, DOI 10.1523/JNEUROSCI.0311-14.2014
   Dhar G, 2007, CANCER LETT, V254, P63, DOI 10.1016/j.canlet.2007.02.012
   Dong-Xu W, 2015, INDIAN J CANCER, V52, P182, DOI 10.4103/0019-509X.186576
   Fan Y, 2014, FEBS J, V281, P1750, DOI 10.1111/febs.12737
   Gu W, 2014, ONCOL REP, V31, P397, DOI 10.3892/or.2013.2831
   Han Y, 2014, PATHOLOGY, V46, P396, DOI 10.1097/PAT.0000000000000125
   Hong HH, 2016, ONCOTARGET, V7, P44442, DOI 10.18632/oncotarget.10142
   Ji JF, 2015, BRIT J CANCER, V113, P921, DOI 10.1038/bjc.2015.285
   Ji JF, 2014, ONCOL REP, V31, P533, DOI 10.3892/or.2013.2909
   Jing FY, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317703650
   Lai K, 2014, J CLIN PATHOL, V67, P854, DOI 10.1136/jclinpath-2014-202529
   Leal LF, 2011, J CLIN ENDOCR METAB, V96, P3106, DOI 10.1210/jc.2011-0363
   Li K, 2016, ONCOL LETT, V11, P3896, DOI 10.3892/ol.2016.4481
   Lu ZJ, 2014, MOL MED REP, V10, P2401, DOI 10.3892/mmr.2014.2562
   Ni BB, 2015, INT J ONCOL, V47, P1329, DOI 10.3892/ijo.2015.3109
   Nie W, 2016, CANCER LETT, V371, P99, DOI 10.1016/j.canlet.2015.11.024
   Sebio A, 2014, EXPERT OPIN THER TAR, V18, P611, DOI 10.1517/14728222.2014.906580
   Siegel RL, 2018, CA-CANCER J CLIN, V68, P7, DOI 10.3322/caac.21442
   Tokura Y., 2017, B CHEM SOC JPN, V90, P967
   Tomimaru Y, 2013, LIVER INT, V33, P1100, DOI 10.1111/liv.12188
   Tuo YL, 2015, EUR REV MED PHARMACO, V19, P3403
   Wang F, 2015, ONCOTARGET, V6, P7899, DOI 10.18632/oncotarget.3219
   Wang HM, 2015, INT J CLIN EXP MED, V8, P11824
   Wu MY, 2014, ONCOL REP, V32, P513, DOI 10.3892/or.2014.3266
   Wu SH, 2015, INT J CLIN EXP PATHO, V8, P3882
   Xu MD, 2014, MODERN PATHOL, V27, P1310, DOI 10.1038/modpathol.2014.33
   Yang YX, 2016, ADV EXP MED BIOL, V937, P19, DOI 10.1007/978-3-319-42059-2_2
   Zhang Z, 2015, ONCOGENE, V34, P4808, DOI 10.1038/onc.2014.404
   Zhu YY, 2018, CANCER SCI, V109, P2235, DOI 10.1111/cas.13632
NR 33
TC 3
Z9 3
U1 0
U2 1
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
EI 2046-2069
J9 RSC ADV
JI RSC Adv.
PY 2019
VL 9
IS 25
BP 14160
EP 14166
DI 10.1039/c8ra10468a
PG 7
WC Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry
GA HZ1WI
UT WOS:000468640100024
OA gold
DA 2022-04-25
ER

PT J
AU Lan, SH
   Lin, SC
   Wang, WC
   Yang, YC
   Lee, JC
   Lin, PW
   Chu, ML
   Lan, KY
   Zuchini, R
   Liu, HS
   Wu, SY
AF Lan, Sheng-Hui
   Lin, Shu-Ching
   Wang, Wei-Chen
   Yang, Yu-Chan
   Lee, Jenq-Chang
   Lin, Pei-Wen
   Chu, Man-Ling
   Lan, Kai-Ying
   Zuchini, Roberto
   Liu, Hsiao-Sheng
   Wu, Shan-Ying
TI Autophagy Upregulates miR-449a Expression to Suppress Progression of
   Colorectal Cancer
SO FRONTIERS IN ONCOLOGY
LA English
DT Article
DE autophagy; miR-449a; FoxO1; colorectal cancer; tumorigenesis
ID C-MYC; TUMORIGENESIS; SURVIVAL; DISEASE; FOXO1; GENE
AB Many studies reported that microRNAs (miRNAs) target autophagy-related genes to affect carcinogenesis, however, autophagy-deficiency-related miRNA dysfunction in cancer development remains poorly explored. During autophagic progression, we identified miR-449a as the most up-regulated miRNA. MiR-449a expression was low in the tumor parts of CRC patient specimens and inversely correlated with tumor stage and metastasis with the AUC (area under the curve) of 0.899 and 0.736 as well as poor overall survival rate, indicating that miR-449a has the potential to be a prognostic biomarker. In the same group of CRC specimens, low autophagic activity (low Beclin 1 expression and high p62 accumulation) was detected, which was significantly associated with miR-449a expression. Mechanistic studies disclosed that autophagy upregulates miR-449a expression through degradation of the coactivator p300 protein which acetylates the transcription factor Forkhead Box O1 (FoxO1). Unacetylated FoxO1 translocated to the nucleus and bound to the miR-449a promoter to drive gene expression. Either activation of autophagy by the inducer or overexpression of exogenous miR-449a decreases the expression of target gene LEF-1 and cyclin D1, which lead to decreased proliferation, colony formation, migration, and invasion of CRC cells. Autophagy-miR-449a-tartet genes mediated suppression of tumor formation was further confirmed in the xenograft mouse model. In conclusion, this study reveals a novel mechanism wherein autophagy utilizes miR-449a-LEF1-cyclin D1 axis to suppress CRC tumorigenesis. Our findings open a new avenue toward prognosis and treatment of CRC patients by manipulating autophagy-miR-449a axis.
C1 [Lan, Sheng-Hui; Lan, Kai-Ying] Natl Yang Ming Chiao Tung Univ, Dept Life Sci, Taipei, Taiwan.
   [Lan, Sheng-Hui; Lan, Kai-Ying] Natl Yang Ming Chiao Tung Univ, Inst Genome Sci, Taipei, Taiwan.
   [Lan, Sheng-Hui] Natl Yang Ming Chiao Tung Univ, Canc Progress Res Ctr, Taipei, Taiwan.
   [Lin, Shu-Ching; Wang, Wei-Chen; Yang, Yu-Chan; Liu, Hsiao-Sheng] Natl Cheng Kung Univ, Dept Microbiol & Immunol, Coll Med, Tainan, Taiwan.
   [Lee, Jenq-Chang] Natl Cheng Kung Univ Hosp, Dept Surg, Coll Med, Tainan, Taiwan.
   [Lin, Pei-Wen; Chu, Man-Ling; Liu, Hsiao-Sheng] Kaohsiung Med Univ, Coll Med, Grad Inst Clin Med, Ctr Canc Res, Kaohsiung, Taiwan.
   [Zuchini, Roberto] Hosp Ctr Med, Dept Gastroenterol, Guatemala City, Guatemala.
   [Liu, Hsiao-Sheng] Kaohsiung Med Univ, Coll Med, Master Sci Program Trop Med, Kaohsiung, Taiwan.
   [Wu, Shan-Ying] Taipei Med Univ, Dept Microbiol & Immunol, Coll Med, Taipei, Taiwan.
   [Wu, Shan-Ying] Taipei Med Univ, Coll Med, Grad Inst Med Sci, Taipei, Taiwan.
RP Liu, HS (corresponding author), Natl Cheng Kung Univ, Dept Microbiol & Immunol, Coll Med, Tainan, Taiwan.; Liu, HS (corresponding author), Kaohsiung Med Univ, Coll Med, Grad Inst Clin Med, Ctr Canc Res, Kaohsiung, Taiwan.; Liu, HS (corresponding author), Kaohsiung Med Univ, Coll Med, Master Sci Program Trop Med, Kaohsiung, Taiwan.; Wu, SY (corresponding author), Taipei Med Univ, Dept Microbiol & Immunol, Coll Med, Taipei, Taiwan.; Wu, SY (corresponding author), Taipei Med Univ, Coll Med, Grad Inst Med Sci, Taipei, Taiwan.
EM hsliu713@kmu.edu.tw; shanyingwu@tmu.edu.tw
OI Wu, Shan-Ying/0000-0003-2380-5760
FU Ministry of Science and Technology, Taiwan, R.O.C.Ministry of Science
   and Technology, Taiwan [MOST 109-2314-B-038-119-MY2, MOST
   104-2320-B-006-021-MY3]; Taipei Medical University [TMU108-AE1-B39];
   Ministry of Health and WelfareMinistry of Health, Labour and Welfare,
   Japan [MOHW 106-TDU-B-211-124-003]; Kaohsiung Medical University
   Research Center Grant [KMU-TC108A04-0, KMU-TC108A04-2, KMU-TC109A04-1]
FX This study was supported by the grants from the Ministry of Science and
   Technology, Taiwan, R.O.C. (MOST 109-2314-B-038-119-MY2 to S-YW; MOST
   104-2320-B-006-021-MY3 to H-SL), Taipei Medical University
   (TMU108-AE1-B39 to S-YW), Ministry of Health and Welfare (MOHW
   106-TDU-B-211-124-003 to H-SL) and Kaohsiung Medical University Research
   Center Grant (KMU-TC108A04-0, KMU-TC108A04-2, and KMU-TC109A04-1 to
   H-SL).
CR An CH, 2011, PATHOL RES PRACT, V207, P433, DOI 10.1016/j.prp.2011.05.002
   Balgi AD, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007124
   Chandrashekar DS, 2017, NEOPLASIA, V19, P649, DOI 10.1016/j.neo.2017.05.002
   Chen JH, 2007, EPIGENETICS-US, V2, P92, DOI 10.4161/epi.2.2.4326
   Choi JH, 2014, GASTROENT RES PRACT, V2014, DOI 10.1155/2014/179586
   Chu CA, 2019, EBIOMEDICINE, V43, P270, DOI 10.1016/j.ebiom.2019.04.010
   Deng XS, 2021, CLIN LAB, V67, P738, DOI 10.7754/Clin.Lab.2020.200628
   Deretic V, 2012, TRENDS CELL BIOL, V22, P397, DOI 10.1016/j.tcb.2012.04.008
   Feng Y, 2018, ONCOL REP, V40, P1684, DOI 10.3892/or.2018.6566
   Foerster EG, 2022, AUTOPHAGY, V18, P86, DOI 10.1080/15548627.2021.1909406
   Frankel LB, 2012, CARCINOGENESIS, V33, P2018, DOI 10.1093/carcin/bgs266
   Fu DK, 2021, MEDICINE, V100, DOI 10.1097/MD.0000000000025022
   Grimm WA, 2016, GUT, V65, P456, DOI 10.1136/gutjnl-2014-308735
   Ishihama K, 2007, J CLIN PATHOL, V60, P1205, DOI 10.1136/jcp.2005.029165
   Jacomin AC, 2016, AUTOPHAGY, V12, P1945, DOI 10.1080/15548627.2016.1207016
   Jiramongkol Y, 2020, CANCER METAST REV, V39, P681, DOI 10.1007/s10555-020-09883-w
   Kheir TB, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-29
   Kim YH, 2021, AUTOPHAGY, V17, P2345, DOI 10.1080/15548627.2020.1826690
   Klotz LO, 2015, REDOX BIOL, V6, P51, DOI 10.1016/j.redox.2015.06.019
   Komatsu M, 2007, CELL, V131, P1149, DOI 10.1016/j.cell.2007.10.035
   Lan SH, 2014, HEPATOLOGY, V59, P505, DOI 10.1002/hep.26659
   Li L, 2018, ONCOL RES, V26, P547, DOI 10.3727/096504017X15016337254605
   Li XD, 2021, EXP THER MED, V22, DOI 10.3892/etm.2021.10139
   Li YQ, 2008, LAB INVEST, V88, P98, DOI 10.1038/labinvest.3700702
   Liang C, 2006, NAT CELL BIOL, V8, P688, DOI 10.1038/ncb1426
   Lin AY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016636
   McFadyen MCE, 2004, MOL CANCER THER, V3, P363
   Montalto FI, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9122648
   Naderi T, 2020, IRAN J BASIC MED SCI, V23, P376, DOI 10.22038/IJBMS.2019.40695.9615
   Niki M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-10500-0
   Noonan EJ, 2009, ONCOGENE, V28, P1714, DOI 10.1038/onc.2009.19
   Olaru AV, 2013, INFLAMM BOWEL DIS, V19, P471, DOI 10.1097/MIB.0b013e31827e78eb
   Ozsolak F, 2008, GENE DEV, V22, P3172, DOI 10.1101/gad.1706508
   Rana T, 2021, MOL NEUROBIOL, V58, P4886, DOI 10.1007/s12035-021-02472-0
   Saha S, 2018, BIOMED PHARMACOTHER, V104, P485, DOI 10.1016/j.biopha.2018.05.007
   Sun XH, 2017, ONCOTARGET, V8, P100975, DOI 10.18632/oncotarget.10900
   Sung HH, 2022, CLIN EXP HYPERTENS, V44, P146, DOI 10.1080/10641963.2021.2007943
   Tseng YS, 2006, CANCER LETT, V241, P93, DOI 10.1016/j.canlet.2005.10.014
   Wu SY, 2019, AUTOPHAGY, V15, P729, DOI 10.1080/15548627.2019.1569918
   Wu SY, 2018, HEPATOLOGY, V68, P141, DOI 10.1002/hep.29781
   Wu SY, 2011, NEOPLASIA, V13, P1171, DOI 10.1593/neo.11888
   Wu XH, 2020, J COMPUT BIOL, V27, P834, DOI 10.1089/cmb.2019.0215
   Xing HL, 2014, BMC PLANT BIOL, V14, DOI 10.1186/s12870-014-0327-y
   Zhang XP, 2019, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00802
   Zhao Y, 2010, NAT CELL BIOL, V12, P665, DOI 10.1038/ncb2069
   Zheng XX, 2021, CANCER LETT, V497, P190, DOI 10.1016/j.canlet.2020.10.009
   Zhou KC, 2017, FRONT MOL BIOSCI, V4, DOI 10.3389/fmolb.2017.00046
NR 47
TC 0
Z9 0
U1 3
U2 3
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2234-943X
J9 FRONT ONCOL
JI Front. Oncol.
PD OCT 19
PY 2021
VL 11
AR 738144
DI 10.3389/fonc.2021.738144
PG 13
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA WT4DP
UT WOS:000715816900001
PM 34737955
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Sun, SY
   Hu, XT
   Yu, XF
   Zhang, YY
   Liu, XH
   Liu, YH
   Wu, SH
   Li, YY
   Cui, SX
   Qu, XJ
AF Sun, Shi-Yue
   Hu, Xue-Tao
   Yu, Xin-Feng
   Zhang, Yue-Ying
   Liu, Xiao-Hui
   Liu, Yuan-Hang
   Wu, Shu-Hua
   Li, Yang-Yang
   Cui, Shu-Xiang
   Qu, Xian-Jun
TI Nuclear translocation of ATG5 induces DNA mismatch repair deficiency
   (MMR-D)/microsatellite instability (MSI) via interacting with Mis18
   alpha in colorectal cancer
SO BRITISH JOURNAL OF PHARMACOLOGY
LA English
DT Article
DE 5-FU resistance; colorectal cancer; hypermethylation of MLH1 promoter
   CpG island; Mis18a; MMR-D/MSI; nuclear translocation of ATG5
ID REVISED BETHESDA GUIDELINES; MICROSATELLITE INSTABILITY; CENTROMERIC
   CHROMATIN; LIVER METASTASES; AUTOPHAGY; EXPRESSION; THERAPY; CARCINOMAS;
   MANAGEMENT; ADJUVANT
AB Background and Purpose It is well known that microsatellite instability-high (MSI-H) is associated with 5-fluorouracil (5-FU) resistance in colorectal cancer. MSI-H is the phenotype of DNA mismatch repair deficiency (MMR-D), mainly occurring due to hypermethylation of MLH1 promoter CpG island. However, the mechanisms of MMR-D/MSI-H are unclear. We aim to investigate the pathway of MMR-D/MSI-H involved in 5-FU resistance.
   Experimental Approach Human colorectal cancer specimens were diagnosed for MSI-H by immunohistochemistry and western blotting. Proteome microarray interactome assay was performed to screen nuclear proteins interacting with ATG5. Nuclear ATG5 and ATG5-Mis18 alpha overexpression were analysed in ATG5(high) colorectal cancer bearing mice. The methylation assay determined the hypermethylation of hMLH1 promoter CpG island in freshly isolated human colorectal cancer tissue samples and HT29(atg5) and SW480(atg5) cancer cells.
   Key Results In ATG5(high) colorectal cancer patients, 5-FU-based therapy resulted in nuclear translocation of ATG5, leading to MSI-H. Colorectal cancer in Atg5 Tg mice demonstrated 5-FU resistance, compared to Atg5(+/-) and WT mice. Proteome microarray assay identified Mis18 alpha, a protein localized on the centromere and a source for methylation of the underlying chromatin, which responded to the translocated nuclear ATG5 leading to ATG5-Mis18 alpha conjugate overexpression. This resulted in MLH1 deficiency due to hypermethylation of hMLH1 promoter CpG island, while the deletion of nuclear Mis18 alpha failed to induce ATG5-Mis18 alpha complex and MMR-D/MSI-H.
   Conclusions and Implications Nuclear ATG5 resulted in MMR-D/MSI-H through its interaction with Mis18 alpha in ATG5(high) colorectal cancer cells. We suggest that ATG5-Mis18 alpha or Mis18 alpha may be a therapeutic target for treating colorectal cancer.
C1 [Sun, Shi-Yue; Hu, Xue-Tao; Yu, Xin-Feng; Liu, Xiao-Hui; Qu, Xian-Jun] Capital Med Univ, Sch Basic Med Sci, Dept Pharmacol, Beijing, Peoples R China.
   [Sun, Shi-Yue] China Acad Chinese Med Sci, Inst Acu Moxibust, Beijing, Peoples R China.
   [Zhang, Yue-Ying] Shandong First Med Univ & Shandong Acad Med Sci, Dept Expt Pathol, Coll Basic Med Sci, Jinan, Peoples R China.
   [Liu, Yuan-Hang; Wu, Shu-Hua; Li, Yang-Yang] Hosp Bin Zhou Med Coll, Dept Pathol, Binzhou, Peoples R China.
   [Cui, Shu-Xiang] Capital Med Univ, Sch Publ Hlth, Toxicol & Sanit Chem, Beijing, Peoples R China.
RP Qu, XJ (corresponding author), Capital Med Univ, Sch Basic Med Sci, Dept Pharmacol, Beijing, Peoples R China.; Cui, SX (corresponding author), Capital Med Univ, Sch Publ Hlth, Toxicol & Sanit Chem, Beijing, Peoples R China.
EM sxccui@ccmu.edu.cn; qxj@ccmu.edu.cn
FU Beijing Municipal Commission of EducationBeijing Municipal Commission of
   Education [KZ201810025033]; National Natural Science Foundation of
   ChinaNational Natural Science Foundation of China (NSFC) [81872884,
   81973350]; Natural Science Foundation of Beijing MunicipalityBeijing
   Natural Science Foundation
FX Beijing Municipal Commission of Education, Grant/Award Number:
   KZ201810025033; National Natural Science Foundation of China,
   Grant/Award Numbers: 81872884, 81973350; Natural Science Foundation of
   Beijing Municipality
CR Achilli P, 2021, INT J CANCER, V148, P161, DOI 10.1002/ijc.33203
   Alexander SPH, 2019, BRIT J PHARMACOL, V176, pS229, DOI 10.1111/bph.14750
   Alexander SPH, 2018, BRIT J PHARMACOL, V175, P407, DOI 10.1111/bph.14112
   An CH, 2005, CLIN CANCER RES, V11, P656
   Ashktorab H, 2005, INT J CANCER, V116, P914, DOI 10.1002/ijc.21062
   Barchitta M, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20153842
   Baretti M, 2018, CLIN COLORECTAL CANC, V17, pE489, DOI 10.1016/j.clcc.2018.03.010
   Bayraktar S, 2010, CLIN COLORECTAL CANC, V9, P144, DOI 10.3816/CCC.2010.n.019
   Benatti P, 2005, CLIN CANCER RES, V11, P8332, DOI 10.1158/1078-0432.CCR-05-1030
   Chen LZ, 2019, INT J CLIN EXP PATHO, V12, P3685
   Chen Y, 2013, MOL CELL PROTEOMICS, V12, P2804, DOI 10.1074/mcp.M112.025882
   Curtis MJ, 2018, BRIT J PHARMACOL, V175, P987, DOI 10.1111/bph.14153
   Dawicki-McKenna JM, 2019, CURR BIOL, V29, pR35, DOI 10.1016/j.cub.2018.11.044
   Devis-Jauregui L, 2021, AUTOPHAGY, V17, P1077, DOI 10.1080/15548627.2020.1752548
   Duldulao MP, 2012, J SURG RES, V174, P1, DOI 10.1016/j.jss.2011.06.016
   French BT, 2017, DEV CELL, V42, P190, DOI 10.1016/j.devcel.2017.06.021
   Gallois C, 2018, CLIN CANCER RES, V24, P4745, DOI 10.1158/1078-0432.CCR-18-0866
   Geng J, 2019, BRIT J PHARMACOL, V176, P4574, DOI 10.1111/bph.14823
   Gerada C, 2020, MOL ONCOL, V14, P1913, DOI 10.1002/1878-0261.12774
   Giansanti V, 2011, APOPTOSIS, V16, P321, DOI 10.1007/s10495-011-0589-x
   Gil J, 2016, BIOMARK MED, V10, P1081, DOI 10.2217/bmm-2016-0083
   Gologan A, 2005, ARCH PATHOL LAB MED, V129, P1390
   Gomes A, 2014, REV PORT PNEUMOL, V20, P20, DOI 10.1016/j.rppneu.2013.07.003
   Gonzalez-Garcia I, 2000, JNCI-J NATL CANCER I, V92, P544, DOI 10.1093/jnci/92.7.544
   Kawakami H, 2015, J GASTROINTEST ONCOL, V6, P676, DOI 10.3978/j.issn.2078-6891.2015.065
   Kawakami H, 2015, CURR TREAT OPTION ON, V16, DOI 10.1007/s11864-015-0348-2
   Kim IS, 2012, MOL CELL, V46, P260, DOI 10.1016/j.molcel.2012.03.021
   Kuma A, 2004, NATURE, V432, P1032, DOI 10.1038/nature03029
   Lee M, 2018, ONCOTARGET, V9, P1563, DOI 10.18632/oncotarget.22707
   Li XY, 2019, BIOMED PHARMACOTHER, V119, DOI 10.1016/j.biopha.2019.109415
   Lilley E, 2020, BRIT J PHARMACOL, V177, P3611, DOI 10.1111/bph.15178
   Lin L, 2015, MOL CELL ONCOL, V2, DOI 10.4161/23723556.2014.985913
   Lin TY, 2020, AUTOPHAGY, V16, P1296, DOI 10.1080/15548627.2019.1671643
   Lindqvist LM, 2015, CELL DEATH DISCOV, V1, DOI 10.1038/cddiscovery.2015.36
   Maskey D, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3130
   Matsubara N, 2004, DIS MARKERS, V20, P277, DOI 10.1155/2004/371941
   Morak M, 2018, J MED GENET, V55, P240, DOI 10.1136/jmedgenet-2017-104744
   Nardi IK, 2016, MOL CELL, V61, P774, DOI 10.1016/j.molcel.2016.02.014
   Nasti G, 2013, BRIT J CANCER, V108, P1566, DOI 10.1038/bjc.2013.140
   Pan DQ, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12019-6
   Park KC, 2017, J INVEST DERMATOL, V137, P414, DOI 10.1016/j.jid.2016.09.012
   du Sert NP, 2020, J PHYSIOL-LONDON, V598, P3793, DOI [10.1113/EP088870, 10.1371/journal.pbio.3000411, 10.1113/JP280389, 10.1111/bph.15193, 10.1177/0271678X20943823, 10.1371/journal.pbio.3000410, 10.1186/s12917-020-02451-y]
   Pyo JO, 2005, J BIOL CHEM, V280, P20722, DOI 10.1074/jbc.M413934200
   Pyo JO, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3300
   Sargent DJ, 2010, J CLIN ONCOL, V28, P3219, DOI 10.1200/JCO.2009.27.1825
   Sekhon BK, 2008, ASSAY DRUG DEV TECHN, V6, P711, DOI 10.1089/adt.2008.148
   Simon HU, 2014, AUTOPHAGY, V10, P176, DOI 10.4161/auto.26916
   Sinicrope FA, 2006, GASTROENTEROLOGY, V131, P729, DOI 10.1053/j.gastro.2006.06.005
   Sinicrope FA, 2015, GASTROENTEROLOGY, V148, P88, DOI 10.1053/j.gastro.2014.09.041
   Song HY, 2020, MOL CANCER THER, V19, P258, DOI 10.1158/1535-7163.MCT-19-0600
   Song ZY, 2019, ONCOGENE, V38, P1560, DOI 10.1038/s41388-018-0519-2
   Sun CC, 2014, PATHOL RES PRACT, V210, P668, DOI 10.1016/j.prp.2014.06.016
   Tang JC, 2016, CHINESE MED J-PEKING, V129, P456, DOI 10.4103/0366-6999.176069
   Terdiman JP, 2001, GASTROENTEROLOGY, V120, P21, DOI 10.1053/gast.2001.20874
   TRAINER DL, 1988, INT J CANCER, V41, P287, DOI 10.1002/ijc.2910410221
   Umar A, 2004, J NATL CANCER I, V96, P261, DOI 10.1093/jnci/djh034
   Vilar E, 2010, NAT REV CLIN ONCOL, V7, P153, DOI 10.1038/nrclinonc.2009.237
   Wang L, 2015, CANCER BIOL THER, V16, P383, DOI 10.1080/15384047.2014.1002331
   Zeinalian Mehrdad, 2018, Adv Biomed Res, V7, P28, DOI 10.4103/abr.abr_185_16
   Zhang YH, 2020, PHARMACOL RES, V155, DOI 10.1016/j.phrs.2020.104717
   Zhang YM, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000008242
NR 61
TC 2
Z9 2
U1 1
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0007-1188
EI 1476-5381
J9 BRIT J PHARMACOL
JI Br. J. Pharmacol.
PD JUN
PY 2021
VL 178
IS 11
BP 2351
EP 2369
DI 10.1111/bph.15422
EA APR 2021
PG 19
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA SB9SU
UT WOS:000645256900001
PM 33645631
DA 2022-04-25
ER

PT J
AU Rathore, B
   Sunwoo, K
   Jangili, P
   Kim, J
   Kim, JH
   Huang, MN
   Xiong, J
   Sharma, A
   Yang, ZG
   Qu, JL
   Kim, JS
AF Rathore, Bhowmira
   Sunwoo, Kyoung
   Jangili, Paramesh
   Kim, Jiseon
   Kim, Ji Hyeon
   Huang, Meina
   Xiong, Jia
   Sharma, Amit
   Yang, Zhigang
   Qu, Junle
   Kim, Jong Seung
TI Nanomaterial designing strategies related to cell lysosome and their
   biomedical applications: A review
SO BIOMATERIALS
LA English
DT Review
DE Lyososome; Nanomaterial; Diagnosis; Therapeutics;
   Endocytosis/non-endocyotic; Autophagy
ID NANOPARTICLES INDUCE AUTOPHAGY; COLORECTAL-CANCER CELLS; WALLED CARBON
   NANOTUBES; TARGETED DRUG-DELIVERY; MEMBRANE PERMEABILIZATION; DEATH;
   IMPAIRMENT; MECHANISM; PEPTIDES; GRAPHENE
AB Lysosomes, an important organelle of eukaryotic cells, are covered with the cell membrane and contain an array of degradative enzymes. The disrupt in lysosomal functions may lead to the development of severe diseases. In nanotechnology, nanomaterials working mechanism and its biomedical output are highly dependent on the lysosomes as it plays a crucial role in intracellular transport. Several nanomaterials specifically designed for lysosome-related actions are highly advantageous in trafficking and delivering the loaded imaging/therapeutic agents. But for other applications, especially gene-based therapeutic delivery into the sub-organelles such as mitochondria and nucleus, lysosomal related degradation could be an obstacle to achieve a maximal therapeutic index. In order to understand the relationship between lysosomes and designed nanomaterials for kind of desired application in biomedical research, complete knowledge of their various designing strategies, size dependent or ligand supportive cellular uptake mechanisms, trafficking, and localizations in eukaryotic cells is highly desired. In this review, we intended to discuss various nanomaterial types that have been applied in biomedical applications based on lysosomal internalization and escape from endo/lysosomes and explored their related advantages/disadvantages. Additionally, we also deliberated nanomaterials direct translocation mechanism, their autophagic accumulation and the underlying mechanism to induced autophagy. Finally, some challenges and critical issues in current research from clinical application perspective has also been addressed. Great understanding of these factors will help in understanding and facilitating the development of safe and effective lysosomal related nanomaterial-based imaging/therapeutic systems for future applications.
C1 [Rathore, Bhowmira; Huang, Meina; Xiong, Jia; Yang, Zhigang; Qu, Junle] Shenzhen Univ, Coll Phys & Optoelect Engn, Minist Educ & Guangdong Prov, Key Lab Optoelect Devices & Syst, Shenzhen 518060, Peoples R China.
   [Sunwoo, Kyoung; Jangili, Paramesh; Kim, Jiseon; Kim, Ji Hyeon; Sharma, Amit; Kim, Jong Seung] Korea Univ, Dept Chem, Seoul 02841, South Korea.
RP Yang, ZG; Qu, JL (corresponding author), Shenzhen Univ, Coll Phys & Optoelect Engn, Minist Educ & Guangdong Prov, Key Lab Optoelect Devices & Syst, Shenzhen 518060, Peoples R China.; Sharma, A; Kim, JS (corresponding author), Korea Univ, Dept Chem, Seoul 02841, South Korea.
EM amitorg83@gmail.com; zhgyang@szu.edu.cn; jlqu@szu.edu.cn;
   jongskim@korea.ac.kr
RI Jangili, Paramesh/AAA-4652-2022; Sessler, Jonathan/AAY-7091-2021; Kim,
   Jong Seung/N-4504-2015; Sharma, Amit/F-7316-2018
OI Kim, Jong Seung/0000-0003-3477-1172; Sharma, Amit/0000-0003-2815-8208;
   PARAMESH, JANGILI/0000-0003-4220-8443; Sunwoo,
   Kyoung/0000-0003-0041-5022
FU National Research Foundation of KoreaNational Research Foundation of
   Korea [CRI 2018R1A3B1052702]; National Natural Science Foundation of
   ChinaNational Natural Science Foundation of China (NSFC)
   [61875131/61525503/61620106016/61835009/81727804]; National Basic
   Research Program of ChinaNational Basic Research Program of China
   [2015CB352005]; Guangdong Natural Science Foundation Innovation Team
   [2014A030312008]; National Key R&D Program of China [2017YFA0700500];
   Guangdong Province [2015KGJHZ002/2016KCXTD007]; Shenzhen Basic Research
   Project
   [JCYJ20170818100931714/JCYJ20150930104948169/JCYJ20160328144746940/JCYJ2
   0170412105003520]
FX This work was collaboratory supported by the National Research
   Foundation of Korea (CRI 2018R1A3B1052702, J.S.K); the National Natural
   Science Foundation of China
   (61875131/61525503/61620106016/61835009/81727804); the National Basic
   Research Program of China (2015CB352005); Guangdong Natural Science
   Foundation Innovation Team (2014A030312008); the National Key R&D
   Program of China (2017YFA0700500); Guangdong Province
   (2015KGJHZ002/2016KCXTD007) and Shenzhen Basic Research Project
   (JCYJ20170818100931714/JCYJ20150930104948169/JCYJ20160328144746940/JCYJ2
   0170412105003520).
CR Aluri R, 2018, BIOMACROMOLECULES, V19, P2166, DOI 10.1021/acs.biomac.8b00334
   Anozie UC, 2017, ADV DRUG DELIVER REV, V122, P65, DOI 10.1016/j.addr.2017.01.001
   Cerda MB, 2015, RSC ADV, V5, P58345, DOI 10.1039/c5ra06562c
   Berger E., 2017, NANOBIOMEDICINE, V4, P1
   Blanco E, 2015, NAT BIOTECHNOL, V33, P941, DOI 10.1038/nbt.3330
   Bossi E, 2016, SCI REP-UK, V6, DOI 10.1038/srep22254
   Bourdenx M, 2016, AUTOPHAGY, V12, P472, DOI 10.1080/15548627.2015.1136769
   Boya P, 2008, ONCOGENE, V27, P6434, DOI 10.1038/onc.2008.310
   Breunig M, 2008, EUR J PHARM BIOPHARM, V68, P112, DOI 10.1016/j.ejpb.2007.06.010
   Brunetti-Pierri N, 2008, MOL GENET METAB, V94, P391, DOI 10.1016/j.ymgme.2008.04.012
   Chen GJ, 2017, J CONTROL RELEASE, V259, P105, DOI 10.1016/j.jconrel.2017.01.042
   Chen J, 2016, J COLLOID INTERF SCI, V484, P298, DOI 10.1016/j.jcis.2016.09.009
   Chen LJ, 2015, NANOSCALE, V7, P14080, DOI 10.1039/c5nr03527a
   Chen XM, 2018, ANGEW CHEM INT EDIT, V57, P12519, DOI 10.1002/anie.201807373
   Cheng W, 2017, NANOSCALE, V9, P17063, DOI 10.1039/c7nr05450e
   Clerc P, 2018, J CONTROL RELEASE, V270, P120, DOI 10.1016/j.jconrel.2017.11.050
   Cohignac V, 2018, AUTOPHAGY, V14, P1323, DOI 10.1080/15548627.2018.1474993
   Derivery E, 2017, J AM CHEM SOC, V139, P10172, DOI 10.1021/jacs.7b02952
   Ding L, 2017, NANO LETT, V17, P6790, DOI 10.1021/acs.nanolett.7b03021
   Donida B, 2018, EUR J PHARM BIOPHARM, V133, P96, DOI 10.1016/j.ejpb.2018.10.005
   Duan JC, 2014, INT J NANOMED, V9, P5131, DOI 10.2147/IJN.S71074
   Frohlich E, 2013, CURR DRUG METAB, V14, P976
   Futerman AH, 2004, NAT REV MOL CELL BIO, V5, P554, DOI 10.1038/nrm1423
   Gangopadhyay M, 2016, J MATER CHEM B, V4, P1862, DOI 10.1039/c5tb02563j
   Gao W, 2014, CHEM COMMUN, V50, P8117, DOI 10.1039/c4cc03793f
   Ge K, 2016, RSC ADV, V6, P21725, DOI 10.1039/c6ra01625a
   Ghosh S, 2019, ACS APPL BIO MATER, V2, P339, DOI 10.1021/acsabm.8b00617
   Glick D, 2010, J PATHOL, V221, P3, DOI 10.1002/path.2697
   Guo S, 2011, J NANOMATER, V2011, P11
   Gupta M, 2017, ACS OMEGA, V2, P9002, DOI 10.1021/acsomega.7b01230
   Herce HD, 2014, J AM CHEM SOC, V136, P17459, DOI 10.1021/ja507790z
   Hong XQ, 2018, ORG BIOMOL CHEM, V16, P8025, DOI 10.1039/c8ob01957f
   Hu WB, 2016, ACS APPL MATER INTER, V8, P12039, DOI 10.1021/acsami.6b02721
   Huang YP, 2017, MAT SCI ENG C-MATER, V70, P763, DOI 10.1016/j.msec.2016.09.052
   Jaattela M, 2004, ONCOGENE, V23, P2746, DOI 10.1038/sj.onc.1207513
   Jiang Y., 2015, ANGEW CHEM, V127, P516
   Joris F, 2018, J CONTROL RELEASE, V269, P266, DOI 10.1016/j.jconrel.2017.11.019
   Ju EG, 2016, CHEM COMMUN, V52, P12598, DOI 10.1039/c6cc06467a
   Leanza L, 2013, FRONT PHYSIOL, V4, DOI 10.3389/fphys.2013.00227
   Lee H, 2015, ACS NANO, V9, P9859, DOI 10.1021/acsnano.5b05138
   Lee MH, 2018, CHEM SOC REV, V47, P28, DOI 10.1039/c7cs00557a
   Li H, 2018, CHEM COMMUN, V54, P3520, DOI [10.1039/C8CC00440D, 10.1039/c8cc00440d]
   Li JM, 2016, J MATER CHEM B, V4, P6620, DOI 10.1039/c6tb01462c
   Li LJ, 2017, NANOSCALE, V9, P314, DOI 10.1039/c6nr07004c
   Li ZH, 2017, DRUG DELIV, V24, P45, DOI 10.1080/10717544.2017.1391889
   Lim EK, 2015, CHEM REV, V115, P327, DOI 10.1021/cr300213b
   Lin JQ, 2013, ACS NANO, V7, P10799, DOI 10.1021/nn4040553
   Liu J, 2017, INT J NANOMED, V12, P8085, DOI 10.2147/IJN.S149070
   Manthe R, 2014, HDB NANOBIOMEDICAL R, V2, P261
   Mirshafiee V, 2018, ACS NANO, V12, P3836, DOI 10.1021/acsnano.8b01086
   Mizushima N, 2007, GENE DEV, V21, P2861, DOI 10.1101/gad.1599207
   Montet X, 2006, J MED CHEM, V49, P6087, DOI 10.1021/jm060515m
   Mrschtik M, 2015, FEBS J, V282, P1858, DOI 10.1111/febs.13253
   Muro S, 2012, DRUG DELIV TRANSL RE, V2, P169, DOI 10.1007/s13346-012-0072-4
   Muro S, 2012, J CONTROL RELEASE, V164, P125, DOI 10.1016/j.jconrel.2012.05.052
   Nakamura S, 2017, J CELL SCI, V130, P1209, DOI 10.1242/jcs.196352
   Parenti G, 2013, INT J MOL MED, V31, P11, DOI 10.3892/ijmm.2012.1187
   Platt FM, 2012, J CELL BIOL, V199, P723, DOI 10.1083/jcb.201208152
   Pramanik SK, 2017, CHEM COMMUN, V53, P12672, DOI 10.1039/c7cc08185e
   Repnik U, 2014, MITOCHONDRION, V19, P49, DOI 10.1016/j.mito.2014.06.006
   Rettig GR, 2007, EXPERT OPIN BIOL TH, V7, P799, DOI 10.1517/14712598.7.6.799
   Rothbard JB, 2004, J AM CHEM SOC, V126, P9506, DOI 10.1021/ja0482536
   Sanchez C, 2014, ACS NANO, V8, P1350, DOI 10.1021/nn404954s
   Serrano-Puebla A, 2018, BIOCHEM SOC T, V46, P207, DOI 10.1042/BST20170130
   Sharma A, 2019, CHEM SOC REV, V48, P771, DOI 10.1039/c8cs00304a
   Sharma A, 2018, CHEM-US, V4, P2370, DOI 10.1016/j.chempr.2018.08.002
   Shen SL, 2018, SENSOR ACTUAT B-CHEM, V256, P261, DOI 10.1016/j.snb.2017.10.103
   Tao W., 2017, ADV MATER, V29
   Tao W, 2018, ADV MATER, V30, DOI 10.1002/adma.201802061
   Trudeau KM, 2016, J CELL BIOL, V214, P25, DOI 10.1083/jcb.201511042
   Walrant A, 2017, ACCOUNTS CHEM RES, V50, P2968, DOI 10.1021/acs.accounts.7b00455
   Wan B, 2013, TOXICOL LETT, V221, P118, DOI 10.1016/j.toxlet.2013.06.208
   Wang FJ, 2018, TRAFFIC, V19, P918, DOI 10.1111/tra.12613
   Wang J, 2017, INT J NANOMED, V12, P809, DOI 10.2147/IJN.S123596
   Wang Q., 2018, ADV FUNCT MATER, V28
   Wei YF, 2009, BIOCONJUGATE CHEM, V20, P1752, DOI 10.1021/bc8003777
   Wilczewska AZ, 2012, PHARMACOL REP, V64, P1020, DOI 10.1016/S1734-1140(12)70901-5
   Wu JL, 2016, RSC ADV, V6, P69083, DOI 10.1039/c6ra04219h
   Wu JC, 2017, BIOMATERIALS, V120, P1, DOI 10.1016/j.biomaterials.2016.11.011
   Wu XM, 2014, J AM CHEM SOC, V136, P3579, DOI 10.1021/ja412380j
   Xiang HJ, 2016, CHEM COMMUN, V52, P148, DOI 10.1039/c5cc07006f
   Xue SS, 2017, CHEM COMMUN, V53, P842, DOI 10.1039/c6cc08296c
   Xue X, 2014, NANO LETT, V14, P5110, DOI 10.1021/nl501839q
   Yang K, 2013, CHEM SOC REV, V42, P530, DOI 10.1039/c2cs35342c
   Yu HJ, 2017, SENSOR ACTUAT B-CHEM, V252, P313, DOI 10.1016/j.snb.2017.05.164
   Yu YB, 2014, J HAZARD MATER, V270, P176, DOI 10.1016/j.jhazmat.2014.01.028
   Yuan XX, 2018, ACS APPL BIO MATER, V1, P511, DOI 10.1021/acsabm.8b00238
   Yuan YY, 2015, ANGEW CHEM INT EDIT, V54, P11419, DOI 10.1002/anie.201503640
   Zamore PD, 2000, CELL, V101, P25, DOI 10.1016/S0092-8674(00)80620-0
   Zeng LL, 2017, CHEM SOC REV, V46, P5771, DOI 10.1039/c7cs00195a
   Zeng YP, 2015, RSC ADV, V5, P57725, DOI 10.1039/c5ra07535a
   Zhang L, 2018, RSC ADV, V8, P4130, DOI 10.1039/c7ra11400a
   Zhou HL, 2018, J MATER CHEM B, V6, P8127, DOI 10.1039/c8tb02390e
   Zhou LJ, 2017, THERANOSTICS, V7, P764, DOI 10.7150/thno.15757
   Zhu XB, 2018, ACS NANO, V12, P2922, DOI 10.1021/acsnano.8b00516
NR 95
TC 46
Z9 47
U1 19
U2 188
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0142-9612
EI 1878-5905
J9 BIOMATERIALS
JI Biomaterials
PD AUG
PY 2019
VL 211
BP 25
EP 47
DI 10.1016/j.biomaterials.2019.05.002
PG 23
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Engineering; Materials Science
GA IC4NH
UT WOS:000470942100003
PM 31078050
DA 2022-04-25
ER

PT J
AU Kaneko, M
   Nozawa, H
   Hiyoshi, M
   Tada, N
   Murono, K
   Nirei, T
   Emoto, S
   Kishikawa, J
   Iida, Y
   Sunami, E
   Tsuno, NH
   Kitayama, J
   Takahashi, K
   Watanabe, T
AF Kaneko, Manabu
   Nozawa, Hiroaki
   Hiyoshi, Masaya
   Tada, Noriko
   Murono, Koji
   Nirei, Takako
   Emoto, Shigenobu
   Kishikawa, Junko
   Iida, Yuuki
   Sunami, Eiji
   Tsuno, Nelson H.
   Kitayama, Joji
   Takahashi, Koki
   Watanabe, Toshiaki
TI Temsirolimus and chloroquine cooperatively exhibit a potent antitumor
   effect against colorectal cancer cells
SO JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
LA English
DT Article
DE Temsirolimus; Chloroquine; Colorectal cancer; mTOR; Autophagy;
   Angiogenesis
ID HISTONE DEACETYLASE INHIBITOR; CHRONIC LYMPHOCYTIC-LEUKEMIA; MALIGNANT
   GLIOMA-CELLS; MAMMALIAN TARGET; RAD001 EVEROLIMUS; INDUCED APOPTOSIS;
   INDUCED AUTOPHAGY; MTOR INHIBITORS; RAPAMYCIN; GROWTH
AB Temsirolimus (TEM) is a novel, water-soluble mammalian target of rapamycin (mTOR) inhibitor that has shown activity against a wide range of cancers in preclinical models, but its efficacy against colorectal cancer (CRC) has not been fully explored.
   We evaluated the antitumor effect of TEM in CRC cell lines (CaR-1, HT-29, Colon26) in vitro and in vivo. In vitro, cell growth inhibition was assessed using a MTS assay. Apoptosis induction and cell cycle effects were measured using flow cytometry. Modulation of mTOR signaling was measured using immunoblotting. Antitumor activity as a single agent was evaluated in a mouse subcutaneous tumor model of CRC. The effects of adding chloroquine, an autophagy inhibitor, to TEM were evaluated in vitro and in vivo.
   In vitro, TEM was effective in inhibiting the growth of two CRC cell lines with highly activated AKT, possibly through the induction of G1 cell cycle arrest via a reduction in cyclin D1 expression, whereas TEM reduced HIF-1 alpha and VEGF in all three cell lines. In a mouse subcutaneous tumor model, TEM inhibited the growth of tumors in all cell lines, not only through direct growth inhibition but also via an anti-angiogenic effect. We also explored the effects of adding chloroquine, an autophagy inhibitor, to TEM. Chloroquine significantly potentiated the antitumor activity of TEM in vitro and in vivo. Moreover, the combination therapy triggered enhanced apoptosis, which corresponded to an increased Bax/Bcl-2 ratio.
   Based on these data, we propose TEM with or without chloroquine as a new treatment option for CRC.
C1 [Kaneko, Manabu; Nozawa, Hiroaki; Hiyoshi, Masaya; Tada, Noriko; Murono, Koji; Nirei, Takako; Emoto, Shigenobu; Kishikawa, Junko; Iida, Yuuki; Sunami, Eiji; Kitayama, Joji; Watanabe, Toshiaki] Univ Tokyo, Dept Surg Oncol, Fac Med, Bunkyo Ku, Tokyo 1138655, Japan.
   [Tsuno, Nelson H.; Takahashi, Koki] Univ Tokyo, Dept Transfus Med, Fac Med, Bunkyo Ku, Tokyo 1138655, Japan.
RP Kaneko, M (corresponding author), Univ Tokyo, Dept Surg Oncol, Fac Med, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.
EM m.kaneko@fancy.ocn.ne.jp
RI Murono, Koji/AAC-3958-2020
CR Altomare I, 2011, ONCOLOGIST, V16, P1131, DOI 10.1634/theoncologist.2011-0078
   Amaravadi RK, 2007, J CLIN INVEST, V117, P326, DOI 10.1172/JCI28833
   Bellodi C, 2009, J CLIN INVEST, V119, P1109, DOI 10.1172/JCI35660
   Bursch W, 1996, CARCINOGENESIS, V17, P1595, DOI 10.1093/carcin/17.8.1595
   Carew JS, 2007, BLOOD, V110, P313, DOI 10.1182/blood-2006-10-050260
   Carew JS, 2011, TARGET ONCOL, V6, P17, DOI 10.1007/s11523-011-0167-8
   Carew JS, 2011, J BIOL CHEM, V286, P6602, DOI 10.1074/jbc.M110.151324
   Carew JS, 2010, J CELL MOL MED, V14, P2448, DOI 10.1111/j.1582-4934.2009.00832.x
   Chau I, 2009, BRIT J CANCER, V100, P1704, DOI 10.1038/sj.bjc.6605061
   Chen TH, 2005, PHARMACOL RES, V51, P329, DOI 10.1016/j.phrs.2004.10.004
   Del Bufalo D, 2006, CANCER RES, V66, P5549, DOI 10.1158/0008-5472.CAN-05-2825
   Ding ZB, 2011, CLIN CANCER RES, V17, P6229, DOI 10.1158/1078-0432.CCR-11-0816
   Fan CD, 2006, BIOORGAN MED CHEM, V14, P3218, DOI 10.1016/j.bmc.2005.12.035
   Guba M, 2005, TRANSPL INT, V18, P89, DOI 10.1111/j.1432-2277.2004.00026.x
   Guo XL, 2013, J MOL MED, V91, P473, DOI 10.1007/s00109-012-0966-0
   Hayun R, 2009, LEUKEMIA LYMPHOMA, V50, P625, DOI 10.1080/10428190902789181
   Hu YL, 2012, AUTOPHAGY, V8, P979, DOI 10.4161/auto.20232
   Hu YL, 2012, CANCER RES, V72, P1773, DOI 10.1158/0008-5472.CAN-11-3831
   Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]
   Jiang PD, 2008, CELL PHYSIOL BIOCHEM, V22, P431, DOI 10.1159/000185488
   Kanzawa T, 2003, CANCER RES, V63, P2103
   Kanzawa T, 2004, CELL DEATH DIFFER, V11, P448, DOI 10.1038/sj.cdd.4401359
   Kapoor A, 2009, CANCER-AM CANCER SOC, V115, P3618, DOI 10.1002/cncr.24409
   Kim DD, 2012, EXPERT OPIN INV DRUG, V21, P1775, DOI 10.1517/13543784.2012.721353
   Lagneaux L, 2002, LEUKEMIA LYMPHOMA, V43, P1087, DOI 10.1080/10428190290021506
   Lane HA, 2009, CLIN CANCER RES, V15, P1612, DOI 10.1158/1078-0432.CCR-08-2057
   Mabuchi S, 2007, CLIN CANCER RES, V13, P4261, DOI 10.1158/1078-0432.CCR-06-2770
   Mabuchi S, 2007, CANCER RES, V67, P2408, DOI 10.1158/0008-5472.CAN-06-4490
   Manegold PC, 2008, CLIN CANCER RES, V14, P892, DOI 10.1158/1078-0432.CCR-07-0955
   Miyake N, 2012, ONCOL REP, V28, P848, DOI 10.3892/or.2012.1855
   Nguyen SA, 2012, CURR TREAT OPTION ON, V13, P71, DOI 10.1007/s11864-011-0180-2
   Nozawa H, 2007, CANCER LETT, V251, P105, DOI 10.1016/j.canlet.2006.11.008
   Paglin S, 2001, CANCER RES, V61, P439
   Park BC, 2008, TOXICOL LETT, V178, P52, DOI 10.1016/j.toxlet.2008.02.003
   Phung TL, 2006, CANCER CELL, V10, P159, DOI 10.1016/j.ccr.2006.07.003
   Rao R, 2012, MOL CANCER THER, V11, P973, DOI 10.1158/1535-7163.MCT-11-0979
   Semela D, 2007, J HEPATOL, V46, P840, DOI 10.1016/j.jhep.2006.11.021
   Shinohara ET, 2005, ONCOGENE, V24, P5414, DOI 10.1038/sj.onc.1208715
   Sun SY, 2005, CANCER RES, V65, P7052, DOI 10.1158/0008-5472.CAN-05-0917
   Takeuchi H, 2005, CANCER RES, V65, P3336, DOI 10.1158/0008-5472.CAN-04-3640
   Van Cutsem E, 2010, ANN ONCOL, V21, pv93, DOI 10.1093/annonc/mdq222
   Wan XL, 2006, NEOPLASIA, V8, P394, DOI 10.1593/neo.05820
   Zhang JF, 2007, TRANSPL IMMUNOL, V17, P162, DOI 10.1016/j.trim.2006.12.003
   Zheng YZ, 2009, CANCER INVEST, V27, P286, DOI 10.1080/07357900802427927
   Zhu Keyi, 2009, Proceedings of the American Association for Cancer Research Annual Meeting, V50, P451, DOI 10.1038/onc.2009.343
NR 45
TC 19
Z9 20
U1 2
U2 17
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0171-5216
EI 1432-1335
J9 J CANCER RES CLIN
JI J. Cancer Res. Clin. Oncol.
PD MAY
PY 2014
VL 140
IS 5
BP 769
EP 781
DI 10.1007/s00432-014-1628-0
PG 13
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA AF0WA
UT WOS:000334434000008
PM 24619662
DA 2022-04-25
ER

PT J
AU Dutta, N
   Pemmaraju, DB
   Ghosh, S
   Ali, A
   Mondal, A
   Majumder, C
   Nelson, VK
   Mandal, SC
   Misra, AK
   Rengan, AK
   Ravichandiran, V
   Che, CT
   Gurova, KV
   Gudkov, AV
   Pal, M
AF Dutta, Naibedya
   Pemmaraju, Deepak Bharadwaj
   Ghosh, Suvranil
   Ali, Asif
   Mondal, Ayan
   Majumder, Chirantan
   Nelson, Vinod K.
   Mandal, Subhash C.
   Misra, Anup K.
   Rengan, Aravind K.
   Ravichandiran, Velyutham
   Che, Chun-Tao
   Gurova, Katerina, V
   Gudkov, Andrei, V
   Pal, Mahadeb
TI Alkaloid-rich fraction of Ervatamia coronaria sensitizes colorectal
   cancer through modulating AMPK and mTOR signalling pathways
SO JOURNAL OF ETHNOPHARMACOLOGY
LA English
DT Article
DE Ervatamia coronaria; Alkaloid fraction; Colorectal cancer; Autophagy
   activator; mTOR inhibitor
ID INDOLE ALKALOIDS; CELL-GROWTH; AUTOPHAGY; P53; PHOSPHORYLATION;
   CONSTITUENTS; METABOLISM; TARGETS; LEAVES
AB Ethnopharmacological relevance: Ervatamia coronaria, a popular garden plant in India and some other parts of the world is known traditionally for its anti-inflammatory and anti-cancer properties. The molecular bases of these functions remain poorly understood. Aim of the study: Efficacies of the existing therapies for colorectal cancer (CRC) are limited by their lifethreatening side effects and unaffordability. Therefore, identifying a safer, efficient, and affordable therapeutic is urgent. We studied the anti-CRC activity of an alkaloid-rich fraction of E. coronaria leaf extracts (AFE) and associated underlying mechanism. Materials and methods: Activity guided solvant fractionation was adopted to identify the activity in AFE. Different cell lines, and tumor grown in syngeneic mice were used to understand the anti-CRC effect. Methodologies such as LCMS, MTT, RT-qPCR, immunoblot, immunohistochemistry were employed to understand the molecular basis of its activity. Results: We showed that AFE, which carries about six major compounds, is highly toxic to colorectal cancer (CRC) cells. AFE induced cell cycle arrest at G1 phase and p21 and p27 genes, while those of CDK2, CDK-4, cyclin-D, and cyclin-E genes were downregulated in HCT116 cells. It predominantly induced apoptosis in HCT116p53+/+ cells while the HCT116p53-/- cells under the same treatment condition died by autophagy. Notably, AFE induced upregulation of AMPK phosphorylation, and inhibition of both of the mTOR complexes as indicated by inhibition of phosphorylation of S6K1, 4EBP1, and AKT. Furthermore, AFE inhibited mTOR-driven conversion of cells from reversible cell cycle arrest to senescence (geroconversion) as well as ERK activity. AFE activity was independent of ROS produced, and did not primarily target the cellular DNA or cytoskeleton. AFE also efficiently regressed CT26-derived solid tumor in Balb/c mice acting alone or in synergy with 5FU through inducing autophagy as a major mechanism of action as indicated by upregulation of Beclin 1 and phospho-AMPK, and inhibition of phospho-S6K1 levels in the tumor tissue lysates. Conclusion: AFE induced CRC death through activation of both apoptotic and autophagy pathways without affecting the normal cells. This study provided a logical basis for consideration of AFE in future therapy regimen to overcome the limitations associated with existing anti-CRC chemotherapy.
C1 [Dutta, Naibedya; Pemmaraju, Deepak Bharadwaj; Ghosh, Suvranil; Ali, Asif; Mondal, Ayan; Majumder, Chirantan; Misra, Anup K.; Pal, Mahadeb] Bose Inst, Div Mol Med, P1-12 CIT Scheme VIIM, Kolkata, India.
   [Pemmaraju, Deepak Bharadwaj; Rengan, Aravind K.] IIT, Dept Biomed Engn, Hyderabad, India.
   [Nelson, Vinod K.; Mandal, Subhash C.] Jadavpur Univ, Dept Pharmaceut Technol, Kolkata, India.
   [Ravichandiran, Velyutham] Natl Inst Pharmaceut Res & Educ NIPER, Kolkata, India.
   [Che, Chun-Tao] Univ Illinois, Dept Pharmaceut Sci, Chicago, IL USA.
   [Gurova, Katerina, V; Gudkov, Andrei, V] Roswell Pk Canc Inst, Dept Cell Stress Biol, Buffalo, NY USA.
   [Pemmaraju, Deepak Bharadwaj] Natl Inst Pharmaceut Educ & Res, Dept Pharmacol & Toxicol, Gauhati, India.
RP Pal, M (corresponding author), Bose Inst, Div Mol Med, P1-12 CIT Scheme VIIM, Kolkata, India.
EM palmahadeb@gmail.com
OI Pemmaraju, Deepak Bharadwaj/0000-0002-6588-1481; Mandal, Subhash
   Chandra/0000-0002-9079-489X
FU ICMR SRF fellowship; DBTDepartment of Biotechnology (DBT) India;
   SERBDepartment of Science & Technology (India)Science Engineering
   Research Board (SERB), India; Bose InstituteDepartment of Science &
   Technology (India)
FX We thank Sibsankar Roy, Samit Adhya, Manikuntala Kundu, Gopal
   Chakrabarti for sharing antibodies. We thank Sanghamitra Raha, and
   Srabani Pal for their constant support. We thank Rahul L Gajbhiye for
   his help in LCMS analysis. ND is a recipient of ICMR SRF fellowship. DP
   was supported by funds from DBT. SG is a CSIR adhoc senior research
   fellow. We thank SERB, DBT and Bose Institute for financial support.
CR Bahrami A, 2018, J CELL BIOCHEM, V119, P111, DOI 10.1002/jcb.26183
   Bao MF, 2013, J NAT PROD, V76, P1406, DOI 10.1021/np400130y
   Basu C, 2019, EXP DERMATOL, V28, P1328, DOI 10.1111/exd.14041
   Bera S, 2021, ARCH BIOCHEM BIOPHYS, V708, DOI 10.1016/j.abb.2021.108940
   Berian JR, 2015, JAMA-J AM MED ASSOC, V314, P613, DOI 10.1001/jama.2015.9379
   Brenner H, 2014, LANCET, V383, P1490, DOI 10.1016/S0140-6736(13)61649-9
   Brosh R, 2009, NAT REV CANCER, V9, P701, DOI 10.1038/nrc2693
   Cazzalini O, 2010, MUTAT RES-REV MUTAT, V704, P12, DOI 10.1016/j.mrrev.2010.01.009
   Cragg GM, 2013, BBA-GEN SUBJECTS, V1830, P3670, DOI 10.1016/j.bbagen.2013.02.008
   Denton D, 2015, IMMUNOL CELL BIOL, V93, P35, DOI 10.1038/icb.2014.85
   Dhabal S, 2018, J BIOL CHEM, V293, P14040, DOI 10.1074/jbc.RA118.002321
   Doherty J, 2018, NAT CELL BIOL, V20, P1110, DOI 10.1038/s41556-018-0201-5
   Dutta N, 2021, BBA-GEN SUBJECTS, V1865, DOI 10.1016/j.bbagen.2021.129885
   Ghate N.B., 2013, INT J PHARM BIO SCI, V4, P373
   Ghosh S., FREE RADICAL BIO MED, V20, P136, DOI [10.1016/j.reeradbiomed.2021.05.037, DOI 10.1016/J.REERADBIOMED.2021.05.037]
   Goodwin Rachel A, 2009, Clin Colon Rectal Surg, V22, P251, DOI 10.1055/s-0029-1242465
   Guenzle J, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22010030
   Gwinn DM, 2008, MOL CELL, V30, P214, DOI 10.1016/j.molcel.2008.03.003
   Hardie DG, 2011, GENE DEV, V25, P1895, DOI 10.1101/gad.17420111
   Hazra J, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0168165
   Hellinger Michael D, 2006, Clin Colon Rectal Surg, V19, P228, DOI 10.1055/s-2006-956445
   Henriques AT, 1996, J ETHNOPHARMACOL, V50, P19, DOI 10.1016/0378-8741(95)01328-8
   Herzig S, 2018, NAT REV MOL CELL BIO, V19, P121, DOI 10.1038/nrm.2017.95
   Huang KZ, 2014, SEMIN CELL DEV BIOL, V36, P79, DOI 10.1016/j.semcdb.2014.09.011
   Hullatti K, 2013, PHARM BIOL, V51, P601, DOI 10.3109/13880209.2012.753919
   Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2
   Jaromy M, 2021, EUR J PHARMACOL, V897, DOI 10.1016/j.ejphar.2021.173956
   Kaeser MD, 2004, J BIOL CHEM, V279, P7598, DOI 10.1074/jbc.M311732200
   Kim YC, 2015, J CLIN INVEST, V125, P25, DOI 10.1172/JCI73939
   Leontieva OV, 2014, P NATL ACAD SCI USA, V111, P8832, DOI 10.1073/pnas.1405723111
   Liebl MC, 2021, CANCERS, V13, DOI 10.3390/cancers13092125
   Liu FF, 2018, ACTA PHARM SIN B, V8, P552, DOI 10.1016/j.apsb.2018.01.008
   Ma K, 2014, J NAT PROD, V77, P1156, DOI 10.1021/np401098y
   Marullo R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081162
   Mihaylova MM, 2011, NAT CELL BIOL, V13, P1016, DOI 10.1038/ncb2329
   Mukherjee A, 2021, J MOL LIQ, V337, DOI 10.1016/j.molliq.2021.116504
   Nelson V.K., 2016, AZADIRADIONE AMELIOR, V7
   Newman DJ, 2020, PLANTA MED, V86, P891, DOI 10.1055/a-1095-1111
   Oh WJ, 2011, CELL CYCLE, V10, P2305, DOI 10.4161/cc.10.14.16586
   Otto T, 2017, NAT REV CANCER, V17, P93, DOI 10.1038/nrc.2016.138
   Paul S, 2020, PHYTOMEDICINE, V67, DOI 10.1016/j.phymed.2019.153152
   Paul S, 2018, J BIOL CHEM, V293, P19303, DOI 10.1074/jbc.RA118.003376
   Pratchayasakul W, 2008, INDIAN J MED RES, V127, P317
   Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858
   Royds JA, 2006, CELL DEATH DIFFER, V13, P1017, DOI 10.1038/sj.cdd.4401913
   Salminen A, 2011, J MOL MED, V89, P667, DOI 10.1007/s00109-011-0748-0
   Saxton RA, 2017, CELL, V168, P960, DOI [10.1016/j.cell.2017.02.004, 10.1016/j.cell.2017.03.035]
   Siddiqui N, 2015, BIOCHEM SOC T, V43, P763, DOI 10.1042/BST20150126
   Solomon H, 2018, ONCOGENE, V37, P1669, DOI 10.1038/s41388-017-0060-8
   Stehn JR, 2013, CANCER RES, V73, P5169, DOI 10.1158/0008-5472.CAN-12-4501
   Sun XT, 2017, CANCER BIOMARK, V20, P67, DOI 10.3233/CBM-170112
   TALAPATRA B, 1975, PHYTOCHEMISTRY, V14, P1652, DOI 10.1016/0031-9422(75)85375-1
   Wang XW, 2014, WORLD J GASTROENTERO, V20, P4178, DOI 10.3748/wjg.v20.i15.4178
   Xie Jianling, 2016, F1000Res, V5, DOI 10.12688/f1000research.9207.1
   Xu M, 2018, NAT MED, V24, P1246, DOI 10.1038/s41591-018-0092-9
NR 55
TC 0
Z9 0
U1 13
U2 13
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0378-8741
EI 1872-7573
J9 J ETHNOPHARMACOL
JI J. Ethnopharmacol.
PD JAN 30
PY 2022
VL 283
AR 114666
DI 10.1016/j.jep.2021.114666
EA NOV 2021
PG 12
WC Plant Sciences; Chemistry, Medicinal; Integrative & Complementary
   Medicine; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary
   Medicine
GA WW6QK
UT WOS:000718038400004
PM 34592338
DA 2022-04-25
ER

PT J
AU Wu, JC
   Tsai, ML
   Lai, CS
   Lo, CY
   Ho, CT
   Wang, YJ
   Pan, MH
AF Wu, Jia-Ching
   Tsai, Mei-Ling
   Lai, Ching-Shu
   Lo, Chih-Yu
   Ho, Chi-Tang
   Wang, Ying-Jan
   Pan, Min-Hsiung
TI Polymethoxyflavones prevent benzo[a]pyrene/dextran sodium
   sulfate-induced colorectal carcinogenesis through modulating xenobiotic
   metabolism and ameliorate autophagic defect in ICR mice
SO INTERNATIONAL JOURNAL OF CANCER
LA English
DT Article
DE polycyclic aromatic hydrocarbons; polymethoxyflavones; colorectal
   cancer; autophagic defect; microbiota
ID POLYCYCLIC AROMATIC-HYDROCARBONS; NATURAL DIETARY COMPOUNDS; IN-VIVO;
   SIGNALING PATHWAY; DNA-ADDUCTS; CANCER-RISK; MICROBIOTA; CELLS; MODEL;
   TETRAHYDROCURCUMIN
AB Polycyclic aromatic hydrocarbons (PAHs) are widespread environmental carcinogenic pollutants and they have become an important issue in food contamination. Dietary intake of PAHs has been recognized as a major route of human exposure. However, the mechanisms behind dietary PAH-induced colorectal cancer (CRC) remain unclear. Several studies have shown that polymethoxyflavones (PMFs) are effective in preventing carcinogen-induced CRC or colitis. In this study, we investigated the preventive effect of PMFs on benzo[a]pyrene/dextran sulfate sodium (BaP/DSS)-induced colorectal tumorigenesis in ICR mice. We found that PMFs significantly prevented BaP/DSS-induced colorectal tumor formation. BaP mutagenic metabolite and DNA adducts were found to be reduced in colonic tissue in the PMFs-treated groups through the modulation of BaP metabolism. At the molecular level, the results of RNA-sequencing indicated that PMFs ameliorated BaP/DSS-induced abnormal molecular mechanism change including activated inflammation, downregulated anti-oxidation targets, and induced metastasis genes. The autophagic defect caused by BaP/DSS-induced tumorigenesis was improved by pretreatment with PMFs. We found BaP/DSS-induced CRC may be a Wnt/beta-catenin independent process. Additionally, consumption of PMFs extracts also altered the composition of gut microbiota and made it similar to that in the control group by increasing butyrate-producing probiotics and decreasing CRC-related bacteria. BaP in combination with DSS significantly induced colorectal tumorigenesis through induced DNA adduct formation, abnormal gene expression, and imbalanced gut microbiota composition. PMFs were a powerful preventive agent that suppressed BaP/DSS-induced CRC via modulating multiple pathways as well as ameliorating autophagic defect. These results demonstrated for the first time the chemopreventive efficacy and comprehensive mechanisms of dietary PMFs for preventing BaP/DSS-induced colorectal carcinogenesis.
C1 [Wu, Jia-Ching; Wang, Ying-Jan] Natl Cheng Kung Univ, Coll Med, Dept Environm & Occupat Hlth, Tainan 704, Taiwan.
   [Tsai, Mei-Ling; Lai, Ching-Shu] Natl Kaohsiung Marine Univ, Dept Seafood Sci, Kaohsiung 811, Taiwan.
   [Lo, Chih-Yu] Natl Chiayi Univ, Dept Food Sci, 300 Syuefu Rd, Chiayi 600, Taiwan.
   [Ho, Chi-Tang] Rutgers State Univ, Dept Food Sci, New Brunswick, NJ 08901 USA.
   [Wang, Ying-Jan] Natl Cheng Kung Univ, Coll Med, Dept Food Safety Hyg & Risk Management, Tainan 704, Taiwan.
   [Wang, Ying-Jan] Taipei Med Univ, Grad Inst Clin Med, Coll Med, Taipei 110, Taiwan.
   [Pan, Min-Hsiung] China Med Univ, China Med Univ Hosp, Dept Med Res, Taichung 40402, Taiwan.
   [Pan, Min-Hsiung] Asia Univ, Dept Hlth & Nutr Biotechnol, Taichung, Taiwan.
   [Pan, Min-Hsiung] Natl Taiwan Univ, Inst Food Sci & Technol, 1,Sect 4,Roosevelt Rd, Taipei 10617, Taiwan.
RP Pan, MH (corresponding author), Natl Taiwan Univ, Inst Food Sci & Technol, 1,Sect 4,Roosevelt Rd, Taipei 10617, Taiwan.; Wang, YJ (corresponding author), Natl Cheng Kung Univ, Med Coll, Dept Environm & Occupat Hlth, 138 Sheng Li Rd, Tainan 70428, Taiwan.
EM yjwang@mail.ncku.edu.tw; mhpan@ntu.edu.tw
RI Pan, Min-Hsiung/AAT-8865-2021
OI Pan, Min-Hsiung/0000-0002-5188-7030
FU Ministry of Science and TechnologyMinistry of Education, Culture,
   Sports, Science and Technology, Japan (MEXT) [105-2320-B-002-031-MY3,
   105-2628-B-002-003-MY3]
FX Grant sponsor: Ministry of Science and Technology; Grant numbers:
   105-2320-B-002-031-MY3, 105-2628-B-002-003-MY3
CR Baird WM, 2005, ENVIRON MOL MUTAGEN, V45, P106, DOI 10.1002/em.20095
   Bansal V, 2015, ENVIRON INT, V84, P26, DOI 10.1016/j.envint.2015.06.016
   Baxter NT, 2014, MICROBIOME, V2, DOI 10.1186/2049-2618-2-20
   Bishehsari F, 2014, WORLD J GASTROENTERO, V20, P6055, DOI 10.3748/wjg.v20.i20.6055
   Boffetta P, 1997, CANCER CAUSE CONTROL, V8, P444, DOI 10.1023/A:1018465507029
   Bruner SD, 2016, CLIN PHARMACOL THER, V99, P585, DOI 10.1002/cpt.348
   Caporaso JG, 2011, P NATL ACAD SCI USA, V108, P4516, DOI 10.1073/pnas.1000080107
   Chen WG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039743
   da Costa J, 2009, AM J DENT, V22, P92
   Duchartre Y, 2016, CRIT REV ONCOL HEMAT, V99, P141, DOI 10.1016/j.critrevonc.2015.12.005
   Eid HM, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00387
   Galluzzi L, 2015, EMBO J, V34, P856, DOI 10.15252/embj.201490784
   Hadizadeh F., 2017, GUT
   Hakura A, 1998, MUTAT RES-FUND MOL M, V398, P123, DOI 10.1016/S0027-5107(97)00248-0
   Hakura A, 2013, PYRENE CHEM PROPERTI, P43
   Kabatkova M, 2015, MUTAGENESIS, V30, P565, DOI 10.1093/mutage/gev019
   Kahl CR, 2003, ENDOCR REV, V24, P719, DOI 10.1210/er.2003-0008
   Kim H, 2017, J NUTR BIOCHEM, V43, P107, DOI 10.1016/j.jnutbio.2017.02.005
   Lai CS, 2011, MOL NUTR FOOD RES, V55, P1819, DOI 10.1002/mnfr.201100290
   Leone A, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/2597581
   Li SY, 2017, ONCOL REP, V38, P1637, DOI 10.3892/or.2017.5849
   Long AS, 2016, TOXICOL APPL PHARM, V290, P31, DOI 10.1016/j.taap.2015.11.010
   Lucas C, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18061310
   Ma YN, 2015, ENVIRON INT, V84, P7, DOI 10.1016/j.envint.2015.07.006
   Nebert DW, 2013, MOL PHARMACOL, V84, P304, DOI 10.1124/mol.113.086637
   Omar Al-Hassi H, 2017, GUT
   Owusu Daniel, 2015, Int J High Risk Behav Addict, V4, pe23424, DOI 10.5812/ijhrba.4(2)2015.23424
   Pan MH, 2008, CHEM SOC REV, V37, P2558, DOI 10.1039/b801558a
   Pan MH, 2011, MOL NUTR FOOD RES, V55, P32, DOI 10.1002/mnfr.201000412
   Park SM, 2016, MOL CELL, V62, P479, DOI 10.1016/j.molcel.2016.04.011
   Peran L, 2005, WORLD J GASTROENTERO, V11, P5185
   Schwab C, 2014, ISME J, V8, P1101, DOI 10.1038/ismej.2013.223
   Shabalala S, 2017, LIFE SCI, V180, P160, DOI 10.1016/j.lfs.2017.05.003
   Shangguan HD, 2015, BIORESOURCE TECHNOL, V193, P456, DOI 10.1016/j.biortech.2015.06.151
   Sonoda J, 2015, J TOXICOL PATHOL, V28, P109, DOI 10.1293/tox.2014-0061
   Tanaka Takuji, 2009, J Carcinog, V8, P5
   Tang YX, 2009, MOL CANCER THER, V8, P458, DOI 10.1158/1535-7163.MCT-08-0885
   Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262
   Turati F, 2012, EUR J CLIN NUTR, V66, P517, DOI 10.1038/ejcn.2011.217
   Van RT, 2017, MICROBIOL SPECTR, V5
   Wells K, 2017, SURG CLIN N AM, V97, P605, DOI 10.1016/j.suc.2017.01.009
   Wu JC, 2017, J FOOD DRUG ANAL, V25, P176, DOI 10.1016/j.jfda.2016.10.019
   Wu JC, 2015, MOL NUTR FOOD RES, V59, P2511, DOI 10.1002/mnfr.201500373
   Wu JC, 2011, MOL NUTR FOOD RES, V55, P1646, DOI 10.1002/mnfr.201100454
   Yamashiro K, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171521
   Yin XD, 2016, ONCOTARGET, V7, P51720, DOI 10.18632/oncotarget.10102
   Zelinkova Z, 2015, POLYCYCL AROMAT COMP, V35, P248, DOI 10.1080/10406638.2014.918550
   Zeng S, 2017, MOL CANC THER
   Zhu J, 2014, J APPL MICROBIOL, V117, P208, DOI 10.1111/jam.12499
   Zuo J, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-880
NR 50
TC 11
Z9 12
U1 5
U2 43
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0020-7136
EI 1097-0215
J9 INT J CANCER
JI Int. J. Cancer
PD APR 15
PY 2018
VL 142
IS 8
BP 1689
EP 1701
DI 10.1002/ijc.31190
PG 13
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA FW3CX
UT WOS:000425184800021
PM 29197069
OA Bronze
DA 2022-04-25
ER

PT J
AU Ruan, LH
   Liu, WF
   Yang, YH
   Chu, ZJ
   Yang, C
   Yang, TB
   Sun, JJ
AF Ruan, Longhui
   Liu, Weifeng
   Yang, Yanhui
   Chu, Zhijie
   Yang, Cheng
   Yang, Tianbao
   Sun, Junjun
TI TRIM16 overexpression inhibits the metastasis of colorectal cancer
   through mediating Snail degradation
SO EXPERIMENTAL CELL RESEARCH
LA English
DT Article
DE TRIM16; EMT; Colorectal cancer; Cell migration; Ubiquitination
ID FAMILY PROTEINS; EMT; AUTOPHAGY; ROLES
AB Tripartite motif containing 16 (TRIM16) is a member of the tripartite motif protein family and functions as a potential tumor suppressor in several cancers. However, the specific function and clinical significance of TRIM16 in colorectal cancer (CRC) remains unclear. In this study, we observed that low TRIM16 expression was detected frequently in primary colorectal cancer (CRC) tissues and was closely associated with a better prognosis. Functional studies demonstrate that TRIM16 overexpression notably inhibits the metastasis abilities of CRC in vivo and in vitro. Mechanistically, our results demonstrated that TRIM16 directly bound and ubiquitinated Snail family transcriptional repressor 1 (Snail), an important transcriptional factor of the epithelial-mesenchymal transition (EMT) process suppressing the EMT in CRC. Additionally, our data revealed that the inhibition effect of TRIM16 on cancer metastasis was dependent on Snail degradation. Collectively, our study is the first to report that TRIM16 plays a crucial anti-tumor role in CRC tumorigenesis. We also provided novel evidence that TRIM16 might act as a prognostic and therapeutic target to assess and inhibit CRC progression.
C1 [Sun, Junjun] Henan Univ Sci & Technol, Affiliated Hosp 1, Luoyang 471003, Peoples R China.
   Henan Univ Sci & Technol, Coll Clin Med, Luoyang 471003, Peoples R China.
RP Sun, JJ (corresponding author), Henan Univ Sci & Technol, Affiliated Hosp 1, Luoyang 471003, Peoples R China.
EM lyhnkjdx@163.com
FU Natural Science Foundation of Henan Province [152300410205]
FX The authors gratefully acknowledge the financial assistance provided by
   the Natural Science Foundation of Henan Province (152300410205).
CR Aiello NM, 2019, J EXP MED, V216, P1016, DOI 10.1084/jem.20181827
   Nieto MA, 2016, CELL, V166, P21, DOI 10.1016/j.cell.2016.06.028
   Nieto MA, 2013, SCIENCE, V342, P708, DOI 10.1126/science.1234850
   Bakir B, 2020, TRENDS CELL BIOL, V30, P764, DOI 10.1016/j.tcb.2020.07.003
   Brabletz T, 2018, NAT REV CANCER, V18, P128, DOI 10.1038/nrc.2017.118
   Dongre A, 2019, NAT REV MOL CELL BIO, V20, P69, DOI 10.1038/s41580-018-0080-4
   Hatakeyama S, 2017, TRENDS BIOCHEM SCI, V42, P297, DOI 10.1016/j.tibs.2017.01.002
   Huo XW, 2015, BIOCHEM BIOPH RES CO, V460, P1021, DOI 10.1016/j.bbrc.2015.03.144
   Jena KK, 2018, EMBO J, V37, DOI 10.15252/embj.201798358
   Kim PY, 2013, APOPTOSIS, V18, P639, DOI 10.1007/s10495-013-0813-y
   Kow AWC, 2019, J GASTROINTEST ONCOL, V10, P1274, DOI 10.21037/jgo.2019.08.06
   Li LL, 2016, INT J ONCOL, V48, P1639, DOI 10.3892/ijo.2016.3398
   Li YC, 2020, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.01525
   Liu HLC, 1998, MOL ENDOCRINOL, V12, P1733, DOI 10.1210/me.12.11.1733
   Lv W, 2020, BIOCHEM BIOPH RES CO, V529, P799, DOI 10.1016/j.bbrc.2020.05.187
   Nagy Z, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-76722-x
   Noren A, 2016, EUR J CANCER, V53, P105, DOI 10.1016/j.ejca.2015.10.055
   Ozato K, 2008, NAT REV IMMUNOL, V8, P849, DOI 10.1038/nri2413
   Pastushenko I, 2019, TRENDS CELL BIOL, V29, P212, DOI 10.1016/j.tcb.2018.12.001
   Pohl C, 2019, SCIENCE, V366, P818, DOI 10.1126/science.aax3769
   Qi L, 2016, INT J MOL MED, V38, P1734, DOI 10.3892/ijmm.2016.2774
   Siegel RL, CA-CANCER J CLIN, V71, P7
   Spirina LV, 2018, B EXP BIOL MED+, V166, P237, DOI 10.1007/s10517-018-4322-4
   Wang Y, 2019, ADV EXP MED BIOL, V1206, P527, DOI 10.1007/978-981-15-0602-4_25
   Wang YF, 2013, CURR CANCER DRUG TAR, V13, P963, DOI 10.2174/15680096113136660102
   Yang J, 2020, NAT REV MOL CELL BIO, V21, P341, DOI 10.1038/s41580-020-0237-9
   Yao JT, 2016, ONCOL REP, V35, P1204, DOI 10.3892/or.2015.4437
   Zhao Y, 2020, FRONT CELL DEV BIOL, V8
   Zhao Y, 2020, EXP CELL RES, V397, DOI 10.1016/j.yexcr.2020.112336
NR 29
TC 0
Z9 0
U1 1
U2 2
PU ELSEVIER INC
PI SAN DIEGO
PA 525 B STREET, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0014-4827
EI 1090-2422
J9 EXP CELL RES
JI Exp. Cell Res.
PD SEP 1
PY 2021
VL 406
IS 1
AR 112735
DI 10.1016/j.yexcr.2021.112735
EA JUL 2021
PG 11
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA TZ6OL
UT WOS:000684590000009
PM 34265287
DA 2022-04-25
ER

PT J
AU Kim, MJ
   Koo, JE
   Han, GY
   Kim, B
   Lee, YS
   Ahn, C
   Kim, CW
AF Kim, Min-Jung
   Koo, Jeong-Eun
   Han, Gi-Yeon
   Kim, Buyun
   Lee, Yoo-Sun
   Ahn, Chiyoung
   Kim, Chan-Wha
TI Dual-Blocking of PI3K and mTOR Improves Chemotherapeutic Effects on
   SW620 Human Colorectal Cancer Stem Cells by Inducing Differentiation
SO JOURNAL OF KOREAN MEDICAL SCIENCE
LA English
DT Article
DE Cancer Stem Cells; PI3K; mTOR; Drug Resistance; Differentiation Therapy
ID BREAST-CANCER; PATHWAY; RAPAMYCIN; INHIBITORS; THERAPY; IDENTIFICATION;
   NVP-BEZ235; RESISTANCE; AUTOPHAGY; TARGET
AB Cancer stem cells (CSCs) have tumor initiation, self-renewal, metastasis and chemoresistance properties in various tumors including colorectal cancer. Targeting of CSCs may be essential to prevent relapse of tumors after chemotherapy. Phosphatidylinositol-3-kinase (PI3K) and mammalian target of rapamycin (mTOR) signals are central regulators of cell growth, proliferation, differentiation, and apoptosis. These pathways are related to colorectal tumorigenesis. This study focused on PI3K and mTOR pathways by inhibition which initiate differentiation of SW620 derived CSCs and investigated its effect on tumor progression. By using rapamycin, LY294002, and NVP-BEZ235, respectively, PI3K and mTOR signals were blocked independently or dually in colorectal CSCs. Colorectal CSCs gained their differentiation property and lost their sternness properties most significantly in dual -blocked CSCs. After treated with anti-cancer drug (paclitaxel) on the differentiated CSCs cell viability, self-renewal ability and differentiation status were analyzed. As a result dual-blocking group has most enhanced sensitivity for anti-cancer drug. Xenograft tumorigenesis assay by using immunodeficiency mice also shows that dual-inhibited group more effectively increased drug sensitivity and suppressed tumor growth compared to single-inhibited groups. Therefore it could have potent anti-cancer effects that dual blocking of PI3K and mTOR induces differentiation and improves chemotherapeutic effects on SW620 human colorectal CSCs.
C1 [Kim, Min-Jung; Koo, Jeong-Eun; Han, Gi-Yeon; Kim, Buyun; Lee, Yoo-Sun; Kim, Chan-Wha] Korea Univ, Coll Life Sci & Biotechnol, Dept Biotechnol, 145 Anam Ro, Seoul 02841, South Korea.
   [Kim, Min-Jung; Ahn, Chiyoung] Minist Food & Drug Safety, Cheongju, South Korea.
RP Kim, CW (corresponding author), Korea Univ, Coll Life Sci & Biotechnol, Dept Biotechnol, 145 Anam Ro, Seoul 02841, South Korea.
EM cwkim@korea.ac.kr
FU Ministry of Trade, Industry and Energy [1147890]
FX This work was supported by Ministry of Trade, Industry and Energy
   (1147890, 2014)
CR Alison MR, 2012, CANCER TREAT REV, V38, P589, DOI 10.1016/j.ctrv.2012.03.003
   Barker N, 2007, NATURE, V449, P1003, DOI 10.1038/nature06196
   Botchkina G, 2013, CANCER LETT, V338, P127, DOI 10.1016/j.canlet.2012.04.006
   Choi KS, 2005, BIOCHEM BIOPH RES CO, V330, P1299, DOI 10.1016/j.bbrc.2005.03.111
   Dean M, 2005, NAT REV CANCER, V5, P275, DOI 10.1038/nrc1590
   Dontu G, 2003, CELL PROLIFERAT, V36, P59, DOI 10.1046/j.1365-2184.36.s.1.6.x
   Dubrovska A, 2010, CLIN CANCER RES, V16, P5692, DOI 10.1158/1078-0432.CCR-10-1601
   Engelman JA, 2009, NAT REV CANCER, V9, P550, DOI 10.1038/nrc2664
   Faivre S, 2006, NAT REV DRUG DISCOV, V5, P671, DOI 10.1038/nrd2062
   Fan QW, 2006, CANCER CELL, V9, P341, DOI 10.1016/j.ccr.2006.03.029
   Fang DD, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067258
   Guertin DA, 2007, CANCER CELL, V12, P9, DOI 10.1016/j.ccr.2007.05.008
   Hay N, 2005, CANCER CELL, V8, P179, DOI 10.1016/j.ccr.2005.08.008
   Jordan CT, 2006, NEW ENGL J MED, V355, P1253, DOI 10.1056/NEJMra061808
   Katso R, 2001, ANNU REV CELL DEV BI, V17, P615, DOI 10.1146/annurev.cellbio.17.1.615
   Kim DD, 2012, EXPERT OPIN INV DRUG, V21, P1775, DOI 10.1517/13543784.2012.721353
   Koehl GE, 2010, ONCOGENE, V29, P1553, DOI 10.1038/onc.2009.435
   Lee EK, 2010, J PROTEOME RES, V9, P5108, DOI 10.1021/pr100378z
   Lin SJ, 2015, ONCOTARGET, V6, P39329, DOI 10.18632/oncotarget.5744
   Liu PX, 2009, NAT REV DRUG DISCOV, V8, P627, DOI 10.1038/nrd2926
   Lobo NA, 2007, ANNU REV CELL DEV BI, V23, P675, DOI 10.1146/annurev.cellbio.22.010305.104154
   Maira SM, 2008, MOL CANCER THER, V7, P1851, DOI 10.1158/1535-7163.MCT-08-0017
   O'Brien CA, 2007, NATURE, V445, P106, DOI 10.1038/nature05372
   Osaki M, 2004, APOPTOSIS, V9, P667, DOI 10.1023/B:APPT.0000045801.15585.dd
   Palozza P, 2009, CANCER LETT, V283, P108, DOI 10.1016/j.canlet.2009.03.031
   Pandurangan AK, 2013, ASIAN PAC J CANCER P, V14, P2201, DOI 10.7314/APJCP.2013.14.4.2201
   Petrelli A, 2015, ONCOTARGET, V6, P2315, DOI 10.18632/oncotarget.2962
   Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384
   Rich JN, 2007, CANCER RES, V67, P8980, DOI 10.1158/0008-5472.CAN-07-0895
   Sabatini DM, 2006, NAT REV CANCER, V6, P729, DOI 10.1038/nrc1974
   Serra V, 2008, CANCER RES, V68, P8022, DOI 10.1158/0008-5472.CAN-08-1385
   Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138
   Slattery ML, 2010, CARCINOGENESIS, V31, P1604, DOI 10.1093/carcin/bgq142
   Takeuchi H, 2005, CANCER RES, V65, P3336, DOI 10.1158/0008-5472.CAN-04-3640
   Tang C, 2007, FASEB J, V21, P3777, DOI 10.1096/fj.07-8560rev
   Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839
   YATSCOFF RW, 1993, THER DRUG MONIT, V15, P478, DOI 10.1097/00007691-199312000-00004
NR 37
TC 10
Z9 11
U1 0
U2 13
PU KOREAN ACAD MEDICAL SCIENCES
PI SEOUL
PA 302 75 DONG DU ICHON, DONG YONGSAN KU, SEOUL 140 031, SOUTH KOREA
SN 1011-8934
EI 1598-6357
J9 J KOREAN MED SCI
JI J. Korean Med. Sci.
PD MAR
PY 2016
VL 31
IS 3
BP 360
EP +
DI 10.3346/jkms.2016.31.3.360
PG 13
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA DG2LN
UT WOS:000371898700006
PM 26955235
OA Green Published, Green Submitted, gold
DA 2022-04-25
ER

PT J
AU Rahman, FU
   Ali, A
   Duong, HQ
   Khan, IU
   Bhatti, MZ
   Li, ZT
   Wang, H
   Zhang, DW
AF Rahman, Faiz-Ur
   Ali, Amjad
   Duong, Hong-Quan
   Khan, Inam Ullah
   Bhatti, Muhammad Zeeshan
   Li, Zhan-Ting
   Wang, Hui
   Zhang, Dan-Wei
TI ONS-donor ligand based Pt(II) complexes display extremely high
   anticancer potency through autophagic cell death pathway
SO EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
DE ONS-Donor Pt(II) complexes; In vitro cytotoxicity; Caspase 3/7
   activation; Autophagy; E. Coli growth
ID IN-VITRO ANTICANCER; PLATINUM(II) COMPLEXES; ESCHERICHIA-COLI;
   CISPLATIN; GROWTH; INHIBITION; RESISTANCE; PHENANTHRIPLATIN; EXPRESSION;
   DIVISION
AB The current study unveils ONS-donor ligand based Pt(II) complexes with unusual anticancer potency showing higher anticancer effect as compared to cisplatin. This series of Pt(lI)(R-salicylaldimine)Cl (C1a-C4a) (R = 5-H, 5-CH3, F, 3-CH3O) complexes were prepared in single step in good isolated yields from commercially available materials. The chloride ancillary ligand of "a" series (C1a-C4a) was replaced with 4-picoline and "b" series of four complexes Pt(II)(R-salicylaldimine)(4-picoline)BF4 (C1b-C4b) (R = 5-H, 5-CH3, F, 3-CH3O) was obtained. All these complexes were characterized by different structure elucidation techniques. Among these, the structures of C1a, C2a, C2b and Cab were determined in solid state by single crystal X-ray analysis. We found quick aquation of "a" series of complexes in DMSO/water mixture that was well investigated by H-1 NMNR, LCMS and ESI-MS, while "b" series of these complexes was quite stable over a month as described by the 1H NMNR in DMSO/D2O mixture. This ONS-donor ligand based class of Pt(11) complexes showed unusual anticancer potency in non-small cell lung cancer A549, colorectal cancer HT-29 and triple negative breast cancer MDA-MB-231 cells. These Pt(II) complexes induced PARP cleavage and significantly inhibited colony formation ability of cancer cells. Mechanistically, we found reduced aggressive growth of cancer cells by the induction of autophagic cell death via LC3-I/LC3-II expression and recruitment of LC3B to autophagosomal membrane. These complexes induced p21 expression, that suggested their potentials to suppress cell cycle progression. Significant activation of Caspase3/7-dependent apoptotic signaling was observed in cancer cells treated with these Pt(II) complexes. Morphological changes of cancer cells suggested their potentials to modulate epithelial-mesenchymal-transition (EMT) like features of cancer cells. Gel electrophoresis study revealed their interaction with plasmid DNA. Similarly, strong growth retardation effect and filamentous morphology was observed in Escherichia coli (E. coli). These ONS-donor Pt(II) complexes possessed strong anticancer effect in multiple human cancer cells via activation of multiple pathways for apoptotic and autophagic cell death. (C) 2018 Elsevier Masson SAS. All rights reserved.
C1 [Rahman, Faiz-Ur] Shanghai Univ, Dept Chem, Ctr Supramol Mat & Catalysis, Shanghai 200444, Peoples R China.
   [Rahman, Faiz-Ur; Li, Zhan-Ting; Wang, Hui; Zhang, Dan-Wei] Fudan Univ, Dept Chem, 2005 Songhu Rd, Shanghai 200438, Peoples R China.
   [Ali, Amjad; Bhatti, Muhammad Zeeshan] East China Normal Univ, Shanghai Key Lab Regulatory Biol, Inst Biomed Sci, Sch Life Sci, 500 Dongchuan Rd, Shanghai 200241, Peoples R China.
   [Ali, Amjad] CECOS Univ IT & Emerging Sci, Inst Integrat Biosci, Peshawar, Kpk, Pakistan.
   [Duong, Hong-Quan] Duy Tan Univ, Inst Res & Dev, K7-25 Quang Trung, Danang 550000, Vietnam.
   [Khan, Inam Ullah] Fudan Univ, Sch Life Sci, State Key Lab Genet Engn, Lab Mol Immunol, 220 Handan Rd, Shanghai 200433, Peoples R China.
   [Bhatti, Muhammad Zeeshan] Natl Univ Med Sci, Dept Biol Sci, Rawalpindi 46000, Pakistan.
RP Wang, H; Zhang, DW (corresponding author), Fudan Univ, Dept Chem, 2005 Songhu Rd, Shanghai 200438, Peoples R China.
EM wanghui@fudan.edu.cn; zhangdw@fudan.edu.cn
RI Li, Zhan-Ting/V-7552-2017; Rahman, Faiz-Ur/S-4598-2019; Bhatti, Muhammad
   Zeeshan/ACS-5136-2022
OI Li, Zhan-Ting/0000-0003-3954-0015; Rahman, Faiz-Ur/0000-0002-4006-8881;
   Bhatti, Muhammad Zeeshan/0000-0003-0532-0532
FU Ministry of Science and Technology of ChinaMinistry of Science and
   Technology, China [2013CB834501]; Science and Technology Commission of
   Shanghai MunicipalityScience & Technology Commission of Shanghai
   Municipality (STCSM) [13NM1400200]; National Natural Science Foundation
   of ChinaNational Natural Science Foundation of China (NSFC) [21102017];
   China postdoctoral association
FX The authors acknowledge the Ministry of Science and Technology of China
   (2013CB834501), The Science and Technology Commission of Shanghai
   Municipality (13NM1400200), the National Natural Science Foundation of
   China (No. 21102017) and China postdoctoral association for providing
   postdoctoral fellowship.
CR Ahmad S, 2017, POLYHEDRON, V138, P109, DOI 10.1016/j.poly.2017.09.016
   ANDERSEN KK, 1964, J AM CHEM SOC, V86, P5637, DOI 10.1021/ja01078a047
   Berners-Price SJ, 2011, ANGEW CHEM INT EDIT, V50, P804, DOI 10.1002/anie.201004552
   Bugarcic ZD, 2012, DALTON T, V41, P12329, DOI 10.1039/c2dt31045g
   Burger AM, 2004, CANC DRUG DISC DEV, P29
   Che CM, 2010, CHEM-EUR J, V16, P233, DOI 10.1002/chem.200902183
   Clavel CM, 2015, J MED CHEM, V58, P3356, DOI 10.1021/jm501655t
   Cubo L, 2009, INORG CHIM ACTA, V362, P1022, DOI 10.1016/j.ica.2008.03.117
   Cutillas N, 2013, COORDIN CHEM REV, V257, P2784, DOI 10.1016/j.ccr.2013.03.024
   Duong HQ, 2012, ONCOL REP, V27, P182, DOI 10.3892/or.2011.1503
   Evans DA, 2000, J AM CHEM SOC, V122, P7905, DOI 10.1021/ja992543i
   Garcia-Berrocal JR, 2007, BRIT J PHARMACOL, V152, P1012, DOI 10.1038/sj.bjp.0707405
   Govender P, 2011, DALTON T, V40, P1158, DOI 10.1039/c0dt00761g
   Guo WJ, 2013, AUTOPHAGY, V9, P996, DOI 10.4161/auto.24407
   Guo ZQ, 2014, CHEM COMMUN, V50, P1711, DOI 10.1039/c3cc47150k
   Haggar Fatima A, 2009, Clin Colon Rectal Surg, V22, P191, DOI 10.1055/s-0029-1242458
   Haghdoost M, 2017, EUR J MED CHEM, V132, P282, DOI 10.1016/j.ejmech.2017.03.029
   Hall MD, 2014, CANCER RES, V74, P3913, DOI 10.1158/0008-5472.CAN-14-0247
   Harper BW, 2010, CHEM-EUR J, V16, P7064, DOI 10.1002/chem.201000148
   Hernandez-Balderas U, 2015, POLYHEDRON, V90, P165, DOI 10.1016/j.poly.2015.02.004
   Hiroi K, 2000, TETRAHEDRON, V56, P4701, DOI 10.1016/S0040-4020(00)00393-8
   Holohan C, 2013, NAT REV CANCER, V13, P714, DOI 10.1038/nrc3599
   Jin Z., 2014, CANCER BIOL THER, V4, P147, DOI DOI 10.4161/CBT.4.2.1508
   Johnstone TC, 2014, J AM CHEM SOC, V136, P2126, DOI 10.1021/ja4125115
   Johnstone TC, 2014, J AM CHEM SOC, V136, P116, DOI 10.1021/ja411742c
   Kalita M, 2015, POLYHEDRON, V97, P140, DOI 10.1016/j.poly.2015.05.020
   Kathiresan S, 2016, RSC ADV, V6, P1810, DOI 10.1039/c5ra20607c
   Koberle B, 2010, BBA-REV CANCER, V1806, P172, DOI 10.1016/j.bbcan.2010.07.004
   Komiya N, 2011, J AM CHEM SOC, V133, P6493, DOI 10.1021/ja110398p
   Kumar SB, 2017, J MOL STRUCT, V1143, P163, DOI 10.1016/j.molstruc.2017.04.081
   Levi R.S.A.J.A., 1981, BMJ-BRIT MED J, V282, P2003
   Ma GL, 2010, CHEM COMMUN, V46, P6938, DOI 10.1039/c0cc01408g
   Makhubela BCE, 2014, J ORGANOMET CHEM, V772, P229, DOI 10.1016/j.jorganchem.2014.08.034
   Malacea R, 2008, J MOL STRUCT, V890, P249, DOI 10.1016/j.molstruc.2008.04.007
   Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205
   Marzo T, 2018, J INORG BIOCHEM, V183, P101, DOI 10.1016/j.jinorgbio.2018.03.009
   Mellah M, 2007, CHEM REV, V107, P5133, DOI 10.1021/cr068440h
   Milosavljevic N, 2010, CANCER RES, V70, P7514, DOI 10.1158/0008-5472.CAN-10-1253
   Mizushima N, 2010, CELL, V140, P313, DOI 10.1016/j.cell.2010.01.028
   Saborit JM, 2017, DALTON T, V46, P11214, DOI 10.1039/c7dt02127e
   Muhammad N, 2014, CURR OPIN CHEM BIOL, V19, P144, DOI 10.1016/j.cbpa.2014.02.003
   Park GY, 2012, P NATL ACAD SCI USA, V109, P11987, DOI 10.1073/pnas.1207670109
   Patterson AE, 2014, INORG CHIM ACTA, V415, P88, DOI 10.1016/j.ica.2014.02.028
   Proetto M, 2012, EUR J MED CHEM, V53, P168, DOI 10.1016/j.ejmech.2012.03.053
   Rahman FU, 2018, INORG CHEM COMMUN, V97, P157, DOI 10.1016/j.inoche.2018.09.026
   Rahman FU, 2018, EUR J MED CHEM, V157, P1480, DOI 10.1016/j.ejmech.2018.08.054
   Rahman FU, 2018, EUR J MED CHEM, V143, P1039, DOI 10.1016/j.ejmech.2017.11.044
   Rahman FU, 2017, EUR J MED CHEM, V131, P263, DOI 10.1016/j.ejmech.2017.03.014
   Rahman FU, 2017, EUR J MED CHEM, V125, P1064, DOI 10.1016/j.ejmech.2016.10.031
   Rahman FU, 2015, POLYHEDRON, V100, P264, DOI 10.1016/j.poly.2015.08.034
   Rahman FU, 2015, DALTON T, V44, P9872, DOI 10.1039/c5dt01098e
   Rahman FU, 2015, DALTON T, V44, P2166, DOI 10.1039/c4dt03018d
   Reedijk J, 2009, EUR J INORG CHEM, P1303, DOI 10.1002/ejic.200900054
   Roebuck JW, 2016, DALTON T, V45, P3734, DOI 10.1039/c5dt04288g
   ROSENBERG B, 1969, NATURE, V222, P385, DOI 10.1038/222385a0
   ROSENBERG B, 1965, NATURE, V205, P698, DOI 10.1038/205698a0
   ROSENBERG B, 1967, J BACTERIOL, V93, P716, DOI 10.1128/JB.93.2.716-721.1967
   ROSENBERG B, 1967, J BIOL CHEM, V242, P1347
   Schiller JH, 2013, J CLIN ONCOL, V31, P981, DOI 10.1200/JCO.2012.47.5772
   Schulz E, 2003, RUSS CHEM B+, V52, P2588, DOI 10.1023/B:RUCB.0000019876.55079.3a
   Sheldrick G M., 1997, WINDOWS PROGRAM CRYS, V88
   Sheldrick GM, 2008, ACTA CRYSTALLOGR A, V64, P112, DOI 10.1107/S0108767307043930
   SHERMAN SE, 1987, CHEM REV, V87, P1153, DOI 10.1021/cr00081a013
   Song XL, 2013, CHEM COMMUN, V49, P4992, DOI 10.1039/c3cc40320c
   Stewart DJ, 2007, CRIT REV ONCOL HEMAT, V63, P12, DOI 10.1016/j.critrevonc.2007.02.001
   Wang D, 2010, P NATL ACAD SCI USA, V107, P9584, DOI 10.1073/pnas.1002565107
   Wheate NJ, 2010, DALTON T, V39, P8113, DOI 10.1039/c0dt00292e
   Wilson JJ, 2014, CHEM REV, V114, P4470, DOI 10.1021/cr4004314
   Wong E, 1999, CHEM REV, V99, P2451, DOI 10.1021/cr980420v
   Zheng F, 2013, DALTON T, V42, P11163, DOI 10.1039/c3dt51283e
   Zhou W, 2018, CHEM COMMUN, V54, P2788, DOI 10.1039/c8cc00393a
NR 71
TC 14
Z9 15
U1 2
U2 23
PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY-LES-MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE
SN 0223-5234
EI 1768-3254
J9 EUR J MED CHEM
JI Eur. J. Med. Chem.
PD FEB 15
PY 2019
VL 164
BP 546
EP 561
DI 10.1016/j.ejmech.2018.12.052
PG 16
WC Chemistry, Medicinal
WE Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC)
SC Pharmacology & Pharmacy
GA HK8EE
UT WOS:000458221400036
PM 30622026
DA 2022-04-25
ER

PT J
AU Chaeichi-Tehrani, N
   Ferns, GA
   Hassanian, SM
   Khazaei, M
   Avan, A
AF Chaeichi-Tehrani, Negin
   Ferns, Gordon A.
   Hassanian, Seyed Mahdi
   Khazaei, Majid
   Avan, Amir
TI The Therapeutic Potential of Targeting Autophagy in the Treatment of
   Cancer
SO CURRENT CANCER DRUG TARGETS
LA English
DT Review
DE Autophagy; lysosomes; pharmacologic agents; gastrointestinal cancers;
   therapeutic potential; chemotherapeutic drug
ID HEPATOCELLULAR-CARCINOMA CELLS; PANCREATIC-CANCER; INDUCED APOPTOSIS;
   ANTITUMOR-ACTIVITY; COLORECTAL-CANCER; PHOSPHATIDYLINOSITOL 3'-KINASE;
   INHIBITS AUTOPHAGY; STEM-CELLS; GROWTH; ADENOCARCINOMA
AB Autophagy is a mechanism by which unwanted cellular components are degraded through a pathway that involves the lysosomes and contributes to several pathological conditions such as cancer. Gastrointestinal cancers affect the digestive organs from the esophagus to the anus and are among the most commonly diagnosed cancers globally. The modulation of autophagy using pharmacologic agents offers a great potential for cancer therapy. In this review, some commonly used compounds, together with their molecular target and the mechanism through which they stimulate or block the autophagy pathway, as well as their therapeutic benefit in treating patients with gastrointestinal cancers, are summarized.
C1 [Chaeichi-Tehrani, Negin; Hassanian, Seyed Mahdi; Avan, Amir] Mashhad Univ Med Sci, Fac Med, Student Res Comm, Mashhad, Razavi Khorasan, Iran.
   [Chaeichi-Tehrani, Negin; Hassanian, Seyed Mahdi; Khazaei, Majid; Avan, Amir] Mashhad Univ Med Sci, Metab Syndrome Res Ctr, Mashhad, Razavi Khorasan, Iran.
   [Avan, Amir] Mashhad Univ Med Sci, Dept Med Genet, Mashhad, Razavi Khorasan, Iran.
   [Avan, Amir] Mashhad Univ Med Sci, Fac Med, Mashhad, Razavi Khorasan, Iran.
   [Ferns, Gordon A.] Brighton & Sussex Med Sch, Dept Med Educ, Brighton, Sussex, England.
RP Khazaei, M (corresponding author), Mashhad Univ Med Sci, Fac Med, Student Res Comm, Mashhad, Razavi Khorasan, Iran.
EM avana@mums.ac.ir
FU Mashhad University of Medical Sciences
FX This study was supported by a grant awarded to Amir Avan by the Mashhad
   University of Medical Sciences grant No:
CR Akkoc Y, 2018, TURK J GASTROENTEROL, V29, P270, DOI 10.5152/tjg.2018.150318
   Al-Bari MAA, 2015, J ANTIMICROB CHEMOTH, V70, P1608, DOI 10.1093/jac/dkv018
   Amaravadi RK, 2012, AUTOPHAGY, V8, P1383, DOI 10.4161/auto.20958
   Barth S, 2010, J PATHOL, V221, P117, DOI 10.1002/path.2694
   Bearzatto A, 1996, INT J ONCOL, V9, P57
   Ben-Zvi I, 2012, CLIN REV ALLERG IMMU, V42, P145, DOI 10.1007/s12016-010-8243-x
   Burada F, 2015, WORLD J GASTRO ONCOL, V7, P271, DOI 10.4251/wjgo.v7.i11.271
   Cai Q, 2020, INT J NANOMED, V15, P253, DOI 10.2147/IJN.S231289
   Chak A, 2015, CLIN GASTROENTEROL H, V13, P665, DOI 10.1016/j.cgh.2014.08.040
   Chang Y, 2012, GASTROENTEROLOGY, V143, P177, DOI 10.1053/j.gastro.2012.04.009
   Dielschneider RF, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/3749157
   Dong XQ, 2016, CELL DEATH DISCOV, V2, DOI 10.1038/cddiscovery.2016.87
   Dong Y, 2019, EUR REV MED PHARMACO, V23, P1047, DOI 10.26355/eurrev_201902_16992
   Donohue E, 2013, J CANCER, V4, P585, DOI 10.7150/jca.7030
   Egan DF, 2015, MOL CELL, V59, P285, DOI 10.1016/j.molcel.2015.05.031
   Floris G, 2013, CLIN CANCER RES, V19, P620, DOI 10.1158/1078-0432.CCR-12-2853
   Folkerts H, 2019, MED RES REV, V39, P517, DOI 10.1002/med.21531
   Fujiwara M, 2008, J EXP CLIN CANC RES, V27, DOI 10.1186/1756-9966-27-76
   Gao JJ, 2015, WORLD J GASTROENTERO, V21, P12059, DOI 10.3748/wjg.v21.i42.12059
   Gil-Ad I, 2008, INT J ONCOL, V33, P277, DOI 10.3892/ijo_00000007
   Hashimoto D, 2014, EUR J CANCER, V50, P1382, DOI 10.1016/j.ejca.2014.01.011
   He CJ, 2015, ONCOTARGET, V6, P28867, DOI 10.18632/oncotarget.4814
   He XX, 2018, MOL MED REP, V17, P6768, DOI 10.3892/mmr.2018.8661
   Heckmann BL, 2013, BRIT J PHARMACOL, V168, P163, DOI 10.1111/j.1476-5381.2012.02110.x
   Huang ST, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20163978
   Huang Tianzhi, 2018, Critical Reviews in Oncogenesis, V23, P247, DOI 10.1615/CritRevOncog.2018027913
   Huggett MT, 2014, BRIT J CANCER, V110, P1698, DOI 10.1038/bjc.2014.95
   Hundal R, 2014, CLIN EPIDEMIOL, V6, P99, DOI 10.2147/CLEP.S37357
   Jiang PD, 2014, CELL RES, V24, P69, DOI 10.1038/cr.2013.161
   Kondratskyi A, 2018, AUTOPHAGY, V14, P3, DOI 10.1080/15548627.2017.1384887
   Koustas E, 2019, CANCERS, V11, DOI 10.3390/cancers11040533
   Law BYK, 2014, SCI REP-UK, V4, DOI 10.1038/srep05510
   Li B, 2014, ONCOTARGET, V5, P11576, DOI 10.18632/oncotarget.2596
   Li FP, 2019, ONCOL REP, V42, P1647, DOI 10.3892/or.2019.7286
   Li LQ, 2016, TUMOR BIOL, V37, P653, DOI 10.1007/s13277-015-3842-z
   Li X, 2020, MOL CANCER, V19, DOI 10.1186/s12943-019-1085-0
   Liang X, 2014, CELL BIOSCI, V4, DOI 10.1186/2045-3701-4-10
   Limpert AS, 2018, TRENDS PHARMACOL SCI, V39, P1021, DOI 10.1016/j.tips.2018.10.004
   Mahalingam D, 2014, AUTOPHAGY, V10, P1403, DOI 10.4161/auto.29231
   Manogaran P, 2019, CURR TOP MED CHEM, V19, P2940, DOI 10.2174/1568026619666191116160908
   Mauthe M, 2018, AUTOPHAGY, V14, P1435, DOI 10.1080/15548627.2018.1474314
   Mauvezin C, 2015, AUTOPHAGY, V11, P1437, DOI 10.1080/15548627.2015.1066957
   McAfee Q, 2012, P NATL ACAD SCI USA, V109, P8253, DOI 10.1073/pnas.1118193109
   Motoi Y, 2014, ACS CHEM NEUROSCI, V5, P434, DOI 10.1021/cn500056q
   Mukubou H, 2010, INT J ONCOL, V37, P821, DOI 10.3892/ijo_00000732
   Ng SSW, 2001, CLIN CANCER RES, V7, P3269
   Park WH, 2003, INT J ONCOL, V22, P377
   Pasquier B, 2016, CELL MOL LIFE SCI, V73, P985, DOI 10.1007/s00018-015-2104-y
   Patil SP, 2015, J COMPUT AID MOL DES, V29, P155, DOI 10.1007/s10822-014-9811-6
   Pesce E, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01464
   Qiao XR, 2018, CANCER COMMUN, V38, DOI 10.1186/s40880-018-0309-9
   Rattanawong A, 2018, ONCOL REP, V39, P227, DOI 10.3892/or.2017.6084
   Ronan B, 2014, NAT CHEM BIOL, V10, P1013, DOI 10.1038/nchembio.1681
   Sasaki K, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-370
   Scott AJ, 2018, MOL CANCER THER, V17, P2112, DOI 10.1158/1535-7163.MCT-17-0131
   Semba S, 2002, CLIN CANCER RES, V8, P1957
   Song XX, 2018, CURR BIOL, V28, P2388, DOI 10.1016/j.cub.2018.05.094
   Song YJ, 2013, CANCER LETT, V339, P70, DOI 10.1016/j.canlet.2013.07.021
   Tang JY, 2014, BIOCHEM BIOPH RES CO, V453, P533, DOI 10.1016/j.bbrc.2014.09.115
   Taniguchi H, 2016, CANCER SCI, V107, P1556, DOI 10.1111/cas.13069
   Timme CR, 2013, APOPTOSIS, V18, P1163, DOI 10.1007/s10495-013-0883-x
   Vakifahmetoglu-Norberg H, 2013, GENE DEV, V27, P1718, DOI 10.1101/gad.220897.113
   Valcifahmetoglu-Norberg H, 2015, J CLIN INVEST, V125, P5, DOI 10.1172/JCI73937
   Verbaanderd C, 2017, ECANCERMEDICALSCIENC, V11, DOI 10.3332/ecancer.2017.781
   Wainberg ZA, 2015, CANCER CHEMOTH PHARM, V76, P61, DOI 10.1007/s00280-015-2744-5
   Wang QD, 2002, CLIN CANCER RES, V8, P1940
   Wang X, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-36214-5
   Wei R, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1043-0
   Wu YC, 2009, BIOCHEM BIOPH RES CO, V382, P451, DOI 10.1016/j.bbrc.2009.03.051
   Xu N, 2012, BIOCHEM BIOPH RES CO, V423, P826, DOI 10.1016/j.bbrc.2012.06.048
   Xu YH, 2013, ONCOL REP, V29, P2019, DOI 10.3892/or.2013.2338
   Yang AN, 2018, CANCER DISCOV, V8, P276, DOI 10.1158/2159-8290.CD-17-0952
   Yang A, 2014, AUTOPHAGY, V10, P1683, DOI 10.4161/auto.29961
   Yang SY, 2011, INT J ONCOL, V38, P1695, DOI 10.3892/ijo.2011.982
   Yang YP, 2013, ACTA PHARMACOL SIN, V34, P625, DOI 10.1038/aps.2013.5
   Zhou G, 2019, ONCOL LETT, V17, P2266, DOI 10.3892/ol.2018.9857
   Zhu MM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041763
NR 77
TC 1
Z9 1
U1 1
U2 1
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1568-0096
EI 1873-5576
J9 CURR CANCER DRUG TAR
JI Curr. Cancer Drug Targets
PY 2021
VL 21
IS 9
BP 725
EP 736
DI 10.2174/1568009621666210601113144
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA XO7LW
UT WOS:000730363400001
PM 34077348
DA 2022-04-25
ER

PT J
AU Su, T
   Zhu, JC
   Sun, RQ
   Zhang, HH
   Huang, QH
   Zhang, XD
   Du, RL
   Qiu, LQ
   Cao, RH
AF Su, Tong
   Zhu, Jiongchang
   Sun, Rongqin
   Zhang, Huihui
   Huang, Qiuhua
   Zhang, Xiaodong
   Du, Runlei
   Qiu, Liqin
   Cao, Rihui
TI Design, synthesis and biological evaluation of new quinoline derivatives
   as potential antitumor agents
SO EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
DE Synthesis; Quinoline derivative; Antitumor; Autophagy; ATG5
ID COLORECTAL-CANCER; AUTOPHAGY; MECHANISM
AB A series of new quinoline derivatives was designed, synthesized and evaluated for their antiproliferative activity. The results demonstrated that compounds 11p, lls, 11v, llx and 11y exhibited potent anti proliferative activity with 10(50) value of lower than 10 mu M against seven human tumor cell lines, and N-(3methoxypheny1)-7- (3-phenylpropoxy)quinolin-4-amine 11x was found to be the most potent anti proliferative agent against HCT-116, RKO, A2780 and Hela cell lines with an 10(50) value of 2.56, 3.67, 3.46 and 2.71 mu M, respectively. The antitumor efficacy of the representative compound 11x in mice was also evaluated, and the results showed that compound 11x effectively inhibited tumor growth and decreased tumor weight in animal models. Further investigation on mechanism of action indicated that compound llx could inhibit colorectal cancer growth through ATG5-depenent autophagy pathway. Therefore, these quinoline derivatives are a new class of molecules that have the potential to be developed as new antitumor drugs. 2019 Elsevier Masson SAS. All rights reserved.
C1 [Zhu, Jiongchang; Sun, Rongqin; Huang, Qiuhua; Qiu, Liqin; Cao, Rihui] Sun Yat Sen Univ, Sch Chem, 135 Xin Gang West Rd, Guangzhou 510275, Guangdong, Peoples R China.
   [Su, Tong; Zhang, Xiaodong; Du, Runlei] Wuhan Univ, Coll Life Sci, 299 Ba Yi Rd, Wuchang 430072, Peoples R China.
   [Zhang, Huihui] Hunan Normal Univ, Sch Med, Key Lab Study & Discovery Small Targeted Mol Huna, Changsha 410013, Hunan, Peoples R China.
RP Cao, RH (corresponding author), Sun Yat Sen Univ, Sch Chem, 135 Xin Gang West Rd, Guangzhou 510275, Guangdong, Peoples R China.
EM caorihui@mail.sysu.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81872271]; Natural Science Foundation of
   Guangdong ProvinceNational Natural Science Foundation of Guangdong
   Province [S2013010012138, 2016A030313349]; Research Foundation of
   Education Bureau of Hunan Province [1613161]; Fundamental Research Funds
   for the Central UniversitiesFundamental Research Funds for the Central
   Universities [413000099]; Zhongnan Hospital of Wuhan University Science,
   Technology and Innovation Seed Fund Project [cxpy2017005]
FX This work was supported by grants from National Natural Science
   Foundation of China [81872271], the Natural Science Foundation of
   Guangdong Province [S2013010012138 and 2016A030313349], Research
   Foundation of Education Bureau of Hunan Province[1613161] and the
   Fundamental Research Funds for the Central Universities [413000099] and
   Zhongnan Hospital of Wuhan University Science, Technology and Innovation
   Seed Fund Project [cxpy2017005].
CR Abdellatif KRA, 2017, MED CHEM RES, V26, P929, DOI 10.1007/s00044-017-1798-9
   Abouzid K, 2008, BIOORGAN MED CHEM, V16, P7543, DOI 10.1016/j.bmc.2008.07.038
   Aldred KJ, 2012, BIOCHEMISTRY-US, V51, P370, DOI 10.1021/bi2013905
   Amaravadi R., 2016, GENES DEV, V30
   Chaurio RA, 2009, MOLECULES, V14, P4892, DOI 10.3390/molecules14124892
   Galluzzi L, 2015, EMBO J, V34, P856, DOI 10.15252/embj.201490784
   Gong K, 2012, J BIOL CHEM, V287, P35576, DOI 10.1074/jbc.M112.370585
   Kaur K, 2010, EUR J MED CHEM, V45, P3245, DOI 10.1016/j.ejmech.2010.04.011
   Khelifi I, 2017, EUR J MED CHEM, V127, P1025, DOI 10.1016/j.ejmech.2016.11.012
   Kouznetsov VV, 2016, MED CHEM RES, V25, P2718, DOI 10.1007/s00044-016-1688-6
   Kumar AR, 2015, INDIAN J CHEM B, V54, P1495
   Levy J. M. M., 2017, NATURE REV, V17
   Li K, 2016, BIOORGAN MED CHEM, V24, P1889, DOI 10.1016/j.bmc.2016.03.016
   Li SZ, 2019, EUR J MED CHEM, V162, P666, DOI 10.1016/j.ejmech.2018.11.048
   Liang PS, 2019, MED CLIN N AM, V103, P111, DOI [10.1016/j.mcna.2018.08.010, 10]
   Marciniec K, 2017, MOLECULES, V22, DOI 10.3390/molecules22020300
   Mizushima N, 2011, ANNU REV CELL DEV BI, V27, P107, DOI 10.1146/annurev-cellbio-092910-154005
   Nasierowska-Guttmejer Anna, 2000, Pathology and Oncology Research, V6, P275
   Roncucci L, 2015, EUR J INTERN MED, V26, P752, DOI 10.1016/j.ejim.2015.08.019
   Salahuddin, 2015, MED CHEM RES, V24, P2514, DOI 10.1007/s00044-014-1308-2
   Shilabin AG, 2012, ACS MED CHEM LETT, V3, P592, DOI 10.1021/ml3001006
   Siegel RL, 2018, CA-CANCER J CLIN, V68, P7, DOI 10.3322/caac.21442
   Srivastava SK, 2007, ANTI-CANCER AGENT ME, V7, P685, DOI 10.2174/187152007784111313
   Sun J, 2013, EUR J MED CHEM, V60, P23, DOI 10.1016/j.ejmech.2012.11.039
   Wang L, 2015, BIOORGAN MED CHEM, V23, P4364, DOI 10.1016/j.bmc.2015.06.024
   Wang XQ, 2017, BIOORGAN MED CHEM, V25, P886, DOI 10.1016/j.bmc.2016.12.002
   Weiner J.A., 2018, INT J MOL SCI, V19
   White E, 2012, NAT REV CANCER, V12, P401, DOI 10.1038/nrc3262
   Zhang ZY, 2017, EUR J MED CHEM, V140, P239, DOI 10.1016/j.ejmech.2017.09.017
   陈黔, 2005, [中国新药杂志, Chinese Journal New Drugs], V14, P1231
NR 30
TC 23
Z9 23
U1 1
U2 32
PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY-LES-MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE
SN 0223-5234
EI 1768-3254
J9 EUR J MED CHEM
JI Eur. J. Med. Chem.
PD SEP 15
PY 2019
VL 178
BP 154
EP 167
DI 10.1016/j.ejmech.2019.05.088
PG 14
WC Chemistry, Medicinal
WE Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC)
SC Pharmacology & Pharmacy
GA IQ3PR
UT WOS:000480664100013
PM 31181480
DA 2022-04-25
ER

PT J
AU Lee, SH
   Moon, HJ
   Lee, YS
   Kang, CD
   Kim, SH
AF Lee, Su-Hoon
   Moon, Hyun-Jung
   Lee, Young-Shin
   Kang, Chi-Dug
   Kim, Sun-Hee
TI Potentiation of TRAIL-induced cell death by nonsteroidal
   anti-inflammatory drug in human hepatocellular carcinoma cells through
   the ER stress-dependent autophagy pathway
SO ONCOLOGY REPORTS
LA English
DT Article
DE hepatocellular carcinoma; TRAIL; non-steroidal anti-inflammatory drug;
   autophagy; CD44; c-FLIP; endoplasmic reticulum stress
ID COLON-CANCER CELLS; INDUCED APOPTOSIS; C-FLIP; UP-REGULATION; DUAL ROLE;
   EXPRESSION; CHOP; DEGRADATION; COMBINATION; CROSSTALK
AB Hepatocellular carcinoma (HCC) is the most commonly diagnosed primary liver malignancy. The limited success with relapse of the disease in HCC therapy is frequently associated with the acquired resistance to anticancer drugs. To develop a strategy and design for overcoming the resistance of HCC cells to TNF-related apoptosis inducing ligand (TRAIL)-induced cell death, we evaluated the efficacy of a non-steroidal anti-inflammatory drug (NSAID) in combination with TRAIL against TRAIL-resistant HCC cells expressing a high level of CD44. We revealed by MTT and western blotting, respectively, that celecoxib (CCB), an NSAID, and 2,5-dimethyl celecoxib (DMC), a non-cyclooxygenase (COX)-2 inhibitor analog of CCB, were able to sensitize TRAIL-resistant HCC cells to TRAIL, implicating a COX-independent mechanism. CCB dose-dependently enhanced LC3-II and reduced p62 levels through AMPK activation and inhibition of the Akt/mTOR pathway and upregulated expression of ATF4/CHOP, leading to activation of endoplasmic reticulum (ER) stress-dependent autophagy. The TRAIL sensitization capacity of CCB in TRAIL-resistant HCC cells was abrogated by an ER stress inhibitor. In addition, we also revealed by flow cytometry and western blotting, respectively, that accelerated downregulation of TRAIL-mediated c-FLIP expression, DR5 activation and CD44 degradation/downregulation by NSAID resulted in activation of caspases and poly(ADP-ribose) polymerase (PARP), leading to the sensitization of TRAIL-resistant HCC cells to TRAIL and thereby reversal of TRAIL resistance. From these results, we propose that NSAID in combination with TRAIL may improve the antitumor activity of TRAIL in TRAIL-resistant HCC, and this approach may serve as a novel strategy that maximizes the therapeutic efficacy of TRAIL for clinical application.
C1 [Lee, Su-Hoon; Moon, Hyun-Jung; Lee, Young-Shin; Kang, Chi-Dug; Kim, Sun-Hee] Pusan Natl Univ, Dept Biochem, Sch Med, Yangsan 626870, Gyeongsangnam D, South Korea.
RP Kang, CD; Kim, SH (corresponding author), Pusan Natl Univ, Dept Biochem, Sch Med, Yangsan 626870, Gyeongsangnam D, South Korea.
EM kcdshbw@pusan.ac.kr; ksh7738@pusan.ac.kr
FU Pusan National UniversityPusan National University
FX The present study was supported by Pusan National University Research
   Grant, 2019.
CR Akrami H, 2018, CELL BIOL INT, V42, P949, DOI 10.1002/cbin.10959
   B'chir W, 2014, CELL SIGNAL, V26, P1385, DOI 10.1016/j.cellsig.2014.03.009
   Bhattacharya S, 2017, INVEST OPHTH VIS SCI, V58, P2366, DOI 10.1167/iovs.16-21162
   Chen L, 2016, APOPTOSIS, V21, P1291, DOI 10.1007/s10495-016-1287-5
   Chen L, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.234
   Chen SZ, 2019, CANCER LETT, V460, P1, DOI 10.1016/j.canlet.2019.114428
   Chen YQ, 2017, J CELL COMMUN SIGNAL, V11, P219, DOI 10.1007/s12079-016-0364-4
   Cubillos-Ruiz JR, 2017, CELL, V168, P692, DOI 10.1016/j.cell.2016.12.004
   Duffy A, 2015, CANCER CHEMOTH PHARM, V75, P439, DOI 10.1007/s00280-014-2637-z
   Endo H, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2013.550
   Haakenson JK, 2015, J BIOL CHEM, V290, P8632, DOI 10.1074/jbc.M114.609677
   Hassanzadeh A, 2018, J CELL PHYSIOL, V233, P6470, DOI 10.1002/jcp.26585
   He MX, 2015, J IMMUNOL, V194, P3444, DOI 10.4049/jimmunol.1400469
   Hegazy AM, 2016, J BIOL CHEM, V291, P21496, DOI 10.1074/jbc.M116.734756
   Huang Y, 2016, INT J ONCOL, V49, P153, DOI 10.3892/ijo.2016.3525
   Jendrossek V, 2013, CANCER LETT, V332, P313, DOI 10.1016/j.canlet.2011.01.012
   Jeon MY, 2018, MOLECULES, V23, DOI 10.3390/molecules23113030
   Ji JF, 2012, SEMIN ONCOL, V39, P461, DOI 10.1053/j.seminoncol.2012.05.011
   Jiang PD, 2015, METHODS, V75, P13, DOI 10.1016/j.ymeth.2014.11.021
   Jiang W, 2019, BIOMED PHARMACOTHER, V110, P641, DOI 10.1016/j.biopha.2018.12.004
   Kim S, 2018, MOLECULES, V23, DOI 10.3390/molecules23071614
   Koehler BC, 2009, WORLD J GASTROENTERO, V15, P5924, DOI 10.3748/wjg.15.5924
   Ku Ja-Lok, 2005, Cancer Res Treat, V37, P1, DOI 10.4143/crt.2005.37.1.1
   Kumar D, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-171
   Lee JY, 2013, MOL CANCER THER, V12, P274, DOI 10.1158/1535-7163.MCT-12-0054
   Lee SH, 2016, ONCOL RES, V24, P495, DOI 10.3727/096504016X14685034103950
   Luo YK, 2016, CANCER CELL INT, V16, DOI 10.1186/s12935-016-0325-2
   Matsumoto H, 2013, BIOL OPEN, V2, P1084, DOI 10.1242/bio.20135033
   Matter MS, 2014, J HEPATOL, V60, P855, DOI 10.1016/j.jhep.2013.11.031
   Moon HJ, 2019, ONCOL RES, V27, P835, DOI 10.3727/096504019X15517850319579
   Nanbu T, 2018, ONCOL REP, V39, P367, DOI 10.3892/or.2017.6105
   Nazim UM, 2018, ONCOTARGET, V9, P4161, DOI 10.18632/oncotarget.23647
   Nazio F, 2019, CELL DEATH DIFFER, V26, P690, DOI 10.1038/s41418-019-0292-y
   Noh HJ, 2012, J CELL BIOCHEM, V113, P3692, DOI 10.1002/jcb.24242
   Pennarun B, 2013, J PATHOL, V229, P410, DOI 10.1002/path.4138
   Rozeik Mohammed Saeed, 2017, Electron Physician, V9, P4708, DOI 10.19082/4708
   Sheng JY, 2018, AM J CANCER RES, V8, P354
   Song SL, 2017, J CELL PHYSIOL, V232, P2977, DOI 10.1002/jcp.25785
   Su MF, 2013, J ONCOL, V2013, DOI 10.1155/2013/102735
   Trivedi R, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00069
   Umar A, 2016, SEMIN ONCOL, V43, P65, DOI 10.1053/j.seminoncol.2015.09.010
   Wu W, 2018, CANCER LETT, V417, P112, DOI 10.1016/j.canlet.2017.12.036
   Xu JN, 2016, J CELL BIOCHEM, V117, P1136, DOI 10.1002/jcb.25397
   Yu C, 2018, CANCER MED-US, V7, P471, DOI 10.1002/cam4.1287
   Zhang Z, 2018, CANCER MANAG RES, V10, P4631, DOI 10.2147/CMAR.S175212
NR 45
TC 4
Z9 4
U1 0
U2 3
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1021-335X
EI 1791-2431
J9 ONCOL REP
JI Oncol. Rep.
PD SEP
PY 2020
VL 44
IS 3
BP 1136
EP 1148
DI 10.3892/or.2020.7662
PG 13
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA NF8SU
UT WOS:000563563700027
PM 32705218
OA hybrid, Green Published
DA 2022-04-25
ER

PT J
AU Shi, XF
   Zhang, HY
   Jin, WD
   Liu, WC
   Yin, HJ
   Li, YX
   Dong, HJ
AF Shi, Xiafei
   Zhang, Hongyu
   Jin, Wendong
   Liu, Weichao
   Yin, Huijuan
   Li, Yingxin
   Dong, Huajiang
TI Metronomic photodynamic therapy with 5-aminolevulinic acid induces
   apoptosis and autophagy in human SW837 colorectal cancer cells
SO JOURNAL OF PHOTOCHEMISTRY AND PHOTOBIOLOGY B-BIOLOGY
LA English
DT Article
DE Metronomic photodynamic therapy; Apoptosis; Autophagy; Colorectal
   cancer; 5-Aminolevulinic acid (ALA)
ID FLUENCE RATE; FEASIBILITY; GLIOMA; MODEL
AB Metronomic photodynamic therapy (mPDT) has emerged as an attractive treatment for the selective destruction of tumor cells by induction of apoptosis. Here, we compared the effects of mPDT and acute photodynamic therapy (aPDT) on human SW837 colorectal cancer (CRC) cells. CRC cells were subjected to mPDT using various exposure durations, concentrations of 5-aminolevulinic acid (ALA), fluence rates and energy densities. The effects were compared with those induced by aPDT. We found that apoptosis and autophagy were earlier induced to a greater extent by mPDT than by the same dose applied as aPDT. The survival rates for mPDT vs. aPDT were 35.2%, 32.4%, 27.6%, 31.6% vs. 85.7%, 71.1%, 67.8%, 42.1% after 3, 6, 12, and 24 h PDT, respectively. For the same time points, the apoptotic rates for mPDT vs. aPDT were 43.2%, 47.3%, 54.7%, and 50.3% vs. 14.6%, 17.6%, 27.1%, and 53.2%, respectively. mPDT induced a peak rate of autophagy of 20.0% at 3 h, whereas aPDT induced two smaller peaks at 3 h (14.1%) and 12 h (15.8%). Advanced autophagosomes were more abundant in mPDT- than aPDT-treated cells and appeared earlier after mPDT (3 h) than after aPDT (3-12 h). Western Bloting results showed that the ratio of LC3B-II/beta - actin at 3 h was higher (1.04 times) after mPDT than aPDT. Collectively, these datas indicated that ALA-mPDT was more effective than the same dose of ALA-aPDT at inducing SW837 CRC cell death via apoptosis and autophagy. Thus, mPDT may be a superior choice than aPDT for the treatment of human CRC.
C1 [Shi, Xiafei; Jin, Wendong; Liu, Weichao; Yin, Huijuan; Li, Yingxin] Chinese Acad Med Sci, Peking Union Med Coll, Inst Biomed Engn, Lab Laser Med, Tianjin 300192, Peoples R China.
   [Zhang, Hongyu] Shanxi Prov Tumor Hosp, PETCT Ctr, Taiyuan 030013, Shanxi, Peoples R China.
   [Dong, Huajiang] Logist Univ Chinese Peoples Armed Police Forces, Tianjin 300309, Peoples R China.
RP Yin, HJ; Li, YX (corresponding author), Chinese Acad Med Sci, Peking Union Med Coll, Inst Biomed Engn, Lab Laser Med, Tianjin 300192, Peoples R China.
EM yinhj@bme.cams.cn; yingxinli2005@126.com
FU Fund Program for the Scientific Activities of Selected Returned Overseas
   Professionals in Shanxi Province
FX We thank the Fund Program for the Scientific Activities of Selected
   Returned Overseas Professionals in Shanxi Province for support.
CR Agostinis P, 2011, CA-CANCER J CLIN, V61, P250, DOI 10.3322/caac.20114
   Ahn MY, 2013, J ORAL PATHOL MED, V42, P17, DOI 10.1111/j.1600-0714.2012.01187.x
   Bisland SK, 2004, PHOTOCHEM PHOTOBIOL, V80, P22, DOI 10.1562/2004-03-05-RA-100.1
   Bogaards A, 2005, PHOTOCH PHOTOBIO SCI, V4, P438, DOI 10.1039/b414829k
   Bonora M, 2015, ONCOGENE, V34, P1608, DOI [10.1038/onc.2014.462, 10.1038/onc.2014.96]
   Busch TM, 2006, LASER SURG MED, V38, P494, DOI 10.1002/lsm.20355
   Buytaert E, 2007, BBA-REV CANCER, V1776, P86, DOI 10.1016/j.bbcan.2007.07.001
   Chen SN, 2010, BBA-REV CANCER, V1806, P220, DOI 10.1016/j.bbcan.2010.07.003
   Davies N, 2007, PHOTODIAGN PHOTODYN, V4, P184, DOI 10.1016/j.pdpdt.2007.03.005
   Davies N, 2007, PHOTODIAGN PHOTODYN, V4, P202, DOI 10.1016/j.pdpdt.2007.06.002
   Dini L, 2010, CANCER BIOL THER, V10, P1048, DOI 10.4161/cbt.10.10.13371
   Essick EE, 2010, OXID MED CELL LONGEV, V3, P168, DOI 10.4161/oxim.3.3.12106
   Ferlay J, 2013, EUR J CANCER, V49, P1374, DOI 10.1016/j.ejca.2012.12.027
   Gao H, 2016, J PHOTOCH PHOTOBIO B, V163, P162, DOI 10.1016/j.jphotobiol.2016.08.038
   Guo HW, 2015, PHOTODIAGN PHOTODYN, V12, P504, DOI 10.1016/j.pdpdt.2015.04.007
   Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]
   KAYE AH, 1987, J NEUROSURG, V67, P500, DOI 10.3171/jns.1987.67.4.0500
   Levy JMM, 2011, PHARMACOL THERAPEUT, V131, P130, DOI 10.1016/j.pharmthera.2011.03.009
   LOH CS, 1994, ENDOSCOPY, V26, P243, DOI 10.1055/s-2007-1008952
   Maycotte P, 2011, CANCER BIOL THER, V11, P127, DOI 10.4161/cbt.11.2.14627
   MOAN J, 1992, PHOTOCHEM PHOTOBIOL, V55, P931, DOI 10.1111/j.1751-1097.1992.tb08541.x
   Mornex F, 2006, INT J RADIAT ONCOL, V66, P1152, DOI 10.1016/j.ijrobp.2006.06.015
   MULLER PJ, 1995, SEMIN SURG ONCOL, V11, P346, DOI 10.1002/ssu.2980110504
   Mulsow J, 2011, BRIT J SURG, V98, P1785, DOI 10.1002/bjs.7653
   Nakamura T, 2003, GASTROINTEST ENDOSC, V57, P266, DOI 10.1067/mge.2003.57
   Ohtani K, 2017, PHOTODIAGN PHOTODYN, V20, P210, DOI 10.1016/j.pdpdt.2017.10.001
   Ong YH, 2018, PHYS MED BIOL, V63, DOI 10.1088/1361-6560/aa9874
   Rusten TE, 2010, NAT CELL BIOL, V12, P207, DOI 10.1038/ncb0310-207
   Scherer KM, 2017, ANTI-CANCER AGENT ME, V17, P171, DOI 10.2174/1871520616666160513131723
   Shi XF, 2018, J PHOTOCH PHOTOBIO B, V181, P143, DOI 10.1016/j.jphotobiol.2018.03.012
   Wang HW, 2007, PHOTOCHEM PHOTOBIOL, V83, P1040, DOI 10.1111/j.1751-1097.2007.00139.x
   Wilson BC, 1997, LASER MED SCI, V12, P182, DOI 10.1007/BF02765099
   Xie JM, 2014, CANCER RES, V74, P5127, DOI 10.1158/0008-5472.CAN-13-3517
   Yamagishi K, 2019, NAT BIOMED ENG, V3, P27, DOI 10.1038/s41551-018-0261-7
   Yang ZNJ, 2011, CANCER BIOL THER, V11, P169, DOI 10.4161/cbt.11.2.14663
   Yao TT, 2013, GENET MOL RES, V12, P312, DOI 10.4238/2013.February.4.5
   Ye XY, 2016, MOLECULES, V21, DOI 10.3390/molecules21101347
   Zhu YX, 2017, NANOSCALE, V9, P12874, DOI 10.1039/c7nr02279d
NR 38
TC 9
Z9 9
U1 3
U2 14
PU ELSEVIER SCIENCE SA
PI LAUSANNE
PA PO BOX 564, 1001 LAUSANNE, SWITZERLAND
SN 1011-1344
EI 1873-2682
J9 J PHOTOCH PHOTOBIO B
JI J. Photochem. Photobiol. B-Biol.
PD SEP
PY 2019
VL 198
AR 111586
DI 10.1016/j.jphotobiol.2019.111586
PG 9
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA IY4JM
UT WOS:000486357300018
PM 31437760
DA 2022-04-25
ER

PT J
AU Singh, MP
   Khaket, TP
   Bajpai, VK
   Alfarraj, S
   Kim, SG
   Chen, L
   Huh, YS
   Han, YK
   Kang, SC
AF Singh, Mahendra Pal
   Khaket, Tejinder Pal
   Bajpai, Vivek K.
   Alfarraj, Saleh
   Kim, Se-Gie
   Chen, Lei
   Huh, Yun Suk
   Han, Young-Kyu
   Kang, Sun Chul
TI Morin Hydrate Sensitizes Hepatoma Cells and Xenograft Tumor towards
   Cisplatin by Downregulating PARP-1-HMGB1 Mediated Autophagy
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE apoptosis; autophagy; cisplatin; HMGB1; morin hydrate
ID HEPATOCELLULAR-CARCINOMA; CANCER CELLS; DNA-DAMAGE; COLORECTAL-CANCER;
   INHIBITION; APOPTOSIS; STRESS; RESISTANT; DEATH; HMGB1
AB The cross-talk between apoptosis and autophagy influences anticancer drug sensitivity and cellular death in various cancer cell lines. However, the fundamental mechanisms behind this phenomenon are still unidentified. We demonstrated anti-cancerous role of cisplatin (CP) and morin hydrate (Mh) as an individual and/or in combination (CP-Mh) in hepatoma cells and tumor model. Exposure of CP resulted in the production of intracellular reactive oxygen species (ROS)-mediated cellular vacuolization, expansion of mitochondria membrane and activation of endoplasmic reticulum (ER)-stress. Consequently, Cyt c translocation led to the increase of Bax/Bcl-2 ratio, which simultaneously triggered caspase-mediated cellular apoptosis. In addition, CP-induced PARP-1 activation led to ADP-ribosylation of HMGB1, which consequently developed autophagy as evident by the LC3I/II ratio. Chemically-induced inhibition of autophagy marked by increased cell death signified a protective role of autophagy against CP treatment. CP-Mh abrogates the PARP-1 expression and significantly reduced HMGB1-cytoplasmic translocation with subsequent inhibition of the HMGB1-Beclin1 complex formation. In the absence of PARP-1, a reduced HMGB1 mediated autophagy was observed followed by induced caspase-dependent apoptosis. To confirm the role of PARP-1-HMGB1 signaling in autophagy, we used the PARP-1 inhibitor, 4-amino-1,8-naphthalimide (ANI), HMGB1 inhibitor, ethyl pyruvate (EP), autophagy inhibitors, 3-methyl adenine (3-MA) and bafilomycin (baf) and small interfering RNAs (siRNA) to target Atg5 in combination of CP and Mh. Exposure to these inhibitors enhanced the sensitivity of HepG2 cells to CP. Collectively, our findings indicate that CP-Mh in combination served as a prominent regulator of autophagy and significant inducer of apoptosis that maintains a homeostatic balance towards HepG2 cells and the subcutaneous tumor model.
C1 [Singh, Mahendra Pal; Kang, Sun Chul] Daegu Univ, Dept Biotechnol, Gyongsan 38453, Gyeongbuk, South Korea.
   [Singh, Mahendra Pal] Mayo Clin, Dept Immunol, Rochester, MN 55905 USA.
   [Khaket, Tejinder Pal] Ohio State Univ, Dept Radiat Oncol, Columbus, OH 43210 USA.
   [Bajpai, Vivek K.; Han, Young-Kyu] Dongguk Univ Seoul, Dept Energy & Mat Engn, 30 Pildong Ro 1 Gil, Seoul 04620, South Korea.
   [Alfarraj, Saleh] King Saud Univ, Coll Sci, Zool Dept, Riyadh 11451, Saudi Arabia.
   [Kim, Se-Gie] Daegu Catholic Univ, Dept Pharmaceut Engn, Gyeongsan 38430, Gyeongbuk, Saudi Arabia.
   [Chen, Lei] Fujian Agr & Forestry Univ, Coll Food Sci, Fuzhou 350002, Peoples R China.
   [Huh, Yun Suk] Inha Univ, Biohybrid Syst Res Ctr BSRC, Dept Biol Engn, 100 Inha Ro, Incheon 22212, South Korea.
RP Kang, SC (corresponding author), Daegu Univ, Dept Biotechnol, Gyongsan 38453, Gyeongbuk, South Korea.; Han, YK (corresponding author), Dongguk Univ Seoul, Dept Energy & Mat Engn, 30 Pildong Ro 1 Gil, Seoul 04620, South Korea.; Chen, L (corresponding author), Fujian Agr & Forestry Univ, Coll Food Sci, Fuzhou 350002, Peoples R China.
EM mahendra.rathore9@gmail.com; tejkhaket@gmail.com; vbiotech04@gmail.com;
   salfarraj@hotmail.com; sgkim7@cu.ac.kr; chenlei841114@hotmail.com;
   yunsuk.huh@inha.ac.kr; ykenergy@dongguk.edu; sckang@daegu.ac.kr
RI Singh, Mahendra Pal/J-8391-2019
OI Huh, Yun Suk/0000-0003-1612-4473
FU National Research Foundation of South Korea (NRF) [016R1A2B4009227,
   2016H1D3A1938249, 2017R1D1A1B03036569, RSP-2020/7]; King Saud
   University, Riyadh, Saudi ArabiaKing Saud University [RSP-2020/7]
FX This research was funded by the National Research Foundation of South
   Korea (NRF) - 016R1A2B4009227, 2016H1D3A1938249, and 2017R1D1A1B03036569
   grants. This research was funded by the Researchers Supporting Project
   Number (RSP-2020/7), King Saud University, Riyadh, Saudi Arabia.
CR Bae Jong Myon, 2002, Cancer Res Treat, V34, P77, DOI 10.4143/crt.2002.34.2.77
   Bajpai VK, 2020, THERANOSTICS, V10, P7841, DOI 10.7150/thno.42291
   Borst P, 2008, CELL CYCLE, V7, P1353, DOI 10.4161/cc.7.10.5930
   Caselli A, 2016, CURR MED CHEM, V23, P774, DOI 10.2174/0929867323666160106150821
   Cook KL, 2015, FUTURE MED CHEM, V7, P1529, DOI [10.4155/fmc.15.80, 10.4155/FMC.15.80]
   Diaz-Ruiz C, 2001, HISTOL HISTOPATHOL, V16, P415, DOI 10.14670/HH-16.415
   Dimassi Kaouther, 2014, Pan Afr Med J, V19, P148, DOI 10.11604/pamj.2014.19.148.4195
   Ding ZB, 2011, CLIN CANCER RES, V17, P6229, DOI 10.1158/1078-0432.CCR-11-0816
   Forner A, 2012, LANCET, V379, P1245, DOI 10.1016/S0140-6736(11)61347-0
   Guo XL, 2013, J MOL MED, V91, P473, DOI 10.1007/s00109-012-0966-0
   Hirama M, 2006, ONCOL REP, V16, P997
   Hoyer-Hansen M, 2007, CELL DEATH DIFFER, V14, P1576, DOI 10.1038/sj.cdd.4402200
   Jakhar R, 2014, INT IMMUNOPHARMACOL, V22, P356, DOI 10.1016/j.intimp.2014.07.020
   Jing Z, 2016, CANCER LETT, V372, P226, DOI 10.1016/j.canlet.2016.01.006
   Kudo M, 2012, LIVER CANCER, V1, P62, DOI 10.1159/000342402
   Li JZ, 2006, CURR MOL MED, V6, P45, DOI 10.2174/156652406775574523
   Li M, 2015, ONCOGENE, V34, P3349, DOI 10.1038/onc.2014.295
   Liu DL, 2011, MED ONCOL, V28, P105, DOI 10.1007/s12032-009-9397-3
   Luo X, 2012, GENE DEV, V26, P417, DOI 10.1101/gad.183509.111
   Maddalena F, 2011, CANCER RES, V71, P7659, DOI 10.1158/0008-5472.CAN-11-2172
   Rodriguez-Vargas JM, 2012, CELL RES, V22, P1181, DOI 10.1038/cr.2012.70
   Michels J, 2013, CANCER RES, V73, P2271, DOI 10.1158/0008-5472.CAN-12-3000
   Munoz-Gamez JA, 2005, BIOCHEM J, V386, P119, DOI 10.1042/BJ20040776
   Munoz-Gomez JA, 2009, AUTOPHAGY, V5, P61, DOI 10.4161/auto.5.1.7272
   Gutierrez RMP, 2008, J ETHNOPHARMACOL, V117, P1, DOI 10.1016/j.jep.2008.01.025
   Shi YH, 2011, AUTOPHAGY, V7, P1159, DOI 10.4161/auto.7.10.16818
   Singh MP, 2019, CANCERS, V11, DOI 10.3390/cancers11070986
   Singh MP, 2017, BIOMED PHARMACOTHER, V88, P151, DOI 10.1016/j.biopha.2017.01.027
   Singh MP, 2015, INT J MOL MED, V36, P992, DOI 10.3892/ijmm.2015.2306
   SINGH NP, 1988, EXP CELL RES, V175, P184, DOI 10.1016/0014-4827(88)90265-0
   Sun Y, 2013, ONCOL RES, V21, P261, DOI 10.3727/096504014X13946388748992
   Tang D, 2010, ONCOGENE, V29, P5299, DOI 10.1038/onc.2010.261
   Tang DL, 2010, J CELL BIOL, V190, P881, DOI 10.1083/jcb.200911078
   Wang CY, 1999, NAT MED, V5, P412, DOI 10.1038/7410
   Wang Zhifeng, 2012, Front Med, V6, P156, DOI 10.1007/s11684-012-0197-3
   White E, 2009, CLIN CANCER RES, V15, P5308, DOI 10.1158/1078-0432.CCR-07-5023
   Wolfe KL, 2008, J AGR FOOD CHEM, V56, P8404, DOI 10.1021/jf8013074
   Wyrsch P, 2012, MOL CELL BIOL, V32, P3541, DOI 10.1128/MCB.00437-12
   Yang MH, 2015, AUTOPHAGY, V11, P214, DOI 10.4161/15548627.2014.994400
   Yin HB, 2017, ONCOTARGET, V8, P71642, DOI 10.18632/oncotarget.17796
   Youn JH, 2006, J IMMUNOL, V177, P7889, DOI 10.4049/jimmunol.177.11.7889
   Yuan X, 2015, SCI REP-UK, V5, DOI 10.1038/srep12889
   Zhang Y, 2012, ONCOGENE, V31, P1055, DOI 10.1038/onc.2011.290
NR 43
TC 6
Z9 6
U1 0
U2 5
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD NOV
PY 2020
VL 21
IS 21
AR 8253
DI 10.3390/ijms21218253
PG 24
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA OQ8VA
UT WOS:000589052800001
PM 33158052
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Soni, M
   Patel, Y
   Markoutsa, E
   Jie, CF
   Liu, S
   Xu, PS
   Chen, HX
AF Soni, Mithil
   Patel, Yogin
   Markoutsa, Eleni
   Jie, Chunfa
   Liu, Shou
   Xu, Peisheng
   Chen, Hexin
TI Autophagy, Cell Viability, and Chemoresistance Are Regulated By miR-489
   in Breast Cancer
SO MOLECULAR CANCER RESEARCH
LA English
DT Article
ID HEPATOCELLULAR-CARCINOMA; MULTIDRUG-RESISTANCE; COLORECTAL-CANCER;
   TUMOR-GROWTH; LAPTM4B; INHIBITION; CHEMOTHERAPY; PROLIFERATION;
   CONTRIBUTES; SUPPRESSION
AB It is postulated that the complexity and heterogeneity in cancer may hinder most efforts that target a single pathway. Thus, discovery of novel therapeutic agents targeting multiple pathways, such as miRNAs, holds promise for future cancer therapy. One such miRNA, miR-489, is downregulated in a majority of breast cancer cells and several drug-resistant breast cancer cell lines, but its role and underlying mechanism for tumor suppression and drug resistance needs further investigation. The current study identifies autophagy as a novel pathway targeted by miR-489 and reports Unc-51 like autophagy activating kinase 1 (ULK1) and lysosomal protein transmembrane 4 beta (LAPTM4B) to be direct targets of miR-489. Furthermore, the data demonstrate autophagy inhibition and LAPTM4B downregulation as a major mechanism responsible for miR-489-mediated doxorubicin sensitization. Finally, miR-489 and LAPTM4B levels were inversely correlated in human tumor clinical specimens, and more importantly, miR-489 expression levels predict overall survival in patients with 8q22 amplification (the region in which LAPTM4B resides).
   Implications: These findings expand the understanding of miR-489-mediated tumor suppression and chemosensitization in and suggest a strategy for using miR-489 as a therapeutic sensitizer in a defined subgroup of resistant breast cancer patients. (C) 2018 AACR.
C1 [Soni, Mithil; Patel, Yogin; Liu, Shou; Chen, Hexin] Univ South Carolina, Dept Biol Sci, 715 Sumter St,PSC621, Columbia, SC 29205 USA.
   [Soni, Mithil; Patel, Yogin; Liu, Shou; Chen, Hexin] Univ South Carolina, Ctr Colon Canc Res, Columbia, SC 29208 USA.
   [Markoutsa, Eleni; Xu, Peisheng] Univ South Carolina, South Carolina Coll Pharm, Dept Drug Discovery & Biomed Sci, Columbia, SC 29208 USA.
   [Jie, Chunfa] Des Moines Univ, Biomed Sci Program, Sci, Des Moines, IA USA.
RP Chen, HX (corresponding author), Univ South Carolina, Dept Biol Sci, 715 Sumter St,PSC621, Columbia, SC 29205 USA.
EM hchen@biol.sc.edu
RI chen, hexin/F-1714-2011
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [5R01 CA178386-04, 1R15CA188847-01A1,
   1R01AG054839-01A1]; USC ASPIRE-1 grant; USC ASPIRE postdoctoral
   fellowship; USC SPARC graduate fellowship; NATIONAL CANCER
   INSTITUTEUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)
   [R01CA178386, R15CA188847] Funding Source: NIH RePORTER; NATIONAL
   INSTITUTE ON AGINGUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   on Aging (NIA) [R01AG054839] Funding Source: NIH RePORTER
FX The authors thank Dr. Thomas Blom and Dr. Elina Ikonen for providing
   LAPTM4B-mCherry and pcDNA-3xFLAG-LAPTM4B vectors, Dr. Jayanta Debnath
   for mCherry-EGFP-LC3B (Addgene # 22418) vector, and Dr. Do-Hyung Kim for
   HA-ULK1 vector (Addgene # 31963). This work was partially supported by
   the NIH grant (5R01 CA178386-04) and the USC ASPIRE-1 grant (to H.
   Chen), the NIH grants (1R15CA188847-01A1 and 1R01AG054839-01A1; to P.
   Xu), the USC ASPIRE postdoctoral fellowship (to S. Liu), and the USC
   SPARC graduate fellowship (to M. Soni).
CR Adams BD, 2016, CANCER RES, V76, P927, DOI 10.1158/0008-5472.CAN-15-2321
   Blom T, 2015, NAT CHEM BIOL, V11, P799, DOI [10.1038/nchembio.1889, 10.1038/NCHEMBIO.1889]
   BORST P, 1993, PHARMACOL THERAPEUT, V60, P289, DOI 10.1016/0163-7258(93)90011-2
   Button RW, 2017, J BIOL CHEM, V292, P13599, DOI 10.1074/jbc.M117.782276
   Chan EYW, 2009, MOL CELL BIOL, V29, P157, DOI 10.1128/MCB.01082-08
   Chen X, 2016, J PATHOL, V239, P459, DOI 10.1002/path.4743
   Chittaranjan S, 2014, CLIN CANCER RES, V20, P3159, DOI 10.1158/1078-0432.CCR-13-2060
   Choi J, 2011, FERTIL STERIL, V95, P1482, DOI 10.1016/j.fertnstert.2010.06.006
   de Ronde JJ, 2013, BREAST CANCER RES TR, V137, P213, DOI 10.1007/s10549-012-2340-x
   Dvinge H, 2013, NATURE, V497, P378, DOI 10.1038/nature12108
   Eskelinen EL, 2011, CURR OPIN PHARMACOL, V11, P294, DOI 10.1016/j.coph.2011.03.009
   Esparza-Lopez J, 2017, REV INVEST CLIN, V69, P66
   Fulda S, 2015, ONCOGENE, V34, P5105, DOI 10.1038/onc.2014.458
   Geng Y, 2010, NEURO-ONCOLOGY, V12, P473, DOI 10.1093/neuonc/nop048
   Gray J, 2012, NATURE, V486, P328, DOI 10.1038/486328a
   Gugnoni M, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.415
   Guo BQ, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2790-3
   Hara T, 2008, J CELL BIOL, V181, P497, DOI 10.1083/jcb.200712064
   Hu YL, 2012, CANCER RES, V72, P4294, DOI 10.1158/0008-5472.CAN-12-1076
   Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783
   Jiang L, 2014, FEBS LETT, V588, P2009, DOI 10.1016/j.febslet.2014.04.024
   Kanematsu S, 2010, ANTICANCER RES, V30, P3381
   Kikkawa N, 2010, BRIT J CANCER, V103, P877, DOI 10.1038/sj.bjc.6605811
   Kim DG, 2014, ONCOTARGET, V5, P4438, DOI 10.18632/oncotarget.2034
   Kiyono K, 2009, CANCER RES, V69, P8844, DOI 10.1158/0008-5472.CAN-08-4401
   Klionsky DJ, 2012, AUTOPHAGY, V8, P445, DOI 10.4161/auto.19496
   Lee EJ, 2011, AUTOPHAGY, V7, P689, DOI 10.4161/auto.7.7.15450
   Li CG, 2015, CELL PHYSIOL BIOCHEM, V35, P1303, DOI 10.1159/000373952
   Li J, 2016, ONCOL RES, V24, P391, DOI 10.3727/096504016X14666990347518
   Li L, 2010, ONCOGENE, V29, P5785, DOI 10.1038/onc.2010.303
   Li SD, 2008, J CONTROL RELEASE, V126, P77, DOI 10.1016/j.jconrel.2007.11.002
   Li SD, 2006, MOL PHARMACEUT, V3, P579, DOI 10.1021/mp060039w
   Li Y, 2012, AUTOPHAGY, V8, P273, DOI 10.4161/auto.8.2.18941
   Li Y, 2011, CANCER RES, V71, P7481, DOI 10.1158/0008-5472.CAN-11-0940
   Li Y, 2010, NAT MED, V16, P214, DOI 10.1038/nm.2090
   Li Y, 2016, ONCOL LETT, V12, P523, DOI 10.3892/ol.2016.4613
   Lin YX, 2017, TRANSL ONCOL, V10, P211, DOI 10.1016/j.tranon.2017.01.010
   Liu QF, 2017, MOL CARCINOGEN, V56, P1312, DOI 10.1002/mc.22593
   Maycotte P, 2014, CANCER RES, V74, P2579, DOI 10.1158/0008-5472.CAN-13-3470
   Meng Y, 2016, ONCOGENE, V35, P6359, DOI 10.1038/onc.2016.189
   Miller TE, 2008, J BIOL CHEM, V283, P29897, DOI 10.1074/jbc.M804612200
   Mizushima N, 2010, CELL, V140, P313, DOI 10.1016/j.cell.2010.01.028
   Pan BZ, 2015, ONCOTARGET, V6, P32805, DOI 10.18632/oncotarget.5352
   Patel Y, 2016, JOVE-J VIS EXP, V112
   Patel Y, 2016, ONCOTARGET, V7, P18295, DOI 10.18632/oncotarget.7577
   Shingu T, 2009, INT J CANCER, V124, P1060, DOI 10.1002/ijc.24030
   Tao YM, 2017, ONCOTARGET, V8, P36410, DOI 10.18632/oncotarget.16850
   Wei RX, 2016, BIOSCIENCE REP, V36, DOI 10.1042/BSR20160238
   White E, 2015, CLIN CANCER RES, V21, P5037, DOI 10.1158/1078-0432.CCR-15-0490
   Wu HJ, 2014, ANTI-CANCER DRUG, V25, P799, DOI 10.1097/CAD.0000000000000107
   Xie ZT, 2015, TUMOR BIOL, V36, P6497, DOI 10.1007/s13277-015-3340-3
   Zhai HY, 2015, ONCOTARGET, V6, P19735, DOI 10.18632/oncotarget.3771
   Zhang B, 2016, AM J CANCER RES, V6, P2021
   Zhou J, 2015, AUTOPHAGY, V11, P1259, DOI 10.1080/15548627.2015.1056970
NR 54
TC 33
Z9 34
U1 0
U2 6
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1541-7786
EI 1557-3125
J9 MOL CANCER RES
JI Mol. Cancer Res.
PD SEP
PY 2018
VL 16
IS 9
BP 1348
EP 1360
DI 10.1158/1541-7786.MCR-17-0634
PG 13
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA GS9HI
UT WOS:000444027800003
PM 29784669
OA Green Accepted, Bronze
DA 2022-04-25
ER

PT J
AU Hong, EH
   Heo, EY
   Song, JH
   Kwon, BE
   Lee, JY
   Park, Y
   Kim, J
   Chang, SY
   Chin, YW
   Jeon, SM
   Ko, HJ
AF Hong, Eun-Hye
   Heo, Eun-Young
   Song, Jae-Hyoung
   Kwon, Bo-Eun
   Lee, Jae-Young
   Park, Yaejeong
   Kim, Jinwoong
   Chang, Sun-Young
   Chin, Young-Won
   Jeon, Sang-Min
   Ko, Hyun-Jeong
TI Trans-scirpusin A showed antitumor effects via autophagy activation and
   apoptosis induction of colorectal cancer cells
SO ONCOTARGET
LA English
DT Article
DE trans-scirpusin A; colorectal cancer cells; AMPK; autophagy; apoptosis
ID IN-VIVO; POLYPHENOLIC COMPOUNDS; BREAST-CANCER; RESVERATROL; DIMER;
   TUMORIGENESIS; INHIBITION; EXPRESSION; PREVENTION; RESPONSES
AB Trans-Scirpusin A (TSA) is a resveratrol oligomer found in Borassus flabelliferL. We found that TSA inhibited the growth of colorectal cancer Her2/CT26 cells in vivo in mice. Although some cytotoxic T lymphocytes (CTLs) were induced against the tumor-associated antigen Her2, TSA treatment did not significantly increase the level of Her2-specific CTL response compared to that with vehicle treatment. However, there was a significant increase in the level of TNF-a mRNA in tumor tissue and Her2specific Ab (antibody) production. More importantly, we found that TSA overcomes the tumor-associated immunosuppressive microenvironment by reducing the number of CD25+ FoxP3+ regulatory T cells and myeloid-derived suppressor cells (MDSCs). We detected the induction of autophagy in TSA-treated Her2/CT26 cells, based on the increased level of the mammalian autophagy protein LC3 puncta, and increased conversion of LC3-I to LC3-II. Further, TSA induced 5' AMP-activated protein kinase (p-AMPK) (T172) and inhibited mammalian target of rapamycin complex 1 (mTORC1) activity as estimated by phosphorylated ribosomal protein S6 kinase beta-1 (p-p70S6K) levels, thereby suggesting that TSA-mediated AMPK activation and inhibition of mTORC1 pathway might be associated with autophagy induction. TSA also induced apoptosis of Her2/CT26 cells, as inferred by the increased sub-G1 mitotic phases in these cells, Annexin V/PI-double positive results, and TUNELpositive cells. Finally, we found that the combined treatment of mice with docetaxel and TSA successfully inhibited tumor growth to a greater extent than docetaxel alone. Therefore, we propose the use of TSA for supplementary anticancer therapy to support anti-neoplastic drugs, such as docetaxel, by inducing apoptosis in cancer cells and resulting in the induction of neighborhood anti-cancer immunity.
C1 [Hong, Eun-Hye; Heo, Eun-Young; Song, Jae-Hyoung; Kwon, Bo-Eun; Lee, Jae-Young; Ko, Hyun-Jeong] Kangwon Natl Univ, Coll Pharm, Lab Microbiol & Immunol, Chunchon 24341, Gangwon Do, South Korea.
   [Chang, Sun-Young] Ajou Univ, Coll Pharm, Lab Microbiol, Suwon 16499, Gyeonggi Do, South Korea.
   [Chang, Sun-Young; Jeon, Sang-Min] Ajou Univ, RIPST, Suwon 16499, Gyeonggi Do, South Korea.
   [Jeon, Sang-Min] Ajou Univ, Coll Pharm, Lab Canc Signaling & Metab Network, Suwon 16499, Gyeonggi Do, South Korea.
   [Park, Yaejeong; Kim, Jinwoong] Seoul Natl Univ, Coll Pharm, Seoul 08826, South Korea.
   [Park, Yaejeong; Kim, Jinwoong] Seoul Natl Univ, Res Inst Pharmaceut Sci, Seoul 08826, South Korea.
   [Chin, Young-Won] Dongguk Univ Seoul, Coll Pharm, Goyang 10326, Gyeonggi Do, South Korea.
   [Chin, Young-Won] Dongguk Univ Seoul, Integrated Res Inst Drug Dev, Goyang 10326, Gyeonggi Do, South Korea.
   [Ko, Hyun-Jeong] Adv Inst Convergence Technol, Convergence Res Ctr Funct Plant Prod, Suwon 16229, Gyeonggi Do, South Korea.
RP Ko, HJ (corresponding author), Kangwon Natl Univ, Coll Pharm, Lab Microbiol & Immunol, Chunchon 24341, Gangwon Do, South Korea.; Jeon, SM (corresponding author), Ajou Univ, RIPST, Suwon 16499, Gyeonggi Do, South Korea.; Jeon, SM (corresponding author), Ajou Univ, Coll Pharm, Lab Canc Signaling & Metab Network, Suwon 16499, Gyeonggi Do, South Korea.; Ko, HJ (corresponding author), Adv Inst Convergence Technol, Convergence Res Ctr Funct Plant Prod, Suwon 16229, Gyeonggi Do, South Korea.
EM smjeon@ajou.ac.kr; hjko@kangwon.ac.kr
RI Jeon, Sang-Min/I-7917-2018
OI Jeon, Sang-Min/0000-0002-0132-925X; Ko, Hyun-Jeong/0000-0002-3844-928X;
   Chin, Young-Won/0000-0001-6964-1779
FU Basic Science Research Program through the National Research Foundation
   of Korea (NRF) - Ministry of Science, ICT and Future Planning
   [NRF-2016R1A4A1010115]; Kangwon National University [520150291]; Korean
   Health Technology R&D Project, Ministry of Health & Welfare, Republic of
   Korea [HI15C0450]; National Research Foundation of Korea (NRF) grants -
   Ministry of Science, ICT and Future Planning [NRF-2015M2B2A6028602]
FX This research was supported by the Basic Science Research Program
   through the National Research Foundation of Korea (NRF) funded by the
   Ministry of Science, ICT and Future Planning (NRF-2016R1A4A1010115).
   This study was supported by the 2015 Research Grant from Kangwon
   National University (No. 520150291) and was supported by a grant from
   the Korean Health Technology R&D Project, Ministry of Health & Welfare,
   Republic of Korea (HI15C0450). This study was supported by the National
   Research Foundation of Korea (NRF) grants funded by the Ministry of
   Science, ICT and Future Planning (No. NRF-2015M2B2A6028602).
CR Abdal Dayem A, 2016, NUTRIENTS, V8
   Aggarwal BB, 2004, ANTICANCER RES, V24, P2783
   Baek SH, 2016, PHYTOMEDICINE, V23, P566, DOI 10.1016/j.phymed.2016.02.011
   Berrougui H, 2009, ATHEROSCLEROSIS, V207, P420, DOI 10.1016/j.atherosclerosis.2009.05.017
   Bognar E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065355
   Brglez Mojzer E, 2016, MOLECULES, V21
   Fantini M, 2015, INT J MOL SCI, V16, P9236, DOI 10.3390/ijms16059236
   Feng Y, 2016, PHARM BIOL, V54, P1027, DOI 10.3109/13880209.2015.1093510
   Hasima N, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.467
   Hausenblas HA, 2015, MOL NUTR FOOD RES, V59, P147, DOI 10.1002/mnfr.201400173
   Hwang D, 2015, SCI REP-UK, V5, DOI 10.1038/srep10029
   Jiang ZD, 2016, NUTRIENTS, V8, DOI 10.3390/nu8100546
   Kim HJ, 2014, BIOMOL THER, V22, P275, DOI 10.4062/biomolther.2014.068
   Kim YJ, 2008, INT J CANCER, V122, P2774, DOI 10.1002/ijc.23444
   Kim Young-In, 2014, Immune Netw, V14, P100, DOI 10.4110/in.2014.14.2.100
   Kong QJ, 2010, J SCI FOOD AGR, V90, P823, DOI 10.1002/jsfa.3890
   Lee BR, 2014, ONCOTARGET, V5, P12331, DOI 10.18632/oncotarget.2589
   Leonard SS, 2003, BIOCHEM BIOPH RES CO, V309, P1017, DOI 10.1016/j.bbrc.2003.08.105
   Machova Urdzikova L, 2016, INT J MOL SCI, V17
   Meng J, 2016, SCI REP-UK, V6, DOI 10.1038/srep22390
   Mocanu MM, 2015, MOLECULES, V20, P22578, DOI 10.3390/molecules201219864
   Morikawa T, 2010, CHEM PHARM BULL, V58, P1379, DOI 10.1248/cpb.58.1379
   Riccioni G, 2015, INT J FOOD SCI NUTR, V66, P603, DOI 10.3109/09637486.2015.1077796
   Rinner B, 2009, ANTICANCER RES, V29, P4519
   Riviere C, 2010, BIOORG MED CHEM LETT, V20, P3441, DOI 10.1016/j.bmcl.2009.09.074
   Sano S, 2011, J AGR FOOD CHEM, V59, P6209, DOI 10.1021/jf104959t
   Saud SM, 2014, CARCINOGENESIS, V35, P2778, DOI 10.1093/carcin/bgu209
   Shrotriya S, 2015, MOL CARCINOGEN, V54, P291, DOI 10.1002/mc.22099
   Smeriglio A, 2016, PHYTOTHER RES, V30, P1298, DOI 10.1002/ptr.5623
   Song JH, 2015, BIOMOL THER, V23, P465, DOI 10.4062/biomolther.2015.095
   Song SY, 2016, ONCOTARGET, V7, P77348, DOI 10.18632/oncotarget.12668
   Tome-Carneiro J, 2013, ANN NY ACAD SCI, V1290, P37, DOI 10.1111/nyas.12150
   Weber K, 2011, MYCOSES, V54, P30, DOI 10.1111/j.1439-0507.2009.01763.x
   Weiskirchen S, 2016, ADV NUTR, V7, P706, DOI 10.3945/an.115.011627
   Whitlock NC, 2012, NUTR CANCER, V64, P493, DOI 10.1080/01635581.2012.667862
NR 35
TC 11
Z9 11
U1 1
U2 14
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD JUN 20
PY 2017
VL 8
IS 25
BP 41401
EP 41411
DI 10.18632/oncotarget.17388
PG 11
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA EY8YG
UT WOS:000404283700118
PM 28489607
OA gold, Green Published, Green Submitted
DA 2022-04-25
ER

PT J
AU Peng, JQ
   Wang, Q
   Zhou, J
   Zhao, SL
   Di, P
   Chen, Y
   Tao, L
   Du, QM
   Shen, XC
   Chen, Y
AF Peng, Jianqing
   Wang, Qin
   Zhou, Jia
   Zhao, Shuli
   Di, Pan
   Chen, Yan
   Tao, Ling
   Du, Qianming
   Shen, Xiangchun
   Chen, Yi
TI Targeted Lipid Nanoparticles Encapsulating Dihydroartemisinin and
   Chloroquine Phosphate for Suppressing the Proliferation and Liver
   Metastasis of Colorectal Cancer
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE chloroquine phosphate; lipid nanoparticles; colorectal cancer; liver
   metastasis; ROS; dihydroartemisinin
ID CELL-CYCLE ARREST; AUTOPHAGY; ARTEMISININ; ANGIOGENESIS; DERIVATIVES;
   FERROPTOSIS; INHIBITION; INDUCTION; GROWTH
AB Antimalarial drugs Dihydroartemisinin (DHA) and chloroquine phosphate (CQ) exhibit evident anti-cancer activity, particularly as combination therapy. DHA and CQ combination therapy has been proved to exhibit higher cytotoxic effect in tumor cells and lower toxicity to normal cells than combination of artemisinin derivatives (ARTs) and anticancer chemotherapy drugs. However, different physiochemical properties of DHA and CQ, leading to distinctive in vivo outcomes, considerably limited their synergistic effect in cancer treatment. Herein, we developed a lipid nanoparticle (LNP) for co-delivery of DHA and CQ to inhibit proliferation and metastasis of colorectal cancer. Considering the beneficial effects of acid/reactive oxide species (ROS)-sensitive phospholipids and targeting ligands for colorectal cancer cells, an RGD peptide-modified pH/ROS dual-sensitive LNP loaded with DHA and CQ (RLNP/DC) was prepared. It exhibited optimal cytotoxicity and suppression of invasion and metastasis in HCT116 cells in vitro, attributable to irreversible upregulation of intracellular ROS levels, downregulation of VEGF expression, and upregulation of paxillin expression. A mouse model of orthotopic metastasis of colorectal cancer was established to evaluate anti-proliferation and anti-metastasis effects of RLNP/DC in vivo. Thus, an optimized nanoplatform for DHA and CQ combination therapy was developed in this study that offered potential antitumor efficacy against colorectal cancer.
C1 [Peng, Jianqing; Wang, Qin; Zhou, Jia; Di, Pan; Chen, Yan; Tao, Ling; Shen, Xiangchun; Chen, Yi] Guizhou Med Univ, State Key Lab Funct & Applicat Med Plants, Guiyang, Peoples R China.
   [Peng, Jianqing; Wang, Qin; Zhou, Jia; Di, Pan; Chen, Yan; Tao, Ling; Shen, Xiangchun; Chen, Yi] Guizhou Med Univ, High Efficacy Applicat Nat Med Resources Engn Ct, Sch Pharmaceut Sci, Guiyang, Peoples R China.
   [Zhao, Shuli; Du, Qianming] Nanjing Med Univ, Nanjing Hosp 1, Gen Clin Res Ctr, Nanjing, Peoples R China.
   [Zhao, Shuli; Du, Qianming] China Pharmaceut Univ, Sch Basic Med & Clin Pharm, Dept Clin Pharm, Nanjing, Peoples R China.
RP Shen, XC; Chen, Y (corresponding author), Guizhou Med Univ, State Key Lab Funct & Applicat Med Plants, Guiyang, Peoples R China.; Shen, XC; Chen, Y (corresponding author), Guizhou Med Univ, High Efficacy Applicat Nat Med Resources Engn Ct, Sch Pharmaceut Sci, Guiyang, Peoples R China.; Du, QM (corresponding author), Nanjing Med Univ, Nanjing Hosp 1, Gen Clin Res Ctr, Nanjing, Peoples R China.; Du, QM (corresponding author), China Pharmaceut Univ, Sch Basic Med & Clin Pharm, Dept Clin Pharm, Nanjing, Peoples R China.
EM duqianming@njmu.edu.cn; shenxiangchun@126.com; chenyi_19890319@126.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81960647, 81702833]; Guizhou Provincial
   Natural Science Foundation [(2019)1255]; Excellent Young Talents Plan of
   Guizhou Medical University [2020-102, 2021-103]; High-level Overseas
   Talent Fund for Home Work from the Ministry of Human Resources and
   Social Security [RSBLXHGZ202001]; Foundation for Training Programs of
   Innovation and Entrepreneurship for Undergraduates of Guizhou Medical
   University [S202010660037]; Jiangsu Provincial Special Program of
   Medical Science [BE2019617]; Distinguished Young Scholars of Nanjing
   [JQX20008]
FX This work was financially supported by the National Natural Science
   Foundation of China (81960647, 81702833), the Guizhou Provincial Natural
   Science Foundation ((2019)1255), the Excellent Young Talents Plan of
   Guizhou Medical University (Nos. 2020-102, 2021-103), the High-level
   Overseas Talent Fund for Home Work from the Ministry of Human Resources
   and Social Security (RSBLXHGZ202001), the Foundation for Training
   Programs of Innovation and Entrepreneurship for Undergraduates of
   Guizhou Medical University (No. S202010660037), the Jiangsu Provincial
   Special Program of Medical Science (BE2019617), and the Distinguished
   Young Scholars of Nanjing (JQX20008).
CR Bhaw-Luximon A, 2017, CANCER CHEMOTH PHARM, V79, P451, DOI 10.1007/s00280-017-3251-7
   Biscaglia F, 2019, ACS APPL NANO MATER, V2, P6436, DOI 10.1021/acsanm.9b01392
   Button RW, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.434
   Chen H, 2010, INT J HEMATOL, V92, P587, DOI 10.1007/s12185-010-0697-3
   Chen K, 2014, ANTI-CANCER DRUG, V25, P652, DOI 10.1097/CAD.0000000000000089
   Chen LX, 2020, THERANOSTICS, V10, P11063, DOI 10.7150/thno.45674
   Chen SS, 2015, CANCER BIOL THER, V16, P770, DOI 10.1080/15384047.2015.1026477
   Cicchini M, 2015, CLIN CANCER RES, V21, P498, DOI 10.1158/1078-0432.CCR-13-2438
   Dong FY, 2014, CANCER BIOL THER, V15, P1479, DOI 10.4161/15384047.2014.955728
   Espinosa-Diez C, 2015, REDOX BIOL, V6, P183, DOI 10.1016/j.redox.2015.07.008
   Ganguli A, 2014, BIOCHIMIE, V107, P338, DOI 10.1016/j.biochi.2014.10.001
   Gao N, 2011, APOPTOSIS, V16, P511, DOI 10.1007/s10495-011-0580-6
   Hou W, 2016, AUTOPHAGY, V12, P1425, DOI 10.1080/15548627.2016.1187366
   Hu W, 2014, CANCER LETT, V343, P239, DOI 10.1016/j.canlet.2013.09.035
   Lee J, 2012, BIOCHEM J, V441, P523, DOI 10.1042/BJ20111451
   Lin RY, 2016, CANCER LETT, V381, P165, DOI 10.1016/j.canlet.2016.07.033
   LITZINGER DC, 1992, BIOCHIM BIOPHYS ACTA, V1113, P201, DOI 10.1016/0304-4157(92)90039-D
   Liu YL, 2013, ONCOL REP, V30, P1723, DOI 10.3892/or.2013.2658
   Mercer AE, 2007, J BIOL CHEM, V282, P9372, DOI 10.1074/jbc.M610375200
   Ogilby PR, 2010, CHEM SOC REV, V39, P3181, DOI 10.1039/b926014p
   Peng JQ, 2019, J CONTROL RELEASE, V302, P42, DOI 10.1016/j.jconrel.2019.03.021
   Redmann M, 2017, REDOX BIOL, V11, P73, DOI 10.1016/j.redox.2016.11.004
   Saeed MEM, 2015, ANTICANCER RES, V35, P1929
   Saha S, 2018, BIOMED PHARMACOTHER, V104, P485, DOI 10.1016/j.biopha.2018.05.007
   Shen Y, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00444
   SHTERMAN N, 1991, PATHOBIOLOGY, V59, P19, DOI 10.1159/000163611
   Simoes S, 2004, ADV DRUG DELIVER REV, V56, P947, DOI 10.1016/j.addr.2003.10.038
   Slezakova S, 2017, ANTICANCER RES, V37, P5995, DOI 10.21873/anticanres.12046
   Sung HH, 2022, CLIN EXP HYPERTENS, V44, P146, DOI 10.1080/10641963.2021.2007943
   Torgersen ML, 2013, BLOOD, V122, P2467, DOI 10.1182/blood-2013-05-500629
   Wang SJ, 2011, CANCER CHEMOTH PHARM, V68, P1421, DOI 10.1007/s00280-011-1643-7
   Wang Y, 2018, BIOMATERIALS, V168, P1, DOI 10.1016/j.biomaterials.2017.10.039
   Wong YK, 2017, MED RES REV, V37, P1492, DOI 10.1002/med.21446
   Zetter BR, 1998, ANNU REV MED, V49, P407, DOI 10.1146/annurev.med.49.1.407
   Zhang CZ, 2012, BIOCHEM PHARMACOL, V83, P1278, DOI 10.1016/j.bcp.2012.02.002
NR 35
TC 0
Z9 0
U1 18
U2 18
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 1663-9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD OCT 8
PY 2021
VL 12
AR 720777
DI 10.3389/fphar.2021.720777
PG 17
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA WM2LE
UT WOS:000710921500001
PM 34690764
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Trincheri, NF
   Follo, C
   Nicotra, G
   Peracchio, C
   Castino, R
   Isidoro, C
AF Trincheri, Nicol F.
   Follo, Carlo
   Nicotra, Giuseppina
   Peracchio, Claudia
   Castino, Roberta
   Isidoro, Ciro
TI Resveratrol-induced apoptosis depends on the lipid kinase activity of
   Vps34 and on the formation of autophagolysosomes
SO CARCINOGENESIS
LA English
DT Article
ID CANCER CHEMOPREVENTIVE AGENT; ISOLATED RAT HEPATOCYTES; CELL-DEATH;
   AUTOPHAGOSOME FORMATION; PROTEIN-DEGRADATION; COLORECTAL-CANCER;
   INHIBITION; TUMORIGENESIS; ROLES; DIFFERENTIATION
AB In human colorectal DLD1 cancer cells, the dietary bioflavonoid resveratrol (RV) rapidly induced autophagy. This effect was reversible (on removal of the drug) and was associated with increased expression and cytosolic redistribution of the proteins Beclin1 and LC3 II. Supplementing the cells with asparagine (Asn) abrogated the Beclin-dependent autophagy. When applied acutely (2 h), RV was not toxic; however, reiterate chronic (48 h) exposure to RV eventually led to annexin V- and terminal deoxinucleotidyl transferase-mediated dUTP-biotin nick end labeling-positive cell death. This toxic effect was autophagy dependent, as it was prevented either by Asn, by expressing a dominant-negative lipid kinase-deficient class III phosphoinositide 3-phosphate kinase, or by RNA interference knockdown of Beclin1. Lamp2b silencing abolished the fusion of autophagosomes with lysosomes and preserved cell viability despite the ongoing formation of autophagosomes in cells chronically exposed to RV. The pan-caspase inhibitor benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone inhibited RV-induced cell death, but not autophagy. These results uncover a novel pathway of RV cytotoxicity in which autophagy plays a dual role: (i) at first, it acts as a prosurvival stress response and (ii) at a later time, it switches to a caspase-dependent apoptosis pathway. The present data also indicate that genetic or epigenetic inactivation of autophagy proteins in cancer cells may confer resistance to RV-mediated killing.
C1 [Trincheri, Nicol F.; Follo, Carlo; Nicotra, Giuseppina; Peracchio, Claudia; Castino, Roberta; Isidoro, Ciro] Univ Piemonte Orientale, Dipartimento Sci Med, Lab Patol Mol, I-28100 Novara, Italy.
RP Isidoro, C (corresponding author), Univ Piemonte Orientale, Dipartimento Sci Med, Lab Patol Mol, Via Solaroli 17, I-28100 Novara, Italy.
EM isidoro@med.unipmn.it
RI Isidoro, Ciro/J-6063-2016
OI Isidoro, Ciro/0000-0002-5494-3034; Follo, Carlo/0000-0001-9711-2655
CR Abedin MJ, 2007, CELL DEATH DIFFER, V14, P500, DOI 10.1038/sj.cdd.4402039
   Amaravadi RK, 2007, J CLIN INVEST, V117, P326, DOI 10.1172/JCI28833
   Bampton ETW, 2005, AUTOPHAGY, V1, P23, DOI 10.4161/auto.1.1.1495
   Baur JA, 2006, NATURE, V444, P337, DOI 10.1038/nature05354
   Baur JA, 2006, NAT REV DRUG DISCOV, V5, P493, DOI 10.1038/nrd2060
   Boocock DJ, 2007, CANCER EPIDEM BIOMAR, V16, P1246, DOI 10.1158/1055-9965.EPI-07-0022
   Bursch W, 2001, CELL DEATH DIFFER, V8, P569, DOI 10.1038/sj.cdd.4400852
   Bursch W, 1996, CARCINOGENESIS, V17, P1595, DOI 10.1093/carcin/17.8.1595
   Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001
   Di Cristofano A, 2000, CELL, V100, P387, DOI 10.1016/S0092-8674(00)80674-1
   Eskelinen Eeva-Liisa, 2006, Molecular Aspects of Medicine, V27, P495, DOI 10.1016/j.mam.2006.08.005
   Fremont L, 2000, LIFE SCI, V66, P663, DOI 10.1016/S0024-3205(99)00410-5
   Gonzalez-Polo RA, 2005, J CELL SCI, V118, P3091, DOI 10.1242/jcs.02447
   Gusman J, 2001, CARCINOGENESIS, V22, P1111, DOI 10.1093/carcin/22.8.1111
   HOYVIK H, 1991, J CELL BIOL, V113, P1305, DOI 10.1083/jcb.113.6.1305
   Jang MS, 1997, SCIENCE, V275, P218, DOI 10.1126/science.275.5297.218
   Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720
   Kessel D, 2007, CANCER LETT, V249, P294, DOI 10.1016/j.canlet.2006.09.009
   Kihara A, 2001, EMBO REP, V2, P330, DOI 10.1093/embo-reports/kve061
   Lee KW, 2006, BIOFACTORS, V26, P105, DOI 10.1002/biof.5520260202
   Levine B, 2005, J CLIN INVEST, V115, P2679, DOI 10.1172/JCI26390
   Liang C, 2006, NAT CELL BIOL, V8, P688, DOI 10.1038/ncb1426
   Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257
   Liang YC, 2003, BIOCHEM PHARMACOL, V65, P1053, DOI 10.1016/S0006-2952(03)00011-X
   MAHYAR R, 2002, BMC CANCER, V2, P27
   Mahyar-Roemer M, 2001, INT J CANCER, V94, P615, DOI 10.1002/ijc.1516
   MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545
   Mizushima N, 2001, J CELL BIOL, V152, P657, DOI 10.1083/jcb.152.4.657
   Mohan J, 2006, J BIOL CHEM, V281, P17599, DOI 10.1074/jbc.M602641200
   Munafo DB, 2001, J CELL SCI, V114, P3619
   OGIER D, 2003, BIOCHIM BIOPHYS ACTA, V2, P113
   Opipari AW, 2004, CANCER RES, V64, P696, DOI 10.1158/0008-5472.CAN-03-2404
   Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039
   Sale S, 2004, BRIT J CANCER, V90, P736, DOI 10.1038/sj.bjc.6601568
   SCHATZKIN A, 1995, EUR J CANCER, V31A, P1198, DOI 10.1016/0959-8049(95)00138-9
   Schneider Y, 2001, NUTR CANCER, V39, P102, DOI 10.1207/S15327914nc391_14
   Schneider Y, 2000, CANCER LETT, V158, P85, DOI 10.1016/S0304-3835(00)00511-5
   SEGLEN PO, 1982, P NATL ACAD SCI-BIOL, V79, P1889, DOI 10.1073/pnas.79.6.1889
   SEGLEN PO, 1980, BIOCHIM BIOPHYS ACTA, V630, P103, DOI 10.1016/0304-4165(80)90141-5
   SHENGKAN J, 2007, AUTOPHAGY, V3, P28
   Suzuki K, 2001, EMBO J, V20, P5971, DOI 10.1093/emboj/20.21.5971
   Tessitore L, 2000, CARCINOGENESIS, V21, P1619, DOI 10.1093/carcin/21.8.1619
   Trincheri NF, 2007, CARCINOGENESIS, V28, P922, DOI 10.1093/carcin/bgl223
   Wolter F, 2002, J NUTR, V132, P2082, DOI 10.1093/jn/132.7.2082
   Wolter F, 2001, J NUTR, V131, P2197, DOI 10.1093/jn/131.8.2197
   Yorimitsu T, 2005, CELL DEATH DIFFER, V12, P1542, DOI 10.1038/sj.cdd.4401765
NR 46
TC 87
Z9 90
U1 0
U2 5
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0143-3334
J9 CARCINOGENESIS
JI Carcinogenesis
PD FEB
PY 2008
VL 29
IS 2
BP 381
EP 389
DI 10.1093/carcin/bgm271
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 272AW
UT WOS:000253830800019
PM 18048384
OA Bronze
DA 2022-04-25
ER

PT J
AU Lee, HM
   Choi, KC
AF Lee, Hae-Miru
   Choi, Kyung-Chul
TI Cigarette smoke extract and isoprene resulted in the induction of
   apoptosis and autophagy in human placenta choriocarcinoma JEG-3 cells
SO ENVIRONMENTAL TOXICOLOGY
LA English
DT Article
DE cell cycle; cigarette smoke; EMT; isoprene; placenta choriocarcinoma
ID ENDOPLASMIC-RETICULUM STRESS; COLON-CANCER CELLS; KEAP1-NRF2 PATHWAY;
   MAINSTREAM SMOKE; ROS PRODUCTION; IN-VITRO; EXPOSURE; NRF2; ER;
   PHOSPHORYLATION
AB In this study, the effects of cigarette smoke (CS) on the induction of apoptosis via reactive oxygen species (ROS) production and endoplasmic reticulum stress (ER stress) of JEG-3 human choriocarcinoma cells were examined to confirm the relationship between CS and placenta development. Upon TUNEL assay, CS extract (3R4F; 0.3 and 2.1 M) increased JEG-3 apoptosis. Western blot assay revealed that the protein expressions of p53, Bax, and CCAAT-enhancer-binding protein homologous protein (CHOP) increased, while the levels of Bcl-2 were reduced following CS extract treatment. Moreover, 2,7-dichlorofluorescein diacetate (DCFH-DA) assay revealed increased ROS production. Upon 3-(4-5-dimethylthiazol-2-yl)-2.5-dyhphenyltetrazolium bromide (MTT) assay, isoprene (IP), one of ingredients of CS, deceased JEG-3 cell viability (10(-11) to 10(-6) M). After based on the MTT assay, two IP concentrations of 10(-11) and 10(-8) M were selected and the protein expressions of cyclin D1, cyclin E1, p21, and p27 decreased in response to IP. Furthermore, IP showed the greatest increase in autophagy at 24 hours and further induction of cell death at 72 hours upon monodansylacadaverine and TUNEL assay. Western blot analysis confirmed the increase in autophagy markers, LC3 and p62, as well as the increase or decrease of apoptosis markers p53, Bax, CHOP, and Bcl-2 in response to its treatments. In addition to confirming increases in ROS through DCFH-DA, we also confirmed the expression of Nrf2, an antioxidant marker, and the expression of Kelch-like ECH-associated protein 1 (KEAP1), which specifically degrades Nrf2, by Western blot. Taken together, these results indicate that CS and IP may inhibit the development of placenta via activation of ROS by inducing apoptosis and autophagy by affecting the expression of KEAP1, which regulates Nrf2 expression.
C1 [Lee, Hae-Miru; Choi, Kyung-Chul] Chungbuk Natl Univ, Coll Vet Med, Lab Biochem & Immunol, Cheongju 28644, Chungbuk, South Korea.
RP Choi, KC (corresponding author), Chungbuk Natl Univ, Coll Vet Med, Lab Biochem & Immunol, Cheongju 28644, Chungbuk, South Korea.
EM kchoi@cbu.ac.kr
FU Ministry of Food and Drug Safety (Korea)Ministry of Food & Drug Safety
   (MFDS) [14182MFDS977]
FX Ministry of Food and Drug Safety (Korea), Award/Grant number:
   14182MFDS977.
CR ADAMS JD, 1987, CARCINOGENESIS, V8, P729, DOI 10.1093/carcin/8.5.729
   ADLKOFER F, 1990, J CANCER RES CLIN, V116, P591, DOI 10.1007/BF01637079
   [Anonymous], 2004, IARC MONOGR EVAL CAR, V83, P1
   Bampton ETW, 2005, AUTOPHAGY, V1, P23, DOI 10.4161/auto.1.1.1495
   Cullinan SB, 2003, MOL CELL BIOL, V23, P7198, DOI 10.1128/MCB.23.20.7198-7209.2003
   Cullinan SB, 2006, INT J BIOCHEM CELL B, V38, P317, DOI 10.1016/j.biocel.2005.09.018
   DOERR JK, 1995, CHEM RES TOXICOL, V8, P963, DOI 10.1021/tx00049a010
   Eldridge A, 2015, REGUL TOXICOL PHARM, V71, P409, DOI 10.1016/j.yrtph.2015.01.006
   Fadiel A, 2013, REPROD SCI, V20, P917, DOI 10.1177/1933719112468946
   Fenga C, 2016, BIOMED REP, V4, P282, DOI 10.3892/br.2016.575
   Genbacev O, 2000, REPROD TOXICOL, V14, P495, DOI 10.1016/S0890-6238(00)00107-6
   Genbacev O, 2003, REPROD TOXICOL, V17, P509, DOI 10.1016/S0890-6238(03)00094-7
   Griffiths A N, 2005, J Obstet Gynaecol, V25, P432, DOI 10.1080/01443610500160550
   Gruslin A, 2001, BIOL REPROD, V65, P1164, DOI 10.1095/biolreprod65.4.1164
   Hanaki T, 2016, BBA-GEN SUBJECTS, V1860, P2404, DOI 10.1016/j.bbagen.2016.07.008
   Hitchman SC, 2011, B WORLD HEALTH ORGAN, V89, P195, DOI 10.2471/BLT.10.079905
   Hong SH, 2016, J BIOMED RES, V30, P203, DOI 10.7555/JBR.30.2016K0012
   Ichimura Y, 2010, SEMIN IMMUNOPATHOL, V32, P431, DOI 10.1007/s00281-010-0220-1
   Kansanen E, 2013, REDOX BIOL, V1, P45, DOI 10.1016/j.redox.2012.10.001
   Kim CW, 2017, ENVIRON TOXICOL, V32, P690, DOI 10.1002/tox.22271
   Kitamura M, 2010, BIOMETALS, V23, P941, DOI 10.1007/s10534-010-9296-2
   Kouroku Y, 2007, CELL DEATH DIFFER, V14, P230, DOI 10.1038/sj.cdd.4401984
   Kovac S, 2015, BBA-GEN SUBJECTS, V1850, P794, DOI 10.1016/j.bbagen.2014.11.021
   Kyrylkova Kateryna, 2012, Methods Mol Biol, V887, P41, DOI 10.1007/978-1-61779-860-3_5
   Lee CH, 2017, TUBERC RESPIR DIS, V80, P83, DOI 10.4046/trd.2017.80.1.83
   Lee HM, 2016, ENVIRON TOXICOL PHAR, V45, P80, DOI 10.1016/j.etap.2016.05.016
   Legakis JE, 2007, AUTOPHAGY, V3, P422, DOI 10.4161/auto.4129
   Liu HH, 2011, J CELL BIOCHEM, V112, P3695, DOI 10.1002/jcb.23303
   MELNICK RL, 1994, CANCER RES, V54, P5333
   Menon R, 2011, PLACENTA, V32, P317, DOI 10.1016/j.placenta.2011.01.015
   Michel O, 2016, HNO, V64, P122, DOI 10.1007/s00106-015-0097-3
   Nelson EAS, 2001, EARLY HUM DEV, V64, P7, DOI 10.1016/S0378-3782(01)00165-7
   NEWCOMB PA, 1992, MED CLIN N AM, V76, P305, DOI 10.1016/S0025-7125(16)30355-8
   Penaranda Fajardo N. M, 2016, BIOCHEM PHARMACOL, V118, P1, DOI [10.1016/j.bcp.2016.04.00827106078, DOI 10.1016/j.bcp.2016.04.008]
   Pesch B, 2012, INT J CANCER, V131, P1210, DOI 10.1002/ijc.27339
   Ryoo HD, 2016, FEBS J, V283, P3718, DOI 10.1111/febs.13755
   Senft D, 2015, TRENDS BIOCHEM SCI, V40, P141, DOI 10.1016/j.tibs.2015.01.002
   Sobus SL, 2014, CANCER-AM CANCER SOC, V120, P3617, DOI 10.1002/cncr.28904
   Szegezdi E, 2006, EMBO REP, V7, P880, DOI 10.1038/sj.embor.7400779
   Taguchi K, 2011, GENES CELLS, V16, P123, DOI 10.1111/j.1365-2443.2010.01473.x
   Verbrugge I, 2010, CELL, V143, P1192, DOI 10.1016/j.cell.2010.12.004
   VICOVAC L, 1995, PLACENTA, V16, P41, DOI 10.1016/0143-4004(95)90080-2
   Wojtala A, 2014, METHOD ENZYMOL, V542, P243, DOI 10.1016/B978-0-12-416618-9.00013-3
   Yang ZF, 2010, CURR OPIN CELL BIOL, V22, P124, DOI 10.1016/j.ceb.2009.11.014
   Yorimitsu T, 2007, AUTOPHAGY, V3, P160, DOI 10.4161/auto.3653
   Zeeshan HMA, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17030327
   Zhao XR, 2013, TRANSL STROKE RES, V4, P71, DOI 10.1007/s12975-012-0245-y
   Zhao Y, 2016, TOXICOL MECH METHOD, V26, P75, DOI 10.3109/15376516.2015.1082001
NR 48
TC 15
Z9 15
U1 0
U2 14
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1520-4081
EI 1522-7278
J9 ENVIRON TOXICOL
JI Environ. Toxicol.
PD FEB
PY 2018
VL 33
IS 2
BP 178
EP 190
DI 10.1002/tox.22506
PG 13
WC Environmental Sciences; Toxicology; Water Resources
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Environmental Sciences & Ecology; Toxicology; Water Resources
GA FS2TT
UT WOS:000419632600006
PM 29135079
DA 2022-04-25
ER

PT J
AU Kolap, RM
   Datkhile, KD
   Zimare, SB
AF Kolap, Rupali Mukesh
   Datkhile, Kailash D.
   Zimare, Saurabha Bhimrao
TI Bioprospecting of Lobelia nicotianifolia Roth. plant parts for
   antioxidant and cytotoxic activity and its phytoconstituents
SO PHARMACOGNOSY MAGAZINE
LA English
DT Article
DE Antioxidant; cytotoxic; HCT-15; HeLa; Lobelia nicotianifolia; MCF-7
ID IN-VITRO; ANTICANCER ACTIVITY; CANCER-CELLS; ACID; SESQUITERPENES;
   APOPTOSIS; AUTOPHAGY; GROWTH; ESTER; LEAF
AB Background: Though the Lobelia nicotianifolia Roth. is ethnobotanically important plant of India and Sri Lanka its phytoconstituents, antioxidant, and anticancer potential was not yet reported. Objective: The objective of this study is to analyze the phytoconstituents of plant parts of L. nicotianifolia and to determine its antioxidant and cytotoxic potential. Materials and Methods: The plant parts of L. nicotianifolia were extracted with different solvents and qualitative analysis revealed the presence of different phytoconstituents. Total phenolic content (TPC) and total flavonoid content (TFC) were recorded in all plant parts. The extracts were subjected to the antioxidant assays and the potent methanolic extracts were used for cytotoxicity study and further characterized by Fourier-transform infrared spectroscopy and liquid chromatography with a high resolution mass spectrometer (LC-HRMS). Results: The qualitative analysis showed the presence of a wide array of phytoconstituents in L. nicotianifolia plant parts. A significantly higher TPC, TFC, and antioxidant activities were seen in methanolic stem extract. Stem extract showed maximum cytotoxicity against human breast adenocarcinoma (MCF-7) and human cervical adenocarcinoma (HeLa) cell lines whereas, root extract had higher cytotoxicity against human colon adenocarcinoma (HCT-15) cells. The results of cell viability indicated that the methanolic extracts of L. nicotianifolia plant parts exhibited a range of cytotoxic activity in a concentration and time dependent manner against selected cancer cell lines. The LC-HRMS showed the presence of cytotoxic compounds comparatively higher in stem. Conclusion: The study confirms the antioxidant and cytotoxic potential of L. nicotianifolia. To understand the detailed mechanism of cytotoxicity of L. nicotianifolia, it is necessary to study the molecular mechanism involved in this study.
C1 [Kolap, Rupali Mukesh; Zimare, Saurabha Bhimrao] Naoroji Godrej Ctr Plant Res, Lawkim Motor Campus, Shirwal, Maharashtra, India.
   [Datkhile, Kailash D.] Krishna Inst Med Sci Univ, Mol & Genet Lab, Satara, Maharashtra, India.
RP Zimare, SB (corresponding author), Naoroji Godrej Ctr Plant Res, Lawkim Motor Campus, Shirwal, Maharashtra, India.
EM saurabhabot@gmail.com
CR Ahamed A, 2020, SAUDI J BIOL SCI, V27, P666, DOI 10.1016/j.sjbs.2019.11.043
   Akar Z, 2017, J ENZYM INHIB MED CH, V32, P640, DOI 10.1080/14756366.2017.1284068
   Alizadeh F, 2015, SM J PHARM THER, V1, P1
   Arruebo Manuel, 2011, Cancers (Basel), V3, P3279, DOI 10.3390/cancers3033279
   Aryal S, 2019, PLANTS-BASEL, V8, DOI 10.3390/plants8040096
   Ashmawy AM, 2021, NAT PROD RES, V35, P4133, DOI 10.1080/14786419.2020.1736064
   Aslam M.S., 2014, J CANC THER, V5, P817, DOI 10.4236/jct.2014.58089
   Avato P, 2017, ANTI-CANCER AGENT ME, V17, P1508, DOI 10.2174/1871520617666170727152805
   Bai LY, 2015, J FUNCT FOODS, V18, P368, DOI 10.1016/j.jff.2015.07.017
   Baker MJ, 2014, NAT PROTOC, V9, P1771, DOI 10.1038/nprot.2014.110
   Beccaria M, 2020, ANALYST, V145, P1129, DOI 10.1039/c9an02145k
   Bendary E., 2013, Annals of Agricultural Science (Cairo), V58, P173, DOI 10.1016/j.aoas.2013.07.002
   Bulle Saradamma, 2016, Pharmacogn Rev, V10, P43, DOI 10.4103/0973-7847.176575
   Chang KC, 2003, PLANTA MED, V69, P667, DOI 10.1055/s-2003-41120
   Chen HX, 2012, NAT PROD RES, V26, P2112, DOI 10.1080/14786419.2011.622275
   Chen MW, 2014, CHIN J NAT MEDICINES, V12, P103, DOI 10.1016/S1875-5364(14)60016-9
   Chua LS, 2019, MOLECULES, V24, DOI 10.3390/molecules24071416
   Dai J, 2010, MOLECULES, V15, P7313, DOI 10.3390/molecules15107313
   Dailey OD, 2011, ANTICANCER RES, V31, P3165
   Denicolai E, 2014, ONCOTARGET, V5, P10934, DOI 10.18632/oncotarget.2541
   Dilshad E, 2020, BIOCATAL AGR BIOTECH, V24, DOI 10.1016/j.bcab.2020.101539
   Dobhal MP, 2004, J ORG CHEM, V69, P6165, DOI 10.1021/jo0491408
   Durak T, 2020, ENVIRON EXP BOT, V169, DOI 10.1016/j.envexpbot.2019.103915
   Feng XM, 2019, ONCOL LETT, V17, P4761, DOI 10.3892/ol.2019.10171
   Folquitto DG, 2019, FITOTERAPIA, V134, P23, DOI 10.1016/j.fitote.2018.12.021
   Ghosh S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082529
   Guimarães Karina Carvalho, 2020, Braz. J. Food Technol., V23, pe2019015, DOI 10.1590/1981-6723.01519
   Han M, 2018, BIOMED PHARMACOTHER, V103, P272, DOI 10.1016/j.biopha.2018.04.014
   Harada H, 2002, ANTICANCER RES, V22, P2587
   Hernandez-Tiedra S, 2016, AUTOPHAGY, V12, P2213, DOI 10.1080/15548627.2016.1213927
   Iloki-Assanga Simon B, 2015, BMC Res Notes, V8, P396, DOI 10.1186/s13104-015-1388-1
   Islam M. T., 2016, African Journal of Pharmacy and Pharmacology, V10, P1025
   Jiang Yanyan, 2009, Zhongguo Zhong Yao Za Zhi, V34, P294
   Jozsef VV, 2017, J PLANT BIOCH PHYSL, V5, P1
   Juang YP, 2020, MOLECULES, V25, DOI 10.3390/molecules25214974
   Kalaimathi SK, 2015, INT J LIFE SCI PHARM, V5, pL20
   Khan AA, 2013, ANTICANCER RES, V33, P2517
   Ko JH, 2018, MOLECULES, V23, DOI 10.3390/molecules23030621
   Kogure K, 2005, J NUTR SCI VITAMINOL, V51, P392, DOI 10.3177/jnsv.51.392
   Kumar R, 2004, ONCOL RES, V14, P247
   Law BYK, 2016, ONCOTARGET, V7, P8090, DOI 10.18632/oncotarget.6980
   Li KC, 2015, AM J CHINESE MED, V43, P269, DOI 10.1142/S0192415X15500184
   Li XX, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2640-3
   Lobo V, 2010, Pharmacogn Rev, V4, P118, DOI 10.4103/0973-7847.70902
   Londhe AN, 2001, FLORA MAHARASHTRA ST, P277
   Lu XG, 2016, BIOMED PHARMACOTHER, V84, P330, DOI 10.1016/j.biopha.2016.09.041
   Mabberley D. J, 2018, MABBERLEYS PLANT BOO
   Macur K, 2018, CHROMATOGRAPHIA, V81, P47, DOI 10.1007/s10337-017-3382-3
   Mazumder K, 2020, MOLECULES, V25, DOI 10.3390/molecules25081904
   Montenegro I, 2014, MOLECULES, V19, P18993, DOI 10.3390/molecules191118993
   Mortaz E, 2008, J MOL MED, V86, P1045, DOI 10.1007/s00109-008-0360-0
   Murthy NK, 2011, J CHEM PHARM RES, V3, P218
   Nawaz H, 2020, BRAZ J PHARM SCI, V56, DOI 10.1590/s2175-97902019000417129
   Nethan Suzanne, 2017, Asian Pac J Cancer Prev, V18, P2005, DOI 10.22034/APJCP.2017.18.7.2005
   Pisoschi AM, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/9130976
   Pochapski MT, 2011, PHARMACOGN MAG, V7, P165, DOI 10.4103/0973-1296.80682
   Sak Katrin, 2014, Pharmacogn Rev, V8, P122, DOI 10.4103/0973-7847.134247
   Saleh KA, 2019, MOLECULES, V24, DOI 10.3390/molecules24030507
   Seca AML, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19010263
   Shabbits JA, 2003, BBA-BIOMEMBRANES, V1612, P98, DOI 10.1016/S0005-2736(03)00108-1
   Sharma V, 2011, J PLANT BIOCHEM BIOT, V20, P190, DOI 10.1007/s13562-011-0045-6
   Singh K, 2018, SAUDI PHARM J, V26, P177, DOI 10.1016/j.jsps.2017.12.013
   Stolom S, 2016, TROP J PHARM RES, V15, P1715, DOI 10.4314/tjpr.v15i8.17
   Sun JM, 2012, CHEM NAT COMPD+, V48, P416, DOI 10.1007/s10600-012-0263-8
   Tamboli A, 2011, PHARMACOLOGYONLINE, V3, P7
   Tamboli Abrar M., 2012, Asian Pacific Journal of Tropical Biomedicine, V2, P537, DOI 10.1016/S2221-1691(12)60092-6
   Tang MY, 2021, PHARMACOL RES, V163, DOI 10.1016/j.phrs.2020.105207
   Tinoush B, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00832
   Tsimplouli C, 2012, EUR J NUTR, V51, P181, DOI 10.1007/s00394-011-0204-5
   Valko M, 2007, INT J BIOCHEM CELL B, V39, P44, DOI 10.1016/j.biocel.2006.07.001
   Venepally V, 2019, INDIAN J PHARM SCI, V81, P737, DOI 10.36468/pharmaceutical-sciences.565
   Vigneshwaran V, 2014, AJPCT, V2, P1404
   Wada K, 2019, MOLECULES, V24, DOI 10.3390/molecules24122317
   [王培培 Wang Peipei], 2013, [中草药, Chinese Traditional and Herbal Drugs], V44, P794
   Weir HK, 2015, PREV CHRONIC DIS, V12, DOI 10.5888/pcd12.140482
   Wink Michael, 2015, Medicines (Basel), V2, P251, DOI 10.3390/medicines2030251
   Yan XH, 2017, CELL BIOSCI, V7, DOI 10.1186/s13578-017-0179-x
   Yin PJ, 2012, CHIN J NAT MEDICINES, V10, P383, DOI 10.1016/S1875-5364(12)60077-6
   Yoo YC, 2007, ARCH PHARM RES, V30, P361, DOI 10.1007/BF02977619
   Zerbini LF, 2014, MOL CANCER THER, V13, P1929, DOI 10.1158/1535-7163.MCT-13-0750
   Zhang J, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01042
   Zheleva-Dimitrova D, 2010, PHARMACOGN MAG, V6, P74, DOI 10.4103/0973-1296.62889
NR 82
TC 0
Z9 0
U1 3
U2 3
PU WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI MUMBAI
PA WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2
   VILLAGE MAROL, ANDHERI EAST, MUMBAI, Maharashtra, INDIA
SN 0973-1296
EI 0976-4062
J9 PHARMACOGN MAG
JI Pharmacogn. Mag.
PD APR-JUN
PY 2021
VL 17
IS 6
SU 2
BP S162
EP S171
DI 10.4103/pm.pm_398_20
PG 10
WC Chemistry, Medicinal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA XH2YZ
UT WOS:000725307600005
DA 2022-04-25
ER

PT J
AU Swiderek, E
   Kalas, W
   Wysokinska, E
   Pawlak, A
   Rak, J
   Strzadala, L
AF Swiderek, Ewelina
   Kalas, Wojciech
   Wysokinska, Edyta
   Pawlak, Alicja
   Rak, Janusz
   Strzadala, Leon
TI The interplay between epigenetic silencing, oncogenic KRas and HIF-1
   regulatory pathways in control of BNIP3 expression in human colorectal
   cancer cells
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE 5-Aza-2 '-deoxycytidine; BNIP3; Colorectal cancer; HIF-1; Hypoxia; KRas
ID TRANSCRIPTIONAL REPRESSOR; COMBINED THERAPY; DNA METHYLATION; DEATH;
   AUTOPHAGY; HYPOXIA; PROTEIN; MITOCHONDRIAL; IRINOTECAN; RESISTANCE
AB Bcl-2/adenovirus E1B-19 kDa-interacting protein 3 (BNIP3) is an important mediator of cell survival and a member of the Bcl-2 family of proteins that regulate programmed cell death and autophagy. We have previously established a link between the expression of oncogenic HRas and up-regulation of BNIP3 and the control of autophagy in cancer cells. However, in view of varied expression of BNIP3 in different tumor types and emerging uncertainties as to the role of epigenetic silencing, oncogenic regulation and the role of BNIP3 in cancer are still poorly understood.
   In the present study we describe profound effect of KRas on the expression of methylated BNIP3 in colorectal cancer cells and explore the interplay between HIF-1, hypoxia pathway and oncogenic KRas in this context. We observed that BNIP3 mRNA remains undetectable in aggressive DLD-1 cells harboring G13D mutant KRAS and HT-29 colorectal cancer cells unless the cells are exposed to demethylating agents such as 5-aza-2'-deoxycytidine. Following this treatment BNIP3 expression remains uniquely dependent on the Ras activity. We found that hypoxia or pharmacological activation of HIF-1 alone contributes to, but is not sufficient for efficient induction of BNIP3 mRNA transcription in cells lacking mutant KRas activity. The up-regulation of BNIP3 by KRas in this setting is mediated by the MAPK pathway, and is attenuated by the respective inhibitors (PD98059, U0126). Thus, we demonstrate the novel mechanism where activity of Ras is essential for 5-aza-2'-deoxycytidine-mediated BNIP3 expression. Moreover, we found that 5-aza-2'-deoxycytidine-mediated or enforced up-regulation of BNIP3 in DLD-1 cells results in KRas-dependent resistance to 5-Fluorouracil. (C) 2013 Elsevier Inc. All rights reserved.
C1 [Swiderek, Ewelina; Kalas, Wojciech; Wysokinska, Edyta; Pawlak, Alicja; Strzadala, Leon] Polish Acad Sci, Ludwik Hirszfeld Inst Immunol & Expt Therapy, Wroclaw, Poland.
   [Rak, Janusz] McGill Univ, Montreal Childrens Hosp Res Inst, Montreal, PQ H3A 2T5, Canada.
RP Strzadala, L (corresponding author), Polish Acad Sci, Inst Immunol & Expt Therapy, Weigla 12, PL-53114 Wroclaw, Poland.
EM strzadal@iitd.pan.wroc.pl
RI Kałas, Wojciech/AAB-4469-2019
OI Kałas, Wojciech/0000-0003-2656-5192; Strzadala,
   Leon/0000-0002-7323-2254; Wysokinska, Edyta/0000-0003-1003-2463
FU NCN Grant [2011/01/B/NZ4/00938]
FX This work was supported by NCN Grant No. 2011/01/B/NZ4/00938.
CR An HJ, 2006, J BIOL CHEM, V281, P33939, DOI 10.1074/jbc.M605819200
   An HJ, 2011, MOL CELLS, V31, P579, DOI 10.1007/s10059-011-0065-z
   Berkovich E, 2001, J BIOL CHEM, V276, P42851, DOI 10.1074/jbc.M103596200
   Burton TR, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.100
   Burton TR, 2009, J NEUROSCI, V29, P4189, DOI 10.1523/JNEUROSCI.5747-08.2009
   Cosse JP, 2010, BIOCHEM PHARMACOL, V80, P1160, DOI 10.1016/j.bcp.2010.07.009
   Crea F, 2009, MOL CANCER THER, V8, P1964, DOI 10.1158/1535-7163.MCT-09-0027
   Emerling BM, 2008, P NATL ACAD SCI USA, V105, P2622, DOI 10.1073/pnas.0706790105
   Erkan M, 2005, ONCOGENE, V24, P4421, DOI 10.1038/sj.onc.1208642
   Hiraki M, 2010, ONCOL REP, V23, P191, DOI 10.3892/or_00000622
   Ishiguro M, 2007, ANN SURG ONCOL, V14, P1752, DOI 10.1245/s10434-006-9285-4
   Kalas W, 2013, ANTICANCER RES, V33, P1429
   Kalas W, 2011, ANTICANCER RES, V31, P2869
   Lee H, 2006, MOL CELLS, V21, P1
   Liu FY, 2011, CANCER RES, V71, P6807, DOI 10.1158/0008-5472.CAN-11-1575
   MACLEOD AR, 1995, J BIOL CHEM, V270, P11327, DOI 10.1074/jbc.270.19.11327
   Mellor HR, 2007, CANCER METAST REV, V26, P553, DOI 10.1007/s10555-007-9080-0
   Murai M, 2005, CLIN CANCER RES, V11, P1021
   Okami J, 2004, CANCER RES, V64, P5338, DOI 10.1158/0008-5472.CAN-04-0089
   Ray R, 2000, J BIOL CHEM, V275, P1439, DOI 10.1074/jbc.275.2.1439
   Shaw J, 2008, P NATL ACAD SCI USA, V105, P20734, DOI 10.1073/pnas.0807735105
   Shimizu S, 2010, ONCOL LETT, V1, P865, DOI 10.3892/ol_00000153
   SHIRASAWA S, 1993, SCIENCE, V260, P85, DOI 10.1126/science.8465203
   Swiderek E, 2013, POSTEP HIG MED DOSW, V67, P363
   Swoboda E, 2009, POSTEP HIG MED DOSW, V63, P418
   Tracy K, 2007, AUTOPHAGY, V3, P616, DOI 10.4161/auto.4892
   Valdez BC, 2010, LEUKEMIA RES, V34, P364, DOI 10.1016/j.leukres.2009.08.014
   Vijayalingam S, 2010, Genes Cancer, V1, P964, DOI 10.1177/1947601910386110
   White E, 2008, ERNST SCHERING FOUND, V4, P23, DOI 10.1007/2789_2008_087
   Yang SH, 2011, GENE DEV, V25, P717, DOI 10.1101/gad.2016111
   Yoo BH, 2010, J BIOL CHEM, V285, P5438, DOI 10.1074/jbc.M109.046789
   Yoon J, 2011, CANCER RES, V71, P445, DOI 10.1158/0008-5472.CAN-10-3058
   Yurkova N, 2008, CIRC RES, V102, P472, DOI 10.1161/CIRCRESAHA.107.164731
NR 33
TC 16
Z9 17
U1 0
U2 14
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD NOV 29
PY 2013
VL 441
IS 4
BP 707
EP 712
DI 10.1016/j.bbrc.2013.10.098
PG 6
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA 272BH
UT WOS:000328434800003
PM 24211581
DA 2022-04-25
ER

PT J
AU Li, JX
   Yan, Q
   Liu, N
   Zheng, WJ
   Hu, M
   Yu, ZM
   Zhou, YD
   Wang, XW
   Liang, FX
   Chen, R
AF Li, Jin-xiao
   Yan, Qian
   Liu, Na
   Zheng, Wen-jiang
   Hu, Man
   Yu, Zhao-min
   Zhou, Yu-dian
   Wang, Xiong-wen
   Liang, Feng-xia
   Chen, Rui
TI The Prognostic Value of Autophagy-Related Markers Bclin-1 and LC-3 in
   Colorectal Cancers: A Systematic Review and Meta-analysis
SO EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE
LA English
DT Review
ID BECLIN 1; FAVORABLE PROGNOSIS; EXPRESSION; LC3; CARCINOMAS; GUIDELINES;
   PHYSIOLOGY; RELEVANCE; PROTEINS; PATTERNS
AB Objective. At present, the relationship between autophagosomes and the prognosis of various cancers has become a subject of active investigation. A series of studies have demonstrated the correlation between autophagy microtubule-associated protein light chain 3 (LC-3), Beclin-1, and colorectal cancer (CRC). Since autophagy has dual regulatory roles in tumors, the results of this correlation are also uncertain. Hence, we summarized the relationship between Beclin-1, LC-3, and CRC using systematic reviews and meta-analysis to clarify their prognostic significance in it. Methods. PubMed, EMBASE, Cochrane Library, and Web of Science databases were searched online up to April 1, 2019. The quality of the involving studies was assessed against the Newcastle-Ottawa Scale (NOS). Pooled hazard ratio (HR) and 95% confidence interval (CI) in a fixed or random effects model were used to assess the strength of correlation between Beclin-1, LC-3, and CRC. Results. A total of 9 articles were collected, involving 2,297 patients. Most literatures scored more than 6 points, suggesting that the quality of our including research was acceptable. Our finding suggested that the expression of Beclin-1 was not associated with overall survival (HR = 0.68, 95% CI (0.31-1.52), P=0.351). Nonetheless, LC-3 expression exerted significant impact on OS (HR = 0.51, 95% CI (0.35-0.74), P<0.05). Subgroup analysis exhibited that Beclin-1 expression was associated with OS at TNM stage III (HR = 0.04, 95% CI = 0.02-0.08, P<0.05), surgical treatment (HR = 1.53, 95% CI (1.15-2.02), P=0.003), and comprehensive treatment (HR = 0.27 95% CI (0.08-0.92), P=0.036), respectively. Similarly, the results showed the increased LC-3 expression in CRC was related to OS in multivariate analyses (HR = 0.44, 95% CI (0.34-0.57), P<0.05), stages (HR = 0.51, 95% CI (0.35-0.74), P<0.05), and comprehensive treatment (HR = 0.44, 95% CI (0.34-0.57), P<0.05). Conclusions. Autophagy-related proteins of LC-3 might be an important marker of CRC progression. However, since the number of the original studies was limited, more well-designed, large-scale, high-quality studies are warranted to provide more convincing and reliable information.
C1 [Li, Jin-xiao; Hu, Man; Yu, Zhao-min; Chen, Rui] Huazhong Univ Sci & Technol, Dept Integrated Tradit Chinese & Western Med, Tongji Med Coll, Union Hosp, Wuhan 430022, Peoples R China.
   [Yan, Qian; Zheng, Wen-jiang] Guangzhou Univ Chinese Med, Guangzhou 510405, Peoples R China.
   [Liu, Na] Chengdu Univ Chinese Med, Dept Acupuncture & Moxibust, Chengdu 610075, Peoples R China.
   [Zhou, Yu-dian; Liang, Feng-xia] Hubei Univ Chinese Med, Dept Acupuncture & Moxibust, Wuhan 430065, Peoples R China.
   [Wang, Xiong-wen] Guangzhou Univ Tradit Chinese Med, Affiliated Hosp 1, Guangzhou 510405, Peoples R China.
RP Chen, R (corresponding author), Huazhong Univ Sci & Technol, Dept Integrated Tradit Chinese & Western Med, Tongji Med Coll, Union Hosp, Wuhan 430022, Peoples R China.
EM 962939252@qq.com; 20171101040@stu.gzucm.edu.cn; 1454542867@qq.com;
   20171101136@stu.gzucm.edu.cn; 994485699@qq.com; 785773912@qq.com;
   531245554@qq.com; awen681029@163.com; 315938821@qq.com; unioncr@163.com
OI Zheng, Wenjiang/0000-0001-5234-0339
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81774401, 81574065]
FX This meta-analysis was supported by the National Natural Science
   Foundation of China (Grant nos. 81774401 and 81574065).
CR Arnold M, 2017, GUT, V66, P683, DOI 10.1136/gutjnl-2015-310912
   Burada F, 2015, WORLD J GASTRO ONCOL, V7, P271, DOI 10.4251/wjgo.v7.i11.271
   Chen HY, 2011, CANCER PREV RES, V4, P973, DOI 10.1158/1940-6207.CAPR-10-0387
   Chen Z, 2016, AM J TRANSL RES, V8, P1190
   Choi JH, 2014, GASTROENT RES PRACT, V2014, DOI 10.1155/2014/179586
   Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Gil J, 2016, BIOMARK MED, V10, P1081, DOI 10.2217/bmm-2016-0083
   Karpathiou G, 2011, CHEST, V140, P127, DOI 10.1378/chest.10-1831
   Kekelidze M, 2013, WORLD J GASTROENTERO, V19, P8502, DOI 10.3748/wjg.v19.i46.8502
   Klionsky DJ, 2016, AUTOPHAGY, V12, P1, DOI 10.1080/15548627.2015.1100356
   Klionsky DJ, 2014, AUTOPHAGY, V10, P1691, DOI 10.4161/auto.36187
   Koukourakis MI, 2010, BRIT J CANCER, V103, P1209, DOI 10.1038/sj.bjc.6605904
   Koustas E, 2019, AM J CLIN ONCOL-CANC, V42, P767, DOI 10.1097/COC.0000000000000592
   Koustas E, 2019, CANCERS, V11, DOI 10.3390/cancers11040533
   Levy JMM, 2011, PHARMACOL THERAPEUT, V131, P130, DOI 10.1016/j.pharmthera.2011.03.009
   Li BX, 2009, AUTOPHAGY, V5, P303, DOI 10.4161/auto.5.3.7491
   Liu EY, 2012, J CELL SCI, V125, P2349, DOI 10.1242/jcs.093708
   Liu L, 2017, ONCOL LETT, V14, P4319, DOI 10.3892/ol.2017.6687
   Mancias JD, 2016, J MOL BIOL, V428, P1659, DOI 10.1016/j.jmb.2016.02.027
   Mokarram P, 2017, AUTOPHAGY, V13, P781, DOI 10.1080/15548627.2017.1290751
   Nagelkerke A, 2015, SEMIN CANCER BIOL, V31, P99, DOI 10.1016/j.semcancer.2014.06.001
   Park JM, 2013, CANCER BIOL THER, V14, P100, DOI 10.4161/cbt.22954
   Parmar MKB, 1998, STAT MED, V17, P2815, DOI 10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8
   Qin ZQ, 2018, WORLD J SURG ONCOL, V16, DOI 10.1186/s12957-018-1465-8
   Qureshi-Baig K, 2020, AUTOPHAGY, V16, P1436, DOI 10.1080/15548627.2019.1687213
   Ryan KM, 2011, EUR J CANCER, V47, P44, DOI 10.1016/j.ejca.2010.10.020
   Schaaf MBE, 2016, FASEB J, V30, P3961, DOI 10.1096/fj.201600698R
   Schmitz KJ, 2016, WORLD J SURG ONCOL, V14, DOI 10.1186/s12957-016-0946-x
   Shim BY, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2250-0
   Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993
   Siegel RL, 2019, CA-CANCER J CLIN, V69, P7, DOI 10.3322/caac.21551
   Sivridis E, 2011, AUTOPHAGY, V7, P74, DOI 10.4161/auto.7.1.13947
   Sivridis E, 2010, AM J PATHOL, V176, P2477, DOI 10.2353/ajpath.2010.090049
   Tanida Isei, 2008, V445, P77, DOI 10.1007/978-1-59745-157-4_4
   Toton E, 2014, J PHYSIOL PHARMACOL, V65, P459
   Wells GA, 2020, NEWCASTLE OTTAWA SCA
   Wild P, 2014, J CELL SCI, V127, P3, DOI 10.1242/jcs.140426
   Wu SH, 2015, HUM PATHOL, V46, P1752, DOI 10.1016/j.humpath.2015.07.016
   Wu SH, 2015, INT J CLIN EXP PATHO, V8, P3882
   Yang ZL, 2015, CLIN RES HEPATOL GAS, V39, P98, DOI 10.1016/j.clinre.2014.06.014
   Zhang JY, 2019, JPN J CLIN ONCOL, V49, P438, DOI 10.1093/jjco/hyz035
   Zhang MY, 2014, INT J MOL SCI, V15, P14372, DOI 10.3390/ijms150814372
   Zhao Z, 2017, MINERVA MED, V108, P277, DOI 10.23736/S0026-4806.16.04767-4
   Zheng TL, 2018, ONCOTARGETS THER, V11, P4167, DOI 10.2147/OTT.S164987
   Zhou HY, 2016, CANCER BIOMARK, V17, P1, DOI 10.3233/CBM-160613
NR 46
TC 2
Z9 2
U1 0
U2 4
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1741-427X
EI 1741-4288
J9 EVID-BASED COMPL ALT
JI Evid.-based Complement Altern. Med.
PD MAR 23
PY 2020
VL 2020
AR 8475840
DI 10.1155/2020/8475840
PG 11
WC Integrative & Complementary Medicine
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Integrative & Complementary Medicine
GA LC0GU
UT WOS:000525010000001
PM 32280357
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Wang, YF
   Xie, JY
   Wang, H
   Huang, HX
   Xie, P
AF Wang, Yanfeng
   Xie, Jianying
   Wang, Hao
   Huang, Haixia
   Xie, Ping
TI Beclin-1 suppresses gastric cancer progression by promoting apoptosis
   and reducing cell migration
SO ONCOLOGY LETTERS
LA English
DT Article
DE Beclin-1; gastric cancer; tumorigenesis; apoptosis; migration
ID COLORECTAL-CANCER; 1 EXPRESSION; AUTOPHAGY; CARCINOMA; LC3;
   CHEMORADIATION; EFFICACY
AB To investigate Beclin-1 expression in gastric cancer and its clinical relevance, 60 samples were collected from patients with gastric carcinoma, which were subjected to immunohistochemical staining and analysis. Associations of Beclin-1 expression with the clinical parameters of the patients, including tumor size, histological differentiation and metastatic status, were examined by statistical analysis. The results demonstrated that Beclin-1 expression in gastric carcinoma tissue was significantly associated with the tumor, node, metastasis stage and tumor invasion status. Further experiments indicated that Beclin-1 overexpression promoted MKN-45 gastric cancer cell apoptosis and inhibited their migration. These data suggested that Beclin-1 was a suppressor of tumorigenesis in gastric cancer and a potential therapeutic target for patients with gastric cancer.
C1 [Wang, Yanfeng] Heilongjiang Prov Land Reclamat Headquarter Gen H, Dept Pathol, Harbin 150088, Heilongjiang, Peoples R China.
   [Xie, Jianying; Huang, Haixia; Xie, Ping] King Med Diagnost Ctr, Dept Pathol, 3377 Kangxin Rd, Shanghai 201321, Peoples R China.
   [Wang, Hao] Heilongjiang Prov Land Reclamat Headquarter Gen H, Dept Phys Diagnost, Harbin 150088, Heilongjiang, Peoples R China.
RP Xie, P (corresponding author), King Med Diagnost Ctr, Dept Pathol, 3377 Kangxin Rd, Shanghai 201321, Peoples R China.
EM xieping76@hotmail.com
FU Natural Science Foundation of Shanghai Health and Family Planning
   Commission [201540088]; China National Natural Science Foundation of
   ChinaNational Natural Science Foundation of China (NSFC) [81370961]
FX The present study was supported by grants from the Natural Science
   Foundation of Shanghai Health and Family Planning Commission (grant no.
   201540088) and the China National Natural Science Foundation of China
   (grant no. 81370961).
CR Burada F, 2015, WORLD J GASTRO ONCOL, V7, P271, DOI 10.4251/wjgo.v7.i11.271
   Chen N, 2009, BBA-MOL CELL RES, V1793, P1516, DOI 10.1016/j.bbamcr.2008.12.013
   Chen YS, 2013, PATHOL RES PRACT, V209, P562, DOI 10.1016/j.prp.2013.06.006
   Fei BY, 2016, ONCOL LETT, V11, P2271, DOI 10.3892/ol.2016.4183
   Gallagher LE, 2016, CELLS-BASEL, V5, DOI 10.3390/cells5020024
   Geng ZH, 2016, AM J TRANSL RES, V8, P1886
   Guo GF, 2011, WORLD J GASTROENTERO, V17, P4779, DOI 10.3748/wjg.v17.i43.4779
   Hasima N, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.467
   Kang R, 2011, CELL DEATH DIFFER, V18, P571, DOI 10.1038/cdd.2010.191
   Kongara S, 2010, MOL CANCER RES, V8, P873, DOI 10.1158/1541-7786.MCR-09-0494
   Levine B, 2008, AUTOPHAGY, V4, P600, DOI 10.4161/auto.6260
   Lian J, 2011, CELL DEATH DIFFER, V18, P60, DOI 10.1038/cdd.2010.74
   Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257
   Lozy F, 2012, SEMIN CELL DEV BIOL, V23, P395, DOI 10.1016/j.semcdb.2012.01.005
   Luo S, 2010, CELL DEATH DIFFER, V17, P268, DOI 10.1038/cdd.2009.121
   Maiuri MC, 2007, EMBO J, V26, P2527, DOI 10.1038/sj.emboj.7601689
   Mathew R, 2007, GENE DEV, V21, P1367, DOI 10.1101/gad.1545107
   Miracco C, 2010, HUM PATHOL, V41, P503, DOI 10.1016/j.humpath.2009.09.004
   Nikoletopoulou V, 2013, BBA-MOL CELL RES, V1833, P3448, DOI 10.1016/j.bbamcr.2013.06.001
   Ozpolat B, 2015, CANCER MANAG RES, V7, P291, DOI 10.2147/CMAR.S34859
   Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002
   Qiu DM, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-327
   Sakakura K, 2015, CANCER SCI, V106, P1, DOI [10.1111/cas.12559, 10.1111/cas.12579]
   Tang JY, 2013, HUM PATHOL, V44, P2558, DOI 10.1016/j.humpath.2013.06.017
   Wang YW, 2013, J ORAL PATHOL MED, V42, P557, DOI 10.1111/jop.12049
   Washington K, 2010, ANN SURG ONCOL, V17, P3077, DOI 10.1245/s10434-010-1362-z
   Weng JQ, 2014, ORAL ONCOL, V50, P983, DOI 10.1016/j.oraloncology.2014.06.020
   Won KY, 2015, PATHOL RES PRACT, V211, P308, DOI 10.1016/j.prp.2014.11.005
   Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100
   Zaanan A, 2015, INT J CANCER, V137, P1498, DOI 10.1002/ijc.29496
   Zhao GX, 2015, ANN MED, V47, P305, DOI 10.3109/07853890.2015.1040831
   Zhao Y, 2014, TUMOR BIOL, V35, P1955, DOI 10.1007/s13277-013-1261-6
NR 32
TC 6
Z9 9
U1 1
U2 2
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792-1074
EI 1792-1082
J9 ONCOL LETT
JI Oncol. Lett.
PD DEC
PY 2017
VL 14
IS 6
BP 6857
EP 6862
DI 10.3892/ol.2017.7046
PG 6
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA FP0LV
UT WOS:000417293400072
PM 29163705
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Zhu, JM
   Chen, SS
   Yang, BX
   Mao, WD
   Yang, X
   Cai, J
AF Zhu, Jiamin
   Chen, Shusen
   Yang, Baixia
   Mao, Weidong
   Yang, Xi
   Cai, Jing
TI Molecular mechanisms of lncRNAs in regulating cancer cell
   radiosensitivity
SO BIOSCIENCE REPORTS
LA English
DT Review
ID LONG NONCODING RNA; EPITHELIAL-MESENCHYMAL TRANSITION; HUMAN
   COLORECTAL-CANCER; ENHANCES RADIOSENSITIVITY; DOWN-REGULATION;
   LUNG-CANCER; NASOPHARYNGEAL CARCINOMA; RADIATION-RESISTANCE;
   TUMOR-CELLS; STEM-CELLS
AB Radiotherapy is one of the main modalities of cancer treatment. However, tumor recurrence following radiotherapy occurs in many cancer patients. A key to solving this problem is the optimization of radiosensitivity. In recent years, long non-coding RNAs (lncRNAs), which affect the occurrence and development of tumors through a variety of mechanisms, have become a popular research topic. LncRNAs have been found to influence radiosensitivity by regulating various mechanisms, including DNA damage repair, cell cycle arrest, apoptosis, cancer stem cells regulation, epithelial-mesenchymal transition, and autophagy. LncRNAs are expected to become a potential therapeutic target for radiotherapy in the future. This article reviews recent advances in the role and mechanism of lncRNAs in tumor radiosensitivity.
C1 [Zhu, Jiamin; Mao, Weidong] Southeast Univ, Coll Med, Affiliated Jiangyin Hosp, Dept Oncol, 163 Shoushan Rd, Jiangyin 214400, Peoples R China.
   [Zhu, Jiamin; Chen, Shusen; Yang, Baixia; Cai, Jing] Nantong Univ, Affiliated Tumor Hosp, Nantong Tumor Hosp, Dept Radiat Oncol, Nantong 226321, Peoples R China.
   [Yang, Xi] Fudan Univ, Shanghai Med Coll, Dept Oncol, Dept Radiat Oncol,Shanghai Canc Ctr, Shanghai 200032, Peoples R China.
RP Cai, J (corresponding author), Nantong Univ, Affiliated Tumor Hosp, Nantong Tumor Hosp, Dept Radiat Oncol, Nantong 226321, Peoples R China.; Yang, X (corresponding author), Fudan Univ, Shanghai Med Coll, Dept Oncol, Dept Radiat Oncol,Shanghai Canc Ctr, Shanghai 200032, Peoples R China.
EM ntgeorge@qq.com; cj7227@sina.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81703024]
FX This study was sponsored by grants from the National Natural Science
   Foundation of China [81703024].
CR Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236
   Brodie S, 2017, ONCOTARGET, V8, P31798, DOI 10.18632/oncotarget.15991
   Butof R, 2013, RADIOTHER ONCOL, V108, P388, DOI 10.1016/j.radonc.2013.06.002
   Bussink J, 2008, LANCET ONCOL, V9, P288, DOI 10.1016/S1470-2045(08)70073-1
   Chang L, 2016, ONCOTARGET, V7, P11002, DOI 10.18632/oncotarget.6760
   Chen CX, 2018, BRAZ J MED BIOL RES, V51, DOI [10.1590/1414-431X20187080, 10.1590/1414-431x20187080]
   Chen JX, 2015, INT J CLIN EXP PATHO, V8, P7878
   Chen LJ, 2019, J CELL BIOCHEM, V120, P6178, DOI 10.1002/jcb.27905
   Chen MQ, 2018, FRONT GENET, V9, DOI 10.3389/fgene.2018.00611
   Chen QN, 2017, ONCOTARGET, V8, P1925, DOI 10.18632/oncotarget.12461
   Chen YF, 2017, MOL CANCER RES, V15, P418, DOI 10.1158/1541-7786.MCR-16-0366
   Chen YS, 2015, MOL MED REP, V12, P1645, DOI 10.3892/mmr.2015.3623
   Clarke Michael F, 2006, Cancer Res, V66, P9339, DOI 10.1158/0008-5472.CAN-06-3126
   Crea F, 2014, ONCOTARGET, V5, P764, DOI 10.18632/oncotarget.1769
   Creighton CJ, 2010, J MAMMARY GLAND BIOL, V15, P253, DOI 10.1007/s10911-010-9173-1
   Delaney G, 2005, CANCER-AM CANCER SOC, V104, P1129, DOI 10.1002/cncr.21324
   Dinger ME, 2008, PLOS COMPUT BIOL, V4, DOI 10.1371/journal.pcbi.1000176
   Foroni C, 2012, CANCER TREAT REV, V38, P689, DOI 10.1016/j.ctrv.2011.11.001
   Frank NY, 2010, J CLIN INVEST, V120, P41, DOI 10.1172/JCI41004
   Ganoth D, 2001, NAT CELL BIOL, V3, P321, DOI 10.1038/35060126
   Gao JB, 2019, INT J BIOL MACROMOL, V126, P994, DOI 10.1016/j.ijbiomac.2018.12.176
   Georgescu Maria-Magdalena, 2010, Genes Cancer, V1, P1170, DOI 10.1177/1947601911407325
   Ghiam AF, 2017, ONCOTARGET, V8, P4668, DOI 10.18632/oncotarget.13576
   Goldstein M, 2015, ANNU REV MED, V66, P129, DOI 10.1146/annurev-med-081313-121208
   Gondhowiardjo Soehartati, 2004, Acta Med Indones, V36, P100
   Good JS, 2013, CLIN ONCOL-UK, V25, P569, DOI 10.1016/j.clon.2013.06.009
   Gupta AK, 2003, INT J RADIAT ONCOL, V56, P846, DOI 10.1016/S0360-3016(03)00214-1
   Hou P, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.249
   Hu XG, 2017, CANCER BIOL THER, V18, P331, DOI 10.1080/15384047.2017.1310348
   Huarte M, 2010, CELL, V142, P409, DOI 10.1016/j.cell.2010.06.040
   Jiang HJ, 2017, RADIAT ONCOL, V12, DOI 10.1186/s13014-017-0802-3
   Jiang YH, 2016, TUMOR BIOL, V37, P3957, DOI 10.1007/s13277-015-4234-0
   Jin C, 2016, TUMOR BIOL, V37, P4025, DOI 10.1007/s13277-015-4227-z
   Ke SB, 2015, INT J ONCOL, V46, P1051, DOI 10.3892/ijo.2014.2793
   Kramer DL, 1999, CANCER RES, V59, P1278
   Lai Y, 2018, CELL BIOL INT, V42, P227, DOI 10.1002/cbin.10890
   Li HB, 2018, J CANCER RES CLIN, V144, P1623, DOI 10.1007/s00432-018-2675-8
   Li J, 2015, TUMOR BIOL, V36, P3611, DOI 10.1007/s13277-014-2998-2
   Li ZJ, 2017, J ORAL PATHOL MED, V46, P583, DOI 10.1111/jop.12538
   Liu GB, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18020367
   Lu HZ, 2016, TUMOR BIOL, V37, P1683, DOI 10.1007/s13277-015-3946-5
   Lu YY, 2016, TUMOR BIOL, V37, P11733, DOI 10.1007/s13277-015-4773-4
   Ma XK, 2018, ONCOTARGETS THER, V11, P8399, DOI 10.2147/OTT.S182573
   Mercer TR, 2009, NAT REV GENET, V10, P155, DOI 10.1038/nrg2521
   Peng WX, 2017, ONCOGENE, V36, P5661, DOI 10.1038/onc.2017.184
   Ponting CP, 2009, CELL, V136, P629, DOI 10.1016/j.cell.2009.02.006
   Rey S, 2017, ADV DRUG DELIVER REV, V109, P45, DOI 10.1016/j.addr.2016.10.002
   Sarfi M, 2019, J CELL PHYSIOL, V234, P16971, DOI 10.1002/jcp.28417
   Scheel C, 2011, CELL, V145, P926, DOI 10.1016/j.cell.2011.04.029
   Shen YM, 2017, EXP CELL RES, V358, P188, DOI 10.1016/j.yexcr.2017.06.016
   Shimura T, 2010, ONCOGENE, V29, P4826, DOI 10.1038/onc.2010.238
   Skvortsova I, 2015, SEMIN CANCER BIOL, V35, P39, DOI 10.1016/j.semcancer.2015.09.009
   Smith L, 2009, NEOPLASIA, V11, P1194, DOI 10.1593/neo.09902
   Stewart DJ, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/djt356
   Tan JM, 2015, FEBS LETT, V589, P3175, DOI 10.1016/j.febslet.2015.08.020
   Tang T, 2019, J CELL PHYSIOL, V234, P12918, DOI 10.1002/jcp.27958
   Thomson DW, 2016, NAT REV GENET, V17, P272, DOI 10.1038/nrg.2016.20
   Wang GY, 2014, ONCOL REP, V31, P1839, DOI 10.3892/or.2014.3047
   Wang XX, 2018, CELL CYCLE, V17, P439, DOI 10.1080/15384101.2018.1442625
   Wang YJ, 2017, ONCOTARGET, V8, P70156, DOI 10.18632/oncotarget.19596
   Wu CL, 2018, CANCER MANAG RES, V10, P5261, DOI 10.2147/CMAR.S174066
   Wu DP, 2017, CELL PHYSIOL BIOCHEM, V42, P2453, DOI 10.1159/000480209
   Xin Y, 2017, J CANCER RES CLIN, V143, P2147, DOI 10.1007/s00432-017-2487-2
   Xue J, 2018, ONCOGENE, V37, P953, DOI 10.1038/onc.2017.401
   Yang PX, 2017, J GASTROEN HEPATOL, V32, P837, DOI 10.1111/jgh.13606
   Yang X, 2018, EUR REV MED PHARMACO, V22, P1315, DOI 10.26355/eurrev_201803_14473
   Yang XD, 2018, ONCOL REP, V40, P1554, DOI 10.3892/or.2018.6573
   Yang Y, 2015, TUMOR BIOL, V36, P4079, DOI 10.1007/s13277-015-3496-x
   Yoon JH, 2012, MOL CELL, V47, P648, DOI 10.1016/j.molcel.2012.06.027
   Zaman S, 2014, LEUKEMIA LYMPHOMA, V55, P1980, DOI 10.3109/10428194.2013.855307
   Zhang HF, 2015, ONCOTARGET, V6, P6218, DOI 10.18632/oncotarget.3358
   Zhang J, 2015, GENOM PROTEOM BIOINF, V13, P17, DOI 10.1016/j.gpb.2015.02.001
   Zhang J, 2018, BIOSCIENCE REP, V38, DOI 10.1042/BSR20181599
   Zhang M, 2018, ONCOL RES, V26, P1245, DOI 10.3727/096504017X14944585873668
   Zhang WQ, 2018, CIRC RES, V123, P773, DOI 10.1161/CIRCRESAHA.118.312497
   Zhang YY, 2016, NAT STRUCT MOL BIOL, V23, P522, DOI 10.1038/nsmb.3211
   Zheng R, 2016, INT J RADIAT ONCOL, V96, P877, DOI 10.1016/j.ijrobp.2016.07.036
   Zhou Y, 2019, MOL CELL BIOCHEM, V450, P125, DOI 10.1007/s11010-018-3379-8
   Zou YM, 2018, EUR J CELL BIOL, V97, P369, DOI 10.1016/j.ejcb.2018.04.005
NR 79
TC 16
Z9 16
U1 2
U2 6
PU PORTLAND PRESS LTD
PI LONDON
PA CHARLES DARWIN HOUSE, 12 ROGER STREET, LONDON WC1N 2JU, ENGLAND
SN 0144-8463
EI 1573-4935
J9 BIOSCIENCE REP
JI Biosci. Rep.
PD AUG 28
PY 2019
VL 39
AR BSR20190590
DI 10.1042/BSR20190590
PN 8
PG 9
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA IT6LX
UT WOS:000482987000001
PM 31391206
OA Green Published, Green Submitted, gold
DA 2022-04-25
ER

PT J
AU Sun, PF
   Wang, HH
   He, ZY
   Chen, XY
   Wu, QC
   Chen, WK
   Sun, ZR
   Weng, ML
   Zhu, MM
   Ma, D
   Miao, CH
AF Sun, Pengfei
   Wang, Huihui
   He, Zhiyong
   Chen, Xiangyuan
   Wu, Qichao
   Chen, Wankun
   Sun, Zhirong
   Weng, Meilin
   Zhu, Minmin
   Ma, Duan
   Miao, Changhong
TI Fasting inhibits colorectal cancer growth by reducing M2 polarization of
   tumor-associated macrophages
SO ONCOTARGET
LA English
DT Article
DE fasting; tumor-associated macrophages; colorectal cancer; adenosine;
   autophagy
ID SUPPRESSOR-CELLS; AUTOPHAGY; RESTRICTION; PROGRESSION; BLOCKADE; OBESITY
AB Dietary restriction has been recognized as a healthy and natural therapy for cancer. It is reported that different forms of dietary restriction can promote antitumor immunity. However, it is not clear how fasting affects tumor-associated macrophages (TAMs). This study aims to investigate the relationship between fasting and antitumor immunity in terms of tumor-associated macrophages. In vivo, the results showed that alternate day fasting for 2 weeks inhibitted the tumor growth of mice without causing a reduction of body weight. Meanwhile, M2 polarization of tumor-associated macrophages in tumor tissues of alternate day fasting group was also decreased. In vitro, fasting induced the autophagy of CT26 cells, decreased the generation of extracellular adenosine by supressing the expression of CD73 in CT26 cells. Decreasing adenosine inhibitted M2 polarization of RAW264.7 cells through inactivating JAK1/STAT3 signal pathway in fasting condition. Eventually, the proliferation of CT26 cancer cells declined on account of fasting-facilitated antitumor immunity. These results suggested that fasting suppressed M2 polarization of tumorassociated macrophages to inhibit tumor growth through decreasing the level of adenosine in the tumor microenvironment both in vivo and in vitro. This process was associated with increasing autophagy of tumor cells.
C1 [Sun, Pengfei; Wang, Huihui; He, Zhiyong; Chen, Xiangyuan; Wu, Qichao; Chen, Wankun; Sun, Zhirong; Weng, Meilin; Zhu, Minmin; Miao, Changhong] Fudan Univ, Shanghai Med Coll, Dept Anesthesiol, Shanghai Canc Ctr,Dept Oncol, Shanghai, Peoples R China.
   [Ma, Duan] Fudan Univ, Dept Biochem & Mol Biol,Inst Biomed Sci, Key Lab Metab & Mol Med,Sch Basic Med Sci, Collaborat Innovat Ctr Genet & Dev,Minist Educ, Shanghai, Peoples R China.
RP Miao, CH (corresponding author), Fudan Univ, Shanghai Med Coll, Dept Anesthesiol, Shanghai Canc Ctr,Dept Oncol, Shanghai, Peoples R China.; Ma, D (corresponding author), Fudan Univ, Dept Biochem & Mol Biol,Inst Biomed Sci, Key Lab Metab & Mol Med,Sch Basic Med Sci, Collaborat Innovat Ctr Genet & Dev,Minist Educ, Shanghai, Peoples R China.
EM duanma@fudan.edu.cn; miaochh@aliyun.com
RI Ma, Duan/I-8330-2014
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81372101]
FX This work was is supported by the National Natural Science Foundation of
   China (No. 81372101).
CR Arranz A, 2012, P NATL ACAD SCI USA, V109, P9517, DOI 10.1073/pnas.1119038109
   Bardou M, 2013, GUT, V62, P933, DOI 10.1136/gutjnl-2013-304701
   Bianchi F, 2013, CELL TRANSPLANT, V22, P2063, DOI 10.3727/096368912X657855
   Bianchi G, 2015, ONCOTARGET, V6, P11806, DOI 10.18632/oncotarget.3688
   Cekic C, 2012, J IMMUNOL, V188, P198, DOI 10.4049/jimmunol.1101845
   Chen WK, 2016, ONCOTARGET, V7, P78726, DOI 10.18632/oncotarget.12807
   Csoka B, 2012, FASEB J, V26, P376, DOI 10.1096/fj.11-190934
   D'Aronzo M, 2015, ONCOTARGET, V6, P18545, DOI 10.18632/oncotarget.4186
   Gessi S, 2011, BBA-BIOMEMBRANES, V1808, P1400, DOI 10.1016/j.bbamem.2010.09.020
   Hao NB, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/948098
   Hatfield SM, 2016, CURR OPIN PHARMACOL, V29, P90, DOI 10.1016/j.coph.2016.06.009
   Ho TT, 2017, NATURE, V543, P205, DOI 10.1038/nature21388
   Husain Z, 2013, J IMMUNOL, V191, P1486, DOI 10.4049/jimmunol.1202702
   Iannone R, 2013, NEOPLASIA, V15, P1400, DOI 10.1593/neo.131748
   Kang K, 2008, CELL METAB, V7, P485, DOI 10.1016/j.cmet.2008.04.002
   Koscso B, 2013, J LEUKOCYTE BIOL, V94, P1309, DOI 10.1189/jlb.0113043
   Lashinger LM, 2016, CANCER METAB, V4, DOI 10.1186/s40170-016-0158-4
   Lee C, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003293
   Leelatian N, 2017, CYTOM PART B-CLIN CY, V92, P68, DOI 10.1002/cyto.b.21481
   LEVIN B, 1992, CANCER-AM CANCER SOC, V70, P1723, DOI 10.1002/1097-0142(19920915)70:4+<1723::AID-CNCR2820701612>3.0.CO;2-3
   Luo JH, 2014, METHODS MOL BIOL, V1135, P357, DOI 10.1007/978-1-4939-0320-7_29
   Ma DF, 2010, HUM PATHOL, V41, P1550, DOI 10.1016/j.humpath.2010.04.008
   Mantovani A, 2002, TRENDS IMMUNOL, V23, P549, DOI 10.1016/S1471-4906(02)02302-5
   Martinez-Useros J, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-0772-5
   Mendelsohn AR, 2014, REJUV RES, V17, P385, DOI 10.1089/rej.2014.1595
   Mizushima N, 2004, MOL BIOL CELL, V15, P1101, DOI 10.1091/mbc.E03-09-0704
   Morello S, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2015.1108515
   Ohta A, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00109
   Pietrocola F, 2016, CANCER CELL, V30, P147, DOI 10.1016/j.ccell.2016.05.016
   Qian BZ, 2010, CELL, V141, P39, DOI 10.1016/j.cell.2010.03.014
   Rao S, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4056
   Safdie F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044603
   Sica A, 2006, EUR J CANCER, V42, P717, DOI 10.1016/j.ejca.2006.01.003
   Van Blarigan EL, 2015, J CLIN ONCOL, V33, P1825, DOI 10.1200/JCO.2014.59.7799
   van Niekerk G, 2016, FRONT ONCOL, V6, DOI 10.3389/fonc.2016.00242
   Wei Q, 2013, PURINERG SIGNAL, V9, P271, DOI 10.1007/s11302-012-9350-3
   White E, 2012, NAT REV CANCER, V12, P401, DOI 10.1038/nrc3262
NR 37
TC 30
Z9 31
U1 5
U2 21
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD SEP 26
PY 2017
VL 8
IS 43
BP 74649
EP 74660
DI 10.18632/oncotarget.20301
PG 12
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA FI2HT
UT WOS:000411760400106
PM 29088814
OA Green Submitted, gold, Green Published
DA 2022-04-25
ER

PT J
AU Han, Y
   Xue, XF
   Shen, HG
   Guo, XB
   Wang, X
   Yuan, B
   Guo, XP
   Kuang, YT
   Zhi, QM
   Zhao, H
AF Han, Ye
   Xue, Xiao-Feng
   Shen, Hu-Gang
   Guo, Xiao-Bo
   Wang, Xu
   Yuan, Bin
   Guo, Xing-Po
   Kuang, Yu-Ting
   Zhi, Qiao-Ming
   Zhao, Hong
TI Prognostic Significance of Beclin-1 Expression in Colorectal Cancer: a
   Meta-analysis
SO ASIAN PACIFIC JOURNAL OF CANCER PREVENTION
LA English
DT Article
DE Beclin-1; colorectal cancer; prognosis; meta-analysis
ID GASTRIC-CANCER; AUTOPHAGY; PROTEIN
AB Objective: Beclin-1 has recently been observed as an essential marker of autophagy in several cancers. However, the prognostic role of Beclin-1 in colorectal neoplasia remains controversial. Our study aimed to evaluate the potential association between Beclin-1 expression and the outcome of colorectal cancer patients. Materials and Methods: All related studies were systematically searched in Pubmed, Embase, Springer and Chinese National Knowledge Infrastructure databases (CNKI), and then a meta-analysis was performed to determine the association of Beclin-1 expression with clinical outcomes. Finally, a total of 6 articles were included in our analysis. Results: Our data showed that high Beclin-1 expression in patients with CRC was associated with poor prognosis in terms of tumor distant metastasis (OR=2.090, 95% CI=1.061-4.119, p=0.033) and overall survival (RR=1.422, 95% CI=1.032-1.959, p=0.031). However, we did not found any correlation between Beclin-1 over-expression and tumor differentiation (OR=1.711, 95% CI=0.920-3.183, p=0.090). In addition, there was no evidence of publication bias as suggested by Egger's tests for tumor distant metastasis (p=1.000), differentiation (p=1.000) and OS (p=0.308). Conclusions: Our present meta-analysis indicated that elevated Beclin-1 expression iss associated with tumor metastasis and a poor prognosis in patients with CRC. Beclin-1 might serve as an efficient prognostic indicator in CRC, and could be a new molecular target in CRC therapy.
C1 [Han, Ye; Xue, Xiao-Feng; Wang, Xu; Yuan, Bin; Guo, Xing-Po; Kuang, Yu-Ting; Zhi, Qiao-Ming; Zhao, Hong] Soochow Univ, Affiliated Hosp 1, Dept Gen Surg, Suzhou, Peoples R China.
   [Shen, Hu-Gang] Kunshan Hosp Tradit Chinese Med, Dept Gen Surg, Kunshan, Peoples R China.
   [Guo, Xiao-Bo] Shandong Univ, Prov Hosp, Dept Gastrointestinal Surg, Jinan 250100, Peoples R China.
RP Zhi, QM (corresponding author), Soochow Univ, Affiliated Hosp 1, Dept Gen Surg, Suzhou, Peoples R China.
EM strexboy@163.com; zhaohong600@sina.com
FU National youthful Science Foundation of China [81201905, 81302147];
   National Science Foundation of Jiangsu Province, China [BK20130270]
FX This study was supported by a grant from the National youthful Science
   Foundation of China (No. 81201905 and 81302147), the National Science
   Foundation of Jiangsu Province, China (No. BK20130270).
CR Ahn CH, 2007, APMIS, V115, P1344, DOI 10.1111/j.1600-0463.2007.00858.x
   Cao Y, 2007, CELL RES, V17, P839, DOI 10.1038/cr.2007.78
   Chen ZH, 2013, DIGEST DIS SCI, V58, P2887, DOI 10.1007/s10620-013-2732-8
   Geng QR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045968
   Guo GF, 2011, WORLD J GASTROENTERO, V17, P4779, DOI 10.3748/wjg.v17.i43.4779
   Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]
   Kekelidze M, 2013, WORLD J GASTROENTERO, V19, P8502, DOI 10.3748/wjg.v19.i46.8502
   Khiewkhern S, 2013, ASIAN PAC J CANCER P, V14, P3903, DOI 10.7314/APJCP.2013.14.6.3903
   Kim HS, 2011, PATHOL RES PRACT, V207, P247, DOI 10.1016/j.prp.2011.02.007
   Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717
   Koneri K, 2007, ANTICANCER RES, V27, P1453
   Koneri Kenji, 2003, Nihon Rinsho, V61 Suppl 7, P247
   Koukourakis MI, 2010, BRIT J CANCER, V103, P1209, DOI 10.1038/sj.bjc.6605904
   Li BX, 2009, AUTOPHAGY, V5, P303, DOI 10.4161/auto.5.3.7491
   Maiuri MC, 2009, CELL DEATH DIFFER, V16, P87, DOI 10.1038/cdd.2008.131
   Miracco C, 2007, INT J ONCOL, V30, P429
   Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639
   Park JM, 2013, CANCER BIOL THER, V14, P100, DOI 10.4161/cbt.22954
   Parmar MKB, 1998, STAT MED, V17, P2815, DOI 10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8
   Song H, 2004, WORLD J GASTROENTERO, V10, P509, DOI 10.3748/wjg.v10.i4.509
   Sui YQ, 2012, J CLIN EXP PATHOL, V28, P282
   Tong GX, 2014, ASIAN PAC J CANCER P, V15, P1015, DOI 10.7314/APJCP.2014.15.2.1015
   Xia P, 2013, TUMOR BIOL, V34, P3303, DOI 10.1007/s13277-013-1049-8
   Zafar SY, 2013, CANCER-AM CANCER SOC, V119, P854, DOI 10.1002/cncr.27815
   Zeng XH, 2006, J CELL SCI, V119, P259, DOI 10.1242/jcs.02735
   Zhang HQ, 2013, ASIAN PAC J CANCER P, V14, P4685, DOI 10.7314/APJCP.2013.14.8.4685
   Zois CE, 2009, AUTOPHAGY, V5, P442, DOI 10.4161/auto.5.4.7667
NR 27
TC 25
Z9 26
U1 0
U2 0
PU ASIAN PACIFIC ORGANIZATION CANCER PREVENTION
PI GYEONGGI-DO
PA APJCP HEAD OFFICE, KOREAN NATL CANCER CENTER, 323 ILAN -RO,
   ILSANDONG-GU, GOYANG-SI, GYEONGGI-DO, 410-769, SOUTH KOREA
SN 1513-7368
J9 ASIAN PAC J CANCER P
JI Asian Pac. J. Cancer Prev.
PY 2014
VL 15
IS 11
BP 4583
EP 4587
DI 10.7314/APJCP.2014.15.11.4583
PG 5
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA AK7VD
UT WOS:000338634900034
PM 24969889
OA gold, Green Submitted
DA 2022-04-25
ER

PT J
AU Tian, Y
   Wang, KM
   Fan, YR
   Wang, Y
   Sun, LQ
   Wang, L
   Wang, JR
   Wang, ZX
   Li, J
   Ye, Y
   Ji, GZ
AF Tian, Yun
   Wang, Keming
   Fan, Yingrui
   Wang, Yan
   Sun, Liqun
   Wang, Li
   Wang, Jirong
   Wang, Zhaoxia
   Li, Juan
   Ye, Ying
   Ji, Guozhong
TI Chemopreventive Effect of Dietary Glutamineon Colitis-Associated
   Colorectal Cancer Is Associated with Modulation of the DEPTOR/mTOR
   Signaling Pathway
SO NUTRIENTS
LA English
DT Article
DE colitis; colorectal cancer; glutamine; DEPTOR; mTOR signaling
ID INTESTINAL EPITHELIAL-CELLS; INFLAMMATORY-BOWEL-DISEASE; PREVENTS
   MUCOSAL INJURY; MTOR INHIBITOR; GROWTH; AUTOPHAGY; HYPERPERMEABILITY;
   TUMORIGENESIS; MODEL; MICE
AB Glutamine plays a protective role in colitis and colitis-associated colorectal cancer (CAC); however, the protective mechanisms are largely unknown to date. DEP domain-containing mTOR-interacting protein (DEPTOR)/mammalian Target of Rapamycin (mTOR) signaling plays an important role in carcinogenesis. The present study investigated the potential molecular mechanisms for the protective effect of glutamine in a murine model of azoxymethane (AOM)/dextran sulfate sodium (DSS)-induced CAC. The effects of glutamine on DEPTOR/mTOR signaling and protein light chain 3 (LC3) were evaluated. Administration of glutamine was associated with attenuated development of CAC. Increased expression of DEPTOR and decreased expressions of factors of mTOR signaling, including phospho-mTOR, phospho-STAT3, phospho-Akt, and phospho-S6, were observed in AOM/DSS mice administered glutamine. Furthermore, oral glutamine was associated with increased LC3-II expression in AOM/DSS mice. The present study indicates that regulation of DEPTOR/mTOR signaling may be an important mechanism for glutamine in prevention against the development of CAC. In addition, the chemopreventive effect of dietary glutamine on CAC is, at least in part, associated with the induction of autophagy.
C1 [Tian, Yun; Wang, Keming; Fan, Yingrui; Wang, Li; Wang, Jirong; Wang, Zhaoxia; Li, Juan] Nanjing Med Univ, Dept Oncol, Affiliated Hosp 2, 121 Jiangjiayuan Rd, Nanjing 210011, Jiangsu, Peoples R China.
   [Wang, Yan] Nanjing Med Univ, Dept Pathol, Affiliated Hosp 2, 121 Jiangjiayuan Rd, Nanjing 210011, Jiangsu, Peoples R China.
   [Sun, Liqun] Nanjing Med Univ, Dept Intens Care Unit, Affiliated Hosp 2, 121 Jiangjiayuan Rd, Nanjing 210011, Jiangsu, Peoples R China.
   [Ye, Ying] Xuzhou Med Univ, Affiliated Hosp, Emergency Ctr, Xuzhou 221002, Peoples R China.
   [Ji, Guozhong] Nanjing Med Univ, Inst Digest Endoscopy, Affiliated Hosp 2, 121 Jiangjiayuan Rd, Nanjing 210011, Peoples R China.
   [Ji, Guozhong] Nanjing Med Univ, Med Ctr Digest Dis, Affiliated Hosp 2, 121 Jiangjiayuan Rd, Nanjing 210011, Peoples R China.
RP Ji, GZ (corresponding author), Nanjing Med Univ, Inst Digest Endoscopy, Affiliated Hosp 2, 121 Jiangjiayuan Rd, Nanjing 210011, Peoples R China.; Ji, GZ (corresponding author), Nanjing Med Univ, Med Ctr Digest Dis, Affiliated Hosp 2, 121 Jiangjiayuan Rd, Nanjing 210011, Peoples R China.
EM summer.cloud@live.cn; drkemingwang@sina.cn; drfanyingrui@sohu.com;
   dryanwang@sina.com; lixiang@kplink.cn; drliqunsun@sina.com;
   rabbitwjr@126.com; zhaoxiawang88@hotmail.com; ljsmz1229@163.com;
   xzmcyy@163.com; drjiguozhong@sina.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81302110]; Nanjing Medical University
   [2014NJMUZD071]
FX This study was supported by funding from National Natural Science
   Foundation of China (Grant 81302110) and Funding from Nanjing Medical
   University (Grant 2014NJMUZD071).
CR Bhonde MR, 2008, AM J PHYSIOL-GASTR L, V295, pG1237, DOI 10.1152/ajpgi.90537.2008
   Boukhettala N, 2012, AMINO ACIDS, V42, P375, DOI 10.1007/s00726-010-0814-x
   Brenner H, 2014, LANCET, V383, P1490, DOI 10.1016/S0140-6736(13)61649-9
   COOPER HS, 1993, LAB INVEST, V69, P238
   Dancey J, 2010, NAT REV CLIN ONCOL, V7, P209, DOI 10.1038/nrclinonc.2010.21
   Deng L, 2010, AM J PATHOL, V176, P952, DOI 10.2353/ajpath.2010.090622
   Gao DM, 2011, MOL CELL, V44, P290, DOI 10.1016/j.molcel.2011.08.030
   Ge W, 2012, J CELL MOL MED, V16, P616, DOI 10.1111/j.1582-4934.2011.01347.x
   Guertin DA, 2007, CANCER CELL, V12, P9, DOI 10.1016/j.ccr.2007.05.008
   Gulhati P, 2011, CANCER RES, V71, P3246, DOI 10.1158/0008-5472.CAN-10-4058
   Itzkowitz SH, 2004, AM J PHYSIOL-GASTR L, V287, pG7, DOI 10.1152/ajpgi.00079.2004
   Kouznetsova L, 1999, JPEN-PARENTER ENTER, V23, P136, DOI 10.1177/0148607199023003136
   Manhart N, 2001, ANN SURG, V234, P92, DOI 10.1097/00000658-200107000-00014
   MARC RJ, 2009, AMINO ACIDS, V37, P111, DOI DOI 10.1007/S00726-008-0225-4
   Nakajo T, 2005, BIOCHEM BIOPH RES CO, V326, P174, DOI 10.1016/j.bbrc.2004.11.015
   Peterson TR, 2009, CELL, V137, P873, DOI 10.1016/j.cell.2009.03.046
   Sabatini DM, 2006, NAT REV CANCER, V6, P729, DOI 10.1038/nrc1974
   Sakiyama T, 2009, GASTROENTEROLOGY, V136, P924, DOI 10.1053/j.gastro.2008.12.002
   Sengupta S, 2010, NATURE, V468, P1100, DOI 10.1038/nature09584
   Sengupta S, 2010, MOL CELL, V40, P310, DOI 10.1016/j.molcel.2010.09.026
   Sukhotnik I, 2007, DIGEST DIS SCI, V52, P1497, DOI 10.1007/s10620-006-9629-8
   Swaid F, 2013, NUTR METAB, V10, DOI 10.1186/1743-7075-10-53
   Tian Y, 2013, CARCINOGENESIS, V34, P1593, DOI 10.1093/carcin/bgt088
   van der Vos KE, 2012, AUTOPHAGY, V8, P1862, DOI 10.4161/auto.22152
   Vermeulen MAR, 2011, WORLD J GASTROENTERO, V17, P1569, DOI 10.3748/wjg.v17.i12.1569
   Wang ZW, 2012, NEOPLASIA, V14, P368, DOI 10.1593/neo.12542
   Wouters BG, 2008, NAT REV CANCER, V8, P851, DOI 10.1038/nrc2501
   Xi PB, 2012, J NUTR BIOCHEM, V23, P1012, DOI 10.1016/j.jnutbio.2011.05.009
   Xue HY, 2011, JPEN-PARENTER ENTER, V35, P188, DOI 10.1177/0148607110381407
   Zhang YJ, 2012, CELL CYCLE, V11, P594, DOI 10.4161/cc.11.3.19096
   Zoncu R, 2011, NAT REV MOL CELL BIO, V12, P21, DOI 10.1038/nrm3025
NR 31
TC 6
Z9 6
U1 1
U2 8
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 2072-6643
J9 NUTRIENTS
JI Nutrients
PD MAY
PY 2016
VL 8
IS 5
AR 261
DI 10.3390/nu8050261
PG 9
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA DP8XI
UT WOS:000378780900022
PM 27144580
OA Green Published, Green Submitted, gold
DA 2022-04-25
ER

PT J
AU Kao, RH
   Lai, GM
   Chow, JM
   Liao, CH
   Zheng, YM
   Tsai, WL
   Hsia, S
   Lai, IC
   Lee, HL
   Chuang, SE
   Whang-Peng, J
   Yao, CJ
AF Kao, Ruey-Ho
   Lai, Gi-Ming
   Chow, Jyh-Ming
   Liao, Chien-Huang
   Zheng, Yu-Mei
   Tsai, Wei-Lun
   Hsia, Simon
   Lai, I-Chun
   Lee, Hsin-Lun
   Chuang, Shuang-En
   Whang-Peng, Jacqueline
   Yao, Chih-Jung
TI Opposite Regulation of CHOP and GRP78 and Synergistic Apoptosis
   Induction by Selenium Yeast and Fish Oil via AMPK Activation in Lung
   Adenocarcinoma Cells
SO NUTRIENTS
LA English
DT Article
DE selenium; fish oil; lung adenocarcinoma; ER stress; apoptosis
ID ENDOPLASMIC-RETICULUM STRESS; COLON-CANCER CELLS; PROTEIN-KINASE; GROWTH
   ARREST; FATTY-ACIDS; STEM-CELLS; ER STRESS; CHEMOPREVENTION;
   SUPPLEMENTATION; AUTOPHAGY
AB Selenium has been intensively studied for the use of cancer prevention and treatment. However, the clinical effects are still plausible. To enhance its efficacy, a combinational study of selenium yeast (SY) and fish oil (FO) was performed in A549, CL1-0, H1299, HCC827 lung adenocarcinoma (LADC) cells to investigate the enhancement in apoptosis induction and underlying mechanism. By sulforhodamine B staining, Western blot and flow cytometric assays, we found a synergism between SY and FO in growth inhibition and apoptosis induction of LADC cells. In contrast, the fetal lung fibroblast cells (MRC-5) were unsusceptible to this combination effect. FO synergized SY-induced apoptosis of A549 cells, accompanied with synergistic activation of AMP-activated protein kinase (AMPK) and reduction of Cyclooxygenase (COX)-2 and -catenin. Particularly, combining with FO not only enhanced the SY-elevated proapoptotic endoplasmic reticulum (ER) stress marker CCAAT/enhancer-binding protein homologous protein (CHOP), but also reduced the cytoprotective glucose regulated protein of molecular weight 78 kDa (GRP78). Consequently, the CHOP downstream targets such as phospho-JNK and death receptor 5 were also elevated, along with the cleavage of caspase-8, -3, and the ER stress-related caspase-4. Accordingly, inhibition of AMPK by compound C diminished the synergistic apoptosis induction, and elevated CHOP/GRP78 ratio by SY combined with FO. The AMPK-dependent synergism suggests the combination of SY and FO for chemoprevention and integrative treatment of LADC.
C1 [Kao, Ruey-Ho; Lai, Gi-Ming; Chow, Jyh-Ming; Liao, Chien-Huang; Tsai, Wei-Lun; Whang-Peng, Jacqueline; Yao, Chih-Jung] Taipei Med Univ, Wan Fang Hosp, Canc Ctr, Taipei 11696, Taiwan.
   [Kao, Ruey-Ho; Lai, Gi-Ming; Chow, Jyh-Ming; Whang-Peng, Jacqueline] Taipei Med Univ, Wan Fang Hosp, Dept Internal Med, Div Hematol & Med Oncol, Taipei 11696, Taiwan.
   [Kao, Ruey-Ho; Lai, Gi-Ming; Whang-Peng, Jacqueline] Taipei Med Univ, Taipei Canc Ctr, Taipei 11031, Taiwan.
   [Kao, Ruey-Ho; Lai, Gi-Ming; Chow, Jyh-Ming; Yao, Chih-Jung] Taipei Med Univ, Coll Med, Sch Med, Dept Internal Med, Taipei 11031, Taiwan.
   [Lai, Gi-Ming; Chuang, Shuang-En] Natl Hlth Res Inst, Natl Inst Canc Res, Miaoli 35053, Taiwan.
   [Hsia, Simon] Taiwan Nutraceut Assoc, Taipei 10596, Taiwan.
   [Lai, I-Chun] Taipei Vet Gen Hosp, Dept Oncol, Div Radiat Oncol, Taipei 11217, Taiwan.
   [Lee, Hsin-Lun] Taipei Med Univ, Taipei Med Univ Hosp, Dept Radiat Oncol, Taipei 11031, Taiwan.
RP Yao, CJ (corresponding author), Taipei Med Univ, Wan Fang Hosp, Canc Ctr, Taipei 11696, Taiwan.; Yao, CJ (corresponding author), Taipei Med Univ, Coll Med, Sch Med, Dept Internal Med, Taipei 11031, Taiwan.
EM rueykao@gmail.com; gminlai@nhri.org.tw; chow0803@yahoo.com.tw;
   a2639264@ms25.hinet.net; lilindr3@gmail.com; clairgg@hotmail.com;
   Dr.Simon.hsia@gmail.com; littlelai0114@gmail.com; b001089024@tmu.edu.tw;
   sechuang@nhri.org.tw; jqwpeng@nhri.org.tw; yaochihjung@gmail.com
FU Wan Fang Hospital; Taipei Medical University; New Health Products Co.,
   Ltd., Taipei, Taiwan [W327]; Health and welfare surcharge of tobacco
   products [MOHW107-TDU-B-212-114020]; Ministry of Science and Technology,
   TaiwanMinistry of Science and Technology, Taiwan [MOST
   104-2314-B-038-077-MY3]
FX This work was supported by the joint grant of Wan Fang Hospital, Taipei
   Medical University and New Health Products Co., Ltd., Taipei, Taiwan
   (Grant W327), Health and welfare surcharge of tobacco products
   (MOHW107-TDU-B-212-114020) and Ministry of Science and Technology,
   Taiwan (MOST 104-2314-B-038-077-MY3). This work was partially supported
   by the joint grant of Wan Fang Hospital, Taipei Medical University and
   New Health Products Co., Ltd., Taipei, Taiwan (Grant W327). Gi-Ming Lai
   and Chih-Jung Yao are the Principle Investigator and Co-Principle
   Investigator of the Grant W327, respectively.
CR Aktas BH, 2013, ONCOTARGET, V4, P1606, DOI 10.18632/oncotarget.1186
   Banerjee S, 2012, NUTR RES, V32, P985, DOI 10.1016/j.nutres.2012.10.005
   Cai XL, 2016, SCI REP-UK, V6, DOI 10.1038/srep19213
   Cai ZH, 2018, CLIN CHIM ACTA, V483, P156, DOI 10.1016/j.cca.2018.04.033
   Chou TC, 2010, CANCER RES, V70, P440, DOI 10.1158/0008-5472.CAN-09-1947
   Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001
   D'Eliseo D, 2016, J CLIN MED, V5, DOI 10.3390/jcm5020015
   Denisenko TV, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0063-y
   Evans SO, 2017, ANTICANCER RES, V37, P6497, DOI 10.21873/anticanres.12106
   Fasano E, 2012, BBA-MOL BASIS DIS, V1822, P1762, DOI 10.1016/j.bbadis.2012.08.003
   Fritz H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026259
   Hu Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064362
   Huang XL, 2010, CANCER LETT, V296, P123, DOI 10.1016/j.canlet.2010.04.002
   Hwang JT, 2006, CANCER RES, V66, P10057, DOI 10.1158/0008-5472.CAN-06-1814
   Jakobsen CH, 2008, J LIPID RES, V49, P2089, DOI 10.1194/jlr.M700389-JLR200
   Jing K, 2011, AUTOPHAGY, V7, P1348, DOI 10.4161/auto.7.11.16658
   Kajbaf F, 2016, CLIN PHARMACOKINET, V55, P439, DOI 10.1007/s40262-015-0323-x
   Karp DD, 2013, J CLIN ONCOL, V31, P4179, DOI 10.1200/JCO.2013.49.2173
   Kim N, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/239764
   Kim S, 2018, ONCOL REP, V39, P239, DOI 10.3892/or.2017.6101
   Kuriki K, 2003, J NUTR, V133, P3643, DOI 10.1093/jn/133.11.3643
   Leclerc GM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074420
   Lee YK, 2010, CARCINOGENESIS, V31, P1092, DOI 10.1093/carcin/bgq040
   Lizardo MM, 2016, NEOPLASIA, V18, P699, DOI 10.1016/j.neo.2016.09.001
   Lu JX, 2016, NUTR CANCER, V68, P1, DOI 10.1080/01635581.2016.1105267
   Lu M, 2014, SCIENCE, V345, P98, DOI 10.1126/science.1254312
   Luo HY, 2012, COLLOID SURFACE B, V94, P304, DOI 10.1016/j.colsurfb.2012.02.006
   Minihane AM, 2013, EUR J CLIN NUTR, V67, P536, DOI 10.1038/ejcn.2013.19
   Murdolo G, 2017, ADV CANCER RES, V136, P235, DOI 10.1016/bs.acr.2017.07.006
   Murphy RA, 2011, CANCER-AM CANCER SOC, V117, P3774, DOI 10.1002/cncr.25933
   Park SY, 2016, ONCOL REP, V35, P1566, DOI 10.3892/or.2015.4519
   Reid ME, 2004, J TRACE ELEM MED BIO, V18, P69, DOI 10.1016/j.jtemb.2004.03.004
   Schonthal AH, 2009, CANCER LETT, V275, P163, DOI 10.1016/j.canlet.2008.07.005
   Schrauzer GN, 2006, PURE APPL CHEM, V78, P105, DOI 10.1351/pac200678010105
   Shigemi Z, 2017, CHEM-BIOL INTERACT, V266, P28, DOI 10.1016/j.cbi.2017.01.027
   Sinha R, 2004, CURR CANCER DRUG TAR, V4, P13, DOI 10.2174/1568009043481614
   Tabas I, 2011, NAT CELL BIOL, V13, P184, DOI 10.1038/ncb0311-184
   Tracy S, 2004, CANCER RES, V64, P7241, DOI 10.1158/0008-5472.CAN-04-1905
   Travis WD, 2015, J THORAC ONCOL, V10, P1243, DOI 10.1097/JTO.0000000000000630
   Wang H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0052912
   Wu Y, 2005, CANCER RES, V65, P9073, DOI 10.1158/0008-5472.CAN-05-2016
   Yin YQ, 2017, LIPIDS HEALTH DIS, V16, DOI 10.1186/s12944-017-0474-x
   Yu Y, 2017, MOL CELL BIOCHEM, V424, P173, DOI 10.1007/s11010-016-2853-4
   Zimmermann M, 2011, METHODS MOL BIOL, V740, P57, DOI 10.1007/978-1-61779-108-6_8
   Zu K, 2006, ONCOGENE, V25, P546, DOI 10.1038/sj.onc.1209071
   Zu K, 2003, CANCER RES, V63, P6988
NR 46
TC 5
Z9 5
U1 0
U2 3
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 2072-6643
J9 NUTRIENTS
JI Nutrients
PD OCT
PY 2018
VL 10
IS 10
AR 1458
DI 10.3390/nu10101458
PG 17
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA GY7UM
UT WOS:000448821300124
PM 30297634
OA Green Published, gold, Green Submitted
DA 2022-04-25
ER

PT J
AU Zhang, LT
   Lu, PF
   Yan, LH
   Yang, LJ
   Wang, YT
   Chen, JJ
   Dai, J
   Li, YH
   Kang, ZM
   Bai, T
   Xi, YF
   Xu, J
   Sun, GQ
   Yang, T
AF Zhang, Litao
   Lu, Peifen
   Yan, Lihong
   Yang, Lijun
   Wang, Yutao
   Chen, Junjun
   Dai, Jie
   Li, Yahui
   Kang, Zhiming
   Bai, Tao
   Xi, Yanfeng
   Xu, Jun
   Sun, Gongqin
   Yang, Tao
TI MRPL35 Is Up-Regulated in Colorectal Cancer and Regulates Colorectal
   Cancer Cell Growth and Apoptosis
SO AMERICAN JOURNAL OF PATHOLOGY
LA English
DT Article
ID DNA-DAMAGE RESPONSE; MOLECULAR-MECHANISMS; OXIDATIVE STRESS; SODIUM
   SELENITE; ATM KINASE; P53; AUTOPHAGY; MITOCHONDRIA; ACTIVATION; DEATH
AB Mitochondrial ribosome proteins (MRPs), which are encoded by the nuclear genomic DNA, are important for mitochondrial-encoded protein synthesis and mitochondrial function. Emerging evidence suggests that several MRPs also exhibit important extra-mitochondrial. functions, such as involvement in apoptosis, protein biosynthesis, and signal transduction. In this study, we demonstrate a significant role of MRP L35 (MRPL35) in colorectal cancer (CRC). The expression of MRPL35 was higher in CRC tissues than in matched cancer-adjacent tissues and higher in CRC cells than in normal mucosal epithelial cells. Higher MRPL35 expression in CRC tissue correlated with shorter overall survival for CRC patients. In vitro, down-regulation of MRPL35 led to increased production of reactive oxygen species (ROS) together with DNA damage, loss of cell proliferation, G(2)/M arrest, a decrease in mitochondrial membrane potential, apoptosis, and autophagy induction. MRPL35 knockdown inhibited tumor proliferation in a CRC xenograft nude mouse model. Furthermore, overexpression of MRPL35 or treatment of cells with the ROS scavenger, N-acetyl cysteine, abrogated ROS production, cell cycle arrest, and apoptosis in vitro. These findings suggest that MRPL35 plays an essential role in the development of CRC and may be a potential therapeutic target for CRC.
C1 [Zhang, Litao; Lu, Peifen; Yan, Lihong; Wang, Yutao; Chen, Junjun; Dai, Jie; Li, Yahui; Kang, Zhiming; Sun, Gongqin; Yang, Tao] Shanxi Med Univ, Dept Biochem & Mol Biol, Taiyuan, Shanxi, Peoples R China.
   [Yang, Lijun] Shanxi Med Univ, Dept Pharmacol, Taiyuan, Shanxi, Peoples R China.
   [Bai, Tao] Shanxi Med Univ, Affiliated Hosp 1, Dept Pathol, Taiyuan, Shanxi, Peoples R China.
   [Xi, Yanfeng] Shanxi Prov Canc Hosp, Dept Pathol, Taiyuan, Shanxi, Peoples R China.
   [Xu, Jun] Shanxi Grand Hosp, Dept Gen Surg, Taiyuan, Shanxi, Peoples R China.
   [Sun, Gongqin] Univ Rhode Isl, Dept Cell & Mol Biol, Kingston, RI 02881 USA.
RP Yang, T (corresponding author), 56 Xinjian S Rd, Taiyuan 030001, Shanxi, Peoples R China.; Sun, GQ (corresponding author), 120 Flag Rd, Kingston, RI 02881 USA.
EM gongqinsun@uri.edu; yangtao056cn@126.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81101895, 81441021]; Shanxi Scholarship
   Council of China [2016-050]; Program for the Scientific Activities of
   Selected Returned Overseas Professionals in Shanxi ProvinceScientific
   Research Foundation for the Returned Overseas Chinese Scholars
   [2014-779]
FX Supported by the National Natural Science Foundation of China grants
   81101895 and 81441021, the Shanxi Scholarship Council of China grant
   2016-050, and the Program for the Scientific Activities of Selected
   Returned Overseas Professionals in Shanxi Province grant 2014-779.
CR Azad MB, 2008, AUTOPHAGY, V4, P195, DOI 10.4161/auto.5278
   Bakkenist CJ, 2004, TRENDS CELL BIOL, V14, P339, DOI 10.1016/j.tcb.2004.05.001
   Balaburski GM, 2010, TRENDS CELL BIOL, V20, P363, DOI 10.1016/j.tcb.2010.02.007
   Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674
   Botti J, 2006, AUTOPHAGY, V2, P67, DOI 10.4161/auto.2.2.2458
   Boutros R, 2007, NAT REV CANCER, V7, P495, DOI 10.1038/nrc2169
   Box JM, 2017, MOL BIOL CELL, V28, P3489, DOI 10.1091/mbc.E17-04-0239
   Brandon M, 2006, ONCOGENE, V25, P4647, DOI 10.1038/sj.onc.1209607
   Bunz F, 2011, CURR CANCER RES, P35, DOI 10.1007/978-1-4419-8044-1_2
   Burma S, 2001, J BIOL CHEM, V276, P42462, DOI 10.1074/jbc.C100466200
   Campaner S, 2012, CELL DIV, V7, DOI 10.1186/1747-1028-7-6
   Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677
   Chang CT, 2017, FOOD CHEM TOXICOL, V103, P1, DOI 10.1016/j.fct.2017.02.019
   Chen Y, 2014, AUTOPHAGY, V4, P246
   Chen YC, 2007, J CELL BIOCHEM, V100, P981, DOI 10.1002/jcb.21079
   Committee for the Update of the Guide for the Care and Use of Laboratory Animals, 2011, GUIDE CARE USE LAB A
   Crighton D, 2007, AUTOPHAGY, V3, P72, DOI 10.4161/auto.3438
   Crighton D, 2006, CELL, V126, P121, DOI 10.1016/j.cell.2006.05.034
   D'Anneo A, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.415
   Djavaheri-Mergny M, 2006, J BIOL CHEM, V281, P30373, DOI 10.1074/jbc.M602097200
   Fan CD, 2013, FREE RADICAL BIO MED, V65, P305, DOI 10.1016/j.freeradbiomed.2013.07.002
   Fridman JS, 2003, ONCOGENE, V22, P9030, DOI 10.1038/sj.onc.1207116
   Gao Y, 2017, ONCOTARGET, V8, P71772, DOI 10.18632/oncotarget.17888
   Gopisetty G, 2016, GENE, V589, P27, DOI 10.1016/j.gene.2016.05.008
   Grothey A, 2013, J CLIN ONCOL, V31, P1609, DOI 10.1200/JCO.2012.47.4452
   Guan JJ, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2014.546
   Guerra L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008924
   Hamanaka RB, 2010, TRENDS BIOCHEM SCI, V35, P505, DOI 10.1016/j.tibs.2010.04.002
   Hara M, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2062
   Henry-Mowatt J, 2004, ONCOGENE, V23, P2850, DOI 10.1038/sj.onc.1207534
   Huang Q, 2009, CELL DEATH DIFFER, V16, P264, DOI 10.1038/cdd.2008.151
   Huang SH, 2012, J AGR FOOD CHEM, V60, P665, DOI 10.1021/jf204193v
   Ishii T, 2005, CANCER RES, V65, P203
   Kang J, 2005, MOL CELL BIOL, V25, P661, DOI 10.1128/MCB.25.2.661-670.2005
   Kenmochi N, 2001, GENOMICS, V77, P65, DOI 10.1006/geno.2001.6622
   Kim EH, 2007, CANCER RES, V67, P6314, DOI 10.1158/0008-5472.CAN-06-4217
   Kuma A, 2004, NATURE, V432, P1032, DOI 10.1038/nature03029
   Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758
   Lee J, 2001, MOL BIOL CELL, V12, P551, DOI 10.1091/mbc.12.3.551
   Lee JH, 2007, ONCOGENE, V26, P7741, DOI 10.1038/sj.onc.1210872
   Levine AJ, 2009, NAT REV CANCER, V9, P749, DOI 10.1038/nrc2723
   Li HB, 2016, DNA CELL BIOL, V35, P680, DOI 10.1089/dna.2016.3271
   Li LL, 2015, CELL MOL NEUROBIOL, V35, P615, DOI 10.1007/s10571-015-0166-x
   Lin SS, 2018, J CELL PHYSIOL, V233, P5119, DOI 10.1002/jcp.26356
   Liu H, 2017, J CANCER, V8, P1586, DOI 10.7150/jca.18735
   Liu L, 2018, ONCOGENE, V37, P86, DOI 10.1038/onc.2017.314
   Ly JD, 2003, APOPTOSIS, V8, P115, DOI 10.1023/A:1022945107762
   Maiuri MC, 2010, CURR OPIN CELL BIOL, V22, P181, DOI 10.1016/j.ceb.2009.12.001
   Malumbres M, 2005, TRENDS BIOCHEM SCI, V30, P630, DOI 10.1016/j.tibs.2005.09.005
   Marine JC, 2006, CELL DEATH DIFFER, V13, P927, DOI 10.1038/sj.cdd.4401912
   MARTINEZCAYUELA M, 1995, BIOCHIMIE, V77, P147, DOI 10.1016/0300-9084(96)88119-3
   McIlwain DR, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a008656
   Mizushima N, 2001, J CELL BIOL, V152, P657, DOI 10.1083/jcb.152.4.657
   O'Connell MJ, 2000, TRENDS CELL BIOL, V10, P296, DOI 10.1016/S0962-8924(00)01773-6
   O'Prey J, 2009, CELL CYCLE, V8, P2260, DOI 10.4161/cc.8.14.9050
   OConnell MJ, 1997, EMBO J, V16, P545, DOI 10.1093/emboj/16.3.545
   Palchaudhuri R, 2007, CURR OPIN BIOTECH, V18, P497, DOI 10.1016/j.copbio.2007.09.006
   Park SH, 2012, TOXICOL LETT, V212, P252, DOI 10.1016/j.toxlet.2012.06.007
   Perse M, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/725710
   PIETROMONACO SF, 1991, BIOCHIMIE, V73, P827, DOI 10.1016/0300-9084(91)90062-6
   Pu M, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317709127
   Redza-Dutordoir M, 2016, BBA-MOL CELL RES, V1863, P2977, DOI 10.1016/j.bbamcr.2016.09.012
   Richter U, 2013, CURR BIOL, V23, P535, DOI 10.1016/j.cub.2013.02.019
   Riedl SJ, 2004, NAT REV MOL CELL BIO, V5, P897, DOI 10.1038/nrm1496
   Riley T, 2008, NAT REV MOL CELL BIO, V9, P402, DOI 10.1038/nrm2395
   Schreuders EH, 2015, GUT, V64, P1637, DOI 10.1136/gutjnl-2014-309086
   Shiloh Y, 2001, ADV CANCER RES, V83, P209, DOI 10.1016/S0065-230X(01)83007-4
   Shiloh Y, 2006, TRENDS BIOCHEM SCI, V31, P402, DOI 10.1016/j.tibs.2006.05.004
   Siegel R, 2014, CA-CANCER J CLIN, V64, P104, DOI 10.3322/caac.21220
   Srinivasan S, 2017, BBA-BIOENERGETICS, V1858, P602, DOI 10.1016/j.bbabio.2017.01.004
   Takahashi M, 2013, CANCER MED-US, V2, P1, DOI 10.1002/cam4.39
   Vousden KH, 2007, NAT REV MOL CELL BIO, V8, P275, DOI 10.1038/nrm2147
   Vyas S, 2016, CELL, V166, P555, DOI 10.1016/j.cell.2016.07.002
   Wallace DC, 2005, COLD SH Q B, V70, P363, DOI 10.1101/sqb.2005.70.035
   Wallace DC, 2012, NAT REV CANCER, V12, P685, DOI 10.1038/nrc3365
   Yang Y, 2013, CURR MED CHEM, V20, P3677, DOI 10.2174/0929867311320999165
   Yoo YA, 2005, MOL CELL BIOL, V25, P6603, DOI 10.1128/MCB.25.15.6603-6616.2005
   2001, FEBS LETT, V492, P166
   2016, FOOD CHEM TOXICOL, V97, P336, DOI DOI 10.1016/J.FCT.2016.09.028
   2014, NEURO-ONCOLOGY, V16, P946, DOI DOI 10.1093/NEUONC/NOT308
NR 80
TC 8
Z9 8
U1 2
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9440
EI 1525-2191
J9 AM J PATHOL
JI Am. J. Pathol.
PD MAY
PY 2019
VL 189
IS 5
BP 1105
EP 1120
DI 10.1016/j.ajpath.2019.02.003
PG 16
WC Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology
GA HY3GI
UT WOS:000468010900016
PM 30862482
OA Bronze
DA 2022-04-25
ER

PT J
AU Bortnik, S
   Gorski, SM
AF Bortnik, Svetlana
   Gorski, Sharon M.
TI Clinical Applications of Autophagy Proteins in Cancer: From Potential
   Targets to Biomarkers
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Review
DE autophagy; cancer; biomarkers; immunohistochemistry
ID LIGHT-CHAIN 3B; BECLIN 1; PROGNOSTIC-SIGNIFICANCE; POOR-PROGNOSIS;
   COLORECTAL-CANCER; LUNG-CANCER; SELECTIVE INHIBITOR; MAMMALIAN
   AUTOPHAGY; MARKERS BECLIN-1; HIGH EXPRESSION
AB Autophagy, a lysosome-mediated intracellular degradation and recycling pathway, plays multiple context-dependent roles in tumorigenesis and treatment resistance. Encouraging results from various preclinical studies have led to the initiation of numerous clinical trials with the intention of targeting autophagy in various cancers. Accumulating knowledge of the particular mechanisms and players involved in different steps of autophagy regulation led to the ongoing discovery of small molecule inhibitors designed to disrupt this highly orchestrated process. However, the development of validated autophagy-related biomarkers, essential for rational selection of patients entering clinical trials involving autophagy inhibitors, is lagging behind. One possible source of biomarkers for this purpose is the autophagy machinery itself. In this review, we address the recent trends, challenges and advances in the assessment of the biomarker potential of clinically relevant autophagy proteins in human cancers.
C1 [Bortnik, Svetlana; Gorski, Sharon M.] BC Canc Agcy, Canadas Michael Smith Genome Sci Ctr, Vancouver, BC V5Z 1L3, Canada.
   [Bortnik, Svetlana; Gorski, Sharon M.] Univ British Columbia, Interdisciplinary Oncol Program, Vancouver, BC V5Z 1L3, Canada.
   [Gorski, Sharon M.] Simon Fraser Univ, Dept Mol Biol & Biochem, Burnaby, BC V5A 1S6, Canada.
   [Gorski, Sharon M.] Simon Fraser Univ, Ctr Cell Biol Dev & Dis, Burnaby, BC V5A 1S6, Canada.
RP Gorski, SM (corresponding author), BC Canc Agcy, Canadas Michael Smith Genome Sci Ctr, Vancouver, BC V5Z 1L3, Canada.; Gorski, SM (corresponding author), Univ British Columbia, Interdisciplinary Oncol Program, Vancouver, BC V5Z 1L3, Canada.; Gorski, SM (corresponding author), Simon Fraser Univ, Dept Mol Biol & Biochem, Burnaby, BC V5A 1S6, Canada.; Gorski, SM (corresponding author), Simon Fraser Univ, Ctr Cell Biol Dev & Dis, Burnaby, BC V5A 1S6, Canada.
EM sbortnik@bcgsc.ca; sgorski@bcgsc.ca
RI Gorski, Sharon M/E-9375-2012
OI Gorski, Sharon M/0000-0002-3821-8289
FU CIHR Frederick Banting and Charles Best Canada Graduate Scholarship
   Doctoral AwardCanadian Institutes of Health Research (CIHR); University
   of British Columbia Four Year Doctoral Fellowship (4YF) Award; Avon
   Foundation for Women-Canada grant [OBC127216]; CIHRCanadian Institutes
   of Health Research (CIHR)
FX The authors thank Kevin C. Yang, Morgana Xu and Robert Camfield for
   helpful discussions and comments on the manuscript. S. Bortnik is
   supported by a CIHR Frederick Banting and Charles Best Canada Graduate
   Scholarship Doctoral Award, as well as the University of British
   Columbia Four Year Doctoral Fellowship (4YF) Award. The authors are
   grateful for support from CIHR in partnership with Avon Foundation for
   Women-Canada grant OBC127216.
CR Akin D, 2014, AUTOPHAGY, V10, P2021, DOI 10.4161/auto.32229
   Amaravadi R, 2016, GENE DEV, V30, P1913, DOI 10.1101/gad.287524.116
   An CH, 2011, PATHOL RES PRACT, V207, P433, DOI 10.1016/j.prp.2011.05.002
   Bago R, 2014, BIOCHEM J, V463, P413, DOI 10.1042/BJ20140889
   Bento CF, 2016, ANNU REV BIOCHEM, V85, P685, DOI 10.1146/annurev-biochem-060815-014556
   Cao QH, 2016, AM J TRANSL RES, V8, P3831
   Cao Y, 2007, CELL RES, V17, P839, DOI 10.1038/cr.2007.78
   Carvajal-Hausdorf DE, 2015, LAB INVEST, V95, P385, DOI 10.1038/labinvest.2014.157
   Cha YJ, 2014, INT J CLIN EXP PATHO, V7, P3389
   Choi J, 2013, HISTOPATHOLOGY, V62, P275, DOI 10.1111/his.12002
   Clotaire DZJ, 2016, BIOCHEM BIOPH RES CO, V472, P194, DOI 10.1016/j.bbrc.2016.02.093
   Crutchfield CA, 2016, CLIN PROTEOM, V13, DOI 10.1186/s12014-015-9102-9
   Deretic V, 2013, NAT REV IMMUNOL, V13, P722, DOI 10.1038/nri3532
   Dowdle WE, 2014, NAT CELL BIOL, V16, P1069, DOI 10.1038/ncb3053
   Egan DF, 2015, MOL CELL, V59, P285, DOI 10.1016/j.molcel.2015.05.031
   Eissa S, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317698360
   El-Mashed S, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1574-5
   Feng YC, 2014, CELL RES, V24, P24, DOI 10.1038/cr.2013.168
   Fujita N, 2008, MOL BIOL CELL, V19, P2092, DOI 10.1091/mbc.E07-12-1257
   Galluzzi L, 2015, EMBO J, V34, P856, DOI 10.15252/embj.201490784
   Geng JF, 2008, EMBO REP, V9, P859, DOI 10.1038/embor.2008.163
   Giatromanolaki A, 2010, J CLIN PATHOL, V63, P867, DOI 10.1136/jcp.2010.079525
   Goossens N, 2015, TRANSL CANCER RES, V4, P256, DOI 10.3978/j.issn.2218-676X.2015.06.04
   Green DR, 2014, CELL, V157, P65, DOI 10.1016/j.cell.2014.02.049
   Guo GF, 2011, WORLD J GASTROENTERO, V17, P4779, DOI 10.3748/wjg.v17.i43.4779
   Guo JY, 2013, CELL, V155, P1216, DOI 10.1016/j.cell.2013.11.019
   Guo JY, 2011, GENE DEV, V25, P460, DOI 10.1101/gad.2016311
   Han Y, 2014, ASIAN PAC J CANCER P, V15, P4583, DOI 10.7314/APJCP.2014.15.11.4583
   Hanada T, 2007, J BIOL CHEM, V282, P37298, DOI 10.1074/jbc.C700195200
   He YY, 2014, TUMOR BIOL, V35, P7317, DOI 10.1007/s13277-014-2060-4
   Inoue D, 2012, CANCER SCI, V103, P760, DOI 10.1111/j.1349-7006.2012.02216.x
   Italiano A, 2011, J CLIN ONCOL, V29, P4718, DOI 10.1200/JCO.2011.38.3729
   Iwadate R, 2015, AM J PATHOL, V185, P2523, DOI 10.1016/j.ajpath.2015.05.008
   Iwadate R, 2014, ACTA HISTOCHEM CYTOC, V47, P295, DOI 10.1267/ahc.14048
   Jiang L, 2014, INT J CLIN EXP MED, V7, P1349
   Jiang XJ, 2015, J CLIN INVEST, V125, P47, DOI 10.1172/JCI73942
   Jo YK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052705
   Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720
   Karpathiou G, 2011, CHEST, V140, P127, DOI 10.1378/chest.10-1831
   Katsuragi Y, 2015, FEBS J, V282, P4672, DOI 10.1111/febs.13540
   Kennedy BK, 2016, CELL METAB, V23, P990, DOI 10.1016/j.cmet.2016.05.009
   Kim MS, 2011, APMIS, V119, P802, DOI 10.1111/j.1600-0463.2011.02812.x
   Klionsky DJ, 2016, AUTOPHAGY, V12, P1, DOI 10.1080/15548627.2015.1100356
   Ko YH, 2013, PANCREAS, V42, P829, DOI 10.1097/MPA.0b013e318279d0dc
   Koukourakis MI, 2010, BRIT J CANCER, V103, P1209, DOI 10.1038/sj.bjc.6605904
   Kraya AA, 2015, AUTOPHAGY, V11, P60, DOI 10.4161/15548627.2014.984273
   Ladoire S, 2015, AUTOPHAGY, V11, P1878, DOI 10.1080/15548627.2015.1082022
   Lazarus MB, 2015, BIOORGAN MED CHEM, V23, P5483, DOI 10.1016/j.bmc.2015.07.034
   Lazova R, 2012, CLIN CANCER RES, V18, P370, DOI 10.1158/1078-0432.CCR-11-1282
   Lebovitz CB, 2015, AUTOPHAGY, V11, P1668, DOI 10.1080/15548627.2015.1067362
   Lebovitz CB, 2012, CLIN CANCER RES, V18, P1214, DOI 10.1158/1078-0432.CCR-11-2465
   Levine B, 2011, NATURE, V469, P323, DOI 10.1038/nature09782
   Liao WJ, 2014, ANAT REC, V297, P653, DOI 10.1002/ar.22895
   Lin MG, 2016, CURR OPIN CELL BIOL, V39, P61, DOI 10.1016/j.ceb.2016.02.010
   Liu JL, 2014, BRIT J CANCER, V111, P944, DOI 10.1038/bjc.2014.355
   Liu JL, 2011, CELL, V147, P223, DOI 10.1016/j.cell.2011.08.037
   Liu PF, 2014, AUTOPHAGY, V10, P1454, DOI 10.4161/auto.29556
   Luo HY, 2014, WORLD J GASTROENTERO, V20, P3858, DOI 10.3748/wjg.v20.i14.3858
   Luo Rong-Zhen, 2013, Onco Targets Ther, V6, P883, DOI 10.2147/OTT.S46222
   Ma XH, 2014, J CLIN INVEST, V124, P1406, DOI 10.1172/JCI70454
   Mahalingam D, 2014, AUTOPHAGY, V10, P1403, DOI 10.4161/auto.29231
   Manjithaya R, 2011, TRENDS CELL BIOL, V21, P67, DOI 10.1016/j.tcb.2010.09.009
   Masuda G, 2016, ANTICANCER RES, V36, P129
   McAfee Q, 2012, P NATL ACAD SCI USA, V109, P8253, DOI 10.1073/pnas.1118193109
   McAlpine F, 2013, AUTOPHAGY, V9, P361, DOI 10.4161/auto.23066
   Mehta Sunali, 2010, Ther Adv Med Oncol, V2, P125, DOI 10.1177/1758834009360519
   Miao YF, 2010, HEPATO-GASTROENTEROL, V57, P257
   Mizushima N, 2004, MOL BIOL CELL, V15, P1101, DOI 10.1091/mbc.E03-09-0704
   Mizushima N, 2011, ANNU REV CELL DEV BI, V27, P107, DOI 10.1146/annurev-cellbio-092910-154005
   Nguyen TG, 2014, ASSAY DRUG DEV TECHN, V12, P176, DOI 10.1089/adt.2013.561
   Oldenhuis CNAM, 2008, EUR J CANCER, V44, P946, DOI 10.1016/j.ejca.2008.03.006
   Pasquier B, 2015, J MED CHEM, V58, P376, DOI 10.1021/jm5013352
   Petherick KJ, 2015, J BIOL CHEM, V290, P11376, DOI [10.1074/jbc.C114.627778, 10.1074/jbc.A114.627778]
   Pfisterer SG, 2014, J LIPID RES, V55, P1267, DOI 10.1194/jlr.M046359
   Poklepovic A, 2014, AUTOPHAGY, V10, P1478, DOI 10.4161/auto.29428
   Puissant A, 2012, AM J CANCER RES, V2, P397
   Rangwala R, 2014, AUTOPHAGY, V10, P1369, DOI 10.4161/auto.29118
   Ravikumar B, 2010, PHYSIOL REV, V90, P1383, DOI 10.1152/physrev.00030.2009
   Rebecca VW, 2016, ONCOGENE, V35, P1, DOI 10.1038/onc.2015.99
   Rolland P, 2007, ENDOCR-RELAT CANCER, V14, P73, DOI 10.1677/erc.1.01312
   Ronan B, 2014, NAT CHEM BIOL, V10, P1013, DOI 10.1038/nchembio.1681
   Rosenfeld MR, 2014, AUTOPHAGY, V10, P1359, DOI 10.4161/auto.28984
   Rothe K, 2014, BLOOD, V123, P3622, DOI 10.1182/blood-2013-07-516807
   Sarkar S, 2013, BIOCHEM SOC T, V41, P1103, DOI 10.1042/BST20130134
   Satoo K, 2009, EMBO J, V28, P1341, DOI 10.1038/emboj.2009.80
   Schaaf MBE, 2016, FASEB J, V30, P3961, DOI 10.1096/fj.201600698R
   Schlafli AM, 2016, ONCOTARGET, V7, P39544, DOI 10.18632/oncotarget.9647
   Schmitz KJ, 2016, WORLD J SURG ONCOL, V14, DOI 10.1186/s12957-016-0946-x
   Shen S, 2011, ONCOGENE, V30, P4544, DOI 10.1038/onc.2011.168
   Shpilka T, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-7-226
   Sivridis E, 2010, AM J PATHOL, V176, P2477, DOI 10.2353/ajpath.2010.090049
   Solitro AR, 2016, FUTURE MED CHEM, V8, P73, DOI 10.4155/fmc.15.166
   Spowart JE, 2012, J PATHOL, V228, P437, DOI 10.1002/path.4090
   Subramani S, 2013, EMBO REP, V14, P143, DOI 10.1038/embor.2012.220
   Sun SX, 2016, ONCOTARGETS THER, V9, P4975, DOI 10.2147/OTT.S107876
   Tang JY, 2013, ANTICANCER RES, V33, P5611
   Tang J, 2012, BREAST CANCER RES TR, V134, P549, DOI 10.1007/s10549-012-2080-y
   Tanida I, 2004, J BIOL CHEM, V279, P36268, DOI 10.1074/jbc.M401461200
   Nguyen TN, 2016, J CELL BIOL, V215, P857, DOI 10.1083/jcb.201607039
   Thorburn A, 2014, MOL PHARMACOL, V85, P830, DOI 10.1124/mol.114.091850
   Wang L, 2015, BIOCHEM BIOPH RES CO, V458, P816, DOI 10.1016/j.bbrc.2015.02.037
   Wang XF, 2015, INT J CLIN EXP PATHO, V8, P10644
   Wani WY, 2015, LAB INVEST, V95, P14, DOI 10.1038/labinvest.2014.131
   Weidberg H, 2010, EMBO J, V29, P1792, DOI 10.1038/emboj.2010.74
   Winardi D, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/723176
   Wu DH, 2014, TUMOR BIOL, V35, P12225, DOI 10.1007/s13277-014-2531-7
   Wu SF, 2016, TUMOR BIOL, V37, P6943, DOI 10.1007/s13277-015-4587-4
   Wu SH, 2015, INT J CLIN EXP PATHO, V8, P3882
   Xi SY, 2013, BIOCHEM BIOPH RES CO, V431, P760, DOI 10.1016/j.bbrc.2012.12.151
   Xu HT, 2013, INT J CLIN EXP PATHO, V6, P711
   Yang MP, 2015, ONCOTARGET, V6, P7084, DOI 10.18632/oncotarget.3054
   Yang ZF, 2010, CURR OPIN CELL BIOL, V22, P124, DOI 10.1016/j.ceb.2009.11.014
   Yun M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117375
   Zhang Liang, 2016, COMPLEX VAR ELLIPTIC, V2016, P19
   Zhang MY, 2014, INT J MOL SCI, V15, P14372, DOI 10.3390/ijms150814372
   Zhao H, 2013, MED ONCOL, V30, DOI 10.1007/s12032-013-0475-1
   Zhong ZY, 2016, CELL, V166, P288, DOI 10.1016/j.cell.2016.05.051
   Zhou HY, 2016, CANCER BIOMARK, V17, P1, DOI 10.3233/CBM-160613
   Zou YF, 2015, ONCOL LETT, V10, P1583, DOI 10.3892/ol.2015.3417
NR 119
TC 33
Z9 34
U1 1
U2 9
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD JUL
PY 2017
VL 18
IS 7
AR 1496
DI 10.3390/ijms18071496
PG 16
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA FF2SJ
UT WOS:000408746800165
PM 28696368
OA Green Published, Green Submitted, gold
DA 2022-04-25
ER

PT J
AU Schonthal, AH
AF Schoenthal, Axel H.
TI Pharmacological targeting of endoplasmic reticulum stress signaling in
   cancer
SO BIOCHEMICAL PHARMACOLOGY
LA English
DT Review
DE Autophagy; Chemoresistance; GRP78 inhibitors; Yin-Yang principle
ID UNFOLDED PROTEIN RESPONSE; N-LINKED GLYCOSYLATION; DEPENDENT KINASE-1
   INHIBITOR; GLUCOSE-REGULATED PROTEINS; CHAPERONE DOWN-REGULATOR;
   COLON-CARCINOMA CELLS; HUMAN-MELANOMA CELLS; NON-COXIB ANALOG; PHASE-I
   TRIAL; ER STRESS
AB The endoplasmic reticulum (ER) stress response constitutes a cellular process that can be triggered by a great variety of conditions that cause imbalances in intracellular homeostasis and threaten proper cell functioning. In response, the ER stress response activates an adaptive effort aimed at neutralizing these threats and reestablishing homeostasis. However, if these countermeasures are unsuccessful and severe imbalances persist, the ER stress response may abandon its pro-survival efforts and instead may initiate a pro-apoptotic program to eliminate the faulty cell for the benefit of the organism as a whole. Because vigorous growth of malignant tumors may create stressful conditions, such as hypoglycemia, hypoxia, or accumulation of misfolded proteins during revved up protein synthesis, the adaptive, pro-survival components of the ER stress response system (e.g., GRP78/BiP) are frequently found chronically activated in tumor cells. This differential to non-stressed normal. cells has been proposed to represent an Achilles' heel of tumor cells that may be exploitable by therapeutic intervention. In this model, the goal would be to further aggravate the pre-existing stress conditions in tumor cells with appropriate pharmacological agents, so that the already engaged pro-survival mechanism would be overwhelmed and the ER stress response forced to switch to its pro-apoptotic mode (e.g., CHOP/GADD153). This review will discuss the principle of pharmacological ER stress aggravation, and will present preclinical models with promise for cancer therapeutic applications. (C) 2012 Elsevier Inc. All rights reserved.
C1 [Schoenthal, Axel H.] Univ So Calif, Keck Sch Med, Dept Mol Microbiol & Immunol, Los Angeles, CA 90033 USA.
RP Schonthal, AH (corresponding author), Dept Mol Microbiol & Immunol, 2011 Zonal Ave,HMR-405, Los Angeles, CA 90033 USA.
EM schontha@usc.edu
RI Schonthal, Axel/ABH-3846-2020
OI Schonthal, Axel/0000-0003-0662-5653
CR Adachi Y, 2008, CELL STRUCT FUNCT, V33, P75, DOI 10.1247/csf.07044
   Adams J, 2004, CANCER INVEST, V22, P304, DOI 10.1081/CNV-120030218
   Alberts B, 2008, MOL BIOL CELL, Vfifth
   Arap MA, 2004, CANCER CELL, V6, P275, DOI 10.1016/j.ccr.2004.08.018
   Back SH, 2012, ANNU REV BIOCHEM, V81, P767, DOI 10.1146/annurev-biochem-072909-095555
   Backer JM, 2009, NEOPLASIA, V11, P1165, DOI 10.1593/neo.09878
   Banerjee A, 2011, J BIOL CHEM, V286, P29127, DOI 10.1074/jbc.M110.169771
   Banerjee S, 2008, CANCER LETT, V269, P226, DOI 10.1016/j.canlet.2008.03.052
   Beddoe T, 2010, TRENDS BIOCHEM SCI, V35, P411, DOI 10.1016/j.tibs.2010.02.003
   Beretta GL, 2010, BIOCHEM PHARMACOL, V79, P1108, DOI 10.1016/j.bcp.2009.12.002
   Bernales S, 2006, PLOS BIOL, V4, P2311, DOI 10.1371/journal.pbio.0040423
   Bernstein WB, 2008, CURR OPIN HIV AIDS, V3, P666, DOI 10.1097/COH.0b013e328313915d
   Booth L, 2012, CANCER BIOL THER, V13, P224, DOI 10.4161/cbt.13.4.18877
   Boya P, 2002, CELL DEATH DIFFER, V9, P465, DOI 10.1038/sj.cdd.4401006
   Boyce M, 2006, CELL DEATH DIFFER, V13, P363, DOI 10.1038/sj.cdd.4401817
   Braakman I, 2011, ANNU REV BIOCHEM, V80, P71, DOI 10.1146/annurev-biochem-062209-093836
   Briceno E, 2007, SURG NEUROL, V67, P388, DOI 10.1016/j.surneu.2006.08.080
   Bruning A, 2011, CURR CANCER DRUG TAR, V11, P799, DOI 10.2174/156800911796798913
   Bruning A, 2011, METHOD ENZYMOL, V491, P127, DOI 10.1016/B978-0-12-385928-0.00008-0
   Bruning A, 2009, CANCER BIOL THER, V8, P222
   Bruning A, 2008, BIOCHEM BIOPH RES CO, V377, P1309, DOI 10.1016/j.bbrc.2008.10.167
   Bruning A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2602
   Bruning Ansgar, 2010, Curr Mol Pharmacol, V3, P91
   Brunner TB, 2008, J CLIN ONCOL, V26, P2699, DOI 10.1200/JCO.2007.15.2355
   Carew JS, 2006, BLOOD, V107, P222, DOI 10.1182/blood-2005-05-1923
   Carrasco DR, 2007, CANCER CELL, V11, P349, DOI 10.1016/j.ccr.2007.02.015
   Casanova JE, 2007, TRAFFIC, V8, P1476, DOI 10.1111/j.1600-0854.2007.00634.x
   Chami M, 2008, MOL CELL, V32, P641, DOI 10.1016/j.molcel.2008.11.014
   Chardin P, 1999, CELL, V97, P153, DOI 10.1016/S0092-8674(00)80724-2
   Chen MF, 2011, P NATL ACAD SCI USA, V108, P9119, DOI 10.1073/pnas.1100028108
   Cho HY, 2009, CANCER LETT, V282, P87, DOI 10.1016/j.canlet.2009.03.007
   Choi JH, 2010, EXP MOL MED, V42, P811, DOI 10.3858/emm.2010.42.12.084
   Choo SJ, 2005, J ANTIBIOT, V58, P210, DOI 10.1038/ja.2005.26
   Christensen SB, 2009, ANTI-CANCER AGENT ME, V9, P276, DOI 10.2174/1871520610909030276
   Christofk HR, 2008, NATURE, V452, P230, DOI 10.1038/nature06734
   Contessa JN, 2008, CANCER RES, V68, P3803, DOI 10.1158/0008-5472.CAN-07-6389
   Contessa JN, 2010, CLIN CANCER RES, V16, P3205, DOI 10.1158/1078-0432.CCR-09-3331
   Cuneo KC, 2007, CANCER RES, V67, P4886, DOI 10.1158/0008-5472.CAN-06-3684
   Dara L, 2011, HEPATOLOGY, V53, P1752, DOI 10.1002/hep.24279
   Davenport EL, 2007, BLOOD, V110, P2641, DOI 10.1182/blood-2006-11-053728
   Denmeade SR, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003886
   Denmeade SR, 2003, J NATL CANCER I, V95, P990, DOI 10.1093/jnci/95.13.990
   Ding WX, 2007, J BIOL CHEM, V282, P4702, DOI 10.1074/jbc.M609267200
   Dogne JM, 2008, CURR PHARM DESIGN, V14, P679, DOI 10.2174/138161208783877938
   DUKSIN D, 1982, J BIOL CHEM, V257, P3105
   ELBEIN AD, 1981, TRENDS BIOCHEM SCI, V6, P219, DOI 10.1016/0968-0004(81)90080-3
   Ermakova SP, 2006, CANCER RES, V66, P9260, DOI 10.1158/0008-5472.CAN-06-1586
   Fels DR, 2008, CANCER RES, V68, P9323, DOI 10.1158/0008-5472.CAN-08-2873
   Fels DR, 2006, CANCER BIOL THER, V5, P723, DOI 10.4161/cbt.5.7.2967
   Fernandez PM, 2000, BREAST CANCER RES TR, V59, P15, DOI 10.1023/A:1006332011207
   Fribley A, 2004, MOL CELL BIOL, V24, P9695, DOI 10.1128/MCB.24.22.9695-9704.2004
   Fu Y, 2006, CANCER BIOL THER, V5, P741, DOI 10.4161/cbt.5.7.2970
   Gariboldi M, 2012, ONCOGENE
   Gazit G, 1999, BREAST CANCER RES TR, V54, P135, DOI 10.1023/A:1006102411439
   Gills JJ, 2008, AUTOPHAGY, V4, P107, DOI 10.4161/auto.5224
   Gills J, 2007, CLIN CANCER RES, V13, P5183, DOI 10.1158/1078-0432.CCR-07-0161
   Gorska M, 2012, FRONT BIOSCI-LANDMRK, V17, P2269, DOI 10.2741/4050
   Grosch S, 2006, JNCI-J NATL CANCER I, V98, P736, DOI 10.1093/jnci/djj206
   Gupta AK, 2005, CANCER RES, V65, P8256, DOI 10.1158/0008-5472.CAN-05-1220
   Gupta AK, 2007, NEOPLASIA, V9, P271, DOI 10.1593/neo.07124
   HAKII H, 1986, J CANCER RES CLIN, V111, P177, DOI 10.1007/BF00389230
   Hamed HA, 2010, CANCER BIOL THER, V9, P526, DOI 10.4161/cbt.9.7.11116
   Hasnain SZ, 2012, IMMUNOL CELL BIOL, V90, P260, DOI 10.1038/icb.2011.112
   Hayakawa Y, 2008, J ANTIBIOT, V61, P365, DOI 10.1038/ja.2008.51
   Healy SJM, 2009, EUR J PHARMACOL, V625, P234, DOI 10.1016/j.ejphar.2009.06.064
   Hetz C, 2012, NAT REV MOL CELL BIO, V13, P89, DOI 10.1038/nrm3270
   Hiss D, 1996, EUR J CANCER, V32A, P2164, DOI 10.1016/S0959-8049(96)00262-6
   Hong M, 2005, J BIOL CHEM, V280, P16821, DOI 10.1074/jbc.M413753200
   Hoozemans JJM, 2012, INT J BIOCHEM CELL B, V44, P1295, DOI 10.1016/j.biocel.2012.04.023
   Hsu JL, 2009, N-S ARCH PHARMACOL, V380, P373, DOI 10.1007/s00210-009-0453-5
   Hsu PP, 2008, CELL, V134, P703, DOI 10.1016/j.cell.2008.08.021
   Hwang JH, 2008, J CELL PHYSIOL, V215, P243, DOI 10.1002/jcp.21308
   Jager R, 2012, BIOL CELL, V104, P259, DOI 10.1111/boc.201100055
   Janku F, 2011, NAT REV CLIN ONCOL, V8, P528, DOI 10.1038/nrclinonc.2011.71
   Jhaveri K, 2012, BBA-MOL CELL RES, V1823, P742, DOI 10.1016/j.bbamcr.2011.10.008
   Jiang CC, 2007, CANCER RES, V67, P9750, DOI 10.1158/0008-5472.CAN-07-2047
   Jiang CC, 2007, CANCER RES, V67, P5880, DOI 10.1158/0008-5472.CAN-07-0213
   Jiang W, 2007, CANCER RES, V67, P1221, DOI 10.1158/0008-5472.CAN-06-3377
   Johnson AJ, 2002, BIOCHEM J, V366, P831, DOI 10.1042/BJ20020279
   Kanzawa T, 2004, CELL DEATH DIFFER, V11, P448, DOI 10.1038/sj.cdd.4401359
   Kardosh A, 2008, CANCER RES, V68, P843, DOI 10.1158/0008-5472.CAN-07-5555
   Kashfi K, 2005, BIOCHEM PHARMACOL, V70, P969, DOI 10.1016/j.bcp.2005.05.004
   Kim I, 2008, NAT REV DRUG DISCOV, V7, P1013, DOI 10.1038/nrd2755
   Kim JY, 2010, J CELL PHYSIOL, V224, P33, DOI 10.1002/jcp.22085
   Kojima E, 2003, FASEB J, V17, P1573, DOI 10.1096/fj.02-1184fje
   Koki Alane T, 2002, Cancer Control, V9, P28
   Kroemer G, 2008, CANCER CELL, V13, P472, DOI 10.1016/j.ccr.2008.05.005
   Lawson B, 1998, J CELL PHYSIOL, V174, P170, DOI 10.1002/(SICI)1097-4652(199802)174:2<170::AID-JCP4>3.3.CO;2-A
   Lee AS, 2007, CANCER RES, V67, P3496, DOI 10.1158/0008-5472.CAN-07-0325
   LEE AS, 1981, P NATL ACAD SCI-BIOL, V78, P4922, DOI 10.1073/pnas.78.8.4922
   Lee E, 2006, CANCER RES, V66, P7849, DOI 10.1158/0008-5472.CAN-06-1660
   Lee JS, 2012, TOXICOL LETT, V211, P29, DOI 10.1016/j.toxlet.2012.02.017
   Ling YH, 2009, CANCER CHEMOTH PHARM, V64, P539, DOI 10.1007/s00280-008-0902-8
   LIU ES, 1992, J BIOL CHEM, V267, P7128
   Liu Y, 2007, MOL PHARMACEUT, V4, P435, DOI 10.1021/mp060122j
   Livesey KM, 2009, CURR OPIN INVEST DR, V10, P1269
   Luo B, 2012, ONCOGENE
   Ma YJ, 2002, J MOL BIOL, V318, P1351, DOI 10.1016/S0022-2836(02)00234-6
   Malhi H, 2011, J HEPATOL, V54, P795, DOI 10.1016/j.jhep.2010.11.005
   Malhotra JD, 2007, SEMIN CELL DEV BIOL, V18, P716, DOI 10.1016/j.semcdb.2007.09.003
   Marciniak SJ, 2004, GENE DEV, V18, P3066, DOI 10.1101/gad.1250704
   Marcu MG, 2002, MOL CELL BIOL, V22, P8506, DOI 10.1128/MCB.22.24.8506-8513.2002
   Martin-Castillo B, 2010, CELL CYCLE, V9, P1057, DOI 10.4161/cc.9.6.10994
   Matsumoto A, 2000, CANCER RES, V60, P3921
   McCullough KD, 2001, MOL CELL BIOL, V21, P1249, DOI 10.1128/MCB.21.4.1249-1259.2001
   Meister S, 2007, CANCER RES, V67, P1783, DOI 10.1158/0008-5472.CAN-06-2258
   Mimura N, 2012, BLOOD, V119, P5772, DOI 10.1182/blood-2011-07-366633
   Misra UK, 2009, J CELL BIOCHEM, V106, P381, DOI 10.1002/jcb.22016
   Misra UK, 2006, J BIOL CHEM, V281, P13694, DOI 10.1074/jbc.M511694200
   Moon JL, 2012, BIOCHEM BIOPH RES CO, V417, P760, DOI 10.1016/j.bbrc.2011.12.030
   Mujtaba T, 2011, DISCOV MED, V12, P471
   Nawrocki ST, 2005, CANCER RES, V65, P11510, DOI 10.1158/0008-5472.CAN-05-2394
   Nawrocki ST, 2005, CANCER RES, V65, P11658, DOI 10.1158/0008-5472.CAN-05-2370
   Neckers L, 2012, CLIN CANCER RES, V18, P64, DOI 10.1158/1078-0432.CCR-11-1000
   Ni M, 2011, BIOCHEM J, V434, P181, DOI 10.1042/BJ20101569
   Ni M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006868
   Nishitoh H, 2012, J BIOCHEM, V151, P217, DOI 10.1093/jb/mvr143
   Noda I, 1999, INT J CANCER, V80, P279, DOI 10.1002/(SICI)1097-0215(19990118)80:2<279::AID-IJC18>3.0.CO;2-N
   Obeng EA, 2006, BLOOD, V107, P4907, DOI 10.1182/blood-2005-08-3531
   Ogata M, 2006, MOL CELL BIOL, V26, P9220, DOI 10.1128/MCB.01453-06
   OHUCHI K, 1989, BIOCHIM BIOPHYS ACTA, V1003, P9, DOI 10.1016/0005-2760(89)90091-X
   Oyadomari S, 2004, CELL DEATH DIFFER, V11, P381, DOI 10.1038/sj.cdd.4401373
   Pahl HL, 1999, PHYSIOL REV, V79, P683, DOI 10.1152/physrev.1999.79.3.683
   Park HR, 2007, TOXICOLOGY, V229, P253, DOI 10.1016/j.tox.2006.11.049
   Park HR, 2002, TETRAHEDRON LETT, V43, P6941, DOI 10.1016/S0040-4039(02)01624-6
   Parmar VM, 2012, ADV EXP MED BIOL, V738, P153, DOI 10.1007/978-1-4614-1680-7_10
   Paton AW, 2006, NATURE, V443, P548, DOI 10.1038/nature05124
   PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8
   Peyroche A, 1999, MOL CELL, V3, P275, DOI 10.1016/S1097-2765(00)80455-4
   Phillips LR, 1998, J PHARMACEUT BIOMED, V16, P1301, DOI 10.1016/S0731-7085(97)00142-8
   Piccinini M, 2005, ANTIVIR THER, V10, P215
   Porchia LM, 2007, MOL PHARMACOL, V72, P1124, DOI 10.1124/mol.107.037556
   Porter JR, 2009, CURR TOP MED CHEM, V9, P1386, DOI 10.2174/156802609789895719
   PRICE BD, 1992, J CELL PHYSIOL, V152, P545, DOI 10.1002/jcp.1041520314
   Pyrko P, 2007, CANCER RES, V67, P10920, DOI 10.1158/0008-5472.CAN-07-0796
   Pyrko P, 2007, CANCER RES, V67, P9809, DOI 10.1158/0008-5472.CAN-07-0625
   Pyrko P, 2007, MOL CANCER THER, V6, P1262, DOI 10.1158/1535-7163.MCT-06-0629
   Rengan R, 2012, J THORAC ONCOL, V7, P709, DOI 10.1097/JTO.0b013e3182435aa6
   Richardson PG, 2011, BRIT J HAEMATOL, V152, P367, DOI 10.1111/j.1365-2141.2010.08360.x
   Richardson PG, 2011, BRIT J HAEMATOL, V153, P729, DOI 10.1111/j.1365-2141.2011.08664.x
   Roccaro AM, 2006, CURR PHARM BIOTECHNO, V7, P441, DOI 10.2174/138920106779116865
   Ron D, 2008, CELL, V132, P24, DOI 10.1016/j.cell.2007.12.017
   Ron D, 2007, NAT REV MOL CELL BIO, V8, P519, DOI 10.1038/nrm2199
   Rutkowski DT, 2006, PLOS BIOL, V4, P2024, DOI 10.1371/journal.pbio.0040374
   Saito S, 2009, CANCER RES, V69, P4225, DOI 10.1158/0008-5472.CAN-08-2689
   Schonthal AH, 2007, BRIT J CANCER, V97, P1465, DOI 10.1038/sj.bjc.6604049
   Schonthal AH, 2008, EXPERT OPIN INV DRUG, V17, P197, DOI 10.1517/13543784.17.2.197
   Schonthal AH, 2011, CURR PHARM DESIGN, V17, P2428
   SCHONTHAL AH, 2006, NEUROSURG FOCUS, V20, P1
   Schonthal AH, 2009, CANCER LETT, V275, P163, DOI 10.1016/j.canlet.2008.07.005
   Shaffer AL, 2004, IMMUNITY, V21, P81, DOI 10.1016/j.immuni.2004.06.010
   Shani G, 2008, MOL CELL BIOL, V28, P666, DOI 10.1128/MCB.01716-07
   Shaw RJ, 2006, CURR OPIN CELL BIOL, V18, P598, DOI 10.1016/j.ceb.2006.10.005
   Shiraishi T, 2005, CANCER RES, V65, P6364, DOI 10.1158/0008-5472.CAN-05-0312
   Shore GC, 2011, CURR OPIN CELL BIOL, V23, P143, DOI 10.1016/j.ceb.2010.11.003
   Singh BN, 2011, BIOCHEM PHARMACOL, V82, P1807, DOI 10.1016/j.bcp.2011.07.093
   Solomon VR, 2009, EUR J PHARMACOL, V625, P220, DOI 10.1016/j.ejphar.2009.06.063
   Sommer T, 2002, DEV CELL, V3, P1, DOI 10.1016/S1534-5807(02)00210-1
   Sun FC, 2006, BIOCHEM J, V396, P31, DOI 10.1042/BJ20051916
   Sun LH, 2012, J CHEMOTHERAPY, V24, P161, DOI 10.1179/1973947812Y.0000000011
   Suzuki T, 2007, ARCH BIOCHEM BIOPHYS, V468, P1, DOI 10.1016/j.abb.2007.09.004
   Tabas I, 2011, NAT CELL BIOL, V13, P184, DOI 10.1038/ncb0311-184
   Taiyab A, 2009, BIOCHEM PHARMACOL, V78, P142, DOI 10.1016/j.bcp.2009.04.001
   Thomas S, 2012, CANCER LETT, V325, P63, DOI 10.1016/j.canlet.2012.05.030
   Tian XB, 2011, J BIOL CHEM, V286, P29408, DOI 10.1074/jbc.M110.197665
   Travers J, 2012, DRUG DISCOV TODAY, V17, P242, DOI 10.1016/j.drudis.2011.12.021
   Treiman M, 1998, TRENDS PHARMACOL SCI, V19, P131, DOI 10.1016/S0165-6147(98)01184-5
   Tseng PH, 2005, BLOOD, V105, P4021, DOI 10.1182/blood-2004-07-2967
   Tseng PH, 2006, MOL PHARMACOL, V70, P1534, DOI 10.1124/mol.106.023911
   Tsutsumi S, 2004, CELL DEATH DIFFER, V11, P1009, DOI 10.1038/sj.cdd.4401436
   Umeda Y, 2005, J ANTIBIOT, V58, P206, DOI 10.1038/ja.2005.25
   Vidal RL, 2012, AUTOPHAGY
   Virrey JJ, 2008, MOL CANCER RES, V6, P1268, DOI 10.1158/1541-7786.MCR-08-0060
   Virrey JJ, 2010, MOL CANCER THER, V9, P631, DOI 10.1158/1535-7163.MCT-09-0652
   Wang J, 2009, J CELL MOL MED, V13, P3888, DOI 10.1111/j.1582-4934.2009.00873.x
   Wang YC, 2008, CANCER RES, V68, P2820, DOI 10.1158/0008-5472.CAN-07-1336
   Welch W J, 1987, Adv Exp Med Biol, V225, P287
   Weng SC, 2008, MOL CANCER THER, V7, P800, DOI 10.1158/1535-7163.MCT-07-0434
   Whitesell L, 2012, BBA-MOL CELL RES, V1823, P756, DOI 10.1016/j.bbamcr.2011.12.006
   Winther AML, 2010, J BIOL CHEM, V285, P28883, DOI 10.1074/jbc.M110.136242
   Wlodkowic D, 2007, LEUKEMIA RES, V31, P1687, DOI 10.1016/j.leukres.2007.03.008
   Yacoub A, 2006, MOL PHARMACOL, V70, P589, DOI 10.1124/mol.106.025007
   Yeh YA, 1995, CANCER BIOCHEM BIOPH, V15, P11
   Yin JJ, 2012, AUTOPHAGY, V8, P158, DOI 10.4161/auto.8.2.18807
   Yorimitsu T, 2006, J BIOL CHEM, V281, P30299, DOI 10.1074/jbc.M607007200
   Yu DH, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003951
   Zeng J, 2011, CANCER BIOL THER, V12, P657, DOI 10.4161/cbt.12.7.17172
   Zhang HY, 2009, EXP MOL MED, V41, P362, DOI 10.3858/emm.2009.41.5.041
   Zhang LJ, 2009, MOL CELL BIOCHEM, V327, P171, DOI 10.1007/s11010-009-0055-z
   Zhang S, 2007, CLIN CANCER RES, V13, P4750, DOI 10.1158/1078-0432.CCR-07-0136
   Zhang XC, 2011, LEUKEMIA RES, V35, P940, DOI 10.1016/j.leukres.2011.03.016
   Zhang Y, 2010, J BIOL CHEM, V285, P15065, DOI 10.1074/jbc.M109.087445
   Zhou YH, 1998, J NATL CANCER I, V90, P381, DOI 10.1093/jnci/90.5.381
   Zhu JX, 2004, CANCER RES, V64, P4309, DOI 10.1158/0008-5472.CAN-03-4063
NR 194
TC 137
Z9 144
U1 1
U2 48
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0006-2952
EI 1873-2968
J9 BIOCHEM PHARMACOL
JI Biochem. Pharmacol.
PD MAR 1
PY 2013
VL 85
IS 5
SI SI
BP 653
EP 666
DI 10.1016/j.bcp.2012.09.012
PG 14
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 090UB
UT WOS:000315004400008
PM 23000916
DA 2022-04-25
ER

PT J
AU Tan, KP
   Ho, MY
   Cho, HC
   Yu, J
   Hung, JT
   Yu, ALT
AF Tan, Keng-Poo
   Ho, Ming-Yi
   Cho, Huan-Chieh
   Yu, John
   Hung, Jung-Tung
   Yu, Alice Lin-Tsing
TI Fucosylation of LAMP-1 and LAMP-2 by FUT1 correlates with lysosomal
   positioning and autophagic flux of breast cancer cells
SO CELL DEATH & DISEASE
LA English
DT Article
ID COLON-CARCINOMA CELLS; ENDOPLASMIC-RETICULUM STRESS; BLOOD GROUP
   ANTIGENS; MEMBRANE-GLYCOPROTEINS; ADENOCARCINOMA CELLS; SURFACE
   EXPRESSION; PROTEINS; ADHESION; DIFFERENTIATION; PROLIFERATION
AB Alpha1,2-fucosyltransferases, FUT1 and FUT2, which transfer fucoses onto the terminal galactose of N-acetyl-lactosamine via alpha 1,2-linkage have been shown to be highly expressed in various types of cancers. A few studies have shown the involvement of FUT1 substrates in tumor cell proliferation and migration. Lysosome-associated membrane protein 1, LAMP-1, has been reported to carry alpha1,2-fucosylated Lewis Y (LeY) antigens in breast cancer cells, however, the biological functions of LeY on LAMP-1 remain largely unknown. Whether or not its family member, LAMP-2, displays similar modifications and functions as LAMP-1 has not yet been addressed. In this study, we have presented evidence supporting that both LAMP-1 and 2 are substrates for FUT1, but not FUT2. We have also demonstrated the presence of H2 and LeY antigens on LAMP-1 by a targeted nanoLC-MS3 and the decreased levels of fucosylation on LAMP-2 by MALDI-TOF analysis upon FUT1 knockdown. In addition, we found that the expression of LeY was substantial in less invasive ER+/PR+/HER - breast cancer cells (MCF-7 and T47D) but negligible in highly invasive triple-negative MDA-MB-231 cells, of which LeY levels were correlated with the levels of LeY carried by LAMP-1 and 2. Intriguingly, we also observed a striking change in the subcellular localization of lysosomes upon FUT1 knockdown from peripheral distribution of LAMP-1 and 2 to a preferential perinuclear accumulation. Besides that, knockdown of FUT1 led to an increased rate of autophagic flux along with diminished activity of mammalian target of rapamycin complex 1 (mTORC1) and enhanced autophagosome-lysosome fusion. This may be associated with the predominantly perinuclear distribution of lysosomes mediated by FUT1 knockdown as lysosomal positioning has been reported to regulate mTOR activity and autophagy. Taken together, our results suggest that downregulation of FUT1, which leads to the perinuclear localization of LAMP-1 and 2, is correlated with increased rate of autophagic flux by decreasing mTOR signaling and increasing autolysosome formation.
C1 [Tan, Keng-Poo] Natl Yang Ming Univ, Inst Microbiol & Immunol, Taipei, Taiwan.
   [Tan, Keng-Poo; Ho, Ming-Yi; Cho, Huan-Chieh; Yu, John; Hung, Jung-Tung; Yu, Alice Lin-Tsing] Chang Gung Mem Hosp Linkou, Inst Stem Cell & Translat Canc Res, 5 Fuxing St, Taoyuan 333, Taiwan.
   [Yu, John; Yu, Alice Lin-Tsing] Chang Gung Univ, Taoyuan, Taiwan.
   [Yu, Alice Lin-Tsing] Univ Calif San Diego, Dept Pediat, San Diego, CA 92103 USA.
RP Yu, ALT (corresponding author), Chang Gung Mem Hosp Linkou, Inst Stem Cell & Translat Canc Res, 5 Fuxing St, Taoyuan 333, Taiwan.
EM a1yu@ucsd.edu
RI yu, john/AAA-9255-2021
OI yu, alice/0000-0003-2444-0505; Yu, John/0000-0002-3237-4272
FU Chang Gung Medical Foundation [OMRPG3C0012]; Ministry of Science and
   TechnologyMinistry of Education, Culture, Sports, Science and
   Technology, Japan (MEXT) [MOST 103-2321-B-182A-005, MOST
   104-2321-B-182A-003]; Academia SinicaAcademia Sinica - Taiwan
FX We were indebted to Dr Chuang-Yu Lin for his technical support of the
   TCS SP8 confocal microscope. We also thank Dr Chi-Huey Wong from
   Academia Sinica for providing fucose alkyne and biotinylated azido
   probe. This work was supported by grants from the Chang Gung Medical
   Foundation (OMRPG3C0012), Academia Sinica and Ministry of Science and
   Technology (MOST 103-2321-B-182A-005 and MOST 104-2321-B-182A-003).
CR AKASAKI K, 1995, EXP CELL RES, V220, P464, DOI 10.1006/excr.1995.1338
   AMOS B, 1990, J BIOL CHEM, V265, P19192
   Aubert M, 2000, CANCER RES, V60, P1449
   BARRIOCANAL JG, 1986, J BIOL CHEM, V261, P6755
   Bellot G, 2009, MOL CELL BIOL, V29, P2570, DOI 10.1128/MCB.00166-09
   Belo AI, 2015, FEBS LETT, V589, P2359, DOI 10.1016/j.febslet.2015.07.035
   Bohensky J, 2007, AUTOPHAGY, V3, P207, DOI 10.4161/auto.3708
   CARLSSON SR, 1988, J BIOL CHEM, V263, P18911
   CARLSSON Sr, 1990, J BIOL CHEM, V265, P20488
   Cordel S, 2000, INT J CANCER, V85, P142, DOI 10.1002/(SICI)1097-0215(20000101)85:1<142::AID-IJC24>3.0.CO;2-K
   DOMON B, 1988, GLYCOCONJUGATE J, V5, P397, DOI 10.1007/BF01049915
   Elfrink HL, 2013, MOL CELLS, V35, P291, DOI 10.1007/s10059-013-2286-9
   Eskelinen Eeva-Liisa, 2006, Molecular Aspects of Medicine, V27, P495, DOI 10.1016/j.mam.2006.08.005
   Eskelinen EL, 2003, TRENDS CELL BIOL, V13, P137, DOI 10.1016/S0962-8924(03)00005-9
   Eskelinen EL, 2002, MOL BIOL CELL, V13, P3355, DOI 10.1091/mbc.E02-02-0114
   FUKUDA M, 1991, J BIOL CHEM, V266, P21327
   GARRIGUES J, 1994, J CELL BIOL, V125, P129, DOI 10.1083/jcb.125.1.129
   Goupille C, 2000, GLYCOBIOLOGY, V10, P375, DOI 10.1093/glycob/10.4.375
   Huynh KK, 2007, EMBO J, V26, P313, DOI 10.1038/sj.emboj.7601511
   Isozaki T, 2014, ARTHRITIS RES THER, V16, DOI 10.1186/ar4456
   Kadowaki Motoni, 2006, Molecular Aspects of Medicine, V27, P426, DOI 10.1016/j.mam.2006.08.010
   Kawai S, 2013, ONCOL REP, V29, P13, DOI 10.3892/or.2012.2120
   Korolchuk VI, 2011, AUTOPHAGY, V7, P927, DOI 10.4161/auto.7.8.15862
   Korolchuk VI, 2011, NAT CELL BIOL, V13, P453, DOI 10.1038/ncb2204
   Krishnan V, 2005, CLIN EXP METASTAS, V22, P11, DOI 10.1007/s10585-005-2036-2
   Kroemer G, 2005, NAT REV CANCER, V5, P886, DOI 10.1038/nrc1738
   Kundra R, 1999, J BIOL CHEM, V274, P31039, DOI 10.1074/jbc.274.43.31039
   LABARRIERE N, 1994, CANCER RES, V54, P6275
   Le Pendu J, 2001, APMIS, V109, P9
   LEE N, 1990, J BIOL CHEM, V265, P20476
   Liu JJ, 2010, ONCOL REP, V23, P833, DOI 10.3892/or_00000705
   Marionneau S, 2001, BIOCHIMIE, V83, P565, DOI 10.1016/S0300-9084(01)01321-9
   Mejias-Luque R, 2007, CANCER SCI, V98, P1000, DOI 10.1111/j.1349-7006.2007.00484.x
   Moehler TM, 2008, J CELL PHYSIOL, V215, P27, DOI 10.1002/jcp.21285
   Mohamed MM, 2006, NAT REV CANCER, V6, P764, DOI 10.1038/nrc1949
   ORIOL R, 1992, APMIS, V100, P28
   Palumberi D, 2010, J CELL BIOCHEM, V111, P229, DOI 10.1002/jcb.22692
   Pous C, 2011, NAT CELL BIOL, V13, P342, DOI 10.1038/ncb0411-342
   Qin L, 2010, AUTOPHAGY, V6, P239, DOI 10.4161/auto.6.2.11062
   Saftig P, 2009, NAT REV MOL CELL BIO, V10, P623, DOI 10.1038/nrm2745
   SAITOH O, 1992, J BIOL CHEM, V267, P5700
   Sancak Y, 2008, SCIENCE, V320, P1496, DOI 10.1126/science.1157535
   Sancak Y, 2010, CELL, V141, P290, DOI 10.1016/j.cell.2010.02.024
   Sasaki M, 2015, HUM PATHOL, V46, P202, DOI 10.1016/j.humpath.2014.09.016
   SAWADA R, 1993, J BIOL CHEM, V268, P12675
   Schwake M, 2013, TRAFFIC, V14, P739, DOI 10.1111/tra.12056
   Singletary K, 2008, CANCER EPIDEM BIOMAR, V17, P1596, DOI 10.1158/1055-9965.EPI-07-2917
   SUN J, 1995, P NATL ACAD SCI USA, V92, P5724, DOI 10.1073/pnas.92.12.5724
   Tanaka Y, 2000, NATURE, V406, P902, DOI 10.1038/35022595
   Wang RC, 2010, FEBS LETT, V584, P1417, DOI 10.1016/j.febslet.2010.01.009
   Xu Dong-Wei, 2015, Asian Pac J Cancer Prev, V16, P2167
   Yorimitsu T, 2006, J BIOL CHEM, V281, P30299, DOI 10.1074/jbc.M607007200
   YOUAKIM A, 1989, CANCER RES, V49, P6889
   Zhang ZB, 2008, BBA-MOL CELL RES, V1783, P287, DOI 10.1016/j.bbamcr.2007.10.007
NR 54
TC 32
Z9 32
U1 0
U2 12
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-4889
J9 CELL DEATH DIS
JI Cell Death Dis.
PD AUG
PY 2016
VL 7
AR e2347
DI 10.1038/cddis.2016.243
PG 11
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA DU2YP
UT WOS:000382077800001
PM 27560716
OA Green Published, gold, Green Submitted
DA 2022-04-25
ER

PT J
AU Li, G
   Zhang, C
   Liang, W
   Zhang, YB
   Shen, YH
   Tian, XH
AF Li, Ge
   Zhang, Chuang
   Liang, Wei
   Zhang, Yanbing
   Shen, Yunheng
   Tian, Xinhui
TI Berberine regulates the Notch1/PTEN/PI3K/AKT/mTOR pathway and acts
   synergistically with 17-AAG and SAHA in SW480 colon cancer cells
SO PHARMACEUTICAL BIOLOGY
LA English
DT Article
DE Connectivity map; synergistic effect; mechanism
ID DIABETES-MELLITUS; CYCLE ARREST; INHIBITION; APOPTOSIS; TARGET; GROWTH;
   MECHANISMS; COMPONENTS; AUTOPHAGY
AB Context: Berberine (BBR) is used to treat diarrhoea and gastroenteritis in the clinic. It was found to have anticolon cancer effects.
   Objective: To study the anticolon cancer mechanism of BBR by connectivity map (CMAP) analysis.
   Materials and methods: CMAP based mechanistic prediction was conducted by comparing gene expression profiles of 10 mu M BBR treated MCF-7 cells with that of clinical drugs such as helveticoside, ianatoside C, pyrvinium, gossypol and trifluoperazine. The treatment time was 12 h and two biological replications were performed. The DMSO-treated cells were selected as a control. The interaction between 100 mu M BBR and target protein was measured by cellular thermal shift assay. The protein expression of 1-9 mu M BBR treated SW480 cells were measured by WB assay. Apoptosis, cell cycle arrest, mitochondrial membrane potential (MMP) of 1-9 mu M BBR treated SW480 cells were measured by flow cytometry and Hoechst 33342 staining methods.
   Results: CMAP analysis found 14 Hsp90, HDAC, PI3K or mTOR protein inhibitors have similar functions with BBR. The experiments showed that BBR inhibited SW480 cells proliferation with IC50 of 3.436 mu M, induced apoptosis, autophage, MMP depolarization and arrested G1 phase of cell cycle at 1.0 mu M. BBR dose-dependently up-regulated PTEN, while inhibited Notch1, PI3K, Akt and mTOR proteins at 1.0-9.0 mu M (p < 0.05). BBR also acted synergistically with Hsp90 and HDAC inhibitor (0.01 mu M) in SW480 cells at 0.5 and 1.0 mu M.
   Discussion and conclusions: The integrative gene expression-based chemical genomic method using CMAP analysis may be applicable for mechanistic studies of other multi-targets drugs.
C1 [Li, Ge; Liang, Wei; Tian, Xinhui] Shanghai Univ Tradit Chinese Med, Inst Interdisciplinary Integrat Med Res, Shanghai, Peoples R China.
   [Zhang, Chuang; Zhang, Yanbing] Zhengzhou Univ, Sch Pharm, Zhengzhou, Peoples R China.
   [Shen, Yunheng] Naval Med Univ, Sch Pharm, Shanghai, Peoples R China.
RP Tian, XH (corresponding author), Shanghai Univ Tradit Chinese Med, Inst Interdisciplinary Integrat Med Res, Shanghai, Peoples R China.
EM tianxinhui@126.com
FU Shanghai University of Traditional Chinese Medicine; The 13th College
   Students' Innovative Activity Project of SHUTCM; National Science and
   Technology Major Project of China [2018ZX09731016-005]
FX The work was supported by Grants from Shanghai University of Traditional
   Chinese Medicine, The 13th College Students' Innovative Activity Project
   of SHUTCM, and National Science and Technology Major Project of China
   [2018ZX09731016-005].
CR Alzamora R, 2011, FRONT PHYSIOL, V2, DOI 10.3389/fphys.2011.00033
   Farooqi AA, 2019, CANCERS, V11, DOI 10.3390/cancers11040478
   Feng Yibin, 2009, Chin Med, V4, P16, DOI 10.1186/1749-8546-4-16
   Fukuda K, 1999, J ETHNOPHARMACOL, V66, P227, DOI 10.1016/S0378-8741(98)00162-7
   Gao XJ, 2019, J CELL MOL MED, V23, P6797, DOI 10.1111/jcmm.14560
   Hieronymus H, 2006, CANCER CELL, V10, P321, DOI 10.1016/j.ccr.2006.09.005
   Hsu WH, 2007, ARCH TOXICOL, V81, P719, DOI 10.1007/s00204-006-0169-y
   Huang C, 2020, J CELL COMMUN SIGNAL, V14, P53, DOI 10.1007/s12079-019-00525-7
   Huang C, 2019, J CELL PHYSIOL, V234, P11679, DOI 10.1002/jcp.27835
   Huang C, 2017, ONCOL REP, V37, P1637, DOI 10.3892/or.2017.5379
   Kazaz IO, 2020, AM J EMERG MED, V38, P33, DOI 10.1016/j.ajem.2019.04.001
   Kim YC, 2015, J CLIN INVEST, V125, P25, DOI 10.1172/JCI73939
   Lamb J, 2006, SCIENCE, V313, P1929, DOI 10.1126/science.1132939
   Lan JR, 2015, J ETHNOPHARMACOL, V161, P69, DOI 10.1016/j.jep.2014.09.049
   Lee YR, 2018, NAT REV MOL CELL BIO, V19, P547, DOI 10.1038/s41580-018-0015-0
   Li WD, 2015, MOL CARCINOGEN, V54, P1096, DOI 10.1002/mc.22179
   Lin JG, 1999, AM J CHINESE MED, V27, P265, DOI 10.1142/S0192415X99000306
   Lu L, 2019, INT J MOL MED, V43, P1679, DOI 10.3892/ijmm.2019.4105
   Lu YF, 2018, ONCOL LETT, V15, P5971, DOI 10.3892/ol.2018.7997
   Luongo F, 2019, CANCERS, V11, DOI 10.3390/cancers11081076
   Lv C, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0247-5
   Lv C, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-00535-8
   Ma XL, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00782
   Mao LY, 2018, ONCOL REP, V39, P2436, DOI 10.3892/or.2018.6318
   Mariadason JM, 2008, EPIGENETICS-US, V3, P28, DOI 10.4161/epi.3.1.5736
   Mohammadinejad R, 2019, J CELL PHYSIOL, V234, P14914, DOI 10.1002/jcp.28325
   Molina DM, 2013, SCIENCE, V341, P84, DOI 10.1126/science.1233606
   Mondal A, 2016, BIOMED PHARMACOTHER, V84, P1906, DOI 10.1016/j.biopha.2016.10.096
   Murthy KNC, 2012, EUR J PHARMACOL, V688, P14, DOI 10.1016/j.ejphar.2012.05.004
   Neckers L, 2007, J BIOSCIENCES, V32, P517, DOI 10.1007/s12038-007-0051-y
   Newman DJ, 2016, J NAT PROD, V79, P629, DOI 10.1021/acs.jnatprod.5b01055
   Park JJ, 2012, BIOCHEM BIOPH RES CO, V426, P461, DOI 10.1016/j.bbrc.2012.08.091
   Pirmoradi Z, 2019, IRAN J BASIC MED SCI, V22, P154, DOI 10.22038/ijbms.2018.31225.7534
   Qiao L, 2009, CARCINOGENESIS, V30, P1979, DOI 10.1093/carcin/bgp236
   Ruan H, 2017, ONCOGENE, V36, P6906, DOI 10.1038/onc.2017.296
   Sahebkar A, 2017, CURR OPIN LIPIDOL, V28, P282, DOI 10.1097/MOL.0000000000000409
   Schopf FH, 2017, NAT REV MOL CELL BIO, V18, P345, DOI 10.1038/nrm.2017.20
   Siegel RL, 2019, CA-CANCER J CLIN, V69, P7, DOI 10.3322/caac.21551
   Tanida Isei, 2008, V445, P77, DOI 10.1007/978-1-59745-157-4_4
   Tian XH, 2016, ORG BIOMOL CHEM, V14, P2618, DOI 10.1039/c5ob02661j
   Wang BJ, 2018, TOXINS, V10, DOI 10.3390/toxins10100398
   Wang LH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056666
   Wang LH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036418
   Wu K, 2012, INT J ONCOL, V41, P292, DOI 10.3892/ijo.2012.1423
   Wu YY, 2018, BIOMED PHARMACOTHER, V107, P1447, DOI 10.1016/j.biopha.2018.08.130
   Xu LN, 2012, BIOCELL, V36, P113
   Xu WS, 2007, ONCOGENE, V26, P5541, DOI 10.1038/sj.onc.1210620
   Yao MJ, 2019, BMC COMPLEM ALTERN M, V19, DOI 10.1186/s12906-019-2615-4
   Yu ML, 2014, MOL MED REP, V9, P249, DOI 10.3892/mmr.2013.1762
   Zhang Y, 2010, CANCER-AM CANCER SOC, V116, P5207, DOI 10.1002/cncr.25449
   Zhao J, 2019, PHARMACOL RES, V147, DOI 10.1016/j.phrs.2019.104365
NR 51
TC 5
Z9 5
U1 9
U2 17
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1388-0209
EI 1744-5116
J9 PHARM BIOL
JI Pharm. Biol.
PD JAN 1
PY 2021
VL 59
IS 1
BP 21
EP 30
DI 10.1080/13880209.2020.1865407
PG 10
WC Plant Sciences; Medical Laboratory Technology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Plant Sciences; Medical Laboratory Technology; Pharmacology & Pharmacy
GA PQ5SU
UT WOS:000606606200001
PM 33417512
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Xu, JW
   Patel, NH
   Saleh, T
   Cudjoe, EK
   Alotaibi, M
   Wu, YL
   Lima, S
   Hawkridge, AM
   Gewirtz, DA
AF Xu, Jingwen
   Patel, Nipa H.
   Saleh, Tareq
   Cudjoe, Emmanuel K., Jr.
   Alotaibi, Moureq
   Wu, Yingliang
   Lima, Santiago
   Hawkridge, Adam M.
   Gewirtz, David A.
TI Differential Radiation Sensitivity in p53 Wild-Type and p53-Deficient
   Tumor Cells Associated with Senescence but not Apoptosis or
   (Nonprotective) Autophagy
SO RADIATION RESEARCH
LA English
DT Article
ID COLORECTAL-CANCER CELLS; ACCELERATED SENESCENCE; CARCINOMA-CELLS; GROWTH
   ARREST; INHIBITION; THERAPY; RADIOTHERAPY; CONTRIBUTES; BIOMARKERS;
   DEATH
AB Studies of radiation interaction with tumor cells often focus on apoptosis as an end point; however, clinically relevant doses of radiation also promote autophagy and senescence. Moreover, functional p53 has frequently been implicated in contributing to radiation sensitivity through the facilitation of apoptosis. To address the involvement of apoptosis, autophagy, senescence and p53 status in the response to radiation, the current studies utilized isogenic H460 non-small cell lung cancer cells that were either p53-wild type (H460wt) or null (H460crp53). As anticipated, radiosensitivity was higher in the H460wt cells than in the H460crp53 cell line; however, this differential radiation sensitivity did not appear to be a consequence of apoptosis. Furthermore, radiosensitivity did not appear to be reduced in association with the promotion of autophagy, as autophagy was markedly higher in the H460wt cells. Despite radiosensitization by chloroquine in the H460wt cells, the radiation-induced autophagy proved to be essentially nonprotective, as inhibition of autophagy via 3-methyl adenine (3-MA), bafilomycin A1 or ATG5 silencing failed to alter radiation sensitivity or promote apoptosis in either the H460wt or H460crp53 cells. Radiosensitivity appeared to be most closely associated with senescence, which occurred earlier and to a greater extent in the H460wt cells. This finding is consistent with the in-depth proteomics analysis on the secretomes from the H460wt and H460crp53 cells (with or without radiation exposure) that showed no significant association with radioresistance-related proteins, whereas several senescence-associated secretory phenotype (SASP) factors were upregulated in H460wt cells relative to H460crp53 cells. Taken together, these findings indicate that senescence, rather than apoptosis, plays a central role in determination of radiosensitivity; furthermore, autophagy is likely to have minimal influence on radiosensitivity under conditions where autophagy takes the nonprotective form. (C) 2018 by Radiation Research Society
C1 [Xu, Jingwen; Wu, Yingliang] Shenyang Pharmaceut Univ, Dept Pharmacol & Toxicol, Shenyang, Liaoning, Peoples R China.
   [Patel, Nipa H.; Saleh, Tareq; Gewirtz, David A.] Virginia Commonwealth Univ, Dept Pharmacol & Toxicol, Med Coll Virginia Campus, Richmond, VA 23298 USA.
   [Patel, Nipa H.; Saleh, Tareq; Gewirtz, David A.] Virginia Commonwealth Univ, Dept Med, Med Coll Virginia Campus, Richmond, VA 23298 USA.
   [Cudjoe, Emmanuel K., Jr.; Hawkridge, Adam M.] Virginia Commonwealth Univ, Dept Pharmacotherapy & Outcome Sci, Med Coll Virginia Campus, Richmond, VA 23298 USA.
   [Cudjoe, Emmanuel K., Jr.; Hawkridge, Adam M.] Virginia Commonwealth Univ, Dept Pharmaceut, Med Coll Virginia Campus, Richmond, VA 23298 USA.
   [Lima, Santiago] Virginia Commonwealth Univ, Dept Biol, Med Coll Virginia Campus, Richmond, VA 23298 USA.
   [Patel, Nipa H.; Saleh, Tareq; Lima, Santiago; Hawkridge, Adam M.; Gewirtz, David A.] Virginia Commonwealth Univ, Massey Canc Ctr, 401 Coll St, Richmond, VA 23298 USA.
   [Alotaibi, Moureq] King Saud Univ, Coll Pharm, Dept Pharmacol & Toxicol, Riyadh, Saudi Arabia.
RP Gewirtz, DA (corresponding author), Virginia Commonwealth Univ, Massey Canc Ctr, 401 Coll St, Richmond, VA 23298 USA.
EM david.gewirtz@vcuhealth.org
RI Saleh, Tareq/AGY-9225-2022; Patel, Nipa/AAK-3632-2021
OI Cudjoe, Emmanuel/0000-0003-1258-4034; Saleh, Tareq/0000-0002-2878-1107
FU Office of the Assistant Secretary of Defense for Health Affairs through
   the Breast Cancer Research Program [W81XWH-14-1-0088]; Massey Center
   Support Grant [P30 CA016059]; National Institutes of HealthUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USA [K22 CA187314]; China Scholarship CouncilChina Scholarship
   Council; NIH-NCI Cancer Center Flow Cytometry Shared Resource; NIH-NCI
   Cancer CenterUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P30
   CA016059]; NATIONAL CANCER INSTITUTEUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Cancer Institute (NCI) [K22CA187314, P30CA016059] Funding Source: NIH
   RePORTER
FX Work in Dr. Gewirtz's laboratory was supported by the Office of the
   Assistant Secretary of Defense for Health Affairs through the Breast
   Cancer Research Program (grant no. W81XWH-14-1-0088 to DAG) and a Massey
   Center Support Grant (no. P30 CA016059). Santiago Lima was supported by
   the National Institutes of Health (grant no. K22 CA187314). We
   gratefully acknowledge financial support (JX) from the China Scholarship
   Council. Services and products in support of the research project were
   generated by the VCU Massey Cancer Center Flow Cytometry Shared
   Resource, supported in part, with funding from NIH-NCI Cancer Center
   Support Grant no. P30 CA016059.
CR Abedin MJ, 2007, CELL DEATH DIFFER, V14, P500, DOI 10.1038/sj.cdd.4402039
   Allal AS, 2004, PROTEOMICS, V4, P2261, DOI 10.1002/pmic.200300854
   Alotaibi M, 2016, RADIAT RES, V185, P229, DOI 10.1667/RR14202.1
   Amaravadi RK, 2007, CLIN CANCER RES, V13, P7271, DOI 10.1158/1078-0432.CCR-07-1595
   Apel A, 2008, CANCER RES, V68, P1485, DOI 10.1158/0008-5472.CAN-07-0562
   Becker L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033297
   Bristol ML, 2013, J PHARMACOL EXP THER, V344, P544, DOI 10.1124/jpet.112.199802
   Cerniglia GJ, 2012, MOL PHARMACOL, V82, P1230, DOI 10.1124/mol.112.080408
   Chaachouay H, 2011, RADIOTHER ONCOL, V99, P287, DOI 10.1016/j.radonc.2011.06.002
   Chaanine AH, 2015, PHYSIOL REP, V3, DOI 10.14814/phy2.12413
   Chakradeo S, 2015, MOL PHARMACOL, V87, P803, DOI 10.1124/mol.114.095273
   Chen PJ, 2017, FREE RADICAL BIO MED, V104, P280, DOI 10.1016/j.freeradbiomed.2017.01.033
   Chen Y, 2008, CELL DEATH DIFFER, V15, P171, DOI 10.1038/sj.cdd.4402233
   Chen YS, 2015, MOL MED REP, V12, P1645, DOI 10.3892/mmr.2015.3623
   Chenau J, 2009, J PROTEOME RES, V8, P4579, DOI 10.1021/pr900383g
   Cheng GH, 2013, CANCER BIOTHER RADIO, V28, P153, DOI 10.1089/cbr.2012.1297
   Codogno P, 2005, CELL DEATH DIFFER, V12, P1509, DOI 10.1038/sj.cdd.4401751
   Coppe JP, 2010, ANNU REV PATHOL-MECH, V5, P99, DOI 10.1146/annurev-pathol-121808-102144
   Cuddihy AR, 2004, CANCER METAST REV, V23, P237, DOI 10.1023/B:CANC.0000031764.81141.e4
   Debacq-Chainiaux F, 2009, NAT PROTOC, V4, P1798, DOI 10.1038/nprot.2009.191
   DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363
   Dupont N, 2011, EMBO J, V30, P4701, DOI 10.1038/emboj.2011.398
   Efimova EV, 2010, CANCER RES, V70, P6277, DOI 10.1158/0008-5472.CAN-09-4224
   Eng CH, 2016, P NATL ACAD SCI USA, V113, P182, DOI 10.1073/pnas.1515617113
   Fang L, 1999, ONCOGENE, V18, P2789, DOI 10.1038/sj.onc.1202615
   Fei PW, 2003, ONCOGENE, V22, P5774, DOI 10.1038/sj.onc.1206677
   Feng XP, 2010, CANCER RES, V70, P3450, DOI 10.1158/0008-5472.CAN-09-4099
   Flor AC, 2017, CELL DEATH DISCOV, V3, DOI 10.1038/cddiscovery.2017.75
   Frame FM, 2016, CANCER MED-US, V5, P61, DOI 10.1002/cam4.553
   Garbar C, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-07489-x
   Gewirtz DA, 2018, BIOCHEM PHARMACOL, V153, P46, DOI 10.1016/j.bcp.2018.01.048
   Gewirtz DA, 2016, CANCER RES, V76, P5610, DOI 10.1158/0008-5472.CAN-16-0722
   Gewirtz DA, 2014, RADIAT RES, V182, P363, DOI 10.1667/RR13774.1
   Gewirtz DA, 2014, BIOCHEM PHARMACOL, V90, P208, DOI 10.1016/j.bcp.2014.05.016
   Gewirtz DA, 2014, AUTOPHAGY, V10, P391, DOI 10.4161/auto.27719
   Gewirtz DA, 2014, CANCER RES, V74, P647, DOI 10.1158/0008-5472.CAN-13-2966
   Gewirtz DA, 2014, J CELL PHYSIOL, V229, P6, DOI 10.1002/jcp.24420
   Gewirtz DA, 2013, AUTOPHAGY, V9, P808, DOI 10.4161/auto.23922
   Goehe RW, 2012, J PHARMACOL EXP THER, V343, P763, DOI 10.1124/jpet.112.197590
   Gomes AR, 2015, CLIN MOL HEPATOL, V21, P257, DOI 10.3350/cmh.2015.21.3.257
   Gudkov AV, 2003, NAT REV CANCER, V3, P117, DOI 10.1038/nrc992
   Hu RK, 2016, J PROTEOME RES, V15, P477, DOI 10.1021/acs.jproteome.5b00819
   Hu YL, 2012, CANCER RES, V72, P1773, DOI 10.1158/0008-5472.CAN-11-3831
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923
   Huang YH, 2014, AUTOPHAGY, V10, P1212, DOI 10.4161/auto.28772
   Ito H, 2005, INT J ONCOL, V26, P1401
   Jones KR, 2005, INT J RADIAT BIOL, V81, P445, DOI 10.1080/09553000500168549
   Kim EL, 2010, NEURO-ONCOLOGY, V12, P389, DOI 10.1093/neuonc/nop046
   Kim ES, 2016, ADV EXP MED BIOL, V893, P189, DOI 10.1007/978-3-319-24223-1_10
   Klionsky DJ, 2016, AUTOPHAGY, V12, P1, DOI 10.1080/15548627.2015.1100356
   Ko A, 2014, CELL DEATH DIFFER, V21, P92, DOI 10.1038/cdd.2013.124
   Kraya AA, 2015, AUTOPHAGY, V11, P60, DOI 10.4161/15548627.2014.984273
   Lacombe J, 2013, EXPERT REV PROTEOMIC, V10, P33, DOI [10.1586/epr.12.68, 10.1586/EPR.12.68]
   Levy JMM, 2011, PHARMACOL THERAPEUT, V131, P130, DOI 10.1016/j.pharmthera.2011.03.009
   Lima SNP, 2020, ARCH PHYSIOL BIOCHEM, V126, P341, DOI 10.1080/13813455.2018.1538247
   Lin JJ, 2016, TRENDS CANCER, V2, P350, DOI 10.1016/j.trecan.2016.05.010
   Lomonaco SL, 2009, INT J CANCER, V125, P717, DOI 10.1002/ijc.24402
   Luo HM, 2013, LUNG CANCER, V81, P167, DOI 10.1016/j.lungcan.2013.04.017
   Maier P, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17010102
   Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239
   Mauvezin C, 2015, AUTOPHAGY, V11, P1437, DOI 10.1080/15548627.2015.1066957
   Maycotte P, 2012, AUTOPHAGY, V8, P200, DOI 10.4161/auto.8.2.18554
   Maycotte P, 2011, CANCER BIOL THER, V11, P127, DOI 10.4161/cbt.11.2.14627
   Mazure NM, 2010, CURR OPIN CELL BIOL, V22, P177, DOI 10.1016/j.ceb.2009.11.015
   Michaud M, 2011, SCIENCE, V334, P1573, DOI 10.1126/science.1208347
   Okada H, 2004, NAT REV CANCER, V4, P592, DOI 10.1038/nrc1412
   Paglin S, 2001, CANCER RES, V61, P439
   Palmeira-dos-Santos C, 2014, J CANCER RES CLIN, V140, P909, DOI 10.1007/s00432-014-1640-4
   Pan CP, 2009, MOL CELL PROTEOMICS, V8, P443, DOI 10.1074/mcp.M800258-MCP200
   Perez-Soler R, 2009, ONCOGENE, V28, pS38, DOI 10.1038/onc.2009.200
   Qu XZ, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173712
   Quick QA, 2006, J NEUROSURG, V105, P111, DOI 10.3171/jns.2006.105.1.111
   Rangwala R, 2014, AUTOPHAGY, V10, P1369, DOI 10.4161/auto.29118
   Rosenfeld MR, 2014, AUTOPHAGY, V10, P1359, DOI 10.4161/auto.28984
   Saleh T, 2016, BBA-GEN SUBJECTS, V1860, P2130, DOI 10.1016/j.bbagen.2016.06.012
   Sasaki K, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-370
   Sato K, 2007, CANCER RES, V67, P9677, DOI 10.1158/0008-5472.CAN-07-1462
   Schonewolf CA, 2014, WORLD J GASTRO ONCOL, V6, P74, DOI 10.4251/wjgo.v6.i3.74
   Shafaee Z, 2006, CANCER CHEMOTH PHARM, V58, P765, DOI 10.1007/s00280-006-0227-4
   Sharma K, 2014, AUTOPHAGY, V10, P2346, DOI 10.4161/15548627.2014.993283
   Sharma K, 2014, INT J MOL SCI, V15, P10034, DOI 10.3390/ijms150610034
   Shimizu S, 2014, INT J MOL SCI, V15, P3145, DOI 10.3390/ijms15023145
   Siegel RL, 2018, CA-CANCER J CLIN, V68, P7, DOI 10.3322/caac.21442
   Skvortsov S, 2014, EXPERT REV PROTEOMIC, V11, P207, DOI 10.1586/14789450.2014.893194
   Su HF, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0464-6
   Suzuki K, 2001, RADIAT RES, V155, P248, DOI 10.1667/0033-7587(2001)155[0248:RISLGA]2.0.CO;2
   Wang F, 2018, CELL PHYSIOL BIOCHEM, V45, P54, DOI 10.1159/000486222
   Widel M, 2015, MUTAT RES-FUND MOL M, V778, P61, DOI 10.1016/j.mrfmmm.2015.06.003
   Xu Z, 2017, ONCOL REP
   Yun HS, 2016, CANCER BIOL THER, V17, P208, DOI 10.1080/15384047.2016.1139232
   Zhou Y, 2014, SCI REP-UK, V4, DOI 10.1038/srep05382
NR 92
TC 11
Z9 12
U1 2
U2 9
PU RADIATION RESEARCH SOC
PI LAWRENCE
PA 810 E TENTH STREET, LAWRENCE, KS 66044 USA
SN 0033-7587
EI 1938-5404
J9 RADIAT RES
JI Radiat. Res.
PD NOV
PY 2018
VL 190
IS 5
BP 538
EP 557
DI 10.1667/RR15099.1
PG 20
WC Biology; Biophysics; Radiology, Nuclear Medicine & Medical Imaging
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Life Sciences & Biomedicine - Other Topics; Biophysics; Radiology,
   Nuclear Medicine & Medical Imaging
GA HC8WE
UT WOS:000452084900009
PM 30132722
OA Green Accepted
DA 2022-04-25
ER

PT J
AU Wang, JH
   Xing, YJ
   Wang, YY
   He, YD
   Wang, LT
   Peng, SH
   Yang, LF
   Xie, JQ
   Li, XT
   Qiu, WW
   Yi, ZF
   Liu, MY
AF Wang, Jinhua
   Xing, Yajing
   Wang, Yingying
   He, Yundong
   Wang, Liting
   Peng, Shihong
   Yang, Lianfang
   Xie, Jiuqing
   Li, Xiaotao
   Qiu, Wenwei
   Yi, Zhengfang
   Liu, Mingyao
TI A novel BMI-1 inhibitor QW24 for the treatment of stem-like colorectal
   cancer
SO JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
LA English
DT Article
DE Colorectal cancer; Cancer stem-like; BMI-1
ID SURVIVORSHIP STATISTICS; MESENCHYMAL TRANSITION; SELF-RENEWAL; IN-VITRO;
   CELLS; METASTASIS; EXPRESSION; SURVIVAL; GROWTH; CHEMOTHERAPY
AB Background Cancer-initiating cell (CIC), a functionally homogeneous stem-like cell population, is resonsible for driving the tumor maintenance and metastasis, and is a source of chemotherapy and radiation-therapy resistance within tumors. Targeting CICs self-renewal has been proposed as a therapeutic goal and an effective approach to control tumor growth. BMI-1, a critical regulator of self-renewal in the maintenance of CICs, is identified as a potential target for colorectal cancer therapy. Methods Colorectal cancer stem-like cell lines HCT116 and HT29 were used for screening more than 500 synthetic compounds by sulforhodamine B (SRB) cell proliferation assay. The candidate compound was studied in vitro by SRB cell proliferation assay, western blotting, cell colony formation assay, quantitative real-time PCR, flow cytometry analysis, and transwell migration assay. Sphere formation assay and limiting dilution analysis (LDA) were performed for measuring the effect of compound on stemness properties. In vivo subcutaneous tumor growth xenograft model and liver metastasis model were performed to test the efficacy of the compound treatment. Student's t test was applied for statistical analysis. Results We report the development and characterization of a small molecule inhibitor QW24 against BMI-1. QW24 potently down-regulates BMI-1 protein level through autophagy-lysosome degradation pathway without affecting the BMI-1 mRNA level. Moreover, QW24 significantly inhibits the self-renewal of colorectal CICs in stem-like colorectal cancer cell lines, resulting in the abrogation of their proliferation and metastasis. Notably, QW24 significantly suppresses the colorectal tumor growth without obvious toxicity in the subcutaneous xenograft model, as well as decreases the tumor metastasis and increases mice survival in the liver metastasis model. Moreover, QW24 exerts a better efficiency than the previously reported BMI-1 inhibitor PTC-209. Conclusions Our preclinical data show that QW24 exerts potent anti-tumor activity by down-regulating BMI-1 and abrogating colorectal CICs self-renewal without obvious toxicity in vivo, suggesting that QW24 could potentially be used as an effective therapeutic agent for clinical colorectal cancer treatment.
C1 [Wang, Jinhua; Xing, Yajing; He, Yundong; Peng, Shihong; Xie, Jiuqing; Yi, Zhengfang; Liu, Mingyao] East China Normal Univ, East China Normal Univ & Shanghai Fengxian Dist C, Shanghai Key Lab Regulatory Biol, Inst Biomed Sci, Shanghai 200241, Peoples R China.
   [Wang, Jinhua; Xing, Yajing; He, Yundong; Peng, Shihong; Xie, Jiuqing; Yi, Zhengfang; Liu, Mingyao] East China Normal Univ, Sch Life Sci, Shanghai 200241, Peoples R China.
   [Wang, Yingying; Wang, Liting; Yang, Lianfang; Qiu, Wenwei; Yi, Zhengfang] East China Normal Univ, Shanghai Engn Res Ctr Mol Therapeut & New Drug De, Sch Chem & Mol Engn, Shanghai 200062, Peoples R China.
   [Li, Xiaotao] Baylor Coll Med, Dept Mol & Cellular Biol, Dan L Duncan Canc Ctr, Houston, TX 77030 USA.
RP Yi, ZF; Liu, MY (corresponding author), East China Normal Univ, East China Normal Univ & Shanghai Fengxian Dist C, Shanghai Key Lab Regulatory Biol, Inst Biomed Sci, Shanghai 200241, Peoples R China.; Yi, ZF; Liu, MY (corresponding author), East China Normal Univ, Sch Life Sci, Shanghai 200241, Peoples R China.; Qiu, WW; Yi, ZF (corresponding author), East China Normal Univ, Shanghai Engn Res Ctr Mol Therapeut & New Drug De, Sch Chem & Mol Engn, Shanghai 200062, Peoples R China.
EM wangjh91@163.com; wwqiu@chem.ecnu.edu.cn; zfyi@bio.ecnu.edu.cn;
   myliu@bio.ecnu.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81472788, 81773204, 81330049]; Major State
   Basic Research Development Program of ChinaNational Basic Research
   Program of China [2015CB910400]; Shanghai Science and Technology Council
   [18ZR1411200]; National Key R&D Program of China [2018YFA0507000];
   Innovation program of Shanghai municipal education commissionInnovation
   Program of Shanghai Municipal Education Commission
   [2017-01-07-00-05-E00011]; ECNU public platform for Innovation
FX This work was partially supported by National Natural Science Foundation
   of China (No. 81472788, No. 81773204, No. 81330049), Major State Basic
   Research Development Program of China (2015CB910400), Shanghai Science
   and Technology Council (Grant 18ZR1411200), National Key R&D Program of
   China (2018YFA0507000), Innovation program of Shanghai municipal
   education commission (2017-01-07-00-05-E00011 to M.L.) and ECNU public
   platform for Innovation (011).
CR Abbasian M, 2019, J CANCER RES CLIN, V145, P97, DOI 10.1007/s00432-018-2769-3
   Abbasian M, 2019, J BIOMED MATER RES B, V107, P1264, DOI 10.1002/jbm.b.34219
   Adam R, 2003, ANN ONCOL, V14, P13, DOI 10.1093/annonc/mdg731
   Bansal N, 2016, CLIN CANCER RES, V22, P6176, DOI 10.1158/1078-0432.CCR-15-3107
   Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236
   Bhattacharya R, 2009, CANCER RES, V69, P9090, DOI 10.1158/0008-5472.CAN-09-2552
   Botchkina GI, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-192
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
   Butler SJ, 2017, BIOCHEM BIOPH RES CO, V490, P29, DOI 10.1016/j.bbrc.2017.05.176
   Cao LX, 2011, J CELL BIOCHEM, V112, P2729, DOI 10.1002/jcb.23234
   Chandrashekar DS, 2017, NEOPLASIA, V19, P649, DOI 10.1016/j.neo.2017.05.002
   Chen DM, 2017, CELL STEM CELL, V20, P621, DOI 10.1016/j.stem.2017.02.003
   Chen KL, 2011, CLIN EXP METASTAS, V28, P751, DOI 10.1007/s10585-011-9407-7
   Choi D, 2009, WORLD J GASTROENTERO, V15, P2258, DOI 10.3748/wjg.15.2258
   DeSantis CE, 2014, CA-CANCER J CLIN, V64, P252, DOI 10.3322/caac.21235
   Dey A, 2018, MOL CANCER THER, V17, P39, DOI 10.1158/1535-7163.MCT-17-0574
   Dey A, 2016, AUTOPHAGY, V12, P659, DOI 10.1080/15548627.2016.1147670
   Diehn M, 2009, SEMIN RADIAT ONCOL, V19, P78, DOI 10.1016/j.semradonc.2008.11.002
   Franken NAP, 2006, NAT PROTOC, V1, P2315, DOI 10.1038/nprot.2006.339
   Ganaie AA, 2018, CLIN CANC RES
   Griffith J, 2017, ONCOL REP, V37, P2382, DOI 10.3892/or.2017.5478
   Grothey A, 2013, LANCET, V381, P303, DOI 10.1016/S0140-6736(12)61900-X
   Guo BH, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-10
   Han XY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073341
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   He YD, 2018, NUCLEIC ACIDS RES, V46, P1895, DOI 10.1093/nar/gkx1306
   He YD, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13122
   Helming KC, 2014, NAT MED, V20, P251, DOI 10.1038/nm.3480
   Hu YF, 2009, J IMMUNOL METHODS, V347, P70, DOI 10.1016/j.jim.2009.06.008
   Huang BQ, 2017, CANCER RES, V77, P3194, DOI 10.1158/0008-5472.CAN-16-3146
   Hugen N, 2014, ANN ONCOL, V25, P651, DOI 10.1093/annonc/mdt591
   Jin M, 2014, CANCER RES, V74, P4183, DOI 10.1158/0008-5472.CAN-14-0404
   Jin X, 2017, NAT MED, V23, P1352, DOI 10.1038/nm.4415
   Kramer N, 2013, MUTAT RES-REV MUTAT, V752, P10, DOI 10.1016/j.mrrev.2012.08.001
   Kreso A, 2014, NAT MED, V20, P29, DOI 10.1038/nm.3418
   Kvinlaug BT, 2007, EXPERT OPIN THER TAR, V11, P915, DOI 10.1517/14728222.11.7.915
   LaBarge MA, 2010, CLIN CANCER RES, V16, P3121, DOI 10.1158/1078-0432.CCR-09-2933
   Lacerda L, 2010, DRUG RESIST UPDATE, V13, P99, DOI 10.1016/j.drup.2010.08.001
   Li AP, 2001, DRUG DISCOV TODAY, V6, P357, DOI 10.1016/S1359-6446(01)01712-3
   Li DW, 2010, J CANCER RES CLIN, V136, P997, DOI 10.1007/s00432-009-0745-7
   Li XD, 2016, CELL PHYSIOL BIOCHEM, V39, P2421, DOI 10.1159/000452510
   Lu J, 2013, CANCER CELL, V23, P171, DOI 10.1016/j.ccr.2012.12.021
   Lukacs RU, 2010, CELL STEM CELL, V7, P682, DOI 10.1016/j.stem.2010.11.013
   Mauthe M, 2018, AUTOPHAGY, V14, P1435, DOI 10.1080/15548627.2018.1474314
   Miller KD, 2016, CA-CANCER J CLIN, V66, P271, DOI 10.3322/caac.21349
   Morton CL, 2007, NAT PROTOC, V2, P247, DOI 10.1038/nprot.2007.25
   Myung J, 2001, MED RES REV, V21, P245, DOI 10.1002/med.1009.abs
   Nishida Y, 2017, BLOOD CANCER J, V7, DOI 10.1038/bcj.2017.8
   Paranjape AN, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-785
   Pastrana E, 2011, CELL STEM CELL, V8, P486, DOI 10.1016/j.stem.2011.04.007
   Rajput A, 2008, J SURG RES, V147, P276, DOI 10.1016/j.jss.2007.04.021
   Sadanandam A, 2013, NAT MED, V19, P619, DOI 10.1038/nm.3175
   Sangiorgi E, 2008, NAT GENET, V40, P915, DOI 10.1038/ng.165
   Siegel RL, 2017, CA-CANCER J CLIN, V67, P177, DOI 10.3322/caac.21395
   Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387
   Sun L, 2012, ONCOGENE, V31, P432, DOI 10.1038/onc.2011.263
   Tan SH, 2015, CANCER CELL, V28, P683, DOI 10.1016/j.ccell.2015.11.004
   Teo WH, 2017, INT J ONCOL, V51, P1415, DOI 10.3892/ijo.2017.4135
   Thul PJ, 2017, SCIENCE, V356, DOI 10.1126/science.aal3321
   TOMAYKO MM, 1989, CANCER CHEMOTH PHARM, V24, P148, DOI 10.1007/BF00300234
   Touil Y, 2014, CLIN CANCER RES, V20, P837, DOI 10.1158/1078-0432.CCR-13-1854
   Trumpp A, 2008, NAT CLIN PRACT ONCOL, V5, P337, DOI 10.1038/ncponc1110
   Valderrama-Trevino Alan I, 2017, Euroasian J Hepatogastroenterol, V7, P166, DOI 10.5005/jp-journals-10018-1241
   Wang EF, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017918
   Wang MC, 2015, ONCOL LETT, V10, P583, DOI 10.3892/ol.2015.3361
   Wang XJ, 2013, AUTOPHAGY, V9, P1500, DOI 10.4161/auto.25573
   Wang YY, 2012, WORLD J SURG, V36, P1189, DOI 10.1007/s00268-012-1514-3
   Wang ZW, 2010, DRUG RESIST UPDATE, V13, P109, DOI 10.1016/j.drup.2010.07.001
   Xiong D, 2015, CANCER BIOL THER, V16, P756, DOI 10.1080/15384047.2015.1026472
   Yeung TM, 2010, P NATL ACAD SCI USA, V107, P3722, DOI 10.1073/pnas.0915135107
   Yin XL, 2012, CANCER LETT, V322, P92, DOI 10.1016/j.canlet.2012.02.015
   Yong KJ, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad6066
   Yoo YA, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12943
   Zaczek A, 2017, POSTEP HIG MED DOSW, V71, P811, DOI 10.5604/01.3001.0010.4649
   Zeuner A, 2014, CELL STEM CELL, V15, P692, DOI 10.1016/j.stem.2014.11.012
   Zhang BX, 2009, CANCER LETT, V277, P114, DOI 10.1016/j.canlet.2008.11.035
   Zhang HL, 2011, BIOCHEM BIOPH RES CO, V404, P273, DOI 10.1016/j.bbrc.2010.11.106
NR 77
TC 7
Z9 7
U1 0
U2 8
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1756-9966
J9 J EXP CLIN CANC RES
JI J. Exp. Clin. Cancer Res.
PD OCT 22
PY 2019
VL 38
IS 1
AR 422
DI 10.1186/s13046-019-1392-8
PG 14
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA JG1VG
UT WOS:000491864700001
PM 31640758
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Wang, F
   Xia, XJ
   Yang, CY
   Shen, JL
   Mai, JH
   Kim, HC
   Kirui, D
   Kang, Y
   Fleming, JB
   Koay, EJ
   Mitra, S
   Ferrari, M
   Shen, HF
AF Wang, Feng
   Xia, Xiaojun
   Yang, Chunying
   Shen, Jianliang
   Mai, Junhua
   Kim, Han-Cheon
   Kirui, Dickson
   Kang, Ya'an
   Fleming, Jason B.
   Koay, Eugene J.
   Mitra, Sankar
   Ferrari, Mauro
   Shen, Haifa
TI SMAD4 Gene Mutation Renders Pancreatic Cancer Resistance to Radiotherapy
   through Promotion of Autophagy
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID TUMOR-SUPPRESSOR GENE; DUCTAL ADENOCARCINOMA; ADJUVANT RADIOTHERAPY;
   GENOMIC INSTABILITY; COLORECTAL-CANCER; CELLS; TRIAL; CARCINOMA;
   THERAPY; CHEMOTHERAPY
AB Purpose: Understanding the mechanism of radioresistance could help develop strategies to improve therapeutic response of patients with PDAC. The SMAD4 gene is frequently mutated in pancreatic cancer. In this study, we investigated the role of SMAD4 deficiency in pancreatic cancer cells' response to radiotherapy.
   Experimental Design: We downregulated SMAD4 expression with SMAD4 siRNA or SMAD4 shRNA and overexpressed SMAD4 in SMAD4 mutant pancreatic cancer cells followed by clonogenic survival assay to evaluate their effects on cell radioresistance. To study the mechanism of radioresistance, the effects of SMAD4 loss on reactive oxygen species (ROS) and autophagy were determined by flow cytometry and immunoblot analysis, respectively. Furthermore, we measured radioresistance by clonogenic survival assay after treatment with autophagy inhibitor (Chloroquine) and ROS inhibitor (N-acetyl-L-cysteine) in SMAD4-depleted pancreatic cancer cells. Finally, the effects of SMAD4 on radioresistance were also confirmed in an orthotopic tumor model derived from SMAD4-depleted Panc-1 cells.
   Results: SMAD4-depleted pancreatic cancer cells were more resistant to radiotherapy based on clonogenic survival assay. Overexpression of wild-type SMAD4 in SMAD4-mutant cells rescued their radiosensitivity. Radioresistance mediated by SMAD4 depletion was associated with persistently higher levels of ROS and radiation-induced autophagy. Finally, SMAD4 depletion induced in vivo radioresistance in Panc-1-derived orthotopic tumor model (P = 0.038). More interestingly, we observed that the protein level of SMAD4 is inversely correlated with autophagy in orthotopic tumor tissue samples.
   Conclusions: Our results demonstrate that defective SMAD4 is responsible for radioresistance in pancreatic cancer through induction of ROS and increased level of radiation-induced autophagy. (C) 2018 AACR.
C1 [Wang, Feng; Xia, Xiaojun; Shen, Jianliang; Mai, Junhua; Kim, Han-Cheon; Kirui, Dickson; Ferrari, Mauro; Shen, Haifa] Houston Methodist Res Inst, Dept Nanomed, Houston, TX USA.
   [Wang, Feng] Tongji Univ, Peoples Hosp Shanghai 10, Dept Gastroenterol, Shanghai, Peoples R China.
   [Xia, Xiaojun] Sun Yat Sen Univ, State Key Lab Oncol South China, Dept Expt Med, Ctr Canc, Guangzhou, Guangdong, Peoples R China.
   [Yang, Chunying; Mitra, Sankar] Houston Methodist Res Inst, Dept Radiat Oncol, Houston, TX USA.
   [Kang, Ya'an; Fleming, Jason B.] Univ Texas MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA.
   [Koay, Eugene J.] Univ Texas MD Anderson Canc Ctr, Dept Radiat Oncol, Houston, TX 77030 USA.
   [Ferrari, Mauro] Weill Cornell Med Coll, Dept Med, New York, NY USA.
   [Shen, Haifa] Weill Cornell Med Coll, Dept Cell & Dev Biol, New York, NY USA.
   [Shen, Haifa] Houston Methodist Canc Ctr, Houston, TX USA.
RP Shen, HF (corresponding author), Houston Methodist Res Inst, 6670 Bertner Ave,R8-214, Houston, TX 77030 USA.
EM hshen@houstonmethodist.org
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [1R01CA193880, U54CA143837,
   U54CA210181]; Department of DefenseUnited States Department of Defense
   [W81XWH-12-1-0414]; National Natural Science Foundation of ChinaNational
   Natural Science Foundation of China (NSFC) [31771497, 81472578]; Ernest
   Cockrell Jr. Presidential Distinguished Chair; NATIONAL CANCER
   INSTITUTEUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)
   [U54CA143837, R01CA193880, U54CA210181] Funding Source: NIH RePORTER
FX The authors acknowledge financial support from the following sources:
   NIH grants (Nos. 1R01CA193880, U54CA143837, and U54CA210181), Department
   of Defense grants (No. W81XWH-12-1-0414), National Natural Science
   Foundation of China (No. 31771497, 81472578), and the Ernest Cockrell
   Jr. Presidential Distinguished Chair.
CR Adler G, 2007, DEUT MED WOCHENSCHR, V132, P1696, DOI 10.1055/s-2007-984952
   Amaravadi RK, 2007, J CLIN INVEST, V117, P326, DOI 10.1172/JCI28833
   Apel A, 2008, CANCER RES, V68, P1485, DOI 10.1158/0008-5472.CAN-07-0562
   Bardeesy N, 2006, GENE DEV, V20, P3130, DOI 10.1101/gad.1478706
   Barhoumi M, 2011, CANCER RADIOTHER, V15, P182, DOI 10.1016/j.canrad.2010.10.001
   Bhola NE, 2013, J CLIN INVEST, V123, P1348, DOI 10.1172/JCI65416
   Blackford A, 2009, CLIN CANCER RES, V15, P4674, DOI 10.1158/1078-0432.CCR-09-0227
   Bornstein S, 2009, J CLIN INVEST, V119, P3408, DOI 10.1172/JCI38854
   Broz DK, 2013, GENE DEV, V27, P1016, DOI 10.1101/gad.212282.112
   Chen JH, 2015, AUTOPHAGY, V11, P239, DOI 10.1080/15548627.2015.1009767
   Chen Y, 2008, CELL DEATH DIFFER, V15, P171, DOI 10.1038/sj.cdd.4402233
   Crane CH, 2011, J CLIN ONCOL, V29, P3037, DOI 10.1200/JCO.2010.33.8038
   Filomeni G, 2010, AUTOPHAGY, V6, P999, DOI 10.4161/auto.6.7.12754
   Fleming NI, 2013, CANCER RES, V73, P725, DOI 10.1158/0008-5472.CAN-12-2706
   Gewirtz DA, 2014, CANCER RES, V74, P647, DOI 10.1158/0008-5472.CAN-13-2966
   Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350
   Iacobuzio-Donahue CA, 2009, J CLIN ONCOL, V27, P1806, DOI 10.1200/JCO.2008.17.7188
   Izeradjene K, 2007, CANCER CELL, V11, P229, DOI 10.1016/j.ccr.2007.01.017
   Kamisawa T, 2016, LANCET, V388, P73, DOI 10.1016/S0140-6736(16)00141-0
   Kang YL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113520
   Kanzawa T, 2004, CELL DEATH DIFFER, V11, P448, DOI 10.1038/sj.cdd.4401359
   Kleeff J, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.22
   Klinkenbijl JH, 1999, ANN SURG, V230, P776, DOI 10.1097/00000658-199912000-00006
   Kooby DA, 2013, ANN SURG ONCOL, V20, P3634, DOI 10.1245/s10434-013-3047-x
   Li L, 2013, CELL SIGNAL, V25, P50, DOI 10.1016/j.cellsig.2012.09.020
   Loehrer PJ, 2011, J CLIN ONCOL, V29, P4105, DOI 10.1200/JCO.2011.34.8904
   Makohon-Moore A, 2016, NAT REV CANCER, V16, P553, DOI 10.1038/nrc.2016.66
   Neoptolemos J, 1999, ANN SURG, V230, P782
   Neoptolemos JP, 2011, EUR J CANCER, V47, pS378, DOI 10.1016/S0959-8049(11)70210-6
   Neoptolemos JP, 2001, LANCET, V358, P1576, DOI 10.1016/S0140-6736(01)06651-X
   Neoptolemos JP, 2004, NEW ENGL J MED, V350, P1200, DOI 10.1056/NEJMoa032295
   Nikolic A, 2011, CANCER EPIDEMIOL, V35, P265, DOI 10.1016/j.canep.2010.10.002
   Papageorgis P, 2011, CANCER RES, V71, P998, DOI 10.1158/0008-5472.CAN-09-3269
   Rieber M, 2008, CANCER BIOL THER, V7, P1561, DOI 10.4161/cbt.7.10.6540
   Scherz-Shouval R, 2007, TRENDS CELL BIOL, V17, P422, DOI 10.1016/j.tcb.2007.07.009
   Scherz-Shouval R, 2007, EMBO J, V26, P1749, DOI 10.1038/sj.emboj.7601623
   Scherz-Shouval R, 2011, TRENDS BIOCHEM SCI, V36, P30, DOI 10.1016/j.tibs.2010.07.007
   Siegel RL, 2016, CA-CANCER J CLIN, V66, P7, DOI 10.3322/caac.21332
   Tanida I, 2011, ANTIOXID REDOX SIGN, V14, P2201, DOI 10.1089/ars.2010.3482
   Tascilar M, 2001, CLIN CANCER RES, V7, P4115
   Tempero MA, 2012, J NATL COMPR CANC NE, V10, P703, DOI 10.6004/jnccn.2012.0073
   Tsugawa H, 2012, CELL HOST MICROBE, V12, P764, DOI 10.1016/j.chom.2012.10.014
   Valdiglesias V, 2013, MUTAT RES-REV MUTAT, V753, P24, DOI 10.1016/j.mrrev.2013.02.001
   Waddell N, 2015, NATURE, V518, P495, DOI 10.1038/nature14169
   Wang F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018434
   Wang LH, 2007, CLIN CANCER RES, V13, P102, DOI 10.1158/1078-0432.CCR-06-1467
   Wang P, 2013, GASTROENTEROLOGY, V145, P1133, DOI 10.1053/j.gastro.2013.07.048
   Werner J, 2013, NAT REV CLIN ONCOL, V10, P323, DOI 10.1038/nrclinonc.2013.66
   Whittle MC, 2015, CELL, V161, P1345, DOI 10.1016/j.cell.2015.04.048
   Yoneyama H, 2015, ANTI-CANCER DRUG, V26, P90, DOI 10.1097/CAD.0000000000000165
   Yu J, 2015, GUT, V64, P636, DOI 10.1136/gutjnl-2013-306620
NR 51
TC 61
Z9 62
U1 2
U2 18
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
EI 1557-3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD JUL 1
PY 2018
VL 24
IS 13
BP 3176
EP 3185
DI 10.1158/1078-0432.CCR-17-3435
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA GL6DS
UT WOS:000437270800023
PM 29602802
OA Bronze, Green Accepted
DA 2022-04-25
ER

PT J
AU Zhu, HB
   Klement, JD
   Lu, CW
   Redd, PS
   Yang, DF
   Smith, AD
   Poschel, DB
   Zou, J
   Liu, D
   Wang, PG
   Ostrov, D
   Coant, N
   Hannun, YA
   Colby, AH
   Grinstaff, MW
   Liu, KB
AF Zhu, Huabin
   Klement, John D.
   Lu, Chunwan
   Redd, Priscilla S.
   Yang, Dafeng
   Smith, Alyssa D.
   Poschel, Dakota B.
   Zou, Juan
   Liu, Ding
   Wang, Peng George
   Ostrov, David
   Coant, Nicolas
   Hannun, Yusuf A.
   Colby, Aaron H.
   Grinstaff, Mark W.
   Liu, Kebin
TI Asah2 Represses the p53-Hmox1 Axis to Protect Myeloid-Derived Suppressor
   Cells from Ferroptosis
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID CANCER; DEATH; CERAMIDE; METABOLISM; SPHINGOLIPIDS; PATHOGENESIS;
   FACILITATE; AUTOPHAGY; PROMOTES; PD-L1
AB Myeloid-derived suppressor cells (MDSCs) are immune suppressive cells that massively accumulate under pathological conditions to suppress T cell immune response. Dysregulated cell death contributes to MDSC accumulation, but the molecular mechanism underlying this cell death dysregulation is not fully understood. In this study, we report that neutral ceramidase (N-acylsphingosine amidohydrolase [ASAH2]) is highly expressed in tumor-infiltrating MDSCs in colon carcinoma and acts as an MDSC survival factor. To target ASAH2, we performed molecular docking based on human ASAH2 protein structure. Enzymatic inhibition analysis of identified hits determined NC06 as an ASAH2 inhibitor. Chemical and nuclear magnetic resonance analysis determined NC06 as 7-chloro-2-(3-chloroanilino)pyrano[3,4-e][1,3]oxazine-4,5-dione. NC06 inhibits ceramidase activity with an IC50 of 10.16-25.91 mu M for human ASAH2 and 18.6-30.2 mu M for mouse Asah2 proteins. NC06 induces MDSC death in a dosedependent manner, and inhibition of ferroptosis decreased NC06-induced MDSC death. NC06 increases glutathione synthesis and decreases lipid reactive oxygen species to suppress ferroptosis in MDSCs. Gene expression profiling identified the p53 pathway as the Asah2 target in MDSCs. Inhibition of Asah2 increased p53 protein stability to upregulate Hmox1 expression to suppress lipid reactive oxygen species production to suppress ferroptosis inMDSCs. NC06 therapy increases MDSC death and reduces MDSC accumulation in tumor-bearing mice, resulting in increased activation of tumor-infiltrating CTLs and suppression of tumor growth in vivo. Our data indicate that ASAH2 protects MDSCs from ferroptosis through destabilizing p53 protein to suppress the p53 pathway inMDSCs in the tumor microenvironment. Targeting ASAH2 with NC06 to induce MDSC ferroptosis is potentially an effective therapy to suppress MDSC accumulation in cancer immunotherapy.
C1 [Zhu, Huabin; Klement, John D.; Lu, Chunwan; Redd, Priscilla S.; Yang, Dafeng; Smith, Alyssa D.; Poschel, Dakota B.; Liu, Kebin] Med Coll Georgia, Dept Biochem & Mol Biol, 1410 Laney Walker Blvd, Augusta, GA 30912 USA.
   [Zhu, Huabin; Klement, John D.; Lu, Chunwan; Redd, Priscilla S.; Yang, Dafeng; Smith, Alyssa D.; Poschel, Dakota B.; Liu, Kebin] Med Coll Georgia, Georgia Canc Ctr, Augusta, GA 30912 USA.
   [Zhu, Huabin; Klement, John D.; Lu, Chunwan; Redd, Priscilla S.; Yang, Dafeng; Smith, Alyssa D.; Poschel, Dakota B.; Liu, Kebin] Charlie Norwood VA Med Ctr, Augusta, GA 30904 USA.
   [Zou, Juan] Augusta Univ, Dept Chem & Phys, Augusta, GA 30912 USA.
   [Liu, Ding; Wang, Peng George] Georgia State Univ, Dept Chem, Atlanta, GA 30303 USA.
   [Ostrov, David] Univ Florida, Dept Pathol Immunol & Lab Med, Gainesville, FL 32610 USA.
   [Coant, Nicolas; Hannun, Yusuf A.] SUNY Stony Brook, Stony Brook Canc Ctr, Stony Brook, NY 11794 USA.
   [Colby, Aaron H.] Ion Pharmaceut, Brookline, MA 02445 USA.
   [Colby, Aaron H.; Grinstaff, Mark W.] Boston Univ, Dept Biomed Engn, Boston, MA 02215 USA.
RP Liu, KB (corresponding author), Med Coll Georgia, Dept Biochem & Mol Biol, 1410 Laney Walker Blvd, Augusta, GA 30912 USA.
EM Kliu@augusta.edu
OI Zhu, Huabin/0000-0002-4557-795X; COANT, Nicolas/0000-0001-9237-2132
FU National Institutes of Health (NIH)United States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USA [R01 CA133085,
   R01 CA227433, F30 CA226436, F31 CA257212]; U.S. Department of Veterans
   Affairs GrantUS Department of Veterans Affairs [CX001364]
FX This work was supported by National Institutes of Health (NIH) Grants
   R01 CA133085 and R01 CA227433 (to K.L.), F30 CA226436 (to J.D.K.), and
   F31 CA257212 (to A.D.S.), and U.S. Department of Veterans Affairs Grant
   CX001364 (to K.L.).
CR Agmon E, 2017, CURR OPIN CHEM BIOL, V39, P83, DOI 10.1016/j.cbpa.2017.06.002
   Airola MV, 2015, STRUCTURE, V23, P1482, DOI 10.1016/j.str.2015.06.013
   Alissafi T, 2018, J CLIN INVEST, V128, P3840, DOI 10.1172/JCI120888
   Bosiljcic M, 2019, BREAST CANCER RES, V21, DOI 10.1186/s13058-019-1189-x
   Bunt SK, 2006, J IMMUNOL, V176, P284, DOI 10.4049/jimmunol.176.1.284
   Casasampere M, 2019, J LIPID RES, V60, P1174, DOI 10.1194/jlr.D092759
   Chang LC, 2018, CANCER LETT, V416, P124, DOI 10.1016/j.canlet.2017.12.025
   Chen WM, 2009, MOL CELL, V34, P663, DOI 10.1016/j.molcel.2009.04.029
   Chiang SK, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20010039
   Coant Nicolas, 2019, Advances in Biological Regulation, V71, P141, DOI 10.1016/j.jbior.2018.10.005
   Coe GL, 2016, SCI REP-UK, V6, DOI 10.1038/srep30816
   Condamine T, 2014, J CLIN INVEST, V124, P2626, DOI 10.1172/JCI74056
   Cutler RG, 2004, P NATL ACAD SCI USA, V101, P2070, DOI 10.1073/pnas.0305799101
   Dany M, 2015, BBA-MOL CELL RES, V1853, P2834, DOI 10.1016/j.bbamcr.2014.12.039
   Dixon SJ, 2012, CELL, V149, P1060, DOI 10.1016/j.cell.2012.03.042
   Dominguez GA, 2017, CLIN CANCER RES, V23, P2942, DOI 10.1158/1078-0432.CCR-16-1784
   Fang XX, 2019, P NATL ACAD SCI USA, V116, P2672, DOI 10.1073/pnas.1821022116
   Fleming V, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00398
   Garcia-Barros M, 2016, FASEB J, V30, P4159, DOI 10.1096/fj.201600611R
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Hassannia B, 2019, CANCER CELL, V35, P830, DOI 10.1016/j.ccell.2019.04.002
   Haverkamp JM, 2014, IMMUNITY, V41, P947, DOI 10.1016/j.immuni.2014.10.020
   Hodge JW, 1999, CANCER RES, V59, P5106
   Ibrahim ML, 2018, CELL REP, V25, P3036, DOI 10.1016/j.celrep.2018.11.050
   Jiang L, 2015, NATURE, V520, P57, DOI 10.1038/nature14344
   Jiang WH, 2014, BBA-MOL CELL BIOL L, V1841, P783, DOI 10.1016/j.bbalip.2013.09.005
   Lasry A, 2016, NAT IMMUNOL, V17, P230, DOI 10.1038/ni.3384
   Lee WC, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-68061-8
   Lin H, 2018, J CLIN INVEST, V128, P805, DOI 10.1172/JCI96113
   Lu CW, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2016.1247135
   Meiller A, 2007, NUCLEIC ACIDS RES, V35, P6924, DOI 10.1093/nar/gkm824
   Nagaraj S, 2008, CANCER RES, V68, P2561, DOI 10.1158/0008-5472.CAN-07-6229
   Nakamura K, 2020, CELL MOL IMMUNOL, V17, P1, DOI 10.1038/s41423-019-0306-1
   O'Boyle NM, 2011, J CHEMINFORMATICS, V3, DOI 10.1186/1758-2946-3-33
   Ogretmen B, 2004, NAT REV CANCER, V4, P604, DOI 10.1038/nrc1411
   Ogretmen B, 2006, FEBS LETT, V580, P5467, DOI 10.1016/j.febslet.2006.08.052
   Oleinik N, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aax1978
   Ostrand-Rosenberg S, 2020, CANCER IMMUNOL IMMUN, V69, P215, DOI 10.1007/s00262-019-02388-8
   Papanikolaou G, 2005, TOXICOL APPL PHARM, V202, P199, DOI 10.1016/j.taap.2004.06.021
   Park MA, 2010, MOL CANCER THER, V9, P2220, DOI 10.1158/1535-7163.MCT-10-0274
   Parker KH, 2016, J LEUKOCYTE BIOL, V100, P463, DOI 10.1189/jlb.3HI0715-305R
   Pawelec G, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01099
   Roth F, 2012, CANCER RES, V72, P1373, DOI 10.1158/0008-5472.CAN-11-2772
   Sceneay J, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.22355
   Senkal CE, 2010, FASEB J, V24, P296, DOI 10.1096/fj.09-135087
   Sinha P, 2005, J IMMUNOL, V174, P636, DOI 10.4049/jimmunol.174.2.636
   Sinha P, 2011, BLOOD, V117, P5381, DOI 10.1182/blood-2010-11-321752
   Stockwell BR, 2017, CELL, V171, P273, DOI 10.1016/j.cell.2017.09.021
   Tang HD, 2018, J CLIN INVEST, V128, P580, DOI 10.1172/JCI96061
   Tarangelo A, 2018, CELL REP, V22, P569, DOI 10.1016/j.celrep.2017.12.077
   Truhlar DG, 2007, J COMPUT CHEM, V28, P73, DOI 10.1002/jcc.20529
   Veglia F, 2019, NATURE, V569, P73, DOI 10.1038/s41586-019-1118-2
   Wang WM, 2019, NATURE, V569, P270, DOI 10.1038/s41586-019-1170-y
   Weber J, 2016, CANCER IMMUNOL RES, V4, P345, DOI 10.1158/2326-6066.CIR-15-0193
   Weber R, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01310
   White-Gilbertson S, 2009, ONCOGENE, V28, P1132, DOI 10.1038/onc.2008.468
   Yang WS, 2014, CELL, V156, P317, DOI 10.1016/j.cell.2013.12.010
   Zhang YL, 2018, NAT CELL BIOL, V20, P1181, DOI 10.1038/s41556-018-0178-0
   Zhao XQ, 2012, J CLIN INVEST, V122, P4094, DOI 10.1172/JCI64115
   Zimmerman Mary, 2010, J Vis Exp, DOI 10.3791/2077
NR 60
TC 6
Z9 7
U1 3
U2 14
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
EI 1550-6606
J9 J IMMUNOL
JI J. Immunol.
PD MAR 15
PY 2021
VL 206
IS 6
BP 1395
EP 1404
DI 10.4049/jimmunol.2000500
PG 10
WC Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology
GA QU6XN
UT WOS:000627424200024
PM 33547170
OA Bronze, Green Accepted
DA 2022-04-25
ER

PT J
AU Geremia, A
   Sartori, R
   Baraldo, M
   Nogara, L
   Balmaceda, V
   Dumitras, GA
   Ciciliot, S
   Scalabrin, M
   Nolte, H
   Blaauw, B
AF Geremia, Alessia
   Sartori, Roberta
   Baraldo, Martina
   Nogara, Leonardo
   Balmaceda, Valeria
   Dumitras, Georgia Ana
   Ciciliot, Stefano
   Scalabrin, Marco
   Nolte, Hendrik
   Blaauw, Bert
TI Activation of Akt-mTORC1 signalling reverts cancer-dependent muscle
   wasting
SO JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE
LA English
DT Article; Early Access
DE Cancer cachexia; mTOR; Raptor; Akt; Muscle growth; Skeletal muscle force
ID CACHEXIA; PREVENTS; FORCE
AB Background Cancer-related muscle wasting occurs in most cancer patients. An important regulator of adult muscle mass and function is the Akt-mTORC1 pathway. While Akt-mTORC1 signalling is important for adult muscle homeostasis, it is also a major target of numerous cancer treatments. Which role Akt-mTORC1 signalling plays during cancer cachexia in muscle is currently not known. Here, we aimed to determine how activation or inactivation of the pathway affects skeletal muscle during cancer cachexia. Methods We used inducible, muscle-specific Raptor ko (mTORC1) mice to determine the effect of reduced mTOR signalling during cancer cachexia. On the contrary, in order to understand if skeletal muscles maintain their anabolic capacity and if activation of Akt-mTORC1 signalling can reverse cancer cachexia, we generated mice in which we can inducibly activate Akt specifically in skeletal muscles. Results We found that mTORC1 signalling is impaired during cancer cachexia, using the Lewis lung carcinoma and C26 colon cancer model, and is accompanied by a reduction in protein synthesis rates of 57% (P < 0.01). Further reduction of mTOR signalling, as seen in Raptor ko animals, leads to a 1.5-fold increase in autophagic flux (P > 0.001), but does not further increase muscle wasting. On the other hand, activation of Akt-mTORC1 signalling in already cachectic animals completely reverses the 15-20% loss in muscle mass and force (P < 0.001). Interestingly, Akt activation only in skeletal muscle completely normalizes the transcriptional deregulation observed in cachectic muscle, despite having no effect on tumour size or spleen mass. In addition to stimulating muscle growth, it is also sufficient to prevent the increase in protein degradation normally observed in muscles from tumour-bearing animals. Conclusions Here, we show that activation of Akt-mTORC1 signalling is sufficient to completely revert cancer-dependent muscle wasting. Intriguingly, these results show that skeletal muscle maintains its anabolic capacities also during cancer cachexia, possibly giving a rationale behind some of the beneficial effects observed in exercise in cancer patients.
C1 [Geremia, Alessia; Sartori, Roberta; Baraldo, Martina; Nogara, Leonardo; Balmaceda, Valeria; Dumitras, Georgia Ana; Ciciliot, Stefano; Scalabrin, Marco; Blaauw, Bert] Veneto Inst Mol Med VIMM, Via Orus 1, Padua, Italy.
   [Geremia, Alessia; Baraldo, Martina; Nogara, Leonardo; Dumitras, Georgia Ana; Scalabrin, Marco; Blaauw, Bert] Univ Padua, Dept Biomed Sci, Padua, Italy.
   [Nolte, Hendrik] Max Planck Inst Biol Ageing, Cologne, Germany.
RP Blaauw, B (corresponding author), Veneto Inst Mol Med VIMM, Via Orus 1, Padua, Italy.
EM bert.blaauw@unipd.it
OI Sartori, Roberta/0000-0002-2763-9838; BLAAUW, BERT/0000-0002-4167-5106
FU French Muscular Dystrophy Association [Association Francaise contre les
   Myopathies (AFMTelethon)] [21865]; Associazione Italiana per la Ricerca
   sul Cancro (AIRC)Fondazione AIRC per la ricerca sul cancro [20406];
   University of Padua (Universita degli Studi di Padova)
   (STARSMyoAktivation)
FX This work was supported by grants from the French Muscular Dystrophy
   Association [Association Francaise contre les Myopathies (AFMTelethon)
   to B.B., No. 21865], University of Padua (Universita degli Studi di
   Padova) (STARSMyoAktivation to B.B.), and Associazione Italiana per la
   Ricerca sul Cancro (AIRC) 20406 to B.B.
CR Antoun S, 2010, J CLIN ONCOL, V28, P1054, DOI 10.1200/JCO.2009.24.9730
   Argiles JM, 2014, NAT REV CANCER, V14, P754, DOI 10.1038/nrc3829
   Baraldo M, 2020, J CACHEXIA SARCOPENI, V11, P208, DOI 10.1002/jcsm.12496
   Blaauw B, 2008, HUM MOL GENET, V17, P3686, DOI 10.1093/hmg/ddn264
   Blaauw B, 2009, FASEB J, V23, P3896, DOI 10.1096/fj.09-131870
   Castets P, 2020, FRONT MOL NEUROSCI, V13, DOI 10.3389/fnmol.2020.00162
   Castets P, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11227-4
   Chen XZ, 2016, J CACHEXIA SARCOPENI, V7, P224, DOI 10.1002/jcsm.12054
   Civiletto G, 2018, EMBO MOL MED, V10, DOI 10.15252/emmm.201708799
   Crosby P, 2019, CELL, V177, P896, DOI 10.1016/j.cell.2019.02.017
   Dogra C, 2007, FASEB J, V21, P1857, DOI 10.1096/fj.06-7537com
   Engelen MPKJ, 2015, ANN ONCOL, V26, P1960, DOI 10.1093/annonc/mdv271
   Fearon K, 2011, LANCET ONCOL, V12, P489, DOI 10.1016/S1470-2045(10)70218-7
   Gyawali B, 2016, MOL CLIN ONCOL, V5, P641, DOI 10.3892/mco.2016.1015
   Johnston AJ, 2015, CELL, V162, P1365, DOI 10.1016/j.cell.2015.08.031
   Judge SM, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-997
   Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5
   Lossie J, 2014, BIOCHEM BIOPH RES CO, V450, P464, DOI 10.1016/j.bbrc.2014.05.142
   Marabita M, 2016, CELL REP, V17, P501, DOI 10.1016/j.celrep.2016.09.020
   Milan G, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7670
   Nolte H, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-31154-6
   Pereira MG, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00963
   Pigna E, 2016, SCI REP-UK, V6, DOI 10.1038/srep26991
   Prado CM, 2013, AM J CLIN NUTR, V98, P1012, DOI 10.3945/ajcn.113.060228
   Puppa MJ, 2014, FASEB J, V28, P998, DOI 10.1096/fj.13-240580
   Puppa MJ, 2012, J CACHEXIA SARCOPENI, V3, P117, DOI 10.1007/s13539-011-0047-1
   Sandri M, 2013, BIOGERONTOLOGY, V14, P303, DOI 10.1007/s10522-013-9432-9
   Sandri M, 2004, CELL, V117, P399, DOI 10.1016/S0092-8674(04)00400-3
   Sartori R, 2021, SCI TRANSL MED, V13, DOI 10.1126/scitranslmed.aay9592
   Schiaffino S, 2021, J NEUROMUSCULAR DIS, V8, P169, DOI 10.3233/JND-200568
   Schuler M, 2005, GENESIS, V41, P165, DOI 10.1002/gene.20107
   Solagna F, 2020, ACTA PHYSIOL, V230, DOI 10.1111/apha.13496
   Suriben R, 2020, NAT MED, V26, P1264, DOI 10.1038/s41591-020-0945-x
   Talbert EE, 2019, CELL REP, V28, P1612, DOI 10.1016/j.celrep.2019.07.016
   Tyanova S, 2016, NAT METHODS, V13, P731, DOI [10.1038/NMETH.3901, 10.1038/nmeth.3901]
   von Haehling S, 2019, J CACHEXIA SARCOPENI, V10, P1143, DOI 10.1002/jcsm.12501
   White JP, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024650
   Winbanks CE, 2013, J CELL BIOL, V203, P345, DOI 10.1083/jcb.201211134
   Zhou XL, 2010, CELL, V142, P531, DOI 10.1016/j.cell.2010.07.011
NR 39
TC 1
Z9 1
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2190-5991
EI 2190-6009
J9 J CACHEXIA SARCOPENI
JI J. Cachexia Sarcopenia Muscle
DI 10.1002/jcsm.12854
EA NOV 2021
PG 14
WC Geriatrics & Gerontology; Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology; General & Internal Medicine
GA WS0NL
UT WOS:000714886900001
PM 34741441
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Yang, Y
   Feng, MY
   Bai, LL
   Zhang, MX
   Zhou, KX
   Liao, WT
   Lei, WT
   Zhang, N
   Huang, JX
   Li, Q
AF Yang, Yang
   Feng, Mingyang
   Bai, LiangLiang
   Zhang, Mengxi
   Zhou, Kexun
   Liao, Weiting
   Lei, Wanting
   Zhang, Nan
   Huang, Jiaxing
   Li, Qiu
TI The Effects of Autophagy-Related Genes and lncRNAs in Therapy and
   Prognosis of Colorectal Cancer
SO FRONTIERS IN ONCOLOGY
LA English
DT Article
DE colorectal cancer; autophagy; gene; lncRNA; prognosis; immune
ID IMMUNOTHERAPY
AB Cellular autophagy plays an important role in the occurrence and development of colorectal cancer (CRC). Whether autophagy-related genes and lncRNAs can be used as ideal markers in CRC is still controversial. The purpose of this study is to identify novel treatment and prognosis markers of CRC. We downloaded transcription and clinical data of CRC from the GEO (GSE40967, GSE12954, GSE17536) and TCGA database, screened for differentially autophagy-related genes (DEAGs) and lncRNAs, constructed prognostic model, and analyzed its relationship with immune infiltration. TCGA and GEO datasets (GSE12954 and GSE17536) were used to validate the effect of the model. Oncomine database and Human Protein Atlas verified the expression of DEAGs. We obtained a total of 151 DEAGs in three verification sets collaboratively. Then we constructed a risk prognostic model through Lasso regression to obtain 15 prognostic DEAGs from the training set and verified the risk prognostic model in three verification sets. The low-risk group survived longer than the high-risk group. Age, gender, pathological stage, and TNM stage were related to the prognostic risk of CRC. On the other hand, BRAF status, RFS event, and tumor location are considered as most significant risk factors of CRC in the training set. Furthermore, we found that the immune score of the low-risk group was higher. The content of CD8 + T cells, active NK cells, macrophages M0, macrophages M1, and active dendritic cells was noted more in the high-risk group. The content of plasma cells, resting memory CD4 + T cells, resting NK cells, resting mast cells, and neutrophil cells was higher in the low-risk group. After all, the Oncomine database and immunohistochemistry verified that the expression level of most key autophagy-related genes was consistent with the results that we found. In addition, we obtained six lncRNAs co-expressed with DEAGs from the training set and found that the survival time was longer in the low-risk group. This finding was verified in the verification set and showed same trend to the results mentioned above. In the final analysis, these results indicate that autophagy-related genes and lncRNAs can be used as prognostic and therapeutic markers for CRC.
C1 [Yang, Yang; Feng, Mingyang; Bai, LiangLiang; Zhang, Mengxi; Zhou, Kexun; Liao, Weiting; Lei, Wanting; Zhang, Nan; Huang, Jiaxing; Li, Qiu] Sichuan Univ, West China Hosp, Canc Ctr, Dept Med Oncol, Chengdu, Sichuan, Peoples R China.
   [Yang, Yang; Feng, Mingyang; Bai, LiangLiang; Zhang, Mengxi; Zhou, Kexun; Liao, Weiting; Lei, Wanting; Zhang, Nan; Huang, Jiaxing; Li, Qiu] Sichuan Univ, West China Biomed Big Data Ctr, Chengdu, Sichuan, Peoples R China.
RP Li, Q (corresponding author), Sichuan Univ, West China Hosp, Canc Ctr, Dept Med Oncol, Chengdu, Sichuan, Peoples R China.; Li, Q (corresponding author), Sichuan Univ, West China Biomed Big Data Ctr, Chengdu, Sichuan, Peoples R China.
EM fbqiu9@163.com
CR Arai H, 2019, CANCER TREAT REV, V81, DOI 10.1016/j.ctrv.2019.101912
   Bernardini JP, 2017, ONCOGENE, V36, P1315, DOI 10.1038/onc.2016.302
   Brody H, 2015, NATURE, V521, pS1, DOI 10.1038/521S1a
   Burada F, 2015, WORLD J GASTRO ONCOL, V7, P271, DOI 10.4251/wjgo.v7.i11.271
   Chang WT, 2017, MOLECULES, V22, DOI 10.3390/molecules22050854
   Chi HC, 2016, AUTOPHAGY, V12, P2271, DOI 10.1080/15548627.2016.1230583
   Christensen JG, 2020, J INTERN MED, V288, P183, DOI 10.1111/joim.13057
   Dekker E, 2019, LANCET, V394, P1467, DOI 10.1016/S0140-6736(19)32319-0
   Demarchi F, 2007, AUTOPHAGY, V3, P235, DOI 10.4161/auto.3661
   Deshpande M, 2020, CANCERS, V12, DOI 10.3390/cancers12113319
   El-Zaatari M, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00051
   Fan JQ, 2018, THERANOSTICS, V8, P5784, DOI 10.7150/thno.29035
   Gauthier A, 2013, HEPATOL RES, V43, P147, DOI 10.1111/j.1872-034X.2012.01113.x
   Gmeiner WH, 2020, CANCERS, V12, DOI 10.3390/cancers12061641
   Gozuacik D, 2006, AUTOPHAGY, V2, P74, DOI 10.4161/auto.2.2.2459
   Guo L, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01052
   Guo PT, 2017, MOL MED REP, V15, P724, DOI 10.3892/mmr.2016.6049
   Heldring N, 2014, NEURO-ONCOLOGY, V16, P241, DOI 10.1093/neuonc/not214
   Jo YK, 2018, ANTICANCER RES, V38, P271, DOI 10.21873/anticanres.12218
   Kang LM, 2021, J NEUROL, V268, P3269, DOI 10.1007/s00415-020-09942-w
   Kang R, 2011, CELL DEATH DIFFER, V18, P571, DOI 10.1038/cdd.2010.191
   Kim BK, 2018, BRIT J CANCER, V119, P1347, DOI 10.1038/s41416-018-0289-1
   Kimmelman AC, 2017, CELL METAB, V25, P1037, DOI 10.1016/j.cmet.2017.04.004
   Koustas E, 2019, CANCERS, V11, DOI 10.3390/cancers11040533
   Levy JMM, 2017, NAT REV CANCER, V17, P528, DOI 10.1038/nrc.2017.53
   Li CG, 2020, ANN TRANSL MED, V8, DOI 10.21037/atm.2020.02.173
   Li ZD, 2019, GENE, V691, P106, DOI 10.1016/j.gene.2018.11.099
   Lichtenstern CR, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9030618
   Lin SC, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1303-z
   Lin TY, 2020, AUTOPHAGY, V16, P1296, DOI 10.1080/15548627.2019.1671643
   Ma J, 2020, J CELL MOL MED, V24, P6472, DOI 10.1111/jcmm.15298
   Majidzadeh H, 2020, COLLOID SURFACE B, V194, DOI 10.1016/j.colsurfb.2020.111188
   Marmol I, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18010197
   Mokarram P, 2017, AUTOPHAGY, V13, P781, DOI 10.1080/15548627.2017.1290751
   Molina-Cerrillo J, 2020, CANCERS, V12, DOI 10.3390/cancers12061571
   Natarajan S, 2018, MOL MED REP, V18, P4147, DOI 10.3892/mmr.2018.9404
   Olino K, 2020, SEMIN CANCER BIOL, V65, P114, DOI 10.1016/j.semcancer.2020.01.001
   Oliver GR, 2015, CLIN CHEM, V61, P124, DOI 10.1373/clinchem.2014.224360
   Onorati AV, 2018, CANCER-AM CANCER SOC, V124, P3307, DOI 10.1002/cncr.31335
   Pietrantonio F, 2020, CANCER TREAT REV, V82, DOI 10.1016/j.ctrv.2019.101935
   Qaderi SM, 2020, EJSO-EUR J SURG ONC, V46, P1779, DOI 10.1016/j.ejso.2020.06.017
   Sheikh-Zeineddini N, 2020, EUR J PHARMACOL, V870, DOI 10.1016/j.ejphar.2019.172821
   Shih JH, 2020, NUCLEIC ACIDS RES, V48, P1175, DOI 10.1093/nar/gkz1149
   Steyerberg EW, 2014, EUR HEART J, V35, P1925, DOI 10.1093/eurheartj/ehu207
   Tang ZB, 2018, INT J NANOMED, V13, P2907, DOI 10.2147/IJN.S159388
   Thongchot S, 2018, MOL CARCINOGEN, V57, P1735, DOI 10.1002/mc.22893
   Wiener Z, 2014, CELL REP, V8, P1943, DOI 10.1016/j.celrep.2014.08.034
   Wu YH, 2018, SIGNAL TRANSDUCT TAR, V3, DOI 10.1038/s41392-018-0031-8
   Xu Y, 2020, AUTOPHAGY, V16, P3, DOI 10.1080/15548627.2019.1603547
   Yan LL, 2018, TOXICOL LETT, V295, P153, DOI 10.1016/j.toxlet.2018.06.1066
   Zhang L, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.139
   Zhao YL, 2018, FOOD FUNCT, V9, P4548, DOI [10.1039/c8fo00850g, 10.1039/C8FO00850G]
   Zhou BR, 2020, SEMIN CANCER BIOL, V66, P89, DOI 10.1016/j.semcancer.2019.03.002
NR 53
TC 2
Z9 2
U1 2
U2 2
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2234-943X
J9 FRONT ONCOL
JI Front. Oncol.
PD MAR 11
PY 2021
VL 11
AR 582040
DI 10.3389/fonc.2021.582040
PG 16
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA RC0AS
UT WOS:000632467000001
PM 33777735
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Giatromanolaki, A
   Sivridis, E
   Mendrinos, S
   Koutsopoulos, AV
   Koukourakis, MI
AF Giatromanolaki, Alexandra
   Sivridis, Efthimios
   Mendrinos, Savvas
   Koutsopoulos, Anastasios V.
   Koukourakis, Michael I.
TI Autophagy proteins in prostate cancer: Relation with anaerobic
   metabolism and Gleason score
SO UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
LA English
DT Article
DE Autophagy; LC3A; LC3B; p62; LDH5; Prostate cancer
ID COLORECTAL-CANCER; CARCINOMAS; SURVIVAL; HYPOXIA; CELLS; LC3;
   EXPRESSION; PROGNOSIS; PATTERNS; THERAPY
AB Objectives: Up-regulation of autophagy provides an important survival mechanism to normal and malignant cells residing in a hypoxic and unfavorable nutritional environment. Yet, its role in the biology of prostate cancer remains poorly understood.
   Methods: In this study we investigated the expression of four major autophagy proteins, namely the microtubule-associated protein 1 light chain 3A (LC3A), LC3B. Beclin 1. and p62, together with an enzyme of anaerobic metabolism, the lactate dehydrogenase 5 (LDH5), in relation to Gleason score and extraprostatic invasion. A series of 96 prostate adenocarcinomas was examined using immunohistochemical techniques and appropriate antibodies.
   Results: The LC3A protein was expressed in the form of "stone-like" structures, and diffuse cytoplasmic staining. the LC3B reactivity was solely cytoplasmic, whereas that of p62 and LDH5 was both cytoplasmic and nuclear. A median count of 0.90 "stone-like" structures per 200x optical field (range 0-3.6) was highly associated with a high Gleason score. Similarly, a strong cytoplasmic LC3A, LC3B, and p62 expression, when extensive (present in >50% tumor cells per section), was significantly associated with LDH5 and a high Gleason score. In addition, extensive cytoplasmic p62 expression was related with LC3A and B reactivity and also with extraprostatic invasion. Extensive Beclin-1 expression was significantly linked with extraprostatic invasion and also with p62 and LDH5 expression.
   Conclusions: Immunohistochemical detection of autophagy proteins may potentially prove to be useful as prognostic markers and a tool for the stratification of patients in therapeutic trials targeting autophagy in prostate cancer. (C) 2014 Elsevier Inc. All rights reserved.
C1 [Giatromanolaki, Alexandra; Sivridis, Efthimios; Koutsopoulos, Anastasios V.] Democritus Univ Thrace, Univ Gen Hosp Alexandroupolis, Dept Pathol, Alexandroupolis, Greece.
   [Koukourakis, Michael I.] Democritus Univ Thrace, Univ Gen Hosp Alexandroupolis, Dept Radiotherapy Oncol, Alexandroupolis, Greece.
   [Mendrinos, Savvas] Div Pathol Integrated Med Profess, New York, NY USA.
RP Giatromanolaki, A (corresponding author), Democritus Univ Thrace, Univ Gen Hosp Alexandroupolis, Dept Pathol, Alexandroupolis, Greece.
EM agiatrom@med.duth.gr
RI Koutsopoulos, Anastasios/AAO-9498-2020
OI Koutsopoulos, Anastasios/0000-0002-8430-7565
FU Tumor and Angiogenesis Research Group
FX The study was financially supported by the Tumor and Angiogenesis
   Research Group.
CR Brown JM, 1998, CANCER RES, V58, P1408
   Cao Y, 2007, CELL RES, V17, P839, DOI 10.1038/cr.2007.78
   Hippert MM, 2006, CANCER RES, V66, P9349, DOI 10.1158/0008-5472.CAN-06-1597
   Hu YL, 2012, CANCER RES, V72, P1773, DOI 10.1158/0008-5472.CAN-11-3831
   Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720
   Karpathiou G, 2011, CHEST, V140, P127, DOI 10.1378/chest.10-1831
   Koukourakis MI, 2010, BRIT J CANCER, V103, P1209, DOI 10.1038/sj.bjc.6605904
   Koukourakis MI, 2006, J CLIN ONCOL, V24, P4301, DOI 10.1200/JCO.2006.05.9501
   Koukourakis MI, 2013, HISTOPATHOLOGY, V62, P962, DOI 10.1111/his.12080
   Kung Hsing-Jien, 2011, Hormones & Cancer, V2, P38, DOI 10.1007/s12672-010-0053-3
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Levy JMM, 2011, PHARMACOL THERAPEUT, V131, P130, DOI 10.1016/j.pharmthera.2011.03.009
   Mikhaylova O, 2012, CANCER CELL, V21, P532, DOI 10.1016/j.ccr.2012.02.019
   Mizushima N, 2010, CURR OPIN CELL BIOL, V22, P132, DOI 10.1016/j.ceb.2009.12.004
   Pankiv S, 2007, J BIOL CHEM, V282, P24131, DOI 10.1074/jbc.M702824200
   Pouyssegur J, 2001, Novartis Found Symp, V240, P186
   Rosenfeldt MT, 2011, CARCINOGENESIS, V32, P955, DOI 10.1093/carcin/bgr031
   Rzymski T, 2010, ONCOGENE, V29, P4424, DOI 10.1038/onc.2010.191
   Sivridis E, 2012, UROL ONCOL
   Sivridis E, 2011, MELANOMA RES, V21, P188, DOI 10.1097/CMR.0b013e328346612c
   Sivridis E, 2011, AUTOPHAGY, V7, P74, DOI 10.4161/auto.7.1.13947
   Sivridis E, 2010, AUTOPHAGY, V6, P830, DOI 10.4161/auto.6.6.12588
   Sivridis E, 2010, AM J PATHOL, V176, P2477, DOI 10.2353/ajpath.2010.090049
   Spowart JE, 2012, J PATHOL
   Suh Y, 2010, CARCINOGENESIS, V31, P1424, DOI 10.1093/carcin/bgq115
   Toepfer N, 2011, CANCER BIOL THER, V12, P691, DOI 10.4161/cbt.12.8.15978
   Xie ZP, 2007, NAT CELL BIOL, V9, P1102, DOI 10.1038/ncb1007-1102
   Xu SP, 2011, PROSTATE, V71, P1216, DOI 10.1002/pros.21337
   Yang ZNJ, 2011, MOL CANCER THER, V10, P1533, DOI 10.1158/1535-7163.MCT-11-0047
NR 29
TC 15
Z9 15
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1078-1439
EI 1873-2496
J9 UROL ONCOL-SEMIN ORI
JI Urol. Oncol.-Semin. Orig. Investig.
PD JAN
PY 2014
VL 32
IS 1
DI 10.1016/j.urolonc.2013.04.003
PG 8
WC Oncology; Urology & Nephrology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Urology & Nephrology
GA AX9SW
UT WOS:000347243300062
PM 23787295
DA 2022-04-25
ER

PT J
AU Zhou, ZH
   Wang, QL
   Mao, LH
   Li, XQ
   Liu, P
   Song, JW
   Liu, X
   Xu, F
   Lei, J
   He, S
AF Zhou, Zhi-Hang
   Wang, Qing-Liang
   Mao, Lin-Hong
   Li, Xiao-Qin
   Liu, Peng
   Song, Jin-Wen
   Liu, Xue
   Xu, Feng
   Lei, Jing
   He, Song
TI Chromatin accessibility changes are associated with enhanced growth and
   liver metastasis capacity of acid-adapted colorectal cancer cells
SO CELL CYCLE
LA English
DT Article
DE Colorectal cancer; acidosis; chromatin accessibility; NFIB; metastasis
ID GLUTAMINE-METABOLISM; MELANOMA-CELLS; PH; DRIVES; MICROENVIRONMENT;
   TRANSCRIPTION; PROGRESSION; AUTOPHAGY; BREAST; NFIB
AB The acidic extracellular microenvironment, namely acidosis, is a biochemical hallmark of solid tumors. However, the tumorigenicity, metastatic potential, gene expression profile and chromatin accessibility of acidosis-adapted colorectal cancer cells remain unknown. The colorectal cancer cell SW620 was cultured in acidic medium (pH 6.5) for more than 3 months to be acidosis-adapted (SW620-AA). In comparison to parental cells, SW620-AA cells exhibit enhanced tumorigenicity and liver metastatic potential in vivo. Following mRNA and lncRNA expression profiling, we validated that OLMF1, NFIB, SMAD9, DGKB are upregulated, while SESN2, MAP1B, UTRN, PCDH19, IL18, LMO2, CNKSR3, GXYLT2 are downregulated in SW620-AA cells. The differentially expressed mRNAs were significantly enriched in DNA remodeling-associated pathways including HDACs deacetylate histones, SIRT1 pathway, DNA methylation, DNA bending complex, and RNA polymerase 1 chain elongation. Finally, chromatin accessibility evaluation by ATAC-sequencing revealed that the differentially opened peaks were enriched in pathways such as small cell lung cancer, pathways in cancer, ErbB signaling, endometrial cancer, and chronic myeloid leukemia, which were mainly distributed in intergenic regions and introns. These results suggest that the chromatin accessibility changes are correlated with enhanced growth and liver metastasis capacity of acid-adapted colorectal cancer cells.
C1 [Zhou, Zhi-Hang; Mao, Lin-Hong; Li, Xiao-Qin; Xu, Feng; Lei, Jing; He, Song] Chongqing Med Univ, Affiliated Hosp 2, Dept Gastroenterol, Chongqing, Peoples R China.
   [Zhou, Zhi-Hang] 309th Hosp PLA, Dept Pathol, Beijing, Peoples R China.
   [Wang, Qing-Liang] Chongqing Med Univ, Affiliated Hosp 2, Dept Pathol, Chongqing, Peoples R China.
   [Liu, Peng] Gen Hosp Guangzhou Mil Command, Chest Pain Ctr, Dept Emergency, Guangzhou, Guangdong, Peoples R China.
   [Song, Jin-Wen] 302nd Hosp PLA, Treatment & Res Ctr Infect Dis, Beijing, Peoples R China.
   [Liu, Xue] Jining Med Univ, Basic Sci Sch, Dept Pathol, Jining, Shandong, Peoples R China.
RP He, S (corresponding author), Chongqing Med Univ, Affiliated Hosp 2, Dept Gastroenterol, Chongqing, Peoples R China.
EM hedoctor65@sina.com
RI zhou, zhi-hang/AAA-4010-2021
OI Song, Jin-Wen/0000-0002-8582-8012; Zhou, Zhihang/0000-0003-1356-9872;
   Liu, Peng/0000-0002-3394-971X
FU National Natural Science Fund for Youth [81602097]; Beijing Municipal
   Natural Science FoundationBeijing Natural Science Foundation [7182162];
   Beijing Nova ProjectBeijing Municipal Science & Technology Commission
   [Z181100006218016]
FX This study was funded by the National Natural Science Fund for Youth
   [No. 81602097]; Beijing Municipal Natural Science Foundation [7182162];
   Beijing Nova Project [Z181100006218016].
CR Abrego J, 2017, CANCER LETT, V400, P37, DOI 10.1016/j.canlet.2017.04.029
   Buenrostro Jason D, 2015, Curr Protoc Mol Biol, V109, DOI 10.1002/0471142727.mb2129s109
   Chao M, 2016, ELIFE, V5, DOI [10.7754/eLife.15691, 10.7554/eLife.15691]
   Chen JLY, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000293
   Cheng W, 2017, ONCOTARGET, V8, P80429, DOI 10.18632/oncotarget.19035
   Corbet C, 2017, NAT REV CANCER, V17, P577, DOI 10.1038/nrc.2017.77
   Corbet C, 2016, CELL METAB, V24, P311, DOI 10.1016/j.cmet.2016.07.003
   Corbet C, 2014, CANCER RES, V74, P5507, DOI 10.1158/0008-5472.CAN-14-0705
   Damaghi M, 2017, CELL CYCLE, V16, P1739, DOI 10.1080/15384101.2016.1231284
   Denny SK, 2016, CELL, V166, P328, DOI 10.1016/j.cell.2016.05.052
   Estrella V, 2013, CANCER RES, V73, P1524, DOI 10.1158/0008-5472.CAN-12-2796
   Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210
   Filatova A, 2016, CANCER RES, V76, P5845, DOI 10.1158/0008-5472.CAN-15-2630
   Flinck M, 2018, CELL CYCLE, V17, P1056, DOI [10.1080/15384101.2018.1464850, 10.6084/m9.figshare.6505886]
   Fukumura D, 2001, CANCER RES, V61, P6020
   Jeon MS, 2016, CANCER RES TREAT, V48, P676, DOI 10.4143/crt.2015.153
   Lake SL, 2013, AM J PATHOL, V182, P678, DOI 10.1016/j.ajpath.2012.11.036
   Liu Y, 2016, SCI REP-UK, V6, DOI 10.1038/srep36050
   Moellering RE, 2008, CLIN EXP METASTAS, V25, P411, DOI 10.1007/s10585-008-9145-7
   Pellegrini P, 2014, AUTOPHAGY, V10, P562, DOI 10.4161/auto.27901
   Peppicelli S, 2017, CELL MOL LIFE SCI, V74, P2761, DOI 10.1007/s00018-017-2496-y
   Peppicelli S, 2013, CLIN EXP METASTAS, V30, P957, DOI 10.1007/s10585-013-9595-4
   Riemann A, 2014, PFLUG ARCH EUR J PHY, V466, P2127, DOI 10.1007/s00424-014-1458-6
   Rofstad EK, 2006, CANCER RES, V66, P6699, DOI 10.1158/0008-5472.CAN-06-0983
   Ryder C, 2012, J BIOL CHEM, V287, P27863, DOI 10.1074/jbc.M112.384685
   Semenova EA, 2016, CELL REP, V16, P631, DOI 10.1016/j.celrep.2016.06.020
   Wang L, 2015, INT J CANCER, V136, pE107, DOI 10.1002/ijc.29153
   Wei JL, 2017, ONCOTARGET, V8, P49318, DOI 10.18632/oncotarget.17595
   Wojtkowiak JW, 2012, CANCER RES, V72, P3938, DOI 10.1158/0008-5472.CAN-11-3881
   Yang B, 2018, CANCER MED-US, V7, P1756, DOI 10.1002/cam4.1434
   Zhang T, 2018, ASIA-PAC J CLIN ONCO, V14, pe352, DOI 10.1111/ajco.12982
   Zhao MN, 2016, CELL CYCLE, V15, P1125, DOI 10.1080/15384101.2016.1158374
   Zhou ZH, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-017-0599-9
   Zhou ZH, 2015, J PATHOL, V236, P467, DOI 10.1002/path.4541
NR 34
TC 11
Z9 11
U1 1
U2 10
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1538-4101
EI 1551-4005
J9 CELL CYCLE
JI Cell Cycle
PD FEB 16
PY 2019
VL 18
IS 4
BP 511
EP 522
DI 10.1080/15384101.2019.1578145
PG 12
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA HN7GM
UT WOS:000460357100011
PM 30712429
OA Green Published, Bronze
DA 2022-04-25
ER

PT J
AU Mahalingam, D
   Mita, M
   Sarantopoulos, J
   Wood, L
   Amaravadi, RK
   Davis, LE
   Mita, A
   Curiel, TJ
   Espitia, CM
   Nawrocki, ST
   Giles, FJ
   Carew, JS
AF Mahalingam, Devalingam
   Mita, Monica
   Sarantopoulos, John
   Wood, Leslie
   Amaravadi, Ravi K.
   Davis, Lisa E.
   Mita, Alain
   Curiel, Tyler J.
   Espitia, Claudia M.
   Nawrocki, Steffan T.
   Giles, Francis J.
   Carew, Jennifer S.
TI Combined autophagy and HDAC inhibition A phase I safety, tolerability,
   pharmacokinetic, and pharmacodynamic analysis of hydroxychloroquine in
   combination with the HDAC inhibitor vorinostat in patients with advanced
   solid tumors
SO AUTOPHAGY
LA English
DT Article
DE autophagy; cancer; clinical trial; hydroxychloroquine; vorinostat
ID HISTONE DEACETYLASE INHIBITORS; TARGETING AUTOPHAGY; CANCER-TREATMENT;
   CELL-DEATH; THERAPY; MECHANISMS; RESISTANCE; MODEL; SAHA
AB We previously reported that inhibition of autophagy significantly augmented the anticancer activity of the histone deacetylase (HDAC) inhibitor vorinostat (VOR) through a cathepsin D-mediated mechanism. We thus conducted a first-in-human study to investigate the safety, preliminary efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of the combination of the autophagy inhibitor hydroxychloroquine (HCQ) and VOR in patients with advanced solid tumors. Of 27 patients treated in the study, 24 were considered fully evaluable for study assessments and toxicity. Patients were treated orally with escalating doses of HCQ daily (QD) (d 2 to 21 of a 21-d cycle) in combination with 400 mg VOR QD (d one to 21). Treatment-related adverse events (AE) included grade 1 to 2 nausea, diarrhea, fatigue, weight loss, anemia, and elevated creatinine. Grade 3 fatigue and/or myelosuppression were observed in a minority of patients. Fatigue and gastrointestinal AE were dose-limiting toxicities. Six-hundred milligrams HCQ and 400 mg VOR was established as the maximum tolerated dose and recommended phase II regimen. One patient with renal cell carcinoma had a confirmed durable partial response and 2 patients with colorectal cancer had prolonged stable disease. The addition of HCQ did not significantly impact the PK profile of VOR. Treatment-related increases in the expression of CDKN1A and CTSD were more pronounced in tumor biopsies than peripheral blood mononuclear cells. Based on the safety and preliminary efficacy of this combination, additional clinical studies are currently being planned to further investigate autophagy inhibition as a new approach to increase the efficacy of HDAC inhibitors.
C1 [Mahalingam, Devalingam; Mita, Monica; Sarantopoulos, John; Wood, Leslie; Mita, Alain; Curiel, Tyler J.; Espitia, Claudia M.; Nawrocki, Steffan T.; Giles, Francis J.; Carew, Jennifer S.] Univ Texas Hlth Sci Ctr San Antonio, Canc Therapy & Res Ctr, San Antonio, TX 78229 USA.
   [Mita, Monica; Mita, Alain] Univ Calif Los Angeles, Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA.
   [Amaravadi, Ravi K.] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA.
   [Amaravadi, Ravi K.] Univ Penn, Dept Med, Philadelphia, PA 19104 USA.
   [Davis, Lisa E.] Univ Sci, Philadelphia, PA USA.
   [Giles, Francis J.] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA.
   [Carew, Jennifer S.] Cleveland Clin, Taussig Canc Inst, Cleveland, OH 44106 USA.
RP Carew, JS (corresponding author), Univ Texas Hlth Sci Ctr San Antonio, Canc Therapy & Res Ctr, San Antonio, TX 78229 USA.
EM mahalingam@uthscsa.edu; carewj@ccf.org
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [R21CA139476, P30CA054174]; Merck,
   Inc.Merck & Company; NATIONAL CANCER INSTITUTEUnited States Department
   of Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Cancer Institute (NCI) [R21CA139476, P30CA054174] Funding
   Source: NIH RePORTER
FX This research was supported by NIH grants R21CA139476 (FG) and
   P30CA054174 (TC). The authors would like to thank Merck, Inc. for
   providing vorinostat in support of this study.
CR Amaravadi RK, 2007, J CLIN INVEST, V117, P326, DOI 10.1172/JCI28833
   Amaravadi RK, 2011, CLIN CANCER RES, V17, P654, DOI 10.1158/1078-0432.CCR-10-2634
   Carew JS, 2008, CANCER LETT, V269, P7, DOI 10.1016/j.canlet.2008.03.037
   Carew JS, 2008, CANCER RES, V68, P4783, DOI 10.1158/0008-5472.CAN-07-6483
   Carew JS, 2007, AUTOPHAGY, V3, P464, DOI 10.4161/auto.4311
   Carew JS, 2007, BLOOD, V110, P313, DOI 10.1182/blood-2006-10-050260
   Carew Jennifer S, 2012, Cancer Manag Res, V4, P357, DOI 10.2147/CMAR.S26133
   Carew JS, 2011, J BIOL CHEM, V286, P6602, DOI 10.1074/jbc.M110.151324
   Carew Jennifer S, 2008, Biologics, V2, P201
   Carew JS, 2010, J CELL MOL MED, V14, P2448, DOI 10.1111/j.1582-4934.2009.00832.x
   Guo JY, 2011, GENE DEV, V25, P460, DOI 10.1101/gad.2016311
   Janku F, 2011, NAT REV CLIN ONCOL, V8, P528, DOI 10.1038/nrclinonc.2011.71
   Kelly WK, 2005, J CLIN ONCOL, V23, P3923, DOI 10.1200/JCO.2005.14.167
   Lane AA, 2009, J CLIN ONCOL, V27, P5459, DOI 10.1200/JCO.2009.22.1291
   Lazova R, 2012, CLIN CANCER RES, V18, P370, DOI 10.1158/1078-0432.CCR-11-1282
   Lee JH, 2012, ADV CANCER RES, V116, P39, DOI 10.1016/B978-0-12-394387-3.00002-1
   Lin Y, 2001, Biostatistics, V2, P203, DOI 10.1093/biostatistics/2.2.203
   McAfee Q, 2012, P NATL ACAD SCI USA, V109, P8253, DOI 10.1073/pnas.1118193109
   Parise RA, 2006, J CHROMATOGR B, V840, P108, DOI 10.1016/j.jchromb.2006.04.044
   Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45
   Rangwala R, 2014, AUTOPHAGY, V10, P1391, DOI 10.4161/auto.29119
   Rangwala R, 2014, AUTOPHAGY, V10, P1369, DOI 10.4161/auto.29118
   Rao R, 2012, MOL CANCER THER, V11, P973, DOI 10.1158/1535-7163.MCT-11-0979
   Robey RW, 2011, MOL PHARMACEUT, V8, P2021, DOI 10.1021/mp200329f
   Rosenfeld MR, 2014, AUTOPHAGY, V10, P1359, DOI 10.4161/auto.28984
   Rubinsztein DC, 2012, NAT REV DRUG DISCOV, V11, P709, DOI 10.1038/nrd3802
   Shao YF, 2004, P NATL ACAD SCI USA, V101, P18030, DOI 10.1073/pnas.0408345102
   Spiegel S, 2012, ONCOGENE, V31, P537, DOI 10.1038/onc.2011.267
   Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205
   Torgersen ML, 2013, BLOOD, V122, P2467, DOI 10.1182/blood-2013-05-500629
   Trotti A, 2003, SEMIN RADIAT ONCOL, V13, P176, DOI 10.1016/S1053-4296(03)00031-6
   Vogl DT, 2014, AUTOPHAGY, V10, P1380, DOI 10.4161/auto.29264
   White E, 2012, NAT REV CANCER, V12, P401, DOI 10.1038/nrc3262
   Yang ZF, 2010, CURR OPIN CELL BIOL, V22, P124, DOI 10.1016/j.ceb.2009.11.014
NR 34
TC 184
Z9 187
U1 2
U2 21
PU LANDES BIOSCIENCE
PI AUSTIN
PA 1806 RIO GRANDE ST, AUSTIN, TX 78702 USA
SN 1554-8627
EI 1554-8635
J9 AUTOPHAGY
JI Autophagy
PD AUG
PY 2014
VL 10
IS 8
BP 1403
EP 1414
DI 10.4161/auto.29231
PG 12
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA AN0HU
UT WOS:000340266200006
PM 24991835
OA Green Published, Bronze
DA 2022-04-25
ER

PT J
AU Meng, CQ
   Zhou, X
   Teng, YH
   Wu, CN
   Wu, J
   Tian, F
   Zhou, Y
   Zou, X
   Wang, RP
AF Meng, Chunqin
   Zhou, Xue
   Teng, Yuhao
   Wu, Cunen
   Wu, Jian
   Tian, Fang
   Zhou, Yao
   Zou, Xi
   Wang, Ruiping
TI Mechanisms of Raddeanin A-induced autophagy and apoptosis in human
   colorectal cancer cells
SO INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE
LA English
DT Article
DE Raddeanin A; autophagy; apoptosis; HCT116 cells; induce
AB Several studies have confirmed that the Chinese medicine Raddeanin A (RA), which is extracted from the plant Anemone raddeana Regel, can inhibit the proliferation of a variety of tumor cell lines. Previously, our team demonstrated that RA could induce apoptosis and autophagy in human gastric cancer cells. Objective: This experiment was intended to explore whether RA can induce autophagy and apoptosis in human colorectal cancer HCT116 cells and to investigate the mechanisms and relationship between autophagy and apoptosis. Methods: Cell proliferation was detected via MTT assay. Transmission electron microscope was used to observe autophagosomes as a marker for autophagy. Apoptosis was examined via Hoechst 33258 staining. Flowcytometry was used to calculate the rate of apoptosis. The expression of related genes and proteins were tested by reverse transcription-polymerase chain reaction (RT-PCR) and western blot, respectively. Results: Cell viability gradually decreased with an increase of drug concentration and disposal time. This result indicated that RA could significantly inhibit the growth of HCT116 cells in a manner that was both time-and concentration dependent. RA induced autophagy and apoptosis in HCT116 cells. RT-PCR and western blot showed that the expression of genes and proteins related to autophagy increased. Moreover, the expression of proteins that suppress apoptosis decreased while pro-apoptotic protein levels increased. The expression of proteins involved in the PI3K-AKT-mTOR signaling pathway also decreased, while caspase-8 and 9 levels increased. Compared with RA treatment alone, the apoptosis rate decreased when HCT116 cells were treated with RA and hydroxychloroquine (HCQ) together. However, when RA and rapamycin (RAPA) were given together, the apoptosis rate increased. Conclusion: RA induces autophagy by regulating the PI3K-AKT-mTOR signaling pathway and apoptosis through intrinsic and extrinsic pathways. Autophagy induced by RA in HCT116 cells can promote cell apoptosis.
C1 [Meng, Chunqin; Teng, Yuhao; Wu, Jian; Tian, Fang; Zou, Xi; Wang, Ruiping] Nanjing Univ Chinese Med, Jiangsu Prov Hosp Tradit Chinese Med, Dept Oncol, Affiliated Hosp, Nanjing 210029, Jiangsu, Peoples R China.
   [Meng, Chunqin; Wu, Cunen; Zhou, Yao] Nanjing Univ Chinese Med, Dept Clin Med Coll 1, Nanjing 210023, Jiangsu, Peoples R China.
   [Zhou, Xue] Nanjing Hosp Tradit Chinese Med, Dept Acupuncture, Nanjing 210029, Jiangsu, Peoples R China.
RP Zou, X; Wang, RP (corresponding author), Nanjing Univ Chinese Med, Affiliated Hosp, Dept Oncol, Nanjing 210029, Jiangsu, Peoples R China.
EM zxvery@162.com; wrp61@163.com
OI Teng, YU-hao/0000-0002-1475-1599
FU State Administration of Traditional Chinese Medicine of China
   [JDZX2012087]; Jiangsu Provincial Commission of Health and Family
   Planning [BJ14013]; Talent Project of Traditional Chinese Medicine in
   Jiangsu Province [LJ200908]; Innovation Project Research of Ordinary
   University in Jiangsu Province [KYLX16_ 1145]; People Pro-gramme of the
   European Union's Seventh Framework Programme (FP7) under REA grant
   [PIRSES-GA-2013-61258]
FX This work was supported by the State Administration of Traditional
   Chinese Medicine of China (grant# JDZX2012087), Jiangsu Provincial
   Commission of Health and Family Planning (grant# BJ14013), Talent
   Project of Traditional Chinese Medicine in Jiangsu Province (No.
   LJ200908), the Innovation Project Research of Ordinary University in
   Jiangsu Province (No. KYLX16_ 1145), and the People Pro-gramme of the
   European Union's Seventh Framework Programme (FP7/2007-2013/under REA
   grant agreement No. PIRSES-GA-2013-61258: China and Europe taking care
   of healthcare solutions.
CR Dayou L, 2005, ACAD PERIODICAL CHAN, V19, P71
   Guan YY, 2015, PHYTOMEDICINE, V22, P103, DOI 10.1016/j.phymed.2014.11.008
   Hui L., 2013, RES EFFECT AKT BETTA
   Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]
   Kihara A, 2001, J CELL BIOL, V152, P519, DOI 10.1083/jcb.152.3.519
   Li BX, 2010, CHIN J CLIN, V4, P395
   Mathew R, 2007, NAT REV CANCER, V7, P961, DOI 10.1038/nrc2254
   Mokarram P, 2017, AUTOPHAGY, V13, P781, DOI 10.1080/15548627.2017.1290751
   Price TJ, 2017, LANCET ONCOL, V18, P157, DOI 10.1016/S1470-2045(17)30002-5
   Qian S, 2014, CHEM PHARM BULL, V62, P779, DOI 10.1248/cpb.c14-00138
   Teng YH, 2016, EVID-BASED COMPL ALT, V2016, DOI 10.1155/2016/9406758
   US Cancer Statistics Working Group, 2010, US CANC STAT USCS 19
   Wang Ming-Kui, 2008, Ai Zheng, V27, P910
   Xiaoyi W., 2004, CHINESE J ANAL CHEM, V32, P587
   Xue G, 2013, BIOCHEM BIOPH RES CO, V439, P196, DOI 10.1016/j.bbrc.2013.08.060
   Yanagisawa H, 2003, CELL DEATH DIFFER, V10, P798, DOI 10.1038/sj.cdd.4401246
   Yang JW, 2013, RES RELATIONSHIP MEC, P12
   Yee KS, 2009, CELL DEATH DIFFER, V16, P1135, DOI 10.1038/cdd.2009.28
   Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X
   [张嘉岷 Zhang Jiamin], 2003, [中国新药杂志, Chinese Journal New Drugs], V12, P191
   Zhongjie Z, 2004, CHINESE PHARM J, V39, P493
   刘丹, 2014, [中药药理与临床, Pharmacology and Clinics of Chinese Materia Medica], V30, P49
NR 22
TC 0
Z9 0
U1 0
U2 1
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1940-5901
J9 INT J CLIN EXP MED
JI Int. J. Clin. Exp. Med.
PY 2017
VL 10
IS 11
BP 15766
EP 15774
PG 9
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA FO5IA
UT WOS:000416885900102
DA 2022-04-25
ER

PT J
AU Kang, KB
   Zhu, CJ
   Yong, SK
   Gao, QH
   Wong, MC
AF Kang, Khong Bee
   Zhu, Congju
   Yong, Sook Kwin
   Gao, Qiuhan
   Wong, Meng Cheong
TI Enhanced sensitivity of celecoxib in human glioblastoma cells: Induction
   of DNA damage leading to p53-dependent G(1) cell cycle arrest and
   autophagy
SO MOLECULAR CANCER
LA English
DT Article
ID COX-2 INHIBITOR CELECOXIB; COLON-CARCINOMA CELLS; U87MG GLIOMA-CELLS;
   DOWN-REGULATION; CANCER-CELLS; IN-VITRO; CYCLOOXYGENASE-2 INHIBITORS;
   INDUCED APOPTOSIS; STRAND BREAKS; TUMOR-GROWTH
AB Background: Selective cyclooxygenase (COX)-2 inhibitors elicit anti-proliferative responses in various tumours, however the underlying anti-tumour mechanisms are unclear. Mutational inactivation of the tumour suppressor p53 gene is frequent in malignant gliomas. The role of p53 mutation in the anti-tumour responses of the selective COX-2 inhibitor celecoxib in human glioblastoma cells is unknown. In this study, we used human glioblastoma cells with various p53 status; U87MG (with high and low p53 functional levels), LN229 (functional p53) and U373MG (mutant p53) cells. Inhibition of p53 was achieved in U87MG cells transfected with E6 oncoprotein (U87MG-E6) and treated with pifithrin-alpha, a reversible inhibitor of p53 (U87MG-PFT). We investigated whether the anti-glioblastoma responses of celecoxib were p53-dependent, and whether celecoxib induced DNA damage leading to p53-dependent G(1) cell cycle arrest, followed by autophagy or apoptosis.
   Results: Our findings demonstrated that celecoxib concentration-dependently reduced glioblastoma cell viability, following 24 and 72 hours of treatment. Inhibition of functional p53 in glioblastoma cells significantly reduced the anti-proliferative effect of celecoxib. In U87MG cells, celecoxib (8 and 30 mu M) significantly induced DNA damage and inhibited DNA synthesis, corresponding with p53 activation. Celecoxib induced G(1)-phase cell cycle arrest, accompanied with p21 activation in U87MG cells. Cell cycle progression of U87MG-E6 and U87MG-PFT cells was not affected by celecoxib. In parallel, celecoxib induced G(1) cell cycle arrest in LN229 cells, but not in U373MG cells. Autophagy was induced by celecoxib in U87MG and LN229 cells, as shown by the significantly greater population of acridine orange-stained cells and increased levels of LC3-II protein (in comparison with non-treated controls). Celecoxib did not induce significant autophagy in U87MG-PFT, U87MG-E6 and U373MG cells, which lack functional p53. Regardless of p53 status, celecoxib caused no significant difference in apoptosis level of U87MG, U87MG-PFT, U87MG-E6 and U373MG cells.
   Conclusion: Our findings reveal that p53 increases human glioblastoma sensitivity to celecoxib. Celecoxib inhibits glioblastoma cell viability by induction of DNA damage, leading to p53-dependent G(1) cell cycle arrest and p53-dependent autophagy, but not apoptosis.
C1 [Kang, Khong Bee; Zhu, Congju; Yong, Sook Kwin; Gao, Qiuhan; Wong, Meng Cheong] Natl Canc Ctr, Humphrey Oei Inst Canc Res, Div Med Sci, Brain Tumour Res Lab, Singapore 169610, Singapore.
RP Kang, KB (corresponding author), Natl Canc Ctr, Humphrey Oei Inst Canc Res, Div Med Sci, Brain Tumour Res Lab, 11 Hosp Dr, Singapore 169610, Singapore.
EM dmskkb@nccs.com.sg; dmszcj@nccs.com.sg; nmsyskg@nccs.com.sg;
   chrisgqh@yahoo.com.sg; dmswmc@nccs.com.sg
RI ZHU, CONGJU/H-6369-2011
FU Singhealth Foundation, SingaporeSingHealth [SHF/FG023/2004]; Singapore
   Millennium Foundation, Singapore.Singapore Millennium Foundation
FX The authors would like to thank A/Prof. Russell Pieper (UCSF
   Comprehensive Cancer Centre, San Francisco, CA) for providing the stable
   transfectant U87MG-E6 cells, and Yin Ling Wong for technical assistance
   in performing part of the cell viability assays. This study was
   supported by a grant from Singhealth Foundation, Singapore
   (SHF/FG023/2004). K. B. Kang was a recipient of the Post-doctoral
   Research Fellowship from the Singapore Millennium Foundation, Singapore.
CR Arico S, 2002, J BIOL CHEM, V277, P27613, DOI 10.1074/jbc.M201119200
   Batista LFZ, 2007, CANCER RES, V67, P11886, DOI 10.1158/0008-5472.CAN-07-2964
   Cervi D, 2004, ONCOGENE, V23, P2305, DOI 10.1038/sj.onc.1207400
   Crighton D, 2006, CELL, V126, P121, DOI 10.1016/j.cell.2006.05.034
   Deininger MH, 1999, ACTA NEUROPATHOL, V98, P240, DOI 10.1007/s004010051075
   Dvory-Sobol H, 2006, EUR J CANCER, V42, P422, DOI 10.1016/j.ejca.2005.11.009
   ELDEIRY WS, 1994, CANCER RES, V54, P1169
   Feng ZH, 2005, P NATL ACAD SCI USA, V102, P8204, DOI 10.1073/pnas.0502857102
   Grosch S, 2001, FASEB J, V15, P2742, DOI 10.1096/fj.01-0299fje
   Grosch S, 2005, BIOCHEM PHARMACOL, V69, P831, DOI 10.1016/j.bcp.2004.11.026
   Han C, 2004, CANCER RES, V64, P1369, DOI 10.1158/0008-5472.CAN-03-1086
   Hida T, 1998, CANCER RES, V58, P3761
   Hippert MM, 2006, CANCER RES, V66, P9349, DOI 10.1158/0008-5472.CAN-06-1597
   Ho CC, 2003, EUR J CLIN INVEST, V33, P875, DOI 10.1046/j.1365-2362.2003.01240.x
   Hsu CS, 2002, BIOCHEM BIOPH RES CO, V293, P705
   Joki T, 2000, CANCER RES, V60, P4926
   Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720
   Kang KB, 2007, INT J RADIAT ONCOL, V67, P888, DOI 10.1016/j.ijrobp.2006.09.055
   Kardosh A, 2004, CANCER BIOL THER, V3, P55, DOI 10.4161/cbt.3.1.571
   Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717
   Komarova EA, 2000, BIOCHEMISTRY-MOSCOW+, V65, P41
   Lee SH, 2005, J BIOL CHEM, V280, P28337, DOI 10.1074/jbc.M504178200
   Levin VA, 2006, J NEURO-ONCOL, V78, P85, DOI 10.1007/s11060-005-9062-4
   Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1
   Levine B, 2008, NAT CELL BIOL, V10, P637, DOI 10.1038/ncb0608-637
   Liu WM, 2003, AM J CLIN ONCOL-CANC, V26, pS103, DOI 10.1097/00000421-200308002-00013
   Maier TJ, 2004, BIOCHEM PHARMACOL, V67, P1469, DOI 10.1016/j.bcp.2003.12.014
   Marnett LJ, 1999, J BIOL CHEM, V274, P22903, DOI 10.1074/jbc.274.33.22903
   Masferrer JL, 2000, CANCER RES, V60, P1306
   Matsuo M, 2001, ACTA NEUROPATHOL, V102, P181
   Matthias C, 2006, ANTICANCER RES, V26, P2003
   Mazzanti R, 2009, BIOCHEM PHARMACOL, V78, P21, DOI 10.1016/j.bcp.2009.03.013
   McAdam BF, 1999, P NATL ACAD SCI USA, V96, P272, DOI 10.1073/pnas.96.1.272
   MILAS L, 1990, CANCER RES, V50, P4473
   Nam DH, 2004, ONCOL REP, V11, P263
   Narayanan BA, 2003, CLIN CANCER RES, V9, P3503
   NEWCOMB EW, 1993, BRAIN PATHOL, V3, P229, DOI 10.1111/j.1750-3639.1993.tb00749.x
   Norbury CJ, 2004, ONCOGENE, V23, P2797, DOI 10.1038/sj.onc.1207532
   Paglin S, 2001, CANCER RES, V61, P439
   Petersen C, 2000, CLIN CANCER RES, V6, P2513
   Portnow J, 2002, NEURO-ONCOLOGY, V4, P22, DOI 10.1093/neuonc/4.1.22
   Pyrko P, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-19
   Qiao L, 1998, BIOCHEM PHARMACOL, V55, P53, DOI 10.1016/S0006-2952(97)00400-0
   Ryan EP, 2008, CANCER IMMUNOL IMMUN, V57, P347, DOI 10.1007/s00262-007-0374-4
   Seo SK, 2007, APOPTOSIS, V12, P195, DOI 10.1007/s10495-006-0527-5
   Shiff SJ, 1999, J EXP MED, V190, P445, DOI 10.1084/jem.190.4.445
   Shono T, 2001, CANCER RES, V61, P4375
   Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330
   Swamy MV, 2003, CANCER RES, V63, P5239
   Tardieu D, 2000, CARCINOGENESIS, V21, P973, DOI 10.1093/carcin/21.5.973
   TESSITORE L, 1988, BIOCHEM J, V251, P483, DOI 10.1042/bj2510483
   Xu GW, 2005, INT J CANCER, V116, P187, DOI 10.1002/ijc.21071
   Xu GW, 2001, CANCER RES, V61, P4155
   Yao KC, 2003, J NEUROSURG, V98, P378, DOI 10.3171/jns.2003.98.2.0378
   Yoshinaka R, 2006, ANTICANCER RES, V26, P4245
   Zeng XH, 2007, CLIN CANCER RES, V13, P1315, DOI 10.1158/1078-0432.CCR-06-1517
NR 56
TC 69
Z9 73
U1 1
U2 10
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1476-4598
J9 MOL CANCER
JI Mol. Cancer
PD AUG 25
PY 2009
VL 8
AR 66
DI 10.1186/1476-4598-8-66
PG 16
WC Biochemistry & Molecular Biology; Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology
GA 496DS
UT WOS:000269950000001
PM 19706164
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Jiang, YW
   Xiao, LB
   Fu, WW
   Tang, YX
   Lertnimitphun, P
   Kim, N
   Zheng, CW
   Tan, HS
   Lu, Y
   Xu, HX
AF Jiang, Yiwen
   Xiao, Lianbo
   Fu, Wenwei
   Tang, Yuexun
   Lertnimitphun, Peeraphong
   Kim, Nami
   Zheng, Changwu
   Tan, Hongsheng
   Lu, Yue
   Xu, Hongxi
TI Gaudichaudione H Inhibits Inflammatory Responses in Macrophages and
   Dextran Sodium Sulfate-Induced Colitis in Mice
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE gaudichaudione H; macrophages; colitis; nitric oxide; nuclear
   factor-kappa B; mitogen-activated protein kinases
ID LPS-INDUCED INFLAMMATION; NF-KAPPA-B; SIGNALING PATHWAYS; NITRIC-OXIDE;
   ACTIVATION; GARCINIA; MECHANISMS; EXPRESSION; RECEPTORS; INDUCTION
AB Macrophages-involved inflammation is considered to induce the damage in various diseases. Herein, novel therapeutics inhibiting over-activation of macrophages could prove an effective strategy to prevent inflammation-related diseases. Gaudichaudione H (GH), which is a natural small molecular compound isolated from Garcinia oligantha Merr. (Clusiaceae) has previously been demonstrated its anti-cancer effects on several cancer cell lines. However, no report has been published about the anti-inflammatory effect of GH to date. This study aims to examine the anti-inflammatory effects and potential molecular mechanism of GH, and provide new insights toward the treatment of inflammation. GH inhibited nitric oxide (NO) production, inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) expression, cytokine interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) production, and messenger RNA (mRNA) expression to attenuate inflammatory responses in lipopolysaccharide (LPS)-induced RAW 264.7 cells or stimulated bone marrow-derived macrophages (BMDMs). GH inhibited nuclear factor-kappa B (NF-kappa B) and mitogen-activated protein kinase (MAPK) pathways, the nuclear translocation of transcription factors NF-kappa B and activator protein 1 (AP-1), as well as upstream signaling of the toll-like receptor 4 (TLR4)-myeloid differentiation primary response 88 (MyD88) pathway in stimulated macrophages. Furthermore, the result of the intracellular signaling array showed that the phosphorylation of adenosine 5'-monophosphate-activated protein kinase-alpha (AMPK alpha), proline-rich Akt substrate of 40 kDa (PRAS40), and p38 could be down regulated by GH in BMDMs, indicating that the mechanism by which GH inhibited inflammation may be also associated with the energy metabolism pathway, PRAS40-mediated NF-kappa B pathway, cell proliferation, apoptosis, and autophagy, etc. In addition, GH alleviated dextran sodium sulfate (DSS)-induced colitis in mice by ameliorating weight loss, stool consistency change, blood in the stool, and colon shortening. GH decreased the protein and mRNA levels of IL-6 and TNF-alpha, iNOS and COX-2 mRNA expression, the activation of NF-kappa B and MAPK pathways, the phosphorylation of AMPK alpha and PRAS40, histological damage, and infiltration of macrophages in the colons of mice with DSS-induced colitis. Taken together, our results support that GH exerts the anti-inflammatory effects in macrophages in vitro through regulation of NF-kappa B and MAPK pathways, and DSS-induced colitis mouse model in vivo. These findings suggest that GH may be a promising candidate in treating macrophage-related inflammatory disease.
C1 [Jiang, Yiwen; Fu, Wenwei; Tang, Yuexun; Lertnimitphun, Peeraphong; Kim, Nami; Zheng, Changwu; Tan, Hongsheng; Lu, Yue; Xu, Hongxi] Shanghai Univ Tradit Chinese Med, Sch Pharm, Shanghai, Peoples R China.
   [Xiao, Lianbo] Shanghai Acad Chinese Med Sci, Guanghua Integrat Med Hosp, Inst Arthrit Res, Shanghai, Peoples R China.
RP Lu, Y; Xu, HX (corresponding author), Shanghai Univ Tradit Chinese Med, Sch Pharm, Shanghai, Peoples R China.
EM lvyue126@hotmail.com; xuhongxi88@gmail.com
RI Xu, Hongxi/AAC-2799-2020; Zheng, Changwu/P-5319-2014
OI Zheng, Changwu/0000-0002-0869-8314; Xu, Hongxi/0000-0001-6238-4511
FU National Natural Science Foundation of China (NSFC)National Natural
   Science Foundation of China (NSFC) [81803545, 81602990]; Professor of
   Special Appointment (Eastern Scholar) at Shanghai Institutions of Higher
   Learning; Three-year development plan project for Traditional Chinese
   Medicine [ZY(2018-2020)-CCCX-2001-02]
FX This work was financially sponsored by grants from the National Natural
   Science Foundation of China (NSFC) Grants 81803545 and 81602990;
   Professor of Special Appointment (Eastern Scholar) at Shanghai
   Institutions of Higher Learning; the Three-year development plan project
   for Traditional Chinese Medicine (ZY(2018-2020)-CCCX-2001-02) for
   financial support.
CR Abarikwu SO, 2014, BBA-GEN SUBJECTS, V1840, P2373, DOI 10.1016/j.bbagen.2014.03.006
   Aderem A, 2000, NATURE, V406, P782, DOI 10.1038/35021228
   Ajibade AA, 2013, TRENDS IMMUNOL, V34, P307, DOI 10.1016/j.it.2013.03.007
   Aktan F, 2004, LIFE SCI, V75, P639, DOI 10.1016/j.lfs.2003.10.042
   Biswas SK, 2010, NAT IMMUNOL, V11, P889, DOI 10.1038/ni.1937
   Chiarugi V, 1998, INT J MOL MED, V2, P715
   Dong C, 2002, ANNU REV IMMUNOL, V20, P55, DOI 10.1146/annurev.immunol.20.091301.131133
   Duque GA, 2014, FRONT IMMUNOL, V5, P1, DOI 10.3389/fimmu.2014.00491
   Fujioka S, 2004, MOL CELL BIOL, V24, P7806, DOI 10.1128/MCB.24.17.7806-7819.2004
   Fujiwara Nagatoshi, 2005, Current Drug Targets - Inflammation and Allergy, V4, P281, DOI 10.2174/1568010054022024
   Fusella F, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01829-1
   Gao XM, 2012, BIOORG MED CHEM LETT, V22, P2350, DOI 10.1016/j.bmcl.2012.01.068
   Guha M, 2001, CELL SIGNAL, V13, P85, DOI 10.1016/S0898-6568(00)00149-2
   Hamidzadeh K, 2017, ANNU REV PHYSIOL, V79, P567, DOI 10.1146/annurev-physiol-022516-034348
   Hoesel B, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-86
   Jhanwar-Uniyal Meena, 2017, Advances in Biological Regulation, V64, P39, DOI 10.1016/j.jbior.2016.12.001
   Kagan JC, 2006, CELL, V125, P943, DOI 10.1016/j.cell.2006.03.047
   Kam PCA, 2000, ANAESTHESIA, V55, P442, DOI 10.1046/j.1365-2044.2000.01271.x
   Kaminska B, 2005, BBA-PROTEINS PROTEOM, V1754, P253, DOI 10.1016/j.bbapap.2005.08.017
   Khan NM, 2017, FREE RADICAL BIO MED, V106, P288, DOI 10.1016/j.freeradbiomed.2017.02.041
   Kumar S, 2013, FITOTERAPIA, V89, P86, DOI 10.1016/j.fitote.2013.05.010
   Lai JL, 2017, INFLAMMATION, V40, P1, DOI 10.1007/s10753-016-0447-7
   Lee S, 2015, PLOS ONE, V10, DOI [10.1371/journal.pone.0136385, 10.1371/journal.pone.0128448]
   Leonhardt A, 2003, BRIT J PHARMACOL, V138, P655, DOI 10.1038/sj.bjp.0705092
   Libman A, 2006, J ETHNOPHARMACOL, V106, P303, DOI 10.1016/j.jep.2005.11.034
   Liu T, 2017, SIGNAL TRANSDUCT TAR, V2, DOI 10.1038/sigtrans.2017.23
   Lu Y, 2018, BRIT J PHARMACOL, V175, P1085, DOI 10.1111/bph.14150
   Lu Y, 2016, BIOCHEM PHARMACOL, V100, P61, DOI 10.1016/j.bcp.2015.11.004
   Lu Y, 2015, MOL CELL BIOCHEM, V406, P263, DOI 10.1007/s11010-015-2444-9
   Na YR, 2019, NAT REV GASTRO HEPAT, V16, P531, DOI 10.1038/s41575-019-0172-4
   Ordas I, 2012, LANCET, V380, P1606, DOI 10.1016/S0140-6736(12)60150-0
   Park JY, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171322
   Perse M, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/718617
   Qi SM, 2012, INT IMMUNOPHARMACOL, V12, P278, DOI 10.1016/j.intimp.2011.12.001
   Sharma J. N., 2007, Inflammopharmacology, V15, P252, DOI 10.1007/s10787-007-0013-x
   Syam S, 2014, J ETHNOPHARMACOL, V153, P435, DOI 10.1016/j.jep.2014.02.051
   Talley NJ, 2011, AM J GASTROENTEROL, V106, pS2, DOI 10.1038/ajg.2011.58
   Tang YX, 2016, J NAT PROD, V79, P1752, DOI 10.1021/acs.jnatprod.6b00137
   Wang L, 2017, P NATL ACAD SCI USA, V114, P13507, DOI 10.1073/pnas.1714386114
   Wang QH, 2013, J ETHNOPHARMACOL, V146, P9, DOI 10.1016/j.jep.2012.12.013
   Wang W, 2015, BIOCHEM BIOPH RES CO, V462, P119, DOI 10.1016/j.bbrc.2015.04.097
   Wen XD, 2013, AM J CHINESE MED, V41, P1097, DOI 10.1142/S0192415X13500742
   Ye JP, 2013, FRONT MED-PRC, V7, P14, DOI 10.1007/s11684-013-0262-6
   Zhang D., 2015, SCI REP, V5, P1
   Zhu G, 2017, ONCOGENESIS, V6, DOI 10.1038/oncsis.2017.80
NR 45
TC 3
Z9 4
U1 6
U2 14
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1663-9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD JAN 17
PY 2020
VL 10
AR 1561
DI 10.3389/fphar.2019.01561
PG 17
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA KH8OY
UT WOS:000510911300001
PM 32009962
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Liu, CC
   DeRoo, EP
   Stecyk, C
   Wolsey, M
   Szuchnicki, M
   Hagos, EG
AF Liu, Changchang
   DeRoo, Elise P.
   Stecyk, Catherine
   Wolsey, Margaret
   Szuchnicki, Mateusz
   Hagos, Engda G.
TI Impaired autophagy in mouse embryonic fibroblasts null for Kruppel-like
   Factor 4 promotes DNA damage and increases apoptosis upon serum
   starvation
SO MOLECULAR CANCER
LA English
DT Article
DE Kruppel-like Factor 4; Autophagy; Apoptosis; Mammalian target of
   rapamycin; DNA damage; Mouse embryonic fibroblasts; Autophagy related
   genes
ID TRANSCRIPTION FACTOR KLF4; TUMOR-SUPPRESSOR GENE; COLORECTAL-CANCER;
   DOWN-REGULATION; CELL-DEATH; MTOR; TUMORIGENESIS; MACROAUTOPHAGY;
   INHIBITION; KRUPPEL-LIKE-FACTOR-4
AB Background: Autophagy is a major cellular process by which cytoplasmic components such as damaged organelles and misfolded proteins are recycled. Although low levels of autophagy occur in cells under basal conditions, certain cellular stresses including nutrient depletion, DNA damage, and oxidative stress are known to robustly induce autophagy. Kruppel-like factor 4 (KLF4) is a zinc-finger transcription factor activated during oxidative stress to maintain genomic stability. Both autophagy and KLF4 play important roles in response to stress and function in tumor suppression.
   Methods: To explore the role of KLF4 on autophagy in mouse embryonic fibroblasts (MEFs), we compared wild-type with Klf4 deficient cells. To determine the levels of autophagy, we starved MEFs for different times with Earle's balanced salts solution (EBSS). Rapamycin was used to manipulate mTOR activity and autophagy. The percentage of cells with gamma-H2AX foci, a marker for DNA damage, and punctate pattern of GFP-LC3 were counted by confocal microscopy. The effects of the drug treatments, Klf4 overexpression, or Klf4 transient silencing on autophagy were analyzed using Western blot. Trypan Blue assay and flow cytometry were used to study cell viability and apoptosis, respectively. qPCR was also used to assay basal and the effects of Klf4 overexpression on Atg7 expression levels.
   Results: Here our data suggested that Klf4(-/-) MEFs exhibited impaired autophagy, which sensitized them to cell death under nutrient deprivation. Secondly, DNA damage in Klf4-null MEFs increased after treatment with EBSS and was correlated with increased apoptosis. Thirdly, we found that Klf4(-/-) MEFs showed hyperactive mTOR activity. Furthermore, we demonstrated that rapamycin reduced the increased level of mTOR in Klf4-/-MEFs, but did not restore the level of autophagy. Finally, re-expression of Klf4 in Klf4 deficient MEFs resulted in increased levels of LC3II, a marker for autophagy, and Atg7 expression level when compared to GFP-control transfected Klf4(-/-) MEFs.
   Conclusion: Taken together, our results strongly suggest that KLF4 plays a critical role in the regulation of autophagy and suppression of mTOR activity. In addition, we showed that rapamycin decreased the level of mTOR in Klf4(-/-) MEFs, but did not restore autophagy. This suggests that KLF4 regulates autophagy through both mTOR-dependent and independent mechanisms. Furthermore, for the first time, our findings provide novel insights into the mechanism by which KLF4 perhaps prevents DNA damage and apoptosis through activation of autophagy.
C1 [Liu, Changchang; DeRoo, Elise P.; Stecyk, Catherine; Wolsey, Margaret; Szuchnicki, Mateusz; Hagos, Engda G.] Colgate Univ, Dept Biol, Hamilton, NY 13346 USA.
   [DeRoo, Elise P.] Boston Childrens Hosp, Program Cellular & Mol Med, Boston, MA 02115 USA.
   [DeRoo, Elise P.] Harvard Univ, Sch Med Sch, Boston, MA 02115 USA.
   [Stecyk, Catherine] Tufts Univ, Cummings Sch Vet Med, North Grafton, MA 01536 USA.
RP Hagos, EG (corresponding author), Colgate Univ, Dept Biol, 13 Oak Dr,Olin Hall 205A, Hamilton, NY 13346 USA.
EM ehagos@colgate.edu
RI , ehagos/AAY-8486-2020
FU Colgate University Research Council
FX This work was supported in part by Picker Research Fellowship and Major
   Grant from Colgate University Research Council. We acknowledge the lab
   of Dr. Vincent W. Yang (Stony Brook Medical School, NY) for providing
   KLF4-GFP and GFP constructs. The authors would also like to thank Dr.
   Kenneth Belanger for critically reviewing the manuscript.
CR Abedin MJ, 2007, CELL DEATH DIFFER, V14, P500, DOI 10.1038/sj.cdd.4402039
   El-Karim EA, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-89
   Evans PM, 2008, ACTA BIOCH BIOPH SIN, V40, P554, DOI 10.1111/j.1745-7270.2008.00439.x
   Foster KW, 2005, ONCOGENE, V24, P1491, DOI 10.1038/sj.onc.1208307
   Foster KW, CANC RES
   GarrettSinha LA, 1996, J BIOL CHEM, V271, P31384, DOI 10.1074/jbc.271.49.31384
   Geng JF, 2008, EMBO REP, V9, P859, DOI 10.1038/embor.2008.163
   Glick D, 2010, J PATHOL, V221, P3, DOI 10.1002/path.2697
   Gulhati P, 2009, CLIN CANCER RES, V15, P7207, DOI 10.1158/1078-0432.CCR-09-1249
   Hagos EG, 2009, ONCOGENE, V28, P1197, DOI 10.1038/onc.2008.465
   Hagos EG, 2011, AM J CANCER RES, V1, P85
   Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704
   Hu WX, 2009, CLIN CANCER RES, V15, P5688, DOI 10.1158/1078-0432.CCR-09-0310
   Jackson WT, 2005, PLOS BIOL, V3, P861, DOI 10.1371/journal.pbio.0030156
   Jin SK, 2006, AUTOPHAGY, V2, P80, DOI 10.4161/auto.2.2.2460
   Jung CH, 2010, FEBS LETT, V584, P1287, DOI 10.1016/j.febslet.2010.01.017
   Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720
   Kabeya Y, 2004, J CELL SCI, V117, P2805, DOI 10.1242/jcs.01131
   Karantza-Wadsworth V, 2007, GENE DEV, V21, P1621, DOI 10.1101/gad.1565707
   Katz JP, 2002, DEVELOPMENT, V129, P2619
   Komatsu M, 2005, J CELL BIOL, V169, P425, DOI 10.1083/jcb.200412022
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Liu CC, 2015, MOL CARCINOGEN, V54, P889, DOI 10.1002/mc.22161
   Marino G, 2007, J BIOL CHEM, V282, P18573, DOI 10.1074/jbc.M701194200
   Mathew R, 2007, NAT REV CANCER, V7, P961, DOI 10.1038/nrc2254
   Mathew R, 2007, GENE DEV, V21, P1367, DOI 10.1101/gad.1545107
   Mathew R, 2011, CURR OPIN GENET DEV, V21, P113, DOI 10.1016/j.gde.2010.12.008
   Mehrpour M, 2010, CELL RES, V20, P748, DOI 10.1038/cr.2010.82
   Mizushima N, 2010, CELL, V140, P313, DOI 10.1016/j.cell.2010.01.028
   Ng S, 2011, AUTOPHAGY, V7, P1173, DOI 10.4161/auto.7.10.16681
   Ohnishi S, 2003, BIOCHEM BIOPH RES CO, V308, P251, DOI 10.1016/S0006-291X(03)01356-1
   Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039
   Rabinowitz JD, 2010, SCIENCE, V330, P1344, DOI 10.1126/science.1193497
   Ramirez-Valle F, 2008, J CELL BIOL, V181, P293, DOI 10.1083/jcb.200710215
   Roos WP, 2006, TRENDS MOL MED, V12, P440, DOI 10.1016/j.molmed.2006.07.007
   Rosenfeldt MT, 2011, CARCINOGENESIS, V32, P955, DOI 10.1093/carcin/bgr031
   Sato T, 2010, ONCOGENE, V29, P2746, DOI 10.1038/onc.2010.28
   Shields JM, 1996, J BIOL CHEM, V271, P20009, DOI 10.1074/jbc.271.33.20009
   Wang Y, 2013, AUTOPHAGY, V9, P2069, DOI 10.4161/auto.26447
   Wang Y, 2012, BRIT J PHARMACOL, V165, P2378, DOI 10.1111/j.1476-5381.2011.01734.x
   Wei DY, 2006, CARCINOGENESIS, V27, P23, DOI 10.1093/carcin/bgi243
   Wei DY, 2005, CANCER RES, V65, P2746, DOI 10.1158/0008-5472.CAN-04-3619
   Yang ZF, 2010, NAT CELL BIOL, V12, P814, DOI 10.1038/ncb0910-814
   Yoon HS, 2003, J BIOL CHEM, V278, P2101, DOI 10.1074/jbc.M211027200
   Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100
   Zammarchi F, 2011, AM J PATHOL, V178, P361, DOI 10.1016/j.ajpath.2010.11.021
   Zhang WQ, 2000, J BIOL CHEM, V275, P18391, DOI 10.1074/jbc.C000062200
   Zhao WD, 2004, ONCOGENE, V23, P395, DOI 10.1038/sj.onc.1207067
NR 48
TC 31
Z9 33
U1 0
U2 13
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1476-4598
J9 MOL CANCER
JI Mol. Cancer
PD MAY 6
PY 2015
VL 14
AR 101
DI 10.1186/s12943-015-0373-6
PG 13
WC Biochemistry & Molecular Biology; Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology
GA CH3NZ
UT WOS:000353938700001
PM 25944097
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Astanina, E
   Bussolino, F
   Doronzo, G
AF Astanina, Elena
   Bussolino, Federico
   Doronzo, Gabriella
TI Multifaceted activities of transcription factor EB in cancer onset and
   progression
SO MOLECULAR ONCOLOGY
LA English
DT Review
DE angiogenesis; autophagy; cell&#8208; cycle; lysosome; metabolism; tumor
   microenvironment
ID RENAL-CELL CARCINOMA; REGULATING LYSOSOMAL BIOGENESIS; INNATE
   IMMUNE-RESPONSE; AMINO-ACID LEVELS; FACTOR TFEB; RAG GTPASES; DEPENDENT
   REGULATION; COLORECTAL-CANCER; TUMOR-SUPPRESSOR; AUTOPHAGY
AB Transcription factor EB (TFEB) represents an emerging player in cancer biology. Together with microphthalmia-associated transcription factor, transcription factor E3 and transcription factor EC, TFEB belongs to the microphthalmia family of bHLH-leucine zipper transcription factors that may be implicated in human melanomas, renal and pancreatic cancers. TFEB was originally described as being translocated in a juvenile subset of pediatric renal cell carcinoma; however, whole-genome sequencing reported that somatic mutations were sporadically found in many different cancers. Besides its oncogenic activity, TFEB controls the autophagy-lysosomal pathway by recognizing a recurrent motif present in the promoter regions of a set of genes that participate in lysosome biogenesis; furthermore, its dysregulation was found to have a crucial pathogenic role in different tumors by modulating the autophagy process. Other than regulating cancer cell-autonomous responses, recent findings indicate that TFEB participates in the regulation of cellular functions of the tumor microenvironment. Here, we review the emerging role of TFEB in regulating cancer cell behavior and choreographing tumor-microenvironment interaction. Recognizing TFEB as a hub of network of signals exchanged within the tumor between cancer and stroma cells provides a fresh perspective on the molecular principles of tumor self-organization, promising to reveal numerous new and potentially druggable vulnerabilities.
C1 [Astanina, Elena; Bussolino, Federico; Doronzo, Gabriella] Univ Torino, Dept Oncol, Sp 142,Km 3.95, I-10060 Candiolo, Italy.
   [Astanina, Elena; Bussolino, Federico; Doronzo, Gabriella] Candiolo Canc Inst IRCCS FPO, Candiolo, Italy.
RP Bussolino, F (corresponding author), Univ Torino, Dept Oncol, Sp 142,Km 3.95, I-10060 Candiolo, Italy.
EM Federico.bussolino@unito.it
RI Doronzo, Gabriella/AAC-4953-2022; Bussolino, Federico/K-2500-2016
OI Doronzo, Gabriella/0000-0002-3693-8178; Bussolino,
   Federico/0000-0002-5348-1341
FU AIRC - Associazione Italiana Per la Ricerca sul CancroFondazione AIRC
   per la ricerca sul cancro [22910]; Regione PiemonteRegione Piemonte
   [A1907A]; Ministero dell'Universita e della RicercaMinistry of
   Education, Universities and Research (MIUR) [2017237P5X]; FPRC 5xmille
   2016 MIUR (Biofilm); ERA-Net Transcan2 [TRS-2018-00000689]; Fondazione
   CRTFondazione CRT
FX This work was supported by AIRC - Associazione Italiana Per la Ricerca
   sul Cancro (grant 22910), Regione Piemonte (grant A1907A, Deflect),
   Fondazione CRT, Ministero dell'Universita e della Ricerca (PRIN 2017,
   grant 2017237P5X), FPRC 5xmille 2016 MIUR (Biofilm) and ERA-Net
   Transcan2 (grant TRS-2018-00000689) to FB.
CR Albo D, 2011, CANCER-AM CANCER SOC, V117, P4834, DOI 10.1002/cncr.26117
   Nieto MA, 2016, CELL, V166, P21, DOI 10.1016/j.cell.2016.06.028
   Annunziata I, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11568-0
   Argani P, 2015, SEMIN DIAGN PATHOL, V32, P103, DOI 10.1053/j.semdp.2015.02.003
   Ballesteros-Alvarez J, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0238546
   Bao JT, 2016, PROTEIN CELL, V7, P417, DOI 10.1007/s13238-016-0269-2
   Bar-Peled L, 2013, SCIENCE, V340, P1100, DOI 10.1126/science.1232044
   Bar-Peled L, 2012, CELL, V150, P1196, DOI 10.1016/j.cell.2012.07.032
   Blessing AM, 2017, AUTOPHAGY, V13, P506, DOI 10.1080/15548627.2016.1268300
   Bretou M, 2017, SCI IMMUNOL, V2, DOI 10.1126/sciimmunol.aak9573
   Bushweller JH, 2019, NAT REV CANCER, V19, P611, DOI 10.1038/s41568-019-0196-7
   Byun S, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-14384-z
   Calcagni A, 2016, ELIFE, V5, DOI 10.7554/eLife.17047
   Carmeliet P, 2011, NAT REV DRUG DISCOV, V10, P417, DOI 10.1038/nrd3455
   CARR CS, 1990, MOL CELL BIOL, V10, P4384, DOI 10.1128/MCB.10.8.4384
   Chamorro-Jorganes A, 2011, ARTERIOSCL THROM VAS, V31, P2595, DOI 10.1161/ATVBAHA.111.236521
   Chauhan S, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9620
   Chen DS, 2017, NATURE, V541, P321, DOI 10.1038/nature21349
   Chen DG, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03225-9
   Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766
   Davis IJ, 2003, P NATL ACAD SCI USA, V100, P6051, DOI 10.1073/pnas.0931430100
   Di Malta C, 2017, SCIENCE, V356, P1188, DOI 10.1126/science.aag2553
   Doronzo G, 2019, EMBO J, V38, DOI 10.15252/embj.201798250
   Du J, 2019, MOL CARCINOGEN, V58, P2149, DOI 10.1002/mc.23105
   El-Houjeiri L, 2019, CELL REP, V26, P3613, DOI 10.1016/j.celrep.2019.02.102
   Fan YB, 2018, CIRC RES, V122, P945, DOI 10.1161/CIRCRESAHA.118.312672
   Fang L, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2017.1312042
   Ferron M, 2013, GENE DEV, V27, P955, DOI 10.1101/gad.213827.113
   FISHER DE, 1991, GENE DEV, V5, P2342, DOI 10.1101/gad.5.12a.2342
   Giatromanolaki Alexandra, 2017, Clin Breast Cancer, V17, pe119, DOI 10.1016/j.clbc.2016.11.006
   Giatromanolaki A, 2015, LUNG CANCER, V90, P98, DOI 10.1016/j.lungcan.2015.07.008
   Goding CR, 2019, GENE DEV, V33, P983, DOI 10.1101/gad.324657.119
   Gray MA, 2016, CURR BIOL, V26, P1955, DOI 10.1016/j.cub.2016.05.070
   Gross B, 2017, NAT REV ENDOCRINOL, V13, P36, DOI 10.1038/nrendo.2016.135
   Gupta S, 2017, MODERN PATHOL, V30, P998, DOI 10.1038/modpathol.2017.24
   Hallsson JH, 2004, GENETICS, V167, P233, DOI 10.1534/genetics.167.1.233
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Hartman ML, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21082980
   Hasumi H, 2016, INT J UROL, V23, P204, DOI 10.1111/iju.13015
   Hayama Y, 2018, J IMMUNOL, V200, P3790, DOI 10.4049/jimmunol.1701283
   He RZ, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1343-4
   HEMESATH TJ, 1994, GENE DEV, V8, P2770, DOI 10.1101/gad.8.22.2770
   Hsu CL, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03340-7
   Huan CM, 2006, NAT IMMUNOL, V7, P1082, DOI 10.1038/ni1378
   Huan CM, 2005, J BIOL CHEM, V280, P30225, DOI 10.1074/jbc.M502380200
   Jeong E, 2018, ELIFE, V7, DOI 10.7554/eLife.40856
   Kalluri R, 2016, NAT REV CANCER, V16, P582, DOI 10.1038/nrc.2016.73
   Klein K, 2016, INT J ONCOL, V49, P164, DOI 10.3892/ijo.2016.3505
   Kuiper RP, 2004, NUCLEIC ACIDS RES, V32, P2315, DOI 10.1093/nar/gkh571
   Kuiper RP, 2003, HUM MOL GENET, V12, P1661, DOI 10.1093/hmg/ddg178
   Kwon JJ, 2016, ONCOTARGET, V7, P71635, DOI 10.18632/oncotarget.11928
   Labelle M, 2012, CANCER DISCOV, V2, P1091, DOI 10.1158/2159-8290.CD-12-0329
   Lambert AW, 2017, CELL, V168, P670, DOI 10.1016/j.cell.2016.11.037
   Lapierre LR, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3267
   Lee TI, 2013, CELL, V152, P1237, DOI 10.1016/j.cell.2013.02.014
   Levine B, 2019, CELL, V176, P11, DOI 10.1016/j.cell.2018.09.048
   Levy JMM, 2017, NAT REV CANCER, V17, P528, DOI 10.1038/nrc.2017.53
   Li L, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04849-7
   Li S, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09634-8
   Li SX, 2020, MOL CANCER RES, V18, P1650, DOI 10.1158/1541-7786.MCR-20-0180
   Li Y, 2016, NAT CELL BIOL, V18, P1065, DOI 10.1038/ncb3407
   Li Y, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-000543
   Liang J, 2018, ONCOTARGETS THER, V11, P8089, DOI 10.2147/OTT.S180112
   Lin XX, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06624-0
   Lister JA, 2011, DEV DYNAM, V240, P2529, DOI 10.1002/dvdy.22743
   Liu H, 2014, AUTOPHAGY, V10, P372, DOI 10.4161/auto.27163
   Lu HC, 2017, SCI SIGNAL, V10, DOI 10.1126/scisignal.aah4214
   Luo WW, 2016, INT J BIOCHEM CELL B, V78, P31, DOI 10.1016/j.biocel.2016.06.020
   Ma SM, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/4693703
   Mansueto G, 2017, CELL METAB, V25, P182, DOI 10.1016/j.cmet.2016.11.003
   Mantovani A, 2017, NAT REV CLIN ONCOL, V14, P399, DOI 10.1038/nrclinonc.2016.217
   Mantovani A, 2015, J EXP MED, V212, P435, DOI 10.1084/jem.20150295
   Marchand B, 2015, J BIOL CHEM, V290, P5592, DOI 10.1074/jbc.M114.616714
   Martina JA, 2018, J BIOL CHEM, V293, P12525, DOI 10.1074/jbc.RA118.003471
   Martina JA, 2013, J CELL BIOL, V200, P475, DOI 10.1083/jcb.201209135
   Martina JA, 2012, AUTOPHAGY, V8, P903, DOI 10.4161/auto.19653
   Maus M, 2017, CELL METAB, V25, P698, DOI 10.1016/j.cmet.2016.12.021
   Medina DL, 2015, NAT CELL BIOL, V17, P288, DOI 10.1038/ncb3114
   Meireles AM, 2018, DEV CELL, V47, P319, DOI 10.1016/j.devcel.2018.10.003
   Mendel L, 2018, GENE CHROMOSOME CANC, V57, P99, DOI 10.1002/gcc.22513
   Miller AJ, 2005, J BIOL CHEM, V280, P146, DOI 10.1074/jbc.M411757200
   Miller-Hodges E, 2012, J PATHOL, V226, P229, DOI 10.1002/path.2977
   Moller K, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-37522-6
   MUHLEGOLL C, 1994, BIOCHEMISTRY-US, V33, P11296, DOI 10.1021/bi00203a027
   Nager M, 2018, AUTOPHAGY, V14, P619, DOI 10.1080/15548627.2017.1423439
   Nakamura S, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10944
   Napolitano G, 2020, NATURE, V585, P597, DOI 10.1038/s41586-020-2444-0
   Napolitano G, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05862-6
   Napolitano G, 2016, J CELL SCI, V129, P2475, DOI 10.1242/jcs.146365
   Neill T, 2017, J BIOL CHEM, V292, P16211, DOI 10.1074/jbc.M116.769950
   Nowosad A, 2020, NAT CELL BIOL, V22, P1076, DOI 10.1038/s41556-020-0554-4
   Nusse R, 2017, CELL, V169, P985, DOI 10.1016/j.cell.2017.05.016
   Palmieri M, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14338
   Palmieri M, 2011, HUM MOL GENET, V20, P3852, DOI 10.1093/hmg/ddr306
   Parenti G, 2015, ANNU REV MED, V66, P471, DOI 10.1146/annurev-med-122313-085916
   Partecke LI, 2016, PANCREATOLOGY, V16, P423, DOI 10.1016/j.pan.2016.03.005
   Pastore N, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16300-x
   Pastore N, 2016, AUTOPHAGY, V12, P1240, DOI 10.1080/15548627.2016.1179405
   Pena-Llopis S, 2011, EMBO J, V30, P3242, DOI 10.1038/emboj.2011.257
   Perera R, 2015, NATURE, V524, P361, DOI 10.1038/nature14587
   Petit CS, 2013, J CELL BIOL, V202, P1107, DOI 10.1083/jcb.201307084
   Pisonero-Vaquero S, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9051186
   Pouyssegur J, 2006, NATURE, V441, P437, DOI 10.1038/nature04871
   Reed CB, 2020, J NEUROSCI, V40, P6165, DOI 10.1523/JNEUROSCI.0951-20.2020
   Rock KL, 2016, TRENDS IMMUNOL, V37, P724, DOI 10.1016/j.it.2016.08.010
   Roczniak-Ferguson A, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002790
   Ryan DP, 2014, NEW ENGL J MED, V371, P1039, DOI 10.1056/NEJMra1404198
   Salma N, 2017, MOL CELL BIOL, V37, DOI 10.1128/MCB.00608-16
   Samie M, 2015, NAT IMMUNOL, V16, P729, DOI 10.1038/ni.3196
   Sancak Y, 2010, CELL, V141, P290, DOI 10.1016/j.cell.2010.02.024
   Sardiello M, 2009, SCIENCE, V325, P473, DOI 10.1126/science.1174447
   Schaaf MB, 2019, CELL DEATH DIFFER, V26, P665, DOI 10.1038/s41418-019-0287-8
   Schumacher TN, 2015, SCIENCE, V348, P69, DOI 10.1126/science.aaa4971
   Seok S, 2014, NATURE, V516, P108, DOI 10.1038/nature13949
   Settembre C, 2013, NAT CELL BIOL, V15, P647, DOI 10.1038/ncb2718
   Settembre C, 2012, EMBO J, V31, P1095, DOI 10.1038/emboj.2012.32
   Settembre C, 2011, SCIENCE, V332, P1429, DOI 10.1126/science.1204592
   Sha YB, 2017, EMBO J, V36, P2544, DOI 10.15252/embj.201796699
   Shang DT, 2021, AUTOPHAGY, V17, P1065, DOI 10.1080/15548627.2020.1752511
   Silvestrini MJ, 2018, CELL REP, V23, P1915, DOI 10.1016/j.celrep.2018.04.063
   Slade L, 2020, BIOCHEM J, V477, P137, DOI 10.1042/BCJ20190596
   Slade L, 2017, MOL CANCER RES, V15, P1637, DOI 10.1158/1541-7786.MCR-17-0320
   Song WC, 2019, ARTERIOSCL THROM VAS, V39, P719, DOI 10.1161/ATVBAHA.119.312316
   Steingrimsson E, 2004, ANNU REV GENET, V38, P365, DOI 10.1146/annurev.genet.38.072902.092717
   Steingrimsson E, 1998, DEVELOPMENT, V125, P4607
   Sur I, 2016, NAT REV CANCER, V16, P483, DOI 10.1038/nrc.2016.62
   Swanson BJ, 2007, CANCER RES, V67, P10222, DOI 10.1158/0008-5472.CAN-06-2483
   Tan SJ, 2019, EXP CELL RES, V382, DOI 10.1016/j.yexcr.2019.05.014
   Tiwari A, 2013, AM J PHYSIOL-HEART C, V304, pH687, DOI 10.1152/ajpheart.00744.2012
   Tontonoz P, 2008, ANNU REV BIOCHEM, V77, P289, DOI 10.1146/annurev.biochem.77.061307.091829
   Trivedi PC, 2020, BBA-MOL BASIS DIS, V1866, DOI 10.1016/j.bbadis.2020.165832
   Tsun ZY, 2013, MOL CELL, V52, P495, DOI 10.1016/j.molcel.2013.09.016
   Vega-Rubin-de-Celis S, 2017, AUTOPHAGY, V13, P464, DOI 10.1080/15548627.2016.1271514
   Villena JA, 2015, FEBS J, V282, P647, DOI 10.1111/febs.13175
   Visvikis O, 2014, IMMUNITY, V40, P896, DOI 10.1016/j.immuni.2014.05.002
   Wang YF, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17363-6
   Wang YS, 2020, EMBO REP, V21, DOI 10.15252/embr.201948335
   White E, 2015, J CLIN INVEST, V125, P42, DOI 10.1172/JCI73941
   Xia QY, 2020, AM J SURG PATHOL, V44, P477, DOI 10.1097/PAS.0000000000001408
   Xie XQ, 2015, CANCER DISCOV, V5, P410, DOI 10.1158/2159-8290.CD-14-1473
   Xu HX, 2015, ANNU REV PHYSIOL, V77, P57, DOI 10.1146/annurev-physiol-021014-071649
   Yin QY, 2020, J CELL BIOL, V219, DOI 10.1083/jcb.201911036
   Yoneshima E, 2016, J CELL PHYSIOL, V231, P1321, DOI 10.1002/jcp.25235
   Young NP, 2016, GENE DEV, V30, P535, DOI 10.1101/gad.274142.115
   Yu SL, 2020, LIFE SCI, V246, DOI 10.1016/j.lfs.2020.117418
   Yuan YJ, 2020, STEM CELLS, V38, P639, DOI 10.1002/stem.3144
   Zahalka AH, 2020, NAT REV CANCER, V20, P143, DOI 10.1038/s41568-019-0237-2
   Zahalka AH, 2017, SCIENCE, V358, P321, DOI 10.1126/science.aah5072
   Zeng CJ, 2016, GASTROENTEROLOGY, V150, P1633, DOI 10.1053/j.gastro.2016.02.076
   Zhan HQ, 2018, INT J ONCOL, V52, P933, DOI 10.3892/ijo.2018.4239
   Zhang C, 2019, CLIN CANCER RES, V25, P6827, DOI 10.1158/1078-0432.CCR-19-0733
   Zhang JB, 2018, AUTOPHAGY, V14, P1043, DOI 10.1080/15548627.2018.1447290
   Zhang ZY, 2021, AUTOPHAGY, V17, P1841, DOI 10.1080/15548627.2020.1788889
   Zhao B, 2020, CELL DEATH DISCOV, V6, DOI 10.1038/s41420-020-0246-7
   Zhong ZY, 2016, CELL, V166, P288, DOI 10.1016/j.cell.2016.05.051
NR 155
TC 10
Z9 10
U1 2
U2 10
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1574-7891
EI 1878-0261
J9 MOL ONCOL
JI Mol. Oncol.
PD FEB
PY 2021
VL 15
IS 2
BP 327
EP 346
DI 10.1002/1878-0261.12867
EA DEC 2020
PG 20
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA QB6TZ
UT WOS:000601107800001
PM 33252196
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Wu, SH
   Sun, CB
   Li, YY
   Gao, XQ
   He, S
   Li, TY
   Tian, D
AF Wu Shuhua
   Sun Chenbo
   Li Yangyang
   Gao Xiangqian
   He Shuang
   Li Tangyue
   Tian Dong
TI Autophagy-related genes Raptor, Rictor, and Beclin1 expression and
   relationship with multidrug resistance in colorectal carcinoma
SO HUMAN PATHOLOGY
LA English
DT Article
DE Colorectal cancer; MDR; Raptor; Rictor; Beclin1; Prognosis
ID MAMMALIAN TARGET; DEGRADATION; INHIBITION
AB This study aims to evaluate the relationship between the expressions of autophagy-related genes Raptor, Rictor, and Beclin1 and the expression of multidrug resistance (MDR) gene in colorectal cancer (CRC) patients. Immunohistochemistry and real-time polymerase chain reaction were used to detect the protein and messenger RNA expressions of mammalian target of rapamycin (mTOR), Raptor, Rictor, Beclin1, light chain 3 (LC3), and MDR-1 in 279 CRC specimens. Patients were followed up annually by telephone or at an outpatient clinic. Results revealed that the protein and messenger RNA expressions of Beclin1, LC3, mTOR, Raptor, Rictor, and MDR-1 in CRC are significantly higher than in adjacent tissues. LC3 expression in poorly differentiated CRC is higher than that in well-differentiated CRC, and the expression of mTOR, Raptor, Rictor, and LC3 in lymph node metastasis is higher than that obtained in the absence of lymph node metastasis. The expression of LC3 is positively correlated with those of Beclin1 and Rictor and negatively correlated with Raptor and mTOR in CRC. The expression of Raptor is negatively correlated with Rictor. The expression of MDR-1 is positively correlated with those of Beclin1, LC3, and Rictor and negatively correlated with Raptor and mTOR. Kaplan-Meier analysis revealed that the 5-year survival rate of patients without lymph node metastasis; positive expression of Rictor, Beclin1, and LC3; and negative expression of Raptor and mTOR were higher than those with these characteristics. To conclude, the expressions of Beclin1, Raptor, and Rictor are related to the development and progression of colorectal carcinoma and MDR. (C) 2015 Elsevier Inc. All rights reserved.
C1 [Wu Shuhua; Li Yangyang; Gao Xiangqian; He Shuang; Tian Dong] Binzhou Med Univ Hosp, Dept Pathol, Binzhou 256603, Shandong, Peoples R China.
   [Sun Chenbo; Li Tangyue] Binzhou Med Univ, Dept Pathol, Binzhou 256603, Shandong, Peoples R China.
RP Wu, SH (corresponding author), Binzhou Med Univ Hosp, Dept Pathol, Binzhou 256603, Shandong, Peoples R China.
EM wsh6108@126.com; dongtianbz@163.com
FU Scientific and Technological Project of Shandong Province, Binzhou,
   China
FX This work was supported by Scientific and Technological Project of
   Shandong Province, Binzhou, China.
CR Cao Y, 2007, CELL RES, V17, P839, DOI 10.1038/cr.2007.78
   El-Readi MZ, 2010, EUR J PHARMACOL, V626, P139, DOI 10.1016/j.ejphar.2009.09.040
   Eum KH, 2011, MOL CELLS, V31, P231, DOI 10.1007/s10059-011-0034-6
   Fu X, 2013, BREAST S2, pS12
   Guertin DA, 2007, CANCER CELL, V12, P9, DOI 10.1016/j.ccr.2007.05.008
   Gulhati P, 2009, CLIN CANCER RES, V15, P7207, DOI 10.1158/1078-0432.CCR-09-1249
   Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006
   Jung CH, 2010, FEBS LETT, V584, P1287, DOI 10.1016/j.febslet.2010.01.017
   Kohli L, 2013, AUTOPHAGY, V9, P1438, DOI 10.4161/auto.25837
   Kristensen AR, 2008, MOL CELL PROTEOMICS, V7, P2419, DOI 10.1074/mcp.M800184-MCP200
   Li N, 2013, BIOCHEM BIOPH RES CO, V439, P187, DOI 10.1016/j.bbrc.2013.08.065
   Lin CJ, 2012, FREE RADICAL BIO MED, V52, P377, DOI 10.1016/j.freeradbiomed.2011.10.487
   Ming HY, 2014, PLOS ONE, V9
   National Comprehensive Cancer Network, 2015, NCCN CLIN PRACT GUID
   Shu JY, 2011, PLOS ONE, V6
   Tanida I, 2005, AUTOPHAGY, V1, P84, DOI 10.4161/auto.1.2.1697
   Teimoori-Toolabi L, 2015, ANTI-CANCER DRUG, V26, P187, DOI 10.1097/CAD.0000000000000175
   Vlahakis A, 2014, AUTOPHAGY, V10, P2085, DOI 10.4161/auto.36262
   Wang XR, 2008, CANCER RES, V68, P7409, DOI 10.1158/0008-5472.CAN-08-1522
   Wen FF, 2014, INT J CLIN EXP PATHO, V7, P8295
   Xu N, 2012, BIOCHEM BIOPH RES CO, V423, P826, DOI 10.1016/j.bbrc.2012.06.048
   Zheng ZZ, 2012, AUTOPHAGY, V8, P1
   Zhi HC, 2013, DIGEST DIS SCI, V58, P2887
NR 23
TC 35
Z9 42
U1 0
U2 13
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0046-8177
EI 1532-8392
J9 HUM PATHOL
JI Hum. Pathol.
PD NOV
PY 2015
VL 46
IS 11
BP 1752
EP 1759
DI 10.1016/j.humpath.2015.07.016
PG 8
WC Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology
GA CV6DJ
UT WOS:000364360600022
PM 26363527
DA 2022-04-25
ER

PT J
AU Cao, J
   Bhatnagar, S
   Wang, JW
   Qi, XY
   Prabha, S
   Panyam, J
AF Cao, Jin
   Bhatnagar, Shubhmita
   Wang, Jiawei
   Qi, Xueyong
   Prabha, Swayam
   Panyam, Jayanth
TI Cancer stem cells and strategies for targeted drug delivery
SO DRUG DELIVERY AND TRANSLATIONAL RESEARCH
LA English
DT Review
DE Cancer stem cells (CSCs); Drug delivery system; Anti-tumor therapy;
   Drug-resistance; Cancer biology
ID ACUTE MYELOID-LEUKEMIA; OVERCOME MULTIDRUG-RESISTANCE; FACILITATED
   AUTOPHAGY INHIBITION; HUMAN PANCREATIC-CANCER; BREAST-CANCER; ABC
   TRANSPORTERS; HEPATOCELLULAR-CARCINOMA; COLORECTAL-CANCER;
   HYALURONIC-ACID; P-GLYCOPROTEIN
AB Cancer stem cells (CSCs) are a small proportion of cancer cells with high tumorigenic activity, self-renewal ability, and multilineage differentiation potential. Standard anti-tumor therapies including conventional chemotherapy, radiation therapy, and molecularly targeted therapies are not effective against CSCs, and often lead to enrichment of CSCs that can result in tumor relapse. Therefore, it is hypothesized that targeting CSCs is key to increasing the efficacy of cancer therapies. In this review, CSC properties including CSC markers, their role in tumor growth, invasiveness, metastasis, and drug resistance, as well as CSC microenvironment are discussed. Further, CSC-targeted strategies including the use of targeted drug delivery systems are examined.
C1 [Cao, Jin; Qi, Xueyong] Jiangsu Univ, Sch Pharm, Zhenjiang 212013, Jiangsu, Peoples R China.
   [Cao, Jin; Bhatnagar, Shubhmita; Wang, Jiawei; Prabha, Swayam; Panyam, Jayanth] Univ Minnesota, Coll Pharm, Minneapolis, MN 55455 USA.
   [Bhatnagar, Shubhmita; Panyam, Jayanth] Temple Univ, Sch Pharm, Philadelphia, PA 19140 USA.
   [Prabha, Swayam] Temple Univ, Lewis Katz Sch Med, Canc Res & Mol Biol, Philadelphia, PA 19140 USA.
   [Prabha, Swayam] Temple Univ, Lewis Katz Sch Med, Dept Pharmacol, Philadelphia, PA 19140 USA.
   [Wang, Jiawei] Univ Texas Austin, Coll Pharm, Austin, TX 78712 USA.
RP Panyam, J (corresponding author), Univ Minnesota, Coll Pharm, Minneapolis, MN 55455 USA.; Panyam, J (corresponding author), Temple Univ, Sch Pharm, Philadelphia, PA 19140 USA.
EM jayanth.panyam@temple.edu
RI Bhatnagar, Shubhmita/ABB-8557-2021
OI Bhatnagar, Shubhmita/0000-0002-2721-9307
FU Community of Pharmaceutical Development (CPD), Office of Discovery and
   Translation (ODAT) at the University of Minnesota; Randy Shaver
   Foundation; NIHUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [R01EB019893]
FX Funding was provided by the Community of Pharmaceutical Development
   (CPD), Office of Discovery and Translation (ODAT) at the University of
   Minnesota, the Randy Shaver Foundation, and NIH R01EB019893.
CR Abbaszadegan MR, 2017, J CELL PHYSIOL, V232, P2008, DOI 10.1002/jcp.25759
   Agliano A, 2017, SEMIN CANCER BIOL, V44, P25, DOI 10.1016/j.semcancer.2017.03.003
   Ajani JA, 2015, SEMIN ONCOL, V42, pS3, DOI 10.1053/j.seminoncol.2015.01.001
   Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100
   Alakhov VY, 1996, BIOCONJUGATE CHEM, V7, P209, DOI 10.1021/bc950093n
   Almozyan S, 2017, INT J CANCER, V141, P1402, DOI 10.1002/ijc.30834
   Alshaer W, 2015, BIOCONJUGATE CHEM, V26, P1307, DOI 10.1021/bc5004313
   Aminuddin A, 2016, FRONT PHARMACOL, V7, DOI 10.3389/fphar.2016.00244
   An X, 2017, ACTA PHARM SIN B, V7, P38, DOI 10.1016/j.apsb.2016.09.002
   Andrews TE, 2013, DRUG DELIV TRANSL RE, V3, P121, DOI 10.1007/s13346-012-0075-1
   Apel A, 2008, CANCER RES, V68, P1485, DOI 10.1158/0008-5472.CAN-07-0562
   Appelbaum FR, 2017, BLOOD, V130, P2373, DOI 10.1182/blood-2017-09-797712
   Au JLS, 2016, ADV DRUG DELIVER REV, V97, P280, DOI 10.1016/j.addr.2015.12.002
   Badrinath N, 2019, CANCERS, V11, DOI 10.3390/cancers11030310
   Baeuerle PA, 2007, BRIT J CANCER, V96, P417, DOI 10.1038/sj.bjc.6603494
   Bahmad HF, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00347
   Bar EE, 2007, STEM CELLS, V25, P2524, DOI 10.1634/stemcells.2007-0166
   Behrooz AB, 2019, J DRUG TARGET, V27, P257, DOI 10.1080/1061186X.2018.1479756
   Bertino JR, 2009, BEST PRACT RES CL HA, V22, P577, DOI 10.1016/j.beha.2009.09.004
   Bighetti-Trevisan RL, 2019, STEM CELLS INT, V2019, DOI 10.1155/2019/9618065
   Bomken S, 2010, BRIT J CANCER, V103, P439, DOI 10.1038/sj.bjc.6605821
   Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730
   Borah A, 2015, ONCOGENESIS, V4, DOI 10.1038/oncsis.2015.35
   Bourguignon LYW, 2008, J BIOL CHEM, V283, P17635, DOI 10.1074/jbc.M800109200
   Cabrera MC, 2015, WORLD J STEM CELLS, V7, P27, DOI 10.4252/wjsc.v7.i1.27
   Cao CQ, 2014, ADV MATER, V26, P2566, DOI 10.1002/adma.201304544
   Carnero A, 2016, BIOESSAYS, V38, pS65, DOI 10.1002/bies.201670911
   Cetinbas NM, 2017, BIOL ENG STEM CELL N
   Chan KS, 2009, P NATL ACAD SCI USA, V106, P14016, DOI 10.1073/pnas.0906549106
   Chang CM, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18050903
   Chen BA, 2010, INT J NANOMED, V5, P437
   Chen BA, 2009, INT J NANOMED, V4, P201
   Chen DZ, 2018, INT J NANOMED, V13, P6855, DOI 10.2147/IJN.S181928
   Chen YN, 2018, ADV SCI, V5, DOI 10.1002/advs.201700964
   Chenna V, 2012, MOL CANCER THER, V11, P165, DOI 10.1158/1535-7163.MCT-11-0341
   Choi AMK, 2013, NEW ENGL J MED, V368, P651, DOI [10.1056/NEJMra1205406, 10.1056/NEJMc1303158]
   Choi YJ, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19030710
   Choi YJ, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17122077
   Clarke Michael F, 2006, Cancer Res, V66, P9339, DOI 10.1158/0008-5472.CAN-06-3126
   Clement V, 2007, CURR BIOL, V17, P165, DOI 10.1016/j.cub.2006.11.033
   Collins AT, 2005, CANCER RES, V65, P10946, DOI 10.1158/0008-5472.CAN-05-2018
   Cucco C, 1996, CANCER RES, V56, P4332
   Cufi S, 2011, CELL CYCLE, V10, P3871, DOI 10.4161/cc.10.22.17976
   D'Andrea V, 2014, G CHIR, V35, P257, DOI 10.11138/gchir/2014.35.11.257
   Dandawate PR, 2016, SEMIN CANCER BIOL, V40-41, P192, DOI 10.1016/j.semcancer.2016.09.001
   Das M, 2018, INT J BIOCHEM CELL B, V103, P115, DOI 10.1016/j.biocel.2018.08.011
   Dayem Ahmed Abdal, 2010, Cancers (Basel), V2, P859, DOI 10.3390/cancers2020859
   Dean M, 2009, J MAMMARY GLAND BIOL, V14, P3, DOI 10.1007/s10911-009-9109-9
   Deng ZL, 2015, BMC IMMUNOL, V16, DOI 10.1186/s12865-014-0064-x
   Deonarain MP, 2009, MABS-AUSTIN, V1, P12, DOI 10.4161/mabs.1.1.7347
   Dewhirst MW, 2017, NAT REV CANCER, V17, P738, DOI 10.1038/nrc.2017.93
   Dianat-Moghadam H, 2018, J CONTROL RELEASE, V288, P62, DOI 10.1016/j.jconrel.2018.08.043
   Diehn M, 2009, NATURE, V458, P780, DOI 10.1038/nature07733
   Dierks C, 2008, CANCER CELL, V14, P238, DOI 10.1016/j.ccr.2008.08.003
   Du ZY, 2011, DIGEST DIS SCI, V56, P741, DOI 10.1007/s10620-010-1340-0
   Duan JJ, 2013, STEM CELLS DEV, V22, P2221, DOI 10.1089/scd.2012.0613
   Easwaran H, 2014, MOL CELL, V54, P716, DOI 10.1016/j.molcel.2014.05.015
   El Hout M, 2020, MOL CANCER, V19, DOI 10.1186/s12943-019-1126-8
   Elgundi Z, 2020, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.01482
   Eliaz RE, 2001, CANCER RES, V61, P2592
   Eramo A, 2008, CELL DEATH DIFFER, V15, P504, DOI 10.1038/sj.cdd.4402283
   Espinoza I, 2013, ONCOTARGETS THER, V6, P1249, DOI 10.2147/OTT.S36162
   Fan X, 2010, STEM CELLS, V28, P5, DOI 10.1002/stem.254
   Fang D, 2005, CANCER RES, V65, P9328, DOI 10.1158/0008-5472.CAN-05-1343
   Farahmand L, 2018, J DRUG TARGET, V26, P649, DOI 10.1080/1061186X.2017.1405426
   Farnie G, 2015, ONCOTARGET, V6, P30472, DOI 10.18632/oncotarget.5401
   Feng CL, 2017, INT J PHARMACEUT, V528, P322, DOI 10.1016/j.ijpharm.2017.06.022
   Ferrero E, 1999, J LEUKOCYTE BIOL, V65, P151, DOI 10.1002/jlb.65.2.151
   Fiorillo M, 2015, ONCOTARGET, V6, P3553, DOI 10.18632/oncotarget.3348
   Fletcher JI, 2010, NAT REV CANCER, V10, P147, DOI 10.1038/nrc2789
   Floor S, 2011, ONCOGENE, V30, P4609, DOI 10.1038/onc.2011.184
   Frank NY, 2005, CANCER RES, V65, P4320, DOI 10.1158/0008-5472.CAN-04-3327
   Fu CH, 2019, ONCOL LETT, V18, P5897, DOI 10.3892/ol.2019.10952
   Fuchs D, 2010, BIOCHEM BIOPH RES CO, V394, P1098, DOI 10.1016/j.bbrc.2010.03.138
   Fung TK, 2013, STEM CELLS CANC STEM, V10, P163
   Gadhoum Z, 2004, LEUKEMIA LYMPHOMA, V45, P1501, DOI 10.1080/1042819042000206687
   Galadari S, 2017, FREE RADICAL BIO MED, V104, P144, DOI 10.1016/j.freeradbiomed.2017.01.004
   Galavotti S, 2013, ONCOGENE, V32, P699, DOI 10.1038/onc.2012.111
   Ganta S, 2009, MOL PHARMACEUT, V6, P928, DOI 10.1021/mp800240j
   Garcia-Mayea Y, 2020, SEMIN CANCER BIOL, V60, P166, DOI 10.1016/j.semcancer.2019.07.022
   Garcia-Mazas C, 2017, INT J PHARMACEUT, V523, P490, DOI 10.1016/j.ijpharm.2016.12.013
   Ghani FI, 2011, BIOCHEM BIOPH RES CO, V404, P735, DOI 10.1016/j.bbrc.2010.12.054
   Ghosh N, 2009, CANCER LETT, V277, P1, DOI 10.1016/j.canlet.2008.08.005
   Gilboa E, 2007, J CLIN INVEST, V117, P1195, DOI 10.1172/JCI31205
   Gillet JP, 2010, METHODS MOL BIOL, V596, P47, DOI 10.1007/978-1-60761-416-6_4
   Glumac PM, 2018, CLIN TRANSL MED, V7, DOI 10.1186/s40169-018-0198-1
   Gong C, 2013, ONCOGENE, V32, P2261, DOI 10.1038/onc.2012.252
   Goodarzi N, 2011, J MED HYPOTHESES IDE, V5, P26
   Goodarzi N, 2014, CHEM BIOL DRUG DES, V83, P741, DOI 10.1111/cbdd.12288
   Griguer CE, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003655
   Grossenbacher SK, 2016, J IMMUNOTHER CANCER, V4, DOI 10.1186/s40425-016-0124-2
   Gu JW, 2012, VASC CELL, V4, DOI 10.1186/2045-824X-4-7
   Gul-Uludag H, 2014, LEUKEMIA RES, V38, P1299, DOI 10.1016/j.leukres.2014.08.008
   Guo Q, 2017, ANTI-CANCER AGENT ME, V17, P1466, DOI 10.2174/1871520617666171016105704
   Guo WJ, 2010, EXP TOXICOL PATHOL, V62, P577, DOI 10.1016/j.etp.2009.08.001
   Halappanavar S, 2018, WIRES NANOMED NANOBI, V10, DOI 10.1002/wnan.1465
   Han L, 2013, ACTA PHARM SIN B, V3, P65, DOI 10.1016/j.apsb.2013.02.006
   Han ML, 2016, ACTA PHARMACOL SIN, V37, P1606, DOI 10.1038/aps.2016.93
   Haraguchi N, 2010, J CLIN INVEST, V120, P3326, DOI 10.1172/JCI42550
   Hashemitabar S, 2019, J BIOSCIENCES, V44, DOI 10.1007/s12038-019-9854-x
   Hauswirth AW, 2007, EUR J CLIN INVEST, V37, P73, DOI 10.1111/j.1365-2362.2007.01746.x
   Heddleston JM, 2009, CELL CYCLE, V8, P3274, DOI 10.4161/cc.8.20.9701
   Herheliuk Tetiana, 2019, Stem Cell Investig, V6, P21, DOI 10.21037/sci.2019.06.07
   Herrmann H, 2014, BLOOD, V123, P3951, DOI 10.1182/blood-2013-10-536078
   Hong IS, 2015, INT J NANOMED, V10, P251, DOI 10.2147/IJN.S88310
   Hosen N, 2007, P NATL ACAD SCI USA, V104, P11008, DOI 10.1073/pnas.0704271104
   Hou H, 2017, NEOPLASMA, V64, P81, DOI 10.4149/neo_2017_110
   Huang FT, 2012, INT J ONCOL, V41, P1707, DOI 10.3892/ijo.2012.1597
   Huang JB, 2016, J BIOMED NANOTECHNOL, V12, P1463, DOI 10.1166/jbn.2016.2234
   Huang P, 2014, ADV MATER, V26, P6401, DOI 10.1002/adma.201400914
   Huang WB, 2016, ONCOL REP, V35, P978, DOI 10.3892/or.2015.4453
   Huang YT, 2017, J THORAC DIS, V9, pE168, DOI 10.21037/jtd.2017.02.30
   Huo MR, 2017, J CONTROL RELEASE, V245, P81, DOI 10.1016/j.jconrel.2016.11.013
   Hurton LV, 2016, P NATL ACAD SCI USA, V113, pE7788, DOI 10.1073/pnas.1610544113
   Iozzo RV, 2011, J CELL MOL MED, V15, P1013, DOI 10.1111/j.1582-4934.2010.01236.x
   Ishimoto T, 2011, CANCER CELL, V19, P387, DOI 10.1016/j.ccr.2011.01.038
   JACHEZ B, 1993, J NATL CANCER I, V85, P478, DOI 10.1093/jnci/85.6.478
   Jaggupilli A, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/708036
   Jang GB, 2015, SCI REP-UK, V5, DOI 10.1038/srep12465
   Janiszewska M, 2012, GENE DEV, V26, P1926, DOI 10.1101/gad.188292.112
   Jin DJ, 2015, ONCOL REP, V33, P515, DOI 10.3892/or.2014.3638
   Jordan CT, 2000, LEUKEMIA, V14, P1777, DOI 10.1038/sj.leu.2401903
   Justilien V, 2015, CLIN CANCER RES, V21, P505, DOI 10.1158/1078-0432.CCR-14-0507
   Kalscheuer S, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-48993-6
   Kanai Y, 2003, CANCER LETT, V192, P75, DOI 10.1016/S0304-3835(02)00689-4
   Kappler Roland, 2012, Front Biosci (Schol Ed), V4, P277
   KARTNER N, 1985, NATURE, V316, P820, DOI 10.1038/316820a0
   Kato T, 2010, GENE THER, V17, P1363, DOI 10.1038/gt.2010.88
   Ke XY, 2014, BIOMATERIALS, V35, P1096, DOI 10.1016/j.biomaterials.2013.10.049
   Kebenko M, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1450710
   Khanna Vidhi, 2019, Future Drug Discov, V1, pFDD8, DOI 10.4155/fdd-2019-0005
   Kim HM, 2012, ANN SURG ONCOL, V19, pS539, DOI 10.1245/s10434-011-2040-5
   Kim JS, 2018, J CONTROL RELEASE, V269, P245, DOI 10.1016/j.jconrel.2017.11.026
   Kim M, 2002, CLIN CANCER RES, V8, P22
   Kitamura H, 2009, LUNG CANCER, V66, P275, DOI 10.1016/j.lungcan.2009.07.019
   Kobayashi CI, 2012, J CELL PHYSIOL, V227, P421, DOI 10.1002/jcp.22764
   Korpetinou A, 2014, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00327
   Krishnamurthy S, 2014, BIOMATERIALS, V35, P9177, DOI 10.1016/j.biomaterials.2014.07.018
   Kryczek I, 2012, INT J CANCER, V130, P29, DOI 10.1002/ijc.25967
   Kumar D, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-171
   Lagadinou ED, 2013, CELL STEM CELL, V12, P329, DOI 10.1016/j.stem.2012.12.013
   Lamichhane SP, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2634-1
   LAPIDOT T, 1994, NATURE, V367, P645, DOI 10.1038/367645a0
   Lathia JD, 2011, CELL STEM CELL, V8, P482, DOI 10.1016/j.stem.2011.04.013
   Laws K, 2018, CHEMBIOCHEM, V19, P2246, DOI 10.1002/cbic.201800358
   Laws K, 2018, ANGEW CHEM INT EDIT, V57, P287, DOI 10.1002/anie.201710910
   Lazzari G, 2018, ACTA BIOMATER, V78, P296, DOI 10.1016/j.actbio.2018.08.008
   Ley TJ, 2013, NEW ENGL J MED, V368, P2059, DOI 10.1056/NEJMoa1301689
   Li CW, 2007, CANCER RES, V67, P1030, DOI 10.1158/0008-5472.CAN-06-2030
   Li HJ, 2019, BIOMATERIALS, V200, P1, DOI 10.1016/j.biomaterials.2019.01.048
   Li J, 2015, CANCER LETT, V360, P177, DOI 10.1016/j.canlet.2015.02.006
   Lin Q, 2013, BIOMATERIALS, V34, P7191, DOI 10.1016/j.biomaterials.2013.06.004
   Lin YH, 2015, CANCER CHEMOTH PHARM, V75, P879, DOI 10.1007/s00280-014-2634-2
   Ling X, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0899-8
   Liou GY, 2010, FREE RADICAL RES, V44, P479, DOI 10.3109/10715761003667554
   LIU AY, 1994, CANCER LETT, V76, P63, DOI 10.1016/0304-3835(94)90135-X
   Liu DD, 2020, THERANOSTICS, V10, P1181, DOI 10.7150/thno.38989
   Liu DL, 2011, MED ONCOL, V28, P105, DOI 10.1007/s12032-009-9397-3
   Liu HG, 2015, AM J CANCER RES, V5, P880
   Liu T, 2016, ONCOTARGET, V7, P83502, DOI 10.18632/oncotarget.13148
   Liu Y, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms6988
   Lomonaco SL, 2009, INT J CANCER, V125, P717, DOI 10.1002/ijc.24402
   Loureiro R, 2017, SEMIN CANCER BIOL, V47, P18, DOI 10.1016/j.semcancer.2017.06.012
   Lu B, 2016, FRONT PHARMACOL, V7, DOI 10.3389/fphar.2016.00084
   Lu HH, 2014, NAT CELL BIOL, V16, P1105, DOI 10.1038/ncb3041
   Lu L, 2019, J MATER CHEM B, V7, P2054, DOI 10.1039/c8tb03165g
   Lu YP, 2016, EUR J PHARMACOL, V771, P130, DOI 10.1016/j.ejphar.2015.12.026
   Luna JI, 2017, EXPERT OPIN BIOL TH, V17, P313, DOI 10.1080/14712598.2017.1271874
   Luo B, 2013, ONCOGENE, V32, P805, DOI 10.1038/onc.2012.130
   Luo M, 2019, SEMIN RADIAT ONCOL, V29, P42, DOI 10.1016/j.semradonc.2018.10.003
   Ma JZ, 2018, ARTIF CELL NANOMED B, V46, P1864, DOI 10.1080/21691401.2017.1394874
   Ma S, 2007, GASTROENTEROLOGY, V132, P2542, DOI 10.1053/j.gastro.2007.04.025
   Ma X, 2013, BIOMATERIALS, V34, P4452, DOI 10.1016/j.biomaterials.2013.02.066
   Magee JA, 2012, CANCER CELL, V21, P283, DOI 10.1016/j.ccr.2012.03.003
   Majumder S, 2012, CANCER RES, V72, DOI 10.1158/1538-7445.AM2012-5606
   Mamaeva V, 2016, MOL THER, V24, P926, DOI 10.1038/mt.2016.42
   Mamaeva V, 2011, MOL THER, V19, P1538, DOI 10.1038/mt.2011.105
   Mancini R, 2018, ONCOGENE, V37, P2367, DOI 10.1038/s41388-018-0141-3
   Matsui W, 2004, BLOOD, V103, P2332, DOI 10.1182/blood-2003-09-3064
   Merchant AA, 2010, CLIN CANCER RES, V16, P3130, DOI 10.1158/1078-0432.CCR-09-2846
   Miller-Kleinhenz J, 2018, BIOMATERIALS, V152, P47, DOI 10.1016/j.biomaterials.2017.10.035
   Minko T, 1998, J CONTROL RELEASE, V54, P223, DOI 10.1016/S0168-3659(98)00009-1
   Mitra P, 2006, P NATL ACAD SCI USA, V103, P16394, DOI 10.1073/pnas.0603734103
   MIYAMOTO S, 2018, SAPPORO MED J, V87, P102, DOI DOI 10.1158/2326-6066.CIR-17-0518
   Miyata T, 2017, ANTICANCER RES, V37, P2541, DOI 10.21873/anticanres.11597
   Mizushima N, 2007, GENE DEV, V21, P2861, DOI 10.1101/gad.1599207
   Mladinich M, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/5285892
   Mochizuki M, 2016, SCI REP-UK, V6, DOI 10.1038/srep30707
   Mohammadi M, 2015, INT J PHARMACEUT, V485, P50, DOI 10.1016/j.ijpharm.2015.02.031
   Mokhtarzadeh A, 2017, J CONTROL RELEASE, V266, P166, DOI 10.1016/j.jconrel.2017.09.028
   Mummery C, 2014, STEM CELLS, P315
   Najafi M, 2019, LIFE SCI, V234, DOI 10.1016/j.lfs.2019.116781
   Nanayakkara AK, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-19325-x
   Nazio F, 2019, CELL DEATH DIFFER, V26, P690, DOI 10.1038/s41418-019-0292-y
   Nguyen LV, 2012, NAT REV CANCER, V12, P133, DOI 10.1038/nrc3184
   Nikitovic D, 2018, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00069
   Noguchi K, 2014, PHARMACOGN PERS MED, V7, P53, DOI 10.2147/PGPM.S38295
   O'Brien CA, 2007, NATURE, V445, P106, DOI 10.1038/nature05372
   Ohlfest JR, 2013, DRUG DELIV TRANSL RE, V3, P195, DOI 10.1007/s13346-012-0066-2
   Ozben T, 2006, FEBS LETT, V580, P2903, DOI 10.1016/j.febslet.2006.02.020
   Pan YZ, 2009, MOL PHARMACOL, V75, P1374, DOI 10.1124/mol.108.054163
   Pang R, 2010, CELL STEM CELL, V6, P603, DOI 10.1016/j.stem.2010.04.001
   Pannuti A, 2010, CLIN CANCER RES, V16, P3141, DOI 10.1158/1078-0432.CCR-09-2823
   Park S, 2006, BREAST CANCER RES TR, V99, P9, DOI 10.1007/s10549-006-9175-2
   Patil Y, 2009, J CONTROL RELEASE, V136, P21, DOI 10.1016/j.jconrel.2009.01.021
   Pattabiraman DR, 2014, NAT REV DRUG DISCOV, V13, P497, DOI 10.1038/nrd4253
   Peacock CD, 2007, P NATL ACAD SCI USA, V104, P4048, DOI 10.1073/pnas.0611682104
   Peetla C, 2013, ADV DRUG DELIVER REV, V65, P1686, DOI 10.1016/j.addr.2013.09.004
   Peiris-Pages M, 2016, BREAST CANCER RES, V18, DOI 10.1186/s13058-016-0712-6
   Penfornis Patrice, 2017, Front Biosci (Elite Ed), V9, P162
   Peng G, 2015, TRENDS PHARMACOL SCI, V36, P374, DOI 10.1016/j.tips.2015.03.003
   Petpiroon N, 2019, MOL PHARMACOL, V95, P418, DOI 10.1124/mol.118.114447
   Petrova R, 2014, DEVELOPMENT, V141, P3445, DOI 10.1242/dev.083691
   Pi YF, 2015, CURR PHARM DESIGN, V21, P6236, DOI 10.2174/1381612821666151027153611
   Pineiro R, 2011, ONCOGENE, V30, P142, DOI 10.1038/onc.2010.417
   Ping YF, 2016, CANCER LETT, V380, P561, DOI 10.1016/j.canlet.2015.05.010
   Plaks V, 2015, CELL STEM CELL, V16, P225, DOI 10.1016/j.stem.2015.02.015
   Prestwich GD, 1998, J CONTROL RELEASE, V53, P93, DOI 10.1016/S0168-3659(97)00242-3
   Prince ME, 2007, P NATL ACAD SCI USA, V104, P973, DOI 10.1073/pnas.0610117104
   Prud'homme GJ, 2012, CURR PHARM DESIGN, V18, P2838
   Puerta-Fernandez E, 2003, FEMS MICROBIOL REV, V27, P75, DOI 10.1016/S0168-6445(03)00020-2
   Putzer BM, 2017, ADV DRUG DELIVER REV, V120, P89, DOI 10.1016/j.addr.2017.07.013
   Purushothaman B, 2018, EUR J MED CHEM, V156, P747, DOI 10.1016/j.ejmech.2018.07.048
   Rabindran SK, 2000, CANCER RES, V60, P47
   Rajayi H, 2019, INT REV IMMUNOL, V38, P267, DOI 10.1080/08830185.2019.1669593
   Ramaswamy B, 2012, CANCER RES, V72, P5048, DOI 10.1158/0008-5472.CAN-12-1248
   Rashidi MRW, 2019, NEOPLASIA, V21, P822, DOI 10.1016/j.neo.2019.06.005
   Recalcati S, 2019, FREE RADICAL BIO MED, V133, P216, DOI 10.1016/j.freeradbiomed.2018.07.015
   Redmer T, 2017, ONCOGENESIS, V6, DOI 10.1038/oncsis.2016.88
   Regan JL, 2017, CELL REP, V21, P2813, DOI 10.1016/j.celrep.2017.11.025
   Richards DA, 2017, CHEM SCI, V8, P63, DOI 10.1039/c6sc02403c
   RIORDAN JR, 1985, NATURE, V316, P817, DOI 10.1038/316817a0
   Ruban EL, 2014, BIOCHEM SOC T, V42, P1372, DOI 10.1042/BST20140151
   Salnikov AV, 2009, J CELL MOL MED, V13, P4023, DOI 10.1111/j.1582-4934.2009.00723.x
   Sancho P, 2016, BRIT J CANCER, V114, P1305, DOI 10.1038/bjc.2016.152
   Sancho P, 2015, CELL METAB, V22, P590, DOI 10.1016/j.cmet.2015.08.015
   Saraswathy M, 2013, BIOTECHNOL ADV, V31, P1397, DOI 10.1016/j.biotechadv.2013.06.004
   Schmohl JU, 2017, CANCER RES TREAT, V49, P1140, DOI 10.4143/crt.2016.491
   Schonberg DL, 2015, CANCER CELL, V28, P441, DOI 10.1016/j.ccell.2015.09.002
   Schulz A, 2019, CANCERS, V11, DOI 10.3390/cancers11060862
   SELL S, 1993, ENVIRON HEALTH PERSP, V101, P15, DOI 10.2307/3431838
   Serna N, 2020, J CONTROL RELEASE, V320, P96, DOI 10.1016/j.jconrel.2020.01.019
   Shaikh MV, 2016, CANCER BIOMARK, V16, P301, DOI 10.3233/CBM-160590
   Sharma B, 1998, J CLIN INVEST, V102, P1599, DOI 10.1172/JCI3793
   Shen S, 2019, SMALL, V15, DOI 10.1002/smll.201902118
   Shen S, 2015, BIOMATERIALS, V70, P71, DOI 10.1016/j.biomaterials.2015.08.026
   Shi FF, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287-018-0885-2
   Shi L, 2015, TUMOR BIOL, V36, P7107, DOI 10.1007/s13277-015-3427-x
   Shi XK, 2012, ANTIOXID REDOX SIGN, V16, P1215, DOI 10.1089/ars.2012.4529
   Shigdar S, 2013, CANCER LETT, V330, P84, DOI 10.1016/j.canlet.2012.11.032
   Sidney LE, 2014, STEM CELLS, V32, P1380, DOI 10.1002/stem.1661
   Sims-Mourtada J, 2006, CLIN CANCER RES, V12, P6565, DOI 10.1158/1078-0432.CCR-06-0176
   Singh BN, 2012, BIOCHEM PHARMACOL, V84, P1154, DOI 10.1016/j.bcp.2012.08.007
   Singh D, 2017, DRUG DISCOV TODAY, V22, P952, DOI 10.1016/j.drudis.2017.04.005
   Singh SK, 2003, CANCER RES, V63, P5821
   Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128
   Smith AG, 2019, J PATHOL, V247, P708, DOI 10.1002/path.5222
   Song YJ, 2013, CANCER LETT, V339, P70, DOI 10.1016/j.canlet.2013.07.021
   Stilgenbauer M, 2019, CHEM COMMUN, V55, P6106, DOI 10.1039/c9cc02081k
   Stroomer JWG, 2000, CLIN CANCER RES, V6, P3046
   Su RJ, 2015, AM J CLIN PATHOL, V144, pA139, DOI 10.1093/ajcp/144.suppl2.139
   Suda T, 2011, CELL STEM CELL, V9, P298, DOI 10.1016/j.stem.2011.09.010
   Suetsugi A, 2006, BIOCHEM BIOPH RES CO, V351, P820, DOI 10.1016/j.bbrc.2006.10.128
   Sun R, 2016, BIOMATERIALS, V103, P44, DOI 10.1016/j.biomaterials.2016.06.038
   Sun TM, 2014, BIOMATERIALS, V35, P836, DOI 10.1016/j.biomaterials.2013.10.011
   Sun Y, 2015, ADV HEALTHC MATER, V4, P1675, DOI 10.1002/adhm.201500190
   Sun YJ, 2014, THERANOSTICS, V4, P845, DOI 10.7150/thno.8343
   Suwala AK, 2016, J NEUROPATH EXP NEUR, V75, P388, DOI 10.1093/jnen/nlw013
   Swaminathan SK, 2013, J CONTROL RELEASE, V171, P280, DOI 10.1016/j.jconrel.2013.07.014
   Swaminathan SK, 2013, DRUG DELIV TRANSL RE, V3, P143, DOI 10.1007/s13346-012-0099-6
   Swaminathan SK, 2010, J IMMUNOL METHODS, V361, P110, DOI 10.1016/j.jim.2010.07.007
   Szakacs G, 2006, NAT REV DRUG DISCOV, V5, P219, DOI 10.1038/nrd1984
   Szarynska M, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-30525-3
   TAKADA M, 1994, PANCREAS, V9, P748, DOI 10.1097/00006676-199411000-00013
   Takaishi S, 2009, STEM CELLS, V27, P1006, DOI 10.1002/stem.30
   Takebe N, 2011, NAT REV CLIN ONCOL, V8, P97, DOI 10.1038/nrclinonc.2010.196
   Tan T, 2018, ADV SCI, V5, DOI 10.1002/advs.201801012
   Tarasova NI, 2005, J MED CHEM, V48, P3768, DOI 10.1021/jm049065t
   Teodori E, 2006, CURR DRUG TARGETS, V7, P893, DOI 10.2174/138945006777709520
   Terris B, 2010, J HEPATOL, V52, P280, DOI 10.1016/j.jhep.2009.10.026
   Todaro M, 2014, CELL STEM CELL, V14, P342, DOI 10.1016/j.stem.2014.01.009
   Torres A, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19092697
   Trachootham D, 2009, NAT REV DRUG DISCOV, V8, P579, DOI 10.1038/nrd2803
   Vasiliou Vasilis, 2008, Hum Genomics, V3, P1
   Venne A, 1996, CANCER RES, V56, P3626
   Verma RK, 2015, NANOMED-NANOTECHNOL, V11, P2061, DOI 10.1016/j.nano.2015.07.001
   Visvader JE, 2008, NAT REV CANCER, V8, P755, DOI 10.1038/nrc2499
   Visweswaran M, 2020, STEM CELLS, V38, P6, DOI 10.1002/stem.3101
   Wainwright EN, 2017, TRENDS CANCER, V3, P372, DOI 10.1016/j.trecan.2017.04.004
   Waldron NN, 2011, MOL CANCER THER, V10, P1829, DOI 10.1158/1535-7163.MCT-11-0206
   Walter RB, 2012, BLOOD, V119, P6198, DOI 10.1182/blood-2011-11-325050
   Wang AB, 2017, CANCER LETT, V385, P87, DOI 10.1016/j.canlet.2016.10.039
   Wang HF, 2018, ACS NANO, V12, P11600, DOI 10.1021/acsnano.8b06846
   Wang KM, 2012, EXP HEMATOL ONCOL, V1, DOI 10.1186/2162-3619-1-36
   Wang Q, 2017, BIOMED PHARMACOTHER, V96, P396, DOI 10.1016/j.biopha.2017.10.008
   Wang SS, 2015, ONCOTARGETS THER, V8, P2973, DOI 10.2147/OTT.S91863
   Wang XX, 2011, BIOMATERIALS, V32, P5673, DOI 10.1016/j.biomaterials.2011.04.029
   Wang XZ, 2019, J BIOMED MATER RES A, V107, P383, DOI 10.1002/jbm.a.36549
   Wang XQ, 2014, J NEUROSCI, V34, P8585, DOI 10.1523/JNEUROSCI.2935-13.2014
   Wang ZW, 2010, DRUG RESIST UPDATE, V13, P109, DOI 10.1016/j.drup.2010.07.001
   Wong TL, 2017, BBA-MOL BASIS DIS, V1863, P1728, DOI 10.1016/j.bbadis.2017.05.012
   Wu TC, 2017, ACTA PHARMACOL SIN B, V7, P65, DOI 10.1016/j.apsb.2016.04.003
   Wu YH, 2017, CLIN EXP PHARMACOL P, V44, P602, DOI 10.1111/1440-1681.12732
   Xiang SN, 2018, SMALL, V14, DOI 10.1002/smll.201704245
   Xu JJ, 2011, J APPL TOXICOL, V31, P164, DOI 10.1002/jat.1577
   Xu LM, 2018, SMALL, V14, DOI 10.1002/smll.201800785
   Xu YY, 2014, BIOMATERIALS, V35, P4667, DOI 10.1016/j.biomaterials.2014.02.035
   Yan YM, 2015, STEM CELL TRANSL MED, V4, P1033, DOI 10.5966/sctm.2015-0048
   Yang CH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099412
   Yang Y, 2016, AM J TRANSL RES, V8, P3986
   Yang Z, 2017, J MATER CHEM B, V5, P6762, DOI 10.1039/c7tb01510k
   Ye J, 2014, TUMOR BIOL, V35, P3945, DOI 10.1007/s13277-013-1561-x
   Ye XQ, 2011, INT J CANCER, V129, P820, DOI 10.1002/ijc.25944
   Yi Y, 2019, J CONTROL RELEASE, V295, P268, DOI 10.1016/j.jconrel.2019.01.006
   Yilmaz OH, 2006, NATURE, V441, P475, DOI 10.1038/nature04703
   Yoshida GJ, 2016, CANCER SCI, V107, P5, DOI 10.1111/cas.12817
   Yu L, 2016, ONCOTARGET, V7, P33055, DOI 10.18632/oncotarget.8849
   Yu Y, 2012, BIOMATERIALS, V33, P1808, DOI 10.1016/j.biomaterials.2011.10.085
   Zalewski B, 2001, FOLIA HISTOCHEM CYTO, V39, P152
   Zhang L, 2012, BIOMATERIALS, V33, P565, DOI 10.1016/j.biomaterials.2011.09.055
   Zhang S, 2008, CANCER RES, V68, P4311, DOI 10.1158/0008-5472.CAN-08-0364
   Zhang XF, 2016, INT J NANOMED, V11, P3655, DOI 10.2147/IJN.S111279
   Zhao P, 2016, BIOMATERIALS, V93, P1, DOI 10.1016/j.biomaterials.2016.03.032
   Zhao P, 2014, MOL PHARMACEUT, V11, P2703, DOI 10.1021/mp5002312
   Zhao Y, 2018, SEMIN CANCER BIOL, V53, P139, DOI 10.1016/j.semcancer.2018.08.002
   Zheng F, 2018, J IMMUNOTHER, V41, P361, DOI 10.1097/CJI.0000000000000242
   Zhi XL, 2015, HEPATOLOGY, V61, P598, DOI 10.1002/hep.27558
   Zhou DH, 2014, ADV CANCER RES, V122, P1, DOI 10.1016/B978-0-12-420117-0.00001-3
   Zhou QM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136694
   Zhou WY, 2012, EMBO J, V31, P2103, DOI 10.1038/emboj.2012.71
   Zhou Y, 2012, BIOMATERIALS, V33, P1863, DOI 10.1016/j.biomaterials.2011.11.029
   Zhu XH, 2015, INT J ONCOL, V46, P215, DOI 10.3892/ijo.2014.2715
   Zhu YY, 2015, AM J CANCER RES, V5, P894
   Zhuang WZ, 2011, INT J CANCER, V129, P2720, DOI 10.1002/ijc.25975
   Zunino F, 1999, DRUG RESIST UPDATE, V2, P351, DOI 10.1054/drup.1999.0108
   Zuo ZQ, 2016, BIOMATERIALS, V82, P48, DOI 10.1016/j.biomaterials.2015.12.014
NR 336
TC 4
Z9 4
U1 4
U2 20
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 2190-393X
EI 2190-3948
J9 DRUG DELIV TRANSL RE
JI Drug Deliv. Transl. Res.
PD OCT
PY 2021
VL 11
IS 5
BP 1779
EP 1805
DI 10.1007/s13346-020-00863-9
EA OCT 2020
PG 27
WC Instruments & Instrumentation; Medicine, Research & Experimental;
   Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Instruments & Instrumentation; Research & Experimental Medicine;
   Pharmacology & Pharmacy
GA UO0VO
UT WOS:000582087400001
PM 33095384
DA 2022-04-25
ER

PT J
AU Zhao, YZ
   Zhang, YY
   Han, H
   Fan, RP
   Hu, Y
   Zhong, L
   Kou, JP
   Yu, BY
AF Zhao Ya-Zheng
   Zhang Yuan-Yuan
   Han Han
   Fan Rui-Ping
   Hu Yang
   Zhong Liang
   Kou Jun-Ping
   Yu Bo-Yang
TI Advances in the antitumor activities and mechanisms of action of
   steroidal saponins
SO CHINESE JOURNAL OF NATURAL MEDICINES
LA English
DT Article
DE Steroidal saponins; Tumor; Mechanism
ID COLORECTAL-CANCER CELLS; EPITHELIAL-MESENCHYMAL TRANSITION; REVERSES
   MULTIDRUG-RESISTANCE; DWARF LILYTURF TUBER; PARIS SAPONIN; IN-VITRO; P38
   MAPK; HEPATOCELLULAR-CARCINOMA; INHIBITS GROWTH; OPHIOPOGONIN B
AB The steroidal saponins are one of the saponin types that exist in an unbound state and have various pharmacological activities, such as anticancer, anti-inflammatory, antiviral, antibacterial and nerves-calming properties. Cancer is a growing health problem worldwide. Significant progress has been made to understand the antitumor effects of steroidal saponins in recent years. According to reported findings, steroidal saponins exert various antitumor activities, such as inhibiting proliferation, inducing apoptosis and autophagy, and regulating the tumor microenvironment, through multiple related signaling pathways. This article focuses on the advances in domestic and foreign studies on the antitumor activity and mechanism of actions of steroidal saponins in the last five years to provide a scientific basis and research ideas for further development and clinical application of steroidal saponins.
C1 [Zhao Ya-Zheng; Zhang Yuan-Yuan; Han Han; Fan Rui-Ping; Hu Yang; Zhong Liang; Kou Jun-Ping; Yu Bo-Yang] China Pharmaceut Univ, Dept Complex Prescript Tradit Chinese Med, Jiangsu Key Lab TCM Evaluat & Translat Res, Nanjing 211198, Jiangsu, Peoples R China.
RP Kou, JP; Yu, BY (corresponding author), China Pharmaceut Univ, Dept Complex Prescript Tradit Chinese Med, Jiangsu Key Lab TCM Evaluat & Translat Res, Nanjing 211198, Jiangsu, Peoples R China.
EM junpingkou@cpu.edu.cn; boyangyu59@163.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81503295]; 2011 Program for Excellent
   Scientific and Technological Innovation Team of Jiangsu Higher
   Education; Priority Academic Program Development of Jiangsu Higher
   Education Institutions; Jiangsu Province 2011 Plan for Collaborative
   Innovation
FX This work was supported by the National Natural Science Foundation of
   China (No. 81503295), 2011 Program for Excellent Scientific and
   Technological Innovation Team of Jiangsu Higher Education, a Project
   Funded by the Priority Academic Program Development of Jiangsu Higher
   Education Institutions, and Jiangsu Province 2011 Plan for Collaborative
   Innovation.
CR Auyeung KKW, 2014, NUTR CANCER, V66, P662, DOI 10.1080/01635581.2014.894093
   Bai CH, 2016, N-S ARCH PHARMACOL, V389, P573, DOI 10.1007/s00210-016-1217-7
   Bian DZ, 2011, ARCH PHARM RES, V34, P997, DOI 10.1007/s12272-011-0617-y
   Butler MS, 2008, NAT PROD REP, V25, P475, DOI 10.1039/b514294f
   Cai H, 2014, ACTA PHARMACOL SIN, V35, P65, DOI 10.1038/aps.2013.133
   Chang HY, 2011, J AGR FOOD CHEM, V59, P5357, DOI 10.1021/jf200598w
   Chen GL, 2013, AFR J TRADIT COMPLEM, V10, P503, DOI 10.4314/ajtcam.v10i3.17
   Chen MJ, 2016, INT J ONCOL, V49, P316, DOI 10.3892/ijo.2016.3514
   Chen MJ, 2013, ONCOL REP, V29, P430, DOI 10.3892/or.2012.2131
   Chen S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020164
   Cheng G, 2016, MOL MED REP, V14, P3199, DOI 10.3892/mmr.2016.5663
   Chun J, 2014, ARCH PHARM RES, V37, P1477, DOI 10.1007/s12272-013-0279-z
   Das S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046641
   Dong YH, 2011, APOPTOSIS, V16, P394, DOI 10.1007/s10495-011-0573-5
   Fulda S, 2015, ONCOGENE, V34, P5105, DOI 10.1038/onc.2014.458
   Gao YF, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1295-9
   Garcia-Prieto C, 2013, J BIOL CHEM, V288, P3240, DOI 10.1074/jbc.M112.384776
   Gu LH, 2013, J TRADIT CHIN MED, V33, P325, DOI 10.1016/S0254-6272(13)60174-0
   Haiming Z, 2016, J TRADIT CHIN MED, V36, P261
   Hao DC, 2013, CHIN J NAT MEDICINES, V11, P330, DOI [10.3724/SP.J.1009.2013.00330, 10.1016/S1875-5364(13)60050-3]
   Hassan M, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/150845
   He Hao, 2015, Asian Pac J Cancer Prev, V16, P1169
   He ZM, 2014, PHYTOMEDICINE, V21, P871, DOI 10.1016/j.phymed.2014.02.002
   Jan TR, 2007, PLANTA MED, V73, P421, DOI 10.1055/s-2007-967169
   Jaramillo S, 2016, J FUNCT FOODS, V26, P1, DOI 10.1016/j.jff.2016.07.007
   Jin JC, 2013, MOL MED REP, V7, P1831, DOI 10.3892/mmr.2013.1428
   Jin JC, 2013, MOL MED REP, V7, P1646, DOI 10.3892/mmr.2013.1366
   Jung DH, 2010, INT IMMUNOPHARMACOL, V10, P1047, DOI 10.1016/j.intimp.2010.06.004
   Jung O, 2016, BIOORG MED CHEM LETT, V26, P3963, DOI 10.1016/j.bmcl.2016.07.004
   Kang XH, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/243859
   Kerr JF, 2015, CANCER, V73, P2013, DOI DOI 10.1002/1097-0142(19940415)73:8<2013::AID-
   Kharb M, 2012, INT J DRUG RES TECH, V2, P177
   Kim DS, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/981675
   Kim EA, 2014, APOPTOSIS, V19, P1165, DOI 10.1007/s10495-014-0994-z
   Kim WK, 2016, J NAT PROD, V79, P1097, DOI 10.1021/acs.jnatprod.6b00006
   Kirmizibekmez H, 2014, PHYTOTHER RES, V28, P534, DOI 10.1002/ptr.5012
   Lepage C, 2011, CANCER LETT, V301, P193, DOI 10.1016/j.canlet.2010.12.003
   Lepage C, 2010, INT J ONCOL, V36, P1183, DOI 10.3892/ijo_00000601
   Li F, 2010, CANCER LETT, V292, P197, DOI 10.1016/j.canlet.2009.12.003
   Li N, 2013, STEROIDS, V78, P1, DOI 10.1016/j.steroids.2012.10.001
   Li WS, 2012, BIOCHEM PHARMACOL, V84, P172, DOI 10.1016/j.bcp.2012.04.006
   Li YW, 2015, CHIN J NAT MEDICINES, V13, P461, DOI 10.1016/S1875-5364(15)30040-6
   Li Y, 2013, MOLECULES, V18, P12916, DOI 10.3390/molecules181012916
   Li YH, 2015, J ETHNOPHARMACOL, V168, P136, DOI 10.1016/j.jep.2015.03.063
   Li YH, 2014, J ETHNOPHARMACOL, V154, P728, DOI 10.1016/j.jep.2014.04.049
   Li YH, 2014, BIOCHEM PHARMACOL, V88, P150, DOI 10.1016/j.bcp.2014.01.018
   Liang F, 2016, PHYTOCHEM LETT, V16, P294, DOI 10.1016/j.phytol.2016.05.011
   Lin SS, 2014, CHIN J NAT MEDICINES, V12, P833, DOI 10.1016/S1875-5364(14)60125-4
   Liu J, 2016, RSC ADV, V6, P92330, DOI 10.1039/c6ra20811h
   Liu J, 2016, ENVIRON TOXICOL PHAR, V46, P103, DOI 10.1016/j.etap.2016.07.004
   Liu M, 2015, PHARM BIOL, V53, P1, DOI 10.3109/13880209.2014.907323
   Liu W, 2016, MOL CARCINOGEN, V55, P440, DOI 10.1002/mc.22293
   Liu Z, 2017, EUR J MED CHEM, V125, P760, DOI 10.1016/j.ejmech.2016.09.066
   Long FY, 2015, J ETHNOPHARMACOL, V162, P112, DOI 10.1016/j.jep.2014.12.065
   Lu ZJ, 2010, CELL PHYSIOL BIOCHEM, V26, P609, DOI 10.1159/000322328
   Lutgendorf S, 2015, CANCER, V89, P1402
   Lv LL, 2013, FOOD CHEM TOXICOL, V59, P657, DOI 10.1016/j.fct.2013.07.012
   Ma ST, 2011, FOOD CHEM TOXICOL, V49, P2243, DOI 10.1016/j.fct.2011.06.022
   Mao ZJ, 2012, INT J MOL SCI, V13, P6521, DOI 10.3390/ijms13056521
   Mohammad RY, 2013, ASIAN PAC J CANCER P, V14, P6945, DOI 10.7314/APJCP.2013.14.11.6945
   Mu SM, 2012, BIOCHEM BIOPH RES CO, V418, P347, DOI 10.1016/j.bbrc.2012.01.024
   Thao NP, 2014, BIOL PHARM BULL, V37, P315, DOI 10.1248/bpb.b13-00705
   Piao XM, 2018, INT J MOL MED, V42, P1018, DOI 10.3892/ijmm.2018.3647
   Qiu DZ, 2013, BMC COMPLEM ALTERN M, V13, DOI 10.1186/1472-6882-13-185
   Qiu P., 2016, RSC ADV, V6, P115029
   Roudsari LC, 2016, ADV DRUG DELIVER REV, V97, P250, DOI 10.1016/j.addr.2015.11.004
   Roy A, 2017, ANTICANCER AGENT MED
   Siegel RL, 2015, CA-CANCER J CLIN, V60, P277, DOI DOI 10.3322/CAAC.20073
   SUN H, 2014, BIOMED RES INT, V2014, DOI DOI 10.1155/2014/805926
   Teng WJ, 2015, GENET MOL RES, V14, P5793, DOI 10.4238/2015.May.29.11
   Tong QY, 2012, STEROIDS, V77, P1219, DOI 10.1016/j.steroids.2012.04.019
   Uemura T, 2011, J NUTR, V141, P17, DOI 10.3945/jn.110.125591
   Waheed A, 2012, EUR J PHARM SCI, V47, P464, DOI 10.1016/j.ejps.2012.07.004
   Waiwut P, 2012, INT J ONCOL, V40, P203, DOI 10.3892/ijo.2011.1182
   Wang GP, 2013, INT J MOL MED, V31, P219, DOI 10.3892/ijmm.2012.1178
   Wang H, 2013, PHYTOMEDICINE, V20, P985, DOI 10.1016/j.phymed.2013.04.014
   Wang N, 2013, BBA-MOL CELL RES, V1833, P2890, DOI 10.1016/j.bbamcr.2013.07.018
   Wang WC, 2014, EXP CELL RES, V323, P255, DOI 10.1016/j.yexcr.2014.01.028
   Wang X, 2014, BIOL PHARM BULL, V37, P1450, DOI 10.1248/bpb.b14-00122
   Wang YH, 2013, BIOCHEM BIOPH RES CO, V441, P825, DOI 10.1016/j.bbrc.2013.10.148
   Wang Y, 2014, EUR J PHARMACOL, V735, P52, DOI 10.1016/j.ejphar.2014.04.018
   Wei SH, 2014, PATHOBIOLOGY, V81, P123, DOI 10.1159/000357622
   Wu X, 2012, PHYTOCHEMISTRY, V81, P133, DOI 10.1016/j.phytochem.2012.05.034
   Xiao X, 2014, CANCER CHEMOTH PHARM, V73, P807, DOI 10.1007/s00280-014-2408-x
   Yan S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131560
   Yin PH, 2012, ASIAN PAC J CANCER P, V13, P5339, DOI 10.7314/APJCP.2012.13.11.5339
   Yu L, 2014, ONCOL REP, V31, P321, DOI 10.3892/or.2013.2841
   Zeng KW, 2013, EUR J PHARMACOL, V714, P261, DOI 10.1016/j.ejphar.2013.04.026
   Zhang DM, 2013, CARCINOGENESIS, V34, P1331, DOI 10.1093/carcin/bgt060
   Zhang T, 2012, BREAST CANCER RES TR, V135, P445, DOI 10.1007/s10549-012-2175-5
   Zhang WY, 2016, MOL MED REP, V13, P4981, DOI 10.3892/mmr.2016.5198
   Zhang WJ, 2014, EUR J MED RES, V19, DOI 10.1186/2047-783X-19-41
   Zhang YY, 2012, CHIN J NAT MEDICINES, V10, P436, DOI [10.3724/SP.J.1009.2012.00436, 10.1016/S1875-5364(12)60084-3]
   Zhang YY, 2015, MOL MED REP, V12, P1493, DOI 10.3892/mmr.2015.3541
   Zhang YY, 2012, MOL MED REP, V6, P1121, DOI 10.3892/mmr.2012.1047
   Zhao LM, 2010, ONCOL REP, V24, P375, DOI 10.3892/or_00000870
   Zhao PJ, 2015, MOL MED REP, V11, P327, DOI 10.3892/mmr.2014.2655
   Zhao RP, 2014, CHIN J NAT MEDICINES, V12, P24, DOI [10.3724/SP.J.1009.2014.00024, 10.1016/S1875-5364(14)60005-4]
   Zhao RP, 2013, ONCOL REP, V29, P1379, DOI 10.3892/or.2013.2272
   Zhao YC, 2011, ONCOL REP, V26, P919, DOI 10.3892/or.2011.1358
   Zheng L, 2014, CHIN J NAT MEDICINES, V12, P142, DOI 10.1016/S1875-5364(14)60023-6
   Zhu GL, 2014, CHIN J NAT MEDICINES, V12, P213, DOI 10.1016/S1875-5364(14)60035-2
   Zhu XH, 2016, MED SCI MONITOR, V22, P1435, DOI 10.12659/MSM.898558
   Zhu ZT, 2012, WORLD J SURG ONCOL, V10, DOI 10.1186/1477-7819-10-228
   Zins K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074924
NR 105
TC 20
Z9 24
U1 7
U2 41
PU CHINESE JOURNAL NATURAL MEDICINES
PI NANJING
PA 24, TONGJIA XIANG, NANJING, 210009, PEOPLES R CHINA
SN 2095-6975
EI 1875-5364
J9 CHIN J NAT MEDICINES
JI Chin. J. Nat. Med.
PD OCT
PY 2018
VL 16
IS 10
BP 732
EP 748
DI 10.1016/S1875-5364(18)30113-4
PG 17
WC Integrative & Complementary Medicine; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Integrative & Complementary Medicine; Pharmacology & Pharmacy
GA GW7VC
UT WOS:000447179300002
PM 30322607
DA 2022-04-25
ER

PT J
AU Gong, WY
   Zhao, ZX
   Liu, BJ
   Lu, LW
   Dong, JC
AF Gong, Wei-Yi
   Zhao, Zheng-Xiao
   Liu, Bao-Jun
   Lu, Lin-Wei
   Dong, Jing-Cheng
TI Exploring the chemopreventive properties and perspectives of baicalin
   and its aglycone baicalein in solid tumors
SO EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Review
DE Baicalin; Baicalein; Solid tumor; Bioavailability
ID CELLS IN-VITRO; EPITHELIAL-MESENCHYMAL TRANSITION; COLORECTAL-CANCER
   CELLS; BREAST-CANCER; HEPATOCELLULAR-CARCINOMA; DOWN-REGULATION;
   SCUTELLARIA-BAICALENSIS; CYCLE ARREST; 12-LIPOXYGENASE INHIBITION;
   MATRIX METALLOPROTEINASES
AB Solid tumors contain a huge mass of malignant tumors other than hematological malignancies. Novel therapies based on bio-safe agents against solid tumors are urgently required. Baicalin and its aglycone baicalein, the major bioactive flavones derived from Scutellaria baicalensis, have potential roles in the management of cancer. The chemopreventive properties governed by baicalin and baicalein were multifold, via apoptosis induction, autophagy triggering, cell cycle arrest, inhibition of 12-lipoxygenase and metastasis suppression. However, their poor solubility and low oral bioavailability severely limited the clinical application. This extensive review focused on the promising anti-cancer activities of baicalin and baicalein and new techniques to improve their bioavailability. (C) 2016 Elsevier Masson SAS. All rights reserved.
C1 [Gong, Wei-Yi; Zhao, Zheng-Xiao; Liu, Bao-Jun; Lu, Lin-Wei; Dong, Jing-Cheng] Fudan Univ, Huashan Hosp, Dept Integrat Med, 12 Middle Wulumiqi Rd, Shanghai, PR, Peoples R China.
   [Gong, Wei-Yi; Zhao, Zheng-Xiao; Liu, Bao-Jun; Lu, Lin-Wei; Dong, Jing-Cheng] Fudan Univ, Inst Integrat Med, 12 Middle Wulumuqi Rd, Shanghai, PR, Peoples R China.
RP Dong, JC (corresponding author), Fudan Univ, Huashan Hosp, Dept Integrat Med, 12 Middle Wulumiqi Rd, Shanghai, PR, Peoples R China.; Dong, JC (corresponding author), Fudan Univ, Inst Integrat Med, 12 Middle Wulumuqi Rd, Shanghai, PR, Peoples R China.
EM jcdong2004@126.com
OI Dong, Jingcheng/0000-0002-5194-367X
FU National Natural Science Foundation for Distinguished Young Scholars of
   ChinaNational Natural Science Foundation of China (NSFC)National Science
   Fund for Distinguished Young Scholars [81403148]; National Natural
   Science Foundation of ChinaNational Natural Science Foundation of China
   (NSFC) [81673916]; Development Project of Shanghai Peak Disciplines
   -Integrative Medicine [20150407]
FX This study was funded by grants from National Natural Science Foundation
   for Distinguished Young Scholars of China (Grant No. 81403148), National
   Natural Science Foundation of China (Grant No. 81673916) and Development
   Project of Shanghai Peak Disciplines -Integrative Medicine (Grant No.
   20150407).
CR Agarwal S, 2009, EXP DERMATOL, V18, P939, DOI 10.1111/j.1600-0625.2009.00874.x
   Aryal P, 2014, FEBS J, V281, P4644, DOI 10.1111/febs.12969
   Bednar W, 2007, FOOD CHEM TOXICOL, V45, P508, DOI 10.1016/j.fct.2006.08.013
   Chang HT, 2015, J NAT PROD, V78, P1624, DOI 10.1021/acs.jnatprod.5b00173
   Chang WH, 2002, PLANTA MED, V68, P128, DOI 10.1055/s-2002-20246
   Chen CH, 2009, FOOD CHEM TOXICOL, V47, P638, DOI 10.1016/j.fct.2008.12.024
   Chen FL, 2014, MOL MED REP, V10, P1999, DOI 10.3892/mmr.2014.2452
   Chen KL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072927
   Chen WC, 2012, MOLECULES, V17, P3844, DOI 10.3390/molecules17043844
   Chen YY, 2016, COLLOID SURFACE B, V140, P74, DOI 10.1016/j.colsurfb.2015.11.018
   Cheng YH, 2012, TOXICOL APPL PHARM, V263, P360, DOI 10.1016/j.taap.2012.07.010
   Chiu YW, 2011, TOXICOL APPL PHARM, V255, P316, DOI 10.1016/j.taap.2011.07.008
   Chung H, 2015, BIOCHEM BIOPH RES CO, V458, P707, DOI 10.1016/j.bbrc.2015.02.032
   Deryugina EI, 2006, CANCER METAST REV, V25, P9, DOI 10.1007/s10555-006-7886-9
   Du GJ, 2010, EUR J PHARMACOL, V630, P121, DOI 10.1016/j.ejphar.2009.12.014
   Folkman J, 2003, CANCER BIOL THER, V2, pS127
   Gade S, 2015, J ENVIRON PATHOL TOX, V34, P298, DOI 10.1615/JEnvironPatholToxicolOncol.2015013806
   Gao JY, 2011, TOXICOL APPL PHARM, V254, P221, DOI 10.1016/j.taap.2011.03.016
   Gao XY, 2015, EXP THER MED, V9, P1665, DOI 10.3892/etm.2015.2329
   Glick D, 2010, J PATHOL, V221, P3, DOI 10.1002/path.2697
   Gong WY, 2014, INT J ONCOL, V44, P1561, DOI 10.3892/ijo.2014.2320
   Guo ZX, 2015, MOL CELL BIOCHEM, V406, P111, DOI 10.1007/s11010-015-2429-8
   Han SW, 2010, CURR CANCER DRUG TAR, V10, P566, DOI 10.2174/156800910791859461
   Hoon DSB, 2011, J SURG ONCOL, V103, P508, DOI 10.1002/jso.21690
   Jing K, 2012, EXP MOL MED, V44, P69, DOI 10.3858/emm.2012.44.2.028
   Kim SJ, 2012, MOL MED REP, V6, P1443, DOI 10.3892/mmr.2012.1085
   Kim SD, 2014, BIOCHEM PHARMACOL, V92, P251, DOI 10.1016/j.bcp.2014.09.019
   Kiraz Y, 2016, TUMOR BIOL, V37, P8471, DOI 10.1007/s13277-016-5035-9
   Lee HZ, 2005, ANTICANCER RES, V25, P959
   Lee JH, 2008, ANTICANCER RES, V28, P1701
   Leung HWC, 2007, FOOD CHEM TOXICOL, V45, P403, DOI 10.1016/j.fct.2006.08.021
   Li K, 2015, J BUON, V20, P1368
   Li XL, 2015, MED ONCOL, V32, DOI 10.1007/s12032-015-0527-9
   Li-Weber M, 2013, CANCER LETT, V332, P304, DOI 10.1016/j.canlet.2010.07.015
   Li-Weber M, 2009, CANCER TREAT REV, V35, P57, DOI 10.1016/j.ctrv.2008.09.005
   Liang J, 2013, DRUG DELIV, V20, P319, DOI 10.3109/10717544.2013.834420
   Liang RR, 2012, INT J ONCOL, V41, P969, DOI 10.3892/ijo.2012.1510
   Lin CJ, 2013, INT J ONCOL, V42, P993, DOI 10.3892/ijo.2013.1791
   Lin YT, 2007, IN VIVO, V21, P1053
   Liu JJ, 2003, INT J CANCER, V106, P559, DOI 10.1002/ijc.11267
   Liu Q, 2016, DRUG DELIV, V23, P1364, DOI 10.3109/10717544.2015.1031295
   Liu TY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0114851
   Liu W, 1998, INT J ONCOL, V12, P1321
   Lovey J, 2013, CANCER LETT, V335, P495, DOI 10.1016/j.canlet.2013.03.012
   Lu QY, 2012, PANCREAS, V41, P571, DOI 10.1097/MPA.0b013e318232e130
   Luo R, 2014, BIOORG MED CHEM LETT, V24, P1334, DOI 10.1016/j.bmcl.2014.01.053
   Ma XC, 2016, DRUG DES DEV THER, V10, P1419, DOI 10.2147/DDDT.S102541
   Mathew R, 2007, NAT REV CANCER, V7, P961, DOI 10.1038/nrc2254
   Miocinovic R, 2005, INT J ONCOL, V26, P241
   Mu JS, 2016, J CANCER, V7, P453, DOI 10.7150/jca.13548
   Naveenkumar C, 2012, FUND CLIN PHARMACOL, V26, P259, DOI 10.1111/j.1472-8206.2010.00910.x
   Nelson AR, 2000, J CLIN ONCOL, V18, P1135, DOI 10.1200/JCO.2000.18.5.1135
   Nie DT, 2006, J BIOL CHEM, V281, P18601, DOI 10.1074/jbc.M601887200
   Piao YS, 2008, CARCINOGENESIS, V29, P440, DOI 10.1093/carcin/bgm274
   Pidgeon GP, 2002, CANCER RES, V62, P2721
   Rui XJ, 2016, ONCOL LETT, V11, P685, DOI 10.3892/ol.2015.3935
   Shang DD, 2015, ONCOL REP, V33, P2077, DOI 10.3892/or.2015.3786
   Shu YJ, 2014, ANTI-CANCER AGENT ME, V14, P1136, DOI 10.2174/1871520614666140223191626
   Srinivas NR, 2010, XENOBIOTICA, V40, P357, DOI 10.3109/00498251003663724
   Steeg PS, 2006, NAT MED, V12, P895, DOI 10.1038/nm1469
   Takahashi H, 2011, BBA-MOL CELL RES, V1813, P1465, DOI 10.1016/j.bbamcr.2011.05.003
   Tan HY, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.271
   Taniguchi H, 2008, CANCER RES, V68, P8918, DOI 10.1158/0008-5472.CAN-08-1120
   Wang CZ, 2015, INT J ONCOL, V47, P1749, DOI 10.3892/ijo.2015.3173
   Wang L, 2010, CANCER LETT, V297, P42, DOI 10.1016/j.canlet.2010.04.022
   Wang N, 2014, CHEM-BIOL INTERACT, V221, P99, DOI 10.1016/j.cbi.2014.08.003
   Wang W, 2015, INT J NANOMED, V10, P3737, DOI 10.2147/IJN.S80297
   Wang XF, 2013, ANTI-CANCER AGENT ME, V13, P923, DOI 10.2174/18715206113139990143
   Wang YF, 2015, PHYTOTHER RES, V29, P674, DOI 10.1002/ptr.5298
   Wang ZX, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/732516
   Wei YM, 2014, INT J NANOMED, V9, P3623, DOI 10.2147/IJN.S66312
   Weng CJ, 2012, CANCER TREAT REV, V38, P76, DOI 10.1016/j.ctrv.2011.03.001
   Wong BCY, 2001, CARCINOGENESIS, V22, P1349, DOI 10.1093/carcin/22.9.1349
   Wu B, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-527
   Wu HY, 2014, ACTA PHARM SIN B, V4, P217, DOI 10.1016/j.apsb.2014.03.002
   Wu JY, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/579751
   Xing J, 2005, LIFE SCI, V78, P140, DOI 10.1016/j.lfs.2005.04.072
   Xu XM, 2012, HEPATOB PANCREAT DIS, V11, P193, DOI 10.1016/S1499-3872(12)60147-7
   Xu XF, 2011, INVEST NEW DRUG, V29, P637, DOI 10.1007/s10637-010-9402-x
   Yan H, 2015, ANTI-CANCER DRUG, V26, P649, DOI 10.1097/CAD.0000000000000230
   Yan X, 2015, ONCOL REP, V33, P737, DOI 10.3892/or.2014.3669
   Yang BL, 2013, INT J COLORECTAL DIS, V28, P547, DOI 10.1007/s00384-012-1562-z
   Yang J, 2008, DEV CELL, V14, P818, DOI 10.1016/j.devcel.2008.05.009
   Yoshimura R, 2004, INT J MOL MED, V13, P41
   Yu CH, 2013, ONCOL REP, V30, P2411, DOI 10.3892/or.2013.2726
   Yu Y, 2015, INT J CLIN EXP MED, V8, P8958
   Yue PF, 2013, INT J NANOMED, V8, P2961, DOI 10.2147/IJN.S44924
   Zhang HQ, 2014, J COLLOID INTERF SCI, V434, P40, DOI 10.1016/j.jcis.2014.07.045
   Zhang HB, 2013, ONCOL LETT, V5, P722, DOI 10.3892/ol.2012.1069
   Zhang JJ, 2011, INT J PHARMACEUT, V420, P180, DOI 10.1016/j.ijpharm.2011.08.023
   Zhang XJ, 2012, ONCOL REP, V27, P1128, DOI 10.3892/or.2011.1599
   Zhang ZN, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090318
   Zhao L, 2013, INT J NANOMED, V8, P3769, DOI 10.2147/IJN.S51578
   Zheng YH, 2014, PHYTOTHER RES, V28, P1342, DOI 10.1002/ptr.5135
   Zhou BR, 2011, ARCH PHARM RES, V34, P261, DOI 10.1007/s12272-011-0212-2
   Zhou QM, 2009, ACTA PHARMACOL SIN, V30, P1648, DOI 10.1038/aps.2009.166
   Ziegler DS, 2008, J CLIN ONCOL, V26, P493, DOI 10.1200/JCO.2007.13.9717
NR 97
TC 59
Z9 62
U1 5
U2 43
PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY-LES-MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE
SN 0223-5234
EI 1768-3254
J9 EUR J MED CHEM
JI Eur. J. Med. Chem.
PD JAN 27
PY 2017
VL 126
BP 844
EP 852
DI 10.1016/j.ejmech.2016.11.058
PG 9
WC Chemistry, Medicinal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA EO6LP
UT WOS:000396804600064
PM 27960146
DA 2022-04-25
ER

PT J
AU Schroll, MM
   LaBonia, GJ
   Ludwig, KR
   Hummon, AB
AF Schroll, Monica M.
   LaBonia, Gabriel J.
   Ludwig, Katelyn R.
   Hummon, Amanda B.
TI Glucose Restriction Combined with Autophagy Inhibition and Chemotherapy
   in HCT 116 Spheroids Decreases Cell Clonogenicity and Viability
   Regulated by Tumor Suppressor Genes
SO JOURNAL OF PROTEOME RESEARCH
LA English
DT Article
DE nutrient restriction; autophagy; chloroquine; colorectal cancer;
   proteomics; iTRAQ; MALDI imaging mass spectrometry; three-dimensional
   cell culture
ID MASS-SPECTROMETRY; NUCLEAR-PROTEIN; NUTRIENT RESTRICTION; DIFFERENT
   REGIONS; IN-VITRO; CANCER; CHLOROQUINE; METABOLISM; IRINOTECAN; THERAPY
AB Drug resistance is a prevalent phenomenon that decreases the efficacy of cancer treatments and contributes to cancer progression and metastasis. Weakening drug-resistant cancer cells prior to chemotherapy is a potential strategy to combat chemoresistance. One approach to damage resistant cancer cells is modulation of nutritional intake. The combination of nutrient restriction with targeted compound treatment results in pronounced molecular changes. This study provides valuable information about augmenting existing chemotherapeutic regimes with simultaneous glucose restriction and autophagy inhibition in colorectal cancer cells. In this study, we explore the chemical pathways that drive the cellular response to nutrient restriction, autophagy inhibition, and the chemotherapy irinotecan using global quantitative proteomics and imaging mass spectrometry. We determined that significant pathways were altered including autophagy and metabolism via glycplysis, gluconeogenesis, and sucrose degradation. We also found that period circadian clock 2 (PER2), a tumor suppressor protein, was significantly up-regulated only when glucose was restricted with autophagy inhibition and chemotherapy. The upstream regulators of these differentially regulated pathways were determined to have implications in cancer, showing an increase in tumor suppressor proteins and a decrease in nuclear protein 1 (NUPR1) an important protein in chemoresistance. We also evaluated the phenotypic response of these cells and discovered autophagy inhibition and chemotherapy treatment increased apoptosis and decreased cell Clonogenicity and viability. When glucose restriction was combined with autophagy inhibition and chemotherapy, all of the phenotypic results were intensified. In sum, our results indicate that glucose metabolism is of great importance in the ability of cancer cells to survive chemotherapy. By weakening cancer cells with glucose restriction and autophagy inhibition prior to chemotherapy, cancer cells become more sensitive to therapy.
C1 [Hummon, Amanda B.] Univ Notre Dame, Dept Chem & Biochem, Notre Dame, IN 46556 USA.
   Univ Notre Dame, Harper Canc Res Inst, Notre Dame, IN 46556 USA.
RP Hummon, AB (corresponding author), Univ Notre Dame, Dept Chem & Biochem, Notre Dame, IN 46556 USA.
EM ahummon@nd.edu
OI Hummon, Amanda/0000-0002-1969-9013
FU National Institutes of Health Training Grant - Chemistry Biochemistry
   Biology Interface ProgramUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [T32GM075762];
   National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [R01GM110406];
   National Science Foundation (CAREER Award)National Science Foundation
   (NSF) [CHE-1351595]; National Science FoundationNational Science
   Foundation (NSF) [1625944]; NATIONAL INSTITUTE OF GENERAL MEDICAL
   SCIENCESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of General
   Medical Sciences (NIGMS) [T32GM075762, R01GM110406] Funding Source: NIH
   RePORTER
FX M.S. was supported by National Institutes of Health Training Grant -
   Chemistry Biochemistry Biology Interface Program (T32GM075762). A.B.H.
   was supported by the National Institutes of Health (R01GM110406) and the
   National Science Foundation (CAREER Award, CHE-1351595). The
   UltrafleXtreme instrument (MALDI-TOF-TOF) was acquired through National
   Science Foundation award #1625944. We gratefully acknowledge the
   assistance of Dr. Susan Skube for her edits and the Notre Dame Mass
   Spectrometry and Proteomics Facility (MSPF).
CR Amaravadi RK, 2007, CLIN CANCER RES, V13, P7271, DOI 10.1158/1078-0432.CCR-07-1595
   Beger RD, 2013, METABOLITES, V3, P552, DOI 10.3390/metabo3030552
   Cano CE, 2010, THESCIENTIFICWORLDJO, V10, P1958, DOI 10.1100/tsw.2010.186
   Chowdhury U, 2009, CANCER METAST REV, V28, P225, DOI 10.1007/s10555-009-9183-x
   Espina V, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010240
   Fan CD, 2006, BIOORGAN MED CHEM, V14, P3218, DOI 10.1016/j.bmc.2005.12.035
   FREYER JP, 1980, CANCER RES, V40, P3956
   Gery S, 2007, ONCOGENE, V26, P7916, DOI 10.1038/sj.onc.1210585
   Hamidi T, 2012, J CLIN INVEST, V122, P2092, DOI 10.1172/JCI60144
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Harhaji-Trajkovic L, 2012, PHARM RES-DORDR, V29, P2249, DOI 10.1007/s11095-012-0753-1
   Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809
   Hua H, 2007, CANCER GENE THER, V14, P815, DOI 10.1038/sj.cgt.7701061
   JENSEN PB, 1994, CANCER RES, V54, P2959
   Kimura T, 2013, CANCER RES, V73, P3, DOI 10.1158/0008-5472.CAN-12-2464
   Kinchen JM, 2008, NAT REV MOL CELL BIO, V9, P781, DOI 10.1038/nrm2515
   Klement RJ, 2011, NUTR METAB, V8, DOI 10.1186/1743-7075-8-75
   LaBonia GJ, 2016, PROTEOMICS, V16, P1814, DOI 10.1002/pmic.201500524
   Lashinger LM, 2016, CANCER METAB, V4, DOI 10.1186/s40170-016-0158-4
   Lee C, 2012, DRUG RESIST UPDATE, V15, P114, DOI 10.1016/j.drup.2012.01.004
   Li HH, 2011, ANAL CHEM, V83, P8794, DOI 10.1021/ac202356g
   Liang X, 2014, CELL BIOSCI, V4, DOI 10.1186/2045-3701-4-10
   Liu X, 2015, ANAL CHEM, V87, P9508, DOI 10.1021/acs.analchem.5b00419
   Liu X, 2015, J AM SOC MASS SPECTR, V26, P577, DOI 10.1007/s13361-014-1071-0
   Liu X, 2013, ANAL CHEM, V85, P6295, DOI 10.1021/ac400519c
   Longo VD, 2014, CELL METAB, V19, P181, DOI 10.1016/j.cmet.2013.12.008
   Lv MM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115147
   Mattson MP, 2005, J NUTR BIOCHEM, V16, P129, DOI 10.1016/j.jnutbio.2004.12.007
   Melchior F, 2003, TRENDS BIOCHEM SCI, V28, P612, DOI 10.1016/j.tibs.2003.09.002
   Munro AJ, 2005, BRIT J CANCER, V92, P434, DOI 10.1038/sj.bjc.6602358
   Norheim F, 2012, NUTRIENTS, V4, P1898, DOI 10.3390/nu4121898
   Pampaloni F, 2007, NAT REV MOL CELL BIO, V8, P839, DOI 10.1038/nrm2236
   Panieri E, 2010, AGING-US, V2, P487, DOI 10.18632/aging.100183
   Pellegrini P, 2014, AUTOPHAGY, V10, P562, DOI 10.4161/auto.27901
   Persidis A, 1999, NAT BIOTECHNOL, V17, P94, DOI 10.1038/5289
   Projean D, 2003, DRUG METAB DISPOS, V31, P748, DOI 10.1124/dmd.31.6.748
   Raffaghello L, 2010, CELL CYCLE, V9, P4474, DOI 10.4161/cc.9.22.13954
   Raghunand N, 2003, BIOCHEM PHARMACOL, V66, P1219, DOI 10.1016/S0006-2952(03)00468-4
   Rougier P, 1998, LANCET, V352, P1407, DOI 10.1016/S0140-6736(98)03085-2
   Schroll MM, 2016, NUTR RES, V36, P1068, DOI 10.1016/j.nutres.2016.08.002
   Senichkin VV, 2016, MOL BIOL+, V50, P362, DOI 10.1134/S0026893316030109
   Sui X, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.350
   SUTHERLAND RM, 1988, SCIENCE, V240, P177, DOI 10.1126/science.2451290
   SUTHERLAND RM, 1986, CANCER RES, V46, P5320
   TANNOCK IF, 1989, CANCER RES, V49, P4373
   van Niekerk G, 2016, FRONT ONCOL, V6, DOI 10.3389/fonc.2016.00242
   Vasseur S, 1999, EUR J BIOCHEM, V259, P670, DOI 10.1046/j.1432-1327.1999.00092.x
   Warburg O, 1924, NATURWISSENSCHAFTEN, V12, P1131, DOI 10.1007/BF01504608
   White E, 2015, J CLIN INVEST, V125, P42, DOI 10.1172/JCI73941
   Wood PA, 2006, MOL CANCER THER, V5, P2023, DOI 10.1158/1535-7163.MCT-06-0177
   Wood PA, 2009, INTEGR CANCER THER, V8, P303, DOI 10.1177/1534735409355292
   Yamada KM, 2007, CELL, V130, P601, DOI 10.1016/j.cell.2007.08.006
   Yang ZNJ, 2011, MOL CANCER THER, V10, P1533, DOI 10.1158/1535-7163.MCT-11-0047
   Zheng YZ, 2009, CANCER INVEST, V27, P286, DOI 10.1080/07357900802427927
NR 54
TC 20
Z9 22
U1 0
U2 22
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1535-3893
EI 1535-3907
J9 J PROTEOME RES
JI J. Proteome Res.
PD AUG
PY 2017
VL 16
IS 8
BP 3009
EP 3018
DI 10.1021/acs.jproteome.7b00293
PG 10
WC Biochemical Research Methods
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA FD1OY
UT WOS:000407307800030
PM 28650662
OA Green Accepted
DA 2022-04-25
ER

PT J
AU Weidner, P
   Sohn, M
   Gutting, T
   Friedrich, T
   Gaiser, T
   Magdeburg, J
   Kienle, P
   Ruh, H
   Hopf, C
   Behrens, HM
   Rocken, C
   Hanoch, T
   Seger, R
   Ebert, MPA
   Burgermeister, E
AF Weidner, Philip
   Soehn, Michaela
   Gutting, Tobias
   Friedrich, Teresa
   Gaiser, Timo
   Magdeburg, Julia
   Kienle, Peter
   Ruh, Hermelindis
   Hopf, Carsten
   Behrens, Hans-Michael
   Roecken, Christoph
   Hanoch, Tamar
   Seger, Rony
   Ebert, Matthias P. A.
   Burgermeister, Elke
TI Myotubularin-related protein 7 inhibits insulin signaling in colorectal
   cancer
SO ONCOTARGET
LA English
DT Article
DE colorectal cancer; insulin; MTMR7; phosphatase; myotubularin
ID GASTRIC-CANCER; METAANALYSIS; PROGRESSION; RECURRENCE; CAVEOLIN-1;
   EXPRESSION; MUTATIONS; AUTOPHAGY; GENOMICS; FAMILY
AB Phosphoinositide (PIP) phosphatases such as myotubularins (MTMs) inhibit growth factor receptor signaling. However, the function of myotubularin-related protein 7 (MTMR7) in cancer is unknown. We show that MTMR7 protein was down-regulated with increasing tumor grade (G), size (T) and stage (UICC) in patients with colorectal cancer (CRC) (n=1786). The presence of MTMR7 in the stroma correlated with poor prognosis, whereas MTMR7 expression in the tumor was not predictive for patients' survival. Insulin reduced MTMR7 protein levels in human CRC cell lines, and CRC patients with type 2 diabetes mellitus (T2DM) or loss of imprinting (LOI) of insulin-like growth factor 2 (IGF2) had an increased risk for MTMR7 loss. Mechanistically, MTMR7 lowered PIPs and inhibited insulin-mediated AKT-ERK1/2 signaling and proliferation in human CRC cell lines. MTMR7 provides a novel link between growth factor signaling and cancer, and may thus constitute a potential marker or drug target for human CRC.
C1 [Weidner, Philip; Soehn, Michaela; Gutting, Tobias; Friedrich, Teresa; Ebert, Matthias P. A.; Burgermeister, Elke] Heidelberg Univ, Med Fac Mannheim, Univ Med Mannheim, Dept Med 2, D-68167 Mannheim, Germany.
   [Gaiser, Timo] Heidelberg Univ, Med Fac Mannheim, Univ Med Mannheim, Inst Pathol, D-68167 Mannheim, Germany.
   [Magdeburg, Julia; Kienle, Peter] Heidelberg Univ, Med Fac Mannheim, Univ Med Mannheim, Dept Surg, D-68167 Mannheim, Germany.
   [Ruh, Hermelindis; Hopf, Carsten] Mannheim Univ Appl Sci, ABIMAS Res Ctr, D-68163 Mannheim, Germany.
   [Behrens, Hans-Michael; Roecken, Christoph] Univ Kiel, Inst Pathol, D-24105 Kiel, Germany.
   [Hanoch, Tamar; Seger, Rony] Weizmann Inst Sci, Dept Biol Regulat, I-7610001 Rehovot, Israel.
RP Burgermeister, E (corresponding author), Heidelberg Univ, Med Fac Mannheim, Univ Med Mannheim, Dept Med 2, D-68167 Mannheim, Germany.
EM elke.burgermeister@medma.uni-heidelberg.de
RI Röcken, Christoph/A-9239-2010; Hopf, Carsten/A-3275-2015
OI Röcken, Christoph/0000-0002-6989-8002; Hopf, Carsten/0000-0003-0802-6451
FU Cooperation Program in Cancer Research of the Deutsches
   Krebsforschungszentrum (DKFZ) [Ca158]; Israel's Ministry of Science,
   Technology and Space (MOST); DKFZ-MOST [Ca158]; Deutsche
   KrebshilfeDeutsche Krebshilfe [108287, 111086]; Deutsche
   Forschungsgemeinschaft (DFG)German Research Foundation (DFG) [BU2285];
   Land Baden-Wurttemberg (ZO IV); EFRE (ZAFH ABIMAS); DFGGerman Research
   Foundation (DFG)European Commission [SFB 824, TP B1]; ZOBEL (Center of
   Geriatric Biology and Oncology); Land Baden-Wurttemberg
   (Perspektivforderung)
FX This work was supported in part by grants to EB and RS from the
   Cooperation Program in Cancer Research (Ca158) of the Deutsches
   Krebsforschungszentrum (DKFZ) and Israel's Ministry of Science,
   Technology and Space (MOST). MS was granted a doctoral fellowship within
   this program (DKFZ-MOST: Ca158). EB received additional funds from
   Deutsche Krebshilfe (#108287; #111086) and Deutsche
   Forschungsgemeinschaft (DFG) (BU2285). CH was funded by Land
   Baden-Wurttemberg (ZO IV) and EFRE (ZAFH ABIMAS). ME was funded by DFG
   (SFB 824, TP B1), ZOBEL (Center of Geriatric Biology and Oncology) and
   Land Baden-Wurttemberg (Perspektivforderung).
CR Al-Qusairi L, 2013, FASEB J, V27, P3384, DOI 10.1096/fj.12-220947
   Baba Y, 2010, GASTROENTEROLOGY, V139, P1855, DOI 10.1053/j.gastro.2010.07.050
   Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003
   Belharazem D, J GASTROENTEROL
   Boger C, 2015, GASTRIC CANCER, V18, P784, DOI 10.1007/s10120-014-0435-2
   Burgermeister E, 2007, CANCER RES, V67, P8519, DOI 10.1158/0008-5472.CAN-07-1125
   Burgermeister E, 2011, MOL CELL BIOL, V31, P3497, DOI 10.1128/MCB.01421-10
   Cao CH, 2008, MOL BIOL CELL, V19, P3334, DOI 10.1091/mbc.E08-04-0367
   Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095
   Chiarini F, 2015, TRENDS PHARMACOL SCI, V36, P124, DOI 10.1016/j.tips.2014.11.004
   Cox AD, 2014, NAT REV DRUG DISCOV, V13, P828, DOI 10.1038/nrd4389
   De Roock W, 2011, LANCET ONCOL, V12, P594, DOI 10.1016/S1470-2045(10)70209-6
   Ebert MPA, 2012, NEW ENGL J MED, V366, P44, DOI 10.1056/NEJMoa1009473
   Fetalvero KM, 2013, MOL CELL BIOL, V33, P98, DOI 10.1128/MCB.01075-12
   Fulop A, 2013, ANAL CHEM, V85, P9156, DOI 10.1021/ac4018154
   Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088
   Guo LY, 2013, P NATL ACAD SCI USA, V110, pE1849, DOI 10.1073/pnas.1305070110
   Guraya SY, 2015, WORLD J GASTROENTERO, V21, P6026, DOI 10.3748/wjg.v21.i19.6026
   Hao F, 2016, FEBS LETT, V590, P161, DOI 10.1002/1873-3468.12048
   Heppner BI, 2014, BRIT J CANCER, V111, P1977, DOI 10.1038/bjc.2014.483
   Hnia K, 2012, TRENDS MOL MED, V18, P317, DOI 10.1016/j.molmed.2012.04.004
   Karapetis CS, 2008, NEW ENGL J MED, V359, P1757, DOI 10.1056/NEJMoa0804385
   Lawlor MW, 2014, AM J PATHOL, V184, P1831, DOI 10.1016/j.ajpath.2014.03.003
   Lito P, 2013, NAT MED, V19, P1401, DOI 10.1038/nm.3392
   Liu R, 2014, ARCH MED RES, V45, P318, DOI 10.1016/j.arcmed.2014.04.003
   Mei J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004979
   Metzger ML, 2016, HISTOPATHOLOGY, V68, P241, DOI 10.1111/his.12745
   Mochizuki Y, 2003, P NATL ACAD SCI USA, V100, P9768, DOI 10.1073/pnas.1333958100
   Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252
   Nicot AS, 2008, TRAFFIC, V9, P1240, DOI 10.1111/j.1600-0854.2008.00754.x
   Park J, 2014, NAT REV ENDOCRINOL, V10, P455, DOI 10.1038/nrendo.2014.94
   Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45
   Pole JCM, 2006, ONCOGENE, V25, P5693, DOI 10.1038/sj.onc.1209570
   Pollak M, 2012, NAT REV CANCER, V12, P159, DOI 10.1038/nrc3215
   Razidlo GL, 2011, J BIOL CHEM, V286, P20005, DOI 10.1074/jbc.M110.197749
   Shackelford DB, 2009, NAT REV CANCER, V9, P563, DOI 10.1038/nrc2676
   Shi JG, 2015, SCI REP-UK, V5, DOI 10.1038/srep17591
   Shimobayashi M, 2014, NAT REV MOL CELL BIO, V15, P155, DOI 10.1038/nrm3757
   Tebbutt N, 2013, NAT REV CANCER, V13, P663, DOI 10.1038/nrc3559
   Zhou W, 2002, LANCET, V359, P219, DOI 10.1016/S0140-6736(02)07448-2
   Zou J, 2012, P NATL ACAD SCI USA, V109, P9539, DOI 10.1073/pnas.1207021109
NR 41
TC 14
Z9 15
U1 0
U2 4
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD AUG 2
PY 2016
VL 7
IS 31
BP 50490
EP 50506
DI 10.18632/oncotarget.10466
PG 17
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA DY8ZS
UT WOS:000385422000127
PM 27409167
OA gold, Green Published, Green Submitted
DA 2022-04-25
ER

PT J
AU Lou, J
   Yang, XX
   Shan, WX
   Jin, Z
   Ding, JH
   Hu, YX
   Liao, QS
   Du, Q
   Xie, R
   Xu, JY
AF Lou, Jun
   Yang, Xiaoxu
   Shan, Weixi
   Jin, Zhe
   Ding, Jianhong
   Hu, Yanxia
   Liao, Qiushi
   Du, Qian
   Xie, Rui
   Xu, Jingyu
TI Effects of calcium-permeable ion channels on various digestive diseases
   in the regulation of autophagy
SO MOLECULAR MEDICINE REPORTS
LA English
DT Review
DE calcium; autophagy; ion channel; calcium signaling; digestive system
   diseases
ID ENDOPLASMIC-RETICULUM STRESS; GASTRIC-CANCER; HELICOBACTER-PYLORI;
   COLORECTAL-CANCER; CA2+; PANCREATITIS; CARCINOMA; INHIBITION; MECHANISM;
   APOPTOSIS
AB Autophagy is a process of degradation and catabolism in cells. By removing damaged or dysfunctional organelles, autophagy interacts with the ubiquitin-proteasome degradation system to jointly regulate cell function and energy homeostasis. Since autophagy plays a key role in physiology, disorders of the autophagy mechanism are associated with various diseases. Therefore, thorough understanding of the autophagy regulatory mechanism are crucially important in the diagnosis and treatment of diseases. To date, ion channels may affect the development and treatment of diseases by regulating autophagy, especially calcium-permeable ion channels, in the process of digestive system diseases. However, the mechanism by which calcium ions and their channels regulate autophagy is still poorly understood, thus emphasizing the need for further research in this field. The present review intends to discuss the association, mechanism and application of calcium ions, their channels and autophagy in the occurrence and development of digestive system diseases.
C1 [Lou, Jun; Yang, Xiaoxu; Shan, Weixi; Jin, Zhe; Ding, Jianhong; Hu, Yanxia; Liao, Qiushi; Du, Qian; Xie, Rui; Xu, Jingyu] Zunyi Med Univ, Affiliated Hosp, Dept Gastroenterol, 149 Dalian Rd, Zunyi 563003, Guizhou, Peoples R China.
RP Xie, R; Xu, JY (corresponding author), Zunyi Med Univ, Affiliated Hosp, Dept Gastroenterol, 149 Dalian Rd, Zunyi 563003, Guizhou, Peoples R China.
EM xr19841029@aliyun.com; xujingyu_gzzy@126.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81970541]; Graduate Research Fund Project of
   Guizhou Province [(2019) 088]
FX This study was supported by research grants from the National Natural
   Science Foundation of China (grant no. 81970541 to JY); and the Graduate
   Research Fund Project of Guizhou Province [grant no. YJSCXJH (2019) 088
   to XXY].
CR Abdelmohsen K, 2012, MOL CELL BIOL, V32, P2530, DOI 10.1128/MCB.00510-12
   Alexander SPH, 2015, BRIT J PHARMACOL, V172, P5729, DOI 10.1111/bph.13347
   Almasi S, 2018, J BIOL CHEM, V293, P3637, DOI 10.1074/jbc.M117.817635
   Arnold M, 2017, GUT, V66, P683, DOI 10.1136/gutjnl-2015-310912
   Banks PA, 2013, GUT, V62, P102, DOI 10.1136/gutjnl-2012-302779
   Behrends C, 2010, NATURE, V466, P68, DOI 10.1038/nature09204
   Bernardi P, 2012, CELL CALCIUM, V52, P22, DOI 10.1016/j.ceca.2012.03.004
   Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155
   Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035
   Berridge MJ, 2002, CELL CALCIUM, V32, P235, DOI 10.1016/S0143416002001823
   Biczo G, 2018, GASTROENTEROLOGY, V154, P689, DOI 10.1053/j.gastro.2017.10.012
   Bround MJ, 2013, J BIOL CHEM, V288, P18975, DOI 10.1074/jbc.M112.427062
   Capurro MI, 2020, AUTOPHAGY, V16, P169, DOI 10.1080/15548627.2019.1677322
   Capurro MI, 2019, NAT MICROBIOL, V4, P1411, DOI 10.1038/s41564-019-0441-6
   Cardenas C, 2010, CELL, V142, P270, DOI 10.1016/j.cell.2010.06.007
   Catterall WA, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a003947
   Chen X, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052347
   Choi AMK, 2013, NEW ENGL J MED, V368, P651, DOI [10.1056/NEJMra1205406, 10.1056/NEJMc1303158]
   Crociani O, 2013, SCI REP-UK, V3, DOI 10.1038/srep03308
   Cuervo AM, 2014, CELL RES, V24, P92, DOI 10.1038/cr.2013.153
   Cusi K, 2012, GASTROENTEROLOGY, V142, P711, DOI 10.1053/j.gastro.2012.02.003
   Czaja MJ, 2015, HEPATOLOGY, V62, P312, DOI 10.1002/hep.27858
   Decuypere JP, 2015, AUTOPHAGY, V11, P1944, DOI 10.1080/15548627.2015.1083666
   Decuypere JP, 2011, CELL CALCIUM, V50, P242, DOI 10.1016/j.ceca.2011.04.001
   Diaz-Laviada I, 2014, PROG DRUG RES, V68, P181, DOI 10.1007/978-3-0348-0828-6_8
   Du JY, 2014, P NATL ACAD SCI USA, V111, P8961, DOI 10.1073/pnas.1407018111
   East DA, 2013, AUTOPHAGY, V9, P1710, DOI 10.4161/auto.25367
   Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210
   Foegeding NJ, 2016, TOXINS, V8, DOI 10.3390/toxins8060173
   Frick TW, 2012, SURGERY, V152, pS157, DOI 10.1016/j.surg.2012.05.013
   Fukase K, 2008, LANCET, V372, P392, DOI 10.1016/S0140-6736(08)61159-9
   Gao WT, 2008, AUTOPHAGY, V4, P754, DOI 10.4161/auto.6360
   Gerasimenko JV, 2014, J PHYSIOL-LONDON, V592, P269, DOI 10.1113/jphysiol.2013.261784
   Gerasimenko JV, 2013, P NATL ACAD SCI USA, V110, P13186, DOI 10.1073/pnas.1300910110
   Gonzalez-Rodriguez A, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.162
   GORDON PB, 1993, J BIOL CHEM, V268, P26107
   Grotemeier A, 2010, CELL SIGNAL, V22, P914, DOI 10.1016/j.cellsig.2010.01.015
   Gueguinou M, 2016, ONCOTARGET, V7, P36168, DOI 10.18632/oncotarget.8786
   Gukovsky I, 2013, GASTROENTEROLOGY, V144, P1199, DOI 10.1053/j.gastro.2013.02.007
   Guo YJ, 2019, CHANNELS, V13, P367, DOI 10.1080/19336950.2019.1664038
   Guse AH, 2008, SCI SIGNAL, V1, DOI 10.1126/scisignal.144re10
   Harris J, 2011, CYTOKINE, V56, P140, DOI 10.1016/j.cyto.2011.08.022
   Hoyer-Hansen M, 2007, MOL CELL, V25, P193, DOI 10.1016/j.molcel.2006.12.009
   Hua W, 2019, AUTOPHAGY, V15, P707, DOI 10.1080/15548627.2018.1557835
   Huang QC, 2017, CANCER LETT, V403, P108, DOI 10.1016/j.canlet.2017.05.034
   Jing Z, 2016, CANCER LETT, V372, P226, DOI 10.1016/j.canlet.2016.01.006
   Kania E, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00140
   Kellenberger S, 2002, PHYSIOL REV, V82, P735, DOI 10.1152/physrev.00007.2002
   Khan MT, 2010, J BIOL CHEM, V285, P16912, DOI 10.1074/jbc.M110.114207
   Klionsky DJ, 2016, AUTOPHAGY, V12, P1, DOI 10.1080/15548627.2015.1100356
   Klionsky DJ, 2013, J INNATE IMMUN, V5, P427, DOI 10.1159/000351979
   Kondratska K, 2014, BBA-MOL CELL RES, V1843, P2263, DOI 10.1016/j.bbamcr.2014.02.012
   Kondratskyi A, 2013, FRONT PHYSIOL, V4, DOI 10.3389/fphys.2013.00272
   Kroemer G, 2010, MOL CELL, V40, P280, DOI 10.1016/j.molcel.2010.09.023
   Kuang Q, 2015, CELL MOL LIFE SCI, V72, P3677, DOI 10.1007/s00018-015-1948-5
   Lalazar G, 2016, AM J PHYSIOL-GASTR L, V311, pG377, DOI 10.1152/ajpgi.00124.2016
   Lankisch PG, 2015, LANCET, V386, P85, DOI 10.1016/S0140-6736(14)60649-8
   Levine B, 2011, NATURE, V469, P323, DOI 10.1038/nature09782
   Li LQ, 2016, TUMOR BIOL, V37, P653, DOI 10.1007/s13277-015-3842-z
   Li WW, 2012, CELL MOL LIFE SCI, V69, P1125, DOI 10.1007/s00018-011-0865-5
   Lur G, 2009, CURR BIOL, V19, P1648, DOI 10.1016/j.cub.2009.07.072
   Marrache F, 2008, GASTROENTEROLOGY, V135, P1277, DOI 10.1053/j.gastro.2008.06.078
   Miyagawa K, 2016, AM J PATHOL, V186, P1861, DOI 10.1016/j.ajpath.2016.03.003
   Mizushima N, 2007, GENE DEV, V21, P2861, DOI 10.1101/gad.1599207
   Mizushima N, 2011, ANNU REV CELL DEV BI, V27, P107, DOI 10.1146/annurev-cellbio-092910-154005
   Nilius B, 2003, ACTA PHYSIOL SCAND, V177, P119, DOI 10.1046/j.1365-201X.2003.01060.x
   O'Neill CM, 2013, ENDOCRINOLOGY, V154, P3077, DOI 10.1210/en.2012-2138
   Pandol SJ, 2007, GASTROENTEROLOGY, V132, P1127, DOI 10.1053/j.gastro.2007.01.055
   Park HW, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5834
   Parys JB, 2012, CELL COMMUN SIGNAL, V10, DOI 10.1186/1478-811X-10-17
   Pedersen SF, 2005, CELL CALCIUM, V38, P233, DOI 10.1016/j.ceca.2005.06.028
   Pereira GJS, 2011, J BIOL CHEM, V286, P27875, DOI 10.1074/jbc.C110.216580
   Perez-Neut M, 2016, ONCOTARGET, V7, P21991, DOI 10.18632/oncotarget.7831
   Petersen OH, 2006, TRENDS PHARMACOL SCI, V27, P113, DOI 10.1016/j.tips.2005.12.006
   Petersen OH, 2008, ANNU REV PHYSIOL, V70, P273, DOI 10.1146/annurev.physiol.70.113006.100618
   Petersen OH, 2017, J PHYSIOL-LONDON, V595, P2999, DOI 10.1113/JP272772
   Petroni G, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2349-8
   Rah SY, 2017, FASEB J, V31, P3126, DOI 10.1096/fj.201601290R
   Ramsey IS, 2006, ANNU REV PHYSIOL, V68, P619, DOI 10.1146/annurev.physiol.68.040204.100431
   Rassow J, 2012, MICROBES INFECT, V14, P1026, DOI 10.1016/j.micinf.2012.07.002
   Ravikumar B, 2010, PHYSIOL REV, V90, P1383, DOI 10.1152/physrev.00030.2009
   Rizzuto R, 2012, NAT REV MOL CELL BIO, V13, P566, DOI 10.1038/nrm3412
   Rocken C, 2017, EXPERT REV MOL DIAGN, V17, P293, DOI 10.1080/14737159.2017.1286985
   Ruan HB, 2017, GENE DEV, V31, P1655, DOI 10.1101/gad.305441.117
   Selli C, 2016, MOL CELL BIOCHEM, V420, P129, DOI 10.1007/s11010-016-2776-0
   Selli C, 2015, BIOMED PHARMACOTHER, V71, P194, DOI 10.1016/j.biopha.2015.02.024
   Shi CS, 2008, J BIOL CHEM, V283, P33175, DOI 10.1074/jbc.M804478200
   Shi M, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-26
   Smaili SS, 2013, CURR MOL MED, V13, P252
   Sui XB, 2014, SCI REP-UK, V4, DOI 10.1038/srep04694
   Sun X, 2011, BRAIN RES, V1396, P77, DOI 10.1016/j.brainres.2011.04.011
   Suzuki R, 2014, ANTICANCER RES, V34, P4685
   Tang BD, 2017, J CELL MOL MED, V21, P904, DOI 10.1111/jcmm.13029
   Tian XJ, 2015, PLOS BIOL, V13, DOI 10.1371/journal.pbio.1002103
   Tomar D, 2016, CELL REP, V15, P1673, DOI 10.1016/j.celrep.2016.04.050
   Wang D, 2019, BIOMED PHARMACOTHER, V117, DOI 10.1016/j.biopha.2019.109061
   Wang L, 2017, SCI REP-UK, V7, DOI 10.1038/srep44265
   WARD JB, 1995, LANCET, V346, P1016, DOI 10.1016/S0140-6736(95)91695-4
   Wei CC, 2018, FASEB J, V32, P6666, DOI 10.1096/fj.201800463
   Wemmie JA, 2013, NAT REV NEUROSCI, V14, P461, DOI 10.1038/nrn3529
   Williams A, 2008, NAT CHEM BIOL, V4, P295, DOI 10.1038/nchembio.79
   Xu B, 2014, INT J CLIN EXP PATHO, V7, P3620
   Yang N, 2013, CANCER LETT, V330, P163, DOI 10.1016/j.canlet.2012.11.040
   Yang YZ, 2019, J BIOL CHEM, V294, P772, DOI 10.1074/jbc.RA118.005166
   Yin ZY, 2016, MICROB CELL, V3, P457, DOI 10.15698/mic2016.12.546
   Yu FH, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-3-207
   Zhang Q, 2017, GENE, V608, P79, DOI 10.1016/j.gene.2017.01.014
   Zhong JT, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039378
   Zhou RP, 2016, AGING DIS, V7, P491, DOI 10.14336/AD.2015.1213
   Zhu ZD, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0073-9
NR 110
TC 0
Z9 0
U1 7
U2 8
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1791-2997
EI 1791-3004
J9 MOL MED REP
JI Mol. Med. Rep.
PD SEP
PY 2021
VL 24
IS 3
AR 680
DI 10.3892/mmr.2021.12319
PG 11
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Research & Experimental Medicine
GA TV2RI
UT WOS:000681572200001
PM 34318907
DA 2022-04-25
ER

PT J
AU Chen, GQ
   Gong, RH
   Yang, DJ
   Zhang, G
   Lu, AP
   Yan, SC
   Lin, SH
   Bian, ZX
AF Chen, Guo-Qing
   Gong, Rui-Hong
   Yang, Da-Jian
   Zhang, Ge
   Lu, Ai-Ping
   Yan, Siu-Cheong
   Lin, Shu-Hai
   Bian, Zhao-Xiang
TI Halofuginone dually regulates autophagic flux through nutrient-sensing
   pathways in colorectal cancer
SO CELL DEATH & DISEASE
LA English
DT Article
ID CALORIC RESTRICTION MIMETICS; KINASE ULK1; METABOLISM; MTOR; AMPK;
   PHOSPHORYLATION; INDUCTION; TARGETS; COMPLEX; STRESS
AB Autophagy has a key role in metabolism and impacts on tumorigenesis. Our previous study found that halofuginone (HF) exerts anticancer activity in colorectal cancer (CRC) by downregulating Akt/mTORC1 (mechanistic target of rapamycin complex 1) signaling pathway. But whether and how HF regulates autophagy and metabolism to inhibit cancer growth remains an open question. Here, we unveil that HF activates ULK1 by downregulation of its phosphorylation site at Ser757 through Akt/mTORC1 signaling pathway, resulting in induction of autophagic flux under nutrient-rich condition. On the other hand, HF inactivates ULK1 by downregulation of its phosphorylation sites at Ser317 and Ser777 through LKB1/AMPK signaling pathway, resulting in autophagic inhibition under nutrient-poor condition. Furthermore, Atg7-dependent autophagosome formation is also induced under nutrient-rich condition or blocked in nutrient-poor environment, respectively, upon HF treatment. More interestingly, we also found that HF inhibits glycolysis under nutrient-rich condition, whereas inhibits gluconeogenesis under nutrient-poor condition in an Atg7-dependent manner, suggesting that autophagy has a pivotal role of glucose metabolism upon HF treatment. Subsequent studies showed that HF treatment retarded tumor growth in xenograft mice fed with either standard chow diet or caloric restriction through dual regulation of autophagy in vivo. Together, HF has a dual role in autophagic modulation depending on nutritional conditions for anti-CRC.
C1 [Chen, Guo-Qing; Gong, Rui-Hong; Zhang, Ge; Lu, Ai-Ping; Lin, Shu-Hai; Bian, Zhao-Xiang] Hong Kong Baptist Univ, Sch Chinese Med, Ctr Clin Res Chinese Med, Lab Brain & Gut Res, Hong Kong, Hong Kong, Peoples R China.
   [Chen, Guo-Qing; Yang, Da-Jian] Chongqing Acad Chinese Mat Med, Chongqing, Peoples R China.
   [Yan, Siu-Cheong] Hong Kong Polytech Univ, Dept Appl Biol & Chem Technol, Kowloon, Hong Kong, Peoples R China.
   [Lin, Shu-Hai] Shanghai Jiao Tong Univ, Sch Med, Shanghai Key Lab Tumor Microenvironm & Inflammat, Dept Biochem & Mol Cell Biol, 280 S Chongqing Rd, Shanghai 200025, Peoples R China.
RP Lin, SH; Bian, ZX (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Shanghai Key Lab Tumor Microenvironm & Inflammat, Dept Biochem & Mol Cell Biol, 280 S Chongqing Rd, Shanghai 200025, Peoples R China.
EM slin@shsmu.edu.cn; bzxiang@hkbu.edu.hk
RI Zhang, Ge/K-9118-2019
OI Zhang, Ge/0000-0002-7807-7695; Yan, Siu-cheoong/0000-0001-7486-3069;
   chen, guoqing/0000-0002-3671-5257; Lin, Shuhai/0000-0002-4782-5320
FU Chongqing Science & Technology CommissionNatural Science Foundation
   Project of CQ CSTC [cstc2016jcyjA0071]; Hong Kong Research Grants
   Council/General Research FundHong Kong Research Grants Council
   [12104415]; National NaturalScience Foundation of ChinaNational Natural
   Science Foundation of China (NSFC) [21377106]
FX This work was financially supported by Chongqing Science & Technology
   Commission (No. cstc2016jcyjA0071) to G-QC, Hong Kong Research Grants
   Council/General Research Fund (No. 12104415) to Z-X B, and the National
   NaturalScience Foundation of China (No. 21377106) to S-HL.
CR Chan EY, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.284pe51
   Chen GQ, 2015, ONCOTARGET, V6, P24148, DOI 10.18632/oncotarget.4376
   Cheong H, 2012, NAT BIOTECHNOL, V30, P671, DOI 10.1038/nbt.2285
   Egan DF, 2015, MOL CELL, V59, P285, DOI 10.1016/j.molcel.2015.05.031
   Egan DF, 2011, AUTOPHAGY, V7, P645, DOI 10.4161/auto.7.6.15123
   Guo JY, 2016, GENE DEV, V30, P1704, DOI 10.1101/gad.283416.116
   He CC, 2009, ANNU REV GENET, V43, P67, DOI 10.1146/annurev-genet-102808-114910
   Inoki K, 2012, ANNU REV PHARMACOL, V52, P381, DOI 10.1146/annurev-pharmtox-010611-134537
   Kim J, 2011, NAT CELL BIOL, V13, P132, DOI 10.1038/ncb2152
   Kimmelman AC, 2011, GENE DEV, V25, P1999, DOI 10.1101/gad.17558811
   Kroemer G, 2010, MOL CELL, V40, P280, DOI 10.1016/j.molcel.2010.09.023
   Levine B, 2015, J CLIN INVEST, V125, P14, DOI 10.1172/JCI73938
   Madeo F, 2014, NAT REV DRUG DISCOV, V13, P727, DOI 10.1038/nrd4391
   Mandelbaum J., 2015, AUTOPHAGY, DOI [10.1080/15548627.2015.1056966., DOI 10.1080/15548627.2015.1056966]
   Mizushima N, 2007, GENE DEV, V21, P2861, DOI 10.1101/gad.1599207
   Mizushima N, 2010, CELL, V140, P313, DOI 10.1016/j.cell.2010.01.028
   N'Diaye EN, 2009, AUTOPHAGY, V5, P573, DOI 10.4161/auto.5.4.8312
   Pietrocola F, 2016, AUTOPHAGY, V12, P1962, DOI 10.1080/15548627.2016.1214778
   Pietrocola F, 2016, CANCER CELL, V30, P147, DOI 10.1016/j.ccell.2016.05.016
   Rabinowitz JD, 2010, SCIENCE, V330, P1344, DOI 10.1126/science.1193497
   Rebecca VW, 2016, ONCOGENE, V35, P1, DOI 10.1038/onc.2015.99
   Selman C, 2006, PHYSIOL GENOMICS, V27, P187, DOI 10.1152/physiolgenomics.00084.2006
   Sengupta S, 2010, MOL CELL, V40, P310, DOI 10.1016/j.molcel.2010.09.026
   Wang HJ, 2015, AUTOPHAGY, V11, P2089, DOI 10.1080/15548627.2015.1091139
   White E, 2015, CLIN CANCER RES, V21, P5037, DOI 10.1158/1078-0432.CCR-15-0490
   White E, 2015, J CLIN INVEST, V125, P42, DOI 10.1172/JCI73941
   White E, 2012, NAT REV CANCER, V12, P401, DOI 10.1038/nrc3262
   Yang ZF, 2010, CURR OPIN CELL BIOL, V22, P124, DOI 10.1016/j.ceb.2009.11.014
   Yue Z, 2007, AUTOPHAGY, V3, P139, DOI 10.4161/auto.3602
   Zhang Z, 2016, CURR PROTOC TOXICOL, V69
   Zhi Xiaoyong, 2015, F1000Prime Rep, V7, P18, DOI 10.12703/P7-18
NR 31
TC 15
Z9 17
U1 0
U2 13
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-4889
J9 CELL DEATH DIS
JI Cell Death Dis.
PD MAY
PY 2017
VL 8
AR e2789
DI 10.1038/cddis.2017.203
PG 11
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA EW0QG
UT WOS:000402195700055
PM 28492544
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Chen, YQ
   Zhu, WT
   Lin, CY
   Yuan, ZW
   Li, ZH
   Yan, PK
AF Chen, Yi-Qing
   Zhu, Wen-Ting
   Lin, Cai-Yan
   Yuan, Zhong-Wen
   Li, Zhen-Hua
   Yan, Peng-Ke
TI Delivery of Rapamycin by Liposomes Synergistically Enhances the
   Chemotherapy Effect of 5-Fluorouracil on Colorectal Cancer
SO INTERNATIONAL JOURNAL OF NANOMEDICINE
LA English
DT Article
DE rapamycin liposomes; 5-fluorouracil; Akt/mTOR; P53; colorectal cancer
ID CYTOTOXICITY; MICELLES; NANOPARTICLES; ACTIVATION; CISPLATIN; AUTOPHAGY
AB Background: Rapamycin is a promising agent for treating tumors, but clinical applications of rapamycin are limited due to its poor water solubility and low bioavailability. This paper constructs a liposome delivery system for rapamycin to improve the effect in treating colorectal cancer.
   Methods: We prepared the rapamycin liposomes using the ethanol injection method. The cellular uptake and biodistribution were detected by LC-MS and in vivo imaging system. MTT assay, transwell migration experiment, flow cytometry, and Western blot analysis evaluated the antitumor effect of rapamycin liposomes in vitro. Furthermore, HCT-116 tumor-bearing mice were used to assess the therapeutic efficacy of rapamycin liposomes in vivo.
   Results: The prepared rapamycin liposomes had a particle size of 100 +/- 5.5 nm and with a narrow size distribution. In vitro cellular uptake experiments showed that the uptake of rapamycin liposomes by colorectal cells was higher than that of free rapamycin. Subsequently, in vivo imaging experiments also demonstrated that rapamycin liposomes exhibited higher tumor accumulation. Therefore, the ability of rapamycin liposomes to inhibit tumor proliferation, migration and to induce tumor apoptosis is superior to that of free rapamycin. We also demonstrated in vivo good antitumor efficacy of the rapamycin liposomes in HCT-116 xenograft mice. In addition, rapamycin liposomes and 5-FU can synergistically improve the efficacy of colorectal cancer via the Akt/mTOR and P53 pathways.
   Conclusion: Collectively, rapamycin liposomes are a potential treatment for colorectal cancer, as it not only improves rapamycin's antitumor effect but also synergistically enhances 5-FU's chemotherapy effect.
C1 [Chen, Yi-Qing; Zhu, Wen-Ting; Lin, Cai-Yan; Yuan, Zhong-Wen; Li, Zhen-Hua; Yan, Peng-Ke] Guangzhou Med Univ, Affiliated Hosp 3, Guangzhou 510150, Peoples R China.
RP Yan, PK (corresponding author), Guangzhou Med Univ, Affiliated Hosp 3, Guangzhou 510150, Peoples R China.
EM gysyypk@126.com
OI Yan, PengKe/0000-0002-8356-2986
FU Science and Technology Major Project Foundation of Guangzhou of
   Guangdong [201604020166]; Guangzhou Science and Technology Program key
   projects [201903010014]
FX This work was supported by the Science and Technology Major Project
   Foundation of Guangzhou of Guangdong (Grant-in-Aid 201604020166) and
   Guangzhou Science and Technology Program key projects (No.
   201903010014).
CR Alzahrani AS, 2019, SEMIN CANCER BIOL, V59, P125, DOI 10.1016/j.semcancer.2019.07.009
   Ashour AE, 2019, INT J NANOMED, V14, P9259, DOI 10.2147/IJN.S223368
   Chao TH, 2014, ANTICANCER RES, V34, P3329
   Chen YC, 2013, BIOMATERIALS, V34, P1115, DOI 10.1016/j.biomaterials.2012.10.034
   Costa RLB, 2018, BREAST CANCER RES TR, V169, P397, DOI 10.1007/s10549-018-4697-y
   Dai WB, 2014, BIOMATERIALS, V35, P5347, DOI 10.1016/j.biomaterials.2014.03.036
   Dekker E, 2019, LANCET, V394, P1467, DOI 10.1016/S0140-6736(19)32319-0
   Duan L, 2020, THERANOSTICS, V10, P462, DOI 10.7150/thno.37593
   Eftekhari Reza Baradaran, 2019, Pharmaceutical Nanotechnology, V7, P90, DOI 10.2174/2211738507666190321112237
   Falkowski S, 2019, THER DRUG MONIT, V41, P568, DOI 10.1097/FTD.0000000000000628
   Fan RR, 2015, INT J NANOMED, V10, P7291, DOI 10.2147/IJN.S89066
   Flaifel A, 2019, CLIN CANCER RES, V25, P6080, DOI 10.1158/1078-0432.CCR-19-1135
   Gao X, 2015, BIOMATERIALS, V53, P646, DOI 10.1016/j.biomaterials.2015.02.108
   Gilabert-Oriol R, 2017, DRUG DELIV TRANSL RE, V7, P544, DOI 10.1007/s13346-017-0380-9
   Gopalakrishnan K, 2018, MUTAT RES-GEN TOX EN, V836, P103, DOI 10.1016/j.mrgentox.2018.03.008
   Haeri A, 2018, ARTIF CELL NANOMED B, V46, pS1, DOI 10.1080/21691401.2017.1408123
   Huang GL, 2018, J CONTROL RELEASE, V278, P122, DOI 10.1016/j.jconrel.2018.04.015
   Iorio AL, 2019, J CLIN MED, V8, DOI 10.3390/jcm8030331
   Jhanwar-Uniyal Meena, 2019, Advances in Biological Regulation, V72, P51, DOI 10.1016/j.jbior.2019.03.003
   Kabary DM, 2018, COLLOID SURFACE B, V169, P183, DOI 10.1016/j.colsurfb.2018.05.008
   Kalyane D, 2019, MAT SCI ENG C-MATER, V98, P1252, DOI 10.1016/j.msec.2019.01.066
   Kang H, 2020, ADV HEALTHC MATER, V9, DOI 10.1002/adhm.201901223
   Lang JY, 2019, ACS NANO, V13, P2176, DOI 10.1021/acsnano.8b08823
   Lei HW, 2018, ANN HEPATOL, V17, P645, DOI 10.5604/01.3001.0012.0948
   Li BY, 2019, J BUON, V24, P739
   Li Y, 2018, INT J NANOMED, V13, P1241, DOI 10.2147/IJN.S158290
   Li YQ, 2019, BIOMATER SCI-UK, V7, P3779, DOI 10.1039/c9bm00653b
   Li YH, 2019, NANO LETT, V19, P5806, DOI 10.1021/acs.nanolett.9b02769
   Marquard FE, 2020, BIOCHEM PHARMACOL, V172, DOI 10.1016/j.bcp.2019.113729
   Mazrouei R, 2019, J MED SIGNALS SENS, V9, P196, DOI 10.4103/jmss.JMSS_44_18
   Mirza-Aghazade M, 2020, LIFE SCI, V255, DOI 10.1016/j.lfs.2020.117481
   Murugan AK, 2019, SEMIN CANCER BIOL, V59, P92, DOI 10.1016/j.semcancer.2019.07.003
   Perry JL, 2017, NANO LETT, V17, P2879, DOI 10.1021/acs.nanolett.7b00021
   Pu YC, 2019, EUR J MED CHEM, V183, DOI 10.1016/j.ejmech.2019.111720
   Shen YQ, 2018, J PINEAL RES, V64, DOI 10.1111/jpi.12461
   Tao W, 2016, THERANOSTICS, V6, P470, DOI 10.7150/thno.14184
   Tian T, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20030755
   Wang HT, 2019, INT J BIOL SCI, V15, P929, DOI 10.7150/ijbs.32489
   Wang SP, 2015, EXPERT OPIN DRUG DEL, V12, P361, DOI 10.1517/17425247.2014.951634
   Xu ZR, 2020, APPL MICROBIOL BIOT, V104, P575, DOI 10.1007/s00253-019-10257-8
   Yan XD, 2005, J LIPOSOME RES, V15, P109, DOI 10.1081/LPR-200064971
   Yang JW, 2018, J CANCER RES THER, V14, pS1141, DOI 10.4103/0973-1482.204898
   Yoon HY, 2019, INT J NANOMED, V14, P6249, DOI 10.2147/IJN.S216432
   Zhao TT, 2015, MAT SCI ENG C-MATER, V53, P196, DOI 10.1016/j.msec.2015.04.022
   Zhao ZM, 2020, CELL, V181, P151, DOI 10.1016/j.cell.2020.02.001
   Zhou WJ, 2018, NEOPLASIA, V20, P69, DOI 10.1016/j.neo.2017.11.003
NR 46
TC 3
Z9 3
U1 15
U2 22
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-2013
J9 INT J NANOMED
JI Int. J. Nanomed.
PY 2021
VL 16
BP 269
EP 281
DI 10.2147/IJN.S270939
PG 13
WC Nanoscience & Nanotechnology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics; Pharmacology & Pharmacy
GA PR9RR
UT WOS:000607568400001
PM 33469286
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Chen, YS
   Yang, Z
   Deng, B
   Wu, DJ
   Quan, YJ
   Min, ZJ
AF Chen, Yusheng
   Yang, Zhou
   Deng, Bo
   Wu, Dejun
   Quan, Yingjun
   Min, Zhijun
TI Interleukin 1 beta/1RA axis in colorectal cancer regulates tumor
   invasion, proliferation and apoptosis via autophagy
SO ONCOLOGY REPORTS
LA English
DT Article
DE interleukin 1 beta; interleukin 1RA; autophagy; epithelial-mesenchymal
   transformation; colorectal cancer
ID GENE-EXPRESSION; INFLAMMATION; ACTIVATION; IL-6; EMT
AB Interleukin (IL)-1 beta is a member of the IL-1 family of proteins. IL-1 receptor antagonist (IL-1RA) is an agent that binds to the IL-1 receptor, preventing IL-1 from transmitting signals to cells. The present study aimed to identify the role of the IL-1 beta/1RA axis in epithelial-mesenchymal transition (EMT), cell invasion, migration, proliferation and clone formation in colorectal cancer (CRC) and to determine its underlying mechanisms of action. Significantly increased expression of both IL-1 beta and IL-1RA was identified in CRC patient data uploaded in The Cancer Genome Atlas database, and in tumor tissues when compared with matched control tissue. High expression of IL-1 beta was associated with an increased rate of overall survival and recurrence-free survival. Further research revealed that the IL-1 beta gene was co-expressed with the IL-1RA gene in tumors of CRC patients. It was additionally determined that recombinant human (rh)IL-1 beta suppressed autophagy as well as EMT in HCT-116 cells compared with control-treated cells, whereas rhIL-1RA exhibited the opposite effect. In addition, autophagy activator rapamycin (RAPA) rescued the inhibition of EMT in rhIL-1 beta-treated HCT-116 cells. Moreover, rhIL-1 beta inhibited cell invasion, migration, proliferation and colony-formation ability, when compared with a control treatment. Compared with a control treatment rhIL-1RA promoted cell invasion, migration, proliferation, but had no effect on clone formation ability. Furthermore, both rhIL-1RA and RAPA rescued inhibition of cell invasion, migration and clone formation ability in rhIL-1 beta-treated HCT-116 cells. RAPA, but not rhIL-1RA, rescue inhibited proliferation in rhIL-1 beta-treated HCT-116 cells compared with controls. In addition, it was confirmed that rhIL-1 beta inhibited the growth of subcutaneous xenografts in nude mice, when compared with control treatments. These results indicated that upregulation of the IL-1 beta/1RA axis in CRC regulated EMT, cell invasion and migration, proliferation and clone formation via autophagy.
C1 [Chen, Yusheng; Yang, Zhou; Wu, Dejun; Min, Zhijun] Fudan Univ, Pudong Med Ctr, Dept Gen Surg, Shanghai Pudong Hosp, 2800 Gongwei Rd, Shanghai 201399, Peoples R China.
   [Deng, Bo] Shanghai Jiao Tong Univ, Div Nephrol, Shanghai Peoples Hosp 9, Sch Med, Shanghai 200011, Peoples R China.
   [Quan, Yingjun] Shanghai Jiao Tong Univ, Sch Med, Dept Gen Surg, Tongren Hosp, 1111 Xianxia Rd, Shanghai 200050, Peoples R China.
RP Min, ZJ (corresponding author), Fudan Univ, Pudong Med Ctr, Dept Gen Surg, Shanghai Pudong Hosp, 2800 Gongwei Rd, Shanghai 201399, Peoples R China.; Quan, YJ (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Dept Gen Surg, Tongren Hosp, 1111 Xianxia Rd, Shanghai 200050, Peoples R China.
EM qyjasmine@126.com; minzhijun@126.com
FU Puxiu Medical Talents Training Program of Pudong Hospital [PX201702]
FX The present study was funded by Puxiu Medical Talents Training Program
   of Pudong Hospital (grant no. PX201702).
CR Chandrashekar DS, 2017, NEOPLASIA, V19, P649, DOI 10.1016/j.neo.2017.05.002
   Fan DH, 2015, J CLIN ENDOCR METAB, V100, pE561, DOI 10.1210/jc.2014-3257
   Galavotti S, 2013, ONCOGENE, V32, P699, DOI 10.1038/onc.2012.111
   Huang C, 2011, NEOPLASMA, V58, P396, DOI 10.4149/neo_2011_05_396
   Huang QJ, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-18
   Ito H, 1999, SCAND J GASTROENTERO, V34, P1139
   Kessenbrock K, 2010, CELL, V141, P52, DOI 10.1016/j.cell.2010.03.015
   Lee Sylvia, 2011, Cancers (Basel), V3, P3856, DOI 10.3390/cancers3043856
   Lewis CE, 2006, CANCER RES, V66, P605, DOI 10.1158/0008-5472.CAN-05-4005
   Li J, 2013, CARCINOGENESIS, V34, P1343, DOI 10.1093/carcin/bgt063
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Long AG, 2017, CURR COLORECT CANC R, V13, P341, DOI 10.1007/s11888-017-0373-6
   Masters SL, 2010, NAT IMMUNOL, V11, P897, DOI 10.1038/ni.1935
   Soria G, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-130
   Tang ZF, 2017, NUCLEIC ACIDS RES, V45, pW98, DOI 10.1093/nar/gkx247
   Taniguchi K, 2014, SEMIN IMMUNOL, V26, P54, DOI 10.1016/j.smim.2014.01.001
   Wang WB, 2017, J CLIN ENDOCR METAB, V102, P634, DOI 10.1210/jc.2016-1999
   Zhang W, 2018, BIOCHIMIE, V144, P21, DOI 10.1016/j.biochi.2017.10.002
NR 18
TC 4
Z9 5
U1 2
U2 3
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1021-335X
EI 1791-2431
J9 ONCOL REP
JI Oncol. Rep.
PD MAR
PY 2020
VL 43
IS 3
BP 908
EP 918
DI 10.3892/or.2020.7475
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA KU3CB
UT WOS:000519584500015
PM 32020215
OA hybrid, Green Published
DA 2022-04-25
ER

PT J
AU Verrier, F
   Deniaud, A
   LeBras, M
   Metivier, D
   Kroemer, G
   Mignotte, B
   Jan, G
   Brenner, C
AF Verrier, F
   Deniaud, A
   LeBras, M
   Metivier, D
   Kroemer, G
   Mignotte, B
   Jan, G
   Brenner, C
TI Dynamic evolution of the adenine nucleotide translocase interactome
   during chemotherapy-induced apoptosis
SO ONCOGENE
LA English
DT Article
DE ADP/ATP carrier; cell death; glutathion-S-transferase; mitochondrion;
   permeability transition
ID MITOCHONDRIAL PERMEABILITY TRANSITION; CYTOCHROME-C RELEASE; DEPENDENT
   ANION CHANNEL; BCL-2 FAMILY PROTEINS; BENZODIAZEPINE-RECEPTOR; SIGNALING
   PATHWAY; BAX TRANSLOCATION; OXIDATIVE STRESS; PORE COMPLEX; BH4 DOMAIN
AB The mitochondrial permeability transition pore complex (PTPC) is involved in the control of the mitochondrial membrane permeabilization during apoptosis, necrosis and autophagy. Indeed, the adenine nucleotide translocator (ANT) and the voltage-dependent anion channel (VDAC), two major components of PTPC, are the targets of a variety of proapoptotic inducers. Using co-immunoprecipitation and proteomic analysis, we identified some of the interacting partners of ANT in several normal tissues and human cancer cell lines. During chemotherapy-induced apoptosis, some of these interactions were constant (e g. ANT-VDAC), whereas others changed strongly concomitantly with the dissipation of the mitochondrial transmembrane potential and until nuclear degradation occurred (e.g. Bax, Bcl-2, subunits of the respiratory chain, a subunit of the phosphatase PP2A, phospholipase PLC beta 4 and IP3 receptor). In addition, a glutathione-S-transferase (GST) interacts with ANT in normal tissue, in colon carcinoma cells and in vitro. This interaction is lost during apoptosis induction, suggesting that GST behaves as an endogenous repressor of PTPC and ANT pore opening. Thus, ANT is connected to mitochondrial proteins as well as to proteins from other organelles such as the endoplasmic reticulum forming a dynamic polyprotein complex. Changes within this ANT interactome coordinate the lethal response of cells to apoptosis induction.
C1 Univ Versailles, CNRS, FRE 2445, F-78035 Versailles, France.
   Inst Gustave Roussy, CNRS, UMR 8125, F-94805 Villejuif, France.
   INRA, UR 121, Rech Technol Laitiere Lab, F-35042 Rennes, France.
RP Brenner, C (corresponding author), Univ Versailles, CNRS, FRE 2445, 45 Ave Etats Unis, F-78035 Versailles, France.
EM cbrenner@genetique.uvsq.fr
RI Mignotte, Bernard/A-3499-2009; Deniaud, Aurelien/L-5093-2019; Jan,
   Gwenael/K-6767-2014; KROEMER, Guido/B-4263-2013
OI Mignotte, Bernard/0000-0002-8512-8518; KROEMER,
   Guido/0000-0002-9334-4405; LE BRAS, PhD, HDR,
   Morgane/0000-0003-4317-5591
CR Adler V, 1999, EMBO J, V18, P1321, DOI 10.1093/emboj/18.5.1321
   ARMSTRONG JS, 2002, FASEB J, V7, P7
   Belzacq AS, 2003, CURR DRUG TARGETS, V4, P517, DOI 10.2174/1389450033490867
   Belzacq AS, 2003, CANCER RES, V63, P541
   Belzacq AS, 2001, ONCOGENE, V20, P7579, DOI 10.1038/sj.onc.1204953
   Bernardi P, 1998, BIOFACTORS, V8, P273, DOI 10.1002/biof.5520080315
   Beutner G, 1996, FEBS LETT, V396, P189, DOI 10.1016/0014-5793(96)01092-7
   Bottero V, 2001, J BIOL CHEM, V276, P21317, DOI 10.1074/jbc.M005850200
   Brenner C, 2000, METHOD ENZYMOL, V322, P243
   Brenner C, 2000, SCIENCE, V289, P1150, DOI 10.1126/science.289.5482.1150
   Brenner C, 2003, J CLIN IMMUNOL, V23, P73, DOI 10.1023/A:1022541009662
   Brenner C, 2000, ONCOGENE, V19, P329, DOI 10.1038/sj.onc.1203298
   Bribes E, 2003, IMMUNOL LETT, V85, P13, DOI 10.1016/S0165-2478(02)00177-3
   Cao GD, 2001, J CEREBR BLOOD F MET, V21, P321, DOI 10.1097/00004647-200104000-00001
   Capano M, 2002, BIOCHEM J, V367, P169, DOI 10.1042/BJ20020805
   Castedo M, 2002, EMBO J, V21, P4070, DOI 10.1093/emboj/cdf391
   Cheng EHY, 2003, SCIENCE, V301, P513, DOI 10.1126/science.1083995
   Crompton M, 1999, BIOCHEM J, V341, P233, DOI 10.1042/0264-6021:3410233
   Crompton M, 2002, BIOCHIMIE, V84, P143, DOI 10.1016/S0300-9084(02)01368-8
   Crompton M, 2000, CURR OPIN CELL BIOL, V12, P414, DOI 10.1016/S0955-0674(00)00110-1
   Danial NN, 2003, NATURE, V424, P952, DOI 10.1038/nature01825
   De Giorgi F, 2002, FASEB J, V16, P607, DOI 10.1096/fj.01-0269fje
   Denis GV, 2003, J BIOL CHEM, V278, P5775, DOI 10.1074/jbc.M210202200
   Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891
   Dorner A, 1997, MOL CELL BIOCHEM, V174, P261, DOI 10.1023/A:1006825028170
   Dulhunty A, 2001, J BIOL CHEM, V276, P3319, DOI 10.1074/jbc.M007874200
   Elmore SP, 2001, FASEB J, V15, P2286, DOI 10.1096/fj.01-0206fje
   Friberg H, 2002, BIOCHIMIE, V84, P241, DOI 10.1016/S0300-9084(02)01381-0
   Gardner JL, 2001, ARCH BIOCHEM BIOPHYS, V390, P19, DOI 10.1006/abbi.2001.2352
   Gilot D, 2002, J BIOL CHEM, V277, P49220, DOI 10.1074/jbc.M207325200
   Gottlieb E, 2003, CELL DEATH DIFFER, V10, P709, DOI 10.1038/sj.cdd.4401231
   GUNTER TE, 1990, AM J PHYSIOL, V258, pC755, DOI 10.1152/ajpcell.1990.258.5.C755
   Hajnoczky G, 2000, J BIOENERG BIOMEMBR, V32, P15, DOI 10.1023/A:1005504210587
   Halestrap AP, 1997, J BIOL CHEM, V272, P3346, DOI 10.1074/jbc.272.6.3346
   Halestrap AP, 2002, BIOCHIMIE, V84, P153, DOI 10.1016/S0300-9084(02)01375-5
   Halestrap AP, 2003, CURR MED CHEM, V10, P1507, DOI 10.2174/0929867033457278
   Hande KR, 1998, EUR J CANCER, V34, P1514, DOI 10.1016/S0959-8049(98)00228-7
   Haouzi D, 2002, APOPTOSIS, V7, P395, DOI 10.1023/A:1020026923038
   Haouzi D, 2001, HEPATOLOGY, V33, P1181, DOI 10.1053/jhep.2001.24235
   Hayes JD, 1995, CRIT REV BIOCHEM MOL, V30, P445, DOI 10.3109/10409239509083491
   Ichas F, 1997, CELL, V89, P1145, DOI 10.1016/S0092-8674(00)80301-3
   Ichas F, 1998, BBA-BIOENERGETICS, V1366, P33, DOI 10.1016/S0005-2728(98)00119-4
   Jan G, 2002, CELL DEATH DIFFER, V9, P179, DOI 10.1038/sj.cdd.4400935
   Jouaville LS, 1998, MOL CELL BIOCHEM, V184, P371, DOI 10.1023/A:1006850121769
   Karpinich NO, 2002, J BIOL CHEM, V277, P16547, DOI 10.1074/jbc.M110629200
   Kroemer G, 1997, IMMUNOL TODAY, V18, P44, DOI 10.1016/S0167-5699(97)80014-X
   Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   Larochette N, 1999, EXP CELL RES, V249, P413, DOI 10.1006/excr.1999.4519
   Lemasters JJ, 1997, MOL CELL BIOCHEM, V174, P159, DOI 10.1023/A:1006827601337
   Li H, 2000, SCIENCE, V289, P1159, DOI 10.1126/science.289.5482.1159
   Majumder PK, 2001, CELL GROWTH DIFFER, V12, P465
   Marchenko ND, 2000, J BIOL CHEM, V275, P16202, DOI 10.1074/jbc.275.21.16202
   Martinou JC, 2000, NAT CELL BIOL, V2, pE41, DOI 10.1038/35004069
   Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027
   Marzo I, 1998, J EXP MED, V187, P1261, DOI 10.1084/jem.187.8.1261
   MCENERY MW, 1992, P NATL ACAD SCI USA, V89, P3170, DOI 10.1073/pnas.89.8.3170
   Murga C, 2002, ONCOGENE, V21, P207, DOI 10.1038/sj.onc.1205036
   Ott M, 2002, P NATL ACAD SCI USA, V99, P1259, DOI 10.1073/pnas.241655498
   Ravagnan L, 1999, ONCOGENE, V18, P2537, DOI 10.1038/sj.onc.1202625
   Reddy RK, 2003, J BIOL CHEM, V278, P20915, DOI 10.1074/jbc.M212328200
   Reed JC, 2002, MOL CELL, V9, P1, DOI 10.1016/S1097-2765(02)00437-9
   Reed JC, 1998, BBA-BIOENERGETICS, V1366, P127, DOI 10.1016/S0005-2728(98)00108-X
   Robertson JD, 2000, J BIOL CHEM, V275, P32438, DOI 10.1074/jbc.C000518200
   Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959
   Shimizu S, 2000, P NATL ACAD SCI USA, V97, P3100, DOI 10.1073/pnas.97.7.3100
   Shimizu S, 2000, J BIOL CHEM, V275, P12321, DOI 10.1074/jbc.275.16.12321
   Susin SA, 2000, METHOD ENZYMOL, V322, P205
   SZABO I, 1992, J BIOL CHEM, V267, P2940
   SZABO I, 1992, J BIOENERG BIOMEMBR, V24, P111, DOI 10.1007/BF00769537
   Woodfield K, 1998, BIOCHEM J, V336, P287, DOI 10.1042/bj3360287
   Yin ZM, 2000, CANCER RES, V60, P4053
   ZAMZAMI N, 1995, J EXP MED, V181, P1661, DOI 10.1084/jem.181.5.1661
   ZORATTI M, 1994, J BIOENERG BIOMEMBR, V26, P543, DOI 10.1007/BF00762739
NR 74
TC 78
Z9 82
U1 0
U2 5
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-9232
EI 1476-5594
J9 ONCOGENE
JI Oncogene
PD OCT 21
PY 2004
VL 23
IS 49
BP 8049
EP 8064
DI 10.1038/sj.onc.1208001
PG 16
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
GA 865HE
UT WOS:000224692500003
PM 15377997
DA 2022-04-25
ER

PT J
AU Wu, X
   Zhou, Z
   Xu, S
   Liao, CL
   Chen, X
   Li, B
   Peng, JW
   Li, D
   Yang, LF
AF Wu, Xia
   Zhou, Zhuan
   Xu, San
   Liao, Chaoliang
   Chen, Xi
   Li, Bo
   Peng, Jinwu
   Li, Dan
   Yang, Lifang
TI Extracellular vesicle packaged LMP1-activated fibroblasts promote tumor
   progression via autophagy and stroma-tumor metabolism coupling
SO CANCER LETTERS
LA English
DT Article
DE Latent membrane protein 1; Extracellular vesicle; Cancer-associated
   fibroblast; Reverse Warburg effect; Nasopharyngeal carcinoma
ID CANCER-ASSOCIATED FIBROBLASTS; EPSTEIN-BARR-VIRUS; METASTATIC NICHE
   FORMATION; NASOPHARYNGEAL CARCINOMA; COLORECTAL-CANCER; EXOSOMES;
   GLYCOLYSIS; INITIATE; THERAPY; GROWTH
AB Several reports have demonstrated that Epstein-Barr virus (EBV) encoded latent membrane protein 1 (LMP1), which is transferred by extracellular vesicles (EVs) or exosomes, can promote cancer progression. However, its mechanism is still not fully understood. In the present study, we demonstrated that EV packaged LMP1 can activate normal fibroblasts (NFs) into cancer-associated fibroblasts (CAFs). The NF-kappa B p65 pathway is the key signal that promotes the activation of NFs to CAFs in nasopharyngeal carcinoma (NPC). In activated CAFs, aerobic glycolysis and autophagy were increased. Moreover, glucose uptake and lactate production were decreased, and mitochondrial activity in tumor cells was enhanced, which supported the Reverse Warburg Effect (RWE). During this process, upregulation of MCT4 in CAFs and MCT1 in tumor cells was observed. The NF-kappa B p65 pathway also plays an important role in the regulation of MCT4. Furthermore, co-culture with CAFs promoted the proliferation, migration and radiation resistance of NPC cells. And EV packaged LMP1 promoted tumor proliferation and pre-metastatic niche formation by activating CAFs in vivo. Our findings indicate that EV packaged LMP1-activated CAFs promote tumor progression via autophagy and stroma-tumor metabolism coupling.
C1 [Wu, Xia; Zhou, Zhuan; Xu, San; Liao, Chaoliang; Yang, Lifang] Cent South Univ, Xiangya Hosp, Dept Oncol, Key Lab Carcinogenesis & Canc Invas,Minist Educ, Changsha, Peoples R China.
   [Wu, Xia; Zhou, Zhuan; Xu, San; Liao, Chaoliang; Yang, Lifang] Cent South Univ, Sch Basic Med Sci, Canc Res Inst, Changsha, Peoples R China.
   [Chen, Xi; Li, Dan] Hunan Univ, Coll Biol, Inst Mol Med & Oncol, Changsha, Peoples R China.
   [Li, Bo; Peng, Jinwu] Cent South Univ, Xiangya Hosp, Dept Pathol, Changsha, Peoples R China.
RP Yang, LF (corresponding author), Cent South Univ, Xiangya Rd 110, Changsha 410078, Peoples R China.; Li, D (corresponding author), Hunan Univ, Tianma Rd 27, Changsha 410082, Peoples R China.
EM sw_ld@hnu.edu.cn; yanglifang@csu.edu.cn
OI yang, lifang/0000-0002-3012-8350
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81372182, 81672761]; Natural Science
   Foundation of Hunan Province, ChinaNatural Science Foundation of Hunan
   Province [2018JJ2545]
FX This work was supported by the grants from the National Natural Science
   Foundation of China (No. 81372182, 81672761) and the Natural Science
   Foundation of Hunan Province, China (2018JJ2545).
CR Aga M, 2014, ONCOGENE, V33, P4613, DOI 10.1038/onc.2014.66
   Anderberg C, 2009, CELL CYCLE, V8, P1461, DOI 10.4161/cc.8.10.8557
   Baroni S, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.224
   Boelens MC, 2014, CELL, V159, P499, DOI 10.1016/j.cell.2014.09.051
   Bu L, 2019, ONCOGENE, V38, P4887, DOI 10.1038/s41388-019-0765-y
   Cao Y, 2017, NPJ PRECIS ONCOL, V1, DOI 10.1038/s41698-017-0018-x
   Chan JSK, 2018, ONCOGENE, V37, P160, DOI 10.1038/onc.2017.319
   Chen CC, 2014, ONCOGENE, V33, P3648, DOI 10.1038/onc.2013.345
   Chen XW, 2017, ONCOGENE, V36, P5045, DOI 10.1038/onc.2017.118
   Chua MLK, 2016, LANCET, V387, P1012, DOI 10.1016/S0140-6736(15)00055-0
   Costa-Silva B, 2015, NAT CELL BIOL, V17, P816, DOI 10.1038/ncb3169
   Diehl K, 2018, ONCOGENE, V37, P39, DOI 10.1038/onc.2017.299
   Fang T, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02583-0
   Fiaschi T, 2012, CANCER RES, V72, P5130, DOI 10.1158/0008-5472.CAN-12-1949
   Goulet CR, 2018, MOL CANCER RES, V16, P1196, DOI 10.1158/1541-7786.MCR-17-0784
   Gui YR, 2019, CLIN CANCER RES, V25, P7229, DOI 10.1158/1078-0432.CCR-19-1268
   Hurwitz SN, 2017, J VIROL, V91, DOI 10.1128/JVI.02251-16
   Kalluri R, 2016, NAT REV CANCER, V16, P582, DOI 10.1038/nrc.2016.73
   Kaplan RN, 2005, NATURE, V438, P820, DOI 10.1038/nature04186
   Katanov C, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287-015-0080-7
   Li HY, 2019, AUTOPHAGY, V15, P113, DOI 10.1080/15548627.2018.1509818
   Li P, 2017, THERANOSTICS, V7, P789, DOI 10.7150/thno.18133
   Liao CL, 2020, CANCER SCI, V111, P857, DOI 10.1111/cas.14305
   Liu J, 2016, CANCER LETT, V379, P49, DOI 10.1016/j.canlet.2016.05.022
   Liu R, 2012, CANCER BIOL THER, V13, P123, DOI 10.4161/cbt.13.3.18696
   Luftig M, 2004, P NATL ACAD SCI USA, V101, P141, DOI 10.1073/pnas.2237183100
   Martinez-Outschoorn UE, 2013, CELL CYCLE, V12, P2580, DOI 10.4161/cc.25510
   Martinez-Outschoorn UE, 2011, INT J BIOCHEM CELL B, V43, P1045, DOI 10.1016/j.biocel.2011.01.023
   Meckes DG, 2010, P NATL ACAD SCI USA, V107, P20370, DOI 10.1073/pnas.1014194107
   Naito Y, 2019, ONCOGENE, V38, P5566, DOI 10.1038/s41388-019-0832-4
   New J, 2017, CANCER RES, V77, P6679, DOI 10.1158/0008-5472.CAN-17-1077
   Ostman A, 2009, CURR OPIN GENET DEV, V19, P67, DOI 10.1016/j.gde.2009.01.003
   Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034
   Ostrowski M, 2010, NAT CELL BIOL, V12, P19, DOI 10.1038/ncb2000
   Pavlides S, 2009, CELL CYCLE, V8, P3984, DOI 10.4161/cc.8.23.10238
   Sahai E, 2020, NAT REV CANCER, V20, P174, DOI 10.1038/s41568-019-0238-1
   Tao YG, 2015, EXPERT REV MOL MED, V17, DOI 10.1017/erm.2015.13
   Thery C, 2018, J EXTRACELL VESICLES, V7, DOI 10.1080/20013078.2018.1535750
   Tkach M, 2016, CELL, V164, P1226, DOI 10.1016/j.cell.2016.01.043
   Wang YB, 2017, EBIOMEDICINE, V17, P45, DOI 10.1016/j.ebiom.2017.02.019
   Webber JP, 2015, ONCOGENE, V34, P319, DOI 10.1038/onc.2013.560
   Webber J, 2010, CANCER RES, V70, P9621, DOI 10.1158/0008-5472.CAN-10-1722
   Wen SW, 2016, CANCER RES, V76, P6816, DOI 10.1158/0008-5472.CAN-16-0868
   Xiao L, 2014, ONCOGENE, V33, P4568, DOI 10.1038/onc.2014.32
   Young LS, 2016, NAT REV CANCER, V16, P789, DOI 10.1038/nrc.2016.92
   Yu ZQ, 2017, ONCOTARGET, V8, P63461, DOI 10.18632/oncotarget.18831
   Zhai YY, 2017, PAK J PHARM SCI, V30, P263
   Zhang XN, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0959-5
   Zhang ZB, 2019, CANCER MED-US, V8, P6082, DOI 10.1002/cam4.2506
   Zhou WJ, 2017, CELL CYCLE, V16, P73, DOI 10.1080/15384101.2016.1252882
NR 50
TC 34
Z9 38
U1 9
U2 39
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0304-3835
EI 1872-7980
J9 CANCER LETT
JI Cancer Lett.
PD MAY 28
PY 2020
VL 478
BP 93
EP 106
DI 10.1016/j.canlet.2020.03.004
PG 14
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA LD2MV
UT WOS:000525868400010
PM 32160975
DA 2022-04-25
ER

PT J
AU Xu, ZJ
   Yan, YL
   Qian, L
   Gong, ZC
AF Xu, Zhijie
   Yan, Yuanliang
   Qian, Long
   Gong, Zhicheng
TI Long non-coding RNAs act as regulators of cell autophagy in diseases
   (Review)
SO ONCOLOGY REPORTS
LA English
DT Review
DE lncRNAs; autophagy; autophagy-associated diseases; molecular mechanism;
   cancers
ID VASCULAR ENDOTHELIAL-CELLS; DOWN-REGULATION; CANCER-CELLS;
   HEPATOCELLULAR-CARCINOMA; COLORECTAL-CANCER; LUNG-CANCER; MICRORNA;
   APOPTOSIS; PROLIFERATION; PVT1
AB Identification of long non-coding RNAs (lncRNAs) has provided a substantial increase in our understanding of the non-coding transcriptome. Studies have revealed a crucial function of IncRNAs in the modulation of cell autophagy in vitro and in vivo, further contributing to the hallmarks of disease phenotypes. These findings have profoundly altered our understanding of disease pathobiology, and may lead to the emergence of new biological concepts underlying autophagy-associated diseases, such as the carcinomas. Studies on the molecular mechanism of the lncRNA-autophagy axis may offer additional avenues for therapeutic intervention and biomarker assessment. In this review, we discuss recent findings on the multiple molecular roles of regulatory IncRNAs in the signaling pathways of cell autophagy. The emerging knowledge in this rapidly advancing field will offer novel insights into human diseases, especially cancers.
C1 [Xu, Zhijie] Cent S Univ, Xiangya Hosp, Dept Pathol, Changsha 410008, Hunan, Peoples R China.
   [Xu, Zhijie] Cent S Univ, Sch Basic Med, Dept Pathol, Changsha 410008, Hunan, Peoples R China.
   [Yan, Yuanliang; Qian, Long; Gong, Zhicheng] Cent S Univ, Xiangya Hosp, Dept Pharm, 87 Xiangya Rd, Changsha 410008, Hunan, Peoples R China.
   [Yan, Yuanliang; Qian, Long; Gong, Zhicheng] Cent S Univ, Inst Hosp Pharm, Changsha 410008, Hunan, Peoples R China.
RP Gong, ZC (corresponding author), Cent S Univ, Xiangya Hosp, Dept Pharm, 87 Xiangya Rd, Changsha 410008, Hunan, Peoples R China.
EM gongzhicheng2013@163.com
RI Yan, Yuanliang/K-7149-2019
OI Xu, Zhijie/0000-0003-2047-883X
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81572946]; Changsha Science and Technology
   Project [k1508024-31]; Clinical and Rehabilitation Research Foundation
   of Xiangya Hospital Beidaweiming
FX This study was supported by the National Natural Science Foundation of
   China (no. 81572946), the Changsha Science and Technology Project (no.
   k1508024-31), and the Clinical and Rehabilitation Research Foundation of
   Xiangya Hospital Beidaweiming.
CR Ballantyne MD, 2016, CLIN PHARMACOL THER, V99, P494, DOI 10.1002/cpt.355
   Bento CF, 2016, ANNU REV BIOCHEM, V85, P685, DOI 10.1146/annurev-biochem-060815-014556
   Bhattacharya A, 2016, NUCLEIC ACIDS RES, V44, pD1005, DOI 10.1093/nar/gkv1220
   Chen CL, 2015, BIOMATERIALS, V44, P71, DOI 10.1016/j.biomaterials.2014.12.023
   Chen YQ, 2016, AUTOPHAGY, V12, P1029, DOI 10.1080/15548627.2016.1164357
   Cheng Y, 2013, PHARMACOL REV, V65, P1162, DOI 10.1124/pr.112.007120
   Choudhry H, 2016, MOL ASPECTS MED, V47-48, P35, DOI 10.1016/j.mam.2016.01.003
   Das S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098965
   Deng YJ, 2014, AUTOPHAGY, V10, P1776, DOI 10.4161/auto.29746
   Dey BK, 2014, GENE DEV, V28, P491, DOI 10.1101/gad.234419.113
   Dong L, 2016, CANCER EPIDEM BIOMAR, V25, P1158, DOI 10.1158/1055-9965.EPI-16-0006
   Evangelisti C, 2015, BBA-MOL CELL RES, V1853, P14, DOI 10.1016/j.bbamcr.2014.09.023
   Faghihi MA, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-5-r56
   Flockhart RJ, 2012, GENOME RES, V22, P1006, DOI 10.1101/gr.140061.112
   Franklin JL, 2013, BIOCHEM BIOPH RES CO, V440, P99, DOI 10.1016/j.bbrc.2013.09.040
   Gallagher LE, 2016, CELLS-BASEL, V5, DOI 10.3390/cells5020024
   Galluzzi L, 2016, NAT REV NEUROSCI, V17, P467, DOI 10.1038/nrn.2016.51
   Ge D, 2014, AUTOPHAGY, V10, P957, DOI 10.4161/auto.28363
   Gibbings D, 2013, AUTOPHAGY, V9, P781, DOI 10.4161/auto.23694
   Gibbings D, 2012, NAT CELL BIOL, V14, P1314, DOI 10.1038/ncb2611
   Goodall ML, 2014, AUTOPHAGY, V10, P1120, DOI 10.4161/auto.28594
   Hall DP, 2014, CANCER CELL, V26, P738, DOI 10.1016/j.ccell.2014.09.015
   Hoyer-Hansen M, 2008, AUTOPHAGY, V4, P574, DOI 10.4161/auto.5921
   Huang SY, 2015, AUTOPHAGY, V11, P2172, DOI 10.1080/15548627.2015.1106663
   Jia GH, 2015, BBA-MOL BASIS DIS, V1852, P219, DOI 10.1016/j.bbadis.2014.06.025
   Kang YH, 2015, ANTICANCER RES, V35, P2795
   Li W, 2014, J BIOL CHEM, V289, P10691, DOI 10.1074/jbc.M113.537050
   Li WF, 2016, TUMOR BIOL, V37, P5885, DOI 10.1007/s13277-015-4456-1
   Li ZG, 2016, BEHAV BRAIN RES, V305, P265, DOI 10.1016/j.bbr.2016.03.023
   Liu XW, 2016, NAT CELL BIOL, V18, P431, DOI 10.1038/ncb3328
   Liu ZQ, 2016, BIOCHEM BIOPH RES CO, V473, P1268, DOI 10.1016/j.bbrc.2016.04.054
   Lorenzen JM, 2016, NAT REV NEPHROL, V12, P360, DOI 10.1038/nrneph.2016.51
   Lu W, 2015, STEM CELLS DEV, V24, P1133, DOI 10.1089/scd.2014.0353
   McCarthy N, 2012, NAT REV CANCER, V12, P454, DOI 10.1038/nrc3302
   Ouimet M, 2016, NAT IMMUNOL, V17, P677, DOI 10.1038/ni.3434
   Paraskevopoulou MD, 2016, NUCLEIC ACIDS RES, V44, pD231, DOI 10.1093/nar/gkv1270
   Park JH, 2016, BIOCHEM BIOPH RES CO, V477, P277, DOI 10.1016/j.bbrc.2016.06.057
   Pawar K, 2016, SCI REP-UK, V6, DOI 10.1038/srep19416
   Peng N, 2014, SCI REP-UK, V4, DOI 10.1038/srep05519
   Piccoli MT, 2015, J MOL CELL CARDIOL, V89, P59, DOI 10.1016/j.yjmcc.2015.02.002
   Qi P, 2016, MOL CANCER, V15, DOI 10.1186/s12943-016-0524-4
   Qu L, 2016, CANCER CELL, V29, P653, DOI 10.1016/j.ccell.2016.03.004
   Roos WP, 2016, NAT REV CANCER, V16, P20, DOI 10.1038/nrc.2015.2
   Rubinsztein DC, 2012, NAT REV DRUG DISCOV, V11, P709, DOI 10.1038/nrd3802
   Ryter SW, 2013, MOL CELLS, V36, P7, DOI 10.1007/s10059-013-0140-8
   Song J, 2014, J ORTHOP RES, V32, P1628, DOI 10.1002/jor.22718
   Sueda T, 2016, SCI REP-UK, V6, DOI 10.1038/srep18949
   Sun M, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-68
   Tiberio P, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/731479
   Tseng YY, 2014, NATURE, V512, P82, DOI 10.1038/nature13311
   Viereck J, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf1475
   Wajapeyee N, 2008, CELL, V132, P363, DOI 10.1016/j.cell.2007.12.032
   Wan L, 2016, MOL CANCER THER, V15, P1082, DOI 10.1158/1535-7163.MCT-15-0707
   Wang K, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7779
   Wang P, 2015, NUCLEIC ACIDS RES, V43, P3478, DOI 10.1093/nar/gkv233
   Wang P, 2014, NEUROCHEM RES, V39, P1279, DOI 10.1007/s11064-014-1310-6
   Wang RC, 2012, SCIENCE, V338, P956, DOI 10.1126/science.1225967
   Wang Y, 2014, ONCOL LETT, V8, P1947, DOI 10.3892/ol.2014.2487
   Wang YG, 2016, FASEB J, V30, P3133, DOI 10.1096/fj.201500058R
   Wurzer B, 2015, ELIFE, V4, DOI 10.7554/eLife.08941
   Xie YC, 2015, AUTOPHAGY, V11, P28, DOI 10.4161/15548627.2014.984267
   Ying L, 2013, MOL BIOSYST, V9, P407, DOI 10.1039/c2mb25386k
   Yoon JH, 2014, SEMIN CELL DEV BIOL, V34, P9, DOI 10.1016/j.semcdb.2014.05.015
   Yoon JH, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3939
   Yoon JH, 2012, MOL CELL, V47, P648, DOI 10.1016/j.molcel.2012.06.027
   Zeng CW, 2015, J HEMATOL ONCOL, V8, DOI 10.1186/s13045-015-0223-4
   Zhang SR, 2016, APMIS, V124, P649, DOI 10.1111/apm.12555
   Zhao Y, 2014, ONCOL REP, V31, P358, DOI 10.3892/or.2013.2850
   Zheng HT, 2016, CANCER RES TREAT, V48, P698, DOI 10.4143/crt.2015.118
NR 69
TC 48
Z9 50
U1 1
U2 21
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1021-335X
EI 1791-2431
J9 ONCOL REP
JI Oncol. Rep.
PD MAR
PY 2017
VL 37
IS 3
BP 1359
EP 1366
DI 10.3892/or.2017.5416
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA EN7MJ
UT WOS:000396186600007
PM 28184916
OA Green Submitted, Green Published, hybrid
DA 2022-04-25
ER

PT J
AU Feng, Y
   Gao, YJ
   Wang, DY
   Xu, ZH
   Sun, WX
   Ren, P
AF Feng, Ye
   Gao, Yongjian
   Wang, Dayu
   Xu, Zhonghang
   Sun, Weixuan
   Ren, Ping
TI Autophagy Inhibitor (LY294002) and 5-fluorouracil (5-FU)
   Combination-Based Nanoliposome for Enhanced Efficacy Against Esophageal
   Squamous Cell Carcinoma
SO NANOSCALE RESEARCH LETTERS
LA English
DT Article
DE Esophageal cancer; 5-fluorouracil; Autophagy inhibitor; Apoptosis;
   Liposome
ID COLORECTAL-CANCER CELLS; ANTICANCER LIPID NANOPARTICLES; DRUG-DELIVERY
   SYSTEMS; GROWTH-INHIBITION; SOLID TUMORS; APOPTOSIS; CLEAVAGE
AB In this study, 5-fluorouracil (5-FU) and LY294002 (LY)-loaded PEGylated nanoliposome was prepared to target esophageal squamous cell carcinoma (ESCC). The particles were characterized in terms of physicochemical and biological parameters. The co-delivery of autophagy inhibitor and chemotherapeutic drug in a single carrier was successfully accomplished. The two components from 5-FU and LY-loaded PEGylated nanoliposome (FLNP) released in a controlled manner with LY relatively released faster compared to that of 5-FU. FLNP showed a receptor-mediated cellular uptake that will allow the gradual release of drug in the acidic environment The cellular uptake of nanoparticles (NP) was further confirmed by FACS analysis. The combination of 5-FU and LY resulted in higher cytotoxic effect compared to that of individual drugs. Most importantly, FLNP exhibited a significantly higher anticancer effect in cancer cells compared to that of free cocktail combinations. The faster release of LY from FLNP leads to autophagy inhibition that improves the sensitivity of cancer cells towards 5-FU, resulting in more cell death. Consistently, FLNP induced a greater apoptosis (similar to 48%) of cancer cells compared to that of any other groups. Western blot analysis clearly showed that 5-FU and LY individually increased the expression of caspase-3 and PARP, while as expected FLNP induced a remarkable expression of these protein markers indicating the superior anticancer effect. We believe that the programmed release of autophagy inhibitor and chemotherapeutic drug from a single nanocarrier will increase the prospect of anticancer therapy in ESCC.
C1 [Feng, Ye; Gao, Yongjian; Wang, Dayu; Xu, Zhonghang; Sun, Weixuan] Jilin Univ, China Japan Friendship Hosp, Dept Gastrointestinal Surg, Changchun 130033, Jilin, Peoples R China.
   [Ren, Ping] Jilin Univ, Dept Thorac Surg, Hosp 1, Changchun 130033, Jilin, Peoples R China.
RP Ren, P (corresponding author), Jilin Univ, Dept Thorac Surg, Hosp 1, Changchun 130033, Jilin, Peoples R China.
EM zhaoke8618@126.com; pingren1962@yahoo.com
FU First Hospital of Jilin University, Changchun China
FX This study was supported from the grant of The First Hospital of Jilin
   University, Changchun China.
CR Allen TM, 2013, ADV DRUG DELIVER REV, V65, P36, DOI 10.1016/j.addr.2012.09.037
   Casiano CA, 1998, CELL DEATH DIFFER, V5, P183, DOI 10.1038/sj.cdd.4400336
   Chen MQ, 2014, J CHIN MED ASSOC, V77, P562, DOI 10.1016/j.jcma.2014.05.014
   Grem JL, 2000, INVEST NEW DRUG, V18, P299, DOI 10.1023/A:1006416410198
   Han WD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028491
   Kumar Priyank, 2012, Cells, V1, P558, DOI 10.3390/cells1030558
   Li Q, 2015, LIFE SCI, V127, P106, DOI 10.1016/j.lfs.2015.01.028
   Longley DB, 2003, NAT REV CANCER, V3, P330, DOI 10.1038/nrc1074
   Luo KJ, 2012, ANN THORAC SURG, V93, P1682, DOI 10.1016/j.athoracsur.2012.01.102
   Meng L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033434
   Mohan A, 2016, EUR J PHARM BIOPHARM, V99, P73, DOI 10.1016/j.ejpb.2015.11.017
   Ramasamy T, 2015, CHEM COMMUN, V51, P5758, DOI 10.1039/c5cc00482a
   Ramasamy T, 2017, J CONTROL RELEASE, V258, P226, DOI 10.1016/j.jconrel.2017.04.043
   Ramasamy T, 2017, ACTA BIOMATER, V48, P131, DOI 10.1016/j.actbio.2016.10.034
   Ramasamy T, 2014, ACTA BIOMATER, V10, P5116, DOI 10.1016/j.actbio.2014.08.021
   Sheen JH, 2011, CANCER CELL, V19, P613, DOI 10.1016/j.ccr.2011.03.012
   Soldani C, 2001, EXP CELL RES, V269, P193, DOI 10.1006/excr.2001.5293
   Sun LL, 2015, INT J CANCER, V136, pE569, DOI 10.1002/ijc.29211
   Sundaramoorthy P, 2016, ACTA BIOMATER, V42, P220, DOI 10.1016/j.actbio.2016.07.006
   Sundaramoorthy P, 2015, COLLOID SURFACE B, V135, P793, DOI 10.1016/j.colsurfb.2015.08.039
   Thant AA, 2008, ANTICANCER RES, V28, P3579
   Tokunaga E, 2000, EUR J CANCER, V36, P1998, DOI 10.1016/S0959-8049(00)00200-8
   Tong D, 2000, ORAL ONCOL, V36, P236, DOI 10.1016/S1368-8375(99)00079-2
   Wilson TR, 2006, ANN ONCOL, V17, pX315, DOI 10.1093/annonc/mdl280
NR 24
TC 27
Z9 27
U1 3
U2 11
PU SPRINGEROPEN
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 1556-276X
J9 NANOSCALE RES LETT
JI Nanoscale Res. Lett.
PD OCT 17
PY 2018
VL 13
AR 325
DI 10.1186/s11671-018-2716-x
PG 9
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary;
   Physics, Applied
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics; Materials Science; Physics
GA GX5CT
UT WOS:000447759800001
PM 30328537
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU You, LJ
   Geng, H
   Yang, XF
   Wei, GL
   Zhu, YD
   Ge, GB
   Lei, M
   Wang, DD
AF You, Li-Jiao
   Geng, Huan
   Yang, Xiao-Fang
   Wei, Gui-Lin
   Zhu, Ya-Di
   Ge, Guang-Bo
   Lei, Ming
   Wang, Dan-Dan
TI The comparison analysis of polyphyllin I and its analogues induced
   apoptosis of colon and lung cancer cells via mitochondrial dysfunction
SO BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY
LA English
DT Article
DE cell apoptosis; Chonglou; comparison analysis; mitochondrial
   dysfunction; polyphyllin I and its analogues
ID ROS; AUTOPHAGY; SAPONINS
AB Polyphyllin I (PPI) and its analogues, including polyphyllin II (PPII), polyphyllin VI (PPVI) and polyphyllin VII (PPVII), are major bioactive compounds isolated from the Chinese herb Chonglou. However, the susceptibilities of PPI and its analogues towards the different cell lines are diversified and the mechanisms are not fully clarified. Thus, the present study aimed to investigate the cytotoxicity of PPI and its analogues on two different cell lines, as well as to explore the underlying mechanisms of these agents via inducing mitochondrial dysfunction. The results showed that PPI and its analogues were cytotoxic agents towards both A549 and HT-29 cells, with IC50 values ranged from 1.0 to 4.5 mu mol/L. Further investigations demonstrated that they decreased the mitochondrial membrane potentials of both A549 and HT-29 cells in a dose-dependent manner. Among all tested compounds, PPVI and PPI induced the most obvious changes in Ca2+ haemostasis in these two cell lines. In addition, they could induce the accumulation of ROS in cells and down-regulated the Bcl-2 expression, up-regulated the Bax expression and induced the activity of cleaved caspase-3 in cells. Collectively, our findings clearly demonstrated the cytotoxic differences and mechanisms of PPI and its analogues induced cell apoptosis and could partially explain the anticancer effects of these natural constituents in Chonglou.
C1 [You, Li-Jiao; Geng, Huan; Yang, Xiao-Fang; Zhu, Ya-Di; Lei, Ming] Shanghai Univ TCM, Peoples Hosp 7, Shanghai 200137, Peoples R China.
   [You, Li-Jiao; Geng, Huan; Wei, Gui-Lin; Zhu, Ya-Di; Ge, Guang-Bo; Wang, Dan-Dan] Shanghai Univ Tradit Chinese Med, Inst Interdisciplinary Integrat Med Res, Shanghai 201203, Peoples R China.
RP Lei, M (corresponding author), Shanghai Univ TCM, Peoples Hosp 7, Shanghai 200137, Peoples R China.; Wang, DD (corresponding author), Shanghai Univ Tradit Chinese Med, Inst Interdisciplinary Integrat Med Res, Shanghai 201203, Peoples R China.
EM leiming6891@163.com; wangdandan801@126.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81973649, 81922070, 82073813, 81803489];
   Three-year Action Plan of Shanghai TCM Development
   [ZY-(201-2020)-CCCX-5001]; National Key Research and Development Program
   of China [2020YFC0845400, 2017YFC1700200, 2017YFC1702000]; Outstanding
   Clinical Discipline Project of Shanghai Pudong [PWYgy201801]; Leading
   Medical Talent Training Program of Pudong Health Bureau of Shanghai
   [PWR12019-02]; National Science and Technology Major Project of China
   [2018ZX09731016]; Shanghai University of Traditional Chinese Medicine
   "Postgraduate Innovation Training Project" [Y2021022]
FX National Natural Science Foundation of China, Grant/Award Number:
   81973649, 81922070, 82073813 and 81803489; Three-year Action Plan of
   Shanghai TCM Development, Grant/Award Number: ZY-(201-2020)-CCCX-5001;
   National Key Research and Development Program of China, Grant/Award
   Number: 2020YFC0845400, 2017YFC1700200 and 2017YFC1702000; Outstanding
   Clinical Discipline Project of Shanghai Pudong, Grant/Award Number:
   PWYgy201801; Leading Medical Talent Training Program of Pudong Health
   Bureau of Shanghai, Grant/Award Number: PWR12019-02; National Science
   and Technology Major Project of China, Grant/Award Number:
   2018ZX09731016; Shanghai University of Traditional Chinese Medicine
   "Postgraduate Innovation Training Project", Grant/Award Number: Y2021022
CR Amoedo ND, 2014, INT J BIOCHEM CELL B, V51, P53, DOI 10.1016/j.biocel.2014.03.009
   Bagkos G, 2014, MED HYPOTHESES, V83, P175, DOI 10.1016/j.mehy.2014.05.001
   Banjara S, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10010128
   Chang JL, 2015, J ETHNOPHARMACOL, V170, P117, DOI 10.1016/j.jep.2015.05.006
   Chen J, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/2328401
   Deng XH, 2020, INT J BIOL SCI, V16, P1403, DOI 10.7150/ijbs.41768
   Escobar ML, 2019, J HISTOCHEM CYTOCHEM, V67, P873, DOI 10.1369/0022155419881127
   Fitzmaurice C, 2019, JAMA ONCOL, V5, P1749, DOI 10.1001/jamaoncol.2019.2996
   Gu LH, 2016, ONCOL LETT, V12, P4969, DOI 10.3892/ol.2016.5348
   Han WH, 2015, INT J CLIN EXP MED, V8, P20664
   Jiang SY, 2019, INT J ONCOL, V54, P1933, DOI 10.3892/ijo.2019.4785
   Lee BZ, 2020, J MICROBIOL BIOTECHN, V30, P1214, DOI 10.4014/jmb.2006.06022
   Lin LT, 2019, MOLECULES, V24, DOI 10.3390/molecules24112102
   Liu GB, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18020367
   Long J., 2020, BIOMED RES INT, V2020, P1
   Luo QH, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/5241941
   Manouchehri N, 2019, IRAN J PHARM RES, V18, P1445, DOI 10.22037/ijpr.2019.1100711
   NavaneethaKrishnan S, 2020, ONCOGENE, V39, P2797, DOI 10.1038/s41388-020-1188-5
   Pang DJ, 2020, BIOL OPEN, V9, DOI 10.1242/bio.046854
   Park J, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21176229
   Perrone M, 2020, INT REV CEL MOL BIO, V350, P119, DOI 10.1016/bs.ircmb.2019.11.002
   Ramadan MA, 2019, CYTOTECHNOLOGY, V71, P461, DOI 10.1007/s10616-018-0287-4
   Salehi F, 2020, INT J BIOL MACROMOL, V164, P3645, DOI 10.1016/j.ijbiomac.2020.08.084
   Salimi A, 2015, REDOX BIOL, V6, P461, DOI 10.1016/j.redox.2015.08.021
   Siu FM, 2008, PROTEOMICS, V8, P3105, DOI 10.1002/pmic.200700829
   Sola-Riera C, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008297
   Teng JF, 2020, CANCERS, V12, DOI 10.3390/cancers12010193
   Tveden-Nyborg P, 2021, BASIC CLIN PHARMACOL, V128, P4, DOI 10.1111/bcpt.13492
   Vandamme M, 2012, INT J CANCER, V130, P2185, DOI 10.1002/ijc.26252
   Wang WP, 2019, J CELL PHYSIOL, V234, P7078, DOI 10.1002/jcp.27462
   Xu XH, 2016, MOLECULES, V21, DOI 10.3390/molecules21101326
   Yan Y., 2019, ONCOL REP, V41, P3005
   Yuan YL, 2019, DRUG DES DEV THER, V13, P3091, DOI 10.2147/DDDT.S194961
   Zhang Denglu, 2018, Curr Urol, V11, P144, DOI 10.1159/000447209
   Zhang J, 2015, MED SCI MONITOR, V21, P2535, DOI 10.12659/MSM.895084
   Zhou L, 2020, BMC MUSCULOSKEL DIS, V21, DOI 10.1186/s12891-020-3077-z
   Zorov DB, 2014, PHYSIOL REV, V94, P909, DOI 10.1152/physrev.00026.2013
NR 37
TC 1
Z9 1
U1 2
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1742-7835
EI 1742-7843
J9 BASIC CLIN PHARMACOL
JI Basic Clin. Pharmacol. Toxicol.
PD JUL
PY 2021
VL 129
IS 1
BP 15
EP 25
DI 10.1111/bcpt.13596
EA MAY 2021
PG 11
WC Pharmacology & Pharmacy; Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy; Toxicology
GA SP1VJ
UT WOS:000649975500001
PM 33915023
DA 2022-04-25
ER

PT J
AU Lorente, J
   Velandia, C
   Leal, JA
   Garcia-Mayea, Y
   Lyakhovich, A
   Kondoh, H
   LLeonart, ME
AF Lorente, Juan
   Velandia, Carolina
   Leal, Jose A.
   Garcia-Mayea, Yoelsis
   Lyakhovich, Alex
   Kondoh, Hiroshi
   LLeonart, Matilde E.
TI The interplay between autophagy and tumorigenesis: exploiting autophagy
   as a means of anticancer therapy
SO BIOLOGICAL REVIEWS
LA English
DT Review
DE autophagy; cancer; cancer stem cells; oxidative stress; therapy
ID UNFOLDED PROTEIN RESPONSE; CANCER-CELLS; INDUCED APOPTOSIS;
   MITOCHONDRIAL DYSFUNCTION; COLORECTAL-CANCER; ATG PROTEINS; INHIBITION;
   METABOLISM; SURVIVAL; TUMORS
AB In wild-type cells, autophagy represents a tumour-suppressor mechanism, and dysfunction of the autophagy machinery increases genomic instability, DNA damage, oxidative stress and stem/progenitor expansion, which are events associated with cancer onset. Autophagy occurs at a basal level in all cells depending on cell type and cellular microenvironment. However, the role of autophagy in cancer is diverse and can promote different outcomes even in a single tumour. For example, in hypoxic tumour regions, autophagy emerges as a protective mechanism and allows cancer cell survival. By contrast, in cancer cells surrounding the tumour mass, the induction of autophagy by radio- or chemotherapy promotes cell death and significantly reduces the tumour mass. Importantly, inhibition of autophagy compromises tumorigenesis by mechanisms that are not entirely understood. The aim of this review is to explain the apparently contradictory role of autophagy as a mechanism that both promotes and inhibits tumorigenesis using different models. The induction/inhibition of autophagy as a mechanism for cancer treatment is also discussed.
C1 [Lorente, Juan; Velandia, Carolina; Leal, Jose A.; Garcia-Mayea, Yoelsis; Lyakhovich, Alex; LLeonart, Matilde E.] Vall dHebron Hosp, Pathol Dept, Biomed Res Canc Stem Cell Grp, Barcelona 08035, Spain.
   [Lorente, Juan; Velandia, Carolina] Vall dHebron Hosp, Otolaryngol Dept, Barcelona 08035, Spain.
   [Kondoh, Hiroshi] Kyoto Univ, Grad Sch Med, Dept Geriatr Med, Kyoto 6068507, Japan.
RP LLeonart, ME (corresponding author), Vall dHebron Hosp, Pathol Dept, Biomed Res Canc Stem Cell Grp, Barcelona 08035, Spain.
EM matilde.lleonart@vhir.org
RI LLeonart, Matilde E./Q-2662-2019; Mayea, Yoelsis Garcia/AAI-5845-2021;
   Lyakhovich, Alex/B-4410-2008
OI LLeonart, Matilde E./0000-0002-6196-7405; Mayea, Yoelsis
   Garcia/0000-0002-9395-7471; Lyakhovich, Alex/0000-0002-8279-4697
FU Instituto de Salud Carlos IIIInstituto de Salud Carlos IIIEuropean
   Commission [PI12/01104, PI15/01262]; European Regional Development Fund
   (ERDF)European Commission; Marie Curie - COFUND program, Spain [INCOMED
   - GA 267128]; Vall d'Hebron Institut de Recerca (VHIR)
FX This work was supported by grants from the Instituto de Salud Carlos III
   (grant PI12/01104 and PI15/01262 (M.E.LL.) cofinanced by the European
   Regional Development Fund (ERDF). M.E.LL. is a FIS investigator
   (Instituto de Salud Carlos III, ref. CP03/00101). A.L. received support
   from the Marie Curie - COFUND program (INCOMED - GA 267128), Spain.
   Y.G.-M. is funded by a Vall d'Hebron Institut de Recerca (VHIR),
   fellowship.
CR Amaravadi RK, 2007, J CLIN INVEST, V117, P326, DOI 10.1172/JCI28833
   Amaravadi RK, 2008, J CLIN INVEST, V118, P3837, DOI 10.1172/JCI37667
   Artero-Castro A, 2015, AUTOPHAGY, V11, P1499, DOI 10.1080/15548627.2015.1063764
   Artero-Castro A, 2011, HUM PATHOL, V42, P194, DOI 10.1016/j.humpath.2010.04.020
   Blommaart EFC, 1997, EUR J BIOCHEM, V243, P240, DOI 10.1111/j.1432-1033.1997.0240a.x
   Brooks GD, 2016, CANCER RES, V76, P866, DOI 10.1158/0008-5472.CAN-15-2388
   Button RW, 2016, ONCOTARGET, V7, P5157, DOI 10.18632/oncotarget.6986
   Carew JS, 2007, BLOOD, V110, P313, DOI 10.1182/blood-2006-10-050260
   Castro ME, 2008, CARCINOGENESIS, V29, P1343, DOI 10.1093/carcin/bgm302
   Chaurasia M, 2016, FREE RADICAL RES, V50, P273, DOI 10.3109/10715762.2015.1129534
   Chen Y, 2014, CELL PROLIFERAT, V47, P105, DOI 10.1111/cpr.12095
   Chen YB, 2012, J SURG ONCOL, V105, P542, DOI 10.1002/jso.22151
   Chiu CC, 2011, CLIN CANCER RES, V17, P4629, DOI 10.1158/1078-0432.CCR-10-2107
   Cicchini M, 2014, AUTOPHAGY, V10, P2036, DOI 10.4161/auto.34398
   Daftuar L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068667
   De Keersmaecker K, 2013, NAT GENET, V45, P186, DOI 10.1038/ng.2508
   de las Heras-Rubio A, 2014, CANCER METAST REV, V33, P115, DOI 10.1007/s10555-013-9460-6
   Di Fazio P, 2016, ONCOTARGET, V7, P28998, DOI 10.18632/oncotarget.8585
   Doudna JA, 2002, CELL, V109, P153, DOI 10.1016/S0092-8674(02)00725-0
   Eng CH, 2016, P NATL ACAD SCI USA, V113, P182, DOI 10.1073/pnas.1515617113
   Ertmer A, 2007, LEUKEMIA, V21, P936, DOI 10.1038/sj.leu.2404606
   Gewirtz DA, 2014, J CELL PHYSIOL, V229, P6, DOI 10.1002/jcp.24420
   Godbole AM, 2012, MOL CANCER THER, V11, P898, DOI 10.1158/1535-7163.MCT-11-0860
   Grimm WA, 2016, GUT, V65, P456, DOI 10.1136/gutjnl-2014-308735
   Guo JY, 2013, GENE DEV, V27, P1447, DOI 10.1101/gad.219642.113
   Higgins R, 2015, MOL CELL, V59, P35, DOI 10.1016/j.molcel.2015.04.026
   Huang CY, 2015, SCI REP-UK, V5, DOI 10.1038/srep14045
   Janku F, 2011, NAT REV CLIN ONCOL, V8, P528, DOI 10.1038/nrclinonc.2011.71
   Jiang L, 2015, CELL CYCLE, V14, P2881, DOI 10.1080/15384101.2015.1068479
   Karnoub AE, 2007, NATURE, V449, P557, DOI 10.1038/nature06188
   Kim EJ, 2013, J CELL BIOCHEM, V114, P1248, DOI 10.1002/jcb.24465
   Kohli L, 2013, CANCER RES, V73, P4395, DOI 10.1158/0008-5472.CAN-12-3765
   Lefort S, 2014, AUTOPHAGY, V10, P2122, DOI 10.4161/15548627.2014.981788
   Levy JMM, 2014, CANCER DISCOV, V4, P773, DOI 10.1158/2159-8290.CD-14-0049
   Lightowlers RN, 2015, SCIENCE, V349, P1494, DOI 10.1126/science.aac7516
   Liu JL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0141308
   Ljungstrom V, 2016, BLOOD, V127, P1007, DOI 10.1182/blood-2015-10-674572
   Lyakhovich A, 2016, BBA-REV CANCER, V1865, P184, DOI 10.1016/j.bbcan.2016.02.006
   Macintosh RL, 2013, SEMIN CANCER BIOL, V23, P344, DOI 10.1016/j.semcancer.2013.05.006
   MARINO G, 2007, THE JOURNAL OF BIOLO, V282, P18573, DOI DOI 10.1074/JBC.M701194200
   Martin I, 2014, CELL, V157, P472, DOI 10.1016/j.cell.2014.01.064
   Martinez-Outschoorn UE, 2010, CELL CYCLE, V9, P4297, DOI 10.4161/cc.9.21.13817
   Mathew R, 2007, NAT REV CANCER, V7, P961, DOI 10.1038/nrc2254
   Mathew R, 2009, CELL, V137, P1062, DOI 10.1016/j.cell.2009.03.048
   McAfee Q, 2012, P NATL ACAD SCI USA, V109, P8253, DOI 10.1073/pnas.1118193109
   Mizushima N, 2011, ANNU REV CELL DEV BI, V27, P107, DOI 10.1146/annurev-cellbio-092910-154005
   Morgado-Palacin L, 2015, CELL REP, V13, P712, DOI 10.1016/j.celrep.2015.09.038
   Morikawa A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125762
   Nie TJ, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.423
   Nogueira V, 2013, CLIN CANCER RES, V19, P4309, DOI 10.1158/1078-0432.CCR-12-1424
   Notte A, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.167
   Perera R, 2015, NATURE, V524, P361, DOI 10.1038/nature14587
   Plantinga TS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094086
   Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039
   Resende C, 2016, GASTRIC CANCER, V19, P74, DOI 10.1007/s10120-014-0448-x
   Ronan B, 2014, NAT CHEM BIOL, V10, P1013, DOI 10.1038/nchembio.1681
   Rosenfeldt MT, 2013, NATURE, V504, P296, DOI 10.1038/nature12865
   ROUSCHOP KM, 2010, THE JOURNAL OF CLINI, V120, P127, DOI DOI 10.1172/JCI40027
   Rubinsztein DC, 2012, NAT REV DRUG DISCOV, V11, P709, DOI 10.1038/nrd3802
   Sakakura K, 2015, CANCER SCI, V106, P1, DOI [10.1111/cas.12559, 10.1111/cas.12579]
   Salah FS, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.93
   Savarino A, 2006, LANCET ONCOL, V7, P792, DOI 10.1016/S1470-2045(06)70875-0
   Seront E, 2013, BRIT J CANCER, V109, P2597, DOI 10.1038/bjc.2013.644
   Shao LN, 2016, MOL MED REP, V13, P2661, DOI 10.3892/mmr.2016.4820
   Singh P, 2011, BIOCHEM BIOPH RES CO, V415, P181, DOI 10.1016/j.bbrc.2011.10.054
   Solanki NR, 2016, J IMMUNOL, V197, P2280, DOI 10.4049/jimmunol.1600815
   Steidl C, 2010, NEW ENGL J MED, V362, P875, DOI 10.1056/NEJMoa0905680
   Strohecker AM, 2013, CANCER DISCOV, V3, P1272, DOI 10.1158/2159-8290.CD-13-0397
   Takahashi Y, 2007, NAT CELL BIOL, V9, P1142, DOI 10.1038/ncb1634
   Takeuchi H, 2005, CANCER RES, V65, P3336, DOI 10.1158/0008-5472.CAN-04-3640
   Turcotte S, 2008, CANCER CELL, V14, P90, DOI 10.1016/j.ccr.2008.06.004
   Valentin-Vega YA, 2012, BLOOD, V119, P1490, DOI 10.1182/blood-2011-08-373639
   van der Burgh R, 2014, J BIOL CHEM, V289, P5000, DOI 10.1074/jbc.M113.536920
   Viale A, 2014, NATURE, V514, P628, DOI 10.1038/nature13611
   Waickman AT, 2012, IMMUNOL REV, V249, P43, DOI 10.1111/j.1600-065X.2012.01152.x
   Weinberg F, 2010, P NATL ACAD SCI USA, V107, P8788, DOI 10.1073/pnas.1003428107
   White E, 2016, CSH PERSPECT MED, V6, DOI 10.1101/cshperspect.a026120
   Wu YT, 2010, J BIOL CHEM, V285, P10850, DOI 10.1074/jbc.M109.080796
   Xu YF, 2016, AUTOPHAGY, V12, P1118, DOI 10.1080/15548627.2016.1175693
   Yang A, 2014, CANCER DISCOV, V4, P905, DOI 10.1158/2159-8290.CD-14-0362
   Yang MC, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0449-3
   Yang PM, 2013, SCI REP-UK, V3, DOI 10.1038/srep03219
   Young ARJ, 2009, GENE DEV, V23, P798, DOI 10.1101/gad.519709
   Yousefi S, 2006, NAT CELL BIOL, V8, P1124, DOI 10.1038/ncb1482
   Zhang F, 2006, J BIOL CHEM, V281, P30036, DOI 10.1074/jbc.M604674200
NR 85
TC 33
Z9 36
U1 4
U2 17
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1464-7931
EI 1469-185X
J9 BIOL REV
JI Biol. Rev.
PD FEB
PY 2018
VL 93
IS 1
BP 152
EP 165
DI 10.1111/brv.12337
PG 14
WC Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Life Sciences & Biomedicine - Other Topics
GA FS7GK
UT WOS:000419965700008
PM 28464404
DA 2022-04-25
ER

PT J
AU Zhu, Y
   Huang, SM
   Chen, SY
   Chen, JX
   Wang, ZQ
   Wang, YD
   Zheng, HX
AF Zhu, Yin
   Huang, Shimiao
   Chen, Shengyuan
   Chen, Jiaxuan
   Wang, Zhiqing
   Wang, Yadong
   Zheng, Haoxuan
TI SOX2 promotes chemoresistance, cancer stem cells properties, and
   epithelial-mesenchymal transition by beta-catenin and Beclin1/autophagy
   signaling in colorectal cancer
SO CELL DEATH & DISEASE
LA English
DT Article
ID MULTIDRUG-RESISTANCE; INITIATING CELLS; CHROMOSOME 17Q; AUTOPHAGY;
   METASTASIS; EXPRESSION; PATHWAY; ACTIVATION; SUPPRESSION; PROGRESSION
AB Sex-determining region Y-box2 (SOX2), a master regulator of embryonic and induced pluripotent stem cells, drives cancer stem cells (CSCs) properties, fuels tumor initiation, and contributes to tumor aggressiveness. Our previous study has demonstrated the oncogenic role of SOX2 in colorectal cancer (CRC). In this study, we sought to elucidate the underlying mechanisms. Cell function experiments were performed to detect chemoresistance, proliferation, stemness, migration, and invasion in vitro. Chromatin immunoprecipitation, co-immunoprecipitation, luciferase reporter assay, and immunofluorescence were performed to explore the regulation of ABCC2, beta-catenin, and Beclin1 by SOX2. The carcinogenic role of SOX2-beta-catenin/Beclin1-ABCC2 axis in vivo was analyzed by CRC tissues and xenograft models. Here, we reported that SOX2 sustained chemoresistance by transcriptional activation of ABCC2 expression. Suppressing either beta-catenin or autophagy signaling curbed SOX2-driven chemoresistance, stemness, and epithelial-mesenchymal transition (EMT). Mechanistically, SOX2 combined with beta-catenin and increased its nuclear expression and transcriptional activity. Transcriptional activation of Beclin1 expression by SOX2 consequently activating autophagy and inducing malignant phenotype. Furthermore, overexpression of beta-catenin or Beclin1 facilitated ABCC2 expression. The clinical analyses showed that high expression of ABCC2 and Beclin1 were positively correlated with SOX2 and were associated with poor prognosis in CRC patients. Finally, xenograft models revealed that inhibition of SOX2 expression and autophagy restrained tumor growth and chemoresistance in vivo. Conclusively, we demonstrated a novel mechanism by which the SOX2-beta-catenin/Beclin1/autophagy signaling axis regulates chemoresistance, stemness, and EMT in CRC. Our findings provide novel insights into CRC carcinogenesis and may help develop potential therapeutic candidates for CRC.
C1 [Zhu, Yin; Huang, Shimiao; Chen, Shengyuan; Chen, Jiaxuan; Wang, Zhiqing; Wang, Yadong; Zheng, Haoxuan] Southern Med Univ, Nanfang Hosp, Dept Gastroenterol, Guangdong Prov Key Lab Gastroenterol, Guangzhou, Peoples R China.
RP Zheng, HX (corresponding author), Southern Med Univ, Nanfang Hosp, Dept Gastroenterol, Guangdong Prov Key Lab Gastroenterol, Guangzhou, Peoples R China.
EM haoxuan.zheng@qq.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81773191]; National Major New Drug Creation
   Science and Technology Major Special Fund Funding Project
   [2020ZX09201017]; Guangdong Gastrointestinal Disease Research Center
   [2017B020209003]
FX The present work was supported by the National Natural Science
   Foundation of China (No. 81773191), National Major New Drug Creation
   Science and Technology Major Special Fund Funding Project (No.
   2020ZX09201017), and Guangdong Gastrointestinal Disease Research Center
   (No. 2017B020209003).
CR Ahn CH, 2007, APMIS, V115, P1344, DOI 10.1111/j.1600-0463.2007.00858.x
   Bass AJ, 2009, NAT GENET, V41, P1238, DOI 10.1038/ng.465
   Basu-Roy U, 2012, ONCOGENE, V31, P2270, DOI 10.1038/onc.2011.405
   Bian J, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9092125
   Chen JX, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2361-z
   Chen YP, 2008, J BIOL CHEM, V283, P17969, DOI 10.1074/jbc.M802917200
   Choi HK, 2007, ENDOCR-RELAT CANCER, V14, P293, DOI 10.1677/ERC-06-0016
   Dalerba P, 2007, P NATL ACAD SCI USA, V104, P10158, DOI 10.1073/pnas.0703478104
   Dalerba P, 2007, ANNU REV MED, V58, P267, DOI 10.1146/annurev.med.58.062105.204854
   Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001
   Fan Q, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0673-y
   Favaro R, 2014, CANCER RES, V74, P1833, DOI 10.1158/0008-5472.CAN-13-1942
   Funderburk SF, 2010, TRENDS CELL BIOL, V20, P355, DOI 10.1016/j.tcb.2010.03.002
   GAO X, 1995, CANCER RES, V55, P1002
   Guo JY, 2011, GENE DEV, V25, P460, DOI 10.1101/gad.2016311
   Huang LM, 2013, J HEMATOL ONCOL, V6, DOI 10.1186/1756-8722-6-49
   Jeon HM, 2011, CANCER RES, V71, P3410, DOI 10.1158/0008-5472.CAN-10-3340
   Karantza-Wadsworth V, 2007, GENE DEV, V21, P1621, DOI 10.1101/gad.1565707
   Kathawala RJ, 2015, DRUG RESIST UPDATE, V18, P1, DOI 10.1016/j.drup.2014.11.002
   Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717
   Lai QH, 2020, AGING-US, V12, P16270, DOI 10.18632/aging.103648
   Li XF, 2013, CANCER LETT, V336, P379, DOI 10.1016/j.canlet.2013.03.027
   de Andres JL, 2020, J HEMATOL ONCOL, V13, DOI 10.1186/s13045-020-00966-3
   Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027
   Mathew R, 2007, GENE DEV, V21, P1367, DOI 10.1101/gad.1545107
   Moitra K, 2011, CLIN PHARMACOL THER, V89, P491, DOI 10.1038/clpt.2011.14
   Nobili S, 2020, SEMIN CANCER BIOL, V60, P72, DOI 10.1016/j.semcancer.2019.08.006
   Pagotto A, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.327
   Piva M, 2014, EMBO MOL MED, V6, P66, DOI 10.1002/emmm.201303411
   Saigusa S, 2009, ANN SURG ONCOL, V16, P3488, DOI 10.1245/s10434-009-0617-z
   SAITO H, 1993, CANCER RES, V53, P3382
   Schuijers J, 2014, EMBO J, V33, P146, DOI 10.1002/embj.201385358
   Sharifi MN, 2016, CELL REP, V15, P1660, DOI 10.1016/j.celrep.2016.04.065
   Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128
   Sugano T, 2015, MOL CANCER THER, V14, P2433, DOI 10.1158/1535-7163.MCT-15-0050
   Tan YS, 2018, CLIN CANCER RES, V24, P4242, DOI 10.1158/1078-0432.CCR-17-2807
   Tanaka M, 2011, CANCER-AM CANCER SOC, V117, P744, DOI 10.1002/cncr.25510
   Tian T, 2012, J BIOMED RES, V26, P336, DOI 10.7555/JBR.26.20120045
   Wang B, 2017, CELL COMMUN SIGNAL, V15, DOI 10.1186/s12964-017-0179-9
   Wang S, 2013, CELL STEM CELL, V13, P617, DOI 10.1016/j.stem.2013.10.005
   Warrier S, 2012, CELL BIOL INT, V36, P1137, DOI 10.1042/CBI20110539
   White E, 2012, NAT REV CANCER, V12, P401, DOI 10.1038/nrc3262
   Wilson BJ, 2014, CANCER RES, V74, P4196, DOI 10.1158/0008-5472.CAN-14-0582
   Wu H, 2019, AUTOPHAGY, V15, P1506, DOI 10.1080/15548627.2019.1586250
   Yang MC, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0449-3
   Yang N, 2014, TUMOR BIOL, V35, P7965, DOI 10.1007/s13277-014-2045-3
   Zhang MY, 2014, INT J MOL SCI, V15, P14372, DOI 10.3390/ijms150814372
   Zheng HX, 2013, ONCOGENE, V32, P1183, DOI 10.1038/onc.2012.126
   Zheng HX, 2014, CARCINOGENESIS, V35, P173, DOI 10.1093/carcin/bgt274
NR 49
TC 4
Z9 4
U1 4
U2 5
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 2041-4889
J9 CELL DEATH DIS
JI Cell Death Dis.
PD MAY 5
PY 2021
VL 12
IS 5
AR 449
DI 10.1038/s41419-021-03733-5
PG 16
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA SK5HZ
UT WOS:000656247600003
PM 33953166
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Raufi, AG
   Liguori, NR
   Carlsen, L
   Parker, C
   Borrero, LH
   Zhang, SL
   Tian, XB
   Louie, A
   Zhou, LL
   Seyhan, AA
   El-Deiry, WS
AF Raufi, Alexander G.
   Liguori, Nicholas R.
   Carlsen, Lindsey
   Parker, Cassandra
   Hernandez Borrero, Liz
   Zhang, Shengliang
   Tian, Xiaobing
   Louie, Anna
   Zhou, Lanlan
   Seyhan, Attila A.
   El-Deiry, Wafik S.
TI Therapeutic Targeting of Autophagy in Pancreatic Ductal Adenocarcinoma
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Review
DE autophagy; pancreatic cancer; MEK inhibitors; ONC212; chloroquine; Atg5;
   LC3; beclin 1
ID ENDOPLASMIC-RETICULUM STRESS; HYPOXIA-INDUCIBLE FACTOR; SMALL-MOLECULE
   NSC59984; COLORECTAL-CANCER; CELL-SURVIVAL; RESTORES P53; ER STRESS;
   TRANSLATIONAL CONTROL; ANTITUMOR-ACTIVITY; KINASE ULK1
AB Pancreatic ductal adenocarcinoma (PDAC) is an aggressive disease characterized by early metastasis, late detection, and poor prognosis. Progress towards effective therapy has been slow despite significant efforts. Novel treatment approaches are desperately needed and autophagy, an evolutionary conserved process through which proteins and organelles are recycled for use as alternative energy sources, may represent one such target. Although incompletely understood, there is growing evidence suggesting that autophagy may play a role in PDAC carcinogenesis, metastasis, and survival. Early clinical trials involving autophagy inhibiting agents, either alone or in combination with chemotherapy, have been disappointing. Recently, evidence has demonstrated synergy between the MAPK pathway and autophagy inhibitors in PDAC, suggesting a promising therapeutic intervention. In addition, novel agents, such as ONC212, have preclinical activity in pancreatic cancer, in part through autophagy inhibition. We discuss autophagy in PDAC tumorigenesis, metabolism, modulation of the immune response, and preclinical and clinical data with selected autophagy modulators as therapeutics.
C1 [Raufi, Alexander G.; Liguori, Nicholas R.; Carlsen, Lindsey; Parker, Cassandra; Hernandez Borrero, Liz; Zhang, Shengliang; Tian, Xiaobing; Louie, Anna; Zhou, Lanlan; Seyhan, Attila A.; El-Deiry, Wafik S.] Brown Univ, Warren Alpert Med Sch, Lab Translat Oncol & Expt Canc Therapeut, Providence, RI 02912 USA.
   [Raufi, Alexander G.; El-Deiry, Wafik S.] Lifespan Hlth Syst & Brown Univ, Dept Med, Div Hematol Oncol, Providence, RI 02912 USA.
   [Raufi, Alexander G.; Carlsen, Lindsey; Zhang, Shengliang; Tian, Xiaobing; Zhou, Lanlan; Seyhan, Attila A.; El-Deiry, Wafik S.] Lifespan Hlth Syst & Brown Univ, Joint Program Canc Biol, Providence, RI 02912 USA.
   [Raufi, Alexander G.; Carlsen, Lindsey; Zhang, Shengliang; Tian, Xiaobing; Zhou, Lanlan; Seyhan, Attila A.; El-Deiry, Wafik S.] Brown Univ, Ctr Canc, Providence, RI 02912 USA.
   [Liguori, Nicholas R.] Temple Univ, Lewis Katz Sch Med, Philadelphia, PA 19122 USA.
   [Carlsen, Lindsey; Hernandez Borrero, Liz; El-Deiry, Wafik S.] Brown Univ, Pathobiol Grad Program, Warren Alpert Med Sch, Providence, RI 02912 USA.
   [Parker, Cassandra; Louie, Anna] Brown Univ, Dept Surg, Warren Alpert Med Sch, Providence, RI 02912 USA.
   [Zhang, Shengliang; Tian, Xiaobing; Zhou, Lanlan; Seyhan, Attila A.; El-Deiry, Wafik S.] Brown Univ, Dept Pathol & Lab Med, Warren Alpert Med Sch, Providence, RI 02912 USA.
RP Raufi, AG; El-Deiry, WS (corresponding author), Brown Univ, Warren Alpert Med Sch, Lab Translat Oncol & Expt Canc Therapeut, Providence, RI 02912 USA.; Raufi, AG; El-Deiry, WS (corresponding author), Lifespan Hlth Syst & Brown Univ, Dept Med, Div Hematol Oncol, Providence, RI 02912 USA.; Raufi, AG; El-Deiry, WS (corresponding author), Lifespan Hlth Syst & Brown Univ, Joint Program Canc Biol, Providence, RI 02912 USA.; Raufi, AG; El-Deiry, WS (corresponding author), Brown Univ, Ctr Canc, Providence, RI 02912 USA.; El-Deiry, WS (corresponding author), Brown Univ, Pathobiol Grad Program, Warren Alpert Med Sch, Providence, RI 02912 USA.; El-Deiry, WS (corresponding author), Brown Univ, Dept Pathol & Lab Med, Warren Alpert Med Sch, Providence, RI 02912 USA.
EM wafik@brown.edu; alexander_raufi@brown.edu
CR Akin D, 2014, AUTOPHAGY, V10, P2021, DOI 10.4161/auto.32229
   Allen JE, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3004828
   Amaravadi RK, 2012, AUTOPHAGY, V8, P1383, DOI 10.4161/auto.20958
   B'chir W, 2013, NUCLEIC ACIDS RES, V41, P7683, DOI 10.1093/nar/gkt563
   Bago R, 2014, BIOCHEM J, V463, P413, DOI 10.1042/BJ20140889
   Bassett EA, 2008, CLIN CANCER RES, V14, P6376, DOI 10.1158/1078-0432.CCR-08-1526
   Bellot G, 2009, MOL CELL BIOL, V29, P2570, DOI 10.1128/MCB.00166-09
   Bian J, 2021, TRANSL GASTROENT HEP, V6, DOI 10.21037/tgh.2020.04.03
   Borrero LH, 2021, ELIFE, V10, DOI 10.7554/eLife.70429
   Borrero LJH, 2021, BBA-REV CANCER, V1876, DOI 10.1016/j.bbcan.2021.188556
   Bryant KL, 2019, NAT MED, V25, P628, DOI 10.1038/s41591-019-0368-8
   Carew JS, 2007, BLOOD, V110, P313, DOI 10.1182/blood-2006-10-050260
   Carew JS, 2017, CLIN CANCER RES, V23, P2869, DOI 10.1158/1078-0432.CCR-16-1742
   Carew JS, 2017, AUTOPHAGY, V13, P765, DOI 10.1080/15548627.2017.1280222
   Carneiro BA, 2020, NAT REV CLIN ONCOL, V17, P395, DOI 10.1038/s41571-020-0341-y
   Chen SY, 2016, J CELL BIOCHEM, V117, P267, DOI 10.1002/jcb.25283
   Clarke AJ, 2019, NAT REV IMMUNOL, V19, P170, DOI 10.1038/s41577-018-0095-2
   Cunha LD, 2018, CELL, V175, P429, DOI 10.1016/j.cell.2018.08.061
   Deegan S, 2015, BIOCHEM BIOPH RES CO, V456, P305, DOI 10.1016/j.bbrc.2014.11.076
   Deegan S, 2013, CELL MOL LIFE SCI, V70, P2425, DOI 10.1007/s00018-012-1173-4
   Dennis MD, 2013, CELL SIGNAL, V25, P2709, DOI 10.1016/j.cellsig.2013.08.038
   Dey S, 2010, J BIOL CHEM, V285, P33165, DOI 10.1074/jbc.M110.167213
   Dolgin E, 2019, NAT REV DRUG DISCOV, V18, P408, DOI 10.1038/d41573-019-00072-1
   Donohue E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114964
   Donohue E, 2013, J CANCER, V4, P585, DOI 10.7150/jca.7030
   Donohue E, 2011, J BIOL CHEM, V286, P7290, DOI 10.1074/jbc.M110.139915
   Dowdle WE, 2014, NAT CELL BIOL, V16, P1069, DOI 10.1038/ncb3053
   Egan DF, 2015, MOL CELL, V59, P285, DOI 10.1016/j.molcel.2015.05.031
   Ferrarini I, 2021, MOL CANCER THER, V20, P1572, DOI 10.1158/1535-7163.MCT-20-0962
   Firat E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047357
   Frieboes HB, 2014, J PANCREAS, V15, P189, DOI 10.6092/1590-8577/1900
   Fujii S, 2008, CANCER SCI, V99, P1813, DOI 10.1111/j.1349-7006.2008.00893.x
   Germic N, 2019, CELL DEATH DIFFER, V26, P715, DOI 10.1038/s41418-019-0297-6
   Ghadimi MP, 2012, MOL CANCER THER, V11, P1758, DOI 10.1158/1535-7163.MCT-12-0015
   Gorgulu K, 2019, GASTROENTEROLOGY, V156, P203, DOI 10.1053/j.gastro.2018.09.053
   Golan T, 2019, NEW ENGL J MED, V381, P317, DOI 10.1056/NEJMoa1903387
   Guan BJ, 2014, J BIOL CHEM, V289, P12593, DOI 10.1074/jbc.M113.543215
   Guo JY, 2016, GENE DEV, V30, P1704, DOI 10.1101/gad.283416.116
   Guo JY, 2013, GENE DEV, V27, P1447, DOI 10.1101/gad.219642.113
   Han WD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018691
   Harding HP, 2000, MOL CELL, V5, P897, DOI 10.1016/S1097-2765(00)80330-5
   Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809
   Hernandez-Borrero LJ, 2018, CELL CYCLE, V17, P557, DOI 10.1080/15384101.2017.1346762
   Honda A, 2016, ACS MED CHEM LETT, V7, P72, DOI 10.1021/acsmedchemlett.5b00335
   Hong Z, 2017, J CELL BIOL, V216, P4217, DOI 10.1083/jcb.201611073
   Horsman MR, 2016, J RADIAT RES, V57, pI90, DOI 10.1093/jrr/rrw007
   Hu YL, 2012, CANCER RES, V72, P4294, DOI 10.1158/0008-5472.CAN-12-1076
   Huang TZ, 2017, CANCER CELL, V32, P840, DOI 10.1016/j.ccell.2017.11.005
   Jacquel A, 2012, BLOOD, V119, P4527, DOI 10.1182/blood-2011-11-392167
   Javle MM, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-368
   Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010
   Jhaveri AV, 2020, CANCER RES, V80, DOI 10.1158/1538-7445.AM2020-6225
   Kaelin WG, 2011, COLD SH Q B, V76, P335, DOI 10.1101/sqb.2011.76.010975
   Kang R, 2010, CELL DEATH DIFFER, V17, P666, DOI 10.1038/cdd.2009.149
   Karasic TB, 2019, JAMA ONCOL, V5, P993, DOI 10.1001/jamaoncol.2019.0684
   Karsli-Uzunbas G, 2014, CANCER DISCOV, V4, P914, DOI 10.1158/2159-8290.CD-14-0363
   Kazemi S, 2007, MOL BIOL CELL, V18, P3635, DOI 10.1091/mbc.E07-01-0053
   Kim J, 2011, NAT CELL BIOL, V13, P132, DOI 10.1038/ncb2152
   Kinsey CG, 2019, NAT MED, V25, P620, DOI 10.1038/s41591-019-0367-9
   Kline CLB, 2016, SCI SIGNAL, V9, DOI 10.1126/scisignal.aac4374
   Klionsky DJ, 2008, AUTOPHAGY, V4, P151, DOI 10.4161/auto.5338
   Kouroku Y, 2007, CELL DEATH DIFFER, V14, P230, DOI 10.1038/sj.cdd.4401984
   Kroemer G, 2010, MOL CELL, V40, P280, DOI 10.1016/j.molcel.2010.09.023
   Kume S, 2010, J CLIN INVEST, V120, P1043, DOI 10.1172/JCI41376
   Kurdi A, 2017, BIOCHEM PHARMACOL, V138, P150, DOI 10.1016/j.bcp.2017.06.119
   Kuribayashi K, 2008, CANCER BIOL THER, V7, P2034, DOI 10.4161/cbt.7.12.7460
   Lazarus MB, 2015, BIOORGAN MED CHEM, V23, P5483, DOI 10.1016/j.bmc.2015.07.034
   Lazarus MB, 2015, ACS CHEM BIOL, V10, P257, DOI 10.1021/cb500835z
   Lebovitz CB, 2015, AUTOPHAGY, V11, P1668, DOI 10.1080/15548627.2015.1067362
   Lev A, 2017, ONCOTARGET, V8, P81776, DOI 10.18632/oncotarget.20819
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Levy JMM, 2020, CELL DEATH DIFFER, V27, P843, DOI [10.1038/s41418-019-0474, 10.1038/s41418-019-0474-7]
   Li YH, 2012, CANCER RES, V72, P3535, DOI 10.1158/0008-5472.CAN-11-3103
   Liang XY, 2012, CANCER RES, V72, P2791, DOI 10.1158/0008-5472.CAN-12-0320
   Liberti MV, 2016, TRENDS BIOCHEM SCI, V41, P211, DOI 10.1016/j.tibs.2015.12.001
   Limpert AS, 2018, TRENDS PHARMACOL SCI, V39, P1021, DOI 10.1016/j.tips.2018.10.004
   Lin JH, 2007, SCIENCE, V318, P944, DOI 10.1126/science.1146361
   Lin JH, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004170
   Liu CY, 2000, J BIOL CHEM, V275, P24881, DOI 10.1074/jbc.M004454200
   Maes H, 2014, CANCER CELL, V26, P190, DOI 10.1016/j.ccr.2014.06.025
   Majmundar AJ, 2010, MOL CELL, V40, P294, DOI 10.1016/j.molcel.2010.09.022
   Masson N, 2014, CANCER METAB, V2, DOI 10.1186/2049-3002-2-3
   Mazure NM, 2010, CURR OPIN CELL BIOL, V22, P177, DOI 10.1016/j.ceb.2009.11.015
   McAfee Q, 2012, P NATL ACAD SCI USA, V109, P8253, DOI 10.1073/pnas.1118193109
   Miller KD, 2016, CA-CANCER J CLIN, V66, P271, DOI 10.3322/caac.21349
   Minassian LM, 2019, ADV EXP MED BIOL, V1136, P123, DOI 10.1007/978-3-030-12734-3_9
   Mizushima N, 2011, ANNU REV CELL DEV BI, V27, P107, DOI 10.1146/annurev-cellbio-092910-154005
   Moore MJ, 2007, J CLIN ONCOL, V25, P1960, DOI 10.1200/JCO.2006.07.9525
   Mortensen M, 2011, J EXP MED, V208, P455, DOI 10.1084/jem.20101145
   Nawrocki ST, 2016, BLOOD, V128, DOI 10.1182/blood.V128.22.525.525
   Nicastri MC, 2018, MOL CELL ONCOL, V5, DOI 10.1080/23723556.2017.1395504
   Novak I, 2010, EMBO REP, V11, P45, DOI 10.1038/embor.2009.256
   Pakos-Zebrucka K, 2016, EMBO REP, V17, P1374, DOI 10.15252/embr.201642195
   Perera R, 2015, NATURE, V524, P361, DOI 10.1038/nature14587
   Petherick KJ, 2015, J BIOL CHEM, V290, P11376, DOI [10.1074/jbc.C114.627778, 10.1074/jbc.A114.627778]
   Pietrocola F, 2016, CANCER CELL, V30, P147, DOI 10.1016/j.ccell.2016.05.016
   Piffoux M, 2021, BRIT J CANCER, V124, P333, DOI 10.1038/s41416-020-01039-5
   Prabhu VV, 2016, CANCER RES, V76, P1989, DOI 10.1158/0008-5472.CAN-14-2430
   Prabhu VV, 2015, CANCER RES, V75, P1423, DOI 10.1158/0008-5472.CAN-13-3451
   Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039
   Raufi AG, 2021, CANCER RES, V81
   Rebecca VW, 2017, CANCER DISCOV, V7, P1266, DOI 10.1158/2159-8290.CD-17-0741
   Reggiori F, 2017, J MOL BIOL, V429, P486, DOI 10.1016/j.jmb.2017.01.002
   Richardson C, 2017, CELL CYCLE, V16, P1719, DOI 10.1080/15384101.2017.1356514
   Roczniak-Ferguson A, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002790
   Ron D, 2002, J CLIN INVEST, V110, P1383, DOI 10.1172/JCI200216784
   Ronan B, 2014, NAT CHEM BIOL, V10, P1013, DOI 10.1038/nchembio.1681
   Rouschop KMA, 2010, J CLIN INVEST, V120, P127, DOI 10.1172/JCI40027
   Rutkowski DT, 2006, PLOS BIOL, V4, P2024, DOI 10.1371/journal.pbio.0040374
   Rzymski T, 2010, ONCOGENE, V29, P4424, DOI 10.1038/onc.2010.191
   Samaras P, 2017, CANCER CHEMOTH PHARM, V80, P1005, DOI 10.1007/s00280-017-3446-y
   Shang LB, 2011, P NATL ACAD SCI USA, V108, P4788, DOI 10.1073/pnas.1100844108
   Shao S, 2014, INT J ONCOL, V44, P1661, DOI 10.3892/ijo.2014.2313
   Showkat M, 2014, CELL SIGNAL, V26, P2117, DOI 10.1016/j.cellsig.2014.06.008
   Sotelo J, 2006, ANN INTERN MED, V144, P337, DOI 10.7326/0003-4819-144-5-200603070-00008
   Stein MN, 2017, CLIN CANCER RES, V23, P4163, DOI 10.1158/1078-0432.CCR-16-2658
   Strohecker AM, 2013, CANCER DISCOV, V3, P1272, DOI 10.1158/2159-8290.CD-13-0397
   Suraweera A, 2012, MOL CELL, V48, P242, DOI 10.1016/j.molcel.2012.08.003
   Szegezdi E, 2006, EMBO REP, V7, P880, DOI 10.1038/sj.embor.7400779
   Takamura A, 2011, GENE DEV, V25, P795, DOI 10.1101/gad.2016211
   Talloczy Z, 2002, P NATL ACAD SCI USA, V99, P190, DOI 10.1073/pnas.012485299
   Tang F, 2017, ONCOL REP, V37, P3449, DOI 10.3892/or.2017.5635
   Tian T, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20030755
   Tian XB, 2021, NEOPLASIA, V23, P304, DOI 10.1016/j.neo.2021.01.004
   Viale A, 2014, NATURE, V514, P628, DOI 10.1038/nature13611
   Wagner J, 2018, J CLIN INVEST, V128, P2325, DOI 10.1172/JCI96711
   Wagner J, 2017, CELL CYCLE, V16, P1790, DOI 10.1080/15384101.2017.1325046
   Wang WG, 2006, P NATL ACAD SCI USA, V103, P11003, DOI 10.1073/pnas.0604507103
   White E, 2016, CSH PERSPECT MED, V6, DOI 10.1101/cshperspect.a026120
   White E, 2015, J CLIN INVEST, V125, P42, DOI 10.1172/JCI73941
   Whitney ML, 2009, BIOCHEM BIOPH RES CO, V379, P451, DOI 10.1016/j.bbrc.2008.12.079
   Wilson WR, 2011, NAT REV CANCER, V11, P393, DOI 10.1038/nrc3064
   Wolpin BM, 2014, ONCOLOGIST, V19, P637, DOI 10.1634/theoncologist.2014-0086
   Wolpin BM, 2009, J CLIN ONCOL, V27, P193, DOI 10.1200/JCO.2008.18.9514
   Wong PM, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9048
   Wood SD, 2017, ACS MED CHEM LETT, V8, P1258, DOI 10.1021/acsmedchemlett.7b00344
   Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141
   Yamamoto K, 2020, NATURE, V581, P100, DOI 10.1038/s41586-020-2229-5
   Yang AN, 2018, CANCER DISCOV, V8, P276, DOI 10.1158/2159-8290.CD-17-0952
   Yang A, 2014, AUTOPHAGY, V10, P1683, DOI 10.4161/auto.29961
   Yang A, 2014, CANCER DISCOV, V4, P905, DOI 10.1158/2159-8290.CD-14-0362
   Yang SH, 2011, GENE DEV, V25, P717, DOI 10.1101/gad.2016111
   Ye JB, 2010, EMBO J, V29, P2082, DOI 10.1038/emboj.2010.81
   Young CD, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0656-2
   Young TM, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abb9561
   Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100
   Yun Z, 2014, ADV EXP MED BIOL, V772, P41, DOI 10.1007/978-1-4614-5915-6_2
   Zhang S., 2017, CANCER RES, V77
   Zhang SL, 2018, CANCER RES, V78, DOI 10.1158/1538-7445.AM2018-1866
   Zhang SL, 2017, CANCER RES, V77, DOI 10.1158/1538-7445.AM2017-2156
   Zhang SL, 2015, CANCER RES, V75, P3842, DOI 10.1158/0008-5472.CAN-13-1079
   Zhang Y, 2012, BLOOD, V119, P2895, DOI 10.1182/blood-2011-08-372383
   Zou ZZ, 2012, AUTOPHAGY, V8, P1798, DOI 10.4161/auto.22110
NR 153
TC 0
Z9 0
U1 5
U2 5
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 1663-9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD NOV 30
PY 2021
VL 12
AR 751568
DI 10.3389/fphar.2021.751568
PG 16
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA XO0ZK
UT WOS:000729923200001
PM 34916936
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Wang, L
   Mai, ZH
   Zhao, MX
   Wang, B
   Yu, S
   Wang, XP
   Chen, TS
AF Wang, Lu
   Mai, Zihao
   Zhao, Mengxin
   Wang, Bin
   Yu, Si
   Wang, Xiaoping
   Chen, Tongsheng
TI Aspirin induces oncosis in tumor cells
SO APOPTOSIS
LA English
DT Article
DE Aspirin; Oncosis; Bcl-XL; ATP depletion; Caspase-3
ID MITOCHONDRIAL PERMEABILITY TRANSITION; NONSTEROIDAL ANTIINFLAMMATORY
   DRUGS; MEDIATED INTRINSIC PATHWAY; COLON-CANCER; INDUCED APOPTOSIS;
   CONTROLLED-TRIAL; NECROSIS; ACETAMINOPHEN; ACTIVATION; PREVENTION
AB In contrast to the well-known anti-tumor mechanisms of aspirin in inducing apoptosis or autophagy, we here for the first time report oncosis induced by aspirin in tumor cells. In vitro and in vivo analysis showed that aspirin induced compromised Bcl-XL level and subsequent ATP depletion. Overexpression of CFP-Bcl-XL in Hela and A549 cells observably inhibited aspirin-induced ATP depletion and almost completely inhibited the aspirin-induced cells bubbling, while pharmacological inhibition of endogenous Bcl-XL activity by ABT-737 remarkably promoted aspirin-induced ATP depletion and cells bubbling, suggesting the key inhibitory role of Bcl-XL in aspirin-induced oncosis. Overexpression of Bax/Bad significantly promoted aspirin-induced oncosis. In addition, cells cultured in a glucose-free medium with low ATP level exhibited higher percentage of bubbling cells than the cells cultured in a glucose medium with high ATP level under aspirin treatment, indicating the important role of ATP depletion in aspirin-induced oncosis. Furthermore, caspase-3 was demonstrated to be not involved in aspirin-induced oncosis. Animal studies showed that aspirin treatment significantly inhibited tumors growth, but did not induce toxicities to mice. Collectively, aspirin inhibits tumors growth in mice and induces oncosis in which the compromised Bcl-XL and intracellular ATP depletion play a dominant role, which provides insights into the therapeutic strategy of aspirin in oncology.
C1 [Wang, Lu; Mai, Zihao; Wang, Bin; Yu, Si; Chen, Tongsheng] South China Normal Univ, MOE Key Lab Laser Life Sci, Guangzhou 510631, Guangdong, Peoples R China.
   [Wang, Lu; Mai, Zihao; Wang, Bin; Yu, Si; Chen, Tongsheng] South China Normal Univ, Coll Biophoton, Guangzhou 510631, Guangdong, Peoples R China.
   [Zhao, Mengxin; Wang, Xiaoping] Jinan Univ, Affiliated Hosp 1, Dept Pain Management, Guangzhou 5610632, Guangdong, Peoples R China.
RP Chen, TS (corresponding author), South China Normal Univ, MOE Key Lab Laser Life Sci, Guangzhou 510631, Guangdong, Peoples R China.; Chen, TS (corresponding author), South China Normal Univ, Coll Biophoton, Guangzhou 510631, Guangdong, Peoples R China.; Wang, XP (corresponding author), Jinan Univ, Affiliated Hosp 1, Dept Pain Management, Guangzhou 5610632, Guangdong, Peoples R China.
EM txp2938@jnu.edu.cn; chentsh@scnu.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [61875056, 61527825, 81572184]
FX This work was supported by the National Natural Science Foundation of
   China (Grant Nos. 61875056, 61527825 and 81572184).
CR Ahmed N, 2010, J THROMB THROMBOLYS, V29, P416, DOI 10.1007/s11239-009-0366-7
   Alavian KN, 2014, P NATL ACAD SCI USA, V111, P10580, DOI 10.1073/pnas.1401591111
   Alavian KN, 2011, NAT CELL BIOL, V13, P1224, DOI 10.1038/ncb2330
   Alfonso L, 2014, BRIT J CANCER, V111, P61, DOI 10.1038/bjc.2014.271
   Bajt ML, 2008, J PHARMACOL EXP THER, V324, P8, DOI 10.1124/jpet.107.129445
   Cao Y, 2016, JAMA ONCOL, V2, P762, DOI 10.1001/jamaoncol.2015.6396
   Cha YI, 2007, ANNU REV MED, V58, P239, DOI 10.1146/annurev.med.57.121304.131253
   Chen YB, 2011, J CELL BIOL, V195, P263, DOI 10.1083/jcb.201108059
   Chen ZG, 2018, THERANOSTICS, V8, P4447, DOI 10.7150/thno.24284
   Chen ZM, 1997, LANCET, V349, P1641, DOI 10.1016/S0140-6736(97)04010-5
   Chiarugi A, 2005, FASEB J, V19, P1783, DOI 10.1096/fj.05-4200rev
   Cooley-Andrade O, 2016, EUR J VASC ENDOVASC, V51, P846, DOI 10.1016/j.ejvs.2016.03.008
   Degterev A, 2008, NAT REV MOL CELL BIO, V9, P378, DOI 10.1038/nrm2393
   Del Nagro C, 2014, J BIOL CHEM, V289, P35182, DOI 10.1074/jbc.M114.580159
   Del Re DP, 2014, MOL CELL, V54, P639, DOI 10.1016/j.molcel.2014.04.007
   Din FVN, 2012, GASTROENTEROLOGY, V142, P1504, DOI 10.1053/j.gastro.2012.02.050
   Du MY, 2018, APPL PHYS LETT, V112, DOI 10.1063/1.5021466
   ELWOOD PC, 1974, BRIT MED J, V1, P436, DOI 10.1136/bmj.1.5905.436
   Elwood PC, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152402
   Fields WS, 1977, INPHARMA, V98, P10
   Fuster V, 2011, CIRCULATION, V123, P768, DOI 10.1161/CIRCULATIONAHA.110.963843
   Garcia-Belincon M, 2015, J BIOL CHEM, V290, P20841, DOI 10.1074/jbc.M115.644179
   Gobe G, 2002, CANC INVEST, V20, P9
   Gu Q, 2005, CARCINOGENESIS, V26, P541, DOI 10.1093/carcin/bgh345
   Hanif R, 1996, BIOCHEM PHARMACOL, V52, P237, DOI 10.1016/0006-2952(96)00181-5
   Hickman JA, 2008, J NEUROPHYSIOL, V99, P1515, DOI 10.1152/jn.00598.2007
   Jaeschke H, 2003, GASTROENTEROLOGY, V125, P1246, DOI 10.1016/S0016-5085(03)01209-5
   Jana NR, 2008, CELL MOL LIFE SCI, V65, P1295, DOI 10.1007/s00018-008-7511-x
   Johannesdottir SA, 2012, CANCER-AM CANCER SOC, V118, P4768, DOI 10.1002/cncr.27406
   KANE DJ, 1995, J NEUROSCI RES, V40, P269, DOI 10.1002/jnr.490400216
   Khandelwal N, 2011, CELL DEATH DIFFER, V18, P1889, DOI 10.1038/cdd.2011.79
   Klee M, 2005, J CELL BIOL, V168, P723, DOI 10.1083/jcb.200408169
   Knight TR, 2002, TOXICOL APPL PHARM, V181, P133, DOI 10.1006/taap.2002.9407
   Kon K, 2004, HEPATOLOGY, V40, P1170, DOI 10.1002/hep.20437
   Leist M, 1997, J EXP MED, V185, P1481, DOI 10.1084/jem.185.8.1481
   Liao XY, 2012, NEW ENGL J MED, V367, P1596, DOI 10.1056/NEJMoa1207756
   Liu XL, 2003, J PHARMACOL EXP THER, V304, P63, DOI 10.1124/jpet.102.043406
   Liu XL, 2004, ANNU REV PHARMACOL, V44, P349, DOI 10.1146/annurev.pharmtox.44.101802.121804
   Martinou JC, 2011, DEV CELL, V21, P92, DOI 10.1016/j.devcel.2011.06.017
   McNally MA, 2013, MITOCHONDRION, V13, P119, DOI 10.1016/j.mito.2013.01.004
   Mills EM, 2002, J BIOL CHEM, V277, P27385, DOI 10.1074/jbc.M111860200
   Nicotera P, 2004, ONCOGENE, V23, P2757, DOI 10.1038/sj.onc.1207559
   Ogawa F, 2014, BIOMED PHARMACOTHER, V68, P79, DOI 10.1016/j.biopha.2013.11.006
   Ouyang NT, 2008, CARCINOGENESIS, V29, P1794, DOI 10.1093/carcin/bgn127
   Pang YL, 2016, EXP CELL RES, V347, P251, DOI 10.1016/j.yexcr.2016.06.012
   Perelman A, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.171
   Peters AA, 2017, ONCOGENE, V36, P6490, DOI 10.1038/onc.2017.234
   Qin GQ, 2015, EXP CELL RES, V336, P308, DOI 10.1016/j.yexcr.2015.07.004
   Redlak MJ, 2005, AM J PHYSIOL-GASTR L, V289, pG731, DOI 10.1152/ajpgi.00150.2005
   Rigas B, 2000, MED HYPOTHESES, V54, P210, DOI 10.1054/mehy.1999.0023
   Roelofs HMJ, 2014, BMC GASTROENTEROL, V14, DOI 10.1186/1471-230X-14-1
   Saad-Hossne R, 2013, WORLD J HEPATOL, V5, P372, DOI 10.4254/wjh.v5.i7.372
   Sandercock P, 1997, LANCET, V349, P1569
   Stark LA, 2001, FASEB J, V15, P1273, DOI 10.1096/fj.00-0529fje
   Subbegowda R, 1998, CANCER RES, V58, P2772
   Tan XL, 2011, CANCER PREV RES, V4, P1835, DOI 10.1158/1940-6207.CAPR-11-0146
   Trump BF, 1997, TOXICOL PATHOL, V25, P82, DOI 10.1177/019262339702500116
   Vanden Berghe T, 2010, CELL DEATH DIFFER, V17, P922, DOI 10.1038/cdd.2009.184
   Weerasinghe P, 2001, CELL BIOL TOXICOL, V17, P371, DOI 10.1023/A:1013796432521
   Weerasinghe P, 2006, EXP TOXICOL PATHOL, V58, P21, DOI 10.1016/j.etp.2006.01.008
   Weerasinghe P, 2012, EXP MOL PATHOL, V93, P302, DOI 10.1016/j.yexmp.2012.09.018
   WEISSMANN G, 1991, SCI AM, V264, P84, DOI 10.1038/scientificamerican0191-84
   Yue W, 2014, CANCER PREV RES, V7, P388, DOI 10.1158/1940-6207.CAPR-13-0337
   Zimmermann KC, 2000, NEOPLASIA, V2, P505, DOI 10.1038/sj.neo.7900120
NR 64
TC 8
Z9 8
U1 2
U2 18
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1360-8185
EI 1573-675X
J9 APOPTOSIS
JI Apoptosis
PD OCT
PY 2019
VL 24
IS 9-10
BP 758
EP 772
DI 10.1007/s10495-019-01555-7
PG 15
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA IU6HS
UT WOS:000483688000007
PM 31243598
DA 2022-04-25
ER

PT J
AU Yang, HZ
   Ma, Y
   Zhou, Y
   Xu, LM
   Chen, XJ
   Ding, WB
   Zou, HB
AF Yang, Hao-Zheng
   Ma, Yi
   Zhou, Yan
   Xu, Long-Mei
   Chen, Xiao-Jing
   Ding, Wen-Bin
   Zou, Han-Bing
TI Autophagy contributes to the enrichment and survival of colorectal
   cancer stem cells under oxaliplatin treatment
SO CANCER LETTERS
LA English
DT Article
DE Colorectal cancer; Autophagy; Cancer stem cells; Chemoresistance
ID INITIATING CELLS; INHIBITION; MAINTENANCE; PROMOTES; INDUCTION;
   VIABILITY; PATHWAY; CD44
AB Currently, chemoresistance is an important cause of treatment failure in colorectal cancer. Cancer stem cells, which are a population of multi-potent cells with the capacity to self-renew and differentiate, have been found to participate in chemoresistance. In the present study, the chemotherapeutic drug oxaliplatin induced autophagy in colorectal cancer cell lines, which in turn protected cancer cells from apoptosis. Further results showed that oxaliplatin-induced autophagy enriched the population of colorectal CSCs and participated in maintaining the sternness of colorectal CSCs, thus making the cells more resistant to chemotherapy. Taken together, the results indicate that autophagy might enhance the chemoresistance of colorectal cancer cells by protecting the stemness and chemoresistance of colorectal CSCs. Our study demonstrates that autophagy plays a pro-survival role in colorectal CSCs subjected to oxaliplatin. Therefore, targeting autophagy may be considered as a potential therapeutic strategy to address chemoresistance in the treatment of colorectal cancer. (C) 2015 Elsevier Ireland Ltd. All rights reserved.
C1 [Yang, Hao-Zheng; Zhou, Yan; Xu, Long-Mei; Chen, Xiao-Jing; Ding, Wen-Bin; Zou, Han-Bing] Shanghai Jiao Tong Univ, Sch Med, Ren Ji Hosp, Cent Lab, Shanghai 200127, Peoples R China.
   [Ma, Yi] Shanghai Jiao Tong Univ, Sch Med, Ren Ji Hosp, Dept Biobank, Shanghai 200127, Peoples R China.
RP Ding, WB (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Ren Ji Hosp, Cent Lab, Shanghai 200127, Peoples R China.
EM wbding@shsmu.edu.cn; coolice0917@163.com
FU Science and Technology Commission of Shanghai Municipality and Renji
   hospital [124119a1300, 12DZ2295005]; Shanghai JiaoTong University School
   of Medicine [RJZZ14-009]
FX This work was supported by the Science and Technology Commission of
   Shanghai Municipality (124119a1300; 12DZ2295005) and Renji hospital,
   Shanghai JiaoTong University School of Medicine (RJZZ14-009).
CR Amaravadi RK, 2007, J CLIN INVEST, V117, P326, DOI 10.1172/JCI28833
   Apel A, 2008, CANCER RES, V68, P1485, DOI 10.1158/0008-5472.CAN-07-0562
   Bjorkoy G, 2009, METHOD ENZYMOL, V452, P181, DOI 10.1016/S0076-6879(08)03612-4
   Cammareri P, 2010, CANCER RES, V70, P4655, DOI 10.1158/0008-5472.CAN-09-3953
   Chaachouay H, 2011, RADIOTHER ONCOL, V99, P287, DOI 10.1016/j.radonc.2011.06.002
   Chu P, 2009, INT J CANCER, V124, P1312, DOI 10.1002/ijc.24061
   Colak S, 2014, CELL DEATH DIFFER, V21, P1170, DOI 10.1038/cdd.2014.37
   Dave B, 2009, J MAMMARY GLAND BIOL, V14, P79, DOI 10.1007/s10911-009-9117-9
   Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001
   Du L, 2008, CLIN CANCER RES, V14, P6751, DOI 10.1158/1078-0432.CCR-08-1034
   Dubrovska A, 2009, P NATL ACAD SCI USA, V106, P268, DOI 10.1073/pnas.0810956106
   Ertmer A, 2007, LEUKEMIA, V21, P936, DOI 10.1038/sj.leu.2404606
   Fan CW, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.337
   Goldberg RM, 2006, J CLIN ONCOL, V24, P3347, DOI 10.1200/JCO.2006.06.1317
   Gong C, 2013, ONCOGENE, V32, P2261, DOI 10.1038/onc.2012.252
   Gong C, 2012, AUTOPHAGY, V8, P1853, DOI 10.4161/auto.21996
   Grothey A, 2010, ONCOLOGY-BASEL, V79, P389, DOI 10.1159/000323491
   Haraguchi N, 2008, ANN SURG ONCOL, V15, P2927, DOI 10.1245/s10434-008-0074-0
   Ju SY, 2014, STEM CELL RES, V12, P86, DOI 10.1016/j.scr.2013.09.011
   Kantara C, 2014, CANCER RES, V74, P2487, DOI 10.1158/0008-5472.CAN-13-3536
   Keniry M, 2008, ONCOGENE, V27, P5477, DOI 10.1038/onc.2008.248
   Klionsky DJ, 2008, AUTOPHAGY, V4, P151, DOI 10.4161/auto.5338
   Komatsu M, 2005, J CELL BIOL, V169, P425, DOI 10.1083/jcb.200412022
   Lara-Padilla E, 2012, CURR STEM CELL RES T, V7, P26, DOI 10.2174/157488812798483412
   Li XQ, 2010, CANCER RES, V70, P5942, DOI 10.1158/0008-5472.CAN-10-0157
   Ma Y, 2014, ONCOTARGET, V5, P9169, DOI 10.18632/oncotarget.2396
   Ma Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093175
   Magee JA, 2012, CANCER CELL, V21, P283, DOI 10.1016/j.ccr.2012.03.003
   Mathew R, 2007, NAT REV CANCER, V7, P961, DOI 10.1038/nrc2254
   Mathew R, 2009, CELL, V137, P1062, DOI 10.1016/j.cell.2009.03.048
   Mizushima N, 2001, J CELL BIOL, V152, P657, DOI 10.1083/jcb.152.4.657
   Mizushima N, 2010, CELL, V140, P313, DOI 10.1016/j.cell.2010.01.028
   Mousavi SA, 2003, BIOCHEM J, V372, P861, DOI 10.1042/BJ20021136
   O'Brien CA, 2007, NATURE, V445, P106, DOI 10.1038/nature05372
   O'Donovan TR, 2011, AUTOPHAGY, V7, P509, DOI 10.4161/auto.7.5.15066
   Ohata H, 2012, CANCER RES, V72, P5101, DOI 10.1158/0008-5472.CAN-11-3812
   Palmeira-dos-Santos C, 2014, J CANCER RES CLIN, V140, P909, DOI 10.1007/s00432-014-1640-4
   Pan HZ, 2013, EMBO MOL MED, V5, P327, DOI 10.1002/emmm.201201999
   Punt CJA, 2009, NAT REV CLIN ONCOL, V6, P731, DOI 10.1038/nrclinonc.2009.168
   Qadir MA, 2008, BREAST CANCER RES TR, V112, P389, DOI 10.1007/s10549-007-9873-4
   Rausch V, 2012, J PATHOL, V227, P325, DOI 10.1002/path.3994
   Ricci-Vitiani L, 2009, J MOL MED, V87, P1097, DOI 10.1007/s00109-009-0518-4
   Schmeisser H, 2013, AUTOPHAGY, V9, P683, DOI 10.4161/auto.23921
   Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166
   Singh BN, 2012, BIOCHEM PHARMACOL, V84, P1154, DOI 10.1016/j.bcp.2012.08.007
   Song YJ, 2013, CANCER LETT, V339, P70, DOI 10.1016/j.canlet.2013.07.021
   Visvader JE, 2012, CELL STEM CELL, V10, P717, DOI 10.1016/j.stem.2012.05.007
   Warr MR, 2013, NATURE, V494, P323, DOI 10.1038/nature11895
   Yang ZF, 2009, CURR TOP MICROBIOL, V335, P1, DOI 10.1007/978-3-642-00302-8_1
   Zhou JB, 2007, P NATL ACAD SCI USA, V104, P16158, DOI 10.1073/pnas.0702596104
   Zhu K, 2010, ONCOGENE, V29, P451, DOI 10.1038/onc.2009.343
NR 51
TC 38
Z9 44
U1 3
U2 36
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0304-3835
EI 1872-7980
J9 CANCER LETT
JI Cancer Lett.
PD MAY 28
PY 2015
VL 361
IS 1
BP 128
EP 136
DI 10.1016/j.canlet.2015.02.045
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA CF6OH
UT WOS:000352675500016
PM 25749420
DA 2022-04-25
ER

PT J
AU de Oliveira, MR
   Nabavi, SF
   Nabavi, SM
   Jardim, FR
AF de Oliveira, Marcos Roberto
   Nabavi, Seyed Fazel
   Nabavi, Seyed Mohammad
   Jardim, Fernanda Rafaela
TI Omega-3 polyunsaturated fatty acids and mitochondria, back to the future
SO TRENDS IN FOOD SCIENCE & TECHNOLOGY
LA English
DT Review
DE Omega-3 fatty acids; Mitochondria; Antioxidant; Apoptosis; Mitochondrial
   biogenesis
ID COLON-CANCER CELLS; ENDOPLASMIC-RETICULUM STRESS; ACTIVATED
   PROTEIN-KINASES; ALPHA-LINOLENIC ACID; DOCOSAHEXAENOIC ACID;
   EICOSAPENTAENOIC ACID; OXIDATIVE STRESS; INDUCED APOPTOSIS; FISH-OIL;
   CYTOCHROME-C
AB Background: Mitochondrion, a double-membrane bound organelle, plays a critical role in eukaryotic cells energy production. Further to its role as ATP-producing factory, mitochondrion has distinct role in a number of cellular functions including calcium and redox signaling, apoptosis, and autophagy. Extensive studies showed the crucial role of mitochondrial dysfunction in pathophysiology of different diseases such as cardiovascular diseases, neurodegenerative diseases, among others. Recently extensive evidences report the promising effects of omega-3 polyunsaturated fatty acids on mitochondrial structure and functions as well as mitochondrial diseases.
   Scope and approach: In this paper, we critically review the available evidences on beneficial role of omega-3 polyunsaturated fatty acids on mitochondrial dynamic and biogenesis. We also discuss about chemistry, source, and bioavailability of omega-3 polyunsaturated fatty acids.
   Key findings and conclusions: These findings lead to an upsurge of interest in finding a new effective therapeutic strategy based on targeting mitochondrial dysfunction for above-mentioned diseases. Recently, a great body of evidences obtained from experimental studies shows the promising role of omega-3 polyunsaturated fatty acids on mitochondrial function and dynamics. Different clinical trials have also addressed the promising role of omega-3 polyunsaturated fatty acids on different disease and these facts may be related to its favorable effects on mitochondria. (C) 2017 Elsevier Ltd. All rights reserved.
C1 [de Oliveira, Marcos Roberto] Fed Univ Mato Grosso UFMT, Dept Chem, ICET, Ave Fernando Correa da Costa 2367, BR-78060900 Cuiaba, MT, Brazil.
   [Nabavi, Seyed Fazel; Nabavi, Seyed Mohammad] Baqiyatallah Univ Med Sci, Appl Biotechnol Res Ctr, POB 19395-5487, Tehran, Iran.
   [Jardim, Fernanda Rafaela] Forens Inst, IGP, Dept Pericias Labs, Forens Toxicol Div,Postmortem Toxicol Sect, Ave Ipiranga 1807, BR-90160093 Porto Alegre, RS, Brazil.
RP de Oliveira, MR (corresponding author), Fed Univ Mato Grosso UFMT, Dept Chem, ICET, Ave Fernando Correa da Costa 2367, BR-78060900 Cuiaba, MT, Brazil.; Nabavi, SM (corresponding author), Baqiyatallah Univ Med Sci, Appl Biotechnol Res Ctr, POB 19395-5487, Tehran, Iran.
EM mrobioq@yahoo.com.br; Nabavi208@gmail.com
RI Nabavi, Seyed Mohammad/G-5335-2010; Nabavi, Seyed Fazel/A-2223-2010; de
   Oliveira, Marcos Roberto/D-7470-2015
OI Nabavi, Seyed Mohammad/0000-0001-8859-5675; de Oliveira, Marcos
   Roberto/0000-0003-2414-6605
CR Agrawal R, 2014, BBA-MOL BASIS DIS, V1842, P535, DOI 10.1016/j.bbadis.2013.12.004
   Anderson BM, 2009, LIPIDS HEALTH DIS, V8, DOI 10.1186/1476-511X-8-33
   Arita K, 2001, BIOCHEM PHARMACOL, V62, P821, DOI 10.1016/S0006-2952(01)00723-7
   Arterburn LM, 2006, AM J CLIN NUTR, V83, p1467S, DOI 10.1093/ajcn/83.6.1467S
   Ascenzi P, 2015, IUBMB LIFE, V67, P98, DOI 10.1002/iub.1350
   Atamna H, 2012, BIOFACTORS, V38, P158, DOI 10.1002/biof.197
   Barrow CJ, 2009, J FUNCT FOOD, V1, P38, DOI 10.1016/j.jff.2008.09.006
   Bays HE, 2007, AM J CARDIOL, V99, p35C, DOI 10.1016/j.amjcard.2006.11.020
   BELURY MA, 1995, NUTR REV, V53, P83
   Berbusse GW, 2016, FRONT CELL NEUROSCI, V10, DOI 10.3389/fncel.2016.00179
   Birben E, 2012, WORLD ALLERGY ORGAN, V5, P9, DOI 10.1097/WOX.0b013e3182439613
   Bo L, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152216
   Bourre J M, 2004, J Nutr Health Aging, V8, P163
   Brenna JT, 2009, PROSTAG LEUKOTR ESS, V80, P85, DOI 10.1016/j.plefa.2009.01.004
   Brown GC, 2003, MOL NEUROBIOL, V27, P325, DOI 10.1385/MN:27:3:325
   Bu JY, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/6906712
   Burdge GC, 2005, REPROD NUTR DEV, V45, P581, DOI 10.1051/rnd:2005047
   Cadet JL, 2005, NEUROTOX RES, V8, P199, DOI 10.1007/BF03033973
   Calabrese V, 2001, NEUROCHEM RES, V26, P739, DOI 10.1023/A:1010955807739
   Calder PC, 2013, BRIT J CLIN PHARMACO, V75, P645, DOI 10.1111/j.1365-2125.2012.04374.x
   Cameron RB, 2016, J MED CHEM, V59, P10411, DOI 10.1021/acs.jmedchem.6b00669
   Candas D, 2014, ANTIOXID REDOX SIGN, V20, P1599, DOI 10.1089/ars.2013.5305
   Cansell M, 2003, LIPIDS, V38, P551, DOI 10.1007/s11745-003-1341-0
   Cao J, 2006, CLIN CHEM, V52, P2265, DOI 10.1373/clinchem.2006.072322
   Capo X, 2015, EUR J NUTR, V54, P35, DOI 10.1007/s00394-014-0683-2
   Casanova E, 2014, J NUTR BIOCHEM, V25, P1003, DOI 10.1016/j.jnutbio.2014.05.003
   Casanova E, 2014, BBA-BIOENERGETICS, V1837, P783, DOI 10.1016/j.bbabio.2014.01.014
   Cavaliere G, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149033
   Cederbaum AI, 2001, FREE RADICAL BIO MED, V31, P1539, DOI 10.1016/S0891-5849(01)00743-2
   Chen Q, 1997, J BIOL CHEM, V272, P14532, DOI 10.1074/jbc.272.23.14532
   Chen Y, 2014, BIOCATAL AGR BIOTECH, V3, P38, DOI 10.1016/j.bcab.2013.08.007
   Chenevier-Gobeaux C, 2006, INFLAMM RES, V55, P483, DOI 10.1007/s00011-006-6036-8
   Cicero AFG, 2009, CURR VASC PHARMACOL, V7, P330, DOI 10.2174/157016109788340659
   Cieslik M, 2013, NEUROCHEM INT, V62, P626, DOI 10.1016/j.neuint.2013.02.016
   Collins ML, 2014, FOOD CHEM TOXICOL, V72, P162, DOI 10.1016/j.fct.2014.07.021
   Colquhoun A, 2001, CELL BIOCHEM FUNCT, V19, P97, DOI 10.1002/cbf.902
   Colquhoun A, 2001, BBA-MOL CELL BIOL L, V1533, P207, DOI 10.1016/S1388-1981(01)00136-6
   Colquhoun A, 2009, J UROLOGY, V181, P1885, DOI 10.1016/j.juro.2008.11.092
   Cortie CH, 2012, INT J MOL SCI, V13, P15447, DOI 10.3390/ijms131115447
   Crane FL, 2008, BIOFACTORS, V32, P5, DOI 10.1002/biof.5520320102
   Crnkovic S, 2012, FREE RADICAL BIO MED, V52, P1786, DOI 10.1016/j.freeradbiomed.2012.02.036
   Cui ZG, 2014, CHEM-BIOL INTERACT, V215, P46, DOI 10.1016/j.cbi.2014.03.005
   Dabkowski ER, 2013, CARDIOVASC DRUG THER, V27, P499, DOI 10.1007/s10557-013-6487-4
   Davidson MH, 2013, CURR OPIN LIPIDOL, V24, P467, DOI 10.1097/MOL.0000000000000019
   de Oliveira M. R., 2016, NEUROTOX RES, P1
   de Oliveira M. R., 2016, MOL NEUROBIOLOGY
   de Oliveira MR, 2016, TOXICOL LETT, V258, P185, DOI 10.1016/j.toxlet.2016.07.001
   de Oliveira MR, 2016, BIOTECHNOL ADV, V34, P813, DOI 10.1016/j.biotechadv.2016.04.004
   de Oliveira MR, 2016, BIOTECHNOL ADV, V34, P532, DOI 10.1016/j.biotechadv.2015.12.014
   de Oliveira MR, 2016, PHARMACOL RES, V104, P70, DOI 10.1016/j.phrs.2015.12.027
   de Oliveira MR, 2016, TOXICOL IN VITRO, V32, P41, DOI 10.1016/j.tiv.2015.12.005
   de Oliveira MR, 2016, BBA-GEN SUBJECTS, V1860, P727, DOI 10.1016/j.bbagen.2016.01.017
   de Oliveira MR, 2016, NEUROCHEM INT, V92, P58, DOI 10.1016/j.neuint.2015.12.006
   de Oliveira MR, 2015, CHEM-BIOL INTERACT, V242, P396, DOI 10.1016/j.cbi.2015.11.003
   de Oliveira MR, 2009, CELL BIOL TOXICOL, V25, P545, DOI 10.1007/s10565-008-9111-9
   de Oliveira MR, 2015, OXID MED CELL LONGEV, V2015, DOI 10.1155/2015/140267
   Debska G, 2001, BRAIN RES, V892, P42, DOI 10.1016/S0006-8993(00)03187-5
   Delgado-Lista J, 2012, BRIT J NUTR, V107, pS201, DOI 10.1017/S0007114512001596
   Denzer I, 2016, PHARMACOL RES, V103, P80, DOI 10.1016/j.phrs.2015.11.019
   Devi KP, 2015, ANTI-CANCER AGENT ME, V15, P888, DOI 10.2174/1871520615666150424124606
   Domenichiello AF, 2015, PROG LIPID RES, V59, P54, DOI 10.1016/j.plipres.2015.04.002
   Domergue F, 2005, BIOCHEM J, V389, P483, DOI 10.1042/BJ20050111
   Dos Santos P, 2002, AM J PHYSIOL-HEART C, V283, pH284, DOI 10.1152/ajpheart.00034.2002
   Dyall SC, 2008, NEUROMOL MED, V10, P219, DOI 10.1007/s12017-008-8036-z
   Dyerberg J, 2010, PROSTAG LEUKOTR ESS, V83, P137, DOI 10.1016/j.plefa.2010.06.007
   Ehrenborg E, 2009, PHARMACOL REV, V61, P373, DOI 10.1124/pr.109.001560
   EKSTROM G, 1989, BIOCHEM PHARMACOL, V38, P1313, DOI 10.1016/0006-2952(89)90338-9
   Emsley R, 2008, PSYCHIAT RES, V161, P284, DOI 10.1016/j.psychres.2007.06.029
   Eritsland J, 2000, AM J CLIN NUTR, V71, p197S, DOI 10.1093/ajcn/71.1.197S
   Flachs P, 2009, CLIN SCI, V116, P1, DOI 10.1042/CS20070456
   Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871
   Ganesan B, 2014, CRIT REV FOOD SCI, V54, P98, DOI 10.1080/10408398.2011.578221
   Garman JH, 2009, AM J PHYSIOL-RENAL, V296, pF306, DOI 10.1152/ajprenal.90326.2008
   Garrel C, 2012, INT J BIOCHEM CELL B, V44, P123, DOI 10.1016/j.biocel.2011.10.007
   German OL, 2006, J NEUROCHEM, V98, P1507, DOI 10.1111/j.1471-4159.2006.04061.x
   Giros A, 2009, CANCER PREV RES, V2, P732, DOI 10.1158/1940-6207.CAPR-08-0197
   GLAUBER H, 1988, ANN INTERN MED, V108, P663, DOI 10.7326/0003-4819-108-5-663
   GOODNIGHT SH, 1981, BLOOD, V58, P880
   Graciano MF, 2016, J PHYSIOL BIOCHEM, V72, P699, DOI 10.1007/s13105-016-0509-1
   Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320
   Gruber J, 2013, BIOTECHNOL ADV, V31, P563, DOI 10.1016/j.biotechadv.2012.09.005
   Guillot N, 2009, FASEB J, V23, P2909, DOI 10.1096/fj.09-133421
   Ha EEJ, 2014, BIOFACTORS, V40, P419, DOI 10.1002/biof.1169
   Halliwell B, 2006, J NEUROCHEM, V97, P1634, DOI 10.1111/j.1471-4159.2006.03907.x
   Harris WS, 2007, AM J CLIN NUTR, V86, P1621
   Hofmanova J, 2005, CANCER LETT, V218, P33, DOI 10.1016/j.canlet.2004.07.038
   Hong DD, 2003, BBA-MOL CELL BIOL L, V1635, P29, DOI 10.1016/j.bbalip.2003.10.003
   Huang W, 2015, BIOFACTORS, V41, P453, DOI 10.1002/biof.1246
   Huang YX, 2006, BBA-GEN SUBJECTS, V1760, P1827, DOI 10.1016/j.bbagen.2006.08.013
   Huerta S, 2007, J SURG RES, V142, P184, DOI 10.1016/j.jss.2006.12.551
   Iwase H, 1998, BIOCHEM BIOPH RES CO, V243, P485, DOI 10.1006/bbrc.1998.8126
   Jang BC, 2004, BIOCHEM PHARMACOL, V67, P1819, DOI 10.1016/j.bcp.2004.01.018
   Jeong S, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-481
   Johansson I, 2015, AUTOPHAGY, V11, P1636, DOI 10.1080/15548627.2015.1061170
   Johnson ML, 2015, AGING CELL, V14, P734, DOI 10.1111/acel.12352
   Jonckheere AI, 2012, J INHERIT METAB DIS, V35, P211, DOI 10.1007/s10545-011-9382-9
   Joshi AU, 2016, CELL CALCIUM, V60, P218, DOI 10.1016/j.ceca.2016.04.010
   Jump DB, 2002, J BIOL CHEM, V277, P8755, DOI 10.1074/jbc.R100062200
   Kanfer G, 2016, BIOCHEM SOC T, V44, P510, DOI 10.1042/BST20150274
   Kanno S, 2015, TOXICOL LETT, V232, P393, DOI 10.1016/j.toxlet.2014.11.016
   Kaur P, 2007, TOXICOL SCI, V100, P423, DOI 10.1093/toxsci/kfm224
   Khairallah RJ, 2010, J PHARMACOL EXP THER, V335, P155, DOI 10.1124/jpet.110.170605
   Khairallah RJ, 2010, BBA-BIOENERGETICS, V1797, P1555, DOI 10.1016/j.bbabio.2010.05.007
   Ki YW, 2012, TOXICOL LETT, V211, P18, DOI 10.1016/j.toxlet.2012.02.022
   Kidd PM, 2007, ALTERN MED REV, V12, P207
   Kim HJ, 2005, J CELL PHYSIOL, V204, P881, DOI 10.1002/jcp.20351
   Kolanowski W, 2006, EUR FOOD RES TECHNOL, V222, P472, DOI 10.1007/s00217-005-0089-8
   Kolar S, 2011, CANCER-AM CANCER SOC, V117, P5294, DOI 10.1002/cncr.26205
   Kolar SSN, 2007, CANCER RES, V67, P5561, DOI 10.1158/0008-5472.CAN-06-4716
   Kopecky J, 2009, P NUTR SOC, V68, P361, DOI 10.1017/S0029665109990231
   Koumura T, 2005, FREE RADICAL RES, V39, P1083, DOI 10.1080/10715760500264654
   Koumura T, 2005, FREE RADICAL RES, V39, P225, DOI 10.1080/10715760500043587
   Kris-Etherton PM, 2002, CIRCULATION, V106, P2747, DOI 10.1161/01.CIR.0000038493.65177.94
   Kris-Etherton PM, 2000, AM J CLIN NUTR, V71, p179S, DOI 10.1093/ajcn/71.1.179S
   Kulawiak B, 2008, EXP NEUROL, V212, P543, DOI 10.1016/j.expneurol.2008.05.004
   Kurlak LO, 1999, ARCH DIS CHILD-FETAL, V80, pF148, DOI 10.1136/fn.80.2.F148
   Lalia AZ, 2015, DIABETES CARE, V38, P1228, DOI 10.2337/dc14-3101
   Latham P, 2001, GUT, V49, P97, DOI 10.1136/gut.49.1.97
   Le Guen M, 2016, AM J PHYSIOL-ENDOC M, V310, pE213, DOI 10.1152/ajpendo.00468.2014
   Lee HJ, 2015, BIOCHEM BIOPH RES CO, V457, P95, DOI 10.1016/j.bbrc.2014.12.085
   Lee M, 2007, J NUTR BIOCHEM, V18, P348, DOI 10.1016/j.jnutbio.2006.06.003
   Leroy C, 2008, BBA-MOL CELL BIOL L, V1781, P685, DOI 10.1016/j.bbalip.2008.07.009
   Lesnefsky EJ, 2016, CIRC RES, V118, P1593, DOI 10.1161/CIRCRESAHA.116.307505
   Li XX, 2015, J HISTOCHEM CYTOCHEM, V63, P301, DOI 10.1369/0022155415574818
   Li X, 2016, EXP CELL RES, V347, P212, DOI 10.1016/j.yexcr.2016.08.007
   Liu W, 2014, TOXICOL LETT, V224, P1, DOI 10.1016/j.toxlet.2013.10.009
   Liu XB, 2008, J CLIN BIOCHEM NUTR, V43, P26, DOI 10.3164/jcbn.2008040
   Lonergan PE, 2004, J NEUROCHEM, V91, P20, DOI 10.1111/j.1471-4159.2004.02689.x
   Lucena CF, 2015, PANCREAS, V44, P287, DOI 10.1097/MPA.0000000000000249
   Ma DWL, 2004, J NUTR BIOCHEM, V15, P700, DOI 10.1016/j.jnutbio.2004.08.002
   Madsen L, 1999, LIPIDS, V34, P951, DOI 10.1007/s11745-999-0445-x
   Maggio M, 2009, CURR PHARM DESIGN, V15, P4157, DOI 10.2174/138161209789909728
   Majumder PK, 2000, J BIOL CHEM, V275, P21793, DOI 10.1074/jbc.C000048200
   Manzanero S, 2013, NEUROCHEM INT, V62, P712, DOI 10.1016/j.neuint.2012.11.009
   Mari M, 2009, ANTIOXID REDOX SIGN, V11, P2685, DOI [10.1089/ars.2009.2695, 10.1089/ARS.2009.2695]
   Mari M, 2013, BBA-GEN SUBJECTS, V1830, P3317, DOI 10.1016/j.bbagen.2012.10.018
   Martins DA, 2013, MAR DRUGS, V11, P2259, DOI 10.3390/md11072259
   Matravadia S, 2014, AM J PHYSIOL-ENDOC M, V307, pE102, DOI 10.1152/ajpendo.00032.2014
   McCullough KD, 2001, MOL CELL BIOL, V21, P1249, DOI 10.1128/MCB.21.4.1249-1259.2001
   Meluzzi A, 2000, POULTRY SCI, V79, P539, DOI 10.1093/ps/79.4.539
   Mendez L, 2017, J NUTR BIOCHEM, V41, P84, DOI 10.1016/j.jnutbio.2016.12.005
   Mendez L, 2013, FREE RADICAL BIO MED, V55, P8, DOI 10.1016/j.freeradbiomed.2012.11.004
   Metodiewa D, 1999, NEUROTOX RES, V1, P197, DOI 10.1007/BF03033290
   Mihaylova M., 2008, CELL, V134
   Moreira PI, 2004, J NEUROENDOCRINOL, V16, P32, DOI 10.1111/j.1365-2826.2004.01107.x
   Moretti V. M., 2008, HDB PROCESSED MEATS, P233
   Morgan TM, 2009, CURR CANCER DRUG TAR, V9, P237, DOI 10.2174/156800909787580999
   Nabavi SF, 2015, CANCER METAST REV, V34, P359, DOI 10.1007/s10555-015-9572-2
   Nagakura T, 2000, EUR RESPIR J, V16, P861, DOI 10.1183/09031936.00.16586100
   Nakka VP, 2008, MOL NEUROBIOL, V37, P7, DOI 10.1007/s12035-007-8013-9
   Naoi M, 2005, MOL NEUROBIOL, V31, P81, DOI 10.1385/MN:31:1-3:081
   Ng Y, 2005, CARCINOGENESIS, V26, P1914, DOI 10.1093/carcin/bgi163
   Nicholls DG, 1998, BIOFACTORS, V8, P287, DOI 10.1002/biof.5520080317
   Nikoletopoulou V, 2014, NEUROCHEM RES, V39, P542, DOI 10.1007/s11064-013-0997-0
   Nury T, 2015, STEROIDS, V99, P194, DOI 10.1016/j.steroids.2015.02.003
   O'Connell KA, 2013, PHYSIOL REP, V1, DOI 10.1002/phy2.9
   Ogen-Shtern N, 2016, BRAIN RES, V1648, P658, DOI 10.1016/j.brainres.2016.03.044
   Ohtani H, 2012, NITRIC OXIDE-BIOL CH, V26, P95, DOI 10.1016/j.niox.2011.12.007
   Olszewska A, 2014, BBA-BIOENERGETICS, V1837, P1602, DOI 10.1016/j.bbabio.2014.07.010
   OVERGAARD J, 1989, INT J RADIAT ONCOL, V16, P535, DOI 10.1016/0360-3016(89)90470-7
   Ovide-Bordeaux S, 2004, AM J PHYSIOL-REG I, V286, pR519, DOI 10.1152/ajpregu.00303.2003
   Pacetti D, 2013, CURR NUTR FOOD SCI, V9, P283, DOI 10.2174/15734013113096660015
   Park SH, 2002, J APPL PHYSIOL, V92, P2475, DOI 10.1152/japplphysiol.00071.2002
   Parker HM, 2012, J HEPATOL, V56, P944, DOI 10.1016/j.jhep.2011.08.018
   Peet M, 2005, DRUGS, V65, P1051, DOI 10.2165/00003495-200565080-00002
   Pepe S, 2005, EXP GERONTOL, V40, P369, DOI 10.1016/j.exger.2005.03.005
   Qadhi R, 2013, TOXICOL LETT, V219, P288, DOI 10.1016/j.toxlet.2013.03.010
   Racine RA, 2007, CURR OPIN CLIN NUTR, V10, P123, DOI 10.1097/MCO.0b013e3280129652
   Ramos ES, 2016, BBA-BIOENERGETICS, V1857, P1277, DOI 10.1016/j.bbabio.2016.04.002
   Ramos KL, 2003, GLIA, V43, P149, DOI 10.1002/glia.10246
   Ratnayake WMN, 2009, ANN NUTR METAB, V55, P8, DOI 10.1159/000228994
   Raza H, 2012, INT J MOL SCI, V13, P5751, DOI 10.3390/ijms13055751
   Ribeiro B, 2009, MICROCHEM J, V93, P29, DOI 10.1016/j.microc.2009.04.005
   ROGERS S, 1987, ATHEROSCLEROSIS, V63, P137, DOI 10.1016/0021-9150(87)90113-4
   Rotstein NP, 2003, INVEST OPHTH VIS SCI, V44, P2252, DOI 10.1167/iovs.02-0901
   Ryckebosch E., 2012, Lipid Technology, V24, P128, DOI 10.1002/lite.201200197
   Sadli N, 2013, CELL PHYSIOL BIOCHEM, V32, P243, DOI 10.1159/000354433
   SanGiovanni JP, 2005, PROG RETIN EYE RES, V24, P87, DOI 10.1016/j.preteyeres.2004.06.002
   Sargent J, 1999, AQUACULTURE, V177, P191, DOI 10.1016/S0044-8486(99)00083-6
   Sato T, 2005, CIRCULATION, V111, P198, DOI 10.1161/01.CIR.0000151099.15706.B1
   Sazanov LA, 2015, NAT REV MOL CELL BIO, V16, P375, DOI 10.1038/nrm3997
   Schafer E, 2006, J BIOL CHEM, V281, P15370, DOI 10.1074/jbc.M513525200
   Schuchardt JP, 2011, LIPIDS HEALTH DIS, V10, DOI 10.1186/1476-511X-10-145
   Shahidi F., 2001, OMEGA 3 FATTY ACIDS
   Shapira N, 2008, ISR MED ASSOC J, V10, P262
   Shayakhmetova GM, 2015, TOXICOL LETT, V234, P59, DOI 10.1016/j.toxlet.2015.02.008
   SHIMIZU S, 1995, NATURE, V374, P811, DOI 10.1038/374811a0
   Shin S, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/568671
   Siddiqui RA, 2007, NUTR CLIN PRACT, V22, P74, DOI 10.1177/011542650702200174
   SILIPRANDI D, 1974, FEBS LETT, V42, P197, DOI 10.1016/0014-5793(74)80784-2
   Simopoulos AP, 2002, J AM COLL NUTR, V21, P495, DOI 10.1080/07315724.2002.10719248
   Simopoulos AP, 2000, POULTRY SCI, V79, P961, DOI 10.1093/ps/79.7.961
   Skender B, 2014, BBA-MOL CELL BIOL L, V1841, P1308, DOI 10.1016/j.bbalip.2014.06.005
   Smith W.L., 2002, VANCE BIOCH LIPIDS L, P341, DOI 10.1016/S0167-7306(02)36015-0
   Stanley WC, 2013, J CARDIOVASC TRANSL, V6, P1000, DOI 10.1007/s12265-013-9511-y
   Stucki DM, 2016, FREE RADICAL BIO MED, V97, P427, DOI 10.1016/j.freeradbiomed.2016.07.005
   Szewczyk A, 2006, BBA-BIOENERGETICS, V1757, P715, DOI 10.1016/j.bbabio.2006.05.002
   Szewczyk A, 2009, IUBMB LIFE, V61, P134, DOI 10.1002/iub.155
   Tajeddine N, 2016, BBA-GEN SUBJECTS, V1860, P1079, DOI 10.1016/j.bbagen.2016.02.013
   Taneda S, 2010, AM J PHYSIOL-RENAL, V299, pF1451, DOI 10.1152/ajprenal.00637.2009
   Tapiero H, 2002, BIOMED PHARMACOTHER, V56, P215, DOI 10.1016/S0753-3322(02)00193-2
   Tirosh O, 2003, BIOFACTORS, V17, P297, DOI 10.1002/biof.5520170129
   Tsuzuki T, 2007, BBA-MOL CELL BIOL L, V1771, P20, DOI 10.1016/j.bbalip.2006.11.006
   Vaagenes H, 1999, BIOCHEM PHARMACOL, V58, P1133, DOI 10.1016/S0006-2952(99)00198-7
   Valero T, 2014, CURR PHARM DESIGN, V20, P5507, DOI 10.2174/138161282035140911142118
   VALLE VGR, 1993, ARCH BIOCHEM BIOPHYS, V307, P1, DOI 10.1006/abbi.1993.1551
   van de Wier B, 2015, CHEM-BIOL INTERACT, V242, P139, DOI 10.1016/j.cbi.2015.09.024
   Vaughan RA, 2012, LIPIDS HEALTH DIS, V11, DOI 10.1186/1476-511X-11-142
   Venegas-Caleron M, 2010, PROG LIPID RES, V49, P108, DOI 10.1016/j.plipres.2009.10.001
   Vericel E, 2003, J THROMB HAEMOST, V1, P566, DOI 10.1046/j.1538-7836.2003.00076.x
   Victor VM, 2009, CURR MED CHEM, V16, P4654, DOI 10.2174/092986709789878265
   Vidgren HM, 1997, LIPIDS, V32, P697, DOI 10.1007/s11745-997-0089-x
   von Ballmoos C, 2009, ANNU REV BIOCHEM, V78, P649, DOI 10.1146/annurev.biochem.78.081307.104803
   Wada T, 2004, ONCOGENE, V23, P2838, DOI 10.1038/sj.onc.1207556
   Wallace JMW, 2000, ANN NUTR METAB, V44, P157, DOI 10.1159/000012839
   WANG Z, 2016, CELL DEATH DIS, V7
   Willumsen N, 1996, LIPIDS, V31, P579, DOI 10.1007/BF02523828
   WOLFE LS, 1982, J NEUROCHEM, V38, P1, DOI 10.1111/j.1471-4159.1982.tb10847.x
   Wu Defeng, 2005, Toxicol Appl Pharmacol, V207, P70, DOI 10.1016/j.taap.2005.01.057
   Wu FJ, 2014, NEUROCHEM INT, V64, P9, DOI 10.1016/j.neuint.2013.10.015
   Zarrouk A, 2015, J NUTR HEALTH AGING, V19, P198, DOI 10.1007/s12603-014-0518-0
   Zelko IN, 2002, FREE RADICAL BIO MED, V33, P337, DOI 10.1016/S0891-5849(02)00905-X
   Zhang CC, 2015, ARCH MED SCI, V11, P1081, DOI 10.5114/aoms.2015.54865
   Zhang HY, 2009, TOXICOL SCI, V110, P376, DOI 10.1093/toxsci/kfp101
   Zhang YY, 2015, BIOCHEM BIOPH RES CO, V456, P926, DOI 10.1016/j.bbrc.2014.12.036
   Zhou XY, 2016, BBA-GEN SUBJECTS, V1860, P2037, DOI 10.1016/j.bbagen.2016.05.032
   Zongping L, 2013, OXIDATIVE MED CELLUL, V2013
   Zou XJ, 2012, EXP BIOL MED, V237, P1341, DOI 10.1258/ebm.2012.012041
   Zsurka G, 2013, IUBMB LIFE, V65, P263, DOI 10.1002/iub.1126
NR 229
TC 15
Z9 17
U1 1
U2 34
PU ELSEVIER SCIENCE LONDON
PI LONDON
PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND
SN 0924-2244
EI 1879-3053
J9 TRENDS FOOD SCI TECH
JI Trends Food Sci. Technol.
PD SEP
PY 2017
VL 67
BP 76
EP 92
DI 10.1016/j.tifs.2017.06.019
PG 17
WC Food Science & Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Food Science & Technology
GA FE2UX
UT WOS:000408073600008
DA 2022-04-25
ER

PT J
AU Foth, M
   McMahon, M
AF Foth, Mona
   McMahon, Martin
TI Autophagy Inhibition in BRAF-Driven Cancers
SO CANCERS
LA English
DT Review
DE BRAF; MEK1; 2; autophagy; targeted therapy; drug resistance; metabolism
ID ENDOPLASMIC-RETICULUM STRESS; MUTANT COLORECTAL-CANCER; ADVANCED SOLID
   TUMORS; PHASE-I TRIAL; ACQUIRED-RESISTANCE; MELANOMA-CELLS; ONCOGENIC
   KRAS; MAPK PATHWAY; RAG GTPASES; BRAF(V600E) INHIBITION
AB Simple Summary BRAF is a protein kinase that is frequently mutationally activated in cancer. Mutant BRAF can be pharmacologically inhibited, which in combination with blockade of its direct effector, MEK1/2, is an FDA-approved therapeutic strategy for several BRAF-mutated cancer patients, such as melanoma, non-small-cell lung carcinoma, and thyroid cancer. However, therapy resistance is a major clinical challenge, highlighting the need for comprehensive investigations on the biological causes of such resistance, as well as to develop novel therapeutic strategies to improve patient survival. Autophagy is a cellular recycling process, which has been shown to allow cancer cells to escape from BRAF inhibition. Combined blockade of autophagy and BRAF signaling is a novel therapeutic strategy that is currently being tested in clinical trials. This review describes the relationship between BRAF-targeted therapy and autophagy regulation and discusses possible future treatment strategies. Several BRAF-driven cancers, including advanced BRAF(V600E/K)-driven melanoma, non-small-cell lung carcinoma, and thyroid cancer, are currently treated using first-line inhibitor combinations of BRAF(V600E) plus MEK1/2. However, despite the success of this vertical inhibition strategy, the durability of patient response is often limited by the phenomenon of primary or acquired drug resistance. It has recently been shown that autophagy, a conserved cellular recycling process, is increased in BRAF-driven melanoma upon inhibition of BRAF(V600E) signaling. Autophagy is believed to promote tumor progression of established tumors and also to protect cancer cells from the cytotoxic effects of chemotherapy. To this end, BRAF inhibitor (BRAFi)-resistant cells often display increased autophagy compared to responsive lines. Several mechanisms have been proposed for BRAFi-induced autophagy, such as activation of the endoplasmic reticulum (ER) stress gatekeeper GRP78, AMP-activated protein kinase, and transcriptional regulation of the autophagy regulating transcription factors TFEB and TFE3 via ERK1/2 or mTOR inhibition. This review describes the relationship between BRAF-targeted therapy and autophagy regulation, and discusses possible future treatment strategies of combined inhibition of oncogenic signaling plus autophagy for BRAF-driven cancers.
C1 [Foth, Mona; McMahon, Martin] Huntsman Canc Inst, Salt Lake City, UT 84112 USA.
   [McMahon, Martin] Univ Utah, Dept Dermatol, Salt Lake City, UT 84112 USA.
RP McMahon, M (corresponding author), Huntsman Canc Inst, Salt Lake City, UT 84112 USA.; McMahon, M (corresponding author), Univ Utah, Dept Dermatol, Salt Lake City, UT 84112 USA.
EM mona.foth@hci.utah.edu; martin.mcmahon@hci.utah.edu
OI Foth, Mona/0000-0001-6507-8114
CR Ahronian LG, 2015, CANCER DISCOV, V5, P358, DOI 10.1158/2159-8290.CD-14-1518
   Amaravadi RK, 2007, J CLIN INVEST, V117, P326, DOI 10.1172/JCI28833
   Arico S, 2001, J BIOL CHEM, V276, P35243, DOI 10.1074/jbc.C100319200
   Armstrong JL, 2011, CLIN CANCER RES, V17, P2216, DOI 10.1158/1078-0432.CCR-10-3003
   Arozarena I, 2017, ANN TRANSL MED, V5, DOI 10.21037/atm.2017.06.09
   BAMM, BAMM TRIAL BRAF AUT BAMM TRIAL BRAF AUT
   Bar-Peled L, 2012, CELL, V150, P1196, DOI 10.1016/j.cell.2012.07.032
   Bauer D, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.6
   Boussemart L, 2014, NATURE, V513, P105, DOI 10.1038/nature13572
   Boutelle AM, 2021, TRENDS CELL BIOL, V31, P298, DOI 10.1016/j.tcb.2020.12.011
   Broz DK, 2013, AUTOPHAGY, V9, P1440, DOI 10.4161/auto.25833
   Canon J, 2019, NATURE, V575, P217, DOI 10.1038/s41586-019-1694-1
   Carr EL, 2010, J IMMUNOL, V185, P1037, DOI 10.4049/jimmunol.0903586
   Carriere A, 2011, J BIOL CHEM, V286, P567, DOI 10.1074/jbc.M110.159046
   Chong H, 2003, CELL SIGNAL, V15, P463, DOI 10.1016/S0898-6568(02)00139-0
   Cohn AL, 2017, ONCOTARGETS THER, V10, P965, DOI 10.2147/OTT.S120440
   Commisso C, 2013, NATURE, V497, P633, DOI 10.1038/nature12138
   Corcelle E, 2006, CANCER RES, V66, P6861, DOI 10.1158/0008-5472.CAN-05-3557
   Corcoran RB, 2012, CANCER DISCOV, V2, P227, DOI 10.1158/2159-8290.CD-11-0341
   Corcoran RB, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2001148
   Costa-Mattioli M, 2020, SCIENCE, V368, P384, DOI 10.1126/science.aat5314
   Crighton D, 2006, CELL, V126, P121, DOI 10.1016/j.cell.2006.05.034
   Das Thakur M, 2013, NATURE, V494, P251, DOI 10.1038/nature11814
   Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766
   Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001
   Degtyarev M, 2008, J CELL BIOL, V183, P101, DOI 10.1083/jcb.200801099
   Dietrich S, 2016, BLOOD, V127, P2847, DOI 10.1182/blood-2015-11-680074
   Efeyan A, 2012, TRENDS MOL MED, V18, P524, DOI 10.1016/j.molmed.2012.05.007
   Egan DF, 2011, SCIENCE, V331, P456, DOI 10.1126/science.1196371
   Ellis RA, 2014, J INVEST DERMATOL, V134, P1476, DOI 10.1038/jid.2013.497
   Errafiy R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083318
   Ewings KE, 2007, EMBO J, V26, P2856, DOI 10.1038/sj.emboj.7601723
   Facchinetti F, 2020, EUR J CANCER, V132, P211, DOI 10.1016/j.ejca.2020.03.025
   Fan TF, 2016, ONCOTARGET, V7, P59691, DOI 10.18632/oncotarget.10836
   Filomeni G, 2015, CELL DEATH DIFFER, V22, P377, DOI 10.1038/cdd.2014.150
   Flaherty KT, 2012, NEW ENGL J MED, V367, P1694, DOI 10.1056/NEJMoa1210093
   Flaherty KT, 2012, NEW ENGL J MED, V367, P107, DOI 10.1056/NEJMoa1203421
   Foth M, 2016, EXPERT REV MOL DIAGN, V16, P223, DOI 10.1586/14737159.2016.1126511
   Franke JC, 2010, BIOCHEM PHARMACOL, V79, P575, DOI 10.1016/j.bcp.2009.09.022
   Fujita N, 2008, MOL BIOL CELL, V19, P4651, DOI 10.1091/mbc.E08-03-0312
   Fulda S, 2015, ONCOGENE, V34, P5105, DOI 10.1038/onc.2014.458
   Galluzzi L, 2019, CELL, V177, P1682, DOI 10.1016/j.cell.2019.05.026
   Gammoh N, 2016, AUTOPHAGY, V12, P1431, DOI 10.1080/15548627.2016.1190053
   Gopal YNV, 2014, CANCER RES, V74, P7037, DOI 10.1158/0008-5472.CAN-14-1392
   Goulielmaki M, 2016, ONCOTARGET, V7, P9188, DOI 10.18632/oncotarget.6942
   Gozuacik D, 2004, ONCOGENE, V23, P2891, DOI 10.1038/sj.onc.1207521
   Graves LM, 2000, NATURE, V403, P328, DOI 10.1038/35002111
   Guo JY, 2013, GENE DEV, V27, P1447, DOI 10.1101/gad.219642.113
   Guo JY, 2011, GENE DEV, V25, P460, DOI 10.1101/gad.2016311
   Gwinn DM, 2008, MOL CELL, V30, P214, DOI 10.1016/j.molcel.2008.03.003
   Gwinn DM, 2018, CANCER CELL, V33, P91, DOI 10.1016/j.ccell.2017.12.003
   Haladyj Ewa, 2018, Reumatologia (Warsaw), V56, P164, DOI 10.5114/reum.2018.76904
   Hallin J, 2020, CANCER DISCOV, V10, P54, DOI 10.1158/2159-8290.CD-19-1167
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Haq R, 2013, CANCER CELL, V23, P302, DOI 10.1016/j.ccr.2013.02.003
   Hara Y, 2012, EUR J DERMATOL, V22, P128, DOI 10.1684/ejd.2011.1562
   Hauschild A, 2012, LANCET, V380, P358, DOI 10.1016/S0140-6736(12)60868-X
   HOMEWOOD CA, 1972, NATURE, V235, P50, DOI 10.1038/235050a0
   Hu H, 2016, CELL, V164, P433, DOI 10.1016/j.cell.2015.12.042
   Huo YY, 2013, CANCER DISCOV, V3, P894, DOI 10.1158/2159-8290.CD-13-0011
   Hutchinson KE, 2013, CLIN CANCER RES, V19, P6696, DOI 10.1158/1078-0432.CCR-13-1746
   Hutton JE, 2016, MOL CELL PROTEOMICS, V15, P2924, DOI 10.1074/mcp.M116.058925
   Hyman DM, 2015, NEW ENGL J MED, V373, P726, DOI 10.1056/NEJMoa1502309
   Inoki K, 2003, GENE DEV, V17, P1829, DOI 10.1101/gad.1110003
   Ji C, 2016, DRUG DES DEV THER, V10, P2491, DOI 10.2147/DDDT.S112740
   Jones RG, 2005, MOL CELL, V18, P283, DOI 10.1016/j.molcel.2005.03.027
   Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720
   Kakadia S, 2018, ONCOTARGETS THER, V11, P7095, DOI 10.2147/OTT.S182721
   Kaley T, 2018, J CLIN ONCOL, V36, P3477, DOI 10.1200/JCO.2018.78.9990
   Kang HB, 2015, MOL CELL, V59, P345, DOI 10.1016/j.molcel.2015.05.037
   Karsli-Uzunbas G, 2014, CANCER DISCOV, V4, P914, DOI 10.1158/2159-8290.CD-14-0363
   Kaur J, 2015, NAT REV MOL CELL BIO, V16, P461, DOI 10.1038/nrm4024
   Kemper K, 2016, CELL REP, V16, P263, DOI 10.1016/j.celrep.2016.05.064
   Kemper K, 2015, EMBO MOL MED, V7, P1104, DOI 10.15252/emmm.201404914
   Kim E, 2008, NAT CELL BIOL, V10, P935, DOI 10.1038/ncb1753
   Kim J, 2011, NAT CELL BIOL, V13, P132, DOI 10.1038/ncb2152
   Kim MJ, 2011, J BIOL CHEM, V286, P12924, DOI 10.1074/jbc.M110.138958
   Kimmelman AC, 2015, CLIN CANCER RES, V21, P1828, DOI 10.1158/1078-0432.CCR-14-2425
   Kinsey CG, 2019, NAT MED, V25, P620, DOI 10.1038/s41591-019-0367-9
   Koetz-Ploch L, 2017, PIGM CELL MELANOMA R, V30, P328, DOI 10.1111/pcmr.12578
   Kopetz S, 2015, J CLIN ONCOL, V33, P4032, DOI 10.1200/JCO.2015.63.2497
   Koustas E, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0207227
   Krygowska AA, 2018, CSH PERSPECT MED, V8, DOI 10.1101/cshperspect.a031450
   Kulkarni A, 2017, CLIN CANCER RES, V23, P5631, DOI 10.1158/1078-0432.CCR-16-0758
   Lamb CA, 2013, NAT REV MOL CELL BIO, V14, P759, DOI 10.1038/nrm3696
   Lauzier A, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-47659-7
   Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608
   Lazova R, 2012, CLIN CANCER RES, V18, P370, DOI 10.1158/1078-0432.CCR-11-1282
   Lee JW, 2003, BRIT J CANCER, V89, P1958, DOI 10.1038/sj.bjc.6601371
   Levy JMM, 2017, ELIFE, V6, DOI 10.7554/eLife.19671
   Levy JMM, 2014, CANCER DISCOV, V4, P773, DOI 10.1158/2159-8290.CD-14-0049
   Li S, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09634-8
   Li WQ, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-2
   Liu EY, 2015, P NATL ACAD SCI USA, V112, P773, DOI 10.1073/pnas.1409563112
   Liu H, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005864
   Lock R, 2011, MOL BIOL CELL, V22, P165, DOI 10.1091/mbc.E10-06-0500
   Lopez J, 2012, CELL DEATH DIFFER, V19, P1459, DOI 10.1038/cdd.2012.21
   Ma L, 2005, CELL, V121, P179, DOI 10.1016/j.cell.2005.02.031
   Ma XH, 2014, J CLIN INVEST, V124, P1406, DOI 10.1172/JCI70454
   Ma XH, 2011, CLIN CANCER RES, V17, P3478, DOI 10.1158/1078-0432.CCR-10-2372
   Maddodi N, 2010, J INVEST DERMATOL, V130, P1657, DOI 10.1038/jid.2010.26
   Maes H, 2014, EXP DERMATOL, V23, P101, DOI 10.1111/exd.12298
   Martina JA, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2004754
   Martina JA, 2012, AUTOPHAGY, V8, P903, DOI 10.4161/auto.19653
   Mathew R, 2009, CELL, V137, P1062, DOI 10.1016/j.cell.2009.03.048
   Mauthe M, 2018, AUTOPHAGY, V14, P1435, DOI 10.1080/15548627.2018.1474314
   Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9
   Miracco C, 2010, HUM PATHOL, V41, P503, DOI 10.1016/j.humpath.2009.09.004
   Mizushima N, 2020, TRENDS BIOCHEM SCI, V45, P1080, DOI 10.1016/j.tibs.2020.07.006
   Montagut C, 2008, CANCER RES, V68, P4853, DOI 10.1158/0008-5472.CAN-07-6787
   Morgan MJ, 2014, AUTOPHAGY, V10, P1814, DOI 10.4161/auto.32135
   Nascimento EBM, 2010, CELL SIGNAL, V22, P961, DOI 10.1016/j.cellsig.2010.02.002
   Nazarian R, 2010, NATURE, V468, P973, DOI 10.1038/nature09626
   Ojha R, 2019, CANCER DISCOV, V9, P396, DOI 10.1158/2159-8290.CD-18-0348
   Orienti I, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1775-y
   Pankiv S, 2007, J BIOL CHEM, V282, P24131, DOI 10.1074/jbc.M702824200
   Paraiso KHT, 2010, BRIT J CANCER, V102, P1724, DOI 10.1038/sj.bjc.6605714
   Parmenter TJ, 2014, CANCER DISCOV, V4, P423, DOI 10.1158/2159-8290.CD-13-0440
   Perera R, 2015, NATURE, V524, P361, DOI 10.1038/nature14587
   Perna D, 2015, P NATL ACAD SCI USA, V112, pE536, DOI 10.1073/pnas.1418163112
   Planchard D, 2016, LANCET ONCOL, V17, P642, DOI 10.1016/S1470-2045(16)00077-2
   Poillet-Perez L, 2019, GENE DEV, V33, P610, DOI 10.1101/gad.325514.119
   Poillet-Perez L, 2018, NATURE, V563, P569, DOI 10.1038/s41586-018-0697-7
   Poillet-Perez L, 2015, REDOX BIOL, V4, P184, DOI 10.1016/j.redox.2014.12.003
   Poklepovic A, 2014, AUTOPHAGY, V10, P1478, DOI 10.4161/auto.29428
   Poulikakos PI, 2011, NATURE, V480, P387, DOI 10.1038/nature10662
   Prahallad A, 2012, NATURE, V483, P100, DOI 10.1038/nature10868
   Puxeddu E, 2008, TRENDS ENDOCRIN MET, V19, P138, DOI 10.1016/j.tem.2007.12.003
   Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039
   Quast SA, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.344
   Rabinowitz JD, 2010, SCIENCE, V330, P1344, DOI 10.1126/science.1193497
   Rangwala R, 2014, AUTOPHAGY, V10, P1391, DOI 10.4161/auto.29119
   Rangwala R, 2014, AUTOPHAGY, V10, P1369, DOI 10.4161/auto.29118
   Rebecca VW, 2019, CANCER DISCOV, V9, P220, DOI 10.1158/2159-8290.CD-18-0706
   Rebecca VW, 2014, PIGM CELL MELANOMA R, V27, P465, DOI 10.1111/pcmr.12227
   Richtig G, 2017, BRIT J DERMATOL, V177, P936, DOI 10.1111/bjd.15436
   Robert C, 2015, NEW ENGL J MED, V372, P30, DOI 10.1056/NEJMoa1412690
   Rosenfeldt MT, 2013, NATURE, V504, P296, DOI 10.1038/nature12865
   Rzymski T, 2010, ONCOGENE, V29, P4424, DOI 10.1038/onc.2010.191
   Sakamaki JI, 2017, MOL CELL, V66, P517, DOI 10.1016/j.molcel.2017.04.027
   Sancak Y, 2008, SCIENCE, V320, P1496, DOI 10.1126/science.1157535
   Sanduja S, 2016, ONCOGENE, V35, P5295, DOI 10.1038/onc.2016.70
   Santanam U, 2016, GENE DEV, V30, P399, DOI 10.1101/gad.274134.115
   Saxton RA, 2017, CELL, V168, P960, DOI [10.1016/j.cell.2017.02.004, 10.1016/j.cell.2017.03.035]
   Scott DA, 2011, J BIOL CHEM, V286, P42626, DOI 10.1074/jbc.M111.282046
   Selvakumaran M, 2013, CLIN CANCER RES, V19, P2995, DOI 10.1158/1078-0432.CCR-12-1542
   Settembre C, 2012, EMBO J, V31, P1095, DOI 10.1038/emboj.2012.32
   Settembre C, 2011, SCIENCE, V332, P1429, DOI 10.1126/science.1204592
   Shao YP, 2010, CANCER RES, V70, P6670, DOI 10.1158/0008-5472.CAN-09-4471
   Shchors K, 2015, CANCER CELL, V28, DOI 10.1016/j.ccell.2015.08.012
   Sheen JH, 2011, CANCER CELL, V19, P613, DOI 10.1016/j.ccr.2011.03.012
   Shen CH, 2016, NAT MED, V22, P1056, DOI 10.1038/nm.4155
   Shi HB, 2014, CANCER DISCOV, V4, P69, DOI 10.1158/2159-8290.CD-13-0279
   Shi HB, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1727
   Silva JM, 2017, PIGM CELL MELANOMA R, V30, P353, DOI 10.1111/pcmr.12586
   Silva JM, 2014, MOL CANCER RES, V12, P447, DOI 10.1158/1541-7786.MCR-13-0224-T
   Singh SS, 2018, ONCOGENE, V37, P1142, DOI 10.1038/s41388-017-0046-6
   Son J, 2013, NATURE, V496, P101, DOI 10.1038/nature12040
   Sosman JA, 2012, NEW ENGL J MED, V366, P707, DOI 10.1056/NEJMoa1112302
   Sousa CM, 2016, NATURE, V536, P479, DOI 10.1038/nature19084
   Strohecker AM, 2013, CANCER DISCOV, V3, P1272, DOI 10.1158/2159-8290.CD-13-0397
   Subbiah V, 2018, J CLIN ONCOL, V36, P7, DOI 10.1200/JCO.2017.73.6785
   Sun C, 2014, NATURE, V508, P118, DOI 10.1038/nature13121
   Takamura A, 2011, GENE DEV, V25, P795, DOI 10.1101/gad.2016211
   Tanida I, 2005, AUTOPHAGY, V1, P84, DOI 10.4161/auto.1.2.1697
   Tasdemir E, 2008, AUTOPHAGY, V4, P810, DOI 10.4161/auto.6486
   Tiacci E, 2011, NEW ENGL J MED, V364, P2305, DOI 10.1056/NEJMoa1014209
   Topf U, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02694-8
   Towers CG, 2017, CANCER DISCOV, V7, P1218, DOI 10.1158/2159-8290.CD-17-0996
   Trunzer K, 2013, J CLIN ONCOL, V31, P1767, DOI 10.1200/JCO.2012.44.7888
   Tsao H, 2004, J INVEST DERMATOL, V122, P337, DOI 10.1046/j.0022-202X.2004.22243.x
   Tsao H, 2000, CANCER RES, V60, P1800
   Ueno T, 2008, AUTOPHAGY, V4, P692, DOI 10.4161/auto.6085
   Van Allen EM, 2014, CANCER DISCOV, V4, P94, DOI 10.1158/2159-8290.CD-13-0617
   Villanueva J, 2010, CANCER CELL, V18, P683, DOI 10.1016/j.ccr.2010.11.023
   Vogl DT, 2014, AUTOPHAGY, V10, P1380, DOI 10.4161/auto.29264
   Wagle N, 2014, CANCER DISCOV, V4, P61, DOI 10.1158/2159-8290.CD-13-0631
   Wagle N, 2011, J CLIN ONCOL, V29, P3085, DOI 10.1200/JCO.2010.33.2312
   Walter P, 2011, SCIENCE, V334, P1081, DOI 10.1126/science.1209038
   Wan PTC, 2004, CELL, V116, P855, DOI 10.1016/S0092-8674(04)00215-6
   Wang WB, 2017, J CLIN ENDOCR METAB, V102, P634, DOI 10.1210/jc.2016-1999
   Wei HJ, 2011, GENE DEV, V25, P1510, DOI 10.1101/gad.2051011
   Weinberg F, 2010, P NATL ACAD SCI USA, V107, P8788, DOI 10.1073/pnas.1003428107
   White E, 2016, CSH PERSPECT MED, V6, DOI 10.1101/cshperspect.a026120
   Wolpin BM, 2014, ONCOLOGIST, V19, P637, DOI 10.1634/theoncologist.2014-0086
   Xie XQ, 2015, CANCER DISCOV, V5, P410, DOI 10.1158/2159-8290.CD-14-1473
   Xu CY, 2005, J CLIN INVEST, V115, P2656, DOI 10.1172/JCI26373
   Yadav V, 2012, J BIOL CHEM, V287, P28087, DOI 10.1074/jbc.M112.377218
   Yamamoto K, 2020, NATURE, V581, P100, DOI 10.1038/s41586-020-2229-5
   Yang AN, 2018, CANCER DISCOV, V8, P276, DOI 10.1158/2159-8290.CD-17-0952
   Yang A, 2014, CANCER DISCOV, V4, P905, DOI 10.1158/2159-8290.CD-14-0362
   Yang SH, 2011, GENE DEV, V25, P717, DOI 10.1101/gad.2016111
   Ying HQ, 2012, CELL, V149, P656, DOI 10.1016/j.cell.2012.01.058
   Yorimitsu T, 2006, J BIOL CHEM, V281, P30299, DOI 10.1074/jbc.M607007200
   Zafra MP, 2020, CANCER DISCOV, V10, P1654, DOI 10.1158/2159-8290.CD-20-0442
   Zheng B, 2009, MOL CELL, V33, P237, DOI 10.1016/j.molcel.2008.12.026
   Zoncu R, 2011, SCIENCE, V334, P678, DOI 10.1126/science.1207056
NR 197
TC 2
Z9 2
U1 3
U2 3
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2072-6694
J9 CANCERS
JI Cancers
PD JUL
PY 2021
VL 13
IS 14
AR 3498
DI 10.3390/cancers13143498
PG 23
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA TO3EW
UT WOS:000676800500001
PM 34298710
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Filfan, M
   Sandu, RE
   Zavaleanu, AD
   Gresita, A
   Glavan, DG
   Olaru, DG
   Popa-Wagner, A
AF Filfan, Madalina
   Sandu, Raluca Elena
   Zavaleanu, Alexandra-Daniela
   Gresita, Andrei
   Glavan, Daniela-Gabriela
   Olaru, Denissa-Greta
   Popa-Wagner, Aurel
TI Autophagy in aging and disease
SO ROMANIAN JOURNAL OF MORPHOLOGY AND EMBRYOLOGY
LA English
DT Review
DE autophagy; aging; polyamines; neurodegenerative diseases; cancer
ID HEPATITIS-C VIRUS; UNFOLDED PROTEIN RESPONSE; CELL-DEATH; MAMMALIAN
   AUTOPHAGY; OXIDATIVE STRESS; SELF-DIGESTION; LIFE-SPAN; SPERMIDINE;
   APOPTOSIS; INDUCTION
AB Autophagy is a catabolic degradation system used to destroy and recycle the unnecessary or damaged components of a cell. Autophagy is present at a basal level in all mammals and is regulated by some conditions, such as oxidative stress, starvation or hypoxia. In aged tissues, increased but also decreased expression of autophagy-specific proteins, Beclin 1, LC3, Atg5 and Atg7 has been reported. Likewise, it could be shown that the lifespan of yeast, nematodes and flies is prolonged by pharmacologically stimulated autophagy using exogenous administered spermidine. Autophagy is potentially implicated in acute lung injury and sepsis, two main causes of morbidity and mortality worldwide. Finally, a quite recent study supports the hypothesis that autophagy might be useful in vascular disease prevention by stimulating cholesterol efflux, which leads to inhibition of necrotic core formation and lipid accumulation. Since autophagy is also implicated in neuroprotection, in Alzheimer's and Huntington's disease animal models and many others normal and pathological states, including immunity, diabetes mellitus, different kind of tumors, colorectal cancer, different inflammations, lung diseases, neurodegenerative diseases, autophagy is of interest to many biomedical researchers.
C1 [Filfan, Madalina; Glavan, Daniela-Gabriela] Univ Med & Pharm Craiova, Psychiat Clin Hosp 2, Craiova, Romania.
   [Filfan, Madalina; Sandu, Raluca Elena; Zavaleanu, Alexandra-Daniela; Gresita, Andrei] Univ Med & Pharm Craiova, Ctr Clin & Expt Med, Dept Funct Sci, Craiova, Romania.
   [Olaru, Denissa-Greta] MedLife Clin, Dept Ophthalmol, Craiova, Romania.
   [Popa-Wagner, Aurel] Univ Med Essen, Chair Vasc Neurol & Dementia, Hufelandstr 55, D-45147 Essen, Germany.
RP Popa-Wagner, A (corresponding author), Univ Med Essen, Chair Vasc Neurol & Dementia, Hufelandstr 55, D-45147 Essen, Germany.
EM aurel.popa@uk-essen.de
RI Sandu, Raluca Elena/AAH-9340-2019; Popa-Wagner, Aurel/I-2581-2019;
   Aldea, Madalina/AAG-2450-2021; Glavan, Daniela-Gabriela/AAF-4564-2019;
   Popa-Wagner, Aurel/E-2541-2013
OI Aldea, Madalina/0000-0003-0543-3596
CR Ait-Goughoulte M, 2008, J VIROL, V82, P2241, DOI 10.1128/JVI.02093-07
   Barnes PJ, 2003, EUR RESPIR J, V22, P672, DOI 10.1183/09031936.03.00040703
   Beckman KB, 1998, PHYSIOL REV, V78, P547, DOI 10.1152/physrev.1998.78.2.547
   Buttner S, 2014, CELL CYCLE, V13, P3903, DOI 10.4161/15384101.2014.973309
   Chen Y, 2008, CELL DEATH DIFFER, V15, P171, DOI 10.1038/sj.cdd.4402233
   CRAPO JD, 1986, ANNU REV PHYSIOL, V48, P721
   Das G, 2012, COLD SPRING HARB PER, V4
   De Domenico I, 2009, BLOOD, V114, P4546, DOI 10.1182/blood-2009-05-224188
   Demidenko ZN, 2009, CELL CYCLE, V8, P1888, DOI 10.4161/cc.8.12.8606
   Dreux M, 2009, P NATL ACAD SCI USA, V106, P14046, DOI 10.1073/pnas.0907344106
   Eisenberg T, 2009, NAT CELL BIOL, V11, P1305, DOI 10.1038/ncb1975
   Elmore S, 2007, TOXICOL PATHOL, V35, P495, DOI 10.1080/01926230701320337
   Eskelinen EL, 2009, BBA-MOL CELL RES, V1793, P664, DOI 10.1016/j.bbamcr.2008.07.014
   Feng YC, 2014, CELL RES, V24, P24, DOI 10.1038/cr.2013.168
   Ghisalberti CA, 2016, FRONT PHARMACOL, V7, DOI 10.3389/fphar.2016.00147
   Gregory A, 2011, CURR NEUROL NEUROSCI, V11, P254, DOI 10.1007/s11910-011-0181-3
   Guevin C, 2010, VIROLOGY, V405, P1, DOI 10.1016/j.virol.2010.05.032
   Gutierrez MG, 2004, CELL, V119, P753, DOI 10.1016/j.cell.2004.11.038
   Haack TB, 2013, INT REV NEUROBIOL, V110, P85, DOI 10.1016/B978-0-12-410502-7.00005-3
   Haack TB, 2012, AM J HUM GENET, V91, P1144, DOI 10.1016/j.ajhg.2012.10.019
   Harrison DE, 2009, NATURE, V460, P392, DOI 10.1038/nature08221
   Hussain SS, 2011, BIOTECHNOL ADV, V29, P300, DOI 10.1016/j.biotechadv.2011.01.003
   Ke PY, 2014, WORLD J GASTROENTERO, V20, P5773, DOI 10.3748/wjg.v20.i19.5773
   Ke PY, 2011, J CLIN INVEST, V121, P37, DOI 10.1172/JCI41474
   Kishi-Itakura C, 2014, J CELL SCI, V127, P4089, DOI 10.1242/jcs.156034
   Klionsky DJ, 2008, AUTOPHAGY, V4, P740, DOI 10.4161/auto.6398
   Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717
   Kroemer G, 2010, MOL CELL, V40, P280, DOI 10.1016/j.molcel.2010.09.023
   Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017
   Lee S, 2014, ANTIOXID REDOX SIGN, V20, P432, DOI 10.1089/ars.2013.5368
   Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1
   Levine B, 2011, NATURE, V469, P323, DOI 10.1038/nature09782
   Lipinski MM, 2010, P NATL ACAD SCI USA, V107, P14164, DOI 10.1073/pnas.1009485107
   Loos B, 2013, AUTOPHAGY, V9, P1270, DOI 10.4161/auto.25560
   Masiero E, 2009, CELL METAB, V10, P507, DOI 10.1016/j.cmet.2009.10.008
   Menzies FM, 2011, CURR OPIN CELL BIOL, V23, P190, DOI 10.1016/j.ceb.2010.10.010
   Michiels CF, 2016, ATHEROSCLEROSIS, V251, P319, DOI 10.1016/j.atherosclerosis.2016.07.899
   Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639
   Morselli E, 2009, AGING-US, V1, P961, DOI 10.18632/aging.100110
   Nair U, 2011, AUTOPHAGY, V7, P1405, DOI 10.4161/auto.7.12.18315
   Nakagawa I, 2004, SCIENCE, V306, P1037, DOI 10.1126/science.1103966
   Nakahira K, 2014, ANTIOXID REDOX SIGN, V20, P474, DOI 10.1089/ars.2013.5373
   Nishimura K, 2006, J BIOCHEM, V139, P81, DOI 10.1093/jb/mvj003
   Nixon Ralph A, 2012, Cold Spring Harb Perspect Biol, V4, DOI 10.1101/cshperspect.a008839
   Ravikumar B, 2010, PHYSIOL REV, V90, P1383, DOI 10.1152/physrev.00030.2009
   Rubinstein AD, 2012, J CELL SCI, V125, P5259, DOI 10.1242/jcs.115865
   Rubinsztein DC, 2012, NAT REV DRUG DISCOV, V11, P709, DOI 10.1038/nrd3802
   Ryter Stefan W, 2014, Int J Cell Biol, V2014, P502676, DOI 10.1155/2014/502676
   Ryter SW, 2013, MOL CELLS, V36, P7, DOI 10.1007/s10059-013-0140-8
   Saitsu H, 2013, NAT GENET, V45, P445, DOI 10.1038/ng.2562
   Salminen A, 2012, AGEING RES REV, V11, P230, DOI 10.1016/j.arr.2011.12.005
   Sandri M, 2010, AM J PHYSIOL-CELL PH, V298, pC1291, DOI 10.1152/ajpcell.00531.2009
   Simonsen A, 2008, AUTOPHAGY, V4, P176, DOI 10.4161/auto.5269
   Sir D, 2008, HEPATOLOGY, V48, P1054, DOI 10.1002/hep.22464
   Sir D, 2012, J BIOL CHEM, V287, P18036, DOI 10.1074/jbc.M111.320085
   Soda K, 2009, EXP GERONTOL, V44, P727, DOI 10.1016/j.exger.2009.08.013
   Taguwa S, 2011, J VIROL, V85, P13185, DOI 10.1128/JVI.06099-11
   Takamura A, 2011, GENE DEV, V25, P795, DOI 10.1101/gad.2016211
   Tanaka A, 2012, AM J RESP CELL MOL, V46, P507, DOI 10.1165/rcmb.2009-0415OC
   Tung SM, 2010, CELL MICROBIOL, V12, P765, DOI 10.1111/j.1462-5822.2010.01432.x
   Vescovo T, 2012, GASTROENTEROLOGY, V142, P644, DOI 10.1053/j.gastro.2011.11.033
   Vestbo J, 2013, AM J RESP CRIT CARE, V187, P347, DOI 10.1164/rccm.201204-0596PP
   Wang Z, 2001, MOL CELL BIOL, V21, P5742, DOI 10.1128/MCB.21.17.5742-5752.2001
   Wei YH, 2002, EXP BIOL MED, V227, P671, DOI 10.1177/153537020222700901
   Wohlgemuth SE, 2010, EXP GERONTOL, V45, P138, DOI 10.1016/j.exger.2009.11.002
   Yang ZF, 2010, CURR OPIN CELL BIOL, V22, P124, DOI 10.1016/j.ceb.2009.11.014
   Ye Y, 2014, AM J PHYSIOL-LUNG C, V307, pL355, DOI 10.1152/ajplung.00046.2014
   Young ARJ, 2009, GENE DEV, V23, P798, DOI 10.1101/gad.519709
   Zheng TY, 2011, CURR EYE RES, V36, P449, DOI 10.3109/02713683.2011.559301
NR 69
TC 47
Z9 53
U1 0
U2 18
PU EDITURA ACAD ROMANE
PI BUCURESTI
PA CALEA 13 SEPTEMBRIE NR 13, SECTOR 5, BUCURESTI 050711, ROMANIA
SN 1220-0522
J9 ROM J MORPHOL EMBRYO
JI Rom. J. Morphol. Embryol.
PY 2017
VL 58
IS 1
BP 27
EP 31
PG 5
WC Developmental Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Developmental Biology
GA EW5ZD
UT WOS:000402584100004
PM 28523294
DA 2022-04-25
ER

PT J
AU Tamura, N
   Hirano, K
   Kishino, K
   Hashimoto, K
   Amano, O
   Shimada, J
   Sakagami, H
AF Tamura, Nozomi
   Hirano, Kumi
   Kishino, Kaori
   Hashimoto, Ken
   Amano, Osamu
   Shimada, Jun
   Sakagami, Hiroshi
TI Analysis of Type of Cell Death Induced by Topoisomerase Inhibitor SN-38
   in Human Oral Squamous Cell Carcinoma Cell Lines
SO ANTICANCER RESEARCH
LA English
DT Article
DE SN-38; irinotecan; oral sqamous cell carcinoma; apoptosis; autophagy;
   topoisomerase inhibitors; HSC-2; HSC-4 cells
ID 1ST-LINE TREATMENT; COLORECTAL-CANCER; INDUCED APOPTOSIS; PHASE-II;
   IRINOTECAN; CYTOTOXICITY; CHEMOTHERAPY; AUTOPHAGY; FLUOROURACIL; PROTEIN
AB Despite frequent use of topoisomerase inhibitors (TIs) as antitumor agents, their application to oral squamous cell carcinoma (OSCC) has not been reported. We investigated three inhibitors of topoisomerase 1 [camptothecin, irinotecan, SN-38 (active metabolite of irinotecan)] and two inhibitors of topoisomerase II (etoposide, teniposide) for their cytotoxicity towards a total of 15 human tumor cell lines and normal cultured cells. All TIs exhibited higher cytotoxicity towards tumor cell lines (OSCC, glioblastoma, myelogenous leukemia) as compared with normal mesenchymal (gingival fibroblast, pulp cell, periodontal ligament fibroblast) and epithelial cells (skin keratinocytes). Among TIs, SN-38 had the highest cytotoxicity towards OSCC cell lines, with a tumor specificity index of 1321 compared to mesenchymal cells and 22 compared with epithelial cells. SN-38 induced different types of cell death in two OSCC cell lines: apoptosis (caspase-3 activation and internucleosomal DNA fragmentation) in HSC-2 cells and autophagy (formation of autophagosome and secondary lysosome) in HSC-4 cells. The cell death of HSC-2 and HSC-4 cells was significantly inhibited by pre-treatment with caspase inhibitor (Z-VAD-FMK) and autophagy inhibitors (3-methyladenine, bafilomycin A1), respectively. The present study demonstrated that SN-38 is highly cytotoxic to OSCC cell lines, regardless of the type of induced cell death, suggesting its future application for chemotherapy of OSCC.
C1 [Kishino, Kaori; Hashimoto, Ken; Sakagami, Hiroshi] Meikai Univ, Sch Dent, Div Pharmacol, Sakado, Saitama 3500283, Japan.
   [Tamura, Nozomi; Hirano, Kumi; Shimada, Jun] Meikai Univ, Sch Dent, Div Oral & Maxillofacial Surg, Sakado, Saitama 3500283, Japan.
   [Amano, Osamu] Meikai Univ, Sch Dent, Div Anat, Sakado, Saitama 3500283, Japan.
RP Sakagami, H (corresponding author), Meikai Univ, Sch Dent, Div Pharmacol, Sakado, Saitama 3500283, Japan.
EM sakagami@dent.meikai.ac.jp
OI Sakagami, Hiroshi/0000-0001-8001-2121
FU Ministry of Education, Science, Sports and Culture of JapanMinistry of
   Education, Culture, Sports, Science and Technology, Japan (MEXT)
   [19592156]
FX This study was supported in part by a Grant-in-Aid from the Ministry of
   Education, Science, Sports and Culture of Japan (Sakagami, No.19592156).
   The Authors acknowledge Drs. Kunii and Kanda for their technical
   assistance.
CR Bhattacharya A, 2008, NEOPLASIA, V10, P857, DOI 10.1593/neo.08424
   Broker LE, 2005, CLIN CANCER RES, V11, P3155, DOI 10.1158/1078-0432.CCR-04-2223
   Chabner B. A., 2006, GOODMAN GILMANS PHAR, P1315
   de Gramont A, 2000, J CLIN ONCOL, V18, P2938, DOI 10.1200/JCO.2000.18.16.2938
   DERBNATH J, 2005, AUTOPHAGY, V1, P66
   Douillard JY, 2000, LANCET, V355, P1041, DOI 10.1016/S0140-6736(00)02034-1
   Dunn William A. Jr., 1994, Trends in Cell Biology, V4, P139, DOI 10.1016/0962-8924(94)90069-8
   Fujisawa S, 2002, TOXICOLOGY, V177, P39, DOI 10.1016/S0300-483X(02)00194-4
   GUPTA M, 1995, BBA-GENE STRUCT EXPR, V1262, P1, DOI 10.1016/0167-4781(95)00029-G
   Han JY, 2005, CANCER-AM CANCER SOC, V104, P2759, DOI 10.1002/cncr.21563
   Hanley K, 1999, J INVEST DERMATOL, V113, P788, DOI 10.1046/j.1523-1747.1999.00743.x
   HSIANG YH, 1989, CANCER RES, V49, P5077
   HUSAIN I, 1994, CANCER RES, V54, P539
   Ideo A, 2009, ANTICANCER RES, V29, P175
   Ishihara M, 2006, ANTICANCER RES, V26, P2883
   Jin SK, 2006, AUTOPHAGY, V2, P80, DOI 10.4161/auto.2.2.2460
   Kantoh K, 2010, IN VIVO, V24, P843
   Kishino K, 2008, ANTICANCER RES, V28, P2577
   Otsuki S, 2011, TOXICOLOGY, V287, P131, DOI 10.1016/j.tox.2011.06.007
   Pectasides D, 2002, EUR J CANCER, V38, P1194, DOI 10.1016/S0959-8049(02)00027-8
   Robey RW, 2007, CANCER METAST REV, V26, P39, DOI 10.1007/s10555-007-9042-6
   Takeba Y, 2007, BIOL PHARM BULL, V30, P1400, DOI 10.1248/bpb.30.1400
   Takeba Y, 2007, J PHARMACOL SCI, V104, P232, DOI 10.1254/jphs.FP0070442
   Wu YC, 2009, BIOCHEM BIOPH RES CO, V382, P451, DOI 10.1016/j.bbrc.2009.03.051
   Wu YT, 2010, J BIOL CHEM, V285, P10850, DOI 10.1074/jbc.M109.080796
   YANAGISAWASHIOTA F, 1995, ANTICANCER RES, V15, P259
NR 26
TC 11
Z9 11
U1 0
U2 3
PU INT INST ANTICANCER RESEARCH
PI ATHENS
PA EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22,
   ATHENS 19014, GREECE
SN 0250-7005
J9 ANTICANCER RES
JI Anticancer Res.
PD NOV
PY 2012
VL 32
IS 11
BP 4823
EP 4832
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 043EA
UT WOS:000311524500025
PM 23155248
DA 2022-04-25
ER

PT J
AU Gu, MC
   Gao, YL
   Chang, PY
AF Gu, Meichen
   Gao, Yanli
   Chang, Pengyu
TI KRAS Mutation Dictates the Cancer Immune Environment in Pancreatic
   Ductal Adenocarcinoma and Other Adenocarcinomas
SO CANCERS
LA English
DT Review
DE KRAS gene; pancreatic ductal adenocarcinoma; cancer immunity; immune
   checkpoint blockade
ID PACLITAXEL NAB-P; STEREOTACTIC BODY RADIOTHERAPY; CONSENSUS MOLECULAR
   SUBTYPES; GEMCITABINE GEM; MUTANT KRAS; PHASE-I; IMMUNOTHERAPY;
   COMBINATION; CELLS; TREMELIMUMAB
AB Simple Summary
   The vast majority of patients with pancreatic ductal adenocarcinomas harbor KRAS mutations in their tumors. Functionally, mutated KRAS is not only dedicated to tumor cell proliferation, survival and invasiveness, but also causing the immunosuppression in this cancer. In this situation, current data indicating the therapeutic effects of immune checkpoint inhibitors on pancreatic ductal adenocarcinomas are still not satisfying. In order to reflect the present bottleneck of immune checkpoint inhibitors in managing this cancer, we mainly provide information associated with the mechanism by which KRAS mutations establish the immunosuppressive milieus in pancreatic ductal adenocarcinomas. Together with other advances in this field, future directions to overcome the KRAS mutation-induced immunosuppression in pancreatic ductal adenocarcinomas are raised as well. Meanwhile, lung adenocarcinomas and colorectal adenocarcinomas are enumerated to compare with pancreatic ductal adenocarcinomas, aiming to indicate the specificity of KRAS mutations in dictating tumoral immune milieus among these cancers.
   Generally, patients with pancreatic ductal adenocarcinoma, especially those with wide metastatic lesions, have a poor prognosis. Recently, a breakthrough in improving their survival has been achieved by using first-line chemotherapy, such as gemcitabine plus nab-paclitaxel or oxaliplatin plus irinotecan plus 5-fluorouracil plus calcium folinate. Unfortunately, regimens with high effectiveness are still absent in second- or later-line settings. In addition, although immunotherapy using checkpoint inhibitors definitively represents a novel method for metastatic cancers, monotherapy using checkpoint inhibitors is almost completely ineffective for pancreatic ductal adenocarcinomas largely due to the suppressive immune milieu in such tumors. Critically, the genomic alteration pattern is believed to impact cancer immune environment. Surprisingly, KRAS gene mutation is found in almost all pancreatic ductal adenocarcinomas. Moreover, KRAS mutation is indispensable for pancreatic carcinogenesis. On these bases, a relationship likely exists between this oncogene and immunosuppression in this cancer. During pancreatic carcinogenesis, KRAS mutation-driven events, such as metabolic reprogramming, cell autophagy, and persistent activation of the yes-associated protein pathway, converge to cause immune evasion. However, intriguingly, KRAS mutation can dictate a different immune environment in other types of adenocarcinoma, such as colorectal adenocarcinoma and lung adenocarcinoma. Overall, the KRAS mutation can drive an immunosuppression in pancreatic ductal adenocarcinomas or in colorectal carcinomas, but this mechanism is not true in KRAS-mutant lung adenocarcinomas, especially in the presence of TP53 inactivation. As a result, the response of these adenocarcinomas to checkpoint inhibitors will vary.
C1 [Gu, Meichen; Chang, Pengyu] First Hosp Jilin Univ, Dept Radiat Oncol & Therapy, Changchun 130021, Peoples R China.
   [Gao, Yanli] First Hosp Jilin Univ, Dept Pediat Ultrasound, Changchun 130021, Peoples R China.
RP Chang, PY (corresponding author), First Hosp Jilin Univ, Dept Radiat Oncol & Therapy, Changchun 130021, Peoples R China.
EM gumc20@mails.jlu.edu.cn; gaoyanli@jlu.edu.cn; changpengyu@jlu.edu.cn
OI Gu, Meichen/0000-0002-3236-7785
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81874254]; Scientific and Technological
   Developing Scheme Foundation of Jilin Province [20200201400JC];
   Foundation of Scientific Research Planning Project of the 13th Five-year
   Plan of Jilin Provincial Department of Education [JJKH20201043KJ]
FX This work was supported by National Natural Science Foundation of China
   [Grant No. 81874254], by Scientific and Technological Developing Scheme
   Foundation of Jilin Province [Grant No. 20200201400JC], and by
   Foundation of Scientific Research Planning Project of the 13th Five-year
   Plan of Jilin Provincial Department of Education [Grant No.
   JJKH20201043KJ].
CR Aglietta M, 2014, ANN ONCOL, V25, P1750, DOI 10.1093/annonc/mdu205
   Allen E, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aak9679
   Bailey P, 2016, NATURE, V531, P47, DOI 10.1038/nature16965
   Beatty GL, 2015, GASTROENTEROLOGY, V149, P201, DOI 10.1053/j.gastro.2015.04.010
   Blagih J, 2020, CELL REP, V30, P481, DOI 10.1016/j.celrep.2019.12.028
   Blair AB, 2019, J CLIN INVEST, V129, P1742, DOI 10.1172/JCI124077
   Borazanci EH, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2018.36.4_suppl.358
   Boutin AT, 2017, GENE DEV, V31, P370, DOI 10.1101/gad.293449.116
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
   Briere DM, 2021, MOL CANCER THER, V20, P975, DOI 10.1158/1535-7163.MCT-20-0462
   Burrack AL, 2019, CELL REP, V28, P2140, DOI 10.1016/j.celrep.2019.07.059
   Canon J, 2019, NATURE, V575, P217, DOI 10.1038/s41586-019-1694-1
   Chang CH, 2015, CELL, V162, P1229, DOI 10.1016/j.cell.2015.08.016
   Christenson ES, 2020, LANCET ONCOL, V21, pE135, DOI 10.1016/S1470-2045(19)30795-8
   Conroy T, 2011, NEW ENGL J MED, V364, P1817, DOI 10.1056/NEJMoa1011923
   Corcoran RB, 2011, CANCER RES, V71, P5020, DOI 10.1158/0008-5472.CAN-11-0908
   Cox AD, 2014, NAT REV DRUG DISCOV, V13, P828, DOI 10.1038/nrd4389
   Dawood S, 2014, ONCOLOGY-NY, V28, P1101
   De Nicola GM, 2011, NATURE, V475, P106, DOI 10.1038/nature10189
   Diaz LA, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2018.36.4_suppl.TPS877
   Dong ZY, 2017, CLIN CANCER RES, V23, P3012, DOI 10.1158/1078-0432.CCR-16-2554
   Eibl G, 2019, SEMIN CANCER BIOL, V54, P50, DOI 10.1016/j.semcancer.2017.10.007
   Feig C, 2013, P NATL ACAD SCI USA, V110, P20212, DOI 10.1073/pnas.1320318110
   Fukuoka S, 2020, J CLIN ONCOL, V38, P2053, DOI 10.1200/JCO.19.03296
   Fukurnura D, 2018, NAT REV CLIN ONCOL, V15, P325, DOI 10.1038/nrclinonc.2018.29
   Gan LL, 2020, CANCERS, V12, DOI 10.3390/cancers12071872
   Ganesh K, 2019, NAT REV GASTRO HEPAT, V16, P361, DOI 10.1038/s41575-019-0126-x
   Ghiringhelli F, 2020, J CLIN ONCOL, V38
   Gruber R, 2016, GASTROENTEROLOGY, V151, P526, DOI 10.1053/j.gastro.2016.05.006
   Gu M, 2021, THER ADV MED ONCOL, V13, DOI 10.1177/17588359211006950
   Guinney J, 2015, NAT MED, V21, P1350, DOI 10.1038/nm.3967
   Hallin J, 2020, CANCER DISCOV, V10, P54, DOI 10.1158/2159-8290.CD-19-1167
   He P, 2018, GASTROENTEROLOGY, V154, P1494, DOI 10.1053/j.gastro.2017.12.005
   Henriksen A, 2019, CANCER TREAT REV, V78, P17, DOI 10.1016/j.ctrv.2019.06.005
   Hingorani SR, 2005, CANCER CELL, V7, P469, DOI 10.1016/j.ccr.2005.04.023
   Hong DS, 2020, NEW ENGL J MED, V383, P1207, DOI 10.1056/NEJMoa1917239
   Humpton TJ, 2019, CANCER DISCOV, V9, P1268, DOI 10.1158/2159-8290.CD-18-1409
   Jiang H, 2016, NAT MED, V22, P851, DOI 10.1038/nm.4123
   Johnson BA, 2017, CLIN CANCER RES, V23, P1656, DOI 10.1158/1078-0432.CCR-16-2318
   Jones SA, 2018, NAT REV IMMUNOL, V18, P773, DOI 10.1038/s41577-018-0066-7
   Joyce JA, 2015, SCIENCE, V348, P74, DOI 10.1126/science.aaa6204
   Kamath SD, 2020, ONCOLOGIST, V25, pE808, DOI 10.1634/theoncologist.2019-0473
   Kamisawa T, 2016, LANCET, V388, P73, DOI 10.1016/S0140-6736(16)00141-0
   Keenan BP, 2014, GASTROENTEROLOGY, V146, P1784, DOI 10.1053/j.gastro.2014.02.055
   Kerr EM, 2016, NATURE, V531, P110, DOI 10.1038/nature16967
   Kottakis F, 2016, NATURE, V539, P390, DOI 10.1038/nature20132
   Lal N, 2018, CLIN CANCER RES, V24, P224, DOI 10.1158/1078-0432.CCR-17-1090
   Le DT, 2020, J CLIN ONCOL, V38, P11, DOI 10.1200/JCO.19.02107
   Li S, 2019, ANGIOGENESIS, V22, P15, DOI 10.1007/s10456-018-9645-2
   Liang TT, 2020, ONCOIMMUNOLOGY, V9, DOI 10.1080/2162402X.2020.1773205
   Liao WT, 2019, CANCER CELL, V35, P559, DOI 10.1016/j.ccell.2019.02.008
   Liu XM, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1117-9
   Lu CW, 2017, JNCI-J NATL CANCER I, V109, DOI 10.1093/jnci/djw283
   Luchini C, 2021, GUT, V70, P148, DOI 10.1136/gutjnl-2020-320726
   Luke JJ, 2018, J CLIN ONCOL, V36, P1611, DOI 10.1200/JCO.2017.76.2229
   Mace TA, 2018, GUT, V67, P320, DOI 10.1136/gutjnl-2016-311585
   Marabelle A, 2020, J CLIN ONCOL, V38, P1, DOI 10.1200/JCO.19.02105
   Murakami S, 2017, ONCOGENE, V36, P1232, DOI 10.1038/onc.2016.288
   Nollmann FI, 2020, BIOMEDICINES, V8, DOI 10.3390/biomedicines8080281
   O'Reilly EM, 2019, JAMA ONCOL, V5, P1431, DOI 10.1001/jamaoncol.2019.1588
   Overman MJ, 2018, J CLIN ONCOL, V36, P773, DOI 10.1200/JCO.2017.76.9901
   Renouf DJ, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2018.36.4_suppl.349
   Riaz N, 2017, CELL, V171, P934, DOI 10.1016/j.cell.2017.09.028
   Ribas A, 2018, SCIENCE, V359, P1350, DOI 10.1126/science.aar4060
   Allende MTS, 2017, PANCREAS, V46, P913, DOI 10.1097/MPA.0000000000000867
   Sanford DE, 2013, CLIN CANCER RES, V19, P3404, DOI 10.1158/1078-0432.CCR-13-0525
   Schumacher TN, 2019, ANNU REV IMMUNOL, V37, P173, DOI 10.1146/annurev-immunol-042617-053402
   Sivaram N, 2019, J CLIN INVEST, V129, P3264, DOI 10.1172/JCI123540
   Skoulidis F, 2018, CANCER DISCOV, V8, P822, DOI 10.1158/2159-8290.CD-18-0099
   Smeby J, 2018, ANN ONCOL, V29, P1227, DOI 10.1093/annonc/mdy085
   Sodir NM, 2020, CANCER DISCOV, V10, P588, DOI 10.1158/2159-8290.CD-19-0435
   Sohal DPS, 2020, J CLIN ONCOL, V38, P3217, DOI 10.1200/JCO.20.01364
   Stewart RA, 2018, CANCER RES, V78, P6717, DOI 10.1158/0008-5472.CAN-18-2652
   Tran E, 2016, NEW ENGL J MED, V375, P2255, DOI 10.1056/NEJMoa1609279
   Tran E, 2015, SCIENCE, V350, P1387, DOI 10.1126/science.aad1253
   Vakiani E, 2012, J CLIN ONCOL, V30, P2956, DOI 10.1200/JCO.2011.38.2994
   Vincent A, 2011, LANCET, V378, P607, DOI 10.1016/S0140-6736(10)62307-0
   Von Hoff DD, 2013, NEW ENGL J MED, V369, P1691, DOI 10.1056/NEJMoa1304369
   Wainberg ZA, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.4_suppl.298
   Wainberg ZA, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.4_suppl.412
   Wang G, 2019, J CELL PHYSIOL, V234, P5601, DOI 10.1002/jcp.27388
   Wang Q, 2018, CANCER LETT, V438, P17, DOI 10.1016/j.canlet.2018.08.028
   Waters AM, 2018, CSH PERSPECT MED, V8, DOI 10.1101/cshperspect.a031435
   Weiss GJ, 2017, BRIT J CANCER, V117, P33, DOI 10.1038/bjc.2017.145
   Wellenstein MD, 2018, IMMUNITY, V48, P399, DOI 10.1016/j.immuni.2018.03.004
   Xie CQ, 2020, CLIN CANCER RES, V26, P2318, DOI 10.1158/1078-0432.CCR-19-3624
   Yamamoto K, 2020, NATURE, V581, P100, DOI 10.1038/s41586-020-2229-5
   Yang WJ, 2020, ANN TRANSL MED, V8, DOI 10.21037/atm.2020.02.11
   Yoshimura A, 2011, CURR TOP MICROBIOL, V350, P127, DOI 10.1007/82_2010_87
   Yuki S, 2020, J CLIN ONCOL, V38
   Yun JY, 2009, SCIENCE, V325, P1555, DOI 10.1126/science.1174229
   Zhang Q, 2019, CANCER RES, V79, P3940, DOI 10.1158/0008-5472.CAN-19-0761
   Zhang WY, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005049
   Zhao X, 2017, CANCER LETT, V402, P61, DOI 10.1016/j.canlet.2017.05.015
   Zhu Y, 2014, CANCER RES, V74, P5057, DOI 10.1158/0008-5472.CAN-13-3723
NR 95
TC 3
Z9 3
U1 2
U2 8
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2072-6694
J9 CANCERS
JI Cancers
PD MAY
PY 2021
VL 13
IS 10
AR 2429
DI 10.3390/cancers13102429
PG 16
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA SI2FU
UT WOS:000654642500001
PM 34069772
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Ardakani, AA
   Ghader, A
   Asgari, H
   Keshavarz, M
   Tazehmahalleh, FE
   Arae, MHM
   Malekzadeh, M
   Ghaznavi, H
   Shakeri-Zadeh, A
AF Ardakani, Ali Abbasian
   Ghader, Alireza
   Asgari, Hamid
   Keshavarz, Marzieh
   Tazehmahalleh, Fatemeh Ebrahimi
   Arae, Mohammad Hosein Majles
   Malekzadeh, Malekeh
   Ghaznavi, Habib
   Shakeri-Zadeh, Ali
TI The capability of nonlinear optical characteristics as a predictor for
   cellular uptake of nanoparticles and cell damage
SO PHOTODIAGNOSIS AND PHOTODYNAMIC THERAPY
LA English
DT Article
DE Nanotechnology; Cell damage; Z-Scan; Nonlinear optical characteristics;
   Refractive index
ID CISPLATIN; CANCER; CHEMOTHERAPY; DOXORUBICIN; SCATTERING; AUTOPHAGY
AB Current methods for determining the cellular effects of a treatment modality need expensive materials and much time to provide a researcher with results. The aim of this study was to evaluate the potential of nonlinear optical characteristics of cancer cells using Z-scan technique to monitor the level of cellular uptake and cell damage caused by a nanotechnology based treatment modality. Two nanocomplexes were synthesized and characterized. The first one was made of alginate hydrogel co-loaded with cisplatin and gold nanoparticles (AuNPs) named as ACA nanocomplex. The second one, named as AA nanocomplex, was the same as ACA, but without cisplatin and this AA nanocomplex was considered as the control for ACA. Different groups of CT26 mouse colon cancer cell line received various treatments of cisplatin, ACA, and AA nanocomplexes and then the samples were prepared for Z-scan studies. The MTT assay was used to evaluate the cytotoxicity induced by different treatment modalities. Transmission electron microscopy (TEM) and inductively coupled plasma-mass spectrometry (ICP-MS) were used for qualitative and quantitative assessments of the level of AuNPs cellular uptake. The trend of nonlinear optical properties changes for treated cells was in agreement with MTT, TEM and ICP-MS results. Z-scan technique was able to successfully indicate the occurrence of cell damage. It was also capable to determine the intensity of cell damage induced by ACA nanocomplex in comparison to free cisplatin. Furthermore, Z-scan results showed that it was able to discriminate the differences of optical properties of the cells incubated with ACA nanocomplex for various incubation times. Nonlinear optical characteristics of a cell may be considered as a reliable indicator to predict the level of cellular effects induced by a nanotechnology based treatment modality. The protocol suggested in this article does not waste materials, not take much time to provide the results, and it is inexpensive technique.
C1 [Ardakani, Ali Abbasian; Ghader, Alireza; Asgari, Hamid; Shakeri-Zadeh, Ali] IUMS, Finetech Med Res Ctr, Tehran, Iran.
   [Ardakani, Ali Abbasian; Ghader, Alireza; Malekzadeh, Malekeh; Shakeri-Zadeh, Ali] IUMS, Sch Med, Med Phys Dept, Tehran, Iran.
   [Keshavarz, Marzieh] Shiraz Univ Med Sci, Sch Med, Dept Med Phys, Tehran, Iran.
   [Tazehmahalleh, Fatemeh Ebrahimi] Univ Hosp Cologne, Cologne, Germany.
   [Arae, Mohammad Hosein Majles] Kharazmi Univ, ASRC, Biophoton Lab, Dept Phys, Karaj, Iran.
   [Ghaznavi, Habib] Zahedan Univ Med Sci ZaUMS, Zahedan, Iran.
RP Ghaznavi, H; Shakeri-Zadeh, A (corresponding author), IUMS, Tehran, Iran.
EM dr.ghaznavi@zaums.ac.ir; shakeriz@iums.ac.ir
RI ghaznavi, habib/H-2293-2017; Ardakani, Ali Abbasian/A-2228-2015
OI Ardakani, Ali Abbasian/0000-0001-7536-0973; Ghader,
   Alireza/0000-0002-6100-0261
FU Ministry of Health & Medical Education (MOHME) of Iran; Zahedan
   University of Medical Sciences [7970]
FX All supports received from the Ministry of Health & Medical Education
   (MOHME) of Iran are acknowledged. This study was also supported by
   Zahedan University of Medical Sciences (grant number 7970).
CR Afizadeh R, 2019, J CHEM NEUROANAT, V96, P126, DOI 10.1016/j.jchemneu.2019.01.003
   Ahmed B, 2017, SCI REP-UK, V7, DOI 10.1038/srep40685
   Alamzadeh Z, 2019, J PHOTOCH PHOTOBIO B, V192, P19, DOI 10.1016/j.jphotobiol.2019.01.005
   Alves S, 2019, PHOTODIAGN PHOTODYN, V26, P36, DOI 10.1016/j.pdpdt.2019.02.012
   Arya BD, 2018, NANOMEDICINE-UK, V13, P2261, DOI 10.2217/nnm-2018-0086
   Beik J, 2018, MED PHYS, V45, P4306, DOI 10.1002/mp.13100
   Bigio IJ, 2004, CANCER BIOL THER, V3, P259, DOI 10.4161/cbt.3.3.694
   Chen JL, 2018, BIOTECHNOL BIOENG, V115, P351, DOI 10.1002/bit.26475
   Coussens NP, 2018, CTS-CLIN TRANSL SCI, V11, P461, DOI 10.1111/cts.12570
   Cox AJ, 2002, AM J PHYS, V70, P620, DOI 10.1119/1.1466815
   Ghader A, 2018, PHOTODIAGN PHOTODYN, V23, P171, DOI 10.1016/j.pdpdt.2018.06.015
   Hu S, 2016, ACTA BIOCH BIOPH SIN, V48, P528, DOI 10.1093/abbs/gmw026
   Keshavarz M, 2018, J BIOMATER APPL, V33, P161, DOI 10.1177/0885328218782355
   Lee J, 2017, ACTA PHARMACOL SIN, V38, P848, DOI 10.1038/aps.2017.16
   Lin JF, 2017, DRUG DES DEV THER, V11, P1517, DOI 10.2147/DDDT.S126464
   Lorusso V, 2016, THER CLIN RISK MANAG, V12, P917, DOI 10.2147/TCRM.S89215
   Lu J. Q., 2000, INT SOC OPT PHOTONIC, P176
   Mourant JR, 2000, J BIOMED OPT, V5, P131, DOI 10.1117/1.429979
   Salman M, 2016, PHOTODIAGN PHOTODYN, V16, P54, DOI 10.1016/j.pdpdt.2016.08.001
   Salman M, 2016, OPTIK, V127, P3867, DOI 10.1016/j.ijleo.2016.01.072
   Shakeri-Zadeh A, 2009, J NANOTECHNOLOGY PRO, V1
   SHEIKBAHAE M, 1989, OPT LETT, V14, P955, DOI 10.1364/OL.14.000955
   Song WT, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04605-x
   Tan LJ, 2017, ACTA BIOMATER, V57, P498, DOI 10.1016/j.actbio.2017.05.019
   Xi JQ, 2017, INT J NANOMED, V12, P3331, DOI 10.2147/IJN.S132270
   Zhai XY, 2016, CANCER MED-US, V5, P2286, DOI 10.1002/cam4.814
   Zhang RX, 2017, ADV FUNCT MATER, V27, DOI 10.1002/adfm.201700804
   Zhang XY, 2018, INT J BIOCHEM CELL B, V95, P9, DOI 10.1016/j.biocel.2017.12.010
NR 28
TC 0
Z9 0
U1 0
U2 8
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1572-1000
EI 1873-1597
J9 PHOTODIAGN PHOTODYN
JI Photodiagnosis Photodyn. Ther.
PD SEP
PY 2019
VL 27
BP 442
EP 448
DI 10.1016/j.pdpdt.2019.07.023
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA IW3HH
UT WOS:000484870600073
PM 31362112
DA 2022-04-25
ER

PT J
AU Orienti, I
   Francescangeli, F
   De Angelis, ML
   Fecchi, K
   Bongiorno-Borbone, L
   Signore, M
   Peschiaroli, A
   Boe, A
   Bruselles, A
   Costantino, A
   Eramo, A
   Salvati, V
   Sette, G
   Contavalli, P
   Zolla, L
   Oki, T
   Kitamura, T
   Spada, M
   Giuliani, A
   Baiocchi, M
   La Torre, F
   Melino, G
   Tartaglia, M
   De Maria, R
   Zeuner, A
AF Orienti, Isabella
   Francescangeli, Federica
   De Angelis, Maria Laura
   Fecchi, Katia
   Bongiorno-Borbone, Lucilla
   Signore, Michele
   Peschiaroli, Angelo
   Boe, Alessandra
   Bruselles, Alessandro
   Costantino, Angelita
   Eramo, Adriana
   Salvati, Valentina
   Sette, Giovanni
   Contavalli, Paola
   Zolla, Lello
   Oki, Toshihiko
   Kitamura, Toshio
   Spada, Massimo
   Giuliani, Alessandro
   Baiocchi, Marta
   La Torre, Filippo
   Melino, Gerry
   Tartaglia, Marco
   De Maria, Ruggero
   Zeuner, Ann
TI A new bioavailable fenretinide formulation with antiproliferative,
   antimetabolic, and cytotoxic effects on solid tumors
SO CELL DEATH & DISEASE
LA English
DT Article
ID PHASE-I TRIAL; LOW-DOSE TAMOXIFEN; CANCER STEM-CELLS; DIHYDROCERAMIDE
   DESATURASE; HIGH-RISK; ORAL FENRETINIDE; NEUROBLASTOMA; IDENTIFICATION;
   TARGET; CYCLE
AB Fenretinide is a synthetic retinoid characterized by anticancer activity in preclinical models and favorable toxicological profile, but also by a low bioavailability that hindered its clinical efficacy in former clinical trials. We developed a new formulation of fenretinide complexed with 2-hydroxypropyl-beta-cyclodextrin (nanofenretinide) characterized by an increased bioavailability and therapeutic efficacy. Nanofenretinide was active in cell lines derived from multiple solid tumors, in primary spheroid cultures and in xenografts of lung and colorectal cancer, where it inhibited tumor growth independently from the mutational status of tumor cells. A global profiling of pathways activated by nanofenretinide was performed by reverse-phase proteomic arrays and lipid analysis, revealing widespread repression of the mTOR pathway, activation of apoptotic, autophagic and DNA damage signals and massive production of dihydroceramide, a bioactive lipid with pleiotropic effects on several biological processes. In cells that survived nanofenretinide treatment there was a decrease of factors involved in cell cycle progression and an increase in the levels of p16 and phosphorylated p38 MAPK with consequent block in G0 and early G1. The capacity of nanofenretinide to induce cancer cell death and quiescence, together with its elevated bioavailability and broad antitumor activity indicate its potential use in cancer treatment and chemoprevention.
C1 [Orienti, Isabella] Univ Bologna, Dept Pharm & Biotechnol, Via San Donato 19-2, I-40127 Bologna, Italy.
   [Francescangeli, Federica; De Angelis, Maria Laura; Bruselles, Alessandro; Costantino, Angelita; Eramo, Adriana; Salvati, Valentina; Sette, Giovanni; Contavalli, Paola; Baiocchi, Marta; Zeuner, Ann] Ist Super Sanita, Dept Oncol & Mol Med, Viale Regina Elena 299, I-00161 Rome, Italy.
   [Fecchi, Katia] Ist Super Sanita, Ctr Gender Specif Med, Viale Regina Elena 299, I-00161 Rome, Italy.
   [Bongiorno-Borbone, Lucilla; Peschiaroli, Angelo; Melino, Gerry] Univ Roma Tor Vergata, Dept Expt Med & Surg, Via Montpellier 1, I-00133 Rome, Italy.
   [Signore, Michele] Ist Super Sanita, RPPA Unit, Core Facil, Prote, Viale Regina Elena 299, I-00161 Rome, Italy.
   [Boe, Alessandra] Ist Super Sanita, Core Facil, Rome, Italy.
   [Costantino, Angelita] Univ Catania, Dept Biomed & Biotechnol Sci BIOMETEC, Via Santa Sofia 97, I-95123 Catania, Italy.
   [Zolla, Lello] Univ Tuscia, DAFNE Dept, Via S Camillo de Lellis, I-01100 Viterbo, Italy.
   [Oki, Toshihiko; Kitamura, Toshio] Univ Tokyo, Inst Med Sci, Div Cellular Therapy, Minato Ku, Tokyo 1088639, Japan.
   [Oki, Toshihiko; Kitamura, Toshio] Univ Tokyo, Inst Med Sci, Div Stem Cell Signaling, Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.
   [Spada, Massimo] Ist Super Sanita, Ctr Anim Res & Welf, Rome, Italy.
   [Giuliani, Alessandro] Ist Super Sanita, Environm & Hlth Dept, Rome, Italy.
   [La Torre, Filippo] Sapienza Univ, Div Emergency & Trauma Surg, Surg Sci & Emergency Dept, Emergency Dept,Policlin Umberto 1, Viale Policlin 155, I-00161 Rome, Italy.
   [Tartaglia, Marco] Osped Pediat Bambino Gesu, Genet & Rare Dis Res Div, Viale San Paolo 15, I-00146 Rome, Italy.
   [De Maria, Ruggero] Univ Cattolica Sacro Cuore, Inst Gen Pathol, Largo Francesco Vito 1, I-00168 Rome, Italy.
RP Zeuner, A (corresponding author), Ist Super Sanita, Dept Oncol & Mol Med, Viale Regina Elena 299, I-00161 Rome, Italy.; De Maria, R (corresponding author), Univ Cattolica Sacro Cuore, Inst Gen Pathol, Largo Francesco Vito 1, I-00168 Rome, Italy.
EM ruggerodemaria@gmail.com; a.zeuner@gmail.com
RI Boe, Alessandra/AAA-2653-2019; Signore, Michele/J-8563-2016; De Angelis,
   Maria Laura/Y-4004-2019; Giuliani, Alessandro/K-7589-2016; Kitamura,
   Toshio/AAA-2071-2021; Spada, Massimo/Z-1345-2019; Zeuner,
   Ann/K-8607-2016; Francescangeli, Federica/K-6500-2016; Bruselles,
   Alessandro/M-7908-2017; Orienti, Isabella/X-2462-2019; Eramo,
   Adriana/K-6694-2016; La Torre, Filippo/AAI-7284-2020; Giuliani,
   Alessandro/AAF-1740-2020; Bruselles, Alessandro/M-6012-2019; Tartaglia,
   Marco/K-2955-2018; salvati, Valentina/J-1264-2018; Zeuner,
   Ann/A-8529-2010; Fecchi, Katia/N-1380-2017; Sette, Giovanni/K-6692-2016
OI Boe, Alessandra/0000-0002-8888-7501; Signore,
   Michele/0000-0002-0262-842X; De Angelis, Maria
   Laura/0000-0003-4220-8822; Giuliani, Alessandro/0000-0002-4640-804X;
   Spada, Massimo/0000-0003-0751-1893; Francescangeli,
   Federica/0000-0002-1086-5265; Bruselles, Alessandro/0000-0002-1556-4998;
   Eramo, Adriana/0000-0002-0814-6683; La Torre,
   Filippo/0000-0002-0787-8794; Giuliani, Alessandro/0000-0002-4640-804X;
   Bruselles, Alessandro/0000-0002-1556-4998; Tartaglia,
   Marco/0000-0001-7736-9672; salvati, Valentina/0000-0002-0322-3504;
   PESCHIAROLI, ANGELO/0000-0001-6311-2382; ORIENTI,
   ISABELLA/0000-0003-1972-2807; Zeuner, Ann/0000-0002-8295-3715;
   Costantino, Angelita/0000-0002-2519-6279; Fecchi,
   Katia/0000-0003-4397-5783; Sette, Giovanni/0000-0002-3378-2446;
   Baiocchi, Marta/0000-0003-0976-0690
FU AIRCFondazione AIRC per la ricerca sul cancro [15749, 20744]; ERA-NET
   TRANSCAN Ref TACTIC JTC 2014; Sapienza University of Rome [C26H15ZKWL];
   AIRC 5 x 1000 Molecular Clinical Oncology Extension ProgramFondazione
   AIRC per la ricerca sul cancro [9979]; MRCUK Research & Innovation
   (UKRI)Medical Research Council UK (MRC) [MC_U132670600, MC_UU_00025/2]
   Funding Source: UKRI
FX We thank Paola Di Matteo and Stefano Guida for excellent technical
   assistance, Antonio Di Virgilio and Daniele Macchia for their essential
   contribution for in vivo experiments. This work was supported by the
   following grants: AIRC IG 2017 Ref: 20744, AIRC IG 2014 Ref: 15749,
   ERA-NET TRANSCAN Ref TACTIC JTC 2014 to A.Z., by Awards 2015 Sapienza
   University of Rome C26H15ZKWL grant to F.L.T. and by AIRC 5 x 1000
   Molecular Clinical Oncology Extension Program Ref 9979 grant to R.D.M.,
   G.M. and M.T.
CR Adam AP, 2009, CANCER RES, V69, P5664, DOI 10.1158/0008-5472.CAN-08-3820
   Aguirre-Ghiso JA, 2018, ANNU REV CANC BIOL, V2, P377, DOI 10.1146/annurev-cancerbio-030617-050446
   Bilski P, 2002, FREE RADICAL BIO MED, V33, P938, DOI 10.1016/S0891-5849(02)00982-6
   Botella SM, 1996, J PHARMACEUT BIOMED, V14, P909, DOI 10.1016/0731-7085(95)01672-4
   Bragado P, 2013, NAT CELL BIOL, V15, P1351, DOI 10.1038/ncb2861
   Brewster ME, 2007, ADV DRUG DELIVER REV, V59, P645, DOI 10.1016/j.addr.2007.05.012
   Camerini T, 2001, J CLIN ONCOL, V19, P1664, DOI 10.1200/JCO.2001.19.6.1664
   Carosio R, 2012, J PHARM PHARMACOL, V64, P228, DOI 10.1111/j.2042-7158.2011.01403.x
   COBLEIGH MA, 1993, J CLIN ONCOL, V11, P474, DOI 10.1200/JCO.1993.11.3.474
   Cooper JP, 2017, EXP BIOL MED, V242, P1178, DOI 10.1177/1535370217706952
   D'Alessandro A, 2011, J PROTEOMICS, V74, P2138, DOI 10.1016/j.jprot.2011.06.006
   De Angelis ML, 2018, CELL BIOL TOXICOL, V34, P459, DOI 10.1007/s10565-018-9423-3
   De Angelis ML, 2016, STEM CELL TRANSL MED, V5, P511, DOI 10.5966/sctm.2015-0214
   Decensi A, 2000, CANCER EPIDEM BIOMAR, V9, P1071
   Decensi A, 2009, J CLIN ONCOL, V27, P3749, DOI 10.1200/JCO.2008.19.3797
   Dieter SM, 2011, CELL STEM CELL, V9, P357, DOI 10.1016/j.stem.2011.08.010
   Eramo A, 2008, CELL DEATH DIFFER, V15, P504, DOI 10.1038/sj.cdd.4402283
   Espina Virginia, 2008, V441, P113, DOI 10.1007/978-1-60327-047-2_8
   Esteves F, 2013, J LIPOSOME RES, V23, P83, DOI 10.3109/08982104.2012.742539
   Francescangeli F, 2015, CELL DEATH DIFFER, V22, P1700, DOI 10.1038/cdd.2015.19
   Francescangeli F, 2012, STEM CELLS, V30, P1819, DOI 10.1002/stem.1163
   Gagliostro V, 2012, INT J BIOCHEM CELL B, V44, P2135, DOI 10.1016/j.biocel.2012.08.025
   Garaventa A, 2003, CLIN CANCER RES, V9, P2032
   Islam W, 2018, MOL CANCER THER, V17, P2643, DOI 10.1158/1535-7163.MCT-18-0696
   Jasti B. R, 2001, P AM SOC CLIN ONCOL, V20
   Johansson H, 2008, CANCER RES, V68, P9512, DOI 10.1158/0008-5472.CAN-08-0553
   Kim RS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035569
   Kraveka JM, 2007, J BIOL CHEM, V282, P16718, DOI 10.1074/jbc.M700647200
   Kreso A, 2014, CELL STEM CELL, V14, P275, DOI 10.1016/j.stem.2014.02.006
   Kummar S, 2011, ANTICANCER RES, V31, P961
   Lee YS, 2012, CANCER BIOL THER, V13, P92, DOI 10.4161/cbt.13.2.18870
   Lovat PE, 2004, JNCI-J NATL CANCER I, V96, P1288, DOI 10.1093/jnci/djh254
   Martins-Neves SR, 2018, PHARMACOL RES, V137, P193, DOI 10.1016/j.phrs.2018.10.011
   Maurer BJ, 2007, CLIN CANCER RES, V13, P3079, DOI 10.1158/1078-0432.CCR-06-1889
   Maurer BJ, 2013, PEDIATR BLOOD CANCER, V60, P1801, DOI 10.1002/pbc.24643
   Mohrbacher AM, 2017, CLIN CANCER RES, V23, P4550, DOI 10.1158/1078-0432.CCR-17-0234
   Moore MM, 2010, CANCER CHEMOTH PHARM, V66, P845, DOI 10.1007/s00280-009-1228-x
   Oki T, 2014, SCI REP-UK, V4, DOI 10.1038/srep04012
   Oridate N, 1997, J NATL CANCER I, V89, P1191, DOI 10.1093/jnci/89.16.1191
   Pienta KJ, 1997, AM J CLIN ONCOL-CANC, V20, P36, DOI 10.1097/00000421-199702000-00008
   Puduvalli VK, 2004, J CLIN ONCOL, V22, P4282, DOI 10.1200/JCO.2004.09.096
   Rahmaniyan M, 2011, J BIOL CHEM, V286, P24754, DOI 10.1074/jbc.M111.250779
   Reynolds C, 2007, J CLIN ONCOL, V25
   Schneider BJ, 2009, INVEST NEW DRUG, V27, P571, DOI 10.1007/s10637-009-9228-6
   Sette G, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.217
   Siddique MM, 2013, MOL CELL BIOL, V33, P2353, DOI 10.1128/MCB.00226-13
   Tanida Isei, 2008, V445, P77, DOI 10.1007/978-1-59745-157-4_4
   Vaishampayan U, 2005, INVEST NEW DRUG, V23, P179, DOI 10.1007/s10637-005-5864-7
   Vermeulen L, 2008, P NATL ACAD SCI USA, V105, P13427, DOI 10.1073/pnas.0805706105
   Vermeulen L, 2010, NAT CELL BIOL, V12, P468, DOI 10.1038/ncb2048
   Veronesi U, 2006, ANN ONCOL, V17, P1065, DOI 10.1093/annonc/mdl047
   Villablanca JG, 2006, J CLIN ONCOL, V24, P3423, DOI 10.1200/JCO.2005.03.9271
   Villablanca JG, 2011, CLIN CANCER RES, V17, P6858, DOI 10.1158/1078-0432.CCR-11-0995
   Zeuner A, 2015, MOL CELL ONCOL, V2, DOI 10.4161/23723548.2014.968067
   Zhang H, 2013, P NATL ACAD SCI USA, V110, P5606, DOI 10.1073/pnas.1302352110
NR 55
TC 20
Z9 20
U1 0
U2 6
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-4889
J9 CELL DEATH DIS
JI Cell Death Dis.
PD JUL 23
PY 2019
VL 10
AR 529
DI 10.1038/s41419-019-1775-y
PG 19
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA IM6JH
UT WOS:000478098700001
PM 31332161
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Xiao, M
   Benoit, A
   Hasmim, M
   Duhem, C
   Vogin, G
   Berchem, G
   Noman, MZ
   Janji, B
AF Xiao, Malina
   Benoit, Alice
   Hasmim, Meriem
   Duhem, Caroline
   Vogin, Guillaume
   Berchem, Guy
   Noman, Muhammad Zaeem
   Janji, Bassam
TI Targeting Cytoprotective Autophagy to Enhance Anticancer Therapies
SO FRONTIERS IN ONCOLOGY
LA English
DT Review
DE autophagy; cancer resistance; chemotherapy; radiotherapy; targeted
   therapy; immunotherapy
ID CANCER-CELLS; COLORECTAL-CANCER; INHIBITING AUTOPHAGY; CHLOROQUINE;
   RESISTANCE; PROMOTES; RADIOSENSITIVITY; ANGIOGENESIS; SIMVASTATIN;
   INDUCTION
AB Autophagy is a highly regulated multi-step process that occurs at the basal level in almost all cells. Although the deregulation of the autophagy process has been described in several pathologies, the role of autophagy in cancer as a cytoprotective mechanism is currently well established and supported by experimental and clinical evidence. Our understanding of the molecular mechanism of the autophagy process has largely contributed to defining how we can harness this process to improve the benefit of cancer therapies. While the role of autophagy in tumor resistance to chemotherapy is extensively documented, emerging data point toward autophagy as a mechanism of cancer resistance to radiotherapy, targeted therapy, and immunotherapy. Therefore, manipulating autophagy has emerged as a promising strategy to overcome tumor resistance to various anti-cancer therapies, and autophagy modulators are currently evaluated in combination therapies in several clinical trials. In this review, we will summarize our current knowledge of the impact of genetically and pharmacologically modulating autophagy genes and proteins, involved in the different steps of the autophagy process, on the therapeutic benefit of various cancer therapies. We will also briefly discuss the challenges and limitations to developing potent and selective autophagy inhibitors that could be used in ongoing clinical trials.
C1 [Xiao, Malina; Benoit, Alice; Hasmim, Meriem; Berchem, Guy; Noman, Muhammad Zaeem; Janji, Bassam] Luxembourg Inst Hlth, Dept Oncol, Tumor Immunotherapy & Microenvironrnent TIME Grp, Luxembourg, Luxembourg.
   [Duhem, Caroline; Berchem, Guy] Ctr Hosp Luxembourg, Dept Hematooncol, Luxembourg, Luxembourg.
   [Vogin, Guillaume] Univ Lorraine, UMR 7365, Ingn Mol & Physiopathol Articulaire IMoPA, Vandoeuvre Les Nancy, France.
   [Vogin, Guillaume] Ctr Francois Baolesse, Esch Sur Alzette, Luxembourg.
RP Janji, B (corresponding author), Luxembourg Inst Hlth, Dept Oncol, Tumor Immunotherapy & Microenvironrnent TIME Grp, Luxembourg, Luxembourg.
EM bassam.janji@lih.lu
RI Berchem, Guy/C-9364-2014; NOMAN, Muhammmad Zaeem/AAJ-1466-2021
OI Berchem, Guy/0000-0003-0157-2257; NOMAN, Muhammmad
   Zaeem/0000-0002-1837-3097
FU Luxembourg Institute of Health; Luxembourg National Research
   FundLuxembourg National Research Fund [PRIDE15/10675146/CANBIO,
   C18/BM/12670304/COMBATIC]; FNRS TelevieFonds de la Recherche
   Scientifique - FNRS [7.4606.18, 7.4579.20]; Fondation Cancer, Luxembourg
   [FC/2018/06]; Kriibskrank Kanner Foundation, Luxembourg; RCMS
   foundation; Action LIONS Vaincre le Cancer Luxembourg; Janssen Cilag
   Pharma; Roche Pharma
FX This work was supported by Luxembourg Institute of Health and grants
   from the Luxembourg National Research Fund (PRIDE15/10675146/CANBIO and
   C18/BM/12670304/COMBATIC); FNRS Televie (grants 7.4606.18 and
   7.4579.20); Fondation Cancer, Luxembourg (FC/2018/06); Kriibskrank
   Kanner Foundation, Luxembourg (2019); RCMS foundation, and Action LIONS
   Vaincre le Cancer Luxembourg. The authors also declare that this study
   received funding from Janssen Cilag Pharma and Roche Pharma. These
   funders were not involved in the study design, collection, analysis,
   interpretation of data, the writing of this article or the decision to
   submit it for publication.
CR Adrich LN, 2015, J AM CHEM SOC, V137, P5563, DOI 10.1021/jacs.5b02150
   Aga T, 2019, AURIS NASUS LARYNX, V46, P443, DOI 10.1016/j.anl.2018.10.013
   Akin D, 2014, AUTOPHAGY, V10, P2021, DOI 10.4161/auto.32229
   Alizadeh J, 2017, SCI REP-UK, V7, DOI 10.1038/srep44841
   Amaravadi RK, 2007, J CLIN INVEST, V117, P326, DOI 10.1172/JCI28833
   Baginska J, 2013, P NATL ACAD SCI USA, V110, P17450, DOI 10.1073/pnas.1304790110
   Bellot G, 2009, MOL CELL BIOL, V29, P2570, DOI 10.1128/MCB.00166-09
   Benjamin D, 2011, NAT REV DRUG DISCOV, V10, P868, DOI 10.1038/nrd3531
   Bhargava HK, 2020, P NATL ACAD SCI USA, V117, P17003, DOI 10.1073/pnas.2008030117
   Bortnik S, 2016, ONCOTARGET, V7, P66970, DOI 10.18632/oncotarget.11408
   Bryant KL, 2019, NAT MED, V25, P628, DOI 10.1038/s41591-019-0368-8
   Carew JS, 2017, CLIN CANCER RES, V23, P2869, DOI 10.1158/1078-0432.CCR-16-1742
   Carew JS, 2011, J BIOL CHEM, V286, P6602, DOI 10.1074/jbc.M110.151324
   Cassidy LD, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-14187-x
   Chaachouay H, 2011, RADIOTHER ONCOL, V99, P287, DOI 10.1016/j.radonc.2011.06.002
   Chen DG, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03225-9
   Chen JH, 2018, MOL MED REP, V17, P6859, DOI 10.3892/mmr.2018.8686
   Chen YR, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-02885-0
   Chen YS, 2015, MOL MED REP, V12, P1645, DOI 10.3892/mmr.2015.3623
   Chen YY, 2015, NEURO-ONCOLOGY, V17, P407, DOI 10.1093/neuonc/nou219
   Chittaranjan S, 2014, CLIN CANCER RES, V20, P3159, DOI 10.1158/1078-0432.CCR-13-2060
   Choi HS, 2013, TUBERC RESPIR DIS, V75, P9, DOI 10.4046/trd.2013.75.1.9
   Chu HY, 2018, CANCER LETT, V423, P105, DOI 10.1016/j.canlet.2018.03.003
   Chu JQ, 2018, ARCH BIOCHEM BIOPHYS, V644, P29, DOI 10.1016/j.abb.2018.03.001
   CLARK GM, 1984, J CLIN ONCOL, V2, P1102, DOI 10.1200/JCO.1984.2.10.1102
   Crazzolara R, 2009, BLOOD, V113, P3297, DOI 10.1182/blood-2008-02-137752
   Cufi S, 2013, SCI REP-UK, V3, DOI 10.1038/srep02469
   Daskalaki I, 2018, FRONT CELL DEV BIOL, V6, DOI 10.3389/fcell.2018.00104
   DEDUVE C, 1966, ANNU REV PHYSIOL, V28, P435, DOI 10.1146/annurev.ph.28.030166.002251
   Dyczynski M, 2018, CANCER LETT, V435, P32, DOI 10.1016/j.canlet.2018.07.028
   Egan DF, 2015, MOL CELL, V59, P285, DOI 10.1016/j.molcel.2015.05.031
   Eng CH, 2016, P NATL ACAD SCI USA, V113, P182, DOI 10.1073/pnas.1515617113
   Ertmer A, 2007, LEUKEMIA, V21, P936, DOI 10.1038/sj.leu.2404606
   Fu RQ, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0276-8
   Fu W, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.498
   Fu YY, 2019, AUTOPHAGY, V15, P295, DOI 10.1080/15548627.2018.1517073
   Geng Y, 2010, NEURO-ONCOLOGY, V12, P473, DOI 10.1093/neuonc/nop048
   Gewirtz DA, 2016, CANCER RES, V76, P5610, DOI 10.1158/0008-5472.CAN-16-0722
   Giampieri R, 2016, CRIT REV ONCOL HEMAT, V100, P99, DOI 10.1016/j.critrevonc.2016.02.005
   Gu Y, 2017, ONCOTARGET, V8, P52156, DOI 10.18632/oncotarget.11044
   Guerra F, 2019, CANCERS, V11, DOI 10.3390/cancers11081096
   Guerra F, 2019, CANCERS, V11, DOI 10.3390/cancers11010052
   Guo JY, 2013, CELL, V155, P1216, DOI 10.1016/j.cell.2013.11.019
   Huang CF, 2016, PATHOL ONCOL RES, V22, P109, DOI 10.1007/s12253-015-9981-0
   Huang TZ, 2017, CANCER CELL, V32, P840, DOI 10.1016/j.ccell.2017.11.005
   Itakura E, 2012, CELL, V151, P1256, DOI 10.1016/j.cell.2012.11.001
   Ito H, 2005, INT J ONCOL, V26, P1401
   Jain RK, 2017, UROL ONCOL-SEMIN ORI, V35, P640, DOI 10.1016/j.urolonc.2017.08.010
   Jamali L, 2020, UROL J, V17, P156, DOI 10.22037/uj.v0i0.4935
   Janji B, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00887
   Janji B, 2016, ONCOTARGET, V7, P17591, DOI 10.18632/oncotarget.7540
   Jung CH, 2010, FEBS LETT, V584, P1287, DOI 10.1016/j.febslet.2010.01.017
   Kang C, 2016, AUTOPHAGY, V12, P898, DOI 10.1080/15548627.2015.1121361
   Ketola K, 2010, MOL CANCER THER, V9, P3175, DOI 10.1158/1535-7163.MCT-10-0368
   Kim J, 2011, NAT CELL BIOL, V13, P132, DOI 10.1038/ncb2152
   Kim T S, 1989, J Neurosci Nurs, V21, P342
   Kimmelman AC, 2011, GENE DEV, V25, P1999, DOI 10.1101/gad.17558811
   Klionsky DJ, 2016, AUTOPHAGY, V12, P1, DOI 10.1080/15548627.2015.1100356
   Kou XH, 2017, EUR J PHARMACOL, V813, P161, DOI 10.1016/j.ejphar.2017.08.022
   Koukourakis MI, 2015, BIOCHEM BIOPH RES CO, V461, P268, DOI 10.1016/j.bbrc.2015.04.014
   Kuchitsu Y, 2018, CELLS-BASEL, V7, DOI 10.3390/cells7110215
   Kurdi A, 2017, BIOCHEM PHARMACOL, V138, P150, DOI 10.1016/j.bcp.2017.06.119
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Levy JMM, 2017, NAT REV CANCER, V17, P528, DOI 10.1038/nrc.2017.53
   Li LQ, 2016, TUMOR BIOL, V37, P653, DOI 10.1007/s13277-015-3842-z
   Li TY, 2019, CANCER MANAG RES, V11, P9353, DOI 10.2147/CMAR.S219689
   Lin JF, 2017, DRUG DES DEV THER, V11, P1517, DOI 10.2147/DDDT.S126464
   Liu HY, 2020, MED SCI MONITOR, V26, DOI 10.12659/MSM.922217
   Liu JL, 2011, CELL, V147, P223, DOI 10.1016/j.cell.2011.08.037
   Liu PF, 2018, THERANOSTICS, V8, P830, DOI 10.7150/thno.22012
   Liu SL, 2015, INT J ONCOL, V46, P2399, DOI 10.3892/ijo.2015.2937
   Liu ZY, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177694
   Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857
   Ma B, 2013, J ORAL PATHOL MED, V42, P774, DOI 10.1111/jop.12066
   Madsen CD, 2015, NAT CELL BIOL, V17, P68, DOI 10.1038/ncb3083
   Maes H, 2014, CANCER CELL, V26, P190, DOI 10.1016/j.ccr.2014.06.025
   Martins WK, 2017, BBA-GEN SUBJECTS, V1861, P3129, DOI 10.1016/j.bbagen.2016.10.018
   Martins WK, 2015, SCI REP-UK, V5, DOI 10.1038/srep12425
   Mauthe M, 2018, AUTOPHAGY, V14, P1435, DOI 10.1080/15548627.2018.1474314
   Maycotte P, 2012, AUTOPHAGY, V8, P200, DOI 10.4161/auto.8.2.18554
   Mele L, 2020, CANCER TREAT REV, V88, DOI 10.1016/j.ctrv.2020.102043
   Mgrditchian T, 2017, P NATL ACAD SCI USA, V114, pE9271, DOI 10.1073/pnas.1703921114
   Morell C, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162977
   Mou LJ, 2019, J BUON, V24, P1870
   Nawrocki ST, 2019, LEUKEMIA, V33, P2971, DOI 10.1038/s41375-019-0529-2
   Noman MZ, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aax7881
   Noman MZ, 2011, CANCER RES, V71, P5976, DOI 10.1158/0008-5472.CAN-11-1094
   O'Donovan TR, 2011, AUTOPHAGY, V7, P509, DOI 10.4161/auto.7.5.15066
   Palorini F, 2016, RADIOTHER ONCOL, V119, P123, DOI 10.1016/j.radonc.2016.02.025
   Pan BZ, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-165
   Park JM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100819
   Peeters M, 2012, CANCER TREAT REV, V38, P397, DOI 10.1016/j.ctrv.2011.08.002
   Poillet-Perez L, 2018, NATURE, V563, P569, DOI 10.1038/s41586-018-0697-7
   Prieto-Dominguez N, 2016, FRONT PHARMACOL, V7, DOI 10.3389/fphar.2016.00151
   Qian ZJ, 2001, J BIOL CHEM, V276, P22439, DOI 10.1074/jbc.M009323200
   Qiu L, 2020, LIFE SCI, V243, DOI 10.1016/j.lfs.2019.117234
   Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039
   Rao S, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4056
   Ratikan JA, 2013, INT J RADIAT ONCOL, V87, P761, DOI 10.1016/j.ijrobp.2013.07.024
   Robert G, 2019, AUTOPHAGY, V15, P927, DOI 10.1080/15548627.2019.1586259
   Rosenfeldt MT, 2013, NATURE, V504, P296, DOI 10.1038/nature12865
   Roy LO, 2015, INVEST NEW DRUG, V33, P1020, DOI 10.1007/s10637-015-0275-x
   Safaei R, 2005, MOL CANCER THER, V4, P1595, DOI 10.1158/1535-7163.MCT-05-0102
   Schlutermann D, 2018, UROL ONCOL-SEMIN ORI, V36, DOI 10.1016/j.urolonc.2017.11.021
   Schonewolf CA, 2014, WORLD J GASTRO ONCOL, V6, P74, DOI 10.4251/wjgo.v6.i3.74
   Shao S, 2014, INT J ONCOL, V44, P1661, DOI 10.3892/ijo.2014.2313
   Shojaei S, 2020, FEBS J, V287, P1005, DOI 10.1111/febs.15069
   Singh SS, 2018, ONCOGENE, V37, P1142, DOI 10.1038/s41388-017-0046-6
   Song YX, 2017, AM J TRANSL RES, V9, P1934
   Stratigos M, 2016, TRANSL LUNG CANCER R, V5, P389, DOI 10.21037/tlcr.2016.08.04
   Sui X, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.350
   Takamura A, 2011, GENE DEV, V25, P795, DOI 10.1101/gad.2016211
   Takanezawa Y, 2018, BIOCHEM BIOPH RES CO, V498, P603, DOI 10.1016/j.bbrc.2018.03.029
   Tang F, 2017, ONCOL REP, V37, P3449, DOI 10.3892/or.2017.5635
   Thompson BJ, 2015, J CELL BIOL, V210, P871, DOI 10.1083/jcb.201507005
   Towers CG, 2016, EBIOMEDICINE, V14, P15, DOI 10.1016/j.ebiom.2016.10.034
   Tsubone T.M., 2020, ADV BIOCH BIOTECHNOL, V5, DOI DOI 10.29011/2574-7258.001098
   Wang F, 2018, CELL PHYSIOL BIOCHEM, V45, P54, DOI 10.1159/000486222
   Wang M, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-1187-4
   Wang XK, 2019, CANCER CELL INT, V19, DOI 10.1186/s12935-019-0951-6
   Wei MF, 2014, AUTOPHAGY, V10, P1179, DOI 10.4161/auto.28679
   Wiedmer T, 2017, MOL CANCER THER, V16, P2502, DOI 10.1158/1535-7163.MCT-17-0136
   Wu CL, 2019, INT J MOL MED, V43, P1866, DOI 10.3892/ijmm.2019.4089
   Wu WB, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169229
   Xi GM, 2011, CANCER LETT, V307, P141, DOI 10.1016/j.canlet.2011.03.026
   Xiao Melina, 2018, Critical Reviews in Oncogenesis, V23, P321, DOI 10.1615/CritRevOncog.2018027526
   Xie FJ, 2018, J CANCER, V9, P1050, DOI 10.7150/jca.23388
   Xu H, 2005, MOL CANCER THER, V4, P435
   Yamamoto K, 2020, NATURE, V581, P100, DOI 10.1038/s41586-020-2229-5
   Ye HX, 2016, BMC NEUROL, V16, DOI 10.1186/s12883-016-0700-6
   Yoon YH, 2010, INVEST OPHTH VIS SCI, V51, P6030, DOI 10.1167/iovs.10-5278
   Yu L, 2018, AUTOPHAGY, V14, P207, DOI 10.1080/15548627.2017.1378838
   Yu Y, 2012, LEUKEMIA, V26, P1752, DOI 10.1038/leu.2012.65
   Yuan H, 2014, WORLD J GASTROENTERO, V20, P4953, DOI 10.3748/wjg.v20.i17.4953
   Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100
   Ramirez JAZ, 2020, INT IMMUNOPHARMACOL, V84, DOI 10.1016/j.intimp.2020.106495
   Zhang H, 2018, ACTA BIOCH BIOPH SIN, V50, P532, DOI 10.1093/abbs/gmy036
   Zhang Q, 2013, J EXP CLIN CANC RES, V32, DOI 10.1186/1756-9966-32-99
   Zhang RJ, 2015, MOL MED REP, V12, P1727, DOI 10.3892/mmr.2015.3588
   Zhang SF, 2015, AUTOPHAGY, V11, P225, DOI 10.1080/15548627.2014.998931
   Zhang Y, 2012, ONCOGENE, V31, P1055, DOI 10.1038/onc.2011.290
   Zhao XG, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126147
   Zhao Z, 2018, J CANCER, V9, P3407, DOI 10.7150/jca.24201
   Zhen ZJ, 2017, CANCER SCI, V108, P1485, DOI 10.1111/cas.13279
   Zheng B, 2015, BIOCHEM BIOPH RES CO, V459, P234, DOI 10.1016/j.bbrc.2015.02.084
   Zhou FX, 2018, THERANOSTICS, V8, P5200, DOI 10.7150/thno.27806
NR 146
TC 4
Z9 4
U1 8
U2 12
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2234-943X
J9 FRONT ONCOL
JI Front. Oncol.
PD FEB 25
PY 2021
VL 11
AR 626309
DI 10.3389/fonc.2021.626309
PG 13
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA QU7IC
UT WOS:000627451800001
PM 33718194
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Chen, YL
   Yan, MY
   Chien, SY
   Kuo, SJ
   Chen, DR
   Cheng, CY
   Su, CC
AF Chen, Yao-Li
   Yan, Meng-Yi
   Chien, Su-Yu
   Kuo, Shou-Jen
   Chen, Dar-Ren
   Cheng, Chun-Yuan
   Su, Chin-Cheng
TI Sann-Joong-Kuey-Jian-Tang inhibits hepatocellular carcinoma Hep-G2 cell
   proliferation by increasing TNF-alpha, Caspase-8, Caspase-3 and Bax but
   by decreasing TCTP and Mcl-1 expression in vitro
SO MOLECULAR MEDICINE REPORTS
LA English
DT Article
DE Sann-Joong-Kuey-Jian-Tang; Hep-G2 cells; apoptosis; TCTP; TNF-alpha
ID PROTEIN EXPRESSION; FORTILIN
AB Hepatic cancer remains a challenging disease and there is a need to identify new treatments. Sann-Joong-Kuey-Jian-Tang (SJKJT), a traditional medicinal prescription, has been used to treat lymphadenopathy and exhibits cytotoxic activity in many types of human cancer cells. Our previous studies revealed that SJKJT is capable of inhibiting colon cancer colo 205 cells by inducing autophagy and apoptosis. However, the effects and molecular mechanisms of SJKJT in human hepatocellular carcinoma have not been clearly elucidated. In the present study we evaluated the effects of SJKJT in human hepatic cellular carcinoma Hep-G2 cells. The cytotoxicity of SJKJT in Hep-G2 cells was measured by MTT assay. The cell cycles were analyzed by fluorescence-activated cell sorting (FACS). The protein expression of translationally controlled tumor protein (TCTP), Mcl-1, Fas, TNF-alpha, Caspase-8, Caspase-3 and Bax in Hep-G2 cells treated with SJKJT was evaluated by western blotting. The protein expression of Caspase-3 was also detected by immunofluorescence staining. The results showed that SJKJT inhibits Hep-G2 cells in a time- and dose-dependent manner. During SJKJT treatment for 48 and 72 h, the half-maximum inhibitory concentration (IC50) was 1.48 and 0.94 mg/ml, respectively. The FACS results revealed that increased doses of SJKJT were capable of increasing the percentage of cells in the sub-G1 phase. Immunofluorescence staining showed that Hep-G2 treated with SJKJT had increased expression of Caspase-3. The western blot results showed that the protein expression of Fas, TNF-alpha, Caspase-8, Caspase-3 and Bax was upregulated, but that of TCTP and Mcl-1 was downregulated in Hep-G2 cells treated with SJKJT. In conclusion, these findings indicated that SJKJT inhibits Hep-G2 cells. One of the molecular mechanisms responsible for this may be the increased Fas, TNF-alpha, Caspase-8, Caspase-3 and Bax expression; another mechanism may be via decreasing TCTP and Mcl-1 expression in order to induce apoptosis.
C1 [Chen, Yao-Li; Yan, Meng-Yi; Kuo, Shou-Jen; Chen, Dar-Ren; Cheng, Chun-Yuan; Su, Chin-Cheng] Changhua Christian Hosp, Dept Surg, Changhua 50006, Taiwan.
   [Su, Chin-Cheng] Changhua Christian Hosp, Tumor Res Ctr Integrat Med, Changhua 50006, Taiwan.
   [Kuo, Shou-Jen; Chen, Dar-Ren; Su, Chin-Cheng] Changhua Christian Hosp, Comprehens Breast Canc Ctr, Changhua 50006, Taiwan.
   [Chien, Su-Yu] Changhua Christian Hosp, Dept Pharm, Changhua 50006, Taiwan.
   [Su, Chin-Cheng] China Med Univ, Coll Chinese Med, Sch Chinese Med, Taichung 40402, Taiwan.
RP Su, CC (corresponding author), Changhua Christian Hosp, Comprehens Breast Canc Ctr, Dept Surg, Tumor Res Ctr Integrat Med, 135 Nan Hsiao St, Changhua 50006, Changhua County, Taiwan.
EM succ.maeva@msa.hinet.net
FU Changhua Christian Hospital [100-CCH-ICO-06-3]
FX This study was supported by grant 100-CCH-ICO-06-3 from Changhua
   Christian Hospital.
CR [Anonymous], 2012, STAT CAUS DEATH 2010, P153
   CARSWELL EA, 1975, P NATL ACAD SCI USA, V72, P3666, DOI 10.1073/pnas.72.9.3666
   Cheng CY, 2010, MOL MED REP, V3, P63, DOI 10.3892/mmr_00000219
   Cheng CY, 2009, MOL MED REP, V2, P707, DOI 10.3892/mmr_00000160
   Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001
   Gaur U, 2003, BIOCHEM PHARMACOL, V66, P1403, DOI 10.1016/S0006-2952(03)00490-8
   Graidist P, 2004, J BIOL CHEM, V279, P40868, DOI 10.1074/jbc.M401454200
   Hsu YL, 2006, BIOL PHARM BULL, V29, P2388, DOI 10.1248/bpb.29.2388
   Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]
   Leung TWT, 2001, SEMIN ONCOL, V28, P514, DOI 10.1053/sonc.2001.26954
   Liu H, 2005, MOL CELL BIOL, V25, P3117, DOI 10.1128/MCB.25.8.3117-3126.2005
   Lowe SW, 2004, NATURE, V432, P307, DOI 10.1038/nature03098
   Susini L, 2008, CELL DEATH DIFFER, V15, P1211, DOI 10.1038/cdd.2008.18
   Zhang D, 2002, J BIOL CHEM, V277, P37430, DOI 10.1074/jbc.M207413200
NR 14
TC 7
Z9 10
U1 0
U2 7
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1791-2997
EI 1791-3004
J9 MOL MED REP
JI Mol. Med. Rep.
PD MAY
PY 2013
VL 7
IS 5
BP 1487
EP 1493
DI 10.3892/mmr.2013.1381
PG 7
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Research & Experimental Medicine
GA 136TF
UT WOS:000318385600021
PM 23525225
OA Bronze
DA 2022-04-25
ER

PT J
AU De Luise, M
   Girolimetti, G
   Okere, B
   Porcelli, AM
   Kurelac, I
   Gasparre, G
AF De Luise, Monica
   Girolimetti, Giulia
   Okere, Bernard
   Porcelli, Anna Maria
   Kurelac, Ivana
   Gasparre, Giuseppe
TI Molecular and metabolic features of oncocytomas: Seeking the blueprints
   of indolent cancers
SO BIOCHIMICA ET BIOPHYSICA ACTA-BIOENERGETICS
LA English
DT Review
DE Oncocytic tumors; Mitochondrial DNA mutations; Mitochondrial biogenesis;
   Autophagy; Mitophagy; Respiratory complex I
ID MITOCHONDRIAL-DNA MUTATIONS; BIRT-HOGG-DUBE; HURTHLE CELL-CARCINOMA;
   RESPIRATORY COMPLEX I; OXIDATIVE-PHOSPHORYLATION; RENAL ONCOCYTOMA;
   RECTAL ADENOCARCINOMA; HUMAN-PAPILLOMAVIRUS; POINT MUTATIONS; MTDNA
   MUTATIONS
AB Oncocytic tumors are a peculiar subset of human neoplasms in which mitochondria have been proven to have a prominent role. A number of paradoxes render these clinical entities interesting from the translational research point of view. Most oncocytic tumors are generally metabolically constrained due to the impaired respiratory capacity and lack of the ability to respond to hypoxia, yet they maintain features that allow them to strive and persist in an indolent form. Their unique molecular and metabolic characteristics are an object of investigation that may reveal novel ways for therapeutic strategies based on metabolic targeting. With this aim in mind, we here examine the current knowledge on oncocytomas and delve into the molecular causes and consequences that revolve around the oncocytic phenotype, to understand whether we can learn to design therapies from the dissection of benign neoplasms. This article is part of a Special Issue entitled Mitochondria in Cancer, edited by Giuseppe Gasparre, Rodrigue Rossignol and Pierre Sonveaux. (C) 2017 Elsevier B.V. All rights reserved.
C1 [De Luise, Monica; Girolimetti, Giulia; Okere, Bernard; Kurelac, Ivana; Gasparre, Giuseppe] Univ Hosp S Orsola Malpighi, Unit Med Genet, Dept Med & Surg Sci DIMEC, Via G Massarenti 9, I-40138 Bologna, BO, Italy.
   [Okere, Bernard; Porcelli, Anna Maria] Univ Bologna, Dept Pharm & Biotechnol FABIT, Via Selmi 3, Bologna, Italy.
   [Porcelli, Anna Maria] Univ Bologna, Interdept Ind Res Ctr Hlth Sci & Technol, Bologna, Italy.
   [Kurelac, Ivana] Francis Crick Inst, Tumour Host Interact Lab, 1 Midland Rd, London NW1 1AT, England.
RP Kurelac, I (corresponding author), Univ Hosp S Orsola Malpighi, Unit Med Genet, Dept Med & Surg Sci DIMEC, Via G Massarenti 9, I-40138 Bologna, BO, Italy.
EM ivana_kurelac@yahoo.com
RI De Luise, Monica/AAC-5959-2022; Kurelac, Ivana/K-3070-2016; GIROLIMETTI,
   GIULIA/J-6648-2018; Gasparre, Giuseppe/K-3879-2016
OI De Luise, Monica/0000-0002-3486-3985; Kurelac,
   Ivana/0000-0002-8364-9985; Girolimetti, Giulia/0000-0001-8917-3634;
   Gasparre, Giuseppe/0000-0003-1229-9006
FU Italian Association for Cancer Research (AIRC) JANEUTICSFondazione AIRC
   per la ricerca sul cancro [IG14242 JANEUTICS, IG17387 TOUCHME]; Italian
   Ministry of HealthMinistry of Health, Italy [GR-2013-02356666 DISCO
   TRIP]; Worldwide Cancer Research [15-1144 DHoMOs]; European
   CommissionEuropean CommissionEuropean Commission Joint Research Centre
   [ITN -317433 MEET]; triennial AIRC fellowship "Livia Perotti"
FX This paper was supported by the Italian Association for Cancer Research
   (AIRC) grants IG14242 JANEUTICS to G. Gasparre and IG17387 TOUCHME to
   AMP. It was also supported by the Italian Ministry of Health project
   GR-2013-02356666 DISCO TRIP, Worldwide Cancer Research project 15-1144
   DHoMOs and the European Commission FP7 Marie Curie ITN -317433 MEET to
   G. Gasparre. G. Girolimetti is supported by a triennial AIRC fellowship
   "Livia Perotti".
CR Aanen DK, 2012, TRENDS GENET, V28, P1, DOI 10.1016/j.tig.2011.10.001
   Alsbeih GA, 2009, CLIN CANCER RES, V15, P7352, DOI 10.1158/1078-0432.CCR-09-0960
   Ambrosini-Spaltro A, 2006, VIRCHOWS ARCH, V448, P442, DOI 10.1007/s00428-005-0137-6
   Asa SL, 2004, CANC TREAT, V122, P23
   Bartoletti-Stella A, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.187
   Bennett DC, 2003, ONCOGENE, V22, P3063, DOI 10.1038/sj.onc.1206446
   Bisceglia M, 2004, INT J SURG PATHOL, V12, P231, DOI 10.1177/106689690401200304
   Boesch P, 2011, BBA-MOL CELL RES, V1813, P186, DOI 10.1016/j.bbamcr.2010.10.002
   Bonora E, 2006, CANCER RES, V66, P6087, DOI 10.1158/0008-5472.CAN-06-0171
   Brandon M, 2006, ONCOGENE, V25, P4647, DOI 10.1038/sj.onc.1209607
   Bridges HR, 2014, BIOCHEM J, V462, P475, DOI 10.1042/BJ20140620
   BUSUTTIL A, 1977, CLIN OTOLARYNGOL, V2, P199, DOI 10.1111/j.1365-2273.1977.tb01358.x
   Calabrese C, 2013, CANCER METAB, V1, DOI 10.1186/2049-3002-1-11
   Campisi J, 2005, CELL, V120, P513, DOI 10.1016/j.cell.2005.02.003
   Chatterjee A, 2011, CANCER PREV RES, V4, P638, DOI 10.1158/1940-6207.CAPR-10-0326
   Cline SD, 2012, BBA-GENE REGUL MECH, V1819, P979, DOI 10.1016/j.bbagrm.2012.06.002
   Cloos CR, 2009, RADIAT RES, V171, P581, DOI 10.1667/RR1395.1
   Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200
   Coller HA, 2001, NAT GENET, V28, P147, DOI 10.1038/88859
   Costa-Guda Jessica, 2007, BMC Endocr Disord, V7, P8, DOI 10.1186/1472-6823-7-8
   Cunningham JT, 2007, NATURE, V450, P736, DOI 10.1038/nature06322
   DeBerardinis RJ, 2008, CELL METAB, V7, P11, DOI 10.1016/j.cmet.2007.10.002
   Duffy A, 2015, CANCER CHEMOTH PHARM, V75, P439, DOI 10.1007/s00280-014-2637-z
   Evangelisti C, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1122-3
   Ferreira-da-Silva A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122308
   Furuta M, 2004, CANCER LETT, V212, P105, DOI 10.1016/j.canlet.2004.03.002
   Fuzesi L, 2005, CANCER GENET CYTOGEN, V160, P120, DOI 10.1016/j.cancergencyto.2004.12.010
   Ganly I, 2013, J CLIN ENDOCR METAB, V98, pE962, DOI 10.1210/jc.2012-3539
   Gasparre G., 2013, COLD SPRING HARB PER, V5
   Gasparre G, 2008, HUM MOL GENET, V17, P986, DOI 10.1093/hmg/ddm371
   Gasparre G, 2007, P NATL ACAD SCI USA, V104, P9001, DOI 10.1073/pnas.0703056104
   Gasparre G, 2011, CANCER RES, V71, P6220, DOI 10.1158/0008-5472.CAN-11-1042
   Gasparre G, 2011, BBA-BIOENERGETICS, V1807, P633, DOI 10.1016/j.bbabio.2010.08.006
   Gasparre G, 2009, HUM MUTAT, V30, P391, DOI 10.1002/humu.20870
   Goffredo P, 2013, CANCER-AM CANCER SOC, V119, P504, DOI 10.1002/cncr.27770
   Guaragnella N, 2014, BIOCHEM PHARMACOL, V92, P62, DOI 10.1016/j.bcp.2014.07.027
   Guerra F, 2012, J CLIN ONCOL, V30, pE373, DOI 10.1200/JCO.2012.43.5933
   Guo JY, 2013, GENE DEV, V27, P1447, DOI 10.1101/gad.219642.113
   Ha J, 2015, MOL ASPECTS MED, V46, P46, DOI 10.1016/j.mam.2015.08.002
   Haifler M, 2012, UROL ONCOL-SEMIN ORI, V30, P362, DOI 10.1016/j.urolonc.2009.11.024
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Haq R, 2013, CANCER CELL, V23, P302, DOI 10.1016/j.ccr.2013.02.003
   Havaki S, 2015, CANCER LETT, V356, P43, DOI 10.1016/j.canlet.2014.01.023
   Iommarini L, 2014, HUM MOL GENET, V23, P1453, DOI 10.1093/hmg/ddt533
   Jih DM, 2002, AM J DERMATOPATH, V24, P468, DOI 10.1097/00000372-200212000-00002
   Joshi S, 2015, CELL REP, V13, P1895, DOI 10.1016/j.celrep.2015.10.059
   Ju YS, 2014, ELIFE, V3, DOI 10.7554/eLife.02935
   Junker K, 2001, EUR UROL, V40, P330, DOI 10.1159/000049795
   Khaidakov M, 2005, MOL CANCER, V4, DOI 10.1186/1476-4598-4-36
   Kirdar S, 2009, RHINOLOGY, V47, P349, DOI 10.4193/Rhin09.010
   KOVACS G, 1989, AM J PATHOL, V134, P967
   Kuilman T, 2008, CELL, V133, P1019, DOI 10.1016/j.cell.2008.03.039
   Kurelac I., 2015, TUMOR CELL METAB, P199
   Kurelac I, 2015, AM J CANCER RES, V5, P1954
   Kurelac I, 2014, PATHOLOGY, V46, P250, DOI 10.1097/PAT.0000000000000079
   Kurelac I, 2013, HUM MOL GENET, V22, P226, DOI 10.1093/hmg/dds422
   Lang M, 2015, MODERN PATHOL, V28, P1458, DOI 10.1038/modpathol.2015.101
   Larman TC, 2012, P NATL ACAD SCI USA, V109, P14087, DOI 10.1073/pnas.1211502109
   Lau SK, 2015, HEAD NECK PATHOL, V9, P39, DOI 10.1007/s12105-014-0543-7
   Lee JY, 2010, J CELL BIOL, V189, P671, DOI 10.1083/jcb.201001039
   Lerin C, 2006, CELL METAB, V3, P429, DOI 10.1016/j.cmet.2006.04.013
   Lewis W, 2007, LAB INVEST, V87, P326, DOI 10.1038/labinvest.3700523
   Li S, 2015, CURR TOP MED CHEM, V15, P720, DOI 10.2174/1568026615666150302105343
   Lindner A, 1997, MOL CELL BIOCHEM, V174, P297, DOI 10.1023/A:1006823818118
   Lisanti MP, 2013, CELL CYCLE, V12, P2723, DOI 10.4161/cc.25695
   Liu J, 2012, MOL BIOL EVOL, V29, P1255, DOI 10.1093/molbev/msr290
   Llommarini L, 2013, INT J BIOCHEM CELL B, V45, P47
   Lodi T, 2015, FRONT GENET, V6, DOI 10.3389/fgene.2015.00106
   Luo C, 2016, NATURE, V537, P422, DOI 10.1038/nature19347
   Malakhova L, 2005, CELL MOL BIOL LETT, V10, P721
   Marucci G, 2013, HUM PATHOL, V44, P1867, DOI 10.1016/j.humpath.2013.02.014
   Maximo V, 2002, AM J PATHOL, V160, P1857, DOI 10.1016/S0002-9440(10)61132-7
   Maximo V, 2005, BRIT J CANCER, V92, P1892, DOI 10.1038/sj.bjc.6602547
   Maximo V, 2012, ENDOCR-RELAT CANCER, V19, pR131, DOI 10.1530/ERC-11-0354
   Mayr JA, 2008, CLIN CANCER RES, V14, P2270, DOI 10.1158/1078-0432.CCR-07-4131
   Mearini L, 2013, UROL INT, V91, P125, DOI 10.1159/000345141
   Mete O, 2012, ADV ANAT PATHOL, V19, P363, DOI 10.1097/PAP.0b013e318271a5ac
   Moiseeva O, 2009, MOL CELL BIOL, V29, P4495, DOI 10.1128/MCB.01868-08
   Mortensen M, 2010, P NATL ACAD SCI USA, V107, P832, DOI 10.1073/pnas.0913170107
   Muller-Hocker J, 2014, AM J PATHOL, V184, P2922, DOI 10.1016/j.ajpath.2014.07.015
   Mullen AR, 2012, NATURE, V481, P385, DOI 10.1038/nature10642
   Murphy JEJ, 2005, MUTAT RES-GEN TOX EN, V585, P127, DOI 10.1016/j.mrgentox.2005.04.011
   Narendra DP, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000298
   Nelen MR, 1997, HUM MOL GENET, V6, P1383, DOI 10.1093/hmg/6.8.1383
   Nickerson ML, 2002, CANCER CELL, V2, P157, DOI 10.1016/S1535-6108(02)00104-6
   Nishioka H, 2002, NEUROPATHOLOGY, V22, P19, DOI 10.1046/j.0919-6544.2001.00426.x
   Nisoli E, 2003, SCIENCE, V299, P896, DOI 10.1126/science.1079368
   Okon K, 2008, POL J PATHOL, V59, P107
   Park JS, 2009, HUM MOL GENET, V18, P1578, DOI 10.1093/hmg/ddp069
   Partridge MA, 2009, J TOXICOL ENV HEAL A, V72, P301, DOI 10.1080/15287390802526381
   Pereira L, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-53
   Picken MM, 2008, AM J CLIN PATHOL, V129, P377, DOI 10.1309/KC2465ANDWVAXYDM
   Pisanu A, 2010, WORLD J SURG, V34, P836, DOI 10.1007/s00268-009-0357-z
   Pollock PM, 2003, NAT GENET, V33, P19, DOI 10.1038/ng1054
   Porcelli AM, 2010, HUM MOL GENET, V19, P1019, DOI 10.1093/hmg/ddp566
   Pradella LM, 2013, EUR J HUM GENET, V21, P1169, DOI 10.1038/ejhg.2013.8
   Puigserver P, 2001, MOL CELL, V8, P971, DOI 10.1016/S1097-2765(01)00390-2
   Ragazzi M, 2011, HUM PATHOL, V42, P166, DOI 10.1016/j.humpath.2010.07.014
   Rodgers JT, 2005, NATURE, V434, P113, DOI 10.1038/nature03354
   Rouzbahman M, 2006, J CLIN PATHOL, V59, P1039, DOI 10.1136/jcp.2005.031997
   Roy P, 2012, J SURG ONCOL, V105, P130, DOI 10.1002/jso.22073
   Salmena L, 2008, CELL, V133, P403, DOI 10.1016/j.cell.2008.04.013
   Sasano H, 2007, ENDOCR PATHOL, V17, P345
   Savagner F, 2003, BIOCHEM BIOPH RES CO, V310, P779, DOI 10.1016/j.bbrc.2003.09.076
   Scarpulla RC, 2008, ANN NY ACAD SCI, V1147, P321, DOI 10.1196/annals.1427.006
   Schmidt LS, 2013, FAM CANCER, V12, P357, DOI 10.1007/s10689-012-9574-y
   Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187
   Shidara Y, 2005, CANCER RES, V65, P1655, DOI 10.1158/0008-5472.CAN-04-2012
   Simonnet H, 2003, CARCINOGENESIS, V24, P1461, DOI 10.1093/carcin/bgg109
   Smolkova K, 2011, INT J BIOCHEM CELL B, V43, P950, DOI 10.1016/j.biocel.2010.05.003
   Stafford P, 2010, J HUM GENET, V55, P605, DOI 10.1038/jhg.2010.76
   Stephenson LM, 2009, AUTOPHAGY, V5, P625, DOI 10.4161/auto.5.5.8133
   Tallini G, 1998, VIRCHOWS ARCH, V433, P5, DOI 10.1007/s004280050209
   Tennant DA, 2009, CARCINOGENESIS, V30, P1269, DOI 10.1093/carcin/bgp070
   Teyssier C, 2005, GENE DEV, V19, P1466, DOI 10.1101/gad.1295005
   Torrano V, 2016, NAT CELL BIOL, V18, P645, DOI 10.1038/ncb3357
   Vatrinet R, 2015, INT J BIOCHEM CELL B, V63, P41, DOI 10.1016/j.biocel.2015.01.017
   Vidone M, 2015, INT J BIOCHEM CELL B, V63, P46, DOI 10.1016/j.biocel.2015.01.027
   Wallace DC, 2005, ANNU REV GENET, V39, P359, DOI 10.1146/annurev.genet.39.110304.095751
   WALTER TA, 1989, CANCER GENET CYTOGEN, V43, P15, DOI 10.1016/0165-4608(89)90123-4
   Wei SZ, 2015, ENDOCR PATHOL, V26, P365, DOI 10.1007/s12022-015-9403-6
   Wise DR, 2011, P NATL ACAD SCI USA, V108, P19611, DOI 10.1073/pnas.1117773108
   Xu J, 2012, CRIT REV FOOD SCI, V52, P373, DOI 10.1080/10408398.2010.500245
   Xu RH, 2005, CANCER RES, V65, P613
   Yao Z, 2013, ONCOGENE, V32, P2592, DOI 10.1038/onc.2012.259
   Yen TH, 2010, CELL PROLIFERAT, V43, P287, DOI 10.1111/j.1365-2184.2010.00681.x
   YOO SK, 2016, PLOS GENET, V12, DOI DOI 10.1371/J0URNAL.PGEN.1006239
   Young MJ, 2016, CURR OPIN GENET DEV, V38, P52, DOI 10.1016/j.gde.2016.03.005
   Zhang HF, 2008, J BIOL CHEM, V283, P10892, DOI 10.1074/jbc.M800102200
   Zhang HF, 2007, CANCER CELL, V11, P407, DOI 10.1016/j.ccr.2007.04.001
   Zimmermann Franz A, 2011, Front Biosci (Elite Ed), V3, P315
   Zong HH, 2002, P NATL ACAD SCI USA, V99, P15983, DOI 10.1073/pnas.252625599
   Zou P, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/4085727
NR 133
TC 12
Z9 12
U1 0
U2 8
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0005-2728
EI 1879-2650
J9 BBA-BIOENERGETICS
JI Biochim. Biophys. Acta-Bioenerg.
PD AUG
PY 2017
VL 1858
IS 8
SI SI
BP 591
EP 601
DI 10.1016/j.bbabio.2017.01.009
PG 11
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA FA9KF
UT WOS:000405763800005
PM 28115060
OA Bronze
DA 2022-04-25
ER

PT J
AU Roussi, S
   Gosse, F
   Aoude-Werner, D
   Zhang, X
   Marchioni, E
   Geoffroy, P
   Miesch, M
   Raul, F
AF Roussi, Stamatiki
   Gosse, Francine
   Aoude-Werner, Dalal
   Zhang, Xin
   Marchioni, Eric
   Geoffroy, Philippe
   Miesch, Michel
   Raul, Francis
TI Mitochondrial perturbation, oxidative stress and lysosomal
   destabilization are involved in 7 beta-hydroxysitosterol and 7
   beta-hydroxycholesterol triggered apoptosis in human colon cancer cells
SO APOPTOSIS
LA English
DT Article
DE apoptosis; Caco-2 cells; 7 beta-hydroxysitosterol; 7
   beta-hydroxycholesterol; mitochondria; lysosomes
ID BCL-2 FAMILY PROTEINS; BETA-SITOSTEROL OXIDES; CYTOCHROME-C RELEASE;
   MEMBRANE PERMEABILIZATION; DNA-DAMAGE; DEATH; OXYSTEROLS; MECHANISMS;
   ACTIVATION; AUTOPHAGY
AB We reported previously that 7 beta-hydroxysitosterol and 7 beta-hydroxycholesterol induced apoptosis in Caco-2 cells. Apoptosis caused by 7 beta-hydroxysitosterol but not by 7 beta-hydroxycholesterol was related to a caspase-dependent process. In the present report, we compared the effects of both compounds on mitochondria integrity and on various modulators of apoptosis. When Caco-2 cells were exposed to both hydroxysterols, no changes in Bcl-2 and Bax expressions were detected indicating a Bcl-2/Bax-independent cell death pathway, whereas loss of mitochondrial membrane potential and cytochrome c release were observed. Endonuclease G expression and enhanced production of reactive oxygen species were detected in 7 beta-hydroxycholesterol treated cells, but not with 7 beta-hydroxysitosterol. Loss of mitochondrial membrane potential and cell death produced by both hydroxysterols were prevented by vitamin C. Lysosomal membrane integrity was altered with both hydroxysterols, but 7 beta-hydroxysitosterol was significantly more active on than 7 beta-hydroxycholesterol. Both hydroxysterols induced apoptosis by mitochondrial membrane permeabilization. However, 7 beta-hydroxycholesterol exhibited a specific enhancement of oxidative stress and of endonuclease G expression despite its closely related chemical structure with 7 beta-hydroxysitosterol. The two hydroxysterols exhibit different lipophilic properties which may explain their different biological effects.
C1 IRCAD, Lab Nutr Canc Prevent, F-67091 Strasbourg, France.
   Univ Strasbourg, INSERM, U682, IRCAD, F-67091 Strasbourg, France.
   Aerial, F-67300 Schiltigheim, France.
   ULP, CNRS, UMR 7512, Fac Pharm,Lab Chim Analyt & Sci Aliment, F-67400 Illkirch Graffenstaden, France.
   ULP, CNRS, UMR 7123, Lab Chim Organ Synthet, F-67008 Strasbourg, France.
RP Roussi, S (corresponding author), IRCAD, Lab Nutr Canc Prevent, 1,Pl Hop, F-67091 Strasbourg, France.
EM roussi@ulp.u-strasbg.fr
RI Akram, Muhammad Usman U/I-4917-2013
OI Akram, Muhammad Usman U/0000-0002-0999-6567; Aoude-Werner,
   Dalal/0000-0003-0262-3896
CR Antonsson B, 2004, MOL CELL BIOCHEM, V256, P141, DOI 10.1023/B:MCBI.0000009865.70898.36
   Antunes F, 2001, BIOCHEM J, V356, P549, DOI 10.1042/0264-6021:3560549
   Armstrong JS, 2006, BIOESSAYS, V28, P253, DOI 10.1002/bies.20370
   Awad AB, 1996, ANTICANCER RES, V16, P2797
   Benimetskaya L, 2004, CLIN CANCER RES, V10, P8371, DOI 10.1158/1078-0432.CCR-04-1294
   BLOCH KE, 1983, CRC CR REV BIOCH MOL, V14, P47, DOI 10.3109/10409238309102790
   Boudard D, 2002, AM J HEMATOL, V70, P115, DOI 10.1002/ajh.10108
   Breckenridge DG, 2004, CURR OPIN CELL BIOL, V16, P647, DOI 10.1016/j.ceb.2004.09.009
   Brown AJ, 1999, ATHEROSCLEROSIS, V142, P1, DOI 10.1016/S0021-9150(98)00196-8
   Chen Q, 2003, CELL DEATH DIFFER, V10, P323, DOI 10.1038/sj.cdd.4401148
   Chwieralski CE, 2006, APOPTOSIS, V11, P143, DOI 10.1007/s10495-006-3486-y
   de Jong A, 2003, J NUTR BIOCHEM, V14, P362, DOI 10.1016/S0955-2863(03)00002-0
   Egler RA, 2005, ONCOGENE, V24, P8038, DOI 10.1038/sj.onc.1208821
   Enns GM, 2003, MOL GENET METAB, V80, P11, DOI 10.1016/j.ymgme.2003.08.009
   Fleury C, 2002, BIOCHIMIE, V84, P131, DOI 10.1016/S0300-9084(02)01369-X
   Garrido C, 2006, CELL DEATH DIFFER, V13, P1423, DOI 10.1038/sj.cdd.4401950
   HATCH GM, 1993, J LIPID RES, V34, P1873
   Henry-Mowatt J, 2004, ONCOGENE, V23, P2850, DOI 10.1038/sj.onc.1207534
   KARCZEWSKI JM, 2000, ANN NY ACAD SCI, V15, P275
   Kim R, 2006, CANCER CHEMOTH PHARM, V57, P545, DOI 10.1007/s00280-005-0111-7
   Kim R, 2006, J PATHOL, V208, P319, DOI 10.1002/path.1885
   KRAJEWSKI S, 1993, CANCER RES, V53, P4701
   Kroemer G, 2005, NAT MED, V11, P725, DOI 10.1038/nm1263
   Kroemer G, 2005, NAT REV CANCER, V5, P886, DOI 10.1038/nrc1738
   Lea LJ, 2004, FOOD CHEM TOXICOL, V42, P771, DOI 10.1016/j.fct.2003.12.014
   Lemaire-Ewing S, 2005, CELL BIOL TOXICOL, V21, P97, DOI 10.1007/s10565-005-0141-2
   Lizard G, 1997, FEBS LETT, V419, P276, DOI 10.1016/S0014-5793(97)01473-7
   Maguire L, 2003, BRIT J NUTR, V90, P767, DOI 10.1079/BJN2003956
   Massey JB, 2006, CURR OPIN LIPIDOL, V17, P296, DOI 10.1097/01.mol.0000226123.17629.ab
   Miguet-Alfonsi C, 2002, BIOCHEM PHARMACOL, V64, P527, DOI 10.1016/S0006-2952(02)01110-3
   Miura Y, 2004, BIOSCI BIOTECH BIOCH, V68, P2415, DOI 10.1271/bbb.68.2415
   Prunet C, 2005, J BIOCHEM MOL TOXIC, V19, P311, DOI 10.1002/jbt.20096
   Roussi S, 2005, CELL DEATH DIFFER, V12, P128, DOI 10.1038/sj.cdd.4401530
   Ryan E, 2005, BRIT J NUTR, V94, P443, DOI 10.1079/BJN20051500
   Ryan L, 2005, BRIT J NUTR, V94, P519, DOI 10.1079/BJN20051524
   Schroepfer GJ, 2000, PHYSIOL REV, V80, P361, DOI 10.1152/physrev.2000.80.1.361
   Shimizu S, 2004, NAT CELL BIOL, V6, P1221, DOI 10.1038/ncb1192
   Tapiero H, 2003, BIOMED PHARMACOTHER, V57, P321, DOI 10.1016/S0753-3322(03)00104-5
   Touyz RM, 2004, J HYPERTENS, V22, P1141, DOI 10.1097/00004872-200406000-00015
   Tsujimoto Y, 2003, J CELL PHYSIOL, V195, P158, DOI 10.1002/jcp.10254
   Valko M, 2004, MOL CELL BIOCHEM, V266, P37, DOI 10.1023/B:MCBI.0000049134.69131.89
   van Loo G, 2001, CELL DEATH DIFFER, V8, P1136, DOI 10.1038/sj.cdd.4400944
   Wenzel U, 2004, CARCINOGENESIS, V25, P703, DOI 10.1093/carcin/bgh079
   Yu J, 2005, BIOCHEM BIOPH RES CO, V331, P851, DOI 10.1016/j.bbrc.2005.03.189
   Yuan XM, 2002, P NATL ACAD SCI USA, V99, P6286, DOI 10.1073/pnas.092135599
   Yuan XM, 2000, FREE RADICAL BIO MED, V28, P208, DOI 10.1016/S0891-5849(99)00220-8
   Zhang X, 2005, STEROIDS, V70, P896, DOI 10.1016/j.steroids.2005.06.004
NR 47
TC 55
Z9 57
U1 0
U2 12
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1360-8185
EI 1573-675X
J9 APOPTOSIS
JI Apoptosis
PD JAN
PY 2007
VL 12
IS 1
BP 87
EP 96
DI 10.1007/s10495-006-0485-y
PG 10
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 118UO
UT WOS:000242968200007
PM 17136497
DA 2022-04-25
ER

PT J
AU Murphy, A
   Costa, M
AF Murphy, Anthony
   Costa, Max
TI Nuclear protein 1 imparts oncogenic potential and chemotherapeutic
   resistance in cancer
SO CANCER LETTERS
LA English
DT Review
DE NUPR1; Chemotherapeutic resistance; Breast cancer; Lung cancer;
   Colorectal cancer
ID HUMAN BREAST-CANCER; P8 MESSENGER-RNA; TRANSCRIPTION FACTORS; TUMOR
   PROGRESSION; CELL GROWTH; EXPRESSION; NUPR1; STRESS; METASTASIS;
   COM-1/P8
AB Nuclear protein 1 (NUPR1) also known as p8 and candidate of metastasis 1 (COM1) functions as a transcriptional regulator, and plays a role in cell cycle, DNA damage response, apoptosis, autophagy, and chromatin remodeling in response to various cellular stressors. Since it was first suggested to contribute to cancer development and progression in 1999, a number of studies have sought to reveal its function. However, NUPR1 and its biological relevance in cancer have proven difficult to pinpoint. Based on evidence of NUPR1 expression in cancers, its function extends from carcinogenesis and tumorigenesis to metastasis and chemotherapeutic resistance. A tumor suppressive function of NUPR1 has also been documented in multiple cancers. By and large, literature involving NUPR1 and cancer is confined to pancreatic and breast cancers, yet significant progress has been made with respect to NUPR1 expression and its function in lung, colorectal, blood, and prostate cancers, among others. Recent evidence strongly supports the notion that NUPR1 is key in chemotherapeutic resistance by mediating both anti-apoptotic activity and autophagy when challenged with anti-cancer compounds. Therefore, it is of significant importance to understand the broad range of molecular functions directed by NUPR1. In this review, NUPR1 expression and its role in breast, lung, and colorectal cancer development and progression will be addressed.
C1 [Murphy, Anthony; Costa, Max] NYU, Sch Med, Dept Environm Med, New York, NY 10003 USA.
RP Costa, M (corresponding author), 341 East 25th St, New York, NY 10016 USA.
EM Anthony.Murphy@nyumc.org; Max.Costa@nyumc.org
OI Murphy, Anthony/0000-0002-0967-2896
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [ES000260, ES022935, ES023174,
   ES026138]
FX This research was funded by the following NIH grants: ES000260,
   ES022935, ES023174, ES026138.
CR Aguado-Llera D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078101
   Averous J, 2011, BIOCHEM BIOPH RES CO, V413, P24, DOI 10.1016/j.bbrc.2011.08.028
   Bos PD, 2009, NATURE, V459, P1005, DOI 10.1038/nature08021
   Bratland A, 2000, CANCER RES, V60, P5578
   BRUNNER N, 1993, CANCER RES, V53, P3229
   Cano CE, 2011, J CELL PHYSIOL, V226, P1439, DOI 10.1002/jcp.22324
   Carracedo A, 2006, CANCER CELL, V9, P301, DOI 10.1016/j.ccr.2006.03.005
   Chen DQ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157317
   Chen SS, 2015, CANCER BIOL THER, V16, P770, DOI 10.1080/15384047.2015.1026477
   Chowdhury U, 2009, CANCER METAST REV, V28, P225, DOI 10.1007/s10555-009-9183-x
   Clark DW, 2008, CURR CANCER DRUG TAR, V8, P421, DOI 10.2174/156800908785133196
   Dai XF, 2017, J CANCER, V8, P3131, DOI 10.7150/jca.18457
   Davies Mansel L., 2010, Cancer Genomics & Proteomics, V7, P75
   Encinar JA, 2001, J BIOL CHEM, V276, P2742, DOI 10.1074/jbc.M008594200
   Feng ZZ, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-1046-3
   Fish L, 2018, NAT MED, V24, P1743, DOI 10.1038/s41591-018-0230-4
   Garcia-Montero A, 2001, EUR J CELL BIOL, V80, P720, DOI 10.1078/0171-9335-00209
   Garcia-Montero AC, 2001, BIOCHEM J, V357, P249, DOI 10.1042/0264-6021:3570249
   Gironella M, 2009, J CELL PHYSIOL, V221, P594, DOI 10.1002/jcp.21889
   Glick D, 2010, J PATHOL, V221, P3, DOI 10.1002/path.2697
   Goruppi S, 2004, J BIOL CHEM, V279, P20950, DOI 10.1074/jbc.M312401200
   Goruppi S, 2007, MOL CELL BIOL, V27, P993, DOI 10.1128/MCB.00996-06
   Grasso D, 2015, SCI REP-UK, V5, DOI 10.1038/srep17549
   Guo XT, 2012, ANAT REC, V295, P2114, DOI 10.1002/ar.22571
   Heppner GH, 2000, BREAST CANCER RES, V2, P331
   Hoffmeister A, 2002, J BIOL CHEM, V277, P22314, DOI 10.1074/jbc.M201657200
   Hollern DP, 2014, MOL CELL BIOL, V34, P3229, DOI 10.1128/MCB.00737-14
   Ito Y, 2005, ANTICANCER RES, V25, P833
   Jiang WG, 2005, INT J CANCER, V117, P730, DOI 10.1002/ijc.21221
   Jiang WG, 2005, BIOCHEM BIOPH RES CO, V330, P253, DOI 10.1016/j.bbrc.2005.02.157
   Jiang YF, 1999, BIOCHEM BIOPH RES CO, V260, P686, DOI 10.1006/bbrc.1999.0953
   Jin HJ, 2009, ENVIRON RES LETT, V4, DOI 10.1088/1748-9326/4/4/045206
   Jung SH, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-382
   Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6
   Kent LN, 2019, NAT REV CANCER, V19, P326, DOI 10.1038/s41568-019-0143-7
   Kinyamu HK, 2020, J BIOL CHEM, V295, P1271, DOI 10.1074/jbc.RA119.011174
   Li X, 2012, ANTICANCER RES, V32, P1229
   Li YZ, 2020, ONCOL REP, V43, P681, DOI 10.3892/or.2020.7455
   MacLeod RAF, 1999, INT J CANCER, V83, P555
   Malicet C, 2006, P NATL ACAD SCI USA, V103, P2671, DOI 10.1073/pnas.0508955103
   Malicet C, 2006, BIOCHEM BIOPH RES CO, V339, P284, DOI 10.1016/j.bbrc.2005.11.018
   Mallo GV, 1997, J BIOL CHEM, V272, P32360, DOI 10.1074/jbc.272.51.32360
   Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799
   Mu YC, 2018, AUTOPHAGY, V14, P654, DOI 10.1080/15548627.2017.1338556
   NAUNDORF H, 1992, BREAST CANCER RES TR, V23, P87, DOI 10.1007/BF01831480
   Neira JL, 2019, BBA-PROTEINS PROTEOM, V1867, DOI 10.1016/j.bbapap.2019.07.005
   Neira JL, 2017, SCI REP-UK, V7, DOI 10.1038/srep39732
   Olsen JG, 2017, CELL MOL LIFE SCI, V74, P3175, DOI 10.1007/s00018-017-2560-7
   Oxelmark E, 2006, MOL CELL BIOL, V26, P5205, DOI 10.1128/MCB.00009-06
   Qian K, 2019, J CELL BIOCHEM, V120, P15756, DOI 10.1002/jcb.28845
   Ree AH, 1999, CANCER RES, V59, P4675
   Ree AH, 2000, CLIN CANCER RES, V6, P1778
   Ree AH, 2002, ANTICANCER RES, V22, P1949
   Rehn Alexandra Beatrice, 2015, Subcell Biochem, V78, P113, DOI 10.1007/978-3-319-11731-7_6
   Santofimia-Castano P, 2019, J CLIN INVEST, V129, P2500, DOI 10.1172/JCI127223
   Santofimia-Castano P, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-35020-3
   Santofimia-Castano P, 2017, P NATL ACAD SCI USA, V114, pE6332, DOI 10.1073/pnas.1619932114
   Schroll MM, 2017, J PROTEOME RES, V16, P3009, DOI 10.1021/acs.jproteome.7b00293
   Shekhar MPV, 2013, ONCOTARGET, V4, P231, DOI 10.18632/oncotarget.818
   Shi Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051076
   Simpson NE, 2010, CANCER RES, V70, P8446, DOI 10.1158/0008-5472.CAN-10-1590
   Solzak JP, 2020, CANCER RES, V80, DOI 10.1158/1538-7445.SABCS19-P3-10-12
   Subik K, 2010, BREAST CANCER-BASIC, V4, P35
   Sui X, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.350
   Urra H, 2016, TRENDS CANCER, V2, P252, DOI 10.1016/j.trecan.2016.03.007
   Urrutia R, 2014, J MOL MODEL, V20, DOI 10.1007/s00894-014-2357-7
   Valacco MP, 2006, J CELL BIOCHEM, V97, P1066, DOI 10.1002/jcb.20682
   Vincent AJ, 2012, FEBS LETT, V586, P3429, DOI 10.1016/j.febslet.2012.07.063
   Wang LQ, 2019, INT J BIOCHEM CELL B, V106, P46, DOI 10.1016/j.biocel.2018.09.015
   Yeh CT, 2012, AM J RESP CRIT CARE, V186, P1180, DOI 10.1164/rccm.201207-1180OC
   Zhong CH, 2019, J CELL PHYSIOL, V234, P15775, DOI 10.1002/jcp.28236
NR 71
TC 7
Z9 8
U1 1
U2 10
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0304-3835
EI 1872-7980
J9 CANCER LETT
JI Cancer Lett.
PD DEC 1
PY 2020
VL 494
BP 132
EP 141
DI 10.1016/j.canlet.2020.08.019
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA OF9NS
UT WOS:000581525200017
PM 32835767
OA Green Accepted
DA 2022-04-25
ER

PT J
AU Kim, CW
   HA, YJ
   Tak, KH
   Roh, SA
   Kim, SK
   Kim, SY
   Kim, YS
   Cho, DH
   Kim, JC
AF Kim, Chan Wook
   HA, Ye Jin
   Tak, Ka Hee
   Roh, Seon Ae
   Kim, Seon-Kyu
   Kim, Seon-Young
   Kim, Yong Sung
   Cho, Dong-Hyung
   Kim, Jin Cheon
TI Clinically Applicable Serum Biomarkers Among 14 Candidates Associated
   With Recurrence of Stage II and III Colorectal Cancer
SO ANTICANCER RESEARCH
LA English
DT Article
DE Colorectal cancer; biomarkers; recurrence; CEA; CKS2; OAS2; ATG5
ID CARCINOEMBRYONIC ANTIGEN; UP-REGULATION; EXPRESSION; PROGNOSIS; GENES;
   IDENTIFICATION; CLASSIFIER; AUTOPHAGY; PREDICTS; MARKERS
AB Background/Aim: We evaluated the predictive value of candidate serum biomarkers for recurrence in stage II and III colorectal cancer (CRC) after curative surgery. Patients and Methods: A total of 33 and 120 patients with CRC with or without recurrence at 5 years after curative surgery were included in the training set and the validation set, respectively. Possible serum biomarkers were examined for associations with CRC recurrence using receiver operating characteristics (ROC) curve analysis. Results: In the training set, the expression levels of the 14 biomarkers were compared according to recurrence. Among them, five biomarkers that had significantly different expression levels were validated in 60 patients with recurrence at 5 years after curative surgery and 60 patients without. Multivariate analysis showed that natural log-transformed values of carcinoembryonic antigen (CEA), cyclin-dependent kinase regulatory subunit 2 (CKS2), 2'-5'-oligoadenylate synthetase 2 (OAS2), and autophagy-related gene 5 (ATG5) in preoperative serum were significantly related to recurrence. ROC analysis showed that these biomarkers were able to discriminate patients with recurrence from those without (area under the curve=0.828, 95% confidence interval=0.755-0.990). Conclusion: Preoperative serum levels of CEA, CKS2, OAS2 and ATG5 were independent risk factors for recurrence. A combination of serum CEA, CKS2, OAS2 and ATG5 predicted tumor recurrence well in patients with stage II and III CRC.
C1 [Kim, Chan Wook; Kim, Jin Cheon] Univ Ulsan, Dept Surg, Asan Med Ctr, Coll Med, 88 Olymp Ro 43-gil, Seoul 05505, South Korea.
   [HA, Ye Jin; Tak, Ka Hee; Roh, Seon Ae] Univ Ulsan, Asan Inst Life Sci, Asan Med Ctr, Coll Med, Seoul, South Korea.
   [Kim, Seon-Kyu; Kim, Seon-Young; Kim, Yong Sung] Korea Res Inst Biosci & Biotechnol, Personalized Genom Med Res Ctr, Daejeon, South Korea.
   [Cho, Dong-Hyung] Kyungpook Natl Univ, Sch Life Sci, Daegu, South Korea.
RP Kim, JC (corresponding author), Univ Ulsan, Dept Surg, Asan Med Ctr, Coll Med, 88 Olymp Ro 43-gil, Seoul 05505, South Korea.
EM jckim@amc.seoul.kr
OI Kim, Seon-Kyu/0000-0002-4176-5187
FU National Research Foundation of Korea - Korea government (NSIT)
   [2020R1C11009345, 2017R1A2B1009062, 2016R1E1A1A02919844]
FX Statistical analyses were supervised by research associate Min Kyu Han
   at the Department of Clinical Epidemiology and Biostatistics. This study
   was cooperatively supported by grants (2020R1C11009345,
   2017R1A2B1009062, and 2016R1E1A1A02919844) from the National Research
   Foundation of Korea funded by the Korea government (NSIT).
CR Amaravadi R, 2016, GENE DEV, V30, P1913, DOI 10.1101/gad.287524.116
   An CH, 2011, PATHOL RES PRACT, V207, P433, DOI 10.1016/j.prp.2011.05.002
   [Anonymous], 2017, AM JOINT COMMITEE CA, VEighth
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
   CarpelanHolmstrom M, 1996, EUR J CANCER, V32A, P1156, DOI 10.1016/0959-8049(96)00030-5
   Cho DH, 2012, ANTICANCER RES, V32, P4091
   Cho DH, 2010, MOL MED, V16, P271, DOI 10.2119/molmed.2009.00187
   Choi JH, 2014, GASTROENT RES PRACT, V2014, DOI 10.1155/2014/179586
   Choi UY, 2015, EXP MOL MED, V47, DOI 10.1038/emm.2014.110
   Dar AA, 2016, IMMUNOLOGY, V147, P251, DOI 10.1111/imm.12560
   Domingo-Gil E, 2006, APOPTOSIS, V11, P725, DOI 10.1007/s10495-006-5541-0
   Duffy MJ, 2001, CLIN CHEM, V47, P624
   Feng X, 2002, J NEUROIMMUNOL, V129, P205, DOI 10.1016/S0165-5728(02)00182-0
   Guraya SY, 2019, CLIN COLORECTAL CANC, V18, pE223, DOI 10.1016/j.clcc.2019.01.003
   Hundt S, 2007, CANCER EPIDEM BIOMAR, V16, P1935, DOI 10.1158/1055-9965.EPI-06-0994
   Jo YK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052705
   Jung KW, 2019, CANCER RES TREAT, V51, P417, DOI 10.4143/crt.2019.138
   Kang MA, 2009, J CANCER RES CLIN, V135, P761, DOI 10.1007/s00432-008-0510-3
   Kawakami K, 2006, ONCOL REP, V16, P521
   Kim CW, 2011, ANN SURG ONCOL, V18, P3271, DOI 10.1245/s10434-011-1740-1
   Kim JC, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0202856
   Kim JC, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155160
   Kim SK, 2014, MOL ONCOL, V8, P1653, DOI 10.1016/j.molonc.2014.06.016
   Kim Y, 2009, ONCOL REP, V22, P799, DOI 10.3892/or_00000502
   Lee JL, 2019, WORLD J GASTROENTERO, V25, P1341, DOI 10.3748/wjg.v25.i11.1341
   Levy JMM, 2017, NAT REV CANCER, V17, P528, DOI 10.1038/nrc.2017.53
   MOERTEL CG, 1986, CANCER, V58, P603, DOI 10.1002/1097-0142(19860801)58:3<603::AID-CNCR2820580302>3.0.CO;2-K
   Park IJ, 2005, J KOREAN MED SCI, V20, P624, DOI 10.3346/jkms.2005.20.4.624
   Qi JJ, 2016, GUT, V65, P1690, DOI 10.1136/gutjnl-2014-307900
   Saurer L, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-14516-4
   Shen DY, 2010, LIVER INT, V30, P119, DOI 10.1111/j.1478-3231.2009.02106.x
   Wang G, 2015, TUMOR BIOL, V36, P1055, DOI 10.1007/s13277-014-2736-9
   YOUDEN WJ, 1950, CANCER-AM CANCER SOC, V3, P32, DOI 10.1002/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3
   Yu MH, 2015, AM J CANCER RES, V5, P2708
   Yu MH, 2013, ONCOL LETT, V6, P777, DOI 10.3892/ol.2013.1456
NR 35
TC 0
Z9 0
U1 1
U2 1
PU INT INST ANTICANCER RESEARCH
PI ATHENS
PA EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22,
   ATHENS 19014, GREECE
SN 0250-7005
EI 1791-7530
J9 ANTICANCER RES
JI Anticancer Res.
PD SEP
PY 2021
VL 41
IS 9
BP 4651
EP 4658
DI 10.21873/anticanres.15279
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA WZ8RL
UT WOS:000720228900008
PM 34475094
DA 2022-04-25
ER

PT J
AU Lin, G
   Hill, DK
   Andrejeva, G
   Boult, JKR
   Troy, H
   Fong, ACLFWT
   Orton, MR
   Panek, R
   Parkes, HG
   Jafar, M
   Koh, DM
   Robinson, SP
   Judson, IR
   Griffiths, JR
   Leach, MO
   Eykyn, TR
   Chung, YL
AF Lin, G.
   Hill, D. K.
   Andrejeva, G.
   Boult, J. K. R.
   Troy, H.
   Fong, A-C L. F. W. T.
   Orton, M. R.
   Panek, R.
   Parkes, H. G.
   Jafar, M.
   Koh, D-M
   Robinson, S. P.
   Judson, I. R.
   Griffiths, J. R.
   Leach, M. O.
   Eykyn, T. R.
   Chung, Y-L
TI Dichloroacetate induces autophagy in colorectal cancer cells and tumours
SO BRITISH JOURNAL OF CANCER
LA English
DT Article
DE dichloroacetate; hyperpolarised C-13-MRS; H-1-MRS; autophagy;
   monocarboxylate transporter-1 inhibitor; [1-C-13]pyruvate; pyruvate to
   lactate exchange rate
ID IN-VITRO; APOPTOSIS; PYRUVATE; GLYCOLYSIS; METABOLISM; RESISTANCE;
   MITOCHONDRIA; INHIBITION; CYTOPLASM; LACTATE
AB Background: Dichloroacetate (DCA) has been found to have antitumour properties.
   Methods: We investigated the cellular and metabolic responses to DCA treatment and recovery in human colorectal (HT29, HCT116 WT and HCT116 Bax-ko), prostate carcinoma cells (PC3) and HT29 xenografts by flow cytometry, western blotting, electron microscopy, H-1 and hyperpolarised C-13-magnetic resonance spectroscopy.
   Results: Increased expression of the autophagy markers LC3B II was observed following DCA treatment both in vitro and in vivo. We observed increased production of reactive oxygen species (ROS) and mTOR inhibition (decreased pS6 ribosomal protein and p4E-BP1 expression) as well as increased expression of MCT1 following DCA treatment. Steady-state lactate excretion and the apparent hyperpolarised [1-C-13] pyruvate-to-lactate exchange rate (k(PL)) were decreased in DCA-treated cells, along with increased NAD(+)/NADH ratios and NAD(+). Steady-state lactate excretion and k(PL) returned to, or exceeded, control levels in cells recovered from DCA treatment, accompanied by increased NAD(+) and NADH. Reduced k(PL) with DCA treatment was found in HT29 tumour xenografts in vivo.
   Conclusions: DCA induces autophagy in cancer cells accompanied by ROS production and mTOR inhibition, reduced lactate excretion, reduced k(PL) and increased NAD(+)/NADH ratio. The observed cellular and metabolic changes recover on cessation of treatment.
C1 [Lin, G.; Hill, D. K.; Andrejeva, G.; Boult, J. K. R.; Troy, H.; Fong, A-C L. F. W. T.; Orton, M. R.; Panek, R.; Parkes, H. G.; Jafar, M.; Koh, D-M; Robinson, S. P.; Leach, M. O.; Eykyn, T. R.; Chung, Y-L] Inst Canc Res London, Canc Res UK Canc Imaging Ctr, Div Radiotherapy & Imaging, Sutton SM2 5PT, Surrey, England.
   [Lin, G.; Hill, D. K.; Andrejeva, G.; Boult, J. K. R.; Troy, H.; Fong, A-C L. F. W. T.; Orton, M. R.; Panek, R.; Parkes, H. G.; Jafar, M.; Koh, D-M; Robinson, S. P.; Leach, M. O.; Eykyn, T. R.; Chung, Y-L] Royal Marsden Hosp, Sutton SM2 5PT, Surrey, England.
   [Lin, G.] Chang Gung Univ, Chang Gung Mem Hosp Linkou, Coll Med, Dept Med Imaging & Intervent, Taoyuan 333, Taiwan.
   [Judson, I. R.] Inst Canc Res London, Canc Res UK Canc Therapeut Unit, Sutton SM2 5NG, Surrey, England.
   [Griffiths, J. R.] CR UK Cambridge Inst, Li Ka Shing Ctr, Cambridge CB2 0RE, England.
   [Eykyn, T. R.] St Thomas Hosp, Kings Coll London, Rayne Inst, Div Imaging Sci & Biomed Engn, London SE1 7EH, England.
RP Leach, MO (corresponding author), Inst Canc Res London, Canc Res UK Canc Imaging Ctr, Div Radiotherapy & Imaging, Sutton SM2 5PT, Surrey, England.
EM martin.leach@icr.ac.uk; ylichung@icr.ac.uk
RI leach, martin o/C-2248-2008; Parkes, Harold G/I-7412-2012; Chung,
   Yuen-Li/K-2269-2019; Eykyn, Thomas/J-3284-2016; Lin, Gigin/A-2676-2017
OI leach, martin o/0000-0002-0756-5368; Chung, Yuen-Li/0000-0003-0807-1658;
   Eykyn, Thomas/0000-0003-1768-3808; Lin, Gigin/0000-0001-7246-1058;
   Panek, Rafal/0000-0002-9432-6698; Koh, Dow-Mu/0000-0001-7654-8011;
   Robinson, Simon/0000-0003-4101-7274; Andrejeva,
   Gabriela/0000-0002-3508-7682; Parkes, Harold/0000-0003-4981-864X; Hill,
   Deborah/0000-0002-6441-5489
FU CRUKCancer Research UK; EPSRC Cancer Imaging CentreUK Research &
   Innovation (UKRI)Engineering & Physical Sciences Research Council
   (EPSRC) [C1060/A10334]; CRUKCancer Research UK [C1060/A16464]; NHS;
   Chang Gung Medical Foundation (Taiwan) [CMRPG370441]; MRCUK Research &
   Innovation (UKRI)Medical Research Council UK (MRC) [MRC119X]; EPSRCUK
   Research & Innovation (UKRI)Engineering & Physical Sciences Research
   Council (EPSRC) [EP/H046526/1] Funding Source: UKRI; MRCUK Research &
   Innovation (UKRI)Medical Research Council UK (MRC) [G0701533] Funding
   Source: UKRI; Cancer Research UKCancer Research UK [16464, 11562]
   Funding Source: researchfish; Engineering and Physical Sciences Research
   CouncilUK Research & Innovation (UKRI)Engineering & Physical Sciences
   Research Council (EPSRC) [EP/H046526/1, GR/S23612/01] Funding Source:
   researchfish; Medical Research CouncilUK Research & Innovation
   (UKRI)Medical Research Council UK (MRC)European Commission [G0701533,
   1100738] Funding Source: researchfish; National Institute for Health
   ResearchNational Institute for Health Research (NIHR) [NF-SI-0512-10162]
   Funding Source: researchfish
FX We acknowledge the support received from the CRUK and EPSRC Cancer
   Imaging Centre in association with the MRC and Department of Health
   (England) grant C1060/A10334, CRUK grant C1060/A16464, also NHS funding
   to the NIHR Biomedical Research Centre, Chang Gung Medical Foundation
   (Taiwan) grant CMRPG370441 and MRC-funded studentship (MRC119X). MOL is
   an NIHR Senior Investigator. We thank Alice Warley at the Kings College
   London Centre for Ultrastructural Imaging (CUI) for providing facilities
   for electron microscopy.
CR Alexander A, 2010, P NATL ACAD SCI USA, V107, P4153, DOI 10.1073/pnas.0913860107
   Ayyanathan K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039949
   BOARD M, 1990, BIOCHEM J, V265, P503, DOI 10.1042/bj2650503
   Bonnet S, 2007, CANCER CELL, V11, P37, DOI 10.1016/j.ccr.2006.10.020
   Cao WG, 2008, PROSTATE, V68, P1223, DOI 10.1002/pros.20788
   Chen Y, 2009, CELL DEATH DIFFER, V16, P1040, DOI 10.1038/cdd.2009.49
   Chen YQ, 2008, AUTOPHAGY, V4, P246, DOI 10.4161/auto.5432
   Christensen CE, 2014, J BIOL CHEM, V289, P2344, DOI 10.1074/jbc.M113.498626
   Chung YL, 2008, ERNST SCHERING FOUND, V4, P55, DOI 10.1007/2789_2008_089
   Chung YL, 2003, J NATL CANCER I, V95, P1624, DOI 10.1093/jnci/djg084
   Chung YL, 2011, METABOLOMIC STUDIES, DOI [10.1002/9780470034590.emrstm1093, DOI 10.1002/9780470034590.EMRSTM1093]
   Day SE, 2007, NAT MED, V13, P1382, DOI 10.1038/nm1650
   Fiebiger W, 2011, CLIN TRANSL ONCOL, V13, P43, DOI 10.1007/s12094-011-0615-z
   Geisler S, 2010, NAT CELL BIOL, V12, P119, DOI 10.1038/ncb2012
   Golman K, 2006, CANCER RES, V66, P10855, DOI 10.1158/0008-5472.CAN-06-2564
   Golman K, 2006, P NATL ACAD SCI USA, V103, P11270, DOI 10.1073/pnas.0601319103
   Han J, 2008, J BIOL CHEM, V283, P19665, DOI 10.1074/jbc.M710169200
   Harris T, 2009, P NATL ACAD SCI USA, V106, P18131, DOI 10.1073/pnas.0909049106
   Hill DK, 2013, NMR BIOMED, V26, P1321, DOI 10.1002/nbm.2957
   Hill DK, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0071996, 10.1371/journal.pone.0074627]
   Jung CH, 2010, FEBS LETT, V584, P1287, DOI 10.1016/j.febslet.2010.01.017
   Kroemer G, 2010, MOL CELL, V40, P280, DOI 10.1016/j.molcel.2010.09.023
   Kumar A, 2012, CHEM-BIOL INTERACT, V199, P29, DOI 10.1016/j.cbi.2012.06.005
   Kumar K, 2013, J MOL MED, V91, P749, DOI 10.1007/s00109-013-0996-2
   Lin GH, 2014, J COMB OPTIM, V27, P1, DOI 10.1007/s10878-013-9600-5
   Liu LP, 2008, J BIOL CHEM, V283, P31153, DOI 10.1074/jbc.M805056200
   Madhok BM, 2010, BRIT J CANCER, V102, P1746, DOI 10.1038/sj.bjc.6605701
   Michelakis ED, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000677
   Narendra DP, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000298
   Park JM, 2013, NEURO-ONCOLOGY, V15, P433, DOI 10.1093/neuonc/nos319
   Rabinowitz JD, 2010, SCIENCE, V330, P1344, DOI 10.1126/science.1193497
   Rzymski T, 2009, CELL CYCLE, V8, P3838, DOI 10.4161/cc.8.23.10086
   Sanchez WY, 2013, BRIT J CANCER, V108, P1624, DOI 10.1038/bjc.2013.120
   Santidrian AF, 2013, J CLIN INVEST, V123, P1068, DOI 10.1172/JCI64264
   Scherz-Shouval R, 2007, EMBO J, V26, P1749, DOI 10.1038/sj.emboj.7601623
   Seth P, 2011, NEOPLASIA, V13, P60, DOI 10.1593/neo.101020
   Shen YC, 2013, BRIT J CANCER, V108, P72, DOI 10.1038/bjc.2012.559
   Sitter B, 2002, NMR BIOMED, V15, P327, DOI 10.1002/nbm.775
   Sun RC, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-142
   Sun RC, 2010, BREAST CANCER RES TR, V120, P253, DOI 10.1007/s10549-009-0435-9
   Sun WY, 2009, CLIN CANCER RES, V15, P476, DOI 10.1158/1078-0432.CCR-08-0930
   Tong JT, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/740564
   Tyagi RK, 1996, MAGN RESON MED, V35, P194, DOI 10.1002/mrm.1910350210
   Ward CS, 2010, CANCER RES, V70, P1296, DOI 10.1158/0008-5472.CAN-09-2251
   WILLIAMSON DH, 1967, BIOCHEM J, V103, P514, DOI 10.1042/bj1030514
   Witney TH, 2011, J BIOL CHEM, V286, P24572, DOI 10.1074/jbc.M111.237727
   Wong CH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009996
   Workman P, 2010, BRIT J CANCER, V102, P1555, DOI 10.1038/sj.bjc.6605642
   Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989
NR 49
TC 46
Z9 48
U1 1
U2 17
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0007-0920
EI 1532-1827
J9 BRIT J CANCER
JI Br. J. Cancer
PD JUL 15
PY 2014
VL 111
IS 2
BP 375
EP 385
DI 10.1038/bjc.2014.281
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA AL5LX
UT WOS:000339176300019
PM 24892448
OA hybrid, Green Published
DA 2022-04-25
ER

PT J
AU Chang, YT
   Tseng, HC
   Huang, CC
   Chen, YP
   Chiang, HC
   Chou, FP
AF Chang, Ying-Tse
   Tseng, Hsien-Chun
   Huang, Chi-Chou
   Chen, Ya-Pei
   Chiang, Huei-Ching
   Chou, Fen-Pi
TI Relative down-regulation of apoptosis and autophagy genes in colorectal
   cancer
SO EUROPEAN JOURNAL OF CLINICAL INVESTIGATION
LA English
DT Article
DE Gene expression; programmed cell death; RT-qPCR
ID EXPRESSION; YEAST; CELL; MACROAUTOPHAGY; INHIBITION; PATHWAYS; BECLIN-1;
   PROTEIN; GROWTH; DEATH
AB P>Background
   Cancer is often caused by disturbance in the regulation and/or execution of programmed cell death (PCD, including apoptosis and autophagy). Our aim was to investigate these two pathways simultaneously in the same samples to understand further the pathological roles of PCDs in colorectal cancer.
   Materials and methods
   Real time quantitative PCR (RT-qPCR) array was used to analyse the mRNA levels of 22 apoptosis and autophagy-related genes involved in pro- and anti-action of the pathways in 15 paired (tumour and non-cancerous part) colorectal samples using Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) as the reference gene.
   Results
   GAPDH mRNA content was significantly higher (approximately 4 center dot 01 fold) in tumour tissue than that of paired non-cancerous part. The absolute mRNA levels for most of the 22 genes were higher in the tumour tissue also. However, after normalization with GAPDH Ct, the expressions of all the analysed genes were decreased in the tumour tissues, except for damage-regulated autophagy modulator (DRAM). The expression of most of the genes involved in the same pathway was closely correlated to each other in both tumour and non-cancerous tissues, and the correlation of tumour necrosis factor receptor (TNFR) and Akt to other genes in the same pathway was increased in tumour tissues.
   Conclusions
   The high level expression of GAPDH might reflect the metabolic state of cancer cells, and PCDs were down-regulated in the tumour tissues when metabolic state was taken into consideration. This relative suppression of PCDs in tumour tissue is supposed to be in favour of cancer cell survival.
C1 [Chang, Ying-Tse] Tungs Taichung Metro Harbor Hosp, Div Gastroenterol, Taichung Cty, Taiwan.
   [Tseng, Hsien-Chun; Chen, Ya-Pei; Chou, Fen-Pi] Chung Shan Med Univ Hosp, Coll Med, Inst Biochem & Biotechnol, Taichung, Taiwan.
   [Tseng, Hsien-Chun; Chou, Fen-Pi] Chung Shan Med Univ Hosp, Dept Radiat Oncol, Taichung, Taiwan.
   [Huang, Chi-Chou] Chung Shan Med Univ Hosp, Dept Colorectal Surg, Taichung, Taiwan.
   [Chiang, Huei-Ching] Chung Shan Med Univ Hosp, Dept Pathol, Taichung, Taiwan.
RP Chou, FP (corresponding author), Chung Shan Med Univ, Inst Biochem & Biotechnol, 110,Sec 1,Jianguo N Rd, Taichung 402, Taiwan.
EM fpchou@csmu.edu.tw
FU Chung Shan Medical University, Taichung, Taiwan [CSMU-TTM-097-003];
   Tungs' Taichung Metro Harbor Hospital, Taichung County, Taiwan
FX This work was supported by the grant (CSMU-TTM-097-003) funded by Chung
   Shan Medical University, Taichung, Taiwan, and Tungs' Taichung Metro
   Harbor Hospital, Taichung County, Taiwan. All authors have nothing to
   declare for interest conflict and financial disclosure.
CR Ahn CH, 2007, APMIS, V115, P1344, DOI 10.1111/j.1600-0463.2007.00858.x
   Bursch W, 2000, J CELL SCI, V113, P1189
   Coppola D, 2008, CANCER-AM CANCER SOC, V113, P2665, DOI 10.1002/cncr.23892
   Degterev A, 2003, ONCOGENE, V22, P8543, DOI 10.1038/sj.onc.1207107
   Eisenberg-Lerner A, 2009, CELL DEATH DIFFER, V16, P966, DOI 10.1038/cdd.2009.33
   Elmore SP, 2001, FASEB J, V15, P2286, DOI 10.1096/fj.01-0206fje
   Giannopoulou E, 2009, ANTICANCER RES, V29, P5077
   Hector S, 2009, BBA-REV CANCER, V1795, P117, DOI 10.1016/j.bbcan.2008.12.002
   Huber HJ, 2007, BIOINFORMATICS, V23, P648, DOI 10.1093/bioinformatics/btl684
   Igney FH, 2002, NAT REV CANCER, V2, P277, DOI 10.1038/nrc776
   Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720
   Kanzawa T, 2004, CELL DEATH DIFFER, V11, P448, DOI 10.1038/sj.cdd.4401359
   Kelekar A, 2005, ANN NY ACAD SCI, V1066, P259, DOI 10.1196/annals.1363.015
   King A, 2009, CURR OPIN CELL BIOL, V21, P885, DOI 10.1016/j.ceb.2009.09.009
   Klionsky DJ, 2007, AUTOPHAGY, V3, P181, DOI 10.4161/auto.3678
   Klionsky DJ, 2003, DEV CELL, V5, P539, DOI 10.1016/S1534-5807(03)00296-X
   Lee IT, 2010, J CELL PHYSIOL, V224, P454, DOI 10.1002/jcp.22142
   Li BX, 2009, AUTOPHAGY, V5, P303, DOI 10.4161/auto.5.3.7491
   Li J, 2010, EUR J CANCER, V46, P1900, DOI 10.1016/j.ejca.2010.02.021
   Meijer AJ, 2004, INT J BIOCHEM CELL B, V36, P2445, DOI 10.1016/j.biocel.2004.02.002
   Mizushima N, 2004, MOL BIOL CELL, V15, P1101, DOI 10.1091/mbc.E03-09-0704
   Petiot A, 2000, J BIOL CHEM, V275, P992, DOI 10.1074/jbc.275.2.992
   Rehm M, 2006, EMBO J, V25, P4338, DOI 10.1038/sj.emboj.7601295
   Rivas MA, 2008, EXP CELL RES, V314, P509, DOI 10.1016/j.yexcr.2007.10.005
   Scarlatti F, 2004, J BIOL CHEM, V279, P18384, DOI 10.1074/jbc.M313561200
   Scorrano L, 2003, BIOCHEM BIOPH RES CO, V304, P437, DOI 10.1016/S0006-291X(03)00615-6
   Takei Y, 2008, MOL BIOL CELL, V19, P855, DOI 10.1091/mbc.E07-06-0624
   Tanida I, 2004, INT J BIOCHEM CELL B, V36, P2503, DOI 10.1016/j.biocel.2004.05.009
   Tennant DA, 2009, CARCINOGENESIS, V30, P1269, DOI 10.1093/carcin/bgp070
   TSUKADA M, 1993, FEBS LETT, V333, P169, DOI 10.1016/0014-5793(93)80398-E
   Twomey C, 2005, J CELL MOL MED, V9, P345, DOI 10.1111/j.1582-4934.2005.tb00360.x
NR 31
TC 15
Z9 16
U1 0
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0014-2972
EI 1365-2362
J9 EUR J CLIN INVEST
JI Eur. J. Clin. Invest.
PD JAN
PY 2011
VL 41
IS 1
BP 84
EP 92
DI 10.1111/j.1365-2362.2010.02383.x
PG 9
WC Medicine, General & Internal; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine; Research & Experimental Medicine
GA 691WA
UT WOS:000285110300012
PM 20880300
DA 2022-04-25
ER

PT J
AU Saporita, AJ
   Maggi, LB
   Apicelli, AJ
   Weber, JD
AF Saporita, Anthony J.
   Maggi, Leonard B., Jr.
   Apicelli, Anthony J.
   Weber, Jason D.
TI Therapeutic targets in the ARF tumor suppressor pathway
SO CURRENT MEDICINAL CHEMISTRY
LA English
DT Review
DE ARF; Mdm2; p53; nucleophosmin; nucleolus; ribosome biogenesis
ID SQUAMOUS-CELL CARCINOMA; ACUTE LYMPHOBLASTIC-LEUKEMIA; HUMAN
   HEPATOCELLULAR-CARCINOMA; ABERRANT PROMOTER METHYLATION; ACUTE
   MYELOGENOUS LEUKEMIA; NERVOUS-SYSTEM LYMPHOMAS; CPG ISLAND METHYLATION;
   HUMAN BLADDER-CANCER; HUMAN COLON-CANCER; WILD-TYPE P53
AB One of the outstanding fundamental questions in cancer cell biology concerns how cells coordinate cellular growth (or macromolecular synthesis) with cell cycle progression and mitosis. Intuitively, rapidly dividing cells must have some control over these processes; otherwise cells would continue to shrink in volume with every passing cycle, similar to the cytoreductive divisions seen in the very early stagges of embryogenesis. The problem is easily solved in unicellular organisms, such as yeast, as their growth rates are entirely dependent on nutrient availability. Multicellular organisms Such as mammals, however, must have acquired additional levels of control, as nutrient availability is seldom an issue and the organism has a prodigious capacity to store necessary metabolites in the form of glycogen, lipids, and protein, Furthermore, the specific needs and specialized architecture of tissues must constrain growth for growth's sake; if not, the necessary function of the organ could be lost. While certainly a myriad of mechanisms for preventing this exist via initiating cell death (e.g. apoptosis, autophagy, necrosis), these all depend on some external cue; such as death signals, hypoxia, lack of nutrients or survival signals. However there must also be some cell autonomous method for surveying against inappropriate growth signals (such as oncogenic stress) that occur in a stochastic fashion, possibly as a result of random mutations. The ARF tumor suppressor seems to Fulfill that role, as its expression is near undetectable in normal tissues, yet is potently induced by oncogenic stress (such as overexpression of oncogenic Ras or myc). As a result of induced expression of ARF, the tumor suppressor protein p53 is stabilized and promotes cell cycle arrest. Mutations or epiggenetic alterations of the INK4a/Arflocus are second only to p53 mutations in cancer cells, and in some cancers, alterations in both Arf and p53 observed, suggesting that these two tumor suppressors act coordinately to prevent unwarranted cell growth and proliferation. The aim of this review is to characterize the current knowledge in the field about both p53-dependent and independent functions of ARF as well as to summarize the present models for how ARF might control rates of cell proliferation and/or macromolecular synthesis. We will discuss potential therapeutic targets in the ARF pathway, and some preliminary attempts at enhancing or restoring the activity of this important tumor suppressor.
C1 Washington Univ, Sch Med, Siteman Canc Ctr, Dept Internal Med,Div Mol Oncol, St Louis, MO 63110 USA.
   Washington Univ, Sch Med, Siteman Canc Ctr, Dept Cell Biol,Div Mol Oncol, St Louis, MO 63110 USA.
RP Weber, JD (corresponding author), Washington Univ, Sch Med, Dept Internal Med, Div Mol Oncol, St Louis, MO 63110 USA.
EM jweber@im.wustl.edu
RI Maggi, Leonard/L-5217-2019; Apicelli, Anthony/AAB-8879-2021
OI Maggi, Leonard/0000-0003-0138-0984; Apicelli,
   Anthony/0000-0001-6791-8113; Weber, Jason/0000-0002-1069-6983
FU NCI NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)
   [T32CA11327501] Funding Source: Medline; NIGMS NIH HHSUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of General Medical Sciences (NIGMS)
   [R01GM066032, R01 GM066032-05, R01 GM066032] Funding Source: Medline;
   NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department
   of Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of General Medical Sciences (NIGMS) [R01GM066032]
   Funding Source: NIH RePORTER
CR Alonso ME, 2003, CANCER GENET CYTOGEN, V144, P134, DOI 10.1016/S0165-4608(02)00928-7
   Amatya VJ, 2005, ACTA NEUROPATHOL, V110, P178, DOI 10.1007/s00401-005-1041-5
   Amatya VJ, 2004, MODERN PATHOL, V17, P705, DOI 10.1038/modpathol.3800111
   Anzola M, 2004, EUR J GASTROEN HEPAT, V16, P19, DOI 10.1097/00042737-200401000-00004
   Ayrault O, 2004, ONCOGENE, V23, P8097, DOI 10.1038/sj.onc.1207968
   Baek MJ, 2000, CANCER, V89, P60, DOI 10.1002/1097-0142(20000701)89:1<60::AID-CNCR9>3.0.CO;2-3
   Bernardi R, 2004, NAT CELL BIOL, V6, P665, DOI 10.1038/ncb1147
   Bertwistle D, 2004, MOL CELL BIOL, V24, P985, DOI 10.1128/MCB.24.3.985-996.2004
   Bjornsti MA, 2004, NAT REV CANCER, V4, P335, DOI 10.1038/nrc1362
   Blokx WAM, 2005, AM J SURG PATHOL, V29, P125, DOI 10.1097/01.pas.0000146003.00727.7a
   BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9
   Bostrom J, 2001, AM J PATHOL, V159, P661, DOI 10.1016/S0002-9440(10)61737-3
   Brady SN, 2004, MOL CELL BIOL, V24, P9327, DOI 10.1128/MCB.24.21.9327-9338.2004
   Brown VL, 2004, J INVEST DERMATOL, V122, P1284, DOI 10.1111/j.0022-202X.2004.22501.x
   Brucher BLDM, 2006, INT J CANCER, V119, P1298, DOI 10.1002/ijc.21990
   Burri N, 2001, LAB INVEST, V81, P217, DOI 10.1038/labinvest.3780230
   Cairns P, 2004, ANN NY ACAD SCI, V1022, P40, DOI 10.1196/annals.1318.007
   Carmo-Fonseca M, 2000, NAT CELL BIOL, V2, pE107, DOI 10.1038/35014078
   Carrasco DR, 2006, CANCER CELL, V9, P379, DOI 10.1016/j.ccr.2006.03.028
   Chang LL, 2003, J UROLOGY, V170, P595, DOI 10.1097/01.ju.0000067626.37837.3e
   Chapman EJ, 2005, CLIN CANCER RES, V11, P5740, DOI 10.1158/1078-0432.CCR-05-0411
   Chen DL, 2005, CELL, V121, P1071, DOI 10.1016/j.cell.2005.03.037
   Christophorou MA, 2006, NATURE, V443, P214, DOI 10.1038/nature05077
   Christophorou MA, 2005, NAT GENET, V37, P718, DOI 10.1038/ng1572
   Colombo E, 2006, CANCER RES, V66, P3044, DOI 10.1158/0008-5472.CAN-05-2378
   Colombo E, 2005, MOL CELL BIOL, V25, P8874, DOI 10.1128/MCB.25.20.8874-8886.2005
   Dasgupta B, 2005, CANCER RES, V65, P2755, DOI 10.1158/0008-5472.CAN-04-4058
   Datta A, 2005, MOL CELL BIOL, V25, P8024, DOI 10.1128/MCB.25.18.8024-8036.2005
   Datta A, 2004, J BIOL CHEM, V279, P36698, DOI 10.1074/jbc.M312305200
   Datta K, 2001, CANCER RES, V61, P1768
   Daujat S, 2001, TRENDS GENET, V17, P459, DOI 10.1016/S0168-9525(01)02369-1
   David-Pfeuty T, 2002, ONCOGENE, V21, P6779, DOI 10.1038/sj.onc.1205871
   den Besten W, 2005, CELL CYCLE, V4, P1593
   DiGiammarino EL, 2001, BIOCHEMISTRY-US, V40, P2379, DOI 10.1021/bi0024005
   Dominguez G, 2003, MUTAT RES-FUND MOL M, V530, P9, DOI 10.1016/S0027-5107(03)00133-7
   Dominguez G, 2002, CLIN CANCER RES, V8, P980
   Dulaimi E, 2004, CLIN CANCER RES, V10, P3972, DOI 10.1158/1078-0432.CCR-04-0175
   Efeyan A, 2006, NATURE, V443, P159, DOI 10.1038/443159a
   Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658
   Esteller M, 2000, CANCER RES, V60, P129
   Faderl S, 2000, CANCER, V89, P1976, DOI 10.1002/1097-0142(20001101)89:9<1976::AID-CNCR14>3.3.CO;2-E
   Faderl S, 1999, CLIN CANCER RES, V5, P1855
   Faderl S, 1999, CYTOKINES CELL MOL T, V5, P159
   Falini B, 2005, NEW ENGL J MED, V352, P254, DOI 10.1056/NEJMoa041974
   Fingar DC, 2004, ONCOGENE, V23, P3151, DOI 10.1038/sj.onc.1207542
   FitzGerald MG, 1996, P NATL ACAD SCI USA, V93, P8541, DOI 10.1073/pnas.93.16.8541
   Frank AJ, 2004, MOL BRAIN RES, V121, P137, DOI 10.1016/j.molbrainres.2003.11.016
   Fulci G, 2000, ONCOGENE, V19, P3816, DOI 10.1038/sj.onc.1203700
   Furonaka O, 2004, PATHOL INT, V54, P549, DOI 10.1111/j.1440-1827.2004.01663.x
   Ganguli G, 2003, MOL CANCER RES, V1, P1027
   Gardie B, 1998, BLOOD, V91, P1016, DOI 10.1182/blood.V91.3.1016.1016_1016_1020
   Ghimenti C, 2003, J NEURO-ONCOL, V61, P95, DOI 10.1023/A:1022127302008
   Godraind C, 2003, NEUROPATH APPL NEURO, V29, P462, DOI 10.1046/j.1365-2990.2003.00484.x
   Gonzalez-Gomez P, 2004, INT J MOL MED, V13, P93
   Gonzalez-Gomez P, 2003, ONCOL REP, V10, P1519
   Grafstrom E, 2005, CLIN CANCER RES, V11, P2991, DOI 10.1158/1078-0432.CCR-04-1731
   Grisendi S, 2005, NATURE, V437, P147, DOI 10.1038/nature03915
   Grisendi S, 2006, NAT REV CANCER, V6, P493, DOI 10.1038/nrc1885
   Groth A, 2000, J BIOL CHEM, V275, P27473
   Gutierrez MI, 2004, MODERN PATHOL, V17, P1268, DOI 10.1038/modpathol.3800177
   Hasan MK, 2002, J BIOL CHEM, V277, P37765, DOI 10.1074/jbc.M204177200
   Hashiguchi Y, 2001, HUM PATHOL, V32, P988, DOI 10.1053/hupa.2001.27115
   Hernandez L, 2005, CANCER RES, V65, P2199, DOI 10.1158/0008-5472.CAN-04-1526
   Hewitt C, 2002, HUM MOL GENET, V11, P1273, DOI 10.1093/hmg/11.11.1273
   Hofmann WK, 2001, LEUKEMIA LYMPHOMA, V42, P1107, DOI 10.3109/10428190109097731
   Hsu HS, 2004, CLIN CANCER RES, V10, P4734, DOI 10.1158/1078-0432.CCR-03-0704
   Huang HY, 2005, J CLIN ONCOL, V23, P548, DOI 10.1200/JCO.2005.02.081
   Inda MM, 2006, HISTOPATHOLOGY, V48, P579, DOI 10.1111/j.1365-2559.2006.02374.x
   Ishida E, 2005, ORAL ONCOL, V41, P614, DOI 10.1016/j.oraloncology.2005.02.003
   Itahana K, 2003, MOL CELL, V12, P1151, DOI 10.1016/S1097-2765(03)00431-3
   Ito T, 2004, J GASTROENTEROL, V39, P355, DOI 10.1007/s00535-003-1302-9
   Iwato M, 2000, CANCER RES, V60, P2113
   Jackson MW, 2001, J BIOL CHEM, V276, P25336, DOI 10.1074/jbc.M010685200
   Jarmalaite S, 2003, INT J CANCER, V106, P913, DOI 10.1002/ijc.11322
   Jefferies HBJ, 1997, EMBO J, V16, P3693, DOI 10.1093/emboj/16.12.3693
   JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0
   Judson H, 2006, J PATHOL, V210, P344, DOI 10.1002/path.2044
   Kamijo T, 1999, CANCER RES, V59, P2217
   Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3
   Kannan K, 2000, INT J ONCOL, V16, P585
   Kawada Y, 2001, JPN J CANCER RES, V92, P1293, DOI 10.1111/j.1349-7006.2001.tb02152.x
   Kawamoto K, 2006, BIOCHEM BIOPH RES CO, V339, P790, DOI 10.1016/j.bbrc.2005.11.072
   Klump B, 2003, CLIN CANCER RES, V9, P1773
   Konishi N, 2002, AM J PATHOL, V160, P1207, DOI 10.1016/S0002-9440(10)62547-3
   Korgaonkar C, 2005, MOL CELL BIOL, V25, P1258, DOI 10.1128/MCB.25.4.1258-1271.2005
   Korgaonkar C, 2002, MOL CELL BIOL, V22, P196, DOI 10.1128/MCB.22.1.196-206.2002
   Kourea HP, 1999, AM J PATHOL, V155, P1855, DOI 10.1016/S0002-9440(10)65504-6
   Kreimer-Erlacher H, 2003, J INVEST DERMATOL, V120, P676, DOI 10.1046/j.1523-1747.2003.12085.x
   Kubo Y, 1997, BIOCHEM BIOPH RES CO, V232, P38, DOI 10.1006/bbrc.1997.6217
   Labuhn M, 2001, ONCOGENE, V20, P1103, DOI 10.1038/sj.onc.1204197
   Landi MT, 2004, J MED GENET, V41, P557, DOI 10.1136/jmg.2003.016907
   Lang JC, 2002, INT J ONCOL, V21, P401
   Laud K, 2006, J MED GENET, V43, P39, DOI 10.1136/jmg.2005.033498
   Lee C, 2005, CANCER RES, V65, P9834, DOI 10.1158/0008-5472.CAN-05-1759
   Lee M, 2006, PATHOL RES PRACT, V202, P415, DOI 10.1016/j.prp.2005.11.011
   Liggett WH, 1996, CANCER RES, V56, P4119
   Lim KP, 2005, ONCOL REP, V14, P963
   Lind GE, 2004, MOL CANCER, V3, DOI 10.1186/1476-4598-3-28
   Llanos S, 2001, NAT CELL BIOL, V3, P445, DOI 10.1038/35074506
   Lohrum MAE, 2000, CURR BIOL, V10, P539, DOI 10.1016/S0960-9822(00)00472-3
   Lohrum MAE, 2000, NAT CELL BIOL, V2, P179, DOI 10.1038/35004057
   LUNA RMD, 1995, NATURE, V378, P203
   Maggi LB, 2005, CANCER INVEST, V23, P599, DOI 10.1080/07357900500283085
   McDonnell TJ, 1999, J PATHOL, V188, P322, DOI 10.1002/(SICI)1096-9896(199907)188:3<322::AID-PATH372>3.0.CO;2-F
   McKeller RN, 2002, P NATL ACAD SCI USA, V99, P3848, DOI 10.1073/pnas.052484199
   Midgley CA, 2000, ONCOGENE, V19, P2312, DOI 10.1038/sj.onc.1203593
   Momand J, 1998, NUCLEIC ACIDS RES, V26, P3453, DOI 10.1093/nar/26.15.3453
   Morris MR, 2003, ONCOGENE, V22, P6794, DOI 10.1038/sj.onc.1206914
   Nagy E, 2003, EUR J CANCER, V39, P2298, DOI 10.1016/S0959-8049(03)00552-5
   Nakamura M, 2001, CANCER RES, V61, P6335
   Nakamura M, 2001, BRAIN PATHOL, V11, P159
   Nakamura M, 2006, ONCOLOGY-BASEL, V70, P212, DOI 10.1159/000094322
   Newcomb EW, 2000, HUM PATHOL, V31, P115, DOI 10.1016/S0046-8177(00)80207-5
   Nicholson SA, 2001, CANCER RES, V61, P5636
   Nishimine M, 2003, ONCOL REP, V10, P555
   Oda Y, 2005, J PATHOL, V207, P410, DOI 10.1002/path.1848
   Oh JH, 2006, CLIN ORTHOP RELAT R, P216, DOI 10.1097/01.blo.0000188063.56091.69
   Okuda M, 2000, CELL, V103, P127, DOI 10.1016/S0092-8674(00)00093-3
   Orlow I, 1999, AM J PATHOL, V155, P105, DOI 10.1016/S0002-9440(10)65105-X
   Paliwal S, 2006, MOL CELL BIOL, V26, P2360, DOI 10.1128/MCB.26.6.2360-2372.2006
   Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870
   Papp T, 2001, INT J ONCOL, V18, P425
   Peng CY, 2002, ANTICANCER RES, V22, P1265
   Perrone F, 2003, INT J CANCER, V105, P196, DOI 10.1002/ijc.11062
   Perrone F, 2005, CANCER-AM CANCER SOC, V104, P159, DOI 10.1002/cncr.21113
   Perrone F, 2003, CLIN CANCER RES, V9, P4132
   Pinyol M, 2000, AM J PATHOL, V156, P1987, DOI 10.1016/S0002-9440(10)65071-7
   Plescia J, 2005, CANCER CELL, V7, P457, DOI 10.1016/j.ccr.2005.03.035
   Pollice A, 2004, J BIOL CHEM, V279, P6345, DOI 10.1074/jbc.M310957200
   Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2
   Prowse AH, 2003, J MED GENET, V40, DOI 10.1136/jmg.40.8.e102
   Puig S, 2000, MELANOMA RES, V10, P231, DOI 10.1097/00008390-200010030-00004
   QUELLE DE, 1995, CELL, V83, P993
   Quelle DE, 1997, P NATL ACAD SCI USA, V94, P669, DOI 10.1073/pnas.94.2.669
   Randerson-Moor JA, 2001, HUM MOL GENET, V10, P55, DOI 10.1093/hmg/10.1.55
   Ringshausen I, 2006, CANCER CELL, V10, P501, DOI 10.1016/j.ccr.2006.10.010
   Rizos H, 2005, CELL CYCLE, V4, P597, DOI 10.4161/cc.4.4.1588
   Rizos H, 2003, J BIOL CHEM, V278, P4981, DOI 10.1074/jbc.M210978200
   Rizos H, 2001, J BIOL CHEM, V276, P41424, DOI 10.1074/jbc.M105299200
   Rizos H, 2001, ONCOGENE, V20, P5543, DOI 10.1038/sj.onc.1204728
   Rodway H, 2004, ONCOGENE, V23, P6186, DOI 10.1038/sj.onc.1207854
   Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554
   Rousseau E, 2003, NEUROPATH APPL NEURO, V29, P574, DOI 10.1046/j.0305-1846.2003.00505.x
   Rubbi CP, 2003, EMBO J, V22, P6068, DOI 10.1093/emboj/cdg579
   Sakuma K, 2004, INT J CANCER, V112, P273, DOI 10.1002/ijc.20420
   Sarbia M, 2004, INT J CANCER, V111, P224, DOI 10.1002/ijc.20212
   Sarkar S, 2000, CANCER RES, V60, P3862
   Sato F, 2002, CANCER RES, V62, P1148
   Shahnavaz SA, 2001, CANCER RES, V61, P2371
   Shen L, 2003, GASTROENTEROLOGY, V124, P626, DOI 10.1053/gast.2003.50102
   Sherr CJ, 2006, NAT REV CANCER, V6, P663, DOI 10.1038/nrc1954
   Shintani S, 2001, ORAL ONCOL, V37, P498, DOI 10.1016/S1368-8375(00)00142-1
   Silva J, 2003, J PATHOL, V199, P289, DOI 10.1002/path.1297
   Silva J, 2001, ONCOGENE, V20, P4586, DOI 10.1038/sj.onc.1204617
   Simon M, 2001, J NEURO-ONCOL, V55, P149, DOI 10.1023/A:1013863630293
   Smeds J, 2002, CARCINOGENESIS, V23, P645, DOI 10.1093/carcin/23.4.645
   Snyder EL, 2004, PLOS BIOL, V2, P186, DOI 10.1371/journal.pbio.0020036
   Soufir N, 2000, J NATL CANCER I, V92, P1841, DOI 10.1093/jnci/92.22.1841
   Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001
   Sugimoto M, 2003, MOL CELL, V11, P415, DOI 10.1016/S1097-2765(03)00057-1
   Tago K, 2005, P NATL ACAD SCI USA, V102, P7689, DOI 10.1073/pnas.0502978102
   Takahira T, 2004, CANCER SCI, V95, P651, DOI 10.1111/j.1349-7006.2004.tb03324.x
   Tannapfel A, 2002, J PATHOL, V197, P624, DOI 10.1002/path.1139
   Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937
   Tompkins V, 2006, CELL CYCLE, V5, P641
   Tompkins VS, 2007, J BIOL CHEM, V282, P1322, DOI 10.1074/jbc.M609612200
   Tovar C, 2006, P NATL ACAD SCI USA, V103, P1888, DOI 10.1073/pnas.0507493103
   Tsuchiya T, 2000, CANCER GENET CYTOGEN, V120, P91, DOI 10.1016/S0165-4608(99)00255-1
   Tsujimoto H, 2002, PATHOL RES PRACT, V198, P785, DOI 10.1078/0344-0338-00337
   Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472
   Vieth M, 2004, VIRCHOWS ARCH, V445, P135, DOI 10.1007/s00428-004-1042-0
   Viswanathan M, 2001, ORAL ONCOL, V37, P341, DOI 10.1016/S1368-8375(00)00112-3
   Watanabe T, 2003, CLIN CANCER RES, V9, P4884
   Watanabe T, 2001, J NEUROPATH EXP NEUR, V60, P1181, DOI 10.1093/jnen/60.12.1181
   Watanabe T, 2001, ACTA NEUROPATHOL, V101, P185
   Weber A, 2003, PATHOL RES PRACT, V199, P391, DOI 10.1078/0344-0338-00435
   Weber A, 2002, VIRCHOWS ARCH, V441, P133, DOI 10.1007/s00428-002-0637-6
   Weber JD, 2000, MOL CELL BIOL, V20, P2517, DOI 10.1128/MCB.20.7.2517-2528.2000
   Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991
   Weber JD, 2000, GENE DEV, V14, P2358, DOI 10.1101/gad.827300
   Weihrauch M, 2002, HUM PATHOL, V33, P884, DOI 10.1053/hupa.2002.126880
   Wolter M, 2001, J NEUROPATH EXP NEUR, V60, P1170, DOI 10.1093/jnen/60.12.1170
   Woods YL, 2004, J BIOL CHEM, V279, P50157, DOI 10.1074/jbc.M405414200
   Xing EP, 1999, CLIN CANCER RES, V5, P2704
   Xirodimas DP, 2002, FEBS LETT, V528, P207, DOI 10.1016/S0014-5793(02)03310-0
   Yamamoto H, 2002, GENE CHROMOSOME CANC, V33, P322, DOI 10.1002/gcc.10010
   Yang B, 2005, MODERN PATHOL, V18, P412, DOI 10.1038/modpathol.3800287
   Yang YL, 2005, CANCER CELL, V7, P547, DOI 10.1016/j.ccr.2005.04.029
   Yu Y, 2006, MOL CELL BIOL, V26, P3798, DOI 10.1128/MCB.26.10.3798-3809.2006
   Zhang J, 2005, CLIN CANCER RES, V11, P6544, DOI 10.1158/1078-0432.CCR-05-0374
   Zhang SJ, 2005, CANCER SCI, V96, P38, DOI 10.1111/j.1349-7006.2005.00003.x
   Zhang YP, 1999, MOL CELL, V3, P579, DOI 10.1016/S1097-2765(00)80351-2
   Zhao L, 2003, MOL CANCER RES, V1, P195
   Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424
   Zochbauer-Muller S, 2001, CANCER RES, V61, P249
NR 195
TC 35
Z9 36
U1 0
U2 6
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 0929-8673
EI 1875-533X
J9 CURR MED CHEM
JI Curr. Med. Chem.
PY 2007
VL 14
IS 17
BP 1815
EP 1827
PG 13
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Pharmacology &
   Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
GA 186JE
UT WOS:000247774200002
PM 17627519
DA 2022-04-25
ER

PT J
AU Vigen, RA
   Kodama, Y
   Viset, T
   Fossmark, R
   Waldum, H
   Kidd, M
   Wang, TC
   Modlin, IM
   Chen, D
   Zhao, CM
AF Vigen, Reidar Alexander
   Kodama, Yosuke
   Viset, Trond
   Fossmark, Reidar
   Waldum, Helge
   Kidd, Mark
   Wang, Timothy C.
   Modlin, Irvin M.
   Chen, Duan
   Zhao, Chun-Mei
TI Immunohistochemical evidence for an impairment of autophagy in
   tumorigenesis of gastric carcinoids and adenocarcinomas in rodent models
   and patients
SO HISTOLOGY AND HISTOPATHOLOGY
LA English
DT Article
DE Cotton rats; Mastomys; INS-GAS mice; patients
ID DOUBLE-EDGED-SWORD; COTTON RATS; COLORECTAL CANCERS; CELL CARCINOMAS;
   BECLIN-1; ANTAGONIST; EXPRESSION; LOXTIDINE; APOPTOSIS; DEATH
AB Background/Aim: Autophagy has dual roles in tumorigenesis: tumor-promoting or tumor-suppressing. The aim of the present study was to examine autophagy-related markers by immunohistochemistry in gastric carcinoids and adenocarcinomas in rodent models and patients.
   Methods: Gastric carcinoids in Mastomys were induced by loxtidine treatment. Spontaneously developed gastric adenocarcinomas in Japanese cotton rats and INS-GAS transgenic mice were included. Patient tissue samples of gastric carcinoids or adenocarcinomas were collected. Immunohistochemistry was performed against autophagy-related gene protein-6 (ATG-6, also called beclin-1), ATG-5 and ATG-16.
   Results: In tumor-free Mastomys, ATG-5, ATG-16 and beclin-1 were immunepositive in the gastric mucosa. In tumor-bearing Mastomys, ATG-5 and ATG-16 were negative in the tumors, whereas beclin-1 was positive in four of five animals. In carcinoid patients, ATG-5 was negative in six of ten, ATG-16 negative in nine of ten, and beclin-1 negative in three of ten patients. In cotton rats, ATG-5 and ATG-16 were negative in all tumors. Beclin-1 was negative in three of five rats. In INS-GAS mice, ATG-5 and beclin-1 were positive in the tumor area, but the numbers of immunopositive cells per gland were reduced by about 50% in comparison with wildtype mice. In adenocarcinoma patients, ATG-5 and ATG-16 were negative in eight of ten, and beclin-1 positive in all ten patients.
   Conclusions: An impaired autophagy took place at the stage of formation of ATG-5-ATG-12-ATG-16 complex in both gastric carcinoids and adenocarcinoma of both rodent models and patients. ATG-5 and ATG-16 might be better markers than beclin-1 in assessing autophagy in these lesions.
C1 [Vigen, Reidar Alexander; Kodama, Yosuke; Fossmark, Reidar; Waldum, Helge; Chen, Duan; Zhao, Chun-Mei] Norwegian Univ Sci & Technol NTNU, Dept Canc Res & Mol Med, NO-7006 Trondheim, Norway.
   [Viset, Trond] St Olavs Univ Hosp, Dept Pathol, Trondheim, Norway.
   [Fossmark, Reidar; Waldum, Helge] St Olavs Univ Hosp, Dept Med Genet & Gastroenterol & Hepatol, Trondheim, Norway.
   [Kidd, Mark; Modlin, Irvin M.] Yale Univ, Sch Med, Dept Gastrointestinal Surg Pathobiol, New Haven, CT USA.
   [Wang, Timothy C.] Columbia Univ, Med Ctr, Dept Med, New York, NY USA.
   [Wang, Timothy C.] Columbia Univ, Med Ctr, Irving Canc Res Ctr, New York, NY USA.
RP Zhao, CM (corresponding author), Norwegian Univ Sci & Technol NTNU, Dept Canc Res & Mol Med, Erling Skjalgssons Gate 1, NO-7006 Trondheim, Norway.
EM chun-mei.zhao@ntnu.no
RI Fossmark, Reidar/AAP-6442-2021
OI Fossmark, Reidar/0000-0002-5365-9357; Waldum, Helge/0000-0002-3137-0843;
   Wang, Timothy/0000-0001-5730-3019
FU Research Council of NorwayResearch Council of Norway; Medical Faculty
   and St. Olavs' University Hospital; Liaison Committee between the
   Central Norway Regional Health Authority (RHA); Faculty of Medicine of
   NTNU; Central Norway Regional FUGE programme
FX This study was supported by grants from the Research Council of Norway
   and the Joint Programme of the Medical Faculty and St. Olavs' University
   Hospital, and the Liaison Committee between the Central Norway Regional
   Health Authority (RHA). Dr. Vigen has received a fellowship from the
   Faculty of Medicine of NTNU, and Kodama received a fellowship from
   Central Norway Regional FUGE programme. The histology was performed
   partly at the Cellular and Molecular Imaging Core Facility, NTNU.
CR Ahn CH, 2007, APMIS, V115, P1344, DOI 10.1111/j.1600-0463.2007.00858.x
   Apel A, 2009, INT J CANCER, V125, P991, DOI 10.1002/ijc.24500
   Chen N, 2010, FEBS LETT, V584, P1427, DOI 10.1016/j.febslet.2009.12.034
   Clarke PGH, 2002, TRENDS PHARMACOL SCI, V23, P308, DOI 10.1016/S0165-6147(02)02041-2
   Eisenberg-Lerner A, 2009, APOPTOSIS, V14, P376, DOI 10.1007/s10495-008-0307-5
   Fossmark R, 2005, APMIS, V113, P436, DOI 10.1111/j.1600-0463.2005.apm_134.x
   Fossmark R, 2004, CANCER RES, V64, P3687, DOI 10.1158/0008-5472.CAN-03-3647
   Fossmark R, 2004, ENDOCR-RELAT CANCER, V11, P149, DOI 10.1677/erc.0.0110149
   Furuya D, 2005, EXP CELL RES, V307, P26, DOI 10.1016/j.yexcr.2005.02.023
   Gozuacik D, 2007, CURR TOP DEV BIOL, V78, P217, DOI 10.1016/S0070-2153(06)78006-1
   Kang MR, 2009, J PATHOL, V217, P702, DOI 10.1002/path.2509
   Martinsen TC, 2003, CARCINOGENESIS, V24, P1887, DOI 10.1093/carcin/bgg156
   Marx J, 2006, SCIENCE, V312, P1160, DOI 10.1126/science.312.5777.1160
   Pavlides S, 2010, CELL CYCLE, V9, P3485, DOI 10.4161/cc.9.17.12721
   Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039
   Rosenfeldt MT, 2011, CARCINOGENESIS, V32, P955, DOI 10.1093/carcin/bgr031
   Rosenfeldt MT, 2009, EXPERT REV MOL MED, V11, DOI 10.1017/S1462399409001306
   Shen Y, 2008, AUTOPHAGY, V4, P1067, DOI 10.4161/auto.6827
   Shintani M, 2011, BIOMED RES-TOKYO, V32, P379, DOI 10.2220/biomedres.32.379
   Tu SP, 2011, CANCER RES, V71, P4247, DOI 10.1158/0008-5472.CAN-10-4009
   Vigen RA, 2012, MED MOL MORPHOL, V45, P80, DOI 10.1007/s00795-011-0544-5
   Wang TC, 2000, GASTROENTEROLOGY, V118, P36, DOI 10.1016/S0016-5085(00)70412-4
   White E, 2009, CLIN CANCER RES, V15, P5308, DOI 10.1158/1078-0432.CCR-07-5023
   Wilkinson S, 2010, CURR OPIN GENET DEV, V20, P57, DOI 10.1016/j.gde.2009.12.004
   Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100
NR 25
TC 14
Z9 14
U1 0
U2 6
PU F HERNANDEZ
PI MURCIA
PA PLAZA FUENSANTA 2-7 C, 30008 MURCIA, SPAIN
SN 0213-3911
EI 1699-5848
J9 HISTOL HISTOPATHOL
JI Histol. Histopath.
PD APR
PY 2013
VL 28
IS 4
BP 531
EP 542
PG 12
WC Cell Biology; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Pathology
GA 107BP
UT WOS:000316190000013
PM 23389729
DA 2022-04-25
ER

PT J
AU Morales, PR
   Dillehay, DL
   Moody, SJ
   Pallas, DC
   Pruett, S
   Allgood, JC
   Symolon, H
   Merrill, AH
AF Morales, Pablo R.
   Dillehay, Dirck L.
   Moody, Steven J.
   Pallas, David C.
   Pruett, Sarah
   Allgood, Jeremy C.
   Symolon, Holly
   Merrill, Alfred H., Jr.
TI Safingol toxicology after oral administration to TRAMP mice:
   Demonstration of safingol uptake and metabolism by N-acylation and
   n-methylation
SO DRUG AND CHEMICAL TOXICOLOGY
LA English
DT Article
DE cancer; hepatotoxicity; mass spectrometry; safingol; safingol
   metabolites; sphingolipids; TRAMP mice
ID PROTEIN-KINASE-C; 1,2-DIMETHYLHYDRAZINE-TREATED CF1 MICE; TANDEM
   MASS-SPECTROMETRY; INHIBITOR SAFINGOL; IN-VITRO; COLON-CANCER; CRYPT
   FOCI; CELL LINES; SPHINGOLIPIDS; SPHINGOSINE
AB Safingol [(2S, 3S)-2-amino-1,3-octadecanediol] is an unnatural L-threo-stereoisomer of sphinganine that is cytotoxic for cancer cells in culture and is being tested in phase 1 human clinical trials. To determine if safingol can be absorbed orally and if it affects prostate cancer in a mouse strain used in prostate cancer studies, safingol was fed to TRAMP (transgenic adenocarcinoma of mouse prostate) mice for 2 weeks at 0.0125% to 0.1% w/w of the diet. Analysis of safingol and safingol metabolites in blood and tissues by liquid chromatography electrospray ionization tandem mass spectrometry revealed uptake in tissue and extensive conversion of safingol to N-acyl species (comparable to natural "ceramides") and mono-, di-, and tri-N-methyl metabolites that have not been observed previously. Safingol caused significant hepatotoxicity at all dosages, as reflected in elevated liver alanine aminotransferase, and at the highest dose (0.1 %) caused changes in liver histology (appearance of autophagosomal vacuoles) and renal toxicity (based on elevation of blood urea nitrogen) and decreases in packed blood cell volume and body weight. Safingol did not inhibit the prostate pre-neoplastic lesion (prostate intraepithelial neoplasia) in TRAMP mice; however, additional studies at lower dosages for longer time were not pursued due to host toxicity. Safingol and its N-methyl metabolites were cytotoxic to both a human prostate cell line (DU145) and mouse BALB 3T3 cells; therefore, the host and potential antitumor toxicity may be due to multiple molecular species of safingol.
C1 Emory Univ, Sch Med, Dept Pathol & Lab Med, Atlanta, GA 30322 USA.
   Emory Univ, Sch Med, Div Anim Resources, Atlanta, GA 30322 USA.
   Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA.
   Emory Univ, Sch Med, Winship Canc Inst, Atlanta, GA 30322 USA.
   Emory Univ, Dept Chem, Atlanta, GA 30322 USA.
   Georgia Inst Technol, Sch Biol, Atlanta, GA 30332 USA.
   Georgia Inst Technol, Sch Chem, Atlanta, GA 30332 USA.
   Georgia Inst Technol, Sch Biochem, Atlanta, GA 30332 USA.
   Georgia Inst Technol, Petit Inst Bioengn & Biosci, Atlanta, GA 30332 USA.
RP Dillehay, DL (corresponding author), Emory Univ, Sch Med, Dept Pathol & Lab Med, Whitehead Biomed Res Bldg,615 Michael St, Atlanta, GA 30322 USA.
EM ddilleh@dar.emory.edu
RI Pruett, Sarah/C-7433-2009
OI Merrill, Alfred/0000-0002-6673-968X
FU NCI NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R01
   CA057327, CA87525, CA57327, U19 CA087525] Funding Source: Medline;
   NATIONAL CANCER INSTITUTEUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Cancer
   Institute (NCI) [R01CA057327, U19CA087525] Funding Source: NIH RePORTER
CR BUEHRER BM, 1992, J BIOL CHEM, V267, P3154
   Carfagna MA, 1996, TOXICOL APPL PHARM, V137, P173, DOI 10.1006/taap.1996.0070
   Cuvillier O, 2002, BBA-MOL CELL BIOL L, V1585, P153, DOI 10.1016/S1388-1981(02)00336-0
   DILLEHAY DL, 1994, J NUTR, V124, P615, DOI 10.1093/jn/124.5.615
   Foster BA, 1997, CANCER RES, V57, P3325
   GREENBERG NM, 1994, MOL ENDOCRINOL, V8, P230, DOI 10.1210/me.8.2.230
   HANNUN YA, 1986, J BIOL CHEM, V261, P2604
   Humpf HU, 1998, J BIOL CHEM, V273, P19060, DOI 10.1074/jbc.273.30.19060
   IGARASHI Y, 1989, BIOCHEM BIOPH RES CO, V164, P1411, DOI 10.1016/0006-291X(89)91827-5
   Inamine M, 2005, CANCER SCI, V96, P876, DOI 10.1111/j.1349-7006.2005.00127.x
   Jarvis WD, 1998, MOL PHARMACOL, V54, P844, DOI 10.1124/mol.54.5.844
   KEDDERIS LB, 1995, FUND APPL TOXICOL, V25, P201, DOI 10.1006/faat.1995.1056
   Komatsu M, 2005, J CELL BIOL, V169, P425, DOI 10.1083/jcb.200412022
   Lemonnier LA, 2003, ARCH BIOCHEM BIOPHYS, V419, P129, DOI 10.1016/j.abb.2003.08.023
   Maurer BJ, 2000, JNCI-J NATL CANCER I, V92, P1897, DOI 10.1093/jnci/92.23.1897
   Menaldino DS, 2003, PHARMACOL RES, V47, P373, DOI 10.1016/S1043-6618(03)00054-9
   Merrill AH, 2005, METHODS, V36, P207, DOI 10.1016/j.ymeth.2005.01.009
   Milstien S, 2006, CANCER CELL, V9, P148, DOI 10.1016/j.ccr.2006.02.025
   Nardacci R, 2000, CELL MOL BIOL, V46, P1277
   *NAT TOX PROGR, 2001, 4961352 NTP
   *NRC RES COUNC GUI, 1985, PUBL, V88
   Ogretmen B, 2004, NAT REV CANCER, V4, P604, DOI 10.1038/nrc1411
   RILEY RT, 1994, J NUTR, V124, P594, DOI 10.1093/jn/124.4.594
   RILEY RT, 2006, IN PRESS TOXICOL SCI
   SACHS CW, 1995, J BIOL CHEM, V270, P26639, DOI 10.1074/jbc.270.44.26639
   SALAS M, 1980, PATHOL RES PRACT, V167, P217, DOI 10.1016/S0344-0338(80)80052-5
   Schmelz EM, 2004, FRONT BIOSCI, V9, P2632, DOI 10.2741/1422
   Schmelz EM, 2000, J NUTR, V130, P522, DOI 10.1093/jn/130.3.522
   SCHMELZ EM, 1994, J NUTR, V124, P702, DOI 10.1093/jn/124.5.702
   Schmelz EM, 1996, CANCER RES, V56, P4936
   Schmelz EM, 2001, CANCER RES, V61, P6723
   Schwartz GK, 1997, CLIN CANCER RES, V3, P537
   SCHWARTZ GK, 1995, J NATL CANCER I, V87, P1394, DOI 10.1093/jnci/87.18.1394
   Silins I, 2003, CARCINOGENESIS, V24, P1077, DOI 10.1093/carcin/bgg055
   Sosnowski J, 1997, J UROLOGY, V158, P269, DOI 10.1097/00005392-199707000-00084
   Sullards MC, 2000, J MASS SPECTROM, V35, P347, DOI 10.1002/(SICI)1096-9888(200003)35:3<347::AID-JMS941>3.0.CO;2-3
   Suzuki E, 2004, P NATL ACAD SCI USA, V101, P14788, DOI 10.1073/pnas.0406536101
   Symolon H, 2004, J NUTR, V134, P1157, DOI 10.1093/jn/134.5.1157
   Vesper H, 1999, J NUTR, V129, P1239, DOI 10.1093/jn/129.7.1239
   Zheng W, 2006, BBA-BIOMEMBRANES, V1758, P1864, DOI 10.1016/j.bbamem.2006.08.009
NR 40
TC 14
Z9 14
U1 0
U2 1
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0148-0545
EI 1525-6014
J9 DRUG CHEM TOXICOL
JI Drug Chem. Toxicol.
PY 2007
VL 30
IS 3
BP 197
EP 216
DI 10.1080/01480540701375018
PG 20
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy; Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry; Pharmacology & Pharmacy; Toxicology
GA 183WG
UT WOS:000247602500004
PM 17613006
DA 2022-04-25
ER

PT J
AU Ogando, DG
   Choi, M
   Shyam, R
   Li, SM
   Bonanno, JA
AF Ogando, Diego G.
   Choi, Moonjung
   Shyam, Rajalekshmy
   Li, Shimin
   Bonanno, Joseph A.
TI Ammonia sensitive SLC4A11 mitochondrial uncoupling reduces glutamine
   induced oxidative stress
SO REDOX BIOLOGY
LA English
DT Article
DE Slc4a11; Glutamine; Ammonia; Reactive oxygen species; Mitochondrial
   uncoupling
ID ION-TRANSPORT; CANCER-CELLS; PROTEIN; AUTOPHAGY; METABOLISM;
   HYPERAMMONEMIA; MUTATIONS; CHED2; MICE
AB SLC4A11 is a NH3 sensitive membrane transporter with H+ channel-like properties that facilitates Glutamine catabolism in Human and Mouse corneal endothelium (CE). Loss of SLC4A11 activity induces oxidative stress and cell death, resulting in Congenital Hereditary Endothelial Dystrophy (CHED) with corneal edema and vision loss. However, the mechanism by which SLC4A11 prevents ROS production and protects CE is unknown. Here we demonstrate that SLC4A11 is localized to the inner mitochondrial membrane of CE and SLC4A11 transfected PS120 fibroblasts, where it acts as an NH3-sensitive mitochondrial uncoupler that enhances glutamine-dependent oxygen consumption, electron transport chain activity, and ATP levels by suppressing damaging Reactive Oxygen Species (ROS) production. In the presence of glutamine, Slc4a11(-/-) (KO) mouse CE generate significantly greater mitochondrial superoxide, a greater proportion of damaged depolarized mitochondria, and more apoptotic cells than WT. KO CE can be rescued by MitoQ, reducing NH3 production by GLS1 inhibition or dimethyl alpha Ketoglutarate supplementation, or by BAM15 mitochondrial uncoupling. Slc4a11 KO mouse corneal edema can be partially reversed by aKetoglutarate eye drops. Moreover, we demonstrate that this role for SLC4A11 is not specific to CE cells, as SLC4A11 knockdown in glutamine-addicted colon carcinoma cells reduced glutamine catabolism, increased ROS production, and inhibited cell proliferation. Overall, our studies reveal a unique metabolic mechanism that reduces mitochondrial oxidative stress while promoting glutamine catabolism.
C1 [Ogando, Diego G.; Choi, Moonjung; Shyam, Rajalekshmy; Li, Shimin; Bonanno, Joseph A.] Indiana Univ, Sch Optometry, Bloomington, IN 47405 USA.
RP Bonanno, JA (corresponding author), Indiana Univ, Sch Optometry, Bloomington, IN 47405 USA.
EM jbonanno@indiana.edu
OI Shyam, Rajalekshmy/0000-0003-2154-4173; Choi,
   Moonjung/0000-0002-7218-4924
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [NEI/5R01EY008834]; Indiana University
   CTSI Postdoctoral Fellow NIH/NCATS CTSI [TL1 TR002531, UL1
   TR002529.gs1]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL
   SCIENCESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Advancing
   Translational Sciences (NCATS) [TL1TR002531] Funding Source: NIH
   RePORTER; NATIONAL EYE INSTITUTEUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National Eye
   Institute (NEI) [R01EY008834] Funding Source: NIH RePORTER
FX NIH NEI/5R01EY008834 (JAB). RS is an Indiana University CTSI
   Postdoctoral Fellow NIH/NCATS CTSI TL1 TR002531 and UL1 TR002529.gs1
CR Adlimoghaddam A, 2016, FRONT MOL NEUROSCI, V9, DOI 10.3389/fnmol.2016.00057
   Alka K, 2018, INVEST OPHTH VIS SCI, V59, P4258, DOI 10.1167/iovs.18-24301
   Altman BJ, 2016, NAT REV CANCER, V16, P619, DOI 10.1038/nrc.2016.71
   Berry BJ, 2018, J MOL BIOL, V430, P3873, DOI 10.1016/j.jmb.2018.03.025
   Cetinbas NM, 2016, SCI REP-UK, V6, DOI 10.1038/srep32606
   Cheong H, 2011, P NATL ACAD SCI USA, V108, P11121, DOI 10.1073/pnas.1107969108
   Dasarathy S, 2017, METAB BRAIN DIS, V32, P529, DOI 10.1007/s11011-016-9938-3
   Davuluri G, 2016, J PHYSIOL-LONDON, V594, P7341, DOI 10.1113/JP272796
   Eng CH, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000911
   Gottsch JD, 2003, INVEST OPHTH VIS SCI, V44, P594, DOI 10.1167/iovs.02-0300
   Grivennikova VG, 2008, FEBS LETT, V582, P2719, DOI 10.1016/j.febslet.2008.06.054
   Guha S, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-03654-4
   Han SB, 2013, INVEST OPHTH VIS SCI, V54, P6179, DOI 10.1167/iovs.13-12089
   Harder LM, 2014, AUTOPHAGY, V10, P339, DOI 10.4161/auto.26863
   Hogan MJ, 1971, HISTOLOGY HUMAN EYE
   Hurtaud C, 2007, CELL MOL LIFE SCI, V64, P1853, DOI 10.1007/s00018-007-7039-5
   Jalimarada SS, 2014, MOL VIS, V20, P1668
   Jayakumar AR, 2004, GLIA, V46, P296, DOI 10.1002/glia.20003
   Jiao XD, 2007, J MED GENET, V44, P64, DOI 10.1136/jmg.2006.044644
   Jurkunas UV, 2010, AM J PATHOL, V177, P2278, DOI 10.2353/ajpath.2010.100279
   Kao LY, 2016, AM J PHYSIOL-CELL PH, V311, pC820, DOI 10.1152/ajpcell.00233.2016
   Kao LY, 2015, AM J PHYSIOL-CELL PH, V308, pC176, DOI 10.1152/ajpcell.00271.2014
   Kareyeva AV, 2011, FEBS LETT, V585, P385, DOI 10.1016/j.febslet.2010.12.019
   Kenwood BM, 2014, MOL METAB, V3, P114, DOI 10.1016/j.molmet.2013.11.005
   Kitajima S, 2017, ONCOTARGET, V8
   Klionsky DJ, 2016, AUTOPHAGY, V12, P1, DOI 10.1080/15548627.2015.1100356
   Ko YH, 2011, CANCER BIOL THER, V12, P1085, DOI 10.4161/cbt.12.12.18671
   Langford MP, 2007, CLIN OPHTHALMOL, V1, P43
   Li SM, 2016, AM J PHYSIOL-CELL PH, V311, pC116, DOI 10.1152/ajpcell.00095.2016
   Li XY, 2013, J HEMATOL ONCOL, V6, DOI 10.1186/1756-8722-6-19
   Litman Thomas, 2009, Handb Exp Pharmacol, P327, DOI 10.1007/978-3-540-79885-9_17
   Loganathan SK, 2016, AM J PHYSIOL-CELL PH, V311, pC735, DOI 10.1152/ajpcell.00078.2016
   Loganathan SK, 2016, AM J PHYSIOL-CELL PH, V310, pC161, DOI 10.1152/ajpcell.00246.2015
   Mailloux RJ, 2011, FREE RADICAL BIO MED, V51, P1106, DOI 10.1016/j.freeradbiomed.2011.06.022
   Malik AN, 2016, MITOCHONDRION, V29, P59, DOI 10.1016/j.mito.2016.05.003
   Myers EJ, 2016, AM J PHYSIOL-CELL PH, V311, pC945, DOI 10.1152/ajpcell.00259.2016
   Ogando DG, 2013, AM J PHYSIOL-CELL PH, V305, pC716, DOI 10.1152/ajpcell.00056.2013
   Parker MD, 2001, BIOCHEM BIOPH RES CO, V282, P1103, DOI 10.1006/bbrc.2001.4692
   Qin LZ, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0187385
   Qureshi K, 1998, NEUROCHEM RES, V23, P855, DOI 10.1023/A:1022406911604
   Schmedt T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051427
   Siddiqui S, 2014, CORNEA, V33, P247, DOI 10.1097/ICO.0000000000000041
   Skowronska M, 2013, NEUROCHEM INT, V62, P731, DOI 10.1016/j.neuint.2012.10.013
   Valente AJ, 2017, ACTA HISTOCHEM, V119, P315, DOI 10.1016/j.acthis.2017.03.001
   Verdin E, 2015, SCIENCE, V350, P1208, DOI 10.1126/science.aac4854
   Vilas GL, 2012, HUM MUTAT, V33, P419, DOI 10.1002/humu.21655
   Vozza A, 2014, P NATL ACAD SCI USA, V111, P960, DOI 10.1073/pnas.1317400111
   Wang YQ, 2012, AUTOPHAGY, V8, P1462, DOI 10.4161/auto.21211
   Zhang WL, 2017, INVEST OPHTH VIS SCI, V58, P3723, DOI 10.1167/iovs.17-21781
   Zhang W, 2017, EBIOMEDICINE, V16, P292, DOI 10.1016/j.ebiom.2017.01.004
   Zhang WL, 2015, J BIOL CHEM, V290, P16894, DOI 10.1074/jbc.M114.627455
   Zhdanov AV, 2014, BBA-BIOENERGETICS, V1837, P51, DOI 10.1016/j.bbabio.2013.07.008
NR 52
TC 16
Z9 16
U1 1
U2 6
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2213-2317
J9 REDOX BIOL
JI Redox Biol.
PD SEP
PY 2019
VL 26
AR 101260
DI 10.1016/j.redox.2019.101260
PG 14
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA JI9ZE
UT WOS:000493821500004
PM 31254733
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Xu, ZB
   Chi, P
   Pan, J
   Shen, SF
   Sun, YW
   Wang, XJ
   Lu, XR
AF Xu, Zongbin
   Chi, Pan
   Pan, Jie
   Shen, Songfei
   Sun, Yanwu
   Wang, Xiaojie
   Lu, Xingrong
TI Knockdown of KLK11 inhibits cell proliferation and increases oxaliplatin
   sensitivity in human colorectal cancer
SO EXPERIMENTAL AND THERAPEUTIC MEDICINE
LA English
DT Article
DE colorectal cancer; kallikrein 11; oxaliplatin; drug resistance;
   apoptosis
ID EXPRESSION LEVELS; PLUS OXALIPLATIN; LIVER METASTASES; 1ST-LINE THERAPY;
   PHASE-III; CHEMOTHERAPY; APOPTOSIS; IDENTIFICATION; CARCINOMA; AUTOPHAGY
AB It has been reported that kallikrein 11 (KLK11) is crucially involved in the development and progression of various types of cancer. However, the molecular mechanisms that underlie the involvement of KLK11 in aberrant colorectal cancer (CRC) cell growth remain largely unclear. The aim of the present study was to investigate the role of KLK11 and the effects of KLK11 on oxaliplatin (L-OHP) chemosensitivity by knocking down KLK11 in LOVO and HCT-8 cells. Loss-of-function assays revealed KLK11 inhibition significantly inhibited growth and induced apoptosis of CRC cells in vitro. Notably, further experiments found that knockdown of KLK11 expression increased the L-OHP chemosensitivity of CRC cells. KLK11 inhibition of increased L-OHP-induced apoptosis may be associated with activation of caspase-3 cleavage and the apoptosis signaling pathway. The present results indicated that KLK11 may be an potential target of interest for future research into therapies for CRC.
C1 [Xu, Zongbin; Chi, Pan; Sun, Yanwu; Wang, Xiaojie; Lu, Xingrong] Fujian Med Univ, Union Hosp, Dept Colorectal Surg, 29 Xinquan Rd, Fuzhou 350001, Fujian, Peoples R China.
   [Pan, Jie] Fujian Med Univ, Union Hosp, Dept Emergency Surg, Fuzhou 350001, Fujian, Peoples R China.
   [Shen, Songfei] Fujian Med Univ, Union Hosp, Dept Med Oncol, Fuzhou 350001, Fujian, Peoples R China.
RP Lu, XR (corresponding author), Fujian Med Univ, Union Hosp, Dept Colorectal Surg, 29 Xinquan Rd, Fuzhou 350001, Fujian, Peoples R China.
EM luxingrong2015@163.com
CR Alexopoulou DK, 2014, BIOMARK MED, V8, P671, DOI [10.2217/bmm.13.151, 10.2217/BMM.13.151]
   Cassidy J, 2008, J CLIN ONCOL, V26, P2006, DOI 10.1200/JCO.2007.14.9898
   Cunningham D, 2010, LANCET, V375, P1030, DOI 10.1016/S0140-6736(10)60353-4
   Diaz-Rubio E, 2007, J CLIN ONCOL, V25, P4224, DOI 10.1200/JCO.2006.09.8467
   Gan L, 2000, GENE, V257, P119, DOI 10.1016/S0378-1119(00)00382-6
   Gillet JP, 2010, METHODS MOL BIOL, V596, P47, DOI 10.1007/978-1-60761-416-6_4
   Kim SY, 2015, INT J MED SCI, V12, P92, DOI 10.7150/ijms.10497
   Kuo IM, 2015, WORLD J SURG ONCOL, V13, DOI 10.1186/s12957-015-0497-6
   Li ST, 2013, FUTURE ONCOL, V9, P727, DOI [10.2217/FON.13.25, 10.2217/fon.13.25]
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Mavridis K, 2010, FUTURE ONCOL, V6, P269, DOI [10.2217/fon.09.149, 10.2217/FON.09.149]
   Nakamura T, 2003, PROSTATE, V54, P299, DOI 10.1002/pros.10191
   Niitsu H, 2015, WORLD J SURG ONCOL, V13, DOI 10.1186/s12957-015-0570-1
   Nordlinger B, 2008, LANCET, V371, P1007, DOI 10.1016/S0140-6736(08)60455-9
   Ouyang L, 2012, CELL PROLIFERAT, V45, P487, DOI 10.1111/j.1365-2184.2012.00845.x
   Patsis C, 2012, CLIN BIOCHEM, V45, P623, DOI 10.1016/j.clinbiochem.2012.03.005
   Pettersson F, 2002, BRIT J CANCER, V87, P555, DOI 10.1038/sj.bjc.6600496
   Porter AG, 1999, CELL DEATH DIFFER, V6, P99, DOI 10.1038/sj.cdd.4400476
   Seki K, 2014, INT J MED SCI, V11, P641, DOI 10.7150/ijms.7643
   Siegel R, 2014, CA-CANCER J CLIN, V64, P104, DOI 10.3322/caac.21220
   Talbot R, 2010, LANCET, V376, P330, DOI 10.1016/S0140-6736(10)61182-8
   Tol J, 2009, NEW ENGL J MED, V360, P563, DOI 10.1056/NEJMoa0808268
   Tu JH, 2015, EXP THER MED, V9, P17, DOI 10.3892/etm.2014.2063
   Unal D, 2013, PATHOL RES PRACT, V209, P779, DOI 10.1016/j.prp.2013.09.004
   Van Cutsem E, 2006, EUR J CANCER, V42, P2212, DOI 10.1016/j.ejca.2006.04.012
   Wang QJ, 2015, EXP THER MED, V9, P1314, DOI 10.3892/etm.2015.2230
   Wang Y, 2014, INT J MED SCI, V11, P691, DOI 10.7150/ijms.8880
   Wen YG, 2011, J SURG ONCOL, V104, P516, DOI 10.1002/jso.21981
   Zhou FF, 2011, FEBS J, V278, P403, DOI 10.1111/j.1742-4658.2010.07965.x
   Zhu XC, 2012, INT J MOL MED, V30, P1321, DOI 10.3892/ijmm.2012.1140
NR 30
TC 9
Z9 9
U1 0
U2 1
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792-0981
EI 1792-1015
J9 EXP THER MED
JI Exp. Ther. Med.
PD NOV
PY 2016
VL 12
IS 5
BP 2855
EP 2860
DI 10.3892/etm.2016.3723
PG 6
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA ED4ME
UT WOS:000388822000009
PM 27882085
OA Green Submitted, Green Published, gold
DA 2022-04-25
ER

PT J
AU Liu, JL
   Chen, FF
   Chang, SF
   Chen, CN
   Lung, J
   Lo, CH
   Lee, FH
   Lu, YC
   Hung, CH
AF Liu, Jing-Lan
   Chen, Fen-Fen
   Chang, Shun-Fu
   Chen, Cheng-Nan
   Lung, Jrhau
   Lo, Cheng-Hsing
   Lee, Fang-Hui
   Lu, Ying-Chou
   Hung, Chien-Hui
TI Expression of Beclin Family Proteins Is Associated with Tumor
   Progression in Oral Cancer
SO PLOS ONE
LA English
DT Article
ID SQUAMOUS-CELL CARCINOMA; POOR-PROGNOSIS; COLORECTAL-CANCER; COUPLED
   RECEPTORS; AUTOPHAGY GENE; BREAST-CANCER; ADENOCARCINOMA; TUMORIGENESIS;
   BCL-2; HIF-1-ALPHA
AB Background
   Beclin 1 and Beclin 2 are autophagy-related proteins that show similar amino acid sequences and domain structures. Beclin 1 established the first connection between autophagy and cancer. However, the role of Beclin 2 in cancer is unclear. The aims of this study were to analyze Beclin 1 and Beclin 2 expressions in oral cancer tissues and in cell lines, and to evaluate their possible roles in cancer progression.
   Methods
   We investigated Beclin 1 and Beclin 2 expressions by immunohistochemistry in 195 cases of oral cancer. The prognostic roles of Beclin 1 and Beclin 2 were analyzed statistically. In vitro, overexpression and knockdown of Beclin proteins were performed on an oral cancer cell line, SAS. The immunofluorescence and autophagy flux assays confirmed that Beclin proteins were involved in autophagy. The impacts of Beclin 1 and Beclin 2 on autophagy and tumor growth were evaluated by conversion of LC3-I to LC3-II and by clonogenic assays, respectively.
   Results
   Oral cancer tissues exhibited aberrant expressions of Beclin 1 and Beclin 2. The cytoplasmic Beclin 1 and Beclin 2 expressions were unrelated in oral cancer tissues. In survival analyses, high cytoplasmic Beclin 1 expression was associated with low disease specific survival, and negative nuclear Beclin 1 expression was associated with high recurrent free survival. Patients with either high or low cytoplasmic Beclin 2 expression had significantly lower overall survival and disease specific survival rates than those with moderate expression. In oral cancer cells, overexpression of either Beclin 1 or Beclin 2 led to autophagy activation and increased clonogenic survival; knockdown of Beclin 2 impaired autophagy and increased clonogenic survival.
   Conclusions
   Our results indicated that distinct patterns of Beclin 1 and Beclin 2 were associated with aggressive clinical outcomes. Beclin 1 overexpression, as well as Beclin 2 overexpression and depletion, contributed to tumor growth. These findings suggest Beclin proteins are associated with tumorigenesis.
C1 [Liu, Jing-Lan; Chen, Fen-Fen] Chang Gung Mem Hosp, Chiayi Branch, Dept Pathol, Chiayi, Taiwan.
   [Liu, Jing-Lan; Hung, Chien-Hui] Chang Gung Univ, Coll Med, Grad Inst Clin Med Sci, Taoyuan, Taiwan.
   [Chang, Shun-Fu] Chang Gung Mem Hosp, Chiayi Branch, Dept Med Res & Dev, Chiayi, Taiwan.
   [Chen, Cheng-Nan] Natl Chiayi Univ, Dept Biochem Sci & Technol, Chiayi 60004, Taiwan.
   [Lung, Jrhau] Chang Gung Mem Hosp, Chiayi Branch, Dept Med, Div Pulm & Crit Care Med, Chiayi, Taiwan.
   [Lo, Cheng-Hsing; Lee, Fang-Hui] St Martin De Porres Hosp, Dept Oral & Maxillofacial Surg, Chiayi, Taiwan.
   [Lu, Ying-Chou] St Martin De Porres Hosp, Dept Otolaryngol, Chiayi, Taiwan.
RP Hung, CH (corresponding author), Chang Gung Univ, Coll Med, Grad Inst Clin Med Sci, Taoyuan, Taiwan.
EM hungc01@mail.cgu.edu.tw
FU Ministry of Science and Technology of TaiwanMinistry of Science and
   Technology, Taiwan [MOST 103-2320-B-182A-018-, NMRPG6D0071, MOST
   104-2320-B-182A-012-, NMRPG6E0041]; Chang Gung Memorial Hospital Chiayi
   Branch [CMRPG6E0071]; Chang Gung Medical Research Center [CMRPD6C0013]
FX This work was supported by grants from the Ministry of Science and
   Technology of Taiwan (MOST 103-2320-B-182A-018-, NMRPG6D0071) (MOST
   104-2320-B-182A-012-, NMRPG6E0041), Chang Gung Memorial Hospital Chiayi
   Branch (CMRPG6E0071), and Chang Gung Medical Research Center
   (CMRPD6C0013). The funders had no role in study design, data collection
   and analysis, decision to publish, or preparation of the manuscript.
CR Buraschi S, 2013, P NATL ACAD SCI USA, V110, pE2582, DOI 10.1073/pnas.1305732110
   Camp RL, 2004, CLIN CANCER RES, V10, P7252, DOI 10.1158/1078-0432.CCR-04-0713
   Charafe-Jaufrret E, 2004, J PATHOL, V202, P265, DOI 10.1002/path.1515
   Chaturvedi AK, 2013, J CLIN ONCOL, V31, P4550, DOI 10.1200/JCO.2013.50.3870
   Chen YS, 2009, PATHOL ONCOL RES, V15, P487, DOI 10.1007/s12253-008-9143-8
   Ding ZB, 2008, CANCER RES, V68, P9167, DOI 10.1158/0008-5472.CAN-08-1573
   Dong LW, 2011, AUTOPHAGY, V7, P1222, DOI 10.4161/auto.7.10.16610
   Dong M, 2013, MED ONCOL, V30, DOI 10.1007/s12032-012-0355-0
   Dorsam RT, 2007, NAT REV CANCER, V7, P79, DOI 10.1038/nrc2069
   Edge SB, 2010, ANN SURG ONCOL, V17, P1471, DOI 10.1245/s10434-010-0985-4
   Fan W, 2011, P NATL ACAD SCI USA, V108, P7769, DOI 10.1073/pnas.1016472108
   Galluzzi L, 2015, EMBO J, V34, P856, DOI 10.15252/embj.201490784
   Giatromanolaki A, 2011, GYNECOL ONCOL, V123, P147, DOI 10.1016/j.ygyno.2011.06.023
   Guo JY, 2013, CELL, V155, P1216, DOI 10.1016/j.cell.2013.11.019
   Han J, 2013, J BIOL CHEM, V288, P20315, DOI 10.1074/jbc.M113.461350
   Han Y, 2014, ASIAN PAC J CANCER P, V15, P4583, DOI 10.7314/APJCP.2014.15.11.4583
   He CC, 2013, CELL, V154, P1085, DOI 10.1016/j.cell.2013.07.035
   Huang JJ, 2011, HUM PATHOL, V42, P1459, DOI 10.1016/j.humpath.2010.12.014
   Huang JJ, 2010, AUTOPHAGY, V6, P777, DOI 10.4161/auto.6.6.12784
   Huang L, 2013, PATHOL ONCOL RES, V19, P771, DOI 10.1007/s12253-013-9642-0
   Kenific CM, 2015, TRENDS CELL BIOL, V25, P37, DOI 10.1016/j.tcb.2014.09.001
   Kihara A, 2001, EMBO REP, V2, P330, DOI 10.1093/embo-reports/kve061
   Kim HS, 2011, PATHOL RES PRACT, V207, P247, DOI 10.1016/j.prp.2011.02.007
   Kononen J, 1998, NAT MED, V4, P844, DOI 10.1038/nm0798-844
   Koukourakis MI, 2010, BRIT J CANCER, V103, P1209, DOI 10.1038/sj.bjc.6605904
   Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257
   Liang XH, 2001, CANCER RES, V61, P3443
   LIN H, 2013, MATH PROBL ENG, V2013, P1, DOI DOI 10.1371/J0URNAL.P0NE.0060516
   Liu J, 2014, BIOFUELS FROM ALGAE, P111
   Liu JL, 2013, BMC VET RES, V9, DOI 10.1186/1746-6148-9-75
   Liu JL, 2011, CELL, V147, P223, DOI 10.1016/j.cell.2011.08.037
   Maejima Y, 2013, NAT MED, V19, P1478, DOI 10.1038/nm.3322
   Nicotra G, 2010, MODERN PATHOL, V23, P937, DOI 10.1038/modpathol.2010.80
   Parkhitko A, 2011, P NATL ACAD SCI USA, V108, P12455, DOI 10.1073/pnas.1104361108
   Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002
   Perez E, 2015, ONCOGENE, V34, P3369, DOI 10.1038/onc.2014.285
   Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039
   Ram H, 2011, J MAXILLOFAC ORAL SU, V10, P132, DOI 10.1007/s12663-011-0195-z
   Rosenfeldt MT, 2013, NATURE, V504, P296, DOI 10.1038/nature12865
   Rothenberg SM, 2012, J CLIN INVEST, V122, P1951, DOI 10.1172/JCI59889
   Sakakura K, 2015, CANCER SCI, V106, P1, DOI [10.1111/cas.12559, 10.1111/cas.12579]
   Subramani S, 2013, EMBO REP, V14, P143, DOI 10.1038/embor.2012.220
   Tang JY, 2013, ANTICANCER RES, V33, P5611
   Valentin-Vega YA, 2012, BLOOD, V119, P1490, DOI 10.1182/blood-2011-08-373639
   Wan XB, 2010, AUTOPHAGY, V6, P395, DOI 10.4161/auto.6.3.11303
   Wang JR, 2013, J INEQUAL APPL, P1, DOI 10.1186/1029-242X-2013-308
   Warnakulasuriya S, 2009, ORAL ONCOL, V45, P309, DOI 10.1016/j.oraloncology.2008.06.002
   Wei YJ, 2013, CELL, V154, P1269, DOI 10.1016/j.cell.2013.08.015
   Won KY, 2012, HUM PATHOL, V43, P62, DOI 10.1016/j.humpath.2011.04.007
   Wu XY, 2013, TUMOR BIOL, V34, P713, DOI 10.1007/s13277-012-0599-5
   Yao Q, 2011, TUMOR BIOL, V32, P1163, DOI 10.1007/s13277-011-0219-9
   Yu M, 2013, TUMOR BIOL, V34, P1071, DOI 10.1007/s13277-013-0648-8
   Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100
NR 53
TC 4
Z9 6
U1 1
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 27
PY 2015
VL 10
IS 10
AR 0141308
DI 10.1371/journal.pone.0141308
PG 18
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA CU8PC
UT WOS:000363804200047
PM 26506105
OA Green Published, Green Submitted, gold
DA 2022-04-25
ER

PT J
AU Yang, LF
   Xing, YJ
   Xiao, JX
   Xie, J
   Gao, W
   Xie, JQ
   Wang, LT
   Wang, JH
   Liu, MY
   Yi, ZF
   Qiu, WW
AF Yang, Lian-Fang
   Xing, Yajing
   Xiao, Jie-Xin
   Xie, Jia
   Gao, Wei
   Xie, Jiuqing
   Wang, Li-Ting
   Wang, Jinhua
   Liu, Mingyao
   Yi, Zhengfang
   Qiu, Wen-Wei
TI Synthesis of Cyanoenone-Modified Diterpenoid Analogs as Novel
   Bmi-1-Mediated Antitumor Agents
SO ACS MEDICINAL CHEMISTRY LETTERS
LA English
DT Article
DE Diterpenoid; cyanoenone; antitumor; colorectal cancer; Bmi-1
ID MYELOID-LEUKEMIA CELLS; COLORECTAL-CANCER; BARDOXOLONE METHYL;
   DOWN-REGULATION; BMI-1; GROWTH; APOPTOSIS; AUTOPHAGY; SURVIVAL;
   PROLIFERATION
AB Bmi-1 is overexpressed in colorectal cancer (CRC) and served as a novel therapeutic target for the treatment of CRC. A series of novel cyanoenone-modified diterpenoid analogs was synthesized and investigated for their antiproliferative activity against CRC cells. The results showed that most of these compounds exhibited potent antiproliferative and Bmi-1 inhibitory activity. Among them, the most active compound 33 (SH498) showed more potent antiproliferative activity than the positive control compound PTC-209. These synthetic diterpenoid analogs were less toxic for normal human fibroblasts (HAF) than for CRC cells. Especially 33, its selectivity index (SI) between HAF and tumor cells was 7.3-13.1, which was much better than PTC-209. The polycomb repressive complex 1 (PRC1) complex, transwell migration, colony formation, cancer stem cell proliferation, and apoptosis assays of 33 were performed on CRC cell lines. The in vivo antitumor effect of 33 was also observed in HCT116 tumor-bearing mice.
C1 [Yang, Lian-Fang; Xiao, Jie-Xin; Gao, Wei; Wang, Li-Ting; Qiu, Wen-Wei] East China Normal Univ, Shanghai Engn Res Ctr Mol Therapeut & New Drug De, Sch Chem & Mol Engn, Shanghai 200062, Peoples R China.
   [Xing, Yajing; Xie, Jia; Xie, Jiuqing; Wang, Jinhua; Liu, Mingyao; Yi, Zhengfang] East China Normal Univ, Shanghai Key Lab Regulatory Biol, Inst Biomed Sci, Shanghai 200241, Peoples R China.
   [Xing, Yajing; Xie, Jia; Xie, Jiuqing; Wang, Jinhua; Liu, Mingyao; Yi, Zhengfang] East China Normal Univ, Sch Life Sci, Shanghai 200241, Peoples R China.
RP Qiu, WW (corresponding author), East China Normal Univ, Shanghai Engn Res Ctr Mol Therapeut & New Drug De, Sch Chem & Mol Engn, Shanghai 200062, Peoples R China.; Yi, ZF (corresponding author), East China Normal Univ, Shanghai Key Lab Regulatory Biol, Inst Biomed Sci, Shanghai 200241, Peoples R China.; Yi, ZF (corresponding author), East China Normal Univ, Sch Life Sci, Shanghai 200241, Peoples R China.
EM zfyi@bio.ecnu.edu.cn; wwqiu@chem.ecnu.edu.cn
FU Shanghai Science and Technology Council [18ZR1411200]; National Natural
   Science Foundation of ChinaNational Natural Science Foundation of China
   (NSFC) [81472788, 81773204]; Major State Basic Research Development
   Program of ChinaNational Basic Research Program of China [2015CB910400]
FX Shanghai Science and Technology Council (Grant. 18ZR1411200), National
   Natural Science Foundation of China (81472788, 81773204), and Major
   State Basic Research Development Program of China (2015CB910400).
CR Alimova IN, 2009, CELL CYCLE, V8, P909, DOI 10.4161/cc.8.6.7933
   Bansal N, 2016, CLIN CANCER RES, V22, P6176, DOI 10.1158/1078-0432.CCR-15-3107
   Bolomsky A, 2016, J HEMATOL ONCOL, V9, DOI 10.1186/s13045-016-0247-4
   Botchkina G, 2013, CANCER LETT, V338, P127, DOI 10.1016/j.canlet.2012.04.006
   Chen KL, 2011, CLIN EXP METASTAS, V28, P751, DOI 10.1007/s10585-011-9407-7
   Cunningham D, 2010, LANCET, V375, P1030, DOI 10.1016/S0140-6736(10)60353-4
   Dey A, 2016, AUTOPHAGY, V12, P659, DOI 10.1080/15548627.2016.1147670
   Dimri M, 2016, ONCOTARGET, V7, P36220, DOI 10.18632/oncotarget.8811
   Eschenmoser A, 2005, HELV CHIM ACTA, V88, P3011, DOI 10.1002/hlca.200590245
   Gao Xiaohua, 2011, J Exp Ther Oncol, V9, P119
   Gao XH, 2010, ANTICANCER RES, V30, P785
   Guo BH, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-10
   Hong DS, 2012, CLIN CANCER RES, V18, P3396, DOI 10.1158/1078-0432.CCR-11-2703
   Huang R, 2011, FASEB J, V25, P4138, DOI 10.1096/fj.11-185033
   Kaur R, 2011, EUR J MED CHEM, V46, P1356, DOI 10.1016/j.ejmech.2011.01.061
   Khosravi Shadmani F, 2017, EPIDEMIOL HEALTH, V39, DOI 10.4178/epih.e2017020
   Kim JH, 2004, CANCER LETT, V203, P217, DOI 10.1016/j.canlet.2003.07.009
   Konopleva M, 2005, LEUKEMIA, V19, P1350, DOI 10.1038/sj.leu.2403828
   Konopleva M, 2004, CANCER RES, V64, P7927, DOI 10.1158/0008-5472.CAN-03-2402
   Kreso A, 2014, NAT MED, V20, P29, DOI 10.1038/nm.3418
   Li XD, 2016, CELL PHYSIOL BIOCHEM, V39, P2421, DOI 10.1159/000452510
   Li ZZ, 2006, J BIOL CHEM, V281, P20643, DOI 10.1074/jbc.M602461200
   Mourgues L, 2015, LEUKEMIA, V29, P1993, DOI 10.1038/leu.2015.112
   Nishida Y, 2017, BLOOD CANCER J, V7, DOI 10.1038/bcj.2017.8
   Nishida Y, 2015, CANCER SCI, V106, P1705, DOI 10.1111/cas.12833
   Shanmugam MK, 2014, CANCER LETT, V346, P206, DOI 10.1016/j.canlet.2014.01.016
   STORK G, 1955, J AM CHEM SOC, V77, P5068, DOI 10.1021/ja01624a038
   Suh N, 2003, CANCER RES, V63, P1371
   VEZINA C, 1975, J ANTIBIOT, V28, P721, DOI 10.7164/antibiotics.28.721
   Wang YD, 2015, INT J CLIN EXP PATHO, V8, P5182
   Wang YY, 2015, DRUG DES DEV THER, V9, P993, DOI 10.2147/DDDT.S73493
   Wang YY, 2016, EUR J MED CHEM, V120, P13, DOI 10.1016/j.ejmech.2016.04.071
   Zhang ZF, 2016, INT J MOL MED, V38, P1199, DOI 10.3892/ijmm.2016.2730
NR 33
TC 5
Z9 6
U1 2
U2 10
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1948-5875
J9 ACS MED CHEM LETT
JI ACS Med. Chem. Lett.
PD NOV
PY 2018
VL 9
IS 11
BP 1105
EP 1110
DI 10.1021/acsmedchemlett.8b00345
PG 11
WC Chemistry, Medicinal
WE Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC)
SC Pharmacology & Pharmacy
GA HA0HK
UT WOS:000449888400008
PM 30429953
OA Green Published
DA 2022-04-25
ER

PT J
AU Cheng, CY
   Wang, T
   Song, ZQ
   Peng, LJ
   Gao, MQ
   Hermine, O
   Rousseaux, S
   Khochbin, S
   Mi, JQ
   Wang, J
AF Cheng, Chunyan
   Wang, Tao
   Song, Zhiqun
   Peng, Lijun
   Gao, Mengqing
   Hermine, Olivier
   Rousseaux, Sophie
   Khochbin, Saadi
   Mi, Jian-Qing
   Wang, Jin
TI Induction of autophagy and autophagy-dependent apoptosis in diffuse
   large B-cell lymphoma by a new antimalarial artemisinin derivative,
   SM1044
SO CANCER MEDICINE
LA English
DT Article
DE Apoptosis; artemisinin derivative; autophagy; DLBCL; Survivin
ID SURVIVIN SUPPRESSANT; IN-VIVO; HEPATOCELLULAR-CARCINOMA; COMBINATION
   THERAPY; COLORECTAL-CANCER; DEATH; EXPRESSION; RITUXIMAB; PROTEINS;
   GROWTH
AB Diffuse large B-cell lymphoma (DLBCL) is the most common form of non-Hodgkin's lymphoma. R-CHOP is currently the standard therapy for DLBCL, but the prognosis of refractory or recurrent patients remains poor. In this study, we synthesized a new water-soluble antimalarial drug artemisinin derivative, SM1044. The treatment of DLBCL cell lines with SM1044 induces autophagy-dependent apoptosis, which is directed by an accelerated degradation of the antiapoptosis protein Survivin, via its acetylation-dependent interaction with the autophagy-related protein LC3-II. Additionally, SM1044 also stimulates the de novo synthesis of ceramide, which in turn activates the CaMKK2-AMPK-ULK1 axis, leading to the initiation of autophagy. Our findings not only elucidate the mechanism of autophagy-dependent apoptosis in DLBCL cells, but also suggest that SM1044 is a promising therapeutic molecule for the treatment of DLBCL, along with R-CHOP regimen.
C1 [Cheng, Chunyan; Wang, Tao; Peng, Lijun; Gao, Mengqing; Mi, Jian-Qing; Wang, Jin] Shanghai Jiao Tong Univ, Sch Med,State Key Lab Med Genom, Rui Jin Hosp,Dept Hematol,Shanghai Inst Hematol, Pole Sinofrancais Sci Vivant & Genom,Collaborat I, Shanghai, Peoples R China.
   [Song, Zhiqun] Nanjing Med Univ, Affiliated Hosp 1, Dept Blood Transfus, Nanjing, Jiangsu, Peoples R China.
   [Hermine, Olivier] Univ Paris 05, Hop Necker Enfants Malad, AP HP, Serv Hematol Adultes, Paris, France.
   [Rousseaux, Sophie; Khochbin, Saadi] Univ Grenoble Alpes, Inst Adv Biosci, INSERM U1209, CNRS UMR 5309, La Tronche, France.
RP Mi, JQ; Wang, J (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Rui Jin Hosp,Shanghai Inst Hematol,State Key Lab, Pole Sinofrancais Sci Vivant & Genom,Collaborat I, 197 Rui Jin Er Rd, Shanghai 200025, Peoples R China.; Mi, JQ; Wang, J (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Rui Jin Hosp,Shanghai Inst Hematol,Dept Hematol, Pole Sinofrancais Sci Vivant & Genom,Collaborat I, 197 Rui Jin Er Rd, Shanghai 200025, Peoples R China.
EM jianqingmi@shsmu.edu.cn; jinwang@shsmu.edu.cn
RI Khochbin, Saadi/M-8090-2013; Rousseaux, Sophie/G-1697-2013; Hermine,
   Olivier/Q-7072-2018
OI Khochbin, Saadi/0000-0002-0455-0857; Rousseaux,
   Sophie/0000-0001-5246-5350; Wang, Tao/0000-0002-5178-6969
FU Natural Science Foundation of ChinaNational Natural Science Foundation
   of China (NSFC) [81570178, 81670147]; Shanghai Leading Talent Projects
   [2015048]; Academic Leader Program of Shanghai Science and Technology
   CommitteeShanghai Science & Technology Committee [16XD1402000];
   International Cooperation Projects of Shanghai Science and Technology
   Committee [15410710200]; INCaInstitut National du Cancer (INCA) France
   [RPT13001CCA]; plan cancer (ITMO Cancer) [CH7-INS15B66, ASC16012CSA];
   Fondation ARC [RAC16042CLA]; Fondation pour la Recherche Medicale
   (FRM)Fondation pour la Recherche Medicale; ANRFrench National Research
   Agency (ANR)
FX This study was supported by the Natural Science Foundation of China
   (81570178 to J. Wang and 81670147 to J. Mi), the Shanghai Leading Talent
   Projects (2015048 to J. Mi), the Academic Leader Program of Shanghai
   Science and Technology Committee (16XD1402000 to J. Mi), and the
   International Cooperation Projects of Shanghai Science and Technology
   Committee (15410710200 to J. Mi). SK Laboratory is supported by INCa
   (RPT13001CCA), plan cancer (ITMO Cancer, CH7-INS15B66, ASC16012CSA),
   Fondation ARC (RAC16042CLA), Fondation pour la Recherche Medicale (FRM),
   and ANR EpiSperm4 (EpiSperm4) grants.
CR Adida C, 2000, BLOOD, V96, P1921
   Altieri DC, 2015, SEMIN CELL DEV BIOL, V39, P91, DOI 10.1016/j.semcdb.2014.12.007
   Anderson KA, 2008, CELL METAB, V7, P377, DOI 10.1016/j.cmet.2008.02.011
   Ansell SM, 2004, LEUKEMIA, V18, P616, DOI 10.1038/sj.leu.2403281
   Bertino P, 2013, INT J CANCER, V133, P612, DOI 10.1002/ijc.28048
   Chaganti S, 2016, BRIT J HAEMATOL, V174, P43, DOI 10.1111/bjh.14136
   Cheson BD, 2012, CANCER-AM CANCER SOC, V118, P3128, DOI 10.1002/cncr.26510
   Clarke PGH, 2012, AUTOPHAGY, V8, P867, DOI 10.4161/auto.20380
   Connell CM, 2008, J BIOL CHEM, V283, P3289, DOI 10.1074/jbc.M704461200
   Das AK, 2015, ANN MED HEALTH SCI R, V5, P93, DOI 10.4103/2141-9248.153609
   Espert L, 2006, J CLIN INVEST, V116, P2161, DOI 10.1172/JCI26185
   Friedberg JW, 2011, HEMATOL-AM SOC HEMAT, P498, DOI 10.1182/asheducation-2011.1.498
   Ghosh SK, 2014, INT J CANCER, V134, P1758, DOI 10.1002/ijc.28499
   Giodini A, 2002, CANCER RES, V62, P2462
   Guenther GG, 2008, P NATL ACAD SCI USA, V105, P17402, DOI 10.1073/pnas.0802781105
   Hamidullah, 2015, INT J BIOCHEM CELL B, V65, P275, DOI 10.1016/j.biocel.2015.06.016
   Hardie DG, 2013, BMC BIOL, V11, DOI 10.1186/1741-7007-11-36
   He LW, 2016, EUR J MED CHEM, V111, P183, DOI 10.1016/j.ejmech.2016.01.056
   Holien T, 2013, EUR J HAEMATOL, V91, P339, DOI 10.1111/ejh.12176
   Hou JM, 2008, CLIN CANCER RES, V14, P5519, DOI 10.1158/1078-0432.CCR-08-0197
   Hsieh CT, 2014, CELL SIGNAL, V26, P1400, DOI 10.1016/j.cellsig.2014.03.004
   Kaneko N, 2014, CLIN CANCER RES, V20, P1814, DOI 10.1158/1078-0432.CCR-13-2707
   Kawasaki H, 1998, CANCER RES, V58, P5071
   Kim J, 2011, NAT CELL BIOL, V13, P132, DOI 10.1038/ncb2152
   Lee JYC, 2016, FRONT PHARMACOL, V7, DOI 10.3389/fphar.2016.00081
   Li DD, 2009, ONCOGENE, V28, P886, DOI 10.1038/onc.2008.441
   Li J, 2013, INT J CANCER, V132, P1098, DOI 10.1002/ijc.27757
   Li Y, 2000, J MED CHEM, V43, P1635, DOI 10.1021/jm990552w
   Li Y, 2012, ACTA PHARMACOL SIN, V33, P1141, DOI 10.1038/aps.2012.104
   Liu YG, 2010, ORG LETT, V12, P1420, DOI 10.1021/ol902890j
   Liu ZY, 2015, MODERN PATHOL, V28, P1297, DOI 10.1038/modpathol.2015.94
   McAlpine F, 2013, AUTOPHAGY, V9, P361, DOI 10.4161/auto.23066
   Mizushima N, 2011, ANNU REV CELL DEV BI, V27, P107, DOI 10.1146/annurev-cellbio-092910-154005
   Or YYY, 2014, MOL MED REP, V10, P2025, DOI 10.3892/mmr.2014.2413
   Pankova-Kholmyansky I, 2003, CELL MOL LIFE SCI, V60, P577, DOI 10.1007/s000180300049
   Perry AM, 2012, CANCER CONTROL, V19, P214, DOI 10.1177/107327481201900306
   Roca H, 2008, J BIOL CHEM, V283, P25057, DOI 10.1074/jbc.M801073200
   Satoh T, 2009, CLIN CANCER RES, V15, P3872, DOI 10.1158/1078-0432.CCR-08-1946
   Sieber S, 2009, INT J ONCOL, V35, P149, DOI 10.3892/ijo_00000323
   Small S, 2010, LEUKEMIA, V24, P1920, DOI 10.1038/leu.2010.198
   Tamas P, 2006, J EXP MED, V203, P1665, DOI 10.1084/jem.20052469
   Uddin S, 2006, BLOOD, V108, P4178, DOI 10.1182/blood-2006-04-016907
   Vara D, 2011, CELL DEATH DIFFER, V18, P1099, DOI 10.1038/cdd.2011.32
   Wang QW, 2011, CANCER LETT, V302, P29, DOI 10.1016/j.canlet.2010.12.007
   Wang YX, 2015, TOXINS, V7, P3030, DOI 10.3390/toxins7083030
   Xu D, 2013, MOL MED REP, V8, P379, DOI 10.3892/mmr.2013.1504
   Yu L, 2006, P NATL ACAD SCI USA, V103, P4952, DOI 10.1073/pnas.0511288103
   Zhang Y-F, 2015, MEDICINE, V94
   Zhao LL, 2015, CANCER MED-US, V4, P1754, DOI 10.1002/cam4.511
NR 49
TC 31
Z9 31
U1 3
U2 16
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2045-7634
J9 CANCER MED-US
JI Cancer Med.
PD FEB
PY 2018
VL 7
IS 2
BP 380
EP 396
DI 10.1002/cam4.1276
PG 17
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA FV6TE
UT WOS:000424713800011
PM 29277967
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Notaro, A
   Sabella, S
   Pellerito, O
   Vento, R
   Calvaruso, G
   Giuliano, M
AF Notaro, Antonietta
   Sabella, Selenia
   Pellerito, Ornella
   Vento, Renza
   Calvaruso, Giuseppe
   Giuliano, Michela
TI The secreted protein acidic and rich in cysteine is a critical mediator
   of cell death program induced by WIN/TRAIL combined treatment in
   osteosarcoma cells
SO INTERNATIONAL JOURNAL OF ONCOLOGY
LA English
DT Article
DE SPARC; cannabinoids; osteosarcoma; apoptosis; caspase-8 activation
ID COLORECTAL CANCERS; BREAST-CANCER; SPARC; MATRIX; APOPTOSIS; EXPRESSION;
   OSTEONECTIN; INHIBITION; ACTIVATION; PROMOTER
AB Secreted protein acidic and rich in cysteine (SPARC) is a multi-functional protein which modulates cell-cell and cell-matrix interactions. In cancer cells, SPARC behaves as a tumor promoter in a number of tumors, but it can also act as a tumor suppressor factor. Our previous results showed that the synthetic cannabinoid WIN55,212-2 (WIN), a potent cannabinoid receptor agonist, is able to sensitize osteosarcoma MG63 cells to TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis which is accompanied with endoplasmic reticulum (ER)-stress induction and the increase in autophagic markers. In the present investigation, we studied the role of SPARC in WIN/TRAIL-induced apoptosis demonstrating that WIN increased the level of SPARC protein and mRNA in a time-dependent manner. This event was functional to WIN/TRAIL-dependent apoptosis as demonstrated by RNA interfering analysis which indicated that SPARC-silenced cells were less sensitive to cytotoxic effects induced by the combined treatment. Our experiments also demonstrate that SPARC interacts with caspase-8 thus probably favoring its translocation to plasma membrane and the activation of extrinsic apoptotic pathway. In conclusion, to the best of our knowledge, our results are the first to show that WIN-dependent increase in the level of SPARC plays a critical role in sensitizing osteosarcoma cells to TRAIL action.
C1 [Notaro, Antonietta; Sabella, Selenia; Vento, Renza; Calvaruso, Giuseppe; Giuliano, Michela] Univ Palermo, Polyclin, Biochem Lab, Dept Biol Chem & Pharmaceut Sci & Technol, Via Vespro 129, I-90128 Palermo, Italy.
   [Pellerito, Ornella] Toronto Western Hosp, Dept Genet & Dev, Toronto, ON M5T 2S8, Canada.
RP Giuliano, M (corresponding author), Univ Palermo, Polyclin, Biochem Lab, Dept Biol Chem & Pharmaceut Sci & Technol, Via Vespro 129, I-90128 Palermo, Italy.
EM michela.giuliano@unipa.it
OI Notaro, Antonietta/0000-0002-9822-0823
CR Alford AI, 2006, BONE, V38, P749, DOI 10.1016/j.bone.2005.11.017
   BELLAHCENE A, 1995, AM J PATHOL, V146, P95
   Bradshaw AD, 2001, J CLIN INVEST, V107, P1049, DOI 10.1172/JCI12939
   Brekken RA, 2001, MED SCI MONITOR, V13, P25
   Cheetham S, 2008, BRIT J CANCER, V98, P1810, DOI 10.1038/sj.bjc.6604377
   Chen ZY, 2014, SCI REP-UK, V4, DOI 10.1038/srep07035
   Delany AM, 2003, ENDOCRINOLOGY, V144, P2588, DOI 10.1210/en.2002-221044
   Horie K, 2010, CANCER SCI, V101, P913, DOI 10.1111/j.1349-7006.2009.01476.x
   Kunigal S, 2006, INT J ONCOL, V29, P1349
   LANE TF, 1994, FASEB J, V8, P163, DOI 10.1096/fasebj.8.2.8119487
   Letourneau PA, 2011, J PEDIATR SURG, V46, P1333, DOI 10.1016/j.jpedsurg.2010.12.013
   Mateo F, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-237
   Mok SC, 1996, ONCOGENE, V12, P1895
   Motamed K, 2002, J CELL BIOCHEM, V84, P759, DOI 10.1002/jcb.10095
   Notaro A, 2014, INT J BIOL SCI, V10, P466, DOI 10.7150/ijbs.8337
   Ottaviani G, 2009, CANCER TREAT RES, V152, P3, DOI 10.1007/978-1-4419-0284-9_1
   Pellerito O, 2014, APOPTOSIS, V19, P1029, DOI 10.1007/s10495-014-0985-0
   Portanova P, 2013, INT J ONCOL, V43, P121, DOI 10.3892/ijo.2013.1945
   Rentz TJ, 2007, J BIOL CHEM, V282, P22062, DOI 10.1074/jbc.M700167200
   Sailaja GS, 2013, INT J ONCOL, V42, P188, DOI 10.3892/ijo.2012.1678
   Shi Q, 2004, J BIOL CHEM, V279, P52200, DOI 10.1074/jbc.M409630200
   Tai IT, 2008, DRUG RESIST UPDATE, V11, P231, DOI 10.1016/j.drup.2008.08.005
   Tang MJ, 2007, J BIOL CHEM, V282, P34457, DOI 10.1074/jbc.M704459200
   Yunker CK, 2008, INT J CANCER, V122, P2735, DOI 10.1002/ijc.23450
   Zhang JL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044618
NR 25
TC 9
Z9 9
U1 0
U2 8
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1019-6439
EI 1791-2423
J9 INT J ONCOL
JI Int. J. Oncol.
PD MAR
PY 2016
VL 48
IS 3
BP 1039
EP 1044
DI 10.3892/ijo.2015.3307
PG 6
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA DC4IS
UT WOS:000369185000019
PM 26698404
OA Bronze
DA 2022-04-25
ER

PT J
AU Kaur, H
   Moreau, R
AF Kaur, Harleen
   Moreau, Regis
TI Curcumin represses mTORC1 signaling in Caco-2 cells by a two-sided
   mechanism involving the loss of IRS-1 and activation of AMPK
SO CELLULAR SIGNALLING
LA English
DT Article
DE Raptor; PRAS40; ERK; p38; Nutrient signaling; Turmeric
ID MAMMALIAN TARGET; TUBEROUS-SCLEROSIS; PROTEIN-KINASE; EVEROLIMUS
   INTERFERES; INSULIN-RESISTANCE; P38 MAPK; RAPAMYCIN; AUTOPHAGY; AKT;
   PHOSPHORYLATION
AB The mechanistic target of rapamycin complex 1 (mTORC1) is a central modulator of inflammation and tumorigenesis in the gastrointestinal tract. Growth factors upregulate mTORC1 via the PI3K/AKT and/or Ras/MAPK signal pathways. Curcumin (CUR), a polyphenol found in turmeric roots (Curcuma longa) can repress mTORC1 kinase activity in colon cancer cell lines; however, key aspects of CUR mechanism of action remain to be elucidated including its primary cellular target. We investigated the molecular effects of physiologically attainable concentration of CUR (20 mu M) in the intestinal lumen on mTORC1 signaling in Caco-2 cells. CUR markedly inhibited mTORC1 kinase activity as determined by the decreased phosphorylation of p70S6K (Thr389, -99%, P < 0.0001) and S6 (Ser235/236, -92%, P < 0.0001). Mechanistically, CUR decreased IRS-1 protein abundance (-80%, P < 0.0001) thereby downregulating AKT phosphorylation (Ser473, -94%, P < 0.0001) and in turn PRAS40 phosphorylation (Thr246, -99%, P < 0.0001) while total PRAS40 abundance was unchanged. The use of proteasome inhibitor MG132 showed that CUR-mediated loss of IRS-1 involved proteasomal degradation. CUR lowered Raptor protein abundance, which combined with PRAS40 hypophosphorylation, suggests CUR repressed mTORC1 activity by inducing compositional changes that hinder the complex assembly. In addition, CUR activated AMPK (Thr172 phosphorylation, P < 0.0001), a recognized repressor of mTORC1, and AMPK upstream regulator LKB1. Although cargo adapter protein p62 was decreased by CUR (-49%, P < 0.004), CUR did not significantly induce autophagy. Inhibition of AKT/mTORC1 signaling by CUR may have lifted the cross-inhibition onto MAPK signaling, which became induced; p-ERK1/2 (+670%, P < 0.0001), p-p38 (+1433%, P < 0.0001). By concomitantly targeting IRS-1 and AMPK, CUR's mechanism of mTORC1 inhibition is distinct from that of rapamycin.
C1 [Kaur, Harleen; Moreau, Regis] Univ Nebraska, Dept Nutr & Hlth Sci, Lincoln, NE 68583 USA.
RP Moreau, R (corresponding author), Univ Nebraska, Dept Nutr & Hlth Sci, Lincoln, NE 68583 USA.
EM rmoreau2@unl.edu
OI Moreau, Regis/0000-0003-0532-9887
FU Agriculture and Food Research Initiative from the USDA National
   Institute of Food and Agriculture (Program: Food Safety, Nutrition, and
   Health) [2016-67017-24431, A1341]; Nebraska Agricultural Experiment
   Station; USDA National Institute of Food and AgricultureUnited States
   Department of Agriculture (USDA) [230874]
FX This work was supported in part by the Agriculture and Food Research
   Initiative (Award Number 2016-67017-24431) to R.M. from the USDA
   National Institute of Food and Agriculture (Program: Food Safety,
   Nutrition, and Health -A1341); and the Nebraska Agricultural Experiment
   Station with funding from the Hatch Act (Accession Number 230874)
   through the USDA National Institute of Food and Agriculture.
CR [Anonymous], 1996, J Cell Biochem Suppl, V26, P72
   Aoki H, 2007, MOL PHARMACOL, V72, P29, DOI 10.1124/mol.106.033167
   Banerjee D, 2018, BIOCHIMIE, V151, P139, DOI 10.1016/j.biochi.2018.06.001
   Beevers CS, 2009, CANCER RES, V69, P1000, DOI 10.1158/0008-5472.CAN-08-2367
   Broom OJ, 2009, CLIN EXP IMMUNOL, V158, P272, DOI 10.1111/j.1365-2249.2009.04033.x
   Carracedo A, 2008, J CLIN INVEST, V118, P3065, DOI [10.1172/jCI34739, 10.1172/JCI34739]
   Castro AF, 2003, J BIOL CHEM, V278, P32493, DOI 10.1074/jbc.C300226200
   Chaube B, 2015, CELL DEATH DISCOV, V1, DOI 10.1038/cddiscovery.2015.63
   Chen YQ, 2014, J BIOL CHEM, V289, P1164, DOI 10.1074/jbc.M113.526335
   Choi SI, 2014, BIOCHEM BIOPH RES CO, V450, P1505, DOI 10.1016/j.bbrc.2014.07.035
   Clavarino G, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002708
   Costa MM, 2012, INT J EXP PATHOL, V93, P188, DOI 10.1111/j.1365-2613.2012.00817.x
   Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322
   Crino PB, 2006, NEW ENGL J MED, V355, P1345, DOI 10.1056/NEJMra055323
   Dan HC, 2014, J BIOL CHEM, V289, P25227, DOI 10.1074/jbc.M114.554881
   Deng L, 2010, AM J PATHOL, V176, P952, DOI 10.2353/ajpath.2010.090622
   Du JH, 2008, BIOCHEM BIOPH RES CO, V368, P402, DOI 10.1016/j.bbrc.2008.01.099
   Du YF, 2015, INT J ONCOL, V47, P2064, DOI 10.3892/ijo.2015.3202
   Garami A, 2003, MOL CELL, V11, P1457, DOI 10.1016/S1097-2765(03)00220-X
   Guan KL, 2000, J BIOL CHEM, V275, P27354
   Guan YT, 2015, J IMMUNOL, V195, P339, DOI 10.4049/jimmunol.1303356
   Hallowell RW, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14208
   Han F, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07188-9
   Hara K, 2002, CELL, V110, P177, DOI 10.1016/S0092-8674(02)00833-4
   He Z, 2014, ONCOL REP, V32, P1873, DOI 10.3892/or.2014.3421
   Herrero-Martin G, 2009, EMBO J, V28, P677, DOI 10.1038/emboj.2009.8
   Inoki K, 2005, NAT GENET, V37, P19, DOI 10.1038/ng1494
   Jewell JL, 2013, TRENDS BIOCHEM SCI, V38, P233, DOI 10.1016/j.tibs.2013.01.004
   Jiang HF, 2014, DIABETOLOGIA, V57, P2393, DOI 10.1007/s00125-014-3350-5
   Jiao DM, 2016, MOL THER-ONCOLYTICS, V3, DOI 10.1038/mto.2016.18
   Johnson SM, 2009, ANTICANCER RES, V29, P3185
   Kaur H, 2019, CELL MOL LIFE SCI, V76, P2525, DOI 10.1007/s00018-019-03085-6
   Kaur H, 2018, J NUTR BIOCHEM, V57, P276, DOI 10.1016/j.jnutbio.2018.04.010
   Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5
   Kim J, 2011, NAT CELL BIOL, V13, P132, DOI 10.1038/ncb2152
   Koehl GE, 2010, ONCOGENE, V29, P1553, DOI 10.1038/onc.2009.435
   Kong FQ, 2016, FRONT PHARMACOL, V7, DOI 10.3389/fphar.2016.00369
   Korolchuk VI, 2009, MOL CELL, V33, P517, DOI 10.1016/j.molcel.2009.01.021
   Kovacic S, 2003, J BIOL CHEM, V278, P39422, DOI 10.1074/jbc.M305371200
   Kuper MA, 2011, J SURG RES, V167, P158, DOI 10.1016/j.jss.2009.07.013
   Kuper MA, 2016, WORLD J GASTROENTERO, V22, P4321, DOI 10.3748/wjg.v22.i17.4321
   Kwiatkowski DJ, 2005, HUM MOL GENET, V14, pR251, DOI 10.1093/hmg/ddi260
   Lanna A, 2014, NAT IMMUNOL, V15, P965, DOI 10.1038/ni.2981
   Lee YK, 2010, ONCOL REP, V24, P1493, DOI 10.3892/or_00001010
   Li J, 2005, CIRC RES, V97, P872, DOI 10.1161/01.RES.0000187458.77026.10
   Li QK, 2013, MOL CELL ENDOCRINOL, V365, P25, DOI 10.1016/j.mce.2012.08.022
   Lin XJ, 2018, MUCOSAL IMMUNOL, V11, P1663, DOI 10.1038/s41385-018-0018-3
   Linke M, 2017, FEBS LETT, V591, P3089, DOI 10.1002/1873-3468.12711
   Liu WJ, 2016, CELL MOL BIOL LETT, V21, DOI 10.1186/s11658-016-0031-z
   Lyons J, 2018, PLOS BIOL, V16, DOI 10.1371/journal.pbio.2002417
   Mendoza MC, 2011, TRENDS BIOCHEM SCI, V36, P320, DOI 10.1016/j.tibs.2011.03.006
   Moelling K, 2002, J BIOL CHEM, V277, P31099, DOI 10.1074/jbc.M111974200
   Myeku N, 2011, J BIOL CHEM, V286, P22426, DOI 10.1074/jbc.M110.149252
   Nakashima K, 2007, BIOSCI BIOTECH BIOCH, V71, P1650, DOI 10.1271/bbb.70057
   Nishioka C, 2009, INT J CANCER, V125, P1710, DOI 10.1002/ijc.24472
   Roberts JL, 2016, BBA-MOL CELL BIOL L, V1861, P166, DOI 10.1016/j.bbalip.2015.12.001
   Roux PP, 2004, MICROBIOL MOL BIOL R, V68, P320, DOI 10.1128/MMBR.68.2.320-344.2004
   Sancak Y, 2007, MOL CELL, V25, P903, DOI 10.1016/j.molcel.2007.03.003
   Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148
   Schaffer M, 2007, LANGENBECK ARCH SURG, V392, P297, DOI 10.1007/s00423-007-0174-5
   Thiem S, 2013, J CLIN INVEST, V123, P767, DOI 10.1172/JCI65086
   Thomas SS, 2015, KIDNEY INT, V88, P1233, DOI 10.1038/ki.2015.305
   Thompson HGR, 2003, ONCOGENE, V22, P2322, DOI 10.1038/sj.onc.1206325
   Vliet JAD, 2006, TRANSPLANTATION, V82, P1477, DOI 10.1097/01.tp.0000246078.09845.9c
   Wang JF, 2020, TOXICOL IN VITRO, V65, DOI 10.1016/j.tiv.2020.104793
   Xiao K, 2013, J PHARMACOL SCI, V123, P102, DOI 10.1254/jphs.13085FP
   Yang HJ, 2013, NATURE, V497, P217, DOI 10.1038/nature12122
   Yin H, 2013, IMMUNOLOGY, V139, P494, DOI 10.1111/imm.12096
   Yu SW, 2008, MOL CANCER THER, V7, P2609, DOI 10.1158/1535-7163.MCT-07-2400
   Zhang B, 2019, FRONT CELL NEUROSCI, V12, DOI 10.3389/fncel.2018.00531
   Zhang Y, 2003, NAT CELL BIOL, V5, P578, DOI 10.1038/ncb999
   Zhao JH, 2015, P NATL ACAD SCI USA, V112, P15790, DOI 10.1073/pnas.1521919112
   Zhao Y, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0648-1
   Zheng M, 2011, NAT CELL BIOL, V13, P263, DOI 10.1038/ncb2168
   Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741
   Zoncu R, 2011, NAT REV MOL CELL BIO, V12, P21, DOI 10.1038/nrm3025
NR 76
TC 6
Z9 6
U1 0
U2 11
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0898-6568
EI 1873-3913
J9 CELL SIGNAL
JI Cell. Signal.
PD FEB
PY 2021
VL 78
AR 109842
DI 10.1016/j.cellsig.2020.109842
PG 11
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA PN8SQ
UT WOS:000604742800002
PM 33234350
OA Bronze
DA 2022-04-25
ER

PT J
AU Ahlam, AA
   Shaniba, VS
   Jayasree, PR
   Kumar, PRM
AF Ahlam, Abdul Aziz
   Shaniba, V. S.
   Jayasree, P. R.
   Kumar, P. R. Manish
TI Spondias pinnata(L.f.) Kurz Leaf Extract Derived Zinc Oxide
   Nanoparticles Induce Dual Modes of Apoptotic-Necrotic Death in HCT 116
   and K562 Cells
SO BIOLOGICAL TRACE ELEMENT RESEARCH
LA English
DT Article
DE Spondias pinnata; Zinc oxide nanoparticles; HCT 116; K562; Apoptosis;
   Necrosis
ID SOL-GEL SYNTHESIS; METAL NANOPARTICLES; ANTICANCER ACTIVITY;
   SPONDIAS-PINNATA; GREEN SYNTHESIS; PLANT-EXTRACTS; CYTOTOXICITY;
   AUTOPHAGY; SIGNAL
AB This study evaluates the effects of phyto-derived zinc oxide nanoparticles (ZnONPs) on human cancer cells, colon carcinoma HCT 116, and chronic myelogenous leukemic K562, along with normal lymphocytes/erythrocytes. The commercial, chemically synthesized ZnONPs (cZnONPs) were also assessed in parallel. Using an eco-friendly approach devoid of harmful chemicals, biogenic nanoparticles were synthesized from aqueous leaf extract ofSpondias pinnata(SpLZnONPs) by a sol-gel method. Optical, structural, and elemental characterization of both particle types were carried out deploying UV-Vis/photoluminescence spectroscopy, FTIR, XRD, FESEM, HRTEM, and EDX. Both SpLZnONPs and cZnONPs displayed hexagonal wurtzite structure with particle sizes averaging 30 and 48.5 nm, respectively. SpLZnONPs were found to be cytotoxic to both cancer cell types while cZnONPs exhibited toxicity only against HCT 116 cells. Interestingly, the cytomorphological changes and analysis of DNA laddering pattern observed in these treated cells were indicative of simultaneous induction of dual modes of death involving apoptosis and necrosis. Flow cytometric analysis of cell-cycle distribution, clonogenic, wound healing, and comet assays provided evidences of the antiproliferative potential of the tested nanoparticles. Apoptosis induction via oxidative stress-mediated Ca(2+)release, ROS generation, loss of mitochondrial membrane potential, and externalization of phosphatidylserine was also determined biochemically. Relative expression of apoptotic genes was quantified using RT-qPCR and Western blot analysis. Mitotic index analysis, MTT, and hemolytic assays on lymphocytes and erythrocytes clearly revealed the absence of any deleterious effect(s) of SpLZnONPs in these cells compared with the toxicity of the chemically derived cZnONPs, thereby attesting to the biocompatibility and selective action of the biogenic nanoparticles.
C1 [Ahlam, Abdul Aziz; Shaniba, V. S.; Kumar, P. R. Manish] Univ Calicut, Dept Biotechnol, Recombinant DNA Lab, Calicut 673635, Kerala, India.
   [Jayasree, P. R.] Univ Calicut, Sch Hlth Sci, Calicut 673635, Kerala, India.
RP Kumar, PRM (corresponding author), Univ Calicut, Dept Biotechnol, Recombinant DNA Lab, Calicut 673635, Kerala, India.
EM ahlamabdulaziz@gmail.com; Shanibavsn@gmail.com; jayasreepr@uoc.ac.in;
   manishramakrishnan@rediffmail.com
FU INSPIRE fellowship - Department of Science and Technology (DST),
   Government of India [IF140004]
FX AAA acknowledges receipt of INSPIRE fellowship (IF140004) awarded by the
   Department of Science and Technology (DST), Government of India.
CR Ahamed M, 2011, TOXICOLOGY, V283, P101, DOI 10.1016/j.tox.2011.02.010
   Ahmed S, 2017, J PHOTOCH PHOTOBIO B, V166, P272, DOI [10.1016/j.JPhotobiol.2016.12.011, 10.1016/j.jphotobiol.2016.12.011]
   Akhtar MJ, 2012, INT J NANOMED, V7, P845, DOI 10.2147/IJN.S29129
   Al-Shabib NA, 2016, SCI REP-UK, V6, DOI 10.1038/srep36761
   Attanayake A. P., 2015, International Journal of Green Pharmacy, V9, P26, DOI 10.4103/0973-8258.150918
   Aviello G, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019628
   Aziz AA, 2019, CURR SCI INDIA, V117, P1492, DOI 10.18520/cs/v117/i9/1492-1504
   Backes CS, 2018, J BIOL CHEM, V293, P16348, DOI 10.1074/jbc.RA118.004549
   Bai DP, 2017, INT J NANOMED, V12, P6521, DOI 10.2147/IJN.S140071
   Birge RB, 2016, CELL DEATH DIFFER, V23, P962, DOI 10.1038/cdd.2016.11
   Bora NS, 2014, INT J PHARM SCI RES, V5, P1138, DOI 10.13040/IJPSR.0975-8232.5(4).1138-45
   Chandra D, 2002, J BIOL CHEM, V277, P50842, DOI 10.1074/jbc.M207622200
   Chaudhuri D, 2016, BMC COMPLEM ALTERN M, V16, DOI 10.1186/s12906-016-1244-4
   Chaudhuri D, 2015, PHARMACOGN MAG, V11, P269, DOI 10.4103/0973-1296.153078
   Ng CT, 2017, INT J NANOMED, V12, P1621, DOI 10.2147/IJN.S124403
   Darroudi M, 2013, CERAM INT, V39, P9195, DOI 10.1016/j.ceramint.2013.05.021
   Das J., 2011, International Journal of Research in Pharmaceutical and Biomedical Sciences, V2, P1805
   Dobrucka R, 2016, SAUDI J BIOL SCI, V23, P517, DOI 10.1016/j.sjbs.2015.05.016
   Eruslanov E, 2009, METHODS MOL BIOL
   Ezealisiji KM, 2019, INT NANO LETT, V9, P99, DOI 10.1007/s40089-018-0263-1
   Farasat M, 2020, BIOLOGIA, V75, P161, DOI 10.2478/s11756-019-00325-9
   Franken NAP, 2006, NAT PROTOC, V1, P2315, DOI 10.1038/nprot.2006.339
   Galluzzi L, 2018, CELL DEATH DIFFER, V25, P486, DOI 10.1038/s41418-017-0012-4
   Jiang JH, 2018, BIOINORG CHEM APPL, V2018, DOI 10.1155/2018/1062562
   Jin ZY, 2005, CANCER BIOL THER, V4, P139, DOI 10.4161/cbt.4.2.1508
   Junqueira LC, 2004, HISTOLOGIA BASICA, P285
   Kadhem HA., 2019, NANO BIOMED ENG, V11, P35, DOI [DOI 10.5101/NBE.V11I1.P35-43, 10.5101/nbe.v11i1.p35-43]
   Kamal S, 2015, INT J PHARM SCI RES, V6, P3351, DOI 10.13040/IJPSR.0975-8232.6(8).3351-58
   Kang TS, 2015, LWT-FOOD SCI TECHNOL, V60, P1143, DOI 10.1016/j.lwt.2014.10.005
   Kavithaa K., 2016, INT J MOD SCI, V2, P46, DOI [10.1016/j.kijoms.2016.01.002, DOI 10.1016/J.KIJOMS.2016.01.002]
   Khan M, 2015, TOXICOL REP, V2, P765, DOI 10.1016/j.toxrep.2015.02.004
   Khandel P, 2018, J NANOSTRUCTURE CHEM, V8, P217, DOI 10.1007/s40097-018-0267-4
   Khazaei S, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00005
   Khomdram S, 2014, ANN AGR RES, V35, P129
   Kosmider B, 2004, MUTAT RES-GEN TOX EN, V563, P61, DOI 10.1016/j.mrgentox.2004.05.018
   Kuppusamy P, 2016, BIOL TRACE ELEM RES, V173, P297, DOI 10.1007/s12011-016-0666-7
   Lakshmipriya T, 2018, PROTOPLASMA, V255, P203, DOI 10.1007/s00709-017-1137-5
   Limo MJ, 2018, CHEM REV, V118, P11118, DOI 10.1021/acs.chemrev.7b00660
   Lin CY, 2016, CELL DEATH DISCOV, V2, DOI 10.1038/cddiscovery.2016.65
   Liu JJ, 2018, NANO TODAY, V21, P55, DOI 10.1016/j.nantod.2018.06.008
   Liu K, 2015, MED SCI MONIT BASIC, V21, P15, DOI 10.12659/MSMBR.893327
   Mahamuni PP, 2019, BIOCHEM BIOPHYS REP, V17, P71, DOI 10.1016/j.bbrep.2018.11.007
   Mathuram TL, 2016, ENVIRON TOXICOL PHAR, V46, P194, DOI 10.1016/j.etap.2016.07.013
   Mozdoori N, 2017, MAT SCI ENG C-MATER, V78, P949, DOI 10.1016/j.msec.2017.03.300
   Muniandy K, 2018, EVID-BASED COMPL ALT, V2018, DOI 10.1155/2018/3142073
   Namvar F, 2015, EVID-BASED COMPL ALT, V2015, DOI 10.1155/2015/593014
   Narendhran S, 2016, B MATER SCI, V39, P1, DOI 10.1007/s12034-015-1136-0
   Ogunyemi SO, 2019, ARTIF CELL NANOMED B, V47, P341, DOI 10.1080/21691401.2018.1557671
   Rello S, 2005, APOPTOSIS, V10, P201, DOI 10.1007/s10495-005-6075-6
   Sahu Devashri, 2013, ISRN Toxicol, V2013, P316075, DOI 10.1155/2013/316075
   Samat NA, 2013, CERAM INT, V39, pS545, DOI 10.1016/j.ceramint.2012.10.132
   Shaniba VS, 2019, BIOL TRACE ELEM RES, V192, P160, DOI 10.1007/s12011-019-1653-6
   Sharma A, 2018, J DRUG TARGET, V26, P617, DOI 10.1080/1061186X.2017.1400553
   Siddiquah A, 2018, EXCLI J, V17, P671, DOI 10.17179/excli2018-1327
   Sreekanth D, 2007, PHYTOMEDICINE, V14, P739, DOI 10.1016/j.phymed.2007.03.017
   Wahab R, 2008, APPL SURF SCI, V254, P2037, DOI 10.1016/j.apsusc.2007.08.038
   Wang H, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.138
   Wang L, 2018, ARTIF CELL NANOMED B, V46, pS1102, DOI 10.1080/21691401.2018.1446018
   Wang MM, 2017, J NANOMATER, V2017, DOI 10.1155/2017/8457960
   Wang Y, 2019, J PHOTOCH PHOTOBIO B, V201, DOI 10.1016/j.jphotobiol.2019.111624
   Widiarti N, 2017, IOP CONF SER-MAT SCI, V172, DOI 10.1088/1757-899X/172/1/012036
   Yusof HM, 2019, J ANIM SCI BIOTECHNO, V10, DOI 10.1186/s40104-019-0368-z
NR 62
TC 2
Z9 2
U1 1
U2 6
PU HUMANA PRESS INC
PI TOTOWA
PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA
SN 0163-4984
EI 1559-0720
J9 BIOL TRACE ELEM RES
JI Biol. Trace Elem. Res.
PD MAY
PY 2021
VL 199
IS 5
BP 1778
EP 1801
DI 10.1007/s12011-020-02303-8
EA AUG 2020
PG 24
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA RC0CV
UT WOS:000556650800002
PM 32761516
DA 2022-04-25
ER

PT J
AU Wang, Y
   Xia, CH
   Lun, ZQ
   Lv, YX
   Chen, W
   Li, T
AF Wang, Yu
   Xia, Chunhui
   Lun, Zhiqiang
   Lv, Yanxin
   Chen, Wei
   Li, Tao
TI Crosstalk between p38 MAPK and caspase-9 regulates mitochondria-mediated
   apoptosis induced by tetra-alpha-(4-carboxyphenoxy) phthalocyanine zinc
   photodynamic therapy in LoVo cells
SO ONCOLOGY REPORTS
LA English
DT Article
DE tetra-alpha-(4-carboxyphenoxy) phthalocyanine zinc; photodynamic
   therapy; p38 MAPK; caspase-9; signaling crosstalk; apoptosis;
   mitochondria
ID ACTIVATED PROTEIN-KINASE; IN-VITRO; OXIDATIVE STRESS; DEATH PATHWAYS;
   CANCER-THERAPY; BCL-2 FAMILY; PHOTOSENSITIZER; INDUCTION; AUTOPHAGY;
   AGENT
AB Photodynamic therapy (PDT) is considered to be an advancing antitumor technology. PDT using hydrophilic/lipophilic tetra-alpha-(4-carboxyphenoxy) phthalocyanine zinc (T alpha PcZn-PDT) has exhibited antitumor activity in Bel-7402 hepatocellular cancer cells. However, the manner in which p38 MAPK and caspase-9 are involved in the regulation of mitochondria-mediated apoptosis in the T alpha PcZn-PDT-treated LoVo human colon carcinoma cells remains unclear. Therefore, in the present study, a siRNA targeting p38 MAPK (siRNA-p38 MAPK) and the caspase-9 specific inhibitor z-LEHD-fmk were used to examine the crosstalk between p38 MAPK and caspase-9 during mitochondria-mediated apoptosis in the T alpha PcZn-PDT-treated LoVo cells. The findings revealed that the T alpha PcZn-PDT treatment of LoVo cells resulted in the induction of apoptosis, the formation of p38 MAPK/caspase-9 complexes, the activation of p38 MAPK, caspase-9, caspase-3 and Bid, the downregulation of Bcl-2, the reduction of mitochondrial membrane potential (Delta Psi m), the upregulation of Bax and the release of apoptosis-inducing factor (AIF) and cytochrome c (Cyto c). By contrast, siRNA-p38 MAPK or z-LEHD-fmk both attenuated the effects of T alpha PcZn-PDT in the LoVo cells. Furthermore, the results revealed that siRNA-p38 MAPK had more significant inhibitory effects on apoptosis and mitochondria compared with the effects of z-LEHD-fmk in T alpha PcZn-PDT-treated LoVo cells. These findings indicated that p38 MAPK plays the major regulatory role in the crosstalk between p38 MAPK and caspase-9 and that direct interaction between p38 MAPK and caspase-9 may regulate mitochondria-mediated apoptosis in the T alpha PcZn-PDT-treated LoVo cells.
C1 [Wang, Yu; Xia, Chunhui; Lun, Zhiqiang; Lv, Yanxin; Li, Tao] Qiqihar Med Univ, Dept Basic Med, 333 Bukuibeier Rd, Qiqihar 161006, Heilongjiang, Peoples R China.
   [Chen, Wei] Qiqihar Univ, Coll Chem & Chem Engn, Qiqihar 161006, Heilongjiang, Peoples R China.
RP Li, T (corresponding author), Qiqihar Med Univ, Dept Basic Med, 333 Bukuibeier Rd, Qiqihar 161006, Heilongjiang, Peoples R China.
EM litao888@qmu.edu.cn
FU Natural Science Foundation of Heilongjiang ProvinceNatural Science
   Foundation of Heilongjiang Province [ZD201318]
FX The project was supported by the Natural Science Foundation of
   Heilongjiang Province (no. ZD201318).
CR Acedo P, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.77
   Ameeramja J, 2016, J HAZARD MATER, V301, P554, DOI 10.1016/j.jhazmat.2015.09.037
   Bi M. C., 2013, EVID-BASED COMPL ALT, V2013
   Bu HQ, 2014, ONCOL REP, V31, P975, DOI 10.3892/or.2013.2888
   Cakir D, 2015, DALTON T, V44, P9646, DOI 10.1039/c5dt00747j
   Chen M, 2007, J BIOL CHEM, V282, P33888, DOI 10.1074/jbc.M702969200
   Doti N, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2013.518
   Festa M, 2011, J NAT PROD, V74, P2505, DOI 10.1021/np200390x
   Gillies LA, 2014, J CELL BIOCHEM, V115, P632, DOI 10.1002/jcb.24709
   Guerrero AD, 2012, J CLIN CELL IMMUNOL, V3
   Han J, 2014, J BIOL CHEM, V289, P6485, DOI 10.1074/jbc.M113.536854
   Hsiao PC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105342
   Hui KY, 2014, CANCER LETT, V354, P189, DOI 10.1016/j.canlet.2014.08.009
   Jeong HS, 2011, BBA-MOL CELL RES, V1813, P80, DOI 10.1016/j.bbamcr.2010.09.016
   Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682
   Juric V, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031303
   Karch J, 2015, CIRC RES, V116, P1800, DOI 10.1161/CIRCRESAHA.116.305421
   Kessel David, 2006, Med Laser Appl, V21, P219, DOI 10.1016/j.mla.2006.05.006
   Kim JY, 2011, APOPTOSIS, V16, P347, DOI 10.1007/s10495-010-0567-8
   Kong DC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069403
   Kuzyniak W, 2016, PHOTODIAGN PHOTODYN, V13, P148, DOI 10.1016/j.pdpdt.2015.07.001
   Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4
   Liu Y, 2015, MOL CELL BIOCHEM, V403, P267, DOI 10.1007/s11010-015-2356-8
   Lucena SR, 2015, INT J MOL SCI, V16, P25912, DOI 10.3390/ijms161025912
   Marino J, 2013, INT J BIOCHEM CELL B, V45, P2553, DOI 10.1016/j.biocel.2013.08.012
   Mfouo-Tynga I, 2015, INT J MOL SCI, V16, P10228, DOI 10.3390/ijms160510228
   Nie C, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.461
   Park GB, 2011, CANCER LETT, V313, P235, DOI 10.1016/j.canlet.2011.09.011
   Park HS, 2013, MAR DRUGS, V11, P2347, DOI 10.3390/md11072347
   Seervi M, 2015, CURR TOP DEV BIOL, V114, P43, DOI 10.1016/bs.ctdb.2015.07.019
   Sevrioukova IF, 2011, ANTIOXID REDOX SIGN, V14, P2545, DOI 10.1089/ars.2010.3445
   Shao JW, 2013, CANCER LETT, V330, P49, DOI 10.1016/j.canlet.2012.11.017
   Sreekanth GP, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149486
   Sui XB, 2014, CANCER LETT, V344, P174, DOI 10.1016/j.canlet.2013.11.019
   Tait SWG, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a008706
   Tor YS, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127441
   Wang Y, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/281912
   Whitacre CM, 2000, CLIN CANCER RES, V6, P2021
   Wright DB, 1999, AM J PSYCHOL, V112, P497, DOI 10.2307/1423648
   Wu H. Y., 2009, J LIAONING NORMAL U, V32, P94
   Xia CH, 2011, MOLECULES, V16, P1389, DOI 10.3390/molecules16021389
   Xue LY, 1999, CELL DEATH DIFFER, V6, P855, DOI 10.1038/sj.cdd.4400558
   Yang JB, 2016, ACTA PHARMACOL SIN, V37, P950, DOI 10.1038/aps.2016.34
   Yslas EI, 2007, BIOORGAN MED CHEM, V15, P4651, DOI 10.1016/j.bmc.2007.03.079
   Zhao W, 2015, SCI REP-UK, V5, DOI 10.1038/srep17175
   Zhao ZX, 2012, INORG CHEM, V51, P812, DOI 10.1021/ic201178e
   Zheng YQ, 2016, J AGR FOOD CHEM, V64, P2541, DOI 10.1021/acs.jafc.5b05343
   Zou SB, 2016, PHARMACOL REP, V68, P7, DOI 10.1016/j.pharep.2015.06.004
NR 48
TC 18
Z9 20
U1 0
U2 24
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1021-335X
EI 1791-2431
J9 ONCOL REP
JI Oncol. Rep.
PD JAN
PY 2018
VL 39
IS 1
BP 61
EP 70
DI 10.3892/or.2017.6071
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA FQ4WD
UT WOS:000418358200007
PM 29115534
OA Green Submitted, Green Published, hybrid
DA 2022-04-25
ER

PT J
AU Qian, QY
   Zhou, H
   Chen, Y
   Shen, CL
   He, SB
   Zhao, H
   Wang, L
   Wan, DW
   Gu, W
AF Qian, Qinyi
   Zhou, Hao
   Chen, Yan
   Shen, Chenglong
   He, Songbing
   Zhao, Hua
   Wang, Liang
   Wan, Daiwei
   Gu, Wen
TI VMP1 related autophagy and apoptosis in colorectal cancer cells: VMP1
   regulates cell death
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Autophagy; Apoptosis; Colorectal cancer; VMP1
ID MOLECULAR-MECHANISMS; MEDIATED CLEAVAGE; BECLIN-1; AMBRA1; PANCREATITIS;
   INHIBITION; EXPRESSION; SURVIVAL; THERAPY
AB Vacuole membrane protein 1 (VMP1) is an autophagy-related protein and identified as a key regulator of autophagy in recent years. In pancreatic cell lines, VMP1-dependent autophagy has been linked to positive regulation of apoptosis. However, there are no published reports on the role of VMP1 in autophagy and apoptosis in colorectal cancers. Therefore, to address this gap of knowledge, we decided to interrogate regulation of autophagy and apoptosis by VMP1. We have studied the induction of autophagy by starvation and rapamycin treatment in colorectal cell lines using electron microscopy, immunofluorescence, and immunoblotting. We found that starvation-induced autophagy correlated with an increase in VMP1 expression, that VMP1 interacted with BECLIN1, and that siRNA mediated down-regulation of VMP1-reduced autophagy. Next, we examined the relationship between VMP1-dependent autophagy and apoptosis and found that VMP1 down-regulation sensitizes cells to apoptosis and that agents that induce apoptosis down-regulate VMP1. In conclusion, similar to its reported role in other cell types, VMP1 is an important regulator of autophagy in colorectal cell lines. However, in contrast to its role in pancreatic cell lines, in colorectal cancer cells, VMP1-dependent autophagy appears to be pro-survival rather than pro-cell death. (C) 2013 Elsevier Inc. All rights reserved.
C1 [Zhou, Hao; Chen, Yan; He, Songbing; Zhao, Hua; Wang, Liang; Gu, Wen] Soochow Univ, Dept Gen Surg, Affiliated Hosp 1, Suzhou 215006, Peoples R China.
   [Qian, Qinyi] Changshu 2 Peoples Hosp, Dept Ultrasonograph, Changshu, Peoples R China.
   [Wan, Daiwei] Sun Yat Sen Univ, Dept Hepatobiliary Surg, Affiliated Hosp 1, Guangzhou 510080, Guangdong, Peoples R China.
   [Shen, Chenglong] Changshu 2 Peoples Hosp, Dept Gen Surg, Changshu, Peoples R China.
RP Wan, DW (corresponding author), Sun Yat Sen Univ, Dept Hepatobiliary Surg, Affiliated Hosp 1, 58 Zhongshan Rd 2, Guangzhou 510080, Guangdong, Peoples R China.
EM 372710369@qq.com; 505339704@qq.com
CR Ahn CH, 2007, APMIS, V115, P1344, DOI 10.1111/j.1600-0463.2007.00858.x
   Cui JZ, 2013, BBA-REV CANCER, V1836, P15, DOI 10.1016/j.bbcan.2013.02.003
   Dusetti NJ, 2002, BIOCHEM BIOPH RES CO, V290, P641, DOI 10.1006/bbrc.2001.6244
   Fan YJ, 2013, CHIN J CANCER, V32, P121, DOI 10.5732/cjc.012.10106
   Fimia GM, 2013, ONCOGENE, V32, P3311, DOI 10.1038/onc.2012.455
   Fimia GM, 2007, NATURE, V447, P1121, DOI 10.1038/nature05925
   Grothey A, 2005, J CLIN ONCOL, V23, P9441, DOI 10.1200/JCO.2005.04.4792
   Jaboin JJ, 2009, METHOD ENZYMOL, V453, P287, DOI 10.1016/S0076-6879(08)04014-7
   Jain K, 2013, AM J CANCER RES, V3, P251
   Kang R, 2011, CELL DEATH DIFFER, V18, P571, DOI 10.1038/cdd.2010.191
   Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1
   Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257
   Lotze MT, 2013, CANCER J, V19, P341, DOI 10.1097/PPO.0b013e31829da0d6
   Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239
   Mathew R, 2011, CURR OPIN GENET DEV, V21, P113, DOI 10.1016/j.gde.2010.12.008
   Mizushima N, 2009, METHOD ENZYMOL, V452, P13, DOI 10.1016/S0076-6879(08)03602-1
   Pagliarini V, 2012, CELL DEATH DIFFER, V19, P1495, DOI 10.1038/cdd.2012.27
   Pandey S, 2012, ASIAN PAC J CANCER P, V13, P4867, DOI 10.7314/APJCP.2012.13.10.4867
   Pardo R, 2010, PANCREATOLOGY, V10, P19, DOI 10.1159/000264680
   Rohn TT, 2011, NEUROBIOL DIS, V43, P68, DOI 10.1016/j.nbd.2010.11.003
   Ropolo A, 2007, J BIOL CHEM, V282, P37124, DOI 10.1074/jbc.M706956200
   Sato K, 2007, CANCER RES, V67, P9677, DOI 10.1158/0008-5472.CAN-07-1462
   Strappazzon F, 2011, EMBO J, V30, P1195, DOI 10.1038/emboj.2011.49
   Troiani T., 2013, CURR MED CH IN PRESS
   Wirawan E, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2009.16
   Wu SB, 2013, BIOCHEM BIOPH RES CO, V434, P898, DOI 10.1016/j.bbrc.2013.04.053
   Xu HD, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063232
   Yousefi S, 2006, NAT CELL BIOL, V8, P1124, DOI 10.1038/ncb1482
   Zheng Hai-yang, 2012, Cancer Biology Medicine, V9, P105, DOI 10.3969/j.issn.2095-3941.2012.02.004
NR 29
TC 14
Z9 14
U1 1
U2 11
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD JAN 17
PY 2014
VL 443
IS 3
BP 1041
EP 1047
DI 10.1016/j.bbrc.2013.12.090
PG 7
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA AA9LM
UT WOS:000331415000043
PM 24365149
DA 2022-04-25
ER

PT J
AU Yao, DH
   Jiang, YN
   Gao, SY
   Shang, L
   Zhao, YQ
   Huang, J
   Wang, JH
   Yang, SL
   Chen, LX
AF Yao, Dahong
   Jiang, Yingnan
   Gao, Suyu
   Shang, Lei
   Zhao, Yuqian
   Huang, Jian
   Wang, Jinhui
   Yang, Shilin
   Chen, Lixia
TI Deconvoluting the complexity of microRNAs in autophagy to improve
   potential cancer therapy
SO CELL PROLIFERATION
LA English
DT Review
ID NEGATIVELY REGULATE AUTOPHAGY; CISPLATIN-INDUCED APOPTOSIS;
   DOWN-REGULATION; INHIBITS AUTOPHAGY; COLORECTAL-CANCER; LUNG-CANCER;
   CELL-DEATH; GASTRIC-CANCER; TUMOR-GROWTH; SENSITIVITY
AB MicroRNAs (miRNAs) (small, non-coding RNAs approximate to 22 nucleotides [nt] in length), have been estimated to regulate in the region of 30% of human gene expression at the post-transcriptional and translational levels. They are also involved in a series of important cellular processes, such as autophagy. Autophagy is well-known to be an evolutionarily conserved lysosomal degradation process in which a cell degrades long-lived proteins and damaged organelles. Recent evidence has shown that miRNAs can function as either oncogenes or tumour-suppressive genes in human cancers. Also, they are well-characterized to be crucial in tumourigenesis, as either oncogenes or tumour suppressors, by regulating autophagy. However, discovering the intricate mechanism of miRNA-modulated autophagy remains in its infancy. Thus, in this review, we focus on summarizing the dual function of oncogenic or tumour-suppressive miRNAs in regulation of autophagy and their roles in carcinogenesis, thereby revealing the regulatory mechanism of miRNA-modulated autophagy in cancer, to shed light on more novel RNA therapeutic strategies in the future.
C1 [Yao, Dahong; Jiang, Yingnan; Gao, Suyu; Zhao, Yuqian; Huang, Jian; Wang, Jinhui; Yang, Shilin; Chen, Lixia] Shenyang Pharmaceut Univ, Sch Tradit Chinese Mat Med, Key Lab Struct Based Drug Design & Discovery, Minist Educ, Shenyang 110016, Peoples R China.
   [Shang, Lei] China Med Univ, Sch Pharm, Shenyang 110122, Peoples R China.
RP Wang, JH; Yang, SL; Chen, LX (corresponding author), Shenyang Pharmaceut Univ, Sch Tradit Chinese Mat Med, Key Lab Struct Based Drug Design & Discovery, Minist Educ, Shenyang 110016, Peoples R China.
EM profwjh@126.com; yangshilin@suda.edu.cn; syzyclx@163.com
RI Chen, Lixia/ABH-1629-2021
OI Chen, Lixia/0000-0003-2196-1428
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81303270, U1303124, 81202403, 81573290]
FX This work was supported by grants from National Natural Science
   Foundation of China (Grant Nos. 81303270, U1303124, 81202403, 81573290).
CR Abraham D, 2011, CLIN CANCER RES, V17, P4772, DOI 10.1158/1078-0432.CCR-11-0242
   Ali S, 2010, CANCER RES, V70, P3606, DOI 10.1158/0008-5472.CAN-09-4598
   An Y, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.123
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5
   Cao LL, 2014, INT J CLIN EXP PATHO, V7, P5582
   Chang Y, 2012, GASTROENTEROLOGY, V143, P177, DOI 10.1053/j.gastro.2012.04.009
   Chatterjee A, 2015, CELL SIGNAL, V27, P189, DOI 10.1016/j.cellsig.2014.11.023
   Chatterjee A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095716
   Chen JS, 2016, ONCOL REP, V35, P3285, DOI 10.3892/or.2016.4719
   Chen K, 2016, TUMOR BIOL, V37, P10539, DOI 10.1007/s13277-016-4929-x
   Chen SS, 2015, CELL PHYSIOL BIOCHEM, V35, P997, DOI 10.1159/000369755
   Chen X, 2016, ONCOTARGET, V7, P9222, DOI 10.18632/oncotarget.7003
   Chen Y, 2014, APOPTOSIS, V19, P1177, DOI 10.1007/s10495-014-0999-7
   Chen Y, 2015, CHEM ENG SCI, V132, P1, DOI 10.1016/j.ces.2015.04.006
   Chen Yong, 2012, Sci Rep, V2, P808, DOI 10.1038/srep00808
   Christoffersen NR, 2010, CELL DEATH DIFFER, V17, P236, DOI 10.1038/cdd.2009.109
   Clotaire DZJ, 2016, BIOCHEM BIOPH RES CO, V472, P194, DOI 10.1016/j.bbrc.2016.02.093
   Comincini S, 2013, CANCER BIOL THER, V14, P574, DOI 10.4161/cbt.24597
   Esposito F, 2012, J CLIN ENDOCR METAB, V97, pE710, DOI 10.1210/jc.2011-3068
   Frankel LB, 2012, CARCINOGENESIS, V33, P2018, DOI 10.1093/carcin/bgs266
   Frankel LB, 2011, EMBO J, V30, P4628, DOI 10.1038/emboj.2011.331
   Fu LL, 2012, CELL PROLIFERAT, V45, P477, DOI 10.1111/j.1365-2184.2012.00840.x
   Fu LL, 2012, INT J BIOCHEM CELL B, V44, P733, DOI 10.1016/j.biocel.2012.02.004
   Gandellini P, 2011, EXPERT OPIN THER TAR, V15, P265, DOI 10.1517/14728222.2011.550878
   Guo X, 2015, ONCOTARGET, V6, P41620, DOI 10.18632/oncotarget.5871
   Gwak HS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047449
   He CC, 2010, CURR OPIN CELL BIOL, V22, P140, DOI 10.1016/j.ceb.2010.01.001
   He J, 2015, AUTOPHAGY, V11, P373, DOI 10.1080/15548627.2015.1009781
   Huang NN, 2015, CANCER BIOL THER, V16, P941, DOI 10.1080/15384047.2015.1040963
   Huang YP, 2012, CELL CYCLE, V11, P1247, DOI 10.4161/cc.11.6.19670
   Huang YP, 2011, CELL CYCLE, V10, P3938, DOI 10.4161/cc.10.22.18107
   Huangfu LT, 2016, ONCOTARGET, V7, P4735, DOI 10.18632/oncotarget.6732
   Korkmaz G, 2012, AUTOPHAGY, V8, P165, DOI 10.4161/auto.8.2.18351
   Kovaleva V, 2012, CANCER RES, V72, P1763, DOI 10.1158/0008-5472.CAN-11-3671
   Li SF, 2016, LIFE SCI, V147, P143, DOI 10.1016/j.lfs.2016.01.044
   Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257
   Lin WM, 2008, CANCER RES, V68, P664, DOI 10.1158/0008-5472.CAN-07-2615
   Liu B, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.422
   Liu B, 2010, ACTA PHARMACOL SIN, V31, P1154, DOI 10.1038/aps.2010.118
   Ma Y, 2014, ONCOTARGET, V5, P9169, DOI 10.18632/oncotarget.2396
   Marino G, 2007, J BIOL CHEM, V282, P18573, DOI 10.1074/jbc.M701194200
   Meenhuis A, 2011, BLOOD, V118, P916, DOI 10.1182/blood-2011-02-336487
   Mikhaylova O, 2012, CANCER CELL, V21, P532, DOI 10.1016/j.ccr.2012.02.019
   Morselli E, 2009, BBA-MOL CELL RES, V1793, P1524, DOI 10.1016/j.bbamcr.2009.01.006
   Motoyama K, 2009, INT J ONCOL, V34, P1069, DOI 10.3892/ijo_00000233
   Pan BZ, 2015, ONCOTARGET, V6, P317, DOI 10.18632/oncotarget.2787
   Pavlides S, 2010, CELL CYCLE, V9, P3485, DOI 10.4161/cc.9.17.12721
   Pennati M, 2014, BIOCHEM PHARMACOL, V87, P579, DOI 10.1016/j.bcp.2013.12.009
   Qased A, 2013, MOL MED REP, V7, P559, DOI 10.3892/mmr.2012.1214
   Ramalinga M, 2015, ONCOTARGET, V6, P34446, DOI 10.18632/oncotarget.5920
   Rathod SS, 2014, FEBS OPEN BIO, V4, P485, DOI 10.1016/j.fob.2014.05.002
   Roccaro AM, 2010, BLOOD, V116, P1506, DOI 10.1182/blood-2010-01-265686
   Seto AG, 2010, INT J BIOCHEM CELL B, V42, P1298, DOI 10.1016/j.biocel.2010.03.003
   Shi GD, 2013, GLIA, V61, P504, DOI 10.1002/glia.22451
   Stiuso P, 2015, MOL THER-NUCL ACIDS, V4, DOI 10.1038/mtna.2015.8
   Sumbul AT, 2014, TUMOR BIOL, V35, P12713, DOI 10.1007/s13277-014-2596-3
   Sun QQ, 2015, INT J CANCER, V136, P1003, DOI 10.1002/ijc.29065
   Tan SF, 2016, INT J MOL MED, V37, P1030, DOI 10.3892/ijmm.2016.2492
   Tekirdag KA, 2016, HISTOL HISTOPATHOL, V31, P841, DOI 10.14670/HH-11-752
   Tekirdag KA, 2013, AUTOPHAGY, V9, P374, DOI 10.4161/auto.23117
   Tschan MP, 2010, 52 ASH ANN M EXP ORL
   Wan G, 2014, AUTOPHAGY, V10, P70, DOI 10.4161/auto.26534
   Wang P, 2013, GASTROENTEROLOGY, V145, P1133, DOI 10.1053/j.gastro.2013.07.048
   Wang ZY, 2014, ONCOTARGET, V5, P7013, DOI 10.18632/oncotarget.2192
   Wu CL, 2013, CELL SIGNAL, V25, P1212, DOI 10.1016/j.cellsig.2013.01.028
   Wu H, 2012, CELL SIGNAL, V24, P2179, DOI 10.1016/j.cellsig.2012.07.001
   Xiao JA, 2011, INT J CARDIOL, V148, P110, DOI 10.1016/j.ijcard.2011.01.029
   Xu N, 2012, BIOCHEM BIOPH RES CO, V423, P826, DOI 10.1016/j.bbrc.2012.06.048
   Xu YH, 2013, ONCOL REP, V29, P2019, DOI 10.3892/or.2013.2338
   Yang XJ, 2013, BIOCHEM BIOPH RES CO, V431, P617, DOI 10.1016/j.bbrc.2012.12.083
   Yu XF, 2016, BIOMED PHARMACOTHER, V77, P37, DOI 10.1016/j.biopha.2015.11.005
   Yu XF, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0480-4
   Zeng LP, 2016, J CELL MOL MED, V20, P559, DOI 10.1111/jcmm.12760
   Zhai HY, 2015, ONCOTARGET, V6, P19735, DOI 10.18632/oncotarget.3771
   Zhang L, 2016, CELL PROLIFERAT, V49, P246, DOI 10.1111/cpr.12247
   Zhang XL, 2015, ONCOL REP, V34, P1557, DOI 10.3892/or.2015.4078
   Zhang Y, 2014, BIOCHEM PHARMACOL, V87, P562, DOI 10.1016/j.bcp.2013.12.004
   Zhao J, 2016, GENE, V576, P828, DOI 10.1016/j.gene.2015.11.013
   Zhu H, 2009, AUTOPHAGY, V5, P816, DOI 10.4161/auto.9064
   Zhu JF, 2012, AM J PATHOL, V180, P2440, DOI 10.1016/j.ajpath.2012.02.023
NR 80
TC 12
Z9 12
U1 1
U2 32
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0960-7722
EI 1365-2184
J9 CELL PROLIFERAT
JI Cell Prolif.
PD OCT
PY 2016
VL 49
IS 5
BP 541
EP 553
DI 10.1111/cpr.12277
PG 13
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA DW6MX
UT WOS:000383766400001
PM 27436709
OA Green Published
DA 2022-04-25
ER

PT J
AU Daskalaki, I
   Gkikas, I
   Tavernarakis, N
AF Daskalaki, Ioanna
   Gkikas, Ilias
   Tavernarakis, Nektarios
TI Hypoxia and Selective Autophagy in Cancer Development and Therapy
SO FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
LA English
DT Review
DE autophagy; cancer; ERphagy; HIFs; hypoxia; mitophagy; mTOR; pexophagy
ID REGULATES MITOCHONDRIAL DYNAMICS; ENDOPLASMIC-RETICULUM TURNOVER;
   UNFOLDED PROTEIN RESPONSE; NF-KAPPA-B; CELL-DEATH; ER STRESS;
   COLORECTAL-CANCER; INDUCIBLE FACTORS; BNIP3 PROTEIN; TRANSCRIPTIONAL
   RESPONSE
AB Low oxygen availability, a condition known as hypoxia, is a common feature of various pathologies including stroke, ischemic heart disease, and cancer. Hypoxia adaptation requires coordination of intricate pathways and mechanisms such as hypoxia-inducible factors (HIFs), the unfolded protein response (UPR), mTOR, and autophagy. Recently, great effort has been invested toward elucidating the interplay between hypoxia-induced autophagy and cancer cell metabolism. Although novel types of selective autophagy have been identified, including mitophagy, pexophagy, lipophagy, ERphagy and nucleophagy among others, their potential interface with hypoxia response mechanisms remains poorly understood. Autophagy activation facilitates the removal of damaged cellular compartments and recycles components, thus promoting cell survival. Importantly, tumor cells rely on autophagy to support self-proliferation and metastasis; characteristics related to poor disease prognosis. Therefore, a deeper understanding of the molecular crosstalk between hypoxia response mechanisms and autophagy could provide important insights with relevance to cancer and hypoxia-related pathologies. Here, we survey recent findings implicating selective autophagy in hypoxic responses, and discuss emerging links between these pathways and cancer pathophysiology.
C1 [Daskalaki, Ioanna; Gkikas, Ilias; Tavernarakis, Nektarios] Fdn Res & Technol Hellas, Inst Mol Biol & Biotechnol, Iraklion, Greece.
   [Daskalaki, Ioanna; Gkikas, Ilias] Univ Crete, Dept Biol, Iraklion, Greece.
   [Tavernarakis, Nektarios] Univ Crete, Sch Med, Dept Basic Sci, Iraklion, Greece.
RP Tavernarakis, N (corresponding author), Fdn Res & Technol Hellas, Inst Mol Biol & Biotechnol, Iraklion, Greece.; Tavernarakis, N (corresponding author), Univ Crete, Sch Med, Dept Basic Sci, Iraklion, Greece.
EM tavernarakis@imbb.forth.gr
RI Tavernarakis, Nektarios/B-9684-2013
OI Tavernarakis, Nektarios/0000-0002-5253-1466; Gkikas,
   Ilias/0000-0002-5899-551X
FU European Research CouncilEuropean Research Council (ERC)European
   Commission [ERC-GA695190-MANNA, ERC-GA737599-NeuronAgeScreen]; European
   Commission Framework Programmes; Greek Ministry of EducationGreek
   Ministry of Development-GSRT
FX We apologize to those colleagues whose work could not be referenced
   owing to space limitations. Work in the authors' laboratory is funded by
   grants from the European Research Council (ERC-GA695190-MANNA,
   ERC-GA737599-NeuronAgeScreen), the European Commission Framework
   Programmes, and the Greek Ministry of Education.
CR Abdel-Mohsen MA, 2017, ANTI-CANCER AGENT ME, V17, P1526, DOI 10.2174/1871520617666170327144122
   Ampofo E, 2013, BBA-GEN SUBJECTS, V1830, P2938, DOI 10.1016/j.bbagen.2012.12.020
   An HJ, 2006, J BIOL CHEM, V281, P33939, DOI 10.1074/jbc.M605819200
   Antonelli M, 2017, ONCOTARGET, V8, P21692, DOI 10.18632/oncotarget.15537
   Azad MB, 2010, ANN NY ACAD SCI, V1210, P8, DOI 10.1111/j.1749-6632.2010.05778.x
   Bellot G, 2009, MOL CELL BIOL, V29, P2570, DOI 10.1128/MCB.00166-09
   Berger J, 2016, BBA-MOL CELL RES, V1863, P934, DOI 10.1016/j.bbamcr.2015.12.005
   Bi MX, 2005, EMBO J, V24, P3470, DOI 10.1038/sj.emboj.7600777
   Bochen F, 2017, ONCOTARGET, V8, P4922, DOI 10.18632/oncotarget.13986
   Brugarolas J, 2004, GENE DEV, V18, P2893, DOI 10.1101/gad.1256804
   Buart S, 2017, ONCOTARGET, V8, P108786, DOI 10.18632/oncotarget.22150
   Burton TR, 2006, INT J CANCER, V118, P1660, DOI 10.1002/ijc.21547
   Cai MJ, 2018, CANCER LETT, V421, P82, DOI 10.1016/j.canlet.2018.02.021
   Capello M, 2016, ONCOTARGET, V7, P5598, DOI 10.18632/oncotarget.6798
   Carloni S, 2014, EXP NEUROL, V255, P103, DOI 10.1016/j.expneurol.2014.03.002
   Cerrada I, 2013, STEM CELLS DEV, V22, P501, DOI 10.1089/scd.2012.0340
   Chae YC, 2016, CANCER CELL, V30, P257, DOI 10.1016/j.ccell.2016.07.004
   Chen G, 2014, MOL CELL, V54, P362, DOI 10.1016/j.molcel.2014.02.034
   Chen K, 2014, MOL BIOL EVOL, V31, P2194, DOI 10.1093/molbev/msu181
   Chen M, 2016, AUTOPHAGY, V12, P689, DOI 10.1080/15548627.2016.1151580
   Chen QY, 2016, BIOCHEM BIOPH RES CO, V474, P168, DOI 10.1016/j.bbrc.2016.04.090
   Chen R, 2018, ONCOL RES, V26, P573, DOI 10.3727/096504017X14954923820137
   Chen T, 2017, GASTROENTEROLOGY, V152, pS564, DOI 10.1016/S0016-5085(17)32041-3
   Chen X, 2014, NATURE, V508, P103, DOI 10.1038/nature13119
   Chen ZH, 2017, AUTOPHAGY, V13, P1244, DOI 10.1080/15548627.2017.1310789
   Chen ZH, 2017, EMBO REP, V18, P495, DOI 10.15252/embr.201643309
   Chi BH, 2017, J UROLOGY, V197, pE570, DOI 10.1016/j.juro.2017.02.1347
   Chourasia AH, 2016, CANCER RES, V76, DOI 10.1158/1538-7445.AM2016-228
   Cosin-Roger J, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00213-3
   Dahabieh MS, 2017, CELL DEATH DIFFER, V24, P1912, DOI 10.1038/cdd.2017.115
   Denko NC, 2008, NAT REV CANCER, V8, P705, DOI 10.1038/nrc2468
   Deosaran E, 2013, J CELL SCI, V126, P939, DOI 10.1242/jcs.114819
   DePavia A, 2016, MOL CELL ONCOL, V3, DOI 10.1080/23723556.2015.1104428
   Di Conza G, 2017, CELL REP, V18, P1699, DOI 10.1016/j.celrep.2017.01.051
   Dikic I, 2018, NAT REV MOL CELL BIO, V19, P349, DOI 10.1038/s41580-018-0003-4
   Dimitrov SD, 2001, FOLIA BIOL-PRAGUE, V47, P120
   Ding F, 2018, J CELL BIOCHEM, V119, P4799, DOI 10.1002/jcb.26676
   Ding M, 2018, MOL CANCER RES, V16, P682, DOI 10.1158/1541-7786.MCR-17-0696
   Dong Q, 2017, INT J RADIAT ONCOL, V99, pE586, DOI 10.1016/j.ijrobp.2017.06.2011
   Eales KL, 2016, ONCOGENESIS, V5, DOI 10.1038/oncsis.2015.50
   Eid N, 2017, WORLD J HEPATOL, V9, P349, DOI 10.4254/wjh.v9.i7.349
   Elsner M, 2011, DIABETES, V60, P200, DOI 10.2337/db09-1401
   Fang HY, 2009, BLOOD, V114, P844, DOI 10.1182/blood-2008-12-195941
   Fang YY, 2015, CELL BIOL INT, V39, P891, DOI 10.1002/cbin.10463
   Farre JC, 2008, DEV CELL, V14, P365, DOI 10.1016/j.devcel.2007.12.011
   Farre JC, 2016, NAT REV MOL CELL BIO, V17, P537, DOI 10.1038/nrm.2016.74
   Feng X, 2011, EMBO J, V30, P3397, DOI 10.1038/emboj.2011.248
   Feng XL, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0575-2
   Fumagalli F, 2016, NAT CELL BIOL, V18, P1173, DOI 10.1038/ncb3423
   Gavert N, 2013, CANCER RES, V73, P5754, DOI 10.1158/0008-5472.CAN-13-0576
   Gopalan V, 2015, EXP CELL RES, V330, P423, DOI 10.1016/j.yexcr.2014.08.006
   Greiner M, 2011, INT J CANCER, V128, P2284, DOI 10.1002/ijc.25580
   Grumati P, 2017, ELIFE, V6, DOI 10.7554/eLife.25555
   Gui L, 2016, EXP THER MED, V11, P2233, DOI 10.3892/etm.2016.3190
   Guo K, 2001, CELL DEATH DIFFER, V8, P367, DOI 10.1038/sj.cdd.4400810
   Hanna RA, 2012, J BIOL CHEM, V287, P19094, DOI 10.1074/jbc.M111.322933
   Haque MH, 2016, SCI REP-UK, V6, DOI 10.1038/srep29173
   He JM, 2017, J CANCER, V8, P1187, DOI 10.7150/jca.18171
   Hetz C, 2009, GENE DEV, V23, P2294, DOI 10.1101/gad.1830709
   Hou HL, 2017, CANCER MED-US, V6, P1871, DOI 10.1002/cam4.1112
   Huang X, 2004, CLIN NEUROPATHOL, V23, P1
   Huang XD, 2012, ASIAN PAC J CANCER P, V13, P4793, DOI 10.7314/APJCP.2012.13.9.4793
   Huang ZQ, 2017, J CELL MOL MED, V21, P467, DOI 10.1111/jcmm.12990
   Hubert A, 2006, J CELL SCI, V119, P3351, DOI 10.1242/jcs.03069
   Ishaq M, 2014, BBA-GEN SUBJECTS, V1840, P3374, DOI 10.1016/j.bbagen.2014.08.019
   Islam F, 2018, GENE CHROMOSOME CANC, V57, P240, DOI 10.1002/gcc.22525
   Islam F, 2017, EXP CELL RES, V357, P260, DOI 10.1016/j.yexcr.2017.05.021
   Jin T, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-64
   Jo DS, 2015, BIOCHEM BIOPH RES CO, V467, P354, DOI 10.1016/j.bbrc.2015.09.153
   Jung CH, 2010, FEBS LETT, V584, P1287, DOI 10.1016/j.febslet.2010.01.017
   Jung V, 2006, MOL CANCER RES, V4, P169, DOI 10.1158/1541-7786.MCR-05-0165
   Kalas W, 2011, ANTICANCER RES, V31, P2869
   Kasem K, 2014, EXP MOL PATHOL, V97, P31, DOI 10.1016/j.yexmp.2014.05.001
   Kaur J, 2015, NAT REV MOL CELL BIO, V16, P461, DOI 10.1038/nrm4024
   Kenific CM, 2016, J CELL BIOL, V212, P577, DOI 10.1083/jcb.201503075
   Khaminets A, 2015, NATURE, V522, P354, DOI 10.1038/nature14498
   Kim J, 2011, NAT CELL BIOL, V13, P132, DOI 10.1038/ncb2152
   Kim LC, 2017, ONCOGENE, V36, P2191, DOI 10.1038/onc.2016.363
   Kim LC, 2009, NAT REV CLIN ONCOL, V6, P587, DOI 10.1038/nrclinonc.2009.129
   Klarer AC, 2014, CANCER METAB, V2, DOI 10.1186/2049-3002-2-2
   Kobayashi M, 2015, LUNG CANCER, V90, P342, DOI 10.1016/j.lungcan.2015.08.015
   Koerbel Christina, 2018, BioMolecular Concepts, V9, P53, DOI 10.1515/bmc-2018-0006
   Koh MY, 2011, CANCER RES, V71, P4015, DOI 10.1158/0008-5472.CAN-10-4142
   Koop EA, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-175
   Krock Bryan L, 2011, Genes Cancer, V2, P1117, DOI 10.1177/1947601911423654
   Kuang Y, 2016, AUTOPHAGY, V12, P2363, DOI 10.1080/15548627.2016.1238552
   Lakkaraju AKK, 2013, MOL CELL, V51, P386, DOI 10.1016/j.molcel.2013.07.009
   Lauer C, 1999, CARCINOGENESIS, V20, P985, DOI 10.1093/carcin/20.6.985
   Lee HJ, 2017, REDOX BIOL, V13, P426, DOI 10.1016/j.redox.2017.07.004
   Lee JN, 2018, BIOCHEM BIOPH RES CO, V501, P696, DOI 10.1016/j.bbrc.2018.05.050
   Lee JT, 2009, CANCER LETT, V279, P185, DOI 10.1016/j.canlet.2009.01.035
   Lee Y, 2011, AM J PHYSIOL-HEART C, V301, pH1924, DOI 10.1152/ajpheart.00368.2011
   Levy JMM, 2017, NAT REV CANCER, V17, P528, DOI 10.1038/nrc.2017.53
   Li BH, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-04811-5
   Li H, 2018, INT J CLIN EXP PATHO, V11, P1909
   Li LF, 2016, ACTA BIOCH BIOPH SIN, V48, P774, DOI 10.1093/abbs/gmw057
   Li W, 2014, J BIOL CHEM, V289, P10691, DOI 10.1074/jbc.M113.537050
   Li XJ, 2016, MOL CELL, V61, P705, DOI 10.1016/j.molcel.2016.02.009
   Li Y, 2017, ONCOTARGET, V8, P63208, DOI 10.18632/oncotarget.18736
   Li Y, 2007, J BIOL CHEM, V282, P35803, DOI 10.1074/jbc.M705231200
   Linxweiler M, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2739-6
   Linxweiler M, 2012, AM J PATHOL, V180, P473, DOI 10.1016/j.ajpath.2011.10.039
   Liu KE, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129667
   Liu L, 2012, NAT CELL BIOL, V14, P177, DOI 10.1038/ncb2422
   Liu R, 2017, CANCER LETT, V390, P48, DOI 10.1016/j.canlet.2016.12.040
   Liu RN, 2015, BIOMED PHARMACOTHER, V72, P52, DOI 10.1016/j.biopha.2015.04.005
   Lu HQ, 2013, AUTOPHAGY, V9, P1720, DOI 10.4161/auto.26550
   Lv MQ, 2017, PROTEIN CELL, V8, P25, DOI 10.1007/s13238-016-0328-8
   Ma D, 2017, J IMMUNOL, V198
   Ma Y, 2018, ENDOCRINOLOGY, V159, P1119, DOI 10.1210/en.2017-03020
   Macher-Goeppinger S, 2017, TRANSL ONCOL, V10, P869, DOI 10.1016/j.tranon.2017.08.008
   Majmundar AJ, 2010, MOL CELL, V40, P294, DOI 10.1016/j.molcel.2010.09.022
   Margariti A, 2013, J BIOL CHEM, V288, P859, DOI 10.1074/jbc.M112.412783
   Masoud GN, 2015, ACTA PHARM SIN B, V5, P378, DOI 10.1016/j.apsb.2015.05.007
   Masson N, 2014, CANCER METAB, V2, DOI 10.1186/2049-3002-2-3
   Matsuda S, 2015, FRONT BIOSCI-LANDMRK, V20, P491, DOI 10.2741/4321
   Maugeri G, 2016, CELL TISSUE RES, V364, P465, DOI 10.1007/s00441-015-2340-3
   Mazure NM, 2010, CURR OPIN CELL BIOL, V22, P177, DOI 10.1016/j.ceb.2009.11.015
   Mei Y., 2013, J PHARM BIOMED ANAL, V1
   Mishra OP, 2009, NEUROSCI LETT, V460, P61, DOI 10.1016/j.neulet.2009.05.041
   Motley AM, 2012, EMBO J, V31, P2852, DOI 10.1038/emboj.2012.151
   Mottet D, 2005, INT J CANCER, V117, P764, DOI 10.1002/ijc.21268
   Mujcic H, 2013, CLIN CANCER RES, V19, P6126, DOI 10.1158/1078-0432.CCR-13-0526
   Mujcic H, 2009, RADIOTHER ONCOL, V92, P450, DOI 10.1016/j.radonc.2009.08.017
   Nagelkerke A, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3373
   Neault M, 2016, CELL REP, V14, P1966, DOI 10.1016/j.celrep.2016.01.068
   Ng Kee Kwong F., 2017, J CLIN CELL IMMUNOL, V8, P502, DOI [10.4172/2155-9899.1000502, DOI 10.4172/2155-9899.1000502]
   Ng KP, 2014, BLOOD, V123, P3316, DOI 10.1182/blood-2013-07-511907
   Niamh M, 2017, CLIN TRANSL RAD ONCO, V2, P63, DOI 10.1016/j.ctro.2017.01.005
   Novak I, 2010, EMBO REP, V11, P45, DOI 10.1038/embor.2009.256
   Okami J, 2004, GASTROENTEROLOGY, V126, pA55
   Ozkirimli E, 2006, PROTEIN SCI, V15, P1051, DOI 10.1110/ps.051999206
   Palikaras K, 2017, PHARMACOL THERAPEUT, V178, P157, DOI 10.1016/j.pharmthera.2017.04.005
   Palikaras K, 2015, NATURE, V521, P525, DOI 10.1038/nature14300
   Papandreou I, 2006, CELL METAB, V3, P187, DOI 10.1016/j.cmet.2006.01.012
   Paquette M, 2018, CANCERS, V10, DOI 10.3390/cancers10010018
   Pereira ER, 2014, J BIOL CHEM, V289, P3352, DOI 10.1074/jbc.M113.507194
   Ploumi C, 2017, FEBS J, V284, P183, DOI 10.1111/febs.13820
   Qian X, 2017, AUTOPHAGY, V13, P1246, DOI 10.1080/15548627.2017.1313945
   Qian X, 2017, MOL CELL, V65, P917, DOI 10.1016/j.molcel.2017.01.027
   Qin LJ, 2016, ONCOTARGET, V7, P1395, DOI 10.18632/oncotarget.6366
   Rahim SAA, 2017, BRIT J CANCER, V117, P813, DOI 10.1038/bjc.2017.263
   Rao S, 2014, AUTOPHAGY, V10, P529, DOI 10.4161/auto.27643
   Rashid HO, 2015, AUTOPHAGY, V11, P1956, DOI 10.1080/15548627.2015.1091141
   Ray R, 2000, J BIOL CHEM, V275, P1439, DOI 10.1074/jbc.275.2.1439
   Rikka S, 2011, CELL DEATH DIFFER, V18, P721, DOI 10.1038/cdd.2010.146
   Rizzardi AE, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-244
   Roberts DJ, 2014, MOL CELL, V53, P521, DOI 10.1016/j.molcel.2013.12.019
   Rouschop KM, 2013, P NATL ACAD SCI USA, V110, P4622, DOI 10.1073/pnas.1210633110
   Rouschop KMA, 2010, J CLIN INVEST, V120, P127, DOI 10.1172/JCI40027
   Roy S, 2017, MOL CELL, V67, P84, DOI 10.1016/j.molcel.2017.05.020
   Rozpedek W, 2016, CURR MOL MED, V16, P533, DOI 10.2174/1566524016666160523143937
   Ruan HL, 2017, EXP CELL RES, V358, P269, DOI 10.1016/j.yexcr.2017.07.004
   Ryan D, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-0948-z
   Sanderson TH, 2015, NEUROSCIENCE, V301, P71, DOI 10.1016/j.neuroscience.2015.05.078
   Sargent G, 2016, J CELL BIOL, V214, P677, DOI 10.1083/jcb.201511034
   Schito L, 2016, TRENDS CANCER, V2, P758, DOI 10.1016/j.trecan.2016.10.016
   Schonenberger MJ, 2015, AUTOPHAGY, V11, P967, DOI 10.1080/15548627.2015.1045180
   Schofield CJ, 2004, NAT REV MOL CELL BIO, V5, P343, DOI 10.1038/nrm1366
   Schuck S, 2014, J CELL SCI, V127, P4078, DOI 10.1242/jcs.154716
   Senft D, 2015, TRENDS BIOCHEM SCI, V40, P141, DOI 10.1016/j.tibs.2015.01.002
   Sermeus A, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.48
   Shaw J, 2008, P NATL ACAD SCI USA, V105, P20734, DOI 10.1073/pnas.0807735105
   Shi LL, 2017, SIGNAL TRANSDUCT TAR, V2, DOI 10.1038/sigtrans.2017.44
   Singh SS, 2018, ONCOGENE, V37, P1142, DOI 10.1038/s41388-017-0046-6
   Smith MD, 2018, DEV CELL, V44, P217, DOI 10.1016/j.devcel.2017.11.024
   Soni S, 2017, ACTA ONCOL, V56, P503, DOI 10.1080/0284186X.2017.1301680
   Sowter HM, 2001, CANCER RES, V61, P6669
   Squatrito M, 2010, CANCER CELL, V18, P619, DOI 10.1016/j.ccr.2010.10.034
   Stagni V, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7886
   Su Y, 2007, CANCER BIOL THER, V6, P202, DOI 10.4161/cbt.6.2.3628
   Townsend KN, 2012, IMMUNOL REV, V249, P176, DOI 10.1111/j.1600-065X.2012.01141.x
   Tracy K, 2007, AUTOPHAGY, V3, P616, DOI 10.4161/auto.4892
   Tracy K, 2007, MOL CELL BIOL, V27, P6229, DOI 10.1128/MCB.02246-06
   Trembley JH, 2009, CELL MOL LIFE SCI, V66, P1858, DOI 10.1007/s00018-009-9154-y
   Trembley JH, 2010, BIOFACTORS, V36, P187, DOI 10.1002/biof.96
   Twig G, 2011, ANTIOXID REDOX SIGN, V14, P1939, DOI 10.1089/ars.2010.3779
   Urra H, 2016, TRENDS CANCER, V2, P252, DOI 10.1016/j.trecan.2016.03.007
   Uyama T, 2012, J BIOL CHEM, V287, P2706, DOI 10.1074/jbc.M111.267575
   Vadysirisack DD, 2012, METHODS MOL BIOL, V821, P45, DOI 10.1007/978-1-61779-430-8_4
   Villa E, 2017, CELL REP, V20, P2846, DOI 10.1016/j.celrep.2017.08.087
   Walter KM, 2014, CELL METAB, V20, P882, DOI 10.1016/j.cmet.2014.09.017
   Walton ZE, 2018, CELL, V174, P72, DOI 10.1016/j.cell.2018.05.009
   Wang MX, 2015, J CANCER RES THER, V11, pC107, DOI 10.4103/0973-1482.163859
   Weber AM, 2015, PHARMACOL THERAPEUT, V149, P124, DOI 10.1016/j.pharmthera.2014.12.001
   Wei HF, 2015, BBA-MOL CELL RES, V1853, P2784, DOI 10.1016/j.bbamcr.2015.03.013
   Wemmert S, 2016, ONCOL LETT, V11, P1661, DOI 10.3892/ol.2016.4135
   Weng L, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-39
   Williams JA, 2015, BIOMOLECULES, V5, P2619, DOI 10.3390/biom5042619
   Wolff NC, 2011, MOL CELL BIOL, V31, P1870, DOI 10.1128/MCB.01393-10
   Wouters BG, 2008, NAT REV CANCER, V8, P851, DOI 10.1038/nrc2501
   Wu H, 2014, AUTOPHAGY, V10, P1712, DOI 10.4161/auto.29568
   Wu WX, 2016, AUTOPHAGY, V12, P1675, DOI 10.1080/15548627.2016.1193656
   Wu WX, 2016, EMBO J, V35, P1368, DOI 10.15252/embj.201593102
   Wu WX, 2014, EMBO REP, V15, P566, DOI 10.1002/embr.201438501
   Yan MM, 2015, ONCOL LETT, V10, P1959, DOI 10.3892/ol.2015.3508
   Yang L, 2018, CHILD NERV SYST, V34, P417, DOI 10.1007/s00381-017-3622-8
   Yang Z, 2013, J EXP MED, V210, P2119, DOI 10.1084/jem.20130252
   Yin G, 2017, BIOSCIENCE REP, V37, DOI 10.1042/BSR20160479
   Yuan Y, 2017, AUTOPHAGY, V13, P1754, DOI 10.1080/15548627.2017.1357792
   Yurkova N, 2008, CIRC RES, V102, P472, DOI 10.1161/CIRCRESAHA.107.164731
   Zhang HF, 2008, J BIOL CHEM, V283, P10892, DOI 10.1074/jbc.M800102200
   Zhang J, 2009, CELL DEATH DIFFER, V16, P939, DOI 10.1038/cdd.2009.16
   Zhang JW, 2015, NAT CELL BIOL, V17, P1259, DOI 10.1038/ncb3230
   Zhang M, 2016, Genet Mol Res, V15, DOI 10.4238/gmr.15017496
   Zhang SY, 2012, TRENDS PHARMACOL SCI, V33, P122, DOI 10.1016/j.tips.2011.11.002
   Zhang TM, 2016, J BIOL CHEM, V291, P21616, DOI 10.1074/jbc.M116.733410
   Zhou JL, 2018, BIOL REPROD, V99, P308, DOI 10.1093/biolre/ioy061
   Zhu YY, 2013, J BIOL CHEM, V288, P1099, DOI 10.1074/jbc.M112.399345
NR 209
TC 77
Z9 78
U1 3
U2 21
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2296-634X
J9 FRONT CELL DEV BIOL
JI Front. Cell. Dev. Biol.
PD SEP 10
PY 2018
VL 6
AR 104
DI 10.3389/fcell.2018.00104
PG 22
WC Cell Biology; Developmental Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Developmental Biology
GA HG9NP
UT WOS:000455335700001
PM 30250843
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Qi, YL
   Zhang, MF
   Li, H
   Frank, JA
   Dai, L
   Liu, HJ
   Zhang, Z
   Wang, C
   Chen, G
AF Qi, Yuanlin
   Zhang, Mingfang
   Li, Hui
   Frank, Jacqueline A.
   Dai, Lu
   Liu, Huijuan
   Zhang, Zhuo
   Wang, Chi
   Chen, Gang
TI Autophagy Inhibition by Sustained Overproduction of IL6 Contributes to
   Arsenic Carcinogenesis
SO CANCER RESEARCH
LA English
DT Article
ID BCL-2 FAMILY-MEMBERS; BECLIN 1; EPITHELIAL-CELLS; COLORECTAL-CANCER;
   LUNG-CANCER; INFLAMMATION; PATHWAY; IL-6; TRANSFORMATION; APOPTOSIS
AB Chronic inflammation has been implicated as an etiologic factor in cancer, whereas autophagy may help preserve cancer cell survival but exert anti-inflammatory effects. How these phenomenas interact during carcinogenesis remains unclear. We explored this question in a human bronchial epithelial cell-based model of lung carcinogenesis that is mediated by subchronic exposure to arsenic. We found that sustained overexpression of the pro-inflammatory IL6 promoted arsenic-induced cell transformation by inhibiting autophagy. Conversely, strategies to enhance autophagy counteracted the effect of IL6 in the model. These findings were confirmed and extended in a mouse model of arsenic-induced lung cancer. Mechanistic investigations suggested that mTOR inhibition contributed to the activation of autophagy, whereas IL6 overexpression was sufficient to block autophagy by supporting Beclin-1/Mcl-1 interaction. Overall, our findings argued that chronic inflammatory states driven by IL6 could antagonize autophagic states that may help preserve cancer cell survival and promote malignant progression, suggesting a need to uncouple inflammation and autophagy controls to enable tumor progression.
C1 [Qi, Yuanlin; Zhang, Mingfang; Li, Hui; Frank, Jacqueline A.; Liu, Huijuan; Chen, Gang] Univ Kentucky, Coll Med, Dept Mol & Biomed Pharmacol, Lexington, KY 40536 USA.
   [Dai, Lu; Zhang, Zhuo] Univ Kentucky, Coll Med, Grad Ctr Toxicol, Lexington, KY 40536 USA.
   [Wang, Chi] Univ Kentucky, Coll Publ Hlth, Markey Canc Ctr, Biostat Shared Resource Facil, Lexington, KY USA.
   [Wang, Chi] Univ Kentucky, Coll Publ Hlth, Dept Biostat, Lexington, KY USA.
   [Qi, Yuanlin] Fujian Med Univ, Sch Basic Med Sci, Dept Biochem & Mol Biol, Fuzhou, Fujian, Peoples R China.
   [Zhang, Mingfang] Fujian Med Univ, Sch Basic Med Sci, Dept Physiol & Pathophysiol, Fuzhou, Fujian, Peoples R China.
RP Chen, G (corresponding author), Univ Kentucky, Coll Med, Dept Mol & Biomed Pharmacol, 125 Hlth Sci Res Bldg,800 Rose St, Lexington, KY 40536 USA.
EM gangchen6@uky.edu
RI Zhang, Zhuo/B-8601-2012
OI Qi, Yuanlin/0000-0002-5253-9732; Zhang, Mingfang/0000-0001-8061-5694
FU American Cancer SocietyAmerican Cancer Society [RSG-11-116-01-CNE];
   NATIONAL CANCER INSTITUTEUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Cancer
   Institute (NCI) [P30CA177558] Funding Source: NIH RePORTER; NATIONAL
   INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISMUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute on Alcohol Abuse & Alcoholism (NIAAA) [R01AA020051]
   Funding Source: NIH RePORTER
FX This work was supported by the American Cancer Society
   (RSG-11-116-01-CNE; G. Chen).
CR Aggarwal BB, 2006, BIOCHEM PHARMACOL, V72, P1605, DOI 10.1016/j.bcp.2006.06.029
   Aivaliotis IL, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/536761
   Bhattacharya S, 2005, BIOCHEM J, V392, P335, DOI 10.1042/BJ20050465
   Brech A, 2009, MOL ONCOL, V3, P366, DOI 10.1016/j.molonc.2009.05.007
   Cavarretta IT, 2008, ADV EXP MED BIOL, V617, P547, DOI 10.1007/978-0-387-69080-3_56
   Chen G, 2004, FASEB J, V18, P1162, DOI 10.1096/fj.04-1551fje
   Cho WCS, 2011, EXPERT OPIN THER TAR, V15, P1127, DOI 10.1517/14728222.2011.599801
   Chung YC, 2003, J SURG ONCOL, V83, P222, DOI 10.1002/jso.10269
   Decker T, 2000, ONCOGENE, V19, P2628, DOI 10.1038/sj.onc.1203481
   Delk NA, 2012, AUTOPHAGY, V8, P650, DOI 10.4161/auto.19226
   Deretic V, 2012, J IMMUNOL, V189, P15, DOI 10.4049/jimmunol.1102108
   Dutta RK, 2012, INT J BIOCHEM CELL B, V44, P942, DOI 10.1016/j.biocel.2012.02.021
   Erlich S, 2007, AUTOPHAGY, V3, P561, DOI 10.4161/auto.4713
   Escudero-Lourdes C, 2012, TOXICOL APPL PHARM, V258, P10, DOI 10.1016/j.taap.2011.10.002
   EUHUS DM, 1986, J SURG ONCOL, V31, P229, DOI 10.1002/jso.2930310402
   Germain M, 2011, EMBO J, V30, P395, DOI 10.1038/emboj.2010.327
   Jeng JH, 2003, CARCINOGENESIS, V24, P1301, DOI 10.1093/carcin/bgg083
   Jo EK, 2012, MICROBES INFECT, V14, P119, DOI 10.1016/j.micinf.2011.08.014
   Jonchere Barbara, 2013, JAKSTAT, V2, pe24353, DOI 10.4161/jkst.24353
   Jones SA, 2013, IMMUNOL CELL BIOL, V91, P250, DOI 10.1038/icb.2012.82
   Kai H, 2005, ANTICANCER RES, V25, P709
   Kang R, 2011, CELL DEATH DIFFER, V18, P571, DOI 10.1038/cdd.2010.191
   Kang R, 2012, AUTOPHAGY, V8, P989, DOI 10.4161/auto.20258
   Kang R, 2012, P NATL ACAD SCI USA, V109, P7031, DOI 10.1073/pnas.1113865109
   Lee G, 2009, CURR OPIN PULM MED, V15, P303, DOI 10.1097/MCP.0b013e32832c975a
   Lee HM, 2011, J IMMUNOL, V186, P1248, DOI 10.4049/jimmunol.1001954
   Levine B, 2008, AUTOPHAGY, V4, P600, DOI 10.4161/auto.6260
   Li XZ, 2013, MOL CELL BIOCHEM, V380, P219, DOI 10.1007/s11010-013-1676-9
   Maiuri MC, 2010, EMBO J, V29, P515, DOI 10.1038/emboj.2009.377
   Mitsuyama K, 2007, ANTICANCER RES, V27, P3749
   Parys JB, 2012, CELL COMMUN SIGNAL, V10, DOI 10.1186/1478-811X-10-17
   Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002
   Pattingre S, 2008, BIOCHIMIE, V90, P313, DOI 10.1016/j.biochi.2007.08.014
   Priault M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008755
   Puthier D, 1999, EUR J IMMUNOL, V29, P3945, DOI 10.1002/(SICI)1521-4141(199912)29:12<3945::AID-IMMU3945>3.0.CO;2-O
   Spencer B, 2009, J NEUROSCI, V29, P13578, DOI 10.1523/JNEUROSCI.4390-09.2009
   Straif K, 2009, LANCET ONCOL, V10, P453, DOI 10.1016/S1470-2045(09)70134-2
   Stueckle TA, 2012, TOXICOL APPL PHARM, V261, P204, DOI 10.1016/j.taap.2012.04.003
   Wang ZS, 2013, TOXICOL APPL PHARM, V271, P20, DOI 10.1016/j.taap.2013.04.018
   White E, 2010, CURR OPIN CELL BIOL, V22, P212, DOI 10.1016/j.ceb.2009.12.008
   Xu Y, 2013, TOXICOL APPL PHARM, V272, P542, DOI 10.1016/j.taap.2013.06.017
   Yang F, 2013, J BIOL CHEM, V288, P6552, DOI 10.1074/jbc.M112.418335
   Zamarron BF, 2011, INT J BIOL SCI, V7, P651, DOI 10.7150/ijbs.7.651
   Zhang T, 2012, TOXICOL SCI, V130, P298, DOI 10.1093/toxsci/kfs240
NR 44
TC 54
Z9 59
U1 1
U2 10
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD JUL 15
PY 2014
VL 74
IS 14
BP 3740
EP 3752
DI 10.1158/0008-5472.CAN-13-3182
PG 13
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA AL1GY
UT WOS:000338875000010
PM 24830721
OA Green Accepted
DA 2022-04-25
ER

PT J
AU Lin, R
   Han, CQ
   Ding, Z
   Shi, HY
   He, RH
   Liu, J
   Qian, W
   Zhang, Q
   Fu, XC
   Deng, XH
   Zhou, SC
   Hou, XH
AF Lin, Rong
   Han, Chaoqun
   Ding, Zhen
   Shi, Huiying
   He, Ruohang
   Liu, Jun
   Qian, Wei
   Zhang, Qin
   Fu, Xiaochao
   Deng, Xiaohua
   Zhou, Shunchang
   Hou, Xiaohua
TI Knock down of BMSC-derived Wnt3a or its antagonist analogs attenuate
   colorectal carcinogenesis induced by chronic Fusobacterium nucleatum
   infection
SO CANCER LETTERS
LA English
DT Article
DE Fusobacterium nucleatum; BMSC; Wnt3a; Apc(Min/+); Colorectal cancer
ID POTENTIATES INTESTINAL TUMORIGENESIS; TG-INTERACTING FACTOR; STEM-CELLS;
   GUT MICROBIOTA; CANCER; PROMOTES; OVEREXPRESSION; INFLAMMATION;
   SUPPRESSION; AUTOPHAGY
AB By establishing the Fusobacterium nucleatum (F. nucleatum) infected-bone mesenchymal stem cells (BMSCs) transplantation model in APC(Min/+) mice, we investigated the role of BMSCs in the development of intestinal tumors induced by F. nucleatum. Apc(Min/+)+F. nucleatum + BMSCs mice showed increased susceptibility to intestinal tumors and accelerated tumor growth. BMSCs could also enhance tumor-initiating capability, invasive traits after F. nucleatum infection in vitro, and tumorigenicity in a nude murine model. Mechanistically, BMSCs were recruited to the submucosa, migrated to the mucosal layer, and might activate the canonical Wnt/beta-catenin/TGIF axis signaling. Further mechanistic results illustrated increased production of the Wnt3a protein was found in Apc(Min/+)+F. nucleatum + BMSCs mice, and BMSCs were likely the major source of Wnt3a. Intriguingly, a deletion of Wnt3a via BMSC interference or antagonist analogs led to a significantly attenuated capacity of Apc(Min/+)+F. nucleatum mice to generate intestinal tumors. The findings suggest that BMSCs have the potential to migrate and accelerate F. nucleatum-induced colorectal tumorigenesis by modulating Wnt3a secretion; knockdown of BMSC-derived Wnt3a or antagonist analogs could attenuate carcinogenesis. Thus, Wnt3a might be a potential pharmaceutical target for the prevention and treatment of F. nucleatum-related colorectal cancer.
C1 [Lin, Rong; Han, Chaoqun; Ding, Zhen; Shi, Huiying; He, Ruohang; Liu, Jun; Qian, Wei; Hou, Xiaohua] Huazhong Univ Sci & Technol, Union Hosp, Div Gastroenterol, Tongji Med Coll, Wuhan 430022, Hubei, Peoples R China.
   [Zhang, Qin] Huazhong Univ Sci & Technol, Union Hosp, Div Pathol, Tongji Med Coll, Wuhan 430022, Hubei, Peoples R China.
   [Fu, Xiaochao; Deng, Xiaohua] Hubei Ctr Ind Culture Collect & Res, Wuhan 430022, Hubei, Peoples R China.
   [Zhou, Shunchang] Huazhong Univ Sci & Technol, Div Expt Anim, Tongji Med Coll, Wuhan 430030, Hubei, Peoples R China.
RP Hou, XH (corresponding author), Huazhong Univ Sci & Technol, Union Hosp, Dept Gastroenterol, Tongji Med Coll, 1277 Jiefang Ave, Wuhan, Hubei, Peoples R China.
EM houxh@hust.edu.cn
OI lin, rong/0000-0001-9463-8942
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81720108006,81470039, 81330014,
   81272656,81800467]
FX This study was supported in part by the National Natural Science
   Foundation of China (No. 81720108006,81470039, 81330014,
   81272656,81800467).
CR Abed J, 2016, CELL HOST MICROBE, V20, P215, DOI 10.1016/j.chom.2016.07.006
   Brennan CA, 2016, ANNU REV MICROBIOL, V70, P395, DOI 10.1146/annurev-micro-102215-095513
   Bullman S, 2017, SCIENCE, V358, P1443, DOI 10.1126/science.aal5240
   Chen ZX, 2014, BIOCHEM BIOPH RES CO, V450, P1402, DOI 10.1016/j.bbrc.2014.07.002
   De Boeck A, 2013, GUT, V62, P550, DOI 10.1136/gutjnl-2011-301393
   Dube C, 2017, AM J GASTROENTEROL, V112, P1790, DOI 10.1038/ajg.2017.360
   Eklof V, 2017, INT J CANCER, V141, P2528, DOI 10.1002/ijc.31011
   Fan HY, 2012, CELL MOL IMMUNOL, V9, P473, DOI 10.1038/cmi.2012.40
   Fong WN, 2020, ONCOGENE, V39, P4925, DOI 10.1038/s41388-020-1341-1
   Gong W, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.276
   Han CQ, 2016, CELL PHYSIOL BIOCHEM, V38, P2464, DOI 10.1159/000445597
   He S, 2015, CHIN J CANCER, V34, DOI 10.1186/s40880-015-0052-4
   Houghton J, 2004, SCIENCE, V306, P1568, DOI 10.1126/science.1099513
   Huang WH, 2013, ONCOGENE, V32, P4343, DOI 10.1038/onc.2012.458
   Kaur N, 2013, MOL CELL NEUROSCI, V54, P44, DOI 10.1016/j.mcn.2013.01.001
   Kostic AD, 2013, CELL HOST MICROBE, V14, P207, DOI 10.1016/j.chom.2013.07.007
   Leung A, 2015, EXPERT REV GASTROENT, V9, P651, DOI 10.1586/17474124.2015.1001745
   Ley RE, 2006, CELL, V124, P837, DOI 10.1016/j.cell.2006.02.017
   Lin R, 2015, STEM CELLS, V33, P3545, DOI 10.1002/stem.2197
   Lin R, 2013, STEM CELLS DEV, V22, P2836, DOI 10.1089/scd.2013.0166
   Liu ZM, 2011, BIOCHEM J, V438, P349, DOI 10.1042/BJ20101653
   Mima K, 2016, GUT, V65, P1973, DOI 10.1136/gutjnl-2015-310101
   Mizutani S, 2020, CANCER SCI, V111, P766, DOI 10.1111/cas.14298
   Nasuno M, 2014, STEM CELLS, V32, P913, DOI 10.1002/stem.1594
   Neish AS, 2009, GASTROENTEROLOGY, V136, P65, DOI 10.1053/j.gastro.2008.10.080
   Newman JV, 2001, J INFECT DIS, V184, P227, DOI 10.1086/321998
   O'Keefe SJD, 2016, NAT REV GASTRO HEPAT, V13, P691, DOI 10.1038/nrgastro.2016.165
   Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74
   Pierre CC, 2015, BBA-MOL BASIS DIS, V1852, P1846, DOI 10.1016/j.bbadis.2015.06.011
   Qi LS, 2015, INT J MOL SCI, V16, P18564, DOI 10.3390/ijms160818564
   Quante M, 2011, CANCER CELL, V19, P257, DOI 10.1016/j.ccr.2011.01.020
   Razzaque MS, 2016, BBA-REV CANCER, V1865, P101, DOI 10.1016/j.bbcan.2015.10.003
   Rubinstein MR, 2013, CELL HOST MICROBE, V14, P195, DOI 10.1016/j.chom.2013.07.012
   Sekiya I, 2002, STEM CELLS, V20, P530, DOI 10.1634/stemcells.20-6-530
   Shi HY, 2017, CELL PHYSIOL BIOCHEM, V42, P2418, DOI 10.1159/000480184
   Song J, 2015, TUMOR BIOL, V36, P2013, DOI 10.1007/s13277-014-2808-x
   Sonnenberg GF, 2012, IMMUNITY, V37, P601, DOI 10.1016/j.immuni.2012.10.003
   Tsai KS, 2011, GASTROENTEROLOGY, V141, P1046, DOI 10.1053/j.gastro.2011.05.045
   Varon C, 2012, GASTROENTEROLOGY, V142, P281, DOI 10.1053/j.gastro.2011.10.036
   Wei ZL, 2016, ONCOTARGET, V7, P46158, DOI 10.18632/oncotarget.10064
   Yang Y., 2016, GASTROENTEROLOGY
   Yeh BW, 2016, TOXICOL APPL PHARM, V290, P98, DOI 10.1016/j.taap.2015.11.007
   Yeh BW, 2012, AM J PATHOL, V181, P1044, DOI 10.1016/j.ajpath.2012.05.024
   Yu J, 2017, GUT, V66, P70, DOI 10.1136/gutjnl-2015-309800
   Yu TC, 2017, CELL, V170, P548, DOI 10.1016/j.cell.2017.07.008
   Zhang MZ, 2015, CANCER CELL, V27, P547, DOI 10.1016/j.ccell.2015.03.002
   Zitvogel L, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.3010473
NR 47
TC 7
Z9 7
U1 6
U2 25
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0304-3835
EI 1872-7980
J9 CANCER LETT
JI Cancer Lett.
PD DEC 28
PY 2020
VL 495
BP 165
EP 179
DI 10.1016/j.canlet.2020.08.032
PG 15
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA OS5OM
UT WOS:000590213100001
PM 32920199
DA 2022-04-25
ER

PT J
AU Chen, YY
   Chen, Y
   Zhang, JX
   Cao, P
   Su, WH
   Deng, YC
   Zhan, N
   Fu, XS
   Huang, Y
   Dong, WG
AF Chen, Yongyu
   Chen, Yan
   Zhang, Jixiang
   Cao, Pan
   Su, Wenhao
   Deng, Yunchao
   Zhan, Na
   Fu, Xiangsheng
   Huang, Yun
   Dong, Weiguo
TI Fusobacterium nucleatum Promotes Metastasis in Colorectal Cancer by
   Activating Autophagy Signaling via the Upregulation of CARD3 Expression
SO THERANOSTICS
LA English
DT Article
DE microbe; gene regulation; gene targeting; colorectal cancer
ID CELLS; CARCINOGENESIS; BINDING
AB Aims: We aimed to measure the abundance of Fusobacterium nucleatum (F. nucleatum) in colorectal cancer (CRC) tissues from patients and to uncover the function of this bacterium in colorectal tumor metastasis.
   Methods: We collected metastatic and non-metastatic CRC tissues to analyze F. nucleatum abundance. Cells were incubated with F. nucleatum or chloroquine (CQ) or were transfected with CARD3-targeting siRNA; the expression of mRNAs and proteins was then measured. CRC cells stably transfected with shRNA-luc were mixed with F. nucleatum and intravenously injected into BALB/cJ mice. APC(Min/+), CARD3(-/-)and CARD3(wt) C57BL mice were given F. nucleatum; some mice were given azoxymethane (AOM) and dextran sodium sulfate (DSS).
   Results: F. nucleatum was abundant in CRC tissues from patients with metastasis. F. nucleatum infection increased CRC cell motility and upregulated the expression of CARD3, LC3-II, Beclin1 and Vimentin, and downregulated the expression of E-cadherin and P62 in CRC cells. These effects were attenuated by treatment with CQ, siCARD3 or both. APC(Min/+) mice gavaged with F. nucleatum developed more aggressive tumors than control mice. After AOM/DSS administration, the colorectums of CARD3(-/-) mice had fewer tumors than those of control mice. Tumors from CARD3(-/-) mice had lower levels of LC3-II and Beclin1 and higher levels of P62 than those from control mice. BALB/cJ mice injected with both CT26-luc cells and F. nucleatum formed more metastases than control mice. CQ treatment, CARD3 knockdown or both reduced the ability of CT26-luc cells to form metastases in vivo.
   Conclusions: F. nucleatum is enriched in CRC tissues from patients with metastasis. F. nucleatum orchestrates CARD3 and autophagy to control CRC metastasis. Measuring and targeting F. nucleatum and its associated pathways will yield approaches for the prevention and treatment of CRC metastasis.
C1 [Chen, Yongyu; Chen, Yan; Zhang, Jixiang; Cao, Pan; Su, Wenhao; Deng, Yunchao; Zhan, Na; Dong, Weiguo] Wuhan Univ, Renmin Hosp, Dept Gastroenterol, Wuhan, Hubei, Peoples R China.
   [Chen, Yongyu; Chen, Yan; Zhang, Jixiang; Cao, Pan; Su, Wenhao; Deng, Yunchao; Zhan, Na; Dong, Weiguo] Key Lab Hubei Prov Digest Syst Dis, Wuhan, Hubei, Peoples R China.
   [Zhang, Jixiang; Su, Wenhao; Zhan, Na] Wuhan Univ, Renmin Hosp, Cent Lab, Wuhan, Hubei, Peoples R China.
   [Fu, Xiangsheng] North Sichuan Med Coll, Affiliated Hosp, Dept Gastroenterol, Rd Wenhua 63, Nanchong City 637000, Region Shunqing, Peoples R China.
   [Huang, Yun] Texas A&M Univ, Inst Biosci & Technol, Ctr Epigenet & Dis Prevent, Houston, TX 77030 USA.
RP Dong, WG (corresponding author), Wuhan Univ, Renmin Hosp, Dept Gastroenterol, Key Lab Hubei Prov Digest Syst Dis, Jiefang Rd 238, Wuhan 430060, Hubei, Peoples R China.
EM dongweiguo@whu.edu.cn
RI Fu, Xiangsheng/H-9411-2019
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81870392, 81372551, 81572426]; Guiding
   Foundation of Renmin Hospital of Wuhan University [RMYD2018Z01]
FX This work was supported by grants from the National Natural Science
   Foundation of China (No. 81870392, No. 81372551, No. 81572426), and the
   Guiding Foundation of Renmin Hospital of Wuhan University (No.
   RMYD2018Z01).
CR Abed J, 2016, CELL HOST MICROBE, V20, P215, DOI 10.1016/j.chom.2016.07.006
   Anand PK, 2011, J BIOL CHEM, V286, P42981, DOI 10.1074/jbc.M111.310599
   Arthur JC, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5724
   Bullman S, 2017, SCIENCE, V358, P1443, DOI 10.1126/science.aal5240
   Caporaso JG, 2010, NAT METHODS, V7, P335, DOI 10.1038/nmeth.f.303
   Castellarin M, 2012, GENOME RES, V22, P299, DOI 10.1101/gr.126516.111
   Chen DL, 2017, THERANOSTICS, V7, P4836, DOI 10.7150/thno.20942
   Chen T, 2018, CANCER IMMUNOL IMMUN, V67, P1635, DOI 10.1007/s00262-018-2233-x
   Chen YY, 2017, ONCOTARGET, V8, P31705, DOI 10.18632/oncotarget.15992
   Dienstmann R, 2017, NAT REV CANCER, V17, P79, DOI 10.1038/nrc.2016.126
   Dower CM, 2018, MOL CANCER THER, V17, P2365, DOI 10.1158/1535-7163.MCT-18-0176
   Dower CM, 2018, AUTOPHAGY, V14, P1110, DOI 10.1080/15548627.2018.1450020
   Du F, 2019, THERANOSTICS, V9, P3879, DOI 10.7150/thno.31716
   Edgar RC, 2013, NAT METHODS, V10, P996, DOI [10.1038/NMETH.2604, 10.1038/nmeth.2604]
   Edgar RC, 2011, BIOINFORMATICS, V27, P2194, DOI 10.1093/bioinformatics/btr381
   Gur C, 2015, IMMUNITY, V42, P344, DOI 10.1016/j.immuni.2015.01.010
   Irving AT, 2014, CELL HOST MICROBE, V15, P623, DOI 10.1016/j.chom.2014.04.001
   Kostic AD, 2013, CELL HOST MICROBE, V14, P207, DOI 10.1016/j.chom.2013.07.007
   Kostic AD, 2012, GENOME RES, V22, P292, DOI 10.1101/gr.126573.111
   Krieg A, 2009, P NATL ACAD SCI USA, V106, P14524, DOI 10.1073/pnas.0907131106
   Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/NMETH.1923, 10.1038/nmeth.1923]
   Li B, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-323
   Li RQ, 2009, BIOINFORMATICS, V25, P1966, DOI 10.1093/bioinformatics/btp336
   Ling H, 2016, GUT, V65, P977, DOI 10.1136/gutjnl-2015-309372
   Liu CY, 2014, FEBS J, V281, P5159, DOI 10.1111/febs.13055
   Liu Z, 2019, J CELL MOL MED, V23, P2083, DOI 10.1111/jcmm.14117
   Magoc T, 2011, BIOINFORMATICS, V27, P2957, DOI 10.1093/bioinformatics/btr507
   Mai DM, 2018, THERANOSTICS, V8, P5213, DOI 10.7150/thno.28001
   Mima K, 2016, GUT, V65, P1973, DOI 10.1136/gutjnl-2015-310101
   Mima K, 2015, JAMA ONCOL, V1, P653, DOI 10.1001/jamaoncol.2015.1377
   Reimand J, 2019, NAT PROTOC, V14, P482, DOI 10.1038/s41596-018-0103-9
   Rubinstein MR, 2013, CELL HOST MICROBE, V14, P195, DOI 10.1016/j.chom.2013.07.012
   Sharifi MN, 2016, CELL REP, V15, P1660, DOI 10.1016/j.celrep.2016.04.065
   Siegel RL, 2019, CA-CANCER J CLIN, V69, P7, DOI 10.3322/caac.21551
   Siegel RL, 2017, CA-CANCER J CLIN, V67, P177, DOI 10.3322/caac.21395
   Singel SM, 2014, BREAST CANCER RES, V16, DOI 10.1186/bcr3629
   Sun TT, 2015, INT J CANCER, V136, P1053, DOI 10.1002/ijc.29061
   Tilg H, 2018, CANCER CELL, V33, P954, DOI 10.1016/j.ccell.2018.03.004
   Travassos LH, 2010, NAT IMMUNOL, V11, P55, DOI 10.1038/ni.1823
   Wang Y, 2018, BIOMATERIALS, V168, P1, DOI 10.1016/j.biomaterials.2017.10.039
   Yang YZ, 2017, GASTROENTEROLOGY, V152, P851, DOI 10.1053/j.gastro.2016.11.018
   Yu JH, 2016, INT J CANCER, V139, P1318, DOI 10.1002/ijc.30168
   Yu TC, 2017, CELL, V170, P548, DOI 10.1016/j.cell.2017.07.008
   Zare A, 2018, CANCERS, V10, DOI 10.3390/cancers10060184
   Zhang YF, 2019, NAT IMMUNOL, V20, P433, DOI 10.1038/s41590-019-0324-2
NR 45
TC 31
Z9 34
U1 5
U2 27
PU IVYSPRING INT PUBL
PI LAKE HAVEN
PA PO BOX 4546, LAKE HAVEN, NSW 2263, AUSTRALIA
SN 1838-7640
J9 THERANOSTICS
JI Theranostics
PY 2020
VL 10
IS 1
BP 323
EP 339
DI 10.7150/thno.38870
PG 17
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA JO0ZI
UT WOS:000497314800022
PM 31903123
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Kumari, M
   Ray, L
   Purohit, MP
   Patnaik, S
   Pant, AB
   Shukla, Y
   Kumar, P
   Gupta, KC
AF Kumari, Manisha
   Ray, L.
   Purohit, M. P.
   Patnaik, S.
   Pant, A. B.
   Shukla, Y.
   Kumar, P.
   Gupta, K. C.
TI Curcumin loading potentiates the chemotherapeutic efficacy of selenium
   nanoparticles in HCT116 cells and Ehrlich's ascites carcinoma bearing
   mice
SO EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
LA English
DT Article
DE Cancer; Selenium nanoparticles; Curcumin; Autophagy; Apoptosis
ID NF-KAPPA-B; HUMAN PROSTATE-CANCER; INDUCED APOPTOSIS; CELLULAR UPTAKE;
   CYCLE ARREST; IN-VITRO; ELEMENTAL SELENIUM; DOWN-REGULATION; INDUCTION;
   EXPRESSION
AB The anticancer properties of selenium (Se) and curcumin nanoparticles in solo formulations as well as in combination with other therapeutic agents have been proved time and again. Exploiting this facet of the two, we clubbed their tumoricidal characteristics and designed curcumin loaded Se nanoparticles (SeCurNPs) to achieve an enhanced therapeutic effect. We evaluated their therapeutic effects on different cancer cell lines and Ehrlich's ascites carcinoma mouse model. In vitro results showed that Se-CurNPs were most effective on colorectal carcinoma cells (HCT116) compared to the other cancer cell lines used and possessed pleiotropic anticancer effects. The therapeutic effect on HCT116 was primarily attributed to an elevated level of autophagy and apoptosis as evident from significant up-regulation of autophagy associated (LOB-II) and pro-apoptotic (Bax) proteins, down-regulation of anti-apoptotic (Bcl-2) protein and Cytochrome c (cyt c) release from mitochondria along with reduced NPKB signaling and EMT based machineries marked by downregulation of inflammation (NFxB, phospho-NFKB) and epithelialmesenchymal transition (CD44, N-cadherin) associated proteins. In vivo studies on Ehrlich's ascites carcinoma (EAC) mice model indicated that Se-CurNPs significantly reduced the tumor load and enhanced the mean survival time (days) of tumor-bearing EAC mice. (C) 2017 Elsevier B.V. All rights reserved.
C1 [Kumari, Manisha; Kumar, P.; Gupta, K. C.] CSIR Inst Genom & Integrat Biol, Delhi Univ Campus,Mall Rd, Delhi 110007, India.
   [Ray, L.; Purohit, M. P.; Patnaik, S.; Pant, A. B.; Shukla, Y.; Gupta, K. C.] CSIR Indian Inst Toxicol Res, MG Marg, Lucknow 226001, Uttar Pradesh, India.
   [Kumari, Manisha; Purohit, M. P.] Acad Sci & Innovat Res AcSIR, New Delhi, India.
   [Gupta, K. C.] Indian Inst Technol, Dept Biol Sci & Bioengn BSBE, Kanpur, Uttar Pradesh, India.
   [Gupta, K. C.] Indian Inst Technol, Ctr Environm Sci & Engn, Kanpur, Uttar Pradesh, India.
RP Gupta, KC (corresponding author), CSIR Inst Genom & Integrat Biol, Delhi Univ Campus,Mall Rd, Delhi 110007, India.; Gupta, KC (corresponding author), Indian Inst Technol, Dept Biol Sci & Bioengn BSBE, Kanpur, Uttar Pradesh, India.; Gupta, KC (corresponding author), Indian Inst Technol, Ctr Environm Sci & Engn, Kanpur, Uttar Pradesh, India.
EM kcgupta9@gmail.com
RI Kumari, Manisha/AAX-5517-2021; Patnaik, Satyakam/O-3617-2019
OI Patnaik, Satyakam/0000-0003-4920-236X
FU CSIR network projectCouncil of Scientific & Industrial Research (CSIR) -
   India [BSC0112]; Indian Council of Medical Research (ICMR), New
   DelhiIndian Council of Medical Research (ICMR); CSIRCouncil of
   Scientific & Industrial Research (CSIR) - India
FX Financial support from CSIR network project BSC0112 is gratefully
   acknowledged. KCG thanks, Indian Council of Medical Research (ICMR), New
   Delhi for awarding Distinguished Scientist Chair at IGIB, Delhi. MK is
   thankful to CSIR for providing Senior Research Fellowship for carrying
   out this work. Ms. N. Arjaria and Mr. Jaishankar, CSIR-IITR are
   acknowledged for helping in TEM studies. Dr. P.N. Saxena, CSIR-IITR is
   acknowledged for helping in SEM studies. Mr. Puneet Khare, CSIR-IITR is
   acknowledged for helping in flow cytometry Mr. S.H.N. Naqvi, CSIR-IITR
   is acknowledged for helping in animal studies. CSIR-Central Drug
   Research Institute, Lucknow is acknowledged for use of sophisticated
   instrumentation facility for FTIR.
CR Barrera LN, 2013, EUR J NUTR, V52, P1327, DOI 10.1007/s00394-012-0442-1
   Bera S, 2013, MUTAGENESIS, V28, P127, DOI 10.1093/mutage/ges064
   Bharti AC, 2003, BLOOD, V101, P1053, DOI 10.1182/blood-2002-05-1320
   Bhattacharjee A, 2017, MOL CELL BIOCHEM, V424, P13, DOI 10.1007/s11010-016-2839-2
   Bolte S, 2006, J MICROSC-OXFORD, V224, P213, DOI 10.1111/j.1365-2818.2006.01706.x
   Buhrmann C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107514
   Chen TF, 2009, BIOMED PHARMACOTHER, V63, P105, DOI 10.1016/j.biopha.2008.03.009
   Chou TC, 2006, PHARMACOL REV, V58, P621, DOI 10.1124/pr.58.3.10
   Chou TC, 2010, CANCER RES, V70, P440, DOI 10.1158/0008-5472.CAN-09-1947
   Combs GF, 1998, PHARMACOL THERAPEUT, V79, P179, DOI 10.1016/S0163-7258(98)00014-X
   Elmore S, 2007, TOXICOL PATHOL, V35, P495, DOI 10.1080/01926230701320337
   Gasparian AV, 2002, MOL CANCER THER, V1, P1079
   Goel A, 2006, CANCER BIOL THER, V5, P529, DOI 10.4161/cbt.5.5.2654
   GREEDER GA, 1980, SCIENCE, V209, P825, DOI 10.1126/science.7406957
   Guo X, 2013, MOL CARCINOGEN, V52, P879, DOI 10.1002/mc.21933
   Hu H, 2008, CLIN CANCER RES, V14, P1150, DOI 10.1158/1078-0432.CCR-07-4037
   Huang F, 2009, FREE RADICAL BIO MED, V46, P1186, DOI 10.1016/j.freeradbiomed.2009.01.026
   Huang YY, 2013, BIOMATERIALS, V34, P7106, DOI 10.1016/j.biomaterials.2013.04.067
   Imani M, 2010, AAPS PHARMSCITECH, V11, P1268, DOI 10.1208/s12249-010-9494-9
   Ito T, 2004, LANGMUIR, V20, P6940, DOI 10.1021/la049524t
   Kong L, 2011, BIOMATERIALS, V32, P6515, DOI 10.1016/j.biomaterials.2011.05.032
   Li H, 2011, CANCER RES, V71, P3625, DOI 10.1158/0008-5472.CAN-10-4475
   Li K, 2010, CANCER INVEST, V28, P479, DOI 10.3109/07357900903476745
   Li KC, 2016, ACS APPL MATER INTER, V8, P12082, DOI 10.1021/acsami.6b04579
   Li S, 2007, MOL CANCER THER, V6, P1031, DOI 10.1158/1535-7163.MCT-06-0643
   Liu T, 2015, NANOMED-NANOTECHNOL, V11, P947, DOI 10.1016/j.nano.2015.01.009
   Liu W, 2012, ACS NANO, V6, P6578, DOI 10.1021/nn202452c
   Lu JJ, 2011, MOL CELL BIOCHEM, V354, P247, DOI 10.1007/s11010-011-0824-3
   Luo HY, 2012, COLLOID SURFACE B, V94, P304, DOI 10.1016/j.colsurfb.2012.02.006
   Madhavi Doddabele, 2014, Integr Med (Encinitas), V13, P24
   Maillet A, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.185
   Mousa Shaker A, 2011, Cancers (Basel), V3, P2888, DOI 10.3390/cancers3032888
   Mukhopadhyay A, 2001, ONCOGENE, V20, P7597, DOI 10.1038/sj.onc.1204997
   Muller RH, 2002, INT J PHARM, V237, P151, DOI 10.1016/S0378-5173(02)00040-6
   Pal S, 2001, BIOCHEM BIOPH RES CO, V288, P658, DOI 10.1006/bbrc.2001.5823
   Parveen S, 2008, J DRUG TARGET, V16, P108, DOI [10.1080/10611860701794353, 10.1080/10611860701794353 ]
   Patel VB, 2010, NUTR CANCER, V62, P958, DOI 10.1080/01635581.2010.510259
   Peer D, 2007, NAT NANOTECHNOL, V2, P751, DOI 10.1038/nnano.2007.387
   Pi J, 2013, BIOORG MED CHEM LETT, V23, P6296, DOI 10.1016/j.bmcl.2013.09.078
   Prokopczyk B, 2000, CANCER LETT, V161, P35, DOI 10.1016/S0304-3835(00)00590-5
   Rai G, 2016, PHYTOMEDICINE, V23, P233, DOI 10.1016/j.phymed.2015.12.020
   Rajitha B, 2016, CANCER LETT, V373, P227, DOI 10.1016/j.canlet.2016.01.052
   Rao J, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-71
   Rashmi R, 2005, CARCINOGENESIS, V26, P713, DOI 10.1093/carcin/bgi025
   Ray L, 2013, BIOMATERIALS, V34, P3064, DOI 10.1016/j.biomaterials.2012.12.044
   Rayman MP, 2012, LANCET, V379, P1256, DOI 10.1016/S0140-6736(11)61452-9
   Reid ME, 2004, J TRACE ELEM MED BIO, V18, P69, DOI 10.1016/j.jtemb.2004.03.004
   Sanmartin C, 2012, INT J MOL SCI, V13, P9649, DOI 10.3390/ijms13089649
   Sreenivasan S, 2015, CURR EYE RES, V40, P1153, DOI 10.3109/02713683.2014.987870
   Sun JB, 2013, COLLOID SURFACE B, V111, P367, DOI 10.1016/j.colsurfb.2013.06.032
   Sun QL, 2016, ONCOTARGET, V7, P28369, DOI 10.18632/oncotarget.8619
   Tan L, 2009, BIOSENS BIOELECTRON, V24, P2268, DOI 10.1016/j.bios.2008.10.030
   Thacker PC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120045
   Tinari A, 2008, METHOD ENZYMOL, V442, P1, DOI 10.1016/S0076-6879(08)01401-8
   Ungvari E, 2014, FOOD CHEM TOXICOL, V64, P298, DOI 10.1016/j.fct.2013.12.004
   Wang HL, 2007, FREE RADICAL BIO MED, V42, P1524, DOI 10.1016/j.freeradbiomed.2007.02.013
   Watson JL, 2008, EXP MOL PATHOL, V84, P230, DOI 10.1016/j.yexmp.2008.02.002
   Watson JL, 2010, CANCER LETT, V297, P1, DOI 10.1016/j.canlet.2010.04.018
   Wirawan E, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2009.16
   Wu HL, 2013, J AGR FOOD CHEM, V61, P9859, DOI 10.1021/jf403564s
   Xia Y, 2015, NANOSCALE RES LETT, V10, DOI 10.1186/s11671-015-1051-8
   Yadav N, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.305
   Yager P, 2006, NATURE, V442, P412, DOI 10.1038/nature05064
   Yallapu MM, 2013, CURR PHARM DESIGN, V19, P1994
   Yallapu MM, 2012, DRUG DISCOV TODAY, V17, P71, DOI 10.1016/j.drudis.2011.09.009
   Yamamoto Y, 2001, J CLIN INVEST, V107, P135, DOI 10.1172/JCI11914
   Yang F, 2012, INT J NANOMED, V7, P835, DOI 10.2147/IJN.S28278
   Yang JY, 2015, INT J CLIN EXP PATHO, V8, P9272
   Yang Z, 2015, BIOMATER SCI-UK, V3, P1035, DOI 10.1039/c4bm00369a
   Yu B, 2016, RSC ADV, V6, P2171, DOI 10.1039/c5ra21460b
   Zebib B, 2010, BIOINORG CHEM APPL, V2010, DOI 10.1155/2010/292760
   Zeng HW, 2013, J NUTR BIOCHEM, V24, P776, DOI 10.1016/j.jnutbio.2012.04.008
   Zeng HW, 2009, J NUTR, V139, P1613, DOI 10.3945/jn.109.110320
   Zhang JS, 2008, TOXICOL SCI, V101, P22, DOI 10.1093/toxsci/kfm221
   Zheng SY, 2012, INT J NANOMED, V7, P3939, DOI 10.2147/IJN.S30940
NR 75
TC 31
Z9 33
U1 2
U2 49
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0939-6411
EI 1873-3441
J9 EUR J PHARM BIOPHARM
JI Eur. J. Pharm. Biopharm.
PD AUG
PY 2017
VL 117
BP 346
EP 362
DI 10.1016/j.ejpb.2017.05.003
PG 17
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA FA0VJ
UT WOS:000405154400035
PM 28499854
DA 2022-04-25
ER

PT J
AU Takada, Y
   Tayama, I
   Sayama, T
   Sasama, H
   Saruta, M
   Kikuchi, A
   Ishimoto, M
   Tsukamoto, C
AF Takada, Yoshitake
   Tayama, Ippei
   Sayama, Takashi
   Sasama, Hiroko
   Saruta, Masayasu
   Kikuchi, Akio
   Ishimoto, Masao
   Tsukamoto, Chigen
TI Genetic analysis of variations in the sugar chain composition at the C-3
   position of soybean seed saponins
SO BREEDING SCIENCE
LA English
DT Article
DE genetic analysis; Glycine max (L.) Merrill; Glycine soja Sieb. et Zucc.;
   DDMP saponin; group A saponin; sugar chain composition; mapping
ID GLYCINE-MAX MERRILL; COLON-CANCER CELLS; GROUP-A SAPONIN;
   SOYASAPOGENOL-A; STRUCTURAL ELUCIDATION; L. MERRILL; SOYASAPONINS;
   MACROAUTOPHAGY; BISDESMOSIDES; CONSTITUENTS
AB Saponins are sterols or triterpene glycosides that are widely distributed in plants. The biosynthesis of soybean saponins is thought to involve many kinds of glycosyltransferases, which is reflected in their structural diversity. Here, we performed linkage analyses of the Sg-3 and Sg-4 loci, which may control the sugar chain composition at the C-3 sugar moieties of the soybean saponin aglycones soyasapogenols A and B. The Sg-3 locus, which controls the production of group A saponin Af, was mapped to chromosome (Chr-) 10. The Sg-4 locus, which controls the production of DDMP saponin beta a, was mapped to Chr-1. To elucidate the preference of sugar chain formation at the C-3 and C-22 positions, we analyzed the F-2 population derived from a cross between a mutant variety, Kinusayaka (sg-1(0)), for the sugar chain structure at C-22 position, and Mikuriya-ao (sg-3), with respect to the segregation of the composition of the group A saponins, and found that the formation of these sugar chains was independently regulated. Furthermore, a novel saponin, predicted to be A0-gamma g, 3-O-[beta-D-galactopyranosyl (1 -> 2)-beta-D-glucuronopyranosyl]-22-O-alpha-L-arabinopyranosyl-soyasapogenol A, appeared in the hypocotyl of F-2 individuals with genotype sg-1(0)/sg-1(0) sg-3/sg-3.
C1 [Takada, Yoshitake; Saruta, Masayasu] NARO Western Reg Agr Res Ctr, Zentsuuji, Kagawa 7658508, Japan.
   [Tayama, Ippei; Sasama, Hiroko; Tsukamoto, Chigen] Iwate Univ, Grad Sch Agr, Morioka, Iwate 0208550, Japan.
   [Sayama, Takashi; Sasama, Hiroko; Ishimoto, Masao] Natl Inst Agrobiol Sci, Tsukuba, Ibaraki 3058602, Japan.
   [Kikuchi, Akio] NARO Tohoku Agr Res Ctr, Akita 0192112, Japan.
RP Takada, Y (corresponding author), NARO Western Reg Agr Res Ctr, 1-3-1 Senyuu, Zentsuuji, Kagawa 7658508, Japan.
EM yottake@affrc.go.jp
FU Ministry of Agriculture, Forestry and Fisheries of JapanMinistry of
   Agriculture Forestry & Fisheries - Japan [18063, DD-3260]
FX This work was supported by the Research Project for Utilizing Advanced
   Technologies in Agriculture, Forestry and Fisheries (18063) and in part
   by the Research Project for Genomics for Agricultural Innovation
   (DD-3260) of the Ministry of Agriculture, Forestry and Fisheries of
   Japan.
CR BURROWS JC, 1987, PHYTOCHEMISTRY, V26, P1214, DOI 10.1016/S0031-9422(00)82387-0
   Ellington AA, 2006, CARCINOGENESIS, V27, P298, DOI 10.1093/carcin/bgi214
   Ellington AA, 2005, CARCINOGENESIS, V26, P159, DOI 10.1093/carcin/bgh297
   Hayashi K, 1997, PLANTA MED, V63, P102, DOI 10.1055/s-2006-957622
   Hwang TY, 2009, DNA RES, V16, P213, DOI 10.1093/dnares/dsp010
   Ishii Y, 2006, BIOL PHARM BULL, V29, P1759, DOI 10.1248/bpb.29.1759
   Kikuchi A, 1999, BREEDING SCI, V49, P167, DOI 10.1270/jsbbs.49.167
   Kinjo J, 1998, PLANTA MED, V64, P233, DOI 10.1055/s-2006-957416
   KITAGAWA I, 1988, CHEM PHARM BULL, V36, P2819
   KITAGAWA I, 1982, CHEM PHARM BULL, V30, P2294
   Kosambi D. D., 1944, ANN EUGENICS, V12, P172
   KUDOU S, 1992, BIOSCI BIOTECH BIOCH, V56, P142, DOI 10.1271/bbb.56.142
   KUDOU S, 1993, BIOSCI BIOTECH BIOCH, V57, P546, DOI 10.1271/bbb.57.546
   Kurosawa Y, 2002, PLANTA, V215, P620, DOI 10.1007/s00425-002-0781-x
   OKUBO K, 1992, BIOSCI BIOTECH BIOCH, V56, P99, DOI 10.1271/bbb.56.99
   Shibuya M, 2010, FEBS LETT, V584, P2258, DOI 10.1016/j.febslet.2010.03.037
   SHIMOYAMADA M, 1991, AGR BIOL CHEM TOKYO, V55, P1403, DOI 10.1080/00021369.1991.10870766
   SHIMOYAMADA M, 1990, AGR BIOL CHEM TOKYO, V54, P77, DOI 10.1080/00021369.1990.10869887
   SHIRAIWA M, 1990, AGR BIOL CHEM TOKYO, V54, P1347, DOI 10.1080/00021369.1990.10870134
   SHIRAIWA M, 1991, AGR BIOL CHEM TOKYO, V55, P323, DOI 10.1080/00021369.1991.10870575
   SHIRAIWA M, 1991, AGR BIOL CHEM TOKYO, V55, P315, DOI 10.1080/00021369.1991.10870574
   Takada Y, 2010, BREEDING SCI, V60, P3, DOI 10.1270/jsbbs.60.3
   TANIYAMA T, 1988, CHEM PHARM BULL, V36, P2829
   TOPPING DL, 1980, AM J CLIN NUTR, V33, P783, DOI 10.1093/ajcn/33.4.783
   TSUKAMOTO C, 1992, PHYTOCHEMISTRY, V31, P4139, DOI 10.1016/0031-9422(92)80429-I
   TSUKAMOTO C, 1993, PHYTOCHEMISTRY, V34, P1351, DOI 10.1016/0031-9422(91)80028-Y
   Tsukamoto C., 1995, J AGR FOOD CHEM, V43, P1184
   Tsukamoto C, 2006, NUTR DIS PREV, P155
   Voorrips RE, 2002, J HERED, V93, P77, DOI 10.1093/jhered/93.1.77
NR 29
TC 26
Z9 27
U1 2
U2 27
PU JAPANESE SOC BREEDING
PI TOKYO
PA UNIV TOKYO, GRADUATE SCHOOL AGRICULTURAL LIFE SCIENCES, BUNKYO-KU,
   TOKYO, 113-8657, JAPAN
SN 1344-7610
EI 1347-3735
J9 BREEDING SCI
JI Breed. Sci.
PD JAN
PY 2011
VL 61
IS 5
SI SI
BP 639
EP 645
DI 10.1270/jsbbs.61.639
PG 7
WC Agronomy; Plant Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Agriculture; Plant Sciences
GA 948NY
UT WOS:000304511100022
PM 23136503
OA Green Published, Bronze, Green Submitted
DA 2022-04-25
ER

PT J
AU Li, H
   Tian, ML
   Yu, G
   Liu, YC
   Wang, X
   Zhang, J
   Ji, SQ
   Zhu, J
   Wan, YL
   Tang, JQ
AF Li, Hui
   Tian, Mao-Lin
   Yu, Ge
   Liu, Yu-Cun
   Wang, Xin
   Zhang, Jing
   Ji, Shi-Qi
   Zhu, Jing
   Wan, Yuan-Lian
   Tang, Jian-Qiang
TI Hyperthermia synergizes with tissue factor knockdown to suppress the
   growth and hepatic metastasis of colorectal cancer in orthotopic tumor
   model
SO JOURNAL OF SURGICAL ONCOLOGY
LA English
DT Article
DE hyperthermia; tissue factor; colorectal cancer; apoptosis; matrix
   metalloproteinase; metastasis
ID FACTOR EXPRESSION; GASTRIC-CANCER; JNK; ANGIOGENESIS; CHEMOTHERAPY;
   COMBINATION; INHIBITION; THROMBOSIS; INDUCTION; AUTOPHAGY
AB Background Tissue factor (TF) is a significant risk factor for tumor growth and hepatic metastasis in patients with colorectal cancer (CRC). This study aimed to investigate whether hyperthermia has synergistic anti-tumor effects with TF knockdown in suppressing CRC progression and metastasis in vitro and in vivo. Methods Human colorectal cancer LOVO cells were treated by hyperthermia at 44 degrees C for 2?hr or/and TF siRNA. Then the cells were subjected to colony formation assay. Apoptosis was analyzed by flow cytometry, confocal microscopy, and transmission electron microscopy. The cell migration and invasion abilities were analyzed by wound healing and matrigel assay. In addition, orthotopic nude mice model of CRC was established. Results Hyperthermia synergized with TF knockdown to reduce colony formation ability, induce apoptosis, and suppress the migration and invasion of LOVO cells in vitro. Moreover, hyperthermia in combination with TF depletion inhibited the growth and hepatic metastasis of CRC in orthotopic nude mice model. Mechanistically, the synergistic effects were at least partly mediated by inducing JNK mediated apoptosis and suppressing matrix metalloproteinases (MMPs) mediated invasion. Conclusions Hyperthermia in combination with TF-targeted therapy could be a potential approach for CRC treatment. J. Surg. Oncol. 2012; 106:689695. (c) 2012 Wiley Periodicals, Inc.
C1 [Wan, Yuan-Lian] Peking Univ, Hosp 1, Lab Colon Canc, Dept Gen Surg, Beijing 100034, Peoples R China.
   [Tian, Mao-Lin] Capital Med Univ, Beijing Chaoyang Hosp, Dept Hernia & Abdominal Wall Surg, Beijing, Peoples R China.
   [Zhang, Jing] Beijing Aerosp Cent Hosp, Dept Cardiovasc Med, Beijing, Peoples R China.
   [Ji, Shi-Qi] Peking Univ, Hosp 1, Dept Urol, Beijing 100034, Peoples R China.
RP Wan, YL (corresponding author), Peking Univ, Hosp 1, Lab Colon Canc, Dept Gen Surg, 8 Xishiku St, Beijing 100034, Peoples R China.
EM wan@bjmu.edu.cn
FU National Natural Sciences Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [30872469]; National Natural Sciences Youth
   Foundation of China [30801092]; "985" Project Foundation of Peking
   University
FX Grant sponsor: National Natural Sciences Foundation of China; Grant
   number: 30872469;; Grant sponsor: National Natural Sciences Youth
   Foundation of China; Grant number: 30801092; Grant sponsor: "985"
   Project Foundation of Peking University.
CR Alcala MA, 2010, J CELL BIOCHEM, V110, P1073, DOI 10.1002/jcb.22619
   Bromberg ME, 1999, THROMB HAEMOSTASIS, V82, P88
   Chen YR, 1998, J BIOL CHEM, V273, P1769, DOI 10.1074/jbc.273.3.1769
   Dhanasekaran DN, 2008, ONCOGENE, V27, P6245, DOI 10.1038/onc.2008.301
   Franko J, 2010, CANCER-AM CANCER SOC, V116, P3756, DOI 10.1002/cncr.25116
   Guan M, 2002, CLIN BIOCHEM, V35, P321, DOI 10.1016/S0009-9120(02)00312-0
   Han SI, 2002, FEBS LETT, V515, P141, DOI 10.1016/S0014-5793(02)02459-6
   Hayashi S, 2010, INT J MOL MED, V25, P81, DOI 10.3892/ijmm_00000316
   Jemal A, 2010, CA-CANCER J CLIN, V60, P277, DOI 10.3322/caac.20073
   Khorana AA, 2007, CLIN CANCER RES, V13, P2870, DOI 10.1158/1078-0432.CCR-06-2351
   Koning GA, 2010, PHARM RES-DORDR, V27, P1750, DOI 10.1007/s11095-010-0154-2
   LEE YJ, 1993, J CELL PHYSIOL, V155, P27, DOI 10.1002/jcp.1041550105
   Li C, 2010, J SURG ONCOL, V102, P361, DOI 10.1002/jso.21628
   Lorin S, 2010, AUTOPHAGY, V6, P153, DOI 10.4161/auto.6.1.10537
   Mantel F, 2010, STRAHLENTHER ONKOL, V186, P587, DOI 10.1007/s00066-010-2154-x
   MOLLS M, 1992, Strahlentherapie und Onkologie, V168, P183
   Moon EJ, 2010, P NATL ACAD SCI USA, V107, P20477, DOI 10.1073/pnas.1006646107
   Nakasaki T, 2002, AM J HEMATOL, V69, P247, DOI 10.1002/ajh.10061
   Pajonk F, 2005, CANCER RES, V65, P4836, DOI 10.1158/0008-5472.CAN-03-2749
   Rickles FR, 2003, CHEST, V124, p58S, DOI 10.1378/chest.124.3_suppl.58S
   Rickles FR, 2001, ACTA HAEMATOL-BASEL, V106, P6, DOI 10.1159/000046583
   Ruf W, 2007, J THROMB HAEMOST, V5, P1584, DOI 10.1111/j.1538-7836.2007.02622.x
   Sawada M, 1999, BRIT J CANCER, V79, P472, DOI 10.1038/sj.bjc.6690073
   Tian ML, 2011, CANCER BIOL THER, V12, P896, DOI 10.4161/cbt.12.10.17679
   Van Cutsem E, 2006, EUR J CANCER, V42, P2212, DOI 10.1016/j.ejca.2006.04.012
   Wagner EF, 2009, NAT REV CANCER, V9, P537, DOI 10.1038/nrc2694
   Wang L, 2007, APOPTOSIS, V12, P1489, DOI 10.1007/s10495-007-0073-9
   Wolpin BM, 2008, GASTROENTEROLOGY, V134, P1296, DOI 10.1053/j.gastro.2008.02.098
   Yamashita H, 2007, J SURG ONCOL, V95, P324, DOI 10.1002/jso.20680
   Zhang JQ, 2008, INT J COLORECTAL DIS, V23, P971, DOI 10.1007/s00384-008-0496-y
   Zhao JS, 2009, CLIN CANCER RES, V15, P208, DOI 10.1158/1078-0432.CCR-08-0407
NR 31
TC 3
Z9 4
U1 2
U2 15
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-4790
EI 1096-9098
J9 J SURG ONCOL
JI J. Surg. Oncol.
PD NOV
PY 2012
VL 106
IS 6
BP 689
EP 695
DI 10.1002/jso.23136
PG 7
WC Oncology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Surgery
GA 026CJ
UT WOS:000310249900007
PM 22532129
DA 2022-04-25
ER

PT J
AU Long, YP
   Gao, ZH
   Hu, X
   Xiang, F
   Wu, ZZ
   Zhang, JH
   Han, X
   Yin, LY
   Qin, JF
   Lan, L
   Yin, FZ
   Wang, Y
AF Long, Yaping
   Gao, Zihe
   Hu, Xiao
   Xiang, Feng
   Wu, Zhaozhen
   Zhang, Jiahui
   Han, Xiao
   Yin, Liyong
   Qin, Junfang
   Lan, Lan
   Yin, Fuzai
   Wang, Yue
TI Downregulation of MCT4 for lactate exchange promotes the cytotoxicity of
   NK cells in breast carcinoma
SO CANCER MEDICINE
LA English
DT Article
DE lactate; MCT4; NK cytotoxicity; NKG2D; NKG2DLs (H60)
ID MONOCARBOXYLATE TRANSPORTER 4; TUMOR METABOLISM; COLORECTAL-CANCER;
   POOR-PROGNOSIS; STROMAL CELLS; PH; EXPRESSION; LYMPHOMA; ACID;
   MICROENVIRONMENT
AB Monocarboxylate transporter-4 (MCT4), a monocarboxylic acid transporter, demonstrates significantly increased expression in the majority of malignancies. We performed an experiment using BALB/C mice, and our results showed that ShMCT4 transfection or the pharmaceutic inhibition of MCT4 with 7acc1 strengthens the activity of NK cells. The results of a calcein assay revealed that the cytotoxicity of NK cells was strengthened via inhibition of MCT4. In addition, ELISA testing showed that the content of perforin and CD107a was increased, and PCR amplification and immunoblotting revealed that the expression of NKG2D and H60 was upregulated after the inhibition of MCT4. Further, we observed an elevated pH value, decreased extracellular lactate flow, and attenuated tumor growth. Therefore, we concluded that the inhibition of MCT4 enhanced the cytotoxicity of NK cells by blocking lactate flux and reversing the acidified tumor microenvironment. In addition to these findings, we also discovered that MCT4 depletion may have a pronounced impact on autophagy, which was surmised by observing that the inhibition of autophagy (3MA) pulled the enhanced cytotoxicity of NK cells downwards. Together, these data suggest that the key effect of MCT4 depletion on NK cells probably utilizes inductive autophagy as a compensatory metabolic mechanism to minimize the acidic extracellular microenvironment associated with lactate export in tumors.
C1 [Long, Yaping; Gao, Zihe; Hu, Xiao; Xiang, Feng; Wu, Zhaozhen; Zhang, Jiahui; Han, Xiao; Qin, Junfang; Wang, Yue] Nankai Univ, Sch Med, 94 Weijin Rd, Tianjin 300071, Peoples R China.
   [Yin, Liyong; Yin, Fuzai] First Hosp Qinhuangdao, Qinhuangdao 066000, Hebei, Peoples R China.
   [Lan, Lan] Tianjin Med Univ, Tianjin Canc Hosp, Tianjin, Peoples R China.
   [Wang, Yue] Nankai Univ, State Key Lab Med Chem Biol, Tianjin, Peoples R China.
RP Wang, Y (corresponding author), Nankai Univ, Sch Med, 94 Weijin Rd, Tianjin 300071, Peoples R China.; Yin, FZ (corresponding author), First Hosp Qinhuangdao, Qinhuangdao 066000, Hebei, Peoples R China.
EM yfz2004747@sina.com; wangyue@nankai.edu.cn
OI Long, Yaping/0000-0002-2706-3656
FU Open Project Program of State Key Laboratory of Medicinal Chemical
   Biology; Open Project Program of Key Laboratory for Tumor Precision
   Medicine of Shaanxi Province; The First Affiliated Hospital of Xi'an
   Jiaotong University, Xi'an, People's Republic of China; 
   [NSFC.81171975];  [NSFC.31770968];  [15JCYBJC26900];  [16JCQNJC11700]
FX We thank Dashuai Zhu (Nankai University, China) for mice IHC technical
   assistance, Yu Liu (Rutgers University, America) for a statistical
   consultant help and Professor Phillip Bryant (Nankai University) and
   Chang Liu (Tianjin University of Sport, China) for linguistic support.
   This work was supported by grants from the NSFC.81171975, NSFC.31770968,
   local 15JCYBJC26900, 16JCQNJC11700, the Open Project Program of State
   Key Laboratory of Medicinal Chemical Biology, and the Open Project
   Program of Key Laboratory for Tumor Precision Medicine of Shaanxi
   Province, The First Affiliated Hospital of Xi'an Jiaotong University,
   Xi'an 710061, People's Republic of China.
CR Adams TA, 2018, MODERN PATHOL, V31, P288, DOI 10.1038/modpathol.2017.126
   Alfarouk KO, 2016, J ENZYM INHIB MED CH, V31, P859, DOI 10.3109/14756366.2016.1140753
   Alter G, 2004, J IMMUNOL METHODS, V294, P15, DOI 10.1016/j.jim.2004.08.008
   Baek G, 2014, CELL REP, V9, P2233, DOI 10.1016/j.celrep.2014.11.025
   Belting L, 2015, EUR J IMMUNOL, V45, P2593, DOI 10.1002/eji.201445375
   Brenner CD, 2010, EUR J IMMUNOL, V40, P494, DOI 10.1002/eji.200939937
   Curry J, 2017, OTOLARYNG HEAD NECK, V157, P798, DOI 10.1177/0194599817709224
   Diehl K, 2018, ONCOGENE, V37, P39, DOI 10.1038/onc.2017.299
   Diers AR, 2012, BIOCHEM J, V444, P561, DOI 10.1042/BJ20120294
   Draoui N, 2014, MOL CANCER THER, V13, P1410, DOI 10.1158/1535-7163.MCT-13-0653
   ENGIN K, 1995, INT J HYPERTHER, V11, P211, DOI 10.3109/02656739509022457
   Fischer K, 2007, BLOOD, V109, P3812, DOI 10.1182/blood-2006-07-035972
   Gao HJ, 2015, J CANCER RES CLIN, V141, P1151, DOI 10.1007/s00432-014-1888-8
   Gardiner CM, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00367
   Gerweck LE, 2006, MOL CANCER THER, V5, P1275, DOI 10.1158/1535-7163.MCT-06-0024
   Gerweck LE, 1996, CANCER RES, V56, P1194
   Gooptu M, 2017, SEMIN ONCOL, V44, P204, DOI 10.1053/j.seminoncol.2017.10.002
   Halestrap AP, 1999, BIOCHEM J, V343, P281, DOI 10.1042/0264-6021:3430281
   Halestrap AP, 2004, PFLUG ARCH EUR J PHY, V447, P619, DOI 10.1007/s00424-003-1067-2
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9
   Hanson DJ, 2015, ONCOTARGET, V6, P33568, DOI 10.18632/oncotarget.5598
   Holdenrieder S, 2006, CANCER IMMUNOL IMMUN, V55, P1584, DOI 10.1007/s00262-006-0167-1
   Husain Z, 2013, J IMMUNOL, V191, P1486, DOI 10.4049/jimmunol.1202702
   Hutcheson J, 2016, CLIN CANCER RES, V22, P3606, DOI 10.1158/1078-0432.CCR-15-1883
   Kirk P, 2000, EMBO J, V19, P3896, DOI 10.1093/emboj/19.15.3896
   Koch C, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01466
   Koukourakis MI, 2006, J CLIN ONCOL, V24, P4301, DOI 10.1200/JCO.2006.05.9501
   Le Floch R, 2011, P NATL ACAD SCI USA, V108, P16663, DOI 10.1073/pnas.1106123108
   Longo DL, 2016, CANCER RES, V76, P6463, DOI 10.1158/0008-5472.CAN-16-0825
   Luz MCD, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18040170
   Mah AY, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.95128
   Marchiq I, 2016, J MOL MED, V94, P155, DOI 10.1007/s00109-015-1307-x
   Mazzio EA, 2010, CELL BIOL TOXICOL, V26, P177, DOI 10.1007/s10565-009-9138-6
   Muller B, 2000, IMMUNOLOGY, V99, P375, DOI 10.1046/j.1365-2567.2000.00975.x
   Parkinson-Lawrence EJ, 2005, CELL IMMUNOL, V236, P161, DOI 10.1016/j.cellimm.2005.08.024
   Petersen C, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-13298-z
   Raghunand N, 2001, NEOPLASIA, V3, P227, DOI 10.1038/sj.neo.7900151
   Rathore AS, 2014, ASIAN PAC J CANCER P, V15, P3757, DOI 10.7314/APJCP.2014.15.8.3757
   Robey IF, 2009, CANCER RES, V69, P2260, DOI 10.1158/0008-5472.CAN-07-5575
   Tan Z, 2015, J BIOL CHEM, V290, P46, DOI 10.1074/jbc.M114.603589
   Voss DM, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-04612-w
   Ward PS, 2012, CANCER CELL, V21, P297, DOI 10.1016/j.ccr.2012.02.014
   Witkiewicz AK, 2012, CELL CYCLE, V11, P1108, DOI 10.4161/cc.11.6.19530
   Yan P, 2014, ASIAN PAC J CANCER P, V15, P8923, DOI 10.7314/APJCP.2014.15.20.8923
   Zhang XM, 2010, J NUCL MED, V51, P1167, DOI 10.2967/jnumed.109.068981
NR 45
TC 17
Z9 18
U1 2
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2045-7634
J9 CANCER MED-US
JI Cancer Med.
PD SEP
PY 2018
VL 7
IS 9
BP 4690
EP 4700
DI 10.1002/cam4.1713
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA GU0MT
UT WOS:000444945200047
PM 30051648
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Vara-Perez, M
   Felipe-Abrio, B
   Agostinis, P
AF Vara-Perez, Monica
   Felipe-Abrio, Blanca
   Agostinis, Patrizia
TI Mitophagy in Cancer: A Tale of Adaptation
SO CELLS
LA English
DT Review
DE mitophagy; mitochondria; autophagy; cancer; tumor microenvironment;
   anti-cancer therapy resistance; mitochondrial dynamics
ID HYPOXIA-INDUCED AUTOPHAGY; SQUAMOUS-CELL CARCINOMA; MITOCHONDRIAL
   QUALITY-CONTROL; PARKIN-MEDIATED MITOPHAGY; TUMOR-SUPPRESSOR GENES;
   RHOMBOID PROTEASE PARL; MARROW STROMAL CELLS; BREAST-CANCER;
   COLORECTAL-CANCER; DOWN-REGULATION
AB In the past years, we have learnt that tumors co-evolve with their microenvironment, and that the active interaction between cancer cells and stromal cells plays a pivotal role in cancer initiation, progression and treatment response. Among the players involved, the pathways regulating mitochondrial functions have been shown to be crucial for both cancer and stromal cells. This is perhaps not surprising, considering that mitochondria in both cancerous and non-cancerous cells are decisive for vital metabolic and bioenergetic functions and to elicit cell death. The central part played by mitochondria also implies the existence of stringent mitochondrial quality control mechanisms, where a specialized autophagy pathway (mitophagy) ensures the selective removal of damaged or dysfunctional mitochondria. Although the molecular underpinnings of mitophagy regulation in mammalian cells remain incomplete, it is becoming clear that mitophagy pathways are intricately linked to the metabolic rewiring of cancer cells to support the high bioenergetic demand of the tumor. In this review, after a brief introduction of the main mitophagy regulators operating in mammalian cells, we discuss emerging cell autonomous roles of mitochondria quality control in cancer onset and progression. We also discuss the relevance of mitophagy in the cellular crosstalk with the tumor microenvironment and in anti-cancer therapy responses.
C1 [Vara-Perez, Monica; Felipe-Abrio, Blanca; Agostinis, Patrizia] Univ Leuven, Dept Cellular & Mol Med, Lab Cell Death Res & Therapy, KU Leuven, Campus Gasthuisberg,Herestr 49, B-3000 Leuven, Belgium.
   [Vara-Perez, Monica; Felipe-Abrio, Blanca; Agostinis, Patrizia] VIB KU Leuven, Lab Cell Death Res & Therapy, Ctr Canc Biol, B-3000 Leuven, Belgium.
RP Agostinis, P (corresponding author), Univ Leuven, Dept Cellular & Mol Med, Lab Cell Death Res & Therapy, KU Leuven, Campus Gasthuisberg,Herestr 49, B-3000 Leuven, Belgium.; Agostinis, P (corresponding author), VIB KU Leuven, Lab Cell Death Res & Therapy, Ctr Canc Biol, B-3000 Leuven, Belgium.
EM monica.varaperez@kuleuven.vib.be; blanca.felipeabrio@kuleuven.vib.be;
   patrizia.agostinis@kuleuven.vib.be
RI Agostinis, Patrizia/AAO-2468-2020; Agostinis, Patrizia/ABI-1177-2020
OI Agostinis, Patrizia/0000-0003-1314-2115; Felipe-Abrio,
   Blanca/0000-0001-7025-3247; Vara-Perez, Monica/0000-0001-6196-4696
FU FWO Doctoral Fellowship from the Flemish Research Foundation
   (FWO-Vlaanderen), BelgiumFWO [1186017N]; EOS consortium [30837538];
   Flemish Research Foundation (FWO-Vlaanderen)FWO [G076617N, G049817N,
   G070115N]; KU LeuvenKU Leuven [C16/15/073]; Stichting tegen Kanker
   [FAF-F/2018/1252]
FX M.V.P. is the recipient of a FWO Doctoral Fellowship from the Flemish
   Research Foundation (FWO-Vlaanderen, 1186017N), Belgium. B.F.A. is
   supported by the EOS consortium (30837538). P.A. is supported by grants
   from the Flemish Research Foundation (FWO-Vlaanderen; G076617N,
   G049817N, G070115N), the EOS consortium (30837538), KU Leuven
   (C16/15/073) and Stichting tegen Kanker (FAF-F/2018/1252).
CR Abdrakhmanov A, 2019, BIOL CHEM, V400, P161, DOI 10.1515/hsz-2018-0210
   Abuhusain HJ, 2013, J BIOL CHEM, V288, P37355, DOI 10.1074/jbc.M113.494740
   Agirre X, 2006, INT J CANCER, V118, P1945, DOI 10.1002/ijc.21584
   Agnihotri S, 2016, CANCER RES, V76, P4708, DOI 10.1158/0008-5472.CAN-15-3079
   Ahmad T, 2014, EMBO J, V33, P994, DOI 10.1002/embj.201386030
   Akada M, 2005, CLIN CANCER RES, V11, P3094, DOI 10.1158/1078-0432.CCR-04-1785
   An JS, 2013, CHINESE MED J-PEKING, V126, P4109, DOI 10.3760/cma.j.issn.0366-6999.20131320
   Anton Z, 2016, AUTOPHAGY, V12, P2386, DOI 10.1080/15548627.2016.1240856
   Asp ML, 2010, INT J CANCER, V126, P756, DOI 10.1002/ijc.24784
   Aversa Z, 2016, SCI REP-UK, V6, DOI 10.1038/srep30340
   Babenko VA, 2018, MOLECULES, V23, DOI 10.3390/molecules23030687
   Baldelli S, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.458
   Ban T, 2017, NAT CELL BIOL, V19, P856, DOI 10.1038/ncb3560
   Barreto R, 2016, FRONT PHYSIOL, V7, DOI 10.3389/fphys.2016.00472
   Basso V, 2018, PHARMACOL RES, V138, P43, DOI 10.1016/j.phrs.2018.09.006
   Bazil JN, 2016, BIOPHYS J, V110, P962, DOI 10.1016/j.bpj.2015.09.036
   Bellot G, 2009, MOL CELL BIOL, V29, P2570, DOI 10.1128/MCB.00166-09
   Bernardini JP, 2017, ONCOGENE, V36, P1315, DOI 10.1038/onc.2016.302
   Bhat N, 2014, EUR J IMMUNOL, V44, P634, DOI 10.1002/eji.201344127
   Bhat ZI, 2019, GENE, V682, P25, DOI 10.1016/j.gene.2018.10.010
   Bhujabal Z, 2017, EMBO REP, V18, P947, DOI 10.15252/embr.201643147
   Bing C, 2000, CANCER RES, V60, P2405
   Boyle KA, 2018, J BIOL CHEM, V293, P14891, DOI 10.1074/jbc.RA117.001469
   Cai XW, 2018, CANCER MED-US, V7, P2504, DOI 10.1002/cam4.1463
   Caicedo A, 2015, SCI REP-UK, V5, DOI 10.1038/srep09073
   Caillet P, 2017, CLIN NUTR, V36, P1473, DOI 10.1016/j.clnu.2016.12.003
   Cairns RA, 2011, NAT REV CANCER, V11, P85, DOI 10.1038/nrc2981
   Carracedo A, 2013, NAT REV CANCER, V13, P227, DOI 10.1038/nrc3483
   Castro M, 2010, J TRANSL MED, V8, DOI 10.1186/1479-5876-8-86
   Chaanine AH, 2016, AM J PHYSIOL-HEART C, V311, pH1540, DOI 10.1152/ajpheart.00549.2016
   Chakraborty PK, 2018, FASEB J, V32, P4145, DOI 10.1096/fj.201701095R
   Chang CM, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18050903
   Chang GN, 2018, TOHOKU J EXP MED, V245, P115, DOI 10.1620/tjem.245.115
   Chang HW, 2019, ONCOGENE, V38, P3729, DOI 10.1038/s41388-019-0697-6
   Chen JL, 2017, MOL CANCER RES, V15, P26, DOI 10.1158/1541-7786.MCR-16-0200-T
   Chen L, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-1083-y
   Chen M, 2016, AUTOPHAGY, V12, P689, DOI 10.1080/15548627.2016.1151580
   Chen SH, 2018, EMBO J, V37, DOI 10.15252/embj.201797508
   Chen Y, 2013, SCIENCE, V340, P471, DOI 10.1126/science.1231031
   Chen ZH, 2017, AUTOPHAGY, V13, P1244, DOI 10.1080/15548627.2017.1310789
   Cheng CT, 2016, CANCER RES, V76, P5006, DOI 10.1158/0008-5472.CAN-15-2921
   Cheng DD, 2015, ONCOTARGET, V6, P42761, DOI 10.18632/oncotarget.6199
   Cheng JJ, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-1017-8
   Cho YM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032778
   Chourasia AH, 2015, EMBO REP, V16, P1145, DOI 10.15252/embr.201540759
   Chu CT, 2014, AUTOPHAGY, V10, P376, DOI 10.4161/auto.27191
   Cianfanelli V, 2015, NAT CELL BIOL, V17, DOI 10.1038/ncb3171
   Cipolat S, 2004, P NATL ACAD SCI USA, V101, P15927, DOI 10.1073/pnas.0407043101
   Cristofani R, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0866-5
   da Silva SD, 2015, ONCOTARGET, V6, P21950, DOI 10.18632/oncotarget.4277
   Dang CV, 2008, NAT REV CANCER, V8, P51, DOI 10.1038/nrc2274
   Davis CHO, 2014, P NATL ACAD SCI USA, V111, P9633, DOI 10.1073/pnas.1404651111
   Del Dotto V, 2017, CELL REP, V19, P2557, DOI 10.1016/j.celrep.2017.05.073
   Dela Cruz M, 2017, ONCOTARGET, V8, P20543, DOI 10.18632/oncotarget.16129
   den Kamp CMO, 2013, AM J CLIN NUTR, V98, P738, DOI 10.3945/ajcn.113.058388
   Deng Q, 2012, CHEMOTHERAPY, V58, P445, DOI 10.1159/000345916
   Dhingra R, 2013, CIRC-HEART FAIL, V6, P335, DOI 10.1161/CIRCHEARTFAILURE.112.000061
   Di Rita A, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05722-3
   Di Rita A, 2018, FRONT CELL NEUROSCI, V12, DOI 10.3389/fncel.2018.00092
   Dikic I, 2018, NAT REV MOL CELL BIO, V19, P349, DOI 10.1038/s41580-018-0003-4
   Dong LF, 2017, ELIFE, V6, DOI 10.7554/eLife.22187
   Drake LE, 2017, SEMIN CANCER BIOL, V47, P110, DOI 10.1016/j.semcancer.2017.04.008
   Du QQ, 2019, CANCER SCI, V110, P2050, DOI 10.1111/cas.14011
   Du Q, 2017, AM J TRANSL RES, V9, P3360
   Dumas JF, 2011, J HEPATOL, V54, P320, DOI 10.1016/j.jhep.2010.08.012
   Durcan TM, 2015, GENE DEV, V29, P989, DOI 10.1101/gad.262758.115
   Duvezin-Caubet S, 2006, J BIOL CHEM, V281, P37972, DOI 10.1074/jbc.M606059200
   Ehses S, 2009, J CELL BIOL, V187, P1023, DOI 10.1083/jcb.200906084
   Eisele L, 2007, ACTA HAEMATOL-BASEL, V117, P8, DOI 10.1159/000096854
   Elwafa RA, 2019, CANCER GENET-NY, V233, P84, DOI [10.1016/j.cancergen.201812.001, 10.1016/j.cancergen.2018.12.001]
   Erkan M, 2005, ONCOGENE, V24, P4421, DOI 10.1038/sj.onc.1208642
   Falasca L, 2015, APOPTOSIS, V20, P1577, DOI 10.1007/s10495-015-1176-3
   Fan S, 2015, ONCOTARGET, V6, P14885, DOI 10.18632/oncotarget.3659
   Fan S, 2015, CANCER LETT, V362, P183, DOI 10.1016/j.canlet.2015.03.045
   Fang CL, 2017, J CANCER, V8, P1153, DOI 10.7150/jca.17986
   Fang HY, 2012, HUM PATHOL, V43, P105, DOI 10.1016/j.humpath.2011.04.012
   Feather CE, 2018, MUSCLE NERVE, V57, P650, DOI 10.1002/mus.25966
   Feng YH, 2019, STEM CELLS DEV, V28, P674, DOI 10.1089/scd.2018.0248
   Fessler E, 2013, CANCER LETT, V341, P97, DOI 10.1016/j.canlet.2012.10.015
   Franchi L, 2009, NAT IMMUNOL, V10, P241, DOI 10.1038/ni.1703
   Francy CA, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-11008-3
   Frazier DP, 2006, ANTIOXID REDOX SIGN, V8, P1625, DOI 10.1089/ars.2006.8.1625
   Friedman JR, 2011, SCIENCE, V334, P358, DOI 10.1126/science.1207385
   Fujimoto T, 2016, J HEPATO-BIL-PAN SCI, V23, P489, DOI 10.1002/jhbp.367
   Gao G, 2014, GENE CHROMOSOME CANC, V53, P392, DOI 10.1002/gcc.22150
   Garcia-Baquero R, 2014, TUMOR BIOL, V35, P5777, DOI 10.1007/s13277-014-1767-6
   Garcia-Baquero R, 2013, J UROLOGY, V190, P723, DOI 10.1016/j.juro.2013.01.105
   Gargini R, 2016, ONCOL REP, V35, P3689, DOI 10.3892/or.2016.4699
   Geisler S, 2010, NAT CELL BIOL, V12, P119, DOI 10.1038/ncb2012
   Gelmetti V, 2017, AUTOPHAGY, V13, P654, DOI 10.1080/15548627.2016.1277309
   Gharanei M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077713
   Glauser L, 2011, J NEUROCHEM, V118, P636, DOI 10.1111/j.1471-4159.2011.07318.x
   Gomes LC, 2011, NAT CELL BIOL, V13, P589, DOI 10.1038/ncb2220
   Gomez-Cabanas L, 2019, J IMMUNOL, V202, P1715, DOI 10.4049/jimmunol.1800575
   Grazioli S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00832
   Greene AW, 2012, EMBO REP, V13, P378, DOI 10.1038/embor.2012.14
   Griparic L, 2007, J CELL BIOL, V178, P757, DOI 10.1083/jcb.200704112
   Gu LJ, 2019, CELL BIOL INT, V43, P290, DOI 10.1002/cbin.11097
   Gugnoni M, 2017, ONCOGENE, V36, P667, DOI 10.1038/onc.2016.237
   Guo JY, 2013, GENE DEV, V27, P1447, DOI 10.1101/gad.219642.113
   Guo JY, 2011, GENE DEV, V25, P460, DOI 10.1101/gad.2016311
   Hammerling BC, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14050
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Hanna RA, 2012, J BIOL CHEM, V287, P19094, DOI 10.1074/jbc.M111.322933
   Hayakawa K, 2016, NATURE, V535, P551, DOI 10.1038/nature18928
   He JM, 2017, J CANCER, V8, P1187, DOI 10.7150/jca.18171
   Held NM, 2015, BIOESSAYS, V37, P867, DOI 10.1002/bies.201500013
   Heller G, 2008, CANCER RES, V68, P44, DOI 10.1158/0008-5472.CAN-07-2531
   Hendgen-Cotta UB, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18040687
   Hiraki M, 2011, ANN SURG ONCOL, V18, P3013, DOI 10.1245/s10434-011-1636-0
   Hiraki M, 2010, ONCOL REP, V23, P191, DOI 10.3892/or_00000622
   Holleman A, 2006, BLOOD, V107, P769, DOI 10.1182/blood-2005-07-2930
   Hoshino A, 2014, P NATL ACAD SCI USA, V111, P3116, DOI 10.1073/pnas.1318951111
   Hou HL, 2017, CANCER MED-US, V6, P1871, DOI 10.1002/cam4.1112
   Hough KP, 2018, REDOX BIOL, V18, P54, DOI 10.1016/j.redox.2018.06.009
   Hsiao CP, 2013, CANCER NURS, V36, P189, DOI 10.1097/NCC.0b013e318263f514
   Hu HH, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djv340
   Hu YL, 2012, CANCER RES, V72, P1773, DOI 10.1158/0008-5472.CAN-11-3831
   Huang CY, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-1019-6
   Huang QC, 2016, AUTOPHAGY, V12, P999, DOI 10.1080/15548627.2016.1166318
   Huang XY, 2018, EXP CELL RES, V368, P75, DOI 10.1016/j.yexcr.2018.04.016
   Hui L, 2019, CLIN TRANSL ONCOL, V21, P596, DOI 10.1007/s12094-018-1958-5
   Inoue S, 2013, GENE DEV, V27, P1101, DOI 10.1101/gad.214577.113
   Ishikawa H, 2009, NATURE, V461, P788, DOI 10.1038/nature08476
   Islam MN, 2012, NAT MED, V18, P759, DOI 10.1038/nm.2736
   Jiang ZM, 2018, MED SCI MONITOR, V24, P4711, DOI 10.12659/MSM.907679
   Jin SM, 2010, J CELL BIOL, V191, P933, DOI 10.1083/jcb.201008084
   Jin T, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-64
   Johns N, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0083618
   Jourdan M, 2009, BRIT J HAEMATOL, V145, P45, DOI 10.1111/j.1365-2141.2008.07562.x
   Ju LP, 2018, BIOCHEM BIOPH RES CO, V506, P485, DOI 10.1016/j.bbrc.2018.10.034
   Julienne CM, 2014, BBA-MOL BASIS DIS, V1842, P726, DOI 10.1016/j.bbadis.2014.02.003
   Kagan VE, 2016, CELL DEATH DIFFER, V23, P1140, DOI 10.1038/cdd.2015.160
   Kameoka S, 2018, TRENDS CELL BIOL, V28, P67, DOI 10.1016/j.tcb.2017.08.011
   Kamino H, 2016, ONCOGENESIS, V5, DOI 10.1038/oncsis.2015.43
   Kang JU, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-237
   Kang R, 2019, AUTOPHAGY, V15, P172, DOI 10.1080/15548627.2018.1526611
   Kannan A, 2016, CLIN CANCER RES, V22, P3348, DOI 10.1158/1078-0432.CCR-15-2456
   Karpathiou G, 2013, APMIS, V121, P592, DOI 10.1111/apm.12026
   Kim JW, 2007, MOL CELL BIOL, V27, P7381, DOI 10.1128/MCB.00440-07
   Kim MJ, 2016, AUTOPHAGY, V12, P1272, DOI 10.1080/15548627.2016.1183081
   Kim YY, 2018, ACTA BIOCH BIOPH SIN, V50, P209, DOI 10.1093/abbs/gmx137
   Kimmelman AC, 2017, CELL METAB, V25, P1037, DOI 10.1016/j.cmet.2017.04.004
   Ko YH, 2013, PANCREAS, V42, P829, DOI 10.1097/MPA.0b013e318279d0dc
   Kodama T, 2016, P NATL ACAD SCI USA, V113, pE3384, DOI 10.1073/pnas.1606876113
   Koo JS, 2016, YONSEI MED J, V57, P482, DOI 10.3349/ymj.2016.57.2.482
   Korobova F, 2013, SCIENCE, V339, P464, DOI 10.1126/science.1228360
   Koybasi S, 2004, J BIOL CHEM, V279, P44311, DOI 10.1074/jbc.M406920200
   Kuiper C, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00010
   Kulikov AV, 2017, BIOCHEM BIOPH RES CO, V482, P432, DOI 10.1016/j.bbrc.2016.10.088
   Kwon D, 2017, FASEB J, V31, P4866, DOI 10.1096/fj.201700328R
   Kwong FNK, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-5140-9
   Lampert MA, 2019, AUTOPHAGY, V15, P1182, DOI 10.1080/15548627.2019.1580095
   Phi LTH, 2018, STEM CELLS INT, V2018, DOI 10.1155/2018/5416923
   Landes T, 2010, EMBO REP, V11, P459, DOI 10.1038/embor.2010.50
   Lathia JD, 2017, TARGET ONCOL, V12, P387, DOI 10.1007/s11523-017-0508-3
   Lee S.J., 2017, TUMOUR BIOL, V39, DOI [10.1177/1010428317733985, DOI 10.1177/1010428317733985]
   Leo C, 2006, INT J GYNECOL CANCER, V16, P1314, DOI 10.1111/j.1525-1438.2006.00394.x
   Leon-Mateos L, 2017, ONCOTARGET, V8, P54708, DOI 10.18632/oncotarget.18025
   Levine B, 2019, CELL, V176, P11, DOI 10.1016/j.cell.2018.09.048
   Li CF, 2018, DEV CELL, V46, P441, DOI 10.1016/j.devcel.2018.07.012
   Li J, 2017, ONCOGENE, V36, P4901, DOI 10.1038/onc.2017.98
   Li ZX, 2017, ANTICANCER RES, V37, P4455, DOI 10.21873/anticanres.11841
   Lin JD, 2005, CELL METAB, V1, P361, DOI 10.1016/j.cmet.2005.05.004
   Lin ZY, 2016, CLIN LAB, V62, P121, DOI 10.7754/Clin.Lab.2015.150607
   Liu JQ, 2018, B ENG GEOL ENVIRON, V77, P515, DOI 10.1007/s10064-017-1003-x
   Liu K, 2017, MOL CELL, V68, P281, DOI 10.1016/j.molcel.2017.09.022
   Liu KE, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129667
   Liu L, 2012, NAT CELL BIOL, V14, P177, DOI 10.1038/ncb2422
   Liu WN, 2008, NEOPLASIA, V10, P897, DOI 10.1593/neo.08428
   Liu ZJ, 2014, CLIN CANCER RES, V20, P4598, DOI 10.1158/1078-0432.CCR-13-3380
   Lock R, 2011, MOL BIOL CELL, V22, P165, DOI 10.1091/mbc.E10-06-0500
   Lopez-Domenech G, 2018, EMBO J, V37, P321, DOI 10.15252/embj.201696380
   Lou E, 2018, FRONT CELL DEV BIOL, V6, DOI 10.3389/fcell.2018.00095
   Lou E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033093
   Lu JJ, 2017, ONCOTARGET, V8, P15539, DOI 10.18632/oncotarget.14695
   Lu YT, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044559
   von Zangen IL, 2007, ACTA NEUROPATHOL, V113, P325, DOI 10.1007/s00401-006-0190-5
   Lv MQ, 2017, PROTEIN CELL, V8, P25, DOI 10.1007/s13238-016-0328-8
   Lyons A, 2017, J BIOL CHEM, V292, P16983, DOI 10.1074/jbc.M117.792838
   Macdonald PJ, 2016, J BIOL CHEM, V291, P493, DOI 10.1074/jbc.M115.680181
   Macher-Goeppinger S, 2017, TRANSL ONCOL, V10, P869, DOI 10.1016/j.tranon.2017.08.008
   Mackeh R, 2013, J CELL SCI, V126, P1071, DOI 10.1242/jcs.115626
   MacKeigan JP, 2005, NAT CELL BIOL, V7, P591, DOI 10.1038/ncb1258
   Maes H, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.94
   Mancias JD, 2016, J MOL BIOL, V428, P1659, DOI 10.1016/j.jmb.2016.02.027
   Manne NDPK, 2013, INT J ONCOL, V42, P2134, DOI 10.3892/ijo.2013.1893
   Marchi S, 2014, BBA-BIOENERGETICS, V1837, P461, DOI 10.1016/j.bbabio.2013.10.015
   Marlein CR, 2017, BLOOD, V130, P1649, DOI 10.1182/blood-2017-03-772939
   Martin L, 2013, J CLIN ONCOL, V31, P1539, DOI 10.1200/JCO.2012.45.2722
   McDonnell E, 2016, CELL REP, V17, P1463, DOI 10.1016/j.celrep.2016.10.012
   McLelland GL, 2018, ELIFE, V7, DOI 10.7554/eLife.32866
   Mehdi SJ, 2011, PATHOL ONCOL RES, V17, P579, DOI 10.1007/s12253-010-9351-x
   Melser S, 2013, CELL METAB, V17, P719, DOI 10.1016/j.cmet.2013.03.014
   Mengwasser J, 2004, ONCOGENE, V23, P7430, DOI 10.1038/sj.onc.1207987
   Millino C, 2017, J CELL PHYSIOL, V232, P426, DOI 10.1002/jcp.25441
   Mishra P, 2014, CELL METAB, V19, P630, DOI 10.1016/j.cmet.2014.03.011
   Mombo BN, 2017, JOVE-J VIS EXP, DOI 10.3791/55245
   Moossavi M, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0900-3
   Moschoi R, 2016, BLOOD, V128, P253, DOI 10.1182/blood-2015-07-655860
   Murakawa T, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8527
   Naik PP, 2018, CELL PROLIFERAT, V51, DOI 10.1111/cpr.12411
   Nakamura Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030767
   Naon D, 2014, BBA-MOL CELL RES, V1843, P2184, DOI 10.1016/j.bbamcr.2014.05.011
   Nazio F, 2019, CELL DEATH DIFFER, V26, P690, DOI 10.1038/s41418-019-0292-y
   Ney PA, 2015, BBA-MOL CELL RES, V1853, P2775, DOI 10.1016/j.bbamcr.2015.02.022
   Nishida Y, 2009, NATURE, V461, P654, DOI 10.1038/nature08455
   Nitta T, 2014, INT J CLIN EXP PATHO, V7, P4913
   Niu Y, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1004-4
   Novak I, 2010, EMBO REP, V11, P45, DOI 10.1038/embor.2009.256
   O'Sullivan TE, 2015, IMMUNITY, V43, P331, DOI 10.1016/j.immuni.2015.07.012
   Osswald M, 2015, NATURE, V528, P93, DOI 10.1038/nature16071
   Palmer CS, 2011, EMBO REP, V12, P565, DOI 10.1038/embor.2011.54
   Paradkar PN, 2009, MOL CELL BIOL, V29, P1007, DOI 10.1128/MCB.01685-08
   Park JH, 2017, MOL NEUROBIOL, V54, P1844, DOI 10.1007/s12035-016-9753-1
   Pasquier J, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-94
   Patheja P, 2017, EXP CELL RES, V355, P182, DOI 10.1016/j.yexcr.2017.04.008
   Pavlova NN, 2016, CELL METAB, V23, P27, DOI 10.1016/j.cmet.2015.12.006
   Peng XZ, 2017, ONCOTARGET, V8, P679, DOI 10.18632/oncotarget.13510
   Penna F, 2013, AM J PATHOL, V182, P1367, DOI 10.1016/j.ajpath.2012.12.023
   Petrova V, 2015, CELL CYCLE, V14, P2484, DOI 10.1080/15384101.2015.1044178
   Petry IB, 2010, CLIN CANCER RES, V16, P451, DOI 10.1158/1078-0432.CCR-09-1617
   Pettersen K, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-02088-2
   Philley JV, 2016, J CELL PHYSIOL, V231, P1364, DOI 10.1002/jcp.25240
   Poillet-Perez L, 2018, NATURE, V563, P569, DOI 10.1038/s41586-018-0697-7
   Poulogiannis G, 2010, P NATL ACAD SCI USA, V107, P15145, DOI 10.1073/pnas.1009941107
   Qian W, 2014, ONCOTARGET, V5, P4180, DOI 10.18632/oncotarget.1944
   Qu B, 2017, J HUAZHONG U SCI-MED, V37, P37, DOI 10.1007/s11596-017-1691-2
   Quicke KM, 2017, EUR J IMMUNOL, V47, P615, DOI 10.1002/eji.201646484
   Rambold AS, 2011, P NATL ACAD SCI USA, V108, P10190, DOI 10.1073/pnas.1107402108
   Randall EC, 2019, MOL CANCER RES, V17, P1155, DOI 10.1158/1541-7786.MCR-18-1057
   Real PJ, 2005, CANCER RES, V65, P8151, DOI 10.1158/0008-5472.CAN-05-1134
   Richter-Dennerlein R, 2014, CELL METAB, V20, P158, DOI 10.1016/j.cmet.2014.04.016
   Roger AJ, 2017, CURR BIOL, V27, pR1177, DOI 10.1016/j.cub.2017.09.015
   Rogov V, 2014, MOL CELL, V53, P167, DOI 10.1016/j.molcel.2013.12.014
   Rogov VV, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-01258-6
   Ross JA, 2017, ONCOTARGET, V8, P65445, DOI 10.18632/oncotarget.18920
   Saita S, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2400
   Sambuudash O, 2017, YONSEI MED J, V58, P749, DOI 10.3349/ymj.2017.58.4.749
   Sapandowski A, 2015, MOL CELL BIOCHEM, V410, P175, DOI 10.1007/s11010-015-2549-1
   Sassano ML, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00174
   Schulten HJ, 2017, J TRANSL MED, V15, DOI 10.1186/s12967-017-1370-x
   Schwarten M, 2009, AUTOPHAGY, V5, P690, DOI 10.4161/auto.5.5.8494
   Sekine S, 2012, J BIOL CHEM, V287, P34635, DOI 10.1074/jbc.M112.357509
   Semenza GL, 2011, BBA-MOL CELL RES, V1813, P1263, DOI 10.1016/j.bbamcr.2010.08.006
   Sentelle RD, 2012, NAT CHEM BIOL, V8, P831, DOI 10.1038/NCHEMBIO.1059
   Serasinghe MN, 2017, HANDB EXP PHARMACOL, V240, P159, DOI 10.1007/164_2016_38
   Shaid S, 2013, CELL DEATH DIFFER, V20, P21, DOI 10.1038/cdd.2012.72
   Shaw GC, 2006, NATURE, V440, P96, DOI 10.1038/nature04512
   Shen YA, 2015, CELL CYCLE, V14, P86, DOI 10.4161/15384101.2014.974419
   Shi G, 2017, CELL REP, V18, P1458, DOI 10.1016/j.celrep.2017.01.029
   Shimizu S, 2010, ONCOL LETT, V1, P865, DOI 10.3892/ol_00000153
   Shirihai OS, 2015, CIRC RES, V116, P1835, DOI 10.1161/CIRCRESAHA.116.306374
   Simsek BC, 2015, EUR REV MED PHARMACO, V19, P3089
   Skipworth RJE, 2007, CLIN NUTR, V26, P667, DOI 10.1016/j.clnu.2007.03.011
   Smirnova E, 2001, MOL BIOL CELL, V12, P2245, DOI 10.1091/mbc.12.8.2245
   Soares CD, 2019, HUM PATHOL, V85, P279, DOI 10.1016/j.humpath.2018.11.009
   Song ZY, 2009, MOL BIOL CELL, V20, P3525, DOI 10.1091/mbc.E09-03-0252
   Sorrentino V, 2018, ANNU REV PHARMACOL, V58, P353, DOI 10.1146/annurev-pharmtox-010716-104908
   Sousa CM, 2016, NATURE, V536, P479, DOI 10.1038/nature19084
   Sowter HM, 2001, CANCER RES, V61, P6669
   Spees JL, 2006, P NATL ACAD SCI USA, V103, P1283, DOI 10.1073/pnas.0510511103
   Starkov AA, 2008, ANN NY ACAD SCI, V1147, P37, DOI 10.1196/annals.1427.015
   Stephens NA, 2010, GENOME MED, V2, DOI 10.1186/gm122
   Strappazzon F, 2015, CELL DEATH DIFFER, V22, P419, DOI 10.1038/cdd.2014.139
   Strappazzon F, 2015, MOL CELL ONCOL, V2, DOI 10.4161/23723556.2014.975647
   Strohecker AM, 2013, CANCER DISCOV, V3, P1272, DOI 10.1158/2159-8290.CD-13-0397
   Sugita H, 2011, ONCOL REP, V25, P513, DOI 10.3892/or.2010.1085
   Sugo M, 2018, EMBO J, V37, DOI 10.15252/embj.201798899
   Tahir SK, 2010, MOL CANCER THER, V9, P545, DOI 10.1158/1535-7163.MCT-09-0651
   Tak H, 2018, BIOCHEM BIOPH RES CO, V497, P1117, DOI 10.1016/j.bbrc.2018.02.189
   Takeda M, 2019, CANCER RES, V79, P1426, DOI 10.1158/0008-5472.CAN-18-2192
   Tan AS, 2015, CELL METAB, V21, P81, DOI 10.1016/j.cmet.2014.12.003
   Tan ZQ, 2016, MOL CANCER THER, V15, P774, DOI 10.1158/1535-7163.MCT-15-0621
   Tanwar DK, 2016, ONCOTARGET, V7, P60021, DOI 10.18632/oncotarget.11047
   Thongchot S, 2014, ASIAN PAC J CANCER P, V15, P5873, DOI 10.7314/APJCP.2014.15.14.5873
   Tian YM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0084150
   Toma MI, 2013, GENE CHROMOSOME CANC, V52, P265, DOI 10.1002/gcc.22026
   Torralba D, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05077-9
   Tsoi J, 2018, CANCER CELL, V33, P890, DOI 10.1016/j.ccell.2018.03.017
   Twig G, 2011, ANTIOXID REDOX SIGN, V14, P1939, DOI 10.1089/ars.2010.3779
   Tzika AA, 2013, INT J ONCOL, V43, P886, DOI 10.3892/ijo.2013.1998
   Unoki M, 2001, ONCOGENE, V20, P4457, DOI 10.1038/sj.onc.1204608
   Vacchelli E, 2015, SCIENCE, V350, P972, DOI 10.1126/science.aad0779
   Van Humbeeck C, 2011, J NEUROSCI, V31, P10249, DOI 10.1523/JNEUROSCI.1917-11.2011
   Vander Heiden MG, 2017, CELL, V168, DOI 10.1016/j.cell.2016.12.039
   Vara-Perez M, 2019, BIOL CHEM, V400, P187, DOI 10.1515/hsz-2018-0208
   da Silva-Camargo CCV, 2018, CANCER BIOL MED, V15, P61, DOI 10.20892/j.issn.2095-3941.2017.0136
   Villa E, 2017, CELL REP, V20, P2846, DOI 10.1016/j.celrep.2017.08.087
   Vives-Bauza C, 2010, P NATL ACAD SCI USA, V107, P378, DOI 10.1073/pnas.0911187107
   von Haehling S, 2014, J CACHEXIA SARCOPENI, V5, P261, DOI 10.1007/s13539-014-0164-8
   Walker BA, 2018, BLOOD, V132, P587, DOI 10.1182/blood-2018-03-840132
   Wallace Daniel F, 2016, Clin Biochem Rev, V37, P51
   Wang J, 2016, SCI REP-UK, V6, DOI 10.1038/srep24641
   Wang WL, 2015, CANCER LETT, V358, P47, DOI 10.1016/j.canlet.2014.12.025
   Wang X, 2015, CELL DEATH DIFFER, V22, P1181, DOI 10.1038/cdd.2014.211
   Wang XN, 2011, CELL, V147, P893, DOI 10.1016/j.cell.2011.10.018
   Wang XM, 2018, INFECT AGENTS CANCER, V13, DOI 10.1186/s13027-018-0212-7
   Wang Y, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-1152-2
   Wang Z, 2017, ONCOTARGET, V8, P104022, DOI 10.18632/oncotarget.21955
   WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309
   Warren S, 1932, AM J MED SCI, V184, P610, DOI 10.1097/00000441-193211000-00002
   Wei RJ, 2018, CELL STRESS CHAPERON, V23, P1295, DOI 10.1007/s12192-018-0937-7
   Wei YJ, 2017, CELL, V168, P224, DOI 10.1016/j.cell.2016.11.042
   Weinberg SE, 2015, NAT CHEM BIOL, V11, P9, DOI 10.1038/nchembio.1712
   Whelan KA, 2017, ONCOGENE, V36, P4843, DOI 10.1038/onc.2017.102
   Whitaker-Menezes D, 2011, CELL CYCLE, V10, P4047, DOI 10.4161/cc.10.23.18151
   Wieder SY, 2015, J INVEST DERMATOL, V135, P2544, DOI 10.1038/jid.2015.196
   Wild P, 2014, J CELL SCI, V127, P3, DOI 10.1242/jcs.140426
   Wong YC, 2014, P NATL ACAD SCI USA, V111, pE4439, DOI 10.1073/pnas.1405752111
   Wu HM, 2016, LUNG, V194, P959, DOI 10.1007/s00408-016-9936-6
   Wu LP, 2019, EBIOMEDICINE, V41, P384, DOI 10.1016/j.ebiom.2019.02.032
   Wu WX, 2014, EMBO REP, V15, P566, DOI 10.1002/embr.201438501
   Wu XM, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00539
   Wu YS, 2016, WORLD J SURG ONCOL, V14, DOI 10.1186/s12957-016-0922-5
   Xiong J, 2017, BLOOD CANCER J, V7, DOI 10.1038/bcj.2017.61
   Xu K, 2017, SCI REP-UK, V7, DOI 10.1038/srep41718
   Xu Q, 2017, DIS MODEL MECH, V10, P1503, DOI 10.1242/dmm.028332
   Yamano K, 2018, ELIFE, V7, DOI 10.7554/eLife.31326
   Yamashita K, 2017, ANN SURG ONCOL, V24, P4025, DOI 10.1245/s10434-017-6096-8
   Yan C, 2017, CANCER LETT, V388, P34, DOI 10.1016/j.canlet.2016.11.018
   Yang D, 2018, THERANOSTICS, V8, P3517, DOI 10.7150/thno.24401
   Yang YL, 2010, LEUKEMIA RES, V34, P18, DOI 10.1016/j.leukres.2009.07.023
   Yao N, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1470-z
   Ye XQ, 2011, INT J CANCER, V129, P820, DOI 10.1002/ijc.25944
   Yin J, 2018, TOXICOL IN VITRO, V51, P1, DOI 10.1016/j.tiv.2018.05.001
   Yoon Y, 2003, MOL CELL BIOL, V23, P5409, DOI 10.1128/MCB.23.15.5409-5420.2003
   Yoshimaru T, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15427
   Youle RJ, 2012, SCIENCE, V337, P1062, DOI 10.1126/science.1219855
   Yu R, 2019, EMBO J, V38, DOI 10.15252/embj.201899748
   Zhang C, 2011, P NATL ACAD SCI USA, V108, P16259, DOI 10.1073/pnas.1113884108
   Zhang H, 2019, EURASIP J ADV SIG PR, DOI 10.1186/s13634-019-0601-0
   Zhao CY, 2017, ONCOTARGET, V8, P20988, DOI 10.18632/oncotarget.15470
   Zhao XX, 2013, LAB INVEST, V93, P8, DOI 10.1038/labinvest.2012.144
   Zheng R, 2015, ONCOTARGET, V6, P17417, DOI 10.18632/oncotarget.4002
   Zhong HQ, 2017, FREE RADICAL BIO MED, V102, P67, DOI 10.1016/j.freeradbiomed.2016.10.494
   Zhong ZY, 2016, CELL, V164, P896, DOI 10.1016/j.cell.2015.12.057
   Zhu YY, 2013, J BIOL CHEM, V288, P1099, DOI 10.1074/jbc.M112.399345
   Ziegler PK, 2018, CELL, V174, P88, DOI 10.1016/j.cell.2018.05.028
   Zuo XX, 2016, TUMOR BIOL, V37, P1309, DOI 10.1007/s13277-015-3932-y
NR 340
TC 85
Z9 85
U1 16
U2 39
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2073-4409
J9 CELLS-BASEL
JI Cells
PD MAY
PY 2019
VL 8
IS 5
AR 493
DI 10.3390/cells8050493
PG 38
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA IC5FZ
UT WOS:000470994400113
PM 31121959
OA gold, Green Published, Green Submitted
HC Y
HP N
DA 2022-04-25
ER

PT J
AU He, SJ
   Cheng, J
   Feng, X
   Yu, Y
   Tian, L
   Huang, Q
AF He, Si-Jia
   Cheng, Jin
   Feng, Xiao
   Yu, Yang
   Tian, Ling
   Huang, Qian
TI The dual role and therapeutic potential of high-mobility group box 1 in
   cancer
SO ONCOTARGET
LA English
DT Review
DE HMGB1; RAGE; TLRs; cancer; anticancer therapy
ID HMGB1 REGULATES AUTOPHAGY; SIGNALING PROTEIN HMGB1; SQUAMOUS-CELL
   CARCINOMA; GLYCATION END-PRODUCTS; DNA-BINDING;
   HEPATOCELLULAR-CARCINOMA; COLORECTAL-CANCER; BREAST-CANCER; RECEPTOR 4;
   ISCHEMIA-REPERFUSION
AB High-mobility group box 1 (HMGB1) is an abundant protein in most eukaryocytes. It can bind to several receptors such as advanced glycation end products (RAGE) and Toll-like receptors (TLRs), in direct or indirect way. The biological effects of HMGB1 depend on its expression and subcellular location. Inside the nucleus, HMGB1 is engaged in many DNA events such as DNA repair, transcription, telomere maintenance, and genome stability. While outside the nucleus, it possesses more complicated functions, including regulating cell proliferation, autophagy, inflammation and immunity. During tumor development, HMGB1 has been characterized as both a pro-and anti-tumoral protein by either promoting or suppressing tumor growth, proliferation, angiogenesis, invasion and metastasis. However, the current knowledge concerning the positive and negative effects of HMGB1 on tumor development is not explicit. Here, we evaluate the role of HMGB1 in tumor development and attempt to reconcile the dual effects of HMGB1 in carcinogenesis. Furthermore, we would like to present current strategies targeting against HMGB1, its receptor or release, which have shown potentially therapeutic value in cancer intervention.
C1 [He, Si-Jia; Cheng, Jin; Feng, Xiao; Tian, Ling; Huang, Qian] Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Ctr Canc, Sch Med, Shanghai, Peoples R China.
   [He, Si-Jia; Cheng, Jin; Feng, Xiao; Tian, Ling; Huang, Qian] Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Shanghai Key Lab Pancreat Dis, Sch Med, Shanghai, Peoples R China.
   [Yu, Yang] Henan Prov Peoples Hosp, Dept Oncol, Zhengzhou, Henan, Peoples R China.
   [Tian, Ling] Shanghai Jiao Tong Univ, Inst Translat Med, Shanghai Gen Hosp, Sch Med, Shanghai, Peoples R China.
RP Huang, Q (corresponding author), Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Ctr Canc, Sch Med, Shanghai, Peoples R China.; Huang, Q (corresponding author), Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Shanghai Key Lab Pancreat Dis, Sch Med, Shanghai, Peoples R China.
EM Qhuang@sjtu.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81572951, 81502648]
FX This research is supported by grants from the National Natural Science
   Foundation of China (81572951) (Qian Huang) and (81502648) (Jin Cheng).
CR Agresti A, 2003, BIOCHEM BIOPH RES CO, V302, P421, DOI 10.1016/S0006-291X(03)00184-0
   Amornsupak K, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-955
   Andersson U, 2010, BBA-GENE REGUL MECH, V1799, P141, DOI 10.1016/j.bbagrm.2009.11.003
   Apetoh L, 2007, NAT MED, V13, P1050, DOI 10.1038/nm1622
   Assenberg R, 2008, BIOCHEM J, V411, P553, DOI 10.1042/BJ20071613
   Bamboat ZM, 2010, HEPATOLOGY, V51, P621, DOI 10.1002/hep.23365
   Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0
   CABART P, 1995, CELL BIOCHEM FUNCT, V13, P125, DOI 10.1002/cbf.290130209
   Calogero S, 1999, NAT GENET, V22, P276, DOI 10.1038/10338
   Campana L, 2008, CURR OPIN IMMUNOL, V20, P518, DOI 10.1016/j.coi.2008.04.012
   Chen RC, 2014, MOL CELL BIOCHEM, V390, P271, DOI 10.1007/s11010-014-1978-6
   Chiba S, 2012, NAT IMMUNOL, V13, P832, DOI 10.1038/ni.2376
   Chitanuwat A, 2013, J ORAL SCI, V55, P45, DOI 10.2334/josnusd.55.45
   Ciucci A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023766
   Dajon M, 2017, IMMUNOBIOLOGY, V222, P89, DOI 10.1016/j.imbio.2016.06.009
   Degryse B, 2001, J CELL BIOL, V152, P1197, DOI 10.1083/jcb.152.6.1197
   Diener KR, 2013, IMMUNOL CELL BIOL, V91, P443, DOI 10.1038/icb.2013.25
   Elenkov I, 2011, INT J BIOL SCI, V7, P691, DOI 10.7150/ijbs.7.691
   Ellerman JE, 2007, CLIN CANCER RES, V13, P2836, DOI 10.1158/1078-0432.CCR-06-1953
   Farid RS, 1996, TOXICOL APPL PHARM, V141, P532, DOI 10.1006/taap.1996.0319
   Feng XJ, 2012, J CELL BIOCHEM, V113, P2009, DOI 10.1002/jcb.24071
   Fuentes E, 2014, THROMB RES, V133, P308, DOI 10.1016/j.thromres.2013.11.007
   Gdynia G, 2010, CANCER RES, V70, P8558, DOI 10.1158/0008-5472.CAN-10-0204
   GE H, 1994, J BIOL CHEM, V269, P17136
   Gebhardt C, 2008, J EXP MED, V205, P275, DOI 10.1084/jem.20070679
   GOODWIN GH, 1973, EUR J BIOCHEM, V38, P14, DOI 10.1111/j.1432-1033.1973.tb03026.x
   Guo ZS, 2013, AM J CANCER RES, V3, P1
   HANSPAL M, 1994, BLOOD, V84, P3494
   Herzog C, 2014, CARDIOVASC RES, V101, P400, DOI 10.1093/cvr/cvt275
   Hoppe G, 2006, EXP CELL RES, V312, P3526, DOI 10.1016/j.yexcr.2006.07.020
   Igney FH, 2002, NAT REV CANCER, V2, P277, DOI 10.1038/nrc776
   Ito I, 2007, J BIOL CHEM, V282, P16336, DOI 10.1074/jbc.M608467200
   Jayaraman L, 1998, GENE DEV, V12, P462, DOI 10.1101/gad.12.4.462
   Jiang WW, 2007, J IMMUNOL, V178, P6495, DOI 10.4049/jimmunol.178.10.6495
   Jiao Y, 2007, ACTA PHARMACOL SIN, V28, P1957, DOI 10.1111/j.1745-7254.2007.00669.x
   Joshi SR, 2012, NUCLEIC ACIDS RES, V40, P10161, DOI 10.1093/nar/gks815
   Jube S, 2012, CANCER RES, V72, P3290, DOI 10.1158/0008-5472.CAN-11-3481
   Kang R, 2014, ONCOGENE, V33, P567, DOI 10.1038/onc.2012.631
   Kang R, 2013, CLIN CANCER RES, V19, P4046, DOI 10.1158/1078-0432.CCR-13-0495
   Kawane K, 2006, NATURE, V443, P998, DOI 10.1038/nature05245
   Kazama H, 2008, IMMUNITY, V29, P21, DOI 10.1016/j.immuni.2008.05.013
   Ke SB, 2015, INT J ONCOL, V46, P1051, DOI 10.3892/ijo.2014.2793
   Kew RR, 2012, J IMMUNOL, V188, P2380, DOI 10.4049/jimmunol.1102454
   Krysko DV, 2012, NAT REV CANCER, V12, P860, DOI 10.1038/nrc3380
   Kuil J, 2012, CHEM SOC REV, V41, P5239, DOI 10.1039/c2cs35085h
   Lai KKY, 2016, TUMOR BIOL, V37, P2127, DOI 10.1007/s13277-015-4018-6
   Laird MD, 2014, GLIA, V62, P26, DOI 10.1002/glia.22581
   LANDSMAN D, 1993, BIOESSAYS, V15, P539, DOI 10.1002/bies.950150807
   Lange SS, 2008, P NATL ACAD SCI USA, V105, P10320, DOI 10.1073/pnas.0803181105
   Lange SS, 2009, DNA REPAIR, V8, P865, DOI 10.1016/j.dnarep.2009.04.001
   Lange SS, 2009, MOL CARCINOGEN, V48, P571, DOI 10.1002/mc.20544
   Lee H, 2010, J PROTEOME RES, V9, P4661, DOI 10.1021/pr100386r
   Lee HJ, 2015, VIRCHOWS ARCH, V467, P701, DOI 10.1007/s00428-015-1861-1
   Lee HJ, 2012, EVID-BASED COMPL ALT, V2012, P1, DOI DOI 10.1371/J0URNAL.P0NE.0034318
   Li JH, 2003, MOL MED, V9, P37, DOI 10.1007/BF03402105
   Li QL, 2014, ONCOTARGET, V5, P6387, DOI 10.18632/oncotarget.2201
   Li YM, 2004, CANCER CELL, V6, P459, DOI 10.1016/j.ccr.2004.09.027
   Liu K, 2014, AUTOPHAGY, V10, P442, DOI 10.4161/auto.27418
   Liu Y, 2015, J HEPATOL, V63, P114, DOI 10.1016/j.jhep.2015.02.009
   Livesey KM, 2012, AUTOPHAGY, V8, P846, DOI 10.4161/auto.19891
   Livesey KM, 2012, CANCER RES, V72, P1996, DOI 10.1158/0008-5472.CAN-11-2291
   Lotze MT, 2005, NAT REV IMMUNOL, V5, P331, DOI 10.1038/nri1594
   Luo Y, 2010, EUR J CANCER, V46, P791, DOI 10.1016/j.ejca.2009.11.011
   Meyer A, 2008, LEUKEMIA LYMPHOMA, V49, P1184, DOI 10.1080/10428190802064909
   Mitsouras K, 2002, MOL CELL BIOL, V22, P4390, DOI 10.1128/MCB.22.12.4390-4401.2002
   Mollica L, 2007, CHEM BIOL, V14, P431, DOI 10.1016/j.chembiol.2007.03.007
   Monney L, 2002, NATURE, V415, P536, DOI 10.1038/415536a
   Moser B, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094118
   MOSEVITSKY MI, 1989, EUR J BIOCHEM, V185, P303, DOI 10.1111/j.1432-1033.1989.tb15116.x
   Muller S, 2004, J INTERN MED, V255, P332, DOI 10.1111/j.1365-2796.2003.01296.x
   Musumeci D, 2014, PHARMACOL THERAPEUT, V141, P347, DOI 10.1016/j.pharmthera.2013.11.001
   Ndhlovu LC, 2012, BLOOD, V119, P3734, DOI 10.1182/blood-2011-11-392951
   Nickel W, 2005, TRAFFIC, V6, P607, DOI 10.1111/j.1600-0854.2005.00302.x
   O'Neill LAJ, 2003, TRENDS IMMUNOL, V24, P287, DOI 10.1016/S1471-4906(03)00115-7
   Ogiku M, 2011, J PHARMACOL EXP THER, V339, P93, DOI 10.1124/jpet.111.182592
   Ohmori H, 2011, EXPERT OPIN THER TAR, V15, P183, DOI 10.1517/14728222.2011.546785
   Palumbo R, 2004, J CELL BIOL, V164, P441, DOI 10.1083/jcb.200304135
   Pang H., 2016, MEDIAT INFLAMM, V2016
   Pang XA, 2014, INT J MOL SCI, V15, P8699, DOI 10.3390/ijms15058699
   Pellegrini L, 2017, ONCOTARGET, V8, P22649, DOI 10.18632/oncotarget.15152
   Penumutchu SR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103947
   PIL PM, 1993, P NATL ACAD SCI USA, V90, P9465, DOI 10.1073/pnas.90.20.9465
   PIL PM, 1992, SCIENCE, V256, P234, DOI 10.1126/science.1566071
   Polanska E, 2012, CHROMOSOMA, V121, P419, DOI 10.1007/s00412-012-0373-x
   Pradere JP, 2014, ONCOGENE, V33, P3485, DOI 10.1038/onc.2013.302
   Prasad R, 2007, MOL CELL, V27, P829, DOI 10.1016/j.molcel.2007.06.029
   PRASAD S, 1990, BIOCHEM INT, V20, P687
   Qiang WG, 2014, BIOCHEM BIOPH RES CO, V445, P363, DOI 10.1016/j.bbrc.2014.02.001
   Ratajczak MZ, 2006, LEUKEMIA, V20, P1915, DOI 10.1038/sj.leu.2404357
   Raucci A, 2008, FASEB J, V22, P3716, DOI 10.1096/fj.08-109033
   Rowell JP, 2012, STRUCTURE, V20, P2014, DOI 10.1016/j.str.2012.09.004
   Sakuishi K, 2011, TRENDS IMMUNOL, V32, P345, DOI 10.1016/j.it.2011.05.003
   Sasahira T, 2007, VIRCHOWS ARCH, V450, P287, DOI 10.1007/s00428-006-0359-2
   Schiraldi M, 2012, J EXP MED, V209, P551, DOI 10.1084/jem.20111739
   Sessa L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086903
   Sims GP, 2010, ANNU REV IMMUNOL, V28, P367, DOI 10.1146/annurev.immunol.021908.132603
   Smolarczyk R, 2012, ARCH IMMUNOL THER EX, V60, P391, DOI 10.1007/s00005-012-0183-0
   Song MJ, 2004, J VIROL, V78, P12940, DOI 10.1128/JVI.78.23.12940-12950.2004
   Sorci G, 2013, BBA-MOL CELL RES, V1833, P101, DOI 10.1016/j.bbamcr.2012.10.021
   Sparvero LJ, 2009, J TRANSL MED, V7, DOI 10.1186/1479-5876-7-17
   Stros M, 2002, J BIOL CHEM, V277, P7157, DOI 10.1074/jbc.M110233200
   Stros M, 2010, BBA-GENE REGUL MECH, V1799, P101, DOI 10.1016/j.bbagrm.2009.09.008
   Sun SP, 2015, ONCOTARGETS THER, V8, DOI 10.2147/OTT.S73366
   Suren D, 2014, MED SCI MONITOR, V20, P530, DOI 10.12659/MSM.890531
   Tadie JM, 2012, MOL MED, V18, P659, DOI 10.2119/molmed.2011.00401
   Taguchi A, 2000, NATURE, V405, P354, DOI 10.1038/35012626
   Takeda T, 2014, TUMOR BIOL, V35, P10555, DOI 10.1007/s13277-014-2328-8
   Tang DL, 2012, NAT IMMUNOL, V13, P808, DOI 10.1038/ni.2396
   Tang DL, 2010, AUTOPHAGY, V6, P1181, DOI 10.4161/auto.6.8.13367
   Tang DL, 2010, J CELL BIOL, V190, P881, DOI 10.1083/jcb.200911078
   Tang DL, 2009, AM J RESP CELL MOL, V41, P651, DOI 10.1165/rcmb.2008-0119OC
   Tian J, 2007, NAT IMMUNOL, V8, P487, DOI 10.1038/ni1457
   Ulloa L, 2005, NAT REV DRUG DISCOV, V4, P673, DOI 10.1038/nrd1797
   Ulloa L, 2006, CYTOKINE GROWTH F R, V17, P189, DOI 10.1016/j.cytogfr.2006.01.003
   Urbich C, 2004, CIRC RES, V95, P343, DOI 10.1161/01.RES.0000137877.89448.78
   van Beijnum JR, 2013, ONCOGENE, V32, P363, DOI 10.1038/onc.2012.49
   van Beijnum JR, 2006, BLOOD, V108, P2339, DOI 10.1182/blood-2006-02-004291
   Wang Q, 2007, BIOCHEM BIOPH RES CO, V360, P14, DOI 10.1016/j.bbrc.2007.05.130
   Wang XJ, 2015, EXP THER MED, V9, P513, DOI 10.3892/etm.2014.2089
   Webb M, 1999, J MOL BIOL, V294, P373, DOI 10.1006/jmbi.1999.3150
   Weng H, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-311
   Weterings E, 2008, CELL RES, V18, P114, DOI 10.1038/cr.2008.3
   Xiao JQ, 2014, PLOS ONE, V9, DOI [10.1371/journal.pone.0090396, 10.1371/journal.pone.0095214]
   Yan HX, 2013, J HEPATOL, V59, P762, DOI 10.1016/j.jhep.2013.05.029
   Yan W, 2012, HEPATOLOGY, V55, P1863, DOI 10.1002/hep.25572
   Yang H, 2010, BBA-GENE REGUL MECH, V1799, P149, DOI 10.1016/j.bbagrm.2009.11.019
   Yaser AM, 2012, INT J MOL SCI, V13, P5982, DOI 10.3390/ijms13055982
   Yu M, 2011, LIFE SCI, V89, P65, DOI 10.1016/j.lfs.2011.05.010
   Yuan FH, 2004, J BIOL CHEM, V279, P20935, DOI 10.1074/jbc.M401931200
   Yumoto Y, 1998, J BIOCHEM-TOKYO, V124, P519, DOI 10.1093/oxfordjournals.jbchem.a022143
   Zamble DB, 1996, BIOCHEMISTRY-US, V35, P10004, DOI 10.1021/bi960453+
   Zhan ZZ, 2012, AUTOPHAGY, V8, P109, DOI 10.4161/auto.8.1.18319
   Zhang CL, 2008, MED HYPOTHESES, V70, P343, DOI 10.1016/j.mehy.2007.05.024
   Zhang J, 2014, INT J ONCOL, V44, P1268, DOI 10.3892/ijo.2014.2285
   Zhao MY, 2011, BMB REP, V44, P601, DOI 10.5483/BMBRep.2011.44.9.601
   Zhao TS, 2015, ONCOTARGET, V6, P27816, DOI 10.18632/oncotarget.4816
   Zuo ZH, 2014, ONCOTARGET, V5, P7458, DOI 10.18632/oncotarget.2150
NR 137
TC 68
Z9 76
U1 2
U2 11
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
SN 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD SEP 8
PY 2017
VL 8
IS 38
BP 64534
EP 64550
DI 10.18632/oncotarget.17885
PG 17
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA FG4XE
UT WOS:000410284800143
PM 28969092
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Zhang, FQ
   Cheong, JK
AF Zhang, Fuquan
   Cheong, Jit Kong
TI The renewed battle against RAS-mutant cancers
SO CELLULAR AND MOLECULAR LIFE SCIENCES
LA English
DT Review
DE KRAS; NRAS; HRAS; Small GTPases; Kinases; Autophagy; Signaling; Cancer
   therapeutics
ID PANCREATIC DUCTAL ADENOCARCINOMA; ADVANCED SOLID TUMORS; CELL
   LUNG-CANCER; ISOPRENYLCYSTEINE CARBOXYL METHYLTRANSFERASE;
   FARNESYL-PROTEIN TRANSFERASE; METASTATIC COLORECTAL-CANCER;
   BLADDER-CARCINOMA ONCOGENE; PHASE-I TRIAL; K-RAS; N-RAS
AB The RAS genes encode for members of a large superfamily of guanosine-5'-triphosphate (GTP)-binding proteins that control diverse intracellular signaling pathways to promote cell proliferation. Somatic mutations in the RAS oncogenes are the most common activating lesions found in human cancers. These mutations invariably result in the gain-of-function of RAS by impairing GTP hydrolysis and are frequently associated with poor responses to standard cancer therapies. In this review, we summarize key findings of past and present landmark studies that have deepened our understanding of the RAS biology in the context of oncogenesis. We also discuss how emerging areas of research could further bolster a renewed global effort to target the largely undruggable oncogenic RAS and/or its activated downstream effector signaling cascades to achieve better treatment outcomes for RAS-mutant cancer patients.
C1 [Zhang, Fuquan; Cheong, Jit Kong] Duke NUS Med Sch, Programme Canc & Stem Cell Biol, 8 Coll Rd, Singapore 169857, Singapore.
RP Cheong, JK (corresponding author), Duke NUS Med Sch, Programme Canc & Stem Cell Biol, 8 Coll Rd, Singapore 169857, Singapore.
EM jitkong.cheong@duke-nus.edu.sg
OI Cheong, Jit Kong/0000-0002-2658-5436
FU NMRC-CBRG New Investigator Grant [NMRC/BNIG/1078/2012]; Duke-NUS-St.
   Baldrick's Foundation Pediatric Cancer Research Fund
   [Duke-NUS-SBF/2015/0004]
FX Space limitations preclude our manuscript from being a comprehensive
   review, and this unfortunately limits appropriate recognition of many of
   our colleagues worldwide, who have contributed immeasurably to the
   development of the RAS field. We thank David Virshup (Duke-NUS) for his
   critical review of our manuscript. This work was supported by an
   NMRC-CBRG New Investigator Grant (NMRC/BNIG/1078/2012) and a
   Duke-NUS-St. Baldrick's Foundation Pediatric Cancer Research Fund
   (Duke-NUS-SBF/2015/0004) to JKC.
CR Aguirre AJ, 2003, GENE DEV, V17, P3112, DOI 10.1101/gad.1158703
   Nguyen AT, 2012, DIS MODEL MECH, V5, P63, DOI 10.1242/dmm.008367
   Barbie DA, 2009, NATURE, V462, P108, DOI 10.1038/nature08460
   Bardeesy N, 2006, P NATL ACAD SCI USA, V103, P5947, DOI 10.1073/pnas.0601273103
   Barnard RA, 2014, AUTOPHAGY, V10, P1415, DOI 10.4161/auto.29165
   Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003
   Bergo MO, 2000, J BIOL CHEM, V275, P17605, DOI 10.1074/jbc.C000079200
   Bivona TG, 2003, NATURE, V424, P694, DOI 10.1038/nature01806
   Bowman BM, 2015, SCI SIGNAL, V8, DOI 10.1126/scisignal.2005607
   Britten CD, 2013, CANCER CHEMOTH PHARM, V71, P1395, DOI 10.1007/s00280-013-2121-1
   Brundage ME, 2014, ONCOGENE, V33, P5626, DOI 10.1038/onc.2013.506
   Carracedo A, 2008, J CLIN INVEST, V118, P3065, DOI [10.1172/jCI34739, 10.1172/JCI34739]
   Carretero J, 2010, CANCER CELL, V17, P547, DOI 10.1016/j.ccr.2010.04.026
   Carriere A, 2011, J BIOL CHEM, V286, P567, DOI 10.1074/jbc.M110.159046
   Cheong JK, 2015, J CLIN INVEST, V125, P1401, DOI 10.1172/JCI78018
   Chiu VK, 2002, NAT CELL BIOL, V4, P343, DOI 10.1038/ncb783
   Collins MA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049707
   Collins MA, 2012, J CLIN INVEST, V122, P639, DOI 10.1172/JCI59227
   Corazzari M, 2015, CELL DEATH DIFFER, V22, P946, DOI 10.1038/cdd.2014.183
   Cox AD, 2015, CLIN CANCER RES, V21, P1819, DOI 10.1158/1078-0432.CCR-14-3214
   Cox AD, 2014, NAT REV DRUG DISCOV, V13, P828, DOI 10.1038/nrd4389
   De Roock W, 2010, LANCET ONCOL, V11, P753, DOI 10.1016/S1470-2045(10)70130-3
   Degtyarev M, 2008, J CELL BIOL, V183, P101, DOI 10.1083/jcb.200801099
   DER CJ, 1982, P NATL ACAD SCI-BIOL, V79, P3637, DOI 10.1073/pnas.79.11.3637
   Dou ZX, 2015, NATURE, V527, P105, DOI 10.1038/nature15548
   Dougherty MK, 2005, MOL CELL, V17, P215, DOI 10.1016/j.molcel.2004.11.055
   Douillard JY, 2013, NEW ENGL J MED, V369, P1023, DOI 10.1056/NEJMoa1305275
   Downward J, 2015, CLIN CANCER RES, V21, P1802, DOI 10.1158/1078-0432.CCR-14-2180
   Elenbaas B, 2001, GENE DEV, V15, P50, DOI 10.1101/gad.828901
   Elgendy M, 2011, MOL CELL, V42, P23, DOI 10.1016/j.molcel.2011.02.009
   End DW, 2001, CANCER RES, V61, P131
   Engelman JA, 2008, NAT MED, V14, P1351, DOI 10.1038/nm.1890
   Esteban LM, 2001, MOL CELL BIOL, V21, P1444, DOI 10.1128/MCB.21.5.1444-1452.2001
   Foster KG, 2010, J BIOL CHEM, V285, P80, DOI 10.1074/jbc.M109.029637
   Freeman AK, 2013, MOL CELL, V49, P751, DOI 10.1016/j.molcel.2012.12.018
   Ganley IG, 2009, J BIOL CHEM, V284, P12297, DOI 10.1074/jbc.M900573200
   Garnett MJ, 2012, NATURE, V483, P570, DOI 10.1038/nature11005
   Gilmartin AG, 2011, CLIN CANCER RES, V17, P989, DOI 10.1158/1078-0432.CCR-10-2200
   GOLDFARB M, 1982, NATURE, V296, P404, DOI 10.1038/296404a0
   Guan KL, 2000, J BIOL CHEM, V275, P27354
   Guo JY, 2011, GENE DEV, V25, P460, DOI 10.1101/gad.2016311
   Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780
   HALL A, 1983, NATURE, V303, P396, DOI 10.1038/303396a0
   HARVEY JJ, 1964, NATURE, V204, P1104, DOI 10.1038/2041104b0
   Hatzivassiliou G, 2010, NATURE, V464, P431, DOI 10.1038/nature08833
   Heidorn SJ, 2010, CELL, V140, P209, DOI 10.1016/j.cell.2009.12.040
   Herrero A, 2015, CANCER CELL, V28, P170, DOI 10.1016/j.ccell.2015.07.001
   Hingorani SR, 2003, CANCER CELL, V4, P437, DOI 10.1016/S1535-6108(03)00309-X
   Hingorani SR, 2005, CANCER CELL, V7, P469, DOI 10.1016/j.ccr.2005.04.023
   Hoeflich KP, 2009, CLIN CANCER RES, V15, P4649, DOI 10.1158/1078-0432.CCR-09-0317
   Hosokawa N, 2009, MOL BIOL CELL, V20, P1981, DOI 10.1091/mbc.E08-12-1248
   Hunter JC, 2015, MOL CANCER RES, V13, P1325, DOI 10.1158/1541-7786.MCR-15-0203
   Ijichi H, 2006, GENE DEV, V20, P3147, DOI 10.1101/gad.1475506
   Inouye K, 2000, J BIOL CHEM, V275, P3737, DOI 10.1074/jbc.275.6.3737
   Jackson EL, 2001, GENE DEV, V15, P3243, DOI 10.1101/gad.943001
   JAMES GL, 1995, J BIOL CHEM, V270, P6221, DOI 10.1074/jbc.270.11.6221
   Johnson L, 2001, NATURE, V410, P1111, DOI 10.1038/35074129
   Johnson L, 1997, GENE DEV, V11, P2468, DOI 10.1101/gad.11.19.2468
   Jung CH, 2009, MOL BIOL CELL, V20, P1992, DOI 10.1091/mbc.E08-12-1249
   Kaur J, 2015, NAT REV MOL CELL BIO, V16, P461, DOI 10.1038/nrm4024
   Kim E, 1999, J BIOL CHEM, V274, P8383, DOI 10.1074/jbc.274.13.8383
   Kim HS, 2013, CELL, V155, P552, DOI 10.1016/j.cell.2013.09.041
   Kim MJ, 2011, J BIOL CHEM, V286, P12924, DOI 10.1074/jbc.M110.138958
   Kimmelman AC, 2015, CLIN CANCER RES, V21, P1828, DOI 10.1158/1078-0432.CCR-14-2425
   KIRSTEN WH, 1967, J NATL CANCER I, V39, P311
   Koera K, 1997, ONCOGENE, V15, P1151, DOI 10.1038/sj.onc.1201284
   Kumar MS, 2012, CELL, V149, P642, DOI 10.1016/j.cell.2012.02.059
   Lampson BL, 2013, CURR BIOL, V23, P70, DOI 10.1016/j.cub.2012.11.031
   Langenau DM, 2007, GENE DEV, V21, P1382, DOI 10.1101/gad.1545007
   LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0
   Levy JMM, 2014, CANCER DISCOV, V4, P773, DOI 10.1158/2159-8290.CD-14-0049
   Lin WC, 2014, P NATL ACAD SCI USA, V111, P2996, DOI 10.1073/pnas.1321155111
   Linardou H, 2008, LANCET ONCOL, V9, P962, DOI 10.1016/S1470-2045(08)70206-7
   Liu EY, 2012, J CELL SCI, V125, P2349, DOI 10.1242/jcs.093708
   Liu JS, 2004, CANCER RES, V64, P1655, DOI 10.1158/0008-5472.CAN-03-3380
   Liu M, 1998, CANCER RES, V58, P4947
   Lock R, 2011, MOL BIOL CELL, V22, P165, DOI 10.1091/mbc.E10-06-0500
   Lundberg AS, 2002, ONCOGENE, V21, P4577, DOI 10.1038/sj.onc.1205550
   Luo J, 2009, CELL, V137, P835, DOI 10.1016/j.cell.2009.05.006
   Ma L, 2005, CELL, V121, P179, DOI 10.1016/j.cell.2005.02.031
   Ma XH, 2014, J CLIN INVEST, V124, P1406, DOI 10.1172/JCI70454
   MacKenzie KL, 2002, ONCOGENE, V21, P4200, DOI 10.1038/sj.onc.1205425
   Mahalingam D, 2014, AUTOPHAGY, V10, P1403, DOI 10.4161/auto.29231
   Manandhar SP, 2007, J BIOMOL SCREEN, V12, P983, DOI 10.1177/1087057107307226
   MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x
   Marcus K, 2015, CLIN CANCER RES, V21, P1810, DOI 10.1158/1078-0432.CCR-14-2148
   McCormick F, 2015, CLIN CANCER RES, V21, P1797, DOI 10.1158/1078-0432.CCR-14-2662
   Mendoza MC, 2011, TRENDS BIOCHEM SCI, V36, P320, DOI 10.1016/j.tibs.2011.03.006
   Milani M, 2009, CANCER RES, V69, P4415, DOI 10.1158/0008-5472.CAN-08-2839
   Morton JP, 2010, GASTROENTEROLOGY, V139, P586, DOI 10.1053/j.gastro.2010.04.055
   Muratcioglu S, 2015, STRUCTURE, V23, P1325, DOI 10.1016/j.str.2015.04.019
   Nan XL, 2015, P NATL ACAD SCI USA, V112, P7996, DOI 10.1073/pnas.1509123112
   Nazarian R, 2010, NATURE, V468, P973, DOI 10.1038/nature09626
   Noda T, 1998, J BIOL CHEM, V273, P3963, DOI 10.1074/jbc.273.7.3963
   Ostrem JM, 2013, NATURE, V503, P548, DOI 10.1038/nature12796
   Ou YH, 2011, MOL CELL, V41, P458, DOI 10.1016/j.molcel.2011.01.019
   PARADA LF, 1982, NATURE, V297, P474, DOI 10.1038/297474a0
   Pells S, 1997, ONCOGENE, V15, P1781, DOI 10.1038/sj.onc.1201354
   Peng SB, 2015, CANCER CELL, V28, P384, DOI 10.1016/j.ccell.2015.08.002
   Pershing NLK, 2015, J CLIN INVEST, V125, P222, DOI 10.1172/JCI77627
   PERUCHO M, 1981, CELL, V27, P467, DOI 10.1016/0092-8674(81)90388-3
   Porter SB, 2007, BBA-MOL CELL RES, V1773, P853, DOI 10.1016/j.bbamcr.2007.03.004
   Potenza N, 2005, EMBO REP, V6, P432, DOI 10.1038/sj.embor.7400397
   Poulikakos PI, 2010, NATURE, V464, P427, DOI 10.1038/nature08902
   PULCIANI S, 1982, P NATL ACAD SCI-BIOL, V79, P2845, DOI 10.1073/pnas.79.9.2845
   Pylayeva-Gupta Y, 2011, NAT REV CANCER, V11, P761, DOI 10.1038/nrc3106
   Rangwala R, 2014, AUTOPHAGY, V10, P1391, DOI 10.4161/auto.29119
   Rangwala R, 2014, AUTOPHAGY, V10, P1369, DOI 10.4161/auto.29118
   Rich JN, 2001, CANCER RES, V61, P3556
   Rosenfeld MR, 2014, AUTOPHAGY, V10, P1359, DOI 10.4161/auto.28984
   SANTOS E, 1988, J BIOL CHEM, V263, P9853
   SANTOS E, 1982, NATURE, V298, P343, DOI 10.1038/298343a0
   Schook LB, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128864
   SCOLNICK EM, 1973, J VIROL, V12, P458, DOI 10.1128/JVI.12.3.458-463.1973
   Scott RC, 2004, DEV CELL, V7, P167, DOI 10.1016/j.devcel.2004.07.009
   Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9
   SHIH C, 1979, P NATL ACAD SCI USA, V76, P5714, DOI 10.1073/pnas.76.11.5714
   SHIH C, 1981, NATURE, V290, P261, DOI 10.1038/290261a0
   SHIH C, 1982, CELL, V29, P161, DOI 10.1016/0092-8674(82)90100-3
   SHIMIZU K, 1983, P NATL ACAD SCI-BIOL, V80, P383, DOI 10.1073/pnas.80.2.383
   Singh H, 2015, J CLIN ONCOL, V33, P3650, DOI 10.1200/JCO.2015.62.1052
   Spiegel J, 2014, NAT CHEM BIOL, V10, P613, DOI 10.1038/nchembio.1560
   Stephen AG, 2014, CANCER CELL, V25, P272, DOI 10.1016/j.ccr.2014.02.017
   Strohecker AM, 2013, CANCER DISCOV, V3, P1272, DOI 10.1158/2159-8290.CD-13-0397
   Tan IB, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-015-0589-1
   To MD, 2008, NAT GENET, V40, P1240, DOI 10.1038/ng.211
   TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624
   Vogl DT, 2014, AUTOPHAGY, V10, P1380, DOI 10.4161/auto.29264
   Wey M, 2013, BIOCHEMISTRY-US, V52, P8465, DOI 10.1021/bi400679q
   White E, 2012, NAT REV CANCER, V12, P401, DOI 10.1038/nrc3262
   Winter-Vann AM, 2005, P NATL ACAD SCI USA, V102, P4336, DOI 10.1073/pnas.0408107102
   Yang SH, 2011, GENE DEV, V25, P717, DOI 10.1101/gad.2016111
   Yao Z, 2015, CANCER CELL, V28, P370, DOI 10.1016/j.ccell.2015.08.001
   Ying HQ, 2012, CELL, V149, P656, DOI 10.1016/j.cell.2012.01.058
   Yu CF, 2002, J BIOL CHEM, V277, P19382, DOI 10.1074/jbc.M200732200
   Yu J, 2001, VIROLOGY, V290, P192, DOI 10.1006/viro.2001.1204
   Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741
NR 137
TC 24
Z9 25
U1 0
U2 31
PU SPRINGER BASEL AG
PI BASEL
PA PICASSOPLATZ 4, BASEL, 4052, SWITZERLAND
SN 1420-682X
EI 1420-9071
J9 CELL MOL LIFE SCI
JI Cell. Mol. Life Sci.
PD MAY
PY 2016
VL 73
IS 9
BP 1845
EP 1858
DI 10.1007/s00018-016-2155-8
PG 14
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA DJ3NH
UT WOS:000374111800006
PM 26892781
DA 2022-04-25
ER

PT J
AU Frazzi, R
AF Frazzi, Raffaele
TI SIRT1 in Secretory Organ Cancer
SO FRONTIERS IN ENDOCRINOLOGY
LA English
DT Review
DE SIRT1; cancer; secretory organs; acetylation; epigenetic modulation
ID LONG NONCODING RNA; EPITHELIAL-MESENCHYMAL TRANSITION;
   PANCREATIC-CANCER; GASTRIC-CANCER; OVARIAN-CANCER; THYROID-CANCER;
   C-MYC; HEPATOCELLULAR-CARCINOMA; PROTECTIVE AUTOPHAGY; TUMOR-SUPPRESSOR
AB Mammalian silent information regulator 1 (SIRT1) is reported to play a role in cancers of the secretory organs, including thyroid, pancreatic endocrine, and ovarian tumors (1-4). A recentmeta-analysis conducted on 37 selected studies of human cancers analyzed the correlations of overall survival (OS), disease-free survival (DFS) and relapse-free survival (RFS) with SIRT1 expression (5). This study reported that SIRT1 overexpression was associated with a worse OS in liver and lung cancers, while it was not correlated with OS in breast cancer, colorectal cancer, or gastric carcinoma. Collectively, the meta-analysis revealed that an unfavorable OS was associated with SIRT1 expression for solid malignancies. Given the growing importance of this class of lysine/histone deacetylases in human endocrine malignancies, a rational and focused literature assessment is desirable in light of future clinical translations.
C1 [Frazzi, Raffaele] Azienda Unita Sanit Locale, IRCCS Reggio Emilia, Lab Translat Res, Reggio Emilia, Italy.
RP Frazzi, R (corresponding author), Azienda Unita Sanit Locale, IRCCS Reggio Emilia, Lab Translat Res, Reggio Emilia, Italy.
EM raffaele.frazzi@ausl.re.it
OI Frazzi, Raffaele/0000-0003-1822-745X
FU Azienda Unita Sanitaria Locale - IRCCS Reggio Emilia, Italy
FX This work has been funded by Azienda Unita Sanitaria Locale - IRCCS
   Reggio Emilia, Italy.
CR Akhter MZ, 2018, ONCOGENE, V37, P2089, DOI 10.1038/s41388-017-0106-y
   Bolm L, 2018, ANTICANCER RES, V38, P3231, DOI 10.21873/anticanres.12588
   Brooks CL, 2009, NAT REV CANCER, V9, P123, DOI 10.1038/nrc2562
   Broutier L, 2017, NAT MED, V23, P1424, DOI 10.1038/nm.4438
   Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997
   Cao WX, 2017, BIOCHEM BIOPH RES CO, V483, P638, DOI 10.1016/j.bbrc.2016.12.090
   Choupani J, 2018, J CELL PHYSIOL, V233, P4443, DOI 10.1002/jcp.26302
   Dang CV, 2006, SEMIN CANCER BIOL, V16, P253, DOI 10.1016/j.semcancer.2006.07.014
   Das A, 2018, CELL, V173, P74, DOI 10.1016/j.cell.2018.02.008
   Deng SC, 2014, CANCER LETT, V355, P184, DOI 10.1016/j.canlet.2014.08.007
   Duntas LH, 2011, J ENDOCRINOL INVEST, V34, P788, DOI 10.3275/7926
   Fang DF, 2015, BIOCHEM BIOPH RES CO, V457, P500, DOI 10.1016/j.bbrc.2014.12.114
   Frazzi R, 2014, INT J MOL SCI, V15, P4977, DOI 10.3390/ijms15034977
   Frazzi R, 2013, INT J CANCER, V132, P1013, DOI 10.1002/ijc.27748
   Fullgrabe J, 2013, AUTOPHAGY, V9, P1621, DOI 10.4161/auto.25803
   Gurusamy KS, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0189631
   Han HS, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01878-6
   Henderson JT, 2018, JAMA-J AM MED ASSOC, V319, P595, DOI 10.1001/jama.2017.21421
   Herranz D, 2013, ONCOGENE, V32, P4052, DOI 10.1038/onc.2012.407
   Hou ZH, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317718135
   Hu XT, 2013, J PATHOL, V229, P62, DOI 10.1002/path.4093
   Humbert M, 2013, BIOCHEM BIOPH RES CO, V431, P264, DOI 10.1016/j.bbrc.2012.12.120
   Jiang S, 2018, INT J CANCER, V143, P1560, DOI 10.1002/ijc.31338
   Jiang S, 2018, SEMIN CANCER BIOL, V50, P1, DOI 10.1016/j.semcancer.2018.04.007
   Kitahara CM, 2016, NAT REV ENDOCRINOL, V12, P646, DOI 10.1038/nrendo.2016.110
   Klieser E, 2017, HUM PATHOL, V65, P41, DOI 10.1016/j.humpath.2017.02.009
   Knight JRP, 2012, CURR OPIN ONCOL, V24, P68, DOI 10.1097/CCO.0b013e32834d813b
   Kobel M, 2008, PLOS MED, V5, P1749, DOI 10.1371/journal.pmed.0050232
   Lee IH, 2008, P NATL ACAD SCI USA, V105, P3374, DOI 10.1073/pnas.0712145105
   Li DD, 2018, ONCOL REP, V39, P695, DOI 10.3892/or.2017.6119
   Lin R, 2007, ONCOGENE, V26, P851, DOI 10.1038/sj.onc.1209846
   Liu Y, 2015, GENE THER, V22, P729, DOI 10.1038/gt.2015.39
   Lv JJ, 2018, AGEING RES REV, V44, P8, DOI 10.1016/j.arr.2018.03.004
   Ma CH, 2018, REDOX BIOL, V15, P504, DOI 10.1016/j.redox.2018.01.010
   Marti N, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0174224
   Menssen A, 2012, P NATL ACAD SCI USA, V109, pE187, DOI 10.1073/pnas.1105304109
   Michalik KM, 2014, CIRC RES, V114, P1389, DOI 10.1161/CIRCRESAHA.114.303265
   Mvunta DH, 2017, APPL IMMUNOHISTO M M, V25, P415, DOI 10.1097/PAI.0000000000000316
   Mvunta DH, 2017, TRANSL ONCOL, V10, P621, DOI 10.1016/j.tranon.2017.05.005
   Noguchi A, 2014, CANCER MED-US, V3, P1553, DOI 10.1002/cam4.310
   Notta F, 2017, GUT, V66, P2170, DOI 10.1136/gutjnl-2016-313317
   Oliver KE, 2014, J CLIN ONCOL, V32, P3353, DOI 10.1200/JCO.2014.57.4574
   Oon CE, 2015, EUR J PHARMACOL, V757, P59, DOI 10.1016/j.ejphar.2015.03.064
   Park SH, 2008, MOL ENDOCRINOL, V22, P2085, DOI 10.1210/me.2007-0512
   Pinton G, 2018, ONCOGENESIS, V7, DOI 10.1038/s41389-018-0027-9
   Qiang L, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-14371-3
   Qin J, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09244-8
   Qiu GL, 2015, FEBS LETT, V589, P2034, DOI 10.1016/j.febslet.2015.05.042
   Shen XB, 2017, ONCOTARGET, V8, P74359, DOI 10.18632/oncotarget.20799
   Shibata T, 2018, CANCER SCI, V109, P1282, DOI 10.1111/cas.13582
   Shih A, 2002, J CLIN ENDOCR METAB, V87, P1223, DOI 10.1210/jc.87.3.1223
   Shuang T, 2015, MED ONCOL, V32, DOI 10.1007/s12032-015-0706-8
   Song NY, 2012, ANN NY ACAD SCI, V1271, P10, DOI 10.1111/j.1749-6632.2012.06762.x
   Sun T, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0167-4
   Tatone C, 2018, HUM REPROD UPDATE, V24, P267, DOI 10.1093/humupd/dmy003
   Tian S, 2017, ONCOTARGET, V8, P11071, DOI 10.18632/oncotarget.14360
   Tseng RC, 2009, NEOPLASIA, V11, P763, DOI 10.1593/neo.09470
   Wang CW, 2017, ONCOTARGET, V8, P66343, DOI 10.18632/oncotarget.18494
   Wang K, 2011, AUTOPHAGY, V7, P966, DOI 10.4161/auto.7.9.15863
   Wang SF, 2018, REDOX BIOL, V17, P89, DOI 10.1016/j.redox.2018.04.006
   Wu SJ, 2017, ONCOTARGET, V8, P62589, DOI 10.18632/oncotarget.19880
   Wu WY, 2016, ONCOTARGET, V7, P84416, DOI 10.18632/oncotarget.12936
   Xin ZL, 2018, AGEING RES REV, V41, P42, DOI 10.1016/j.arr.2017.11.002
   Yang Q, 2013, MOL CANCER RES, V11, P1497, DOI 10.1158/1541-7786.MCR-13-0214
   Yoshimoto R, 2016, BBA-GENE REGUL MECH, V1859, P192, DOI 10.1016/j.bbagrm.2015.09.012
   Yu EJ, 2016, ONCOGENE, V35, P3410, DOI 10.1038/onc.2015.401
   Yuan J, 2009, J CELL BIOL, V185, P203, DOI 10.1083/jcb.200809167
   Zhou XK, 2017, CANCER LETT, V411, P1, DOI 10.1016/j.canlet.2017.09.027
NR 68
TC 12
Z9 12
U1 0
U2 2
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-2392
J9 FRONT ENDOCRINOL
JI Front. Endocrinol.
PD SEP 24
PY 2018
VL 9
AR 569
DI 10.3389/fendo.2018.00569
PG 7
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Endocrinology & Metabolism
GA GU5TF
UT WOS:000445353200001
PM 30319549
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Soliman, NA
   Abd-Ellatif, RN
   ELSaadany, AA
   Shalaby, SM
   Bedeer, AE
AF Soliman, Nema A.
   Abd-Ellatif, Rania N.
   ELSaadany, Amira A.
   Shalaby, Shahinaz M.
   Bedeer, Asmaa E.
TI Luteolin and 5-flurouracil act synergistically to induce cellular
   weapons in experimentally induced Solid Ehrlich Carcinoma: Realistic
   role of P53; a guardian fights in a cellular battle
SO CHEMICO-BIOLOGICAL INTERACTIONS
LA English
DT Article
DE Solid Ehrlich Carcinoma; Luteolin; 5-Fluorouracil; Apoptosis; Cell cycle
   arrest; Autophagy
ID CANCER-CELLS; LUNG-CANCER; SIGNALING PATHWAYS; ANTITUMOR-ACTIVITY;
   COLORECTAL-CANCER; INDUCED APOPTOSIS; CYCLE ARREST; TUMOR;
   5-FLUOROURACIL; EXPRESSION
AB Background: Solid Ehrlich Carcinoma (SEC) is an undifferentiated tumor used in tumor studies and chemotherapy investigations.
   Aim: to assess the anti-tumor potential of luteolin when used either alone or combined to 5-fluorouracil (5-FU) against SEC.
   Method: SEC was induced in 40 female mice; they were categorized into 4 equal groups; group I (untreated SEC), group II (5-FU treated SEC), group III (luteolin treated SEC) and group IV (5-FU + luteolin treated SEC). Tumor volume and weight were calculated. P53, p21, caspase 3 and damage regulated autophagy modulator (DRAM) were assessed. Biomarkers of oxidant/antioxidant status in addition to immunohistochemistry for cylin D1 were evaluated.
   Results: combined administration of luteolin and 5-FU in SEC model increased levels of p53, p21, caspase 3, DRAM and survivability while, tumor volume, weight, thioredoxin reductase one (TR1) activity and cyclin D1 expression showed the reverse with restoration of oxidant/antioxidant indices.
   Conclusion: current results proved the antitumor therapeutic effects of luteolin alone or combined with 5-FU as a novel strategy for cancer therapy.
C1 [Soliman, Nema A.; Abd-Ellatif, Rania N.] Tanta Univ, Fac Med, Dept Med Biochem, Tanta, Egypt.
   [ELSaadany, Amira A.; Shalaby, Shahinaz M.] Tanta Univ, Fac Med, Dept Pharmacol, Tanta, Egypt.
   [Bedeer, Asmaa E.] Tanta Univ, Fac Med, Dept Pathol, Tanta, Egypt.
RP Soliman, NA (corresponding author), Tanta Univ, Fac Med, Med Biochem, Tanta, Egypt.
EM naema.ahmed@med.tanta.edu.eg; rania_drrania@yahoo.com;
   dra_elsaadany@yahoo.com; Shahinazmshams@med.tanta.edu.eg;
   Asmaa.bedeer@gmail.com
RI soliman, nema Ali/ABA-1044-2021; Shalaby, Shahinaz M/C-4756-2018;
   Soliman, Nema/AAB-5281-2022
OI soliman, nema Ali/0000-0003-0281-756X; Shalaby, Shahinaz
   M/0000-0002-9743-6470; 
CR Adamsen BL, 2007, INT J ONCOL, V31, P1491
   Ambasta RK, 2019, BRIEF FUNCT GENOMICS, V18, P230, DOI 10.1093/bfgp/ely036
   Amin ARMR, 2010, J BIOL CHEM, V285, P34557, DOI 10.1074/jbc.M110.141135
   Awara WM, 2004, PHARMACOL RES, V50, P487, DOI 10.1016/j.phrs.2004.04.002
   Barakat W, 2015, ADV PHARMACOL SCI, V2015, DOI 10.1155/2015/132873
   Caputi M, 1999, AM J RESP CELL MOL, V20, P746, DOI 10.1165/ajrcmb.20.4.3366
   Chen P, 2017, ONCOTARGET, V8, P27471, DOI 10.18632/oncotarget.15832
   Chiang CT, 2007, MOL CANCER THER, V6, P2127, DOI 10.1158/1535-7163.MCT-07-0107
   Chong DL, 2017, ANTI-CANCER DRUG, V28, P831, DOI 10.1097/CAD.0000000000000517
   Chu Y, 2018, J BIOL REG HOMEOS AG, V32, P1185
   Cui L, 2016, ONCOL REP, V35, P3639, DOI 10.3892/or.2016.4752
   Dasgupta A, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18010023
   EUHUS DM, 1986, J SURG ONCOL, V31, P229, DOI 10.1002/jso.2930310402
   Handali S, 2018, BIOMED PHARMACOTHER, V108, P1259, DOI 10.1016/j.biopha.2018.09.128
   HOLMGREN A, 1995, METHOD ENZYMOL, V252, P199
   Ju W, 2007, MOL PHARMACOL, V71, P1381, DOI 10.1124/mol.106.032185
   Kim HS, 2008, J BIOL CHEM, V283, P3731, DOI 10.1074/jbc.M704432200
   Kim JK, 2009, J CELL PHYSIOL, V220, P292, DOI 10.1002/jcp.21791
   Kouraklis Gregory, 2006, World J Surg Oncol, V4, P5, DOI 10.1186/1477-7819-4-5
   Liao YX, 2018, J IMMUNOL RES, V2018, DOI 10.1155/2018/4623919
   Lin CH, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1965-7
   Liu HC, 2006, CANCER J, V12, P482, DOI 10.1097/00130404-200611000-00008
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   Lum JJ, 2005, NAT REV MOL CELL BIO, V6, P439, DOI 10.1038/nrm1660
   Manju V, 2007, CELL BIOCHEM FUNCT, V25, P189, DOI 10.1002/cbf.1305
   Maruthanila VL, 2014, ADV PHARMACOL SCI, V2014, DOI 10.1155/2014/832161
   MISRA HP, 1972, J BIOL CHEM, V247, P3170
   Nazim UM, 2017, ONCOTARGET, V8, P18095, DOI 10.18632/oncotarget.14994
   OSMAN AEM, 1993, TUMORI, V79, P268, DOI 10.1177/030089169307900408
   Pandurangan AK, 2014, ASIAN PAC J CANCER P, V15, P5501, DOI 10.7314/APJCP.2014.15.14.5501
   Pandya NB, 2013, INDIAN J PHARMACOL, V45, P464, DOI 10.4103/0253-7613.117754
   Pappas K, 2017, MOL CANCER RES, V15, P1051, DOI 10.1158/1541-7786.MCR-17-0089
   Park SH, 2014, J ENVIRON PATHOL TOX, V33, P219, DOI 10.1615/JEnvironPatholToxicolOncol.2014010923
   Roy S, 2018, CELL BIOCHEM FUNCT, V36, P116, DOI 10.1002/cbf.3322
   Russo A, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18030547
   Russo A, 2016, ONCOTARGET, V7, P79656, DOI 10.18632/oncotarget.13216
   Shi YY, 2018, J ZHEJIANG UNIV-SC B, V19, P750, DOI 10.1631/jzus.B1700456
   SINHA AK, 1972, ANAL BIOCHEM, V47, P389, DOI 10.1016/0003-2697(72)90132-7
   Srivastava S, 2018, J MAXILLOFAC ORAL SU, V17, P597, DOI 10.1007/s12663-018-1126-z
   TOMAYKO MM, 1989, CANCER CHEMOTH PHARM, V24, P148, DOI 10.1007/BF00300234
   Tuorkey MJ, 2016, EUR J CANCER PREV, V25, P65, DOI 10.1097/CEJ.0000000000000128
   Wang H, 2017, ONCOTARGET, V8, P35728, DOI 10.18632/oncotarget.16113
   Xia N, 2016, EXP THER MED, V12, P4049, DOI 10.3892/etm.2016.3854
   Zhao YF, 2011, BIOMED PHARMACOTHER, V65, P151, DOI 10.1016/j.biopha.2011.02.009
NR 44
TC 7
Z9 7
U1 1
U2 3
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0009-2797
EI 1872-7786
J9 CHEM-BIOL INTERACT
JI Chem.-Biol. Interact.
PD SEP 1
PY 2019
VL 310
AR 108740
DI 10.1016/j.cbi.2019.108740
PG 6
WC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Toxicology
GA IS5GD
UT WOS:000482179600024
PM 31288002
DA 2022-04-25
ER

PT J
AU Livesey, KM
   Kang, R
   Vernon, P
   Buchser, W
   Loughran, P
   Watkins, SC
   Zhang, L
   Manfredi, JJ
   Zeh, HJ
   Li, LY
   Lotze, MT
   Tang, DL
AF Livesey, Kristen M.
   Kang, Rui
   Vernon, Philip
   Buchser, William
   Loughran, Patricia
   Watkins, Simon C.
   Zhang, Lin
   Manfredi, James J.
   Zeh, Herbert J., III
   Li, Luyuan
   Lotze, Michael T.
   Tang, Daolin
TI p53/HMGB1 Complexes Regulate Autophagy and Apoptosis
SO CANCER RESEARCH
LA English
DT Article
ID TUMOR-SUPPRESSOR P53; ENDOPLASMIC-RETICULUM STRESS; INDUCED CELL-DEATH;
   GROUP BOX 1; CANCER-CELLS; COLORECTAL-CANCER; DNA-DAMAGE; PROTEIN;
   HMGB1; P62
AB The balance between apoptosis ("programmed cell death") and autophagy ("programmed cell survival") is important in tumor development and response to therapy. Here, we show that high mobility group box 1 (HMGB1) and p53 form a complex that regulates the balance between tumor cell death and survival. We show that knockout of p53 in HCT116 cells increases expression of cytosolic HMGB1 and induces autophagy. Conversely, knockout of HMGB1 in mouse embryonic fibroblasts increases p53 cytosolic localization and decreases autophagy. p53 is thus a negative regulator of the HMGB1/Beclin 1 complex, and HMGB1 promotes autophagy in the setting of diminished p53. HMGB1-mediated autophagy promotes tumor cell survival in the setting of p53-dependent processes. The HMGB1/p53 complex affects the cytoplasmic localization of the reciprocal binding partner, thereby regulating subsequent levels of autophagy and apoptosis. These insights provide a novel link between HMGB1 and p53 in the cross-regulation of apoptosis and autophagy in the setting of cell stress, providing insights into their reciprocal roles in carcinogenesis. Cancer Res; 72(8); 1996-2005. (C) 2012 AACR.
C1 [Watkins, Simon C.] Univ Pittsburgh, Inst Canc, Ctr Biol Imaging, Dept Cell Biol & Physiol, Pittsburgh, PA 15213 USA.
   [Zhang, Lin] Univ Pittsburgh, Inst Canc, Hillman Canc Ctr, Dept Pharmacol & Chem Biol, Pittsburgh, PA 15213 USA.
   [Li, Luyuan] Univ Pittsburgh, Inst Canc, Hillman Canc Ctr, Dept Pathol, Pittsburgh, PA 15213 USA.
   [Manfredi, James J.] Mt Sinai Sch Med, Dept Oncol Sci, New York, NY USA.
   [Livesey, Kristen M.; Kang, Rui; Vernon, Philip; Buchser, William; Loughran, Patricia; Zeh, Herbert J., III; Lotze, Michael T.; Tang, Daolin] Univ Pittsburgh, Inst Canc, Ctr Biol Imaging, Dept Surg, Pittsburgh, PA 15213 USA.
RP Tang, DL (corresponding author), Univ Pittsburgh, Inst Canc, Hillman Canc Ctr, Dept Surg, G-21,5117 Ctr Ave, Pittsburgh, PA 15213 USA.
EM lotzemt@upmc.edu; tangd2@upmc.edu
RI Zhang, Lin/A-7389-2009; Tang, Daolin/B-2905-2010; Li,
   Luyuan/E-8951-2012; Tang, Daolin/ABD-5062-2021; Watkins,
   Simon/ABG-2590-2021; Loughran, Patricia/AAB-1184-2021; Kang,
   Rui/ABD-5291-2021
OI Zhang, Lin/0000-0003-0018-3903; Tang, Daolin/0000-0002-1903-6180;
   Watkins, Simon/0000-0003-4092-1552; Kang, Rui/0000-0003-2725-1574;
   Buchser, William/0000-0002-6675-6359
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [1 P01 CA 101944-04]; Department of
   Surgery, University of Pittsburgh;  [P30CA047904]; NATIONAL CANCER
   INSTITUTEUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)
   [P01CA101944] Funding Source: NIH RePORTER; NATIONAL CENTER FOR
   ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Center for Advancing Translational Sciences (NCATS) [UL1TR000005]
   Funding Source: NIH RePORTER
FX The authors thank Megan Seippel for careful review of the manuscript.
   The authors also thank the Health Sciences Tissue Bank, especially
   Michelle Bisceglia, and the UPMC Network Cancer Registry, especially
   Sharon Winters, for their assistance with this project. This project
   used the UPCI Tissue and Research Pathology Services and Cancer
   Informatics Services Facilities and was supported in part by award
   P30CA047904.; This work was supported by a grant from the NIH 1 P01 CA
   101944-04 (M. T. Lotze) and funding provided by the Department of
   Surgery, University of Pittsburgh (D. Tang and M. T. Lotze).
CR Amaravadi RK, 2011, CLIN CANCER RES, V17, P654, DOI 10.1158/1078-0432.CCR-10-2634
   Banerjee S, 2003, NUCLEIC ACIDS RES, V31, P3236, DOI 10.1093/nar/gkg412
   Bjorkoy G, 2005, J CELL BIOL, V171, P603, DOI 10.1083/jcb.200507002
   Chipuk JE, 2005, SCIENCE, V309, P1732, DOI 10.1126/science.1114297
   Chipuk JE, 2004, SCIENCE, V303, P1010, DOI 10.1126/science.1092734
   Concepcion J, 2009, COMB CHEM HIGH T SCR, V12, P791, DOI 10.2174/138620709789104915
   Crighton D, 2006, CELL, V126, P121, DOI 10.1016/j.cell.2006.05.034
   Edinger AL, 2004, CURR OPIN CELL BIOL, V16, P663, DOI 10.1016/j.ceb.2004.09.011
   Gao W, 2011, CELL DEATH DIFFER, V18, P1598, DOI 10.1038/cdd.2011.33
   Green DR, 2009, NATURE, V458, P1127, DOI 10.1038/nature07986
   Haupt S, 2003, J CELL SCI, V116, P4077, DOI 10.1242/jcs.00739
   Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710
   Huang J, 2012, CANCER RES, V72, P230, DOI 10.1158/0008-5472.CAN-11-2001
   Kang R, 2011, CELL DEATH DIFFER, V18, P571, DOI 10.1038/cdd.2010.191
   Kang R, 2010, CELL DEATH DIFFER, V17, P666, DOI 10.1038/cdd.2009.149
   Kang R, 2011, ANTIOXID REDOX SIGN, V15, P2175, DOI 10.1089/ars.2010.3378
   Kroemer G, 2010, MOL CELL, V40, P280, DOI 10.1016/j.molcel.2010.09.023
   Kroemer G, 2008, NAT REV MOL CELL BIO, V9, P1004, DOI 10.1038/nrm2529
   Livesey KM, 2009, CURR OPIN INVEST DR, V10, P1269
   Lotze MT, 2005, NAT REV IMMUNOL, V5, P331, DOI 10.1038/nri1594
   Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239
   Maiuri MC, 2010, CURR OPIN CELL BIOL, V22, P181, DOI 10.1016/j.ceb.2009.12.001
   Mathew R, 2007, NAT REV CANCER, V7, P961, DOI 10.1038/nrc2254
   Mathew R, 2009, CELL, V137, P1062, DOI 10.1016/j.cell.2009.03.048
   MIYASHITA T, 1995, CELL, V80, P293
   Moenner M, 2007, CANCER RES, V67, P10631, DOI 10.1158/0008-5472.CAN-07-1705
   Moscat J, 2007, TRENDS BIOCHEM SCI, V32, P95, DOI 10.1016/j.tibs.2006.12.002
   Moscat J, 2009, CELL, V137, P1001, DOI 10.1016/j.cell.2009.05.023
   Ogata M, 2006, MOL CELL BIOL, V26, P9220, DOI 10.1128/MCB.01453-06
   RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555
   Scherz-Shouval R, 2010, P NATL ACAD SCI USA, V107, P18511, DOI 10.1073/pnas.1006124107
   Shimizu S, 2004, NAT CELL BIOL, V6, P1221, DOI 10.1038/ncb1192
   Stros M, 2004, BIOCHEMISTRY-US, V43, P7215, DOI 10.1021/bi049928k
   Tang D, 2011, ONCOGENE, V30, P1851, DOI 10.1038/onc.2010.573
   Tang D, 2010, ONCOGENE, V29, P5299, DOI 10.1038/onc.2010.261
   Tang DL, 2011, CELL METAB, V13, P701, DOI 10.1016/j.cmet.2011.04.008
   Tang DL, 2011, ANTIOXID REDOX SIGN, V15, P2185, DOI 10.1089/ars.2010.3666
   Tang DL, 2011, ANTIOXID REDOX SIGN, V14, P1315, DOI 10.1089/ars.2010.3356
   Tang DL, 2010, J CELL BIOL, V190, P881, DOI 10.1083/jcb.200911078
   Tang DL, 2010, BBA-GENE REGUL MECH, V1799, P131, DOI 10.1016/j.bbagrm.2009.11.014
   Tasdemir E, 2008, NAT CELL BIOL, V10, P676, DOI 10.1038/ncb1730
   Thompson HGR, 2003, ONCOGENE, V22, P2322, DOI 10.1038/sj.onc.1206325
   Ulloa L, 2002, P NATL ACAD SCI USA, V99, P12351, DOI 10.1073/pnas.192222999
   Wang P, 2007, P NATL ACAD SCI USA, V104, P4054, DOI 10.1073/pnas.0700020104
   Weiner LM, 2012, NEW ENGL J MED, V366, P1156, DOI 10.1056/NEJMcibr1114526
   Yang ZF, 2010, NAT CELL BIOL, V12, P814, DOI 10.1038/ncb0910-814
   Yao XJ, 2010, J CANCER RES CLIN, V136, P677, DOI 10.1007/s00432-009-0706-1
   Yu H, 2011, EUR J CANCER, V47, P1585, DOI 10.1016/j.ejca.2011.01.019
   Yu JS, 2006, CLIN CANCER RES, V12, P5104, DOI 10.1158/1078-0432.CCR-06-0547
NR 49
TC 171
Z9 191
U1 0
U2 26
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
J9 CANCER RES
JI Cancer Res.
PD APR 15
PY 2012
VL 72
IS 8
BP 1996
EP 2005
DI 10.1158/0008-5472.CAN-11-2291
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 927KH
UT WOS:000302905700011
PM 22345153
OA Green Accepted
DA 2022-04-25
ER

PT J
AU Xu, GL
   Feng, DJ
   Yao, Y
   Li, PP
   Sun, H
   Yang, H
   Li, CX
   Jiang, RQ
   Sun, BC
   Chen, Y
AF Xu, Guolong
   Feng, Dongju
   Yao, Yao
   Li, Peipei
   Sun, Hua
   Yang, Hong
   Li, Changxian
   Jiang, Runqiu
   Sun, Beicheng
   Chen, Yun
TI Listeria-based hepatocellular carcinoma vaccine facilitates anti-PD-1
   therapy by regulating macrophage polarization
SO ONCOGENE
LA English
DT Article
ID PD-1/PD-L1 BLOCKADE; TUMOR MICROENVIRONMENT; COLORECTAL-CANCER; T-CELLS;
   AUTOPHAGY; ACTIVATION; IMMUNOTHERAPY; MECHANISMS; BGJ398; GROWTH
AB Recently, patients with advanced cancers have been benefited greatly from immune checkpoint blockade immunotherapy. However, immune checkpoint blockade is still suboptimal in HCC treatment and more immune modifications are needed to achieve an efficient therapeutic goal. Here, we investigated the combined administration of a Listeria-based HCC vaccine, Lmdd-MPFG, and the anti-PD-1 immune checkpoint blockade antibody. We found that Lmdd-MPFG promoted the expression of PD-L1 in HCC cells but resensitized the tumor local T cell to respond to the anti-PD-1 immunotherapy. Mechanistically, the Lmdd-MPFG vaccine activates the NF-kappa B pathway in the tumor-associated macrophages (TAMs) through the TLR2 and MyD88 pathway, and recruits p62 to activate the autophagy pathway. The overall effect is skewing the TAMs from M2-polarized TAMs into the M1-polarized TAMs. Most importantly, it skewed the cytokine profiles into antitumor one in the tumor microenvironment (TME). This change restores the T-cell reactivity to the anti-PD-1 blockade. Our results suggested that Lmdd-MPFG combined with PD-1 blockade exerted synergistic antitumor effects through modifying TAMs in the TME and removing T-cell inhibitory signals, thereby providing a new potential strategy for HCC treatment.
C1 [Xu, Guolong; Feng, Dongju; Li, Peipei; Yang, Hong; Chen, Yun] Nanjing Med Univ, Dept Immunol, Key Lab Immune Microenvironm & Dis, Nanjing 211166, Jiangsu, Peoples R China.
   [Xu, Guolong; Li, Peipei; Chen, Yun] Nanjing Med Univ, Collaborat Innovat Ctr Canc Personalized Med, Jiangsu Key Lab Canc Biomarkers Prevent & Treatme, Nanjing 211166, Jiangsu, Peoples R China.
   [Yao, Yao; Chen, Yun] Jiangsu Canc Hosp, Res Ctr Clin Oncol, Dept Head & Neck Surg, Nanjing 210018, Jiangsu, Peoples R China.
   [Yao, Yao; Chen, Yun] Jiangsu Inst Canc Res, Nanjing 210018, Jiangsu, Peoples R China.
   [Yao, Yao; Chen, Yun] Nanjing Med Univ, Canc Hosp, Nanjing 210018, Jiangsu, Peoples R China.
   [Sun, Hua] Univ Texas Hlth Sci Ctr Houston, Inst Mol Med, Dept Immunol, Houston, TX 77030 USA.
   [Li, Changxian] Nanjing Med Univ, Liver Transplantat Ctr, Affiliated Hosp 1, Guangzhou Rd 300, Nanjing 210029, Jiangsu, Peoples R China.
   [Jiang, Runqiu; Sun, Beicheng] Nanjing Univ, Affiliated Drum Tower Hosp, Dept Hepatobiliary Surg, Med Sch, Nanjing 210093, Jiangsu, Peoples R China.
RP Chen, Y (corresponding author), Nanjing Med Univ, Dept Immunol, Key Lab Immune Microenvironm & Dis, Nanjing 211166, Jiangsu, Peoples R China.; Chen, Y (corresponding author), Nanjing Med Univ, Collaborat Innovat Ctr Canc Personalized Med, Jiangsu Key Lab Canc Biomarkers Prevent & Treatme, Nanjing 211166, Jiangsu, Peoples R China.; Chen, Y (corresponding author), Jiangsu Canc Hosp, Res Ctr Clin Oncol, Dept Head & Neck Surg, Nanjing 210018, Jiangsu, Peoples R China.; Chen, Y (corresponding author), Jiangsu Inst Canc Res, Nanjing 210018, Jiangsu, Peoples R China.; Chen, Y (corresponding author), Nanjing Med Univ, Canc Hosp, Nanjing 210018, Jiangsu, Peoples R China.
EM chenyun@njmu.edu.cn
OI Xu, Guolong/0000-0002-0425-2040; Sun, Beicheng/0000-0002-8657-7024
FU National Natural Science FoundationNational Natural Science Foundation
   of China (NSFC) [81772602, 9174210027, 81902780]; Qing Lan
   ProjectJiangsu Polytech Institute; Six Talent Peaks Project [JY-018];
   Jiangsu Provincial key research development program of China
   [BE2018750]; "333" projectNatural Science Foundation of Jiangsu Province
FX This work was supported by grants from the National Natural Science
   Foundation (Grant Number: 81772602, 9174210027 to YC, 81902780 to YY).
   The Qing Lan Project, the Six Talent Peaks Project (JY-018), the "333"
   project, Jiangsu Provincial key research development program of China
   (BE2018750 to YC).
CR Atkins MB, 2017, ANN ONCOL, V28, P1484, DOI 10.1093/annonc/mdx151
   Ayers M, 2019, CLIN CANCER RES, V25, P1564, DOI 10.1158/1078-0432.CCR-18-1316
   Balkwill FR, 2012, J CELL SCI, V125, P5591, DOI 10.1242/jcs.116392
   Bel S, 2017, SCIENCE, V357, P1047, DOI 10.1126/science.aal4677
   Chen PW, 2014, AUTOPHAGY, V10, P192, DOI 10.4161/auto.26927
   Chen Y, 2012, ONCOGENE, V31, P2140, DOI 10.1038/onc.2011.395
   Choi AMK, 2013, NEW ENGL J MED, V368, P651, DOI [10.1056/NEJMra1205406, 10.1056/NEJMc1303158]
   Christopher MJ, 2018, NEW ENGL J MED, V379, P2330, DOI 10.1056/NEJMoa1808777
   Concha-Benavente F, 2016, CANCER RES, V76, P1031, DOI 10.1158/0008-5472.CAN-15-2001
   Conway KL, 2013, GASTROENTEROLOGY, V145, P1347, DOI 10.1053/j.gastro.2013.08.035
   Drolia R, 2018, CELL HOST MICROBE, V23, P470, DOI 10.1016/j.chom.2018.03.004
   Dunai C, 2018, J CLIN INVEST, V128, P4251, DOI 10.1172/JCI123121
   El-Khoueiry AB, 2017, LANCET, V389, P2492, DOI 10.1016/S0140-6736(17)31046-2
   Forner A, 2018, LANCET, V391, P1301, DOI 10.1016/S0140-6736(18)30010-2
   Galdiero MR, 2013, IMMUNOBIOLOGY, V218, P1402, DOI 10.1016/j.imbio.2013.06.003
   Garris CS, 2018, IMMUNITY, V49, P1148, DOI 10.1016/j.immuni.2018.09.024
   Hamid O, 2013, NEW ENGL J MED, V369, P134, DOI 10.1056/NEJMoa1305133
   Javle M, 2018, J CLIN ONCOL, V36, P276, DOI 10.1200/JCO.2017.75.5009
   Jung C, 2012, J CLIN INVEST, V122, P2239, DOI 10.1172/JCI58147
   Kroemer G, 2015, J CLIN INVEST, V125, P1, DOI 10.1172/JCI78652
   Ktistakis NT, 2016, TRENDS CELL BIOL, V26, P624, DOI 10.1016/j.tcb.2016.03.006
   Landais I, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004881
   Lane RS, 2018, J EXP MED, V215, P3057, DOI 10.1084/jem.20180654
   Lin PL, 2017, CANCER MED-US, V6, P2052, DOI 10.1002/cam4.1143
   Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857
   Lo Russo G, 2019, CLIN CANCER RES, V25, P989, DOI 10.1158/1078-0432.CCR-18-1390
   Lu X, 2017, NATURE, V543, P728, DOI 10.1038/nature21676
   Makarova-Rusher OV, 2015, J HEPATOL, V62, P1420, DOI 10.1016/j.jhep.2015.02.038
   Martini DJ, 2017, J IMMUNOTHER CANCER, V5, DOI 10.1186/s40425-017-0273-y
   Motzer RJ, 2015, J CLIN ONCOL, V33, P1430, DOI 10.1200/JCO.2014.59.0703
   Murray PJ, 2017, ANNU REV PHYSIOL, V79, P541, DOI 10.1146/annurev-physiol-022516-034339
   Murray PJ, 2014, IMMUNITY, V41, P14, DOI 10.1016/j.immuni.2014.06.008
   Nogova L, 2017, J CLIN ONCOL, V35, P157, DOI 10.1200/JCO.2016.67.2048
   Ouyang ZX, 2019, BIOMATERIALS, V205, P50, DOI 10.1016/j.biomaterials.2019.03.018
   Ruffell B, 2015, CANCER CELL, V27, P462, DOI 10.1016/j.ccell.2015.02.015
   Sheng CJ, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06756-3
   Shi XJ, 2017, CANCER LETT, V406, P27, DOI 10.1016/j.canlet.2017.07.029
   Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166
   Siu EHL, 2018, TRANSL GASTROENT HEP, V3, DOI 10.21037/tgh.2018.10.16
   Sorbara MT, 2018, CELL HOST MICROBE, V23, P644, DOI 10.1016/j.chom.2018.04.008
   Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690
   Vareki SM, 2017, CRIT REV ONCOL HEMAT, V116, P116, DOI 10.1016/j.critrevonc.2017.06.001
   Wallecha A, 2013, J IMMUNOTHER, V36, P468, DOI 10.1097/CJI.0000000000000000
   Webster JA, 2010, J PATHOL, V222, P158, DOI 10.1002/path.2738
   Wu SP, 2018, J THORAC ONCOL, V13, P521, DOI 10.1016/j.jtho.2017.11.132
   Yanik EL, 2017, JAMA ONCOL, V3, P974, DOI 10.1001/jamaoncol.2017.0115
   Yu TC, 2017, CELL, V170, P548, DOI 10.1016/j.cell.2017.07.008
   Zhao S, 2019, CANCER IMMUNOL RES, V7, P630, DOI 10.1158/2326-6066.CIR-17-0640
   Zhong J, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.102
   Zhong ZY, 2016, CELL, V164, P896, DOI 10.1016/j.cell.2015.12.057
NR 50
TC 21
Z9 22
U1 5
U2 16
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-9232
EI 1476-5594
J9 ONCOGENE
JI Oncogene
PD FEB
PY 2020
VL 39
IS 7
BP 1429
EP 1444
DI 10.1038/s41388-019-1072-3
PG 16
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
GA KL2WP
UT WOS:000513289600004
PM 31659256
DA 2022-04-25
ER

PT J
AU Sheng, JY
   Zou, XH
   Cheng, ZQ
   Xiang, Y
   Yang, W
   Lin, Y
   Cui, RJ
AF Sheng, Jiyao
   Zou, Xiaohan
   Cheng, Ziqian
   Xiang, Yien
   Yang, Wei
   Lin, Yang
   Cui, Ranji
TI Recent Advances in Herbal Medicines for Digestive System Malignancies
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Review
DE herbal medicine; digestive system malignancies; comprehensive treatment;
   chemotherapy; side effect
ID TRADITIONAL CHINESE MEDICINE; GASTRIC-CANCER CELLS; HUMAN
   HEPATOCELLULAR-CARCINOMA; SHENQI FUZHENG INJECTION; HUAIER AQUEOUS
   EXTRACT; ENHANCES CISPLATIN CHEMOSENSITIVITY; RANDOMIZED
   CONTROLLED-TRIALS; ADVANCED COLORECTAL-CANCER; TUMOR-BEARING MICE;
   NF-KAPPA-B
AB Herbal medicines, as an important part of traditional Chinese medicine (TCM), have been used to treat digestive system malignancies (DSM) for many years, and have gradually gained recognition worldwide. The role of herbal medicines in the comprehensive treatment of DSM is being improved from adjuvant treatment of the autologous immune function in cancer patients, to the treatment of both the symptoms and disease, direct inhibition of tumor cell growth and proliferation, and induction of tumor cell autophagy and apoptosis. Their specific mechanisms in these treatments are also being explored. The paper reviews the current anti-tumor mechanisms of TCM, including single herbal medicines, Chinese herbal formulations, Chinese medicine preparations and TCM extract, and their application in the comprehensive treatment of digestive system tumors, providing a reference for clinical application of TCM.
C1 [Sheng, Jiyao; Zou, Xiaohan; Cheng, Ziqian; Xiang, Yien; Yang, Wei; Lin, Yang; Cui, Ranji] Jilin Univ, Hosp 2, Jilin Prov Key Lab Mol & Chem Genet, Changchun, Jilin, Peoples R China.
RP Lin, Y (corresponding author), Jilin Univ, Hosp 2, Jilin Prov Key Lab Mol & Chem Genet, Changchun, Jilin, Peoples R China.
EM linyang@jlu.edu.cn
RI cui, ranji/AAV-6234-2021
FU Natural Science Foundation of ChinaNational Natural Science Foundation
   of China (NSFC) [NSFC: 81802613]; Jilin Science and Technology Agency
   [20180101114JC]; Finance Department of Jilin Province
FX This work was supported by grants from Natural Science Foundation of
   China (NSFC: 81802613), Jilin Science and Technology Agency funding
   (20180101114JC), and Finance Department of Jilin Province (2018).
CR Amitani M, 2015, FRONT PHARMACOL, V6, DOI 10.3389/fphar.2015.00150
   Auyeung KK, 2012, J ETHNOPHARMACOL, V141, P635, DOI 10.1016/j.jep.2011.08.010
   Auyeung KKW, 2014, NUTR CANCER, V66, P662, DOI 10.1080/01635581.2014.894093
   Auyeung KKW, 2010, INT J MOL MED, V26, P341, DOI 10.3892/ijmm_00000471
   Bao HD, 2016, ONCOL LETT, V12, P1058, DOI 10.3892/ol.2016.4686
   Bian Y, 2014, P NATL ACAD SCI USA, V111, P1628, DOI 10.1073/pnas.1315588111
   Cao Y, 2014, OXID MED CELL LONGEV, V2014, DOI 10.1155/2014/674219
   Chang C, 2013, ONCOL LETT, V6, P699, DOI 10.3892/ol.2013.1449
   Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000
   Chen J, 2016, AM J TRANSL RES, V8, P4932
   Chen SL, 2014, BIOTECHNOL ADV, V32, P1237, DOI 10.1016/j.biotechadv.2014.07.004
   Chen X, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004520.pub7
   Cho WCS, 2007, CANCER LETT, V252, P43, DOI 10.1016/j.canlet.2006.12.001
   Dang SS, 2009, WORLD J GASTROENTERO, V15, P5669, DOI 10.3748/wjg.15.5669
   Deng LP, 2013, CURR MED CHEM, V20, P159, DOI 10.2174/092986713804806711
   Duan L, 2017, ONCOL LETT, V14, P2300, DOI 10.3892/ol.2017.6407
   Endo M, 2017, NEUROGASTROENT MOTIL, V29, DOI 10.1111/nmo.13139
   Farrell Michael P, 2003, Clin Colorectal Cancer, V2, P253, DOI 10.3816/CCC.2003.n.007
   Finn RS, 2018, HEPATOLOGY, V67, P422, DOI 10.1002/hep.29486
   Fu F, 2014, J CANCER RES THER, V10, P38, DOI 10.4103/0973-1482.139753
   Ge L, 2016, J CLIN PHARM THER, V41, P383, DOI 10.1111/jcpt.12410
   Gong JJ, 2017, MOL CARCINOGEN, V56, P402, DOI 10.1002/mc.22503
   Guo BY, 2015, CANCER CHEMOTH PHARM, V75, P353, DOI 10.1007/s00280-014-2651-1
   Hasebe T, 2017, PHYTOTHER RES, V31, P90, DOI 10.1002/ptr.5735
   He CS, 2016, CELL PHYSIOL BIOCHEM, V40, P1221, DOI 10.1159/000453175
   He XR, 2015, J ETHNOPHARMACOL, V172, P10, DOI 10.1016/j.jep.2015.06.010
   Hsia TC, 2016, ANTICANCER RES, V36, P5989, DOI 10.21873/anticanres.11187
   Hu ZD, 2016, J ETHNOPHARMACOL, V186, P143, DOI 10.1016/j.jep.2016.03.069
   Huang WM, 2013, EXP THER MED, V6, P199, DOI 10.3892/etm.2013.1074
   Huang WH, 2016, INT J MOL MED, V38, P551, DOI 10.3892/ijmm.2016.2632
   Hui KY, 2014, CANCER LETT, V354, P189, DOI 10.1016/j.canlet.2014.08.009
   Ikemoto T, 2014, INT J CLIN ONCOL, V19, P81, DOI 10.1007/s10147-013-0529-6
   Inarrairaegui M, 2018, CLIN CANCER RES, V24, P1518, DOI 10.1158/1078-0432.CCR-17-0289
   Jeong JS, 2010, INTEGR CANCER THER, V9, P331, DOI 10.1177/1534735410383170
   Kadioglu O, 2014, BIOCHEM PHARMACOL, V87, P399, DOI 10.1016/j.bcp.2013.10.025
   Kao ST, 2001, LIFE SCI, V69, P1485, DOI 10.1016/S0024-3205(01)01226-7
   Kim MA, 2008, HISTOPATHOLOGY, V52, P738, DOI 10.1111/j.1365-2559.2008.03021.x
   Kominato K, 2016, MOL MED REP, V14, P2264, DOI 10.3892/mmr.2016.5488
   Koo GB, 2015, CELL RES, V25, P707, DOI 10.1038/cr.2015.56
   Kummar S, 2011, CLIN COLORECTAL CANC, V10, P85, DOI 10.1016/j.clcc.2011.03.003
   Kuo CC, 2014, BIOMARK RES, V2, DOI 10.1186/s40364-014-0026-8
   Lai XY, 2017, DOSE-RESPONSE, V15, DOI 10.1177/1559325816685182
   Lam W, 2015, SCI REP-UK, V5, DOI 10.1038/srep09384
   Lam W, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001270
   Lamy E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053240
   Lao M, 2013, J AM ACAD DERMATOL, V69, DOI 10.1016/j.jaad.2013.04.023
   Lei AP, 2016, ONCOL REP, V35, P2970, DOI 10.3892/or.2016.4684
   Li C, 2015, INT J BIOL MACROMOL, V75, P115, DOI 10.1016/j.ijbiomac.2015.01.016
   Li HL, 2016, MOL MED REP, V14, P1430, DOI 10.3892/mmr.2016.5361
   Li J, 2015, CHIN J INTEGR MED, V21, P71, DOI 10.1007/s11655-014-1768-8
   Li JF, 2016, PHARM BIOL, V54, P3217, DOI 10.1080/13880209.2016.1216133
   Li L, 2017, FUND CLIN PHARMACOL, V31, P17, DOI 10.1111/fcp.12232
   Li XP, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1521-5
   Liang L, 2016, ONCOL REP, V36, P1333, DOI 10.3892/or.2016.4927
   Liu J, 2013, ACTA PHARMACOL SIN, V34, P137, DOI 10.1038/aps.2012.133
   Liu J, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/479426
   Liu P, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-12855-w
   Liu SH, 2012, J ETHNOPHARMACOL, V140, P614, DOI 10.1016/j.jep.2012.01.047
   Liu X, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123478
   Liu Y, 2016, APOPTOSIS, V21, P1398, DOI 10.1007/s10495-016-1297-3
   Liu Y, 2016, TUMOR BIOL, V37, P7589, DOI 10.1007/s13277-015-4642-1
   Liu Y, 2016, TECHNOL CANCER RES T, V15, P487, DOI 10.1177/1533034615587616
   Lu Q, 2016, INT J BIOL MACROMOL, V93, P208, DOI 10.1016/j.ijbiomac.2016.08.049
   Lu S, 2014, INT J BIOL SCI, V10, P415, DOI 10.7150/ijbs.8002
   Luo C, 2012, MOL BIOL REP, V39, P5459, DOI 10.1007/s11033-011-1346-5
   Ma YC, 2015, CANCER CELL INT, V15, DOI 10.1186/s12935-015-0210-4
   Ming M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114573
   Nagata T, 2016, J NAT MED-TOKYO, V70, P627, DOI 10.1007/s11418-016-0989-x
   Ni WJ, 2017, J AGR FOOD CHEM, V65, P2039, DOI 10.1021/acs.jafc.6b05474
   Nishiuchi T, 2013, J ALTERN COMPLEM MED, V19, P593, DOI 10.1089/acm.2012.0177
   Okada K, 2016, SURGERY, V159, P1333, DOI 10.1016/j.surg.2015.11.019
   Pandey A, 2015, NUTR CANCER, V67, P1293, DOI 10.1080/01635581.2015.1085581
   Park SH, 2015, BRAZ J MED BIOL RES, V48, P111, DOI 10.1590/1414-431X20144293
   Pecina-Slaus N, 2010, CANCER CELL INT, V10, DOI 10.1186/1475-2867-10-22
   Galvis CEP, 2013, CHEM BIOL DRUG DES, V82, P477, DOI 10.1111/cbdd.12180
   Puthdee N, 2017, BIOL PHARM BULL, V40, P751, DOI 10.1248/bpb.b16-00428
   Qi FH, 2015, BIOSCI TRENDS, V9, P16, DOI 10.5582/bst.2015.01019
   Qi FH, 2010, BIOSCI TRENDS, V4, P297
   Qi Y, 2017, AM J CHINESE MED, V45, P1157, DOI 10.1142/S0192415X1750063X
   Qiu PJ, 2017, BMC CANCER, V17, DOI 10.1186/s12885-016-3039-x
   Rauh Rolf, 2007, Chin Med, V2, P8
   Rockwell S, 2013, INT J RADIAT BIOL, V89, P16, DOI 10.3109/09553002.2012.717733
   Saif MW, 2014, CANCER CHEMOTH PHARM, V73, P373, DOI 10.1007/s00280-013-2359-7
   Shen M, 2015, SCI REP-UK, V5, DOI 10.1038/srep11836
   Shih TC, 2012, J HEPATOL, V57, P584, DOI 10.1016/j.jhep.2012.04.031
   Siegel RL, 2018, CA-CANCER J CLIN, V68, P7, DOI 10.3322/caac.21442
   Song XJ, 2015, ONCOL REP, V34, P12, DOI 10.3892/or.2015.3950
   Su CC, 2015, AM J CHINESE MED, V43, P581, DOI 10.1142/S0192415X15500366
   Su ZY, 2017, EVID-BASED COMPL ALT, V2017, DOI 10.1155/2017/8753815
   Sun WW, 2017, ONCOTARGET, V8, P46081, DOI 10.18632/oncotarget.17687
   Sun XY, 2016, MOL CELLS, V39, P869, DOI 10.14348/molcells.2016.0023
   Syed SB, 2016, CURR TOP MED CHEM, V16, P2484, DOI 10.2174/1568026616666160212123814
   Tang J, 2009, J ETHNOPHARMACOL, V126, P5, DOI 10.1016/j.jep.2009.08.009
   Taylor CA, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-35
   Tian QE, 2012, BMC COMPLEM ALTERN M, V12, DOI 10.1186/1472-6882-12-94
   Tian QE, 2012, WORLD J GASTROENTERO, V18, P7079, DOI 10.3748/wjg.v18.i47.7079
   Toesca DAS, 2018, INT J RADIAT ONCOL, V100, P1155, DOI 10.1016/j.ijrobp.2017.12.287
   Tomasello G, 2017, JAMA ONCOL, V3, DOI 10.1001/jamaoncol.2017.0278
   Wan XY, 2017, AM J TRANSL RES, V9, P155
   Wang GF, 2018, CURR MED CHEM, V25, P2034, DOI 10.2174/0929867324666170414165253
   Wang J, 2013, BIOCHEM BIOPH RES CO, V439, P47, DOI 10.1016/j.bbrc.2013.08.032
   Wang JC, 2015, J TRADIT CHIN MED, V35, P361, DOI 10.1016/S0254-6272(15)30111-4
   Wang JX, 2014, J ETHNOPHARMACOL, V155, P405, DOI 10.1016/j.jep.2014.05.038
   Wang JX, 2012, J ETHNOPHARMACOL, V139, P788, DOI 10.1016/j.jep.2011.12.019
   Wang JX, 2016, ONCOTARGET, V7, P76076, DOI 10.18632/oncotarget.12589
   Wang M, 2017, J PHARM PHARMACOL, V69, P743, DOI 10.1111/jphp.12706
   Wang N, 2010, J CELL BIOCHEM, V111, P1426, DOI 10.1002/jcb.22869
   Wang T, 2014, J CANCER RES THER, V10, P52, DOI 10.4103/0973-1482.139760
   Wang T, 2013, DIAGN PATHOL, V8, DOI 10.1186/1746-1596-8-179
   Wang T, 2015, ARCH PHARM RES, V38, P282, DOI 10.1007/s12272-014-0383-8
   Wang WJ, 2015, INT J ONCOL, V47, P1912, DOI 10.3892/ijo.2015.3156
   Wang XJ, 2012, BIOCHEM BIOPH RES CO, V428, P525, DOI 10.1016/j.bbrc.2012.10.039
   Wang XL, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17101706
   Wang XL, 2012, ONCOL REP, V28, P1167, DOI 10.3892/or.2012.1961
   Wang XY, 2017, ONCOL REP, V37, P747, DOI 10.3892/or.2016.5292
   Wang Y, 2014, BMC COMPLEM ALTERN M, V14, DOI 10.1186/1472-6882-14-401
   Wilhelm SM, 2004, CANCER RES, V64, P7099, DOI 10.1158/0008-5472.CAN-04-1443
   Wong AST, 2015, NAT PROD REP, V32, P256, DOI 10.1039/c4np00080c
   Wu XS, 2014, ANTI-CANCER DRUG, V25, P1007, DOI 10.1097/CAD.0000000000000124
   Xiao Z, 2017, ONCOTARGET, V8, P1329, DOI 10.18632/oncotarget.13617
   Xie HX, 2015, EXP THER MED, V10, P1212, DOI 10.3892/etm.2015.2600
   Xie SB, 2015, INT J ONCOL, V47, P517, DOI 10.3892/ijo.2015.3023
   Xie T, 2016, ONCOL RES, V24, P447, DOI 10.3727/096504016X14685034103590
   Xie X, 2015, ONCOL LETT, V9, P837, DOI 10.3892/ol.2014.2711
   Xu BB, 2017, CELL DEATH DISCOV, V3, DOI 10.1038/cddiscovery.2016.96
   Xu DJ, 2008, MOLECULES, V13, P2408, DOI 10.3390/molecules13102408
   Xu HL, 2015, DRUG DES DEV THER, V9, P2735, DOI 10.2147/DDDT.S80902
   Xu R., 2017, SHENQI FUZHENG INJEC, V12, DOI [10.1371/journal.pone.0185254, DOI 10.1371/JOURNAL.PONE.0185254]
   Xu ZY, 2017, J CANCER, V8, P3876, DOI 10.7150/jca.20380
   Yae S, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/976926
   Yang B, 2013, INT J BIOL MACROMOL, V62, P287, DOI 10.1016/j.ijbiomac.2013.09.016
   Yang MH, 2012, J CANCER RES CLIN, V138, P1743, DOI 10.1007/s00432-012-1254-7
   Yang NM, 2015, PHARMACOL REP, V67, P388, DOI 10.1016/j.pharep.2014.10.016
   Yang YZ, 2014, TUMOR BIOL, V35, P2747, DOI 10.1007/s13277-013-1362-2
   Yao KH, 2014, J CANCER RES THER, V10, P70, DOI 10.4103/0973-1482.139768
   Ye Q, 2017, CELL PHYSIOL BIOCHEM, V43, P1617, DOI 10.1159/000482025
   Yeh CB, 2010, EUR J MED CHEM, V45, P3981, DOI 10.1016/j.ejmech.2010.05.053
   Yen Y, 2009, ANTICANCER RES, V29, P4083
   Yi TT, 2015, NUTR CANCER, V67, P523, DOI 10.1080/01635581.2015.1004733
   Yong JP, 2015, CURR PHARM DESIGN, V21, P3673, DOI 10.2174/1381612821666150122123748
   Yoshida R, 2013, LAB INVEST, V93, P1068, DOI 10.1038/labinvest.2013.95
   Yoshikawa K, 2015, J AM COLL SURGEONS, V221, P571, DOI 10.1016/j.jamcollsurg.2015.03.004
   You HY, 2016, IN VITRO CELL DEV-AN, V52, P857, DOI 10.1007/s11626-016-0044-y
   Yu R, 2014, CANCER CELL INT, V14, DOI 10.1186/1475-2867-14-49
   Zeng YB, 2016, J NAT PROD, V79, P2032, DOI 10.1021/acs.jnatprod.6b00332
   Zhang AH, 2018, MASS SPECTROM REV, V37, P307, DOI 10.1002/mas.21529
   Zhang CS, 2015, EVID-BASED COMPL ALT, V2015, DOI 10.1155/2015/171356
   Zhang CJ, 2014, ONCOL LETT, V8, P2721, DOI 10.3892/ol.2014.2611
   Zhang D, 2017, ONCOTARGET, V8, P68873, DOI 10.18632/oncotarget.20320
   Zhang JT, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-193
   Zhang JW, 2013, ACTA PHARMACOL SIN, V34, P1084, DOI 10.1038/aps.2013.15
   Zhang SJ, 2014, MOL BIOL REP, V41, P2101, DOI 10.1007/s11033-014-3059-z
   Zhang S, 2017, ANTICANCER RES, V37, P464, DOI 10.21873/anticanres.11338
   Zhang T, 2013, ONCOL LETT, V5, P1171, DOI 10.3892/ol.2013.1145
   Zhang W, 2010, J CHROMATOGR A, V1217, P5785, DOI 10.1016/j.chroma.2010.07.045
   Zhang WM, 2017, INT J BIOL MACROMOL, V105, P852, DOI 10.1016/j.ijbiomac.2017.07.108
   Zhang XL, 2016, IRAN J PHARM RES, V15, P491
   Zhang Y, 2017, FUTURE ONCOL, V13, P1173, DOI 10.2217/fon-2016-0437
   Zhang YS, 2016, ACTA PHARMACOL SIN, V37, P295, DOI 10.1038/aps.2015.116
   Zhao GS, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000007589
   Zheng JS, 2014, INT J BIOL MACROMOL, V64, P106, DOI 10.1016/j.ijbiomac.2013.11.034
   Zheng LC, 2016, ANTICANCER RES, V36, P6031, DOI 10.21873/anticanres.11192
   Zhou H, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-59
   Zhou N, 2017, MOL MED REP, V15, P442, DOI 10.3892/mmr.2016.5999
   Zou YM, 2015, TUMOR BIOL, V36, P2929, DOI 10.1007/s13277-014-2923-8
NR 165
TC 6
Z9 6
U1 5
U2 35
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1663-9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD NOV 20
PY 2018
VL 9
AR 1249
DI 10.3389/fphar.2018.01249
PG 14
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA HB0HY
UT WOS:000450695500001
PM 30524272
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Fernandez-Mateos, J
   Seijas-Tamayo, R
   Klain, JCA
   Borgonon, MP
   Perez-Ruiz, E
   Mesia, R
   del Barco, E
   Coloma, CS
   Dominguez, AR
   Daroqui, JC
   Ruiz, EF
   Cruz-Hernandez, JJ
   Gonzalez-Sarmiento, R
AF Fernandez-Mateos, Javier
   Seijas-Tamayo, Raquel
   Adansa Klain, Juan Carlos
   Pastor Borgonon, Miguel
   Perez-Ruiz, Elisabeth
   Mesia, Ricard
   del Barco, Elvira
   Salvador Coloma, Carmen
   Rueda Dominguez, Antonio
   Caballero Daroqui, Javier
   Fernandez Ruiz, Encarnacion
   Jesus Cruz-Hernandez, Juan
   Gonzalez-Sarmiento, Rogelio
TI Analysis of autophagy gene polymorphisms in Spanish patients with head
   and neck squamous cell carcinoma
SO SCIENTIFIC REPORTS
LA English
DT Article
ID RISK-FACTORS; MOLECULAR-BIOLOGY; COLORECTAL-CANCER; EPIDEMIOLOGY;
   ATG16L1; DISEASE
AB Head and neck squamous cell carcinoma (HNSCC) is the sixth cancer on incidence worldwide. Tobacco and alcohol consumption are the most classical risk factors associated with its development. Autophagy process has a dual effect both in tumourigenesis and tumour suppressing activity. To investigate the importance of this pathway in HNSCC susceptibility, a risk factor matched case-control association study was performed with four candidate polymorphisms in autophagy genes (ATG2B, ATG5, ATG10, ATG16L1). We found an association between the variant in ATG10 rs1864183 and a higher susceptibility to develop laryngeal cancer, ATG2B rs3759601 and pharyngeal cancer and ATG16L1 rs2241880 and oral carcinoma. ATG5 rs2245214 SNP was not associated with any location. Overall, our results indicate the importance of the autophagy pathway in the susceptibility of head and neck squamous cell carcinoma and demonstrate the heterogeneity between its locations encompassed under a single terminology.
C1 [Fernandez-Mateos, Javier; Seijas-Tamayo, Raquel; Adansa Klain, Juan Carlos; del Barco, Elvira; Jesus Cruz-Hernandez, Juan] Univ Hosp Salamanca, IBSAL, Med Oncol Serv, Salamanca 37007, Spain.
   [Fernandez-Mateos, Javier; Seijas-Tamayo, Raquel; Adansa Klain, Juan Carlos; del Barco, Elvira; Jesus Cruz-Hernandez, Juan; Gonzalez-Sarmiento, Rogelio] Univ Salamanca, CSIC, SACYL, Biomed Res Inst Salamanca IBSAL, Salamanca 37007, Spain.
   [Fernandez-Mateos, Javier; Jesus Cruz-Hernandez, Juan; Gonzalez-Sarmiento, Rogelio] Univ Salamanca, Dept Med, IBSAL, Mol Med Unit, Salamanca 37007, Spain.
   [Fernandez-Mateos, Javier; Jesus Cruz-Hernandez, Juan; Gonzalez-Sarmiento, Rogelio] Univ Salamanca, CSIC, Inst Mol & Cellular Biol Canc IBMCC, Salamanca 37007, Spain.
   [Pastor Borgonon, Miguel; Salvador Coloma, Carmen; Caballero Daroqui, Javier] Hosp Univ Politecn La Fe, Med Oncol Serv, Valencia 46026, Spain.
   [Perez-Ruiz, Elisabeth; Rueda Dominguez, Antonio] Agencia Sanitaria Hosp Costa Sol Marbella, Oncol Dept, Div Med Oncol, Marbella 29603, Spain.
   [Mesia, Ricard] Univ Barcelona, IDIBELL, Inst Catala Oncol, Med Oncol Dept, Barcelona 08908, Spain.
   [Fernandez Ruiz, Encarnacion] Agencia Sanitaria Hosp Costa Sol Marbella, Otolaryngol Dept, Marbella 29603, Spain.
RP Cruz-Hernandez, JJ (corresponding author), Univ Hosp Salamanca, IBSAL, Med Oncol Serv, Salamanca 37007, Spain.; Cruz-Hernandez, JJ; Gonzalez-Sarmiento, R (corresponding author), Univ Salamanca, CSIC, SACYL, Biomed Res Inst Salamanca IBSAL, Salamanca 37007, Spain.; Cruz-Hernandez, JJ; Gonzalez-Sarmiento, R (corresponding author), Univ Salamanca, Dept Med, IBSAL, Mol Med Unit, Salamanca 37007, Spain.; Cruz-Hernandez, JJ; Gonzalez-Sarmiento, R (corresponding author), Univ Salamanca, CSIC, Inst Mol & Cellular Biol Canc IBMCC, Salamanca 37007, Spain.
EM ttcc@seom.org; gonzalez@usal.es
RI Ruiz, Elísabeth Pérez/ABI-5900-2020; Fernandez-Mateos,
   Javier/ABH-4726-2020; Gonzalez-Sarmiento, Rogelio/V-5526-2019
OI Ruiz, Elísabeth Pérez/0000-0001-7204-0800; Gonzalez-Sarmiento,
   Rogelio/0000-0002-2726-6795; Salvador, Carmen/0000-0003-0715-4195; Cruz
   Hernandez, Juan Jesus/0000-0003-1980-2751; Fernandez-Mateos,
   Javier/0000-0002-4949-4131
FU Instituto de Salud Carlos IIIInstituto de Salud Carlos IIIEuropean
   Commission [PI11/00519, PI13/01741, PIE14/00066]; FEDER foundsEuropean
   Commission; Health Regional Management of the Junta de Castilla y
   LeonJunta de Castilla y Leon [GRS630/A11]; Consejeria de Educacion-Junta
   de Castilla y LeonJunta de Castilla y Leon; European Social FundEuropean
   Social Fund (ESF) [EDU/1084/2012]
FX This study was supported by the health research program of the
   "Instituto de Salud Carlos III" (PI11/00519, PI13/01741 and PIE14/00066)
   co financed with FEDER founds and for the Health Regional Management of
   the Junta de Castilla y Leon (GRS630/A11). J. Fernandez-Mateos was
   partially supported by a predoctoral research grant from the Consejeria
   de Educacion-Junta de Castilla y Leon and the European Social Fund to
   CC-B (EDU/1084/2012). Moreover the authors thank the 790 individuals who
   consented to participate in this study, and all their colleagues who
   have participated in this study and are not included in the list of
   authors, in alphabetical order: Daniel Almenar Cubells (H.U. Dr. Peset
   de Valencia), Ruth Alvarez Cabellos (H. Virgen de la Salud), Teresa
   Bonfill Abella (Corporacion Sanitaria Parc Tauli), Beatriz Castelo
   Fernandez (H.U. de La Paz), Jose Fuster Salva (H. Son Espases), Jose
   Angel Garcia Saenz (H. Clinico San Carlos), Maria Belen Gonzalez Gragera
   (H. Son Llatzer), Oscar Salvador Gallego Rubio (H. De la Santa Creu I
   Sant Pau), Alicia Hurtado Nuno (H.U. Alcarcon), Ana Lopez Alfonso (H.
   Infanta Leonor), Julio Lambea Sorrosal (H.C.U. Lozano Blesa), Javier
   Martinez Trufero (H.U. Miguel Servet), Isabel Ruiz Martin (Complejo
   Hospitalario de Palencia), Michalina Rusiecka (H. Clinic I Provincial)
   and Sergio Eloy Vazquez Estevez (H. U. Lucus Augusti). We also thank to
   the Spanish Head and Neck Cancer Cooperative Group (TTCC) and the
   Institute of Biomedical Research of Salamanca (IBSAL) for their efforts
   on behalf of the patients and protocol.
CR Azad AK, 2012, CANCER-AM CANCER SOC, V118, P1554, DOI 10.1002/cncr.26446
   Boada-Romero E, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11821
   Burada F, 2015, WORLD J GASTRO ONCOL, V7, P271, DOI 10.4251/wjgo.v7.i11.271
   Cardesa A, 2011, ACTA DERMATOVEN ALP, V20, P161
   Cosway B, 2016, ORAL ONCOL, V54, P1, DOI 10.1016/j.oraloncology.2015.12.007
   Feller L, 2013, ORAL ONCOL, V49, P887, DOI 10.1016/j.oraloncology.2013.07.003
   Ganci F., 2012, MOL GENETICS BIOL HE
   Glick D, 2010, J PATHOL, V221, P3, DOI 10.1002/path.2697
   Hashibe M., 2011, CANCER EPIDEM BIOMAR, V18, P541
   Hashibe M, 2007, J NATL CANCER I, V99, P777, DOI 10.1093/jnci/djk179
   Jefferies S, 1999, BRIT J CANCER, V79, P865, DOI 10.1038/sj.bjc.6690138
   Kishi-Itakura C, 2014, J CELL SCI, V127, P4984, DOI 10.1242/jcs.164293
   Kishi-Itakura C, 2014, J CELL SCI, V127, P4089, DOI 10.1242/jcs.156034
   Leemans CR, 2011, NAT REV CANCER, V11, P9, DOI 10.1038/nrc2982
   Mathew R, 2007, NAT REV CANCER, V7, P961, DOI 10.1038/nrc2254
   Mizushima N, 2007, GENE DEV, V21, P2861, DOI 10.1101/gad.1599207
   Murthy A, 2014, NATURE, V506, P456, DOI 10.1038/nature13044
   Nicoli ER, 2014, ROM J MORPHOL EMBRYO, V55, P57
   Perez-Ordonez B, 2006, J CLIN PATHOL, V59, P445, DOI 10.1136/jcp.2003.007641
   Qin ZZ, 2013, GENE, V527, P491, DOI 10.1016/j.gene.2013.06.067
   Ragin CCR, 2007, J DENT RES, V86, P104, DOI 10.1177/154405910708600202
   Rosenbaum B. Y. P. R., 1979, BIOMETRIKA, V70, P41
   Salem M, 2015, CLIN TRANSL GASTROEN, V6, DOI 10.1038/ctg.2015.47
   Schleinitz D, 2011, METHODS MOL BIOL, V700, P77, DOI 10.1007/978-1-61737-954-3_6
   Seijas-Tamayo R, 2016, CLIN TRANSL ONCOL, V18, P1114, DOI 10.1007/s12094-016-1493-1
   Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993
   Streiner DL, 2012, CHEST, V142, P1380, DOI 10.1378/chest.12-1920
   Sturgis EM, 2004, SEMIN ONCOL, V31, P726, DOI 10.1053/j.seminoncol.2004.09.013
   Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262
   Usategui-Martin R, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128984
   Velikkakath AKG, 2012, MOL BIOL CELL, V23, P896, DOI 10.1091/mbc.E11-09-0785
   White KAM, 2016, CANCER MED-US, V5, P3336, DOI 10.1002/cam4.929
NR 32
TC 15
Z9 15
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD JUL 31
PY 2017
VL 7
AR 6887
DI 10.1038/s41598-017-07270-0
PG 8
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA FX3JW
UT WOS:000425969300020
PM 28761177
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Hoffmann, P
   Lamerz, D
   Hill, P
   Kirchner, M
   Gauss, A
AF Hoffmann, Peter
   Lamerz, David
   Hill, Petra
   Kirchner, Marietta
   Gauss, Annika
TI Gene Polymorphisms of NOD2, IL23R, PTPN2 and ATG16L1 in Patients with
   Crohn's Disease: On the Way to Personalized Medicine?
SO GENES
LA English
DT Article
DE inflammatory bowel disease; Crohn's disease; NOD2; PTPN2; rs7234029;
   IL23R; ustekinumab; anti-interleukin-12; 23
ID INFLAMMATORY-BOWEL-DISEASE; SUSCEPTIBILITY; ASSOCIATIONS; RISK;
   AUTOPHAGY; VARIANTS; CARD15; IMPACT
AB Genetic and environmental factors are involved in the pathogenesis of inflammatory bowel diseases (IBD). The study aimed at investigating the potential influence of single nucleotide polymorphisms (SNPs) NOD2 rs2066844, NOD2 rs2066845, NOD2 rs2066847, IL23R rs11209026, PTPN2 rs2542151, PTPN2 rs7234029, and ATG16L1 rs2241880 on the response to immunomodulatory therapies and disease course in Crohn's disease (CD). This is an uncontrolled retrospective monocentric study including patients from the IBD outpatient clinic of Heidelberg University Hospital. Therapy responses and disease courses were related to genetic findings. 379 patients with CD were included. The presence of at least one PTPN2 rs7234029 risk allele was associated with nonresponse to anti-interleukin-12/23 treatment (89.9% vs. 67.6%, p = 0.005). The NOD2 rs2066844 risk allele was associated with a first-degree family history of colon cancer (12.7% vs. 4.7%, p = 0.02), the ATG16L1 rs2241880 risk allele with ileal CD manifestation (p = 0.027), and the IL23R rs11209026 risk allele with a higher rate of CD-related surgeries per disease year (0.08 vs. 0.02, p = 0.025). The results of this study underline the relevance of genetic influences in CD. The association of the PTPN2 rs7234029 risk allele with nonresponse to anti-interleukin-12/23 treatment in CD patients is a novel finding and requires further investigation.
C1 [Hoffmann, Peter; Lamerz, David; Hill, Petra; Gauss, Annika] Univ Hosp Heidelberg, Dept Gastroenterol & Hepatol, INF 410, D-69120 Heidelberg, Germany.
   [Kirchner, Marietta] Univ Hosp Heidelberg, Inst Med Biometry & Informat, Dept Med Biometry, INF 130-3, D-69120 Heidelberg, Germany.
RP Gauss, A (corresponding author), Univ Hosp Heidelberg, Dept Gastroenterol & Hepatol, INF 410, D-69120 Heidelberg, Germany.
EM Peterhoffmann84@gmail.com; david.lamerz@web.de;
   petra.hill@med.uni-heidelberg.de; kirchner@imbi.uni-heidelberg.de;
   Annika.Gauss@med.uni-heidelberg.de
OI Kirchner, Marietta/0000-0003-0294-2483; Hoffmann,
   Peter/0000-0002-5736-445X
CR Anderson CA, 2011, NAT GENET, V43, P246, DOI 10.1038/ng.764
   Boukercha A, 2015, WORLD J GASTROENTERO, V21, P7786, DOI 10.3748/wjg.v21.i25.7786
   Burton PR, 2007, NATURE, V447, P661, DOI 10.1038/nature05911
   Santos MPC, 2018, ANN GASTROENTEROL, V31, P14, DOI 10.20524/aog.2017.0208
   Pena RD, 2015, REV ESP ENFERM DIG, V107, P560
   Etienne-Mesmin Lucie, 2017, World J Gastrointest Pharmacol Ther, V8, P7, DOI 10.4292/wjgpt.v8.i1.7
   Glas J, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000819
   Glas J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033682
   Iida T, 2017, WORLD J GASTROENTERO, V23, P1944, DOI 10.3748/wjg.v23.i11.1944
   Juanola O, 2015, J GASTROENTEROL, V50, P758, DOI 10.1007/s00535-014-1020-5
   Kaplan GG, 2015, NAT REV GASTRO HEPAT, V12, P720, DOI 10.1038/nrgastro.2015.150
   Kennedy NA, 2018, INFLAMM BOWEL DIS, V24, P583, DOI 10.1093/ibd/izx061
   Liu JW, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089340
   Maaser C, 2019, J CROHNS COLITIS, V13, P144, DOI 10.1093/ecco-jcc/jjy113
   Moller FT, 2015, AM J GASTROENTEROL, V110, P564, DOI 10.1038/ajg.2015.50
   Nuij VJAA, 2017, J TRANSL MED, V15, DOI 10.1186/s12967-017-1355-9
   Nunez C, 2008, GENES IMMUN, V9, P289, DOI 10.1038/gene.2008.16
   Pranculiene G, 2016, MEDICINA-LITHUANIA, V52, P325, DOI 10.1016/j.medici.2016.11.006
   Prescott NJ, 2007, GASTROENTEROLOGY, V132, P1665, DOI 10.1053/j.gastro.2007.03.034
   Salem M, 2015, AUTOPHAGY, V11, P585, DOI 10.1080/15548627.2015.1017187
   Satsangi J, 2006, GUT, V55, P749, DOI 10.1136/gut.2005.082909
   Schaffler H, 2018, J DIGEST DIS, V19, P678, DOI 10.1111/1751-2980.12677
   Schnitzler F, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0236421
   Sidiq T, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00367
   Smyth DJ, 2008, NEW ENGL J MED, V359, P2767, DOI 10.1056/NEJMoa0807917
   Todd JA, 2007, NAT GENET, V39, P857, DOI 10.1038/ng2068
   Wang SL, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00693
   Zhu Y, 2020, INFLAMM RES, V69, P87, DOI 10.1007/s00011-019-01296-y
NR 28
TC 1
Z9 1
U1 1
U2 5
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2073-4425
J9 GENES-BASEL
JI Genes
PD JUN
PY 2021
VL 12
IS 6
AR 866
DI 10.3390/genes12060866
PG 10
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA SY5HC
UT WOS:000665917900001
PM 34198814
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Park, JM
   Tougeron, D
   Huang, SB
   Okamoto, K
   Sinicrope, FA
AF Park, Jae Myung
   Tougeron, David
   Huang, Shengbing
   Okamoto, Koichi
   Sinicrope, Frank A.
TI Beclin 1 and UVRAG Confer Protection from Radiation-Induced DNA Damage
   and Maintain Centrosome Stability in Colorectal Cancer Cells
SO PLOS ONE
LA English
DT Article
ID INDUCED APOPTOSIS; AUTOPHAGY; REPAIR; INHIBITION; RECOMBINATION; CYCLE;
   GENE; LC3; ATM
AB Beclin 1 interacts with UV-irradiation-resistance-associated gene (UVRAG) to form core complexes that induce autophagy. While cells with defective autophagy are prone to genomic instability that contributes to tumorigenesis, it is unknown whether Beclin1 or UVRAG can regulate the DNA damage/repair response to cancer treatment in established tumor cells. We found that siRNA knockdown of Beclin 1 or UVRAG can increase radiation-induced DNA double strand breaks (DSBs), shown by pATM and gamma H2Ax, and promote colorectal cancer cell death. Furthermore, knockdown of Beclin 1, UVRAG or ATG5 increased the percentage of irradiated cells with nuclear foci expressing 53BP1, a marker of nonhomologous end joining but not RAD51 (homologous recombination), compared to control siRNA. Beclin 1 siRNA was shown to attenuate UVRAG expression. Cells with a UVRAG deletion mutant defective in Beclin 1 binding showed increased radiation-induced DSBs and cell death compared to cells with ectopic wild-type UVRAG. Knockdown of Beclin 1 or UVRAG, but not ATG5, resulted in a significant increase in centrosome number (gamma-tubulin staining) in irradiated cells compared to control siRNA. Taken together, these data indicate that Beclin 1 and UVRAG confer protection against radiation-induced DNA DSBs and may maintain centrosome stability in established tumor cells.
C1 [Sinicrope, Frank A.] Mayo Clin, Rochester, MN 55902 USA.
   Mayo Clin, Ctr Canc, Rochester, MN USA.
RP Sinicrope, FA (corresponding author), Mayo Clin, Rochester, MN 55902 USA.
EM sinicrope.frank@mayo.edu
RI tougeron, david/ABF-3217-2020
OI tougeron, david/0000-0002-8065-9635
FU National Cancer InstituteUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Cancer
   Institute (NCI) [5 K05 CA142885, CA113681]; Multi-Organizational
   Thematic Institute for Cancer; French National Cancer InstituteInstitut
   National du Cancer (INCA) France; NATIONAL CANCER INSTITUTEUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Cancer Institute (NCI) [K05CA142885, R01CA113681]
   Funding Source: NIH RePORTER
FX This work was supported by grants from the National Cancer Institute (5
   K05 CA142885 and CA113681, both to FAS). DT is a recipient of financial
   support from the Multi-Organizational Thematic Institute for Cancer and
   the French National Cancer Institute. The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401
   Acu ID, 2010, CANCER RES, V70, P3320, DOI 10.1158/0008-5472.CAN-09-3800
   Aita VM, 1999, GENOMICS, V59, P59, DOI 10.1006/geno.1999.5851
   Amaravadi RK, 2007, J CLIN INVEST, V117, P326, DOI 10.1172/JCI28833
   Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368
   Bonner WM, 2008, NAT REV CANCER, V8, P957, DOI 10.1038/nrc2523
   Bothmer A, 2011, MOL CELL, V42, P319, DOI 10.1016/j.molcel.2011.03.019
   Bourke E, 2007, EMBO REP, V8, P603, DOI 10.1038/sj.embor.7400962
   D'Assoro AB, 2002, ONCOGENE, V21, P6146, DOI 10.1038/sj.onc.1205772
   Flatten K, 2005, J BIOL CHEM, V280, P14349, DOI 10.1074/jbc.M411890200
   Fremont S, 2013, EMBO REP, V14, P364, DOI 10.1038/embor.2013.23
   Fukasawa K, 2007, NAT REV CANCER, V7, P911, DOI 10.1038/nrc2249
   Ganem NJ, 2009, NATURE, V460, P278, DOI 10.1038/nature08136
   Huang SB, 2013, J BIOL CHEM, V288, P33654, DOI 10.1074/jbc.M113.518134
   Huang SB, 2011, J BIOL CHEM, V286, P40002, DOI 10.1074/jbc.M111.297432
   Huang SB, 2010, AUTOPHAGY, V6, P256, DOI 10.4161/auto.6.2.11124
   Ionov Y, 2004, ONCOGENE, V23, P639, DOI 10.1038/sj.onc.1207178
   Itakura E, 2008, MOL BIOL CELL, V19, P5360, DOI 10.1091/mbc.E08-01-0080
   Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720
   Karantza-Wadsworth V, 2007, GENE DEV, V21, P1621, DOI 10.1101/gad.1565707
   Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717
   Kuwahara Y, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.56
   Li XH, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1648
   Liang C, 2006, NAT CELL BIOL, V8, P688, DOI 10.1038/ncb1426
   Liang XH, 2001, CANCER RES, V61, P3443
   Liu J, 2010, CELL, V147, P223
   Mao ZY, 2008, CELL CYCLE, V7, P2902, DOI 10.4161/cc.7.18.6679
   Mathew R, 2007, GENE DEV, V21, P1367, DOI 10.1101/gad.1545107
   Park JM, 2013, CANCER BIOL THER, V14, P100, DOI 10.4161/cbt.22954
   Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2
   Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039
   Sato N, 2000, ONCOGENE, V19, P5281, DOI 10.1038/sj.onc.1203902
   Sinha S, 2008, ONCOGENE, V27, pS137, DOI 10.1038/onc.2009.51
   Suwaki N, 2011, SEMIN CELL DEV BIOL, V22, P898, DOI 10.1016/j.semcdb.2011.07.019
   Ward IM, 2003, MOL CELL BIOL, V23, P2556, DOI 10.1128/MCB.23.7.2556-2563.2003
   Yang ZNJ, 2011, MOL CANCER THER, V10, P1533, DOI 10.1158/1535-7163.MCT-11-0047
   Yousefi S, 2006, NAT CELL BIOL, V8, P1124, DOI 10.1038/ncb1482
   Zhao Z, 2012, AUTOPHAGY, V8, P1392, DOI 10.4161/auto.21035
   Zhao Z, 2012, DEV CELL, V22, P1001, DOI 10.1016/j.devcel.2011.12.027
NR 39
TC 44
Z9 47
U1 2
U2 11
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 23
PY 2014
VL 9
IS 6
AR e100819
DI 10.1371/journal.pone.0100819
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA AL1WV
UT WOS:000338917900098
PM 24956373
OA gold, Green Published, Green Submitted
DA 2022-04-25
ER

PT J
AU Carbone, A
   Parrino, B
   Di Vita, G
   Attanzio, A
   Spano, V
   Montalbano, A
   Barraja, P
   Tesoriere, L
   Livrea, MA
   Diana, P
   Cirrincione, G
AF Carbone, Anna
   Parrino, Barbara
   Di Vita, Gloria
   Attanzio, Alessandro
   Spano, Virginia
   Montalbano, Alessandra
   Barraja, Paola
   Tesoriere, Luisa
   Livrea, Maria Antonia
   Diana, Patrizia
   Cirrincione, Girolamo
TI Synthesis and Antiproliferative Activity of
   Thiazolyl-bis-pyrrolo[2,3-b]pyridines and
   Indolyl-thiazolyl-pyrrolo[2,3-c]pyridines, Nortopsentin Analogues
SO MARINE DRUGS
LA English
DT Article
DE marine alkaloids; bis-indolyl alkaloids; nortopsentins;
   thiazolyl-bis-pyrrolo[2,3-b]pyridines;
   indolyl-thiazolyl-pyrrolo[2,3-c]pyridines; apoptosis; autophagic death;
   antiproliferative activity
ID MARINE ALKALOID NORTOPSENTIN; BIS-INDOLE ALKALOIDS; ANTITUMOR-ACTIVITY;
   RING-SYSTEM; CYTOTOXICITY EVALUATION; BIS(INDOLE) ALKALOIDS; BISINDOLE
   ALKALOIDS; NATURAL-PRODUCTS; POTENT ANTITUMOR; SPONGOSORITES SP
AB Two new series of nortopsentin analogues, in which the imidazole ring of the natural product was replaced by thiazole and indole units were both substituted by 7-azaindole moieties or one indole unit was replaced by a 6-azaindole portion, were efficiently synthesized. Compounds belonging to both series inhibited the growth of HCT-116 colorectal cancer cells at low micromolar concentrations, whereas they did not affect the viability of normal-like intestinal cells. A compound of the former series induced apoptosis, evident as externalization of plasma membrane phosphatidylserine (PS), and changes of mitochondrial trans-membrane potential, while blocking the cell cycle in G2/M phase. In contrast, a derivative of the latter series elicited distinct responses in accordance with the dose. Thus, low concentrations (GI(30)) induced morphological changes characteristic of autophagic death with massive formation of cytoplasmic acid vacuoles without apparent loss of nuclear material, and with arrest of cell cycle at the G1 phase, whereas higher concentrations (GI(70)) induced apoptosis with arrest of cell cycle at the G1 phase.
C1 [Carbone, Anna; Parrino, Barbara; Di Vita, Gloria; Attanzio, Alessandro; Spano, Virginia; Montalbano, Alessandra; Barraja, Paola; Tesoriere, Luisa; Livrea, Maria Antonia; Diana, Patrizia; Cirrincione, Girolamo] Univ Palermo, STEBICEF, Biol Chem & Pharmaceut Sci & Technol Dept, I-90123 Palermo, Italy.
RP Cirrincione, G (corresponding author), Univ Palermo, STEBICEF, Biol Chem & Pharmaceut Sci & Technol Dept, Via Archirafi 32, I-90123 Palermo, Italy.
EM anna.carbone@unipa.it; barbara.parrino@unipa.it; gloria.divita@unipa.it;
   alessandro.attanzio@unipa.it; virginia.spano@unipa.it;
   alessandra.montalbano@unipa.it; paola.barraja@unipa.it;
   luisa.tesoriere@unipa.it; maria.livrea@unipa.it;
   patrizia.diana@unipa.it; girolamo.cirrincione@unipa.it
RI PARRINO, Barbara/AAB-7594-2019
OI PARRINO, Barbara/0000-0003-0163-1579; BARRAJA, Paola/0000-0003-1415-6594
FU Ministero dell'Istruzione dell'Universita e della Ricerca (MIUR)Ministry
   of Education, Universities and Research (MIUR)
FX This work was financially supported by Ministero dell'Istruzione
   dell'Universita e della Ricerca (MIUR).
CR ALVAREZ M, 1991, HETEROCYCLES, V32, P1391
   Bao BQ, 2005, J NAT PROD, V68, P711, DOI 10.1021/np049577a
   Barraja P, 2013, TETRAHEDRON, V69, P6474, DOI 10.1016/j.tet.2013.05.083
   Barraja P, 2012, CHEMMEDCHEM, V7, P1901, DOI 10.1002/cmdc.201200296
   Barraja P, 2012, TETRAHEDRON, V68, P5087, DOI 10.1016/j.tet.2012.04.041
   Barraja P, 2011, CHEMMEDCHEM, V6, P1238, DOI 10.1002/cmdc.201100085
   Barraja P, 2011, BIOORGAN MED CHEM, V19, P2326, DOI 10.1016/j.bmc.2011.02.023
   Barraja P, 2010, BIOORGAN MED CHEM, V18, P4830, DOI 10.1016/j.bmc.2010.04.080
   Barraja P, 2009, TETRAHEDRON LETT, V50, P5389, DOI 10.1016/j.tetlet.2009.07.045
   Barraja P, 2008, TETRAHEDRON, V64, P11625, DOI 10.1016/j.tet.2008.10.022
   Barraja P, 2009, BIOORG MED CHEM LETT, V19, P1711, DOI 10.1016/j.bmcl.2009.01.096
   BARTIK K, 1987, CAN J CHEM, V65, P2118, DOI 10.1139/v87-352
   Bokesch HR, 2000, TETRAHEDRON LETT, V41, P6305, DOI 10.1016/S0040-4039(00)01062-5
   Capon RJ, 1998, J NAT PROD, V61, P660, DOI 10.1021/np970483t
   Carbone A, 2014, CURR MED CHEM, V21, P1654, DOI 10.2174/09298673113206660307
   Carbone A, 2013, J MED CHEM, V56, P7060, DOI 10.1021/jm400842x
   Carbone A, 2013, MAR DRUGS, V11, P643, DOI 10.3390/md11030643
   Casapullo A, 2000, J NAT PROD, V63, P447, DOI 10.1021/np9903292
   Cirrincione G, 1999, J MED CHEM, V42, P2561, DOI 10.1021/jm9806087
   Diana P, 2002, EUR J MED CHEM, V37, P267, DOI 10.1016/S0223-5234(02)01339-9
   Diana P, 2008, J MED CHEM, V51, P2387, DOI 10.1021/jm070834t
   Diana P, 2007, BIOORG MED CHEM LETT, V17, P6134, DOI 10.1016/j.bmcl.2007.09.042
   Diana P, 2007, BIOORG MED CHEM LETT, V17, P2342, DOI 10.1016/j.bmcl.2007.01.065
   Diana P, 2007, BIOORGAN MED CHEM, V15, P343, DOI 10.1016/j.bmc.2006.09.054
   Diana P, 2011, CHEMMEDCHEM, V6, P1291, DOI 10.1002/cmdc.201100027
   Diana P, 2011, CHEMMEDCHEM, V6, P1300, DOI 10.1002/cmdc.201100078
   Diana P, 2011, TETRAHEDRON, V67, P3374, DOI 10.1016/j.tet.2011.03.060
   Diana P, 2010, BIOORGAN MED CHEM, V18, P4524, DOI 10.1016/j.bmc.2010.04.061
   FAHY E, 1991, J NAT PROD, V54, P564, DOI 10.1021/np50074a032
   Fresneda PM, 2001, SYNLETT, P218
   Ganser C, 2012, J MED CHEM, V55, P9531, DOI 10.1021/jm301217c
   Gul W, 2005, LIFE SCI, V78, P442, DOI 10.1016/j.lfs.2005.09.007
   Jacquemard U, 2008, BIOORGAN MED CHEM, V16, P4932, DOI 10.1016/j.bmc.2008.03.034
   Jiang B, 2000, BIOORGAN MED CHEM, V8, P363, DOI 10.1016/S0968-0896(99)00290-4
   Jiang B, 2001, BIOORGAN MED CHEM, V9, P1149, DOI 10.1016/S0968-0896(00)00337-0
   Jiang B, 2001, BIOORG MED CHEM LETT, V11, P475, DOI 10.1016/S0960-894X(00)00704-6
   Kawasaki I, 1996, CHEM PHARM BULL, V44, P1831
   KOHMOTO S, 1988, J ORG CHEM, V53, P3116, DOI 10.1021/jo00248a040
   Kumar D, 2011, BIOORG MED CHEM LETT, V21, P5897, DOI 10.1016/j.bmcl.2011.07.089
   Miyake FY, 2000, ORG LETT, V2, P2121, DOI 10.1021/ol000124g
   Moody C., 2000, ARKIVOC, V2000, P393
   MORRIS SA, 1990, TETRAHEDRON, V46, P715, DOI 10.1016/S0040-4020(01)81355-7
   Paglin S, 2001, CANCER RES, V61, P439
   Parrino B, 2014, J MED CHEM, V57, P9495, DOI 10.1021/jm501244f
   SAKEMI S, 1991, J ORG CHEM, V56, P4304, DOI 10.1021/jo00013a044
   SHIMIZU S, 1982, GANN, V73, P642
   Shin J, 1999, J NAT PROD, V62, P647, DOI 10.1021/np980507b
   Shoemaker RH, 2006, NAT REV CANCER, V6, P813, DOI 10.1038/nrc1951
   Spano V, 2014, EUR J MED CHEM, V74, P340, DOI 10.1016/j.ejmech.2013.10.014
   Sun DX, 2002, PHARMACEUT RES, V19, P1400, DOI 10.1023/A:1020483911355
   Tasdemir E, 2007, CELL CYCLE, V6, P2263, DOI 10.4161/cc.6.18.4681
   TSUJII S, 1988, J ORG CHEM, V53, P5446, DOI 10.1021/jo00258a009
   WRIGHT AE, 1992, J ORG CHEM, V57, P4772, DOI 10.1021/jo00043a045
   Xiong WN, 2001, BIOORGAN MED CHEM, V9, P1773, DOI 10.1016/S0968-0896(01)00070-0
NR 54
TC 49
Z9 50
U1 0
U2 13
PU MDPI AG
PI BASEL
PA POSTFACH, CH-4005 BASEL, SWITZERLAND
SN 1660-3397
J9 MAR DRUGS
JI Mar. Drugs
PD JAN
PY 2015
VL 13
IS 1
BP 460
EP 492
DI 10.3390/md13010460
PG 33
WC Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA AZ7MO
UT WOS:000348403200026
PM 25603343
OA Green Published, Green Submitted, gold
DA 2022-04-25
ER

PT J
AU Zhang, YH
   Cui, SX
   Wan, SB
   Wu, SH
   Qu, XJ
AF Zhang, Yu-hang
   Cui, Shu-xiang
   Wan, Sheng-biao
   Wu, Shu-hua
   Qu, Xian-jun
TI Increased S1P induces S1PR2 internalization to blunt the sensitivity of
   colorectal cancer to 5-fluorouracil via promoting intracellular uracil
   generation
SO ACTA PHARMACOLOGICA SINICA
LA English
DT Article
DE colorectal cancer; 5-FU resistance; sphingosine-1-phosphate (S1P); S1PR2
   internalization; endoplasmic reticulum calcium ([Ca2+](ER)); uracil
   generation; JTE-013
ID THYMIDYLATE SYNTHASE; RESISTANCE; SPHINGOSINE-1-PHOSPHATE;
   CHEMORESISTANCE; INHIBITION; EXPRESSION; AUTOPHAGY; REVEAL; CELLS; MODEL
AB Sphingosine-1-phosphate (S1P), the backbone of most sphingolipids, activating S1P receptors (S1PRs) and the downstream G protein signaling has been implicated in chemoresistance. In this study we investigated the role of S1PR2 internalization in 5-fluorouracil (5-FU) resistance in human colorectal cancer (CRC). Clinical data of randomly selected 60 CRC specimens showed the correlation between S1PR2 internalization and increased intracellular uracil (P < 0.001). Then we explored the regulatory mechanisms in CRC model of villin-S1PR2(-/-)mice and CRC cell lines. We showed that co-administration of S1P promoted S1PR2 internalization from plasma membrane (PM) to endoplasmic reticulum (ER), thus blunted 5-FU efficacy against colorectal tumors in WT mice, compared to that inS1PR2(-/-)mice. In HCT116 and HT-29 cells, application of S1P (10 mu M) empowered S1PR2 to internalize from PM to ER, thus inducing 5-FU resistance, whereas the specific S1PR2 inhibitor JTE-013 (10 mu M) effectively inhibited S1P-induced S1PR2 internalization. Using Mag-Fluo-AM-labeling [Ca2+](ER)and LC-ESI-MS/MS, we revealed that internalized S1PR2 triggered elevating [Ca2+](ER)levels to activate PERK-eLF2 alpha-ATF4 signaling in HCT116 cells. The activated ATF4 upregulated RNASET2-mediated uracil generation, which impaired exogenous 5-FU uptake to blunt 5-FU therapy. Overall, this study reveals a previously unrecognized mechanism of 5-FU resistance resulted from S1PR2 internalization-upregulated uracil generation in colorectal cancer, and provides the novel insight into the significance of S1PR2 localization in predicting the benefit of CRC patients from 5-FU-based chemotherapy.
C1 [Zhang, Yu-hang; Qu, Xian-jun] Capital Med Univ, Sch Basic Med Sci, Dept Pharmacol, Beijing 100069, Peoples R China.
   [Cui, Shu-xiang] Capital Med Univ, Sch Publ Hlth, Dept Toxicol & Sanit Chem, Beijing 100069, Peoples R China.
   [Wan, Sheng-biao] Ocean Univ China, Lab Marine Drugs & Bioprod, Qingdao Natl Lab Marine Sci & Technol, Sch Med & Pharm,Key Lab Marine Drugs,Minist Educ, Qingdao 266100, Peoples R China.
   [Wu, Shu-hua] Hosp Binzhou Med Univ, Dept Pathol, Binzhou 264003, Peoples R China.
RP Qu, XJ (corresponding author), Capital Med Univ, Sch Basic Med Sci, Dept Pharmacol, Beijing 100069, Peoples R China.
EM qxj@sdu.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [91629303, 81673449, 81872884, 81973350];
   Beijing Natural Science FoundationBeijing Natural Science Foundation
   [KZ201710025020, KZ201810025033]; Scientific Research Program of
   Municipal Commission of Education [KZ201710025020, KZ201810025033]
FX This work was supported by the National Natural Science Foundation of
   China (91629303/81673449/81872884/81973350) and the Beijing Natural
   Science Foundation and Scientific Research Program of Municipal
   Commission of Education (KZ201710025020/KZ201810025033). In addition,
   YHZ wants to thank, in particular, the inimitable support and care from
   Wen-yu Wang. Hope to spend the rest of my life with you.
CR Aarthi JJ, 2011, J DENT RES, V90, P841, DOI 10.1177/0022034510389178
   Antoon JW, 2011, CANCER BIOL THER, V11, P678, DOI 10.4161/cbt.11.7.14903
   Auberger P, 2017, BLOOD, V129, P547, DOI 10.1182/blood-2016-07-692707
   Calebiro D, 2010, TRENDS PHARMACOL SCI, V31, P221, DOI 10.1016/j.tips.2010.02.002
   Crea F, 2011, DRUG RESIST UPDATE, V14, P280, DOI 10.1016/j.drup.2011.08.001
   Dai SP, 2009, PHYSIOL REV, V89, P411, DOI 10.1152/physrev.00029.2007
   Dempsey LA, 2019, NAT IMMUNOL, V20, P517, DOI 10.1038/s41590-019-0392-3
   Furukawa T, 2018, PHARMACOL RES, V132, P15, DOI 10.1016/j.phrs.2018.03.019
   Guo YX, 2015, INT J CLIN EXP MED, V8, P20349
   Hait NC, 2009, SCIENCE, V325, P1254, DOI 10.1126/science.1176709
   Halls ML, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a004143
   Haud N, 2011, P NATL ACAD SCI USA, V108, P1099, DOI 10.1073/pnas.1009811107
   Heringdorf DMZ, 2004, J CELL BIOCHEM, V92, P937, DOI 10.1002/jcb.20107
   Jeon SJ, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-2190-0
   Kharel Y, 2012, BIOCHEM J, V447, P149, DOI 10.1042/BJ20120609
   Lee DK, 2018, BIOMOL THER, V26, P546, DOI 10.4062/biomolther.2018.053
   Lifshitz V, 2017, MOL CANCER THER, V16, P2516, DOI 10.1158/1535-7163.MCT-17-0379
   Longley DB, 2003, NAT REV CANCER, V3, P330, DOI 10.1038/nrc1074
   Luhtala N, 2010, TRENDS BIOCHEM SCI, V35, P253, DOI 10.1016/j.tibs.2010.02.002
   Marjaneh RM, 2019, J CELL PHYSIOL, V234, P2306, DOI 10.1002/jcp.27221
   Mathes C, 1998, J BIOL CHEM, V273, P25020, DOI 10.1074/jbc.273.39.25020
   Melendez AJ, 2008, BBA-PROTEINS PROTEOM, V1784, P66, DOI 10.1016/j.bbapap.2007.07.013
   Michalakis S, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19030749
   Mullershausen F, 2009, NAT CHEM BIOL, V5, P428, DOI 10.1038/nchembio.173
   Ogretmen B, 2018, NAT REV CANCER, V18, P33, DOI 10.1038/nrc.2017.96
   Ou JJ, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08902-x
   Parang B, 2016, METHODS MOL BIOL, V1422, P297, DOI 10.1007/978-1-4939-3603-8_26
   Pare L, 2008, BRIT J CANCER, V99, P1050, DOI 10.1038/sj.bjc.6604671
   Reuschlein AK, 2019, GLIA, V67, P1625, DOI 10.1002/glia.23622
   Soong R, 2008, ANN ONCOL, V19, P915, DOI 10.1093/annonc/mdm599
   Spiegel S, 2003, NAT REV MOL CELL BIO, V4, P397, DOI 10.1038/nrm1103
   Stepanovska B, 2020, PHARMACOL RES, V154, DOI 10.1016/j.phrs.2019.02.009
   Straub SV, 2004, BIOL RES, V37, P593
   Suzuki A, 2000, BIOCHEM BIOPH RES CO, V275, P572, DOI 10.1006/bbrc.2000.3318
   Thorn A, 2012, NUCLEIC ACIDS RES, V40, P8733, DOI 10.1093/nar/gks614
   Van Triest B, 2000, ANN ONCOL, V11, P385, DOI 10.1023/A:1008351221345
   VILLA A, 1993, J CELL BIOL, V121, P1041, DOI 10.1083/jcb.121.5.1041
   Wang H, 2018, BIOMED ENVIRON SCI, V31, P561, DOI 10.3967/bes2018.077
   Wu HB, 2017, AUTOPHAGY, V13, P1528, DOI 10.1080/15548627.2017.1336277
   Wu QB, 2018, MOL CLIN ONCOL, V8, P523, DOI 10.3892/mco.2018.1578
   Wu RT, 2016, CANCER RES, V76, P6362, DOI 10.1158/0008-5472.CAN-16-1306
   Zhang YH, 2020, PHARMACOL RES, V155, DOI 10.1016/j.phrs.2020.104717
NR 42
TC 1
Z9 1
U1 2
U2 5
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1671-4083
EI 1745-7254
J9 ACTA PHARMACOL SIN
JI Acta Pharmacol. Sin.
PD MAR
PY 2021
VL 42
IS 3
BP 460
EP 469
DI 10.1038/s41401-020-0460-0
EA JUL 2020
PG 10
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry; Pharmacology & Pharmacy
GA QP8BK
UT WOS:000546883600001
PM 32647340
OA Green Published
DA 2022-04-25
ER

PT J
AU Qu, JY
   Lin, ZH
AF Qu, Junyan
   Lin, Zhenghong
TI Autophagy Regulation by Crosstalk between miRNAs and Ubiquitination
   System
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Review
DE microRNAs; E3 ubiquitin ligases; deubiquitinases; autophagy
ID GROWTH-FACTOR-BETA; E3 LIGASE MARCH7; HEPATOCELLULAR-CARCINOMA;
   DEUBIQUITINATING ENZYMES; CANCER PROGRESSION; CELL-PROLIFERATION;
   PROMOTES AUTOPHAGY; COLORECTAL-CANCER; MULIBREY NANISM; DOWN-REGULATION
AB MicroRNAs (miRNAs) are non-coding single-stranded RNA molecules encoded by endogenous genes with ~22 nucleotides which are involved in the regulation of post-transcriptional gene expression. Ubiquitination and deubiquitination are common post-translational modifications in eukaryotic cells and important pathways in regulating protein degradation and signal transduction, in which E3 ubiquitin ligases and deubiquitinases (DUBs) play a decisive role. MiRNA and ubiquitination are involved in the regulation of most biological processes, including autophagy. Furthermore, in recent years, the direct interaction between miRNA and E3 ubiquitin ligases or deubiquitinases has attracted much attention, and the cross-talk between miRNA and ubiquitination system has been proved to play key regulatory roles in a variety of diseases. In this review, we summarized the advances in autophagy regulation by crosstalk between miRNA and E3 ubiquitin ligases or deubiquitinases.
C1 [Qu, Junyan; Lin, Zhenghong] Chongqing Univ, Sch Life Sci, Chongqing 401331, Peoples R China.
RP Lin, ZH (corresponding author), Chongqing Univ, Sch Life Sci, Chongqing 401331, Peoples R China.
EM qujunyan1229@yeah.net; zhenghonglin@cqu.edu.cn
OI Lin, Zhenghong/0000-0002-6354-0042
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [82172888, 31571454]; Natural Science
   Foundation Project of CQ CSTCNatural Science Foundation Project of CQ
   CSTC [cstc2020jcyj-msxmX0154]
FX This work was supported by the National Natural Science Foundation of
   China (Grant No. 82172888 and 31571454) and Natural Science Foundation
   Project of CQ CSTC (Grant cstc2020jcyj-msxmX0154).
CR Abrahamsen H, 2012, FEBS LETT, V586, P1584, DOI 10.1016/j.febslet.2012.04.046
   Akkoc Y, 2020, BBA-MOL CELL RES, V1867, DOI 10.1016/j.bbamcr.2020.118662
   Alers S, 2012, MOL CELL BIOL, V32, P2, DOI 10.1128/MCB.06159-11
   Ali Syeda Z, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21051723
   Ambros V, 2001, CELL, V107, P823, DOI 10.1016/S0092-8674(01)00616-X
   Aredia F, 2013, FUTURE MED CHEM, V5, P1009, DOI 10.4155/fmc.13.85
   Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002
   Barwari T, 2016, J AM COLL CARDIOL, V68, P2577, DOI 10.1016/j.jacc.2016.09.945
   Bentwich I, 2005, FEBS LETT, V579, P5904, DOI 10.1016/j.febslet.2005.09.040
   Berndsen CE, 2014, NAT STRUCT MOL BIOL, V21, P301, DOI 10.1038/nsmb.2780
   Bharathy S, 2008, CANCER RES, V68, P1656, DOI 10.1158/0008-5472.CAN-07-5089
   Bhatnagar S, 2014, NATURE, V516, P116, DOI 10.1038/nature13955
   Botti-Millet J, 2016, AM J PHYSIOL-CELL PH, V311, pC351, DOI 10.1152/ajpcell.00129.2016
   Bradley JR, 2001, ONCOGENE, V20, P6482, DOI 10.1038/sj.onc.1204788
   Brigant B, 2020, BONE, V137, DOI 10.1016/j.bone.2020.115393
   Brigant B, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20010067
   Brunetti L, 2019, INT J HEMATOL, V110, P150, DOI 10.1007/s12185-018-02578-7
   Bushati N, 2007, ANNU REV CELL DEV BI, V23, P175, DOI 10.1146/annurev.cellbio.23.090506.123406
   Che FF, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.571914
   Che FF, 2019, BIOSCIENCE REP, V39, DOI 10.1042/BSR20182502
   Chekulaeva M, 2009, CURR OPIN CELL BIOL, V21, P452, DOI 10.1016/j.ceb.2009.04.009
   Chen DC, 2019, ONCOGENE, V38, P6429, DOI 10.1038/s41388-019-0891-6
   Chen EJ, 2021, INT J BIOL SCI, V17, P781, DOI 10.7150/ijbs.52517
   Chen GH, 2017, BIOL CHEM, V398, P499, DOI 10.1515/hsz-2016-0211
   Chen ZH, 2017, AUTOPHAGY, V13, P1244, DOI 10.1080/15548627.2017.1310789
   Chen ZH, 2017, EMBO REP, V18, P495, DOI 10.15252/embr.201643309
   Cornelissen T, 2014, HUM MOL GENET, V23, P5227, DOI 10.1093/hmg/ddu244
   Davalos V, 2010, CURR OPIN ONCOL, V22, P35, DOI 10.1097/CCO.0b013e328333dcbb
   Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4
   Deshaies RJ, 2009, ANNU REV BIOCHEM, V78, P399, DOI 10.1146/annurev.biochem.78.101807.093809
   Dong SM, 2018, ONCOTARGETS THER, V11, P7935, DOI 10.2147/OTT.S183303
   Dou Y, 2018, CURR NEUROPHARMACOL, V16, P1306, DOI 10.2174/1570159X16666180412094655
   El Magraoui F, 2015, CELLS-BASEL, V4, P596, DOI 10.3390/cells4040596
   Eletr ZM, 2014, BBA-MOL CELL RES, V1843, P114, DOI 10.1016/j.bbamcr.2013.06.027
   Erpapazoglou Zoi, 2014, Cells, V3, P1027, DOI 10.3390/cells3041027
   Fabian MR, 2010, ANNU REV BIOCHEM, V79, P351, DOI 10.1146/annurev-biochem-060308-103103
   Falini B, 2015, BRIT J HAEMATOL, V170, P305, DOI 10.1111/bjh.13409
   Feng LJ, 2017, AUTOPHAGY, V13, P686, DOI 10.1080/15548627.2017.1280207
   Filipowicz W, 2008, NAT REV GENET, V9, P102, DOI 10.1038/nrg2290
   Finley D, 2009, ANNU REV BIOCHEM, V78, P477, DOI 10.1146/annurev.biochem.78.081507.101607
   Friedman JM, 2009, SWISS MED WKLY, V139, P466, DOI smw-12794
   Fu XT, 2018, CANCER LETT, V412, P108, DOI 10.1016/j.canlet.2017.10.012
   Gao BX, 2008, EMBO REP, V9, P480, DOI 10.1038/embor.2008.37
   Gao J, 2015, ONCOGENE, V34, P4142, DOI 10.1038/onc.2014.348
   Grady WM, 2005, CLIN CANCER RES, V11, P3151, DOI 10.1158/1078-0432.CCR-05-0414
   Gu H, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8112
   Han J, 2020, SCIENCE, V370, P1432, DOI 10.1126/science.abc9546
   Han J, 2009, CELL, V136, P75, DOI 10.1016/j.cell.2008.10.053
   Hatakeyama S, 2017, TRENDS BIOCHEM SCI, V42, P297, DOI 10.1016/j.tibs.2017.01.002
   Hatakeyama S, 2011, NAT REV CANCER, V11, P792, DOI 10.1038/nrc3139
   He H, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2013.533
   He Y, 2019, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01509
   Heath EM, 2017, LEUKEMIA, V31, P798, DOI 10.1038/leu.2017.30
   Hosokawa N, 2009, MOL BIOL CELL, V20, P1981, DOI 10.1091/mbc.E08-12-1248
   Hu CE, 2017, MOL MED REP, V15, P1057, DOI 10.3892/mmr.2017.6125
   Hu JG, 2018, CELL PHYSIOL BIOCHEM, V47, P654, DOI 10.1159/000490020
   Hu JG, 2017, AUTOPHAGY, V13, P333, DOI 10.1080/15548627.2016.1256520
   Hu JG, 2015, ONCOTARGET, V6, P12174, DOI 10.18632/oncotarget.3650
   Huang LM, 2018, CELL PHYSIOL BIOCHEM, V47, P747, DOI 10.1159/000490027
   Ichimura Y, 2000, NATURE, V408, P488, DOI 10.1038/35044114
   Jarome TJ, 2018, NEUROSCIENTIST, V24, P639, DOI 10.1177/1073858418762317
   Jiang JX, 2015, BIOCHEM BIOPH RES CO, V464, P1120, DOI 10.1016/j.bbrc.2015.07.089
   Jiang SX, 2019, J CELL MOL MED, V23, P630, DOI 10.1111/jcmm.13968
   Jin FF, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.461
   Jing ZF, 2019, MOL ONCOL, V13, P2079, DOI 10.1002/1878-0261.12545
   Kabeya Y, 2004, J CELL SCI, V117, P2805, DOI 10.1242/jcs.01131
   Kallijarvi J, 2005, EXP CELL RES, V308, P146, DOI 10.1016/j.yexcr.2005.04.001
   Kallijarvi J, 2002, AM J HUM GENET, V70, P1215, DOI 10.1086/340256
   Karbowski M, 2007, J CELL BIOL, V178, P71, DOI 10.1083/jcb.200611064
   Killackey SA, 2020, J CELL BIOL, V219, DOI 10.1083/jcb.202004029
   Kim D, 2017, J CELL PHYSIOL, V232, P3664, DOI 10.1002/jcp.25841
   Klionsky DJ, 2013, J INNATE IMMUN, V5, P427, DOI 10.1159/000351979
   Kotani T, 2018, P NATL ACAD SCI USA, V115, P10363, DOI 10.1073/pnas.1806727115
   Krol J, 2010, NAT REV GENET, V11, P597, DOI 10.1038/nrg2843
   Lamothe B, 2008, J BIOL CHEM, V283, P24871, DOI 10.1074/jbc.M802749200
   Lee HJ, 2006, GENE EXPR PATTERNS, V6, P277, DOI 10.1016/j.modgep.2005.07.007
   Li CG, 2021, CRIT REV ONCOL HEMAT, V157, DOI 10.1016/j.critrevonc.2020.103124
   Li JD, 2020, CANCER CELL INT, V20, DOI 10.1186/s12935-020-01517-z
   Li M, 2016, BIOCHEM BIOPH RES CO, V471, P361, DOI 10.1016/j.bbrc.2016.02.021
   Li ST, 2014, P NATL ACAD SCI USA, V111, P6970, DOI 10.1073/pnas.1322545111
   Liang HH, 2020, AUTOPHAGY, V16, P1077, DOI 10.1080/15548627.2019.1659610
   Liang JX, 2014, ONCOL REP, V32, P2726, DOI 10.3892/or.2014.3508
   Lin CZ, 2018, KAOHSIUNG J MED SCI, V34, P547, DOI 10.1016/j.kjms.2018.05.003
   Lin ZH, 2012, MOL CELL, V46, P484, DOI 10.1016/j.molcel.2012.03.024
   Ling SB, 2012, CELL MOL BIOL, V58, P1803, DOI 10.1170/213
   Liu H, 2015, CANCER LETT, V361, P218, DOI 10.1016/j.canlet.2015.03.001
   Liu JG, 2018, ONCOL REP, V39, P1631, DOI 10.3892/or.2018.6268
   Liu Y, 2016, MOL MED REP, V14, P2860, DOI 10.3892/mmr.2016.5574
   Liu YL, 2010, J GASTROEN HEPATOL, V25, P1800, DOI 10.1111/j.1440-1746.2010.06352.x
   Luo XB, 2013, J CLIN INVEST, V123, P1939, DOI 10.1172/JCI62185
   Lv X, 2019, J CELL BIOCHEM, V120, P18871, DOI 10.1002/jcb.29207
   Mazure NM, 2010, CURR OPIN CELL BIOL, V22, P177, DOI 10.1016/j.ceb.2009.11.015
   Melo-Cardenas J, 2016, ONCOTARGET, V7, P44848, DOI 10.18632/oncotarget.8602
   Militello RD, 2011, CURR MOL MED, V11, P197
   Mizushima N, 2011, CELL, V147, P728, DOI 10.1016/j.cell.2011.10.026
   Mizushima N, 2011, ANNU REV CELL DEV BI, V27, P107, DOI 10.1146/annurev-cellbio-092910-154005
   Mohr AM, 2015, SEMIN LIVER DIS, V35, P3, DOI 10.1055/s-0034-1397344
   Muthukumarana PADS, 2006, INT IMMUNOPHARMACOL, V6, P1993, DOI 10.1016/j.intimp.2006.09.015
   Nakamura N, 2006, EMBO REP, V7, P1019, DOI 10.1038/sj.embor.7400790
   Nandi D, 2006, J BIOSCIENCES, V31, P137, DOI 10.1007/BF02705243
   Nathan JA, 2008, TRAFFIC, V9, P1130, DOI 10.1111/j.1600-0854.2008.00747.x
   Nathan JA, 2009, EXP CELL RES, V315, P1593, DOI 10.1016/j.yexcr.2008.10.026
   Nazio F, 2013, NAT CELL BIOL, V15, P406, DOI 10.1038/ncb2708
   Nijman SMB, 2005, CELL, V123, P773, DOI 10.1016/j.cell.2005.11.007
   Ning J, 2012, EUR J HISTOCHEM, V56, P289, DOI 10.4081/ejh.2012.e46
   Noda NN, 2011, MOL CELL, V44, P462, DOI 10.1016/j.molcel.2011.08.035
   Pan XF, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1660-8
   Park YY, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.142
   Pasquinelli AE, 2005, CURR OPIN GENET DEV, V15, P200, DOI 10.1016/j.gde.2005.01.002
   Proikas-Cezanne T, 2015, J CELL SCI, V128, P207, DOI 10.1242/jcs.146258
   Pu JY, 2017, ARCH VIROL, V162, P3645, DOI 10.1007/s00705-017-3516-9
   Qin QY, 2016, HYPERTENSION, V67, P107, DOI 10.1161/HYPERTENSIONAHA.115.06062
   Qiu GL, 2015, FEBS LETT, V589, P2034, DOI 10.1016/j.febslet.2015.05.042
   Qu JY, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22115566
   Qu JY, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22041526
   Rajendran P, 2019, J CELL PHYSIOL, V234, P21485, DOI 10.1002/jcp.28895
   Rogov V, 2014, MOL CELL, V53, P167, DOI 10.1016/j.molcel.2013.12.014
   Rubinsztein DC, 2011, CELL, V146, P682, DOI 10.1016/j.cell.2011.07.030
   Schwarz DS, 2003, CELL, V115, P199, DOI 10.1016/S0092-8674(03)00759-1
   Shabalina SA, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-4-105
   Sheu-Gruttadauria J, 2018, CELL, V173, P946, DOI 10.1016/j.cell.2018.02.051
   Shi CY, 2020, SCIENCE, V370, P1431, DOI 10.1126/science.abc9359
   Shirakabe A, 2016, CIRCULATION, V133, P1249, DOI 10.1161/CIRCULATIONAHA.115.020502
   Simonson B, 2015, MINI-REV MED CHEM, V15, P467, DOI 10.2174/1389557515666150324123208
   Spratt DE, 2014, BIOCHEM J, V458, P421, DOI 10.1042/BJ20140006
   Strappazzon F, 2020, PROG MOL BIOL TRANSL, V172, P37, DOI 10.1016/bs.pmbts.2020.03.006
   Sugiura A, 2013, MOL CELL, V51, P20, DOI 10.1016/j.molcel.2013.04.023
   Sui X, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.350
   Sun JL, 2015, DIAGN PATHOL, V10, DOI 10.1186/s13000-015-0309-x
   Swatek KN, 2016, CELL RES, V26, P399, DOI 10.1038/cr.2016.39
   Tan ZY, 2018, ONCOGENE, V37, P5403, DOI 10.1038/s41388-018-0344-7
   Tang YT, 2021, FASEB J, V35, DOI 10.1096/fj.201903183RRR
   Tian F, 2020, BIOL RES, V53, DOI 10.1186/s40659-020-00275-6
   Trang P, 2008, Oncogene, V27 Suppl 2, pS52, DOI 10.1038/onc.2009.353
   Walsh MC, 2015, IMMUNOL REV, V266, P72, DOI 10.1111/imr.12302
   Wang B, 2018, AM J CANCER RES, V8, P2518
   Wang J, 2018, CELL BIOL INT, V42, P1503, DOI 10.1002/cbin.11035
   Wang W, 2018, AUTOPHAGY, V14, P1574, DOI 10.1080/15548627.2018.1463120
   Wang XL, 2016, ONCOTARGET, V7, P81527, DOI 10.18632/oncotarget.13131
   Wang Y L, 2016, Genet Mol Res, V15, DOI 10.4238/gmr15049070
   Wang YQ, 2015, AUTOPHAGY, V11, P595, DOI 10.1080/15548627.2015.1034408
   Weber J, 2019, FRONT PHYSIOL, V10, DOI 10.3389/fphys.2019.00370
   Xie ZP, 2007, NAT CELL BIOL, V9, P1102, DOI 10.1038/ncb1007-1102
   Xiong H, 2017, ONCOGENE, V36, P3528, DOI 10.1038/onc.2016.521
   Xu S, 2016, MOL BIOL CELL, V27, P349, DOI 10.1091/mbc.E15-09-0678
   Yamasaki S, 2007, EMBO J, V26, P113, DOI 10.1038/sj.emboj.7601490
   Yan H, 2019, METHODS, V167, P117, DOI 10.1016/j.ymeth.2019.05.004
   Yang DD, 2011, CELL BIOCHEM BIOPHYS, V61, P703, DOI 10.1007/s12013-011-9229-x
   Yang H, 2014, J EXP MED, V211, P2467, DOI 10.1084/jem.20140283
   Ye P, 2018, BIOMED PHARMACOTHER, V101, P219, DOI 10.1016/j.biopha.2018.02.066
   Yonashiro R, 2006, EMBO J, V25, P3618, DOI 10.1038/sj.emboj.7601249
   Yu L, 2020, ONCOGENE, V39, P4450, DOI 10.1038/s41388-020-1298-0
   Yu L, 2018, AUTOPHAGY, V14, P207, DOI 10.1080/15548627.2017.1378838
   Yu Y, 2012, AUTOPHAGY, V8, P853, DOI 10.4161/auto.20053
   Zang SZ, 2019, ONCOTARGETS THER, V12, P7551, DOI 10.2147/OTT.S212649
   Zhang L, 2018, J MED CHEM, V61, P6491, DOI 10.1021/acs.jmedchem.7b01684
   Zhao BC, 2019, ARCH MED SCI, V15, P498, DOI 10.5114/aoms.2018.73315
   Zhao HE, 2013, ONCOL REP, V29, P1027, DOI 10.3892/or.2013.2234
   Zhao TT, 2018, J CANCER, V9, P1349, DOI 10.7150/jca.22390
   Zheng N, 2017, ANNU REV BIOCHEM, V86, P129, DOI 10.1146/annurev-biochem-060815-014922
   Zhong Y, 2009, NAT CELL BIOL, V11, P468, DOI 10.1038/ncb1854
   Zhou L, 2016, ONCOTARGET, V7, P51943, DOI 10.18632/oncotarget.10460
   Zhou Q, 2021, ANTI-CANCER DRUG, V32, P376, DOI 10.1097/CAD.0000000000000979
   Zhu Y, 2012, NUCLEIC ACIDS RES, V40, P4615, DOI 10.1093/nar/gkr1278
   Zou J, 2017, AM J TRANSL RES, V9, P1357
   Zou Q, 2017, THERANOSTICS, V7, P2289, DOI 10.7150/thno.19439
   Zou TT, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22115754
NR 167
TC 0
Z9 0
U1 4
U2 4
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD NOV
PY 2021
VL 22
IS 21
AR 11912
DI 10.3390/ijms222111912
PG 18
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA WY3SE
UT WOS:000719199500001
PM 34769343
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Li, YZ
   Liu, Y
   Shi, FY
   Cheng, L
   She, JJ
AF Li, Yazhou
   Liu, Yang
   Shi, Feiyu
   Cheng, Liang
   She, Junjun
TI Knockdown of Rap1b Enhances Apoptosis and Autophagy in Gastric Cancer
   Cells via the PI3K/Akt/mTOR Pathway
SO ONCOLOGY RESEARCH
LA English
DT Article
DE Gastric cancer (GC); Rap1b; Autophagy; Apoptosis; PI3K/Akt/mTOR pathway
ID COLORECTAL-CARCINOMA; PROLIFERATION; EXPRESSION; INDUCTION; INVASION
AB Gastric cancer (GC) is the fourth most common malignancy and the second leading cause of cancer mortality around the world. However, the regulatory mechanisms of GC tumorigenesis and cancer cell motility are completely unknown. We investigated the role of a RAS-related protein (Rap1b) in the progression of GC. Our results showed that the expression of Rap1b is aberrantly upregulated in GC tissue samples and human GC cell lines, and the high expression of Rap1b indicated a positive correlation with poor prognosis in patients with GC. Inhibition of endogenous Rap1b dramatically reduced the cell cycle progression but strongly enhanced the apoptosis capacity of human GC cell lines MKN-28 and SGC-7901 cells compared with the control group. Western blotting assay showed that Rap1b inhibition resulted in a significant increase in the ratio of LC3-II to LC3-I, and the levels of p62 protein were decreased in both MKN-28 and SGC-7901 cells. Furthermore, PI3K/Akt/mTOR activation was found to be maintained in a low level in the normal gastric mucosal epithelial cells, while it was significantly upregulated in GC cells, which could be decreased by Rap1b inhibition. The PI3K inhibitor LY294002 was enhanced but activator insulin-like growth factor 1 (IGF-1) blocked the Rap1b silencing-induced enhancement of apoptosis and autophagy in MKN-28 and SGC-7901 cells. In conclusion, we demonstrate that Rap1b expression is aberrantly increased in GC, resulting in the inhibition of autophagy and apoptosis of GC cells by the PI3K/Akt/mTOR pathway. This might provide a new understanding and represent a novel therapeutic target for human GC.
C1 [Li, Yazhou] Hitech People Hosp, Dept Intervent Radiol, Baoji, Peoples R China.
   [Li, Yazhou; Shi, Feiyu; Cheng, Liang; She, Junjun] Xi An Jiao Tong Univ, Dept Gen Surg, Affiliated Hosp 1, Yanta Xi Rd 277, Xian 710061, Peoples R China.
   [Liu, Yang] Xi An Jiao Tong Univ, Honghui Hosp, Dept Orthopaed, Xian, Peoples R China.
RP She, JJ (corresponding author), Xi An Jiao Tong Univ, Dept Gen Surg, Affiliated Hosp 1, Yanta Xi Rd 277, Xian 710061, Peoples R China.
EM junjunshe063@hotmail.com
CR Balcer-Kubiczek E. K., 2009, MOL TARGETS GASTRIC
   Blankfield RP, 2002, NEW ENGL J MED, V346, P65
   Caldas C, 1999, J MED GENET, V36, P873
   de Martel C, 2013, GASTROENTEROL CLIN N, V42, P219, DOI 10.1016/j.gtc.2013.01.003
   Dunlop EA, 2014, SEMIN CELL DEV BIOL, V36, P121, DOI 10.1016/j.semcdb.2014.08.006
   Franke TF, 2003, ONCOGENE, V22, P8983, DOI 10.1038/sj.onc.1207115
   Guo HY, 2012, INT J BIOCHEM CELL B, V44, P1465, DOI 10.1016/j.biocel.2012.05.015
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Kumar D, 2014, CANCER LETT, V343, P179, DOI 10.1016/j.canlet.2013.10.003
   Lee HW, 2014, BMB REP, V47, P697, DOI 10.5483/BMBRep.2014.47.12.069
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Li B., 2016, MOL NEUROBIOL
   Lin KT, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms6917
   Liu M, 2014, INT J MOL MED, V33, P1451, DOI 10.3892/ijmm.2014.1713
   Mitra RS, 2003, ONCOGENE, V22, P6243, DOI 10.1038/sj.onc.1206534
   Park HS, 2011, J FOOD SCI, V76, pT77, DOI 10.1111/j.1750-3841.2011.02099.x
   Peng H, 2014, ONCOL REP, V31, P2055, DOI 10.3892/or.2014.3075
   Rasul A, 2012, ONCOL REP, V27, P1481, DOI 10.3892/or.2012.1694
   Sun L, 2008, J AM SOC NEPHROL, V19, P2293, DOI 10.1681/ASN.2008030336
   Tapia O, 2014, VIRCHOWS ARCH, V465, P25, DOI 10.1007/s00428-014-1588-4
   Vigen RA, 2012, GASTROENTEROLOGY, V142, pS628
   Wang D, 2012, J BIOSCIENCES, V37, P91, DOI 10.1007/s12038-011-9172-4
   Won KY, 2015, PATHOL RES PRACT, V211, P308, DOI 10.1016/j.prp.2014.11.005
   Xie B, 2013, CANCER CELL INT, V13, DOI 10.1186/1475-2867-13-18
   Yang Y., 2015, IEEE T PARALL DISTR, P1, DOI DOI 10.18632/0NC0TARGET.3970
   Ying JE, 2015, ONCOTARGETS THER, V8, P2427, DOI 10.2147/OTT.S88592
   Yu L., 2007, J IMMUNOL, V179, P8322
   Zhang L, 2014, TOXICOL LETT, V228, P248, DOI 10.1016/j.toxlet.2014.05.015
   Zhang MX, 2012, FEBS LETT, V586, P3508, DOI 10.1016/j.febslet.2012.08.007
NR 29
TC 23
Z9 25
U1 0
U2 2
PU COGNIZANT COMMUNICATION CORP
PI PUTNAM VALLEY
PA 18 PEEKSKILL HOLLOW RD, PO BOX 37, PUTNAM VALLEY, NY 10579 USA
SN 0965-0407
EI 1555-3906
J9 ONCOL RES
JI Oncol. Res.
PY 2016
VL 24
IS 5
BP 287
EP 293
DI 10.3727/096504016X14648701447779
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA DX5BQ
UT WOS:000384395200001
PM 27712585
OA Green Published
DA 2022-04-25
ER

PT J
AU Huang, KQ
   Liu, DX
AF huang, Keqiang
   liu, Dongxu
TI Targeting non-canonical autophagy overcomes erlotinib resistance in
   tongue cancer
SO TUMOR BIOLOGY
LA English
DT Article
DE Autophagy; Chemotherapeutic resistance; Erlotinib; ATG5
ID GROWTH-FACTOR RECEPTOR; CELL LUNG-CANCER; TYROSINE KINASE INHIBITORS;
   COLORECTAL-CANCER; ENZALUTAMIDE RESISTANCE; PROSTATE-CANCER;
   NECK-CANCER; EGFR; GENE; PHOSPHORYLATION
AB Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) frequently occurs in many human cancers and hampers their therapeutic use. A large body of evidence has demonstrated the pro-survival role of autophagy in many human cancers. However, whether autophagy is involved in the induction of erlotinib resistance in tongue squamous cell carcinoma (TSCC) remains unknown. In this report, we found that autophagy prior to or induced by erlotinib treatment plays an important role in erlotinib resistance in tongue cancer cells. Using LC3 transfection, we observed that autophagy is upregulated and further induced when treated with erlotinib. Moreover, we found that autophagy plays a cytoprotective role by MTT analysis of the cell viability in TSCCs when treated with rapamycin or hydroxychloroquine (HCQ) in combination with erlotinib. However, 3-methyladenine (3-MA) did not influence the autophagy. Then, through siRNA technology and WB, we found that erlotinib-induced autophagy is mediated by ATG5 but not Beclin1. Also, knockdown of ATG5 significantly decreased the erlotinib resistance and knockdown of Beclin1 did not affect the sensitivity to erlotinib in TSCCs. Taken together, this indicates the critical role of non-canonical autophagy in erlotinib resistance in TSCCs.
C1 [huang, Keqiang] Liaoning Med Univ, Sch Stomatol, 3-40 Songpo Rd, Jinzhou 121000, Liaoning, Peoples R China.
   [huang, Keqiang; liu, Dongxu] Shandong Univ, Shandong Prov Key Lab Oral Tissue Regenerat, Sch Stomatol, Jinan 250012, Peoples R China.
RP Liu, DX (corresponding author), Shandong Univ, Shandong Prov Key Lab Oral Tissue Regenerat, Sch Stomatol, Jinan 250012, Peoples R China.
EM liudongxu@sdu.edu.cn
CR Atula S, 1996, ARCH OTOLARYNGOL, V122, P1313
   Burtness B, 2013, LANCET ONCOL, V14, pE302, DOI 10.1016/S1470-2045(13)70085-8
   Caiazza F, 2015, BIOMARK MED, V9, P363, DOI [10.2217/BMM.15.5, 10.2217/bmm.15.5]
   Cappuzzo F, 2005, J CLIN ONCOL, V23, P5007, DOI 10.1200/JCO.2005.09.111
   Chen G, 2012, BMC MED, V10, DOI 10.1186/1741-7015-10-28
   Ciardiello F, 2001, CLIN CANCER RES, V7, P1459
   Donev IS, 2011, CLIN CANCER RES, V17, P2260, DOI 10.1158/1078-0432.CCR-10-1993
   Feaver CP, 1999, ORAL ONCOL, V35, P450
   Gusenbauer S, 2013, ONCOGENE, V32, P3846, DOI 10.1038/onc.2012.396
   Haddad RI, 2008, NEW ENGL J MED, V359, P1143, DOI 10.1056/NEJMra0707975
   Ishiguro Y, 2013, ONCOTARGET, V4, P550, DOI 10.18632/oncotarget.939
   Larsen AK, 2011, PHARMACOL THERAPEUT, V131, P80, DOI 10.1016/j.pharmthera.2011.03.012
   Lindeman N, 2014, PATHOLOGY S2, V46, pS1
   Lindzen M, 2012, ONCOGENE, V31, P3505, DOI 10.1038/onc.2011.518
   Liu CF, 2014, CLIN CANCER RES, V20, P3198, DOI 10.1158/1078-0432.CCR-13-3296
   Lu Z, 2008, J CLIN INVEST, V118, P3917, DOI 10.1172/JCI35512
   Martin TD, 2014, MOL CELL, V53, P209, DOI 10.1016/j.molcel.2013.12.004
   Messersmith WA, 2008, NEW ENGL J MED, V359, P1834, DOI 10.1056/NEJMe0806778
   Metzger B, 2011, BMC MED GENET, V12, DOI 10.1186/1471-2350-12-144
   Mlcochova J, 2013, J CANCER RES CLIN, V139, P1615, DOI 10.1007/s00432-013-1470-9
   Mueller KL, 2012, TRANSL ONCOL, V5, P327, DOI 10.1593/tlo.12163
   Nguyen HG, 2014, ONCOGENE, V33, P4521, DOI 10.1038/onc.2014.25
   Sequist LV, 2008, J CLIN ONCOL, V26, P2442, DOI 10.1200/JCO.2007.14.8494
   Shien K, 2014, ACTA MED OKAYAMA, V68, P191
   Tan DSW, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-679
   Tsai J, 2008, P NATL ACAD SCI USA, V105, P3041, DOI 10.1073/pnas.0711741105
   Wang RC, 2012, SCIENCE, V338, P956, DOI 10.1126/science.1225967
   Yoshida T, 2014, CLIN CANCER RES, V20, P4059, DOI 10.1158/1078-0432.CCR-13-1559
   Zhang S, 2013, ONCOL REP, V29, P1819, DOI 10.3892/or.2013.2309
NR 29
TC 10
Z9 14
U1 1
U2 7
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD JUL
PY 2016
VL 37
IS 7
BP 9625
EP 9633
DI 10.1007/s13277-015-4689-z
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA DU4HU
UT WOS:000382174500113
PM 26797786
DA 2022-04-25
ER

PT J
AU Zhang, W
   Popovich, DG
AF Zhang, Wei
   Popovich, David G.
TI Effect of soyasapogenol a and soyasapogenol B concentrated extracts on
   Hep-G2 cell proliferation and apoptosis
SO JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY
LA English
DT Article
DE soyasaponins; soyasapogenol; apoptosis; Hep-G2
ID COLON-CANCER CELLS; LIQUID-CHROMATOGRAPHY; TRITERPENOID SAPONINS;
   HELA-CELLS; SOYASAPONINS; INDUCTION; MACROAUTOPHAGY; GINSENOSIDES;
   GINSENG
AB The growth inhibition and the induction of apoptosis brought about by soyasaponins extracted from soy flour (Glycine max (L.)) and concentrated for soyasapogenols A and B formed by hydrolysis were tested for cytoactivity in the human hepatocellular carcinoma cell line Hep-G2. Concentrated soyasapogenol A (SG-A) and soyasapogenol B (SG-B) extracts contained approximately 69.3% and 46.2% of their respective aglycones (soyasapogenols) assessed by HPLC and ESI-MS, while the soyasaponin extract (TS), derived from crude methanol extraction, did not contain any detectable amounts of SG-A or SG-B. An MTT viability assay showed that all three extracts had an effect on Hep-G2 proliferation in a dose-response manner with 72 h LC50 values of 0.594 +/- 0.021 mg/mL for TS, 0.052 +/- 0.011 mg/mL for SG-A, and 0.128 +/- 0.005 mg/mL for SG-B. Apoptotic cells were determined by flow cytometry cell cycle analysis and confocal laser scanning microscopy (CLSM). Cell cycle analysis indicated a significant (P < 0.05) greater sub-G1 buildup of apoptotic cells at 24 h (25.63 +/- 2.1%) and 72 h (47.1 +/- 3.5%) for the SG-A extract compared to SG-B, whereas the TS extract produced only a minor buildup of sub-G1 cells. CLSM confirmed a morphological change of all treatments after 24 h, at the respective LC50 concentrations. These results show that the samples that contained mainly soyasapogenols A and B showed a greater ability to inhibit proliferation of cultured Hep-G2 when compared to a total soyasaponin extract that did not contain any soyasapogenols.
C1 [Zhang, Wei; Popovich, David G.] Natl Univ Singapore, Dept Chem, Singapore 117543, Singapore.
RP Popovich, DG (corresponding author), Natl Univ Singapore, Dept Chem, 3 Sci Dr 3, Singapore 117543, Singapore.
EM chmpdg@nus.edu.sg
RI Zhang, Wei/G-8229-2016
OI Popovich, David/0000-0002-8630-320X; Zhang, Wei/0000-0003-2691-2721
CR Akao T, 1998, J PHARM PHARMACOL, V50, P1155, DOI 10.1111/j.2042-7158.1998.tb03327.x
   Chang WW, 2006, BIOCHEM BIOPH RES CO, V341, P614, DOI 10.1016/j.bbrc.2005.12.216
   Cheeke P.R., 2000, J ANIM SCI, V77, P1, DOI DOI 10.2527/JAS2000.00218812007700ES0009X
   Darzynkiewicz Z, 1996, ANN NY ACAD SCI, V803, P93, DOI 10.1111/j.1749-6632.1996.tb26379.x
   Ellington AA, 2006, CARCINOGENESIS, V27, P298, DOI 10.1093/carcin/bgi214
   Ellington AA, 2005, CARCINOGENESIS, V26, P159, DOI 10.1093/carcin/bgh297
   Guclu-Ustundag O, 2007, CRIT REV FOOD SCI, V47, P231, DOI 10.1080/10408390600698197
   Gurfinkel DM, 2005, INT J FOOD SCI NUTR, V56, P501, DOI 10.1080/09637480500460601
   Gurfinkel DM, 2003, NUTR CANCER, V47, P24, DOI 10.1207/s15327914nc4701_3
   Jin MC, 2006, J CHROMATOGR A, V1108, P31, DOI 10.1016/j.chroma.2005.12.099
   Kinjo J, 2003, BIOL PHARM BULL, V26, P1357, DOI 10.1248/bpb.26.1357
   Miyao H, 1998, PLANTA MED, V64, P5, DOI 10.1055/s-2006-957355
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4
   NOGUCH PD, 1991, CURRENT PROTOCOLS IM
   Popovich DG, 2004, PHYTOCHEMISTRY, V65, P337, DOI 10.1016/j.phytochem.2003.11.020
   Popovich DG, 2002, ARCH BIOCHEM BIOPHYS, V406, P1, DOI 10.1016/S0003-9861(02)00398-3
   Rowlands JC, 2002, FOOD CHEM TOXICOL, V40, P1767, DOI 10.1016/S0278-6915(02)00181-3
   Xiao JX, 2007, EXP TOXICOL PATHOL, V59, P35, DOI 10.1016/j.etp.2007.02.004
   Xiao JX, 2007, TOXICOL IN VITRO, V21, P820, DOI 10.1016/j.tiv.2007.01.025
   Yang YW, 2007, CHROMATOGRAPHIA, V65, P555, DOI 10.1365/s10337-007-0196-8
   Yoshiki Y, 1998, BIOSCI BIOTECH BIOCH, V62, P2291, DOI 10.1271/bbb.62.2291
   Zhang XW, 1999, ANTI-CANCER DRUG, V10, P569, DOI 10.1097/00001813-199907000-00009
   [No title captured]
NR 23
TC 44
Z9 51
U1 0
U2 13
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0021-8561
EI 1520-5118
J9 J AGR FOOD CHEM
JI J. Agric. Food Chem.
PD APR 23
PY 2008
VL 56
IS 8
BP 2603
EP 2608
DI 10.1021/jf0731550
PG 6
WC Agriculture, Multidisciplinary; Chemistry, Applied; Food Science &
   Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Agriculture; Chemistry; Food Science & Technology
GA 290EQ
UT WOS:000255106500009
PM 18361499
DA 2022-04-25
ER

PT J
AU Jung, H
   Seo, SB
AF Jung, Hyeonsoo
   Seo, Sang-Beom
TI Histone lysine demethylase 3B (KDM3B) regulates the propagation of
   autophagy via transcriptional activation of autophagy-related genes
SO PLOS ONE
LA English
DT Article
ID TRANS-RETINOIC ACID; EPIGENETIC REGULATION; METHYLTRANSFERASE;
   INHIBITION; VCP/P97; CANCER; MTOR; MECHANISM; DISEASE; PROTEIN
AB Autophagy, a self-degradative physiological process, is critical for homeostasis maintenance and energy source balancing in response to various stresses, including nutrient deprivation. It is a highly conserved catabolic process in eukaryotes and is indispensable for cell survival as it involves degradation of unessential or excessive components and their subsequent recycling as building blocks for the synthesis of necessary molecules. Although the dysregulation of autophagy has been reported to broadly contribute to various diseases, including cancers and neurodegenerative diseases, the molecular mechanisms underlying the epigenetic regulation of autophagy are poorly elucidated. Here, we report that the level of lysine demethylase 3B (KDM3B) increases in nutrient-deprived HCT116 cells, a colorectal carcinoma cell line, resulting in transcriptional activation of the autophagy-inducing genes. KDM3B was found to enhance the transcription by demethylating H3K9me2 on the promoter of these genes. Furthermore, we observed that the depletion of KDM3B inhibited the autophagic flux in HCT116 cells. Collectively, these data suggested the critical role of KDM3B in the regulation of autophagy-related genes via H3K9me2 demethylation and induction of autophagy in nutrient-starved HCT116 cells.
C1 [Jung, Hyeonsoo; Seo, Sang-Beom] Chung Ang Univ, Coll Nat Sci, Dept Life Sci, Seoul, South Korea.
RP Seo, SB (corresponding author), Chung Ang Univ, Coll Nat Sci, Dept Life Sci, Seoul, South Korea.
EM sangbs@cau.ac.kr
OI Seo, Sang Beom/0000-0003-4709-6022
FU National Research Foundation of Korea (NRF) - Ministry of Science, ICT &
   Future Planning [NRF-2019R1A4A2001609, NRF-2017R1A2B4004407]
FX This work was supported by the National Research Foundation of Korea
   (NRF), funded by the Ministry of Science, ICT & Future Planning
   (NRF-2019R1A4A2001609 and NRF-2017R1A2B4004407) to Sang Beom Seo. The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR An MJ, 2019, BIOCHEM BIOPH RES CO, V508, P576, DOI 10.1016/j.bbrc.2018.11.179
   Axe EL, 2008, J CELL BIOL, V182, P685, DOI 10.1083/jcb.200803137
   Baek SH, 2017, MOL CELL, V65, P781, DOI 10.1016/j.molcel.2016.12.027
   Chen S, 2017, NUCLEIC ACIDS RES, V45, P1144, DOI 10.1093/nar/gkw1025
   Dawson MA, 2012, CELL, V150, P12, DOI 10.1016/j.cell.2012.06.013
   de Narvajas AAM, 2013, MOL CELL BIOL, V33, P3983, DOI 10.1128/MCB.00813-13
   Fimia GM, 2007, NATURE, V447, P1121, DOI 10.1038/nature05925
   Fullgrabe J, 2013, NATURE, V500, P468, DOI 10.1038/nature12313
   Hippert MM, 2006, CANCER RES, V66, P9349, DOI 10.1158/0008-5472.CAN-06-1597
   Hirabayashi M, 2001, CELL DEATH DIFFER, V8, P977, DOI 10.1038/sj.cdd.4400907
   Ichimura Y, 2010, SEMINARS IMMUNOPATHO
   Jung H, 2017, SCI REP-UK, V7, DOI 10.1038/srep46182
   Kang JY, 2018, FASEB J, V32, P5737, DOI 10.1096/fj.201800242R
   Kim JY, 2012, MOL CELL BIOL, V32, P2917, DOI 10.1128/MCB.00133-12
   Kim YC, 2015, J CLIN INVEST, V125, P25, DOI 10.1172/JCI73939
   Kuendgen A, 2006, CANCER-AM CANCER SOC, V106, P112, DOI 10.1002/cncr.21552
   Levine B, 2007, NATURE, V446, P745, DOI 10.1038/446745a
   Levy JMM, 2017, NAT REV CANCER, V17, P528, DOI 10.1038/nrc.2017.53
   Levy JMM, 2014, CANCER DISCOV, V4, P773, DOI 10.1158/2159-8290.CD-14-0049
   LI J, 2017, NATURE COMMUNICATION, V8, DOI DOI 10.1038/NCOMMS1514628440295
   Liu ZZ, 2014, CANCER CELL, V26, P106, DOI 10.1016/j.ccr.2014.05.015
   Marango J, 2008, BLOOD, V111, P3145, DOI 10.1182/blood-2007-06-092122
   Marino G, 2014, NAT REV MOL CELL BIO, V15, P81, DOI 10.1038/nrm3735
   Martinet W, 2009, CLIN SCI, V116, P697, DOI 10.1042/CS20080508
   Mauthe M, 2018, AUTOPHAGY, V14, P1435, DOI 10.1080/15548627.2018.1474314
   Maycotte P, 2014, CANCER RES, V74, P2579, DOI 10.1158/0008-5472.CAN-13-3470
   Meyer H., 2014, VCP P97 SYSTEM GLANC
   Meyer H, 2012, NAT CELL BIOL, V14, P117, DOI 10.1038/ncb2407
   Mizushima N, 2007, GENE DEV, V21, P2861, DOI 10.1101/gad.1599207
   Pyo JO, 2012, EXP MOL MED, V44, P73, DOI 10.3858/emm.2012.44.2.029
   Savickiene J, 2012, CELL MOL BIOL LETT, V17, P501, DOI 10.2478/s11658-012-0024-5
   Schenk T, 2012, NAT MED, V18, P605, DOI 10.1038/nm.2661
   Schneider JL, 2014, CURR OPIN GENET DEV, V26, P16, DOI 10.1016/j.gde.2014.04.003
   Shin HJR, 2016, NATURE, V534, P553, DOI 10.1038/nature18014
   Tam RCY, 2017, EXP CELL RES, V352, P304, DOI 10.1016/j.yexcr.2017.02.017
   Tresse E, 2010, AUTOPHAGY, V6, P217, DOI 10.4161/auto.6.2.11014
   Verma M., 2018, EPIGENETICS AGING LO, V4, P439
   Vilkaitis G, 2005, J BIOL CHEM, V280, P64, DOI 10.1074/jbc.M411126200
   Wang CW, 2003, MOL MED, V9, P65, DOI 10.1007/BF03402040
   Wei FZ, 2015, AUTOPHAGY, V11, P2309, DOI 10.1080/15548627.2015.1117734
   White E, 2015, J CLIN INVEST, V125, P42, DOI 10.1172/JCI73941
   Wu FQ, 2016, J HEPATOL, V65, P314, DOI 10.1016/j.jhep.2016.04.019
   Yin PQ, 2017, VIROL SIN, V32, P245, DOI 10.1007/s12250-016-3914-2
   Zhang H, 2018, AUTOPHAGY
NR 44
TC 1
Z9 1
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 27
PY 2020
VL 15
IS 7
AR e0236403
DI 10.1371/journal.pone.0236403
PG 14
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA MV9ND
UT WOS:000556674500048
PM 32716961
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Sun, J
   Feng, DJ
   Xi, HY
   Luo, JJ
   Zhou, ZW
   Liu, QH
   Chen, Y
   Shao, Q
AF Sun, Jie
   Feng, Dongju
   Xi, Huiyu
   Luo, Jiajing
   Zhou, Zewei
   Liu, Qinghuai
   Chen, Yun
   Shao, Qing
TI CD24 blunts the sensitivity of retinoblastoma to vincristine by
   modulating autophagy
SO MOLECULAR ONCOLOGY
LA English
DT Article
DE autophagy; CD24; lipid raft; retinoblastoma; vincristine
ID TUMOR-SUPPRESSOR; DRUG-RESISTANCE; CANCER CELLS; LIPID RAFTS;
   DOXORUBICIN RESISTANCE; MULTIDRUG-RESISTANCE; TARGETING AUTOPHAGY;
   COLORECTAL-CANCER; SIGNALING PATHWAY; CERVICAL-CANCER
AB Retinoblastoma (RB) is the most common childhood malignant intraocular tumor. The clinical efficacy of vincristine (VCR) in the treatment of RB is severely limited by drug resistance. Here, we found that CD24, a GPI-anchored protein, was overexpressed in human RB tissues and RB cell lines, and was associated with the sensitivity of RB cells in response to VCR therapy. We demonstrated that CD24 plays a critical role in impairing RB sensitivity to VCR via regulating autophagy. Mechanistically, CD24 recruits PTEN to the lipid raft domain and regulates the PTEN/AKT/mTORC1 pathway to activate autophagy. Lipid raft localization was essential for CD24 recruitment function. Collectively, our findings revealed a novel role of CD24 in regulating RB sensitivity to VCR and showed that CD24 is a potential target for improving chemotherapeutic sensitivity and RB patient outcomes.
C1 [Sun, Jie; Xi, Huiyu; Liu, Qinghuai; Shao, Qing] Nanjing Med Univ, Dept Ophthalmol, Affiliated Hosp 1, Nanjing, Peoples R China.
   [Feng, Dongju; Luo, Jiajing; Zhou, Zewei; Chen, Yun] Nanjing Med Univ, Dept Immunol, Key Lab Immune Microenvironm & Dis, Nanjing 211166, Peoples R China.
   [Xi, Huiyu] Xuzhou Med Univ, Xuzhou Eye Res Inst, Dept Ophthalmol, Xuzhou Peoples Hosp 1, Xuzhou, Jiangsu, Peoples R China.
   [Chen, Yun] Nanjing Med Univ, Collaborat Innovat Ctr Canc Personalized Med, Jiangsu Key Lab Canc Biomarkers Prevent & Treatme, Nanjing, Peoples R China.
RP Liu, QH; Shao, Q (corresponding author), Nanjing Med Univ, Dept Ophthalmol, Affiliated Hosp 1, Nanjing, Peoples R China.; Chen, Y (corresponding author), Nanjing Med Univ, Dept Immunol, Key Lab Immune Microenvironm & Dis, Nanjing 211166, Peoples R China.
EM liuqh@njmu.edu.cn; chenyun@njmu.edu.cn; 13913862499@139.com
OI Liu, Qinghuai/0000-0003-1605-1964
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81672673, 81772602, 9174210027]; Qing Lan
   Project, Jiangsu Provincial Key Research Development Program of China
   [BE2018750]
FX This work was supported by grants from the National Natural Science
   Foundation of China (Grant Number: 81672673 to QS, 81772602, 9174210027
   to YC) and the Qing Lan Project, Jiangsu Provincial Key Research
   Development Program of China (BE2018750 to YC).
CR Amaravadi RK, 2011, CLIN CANCER RES, V17, P654, DOI 10.1158/1078-0432.CCR-10-2634
   Arico S, 2001, J BIOL CHEM, V276, P35243, DOI 10.1074/jbc.C100319200
   Bai S, 2016, EYE, V30, P1630, DOI 10.1038/eye.2016.189
   Barkal AA, 2019, NATURE, V572, P392, DOI 10.1038/s41586-019-1456-0
   Bektas S, 2010, PATHOL ONCOL RES, V16, P569, DOI 10.1007/s12253-010-9248-8
   Beta M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114800
   Beugnet A, 2003, J BIOL CHEM, V278, P40717, DOI 10.1074/jbc.M308573200
   Bianchi N, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121567
   Bretz NP, 2012, CELL MOL LIFE SCI, V69, P3863, DOI 10.1007/s00018-012-1055-9
   Chen ZH, 2020, MOL MED, V26, DOI 10.1186/s10020-020-0139-5
   Deng JP, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/517172
   Deng XY, 2017, ONCOTARGET, V8, P38294, DOI 10.18632/oncotarget.16203
   Eyvazi S, 2018, CURR CANCER DRUG TAR, V18, P328, DOI 10.2174/1570163814666170818125036
   Fang XF, 2010, CELL MOL IMMUNOL, V7, P100, DOI 10.1038/cmi.2009.119
   Gilliam DT, 2017, NEUROBIOL DIS, V99, P133, DOI 10.1016/j.nbd.2016.12.011
   Goswami R, 2005, J NEUROSCI RES, V81, P541, DOI 10.1002/jnr.20550
   Ishaq SM, 2016, PAK J MED SCI, V32, P160, DOI 10.12669/pjms.321.8828
   Jiang Y, 2016, ASIAN PAC J TROP MED, V9, P273, DOI 10.1016/j.apjtm.2016.01.028
   Jing X, 2018, CELL PHYSIOL BIOCHEM, V48, P111, DOI 10.1159/000491667
   Kaibori M, 2015, DIGEST DIS SCI, V60, P919, DOI 10.1007/s10620-014-3417-7
   KAY R, 1991, J IMMUNOL, V147, P1412
   Keyes KT, 2010, AM J PHYSIOL-HEART C, V298, pH1198, DOI 10.1152/ajpheart.00915.2009
   Khan N, 2012, INT J CANCER, V130, P1695, DOI 10.1002/ijc.26178
   Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5
   Kim J, 2011, NAT CELL BIOL, V13, P132, DOI 10.1038/ncb2152
   Kumar A, 2015, FUTURE MED CHEM, V7, P1535, DOI 10.4155/fmc.15.88
   Lee TKW, 2011, CELL STEM CELL, V9, P50, DOI 10.1016/j.stem.2011.06.005
   Levy JMM, 2017, NAT REV CANCER, V17, P528, DOI 10.1038/nrc.2017.53
   Li J, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/158084
   Li L, 2017, ONCOTARGET, V8, P109487, DOI 10.18632/oncotarget.22721
   Li YL, 2017, J CELL BIOCHEM, V118, P4498, DOI 10.1002/jcb.26107
   Liu B, 2011, PATHOL ONCOL RES, V17, P45, DOI 10.1007/s12253-010-9278-2
   Lu S, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0681-z
   Milella M, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00024
   Mollinedo Faustino, 2015, Adv Biol Regul, V57, P130, DOI 10.1016/j.jbior.2014.10.003
   Murphree AL, 1996, ARCH OPHTHALMOL-CHIC, V114, P1348, DOI 10.1001/archopht.1996.01100140548005
   Onishi H, 2017, ANTICANCER RES, V37, P561, DOI 10.21873/anticanres.11349
   Ono YJ, 2015, MOL CANCER THER, V14, P2353, DOI 10.1158/1535-7163.MCT-15-0187
   Rahdar M, 2009, P NATL ACAD SCI USA, V106, P480, DOI 10.1073/pnas.0811212106
   Riener MO, 2010, HUM PATHOL, V41, P1558, DOI 10.1016/j.humpath.2009.12.016
   Runz S, 2008, BIOCHEM BIOPH RES CO, V365, P35, DOI 10.1016/j.bbrc.2007.10.139
   Schabath H, 2006, J CELL SCI, V119, P314, DOI 10.1242/jcs.02741
   Shen HY, 2017, GENE, V596, P110, DOI 10.1016/j.gene.2016.10.016
   Shields Carol L, 2004, Cancer Control, V11, P317
   Shukla S, 2017, INT J OPHTHALMOL-CHI, V10, P1655, DOI 10.18240/ijo.2017.11.04
   SPRINGER T, 1978, EUR J IMMUNOL, V8, P539, DOI 10.1002/eji.1830080802
   Staubach S, 2011, EXPERT REV PROTEOMIC, V8, P263, DOI [10.1586/EPR.11.2, 10.1586/epr.11.2]
   Sui X, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.350
   Sun J, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0441-0
   Suzuki KGN, 2015, INT REV CEL MOL BIO, V317, P67, DOI 10.1016/bs.ircmb.2015.02.004
   Wan X, 2016, TUMOR BIOL, V37, P6073, DOI 10.1007/s13277-015-4442-7
   Wu Q, 2014, CANCER LETT, V347, P159, DOI 10.1016/j.canlet.2014.03.013
   Wu XY, 2000, P NATL ACAD SCI USA, V97, P4233, DOI 10.1073/pnas.97.8.4233
   Wu YT, 2009, AUTOPHAGY, V5, P824, DOI 10.4161/auto.9099
   Xu JH, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-016-0487-8
   Yang ZNJ, 2011, MOL CANCER THER, V10, P1533, DOI 10.1158/1535-7163.MCT-11-0047
   Yanik O, 2015, TURK OFTALMOL DERG, V45, P259, DOI 10.4274/tjo.06888
   Yu TC, 2017, CELL, V170, P548, DOI 10.1016/j.cell.2017.07.008
   Zarn JA, 1996, BIOCHEM BIOPH RES CO, V225, P384, DOI 10.1006/bbrc.1996.1184
   Zhou YJ, 2018, J CANCER, V9, P1357, DOI 10.7150/jca.22427
   Zmajkovicova K, 2013, MOL CELL, V50, P43, DOI 10.1016/j.molcel.2013.01.037
NR 61
TC 7
Z9 7
U1 3
U2 10
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1574-7891
EI 1878-0261
J9 MOL ONCOL
JI Mol. Oncol.
PD AUG
PY 2020
VL 14
IS 8
BP 1740
EP 1759
DI 10.1002/1878-0261.12708
EA JUN 2020
PG 20
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA MT6DN
UT WOS:000539822200001
PM 32394616
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Kang, MA
   Kim, MS
   Kim, W
   Um, JH
   Shin, YJ
   Song, JY
   Jeong, JH
AF Kang, Mi Ae
   Kim, Mi-Sook
   Kim, Wonwoo
   Um, Jee-Hyun
   Shin, Young-Joo
   Song, Jie-Young
   Jeong, Jae-Hoon
TI Lanatoside C suppressed colorectal cancer cell growth by inducing
   mitochondrial dysfunction and increased radiation sensitivity by
   impairing DNA damage repair
SO ONCOTARGET
LA English
DT Article
DE lanatoside C; autophagy; mitochondria; DNA damage repair;
   radiosensitivity
ID CARDIAC-GLYCOSIDES; ANTICANCER AGENT; NA+/K+-ATPASE; AUTOPHAGY;
   INHIBITION; APOPTOSIS; OUABAIN; DEATH; 53BP1; RNF8
AB Cardiac glycosides are clinically used for cardiac arrhythmias. In this study, we investigated the mechanism responsible for anti-cancer and radiosensitizing effects of lanatoside C in colorectal cancer cells. Lanatoside C-treated cells showed classic patterns of autophagy, which may have been caused by lanatoside C-induced mitochondrial aggregation or degeneration. This mitochondrial dysfunction was due to disruption of K+ homeostasis, possibly through inhibition of Na+/K+-ATPase activity. In addition, lanatoside C sensitized HCT116 cells (but not HT-29 cells) to radiation in vitro. gamma-H2AX, a representative marker of DNA damage, were sustained longer after combination of irradiation with lanatoside C, suggesting lanatoside C impaired DNA damage repair processes. Recruitment of 53BP1 to damaged DNA, a critical initiation step for DNA damage repair signaling, was significantly suppressed in lanatoside C-treated HCT116 cells. This may have been due to defects in the RNF8- and RNF168-dependent degradation of KDM4A/JMJD2A that increases 53BP1 recruitment to DNA damage sites. Although lanatoside C alone reduced tumor growth in the mouse xenograft tumor model, combination of lanatoside C and radiation inhibited tumor growth more than single treatments. Thus, lanatoside C could be a potential molecule for anti-cancer drugs and radiosensitizing agents.
C1 [Kang, Mi Ae; Kim, Mi-Sook; Kim, Wonwoo; Jeong, Jae-Hoon] Korea Inst Radiol & Med Sci, Res Ctr Radiotherapy, Seoul, South Korea.
   [Kim, Mi-Sook] Korea Inst Radiol & Med Sci, Dept Radiat, Seoul, South Korea.
   [Um, Jee-Hyun] Gachon Univ, Lee Gil Ya Canc & Diabet Inst, Korea Mouse Metab Phenotyping Ctr, Inchon, South Korea.
   [Shin, Young-Joo] Inje Univ, Sanggye Paik Hosp, Dept Radiat Oncol, Seoul, South Korea.
   [Song, Jie-Young] Korea Inst Radiol & Med Sci, Div Radiat Canc Res, Seoul, South Korea.
RP Kim, MS; Jeong, JH (corresponding author), Korea Inst Radiol & Med Sci, Res Ctr Radiotherapy, Seoul, South Korea.
EM mskim@kcch.re.kr; jeongj@kirams.re.kr
RI Song, Jie-Young/AAG-6684-2019; Song, Jie-Young/AAH-1254-2019
OI Song, Jie-Young/0000-0002-5769-3886; 
FU National R&D Program through the Korea Institute of Radiological and
   Medical Sciences - Ministry of Science, ICT & Future Planning
   [711022056/50541-2015]
FX This research was supported by the National R&D Program through the
   Korea Institute of Radiological and Medical Sciences funded by the
   Ministry of Science, ICT & Future Planning (No. 711022056/50541-2015).
CR Andegeko Y, 2001, J BIOL CHEM, V276, P38224
   Badr CE, 2011, NEURO-ONCOLOGY, V13, P1213, DOI 10.1093/neuonc/nor067
   Bartocci Cristina, 2013, Frontiers in Genetics, V4, P128, DOI 10.3389/fgene.2013.00128
   Bohm M, 1997, NEW ENGL J MED, V337, P129
   Botuyan MV, 2006, CELL, V127, P1361, DOI 10.1016/j.cell.2006.10.043
   Cagnol S, 2010, FEBS J, V277, P2, DOI 10.1111/j.1742-4658.2009.07366.x
   Chen DD, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-716
   Corcelle E, 2007, AUTOPHAGY, V3, P57, DOI 10.4161/auto.3424
   Doil C, 2009, CELL, V136, P435, DOI 10.1016/j.cell.2008.12.041
   Fradet-Turcotte A, 2013, NATURE, V499, P50, DOI 10.1038/nature12318
   Hall EJ., 2012, RADIOBIOLOGY RADIOLO
   Haux J, 1999, MED HYPOTHESES, V53, P543, DOI 10.1054/mehy.1999.0985
   Huang YT, 2004, BIOCHEM PHARMACOL, V67, P727, DOI 10.1016/j.bcp.2003.10.013
   Huen MSY, 2007, CELL, V131, P901, DOI 10.1016/j.cell.2007.09.041
   Jangamreddy JR, 2012, HEPAT MON, V12, DOI 10.5812/hepatmon.6159
   Janku F, 2011, NAT REV CLIN ONCOL, V8, P528, DOI 10.1038/nrclinonc.2011.71
   Jin SK, 2001, J CELL SCI, V114, P4139
   Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720
   Kolas NK, 2007, SCIENCE, V318, P1637, DOI 10.1126/science.1150034
   Kondo Y, 2005, NAT REV CANCER, V5, P726, DOI 10.1038/nrc1692
   Kumar R, 2013, FRONT ONCOL, V2, DOI 10.3389/fonc.2012.00214
   LAWRENCE TS, 1988, INT J RADIAT ONCOL, V15, P953, DOI 10.1016/0360-3016(88)90132-0
   Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1
   Lopez-Lazaro M, 2007, EXPERT OPIN THER TAR, V11, P1043, DOI 10.1517/14728222.11.8.1043
   Mallette FA, 2012, EMBO J, V31, P1865, DOI 10.1038/emboj.2012.47
   Mijatovic T, 2012, CURR MED CHEM, V19, P627, DOI 10.2174/092986712798992075
   Newman RA, 2008, MOL INTERV, V8, P36, DOI 10.1124/mi.8.1.8
   Pan ST, 2015, DRUG DES DEV THER, V9, P1601, DOI 10.2147/DDDT.S76057
   Pastor N, 2003, DNA REPAIR, V2, P1353, DOI 10.1016/j.dnarep.2003.08.001
   Prassas I, 2008, NAT REV DRUG DISCOV, V7, P926, DOI 10.1038/nrd2682
   Ralph SJ, 2009, MOL NUTR FOOD RES, V53, P9, DOI 10.1002/mnfr.200800044
   Wang L, 2011, ANTICANCER RES, V31, P2141
   Wang Y, 2012, INT J BIOCHEM CELL B, V44, P1813, DOI 10.1016/j.biocel.2012.06.028
   Winnicka K, 2007, ARCH PHARM RES, V30, P1216, DOI 10.1007/BF02980262
   Yang PY, 2009, MOL CANCER THER, V8, P2319, DOI 10.1158/1535-7163.MCT-08-1085
NR 35
TC 16
Z9 16
U1 0
U2 13
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD FEB 2
PY 2016
VL 7
IS 5
BP 6074
EP 6087
DI 10.18632/oncotarget.6832
PG 14
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA DD5HD
UT WOS:000369952800070
PM 26756216
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Neitzel, C
   Seiwert, N
   Goder, A
   Diehl, E
   Weber, C
   Nagel, G
   Stroh, S
   Rasenberger, B
   Christmann, M
   Fahrer, J
AF Neitzel, Carina
   Seiwert, Nina
   Goeder, Anja
   Diehl, Erika
   Weber, Carina
   Nagel, Georg
   Stroh, Svenja
   Rasenberger, Birgit
   Christmann, Markus
   Fahrer, Joerg
TI Lipoic Acid Synergizes with Antineoplastic Drugs in Colorectal Cancer by
   Targeting p53 for Proteasomal Degradation
SO CELLS
LA English
DT Article
DE lipoic acid; p53; ubiquitin; proteasome; mitochondria; anticancer drugs
ID TRANSCRIPTION FACTOR NRF2; NF-KAPPA-B; O-6-METHYLGUANINE-DNA
   METHYLTRANSFERASE; SELECTIVE AUTOPHAGY; REDOX MODULATION; CELL-DEATH;
   APOPTOSIS; ACTIVATION; EXPRESSION; MECHANISMS
AB Lipoic acid (LA) is a redox-active disulphide compound, which functions as a pivotal co-factor for mitochondrial oxidative decarboxylation. LA and chemical derivatives were shown to target mitochondria in cancer cells with altered energy metabolism, thereby inducing cell death. In this study, the impact of LA on the tumor suppressor protein p53 was analyzed in various colorectal cancer (CRC) cell lines, with a focus on the mechanisms driving p53 degradation. First, LA was demonstrated to trigger the depletion of both wildtype and mutant p53 protein in all CRC cells tested without influencing its gene expression and preceded LA-triggered cytotoxicity. Depletion of p53 coincided with a moderate, LA-dependent ROS production, but was not rescued by antioxidant treatment. LA induced the autophagy receptor p62 and differentially modulated autophagosome formation in CRC cells. However, p53 degradation was not mediated via autophagy as shown by chemical inhibition and genetic abrogation of autophagy. LA treatment also stabilized and activated the transcription factor Nrf2 in CRC cells, which was however dispensable for p53 degradation. Mechanistically, p53 was found to be readily ubiquitinylated and degraded by the proteasomal machinery following LA treatment, which did not involve the E3 ubiquitin ligase MDM2. Intriguingly, the combination of LA and anticancer drugs (doxorubicin, 5-fluorouracil) attenuated p53-mediated stabilization of p21 and resulted in synergistic killing in CRC cells in a p53-dependant manner.
C1 [Neitzel, Carina; Seiwert, Nina; Goeder, Anja; Diehl, Erika; Weber, Carina; Nagel, Georg; Stroh, Svenja; Rasenberger, Birgit; Christmann, Markus; Fahrer, Joerg] Univ Med Ctr Mainz, Inst Toxicol, D-55131 Mainz, Germany.
   [Neitzel, Carina; Seiwert, Nina; Fahrer, Joerg] Justus Liebig Univ Giessen, Rudolf Buchhe Inst Pharmacol, D-35392 Giessen, Germany.
   [Neitzel, Carina; Seiwert, Nina; Fahrer, Joerg] Tech Univ Kaiserslautern, Dept Chem, Div Food Chem & Toxicol, D-67663 Kaiserslautern, Germany.
RP Fahrer, J (corresponding author), Univ Med Ctr Mainz, Inst Toxicol, D-55131 Mainz, Germany.; Fahrer, J (corresponding author), Justus Liebig Univ Giessen, Rudolf Buchhe Inst Pharmacol, D-35392 Giessen, Germany.; Fahrer, J (corresponding author), Tech Univ Kaiserslautern, Dept Chem, Div Food Chem & Toxicol, D-67663 Kaiserslautern, Germany.
EM fahrer@chemie.uni-kl.de
RI Seiwert, Nina/ABD-2627-2020
OI Seiwert, Nina/0000-0003-2169-3670; Goder, Anja/0000-0001-9743-1656
FU Wilhelm Sander Foundation [2016.039.1, 2016.039.2]; University of Mainz
   (Stufe I)
FX This research was funded by Wilhelm Sander Foundation (grant numbers
   2016.039.1 and 2016.039.2 to J. F.), and University of Mainz (Stufe I,
   grant to J. F.).
CR Abolhassani M, 2012, INVEST NEW DRUG, V30, P1331, DOI 10.1007/s10637-011-9692-7
   Abrahams S, 2019, NEUROSCIENCE, V406, P1, DOI 10.1016/j.neuroscience.2019.02.020
   Ahmed D, 2013, ONCOGENESIS, V2, DOI 10.1038/oncsis.2013.35
   Akiba S, 1998, ANAL BIOCHEM, V258, P299, DOI 10.1006/abio.1998.2615
   Bard JAM, 2018, ANNU REV BIOCHEM, V87, P697, DOI 10.1146/annurev-biochem-062917-011931
   Brady CA, 2010, J CELL SCI, V123, P2527, DOI 10.1242/jcs.064501
   Chao CCK, 2015, CLIN CHIM ACTA, V438, P139, DOI 10.1016/j.cca.2014.08.015
   Chen JD, 2016, CSH PERSPECT MED, V6, DOI 10.1101/cshperspect.a026104
   Chou TC, 2006, PHARMACOL REV, V58, P621, DOI 10.1124/pr.58.3.10
   Christmann M, 2016, NUCLEIC ACIDS RES, V44, P10727, DOI 10.1093/nar/gkw873
   Christmann M, 2013, NUCLEIC ACIDS RES, V41, P8403, DOI 10.1093/nar/gkt635
   Cunningham D, 2010, LANCET, V375, P1030, DOI 10.1016/S0140-6736(10)60353-4
   Dai C, 2010, TRENDS MOL MED, V16, P528, DOI 10.1016/j.molmed.2010.09.002
   Danieli A, 2018, J CELL SCI, V131, DOI 10.1242/jcs.214304
   Dorsam B, 2018, P NATL ACAD SCI USA, V115, pE4061, DOI 10.1073/pnas.1712345115
   Dorsam B, 2016, CANCER LETT, V371, P12, DOI 10.1016/j.canlet.2015.11.019
   Dorsam B, 2015, ARCH TOXICOL, V89, P1829, DOI 10.1007/s00204-014-1434-0
   Dorsam B, 2015, ARCH TOXICOL, V89, P797, DOI 10.1007/s00204-014-1281-z
   Fahrer J, 2014, DNA REPAIR, V18, P31, DOI 10.1016/j.dnarep.2014.03.002
   Fahrer J, 2013, CARCINOGENESIS, V34, P2435, DOI 10.1093/carcin/bgt275
   Feuerecker B, 2012, CANCER BIOL THER, V13, P1425, DOI 10.4161/cbt.22003
   Gatei M, 2001, ONCOGENE, V20, P289, DOI 10.1038/sj.onc.1204111
   Glick D, 2010, J PATHOL, V221, P3, DOI 10.1002/path.2697
   Goder A, 2015, CARCINOGENESIS, V36, P817, DOI 10.1093/carcin/bgv070
   HAINAUT P, 1993, CANCER RES, V53, P4469
   Jain A, 2010, J BIOL CHEM, V285, P22576, DOI 10.1074/jbc.M110.118976
   Jarrett JT, 2015, J BIOL CHEM, V290, P3972, DOI 10.1074/jbc.R114.599308
   Jeon MJ, 2016, MOL CELL ENDOCRINOL, V419, P113, DOI 10.1016/j.mce.2015.10.005
   Jones W, 2002, FREE RADICAL BIO MED, V33, P83, DOI 10.1016/S0891-5849(02)00862-6
   Ju J, 2007, CLIN CANCER RES, V13, P4245, DOI 10.1158/1078-0432.CCR-06-2890
   Kalo E, 2012, J CELL SCI, V125, P5578, DOI 10.1242/jcs.106815
   Kim DH, 2011, MOL CARCINOGEN, V50, P222, DOI 10.1002/mc.20709
   Klionsky DJ, 2007, NAT REV MOL CELL BIO, V8, P931, DOI 10.1038/nrm2245
   Komatsu M, 2010, NAT CELL BIOL, V12, P213, DOI 10.1038/ncb2021
   Kruse JP, 2009, CELL, V137, P609, DOI 10.1016/j.cell.2009.04.050
   Lamark T, 2017, ESSAYS BIOCHEM, V61, P609, DOI 10.1042/EBC20170035
   Lau A, 2013, ANTIOXID REDOX SIGN, V18, P91, DOI 10.1089/ars.2012.4754
   Lii CK, 2010, J NUTR, V140, P885, DOI 10.3945/jn.110.121418
   Ma JH, 2006, BIOCHEMISTRY-US, V45, P9238, DOI 10.1021/bi060661u
   Meijer AJ, 2004, INT J BIOCHEM CELL B, V36, P2445, DOI 10.1016/j.biocel.2004.02.002
   Miller M., 2016, J CANC BIOL RES, P4
   Mimmler M, 2016, NUCLEIC ACIDS RES, V44, P10259, DOI 10.1093/nar/gkw791
   Mizushima N, 2011, ANNU REV CELL DEV BI, V27, P107, DOI 10.1146/annurev-cellbio-092910-154005
   Moungjaroen J, 2006, J PHARMACOL EXP THER, V319, P1062, DOI 10.1124/jpet.106.110965
   Muller PAJ, 2013, NAT CELL BIOL, V15, P2, DOI 10.1038/ncb2641
   Muller PAJ, 2009, CELL, V139, P1327, DOI 10.1016/j.cell.2009.11.026
   Nomura T, 2011, BIOPOLYMERS, V95, P410, DOI 10.1002/bip.21594
   Olivier M, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001008
   Paranjpe A, 2013, CARCINOGENESIS, V34, P990, DOI 10.1093/carcin/bgt032
   Park S, 2015, J INVEST MED, V63, P882, DOI 10.1097/JIM.0000000000000233
   Pickering AM, 2012, J BIOL CHEM, V287, P10021, DOI 10.1074/jbc.M111.277145
   Vaidecantos MP, 2015, FREE RADICAL BIO MED, V84, P263, DOI 10.1016/j.freeradbiomed.2015.03.019
   Puchsaka P, 2016, INT J ONCOL, V49, P1445, DOI 10.3892/ijo.2016.3624
   Reljanovic M., 2009, FREE RADICAL RES, V31, P171, DOI [10.1080/10715769900300721, DOI 10.1080/10715769900300721]
   Rieger AM, 2010, J IMMUNOL METHODS, V358, P81, DOI 10.1016/j.jim.2010.03.019
   Rivlin Noa, 2011, Genes Cancer, V2, P466, DOI 10.1177/1947601911408889
   Rochette L, 2013, MOL NUTR FOOD RES, V57, P114, DOI 10.1002/mnfr.201200608
   RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555
   Satoh S, 2008, ANAL CHIM ACTA, V618, P210, DOI 10.1016/j.aca.2008.05.001
   Scotcher J, 2013, CHEM SCI, V4, P1257, DOI 10.1039/c2sc21702c
   Scotcher J, 2011, J AM SOC MASS SPECTR, V22, P888, DOI 10.1007/s13361-011-0088-x
   Seiwert N, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.418
   Sen CK, 1999, CELL DEATH DIFFER, V6, P481, DOI 10.1038/sj.cdd.4400514
   Shay KP, 2012, BBA-MOL CELL RES, V1823, P1102, DOI 10.1016/j.bbamcr.2012.04.002
   Shay KP, 2009, BBA-GEN SUBJECTS, V1790, P1149, DOI 10.1016/j.bbagen.2009.07.026
   SIGEL H, 1978, ARCH BIOCHEM BIOPHYS, V187, P208, DOI 10.1016/0003-9861(78)90025-5
   Simbula G, 2007, APOPTOSIS, V12, P113, DOI 10.1007/s10495-006-0487-9
   Singh A, 2016, ACS CHEM BIOL, V11, P3214, DOI 10.1021/acschembio.6b00651
   Sreedhar AS, 2004, FEBS LETT, V562, P11
   Tebay LE, 2015, FREE RADICAL BIO MED, V88, P108, DOI 10.1016/j.freeradbiomed.2015.06.021
   Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472
   Velu CS, 2007, BIOCHEMISTRY-US, V46, P7765, DOI 10.1021/bi700425y
   VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I
   Wade M, 2013, NAT REV CANCER, V13, P83, DOI 10.1038/nrc3430
   Watson JL, 2010, CANCER LETT, V297, P1, DOI 10.1016/j.canlet.2010.04.018
   Wenzel U, 2005, APOPTOSIS, V10, P359, DOI 10.1007/s10495-005-0810-x
   Williams AB, 2016, CSH PERSPECT MED, V6, DOI 10.1101/cshperspect.a026070
   Yang Y, 2017, EXP CELL RES, V361, P217, DOI 10.1016/j.yexcr.2017.10.020
   Yeudall WA, 2012, CARCINOGENESIS, V33, P442, DOI 10.1093/carcin/bgr270
   Yoo TH, 2013, ANTI-CANCER DRUG, V24, P555, DOI 10.1097/CAD.0b013e32836181eb
   Zachar Z, 2011, J MOL MED, V89, P1137, DOI 10.1007/s00109-011-0785-8
NR 81
TC 8
Z9 8
U1 1
U2 3
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2073-4409
J9 CELLS-BASEL
JI Cells
PD AUG
PY 2019
VL 8
IS 8
AR 794
DI 10.3390/cells8080794
PG 29
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA IV8TI
UT WOS:000484537500027
PM 31366086
OA Green Published, gold, Green Submitted
DA 2022-04-25
ER

PT J
AU Anunobi, R
   Boone, BA
   Cheh, N
   Tang, DL
   Kang, R
   Loux, T
   Lotze, MT
   Zeh, HJ
AF Anunobi, Reginald
   Boone, Brian A.
   Cheh, Nick
   Tang, Daolin
   Kang, Rui
   Loux, Tara
   Lotze, Michael T.
   Zeh, Herbert J.
TI Extracellular DNA promotes colorectal tumor cell survival after
   cytotoxic chemotherapy
SO JOURNAL OF SURGICAL RESEARCH
LA English
DT Article
DE Autophagy; Apoptosis; TLR-9; DAMPs; Damage-associated molecular patterns
   receptors; Extracellular DNA
ID TOLL-LIKE RECEPTORS; SYSTEMIC-LUPUS-ERYTHEMATOSUS; BREAST-CANCER
   PATIENTS; CIRCULATING DNA; HMGB1 RELEASE; DEOXYRIBONUCLEASE ACTIVITY;
   INFLAMMATORY RESPONSES; PANCREATIC-CANCER; BLOOD-PLASMA; IN-VITRO
AB Background: Inflammation promotes the growth and survival of malignant cells. Inflammation within the tumor microenvironment is a result of damage-associated molecular patterns released by dead or dying cells that provide survival signals to the surrounding cells. It has been proposed that extracellular DNA can act as a damage-associated molecular pattern given the association between circulating DNA and autoimmune diseases. Herein, we demonstrate a novel role for genomic extracellular DNA binding to the Toll-like receptor (TLR)-9 on tumor cells in response to cytotoxic insult.
   Materials and methods: The colorectal tumor cell line HCCT116 was used to study the role of DNA in tumor cell response to chemotherapy. Cell viability was assessed using CCK-8 assay. Cell death mechanisms were assessed by YOYO-1 and lactate dehydrogenase staining for necrosis and TUNEL staining for apoptosis. Autophagy was measured by LC3 punctate formation. TLR9-short hairpin RNA was used to knockdown TLR-9 and determine its role in tumor cell response to DNA.
   Results: DNAis released fromnecrotic tumor cells after chemotherapy. Survival after cytotoxic insult is enhanced by the presence of extracellular DNA as a result of inhibition of apoptosis and enhanced autophagy. Knockdown of TLR-9 enhanced apoptosis, diminished autophagy, and decreased survival after cytotoxic insult in the presence or absence of extracellular DNA.
   Conclusions: DNA in the tumor microenvironment promotes survival through induction of autophagy via TLR-9 signaling. This work has important implications for targeting extracellular DNA, TLR-9, and autophagy during treatment with chemotherapy and enhances our understanding of the role of extracellular DNA in the tumor microenvironment. (C) 2018 Elsevier Inc. All rights reserved.
C1 [Anunobi, Reginald; Boone, Brian A.; Cheh, Nick; Tang, Daolin; Kang, Rui; Loux, Tara; Lotze, Michael T.; Zeh, Herbert J.] Univ Pittsburgh, Inst Canc, Hillman Canc Ctr, Dept Surg, UPMC Canc Pavil Suite 417 5150 Ctr Ave, Pittsburgh, PA 15232 USA.
RP Zeh, HJ (corresponding author), Univ Pittsburgh, UPMC Canc Pavil Suite 417 5150 Ctr Ave, Pittsburgh, PA 15232 USA.
EM zehxhx@upmc.edu
RI Kang, Rui/ABD-5291-2021; Tang, Daolin/B-2905-2010; Tang,
   Daolin/ABD-5062-2021
OI Kang, Rui/0000-0003-2725-1574; Tang, Daolin/0000-0002-1903-6180; Boone,
   Brian/0000-0001-9006-059X
FU National Cancer InstituteUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Cancer
   Institute (NCI) [T32CA113263]
FX This work was supported by grant number T32CA113263 from the National
   Cancer Institute.
CR Alcazar-Leyva S, 2009, MED SCI MONITOR, V15, pCR51
   Bailey SL, 2012, DNA REPAIR, V11, P65, DOI 10.1016/j.dnarep.2011.10.007
   Barber GN, 2011, CURR OPIN IMMUNOL, V23, P10, DOI 10.1016/j.coi.2010.12.015
   Barrat FJ, 2005, J EXP MED, V202, P1131, DOI 10.1084/jem.20050914
   Bertin S, 2008, MOL CELL PROTEOMICS, V7, P2311, DOI 10.1074/mcp.M800100-MCP200
   Bertin S, 2008, AUTOPHAGY, V4, P1086, DOI 10.4161/auto.7138
   Boone BA, 2015, CANCER GENE THER, V22, P326, DOI 10.1038/cgt.2015.21
   Boone BA, 2014, METHODS MOL BIOL, V1102, P537, DOI 10.1007/978-1-62703-727-3_29
   Brignole C, 2010, CANCER RES, V70, P9816, DOI 10.1158/0008-5472.CAN-10-1251
   Brinkmann V, 2004, SCIENCE, V303, P1532, DOI 10.1126/science.1092385
   Cherepanova AV, 2008, ANN NY ACAD SCI, V1137, P218, DOI 10.1196/annals.1448.016
   Cui BB, 2012, AUTOIMMUNITY, V45, P593, DOI 10.3109/08916934.2012.719952
   Demers M, 2012, P NATL ACAD SCI USA, V109, P13076, DOI 10.1073/pnas.1200419109
   Dittmar M, 2009, J AUTOIMMUN, V32, P7, DOI 10.1016/j.jaut.2008.09.005
   Dong XD, 2007, J IMMUNOTHER, V30, P596, DOI 10.1097/CJI.0b013e31804efc76
   Droemann D, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-1
   Escamilla-Tilch M, 2013, IMMUNOL CELL BIOL, V91, P601, DOI 10.1038/icb.2013.58
   Galeazzi M, 2003, AUTOIMMUN REV, V2, P50, DOI 10.1016/S1568-9972(02)00101-5
   Garcia JM, 2006, GENE CHROMOSOME CANC, V45, P692, DOI 10.1002/gcc.20334
   Garg AD, 2013, BIOFACTORS, V39, P355, DOI 10.1002/biof.1125
   Gonzalez-Reyes S, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-665
   Hou W, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.493
   Huang Qi-Quan, 2009, Curr Rheumatol Rep, V11, P357
   Ilvesaro JM, 2007, PROSTATE, V67, P774, DOI 10.1002/pros.20562
   Ito N, 2007, J LEUKOCYTE BIOL, V81, P75, DOI 10.1189/jlb.0306169
   Jahr S, 2001, CANCER RES, V61, P1659
   Kang R, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.445
   Kang R, 2010, CELL DEATH DIFFER, V17, P666, DOI 10.1038/cdd.2009.149
   Kindrachuk J, 2008, MINI-REV MED CHEM, V8, P590, DOI 10.2174/138955708784534481
   Li XY, 2015, MOL IMMUNOL, V65, P177, DOI 10.1016/j.molimm.2015.01.023
   Marshak-Rothstein A, 2007, ANNU REV IMMUNOL, V25, P419, DOI 10.1146/annurev.immunol.22.012703.104514
   Matzinger P, 2007, NAT IMMUNOL, V8, P11, DOI 10.1038/ni0107-11
   Mitroulis I, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029318
   Mukae N, 1998, P NATL ACAD SCI USA, V95, P9123, DOI 10.1073/pnas.95.16.9123
   Nojiri K, 2013, ONCOL REP, V29, P1737, DOI 10.3892/or.2013.2322
   Park B, 2008, NAT IMMUNOL, V9, P1407, DOI 10.1038/ni.1669
   Rayburn ER, 2007, INT J ONCOL, V30, P1511
   Rossol M, 2009, ANN RHEUM DIS, V68, P1498, DOI 10.1136/ard.2008.092239
   Schmidt C, 2007, NAT BIOTECHNOL, V25, P825, DOI 10.1038/nbt0807-825
   Silva JM, 2002, CLIN CANCER RES, V8, P3761
   Sirois CM, 2013, J EXP MED, V210, P2447, DOI 10.1084/jem.20120201
   Sur Chowdhury Chanchal, 2014, Arthritis Res Ther, V16, pR122, DOI 10.1186/ar4579
   Tamkovich SN, 2008, B EXP BIOL MED+, V146, P89, DOI 10.1007/s10517-008-0213-4
   Tian J, 2007, NAT IMMUNOL, V8, P487, DOI 10.1038/ni1457
   Valle FM, 2008, AUTOIMMUN REV, V7, P359, DOI 10.1016/j.autrev.2008.02.002
   van der Vaart M, 2008, ANN NY ACAD SCI, V1137, P18, DOI 10.1196/annals.1448.022
   Vollmer J, 2009, ADV DRUG DELIVER REV, V61, P195, DOI 10.1016/j.addr.2008.12.008
   von Landenberg P, 2007, CURR OPIN IMMUNOL, V19, P606, DOI 10.1016/j.coi.2007.10.004
   Wallner M, 2006, CLIN CANCER RES, V12, P7347, DOI 10.1158/1078-0432.CCR-06-1264
   Wen FS, 2013, CANCER RES, V73, P4256, DOI 10.1158/0008-5472.CAN-12-3287
   Xu L, 2010, IMMUNOL LETT, V127, P93, DOI 10.1016/j.imlet.2009.10.002
   Yanai H, 2009, NATURE, V462, P99, DOI 10.1038/nature08512
   Yang HW, 2001, NEOPLASIA, V3, P165, DOI 10.1038/sj.neo.7900141
   Yasutomo K, 2001, NAT GENET, V28, P313, DOI 10.1038/91070
   Zeh HJ, 2005, J IMMUNOTHER, V28, P1, DOI 10.1097/00002371-200501000-00001
   Zhang Q, 2010, NATURE, V464, P104, DOI 10.1038/nature08780
   Zhang QY, 2015, ONCOL REP, V33, P1630, DOI 10.3892/or.2015.3782
NR 57
TC 13
Z9 14
U1 1
U2 12
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0022-4804
EI 1095-8673
J9 J SURG RES
JI J. Surg. Res.
PD JUN
PY 2018
VL 226
BP 181
EP 191
DI 10.1016/j.jss.2018.02.042
PG 11
WC Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Surgery
GA GD1MH
UT WOS:000430263500024
PM 29605400
OA Bronze
DA 2022-04-25
ER

PT J
AU Yao, Z
   Xie, FH
   Li, M
   Liang, ZR
   Xu, WL
   Yang, JH
   Liu, C
   Li, HWW
   Zhou, H
   Qu, LH
AF Yao, Zhuo
   Xie, Fuhua
   Li, Min
   Liang, Zirui
   Xu, Wenli
   Yang, Jianhua
   Liu, Chang
   Li, Hongwangwang
   Zhou, Hui
   Qu, Liang-Hu
TI Oridonin induces autophagy via inhibition of glucose metabolism in
   p53-mutated colorectal cancer cells
SO CELL DEATH & DISEASE
LA English
DT Article
ID IN-VITRO; MONOCARBOXYLATE TRANSPORTER; ANTITUMOR-ACTIVITY; INDUCED
   APOPTOSIS; GROWTH-INHIBITION; SMALL-MOLECULE; EXPRESSION; AMPK; GLUT1;
   VIVO
AB The Warburg effect is an important characteristic of tumor cells, making it an attractive therapeutic target. Current anticancer drug development strategies predominantly focus on inhibitors of the specific molecular effectors involved in tumor cell proliferation. These drugs or natural compounds, many of which target the Warburg effect and the underlying mechanisms, still need to be characterized. To elucidate the anticancer effects of a natural diterpenoid, oridonin, we first demonstrated the anticancer activity of oridonin both in vitro and in vivo in colorectal cancer (CRC) cells. Then miRNA profiling of SW480 cells revealed those intracellular signaling related to energy supply was affected by oridonin, suggesting that glucose metabolism is a potential target for CRC therapy. Moreover, our results indicated that oridonin induced metabolic imbalances by significantly inhibiting glucose uptake and reducing lactate export through significantly downregulating the protein levels of GLUT1 and MCT1 in vitro and vivo. However, the ATP level in oridonin-treated CRC cells was not decreased when oridonin blocked the glucose supply, indicating that oridonin induced autophagy process, an important ATP source in cancer cells. The observation was then supported by the results of LC3-II detection and transmission electron microscopy analysis, which confirmed the presence of autophagy. Furthermore, p-AMPK was rapidly deactivated following oridonin treatment, resulting in downregulation of GLUT1 and induction of autophagy in the cancer cells. Thus our finding helped to clarify the anticancer mechanisms of oridonin and suggested it could be applied as a glucose metabolism-targeting agent for cancer treatment.
C1 [Yao, Zhuo; Xie, Fuhua; Li, Min; Liang, Zirui; Xu, Wenli; Yang, Jianhua; Liu, Chang; Li, Hongwangwang; Zhou, Hui; Qu, Liang-Hu] Sun Yat Sen Univ, Sch Life Sci, State Key Lab Biocontrol, Key Lab Gene Engn,Minist Educ, Guangzhou 510275, Guangdong, Peoples R China.
   [Xie, Fuhua] Gannan Med Univ, Dept Biochem & Mol Biol, Ganzhou 341000, Peoples R China.
RP Zhou, H (corresponding author), Sun Yat Sen Univ, Sch Life Sci, State Key Lab Biocontrol, Key Lab Gene Engn,Minist Educ, Guangzhou 510275, Guangdong, Peoples R China.; Qu, LH (corresponding author), Sun Yat Sen Univ, Dept Biochem & Mol Biol, 135 XinGangXi Rd, Guangzhou 510275, Guangdong, Peoples R China.
EM lsszh@mail.sysu.edu.cn; lssqlh@mail.sysu.edu.cn
OI Liang, Zirui/0000-0002-1778-488X; Qu, Liang-Hu/0000-0003-3657-2863
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [31230042, 31471223]; project of Science and
   Technology of Guangzhou [201504010022]
FX We would like to thank Qiao-Juan Huang, Yi-Ling Chen, and Xiao Hong Chen
   for their technical assistance. This work was supported by the National
   Natural Science Foundation of China (31230042, 31471223) and the project
   of Science and Technology of Guangzhou (201504010022).
CR Adekola K, 2012, CURR OPIN ONCOL, V24, P650, DOI 10.1097/CCO.0b013e328356da72
   Amorim R, 2015, CANCER LETT, V365, P68, DOI 10.1016/j.canlet.2015.05.015
   Buller CL, 2011, AM J PHYSIOL-RENAL, V301, pF588, DOI 10.1152/ajprenal.00472.2010
   Chen B, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-228
   Chen JD, 2016, CSH PERSPECT MED, V6, DOI 10.1101/cshperspect.a026104
   Cheng Y, 2009, AUTOPHAGY, V5, P430, DOI 10.4161/auto.5.3.7896
   Cheong H, 2012, NAT BIOTECHNOL, V30, P671, DOI 10.1038/nbt.2285
   Chung FY, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-241
   Cuff MA, 2002, J PHYSIOL-LONDON, V539, P361, DOI 10.1113/jphysiol.2001.014241
   Dang CV, 2010, CANCER RES, V70, P859, DOI 10.1158/0008-5472.CAN-09-3556
   Eichner LJ, 2010, CELL METAB, V12, P352, DOI 10.1016/j.cmet.2010.09.002
   Elf SE, 2014, CANCER-AM CANCER SOC, V120, P774, DOI 10.1002/cncr.28501
   Flati V, 2008, AM J CARDIOL, V101, p16E, DOI 10.1016/j.amjcard.2008.02.075
   Flaveny CA, 2015, CANCER CELL, V28, P42, DOI 10.1016/j.ccell.2015.05.007
   FUJITA E, 1976, EXPERIENTIA, V32, P203, DOI 10.1007/BF01937766
   Fulda S, 2015, ONCOGENE, V34, P5105, DOI 10.1038/onc.2014.458
   Gao FH, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-610
   Granja S, 2013, CELL PHYSIOL BIOCHEM, V32, P1845, DOI 10.1159/000356617
   Green DR, 2015, COLD SPRING HARB PER, V7, DOI DOI 10.1101/CSHPERSPECT.A006080
   Halestrap AP, 1999, BIOCHEM J, V343, P281, DOI 10.1042/0264-6021:3430281
   Huang HL, 2012, MOL CANCER THER, V11, P1155, DOI 10.1158/1535-7163.MCT-12-0066
   Iacopetta B, 2003, HUM MUTAT, V21, P271, DOI 10.1002/humu.10175
   Ikezoe T, 2005, MOL CANCER THER, V4, P578, DOI 10.1158/1535-7163.MCT-04-0277
   Ikezoe T, 2003, INT J ONCOL, V23, P1187
   Ji Z, 2011, ONCOL LETT, V2, P1303, DOI 10.3892/ol.2011.408
   Jin HY, 2011, J GASTROEN HEPATOL, V26, P706, DOI 10.1111/j.1440-1746.2010.06500.x
   Kim JH, 2011, AUTOPHAGY, V7, P1187, DOI 10.4161/auto.7.10.16643
   Kim KH, 2014, NAT REV ENDOCRINOL, V10, P322, DOI 10.1038/nrendo.2014.35
   Klionsky DJ, 2012, AUTOPHAGY, V8, P445, DOI 10.4161/auto.19496
   Koppenol WH, 2011, NAT REV CANCER, V11, P325, DOI 10.1038/nrc3038
   Kwan HY, 2013, J GASTROENTEROL, V48, P182, DOI 10.1007/s00535-012-0612-1
   Lambert DW, 2002, BRIT J CANCER, V86, P1262, DOI 10.1038/sj.bjc.6600264
   Lee YS, 2006, DIABETES, V55, P2256, DOI 10.2337/db06-0006
   Levine AJ, 2010, SCIENCE, V330, P1340, DOI 10.1126/science.1193494
   Li CY, 2011, INT J BIOCHEM CELL B, V43, P701, DOI 10.1016/j.biocel.2011.01.020
   Li HJ, 2014, ASIAN PAC J CANCER P, V15, P7015, DOI 10.7314/APJCP.2014.15.17.7015
   Li X, 2012, INT J BIOL SCI, V8, P901, DOI 10.7150/ijbs.4554
   Liu QO, 2010, BBA-GENE REGUL MECH, V1799, P854, DOI 10.1016/j.bbagrm.2010.06.004
   Liu W, 2014, ASIAN PAC J CANCER P, V15, P7037, DOI 10.7314/APJCP.2014.15.17.7037
   Liu XL, 2015, METABOLISM, V64, P658, DOI 10.1016/j.metabol.2015.01.015
   Liu XN, 2014, MOL CANCER THER, V13, P596, DOI 10.1158/1535-7163.MCT-13-0579
   Liu Y, 2012, MOL CANCER THER, V11, P1672, DOI 10.1158/1535-7163.MCT-12-0131
   Oronsky BT, 2014, ANTI-CANCER AGENT ME, V14, P1187, DOI 10.2174/1871520614666140804224637
   Pullen TJ, 2012, DIABETES, V61, P1719, DOI 10.2337/db11-1531
   Sakashita M, 2001, EUR J CANCER, V37, P204, DOI 10.1016/S0959-8049(00)00371-3
   Shang RZ, 2016, TUMOR BIOL, V37, P5097, DOI 10.1007/s13277-015-4329-7
   Smyth LA, 2015, IMMUNOLOGY, V144, P197, DOI 10.1111/imm.12390
   Takimoto M, 2013, METABOLISM, V62, P1633, DOI 10.1016/j.metabol.2013.06.010
   Vander Heiden MG, 2011, NAT REV DRUG DISCOV, V10, P671, DOI 10.1038/nrd3504
   Verstraete M, 2013, INT J RADIAT BIOL, V89, P9, DOI 10.3109/09553002.2012.715789
   Wang YD, 2013, AUTOPHAGY, V9, P1624, DOI 10.4161/auto.25873
   Watson J, 2013, OPEN BIOL, V3, DOI 10.1098/rsob.120144
   Wu N, 2013, MOL CELL, V49, P1167, DOI 10.1016/j.molcel.2013.01.035
   Xu JZ, 2012, AUTOPHAGY, V8, P873, DOI 10.4161/auto.19629
   Yang J, 2015, BIOMED PHARMACOTHER, V72, P125, DOI 10.1016/j.biopha.2015.04.016
   Zang LH, 2013, INT IMMUNOPHARMACOL, V15, P414, DOI 10.1016/j.intimp.2013.01.004
   Zhang YH, 2011, ACTA PHARMACOL SIN, V32, P1266, DOI 10.1038/aps.2011.92
   Zhao Y, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.60
   Zhen T, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003562
   Zhou GB, 2007, BLOOD, V109, P3441, DOI 10.1182/blood-2006-06-032250
   Zhu Y, 2007, PHARMAZIE, V62, P439, DOI 10.1691/ph.2007.6.6691
NR 61
TC 65
Z9 70
U1 2
U2 15
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-4889
J9 CELL DEATH DIS
JI Cell Death Dis.
PD FEB
PY 2017
VL 8
AR e2633
DI 10.1038/cddis.2017.35
PG 10
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA GS5YC
UT WOS:000443751300014
PM 28230866
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Liang, J
   Jia, XF
   Wang, K
   Zhao, NK
AF Liang, Jing
   Jia, Xinfeng
   Wang, Kun
   Zhao, Niankun
TI High expression of TFEB is associated with aggressive clinical features
   in colorectal cancer
SO ONCOTARGETS AND THERAPY
LA English
DT Article
DE TFEB; colorectal cancer; clinicopathologic variables; prognostic factor;
   Beclin1
ID TRANSCRIPTIONAL ACTIVATION; FUTURE BIOMARKERS; AUTOPHAGY;
   IDENTIFICATION; EPIDEMIOLOGY; METABOLISM; GENES; RISK
AB Objectives: The transcription factor EB (TFEB), a member of the micropthalmia family, has been found to be associated with autophagy and upregulated in some kinds of tumors. However, very few studies focused on TFEB in colorectal cancer (CRC). TFEB expression status and its relevance to clinical features in CRC would be analyzed in this study.
   Materials and methods: Real-time PCR, Western blot, and immunohistological staining were used to evaluate TFEB expression in CRC tissues and adjacent normal tissues, and the role of TFEB in CRC cell lines was investigated in vitro and in vivo.
   Results: TFEB was expressed at lower level in CRC tissues than normal in both mRNA and protein level. However, there were significantly positive correlations between TFEB expression in cancer tissues and malignant progression of CRC. Cancers with TFEB overexpression always had deeper infiltration and higher lymphatic metastasis rate. Furthermore, patients with high TFEB levels always had poor survival, and higher TFEB expression could be a predictor of survival in multivariate analysis. Meanwhile, knockdown TFEB by shRNA or knockout TFEB by sgRNA in CRC cell lines could significantly inhibit cell proliferation and migration in amino acid-free medium. In addition, we found a positive relationship between TFEB and Beclinl expression, and silencing TFEB inhibited Beclin1 expression in CRC cells.
   Conclusion: TFEB expression correlated with aggressive clinical features in CRC, and higher TFEB expression could be a prognostic factor and potential treatment target of CRC.
C1 [Liang, Jing] Tianjin Binhai New Area Dagang Hosp, Dept Oncol, Nanhuan Rd 1200, Tianjin 300270, Peoples R China.
   [Jia, Xinfeng] Tianjin Civil Affairs Bur Geriatr Hosp, Geriatr Dept, Tianjin 300111, Peoples R China.
   [Wang, Kun] Tianjin Med Univ, Dept Genitourinary Oncol, Canc Inst & Hosp, Natl Clin Res Ctr Canc,Key Lab Canc Prevent & The, Tianjin 300030, Peoples R China.
   [Zhao, Niankun] Tianjin Binhai New Area Dagang Hosp, Dept Internal Med, Tianjin 300270, Peoples R China.
RP Liang, J (corresponding author), Tianjin Binhai New Area Dagang Hosp, Dept Oncol, Nanhuan Rd 1200, Tianjin 300270, Peoples R China.
EM liangjing_blue@163.com
CR Brody H, 2015, NATURE, V521, pS1, DOI 10.1038/521S1a
   Cuyle PJ, 2017, ACTA CLIN BELG, V72, P103, DOI 10.1080/17843286.2016.1262996
   Durinck S, 2015, NAT GENET, V47, P13, DOI 10.1038/ng.3146
   Gayle S, 2017, BLOOD, V129, P1768, DOI 10.1182/blood-2016-09-736892
   Giatromanolaki A, 2015, LUNG CANCER, V90, P98, DOI 10.1016/j.lungcan.2015.07.008
   Hines RB, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2018-022393
   Holch JW, 2017, VISC MED, V33, P70, DOI 10.1159/000454687
   Hu JL, 2018, ONCOGENESIS, V7, DOI 10.1038/s41389-018-0028-8
   Joung J, 2017, NAT PROTOC, V12, P828, DOI 10.1038/nprot.2017.016
   Klein K, 2016, INT J ONCOL, V49, P164, DOI 10.3892/ijo.2016.3505
   Li L, 2018, BIOCHEM PHARMACOL, V150, P265, DOI 10.1016/j.bcp.2018.02.026
   Malouf GG, 2014, CLIN CANCER RES, V20, P4129, DOI 10.1158/1078-0432.CCR-13-3036
   Marley AR, 2016, INT J MOL EPIDEMIOL, V7, P105
   Medina DL, 2011, DEV CELL, V21, P421, DOI 10.1016/j.devcel.2011.07.016
   Napolitano G, 2016, J CELL SCI, V129, P2475, DOI 10.1242/jcs.146365
   Nezich CL, 2015, J CELL BIOL, V210, P435, DOI 10.1083/jcb.201501002
   Perera R, 2015, NATURE, V524, P361, DOI 10.1038/nature14587
   Ploper D, 2015, P NATL ACAD SCI USA, V112, pE420, DOI 10.1073/pnas.1424576112
   Russo M, 2018, BIOCHEM PHARMACOL, V153, P51, DOI 10.1016/j.bcp.2018.02.007
   Samawi HH, 2017, CURR ONCOL, V24, pE513, DOI 10.3747/co.24.3713
   Settembre C, 2013, NAT CELL BIOL, V15, P647, DOI 10.1038/ncb2718
   Wilde L, 2018, BIOCHEM J, V475, P1939, DOI 10.1042/BCJ20170847
   Yu TC, 2017, CELL, V170, P548, DOI 10.1016/j.cell.2017.07.008
   Zarkavelis G, 2017, ANN GASTROENTEROL, V30, P613, DOI 10.20524/aog.2017.0191
   Zeng CJ, 2016, GASTROENTEROLOGY, V150, P1633, DOI 10.1053/j.gastro.2016.02.076
   Zhang J, 2018, CELL MOL LIFE SCI, V75, P1803, DOI 10.1007/s00018-018-2759-2
NR 26
TC 15
Z9 16
U1 1
U2 11
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-6930
J9 ONCOTARGETS THER
JI OncoTargets Ther.
PY 2018
VL 11
BP 8089
EP 8098
DI 10.2147/OTT.S180112
PG 10
WC Biotechnology & Applied Microbiology; Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Oncology
GA HA5ZW
UT WOS:000450359500002
PM 30519051
OA Green Submitted, gold, Green Published
DA 2022-04-25
ER

PT J
AU Law, BYK
   Mok, SWF
   Wu, AG
   Lam, CWK
   Yu, MXY
   Wong, VKW
AF Law, Betty Yuen Kwan
   Mok, Simon Wing Fai
   Wu, An Guo
   Lam, Christopher Wai Kei
   Yu, Margaret Xin Yi
   Wong, Vincent Kam Wai
TI New Potential Pharmacological Functions of Chinese Herbal Medicines via
   Regulation of Autophagy
SO MOLECULES
LA English
DT Review
DE autophagy; natural products; novel functions; Chinese herbal medicines
ID NF-KAPPA-B; APOPTOTIC CELL-DEATH; ACTIVATED PROTEIN-KINASE; ROTTLERIN
   INDUCES AUTOPHAGY; ENDOPLASMIC-RETICULUM STRESS; COLORECTAL-CARCINOMA
   HCT116; RESISTANT PROSTATE-CANCER; PLANT ALKALOID VOACAMINE; INDUCED
   OXIDATIVE STRESS; BLOOD-BRAIN-BARRIER
AB Autophagy is a universal catabolic cellular process for quality control of cytoplasm and maintenance of cellular homeostasis upon nutrient deprivation and environmental stimulus. It involves the lysosomal degradation of cellular components such as misfolded proteins or damaged organelles. Defects in autophagy are implicated in the pathogenesis of diseases including cancers, myopathy, neurodegenerations, infections and cardiovascular diseases. In the recent decade, traditional drugs with new clinical applications are not only commonly found in Western medicines, but also highlighted in Chinese herbal medicines (CHM). For instance, pharmacological studies have revealed that active components or fractions from Chaihu (Radix bupleuri), Hu Zhang (Rhizoma polygoni cuspidati), Donglingcao (Rabdosia rubesens), Hou po (Cortex magnoliae officinalis) and Chuan xiong (Rhizoma chuanxiong) modulate cancers, neurodegeneration and cardiovascular disease via autophagy. These findings shed light on the potential new applications and formulation of CHM decoctions via regulation of autophagy. This article reviews the roles of autophagy in the pharmacological actions of CHM and discusses their new potential clinical applications in various human diseases.
C1 [Law, Betty Yuen Kwan; Mok, Simon Wing Fai; Wu, An Guo; Lam, Christopher Wai Kei; Yu, Margaret Xin Yi; Wong, Vincent Kam Wai] Macau Univ Sci & Technol, State Key Lab Qual Res Chinese Med, Macau, Peoples R China.
RP Wong, VKW (corresponding author), Macau Univ Sci & Technol, State Key Lab Qual Res Chinese Med, Macau, Peoples R China.
EM yklaw@must.edu.mo; smok55@hotmail.com; wag1114@foxmail.com;
   wklam@must.edu.mo; yxyworld@aliyun.com; kawwong@must.edu.mo
OI Wong, Vincent Kam Wai/0000-0002-2951-8108
FU FDCT grant from Science and Technology Development Fund of Macao
   [084/2013/A3, 090/2013/A3]
FX This work was supported by FDCT grant from the Science and Technology
   Development Fund of Macao (Project code: 084/2013/A3 and 090/2013/A3).
CR Aggarwal BB, 2003, ANTICANCER RES, V23, P363
   Aggarwal BB, 2009, INT J BIOCHEM CELL B, V41, P40, DOI 10.1016/j.biocel.2008.06.010
   Ahn MY, 2013, J ORAL PATHOL MED, V42, P17, DOI 10.1111/j.1600-0714.2012.01187.x
   Aichinger M, 2013, J EXP MED, V210, P287, DOI 10.1084/jem.20122149
   Akar U, 2007, MOL CANCER RES, V5, P241, DOI 10.1158/1541-7786.MCR-06-0229
   Akimoto M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126605
   Alers S, 2012, MOL CELL BIOL, V32, P2, DOI 10.1128/MCB.06159-11
   Alghasham AA, 2013, INT J HEALTH SCI-IJH, V7, P77, DOI 10.12816/0006025
   Alinari L, 2011, BLOOD, V118, P6893, DOI 10.1182/blood-2011-06-363879
   Anand P, 2008, CANCER LETT, V267, P133, DOI 10.1016/j.canlet.2008.03.025
   Andrade RM, 2006, J CLIN INVEST, V116, P2366, DOI 10.1172/JCI28796
   Asif H. M., 2014, INT J PHARM BIOMED R, V5, P69
   Azios NG, 2007, NEOPLASIA, V9, P147, DOI 10.1593/neo.06778
   Balgi AD, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007124
   Bandyopadhyay U, 2008, MOL CELL BIOL, V28, P5747, DOI 10.1128/MCB.02070-07
   Bang JS, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2662
   Bang KH, 2000, ARCH PHARM RES, V23, P46, DOI 10.1007/BF02976465
   Bartels AL, 2011, CURR PHARM DESIGN, V17, P2771, DOI 10.2174/138161211797440122
   Bataller R, 2005, J CLIN INVEST, V115, P209, DOI 10.1172/JCI200524282
   Benito PB, 1998, LIFE SCI, V63, P1147, DOI 10.1016/S0024-3205(98)00376-2
   Bezerra DP, 2005, Z NATURFORSCH C, V60, P539
   Boroughs LK, 2015, NAT CELL BIOL, V17, P351, DOI 10.1038/ncb3124
   Brady JM, 2002, DRUG METAB DISPOS, V30, P838, DOI 10.1124/dmd.30.7.838
   BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0
   Bui-Xuan NH, 2010, J ETHNOPHARMACOL, V131, P95, DOI 10.1016/j.jep.2010.06.007
   Buzzai M, 2007, CANCER RES, V67, P6745, DOI 10.1158/0008-5472.CAN-06-4447
   Campbell GR, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002689
   Cao J. X., 2011, CHIN J PHARMACOVIGIL, V8, P38
   Cao J, 2015, INT IMMUNOPHARMACOL, V26, P212, DOI 10.1016/j.intimp.2015.03.028
   Carew JS, 2010, J CELL MOL MED, V14, P2448, DOI 10.1111/j.1582-4934.2009.00832.x
   Chakraborty D, 2012, EUR J PHARMACOL, V694, P20, DOI 10.1016/j.ejphar.2012.08.001
   Chan JYW, 2006, PLANTA MED, V72, P28, DOI 10.1055/s-2005-873149
   Chan YY, 2015, EVID-BASED COMPL ALT, V2015, DOI 10.1155/2015/710895
   Chang KH, 2013, ONCOL LETT, V6, P1435, DOI 10.3892/ol.2013.1548
   Chang WH, 2002, PLANTA MED, V68, P128, DOI 10.1055/s-2002-20246
   Chatterjee C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036916
   Checker R, 2014, INFLAMMATION, V37, P542, DOI 10.1007/s10753-013-9768-y
   Chen CR, 2011, BRIT J PHARMACOL, V164, P1534, DOI 10.1111/j.1476-5381.2011.01456.x
   Chen CF, 2008, ACTA PHARMACOL SIN, V29, P1103, DOI 10.1111/j.1745-7254.2008.00868.x
   Chen G, 2012, APOPTOSIS, V17, P90, DOI 10.1007/s10495-011-0658-1
   Chen JH, 2007, CHIN J CLIN ONCOL, V4, P16, DOI DOI 10.1007/S11805-007-0016-9
   Chen JH, 2015, LEUKEMIA LYMPHOMA, V56, P2953, DOI 10.3109/10428194.2015.1018251
   CHEN KK, 1967, J PHARM SCI-US, V56, P1535, DOI 10.1002/jps.2600561202
   Chen MJ, 2013, ONCOL REP, V29, P430, DOI 10.3892/or.2012.2131
   Chen ML, 2013, AUTOPHAGY, V9, P2033, DOI 10.4161/auto.26336
   Chen SJ, 2014, J NEUROCHEM, V128, P256, DOI 10.1111/jnc.12474
   Chen XC, 2003, EUR J PHARMACOL, V473, P1, DOI 10.1016/S0014-2999(03)01945-9
   Chen Z., 2014, ALTERN MED, V2014, DOI [10.1155/2014/267976, DOI 10.1155/2014/267976]
   Chen ZY, 2010, NEUROSCI LETT, V482, P264, DOI 10.1016/j.neulet.2010.07.052
   Cheng HM, 2011, INT ARCH ALLERGY IMM, V155, P141, DOI 10.1159/000318861
   Cheng PW, 2006, CLIN EXP PHARMACOL P, V33, P612, DOI 10.1111/j.1440-1681.2006.04415.x
   CHIOU GCY, 1991, ACTA PHARMACOL SIN, V12, P99
   Chiu HC, 2009, J BIOMED SCI, V16, DOI 10.1186/1423-0127-16-110
   Chiu PY, 2011, REJUV RES, V14, P173, DOI 10.1089/rej.2010.1094
   Choi HS, 2000, J ETHNOPHARMACOL, V69, P173, DOI 10.1016/S0378-8741(99)00141-5
   Christina AJM, 2006, PHYTOMEDICINE, V13, P196, DOI 10.1016/j.phymed.2004.01.009
   Chrubasik S, 2005, PHYTOMEDICINE, V12, P684, DOI 10.1016/j.phymed.2004.07.009
   Clericuzio M, 2004, J NAT PROD, V67, P1823, DOI 10.1021/np049883o
   Cloonan SM, 2011, INT J CANCER, V128, P1712, DOI 10.1002/ijc.25477
   Colman RJ, 2009, SCIENCE, V325, P201, DOI 10.1126/science.1173635
   Cui HS, 2009, BIOL PHARM BULL, V32, P79, DOI 10.1248/bpb.32.79
   Cui Q, 2007, BIOL PHARM BULL, V30, P859, DOI 10.1248/bpb.30.859
   Dai JP, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042706
   Das Samarjit, 2007, Inflammation & Allergy Drug Targets, V6, P168, DOI 10.2174/187152807781696464
   Davidson CD, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006951
   Dedov VN, 2002, BRIT J PHARMACOL, V137, P793, DOI 10.1038/sj.bjp.0704925
   Delmas D, 2006, CURR DRUG TARGETS, V7, P423, DOI 10.2174/138945006776359331
   Deng YJ, 2014, AUTOPHAGY, V10, P1776, DOI 10.4161/auto.29746
   Deretic V, 2011, IMMUNOL REV, V240, P92, DOI 10.1111/j.1600-065X.2010.00995.x
   Ding N, 2011, CANCER-AM CANCER SOC, V117, P2735, DOI 10.1002/cncr.25711
   Dong XZ, 2013, J ETHNOPHARMACOL, V150, P1053, DOI 10.1016/j.jep.2013.10.018
   DU GH, 2004, HERALD MED, V23, P355
   Duke J. A., 1985, MED PLANTS CHINA, P705
   Easton JB, 2006, ONCOGENE, V25, P6436, DOI 10.1038/sj.onc.1209886
   Elmore SP, 2001, FASEB J, V15, P2286, DOI 10.1096/fj.01-0206fje
   Escandell JM, 2008, BIOCHEM PHARMACOL, V76, P198, DOI 10.1016/j.bcp.2008.05.004
   Escandell JM, 2007, J PHARMACOL EXP THER, V322, P1261, DOI 10.1124/jpet.107.122671
   Fan XD, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0450-z
   Fan XX, 2015, SCI REP-UK, V5, DOI 10.1038/srep16348
   Federici E, 2000, PLANTA MED, V66, P93, DOI 10.1055/s-0029-1243122
   Feng DC, 2008, IMMUNOL LETT, V121, P127, DOI 10.1016/j.imlet.2008.10.001
   Feng YC, 2014, CELL RES, V24, P24, DOI 10.1038/cr.2013.168
   Fingar DC, 2004, ONCOGENE, V23, P3151, DOI 10.1038/sj.onc.1207542
   Fogarty S, 2010, BBA-PROTEINS PROTEOM, V1804, P581, DOI 10.1016/j.bbapap.2009.09.012
   Furuhashi I, 2005, J PHARM PHARMACOL, V57, P1661, DOI 10.1211/jpp.57.12.0017
   Galluzzi L, 2008, CURR MOL MED, V8, P78
   Gao FH, 2012, INT J MOL MED, V29, P649, DOI 10.3892/ijmm.2012.895
   Garcia-Alloza M, 2007, J NEUROCHEM, V102, P1095, DOI 10.1111/j.1471-4159.2007.04613.x
   Gary L, 1996, CHINESE MED TEAS SIM, P190
   George U, 1974, DICT PLANTS USED MAN, P619
   Ghosh R, 2007, NEOPLASIA, V9, P893, DOI 10.1593/neo.07502
   Ghosh R, 2010, ANTICANCER RES, V30, P857
   Gong JJ, 2014, ONCOTARGET, V5, P2529, DOI 10.18632/oncotarget.1810
   Gong XZ, 2015, ARCH TOXICOL, V89, P1057, DOI 10.1007/s00204-014-1302-y
   GRAY AI, 1988, PHYTOCHEMISTRY, V27, P1805, DOI 10.1016/0031-9422(88)80448-5
   Greene N. P., 2012, FASEB J, V26, P869
   Gros F, 2014, BRIT J PHARMACOL, V171, P4337, DOI 10.1111/bph.12792
   Guo QL, 2004, ACTA PHARMACOL SIN, V25, P769
   Gurusamy N, 2010, CARDIOVASC RES, V86, P103, DOI 10.1093/cvr/cvp384
   Gwinn DM, 2008, MOL CELL, V30, P214, DOI 10.1016/j.molcel.2008.03.003
   Han J, 2007, J CHROMATOGR B, V848, P355, DOI 10.1016/j.jchromb.2006.10.061
   Han J, 2015, J ETHNOPHARMACOL, V172, P368, DOI 10.1016/j.jep.2015.05.016
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9
   Hara T, 2006, NATURE, V441, P885, DOI 10.1038/nature04724
   Hardie DG, 2007, NAT REV MOL CELL BIO, V8, P774, DOI 10.1038/nrm2249
   Hardie DG, 2001, BIOESSAYS, V23, P1112, DOI 10.1002/bies.10009
   Harr MW, 2010, AUTOPHAGY, V6, P912, DOI 10.4161/auto.6.7.13290
   Hasima N, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.467
   He F. G., 2008, B CHIN CANC, V17, P108
   He GuiPing, 2012, Chinese Archives of Traditional Chinese Medicine, V30, P583
   He H, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2013.533
   He XR, 2015, J ETHNOPHARMACOL, V172, P10, DOI 10.1016/j.jep.2015.06.010
   Hempen C. H., 2009, MATERIA MED CHINESE, P1016
   Hong H, 2012, J GINSENG RES, V36, P418, DOI 10.5142/jgr.2012.36.4.418
   Hossain A, 2012, APOPTOSIS, V17, P1066, DOI 10.1007/s10495-012-0745-y
   Hotamisligil GS, 2010, CELL, V140, P900, DOI 10.1016/j.cell.2010.02.034
   Hou LY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132829
   Hou YZ, 2004, LIFE SCI, V75, P1775, DOI 10.1016/j.lfs.2004.05.005
   Hou YZ, 2005, J ETHNOPHARMACOL, V100, P140, DOI 10.1016/j.jep.2005.01.051
   Hoyer-Hansen M, 2007, MOL CELL, V25, P193, DOI 10.1016/j.molcel.2006.12.009
   Hsiang CY, 2005, J BIOMED SCI, V12, P791, DOI 10.1007/s11373-005-9003-4
   Hsu K. J., 1996, CHINESE TRADITIONAL, P802
   Hsui CM, 2013, INT J ONCOL, V43, P338, DOI 10.3892/ijo.2013.1942
   Huang J, 2008, J PHARMACOL SCI, V107, P370, DOI 10.1254/jphs.08044FP
   HUANG Q, 1991, CHEM PHARM BULL, V39, P397, DOI 10.1248/cpb.39.397
   Huang Q, 2007, MED RES REV, V27, P609, DOI 10.1002/med.20094
   Huang X, 2010, J CLIN NEUROSCI, V17, P1515, DOI 10.1016/j.jocn.2010.03.051
   Huang YT, 2006, CANCER LETT, V231, P270, DOI 10.1016/j.canlet.2005.02.011
   Huang YT, 1998, J GASTROEN HEPATOL, V13, P266, DOI 10.1111/j.1440-1746.1998.01554.x
   Huang ZQ, 2015, MOL MED REP, V11, P4678, DOI 10.3892/mmr.2015.3322
   Hwang D, 2015, SCI REP-UK, V5, DOI 10.1038/srep10029
   Idris-Usman MS, 2010, J MED PLANTS RES, V4, P659
   Ip SP, 1997, PHYTOTHER RES, V11, P42, DOI 10.1002/(SICI)1099-1573(199702)11:1<42::AID-PTR940>3.3.CO;2-X
   Ippoushi K, 2003, LIFE SCI, V73, P3427, DOI 10.1016/j.lfs.2003.06.022
   Iqbal J, 2009, LEUKEMIA, V23, P1139, DOI 10.1038/leu.2009.3
   Ishaq M, 2014, BBA-GEN SUBJECTS, V1840, P3374, DOI 10.1016/j.bbagen.2014.08.019
   Islam MN, 2013, FOOD CHEM TOXICOL, V55, P541, DOI 10.1016/j.fct.2013.01.054
   Itakura E, 2010, AUTOPHAGY, V6, P764, DOI 10.4161/auto.6.6.12709
   Iwashita M, 2007, EUR J PHARMACOL, V570, P38, DOI 10.1016/j.ejphar.2007.05.073
   Jang SI, 2006, EUR J PHARMACOL, V542, P1, DOI 10.1016/j.ejphar.2006.04.044
   Janku F, 2011, NAT REV CLIN ONCOL, V8, P528, DOI 10.1038/nrclinonc.2011.71
   Jayaprakasam B, 2003, CANCER LETT, V189, P11, DOI 10.1016/S0304-3835(02)00497-4
   Jeong HW, 2009, AM J PHYSIOL-ENDOC M, V296, pE955, DOI 10.1152/ajpendo.90599.2008
   Jia Y. M., 2011, CHINA J CHIN MED, V26, P1078
   Jiang JL, 2009, MOLECULES, V14, P1852, DOI 10.3390/molecules14051852
   Jiang TF, 2013, J NEUROIMMUNE PHARM, V8, P356, DOI 10.1007/s11481-012-9431-7
   Jiao S. D., 2001, 10 LECT USE MED PERS, P711
   Johansen T, 2011, AUTOPHAGY, V7, P279, DOI 10.4161/auto.7.3.14487
   Jung HJ, 2005, ARCH PHARM RES, V28, P557, DOI 10.1007/BF02977758
   Jung HS, 2009, AUTOPHAGY, V5, P241, DOI 10.4161/auto.5.2.7518
   Jung HA, 2010, LIFE SCI, V87, P420, DOI 10.1016/j.lfs.2010.08.005
   KAKEGAWA H, 1992, CHEM PHARM BULL, V40, P1439
   Kang SJ, 2008, BASIC CLIN PHARMACOL, V103, P305, DOI 10.1111/j.1742-7843.2008.00280.x
   Kannaiyan R, 2011, APOPTOSIS, V16, P1028, DOI 10.1007/s10495-011-0629-6
   Kao TK, 2013, EXP NEUROL, V247, P188, DOI 10.1016/j.expneurol.2013.04.010
   Kasai M, 2009, J IMMUNOL, V183, P7278, DOI 10.4049/jimmunol.0804087
   Kihara A, 2001, EMBO REP, V2, P330, DOI 10.1093/embo-reports/kve061
   Kim DG, 2014, ONCOTARGET, V5, P4438, DOI 10.18632/oncotarget.2034
   Kim EH, 2009, J ETHNOPHARMACOL, V126, P320, DOI 10.1016/j.jep.2009.08.027
   Kim JH, 2012, J GINSENG RES, V36, P16, DOI 10.5142/jgr.2012.36.1.16
   Kim JJ, 2012, CELL HOST MICROBE, V11, P457, DOI 10.1016/j.chom.2012.03.008
   KIM SR, 2013, EVID-BASED COMPL ALT, V2013, DOI DOI 10.1155/2013/975350
   Kim YJ, 2015, BIOORG MED CHEM LETT, V25, P2559, DOI 10.1016/j.bmcl.2015.04.054
   Kim YJ, 2010, INT IMMUNOPHARMACOL, V10, P1127, DOI 10.1016/j.intimp.2010.06.017
   Kimura Y, 2001, J NUTR, V131, P1844, DOI 10.1093/jn/131.6.1844
   King FW, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007283
   Kmiec Z, 2001, ADV ANAT EMBRYOL CEL, V161, P1
   Ko H, 2011, J CELL BIOCHEM, V112, P2471, DOI 10.1002/jcb.23171
   Kogure K, 2003, BBA-GEN SUBJECTS, V1622, P1, DOI 10.1016/S0304-4165(03)00095-3
   Kogure K, 1999, BBA-GEN SUBJECTS, V1426, P133, DOI 10.1016/S0304-4165(98)00146-9
   Komatsu M, 2006, NATURE, V441, P880, DOI 10.1038/nature04723
   Kroemer G, 2008, NAT REV MOL CELL BIO, V9, P1004, DOI 10.1038/nrm2529
   Kuballa P, 2012, ANNU REV IMMUNOL, V30, P611, DOI 10.1146/annurev-immunol-020711-074948
   Kuhnl J, 2015, EXP DERMATOL, V24, P42, DOI 10.1111/exd.12588
   Kuete V, 2011, INT J ANTIMICROB AG, V37, P156, DOI 10.1016/j.ijantimicag.2010.10.020
   Kumar D, 2014, CANCER LETT, V343, P179, DOI 10.1016/j.canlet.2013.10.003
   Kumar R, 2012, CARCINOGENESIS, V33, P1909, DOI 10.1093/carcin/bgs219
   Kumar S, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.399
   Kung CP, 2011, CRIT REV EUKAR GENE, V21, P71, DOI 10.1615/CritRevEukarGeneExpr.v21.i1.50
   Kuo PL, 2006, MOL CANCER THER, V5, P3209, DOI 10.1158/1535-7163.MCT-06-0478
   Kwak EJ, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/829650
   Kwon HS, 2008, J MOL MED, V86, P1287, DOI 10.1007/s00109-008-0395-2
   Lai C. S., 2010, CHINA J CHIN MED, V25, P267
   Lai Q, 2015, DRUG DES DEV THER, V9, P4997, DOI 10.2147/DDDT.S89876
   Lammert O, 2000, BRIT J NUTR, V84, P233
   Laplante M, 2010, P NATL ACAD SCI USA, V107, P3281, DOI 10.1073/pnas.1000323107
   Law BYK, 2010, MOL CANCER THER, V9, P718, DOI 10.1158/1535-7163.MCT-09-0700
   Law BYK, 2014, SCI REP-UK, V4, DOI 10.1038/srep05510
   Law BYK, 2014, CHIN MED-UK, V9, DOI 10.1186/1749-8546-9-21
   Lee JH, 2006, J PHARMACOL EXP THER, V316, P271, DOI 10.1124/jpet.105.092486
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Levine B, 2007, NAT REV IMMUNOL, V7, P767, DOI 10.1038/nri2161
   Levine B, 2011, NATURE, V469, P323, DOI 10.1038/nature09782
   Li B, 2014, CLIN EXP RHEUMATOL, V32, P705
   Li C. W., 2009, ASIA PAC TRAIDT MED, V5, P152
   Li FR, 2013, PHARM BIOL, V51, P1196, DOI 10.3109/13880209.2013.784342
   Li HY, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2014.543
   Li HB, 2007, ARCH PHARM RES, V30, P1566, DOI 10.1007/BF02977326
   Li J, 2010, EUR J CANCER, V46, P1900, DOI 10.1016/j.ejca.2010.02.021
   Li J, 2012, ACTA PHARMACOL SIN, V33, P242, DOI 10.1038/aps.2011.152
   Li J, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-215
   Li T, 2010, BIOL PHARM BULL, V33, P40, DOI 10.1248/bpb.33.40
   Li X, 2012, INT J BIOL SCI, V8, P901, DOI 10.7150/ijbs.4554
   Li XQ, 2010, CANCER RES, V70, P5942, DOI 10.1158/0008-5472.CAN-10-0157
   Li YC, 2014, CANCER LETT, V344, P239, DOI 10.1016/j.canlet.2013.11.001
   Li ZT, 2015, TRIALS, V16, DOI 10.1186/s13063-015-0645-x
   Liang JY, 2007, NAT CELL BIOL, V9, P218, DOI 10.1038/ncb1537
   Liang XH, 1998, J VIROL, V72, P8586, DOI 10.1128/JVI.72.11.8586-8596.1998
   Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257
   Lim BO, 2003, J ETHNOPHARMACOL, V84, P23, DOI 10.1016/S0378-8741(02)00257-X
   Lim JH, 2009, CARCINOGENESIS, V30, P729, DOI 10.1093/carcin/bgn265
   Lin JM, 2014, INTEGR CANCER THER, V13, P240, DOI 10.1177/1534735413508811
   Lindmo K, 2006, J CELL SCI, V119, P605, DOI 10.1242/jcs.02855
   Liu HY, 2007, EUR J PHARMACOL, V561, P226, DOI 10.1016/j.ejphar.2007.01.062
   Liu J. Y., 1991, TIANJIN PHARM, V3, P29
   Liu JM, 2013, BIOCHEM BIOPH RES CO, V437, P87, DOI 10.1016/j.bbrc.2013.06.042
   Liu T, 2015, ONCOTARGET, V6, P7992, DOI 10.18632/oncotarget.3505
   Liu Z, 2014, EUR J PHARMACOL, V738, P206, DOI 10.1016/j.ejphar.2014.05.041
   Lok CN, 2011, J BIOL CHEM, V286, P31684, DOI 10.1074/jbc.M110.202531
   Lynch-Day MA, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a009357
   Ma WW, 2007, DRUG TODAY, V43, P659, DOI 10.1358/dot.2007.43.10.1148059
   Madeo F, 2010, NAT CELL BIOL, V12, P842, DOI 10.1038/ncb0910-842
   Magnaudeix A, 2013, NEUROBIOL AGING, V34, P770, DOI 10.1016/j.neurobiolaging.2012.06.026
   Maioli E, 2012, ANN NY ACAD SCI, V1259, P65, DOI 10.1111/j.1749-6632.2012.06514.x
   Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239
   Makhov P, 2014, BRIT J CANCER, V110, P899, DOI 10.1038/bjc.2013.810
   Makin OS, 2002, BIOCHEM SOC T, V30, P521, DOI 10.1042/bst0300521
   Malofeeva EV, 2012, CANCER RES, V72, P6457, DOI 10.1158/0008-5472.CAN-12-1340
   Matkowski A, 2013, CURR MED CHEM, V20, P984
   Maury E, 2010, CIRC RES, V106, P447, DOI 10.1161/CIRCRESAHA.109.208355
   Meisse D, 2002, FEBS LETT, V526, P38, DOI 10.1016/S0014-5793(02)03110-1
   Melendez A, 2003, SCIENCE, V301, P1387, DOI 10.1126/science.1087782
   Meng XB, 2014, TOXICOL APPL PHARM, V279, P63, DOI 10.1016/j.taap.2014.03.026
   Meschini S, 2007, TOXICOL IN VITRO, V21, P197, DOI 10.1016/j.tiv.2006.09.007
   Meschini S, 2008, AUTOPHAGY, V4, P1020, DOI 10.4161/auto.6952
   Miao Q, 2013, INT J MOL SCI, V14, P1370, DOI 10.3390/ijms14011370
   Ming R, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-5-r41
   Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639
   Mizushima N, 2010, CELL, V140, P313, DOI 10.1016/j.cell.2010.01.028
   Mok SWF, 2007, BIOCHEM BIOPH RES CO, V359, P672, DOI 10.1016/j.bbrc.2007.05.163
   Monneaux F, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2711
   Morselli E, 2011, J CELL BIOL, V192, P615, DOI 10.1083/jcb.201008167
   Muralimanoharan SB, 2009, PROSTATE, V69, P494, DOI 10.1002/pros.20899
   Nakahira K, 2011, NAT IMMUNOL, V12, P222, DOI 10.1038/ni.1980
   Nelson R, 2005, NATURE, V435, P773, DOI 10.1038/nature03680
   Newgard CB, 2009, CELL METAB, V9, P311, DOI 10.1016/j.cmet.2009.02.002
   Nishanthi M., 2011, INT J NOVEL TRENDS P, V2, P39
   Nixon RA, 2013, NAT MED, V19, P983, DOI 10.1038/nm.3232
   Noda NN, 2010, FEBS LETT, V584, P1379, DOI 10.1016/j.febslet.2010.01.018
   Nunez CE, 2013, INT J OBESITY, V37, P1473, DOI 10.1038/ijo.2013.27
   Obata Toshio, 2009, Research Communications in Molecular Pathology and Pharmacology, V122-23, P65
   Ogier-Denis E, 2000, J BIOL CHEM, V275, P39090, DOI 10.1074/jbc.M006198200
   OGIERDENIS E, 1995, J BIOL CHEM, V270, P13, DOI 10.1074/jbc.270.1.13
   Okazaki H, 2002, J RHEUMATOL, V29, P707
   Ouyang DY, 2011, ACTA BIOCH BIOPH SIN, V43, P487, DOI 10.1093/abbs/gmr032
   Padhye S, 2012, MED RES REV, V32, P1131, DOI 10.1002/med.20235
   Page N, 2011, ANN RHEUM DIS, V70, P837, DOI 10.1136/ard.2010.139832
   Pan Y, 2009, J ETHNOPHARMACOL, V124, P98, DOI 10.1016/j.jep.2009.04.008
   Pandey MK, 2007, BLOOD, V110, P3517, DOI 10.1182/blood-2007-03-079616
   Panthong A, 2007, J ETHNOPHARMACOL, V111, P335, DOI 10.1016/j.jep.2006.11.038
   Park CS, 2004, J PHARMACOL EXP THER, V309, P705, DOI 10.1124/jpet.103.063693
   Park YK, 2007, INT IMMUNOPHARMACOL, V7, P955, DOI 10.1016/j.intimp.2006.03.018
   Pattingre S, 2003, J BIOL CHEM, V278, P16667, DOI 10.1074/jbc.M210998200
   PEK G, 1989, ARCH GERONTOL GERIAT, V9, P17, DOI 10.1016/0167-4943(89)90021-6
   Petrovski G, 2011, ANN NY ACAD SCI, V1215, P22, DOI 10.1111/j.1749-6632.2010.05843.x
   Pickford F, 2008, J CLIN INVEST, V118, P2190, DOI 10.1172/JCI33585
   Pickhardt M, 2005, J BIOL CHEM, V280, P3628, DOI 10.1074/jbc.M410984200
   Poornima P, 2013, FOOD CHEM, V141, P3598, DOI 10.1016/j.foodchem.2013.05.138
   Pyo JO, 2012, EXP MOL MED, V44, P73, DOI 10.3858/emm.2012.44.2.029
   Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039
   Radulovic S, 2007, J BUON, V12, pS151
   Rasul A, 2012, ONCOL REP, V27, P1481, DOI 10.3892/or.2012.1694
   Ravindran J, 2009, AAPS J, V11, P495, DOI 10.1208/s12248-009-9128-x
   Recio MC, 2004, PLANTA MED, V70, P414, DOI 10.1055/s-2004-818968
   Reginster J Y, 2000, Curr Rheumatol Rep, V2, P472, DOI 10.1007/s11926-000-0023-9
   Reis FS, 2015, MOLECULES, V20, P17872, DOI 10.3390/molecules201017872
   Ren GW, 2015, J NAT MED-TOKYO, V69, P522, DOI 10.1007/s11418-015-0918-4
   Reynertson KA, 2008, FOOD CHEM, V109, P883, DOI 10.1016/j.foodchem.2008.01.021
   Rogosnitzky M, 2011, PHARMACOL REP, V63, P337, DOI 10.1016/S1734-1140(11)70500-X
   Rosenfeld MR, 2010, J CLIN ONCOL, V28
   Rubinsztein DC, 2007, NAT REV DRUG DISCOV, V6, P304, DOI 10.1038/nrd2272
   Rubinsztein DC, 2006, NATURE, V443, P780, DOI 10.1038/nature05291
   Rubinsztein DC, 2012, NAT REV DRUG DISCOV, V11, P709, DOI 10.1038/nrd3802
   RUBY AJ, 1995, CANCER LETT, V94, P79, DOI 10.1016/0304-3835(95)03827-J
   Ryter SW, 2009, AUTOPHAGY, V5, P235, DOI 10.4161/auto.5.2.7495
   Sabatini DM, 2006, NAT REV CANCER, V6, P729, DOI 10.1038/nrc1974
   Saitoh M, 2004, BIOCHEM PHARMACOL, V67, P2005, DOI 10.1016/j.bcp.2004.01.020
   Saitoh T, 2008, NATURE, V456, P264, DOI 10.1038/nature07383
   Salminen A, 2011, J NEUROCHEM, V118, P460, DOI 10.1111/j.1471-4159.2011.07331.x
   Sandur SK, 2006, J BIOL CHEM, V281, P17023, DOI 10.1074/jbc.M601595200
   Sarkar S, 2005, J CELL BIOL, V170, P1101, DOI 10.1083/jcb.200504035
   Sarkar S, 2008, MOL BIOSYST, V4, P895, DOI 10.1039/b804606a
   Sarkar S, 2007, J BIOL CHEM, V282, P5641, DOI 10.1074/jbc.M609532200
   Sarkar S, 2006, AUTOPHAGY, V2, P132, DOI 10.4161/auto.2387
   Saw Constance Lay-Lay, 2010, Chin Med, V5, P37, DOI 10.1186/1749-8546-5-37
   Schaeffer V, 2012, BRAIN, V135, P2169, DOI 10.1093/brain/aws143
   Seo EJ, 2013, PHYTOTHER RES, V27, P829, DOI 10.1002/ptr.4809
   Sexton E, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-45
   Sharma S, 2009, NEUROSCIENCE, V161, P1037, DOI 10.1016/j.neuroscience.2009.04.042
   Shen HM, 2011, AUTOPHAGY, V7, P457, DOI 10.4161/auto.7.5.14226
   Shen SY, 2014, INT J BIOL SCI, V10, P212, DOI 10.7150/ijbs.8056
   Shen YC, 2001, MOL PHARMACOL, V60, P1083, DOI 10.1124/mol.60.5.1083
   Shibata M, 2006, J BIOL CHEM, V281, P14474, DOI 10.1074/jbc.M600364200
   SHIMADA K, 1977, CHEM PHARM BULL, V25, P714
   Shin IJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088617
   Singh BN, 2012, BIOCHEM PHARMACOL, V84, P1154, DOI 10.1016/j.bcp.2012.08.007
   Sokollik C, 2011, CAN J GASTROENTEROL, V25, P667, DOI 10.1155/2011/581264
   Song KS, 2008, AUTOPHAGY, V4, P650, DOI 10.4161/auto.6057
   Song S. J., 2014, Application of Timosaponin AIII in Anemarrhena to Preparation of Antitumor Drugs, Patent No. [CN 103599122 A, 103599122]
   Soubir Titov, 2007, Sheng Wu Gong Cheng Xue Bao, V23, P257
   Spencer B, 2009, J NEUROSCI, V29, P13578, DOI 10.1523/JNEUROSCI.4390-09.2009
   Spilman P, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009979
   Stein M, 2010, PROSTATE, V70, P1388, DOI 10.1002/pros.21172
   Su MY, 2011, J AGR FOOD CHEM, V59, P521, DOI 10.1021/jf104408d
   Sun F, 2012, ACTA PHARMACOL SIN, V33, P431, DOI 10.1038/aps.2011.199
   Sun LD, 2015, BIOCHEM PHARMACOL, V95, P156, DOI 10.1016/j.bcp.2015.03.014
   Sy LK, 2008, CANCER RES, V68, P10229, DOI 10.1158/0008-5472.CAN-08-1983
   Takada Y, 2005, J BIOL CHEM, V280, P17203, DOI 10.1074/jbc.M500077200
   Talloczy Z, 2006, AUTOPHAGY, V2, P24, DOI 10.4161/auto.2176
   Tan XY, 2011, INT J BIOL SCI, V7, P383, DOI 10.7150/ijbs.7.383
   Tan YQ, 2011, CHIN J INTEGR MED, V17, P150, DOI 10.1007/s11655-011-0645-y
   Tang W. C., 1992, CHINESE DRUGS PLANT, P1056
   Tang W, 2012, ACTA PHARMACOL SIN, V33, P1112, DOI 10.1038/aps.2012.108
   Thi KVL, 2012, BIOL PHARM BULL, V35, P1379, DOI 10.1248/bpb.b12-00426
   Thoen LFR, 2011, J HEPATOL, V55, P1353, DOI 10.1016/j.jhep.2011.07.010
   Thyagarajan A, 2010, NUTR CANCER, V62, P630, DOI 10.1080/01635580903532390
   Tian F, 2015, INT J ONCOL, V46, P2355, DOI 10.3892/ijo.2015.2959
   Tillman DM, 2003, CANCER RES, V63, P5118
   Tjong YW, 2011, J ETHNOPHARMACOL, V135, P754, DOI 10.1016/j.jep.2011.04.007
   Mai TT, 2012, CANCER LETT, V321, P144, DOI 10.1016/j.canlet.2012.01.045
   Tsai JP, 2015, ONCOTARGET, V6, P28851, DOI 10.18632/oncotarget.4767
   Tsutsumi T, 2003, BIOL PHARM BULL, V26, P313, DOI 10.1248/bpb.26.313
   Turzanski J, 2009, BRIT J HAEMATOL, V145, P137, DOI 10.1111/j.1365-2141.2008.07555.x
   Tycko R, 2006, Q REV BIOPHYS, V39, P1, DOI 10.1017/S0033583506004173
   Vanhaesebroeck B, 2001, ANNU REV BIOCHEM, V70, P535, DOI 10.1146/annurev.biochem.70.1.535
   Vaya J, 1997, FREE RADICAL BIO MED, V23, P302, DOI 10.1016/S0891-5849(97)00089-0
   Wagner H, 2011, CHROMATOGRAPHIC FINGERPRINT ANALYSIS OF HERBAL MEDICINES: THIN-LAYER AND HIGH PERFORMANCE LIQUID CHROMATOGRAPHY OF CHINESE DRUGS, VOLS 1 AND 2, 2ND EDITION, pXXI
   Wakade AS, 2008, INDIAN J EXP BIOL, V46, P528
   Wan ZT, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039225
   Wang F, 2015, INT J IMMUNOPATH PH, V28, P362, DOI 10.1177/0394632015598849
   Wang GJ, 2002, LIFE SCI, V71, P1081, DOI 10.1016/S0024-3205(02)01794-0
   WANG J, 2015, GASTROENT RES PRACT, V2015, DOI DOI 10.1155/2015/457193
   Wang L, 2005, PLANTA MED, V71, P416, DOI 10.1055/s-2005-864135
   Wang LH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036418
   Wang LM, 2014, BIOCHEM PHARMACOL, V92, P73, DOI 10.1016/j.bcp.2014.07.018
   Wang N, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/934207
   Wang N, 2011, BRIT J PHARMACOL, V164, P731, DOI 10.1111/j.1476-5381.2011.01349.x
   Wang T, 2010, J ETHNOPHARMACOL, V128, P575, DOI 10.1016/j.jep.2010.01.044
   Wang T, 2009, FEBS LETT, V583, P3655, DOI 10.1016/j.febslet.2009.10.046
   Wang XY, 2013, J ETHNOPHARMACOL, V150, P781, DOI 10.1016/j.jep.2013.09.055
   Wang Y, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.358
   Wang YL, 2014, J ETHNOPHARMACOL, V153, P42, DOI 10.1016/j.jep.2014.02.013
   Wang ZY, 2014, ONCOTARGET, V5, P7013, DOI 10.18632/oncotarget.2192
   Weber T, 2002, CLIN CANCER RES, V8, P863
   Wei YJ, 2008, MOL CELL, V30, P678, DOI 10.1016/j.molcel.2008.06.001
   White E, 2012, NAT REV CANCER, V12, P401, DOI 10.1038/nrc3262
   Williams A, 2008, NAT CHEM BIOL, V4, P295, DOI 10.1038/nchembio.79
   Wolfe DM, 2013, EUR J NEUROSCI, V37, P1949, DOI 10.1111/ejn.12169
   Wong VKW, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.217
   Wong VKW, 2015, MOLECULES, V20, P3496, DOI 10.3390/molecules20033496
   Wu AG, 2015, SCI REP-UK, V5, DOI 10.1038/srep17199
   Wu AG, 2013, INT J MOL SCI, V14, P22618, DOI 10.3390/ijms141122618
   Wu J. N., 2002, ILLUSTRATED CHINESE, P712
   Wu M, 2010, CHIN J INTEGR MED, V16, P188, DOI 10.1007/s11655-010-0188-7
   Wu R. T., 2012, U. S. Patent Application, Patent No. [13/685,292, 13685292]
   Wu SP, 2011, DISCOV MED, V11, P325
   Wu WKK, 2010, DRUG RESIST UPDATE, V13, P87, DOI 10.1016/j.drup.2010.04.003
   Wu Zhaoju, 2010, Genes Cancer, V1, P40, DOI 10.1177/1947601909358324
   Xiang XQ, 2004, BIOCHEM BIOPH RES CO, V321, P161, DOI 10.1016/j.bbrc.2004.06.133
   Xiang YZ, 2008, PHYTOTHER RES, V22, P851, DOI 10.1002/ptr.2384
   Xie CM, 2011, FREE RADICAL BIO MED, V51, P1365, DOI 10.1016/j.freeradbiomed.2011.06.016
   Xiong XW, 2012, J BIOL CHEM, V287, P39107, DOI 10.1074/jbc.M112.412569
   Xu BB, 2005, J ASIAN NAT PROD RES, V7, P215, DOI 10.1080/10286020410001690172
   Xu DD, 2013, PHOTODIAGN PHOTODYN, V10, P278, DOI 10.1016/j.pdpdt.2013.01.002
   Xu L., 2002, CHINESE MATERIA MED, P866
   Xu MY, 2014, J NAT PROD, V77, P370, DOI 10.1021/np401022g
   Xu MY, 2013, FOOD CHEM TOXICOL, V59, P703, DOI 10.1016/j.fct.2013.06.059
   Xu Yu-Ying, 2008, Zhongguo Yaolixue Yu Dulixue Zazhi, V22, P151
   Xu YH, 2010, J ETHNOPHARMACOL, V127, P196, DOI 10.1016/j.jep.2009.09.047
   Xue W, 2009, ACTA PHARMACOL SIN, V30, P1211, DOI 10.1038/aps.2009.112
   Yadav VR, 2012, BRIT J PHARMACOL, V165, P741, DOI 10.1111/j.1476-5381.2011.01603.x
   Yang FR, 2013, WORLD J GASTROENTERO, V19, P5326, DOI 10.3748/wjg.v19.i32.5326
   Yang FS, 2005, J BIOL CHEM, V280, P5892, DOI 10.1074/jbc.M404751200
   Yang J. K., 2004, XIAN DAI ZHONG YI ZH
   Yang L, 2010, CELL METAB, V11, P467, DOI 10.1016/j.cmet.2010.04.005
   Yang LQ, 1996, J ETHNOPHARMACOL, V55, P35, DOI 10.1016/S0378-8741(96)01471-7
   Yang X., 2003, ENCY REFERENCE TRADI, P660
   Yang XY, 2007, AM J CHINESE MED, V35, P477, DOI 10.1142/S0192415X07004990
   Yang ZF, 2010, J CELL PHYSIOL, V225, P266, DOI 10.1002/jcp.22261
   Yang ZF, 2010, NAT CELL BIOL, V12, P814, DOI 10.1038/ncb0910-814
   Yang ZF, 2010, CURR OPIN CELL BIOL, V22, P124, DOI 10.1016/j.ceb.2009.11.014
   Yang ZNJ, 2011, MOL CANCER THER, V10, P1533, DOI 10.1158/1535-7163.MCT-11-0047
   Yao Y, 2010, PHARM BIOL, V48, P801, DOI 10.3109/13880200903280042
   Ye JQ, 2011, NAT CHEM BIOL, V7, P25, DOI [10.1038/nchembio.476, 10.1038/NCHEMBIO.476]
   Ye LH, 2012, ANAT REC, V295, P417, DOI 10.1002/ar.21528
   Yeh CT, 2011, EVID-BASED COMPL ALT, V2011, P1, DOI 10.1155/2011/750230
   Yim TK, 1998, PLANTA MED, V64, P607, DOI 10.1055/s-2006-957531
   Yo YT, 2009, J AGR FOOD CHEM, V57, P8266, DOI 10.1021/jf901054c
   Yoon HE, 2014, ONCOL REP, V31, P137, DOI 10.3892/or.2013.2856
   Yoon JS, 2013, PHYTOMEDICINE, V20, P1013, DOI 10.1016/j.phymed.2013.03.024
   [于春艳 Yu Chunyan], 2014, [中国病理生理杂志, Chinese Journal of Pathophysiology], V30, P1967
   Yu J, 2007, CARCINOGENESIS, V28, P632, DOI 10.1093/carcin/bgl168
   Yu WG, 2011, J AGR FOOD CHEM, V59, P12821, DOI 10.1021/jf2042032
   Yu X, 2006, AM J CHINESE MED, V34, P1027, DOI 10.1142/S0192415X06004491
   Yuan G, 2014, J BIOL CHEM, V289, P10607, DOI 10.1074/jbc.M113.528760
   Yue J., 2013, ZHEJIANG ZHONGYIYAO, V37, P606
   Yun SM, 2014, PHYTOTHER RES, V28, P458, DOI 10.1002/ptr.5015
   Zakeri-Milani P, 2008, ARZNEIMITTELFORSCH, V58, P97, DOI 10.1055/s-0031-1296475
   Zalckvar E, 2009, EMBO REP, V10, P285, DOI 10.1038/embor.2008.246
   Zeng R, 2012, ACTA PHARMACOL SIN, V33, P91, DOI 10.1038/aps.2011.143
   Zha QB, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124355
   Zhang B, 2011, EUR J PHARM SCI, V44, P573, DOI 10.1016/j.ejps.2011.09.020
   Zhang DM, 2012, EUR J PHARMACOL, V692, P19, DOI 10.1016/j.ejphar.2012.06.045
   Zhang H, 2008, PHYTOMEDICINE, V15, P587, DOI 10.1016/j.phymed.2007.12.004
   Zhang JD, 2005, J CELL BIOCHEM, V96, P522, DOI 10.1002/jcb.20535
   Zhang J, 2009, SAUDI MED J, V30, P760
   Zhang J, 2013, BIOCHEM PHARMACOL, V86, P317, DOI 10.1016/j.bcp.2013.05.003
   Zhang JQ, 2010, WORLD J GASTROENTERO, V16, P4281, DOI 10.3748/wjg.v16.i34.4281
   Zhang JQ, 2011, ONCOL REP, V26, P115, DOI 10.3892/or.2011.1277
   Zhang JY, 1999, BIOCHEM BIOPH RES CO, V259, P636, DOI 10.1006/bbrc.1999.0831
   Zhang K, 2014, J NEUROIMMUNOL, V273, P42, DOI 10.1016/j.jneuroim.2014.05.014
   Zhang L, 2007, CHROMATOGRAPHIA, V66, P115, DOI 10.1365/s10337-007-0260-4
   Zhang QA, 2011, FOOD CHEM TOXICOL, V49, P61, DOI 10.1016/j.fct.2010.09.032
   Zhang SJ, 2009, MOL BIOL REP, V36, P791, DOI 10.1007/s11033-008-9247-y
   Zhang XJ, 2012, ONCOL REP, V27, P1128, DOI 10.3892/or.2011.1599
   Zhang XW, 2015, J SEP SCI, V38, P2068, DOI 10.1002/jssc.201500123
   Zhang YH, 2011, ACTA PHARMACOL SIN, V32, P1266, DOI 10.1038/aps.2011.92
   Zhang YY, 2015, FOOD CHEM, V166, P352, DOI 10.1016/j.foodchem.2014.06.048
   ZHANG ZH, 1994, ACTA PHARM SINIC, V15, P229
   Zhang ZY, 2013, J CELL MOL MED, V17, P1566, DOI 10.1111/jcmm.12124
   Zhang ZL, 2012, HEART, V98, pE54, DOI 10.1136/heartjnl-2012-302920a.131
   Zhao J, 1999, J EXP MED, V190, P101, DOI 10.1084/jem.190.1.101
   Zhao J, 2015, INT IMMUNOPHARMACOL, V26, P221, DOI 10.1016/j.intimp.2015.03.033
   Zhao KJ, 2003, AM J CHINESE MED, V31, P919, DOI 10.1142/S0192415X03001612
   Zhao LB, 2010, EUR J PHARMACOL, V627, P304, DOI 10.1016/j.ejphar.2009.11.007
   Zhao Z. Z., 2009, ENCY MED PLANTS, P2000
   Zhou LM, 2005, J CLIN PHARMACOL, V45, P1345, DOI 10.1177/0091270005282630
   Zhou XJ, 2012, AUTOPHAGY, V8, P1286, DOI 10.4161/auto.21212
NR 438
TC 35
Z9 38
U1 6
U2 38
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1420-3049
J9 MOLECULES
JI Molecules
PD MAR
PY 2016
VL 21
IS 3
AR 359
DI 10.3390/molecules21030359
PG 45
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA DI9DR
UT WOS:000373802200031
PM 26999089
OA Green Submitted, gold, Green Published
DA 2022-04-25
ER

PT J
AU Mele, L
   del Vecchio, V
   Liccardo, D
   Prisco, C
   Schwerdtfeger, M
   Robinson, N
   Desiderio, V
   Tirino, V
   Papaccio, G
   La Noce, M
AF Mele, Luigi
   del Vecchio, Vitale
   Liccardo, Davide
   Prisco, Claudia
   Schwerdtfeger, Melanie
   Robinson, Nirmal
   Desiderio, Vincenzo
   Tirino, Virginia
   Papaccio, Gianpaolo
   La Noce, Marcella
TI The role of autophagy in resistance to targeted therapies
SO CANCER TREATMENT REVIEWS
LA English
DT Review
DE Autophagy; Drug resistance; Monoclonal antibodies; Targeted therapy;
   Tyrosine kinase inhibitors
ID ENDOPLASMIC-RETICULUM STRESS; SMALL-MOLECULE INHIBITORS; CHRONIC
   MYELOID-LEUKEMIA; PROSTATE-CANCER CELLS; BREAST-CANCER;
   HEPATOCELLULAR-CARCINOMA; MONOCLONAL-ANTIBODY; ANTITUMOR-ACTIVITY;
   COLORECTAL-CANCER; ER STRESS
AB Autophagy is a self-degradative cellular process, involved in stress response such as starvation, hypoxia, and oxidative stress. This mechanism balances macro-molecule recycling to regulate cell homeostasis. In cancer, autophagy play a role in the development and progression, while several studies describe it as one of the key processes in drug resistance. In the last years, in addition to standard anti-cancer treatments such as chemotherapies and irradiation, targeted therapy became one of the most adopted strategies in clinical practices, mainly due to high specificity and reduced side effects. However, similar to standard treatments, drug resistance is the main challenge in most patients. Here, we summarize recent studies that investigated the role of autophagy in drug resistance after targeted therapy in different types of cancers. We highlight positive results and limitations of pre-clinical and clinical studies in which autophagy inhibitors are used in combination with targeted therapies.
C1 [Mele, Luigi; del Vecchio, Vitale; Liccardo, Davide; Prisco, Claudia; Schwerdtfeger, Melanie; Desiderio, Vincenzo; Tirino, Virginia; Papaccio, Gianpaolo; La Noce, Marcella] Univ Campania L Vanvitelli Naples, Dept Expt Med, Naples, Italy.
   [Prisco, Claudia] Nottingham Trent Univ, Sch Sci & Technol, John van Geest Canc Res Ctr, Clifton Lane, Nottingham NG11 8NS, England.
   [Schwerdtfeger, Melanie] Univ Munich, Dept Med 4, Div Clin Pharmacol, Munich, Germany.
   [Robinson, Nirmal] SA Pathol, Ctr Canc Biol, GPO Box 2471, Adelaide, SA, Australia.
   [Robinson, Nirmal] Univ South Australia, GPO Box 2471, Adelaide, SA, Australia.
RP Papaccio, G (corresponding author), Dept Expt Med, Via L Armanni 5, I-80128 Naples, Italy.
EM gianpaolo.papaccio@unicampania.it
RI Mele, Luigi/AAC-9887-2019; La Noce, Marcella/AAM-1750-2021; Papaccio,
   Gianpaolo/B-7150-2014
OI Mele, Luigi/0000-0002-6008-0802; La Noce, Marcella/0000-0002-8782-3821;
   Robinson, Nirmal/0000-0002-7361-9491; Papaccio,
   Gianpaolo/0000-0002-4014-5306; DEL VECCHIO, VITALE/0000-0002-7323-4444;
   Schwerdtfeger, Melanie/0000-0001-8193-3328
FU University of Campania "Luigi Vanvitelli" (Naples, Italy)
FX The costs of the open access publication were supported by the
   "Programma Valere 2020" of the University of Campania "Luigi Vanvitelli"
   (Naples, Italy).
CR Alers S, 2012, MOL CELL BIOL, V32, P2, DOI 10.1128/MCB.06159-11
   Alinari L, 2011, BLOOD, V118, P6893, DOI 10.1182/blood-2011-06-363879
   Amaral C, 2018, J STEROID BIOCHEM, V183, P51, DOI 10.1016/j.jsbmb.2018.05.006
   Amaral C, 2013, J STEROID BIOCHEM, V135, P51, DOI 10.1016/j.jsbmb.2012.12.017
   Amrein L, 2011, LEUKEMIA RES, V35, P99, DOI 10.1016/j.leukres.2010.05.029
   [Anonymous], 2016, GUIDELINES USE INTER, DOI [10.1080/15548627.2015.1100356, DOI 10.1080/15548627.2015.1100356]
   Ansell SM, 2015, MAYO CLIN PROC, V90, P1152, DOI 10.1016/j.mayocp.2015.04.025
   Baranowska K, 2016, ONCOTARGET, V7, P70845, DOI 10.18632/oncotarget.12226
   Baudino Troy A, 2015, Curr Drug Discov Technol, V12, P3
   Beck D, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2003057
   Bertuccio P, 2013, INT J CANCER, V132, P427, DOI 10.1002/ijc.27624
   Bisaro B, 2016, ONCOTARGET, V7, P4442, DOI 10.18632/oncotarget.6710
   Booth L, 2018, CANCER BIOL THER, V19, P239, DOI 10.1080/15384047.2018.1423927
   Boutin B, 2013, PROSTATE, V73, P1090, DOI 10.1002/pros.22658
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
   Bursch W, 1996, CARCINOGENESIS, V17, P1595, DOI 10.1093/carcin/17.8.1595
   Cai J, 2013, WORLD J SURG ONCOL, V11, DOI 10.1186/1477-7819-11-306
   Chen S, 2014, BLOOD, V124, P2687, DOI 10.1182/blood-2014-03-564534
   Chen SN, 2016, TUMOR BIOL, V37, P2321, DOI 10.1007/s13277-015-3800-9
   Chen ZX, 2019, PROSTATE, V79, P44, DOI 10.1002/pros.23709
   Cheng X, 2018, CANCER LETT, V431, P105, DOI 10.1016/j.canlet.2018.05.046
   Cheng Y, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009715
   Choi AMK, 2013, NEW ENGL J MED, V368, P651, DOI [10.1056/NEJMra1205406, 10.1056/NEJMc1303158]
   Ciardiello F, 2000, CLIN CANCER RES, V6, P3739
   Colagrande S, 2015, WORLD J HEPATOL, V7, P1041, DOI 10.4254/wjh.v7.i8.1041
   Cook KL, 2014, CLIN CANCER RES, V20, P3222, DOI 10.1158/1078-0432.CCR-13-3227
   Cook KL, 2012, CANCER RES, V72, P3337, DOI 10.1158/0008-5472.CAN-12-0269
   Cufi S, 2013, SCI REP-UK, V3, DOI 10.1038/srep02469
   Cufi S, 2012, ONCOTARGET, V3, P1600
   Das G, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a008813
   Delle Cave D, 2018, J CELL PHYSIOL, V233, P1370, DOI 10.1002/jcp.26015
   Deretic V, 2013, NAT REV IMMUNOL, V13, P722, DOI 10.1038/nri3532
   Domingues B, 2018, IMMUNOTARGETS THER, V7, P35, DOI 10.2147/ITT.S134842
   Dong LH, 2013, J HEMATOL ONCOL, V6, DOI 10.1186/1756-8722-6-53
   Duan L, 2011, J BIOL CHEM, V286, P2864, DOI 10.1074/jbc.M110.143271
   Eggersmann TK, 2019, BIODRUGS, V33, P125, DOI 10.1007/s40259-019-00337-6
   Fan JJ, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1840-6
   Felice AJ, 2019, SWISS MED WKLY, V149, DOI 10.4414/smw.2019.20138
   Ferlay J, 2013, EUR J CANCER, V49, P1374, DOI 10.1016/j.ejca.2012.12.027
   Gerber DE, 2008, AM FAM PHYSICIAN, V77, P311
   Goldberg SB, 2012, J THORAC ONCOL, V7, P1602, DOI 10.1097/JTO.0b013e318262de4a
   Granato M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075965
   Groenendijk FH, 2014, MOL ONCOL, V8, P1067, DOI 10.1016/j.molonc.2014.05.004
   Guo GF, 2019, WORLD J GASTROENTERO, V25, P1840, DOI 10.3748/wjg.v25.i15.1840
   Han J, 2013, J BIOL CHEM, V288, P20315, DOI 10.1074/jbc.M113.461350
   Han WD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018691
   Harbeck N, 2017, LANCET, V389, P1134, DOI [10.1016/s0140-6736(16)31891-8, 10.1016/S0140-6736(16)31891-8]
   He CC, 2009, ANNU REV GENET, V43, P67, DOI 10.1146/annurev-genet-102808-114910
   He GQ, 2012, J CANCER RES CLIN, V138, P657, DOI 10.1007/s00432-011-1138-2
   Heine S, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-018-0657-6
   Herbst RS, 2018, NATURE, V553, P446, DOI 10.1038/nature25183
   Hu XX, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-04258-8
   Huang F, 2018, WORLD J GASTROENTERO, V24, P4643, DOI 10.3748/wjg.v24.i41.4643
   Inamura K, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00193
   Ivy SP, 2009, NAT REV CLIN ONCOL, V6, P569, DOI 10.1038/nrclinonc.2009.130
   Jagannathan S, 2015, LEUKEMIA, V29, P2184, DOI 10.1038/leu.2015.157
   Jain K, 2013, AM J CANCER RES, V3, P251
   Ji C, 2016, DRUG DES DEV THER, V10, P2491, DOI 10.2147/DDDT.S112740
   Ji C, 2014, CANCER BIOL THER, V15, P570, DOI 10.4161/cbt.28162
   Jia L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032584
   John S, 2008, CANCER RES, V68, P7855, DOI 10.1158/0008-5472.CAN-07-5875
   Kang C, 2016, AUTOPHAGY, V12, P898, DOI 10.1080/15548627.2015.1121361
   Karsli-Uzunbas G, 2014, CANCER DISCOV, V4, P914, DOI 10.1158/2159-8290.CD-14-0363
   Kharaziha P, 2012, CANCER RES, V72, P5348, DOI 10.1158/0008-5472.CAN-12-0658
   Kim ES, 2001, CURR OPIN ONCOL, V13, P506, DOI 10.1097/00001622-200111000-00014
   Kimura T, 2013, CANCER RES, V73, P3, DOI 10.1158/0008-5472.CAN-12-2464
   Kinsey CG, 2019, NAT MED, V25, P620, DOI 10.1038/s41591-019-0367-9
   Kranzbuhler B, 2019, PROSTATE, V79, P206, DOI 10.1002/pros.23725
   Lackner MR, 2012, FUTURE ONCOL, V8, P999, DOI [10.2217/fon.12.86, 10.2217/FON.12.86]
   Lamb CA, 2013, NAT REV MOL CELL BIO, V14, P759, DOI 10.1038/nrm3696
   Lamberti M, 2015, INT J ONCOL, V46, P1893, DOI 10.3892/ijo.2015.2904
   Li S, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09634-8
   Li XQ, 2010, CANCER RES, V70, P5942, DOI 10.1158/0008-5472.CAN-10-0157
   Li XY, 2019, BIOMED PHARMACOTHER, V119, DOI 10.1016/j.biopha.2019.109415
   Li YY, 2013, LUNG CANCER, V81, P354, DOI 10.1016/j.lungcan.2013.05.012
   Liu JL, 2011, CELL, V147, P223, DOI 10.1016/j.cell.2011.08.037
   Liu L, 2017, ONCOTARGET, V8, P57707, DOI 10.18632/oncotarget.17202
   Llovet JM, 2014, CLIN CANCER RES, V20, P2072, DOI 10.1158/1078-0432.CCR-13-0547
   Rodriguez AL, 2015, ENCRUC REV CRIT CIEN, V10
   Longley DB, 2005, J PATHOL, V205, P275, DOI 10.1002/path.1706
   Lui A, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2490-z
   Ma XH, 2014, J CLIN INVEST, V124, P1406, DOI 10.1172/JCI70454
   Ma XK, 2019, CANCER BIOTHER RADIO, V34, P181, DOI 10.1089/cbr.2018.2559
   Marinkovic M, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/8023821
   Mathew R, 2007, NAT REV CANCER, V7, P961, DOI 10.1038/nrc2254
   McAfee Q, 2012, P NATL ACAD SCI USA, V109, P8253, DOI 10.1073/pnas.1118193109
   Mele L, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1164-5
   Mele L, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0635-5
   Mi YJ, 2010, CANCER RES, V70, P7981, DOI 10.1158/0008-5472.CAN-10-0111
   Mitchell R, 2018, JNCI-J NATL CANCER I, V110, P467, DOI 10.1093/jnci/djx236
   Mitou G, 2015, ONCOTARGET, V6, P30149, DOI 10.18632/oncotarget.4999
   Mizushima N, 2018, NAT CELL BIOL, V20, P521, DOI 10.1038/s41556-018-0092-5
   Mizushima N, 2011, CELL, V147, P728, DOI 10.1016/j.cell.2011.10.026
   Mizushima N, 2011, ANNU REV CELL DEV BI, V27, P107, DOI 10.1146/annurev-cellbio-092910-154005
   Mortezavi A, 2019, WORLD J UROL, V37, P351, DOI 10.1007/s00345-018-2385-5
   Nagar B, 2002, CANCER RES, V62, P4236
   Nawrocki ST, 2005, CANCER RES, V65, P11510, DOI 10.1158/0008-5472.CAN-05-2394
   Nguyen HG, 2014, ONCOGENE, V33, P4521, DOI 10.1038/onc.2014.25
   Orcutt KP, 2011, CANCER RES, V71, P3932, DOI 10.1158/0008-5472.CAN-10-3425
   Peeters M, 2012, CANCER TREAT REV, V38, P397, DOI 10.1016/j.ctrv.2011.08.002
   Petrelli F, 2012, LUNG CANCER, V78, P8, DOI 10.1016/j.lungcan.2012.06.009
   Presta LG, 1997, CANCER RES, V57, P4593
   Qadir MA, 2008, BREAST CANCER RES TR, V112, P389, DOI 10.1007/s10549-007-9873-4
   Rosich L, 2013, AUTOPHAGY, V9, P115, DOI 10.4161/auto.22483
   Russell RC, 2013, NAT CELL BIOL, V15, P741, DOI 10.1038/ncb2757
   Samaddar JS, 2008, MOL CANCER THER, V7, P2977, DOI 10.1158/1535-7163.MCT-08-0447
   San Jose-Eneriz E, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-69
   San Miguel JF, 2008, NEW ENGL J MED, V359, P906, DOI 10.1056/NEJMoa0801479
   Scott AJ, 2018, MOL CANCER THER, V17, P2112, DOI 10.1158/1535-7163.MCT-17-0131
   SESHADRI R, 1993, J CLIN ONCOL, V11, P1936, DOI 10.1200/JCO.1993.11.10.1936
   Sheng JY, 2018, AM J CANCER RES, V8, P354
   Shi YH, 2011, AUTOPHAGY, V7, P1159, DOI 10.4161/auto.7.10.16818
   Shimizu S, 2012, INT J CANCER, V131, P548, DOI 10.1002/ijc.26374
   Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387
   Sueda T, 2016, SCI REP-UK, V6, DOI 10.1038/srep18949
   Sun T, 2017, CELL PHYSIOL BIOCHEM, V44, P716, DOI 10.1159/000485285
   Thorpe LM, 2015, NAT REV CANCER, V15, P7, DOI 10.1038/nrc3860
   Tong Y, 2012, ACTA PHARMACOL SIN, V33, P542, DOI 10.1038/aps.2011.192
   Torgersen ML, 2013, BLOOD, V122, P2467, DOI 10.1182/blood-2013-05-500629
   Torka P, 2019, CURR HEMATOL MALIG R, V14, P426, DOI 10.1007/s11899-019-00542-8
   Vazquez-Martin A, 2011, GENE CHROMOSOME CANC, V50, P284, DOI 10.1002/gcc.20846
   Vazquez-Martin A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006251
   Vera-Ramirez L, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04070-6
   Vijayaraghavan S, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15916
   Waks AG, 2019, JAMA-J AM MED ASSOC, V321, P288, DOI 10.1001/jama.2018.19323
   Wang DW, 2019, ONCOGENE, V38, P3458, DOI 10.1038/s41388-019-0675-z
   Wang J, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0747-0
   White E, 2012, NAT REV CANCER, V12, P401, DOI 10.1038/nrc3262
   Wood JM, 2000, CANCER RES, V60, P2178
   Wu L, 2017, IRAN J BASIC MED SCI, V20, P990, DOI 10.22038/IJBMS.2017.9263
   Wu YT, 2010, J BIOL CHEM, V285, P10850, DOI 10.1074/jbc.M109.080796
   Xie XQ, 2015, CANCER DISCOV, V5, P410, DOI 10.1158/2159-8290.CD-14-1473
   Yu XF, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0480-4
   Yu Y, 2012, LEUKEMIA, V26, P1752, DOI 10.1038/leu.2012.65
   Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100
   Zambrano J, 2016, BREAST CANCER-BASIC, V10, P13, DOI 10.4137/BCBCR.S32791
   Zhai B, 2014, MOL CANCER THER, V13, P1589, DOI 10.1158/1535-7163.MCT-13-1043
   Zhao Z, 2018, J CANCER, V9, P3407, DOI 10.7150/jca.24201
   Zhu XM, 2013, J CELL BIOCHEM, V114, P2643, DOI 10.1002/jcb.24611
NR 139
TC 33
Z9 34
U1 4
U2 17
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0305-7372
EI 1532-1967
J9 CANCER TREAT REV
JI Cancer Treat. Rev.
PD AUG
PY 2020
VL 88
AR 102043
DI 10.1016/j.ctrv.2020.102043
PG 14
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA MM6HO
UT WOS:000550255600007
PM 32505806
OA hybrid, Green Accepted
DA 2022-04-25
ER

PT J
AU Yang, SR
   He, XL
   Zhao, J
   Wang, DL
   Guo, SS
   Gao, T
   Wang, G
   Jin, C
   Yan, ZY
   Wang, N
   Wang, YX
   Zhao, YL
   Xing, JL
   Huang, QC
AF Yang, Shirong
   He, Xianli
   Zhao, Jing
   Wang, Dalin
   Guo, Shanshan
   Gao, Tian
   Wang, Gang
   Jin, Chao
   Yan, Zeyu
   Wang, Nan
   Wang, Yongxing
   Zhao, Yilin
   Xing, Jinliang
   Huang, Qichao
TI Mitochondrial transcription factor A plays opposite roles in the
   initiation and progression of colitis-associated cancer
SO CANCER COMMUNICATIONS
LA English
DT Article
DE colitis; colitis-associated cancer; colorectal cancer; energy
   metabolism; inflammatory bowel diseases; intestinal homeostasis;
   mitochondrial transcription factor A (TFAM)
ID HEPATOCELLULAR-CARCINOMA; ULCERATIVE-COLITIS; CELL-SURVIVAL; TFAM; DNA;
   TUMORIGENESIS; INFLAMMATION; ACTIVATION; AUTOPHAGY; MUTATION
AB Background Mitochondria are key regulators in cell proliferation and apoptosis. Alterations in mitochondrial function are closely associated with inflammation and tumorigenesis. This study aimed to investigate whether mitochondrial transcription factor A (TFAM), a key regulator of mitochondrial DNA transcription and replication, is involved in the initiation and progression of colitis-associated cancer (CAC). Methods TFAM expression was examined in tissue samples of inflammatory bowel diseases (IBD) and CAC by immunohistochemistry. Intestinal epithelial cell (IEC)-specific TFAM-knockout mice (TFAM(oIEC)) and colorectal cancer (CRC) cells with TFAM knockdown or overexpression were used to evaluate the role of TFAM in colitis and the initiation and progression of CAC. The underlying mechanisms of TFAM were also explored by analyzing mitochondrial respiration function and biogenesis. Results The expression of TFAM was downregulated in active IBD and negatively associated with the disease activity. The downregulation of TFAM in IECs was induced by interleukin-6 in a signal transducer and activator of transcription 3 (STAT3)/miR-23b-dependent manner. In addition, TFAM knockout impaired IEC turnover to promote dextran sulfate sodium (DSS)-induced colitis in mice. Of note, TFAM knockout increased the susceptibility of mice to azoxymethane/DSS-induced CAC and TFAM overexpression protected mice from intestinal inflammation and colitis-associated tumorigenesis. By contrast, TFAM expression was upregulated in CAC tissues and contributed to cell growth. Furthermore, it was demonstrated that beta-catenin induced the upregulation of TFAM through c-Myc in CRC cells. Mechanistically, TFAM promoted the proliferation of both IECs and CRC cells by increasing mitochondrial biogenesis and activity. Conclusions TFAM plays a dual role in the initiation and progression of CAC, providing a novel understanding of CAC pathogenesis.
C1 [Yang, Shirong; Zhao, Jing; Guo, Shanshan; Wang, Gang; Zhao, Yilin; Xing, Jinliang; Huang, Qichao] Fourth Mil Med Univ, State Key Lab Canc Biol, Xian 710032, Shaanxi, Peoples R China.
   [Yang, Shirong; Zhao, Jing; Guo, Shanshan; Wang, Gang; Zhao, Yilin; Xing, Jinliang; Huang, Qichao] Fourth Mil Med Univ, Dept Physiol & Pathophysiol, Xian 710032, Shaanxi, Peoples R China.
   [Yang, Shirong; He, Xianli; Gao, Tian; Jin, Chao; Yan, Zeyu; Wang, Nan] Fourth Mil Med Univ, Tangdu Hosp, Dept Gen Surg, Xian 710032, Shaanxi, Peoples R China.
   [Wang, Dalin] Fourth Mil Med Univ, Xijing Hosp, Dept Hepatobiliary Surg, Xian 710032, Shaanxi, Peoples R China.
   [Wang, Yongxing] Fourth Mil Med Univ, Xijing Hosp, Dept Resp Med, Xian 710032, Shaanxi, Peoples R China.
RP Xing, JL; Huang, QC (corresponding author), Fourth Mil Med Univ, State Key Lab Canc Biol, Xian 710032, Shaanxi, Peoples R China.; Xing, JL; Huang, QC (corresponding author), Fourth Mil Med Univ, Dept Physiol & Pathophysiol, Xian 710032, Shaanxi, Peoples R China.
EM xingjl@fmmu.edu.cn; huangqichao@fmmu.edu.cn
RI Huang, Qichao/K-5706-2018
FU NationalNatural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [82072722, 81830070, 81772935, 81672340];
   StateKey Laboratory ofCancer Biology Project [CBSKL2019ZZ26]
FX NationalNatural Science Foundation of China, Grant/Award Numbers:
   82072722, 81830070, 81772935, 81672340; StateKey Laboratory ofCancer
   Biology Project, Grant/Award Number: CBSKL2019ZZ26
CR Araujo LF, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-31170-6
   Asquith M, 2010, J EXP MED, V207, P1573, DOI 10.1084/jem.20101330
   Baker AM, 2019, GUT, V68, P985, DOI 10.1136/gutjnl-2018-316191
   Blander JM, 2018, CURR OPIN GASTROEN, V34, P413, DOI 10.1097/MOG.0000000000000481
   Boone DL, 2013, GASTROENTEROLOGY, V145, P933, DOI 10.1053/j.gastro.2013.09.034
   Cagatay T, 2002, ONCOGENE, V21, P7971, DOI 10.1038/sj.onc.1205919
   Carey R, 2008, INFLAMM BOWEL DIS, V14, P446, DOI 10.1002/ibd.20342
   Cho K, 2013, FREE RADICAL BIO MED, V60, P201, DOI 10.1016/j.freeradbiomed.2013.02.022
   Chung KW, 2019, CELL METAB, V30, P784, DOI 10.1016/j.cmet.2019.08.003
   Dong LF, 2019, CANCER COMMUN, V39, DOI 10.1186/s40880-019-0412-6
   Feagins LA, 2009, NAT REV GASTRO HEPAT, V6, P297, DOI 10.1038/nrgastro.2009.44
   Fratila OC, 2010, J GASTROINTEST LIVER, V19, P147
   Gomes LC, 2011, NAT CELL BIOL, V13, P589, DOI 10.1038/ncb2220
   Grivennikov S, 2009, CANCER CELL, V15, P103, DOI 10.1016/j.ccr.2009.01.001
   Guo JH, 2011, CANCER RES, V71, P2978, DOI 10.1158/0008-5472.CAN-10-3482
   Haberman Y, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-07841-3
   Huang QC, 2016, AUTOPHAGY, V12, P999, DOI 10.1080/15548627.2016.1166318
   Jang YJ, 2019, GUT MICROBES, V10, P696, DOI 10.1080/19490976.2019.1589281
   Janssen KP, 2006, GASTROENTEROLOGY, V131, P1096, DOI 10.1053/j.gastro.2006.08.011
   Jiang JD, 2013, ONCOL REP, V30, P2105, DOI 10.3892/or.2013.2712
   Kaldma A, 2014, INT J BIOCHEM CELL B, V55, P171, DOI 10.1016/j.biocel.2014.09.004
   Kim JJ, 2012, JOVE-J VIS EXP, DOI 10.3791/3678
   KUSUGAMI K, 1995, DIGEST DIS SCI, V40, P949, DOI 10.1007/BF02064182
   Larsson NG, 1998, NAT GENET, V18, P231, DOI 10.1038/ng0398-231
   Li J, 2017, ONCOGENE, V36, P4901, DOI 10.1038/onc.2017.98
   Lin CS, 2018, ONCOL REP, V39, P316, DOI 10.3892/or.2017.6087
   Lyonnais S, 2017, SCI REP-UK, V7, DOI 10.1038/srep43992
   Matsumoto H, 2010, BMC GASTROENTEROL, V10, DOI 10.1186/1471-230X-10-44
   Missiroli S, 2020, J CLIN MED, V9, DOI 10.3390/jcm9030740
   Parang B, 2016, METHODS MOL BIOL, V1422, P297, DOI 10.1007/978-1-4939-3603-8_26
   Qiao LH, 2017, ONCOTARGET, V8, P84373, DOI 10.18632/oncotarget.21033
   Qu Lin-Lin, 2015, Chin Med J (Engl), V128, P680, DOI 10.4103/0366-6999.151675
   Ramachandran A, 2017, NUCLEIC ACIDS RES, V45, P861, DOI 10.1093/nar/gkw1157
   Reifen R, 2015, NUTRITION, V31, P1402, DOI 10.1016/j.nut.2015.05.011
   Ren TT, 2018, ANTIOXID REDOX SIGN, V28, P1120, DOI 10.1089/ars.2017.6990
   Rhodes JM, 2002, TRENDS MOL MED, V8, P10, DOI 10.1016/S1471-4914(01)02194-3
   Rodriguez-Canales M, 2020, MEDIAT INFLAMM, V2020, DOI 10.1155/2020/5062506
   Shi YH, 2012, P NATL ACAD SCI USA, V109, P16510, DOI 10.1073/pnas.1119738109
   Soderholm JD, 2002, GUT, V50, P307, DOI 10.1136/gut.50.3.307
   Song M, 2018, J CACHEXIA SARCOPENI, V9, P106, DOI 10.1002/jcsm.12250
   Sun XC, 2018, SIGNAL TRANSDUCT TAR, V3, DOI 10.1038/s41392-018-0011-z
   Tang ZY, 2021, CANCER COMMUN, V41, P16, DOI 10.1002/cac2.12112
   Vernochet C, 2012, CELL METAB, V16, P765, DOI 10.1016/j.cmet.2012.10.016
   Viscido A, 2001, DIGEST LIVER DIS, V33, P686, DOI 10.1016/S1590-8658(01)80046-3
   Wang B, 2012, HEPATOLOGY, V56, P186, DOI 10.1002/hep.25632
   Wang G, 2019, INT J CANCER, V144, P2516, DOI 10.1002/ijc.31978
   Wang Y, 2016, INT J BIOL MARKER, V31, pE382, DOI 10.5301/jbm.5000211
   Watanabe T, 2011, INFLAMM BOWEL DIS, V17, P802, DOI 10.1002/ibd.21365
   Weinberg F, 2010, P NATL ACAD SCI USA, V107, P8788, DOI 10.1073/pnas.1003428107
   Wen YA, 2019, CELL DEATH DIFFER, V26, P1955, DOI 10.1038/s41418-018-0265-6
   West AP, 2015, NATURE, V520, P553, DOI 10.1038/nature14156
   Woo DK, 2012, AM J PATHOL, V180, P24, DOI 10.1016/j.ajpath.2011.10.003
   Xie DY, 2016, ONCOTARGET, V7, P11609, DOI 10.18632/oncotarget.7018
   Xing JL, 2008, JNCI-J NATL CANCER I, V100, P1104, DOI 10.1093/jnci/djn213
   Zaki MH, 2010, IMMUNITY, V32, P379, DOI 10.1016/j.immuni.2010.03.003
   Zheng J, 2012, ONCOL LETT, V4, P1151, DOI 10.3892/ol.2012.928
NR 56
TC 2
Z9 2
U1 3
U2 9
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
EI 2523-3548
J9 CANCER COMMUN
JI Cancer Commun.
PD AUG
PY 2021
VL 41
IS 8
BP 695
EP 714
DI 10.1002/cac2.12184
EA JUN 2021
PG 20
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA UA5CY
UT WOS:000664640600001
PM 34160895
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Zhao, CP
   Dang, ZQ
   Sun, JB
   Yuan, SQ
   Xie, L
AF Zhao, Changpu
   Dang, Zhongqin
   Sun, Junbo
   Yuan, Shuaiqiang
   Xie, Li
TI Up-regulation of microRNA-30b/30d cluster represses hepatocyte apoptosis
   in mice with fulminant hepatic failure by inhibiting CEACAM1
SO IUBMB LIFE
LA English
DT Article
DE apoptosis; carcinoembryonic antigen-related cell adhesion molecule 1;
   fulminant hepatic failure; MicroRNA-30b; MicroRNA-30d
ID COLON-CANCER CELLS; MIR-30B; MIGRATION; INVASION; AUTOPHAGY; GROWTH;
   INJURY
AB Recently, impacts of microRNAs have been unraveled in human diseases, and we aimed to confirm the role of miR-30b/30d in fulminant hepatic failure (FHF). Expression of miR-30b/30d and CEACAM1 in serum of FHF patients and healthy people was measured by reverse transcription quantitative polymerase chain reaction (RT-qPCR) and Western blot analysis. Mice FHF models were established by injection of D-Galn and lipopolysaccharide, and were treated with miR-30b/30d mimics. Oxidative stress, liver injury, and inflammatory reaction in mouse liver tissues were measured using oxidative stress-related factor kits, hematoxylin-eosin staining and enzyme-linked immunosorbent assay, respectively. Moreover, cell cycle distribution and apoptosis of hepatocytes of mice were determined by flow cytometry, and the target relation between miR-30b/30d and CEACAM1 was confirmed by bioinformatic method and dual luciferase reporter gene assay. MiR-30b/30d expression was positively, and CEACAM1 expression was negatively related to prognosis of FHF patients. Up-regulation of miR-30b/30d attenuated oxidative stress, liver injury, and inflammatory reaction, and improved survival rate of FHF mice. Furthermore, elevated miR-30b/30d ameliorated apoptosis and cell cycle arrest of hepatocytes of FHF mice. CEACAM1 was a target gene of miR-30b/30d. This study highlights that up-regulated miR-30b/30d attenuates the progression of FHF by targeting CEACAM1, which may be helpful to FHF treatment.
C1 [Zhao, Changpu] Henan Univ Chinese Med, Internal Med Dept, 6 Dongfeng Rd, Zhengzhou 450002, Henan, Peoples R China.
   [Dang, Zhongqin] Henan Univ Chinese Med, Hepatobiliary Spleen & Stomach Dept, Henan Hosp Chinese Med, Affiliated Hosp 2, Zhengzhou, Peoples R China.
   [Sun, Junbo] Henan Univ Chinese Med, Henan Hosp Chinese Med, Personnel Off, Affiliated Hosp 2, Zhengzhou, Peoples R China.
   [Yuan, Shuaiqiang] Henan Acad Chinese Med, Dept Digest, Affiliated Hosp, Zhengzhou, Peoples R China.
   [Xie, Li] Henan Elect Power Hosp, Internal Med Dept, Zhengzhou, Peoples R China.
RP Zhao, CP (corresponding author), Henan Univ Chinese Med, Internal Med Dept, 6 Dongfeng Rd, Zhengzhou 450002, Henan, Peoples R China.
EM zhaochangpu2019@163.com
CR Caserta S, 2016, SCI REP-UK, V6, DOI 10.1038/srep28006
   Chen Y, 2017, BRAZ J MED BIOL RES, V50, DOI [10.1590/1414-431X20176246, 10.1590/1414-431x20176246]
   deLemos Andrew S, 2013, Clin Liver Dis (Hoboken), V2, P156, DOI 10.1002/cld.222
   Ding H, 2018, INT J MOL MED, V42, P873, DOI 10.3892/ijmm.2018.3684
   Ghaemi Z, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00653
   Gu YF, 2013, CHINESE MED J-PEKING, V126, P4435, DOI 10.3760/cma.j.issn.0366-6999.20131112
   Haque R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042542
   Horst AK, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19103110
   Jones DZ, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4258-0
   Kim TS, 2013, CLIN TRANSPLANT, V27, P297, DOI 10.1111/ctr.12055
   Li Q, 2017, BIOCHEM BIOPH RES CO, V485, P506, DOI 10.1016/j.bbrc.2017.02.016
   Li SP, 2016, WORLD J GASTROENTERO, V22, P4501, DOI 10.3748/wjg.v22.i18.4501
   Li T, 2015, GENE, V561, P268, DOI 10.1016/j.gene.2015.02.051
   Li XH, 2016, APOPTOSIS, V21, P708, DOI 10.1007/s10495-016-1238-1
   Liang WC, 2017, J CELL BIOCHEM, V118, P530, DOI 10.1002/jcb.25722
   Liu LL, 2018, EXP THER MED, V15, P2655, DOI 10.3892/etm.2017.5675
   Liu YN, 2018, EBIOMEDICINE, V36, P140, DOI 10.1016/j.ebiom.2018.08.054
   Melman YF, 2015, CIRCULATION, V131, P2202, DOI 10.1161/CIRCULATIONAHA.114.013220
   Oliveira-Ferrer L, 2018, DIS MARKERS, V2018, DOI 10.1155/2018/6714287
   Pavanello S, 2016, TOXICOL LETT, V259, P143, DOI 10.1016/j.toxlet.2016.08.002
   Simonetti O, 2018, MED MOL MORPHOL, V51, P41, DOI 10.1007/s00795-017-0169-4
   Suda T, 2018, HEPATOL COMMUN, V2, P1247, DOI 10.1002/hep4.1240
   Tian SB, 2015, WORLD J GASTROENTERO, V21, P9337, DOI 10.3748/wjg.v21.i31.9337
   Ueshima C, 2017, CANCER MED-US, V6, P845, DOI 10.1002/cam4.1050
   Wallace K, 2008, BIOCHEM J, V411, P1, DOI 10.1042/BJ20071570
   Wang HF, 2016, ONCOTARGET, V7, P82864, DOI 10.18632/oncotarget.12655
   Wu P, 2019, ONCOL REP, V41, P1929, DOI 10.3892/or.2018.6947
   Wu YB, 2017, BIOTECHNOL LETT, V39, P1827, DOI 10.1007/s10529-017-2428-9
   Xiao JJ, 2017, CELL PHYSIOL BIOCHEM, V41, P865, DOI 10.1159/000459899
   Xiong YC, 2018, J CANCER, V9, P2147, DOI 10.7150/jca.25006
   Xu JG, 2018, CELL PHYSIOL BIOCHEM, V45, P1631, DOI 10.1159/000487730
   Yu DS, 2012, INT J MOL MED, V29, P663, DOI 10.3892/ijmm.2012.888
   Yu LX, 2019, ONCOL REP, V41, P257, DOI 10.3892/or.2018.6829
   Zhang N, 2019, EXP THER MED, V17, P3233, DOI 10.3892/etm.2019.7280
   Zhang R, 2017, TUMOR BIOL, V39, P1, DOI 10.1177/1010428317703984
   Zou CX, 2016, ONCOL REP, V36, P2715, DOI 10.3892/or.2016.5056
NR 36
TC 0
Z9 0
U1 3
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1521-6543
EI 1521-6551
J9 IUBMB LIFE
JI IUBMB Life
PD JUL
PY 2020
VL 72
IS 7
BP 1349
EP 1363
DI 10.1002/iub.2256
EA FEB 2020
PG 15
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA ME8CH
UT WOS:000517270900001
PM 32101367
OA Bronze
DA 2022-04-25
ER

PT J
AU Petherick, KJ
   Williams, AC
   Lane, JD
   Ordonez-Moran, P
   Huelsken, J
   Collard, TJ
   Smartt, HJM
   Batson, J
   Malik, K
   Paraskeva, C
   Greenhough, A
AF Petherick, Katy J.
   Williams, Ann C.
   Lane, Jon D.
   Ordonez-Moran, Paloma
   Huelsken, Joerg
   Collard, Tracey J.
   Smartt, Helena J. M.
   Batson, Jennifer
   Malik, Karim
   Paraskeva, Chris
   Greenhough, Alexander
TI Autolysosomal beta-catenin degradation regulates Wnt-autophagy-p62
   crosstalk
SO EMBO JOURNAL
LA English
DT Article
DE autophagy; cancer; LC3; p62; Wnt/beta-catenin
ID TRANSCRIPTION FACTOR NRF2; COLORECTAL-CANCER; WNT/BETA-CATENIN; CASPASE
   CLEAVAGE; STRUCTURAL BASIS; AUTOPHAGY; P62; P62/SQSTM1; INACTIVATION;
   INHIBITION
AB The Wnt/beta-catenin signalling and autophagy pathways each play important roles during development, adult tissue homeostasis and tumorigenesis. Here we identify the Wnt/beta-catenin signalling pathway as a negative regulator of both basal and stress-induced autophagy. Manipulation of beta-catenin expression levels in vitro and in vivo revealed that beta-catenin suppresses autophagosome formation and directly represses p62/SQSTM1 (encoding the autophagy adaptor p62) via TCF4. Furthermore, we show that during nutrient deprivation beta-catenin is selectively degraded via the formation of a beta-catenin-LC3 complex, attenuating beta-catenin/TCF-driven transcription and proliferation to favour adaptation during metabolic stress. Formation of the beta-catenin-LC3 complex is mediated by a W/YXXI/L motif and LC3-interacting region (LIR) in beta-catenin, which is required for interaction with LC3 and non-proteasomal degradation of beta-catenin. Thus, Wnt/beta-catenin represses autophagy and p62 expression, while beta-catenin is itself targeted for autophagic clearance in autolysosomes upon autophagy induction. These findings reveal a regulatory feedback mechanism that place beta-catenin at a key cellular integration point coordinating proliferation with autophagy, with implications for targeting these pathways for cancer therapy.
C1 [Petherick, Katy J.; Williams, Ann C.; Collard, Tracey J.; Smartt, Helena J. M.; Paraskeva, Chris; Greenhough, Alexander] Univ Bristol, Sch Cellular & Mol Med, Canc Res UK Colorectal Tumour Biol Grp, Bristol BS8 1TD, Avon, England.
   [Lane, Jon D.] Univ Bristol, Sch Biochem, Cell Biol Labs, Bristol BS8 1TD, Avon, England.
   [Ordonez-Moran, Paloma; Huelsken, Joerg] Ecole Polytech Fed Lausanne, Swiss Inst Expt Canc Res, Canc Stem Cell Lab, Lausanne, Switzerland.
   [Batson, Jennifer] Univ Bristol, Sch Physiol & Pharmacol, Bristol BS8 1TD, Avon, England.
   [Malik, Karim] Univ Bristol, Sch Cellular & Mol Med, Canc Epigenet Lab, Bristol BS8 1TD, Avon, England.
RP Paraskeva, C (corresponding author), Univ Bristol, Sch Cellular & Mol Med, Canc Res UK Colorectal Tumour Biol Grp, Bristol BS8 1TD, Avon, England.
EM c.paraskeva@bristol.ac.uk; a.greenhough@bristol.ac.uk
RI Lane, Jon D/A-9320-2011; Greenhough, Alexander/J-9308-2012; Huelsken,
   Joerg/AAC-9581-2021; Greenhough, Alexander/Y-6728-2019; Ordonez-Moran,
   Paloma/B-6371-2016
OI Greenhough, Alexander/0000-0002-8306-811X; Huelsken,
   Joerg/0000-0003-3105-9606; Greenhough, Alexander/0000-0002-8306-811X;
   Williams, Ann/0000-0002-6009-7137; Malik, Karim/0000-0002-8965-200X;
   Lane, Jon/0000-0002-6828-5888; Ordonez-Moran, Paloma/0000-0001-7688-1252
FU Medical Research CouncilUK Research & Innovation (UKRI)Medical Research
   Council UK (MRC)European Commission; Wolfson Foundation; Cancer Research
   UKCancer Research UK [C19/A11975]; Citrina Foundation; John James
   Bristol Foundation; Wellcome TrustWellcome TrustEuropean Commission;
   BBSRCUK Research & Innovation (UKRI)Biotechnology and Biological
   Sciences Research Council (BBSRC) [BB/J002704/1] Funding Source: UKRI;
   Biotechnology and Biological Sciences Research CouncilUK Research &
   Innovation (UKRI)Biotechnology and Biological Sciences Research Council
   (BBSRC) [BB/J002704/1] Funding Source: researchfish; Cancer Research
   UKCancer Research UK [11975] Funding Source: researchfish
FX We thank all the members of our lab for their valuable support and
   discussion. In addition, we would like to thank Dr Nick Ktistakis for
   helpful discussion and the autophagy-inducing media recipe; Prof Terje
   Johansen for advice; Dr Benjamin Alman and Raymond Poon for providing
   the myc-tagged beta-catenin<SUP>AAAA</SUP> construct; Dr Eric Fearon for
   providing the beta-catenin<SUP>WT</SUP> and beta-catenin<SUP>S33Y</SUP>
   constructs; Dr Bert Vogelstein for providing the HCT116 CTNNB1 isogenic
   cell lines; Dr Ian McGough and Prof Pete Cullen for the HA-pcDNA3.1
   plasmid; Dr Andrew Herman for cell sorting at the University of Bristol
   FMVS Flow Cytometry Facility; the Medical Research Council and Wolfson
   Foundation for supporting the Wolfson Bioimaging Facility at the
   University of Bristol; Dr Stefan Roberts for critical reading of the
   manuscript. This work was supported by a Cancer Research UK Programme
   Grant (C19/A11975), the Citrina Foundation, the John James Bristol
   Foundation and the Wellcome Trust.
CR Axe EL, 2008, J CELL BIOL, V182, P685, DOI 10.1083/jcb.200803137
   Betin VMS, 2012, AUTOPHAGY, V8, P664, DOI 10.4161/auto.19227
   Betin VMS, 2009, J CELL SCI, V122, P2554, DOI 10.1242/jcs.046250
   Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7
   Bjorkoy G, 2005, J CELL BIOL, V171, P603, DOI 10.1083/jcb.200507002
   Chan TA, 2002, P NATL ACAD SCI USA, V99, P8265, DOI 10.1073/pnas.082240999
   Cheon SS, 2002, P NATL ACAD SCI USA, V99, P6973, DOI 10.1073/pnas.102657399
   Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012
   Duran A, 2008, CANCER CELL, V13, P343, DOI 10.1016/j.ccr.2008.02.001
   Eng CH, 2011, ONCOGENE, V30, P4687, DOI 10.1038/onc.2011.220
   Essers MAG, 2005, SCIENCE, V308, P1181, DOI 10.1126/science.1109083
   Fevr T, 2007, MOL CELL BIOL, V27, P7551, DOI 10.1128/MCB.01034-07
   Gao C, 2010, NAT CELL BIOL, V12, P781, DOI 10.1038/ncb2082
   Geetha T, 2012, BIOMARKERS, V17, P99, DOI 10.3109/1354750X.2011.653986
   Golan T, 2004, J BIOL CHEM, V279, P14879, DOI 10.1074/jbc.M306421200
   Greenhough A, 2010, ONCOGENE, V29, P3398, DOI 10.1038/onc.2010.94
   Hoverter NP, 2008, SCI SIGNAL, V1, DOI 10.1126/scisignal.139pe43
   Ichimura Y, 2008, J BIOL CHEM, V283, P22847, DOI 10.1074/jbc.M802182200
   Inami Y, 2011, J CELL BIOL, V193, P275, DOI 10.1083/jcb.201102031
   Jain A, 2010, J BIOL CHEM, V285, P22576, DOI 10.1074/jbc.M110.118976
   Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720
   Kaidi A, 2007, NAT CELL BIOL, V9, P210, DOI 10.1038/ncb1534
   Kim WD, 2012, J CELL SCI, V125, P1284, DOI 10.1242/jcs.095422
   Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1
   Kirkin V, 2009, MOL CELL, V34, P259, DOI 10.1016/j.molcel.2009.04.026
   Komatsu M, 2007, CELL, V131, P1149, DOI 10.1016/j.cell.2007.10.035
   Komatsu M, 2010, NAT CELL BIOL, V12, P213, DOI 10.1038/ncb2021
   Korolchuk VI, 2009, MOL CELL, V33, P517, DOI 10.1016/j.molcel.2009.01.021
   Kroemer G, 2010, MOL CELL, V40, P280, DOI 10.1016/j.molcel.2010.09.023
   Li VSW, 2012, CELL, V149, P1245, DOI 10.1016/j.cell.2012.05.002
   Ling JH, 2012, CANCER CELL, V21, P105, DOI 10.1016/j.ccr.2011.12.006
   Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2
   Mathew R, 2007, NAT REV CANCER, V7, P961, DOI 10.1038/nrc2254
   Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639
   Mizushima N, 2010, NAT CELL BIOL, V12, P823, DOI 10.1038/ncb0910-823
   Nguyen TN, 2006, NAT METHODS, V3, P135, DOI 10.1038/nmeth0206-135
   Noda NN, 2008, GENES CELLS, V13, P1211, DOI 10.1111/j.1365-2443.2008.01238.x
   Pankiv S, 2007, J BIOL CHEM, V282, P24131, DOI 10.1074/jbc.M702824200
   Smartt HJM, 2012, GUT, V61, P1306, DOI 10.1136/gutjnl-2011-300817
   Sukhdeo K, 2012, LEUKEMIA, V26, P1116, DOI 10.1038/leu.2011.303
   van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0
   White E, 2009, CLIN CANCER RES, V15, P5308, DOI 10.1158/1078-0432.CCR-07-5023
NR 42
TC 183
Z9 186
U1 2
U2 33
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0261-4189
EI 1460-2075
J9 EMBO J
JI Embo J.
PD JUL 3
PY 2013
VL 32
IS 13
BP 1903
EP 1916
DI 10.1038/emboj.2013.123
PG 14
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 176US
UT WOS:000321331900012
PM 23736261
OA Green Published, Green Submitted
DA 2022-04-25
ER

PT J
AU D'Apolito, O
   Garofalo, D
   Gelzo, M
   Paris, D
   Melck, D
   Calemma, R
   Izzo, F
   Palmieri, G
   Castello, G
   Motta, A
   Corso, G
AF D'Apolito, Oceania
   Garofalo, Daniela
   Gelzo, Monica
   Paris, Debora
   Melck, Dominique
   Calemma, Rosa
   Izzo, Francesco
   Palmieri, Giuseppe
   Castello, Giuseppe
   Motta, Andrea
   Corso, Gaetano
TI Basic amino acids and dimethylarginines targeted metabolomics
   discriminates primary hepatocarcinoma from hepatic colorectal metastases
SO METABOLOMICS
LA English
DT Article
DE Hepatic tumorigenesis; Metastases; Tissue metabolic profiling; Arginine;
   Dimethylarginines; Basic amino acids; Mass spectrometry
ID HUMAN HEPATOCELLULAR-CARCINOMA; ARGININOSUCCINATE SYNTHETASE;
   MAGNETIC-RESONANCE; CANCER METABOLISM; ARGININE; PROLIFERATION;
   SPECTROSCOPY; EXPRESSION; AUTOPHAGY; BIOMARKER
AB Hepatocellular carcinoma (HCC) is a very aggressive neoplasia requiring early and accurate diagnosis to improve patient outcomes with timely treatment. The liver is also very frequently colonized by metastases, and the most frequent differential diagnosis is HCC against intrahepatic cholangiocarcinoma or metastatic adenocarcinoma. Metabolomics is a powerful tool for identification of altered biomarkers in cancer, and to evaluate the efficacy of drug treatments. Here we analyzed by HILIC-MS/MS methylated arginines, basic amino acids (Arg, Cit, Orn), and their ratios in the extracts of primary HCC tissues, liver metastases from colorectal carcinoma (MET), cirrhotic related hepatitis-C-virus (CIR), and non-cirrhotic normal liver (NT) adjacent tissues. We found high levels of Arg (p < 0.0001) and Arg/Orn (p < 0.01) in MET compared to other tissues. In MET, compared to NT and CIR, Arg concentration was fivefold higher, while in HCC it was twofold higher. ADMA increased twofold compared to NT and CIR, while in HCC it was 50 % higher. Arg/Cit and ADMA/SDMA ratios were significantly higher in MET compared to NT and CIR (p < 0.005). Arg/Orn, Arg/Cit, and ADMA/SDMA ratios increased progressively from NT, CIR, HCC, to MET tissues. Arg/Cit correlated significantly with Arg/Orn ratios (r = 0.77; p < 0.0001), and discriminates tumor from non-tumor samples. In addition, the discriminant lactate/glucose ratio we previously found by NMR, also correlated significantly with the Arg levels (r = 0.64; p < 0.0001), and discriminated MET from all other tissues. The results indicated that Arg in MET is higher than other tissue classes, suggesting that, together with the lactate/glucose ratio, it can be considered a further biomarker for HCC-metastases differentiation.
C1 [D'Apolito, Oceania; Garofalo, Daniela; Corso, Gaetano] Univ Foggia, Dipartimento Med Clin & Sperimentale, Foggia, Italy.
   [Gelzo, Monica] Univ Naples Federico II, Dipartimento Med Mol & Biotecnol Med, Naples, Italy.
   [Paris, Debora; Melck, Dominique; Motta, Andrea] CNR, Ist Chim Biomol, Pozzuoli, NA, Italy.
   [Calemma, Rosa; Izzo, Francesco; Castello, Giuseppe] Fdn G Pascale, Ist Nazl Studio & Cura Tumori, Naples, Italy.
   [Palmieri, Giuseppe] CNR, Ist Chim Biomol, Sassari, SS, Italy.
   [Castello, Giuseppe] Ctr Ric Oncol Mercogliano, Mercogliano, Italy.
RP Corso, G (corresponding author), Univ Foggia, Dipartimento Med Clin & Sperimentale, Foggia, Italy.
EM andrea.motta@icb.cnr.it; gaetano.corso@unifg.it
RI Corso, Gaetano/H-9450-2013; Paris, Debora/ABI-2224-2020; Gelzo,
   Monica/K-6667-2016; Izzo, Francesco/P-3042-2019; Palmieri,
   Giuseppe/AAX-2627-2021; Paris, Debora/P-1624-2018; Palmieri,
   G/K-6095-2016
OI Corso, Gaetano/0000-0003-4720-1320; Paris, Debora/0000-0003-4526-8353;
   Gelzo, Monica/0000-0002-1500-0746; Izzo, Francesco/0000-0003-3093-5408;
   Paris, Debora/0000-0003-4526-8353; Palmieri, G/0000-0002-4350-2276;
   Motta, Andrea/0000-0002-8643-658X
FU University of Foggia (Premialita PRIN)
FX We are grateful to patients for their important contribution to this
   study. Financial support was received from the University of Foggia
   (Premialita PRIN 2008).
CR Abdelmagid SA, 2008, ENDOCRINOLOGY, V149, P4821, DOI 10.1210/en.2008-0145
   Abdelmagid SA, 2011, J CELL BIOCHEM, V112, P1084, DOI 10.1002/jcb.23022
   Atalay G, 2003, EUR J CANCER, V39, P2439, DOI 10.1016/S0959-8049(03)00601-4
   Beger RD, 2013, METABOLITES, V3, P552, DOI 10.3390/metabo3030552
   Butler EB, 2013, CANCER RES, V73, P2709, DOI 10.1158/0008-5472.CAN-12-3009
   Caso G, 2004, CLIN SCI, V107, P371, DOI 10.1042/CS20040096
   Chaerkady R, 2008, J PROTEOME RES, V7, P4289, DOI 10.1021/pr800197z
   Chan ECY, 2009, J PROTEOME RES, V8, P352, DOI 10.1021/pr8006232
   Chen TL, 2011, MOL CELL PROTEOMICS, V10, DOI 10.1074/mcp.M110.004945
   Cheng PNM, 2007, CANCER RES, V67, P309, DOI 10.1158/0008-5472.CAN-06-1945
   Colli A, 2006, AM J GASTROENTEROL, V101, P513, DOI 10.1111/j.1572-0241.2006.00467.x
   Curado MP, 2007, CANC INCIDENCE 5 CON, VIx, p[160, 961]
   D'Apolito O, 2008, CLIN BIOCHEM, V41, P1391, DOI 10.1016/j.clinbiochem.2008.08.075
   Dhanasekaran R, 2012, HEPATIC MED-EVID RES, V4, P19, DOI 10.2147/HMER.S16316
   Dillon BJ, 2004, CANCER-AM CANCER SOC, V100, P826, DOI 10.1002/cncr.20057
   El-Serag HB, 2007, GASTROENTEROLOGY, V132, P2557, DOI 10.1053/j.gastro.2007.04.061
   Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516
   Forner A, 2012, LANCET, V379, P1245, DOI 10.1016/S0140-6736(11)61347-0
   Gardini G, 2003, J HEPATOL, V39, P793, DOI 10.1016/S0168-8278(03)00386-6
   Glazer ES, 2010, J CLIN ONCOL, V28, P2220, DOI 10.1200/JCO.2009.26.7765
   GONZALEZ GG, 1991, CANCER RES, V51, P2932
   Griffin JL, 2004, NAT REV CANCER, V4, P551, DOI 10.1038/nrc1390
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]
   Kassahun Woubet T, 2006, Exp Clin Transplant, V4, P549
   Kenific CM, 2010, CURR OPIN CELL BIOL, V22, P241, DOI 10.1016/j.ceb.2009.10.008
   Kim YS, 2008, FUTURE ONCOL, V4, P93, DOI 10.2217/14796694.4.1.93
   Koppenol WH, 2011, NAT REV CANCER, V11, P325, DOI 10.1038/nrc3038
   Lam TL, 2009, CANCER LETT, V277, P91, DOI 10.1016/j.canlet.2008.11.031
   Li H, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.345
   Lind DS, 2004, J NUTR, V134, p2837S, DOI 10.1093/jn/134.10.2837S
   Liu SY, 2013, WORLD J GASTROENTERO, V19, P3423, DOI 10.3748/wjg.v19.i22.3423
   Moinard C, 2005, CLIN NUTR, V24, P184, DOI 10.1016/j.clnu.2004.11.001
   Morris SM, 2002, ANNU REV NUTR, V22, P87, DOI 10.1146/annurev.nutr.22.110801.140547
   O'Connell TM, 2012, BIOANALYSIS, V4, P431, DOI [10.4155/BIO.11.326, 10.4155/bio.11.326]
   Paris D, 2010, METABOLOMICS, V6, P405, DOI 10.1007/s11306-010-0209-8
   Pavlides S, 2010, CELL CYCLE, V9, P3485, DOI 10.4161/cc.9.17.12721
   Satriano J, 1998, J BIOL CHEM, V273, P15313, DOI 10.1074/jbc.273.25.15313
   Slebos RJC, 2013, INT J CANCER, V132, P568, DOI 10.1002/ijc.27699
   Syed N, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2012.197
   Szlosarek PW, 2006, CLIN CANCER RES, V12, P7126, DOI 10.1158/1078-0432.CCR-06-1101
   Szuba A, 2008, LEUKEMIA LYMPHOMA, V49, P2316, DOI 10.1080/10428190802510323
   Teerlink T, 2007, J CHROMATOGR B, V851, P21, DOI 10.1016/j.jchromb.2006.07.024
   Vander Heiden MG, 2011, NAT REV DRUG DISCOV, V10, P671, DOI 10.1038/nrd3504
   Vermeersch Kathleen A, 2013, J Carcinog, V12, P9, DOI 10.4103/1477-3163.113622
   World Health Organization, 2008, MORT DAT WHO STAT IN
   Wu LN, 2013, J GASTROEN HEPATOL, V28, P365, DOI 10.1111/jgh.12043
   Yang YX, 2007, J PROTEOME RES, V6, P2605, DOI 10.1021/pr070063h
   Yorimitsu T, 2005, CELL DEATH DIFFER, V12, P1542, DOI 10.1038/sj.cdd.4401765
   Yoshimatsu M, 2011, INT J CANCER, V128, P562, DOI 10.1002/ijc.25366
   Zhao Y, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.60
NR 51
TC 5
Z9 5
U1 0
U2 45
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1573-3882
EI 1573-3890
J9 METABOLOMICS
JI Metabolomics
PD OCT
PY 2014
VL 10
IS 5
BP 1026
EP 1035
DI 10.1007/s11306-014-0641-2
PG 10
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Endocrinology & Metabolism
GA AO5YH
UT WOS:000341422600022
DA 2022-04-25
ER

PT J
AU Hagihara, T
   Kondo, J
   Endo, H
   Ohue, M
   Sakai, Y
   Inoue, M
AF Hagihara, Takeshi
   Kondo, Jumpei
   Endo, Hiroko
   Ohue, Masayuki
   Sakai, Yoshiharu
   Inoue, Masahiro
TI Hydrodynamic stress stimulates growth of cell clusters via the
   ANXA1/PI3K/AKT axis in colorectal cancer
SO SCIENTIFIC REPORTS
LA English
DT Article
ID CIRCULATING TUMOR-CELLS; FLUID SHEAR-STRESS; ANNEXIN A1; FREE SURVIVAL;
   SPHEROIDS; RECEPTOR; PROGRESSION; AUTOPHAGY; DYNAMICS; CULTURE
AB Cancer cells are exposed to various stresses in vivo, including hydrodynamic stress (HDS). HDS on cancer cells in the blood stream can influence the metastatic potential. Recent studies revealed that circulating tumor cell clusters are more responsible for metastasis than circulating single cells. Nevertheless, most studies on HDS are based on single cells prepared from established cancer cell lines. Here, we used cancer tissue-originated spheroids (CTOS) as a patient-derived, 3D organoid model to investigate the effect of HDS on cancer cell clusters. We found that HDS induced the growth of cancer cell clusters in a population of colorectal CTOSs. Microarray analyses revealed that the multifunctional protein, Annexin 1 (ANXA1), was upregulated upon HDS exposure. Chemically-induced membrane damage also triggered the expression of ANXA1. A knockdown of ANXA1 revealed that ANXA1 regulated HDS-stimulated growth in colorectal CTOSs. Mechanistically, activating the PI3K/AKT pathway downstream of ANXA1 contributed to the phenotype. These findings demonstrate that HDS induces the growth of cancer cell clusters via ANXA1/PI3K/AKT axis, which helps to elucidate the prometastatic feature of circulating cancer cell clusters.
C1 [Hagihara, Takeshi; Kondo, Jumpei; Inoue, Masahiro] Kyoto Univ, Grad Sch Med, Dept Clin Bioresource Res & Dev, Sakyo Ku, Yoshida Honmachi, Kyoto 6068501, Japan.
   [Hagihara, Takeshi; Sakai, Yoshiharu] Kyoto Univ, Grad Sch Med, Dept Surg, Div Gastrointestinal Surg, Yoshida Honmachi, Kyoto 6068501, Japan.
   [Hagihara, Takeshi; Kondo, Jumpei; Endo, Hiroko; Ohue, Masayuki; Inoue, Masahiro] Osaka Int Canc Inst, Dept Biochem, Chuo Ku, 3-1-69 Otemae, Osaka 5418567, Japan.
RP Kondo, J (corresponding author), Kyoto Univ, Grad Sch Med, Dept Clin Bioresource Res & Dev, Sakyo Ku, Yoshida Honmachi, Kyoto 6068501, Japan.; Kondo, J (corresponding author), Osaka Int Canc Inst, Dept Biochem, Chuo Ku, 3-1-69 Otemae, Osaka 5418567, Japan.
EM jumpeko@gmail.com
RI Kondo, Jumpei/AAC-4336-2020
OI Kondo, Jumpei/0000-0002-1350-0480
FU P-DIRECT, P-CREATE, Platform Project for Supporting Drug Discovery and
   Life Science Research (Basis for Supporting Innovative Drug Discovery
   and Life Science Research (BINDS)) [JP18am0101084]; Research on
   Development of New Drugs grant from the Japan Agency for Medical
   Research and Development (AMED); Princess Takamatsu Cancer Research Fund
FX This article was supported by a Grants-in-Aid from the P-DIRECT,
   P-CREATE, Platform Project for Supporting Drug Discovery and Life
   Science Research (Basis for Supporting Innovative Drug Discovery and
   Life Science Research (BINDS)) under Grant Number JP18am0101084, the
   Research on Development of New Drugs grant from the Japan Agency for
   Medical Research and Development (AMED), and by a Research Grant of the
   Princess Takamatsu Cancer Research Fund.
CR Aceto N, 2014, CELL, V158, P1110, DOI 10.1016/j.cell.2014.07.013
   Aird WC, 2005, J THROMB HAEMOST, V3, P1392, DOI 10.1111/j.1538-7836.2005.01328.x
   Bacabac RG, 2005, J BIOMECH, V38, P159, DOI 10.1016/j.jbiomech.2004.03.020
   Barnes JM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050973
   Belvedere R, 2016, SCI REP-UK, V6, DOI 10.1038/srep29660
   Berns K, 2016, CLIN CANCER RES, V22, P5238, DOI 10.1158/1078-0432.CCR-15-2996
   Bhardwaj A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127678
   Chen J, 2009, NUCLEIC ACIDS RES, V37, pW305, DOI 10.1093/nar/gkp427
   Cheng TY, 2012, CANCER-AM CANCER SOC, V118, P5757, DOI 10.1002/cncr.27565
   Chiarugi P, 2008, BIOCHEM PHARMACOL, V76, P1352, DOI 10.1016/j.bcp.2008.07.023
   Chivukula VK, 2015, CELL HEALTH CYTOSKEL, V7, P25, DOI 10.2147/CHC.S71852
   Choi HY, 2019, BREAST CANCER RES, V21, DOI 10.1186/s13058-018-1071-2
   CLARKE MSF, 1992, J CELL SCI, V102, P533
   Cohen SJ, 2008, J CLIN ONCOL, V26, P3213, DOI 10.1200/JCO.2007.15.8923
   Cote MC, 2010, J BIOL CHEM, V285, P8013, DOI 10.1074/jbc.M109.098665
   Davenport NR, 2016, MOL BIOL CELL, V27, P2272, DOI 10.1091/mbc.E16-04-0223
   Draeger A, 2011, BIOCHEM PHARMACOL, V81, P703, DOI 10.1016/j.bcp.2010.12.027
   Endo H, 2017, ONCOGENE, V36, P2824, DOI 10.1038/onc.2016.431
   Endo H, 2013, J THORAC ONCOL, V8, P131, DOI 10.1097/JTO.0b013e3182779ccf
   Fan R, 2016, SCI REP-UK, V6, DOI 10.1038/srep27073
   Fu A, 2016, ONCOTARGET, V7, P50239, DOI 10.18632/oncotarget.10360
   Grewal T, 2009, CELL SIGNAL, V21, P847, DOI 10.1016/j.cellsig.2009.01.031
   Hou JM, 2012, J CLIN ONCOL, V30, P525, DOI 10.1200/JCO.2010.33.3716
   Huang Q, 2018, AM J CANCER RES, V8, P763
   Hyler AR, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0194170
   Ip CKM, 2016, SCI REP-UK, V6, DOI 10.1038/srep26788
   Khau T, 2011, FASEB J, V25, P483, DOI 10.1096/fj.09-154096
   Kim SW, 2017, MOL BIOL CELL, V28, P3043, DOI 10.1091/mbc.E17-01-0021
   Kondo J, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8050470
   Kondo J, 2011, P NATL ACAD SCI USA, V108, P6235, DOI 10.1073/pnas.1015938108
   Lee HJ, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14122
   Leoni G, 2013, J CLIN INVEST, V123, P443, DOI 10.1172/JCI65831
   Li CF, 2010, PATHOLOGY, V42, P43, DOI 10.3109/00313020903434405
   Lien SC, 2013, BBA-MOL CELL RES, V1833, P3124, DOI 10.1016/j.bbamcr.2013.08.023
   Masiello T, 2018, CELLS-BASEL, V7, DOI 10.3390/cells7120277
   McNeil AK, 2006, J BIOL CHEM, V281, P35202, DOI 10.1074/jbc.M606406200
   McNeil PL, 2002, J CELL SCI, V115, P873
   Mitchell MJ, 2013, NEW J PHYS, V15, DOI 10.1088/1367-2630/15/1/015008
   Nakajima A, 2015, INT J CANCER, V136, P2949, DOI 10.1002/ijc.29349
   Niinivirta M, 2017, J CANCER, V8, P3975, DOI 10.7150/jca.20889
   Okuyama H, 2016, AM J PATHOL, V186, P899, DOI 10.1016/j.ajpath.2015.12.011
   Onozawa H, 2017, ONCOL REP, V37, P235, DOI 10.3892/or.2016.5234
   Piulats Jose M, 2018, Oncotarget, V9, P15968, DOI 10.18632/oncotarget.24641
   Regmi S, 2017, SCI REP-UK, V7, DOI 10.1038/srep39975
   Sobral-Leite M, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0392-6
   STRONY J, 1993, AM J PHYSIOL, V265, pH1787
   Su N, 2010, TOHOKU J EXP MED, V222, P243, DOI 10.1620/tjem.222.243
   Terasaki M, 1997, J CELL BIOL, V139, P63, DOI 10.1083/jcb.139.1.63
   Walev I, 2001, P NATL ACAD SCI USA, V98, P3185, DOI 10.1073/pnas.051429498
   Yang H, 2016, ONCOTARGET, V7, P16227, DOI 10.18632/oncotarget.7583
   Yusa K, 2011, P NATL ACAD SCI USA, V108, P1531, DOI 10.1073/pnas.1008322108
NR 51
TC 11
Z9 11
U1 0
U2 5
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD DEC 27
PY 2019
VL 9
AR 20027
DI 10.1038/s41598-019-56739-7
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA KG1ER
UT WOS:000509685000001
PM 31882967
OA Green Published, gold, Green Submitted
DA 2022-04-25
ER

PT J
AU Huang, YH
   Sun, Y
   Huang, FY
   Li, YN
   Wang, CC
   Mei, WL
   Dai, HF
   Tan, GH
   Huang, CH
AF Huang, Yong-Hao
   Sun, Yan
   Huang, Feng-Ying
   Li, Yue-Nan
   Wang, Cai-Chun
   Mei, Wen-Li
   Dai, Hao-Fu
   Tan, Guang-Hong
   Huang, Canhua
TI Toxicarioside O induces protective autophagy in a sirtuin-1-dependent
   manner in colorectal cancer cells
SO ONCOTARGET
LA English
DT Article
DE colorectal cancer; toxicarioside O (TCO); autophagy; apoptosis;
   sirtuin-1 (SIRT1)
ID ANTIARIS-TOXICARIA; CARDIAC-GLYCOSIDES; STRESS; APOPTOSIS; SIRT1;
   DEACETYLATION; GLIOBLASTOMA; INVOLVEMENT; STARVATION; HYPOXIA
AB Colorectal cancer is the most common cancer. It has high morbidity and mortality worldwide, and more effective treatment strategies need to be developed. Toxicarioside O (TCO), a natural product derived from Antiaris toxicaria, has been shown to be a potential anticancer agent. However, the molecular mechanisms involved remain poorly understood. In this study, our results demonstrated that TCO can induce both apoptosis and autophagy in colorectal cancer cells. Moreover, TCO-induced autophagy was due to the increase of the expression and activity of the enzyme sirtuin-1 (SIRT1), and subsequent inhibition of the Akt/mTOR pathway. Inhibition of SIRT1 activity by its inhibitor, EX-527, attenuated TCO-induced autophagy. Of interest, inhibition of autophagy by chloroguine, an autophagy inhibitor, enhanced TCO-induced apoptotic cell death, suggesting that autophagy plays a protective role in TCO-induced apoptosis. Together, these findings suggest that combination of TCO and autophagy inhibitor may be a novel strategy suitable for potentiating the anticancer activity of TCO for treatment of colorectal cancer.
C1 [Huang, Yong-Hao; Sun, Yan; Huang, Feng-Ying; Li, Yue-Nan; Wang, Cai-Chun; Tan, Guang-Hong; Huang, Canhua] Hainan Med Coll, Minist Educ, Key Lab Trop Dis & Translat Med, Haikou 571199, Hainan, Peoples R China.
   [Huang, Yong-Hao; Sun, Yan; Huang, Feng-Ying; Li, Yue-Nan; Wang, Cai-Chun; Tan, Guang-Hong; Huang, Canhua] Hainan Med Coll, Hainan Prov Key Lab Trop Med, Haikou 571199, Hainan, Peoples R China.
   [Mei, Wen-Li; Dai, Hao-Fu] Chinese Acad Trop Agr Sci, Inst Trop Biosci & Biotechnol, Haikou 571199, Hainan, Peoples R China.
   [Huang, Canhua] Sichuan Univ, West China Hosp, State Key Lab Biotherapy, Chengdu 610041, Sichuan, Peoples R China.
   [Huang, Canhua] Sichuan Univ, West China Hosp, Canc Ctr, Chengdu 610041, Sichuan, Peoples R China.
RP Tan, GH; Huang, CH (corresponding author), Hainan Med Coll, Minist Educ, Key Lab Trop Dis & Translat Med, Haikou 571199, Hainan, Peoples R China.; Tan, GH; Huang, CH (corresponding author), Hainan Med Coll, Hainan Prov Key Lab Trop Med, Haikou 571199, Hainan, Peoples R China.; Dai, HF (corresponding author), Chinese Acad Trop Agr Sci, Inst Trop Biosci & Biotechnol, Haikou 571199, Hainan, Peoples R China.; Huang, CH (corresponding author), Sichuan Univ, West China Hosp, State Key Lab Biotherapy, Chengdu 610041, Sichuan, Peoples R China.; Huang, CH (corresponding author), Sichuan Univ, West China Hosp, Canc Ctr, Chengdu 610041, Sichuan, Peoples R China.
EM daihaofu@itbb.org.cn; tanhoho@163.com; hcanhua@hotmail.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81460557, 81560599, 81460020]
FX This work was funded by the National Natural Science Foundation of China
   (81460557, 81560599, 81460020). We thank LetPub (www.letpub.com) for its
   linguistic assistance during the preparation of this manuscript.
CR Brenner H, 2014, LANCET, V383, P1490, DOI 10.1016/S0140-6736(13)61649-9
   Cerella C, 2013, MITOCHONDRION, V13, P225, DOI 10.1016/j.mito.2012.06.003
   Dai HF, 2009, J ASIAN NAT PROD RES, V11, P832, DOI 10.1080/10286020903164285
   Dai HF, 2009, MOLECULES, V14, P3694, DOI 10.3390/molecules14093694
   De Roock W, 2011, LANCET ONCOL, V12, P594, DOI 10.1016/S1470-2045(10)70209-6
   Donadelli M, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.36
   Dong WH, 2011, PLANTA MED, V77, P1730, DOI 10.1055/s-0030-1271045
   Dong WH, 2011, J ASIAN NAT PROD RES, V13, P561, DOI 10.1080/10286020.2011.573479
   Dou QH, 2016, CANCER RES, V76, P4457, DOI 10.1158/0008-5472.CAN-15-2887
   Elgendy M, 2011, MOL CELL, V42, P23, DOI 10.1016/j.molcel.2011.02.009
   Ervik M., 2013, GLOBOCAN 2012 V10 CA
   Fulda S, 2015, ONCOGENE, V34, P5105, DOI 10.1038/onc.2014.458
   Gheorghiade M, 2006, CIRCULATION, V113, P2556, DOI 10.1161/CIRCULATIONAHA.105.560110
   Ghosh HS, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009199
   Green DR, 2014, CELL, V157, P65, DOI 10.1016/j.cell.2014.02.049
   Hariharan N, 2010, CIRC RES, V107, P1470, DOI 10.1161/CIRCRESAHA.110.227371
   Huang R, 2015, MOL CELL, V57, P456, DOI 10.1016/j.molcel.2014.12.013
   Janku F, 2011, NAT REV CLIN ONCOL, V8, P528, DOI 10.1038/nrclinonc.2011.71
   Josset E, 2013, ANTICANCER RES, V33, P1845
   Kroemer G, 2010, MOL CELL, V40, P280, DOI 10.1016/j.molcel.2010.09.023
   Kume S, 2010, J CLIN INVEST, V120, P1043, DOI 10.1172/JCI41376
   Lee IH, 2008, P NATL ACAD SCI USA, V105, P3374, DOI 10.1073/pnas.0712145105
   Liu R, 2014, AUTOPHAGY, V10, P1241, DOI 10.4161/auto.28912
   Maes H, 2013, TRENDS MOL MED, V19, P428, DOI 10.1016/j.molmed.2013.04.005
   Marino G, 2014, NAT REV MOL CELL BIO, V15, P81, DOI 10.1038/nrm3735
   McConkey DJ, 2000, CANCER RES, V60, P3807
   Newman RA, 2008, MOL INTERV, V8, P36, DOI 10.1124/mi.8.1.8
   OTTENSMEYER FP, 1972, J ULTRA MOL STRUCT R, V40, P546, DOI 10.1016/S0022-5320(72)80042-X
   Ou X, 2014, STEM CELLS, V32, P1183, DOI 10.1002/stem.1641
   Rubinsztein DC, 2012, NAT REV DRUG DISCOV, V11, P709, DOI 10.1038/nrd3802
   Shi LS, 2010, J NAT PROD, V73, P1214, DOI 10.1021/np9005212
   Shi YH, 2011, AUTOPHAGY, V7, P1159, DOI 10.4161/auto.7.10.16818
   SHRESTHA T, 1992, J ETHNOPHARMACOL, V37, P129, DOI 10.1016/0378-8741(92)90071-X
   Sun ZJ, 2010, APOPTOSIS, V15, P850, DOI 10.1007/s10495-010-0497-5
   Suzuki M, 2014, BBA-MOL BASIS DIS, V1842, P245, DOI 10.1016/j.bbadis.2013.11.023
   Wang K, 2011, AUTOPHAGY, V7, P966, DOI 10.4161/auto.7.9.15863
   Yang PM, 2010, CANCER RES, V70, P7699, DOI 10.1158/0008-5472.CAN-10-1626
   Zuo WJ, 2013, PHYTOCHEM LETT, V6, P1, DOI 10.1016/j.phytol.2012.10.001
NR 38
TC 14
Z9 15
U1 6
U2 23
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD AUG 8
PY 2017
VL 8
IS 32
BP 52783
EP 52791
DI 10.18632/oncotarget.17189
PG 9
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA FC8XE
UT WOS:000407124100063
PM 28881770
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Chavez-Dominguez, R
   Perez-Medina, M
   Lopez-Gonzalez, JS
   Galicia-Velasco, M
   Aguilar-Cazares, D
AF Chavez-Dominguez, Rodolfo
   Perez-Medina, Mario
   Lopez-Gonzalez, Jose S.
   Galicia-Velasco, Miriam
   Aguilar-Cazares, Dolores
TI The Double-Edge Sword of Autophagy in Cancer: From Tumor Suppression to
   Pro-tumor Activity
SO FRONTIERS IN ONCOLOGY
LA English
DT Review
DE autophagy; cell death; metabolic reprograming; metastasis;
   carcinogenesis; tumor microenvironment; immune evasion; chemotherapy and
   targeted therapy resistance
ID HYPOXIA-INDUCED AUTOPHAGY; CELL-DEATH; MOLECULAR-MECHANISMS; ANOIKIS
   RESISTANCE; MITOCHONDRIAL METABOLISM; GLUTAMINE-METABOLISM;
   GLUCOSE-METABOLISM; INHIBITS AUTOPHAGY; REGULATE AUTOPHAGY;
   COLORECTAL-CANCER
AB During tumorigenesis, cancer cells are exposed to a wide variety of intrinsic and extrinsic stresses that challenge homeostasis and growth. Cancer cells display activation of distinct mechanisms for adaptation and growth even in the presence of stress. Autophagy is a catabolic mechanism that aides in the degradation of damaged intracellular material and metabolite recycling. This activity helps meet metabolic needs during nutrient deprivation, genotoxic stress, growth factor withdrawal and hypoxia. However, autophagy plays a paradoxical role in tumorigenesis, depending on the stage of tumor development. Early in tumorigenesis, autophagy is a tumor suppressor via degradation of potentially oncogenic molecules. However, in advanced stages, autophagy promotes the survival of tumor cells by ameliorating stress in the microenvironment. These roles of autophagy are intricate due to their interconnection with other distinct cellular pathways. In this review, we present a broad view of the participation of autophagy in distinct phases of tumor development. Moreover, autophagy participation in important cellular processes such as cell death, metabolic reprogramming, metastasis, immune evasion and treatment resistance that all contribute to tumor development, is reviewed. Finally, the contribution of the hypoxic and nutrient deficient tumor microenvironment in regulation of autophagy and these hallmarks for the development of more aggressive tumors is discussed.
C1 [Chavez-Dominguez, Rodolfo; Perez-Medina, Mario; Lopez-Gonzalez, Jose S.; Galicia-Velasco, Miriam; Aguilar-Cazares, Dolores] Inst Nacl Enfermedades Resp Ismael Cosio Villegas, Dept Enfermedades Cronicodegenerat, Mexico City, DF, Mexico.
   [Chavez-Dominguez, Rodolfo] Univ Nacl Autonoma Mexico, Posgrad Ciencias Biol, Mexico City, DF, Mexico.
   [Perez-Medina, Mario] Inst Politecn Nacl, Dept Bioquim, Lab Quimioterapia Expt, Escuela Nacl Ciencias Biol, Mexico City, DF, Mexico.
RP Aguilar-Cazares, D (corresponding author), Inst Nacl Enfermedades Resp Ismael Cosio Villegas, Dept Enfermedades Cronicodegenerat, Mexico City, DF, Mexico.
EM doloresaguilarcazares@yahoo.com.mx
RI Aguilar-Cazares, Dolores/AAA-4774-2021
OI Lopez-Gonzalez, Jose Sullivan/0000-0003-0746-2286
CR Alizadeh J, 2018, BBA-MOL CELL RES, V1865, P749, DOI 10.1016/j.bbamcr.2018.02.007
   Amaravadi RK, 2019, CANCER DISCOV, V9, P1167, DOI 10.1158/2159-8290.CD-19-0292
   Anderson CM, 2019, INT REV CEL MOL BIO, V347, P145, DOI 10.1016/bs.ircmb.2019.06.002
   Arakawa S, 2017, P JPN ACAD B-PHYS, V93, P378, DOI 10.2183/pjab.93.023
   Baginska J, 2013, P NATL ACAD SCI USA, V110, P17450, DOI 10.1073/pnas.1304790110
   Balaburski GM, 2010, TRENDS CELL BIOL, V20, P363, DOI 10.1016/j.tcb.2010.02.007
   Bartrons R, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00331
   Bhol CS, 2020, SEMIN CANCER BIOL, V66, P22, DOI 10.1016/j.semcancer.2019.05.020
   Chang CC, 2005, J IMMUNOL, V174, P1462, DOI 10.4049/jimmunol.174.3.1462
   Chang CH, 2017, ONCOTARGET, V8, P31199, DOI 10.18632/oncotarget.16105
   Choi YK, 2018, BIOMOL THER, V26, P19, DOI 10.4062/biomolther.2017.178
   Chude CI, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18061279
   Csibi A, 2013, CELL, V153, P840, DOI 10.1016/j.cell.2013.04.023
   Czabotar PE, 2014, NAT REV MOL CELL BIO, V15, P49, DOI 10.1038/nrm3722
   Dasari S, 2014, EUR J PHARMACOL, V740, P364, DOI 10.1016/j.ejphar.2014.07.025
   Daskalaki I, 2018, FRONT CELL DEV BIOL, V6, DOI 10.3389/fcell.2018.00104
   Dower CM, 2018, AUTOPHAGY, V14, P1110, DOI 10.1080/15548627.2018.1450020
   Du H, 2015, AM J PATHOL, V185, P2379, DOI 10.1016/j.ajpath.2015.05.021
   Dunn GP, 2004, ANNU REV IMMUNOL, V22, P329, DOI 10.1146/annurev.immunol.22.012703.104803
   Dupuy F, 2015, CELL METAB, V22, P577, DOI 10.1016/j.cmet.2015.08.007
   Duran RV, 2012, MOL CELL, V47, P349, DOI 10.1016/j.molcel.2012.05.043
   Egan DF, 2011, SCIENCE, V331, P456, DOI 10.1126/science.1196371
   Elia I, 2018, TRENDS CELL BIOL, V28, P673, DOI 10.1016/j.tcb.2018.04.002
   Feng ZH, 2007, CANCER RES, V67, P3043, DOI 10.1158/0008-5472.CAN-06-4149
   Fernandez AF, 2018, NATURE, V558, P136, DOI 10.1038/s41586-018-0162-7
   Fujimoto T, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a004838
   Fung C, 2008, MOL BIOL CELL, V19, P797, DOI 10.1091/mbc.E07-10-1092
   Fung C, 2012, CANCER BIOL THER, V13, P1417, DOI 10.4161/cbt.22002
   Galavotti S, 2013, ONCOGENE, V32, P699, DOI 10.1038/onc.2012.111
   Galluzzi L, 2018, CELL DEATH DIFFER, V25, P486, DOI 10.1038/s41418-017-0012-4
   Gao P, 2009, NATURE, V458, P762, DOI 10.1038/nature07823
   GAO X, 1995, CANCER RES, V55, P1002
   Gewirtz DA, 2014, CANCER RES, V74, P647, DOI 10.1158/0008-5472.CAN-13-2966
   Glienke W, 2011, TUMOR BIOL, V32, P493, DOI 10.1007/s13277-010-0143-4
   Goldsmith J, 2014, METHOD ENZYMOL, V542, P25, DOI 10.1016/B978-0-12-416618-9.00002-9
   Gordan JD, 2007, CANCER CELL, V12, P108, DOI 10.1016/j.ccr.2007.07.006
   Gozuacik D, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00065
   Guan JJ, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2014.546
   Gugnoni M, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.415
   Guo JY, 2011, GENE DEV, V25, P460, DOI 10.1101/gad.2016311
   Han Y, 2020, BIOMED PHARMACOTHER, V121, DOI 10.1016/j.biopha.2019.109580
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Hardie DG, 2012, NAT REV MOL CELL BIO, V13, P251, DOI 10.1038/nrm3311
   Hen O, 2020, SEMIN CANCER BIOL, V60, P157, DOI 10.1016/j.semcancer.2019.09.002
   Ho CJ, 2019, CANCERS, V11, DOI 10.3390/cancers11111775
   Horbinski C, 2010, AM J PATHOL, V177, P1044, DOI 10.2353/ajpath.2010.091270
   Hu SB, 2018, J CELL MOL MED, V22, P5518, DOI 10.1111/jcmm.13825
   Huang X, 2014, ONCOL REP, V31, P1761, DOI 10.3892/or.2014.3015
   Huveneers S, 2009, J CELL SCI, V122, P1059, DOI 10.1242/jcs.039446
   Icard P, 2018, DRUG RESIST UPDATE, V38, P1, DOI 10.1016/j.drup.2018.03.001
   Israelsen WJ, 2015, SEMIN CELL DEV BIOL, V43, P43, DOI 10.1016/j.semcdb.2015.08.004
   Joo WD, 2013, MATURITAS, V76, P308, DOI 10.1016/j.maturitas.2013.09.008
   Karantza-Wadsworth V, 2007, GENE DEV, V21, P1621, DOI 10.1101/gad.1565707
   Kawauchi K, 2008, NAT CELL BIOL, V10, P611, DOI 10.1038/ncb1724
   Kenific CM, 2016, J CELL SCI, V129, P3685, DOI 10.1242/jcs.188490
   Kim J, 2011, NAT CELL BIOL, V13, P132, DOI 10.1038/ncb2152
   Kim JW, 2006, CELL METAB, V3, P177, DOI 10.1016/j.cmet.2006.02.002
   Kim R, 2007, IMMUNOLOGY, V121, P1, DOI 10.1111/j.1365-2567.2007.02587.x
   Kirkin V, 2009, MOL CELL, V34, P259, DOI 10.1016/j.molcel.2009.04.026
   Kitanaka C, 2002, J NATL CANCER I, V94, P358
   Kounakis K, 2019, FRONT CELL DEV BIOL, V7, DOI 10.3389/fcell.2019.00185
   Koundouros N, 2020, BRIT J CANCER, V122, P4, DOI 10.1038/s41416-019-0650-z
   Krakhmal NV, 2015, ACTA NATURAE, V7, P17, DOI 10.32607/20758251-2015-7-2-17-28
   Kroemer G, 2010, MOL CELL, V40, P280, DOI 10.1016/j.molcel.2010.09.023
   Lasche M, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00409
   Lai K, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4536-x
   Lai MC, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153627
   Li L, 2016, MOL CANCER THER, V15, P2232, DOI 10.1158/1535-7163.MCT-16-0008
   Li XQ, 2010, AUTOPHAGY, V6, P1066, DOI 10.4161/auto.6.8.13366
   Li ZD, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-98
   Liao YX, 2019, INT J ONCOL, V55, P1213, DOI 10.3892/ijo.2019.4902
   Liberti MV, 2016, TRENDS BIOCHEM SCI, V41, P211, DOI 10.1016/j.tibs.2015.12.001
   Lin JF, 2017, DRUG DES DEV THER, V11, P1517, DOI 10.2147/DDDT.S126464
   Liu YD, 2019, ONCOTARGETS THER, V12, P1195, DOI 10.2147/OTT.S189687
   Locasale Jason W, 2018, Curr Opin Syst Biol, V8, P32, DOI 10.1016/j.coisb.2017.11.005
   Lu GD, 2015, HEPATOLOGY, V61, P965, DOI 10.1002/hep.27593
   Maan M, 2018, BIOCHEM BIOPH RES CO, V504, P582, DOI 10.1016/j.bbrc.2018.02.097
   Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009
   Fader CM, 2009, BBA-MOL CELL RES, V1793, P1901, DOI 10.1016/j.bbamcr.2009.09.011
   Marinkovic M, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/8023821
   Marino G, 2014, MOL CELL, V53, P710, DOI 10.1016/j.molcel.2014.01.016
   Maroni P, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17040443
   Matoba S, 2006, SCIENCE, V312, P1650, DOI 10.1126/science.1126863
   Min HY, 2018, BIOMOL THER, V26, P45, DOI 10.4062/biomolther.2017.211
   Morselli E, 2011, CELL CYCLE, V10, P2763, DOI 10.4161/cc.10.16.16868
   Mowers EE, 2017, ONCOGENE, V36, P1619, DOI 10.1038/onc.2016.333
   Mowers EE, 2016, AUTOPHAGY, V12, P1679, DOI 10.1080/15548627.2016.1203487
   Nagano Makoto, 2012, Int J Cell Biol, V2012, P310616, DOI 10.1155/2012/310616
   Ng KP, 2012, NAT MED, V18, P521, DOI 10.1038/nm.2713
   Noman MZ, 2011, CANCER RES, V71, P5976, DOI 10.1158/0008-5472.CAN-11-1094
   Noman MZ, 2009, J IMMUNOL, V182, P3510, DOI 10.4049/jimmunol.0800854
   Pan XF, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1660-8
   Panda PK, 2015, SEMIN CELL DEV BIOL, V39, P43, DOI 10.1016/j.semcdb.2015.02.013
   Pankiv S, 2007, J BIOL CHEM, V282, P24131, DOI 10.1074/jbc.M702824200
   Paoli P, 2013, BBA-MOL CELL RES, V1833, P3481, DOI 10.1016/j.bbamcr.2013.06.026
   Park SY, 2020, EXP MOL MED, V52, P569, DOI 10.1038/s12276-020-0423-z
   Park SM, 2009, BIOCHEM BIOPH RES CO, V390, P1340, DOI 10.1016/j.bbrc.2009.10.149
   Parker SJ, 2015, PHARMACOL THERAPEUT, V152, P54, DOI 10.1016/j.pharmthera.2015.05.003
   Pavlova NN, 2016, CELL METAB, V23, P27, DOI 10.1016/j.cmet.2015.12.006
   Peng YF, 2013, AUTOPHAGY, V9, P2056, DOI 10.4161/auto.26398
   Peng YF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074407
   Perez-Hernandez M, 2019, CANCERS, V11, DOI 10.3390/cancers11101599
   Pezzuto A, 2018, CURR MOL MED, V18, P343, DOI 10.2174/1566524018666181109121849
   Pietrocola F, 2013, SEMIN CANCER BIOL, V23, P310, DOI 10.1016/j.semcancer.2013.05.008
   Potter M, 2016, BIOCHEM SOC T, V44, P1499, DOI 10.1042/BST20160094
   Pyo JO, 2005, J BIOL CHEM, V280, P20722, DOI 10.1074/jbc.M413934200
   Qadir MA, 2008, BREAST CANCER RES TR, V112, P389, DOI 10.1007/s10549-007-9873-4
   Qin LJ, 2016, ONCOTARGET, V7, P1395, DOI 10.18632/oncotarget.6366
   Qiu S, 2019, ONCOL LETT, V18, P1969, DOI 10.3892/ol.2019.10494
   Rabinowitz JD, 2010, SCIENCE, V330, P1344, DOI 10.1126/science.1193497
   REICHARDT LF, 1991, ANNU REV NEUROSCI, V14, P531, DOI 10.1146/annurev.ne.14.030191.002531
   Ren TT, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1497-1
   Romanov J, 2012, EMBO J, V31, P4304, DOI 10.1038/emboj.2012.278
   Rosenfeldt MT, 2013, NATURE, V504, P296, DOI 10.1038/nature12865
   Rubinstein AD, 2011, MOL CELL, V44, P698, DOI 10.1016/j.molcel.2011.10.014
   Ruppert SM, 2012, BBA-MOL CELL RES, V1823, P1877, DOI 10.1016/j.bbamcr.2012.06.017
   Russell RC, 2013, NAT CELL BIOL, V15, P741, DOI 10.1038/ncb2757
   Samaddar JS, 2008, MOL CANCER THER, V7, P2977, DOI 10.1158/1535-7163.MCT-08-0447
   Sanchez-Vega F, 2018, CELL, V173, P321, DOI 10.1016/j.cell.2018.03.035
   Schild T, 2018, CANCER CELL, V33, P347, DOI 10.1016/j.ccell.2018.02.001
   Schmukler E, 2014, ONCOTARGET, V5, P577, DOI 10.18632/oncotarget.1775
   Schomel N, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-52169-7
   Seliger B, 2002, SEMIN CANCER BIOL, V12, P3, DOI 10.1006/scbi.2001.0404
   Seliger B, 2019, J CLIN MED, V8, DOI 10.3390/jcm8122168
   Semenza GL, 2007, SCI STKE, DOI DOI 10.1126/STKE.4072007CM8
   Semenza GL, 2010, CURR OPIN GENET DEV, V20, P51, DOI 10.1016/j.gde.2009.10.009
   Sengupta S, 2010, MOL CELL, V40, P310, DOI 10.1016/j.molcel.2010.09.026
   Seyfried Thomas N., 2013, Critical Reviews in Oncogenesis, V18, P43
   Sharifi MN, 2017, MOL CELL ONCOL, V4, DOI 10.1080/23723556.2016.1198299
   Sharifi MN, 2016, CELL REP, V15, P1660, DOI 10.1016/j.celrep.2016.04.065
   Shi K, 2019, J CANCER, V10, P51, DOI 10.7150/jca.26908
   Singh R, 2009, NATURE, V458, P1131, DOI 10.1038/nature07976
   Singh RK, 2012, INT J OPT, V2012, DOI [10.1155/2012/282041, 10.1155/2012/832086]
   Son SM, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16886-2
   St-Pierre J, 2006, CELL, V127, P397, DOI 10.1016/j.cell.2006.09.024
   Stresing V, 2013, ONCOGENE, V32, P724, DOI 10.1038/onc.2012.93
   Su MF, 2013, J ONCOL, V2013, DOI 10.1155/2013/102735
   Su ZY, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0321-5
   Sun L, 2014, FUTURE ONCOL, V10, P1387, DOI [10.2217/FON.14.70, 10.2217/fon.14.70]
   Takahashi Y, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05254-w
   Tan WX, 2019, ONCOL REP, V42, P1343, DOI 10.3892/or.2019.7258
   Tang ZH, 2017, TOXICOL APPL PHARM, V321, P18, DOI 10.1016/j.taap.2017.02.017
   Tasdemir E, 2008, NAT CELL BIOL, V10, P676, DOI 10.1038/ncb1730
   Taylor MA, 2018, APOPTOSIS, V23, P563, DOI 10.1007/s10495-018-1480-9
   Thongchot S, 2014, ASIAN PAC J CANCER P, V15, P5873, DOI 10.7314/APJCP.2014.15.14.5873
   Tian Y, 2015, CELL DEATH DIFFER, V22, P1025, DOI 10.1038/cdd.2014.201
   Tripathi DN, 2013, P NATL ACAD SCI USA, V110, pE2950, DOI 10.1073/pnas.1307736110
   Vera-Ramirez L, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04070-6
   VERHOEVEN AJ, 1983, EUR J BIOCHEM, V133, P241, DOI 10.1111/j.1432-1033.1983.tb07454.x
   Vlahakis A, 2017, J MOL BIOL, V429, P515, DOI 10.1016/j.jmb.2016.11.027
   Wallace DC, 2012, NAT REV CANCER, V12, P685, DOI 10.1038/nrc3365
   Wallace DC, 2010, MITOCHONDRION, V10, P12, DOI 10.1016/j.mito.2009.09.006
   Wang J, 2014, AUTOPHAGY, V10, P766, DOI 10.4161/auto.27954
   Wang YF, 2017, ONCOL LETT, V14, P6857, DOI 10.3892/ol.2017.7046
   Wang YC, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01799
   Wang YY, 2016, SEMIN CELL DEV BIOL, V60, P97, DOI 10.1016/j.semcdb.2016.07.009
   Warburg O, 1927, J GEN PHYSIOL, V8, P519, DOI 10.1085/jgp.8.6.519
   Weinberg F, 2009, ANN NY ACAD SCI, V1177, P66, DOI 10.1111/j.1749-6632.2009.05039.x
   Wen YF, 2015, CLIN CANCER RES, V21, P448, DOI 10.1158/1078-0432.CCR-14-1578
   Whitaker-Menezes D, 2011, CELL CYCLE, V10, P4047, DOI 10.4161/cc.10.23.18151
   White E, 2012, NAT REV CANCER, V12, P401, DOI 10.1038/nrc3262
   Wilkinson S, 2019, FEBS J, V286, P2645, DOI 10.1111/febs.14932
   Wirawan E, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2009.16
   Wise DR, 2008, P NATL ACAD SCI USA, V105, P18782, DOI 10.1073/pnas.0810199105
   Wu JY, 2017, ONCOTARGET, V8, P32332, DOI 10.18632/oncotarget.15974
   Xiao X, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0880-6
   Yamamoto K, 2020, NATURE, V581, P100, DOI 10.1038/s41586-020-2229-5
   Yang J, 2013, ANAT REC, V296, P1501, DOI 10.1002/ar.22769
   Yang SH, 2011, GENE DEV, V25, P717, DOI 10.1101/gad.2016111
   Yang SY, 2011, FRONT BIOSCI-LANDMRK, V16, P531, DOI 10.2741/3703
   Yao Z, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.35
   Yazdani HO, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8020091
   Yonekawa T, 2013, ESSAYS BIOCHEM, V55, P105, DOI [10.1042/BSE0550105, 10.1042/bse0550105]
   Yoo BH, 2018, AUTOPHAGY, V14, P134, DOI 10.1080/15548627.2017.1370171
   Yuan HX, 2013, AUTOPHAGY, V9, P1983, DOI 10.4161/auto.26058
   Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100
   Zhang W, 2018, BIOCHIMIE, V144, P21, DOI 10.1016/j.biochi.2017.10.002
   Zhang XY, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0053931, 10.1371/journal.pone.0061922, 10.1371/journal.pone.0060781]
   Zhao RZ, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0884-2
   Zhao T, 2016, AM J PATHOL, V186, P2183, DOI 10.1016/j.ajpath.2016.04.014
   Zhou L, 2019, FASEB J, V33, P5520, DOI 10.1096/fj.201801983R
   Zhu HD, 2020, J CELL PHYSIOL, V235, P5084, DOI 10.1002/jcp.29377
   Zhu JF, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-1204-7
NR 183
TC 39
Z9 39
U1 7
U2 12
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2234-943X
J9 FRONT ONCOL
JI Front. Oncol.
PD OCT 7
PY 2020
VL 10
AR 578418
DI 10.3389/fonc.2020.578418
PG 19
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA OD4WU
UT WOS:000579853600001
PM 33117715
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Brest, P
   Corcelle, EA
   Cesaro, A
   Chargui, A
   Belaid, A
   Klionsky, DJ
   Vouret-Craviari, V
   Hebuterne, X
   Hofman, P
   Mograbi, B
AF Brest, P.
   Corcelle, E. A.
   Cesaro, A.
   Chargui, A.
   Belaid, A.
   Klionsky, D. J.
   Vouret-Craviari, V.
   Hebuterne, X.
   Hofman, P.
   Mograbi, B.
TI Autophagy and Crohn's Disease: At the Crossroads of Infection,
   Inflammation, Immunity, and Cancer
SO CURRENT MOLECULAR MEDICINE
LA English
DT Review
DE Autophagy; Crohn's disease; infection; inflammation; immunity; cancer
ID GENOME-WIDE ASSOCIATION; INDUCIBLY EXPRESSED GTPASE; BOWEL-DISEASE;
   SUSCEPTIBILITY LOCI; FRAMESHIFT MUTATION; RESISTANCE GTPASES;
   TOXOPLASMA-GONDII; CELLULAR-RESPONSE; GENETIC-VARIANTS; APOPTOTIC CELLS
AB Inflammatory bowel diseases (IBD) are common inflammatory disorders of the gastrointestinal tract that include ulcerative colitis (UC) and Crohn's disease (CD). The incidences of IBD are high in North America and Europe, affecting as many as one in 500 people. These diseases are associated with high morbidity and mortality. Colorectal cancer risk is also increased in IBD, correlating with inflammation severity and duration. IBD are now recognized as complex multigenetic disorders involving at least 32 different risk loci. In 2007, two different autophagy-related genes, ATG16L1 (autophagy-related gene 16-like 1) and IRGM (immunity-related GTPase M) were shown to be specifically involved in CD susceptibility by three independent genome-wide association studies. Soon afterwards, more than forty studies confirmed the involvement of ATG16L1 and IRGM variants in CD susceptibility and gave new information on the importance of macroautophagy (hereafter referred to as autophagy) in the control of infection, inflammation, immunity and cancer. In this review, we discuss how such findings have undoubtedly changed our understanding of CD pathogenesis. A unifying autophagy model then emerges that may help in understanding the development of CD from bacterial infection, to inflammation and finally cancer. The Pandora's box is now open, releasing a wave of hope for new therapeutic strategies in treating Crohn's disease.
C1 [Brest, P.; Cesaro, A.; Chargui, A.; Belaid, A.; Vouret-Craviari, V.; Hebuterne, X.; Hofman, P.; Mograbi, B.] Univ Nice Sophia Antipolis, Fac Med, INSERM, ERI 21,EA 4319, Nice, France.
   [Corcelle, E. A.] Danish Canc Soc, Inst Canc Biol, Apoptosis Dept, Copenhagen, Denmark.
   [Corcelle, E. A.] Danish Canc Soc, Inst Canc Biol, Ctr Genotox Stress Res, Copenhagen, Denmark.
   [Klionsky, D. J.] Univ Michigan, Inst Life Sci, Ann Arbor, MI 48109 USA.
   [Hebuterne, X.] Hop Archet II, Ctr Hosp Univ Nice, Nice, France.
   [Hofman, P.] Pasteur Hosp, Lab Clin & Expt Pathol, Nice, France.
RP Mograbi, B (corresponding author), Univ Nice Sophia Antipolis, Fac Med, INSERM, ERI 21,EA 4319, Nice, France.
EM mograbi@unice.fr
RI brest, patrick/B-7311-2012; Cesaro, Annabelle/AAX-3177-2020; brest,
   patrick/K-6164-2019; Mograbi, Baharia/Q-7953-2019; Mograbi,
   Baharia/N-5531-2018; Hofman, Paul/P-7654-2018
OI brest, patrick/0000-0002-1252-4747; brest, patrick/0000-0002-1252-4747;
   Hofman, Paul/0000-0003-0431-9353; Corcelle-Termeau,
   Elisabeth/0000-0002-3706-3756; Mograbi, Baharia/0000-0002-1025-3429
FU INCAInstitut National du Cancer (INCA) France
   [07/3D1616/Pdoc-110-32/NG-NC]; Alfred Benzon Foundation; Infectiopole
   and Ademe [08 62 C 0044]; Institut National du Cancer, Paris, France
   (INCa)Institut National du Cancer (INCA) France [Vancol R0153AA, INCa
   Inflacol R07129AA]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of General Medical Sciences
   (NIGMS) [R01GM053396] Funding Source: NIH RePORTER
FX The authors would like to thank Dr. R. Bocciardi and I. Ceccherini for
   their helpful comments on the manuscript. PB is funded by grants from
   INCA (07/3D1616/Pdoc-110-32/NG-NC), EAC is funded by the Alfred Benzon
   Foundation, AC and AB are funded by Infectiopole and Ademe (Convention
   n<SUP>o</SUP> 08 62 C 0044). This work was supported by grants from the
   Institut National du Cancer, Paris, France (INCa; Vancol R0153AA and
   INCa Inflacol R07129AA).
CR Ahn CH, 2007, APMIS, V115, P1344, DOI 10.1111/j.1600-0463.2007.00858.x
   Alonso S, 2007, P NATL ACAD SCI USA, V104, P6031, DOI 10.1073/pnas.0700036104
   Andrade RM, 2006, J CLIN INVEST, V116, P2366, DOI 10.1172/JCI28796
   Arico S, 2001, J BIOL CHEM, V276, P35243, DOI 10.1074/jbc.C100319200
   Baert F, 2003, NEW ENGL J MED, V348, P601, DOI 10.1056/NEJMoa020888
   Bafica A, 2007, J IMMUNOL, V179, P5514, DOI 10.4049/jimmunol.179.8.5514
   Baldassano RN, 2007, GUT, V56, P1171, DOI 10.1136/gut.2007.122747
   Baptista ML, 2008, INFLAMM BOWEL DIS, V14, P674, DOI 10.1002/ibd.20372
   Barrett JC, 2008, NAT GENET, V40, P955, DOI 10.1038/ng.175
   Baumgart DC, 2007, LANCET, V369, P1641, DOI 10.1016/S0140-6736(07)60751-X
   Bekpen C, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-11-r92
   Bernstein CN, 2001, CANCER-AM CANCER SOC, V91, P854, DOI 10.1002/1097-0142(20010215)91:4<854::AID-CNCR1073>3.0.CO;2-Z
   Boehm U, 1998, J IMMUNOL, V161, P6715
   Bonen DK, 2003, GASTROENTEROLOGY, V124, P140, DOI 10.1053/gast.2003.50019
   Boyle P, 2005, NAT CLIN PRACT ONCOL, V2, P424, DOI 10.1038/ncponc0288
   Burton PR, 2007, NATURE, V447, P661, DOI 10.1038/nature05911
   Cadwell K, 2008, NATURE, V456, P259, DOI 10.1038/nature07416
   Chen ZH, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003316
   Comes F, 2007, CELL DEATH DIFFER, V14, P693, DOI 10.1038/sj.cdd.4402076
   Cosnes J, 2005, GUT, V54, P237, DOI 10.1136/gut.2004.045294
   Cossart P, 2004, SCIENCE, V304, P242, DOI 10.1126/science.1090124
   Crotzer VL, 2005, P NATL ACAD SCI USA, V102, P7779, DOI 10.1073/pnas.0503088102
   Cummings JRF, 2007, INFLAMM BOWEL DIS, V13, P941, DOI 10.1002/ibd.20162
   Darfeuille-Michaud A, 2002, INT J MED MICROBIOL, V292, P185, DOI 10.1078/1438-4221-00201
   Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001
   Dengjel J, 2005, P NATL ACAD SCI USA, V102, P7922, DOI 10.1073/pnas.0501190102
   Djavaheri-Mergny M, 2006, J BIOL CHEM, V281, P30373, DOI 10.1074/jbc.M602097200
   Dorfel D, 2005, BLOOD, V105, P3199, DOI 10.1182/blood-2004-09-3556
   Duerr RH, 2006, SCIENCE, V314, P1461, DOI 10.1126/science.1135245
   Dumortier J, 2008, INFLAMM BOWEL DIS, V14, P874, DOI 10.1002/ibd.20395
   Ellington AA, 2006, CARCINOGENESIS, V27, P298, DOI 10.1093/carcin/bgi214
   Feng CG, 2008, NAT IMMUNOL, V9, P1279, DOI 10.1038/ni.1653
   Feng CG, 2008, CELL STEM CELL, V2, P83, DOI 10.1016/j.stem.2007.10.007
   Feng CG, 2004, J IMMUNOL, V172, P1163, DOI 10.4049/jimmunol.172.2.1163
   Fisher SA, 2008, NAT GENET, V40, P710, DOI 10.1038/ng.145
   Fowler EV, 2008, AM J GASTROENTEROL, V103, P2519, DOI 10.1111/j.1572-0241.2008.02023.x
   Franke A, 2008, NAT GENET, V40, P713, DOI 10.1038/ng.148
   FUJITA N, 2009, J BIOL CHEM
   Fujita N, 2008, MOL BIOL CELL, V19, P2092, DOI 10.1091/mbc.E07-12-1257
   Fung C, 2008, MOL BIOL CELL, V19, P797, DOI 10.1091/mbc.E07-10-1092
   Gutierrez MG, 2007, P NATL ACAD SCI USA, V104, P1829, DOI 10.1073/pnas.0601437104
   Gaj P, 2008, BMC MED GENET, V9, DOI 10.1186/1471-2350-9-81
   Girardin SE, 2003, J BIOL CHEM, V278, P8869, DOI 10.1074/jbc.C200651200
   Glas J, 2008, AM J GASTROENTEROL, V103, P682, DOI 10.1111/j.1572-0241.2007.01694.x
   Gutierrez MG, 2005, CELL MICROBIOL, V7, P981, DOI 10.1111/j.1462-5822.2005.00527.x
   Gutierrez MG, 2004, CELL, V119, P753, DOI 10.1016/j.cell.2004.11.038
   Hait WN, 2006, CLIN CANCER RES, V12, P1961, DOI 10.1158/1078-0432.CCR-06-0011
   Halfvarson J, 2005, DIGEST LIVER DIS, V37, P768, DOI 10.1016/j.dld.2005.05.005
   Hampe J, 2001, LANCET, V357, P1925, DOI 10.1016/S0140-6736(00)05063-7
   Hampe J, 2007, NAT GENET, V39, P207, DOI 10.1038/ng1954
   Hancock L, 2008, INFLAMM BOWEL DIS, V14, P1667, DOI 10.1002/ibd.20517
   Harris J, 2007, IMMUNITY, V27, P505, DOI 10.1016/j.immuni.2007.07.022
   Henry SC, 2007, J IMMUNOL, V179, P6963, DOI 10.4049/jimmunol.179.10.6963
   Hippert MM, 2006, CANCER RES, V66, P9349, DOI 10.1158/0008-5472.CAN-06-1597
   Huang J, 2009, P NATL ACAD SCI USA, V106, P6226, DOI 10.1073/pnas.0811045106
   Hugot JP, 2001, NATURE, V411, P599, DOI 10.1038/35079107
   Hunn JP, 2008, EMBO J, V27, P2495, DOI 10.1038/emboj.2008.176
   Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43
   Jess T, 2005, AM J GASTROENTEROL, V100, P2486, DOI 10.1111/j.1572-0241.2005.00224.x
   Jess T, 2007, INFLAMM BOWEL DIS, V13, P481, DOI 10.1002/ibd.20036
   Jia GH, 2006, IMMUNOL CELL BIOL, V84, P448, DOI 10.1111/j.1440-1711.2006.01454.x
   Kahan BD, 2005, TRANSPLANTATION, V80, P749, DOI 10.1097/01.TP.0000173770.42403.F7
   Kang MR, 2009, J PATHOL, V217, P702, DOI 10.1002/path.2509
   Kim MS, 2008, HUM PATHOL, V39, P1059, DOI 10.1016/j.humpath.2007.11.013
   Kirkegaard K, 2004, NAT REV MICROBIOL, V2, P301, DOI 10.1038/nrmicro865
   Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717
   Komatsu M, 2005, J CELL BIOL, V169, P425, DOI 10.1083/jcb.200412022
   Kuballa P, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003391
   Kugathasan S, 2008, NAT GENET, V40, P1211, DOI 10.1038/ng.203
   Kuma A, 2004, NATURE, V432, P1032, DOI 10.1038/nature03029
   Kuma A, 2002, J BIOL CHEM, V277, P18619, DOI 10.1074/jbc.M111889200
   Lakatos PL, 2008, DIGEST LIVER DIS, V40, P867, DOI 10.1016/j.dld.2008.03.022
   Latiano A, 2008, WORLD J GASTROENTERO, V14, P4643, DOI 10.3748/wjg.14.4643
   Lee JW, 2007, APMIS, V115, P750, DOI 10.1111/j.1600-0463.2007.apm_640.x
   Levine B, 2005, CELL, V120, P159, DOI 10.1016/j.cell.2005.01.005
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Li BX, 2009, AUTOPHAGY, V5, P303, DOI 10.4161/auto.5.3.7491
   Li CY, 2006, J IMMUNOL, V177, P5163, DOI 10.4049/jimmunol.177.8.5163
   Li J, 2009, ANN SURG ONCOL, V16, P761, DOI 10.1245/s10434-008-0260-0
   Liang C, 2006, NAT CELL BIOL, V8, P688, DOI 10.1038/ncb1426
   Libioulle C, 2007, PLOS GENET, V3, DOI 10.1371/journal.pgen.0030058
   Ling YM, 2006, J EXP MED, V203, P2063, DOI 10.1084/jem.20061318
   MacMicking JD, 2003, SCIENCE, V302, P654, DOI 10.1126/science.1088063
   Maderna P, 2003, BBA-MOL BASIS DIS, V1639, P141, DOI 10.1016/j.bbadis.2003.09.004
   Martens S, 2004, J IMMUNOL, V173, P2594, DOI 10.4049/jimmunol.173.4.2594
   Martens S, 2005, PLOS PATHOG, V1, P187, DOI 10.1371/journal.ppat.0010024
   Massey DCO, 2008, GUT, V57, P1294, DOI 10.1136/gut.2008.157297
   Matsuda C, 2007, CLIN EXP IMMUNOL, V148, P348, DOI 10.1111/j.1365-2249.2007.03345.x
   McCarroll SA, 2008, NAT GENET, V40, P1107, DOI 10.1038/ng.215
   Mills KR, 2004, P NATL ACAD SCI USA, V101, P3438, DOI 10.1073/pnas.0400443101
   Miyairi I, 2007, J IMMUNOL, V179, P1814, DOI 10.4049/jimmunol.179.3.1814
   Mizushima N, 2004, MOL BIOL CELL, V15, P1101, DOI 10.1091/mbc.E03-09-0704
   Mizushima N, 2003, J CELL SCI, V116, P1679, DOI 10.1242/jcs.00381
   Mizushima N, 1999, EMBO J, V18, P3888, DOI 10.1093/emboj/18.14.3888
   Nakagawa I, 2004, SCIENCE, V306, P1037, DOI 10.1126/science.1103966
   Nedjic J, 2008, NATURE, V455, P396, DOI 10.1038/nature07208
   Nomura H, 2009, HUM PATHOL, V40, P83, DOI 10.1016/j.humpath.2008.06.018
   Ogura Y, 2001, NATURE, V411, P603, DOI 10.1038/35079114
   Okazaki T, 2008, INFLAMM BOWEL DIS, V14, P1528, DOI 10.1002/ibd.20512
   Paludan C, 2005, SCIENCE, V307, P593, DOI 10.1126/science.1104904
   Parkes M, 2007, NAT GENET, V39, P830, DOI 10.1038/ng2061
   Perricone C, 2008, GASTROENTEROLOGY, V134, P368, DOI 10.1053/j.gastro.2007.11.017
   Peterson N, 2008, GUT, V57, P1336, DOI 10.1136/gut.2008.152207
   Petiot A, 2000, J BIOL CHEM, V275, P992, DOI 10.1074/jbc.275.2.992
   Prescott NJ, 2007, GASTROENTEROLOGY, V132, P1665, DOI 10.1053/j.gastro.2007.03.034
   Pua HH, 2007, J EXP MED, V204, P25, DOI 10.1084/jem.20061303
   Qu XP, 2007, CELL, V128, P931, DOI 10.1016/j.cell.2006.12.044
   Raelson JV, 2007, P NATL ACAD SCI USA, V104, P14747, DOI 10.1073/pnas.0706645104
   Reinisch W, 2008, AM J GASTROENTEROL, V103, P2284, DOI 10.1111/j.1572-0241.2008.02024.x
   Rich KA, 2003, CELL MICROBIOL, V5, P455, DOI 10.1046/j.1462-5822.2003.00292.x
   Rioux JD, 2007, NAT GENET, V39, P596, DOI 10.1038/ng2032
   Roberts RL, 2008, GENES IMMUN, V9, P561, DOI 10.1038/gene.2008.49
   Roberts RL, 2007, AM J GASTROENTEROL, V102, P2754, DOI 10.1111/j.1572-0241.2007.01525.x
   Saitoh T, 2008, NATURE, V456, P264, DOI 10.1038/nature07383
   Santiago HC, 2005, J IMMUNOL, V175, P8165, DOI 10.4049/jimmunol.175.12.8165
   Sato K, 2007, CANCER RES, V67, P9677, DOI 10.1158/0008-5472.CAN-07-1462
   Scherz-Shouval R, 2007, EMBO J, V26, P1749, DOI 10.1038/sj.emboj.7601623
   Schmid D, 2007, IMMUNITY, V26, P79, DOI 10.1016/j.immuni.2006.10.018
   Singh SB, 2006, SCIENCE, V313, P1438, DOI 10.1126/science.1129577
   Stone MA, 2003, EUR J GASTROEN HEPAT, V15, P1275, DOI 10.1097/00042737-200312000-00004
   Subauste CS, 2007, AUTOPHAGY, V3, P245, DOI 10.4161/auto.3717
   Taylor GA, 2004, NAT REV IMMUNOL, V4, P100, DOI 10.1038/nri1270
   Taylor GA, 1997, J BIOL CHEM, V272, P10639
   Taylor GA, 1996, J BIOL CHEM, V271, P20399, DOI 10.1074/jbc.271.34.20399
   Thorburn J, 2005, MOL BIOL CELL, V16, P1189, DOI 10.1091/mbc.E04-10-0906
   Trincheri NF, 2008, CARCINOGENESIS, V29, P381, DOI 10.1093/carcin/bgm271
   Uthaiah RC, 2003, J BIOL CHEM, V278, P29336, DOI 10.1074/jbc.M211973200
   Van Limbergen J, 2008, INFLAMM BOWEL DIS, V14, P338, DOI 10.1002/ibd.20340
   Wang K, 2009, AM J HUM GENET, V84, P399, DOI 10.1016/j.ajhg.2009.01.026
   Webster AC, 2006, TRANSPLANTATION, V81, P1234, DOI 10.1097/01.tp.0000219703.39149.85
   Weersma RK, 2009, GUT, V58, P388, DOI 10.1136/gut.2007.144865
   Weersma RK, 2008, AM J GASTROENTEROL, V103, P621, DOI 10.1111/j.1572-0241.2007.01660.x
   Wright K, 1997, J BIOL CHEM, V272, P12626, DOI 10.1074/jbc.272.19.12626
   Xu Y, 2007, IMMUNITY, V27, P135, DOI 10.1016/j.immuni.2007.05.022
   Yamazaki K, 2005, HUM MOL GENET, V14, P3499, DOI 10.1093/hmg/ddi379
   Yamazaki K, 2007, J HUM GENET, V52, P575, DOI 10.1007/s10038-007-0156-z
   Yoshioka A, 2008, INT J ONCOL, V33, P461, DOI 10.3892/ijo_00000028
   Zhang HF, 2009, HUM GENET, V125, P627, DOI 10.1007/s00439-009-0660-7
   Zheng HR, 2004, DNA SEQUENCE, V15, P303, DOI 10.1080/10425170400004104
   Zhernakova A, 2008, AM J HUM GENET, V82, P1202, DOI 10.1016/j.ajhg.2008.03.016
   Zhi Jia, 2008, Nan Fang Yi Ke Da Xue Xue Bao, V28, P649
   Zhu JL, 1999, GASTROENTEROLOGY, V117, P1198, DOI 10.1016/S0016-5085(99)70406-3
NR 142
TC 56
Z9 62
U1 0
U2 19
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1566-5240
EI 1875-5666
J9 CURR MOL MED
JI Curr. Mol. Med.
PD JUL
PY 2010
VL 10
IS 5
BP 486
EP 502
DI 10.2174/156652410791608252
PG 17
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA 628OI
UT WOS:000280129400004
PM 20540703
OA Green Accepted
DA 2022-04-25
ER

PT J
AU Sugito, N
   Taniguchi, K
   Kuranaga, Y
   Ohishi, M
   Soga, T
   Ito, Y
   Miyachi, M
   Kikuchi, K
   Hosoi, H
   Akao, Y
AF Sugito, Nobuhiko
   Taniguchi, Kohei
   Kuranaga, Yuki
   Ohishi, Maki
   Soga, Tomoyoshi
   Ito, Yuko
   Miyachi, Mitsuru
   Kikuchi, Ken
   Hosoi, Hajime
   Akao, Yukihiro
TI Cancer-Specific Energy Metabolism in Rhabdomyosarcoma Cells Is Regulated
   by MicroRNA
SO NUCLEIC ACID THERAPEUTICS
LA English
DT Article
DE rhabdomyosarcoma; PTBP1; microRNA; PAX3-FOXO1
ID MUSCLE-SPECIFIC MICRORNA; KINASE MESSENGER-RNA; PYRUVATE-KINASE;
   ALVEOLAR RHABDOMYOSARCOMA; COLORECTAL TUMORS; C-MYC; GROWTH; EXPRESSION;
   FUSION; DIFFERENTIATION
AB Rhabdomyosarcoma (RMS) is a soft tissue sarcoma and is most frequently found in children. In RMS, there are two major subtypes, that is, embryonal RMS and alveolar RMS (ARMS). ARMS has exclusively the worse prognosis and is caused by formation of the chimeric PAX3-FOXO1 gene. Regarding cancer, the Warburg effect is known as a feature of cancer-specific metabolism. Polypyrimidine tract-binding protein 1 (PTBP1), a splicer of pyruvate kinase muscle (PKM) mRNA, is a positive regulator of cancer-specific energy metabolism. We investigated the expression and effects of muscle-specific miR-1 and miR-133b on RMS cells (RD, KYM-1, Rh30, and Rh41) from the view of energy metabolism and regulation of the chimeric gene. As a result, downregulated miR-1 and miR-133b/upregulated PTBP1 were found in RMS cell lines as well as in RMS clinical cases. Ectopic expression of either miR in both types of RMS cells induced autophagic cell death through silencing of PTBP1. Interestingly, we validated that miR-133b also knock downed PAX3-FOXO1. Moreover, we found that PAX3-FOXO1 positively regulated the PKM2-dominant expression through enhanced expression of PTBP1. These findings suggest that the miR-1 and miR-133b/PTBP1 axis and miR-133b/PAX3-FOXO1/PTBP1 axis contributed to the maintenance of cancer-specific energy metabolism.
C1 [Sugito, Nobuhiko; Kuranaga, Yuki; Akao, Yukihiro] Gifu Univ, United Grad Sch Drug Discovery & Med Informat Sci, 1-1 Yanagido, Gifu 5011193, Japan.
   [Taniguchi, Kohei] Osaka Med Coll, Dept Gen & Gastroenterol Surg, Takatsuki, Osaka, Japan.
   [Ohishi, Maki; Soga, Tomoyoshi] Keio Univ, Inst Adv Biosci, Tsuruoka, Yamagata, Japan.
   [Ito, Yuko] Osaka Med Coll, Dept Anat & Cell Biol, Div Life Sci, Takatsuki, Osaka, Japan.
   [Miyachi, Mitsuru; Kikuchi, Ken; Hosoi, Hajime] Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Pediat, Kyoto, Japan.
RP Akao, Y (corresponding author), Gifu Univ, United Grad Sch Drug Discovery & Med Informat Sci, 1-1 Yanagido, Gifu 5011193, Japan.
EM yakao@gifu-u.ac.jp
RI Soga, Tomoyoshi/B-8105-2014; Kikuchi, Ken/ABG-8290-2020
OI Soga, Tomoyoshi/0000-0001-9502-2509; Kikuchi, Ken/0000-0003-3097-7480;
   Miyachi, Mitsuru/0000-0003-4522-2478; Taniguchi,
   Kohei/0000-0003-0648-1370
FU GSK Japan; Ministry of Education, Science, Sports, and Culture of
   JapanMinistry of Education, Culture, Sports, Science and Technology,
   Japan (MEXT) [YA-24659157]
FX This work was supported by a GSK Japan Research Grant and Grant-in-aid
   for scientific research from the Ministry of Education, Science, Sports,
   and Culture of Japan (YA-24659157).
CR Akao Y, 2010, CANCER GENE THER, V17, P398, DOI 10.1038/cgt.2009.88
   Akao Y, 2006, ONCOL REP, V16, P845
   Akao Y, 2006, BIOL PHARM BULL, V29, P903, DOI 10.1248/bpb.29.903
   Ambros V, 2003, CELL, V113, P673, DOI 10.1016/S0092-8674(03)00428-8
   Anderson MJ, 2001, P NATL ACAD SCI USA, V98, P1589, DOI 10.1073/pnas.98.4.1589
   Chen JF, 2006, NAT GENET, V38, P228, DOI 10.1038/ng1725
   Chen M, 2010, CANCER RES, V70, P8977, DOI 10.1158/0008-5472.CAN-10-2513
   Chen X, 2008, CELL, V133, P1106, DOI 10.1016/j.cell.2008.04.043
   Christofk HR, 2008, NATURE, V452, P230, DOI 10.1038/nature06734
   Clower CV, 2010, P NATL ACAD SCI USA, V107, P1894, DOI 10.1073/pnas.0914845107
   Croce CM, 2009, NAT REV GENET, V10, P704, DOI 10.1038/nrg2634
   David CJ, 2010, NATURE, V463, P364, DOI 10.1038/nature08697
   FREDERICKS WJ, 1995, MOL CELL BIOL, V15, P1522
   GALILI N, 1993, NAT GENET, V5, P230, DOI 10.1038/ng1193-230
   Hanna JA, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.159
   Hosoi H, 2016, PEDIATR INT, V58, P81, DOI 10.1111/ped.12867
   Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720
   Kikuchi K, 2008, BIOCHEM BIOPH RES CO, V365, P568, DOI 10.1016/j.bbrc.2007.11.017
   Kuma A, 2007, AUTOPHAGY, V3, P323, DOI 10.4161/auto.4012
   LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y
   Liu N, 2007, P NATL ACAD SCI USA, V104, P20844, DOI 10.1073/pnas.0710558105
   MacQuarrie KL, 2012, SKELET MUSCLE, V2, DOI 10.1186/2044-5040-2-7
   Marshall AD, 2012, SKELET MUSCLE, V2, DOI 10.1186/2044-5040-2-25
   Meza JL, 2006, J CLIN ONCOL, V24, P3844, DOI 10.1200/JCO.2005.05.3801
   Missiaglia E, 2012, J CLIN ONCOL, V30, P1670, DOI 10.1200/JCO.2011.38.5591
   Miyachi M, 2010, BIOCHEM BIOPH RES CO, V400, P89, DOI 10.1016/j.bbrc.2010.08.015
   Noguchi S, 2013, MOL THER, V21, P1204, DOI 10.1038/mt.2013.70
   NOGUCHI T, 1986, J BIOL CHEM, V261, P3807
   Rao PK, 2006, P NATL ACAD SCI USA, V103, P8721, DOI 10.1073/pnas.0602831103
   Rao PK, 2010, FASEB J, V24, P3427, DOI 10.1096/fj.09-150698
   Schlosser I, 2005, ONCOGENE, V24, P520, DOI 10.1038/sj.onc.1208198
   Selbach M, 2008, NATURE, V455, P58, DOI 10.1038/nature07228
   Shiio Y, 2002, EMBO J, V21, P5088, DOI 10.1093/emboj/cdf525
   Shimizu S, 2004, NAT CELL BIOL, V6, P1221, DOI 10.1038/ncb1192
   Soga T, 2003, J PROTEOME RES, V2, P488, DOI 10.1021/pr034020m
   Tang YX, 2009, MOL CANCER THER, V8, P458, DOI 10.1158/1535-7163.MCT-08-0885
   Taniguchi K, 2016, ONCOTARGET, V7, P18940, DOI 10.18632/oncotarget.8005
   Taniguchi K, 2015, CANCER LETT, V363, P17, DOI 10.1016/j.canlet.2015.03.026
   Taniguchi K, 2015, SCI REP-UK, V5, DOI 10.1038/srep08647
   Taulli R, 2009, J CLIN INVEST, V119, P2366, DOI 10.1172/JCI38075
   Walters ZS, 2014, ONCOGENE, V33, P1148, DOI 10.1038/onc.2013.46
   WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309
   Xu CQ, 2007, J CELL SCI, V120, P3045, DOI 10.1242/jcs.010728
   Yan D, 2009, J BIOL CHEM, V284, P29596, DOI 10.1074/jbc.M109.020511
NR 44
TC 13
Z9 13
U1 0
U2 6
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 2159-3337
EI 2159-3345
J9 NUCLEIC ACID THER
JI Nucl. Acid Ther.
PD DEC
PY 2017
VL 27
IS 6
BP 365
EP 377
DI 10.1089/nat.2017.0673
PG 13
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Medicine,
   Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Research &
   Experimental Medicine
GA FN8CJ
UT WOS:000416246300006
PM 28981396
DA 2022-04-25
ER

PT J
AU Sun, XD
   Xu, HX
   Dai, TY
   Xie, LX
   Zhao, Q
   Hao, XC
   Sun, Y
   Wang, XB
   Jiang, N
   Sang, M
AF Sun, Xiaodong
   Xu, Hongxia
   Dai, Tianyu
   Xie, Lixia
   Zhao, Qiang
   Hao, Xincai
   Sun, Yan
   Wang, Xuanbin
   Jiang, Nan
   Sang, Ming
TI Alantolactone inhibits cervical cancer progression by downregulating
   BMI1
SO SCIENTIFIC REPORTS
LA English
DT Article
ID EPITHELIAL-MESENCHYMAL TRANSITION; NF-KAPPA-B; INULA-HELENIUM;
   BREAST-CANCER; STEM-CELLS; SESQUITERPENE LACTONE; HUMAN-PAPILLOMAVIRUS;
   COLORECTAL-CANCER; ISOALANTOLACTONE; CARCINOMA
AB Cervical cancer is the second most common cancer in women. Despite advances in cervical cancer therapy, tumor recurrence and metastasis remain the leading causes of mortality. High expression of BMI1 is significantly associated with poor tumor differentiation, high clinical grade, and poor prognosis of cervical cancer, and is an independent prognostic factor in cervical carcinoma. Alantolactone (AL), a sesquiterpene lactone, exhibits potent anti-inflammatory and anticancer activities. In this paper, we investigated the mechanism of AL in reducing the proliferation, migration, and invasion of HeLa and SiHa cervical cancer cells as well as its promotion of mitochondrial damage and autophagy. BMI1 silencing decreased epithelial-mesenchymal transformation-associated proteins and increased autophagy-associated proteins in HeLa cells. These effects were reversed by overexpression of BMI1 in HeLa cells. Thus, BMI1 expression is positively correlated with invasion and negatively correlated with autophagy in HeLa cells. Importantly, AL decreased the weight, volume, and BMI1 expression in HeLa xenograft tumors. Furthermore, the structure of BMI1 and target interaction of AL were virtually screened using the molecular docking program Autodock Vina; AL decreased the expression of N-cadherin, vimentin, and P62 and increased the expression of LC3B and Beclin-1 in xenograft tumors. Finally, expression of BMI1 increased the phosphorylation of STAT3, which is important for cell proliferation, survival, migration, and invasion. Therefore, we suggest that AL plays a pivotal role in inhibiting BMI1 in the tumorigenesis of cervical cancer and is a potential therapeutic agent for cervical cancer.
C1 [Sun, Xiaodong; Xu, Hongxia; Xie, Lixia; Zhao, Qiang; Hao, Xincai; Sun, Yan; Wang, Xuanbin; Sang, Ming] Hubei Univ Med, Hubei Key Lab Wudang Local Chinese Med Res, Xiangyang Peoples Hosp 1, Hubei Clin Res Ctr Parkinsons Dis, Shiyan 442000, Peoples R China.
   [Dai, Tianyu] Tongji Univ, Shanghai East Hosp, Sch Med, Dept Joint Surg, Shanghai 200092, Peoples R China.
   [Jiang, Nan] Hubei Prov Acad Tradit Chinese Med, Hubei Prov Hosp Tradit Chinese Med, Wuhan 430061, Peoples R China.
RP Sang, M (corresponding author), Hubei Univ Med, Hubei Key Lab Wudang Local Chinese Med Res, Xiangyang Peoples Hosp 1, Hubei Clin Res Ctr Parkinsons Dis, Shiyan 442000, Peoples R China.
EM sangming@whu.edu.cn
RI Wang, Xuanbin/ABC-6550-2021; Sang, Ming/AAE-2187-2022
OI Wang, Xuanbin/0000-0003-0769-2874; 
FU National Natural Science FoundationNational Natural Science Foundation
   of China (NSFC) [81903005]; Hubei Province Innovation Project of Science
   and Technology Cooperation with Foreign countries [2019AHB068];
   experimental animal resources development and utilization project of
   Hubei Province of China [2020DFE025]; Science and Technology Development
   Project of Xiangyang; Institute of Medicine and Nursing at Hubei
   University of Medicine [2017YHKT02]; Scientific Research Project of
   Hubei Province Health Committee [ZY2019F028]
FX This investigation was supported by the grants from the National Natural
   Science Foundation (81903005), the Hubei Province Innovation Project of
   Science and Technology Cooperation with Foreign countries (2019AHB068),
   the experimental animal resources development and utilization project of
   Hubei Province of China (2020DFE025), the Science and Technology
   Development Project of Xiangyang (Project Leader Sang Ming), the
   Innovative Team Project (2017YHKT02) from the Institute of Medicine and
   Nursing at Hubei University of Medicine, the Scientific Research Project
   of Hubei Province Health Committee (ZY2019F028). The funding bodies were
   not involved in the design of this study, in the collection, analysis,
   and interpretation of the data, or in writing of the manuscript.
CR Al-Gammal S Y, 1998, Bull Indian Inst Hist Med Hyderabad, V28, P7
   Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235
   Burley SK, 2019, NUCLEIC ACIDS RES, V47, pD464, DOI 10.1093/nar/gky1004
   Cao R, 2005, MOL CELL, V20, P845, DOI 10.1016/j.molcel.2005.12.002
   Chun J, 2015, CANCER LETT, V357, P393, DOI 10.1016/j.canlet.2014.11.049
   Chun J, 2012, INT IMMUNOPHARMACOL, V14, P375, DOI 10.1016/j.intimp.2012.08.011
   Datta NR, 2019, INT J RADIAT ONCOL, V103, P411, DOI 10.1016/j.ijrobp.2018.09.037
   Datta NR, 2017, GYNECOL ONCOL, V145, P374, DOI 10.1016/j.ygyno.2017.01.033
   Dey A, 2016, AUTOPHAGY, V12, P659, DOI 10.1080/15548627.2016.1147670
   Ding YH, 2016, J HEMATOL ONCOL, V9, DOI 10.1186/s13045-016-0327-5
   ELAWADY MK, 1987, VIROLOGY, V159, P389, DOI 10.1016/0042-6822(87)90478-8
   Falcetta FS, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005342.pub4
   FRIEDL F, 1970, P SOC EXP BIOL MED, V135, P543
   Fu ZZ, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000005853
   Gierlikowska B, 2020, J ETHNOPHARMACOL, V249, DOI 10.1016/j.jep.2019.112311
   Hofbauer S, 2006, FORSCH KOMPLEMENTMED, V13, P18, DOI 10.1159/000091147
   Jeon HM, 2017, ANN TRANSL MED, V5, DOI 10.21037/atm.2016.12.67
   Jiang Y, 2016, ONCOL LETT, V11, P4203, DOI 10.3892/ol.2016.4511
   Johnston AN, 2020, P NATL ACAD SCI USA, V117, P6521, DOI 10.1073/pnas.1916503117
   Kim S, 2019, NUCLEIC ACIDS RES, V47, pD1102, DOI 10.1093/nar/gky1033
   Kreso A, 2014, NAT MED, V20, P29, DOI 10.1038/nm.3418
   Laskowski RA, 2011, J CHEM INF MODEL, V51, P2778, DOI 10.1021/ci200227u
   Lawrence NJ, 2001, BIOORG MED CHEM LETT, V11, P429, DOI 10.1016/S0960-894X(00)00686-7
   Lee JY, 2016, BIOPHARM DRUG DISPOS, V37, P156, DOI 10.1002/bdd.2005
   Lessard J, 2003, NATURE, V423, P255, DOI 10.1038/nature01572
   Li HY, 2014, INT J CLIN EXP PATHO, V7, P3057
   Li JX, 2012, CELL, V150, P339, DOI 10.1016/j.cell.2012.06.019
   Li Y, 2017, ONCOGENE, V36, P6293, DOI 10.1038/onc.2017.223
   Li ZL, 2016, ARCH PHARM RES, V39, P1441, DOI 10.1007/s12272-016-0815-8
   Liu SL, 2005, BREAST CANCER RES, V7, P86, DOI 10.1186/bcr1021
   Liu XQ, 2015, CURR PHARM DESIGN, V21, P1279, DOI 10.2174/1381612821666141211115611
   Liu YR, 2018, PHYTOTHER RES, V32, P643, DOI 10.1002/ptr.6004
   Liu Y, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-52195-5
   Luo M, 2011, ACTA OBSTET GYN SCAN, V90, P737, DOI 10.1111/j.1600-0412.2011.01102.x
   Meissner JD, 1999, J GEN VIROL, V80, P1725, DOI 10.1099/0022-1317-80-7-1725
   Merve A, 2014, ACTA NEUROPATHOL COM, V2, DOI 10.1186/2051-5960-2-10
   Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256
   Morrison BJ, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2111
   Nagao S, 2021, INT J CLIN ONCOL, V26, P207, DOI 10.1007/s10147-020-01787-7
   POPESCU NC, 1987, CYTOGENET CELL GENET, V44, P58, DOI 10.1159/000132342
   Seo JY, 2009, J MED FOOD, V12, P1038, DOI 10.1089/jmf.2009.0072
   Shang QY, 2017, CANCER GENE THER, V24, P367, DOI 10.1038/cgt.2017.31
   Siddique HR, 2012, STEM CELLS, V30, P372, DOI 10.1002/stem.1035
   Stojakowska A, 2006, PHYTOCHEM ANALYSIS, V17, P157, DOI 10.1002/pca.900
   Tavares WR, 2019, ANTIOXIDANTS-BASEL, V8, DOI 10.3390/antiox8050122
   Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007
   Tong YQ, 2012, ASIA-PAC J CLIN ONCO, V8, pE55, DOI 10.1111/j.1743-7563.2012.01564.x
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Wang HB, 2004, NATURE, V431, P873, DOI 10.1038/nature02985
   Wang X, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-017-0563-8
   Wang ZG, 2012, CELL, V148, P228, DOI 10.1016/j.cell.2011.11.030
   Weng ZY, 2016, ONCOL REP, V35, P833, DOI 10.3892/or.2015.4461
   Wu Kou-Juey, 2011, Chang Gung Med J, V34, P229
   Xu CJ, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1467-7
   Xu RJ, 2019, EUR J DRUG METAB PH, V44, P295, DOI 10.1007/s13318-018-0510-x
   Xu RJ, 2015, MOLECULES, V20, P7719, DOI 10.3390/molecules20057719
   Xu R, 2019, ONCOL REP, V42, P688, DOI 10.3892/or.2019.7188
   Ye K, 2018, J CELL BIOCHEM, V119, P1922, DOI 10.1002/jcb.26353
   Yin CT, 2019, J CELL MOL MED, V23, P2194, DOI 10.1111/jcmm.14139
   Zhang X, 2010, INT J GYNECOL CANCER, V20, P1597, DOI 10.1111/IGC.0b013e3181fd080e
   Zhang YB, 2019, J BUON, V24, P2310
   Zhou BL, 2018, J CHROMATOGR B, V1072, P370, DOI 10.1016/j.jchromb.2017.11.039
NR 62
TC 3
Z9 3
U1 3
U2 7
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD APR 29
PY 2021
VL 11
IS 1
AR 9251
DI 10.1038/s41598-021-87781-z
PG 14
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA SK4QK
UT WOS:000656201900016
PM 33927214
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Janji, B
   Hasmim, M
   Parpal, S
   De Milito, A
   Berchem, G
   Noman, MZ
AF Janji, Bassam
   Hasmim, Meriem
   Parpal, Santiago
   De Milito, Angelo
   Berchem, Guy
   Noman, Muhammad Zaeem
TI Lighting up the fire in cold tumors to improve cancer immunotherapy by
   blocking the activity of the autophagy-related protein PIK3C3/VPS34
SO AUTOPHAGY
LA English
DT Article
DE Autophagy; cancer immunotherapy; cold; hot tumors; colorectal cancer;
   immune checkpoints; immune infiltration; melanoma; NK and T CD8 cells;
   proinflammatory cytokines; VPS34
AB Cancer immunotherapy based on Immune checkpoint blockade (ICB) is a promising strategy to treat patients with advanced highly aggressive therapy-resistant tumors. Unfortunately, the clinical reality is that only a small number of patients benefit from the remarkable clinical remissions achieved by ICB. Experimental and clinical evidence claimed that durable clinical benefit observed using ICB depends on the immune status of tumors, notably the presence of cytotoxic effector immune cells. In our paper, we revealed that genetically targeting the autophagy-related protein PIK3C3/VPS34 in melanoma and colorectal tumor cells, or treating tumor-bearing mice with selective inhibitors of the PIK3C3/VPS34 kinase activity, reprograms cold immune desert tumors into hot, inflamed immune infiltrated tumors. Such reprograming results from the establishment of a proinflammatory signature characterized by the release of CCL5 and CXCL10 in the tumor microenvironment, and the subsequent recruitment of natural killer (NK) and CD8(+)T cells into the tumor bed. Furthermore, we reported that combining pharmacological inhibitors of PIK3C3/VPS34 improves the therapeutic benefit of anti-PD-1/PD-L1 immunotherapy. Our results provided the proof-of-concept to set-up innovative clinical trials for cold ICB-unresponsive tumors by combining PIK3C3/VPS34 inhibitors with anti-PDCD1/PD-1 and anti-CD274/PD-L1.
C1 [Janji, Bassam; Hasmim, Meriem; Berchem, Guy; Noman, Muhammad Zaeem] Luxembourg Inst Hlth LIH, Tumor Immunotherapy & Microenvironm TIME Grp, Dept Oncol, Luxembourg, Luxembourg.
   [Parpal, Santiago; De Milito, Angelo] Sprint Biosci, Stockholm, Sweden.
   [Parpal, Santiago; De Milito, Angelo] Karolinska Inst, Canc Ctr Karolinska, Dept Oncol Pathol, Stockholm, Sweden.
   [Berchem, Guy] Ctr Hosp Luxembourg, Dept Hematooncol, Luxembourg, Luxembourg.
RP Janji, B; Noman, MZ (corresponding author), Luxembourg Inst Hlth, Tumor Immunotherapy & MicroenvironmTIME Grp, Dept Oncol, 84 Val Fleuri, L-1526 Luxembourg, Luxembourg.
EM bassam.janji@lih.lu; muhammadzaeem.noman@lih.lu
RI NOMAN, Muhammmad Zaeem/AAJ-1465-2021; NOMAN, Muhammmad
   Zaeem/AAJ-1466-2021; Berchem, Guy/C-9364-2014
OI NOMAN, Muhammmad Zaeem/0000-0002-1837-3097; NOMAN, Muhammmad
   Zaeem/0000-0002-1837-3097; Berchem, Guy/0000-0003-0157-2257; Parpal,
   Santiago/0000-0003-2861-0516; JANJI, Bassam/0000-0002-9763-0943; De
   Milito, Angelo/0000-0003-2591-2914
FU Luxembourg National Research FundLuxembourg National Research Fund
   [C18/BM/12670304/COMBATIC]; FNRS TelevieFonds de la Recherche
   Scientifique - FNRS [7.4606.18]; Fondation Cancer Luxembourg
   [FC/2018/06]; Kriibskrank Kanner Foundation; Janssen Cilag Pharma; Roche
   pharma and Action LIONS Vaincre le Cancer Luxembourg
FX This work was supported by grants from Luxembourg National Research Fund
   C18/BM/12670304/COMBATIC; FNRS Televie (grants 7.4606.18); Fondation
   Cancer Luxembourg (FC/2018/06); Kriibskrank Kanner Foundation (2019);
   Janssen Cilag Pharma; Roche pharma and Action LIONS Vaincre le Cancer
   Luxembourg.
CR Noman MZ, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aax7881
NR 1
TC 6
Z9 6
U1 4
U2 12
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1554-8627
EI 1554-8635
J9 AUTOPHAGY
JI Autophagy
PD NOV 1
PY 2020
VL 16
IS 11
BP 2110
EP 2111
DI 10.1080/15548627.2020.1815439
EA SEP 2020
PG 2
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA OI6MP
UT WOS:000567020700001
PM 32892693
OA hybrid, Green Published
DA 2022-04-25
ER

PT J
AU Varalda, M
   Antona, A
   Bettio, V
   Roy, K
   Vachamaram, A
   Yellenki, V
   Massarotti, A
   Baldanzi, G
   Capello, D
AF Varalda, Marco
   Antona, Annamaria
   Bettio, Valentina
   Roy, Konkonika
   Vachamaram, Ajay
   Yellenki, Vaibhav
   Massarotti, Alberto
   Baldanzi, Gianluca
   Capello, Daniela
TI Psychotropic Drugs Show Anticancer Activity by Disrupting Mitochondrial
   and Lysosomal Function
SO FRONTIERS IN ONCOLOGY
LA English
DT Article
DE lysosomotropism; cationic amphiphilic drugs (CADs); autophagy;
   psychotropic drug; cancer; repositioning
ID MEMBRANE PERMEABILIZATION; CELL-DEATH; METHYL-ESTER; CANCER; AUTOPHAGY;
   PHOSPHOLIPIDOSIS; IDENTIFICATION; INHIBITORS; RISK; ANTIHISTAMINES
AB Background and Purpose: Drug repositioning is a promising strategy for discovering new therapeutic strategies for cancer therapy. We investigated psychotropic drugs for their antitumor activity because of several epidemiological studies reporting lower cancer incidence in individuals receiving long term drug treatment.
   Experimental Approach: We investigated 27 psychotropic drugs for their cytotoxic activity in colorectal carcinoma, glioblastoma and breast cancer cell lines. Consistent with the cationic amphiphilic structure of the most cytotoxic compounds, we investigated their effect on mitochondrial and lysosomal compartments.
   Results: Penfluridol, ebastine, pimozide and fluoxetine, fluspirilene and nefazodone showed significant cytotoxicity, in the low micromolar range, in all cell lines tested. In MCF7 cells these drugs caused mitochondrial membrane depolarization, increased the acidic vesicular compartments and induced phospholipidosis. Both penfluridol and spiperone induced AMPK activation and autophagy. Neither caspase nor autophagy inhibitors rescued cells from death induced by ebastine, fluoxetine, fluspirilene and nefazodone. Treatment with 3-methyladenine partially rescued cell death induced by pimozide and spiperone, whereas enhanced the cytotoxic activity of penfluridol. Conversely, inhibition of lysosomal cathepsins significantly reduced cell death induced by ebastin, penfluridol, pimozide, spiperone and mildly in fluoxetine treated cells. Lastly, Spiperone cytotoxicity was restricted to colorectal cancer and breast cancer and caused apoptotic cell death in MCF7 cells.
   Conclusions: The cytotoxicity of psychotropic drugs with cationic amphiphilic structures relied on simultaneous mitochondrial and lysosomal disruption and induction of cell death that not necessarily requires apoptosis. Since dual targeting of lysosomes and mitochondria constitutes a new promising therapeutic approach for cancer, particularly those in which the apoptotic machinery is defective, these data further support their clinical development for cancer therapy.
C1 [Varalda, Marco; Antona, Annamaria; Bettio, Valentina; Vachamaram, Ajay; Yellenki, Vaibhav; Baldanzi, Gianluca; Capello, Daniela] Univ Piemonte Orientale, Ctr Excellence Aging Sci, Dept Translat Med, Novara, Italy.
   [Varalda, Marco; Bettio, Valentina; Capello, Daniela] Univ Piemonte Orientale, UPO Biobank, Novara, Italy.
   [Roy, Konkonika; Vachamaram, Ajay; Baldanzi, Gianluca] Univ Piemonte Orientale, Ctr Translat Res Allerg & Autoimmune Dis CAAD, Novara, Italy.
   [Massarotti, Alberto] Univ Piemonte Orientale, Dept Pharmaceut Sci, Novara, Italy.
RP Capello, D (corresponding author), Univ Piemonte Orientale, Ctr Excellence Aging Sci, Dept Translat Med, Novara, Italy.; Capello, D (corresponding author), Univ Piemonte Orientale, UPO Biobank, Novara, Italy.
EM daniela.capello@med.uniupo.it
RI Baldanzi, Gianluca/AAO-7673-2021; Bettio, Valentina/AFT-9834-2022
OI Baldanzi, Gianluca/0000-0002-1370-9903; Antona,
   Annamaria/0000-0002-8050-3462
FU Universita del Piemonte Orientale; Italian Ministry of Education,
   University and Research (MIUR) program Departments of Excellence
   2018-2022, AGING Project-Department of Translational Medicine,
   Universita del Piemonte Orientale; Consorzio Interuniversitario di
   Biotecnologie (CIB) [PRIN 201799WCRH]
FX This study was (partially) funded by the Universita del Piemonte
   Orientale-FAR 2016 e FAR 2017 (DC), by the Italian Ministry of
   Education, University and Research (MIUR) program Departments of
   Excellence 2018-2022, AGING Project-Department of Translational
   Medicine, Universita del Piemonte Orientale (DC), by Consorzio
   Interuniversitario di Biotecnologie (CIB) call Network-CIB: Catalisi
   dell'Innovazione nelle Biotecnologie (PRIN 201799WCRH, GB).
CR Aits S, 2015, AUTOPHAGY, V11, P1408, DOI 10.1080/15548627.2015.1063871
   Anderson N, 2006, FEBS LETT, V580, P5533, DOI 10.1016/j.febslet.2006.08.061
   Ashburn TT, 2004, NAT REV DRUG DISCOV, V3, P673, DOI 10.1038/nrd1468
   Biever A, 2015, FRONT MOL NEUROSCI, V8, DOI 10.3389/fnmol.2015.00075
   Boya P, 2008, ONCOGENE, V27, P6434, DOI 10.1038/onc.2008.310
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
   Breiden B, 2020, BIOL CHEM, V401, P31, DOI 10.1515/hsz-2019-0270
   CACCIA S, 1990, CLIN PHARMACOKINET, V18, P434, DOI 10.2165/00003088-199018060-00002
   Chan HL, 2018, PSYCHO-ONCOLOGY, V27, P187, DOI 10.1002/pon.4493
   Chang A, 2011, LUNG CANCER, V71, P3, DOI 10.1016/j.lungcan.2010.08.022
   Chou FHC, 2011, SCHIZOPHR RES, V129, P97, DOI 10.1016/j.schres.2011.02.018
   Chubak J, 2011, INT J CANCER, V128, P227, DOI 10.1002/ijc.25322
   Chude CI, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18061279
   Church Martin K, 2013, Indian J Dermatol, V58, P219, DOI 10.4103/0019-5154.110832
   Cirone M, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1275-z
   Coogan PF, 2009, PHARMACOEPIDEM DR S, V18, P1111, DOI 10.1002/pds.1808
   Dale W, 2016, CLIN GERIATR MED, V32, P35, DOI 10.1016/j.cger.2015.08.007
   Davidson SM, 2017, ANNU REV PHARMACOL, V57, P481, DOI 10.1146/annurev-pharmtox-010715-103101
   De Santi M, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-37247-6
   DEDUVE C, 1974, BIOCHEM PHARMACOL, V23, P2495, DOI 10.1016/0006-2952(74)90174-9
   del Cuvillo A, 2006, J Investig Allergol Clin Immunol, V16 Suppl 1, P3
   Denton D, 2019, CELL DEATH DIFFER, V26, P605, DOI 10.1038/s41418-018-0252-y
   Domagala A, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19082256
   Ellegaard AM, 2016, EBIOMEDICINE, V9, P130, DOI 10.1016/j.ebiom.2016.06.013
   Faustino-Rocha AI, 2017, LIFE SCI, V172, P27, DOI 10.1016/j.lfs.2016.12.008
   Ferlay J, 2019, INT J CANCER, V144, P1941, DOI 10.1002/ijc.31937
   Galluzzi L, 2015, EMBO J, V34, P856, DOI 10.15252/embj.201490784
   Garcia-Quiroz J, 2011, ANTI-CANCER AGENT ME, V11, P307, DOI 10.2174/187152011795347513
   Gassen NC, 2019, FRONT PSYCHIATRY, V10, DOI 10.3389/fpsyt.2019.00337
   Goldman SDB, 2009, BIOANALYSIS, V1, P1445, DOI 10.4155/BIO.09.128
   GONZALEZROTHI RJ, 1995, CHEST, V107, P1763, DOI 10.1378/chest.107.6.1763
   Haji EO, 2012, CURR PHARM DESIGN, V18, P5818, DOI 10.2174/138161212803523699
   Halliwell WH, 1997, TOXICOL PATHOL, V25, P53, DOI 10.1177/019262339702500111
   Hendouei N, 2019, EUR J PHARMACOL, V856, DOI 10.1016/j.ejphar.2019.05.031
   Ho CJ, 2019, CANCERS, V11, DOI 10.3390/cancers11111775
   HOLLEMANS M, 1981, BIOCHIM BIOPHYS ACTA, V643, P140, DOI 10.1016/0005-2736(81)90226-1
   Huang J, 2018, CANCER LETT, V419, P257, DOI 10.1016/j.canlet.2018.01.058
   Kornhuber J, 2008, J MED CHEM, V51, P219, DOI 10.1021/jm070524a
   Kornhuber J, 2010, CELL PHYSIOL BIOCHEM, V26, P9, DOI 10.1159/000315101
   Kroemer G, 2007, PHYSIOL REV, V87, P99, DOI 10.1152/physrev.00013.2006
   Kucharewicz K, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0383-6
   Lawrence RE, 2019, NAT CELL BIOL, V21, P133, DOI 10.1038/s41556-018-0244-7
   Levy JMM, 2020, CELL DEATH DIFFER, V27, P843, DOI [10.1038/s41418-019-0474, 10.1038/s41418-019-0474-7]
   Li HL, 2018, SCHIZOPHR RES, V195, P519, DOI 10.1016/j.schres.2017.08.065
   Liu Y, 2015, CELL DEATH DIFFER, V22, P367, DOI 10.1038/cdd.2014.143
   Logan R, 2014, J PHARM SCI-US, V103, P1572, DOI 10.1002/jps.23949
   Lu SY, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173771
   Lu SY, 2012, TOXICOL IN VITRO, V26, P613, DOI 10.1016/j.tiv.2012.01.025
   Marceau F, 2012, TOXICOL APPL PHARM, V259, P1, DOI 10.1016/j.taap.2011.12.004
   Mauri MC, 2014, EXCLI J, V13, P1163
   Medina VA, 2010, BRIT J PHARMACOL, V161, P755, DOI 10.1111/j.1476-5381.2010.00961.x
   Mizushima N, 2010, CELL, V140, P313, DOI 10.1016/j.cell.2010.01.028
   Modica-Napolitano JS, 2001, ADV DRUG DELIVER REV, V49, P63, DOI 10.1016/S0169-409X(01)00125-9
   Montaser M, 2002, BIOL CHEM, V383, P1305, DOI 10.1515/BC.2002.147
   Mosesson Y, 2008, NAT REV CANCER, V8, P835, DOI 10.1038/nrc2521
   Muehlbacher M, 2012, CHEMMEDCHEM, V7, P1925, DOI 10.1002/cmdc.201200306
   Nadanaciva S, 2011, TOXICOL IN VITRO, V25, P715, DOI 10.1016/j.tiv.2010.12.010
   Ono K, 2003, MOL CELL BIOL, V23, P665, DOI 10.1128/MCB.23.2.665-676.2003
   Petersen NHT, 2013, CANCER CELL, V24, P379, DOI 10.1016/j.ccr.2013.08.003
   Piao SF, 2016, ANN NY ACAD SCI, V1371, P45, DOI 10.1111/nyas.12953
   Qadir M, 2005, CLIN CANCER RES, V11, P2320, DOI 10.1158/1078-0432.CCR-04-1725
   Ranjan A, 2016, SCI REP-UK, V6, DOI 10.1038/srep26165
   Reasor MJ, 2006, EXPERT OPIN DRUG SAF, V5, P567, DOI 10.1517/14740338.5.4.567
   Repnik U, 2017, J CELL SCI, V130, P3124, DOI 10.1242/jcs.204529
   Repnik U, 2014, MITOCHONDRION, V19, P49, DOI 10.1016/j.mito.2014.06.006
   Robey RW, 2018, NAT REV CANCER, V18, P452, DOI 10.1038/s41568-018-0005-8
   Rodriguez-Enriquez S, 2006, AUTOPHAGY, V2, P39, DOI 10.4161/auto.2229
   Frick LR, 2013, LIFE SCI, V92, P525, DOI 10.1016/j.lfs.2013.01.020
   Russell RC, 2014, CELL RES, V24, P42, DOI 10.1038/cr.2013.166
   Sarrouilhe D, 2015, CURR MOL MED, V15, P62, DOI 10.2174/1566524015666150114113411
   Sarrouilhe D, 2019, BIOCHIMIE, V161, P46, DOI 10.1016/j.biochi.2018.06.016
   Schulz M, 2003, PHARMAZIE, V58, P447
   Serrano-Puebla A, 2018, BIOCHEM SOC T, V46, P207, DOI 10.1042/BST20170130
   Shahane SA, 2014, J BIOMOL SCREEN, V19, P66, DOI 10.1177/1087057113502851
   Shaw V, 2021, SEMIN CANCER BIOL, V68, P75, DOI 10.1016/j.semcancer.2019.10.007
   Sivandzade F, 2019, BIO-PROTOCOL, V9, DOI 10.21769/BioProtoc.3128
   Sleire L, 2017, PHARMACOL RES, V124, P74, DOI 10.1016/j.phrs.2017.07.013
   VATER M, 2017, SCI REP UK, V0007
   Velnati S, 2020, J ENZYM INHIB MED CH, V35, P96, DOI 10.1080/14756366.2019.1684911
   Vucicevic L, 2018, CELL STRESS, V2, P282, DOI 10.15698/cst2018.11.161
   Walker AJ, 2012, CANCER CAUSE CONTROL, V23, P1959, DOI 10.1007/s10552-012-0073-0
   Wang FJ, 2018, TRAFFIC, V19, P918, DOI 10.1111/tra.12613
   Wang FJ, 2018, OPEN BIOL, V8, DOI 10.1098/rsob.170271
   Weinberg SE, 2015, NAT CHEM BIOL, V11, P9, DOI 10.1038/nchembio.1712
   Wu YT, 2010, J BIOL CHEM, V285, P10850, DOI 10.1074/jbc.M109.080796
   Zhitomirsky B, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-1227-0
   Zhuo CJ, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01262
   Zong WX, 2016, MOL CELL, V61, P667, DOI 10.1016/j.molcel.2016.02.011
NR 88
TC 7
Z9 8
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2234-943X
J9 FRONT ONCOL
JI Front. Oncol.
PD OCT 19
PY 2020
VL 10
AR 562196
DI 10.3389/fonc.2020.562196
PG 19
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA OI5AL
UT WOS:000583291100001
PM 33194631
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Bai, C
   Zhang, Z
   Zhou, L
   Zhang, HY
   Chen, Y
   Tang, Y
AF Bai, Can
   Zhang, Zhe
   Zhou, Li
   Zhang, Huan-Yu
   Chen, Yan
   Tang, Yong
TI Repurposing Ziyuglycoside II Against Colorectal CancerviaOrchestrating
   Apoptosis and Autophagy
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE Ziyuglycoside II; cancer therapy; autophagy; colorectal cancer; Akt
ID CELL-CYCLE ARREST; PROTECTIVE AUTOPHAGY; TARGETING AUTOPHAGY; CANCER
   CELLS; ACTIVATION; BLOCKING; AXIS
AB Effective chemotherapy drugs for colorectal cancer remain a challenge. In this research, Ziyuglycoside II (Ziyu II), exhibits considerable antitumor activity against CRC cells both in vitro and in vivo. The results showed that Ziyu II induced apoptosis through the accumulation of reactive oxygen species (ROS), which was necessary for Ziyu II to inhibit colorectal cancer cells. Intriguingly, The treatment of Ziyu II triggered complete autophagic flux in CRC cells. Inhibition of autophagy partially reversed Ziyu II-induced growth inhibition, demonstrating a cytotoxic role of autophagy in response to Ziyu II-treated. Mechanism indicated that Ziyu II-induced autophagy by inhibiting Akt/mTOR pathway. Akt reactivation partially reduced Ziyu II-induced LC3-II turnover and LC3 puncta accumulation. Especially, Ziyu II improves the sensitivity of 5-fluorouracil which is the first-line chemotherapy drug in colorectal cancer cells. This research provides novel insight into the molecular mechanism of Ziyu II's anti-proliferation, including apoptosis and autophagy, and lays a foundation for the potential application of Ziyu II in clinical CRC treatment.
C1 [Bai, Can; Tang, Yong] Chengdu Univ Tradit Chinese Med, Acupuncture & Tuina Sch, Chengdu, Peoples R China.
   [Zhang, Zhe; Zhou, Li; Chen, Yan] Sichuan Univ, West China Hosp, State Key Lab Biotherapy & Canc Ctr, Chengdu, Peoples R China.
   [Zhang, Zhe; Zhou, Li; Chen, Yan] Sichuan Univ, West China Sch Basic Med Sci & Forens Med, Chengdu, Peoples R China.
   [Zhang, Zhe; Zhou, Li; Chen, Yan] Collaborat Innovat Ctr Biotherapy, Chengdu, Peoples R China.
   [Zhang, Huan-Yu] Hainan Med Coll, Minist Educ, Key Lab Trop Dis & Translat Med, Affiliated Hosp, Haikou, Hainan, Peoples R China.
   [Zhang, Huan-Yu] Hainan Med Coll, Affiliated Hosp, Dept Neurol, Haikou, Hainan, Peoples R China.
RP Tang, Y (corresponding author), Chengdu Univ Tradit Chinese Med, Acupuncture & Tuina Sch, Chengdu, Peoples R China.
EM tangyong@cdutcm.edu.cn
FU Sino-German Center [GZ919]; Project First-Class Disciplines Development
   of Chengdu University of TCM [CZYHW1901]; Sichuan Science and Technology
   Program [2019YFH0108, 2018HH0123, 2018SZ0257]
FX This manuscript has been released as a pre-print at www.authorea.com
   (Bai et al., 2020). We sincerely thank L Zhang and Z Huang for useful
   discussions. We are grateful to the Sino-German Center (GZ919), The
   Project First-Class Disciplines Development (CZYHW1901) of Chengdu
   University of TCM, and Sichuan Science and Technology Program
   (2019YFH0108, 2018HH0123, 2018SZ0257) for financial support.
CR Bai C., 2020, AUTHOREA, DOI [10.22541/au.158353969.93133955, DOI 10.22541/AU.158353969.93133955]
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
   Chen Y, 2019, J HEPATOL, V70, P66, DOI 10.1016/j.jhep.2018.09.022
   Corsello SM, 2017, NAT MED, V23, P405, DOI 10.1038/nm.4306
   Cui ZF, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06749-2
   Deng S, 2019, CANCER-AM CANCER SOC, V125, P1228, DOI 10.1002/cncr.31978
   Diwanji N, 2018, SEMIN CELL DEV BIOL, V80, P74, DOI 10.1016/j.semcdb.2017.07.004
   Dou QH, 2016, CANCER RES, V76, P4457, DOI 10.1158/0008-5472.CAN-15-2887
   Fulda S, 2015, ONCOGENE, V34, P5105, DOI 10.1038/onc.2014.458
   Geng F, 2017, CANCER BIOTHER RADIO, V32, P149, DOI 10.1089/cbr.2017.2210
   Huang YH, 2017, ONCOTARGET, V8, P52783, DOI 10.18632/oncotarget.17189
   Hussey S, 2008, J PEDIATR GASTR NUTR, V46, P496, DOI 10.1097/MPG.0b013e3181617895
   Jeung YJ, 2016, BBA-MOL CELL RES, V1863, P2584, DOI 10.1016/j.bbamcr.2016.07.005
   Kim HJ, 2017, J TRANSL MED, V15, DOI 10.1186/s12967-017-1223-7
   Kimmelman AC, 2017, CELL METAB, V25, P1037, DOI 10.1016/j.cmet.2017.04.004
   Kubisch J, 2013, SEMIN CANCER BIOL, V23, P252, DOI 10.1016/j.semcancer.2013.06.009
   Kuipers EJ, 2015, NAT REV DIS PRIMERS, V1, DOI 10.1038/nrdp.2015.65
   Lee YK, 2017, EMBO J, V36, P1100, DOI 10.15252/embj.201696315
   Lei YY, 2017, CANCER LETT, V393, P33, DOI 10.1016/j.canlet.2017.02.012
   Letai A, 2017, ANNU REV CANC BIOL, V1, P275, DOI 10.1146/annurev-cancerbio-050216-121933
   Lin L, 2015, MOL CELL ONCOL, V2, DOI 10.4161/23723556.2014.985913
   Liu CY, 2019, BIOMED PHARMACOTHER, V120, DOI 10.1016/j.biopha.2019.109543
   Mejlvang J, 2018, J CELL BIOL, V217, P3640, DOI 10.1083/jcb.201711002
   Mizushima N, 2018, NAT CELL BIOL, V20, P521, DOI 10.1038/s41556-018-0092-5
   Nam SH, 2017, PHYTOTHER RES, V31, P1449, DOI 10.1002/ptr.5874
   Onyoh Elias F, 2019, Curr Gastroenterol Rep, V21, P36, DOI 10.1007/s11894-019-0703-8
   Poillet-Perez L, 2018, NATURE, V563, P569, DOI 10.1038/s41586-018-0697-7
   Pushpakom S, 2019, NAT REV DRUG DISCOV, V18, P41, DOI 10.1038/nrd.2018.168
   Ruocco N, 2016, MAR DRUGS, V14, DOI 10.3390/md14070138
   Siegel RL, 2017, CA-CANCER J CLIN, V67, P177, DOI 10.3322/caac.21395
   Soleimani A, 2018, CURR PHARM DESIGN, V24, P4605, DOI 10.2174/1381612825666190110151957
   Sun T, 2017, CELL PHYSIOL BIOCHEM, V44, P716, DOI 10.1159/000485285
   Sun X, 2019, MED RES REV, V39, P2172, DOI 10.1002/med.21580
   Sun Y, 2018, THERANOSTICS, V8, P2044, DOI 10.7150/thno.23304
   Wang K, 2011, AUTOPHAGY, V7, P966, DOI 10.4161/auto.7.9.15863
   White E, 2009, CLIN CANCER RES, V15, P5308, DOI 10.1158/1078-0432.CCR-07-5023
   Xiang YN, 2019, CANCER MED-US, V8, P1958, DOI 10.1002/cam4.2108
   Yang SY, 2009, TRENDS MOL MED, V15, P225, DOI 10.1016/j.molmed.2009.03.003
   Zhang X, 2018, MINI-REV MED CHEM, V18, P164, DOI 10.2174/1389557517666170228114809
   Zhu AK, 2013, BRAZ J MED BIOL RES, V46, P670, DOI 10.1590/1414-431X20133050
   Zhu X, 2014, TOXICOL LETT, V227, P65, DOI 10.1016/j.toxlet.2014.03.015
   Zhu X, 2013, INT J MOL SCI, V14, P18041, DOI 10.3390/ijms140918041
NR 42
TC 5
Z9 5
U1 4
U2 8
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1663-9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD SEP 18
PY 2020
VL 11
AR 576547
DI 10.3389/fphar.2020.576547
PG 12
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA NY6IL
UT WOS:000576490500001
PM 33071789
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Zhang, N
   Yang, YN
   Wang, ZY
   Yang, J
   Chu, X
   Liu, J
   Zhao, YX
AF Zhang, Nan
   Yang, Yanan
   Wang, Ziyi
   Yang, Jing
   Chu, Xiao
   Liu, Jin
   Zhao, Yongxing
TI Polypeptide-engineered DNA tetrahedrons for targeting treatment of
   colorectal cancer via apoptosis and autophagy
SO JOURNAL OF CONTROLLED RELEASE
LA English
DT Article
DE Colorectal cancer; DNA tetrahedron; Cell apoptosis; Cell autophagy;
   Anti-cancer peptides
ID CD SPECTRA; NANOPARTICLES; DELIVERY
AB Smart delivery of therapeutic peptides that target cellular signaling pathways holds high specificity and great promise for cancer therapy. Here, DNA tetrahedrons (TDs) are designed to carry two therapeutic peptides-FAS peptide and FK-16 peptide. DNA TDs are designed with varied numbers and spatial placement of FAS peptides and FK-16 peptides, and tested for their anti-cancer efficacy. Trimerization of FAS receptors using TDs that are assembled with three FAS peptides enhances FAS-induced cell apoptosis. FK-16 peptides are conjugated to TDs via a peptide sequence sensitive to MMP-2/9 in tumor microenvironment. Therefore, FK-16 peptides are expected to detach from TDs once arrived the tumor microenvironment. A cell penetrating peptide (TAT) is also conjugated to the FK-16 peptide to facilitate its intracellular delivery, which increases the FK-16 peptide-induced cell apoptosis and autophagy. TD-3(TFM)3(FAS) (TFM: TAT+ FK-16+ MMP-2/9) exhibits the highest HT-29 inhibition in vitro and in vivo among all therapies. In addition to the high anti-cancer efficacy, TD-3(TFM)3(FAS) shows a high specificity to HT-29 cells in vitro and in vivo. Low cell inhibition rates and cellular uptake are observed in normal cells. In sum, the multifunctional TD-3(TFM)3(FAS) provides a new platform for the smart delivery of anti-cancer peptides to achieve enhanced efficacy and high specificity.
C1 [Zhang, Nan; Yang, Yanan; Wang, Ziyi; Yang, Jing; Chu, Xiao; Zhao, Yongxing] Zhengzhou Univ, Sch Pharmaceut Sci, Dept Pharmaceut, Zhengzhou 450001, Henan, Peoples R China.
   [Zhang, Nan; Zhao, Yongxing] Key Lab Targeting Therapy & Diag Crit Dis, Zhengzhou 450001, Henan, Peoples R China.
   [Zhang, Nan; Zhao, Yongxing] Minist Educ China, Key Lab Adv Pharmaceut Technol, Zhengzhou 450001, Henan, Peoples R China.
   [Liu, Jin] Fudan Univ, Inst Biomed Sci, Zhongshan Hosp, Shanghai, Peoples R China.
   [Liu, Jin] Fudan Univ, Shanghai Inst Cardiovasc Dis, Zhongshan Hosp, Shanghai, Peoples R China.
RP Zhang, N; Zhao, YX (corresponding author), Zhengzhou Univ, Sch Pharmaceut Sci, 100 KeXue Ave,Room A315, Zhengzhou 450001, Henan, Peoples R China.
EM nanzhang@zzu.edu.cn; zhaoyx@zzu.edu.cn
RI Zhang, Nan/J-6823-2016; Zhang, Nan/AAK-2672-2021
OI Zhang, Nan/0000-0002-0941-482X; Zhang, Nan/0000-0002-0941-482X
FU National Natural Science Foundation of China (NSFC)National Natural
   Science Foundation of China (NSFC) [81573011, 81861138004]; Key Project
   of Ministry of Education of HeNan Province for Higher Education
   Institutions [16A350012]
FX Financial support from the National Natural Science Foundation of China
   (NSFC No. 81573011 and 81861138004) and Key Project of Ministry of
   Education of HeNan Province for Higher Education Institutions (No.
   16A350012) are gratefully acknowledged. We also thank the Center of
   Advanced Analysis & Computational Science, Zhengzhou University for the
   assistance of data acquirement.
CR Binefa G, 2014, WORLD J GASTROENTERO, V20, P6786, DOI 10.3748/wjg.v20.i22.6786
   Brenner H, 2014, LANCET, V383, P1490, DOI 10.1016/S0140-6736(13)61649-9
   Brooks H, 2005, ADV DRUG DELIVER REV, V57, P559, DOI 10.1016/j.addr.2004.12.001
   CHEN Z., 2013, PLOS ONE, V8
   DAVYDOVA OV, 1989, BIOPOLYMERS, V28, P605, DOI 10.1002/bip.360280206
   Fouque A, 2014, BBA-REV CANCER, V1846, P130, DOI 10.1016/j.bbcan.2014.04.007
   Fu QS, 2016, MOL CELL, V61, P602, DOI 10.1016/j.molcel.2016.01.009
   Goodman RP, 2004, CHEM COMMUN, P1372, DOI 10.1039/b402293a
   Heuts J, 2018, PHARM RES-DORDR, V35, DOI 10.1007/s11095-018-2490-6
   Hoskin DW, 2008, BBA-BIOMEMBRANES, V1778, P357, DOI 10.1016/j.bbamem.2007.11.008
   Hu QQ, 2018, ADV HEALTHC MATER, V7, DOI 10.1002/adhm.201701153
   Hu QQ, 2019, CHEM REV, V119, P6459, DOI 10.1021/acs.chemrev.7b00663
   Janssen O, 2003, CELL DEATH DIFFER, V10, P1215, DOI 10.1038/sj.cdd.4401305
   Kanzawa T, 2004, CELL DEATH DIFFER, V11, P448, DOI 10.1038/sj.cdd.4401359
   Kaushal N, 2018, J CONTROL RELEASE, V289, P79, DOI 10.1016/j.jconrel.2018.07.042
   Kumar V, 2016, THERANOSTICS, V6, P710, DOI 10.7150/thno.14203
   Lee H, 2012, NAT NANOTECHNOL, V7, P389, DOI [10.1038/nnano.2012.73, 10.1038/NNANO.2012.73]
   Li X, 2006, J AM CHEM SOC, V128, P5776, DOI 10.1021/ja0584875
   Liu JH, 2012, BIOMATERIALS, V33, P6155, DOI 10.1016/j.biomaterials.2012.05.035
   Liu WF, 2016, STRUCTURE, V24, P2016, DOI 10.1016/j.str.2016.09.009
   Mader JS, 2009, MOL CANCER RES, V7, P689, DOI 10.1158/1541-7786.MCR-08-0274
   Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7
   Qiu F, 2018, BIOMATERIALS, V182, P82, DOI 10.1016/j.biomaterials.2018.07.052
   Ren SH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061304
   Sacchetti F, 2018, PHARM RES-DORDR, V35, DOI 10.1007/s11095-018-2489-z
   Strasser A, 2009, IMMUNITY, V30, P180, DOI 10.1016/j.immuni.2009.01.001
   Sun P., 2018, RSC ADV, V8
   Sun PC, 2017, INT J NANOMED, V12, P2657, DOI 10.2147/IJN.S132929
   TSIKARIS V, 1991, INT J BIOL MACROMOL, V13, P349, DOI 10.1016/0141-8130(91)90017-O
   Yu HL, 2015, J CONTROL RELEASE, V216, P111, DOI 10.1016/j.jconrel.2015.08.021
   Zhang XY, 2016, INT J NANOMED, V11, P1643, DOI 10.2147/IJN.S101030
NR 31
TC 5
Z9 5
U1 11
U2 41
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0168-3659
EI 1873-4995
J9 J CONTROL RELEASE
JI J. Control. Release
PD SEP 10
PY 2019
VL 309
BP 48
EP 58
DI 10.1016/j.jconrel.2019.07.012
PG 11
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry; Pharmacology & Pharmacy
GA JG2NS
UT WOS:000491913100005
PM 31301339
DA 2022-04-25
ER

PT J
AU Liang, XY
   Chavez, ARD
   Schapiro, NE
   Loughran, P
   Thorne, SH
   Amoscato, AA
   Zeh, HJ
   Beer-Stolz, D
   Lotze, MT
   de Vera, ME
AF Liang, Xiaoyan
   Chavez, Antonio Romo de Vivar
   Schapiro, Nicole E.
   Loughran, Patricia
   Thorne, Stephen H.
   Amoscato, Andrew A.
   Zeh, Herbert J.
   Beer-Stolz, Donna
   Lotze, Michael T.
   de Vera, Michael E.
TI Ethyl pyruvate administration inhibits hepatic tumor growth
SO JOURNAL OF LEUKOCYTE BIOLOGY
LA English
DT Article
DE metabolism; cancer models; liver metastases; colorectal cancer;
   inflammation; HMGB1; apoptosis; autophagy
ID GLYCATION END-PRODUCTS; COLORECTAL-CANCER; LIVER METASTASIS; HMGB1
   RELEASE; CELLS; EXPRESSION; INFLAMMATION; AUTOPHAGY; NECROSIS; APOPTOSIS
AB EP is a potent inhibitor of HMGB1 release that has significant anti-inflammatory activities and exerts a protective effect in animal models of inflammation. As inflammation is linked to cancer growth, we hypothesized that EP would have anti-tumor activity and explored its effects in a liver tumor model. Mice injected intraportally with MC38 colorectal cancer cells led to the growth of visible hepatic tumors within 2 weeks. Pretreatment with EP 30 min prior to infusion of tumor cells and continuing daily for 9 days inhibited tumor growth significantly in a dose-dependent manner, with 80 mg/kg EP achieving > 70% reduction in the number of tumor nodules when compared with untreated animals. Delayed treatment with EP also suppressed tumor growth significantly, although to a lesser extent. Tumors had early, marked leukocytic infiltrates, and EP administration decreased innate (NK cells, monocytes) and adaptive (T and B cell lymphocytic) immune cell infiltrates acutely and significantly in the liver. Serum IL-6 and HMGB1 levels, which were elevated following tumor injection, were decreased significantly in EP-treated animals. Tumors showed an increase in apoptosis in EP-treated mice, and tumor cells treated in vitro with EP had marked increases in LC3-II and cleaved PARP, consistent with enhanced autophagic flux and apoptosis. Thus, EP inhibition of tumor growth in the liver was mediated by tumor (induction of apoptosis) and host (decreased inflammation) effects. EP administration may have a therapeutic role in the treatment of cancer in conjunction with other therapeutic agents. J. Leukoc. Biol. 86: 599-607; 2009.
C1 [de Vera, Michael E.] Univ Pittsburgh, UPMC Montefiore, Thomas E Starzl Transplantat Inst, Pittsburgh, PA 15213 USA.
   [Liang, Xiaoyan; Chavez, Antonio Romo de Vivar; Schapiro, Nicole E.; Loughran, Patricia; Thorne, Stephen H.; Amoscato, Andrew A.; Zeh, Herbert J.; Lotze, Michael T.; de Vera, Michael E.] Univ Pittsburgh, Inst Canc, Pittsburgh, PA 15213 USA.
   [Beer-Stolz, Donna] Univ Pittsburgh, Ctr Biol Imaging, Pittsburgh, PA 15213 USA.
RP de Vera, ME (corresponding author), Univ Pittsburgh, UPMC Montefiore, Thomas E Starzl Transplantat Inst, 7 S 3459 5th Ave, Pittsburgh, PA 15213 USA.
EM deverame@upmc.edu
RI Loughran, Patricia/AAB-1184-2021; li, tao/B-2402-2008
OI Amoscato, Andrew/0000-0002-1340-9150
CR Amaravadi RK, 2007, J CLIN INVEST, V117, P326, DOI 10.1172/JCI28833
   Ashizawa T, 2006, ACTA MED OKAYAMA, V60, P325
   Aychek T, 2008, INT J CANCER, V123, P1741, DOI 10.1002/ijc.23375
   Bennett-Guerrero E, 2009, J CARDIOTHOR VASC AN, V23, P324, DOI 10.1053/j.jvca.2008.08.005
   Chen GY, 2009, SCIENCE, V323, P1722, DOI 10.1126/science.1168988
   Cheng BQ, 2007, PANCREAS, V35, P256, DOI 10.1097/MPA.0b013e318064678a
   Chung YC, 2003, J SURG ONCOL, V83, P222, DOI 10.1002/jso.10269
   Condeelis J, 2006, CELL, V124, P263, DOI 10.1016/j.cell.2006.01.007
   Dagda RK, 2008, AUTOPHAGY, V4, P770, DOI 10.4161/auto.6458
   de Visser KE, 2006, NAT REV CANCER, V6, P24, DOI 10.1038/nrc1782
   DeNardo DG, 2008, CANCER METAST REV, V27, P11, DOI 10.1007/s10555-007-9100-0
   Dong XD, 2007, J IMMUNOTHER, V30, P596, DOI 10.1097/CJI.0b013e31804efc76
   Eisenberg-Lerner A, 2009, APOPTOSIS, V14, P376, DOI 10.1007/s10495-008-0307-5
   Ellerman JE, 2007, CLIN CANCER RES, V13, P2836, DOI 10.1158/1078-0432.CCR-06-1953
   FASHENA SJ, 1992, MOL CELL BIOL, V12, P894, DOI 10.1128/MCB.12.2.894
   Gebhardt C, 2008, J EXP MED, V205, P275, DOI 10.1084/jem.20070679
   Gupta S. K., 2000, Indian Journal of Physiology and Pharmacology, V44, P101
   Han YS, 2005, J PHARMACOL EXP THER, V312, P1097, DOI 10.1124/jpet.104.079707
   Hollenbach M, 2008, BIOCHEM PHARMACOL, V76, P631, DOI 10.1016/j.bcp.2008.06.006
   Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010
   Johansson AS, 2008, BRIT J PHARMACOL, V154, P1318, DOI 10.1038/bjp.2008.201
   Karin M, 2006, CELL, V124, P823, DOI 10.1016/j.cell.2006.02.016
   Khatib AM, 2005, AM J PATHOL, V167, P749, DOI 10.1016/S0002-9440(10)62048-2
   Khatib AM, 2002, CANCER RES, V62, P5393
   Kim S, 2009, NATURE, V457, P102, DOI 10.1038/nature07623
   Kuniyasu H, 2003, ONCOL REP, V10, P445
   LAFRENIERE R, 1985, CANCER RES, V45, P3735
   Liang XH, 2001, CANCER RES, V61, P3443
   Lim SC, 2007, INT J MOL MED, V20, P187
   Livesey KM, 2008, CURR OPIN INVEST DR, V9, P1259
   OgierDenis E, 1996, J BIOL CHEM, V271, P28593, DOI 10.1074/jbc.271.45.28593
   Poser I, 2003, MOL CELL BIOL, V23, P2991, DOI 10.1128/MCB.23.8.2991-2998.2003
   Sappington PL, 2005, BIOCHEM PHARMACOL, V70, P1579, DOI 10.1016/j.bcp.2005.08.015
   Sappington PL, 2003, J PHARMACOL EXP THER, V304, P464, DOI 10.1124/jpet.102.043182
   Sasahira T, 2005, VIRCHOWS ARCH, V446, P411, DOI 10.1007/s00428-005-1210-x
   SHAMSUDDIN AM, 1995, CANCER RES, V55, P149
   SLAUGHTER DP, 1953, CANCER, V6, P963, DOI 10.1002/1097-0142(195309)6:5<963::AID-CNCR2820060515>3.0.CO;2-Q
   Susan PP, 2001, J CELL PHYSIOL, V187, P48, DOI 10.1002/1097-4652(2001)9999:9999<00::AID-JCP1050>3.3.CO;2-9
   Taguchi A, 2000, NATURE, V405, P354, DOI 10.1038/35012626
   Tsung A, 2005, TRANSPLANTATION, V79, P196, DOI 10.1097/01.TP.0000151681.07474.2E
   Tsung A, 2007, J EXP MED, V204, P2913, DOI 10.1084/jem.20070247
   Ulloa L, 2002, P NATL ACAD SCI USA, V99, P12351, DOI 10.1073/pnas.192222999
   Vakkila J, 2004, NAT REV IMMUNOL, V4, P641, DOI 10.1038/nri1415
   Volp K, 2006, GUT, V55, P234, DOI 10.1136/gut.2004.062729
   Wang HC, 1999, SCIENCE, V285, P248, DOI 10.1126/science.285.5425.248
   Yamamoto M, 2008, CANCER RES, V68, P9754, DOI 10.1158/0008-5472.CAN-08-1748
   Yu L, 2008, AUTOPHAGY, V4, P567, DOI 10.4161/auto.5902
NR 47
TC 61
Z9 66
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0741-5400
EI 1938-3673
J9 J LEUKOCYTE BIOL
JI J. Leukoc. Biol.
PD SEP
PY 2009
VL 86
IS 3
BP 599
EP 607
DI 10.1189/jlb.0908578
PG 9
WC Cell Biology; Hematology; Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Hematology; Immunology
GA 488VA
UT WOS:000269377200018
PM 19584311
OA Bronze
DA 2022-04-25
ER

PT J
AU Chu, CA
   Wang, YW
   Chen, YL
   Chen, HW
   Chuang, JJ
   Chang, HY
   Ho, CL
   Chang, C
   Chow, NH
   Lee, CT
AF Chu, Chien-An
   Wang, Yi-Wen
   Chen, Yi-Lin
   Chen, Hui-Wen
   Chuang, Jing-Jing
   Chang, Hong-Yi
   Ho, Chung-Liang
   Chang, Chen
   Chow, Nan-Haw
   Lee, Chung-Ta
TI The Role of Phosphatidylinositol 3-Kinase Catalytic Subunit Type 3 in
   the Pathogenesis of Human Cancer
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Review
DE PIK3C3; Vps34; autophagy; colorectal cancer; cancer
ID BECLIN 1; PHOSPHOINOSITIDE 3-KINASES; AUTOPHAGOSOME MATURATION; EMERGING
   MECHANISMS; POOR-PROGNOSIS; VPS34; PROTEIN; INHIBITION; EXPRESSION;
   DEGRADATION
AB Phosphatidylinositol 3-kinase catalytic subunit type 3 (PIK3C3), the mammalian ortholog of yeast vesicular protein sorting 34 (Vps34), belongs to the phosphoinositide 3-kinase (PI3K) family. PIK3C3 can phosphorylate phosphatidylinositol (PtdIns) to generate phosphatidylinositol 3-phosphate (PI3P), a phospholipid central to autophagy. Inhibition of PIK3C3 successfully inhibits autophagy. Autophagy maintains cell survival when modifications occur in the cellular environment and helps tumor cells resist metabolic stress and cancer treatment. In addition, PIK3C3 could induce oncogenic transformation and enhance tumor cell proliferation, growth, and invasion through mechanisms independent of autophagy. This review addresses the structural and functional features, tissue distribution, and expression pattern of PIK3C3 in a variety of human tumors and highlights the underlying mechanisms involved in carcinogenesis. The implications in cancer biology, patient prognosis prediction, and cancer therapy are discussed. Altogether, the discovery of pharmacological inhibitors of PIK3C3 could reveal novel strategies for improving treatment outcomes for PIK3C3-mediated human diseases.</p>
C1 [Chu, Chien-An; Wang, Yi-Wen; Ho, Chung-Liang; Chang, Chen; Chow, Nan-Haw; Lee, Chung-Ta] Natl Cheng Kung Univ, Dept Pathol, Coll Med, Tainan 701401, Taiwan.
   [Chen, Yi-Lin; Chen, Hui-Wen; Ho, Chung-Liang; Chang, Chen; Chow, Nan-Haw; Lee, Chung-Ta] Natl Cheng Kung Univ Hosp, Dept Pathol, Tainan 704302, Taiwan.
   [Chuang, Jing-Jing] Natl Chiayi Univ, Dept Microbiol Immunol & Biopharmaceut, Chiayi 600355, Taiwan.
   [Chang, Hong-Yi] Southern Taiwan Univ Sci & Technol, Dept Biotechnol & Food Technol, Coll Engn, Tainan 710301, Taiwan.
   [Ho, Chung-Liang; Chow, Nan-Haw] Natl Cheng Kung Univ, Inst Mol Med, Coll Med, Tainan 701401, Taiwan.
   [Ho, Chung-Liang; Chow, Nan-Haw] Natl Cheng Kung Univ, Inst Basic Med Sci, Coll Med, Tainan 701401, Taiwan.
   [Lee, Chung-Ta] Natl Cheng Kung Univ Hosp, Dept Pathol, Dou Liou Branch, Tainan 640003, Taiwan.
RP Chow, NH; Lee, CT (corresponding author), Natl Cheng Kung Univ, Dept Pathol, Coll Med, Tainan 701401, Taiwan.; Chow, NH; Lee, CT (corresponding author), Natl Cheng Kung Univ Hosp, Dept Pathol, Tainan 704302, Taiwan.; Chow, NH (corresponding author), Natl Cheng Kung Univ, Inst Mol Med, Coll Med, Tainan 701401, Taiwan.; Chow, NH (corresponding author), Natl Cheng Kung Univ, Inst Basic Med Sci, Coll Med, Tainan 701401, Taiwan.; Lee, CT (corresponding author), Natl Cheng Kung Univ Hosp, Dept Pathol, Dou Liou Branch, Tainan 640003, Taiwan.
EM yihyeh@mail.ncyu.edu.tw; czeus1974@gmail.com
FU Ministry of Science and Technology, TaiwanMinistry of Science and
   Technology, Taiwan [NSC108-2320-B-006-050-MY3, 110-2314-B-006-083,
   110-2320-B-006-026]; National Cheng Kung University Hospital, Tainan,
   Taiwan [NCKUH-10704015, NCKUH-11008004]; Higher Education Sprout
   Project, Ministry of Education
FX This manuscript was supported by research grants
   NSC108-2320-B-006-050-MY3, 110-2314-B-006-083, and 110-2320-B-006-026
   from the Ministry of Science and Technology, Taiwan; NCKUH-10704015, and
   NCKUH-11008004 from the National Cheng Kung University Hospital, Tainan,
   Taiwan. The research was also supported in part by the Higher Education
   Sprout Project, Ministry of Education to the Headquarters of University
   Advancement at National Cheng Kung University, Tainan, Taiwan.
CR Aita VM, 1999, GENOMICS, V59, P59, DOI 10.1006/geno.1999.5851
   Anaya J, 2016, PEERJ COMPUT SCI, DOI 10.7717/peerj-cs.67
   Antonioli M, 2017, TRENDS BIOCHEM SCI, V42, P28, DOI 10.1016/j.tibs.2016.09.008
   Antonioli M, 2014, DEV CELL, V31, P734, DOI 10.1016/j.devcel.2014.11.013
   Axe EL, 2008, J CELL BIOL, V182, P685, DOI 10.1083/jcb.200803137
   Bago R, 2014, BIOCHEM J, V463, P413, DOI 10.1042/BJ20140889
   Baquero P, 2019, LEUKEMIA, V33, P981, DOI 10.1038/s41375-018-0252-4
   Baskaran S, 2014, ELIFE, V3, DOI 10.7554/eLife.05115
   Biswas K, 2013, J BIOL CHEM, V288, P2325, DOI 10.1074/jbc.M112.409656
   Bougen-Zhukov NM, 2020, AM J RESP CELL MOL, V62, P331, DOI 10.1165/rcmb.2019-0050OC
   Boutouja F, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18122541
   Braccini L, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8400
   Campa CC, 2018, NAT CHEM BIOL, V14, P801, DOI 10.1038/s41589-018-0086-4
   Chaikovsky AC, 2021, NATURE, V592, P794, DOI 10.1038/s41586-021-03474-7
   Chandrashekar DS, 2017, NEOPLASIA, V19, P649, DOI 10.1016/j.neo.2017.05.002
   Chang CM, 2019, MOL CELL, V73, P339, DOI 10.1016/j.molcel.2018.10.035
   Chang VHS, 2017, RADIOTHER ONCOL, V122, P476, DOI 10.1016/j.radonc.2017.01.001
   Chen DD, 2012, MOL CELL, V45, P629, DOI 10.1016/j.molcel.2011.12.036
   Chen DS, 2017, NATURE, V541, P321, DOI 10.1038/nature21349
   Chen HY, 2021, CARCINOGENESIS, V42, P880, DOI 10.1093/carcin/bgab030
   Cheung YWS, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21218051
   Chu CA, 2019, EBIOMEDICINE, V43, P270, DOI 10.1016/j.ebiom.2019.04.010
   Cisse O, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1472-9
   Dall'Armi C, 2013, CURR BIOL, V23, pR33, DOI 10.1016/j.cub.2012.10.041
   Dayde D, 2016, ONCOGENE, V35, P3986, DOI 10.1038/onc.2015.480
   Di Leo L, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-22772-2
   Dowdle WE, 2014, NAT CELL BIOL, V16, P1069, DOI 10.1038/ncb3053
   Dyczynski M, 2018, CANCER LETT, V435, P32, DOI 10.1016/j.canlet.2018.07.028
   Falasca M, 2012, BIOCHEM J, V443, P587, DOI 10.1042/BJ20120008
   Fan W, 2011, P NATL ACAD SCI USA, V108, P7769, DOI 10.1073/pnas.1016472108
   Feng X, 2019, AUTOPHAGY, V15, P1130, DOI 10.1080/15548627.2019.1570063
   Filippakis H, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-32256-x
   Franco I, 2016, J AM SOC NEPHROL, V27, P1135, DOI 10.1681/ASN.2014100967
   Gillooly DJ, 2000, EMBO J, V19, P4577, DOI 10.1093/emboj/19.17.4577
   Gulluni F, 2019, TRENDS CELL BIOL, V29, P339, DOI 10.1016/j.tcb.2019.01.001
   Gulluni F, 2017, CANCER CELL, V32, P444, DOI 10.1016/j.ccell.2017.09.002
   Han Y, 2020, BIOMED PHARMACOTHER, V121, DOI 10.1016/j.biopha.2019.109580
   Hippert MM, 2006, CANCER RES, V66, P9349, DOI 10.1158/0008-5472.CAN-06-1597
   Hirsch DS, 2010, CANCER RES, V70, P5974, DOI 10.1158/0008-5472.CAN-09-2682
   Hu YJ, 2020, ONCOTARGETS THER, V13, P6213, DOI 10.2147/OTT.S256072
   Hu ZH, 2020, CELL CYCLE, V19, P193, DOI [10.1080/15384101.2019.1704537, 10.6084/m9.figshare.11474253.v3]
   Huang SB, 2010, AUTOPHAGY, V6, P256, DOI 10.4161/auto.6.2.11124
   Huang YH, 2014, AUTOPHAGY, V10, P1787, DOI 10.4161/auto.29989
   Itakura E, 2008, MOL BIOL CELL, V19, P5360, DOI 10.1091/mbc.E08-01-0080
   Jia W, 2015, AUTOPHAGY, V11, P2335, DOI 10.1080/15548627.2015.1110666
   Jiang X, 2017, ONCOGENE, V36, P6850, DOI 10.1038/onc.2017.295
   Jo YK, 2018, ANTICANCER RES, V38, P271, DOI 10.21873/anticanres.12218
   Kobylarz MJ, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0235551
   Kondo Y, 2005, NAT REV CANCER, V5, P726, DOI 10.1038/nrc1692
   Kristensen L, 2015, LEUKEMIA RES, V39, P555, DOI 10.1016/j.leukres.2015.02.008
   Kumar B, 2021, CANCERS, V13, DOI 10.3390/cancers13092168
   Li AJ, 2015, INT J CLIN EXP MED, V8, P1137
   Li GM, 2021, CELL DEATH DIFFER, V28, P952, DOI 10.1038/s41418-020-00627-5
   Li YJ, 2019, ADV EXP MED BIOL, V1206, P85, DOI 10.1007/978-981-15-0602-4_4
   Li ZD, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-98
   Liang CY, 2008, NAT CELL BIOL, V10, P776, DOI 10.1038/ncb1740
   Liang C, 2006, NAT CELL BIOL, V8, P688, DOI 10.1038/ncb1426
   Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257
   Liu CC, 2016, MOL CELL, V61, P84, DOI 10.1016/j.molcel.2015.11.001
   Liu FC, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2631-9
   Liu H, 2020, J CANCER, V11, P3655, DOI 10.7150/jca.42771
   Liu Z, 2020, ONCOTARGETS THER, V13, P8299, DOI 10.2147/OTT.S257729
   Lu Z, 2014, AUTOPHAGY, V10, P1071, DOI 10.4161/auto.28577
   Ma MS, 2017, CELL RES, V27, P989, DOI 10.1038/cr.2017.94
   Madeira F, 2019, NUCLEIC ACIDS RES, V47, pW636, DOI 10.1093/nar/gkz268
   Maiani E, 2021, NATURE, V592, P799, DOI 10.1038/s41586-021-03422-5
   Margaria JP, 2020, CELL SIGNAL, V66, DOI 10.1016/j.cellsig.2019.109468
   Margaria JP, 2019, BIOMOLECULES, V9, DOI 10.3390/biom9030104
   Meunier G, 2020, ONCOGENESIS, V9, DOI 10.1038/s41389-020-00278-8
   Mgrditchian T, 2017, P NATL ACAD SCI USA, V114, pE9271, DOI 10.1073/pnas.1703921114
   Mohan N, 2016, ONCOTARGET, V7, P52239, DOI 10.18632/oncotarget.10469
   New J, 2017, CANCER RES, V77, P6679, DOI 10.1158/0008-5472.CAN-17-1077
   Ng G, 2005, MOL CARCINOGEN, V43, P183, DOI 10.1002/mc.20097
   Noman MZ, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aax7881
   Noman MZ, 2011, CANCER RES, V71, P5976, DOI 10.1158/0008-5472.CAN-11-1094
   O'Farrell F, 2013, FEBS J, V280, P6322, DOI 10.1111/febs.12486
   Ohashi Y, 2021, AUTOPHAGY, V17, P3897, DOI 10.1080/15548627.2021.1872240
   Ohashi Y, 2020, ELIFE, V9, DOI 10.7554/eLife.58281
   Pankiv S, 2010, J CELL BIOL, V188, P253, DOI 10.1083/jcb.200907015
   Pasquier B, 2016, CELL MOL LIFE SCI, V73, P985, DOI 10.1007/s00018-015-2104-y
   Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002
   Pavlinov I, 2020, AUTOPHAGY, V16, P1547, DOI 10.1080/15548627.2020.1786268
   Polak R, 2019, HAEMATOLOGICA, V104, P738, DOI 10.3324/haematol.2018.193631
   Ponten F, 2008, J PATHOL, V216, P387, DOI 10.1002/path.2440
   Qi Chenyang, 2022, Cancer Res Treat, V54, P182, DOI 10.4143/crt.2020.578
   Quach C, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-13475-w
   Reifler A, 2014, AM J PATHOL, V184, P1819, DOI 10.1016/j.ajpath.2014.02.012
   Ronan B, 2014, NAT CHEM BIOL, V10, P1013, DOI 10.1038/nchembio.1681
   Rong XZ, 2019, J THORAC ONCOL, V14, P1766, DOI 10.1016/j.jtho.2019.06.014
   Rostislavleva K, 2015, SCIENCE, V350, P140, DOI 10.1126/science.aac7365
   Russell RC, 2013, NAT CELL BIOL, V15, P741, DOI 10.1038/ncb2757
   Salminen A, 2013, PROG NEUROBIOL, V106, P33, DOI 10.1016/j.pneurobio.2013.06.002
   Schlafli AM, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-87966-6
   Schlutermann D, 2018, UROL ONCOL-SEMIN ORI, V36, DOI 10.1016/j.urolonc.2017.11.021
   Sencan S, 2021, MOL CELL BIOCHEM, V476, P2075, DOI 10.1007/s11010-021-04063-y
   Shan HY, 2019, LIFE SCI, V233, DOI 10.1016/j.lfs.2019.116701
   Su H, 2018, AUTOPHAGY, V14, P1086, DOI 10.1080/15548627.2017.1385676
   Su H, 2017, MOL CELL, V67, P907, DOI 10.1016/j.molcel.2017.07.024
   Swaminathan G, 2016, AUTOPHAGY, V12, P2404, DOI 10.1080/15548627.2016.1234561
   Tamargo-Gomez I, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19123812
   Tang H, 2015, EBIOMEDICINE, V2, P255, DOI 10.1016/j.ebiom.2015.01.008
   Tiosano D, 2019, PLOS GENET, V15, DOI 10.1371/journal.pgen.1008088
   Uhlen M, 2017, SCIENCE, V357, P660, DOI 10.1126/science.aan2507
   Valente G, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/462658
   Vanhaesebroeck B, 2010, NAT REV MOL CELL BIO, V11, P329, DOI 10.1038/nrm2882
   Vega-Rubin-de-Celis S, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21239210
   Verykiou S, 2019, BRIT J DERMATOL, V180, P346, DOI 10.1111/bjd.17333
   Wang H, 2016, ONCOTARGET, V7, P51174, DOI 10.18632/oncotarget.9433
   Wang JW, 2020, ONCOTARGETS THER, V13, P10275, DOI 10.2147/OTT.S270433
   Wang XB, 2020, MED SCI MONITOR, V26, DOI 10.12659/MSM.920642
   Wang YY, 2017, EXP CELL RES, V351, P24, DOI 10.1016/j.yexcr.2016.12.017
   Wei Y, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/1012789
   Wijshake T, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2020478118
   Xia PY, 2014, CELL RES, V24, P943, DOI 10.1038/cr.2014.85
   Xie WH, 2020, CELL REP, V30, P2807, DOI 10.1016/j.celrep.2020.01.088
   Yamada E, 2012, CELL REP, V1, P557, DOI 10.1016/j.celrep.2012.03.014
   Yang G, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2568-z
   Yang G, 2021, AUTOPHAGY, V17, P1193, DOI 10.1080/15548627.2020.1752979
   Yang S, 2020, ONCOTARGETS THER, V13, P3557, DOI 10.2147/OTT.S247655
   Yang YH, 2013, P NATL ACAD SCI USA, V110, P6841, DOI 10.1073/pnas.1217692110
   Yao YF, 2019, PULM PHARMACOL THER, V55, P38, DOI 10.1016/j.pupt.2019.01.007
   Yoshimori T, 2004, BIOCHEM BIOPH RES CO, V313, P453, DOI 10.1016/j.bbrc.2003.07.023
   You LK, 2015, AUTOPHAGY, V11, P729, DOI 10.1080/15548627.2015.1017192
   Young CD, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0656-2
   Yu WX, 2020, EUR REV MED PHARMACO, V24, P915, DOI 10.26355/eurrev_202001_20076
   Yu XL, 2015, AUTOPHAGY, V11, P1711, DOI 10.1080/15548627.2015.1043076
   Zahedi S, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1880-y
   Zhang M, 2019, CANCER LETT, V442, P483, DOI 10.1016/j.canlet.2018.11.008
   Zhang XW, 2020, AUTOPHAGY, V16, P782, DOI 10.1080/15548627.2019.1635383
   Zhou CF, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01237-y
   Zhou WH, 2012, AUTOPHAGY, V8, P389, DOI 10.4161/auto.18641
   Zhou XA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016358
NR 132
TC 0
Z9 0
U1 6
U2 6
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD OCT
PY 2021
VL 22
IS 20
AR 10964
DI 10.3390/ijms222010964
PG 20
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA WQ4ZU
UT WOS:000713827200001
PM 34681622
OA Green Published
DA 2022-04-25
ER

PT J
AU Wang, TX
   Chen, ZX
   Zhang, W
AF Wang, Tongxin
   Chen, Zhixia
   Zhang, Wei
TI Regulation of autophagy inhibition and inflammatory response in glioma
   by Wnt signaling pathway
SO ONCOLOGY LETTERS
LA English
DT Article
DE Wnt5a/beta-catenin signaling pathway; glioma cells; autophagy;
   inflammatory response
ID COLORECTAL-CANCER; EXPRESSION; CELLS; MTOR; PROLIFERATION; TRANSITION;
   STRESS; TARGET; TUMORS; BRAIN
AB The objective of this study was to investigate the mechanism of the function of Wnt signaling pathway in regulating autophagy and inflammatory response in glioma cells. Human brain glioma cells U118 were selected and divided into three groups: i) the Wnt signaling inhibitor IWR-1 group (the observation group); ii) the PBS negative control group (the PBS group) and iii) the blank control group. After 24 h culture, Wnt5a/beta-catenin protein, autophagy marker, microtubule- associated-proteins-1A1B-light-chain-3C (LC-3) II and Beclin I, and inflammatory factors IL-6 and TNF-alpha protein expression levels were evaluated using western blotting. Compared with both control groups, Wnt5a/beta-catenin, IL-6 and TNF-alpha protein expression levels were significantly lower, and LC-3II and Beclin I protein expression levels were significantly higher in the observation group. In conclusion, Wnt5a/beta-catenin signaling pathway regulates autophagy and inflammatory response of glioma cells.
C1 [Wang, Tongxin; Chen, Zhixia; Zhang, Wei] Yidu Cent Hosp Weifang, Dept Neurosurg, 4138 Linglongshannan Rd, Qingzhou 262500, Shandong, Peoples R China.
RP Wang, TX (corresponding author), Yidu Cent Hosp Weifang, Dept Neurosurg, 4138 Linglongshannan Rd, Qingzhou 262500, Shandong, Peoples R China.
EM drtongxinwang@163.com
CR Adachi K, 2007, STEM CELLS, V25, P2827, DOI 10.1634/stemcells.2007-0177
   Al Dhaheri Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109630
   Banday MZ, 2016, META GENE, V9, P128, DOI 10.1016/j.mgene.2016.06.001
   Bielen H, 2014, DEV NEUROBIOL, V74, P772, DOI 10.1002/dneu.22168
   Boitard M, 2015, CELL REP, V10, P1349, DOI 10.1016/j.celrep.2015.01.061
   Cerpa W, 2008, J BIOL CHEM, V283, P5918, DOI 10.1074/jbc.M705943200
   Chen N, 2011, CANCER BIOL THER, V11, P157, DOI 10.4161/cbt.11.2.14622
   Chen WL, 2016, ONCOTARGET, V7, P62425, DOI 10.18632/oncotarget.11515
   Duchartre Y, 2016, CRIT REV ONCOL HEMAT, V99, P141, DOI 10.1016/j.critrevonc.2015.12.005
   Hamed HA, 2010, CANCER BIOL THER, V9, P526, DOI 10.4161/cbt.9.7.11116
   Kaza N, 2012, BRAIN PATHOL, V22, P89, DOI 10.1111/j.1750-3639.2011.00544.x
   Kikuchi A, 2007, CELL SIGNAL, V19, P659, DOI 10.1016/j.cellsig.2006.11.001
   Lee SC, 2015, ONCOTARGET, V6, P27146, DOI 10.18632/oncotarget.4354
   Lerner UH, 2015, J INTERN MED, V277, P630, DOI 10.1111/joim.12368
   Li SH, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0057604, 10.1371/journal.pone.0067928, 10.1371/journal.pone.0083037]
   Liu F, 2016, SCI REP-UK, V6, DOI 10.1038/srep21260
   Liu WT, 2013, NEURO-ONCOLOGY, V15, P1127, DOI 10.1093/neuonc/not073
   Maguschak KA, 2012, J NEUROIMMUNE PHARM, V7, P763, DOI 10.1007/s11481-012-9350-7
   Nusse R, 2008, CELL RES, V18, P523, DOI 10.1038/cr.2008.47
   Ostrom QT, 2015, NEURO-ONCOLOGY, V17, P1, DOI 10.1093/neuonc/nov189
   Prakash Sharada, 2015, J Oral Maxillofac Pathol, V19, P230, DOI 10.4103/0973-029X.164537
   Shan YZ, 2015, INT J CLIN EXP MED, V8, P9114
   Suh Y, 2010, CARCINOGENESIS, V31, P1424, DOI 10.1093/carcin/bgq115
   Van Camp J, 2014, STEM CELL REV REP, V10, P207, DOI 10.1007/s12015-013-9486-8
   Wu SH, 2015, INT J CLIN EXP PATHO, V8, P3882
   Xue H, 2016, AUTOPHAGY, V12, P1129, DOI 10.1080/15548627.2016.1178446
   Zhao XY, 2011, J NEURO-ONCOL, V102, P367, DOI 10.1007/s11060-010-0346-y
NR 27
TC 5
Z9 7
U1 1
U2 1
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792-1074
EI 1792-1082
J9 ONCOL LETT
JI Oncol. Lett.
PD DEC
PY 2017
VL 14
IS 6
BP 7197
EP 7200
DI 10.3892/ol.2017.7103
PG 4
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA FP0LV
UT WOS:000417293400118
PM 29344152
OA Green Submitted, Green Published, gold
DA 2022-04-25
ER

PT J
AU Xie, YC
   Zhu, S
   Zhong, MZ
   Yang, MH
   Sun, XF
   Liu, JB
   Kroemer, G
   Lotze, M
   Zeh, HJ
   Kang, R
   Tang, DL
AF Xie, Yangchun
   Zhu, Shan
   Zhong, Meizuo
   Yang, Manhua
   Sun, Xiaofan
   Liu, Jinbao
   Kroemer, Guido
   Lotze, Michael
   Zeh, Herbert J., III
   Kang, Rui
   Tang, Daolin
TI Inhibition of Aurora Kinase A Induces Necroptosis in Pancreatic
   Carcinoma
SO GASTROENTEROLOGY
LA English
DT Article
DE Regulated Cell Death; Antitumor Immunity; HMGB1; ATP
ID BREAST-CANCER CELLS; G2/M PHASE ARREST; DRUG-RESISTANCE; CYCLE ARREST;
   THERAPY; DISEASE; GENE; PHOSPHORYLATION; PROLIFERATION; INFLAMMATION
AB BACKGROUND & AIMS: Induction of nonapoptotic cell death could be an approach to eliminate apoptosis-resistant tumors. We investigated necroptosis-based therapies in mouse models of pancreatic ductal adenocarcinoma cancer (PDAC). METHODS: We screened 273 commercially available kinase inhibitors for cytotoxicity against a human PDAC cell line (PANC1). We evaluated the ability of the aurora kinase inhibitor CCT137690 to stimulate necroptosis in PDAC cell lines (PANC1, PANC2.03, CFPAC1, MiaPaCa2, BxPc3, and PANC02) and the HEK293 cell line, measuring loss of plasma membrane integrity, gain in cell volume, swollen organelles, and cytoplasmic vacuoles. We tested the effects of CCT137690 in colon formation assays, and the effects of the necroptosis (necrostatin-1 and necrosulfonamide), apoptosis, autophagy, and ferroptosis inhibitors. We derived cells from tumors that developed in Pdx1-Cre; K-Ras(G12D/+); p53(R172H/+) (KPC) mice. Genes encoding proteins in cell death pathways were knocked out, knocked down, or expressed from transgenes in PDAC cell lines. Athymic nude or B6 mice were given subcutaneous injections of PDAC cells or tail-vein injections of KPC tumor cells. Mice were given CCT137690 (80 mg/kg) or vehicle and tumor growth was monitored; tumor tissues were collected and analyzed by immunohistochemistry. We compared gene expression levels between human pancreatic cancer tissues (n = 130) with patient survival times using the online R2 genomics analysis and visualization platform. RESULTS: CCT137690 induced necrosis-like death in PDAC cell lines and reduced colony formation; these effects required RIPK1, RIPK3, and MLKL, as well as inhibition of aurora kinase A (AURKA). AURKA interacted directly with RIPK1 and RIPK3 to reduce necrosome activation. AURKA-mediated phosphorylation of glycogen synthase kinase 3 beta (GSK3 beta) at serine 9 inhibited activation of the RIPK3 and MLKL necrosome. Mutations in AURKA (D274A) or GSK3 beta (S9A), or pharmacologic inhibitors of RIPK1 signaling via RIPK3 and MLKL, reduced the cytotoxic activity of CCT137690 in PDAC cells. Oral administration of CCT137690 induced necroptosis and immunogenic cell death in subcutaneous and orthotopic tumors in mice, and reduced tumor growth and tumor cell phosphorylation of AURKA and GSK3 beta. CCT137690 increased survival times of mice with orthotopic KPC PDACs and reduced tumor growth, stroma, and metastasis. Increased expression of AURKA and GSK3 beta mRNAs associated with shorter survival times of patients with pancreatic cancer. CONCLUSIONS: We identified the aurora kinase inhibitor CCT137690 as an agent that induces necrosis-like death in PDAC cells, via RIPK1, RIPK3, and MLKL. CCT137690 slowed growth of orthotopic tumors from PDAC cells in mice, and expression of AURKA and GSK3 beta associate with patient survival times. AURKA might be targeted for treatment of pancreatic cancer.
C1 [Xie, Yangchun; Zhu, Shan; Sun, Xiaofan; Liu, Jinbao; Tang, Daolin] Guangzhou Med Univ, Affiliated Hosp 3, Ctr DAMP Biol,Prot Modificat & Degradat Lab, Key Lab Major Obstet Dis Guangdong Prov,Key Lab R, Guangzhou, Guangdong, Peoples R China.
   [Xie, Yangchun; Zhong, Meizuo] Cent S Univ, Xiangya Hosp, Dept Oncol, Changsha, Hunan, Peoples R China.
   [Yang, Manhua] Cent S Univ, Xiangya Hosp, Pediat, Changsha, Hunan, Peoples R China.
   [Xie, Yangchun; Yang, Manhua; Lotze, Michael; Zeh, Herbert J., III; Kang, Rui; Tang, Daolin] Univ Pittsburgh, Dept Surg, Hillman Canc Ctr, Pittsburgh, PA 15253 USA.
   [Kroemer, Guido] Univ Paris 05, Sorbonne Paris Cite, Paris, France.
   [Kroemer, Guido] Ctr Rech Cordeliers, Equipe Labellisee Ligue Natl Canc 11, Paris, France.
   [Kroemer, Guido] INSERM, U1138, Paris, France.
   [Kroemer, Guido] Univ Paris 06, Paris, France.
   [Kroemer, Guido] Metabol & Cell Biol Platforms, Gustave Roussy Canc Campus, Villejuif, France.
   [Kroemer, Guido] Hop Europeeen Georges Pompidou, AP HP, Pole Biol, Paris, France.
   [Kroemer, Guido] Karolinska Univ Hosp, Dept Womens & Childrens Hlth, Stockholm, Sweden.
RP Tang, DL (corresponding author), Univ Pittsburgh, Hillman Canc Ctr, Room G27C,5117 Ctr Ave, Pittsburgh, PA 15253 USA.
EM tangd2@upmc.edu
RI Kroemer, Guido/AAY-9859-2020; Tang, Daolin/ABD-5062-2021; KROEMER,
   Guido/B-4263-2013; Tang, Daolin/B-2905-2010; Kang, Rui/ABD-5291-2021
OI Tang, Daolin/0000-0002-1903-6180; KROEMER, Guido/0000-0002-9334-4405;
   Kang, Rui/0000-0003-2725-1574; Xie, Yangchun/0000-0003-2571-4774
FU US National Institutes of HealthUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USA [R01GM115366,
   R01CA160417, R01CA211070]; Natural Science Foundation of Guangdong
   ProvinceNational Natural Science Foundation of Guangdong Province
   [2016A030308011]; American Cancer SocietyAmerican Cancer Society
   [RSG-16-014-01-CDD]; National Natural Science Foundation of
   ChinaNational Natural Science Foundation of China (NSFC) [31671435,
   81400132, 81772508]; Guangdong Province Universities and Colleges Pearl
   River Scholar Funded Scheme; Ligue contre le Cancer (equipe
   labelisee)Ligue nationale contre le cancer; Agence National de la
   Recherche (ANR)-Projets blancsFrench National Research Agency (ANR);
   ANRFrench National Research Agency (ANR); ERA-Net for Research on Rare
   Diseases; Association pour la recherche sur le cancer (ARC)Fondation ARC
   pour la Recherche sur le Cancer; Canceropole Ile-de-FranceRegion
   Ile-de-France; Institut National du Cancer (INCa)Institut National du
   Cancer (INCA) France; Institut Universitaire de France; Fondation pour
   la Recherche Medicale (FRM)Fondation pour la Recherche Medicale;
   European Commission (ArtForce)European CommissionEuropean Commission
   Joint Research Centre; European Research Council (ERC)European Research
   Council (ERC); LeDucq FoundationLeducq Foundation; LabEx
   Immuno-Oncology; RHU Torino Lumiere; SIRIC Stratified Oncology Cell DNA
   Repair and Tumor Immune Elimination (SOCRATE); SIRIC Cancer Research and
   Personalized Medicine (CARPEM); Paris Alliance of Cancer Research
   Institutes (PACRI);  [P30CA047904]; NATIONAL CANCER INSTITUTEUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Cancer Institute (NCI) [R01CA160417,
   R01CA211070, P30CA047904] Funding Source: NIH RePORTER; NATIONAL
   INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health
   & Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of General Medical Sciences (NIGMS) [R01GM115366] Funding
   Source: NIH RePORTER
FX This work was supported by grants from the US National Institutes of
   Health (R01GM115366, R01CA160417, and R01CA211070), the Natural Science
   Foundation of Guangdong Province (2016A030308011), the American Cancer
   Society (Research Scholar Grant RSG-16-014-01-CDD), the National Natural
   Science Foundation of China (31671435, 81400132, and 81772508), and
   Guangdong Province Universities and Colleges Pearl River Scholar Funded
   Scheme (2017). This project partly used University of Pittsburgh Cancer
   Institute shared resources supported by award P30CA047904. G.K. is
   supported by the Ligue contre le Cancer (equipe labelisee); Agence
   National de la Recherche (ANR)-Projets blancs; ANR under the frame of
   E-Rare-2, the ERA-Net for Research on Rare Diseases; Association pour la
   recherche sur le cancer (ARC); Canceropole Ile-de-France; Institut
   National du Cancer (INCa); Institut Universitaire de France; Fondation
   pour la Recherche Medicale (FRM); the European Commission (ArtForce);
   the European Research Council (ERC); the LeDucq Foundation; the LabEx
   Immuno-Oncology; the RHU Torino Lumiere, the SIRIC Stratified Oncology
   Cell DNA Repair and Tumor Immune Elimination (SOCRATE); the SIRIC Cancer
   Research and Personalized Medicine (CARPEM); and the Paris Alliance of
   Cancer Research Institutes (PACRI).
CR Arbitrario JP, 2010, CANCER CHEMOTH PHARM, V65, P707, DOI 10.1007/s00280-009-1076-8
   Bavetsias V, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00278
   Bavetsias V, 2010, J MED CHEM, V53, P5213, DOI 10.1021/jm100262j
   Carvajal RD, 2006, CLIN CANCER RES, V12, P6869, DOI 10.1158/1078-0432.CCR-06-1405
   Cheong JW, 2010, CANCER LETT, V297, P171, DOI 10.1016/j.canlet.2010.05.009
   Conroy T, 2011, NEW ENGL J MED, V364, P1817, DOI 10.1056/NEJMoa1011923
   Crosio C, 2002, MOL CELL BIOL, V22, P874, DOI 10.1128/MCB.22.3.874-885.2002
   Dar AA, 2009, ONCOGENE, V28, P866, DOI 10.1038/onc.2008.434
   Dondelinger Y, 2014, CELL REP, V7, P971, DOI 10.1016/j.celrep.2014.04.026
   Faisal A, 2011, MOL CANCER THER, V10, P2115, DOI 10.1158/1535-7163.MCT-11-0333
   Fu JY, 2007, MOL CANCER RES, V5, P1, DOI 10.1158/1541-7786.MCR-06-0208
   Galluzzi L, 2017, ANNU REV PATHOL-MECH, V12, P103, DOI 10.1146/annurev-pathol-052016-100247
   Galluzzi L, 2017, NAT REV IMMUNOL, V17, P97, DOI 10.1038/nri.2016.107
   Glienke W, 2012, TUMOR BIOL, V33, P757, DOI 10.1007/s13277-011-0290-2
   Grassilli E, 2013, CLIN CANCER RES, V19, P3820, DOI 10.1158/1078-0432.CCR-12-3289
   Hingorani SR, 2003, CANCER CELL, V4, P437, DOI 10.1016/S1535-6108(03)00309-X
   Jacobs Keith M, 2012, Int J Cell Biol, V2012, P930710, DOI 10.1155/2012/930710
   Jani JP, 2010, MOL CANCER THER, V9, P883, DOI 10.1158/1535-7163.MCT-09-0915
   Kang R, 2017, CELL RES, V27, P916, DOI 10.1038/cr.2017.51
   Katayama H, 2012, CANCER CELL, V21, P196, DOI 10.1016/j.ccr.2011.12.025
   Kelly KR, 2011, CURR DRUG TARGETS, V12, P2067
   Li DH, 2003, CLIN CANCER RES, V9, P991
   Li Z, 2008, NUTR CANCER, V60, P382, DOI 10.1080/01635580701861785
   Ling YH, 1996, MOL PHARMACOL, V49, P832
   Liu P, 2012, LEUKEMIA, V26, P1293, DOI 10.1038/leu.2011.357
   Lu YM, 2014, ONCOL REP, V32, P243, DOI 10.3892/or.2014.3194
   Nikonova AS, 2013, CELL MOL LIFE SCI, V70, P661, DOI 10.1007/s00018-012-1073-7
   Ochiai Takanori, 2008, J Med Dent Sci, V55, P49
   Pasparakis M, 2015, NATURE, V517, P311, DOI 10.1038/nature14191
   Seifert L, 2017, CLIN CANCER RES, V23, P1132, DOI 10.1158/1078-0432.CCR-16-0968
   Seifert L, 2016, NATURE, V532, P245, DOI 10.1038/nature17403
   Su Z, 2016, CELL DEATH DIFFER, V23, P748, DOI 10.1038/cdd.2016.8
   Tang DL, 2012, IMMUNOL REV, V249, P158, DOI 10.1111/j.1600-065X.2012.01146.x
   Torres MP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080580
   Von Hoff DD, 2013, NEW ENGL J MED, V369, P1691, DOI 10.1056/NEJMoa1304369
   Wang HY, 2014, MOL CELL, V54, P133, DOI 10.1016/j.molcel.2014.03.003
   Weinlich R, 2017, NAT REV MOL CELL BIO, V18, P127, DOI 10.1038/nrm.2016.149
   Wu XY, 2014, J EXP CLIN CANC RES, V33, DOI 10.1186/1756-9966-33-13
   Xia ZB, 2013, MOL CANCER RES, V11, P1101, DOI 10.1158/1541-7786.MCR-13-0044
   Yang H, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2016.1149673
   Yoshino Y, 2015, SCI REP-UK, V5, DOI 10.1038/srep13249
   Zhang H, 2011, MOL CELL BIOCHEM, V357, P95, DOI 10.1007/s11010-011-0879-1
   Zou ZZ, 2012, AUTOPHAGY, V8, P1798, DOI 10.4161/auto.22110
NR 43
TC 60
Z9 63
U1 2
U2 26
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0016-5085
EI 1528-0012
J9 GASTROENTEROLOGY
JI Gastroenterology
PD NOV
PY 2017
VL 153
IS 5
BP 1429
EP +
DI 10.1053/j.gastro.2017.07.036
PG 20
WC Gastroenterology & Hepatology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Gastroenterology & Hepatology
GA FL6IM
UT WOS:000414348400040
PM 28764929
OA Green Accepted, Bronze
DA 2022-04-25
ER

PT J
AU Nunez-Olvera, SI
   Chavez-Munguia, B
   Terrones-Gurrola, MCD
   Marchat, LA
   Puente-Rivera, J
   Ruiz-Garcia, E
   Campos-Parra, AD
   Vazquez-Calzada, C
   Lizarraga-Verdugo, ER
   Ramos-Payan, R
   Salinas-Vera, YM
   Lopez-Camarillo, C
AF Nunez-Olvera, Stephanie, I
   Chavez-Munguia, Bibiana
   del Rocio Terrones-Gurrola, Maria Cruz
   Marchat, Laurence A.
   Puente-Rivera, Jonathan
   Ruiz-Garcia, Erika
   Campos-Parra, Alma D.
   Vazquez-Calzada, Carlos
   Lizarraga-Verdugo, Erik R.
   Ramos-Payan, Rosalio
   Salinas-Vera, Yarely M.
   Lopez-Camarillo, Cesar
TI A novel protective role for microRNA-3135b in Golgi apparatus
   fragmentation induced by chemotherapy via GOLPH3/AKT1/mTOR axis in
   colorectal cancer cells
SO SCIENTIFIC REPORTS
LA English
DT Article
ID BREAST-CANCER; GOLPH3 LINKS; DNA-DAMAGE; PROLIFERATION; EXPRESSION;
   PROTEIN; PROGRESSION
AB Chemotherapy activates a novel cytoplasmic DNA damage response resulting in Golgi apparatus fragmentation and cancer cell survival. This mechanism is regulated by Golgi phosphoprotein-3 (GOLPH3)/Myo18A/F-actin axis. Analyzing the functions of miR-3135b, a small non-coding RNA with unknown functions, we found that its forced overexpression attenuates the Golgi apparatus fragmentation induced by chemotherapeutic drugs in colorectal cancer (CRC) cells. First, we found that miR-3135b is downregulated in CRC cell lines and clinical tumors. Bioinformatic predictions showed that miR-3135b could be regulating protein-encoding genes involved in cell survival, resistance to chemotherapy, and Golgi dynamics. In agreement, ectopic transfection of miR-3135b in HCT-15 cancer cells significantly inhibited cell proliferation, sensitized cells to 5-fluoruracil (5-FU), and promoted late apoptosis and necrosis. Also, miR-3135b overexpression impaired the cell cycle progression in HCT-15 and SW-480 cancer cells. Because GOLPH3, a gene involved in maintenance of Golgi structure, was predicted as a potential target of miR-3135b, we studied their functional relationships in response to DNA damage induced by chemotherapy. Immunofluorescence and cellular ultrastructure experiments using antibodies against TGN38 protein, a trans-Golgi network marker, showed that 5-FU and doxorubicin treatments result in an apoptosis-independent stacks dispersal of the Golgi ribbon structure in both HCT-15 and SW-480 cells. Remarkably, these cellular effects were dramatically hindered by transfection of miR-3135b mimics. In addition, our functional studies confirmed that miR-3135b binds to the 3 ' -UTR of GOLPH3 proto-oncogene, and also reduces the levels of p-AKT1 (Ser473) and p-mTOR (Ser2448) signaling transducers, which are key in cell survival and autophagy activation. Moreover, we found that after treatment with 5-FU, TGN38 factor coimmunolocalizes with beclin-1 autophagic protein in discrete structures associated with the fragmented Golgi, suggesting that the activation of pro-survival autophagy is linked to loss of Golgi integrity. These cellular effects in autophagy and Golgi dispersal were reversed by miR-3135b. In summary, we provided experimental evidence suggesting for the first time a novel role for miR-3135b in the protection of chemotherapy-induced Golgi fragmentation via GOLPH3/AKT1/mTOR axis and protective autophagy in colorectal cancer cells.
C1 [Nunez-Olvera, Stephanie, I; Salinas-Vera, Yarely M.; Lopez-Camarillo, Cesar] Univ Autonoma Ciudad Mexico, Posgrad Ciencias Genom, San Lorenzo 290 Col Del Valle, Mexico City 03100, DF, Mexico.
   [Chavez-Munguia, Bibiana; Vazquez-Calzada, Carlos] CINVESTAV IPN, Dept Infectom & Patogenesis Mol, Mexico City, DF, Mexico.
   [del Rocio Terrones-Gurrola, Maria Cruz] Univ Autonoma San Luis Potosi, Coordinac Acad Reg Altiplano, San Luis Potosi, San Luis Potosi, Mexico.
   [Marchat, Laurence A.] Inst Politecn Nacl, Programa Biomed Mol & Red Biotecnol, Mexico City, DF, Mexico.
   [Puente-Rivera, Jonathan] Univ Nacl Autonoma Mexico, Inst Ecol, Dept Ecol Func, Mexico City, DF, Mexico.
   [Ruiz-Garcia, Erika] Inst Nacl Cancerol, Lab Med Translac, Mexico City, DF, Mexico.
   [Ruiz-Garcia, Erika] Inst Nacl Cancerol, Dept Tumores Gastrointestinales, Mexico City, DF, Mexico.
   [Campos-Parra, Alma D.] Inst Nacl Cancerol, Lab Genom, Mexico City, DF, Mexico.
   [Lizarraga-Verdugo, Erik R.; Ramos-Payan, Rosalio] Univ Autonoma Sinaloa, Fac Ciencias Quim Biol, Culiacan, Sinaloa, Mexico.
RP Lopez-Camarillo, C (corresponding author), Univ Autonoma Ciudad Mexico, Posgrad Ciencias Genom, San Lorenzo 290 Col Del Valle, Mexico City 03100, DF, Mexico.
EM cesar.lopez@uacm.edu.mx
RI Lopez-Camarillo, Cesar/I-1946-2019; del Rocío Terrones Gurrola, María
   Cruz/AAS-1463-2021; Puente-Rivera, Jonathan/AAU-5545-2021; Marchat,
   Laurence A./S-8418-2018; Vera, Yarely/AFN-2618-2022
OI Lopez-Camarillo, Cesar/0000-0002-9417-2609; Puente-Rivera,
   Jonathan/0000-0001-6941-6248; Marchat, Laurence A./0000-0003-1615-8614;
   Vera, Yarely/0000-0003-2129-9980; Ruiz-Garcia,
   Erika/0000-0002-0446-123X; Ramos-Payan, Rosalio/0000-0001-7500-7571
FU Ciencia Basica SEP-CONACYT [2018-2019, A1-S-13656]
FX We thank to Universidad Autonoma de la Ciudad de Mexico for
   infrastructure and support. This investigation was partially funded by
   Ciencia Basica SEP-CONACYT 2018-2019 (Grant A1-S-13656).
CR Abraham RT, 2009, PIGM CELL MELANOMA R, V22, P378, DOI 10.1111/j.1755-148X.2009.00596.x
   Buschman MD, 2015, CANCER RES, V75, P624, DOI 10.1158/0008-5472.CAN-14-3081
   Conciatori F, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19082453
   Dippold HC, 2009, CELL, V139, P337, DOI 10.1016/j.cell.2009.07.052
   Farber-Katz SE, 2014, CELL, V156, P413, DOI 10.1016/j.cell.2013.12.023
   Garcia-Osogobio S, 2015, ENDOSCOPIA, V27, P59, DOI DOI 10.1016/j.endomx.2015.06.001
   Ghanbari Reza, 2015, Biomark Cancer, V7, P39, DOI 10.4137/BIC.S25252
   Gosavi P, 2018, J CELL SCI, V131, DOI 10.1242/jcs.211987
   Grothey A, 2018, NEW ENGL J MED, V378, P1177, DOI 10.1056/NEJMoa1713709
   Ha M, 2014, NAT REV MOL CELL BIO, V15, P509, DOI 10.1038/nrm3838
   Hu BS, 2013, TUMOR BIOL, V34, P515, DOI 10.1007/s13277-012-0576-z
   Hua X, 2012, DIAGN PATHOL, V7, DOI 10.1186/1746-1596-7-127
   Ignashkova TI, 2017, TRAFFIC, V18, P530, DOI 10.1111/tra.12493
   Jansson MD, 2012, MOL ONCOL, V6, P590, DOI 10.1016/j.molonc.2012.09.006
   Ke KL, 2017, ONCOL LETT, V14, P5994, DOI 10.3892/ol.2017.6930
   Kunigou O, 2011, ONCOL REP, V26, P1337, DOI 10.3892/or.2011.1413
   Lee M, 2008, MOL CANCER RES, V6, P1316, DOI 10.1158/1541-7786.MCR-07-2209
   Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035
   LI H, 2012, J TRANSL MED, V10, P1, DOI DOI 10.1186/1479-5876-10-S1-S1
   Li HM, 2014, ONCOL REP, V32, P1225, DOI 10.3892/or.2014.3327
   Li WZ, 2015, J CANCER, V6, P420, DOI 10.7150/jca.11228
   Liu YQ, 2017, ONCOL REP, V37, P2441, DOI 10.3892/or.2017.5488
   Nitulescu GM, 2018, INT J ONCOL, V53, P2319, DOI 10.3892/ijo.2018.4597
   Petrosyan Armen, 2015, Biochem Mol Biol J, V1
   Reddy KB, 2015, CANCER CELL INT, V15, DOI 10.1186/s12935-015-0185-1
   Rizzo R, 2017, TISSUE CELL, V49, P170, DOI 10.1016/j.tice.2016.06.008
   Schultz MJ, 2016, CANCER RES, V76, P3978, DOI 10.1158/0008-5472.CAN-15-2834
   Scott KL, 2009, NATURE, V459, P1085, DOI 10.1038/nature08109
   Siegel RL, 2019, CA-CANCER J CLIN, V69, P7, DOI 10.3322/caac.21551
   Slattery ML, 2016, CARCINOGENESIS, V37, P245, DOI 10.1093/carcin/bgv249
   Treiber T, 2017, MOL CELL, V66, P270, DOI 10.1016/j.molcel.2017.03.014
   Vejnar CE, 2012, NUCLEIC ACIDS RES, V40, P11673, DOI 10.1093/nar/gks901
   Walker AS, 2014, J CANCER, V5, P44, DOI 10.7150/jca.7809
   Yamamoto H, 2012, J CELL BIOL, V198, P219, DOI 10.1083/jcb.201202061
   Zaheer U, 2019, CURR PHARM DESIGN, V25, P642, DOI 10.2174/1386207322666190325122821
   Zeng ZL, 2012, CLIN CANCER RES, V18, P4059, DOI 10.1158/1078-0432.CCR-11-3156
   Zhang BH, 2007, DEV BIOL, V302, P1, DOI 10.1016/j.ydbio.2006.08.028
   Zhang WQ, 2020, J INVEST MED, V68, P425, DOI 10.1136/jim-2019-001124
   Zhou B, 2016, ONCOL LETT, V12, P3936, DOI 10.3892/ol.2016.5215
NR 39
TC 7
Z9 7
U1 0
U2 5
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD JUN 29
PY 2020
VL 10
IS 1
AR 10555
DI 10.1038/s41598-020-67550-0
PG 14
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA MJ8TC
UT WOS:000548359400028
PM 32601379
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Wen, B
   Wei, YT
   Mu, LL
   Wen, GR
   Zhao, K
AF Wen, Bin
   Wei, Ying-Ting
   Mu, Lan-Lan
   Wen, Guo-Rong
   Zhao, Kui
TI The molecular mechanisms of celecoxib in tumor development
SO MEDICINE
LA English
DT Review
DE autophagy; cancer stem cells; celecoxib; cyclooxygenase-2; endoplasmic
   reticulum stress; prostaglandin E-2; reactive oxygen species; tumor
ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; ENDOPLASMIC-RETICULUM STRESS;
   EPITHELIAL-MESENCHYMAL TRANSITION; HYPOXIA-INDUCIBLE FACTORS; CARCINOMA
   CELL-GROWTH; NF-KAPPA-B; COLORECTAL-CANCER; PROSTATE-CANCER;
   GASTRIC-CANCER; BREAST-CANCER
AB Background: Clinical studies have shown that celecoxib can significantly inhibit the development of tumors, and basic experiments and in vitro experiments also provide a certain basis, but it is not clear how celecoxib inhibits tumor development in detail. Methods: A literature search of all major academic databases was conducted (PubMed, China National Knowledge Internet (CNKI), Wan-fang, China Science and Technology Journal Database (VIP), including the main research on the mechanisms of celecoxib on tumors. Results: Celecoxib can intervene in tumor development and reduce the formation of drug resistance through multiple molecular mechanisms. Conclusion: Celecoxib mainly regulates the proliferation, migration, and invasion of tumor cells by inhibiting the cyclooxygenases-2/prostaglandin E2 signal axis and thereby inhibiting the phosphorylation of nuclear factor-kappa-gene binding, Akt, signal transducer and activator of transcription and the expression of matrix metalloproteinase 2 and matrix metalloproteinase 9. Meanwhile, it was found that celecoxib could promote the apoptosis of tumor cells by enhancing mitochondrial oxidation, activating mitochondrial apoptosis process, promoting endoplasmic reticulum stress process, and autophagy. Celecoxib can also reduce the occurrence of drug resistance by increasing the sensitivity of cancer cells to chemotherapy drugs.
C1 [Wen, Bin; Wei, Ying-Ting; Mu, Lan-Lan; Wen, Guo-Rong; Zhao, Kui] Zunyi Med Univ, Affiliated Hosp, Dept Gastroenterol, Zunyi 563000, Guizhou, Peoples R China.
RP Zhao, K (corresponding author), Zunyi Med Univ, Affiliated Hosp, Dept Gastroenterol, Zunyi 563000, Guizhou, Peoples R China.
EM Kuizhao95858@msn.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81560467]
FX This study was supported by research grants from the National Natural
   Science Foundation of China (No. 81560467 to KZ).
CR Abdelrahman RS, 2020, CHEM-BIOL INTERACT, V315, DOI 10.1016/j.cbi.2019.108863
   Ahmed S, 2019, PHYTOMEDICINE, V59, DOI 10.1016/j.phymed.2019.152883
   Algra AM, 2012, LANCET ONCOL, V13, P518, DOI 10.1016/S1470-2045(12)70112-2
   Alloza I, 2006, MOL PHARMACOL, V69, P1579, DOI 10.1124/mol.105.020669
   Arefi H, 2020, ARCH PHARM, V353, DOI 10.1002/ardp.201900293
   Arico S, 2002, J BIOL CHEM, V277, P27613, DOI 10.1074/jbc.M201119200
   Avril T, 2017, ONCOGENESIS, V6, DOI 10.1038/oncsis.2017.72
   Barsukova A, 2011, EUR J NEUROSCI, V33, P831, DOI 10.1111/j.1460-9568.2010.07576.x
   Baselyous Y, 2019, EXPERT OPIN DRUG SAF, V18, P153, DOI 10.1080/14740338.2019.1589447
   Chen PW, 2014, AUTOPHAGY, V10, P192, DOI 10.4161/auto.26927
   Chen Q, 2019, BRIT J CANCER, V121, P786, DOI 10.1038/s41416-019-0595-2
   Choi AMK, 2013, NEW ENGL J MED, V368, P651, DOI [10.1056/NEJMra1205406, 10.1056/NEJMc1303158]
   Chu TH, 2014, ONCOTARGET, V5, P1475, DOI 10.18632/oncotarget.1745
   Curry JM, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0224309
   Dai HJ, 2019, MED SCI MONITOR, V25, P7351, DOI 10.12659/MSM.919218
   Deng YH, 2013, CANCER INVEST, V31, P97, DOI 10.3109/07357907.2012.754458
   Ding WX, 2007, J BIOL CHEM, V282, P4702, DOI 10.1074/jbc.M609267200
   Dubois RN, 1998, FASEB J, V12, P1063, DOI 10.1096/fasebj.12.12.1063
   Egashira I, 2017, CANCER SCI, V108, P108, DOI 10.1111/cas.13106
   Ellethy AT, 2019, INT J HEALTH SCI-IJH, V13, P11
   Erland LAE, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0223878
   Finkel T, 2012, J BIOL CHEM, V287, P4434, DOI 10.1074/jbc.R111.271999
   Fraser DM, 2014, BRIT J CANCER, V111, P623, DOI 10.1038/bjc.2014.264
   Gately S, 2004, SEMIN ONCOL, V31, P2, DOI 10.1053/j.seminoncol.2004.03.040
   Glick D, 2010, J PATHOL, V221, P3, DOI 10.1002/path.2697
   Gorrini C, 2013, NAT REV DRUG DISCOV, V12, P931, DOI 10.1038/nrd4002
   Greenhough A, 2009, CARCINOGENESIS, V30, P377, DOI 10.1093/carcin/bgp014
   Gurpinar E, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00181
   Han Y, 2019, CANCERS, V11, DOI 10.3390/cancers11070931
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Heddleston JM, 2010, BRIT J CANCER, V102, P789, DOI 10.1038/sj.bjc.6605551
   Hetz C, 2012, NAT REV MOL CELL BIO, V13, P89, DOI 10.1038/nrm3270
   Higgins CF, 2007, NATURE, V446, P749, DOI 10.1038/nature05630
   Horl WH, 2010, PHARMACEUTICALS, V3, P2291, DOI 10.3390/ph3072291
   Hood JD, 2002, NAT REV CANCER, V2, P91, DOI 10.1038/nrc727
   Hou GX, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0159-4
   Huang CL, 2017, ONCOTARGET, V8, P115254, DOI 10.18632/oncotarget.23250
   Huang KH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082034
   Huang SB, 2010, AUTOPHAGY, V6, P256, DOI 10.4161/auto.6.2.11124
   Hull MA, 2018, LANCET, V392, P2583, DOI 10.1016/S0140-6736(18)31775-6
   Hung JH, 2004, J BIOL CHEM, V279, P46384, DOI 10.1074/jbc.M403568200
   Imamura M, 2019, PEDIATRICS, V144, DOI 10.1542/peds.2019-0319
   Isaji T, 2009, J BIOL CHEM, V284, P12207, DOI 10.1074/jbc.M807920200
   Ishikawa K, 2008, SCIENCE, V320, P661, DOI 10.1126/science.1156906
   Jung SN, 2008, CARCINOGENESIS, V29, P713, DOI 10.1093/carcin/bgn032
   Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720
   Kamei D, 2010, BIOCHEM J, V425, P361, DOI 10.1042/BJ20090045
   Kaushik K, 2019, CYTOTHERAPY, V21, P260, DOI 10.1016/j.jcyt.2019.01.004
   Kern MA, 2002, HEPATOLOGY, V36, P885, DOI 10.1053/jhep.2002.36125
   Kern MA, 2006, CANCER RES, V66, P7059, DOI 10.1158/0008-5472.CAN-06-0325
   Kim MJ, 2014, MOL CELLS, V37, P759, DOI 10.14348/molcells.2014.0232
   Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758
   Lee HS, 2019, EXP MOL MED, V51, DOI 10.1038/s12276-019-0330-3
   Leng J, 2003, HEPATOLOGY, V38, P756, DOI 10.1053/jhep.2003.50380
   Levy JMM, 2017, NAT REV CANCER, V17, P528, DOI 10.1038/nrc.2017.53
   Li T, 2016, ONCOL REP, V35, P3614, DOI 10.3892/or.2016.4764
   Liang DM, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-201
   Lin XM, 2019, INT J BIOCHEM CELL B, V116, DOI 10.1016/j.biocel.2019.105610
   Lipsky PE, 2000, ARCH INTERN MED, V160, P913, DOI 10.1001/archinte.160.7.913
   Liu J, 2019, ADV SCI, V6, DOI 10.1002/advs.201801987
   Liu RJ, 2018, ONCOL LETT, V16, P3029, DOI 10.3892/ol.2018.9035
   Liu XQ, 2019, INT J MOL MED, V44, P683, DOI 10.3892/ijmm.2019.4241
   Lu D, 2012, ONCOGENE, V31, P842, DOI 10.1038/onc.2011.287
   Lu Y, 2016, BIOMED PHARMACOTHER, V84, P1551, DOI 10.1016/j.biopha.2016.11.026
   Lu Y, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-1012-8
   Luo L, 2019, ONCOL LETT, V18, P1442, DOI 10.3892/ol.2019.10442
   Ma HI, 2011, J NEUROSURG, V114, P651, DOI 10.3171/2009.11.JNS091396
   Majmundar AJ, 2010, MOL CELL, V40, P294, DOI 10.1016/j.molcel.2010.09.022
   Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027
   Mann MI, 2006, CANCER BIOL THER, V5, P736, DOI 10.4161/cbt.5.7.2969
   Marin-Hernandez A, 2009, MINI-REV MED CHEM, V9, P1084, DOI 10.2174/138955709788922610
   McCarberg BH, 2015, AM J THER, V22, pe167, DOI 10.1097/MJT.0000000000000123
   Mittal V, 2018, ANNU REV PATHOL-MECH, V13, P395, DOI 10.1146/annurev-pathol-020117-043854
   Moreno-Sanchez R, 1999, BIOCHEM PHARMACOL, V57, P743, DOI 10.1016/S0006-2952(98)00330-X
   Mrena J, 2010, TUMOR BIOL, V31, P1, DOI 10.1007/s13277-009-0001-4
   Mullarky E., 2015, INNOVATIVE MED BASIC, P3, DOI DOI 10.1007/978-4-431-55651-0_1
   Muller AJ, 2007, CURR CANCER DRUG TAR, V7, P31, DOI 10.2174/156800907780006896
   North TE, 2007, NATURE, V447, P1007, DOI 10.1038/nature05883
   Nunes JB, 2015, HUM MOL GENET, V24, P1977, DOI 10.1093/hmg/ddu612
   Oliveira-Ferrer L, 2017, SEMIN CANCER BIOL, V44, P141, DOI 10.1016/j.semcancer.2017.03.002
   Onuora Sarah, 2017, Nat Rev Rheumatol, V13, P324, DOI 10.1038/nrrheum.2017.63
   Pankiv S, 2007, J BIOL CHEM, V282, P24131, DOI 10.1074/jbc.M702824200
   Parzych KR, 2014, ANTIOXID REDOX SIGN, V20, P460, DOI 10.1089/ars.2013.5371
   Poligone B, 2001, J BIOL CHEM, V276, P38658, DOI 10.1074/jbc.M106599200
   Porporato PE, 2015, MOL CELL ONCOL, V2, DOI 10.4161/23723548.2014.968043
   Pritchard R, 2018, BIOCHEM PHARMACOL, V154, P318, DOI 10.1016/j.bcp.2018.05.013
   Ralph SJ, 2019, MED RES REV, V39, P2397, DOI 10.1002/med.21589
   Ralph SJ, 2015, PHARMACEUTICALS-BASE, V8, P62, DOI 10.3390/ph8010062
   Rasheva VI, 2009, APOPTOSIS, V14, P996, DOI 10.1007/s10495-009-0341-y
   Ravanan P, 2017, LIFE SCI, V188, P53, DOI 10.1016/j.lfs.2017.08.029
   Reczek CR, 2017, ANNU REV CANC BIOL, V1, P79, DOI 10.1146/annurev-cancerbio-041916-065808
   Reed GW, 2019, AGING-US, V11, P2181, DOI 10.18632/aging.101930
   Ricciotti E, 2011, ARTERIOSCL THROM VAS, V31, P986, DOI 10.1161/ATVBAHA.110.207449
   Rodriguez-Enriquez S, 2010, INT J BIOCHEM CELL B, V42, P1744, DOI 10.1016/j.biocel.2010.07.010
   Roy HK, 2017, GUT, V66, P285, DOI 10.1136/gutjnl-2015-309996
   Sethi R, 2019, FRONT PSYCHIATRY, V10, DOI 10.3389/fpsyt.2019.00605
   Shan BZ, 2019, EUR REV MED PHARMACO, V23, P9454, DOI 10.26355/eurrev_201911_19439
   Shao JY, 2005, J BIOL CHEM, V280, P26565, DOI 10.1074/jbc.M413056200
   Sharma V, 2011, NEUROCHEM INT, V59, P567, DOI 10.1016/j.neuint.2011.06.018
   Shen AL, 2019, CANCER RES, V79, P2257, DOI 10.1158/0008-5472.CAN-18-3238
   Silverstein FE, 2000, JAMA-J AM MED ASSOC, V284, P1247, DOI 10.1001/jama.284.10.1247
   Skaga E, 2019, J CANCER RES CLIN, V145, P1495, DOI 10.1007/s00432-019-02920-4
   Sproviero D, 2012, J BIOL CHEM, V287, P44490, DOI 10.1074/jbc.M112.427827
   Tai Y, 2019, CANCER MANAG RES, V11, P2831, DOI 10.2147/CMAR.S183376
   Thompson PA, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djw151
   Tomic T, 2019, CANCER EPIDEMIOL, V58, P52, DOI 10.1016/j.canep.2018.11.002
   Tong DL, 2017, CANCER LETT, V389, P23, DOI 10.1016/j.canlet.2016.12.031
   Tsioulias George J, 2015, Curr Pharmacol Rep, V1, P295
   Uram L, 2019, MOLECULES, V24, DOI 10.3390/molecules24203801
   Varga Z, 2017, CUREUS, V9, DOI 10.7759/cureus.1144
   Varma GYN, 2019, J ANTIMICROB CHEMOTH, V74, P3462, DOI 10.1093/jac/dkz391
   Veettil SK, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3757-8
   Walker C, 2018, POSTGRAD MED, V130, P55, DOI 10.1080/00325481.2018.1412799
   Wang DZ, 2015, GASTROENTEROLOGY, V149, P1884, DOI 10.1053/j.gastro.2015.07.064
   Wang P, 2013, MED ONCOL, V30, DOI 10.1007/s12032-013-0552-5
   Wong CC, 2019, THERANOSTICS, V9, P6256, DOI 10.7150/thno.35766
   Xiao JJ, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-2020-4
   Xu J, 2019, AM J TRANSL RES, V11, P6040
   Yamahana H, 2020, BIOCHEM BIOPH RES CO, V521, P137, DOI 10.1016/j.bbrc.2019.10.092
   Yang MY, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/antiox9010026
   Yang ZNJ, 2011, MOL CANCER THER, V10, P1533, DOI 10.1158/1535-7163.MCT-11-0047
   Ye XH, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09375-8
   Yoshida H, 2019, ONCOL LETT, V18, P5793, DOI 10.3892/ol.2019.10975
   Zhang P, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0223760
   Zhang SP, 2019, J NANOBIOTECHNOL, V17, DOI 10.1186/s12951-019-0540-9
   Zhang X, 2019, CELL TRANSPLANT, V28, p1S, DOI 10.1177/0963689719890597
   Zheng Y, 2019, P NATL ACAD SCI USA, V116, P5223, DOI 10.1073/pnas.1819303116
   Zhou PT, 2018, CELL CYCLE, V17, P997, DOI 10.1080/15384101.2018.1467677
   Zhou X, 2015, EUR REV MED PHARMACO, V19, P4087
NR 129
TC 1
Z9 1
U1 2
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025-7974
EI 1536-5964
J9 MEDICINE
JI Medicine (Baltimore)
PD OCT 2
PY 2020
VL 99
IS 40
AR e22544
DI 10.1097/MD.0000000000022544
PG 10
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA OC4HR
UT WOS:000579119300086
PM 33019464
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Fels, DR
   Ye, JB
   Segan, AT
   Kridel, SJ
   Spiotto, M
   Olson, M
   Koong, AC
   Koumenis, C
AF Fels, Diane R.
   Ye, Jiangbin
   Segan, Andrew T.
   Kridel, Steven J.
   Spiotto, Michael
   Olson, Michael
   Koong, Albert C.
   Koumenis, Constantinos
TI Preferential Cytotoxicity of Bortezomib toward Hypoxic Tumor Cells via
   Overactivation of Endoplasmic Reticulum Stress Pathways
SO CANCER RESEARCH
LA English
DT Article
ID UNFOLDED PROTEIN RESPONSE; MULTIPLE-MYELOMA CELLS; ER STRESS;
   GENE-EXPRESSION; MESSENGER-RNA; PROTEASOME INHIBITION; TRANSLATIONAL
   CONTROL; TRANSCRIPTION-FACTOR; DRUG-RESISTANCE; CANCER-THERAPY
AB Hypoxia is a dynamic feature of the tumor microenvironment that contributes to drug resistance and cancer progression. We previously showed that components of the unfolded protein response (UPR), elicited by endoplasmic reticulum (ER) stress, are also activated by hypoxia in vitro and in vivo animal and human patient tumors. Here, we report that ER stressors, such as thapsigargin or the clinically used proteasome inhibitor bortezomib, exhibit significantly higher cytotoxicity toward hypoxic compared with normoxic tumor cells, which is accompanied by enhanced activation of UPR effectors in vitro and UPR reporter activity in vivo. Treatment of cells with the translation inhibitor cycloheximide, which relieves ER load, ameliorated this enhanced cytotoxicity, indicating that the increased cytotoxicity is ER stress-dependent. The mode of cell death was cell type-dependent, because DLD1 colorectal carcinoma cells exhibited enhanced apoptosis, whereas HeLa cervical carcinoma cells activated autophagy, blocked apoptosis, and eventually led to necrosis. Pharmacologic or genetic ablation of autophagy increased the levels of apoptosis. These results show that hypoxic tumor cells, which are generally more resistant to genotoxic agents, are hypersensitive to proteasome inhibitors and suggest that combining bortezomib with therapies that target the normoxic fraction of human tumors can lead to more effective tumor control. [Cancer Res 2008;68(22):9323-30]
C1 [Fels, Diane R.; Ye, Jiangbin; Segan, Andrew T.; Koumenis, Constantinos] Univ Penn, Sch Med, Dept Radiat Oncol, Philadelphia, PA 19104 USA.
   [Fels, Diane R.; Kridel, Steven J.] Wake Forest Univ, Bowman Gray Sch Med, Dept Canc Biol, Winston Salem, NC USA.
   [Spiotto, Michael; Olson, Michael; Koong, Albert C.] Stanford Univ, Dept Radiat Oncol, Sch Med, Stanford, CA 94305 USA.
RP Koumenis, C (corresponding author), Univ Penn, Sch Med, Dept Radiat Oncol, Philadelphia, PA 19104 USA.
EM koumenis@xrt.upenn.edu
RI Ye, Jiangbin/A-1094-2007; Koumenis, Constantinos/B-2002-2008; Spiotto,
   Michael/AAC-8331-2021
OI Koumenis, Costas/0000-0001-5945-4726; Ye, Jiangbin/0000-0003-1117-4869;
   Koong, Albert/0000-0001-9824-1643
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [CA94214, CA112108]; NATIONAL CANCER
   INSTITUTEUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)
   [R01CA094214, R01CA112108] Funding Source: NIH RePORTER
FX Grant support: NIH grants CA94214 (D.R. Fels, J. Ye, A.T. Segan, S.S.
   Kridel, and C. Koumenis) and CA112108 (M. Spiotto, M. Olson, and A.C.
   Koong).
CR Amaravadi RK, 2007, CLIN CANCER RES, V13, P7271, DOI 10.1158/1078-0432.CCR-07-1595
   Ameri K, 2004, BLOOD, V103, P1876, DOI 10.1182/blood-2003-06-1859
   Bernales S, 2006, PLOS BIOL, V4, P2311, DOI 10.1371/journal.pbio.0040423
   Bi MX, 2005, EMBO J, V24, P3470, DOI 10.1038/sj.emboj.7600777
   Blais JD, 2004, MOL CELL BIOL, V24, P7469, DOI 10.1128/MCB.24.17.7469-7482.2004
   Brown JM, 2007, METHOD ENZYMOL, V435, P297, DOI 10.1016/S0076-6879(07)35015-5
   Calfon M, 2002, NATURE, V415, P92, DOI 10.1038/415092a
   Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001
   Denmeade SR, 2003, J NATL CANCER I, V95, P990, DOI 10.1093/jnci/95.13.990
   Ding WX, 2007, AM J PATHOL, V171, P513, DOI 10.2353/ajpath.2007.070188
   Dong DZ, 2008, CANCER RES, V68, P498, DOI 10.1158/0008-5472.CAN-07-2950
   Fribley A, 2004, MOL CELL BIOL, V24, P9695, DOI 10.1128/MCB.24.22.9695-9704.2004
   Fu Y, 2006, CANCER BIOL THER, V5, P741, DOI 10.4161/cbt.5.7.2970
   Harding HP, 2000, MOL CELL, V5, P897, DOI 10.1016/S1097-2765(00)80330-5
   Hideshima T, 2001, CANCER RES, V61, P3071
   Hitomi J, 2004, J CELL BIOL, V165, P347, DOI 10.1083/jcb.200310015
   Jiang HY, 2005, J BIOL CHEM, V280, P14189, DOI 10.1074/jbc.M413660200
   Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720
   Karantza-Wadsworth V, 2007, GENE DEV, V21, P1621, DOI 10.1101/gad.1565707
   Koditz J, 2007, BLOOD, V110, P3610, DOI 10.1182/blood-2007-06-094441
   Koritzinsky M, 2006, EMBO J, V25, P1114, DOI 10.1038/sj.emboj.7600998
   Koumenis C, 2002, MOL CELL BIOL, V22, P7405, DOI 10.1128/MCB.22.21.7405-7416.2002
   Kouroku Y, 2007, CELL DEATH DIFFER, V14, P230, DOI 10.1038/sj.cdd.4401984
   Le QT, 2004, CANCER METAST REV, V23, P293, DOI 10.1023/B:CANC.0000031768.89246.d7
   Lee AH, 2003, P NATL ACAD SCI USA, V100, P9946, DOI 10.1073/pnas.1334037100
   Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257
   Liu LP, 2006, MOL CELL, V21, P521, DOI 10.1016/j.molcel.2006.01.010
   Ma YJ, 2004, NAT REV CANCER, V4, P966, DOI 10.1038/nrc1505
   Ma YJ, 2003, J BIOL CHEM, V278, P34864, DOI 10.1074/jbc.M301107200
   Nawrocki ST, 2005, CANCER RES, V65, P11510, DOI 10.1158/0008-5472.CAN-05-2394
   Novoa I, 2003, EMBO J, V22, P1180, DOI 10.1093/emboj/cdg112
   Obeng EA, 2006, BLOOD, V107, P4907, DOI 10.1182/blood-2005-08-3531
   Ogata M, 2006, MOL CELL BIOL, V26, P9220, DOI 10.1128/MCB.01453-06
   Pyrko P, 2007, CANCER RES, V67, P9809, DOI 10.1158/0008-5472.CAN-07-0625
   Reddy RK, 2003, J BIOL CHEM, V278, P20915, DOI 10.1074/jbc.M212328200
   Richardson PG, 2006, ANNU REV MED, V57, P33, DOI 10.1146/annurev.med.57.042905.122625
   Romero-Ramirez L, 2004, CANCER RES, V64, P5943, DOI 10.1158/0008-5472.CAN-04-1606
   Ron D, 2007, NAT REV MOL CELL BIO, V8, P519, DOI 10.1038/nrm2199
   Scaffidi P, 2002, NATURE, V418, P191, DOI 10.1038/nature00858
   Scheuner D, 2001, MOL CELL, V7, P1165, DOI 10.1016/S1097-2765(01)00265-9
   Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187
   Shin DH, 2008, BLOOD, V111, P3131, DOI 10.1182/blood-2007-11-120576
   Travers KJ, 2000, CELL, V101, P249, DOI 10.1016/S0092-8674(00)80835-1
   Urano F, 2000, SCIENCE, V287, P664, DOI 10.1126/science.287.5453.664
   Veschini L, 2007, BLOOD, V109, P2565, DOI 10.1182/blood-2006-06-032664
   Yorimitsu T, 2006, J BIOL CHEM, V281, P30299, DOI 10.1074/jbc.M607007200
   Yoshida H, 2001, CELL, V107, P881, DOI 10.1016/S0092-8674(01)00611-0
   Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982
NR 48
TC 103
Z9 106
U1 0
U2 11
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
J9 CANCER RES
JI Cancer Res.
PD NOV 15
PY 2008
VL 68
IS 22
BP 9323
EP 9330
DI 10.1158/0008-5472.CAN-08-2873
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 375TQ
UT WOS:000261136600029
PM 19010906
OA Green Accepted
DA 2022-04-25
ER

PT J
AU Lu, MZ
   Zhang, XJ
   Xu, Y
   He, GZ
   Liu, Q
   Zhu, J
   Zhang, CS
AF Lu, Mingzhu
   Zhang, Xianjing
   Xu, Yun
   He, Guangzhao
   Liu, Qian
   Zhu, Jing
   Zhang, Changsong
TI Elevated histone H3 citrullination is associated with increased Beclin1
   expression in HBV-related hepatocellular carcinoma
SO JOURNAL OF MEDICAL VIROLOGY
LA English
DT Article
DE autophagy; Beclin1; citrullination; hepatocellular carcinoma; histone H3
ID COLORECTAL-CANCER; AUTOPHAGY; TARGET; GENE; TUMORIGENESIS; MARKER;
   HEALTH; CELLS
AB Citrullinated histone H3 (H3Cit) is the product of the conversion of peptidylarginine to citrulline in histone H3. We evaluated the H3Cit level in hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) tissues and assessed its association with Beclin1 messenger RNA (mRNA) (a key autophagic regulator). The level of H3Cit was detected by a capture enzyme-linked immunosorbent assay, while Beclin1 mRNA was determined by real-time polymerase chain reaction in 80 HBV-related patients with HCC. We found that the mean level of H3Cit was 72.25 ng/mg in HCC and 44.02 ng/mg in nontumor tissues. The mean HCC/nontumor ratio of Beclin1 mRNA was higher (0.096) in tumor samples than in nontumor specimens (0.056). Specifically, Beclin1 mRNA was elevated in 51 HCC cases (63.75%) and decreased in 29 cases (36.25%). Moreover, the levels of H3Cit and Beclin1 mRNA were significantly associated with vascular invasion and serum AFP levels. A shorter survival (19 months) was associated with a high H3Cit level. We also found increased levels of Beclin1 mRNA in the H3Cit (high) group compared with the H3Cit (low) group. The results implied that elevated histone H3 citrullination is associated with increased Beclin1 expression during the development of HBV-related HCC.
C1 [Lu, Mingzhu; He, Guangzhao; Liu, Qian] Soochow Univ, Changzhou Canc Hosp, Clin Oncol Lab, Changzhou, Peoples R China.
   [Zhang, Xianjing] Nanchang Univ, Clin Med Sch 2, Nanchang, Jiangxi, Peoples R China.
   [Xu, Yun] Nanyang Ctr Hosp, Dept Oncol, Nanyang, Peoples R China.
   [Zhu, Jing; Zhang, Changsong] Nanjing Med Univ, Affiliated Suzhou Sci & Technol Town Hosp, Dept Lab, Suzhou, Peoples R China.
RP Zhang, CS (corresponding author), Nanjing Med Univ, Affiliated Suzhou Sci & Technol Town Hosp, 1 Lijiang Rd, Suzhou 215153, Jiangsu, Peoples R China.
EM changsong@suda.edu.cn
OI zhang, changsong/0000-0002-1425-7339
FU Changzhou Municipal Commission of Health and Family Planning [ZD201816];
   Health Talents Project for Jiangsu [ZDRCC2016020]; Natural Science
   Foundation of Jiangsu ProvinceNatural Science Foundation of Jiangsu
   Province [BE2016656, BRA2018171]; Suzhou New District Science and
   Technology Plan [2019Z009]
FX Changzhou Municipal Commission of Health and Family Planning,
   Grant/Award Number: ZD201816; Health Talents Project for Jiangsu,
   Grant/Award Number: ZDRCC2016020; Natural Science Foundation of Jiangsu
   Province, Grant/Award Numbers: BE2016656, BRA2018171; Suzhou New
   District Science and Technology Plan, Grant/Award Number: 2019Z009
CR Al-Shenawy HA, 2016, APMIS, V124, P229, DOI 10.1111/apm.12498
   Anzilotti C, 2010, AUTOIMMUN REV, V9, P158, DOI 10.1016/j.autrev.2009.06.002
   Bortnik S, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18071496
   Cao Y, 2007, CELL RES, V17, P839, DOI 10.1038/cr.2007.78
   Cha YJ, 2014, INT J CLIN EXP PATHO, V7, P3389
   Chang XT, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-40
   Edge SB, 2010, ANN SURG ONCOL, V17, P1471, DOI 10.1245/s10434-010-0985-4
   El-Khattouti Abdelouahid, 2013, J Cell Death, V6, P37, DOI 10.4137/JCD.S11034
   Erstad DJ, 2018, CANCER-AM CANCER SOC, V124, P3084, DOI 10.1002/cncr.31257
   Fan TT, 2014, CELL BIOSCI, V4, DOI 10.1186/2045-3701-4-49
   Flavahan WA, 2017, SCIENCE, V357, DOI 10.1126/science.aal2380
   Fu LL, 2013, INT J BIOCHEM CELL B, V45, P921, DOI 10.1016/j.biocel.2013.02.007
   Guerrieri F, 2017, BMC GENOMICS, V18, DOI 10.1186/s12864-017-3561-5
   Han Y, 2014, ASIAN PAC J CANCER P, V15, P4583, DOI 10.7314/APJCP.2014.15.11.4583
   Jiang ZM, 2013, WORLD J SURG ONCOL, V11, DOI 10.1186/1477-7819-11-260
   Kotsafti A, 2012, BMC GASTROENTEROL, V12, DOI 10.1186/1471-230X-12-118
   Koukourakis MI, 2010, BRIT J CANCER, V103, P1209, DOI 10.1038/sj.bjc.6605904
   Misztak P, 2018, PHARMACOL REP, V70, P398, DOI 10.1016/j.pharep.2017.08.001
   Nakashima K, 2002, J BIOL CHEM, V277, P49562, DOI 10.1074/jbc.M208795200
   Pfeifer GP, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19041166
   Qiu DM, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-327
   Sharma P, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002934
   Song JR, 2011, J CELL BIOCHEM, V112, P3406, DOI 10.1002/jcb.23274
   Sun K, 2017, CANCER LETT, V388, P198, DOI 10.1016/j.canlet.2016.12.004
   Sun K, 2013, CELL BIOSCI, V3, DOI 10.1186/2045-3701-3-35
   Tanikawa C, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1676
   Thalin C, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0191231
   Thalin C, 2017, IMMUNOL RES, V65, P706, DOI 10.1007/s12026-017-8905-3
   Toton E, 2014, J PHYSIOL PHARMACOL, V65, P459
   Wang S, 2013, BBA-GENE REGUL MECH, V1829, P1126, DOI 10.1016/j.bbagrm.2013.07.003
   Xie DY, 2017, HEPATOBIL SURG NUTR, V6, P387, DOI 10.21037/hbsn.2017.11.01
   Zhang XS, 2012, P NATL ACAD SCI USA, V109, P13331, DOI 10.1073/pnas.1203280109
NR 32
TC 2
Z9 2
U1 0
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0146-6615
EI 1096-9071
J9 J MED VIROL
JI J. Med. Virol.
PD AUG
PY 2020
VL 92
IS 8
BP 1221
EP 1230
DI 10.1002/jmv.25663
EA JAN 2020
PG 10
WC Virology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Virology
GA ML5GX
UT WOS:000507665100001
PM 31900950
DA 2022-04-25
ER

PT J
AU Brown, GT
   Cash, B
   Alnabulsi, A
   Samuel, LM
   Murray, GI
AF Brown, Gordon T.
   Cash, Beatriz
   Alnabulsi, Ayham
   Samuel, Leslie M.
   Murray, Graeme I.
TI The expression and prognostic significance of bcl-2-associated
   transcription factor 1 in rectal cancer following neoadjuvant therapy
SO HISTOPATHOLOGY
LA English
DT Article
DE bcl-2-associated transcription factor 1; biomarker;
   immunohistochemistry; monoclonal antibody; neoadjuvant therapy;
   prognosis; rectal cancer
ID COLORECTAL-CANCER; BCLAF1; DEATH; BTF; CHEMOTHERAPY; ROLES; ALDH1
AB Aimsbcl-2-associated transcription factor 1 (BCLAF1) is a nuclear protein that binds to bcl-related proteins and can induce apoptosis and autophagy. The aim of this study was to investigate the expression of BCLAF1 in a series of rectal cancers following neoadjuvant therapy.
   Methods and resultsImmunohistochemistry was performed on a post-neoadjuvant therapy rectal cancer tissue microarray. It contained rectal cancers (n = 248), lymph node metastases (n = 76), and non-neoplastic rectal mucosal samples (n = 73). A monoclonal antibody against BCLAF1 that we have developed was used. Non-neoplastic rectal epithelium showed nuclear localization of BCLAF1 in both crypt and surface epithelial cells, whereas rectal cancers showed both nuclear and cytoplasmic BCLAF1 expression. Most rectal cancers showed moderate or strong nuclear immunoreactivity, but showed weak cytoplasmic immunoreactivity. Cytoplasmic BCLAF1 expression was increased in primary rectal cancers as compared with non-neoplastic rectal mucosa (P = 0.008). Negative and weak nuclear BCLAF1 expression was associated with a poor prognosis [hazard ratio (HR) 0.502, 95% confidence interval (CI) 0.269-0.939, (2) = 4.876, P = 0.027]. Nuclear BCLAF1 expression was independently prognostic in a multivariate model (HR 0.431, 95% CI 0.221-0.840, P = 0.013).
   ConclusionsThis study has shown that both cytoplasmic BCLAF1 expression and nuclear BCLAF1 expression are increased in post-neoadjuvant therapy rectal cancer, and that negative and weak nuclear BCLAF1 expression are independently associated with a poor prognosis.
C1 [Brown, Gordon T.; Murray, Graeme I.] Univ Aberdeen, Sch Med & Dent, Div Appl Med, Pathol, Foresterhill, Aberdeen AB25 2ZD, Scotland.
   [Cash, Beatriz; Alnabulsi, Ayham] Vertebrate Antibodies, Tillydrone Ave, Aberdeen, Scotland.
   [Samuel, Leslie M.] NHS Grampian, Aberdeen Royal Infirm, Dept Clin Oncol, Aberdeen, Scotland.
RP Brown, GT (corresponding author), Univ Aberdeen, Sch Med & Dent, Div Appl Med, Pathol, Foresterhill, Aberdeen AB25 2ZD, Scotland.
EM g.i.murray@abdn.ac.uk
OI Samuel, Leslie/0000-0002-8402-8670
FU Encompass kick start and SMART: Scotland award schemes of Scottish
   Enterprise and Friends of Anchor
FX This study was supported by funding from the Encompass kick start and
   SMART: Scotland award schemes of Scottish Enterprise and Friends of
   Anchor. The Grampian Biorepository assisted with the immunohistochemical
   investigations.
CR Aklilu M, 2011, NAT REV CLIN ONCOL, V8, P649, DOI 10.1038/nrclinonc.2011.118
   Alnabulsi A, 2012, J PATHOL, V228, P471, DOI 10.1002/path.4031
   Avoranta ST, 2013, HUM PATHOL, V44, P966, DOI 10.1016/j.humpath.2012.10.003
   Brown GT, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090776
   Carpenter B, 2006, BRIT J CANCER, V95, P921, DOI 10.1038/sj.bjc.6603349
   Carpenter B, 2006, BBA-REV CANCER, V1765, P85, DOI 10.1016/j.bbcan.2005.10.002
   Coghlin C, 2015, PROTEOM CLIN APPL, V9, P64, DOI 10.1002/prca.201400082
   D'Alterio C, 2014, INT J CANCER, V135, P379, DOI 10.1002/ijc.28689
   Deng Y, 2014, BRIT J CANCER, V110, P430, DOI 10.1038/bjc.2013.767
   Fleming FJ, 2011, DIS COLON RECTUM, V54, P901, DOI 10.1007/DCR.0b013e31820eeb37
   Glynne-Jones R, 2012, ANN ONCOL, V23, P2517, DOI 10.1093/annonc/mds010
   Hope NR, 2011, HUM PATHOL, V42, P393, DOI 10.1016/j.humpath.2010.08.006
   Kasof GM, 1999, MOL CELL BIOL, V19, P4390
   Kosinski L, 2012, CA-CANCER J CLIN, V62, P173, DOI 10.3322/caac.21138
   Kumarakulasingham M, 2005, CLIN CANCER RES, V11, P3758, DOI 10.1158/1078-0432.CCR-04-1848
   Lamy L, 2013, CANCER CELL, V23, P435, DOI 10.1016/j.ccr.2013.02.017
   Lee YY, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.76
   Liu H, 2007, MOL CELL BIOL, V27, P8480, DOI 10.1128/MCB.01126-07
   McPherson JP, 2009, CELL DEATH DIFFER, V16, P331, DOI 10.1038/cdd.2008.167
   Murray GI, 1998, GUT, V43, P791, DOI 10.1136/gut.43.6.791
   O'Dwyer D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027718
   Renert AF, 2009, J PROTEOME RES, V8, P4810, DOI 10.1021/pr9005316
   Sarras H, 2010, THESCIENTIFICWORLDJO, V10, P1450, DOI 10.1100/tsw.2010.132
   Varia S, 2013, NUCLEUS-AUSTIN, V4, P229, DOI 10.4161/nucl.25187
   Williams GT, 2007, DATASET COLORECTAL C, P1
   Yasuda H, 2009, ONCOL REP, V22, P709, DOI 10.3892/or_00000491
NR 26
TC 16
Z9 18
U1 0
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0309-0167
EI 1365-2559
J9 HISTOPATHOLOGY
JI Histopathology
PD MAR
PY 2016
VL 68
IS 4
BP 556
EP 566
DI 10.1111/his.12780
PG 11
WC Cell Biology; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Pathology
GA DD7BZ
UT WOS:000370080000011
PM 26183150
DA 2022-04-25
ER

PT J
AU Gao, TY
   Liu, XX
   He, BS
   Pan, YQ
   Wang, SK
AF Gao, Tianyi
   Liu, Xiangxiang
   He, Bangshun
   Pan, Yuqin
   Wang, Shukui
TI IGF2 loss of imprinting enhances colorectal cancer stem cells
   pluripotency by promoting tumor autophagy
SO AGING-US
LA English
DT Article
DE IGF2 LOI; CRC; CSCs pluripotency; autophagy
ID RESISTANCE
AB Cancer stem cells (CSCs) are believed to be the driving force behind the tumor growth. We performed this study to further explore the role of IGF2 epigenetic on CRC stem cells pluripotency which showed that IGF2 LOI CRC cells usually had a higher CD133 expression and sphere forming efficiency than MOI cells. IGF2 LOI CSCs were also found to have a higher level of autophagy than MOI CSCs. Moreover, IGF2/IR-A signal was determined to play a more important role in CSCs formation than IGF2/IGF1R. At last, by using miRNA-195 mimics, we fortunately found the increased IR-A expression might be due to the degradation of miRNA-195 in CRC. In conclusion, our results might reveal that IGF2 LOI could promote CRC stem cells pluripotency by promoting CSCs autophagy. For the degradation of miRNA-195, IGF2 showed a higher ability in interacting with overexpressed IR-A rather than IGF1R which would further activate CSCs autophagy. All these findings might provide a novel mechanistic insight into CRC diagnosis and therapy.
C1 [Gao, Tianyi; Wang, Shukui] Nanjing Med Univ, Nanjing Hosp 1, Dept Clin Lab, Nanjing 210006, Jiangsu, Peoples R China.
   [Liu, Xiangxiang; He, Bangshun; Pan, Yuqin; Wang, Shukui] Nanjing Med Univ, Nanjing Hosp 1, Cent Lab, Nanjing 210006, Jiangsu, Peoples R China.
   [Wang, Shukui] Nanjing Med Univ, Jiangsu Collaborat Innovat Ctr Canc Personalized, Nanjing 210006, Jiangsu, Peoples R China.
RP Wang, SK (corresponding author), Nanjing Med Univ, Nanjing Hosp 1, Dept Clin Lab, Nanjing 210006, Jiangsu, Peoples R China.; Wang, SK (corresponding author), Nanjing Med Univ, Nanjing Hosp 1, Cent Lab, Nanjing 210006, Jiangsu, Peoples R China.; Wang, SK (corresponding author), Nanjing Med Univ, Jiangsu Collaborat Innovat Ctr Canc Personalized, Nanjing 210006, Jiangsu, Peoples R China.
EM sk_wang@njmu.edu.cn
FU National Nature Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81972806, 81802093, 81903034]; Key Project
   of Science and Technology Development of Nanjing Medicine [ZDX16001];
   development of Nanjing medical science and technology foundation
   [YKK17123]
FX This project was supported by grants from The National Nature Science
   Foundation of China (No. 81972806), Key Project of Science and
   Technology Development of Nanjing Medicine (ZDX16001) to SKW; The
   National Nature Science Foundation of China (No. 81802093) to HLS; The
   National Nature Science Foundation of China (No. 81903034) and the
   development of Nanjing medical science and technology foundation to
   Tianyi Gao (no. YKK17123).
CR Agarwal V, 2015, ELIFE, V4, DOI 10.7554/eLife.05005
   Batlle E, 2017, NAT MED, V23, P1124, DOI 10.1038/nm.4409
   Brouwer-Visser J, 2015, CYTOKINE GROWTH F R, V26, P371, DOI 10.1016/j.cytogfr.2015.01.002
   Chen HY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056878
   De Martino MC, 2019, ENDOCRINE, V64, P673, DOI 10.1007/s12020-019-01869-1
   Domoto T, 2016, CANCER SCI, V107, P1363, DOI 10.1111/cas.13028
   Fiorit ME, 2017, CURR OPIN PHARMACOL, V35, P1, DOI 10.1016/j.coph.2017.04.006
   Goovaerts T, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06566-7
   Hendouei N, 2019, EUR J PHARMACOL, V856, DOI 10.1016/j.ejphar.2019.05.031
   Honma S, 2019, CANCERS, V11, DOI 10.3390/cancers11050635
   Hua H, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0754-1
   Islam SS, 2019, EBIOMEDICINE, V43, P211, DOI 10.1016/j.ebiom.2019.04.061
   Kasprzak A, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20194915
   Khandia R, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8070674
   Kolligs FT, 2016, VISC MED, V32, P158, DOI 10.1159/000446488
   Lobo NA, 2007, ANNU REV CELL DEV BI, V23, P675, DOI 10.1146/annurev.cellbio.22.010305.104154
   Malaguarnera R, 2014, FRONT ENDOCRINOL, V5, DOI 10.3389/fendo.2014.00010
   Melino G, 2019, MOL ONCOL, V13, P2033, DOI 10.1002/1878-0261.12567
   Murugan AK, 2019, SEMIN CANCER BIOL, V59, P92, DOI 10.1016/j.semcancer.2019.07.003
   Nagini S, 2019, SEMIN CANCER BIOL, V56, P25, DOI 10.1016/j.semcancer.2017.12.010
   Nazio F, 2019, CELL DEATH DIFFER, V26, P690, DOI 10.1038/s41418-019-0292-y
   Orso F, 2020, SEMIN CANCER BIOL, V60, P214, DOI 10.1016/j.semcancer.2019.07.024
   Shimizu T, 2014, CANCER RES, V74, P6531, DOI 10.1158/0008-5472.CAN-14-0914
   Sipos F, 2017, WORLD J GASTROENTERO, V23, P8109, DOI 10.3748/wjg.v23.i46.8109
   Steinbichler TB, 2018, SEMIN CANCER BIOL, V53, P156, DOI 10.1016/j.semcancer.2018.11.006
   Tang YB, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0813-4
   Vella V, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19123814
   Wang FF, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/676724
   Wang YB, 2017, EBIOMEDICINE, V17, P45, DOI 10.1016/j.ebiom.2017.02.019
   Xu WW, 2018, CANCER LETT, V425, P88, DOI 10.1016/j.canlet.2018.03.039
   Yang YX, 2016, ADV EXP MED BIOL, V937, P19, DOI 10.1007/978-3-319-42059-2_2
   Zanella ER, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.3010445
   Zhao X, 2016, ONCOTARGET, V7, P51349, DOI 10.18632/oncotarget.9784
   Ziegler AN, 2014, J BIOL CHEM, V289, P4626, DOI 10.1074/jbc.M113.537597
NR 34
TC 3
Z9 3
U1 1
U2 3
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
SN 1945-4589
J9 AGING-US
JI Aging-US
PD NOV 5
PY 2020
VL 12
IS 21
BP 21236
EP 21252
PG 17
WC Cell Biology; Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Geriatrics & Gerontology
GA OS1NY
UT WOS:000589933300003
PM 33173015
OA Green Published, Green Submitted, gold
DA 2022-04-25
ER

PT J
AU Avnet, S
   Lemma, S
   Cortini, M
   Pellegrini, P
   Perut, F
   Zini, N
   Kusuzaki, K
   Chano, T
   Grisendi, G
   Dominici, M
   De Milito, A
   Baldini, N
AF Avnet, Sofia
   Lemma, Silvia
   Cortini, Margherita
   Pellegrini, Paola
   Perut, Francesca
   Zini, Nicoletta
   Kusuzaki, Katsuyuki
   Chano, Tokuhiro
   Grisendi, Giulia
   Dominici, Massimo
   De Milito, Angelo
   Baldini, Nicola
TI Altered pH gradient at the plasma membrane of osteosarcoma cells is a
   key mechanism of drug resistance
SO ONCOTARGET
LA English
DT Article
DE osteosarcoma; doxorubicin; drug resistance; plasma membrane pH gradient;
   tumor microenvironment
ID COLON-CANCER CELLS; MULTIDRUG-RESISTANCE; THERAPEUTIC TARGET; IN-VITRO;
   METASTATIC NICHE; ACIDIC VESICLES; ACRIDINE-ORANGE; HUMAN-TUMORS;
   V-ATPASE; GLYCOPROTEIN
AB Current therapy of osteosarcoma (OS), the most common primary bone malignancy, is based on a combination of surgery and chemotherapy. Multidrug resistance mediated by P-glycoprotein (P-gp) overexpression has been previously associated with treatment failure and progression of OS, although other mechanisms may also play a role. We considered the typical acidic extracellular pH (pHe) of sarcomas, and found that doxorubicin (DXR) cytotoxicity is reduced in P-gp negative OS cells cultured at pHe 6.5 compared to standard 7.4. Short-time (24-48 hours) exposure to low pHe significantly increased the number and acidity of lysosomes, and the combination of DXR with omeprazole, a proton pump inhibitor targeting lysosomal acidity, significantly enhanced DXR cytotoxicity. In OS xenografts, the combination treatment of DXR and omeprazole significantly reduced tumor volume and body weight loss. The impaired toxicity of DXR at low pHe was not associated with increased autophagy or lysosomal acidification, but rather, as shown by SNARF staining, with a reversal of the pH gradient at the plasma membrane (Delta pH(cm)), eventually leading to a reduced DXR intracellular accumulation. Finally, the reversal of Delta pH(cm) in OS cells promoted resistance not only to DXR, but also to cisplatin and methotrexate, and, to a lesser extent, to vincristine. Altogether, our findings show that, in OS cells, short-term acidosis induces resistance to different chemotherapeutic drugs by a reversal of Delta pH(cm), suggesting that buffer therapies or regimens including proton pump inhibitors in combination to low concentrations of conventional anticancer agents may offer novel solutions to overcome drug resistance.
C1 [Avnet, Sofia; Lemma, Silvia; Cortini, Margherita; Perut, Francesca; Baldini, Nicola] Ist Ortoped Rizzoli, Orthopaed Pathophysiol & Regenerat Med Unit, Bologna, Italy.
   [Pellegrini, Paola; De Milito, Angelo] Karolinska Inst, Dept Oncol Pathol, Canc Ctr Karolinska, Stockholm, Sweden.
   [Zini, Nicoletta] CNR, Inst Mol Genet, Natl Res Council Italy, Bologna, Italy.
   [Zini, Nicoletta] Ist Ortoped Rizzoli, Lab Musculoskeletal Cell Biol, Bologna, Italy.
   [Kusuzaki, Katsuyuki] Takai Hosp, Musculoskeletal Oncol Unit, Nara, Japan.
   [Chano, Tokuhiro] Shiga Univ Med Sci, Dept Clin Lab Med, Otsu, Shiga, Japan.
   [Grisendi, Giulia; Dominici, Massimo] Univ Hosp Modena & Reggio Emilia, Dept Med & Surg Sci Children & Adults, Modena, Italy.
   [Baldini, Nicola] Univ Bologna, Dept Biomed & Neuromotor Sci, Bologna, Italy.
RP Baldini, N (corresponding author), Ist Ortoped Rizzoli, Orthopaed Pathophysiol & Regenerat Med Unit, Bologna, Italy.; Baldini, N (corresponding author), Univ Bologna, Dept Biomed & Neuromotor Sci, Bologna, Italy.
EM nicola.baldini@ior.it
RI Lemma, Silvia/AAY-3835-2020; Perut, Francesca/J-4771-2016; Lemma,
   Silvia/O-1119-2017; Avnet, Sofia/B-3220-2018; Chano,
   Tokuhiro/F-5816-2018; Baldini, Nicola/J-4806-2016; Dominici,
   Massimo/K-8014-2016; Cortini, Margherita/J-7325-2018; Zini,
   Nicoletta/C-7544-2019; Grisendi, Giulia/J-6360-2016
OI Perut, Francesca/0000-0002-3783-7803; Lemma, Silvia/0000-0003-0714-3138;
   Avnet, Sofia/0000-0002-7843-0591; Chano, Tokuhiro/0000-0002-9959-1183;
   Baldini, Nicola/0000-0003-2228-3833; Zini,
   Nicoletta/0000-0002-4442-7079; Grisendi, Giulia/0000-0002-0120-6129;
   Cortini, Margherita/0000-0002-8151-8105; Dominici,
   Massimo/0000-0002-4007-1503; De Milito, Angelo/0000-0003-2591-2914
FU Italian Association for Cancer ResearchFondazione AIRC per la ricerca
   sul cancro [11426, 15608]; Swedish Cancer SocietySwedish Cancer Society
   [CAN 2012/415]
FX Italian Association for Cancer Research (grant No. 11426 and 15608 to
   N.B.), financial support for Scientific Research "5 per 1000 2012" (to
   N.B.), and Swedish Cancer Society (grant # CAN 2012/415 to A.D.).
CR Altan N, 1998, J EXP MED, V187, P1583, DOI 10.1084/jem.187.10.1583
   Avnet S, 2013, BBA-MOL BASIS DIS, V1832, P1105, DOI 10.1016/j.bbadis.2013.04.003
   Baldini N, 1997, NAT MED, V3, P378, DOI 10.1038/nm0497-378
   BALDINI N, 1995, NEW ENGL J MED, V333, P1380, DOI 10.1056/NEJM199511233332103
   BALDINI N, 1992, J CANCER RES CLIN, V119, P121, DOI 10.1007/BF01209668
   Balgi AD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021549
   Breedveld P, 2007, MOL PHARMACOL, V71, P240, DOI 10.1124/mol.106.028167
   Castino R, 2003, J MOL RECOGNIT, V16, P337, DOI 10.1002/jmr.643
   Chou AJ, 2006, EXPERT REV ANTICANC, V6, P1075, DOI 10.1586/14737140.6.7.1075
   Daniel C, 2013, BBA-MOL BASIS DIS, V1832, P606, DOI 10.1016/j.bbadis.2013.01.020
   ENGIN K, 1995, INT J HYPERTHER, V11, P211, DOI 10.3109/02656739509022457
   Erler JT, 2009, CANCER CELL, V15, P35, DOI 10.1016/j.ccr.2008.11.012
   Ferrari S, 2004, CANCER, V100, P1936, DOI 10.1002/cncr.20151
   Ferrari S, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-268
   Fotia C, 2015, CURR PHARM DESIGN, V21, P4088, DOI 10.2174/1381612821666150918144953
   Geran R I, 1977, Natl Cancer Inst Monogr, P151
   GILLIES RJ, 1979, J CELL PHYSIOL, V100, P23, DOI 10.1002/jcp.1041000103
   GRIFFITHS JR, 1991, BRIT J CANCER, V64, P425, DOI 10.1038/bjc.1991.326
   Huang J, 2012, CANCER RES, V72, P230, DOI 10.1158/0008-5472.CAN-11-2001
   JULIANO RL, 1976, BIOCHIM BIOPHYS ACTA, V455, P152, DOI 10.1016/0005-2736(76)90160-7
   Kaplan RN, 2005, NATURE, V438, P820, DOI 10.1038/nature04186
   KEIZER HG, 1989, J NATL CANCER I, V81, P706, DOI 10.1093/jnci/81.9.706
   Klionsky DJ, 2012, AUTOPHAGY, V8, P445, DOI 10.4161/auto.19496
   Lloyd MC, 2016, CANCER RES, V76, P3136, DOI 10.1158/0008-5472.CAN-15-2962
   Luetke A, 2014, CANCER TREAT REV, V40, P523, DOI 10.1016/j.ctrv.2013.11.006
   Mahoney BP, 2003, BIOCHEM PHARMACOL, V66, P1207, DOI 10.1016/S0006-2952(03)00467-2
   Gomes CMF, 2006, NUCL MED BIOL, V33, P831, DOI 10.1016/j.nucmedbio.2006.07.011
   Marino ML, 2012, J BIOL CHEM, V287, P30664, DOI 10.1074/jbc.M112.339127
   MICKISCH GH, 1992, CANCER RES, V52, P4427
   Millot C, 1997, J HISTOCHEM CYTOCHEM, V45, P1255, DOI 10.1177/002215549704500909
   Mimeault M, 2013, J CELL MOL MED, V17, P30, DOI 10.1111/jcmm.12004
   Mizobuchi H, 2008, CLIN ORTHOP RELAT R, V466, P2052, DOI 10.1007/s11999-008-0328-y
   Mohyeldin A, 2010, CELL STEM CELL, V7, P150, DOI 10.1016/j.stem.2010.07.007
   MORIYAMA Y, 1993, BIOCHEM BIOPH RES CO, V196, P699, DOI 10.1006/bbrc.1993.2306
   Peppicelli Silvia, 2015, Oncoscience, V2, P225
   Perut F, 2014, EXP CELL RES, V320, P21, DOI 10.1016/j.yexcr.2013.10.011
   Raghunand N, 1999, BRIT J CANCER, V80, P1005, DOI 10.1038/sj.bjc.6690455
   Raghunand N, 1999, BIOCHEM PHARMACOL, V57, P1047, DOI 10.1016/S0006-2952(99)00021-0
   Rankin Erinn B, 2011, Curr Osteoporos Rep, V9, P46, DOI 10.1007/s11914-011-0047-2
   Rauch C, 2007, EUR BIOPHYS J BIOPHY, V36, P121, DOI 10.1007/s00249-006-0113-3
   Roepe PD, 2000, CURR PHARM DESIGN, V6, P241, DOI 10.2174/1381612003401163
   ROEPE PD, 1993, BIOCHEMISTRY-US, V32, P11042, DOI 10.1021/bi00092a014
   Salerno M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110340
   Santamaria-Martinez A, 2013, J INTERN MED, V274, P127, DOI 10.1111/joim.12024
   Scotlandi K, 1996, CANCER RES, V56, P4570
   Selvendiran K, 2009, INT J CANCER, V125, P2198, DOI 10.1002/ijc.24601
   Serra M, 1995, EUR J CANCER, V31A, P1998, DOI 10.1016/0959-8049(95)00335-5
   Simon SM, 1999, DRUG DISCOV TODAY, V4, P32, DOI 10.1016/S1359-6446(98)01276-8
   Song B, 2009, ONCOGENE, V28, P4065, DOI 10.1038/onc.2009.274
   Song B, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-96
   TANNOCK IF, 1989, CANCER RES, V49, P4373
   TEWEY KM, 1984, SCIENCE, V226, P466, DOI 10.1126/science.6093249
   VALVERDE MA, 1992, NATURE, V355, P830, DOI 10.1038/355830a0
   VAUPEL P, 1989, CANCER RES, V49, P6449
   WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309
   Wojtkowiak JW, 2011, MOL PHARMACEUT, V8, P2032, DOI 10.1021/mp200292c
   Wong CCL, 2011, P NATL ACAD SCI USA, V108, P16369, DOI 10.1073/pnas.1113483108
   Wouters A, 2007, ONCOLOGIST, V12, P690, DOI 10.1634/theoncologist.12-6-690
   Yang QC, 2007, JPN J CLIN ONCOL, V37, P127, DOI 10.1093/jjco/hyl137
   Yang TT, 1996, ANAL BIOCHEM, V241, P103, DOI 10.1006/abio.1996.0383
   Yang YK, 2012, AM J MED SCI, V344, P199, DOI 10.1097/MAJ.0b013e31823e62e5
   Zhao Y, 2009, BIOCHEM BIOPH RES CO, V390, P642, DOI 10.1016/j.bbrc.2009.10.020
NR 62
TC 62
Z9 63
U1 0
U2 15
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD SEP 27
PY 2016
VL 7
IS 39
BP 63408
EP 63423
DI 10.18632/oncotarget.11503
PG 16
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA EB2DN
UT WOS:000387167800046
PM 27566564
OA Green Submitted, gold, Green Published
DA 2022-04-25
ER

PT J
AU Knoll, G
   Bittner, S
   Kurz, M
   Jantsch, J
   Ehrenschwender, M
AF Knoll, Gertrud
   Bittner, Sebastian
   Kurz, Maria
   Jantsch, Jonathan
   Ehrenschwender, Martin
TI Hypoxia regulates TRAIL sensitivity of colorectal cancer cells through
   mitochondrial autophagy
SO ONCOTARGET
LA English
DT Article
DE TRAIL; SMAC mimetic; death receptor; hypoxia
ID ENDOPLASMIC-RETICULUM; INHIBITS APOPTOSIS; MEDIATED APOPTOSIS;
   CALCIUM-RELEASE; XIAP; NECROSIS; ACTIVATION; PROTEINS; BAX; MODULATION
AB The capacity of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) to selectively induce cell death in malignant cells triggered numerous attempts for therapeutic exploitation. In clinical trials, however, TRAIL did not live up to the expectations, as tumors exhibit high rates of TRAIL resistance in vivo. Response to anti-cancer therapy is determined not only by cancer cell intrinsic factors (e.g. oncogenic mutations), but also modulated by extrinsic factors such as the hypoxic tumor microenvironment. Here, we address the effect of hypoxia on pro-apoptotic TRAIL signaling in colorectal cancer cells. We show that oxygen levels modulate susceptibility to TRAIL-induced cell death, which is severely impaired under hypoxia (0.5% O-2). Mechanistically, this is attributable to hypoxia-induced mitochondrial autophagy. Loss of mitochondria under hypoxia restricts the availability of mitochondria-derived pro-apoptotic molecules such as second mitochondria-derived activator of caspase ( SMAC), thereby disrupting amplification of the apoptotic signal emanating from the TRAIL death receptors and efficiently blocking cell death in type-II cells. Moreover, we identify strategies to overcome TRAIL resistance in low oxygen environments. Counteracting hypoxia-induced loss of endogenous SMAC by exogenous substitution of SMAC mimetics fully restores TRAIL sensitivity in colorectal cancer cells. Alternatively, enforcing a mitochondria-independent type-I mode of cell death by targeting the type-II phenotype gatekeeper X-linked inhibitor of apoptosis protein ( XIAP) is equally effective. Together, our results indicate that tumor hypoxia impairs TRAIL efficacy but this limitation can be overcome by combining TRAIL with SMAC mimetics or XIAPtargeting drugs. Our findings may help to exploit the potential of TRAIL in cancer therapy.
C1 [Knoll, Gertrud; Bittner, Sebastian; Kurz, Maria; Jantsch, Jonathan; Ehrenschwender, Martin] Univ Hosp Regensburg, Inst Clin Microbiol & Hyg, D-93053 Regensburg, Germany.
RP Ehrenschwender, M (corresponding author), Univ Hosp Regensburg, Inst Clin Microbiol & Hyg, D-93053 Regensburg, Germany.
EM martin.ehrenschwender@ukr.de
FU Deutsche ForschungsgemeinschaftGerman Research Foundation (DFG) [EH
   465/2-1, JA1993/2-1]; Roggenbuck Stiftung; Walter-Schulz-Stiftung;
   Medical Faculty of the University of Regensburg (ReForM-B)
FX ME and JJ are supported by grants from Deutsche Forschungsgemeinschaft
   (EH 465/2-1 and JA1993/2-1). ME is supported by grants from the
   Roggenbuck Stiftung, the Walter-Schulz-Stiftung and the Medical Faculty
   of the University of Regensburg (ReForM-B).
CR Azijli K, 2013, CELL DEATH DIFFER, V20, P858, DOI 10.1038/cdd.2013.28
   Baba Y, 2010, AM J PATHOL, V176, P2292, DOI 10.2353/ajpath.2010.090972
   Bittner S, 2016, FEBS J, V283, P323, DOI 10.1111/febs.13576
   Brint E, 2013, CELL MOL LIFE SCI, V70, P4085, DOI 10.1007/s00018-013-1327-z
   Carreau A, 2011, J CELL MOL MED, V15, P1239, DOI 10.1111/j.1582-4934.2011.01258.x
   Cummins JM, 2004, CANCER RES, V64, P3006, DOI 10.1158/0008-5472.CAN-04-0046
   Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239
   Eckelman BP, 2006, EMBO REP, V7, P988, DOI 10.1038/sj.embor.7400795
   Ehrenschwender M, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.534
   Ehrenschwender M, 2010, CELL DEATH DIFFER, V17, P1435, DOI 10.1038/cdd.2010.36
   Ellinghaus P, 2013, CANCER MED-US, V2, P611, DOI 10.1002/cam4.112
   Fulda S, 2014, CLIN CANCER RES, V20, P289, DOI 10.1158/1078-0432.CCR-13-0227
   Gillissen B, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.67
   Han J, 2008, J BIOL CHEM, V283, P19665, DOI 10.1074/jbc.M710169200
   Han SH, 2008, BIOCHEM BIOPH RES CO, V375, P684, DOI 10.1016/j.bbrc.2008.08.091
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Hao ZY, 2010, J MOL CELL BIOL, V2, P63, DOI 10.1093/jmcb/mjp034
   Hatfield SM, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa1260
   Hatfield SM, 2014, J MOL MED, V92, P1283, DOI 10.1007/s00109-014-1189-3
   Hou W, 2008, AUTOPHAGY, V4, P940, DOI 10.4161/auto.6769
   Jost PJ, 2009, NATURE, V460, P1035, DOI 10.1038/nature08229
   Jouan-Lanhouet S, 2012, CELL DEATH DIFFER, V19, P2003, DOI 10.1038/cdd.2012.90
   Kim M, 2004, CANCER RES, V64, P4078, DOI 10.1158/0008-5472.CAN-04-0284
   Kim SW, 2016, MOL MED REP, V13, P805, DOI 10.3892/mmr.2015.4592
   Lee TJ, 2006, MOL CANCER THER, V5, P2737, DOI 10.1158/1535-7163.MCT-06-0426
   Lemke J, 2014, CELL DEATH DIFFER, V21, P1350, DOI 10.1038/cdd.2014.81
   Liu L, 2012, NAT CELL BIOL, V14, P177, DOI 10.1038/ncb2422
   Mayes PA, 2005, CANCER BIOL THER, V4, P1068, DOI 10.4161/cbt.4.10.2255
   Nagaraju GP, 2015, CANCER LETT, V366, P11, DOI 10.1016/j.canlet.2015.06.005
   Nijkamp MW, 2010, J HEPATOL, V53, P1069, DOI 10.1016/j.jhep.2010.04.040
   Orrenius S, 2015, BIOCHEM BIOPH RES CO, V460, P72, DOI 10.1016/j.bbrc.2015.01.137
   Park JY, 2015, ONCOTARGET, V6, P5342, DOI 10.18632/oncotarget.3028
   Samuels Y, 2005, CANCER CELL, V7, P561, DOI 10.1016/j.ccr.2005.05.014
   Schneider B, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.45
   Schneider-Brachert W, 2013, INT J MOL SCI, V14, P14475, DOI 10.3390/ijms140714475
   Schug ZT, 2011, CELL DEATH DIFFER, V18, P538, DOI 10.1038/cdd.2010.135
   Semenza GL, 2013, J CLIN INVEST, V123, P3664, DOI 10.1172/JCI67230
   Suzuki Y, 2001, MOL CELL, V8, P613, DOI 10.1016/S1097-2765(01)00341-0
   Urresti J, 2016, J BIOL CHEM, V291, P1221, DOI 10.1074/jbc.M115.677682
   Vanden Berghe T, 2014, NAT REV MOL CELL BIO, V15, P134, DOI 10.1038/nrm3737
   Varfolomeev E, 2007, CELL, V131, P669, DOI 10.1016/j.cell.2007.10.030
   Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517
   Weinmann M, 2004, INT J RADIAT ONCOL, V58, P386, DOI 10.1016/j.ijrobp.2003.09.052
   Westphal D, 2014, CELL DEATH DIFFER, V21, P196, DOI 10.1038/cdd.2013.139
   Wong PP, 2015, CANCER CELL, V27, P123, DOI 10.1016/j.ccell.2014.10.015
   Wozniak AL, 2006, J CELL BIOL, V175, P709, DOI 10.1083/jcb.200608035
   Zhang HF, 2008, J BIOL CHEM, V283, P10892, DOI 10.1074/jbc.M800102200
   Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989
NR 48
TC 15
Z9 17
U1 0
U2 3
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD JUL 5
PY 2016
VL 7
IS 27
BP 41488
EP 41504
DI 10.18632/oncotarget.9206
PG 17
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA DS7DI
UT WOS:000380942600044
PM 27166192
OA Green Submitted, Green Published, gold
DA 2022-04-25
ER

PT J
AU Jin, P
   Jiang, JW
   Xie, N
   Zhou, L
   Huang, Z
   Zhang, L
   Qin, SY
   Fu, SY
   Peng, LY
   Gao, W
   Li, BW
   Lei, YL
   Nice, EC
   Li, CL
   Shao, JC
   Xie, K
AF Jin, Ping
   Jiang, Jingwen
   Xie, Na
   Zhou, Li
   Huang, Zhao
   Zhang, Lu
   Qin, Siyuan
   Fu, Shuyue
   Peng, Liyuan
   Gao, Wei
   Li, Bowen
   Lei, Yunlong
   Nice, Edouard C.
   Li, Changlong
   Shao, Jichun
   Xie, Ke
TI MCT1 relieves osimertinib-induced CRC suppression by promoting autophagy
   through the LKB1/AMPK signaling
SO CELL DEATH & DISEASE
LA English
DT Article
ID MONOCARBOXYLATE TRANSPORTER 1; TYROSINE KINASE INHIBITORS;
   ACQUIRED-RESISTANCE; CANCER-CELLS; EGFR; AZD9291; APOPTOSIS; TUMOR;
   MECHANISMS; PATHWAY
AB Colorectal cancer (CRC) is one of the most frequently diagnosed cancers worldwide. Development of novel chemotherapeutics is still required to enable successful treatment and improve survival for CRC patients. Here, we found that osimertinib (OSI) exhibits potent anti-CRC effects by inducing apoptosis, independent of its selective inhibitory activity targeting the EGFR T790M mutation. Intriguingly, OSI treatment triggers autophagic flux in CRC cells. Inhibition of autophagy markedly augments OSI-induced apoptosis and growth inhibition in CRC cells, suggesting a protective role of autophagy in response to OSI treatment. Mechanistically, OSI upregulates the expression of monocarboxylate transporter 1 (MCT1) and subsequently activates LKB1/AMPK signaling, leading to autophagy induction in CRC cells. Notably, OSI significantly exaggerates the sensitivity of CRC cells to the first-line drugs 5-fluorouracil or oxaliplatin. Taken together, our study unravels a novel mechanism of OSI-mediated protective autophagy involving MCT1/LKB1/AMPK signaling, and suggests the use of OSI as a potential agent for clinical CRC treatment.
C1 [Jin, Ping; Jiang, Jingwen; Xie, Na; Zhou, Li; Huang, Zhao; Zhang, Lu; Qin, Siyuan; Fu, Shuyue; Peng, Liyuan; Gao, Wei; Li, Bowen] Sichuan Univ, West China Hosp, State Key Lab Biotherapy, Chengdu 610041, Sichuan, Peoples R China.
   [Jin, Ping; Jiang, Jingwen; Xie, Na; Zhou, Li; Huang, Zhao; Zhang, Lu; Qin, Siyuan; Fu, Shuyue; Peng, Liyuan; Gao, Wei; Li, Bowen] Sichuan Univ, West China Hosp, Canc Ctr, Chengdu 610041, Sichuan, Peoples R China.
   [Jin, Ping; Jiang, Jingwen; Xie, Na; Zhou, Li; Huang, Zhao; Zhang, Lu; Qin, Siyuan; Fu, Shuyue; Peng, Liyuan; Gao, Wei; Li, Bowen; Li, Changlong] Sichuan Univ, West China Sch Basic Med Sci & Forens Med, Chengdu 610041, Sichuan, Peoples R China.
   [Jin, Ping; Jiang, Jingwen; Xie, Na; Zhou, Li; Huang, Zhao; Zhang, Lu; Qin, Siyuan; Fu, Shuyue; Peng, Liyuan; Gao, Wei; Li, Bowen] Collaborat Innovat Ctr Biotherapy, Chengdu 610041, Sichuan, Peoples R China.
   [Lei, Yunlong] Chongqing Med Univ, Mol Med & Canc Res Ctr, Dept Biochem & Mol Biol, Chongqing 400016, Peoples R China.
   [Nice, Edouard C.] Monash Univ, Dept Biochem & Mol Biol, Clayton, Vic 3800, Australia.
   [Shao, Jichun] China Natl Nucl Corp 416 Hosp, Chengdu Med Coll, Affiliated Hosp 2, Dept Urol, Chengdu, Sichuan, Peoples R China.
   [Xie, Ke] Univ Elect Sci & Technol China, Sichuan Acad Med Sci, Dept Oncol, Chengdu 610054, Sichuan, Peoples R China.
   [Xie, Ke] Univ Elect Sci & Technol China, Sch Med, Sichuan Prov Peoples Hosp, Chengdu 610054, Sichuan, Peoples R China.
RP Shao, JC (corresponding author), China Natl Nucl Corp 416 Hosp, Chengdu Med Coll, Affiliated Hosp 2, Dept Urol, Chengdu, Sichuan, Peoples R China.; Xie, K (corresponding author), Univ Elect Sci & Technol China, Sichuan Acad Med Sci, Dept Oncol, Chengdu 610054, Sichuan, Peoples R China.; Xie, K (corresponding author), Univ Elect Sci & Technol China, Sch Med, Sichuan Prov Peoples Hosp, Chengdu 610054, Sichuan, Peoples R China.
EM shaoji93@163.com; xieke@med.uestc.edu.cn
RI Jiang, Jing wen/AAP-5996-2021
OI Lei, Yunlong/0000-0002-7918-0221; Li, Bowen/0000-0001-8475-4800; Huang,
   Zhao/0000-0001-9994-2070; Zhang, Lu/0000-0002-8325-2793
FU Chinese NSFCNational Natural Science Foundation of China (NSFC)
   [81672867, 81430071, 81790251]; Sichuan Provincial Health and Family
   Planning [18PJ199]; Cadre Health Research Project of Sichuan Province
   [2019-235]; Science & Technology Department of Sichuan Province Applied
   Basic Research Program [2018JYKJ0368]; National 973 Basic Research
   Program of ChinaNational Basic Research Program of China [2013CB911300];
   Sichuan Science and Technology Program [2018RZ0133]
FX This work was supported by the Chinese NSFC (81672867, 81430071,
   81790251), Project from Sichuan Provincial Health and Family Planning
   (18PJ199), Cadre Health Research Project of Sichuan Province (2019-235),
   Science & Technology Department of Sichuan Province Applied Basic
   Research Program (2018JYKJ0368), National 973 Basic Research Program of
   China (2013CB911300), and Sichuan Science and Technology Program
   (2018RZ0133).
CR Amorim R, 2015, CANCER LETT, V365, P68, DOI 10.1016/j.canlet.2015.05.015
   [Anonymous], 2014, Cancer Discov, V4, pOF10, DOI 10.1158/2159-8290.CD-NB2014-077
   [Anonymous], 2019, KEY STAT COLORECTAL
   Chung SJ, 2017, AUTOPHAGY, V13, P1386, DOI 10.1080/15548627.2017.1332565
   Cross DAE, 2014, CANCER DISCOV, V4, P1046, DOI 10.1158/2159-8290.CD-14-0337
   Cuff M, 2005, GASTROENTEROLOGY, V128, P676, DOI 10.1053/j.gastro.2004.12.003
   Dobrenel T, 2016, ANNU REV PLANT BIOL, V67, P261, DOI 10.1146/annurev-arplant-043014-114648
   Eberlein CA, 2015, CANCER RES, V75, P2489, DOI 10.1158/0008-5472.CAN-14-3167
   Fan Q, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0673-y
   Ghobrial IM, 2005, CA-CANCER J CLIN, V55, P178, DOI 10.3322/canjclin.55.3.178
   Green DR, 2014, CELL, V157, P65, DOI 10.1016/j.cell.2014.02.049
   Guo LC, 2017, ONCOTARGETS THER, V10, P5281, DOI 10.2147/OTT.S139382
   He LF, 2018, EXP MOL MED, V50, DOI 10.1038/s12276-018-0128-8
   Hirano T, 2015, ONCOTARGET, V6, P38789, DOI 10.18632/oncotarget.5887
   Jeong SJ, 2019, ANTIOXID REDOX SIGN, V31, P458, DOI 10.1089/ars.2018.7649
   Kim J, 2013, CELL, V152, P290, DOI 10.1016/j.cell.2012.12.016
   Klionsky DJ, 2016, AUTOPHAGY, V12, P1, DOI 10.1080/15548627.2015.1100356
   Kohli L, 2013, CANCER RES, V73, P4395, DOI 10.1158/0008-5472.CAN-12-3765
   Markman B, 2010, ADV CLIN CHEM, V51, P71, DOI 10.1016/S0065-2423(10)51004-7
   Martins SF, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2566-9
   Miranda-Goncalves V, 2017, MOL CARCINOGEN, V56, P2630, DOI 10.1002/mc.22707
   Moutinho C, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/djt322
   Mullard A, 2016, NAT REV DRUG DISCOV, V15, P147, DOI 10.1038/nrd.2016.23
   Onorati AV, 2018, CANCER-AM CANCER SOC, V124, P3307, DOI 10.1002/cncr.31335
   Pinheiro C, 2009, EUR J CANCER, V45, P2418, DOI 10.1016/j.ejca.2009.06.018
   Planchard D, 2015, ANN ONCOL, V26, P2073, DOI 10.1093/annonc/mdv319
   Polanski R, 2014, CLIN CANCER RES, V20, P926, DOI 10.1158/1078-0432.CCR-13-2270
   Politi K, 2015, CANCER CELL, V27, P751, DOI 10.1016/j.ccell.2015.05.012
   Poultsides GA, 2009, J CLIN ONCOL, V27, P3379, DOI 10.1200/JCO.2008.20.9817
   Qian HR, 2017, ONCOTARGET, V8, P62759, DOI 10.18632/oncotarget.18663
   Raices M, 2012, NAT REV MOL CELL BIO, V13, P687, DOI 10.1038/nrm3461
   Rodon J, 2013, NAT REV CLIN ONCOL, V10, P143, DOI 10.1038/nrclinonc.2013.10
   Semenza GL, 2008, J CLIN INVEST, V118, P3835, DOI 10.1172/JCI37373
   Sonveaux P, 2008, J CLIN INVEST, V118, P3930, DOI 10.1172/JCI36843
   Sui X, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.350
   Tajima A, 2004, GASTROENTEROLOGY, V127, P1678, DOI 10.1053/j.gastro.2004.10.001
   Tang ZH, 2018, ANTI-CANCER AGENT ME, V18, P550, DOI 10.2174/1871520617666170719155517
   Tang ZH, 2018, CANCER LETT, V420, P242, DOI 10.1016/j.canlet.2018.02.004
   Toh PPC, 2013, HUM MOL GENET, V22, P5237, DOI 10.1093/hmg/ddt381
   van Gijn W, 2011, LANCET ONCOL, V12, P575, DOI 10.1016/S1470-2045(11)70097-3
   Wang K, 2018, AUTOPHAGY, V14, P269, DOI 10.1080/15548627.2017.1409405
   Wang L, 2015, PHYTOMEDICINE, V22, P1079, DOI 10.1016/j.phymed.2015.08.009
   Wu SH, 2018, RADIAT RES, V189, P283, DOI 10.1667/RR14682.1
   Yang QH, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07132-x
   Yeon M, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00599
   Yoshida GJ, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0835-y
   Yoshida GJ, 2017, J HEMATOL ONCOL, V10, DOI 10.1186/s13045-017-0436-9
   Yoshida GJ, 2015, J EXP CLIN CANC RES, V34, DOI 10.1186/s13046-015-0221-y
   Zeng J, 2018, THERANOSTICS, V8, P109, DOI 10.7150/thno.20356
   Zhang ZR, 2019, J CELL BIOCHEM, V120, P756, DOI 10.1002/jcb.27434
   Zois CE, 2011, AUTOPHAGY, V7, P1371, DOI 10.4161/auto.7.11.16664
NR 51
TC 18
Z9 19
U1 4
U2 12
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-4889
J9 CELL DEATH DIS
JI Cell Death Dis.
PD AUG 13
PY 2019
VL 10
AR 615
DI 10.1038/s41419-019-1844-2
PG 15
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA IS2DD
UT WOS:000481962300001
PM 31409796
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Li, CH
   Li, JW
   Li, Y
   Li, L
   Luo, YL
   Li, JJ
   Zhang, YM
   Wang, YR
   Liu, XZ
   Zhou, XT
   Gong, HX
   Jin, XJ
   Liu, YQ
AF Li, Chenghao
   Li, Jiawei
   Li, Yan
   Li, Ling
   Luo, Yali
   Li, Junjie
   Zhang, Yiming
   Wang, Yanru
   Liu, Xiuzhu
   Zhou, Xiaotian
   Gong, Hongxia
   Jin, Xiaojie
   Liu, Yongqi
TI Isorhamnetin Promotes MKN-45 Gastric Cancer Cell Apoptosis by Inhibiting
   PI3K-Mediated Adaptive Autophagy in a Hypoxic Environment
SO JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY
LA English
DT Article
DE isorhamnetin; apoptosis; autophagy; PI3K; gastric cancer
ID COLORECTAL-CANCER; TUMOR; WORTMANNIN
AB A tumor-related hypoxic microenvironment can promote the proliferation of gastric cancer cells, and hypoxic-induced autophagy is the main mechanism of protection against hypoxia in gastric cancer cells. Isorhamnetin (ISO) is a chemical substance derived from plants, mainly from the sea buckthorn. Previous studies have shown that ISO has antitumor effects, but the effects of ISO against gastric cancer in a hypoxic environment are still unknown. In this study, we investigated the effects of ISO against gastric cancer in a hypoxic environment and the mechanisms underlying ISO-induced gastric cancer cell death. The results show that ISO targeted PI3K and blocked the PI3K-AKT-mTOR signaling pathway, significantly inhibiting gastric cancer cell autophagy in a hypoxic environment, inhibiting cell proliferation, decreasing mitochondrial membrane potential, and promoting mitochondria-mediated apoptosis. ISO, a functional food component, is a promising candidate for the treatment of gastric cancer.
C1 [Li, Chenghao; Li, Jiawei; Li, Yan; Li, Ling; Luo, Yali; Li, Junjie; Zhang, Yiming; Wang, Yanru; Liu, Xiuzhu; Zhou, Xiaotian; Gong, Hongxia; Jin, Xiaojie; Liu, Yongqi] Gansu Univ Chinese Med, Gansu Univ Key Lab Mol Med & Chinese Med Prevent, Lanzhou 730000, Gansu, Peoples R China.
   [Liu, Yongqi] Minist Educ, Key Lab Dun Huang Med & Transformat, Lanzhou 730000, Gansu, Peoples R China.
   [Jin, Xiaojie] Gansu Univ Chinese Med, Coll Pharm, Lanzhou 730000, Peoples R China.
RP Jin, XJ; Liu, YQ (corresponding author), Gansu Univ Chinese Med, Gansu Univ Key Lab Mol Med & Chinese Med Prevent, Lanzhou 730000, Gansu, Peoples R China.; Liu, YQ (corresponding author), Minist Educ, Key Lab Dun Huang Med & Transformat, Lanzhou 730000, Gansu, Peoples R China.; Jin, XJ (corresponding author), Gansu Univ Chinese Med, Coll Pharm, Lanzhou 730000, Peoples R China.
EM jinlovedream@163.com; liuyongqi73@163.com
OI Li, Chenghao/0000-0002-8680-1655
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81960869]; Provincial University Industry
   Support Project in Gansu [2020C-15]; Provincial Key Talent Project
   [GZT2020-9-1]; Basic Research Innovation Group in Gansu [20JR10RA332]
FX This study was supported by the National Natural Science Foundation of
   China (No.81960869), Provincial University Industry Support Project in
   Gansu (2020C-15), and Provincial Key Talent Project (GZT2020-9-1). Basic
   Research Innovation Group in Gansu (20JR10RA332).
CR ABBAS HK, 1988, APPL ENVIRON MICROB, V54, P1268, DOI 10.1128/AEM.54.5.1268-1274.1988
   ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297
   Beveridge T, 1999, J AGR FOOD CHEM, V47, P3480, DOI 10.1021/jf981331m
   Brahimi-Horn MC, 2007, J MOL MED-JMM, V85, P1301, DOI 10.1007/s00109-007-0281-3
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
   Buyel JF, 2018, BIOTECHNOL ADV, V36, P506, DOI 10.1016/j.biotechadv.2018.02.002
   Chipurupalli S, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20030749
   Chiu DKC, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00530-7
   Deng S, 2019, CANCER-AM CANCER SOC, V125, P1228, DOI 10.1002/cncr.31978
   Dong Y, 2019, EUR REV MED PHARMACO, V23, P1047, DOI 10.26355/eurrev_201902_16992
   du Toit A, 2018, AUTOPHAGY, V14, P1060, DOI 10.1080/15548627.2018.1469590
   Folkerts H, 2019, MED RES REV, V39, P517, DOI 10.1002/med.21531
   Gao K, 2019, CANCER COMMUN, V39, DOI 10.1186/s40880-019-0372-x
   Gewirtz DA, 2020, BIOLOGY-BASEL, V9, DOI 10.3390/biology9010012
   Gilkes DM, 2014, NAT REV CANCER, V14, P430, DOI 10.1038/nrc3726
   Hao WJ, 2019, FOOD FUNCT, V10, P5669, DOI 10.1039/c9fo01232j
   Hartgrink HH, 2009, LANCET, V374, P477, DOI 10.1016/S0140-6736(09)60617-6
   Huang YF, 2020, PHARMACOL RES, V158, DOI 10.1016/j.phrs.2020.104939
   Jamali-Raeufy N, 2019, J CHEM NEUROANAT, V102, DOI 10.1016/j.jchemneu.2019.101709
   Jeong SY, 2008, BMB REP, V41, P11, DOI 10.1146/annurev-genet-102108-134850
   Jiang XJ, 2004, ANNU REV BIOCHEM, V73, P87, DOI 10.1146/annurev.biochem.73.011303.073706
   Jing XM, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1089-9
   Kalpage HA, 2019, FASEB J, V33, P1540, DOI 10.1096/fj.201801417R
   Kawamata T, 2008, MOL BIOL CELL, V19, P2039, DOI 10.1091/mbc.E07-10-1048
   Klionsky DJ, 2012, AUTOPHAGY, V8, P445, DOI 10.4161/auto.19496
   Kroemer G, 2010, MOL CELL, V40, P280, DOI 10.1016/j.molcel.2010.09.023
   Levy JMM, 2017, NAT REV CANCER, V17, P528, DOI 10.1038/nrc.2017.53
   Li Y, 2020, J ONCOL, V2020, DOI 10.1155/2020/1723791
   Li Y, 2019, J PHARM ANAL, V9, P392, DOI 10.1016/j.jpha.2019.06.002
   Liu PF, 2009, PLANT FOOD HUM NUTR, V64, P141, DOI 10.1007/s11130-009-0116-1
   Liu Y, 2015, J HEPATOL, V63, P114, DOI 10.1016/j.jhep.2015.02.009
   Lopez J, 2015, BRIT J CANCER, V112, P957, DOI 10.1038/bjc.2015.85
   Manu KA, 2015, CANCER LETT, V363, P28, DOI 10.1016/j.canlet.2015.03.033
   Moustapha A, 2015, CELL DEATH DISCOV, V1, DOI 10.1038/cddiscovery.2015.17
   Munoz-Sanchez J, 2019, J APPL TOXICOL, V39, P556, DOI 10.1002/jat.3749
   Nath S, 2016, PHARMACOL THERAPEUT, V163, P94, DOI 10.1016/j.pharmthera.2016.03.013
   Rahim SAA, 2017, BRIT J CANCER, V117, P813, DOI 10.1038/bjc.2017.263
   Riera-Domingo C, 2020, PHYSIOL REV, V100, P1, DOI 10.1152/physrev.00018.2019
   Semba S, 2002, CLIN CANCER RES, V8, P1957
   Skalski B, 2019, FOOD CHEM TOXICOL, V125, P614, DOI 10.1016/j.fct.2019.02.014
   Smyth EC, 2020, LANCET, V396, P635, DOI 10.1016/S0140-6736(20)31288-5
   Suryakumar G, 2011, J ETHNOPHARMACOL, V138, P268, DOI 10.1016/j.jep.2011.09.024
   Thrift AP, 2020, CLIN GASTROENTEROL H, V18, P534, DOI 10.1016/j.cgh.2019.07.045
   Venerito M, 2019, HELICOBACTER, V24, DOI 10.1111/hel.12643
   Wang FH, 2019, CANCER COMMUN, V39, DOI 10.1186/s40880-019-0349-9
   Wang JL, 2018, BIOMED PHARMACOTHER, V108, P925, DOI 10.1016/j.biopha.2018.09.105
   Wang K, 2020, ONCOL REP, V43, P1103, DOI 10.3892/or.2020.7490
   Wang K, 2020, FRONT CELL DEV BIOL, V7, DOI 10.3389/fcell.2019.00397
   Wang RX, 2019, ANN TRANSL MED, V7, DOI 10.21037/atm.2019.11.39
   Xie ZP, 2007, NAT CELL BIOL, V9, P1102, DOI 10.1038/ncb1007-1102
   Xu ZR, 2020, APPL MICROBIOL BIOT, V104, P575, DOI 10.1007/s00253-019-10257-8
   Zhang Qi, 2020, J Med Virol, V92, P540, DOI 10.1002/jmv.25733
   Zhang RJ, 2020, J AGR FOOD CHEM, V68, P1326, DOI 10.1021/acs.jafc.9b07908
   Zhang X, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0993-y
   Zheng YJ, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00349
NR 55
TC 0
Z9 0
U1 9
U2 14
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0021-8561
EI 1520-5118
J9 J AGR FOOD CHEM
JI J. Agric. Food Chem.
PD JUL 28
PY 2021
VL 69
IS 29
BP 8130
EP 8143
DI 10.1021/acs.jafc.1c02620
EA JUL 2021
PG 14
WC Agriculture, Multidisciplinary; Chemistry, Applied; Food Science &
   Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Agriculture; Chemistry; Food Science & Technology
GA TS8TG
UT WOS:000679919400007
PM 34269571
DA 2022-04-25
ER

PT J
AU Tsai, CY
   Lin, TA
   Huang, SC
   Hsu, JT
   Yeh, CN
   Chen, TC
   Chiu, CT
   Chen, JS
   Yeh, TS
AF Tsai, Chun-Yi
   Lin, Tien-An
   Huang, Shih-Chiang
   Hsu, Jun-Te
   Yeh, Chun-Nan
   Chen, Tse-Ching
   Chiu, Cheng-Tang
   Chen, Jen-Shi
   Yeh, Ta-Sen
TI Is Adjuvant Chemotherapy Necessary for Patients with Deficient Mismatch
   Repair Gastric Cancer?-Autophagy Inhibition Matches the Mismatched
SO ONCOLOGIST
LA English
DT Article
DE Microsatellite instability; Mismatch repair; Gastric cancer; Autophagy
ID TUMOR-INFILTRATING LYMPHOCYTES; MICROSATELLITE-INSTABILITY; STAGE-II;
   PROGNOSTIC IMPLICATIONS; T-CELLS; SURVIVAL; 5-FLUOROURACIL; EFFICACY;
   DENSITY; BENEFIT
AB Purpose The use of microsatellite instability (MSI) and mismatch repair (MMR) as predictive biomarkers for fluorouracil-based adjuvant chemotherapy in colorectal cancer has been a paradigm shift. However, whether this applies to gastric cancer is questionable. Furthermore, we herein investigated whether and how autophagy plays a role in MSI-relevant chemoresistance.
   Materials and Methods A total of 929 patients with deficient MMR (dMMR) and proficient MMR (pMMR) gastric cancers who underwent curative-intent gastrectomy were enrolled. We compared clinicopathological variables and survival among dMMR and pMMR cohorts and tested the responses of MSI-high and microsatellite stable (MSS) gastric cancer cell lines to 5-fluorouracil (5-FU) with or without chloroquine, an autophagy inhibitor.
   Results We identified an 8.9% prevalence of dMMR cases (83 out of 929) in our cohort. This was associated with old age, tumor site at the distal stomach, an intestinal phenotype, fewer nodal metastasis, and early pathological stages. MMR was an independent prognostic factor after multivariate adjustment. Overall survival (OS) of dMMR patients was better than that of the pMMR patients but was only applicable to stage III patients. There was no difference in OS between dMMR patients treated with or without adjuvant chemotherapy, although the latter showed more medical morbidities. The MSI-high gastric cancer cell lines, versus the MSS counterparts, displayed increased resistance to 5-FU and increased autophagy. Interestingly, autophagy inhibition abrogated the chemoresistance.
   Conclusion Our data show that fluorouracil-based adjuvant chemotherapy does not work for dMMR cases, if not worse. Autophagy inhibition and/or immune checkpoint inhibition might be promising alternative strategies for gastric cancer treatment.
   Implications for Practice The use of microsatellite instability (MSI) and mismatch repair (MMR) as predictive biomarkers for adjuvant chemotherapy in colorectal cancer has caused a paradigm shift in cancer therapy, although its implications in gastric cancer are still questionable. The data obtained in the current study indicate that MSI-MMR is an independent prognostic factor for gastric cancer. Standard fluorouracil-based adjuvant chemotherapy did not work for deficient MMR cases, and was likely worse. Instead, strategies like autophagy inhibition and/or immune checkpoint inhibition should be taken into consideration in the future.
C1 [Tsai, Chun-Yi; Lin, Tien-An; Hsu, Jun-Te; Yeh, Chun-Nan; Yeh, Ta-Sen] Chang Gung Univ, Chang Gung Mem Hosp Linkou, Coll Med, Dept Surg, Taoyuan, Taiwan.
   [Huang, Shih-Chiang; Chen, Tse-Ching] Chang Gung Univ, Chang Gung Mem Hosp Linkou, Coll Med, Dept Pathol, Taoyuan, Taiwan.
   [Chiu, Cheng-Tang] Chang Gung Univ, Chang Gung Mem Hosp Linkou, Coll Med, Dept Gastroenterol, Taoyuan, Taiwan.
   [Chen, Jen-Shi] Chang Gung Univ, Chang Gung Mem Hosp Linkou, Coll Med, Dept Med Oncol, Taoyuan, Taiwan.
RP Yeh, TS (corresponding author), Chang Gung Mem Hosp, Dept Surg, 5 Fu Hsing St, Taoyuan, Taiwan.
EM tsy471027@adm.cgmh.org.tw
FU Chang Gung Medical Research Program, Taiwan [CMRPG3D1121-3,
   CMRPG3D1131-3]
FX This work was supported by the Chang Gung Medical Research Program,
   Taiwan (CMRPG3D1121-3 and CMRPG3D1131-3).
CR An JY, 2012, INT J CANCER, V131, P505, DOI 10.1002/ijc.26399
   Bang YJ, 2012, LANCET, V379, P315, DOI 10.1016/S0140-6736(11)61873-4
   Baretti M, 2018, PHARMACOL THERAPEUT, V189, P45, DOI 10.1016/j.pharmthera.2018.04.004
   Bass AJ, 2014, NATURE, V513, P202, DOI 10.1038/nature13480
   Beghelli S, 2006, SURGERY, V139, P347, DOI 10.1016/j.surg.2005.08.021
   Chang SC, 2018, J CANCER, V9, P81, DOI 10.7150/jca.21989
   Choi YY, 2019, ANN SURG, V270, P309, DOI 10.1097/SLA.0000000000002803
   Choi YY, 2014, J SURG ONCOL, V110, P129, DOI 10.1002/jso.23618
   Cristescu R, 2015, NAT MED, V21, P449, DOI 10.1038/nm.3850
   Galluzzi L, 2017, NAT REV CLIN ONCOL, V14, P247, DOI 10.1038/nrclinonc.2016.183
   Haag GM, 2019, INT J CANCER, V144, P1697, DOI 10.1002/ijc.32030
   Hashimoto T, 2019, GASTRIC CANCER, V22, P785, DOI 10.1007/s10120-018-00918-4
   Huang SC, 2019, INT J CANCER, V145, P3218, DOI 10.1002/ijc.32215
   Huang SF, 2018, EJSO-EUR J SURG ONC, V44, P1634, DOI 10.1016/j.ejso.2018.05.036
   Huang Z, 2016, INT J CANCER, V139, P23, DOI 10.1002/ijc.29990
   Kim H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064182
   Kim KJ, 2014, HUM PATHOL, V45, P285, DOI 10.1016/j.humpath.2013.09.004
   Kim SY, 2015, INT J CANCER, V137, P819, DOI 10.1002/ijc.29449
   Le DT, 2015, NEW ENGL J MED, V372, P2509, DOI 10.1056/NEJMoa1500596
   Lee HE, 2008, BRIT J CANCER, V99, P1704, DOI 10.1038/sj.bjc.6604738
   Li J, 2010, EUR J CANCER, V46, P1900, DOI 10.1016/j.ejca.2010.02.021
   Liu YY, 2017, ONCOLOGIST, V22, P97, DOI 10.1634/theoncologist.2016-0239
   Longley DB, 2003, NAT REV CANCER, V3, P330, DOI 10.1038/nrc1074
   Mathiak M, 2017, APPL IMMUNOHISTO M M, V25, P12, DOI 10.1097/PAI.0000000000000264
   Meyers M, 2001, CANCER RES, V61, P5193
   Michel S, 2008, BRIT J CANCER, V99, P1867, DOI 10.1038/sj.bjc.6604756
   Oki E, 2009, ANN SURG ONCOL, V16, P2510, DOI 10.1245/s10434-009-0580-8
   Phillips SM, 2004, BRIT J SURG, V91, P469, DOI 10.1002/bjs.4472
   Polom K, 2018, BRIT J SURG, V105, P159, DOI 10.1002/bjs.10663
   Ribic CM, 2003, NEW ENGL J MED, V349, P247, DOI 10.1056/NEJMoa022289
   Sakuramoto S, 2007, NEW ENGL J MED, V357, P1810, DOI 10.1056/NEJMoa072252
   Sargent DJ, 2010, J CLIN ONCOL, V28, P3219, DOI 10.1200/JCO.2009.27.1825
   Sasaki K, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-370
   Sasako M, 2011, J CLIN ONCOL, V29, P4387, DOI 10.1200/JCO.2011.36.5908
   Smyth EC, 2017, JAMA ONCOL, V3, P1197, DOI 10.1001/jamaoncol.2016.6762
   Subbiah V, 2019, ONCOLOGIST, V24, P1, DOI 10.1634/theoncologist.2017-0519
   Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262
   Weinberg BA, 2018, ONCOLOGIST, V23, P1171, DOI 10.1634/theoncologist.2018-0034
   Zhao FX, 2019, J ENVIRON PATHOL TOX, V38, P21, DOI 10.1615/JEnvironPatholToxicolOncol.2018026876
NR 39
TC 7
Z9 8
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1083-7159
EI 1549-490X
J9 ONCOLOGIST
JI Oncologist
PD JUL
PY 2020
VL 25
IS 7
BP E1021
EP E1030
DI 10.1634/theoncologist.2019-0419
EA FEB 2020
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA MI6PW
UT WOS:000513293300001
PM 32058649
OA Green Published, Bronze
DA 2022-04-25
ER

PT J
AU Liu, WJ
   Zhang, ZY
   Zhang, YX
   Chen, XJ
   Guo, SK
   Lei, Y
   Xu, Y
   Ji, C
   Bi, ZG
   Wang, KH
AF Liu, Weijun
   Zhang, Zhenyong
   Zhang, Yongxue
   Chen, Xinju
   Guo, Shikui
   Lei, Yi
   Xu, Yu
   Ji, Chao
   Bi, Zhigang
   Wang, Kunhua
TI HMGB1-mediated autophagy modulates sensitivity of colorectal cancer
   cells to oxaliplatin via MEK/ERK signaling pathway
SO CANCER BIOLOGY & THERAPY
LA English
DT Article
DE apoptosis; autophagy; colorectal cancer; HMGB1; MEK; ERK pathway;
   oxaliplatin
ID RESISTANCE; APOPTOSIS; CHEMOTHERAPY; MECHANISMS; CETUXIMAB
AB In the present study, we examined the mechanisms of oxaliplatin-induced drug resistance in human colorectal cancer cell lines HT29 and HCT116. Our results demonstrate a significant autophagy expression in CRC cells after an oxaliplatin treatment. Administration of oxaliplatin to human CRC cells significantly enhanced the expression of HMGB1, which regulated the autophagy response and negatively regulate the cell apoptosis. Moreover, a decreased oxaliplatin -induced autophagy response and an increased apoptosis level were detected in stable CRC cells harboring HMGB1 shRNA. Then we noted that HMGB1 significantly induced extracellular signal-regulated kinase (ERK)/Extracellular signal-regulated kinase kinase (MEK) phosphorylation. Taken together, these data suggest that HMGB1-mediated autophagy modulates sensitivity of colorectal cancer cells to oxaliplatin via MEK/ERK signaling pathway.
C1 [Liu, Weijun; Zhang, Zhenyong; Wang, Kunhua] Kunming Univ Sci & Technol, Kunhua Hosp, Dept Anorectal Surg, Peoples Hosp Yunnan Prov 1, Kunming, Yunnan, Peoples R China.
   [Zhang, Yongxue; Guo, Shikui; Lei, Yi; Xu, Yu] Kunming Univ Sci & Technol, Kunhua Hosp, Dept Gen Surg, Peoples Hosp Yunnan Prov 1, Kunming, Yunnan, Peoples R China.
   [Chen, Xinju] Kunming Univ Sci & Technol, Kunhua Hosp, Dept Operating Room, Peoples Hosp Yunnan Prov 1, Kunming, Yunnan, Peoples R China.
   [Ji, Chao] Fujian Med Univ, Affiliated Hosp 1, Dept Dermatol, Fuzhou, Fujian, Peoples R China.
   [Bi, Zhigang] Nanjing Med Univ, Dept Dermatol, BenQ Med Ctr, Nanjing, Jiangsu, Peoples R China.
   [Wang, Kunhua] Kunming Med Univ, Affiliated Hosp 1, Dept Gen Surg, Kunming, Yunnan, Peoples R China.
RP Wang, KH (corresponding author), Kunming Univ Sci & Technol, Kunhua Hosp, Dept Anorectal Surg, Peoples Hosp Yunnan Prov 1, Kunming, Yunnan, Peoples R China.
EM weijunliu.33@gmail.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [30860257, 81101188, 810701297]; Yunnan
   Provincial Department of Education [ZD2011007]
FX This research was supported by grants from the National Natural Science
   Foundation of China (30860257, 81101188 and 810701297), and Yunnan
   Provincial Department of Education (Number: ZD2011007).
CR Adlard JW, 2002, LANCET ONCOL, V3, P75, DOI 10.1016/S1470-2045(02)00648-4
   Bardelli A, 2010, J CLIN ONCOL, V28, P1254, DOI 10.1200/JCO.2009.24.6116
   Cunningham D, 2010, LANCET, V375, P1030, DOI 10.1016/S0140-6736(10)60353-4
   Ekblad L, 2012, ANTICANCER RES, V32, P783
   ElAkawi Z, 1996, CANCER LETT, V105, P5, DOI 10.1016/0304-3835(96)04245-0
   Goldberg RM, 2004, J CLIN ONCOL, V22, P23, DOI 10.1200/JCO.2004.09.046
   Gourdier I, 2002, FEBS LETT, V529, P232, DOI 10.1016/S0014-5793(02)03347-1
   Hamamoto R, 2004, NAT CELL BIOL, V6, P731, DOI 10.1038/ncb1151
   Hector S, 2001, CANCER CHEMOTH PHARM, V48, P398, DOI 10.1007/s002800100363
   Iwatsuki M, 2009, J SURG ONCOL, V100, P261, DOI 10.1002/jso.21275
   Ji C, 2012, BIOCHEM BIOPH RES CO, V425, P825, DOI 10.1016/j.bbrc.2012.07.160
   Ji C, 2012, CELL SIGNAL, V24, P1781, DOI 10.1016/j.cellsig.2012.05.003
   Kweekel DM, 2005, CANCER TREAT REV, V31, P90, DOI 10.1016/j.ctrv.2004.12.006
   Liu FR, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-135
   Liu L, 2011, LEUKEMIA, V25, P23, DOI 10.1038/leu.2010.225
   Livesey KM, 2012, CANCER RES, V72, P1996, DOI 10.1158/0008-5472.CAN-11-2291
   Livesey KM, 2009, CURR OPIN INVEST DR, V10, P1269
   Lotze MT, 2005, NAT REV IMMUNOL, V5, P331, DOI 10.1038/nri1594
   Napier MP, 2000, EUR J SURG ONCOL, V26, P605, DOI 10.1053/ejso.2000.0955
   Poston GJ, 2008, J CLIN ONCOL, V26, P4828, DOI 10.1200/JCO.2008.17.6453
   Saif MW, 2009, JNCI-J NATL CANCER I, V101, P1543, DOI 10.1093/jnci/djp328
   Shaul YD, 2007, BBA-MOL CELL RES, V1773, P1213, DOI 10.1016/j.bbamcr.2006.10.005
   Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI [10.3322/caac.21254, 10.3322/caac.21208, 10.1001/jamaoto.2014.2530, 10.1136/bmj.g1502]
   Tang D, 2010, ONCOGENE, V29, P5299, DOI 10.1038/onc.2010.261
   Vie N, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-14
   Wakasugi T, 2007, ONCOGENE, V26, P5194, DOI 10.1038/sj.onc.1210326
   Waters J, 2001, BRIT J CANCER, V84, P1, DOI 10.1054/bjoc.2000.1552
   White E, 2009, CLIN CANCER RES, V15, P5308, DOI 10.1158/1078-0432.CCR-07-5023
   Xiu P, 2013, CANCER SCI, V104, P375, DOI 10.1111/cas.12088
NR 29
TC 49
Z9 55
U1 3
U2 14
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1538-4047
EI 1555-8576
J9 CANCER BIOL THER
JI Cancer Biol. Ther.
PD APR
PY 2015
VL 16
IS 4
BP 511
EP 517
DI 10.1080/15384047.2015.1017691
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA CH3QO
UT WOS:000353945600003
PM 25778491
OA Green Published, Bronze
DA 2022-04-25
ER

PT J
AU Ser, J
   Lee, JY
   Kim, YH
   Cho, H
AF Ser, Jinhui
   Lee, Ji Yeon
   Kim, Yong Ho
   Cho, Hoonsung
TI Enhanced Efficacy of Photodynamic Therapy by Coupling a Cell-Penetrating
   Peptide with Methylene Blue
SO INTERNATIONAL JOURNAL OF NANOMEDICINE
LA English
DT Article
DE methylene blue; protamine; CPP; photodynamic therapy; bioconjugation;
   anticancer; fluorescent
ID PHOTOCHEMICAL PROPERTIES; MECHANISMS; APOPTOSIS; PHOTOSENSITIZERS;
   CHOLESTEROL; LYSOSOMES; AUTOPHAGY; DEATH
AB Introduction: Photodynamic therapy (PDT), which induces tissue damage by exposing tissue to a specific wavelength of light in the presence of a photosensitizer and oxygen, is a promising alternative treatment that could be used as an adjunct to chemotherapy and surgery in oncology. Cell-penetrating peptides (CPPs) with high arginine content, such as protamine, have membrane translocation and lysosome localization activities. They have been used in an extensive range of drug delivery applications.
   Methods: We conjugated cell-penetrating peptides (CPPs) with methylene blue (MB) and then purification by FPLC. Synthesis structure was characterized by the absorbance spectrum, FPLC, Maldi-TOF, and then evaluated cell viability by cytotoxicity assay after photodynamic therapy (PDT) assay. An uptake imaging assay was used to determine the sites of MB and MB-Pro in subcellular compartments.
   Results: In vitro assays showed that MB-Pro has more efficient photodynamic activities than MB alone for the colon cancer cells, owing to lysosome rupture causing the rapid necrotic cell death. In this study, we coupled protamine with MB for high efficacy PDT. The conjugates localized in the lysosomes and enhanced the efficiency of PDT by inducing necrotic cell death, whereas PDT with non-coupled MB resulted in only apoptotic processes.
   Discussion: Our research aimed to enhance PDT by engineering the photosensitizers using CPPs coupled with methylene blue (MB). MB alone permeates through the cell membrane and distributes into the cytoplasm, whereas coupling of MB dye with CPPs localizes the MB through an endocytic mechanism to a specific organelle where the localized conjugates enhance the generation of reactive oxygen species (ROS) and induce cell damage.
C1 [Ser, Jinhui; Cho, Hoonsung] Chonnam Natl Univ, Sch Mat Sci & Engn, Gwangju 61186, South Korea.
   [Lee, Ji Yeon] Gachon Univ, Gil Med Ctr, Dept Anesthesiol & Pain Med, Incheon 21565, South Korea.
   [Kim, Yong Ho] Gachon Univ, Gachon Pain Ctr, Coll Med, Incheon 21999, South Korea.
   [Kim, Yong Ho] Gachon Univ, Dept Physiol, Coll Med, Incheon 21999, South Korea.
RP Cho, H (corresponding author), Chonnam Natl Univ, Sch Mat Sci & Engn, Gwangju 61186, South Korea.; Kim, YH (corresponding author), Gachon Univ, Gachon Pain Ctr, Coll Med, Incheon 21999, South Korea.; Kim, YH (corresponding author), Gachon Univ, Dept Physiol, Coll Med, Incheon 21999, South Korea.
EM euro16@gachon.ac.kr; cho.hoonsung@jnu.ac.kr
OI Cho, Hoonsung/0000-0003-0778-5640; Ser, Jinhui/0000-0002-8673-7374
FU Basic Science Research Program through the National Research Foundation
   of Korea (NRF) - Ministry of Education [2018R1D1A1B07049867,
   2018R1D1A1B07049089]
FX This study was supported by Basic Science Research Program through the
   National Research Foundation of Korea (NRF) funded by the Ministry of
   Education (2018R1D1A1B07049867 and 2018R1D1A1B07049089).
CR Baptista M, 2002, HDB POLYELECTROLYTES, V1, P165
   Cai JY, 1998, BBA-BIOENERGETICS, V1366, P139, DOI 10.1016/S0005-2728(98)00109-1
   Castano AP, 2004, PHOTODIAGN PHOTODYN, V1, P279, DOI 10.1016/S1572-1000(05)00007-4
   DOLEIDEN FH, 1974, PHOTOCHEM PHOTOBIOL, V20, P519, DOI 10.1111/j.1751-1097.1974.tb06613.x
   Gabrielli D, 2004, PHOTOCHEM PHOTOBIOL, V79, P227, DOI 10.1562/BE-03-27.1
   Garg AD, 2015, PHOTOCH PHOTOBIO SCI, V14, P1410, DOI 10.1039/c4pp00466c
   GIROTTI AW, 1990, PHOTOCHEM PHOTOBIOL, V51, P497, DOI 10.1111/j.1751-1097.1990.tb01744.x
   Guicciardi ME, 2004, ONCOGENE, V23, P2881, DOI 10.1038/sj.onc.1207512
   Haddad R, 1999, J GASTROINTEST SURG, V3, P602, DOI 10.1016/S1091-255X(99)80081-X
   Jiang CL, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/1529520
   Jori G, 1996, J PHOTOCH PHOTOBIO B, V36, P87, DOI 10.1016/S1011-1344(96)07352-6
   Junqueira HC, 2002, PHYS CHEM CHEM PHYS, V4, P2320, DOI 10.1039/b109753a
   Kandela IK, 2002, PHOTOCH PHOTOBIO SCI, V1, P309, DOI 10.1039/b110572h
   Kroemer G, 2005, NAT REV CANCER, V5, P886, DOI 10.1038/nrc1738
   LAMOLA AA, 1973, SCIENCE, V179, P1131, DOI 10.1126/science.179.4078.1131
   Leite IS, 2018, J BIOPHOTONICS, V11, DOI 10.1002/jbio.201600283
   Lemasters JJ, 2005, GASTROENTEROLOGY, V129, P351, DOI 10.1053/j.gastro.2005.06.006
   Maxfield FR, 2014, CSH PERSPECT BIOL, V6, DOI 10.1101/cshperspect.a016931
   Ochsner M, 1997, J PHOTOCH PHOTOBIO B, V39, P1, DOI 10.1016/S1011-1344(96)07428-3
   OLEINICK NL, 1998, RADIAT RES, V150, pS14, DOI DOI 10.2307/357981629.
   Park CK, 2017, INT J NANOMED, V12, P8185, DOI 10.2147/IJN.S148332
   Plaetzer K, 2005, CURR PHARM DESIGN, V11, P1151, DOI 10.2174/1381612053507648
   Reynolds F, 2005, BIOCONJUGATE CHEM, V16, P1240, DOI 10.1021/bc0501451
   Richard JP, 2003, J BIOL CHEM, V278, P585, DOI 10.1074/jbc.M209548200
   Severino D, 2003, PHOTOCHEM PHOTOBIOL, V77, P459, DOI 10.1562/0031-8655(2003)077<0459:IONCIO>2.0.CO;2
   Stewart F, 1998, RADIOTHER ONCOL, V48, P233, DOI 10.1016/S0167-8140(98)00063-2
   Tardivo JP, 2005, PHOTODIAGN PHOTODYN, V2, P175, DOI 10.1016/S1572-1000(05)00097-9
   TUITE EM, 1993, J PHOTOCH PHOTOBIO B, V21, P103, DOI 10.1016/1011-1344(93)80173-7
   VANHILLEGERSBERG R, 1995, BRIT J CANCER, V71, P733, DOI 10.1038/bjc.1995.143
   Verma SK, 2018, MAT SCI ENG C-MATER, V92, P807, DOI 10.1016/j.msec.2018.07.037
   Voet D, 1995, BIOCHEMISTRY-US, P850
NR 31
TC 1
Z9 1
U1 3
U2 14
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-2013
J9 INT J NANOMED
JI Int. J. Nanomed.
PY 2020
VL 15
BP 5803
EP 5811
DI 10.2147/IJN.S254881
PG 9
WC Nanoscience & Nanotechnology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics; Pharmacology & Pharmacy
GA NZ5CV
UT WOS:000577115600008
PM 32821102
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Hu, X
   Li, YQ
   Li, QG
   Ma, YL
   Peng, JJ
   Cai, SJ
AF Hu, Xiang
   Li, Ya-Qi
   Li, Qing-Guo
   Ma, Yan-Lei
   Peng, Jun-Jie
   Cai, San-Jun
TI Osteoglycin-induced VEGF Inhibition Enhances T Lymphocytes Infiltrating
   in Colorectal Cancer
SO EBIOMEDICINE
LA English
DT Article
DE Osteoglycin; Tumor-infiltrating lymphocytes; Colorectal cancer; Immune
   response; Survival
ID SHOCK-PROTEIN GP96; CROSS-PRESENTATION; IMMUNE CELLS; EXPRESSION;
   PROGNOSIS; MIMECAN; INFLAMMATION; ACTIVATION; AUTOPHAGY; INNATE
AB Background: OGN could modify tissue inflammation and immune response via local and circulating innate immune cells, which was suggestive of a reciprocal relationship between OGN and T cell infiltration in cancer. Hence, we aim to measure the OGN expression patterns and immune cells response in colorectal cancer (CRC).
   Methods: This study enrolled three independent sets of patients from TCGA and the Fudan University Shanghai Cancer Center(FUSCC). The effect of OGN on T cell infiltration and the mechanism were examined in vitro and in vivo.
   Findings: Tumor OGN expression levels were positively associated with CD3, CD8, and PTPRC expressions in the training and testing sets from TCGA, respectively. In validation set from FUSCC, OGN expression level also paralleled positively with CD8+ cell density in colorectal cancer tissue (p<.001). For a unit decrease in outcome quartile categories, multivariable OR in the lowest (vs highest) OGN expression was 0.17 (95% CI 0.08-0.33). Consistently, immunofluorescence validated that OGN was preferentially expressed with CD8+ cells in both normal epithelium and cancer tissue. Xenograft tumors arising from MC38 cells with OGN-over-expression displayed a significant increase in CD8+ cells recruitment. Hence, high expression of OGN was associated with a profound longer survival (P=.009). In mechanism, elevated OGN expression inhibited the activation of the transcriptional genes HIF-1 alpha in CRC cells, then significantly impeded the expression of VEGF. As a result of this, T cell tumor infiltration was reduced.
   Interpretation: OGN expression is positively associated with CD8+ cell density in colorectal cancer tissue, suggesting a possible influence of OGN expression on tumor reactive T cells in the tumor niche. Fund: No (c) 2018 The Authors. Published by Elsevier B.V.
C1 [Cai, San-Jun] Fudan Univ, Dept Colorectal Surg, Shanghai Canc Ctr, 270 Dongan Rd, Shanghai 20032, Peoples R China.
   Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai 200032, Peoples R China.
RP Cai, SJ (corresponding author), Fudan Univ, Dept Colorectal Surg, Shanghai Canc Ctr, 270 Dongan Rd, Shanghai 20032, Peoples R China.
EM caisanjun_sh@163.com
FU China Postdoctoral Science FoundationChina Postdoctoral Science
   Foundation [2018M632024]
FX This work was supported by China Postdoctoral Science Foundation
   (2018M632024).
CR Colussi D, 2013, INT J MOL SCI, V14, P16365, DOI 10.3390/ijms140816365
   Di Caro G, 2013, J CELL MOL MED, V17, P1088, DOI 10.1111/jcmm.12117
   Fairweather D, 2003, J IMMUNOL, V170, P4731, DOI 10.4049/jimmunol.170.9.4731
   Galon J, 2006, SCIENCE, V313, P1960, DOI 10.1126/science.1129139
   Kaur J, 2015, NAT REV MOL CELL BIO, V16, P461, DOI 10.1038/nrm4024
   Kemball CC, 2010, FUTURE MICROBIOL, V5, P1329, DOI [10.2217/fmb.10.101, 10.2217/FMB.10.101]
   Ladoire S, 2011, CANCER IMMUNOL IMMUN, V60, P909, DOI 10.1007/s00262-011-1046-y
   Lee JY, 2003, GENOMICS, V82, P78, DOI 10.1016/S0888-7543(03)00098-3
   Li DW, 2011, CLIN CANCER RES, V17, P3558, DOI 10.1158/1078-0432.CCR-10-2729
   Li L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090181
   Li YH, 2008, CANCER RES, V68, P6889, DOI 10.1158/0008-5472.CAN-08-0161
   Li YH, 2011, CLIN CANCER RES, V17, P7047, DOI 10.1158/1078-0432.CCR-11-0951
   Liston A, 2014, NAT REV IMMUNOL, V14, P154, DOI 10.1038/nri3605
   Lomnytska MI, 2010, PROTEOM CLIN APPL, V4, P17, DOI 10.1002/prca.200900086
   Mei Y, 2017, CELL COMMUN SIGNAL, V15, DOI 10.1186/s12964-017-0189-7
   Mei Z, 2014, BRIT J CANCER, V110, P1595, DOI 10.1038/bjc.2014.46
   Mlecnik B, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007240
   Nosho K, 2010, J PATHOL, V222, P350, DOI 10.1002/path.2774
   Ogino S, 2009, CLIN CANCER RES, V15, P6412, DOI 10.1158/1078-0432.CCR-09-1438
   Palmqvist R, 2013, CURR COLORECT CANC R, V9, P372, DOI 10.1007/s11888-013-0192-3
   Pawaria S, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1524
   Rienks M, 2017, CELL MOL LIFE SCI, V74, P1511, DOI 10.1007/s00018-016-2423-7
   Rower C, 2011, INT J CLIN EXP PATHO, V4, P454
   Sasaki A, 2008, EJSO-EUR J SURG ONC, V34, P173, DOI 10.1016/j.ejso.2007.08.008
   Sharma P, 2015, SCIENCE, V348, P56, DOI 10.1126/science.aaa8172
   Tasheva E, 2003, MOL VIS, V9, P1
   Tasheva ES, 2001, BBA-GENE STRUCT EXPR, V1517, P333, DOI 10.1016/S0167-4781(00)00288-8
   Vabulas RM, 2002, J BIOL CHEM, V277, P20847, DOI 10.1074/jbc.M200425200
   Wang YH, 2007, EXP BIOL MED, V232, P1152, DOI 10.3181/0701-RM-8
   Wassermann-Dozorets R, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.155
   Yang Y, 2007, IMMUNITY, V26, P215, DOI 10.1016/j.immuni.2006.12.005
NR 31
TC 15
Z9 15
U1 0
U2 9
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 2352-3964
J9 EBIOMEDICINE
JI EBioMedicine
PD AUG
PY 2018
VL 34
BP 35
EP 45
DI 10.1016/j.ebiom.2018.07.021
PG 11
WC Medicine, General & Internal; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine; Research & Experimental Medicine
GA GR8AW
UT WOS:000442928000012
PM 30037719
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Zheng, QY
   Zhang, QY
   Yu, X
   He, YT
   Guo, WZ
AF Zheng, Qingyuan
   Zhang, Qiyao
   Yu, Xiao
   He, Yuting
   Guo, Wenzhi
TI FENDRR: A pivotal, cancer-related, long non-coding RNA
SO BIOMEDICINE & PHARMACOTHERAPY
LA English
DT Review
DE LncRNA; FENDRR; Biomarker; Cancer; Therapeutic target
ID PREDICTS POOR-PROGNOSIS; STEM-CELLS; LUNG-CANCER; GASTRIC-CANCER;
   HEPATOCELLULAR-CARCINOMA; REGULATES AUTOPHAGY; COLORECTAL-CANCER;
   TUMOR-GROWTH; PROLIFERATION; INVASION
AB Long non-coding RNAs (lncRNAs) have more than 200 nucleotides and do not encode proteins. Based on numerous studies, lncRNAs have emerged as new and crucial regulators of biological function and have been implicated in the pathogenesis of a variety of diseases, especially cancers. Specific lncRNAs have been identified as novel molecular biomarkers for cancer diagnosis, prognosis, and treatment efficacy. Fetal-lethal non-coding developmental regulatory RNA (FENDRR, also known as FOXF1-AS1) is a novel lncRNA that is located at chr3q13.31 and has four exons and 3099 nucleotides, and its genomic site is located at chr3q13.31. FENDRR is abnormally expressed in a variety of cancers and is significantly associated with different clinical characteristics. In addition, FENDRR has shown potential as a biomarker for cancer diagnosis, prognosis, and treatment. In this review, we summarize the current understanding of FENDRR and its mechanistic role in cancer progression. We also discuss recent insights into the clinical significance of FENDRR for cancer diagnosis, prognosis, and treatment.
C1 [Zheng, Qingyuan; Zhang, Qiyao; Yu, Xiao; He, Yuting; Guo, Wenzhi] Zhengzhou Univ, Affiliated Hosp 1, Dept Hepatobiliary & Pancreat Surg, Zhengzhou 450052, Peoples R China.
   [Zheng, Qingyuan; Zhang, Qiyao; Yu, Xiao; He, Yuting; Guo, Wenzhi] Zhengzhou Univ, Affiliated Hosp 1, Key Lab Hepatobiliary & Pancreat Surg & Digest Or, Zhengzhou 450052, Peoples R China.
   [Zheng, Qingyuan; Zhang, Qiyao; Yu, Xiao; He, Yuting; Guo, Wenzhi] Henan Univ, Open & Key Lab Hepatobiliary & Pancreat Surg & Di, Zhengzhou 450052, Peoples R China.
   [Zheng, Qingyuan; Zhang, Qiyao; Yu, Xiao; He, Yuting; Guo, Wenzhi] Henan Key Lab Digest Organ Transplantat, Zhengzhou 450052, Peoples R China.
RP He, YT; Guo, WZ (corresponding author), Zhengzhou Univ, Affiliated Hosp 1, Dept Hepatobiliary & Pancreat Surg, Zhengzhou 450052, Peoples R China.
EM fccheyt1@zzu.edu.cn; fccguowz@zzu.edu.cn
FU Youth Talent Lifting Project of Henan Province [2021HYTP059]; Key
   Scientific Research Project of Henan Higher Education Institutions of
   China [21A320026]
FX This work was supported by the Youth Talent Lifting Project of Henan
   Province (2021HYTP059) , and Key Scientific Research Project of Henan
   Higher Education Institutions of China (21A320026) .
CR Abbaszadegan MR, 2017, J CELL PHYSIOL, V232, P2008, DOI 10.1002/jcp.25759
   Atianand MK, 2017, ANNU REV IMMUNOL, V35, P177, DOI 10.1146/annurev-immunol-041015-055459
   Bartonicek N, 2016, MOL CANCER, V15, DOI 10.1186/s12943-016-0530-6
   Belkahla H, 2017, NANOSCALE, V9, P5755, DOI 10.1039/c7nr01469d
   Cao HL, 2019, EUR REV MED PHARMACO, V23, P1012, DOI 10.26355/eurrev_201902_16988
   Chao YJ, 2019, MED SCI MONITOR, V25, P6581, DOI 10.12659/MSM.915100
   Chen JZ, 2018, AGING-US, V10, P3371, DOI 10.18632/aging.101645
   Chen Z, 2014, NAT REV CANCER, V14, P535, DOI 10.1038/nrc3775
   Chennupati SK, 2008, INT J PEDIATR OTORHI, V72, P115, DOI 10.1016/j.ijporl.2007.08.015
   Cheung CHY, 2017, J BIOMED SCI, V24, DOI 10.1186/s12929-017-0343-y
   Cornelison R, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18102171
   Cravo M, 2015, WORLD J GASTROENTERO, V21, P11609, DOI 10.3748/wjg.v21.i41.11609
   Cutts SM, 2005, IUBMB LIFE, V57, P73, DOI 10.1080/15216540500079093
   Cutts SM, 2003, MOL CANCER THER, V2, P661
   DAHLIN DC, 1975, CLIN ORTHOP RELAT R, P23
   Ding XX, 2018, FEBS OPEN BIO, V8, P544, DOI 10.1002/2211-5463.12397
   Dong PX, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1306-9
   Duan Y, 2021, NUTR CANCER, V73, P983, DOI 10.1080/01635581.2020.1779323
   Duff D, 2017, CELL SIGNAL, V35, P250, DOI 10.1016/j.cellsig.2017.03.005
   Esposito R, 2019, CANCER CELL, V35, P545, DOI 10.1016/j.ccell.2019.01.019
   Faderl S, 1999, ANN INTERN MED, V131, P207, DOI 10.7326/0003-4819-131-3-199908030-00008
   Fanale D, 2016, ADV EXP MED BIOL, V937, P93, DOI 10.1007/978-3-319-42059-2_5
   Forrest ME, 2017, CANCER LETT, V407, P106, DOI 10.1016/j.canlet.2017.03.040
   Fu XM, 2017, EUR REV MED PHARMACO, V21, P3239
   Furue Hisashi, 2003, Gan To Kagaku Ryoho, V30, P1404
   Ghafouri-Fard Soudeh, 2020, Biomed Pharmacother, V127, P110158, DOI 10.1016/j.biopha.2020.110158
   Ghetti M, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01187-5
   Gong FC, 2019, EUR J PHARMACOL, V853, P345, DOI 10.1016/j.ejphar.2019.04.022
   Gong XY, 2020, TECHNOL CANCER RES T, V19, DOI 10.1177/1533033820963578
   Gyvyte U, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0209342
   Harding MC, 2018, PREV CHRONIC DIS, V15, DOI 10.5888/pcd15.180151
   He ML, 2014, TUMOR BIOL, V35, P1297, DOI 10.1007/s13277-013-1172-6
   He W, 2019, ONCOL LETT, V17, P103, DOI 10.3892/ol.2018.9624
   He ZC, 2018, AM J TRANSL RES, V10, P3211
   Herrera-Merchan Antonio, 2020, Oncotarget, V11, P1172
   Heymann MF, 2019, CELL IMMUNOL, V343, DOI 10.1016/j.cellimm.2017.10.011
   Hirsch FR, 2017, LANCET, V389, P299, DOI 10.1016/S0140-6736(16)30958-8
   Hu YR, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0743-3
   Huang RX, 2017, ONCOTARGET, V8, P35351, DOI 10.18632/oncotarget.10169
   Jiang XM, 2017, EUR REV MED PHARMACO, V21, P1242
   Jung HM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136036
   Karadurmus N, 2018, J BUON, V23, P1235
   Kovac M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9940
   Li JL, 2017, CELL PROLIFERAT, V50, DOI 10.1111/cpr.12381
   Li WL, 2020, AGING-US, V12, P1512, DOI 10.18632/aging.102697
   Li Y, 2018, ONCOTARGETS THER, V11, P1403, DOI 10.2147/OTT.S149511
   Li YH, 2020, GENE, V749, DOI 10.1016/j.gene.2020.144724
   Liao KL, 2018, MOL IMMUNOL, V101, P182, DOI 10.1016/j.molimm.2018.05.030
   Liu JC, 2019, MINI-REV MED CHEM, V19, P1517, DOI 10.2174/1389557519666190312152358
   Liu JC, 2019, ONCOTARGETS THER, V12, P4287, DOI 10.2147/OTT.S195853
   Liu Y, 2018, BIOCHEM CELL BIOL, V96, P38, DOI 10.1139/bcb-2017-0188
   Liu YH, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/9056458
   Liu YF, 2019, J CELL BIOCHEM, V120, P14165, DOI 10.1002/jcb.28691
   Long QX, 2020, NAT MED, V26, P845, DOI 10.1038/s41591-020-0897-1
   Lorenzen JM, 2016, NAT REV NEPHROL, V12, P360, DOI 10.1038/nrneph.2016.51
   Lungu II, 2019, MOLECULES, V24, DOI 10.3390/molecules24193547
   Luo TH, 2018, TRANSL ONCOL, V11, P1080, DOI 10.1016/j.tranon.2018.06.007
   Ma F, 2016, BIOMED PHARMACOTHER, V84, P1249, DOI 10.1016/j.biopha.2016.10.064
   Mauro MJ, 2001, CURR OPIN ONCOL, V13, P3, DOI 10.1097/00001622-200101000-00002
   Miao ZP, 2017, CANCER SCI, V108, P1953, DOI 10.1111/cas.13344
   Mokdad AH, 2017, JAMA-J AM MED ASSOC, V317, P388, DOI 10.1001/jama.2016.20324
   Mou YH, 2018, CANCER BIOMARK, V23, P95, DOI 10.3233/CBM-181424
   Mun EJ, 2018, CLIN CANCER RES, V24, P266, DOI 10.1158/1078-0432.CCR-17-1117
   Nassar D, 2016, ANNU REV PATHOL-MECH, V11, P47, DOI 10.1146/annurev-pathol-012615-044438
   Peng ZX, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0812-2
   Penticuff JC, 2019, NAT REV UROL, V16, P318, DOI 10.1038/s41585-019-0171-9
   Picci P, 2007, ORPHANET J RARE DIS, V2, DOI 10.1186/1750-1172-2-6
   Pignon T, 2000, REV MED INTERNE, V21, P765, DOI 10.1016/S0248-8663(00)00222-8
   Pinsky PF, 2015, SURG CLIN N AM, V95, P953, DOI 10.1016/j.suc.2015.05.009
   Poulet Christophe, 2020, Int J Mol Sci, V21, DOI 10.3390/ijms21103580
   Qian GY, 2020, CANCER BIOTHER RADIO, V35, P629, DOI 10.1089/cbr.2019.3468
   Qian XY, 2019, TRENDS BIOCHEM SCI, V44, P33, DOI 10.1016/j.tibs.2018.09.012
   Qin XL, 2019, CELL CYCLE, V18, P889, DOI 10.1080/15384101.2019.1598726
   Rahimi M, 2019, COMPUT BIOL MED, V114, DOI 10.1016/j.compbiomed.2019.103362
   Ramnarine VR, 2018, GIGASCIENCE, V7, DOI 10.1093/gigascience/giy050
   Sayiner M, 2019, DIGEST DIS SCI, V64, P910, DOI 10.1007/s10620-019-05537-2
   Shi XY, 2019, EUR REV MED PHARMACO, V23, P232, DOI 10.26355/eurrev_201908_18652
   Shuai Y, 2020, CELL PROLIFERAT, V53, DOI 10.1111/cpr.12716
   Smid D, 2015, BRATISL MED J, V116, P666, DOI 10.4149/BLL_2015_129
   Smyth EC, 2020, LANCET, V396, P635, DOI 10.1016/S0140-6736(20)31288-5
   SPETH PAJ, 1988, CLIN PHARMACOKINET, V15, P15, DOI 10.2165/00003088-198815010-00002
   Steeg PS, 2016, NAT REV CANCER, V16, P201, DOI 10.1038/nrc.2016.25
   Steinbichler TB, 2017, SEMIN CANCER BIOL, V44, P170, DOI 10.1016/j.semcancer.2017.02.006
   Stratton MR, 2009, NATURE, V458, P719, DOI 10.1038/nature07943
   Stuelten CH, 2018, NAT REV CANCER, V18, P296, DOI 10.1038/nrc.2018.15
   Su WZ, 2018, EUR REV MED PHARMACO, V22, P7282, DOI 10.26355/eurrev_201811_16264
   Tang Q, 2018, CELL PHYSIOL BIOCHEM, V47, P893, DOI 10.1159/000490131
   Thin KZ, 2018, PATHOL RES PRACT, V214, P801, DOI 10.1016/j.prp.2018.04.003
   Tian ZQ, 2017, ONCOTARGET, V8, P51703, DOI 10.18632/oncotarget.18512
   Tonda T, 2015, J EPIDEMIOL, V25, P639, DOI 10.2188/jea.JE20140218
   van Meer S, 2013, WORLD J GASTROENTERO, V19, P6744, DOI 10.3748/wjg.v19.i40.6744
   Wang B, 2019, BIOCHEM BIOPH RES CO, V509, P143, DOI 10.1016/j.bbrc.2018.12.091
   Wang JC, 2018, CLIN CHIM ACTA, V485, P229, DOI 10.1016/j.cca.2018.07.004
   Wang J, 2019, J PEDIATR SURG, V54, P2589, DOI 10.1016/j.jpedsurg.2019.08.032
   Wang K, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7779
   Wang LY, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20225758
   Weidle UH, 2017, CANCER GENOM PROTEOM, V14, P143, DOI 10.21873/cgp.20027
   Weingart SN, 2018, LANCET ONCOL, V19, pE191, DOI 10.1016/S1470-2045(18)30094-9
   Xing C, 2021, BIOMED PHARMACOTHER, V134, DOI 10.1016/j.biopha.2020.111158
   Xu JY, 2017, BRIEF BIOINFORM, V18, P236, DOI 10.1093/bib/bbw015
   Xu R, 2019, ARCH MED SCI, V15, P1539, DOI 10.5114/aoms.2019.86707
   Xu TP, 2014, J HEMATOL ONCOL, V7, DOI 10.1186/s13045-014-0063-7
   Xue C, 2020, AM J TRANSL RES, V12, P1873
   Xue M, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0714-8
   Yang BY, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0722-8
   Yang C, 2019, GENE, V687, P73, DOI 10.1016/j.gene.2018.10.087
   Yang JD, 2019, NAT REV GASTRO HEPAT, V16, P589, DOI 10.1038/s41575-019-0186-y
   Yang L, 2018, CARCINOGENESIS, V39, P347, DOI 10.1093/carcin/bgx149
   Yang ZY, 2014, ANAL BIOANAL CHEM, V406, P4013, DOI 10.1007/s00216-014-7722-y
   Ye LC, 2015, TUMOR BIOL, V36, P8747, DOI 10.1007/s13277-015-3627-4
   Yin SL, 2020, J CELL BIOCHEM, V121, P3973, DOI 10.1002/jcb.29555
   Yu DL, 2018, FRONT GENET, V9, DOI 10.3389/fgene.2018.00168
   Yu X, 2018, CELL PROLIFERAT, V51, DOI 10.1111/cpr.12506
   Zaimy MA, 2017, CANCER GENE THER, V24, P233, DOI 10.1038/cgt.2017.16
   Zarrabi K, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0780-z
   Zeng J, 2019, EUR REV MED PHARMACO, V23, P9277, DOI 10.26355/eurrev_201911_19420
   Zeng Z, 2019, ARTIF CELL NANOMED B, V47, P3067, DOI 10.1080/21691401.2019.1640228
   Zhang F, 2019, FEBS LETT, V593, P1993, DOI 10.1002/1873-3468.13480
   Zhang GY, 2018, BIOMARKERS, V23, P435, DOI 10.1080/1354750X.2018.1443509
   Zhang GJ, 2019, BIOMED PHARMACOTHER, V118, DOI 10.1016/j.biopha.2019.109309
   Zhang L, 2018, MOL MED REP, V17, P6449, DOI 10.3892/mmr.2018.8655
   Zhang L, 2017, LUNG CANCER, V109, P21, DOI 10.1016/j.lungcan.2017.04.009
   Zhang MY, 2018, EUR REV MED PHARMACO, V22, P8324, DOI 10.26355/eurrev_201812_16530
   Zhang RR, 2016, ENDOCR PATHOL, V27, P12, DOI 10.1007/s12022-016-9417-8
   Zhang YQ, 2019, EUR REV MED PHARMACO, V23, P7327, DOI 10.26355/eurrev_201909_18838
   Zhao D, 2019, ARTIF CELL NANOMED B, V47, P1342, DOI 10.1080/21691401.2019.1596934
   Zhao JH, 2016, PHARMACOL THERAPEUT, V160, P145, DOI 10.1016/j.pharmthera.2016.02.008
   Zhao LM, 2017, FASEB J, V31, P893, DOI 10.1096/fj.201600994R
   Zhao WY, 2018, CANCER MED-US, V7, P842, DOI 10.1002/cam4.1353
   Zhou H, 2015, PROTEIN CELL, V6, P403, DOI 10.1007/s13238-015-0143-7
   Zhou HY, 2010, CRIT REV EUKAR GENE, V20, P1
   Zhou ML, 2016, STEM CELLS, V34, P55, DOI 10.1002/stem.2219
   Zhu KP, 2017, ONCOTARGET, V8, P71881, DOI 10.18632/oncotarget.17985
   Zhu KP, 2017, INT J BIOL SCI, V13, P1180, DOI 10.7150/ijbs.21722
   Zhu YH, 2020, CANCER CELL INT, V20, DOI 10.1186/s12935-020-01223-w
   Zuela-Sopilniak N, 2019, PHILOS T R SOC B, V374, DOI 10.1098/rstb.2018.0219
NR 136
TC 4
Z9 4
U1 3
U2 4
PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY-LES-MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE
SN 0753-3322
EI 1950-6007
J9 BIOMED PHARMACOTHER
JI Biomed. Pharmacother.
PD MAY
PY 2021
VL 137
AR 111390
DI 10.1016/j.biopha.2021.111390
EA FEB 2021
PG 8
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA RF3PI
UT WOS:000634753200005
PM 33761608
OA gold
DA 2022-04-25
ER

PT J
AU Montero-Melendez, T
   Llor, X
   Garcia-Planella, E
   Perretti, M
   Suarez, A
AF Montero-Melendez, Trinidad
   Llor, Xavier
   Garcia-Planella, Esther
   Perretti, Mauro
   Suarez, Antonio
TI Identification of Novel Predictor Classifiers for Inflammatory Bowel
   Disease by Gene Expression Profiling
SO PLOS ONE
LA English
DT Article
ID MICROARRAY DATA; CROHNS-DISEASE; SIGNATURE; CLASSIFICATION; MANAGEMENT;
   PROGNOSIS; SURVIVAL; CANCER
AB Background: Improvement of patient quality of life is the ultimate goal of biomedical research, particularly when dealing with complex, chronic and debilitating conditions such as inflammatory bowel disease (IBD). This is largely dependent on receiving an accurate and rapid diagnose, an effective treatment and in the prediction and prevention of side effects and complications. The low sensitivity and specificity of current markers burden their general use in the clinical practice. New biomarkers with accurate predictive ability are needed to achieve a personalized approach that take the inter-individual differences into consideration.
   Methods: We performed a high throughput approach using microarray gene expression profiling of colon pinch biopsies from IBD patients to identify predictive transcriptional signatures associated with intestinal inflammation, differential diagnosis (Crohn's disease or ulcerative colitis), response to glucocorticoids (resistance and dependence) or prognosis (need for surgery). Class prediction was performed with self-validating Prophet software package.
   Results: Transcriptional profiling divided patients in two subgroups that associated with degree of inflammation. Class predictors were identified with predictive accuracy ranging from 67 to 100%. The expression accuracy was confirmed by real time-PCR quantification. Functional analysis of the predictor genes showed that they play a role in immune responses to bacteria (PTN, OLFM4 and LILRA2), autophagy and endocytocis processes (ATG16L1, DNAJC6, VPS26B, RABGEF1, ITSN1 and TMEM127) and glucocorticoid receptor degradation (STS and MMD2).
   Conclusions: We conclude that using analytical algorithms for class prediction discovery can be useful to uncover gene expression profiles and identify classifier genes with potential stratification utility of IBD patients, a major step towards personalized therapy.
C1 [Montero-Melendez, Trinidad; Perretti, Mauro] Queen Mary Univ London, Barts & London Sch Med, William Harvey Res Inst, London, England.
   [Llor, Xavier] Univ Illinois, Dept Med, Digest Dis & Nutr Sect, Chicago, IL USA.
   [Llor, Xavier] Univ Illinois, Ctr Canc, Chicago, IL USA.
   [Garcia-Planella, Esther] Univ Autonoma Barcelona, Hosp Santa Creu & St Pau, E-08193 Barcelona, Spain.
   [Suarez, Antonio] Univ Granada, Ctr Invest Biomed, Armilla, Spain.
RP Suarez, A (corresponding author), Univ Granada, Ctr Invest Biomed, Armilla, Spain.
EM asuarez@ugr.es
RI SUAREZ, ANTONIO/L-9221-2014; Montero-Melendez, Trinidad/AAF-6345-2020
OI SUAREZ, ANTONIO/0000-0002-1006-7490; Montero-Melendez,
   Trinidad/0000-0002-3563-376X
FU Fundacio la Marato de TV3 [031531]; Spanish Health Ministry - Carlos III
   Institute [PI61550]
FX This study was funded by Fundacio la Marato de TV3 (031531) and Spanish
   Health Ministry - Carlos III Institute (PI61550). The funders had no
   role in study design, data collection and analysis, decision to publish,
   or preparation of the manuscript.
CR Beaugerie L, 2012, WORLD J GASTROENTERO, V18, P3806, DOI 10.3748/wjg.v18.i29.3806
   Bonapace L, 2010, J CLIN INVEST, V120, P1310, DOI 10.1172/JCI39987
   Bonome T, 2008, CANCER RES, V68, P5478, DOI 10.1158/0008-5472.CAN-07-6595
   D'Haens G, 2008, LANCET, V371, P660, DOI 10.1016/S0140-6736(08)60304-9
   Ford LT, 2010, J CLIN PATHOL, V63, P288, DOI 10.1136/jcp.2009.069252
   Gersemann M, 2012, J CROHNS COLITIS, V6, P425, DOI 10.1016/j.crohns.2011.09.013
   Hakonarson H, 2005, P NATL ACAD SCI USA, V102, P14789, DOI 10.1073/pnas.0409904102
   Lee JC, 2011, J CLIN INVEST, V121, P4170, DOI 10.1172/JCI59255
   Lewis JD, 2011, GASTROENTEROLOGY, V140, P1817, DOI 10.1053/j.gastro.2010.11.058
   Lichtenstein GR, 2009, AM J GASTROENTEROL, V104, P465, DOI 10.1038/ajg.2008.168
   Liu WL, 2010, P NATL ACAD SCI USA, V107, P11056, DOI 10.1073/pnas.1001269107
   Lu HK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033478
   Maloy KJ, 2011, NATURE, V474, P298, DOI 10.1038/nature10208
   McKinney EF, 2010, NAT MED, V16, P586, DOI 10.1038/nm.2130
   Medina I, 2007, BIOINFORMATICS, V23, P390, DOI 10.1093/bioinformatics/btl602
   Oz HS, 2009, DIGEST DIS SCI, V54, P2561, DOI 10.1007/s10620-008-0673-4
   Sengupta S, 2001, GENE DEV, V15, P2367, DOI 10.1101/gad.202201
   Simon R, 2003, J NATL CANCER I, V95, P14, DOI 10.1093/jnci/95.1.14
   Srivastava Maya D, 2004, J Med, V35, P233
   Svensson SL, 2010, J BIOL CHEM, V285, P16105, DOI 10.1074/jbc.M109.081232
   Tedla N, 2011, TISSUE ANTIGENS, V77, P305, DOI 10.1111/j.1399-0039.2011.01633.x
   Thomas PD, 2003, NUCLEIC ACIDS RES, V31, P334, DOI 10.1093/nar/gkg115
   van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967
   van Limbergen J, 2011, GASTROENTEROLOGY, V141, P1566, DOI 10.1053/j.gastro.2011.09.018
NR 24
TC 42
Z9 43
U1 0
U2 11
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 14
PY 2013
VL 8
IS 10
AR e76235
DI 10.1371/journal.pone.0076235
PG 9
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 237RD
UT WOS:000325887300029
PM 24155895
OA Green Published, gold, Green Submitted
DA 2022-04-25
ER

PT J
AU Hartman, KG
   Bortner, JD
   Falk, GW
   Ginsberg, GG
   Jhala, N
   Yu, J
   Martin, MG
   Rustgi, AK
   Lynch, JP
AF Hartman, Kira G.
   Bortner, James D., Jr.
   Falk, Gary W.
   Ginsberg, Gregory G.
   Jhala, Nirag
   Yu, Jian
   Martin, Martin G.
   Rustgi, Anil K.
   Lynch, John P.
TI Modeling human gastrointestinal inflammatory diseases using
   microphysiological culture systems
SO EXPERIMENTAL BIOLOGY AND MEDICINE
LA English
DT Review
DE Inflammation; oxidative stress; autophagy; gastrointestinal disease;
   gastroesophageal reflux disease; Barrett's esophagus; esophageal
   adenocarcinoma; graft versus host disease; inflammatory bowel disease;
   human 3D organotypic model systems
ID VERSUS-HOST-DISEASE; HUMAN ESOPHAGEAL KERATINOCYTES; IN-VITRO MODEL;
   BOWEL-DISEASE; HUMAN-COLON; BARRETTS-ESOPHAGUS; EPITHELIAL-CELLS;
   CROHNS-DISEASE; CDX2 EXPRESSION; GENE-EXPRESSION
AB Gastrointestinal illnesses are a significant health burden for the US population, with 40 million office visits each year for gastrointestinal complaints and nearly 250,000 deaths. Acute and chronic inflammations are a common element of many gastrointestinal diseases. Inflammatory processes may be initiated by a chemical injury (acid reflux in the esophagus), an infectious agent (Helicobacter pylori infection in the stomach), autoimmune processes (graft versus host disease after bone marrow transplantation), or idiopathic (as in the case of inflammatory bowel diseases). Inflammation in these settings can contribute to acute complaints (pain, bleeding, obstruction, and diarrhea) as well as chronic sequelae including strictures and cancer. Research into the pathophysiology of these conditions has been limited by the availability of primary human tissues or appropriate animal models that attempt to physiologically model the human disease. With the many recent advances in tissue engineering and primary human cell culture systems, it is conceivable that these approaches can be adapted to develop novel human ex vivo systems that incorporate many human cell types to recapitulate in vivo growth and differentiation in inflammatory microphysiological environments. Such an advance in technology would improve our understanding of human disease progression and enhance our ability to test for disease prevention strategies and novel therapeutics. We will review current models for the inflammatory and immunological aspects of Barrett's esophagus, acute graft versus host disease, and inflammatory bowel disease and explore recent advances in culture methodologies that make these novel microphysiological research systems possible.
C1 [Hartman, Kira G.; Bortner, James D., Jr.; Falk, Gary W.; Ginsberg, Gregory G.; Rustgi, Anil K.; Lynch, John P.] Univ Penn, Dept Med, Perelman Sch Med, Div Gastroenterol, Philadelphia, PA 19104 USA.
   [Jhala, Nirag] Univ Penn, Perelman Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA.
   [Yu, Jian] Univ Pittsburgh, Sch Med, Inst Canc, Dept Pathol, Pittsburgh, PA 15213 USA.
   [Yu, Jian] Univ Pittsburgh, Sch Med, Inst Canc, Dept Radiat Oncol, Pittsburgh, PA 15213 USA.
   [Martin, Martin G.] Univ Calif Los Angeles, Mattel Childrens Hosp, Div Gastroenterol & Nutr, Dept Pediat, Los Angeles, CA 90095 USA.
   [Martin, Martin G.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
RP Lynch, JP (corresponding author), Univ Penn, Dept Med, Perelman Sch Med, Div Gastroenterol, Philadelphia, PA 19104 USA.
EM lynchj@mail.med.upenn.edu
OI Falk, Gary/0000-0002-7143-1436
FU National Cancer InstituteUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Cancer
   Institute (NCI); Integrated Microphysiological Systems program;
   Intestinal Stem Cell Consortium; NCI Program Project [PO1 CA098101];
   Morphology, Cell Culture, and Molecular Biology Core Facilities of the
   Center for Molecular Studies in Digestive and Liver Disease at the
   University of Pennsylvania [PO1 CA098101, P30-DK050306];  [TR 000536]; 
   [OD 012097];  [DK 085551];  [DK085570];  [MGM DK 085535]; NATIONAL
   CANCER INSTITUTEUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Cancer
   Institute (NCI) [P01CA098101, U54CA163004] Funding Source: NIH RePORTER;
   NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Center for Advancing Translational Sciences (NCATS)
   [U18TR000536] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF
   DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)
   [U01DK085535, P30DK050306, U01DK085570, U01DK085551] Funding Source: NIH
   RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTHUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USA [K26OD012097] Funding Source: NIH RePORTER
FX The authors would like to thank the University of Pennsylvania
   Morphology and Pathology Imaging Core facility for their technical
   expertise and assistance. Tissue samples were kindly provided by the
   Cooperative Human Tissue Network, which is funded by the National Cancer
   Institute. This work is supported as part of the Integrated
   Microphysiological Systems program and the Intestinal Stem Cell
   Consortium with funding to JPL (TR 000536, OD 012097 and DK 085551), JY
   (DK085570), and MGM (DK 085535). This work was also supported by an NCI
   Program Project PO1 CA098101 (AKR) and the Morphology, Cell Culture, and
   Molecular Biology Core Facilities of the Center for Molecular Studies in
   Digestive and Liver Disease at the University of Pennsylvania
   (P30-DK050306 and PO1 CA098101) (AKR).
CR Akbulut S, 2012, WORLD J GASTROENTERO, V18, P5240, DOI 10.3748/wjg.v18.i37.5240
   Amanzada A, 2013, INT J CLIN EXP PATHO, V6, P561
   Arber N, 1996, CANCER EPIDEM BIOMAR, V5, P457
   Baker BM, 2012, J CELL SCI, V125, P3015, DOI 10.1242/jcs.079509
   Barrett JC, 2008, NAT GENET, V40, P955, DOI 10.1038/ng.175
   Barrett MT, 1996, ONCOGENE, V13, P1867
   Bataille F, 2004, GUT, V53, P1314, DOI 10.1136/gut.2003.038208
   Berg DJ, 1996, J CLIN INVEST, V98, P1010, DOI 10.1172/JCI118861
   Bertolotti A, 2001, J CLIN INVEST, V107, P585, DOI 10.1172/JCI11476
   Bissell MJ, 2001, NAT REV CANCER, V1, P46, DOI 10.1038/35094059
   Blazar BR, 2012, NAT REV IMMUNOL, V12, P443, DOI 10.1038/nri3212
   BRUBAKER PL, 1990, AM J PHYSIOL, V258, pG974, DOI 10.1152/ajpgi.1990.258.6.G974
   Carlson MJ, 2009, BLOOD, V113, P1365, DOI 10.1182/blood-2008-06-162420
   Chang CL, 2007, GUT, V56, P906, DOI 10.1136/gut.2006.097915
   Colleypriest BJ, 2009, TRENDS MOL MED, V15, P313, DOI 10.1016/j.molmed.2009.05.001
   Cooke G, 2008, DIGEST DIS SCI, V53, P2851, DOI 10.1007/s10620-008-0240-z
   Elson CO, 2005, IMMUNOL REV, V206, P260, DOI 10.1111/j.0105-2896.2005.00291.x
   Falk GW, 2002, GASTROENTEROLOGY, V122, P1569, DOI 10.1053/gast.2002.33427
   Fanning SL, 2009, J IMMUNOL, V183, P4261, DOI 10.4049/jimmunol.0900971
   Federico A, 2007, INT J CANCER, V121, P2381, DOI 10.1002/ijc.23192
   Fein M, 1998, J Gastrointest Surg, V2, P260, DOI 10.1016/S1091-255X(98)80021-8
   Fitzgerald RC, 2002, GUT, V50, P451, DOI 10.1136/gut.50.4.451
   Fitzgerald RC, 1997, J CELL SCI, V110, P663
   FOGH J, 1977, JNCI-J NATL CANCER I, V59, P221, DOI 10.1093/jnci/59.1.221
   Funakoshi S, 2010, AM J PHYSIOL-GASTR L, V229
   Funakoshi S, 2008, MOL CANCER RES, V6, P1478, DOI 10.1158/1541-7786.MCR-07-2161
   Gao N, 2009, DEV CELL, V16, P588, DOI 10.1016/j.devcel.2009.02.010
   Groisman GM, 2004, MODERN PATHOL, V17, P1282, DOI 10.1038/modpathol.3800182
   Gunther C, 2011, NATURE, V477, P335, DOI 10.1038/nature10400
   Guo RJ, 2004, CANCER BIOL THER, V3, P593, DOI 10.4161/cbt.3.7.913
   Guo RJ, 2004, J BIOL CHEM, V279, P36865, DOI 10.1074/jbc.M405213200
   Guo RJ, 2010, CARCINOGENESIS, V31, P159, DOI 10.1093/carcin/bgp213
   HAMELIN R, 1994, GASTROENTEROLOGY, V107, P1012, DOI 10.1016/0016-5085(94)90225-9
   Hanas JS, 1999, CANCER-AM CANCER SOC, V86, P756, DOI 10.1002/(SICI)1097-0142(19990901)86:5<756::AID-CNCR9>3.0.CO;2-X
   Harada H, 2003, MOL CANCER RES, V1, P729
   Heazlewood CK, 2008, PLOS MED, V5, P440, DOI 10.1371/journal.pmed.0050054
   Heimesaat MM, 2010, GUT, V59, P1079, DOI 10.1136/gut.2009.197434
   Hill GR, 2000, BLOOD, V95, P2754, DOI 10.1182/blood.V95.9.2754.009k25_2754_2759
   Hisamatsu T, 2013, PHARMACOL THERAPEUT, V137, P283, DOI 10.1016/j.pharmthera.2012.10.008
   Huh D, 2013, NAT PROTOC, V8, P2135, DOI 10.1038/nprot.2013.137
   Humphries A, 2008, NAT REV CANCER, V8, P415, DOI 10.1038/nrc2392
   Hvid-Jensen F, 2011, NEW ENGL J MED, V365, P1375, DOI 10.1056/NEJMoa1103042
   Imado T, 2010, TRANSPLANTATION, V90, P1063, DOI 10.1097/TP.0b013e3181f86947
   Imura Y, 2009, ANAL SCI, V25, P1403, DOI 10.2116/analsci.25.1403
   Jacobsohn DA, 2007, ORPHANET J RARE DIS, V2, DOI 10.1186/1750-1172-2-35
   Jaiswal KR, 2007, DIS ESOPHAGUS, V20, P256, DOI 10.1111/j.1442-2050.2007.00683.x
   Jung P, 2011, NAT MED, V17, P1225, DOI 10.1038/nm.2470
   Kalabis J, 2003, FASEB J, V17, P1115, DOI 10.1096/fj.02-0852fje
   Kalabis J, 2012, NAT PROTOC, V7, P235, DOI 10.1038/nprot.2011.437
   Kappelman MD, 2008, GASTROENTEROLOGY, V135, P1907, DOI 10.1053/j.gastro.2008.09.012
   Kaser A, 2008, CELL, V134, P743, DOI 10.1016/j.cell.2008.07.021
   Katada N, 1997, ARCH SURG-CHICAGO, V132, P728
   Kazumori H, 2006, GUT, V55, P16, DOI 10.1136/gut.2005.066209
   Keller MS, 2004, AM J PHYSIOL-GASTR L, V287, pG104, DOI 10.1152/ajpgi.00484.2003
   Kim HJ, 2012, LAB CHIP, V12, P2165, DOI 10.1039/c2lc40074j
   Kimura H, 2008, LAB CHIP, V8, P741, DOI 10.1039/b717091b
   Kohata Y, 2011, J GASTROENTEROL, V46, P883, DOI 10.1007/s00535-011-0405-y
   Kong JP, 2011, NEOPLASIA, V13, P792, DOI 10.1593/neo.11788
   Kong JP, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018280
   Kong J, 2009, CARCINOGENESIS, V30, P122, DOI 10.1093/carcin/bgn227
   Kosoff RE, 2012, J CELL PHYSIOL, V227, P2654, DOI 10.1002/jcp.23007
   Kovbasnjuk O, 2013, STEM CELL RES THER, V4, DOI 10.1186/scrt364
   Kuratnik A, 2013, BIOCHEM PHARMACOL, V85, P1721, DOI 10.1016/j.bcp.2013.04.016
   Lahar N, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026898
   Laroux FS, 2004, INT IMMUNOL, V16, P77, DOI 10.1093/intimm/dxh006
   Lee SJ, 2008, ASH EDUCATION PROGRA, V2008, P134, DOI DOI 10.1182/ASHEDUCATION-2008.1.134
   Leonard F, 2012, ALTEX-ALTERN ANIM EX, V29, P275, DOI 10.14573/altex.2012.3.275
   Leonard F, 2010, MOL PHARMACEUT, V7, P2103, DOI 10.1021/mp1000795
   Liu JH, 2012, AM J PHYSIOL-CELL PH, V302, pC1492, DOI 10.1152/ajpcell.00392.2011
   Liu T, 2007, CARCINOGENESIS, V28, P488, DOI 10.1093/carcin/bgl176
   Loftus EV, 2004, GASTROENTEROLOGY, V126, P1504, DOI 10.1053/j.gastro.2004.01.063
   Lord RV, 2000, J GASTROEN HEPATOL, V15, P730, DOI 10.1046/j.1440-1746.2000.02163.x
   Mahler GJ, 2009, BIOTECHNOL BIOENG, V104, P193, DOI 10.1002/bit.22366
   Marchetti M, 2003, J CELL SCI, V116, P1429, DOI 10.1242/jcs.00338
   McGovern DPB, 2010, NAT GENET, V42, P332, DOI 10.1038/ng.549
   McKay DM, 1997, ALIMENT PHARM THERAP, V11, P70
   Milano F, 2007, GASTROENTEROLOGY, V132, P2412, DOI 10.1053/j.gastro.2007.03.026
   Miyamoto S, 2011, CANCER SCI, V102, P1938, DOI 10.1111/j.1349-7006.2011.02049.x
   Mizoguchi A, 2012, PROG MOL BIOL TRANSL, V105, P263, DOI 10.1016/B978-0-12-394596-9.00009-3
   Monteleone I, 2011, BMC MED, V9, DOI 10.1186/1741-7015-9-122
   Morales CP, 2003, GUT, V52, P327, DOI 10.1136/gut.52.3.327
   Morris CD, 2001, AM J GASTROENTEROL, V96, P990
   Nakagawa H, 1997, ONCOGENE, V14, P1185, DOI 10.1038/sj.onc.1200937
   Nakanishi M, 2013, SEMIN IMMUNOPATHOL, V35, P123, DOI 10.1007/s00281-012-0342-8
   Nicholson AM, 2012, GUT, V61, P1380, DOI 10.1136/gutjnl-2011-301174
   Nikolic B, 2000, J CLIN INVEST, V105, P1289, DOI 10.1172/JCI7894
   Ostanin DV, 2009, AM J PHYSIOL-GASTR L, V296, pG135, DOI 10.1152/ajpgi.90462.2008
   Ostanin DV, 2006, AM J PHYSIOL-GASTR L, V290, pG109, DOI 10.1152/ajpgi.00214.2005
   Ouatu-Lascar R, 1999, GASTROENTEROLOGY, V117, P327, DOI 10.1053/gast.1999.0029900327
   Palanca-Wessels MCA, 2003, CARCINOGENESIS, V24, P1183, DOI 10.1093/carcin/bgg076
   Parkes M, 2007, NAT GENET, V39, P830, DOI 10.1038/ng2061
   Pasquini Marcelo C, 2010, Clin Transpl, P87
   Perminow G, 2009, INFLAMM BOWEL DIS, V15, P1368, DOI 10.1002/ibd.20916
   Phillips RW, 2003, AM J SURG PATHOL, V27, P1442, DOI 10.1097/00000478-200311000-00006
   PHILLIPS TE, 1988, GASTROENTEROLOGY, V94, P1390, DOI 10.1016/0016-5085(88)90678-6
   Picardo SL, 2012, DIGEST SURG, V29, P251, DOI 10.1159/000341498
   Ponec RJ, 1999, GASTROINTEST ENDOSC, V49, P612, DOI 10.1016/S0016-5107(99)70390-1
   Powrie F, 2004, ANN NY ACAD SCI, V1029, P132, DOI 10.1196/annals.1309.030
   POWRIE F, 1995, IMMUNITY, V3, P171, DOI 10.1016/1074-7613(95)90086-1
   Qiu W, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.125
   Quante M, 2012, CANCER CELL, V21, P36, DOI 10.1016/j.ccr.2011.12.004
   QUARONI A, 1979, J CELL BIOL, V80, P248, DOI 10.1083/jcb.80.2.248
   Roig AI, 2010, GASTROENTEROLOGY, V138, P1012, DOI 10.1053/j.gastro.2009.11.052
   Sartor RB, 2006, NAT CLIN PRACT GASTR, V3, P390, DOI 10.1038/ncpgasthep0528
   Sato T, 2011, GASTROENTEROLOGY, V141, P1762, DOI 10.1053/j.gastro.2011.07.050
   Sato T, 2009, NATURE, V459, P262, DOI 10.1038/nature07935
   Sharma P, 2004, GASTROENTEROLOGY, V127, P310, DOI 10.1053/j.gastro.2004.04.010
   Simons BD, 2011, EXP CELL RES, V317, P2719, DOI 10.1016/j.yexcr.2011.07.010
   Souza RF, 2002, GASTROENTEROLOGY, V122, P299, DOI 10.1053/gast.2002.30993
   Spence JR, 2011, NATURE, V470, P105, DOI 10.1038/nature09691
   Stairs DB, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003534
   Stelzner M, 2012, AM J PHYSIOL-GASTR L, V302, pG1359, DOI 10.1152/ajpgi.00493.2011
   Strober W, 2007, J CLIN INVEST, V117, P514, DOI 10.1172/JCI30587
   SUH E, 1994, MOL CELL BIOL, V14, P7340, DOI 10.1128/MCB.14.11.7340
   Tawara I, 2008, EXP HEMATOL, V36, P988, DOI 10.1016/j.exphem.2008.02.010
   Ting C, 2013, BONE MARROW TRANSPL, V48, P4, DOI 10.1038/bmt.2012.9
   Troelsen JT, 1997, BIOCHEM J, V322, P833, DOI 10.1042/bj3220833
   van Sommeren S, 2011, INFLAMM BOWEL DIS, V17, P1714, DOI 10.1002/ibd.21541
   Weaver CT, 2013, ANNU REV PATHOL-MECH, V8, P477, DOI 10.1146/annurev-pathol-011110-130318
   Welz PS, 2011, NATURE, V477, P330, DOI 10.1038/nature10273
   Wiede F, 2011, J CLIN INVEST, V121, P4758, DOI 10.1172/JCI59492
   Yi TS, 2008, BLOOD, V112, P2101, DOI 10.1182/blood-2007-12-126987
   Zhao F, 2010, DEV BIOL, V338, P268, DOI 10.1016/j.ydbio.2009.12.008
   Zhong YQ, 2011, DIGEST DIS SCI, V56, P2865, DOI 10.1007/s10620-011-1696-9
   Zhu JF, 2010, ANNU REV IMMUNOL, V28, P445, DOI 10.1146/annurev-immunol-030409-101212
   ZWEIBAUM A, 1985, J CELL PHYSIOL, V122, P21, DOI 10.1002/jcp.1041220105
   ZWEIBAUM A, 1983, INT J CANCER, V32, P407, DOI 10.1002/ijc.2910320403
NR 127
TC 15
Z9 15
U1 1
U2 24
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1535-3702
EI 1535-3699
J9 EXP BIOL MED
JI Exp. Biol. Med.
PD SEP
PY 2014
VL 239
IS 9
BP 1108
EP 1123
DI 10.1177/1535370214529388
PG 16
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA AQ4MV
UT WOS:000342773100006
PM 24781339
OA Green Accepted
DA 2022-04-25
ER

PT J
AU Okada, Y
   Kato, S
   Sakamoto, Y
   Oishi, T
   Ishioka, C
AF Okada, Yoshinari
   Kato, Shunsuke
   Sakamoto, Yasuhiro
   Oishi, Takayuki
   Ishioka, Chikashi
TI Synthetic lethal interaction of CDK inhibition and autophagy inhibition
   in human solid cancer cell lines
SO ONCOLOGY REPORTS
LA English
DT Article
DE synthetic lethality; cell cycle arrest; CKI; autophagy; apoptosis
ID BREAST-CANCER; APOPTOSIS; THERAPY; MODULATION
AB Cell cycle control is a promising target in cancer treatments, and some small-molecule cyclin-dependent kinase (CDK) inhibitors have exhibited clinical effectiveness. However, no biomarkers predictive of efficacy have been developed. Recent studies have revealed that CDK inhibitor (CKI) proteins, such as p27 and p16, also induced cytoprotective autophagy in cancer cells. However, it is unclear whether small-molecule CKIs also induce autophagy in solid tumors, as induced autophagy promotes cancer cell survival. In this study, we revealed that a CDK4 inhibitor and a CKI with a broad range of targets (flavopiridol) induced autophagy in some, but not all, solid cancer cell lines. Autophagy induction by CDK4 inhibitor was observed in BT474, MDA-MB435S, SKBr3 (derived from breast cancer), A431 (derived from epidermoid cancer), and SW480 (derived from colorectal cancer) cell lines. No such autophagy was observed in MCF7, MDA-MB231 (derived from breast cancer), NCI-N87 (derived from gastric cancer), and KMST-6 (derived from a fibroblast). In the cell lines showing autophagy, which was induced by CDK4 inhibitor, the combination of CDK4 inhibitor and autophagy inhibition by either chloroquine (CQ) or knockdown of ATG5 or BECN1 induced apoptosis. However, it did not induce apoptosis in the cell lines in which autophagy was not induced by CDK4 inhibitor. These findings indicate that the autophagy induced by CDK4 inhibitor mimics stress-induced autophagy in some solid cancer cell lines. The combination of a small-molecule CKI involved in G(1)/S arrest and an autophagy inhibitor leads to a synthetic lethal interaction and could become a new antitumor strategy for solid tumors showing cytoprotective autophagy induced by small-molecule CKIs.
C1 [Okada, Yoshinari; Kato, Shunsuke; Sakamoto, Yasuhiro; Oishi, Takayuki; Ishioka, Chikashi] Tohoku Univ, Dept Clin Oncol, IDAC, Aoba Ku, 4-1 Seiryo Machi, Sendai, Miyagi 9808575, Japan.
RP Ishioka, C (corresponding author), Tohoku Univ, Dept Clin Oncol, IDAC, Aoba Ku, 4-1 Seiryo Machi, Sendai, Miyagi 9808575, Japan.
EM chikashi@tohoku.ac.jp
FU Taiho Pharmaceutical; Tokyo Clinical Oncology Group; Chugai
   Pharmaceutical; Ono Pharmaceutical; Daiichi Sankyo PharmaceuticalDaiichi
   Sankyo Company Limited; Takeda PharmaceuticalTakeda Pharmaceutical
   Company Ltd; Yakult Pharmaceutical
FX We would like to thank Eri Yokota, Satoko Aoki, and Hiromi Nakano for
   their technical assistance. We would also like to thank Enago for the
   English language review. C.I. received lecture fees from Taiho
   Pharmaceutical and Tokyo Clinical Oncology Group and research funding
   from Taiho Pharmaceutical, Chugai Pharmaceutical, Ono Pharmaceutical,
   Daiichi Sankyo Pharmaceutical, Takeda Pharmaceutical, and Yakult
   Pharmaceutical.
CR Amaravadi RK, 2011, CLIN CANCER RES, V17, P654, DOI 10.1158/1078-0432.CCR-10-2634
   Apel A, 2008, CANCER RES, V68, P1485, DOI 10.1158/0008-5472.CAN-07-0562
   Bae H, 2011, MOL CANCER RES, V9, P1232, DOI 10.1158/1541-7786.MCR-11-0098
   Chen N, 2009, BBA-MOL CELL RES, V1793, P1516, DOI 10.1016/j.bbamcr.2008.12.013
   Cook KL, 2011, EXPERT REV ANTICANC, V11, P1283, DOI [10.1586/era.11.111, 10.1586/ERA.11.111]
   Cristofanilli M, 2016, LANCET ONCOL, V17, P425, DOI 10.1016/S1470-2045(15)00613-0
   Foster David A, 2010, Genes Cancer, V1, P1124, DOI 10.1177/1947601910392989
   Fujiwara K, 2008, J BIOL CHEM, V283, P388, DOI 10.1074/jbc.M611043200
   Garber K, 2011, J NATL CANCER I, V103, P708, DOI 10.1093/jnci/djr168
   Golias CH, 2004, INT J CLIN PRACT, V58, P1134, DOI 10.1111/j.1742-1241.2004.00284.x
   Jiang H, 2010, CANCER RES, V70, P7882, DOI 10.1158/0008-5472.CAN-10-1604
   Kakudo Y, 2005, CANCER RES, V65, P2108, DOI 10.1158/0008-5472.CAN-04-2935
   Karantza-Wadsworth V, 2007, GENE DEV, V21, P1621, DOI 10.1101/gad.1565707
   Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1
   Liang JY, 2007, NAT CELL BIOL, V9, P218, DOI 10.1038/ncb1537
   Lin TS, 2009, J CLIN ONCOL, V27, P6012, DOI 10.1200/JCO.2009.22.6944
   Mathew R, 2007, NAT REV CANCER, V7, P961, DOI 10.1038/nrc2254
   Mathew R, 2007, GENE DEV, V21, P1367, DOI 10.1101/gad.1545107
   Molinari M, 2000, CELL PROLIFERAT, V33, P261, DOI 10.1046/j.1365-2184.2000.00191.x
   Orvedahl A, 2011, NATURE, V480, P113, DOI 10.1038/nature10546
   Sakamoto Y, 2011, CANCER SCI, V102, P799, DOI 10.1111/j.1349-7006.2011.01857.x
   Sheen JH, 2011, CANCER CELL, V19, P613, DOI 10.1016/j.ccr.2011.03.012
   Soussi T, 2005, HUM MUTAT, V25, P6, DOI 10.1002/humu.20114
   Watanabe G, 2009, CANCER SCI, V100, P2368, DOI 10.1111/j.1349-7006.2009.01316.x
   White E, 2009, CLIN CANCER RES, V15, P5308, DOI 10.1158/1078-0432.CCR-07-5023
   Yang SH, 2011, GENE DEV, V25, P717, DOI 10.1101/gad.2016111
   Yang ZNJ, 2011, CANCER BIOL THER, V11, P169, DOI 10.4161/cbt.11.2.14663
NR 27
TC 15
Z9 15
U1 1
U2 6
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1021-335X
EI 1791-2431
J9 ONCOL REP
JI Oncol. Rep.
PD JUL
PY 2017
VL 38
IS 1
BP 31
EP 42
DI 10.3892/or.2017.5684
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA EY6JR
UT WOS:000404089500003
PM 28560460
OA Green Published, hybrid, Green Submitted
DA 2022-04-25
ER

PT J
AU Zhang, HL
   Lu, BJ
AF Zhang, Huilin
   Lu, Bingjian
TI The Roles of ceRNAs-Mediated Autophagy in Cancer Chemoresistance and
   Metastasis
SO CANCERS
LA English
DT Review
DE autophagy; ceRNA; lncRNA; circRNAs; miRNA; chemoresistance; metastasis;
   pre-metastasis niche
ID LONG NONCODING RNA; EPITHELIAL-MESENCHYMAL TRANSITION;
   COLORECTAL-CANCER; HEPATOCELLULAR-CARCINOMA; PROMOTES CHEMORESISTANCE;
   REGULATE AUTOPHAGY; PANCREATIC-CANCER; DRUG-RESISTANCE; CELL-SURVIVAL;
   STEM-CELLS
AB Simple Summary
   Chemoresistance and metastasis are the main causes of treatment failure in cancers. Autophagy contribute to the survival and metastasis of cancer cells. Competing endogenous RNA (ceRNA), particularly long non-coding RNAs and circular RNA (circRNA), can bridge the interplay between autophagy and chemoresistance or metastasis in cancers via sponging miRNAs. This review aims to discuss on the function of ceRNA-mediated autophagy in the process of metastasis and chemoresistance in cancers. ceRNA network can sequester the targeted miRNA expression to indirectly upregulate the expression of autophagy-related genes, and thereof participate in autophagy-mediated chemoresistance and metastasis. Our clarification of the mechanism of autophagy regulation in metastasis and chemoresistance may greatly improve the efficacy of chemotherapy and survival in cancer patients. The combination of the tissue-specific miRNA delivery and selective autophagy inhibitors, such as hydroxychloroquine, is attractive to treat cancer patients in the future.
   Chemoresistance and metastasis are the main causes of treatment failure and unfavorable outcome in cancers. There is a pressing need to reveal their mechanisms and to discover novel therapy targets. Autophagy is composed of a cascade of steps controlled by different autophagy-related genes (ATGs). Accumulating evidence suggests that dysregulated autophagy contributes to chemoresistance and metastasis via competing endogenous RNA (ceRNA) networks including lncRNAs and circRNAs. ceRNAs sequester the targeted miRNA expression to indirectly upregulate ATGs expression, and thereof participate in autophagy-mediated chemoresistance and metastasis. Here, we attempt to summarize the roles of ceRNAs in cancer chemoresistance and metastasis through autophagy regulation.
C1 [Zhang, Huilin; Lu, Bingjian] Zhejiang Univ, Sch Med, Womens Hosp, Dept Surg Pathol, Hangzhou 310002, Zhejiang, Peoples R China.
   [Lu, Bingjian] Zhejiang Univ, Sch Med, Womens Hosp, Ctr Uterine Canc Diag & Therapy Res Zhejiang Prov, Hangzhou 310002, Zhejiang, Peoples R China.
RP Lu, BJ (corresponding author), Zhejiang Univ, Sch Med, Womens Hosp, Dept Surg Pathol, Hangzhou 310002, Zhejiang, Peoples R China.; Lu, BJ (corresponding author), Zhejiang Univ, Sch Med, Womens Hosp, Ctr Uterine Canc Diag & Therapy Res Zhejiang Prov, Hangzhou 310002, Zhejiang, Peoples R China.
EM huilinzhang@zju.edu.cn; lbj@zju.edu.cn
FU Natural Science Foundation of ChinaNational Natural Science Foundation
   of China (NSFC) [81872112]; National Key Research and Development
   Program of China [2016YFC1302900]
FX This study is supported by grants from the Natural Science Foundation of
   China (no. 81872112) and National Key Research and Development Program
   of China (2016YFC1302900).
CR Abdullah LN, 2013, CLIN TRANSL MED, V2, DOI 10.1186/2001-1326-2-3
   Acharyya S, 2012, CELL, V150, P165, DOI 10.1016/j.cell.2012.04.042
   An Y, 2017, J CELL MOL MED, V21, P185, DOI 10.1111/jcmm.12952
   Bao X, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.31
   Baskaran S, 2012, AUTOPHAGY, V8, P1851, DOI 10.4161/auto.22077
   Bermudez M, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.01008
   Bonasio R, 2014, ANNU REV GENET, V48, P433, DOI 10.1146/annurev-genet-120213-092323
   Cai Q, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1016-0
   Cao PB, 2021, SEMIN CANCER BIOL, V75, P136, DOI 10.1016/j.semcancer.2020.09.003
   Cao YJ, 2019, CLIN CHIM ACTA, V489, P10, DOI 10.1016/j.cca.2018.11.028
   Celia-Terrassa T, 2018, NAT CELL BIOL, V20, P868, DOI 10.1038/s41556-018-0145-9
   Chan EY, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.284pe51
   Chao HT, 2020, LIFE SCI, V243, DOI 10.1016/j.lfs.2020.117296
   Chen CL, 2015, BIOMATERIALS, V44, P71, DOI 10.1016/j.biomaterials.2014.12.023
   Chen HT, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1030-2
   Chen JF, 2018, MOL CANCER, V17, DOI 10.1186/s12943-017-0756-y
   Chen LL, 2020, NAT REV MOL CELL BIO, V21, P475, DOI 10.1038/s41580-020-0243-y
   Chen YP, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aax5819
   Chen ZH, 2017, CELL DEATH DIFFER, V24, P212, DOI 10.1038/cdd.2016.111
   Chittaranjan S, 2014, CLIN CANCER RES, V20, P3159, DOI 10.1158/1078-0432.CCR-13-2060
   Choi EJ, 2018, PATHOL ONCOL RES, V24, P827, DOI 10.1007/s12253-017-0297-0
   Chu CA, 2019, EBIOMEDICINE, V43, P270, DOI 10.1016/j.ebiom.2019.04.010
   Cristobal I, 2020, CANCERS, V12, DOI 10.3390/cancers12041041
   Cui CC, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01180-y
   Cui XL, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0877-y
   Cui XJ, 2018, ACS APPL MATER INTER, V10, P7821, DOI 10.1021/acsami.7b19183
   Ding CY, 2020, CANCER LETT, V479, P1, DOI 10.1016/j.canlet.2020.03.002
   Dower CM, 2018, AUTOPHAGY, V14, P1110, DOI 10.1080/15548627.2018.1450020
   E Pollok K., 2017, CANCER RES, V77, P198
   Erler JT, 2009, CANCER CELL, V15, P35, DOI 10.1016/j.ccr.2008.11.012
   Errafiy R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083318
   Foster KG, 2010, J BIOL CHEM, V285, P80, DOI 10.1074/jbc.M109.029637
   Frankel LB, 2011, EMBO J, V30, P4628, DOI 10.1038/emboj.2011.331
   Gan XL, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01163-z
   Ganley IG, 2009, J BIOL CHEM, V284, P12297, DOI 10.1074/jbc.M900573200
   Garbar C, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-07489-x
   Gorgulu K, 2019, GASTROENTEROLOGY, V156, P203, DOI 10.1053/j.gastro.2018.09.053
   Guo LL, 2015, WORLD J GASTROENTERO, V21, P11680, DOI 10.3748/wjg.v21.i41.11680
   Guo YX, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0995-1
   Han D, 2020, CIRC RES, V127, pE108, DOI 10.1161/CIRCRESAHA.119.316061
   Hardin H, 2018, LAB INVEST, V98, P1133, DOI 10.1038/s41374-018-0065-0
   Hombach-Klonisch S, 2018, PHARMACOL THERAPEUT, V184, P13, DOI 10.1016/j.pharmthera.2017.10.017
   Hong XH, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01149-x
   Hosokawa N, 2009, MOL BIOL CELL, V20, P1981, DOI 10.1091/mbc.E08-12-1248
   Houg DS, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0842-9
   Hu YR, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0743-3
   Huang FX, 2019, INT J ONCOL, V54, P339, DOI 10.3892/ijo.2018.4614
   Huang FT, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0845-6
   Huang W, 2020, ONCOTARGETS THER, V13, P413, DOI 10.2147/OTT.S237161
   Jahangiri B, 2019, J CELL COMMUN SIGNAL, V13, P53, DOI 10.1007/s12079-018-0471-5
   Jia YY, 2020, ENVIRON INT, V141, DOI 10.1016/j.envint.2020.105755
   Jian XY, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-1134-8
   Jiang PD, 2014, CELL RES, V24, P69, DOI 10.1038/cr.2013.161
   Jiang WX, 2020, DRUG RESIST UPDATE, V50, DOI 10.1016/j.drup.2020.100683
   Judith D, 2019, AUTOPHAGY, V15, P1660, DOI 10.1080/15548627.2019.1632124
   Kang Y, 2019, ONCOTARGETS THER, V12, P10787, DOI 10.2147/OTT.S226044
   Karreth FA, 2013, CANCER DISCOV, V3, P1113, DOI 10.1158/2159-8290.CD-13-0202
   Kim DH, 2003, MOL CELL, V11, P895, DOI 10.1016/S1097-2765(03)00114-X
   Kim J, 2011, NAT CELL BIOL, V13, P132, DOI 10.1038/ncb2152
   Klionsky DJ, 2014, NAT STRUCT MOL BIOL, V21, P336, DOI 10.1038/nsmb.2787
   Kong YY, 2019, LIFE SCI, V237, DOI 10.1016/j.lfs.2019.116902
   Kroemer G, 2010, MOL CELL, V40, P280, DOI 10.1016/j.molcel.2010.09.023
   Kulkarni B, 2019, DRUG DISCOV TODAY, V24, P2058, DOI 10.1016/j.drudis.2019.06.010
   Lazova R, 2012, CLIN CANCER RES, V18, P370, DOI 10.1158/1078-0432.CCR-11-1282
   Lei M, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-1135-7
   Levy JMM, 2017, NAT REV CANCER, V17, P528, DOI 10.1038/nrc.2017.53
   Li C, 2018, CANCER LETT, V418, P185, DOI 10.1016/j.canlet.2018.01.036
   Li CG, 2016, CANCER CHEMOTH PHARM, V78, P1199, DOI 10.1007/s00280-016-3178-4
   Li HM, 2019, WIRES RNA, V10, DOI 10.1002/wrna.1538
   Li JJ, 2020, CLIN EXP PHARMACOL P, V47, P877, DOI 10.1111/1440-1681.13259
   Li J, 2016, J CLIN ONCOL, V34, P1448, DOI 10.1200/JCO.2015.63.5995
   Li ML, 2019, EUR REV MED PHARMACO, V23, P10708, DOI 10.26355/eurrev_201912_19771
   Li PL, 2017, MOL CANCER THER, V16, P739, DOI 10.1158/1535-7163.MCT-16-0591
   Li SP, 2016, ONCOTARGET, V7, P42431, DOI 10.18632/oncotarget.9883
   Li W, 2016, J BONE ONCOL, V5, P80, DOI 10.1016/j.jbo.2016.05.003
   Li XX, 2020, MOL CELL BIOL, V40, DOI 10.1128/MCB.00492-19
   Li XH, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-1138-4
   Li XY, 2020, J CELL PHYSIOL, V235, P3402, DOI 10.1002/jcp.29230
   Li YC, 2019, ONCOTARGETS THER, V12, P2649, DOI 10.2147/OTT.S188054
   Liang GH, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01152-2
   Liu F, 2020, CANCER MED-US, V9, P1079, DOI 10.1002/cam4.2746
   Liu F, 2018, AGING-US, V10, P3806, DOI 10.18632/aging.101674
   Liu JY, 2021, CELL MOL GASTROENTER, V11, P407, DOI 10.1016/j.jcmgh.2020.09.003
   Liu K, 2017, J BIOMED SCI, V24, DOI 10.1186/s12929-017-0353-9
   Liu Y, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0734-5
   Liu Y, 2016, CANCER CELL, V30, P668, DOI 10.1016/j.ccell.2016.09.011
   Liu YQ, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2268-8
   Livesey KM, 2012, CANCER RES, V72, P1996, DOI 10.1158/0008-5472.CAN-11-2291
   Lou WY, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00085
   Ma L, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2352-0
   Ma YW, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317694326
   Ma ZB, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0221104
   Maia J, 2018, FRONT CELL DEV BIOL, V6, DOI 10.3389/fcell.2018.00018
   Mao L, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13923-7
   Marsh T, 2020, DEV CELL, V52, P591, DOI 10.1016/j.devcel.2020.01.025
   Mowers EE, 2017, ONCOGENE, V36, P1619, DOI 10.1038/onc.2016.333
   Ogata M, 2006, MOL CELL BIOL, V26, P9220, DOI 10.1128/MCB.01453-06
   Ojha R, 2015, BIORESEARCH OPEN ACC, V4, P97, DOI 10.1089/biores.2014.0035
   Paquette M, 2018, CANCERS, V10, DOI 10.3390/cancers10010018
   Peng YF, 2013, AUTOPHAGY, V9, P2056, DOI 10.4161/auto.26398
   Perez-Hernandez M, 2019, CANCERS, V11, DOI 10.3390/cancers11101599
   Piwecka M, 2017, SCIENCE, V357, DOI 10.1126/science.aam8526
   Piya S, 2016, BLOOD, V128, P1260, DOI 10.1182/blood-2016-01-692244
   Prabhu KS, 2020, CANCERS, V12, DOI 10.3390/cancers12020351
   Proikas-Cezanne T, 2015, J CELL SCI, V128, P207, DOI 10.1242/jcs.146258
   Qian YY, 2017, ONCOTARGET, V8, P107859, DOI 10.18632/oncotarget.22305
   Quinodoz S, 2014, TRENDS CELL BIOL, V24, P651, DOI 10.1016/j.tcb.2014.08.009
   Rangwala R, 2014, AUTOPHAGY, V10, P1391, DOI 10.4161/auto.29119
   Ranieri R, 2018, CELL DEATH DIFFER, V25, P353, DOI 10.1038/cdd.2017.165
   Reidick C, 2015, CANCERS, V7, P1, DOI 10.3390/cancers7010001
   Ren H, 2016, J CANCER, V7, P1074, DOI 10.7150/jca.14031
   Ren Y, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0758-4
   Rosenfeld MR, 2014, AUTOPHAGY, V10, P1359, DOI 10.4161/auto.28984
   Sceneay J, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.22355
   Shan C, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1069-0
   Shen T, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-018-0638-9
   Shi WJ, 2016, WORLD J GASTRO ONCOL, V8, P673, DOI 10.4251/wjgo.v8.i9.673
   Si YR, 2019, CELL MOL BIOL LETT, V24, DOI 10.1186/s11658-019-0175-8
   Skarkova V, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8030234
   Song C, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-10547-z
   Su DW, 2020, EUR REV MED PHARMACO, V24, P8812, DOI 10.26355/eurrev_202009_22820
   Su M, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1002-6
   Su Y, 2019, J MOL MED, V97, P49, DOI 10.1007/s00109-018-1711-0
   Su ZY, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0321-5
   Sui X, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.350
   Sun JK, 2020, MOL CANCER, V19, DOI 10.1186/s12943-019-1121-0
   Sun T, 2018, PHARMACOL RES, V129, P151, DOI 10.1016/j.phrs.2017.11.009
   Sun W, 2017, ONCOL REP, V38, P3347, DOI 10.3892/or.2017.6056
   Suzuki R, 2020, DRUG DISCOV THER, V14, P35, DOI 10.5582/ddt.2020.01001
   Tan MD, 2019, J CANCER, V10, P4245, DOI 10.7150/jca.32807
   Tay Y, 2014, NATURE, V505, P344, DOI 10.1038/nature12986
   Thomson DW, 2016, NAT REV GENET, V17, P272, DOI 10.1038/nrg.2016.20
   Tian XL, 2019, NPJ PRECIS ONCOL, V3, DOI 10.1038/s41698-019-0080-7
   Vera-Ramirez L, 2020, SEMIN CANCER BIOL, V60, P28, DOI 10.1016/j.semcancer.2019.07.027
   Wang CZ, 2019, WORLD J GASTROENTERO, V25, P5310, DOI 10.3748/wjg.v25.i35.5310
   Wang JY, 2010, NUCLEIC ACIDS RES, V38, P5366, DOI 10.1093/nar/gkq285
   Wang K, 2019, EUR J PHARMACOL, V858, DOI 10.1016/j.ejphar.2019.04.019
   Wang L, 2019, INT J BIOL SCI, V15, P882, DOI 10.7150/ijbs.30290
   Wang WT, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0748-z
   Wang XK, 2019, CANCER CELL INT, V19, DOI 10.1186/s12935-019-0951-6
   Wang YQ, 2017, CELL DEATH DIFFER, V24, P2089, DOI 10.1038/cdd.2017.129
   Wang ZZ, 2019, AGING-US, V11, P4876, DOI 10.18632/aging.102081
   Wei HM, 2019, INT IMMUNOPHARMACOL, V73, P72, DOI 10.1016/j.intimp.2019.04.049
   Wei L, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01185-7
   Wu JF, 2019, ONCOTARGETS THER, V12, P495, DOI 10.2147/OTT.S183940
   Xi ZW, 2019, INT J ONCOL, V54, P239, DOI 10.3892/ijo.2018.4609
   Xu SP, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1017-z
   Xu WP, 2020, GUT, V69, P1309, DOI 10.1136/gutjnl-2019-318830
   Xu ZZ, 2017, ONCOL REP, V38, P3659, DOI 10.3892/or.2017.6040
   Xue M, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0714-8
   Yan L, 2019, BIOCHEM BIOPH RES CO, V519, P172, DOI 10.1016/j.bbrc.2019.08.093
   Yan M, 2020, EUR REV MED PHARMACO, V24, P2229, DOI 10.26355/eurrev_202003_20488
   Yan P, 2019, INT J ONCOL, V55, P988, DOI 10.3892/ijo.2019.4868
   Yang L, 2019, GENE, V697, P94, DOI 10.1016/j.gene.2019.02.036
   Yang L, 2016, MOL BIOSYST, V12, P2605, DOI 10.1039/c6mb00114a
   Yang MC, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0449-3
   Yang WP, 2020, CANCER MANAG RES, V12, P2327, DOI 10.2147/CMAR.S238513
   Yang YX, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-018-1280-8
   Yu FJ, 2020, MOL CELL BIOCHEM, V465, P115, DOI 10.1007/s11010-019-03672-y
   Yu TC, 2017, CELL, V170, P548, DOI 10.1016/j.cell.2017.07.008
   Zhan HX, 2016, CANCER LETT, V374, P261, DOI 10.1016/j.canlet.2016.02.018
   Zhang H, 2015, MOL NEUROBIOL, V51, P89, DOI 10.1007/s12035-014-8787-5
   Zhang H, 2019, DNA CELL BIOL, V38, P857, DOI 10.1089/dna.2019.4770
   Zhang HL, 2020, EXPERT REV ANTICANC, V20, P373, DOI 10.1080/14737140.2020.1760095
   Zhang MY, 2019, ONCOTARGETS THER, V12, P3349, DOI 10.2147/OTT.S197433
   Zhang N, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1932-3
   Zhang QG, 2020, MOL CANCER, V19, DOI 10.1186/s12943-019-1125-9
   Zhang W, 2020, CANCER LETT, V478, P22, DOI 10.1016/j.canlet.2020.02.014
   Zhang W, 2018, BIOCHIMIE, V144, P21, DOI 10.1016/j.biochi.2017.10.002
   Zhang XY, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01171-z
   Zhang Y, 2020, ENERGY SCI ENG, V5, P1, DOI DOI 10.1016/J.LFS.2020.117280
   Zhao W, 2019, AGING-US, V11, P9581, DOI 10.18632/aging.102406
   Zheng XY, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01183-9
   Zhou Y, 2020, ACTA PHARMACOL SIN B, V10, P1563, DOI 10.1016/j.apsb.2019.11.013
   Zhu XL, 2020, CANCER CELL INT, V20, DOI 10.1186/s12935-020-01488-1
   Zhu X, 2019, CANCER CELL INT, V19, DOI 10.1186/s12935-019-0794-1
   Zhu Y, 2019, AGING-US, V11, P1089, DOI 10.18632/aging.101766
NR 177
TC 9
Z9 9
U1 2
U2 7
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2072-6694
J9 CANCERS
JI Cancers
PD OCT
PY 2020
VL 12
IS 10
AR 2926
DI 10.3390/cancers12102926
PG 23
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA OJ7AW
UT WOS:000584110300001
PM 33050642
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Cui, Y
   Bai, YB
   Yang, JN
   Yao, YF
   Zhang, CH
   Liu, C
   Shi, JQ
   Li, QW
   Zhang, JC
   Lu, XL
   Zhang, YQ
AF Cui, Ying
   Bai, Yibing
   Yang, Jiani
   Yao, Yuanfei
   Zhang, Chunhui
   Liu, Chao
   Shi, Jiaqi
   Li, QingWei
   Zhang, Jingchun
   Lu, Xiaolin
   Zhang, Yanqiao
TI SIRT4 is the molecular switch mediating cellular proliferation in
   colorectal cancer through GLS mediated activation of AKT/GSK3
   beta/CyclinD1 pathway
SO CARCINOGENESIS
LA English
DT Article
ID TUMOR-SUPPRESSIVE ACTIVITY; DNA-DAMAGE; GLUTAMINOLYSIS; AUTOPHAGY;
   NETWORK; CHINA; CELLS
AB Mitochondria-localized sirtuin 4 (SIRT4) is associated with malignant phenotypes in colorectal cancer (CRC). However, the molecular mechanisms that drive SIRT4-mediated carcinogenesis are unclear. Initially, we confirmed expression of SIRT4 in CRC through public database and in CRC patient tissues using quantitative real-time reverse transcription PCR. We established HCT116 colorectal cells that overexpressed SIRT4 and HT29 cells were transfected with plasmids bearing a small interfering RNA construct to silence SIRT4. Assays to determine the malignant phenotypes (proliferation, invasion and migration) were performed. Xenograft in vivo models were also constructed. A protein interactome network was built using differentially expressed proteins identified using the liquid chromatography/tandem mass spectrophotometry, the findings of which were confirmed using co-immunoprecipitation, western blotting and phenotype rescue experiments. Decreased SIRT4 expression was associated with malignant phenotypes in vitro and in vivo. The ribosomal biogenesis pathway was enriched in the interactome network. SIRT4 suppression activated glutaminase, thereby initiating AKT activation. Our research provided novel insights into the molecular mechanisms underlying CRC, and identified that SIRT4 exerts its antitumor activity in CRC possibly dependent on glutaminase to inhibit proliferation, migration and invasion via the AKT/GSK3 beta/CyclinD1 pathway.
C1 [Cui, Ying] Harbin Med Univ, Dept Radiat Oncol, Canc Hosp, Harbin, Heilongjiang, Peoples R China.
   [Bai, Yibing; Yang, Jiani; Yao, Yuanfei; Zhang, Chunhui; Liu, Chao; Shi, Jiaqi; Li, QingWei; Zhang, Jingchun; Zhang, Yanqiao] Harbin Med Univ, Dept Gastrointestinal Med Oncol, Canc Hosp, Harbin 150001, Heilongjiang, Peoples R China.
   [Lu, Xiaolin] Harbin Med Univ, Dept Orthoped, Canc Hosp, Harbin 150001, Heilongjiang, Peoples R China.
   [Cui, Ying; Bai, Yibing; Yang, Jiani; Yao, Yuanfei; Zhang, Chunhui; Liu, Chao; Shi, Jiaqi; Li, QingWei; Zhang, Jingchun; Lu, Xiaolin; Zhang, Yanqiao] Heilongjiang Acad Med Sci, Translat Med Res & Cooperat Ctr Northern China, Harbin 150081, Heilongjiang, Peoples R China.
RP Zhang, YQ (corresponding author), Harbin Med Univ, Dept Gastrointestinal Med Oncol, Canc Hosp, Harbin 150001, Heilongjiang, Peoples R China.; Zhang, YQ (corresponding author), Heilongjiang Acad Med Sci, Translat Med Res & Cooperat Ctr Northern China, Harbin 150081, Heilongjiang, Peoples R China.
EM yanqiaozhang@ems.hrbmu.edu.cn
FU National Natural and Science Foundation of China (NSFC) [81672428,
   81872427, 81703000]; Applied Technology Research and Development Program
   of Heilongjiang Province [GA19C002]; Nn10 Excellent Discipline
   Construction Program (Hepatobiliary and Pancreatic Tumor 2017);
   Fundamental Research Funds for the Provincial Universities of
   Heilongjiang Province
FX This work was supported by the National Natural and Science Foundation
   of China (NSFC) (Grant No. 81672428, 81872427, 81703000); Applied
   Technology Research and Development Program of Heilongjiang Province
   (No. GA19C002); Nn10 Excellent Discipline Construction Program (No.
   Hepatobiliary and Pancreatic Tumor 2017) and Fundamental Research Funds
   for the Provincial Universities of Heilongjiang Province.
CR Charitou T, 2019, BRIT J CANCER, V121, P37, DOI 10.1038/s41416-019-0477-7
   Danielsen SA, 2015, BBA-REV CANCER, V1855, P104, DOI 10.1016/j.bbcan.2014.09.008
   Eng CH, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000911
   Fahrer J, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0120-3
   Fernandez-Marcos PJ, 2013, CANCER CELL, V23, P427, DOI 10.1016/j.ccr.2013.04.003
   Fu L, 2017, ONCOGENE, V36, P2724, DOI 10.1038/onc.2016.425
   Greene KS, 2019, P NATL ACAD SCI USA, V116, P26625, DOI 10.1073/pnas.1911954116
   Hamabe A, 2014, P NATL ACAD SCI USA, V111, P15526, DOI 10.1073/pnas.1407717111
   Hong SN, 2018, INTEST RES, V16, P327, DOI 10.5217/ir.2018.16.3.327
   Hsieh AC, 2011, BRIT J CANCER, V105, P329, DOI 10.1038/bjc.2011.241
   Huang GY, 2018, ONCOTARGETS THER, V11, P3395, DOI 10.2147/OTT.S157724
   Jeong SM, 2013, CANCER CELL, V23, P450, DOI 10.1016/j.ccr.2013.02.024
   Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27
   Karimian A, 2019, J CELL BIOCHEM, V120, P10248, DOI 10.1002/jcb.28309
   Lai MD, 2007, CURR GENOMICS, V8, P43
   Nguyen LXT, 2013, P NATL ACAD SCI USA, V110, P20681, DOI 10.1073/pnas.1313097110
   Li Y, 2019, CELL TRANSPLANT, V28, P1664, DOI 10.1177/0963689719885083
   Min ZY, 2019, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00783
   Miyo M, 2015, BRIT J CANCER, V113, P492, DOI 10.1038/bjc.2015.226
   Nakahara Y, 2016, ONCOLOGY-BASEL, V90, P347, DOI 10.1159/000445323
   Planchet E, 2011, J EXP BOT, V62, P605, DOI 10.1093/jxb/erq294
   Polletta L, 2015, AUTOPHAGY, V11, P253, DOI 10.1080/15548627.2015.1009778
   Sharma A, 2013, BBA-PROTEINS PROTEOM, V1834, P1998, DOI 10.1016/j.bbapap.2013.06.012
   Shimura T, 2010, ONCOGENE, V29, P4826, DOI 10.1038/onc.2010.238
   Sun HJ, 2018, ONCOTARGETS THER, V11, P3959, DOI 10.2147/OTT.S156143
   Tao Y, 2019, MOL MED REP, V19, P4973, DOI 10.3892/mmr.2019.10161
   Wang L, 2018, ONCOGENESIS, V7, DOI 10.1038/s41389-018-0036-8
   Warde-Farley D, 2010, NUCLEIC ACIDS RES, V38, pW214, DOI 10.1093/nar/gkq537
   Xi JB, 2019, EXP CELL RES, V381, P1, DOI 10.1016/j.yexcr.2019.04.005
   Yin J, 2019, CHINESE J CANCER RES, V31, P489, DOI 10.21147/j.issn.1000-9604.2019.03.11
   Zhang L, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00098
   Zhao S, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1504-6
   Zhou YY, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09234-6
   Zhu YY, 2018, ONCOL LETT, V16, P1675, DOI 10.3892/ol.2018.8850
NR 34
TC 1
Z9 1
U1 1
U2 7
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0143-3334
EI 1460-2180
J9 CARCINOGENESIS
JI Carcinogenesis
PD MAR
PY 2021
VL 42
IS 3
BP 481
EP 492
DI 10.1093/carcin/bgaa134
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA RZ9OP
UT WOS:000648928600015
PM 33315089
OA Bronze
DA 2022-04-25
ER

PT J
AU Wang, CX
   Peng, R
   Zeng, M
   Zhang, ZH
   Liu, SP
   Jiang, D
   Lu, YY
   Zou, FD
AF Wang, Caixia
   Peng, Rui
   Zeng, Min
   Zhang, Zhenhua
   Liu, Shengpeng
   Jiang, Dan
   Lu, Yuanyuan
   Zou, Fangdong
TI An autoregulatory feedback loop of miR-21/VMP1 is responsible for the
   abnormal expression of miR-21 in colorectal cancer cells
SO CELL DEATH & DISEASE
LA English
DT Article
ID TUMOR-SUPPRESSOR GENE; MICRORNA-21 TARGETS; AUTOPHAGY; 5-FLUOROURACIL;
   METASTASIS; INVASION; PTEN; ACTIVATION; MECHANISMS; RESISTANCE
AB MircoRNA-21 (miR-21) was found to be highly expressed in various solid tumors, and its oncogenic properties have been extensively studied in recent years. However, the reason why miR-21 is highly expressed in various tumors remains elusive. Here, we found that the expression of miR-21 was negatively correlated with the expression of vacuole membrane protein-1 (VMP1) in colorectal cancer. Transcription of VMP1 activated either by small activating RNA (saRNA) or transcriptional activator GLI3 inhibited miR-21 expression through reducing its transcripts of VMP1-miR-21 and pri-miR-21, while no significant change in miR-21 expression after exogenous overexpression VMP1 in colorectal cancer cell HCT116. Considering the overlapping location of VMP1 and miR-21 gene in genome, the result suggested that the transcription of miR-21 was inhibited by the endogenous transcriptional activation of VMP1. Furthermore, we identified that miR-21 inhibited the activation and nuclear translocation of transcription factor EB (TFEB) through reducing the inhibitory of PTEN on AKT phosphorylation, which can directly activate the transcription of VMP1. Loss of miR-21 significantly increased VMP1 expression, which could be blocked by PTEN inhibitor (VO-Ohpic) or TFEB siRNA. These results showed that miR-21 negatively regulated VMP1 transcription through the PTEN/AKT/TFEB pathway, and TFEB-induced transcriptional activation of VMP1 could inhibit miR-21 expression, thus forming a feedback regulatory loop of miR-21/VMP1. We further found that disrupting the miR-21/VMP1 feedback loop will decrease the expression of miR-21, reduce the malignancy, and increase their sensitivity to 5-fluorouracil in colorectal cancer cells. Taken together, our results revealed a novel regulatory mechanism of miR-21 expression, and targeting the miR-21/VMP1 feedback loop may provide a new approach to inhibit miR-21 expression in colorectal cancer cells.
C1 [Wang, Caixia; Peng, Rui; Zeng, Min; Zhang, Zhenhua; Liu, Shengpeng; Zou, Fangdong] Sichuan Univ, Coll Life Sci, Chengdu, Sichuan, Peoples R China.
   [Jiang, Dan] Sichuan Univ, West China Hosp Pathol, Chengdu, Sichuan, Peoples R China.
   [Lu, Yuanyuan] Fourth Mil Med Univ, Xijing Hosp Digest Dis, Xian, Shanxi, Peoples R China.
RP Zou, FD (corresponding author), Sichuan Univ, Coll Life Sci, Chengdu, Sichuan, Peoples R China.
EM fundzou@scu.edu.cn
RI Zhang, Yonghui/AGY-9072-2022
OI Zou, Fangdong/0000-0002-2133-4320; Zou, Fangdong/0000-0003-4011-0856
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81672942]
FX This work was supported by the National Natural Science Foundation of
   China (81672942), and we would like to thank Prof. Lin Zhang at
   University of Pittsburgh for the gift of RKO-miR-21-KO cell.
CR Asangani IA, 2008, ONCOGENE, V27, P2128, DOI 10.1038/sj.onc.1210856
   Bhome R, 2017, AGING-US, V9, P2666, DOI 10.18632/aging.101355
   Bullock MD, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.213
   Davis BN, 2008, NATURE, V454, P56, DOI 10.1038/nature07086
   Deng F, 2018, BIOMED PHARMACOTHER, V97, P1269, DOI 10.1016/j.biopha.2017.11.064
   Deng J, 2014, BIOCHEM BIOPH RES CO, V443, P789, DOI 10.1016/j.bbrc.2013.11.064
   Erlichman C, 1999, J CLIN ONCOL, V17, P1356, DOI 10.1200/JCO.1999.17.5.1356
   Fujita S, 2008, J MOL BIOL, V378, P492, DOI 10.1016/j.jmb.2008.03.015
   Galluzzi L, 2017, NAT REV CLIN ONCOL, V14, P247, DOI 10.1038/nrclinonc.2016.183
   Guo L, 2012, CANCER SCI, V103, P2110, DOI 10.1111/cas.12025
   Guo XZ, 2015, ONCOL REP, V34, P2557, DOI 10.3892/or.2015.4240
   Iliopoulos D, 2010, MOL CELL, V39, P493, DOI 10.1016/j.molcel.2010.07.023
   Korkaya H, 2009, PLOS BIOL, V7, DOI 10.1371/journal.pbio.1000121
   Kumarswamy R, 2011, RNA BIOL, V8, P706, DOI 10.4161/rna.8.5.16154
   LABIANCA R, 1995, LANCET, V345, P939
   Li LC, 2006, P NATL ACAD SCI USA, V103, P17337, DOI 10.1073/pnas.0607015103
   Liu CZ, 2010, J HEPATOL, V53, P98, DOI 10.1016/j.jhep.2010.02.021
   Lo Re AE, 2012, J BIOL CHEM, V287, P25325, DOI 10.1074/jbc.M112.370809
   Loffler D, 2007, BLOOD, V110, P1330, DOI 10.1182/blood-2007-03-081133
   Longley DB, 2003, NAT REV CANCER, V3, P330, DOI 10.1038/nrc1074
   Martens JA, 2004, NATURE, V429, P571, DOI 10.1038/nature02538
   Meng FY, 2007, GASTROENTEROLOGY, V133, P647, DOI 10.1053/j.gastro.2007.05.022
   Morita K, 2019, AUTOPHAGY, V15, P922, DOI 10.1080/15548627.2019.1582952
   Morita K, 2018, J CELL BIOL, V217, P3817, DOI 10.1083/jcb.201804132
   Palmieri M, 2017, CELL CYCLE, V16, P1237, DOI 10.1080/15384101.2017.1337968
   Palmieri M, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14338
   Ribas J, 2012, NUCLEIC ACIDS RES, V40, P6821, DOI 10.1093/nar/gks308
   Ribas J, 2009, CANCER RES, V69, P7165, DOI 10.1158/0008-5472.CAN-09-1448
   Rossi L, 2007, PHARMACOL RES, V56, P248, DOI 10.1016/j.phrs.2007.07.001
   Sauermann M, 2008, ONCOGENE, V27, P1320, DOI 10.1038/sj.onc.1210743
   Savardashtaki A, 2019, EPIGENOMICS-UK, V11, P1627, DOI 10.2217/epi-2019-0110
   Sawant DV, 2013, MOL IMMUNOL, V54, P435, DOI 10.1016/j.molimm.2013.01.006
   Sayed D, 2008, MOL BIOL CELL, V19, P3272, DOI 10.1091/mbc.E08-02-0159
   Schetter AJ, 2008, JAMA-J AM MED ASSOC, V299, P425, DOI 10.1001/jama.299.4.425
   Settembre C, 2011, SCIENCE, V332, P1429, DOI 10.1126/science.1204592
   Shearwin KE, 2005, TRENDS GENET, V21, P339, DOI 10.1016/j.tig.2005.04.009
   Shi CZ, 2016, GUT, V65, P1470, DOI 10.1136/gutjnl-2014-308455
   Shinojima N, 2007, AUTOPHAGY, V3, P635, DOI 10.4161/auto.4916
   Si ML, 2007, ONCOGENE, V26, P2799, DOI 10.1038/sj.onc.1210083
   Song MS, 2014, FRONT GENET, V4, DOI 10.3389/fgene.2013.00301
   Sun Q, 2018, J CELL SCI, V131, DOI 10.1242/jcs.202317
   Talotta F, 2009, ONCOGENE, V28, P73, DOI 10.1038/onc.2008.370
   Valeri N, 2010, P NATL ACAD SCI USA, V107, P21098, DOI 10.1073/pnas.1015541107
   Wang P, 2009, CANCER RES, V69, P8157, DOI 10.1158/0008-5472.CAN-09-1996
   White E, 2012, NAT REV CANCER, V12, P401, DOI 10.1038/nrc3262
   White E, 2010, CURR OPIN CELL BIOL, V22, P212, DOI 10.1016/j.ceb.2009.12.008
   Wu YY, 2017, CELL PHYSIOL BIOCHEM, V43, P945, DOI 10.1159/000481648
   Yu YJ, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0372-7
   Zhang N, 2008, MOLECULES, V13, P1551, DOI 10.3390/molecules13081551
   Zhang ZP, 2013, J BIOL CHEM, V288, P37082, DOI 10.1074/jbc.M113.517953
   Zhao YG, 2017, MOL CELL, V67, P974, DOI 10.1016/j.molcel.2017.08.005
   Zheng LL, 2016, MOL CELL BIOCHEM, V416, P1, DOI 10.1007/s11010-016-2684-3
   Zhu SM, 2007, J BIOL CHEM, V282, P14328, DOI 10.1074/jbc.M611393200
NR 53
TC 8
Z9 8
U1 4
U2 6
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 2041-4889
J9 CELL DEATH DIS
JI Cell Death Dis.
PD DEC 14
PY 2020
VL 11
IS 12
AR 1067
DI 10.1038/s41419-020-03265-4
PG 14
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA PH0RE
UT WOS:000600130400003
PM 33318473
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Yang, YF
   Yan, XB
   Li, XX
   Ma, YL
   Goel, A
AF Yang, Yufei
   Yan, Xuebing
   Li, Xinxiang
   Ma, Yanlei
   Goel, Ajay
TI Long non-coding RNAs in colorectal cancer: Novel oncogenic mechanisms
   and promising clinical applications
SO CANCER LETTERS
LA English
DT Article
DE Colorectal cancer; Long non-coding RNAs; Signaling pathways; Biomarkers
AB Colorectal cancer (CRC) is the third most common malignancy and ranks as the second leading cause of cancer-related deaths worldwide. Despite the improvements in CRC diagnosis and treatment approaches, a considerable proportion of CRC patients still suffers from poor prognosis due to late disease detections and lack of personalized disease managements. Recent evidences have not only provided important molecular insights into their mechanistic behaviors but also indicated that identification of cancer-specific long non-coding RNAs (LncRNAs) could benefit earlier disease detections and improve treatment outcomes in patients suffering from CRC. LncRNAs have raised extensive attentions as they participate in various hallmarks of CRC. The mechanistic evidence gleaned in the recent decade clearly reveals that lncRNAs exert their oncogenic roles by regulating autophagy, epigenetic modifications, enhancing stem phenotype and modifying tumor microenvironment. In view of their pleiotropic functional roles in malignant progression, and their frequently dysregulated expression in CRC patients, they have great potential to be reliable diagnostic and prognostic biomarkers, as well as therapeutic targets for CRC. In the present review, we will focus on the oncogenic roles of lncRNAs and related mechanisms in CRC as well as discuss their clinical potential in the early diagnosis, prognostic prediction and therapeutic translation in patients with this malignancy.
C1 [Yang, Yufei; Li, Xinxiang; Ma, Yanlei] Fudan Univ, Dept Colorectal Surg, Shanghai Canc Ctr, 270 Dongan Rd, Shanghai 200032, Peoples R China.
   [Yang, Yufei; Li, Xinxiang; Ma, Yanlei] Fudan Univ, Shanghai Med Coll, Dept Oncol, 270 Dongan Rd, Shanghai 200032, Peoples R China.
   [Yan, Xuebing] Yangzhou Univ, Dept Oncol, Affiliated Hosp, Yangzhou, Jiangsu, Peoples R China.
   [Goel, Ajay] City Hope Comprehens Canc Ctr, Beckman Res Inst, Dept Mol Diagnost & Expt Therapeut, Duarte, CA 91010 USA.
RP Li, XX; Ma, YL (corresponding author), Fudan Univ, Dept Colorectal Surg, Shanghai Canc Ctr, 270 Dongan Rd, Shanghai 200032, Peoples R China.; Ma, YL (corresponding author), Fudan Univ, Shanghai Med Coll, Dept Oncol, 270 Dongan Rd, Shanghai 200032, Peoples R China.; Goel, A (corresponding author), City Hope Comprehens Canc Ctr, Beckman Res Inst, Dept Mol Diagnost & Expt Therapeut, Duarte, CA 91010 USA.
EM li_xinxiang@hotmail.com; yanleima@fadan.edu.cn; ajgoel@coh.org
OI Goel, Ajay/0000-0003-1396-6341
FU National Institute of Health (NIH)United States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USA [CA72851,
   CA181572, CA184792, CA187956, CA202797]; National Natural Science
   Foundation of ChinaNational Natural Science Foundation of China (NSFC)
   [81920108026, 81871964, 81902422]; National Ten Thousand Plan Young Top
   Talents; Shanghai Young Top Talents [QNBJ1701]; Shanghai Science and
   Technology Development Fund [19410713300, 20XD1421200]; CSCO-Roche Tumor
   Research Fund [Y-2019 Roche-079]; Fudan University Excellence 2025
   Talent Cultivation Plan; Program of Jiangsu Commission of Health
   [M2020024]; Social Development Program of Yangzhou Science and
   Technology Bureau [YZ2020078]
FX The present work was supported by the grants CA72851, CA181572,
   CA184792, CA187956 and CA202797 from the National Institute of Health
   (NIH) to AG. This work was also supported by grants from the National
   Natural Science Foundation of China (Nos. 81920108026, 81871964), the
   National Ten Thousand Plan Young Top Talents (for Dr. Yanlei Ma), the
   Shanghai Young Top Talents (for Dr. Yanlei Ma. No. QNBJ1701), the
   Shanghai Science and Technology Development Fund (No.19410713300, No.
   20XD1421200), the CSCO-Roche Tumor Research Fund (No. Y-2019 Roche-079),
   Fudan University Excellence 2025 Talent Cultivation Plan (for Dr. Yanlei
   Ma), the National Natural Science Foundation of China (for Xuebing Yan,
   No.81902422), Program of Jiangsu Commission of Health (for Xuebing Yan,
   No. M2020024); Social Development Program of Yangzhou Science and
   Technology Bureau (for Xuebing Yan, No. YZ2020078).
CR Alaiyan B, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-196
   [Anonymous], 2020, RNA Biol, V17, P309, DOI 10.1080/15476286.2019.1675952
   Bermudez M, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.01008
   Bi ZF, 2020, ADV SCI, V7, DOI 10.1002/advs.202000915
   Bian ZH, 2018, ONCOGENESIS, V7, DOI 10.1038/s41389-018-0067-1
   Bian ZH, 2018, CLIN CANCER RES, V24, P4808, DOI 10.1158/1078-0432.CCR-17-2967
   Bian ZH, 2016, SCI REP-UK, V6, DOI 10.1038/srep23892
   Bin J, 2021, J CELL PHYSIOL, V236, P523, DOI 10.1002/jcp.29880
   Brenner H, 2014, LANCET, V383, P1490, DOI 10.1016/S0140-6736(13)61649-9
   Chen BQ, 2020, GASTROENTEROLOGY, V159, P2146, DOI 10.1053/j.gastro.2020.08.018
   Chen C, 2020, AGING-US, V12, P11685, DOI 10.18632/aging.103334
   Chen DL, 2017, THERANOSTICS, V7, P4836, DOI 10.7150/thno.20942
   Chen DL, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.421
   Chen XX, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0962-6
   Chujo T, 2016, BBA-GENE REGUL MECH, V1859, P139, DOI 10.1016/j.bbagrm.2015.05.007
   Clemson CM, 2009, MOL CELL, V33, P717, DOI 10.1016/j.molcel.2009.01.026
   Costa-Pereira AP, 2011, AM J CANCER RES, V1, P806
   Cui ZH, 2019, ONCOTARGETS THER, V12, P11531, DOI 10.2147/OTT.S229104
   Dai MY, 2017, SCI REP-UK, V7, DOI 10.1038/srep46572
   Danielsen SA, 2015, BBA-REV CANCER, V1855, P104, DOI 10.1016/j.bbcan.2014.09.008
   Davalos V, 2012, ONCOGENE, V31, P2062, DOI 10.1038/onc.2011.383
   Deng X, 2020, INT J CANCER, V146, P1700, DOI 10.1002/ijc.32608
   Ding DY, 2018, MOL CELLS, V41, P423, DOI 10.14348/molcells.2018.2258
   Dong L, 2016, CANCER EPIDEM BIOMAR, V25, P1158, DOI 10.1158/1055-9965.EPI-16-0006
   Dou J, 2016, AM J TRANSL RES, V8, P98
   Du W, 2012, J CELL MOL MED, V16, P1878, DOI 10.1111/j.1582-4934.2011.01483.x
   Dy GK, 2009, CLIN COLORECTAL CANC, V8, P88, DOI 10.3816/CCC.2009.n.014
   El Bairi K, 2018, CANCER GENET-NY, V220, P49, DOI 10.1016/j.cancergen.2017.11.001
   Fan H, 2018, INT J BIOL MARKER, V33, P415, DOI 10.1177/1724600818777242
   Fan H, 2018, MOL MED REP, V17, P8309, DOI 10.3892/mmr.2018.8907
   Farooqi AA, 2019, SEMIN CANCER BIOL, V58, P65, DOI 10.1016/j.semcancer.2019.01.001
   Fu Y, 2019, MOL CARCINOGEN, V58, P2104, DOI 10.1002/mc.23101
   Gao HY, 2017, ONCOTARGETS THER, V10, P205, DOI 10.2147/OTT.S116178
   Gao RR, 2019, ARCH BIOCHEM BIOPHYS, V663, P183, DOI 10.1016/j.abb.2019.01.005
   Gao YF, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-21048-y
   Goradel NH, 2017, TOXICOL APPL PHARM, V335, P56, DOI 10.1016/j.taap.2017.09.022
   Graham Lloyd D, 2011, Genes Cancer, V2, P829, DOI 10.1177/1947601911431081
   GREENBURG G, 1982, J CELL BIOL, V95, P333, DOI 10.1083/jcb.95.1.333
   Guo JH, 2020, EXP MOL PATHOL, V115, DOI 10.1016/j.yexmp.2020.104448
   Guo X, 2020, ONCOTARGETS THER, V13, P1507, DOI 10.2147/OTT.S231249
   Han P, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0583-1
   Han Y, 2020, BIOMED PHARMACOTHER, V121, DOI 10.1016/j.biopha.2019.109580
   Hart MJ, 1998, CURR BIOL, V8, P573, DOI 10.1016/S0960-9822(98)70226-X
   Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809
   Hu W, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01199-1
   Huang D, 2018, NAT IMMUNOL, V19, P1112, DOI 10.1038/s41590-018-0207-y
   Huang GL, 2016, SCI REP-UK, V6, DOI 10.1038/srep26524
   Jahangiri B, 2019, J CELL COMMUN SIGNAL, V13, P53, DOI 10.1007/s12079-018-0471-5
   Ji DL, 2018, PATHOL RES PRACT, V214, P1524, DOI 10.1016/j.prp.2018.08.014
   Ji L, 2020, MOL THER-NUCL ACIDS, V19, P546, DOI 10.1016/j.omtn.2019.11.027
   Jia GQ, 2018, J CELL BIOCHEM, V119, P7091, DOI 10.1002/jcb.27031
   Jiang H, 2018, CANCER LETT, V425, P78, DOI 10.1016/j.canlet.2018.03.038
   Jiang XH, 2019, ONCOTARGETS THER, V12, P1059, DOI 10.2147/OTT.S192290
   Jiang ZP, 2020, CELL SIGNAL, V66, DOI 10.1016/j.cellsig.2019.109483
   Kim SH, 2018, YONSEI MED J, V59, P588, DOI 10.3349/ymj.2018.59.5.588
   Kogo R, 2011, CANCER RES, V71, P6320, DOI 10.1158/0008-5472.CAN-11-1021
   Lee H, 2014, MOL CELLS, V37, P540, DOI 10.14348/molcells.2014.0151
   Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1
   Li CF, 2017, BIOCHEM BIOPH RES CO, V491, P552, DOI 10.1016/j.bbrc.2017.03.042
   Li H, 2017, MED SCI MONITOR, V23, P919, DOI 10.12659/MSM.903462
   Li PL, 2017, MOL THER-NUCL ACIDS, V8, P356, DOI 10.1016/j.omtn.2017.07.007
   Li PL, 2017, MOL CANCER THER, V16, P739, DOI 10.1158/1535-7163.MCT-16-0591
   Li SL, 2020, CLIN EXP PHARMACOL P, V47, P703, DOI 10.1111/1440-1681.13230
   Li TY, 2017, ONCOL LETT, V14, P7384, DOI 10.3892/ol.2017.7154
   Li X, 2018, INT J ONCOL, V53, P21, DOI 10.3892/ijo.2018.4400
   Li XL, 2017, CELL REP, V20, P2408, DOI 10.1016/j.celrep.2017.08.041
   Li YC, 2019, ONCOTARGETS THER, V12, P2649, DOI 10.2147/OTT.S188054
   Li YL, 2015, ONCOTARGET, V6, P27641, DOI 10.18632/oncotarget.4737
   Liang WC, 2015, ONCOTARGET, V6, P22513, DOI 10.18632/oncotarget.4154
   Lin JG, 2018, BIOMED PHARMACOTHER, V98, P433, DOI 10.1016/j.biopha.2017.12.058
   Ling H, 2013, GENOME RES, V23, P1446, DOI 10.1101/gr.152942.112
   Liu B, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1468-5
   Liu F, 2020, CANCER MED-US, V9, P1079, DOI 10.1002/cam4.2746
   Liu HS, 2019, CLIN CHEM LAB MED, V57, P1073, DOI 10.1515/cclm-2019-0052
   Liu L, 2019, MOL THER-NUCL ACIDS, V17, P644, DOI 10.1016/j.omtn.2019.06.009
   Liu XQ, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000018031
   Liu XX, 2019, ONCOL RES, V27, P99, DOI 10.3727/096504018X15195193936573
   Liu Y, 2015, INT J CLIN EXP PATHO, V8, P11480
   Liu YQ, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2268-8
   Lu YY, 2017, NAT MED, V23, P1331, DOI 10.1038/nm.4424
   Lv SY, 2018, CELL CYCLE, V17, P1245, DOI 10.1080/15384101.2018.1471317
   Ma SP, 2018, AGING-US, V10, P2062, DOI 10.18632/aging.101530
   Ma YL, 2016, GUT, V65, P1494, DOI 10.1136/gutjnl-2014-308392
   MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016
   Mao DL, 2019, TECHNOL CANCER RES T, V18, DOI 10.1177/1533033819883633
   Merry CR, 2015, HUM MOL GENET, V24, P6240, DOI 10.1093/hmg/ddv343
   Munro MJ, 2018, J CLIN PATHOL, V71, P110, DOI 10.1136/jclinpath-2017-204739
   Ni W, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1079-y
   Nissan A, 2012, INT J CANCER, V130, P1598, DOI 10.1002/ijc.26170
   O'Brien SJ, 2018, INT J CANCER, V142, P2501, DOI 10.1002/ijc.31282
   Ouyang SR, 2019, CANCER CELL INT, V19, DOI 10.1186/s12935-019-0784-3
   Ozawa T, 2017, ANN ONCOL, V28, P1882, DOI 10.1093/annonc/mdx248
   Pandya G, 2020, BBA-REV CANCER, V1874, DOI 10.1016/j.bbcan.2020.188423
   Pang YM, 2017, INT J ONCOL, V51, P1077, DOI 10.3892/ijo.2017.4104
   Park SY, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1405-7
   Pichler M, 2020, GUT, V69, P1818, DOI 10.1136/gutjnl-2019-318903
   Ping GF, 2018, AM J TRANSL RES, V10, P138
   Ray SK, 2021, CURR MOL MED, V21, P462, DOI 10.2174/1566524020666201119143943
   Ren J, 2018, THERANOSTICS, V8, P3932, DOI 10.7150/thno.25541
   Ren TJ, 2019, BIOMED PHARMACOTHER, V117, DOI 10.1016/j.biopha.2019.109171
   Ren WD, 2018, GENES-BASEL, V9, DOI 10.3390/genes9120620
   Rosello S, 2018, CANCER TREAT REV, V63, P156, DOI 10.1016/j.ctrv.2018.01.001
   Samuels Y, 2004, CELL CYCLE, V3, P1221, DOI 10.4161/cc.3.10.1164
   Sfakianaki M, 2020, CANCERS, V12, DOI 10.3390/cancers12082058
   Shao QW, 2018, BIOCHEM BIOPH RES CO, V495, P539, DOI 10.1016/j.bbrc.2017.10.076
   Shen XG, 2017, BIOL RES, V50, DOI 10.1186/s40659-017-0136-5
   Shi Q, 2019, MED SCI MONITOR, V25, P7042, DOI 10.12659/MSM.916314
   Shibue T, 2017, NAT REV CLIN ONCOL, V14, P611, DOI 10.1038/nrclinonc.2017.44
   Si YR, 2019, CELL MOL BIOL LETT, V24, DOI 10.1186/s11658-019-0175-8
   Siegel RL, 2019, CA-CANCER J CLIN, V69, P7, DOI 10.3322/caac.21551
   Song FL, 2019, J CELL PHYSIOL, V234, P7420, DOI 10.1002/jcp.27500
   Song JP, 2019, J CELL BIOCHEM, V120, P6937, DOI 10.1002/jcb.27743
   Song W, 2018, ONCOL RES, V26, P261, DOI 10.3727/096504017X15031557924132
   Sun JF, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0771-x
   Sun NN, 2018, GENE, V665, P141, DOI 10.1016/j.gene.2018.04.014
   Sun WH, 2019, AM J CANCER RES, V9, P2515
   Sun ZQ, 2019, ONCOGENE, V38, P2627, DOI 10.1038/s41388-018-0628-y
   Tang DX, 2019, J CELL PHYSIOL, V234, P20816, DOI 10.1002/jcp.28687
   Tang JY, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11447-8
   Tao YM, 2017, ONCOTARGET, V8, P36410, DOI 10.18632/oncotarget.16850
   Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007
   Tsai MC, 2010, SCIENCE, V329, P689, DOI 10.1126/science.1192002
   Vaidya AM, 2019, BIOCONJUGATE CHEM, V30, P907, DOI 10.1021/acs.bioconjchem.9b00028
   Wang F, 2016, BIOMED PHARMACOTHER, V81, P152, DOI 10.1016/j.biopha.2016.04.009
   Wang GY, 2014, ONCOL REP, V31, P1839, DOI 10.3892/or.2014.3047
   Wang HJ, 2018, BIOMED PHARMACOTHER, V106, P1607, DOI 10.1016/j.biopha.2018.07.131
   Wang L, 2018, AGING-US, V10, P3662, DOI 10.18632/aging.101628
   Wang LY, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20225758
   Wang M, 2019, J CANCER, V10, P4603, DOI 10.7150/jca.32065
   Wang M, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-1187-4
   Wang R, 2016, J CANCER RES CLIN, V142, P2291, DOI 10.1007/s00432-016-2238-9
   Wang SS, 2019, INT J STEM CELLS, V12, P347, DOI 10.15283/ijsc19041
   Wang XK, 2019, CANCER CELL INT, V19, DOI 10.1186/s12935-019-0951-6
   Wang XK, 2019, INT J MED SCI, V16, P51, DOI 10.7150/ijms.27359
   Wang XS, 2020, ONCOTARGETS THER, V13, P6373, DOI 10.2147/OTT.S239432
   Wang YN, 2017, BIOMED PHARMACOTHER, V93, P1230, DOI 10.1016/j.biopha.2017.07.024
   Wang Y, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1105-0
   Wang ZK, 2018, BRAZ J MED BIOL RES, V51, DOI [10.1590/1414-431X20176793, 10.1590/1414-431x20176793]
   Wang ZZ, 2019, AGING-US, V11, P4876, DOI 10.18632/aging.102081
   Wei L, 2019, CELL ONCOL, V42, P757, DOI 10.1007/s13402-019-00466-8
   Wu KM, 2018, INT J BIOCHEM CELL B, V99, P219, DOI 10.1016/j.biocel.2018.04.001
   Wu KF, 2017, EXP CELL RES, V350, P312, DOI 10.1016/j.yexcr.2016.12.003
   Wu YM, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1014-2
   Wu YC, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0455-5
   Xian D, 2019, J CELL MOL MED, V23, P3808, DOI 10.1111/jcmm.14071
   Xiao ZG, 2018, CELL PHYSIOL BIOCHEM, V46, P1275, DOI 10.1159/000489110
   Xie F, 2017, ONCOTARGET, V8, P23628, DOI 10.18632/oncotarget.15466
   Xie HB, 2018, CLIN CHIM ACTA, V485, P262, DOI 10.1016/j.cca.2018.07.003
   Xu M, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1063-6
   Xu M, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0894-x
   Xu W, 2020, INT J CANCER, V146, P2901, DOI 10.1002/ijc.32747
   Xue JF, 2018, CANCER BIOMARK, V21, P849, DOI 10.3233/CBM-170780
   Yan Z Y, 2018, Zhonghua Bing Li Xue Za Zhi, V47, P284, DOI 10.3760/cma.j.issn.0529-5807.2018.04.011
   Yang WW, 2018, ONCOL LETT, V16, P3365, DOI 10.3892/ol.2018.9052
   Yang WW, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/2767484
   Yang XD, 2018, ONCOL REP, V40, P1554, DOI 10.3892/or.2018.6573
   Ye CX, 2016, J EXP CLIN CANC RES, V35, DOI 10.1186/s13046-016-0467-z
   Yin ZY, 2016, MICROB CELL, V3, P457, DOI 10.15698/mic2016.12.546
   Yousefi H, 2020, ONCOGENE, V39, P953, DOI 10.1038/s41388-019-1040-y
   Yu JT, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0896-y
   Yuan SL, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/9390878
   Yuan ZX, 2016, INT J ONCOL, V48, P2675, DOI 10.3892/ijo.2016.3447
   Yue B, 2018, MOL THER, V26, P1287, DOI 10.1016/j.ymthe.2018.02.024
   Yun CW, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113466
   Zhang H, 2019, CANCER MED-US, V8, P863, DOI 10.1002/cam4.1813
   Zhang L, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00776
   Zhang M, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-018-0656-7
   Zhang W, 2018, BIOCHIMIE, V144, P21, DOI 10.1016/j.biochi.2017.10.002
   Zhang XF, 2018, EUR REV MED PHARMACO, V22, P2282, DOI 10.26355/eurrev_201804_14816
   Zhang XQ, 2020, CANCER CELL INT, V20, DOI 10.1186/s12935-020-1155-9
   Zhang X, 2017, BIOMED PHARMACOTHER, V96, P877, DOI 10.1016/j.biopha.2017.10.033
   Zhang XT, 2019, MED SCI MONITOR, V25, P6429, DOI 10.12659/MSM.915329
   Zhang Y, 2019, J CELL PHYSIOL, V234, P18524, DOI 10.1002/jcp.28489
   Zhang YY, 2020, AGING-US, V12, P6191, DOI 10.18632/aging.103016
   Zhang ZY, 2016, CANCER LETT, V376, P62, DOI 10.1016/j.canlet.2016.03.022
   Zhao L, 2020, BIOCHEM BIOPH RES CO, V529, P500, DOI 10.1016/j.bbrc.2020.04.049
   Zhao YH, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1804-x
   Zheng S, 2019, AM J TRANSL RES, V11, P6117
   Zheng YS, 2019, J CELL BIOCHEM, V120, P3922, DOI 10.1002/jcb.27676
   Zhi H, 2019, CELL BIOCHEM FUNCT, V37, P340, DOI 10.1002/cbf.3403
   Zhou HB, 2017, EUR REV MED PHARMACO, V21, P3837
   Zhou H, 2020, J CELL BIOCHEM, V121, P2510, DOI 10.1002/jcb.29473
   Zhou QW, 2019, CANCER SCI, V110, P1194, DOI 10.1111/cas.13951
   Zhou X, 2020, ONCOL LETT, V19, P3431, DOI 10.3892/ol.2020.11471
   Zhu J, 2018, CELL PHYSIOL BIOCHEM, V51, P113, DOI 10.1159/000495168
   Zhu PP, 2018, NAT CELL BIOL, V20, P1134, DOI 10.1038/s41556-018-0194-0
   Zhu YP, 2020, J CELL BIOCHEM, V121, P1260, DOI 10.1002/jcb.29359
   Zhu YP, 2017, ONCOTARGET, V8, P111715, DOI 10.18632/oncotarget.22903
   Zou YM, 2018, EUR J CELL BIOL, V97, P369, DOI 10.1016/j.ejcb.2018.04.005
NR 189
TC 4
Z9 4
U1 1
U2 9
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0304-3835
EI 1872-7980
J9 CANCER LETT
JI Cancer Lett.
PD APR 28
PY 2021
VL 504
BP 67
EP 80
DI 10.1016/j.canlet.2021.01.009
EA FEB 2021
PG 14
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA QR7DW
UT WOS:000625376500007
PM 33577977
DA 2022-04-25
ER

PT J
AU Won, SJ
   Yen, CH
   Hsieh, HW
   Chang, SW
   Lin, CN
   Huang, CYF
   Su, CL
AF Won, Shen-Jeu
   Yen, Cheng-Hsin
   Hsieh, Hao-Wen
   Chang, Shao-Wei
   Lin, Chun-Nan
   Huang, Chi-Ying F.
   Su, Chun-Li
TI Using connectivity map to identify natural lignan justicidin A as a
   NF-kappa B suppressor
SO JOURNAL OF FUNCTIONAL FOODS
LA English
DT Article
DE Justicidin A; NF-kappa B; Caspase-independent apoptosis; L1000 gene
   expression profiling; Connectivity map; Human colorectal cancer
ID COLORECTAL-CANCER CELLS; CYTOTOXIC LIGNANS; LUNG-CANCER; APOPTOSIS;
   AUTOPHAGY; INFLAMMATION; PROCUMBENS; DRUG; DEGRADATION; RESISTANCE
AB Justicidin A (JA), a natural lignan, was isolated from the whole plant of Justicia procumbens, one of the most popular traditional Chinese medicines in China and Taiwan. Gene expression signatures of JA from human colorectal cancer HT-29 and hepatocellular carcinoma Hep 3B cells were used to query connectivity map. A NF-kappa B suppressor (15-delta prostaglandin J2) was predicted to display similar molecular action of JA. In JA-treated HT-29 cells, suppression of nuclear NF-kappa B expression and decrease of NF-kappa B DNA-binding activity were indeed observed. The classical pathway was involved in JA-induced inhibition of NF-kappa B, characterized by decreases in phosphorylation of ART, I kappa B kinase (IKK)-beta/IKK-alpha, and I kappa B-alpha. Furthermore, JA caused significant translocation of apoptosis-inducing factor and endonuclease G, caspase-independent apoptotic signaling molecules, from the mitochondrial to the nuclei. Our data suggest anti-inflammatory and cytotoxic mechanisms of JA, and using gene expression signatures to identify novel molecular actions of phytochemicals is an effective approach. (C) 2017 Elsevier Ltd. All rights reserved.
C1 [Won, Shen-Jeu] Natl Cheng Kung Univ, Dept Microbiol & Immunol, Coll Med, Tainan 701, Taiwan.
   [Yen, Cheng-Hsin; Su, Chun-Li] Natl Taiwan Normal Univ, Dept Human Dev & Family Studies, Taipei 106, Taiwan.
   [Hsieh, Hao-Wen; Huang, Chi-Ying F.] Natl Yang Ming Univ, Inst Clin Med, Taipei 112, Taiwan.
   [Chang, Shao-Wei; Huang, Chi-Ying F.] Natl Yang Ming Univ, Inst Biopharmaceut Sci, Taipei 112, Taiwan.
   [Lin, Chun-Nan] Kaohsiung Med Univ, Sch Pharm, Kaohsiung 807, Taiwan.
   [Huang, Chi-Ying F.] Kaohsiung Med Univ, Dept Biochem, Coll Med, Kaohsiung 807, Taiwan.
RP Su, CL (corresponding author), Natl Taiwan Normal Univ, Dept Human Dev & Family Studies, Taipei 106, Taiwan.; Huang, CYF (corresponding author), Natl Yang Ming Univ, Inst Biopharmaceut Sci, Taipei 112, Taiwan.
EM cyhuang5@ym.edu.tw; chunlisu@ntnu.edu.tw
RI Huang, Chi-Ying/AAG-7672-2022; Huang, Chi-Ying/AFL-7729-2022
OI Huang, Chi-Ying/0000-0003-4898-4937; Huang, Chi-Ying/0000-0003-4898-4937
FU National Science Council, TaiwanMinistry of Science and Technology,
   Taiwan [NSC 98-2313-B-003-002-MY3, NSC 101-2313-B-003-002-MY3]; Ministry
   of Science and Technology, TaiwanMinistry of Science and Technology,
   Taiwan [MOST 105-3011-B010-001, MOST 104-2320-B-003-007]
FX This work was supported by grants from the National Science Council,
   Taiwan (NSC 98-2313-B-003-002-MY3 and NSC 101-2313-B-003-002-MY3) and
   the Ministry of Science and Technology, Taiwan (MOST 105-3011-B010-001
   and MOST 104-2320-B-003-007).
CR Cheng HW, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.77
   Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322
   Daugas E, 2000, FASEB J, V14, P729, DOI 10.1096/fasebj.14.5.729
   Day SH, 1999, J NAT PROD, V62, P1056, DOI 10.1021/np9900167
   Day SH, 2002, J NAT PROD, V65, P379, DOI 10.1021/np0101651
   Domanski D, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0164365
   Downward J, 2004, SEMIN CELL DEV BIOL, V15, P177, DOI 10.1016/j.semcdb.2004.01.002
   Fan YH, 2013, PROTEIN CELL, V4, P176, DOI 10.1007/s13238-013-2084-3
   FUKAMIYA N, 1986, J NAT PROD, V49, P348, DOI 10.1021/np50044a030
   Galban S, 2010, CELL DEATH DIFFER, V17, P54, DOI 10.1038/cdd.2009.81
   George J, 2015, NATURE, V524, P47, DOI 10.1038/nature14664
   Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710
   Janakiram NB, 2014, ADV EXP MED BIOL, V816, P25, DOI 10.1007/978-3-0348-0837-8_2
   Jemal A, 2010, CA-CANCER J CLIN, V60, P277, DOI 10.3322/caac.20073
   Kashif M, 2015, SCI REP-UK, V5, DOI 10.1038/srep14118
   Kim HJ, 2006, CELL DEATH DIFFER, V13, P738, DOI 10.1038/sj.cdd.4401877
   Kondo Y, 2005, NAT REV CANCER, V5, P726, DOI 10.1038/nrc1692
   Kuo YL, 2015, EVID-BASED COMPL ALT, V2015, DOI 10.1155/2015/917345
   Lamb J, 2007, NAT REV CANCER, V7, P54, DOI 10.1038/nrc2044
   Lamb J, 2006, SCIENCE, V313, P1929, DOI 10.1126/science.1132939
   Lee JC, 2005, CARCINOGENESIS, V26, P1716, DOI 10.1093/carcin/bgi133
   Lee JC, 2008, BIOCHEM BIOPH RES CO, V372, P236, DOI 10.1016/j.bbrc.2008.05.023
   Lu YH, 2008, PHYTOCHEMISTRY, V69, P225, DOI 10.1016/j.phytochem.2007.06.026
   Nagata S, 2000, EXP CELL RES, V256, P12, DOI 10.1006/excr.2000.4834
   Pankiv S, 2007, J BIOL CHEM, V282, P24131, DOI 10.1074/jbc.M702824200
   Peck D, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-7-r61
   RICE NR, 1993, EMBO J, V12, P4685, DOI 10.1002/j.1460-2075.1993.tb06157.x
   Straus DS, 2000, P NATL ACAD SCI USA, V97, P4844, DOI 10.1073/pnas.97.9.4844
   Su CL, 2007, FEBS J, V274, P3633, DOI 10.1111/j.1742-4658.2007.05896.x
   Su CL, 2006, FEBS LETT, V580, P3185, DOI 10.1016/j.febslet.2006.04.085
   Vaiopoulos AG, 2013, J MOL MED, V91, P1029, DOI 10.1007/s00109-013-1045-x
   van Loo G, 2001, CELL DEATH DIFFER, V8, P1136, DOI 10.1038/sj.cdd.4400944
   Viatour P, 2005, TRENDS BIOCHEM SCI, V30, P43, DOI 10.1016/j.tibs.2004.11.009
   Wang LN, 2011, J SEP SCI, V34, P667, DOI 10.1002/jssc.201000781
   Wen ZN, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018278
   Won SJ, 2015, J FUNCT FOODS, V16, P81, DOI 10.1016/j.jff.2015.04.025
   Won SJ, 2015, J CELL PHYSIOL, V230, P930, DOI 10.1002/jcp.24825
   Xiao GT, 2007, CYTOKINE GROWTH F R, V18, P233, DOI 10.1016/j.cytogfr.2007.04.006
   Yang ZNJ, 2011, MOL CANCER THER, V10, P1533, DOI 10.1158/1535-7163.MCT-11-0047
   Yeh CT, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/910451
   Yeh CT, 2012, AM J RESP CRIT CARE, V186, P1180, DOI 10.1164/rccm.201207-1180OC
   Zhang Y, 2012, CLIN EXP MED, V12, P97, DOI 10.1007/s10238-011-0146-5
NR 42
TC 2
Z9 2
U1 0
U2 7
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1756-4646
J9 J FUNCT FOODS
JI J. Funct. Food.
PD JUL
PY 2017
VL 34
BP 68
EP 76
DI 10.1016/j.jff.2017.04.017
PG 9
WC Food Science & Technology; Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Food Science & Technology; Nutrition & Dietetics
GA EX6WW
UT WOS:000403383800008
DA 2022-04-25
ER

PT J
AU Ghafouri-Fard, S
   Hussen, BM
   Gharebaghi, A
   Eghtedarian, R
   Taheri, M
AF Ghafouri-Fard, Soudeh
   Hussen, Bashdar Mahmud
   Gharebaghi, Alireza
   Eghtedarian, Reyhane
   Taheri, Mohammad
TI LncRNA signature in colorectal cancer
SO PATHOLOGY RESEARCH AND PRACTICE
LA English
DT Review
DE lncRNA; Colorectal cancer; Biomarker
ID EPITHELIAL-MESENCHYMAL TRANSITION; ENDOPLASMIC-RETICULUM STRESS;
   PROMOTES CELL-PROLIFERATION; POOR-PROGNOSIS; SIGNALING PATHWAY;
   NONCODING RNAS; SNHG6 PROMOTES; UP-REGULATION; INVASION; MIGRATION
AB Colorectal cancer (CRC) is among the most frequent cancers and is associated with high mortality particularly when being diagnosed in advanced stages. Although several environmental and intrinsic risk factors have been identified, the underlying cause of CRC is not clear in the majority of cases. Several studies especially in the recent decade have pointed to the role of epigenetic factors in this kind of cancer. Long non-coding RNAs (lncRNAs) as important contributors in the epigenetic mechanisms are involved in the initiation, progression and metastasis of CRC. Tens of oncogenic lncRNAs and a lower number of tumor suppressor lncRNAs have been recently identified to be dysregulated in CRC cells and tissues. Notably, expressions of a number of these transcripts have been dysregulated in serum samples of CRC patients, providing a non-invasive route for detection of this kind of cancer. The involvement of lncRNAs in the regulation of autophagy has provided them the ability to modulate response of CRC cells to chemotherapeutic modalities. In the current manuscript, we review the studies which evaluated the role of lncRNAs in the pathogenesis and progression of CRC to appraise their application as diagnostic/ prognostic markers.
C1 [Ghafouri-Fard, Soudeh; Eghtedarian, Reyhane] Shahid Beheshti Univ Med Sci, Dept Med Genet, Tehran, Iran.
   [Hussen, Bashdar Mahmud] Hawler Med Univ, Coll Pharm, Dept Pharmacognosy, Erbil, Iraq.
   [Gharebaghi, Alireza] Hamadan Univ Med Sci, Neurophysiol Res Ctr, Hamadan, Hamadan, Iran.
   [Taheri, Mohammad] Shahid Beheshti Univ Med Sci, Urol & Nephrol Res Ctr, Tehran, Iran.
RP Taheri, M (corresponding author), Shahid Beheshti Univ Med Sci, Urol & Nephrol Res Ctr, Tehran, Iran.
EM mohammad_823@yahoo.com
RI Gharebaghi, Alireza/AAW-2565-2021
OI Eghtedarian, Reyhane/0000-0002-7603-0009; Hussen,
   Bashdar/0000-0003-1060-6527
FU Shahid Beheshti University of Medical Sciences
FX This study was financially supported by Shahid Beheshti University of
   Medical Sciences.
CR Alaiyan B, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-196
   Amersi Farin, 2005, Clin Colon Rectal Surg, V18, P133, DOI 10.1055/s-2005-916274
   Bermudez M, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.01008
   Bian ZH, 2018, CLIN CANCER RES, V24, P4808, DOI 10.1158/1078-0432.CCR-17-2967
   Bian ZH, 2017, ONCOGENESIS, V6, DOI 10.1038/s41389-017-0008-4
   Bian ZH, 2016, SCI REP-UK, V6, DOI 10.1038/srep23892
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
   Brenner H, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0498-x
   Cabili MN, 2011, GENE DEV, V25, P1915, DOI 10.1101/gad.17446611
   Caravagna G, 2018, NAT METHODS, V15, P707, DOI 10.1038/s41592-018-0108-x
   Chen D, 2017, ONCOTARGET, V8, P70642, DOI 10.18632/oncotarget.19956
   Chen LL, 2016, TRENDS BIOCHEM SCI, V41, P761, DOI 10.1016/j.tibs.2016.07.003
   Chen S., 2019, ONCO THER, V12
   Cheng J, 2005, SCIENCE, V308, P1149, DOI 10.1126/science.1108625
   Ding DY, 2018, MOL CELLS, V41, P423, DOI 10.14348/molcells.2018.2258
   Du C, 2019, EUR REV MED PHARMACO, V23, P6105, DOI 10.26355/eurrev_201907_18424
   Duan YX, 2019, EXP THER MED, V18, P3534, DOI 10.3892/etm.2019.7942
   Fu Y, 2020, CELL COMMUN SIGNAL, V18, DOI 10.1186/s12964-020-0518-0
   Gao TY, 2018, CANCER CELL INT, V18, DOI 10.1186/s12935-018-0506-2
   Gao ZF, 2019, J CELL PHYSIOL, V234, P12029, DOI 10.1002/jcp.27864
   Ghafouri-Fard S, 2019, BIOMED PHARMACOTHER, V118, DOI 10.1016/j.biopha.2019.109129
   Gong AF, 2019, J BUON, V24, P1830
   Hong S, 2020, AGING-US, V12, P5183, DOI 10.18632/aging.102940
   Hu JL, 2019, INT J CANCER, V145, P450, DOI 10.1002/ijc.32103
   Huang CM, 2020, EUR REV MED PHARMACO, V24, P4203, DOI 10.26355/eurrev_202004_21000
   Huang HS, 2019, ONCOL LETT, V18, P3331, DOI 10.3892/ol.2019.10671
   Inadomi JM, 2012, ARCH INTERN MED, V172, P575, DOI 10.1001/archinternmed.2012.332
   Jia H, 2010, RNA, V16, P1478, DOI 10.1261/rna.1951310
   Jiang MC, 2019, AM J CANCER RES, V9, P1354
   Jin Z, 2020, OPEN MED-WARSAW, V15, P175, DOI 10.1515/med-2020-0026
   Karlsson Oskar, 2016, Curr Environ Health Rep, V3, P178, DOI 10.1007/s40572-016-0092-1
   Li B, 2020, AGING-US, V12, P9781, DOI 10.18632/aging.103243
   Li C, 2019, EUR REV MED PHARMACO, V23, P1476, DOI 10.26355/eurrev_201902_17105
   Li C, 2018, ONCOTARGETS THER, V11, P3969, DOI 10.2147/OTT.S163883
   Li D, 2020, CANCER MANAG RES, V12, P4605, DOI 10.2147/CMAR.S249491
   Li ML, 2019, CANCER MANAG RES, V11, P10523, DOI 10.2147/CMAR.S228490
   Li PL, 2017, MOL THER-NUCL ACIDS, V8, P356, DOI 10.1016/j.omtn.2017.07.007
   Li SW, 2016, ONCOTARGET, V7, P25470, DOI 10.18632/oncotarget.8330
   Li T, 2016, ONCOL LETT, V12, P4155, DOI 10.3892/ol.2016.5129
   Lian YF, 2018, MOL THER-NUCL ACIDS, V12, P684, DOI 10.1016/j.omtn.2018.06.012
   Lian YF, 2017, ONCOTARGET, V8, P59435, DOI 10.18632/oncotarget.19738
   Lin JG, 2018, BIOMED PHARMACOTHER, V98, P433, DOI 10.1016/j.biopha.2017.12.058
   Liu FJ, 2018, ONCOL LETT, V15, P8237, DOI 10.3892/ol.2018.8435
   Liu JF, 2020, CANCER MANAG RES, V12, P1835, DOI 10.2147/CMAR.S221996
   Liu N, 2020, ONCOTARGETS THER, V13, P5283, DOI 10.2147/OTT.S248457
   Liu TY, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0873-2
   Liu Y, 2015, INT J CLIN EXP PATHO, V8, P11480
   Liu Z., 2019, BIOSCIENCE REP, V39
   Luan YP, 2020, MOL THER-NUCL ACIDS, V19, P790, DOI 10.1016/j.omtn.2019.12.009
   Luo KL, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1263-3
   Lv SY, 2018, CELL CYCLE, V17, P1245, DOI 10.1080/15384101.2018.1471317
   Ma SP, 2018, AGING-US, V10, P2062, DOI 10.18632/aging.101530
   Marley AR, 2016, INT J MOL EPIDEMIOL, V7, P105
   Mauri G, 2019, MOL ONCOL, V13, P109, DOI 10.1002/1878-0261.12417
   Meng S, 2019, MOL MED REP, V20, P2541, DOI 10.3892/mmr.2019.10510
   Mo SB, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2338-y
   Moranova L, 2019, Klin Onkol, V32, P65, DOI 10.14735/amko20193S65
   Nikolaou S, 2018, TECH COLOPROCTOL, V22, P481, DOI 10.1007/s10151-018-1820-3
   Ohuchi M, 2018, ONCOL LETT, V16, P5275, DOI 10.3892/ol.2018.9240
   Okugawa Y, 2015, GASTROENTEROLOGY, V149, P1204, DOI 10.1053/j.gastro.2015.07.011
   Ou CL, 2020, ADV SCI, V7, DOI 10.1002/advs.201901380
   Ouyang SR, 2019, CANCER CELL INT, V19, DOI 10.1186/s12935-019-0784-3
   Pan K, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2633-7
   Qin WY, 2019, CANCER CELL INT, V19, DOI 10.1186/s12935-019-0895-x
   Ren J, 2018, THERANOSTICS, V8, P3932, DOI 10.7150/thno.25541
   Saeinasab M, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1169-0
   Shan YJ, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0759-7
   Shen MY, 2020, EUR REV MED PHARMACO, V24, P1771, DOI 10.26355/eurrev_202002_20354
   Shen XJ, 2020, BIOSCIENCE REP, V40, DOI 10.1042/BSR20191481
   Shi DB, 2014, MED ONCOL, V31, DOI 10.1007/s12032-014-0031-7
   Shi Y, 2020, J CELL MOL MED, V24, P8363, DOI 10.1111/jcmm.15282
   Siddiqui H, 2019, MOL CLIN ONCOL, V11, P167, DOI 10.3892/mco.2019.1872
   Spurlock CF, 2016, J IMMUNOL, V197, P4509, DOI 10.4049/jimmunol.1600970
   Sun JF, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0771-x
   Sun LC, 2016, BIOSCIENCE REP, V36, DOI 10.1042/BSR20160048
   Sun SZ, 2020, BIOMED PHARMACOTHER, V125, DOI 10.1016/j.biopha.2020.110014
   Tang GH, 2020, FRONT GENET, V10, DOI 10.3389/fgene.2019.01409
   Tang R, 2019, INT J BIOL SCI, V15, P2885, DOI 10.7150/ijbs.38041
   Tao YM, 2017, ONCOTARGET, V8, P36410, DOI 10.18632/oncotarget.16850
   Vatandoost N, 2016, J CANCER RES CLIN, V142, P341, DOI 10.1007/s00432-015-1928-z
   Wang AH, 2019, EUR REV MED PHARMACO, V23, P8310, DOI 10.26355/eurrev_201910_19142
   Wang FW, 2019, J CLIN INVEST, V129, P727, DOI 10.1172/JCI122478
   Wang JZ, 2017, BRAZ J MED BIOL RES, V50, DOI [10.1590/1414-431X20176079, 10.1590/1414-431x20176079]
   Wang W, 2019, WORLD J GASTROENTERO, V25, P3972, DOI 10.3748/wjg.v25.i29.3972
   Wang XK, 2019, INT J MED SCI, V16, P51, DOI 10.7150/ijms.27359
   Wang X, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0860-7
   Wang Y., 2019, Biosci. Rep, V39
   Wang Y, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1105-0
   Wang ZZ, 2019, AGING-US, V11, P4876, DOI 10.18632/aging.102081
   Wei LJ, 2020, EUR REV MED PHARMACO, V24, P130, DOI 10.26355/eurrev_202001_19902
   Wen DC, 2020, BIOMED PHARMACOTHER, V125, DOI 10.1016/j.biopha.2020.110039
   Wu H., 2020, MOL THERAPY NUCL ACI, V20
   Wu YM, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1014-2
   Xian D, 2019, J CELL MOL MED, V23, P3808, DOI 10.1111/jcmm.14071
   Xiao ZG, 2018, CELL PHYSIOL BIOCHEM, V46, P1275, DOI 10.1159/000489110
   Xie F, 2017, ONCOTARGET, V8, P23628, DOI 10.18632/oncotarget.15466
   Xu M, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-018-0690-5
   Xu YL, 2018, MOL MED, V24, DOI 10.1186/s10020-018-0050-5
   Yan ZK, 2020, BIOSCIENCE REP, V40, DOI 10.1042/BSR20201025
   Yang LG, 2020, MOL GENET GENOM MED, V8, DOI 10.1002/mgg3.1112
   Yang ML, 2019, BIOSCIENCE REP, V39, DOI 10.1042/BSR20190708
   Yang SJ, 2018, J CELL MOL MED, V22, P2739, DOI 10.1111/jcmm.13567
   Yang WW, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/2767484
   Yang Y, 2019, CELL BIOL INT, V43, P1463, DOI 10.1002/cbin.11196
   Ye ZY, 2015, INT J CLIN EXP MED, V8, P3707
   Yu BQ, 2020, J CLIN LAB ANAL, V34, DOI 10.1002/jcla.23311
   Yu HR, 2019, ONCOTARGETS THER, V12, P11119, DOI 10.2147/OTT.S228798
   Yu HM, 2019, CELL PROLIFERAT, V52, DOI 10.1111/cpr.12526
   Yu JH, 2019, EUR REV MED PHARMACO, V23, P9371, DOI 10.26355/eurrev_201911_19430
   Yu JT, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0896-y
   Yue N, 2020, EXP THER MED, V20, P1746, DOI 10.3892/etm.2020.8814
   Zamani M, 2018, BIOMARKERS, V23, P105, DOI 10.1080/1354750X.2016.1252961
   Zhang JJ, 2019, EUR REV MED PHARMACO, V23, P8321, DOI 10.26355/eurrev_201910_19143
   Zhang M, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-018-0656-7
   Zhang MY, 2019, CANCER MANAG RES, V11, P10633, DOI 10.2147/CMAR.S228628
   Zhang MB, 2019, CANCER BIOL THER, V20, P524, DOI 10.1080/15384047.2018.1537579
   Zhang MY, 2019, ONCOTARGETS THER, V12, P3349, DOI 10.2147/OTT.S197433
   Zhang W, 2020, J CELL BIOCHEM, V121, P1998, DOI 10.1002/jcb.29434
   Zhang W, 2017, CELL PHYSIOL BIOCHEM, V44, P567, DOI 10.1159/000485091
   Zhang XT, 2019, MED SCI MONITOR, V25, P6429, DOI 10.12659/MSM.915329
   Zhang X, 2020, MOL ONCOL, V14, P2589, DOI 10.1002/1878-0261.12765
   Zhang YH, 2016, AM J TRANSL RES, V8, P5286
   Zhang YY, 2019, CANCER MANAG RES, V11, P1779, DOI 10.2147/CMAR.S192452
   Zhao KX, 2018, CANCER MANAG RES, V10, P6257, DOI 10.2147/CMAR.S177244
   Zhao K, 2020, ONCOTARGETS THER, V13, P2677, DOI 10.2147/OTT.S241011
   Zhao Y, 2018, EUR REV MED PHARMACO, V22, P976, DOI 10.26355/eurrev_201802_14379
   Zhao YC, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1375-9
   Zheng HT, 2014, INT J CLIN EXP PATHO, V7, P3174
   Zheng YS, 2019, J CELL BIOCHEM, V120, P3922, DOI 10.1002/jcb.27676
   Zheng YB, 2016, ONCOTARGET, V7, P83727, DOI 10.18632/oncotarget.13384
   Zheng ZH, 2020, AGING-US, V12, P10517, DOI 10.18632/aging.103276
   Zhou YF, 2020, CANCER MANAG RES, V12, P7579, DOI 10.2147/CMAR.S255787
   Zhu YP, 2017, ONCOTARGET, V8, P111715, DOI 10.18632/oncotarget.22903
NR 133
TC 2
Z9 2
U1 4
U2 5
PU ELSEVIER GMBH
PI MUNICH
PA HACKERBRUCKE 6, 80335 MUNICH, GERMANY
SN 0344-0338
EI 1618-0631
J9 PATHOL RES PRACT
JI Pathol. Res. Pract.
PD JUN
PY 2021
VL 222
AR 153432
DI 10.1016/j.prp.2021.153432
EA APR 2021
PG 11
WC Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology
GA SK5KB
UT WOS:000656253000002
PM 33857856
DA 2022-04-25
ER

PT J
AU Liu, LX
   Pan, YJ
   Ren, XL
   Zeng, ZC
   Sun, JB
   Zhou, K
   Liang, YS
   Wang, FF
   Yan, YR
   Liao, WT
   Ding, YQ
   Liu, XL
   Liang, L
AF Liu, Lixin
   Pan, Yangjian
   Ren, Xiaoli
   Zeng, Zhicheng
   Sun, Jingbo
   Zhou, Kun
   Liang, Yunshi
   Wang, Feifei
   Yan, Yongrong
   Liao, Wenting
   Ding, Yanqing
   Liu, Xiaolong
   Liang, Li
TI GFPT2 promotes metastasis and forms a positive feedback loop with p65 in
   colorectal cancer
SO AMERICAN JOURNAL OF CANCER RESEARCH
LA English
DT Article
DE GFPT2; NF-kappa B pathway; p-65 glycosylation; metastasis; colorectal
   cancer
ID HEXOSAMINE BIOSYNTHESIS; TRANSGENIC MICE; O-GLCNACYLATION;
   UP-REGULATION; GLUCOSE; TRANSFERASE; METABOLISM; AUTOPHAGY; GLUTAMINE;
   PATHWAY
AB As a rate-limiting enzyme of the hexosamine biosynthesis pathway (HBP), which is responsible for glycosylation, Glutamine fructose-6-phosphate amidotransferase 2 (GFPT2) is involved in human breast and lung tumorigenesis. However, whether GFTP2 is associated with tumor metastasis remains unclear. Here, we found that GFPT2 promoted the proliferation, migration, invasion and metastasis of colorectal cancer (CRC) cells. Mechanically, p65 acted as an upstream transcription factor of GFPT2 and regulated its expression and function. In turn, GFPT2 enhanced the glycosylation of p65, which led to the nuclear translocation of p65 and then activated NF-kappa B pathway. Thus, GFTP2 and p65 formed a positive feedback loop to promote the progression of CRC. In addition, GFPT2 was up-regulated in CRC tissues and closely related with liver metastasis (P<0.0001) and tumor stage (P=0.0184). High expression of GFPT2 predicted poor prognosis for CRC patients. Moreover, GFTP2 expression was positively linked with O-linked N-acetylglucosamine transferase in CRC tissues. Our study reveals a new mechanism of GFPT2 in CRC metastasis and provides a new target therapeutic target to deter metastasis.
C1 [Liu, Lixin; Pan, Yangjian; Sun, Jingbo; Zhou, Kun; Liu, Xiaolong] Southern Med Univ, Dept Gen Surg, Affiliated Hosp 3, Guangzhou 510515, Guangdong, Peoples R China.
   [Ren, Xiaoli; Zeng, Zhicheng; Liang, Yunshi; Wang, Feifei; Yan, Yongrong; Liao, Wenting; Ding, Yanqing; Liang, Li] Southern Med Univ, Nanfang Hosp, Dept Pathol, Guangzhou 510515, Guangdong, Peoples R China.
   [Ren, Xiaoli; Zeng, Zhicheng; Liang, Yunshi; Wang, Feifei; Yan, Yongrong; Liao, Wenting; Ding, Yanqing; Liang, Li] Guangdong Prov Key Lab Mol Tumor Pathol, Guangzhou 510515, Guangdong, Peoples R China.
   [Ren, Xiaoli; Zeng, Zhicheng; Liang, Yunshi; Wang, Feifei; Yan, Yongrong; Liao, Wenting; Ding, Yanqing; Liang, Li] Southern Med Univ, Basic Med Coll, Dept Pathol, Guangzhou 510515, Guangdong, Peoples R China.
RP Liu, XL (corresponding author), Southern Med Univ, Dept Gen Surg, Affiliated Hosp 3, 183 West Zhongshan Ave, Guangzhou 510630, Guangdong, Peoples R China.; Liang, L (corresponding author), Southern Med Univ, Dept Pathol, Guangzhou 510515, Guangdong, Peoples R China.
EM lxl1979@i.smu.edu.cn; lli@fimmu.com
FU National key R&D program of China [2017YFC1309002]; National Basic
   Research Program of China (973 Program)National Basic Research Program
   of China [2015CB554002]; National Natural Science Foundation of
   ChinaNational Natural Science Foundation of China (NSFC) [81672821,
   81773101, 81802306]; China Postdoctoral Science FoundationChina
   Postdoctoral Science Foundation [2018M633081, 2018M633079]; Natural
   Science Foundation of Guangdong ProvinceNational Natural Science
   Foundation of Guangdong Province [2018A030310457]
FX This work was supported by the National key R&D program of China
   (2017YFC1309002), National Basic Research Program of China (973 Program,
   2015CB554002), National Natural Science Foundation of China (81672821,
   81773101, 81802306), Project funded by China Postdoctoral Science
   Foundation (2018M633081, 2018M633079), Natural Science Foundation of
   Guangdong Province (2018A030310457).
CR Ali A, 2017, MOL CELLS, V40, P476, DOI 10.14348/molcells.2017.2309
   Alisson-Silva F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060471
   Allison DF, 2012, P NATL ACAD SCI USA, V109, P16888, DOI 10.1073/pnas.1208468109
   Apweiler R, 1999, BBA-GEN SUBJECTS, V1473, P4, DOI 10.1016/S0304-4165(99)00165-8
   Baldwin AS, 2012, IMMUNOL REV, V246, P327, DOI 10.1111/j.1600-065X.2012.01095.x
   Basak S, 2012, IMMUNOL REV, V246, P221, DOI 10.1111/j.1600-065X.2011.01092.x
   Dennis JW, 2009, CELL, V139, P1229, DOI 10.1016/j.cell.2009.12.008
   Fardini Y, 2013, FRONT ENDOCRINOL, V4, DOI 10.3389/fendo.2013.00099
   Gao J, 2018, CARCINOGENESIS, V39, P1222, DOI 10.1093/carcin/bgy097
   Gu MJ, 2018, BMC CANCER, V18, DOI 10.1186/s12885-017-3968-z
   Guan F, 2009, P NATL ACAD SCI USA, V106, P7461, DOI 10.1073/pnas.0902368106
   Hauselmann I, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00028
   Itkonen HM, 2013, CANCER RES, V73, P5277, DOI 10.1158/0008-5472.CAN-13-0549
   Lai JL, 2017, INFLAMMATION, V40, P1, DOI 10.1007/s10753-016-0447-7
   Lynch TP, 2012, J BIOL CHEM, V287, P11070, DOI 10.1074/jbc.M111.302547
   Ma ZY, 2013, J BIOL CHEM, V288, P15121, DOI 10.1074/jbc.M113.470047
   MARSHALL S, 1991, J BIOL CHEM, V266, P4706
   Mi WY, 2011, BBA-MOL BASIS DIS, V1812, P514, DOI 10.1016/j.bbadis.2011.01.009
   Ramakrishnan P, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004097
   Ruan HB, 2013, TRENDS ENDOCRIN MET, V24, P301, DOI 10.1016/j.tem.2013.02.002
   Rumberger JM, 2003, J BIOL CHEM, V278, P28547, DOI 10.1074/jbc.M302793200
   Siegel RL, 2016, CA-CANCER J CLIN, V66, P7, DOI 10.3322/caac.21332
   Simpson NE, 2012, BREAST CANCER RES TR, V133, P959, DOI 10.1007/s10549-011-1871-x
   Slawson C, 2011, NAT REV CANCER, V11, P678, DOI 10.1038/nrc3114
   Sun SC, 2017, NAT REV IMMUNOL, V17, P545, DOI 10.1038/nri.2017.52
   Tang JP, 2000, DIABETES, V49, P1492, DOI 10.2337/diabetes.49.9.1492
   Veerababu G, 2000, DIABETES, V49, P2070, DOI 10.2337/diabetes.49.12.2070
   Wang LS, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-5033-y
   Wise DR, 2010, TRENDS BIOCHEM SCI, V35, P427, DOI 10.1016/j.tibs.2010.05.003
   Xing DQ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024021
   Yde P, 2011, BMC SYST BIOL, V5, DOI 10.1186/1752-0509-5-115
   YkiJarvinen H, 1996, DIABETES, V45, P302, DOI 10.2337/diabetes.45.3.302
   Zhang HL, 2004, J CLIN ENDOCR METAB, V89, P748, DOI 10.1210/jc.2003-031286
   Zhang WR, 2018, CANCER RES, V78, P3445, DOI 10.1158/0008-5472.CAN-17-2928
   Zhou FX, 2018, THERANOSTICS, V8, P5200, DOI 10.7150/thno.27806
NR 35
TC 4
Z9 4
U1 4
U2 6
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 2156-6976
J9 AM J CANCER RES
JI Am. J. Cancer Res.
PY 2020
VL 10
IS 8
BP 2510
EP +
PG 15
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA OC8CX
UT WOS:000579385400020
PM 32905539
DA 2022-04-25
ER

PT J
AU Shi, Y
   Tang, B
   Yu, PW
   Tang, B
   Hao, YX
   Lei, X
   Luo, HX
   Zeng, DZ
AF Shi, Yan
   Tang, Bin
   Yu, Pei-Wu
   Tang, Bo
   Hao, Ying-Xue
   Lei, Xiao
   Luo, Hua-Xing
   Zeng, Dong-Zhu
TI Autophagy Protects against Oxaliplatin-Induced Cell Death via ER Stress
   and ROS in Caco-2 Cells
SO PLOS ONE
LA English
DT Article
ID COLORECTAL-CANCER; GENERATION; RESISTANCE; MECHANISMS; SURVIVAL;
   PATHWAYS; THERAPY
AB Oxaliplatin is included in a number of effective combination regimens used as first and subsequent lines of therapy for metastatic colorectal cancer. Accumulating evidence indicates that autophagy plays a significant role in response to cancer therapy. However, the role of autophagy in oxaliplatin-induced cell death remains to be clarified. In this study, we showed that oxaliplatin induced cell death and autophagy in Caco-2 colorectal cancer cells. The suppression of autophagy using either pharmacologic inhibitors (3-methyladenine, bafilomycin A1) or RNA interference in essential autophagy genes (ATG5 or Beclin1) enhanced the cell death and reactive oxygen species (ROS) production induced by oxaliplatin in Caco-2 cells. Blocking oxaliplatin-induced ROS production by using ROS scavengers (NAC or Tiron) decreased autophagy. Furthermore, numerous dilated endoplasmic reticula (ER) were present in oxaliplatin-treated Caco-2 cells, and blocking ER stress by RNA interference against candidate of metastasis-1 (P8) and C/EBP-homologous protein (CHOP) decreased autophagy and ROS production. Taken together, these data indicate that oxaliplatin activates autophagy as a cytoprotective response via ER stress and ROS in human colorectal cancer cells.
C1 [Shi, Yan; Yu, Pei-Wu; Tang, Bo; Hao, Ying-Xue; Lei, Xiao; Luo, Hua-Xing; Zeng, Dong-Zhu] Third Mil Med Univ, Southwest Hosp, Dept Gen Surg, Chongqing, Peoples R China.
   [Shi, Yan; Yu, Pei-Wu; Tang, Bo; Hao, Ying-Xue; Lei, Xiao; Luo, Hua-Xing; Zeng, Dong-Zhu] Third Mil Med Univ, Southwest Hosp, Ctr Minimal Invas Gastrointestinal Surg, Chongqing, Peoples R China.
   [Tang, Bin] Third Mil Med Univ, Coll Med Lab Sci, Dept Clin Microbiol & Immunol, Chongqing, Peoples R China.
RP Yu, PW (corresponding author), Third Mil Med Univ, Southwest Hosp, Dept Gen Surg, Chongqing, Peoples R China.
EM yupeiwu01@vip.sina.com; zdz1140@yahoo.com.cn
OI Multhoff, Gabriele/0000-0002-2616-3137
CR Arango D, 2004, BRIT J CANCER, V91, P1931, DOI 10.1038/sj.bjc.6602215
   Azad MB, 2009, ANTIOXID REDOX SIGN, V11, P777, DOI 10.1089/ARS.2008.2270
   Bae YS, 2011, MOL CELLS, V32, P491, DOI 10.1007/s10059-011-0276-3
   Cabello CM, 2007, CURR OPIN INVEST DR, V8, P1022
   Chen N, 2011, CANCER BIOL THER, V11, P157, DOI 10.4161/cbt.11.2.14622
   Chen YQ, 2010, CAN J PHYSIOL PHARM, V88, P285, DOI 10.1139/Y10-010
   Ding ZB, 2011, CLIN CANCER RES, V17, P6229, DOI 10.1158/1078-0432.CCR-11-0816
   Grothey A, 2010, ONCOLOGY-BASEL, V79, P389, DOI 10.1159/000323491
   He CC, 2009, ANNU REV GENET, V43, P67, DOI 10.1146/annurev-genet-102808-114910
   Hersey P, 2008, PIGM CELL MELANOMA R, V21, P358, DOI 10.1111/j.1755-148X.2008.00467.x
   Hisamuddin Irfan M, 2004, MedGenMed, V6, P13
   Hu C, 2012, TOXICOL LETT, V210, P78, DOI 10.1016/j.toxlet.2012.01.019
   Huang J, 2011, ANTIOXID REDOX SIGN, V14, P2215, DOI 10.1089/ars.2010.3554
   Klionsky DJ, 2008, AUTOPHAGY, V4, P151, DOI 10.4161/auto.5338
   Kroemer G, 2007, PHYSIOL REV, V87, P99, DOI 10.1152/physrev.00013.2006
   Kung CP, 2011, CRIT REV EUKAR GENE, V21, P71, DOI 10.1615/CritRevEukarGeneExpr.v21.i1.50
   Lee J, 2012, BIOCHEM J, V441, P523, DOI 10.1042/BJ20111451
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Li ZY, 2011, BIOCHEM BIOPH RES CO, V414, P5, DOI 10.1016/j.bbrc.2011.09.046
   Mahoney E, 2012, BLOOD, V120, P1262, DOI 10.1182/blood-2011-12-400184
   Marchetti P, 2004, ANTICANCER RES, V24, P219
   Martins I, 2011, ONCOGENE, V30, P1147, DOI 10.1038/onc.2010.500
   Mathew R, 2009, CELL, V137, P1062, DOI 10.1016/j.cell.2009.03.048
   O'Connell JB, 2004, JNCI-J NATL CANCER I, V96, P1420, DOI 10.1093/jnci/djh275
   Pardini B, 2012, MUTAGENESIS, V27, P161, DOI 10.1093/mutage/ger057
   Santos CXC, 2009, ANTIOXID REDOX SIGN, V11, P2409, DOI [10.1089/ars.2009.2625, 10.1089/ARS.2009.2625]
   Trachootham D, 2008, ANTIOXID REDOX SIGN, V10, P1343, DOI 10.1089/ars.2007.1957
   White E, 2010, CURR OPIN CELL BIOL, V22, P212, DOI 10.1016/j.ceb.2009.12.008
   Yokoyama T, 2008, GENE THER, V15, P1233, DOI 10.1038/gt.2008.98
   Zhou S, 2012, CANC LETT
NR 30
TC 55
Z9 57
U1 0
U2 15
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 30
PY 2012
VL 7
IS 11
AR e51076
DI 10.1371/journal.pone.0051076
PG 8
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 054WM
UT WOS:000312376100278
PM 23226467
OA Green Submitted, Green Published, gold
DA 2022-04-25
ER

PT J
AU Su, L
   Zhang, HL
   Yan, C
   Chen, AP
   Meng, G
   Wei, JW
   Yu, DC
   Ding, YT
AF Su, Lei
   Zhang, Hailin
   Yan, Chen
   Chen, Aiping
   Meng, Gang
   Wei, Jiwu
   Yu, Decai
   Ding, Yitao
TI Superior anti-tumor efficacy of diisopropylamine dichloroacetate
   compared with dichloroacetate in a subcutaneous transplantation breast
   tumor model
SO ONCOTARGET
LA English
DT Article
DE diisopropylamine dichloroacetate; dichloroacetate; subcutaneous
   transplantation breast tumor model; MDA-MB-231 cell line
ID COLORECTAL-CANCER CELLS; CROSS-TALK; IN-VITRO; AUTOPHAGY; METABOLISM;
   MITOCHONDRIA; APOPTOSIS; PREVENTION; THERAPY; KINASE
AB Dichloroacetate (DCA), an inhibitor of pyruvate dehydrogenase kinase, has antitumor properties in various carcinoma models. Diisopropylamine dichloroacetate (DADA), an over-the-counter drug for chronic liver disease, is a derivative of DCA. To date, few studies have evaluated the anticancer potential of DADA in breast cancer. In this study, MDA-MB-231 cells, a breast adenocarcinoma cell line, were used in in vitro and in vivo experiments to evaluate the anti-tumor efficacy of DADA and DCA. The half maximal inhibitory concentration (IC50) of DADA (7.1 +/- 1.1 mmol/L) against MDA-MB-231 cells was significantly lower than that of DCA (15.6 +/- 2.0 mmol/L); 100 mg/kg (0.0004 mol/kg) DADA was better than 100 mg/kg (0.0008 mol/kg) DCA at suppressing the growth of subcutaneous transplantation breast tumor at the same dose after 24 days intervention. Histological examination showed that both DCA and DADA interventions led to necrosis, inflammation, and fibrosis of tumor tissue in a mouse subcutaneous transplantation breast tumor model. DADA treatment inhibited Ki67 expression in tumor tissue. In vitro experiments showed that DADA could inhibit lactic acid production and glucose uptake in MDA-MB-231 cells at 10 mmol/L and these effects were stronger than DCA. DADA administration also induced complete autophagy during early treatment stages and incomplete autophagy and cell death at later treatment stages. In conclusion, DADA showed better anti-tumor efficacy than DCA in a breast cancer model.
C1 [Su, Lei; Yan, Chen; Yu, Decai; Ding, Yitao] Nanjing Univ, Drum Tower Hosp, Sch Med, Dept Hepatobiliary Surg, Nanjing 210008, Jiangsu, Peoples R China.
   [Zhang, Hailin; Chen, Aiping; Meng, Gang; Wei, Jiwu] Nanjing Univ, Sch Med, Jiangsu Key Lab Mol Med, Nanjing 210008, Jiangsu, Peoples R China.
   [Zhang, Hailin; Chen, Aiping; Meng, Gang; Wei, Jiwu] Nanjing Univ, State Key Lab Pharmaceut Biotechnol, Nanjing 210008, Jiangsu, Peoples R China.
RP Yu, DC; Ding, YT (corresponding author), Nanjing Univ, Drum Tower Hosp, Sch Med, Dept Hepatobiliary Surg, Nanjing 210008, Jiangsu, Peoples R China.
EM dryudecai@qq.com; yitao__ding@sina.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81372294, 81372455]
FX This work was supported by the National Natural Science Foundation of
   China (81372294,81372455).
CR Barth S, 2010, J PATHOL, V221, P117, DOI 10.1002/path.2694
   Beral V, 2002, LANCET, V360, P187, DOI 10.1016/S0140-6736(02)09454-0
   Bonnet S, 2007, CANCER CELL, V11, P37, DOI 10.1016/j.ccr.2006.10.020
   Cao WG, 2008, PROSTATE, V68, P1223, DOI 10.1002/pros.20788
   Chen N, 2011, CANCER BIOL THER, V11, P157, DOI 10.4161/cbt.11.2.14622
   Cheong H, 2012, NAT BIOTECHNOL, V30, P671, DOI 10.1038/nbt.2285
   Egger ME, 2013, J SURG RES, V184, P274, DOI 10.1016/j.jss.2013.04.055
   Garcia-Prat L, 2016, ONCOTARGET, V7, P12286, DOI 10.18632/oncotarget.7766
   Gomes LR, 2016, PHARMACOL RES, V107, P300, DOI 10.1016/j.phrs.2016.03.031
   Howell A, 2005, NAT CLIN PRACT ONCOL, V2, P635, DOI 10.1038/ncponc0361
   Klionsky DJ, 2016, AUTOPHAGY, V12, P1, DOI 10.1080/15548627.2015.1100356
   KRAUSHAAR A, 1963, ARZNEIMITTEL-FORSCH, V13, P109
   Kroemer G, 2009, CELL DEATH DIFFER, V16, P3, DOI 10.1038/cdd.2008.150
   Kumar K, 2013, J MOL MED, V91, P749, DOI 10.1007/s00109-013-0996-2
   Lee J, 2012, BIOCHEM J, V441, P523, DOI 10.1042/BJ20111451
   Lew CR, 2015, NAT REV UROL, V12, P383, DOI 10.1038/nrurol.2015.111
   Li XJ, 2016, MOL CELL, V61, P705, DOI 10.1016/j.molcel.2016.02.009
   Lin G, 2014, BRIT J CANCER, V111, P375, DOI 10.1038/bjc.2014.281
   Liu DX, 2015, DRUG DELIV, V22, P136, DOI 10.3109/10717544.2013.870258
   Lodish H, 2000, MOL CELL BIOL, V4th
   Lowenstein J. M., 1969, METHODS ENZYMOLOGY, V13
   Madhok BM, 2010, BRIT J CANCER, V102, P1746, DOI 10.1038/sj.bjc.6605701
   McNear Scott, 2009, Therap Adv Gastroenterol, V2, P29, DOI 10.1177/1756283X08100327
   Moreau K, 2010, CURR OPIN CELL BIOL, V22, P206, DOI 10.1016/j.ceb.2009.12.002
   O'Leary B, 2016, NAT REV CLIN ONCOL, V13, P417, DOI 10.1038/nrclinonc.2016.26
   Osorio A, 2000, BRIT J CANCER, V82, P1266, DOI 10.1054/bjoc.1999.1089
   Petrucelli N, 2010, GENET MED, V12, P245, DOI 10.1097/GIM.0b013e3181d38f2f
   Reeder Jennifer G., 2008, V141, P149
   Rudolph A, 2016, BRIT J CANCER, V114, P125, DOI 10.1038/bjc.2015.439
   Saini KS, 2012, ANN ONCOL, V23, P853, DOI 10.1093/annonc/mdr352
   Sharma GN, 2010, J ADV PHARM TECHNOL, V1, P109
   Su ZY, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0321-5
   Sun RC, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-142
   Sun RC, 2010, BREAST CANCER RES TR, V120, P253, DOI 10.1007/s10549-009-0435-9
   Sun WY, 2009, CLIN CANCER RES, V15, P476, DOI 10.1158/1078-0432.CCR-08-0930
   White E, 2010, CURR OPIN CELL BIOL, V22, P212, DOI 10.1016/j.ceb.2009.12.008
   WHO, TRENDS MAT MORT 1990
   Yamane K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098032
   Yang ZNJ, 2011, MOL CANCER THER, V10, P1533, DOI 10.1158/1535-7163.MCT-11-0047
   Zdenkowski N, 2016, BREAST, V26, P31, DOI 10.1016/j.breast.2015.12.007
NR 40
TC 10
Z9 10
U1 1
U2 11
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD OCT 4
PY 2016
VL 7
IS 40
BP 65721
EP 65731
DI 10.18632/oncotarget.11609
PG 11
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA EB3QQ
UT WOS:000387281000091
PM 27582548
OA gold, Green Published, Green Submitted
DA 2022-04-25
ER

PT J
AU Zheng, TL
   Li, DP
   He, ZF
   Feng, SB
   Zhao, S
AF Zheng, Tianliang
   Li, Deping
   He, Zhanfeng
   Feng, Shuaibing
   Zhao, Song
TI Prognostic and clinicopathological significance of Beclin-1 in
   non-small-cell lung cancer: a meta-analysis
SO ONCOTARGETS AND THERAPY
LA English
DT Article
DE non-small-cell lung cancer; autophagy; Beclin-1; prognosis;
   meta-analysis
ID LYMPH-NODE METASTASIS; POOR-PROGNOSIS; COLORECTAL-CANCER;
   GASTRIC-CANCER; 1 EXPRESSION; GENE BECLIN1; AUTOPHAGY; CARCINOMA;
   ADENOCARCINOMA; APOPTOSIS
AB Background: Autophagy plays a key role in the development of non-small-cell lung cancer (NSCLC). Beclin-1 is essential for the initiation and regulation of autophagy. Accumulated studies have investigated the prognostic role of Beclin-1 in NSCLC, but conclusions remain controversial. Therefore, we conducted this meta-analysis to assess the potential significance of Beclin-1 in NSCLC.
   Materials and methods: PubMed and Fin base databases were searched for eligible studies published before December 31, 2017. Odds ratio (OR) was pooled to evaluate the clinico- pathological significance of Beclin-1 in NSCLC. Hazard ratio (HR) was adopted to assess the association of Beclin-1 with overall survival (OS).
   Results: Eight studies involving 1,159 patients were included in this meta-analysis. The pooled results showed that high Beclin-1 expression was significantly correlated with earlier tumor grade (OR=0.54, 95% CI: 0.36-0.81, P=0.003), less nodal involvement (OR=0.56, 95% CI: 0.37.-0.86, P=0.007), earlier TNM stage (OR=0.62, 95% CI: 0.43-0.89, P=0.010), smaller tumor size (OR=0.54, 95% CI: 0.36.-0.81, P=0.003), better differentiation (OR=0.48, 95% CI: 0.36-.0.64, P<0.001), and less recurrence (OR=0.24, 95% CI: 0.14-0.41, P<0.001). Moreover, high level of Beclin-1 was significantly associated with better OS in NSCLC (HR=0.41, 95% CI: 0.26-0.64, P<0.001).
   Conclusion: Our meta-analysis suggests that high Beclin-1 expression predicts a better clinicopathological status and a better prognosis in NSCLC. Beclin-1 might act as a promising prognostic biomarker for NSCLC.
C1 [Zheng, Tianliang; He, Zhanfeng; Feng, Shuaibing; Zhao, Song] Zhengzhou Univ, Affiliated Hosp 1, Dept Thorac Surg, 1 Jianshe East Rd, Zhengzhou 450052, Henan, Peoples R China.
   [Li, Deping] Zhengzhou Hosp Tradit Chinese Med, Dept Pain Management, Zhengzhou, Henan, Peoples R China.
RP Zhao, S (corresponding author), Zhengzhou Univ, Affiliated Hosp 1, Dept Thorac Surg, 1 Jianshe East Rd, Zhengzhou 450052, Henan, Peoples R China.
EM zzuzhaosong@yahoo.com
FU Youth Innovation Fund Project of the First Affiliated Hospital of
   Zhengzhou University
FX This study was supported by the Youth Innovation Fund Project of the
   First Affiliated Hospital of Zhengzhou University.
CR Cao JP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077922
   Chen YG, 2014, WSPOLCZESNA ONKOL, V18, P171, DOI 10.5114/wo.2014.41395
   Coleman MP, 2011, LANCET, V377, P127, DOI 10.1016/S0140-6736(10)62231-3
   Dai ZJ, 2013, INT J MOL SCI, V14, P273, DOI 10.3390/ijms14010273
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Geng QR, 2012, PLOS ONE, V7
   Giatromanolaki A, 2011, GYNECOL ONCOL, V123, P147, DOI 10.1016/j.ygyno.2011.06.023
   Grimaldi A, 2015, CANCER BIOL THER, V16, P567, DOI 10.1080/15384047.2015.1018494
   Gu Y, 2017, ONCOTARGET, V8, P52156, DOI 10.18632/oncotarget.11044
   Guo GF, 2011, WORLD J GASTROENTERO, V17, P4779, DOI 10.3748/wjg.v17.i43.4779
   Guo JYX, 2016, COLD SH Q B, V81, P73, DOI 10.1101/sqb.2016.81.030981
   Han Y, 2014, ASIAN PAC J CANCER P, V15, P4583, DOI 10.7314/APJCP.2014.15.11.4583
   He YY, 2014, TUMOR BIOL, V35, P7317, DOI 10.1007/s13277-014-2060-4
   Hoyer-Hansen M, 2007, CELL DEATH DIFFER, V14, P1576, DOI 10.1038/sj.cdd.4402200
   Hu ZD, 2016, MOL MED REP, V14, P1567, DOI 10.3892/mmr.2016.5437
   Itakura E, 2009, AUTOPHAGY, V5, P534, DOI 10.4161/auto.5.4.8062
   Jiang LL, 2014, ONCOL REP, V32, P1931, DOI 10.3892/or.2014.3432
   Jung G, 2015, ACTA HAEMATOL-BASEL, V134, P17, DOI 10.1159/000368848
   Kang R, 2011, CELL DEATH DIFFER, V18, P571, DOI 10.1038/cdd.2010.191
   Karpathiou G, 2013, APMIS, V121, P592, DOI 10.1111/apm.12026
   Kim KM, 2012, INT J CANCER, V131, pE362, DOI 10.1002/ijc.26463
   Li X, 2013, ACTA CHIR BELG, V113, P175, DOI 10.1080/00015458.2013.11680907
   LIU JL, 2015, PLOS ONE, V10, DOI DOI 10.1371/JOURNAL.PONE.014130826506105
   Liu J, 2011, TUMOR BIOL, V32, P1113, DOI 10.1007/s13277-011-0211-4
   Lv ZQ, 2015, CLIN RESPIR J, V9, P359, DOI 10.1111/crj.12148
   Masuda G, 2016, ANTICANCER RES, V36, P129
   McKnight Nicole C, 2013, Curr Pathobiol Rep, V1, P231
   Mowers EE, 2017, ONCOGENE, V36, P1619, DOI 10.1038/onc.2016.333
   Park JY, 2014, HEPATO-GASTROENTEROL, V61, P1494, DOI 10.5754/hge13360
   Parmar MKB, 1998, STAT MED, V17, P2815, DOI 10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8
   Qiu DM, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-327
   Rao S, 2014, AUTOPHAGY, V10, P529, DOI 10.4161/auto.27643
   Stang A, 2010, EUR J EPIDEMIOL, V25, P603, DOI 10.1007/s10654-010-9491-z
   Torre LA, 2016, ADV EXP MED BIOL, V893, P1, DOI 10.1007/978-3-319-24223-1_1
   Toton E, 2014, J PHYSIOL PHARMACOL, V65, P459
   Valente G, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/462658
   Wan XB, 2010, AUTOPHAGY, V6, P395, DOI 10.4161/auto.6.3.11303
   Wang J, 2013, PLOS ONE, V8
   Wang WY, 2016, MOL MED REP, V14, P355, DOI 10.3892/mmr.2016.5219
   Wang WY, 2013, MOL MED REP, V7, P1501, DOI 10.3892/mmr.2013.1379
   Wang XF, 2015, INT J CLIN EXP PATHO, V8, P10644
   Weh KM, 2016, MOL CARCINOGEN, V55, P1876, DOI 10.1002/mc.22432
   Won KY, 2012, HUM PATHOL, V43, P62, DOI 10.1016/j.humpath.2011.04.007
   Xia P, 2013, TUMOR BIOL, V34, P3303, DOI 10.1007/s13277-013-1049-8
   Yang ZL, 2015, CLIN RES HEPATOL GAS, V39, P98, DOI 10.1016/j.clinre.2014.06.014
   Yu SJ, 2016, TUMOR BIOL, V37, P15007, DOI 10.1007/s13277-016-5383-5
   Zhang MY, 2014, INT J MOL SCI, V15, P14372, DOI 10.3390/ijms150814372
NR 47
TC 5
Z9 6
U1 0
U2 1
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-6930
J9 ONCOTARGETS THER
JI OncoTargets Ther.
PY 2018
VL 11
BP 4167
EP 4175
DI 10.2147/OTT.S164987
PG 9
WC Biotechnology & Applied Microbiology; Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Oncology
GA GN6JG
UT WOS:000439186900005
PM 30050308
OA Green Submitted, Green Published, gold
DA 2022-04-25
ER

PT J
AU Wu, JF
   Lie, W
   Ning, JZ
   Yu, WM
   Rao, T
   Cheng, F
AF Wu, Junfeng
   Lie, Wei
   Ning, Jinzhuo
   Yu, Weimin
   Rao, Ting
   Cheng, Fan
TI Long noncoding RNA UCA1 targets miR-582-5p and contributes to the
   progression and drug resistance of bladder cancer cells through
   ATG7-mediated autophagy inhibition
SO ONCOTARGETS AND THERAPY
LA English
DT Article
DE IncRNA UCA1; miR-582-5p; bladder cancer; migration and invasion;
   resistance
ID CARCINOMA-ASSOCIATED 1; UROTHELIAL CARCINOMA; UP-REGULATION;
   COLORECTAL-CANCER; LUNG-CANCER; PROLIFERATION; APOPTOSIS; MIGRATION;
   PROMOTES; INVASION
AB Background: Rently, the incidence of bladder cancer has been on the rise. Accumulating researches have been conducted to clarify the molecular mechanisms and potential therapeutic targets of bladder cancer. The present study aims to explore the regulatory mechanism of the urothelial carcinoma-associated 1 (UCA1)-miR-582-5p-ATG7 axis in bladder cancer.
   Methods: Quantitative real-time polymerase chain reaction was used to detect mRNA level. Relative protein expression was detected by western blot, wound healing assay and transwell were used to determine migration and invasion of cells. in addtion, luciferase reporter assay and immunohistochemistry were performed.
   Results: UCA1 expression was upregulated in bladder cancer tissues and cells, while the depletion of UCA1 by shRNA resulted in the suppression of cell proliferation, invasion, migration, and drug resistance. Further studies demonstrated that UCA1 could directly interact with miR-582-5p, and that there was an inverse correlation between miR-582-5p and UCA1. In addition, we found that ATG7 is a target of miR-582-5p and can be downregulated by either miR-582-5p overexpression or UCA1 knockdown. In particular, the autophagy is reduced when UCA1 shRNA is introduced. Moreover, the in vivo experiment further demonstrated the contribution of UCA1 in bladder cancer including tumor growth, invasion, and migration, and UCA1 knockdown can inhibit the aforementioned activities.
   Conclusion: These results provided evidence for a novel UCA1 interaction regulatory network in bladder cancer, that is, UCA1-miR-582-5p-ATG7-autophagy axis. Our study provides a new insight into the treatment of bladder cancer.
C1 [Wu, Junfeng; Ning, Jinzhuo; Yu, Weimin; Rao, Ting; Cheng, Fan] Wuhan Univ, Renmin Hosp, Dept Urol, Wuhan, Hubei, Peoples R China.
   [Lie, Wei] Wuhan Univ, Peoples Hosp, Dept Anesthesiol, Wuhan, Hubei, Peoples R China.
RP Cheng, F (corresponding author), Wuhan Univ, Renmin Hosp, 238 Jiefang Rd, Wuhan 430060, Hubei, Peoples R China.
EM fanchengdoc@sohu.com
CR Antoni S, 2017, EUR UROL, V71, P96, DOI 10.1016/j.eururo.2016.06.010
   Bao LL, 2014, EXP MOL PATHOL, V96, P149, DOI 10.1016/j.yexmp.2013.12.002
   Bian ZH, 2016, SCI REP-UK, V6, DOI 10.1038/srep23892
   Chandrasekar T, 2016, INVESTIG CLIN UROL, V57, pS89, DOI 10.4111/icu.2016.57.S1.S89
   Fan Y, 2014, FEBS J, V281, P1750, DOI 10.1111/febs.12737
   Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210
   Geng JF, 2008, EMBO REP, V9, P859, DOI 10.1038/embor.2008.163
   Homma I, 2009, CANCER SCI, V100, P2331, DOI 10.1111/j.1349-7006.2009.01329.x
   Kang M, 2014, INT J MOL SCI, V15, P8106, DOI 10.3390/ijms15058106
   Lai K, 2014, J CLIN PATHOL, V67, P854, DOI 10.1136/jclinpath-2014-202529
   Li F, 2015, CRIT REV EUKAR GENE, V25, P191, DOI 10.1615/CritRevEukaryotGeneExpr.2015013770
   Li LL, 2018, SAUDI J BIOL SCI, V25, P965, DOI 10.1016/j.sjbs.2018.03.007
   Lin YC, 2016, J UROLOGY, V195, P1126, DOI 10.1016/j.juro.2015.10.128
   Milowich D, 2015, SPRINGERPLUS, V4, DOI 10.1186/s40064-015-1092-6
   Nie W, 2016, CANCER LETT, V371, P99, DOI 10.1016/j.canlet.2015.11.024
   Pan JJ, 2016, CANCER LETT, V382, P64, DOI 10.1016/j.canlet.2016.08.015
   Pilati P, 2012, CURR MED CHEM, V19, P3900, DOI 10.2174/092986712802002473
   Sun SX, 2016, ONCOTARGETS THER, V9, P4975, DOI 10.2147/OTT.S107876
   Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262
   Tuo YL, 2015, EUR REV MED PHARMACO, V19, P3403
   Uchino K, 2013, MOL THER, V21, P610, DOI 10.1038/mt.2012.269
   Wang F, 2015, ONCOTARGET, V6, P1
   Wang SS, 2017, MOL MED REP, V15, P1179, DOI 10.3892/mmr.2017.6111
   Wang SS, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157759
   Wang WW, 2017, JPN J CLIN ONCOL, V47, P690, DOI 10.1093/jjco/hyx073
   Wu SH, 2015, INT J CLIN EXP PATHO, V8, P3882
   Xue M, 2016, CANCER SCI, V107, P18, DOI 10.1111/cas.12844
   Xue M, 2014, TUMOR BIOL, V35, P6901, DOI 10.1007/s13277-014-1925-x
   Xue M, 2014, ONCOL REP, V31, P1993, DOI 10.3892/or.2014.3092
   Zeng XH, 2014, BIOMATERIALS, V35, P1227, DOI 10.1016/j.biomaterials.2013.10.042
   Zhang X, 2015, CANCER GENE THER, V22, P475, DOI 10.1038/cgt.2015.44
   Zhang Y, 2015, TUMOR BIOL, V36, P8309, DOI 10.1007/s13277-015-3582-0
   Zhang Zheng, 2012, Zhonghua Yi Xue Za Zhi, V92, P384
   Zhou J, 2018, EPIGENOMICS-UK, V10, P259, DOI 10.2217/epi-2017-0104
   Zhu JL, 2017, MOL THER-NUCL ACIDS, V7, P299, DOI 10.1016/j.omtn.2017.04.012
NR 35
TC 49
Z9 51
U1 0
U2 8
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-6930
J9 ONCOTARGETS THER
JI OncoTargets Ther.
PY 2019
VL 12
BP 495
EP 508
DI 10.2147/OTT.S183940
PG 14
WC Biotechnology & Applied Microbiology; Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Oncology
GA HH2AA
UT WOS:000455519800004
PM 30666128
OA Green Published, gold, Green Submitted
DA 2022-04-25
ER

PT J
AU Yoo, BH
   Wu, X
   Li, YL
   Haniff, M
   Sasazuki, T
   Shirasawa, S
   Eskelinen, EL
   Rosen, KV
AF Yoo, Byong Hoon
   Wu, Xue
   Li, Yongling
   Haniff, Mehnaaz
   Sasazuki, Takehiko
   Shirasawa, Senji
   Eskelinen, Eeva-Liisa
   Rosen, Kirill V.
TI Oncogenic ras-induced Down-regulation of Autophagy Mediator Beclin-1 Is
   Required for Malignant Transformation of Intestinal Epithelial Cells
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID TUMOR-SUPPRESSOR GENE; ANOIKIS RESISTANCE; COLORECTAL-CANCER; K-RAS;
   PANCREATIC ADENOCARCINOMA; FAMILY PROTEINS; ACTIVATED RAS; CYCLE ARREST;
   IN-VIVO; GROWTH
AB Detachment of non-malignant epithelial cells from the extracellular matrix causes their growth arrest and, ultimately, death. By contrast, cells composing carcinomas, cancers of epithelial origin, can survive and proliferate without being attached to the extracellular matrix. These properties of tumor cells represent hallmarks of malignant transformation and are critical for cancer progression. Previously we identified several mechanisms by which ras, a major oncogene, blocks detachment-induced apoptosis of intestinal epithelial cells, but mechanisms by which Ras promotes proliferation of those cells that remain viable following detachment are unknown. We show here that detachment of non-malignant intestinal epithelial cells promotes formation of autophagosomes, vacuole-like structures that mediate autophagy (a process of cellular self-cannibalization), and that oncogenic ras prevents this autophagosome formation. We also found that ras activates a GTPase RhoA, that RhoA promotes activation of a protease calpain, and that calpain triggers degradation of Beclin-1, a critical mediator of autophagy, in these cells. The reversal of the effect of ras on Beclin-1 (achieved by expression of exogenous Beclin-1) promoted autophagosome formation following cell detachment, significantly reduced the fraction of detached cells in the S phase of the cell cycle and their rate of proliferation without affecting their viability. Furthermore, RNA interference-induced Beclin-1 down-regulation in non-malignant intestinal epithelial cells prevented detachment-dependent reduction of the fraction of these cells in the S phase of the cell cycle. Thus, ras oncogene promotes proliferation of those malignant intestinal epithelial cells that remain viable following detachment via a distinct novel mechanism that involves Ras-induced down-regulation of Beclin-1.
C1 [Rosen, Kirill V.] Dalhousie Univ, Atlantic Res Ctr, CRC, Dept Pediat & Biochem, Halifax, NS B3H 4H7, Canada.
   [Yoo, Byong Hoon; Wu, Xue; Li, Yongling; Haniff, Mehnaaz; Rosen, Kirill V.] Dalhousie Univ, Atlantic Res Ctr, Dept Mol Biol, Halifax, NS B3H 4H7, Canada.
   [Sasazuki, Takehiko] Int Med Ctr Japan, Dept Pathol, Res Inst, Tokyo 1628655, Japan.
   [Shirasawa, Senji] Fukuoka Univ, Sch Med, Dept Cell Biol, Fukuoka 8140180, Japan.
   [Eskelinen, Eeva-Liisa] Univ Helsinki, Div Biochem, Dept Biol & Environm Sci, FIN-00014 Helsinki, Finland.
RP Rosen, KV (corresponding author), Dalhousie Univ, Atlantic Res Ctr, CRC, Dept Pediat & Biochem, Rm C-302,5849 Univ Ave, Halifax, NS B3H 4H7, Canada.
EM kirill.rosen@dal.ca
RI Eskelinen, Eeva-Liisa/AAF-3496-2019
OI Eskelinen, Eeva-Liisa/0000-0003-0006-7785; Rosen,
   Kirill/0000-0002-4317-9907
FU Canadian Cancer Society Research InstituteCanadian Cancer Society (CCS)
FX This work was supported by a grant from the Canadian Cancer Society
   Research Institute (formerly the National Cancer Institute of Canada).
CR Aita VM, 1999, GENOMICS, V59, P59, DOI 10.1006/geno.1999.5851
   Benaud CM, 2001, ONCOGENE, V20, P4554, DOI 10.1038/sj.onc.1204609
   Berezovskaya O, 2005, CANCER RES, V65, P2378, DOI 10.1158/0008-5472.CAN-04-2649
   BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0
   Brink M, 2003, CARCINOGENESIS, V24, P703, DOI 10.1093/carcin/bgg009
   Carragher NO, 2004, NEOPLASIA, V6, P53, DOI 10.1016/S1476-5586(04)80053-8
   Chen JC, 2003, J BIOL CHEM, V278, P2807, DOI 10.1074/jbc.M207943200
   Cox AD, 2003, ONCOGENE, V22, P8999, DOI 10.1038/sj.onc.1207111
   Crighton D, 2006, CELL, V126, P121, DOI 10.1016/j.cell.2006.05.034
   Derouet M, 2007, NEOPLASIA, V9, P536, DOI 10.1593/neo.07217
   Douma S, 2004, NATURE, V430, P1034, DOI 10.1038/nature02765
   Duxbury MS, 2004, ONCOGENE, V23, P465, DOI 10.1038/sj.onc.1207036
   Duxbury MS, 2004, ONCOGENE, V23, P1448, DOI 10.1038/sj.onc.1207247
   Edkins S, 2006, CANCER BIOL THER, V5, P928, DOI 10.4161/cbt.5.8.3251
   Eskelinen EL, 2005, AUTOPHAGY, V1, P1, DOI 10.4161/auto.1.1.1270
   FILMUS J, 1994, ONCOGENE, V9, P3627
   FREEDMAN VH, 1974, CELL, V3, P355, DOI 10.1016/0092-8674(74)90050-6
   FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619
   Frisch SM, 2001, CURR OPIN CELL BIOL, V13, P555, DOI 10.1016/S0955-0674(00)00251-9
   Fritz G, 1999, INT J CANCER, V81, P682, DOI 10.1002/(SICI)1097-0215(19990531)81:5<682::AID-IJC2>3.0.CO;2-B
   Goll DE, 2003, PHYSIOL REV, V83, P731, DOI 10.1152/physrev.00029.2002
   Hoyer-Hansen M, 2005, CELL DEATH DIFFER, V12, P1297, DOI 10.1038/sj.cdd.4401651
   Jacks T, 2002, CELL, V111, P923, DOI 10.1016/S0092-8674(02)01229-1
   Jiang K, 2004, MOL CELL BIOL, V24, P5565, DOI 10.1128/MCB.24.12.5565-5576.2004
   KhosraviFar R, 1998, ADV CANCER RES, V72, P57
   Kroemer G, 2005, NAT REV CANCER, V5, P886, DOI 10.1038/nrc1738
   Lakshmikuttyamma A, 2004, CANCER EPIDEM BIOMAR, V13, P1604
   Levine B, 2005, J CLIN INVEST, V115, P2679, DOI 10.1172/JCI26390
   Li BX, 2009, AUTOPHAGY, V5, P303, DOI 10.4161/auto.5.3.7491
   Li HB, 2009, J BIOL CHEM, V284, P2012, DOI 10.1074/jbc.M805612200
   Liang C, 2006, NAT CELL BIOL, V8, P688, DOI 10.1038/ncb1426
   Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257
   Liu ZP, 2006, J BIOL CHEM, V281, P14738, DOI 10.1074/jbc.M508664200
   Liu ZP, 2005, J BIOL CHEM, V280, P37383, DOI 10.1074/jbc.M503724200
   LJUBIMOV AV, 1992, INT J CANCER, V50, P562, DOI 10.1002/ijc.2910500412
   Lu YL, 1999, ONCOGENE, V18, P7034, DOI 10.1038/sj.onc.1203183
   MCCARTY KS, 1986, CANCER RES, V46, P4244
   Orford K, 1999, J CELL BIOL, V146, P855, DOI 10.1083/jcb.146.4.855
   Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002
   Pollock CB, 2005, CANCER RES, V65, P1244, DOI 10.1158/0008-5472.CAN-04-1911
   Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039
   RAK J, 1995, J CELL BIOL, V131, P1587, DOI 10.1083/jcb.131.6.1587
   Rosen K, 1998, CURR BIOL, V8, P1331, DOI 10.1016/S0960-9822(07)00564-7
   Rosen K, 2000, J CELL BIOL, V149, P447, DOI 10.1083/jcb.149.2.447
   Rosen K, 2001, J BIOL CHEM, V276, P37273, DOI 10.1074/jbc.M106424200
   Sasaki T, 1990, J Enzyme Inhib, V3, P195, DOI 10.3109/14756369009035837
   Scotlandi K, 2002, CANCER GENE THER, V9, P296, DOI 10.1038/sj.cgt.7700442
   Shields JM, 2000, TRENDS CELL BIOL, V10, P147, DOI 10.1016/S0962-8924(00)01740-2
   Shimizu S, 2004, NAT CELL BIOL, V6, P1221, DOI 10.1038/ncb1192
   SHIRASAWA S, 1993, SCIENCE, V260, P85, DOI 10.1126/science.8465203
   Takahashi Y, 2007, NAT CELL BIOL, V9, P1142, DOI 10.1038/ncb1634
   Tsujimoto Y, 2005, CELL DEATH DIFFER, V12, P1528, DOI 10.1038/sj.cdd.4401777
   Wang KKW, 1996, P NATL ACAD SCI USA, V93, P6687, DOI 10.1073/pnas.93.13.6687
   Watnick RS, 2003, CANCER CELL, V3, P219, DOI 10.1016/S1535-6108(03)00030-8
   Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100
NR 55
TC 45
Z9 49
U1 0
U2 2
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD FEB 19
PY 2010
VL 285
IS 8
BP 5438
EP 5449
DI 10.1074/jbc.M109.046789
PG 12
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 565WQ
UT WOS:000275327200037
PM 19778902
OA Green Published, hybrid
DA 2022-04-25
ER

PT J
AU Wang, Y
   Du, J
   Wu, XM
   Abdelrehem, A
   Ren, Y
   Liu, C
   Zhou, X
   Wang, SN
AF Wang, Yu
   Du, Jiang
   Wu, Xuemei
   Abdelrehem, Ahmed
   Ren, Yu
   Liu, Chao
   Zhou, Xuan
   Wang, Sinan
TI Crosstalk between autophagy and microbiota in cancer progression
SO MOLECULAR CANCER
LA English
DT Review
DE Autophagy; Microbiota; Cancer progression; Target therapy
ID HELICOBACTER-PYLORI INFECTION; TUMOR-CELL SURVIVAL;
   FUSOBACTERIUM-NUCLEATUM; PORPHYROMONAS-GINGIVALIS; COLORECTAL-CANCER;
   CHEMOTHERAPY RESISTANCE; VACUOLATING CYTOTOXIN; INDUCED APOPTOSIS;
   HEDGEHOG PATHWAY; KAPPA-B
AB Autophagy is a highly conserved catabolic process seen in eukaryotes and is essentially a lysosome-dependent protein degradation pathway. The dysregulation of autophagy is often associated with the pathogenesis of numerous types of cancers, and can not only promote the survival of cancer but also trigger the tumor cell death. During cancer development, the microbial community might predispose cells to tumorigenesis by promoting mucosal inflammation, causing systemic disorders, and may also regulate the immune response to cancer. The complex relationship between autophagy and microorganisms can protect the body by activating the immune system. In addition, autophagy and microorganisms can crosstalk with each other in multifaceted ways to influence various physiological and pathological responses involved in cancer progression. Various molecular mechanisms, correlating the microbiota disorders and autophagy activation, control the outcomes of protumor or antitumor responses, which depend on the cancer type, tumor microenvironment and disease stage. In this review, we mainly emphasize the leading role of autophagy during the interaction between pathogenic microorganisms and human cancers and investigate the various molecular mechanisms by which autophagy modulates such complicated biological processes. Moreover, we also highlight the possibility of curing cancers with multiple molecular agents targeting the microbiota/autophagy axis. Finally, we summarize the emerging clinical trials investigating the therapeutic potential of targeting either autophagy or microbiota as anticancer strategies, although the crosstalk between them has not been explored thoroughly.
C1 [Wang, Yu; Du, Jiang; Liu, Chao; Zhou, Xuan] Tianjin Med Univ Canc Inst & Hosp, Dept Maxillofacial & Otorhinolaryngol Oncol, Tianjin 300060, Peoples R China.
   [Wang, Yu; Du, Jiang; Liu, Chao; Zhou, Xuan] Tianjin Canc Inst, Key Lab Canc Prevent & Therapy, Tianjin 300060, Peoples R China.
   [Wang, Yu; Du, Jiang; Liu, Chao; Zhou, Xuan] Natl Clin Res Ctr Canc, Tianjin 300060, Peoples R China.
   [Wu, Xuemei; Wang, Sinan] Tianjin Med Univ Gen Hosp, Dept Gastroenterol & Hepatol, Tianjin, Peoples R China.
   [Wu, Xuemei; Wang, Sinan] Tianjin Med Univ, Tianjin Gastroenterol & Hepatol Inst, Tianjin 300052, Peoples R China.
   [Wu, Xuemei; Wang, Sinan] Tianjin Med Univ, Key Lab Immune Microenvironm & Dis, Minist Educ, Tianjin 300070, Peoples R China.
   [Abdelrehem, Ahmed] Alexandria Univ, Fac Dent, Dept Craniomaxillofacial & Plast Surg, Alexandria, Egypt.
   [Ren, Yu] Tianjin Med Univ, Tianjin Res Ctr Basic Med Sci, Tianjin 300070, Peoples R China.
RP Wang, Y; Zhou, X (corresponding author), Tianjin Med Univ Canc Inst & Hosp, Dept Maxillofacial & Otorhinolaryngol Oncol, Tianjin 300060, Peoples R China.; Wang, Y; Zhou, X (corresponding author), Tianjin Canc Inst, Key Lab Canc Prevent & Therapy, Tianjin 300060, Peoples R China.; Wang, Y; Zhou, X (corresponding author), Natl Clin Res Ctr Canc, Tianjin 300060, Peoples R China.; Wang, SN (corresponding author), Tianjin Med Univ Gen Hosp, Dept Gastroenterol & Hepatol, Tianjin, Peoples R China.; Wang, SN (corresponding author), Tianjin Med Univ, Tianjin Gastroenterol & Hepatol Inst, Tianjin 300052, Peoples R China.; Wang, SN (corresponding author), Tianjin Med Univ, Key Lab Immune Microenvironm & Dis, Minist Educ, Tianjin 300070, Peoples R China.
EM wangyu1991@tmu.edu.cn; xuanzhou@tmu.edu.cn; wangsinan@tmu.edu.cn
FU China National Natural Scientific FundNational Natural Science
   Foundation of China (NSFC) [82002892, 82073010, 82172764]; Tianjin
   Education Commission [2019KJ188]; Fundamental Research Funds for the
   Central UniversitiesFundamental Research Funds for the Central
   Universities [3332020079]
FX This work was supported by the China National Natural Scientific Fund
   No. 82002892 (to W.Y.), 82073010 (to Z.X.), 82172764 (to R.Y.); the
   Tianjin Education Commission Funded Projects No.2019KJ188 (to W.Y.); the
   Fundamental Research Funds for the Central Universities No.3332020079
   (to W.SN.)
CR Abdulamir AS, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-249
   Aita VM, 1999, GENOMICS, V59, P59, DOI 10.1006/geno.1999.5851
   Allemailem KS, 2021, INT J NANOMED, V16, P5065, DOI 10.2147/IJN.S321343
   Amaravadi R, 2016, GENE DEV, V30, P1913, DOI 10.1101/gad.287524.116
   Amaravadi RK, 2007, J CLIN INVEST, V117, P326, DOI 10.1172/JCI28833
   Amaravadi RK, 2019, CANCER DISCOV, V9, P1167, DOI 10.1158/2159-8290.CD-19-0292
   Amaravadi RK, 2011, CLIN CANCER RES, V17, P654, DOI 10.1158/1078-0432.CCR-10-2634
   Ambalam P, 2016, BEST PRACT RES CL GA, V30, P119, DOI 10.1016/j.bpg.2016.02.009
   Arnaout A, 2019, BREAST CANCER RES TR, V178, P327, DOI 10.1007/s10549-019-05381-y
   Aviles-Jimenez F, 2016, CLIN MICROBIOL INFEC, V22, DOI 10.1016/j.cmi.2015.10.008
   Ban LX, 2020, LIFE SCI, V254, DOI 10.1016/j.lfs.2020.117695
   Banerjee S, 2017, ONCOTARGET, V8, P36225, DOI 10.18632/oncotarget.16717
   Belanger M, 2006, AUTOPHAGY, V2, P165, DOI 10.4161/auto.2828
   Bi YY, 2021, J CANCER RES CLIN, V147, P499, DOI 10.1007/s00432-020-03422-4
   Bialik S, 2008, ADV EXP MED BIOL, V615, P177, DOI 10.1007/978-1-4020-6554-5_9
   Blommaart EFC, 1997, EUR J BIOCHEM, V243, P240, DOI 10.1111/j.1432-1033.1997.0240a.x
   Brandt S, 2005, P NATL ACAD SCI USA, V102, P9300, DOI 10.1073/pnas.0409873102
   Cai JC, 2018, NAT CELL BIOL, V20, P465, DOI 10.1038/s41556-018-0065-8
   Castellarin M, 2012, GENOME RES, V22, P299, DOI 10.1101/gr.126516.111
   Cerniglia GJ, 2012, MOL PHARMACOL, V82, P1230, DOI 10.1124/mol.112.080408
   Chang CR, 2019, ACS INFECT DIS, V5, P1336, DOI 10.1021/acsinfecdis.9b00032
   Chen DF, 2020, CANCER LETT, V469, P456, DOI 10.1016/j.canlet.2019.11.019
   Chen XH, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.01261
   Chen YY, 2020, THERANOSTICS, V10, P323, DOI 10.7150/thno.38870
   Cho TJ, 2014, ARCH ORAL BIOL, V59, P370, DOI 10.1016/j.archoralbio.2014.01.001
   Choi AMK, 2013, NEW ENGL J MED, V368, P651, DOI [10.1056/NEJMra1205406, 10.1056/NEJMc1303158]
   Chung C, 2020, J HEMATOL ONCOL, V13, DOI 10.1186/s13045-020-00936-9
   de Martel C, 2012, LANCET ONCOL, V13, DOI 10.1016/S1470-2045(12)70137-7
   Debnath J, 2011, J MAMMARY GLAND BIOL, V16, P173, DOI 10.1007/s10911-011-9223-3
   Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001
   Deng HM, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-02742-0
   Duarte VD, 2020, MICROORGANISMS, V8, DOI 10.3390/microorganisms8121994
   Edinger AL, 2004, CURR OPIN CELL BIOL, V16, P663, DOI 10.1016/j.ceb.2004.09.011
   El Khadir M, 2020, INT J CANCER, V147, P3206, DOI 10.1002/ijc.33158
   Elinav E, 2013, NAT REV CANCER, V13, P759, DOI 10.1038/nrc3611
   Eskelinen EL, 2009, BBA-MOL CELL RES, V1793, P664, DOI 10.1016/j.bbamcr.2008.07.014
   Eslami M, 2019, J CELL PHYSIOL, V234, P14800, DOI 10.1002/jcp.28279
   Fan XZ, 2018, GUT, V67, P120, DOI 10.1136/gutjnl-2016-312580
   Farrell JJ, 2012, GUT, V61, P582, DOI 10.1136/gutjnl-2011-300784
   Ferreira RM, 2018, GUT, V67, P226, DOI 10.1136/gutjnl-2017-314205
   Fox JG, 2010, GUT, V59, P88, DOI 10.1136/gut.2009.183749
   Gallimidi AB, 2015, ONCOTARGET, V6, P22613, DOI 10.18632/oncotarget.4209
   Garrett WS, 2015, SCIENCE, V348, P80, DOI 10.1126/science.aaa4972
   Glick D, 2010, J PATHOL, V221, P3, DOI 10.1002/path.2697
   Gnanasekaran J, 2020, CANCERS, V12, DOI 10.3390/cancers12082331
   Gomes LR, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18112351
   Gopalakrishnan V, 2018, SCIENCE, V359, P97, DOI 10.1126/science.aan4236
   Gozuacik D, 2004, ONCOGENE, V23, P2891, DOI 10.1038/sj.onc.1207521
   Guo JY, 2011, GENE DEV, V25, P460, DOI 10.1101/gad.2016311
   Guo J, 2020, J CELL MOL MED, V24, P4324, DOI 10.1111/jcmm.15093
   Guo XG, 2019, J CELL PHYSIOL, V234, P3478, DOI 10.1002/jcp.26828
   Hall DP, 2014, CANCER CELL, V26, P738, DOI 10.1016/j.ccell.2014.09.015
   Han TY, 2018, AUTOPHAGY, V14, P2035, DOI 10.1080/15548627.2018.1491493
   Hartwich A, 2001, INT J COLORECTAL DIS, V16, P202, DOI 10.1007/s003840100288
   He Z, 2019, GUT, V68, P289, DOI 10.1136/gutjnl-2018-317200
   Helmink BA, 2019, NAT MED, V25, P377, DOI 10.1038/s41591-019-0377-7
   Hu FQ, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-23923-1
   Huang R, 2015, AUTOPHAGY, V11, P852, DOI 10.1080/15548627.2015.1038016
   Huang TZ, 2019, AUTOPHAGY, V15, P1100, DOI 10.1080/15548627.2019.1569947
   Irfan M, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.591088
   Ishibashi Y, 2019, ANTICANCER RES, V39, P649, DOI 10.21873/anticanres.13159
   Ito S, 2007, INT J ONCOL, V31, P261
   Jia JY, 2019, AUTOPHAGY, V15, P169, DOI 10.1080/15548627.2018.1505155
   Jiang Honglin, 2022, Gastroenterology, V162, P590, DOI 10.1053/j.gastro.2021.09.066
   Jin CC, 2019, CELL, V176, P998, DOI 10.1016/j.cell.2018.12.040
   Karimi P, 2014, CANCER EPIDEM BIOMAR, V23, P700, DOI 10.1158/1055-9965.EPI-13-1057
   Kim YC, 2015, J CLIN INVEST, V125, P25, DOI 10.1172/JCI73939
   Ko JY, 2019, BIOMOL THER, V27, P337, DOI 10.4062/biomolther.2019.056
   Kostic AD, 2013, CELL HOST MICROBE, V14, P207, DOI 10.1016/j.chom.2013.07.007
   Kostic AD, 2012, GENOME RES, V22, P292, DOI 10.1101/gr.126573.111
   Kundu M, 2008, ANNU REV PATHOL-MECH, V3, P427, DOI 10.1146/annurev.pathmechdis.2.010506.091842
   Lebin JA, 2020, WEST J EMERG MED, V21, P760, DOI 10.5811/westjem.2020.5.47810
   Lee DS, 2007, EXPERT OPIN THER TAR, V11, P757, DOI 10.1517/14728222.11.6.757
   Lee YK, 2018, MSPHERE, V3, DOI 10.1128/mSphere.00587-18
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Levy JMM, 2017, NAT REV CANCER, V17, P528, DOI 10.1038/nrc.2017.53
   Li J, 2009, ANN SURG ONCOL, V16, P761, DOI 10.1245/s10434-008-0260-0
   Li N, 2017, FRONT CELL INFECT MI, V7, DOI 10.3389/fcimb.2017.00417
   Li PY, 2012, CANCER LETT, V314, P213, DOI 10.1016/j.canlet.2011.09.031
   Li Q, 2021, GASTROENTEROLOGY, V160, P1179, DOI 10.1053/j.gastro.2020.09.003
   Li X, 2020, MOL CANCER, V19, DOI 10.1186/s12943-019-1085-0
   Liang GF, 2020, ACS INFECT DIS, V6, P871, DOI 10.1021/acsinfecdis.0c00007
   Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257
   Liao YN, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1165-4
   Lin EW, 2016, ONCOGENE, V35, P5337, DOI 10.1038/onc.2016.34
   Lin HJ, 2017, FRONT CELL INFECT MI, V7, DOI 10.3389/fcimb.2017.00223
   Lin J, 2014, AUTOPHAGY, V10, P2006, DOI 10.4161/auto.36293
   Liu BH, 2016, ONCOTARGET, V7, P22873, DOI 10.18632/oncotarget.8251
   Liu JL, 2011, CELL, V147, P223, DOI 10.1016/j.cell.2011.08.037
   Liu L, 2011, LEUKEMIA, V25, P23, DOI 10.1038/leu.2010.225
   Liu R, 2014, AUTOPHAGY, V10, P1241, DOI 10.4161/auto.28912
   Liu W D, 2017, Zhonghua Yi Xue Za Zhi, V97, P1510, DOI 10.3760/cma.j.issn.0376-2491.2017.19.017
   Liu W, 2012, CANCER RES, V72, P3677, DOI 10.1158/0008-5472.CAN-12-0080
   Liu XC, 2020, INT J ORAL SCI, V12, DOI 10.1038/s41368-020-00101-5
   Liu Y, 2021, BRIT J CANCER, V124, P963, DOI 10.1038/s41416-020-01198-5
   Lock R, 2011, MOL BIOL CELL, V22, P165, DOI 10.1091/mbc.E10-06-0500
   Long XH, 2019, NAT MICROBIOL, V4, P2319, DOI 10.1038/s41564-019-0541-3
   Louis P, 2014, NAT REV MICROBIOL, V12, P661, DOI 10.1038/nrmicro3344
   Lu HP, 2018, J CELL PHYSIOL, V233, P9312, DOI 10.1002/jcp.26343
   Luo W, 2021, BIOMED RES INT, V2021, DOI 10.1155/2021/9986376
   Ma J, 2020, BMC MICROBIOL, V20, DOI 10.1186/s12866-020-01739-1
   Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239
   Mao QX, 2018, CANCER LETT, V415, P40, DOI 10.1016/j.canlet.2017.11.036
   Martinez GP, 2020, CURR PHARM DESIGN, V26, P4467, DOI 10.2174/1381612826666200707132920
   McAfee Q, 2012, P NATL ACAD SCI USA, V109, P8253, DOI 10.1073/pnas.1118193109
   Mima K, 2016, GUT, V65, P1973, DOI 10.1136/gutjnl-2015-310101
   Mimuro H, 2002, MOL CELL, V10, P745, DOI 10.1016/S1097-2765(02)00681-0
   Mizushima N, 2005, CELL DEATH DIFFER, V12, P1535, DOI 10.1038/sj.cdd.4401728
   Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639
   Mizushima N, 2007, GENE DEV, V21, P2861, DOI 10.1101/gad.1599207
   Muhammad JS, 2017, INT J CANCER, V140, P2272, DOI 10.1002/ijc.30657
   Mysak J, 2014, J IMMUNOL RES, V2014, DOI 10.1155/2014/476068
   Nejati S, 2018, MICROB PATHOGENESIS, V117, P43, DOI 10.1016/j.micpath.2018.02.016
   Odds FC, 2000, ANTIMICROB AGENTS CH, V44, P3180, DOI 10.1128/AAC.44.11.3180-3183.2000
   Ojha R, 2015, BIORESEARCH OPEN ACC, V4, P97, DOI 10.1089/biores.2014.0035
   Olsen I, 2019, J ORAL MICROBIOL, V11, DOI 10.1080/20002297.2018.1563410
   Parida S, 2021, CANCER DISCOV, V11, P1138, DOI 10.1158/2159-8290.CD-20-0537
   Parzych KR, 2014, ANTIOXID REDOX SIGN, V20, P460, DOI 10.1089/ars.2013.5371
   Pasquier B, 2015, AUTOPHAGY, V11, P725, DOI 10.1080/15548627.2015.1033601
   Pattingre S, 2008, BIOCHIMIE, V90, P313, DOI 10.1016/j.biochi.2007.08.014
   Petiot A, 2000, J BIOL CHEM, V275, P992, DOI 10.1074/jbc.275.2.992
   Pierard G E, 2000, Expert Opin Pharmacother, V1, P287, DOI 10.1517/14656566.1.2.287
   Ponticelli C, 2017, EXPERT OPIN DRUG SAF, V16, P411, DOI 10.1080/14740338.2017.1269168
   POWIS G, 1994, CANCER RES, V54, P2419
   Pushalkar S, 2018, CANCER DISCOV, V8, P403, DOI 10.1158/2159-8290.CD-17-1134
   Raju D, 2012, GASTROENTEROLOGY, V142, P1160, DOI 10.1053/j.gastro.2012.01.043
   Rebecca VW, 2017, CANCER DISCOV, V7, P1266, DOI 10.1158/2159-8290.CD-17-0741
   Revathi S, 2018, ANTI-CANCER AGENT ME, V18, P1875, DOI 10.2174/1871520618666180806104902
   Ricci V, 2016, TOXINS, V8, DOI 10.3390/toxins8070203
   Rubinstein MR, 2013, CELL HOST MICROBE, V14, P195, DOI 10.1016/j.chom.2013.07.012
   Russo M, 2018, BIOCHEM PHARMACOL, V153, P51, DOI 10.1016/j.bcp.2018.02.007
   Sasaki K, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-370
   Schulze M, 2014, RECENT RESULTS CANC, V201, P393, DOI 10.1007/978-3-642-54490-3_24
   Schwabe RF, 2013, NAT REV CANCER, V13, P800, DOI 10.1038/nrc3610
   Schwartz-Roberts JL, 2015, CANCER RES, V75, P1046, DOI 10.1158/0008-5472.CAN-14-1851
   Sears CL, 2014, J CLIN INVEST, V124, P4166, DOI 10.1172/JCI72334
   Sears CL, 2014, CELL HOST MICROBE, V15, P317, DOI 10.1016/j.chom.2014.02.007
   Seglen P O, 1990, Semin Cell Biol, V1, P441
   Selbach M, 2003, EMBO J, V22, P515, DOI 10.1093/emboj/cdg050
   Selvakumaran M, 2013, CLIN CANCER RES, V19, P2995, DOI 10.1158/1078-0432.CCR-12-1542
   Sfanos KS, 2008, PROSTATE, V68, P306, DOI 10.1002/pros.20680
   Shen JJ, 2020, ONCOGENE, V39, P2961, DOI 10.1038/s41388-020-1197-4
   Shi YY, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1859-8
   Sivan A, 2015, SCIENCE, V350, P1084, DOI 10.1126/science.aac4255
   Sun JW, 2020, CANCER MED-US, V9, P6306, DOI 10.1002/cam4.3206
   Takeda M, 2019, CANCER RES, V79, P1426, DOI 10.1158/0008-5472.CAN-18-2192
   Teimoorian Fatemeh, 2018, Iran J Pathol, V13, P325
   Terebiznik MR, 2009, AUTOPHAGY, V5, P370, DOI 10.4161/auto.5.3.7663
   Tohidpour A, 2016, MICROB PATHOGENESIS, V93, P44, DOI 10.1016/j.micpath.2016.01.005
   Torres PJ, 2015, PEERJ, V3, DOI 10.7717/peerj.1373
   Tsay JCJ, 2018, AM J RESP CRIT CARE, V198, P1188, DOI 10.1164/rccm.201710-2118OC
   Tsoi H, 2017, GASTROENTEROLOGY, V152, P1419, DOI 10.1053/j.gastro.2017.01.009
   Tu SP, 2011, CANCER RES, V71, P4247, DOI 10.1158/0008-5472.CAN-10-4009
   Urbaniak C, 2016, APPL ENVIRON MICROB, V82, P5039, DOI 10.1128/AEM.01235-16
   Vitor JMB, 2011, FEMS IMMUNOL MED MIC, V63, P153, DOI 10.1111/j.1574-695X.2011.00865.x
   Wang FT, 2020, CANCER CHEMOTH PHARM, V86, P221, DOI 10.1007/s00280-020-04100-5
   Wang XY, 2017, CANCER LETT, V385, P128, DOI 10.1016/j.canlet.2016.10.034
   Wang Y, 2019, ADV EXP MED BIOL, V1206, P67, DOI 10.1007/978-981-15-0602-4_3
   Wang ZG, 2017, ONCOTARGET, V8, P31465, DOI 10.18632/oncotarget.16356
   Wei X, 2020, J CANCER RES CLIN, V146, P297, DOI 10.1007/s00432-019-03117-5
   Wilson MR, 2019, SCIENCE, V363, P709, DOI 10.1126/science.aar7785
   Wolpin BM, 2014, ONCOLOGIST, V19, P637, DOI 10.1634/theoncologist.2014-0086
   Wu J, 2018, J CANCER, V9, P4039, DOI 10.7150/jca.25280
   Wu SG, 2009, NAT MED, V15, P1016, DOI 10.1038/nm.2015
   Wu YT, 2010, J BIOL CHEM, V285, P10850, DOI 10.1074/jbc.M109.080796
   Xie C, 2020, GUT MICROBES, V11, P1567, DOI 10.1080/19490976.2020.1774311
   Yahiro K, 2012, J BIOL CHEM, V287, P31104, DOI 10.1074/jbc.M112.387498
   Yamamura K, 2016, CLIN CANCER RES, V22, P5574, DOI 10.1158/1078-0432.CCR-16-1786
   Yang JC, 2014, WORLD J GASTROENTERO, V20, P5283, DOI 10.3748/wjg.v20.i18.5283
   Yang LC, 2008, J NUTR, V138, P2084, DOI 10.3945/jn.108.090985
   Yang SH, 2011, GENE DEV, V25, P717, DOI 10.1101/gad.2016111
   Yang YZ, 2017, GASTROENTEROLOGY, V152, P851, DOI 10.1053/j.gastro.2016.11.018
   Yang ZF, 2009, CURR TOP MICROBIOL, V335, P1, DOI 10.1007/978-3-642-00302-8_1
   Yu TC, 2017, CELL, V170, P548, DOI 10.1016/j.cell.2017.07.008
   Yuan X, 2017, CANCER LETT, V404, P1, DOI 10.1016/j.canlet.2017.07.003
   Yun CW, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113466
   Zaffagnini G, 2016, J MOL BIOL, V428, P1714, DOI 10.1016/j.jmb.2016.02.004
   Zeng XH, 2006, J CELL SCI, V119, P259, DOI 10.1242/jcs.02735
   Zhang F, 2019, ONCOL LETT, V18, P6221, DOI 10.3892/ol.2019.10976
   Zhi Xiaoyong, 2015, F1000Prime Rep, V7, P18, DOI 10.12703/P7-18
   Zhong XL, 2021, CAN J INFECT DIS MED, V2021, DOI 10.1155/2021/6622092
   Zhou ST, 2012, CANCER LETT, V323, P115, DOI 10.1016/j.canlet.2012.02.017
NR 182
TC 1
Z9 1
U1 10
U2 10
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1476-4598
J9 MOL CANCER
JI Mol. Cancer
PD DEC 11
PY 2021
VL 20
IS 1
AR 163
DI 10.1186/s12943-021-01461-0
PG 19
WC Biochemistry & Molecular Biology; Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology
GA XN0TR
UT WOS:000729227800001
PM 34895252
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Yoo, BH
   Zagryazhskaya, A
   Li, YL
   Koomson, A
   Khan, IA
   Sasazuki, T
   Shirasawa, S
   V Rosen, K
AF Yoo, Byong Hoon
   Zagryazhskaya, Anna
   Li, Yongling
   Koomson, Ananda
   Khan, Iman Aftab
   Sasazuki, Takehiko
   Shirasawa, Senji
   V Rosen, Kirill
TI Upregulation of ATG3 contributes to autophagy induced by the detachment
   of intestinal epithelial cells from the extracellular matrix, but
   promotes autophagy-independent apoptosis of the attached cells
SO AUTOPHAGY
LA English
DT Article
DE autophagy; apoptosis; anoikis; ATG3; ATG7; extracellular matrix
ID BCL-X-L; RAS-INDUCED TRANSFORMATION; BECLIN 1 PHOSPHORYLATION;
   DOWN-REGULATION; ANOIKIS RESISTANCE; TUMOR-SUPPRESSOR; IN-VIVO;
   PANCREATIC ADENOCARCINOMA; PHOTODYNAMIC THERAPY; APG3P/AUT1P HOMOLOG
AB Detachment of nonmalignant intestinal epithelial cells from the extracellular matrix (ECM) triggers their growth arrest and, ultimately, apoptosis. In contrast, colorectal cancer cells can grow without attachment to the ECM. This ability is critical for their malignant potential. We found previously that detachment-induced growth arrest of nonmalignant intestinal epithelial cells is driven by their detachment-triggered autophagy, and that RAS, a major oncogene, promotes growth of detached cells by blocking such autophagy. In an effort to identify the mechanisms of detachment-induced autophagy and growth arrest of nonmalignant cells we found here that detachment of these cells causes upregulation of ATG3 and that ATG3 upregulation contributes to autophagy and growth arrest of detached cells. We also observed that when ATG3 expression is artificially increased in the attached cells, ATG3 promotes neither autophagy nor growth arrest but triggers their apoptosis. ATG3 upregulation likely promotes autophagy of the detached but not that of the attached cells because detachment-dependent autophagy requires other detachment-induced events, such as the upregulation of ATG7. We further observed that those few adherent cells that do not die by apoptosis induced by ATG3 become resistant to apoptosis caused by cell detachment, a property that is critical for the ability of normal epithelial cells to become malignant. We conclude that cell-ECM adhesion can switch ATG3 functions: when upregulated in detached cells in the context of other autophagy-promoting events, ATG3 contributes to autophagy. However, when overexpressed in the adherent cells, in the circumstances not favoring autophagy, ATG3 triggers apoptosis.
C1 [Yoo, Byong Hoon; Zagryazhskaya, Anna; Li, Yongling; Koomson, Ananda; Khan, Iman Aftab; V Rosen, Kirill] Dalhousie Univ, Dept Pediat, Halifax, NS, Canada.
   [Yoo, Byong Hoon; Zagryazhskaya, Anna; Li, Yongling; Koomson, Ananda; Khan, Iman Aftab; V Rosen, Kirill] Dalhousie Univ, Dept Biochem & Mol Biol, Halifax, NS, Canada.
   [Sasazuki, Takehiko] Kyushu Univ, Inst Adv Study, Fukuoka 812, Japan.
   [Shirasawa, Senji] Fukuoka Univ, Fac Med, Dept Cell Biol, Fukuoka 81401, Japan.
   [Shirasawa, Senji] Fukuoka Univ, Ctr Adv Mol Med, Fukuoka 81401, Japan.
RP V Rosen, K (corresponding author), Dalhousie Univ, Dept Pediat, Halifax, NS, Canada.
EM kirill.rosen@dal.ca
OI Rosen, Kirill/0000-0002-4317-9907
FU Canadian Institutes of Health Research Nova Scotia Regional Partnership
   Program (CIHR/NSRPP) [125109]; IWK Health Centre PosDoctoral Fellowship;
   CIHR/NS RPP New Investigator award
FX This study was supported by the Canadian Institutes of Health Research
   Nova Scotia Regional Partnership Program (CIHR/NSRPP) operating grant
   125109 and the CIHR/NS RPP New Investigator award held by Kirill Rosen.
   Byong Yoo was a recipient of the IWK Health Centre Research
   Associateship. Yongling Li was a recipient of the IWK Health Centre
   PosDoctoral Fellowship.
CR Berezovskaya O, 2005, CANCER RES, V65, P2378, DOI 10.1158/0008-5472.CAN-04-2649
   Chen N, 2013, ONCOGENE, V32, P2543, DOI 10.1038/onc.2012.277
   Coll ML, 2002, ONCOGENE, V21, P2908, DOI 10.1038/sj.onc.1205388
   Crighton D, 2006, CELL, V126, P121, DOI 10.1016/j.cell.2006.05.034
   Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001
   Derouet M, 2007, NEOPLASIA, V9, P536, DOI 10.1593/neo.07217
   Douma S, 2004, NATURE, V430, P1034, DOI 10.1038/nature02765
   Duxbury MS, 2004, ONCOGENE, V23, P465, DOI 10.1038/sj.onc.1207036
   Duxbury MS, 2004, ONCOGENE, V23, P1448, DOI 10.1038/sj.onc.1207247
   Eskelinen EL, 2005, AUTOPHAGY, V1, P1, DOI 10.4161/auto.1.1.1270
   Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213
   Frankel A, 2001, CANCER RES, V61, P4837
   FREEDMAN VH, 1974, CELL, V3, P355, DOI 10.1016/0092-8674(74)90050-6
   FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619
   Frisch SM, 2001, CURR OPIN CELL BIOL, V13, P555, DOI 10.1016/S0955-0674(00)00251-9
   Gilaberte Y, 2014, J INVEST DERMATOL, V134, P2428, DOI 10.1038/jid.2014.178
   Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0
   Hammond EM, 2005, BIOCHEM BIOPH RES CO, V331, P718, DOI 10.1016/j.bbrc.2005.03.154
   Jacks T, 2002, CELL, V111, P923, DOI 10.1016/S0092-8674(02)01229-1
   Jiang K, 2004, MOL CELL BIOL, V24, P5565, DOI 10.1128/MCB.24.12.5565-5576.2004
   Kabeya Y, 2004, J CELL SCI, V117, P2805, DOI 10.1242/jcs.01131
   Karsli-Uzunbas G, 2014, CANCER DISCOV, V4, P914, DOI 10.1158/2159-8290.CD-14-0363
   Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783
   Klionsky DJ, 2012, AUTOPHAGY, V8, P445, DOI 10.4161/auto.19496
   Kroemer G, 2005, NAT REV CANCER, V5, P886, DOI 10.1038/nrc1738
   Li BX, 2009, AUTOPHAGY, V5, P303, DOI 10.4161/auto.5.3.7491
   Li HB, 2009, J BIOL CHEM, V284, P2012, DOI 10.1074/jbc.M805612200
   Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257
   Lim KH, 2005, CANCER CELL, V7, P533, DOI 10.1016/j.ccr.2005.04.030
   Liu ZP, 2005, J BIOL CHEM, V280, P37383, DOI 10.1074/jbc.M503724200
   Lu YL, 1999, ONCOGENE, V18, P7034, DOI 10.1038/sj.onc.1203183
   Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039
   Radoshevich L, 2010, CELL, V142, P590, DOI 10.1016/j.cell.2010.07.018
   Rak J, 2004, SEMIN CANCER BIOL, V14, P93, DOI 10.1016/j.semcancer.2003.09.014
   RAK J, 1995, J CELL BIOL, V131, P1587, DOI 10.1083/jcb.131.6.1587
   Rak Janusz, 1999, Neoplasia (New York), V1, P23, DOI 10.1038/sj.neo.7900001
   Rosen K, 1998, CURR BIOL, V8, P1331, DOI 10.1016/S0960-9822(07)00564-7
   Rosen K, 2000, J CELL BIOL, V149, P447, DOI 10.1083/jcb.149.2.447
   Rosen K, 2002, J BIOL CHEM, V277, P46123, DOI 10.1074/jbc.M207883200
   Rosen K, 2001, J BIOL CHEM, V276, P37273, DOI 10.1074/jbc.M106424200
   Rosenfeldt MT, 2013, NATURE, V504, P296, DOI 10.1038/nature12865
   Rubinstein AD, 2011, MOL CELL, V44, P698, DOI 10.1016/j.molcel.2011.10.014
   Schafer ZT, 2009, NATURE, V461, P109, DOI 10.1038/nature08268
   Scotlandi K, 2002, CANCER GENE THER, V9, P296, DOI 10.1038/sj.cgt.7700442
   SHIRASAWA S, 1993, SCIENCE, V260, P85, DOI 10.1126/science.8465203
   Takahashi Y, 2007, NAT CELL BIOL, V9, P1142, DOI 10.1038/ncb1634
   Takamura A, 2011, GENE DEV, V25, P795, DOI 10.1101/gad.2016211
   Tanida I, 2003, BIOCHEM BIOPH RES CO, V300, P637, DOI 10.1016/S0006-291X(02)02907-8
   Tanida I, 2002, J BIOL CHEM, V277, P13739, DOI 10.1074/jbc.M200385200
   van Engeland M, 1998, CYTOMETRY, V31, P1, DOI 10.1002/(SICI)1097-0320(19980101)31:1<1::AID-CYTO1>3.0.CO;2-R
   Wang RC, 2012, SCIENCE, V338, P956, DOI 10.1126/science.1225967
   Wei MF, 2014, AUTOPHAGY, V10, P1179, DOI 10.4161/auto.28679
   Wei YJ, 2013, CELL, V154, P1269, DOI 10.1016/j.cell.2013.08.015
   Weidberg H, 2010, EMBO J, V29, P1792, DOI 10.1038/emboj.2010.74
   Wirth M, 2013, SEMIN CANCER BIOL, V23, P301, DOI 10.1016/j.semcancer.2013.05.007
   Wu BX, 2006, MOL VIS, V12, P1292
   Yoo BH, 2012, INT J CANCER, V131, P357, DOI 10.1002/ijc.26368
   Yoo BH, 2011, J BIOL CHEM, V286, P38894, DOI 10.1074/jbc.M111.290692
   Yoo BH, 2010, J BIOL CHEM, V285, P5438, DOI 10.1074/jbc.M109.046789
   Yorimitsu T, 2005, CELL DEATH DIFFER, V12, P1542, DOI 10.1038/sj.cdd.4401765
   Yu JL, 2002, SCIENCE, V295, P1526, DOI 10.1126/science.1068327
   Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100
   Zhao H, 2013, MED ONCOL, V30, DOI 10.1007/s12032-013-0475-1
NR 63
TC 15
Z9 15
U1 1
U2 12
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1554-8627
EI 1554-8635
J9 AUTOPHAGY
JI Autophagy
PD AUG
PY 2015
VL 11
IS 8
BP 1230
EP 1246
DI 10.1080/15548627.2015.1056968
PG 17
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA CP6DZ
UT WOS:000359975900005
PM 26061804
OA Green Published, Bronze
DA 2022-04-25
ER

PT J
AU Roshani-Asl, E
   Mansori, B
   Mohammadi, A
   Najafi, S
   Danesh-Pouya, F
   Rasmi, Y
AF Roshani-Asl, Elmira
   Mansori, Behzad
   Mohammadi, Ali
   Najafi, Souzan
   Danesh-Pouya, Fahima
   Rasmi, Yousef
TI Interaction between DNA damage response and autophagy in colorectal
   cancer
SO GENE
LA English
DT Review
DE DNA damage; DNA repair; Autophagy; Colorectal cancer
ID BECLIN 1 EXPRESSION; FAVORABLE PROGNOSIS; MOLECULAR MACHINERY;
   DOWN-REGULATION; CELLS; INHIBITION; PATHWAY; MECHANISMS; BIOMARKERS;
   SURVIVAL
AB The subjection of DNA to numerous lethal damages is threatening for the stability and integrity of the whole body genome. DNA damage response (DDR) is a critical phosphorylation-based signaling pathway developed for the maintaining of the genome against these threatens. Recent studies showed that various targets of DDR are involved in the activation of autophagy, as one of the important effectors of this signaling. The interplay between DDR and autophagy may have a critical role in the pathogenesis of various malignancies such as colorectal cancer, which can be a basement for the designing novel therapeutic strategies for combating this cancer type. On the other hand, autophagy is also demonstrated to be contributed to the regulation of DDR components. Therefore, in this review article, we will discuss the crosstalk between DDR and autophagy and their exact function in the pathogenesis of various human cancer types, with special attention on colorectal cancer.
C1 [Roshani-Asl, Elmira; Danesh-Pouya, Fahima; Rasmi, Yousef] Urmia Univ Med Sci, Sch Med, Dept Biochem, Orumiyeh, Iran.
   [Roshani-Asl, Elmira; Mansori, Behzad; Najafi, Souzan] Tabriz Univ Med Sci, Immunol Res Ctr, Tabriz, Iran.
   [Mansori, Behzad; Mohammadi, Ali] Univ Southern Denmark, Inst Mol Med, Dept Canc & Inflammat Res, Odense, Denmark.
   [Mansori, Behzad] Tabriz Univ Med Sci, Student Res Comm, Tabriz, Iran.
   [Rasmi, Yousef] Urmia Univ Med Sci, Cellular & Mol Res Ctr, Orumiyeh, Iran.
RP Rasmi, Y (corresponding author), Urmia Univ Med Sci, Sch Med, Dept Biochem, Orumiyeh, Iran.
EM rasmiy@umsu.ac.ir
RI Rasmi, Yousef/H-1783-2017; Roshani Asl, Elmira/ABC-1868-2021; Pouya,
   Fahima Danesh/AAO-9209-2021; Mansoori, Behzad/T-2720-2017
OI Rasmi, Yousef/0000-0003-1506-1909; Pouya, Fahima
   Danesh/0000-0002-2636-9856; Mansoori, Behzad/0000-0001-9444-7134
CR An CH, 2011, PATHOL RES PRACT, V207, P433, DOI 10.1016/j.prp.2011.05.002
   Beggs AD, 2008, CURR GENOMICS, V9, P1, DOI 10.2174/138920208783884865
   Blackford AN, 2017, MOL CELL, V66, P801, DOI 10.1016/j.molcel.2017.05.015
   Burada F, 2015, WORLD J GASTRO ONCOL, V7, P271, DOI 10.4251/wjgo.v7.i11.271
   Chen ZH, 2013, DIGEST DIS SCI, V58, P2887, DOI 10.1007/s10620-013-2732-8
   Cho DH, 2012, ANTICANCER RES, V32, P4091
   Choi AMK, 2013, NEW ENGL J MED, V368, P651, DOI [10.1056/NEJMra1205406, 10.1056/NEJMc1303158]
   Choi JH, 2014, GASTROENT RES PRACT, V2014, DOI 10.1155/2014/179586
   Collins TS, 2005, SEMIN ONCOL, V32, P61, DOI 10.1053/j.seminoncol.2004.09.026
   Coppola D, 2008, CANCER-AM CANCER SOC, V113, P2665, DOI 10.1002/cncr.23892
   Crighton D, 2007, AUTOPHAGY, V3, P72, DOI 10.4161/auto.3438
   Crighton D, 2006, CELL, V126, P121, DOI 10.1016/j.cell.2006.05.034
   Czarny P, 2015, INT J MOL SCI, V16, P2641, DOI 10.3390/ijms16022641
   DEDUVE C, 1966, ANNU REV PHYSIOL, V28, P435, DOI 10.1146/annurev.ph.28.030166.002251
   Dienstmann R, 2017, NAT REV CANCER, V17, P79, DOI 10.1038/nrc.2016.126
   Eliopoulos AG, 2016, FRONT GENET, V7, DOI 10.3389/fgene.2016.00204
   Esclatine A, 2009, CURR TOP MICROBIOL, V335, P33, DOI 10.1007/978-3-642-00302-8_2
   Eskelinen EL, 2009, BBA-MOL CELL RES, V1793, P664, DOI 10.1016/j.bbamcr.2008.07.014
   Fulda S, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00128
   Galluzzi L, 2015, EMBO J, V34, P856, DOI 10.15252/embj.201490784
   Giatromanolaki A, 2010, J CLIN PATHOL, V63, P867, DOI 10.1136/jcp.2010.079525
   Gilbert DC, 2012, BRIT J CANCER, V106, P18, DOI 10.1038/bjc.2011.498
   Gomes LR, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18112351
   Grimm WA, 2016, GUT, V65, P456, DOI 10.1136/gutjnl-2014-308735
   Guo GF, 2011, WORLD J GASTROENTERO, V17, P4779, DOI 10.3748/wjg.v17.i43.4779
   Han Y, 2014, ASIAN PAC J CANCER P, V15, P4583, DOI 10.7314/APJCP.2014.15.11.4583
   He CC, 2009, ANNU REV GENET, V43, P67, DOI 10.1146/annurev-genet-102808-114910
   Hippert MM, 2006, CANCER RES, V66, P9349, DOI 10.1158/0008-5472.CAN-06-1597
   Jo YK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052705
   Kenific CM, 2010, CURR OPIN CELL BIOL, V22, P241, DOI 10.1016/j.ceb.2009.10.008
   Khamis M., 2017, MICROREV CELL MOL BI, P2
   Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717
   Koehler BC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076446
   Lane J.D., 2017, SIGNALLING MECH AUTO
   Li BX, 2009, AUTOPHAGY, V5, P303, DOI 10.4161/auto.5.3.7491
   Li J, 2010, EUR J CANCER, V46, P1900, DOI 10.1016/j.ejca.2010.02.021
   Li YM, 2012, AM J MED SCI, V343, P155, DOI 10.1097/MAJ.0b013e31821f978d
   Maiuri MC, 2010, CURR OPIN CELL BIOL, V22, P181, DOI 10.1016/j.ceb.2009.12.001
   Mao MT, 2017, BIOCHEM BIOPH RES CO, V490, P1244, DOI 10.1016/j.bbrc.2017.07.002
   Mateo J, 2017, CURR PROB CANCER, V41, P247, DOI 10.1016/j.currproblcancer.2017.04.001
   Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639
   Mizushima N, 2007, GENE DEV, V21, P2861, DOI 10.1101/gad.1599207
   Mokarram P, 2017, AUTOPHAGY, V13, P781, DOI 10.1080/15548627.2017.1290751
   Mosieniak G, 2012, MECH AGEING DEV, V133, P444, DOI 10.1016/j.mad.2012.05.004
   Mouw KW, 2017, CANCER DISCOV, V7, P675, DOI 10.1158/2159-8290.CD-17-0226
   Natale F, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15760
   Nazio F., 2018, UBIQUITINATION GOVER
   Ogawa LM, 2017, MOL BIOSYST, V13, P443, DOI 10.1039/c6mb00740f
   Panda PK, 2015, SEMIN CELL DEV BIOL, V39, P43, DOI 10.1016/j.semcdb.2015.02.013
   Polager S, 2008, ONCOGENE, V27, P4860, DOI 10.1038/onc.2008.117
   Qian HR, 2017, ONCOTARGET, V8, P62759, DOI 10.18632/oncotarget.18663
   Rodriguez-Rocha H, 2011, MUTAT RES-FUND MOL M, V711, P158, DOI 10.1016/j.mrfmmm.2011.03.007
   Sato K, 2007, CANCER RES, V67, P9677, DOI 10.1158/0008-5472.CAN-07-1462
   Schonewolf CA, 2014, WORLD J GASTRO ONCOL, V6, P74, DOI 10.4251/wjgo.v6.i3.74
   Seiwert N, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.418
   Selvakumaran M., 2013, CLIN CANC RES
   Siegel RL, 2017, CA-CANCER J CLIN, V67, P177, DOI 10.3322/caac.21395
   Soria-Valles C, 2017, MECH AGEING DEV, V165, P10, DOI 10.1016/j.mad.2016.10.004
   Su ZY, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0321-5
   ten Hoorn S, 2018, METHODS MOL BIOL, V1765, P179, DOI 10.1007/978-1-4939-7765-9_11
   Wang QS, 2018, BIOCHEM BIOPH RES CO, V498, P1058, DOI 10.1016/j.bbrc.2018.03.118
   Wen X., 2016, AUTOPHAGY IS KEY FAC
   Winawer S, 2003, GASTROENTEROLOGY, V124, P544, DOI 10.1053/gast.2003.50044
   Wu Q, 2018, BIOCHEM PHARMACOL, V148, P64, DOI 10.1016/j.bcp.2017.12.004
   Wu SB, 2013, BIOCHEM BIOPH RES CO, V434, P898, DOI 10.1016/j.bbrc.2013.04.053
   Yang MP, 2015, ONCOTARGET, V6, P7084, DOI 10.18632/oncotarget.3054
   Yang ZF, 2010, CURR OPIN CELL BIOL, V22, P124, DOI 10.1016/j.ceb.2009.11.014
   Yang ZL, 2015, CLIN RES HEPATOL GAS, V39, P98, DOI 10.1016/j.clinre.2014.06.014
   Yorimitsu T, 2005, CELL DEATH DIFFER, V12, P1542, DOI 10.1038/sj.cdd.4401765
   Zaanan A, 2015, INT J CANCER, V137, P1498, DOI 10.1002/ijc.29496
   Zhang MY, 2014, INT J MOL SCI, V15, P14372, DOI 10.3390/ijms150814372
   Zheng Hai-yang, 2012, Cancer Biology Medicine, V9, P105, DOI 10.3969/j.issn.2095-3941.2012.02.004
   Zhou HY, 2016, CANCER BIOMARK, V17, P1, DOI 10.3233/CBM-160613
NR 73
TC 4
Z9 4
U1 1
U2 36
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0378-1119
EI 1879-0038
J9 GENE
JI Gene
PD MAR 10
PY 2020
VL 730
AR 144323
DI 10.1016/j.gene.2019.144323
PG 7
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA KH3FU
UT WOS:000510532700004
PM 31917230
DA 2022-04-25
ER

PT J
AU Deng, YY
   Song, PY
   Chen, XH
   Huang, Y
   Hong, LJ
   Jin, Q
   Ji, J
AF Deng, Yongyan
   Song, Pengyu
   Chen, Xiaohui
   Huang, Yue
   Hong, Liangjie
   Jin, Qiao
   Ji, Jian
TI 3-Bromopyruvate-Conjugated Nanoplatform-Induced Pro-Death Autophagy for
   Enhanced Photodynamic Therapy against Hypoxic Tumor
SO ACS NANO
LA English
DT Article
DE pro-death autophagy; hypoxia relief; 3-bromopyruvate; photodynamic
   therapy; respiration inhibition
ID COLORECTAL-CANCER; CELL-DEATH; NANOPARTICLES; APOPTOSIS; DEPLETION;
   RESISTANCE; SYNERGIZE; DELIVERY
AB Autophagy triggered by reactive oxygen species (ROS) in photodynamic therapy (PDT) generally exhibits an anti-apoptotic effect to promote cell survival. Herein, an innovative supramolecular nanoplatform was fabricated for enhanced PDT by converting the role of autophagy from pro-survival to pro-death. The respiration inhibitor 3-bromopyruvate (3BP), which can act as an autophagy promoter and hypoxia ameliorator, was integrated into photosensitizer chlorin e6 (Ce6)-encapsulated nanoparticles to combat hypoxic tumor. 3BP could inhibit respiration by down-regulating HK-II and GAPDH expression to significantly reduce intracellular oxygen consumption rate, which could relieve tumor hypoxia for enhanced photodynamic cancer therapy. More importantly, the autophagy level was significantly elevated by the combination of 3BP and PDT determined by Western blot, immunofluorescent imaging, and transmission electron microscopy. It was very surprising that excessively activated autophagy promoted cell apoptosis, leading to the changeover of autophagy from pro-survival to pro-death. Therefore, PDT combined with 3BP could achieve efficient cell proliferation inhibition and tumor regression. Furthermore, hypoxia-inducible factor-1 alpha (HIF-1 alpha) could be down-regulated after tumor hypoxia was relieved by 3BP. Tumor metastasis could then be effectively inhibited by eliminating primary tumors and down-regulating HIF-1 alpha expression. These results provide an inspiration for future innovative approaches of cancer therapy by triggering pro-death autophagy.
C1 [Deng, Yongyan; Song, Pengyu; Chen, Xiaohui; Huang, Yue; Hong, Liangjie; Jin, Qiao; Ji, Jian] Zhejiang Univ, Dept Polymer Sci & Engn, MOE Key Lab Macromol Synth & Functionalizat, Minist Educ, Hangzhou 310027, Peoples R China.
RP Jin, Q (corresponding author), Zhejiang Univ, Dept Polymer Sci & Engn, MOE Key Lab Macromol Synth & Functionalizat, Minist Educ, Hangzhou 310027, Peoples R China.
EM jinqiao@zju.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [21774110]; Medical Science and Technology
   Project of Zhejiang Province [2019PY020]; Fundamental Research Funds for
   the Central UniversitiesFundamental Research Funds for the Central
   Universities [2019QNA4063]
FX This research was financially supported by the following programs: the
   National Natural Science Foundation of China (21774110), Medical Science
   and Technology Project of Zhejiang Province (2019PY020), and the
   Fundamental Research Funds for the Central Universities (2019QNA4063).
CR Cairns RA, 2011, NAT REV CANCER, V11, P85, DOI 10.1038/nrc2981
   Celli JP, 2010, CHEM REV, V110, P2795, DOI 10.1021/cr900300p
   Chen HC, 2015, J AM CHEM SOC, V137, P1539, DOI 10.1021/ja511420n
   Chen N, 2018, MATER HORIZ, V5, P1204, DOI 10.1039/c8mh00993g
   Cui ZF, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06749-2
   Deng YY, 2018, BIOMATERIALS, V187, P55, DOI 10.1016/j.biomaterials.2018.09.043
   Deng YY, 2018, SMALL, V14, DOI 10.1002/smll.201802420
   Detty MR, 2004, J MED CHEM, V47, P3897, DOI 10.1021/jm040074b
   Duo YH, 2018, ACTA BIOMATER, V79, P317, DOI 10.1016/j.actbio.2018.08.035
   Feng XL, 2019, LASER SURG MED, V51, P352, DOI 10.1002/lsm.23020
   Feng XL, 2015, J BIOENERG BIOMEMBR, V47, P189, DOI 10.1007/s10863-015-9604-1
   Feng XL, 2014, PHOTOCH PHOTOBIO SCI, V13, P1793, DOI 10.1039/c4pp00288a
   Ha SW, 2014, ACS NANO, V8, P5898, DOI 10.1021/nn5009879
   Han HJ, 2020, J AM CHEM SOC, V142, P4944, DOI 10.1021/jacs.0c00650
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Hu DF, 2020, ACS NANO, V14, P347, DOI 10.1021/acsnano.9b05493
   Huang Q, 2016, APOPTOSIS, V21, P749, DOI 10.1007/s10495-016-1243-4
   Huang WC, 2015, J CONTROL RELEASE, V220, P738, DOI 10.1016/j.jconrel.2015.09.016
   Kessel D, 2006, LASER SURG MED, V38, P482, DOI 10.1002/lsm.20334
   Kessel D, 2019, PHOTOCHEM PHOTOBIOL, V95, P119, DOI 10.1111/php.12952
   Ko YH, 2004, BIOCHEM BIOPH RES CO, V324, P269, DOI 10.1016/j.bbrc.2004.09.047
   Legradi J, 2014, ENVIRON SCI TECHNOL, V48, P14703, DOI 10.1021/es5039744
   Li JJ, 2017, ADV FUNCT MATER, V27, DOI 10.1002/adfm.201702108
   Li XS, 2018, ANGEW CHEM INT EDIT, V57, P11522, DOI 10.1002/anie.201805138
   Lovell JF, 2010, CHEM REV, V110, P2839, DOI 10.1021/cr900236h
   Lu HY, 2015, BIOMATERIALS, V42, P30, DOI 10.1016/j.biomaterials.2014.11.029
   Maiuri M. C., 2017, NAT REV MOL CELL BIO, V7, P741
   Markovic ZM, 2012, BIOMATERIALS, V33, P7084, DOI 10.1016/j.biomaterials.2012.06.060
   Marrache S, 2015, CHEM SCI, V6, P1832, DOI 10.1039/c4sc01963f
   Rankin EB, 2016, SCIENCE, V352, P175, DOI 10.1126/science.aaf4405
   Reiners JJ, 2010, AUTOPHAGY, V6, P7, DOI 10.4161/auto.6.1.10220
   Reiniers MJ, 2017, ANAL CHEM, V89, P3853, DOI 10.1021/acs.analchem.7b00043
   Rosenfeldt MT, 2013, NATURE, V504, P296, DOI 10.1038/nature12865
   Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187
   Song XJ, 2016, NANO LETT, V16, P6145, DOI 10.1021/acs.nanolett.6b02365
   Sparsa A, 2013, ONCOL REP, V29, P1196, DOI 10.3892/or.2012.2190
   Thorburn A, 2008, APOPTOSIS, V13, P1, DOI 10.1007/s10495-007-0154-9
   Wan SS, 2019, ACS CENTRAL SCI, V5, P327, DOI 10.1021/acscentsci.8b00822
   Wang T, 2018, SMALL, V14, DOI 10.1002/smll.201802337
   Wang Y, 2019, ACS NANO, V13, P7568, DOI 10.1021/acsnano.9b00143
   Wang Y, 2015, ADV MATER, V27, P2627, DOI 10.1002/adma.201405926
   Wei MF, 2014, AUTOPHAGY, V10, P1179, DOI 10.4161/auto.28679
   Ye SY, 2018, ADV MATER, V30, DOI 10.1002/adma.201801216
   Yu TC, 2017, CELL, V170, P548, DOI 10.1016/j.cell.2017.07.008
   Yu W, 2019, BIOMATERIALS, V192, P128, DOI 10.1016/j.biomaterials.2018.11.019
   Yu WY, 2019, ACS NANO, V13, P1784, DOI 10.1021/acsnano.8b07852
   Zhang Y, 2018, ACS NANO, V12, P651, DOI 10.1021/acsnano.7b07746
   Zhang YJ, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06529-y
   Zheng DW, 2016, ACS NANO, V10, P8715, DOI 10.1021/acsnano.6b04156
   Zhou ZJ, 2016, CHEM SOC REV, V45, P6597, DOI 10.1039/c6cs00271d
   Zhu YX, 2020, BIOMATERIALS, V232, DOI 10.1016/j.biomaterials.2019.119668
NR 51
TC 31
Z9 31
U1 29
U2 168
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1936-0851
EI 1936-086X
J9 ACS NANO
JI ACS Nano
PD AUG 25
PY 2020
VL 14
IS 8
BP 9711
EP 9727
DI 10.1021/acsnano.0c01350
PG 17
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry; Science & Technology - Other Topics; Materials Science
GA NJ9CF
UT WOS:000566341000039
PM 32806075
DA 2022-04-25
ER

PT J
AU Fu, Q
   Yang, F
   Zhao, J
   Yang, XX
   Xiang, TX
   Huai, GL
   Zhang, JS
   Wei, L
   Deng, SP
   Yang, HJ
AF Fu, Qiang
   Yang, Fan
   Zhao, Ji
   Yang, Xingxing
   Xiang, Tengxiao
   Huai, Guoli
   Zhang, Jiashu
   Wei, Liang
   Deng, Shaoping
   Yang, Hongji
TI Bioinformatical identification of key pathways and genes in human
   hepatocellular carcinoma after CSN5 depletion
SO CELLULAR SIGNALLING
LA English
DT Article
DE Bioinformatics analysis; Hepatocellular carcinoma; CSN5 depletion;
   Differentially expressed gene; SMAD5
ID GASTRIC-CANCER CELLS; COLORECTAL-CANCER; TUMOR-SUPPRESSOR; EXPRESSION;
   PROGRESSION; JAB1/CSN5; HEPATOCARCINOGENESIS; OVEREXPRESSION;
   CONTRIBUTE; GENOMICS
AB Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer. It has been previously reported that CSN5 depletion is an effective method in human HCC. In the current study, we aimed to uncover gene signatures and key pathways during HCC. Gene expression profiles of GSE26485 were downloaded from GEO database. Totally, 101 differentially expressed genes (DEGs) were up-regulated and 146 ones were downregulated. Biological processes (BP) and Kyoto Encyclopedia of Genes and Genomes pathway (KEGG) analysis showed that the DEGs were mainly enriched in regulation of cell growth, oxidation-reduction process, mitotic cytokinesis, negative regulation of macroautophagy, endosome organization, lysosome, biosynthesis of antibiotics, small cell lung cancer and glutathione metabolism and so on (P < 0.05). Protein-protein interaction (PPI) network, Kaplan-Meier, log-rank method, western blot, immunohistochemistry and encyclopedia of DNA elements (ENCODE) analysis showed that CSN5 depletion took effects through down-regulation of SMAD5-related pathways which include EXO1, CENPA and NCAPG, resulting in the inactivation of H3K4me3 and H3K36me3. Those genes represent the promising targets for therapeutic intervention in HCC patients.
C1 [Fu, Qiang; Zhao, Ji; Yang, Xingxing; Huai, Guoli; Wei, Liang; Deng, Shaoping; Yang, Hongji] Univ Elect Sci & Technol China, Organ Transplantat Ctr, Sichuan Acad Med Sci, Chengdu 610072, Sichuan, Peoples R China.
   [Fu, Qiang; Zhao, Ji; Yang, Xingxing; Huai, Guoli; Wei, Liang; Deng, Shaoping; Yang, Hongji] Univ Elect Sci & Technol China, Sichuan Prov Peoples Hosp, Sch Med, 1st Ring Rd West 2 Sect 32, Chengdu 610072, Sichuan, Peoples R China.
   [Fu, Qiang; Zhao, Ji; Yang, Xingxing; Huai, Guoli; Zhang, Jiashu; Wei, Liang; Deng, Shaoping; Yang, Hongji] Organ Transplantat Translat Med Key Lab Sichuan P, Chengdu 610072, Sichuan, Peoples R China.
   [Yang, Fan; Zhang, Jiashu] Women & Children Hlth Care Ctr Luoyang, Luoyang 471000, Henan, Peoples R China.
   [Xiang, Tengxiao] Peoples Hosp Changshou Chongqing, Chongqing 401220, Peoples R China.
   [Deng, Shaoping] North Sichuan Med Coll, Nanchong 637100, Sichuan, Peoples R China.
   [Deng, Shaoping] Harvard Med Sch, Massachusetts Gen Hosp, Human Islet Lab, Boston, MA 02114 USA.
RP Deng, SP; Yang, HJ (corresponding author), Univ Elect Sci & Technol China, Sichuan Prov Peoples Hosp, Sch Med, 1st Ring Rd West 2 Sect 32, Chengdu 610072, Sichuan, Peoples R China.
EM sdeng10@163.com; hongji_yang65@126.com
FU Science and Technology Department of Sichuan Province [30504010361,
   2014FZ0123]; Health and Family Planning Commission of Sichuan Province
   [2015SZ0241]; National Natural Science Foundation of ChinaNational
   Natural Science Foundation of China (NSFC) [81571565]
FX Our gratitude goes to GEO and TCGA project which have generated
   comprehensive, multi-dimensional maps of the key genomic changes in
   HepG2, Huh7 cell lines and liver hepatocellular carcinoma. This work was
   supported by grants from the Science and Technology Department of
   Sichuan Province (funding number: No. 30504010361 and No. 2014FZ0123),
   grants from Health and Family Planning Commission of Sichuan Province
   (funding number: No. 2015SZ0241) and grants from the National Natural
   Science Foundation of China (funding number: No. 81571565).
CR An N, 2016, MOL BIOSYST, V12, P541, DOI 10.1039/c5mb00761e
   Bayram S, 2012, MOL BIOL REP, V39, P5943, DOI 10.1007/s11033-011-1406-x
   Bruix J, 2011, HEPATOLOGY, V53, P1020, DOI 10.1002/hep.24199
   Chatterjee R, 2015, INT IMMUNOPHARMACOL, V24, P335, DOI 10.1016/j.intimp.2014.12.024
   Dobbin KK, 2005, CLIN CANCER RES, V11, P565
   Farazi PA, 2006, NAT REV CANCER, V6, P674, DOI 10.1038/nrc1934
   Feldmann G, 2006, ENDOSCOPY, V38, P604, DOI 10.1055/s-2006-925065
   Forner A, 2012, LANCET, V379, P1245, DOI 10.1016/S0140-6736(11)61347-0
   Fu Q, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-26374-9
   Guo H, 2016, HEPATOLOGY, V63, P898, DOI 10.1002/hep.28372
   Haag J, 2006, ARTHRITIS RHEUM, V54, P3878, DOI 10.1002/art.22261
   Harris MA, 2008, NUCLEIC ACIDS RES, V36, pD440, DOI 10.1093/nar/gkm883
   Hejlik DP, 1997, CANCER RES, V57, P3779
   Huang DW, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-9-r183
   Kanehisa M, 2006, NUCLEIC ACIDS RES, V34, pD354, DOI 10.1093/nar/gkj102
   Kaposi-Novak P, 2009, CANCER RES, V69, P2775, DOI 10.1158/0008-5472.CAN-08-3357
   Lee JH, 2008, ONCOL REP, V19, P795
   Lee YH, 2011, ONCOGENE, V30, P4175, DOI 10.1038/onc.2011.126
   Li Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017794
   Liang B, 2016, MED ONCOL, V33, DOI 10.1007/s12032-016-0829-6
   Liu LN, 2012, ONCOL REP, V27, P168, DOI 10.3892/or.2011.1478
   Oh JH, 2005, MAMM GENOME, V16, P942, DOI 10.1007/s00335-005-0075-2
   Pan Y, 2017, ONCOGENE, V36, P1069, DOI 10.1038/onc.2016.271
   Pan YB, 2014, CANCER BIOL THER, V15, P256, DOI 10.4161/cbt.27823
   Pettersson E, 2009, GENOMICS, V93, P105, DOI 10.1016/j.ygeno.2008.10.003
   Shinji S, 2006, ONCOL REP, V15, P539
   Szklarczyk D, 2015, NUCLEIC ACIDS RES, V43, pD447, DOI 10.1093/nar/gku1003
   Tan SK, 2016, ONCOTARGET, V7, P87180, DOI 10.18632/oncotarget.13517
   Thompson CC, 2007, GUT, V56, P95, DOI 10.1136/gut.2005.083691
   van Beijnum JR, 2002, INT J CANCER, V101, P118, DOI 10.1002/ijc.10584
   Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122
   Wang CX, 2017, J GASTROEN HEPATOL, V32, P1525, DOI 10.1111/jgh.13680
   Wang L, 2016, MED ONCOL, V33, DOI 10.1007/s12032-016-0805-1
   Watari A, 2006, ONCOGENE, V25, P7373, DOI 10.1038/sj.onc.1209732
   Wu GM, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-5-r53
   Xu T, 2015, ONCOL REP, V33, P1418, DOI 10.3892/or.2015.3739
   Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118
   Yu WB, 2017, WORLD J HEPATOL, V9, P627, DOI 10.4254/wjh.v9.i13.627
   Zhu Y, 2017, ONCOTARGET, V8, P48725, DOI 10.18632/oncotarget.10706
NR 39
TC 10
Z9 12
U1 0
U2 26
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0898-6568
EI 1873-3913
J9 CELL SIGNAL
JI Cell. Signal.
PD SEP
PY 2018
VL 49
BP 79
EP 86
DI 10.1016/j.cellsig.2018.06.002
PG 8
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA GM6XV
UT WOS:000438323200008
PM 29885455
DA 2022-04-25
ER

PT J
AU Wu, DD
   Liu, SY
   Gao, YR
   Lu, D
   Hong, Y
   Chen, YG
   Dong, PZ
   Wang, DY
   Li, T
   Li, HM
   Ren, ZG
   Guo, JC
   He, F
   Ren, XQ
   Sun, SY
   Duan, SF
   Ji, XY
AF Wu, Dong-Dong
   Liu, Shi-Yu
   Gao, Ying-Ran
   Lu, Dan
   Hong, Ya
   Chen, Ya-Ge
   Dong, Peng-Zhen
   Wang, Da-Yong
   Li, Tao
   Li, Hui-Min
   Ren, Zhi-Guang
   Guo, Jian-Cheng
   He, Fei
   Ren, Xue-Qun
   Sun, Shi-Yong
   Duan, Shao-Feng
   Ji, Xin-Ying
TI Tumour necrosis factor-alpha-induced protein 8-like 2 is a novel
   regulator of proliferation, migration, and invasion in human rectal
   adenocarcinoma cells
SO JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
LA English
DT Article
DE apoptosis; autophagy; rectal adenocarcinoma; signalling pathway; tumour
   necrosis factor-alpha-induced protein 8-like 2
ID CANCER CELLS; TIPE2; AUTOPHAGY; METASTASIS; SUPPRESSES; EXPRESSION;
   THERAPY; GROWTH; INHIBITION; TARGET
AB Tumour necrosis factor-alpha-induced protein 8-like 2 (TIPE2) is a tumour suppressor in many types of cancer. However, the mechanism of action of TIPE2 on the growth of rectal adenocarcinoma is unknown. Our results showed that the expression levels of TIPE2 in human rectal adenocarcinoma tissues were higher than those in adjacent non-tumour tissues. Overexpression of TIPE2 reduced the proliferation, migration, and invasion of human rectal adenocarcinoma cells and down-regulation of TIPE2 showed reverse effects. TIPE2 overexpression increased apoptosis through down-regulating the expression levels of Wnt3a, phospho (p)-beta-Catenin, and p-glycogen synthase kinase-3 beta in rectal adenocarcinoma cells, however, TIPE2 knockdown exhibited reverse trends. TIPE2 overexpression decreased autophagy by reducing the expression levels of p-Smad2, p-Smad3, and transforming growth factor-beta (TGF-beta) in rectal adenocarcinoma cells, however, TIPE2 knockdown showed opposite effects. Furthermore, TIPE2 overexpression reduced the growth of xenografted human rectal adenocarcinoma, whereas TIPE2 knockdown promoted the growth of rectal adenocarcinoma tumours by modulating angiogenesis. In conclusion, TIPE2 could regulate the proliferation, migration, and invasion of human rectal adenocarcinoma cells through Wnt/beta-Catenin and TGF-beta/Smad2/3 signalling pathways. TIPE2 is a potential therapeutic target for the treatment of rectal adenocarcinoma.
C1 [Wu, Dong-Dong; Liu, Shi-Yu; Gao, Ying-Ran; Lu, Dan; Hong, Ya; Chen, Ya-Ge; Dong, Peng-Zhen; Li, Tao; Li, Hui-Min; Ren, Zhi-Guang; Ji, Xin-Ying] Henan Univ, Coll Med, Sch Basic Med Sci, Kaifeng, Peoples R China.
   [Wu, Dong-Dong; Liu, Shi-Yu; Gao, Ying-Ran; Lu, Dan; Hong, Ya; Chen, Ya-Ge; Dong, Peng-Zhen; Wang, Da-Yong; Li, Tao; Li, Hui-Min; Ren, Zhi-Guang; Duan, Shao-Feng; Ji, Xin-Ying] Henan Univ, Henan Int Joint Lab Nucl Prot Regulat, Joint Natl Lab Antibody Drug Engn, Kaifeng, Peoples R China.
   [Wang, Da-Yong] Henan Univ, Affiliated Hosp 1, Kaifeng, Peoples R China.
   [Guo, Jian-Cheng] Zhengzhou Univ, Ctr Precis Med, Zhengzhou, Henan, Peoples R China.
   [He, Fei; Ren, Xue-Qun] Henan Univ, Huaihe Hosp, Kaifeng, Peoples R China.
   [Sun, Shi-Yong] Emory Univ, Sch Med, Dept Hematol & Med Oncol, Atlanta, GA USA.
   [Sun, Shi-Yong] Winship Canc Inst, Atlanta, GA USA.
   [Duan, Shao-Feng] Henan Univ, Sch Pharm, Inst Innovat Drug Design & Evaluat, Kaifeng, Peoples R China.
RP Duan, SF; Ji, XY (corresponding author), Henan Univ, Henan Int Joint Lab Nucl Prot Regulat, Joint Natl Lab Antibody Drug Engn, Kaifeng, Peoples R China.
EM dsf_2007@163.com; 10190096@vip.henu.edu.cn
RI Wu, Dongdong/K-5194-2019; Wu, dongdong/F-6086-2012
OI Wu, Dongdong/0000-0001-6739-8437; 
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81670088, 81802718, U1504817]; Foundation of
   Science & Technology Department of Henan Province, China [162102410009,
   172102410019, 182102310335]; Natural Science Foundation of Education
   Department of Henan Province, China [15A310017]; Science Foundation of
   Kaifeng City, China [1608004, 1703016]; Science Foundation of Henan
   University, China [yqpy20170044]
FX National Natural Science Foundation of China, Grant/Award Number:
   81670088, 81802718, U1504817; Foundation of Science & Technology
   Department of Henan Province, China, Grant/Award Number: 162102410009,
   172102410019, 182102310335; Natural Science Foundation of Education
   Department of Henan Province, China, Grant/Award Number: 15A310017;
   Science Foundation of Kaifeng City, China, Grant/Award Number: 1608004,
   1703016; Science Foundation of Henan University, China, Grant/Award
   Number: yqpy20170044
CR Cao XL, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-149
   Deng BY, 2015, CELL PHYSIOL BIOCHEM, V37, P2434, DOI 10.1159/000438596
   Dinaux AM, 2018, SURGERY, V163, P784, DOI 10.1016/j.surg.2017.10.021
   Ding Y, 2014, SEMIN NEPHROL, V34, P62, DOI 10.1016/j.semnephrol.2013.11.009
   Dokladny K, 2015, AUTOPHAGY, V11, P200, DOI 10.1080/15548627.2015.1009776
   Elinav E, 2013, NAT REV CANCER, V13, P759, DOI 10.1038/nrc3611
   Ellingson BM, 2016, CANCER-AM CANCER SOC, V122, P1718, DOI 10.1002/cncr.29957
   Ellis CT, 2016, J CLIN ONCOL, V34, P1644, DOI 10.1200/JCO.2015.64.2066
   Fan CW, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.337
   Farrow JM, 2014, NAT REV UROL, V11, P508, DOI 10.1038/nrurol.2014.196
   Freundt EC, 2008, CELL, V133, P401, DOI 10.1016/j.cell.2008.04.017
   Garcia-Aguilar J, 2015, LANCET ONCOL, V16, P957, DOI 10.1016/S1470-2045(15)00004-2
   Gus-Brautbar Y, 2012, MOL CELL, V45, P610, DOI 10.1016/j.molcel.2012.01.006
   Heilmann AM, 2014, CANCER RES, V74, P3947, DOI 10.1158/0008-5472.CAN-13-2923
   Hugen N, 2016, NAT REV CLIN ONCOL, V13, P361, DOI 10.1038/nrclinonc.2015.140
   Jiang Y, 2016, NAT CELL BIOL, V18, P851, DOI 10.1038/ncb3388
   Kahn M, 2014, NAT REV DRUG DISCOV, V13, P513, DOI 10.1038/nrd4233
   Keam B, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2834
   Kumar S, 2016, MOL CELL, V62, P520, DOI 10.1016/j.molcel.2016.04.010
   Levy JMM, 2017, NAT REV CANCER, V17, P528, DOI 10.1038/nrc.2017.53
   Li SY, 2005, CLIN CANCER RES, V11, P3574, DOI 10.1158/1078-0432.CCR-04-2077
   Li XM, 2014, CANCER BIOMARK, V14, P233, DOI 10.3233/CBM-140402
   Li ZQ, 2016, ONCOTARGET, V7, P62224, DOI 10.18632/oncotarget.11406
   Liu J, 2018, AUTOPHAGY, V14, P845, DOI 10.1080/15548627.2017.1390636
   Lu Q, 2016, ONCOL RES, V24, P305, DOI 10.3727/096504016X14666990347437
   Mendenhall WM, 2009, AM J CLIN ONCOL-CANC, V32, P629, DOI 10.1097/COC.0b013e31817ff8e4
   Miller I, 2018, CELL REP, V24, P1105, DOI 10.1016/j.celrep.2018.06.110
   Nuchel J, 2018, AUTOPHAGY, V14, P465, DOI 10.1080/15548627.2017.1422850
   Padmavathi G, 2018, CANCER LETT, V432, P260, DOI 10.1016/j.canlet.2018.06.017
   Pan CC, 2015, J BIOL CHEM, V290, P14884, DOI 10.1074/jbc.M114.630178
   Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74
   Rickles AS, 2015, ANN SURG, V262, P891, DOI 10.1097/SLA.0000000000001391
   Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI [10.3322/caac.21254, 10.3322/caac.21208, 10.1001/jamaoto.2014.2530, 10.1136/bmj.g1502]
   Spitzner M, 2014, INT J CANCER, V134, P997, DOI 10.1002/ijc.28429
   Sun HH, 2008, CELL, V133, P415, DOI 10.1016/j.cell.2008.03.026
   Sung JJY, 2015, GUT, V64, P121, DOI 10.1136/gutjnl-2013-306503
   Tolaney SM, 2015, P NATL ACAD SCI USA, V112, P14325, DOI 10.1073/pnas.1518808112
   White E, 2015, CLIN CANCER RES, V21, P5037, DOI 10.1158/1078-0432.CCR-15-0490
   White E, 2015, J CLIN INVEST, V125, P42, DOI 10.1172/JCI73941
   Wu DQ, 2010, TRENDS BIOCHEM SCI, V35, P161, DOI 10.1016/j.tibs.2009.10.002
   Wu DD, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4391-9
   Wu DD, 2018, PHARMACOL RES, V131, P120, DOI 10.1016/j.phrs.2018.03.002
   Wu DD, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-05457-z
   Wu DD, 2015, NITRIC OXIDE-BIOL CH, V50, P38, DOI 10.1016/j.niox.2015.08.004
   Wu DD, 2014, CANCER LETT, V351, P13, DOI 10.1016/j.canlet.2014.05.002
   Yerushalmi Rinat, 2010, Lancet Oncol, V11, P174, DOI 10.1016/S1470-2045(09)70262-1
   Yin H, 2017, CANCER GENE THER, V24, P180, DOI 10.1038/cgt.2017.3
   Zhang C, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-017-0628-8
   Zhang GZ, 2010, MOL IMMUNOL, V47, P2435, DOI 10.1016/j.molimm.2010.06.016
   Zhang GY, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/9647809
   Zhang L, 2011, MOL IMMUNOL, V48, P1209, DOI 10.1016/j.molimm.2011.03.001
   Zhang X, 2009, NAT STRUCT MOL BIOL, V16, P89, DOI 10.1038/nsmb.1522
   Zhang YQ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120884
   Zhang ZH, 2017, MOL IMMUNOL, V85, P230, DOI 10.1016/j.molimm.2017.03.007
   Zhu LN, 2018, J TRANSL MED, V16, DOI 10.1186/s12967-018-1383-0
   Zhu Y, 2016, CANCER GENE THER, V23, P98, DOI 10.1038/cgt.2016.6
NR 56
TC 8
Z9 10
U1 0
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1582-1838
EI 1582-4934
J9 J CELL MOL MED
JI J. Cell. Mol. Med.
PD MAR
PY 2019
VL 23
IS 3
BP 1698
EP 1713
DI 10.1111/jcmm.14065
PG 16
WC Cell Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA HL7KN
UT WOS:000458920000007
PM 30637920
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Zhao, Z
   Zhao, J
   Xue, J
   Zhao, XR
   Liu, PS
AF Zhao, Zhe
   Zhao, Jing
   Xue, Jing
   Zhao, Xinrui
   Liu, Peishu
TI Autophagy inhibition promotes epithelial-mesenchymal transition through
   ROS/HO-1 pathway in ovarian cancer cells
SO AMERICAN JOURNAL OF CANCER RESEARCH
LA English
DT Article
DE Autophagy defect; EMT; HO-1; Zeb1; ovarian cancer
ID HEME OXYGENASE-1; COLORECTAL-CANCER; METASTASIS; EXPRESSION; CARCINOMA;
   INVASION; EMT; ROS; MIGRATION; ZEB1
AB Autophagy has been proved to be involved in metastasis of cancers. However, the detailed mechanisms are still unclear. In this work, we aim to provide the first study of the role that autophagy plays in migration and invasion in ovarian cancer cells. Transwell chamber was used to examine migration and invasion capacities. Western blotting and immunofluorescence were performed to investigate the expressions of mesenchymal markers (Vimentin, N-cadherin), epithelial marker (Keratin), transcript factor (Zeb1) and HO-1. Small interfering RNA (siRNA) was used to generate autophagy defect cells (A2780 Atg7 siRNA and Skov-3 Atg7 siRNA cells). Reactive oxygen species (ROS) were examined by flow cytometry. We found Skov-3 cells exhibited a fibroblastoid like phenotype and more invasive ability with lower level of autophagy than A2780. Transwell chamber showed that autophagy inhibition promoted migration and invasion capacities of autophagy defect cells. Western blotting showed that the expressions of mesenchymal markers and transcript factor were up-regulated, while, the expression of epithelial marker was down-regulated in autophagy defect cells. Conversely, autophagy induction could impair the migration and invasion through reversing epithelial-mesenchymal transition (EMT) in A2780 and Skov-3 cells. Besides, autophagy defect could increase the level of intracellular ROS and the expression of HO-1. NAC (ROS scavenging agent) could inhibit the migration and invasion through reversing EMT and decrease the expression of HO-1. What's more, Znpp (HO-1 inhibitor) impaired the migration and invasion through reversing EMT. In conclusion, our results suggest that autophagy inhibition may promote EMT through ROS/HO-1 pathway in ovarian cancer cells.
C1 [Zhao, Zhe; Zhao, Jing; Xue, Jing; Zhao, Xinrui; Liu, Peishu] Shandong Univ, Dept Obstet & Gynecol, Qilu Hosp, 107 Wenhua Xi Rd, Jinan 250012, Shandong, Peoples R China.
RP Liu, PS (corresponding author), Shandong Univ, Dept Obstet & Gynecol, Qilu Hosp, 107 Wenhua Xi Rd, Jinan 250012, Shandong, Peoples R China.
EM peishuliu@126.com
FU Development and Reform commission Project of Shandong Province
   [26010104081103]
FX This work was supported by grants from Development and Reform commission
   Project of Shandong Province (26010104081103).
CR Bai HM, 2015, ONCOTARGET, V6, P25520, DOI 10.18632/oncotarget.4550
   Cannito S, 2010, ANTIOXID REDOX SIGN, V12, P1383, DOI 10.1089/ars.2009.2737
   Catalano M, 2015, MOL ONCOL, V9, P1612, DOI 10.1016/j.molonc.2015.04.016
   Chau LY, 2015, J BIOMED SCI, V22, DOI 10.1186/s12929-015-0128-0
   Chen X, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147084
   Choi AMK, 2013, NEW ENGL J MED, V368, P651, DOI [10.1056/NEJMra1205406, 10.1056/NEJMc1303158]
   Cichon MA, 2014, ONCOTARGET, V5, P2827, DOI 10.18632/oncotarget.1940
   Costa A, 2014, SEMIN CANCER BIOL, V25, P23, DOI 10.1016/j.semcancer.2013.12.007
   Davidson B, 2015, HUM PATHOL, V46, P1, DOI 10.1016/j.humpath.2014.10.004
   Dey S, 2015, J CLIN INVEST, V125, P2592, DOI 10.1172/JCI78031
   Elloul S, 2010, CLIN EXP METASTAS, V27, P161, DOI 10.1007/s10585-010-9315-2
   Gandini NA, 2014, TUMOR BIOL, V35, P2803, DOI 10.1007/s13277-013-1373-z
   Goodman AI, 1997, P SOC EXP BIOL MED, V214, P54
   Gough DR, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.96
   Grassi G, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.249
   Gueron G, 2014, ONCOTARGET, V5, P4087, DOI 10.18632/oncotarget.1826
   Gulhati P, 2011, CANCER RES, V71, P3246, DOI 10.1158/0008-5472.CAN-10-4058
   Hsu FF, 2015, ONCOGENE, V34, P2410, DOI 10.1038/onc.2014.464
   Kan JY, 2016, ONCOTARGET, V7, P31336, DOI 10.18632/oncotarget.9140
   Kang XW, 2015, CELL PHYSIOL BIOCHEM, V35, P1008, DOI 10.1159/000373928
   Kongara S, 2012, FRONT ONCOL, V2, DOI 10.3389/fonc.2012.00171
   Law AYS, 2010, EXP CELL RES, V316, P3425, DOI 10.1016/j.yexcr.2010.06.026
   Li XF, 2016, MOL CLIN ONCOL, V4, P18, DOI 10.3892/mco.2015.662
   Liao H, 2015, AM J CANCER RES, V5, P125
   LIN H, 2013, MATH PROBL ENG, V2013, P1, DOI DOI 10.1371/J0URNAL.P0NE.0060516
   Liu H, 2015, GEN COMP ENDOCR, V210, P124, DOI 10.1016/j.ygcen.2014.09.006
   Liu RH, 2015, ARCH GYNECOL OBSTET, V291, P1361, DOI 10.1007/s00404-014-3555-3
   Lv Q, 2012, CANCER RES, V72, P3238, DOI 10.1158/0008-5472.CAN-11-3832
   Ma ZH, 2016, IUBMB LIFE, V68, P394, DOI 10.1002/iub.1494
   MAINES MD, 1988, FASEB J, V2, P2557, DOI 10.1096/fasebj.2.10.3290025
   Maines MD, 1996, UROLOGY, V47, P727, DOI 10.1016/S0090-4295(96)00010-6
   Mathew R, 2009, CELL, V137, P1062, DOI 10.1016/j.cell.2009.03.048
   Miow QH, 2015, ONCOGENE, V34, P1899, DOI 10.1038/onc.2014.136
   Mizushima N, 2011, CELL, V147, P728, DOI 10.1016/j.cell.2011.10.026
   Park S, 2014, SHOCK VIB, V2014, DOI 10.1155/2014/929341
   Qiang L, 2014, AUTOPHAGY, V10, P1864, DOI 10.4161/auto.32171
   Qiang L, 2014, P NATL ACAD SCI USA, V111, P9241, DOI 10.1073/pnas.1322913111
   Qin WJ, 2015, ONCOTARGET, V6, P39839, DOI 10.18632/oncotarget.5674
   Seo GS, 2015, ONCOTARGET, V6, P19792, DOI 10.18632/oncotarget.4075
   Siegel RL, 2019, CA-CANCER J CLIN, V69, P7, DOI 10.3322/caac.21551
   Sridhar S, 2012, J PATHOL, V226, P255, DOI 10.1002/path.3025
   Thompson EW, 2008, CLIN EXP METASTAS, V25, P591, DOI 10.1007/s10585-008-9189-8
   Vaughan S, 2011, NAT REV CANCER, V11, P719, DOI 10.1038/nrc3144
   Wang TY, 2015, HISTOPATHOLOGY, V66, P447, DOI 10.1111/his.12562
   Yin HZ, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-436
   Zhang Y, 2016, ONCOTARGETS THER, V9, P1303, DOI 10.2147/OTT.S96723
NR 46
TC 44
Z9 48
U1 0
U2 5
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 2156-6976
J9 AM J CANCER RES
JI Am. J. Cancer Res.
PY 2016
VL 6
IS 10
BP 2162
EP 2177
PG 16
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA EB8CJ
UT WOS:000387618300004
PM 27822409
DA 2022-04-25
ER

PT J
AU Perez-Plasencia, C
   Lopez-Urrutia, E
   Garcia-Castillo, V
   Trujano-Camacho, S
   Lopez-Camarillo, C
   Campos-Parra, AD
AF Perez-Plasencia, Carlos
   Lopez-Urrutia, Eduardo
   Garcia-Castillo, Veronica
   Trujano-Camacho, Samuel
   Lopez-Camarillo, Cesar
   Campos-Parra, Alma D.
TI Interplay Between Autophagy and Wnt/beta-Catenin Signaling in Cancer:
   Therapeutic Potential Through Drug Repositioning
SO FRONTIERS IN ONCOLOGY
LA English
DT Review
DE drug repositinging; autophagy; Wnt; b-catenin; cancer; signaling;
   signaling pathways
ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; BETA-CATENIN; PATHWAY ACTIVATION;
   COLORECTAL-CANCER; EXPRESSION; RESISTANCE; APOPTOSIS; TARGET; CELLS;
   INHIBITION
AB The widespread dysregulation that characterizes cancer cells has been dissected and many regulation pathways common to multiple cancer types have been described in depth. Wnt/beta-catenin signaling and autophagy are among these principal pathways, which contribute to tumor growth and resistance to anticancer therapies. Currently, several therapeutic strategies that target either Wnt/beta-catenin signaling or autophagy are in various stages of development. Targeted therapies that block specific elements that participate in both pathways; are subject toin vitrostudies as well as pre-clinical and early clinical trials. Strikingly, drugs designed for other diseases also impact these pathways, which is relevant since they are already FDA-approved and sometimes even routinely used in the clinic. The main focus of this mini-review is to highlight the importance of drug repositioning to inhibit the Wnt/beta-catenin and autophagy pathways, with an emphasis on the interplay between them. The data we found strongly suggested that this field is worth further examination.
C1 [Perez-Plasencia, Carlos; Lopez-Urrutia, Eduardo; Garcia-Castillo, Veronica] UNAM, Fac Estudios Super Iztacala, Unidad Biomed, Lab Genom Func, Tlalnepantla, Mexico.
   [Perez-Plasencia, Carlos; Trujano-Camacho, Samuel; Campos-Parra, Alma D.] Inst Nacl Cancerol INCan, Lab Genom, Mexico City, DF, Mexico.
   [Lopez-Camarillo, Cesar] Univ Autonoma Ciudad Mexico, Posgrad Ciencias Genom, Mexico City, DF, Mexico.
RP Campos-Parra, AD (corresponding author), Inst Nacl Cancerol INCan, Lab Genom, Mexico City, DF, Mexico.
EM adcamposparra@gmail.com
RI Lopez-Camarillo, Cesar/I-1946-2019
OI Lopez-Camarillo, Cesar/0000-0002-9417-2609; Lopez-Urrutia,
   Eduardo/0000-0002-5307-2003
CR Ahmed K, 2019, CANCER LETT, V449, P45, DOI 10.1016/j.canlet.2019.02.018
   Akin D, 2014, AUTOPHAGY, V10, P2021, DOI 10.4161/auto.32229
   Amaravadi RK, 2019, CANCER DISCOV, V9, P1167, DOI 10.1158/2159-8290.CD-19-0292
   Barbosa EJ, 2019, EUR J PHARM BIOPHARM, V141, P58, DOI 10.1016/j.ejpb.2019.05.004
   Baudino Troy A, 2015, Curr Drug Discov Technol, V12, P3
   Behari J, 2007, J HEPATOL, V46, P849, DOI 10.1016/j.jhep.2006.11.017
   Bitto A, 2014, AGE, V36, P1123, DOI 10.1007/s11357-014-9626-3
   Brown WA, 2001, GUT, V48, P660, DOI 10.1136/gut.48.5.660
   Chaikuad A, 2019, BIOCHEM J, V476, P875, DOI 10.1042/BCJ20190038
   Chu CW, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20030473
   Cicchini M, 2014, AUTOPHAGY, V10, P2036, DOI 10.4161/auto.34398
   Rodrigues BLC, 2020, IMMUNOL INVEST, V49, P386, DOI 10.1080/08820139.2019.1682600
   Datta S, 2019, APOPTOSIS, V24, P414, DOI 10.1007/s10495-019-01526-y
   Dyczynski M, 2018, CANCER LETT, V435, P32, DOI 10.1016/j.canlet.2018.07.028
   Eustace AJ, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4852-1
   Fan Q, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0673-y
   Feng YC, 2017, AUTOPHAGY, V13, P995, DOI 10.1080/15548627.2017.1317427
   Ferlay J, 2019, INT J CANCER, V144, P1941, DOI 10.1002/ijc.31937
   Fulda S, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00128
   Gao C, 2010, NAT CELL BIOL, V12, P781, DOI 10.1038/ncb2082
   Gong J, 2014, FRONT PHYSIOL, V5, DOI 10.3389/fphys.2014.00426
   Harb J, 2019, CURR ONCOL REP, V21, DOI 10.1007/s11912-019-0763-9
   Hawcroft G, 2002, CARCINOGENESIS, V23, P107, DOI 10.1093/carcin/23.1.107
   Hindorff LA, 2011, CARCINOGENESIS, V32, P945, DOI 10.1093/carcin/bgr056
   Huynh H, 2019, INT J ONCOL, V54, P1123, DOI 10.3892/ijo.2019.4693
   Janku F, 2011, NAT REV CLIN ONCOL, V8, P528, DOI 10.1038/nrclinonc.2011.71
   Jin GX, 2014, DRUG DISCOV TODAY, V19, P637, DOI 10.1016/j.drudis.2013.11.005
   Jing QC, 2019, J CELL MOL MED, V23, P4711, DOI 10.1111/jcmm.14394
   Juarez M, 2018, AM J CANCER RES, V8, P317
   Kahn M, 2014, NAT REV DRUG DISCOV, V13, P513, DOI 10.1038/nrd4233
   Kang MR, 2009, J PATHOL, V217, P702, DOI 10.1002/path.2509
   Khaminets A, 2016, TRENDS CELL BIOL, V26, P6, DOI 10.1016/j.tcb.2015.08.010
   Khan AS, 2016, TUMOR BIOL, V37, P11947, DOI 10.1007/s13277-016-5039-5
   Knox SS, 2010, CANCER CELL INT, V10, DOI 10.1186/1475-2867-10-11
   Kuhn K, 2015, CELL DEATH DISCOV, V1, DOI 10.1038/cddiscovery.2015.31
   Lee HJ, 2009, ANGEW CHEM INT EDIT, V48, P6448, DOI 10.1002/anie.200902981
   Li J, 2009, ANN SURG ONCOL, V16, P761, DOI 10.1245/s10434-008-0260-0
   Li RN, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08249-7
   Limpert AS, 2018, TRENDS PHARMACOL SCI, V39, P1021, DOI 10.1016/j.tips.2018.10.004
   Lin RK, 2015, CELL PHYSIOL BIOCHEM, V35, P926, DOI 10.1159/000369749
   Liu D., 2009, MED ONCOL, V28, P105
   Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126
   Lu WY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029290
   Lu WY, 2009, EUR J PHARMACOL, V602, P8, DOI 10.1016/j.ejphar.2008.10.053
   Luo XM, 2018, INT J ONCOL, V53, P904, DOI 10.3892/ijo.2018.4442
   Mahmoud NN, 1998, SURGERY, V124, P225, DOI 10.1016/S0039-6060(98)70124-2
   Nager M, 2018, AUTOPHAGY, V14, P619, DOI 10.1080/15548627.2017.1423439
   Nisar S, 2020, CURR PHARM DESIGN, V26, P429, DOI 10.2174/1381612826666200115095937
   Panda PK, 2018, MOL CARCINOGEN, V57, P664, DOI 10.1002/mc.22791
   Perez-Plasencia Carlos, 2008, Int Arch Med, V1, P10, DOI 10.1186/1755-7682-1-10
   Petherick KJ, 2015, J BIOL CHEM, V290, P11376, DOI [10.1074/jbc.C114.627778, 10.1074/jbc.A114.627778]
   Petherick KJ, 2013, EMBO J, V32, P1903, DOI 10.1038/emboj.2013.123
   Pohl SG, 2017, ONCOGENESIS, V6, DOI 10.1038/oncsis.2017.14
   Pushpakom S, 2019, NAT REV DRUG DISCOV, V18, P41, DOI 10.1038/nrd.2018.168
   Ravanan P, 2017, LIFE SCI, V188, P53, DOI 10.1016/j.lfs.2017.08.029
   Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319
   Sareddy GR, 2013, NEUROCHEM RES, V38, P2313, DOI 10.1007/s11064-013-1142-9
   Spengler G, 2011, ANTICANCER RES, V31, P4201
   Stein U, 2011, NEOPLASIA, V13, P131, DOI 10.1593/neo.101172
   Stolz A, 2014, NAT CELL BIOL, V16, P495, DOI 10.1038/ncb2979
   Su N, 2016, ONCOL LETT, V12, P4623, DOI 10.3892/ol.2016.5289
   Sukhdeo K, 2012, LEUKEMIA, V26, P1116, DOI 10.1038/leu.2011.303
   Talevi A, 2020, EXPERT OPIN DRUG DIS, V15, P397, DOI 10.1080/17460441.2020.1704729
   Tao H, 2017, MOL MED REP, V16, P1701, DOI 10.3892/mmr.2017.6828
   Tickenbrock L, 2008, INT J ONCOL, V33, P1215, DOI 10.3892/ijo_00000111
   Tinsley HN, 2011, CANCER PREV RES, V4, P1275, DOI 10.1158/1940-6207.CAPR-11-0095
   Vazquez-Martin A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006251
   Wang JB, 2019, BIOCHEM J, V476, P535, DOI 10.1042/BCJ20180385
   Wild P, 2014, J CELL SCI, V127, P3, DOI 10.1242/jcs.140426
   Xia JJ, 2010, J INT MED RES, V38, P1294, DOI 10.1177/147323001003800411
   Xu R, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000012912
   Xue HQ, 2018, INT J BIOL SCI, V14, P1232, DOI 10.7150/ijbs.24612
   Yao M, 2017, J CANCER, V8, P220, DOI 10.7150/jca.16850
   Zhan T, 2017, ONCOGENE, V36, P1461, DOI 10.1038/onc.2016.304
   Zhang H, AUTOPHAGY CELL DEATH, DOI [10.5772/intechopen.88050, DOI 10.5772/INTECHOPEN.88050]
   Zhang L, 2017, JNCI-J NATL CANCER I, V109, DOI 10.1093/jnci/djw332
   Zhao ZH, 2017, MED SCI MONITOR, V23, P2906, DOI 10.12659/MSM.904177
NR 77
TC 8
Z9 8
U1 1
U2 2
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2234-943X
J9 FRONT ONCOL
JI Front. Oncol.
PD AUG 18
PY 2020
VL 10
AR 1037
DI 10.3389/fonc.2020.01037
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA NM1OI
UT WOS:000567873100001
PM 33014767
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Hung, KF
   Yang, T
   Kao, SY
AF Hung, Kai-Feng
   Yang, Ting
   Kao, Shou-Yen
TI Cancer stem cell theory: Are we moving past the mist?
SO JOURNAL OF THE CHINESE MEDICAL ASSOCIATION
LA English
DT Review
DE Autophagy; Cancer stem cells; Cellular stress; Epithelial-mesenchymal
   transition; Heterogenicity; Plasticity
ID EPITHELIAL-MESENCHYMAL TRANSITION; ENDOPLASMIC-RETICULUM;
   COLORECTAL-CANCER; INITIATING CELLS; DYNAMIC EQUILIBRIUM;
   DOWN-REGULATION; EXPRESSION; SNAIL; DIFFERENTIATION; HETEROGENEITY
AB Cancer stem cells (CSC) are a subpopulation of tumor cells that have superior capacities of self-renewal, metastatic dissemination, and chemoresistance. These characteristics resemble, to some extent, the outcome of certain biological processes, including epithelial-mesenchymal transition (EMT), autophagy, and cellular stress response. Indeed, it has been shown that the stimuli that induce these processes and CSC are overlapping, and CSC and tumor cells that underwent EMT or autophagy are much alike. However, as the cross talk between CSC, EMT, autophagy, and cellular stress is further explored, these processes are also found to have an opposing role in CSC, depending on the condition and status of cells. This contextual effect is likely due to overwhelming reliance on CSC markers for their identification, and/or discrepancies in recognition of CSC as a particular cell population or cellular state. In this review, we summarize how EMT, autophagy, and cellular stress response are tied or unwound with CSC. We also discuss the current view of CSC theory evolved from the emphasis of heterogenicity and plasticity of CSC.
C1 [Hung, Kai-Feng; Yang, Ting] Taipei Vet Gen Hosp, Dept Med Res, Div Translat Res, Taipei, Taiwan.
   [Hung, Kai-Feng; Kao, Shou-Yen] Natl Yang Ming Univ, Sch Dent, Dept Dent, Taipei, Taiwan.
   [Kao, Shou-Yen] Taipei Vet Gen Hosp, Dept Stomatol, 201,Sect 2,Shi Pai Rd, Taipei 112, Taiwan.
RP Kao, SY (corresponding author), Taipei Vet Gen Hosp, Dept Stomatol, 201,Sect 2,Shi Pai Rd, Taipei 112, Taiwan.
EM sykao@vghtpe.gov.tw
CR Abranches E, 2014, DEVELOPMENT, V141, P2770, DOI 10.1242/dev.108910
   Aigner K, 2007, ONCOGENE, V26, P6979, DOI 10.1038/sj.onc.1210508
   Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100
   Bae KM, 2016, AM J CANCER RES, V6, P1078
   Baulida J, 2015, BBA-REV CANCER, V1856, P55, DOI 10.1016/j.bbcan.2015.05.005
   Beck B, 2015, CELL STEM CELL, V16, P67, DOI 10.1016/j.stem.2014.12.002
   Celia-Terrassa T, 2012, J CLIN INVEST, V122, P1849, DOI 10.1172/JCI59218
   Chambers I, 2007, NATURE, V450, P1230, DOI 10.1038/nature06403
   Chang CW, 2014, CANCER RES, V74, P6291, DOI 10.1158/0008-5472.CAN-14-0626
   Chiou SH, 2008, CLIN CANCER RES, V14, P4085, DOI 10.1158/1078-0432.CCR-07-4404
   Clarke HJ, 2014, CANCER CELL, V25, P563, DOI 10.1016/j.ccr.2014.03.015
   De Craene B, 2005, CANCER RES, V65, P6237, DOI 10.1158/0008-5472.CAN-04-3545
   Dick JE, 2008, BLOOD, V112, P4793, DOI 10.1182/blood-2008-08-077941
   Dieter SM, 2011, CELL STEM CELL, V9, P357, DOI 10.1016/j.stem.2011.08.010
   Dubrovska A, 2009, P NATL ACAD SCI USA, V106, P268, DOI 10.1073/pnas.0810956106
   Eppert K, 2011, NAT MED, V17, P1086, DOI 10.1038/nm.2415
   Faber J, 2007, CANCER RES, V67, P8425, DOI 10.1158/0008-5472.CAN-07-0972
   Ghiaur G, 2012, STEM CELLS, V30, P89, DOI 10.1002/stem.769
   Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014
   Goodell MA, 1996, J EXP MED, V183, P1797, DOI 10.1084/jem.183.4.1797
   Gopal K, 2016, ONCOTARGET, V7, P3111, DOI 10.18632/oncotarget.6630
   Graf T, 2008, CELL STEM CELL, V3, P480, DOI 10.1016/j.stem.2008.10.007
   Guo WJ, 2012, CELL, V148, P1015, DOI 10.1016/j.cell.2012.02.008
   HAMBURGER AW, 1977, SCIENCE, V197, P461, DOI 10.1126/science.560061
   Hayashi K, 2008, CELL STEM CELL, V3, P391, DOI 10.1016/j.stem.2008.07.027
   He HY, 2012, CANCER SCI, V103, P1296, DOI 10.1111/j.1349-7006.2012.02295.x
   Hwang WL, 2014, NAT CELL BIOL, V16, P268, DOI 10.1038/ncb2910
   Hwang WL, 2011, GASTROENTEROLOGY, V141, P279, DOI 10.1053/j.gastro.2011.04.008
   Iida H, 2012, INT J ONCOL, V40, P71, DOI 10.3892/ijo.2011.1207
   Iliopoulos D, 2011, P NATL ACAD SCI USA, V108, P1397, DOI 10.1073/pnas.1018898108
   Kalmar T, 2009, PLOS BIOL, V7, DOI 10.1371/journal.pbio.1000149
   Kong DJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012445
   Kreso A, 2014, CELL STEM CELL, V14, P275, DOI 10.1016/j.stem.2014.02.006
   Kumar RM, 2014, NATURE, V516, P56, DOI 10.1038/nature13920
   Li RH, 2010, CELL STEM CELL, V7, P51, DOI 10.1016/j.stem.2010.04.014
   Lim W, 2016, INT J ONCOL, V49, P991, DOI 10.3892/ijo.2016.3582
   Lorico A, 2011, J ONCOL, V2011, DOI 10.1155/2011/135039
   Lu YP, 2019, EUR RADIOL, V29, P1318, DOI 10.1007/s00330-018-5632-7
   Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027
   Marsden CG, 2009, METHODS MOL BIOL, V590, P363, DOI 10.1007/978-1-60327-378-7_23
   Martincorena I, 2015, SCIENCE, V348, P880, DOI 10.1126/science.aaa6806
   Maycotte P, 2015, MOL CANCER RES, V13, P651, DOI 10.1158/1541-7786.MCR-14-0487
   McGrail DJ, 2018, CELL REP, V23, P2095, DOI 10.1016/j.celrep.2018.04.068
   Medema JP, 2013, NAT CELL BIOL, V15, P338, DOI 10.1038/ncb2717
   Meshorer E, 2006, DEV CELL, V10, P105, DOI 10.1016/j.devcel.2005.10.017
   Meyer IS, 2017, EMBO MOL MED, V9, P1279, DOI 10.15252/emmm.201707565
   Mizrak D, 2008, J PATHOL, V214, P3, DOI 10.1002/path.2283
   Mo J, 2013, MELANOMA RES, V23, P254, DOI 10.1097/CMR.0b013e32836314e3
   Morel AP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002888
   Naka K, 2010, NATURE, V463, P676, DOI 10.1038/nature08734
   Nguyen LV, 2012, NAT REV CANCER, V12, P133, DOI 10.1038/nrc3184
   Ning YX, 2014, MOL MED REP, V9, P1982, DOI 10.3892/mmr.2014.2012
   Ocana OH, 2012, CANCER CELL, V22, P709, DOI 10.1016/j.ccr.2012.10.012
   Parkes EE, 2017, JNCI-J NATL CANCER I, V109, DOI 10.1093/jnci/djw199
   Patil C, 2001, CURR OPIN CELL BIOL, V13, P349, DOI 10.1016/S0955-0674(00)00219-2
   Pattabiraman DR, 2014, NAT REV DRUG DISCOV, V13, P497, DOI 10.1038/nrd4253
   Peng QH, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-017-0644-8
   PENG T, 2011, PLOS ONE, V0006
   Polewski MD, 2017, STEM CELLS DEV, V26, P1236, DOI 10.1089/scd.2017.0123
   Polo JM, 2012, CELL, V151, P1617, DOI 10.1016/j.cell.2012.11.039
   Prabhu VV, 2015, CANCER RES, V75, P1423, DOI 10.1158/0008-5472.CAN-13-3451
   Puisieux A, 2014, NAT CELL BIOL, V16, P488, DOI 10.1038/ncb2976
   Radzisheuskaya A, 2013, NAT CELL BIOL, V15, P579, DOI 10.1038/ncb2742
   Redmer T, 2011, EMBO REP, V12, P720, DOI 10.1038/embor.2011.88
   Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167
   Ron D, 2007, NAT REV MOL CELL BIO, V8, P519, DOI 10.1038/nrm2199
   Roy HK, 2004, MOL CANCER THER, V3, P1159
   Saijo H, 2016, ONCOTARGET, V7, P50043, DOI 10.18632/oncotarget.10571
   Samavarchi-Tehrani P, 2010, CELL STEM CELL, V7, P64, DOI 10.1016/j.stem.2010.04.015
   Seton-Rogers S, 2012, NAT REV CANCER, V12, P377, DOI 10.1038/nrc3282
   Sharif T, 2011, INVEST NEW DRUG, V29, P239, DOI 10.1007/s10637-009-9352-3
   Singh AM, 2007, STEM CELLS, V25, P2534, DOI 10.1634/stemcells.2007-0126
   Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128
   Somervaille TCP, 2006, CANCER CELL, V10, P257, DOI 10.1016/j.ccr.2006.08.020
   Stewart JM, 2011, P NATL ACAD SCI USA, V108, P6468, DOI 10.1073/pnas.1005529108
   Sunayama J, 2011, STEM CELLS, V29, P1327, DOI 10.1002/stem.696
   Sustackova G, 2012, STEM CELLS DEV, V21, P710, DOI 10.1089/scd.2011.0085
   Trott J, 2012, MOL BIOSYST, V8, P744, DOI 10.1039/c1mb05398a
   Tsutsumi S, 2004, CLIN CANCER RES, V10, P7775, DOI 10.1158/1078-0432.CCR-04-1015
   Visvader JE, 2008, NAT REV CANCER, V8, P755, DOI 10.1038/nrc2499
   Wang ZW, 2009, CANCER RES, V69, P2400, DOI 10.1158/0008-5472.CAN-08-4312
   Wangpu XZ, 2015, ONCOTARGET, V6, P33893, DOI 10.18632/oncotarget.5294
   Weiner J.A., 2018, INT J MOL SCI, V19
   Wellner U, 2009, NAT CELL BIOL, V11, P1487, DOI 10.1038/ncb1998
   Ye X, 2015, NATURE, V525, P256, DOI 10.1038/nature14897
   Yeo SK, 2016, CANCER RES, V76, P3397, DOI 10.1158/0008-5472.CAN-15-2946
   Yokoyama A, 2019, NATURE, V565, P312, DOI 10.1038/s41586-018-0811-x
   Yu JY, 2018, CLIN CANCER RES, V24, P2148, DOI 10.1158/1078-0432.CCR-17-1932
NR 88
TC 8
Z9 8
U1 1
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1726-4901
EI 1728-7731
J9 J CHIN MED ASSOC
JI J. Chin. Med. Assoc.
PD NOV
PY 2019
VL 82
IS 11
BP 814
EP 818
DI 10.1097/JCMA.0000000000000186
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA KJ9NI
UT WOS:000512380700006
PM 31469690
OA hybrid
DA 2022-04-25
ER

PT J
AU Mei, HL
   Xiang, Y
   Mei, H
   Fang, B
   Wang, QG
   Cao, DD
   Hu, Y
   Guo, T
AF Mei, Huiling
   Xiang, Yu
   Mei, Heng
   Fang, Bin
   Wang, Qiuguo
   Cao, Dedong
   Hu, Yu
   Guo, Tao
TI Pterostilbene inhibits nutrient metabolism and induces apoptosis through
   AMPK activation in multiple myeloma cells
SO INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
LA English
DT Article
DE multiple myeloma; pterostilbene; AMPK-activated protein kinase; nutrient
   metabolism; apoptosis; autophagy
ID FATTY-ACID SYNTHASE; BREAST-CANCER CELLS; SIGNALING PATHWAY;
   PANCREATIC-CANCER; PROSTATE-CANCER; HEPATOCELLULAR-CARCINOMA;
   GLUCOSE-METABOLISM; ANTITUMOR-ACTIVITY; COLORECTAL-CANCER;
   ENERGY-METABOLISM
AB Multiple myeloma (MM) cells are characterized by an abnormal nutrient metabolism that is distinct from normal plasma cells. Pterostilbene (PTE), a bioactive component of blueberries, has been demonstrated to induce apoptosis in multiple types of cancer cell. The present study evaluated whether PTE treatment affected the survival of MM cells from a metabolic perspective, and the potential mechanisms of this. It was observed that the administration of PTE induced apoptosis, which was mediated by the increased activation of AMP-activated protein kinase (AMPK). Once activated, AMPK decreased the expression and/or activity of key lipo-genic enzymes, including fatty acid synthase and acetyl-CoA carboxylase. In addition, the activation of AMPK suppressed the downstream substrate, mechanistic target of rapamycin, which dephosphorylated eukaryotic initiation factor 4E-binding protein 1, leading to a general decrease in mRNA translation. Pre-treatment with the AMPK inhibitor compound C prior to PTE treatment compromised the anti-myeloma apoptosis effect, suggesting the critical role of AMPK in mediating PTE-induced cell toxicity. Consistent results were obtained in vivo. Finally, autophagy was adaptively upregulated subsequent to PTE treatment; the pro-apoptotic efficacy of PTE was potentiated once autophagic flux was inhibited by 3-methyladenine. Taken together, these data demonstrated that PTE exerts anti-tumor effects on MM cells via AMPK-induced nutrient suppression.
C1 [Mei, Huiling; Xiang, Yu; Mei, Heng; Fang, Bin; Wang, Qiuguo; Hu, Yu; Guo, Tao] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Inst Hematol, 1,277 Jiefang Ave, Wuhan 430022, Hubei, Peoples R China.
   [Mei, Huiling; Mei, Heng; Hu, Yu; Guo, Tao] Huazhong Univ Sci & Technol, Collaborat Innovat Ctr Hematol, Wuhan 430022, Hubei, Peoples R China.
   [Cao, Dedong] Wuhan Univ, Renmin Hosp, Dept Oncol, Wuhan 430060, Hubei, Peoples R China.
RP Hu, Y; Guo, T (corresponding author), Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Inst Hematol, 1,277 Jiefang Ave, Wuhan 430022, Hubei, Peoples R China.
EM dr_huyu@126.com; guotao1968@163.com
CR Agnelli L, 2007, BRIT J HAEMATOL, V136, P565, DOI 10.1111/j.1365-2141.2006.06467.x
   Besse A, 2018, LEUKEMIA, V32, P391, DOI 10.1038/leu.2017.212
   Bjarnadottir O, 2013, BREAST CANCER RES TR, V138, P499, DOI 10.1007/s10549-013-2473-6
   Cao DD, 2015, ONCOL REP, V33, P899, DOI 10.3892/or.2014.3635
   Cao DD, 2014, ONCOL REP, V31, P1205, DOI 10.3892/or.2014.2974
   Chang CH, 2017, INT J ONCOL, V50, P873, DOI 10.3892/ijo.2017.3866
   Chen GG, 2017, ONCOL REP, V38, P488, DOI 10.3892/or.2017.5675
   Chen RJ, 2012, J AGR FOOD CHEM, V60, P11533, DOI 10.1021/jf302778a
   Chim CS, 2018, LEUKEMIA, V32, P252, DOI 10.1038/leu.2017.329
   Dhar S, 2016, ONCOTARGET, V7, P18469, DOI 10.18632/oncotarget.7841
   Dimopoulos MA, 2015, NAT REV CLIN ONCOL, V12, P42, DOI 10.1038/nrclinonc.2014.200
   Dong GZ, 2015, PHYTOTHER RES, V29, P1605, DOI 10.1002/ptr.5442
   Drexler HG, 1999, LEUKEMIA, V13, P1601, DOI 10.1038/sj.leu.2401510
   Duan WX, 2017, CANCER LETT, V385, P225, DOI 10.1016/j.canlet.2016.10.019
   Estrela JM, 2013, CRIT REV CL LAB SCI, V50, P65, DOI 10.3109/10408363.2013.805182
   Farnoushi Y, 2011, BRIT J CANCER, V105, P1708, DOI 10.1038/bjc.2011.445
   Fernando Rodrigo Carlini, 2015, Genes Cancer, V6, P462
   Flaveny CA, 2015, CANCER CELL, V28, P42, DOI 10.1016/j.ccell.2015.05.007
   Garcia D, 2017, MOL CELL, V66, P789, DOI 10.1016/j.molcel.2017.05.032
   Gomez-Zorita S, 2014, J AGR FOOD CHEM, V62, P8371, DOI 10.1021/jf501318b
   Holcik M, 2005, NAT REV MOL CELL BIO, V6, P318, DOI 10.1038/nrm1618
   Inoki K, 2012, ANNU REV PHARMACOL, V52, P381, DOI 10.1146/annurev-pharmtox-010611-134537
   Jing K, 2011, AUTOPHAGY, V7, P1348, DOI 10.4161/auto.7.11.16658
   Kosuru R, 2017, LIFE SCI, V182, P112, DOI 10.1016/j.lfs.2017.06.015
   Kosuru R, 2016, EUR J PHARMACOL, V789, P229, DOI 10.1016/j.ejphar.2016.07.046
   Levy JMM, 2017, NAT REV CANCER, V17, P528, DOI 10.1038/nrc.2017.53
   Li L, 2016, J HEPATOL, V64, P333, DOI 10.1016/j.jhep.2015.10.004
   Lin L, 2012, INT J CANCER, V130, P1459, DOI 10.1002/ijc.26152
   Lin VCH, 2012, J AGR FOOD CHEM, V60, P6399, DOI 10.1021/jf301499e
   Liu YW, 2013, TOXICOLOGY, V304, P120, DOI 10.1016/j.tox.2012.12.018
   Lv S, 2016, ARCH VIROL, V161, P2807, DOI 10.1007/s00705-016-2924-6
   Ma JG, 2015, ONCOTARGET, V6, P20993, DOI 10.18632/oncotarget.3663
   Maiso P, 2015, CANCER RES, V75, P2071, DOI 10.1158/0008-5472.CAN-14-3400
   McCormack DE, 2012, J GASTROINTEST SURG, V16, P1136, DOI 10.1007/s11605-012-1869-7
   Medina EA, 2014, LEUKEMIA, V28, P2080, DOI 10.1038/leu.2014.112
   Mihaylova MM, 2011, NAT CELL BIOL, V13, P1016, DOI 10.1038/ncb2329
   Mohanti BK, 1996, INT J RADIAT ONCOL, V35, P103, DOI 10.1016/S0360-3016(96)85017-6
   Morotomi-Yano K, 2012, EXP CELL RES, V318, P1733, DOI 10.1016/j.yexcr.2012.04.016
   Moschetta M, 2014, BRIT J PHARMACOL, V171, P3801, DOI 10.1111/bph.12749
   Nagao K, 2017, J NUTR BIOCHEM, V43, P151, DOI 10.1016/j.jnutbio.2017.02.009
   Okawa Y, 2008, BRIT J HAEMATOL, V141, P659, DOI 10.1111/j.1365-2141.2008.07114.x
   Pandey PR, 2013, ONCOGENE, V32, P5111, DOI 10.1038/onc.2012.519
   PELLATDECEUNYNK C, 1995, BLOOD, V86, P4001, DOI 10.1182/blood.V86.10.4001.bloodjournal86104001
   Rajkumar SV, 2014, LANCET ONCOL, V15, pE538, DOI 10.1016/S1470-2045(14)70442-5
   Ravikumar B, 2010, PHYSIOL REV, V90, P1383, DOI 10.1152/physrev.00030.2009
   Riche DM, 2013, J TOXICOL-US, V2013, DOI 10.1155/2013/463595
   Shieh JM, 2013, J AGR FOOD CHEM, V61, P6366, DOI 10.1021/jf4012455
   Steinberg GR, 2009, PHYSIOL REV, V89, P1025, DOI 10.1152/physrev.00011.2008
   Svensson RU, 2016, NAT MED, V22, P1108, DOI 10.1038/nm.4181
   Wakimoto R, 2017, ANTICANCER RES, V37, P6153, DOI 10.21873/anticanres.12064
   Wang MD, 2016, HEPATOLOGY, V63, P1272, DOI 10.1002/hep.28415
   Wang P, 2018, BIOFACTORS, V44, P16, DOI 10.1002/biof.1410
   Wang Y, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0731-5
   Wang Y, 2013, HEPATOLOGY, V58, P995, DOI 10.1002/hep.26394
   Wawszczyk J, 2014, ACTA POL PHARM, V71, P1051
   Xie BQ, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17111927
   Yan H, 2015, LEUKEMIA, V29, P196, DOI 10.1038/leu.2014.135
   Yao Z, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.35
   Yu W, 2016, ONCOTARGET, V7, P86075, DOI 10.18632/oncotarget.13342
   Yu W, 2015, ONCOL REP, V33, P2086, DOI 10.3892/or.2015.3809
   Zadra G, 2014, EMBO MOL MED, V6, P519, DOI 10.1002/emmm.201302734
   Zaytseva YY, 2012, CANCER RES, V72, P1504, DOI 10.1158/0008-5472.CAN-11-4057
   Zhang L, 2013, J NUTR BIOCHEM, V24, P903, DOI 10.1016/j.jnutbio.2012.06.008
   Zismanov V, 2015, INT J ONCOL, V46, P860, DOI 10.3892/ijo.2014.2774
NR 64
TC 9
Z9 10
U1 4
U2 15
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1107-3756
EI 1791-244X
J9 INT J MOL MED
JI Int. J. Mol. Med.
PD NOV
PY 2018
VL 42
IS 5
BP 2676
EP 2688
DI 10.3892/ijmm.2018.3857
PG 13
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA GX4LA
UT WOS:000447702700032
PM 30226553
OA Green Published, hybrid, Green Submitted
DA 2022-04-25
ER

PT J
AU Yang, PM
   Liu, YL
   Lin, YC
   Shun, CT
   Wu, MS
   Chen, CC
AF Yang, Pei-Ming
   Liu, Yuan-Ling
   Lin, Yi-Chu
   Shun, Chia-Tung
   Wu, Ming-Shiang
   Chen, Ching-Chow
TI Inhibition of Autophagy Enhances Anticancer Effects of Atorvastatin in
   Digestive Malignancies
SO CANCER RESEARCH
LA English
DT Article
ID CISPLATIN-INDUCED APOPTOSIS; ACID-INDUCED APOPTOSIS; HISTONE
   DEACETYLASE-1; COMPLEX-FORMATION; KINASE INHIBITOR; CELL INVASION;
   CANCER-RISK; PROTEIN; PHOSPHORYLATION; STATINS
AB Preclinical and clinical studies have shown that statins, the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors with cholesterol-lowering properties, exhibited anticancer effects. However, the underlying mechanisms remain ill defined. In this study, we showed that atorvastatin could inhibit the growth of hepatocellular carcinoma (HCC) and colorectal carcinoma (CRC) cells via induction of apoptosis. Atorvastatin also induced autophagy that is a physiologic process involved in the turnover of intracellular organelles. Atorvastatin-induced autophagy was found to be inhibited by AMP-activated protein kinase (AMPK) small interfering RNA. Examination of HCC patients showed the positive correlation between AMPK activity and autophagic marker (beclin-1). Atorvastatin-induced AMPK activation could induce p21 expression, which was also positively correlated with beclin-1 expression in CRC patients. AMPK/p21 signaling caused endoplasmic reticulum (ER) stress response leading to the induction of autophagy. Inhibition of autophagy by an autophagic inhibitor bafilomycin A1 or genetic knockout of autophagy-related gene 5 enhanced atorvastatin-induced cytotoxicity and apoptosis. In summary, activation of AMPK by atorvastatin enhances p21 expression and ER stress response, leading to autophagy, which promotes survival of cancer cells. Combinations of atorvastatin with bafilomycin A1 provide a novel and promising strategy to improve the treatment of digestive malignancies. Cancer Res; 70(19); 7699-709. (C) 2010 AACR.
C1 [Yang, Pei-Ming; Liu, Yuan-Ling; Lin, Yi-Chu; Chen, Ching-Chow] Natl Taiwan Univ, Coll Med, Dept Pharmacol, Taipei 10018, Taiwan.
   [Shun, Chia-Tung] Natl Taiwan Univ Hosp, Dept Forens Med & Pathol, Taipei, Taiwan.
   [Wu, Ming-Shiang] Natl Taiwan Univ Hosp, Dept Internal Med, Div Gastroenterol, Taipei 100, Taiwan.
RP Chen, CC (corresponding author), Natl Taiwan Univ, Coll Med, Dept Pharmacol, 1 Jen Ai Rd,Sect 1, Taipei 10018, Taiwan.
EM chingchowchen@ntu.edu.tw
RI Shun, Chia-Tung/M-1400-2019; Yang, Pei-Ming/G-3763-2014
OI Yang, Pei-Ming/0000-0002-4004-2518; CHEN,
   CHING-CHOW/0000-0002-7810-0939; Wu, Ming-Shiang/0000-0002-1940-6428;
   SHUN, CHIA-TUNG/0000-0002-0468-4468
FU National Science Council of TaiwanMinistry of Science and Technology,
   Taiwan
FX National Science Council of Taiwan research grant.
CR Asada M, 1999, EMBO J, V18, P1223, DOI 10.1093/emboj/18.5.1223
   Baigent C, 2005, LANCET, V366, P1267, DOI 10.1016/S0140-6736(05)67394-1
   Bonovas S, 2006, J CLIN ONCOL, V24, P4808, DOI 10.1200/JCO.2006.06.3560
   Bonovas S, 2009, GASTROENTEROLOGY, V137, P740, DOI 10.1053/j.gastro.2009.02.088
   Cai R, 2001, BIOCHEM BIOPH RES CO, V283, P445, DOI 10.1006/bbrc.2001.4786
   Chan KKW, 2003, CLIN CANCER RES, V9, P10
   Coqueret O, 2003, TRENDS CELL BIOL, V13, P65, DOI 10.1016/S0962-8924(02)00043-0
   Crighton D, 2006, CELL, V126, P121, DOI 10.1016/j.cell.2006.05.034
   El-Serag HB, 2009, GASTROENTEROLOGY, V136, P1601, DOI 10.1053/j.gastro.2009.01.053
   Galasinski SC, 2002, J BIOL CHEM, V277, P19618, DOI 10.1074/jbc.M201174200
   GOUBIN F, 1995, ONCOGENE, V10, P2281
   Hardie DG, 1998, ANNU REV BIOCHEM, V67, P821, DOI 10.1146/annurev.biochem.67.1.821
   Imamura K, 2001, BIOCHEM BIOPH RES CO, V287, P562, DOI 10.1006/bbrc.2001.5627
   Jung SN, 2009, EXP CELL RES, V315, P2433, DOI 10.1016/j.yexcr.2009.05.018
   Kim HS, 2008, J BIOL CHEM, V283, P3731, DOI 10.1074/jbc.M704432200
   Kondo S, 1996, ONCOGENE, V13, P1279
   Kusama T, 2002, GASTROENTEROLOGY, V122, P308, DOI 10.1053/gast.2002.31093
   Leff T, 2003, BIOCHEM SOC T, V31, P224
   Lersch C, 2004, HEPATO-GASTROENTEROL, V51, P1099
   Lin YC, 2008, CANCER RES, V68, P2375, DOI 10.1158/0008-5472.CAN-07-5807
   Lin YC, 2006, CLIN CANCER RES, V12, P7165, DOI 10.1158/1078-0432.CCR-06-1393
   Maisonneuve P, 2005, NEW ENGL J MED, V353, P952
   Maiuri MC, 2009, CELL DEATH DIFFER, V16, P87, DOI 10.1038/cdd.2008.131
   Mathew R, 2007, NAT REV CANCER, V7, P961, DOI 10.1038/nrc2254
   Mcgee SL, 2008, FRONT BIOSCI-LANDMRK, V13, P3022, DOI 10.2741/2907
   Meijer AJ, 2004, BIOCHEM BIOPH RES CO, V313, P397, DOI 10.1016/j.bbrc.2003.07.012
   Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639
   Mizushima N, 2007, AUTOPHAGY, V3, P542, DOI 10.4161/auto.4600
   Paragh G, 2005, CANCER LETT, V222, P17, DOI 10.1016/j.canlet.2004.09.028
   Pflum MKH, 2001, J BIOL CHEM, V276, P47733, DOI 10.1074/jbc.M105590200
   Qiao L, 2002, HEPATOLOGY, V36, P39, DOI 10.1053/jhep.2002.33899
   Sassano A, 2008, CANCER LETT, V260, P11, DOI 10.1016/j.canlet.2007.11.036
   SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149
   Suzuki A, 1999, MOL CELL BIOL, V19, P3842
   Tanida I, 2004, INT J BIOCHEM CELL B, V36, P2503, DOI 10.1016/j.biocel.2004.05.009
   Tasdemir E, 2008, NAT CELL BIOL, V10, P676, DOI 10.1038/ncb1730
   Vousden KH, 2007, NAT REV MOL CELL BIO, V8, P275, DOI 10.1038/nrm2147
   Wu J, 2006, CELL DEATH DIFFER, V13, P374, DOI 10.1038/sj.cdd.4401840
   Yorimitsu T, 2005, CELL DEATH DIFFER, V12, P1542, DOI 10.1038/sj.cdd.4401765
   Zhang G, 2008, J BIOL CHEM, V283, P24343, DOI 10.1074/jbc.M803444200
   Zhang KZ, 2008, NATURE, V454, P455, DOI 10.1038/nature07203
   Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032
NR 42
TC 112
Z9 114
U1 4
U2 19
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD OCT 1
PY 2010
VL 70
IS 19
BP 7699
EP 7709
DI 10.1158/0008-5472.CAN-10-1626
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 660MM
UT WOS:000282647700034
PM 20876807
OA Bronze
DA 2022-04-25
ER

PT J
AU Elshaer, M
   Chen, YR
   Wang, XJ
   Tang, XW
AF Elshaer, Mohamed
   Chen, Yeru
   Wang, Xiu Jun
   Tang, Xiuwen
TI Resveratrol: An overview of its anti-cancer mechanisms
SO LIFE SCIENCES
LA English
DT Review
DE Resveratrol; Cancer metabolism; Nrf2; NLRP3; MAPK; NFkB; MKP-1;
   Autophagy
ID EPITHELIAL-MESENCHYMAL TRANSITION; CHEMOPREVENTIVE AGENT RESVERATROL;
   GROWTH-FACTOR EXPRESSION; SPINAL-CORD-INJURY; FACTOR-KAPPA-B;
   CANCER-CELLS; COLORECTAL-CANCER; INDUCED APOPTOSIS; TUMOR PROGRESSION;
   SIGNALING PATHWAY
AB Cancer is one of the leading causes of death worldwide. Chemotherapy and radiotherapy are the conventional primary treatments for cancer patients. However, most of cancer cells develop resistance to both chemotherapy and radiotherapy after a period of treatment, besides their lethal side-effects. This motivated investigators to seek more effective alternatives with fewer side-effects. In the last few years, resveratrol, a natural polyphenolic phytoalexin, has attracted much attention due to its wide biological effects. In this concise review, we highlight the role of resveratrol in the prevention and therapy of cancer with particular focus on colorectal and skin cancer. Also, we discuss the molecular mechanisms underlying its chemopreventive and therapeutic activity. Finally, we highlight the problems associated with the clinical application of resveratrol and how attempts have been made to overcome these drawbacks.
C1 [Elshaer, Mohamed; Tang, Xiuwen] Zhejiang Univ, Sch Med, Dept Biochem & Genet, Hangzhou 310058, Zhejiang, Peoples R China.
   [Chen, Yeru; Wang, Xiu Jun] Zhejiang Univ, Sch Med, Dept Pharmacol, Hangzhou 310058, Zhejiang, Peoples R China.
RP Tang, XW (corresponding author), Zhejiang Univ, Sch Med, Dept Biochem & Genet, Hangzhou 310058, Zhejiang, Peoples R China.
EM xiuwentang@zju.edu.cn
OI tang, xiuwen/0000-0002-6601-1234
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [31571476, 91643110, 31470752]; Science
   Technology Department of Zhejiang Provence [2017C33082]
FX This work was supported by the National Natural Science Foundation of
   China (31571476, 91643110 and 31470752), Science Technology Department
   of Zhejiang Provence (2017C33082).
CR Afaq F, 2003, TOXICOL APPL PHARM, V186, P28, DOI 10.1016/S0041-008X(02)00014-5
   Andrews CS, 2016, SCI REP-UK, V6, DOI 10.1038/srep34445
   Aziz S. W., 2017, PROTECTIVE MOL MECH
   Banerjee S, 2002, CANCER RES, V62, P4945
   Bao LJ, 2015, MOL MED REP, V11, P91, DOI 10.3892/mmr.2014.2671
   Bhat KPL, 2001, CANCER RES, V61, P7456
   Biagi M, 2015, LIFE SCI, V131, P19, DOI 10.1016/j.lfs.2015.02.024
   Bowers JL, 2000, ENDOCRINOLOGY, V141, P3657, DOI 10.1210/en.141.10.3657
   Brown VA, 2010, CANCER RES, V70, P9003, DOI 10.1158/0008-5472.CAN-10-2364
   Buhrmann C, 2016, NUTRIENTS, V8, DOI 10.3390/nu8030145
   Caltagirone S, 2000, INT J CANCER, V87, P595, DOI 10.1002/1097-0215(20000815)87:4&lt;595::AID-IJC21&gt;3.0.CO;2-5
   Cao ZX, 2004, CLIN CANCER RES, V10, P5253, DOI 10.1158/1078-0432.CCR-03-0588
   Chang CH, 2017, INT J ONCOL, V50, P873, DOI 10.3892/ijo.2017.3866
   Chen Jie, 2009, Zhonghua Zhongliu Zazhi, V31, P15, DOI 10.3760/cma.j.issn.0253-3766.2009.01.004
   Cheng David, 2016, Current Opinion in Toxicology, V1, P134, DOI 10.1016/j.cotox.2016.10.008
   Choi J., 2010, BIOORG MED CHEM LETT, V20
   Chow S.-E. R., 2010, RESVERATROL INDUCED, P872
   Cianciulli A, 2012, TOXICOL IN VITRO, V26, P1122, DOI 10.1016/j.tiv.2012.06.015
   DeBerardinis RJ, 2016, SCI ADV, V2, DOI 10.1126/sciadv.1600200
   Delmas D, 2003, J BIOL CHEM, V278, P41482, DOI 10.1074/jbc.M304896200
   Dorrie J, 2001, CANCER RES, V61, P4731
   Du C, 2017, J ASIAN NAT PROD RES, V19, P890, DOI 10.1080/10286020.2016.1250747
   Duan YC, 2017, EUR J MED CHEM, V126, P246, DOI 10.1016/j.ejmech.2016.11.035
   Dutta D, 2014, FREE RADICAL BIO MED, V74, P252, DOI 10.1016/j.freeradbiomed.2014.06.011
   Fabbrocini G, 2010, EXP DERMATOL, V19, P895, DOI 10.1111/j.1600-0625.2010.01117.x
   Ferrer MD, 2019, CURR MED CHEM, V26, P3225, DOI 10.2174/0929867325666180514112124
   Fuggetta MP, 2006, J EXP CLIN CANC RES, V25, P189
   Fujita Y, 2012, INVEST NEW DRUG, V30, P1878, DOI 10.1007/s10637-011-9749-7
   Fulda S, 2004, CANCER RES, V64, P337, DOI 10.1158/0008-5472.CAN-03-1656
   Gambhir S, 2015, WORLD J GASTROENTERO, V21, P3174, DOI 10.3748/wjg.v21.i11.3174
   Ge J, 2013, BIOMED ENVIRON SCI, V26, P902, DOI 10.3967/bes2013.019
   Gonzalez-Pons M., 2015, COLORECTAL CANC BIOM, V2015
   Gougelet A, 2007, J STEROID BIOCHEM, V104, P110, DOI 10.1016/j.jsbmb.2007.03.002
   Habibie, 2014, INT J ONCOL, V45, P895, DOI 10.3892/ijo.2014.2480
   Harper CE, 2007, CARCINOGENESIS, V28, P1946, DOI 10.1093/carcin/bgm144
   Harper CE, 2009, PROSTATE, V69, P1668, DOI 10.1002/pros.21017
   Hashemzaei M, 2017, EUR J PHARMACOL, V802, P44, DOI 10.1016/j.ejphar.2017.02.038
   He Q, 2017, INT IMMUNOPHARMACOL, V50, P208, DOI 10.1016/j.intimp.2017.06.029
   He X, 2015, CURR DRUG METAB, V16, P850, DOI 10.2174/138920021610151210164501
   Howells LM, 2011, CANCER PREV RES, V4, P1419, DOI 10.1158/1940-6207.CAPR-11-0148
   Hu JQ, 2017, AM J TRANSL RES, V9, P4607
   Hu YQ, 2016, EUR REV MED PHARMACO, V20, P2935
   Huang CS, 1999, CARCINOGENESIS, V20, P237, DOI 10.1093/carcin/20.2.237
   Hung CM, 2017, J AGR FOOD CHEM, V65, P11179, DOI 10.1021/acs.jafc.7b02358
   Jacob P. Jaismy, EUR J PHARM SCI
   Jang MS, 1997, SCIENCE, V275, P218, DOI 10.1126/science.275.5297.218
   Jara P, 2018, MOLECULES, V23, DOI 10.3390/molecules23010014
   Ji Q, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1119-y
   Ji Q, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078700
   Jia M, 2015, BEST PRACT RES CL EN, V29, P557, DOI 10.1016/j.beem.2015.04.008
   Joe AK, 2002, CLIN CANCER RES, V8, P893
   Johnson JJ, 2011, MOL NUTR FOOD RES, V55, P1169, DOI 10.1002/mnfr.201100117
   Kalra N, 2008, LIFE SCI, V82, P348, DOI 10.1016/j.lfs.2007.11.006
   Kasiotis KM, 2013, FOOD CHEM TOXICOL, V61, P112, DOI 10.1016/j.fct.2013.03.038
   Katzke VA, 2015, CANCER J, V21, P104, DOI 10.1097/PPO.0000000000000101
   Kim CW, 2016, PHYTOMEDICINE, V23, P1787, DOI 10.1016/j.phymed.2016.10.016
   Kim DS, 2015, INT ENDOD J, V48, P220, DOI 10.1111/iej.12303
   Kobayashi E. H., 2016, NRF2 SUPPRESSES MACR
   Koppenol WH, 2011, NAT REV CANCER, V11, P325, DOI 10.1038/nrc3038
   Lang FF, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129196
   Li HT, 2009, BIOCHEM PHARMACOL, V78, P1224, DOI 10.1016/j.bcp.2009.06.109
   Li JP, 2014, MOL MED REP, V10, P1717, DOI 10.3892/mmr.2014.2417
   Li W, 2016, EXP CELL RES, V349, P320, DOI 10.1016/j.yexcr.2016.11.002
   Li W, 2013, CURR MED CHEM, V20, P4185
   Li ZG, 2002, CARCINOGENESIS, V23, P1531, DOI 10.1093/carcin/23.9.1531
   Lin HY, 2008, J CELL BIOCHEM, V104, P2131, DOI 10.1002/jcb.21772
   Lin HY, 2011, ANN NY ACAD SCI, V1215, P79, DOI 10.1111/j.1749-6632.2010.05846.x
   Linares MA, 2015, PRIMARY CARE, V42, P645, DOI 10.1016/j.pop.2015.07.006
   Liu Y, 2018, J CELL BIOCHEM, V119, P6162, DOI 10.1002/jcb.26822
   Liu ZL, 2017, ONCOL LETT, V14, P2239, DOI 10.3892/ol.2017.6458
   Liu ZH, 2012, ONCOL LETT, V4, P837, DOI 10.3892/ol.2012.824
   Lu JR, 2015, CANCER LETT, V356, P156, DOI 10.1016/j.canlet.2014.04.001
   Mahyar-Roemer M, 2002, BMC CANCER, V2, DOI 10.1186/1471-2407-2-27
   Malhotra A, 2011, EUR J CANCER PREV, V20, P411, DOI 10.1097/CEJ.0b013e3283481d71
   Marimuthu P, 2018, J BIOMOL STRUCT DYN, V36, P1637, DOI 10.1080/07391102.2017.1331863
   Mathew R, 2007, NAT REV CANCER, V7, P961, DOI 10.1038/nrc2254
   Monika, 2017, CURR DRUG DELIV, V14, P364, DOI [10.2174/1567201814666161109115735, 10.1174/1567101814666161109115735]
   Mukherjee S, 2017, ONCOTARGET, V8, P60904, DOI 10.18632/oncotarget.16648
   Namani A., 2017, REV COMPOUNDS PREVEN
   Namani A, 2014, BBA-MOL CELL RES, V1843, P1875, DOI 10.1016/j.bbamcr.2014.05.003
   Nguyen Anthony V, 2009, Cancer Manag Res, V1, P25
   Orsini F, 2016, ARCH PHARM, V349, P414, DOI 10.1002/ardp.201600022
   Parekh P, 2011, EXP TOXICOL PATHOL, V63, P167, DOI 10.1016/j.etp.2009.11.005
   Patel KR, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005870
   Patel KR, 2010, CANCER RES, V70, P7392, DOI 10.1158/0008-5472.CAN-10-2027
   Piver B, 2001, TOXICOL LETT, V125, P83, DOI 10.1016/S0378-4274(01)00418-0
   Pozo-Guisado E, 2002, BIOCHEM PHARMACOL, V64, P1375, DOI 10.1016/S0006-2952(02)01296-0
   Qin N, 2017, J PHARMACOL SCI, V134, P166, DOI 10.1016/j.jphs.2017.06.002
   Rauf A, 2018, CRIT REV FOOD SCI, V58, P1428, DOI 10.1080/10408398.2016.1263597
   Ravikiran M., 2017, COMB CHEM HIGH T SCR, V20, P376
   Reagan-Shaw S, 2004, ONCOGENE, V23, P5151, DOI 10.1038/sj.onc.1207666
   Revel A, 2003, J APPL TOXICOL, V23, P255, DOI 10.1002/jat.916
   Saud SM, 2014, CARCINOGENESIS, V35, P2778, DOI 10.1093/carcin/bgu209
   Saunier E, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-07006-0
   Schneider Y, 2001, NUTR CANCER, V39, P102, DOI 10.1207/S15327914nc391_14
   Schneider Y, 2000, CANCER LETT, V158, P85, DOI 10.1016/S0304-3835(00)00511-5
   Senthilkumar H. Anandhi, 2018, PHYTOESTROGENS CURRE
   Shao BZ, 2015, FRONT PHARMACOL, V6, DOI 10.3389/fphar.2015.00262
   She QB, 2001, CANCER RES, V61, P1604
   Shen JL, 2016, CANCER MED-US, V5, P2061, DOI 10.1002/cam4.772
   Sheth S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051655
   Singh B, 2014, CARCINOGENESIS, V35, P1872, DOI 10.1093/carcin/bgu120
   Soleas GJ, 2002, CLIN BIOCHEM, V35, P119, DOI 10.1016/S0009-9120(02)00275-8
   Soleas GJ, 2001, METHOD ENZYMOL, V335, P145
   Taguchi A, 2016, AM J REPROD IMMUNOL, V75, P486, DOI 10.1111/aji.12489
   Tak JK, 2012, BMB REP, V45, P242, DOI 10.5483/BMBRep.2012.45.4.242
   Takashina M, 2017, INT J ONCOL, V50, P787, DOI 10.3892/ijo.2017.3859
   Tamaki N, 2014, FREE RADICAL BIO MED, V75, P222, DOI 10.1016/j.freeradbiomed.2014.07.034
   Tessitore L, 2000, CARCINOGENESIS, V21, P1619, DOI 10.1093/carcin/21.8.1619
   Truong VL, 2018, BIOFACTORS, V44, P36, DOI 10.1002/biof.1399
   Urbaniak A, 2017, BIOORG MED CHEM LETT, V27, P2766, DOI 10.1016/j.bmcl.2017.04.066
   Valdameri G, 2012, ACS CHEM BIOL, V7, P321, DOI 10.1021/cb200435y
   Vazquez A, 2016, J CELL SCI, V129, P3367, DOI 10.1242/jcs.181016
   Wang P, 2018, BIOFACTORS, V44, P16, DOI 10.1002/biof.1410
   Wang S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170502
   Wang TTY, 2008, CARCINOGENESIS, V29, P2001, DOI 10.1093/carcin/bgn131
   Wang WR, 2017, CELL PHYSIOL BIOCHEM, V41, P569, DOI 10.1159/000457878
   Wang XQ, 2015, CELL BIOCHEM BIOPHYS, V73, P527, DOI 10.1007/s12013-015-0696-3
   Wieder T, 2001, LEUKEMIA, V15, P1735, DOI 10.1038/sj.leu.2402284
   Willis RE, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17091552
   Yamamoto M, 2018, PHYSIOL REV, V98, P1169, DOI 10.1152/physrev.00023.2017
   Yan B., 2018, RESVERATROL INHIBITS, V2018
   Yousef M., 2017, EFFECTS RESVERATROL, V9
   Yu C, 2003, RAPID COMMUN MASS SP, V17, P307, DOI 10.1002/rcm.918
   Zahner G, 2002, J BIOL CHEM, V277, P9763, DOI 10.1074/jbc.M106307200
   Zhang J, 2013, BIOCHEM PHARMACOL, V86, P317, DOI 10.1016/j.bcp.2013.05.003
   Zhang XS, 2017, FRONT NEUROSCI-SWITZ, V11, DOI 10.3389/fnins.2017.00611
   Zhao HS, 2017, NEUROSCIENCE, V348, P241, DOI 10.1016/j.neuroscience.2017.02.027
   Zhao Y, 2017, BIOMED PHARMACOTHER, V91, P49, DOI 10.1016/j.biopha.2017.04.066
   Zhao YG, 2018, REDOX BIOL, V14, P609, DOI 10.1016/j.redox.2017.11.007
   Zhou CX, 2014, MOL MED REP, V9, P1467, DOI 10.3892/mmr.2014.1950
   Zielinska-Przyjemska M, 2017, TOXICOL IN VITRO, V43, P69, DOI 10.1016/j.tiv.2017.06.004
NR 132
TC 91
Z9 95
U1 6
U2 39
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0024-3205
EI 1879-0631
J9 LIFE SCI
JI Life Sci.
PD AUG 15
PY 2018
VL 207
BP 340
EP 349
DI 10.1016/j.lfs.2018.06.028
PG 10
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA GO3GG
UT WOS:000439876800039
PM 29959028
DA 2022-04-25
ER

PT J
AU Hu, J
   Ding, XL
   Tian, SB
   Chu, YA
   Liu, ZB
   Li, YQ
   Li, XQ
   Wang, GB
   Wang, L
   Wang, Z
AF Hu, Jia
   Ding, Xueliang
   Tian, Shaobo
   Chu, Yanan
   Liu, Zhibo
   Li, Yuqin
   Li, Xiaoqiong
   Wang, Guobin
   Wang, Lin
   Wang, Zheng
TI TRIM39 deficiency inhibits tumor progression and autophagic flux in
   colorectal cancer via suppressing the activity of Rab7
SO CELL DEATH & DISEASE
LA English
DT Article
AB The biological function of TRIM39, a member of TRIM family, remains largely unexplored in cancer, especially in colorectal cancer (CRC). In this study, we show that TRIM39 is upregulated in tumor tissues compared to adjacent normal tissues and associated with poor prognosis in CRC. Functional studies demonstrate that TRIM39 deficiency restrains CRC progression in vitro and in vivo. Our results further find that TRIM39 is a positive regulator of autophagosome-lysosome fusion. Mechanistically, TRIM39 interacts with Rab7 and promotes its activity via inhibiting its ubiquitination at lysine 191 residue. Depletion of TRIM39 inhibits CRC progression and autophagic flux in a Rab7 activity-dependent manner. Moreover, TRIM39 deficiency suppresses CRC progression through inhibiting autophagic degradation of p53. Thus, our findings uncover the roles as well as the relevant mechanisms of TRIM39 in CRC and establish a functional relationship between autophagy and CRC progression, which may provide promising approaches for the treatment of CRC.
C1 [Hu, Jia; Ding, Xueliang; Tian, Shaobo; Chu, Yanan; Liu, Zhibo; Li, Yuqin; Li, Xiaoqiong; Wang, Lin; Wang, Zheng] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Res Ctr Tissue Engn & Regenerat Med, Wuhan 430022, Peoples R China.
   [Wang, Guobin; Wang, Zheng] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Dept Gastrointestinal Surg, Wuhan 430022, Peoples R China.
   [Wang, Lin] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Dept Clin Lab, Wuhan 430022, Peoples R China.
RP Wang, L; Wang, Z (corresponding author), Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Res Ctr Tissue Engn & Regenerat Med, Wuhan 430022, Peoples R China.; Wang, GB; Wang, Z (corresponding author), Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Dept Gastrointestinal Surg, Wuhan 430022, Peoples R China.
EM wgb@hust.edu.cn; lin_wang@hust.edu.cn; zhengwang@hust.edu.cn
FU Natural Science Foundation Program of China Programs [81472740,
   31701202, 81572866, 81773104]; Frontier Exploration Program of Huazhong
   University of Science and Technology [2015TS153]; Integrated Innovative
   Team for Major Human Diseases Program of Tongji Medical College of HUST;
   Academic Medical Doctor Supporting Program of Tongji Medical College of
   HUST
FX This work was supported by the Natural Science Foundation Program of
   China Programs (81472740, 31701202, 81572866, and 81773104), the
   Frontier Exploration Program of Huazhong University of Science and
   Technology (2015TS153), the Integrated Innovative Team for Major Human
   Diseases Program of Tongji Medical College of HUST, and the Academic
   Medical Doctor Supporting Program of Tongji Medical College of HUST.
CR Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
   Brix K, 2008, BIOCHIMIE, V90, P194, DOI 10.1016/j.biochi.2007.07.024
   Cantalupo G, 2001, EMBO J, V20, P683, DOI 10.1093/emboj/20.4.683
   Chen WL, 2018, MED SCI MONITOR, V24, P8033, DOI 10.12659/MSM.911142
   Devenport SN, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8111349
   Geng B, 2019, J CELL MOL MED, V23, P1458, DOI 10.1111/jcmm.14052
   Guerra F, 2016, CELLS-BASEL, V5, DOI 10.3390/cells5030034
   Guo HL, 2017, ONCOTARGET, V8, P61107, DOI 10.18632/oncotarget.17864
   Gutierrez MG, 2004, J CELL SCI, V117, P2687, DOI 10.1242/jcs.01114
   Hatakeyama S, 2017, TRENDS BIOCHEM SCI, V42, P297, DOI 10.1016/j.tibs.2017.01.002
   He CC, 2009, ANNU REV GENET, V43, P67, DOI 10.1146/annurev-genet-102808-114910
   Jager S, 2004, J CELL SCI, V117, P4837, DOI 10.1242/jcs.01370
   Jena KK, 2018, EMBO J, V37, DOI 10.15252/embj.201798358
   Jorissen RN, 2009, CLIN CANCER RES, V15, P7642, DOI 10.1158/1078-0432.CCR-09-1431
   Ju JS, 2009, AUTOPHAGY, V5, P511, DOI 10.4161/auto.5.4.7761
   Kim W, 2011, MOL CELL, V44, P325, DOI 10.1016/j.molcel.2011.08.025
   Kimura S, 2007, AUTOPHAGY, V3, P452, DOI 10.4161/auto.4451
   Kinsey C, 2014, CELL REP, V7, P1143, DOI 10.1016/j.celrep.2014.03.061
   Klionsky DJ, 2012, AUTOPHAGY, V8, P445, DOI 10.4161/auto.19496
   Koveitypour Z, 2019, CELL BIOSCI, V9, DOI 10.1186/s13578-019-0361-4
   Lee SS, 2009, EXP CELL RES, V315, P1313, DOI 10.1016/j.yexcr.2008.11.021
   Liang CY, 2008, NAT CELL BIOL, V10, P776, DOI 10.1038/ncb1740
   Liang Q, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1143-x
   Liu J, 2019, CANCER CELL INT, V19, DOI 10.1186/s12935-019-1054-0
   Liu M, 2018, ONCOL REP, V40, P1251, DOI 10.3892/or.2018.6525
   Ma YY, 2016, LAB INVEST, V96, P37, DOI 10.1038/labinvest.2015.132
   Mandell MA, 2014, DEV CELL, V30, P394, DOI 10.1016/j.devcel.2014.06.013
   Margiotta A, 2017, BBA-MOL CELL RES, V1864, P367, DOI 10.1016/j.bbamcr.2016.11.020
   McAfee Q, 2012, P NATL ACAD SCI USA, V109, P8253, DOI 10.1073/pnas.1118193109
   Modica Graziana, 2020, Small GTPases, V11, P167, DOI 10.1080/21541248.2017.1387686
   Muller Matthias P, 2018, Small GTPases, V9, P5, DOI 10.1080/21541248.2016.1276999
   Pan XF, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1660-8
   Rak A, 2003, SCIENCE, V302, P646, DOI 10.1126/science.1087761
   Ravikumar B, 2002, HUM MOL GENET, V11, P1107, DOI 10.1093/hmg/11.9.1107
   Sapmaz A, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09437-x
   Sasaki K, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-370
   Seabra MC, 2004, CURR OPIN CELL BIOL, V16, P451, DOI 10.1016/j.ceb.2004.06.014
   Sivars U, 2003, NATURE, V425, P856, DOI 10.1038/nature02057
   Song PP, 2016, J NEUROSCI, V36, P2425, DOI 10.1523/JNEUROSCI.2569-15.2016
   Steffan JJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087882
   Su HB, 2011, CIRCULATION, V124, P2117, DOI 10.1161/CIRCULATIONAHA.111.048934
   Sun Y, 2017, ONCOL REP, V38, P43, DOI 10.3892/or.2017.5654
   Suzuki M, 2016, CELL MOL LIFE SCI, V73, P1085, DOI 10.1007/s00018-015-2040-x
   Tan P, 2018, PLOS BIOL, V16, DOI 10.1371/journal.pbio.3000051
   Varshavsky A, 2017, ANNU REV BIOCHEM, V86, P123, DOI 10.1146/annurev-biochem-061516-044859
   Wagner SA, 2011, MOL CELL PROTEOMICS, V10, DOI 10.1074/mcp.M111.013284
   Wang TL, 2012, J CELL PHYSIOL, V227, P2788, DOI 10.1002/jcp.23023
   Wang W, 2017, P NATL ACAD SCI USA, V114, P8366, DOI 10.1073/pnas.1701289114
   Watanabe M, 2017, J BIOCHEM, V161, P135, DOI 10.1093/jb/mvw087
   Wiersma VR, 2015, AUTOPHAGY, V11, P1373, DOI 10.1080/15548627.2015.1063767
   Williams KC, 2011, J BIOL CHEM, V286, P43405, DOI 10.1074/jbc.M111.297069
   Wu MS, 2005, EMBO J, V24, P1491, DOI 10.1038/sj.emboj.7600643
   Zhang L, 2012, P NATL ACAD SCI USA, V109, P20937, DOI 10.1073/pnas.1214156110
   Zhang LG, 2012, P NATL ACAD SCI USA, V109, P20931, DOI 10.1073/pnas.1212047110
   Zhang S, 2019, AUTOPHAGY, V16, P1
   Zhao YG, 2019, J CELL BIOL, V218, P757, DOI 10.1083/jcb.201810099
   Zheng YZ, 2009, CANCER INVEST, V27, P286, DOI 10.1080/07357900802427927
   Zoratto F, 2014, TUMOR BIOL, V35, P6195, DOI 10.1007/s13277-014-1845-9
NR 58
TC 3
Z9 3
U1 5
U2 8
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 2041-4889
J9 CELL DEATH DIS
JI Cell Death Dis.
PD APR 12
PY 2021
VL 12
IS 4
AR 391
DI 10.1038/s41419-021-03670-3
PG 18
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA RM9CZ
UT WOS:000639954300005
PM 33846303
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Sanchez-Martin, V
   Schneider, DA
   Ortiz-Gonzalez, M
   Soriano-Lerma, A
   Linde-Rodriguez, A
   Perez-Carrasco, V
   Gutierrez-Fernandez, J
   Cuadros, M
   Gonzalez, C
   Soriano, M
   Garcia-Salcedo, JA
AF Sanchez-Martin, Victoria
   Schneider, David A.
   Ortiz-Gonzalez, Matilde
   Soriano-Lerma, Ana
   Linde-Rodriguez, Angel
   Perez-Carrasco, Virginia
   Gutierrez-Fernandez, Jose
   Cuadros, Marta
   Gonzalez, Carlos
   Soriano, Miguel
   Garcia-Salcedo, Jose A.
TI Targeting ribosomal G-quadruplexes with naphthalene-diimides as RNA
   polymerase I inhibitors for colorectal cancer treatment
SO CELL CHEMICAL BIOLOGY
LA English
DT Article
ID TRANSCRIPTION; BINDING; VISUALIZATION; TRANSPORTERS; VITRO
AB Guanine quadruplexes (G4s) are non-canonical nucleic acid structures commonly found in regulatory genomic regions. G4 targeting has emerged as a therapeutic approach in cancer. We have screened naphthalene-diimides (NDIs), a class of G4 ligands, in a cellular model of colorectal cancer (CRC). Here, we identify the leading compound T5 with a potent and selective inhibition of cell growth by high-affinity binding to G4s in ribosomal DNA, impairing RNA polymerase I (Pol I) elongation. Consequently, T5 induces a rapid inhibition of Pol I transcription, nucleolus disruption, proteasome-dependent Pol I catalytic subunit A degradation and autophagy. Moreover, we attribute the higher selectivity of carbohydrate-conjugated T5 for tumoral cells to its preferential uptake through the overexpressed glucose transporter 1. Finally, we succinctly demonstrate that T5 could be explored as a therapeutic agent in a patient cohort with CRC. Therefore, we report a mode of action for these NDIs involving ribosomal G4 targeting.
C1 [Sanchez-Martin, Victoria; Ortiz-Gonzalez, Matilde; Soriano-Lerma, Ana; Linde-Rodriguez, Angel; Perez-Carrasco, Virginia; Cuadros, Marta; Soriano, Miguel; Garcia-Salcedo, Jose A.] Univ Granada, Pfizer, Andalusian Reg Govt, GENYO Ctr Genom & Oncol Res, Granada 18016, Spain.
   [Sanchez-Martin, Victoria; Linde-Rodriguez, Angel; Perez-Carrasco, Virginia; Gutierrez-Fernandez, Jose; Garcia-Salcedo, Jose A.] Univ Hosp Virgen de las Nieves, Biosanitary Res Inst IBS Granada, Microbiol Unit, Granada 18014, Spain.
   [Sanchez-Martin, Victoria; Cuadros, Marta] Univ Granada, Dept Biochem Mol Biol & Immunol 3, Granada 18016, Spain.
   [Schneider, David A.] Univ Alabama Birmingham, Dept Biochem & Mol Genet, Birmingham, AL 35294 USA.
   [Ortiz-Gonzalez, Matilde; Soriano, Miguel] Univ Almeria, Ctr Intens Mediterranean Agrosyst & Agrifood Biot, Almeria 04001, Spain.
   [Soriano-Lerma, Ana] Univ Granada, Dept Physiol, Granada 18011, Spain.
   [Gutierrez-Fernandez, Jose] Univ Granada, Dept Microbiol, Granada 18011, Spain.
   [Gonzalez, Carlos] CSIC, Inst Quim Fis Rocasolano, Madrid 28006, Spain.
RP Garcia-Salcedo, JA (corresponding author), Univ Granada, Pfizer, Andalusian Reg Govt, GENYO Ctr Genom & Oncol Res, Granada 18016, Spain.; Garcia-Salcedo, JA (corresponding author), Univ Hosp Virgen de las Nieves, Biosanitary Res Inst IBS Granada, Microbiol Unit, Granada 18014, Spain.
EM jags@genyo.es
RI Soriano, Miguel/L-9532-2014; Gonzalez, Carlos/A-4734-2013
OI Soriano, Miguel/0000-0002-1838-3615; Gonzalez,
   Carlos/0000-0001-8796-1282; Schneider, David/0000-0003-0635-5091
FU European CommissionEuropean CommissionEuropean Commission Joint Research
   Centre; National Institutes of HealthUnited States Department of Health
   & Human ServicesNational Institutes of Health (NIH) - USA [GM084946];
   Government of SpainSpanish Government [FPU16/05822, FPU17/05413];
   University of Almeria
FX We thank Juan Carlos Morales' laboratory (IPLN-CSIC, Granada, Spain) for
   kindly supplying GLUT inhibitors and NDI derivatives. We also thank
   Maria Jose Serrano's laboratory (Genyo, Granada, Spain) for supplying
   HCT116 and HT29 cell lines, and Pedro Real's group (Genyo, Granada,
   Spain) for providing us with MG132 reagent. We thank ``Manuel Rico'' NMR
   laboratory (LMR), a node of the Spanish Large-Scale National Facility
   (ICTS R-LRB) for performing NMR experiments. Finally, we gratefully
   acknowledge Javier Oliver (IPLN-CSIC, Granada, Spain) for supplying LC3
   antibody and his valuable assistance. This work was supported by the
   European Commission (TARBRAINFECT to J.A.G.-S.) and the National
   Institutes of Health (GM084946 to D.A.S.). The Government of Spain
   granted with PhD fellowships FPU16/05822 to V.S.-M. and FPU17/05413 to
   A.S.-L. The University of Almeria granted with PhD fellowship to M.O.-G.
   Funding for open access charge: European Commission.
CR Ahmed AA, 2020, ACS MED CHEM LETT, V11, P1634, DOI 10.1021/acsmedchemlett.0c00317
   Arevalo-Ruiz M, 2017, CHEM-EUR J, V23, P2157, DOI 10.1002/chem.201604886
   Balasubramanian S, 2011, NAT REV DRUG DISCOV, V10, P261, DOI 10.1038/nrd3428
   Bedwell GJ, 2012, GENE, V492, P94, DOI 10.1016/j.gene.2011.10.049
   Biffi G, 2013, NAT CHEM, V5, P182, DOI [10.1038/NCHEM.1548, 10.1038/nchem.1548]
   Boisvert FM, 2012, MOL CELL PROTEOMICS, V11, DOI 10.1074/mcp.M111.011429
   Chambers VS, 2015, NAT BIOTECHNOL, V33, P877, DOI 10.1038/nbt.3295
   Cuenca F, 2008, BIOORG MED CHEM LETT, V18, P1668, DOI 10.1016/j.bmcl.2008.01.050
   de Wit M, 2014, J PROTEOMICS, V99, P26, DOI 10.1016/j.jprot.2014.01.001
   Dekker E, 2019, LANCET, V394, P1467, DOI 10.1016/S0140-6736(19)32319-0
   Drygin D, 2011, CANCER RES, V71, P1418, DOI 10.1158/0008-5472.CAN-10-1728
   Drygin D, 2010, ANNU REV PHARMACOL, V50, P131, DOI 10.1146/annurev.pharmtox.010909.105844
   Drygin D, 2009, CANCER RES, V69, P7653, DOI 10.1158/0008-5472.CAN-09-1304
   Ganapathy V, 2009, PHARMACOL THERAPEUT, V121, P29, DOI 10.1016/j.pharmthera.2008.09.005
   Gorski SA, 2008, MOL CELL, V30, P486, DOI 10.1016/j.molcel.2008.04.021
   Nguyen HT, 2018, ONCOL LETT, V16, P9, DOI 10.3892/ol.2018.8679
   Hansel-Hertsch R, 2018, NAT PROTOC, V13, P551, DOI 10.1038/nprot.2017.150
   Hansel-Hertsch R, 2017, NAT REV MOL CELL BIO, V18, P279, DOI 10.1038/nrm.2017.3
   Hansel-Hertsch R, 2016, NAT GENET, V48, P1267, DOI 10.1038/ng.3662
   Hernandez-Verdun D, 2006, HISTOCHEM CELL BIOL, V125, P127, DOI 10.1007/s00418-005-0046-4
   Hostettmann K., 1991, NEW PHYTOL, V474
   Huppert JL, 2005, NUCLEIC ACIDS RES, V33, P2908, DOI 10.1093/nar/gki609
   Katagiri N, 2015, SCI REP-UK, V5, DOI 10.1038/srep08903
   Keener J, 1998, J BIOL CHEM, V273, P33795, DOI 10.1074/jbc.273.50.33795
   Kuipers EJ, 2015, NAT REV DIS PRIMERS, V1, DOI 10.1038/nrdp.2015.65
   Largy E, 2011, ANAL BIOANAL CHEM, V400, P3419, DOI 10.1007/s00216-011-5018-z
   Lavrado J, 2015, SCI REP-UK, V5, DOI 10.1038/srep09696
   Li Q, 2013, NUCLEIC ACIDS RES, V41, pD1115, DOI 10.1093/nar/gks1101
   Liu Y, 2012, MOL CANCER THER, V11, P1672, DOI 10.1158/1535-7163.MCT-12-0131
   Ma YX, 2015, J CANCER, V6, P658, DOI 10.7150/jca.11647
   Marchetti C, 2018, J MED CHEM, V61, P2500, DOI 10.1021/acs.jmedchem.7b01781
   MU JZ, 1994, BBA-MOL CELL RES, V1222, P483, DOI 10.1016/0167-4889(94)90058-2
   Musso L, 2018, BBA-GEN SUBJECTS, V1862, P615, DOI 10.1016/j.bbagen.2017.12.002
   Neidle S, 2017, NAT REV CHEM, V1, DOI 10.1038/s41570-017-0041
   Ohnmacht SA, 2015, SCI REP-UK, V5, DOI 10.1038/srep11385
   Palma P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112189
   Pelletier J, 2018, NAT REV CANCER, V18, P51, DOI 10.1038/nrc.2017.104
   Pirota V, 2019, MOLECULES, V24, DOI 10.3390/molecules24030426
   Platella C, 2020, NUCLEIC ACIDS RES, V48, P12380, DOI 10.1093/nar/gkaa1001
   Popov A, 2013, NUCLEUS-AUSTIN, V4, P134, DOI 10.4161/nucl.23985
   Rasadean DM, 2017, CHEM-EUR J, V23, P8491, DOI 10.1002/chem.201700957
   Siebeneicher H, 2016, CHEMMEDCHEM, V11, P2261, DOI 10.1002/cmdc.201600276
   Tawani A, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-03906-3
   Thorens B, 2010, AM J PHYSIOL-ENDOC M, V298, pE141, DOI 10.1152/ajpendo.00712.2009
   Todd AK, 2005, NUCLEIC ACIDS RES, V33, P2901, DOI 10.1093/nar/gki553
   Wei T, 2018, CELL REP, V23, P404, DOI 10.1016/j.celrep.2018.03.066
   Xu H, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14432
   Yang J, 2017, ONCOTARGET, V8, P11788, DOI 10.18632/oncotarget.14352
   Zhang SG, 2018, BBA-GEN SUBJECTS, V1862, P1101, DOI 10.1016/j.bbagen.2018.01.022
   Zuffo M, 2019, EUR J MED CHEM, V163, P54, DOI 10.1016/j.ejmech.2018.11.043
NR 50
TC 2
Z9 3
U1 6
U2 6
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 2451-9448
J9 CELL CHEM BIOL
JI Cell Chem. Biol.
PD NOV 18
PY 2021
VL 28
IS 11
BP 1590
EP +
DI 10.1016/j.chembiol.2021.05.021
PG 17
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA XD3WB
UT WOS:000722642500006
PM 34166611
DA 2022-04-25
ER

PT J
AU Yin, J
   Ren, WK
   Huang, XG
   Li, TJ
   Yin, YL
AF Yin, Jie
   Ren, Wenkai
   Huang, Xingguo
   Li, Tiejun
   Yin, Yulong
TI Protein restriction and cancer
SO BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
LA English
DT Review
DE Protein restriction; Cancer; Amino acid; IGF-1; mTOR; FGF21; Autophagy
ID AMINO-ACID PROFILES; CHEMICALLY-INDUCED HEPATOCARCINOGENESIS; CELL
   LUNG-CANCER; FACTOR-I SYSTEM; DIETARY-PROTEIN; BREAST-CANCER;
   PI3K/AKT/MTOR PATHWAY; GLUCOSE-HOMEOSTASIS; COLORECTAL-CANCER; SIGNALING
   PATHWAY
AB Protein restriction without malnutrition is currently an effective nutritional intervention known to prevent diseases and promote health span from yeast to human. Recently, low protein diets are reported to be associated with lowered cancer incidence and mortality risk of cancers in human. In murine models, protein restriction inhibits tumor growth via mTOR signaling pathway. IGF-1, amino acid metabolic programing, FGF21, and autophagy may also serve as potential mechanisms of protein restriction mediated cancer prevention. Together, dietary intervention aimed at reducing protein intake can be beneficial and has the potential to be widely adopted and effective in preventing and treating cancers.
C1 [Yin, Jie; Li, Tiejun; Yin, Yulong] Chinese Acad Sci, Inst Subtrop Agr, Key Lab Agroecol Proc Subtrop Reg, Changsha, Hunan, Peoples R China.
   [Yin, Jie; Li, Tiejun; Yin, Yulong] Minist Agr, Sci Observing & Expt Stn Anim Nutr & Feed Sci Sou, Changsha, Hunan, Peoples R China.
   [Yin, Jie; Li, Tiejun; Yin, Yulong] Hunan Prov Engn Res Ctr Hlth Livestock & Poultry, Changsha, Hunan, Peoples R China.
   [Yin, Jie] Univ Chinese Acad Sci, Beijing, Peoples R China.
   [Ren, Wenkai; Yin, Yulong] South China Agr Univ, Inst Subtrop Anim Nutr & Feed, Coll Anim Sci, Guangdong Prov Key Lab Anim Nutr Control, Guangzhou, Guangdong, Peoples R China.
   [Ren, Wenkai] Yangzhou Univ, Coll Vet Med, Jiangsu Coinnovat Ctr Important Anim Infect Dis, Joint Int Res Lab Agr & Agriprod Safety,Minist Ed, Yangzhou, Jiangsu, Peoples R China.
   [Huang, Xingguo] Hunan Agr Univ, Dept Anim Sci, Changsha, Hunan, Peoples R China.
   [Huang, Xingguo; Li, Tiejun] Hunan Coinnovat Ctr Anim Prod Safety, Changsha, Hunan, Peoples R China.
RP Li, TJ; Yin, YL (corresponding author), Chinese Acad Sci, Inst Subtrop Agr, Changsha 410125, Hunan, Peoples R China.
EM tjli@isa.ac.cn; yinyulong@isa.ac.cn
RI YIN, Jie/H-3578-2019
OI YIN, Jie/0000-0003-1852-1042
FU National Key R&D Program of China [2016YFD0501201]; National Basic
   Research Program of China (973)National Basic Research Program of China
   [2013CB127301]; National Natural Science Foundation of ChinaNational
   Natural Science Foundation of China (NSFC) [31472106, 31772617]; Hunan
   Key Research Program [2017NK2321]; China Agriculture Research System
   [CARS-35]
FX This study was supported by the National Key R&D Program of China
   (2016YFD0501201), National Basic Research Program of China (973)
   (2013CB127301), National Natural Science Foundation of China (No.
   31472106 and 31772617), Hunan Key Research Program (2017NK2321), and
   China Agriculture Research System (CARS-35).
CR Altman BJ, 2016, NAT REV CANCER, V16, P773, DOI 10.1038/nrc.2016.131
   Amobi A, 2017, ADV EXP MED BIOL, V1036, P129, DOI 10.1007/978-3-319-67577-0_9
   Barnes T, 2014, APPL PHYSIOL NUTR ME, V39, P740, DOI 10.1139/apnm-2013-0526
   Bhutia YD, 2015, CANCER RES, V75, P1782, DOI 10.1158/0008-5472.CAN-14-3745
   Brandhorst S, 2013, EXP GERONTOL, V48, P1120, DOI 10.1016/j.exger.2013.02.016
   Cai WK, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14892
   Carroll B, 2015, AMINO ACIDS, V47, P2065, DOI 10.1007/s00726-014-1775-2
   Chalvon-Demersay T, 2016, J NUTR BIOCHEM, V36, P60, DOI 10.1016/j.jnutbio.2016.07.002
   Chiarini F, 2015, TRENDS PHARMACOL SCI, V36, P124, DOI 10.1016/j.tips.2014.11.004
   Christopoulos PF, 2018, CANCER TREAT REV, V63, P79, DOI 10.1016/j.ctrv.2017.11.010
   Christopoulos PF, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0291-7
   Corbet C, 2017, BBA-REV CANCER, V1868, P7, DOI 10.1016/j.bbcan.2017.01.002
   Dawson MA, 2017, SCIENCE, V355, P1147, DOI 10.1126/science.aam7304
   Derezinski P, 2017, INT J MED SCI, V14, P1, DOI 10.7150/ijms.15783
   Ebrahimi S, 2017, CURR MED CHEM, V24, P1321, DOI 10.2174/0929867324666170206142658
   Eitan E, 2017, AGING CELL, V16, P1430, DOI 10.1111/acel.12657
   Fontana L, 2013, ONCOTARGET, V4, P2451, DOI 10.18632/oncotarget.1586
   Fontana L, 2006, AM J CLIN NUTR, V84, P1456, DOI 10.1093/ajcn/84.6.1456
   Garrett WS, 2015, SCIENCE, V348, P80, DOI 10.1126/science.aaa4972
   Geiger R, 2016, CELL, V167, P829, DOI 10.1016/j.cell.2016.09.031
   Gewirtz DA, 2014, CANCER RES, V74, P647, DOI 10.1158/0008-5472.CAN-13-2966
   Godin-Ethier J, 2011, CLIN CANCER RES, V17, P6985, DOI 10.1158/1078-0432.CCR-11-1331
   Gu Y, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0408-1
   Hao F, 2017, GASTROENTEROLOGY, V152, pS802, DOI 10.1016/S0016-5085(17)32773-7
   Hasim A, 2013, MOL BIOL REP, V40, P5853, DOI 10.1007/s11033-013-2691-3
   Hattori A, 2016, EXP HEMATOL, V44, pS78, DOI 10.1016/j.exphem.2016.06.152
   He YC, 2017, BBA-REV CANCER, V1868, P359, DOI 10.1016/j.bbcan.2017.07.002
   Henagan TM, 2016, METABOLISM, V65, P805, DOI 10.1016/j.metabol.2016.02.015
   Hill CM, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-07498-w
   Ho VW, 2011, CANCER RES, V71, P4484, DOI 10.1158/0008-5472.CAN-10-3973
   Huang WJ, 2013, CELL RES, V23, P724, DOI 10.1038/cr.2013.15
   Huang XQ, 2006, MOL CARCINOGEN, V45, P934, DOI 10.1002/mc.20241
   Inagaki T, 2008, CELL METAB, V8, P77, DOI 10.1016/j.cmet.2008.05.006
   Kim HJ, 2015, LUNG CANCER, V90, P522, DOI 10.1016/j.lungcan.2015.10.006
   Kitada M, 2016, DIABETOLOGIA, V59, P1307, DOI 10.1007/s00125-016-3925-4
   Klupczynska A, 2016, LUNG CANCER, V100, P71, DOI 10.1016/j.lungcan.2016.04.008
   Knott M. E., 2016, J MOL BIOMARK DIA S2, V1
   Kralisch S, 2013, J ENDOCRINOL, V216, P135, DOI 10.1530/JOE-12-0367
   Laeger T, 2017, DIABETOLOGIA, V60, P2274, DOI 10.1007/s00125-017-4389-x
   Laeger T, 2016, CELL REP, V16, P707, DOI 10.1016/j.celrep.2016.06.044
   Laeger T, 2014, J CLIN INVEST, V124, P3913, DOI 10.1172/JCI74915
   Lamming DW, 2015, ONCOTARGET, V6, P31233, DOI 10.18632/oncotarget.5180
   Lau MT, 2012, CANCER LETT, V326, P191, DOI 10.1016/j.canlet.2012.08.016
   Leavy O, 2017, NAT REV IMMUNOL, V17, P79, DOI 10.1038/nri.2016.152
   Lee CH, 2010, CANCER RES, V70, P1564, DOI 10.1158/0008-5472.CAN-09-3228
   Levine ME, 2014, CELL METAB, V19, P407, DOI 10.1016/j.cmet.2014.02.006
   Levy JMM, 2017, NAT REV CANCER, V17, P528, DOI 10.1038/nrc.2017.53
   Li HM, 2017, MOL CANCER, V16, DOI 10.1186/s12943-016-0576-5
   Li Z, 2017, CELL DEATH DIFFER, V24, P1205, DOI 10.1038/cdd.2015.95
   Liu PS, 2017, NAT IMMUNOL, V18, P985, DOI 10.1038/ni.3796
   Ma EH, 2017, CELL METAB, V25, P345, DOI 10.1016/j.cmet.2016.12.011
   Marcucci F, 2017, BBA-REV CANCER, V1868, P571, DOI 10.1016/j.bbcan.2017.10.006
   Martins AP, 2012, BIOCHEM BIOPH RES CO, V423, P170, DOI 10.1016/j.bbrc.2012.05.108
   Mayer IA, 2016, ANNU REV MED, V67, P11, DOI 10.1146/annurev-med-062913-051343
   Mayers JR, 2016, SCIENCE, V353, P1161, DOI 10.1126/science.aaf5171
   Meynet O, 2014, TRENDS MOL MED, V20, P419, DOI 10.1016/j.molmed.2014.05.001
   Minard AY, 2016, CELL REP, V17, P29, DOI 10.1016/j.celrep.2016.08.086
   Mirzaei H, 2016, CURR OPIN CLIN NUTR, V19, P74, DOI 10.1097/MCO.0000000000000239
   Mirzaei H, 2014, TRENDS ENDOCRIN MET, V25, P558, DOI 10.1016/j.tem.2014.07.002
   Miyagi Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024143
   Molina-Arcas M, 2013, CANCER DISCOV, V3, P548, DOI 10.1158/2159-8290.CD-12-0446
   Nakaya M, 2014, IMMUNITY, V40, P692, DOI 10.1016/j.immuni.2014.04.007
   Paddon-Jones D, 2015, AM J CLIN NUTR, V101, p1339S, DOI 10.3945/ajcn.114.084061
   Polivka J, 2014, PHARMACOL THERAPEUT, V142, P164, DOI 10.1016/j.pharmthera.2013.12.004
   Potthoff MJ, 2017, NAT REV ENDOCRINOL, V13, P74, DOI 10.1038/nrendo.2016.206
   Proenza AM, 2003, J NUTR BIOCHEM, V14, P133, DOI 10.1016/S0955-2863(02)00225-5
   Ribas A, 2015, CANCER DISCOV, V5, P915, DOI 10.1158/2159-8290.CD-15-0563
   Rubio-Patino C., 2018, CELL METAB, V18, P30120
   Ruf S, 2017, AUTOPHAGY, V13, P486, DOI 10.1080/15548627.2016.1263781
   Sanchez-Lopez E, 2016, ONCOGENE, V35, P2634, DOI 10.1038/onc.2015.326
   Saxton RA, 2017, CELL, V168, P960, DOI [10.1016/j.cell.2017.02.004, 10.1016/j.cell.2017.03.035]
   Scott TA, 2017, CELL, V169, P442, DOI 10.1016/j.cell.2017.03.040
   Shingyoji M, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-77
   Sikalidis AK, 2015, PATHOL ONCOL RES, V21, P9, DOI 10.1007/s12253-014-9860-0
   Simpson SJ, 2017, AGEING RES REV, V39, P78, DOI 10.1016/j.arr.2017.03.001
   Sinclair LV, 2013, NAT IMMUNOL, V14, P500, DOI 10.1038/ni.2556
   Solon-Biet SM, 2015, CELL REP, V11, P1529, DOI 10.1016/j.celrep.2015.05.007
   Standard J, 2014, J NUTR BIOCHEM, V25, P1317, DOI 10.1016/j.jnutbio.2014.07.010
   Stemmer K, 2015, DIABETOLOGIA, V58, P2414, DOI 10.1007/s00125-015-3668-7
   Tannahill GM, 2013, NATURE, V496, P238, DOI 10.1038/nature11986
   Travis RC, 2016, CANCER RES, V76, P2288, DOI 10.1158/0008-5472.CAN-15-1551
   Vander Heiden MG, 2017, CELL, V168, DOI 10.1016/j.cell.2016.12.039
   Wang H, 2015, BRIT J NUTR, V114, P519, DOI 10.1017/S0007114515002172
   Wauson EM, 2013, AUTOPHAGY, V9, P418, DOI 10.4161/auto.22911
   White E, 2015, J CLIN INVEST, V125, P42, DOI 10.1172/JCI73941
   Xu PF, 2015, DIGEST DIS SCI, V60, P3032, DOI 10.1007/s10620-015-3711-z
   Yin J, 2017, J AGR FOOD CHEM, V65, P9297, DOI 10.1021/acs.jafc.7b02746
   Zhang Q, 2015, AM J CANCER RES, V5, P1762
   Zhang Y, 2012, SMART MATER STRUCT, V21, DOI 10.1088/0964-1726/21/7/075007
   Zhang YQ, 2017, CANCER CELL, V31, P820, DOI 10.1016/j.ccell.2017.04.013
   Zhao QH, 2014, ASIA PAC J CLIN NUTR, V23, P429, DOI 10.6133/apjcn.2014.23.3.13
   Zhou YF, 2017, CELL PHYSIOL BIOCHEM, V42, P1431, DOI 10.1159/000479207
   Zitvogel L, 2017, NAT IMMUNOL, V18, P843, DOI 10.1038/ni.3754
   Zitvogel L, 2016, CELL, V165, P276, DOI 10.1016/j.cell.2016.03.001
NR 94
TC 37
Z9 38
U1 4
U2 34
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0304-419X
EI 0006-3002
J9 BBA-REV CANCER
JI Biochim. Biophys. Acta-Rev. Cancer
PD APR
PY 2018
VL 1869
IS 2
BP 256
EP 262
DI 10.1016/j.bbcan.2018.03.004
PG 7
WC Biochemistry & Molecular Biology; Biophysics; Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics; Oncology
GA GH7PG
UT WOS:000433645300015
PM 29596961
DA 2022-04-25
ER

PT J
AU Shukla, S
   Patric, IRP
   Patil, V
   Shwetha, SD
   Hegde, AS
   Chandramouli, BA
   Arivazhagan, A
   Santosh, V
   Somasundaram, K
AF Shukla, Sudhanshu
   Patric, Irene Rosita Pia
   Patil, Vikas
   Shwetha, Shivayogi D.
   Hegde, Alangar S.
   Chandramouli, Bangalore A.
   Arivazhagan, Arimappamagan
   Santosh, Vani
   Somasundaram, Kumaravel
TI Methylation Silencing of ULK2, an Autophagy Gene, Is Essential for
   Astrocyte Transformation and Tumor Growth
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID DNA METHYLATION; CELL-DEATH; MICROSATELLITE INSTABILITY; MAMMARY
   TUMORIGENESIS; COLORECTAL-CANCER; MALIGNANT GLIOMA; POOR-PROGNOSIS;
   GLIOBLASTOMA; PHENOTYPE; SURVIVAL
AB Glioblastoma (GBM) is the most aggressive type of brain tumor and shows very poor prognosis. Here, using genome-wide methylation analysis, we show that G-CIMP+ and G-CIMP-subtypes enrich distinct classes of biological processes. One of the hypermethylated genes in GBM, ULK2, an upstream autophagy inducer, was found to be down-regulated in GBM. Promoter hypermethylation of ULK2 was confirmed by bisulfite sequencing. GBM and glioma cell lines had low levels of ULK2 transcripts, which could be reversed upon methylation inhibitor treatment. ULK2 promoter methylation and transcript levels showed significant negative correlation. Ectopic overexpression of ULK2-induced autophagy, which further enhanced upon nutrient starvation or temozolomide chemotherapy. ULK2 also inhibited the growth of glioma cells, which required autophagy induction as kinase mutant of ULK2 failed to induce autophagy and inhibit growth. Furthermore, ULK2 induced autophagy and inhibited growth in Ras-transformed immortalized Baby Mouse Kidney (iBMK) ATG5(+/+) but not in autophagy-deficient ATG5(-/-) cells. Growth inhibition due to ULK2 induced high levels of autophagy under starvation or chemotherapy utilized apoptotic cell death but not at low levels of autophagy. Growth inhibition by ULK2 also appears to involve catalase degradation and reactive oxygen species generation. ULK2 overexpression inhibited anchorage independent growth, inhibited astrocyte transformation in vitro and tumor growth in vivo. Of all autophagy genes, we found ULK2 and its homologue ULK1 were only down-regulated in all grades of glioma. Thus these results altogether suggest that inhibition of autophagy by ULK1/2 down-regulation is essential for glioma development.
C1 [Shukla, Sudhanshu; Patric, Irene Rosita Pia; Patil, Vikas; Somasundaram, Kumaravel] Indian Inst Sci, Dept Microbiol & Cell Biol, Bangalore 560012, Karnataka, India.
   [Hegde, Alangar S.] Sri Satya Sai Inst Higher Med Sci, Bangalore 560066, Karnataka, India.
   [Chandramouli, Bangalore A.; Arivazhagan, Arimappamagan] Natl Inst Mental Hlth & Neurosci, Dept Neurosurg, Bangalore 560029, Karnataka, India.
   [Shwetha, Shivayogi D.; Santosh, Vani] Natl Inst Mental Hlth & Neurosci, Dept Neuropathol, Bangalore 560029, Karnataka, India.
RP Somasundaram, K (corresponding author), Indian Inst Sci, Dept Microbiol & Cell Biol, Bangalore 560012, Karnataka, India.
EM skumar@mcbl.iisc.ernet.in
RI Shukla, Sudhanshu/K-7830-2017; Shukla, Sudhanshu/AAC-8650-2020; Shukla,
   Sudhanshu/L-3530-2016
OI Shukla, Sudhanshu/0000-0002-5069-9708; Shukla,
   Sudhanshu/0000-0002-5069-9708; Shukla, Sudhanshu/0000-0002-5069-9708
FU Indian Council of Medical ResearchIndian Council of Medical Research
   (ICMR); Department of Biotechnology; Department of Science; University
   Grants CommissionUniversity Grants Commission, India
FX The results published here are in whole or part based upon data
   generated by The Cancer Genome Atlas pilot project established by the
   NCI and NHGRI. The use of datasets from Institute NC, 2005 and Phillips
   et al., 2006 is acknowledged. Infrastructural support by funding from
   Indian Council of Medical Research, Department of Biotechnology,
   Department of Science, and University Grants Commission to the
   Department of Microbiology and Cell Biology is acknowledged. The Central
   Animal Facility of the Indian Institute of Science is acknowledged for
   animal experiments. We thank Professors M. R. S. Rao and P. Kondaiah for
   valuable suggestions. We thank Dr. H. Noushmehr for help in acquiring
   TCGA data. We also thank B. Thota, Shruti Bhargava, K. Chandrashekar, K.
   Prem, and B. C. Shailaja for the help rendered.
CR Arcella A, 2013, BRAIN RES, V1495, P37, DOI 10.1016/j.brainres.2012.11.044
   Baehrecke EH, 2005, NAT REV MOL CELL BIO, V6, P505, DOI 10.1038/nrm1666
   BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0
   Cheong H, 2014, AUTOPHAGY, V10, P45, DOI 10.4161/auto.26505
   Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385
   Cho DH, 2012, ANTICANCER RES, V32, P4091
   Codogno P, 2005, CELL DEATH DIFFER, V12, P1509, DOI 10.1038/sj.cdd.4401751
   Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001
   Devaney JM, 2013, PROSTATE CANCER P D, V16, P292, DOI 10.1038/pcan.2013.21
   Ehrlich M, 2002, J NUTR, V132, p2424S, DOI 10.1093/jn/132.8.2424S
   Ehrlich M, 2002, ONCOGENE, V21, P5400, DOI 10.1038/sj.onc.1205651
   Foltz G, 2006, CANCER RES, V66, P6665, DOI 10.1158/0008-5472.CAN-05-4453
   Fu T, 2012, CLIN CANCER RES, V18, P4743, DOI 10.1158/1078-0432.CCR-12-0707
   Gao W, 2011, CELL DEATH DIFFER, V18, P1598, DOI 10.1038/cdd.2011.33
   Garcia-Manero G, 2008, CURR OPIN ONCOL, V20, P705, DOI 10.1097/CCO.0b013e328313699c
   Goi T, 2003, SURG TODAY, V33, P702, DOI 10.1007/s00595-002-2567-y
   Gonzalez-Gomez P, 2003, INT J ONCOL, V22, P601
   Guo JY, 2011, GENE DEV, V25, P460, DOI 10.1101/gad.2016311
   Hu YL, 2012, CANCER RES, V72, P1773, DOI 10.1158/0008-5472.CAN-11-3831
   Issa JP, 2004, NAT REV CANCER, V4, P988, DOI 10.1038/nrc1507
   Jung CH, 2011, AUTOPHAGY, V7, P1212, DOI 10.4161/auto.7.10.16660
   Kang MR, 2009, J PATHOL, V217, P702, DOI 10.1002/path.2509
   Kanzawa T, 2004, CELL DEATH DIFFER, V11, P448, DOI 10.1038/sj.cdd.4401359
   Karantza-Wadsworth V, 2007, GENE DEV, V21, P1621, DOI 10.1101/gad.1565707
   Kaza N, 2012, BRAIN PATHOL, V22, P89, DOI 10.1111/j.1750-3639.2011.00544.x
   Kim MS, 2008, HUM PATHOL, V39, P1059, DOI 10.1016/j.humpath.2007.11.013
   Kim SJ, 2006, BBA-GENE STRUCT EXPR, V1759, P451, DOI 10.1016/j.bbaexp.2006.09.003
   Kroemer G, 2010, MOL CELL, V40, P280, DOI 10.1016/j.molcel.2010.09.023
   Lee EJ, 2011, AUTOPHAGY, V7, P689, DOI 10.4161/auto.7.7.15450
   Liang C, 2006, NAT CELL BIOL, V8, P688, DOI 10.1038/ncb1426
   Liang CY, 2010, CURR OPIN CELL BIOL, V22, P226, DOI 10.1016/j.ceb.2009.11.003
   Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257
   Louis DN, 2007, ACTA NEUROPATHOL, V114, P97, DOI 10.1007/s00401-007-0243-4
   Martinez R, 2009, EPIGENETICS-US, V4, P255, DOI 10.4161/epi.9130
   McAfee Q, 2012, P NATL ACAD SCI USA, V109, P8253, DOI 10.1073/pnas.1118193109
   Nagarajan RP, 2009, SEMIN CANCER BIOL, V19, P188, DOI 10.1016/j.semcancer.2009.02.005
   Noushmehr H, 2010, CANCER CELL, V17, P510, DOI 10.1016/j.ccr.2010.03.017
   Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039
   Reddy SP, 2008, CLIN CANCER RES, V14, P2978, DOI 10.1158/1078-0432.CCR-07-4821
   Rosenfeldt MT, 2011, CARCINOGENESIS, V32, P955, DOI 10.1093/carcin/bgr031
   Scott RC, 2007, CURR BIOL, V17, P1, DOI 10.1016/j.cub.2006.10.053
   Shaw RJ, 2006, NATURE, V441, P424, DOI 10.1038/nature04869
   Shukla S, 2013, CANCER RES, V73, P6563, DOI 10.1158/0008-5472.CAN-13-0298
   Sreekanthreddy P, 2010, CANCER EPIDEM BIOMAR, V19, P1409, DOI 10.1158/1055-9965.EPI-09-1077
   Stupp R, 2009, LANCET ONCOL, V10, P459, DOI 10.1016/S1470-2045(09)70025-7
   Takahashi Y, 2007, NAT CELL BIOL, V9, P1142, DOI 10.1038/ncb1634
   Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681
   Turcan S, 2012, NATURE, V483, P479, DOI 10.1038/nature10866
   Wang CR, 2013, NAT NEUROSCI, V16, P532, DOI 10.1038/nn.3365
   Wang RC, 2012, SCIENCE, V338, P956, DOI 10.1126/science.1225967
   Wei HJ, 2011, GENE DEV, V25, P1510, DOI 10.1101/gad.2051011
   Wu ZZ, 2010, BIOCHEM PHARMACOL, V80, P262, DOI 10.1016/j.bcp.2010.03.029
   Yu L, 2006, P NATL ACAD SCI USA, V103, P4952, DOI 10.1073/pnas.0511288103
NR 53
TC 56
Z9 58
U1 0
U2 8
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD AUG 8
PY 2014
VL 289
IS 32
BP 22306
EP 22318
DI 10.1074/jbc.M114.567032
PG 13
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA AN4XQ
UT WOS:000340593500042
PM 24923441
OA Green Published, hybrid
DA 2022-04-25
ER

PT J
AU Wu, W
   Hou, B
   Tang, CL
   Liu, FC
   Yang, J
   Pan, T
   Si, K
   Lu, DY
   Wang, XX
   Wang, J
   Xiong, X
   Liu, J
   Xie, CG
AF Wu, Wei
   Hou, Bing
   Tang, Changli
   Liu, Fucheng
   Yang, Jie
   Pan, Tao
   Si, Ke
   Lu, Deyun
   Wang, Xiaoxiang
   Wang, Jing
   Xiong, Xing
   Liu, Ji
   Xie, Chunguang
TI (+)-Usnic Acid Inhibits Migration of c-KIT Positive Cells in Human
   Colorectal Cancer
SO EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE
LA English
DT Article
ID USNIC ACID; TYROSINE KINASE; ENZYME UBC9; PROLIFERATION; AUTOPHAGY;
   INVASION; TOXICITY; MOTILITY; RECEPTOR; GROWTH
AB Inhibition of tumor cell migration is a treatment strategy for patients with colorectal cancer (CRC). SCF-dependent activation of c-KIT is responsible for migration of c-KIT positive [c-KIT(+)] cells of CRC. Drug resistance to Imatinib Mesylate (c-KIT inhibitor) has emerged. Inhibition of mTOR can induce autophagic degradation of c-KIT. (+)-usnic acid [(+)-UA], isolated from lichens, has two major functions including induction of proton shuttle and targeting inhibition of mTOR. To reduce hepatotoxicity, the treatment concentration of (+)-UA should be lower than 10 mu M. HCT116 cells and LS174 cells were employed to investigate the inhibiting effect of (+)-UA (< 10 mu M) on SCF-mediated migration of c-KIT(+) CRC cells. HCT116 cells were employed to investigate the molecular mechanisms. The results indicated that firstly, 8 mu M (+)-UA decreased ATP content via uncoupling; secondly, 8 mu M (+)-UA induced mTOR inhibition, thereby mediated activation suppression of PKC-A, and induced the autophagy of the completed autophagic flux that resulted in the autophagic degradation and transcriptional inhibition of c-KIT and the increase in LDH release; ultimately, 8 mu M (+)-UA inhibited SCF-mediated migration of CRC c-KIT(+) cells. Taken together, 8 mu M could be determined as the effective concentration for (+)-UA to inhibit SCF-mediated migration of CRC c-KIT(+) cells.
C1 [Wu, Wei; Hou, Bing; Liu, Fucheng; Yang, Jie; Pan, Tao; Si, Ke; Lu, Deyun; Wang, Xiaoxiang; Wang, Jing; Xiong, Xing; Liu, Ji] Chengdu Univ Tradit Chinese Med, Chengdu Peoples Hosp 1, Integrated Tradit Chinese Med & Western Med Hosp, Dept Gastroenterol, Chengdu 610041, Sichuan, Peoples R China.
   [Wu, Wei; Xie, Chunguang] Chengdu Univ Tradit Chinese Med, Sch Clin Med, Chengdu 610075, Sichuan, Peoples R China.
   [Wu, Wei; Tang, Changli; Liu, Ji] Chengdu Easton Biopharmaceut Ltd, Chengdu 611731, Sichuan, Peoples R China.
   [Wu, Wei; Liu, Ji] Sichuan Univ, West China Sch Basic Med Sci & Forens Med, Dept Biochem & Mol Biol, Chengdu 610041, Sichuan, Peoples R China.
   [Wu, Wei] Remeadjohn Technol Co Ltd, Chengdu 610044, Sichuan, Peoples R China.
   [Tang, Changli] Xichang Peoples Hosp, Pharm Dept, Xichang 615000, Peoples R China.
RP Liu, J (corresponding author), Chengdu Univ Tradit Chinese Med, Chengdu Peoples Hosp 1, Integrated Tradit Chinese Med & Western Med Hosp, Dept Gastroenterol, Chengdu 610041, Sichuan, Peoples R China.; Xie, CG (corresponding author), Chengdu Univ Tradit Chinese Med, Sch Clin Med, Chengdu 610075, Sichuan, Peoples R China.; Liu, J (corresponding author), Chengdu Easton Biopharmaceut Ltd, Chengdu 611731, Sichuan, Peoples R China.; Liu, J (corresponding author), Sichuan Univ, West China Sch Basic Med Sci & Forens Med, Dept Biochem & Mol Biol, Chengdu 610041, Sichuan, Peoples R China.
EM rongsi8888@sina.com; xiecg88888@sina.com
FU National Natural Science FundNational Natural Science Foundation of
   China (NSFC) [81774302]; Science and Technology Project in Sichuan
   Province [2018JY0662]; Remeadjohn Technology Co., Ltd., Chengdu, China
FX This project was supported by the National Natural Science Fund [Grant
   Number: 81774302]; the Science and Technology Project in Sichuan
   Province [Grant Number: 2018JY0662]; and Remeadjohn Technology Co.,
   Ltd., Chengdu 610044, China. These following researchers, including Dr.
   Hongmei Rang (Department of Gastroenterology, Chengdu First People's
   Hospital, Chengdu 610041, China), Dr. Yanzhi Wang, Prof. Wen Xie and
   Prof. Minshuang Zhu (College of Clinical Medicine, Chengdu University of
   Traditional Chinese Medicine, Chengdu 610075, China), and Prof. Qing Xia
   (Department of Integrated Traditional Chinese and Western Medicine,
   Sichuan Provincial Pancreatitis Centre, West China Hospital, Sichuan
   University, Chengdu, China), have made their contributions to this
   study. We express our deep gratitude to the above researchers.
CR Backorova M., 2002, TOXICOL IN VITRO, V26, P462
   Bessadottir M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051296
   BLUMEJENSEN P, 1993, EMBO J, V12, P4199, DOI 10.1002/j.1460-2075.1993.tb06104.x
   Brisdelli F, 2013, PHYTOTHER RES, V27, P431, DOI 10.1002/ptr.4739
   Bustin SA, 2009, CLIN CHEM, V55, P611, DOI 10.1373/clinchem.2008.112797
   Chen EC, 2015, GASTROENTEROLOGY, V149, P705, DOI 10.1053/j.gastro.2015.05.042
   Chen S, 2014, TOXICOL SCI, V142, P33, DOI 10.1093/toxsci/kfu154
   Choudhary S, 2016, APPL MICROBIOL BIOT, V100, P263, DOI 10.1007/s00253-015-6978-2
   Cocchietto M, 2002, NATURWISSENSCHAFTEN, V89, P137, DOI 10.1007/s00114-002-0305-3
   Ebrahim HY, 2017, J NAT PROD, V80, P932, DOI 10.1021/acs.jnatprod.6b00917
   Eloranta JJ, 2002, J BIOL CHEM, V277, P30798, DOI 10.1074/jbc.M202780200
   Fang Y, 2015, PLOS ONE, V10
   Gupta MK, 2014, CIRC RES, V115, P721, DOI 10.1161/CIRCRESAHA.115.304760
   Hsu HH, 2014, WORLD J GASTROENTERO, V20, P16665, DOI 10.3748/wjg.v20.i44.16665
   Hsueh YS, 2014, ONCOTARGET, V5, P11723, DOI 10.18632/oncotarget.2607
   Isotani M, 2006, VET IMMUNOL IMMUNOP, V114, P168, DOI 10.1016/j.vetimm.2006.07.004
   Joseph A, 2009, MITOCHONDRION, V9, P149, DOI 10.1016/j.mito.2009.02.002
   Kuipers EJ, 2015, NAT REV DIS PRIMERS, V1, DOI 10.1038/nrdp.2015.65
   Liu L, 2008, ONCOGENE, V27, P4998, DOI 10.1038/onc.2008.137
   Mattoscio D, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006262
   Merzoug-Larabi M, 2017, BMC CANCER, V17, DOI 10.1186/s12885-016-3007-5
   Palaniappan M, 2013, MOL CELL ENDOCRINOL, V366, P81, DOI 10.1016/j.mce.2012.12.004
   Ristic S, 2016, CURR PHARM BIOTECHNO, V17, P651, DOI 10.2174/1389201017666160401144825
   Roskoski R, 2005, BIOCHEM BIOPH RES CO, V338, P1307, DOI 10.1016/j.bbrc.2005.09.150
   Rzheshevsky AV, 2014, BIOCHEMISTRY-MOSCOW+, V79, P1056, DOI 10.1134/S0006297914100071
   Santoni M, 2014, BBA-REV CANCER, V1845, P221, DOI 10.1016/j.bbcan.2014.01.007
   Shvets E, 2011, AUTOPHAGY, V7, P683, DOI 10.4161/auto.7.7.15279
   Siemens H, 2013, ONCOTARGET, V4, P1399, DOI 10.18632/oncotarget.1202
   Sonko BJ, 2011, FOOD CHEM TOXICOL, V49, P2968, DOI 10.1016/j.fct.2011.07.047
   Tan J, 2015, ONCOTARGET, V6, P27037, DOI 10.18632/oncotarget.4815
   Tee AR, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19030880
   Vajravelu BN, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140798
   Van Otterloo E, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001122
   Xiao YY, 2017, BMC CANCER, V17, DOI 10.1186/s12885-016-3012-8
   Xiong XX, 2015, INT J ONCOL, V47, P1321, DOI 10.3892/ijo.2015.3103
   Xu Jia, 2013, Zhonghua Wei Chang Wai Ke Za Zhi, V16, P288
   Zhou HY, 2011, CURR PROTEIN PEPT SC, V12, P30
   Zhou HY, 2006, ENDOCRINOLOGY, V147, P2557, DOI 10.1210/en.2005-1404
NR 38
TC 6
Z9 6
U1 2
U2 4
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1741-427X
EI 1741-4288
J9 EVID-BASED COMPL ALT
JI Evid.-based Complement Altern. Med.
PY 2018
VL 2018
AR 5149436
DI 10.1155/2018/5149436
PG 13
WC Integrative & Complementary Medicine
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Integrative & Complementary Medicine
GA GU7QE
UT WOS:000445519100001
PM 30298093
OA gold, Green Published, Green Submitted
DA 2022-04-25
ER

PT J
AU Tang, J
   Wang, DY
   Shen, YG
   Xue, F
AF Tang, Jian
   Wang, Dongyang
   Shen, Yuguang
   Xue, Feng
TI ATG16L2 overexpression is associated with a good prognosis in colorectal
   cancer
SO JOURNAL OF GASTROINTESTINAL ONCOLOGY
LA English
DT Article
DE Colorectal cancer (CRC); prognosis; autophagy; biomarker
ID AUTOPHAGY-RELATED GENES; CROHNS-DISEASE; STATISTICS
AB Background: Colorectal cancer (CRC) is a highly aggressive, high-incidence malignancy. Several biomarkers associated with the prognosis and metastasis of CRC have been identified. Our study aimed to evaluate the value of ATG16L2 protein as a new biomarker to predict the prognosis of patients with CRC. Methods: One hundred and fifty-two pairs of paraffin-embedded tissue samples and 19 fresh tissue samples were collected from the Department of Pathology of Renji Hospital, Shanghai Jiao Tong University School of Medicine. All the patients had undergone surgery in the hospital's Department of Gastrointestinal Surgery between 2013 and 2014. The samples were arranged on two tissue microarrays of normal (n=152) and tumor (n=152) tissue. The tissues were immunostained and graded as low (<50%) or high (>= 50%) according to the proportion of ATG16L2-positive cells. An overexpression plasmid was constructed and transfected into RKO cells, and the cell proliferation and migration ability were detected. Finally, Flag-ATG16L2 RKO cells subcutaneous injection into the skin of BALB/c nude mice to determine the effects of ATG16L2 on the growth of subcutaneously transplanted tumors. Results: ATG16L2 expression was negatively correlated with lymph node metastasis (P<0.05) and tumor node-metastasis stage (P<0.05). High ATG16L2 expression in tumor tissues was related to a good prognosis, with patients with a high expression of ATG16L2 displaying longer overall survival. In vitro, overexpression of ATG16L2 in a CRC cell line RKO cell led to a decrease in cell proliferation but had no obvious influence on cell migration. In vivo, the mice in the Flag-NC (as control) group exhibited faster tumor growth than those in the experiment group. Conclusions: ATG16L2 expression is positively associated with patient prognosis in CRC. Further, ATG16L2 can negatively affect CRC cell proliferation in vitro and in vivo.
C1 [Tang, Jian; Wang, Dongyang; Shen, Yuguang] Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Dept Gastrointestinal Surg, Shanghai, Peoples R China.
   [Xue, Feng] Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Dept Liver Surg & Liver Transplantat, Shanghai, Peoples R China.
RP Xue, F (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Dept Liver Surg & Liver Transplantat, Shanghai, Peoples R China.
EM liversurgery6108_rj@sjtu.edu.cn
FU Science and Technology Commission of Shanghai MunicipalityScience &
   Technology Commission of Shanghai Municipality (STCSM) [19140903002];
   Shanghai Municipal Population and Family Planning Commission [201840374]
FX Science and Technology Commission of Shanghai Municipality, 19140903002;
   Shanghai Municipal Population and Family Planning Commission, 201840374.
CR Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
   Brenner H, 2014, LANCET, V383, P1490, DOI 10.1016/S0140-6736(13)61649-9
   Cartwright TH, 2012, CLIN COLORECTAL CANC, V11, P155, DOI 10.1016/j.clcc.2011.11.001
   Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338
   Choi KS, 2012, EXP MOL MED, V44, P109, DOI 10.3858/emm.2012.44.2.033
   Cufi S, 2012, ONCOTARGET, V3, P1600
   Fowler EV, 2008, AM J GASTROENTEROL, V103, P2519, DOI 10.1111/j.1572-0241.2008.02023.x
   Hawk ET, 2005, J CLIN ONCOL, V23, P378, DOI 10.1200/JCO.2005.08.097
   Huang YP, 2011, CELL CYCLE, V10, P3938, DOI 10.4161/cc.10.22.18107
   Igci M, 2016, GENE, V588, P38, DOI 10.1016/j.gene.2016.04.042
   Ishibashi K, 2011, AUTOPHAGY, V7, P1500, DOI 10.4161/auto.7.12.18025
   Jo YK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052705
   Kang MR, 2009, J PATHOL, V217, P702, DOI 10.1002/path.2509
   Khor B, 2019, J IMMUNOL, V203, P1820, DOI 10.4049/jimmunol.1800419
   Klionsky DJ, 2007, NAT REV MOL CELL BIO, V8, P931, DOI 10.1038/nrm2245
   Kondo Y, 2005, NAT REV CANCER, V5, P726, DOI 10.1038/nrc1692
   Koukourakis MI, 2010, BRIT J CANCER, V103, P1209, DOI 10.1038/sj.bjc.6605904
   Kuma A, 2004, NATURE, V432, P1032, DOI 10.1038/nature03029
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Liu J, 2020, EUR J HOSP PHARM, V27, P267, DOI 10.1136/ejhpharm-2018-001657
   Luo H, 2020, ONCOL LETT, V20, P742, DOI 10.3892/ol.2020.11633
   Ma T, 2016, COLORECTAL DIS, V18, pO420, DOI 10.1111/codi.13507
   Nakamura Y, 2018, ONCOLOGIST, V23, P1310, DOI 10.1634/theoncologist.2017-0621
   Oh SH, 2015, GUT LIVER, V9, P767, DOI 10.5009/gnl15176
   Sato K, 2007, CANCER RES, V67, P9677, DOI 10.1158/0008-5472.CAN-07-1462
   Siegel RL, 2019, CA-CANCER J CLIN, V69, P7, DOI 10.3322/caac.21551
   Siegel RL, 2017, CA-CANCER J CLIN, V67, P177, DOI 10.3322/caac.21395
   Szlendak M, 2020, MOL CLIN ONCOL, V13, DOI 10.3892/mco.2020.2122
   Yang SK, 2014, GUT, V63, P80, DOI 10.1136/gutjnl-2013-305193
   Yin LL, 2014, NEUROSCI LETT, V562, P34, DOI 10.1016/j.neulet.2013.12.070
NR 30
TC 2
Z9 2
U1 5
U2 5
PU AME PUBL CO
PI SHATIN
PA FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG
   00000, PEOPLES R CHINA
SN 2078-6891
EI 2219-679X
J9 J GASTROINTEST ONCOL
JI J. Gastrointest. Oncol.
PD OCT
PY 2021
VL 12
IS 5
BP 2192
EP 2202
DI 10.21037/jgo-21-495
EA SEP 2021
PG 11
WC Oncology; Gastroenterology & Hepatology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Gastroenterology & Hepatology
GA WR6KF
UT WOS:000706453900001
PM 34790384
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Arun, RP
   Sivanesan, D
   Vidyasekar, P
   Verma, RS
AF Arun, Raj Pranap
   Sivanesan, Divya
   Vidyasekar, Prasanna
   Verma, Rama Shanker
TI PTEN/FOXO3/AKT pathway regulates cell death and mediates morphogenetic
   differentiation of Colorectal Cancer Cells under Simulated Microgravity
SO SCIENTIFIC REPORTS
LA English
DT Article
ID TUMOR-SUPPRESSOR; E-CADHERIN; PTEN; MIGRATION; P15(INK4B); INDUCTION;
   AUTOPHAGY; STRESS; STEM; AKT
AB Gravity is a major physical factor determining the stress and strain around cells. Both in space experiments and ground simulation, change in gravity impacts the viability and function of various types of cells as well as in vivo conditions. Cancer cells have been shown to die under microgravity. This can be exploited for better understanding of the biology and identification of novel avenues for therapeutic intervention. Here, we described the effect of microgravity simulated using Rotational Cell Culture System-High Aspect Ratio Vessel (RCCS-HARV) on the viability and morphological changes of colorectal cancer cells. We observed DLD1, HCT116 and SW620 cells die through apoptosis under simulated microgravity (SM). Gene expression analysis on DLD1 cells showed upregulation of tumor suppressors PTEN and FOXO3; leading to AKT downregulation and further induction of apoptosis, through upregulation of CDK inhibitors CDKN2B, CDKN2D. SM induced cell clumps had elevated hypoxia and mitochondrial membrane potential that led to adaptive responses like morphogenetic changes, migration and deregulated autophagy, when shifted to normal culture conditions. This can be exploited to understand the three-dimensional (3D) biology of cancer in the aspect of stress response. This study highlights the regulation of cell function and viability under microgravity through PTEN/FOXO3/AKT pathway.
C1 [Arun, Raj Pranap; Sivanesan, Divya; Verma, Rama Shanker] Indian Inst Technol Madras, Dept Biotechnol, Bhupat & Jyoti Mehta Sch Biosci, Stem Cell & Mol Biol Lab, Madras 600036, Tamil Nadu, India.
   [Vidyasekar, Prasanna] CSI NUS, Singapore, Singapore.
RP Verma, RS (corresponding author), Indian Inst Technol Madras, Dept Biotechnol, Bhupat & Jyoti Mehta Sch Biosci, Stem Cell & Mol Biol Lab, Madras 600036, Tamil Nadu, India.
EM vermars@iitm.ac.in
OI Arun, Raj Pranap/0000-0001-5746-4728; Verma, Rama/0000-0001-7287-7803
FU Defense Research Development organizationDefence Research & Development
   Organisation (DRDO) [DLS/81/48222/LSRB-273/SHDD/2013]; Indian Institute
   of Technology Madras, India; Ministry of Human Resource Department,
   India
FX We wish to thank the Defense Research Development organization for
   supporting this work (DLS/81/48222/LSRB-273/SH&DD/2013). Raj Pranap Arun
   and Divya Sivanesan wish to thank Indian Institute of Technology Madras,
   and Ministry of Human Resource Department, India for their fellowship.
   We thank all the previous researchers and their findings which has led
   us to this output.
CR Agarwal E, 2013, CELL SIGNAL, V25, P1711, DOI 10.1016/j.cellsig.2013.03.025
   Bartkova J, 1996, INT J CANCER, V66, P732, DOI 10.1002/(SICI)1097-0215(19960611)66:6<732::AID-IJC4>3.0.CO;2-0
   Beitner-Johnson D, 2001, CELL SIGNAL, V13, P23, DOI 10.1016/S0898-6568(00)00128-5
   Brenner H, 2014, LANCET, V383, P1490, DOI 10.1016/S0140-6736(13)61649-9
   Burgering BMT, 2003, J LEUKOCYTE BIOL, V73, P689, DOI 10.1189/jlb.1202629
   Campbell K, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8998
   Carracedo A, 2008, ONCOGENE, V27, P5527, DOI 10.1038/onc.2008.247
   Chalhoub N, 2009, ANNU REV PATHOL-MECH, V4, P127, DOI 10.1146/annurev.pathol.4.110807.092311
   Chang CJ, 2008, MOL CELL BIOL, V28, P3281, DOI 10.1128/MCB.00310-08
   Crawford-Young SJ, 2006, INT J DEV BIOL, V50, P183, DOI 10.1387/ijdb.052077sc
   Cui DW, 2014, TUMOR BIOL, V35, P3017, DOI 10.1007/s13277-013-1389-4
   Dillon LM, 2014, CURR DRUG TARGETS, V15, P65, DOI 10.2174/1389450114666140106100909
   Discher D, 2009, ANN BIOMED ENG, V37, P847, DOI 10.1007/s10439-009-9661-x
   Doolin EJ, 1999, TISSUE ENG, V5, P573, DOI 10.1089/ten.1999.5.573
   Fang XJ, 2000, P NATL ACAD SCI USA, V97, P11960, DOI 10.1073/pnas.220413597
   Fournier MV, 2009, CANCER RES, V69, P4545, DOI 10.1158/0008-5472.CAN-08-1694
   Gaignier F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092664
   Gargini R, 2015, STEM CELLS, V33, P646, DOI 10.1002/stem.1904
   Goodwin T. J, 1997, IN VITRO CELLULAR DE, V33
   Helenius K, 2009, MOL CELL BIOL, V29, P315, DOI 10.1128/MCB.00347-08
   Herranz R, 2013, ASTROBIOLOGY, V13, P1, DOI 10.1089/ast.2012.0876
   Holland JD, 2013, CURR OPIN CELL BIOL, V25, P254, DOI 10.1016/j.ceb.2013.01.004
   Hui RCY, 2008, MOL CELL BIOL, V28, P5886, DOI 10.1128/MCB.01265-07
   Ingram M, 1997, IN VITRO CELL DEV-AN, V33, P459
   Jessup JM, 1997, IN VITRO CELL DEV-AN, V33, P352
   JESSUP JM, 1993, J CELL BIOCHEM, V51, P290, DOI 10.1002/jcb.240510308
   Katayama K, 2008, ONCOGENE, V27, P1677, DOI 10.1038/sj.onc.1210813
   Keith B, 2007, CELL, V129, P465, DOI 10.1016/j.cell.2007.04.019
   Kim Y, 2009, CURR MOL MED, V9, P425, DOI 10.2174/156652409788167113
   Kitagishi Y, 2013, INT J MOL MED, V31, P511, DOI 10.3892/ijmm.2013.1235
   Kopp S, 2016, SCI REP-UK, V6, DOI 10.1038/srep26887
   Krimpenfort P, 2007, NATURE, V448, P943, DOI 10.1038/nature06084
   Mackeh R, 2013, J CELL SCI, V126, P1071, DOI 10.1242/jcs.115626
   Malinowsky K, 2014, BRIT J CANCER, V110, P2081, DOI 10.1038/bjc.2014.100
   Mallipattu S, 2015, FASEB J, V29
   Masiello MG, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/652434
   Mitsuhara T, 2013, STEM CELL RES THER, V4, DOI 10.1186/scrt184
   MOOS PJ, 1994, EXP CELL RES, V213, P458, DOI 10.1006/excr.1994.1223
   Negri FV, 2010, BRIT J CANCER, V102, P162, DOI 10.1038/sj.bjc.6605471
   Papaseit C, 2000, P NATL ACAD SCI USA, V97, P8364, DOI 10.1073/pnas.140029597
   Peixoto P, 2016, ONCOGENE, V35, P4481, DOI 10.1038/onc.2015.506
   Polacheck WJ, 2011, P NATL ACAD SCI USA, V108, P11115, DOI 10.1073/pnas.1103581108
   Rhee HW, 2001, IN VITRO CELL DEV-AN, V37, P127
   Rice KM, 2010, BIOTECHNOL APPL BIOC, V55, P85, DOI 10.1042/BA20090258
   Roa I, 2015, DIAGN PATHOL, V10, DOI 10.1186/s13000-015-0381-2
   Ryu HW, 2014, DNA CELL BIOL, V33, P128, DOI 10.1089/dna.2013.2089
   Saika S, 2004, INVEST OPHTH VIS SCI, V45, P100, DOI 10.1167/iovs.03-0700
   Salnikov AV, 2003, FASEB J, V17, P1756, DOI 10.1096/fj.02-1201fje
   Sandona D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033232
   Sandri M, 2004, CELL, V117, P399, DOI 10.1016/S0092-8674(04)00400-3
   Shi F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040365
   Siamwala JH, 2010, PROTOPLASMA, V242, P3, DOI 10.1007/s00709-010-0114-z
   Sui X, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.350
   Sun JH, 2016, J BIOMECH, V49, P45, DOI 10.1016/j.jbiomech.2015.11.007
   Sunayama J, 2011, STEM CELLS, V29, P1327, DOI 10.1002/stem.696
   Tan JL, 2016, MOL CELL, V62, P34, DOI 10.1016/j.molcel.2016.03.013
   Toso A, 2014, CELL REP, V9, P75, DOI 10.1016/j.celrep.2014.08.044
   Vassy J, 2003, ADV SPACE RES-SERIES, V32, P1595, DOI 10.1016/S0273-1177(03)90400-5
   Vidyasekar P, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135958
   Wall SJ, 2007, J BIOL CHEM, V282, P24471, DOI 10.1074/jbc.M702697200
   Yun Z, 2014, ADV EXP MED BIOL, V772, P41, DOI 10.1007/978-1-4614-5915-6_2
   Zhang XB, 2011, BBA-MOL CELL RES, V1813, P1978, DOI 10.1016/j.bbamcr.2011.03.010
NR 62
TC 27
Z9 28
U1 0
U2 8
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD JUL 20
PY 2017
VL 7
AR 5952
DI 10.1038/s41598-017-06416-4
PG 15
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA FB1MN
UT WOS:000405907800006
PM 28729699
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Ko, YH
   Cho, YS
   Won, HS
   An, HJ
   Sun, DS
   Hong, SU
   Park, JH
   Lee, MA
AF Ko, Yoon Ho
   Cho, Young-Seok
   Won, Hye Sung
   An, Ho Jung
   Sun, Der Sheng
   Hong, Soon Uk
   Park, Jin Hee
   Lee, Myung Ah
TI Stage-Stratified Analysis of Prognostic Significance of Bax-Interacting
   Factor-1 Expression in Resected Colorectal Cancer
SO BIOMED RESEARCH INTERNATIONAL
LA English
DT Article
ID DECREASED EXPRESSION; BIF-1; AUTOPHAGY; PROTEIN; TUMOR
AB Background/Aim. Bax-interacting factor-1 (Bif-1) plays a crucial role in apoptosis and autophagy. The aim of this study was to evaluate Bif-1 protein expression and its prognostic significance in colorectal cancer (CRC). Methods. We analyzed Bif-1 protein expression in 251 resected specimens from patients with CRC by immunohistochemistry using tissue microarray. Results. Low Bif-1 expression was observed in 131 patients (52.2%) and high Bif-1 expression in 120 patients (47.8%). No significant differences were observed in clinicopathological parameters between patients with high and low Bif-1 expression. Kaplan-Meier survival analysis showed no difference in survival between patients with high and low Bif-1 expression. Stratified analysis of Bif-1 according to TNM stage demonstrated that low Bif-1 expression was significantly associated with a poor outcome in patients with stages I and II (P = 0.034). Stratified multivariate analysis demonstrated that low Bif-1 expression was an independent indicator of poor prognosis (hazard ratio, 0.459; 95% confidence interval, 0.285-0.739;P = 0.001). Conclusion. Patients with low levels of Bif-1 expression have shortened survival rates in CRC of stages I and II. This suggests that Bif-1 protein expression may be a useful prognostic marker in early-stage CRC.
C1 [Ko, Yoon Ho; Cho, Young-Seok; Won, Hye Sung; An, Ho Jung; Sun, Der Sheng] Catholic Univ Korea, Coll Med, Uijeongbu St Marys Hosp, Dept Internal Med, Uijongbu 480717, South Korea.
   [Hong, Soon Uk] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Pathol, Seoul 138736, South Korea.
   [Park, Jin Hee] Catholic Univ Korea, Coll Med, Dept Biomed Sci, Seoul 137701, South Korea.
   [Lee, Myung Ah] Catholic Univ Korea, Coll Med, Seoul St Marys Hosp, Dept Internal Med, Seoul 137701, South Korea.
RP Cho, YS (corresponding author), Catholic Univ Korea, Coll Med, Uijeongbu St Marys Hosp, Dept Internal Med, Uijongbu 480717, South Korea.
EM yscho@catholic.ac.kr
FU Institute of Clinical Medicine Research, Uijeongbu St. Mary's Hospital;
   Catholic University of Korea; National Research Foundation of Korea
   (NRF)National Research Foundation of Korea; Ministry of Education,
   Science and TechnologyMinistry of Education, Science and Technology,
   Republic of Korea [2010-0023295]; Sanofi-Aventis Korea RD Project
FX This study was supported by a grant of the Institute of Clinical
   Medicine Research, Uijeongbu St. Mary's Hospital, The Catholic
   University of Korea (Young-Seok Cho and Yoon Ho Ko), grant of Basic
   Science Research Program through the National Research Foundation of
   Korea (NRF) funded by the Ministry of Education, Science and Technology
   (2010-0023295) (Young-Seok Cho), and grant of Sanofi-Aventis Korea R&D
   Project made in the program year of 2011 (Young-Seok Cho).
CR Camps J, 2006, CARCINOGENESIS, V27, P419, DOI 10.1093/carcin/bgi244
   Coppola D, 2008, CANCER-AM CANCER SOC, V113, P2665, DOI 10.1002/cncr.23892
   Coppola D, 2008, CLIN GENITOURIN CANC, V6, P117, DOI 10.3816/CGC.2008.n.018
   Coppola D, 2011, PANCREAS, V40, P433, DOI 10.1097/MPA.0b013e318205eb03
   Cuddeback SM, 2001, J BIOL CHEM, V276, P20559, DOI 10.1074/jbc.M101527200
   Fan RG, 2012, ONCOL LETT, V3, P851, DOI 10.3892/ol.2012.562
   Hector S, 2009, BBA-REV CANCER, V1795, P117, DOI 10.1016/j.bbcan.2008.12.002
   Ho J, 2009, J PROTEOME RES, V8, P583, DOI 10.1021/pr8007368
   Jansson A, 2002, J CLIN ONCOL, V20, P811, DOI 10.1200/JCO.20.3.811
   Katkoori VR, 2010, J GASTROINTEST ONCOL, V1, P76, DOI 10.3978/j.issn.2078-6891.2010.019
   Kim MS, 2008, APMIS, V116, P939, DOI 10.1111/j.1600-0463.2008.01091.x
   Kim SY, 2008, PATHOLOGY, V40, P553, DOI 10.1080/00313020802320440
   Knosel T, 2002, VIRCHOWS ARCH, V440, P187, DOI 10.1007/s004280100493
   Knuutila S, 1999, AM J PATHOL, V155, P683, DOI 10.1016/S0002-9440(10)65166-8
   Lee JW, 2006, PATHOLOGY, V38, P312, DOI 10.1080/00313020600820880
   Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257
   Marx J, 2006, SCIENCE, V312, P1160, DOI 10.1126/science.312.5777.1160
   Mathew R, 2009, METHOD ENZYMOL, V453, P53, DOI 10.1016/S0076-6879(08)04004-4
   Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639
   Pierrat B, 2001, GENOMICS, V71, P222, DOI 10.1006/geno.2000.6378
   Pisani P, 1999, INT J CANCER, V83, P18, DOI 10.1002/(SICI)1097-0215(19990924)83:1&lt;18::AID-IJC5&gt;3.0.CO;2-M
   Sturm I, 1999, J CLIN ONCOL, V17, P1364, DOI 10.1200/JCO.1999.17.5.1364
   Sung JJY, 2005, LANCET ONCOL, V6, P871, DOI 10.1016/S1470-2045(05)70422-8
   Takahashi Y, 2005, MOL CELL BIOL, V25, P9369, DOI 10.1128/MCB.25.21.9369-9382.2005
   Takahashi Y, 2007, NAT CELL BIOL, V9, P1142, DOI 10.1038/ncb1634
   Takahashi Y, 2013, BLOOD, V121, P1622, DOI 10.1182/blood-2012-10-459826
   Takahashi Y, 2011, AUTOPHAGY, V7, P61, DOI 10.4161/auto.7.1.14015
   Weitz J, 2005, LANCET, V365, P153, DOI 10.1016/S0140-6736(05)17706-X
NR 28
TC 4
Z9 4
U1 0
U2 3
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2314-6133
EI 2314-6141
J9 BIOMED RES INT
JI Biomed Res. Int.
PY 2013
VL 2013
AR 329839
DI 10.1155/2013/329839
PG 8
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA 231HN
UT WOS:000325407100001
PM 24175288
OA gold, Green Published, Green Submitted
DA 2022-04-25
ER

PT J
AU Bretin, L
   Pinon, A
   Bouramtane, S
   Ouk, C
   Richard, L
   Perrin, ML
   Chaunavel, A
   Carrion, C
   Bregier, F
   Sol, V
   Chaleix, V
   Leger, DY
   Liagre, B
AF Bretin, Ludovic
   Pinon, Aline
   Bouramtane, Soukaina
   Ouk, Catherine
   Richard, Laurence
   Perrin, Marie-Laure
   Chaunavel, Alain
   Carrion, Claire
   Bregier, Frederique
   Sol, Vincent
   Chaleix, Vincent
   Leger, David Yannick
   Liagre, Bertrand
TI Photodynamic Therapy Activity of New Porphyrin-Xylan-Coated Silica
   Nanoparticles in Human Colorectal Cancer
SO CANCERS
LA English
DT Article
DE anticancer drug; porphyrin; silica nanoparticles; drug delivery;
   photodynamic therapy
ID DRUG-CARRIER; IN-VITRO; AUTOPHAGY; APOPTOSIS; PHOTOSENSITIZERS;
   BIODISTRIBUTION; MECHANISMS; EFFICIENCY; INHIBITION; EFFICACY
AB Photodynamic therapy (PDT) using porphyrins has been approved for treatment of several solid tumors due to the generation of cytotoxic reactive oxygen species (ROS). However, low physiological solubility and lack of selectivity towards tumor sites are the main limitations of their clinical use. Nanoparticles are able to spontaneously accumulate in solid tumors through an enhanced permeability and retention (EPR) effect due to leaky vasculature, poor lymphatic drainage, and increased vessel permeability. Herein, we proved the added value of nanoparticle vectorization on anticancer efficacy and tumor-targeting by 5-(4-hydroxyphenyl)-10,15,20-triphenylporphyrin (TPPOH). Using 80 nm silica nanoparticles (SNPs) coated with xylan-TPPOH conjugate (TPPOH-X), we first showed very significant phototoxic effects of TPPOH-X SNPs mediated by post-PDT ROS generation and stronger cell uptake in human colorectal cancer cell lines compared to free TPPOH. Additionally, we demonstrated apoptotic cell death induced by TPPOH-X SNPs-PDT and the interest of autophagy inhibition to increase anticancer efficacy. Finally, we highlighted in vivo, without toxicity, elevated anticancer efficacy of TPPOH-X SNPs through improvement of tumor-targeting compared to a free TPPOH protocol. Our work demonstrated for the first time the strong anticancer efficacy of TPPOH in vitro and in vivo and the merit of SNPs vectorization.
C1 [Bretin, Ludovic; Pinon, Aline; Leger, David Yannick; Liagre, Bertrand] Univ Limoges, Fac Pharm, Lab PEIRENE EA 7500, 2 Rue Docteur Raymond Marcland, F-87025 Limoges, France.
   [Bouramtane, Soukaina; Bregier, Frederique; Sol, Vincent; Chaleix, Vincent] Univ Limoges, Fac Sci & Tech, Lab PEIRENE EA 7500, 123 Ave Albert Thomas, F-87060 Limoges, France.
   [Ouk, Catherine; Carrion, Claire] Univ Limoges, BISCEm Pole Cytometrie Flux Microscop, 2 Rue Docteur Raymond Marcland, F-87025 Limoges, France.
   [Richard, Laurence; Chaunavel, Alain] CHU Limoges, Serv Anat Pathol, 2 Ave Martin Luther King, F-87042 Limoges, France.
   [Perrin, Marie-Laure] Univ Limoges, Fac Med, Lab Bio XLIM UMR CNRS 7252, 2 Rue Docteur Raymond Marcland, F-87025 Limoges, France.
RP Liagre, B (corresponding author), Univ Limoges, Fac Pharm, Lab PEIRENE EA 7500, 2 Rue Docteur Raymond Marcland, F-87025 Limoges, France.
EM ludovic.bretin@unilim.fr; aline.pinon@unilim.fr;
   soukaina.bouramtane@unilim.fr; catherine.ouk@unilim.fr;
   laurence.richard@unilim.fr; marie-laure.perrin@unilim.fr;
   alain.chaunavel@chu-limoges.fr; claire.carrion@unilim.fr;
   frederique.bregier@unilim.fr; vincent.sol@unilim.fr;
   vincent.chaleix@unilim.fr; david.leger@unilim.fr;
   bertrand.liagre@unilim.fr
RI BREGIER, Frederique/AAX-5993-2020
OI BREGIER, Frederique/0000-0002-9880-7616; Pinon,
   Aline/0000-0002-3123-7495; carrion, claire/0000-0003-3221-6319; Liagre,
   Bertrand/0000-0003-4148-2598; BRETIN, Ludovic/0000-0002-2949-0512;
   chaleix, vincent/0000-0002-5324-3095; bouramtane,
   soukaina/0000-0002-7972-5148; sol, vincent/0000-0003-0175-0156;
   CHAUNAVEL, Alain/0000-0003-2419-8974
FU Ministere de l'Enseignement Superieur, de la Recherche et de
   l'Innovation through the European Fund of Regional Development FEDER;
   Conseil Regional Nouvelle Aquitaine
FX The expenses of this work were defrayed in part by the Ministere de
   l'Enseignement Superieur, de la Recherche et de l'Innovation through the
   European Fund of Regional Development FEDER 2014-2020 and by the Conseil
   Regional Nouvelle Aquitaine.
CR Abrahamse H, 2016, BIOCHEM J, V473, P347, DOI 10.1042/BJ20150942
   [Anonymous], 2001, NIH PUBLICATION, V01-4500
   Baldea I, 2015, J PHOTOCH PHOTOBIO B, V151, P142, DOI 10.1016/j.jphotobiol.2015.07.019
   Bharathiraja S, 2017, PHOTODIAGN PHOTODYN, V19, P212, DOI 10.1016/j.pdpdt.2017.06.001
   Bouramtane S, 2019, CARBOHYD POLYM, V213, P168, DOI 10.1016/j.carbpol.2019.02.070
   Brezaniova I, 2018, PHOTODIAGN PHOTODYN, V21, P275, DOI 10.1016/j.pdpdt.2017.12.014
   Chan WT, 2017, INT J NANOMED, V12, P3421, DOI 10.2147/IJN.S126823
   Chen Y, 2013, ADV MATER, V25, P3144, DOI 10.1002/adma.201205292
   Cho MJ, 2009, TOXICOL LETT, V189, P177, DOI 10.1016/j.toxlet.2009.04.017
   Costa LD, 2016, MOLECULES, V21, DOI 10.3390/molecules21040439
   Couleaud P, 2010, NANOSCALE, V2, P1083, DOI 10.1039/c0nr00096e
   Daus S, 2010, MACROMOL BIOSCI, V10, P211, DOI 10.1002/mabi.200900201
   Debele TA, 2015, INT J MOL SCI, V16, P22094, DOI 10.3390/ijms160922094
   DeRosa MC, 2002, COORDIN CHEM REV, V233, P351, DOI 10.1016/S0010-8545(02)00034-6
   Dolmans DEJGJ, 2003, NAT REV CANCER, V3, P380, DOI 10.1038/nrc1071
   Duan X, 2018, APOPTOSIS, V23, P587, DOI 10.1007/s10495-018-1489-0
   Elmore S, 2007, TOXICOL PATHOL, V35, P495, DOI 10.1080/01926230701320337
   Fidanzi-Dugas C, 2017, BBA-GEN SUBJECTS, V1861, P1676, DOI 10.1016/j.bbagen.2017.02.003
   Globocan, 2018, EST CANC INC MORT PR
   Gref R., 2002, SYNTHESIS FUNCTIONAL, P233
   Hackbarth S, 2001, CHEM PHYS, V269, P339, DOI 10.1016/S0301-0104(01)00337-8
   Hamblin Michael R., 2008, P1
   Huang YY, 2012, NANOTECHNOL REV, V1, P111, DOI 10.1515/ntrev-2011-0005
   Iyer AK, 2006, DRUG DISCOV TODAY, V11, P812, DOI 10.1016/j.drudis.2006.07.005
   Janku F, 2011, NAT REV CLIN ONCOL, V8, P528, DOI 10.1038/nrclinonc.2011.71
   Kawczyk-Krupka A, 2016, PHOTODIAGN PHOTODYN, V13, P158, DOI 10.1016/j.pdpdt.2015.07.175
   Kumar R, 2010, ACS NANO, V4, P699, DOI 10.1021/nn901146y
   Kwiatkowski S, 2018, BIOMED PHARMACOTHER, V106, P1098, DOI 10.1016/j.biopha.2018.07.049
   Lai K, 2014, J CLIN PATHOL, V67, P854, DOI 10.1136/jclinpath-2014-202529
   Lee YT, 2018, EUR J PHARMACOL, V834, P188, DOI 10.1016/j.ejphar.2018.07.034
   Lemarchand C, 2004, EUR J PHARM BIOPHARM, V58, P327, DOI 10.1016/j.ejpb.2004.02.016
   Lepage C, 2011, CANCER LETT, V301, P193, DOI 10.1016/j.canlet.2010.12.003
   Li J, 2010, EUR J CANCER, V46, P1900, DOI 10.1016/j.ejca.2010.02.021
   Li X, 2015, CANCER LETT, V357, P219, DOI 10.1016/j.canlet.2014.11.026
   Li Y, 2007, CHEM MATER, V19, P5557, DOI 10.1021/cm071451m
   Liao PY, 2016, J PHOTOCH PHOTOBIO B, V165, P213, DOI 10.1016/j.jphotobiol.2016.10.031
   Liu TL, 2011, BIOMATERIALS, V32, P1657, DOI 10.1016/j.biomaterials.2010.10.035
   Liu X, 2010, BIOMATERIALS, V31, P8198, DOI 10.1016/j.biomaterials.2010.07.069
   Lu J, 2010, SMALL, V6, P1794, DOI 10.1002/smll.201000538
   Ma JL, 2018, CARBOHYD POLYM, V199, P382, DOI 10.1016/j.carbpol.2018.07.003
   Matsuda T, 2018, ANN GASTROENT SURG, V2, P129, DOI 10.1002/ags3.12061
   Mroz Pawel, 2011, Cancers (Basel), V3, P2516, DOI 10.3390/cancers3022516
   Owens DE, 2006, INT J PHARMACEUT, V307, P93, DOI 10.1016/j.ijpharm.2005.10.010
   Plaetzer K, 2003, MED LASER APPL, V18, P7, DOI DOI 10.1078/1615-1615-00082
   Rajesh K.S., 2012, J CANC RES UPDATES, V1, P129
   Roby A, 2007, CANCER BIOL THER, V6, P1136, DOI 10.4161/cbt.6.7.4345
   Roy I, 2003, J AM CHEM SOC, V125, P7860, DOI 10.1021/ja0343095
   Sauraj, 2019, INT J BIOL MACROMOL, V128, P204, DOI 10.1016/j.ijbiomac.2019.01.101
   Sauraj, 2018, CARBOHYD POLYM, V188, P252, DOI 10.1016/j.carbpol.2018.02.006
   Secret E, 2013, CHEM COMMUN, V49, P4202, DOI 10.1039/c3cc38837a
   Sergent JA, 2012, ANN OCCUP HYG, V56, P622, DOI 10.1093/annhyg/mes005
   Shrotri A, 2017, ADV CATAL, V60, P59, DOI 10.1016/bs.acat.2017.09.002
   Simon V, 2010, PHOTOCHEM PHOTOBIOL, V86, P213, DOI 10.1111/j.1751-1097.2009.00620.x
   Skulachev Vladimir P., 1999, Molecular Aspects of Medicine, V20, P139, DOI 10.1016/S0098-2997(99)00008-4
   Tu PH, 2016, ONCOL REP, V35, P3209, DOI 10.3892/or.2016.4703
   Van der Jeught K, 2018, WORLD J GASTROENTERO, V24, P3834, DOI 10.3748/wjg.v24.i34.3834
   Wei MF, 2014, AUTOPHAGY, V10, P1179, DOI 10.4161/auto.28679
   Wolpin BM, 2008, GASTROENTEROLOGY, V134, P1296, DOI 10.1053/j.gastro.2008.02.098
   Wu M, 2019, THERANOSTICS, V9, P20, DOI 10.7150/thno.28857
   Wu X, 2014, NANOMED-NANOTECHNOL, V10, P297, DOI 10.1016/j.nano.2013.08.008
   Xiong L, 2017, ONCOTARGET, V8, P6419, DOI 10.18632/oncotarget.14117
   Xue L, 2018, CURR PROB SURG, V55, P76, DOI 10.1067/j.cpsurg.2018.02.003
   Xue Q, 2015, PHOTODIAGN PHOTODYN, V12, P84, DOI 10.1016/j.pdpdt.2014.12.001
   Youssef Z, 2018, PHOTODIAGN PHOTODYN, V22, P115, DOI 10.1016/j.pdpdt.2018.03.005
   ZHOU CN, 1989, J PHOTOCH PHOTOBIO B, V3, P299, DOI 10.1016/1011-1344(89)80035-1
   Zhou YM, 2016, NANOSCALE, V8, P12394, DOI 10.1039/c5nr07849k
   Zhu J, 2018, CANCER MED-US, V7, P1908, DOI 10.1002/cam4.1418
NR 67
TC 25
Z9 25
U1 4
U2 25
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2072-6694
J9 CANCERS
JI Cancers
PD OCT
PY 2019
VL 11
IS 10
AR 1474
DI 10.3390/cancers11101474
PG 27
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA JQ3CF
UT WOS:000498826000071
PM 31575052
OA Green Submitted, Green Published, gold
DA 2022-04-25
ER

PT J
AU Zhao, WH
   Shi, FQ
   Guo, ZK
   Zhao, JJ
   Song, XY
   Yang, H
AF Zhao, Wenhua
   Shi, Fengqiang
   Guo, Zhikun
   Zhao, Jiaojie
   Song, Xueying
   Yang, Hua
TI Metabolite of ellagitannins, urolithin A induces autophagy and inhibits
   metastasis in human sw620 colorectal cancer cells
SO MOLECULAR CARCINOGENESIS
LA English
DT Article
DE autophagy; colorectal cancer; matrix metallo proteinases; metastasis;
   urolithin A
ID TEA POLYPHENOLS; ELLAGIC ACID; IN-VITRO; POMEGRANATE ELLAGITANNINS;
   DIETARY POLYPHENOLS; APOPTOSIS; MIGRATION; INVASION; INVOLVEMENT;
   EXPRESSION
AB Autophagy is an evolutionarily conserved pathway in which cytoplasmic contents are degraded and recycled. This study found that submicromolar concentrations of urolithin A, a major polyphenol metabolite, induced autophagy in SW620 colorectal cancer (CRC) cells. Exposure to urolithin A also dose-dependently decreased cell proliferation, delayed cell migration, and decreased matrix metalloproteinas-9 (MMP-9) activity. In addition, inhibition of autophagy by Atg5-siRNA, caspases by Z-VAD-FMK suppressed urolithin A-stimulated cell death and anti-metastatic effects. Micromolar urolithin A concentrations induced both autophagy and apoptosis. Urolithin A suppressed cell cycle progression and inhibited DNA synthesis. These results suggest that dietary consumption of urolithin A could induce autophagy and inhibit human CRC cell metastasis. Urolithins may thus contribute to CRC treatment and offer an alternative or adjunct chemotherapeutic agent to combat this disease.
C1 [Zhao, Wenhua; Shi, Fengqiang; Guo, Zhikun; Zhao, Jiaojie; Song, Xueying; Yang, Hua] Capital Med Univ, Sch Pharmaceut Sci, Beijing 100069, Peoples R China.
RP Zhao, WH (corresponding author), Capital Med Univ, Sch Pharmaceut Sci, Beijing 100069, Peoples R China.
EM zwhua@ccmu.edu.cn
FU National Science Foundation of ChinaNational Natural Science Foundation
   of China (NSFC) [21201124]; Beijing Municipal Institutions
   [CITTCD201304176]; Chinese Government [Z141100002114049, KM201310025007]
FX National Science Foundation of China, Grant number: 21201124; Beijing
   Municipal Institutions, Grant number: CIT&TCD201304176; Chinese
   Government, Grant number: Z141100002114049; Chinese Government, Grant
   number: KM201310025007
CR Adams LS, 2010, CANCER PREV RES, V3, P108, DOI 10.1158/1940-6207.CAPR-08-0225
   agata RT, 2015, ONCOTARGET, V27, P1
   Aichinger G, 2017, MOL NUTR FOOD RES, V61, DOI 10.1002/mnfr.201600462
   Babykutty S, 2012, MOL CARCINOGEN, V51, P475, DOI 10.1002/mc.20812
   Bendardaf R, 2010, CANCER INVEST, V28, P38, DOI 10.3109/07357900802672761
   Bialonska D, 2009, J AGR FOOD CHEM, V57, P10181, DOI 10.1021/jf9025794
   Cho H, 2015, FOOD FUNCT, V6, P1675, DOI 10.1039/c5fo00274e
   Deryugina EI, 2006, CANCER METAST REV, V25, P9, DOI 10.1007/s10555-006-7886-9
   Dong YH, 2014, AUTOPHAGY, V10, P296, DOI 10.4161/auto.27210
   Fantini M, 2015, INT J MOL SCI, V16, P9236, DOI 10.3390/ijms16059236
   Ferraresi A, 2017, MOL CARCINOGEN, V56, P1164, DOI 10.1002/mc.22582
   Filomeni G, 2010, AUTOPHAGY, V6, P202, DOI 10.4161/auto.6.2.10971
   Furlanetto V, 2012, J AGR FOOD CHEM, V60, P9162, DOI 10.1021/jf302600q
   Gewirtz DA, 2013, AUTOPHAGY, V9, P1263, DOI 10.4161/auto.25233
   Gimenez-Bastida JA, 2012, FOOD CHEM, V132, P1465, DOI 10.1016/j.foodchem.2011.12.003
   Gonzalez-Sarrias A, 2016, MOL NUTR FOOD RES, V60, P701, DOI 10.1002/mnfr.201500780
   Gonzalez-Sarrias A, 2015, FOOD FUNCT, V6, P1460, DOI [10.1039/C5FO00120J, 10.1039/c5fo00120j]
   Gonzalez-Sarrias A, 2009, MOL NUTR FOOD RES, V53, P686, DOI 10.1002/mnfr.200800150
   Halder B, 2008, CARCINOGENESIS, V29, P129, DOI 10.1093/carcin/bgm233
   Haraguchi T, 2014, J AGR FOOD CHEM, V62, P5589, DOI 10.1021/jf501142k
   Ito S, 2007, INT J ONCOL, V31, P261
   Jane EP, 2017, MOL CARCINOGEN, V56, P1251, DOI 10.1002/mc.22587
   Kang I, 2016, MOL NUTR FOOD RES, V60, P1129, DOI 10.1002/mnfr.201500796
   Kasimsetty SG, 2010, J AGR FOOD CHEM, V58, P2180, DOI 10.1021/jf903762h
   Kasimsetty SG, 2009, J AGR FOOD CHEM, V57, P10636, DOI 10.1021/jf902716r
   Khan N, 2015, CANCER LETT, V359, P155, DOI 10.1016/j.canlet.2015.01.038
   Lall RK, 2015, INT J MOL SCI, V16, P3350, DOI 10.3390/ijms16023350
   Landete JM, 2011, FOOD RES INT, V44, P1150, DOI 10.1016/j.foodres.2011.04.027
   Larrosa M, 2010, J NUTR BIOCHEM, V21, P717, DOI 10.1016/j.jnutbio.2009.04.012
   Lee Won Sup, 2014, J Cancer Prev, V19, P14
   Liao CC, 2013, AUTOPHAGY, V9, P5, DOI 10.4161/auto.22379
   Trung LQ, 2015, MOL NUTR FOOD RES, V59, P2143, DOI 10.1002/mnfr.201500166
   Martinez-Perez C, 2016, BRIT J CANCER, V114, P905, DOI 10.1038/bjc.2016.6
   Mukherjee S, 2013, J NUTR BIOCHEM, V24, P2040, DOI 10.1016/j.jnutbio.2013.07.005
   Nitta T, 2014, INT J CLIN EXP PATHO, V7, P4913
   O'Connell JB, 2004, JNCI-J NATL CANCER I, V96, P1420, DOI 10.1093/jnci/djh275
   Olennikov DN, 2015, NUTRIENTS, V7, P8456, DOI 10.3390/nu7105406
   Piwowarski JP, 2015, MOL NUTR FOOD RES, V59, P2168, DOI 10.1002/mnfr.201500264
   Qiu ZP, 2013, FOOD CHEM TOXICOL, V59, P428, DOI 10.1016/j.fct.2013.06.025
   Rodriguez J, 2017, MOL NUTR FOOD RES, V61, DOI 10.1002/mnfr.201600169
   Sancho M, 2015, NUTR HOSP, V31, P535, DOI 10.3305/nh.2015.31.2.8091
   Su ZY, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0321-5
   Thakur VS, 2012, CARCINOGENESIS, V33, P377, DOI 10.1093/carcin/bgr277
   Thorburn A, 2014, MOL PHARMACOL, V85, P830, DOI 10.1124/mol.114.091850
   Tian LL, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.455
   Tomas-Barberan FA, 2017, MOL NUTR FOOD RES, V61, DOI 10.1002/mnfr.201500901
   Tyagi N, 2010, J RECEPT SIG TRANSD, V30, P78, DOI 10.3109/10799891003614808
   Yang MP, 2015, ONCOTARGET, V6, P7084, DOI 10.18632/oncotarget.3054
   Yu XF, 2017, SCI REP-UK, V7, DOI 10.1038/srep42226
   Zakraoui O, 2017, MOL CARCINOGEN, V56, P18, DOI 10.1002/mc.22470
   Zhao WH, 2015, J CHROMATOGR B, V990, P111, DOI 10.1016/j.jchromb.2015.03.024
   Zhao WH, 2014, BIOCHEM BIOPH RES CO, V445, P346, DOI 10.1016/j.bbrc.2014.01.191
   Zhao X, 2014, NUTRIENTS, V6, P3084, DOI 10.3390/nu6083084
NR 53
TC 34
Z9 35
U1 2
U2 24
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0899-1987
EI 1098-2744
J9 MOL CARCINOGEN
JI Mol. Carcinog.
PD FEB
PY 2018
VL 57
IS 2
BP 193
EP 200
DI 10.1002/mc.22746
PG 8
WC Biochemistry & Molecular Biology; Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology
GA FR9PI
UT WOS:000419405200005
PM 28976622
OA hybrid, Green Published
DA 2022-04-25
ER

PT J
AU Jing, Z
   Fei, WQ
   Zhou, JC
   Zhang, LM
   Chen, LX
   Zhang, XM
   Liang, X
   Xie, JS
   Fang, Y
   Sui, XB
   Han, WD
   Pan, HM
AF Jing, Zhao
   Fei, Weiqiang
   Zhou, Jichun
   Zhang, Lumin
   Chen, Liuxi
   Zhang, Xiaomin
   Liang, Xiao
   Xie, Jiansheng
   Fang, Yong
   Sui, Xinbing
   Han, Weidong
   Pan, Hongming
TI Salvianolic acid B, a novel autophagy inducer, exerts antitumor activity
   as a single agent in colorectal cancer cells
SO ONCOTARGET
LA English
DT Article
DE salvianolic acid B; natural compound; autophagy; cell death; colorectal
   cancer
ID CERVICAL-CANCER; APOPTOSIS; PATHWAY; ACTIVATION; EXPRESSION; RESISTANCE;
   INHIBITOR; MECHANISM; P38
AB Salvianolic Acid B (Sal B), an active compound extracted from the Chinese herb Salvia miltiorrhiza, is attracting more and more attention due to its biological activities, including antioxidant, anticoagulant and antitumor effects. However, autophagy induction in cancer cells by Sal B has never been recognized. In this study, we demonstrated that Sal B induced cell death and triggered autophagy in HCT116 and HT29 cells in a dose-dependent manner. Specific inhibition of autophagy by 3-MA or shRNA targeting Atg5 rescued Sal B-induced cell death in vitro and in vivo, suggesting that Sal B-induced autophagy may play a pro-death role and contribute to the cell death of colorectal cancer cell lines. Furthermore, AKT/mTOR signaling pathway was demonstrated to be a critical mediator in regulating Sal B-induced cell death. Overexpression of AKT by the transfection with AKT plasmid or pretreatment with insulin decreased Sal B-induced autophagy and cell death. Inversely, inhibition of AKT by LY294002 treatment markedly enhanced Sal B-induced autophagy and cell death. Taken together, our results demonstrate, for the first time, that Sal B is a novel autophagy inducer and exerts its antitumor activity as a single agent in colorectal cancer cells through the suppression of AKT/mTOR pathway.
C1 [Jing, Zhao; Chen, Liuxi; Zhang, Xiaomin; Fang, Yong; Sui, Xinbing; Han, Weidong; Pan, Hongming] Zhejiang Univ, Sir Run Run Shaw Hosp, Dept Med Oncol, Coll Med, Hangzhou, Zhejiang, Peoples R China.
   [Jing, Zhao; Fei, Weiqiang; Zhang, Lumin; Xie, Jiansheng; Fang, Yong; Sui, Xinbing; Han, Weidong; Pan, Hongming] Zhejiang Univ, Coll Med, Biomed Res Ctr, Hangzhou, Zhejiang, Peoples R China.
   [Jing, Zhao; Fei, Weiqiang; Zhang, Lumin; Xie, Jiansheng; Fang, Yong; Sui, Xinbing; Han, Weidong; Pan, Hongming] Zhejiang Univ, Coll Med, Key Lab Biotherapy Zhejiang Prov, Hangzhou, Zhejiang, Peoples R China.
   [Zhou, Jichun] Zhejiang Univ, Sir Run Run Shaw Hosp, Dept Surg Oncol, Coll Med, Hangzhou, Zhejiang, Peoples R China.
   [Liang, Xiao] Zhejiang Univ, Sir Run Run Shaw Hosp, Dept Gen Surg, Coll Med, Hangzhou, Zhejiang, Peoples R China.
RP Sui, XB; Han, WD; Pan, HM (corresponding author), Zhejiang Univ, Sir Run Run Shaw Hosp, Dept Med Oncol, Coll Med, Hangzhou, Zhejiang, Peoples R China.; Sui, XB; Han, WD; Pan, HM (corresponding author), Zhejiang Univ, Coll Med, Biomed Res Ctr, Hangzhou, Zhejiang, Peoples R China.; Sui, XB; Han, WD; Pan, HM (corresponding author), Zhejiang Univ, Coll Med, Key Lab Biotherapy Zhejiang Prov, Hangzhou, Zhejiang, Peoples R China.
EM hzzju@aliyun.com; hanwd@126.com; drpanhm@aliyun.com
RI Zhou, Jichun/Q-8646-2019
OI Zhou, Jichun/0000-0002-0727-4034
FU Zhejiang province science and technology project of TCM [2015ZB033];
   National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81301891, 81572361, 81572592]; Zhengshu
   Medical Elite Scholarship Fund
FX This study is supported by grants from Zhejiang province science and
   technology project of TCM (grant No. 2015ZB033), National Natural
   Science Foundation of China (grant No. 81301891, 81572361 and 81572592)
   and Zhengshu Medical Elite Scholarship Fund.
CR Buchser WJ, 2012, CANCER RES, V72, P2970, DOI 10.1158/0008-5472.CAN-11-3396
   Chen J, 2015, ONCOTARGET, V6, P355, DOI 10.18632/oncotarget.2803
   Chen T, 2011, BRAIN RES BULL, V84, P163, DOI 10.1016/j.brainresbull.2010.11.015
   El Hasasna H, 2015, SCI REP-UK, V5, DOI 10.1038/srep13013
   Galluzzi L, 2015, EMBO J, V34, P856, DOI 10.15252/embj.201490784
   Garcia-Cano J, 2015, ONCOTARGET, V6, P15551, DOI 10.18632/oncotarget.3902
   Han XA, 2011, ACTA PHARMACOL SIN, V32, P38, DOI 10.1038/aps.2010.182
   Huang CL, 2016, SCI REP-UK, V6, DOI 10.1038/srep23884
   Janku F, 2011, NAT REV CLIN ONCOL, V8, P528, DOI 10.1038/nrclinonc.2011.71
   Kondo Y, 2005, NAT REV CANCER, V5, P726, DOI 10.1038/nrc1692
   Lao YZ, 2014, AUTOPHAGY, V10, P736, DOI 10.4161/auto.28034
   Lebovitz CB, 2015, AUTOPHAGY, V11, P1949, DOI 10.1080/15548627.2015.1078962
   Lin F, 2013, SHOCK, V39, P317, DOI 10.1097/SHK.0b013e318283773e
   Lu Q, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.344
   Pandey S, 2012, ASIAN PAC J CANCER P, V13, P4867, DOI 10.7314/APJCP.2012.13.10.4867
   Ren ZZ, 2014, BIO-MED MATER ENG, V24, P1333, DOI 10.3233/BME-130936
   Shao FY, 2015, ONCOTARGET, V6, P30939, DOI 10.18632/oncotarget.5132
   Shi J, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.44
   Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993
   Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI [10.3322/caac.21254, 10.3322/caac.21208, 10.1001/jamaoto.2014.2530, 10.1136/bmj.g1502]
   Sui X, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.350
   Wang QL, 2011, HEPATOB PANCREAT DIS, V10, P502, DOI 10.1016/S1499-3872(11)60085-4
   Wang X, 2015, PLOS ONE, V10, DOI [10.1371/journal.pone.0142136, 10.1371/journal.pone.0131771]
   Wang ZS, 2013, CELL MOL NEUROBIOL, V33, P921, DOI 10.1007/s10571-013-9958-z
   Yang Y, 2011, BMC COMPLEM ALTERN M, V11, DOI 10.1186/1472-6882-11-54
   Yang ZF, 2010, NAT CELL BIOL, V12, P814, DOI 10.1038/ncb0910-814
   Zhang Y, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.200
   Zhao F, 2016, ONCOTARGET, V7, P5366, DOI 10.18632/oncotarget.6783
   Zhao XJ, 2015, AUTOPHAGY, V11, P1849, DOI 10.1080/15548627.2015.1017185
   Zhao Y, 2011, J ONCOL, V2011, DOI 10.1155/2011/534548
   Zhong W, 2014, AUTOPHAGY, V10, P1285, DOI 10.4161/auto.28789
   Zhou LM, 2005, J CLIN PHARMACOL, V45, P1345, DOI 10.1177/0091270005282630
NR 32
TC 42
Z9 48
U1 0
U2 18
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD SEP 20
PY 2016
VL 7
IS 38
BP 61509
EP 61519
DI 10.18632/oncotarget.11385
PG 11
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA EB2CN
UT WOS:000387164700053
PM 27557491
OA Green Published, Green Submitted, gold
DA 2022-04-25
ER

PT J
AU Al-Harbi, SA
   Abdulrahman, AO
   Zamzami, MA
   Khan, MI
AF Al-Harbi, Sami A.
   Abdulrahman, Abdulrasheed O.
   Zamzami, Mazin A.
   Khan, Mohammad Imran
TI Urolithins: The Gut Based Polyphenol Metabolites of Ellagitannins in
   Cancer Prevention, a Review
SO FRONTIERS IN NUTRITION
LA English
DT Review
DE anticancer; ellagitannins; metabolites; polyphenols; urolithins
ID ELLAGIC ACID; CELL-CYCLE; COLONIC METABOLITE; COLORECTAL-CANCER;
   IN-VITRO; ANTIPROLIFERATIVE ACTIVITY; POMEGRANATE ELLAGITANNINS;
   MICROBIOTA METABOLITE; NATURAL POLYPHENOLS; DIETARY POLYPHENOLS
AB Cancer as a disease continues to ravage the world population without regard to sex, age, and race. Due to the growing number of cases worldwide, cancer exerts a significant negative impact on global health and the economy. Interestingly, chemotherapy has been used over the years as a therapeutic intervention against cancer. However, high cost, resistance, and toxic by-effects to treatment have overshadowed some of its benefits. In recent times, efforts have been ongoing in searching for anticancer therapeutics of plant origin, focusing on polyphenols. Urolithins are secondary polyphenol metabolites derived from the gut microbial action on ellagitannins and ellagic acid-rich foods such as pomegranate, berries, and nuts. Urolithins are emerging as a new class of anticancer compounds that can mediate their cancer-preventive activities through cell cycle arrest, aromatase inhibition, induction of apoptosis, tumor suppression, promotion of autophagy, and senescence, transcriptional regulation of oncogenes, and growth factor receptors. In this review, we discussed the growing shreds of evidence supporting these secondary phenolic metabolites' anticancer properties. Furthermore, we have pointed out some of the future directions needed to establish urolithins as anticancer agents.
C1 [Al-Harbi, Sami A.] Umm Al Qura Univ, Univ Coll Al Jamoum, Dept Chem, Mecca, Saudi Arabia.
   [Abdulrahman, Abdulrasheed O.; Zamzami, Mazin A.; Khan, Mohammad Imran] King Abdulaziz Univ, Fac Sci, Dept Biochem, Jeddah, Saudi Arabia.
   [Zamzami, Mazin A.; Khan, Mohammad Imran] King Abdulaziz Univ, Fac Sci, Canc Metab & Epigenet Unit, Jeddah, Saudi Arabia.
RP Khan, MI (corresponding author), King Abdulaziz Univ, Fac Sci, Dept Biochem, Jeddah, Saudi Arabia.; Khan, MI (corresponding author), King Abdulaziz Univ, Fac Sci, Canc Metab & Epigenet Unit, Jeddah, Saudi Arabia.
EM mikhan@kau.edu.sa
RI Abdulrahman, Abdulrasheed O./AAT-6410-2021
OI Al-Harbi, Sami A. Al-Harbi/0000-0002-8263-0641
FU Deanship of Scientific Research at Umm Al-Qura University
   [19-SCI-1-01-0031]
FX The authors would like to thank the Deanship of Scientific Research at
   Umm Al-Qura University for supporting this work by Grant Code:
   19-SCI-1-01-0031.
CR Abdulrahman AO, 2020, DIABET METAB SYND OB, V13, P3337, DOI 10.2147/DMSO.S268146
   Adams LS, 2010, CANCER PREV RES, V3, P108, DOI 10.1158/1940-6207.CAPR-08-0225
   Alam MN, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/4154185
   Alauddin M, 2020, MOL NUTR FOOD RES, V64, DOI 10.1002/mnfr.201900390
   Andreux PA, 2019, NAT METAB, V1, P595, DOI 10.1038/s42255-019-0073-4
   Avila-Galvez MA, 2019, MOL NUTR FOOD RES, V63, DOI 10.1002/mnfr.201801239
   Avila-Galvez MA, 2018, J AGR FOOD CHEM, V66, P8547, DOI 10.1021/acs.jafc.8b03100
   Nunez-Sanchez MA, 2016, FOOD CHEM TOXICOL, V92, P8, DOI 10.1016/j.fct.2016.03.011
   Gimenez-Bastida JA, 2020, FOOD CHEM TOXICOL, V139, DOI 10.1016/j.fct.2020.111260
   Ataollahi M R, 2015, J Med Life, V8, P6
   Aune D, 2012, BREAST CANCER RES TR, V134, P479, DOI 10.1007/s10549-012-2118-1
   Bauer NN, 2007, EXP CELL RES, V313, P3832, DOI 10.1016/j.yexcr.2007.08.017
   Bennett EP, 2012, GLYCOBIOLOGY, V22, P736, DOI 10.1093/glycob/cwr182
   Bensaad K, 2006, CELL, V126, P107, DOI 10.1016/j.cell.2006.05.036
   BERENBAUM MC, 1977, CLIN EXP IMMUNOL, V28, P1
   Bobe G, 2010, CANCER PREV RES, V3, P764, DOI 10.1158/1940-6207.CAPR-09-0161
   Bochenek K, 2019, PHOTODIAGN PHOTODYN, V27, P141, DOI 10.1016/j.pdpdt.2019.05.036
   Bosco EE, 2009, CELL MOL LIFE SCI, V66, P370, DOI 10.1007/s00018-008-8552-x
   Bussing I, 2008, TRENDS MOL MED, V14, P400, DOI 10.1016/j.molmed.2008.07.001
   Buhtoiarova TN, 2016, AM J CLIN PATHOL, V145, P8, DOI [10.1093/AJCP/AQV014, 10.1093/ajcp/aqv014]
   Campisi J, 2007, NAT REV MOL CELL BIO, V8, P729, DOI 10.1038/nrm2233
   Ceci C, 2018, NUTRIENTS, V10, DOI 10.3390/nu10111756
   Cerda B, 2005, J AGR FOOD CHEM, V53, P227, DOI 10.1021/jf049144d
   Chang F, 2003, LEUKEMIA, V17, P590, DOI 10.1038/sj.leu.2402824
   Cho H, 2015, FOOD FUNCT, V6, P1675, DOI 10.1039/c5fo00274e
   Chun YJ, 2003, MED RES REV, V23, P657, DOI 10.1002/med.10050
   Correa TAF, 2019, NUTRITION, V59, P150, DOI 10.1016/j.nut.2018.08.010
   Cortes-Martin A, 2018, FOOD FUNCT, V9, P4100, DOI [10.1039/C8FO00956B, 10.1039/c8fo00956b]
   Dahiya NR, 2018, MOL CARCINOGEN, V57, P1332, DOI 10.1002/mc.22848
   De Rosa M, 2015, ONCOL REP, V34, P1087, DOI 10.3892/or.2015.4108
   Doherty SC, 2003, J NATL CANCER I, V95, P1859, DOI 10.1093/jnci/djg120
   Espin JC, 2007, J AGR FOOD CHEM, V55, P10476, DOI 10.1021/jf0723864
   Fanciulli M, 2000, CLIN CANCER RES, V6, P1590
   Farvid MS, 2019, INT J CANCER, V144, P1496, DOI 10.1002/ijc.31653
   Fonseca J, 2019, ONCOL LETT, V17, P697, DOI 10.3892/ol.2018.9526
   Forner A, 2018, LANCET, V391, P1301, DOI 10.1016/S0140-6736(18)30010-2
   Fratantonio D, 2019, PHYTOMEDICINE, V55, P23, DOI 10.1016/j.phymed.2018.08.009
   Fu YJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102535
   Garcia-Villalba R., 2020, DIETARY POLYPHENOLS, P319
   Garcia-Villalba R, 2013, J AGR FOOD CHEM, V61, P8797, DOI 10.1021/jf402498b
   Giorgio C, 2015, MOL NUTR FOOD RES, V59, P2155, DOI 10.1002/mnfr.201500470
   Girish C, 2008, FUND CLIN PHARMACOL, V22, P623, DOI 10.1111/j.1472-8206.2008.00618.x
   Gonzalez-Sancho JM, 2006, ANTICANCER RES, V26, P2669
   Gonzalez-Sarrias A, 2017, EUR J NUTR, V56, P831, DOI 10.1007/s00394-015-1131-7
   Gonzalez-Sarrias A, 2016, MOL NUTR FOOD RES, V60, P701, DOI 10.1002/mnfr.201500780
   Gonzalez-Sarrias A, 2015, FOOD FUNCT, V6, P1460, DOI [10.1039/C5FO00120J, 10.1039/c5fo00120j]
   Gonzalez-Sarrias A, 2014, EUR J NUTR, V53, P853, DOI 10.1007/s00394-013-0589-4
   Gonzalez-Sarrias A, 2010, MOL NUTR FOOD RES, V54, P311, DOI 10.1002/mnfr.200900152
   Gonzalez-Sarrias A, 2009, J AGR FOOD CHEM, V57, P5623, DOI 10.1021/jf900725e
   Gonzalez-Sarrias A, 2009, MOL NUTR FOOD RES, V53, P686, DOI 10.1002/mnfr.200800150
   Grizzi F, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/8707690
   Grossmann ME, 2001, JNCI-J NATL CANCER I, V93, P1687, DOI 10.1093/jnci/93.22.1687
   Guengrich FP, 1999, ANNU REV PHARMACOL, V39, P1, DOI 10.1146/annurev.pharmtox.39.1.1
   Haggar Fatima A, 2009, Clin Colon Rectal Surg, V22, P191, DOI 10.1055/s-0029-1242458
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Hasan MN, 2018, J PESTIC SCI, V43, P168, DOI [10.1584/jpestics.D17-090, 10.1584/jpestics.D17]
   He L, 2017, INT J BIOCHEM CELL B, V90, P29, DOI 10.1016/j.biocel.2017.07.007
   Howell A, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0446-2
   Iarc, 2018, LATEST GLOBAL CANC D
   Iliopoulos D, 2010, MOL CELL, V39, P493, DOI 10.1016/j.molcel.2010.07.023
   Johnson IT, 2007, P NUTR SOC, V66, P207, DOI 10.1017/S0029665107005459
   Kallay E, 2002, J NUTR, V132, p3490S, DOI 10.1093/jn/132.11.3490S
   Kamai T, 2004, CLIN CANCER RES, V10, P4799, DOI 10.1158/1078-0432.CCR-0436-03
   Kamat AM, 2016, LANCET, V388, P2796, DOI 10.1016/S0140-6736(16)30512-8
   Kampa M, 2007, REV PHYSIOL BIOCH P, V159, P79, DOI 10.1007/112_2006_0702
   Kasimsetty SG, 2010, J AGR FOOD CHEM, V58, P2180, DOI 10.1021/jf903762h
   Kawakita A, 2014, PATHOL ONCOL RES, V20, P253, DOI 10.1007/s12253-013-9689-y
   Keefe D., 2018, AGENCY RESPONSE LETT
   Kim EK, 2016, FOOD FUNCT, V7, P3677, DOI 10.1039/c6fo00901h
   Kitson SJ, 2017, CANCER PREV RES, V10, P1, DOI 10.1158/1940-6207.CAPR-16-0224
   Klimczak E., 2010, MACROMICROELEMENTS D
   Knowles MA, 2015, NAT REV CANCER, V15, P25, DOI 10.1038/nrc3817
   Komatsu W, 2018, EUR J PHARMACOL, V833, P411, DOI 10.1016/j.ejphar.2018.06.023
   Krishnan H, 2018, CANCER SCI, V109, P1292, DOI 10.1111/cas.13580
   Lall RK, 2015, INT J MOL SCI, V16, P3350, DOI 10.3390/ijms16023350
   Larrosa M, 2006, J AGR FOOD CHEM, V54, P1611, DOI 10.1021/jf0527403
   Larrosa M, 2006, J NUTR BIOCHEM, V17, P611, DOI 10.1016/j.jnutbio.2005.09.004
   Liberal J, 2017, INVEST NEW DRUG, V35, P671, DOI 10.1007/s10637-017-0483-7
   Lin CH, 2012, BMC COMPLEM ALTERN M, V12, DOI 10.1186/1472-6882-12-201
   Lipinska L, 2014, ACTA SCI POLON-TECHN, V13, P289, DOI 10.17306/J.AFS.2014.3.7
   Lisabeth EM, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a009159
   Liu CF, 2019, REJUV RES, V22, P191, DOI 10.1089/rej.2018.2066
   Liu F, 2019, BIOORGAN MED CHEM, V27, P3372, DOI 10.1016/j.bmc.2019.06.020
   Lv MY, 2019, J CELL BIOCHEM, V120, P17273, DOI 10.1002/jcb.28989
   Marley AR, 2016, INT J MOL EPIDEMIOL, V7, P105
   Martinez-Martinez D, 2019, FOOD CHEM TOXICOL, V124, P273, DOI 10.1016/j.fct.2018.12.014
   Moga MA, 2016, MOLECULES, V21, DOI 10.3390/molecules21081055
   Morice P, 2016, LANCET, V387, P1094, DOI 10.1016/S0140-6736(15)00130-0
   Murray GI, 1997, CANCER RES, V57, P3026
   Nautiyal Jyoti, 2011, J Mol Signal, V6, P7, DOI 10.1186/1750-2187-6-7
   Nitta T, 2014, INT J CLIN EXP PATHO, V7, P4913
   Norden E, 2019, CARCINOGENESIS, V40, P93, DOI 10.1093/carcin/bgy158
   Nunez-Sanchez MA, 2017, J NUTR BIOCHEM, V42, P126, DOI 10.1016/j.jnutbio.2017.01.014
   Nunez-Sanchez MA, 2015, MOL NUTR FOOD RES, V59, P1973, DOI 10.1002/mnfr.201500357
   Nunez-Sanchez MA, 2014, MOL NUTR FOOD RES, V58, P1199, DOI 10.1002/mnfr.201300931
   Oyenihi AB, 2019, J ETHNOPHARMACOL, V229, P54, DOI 10.1016/j.jep.2018.09.037
   Pasquale EB, 2004, NAT NEUROSCI, V7, P417, DOI 10.1038/nn0504-417
   Pasquale EB, 2008, CELL, V133, P38, DOI 10.1016/j.cell.2008.03.011
   Piwowarski JP, 2017, DRUG METAB DISPOS, V45, P657, DOI 10.1124/dmd.117.075200
   Qiu ZP, 2018, BRAZ J MED BIOL RES, V51, DOI [10.1590/1414-431x20187220, 10.1590/1414-431X20187220]
   Qiu ZP, 2013, FOOD CHEM TOXICOL, V59, P428, DOI 10.1016/j.fct.2013.06.025
   Quideau S, 1996, CHEM REV, V96, P475, DOI 10.1021/cr940716a
   Sanchez-Gonzalez C, 2016, EUR J NUTR, V55, P1099, DOI 10.1007/s00394-015-0924-z
   Sanchez-Gonzalez C, 2014, FOOD FUNCT, V5, P2922, DOI [10.1039/c4fo00542b, 10.1039/C4FO00542B]
   Santos IS, 2013, BIOTECHNOL ADV, V31, P514, DOI 10.1016/j.biotechadv.2012.08.005
   Sanyal AJ, 2010, ONCOLOGIST, V15, P14, DOI 10.1634/theoncologist.2010-S4-14
   Scalbert A, 2005, CRIT REV FOOD SCI, V45, P287, DOI 10.1080/1040869059096
   Sharma M, 2010, J AGR FOOD CHEM, V58, P3965, DOI 10.1021/jf902857v
   Shimada T, 2006, DRUG METAB PHARMACOK, V21, P257, DOI 10.2133/dmpk.21.257
   SMITH CAD, 1994, EUR J CANCER, V30A, P1921, DOI 10.1016/0959-8049(94)00382-F
   Song YZ, 2019, MOL THER-ONCOLYTICS, V14, P130, DOI 10.1016/j.omto.2019.04.005
   Stanislawska IJ, 2019, PLANTA MED, V85, P118, DOI 10.1055/a-0755-7715
   Stanislawska IJ, 2018, PHYTOMEDICINE, V46, P176, DOI 10.1016/j.phymed.2018.03.054
   Stolarczyk M, 2013, PHYTOTHER RES, V27, P1842, DOI 10.1002/ptr.4941
   STONER GD, 1995, J CELL BIOCHEM, P169
   Stowell SR, 2015, ANNU REV PATHOL-MECH, V10, P473, DOI 10.1146/annurev-pathol-012414-040438
   Suh JK, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0206374
   Syed DN, 2016, SEMIN CANCER BIOL, V40-41, P130, DOI 10.1016/j.semcancer.2016.04.003
   Taddei ML, 2009, AM J PATHOL, V174, P1492, DOI 10.2353/ajpath.2009.080473
   Tian JY, 2018, CARCINOGENESIS, V39, P307, DOI 10.1093/carcin/bgx141
   Tomas-Barberan FA, 2017, MOL NUTR FOOD RES, V61, DOI 10.1002/mnfr.201500901
   Tomas-Barberan FA, 2014, J AGR FOOD CHEM, V62, P6535, DOI 10.1021/jf5024615
   Torre LA, 2016, CANCER EPIDEM BIOMAR, V25, P16, DOI 10.1158/1055-9965.EPI-15-0578
   Torronen Riitta, 2009, P298, DOI 10.1142/9789812797414_0008
   Vicinanza R, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/247504
   Wang H, 2012, ANTI-CANCER AGENT ME, V12, P1281, DOI 10.2174/187152012803833026
   Wang Y, 2015, TOXICOL IN VITRO, V29, P1107, DOI 10.1016/j.tiv.2015.04.008
   Wiseman RA, 2000, J EPIDEMIOL COMMUN H, V54, P851, DOI 10.1136/jech.54.11.851
   Wu HZ, 2008, BIOMED PHARMACOTHER, V62, P613, DOI 10.1016/j.biopha.2008.06.036
   Wu X, 2004, BJU INT, V93, P143, DOI 10.1111/j.1464-410X.2004.04574.x
   Xu YM, 2003, BIOORGAN MED CHEM, V11, P1593, DOI 10.1016/S0968-0896(02)00452-2
   Ye Diana Zi, 2012, Cell Logist, V2, P105
   Yu L, 2017, J CANCER, V8, P3430, DOI 10.7150/jca.21125
   Zhang Hong-Mei, 2014, Cancer Biology Medicine, V11, P92, DOI 10.7497/j.issn.2095-3941.2014.02.004
   Zhang W, 2016, MOL NUTR FOOD RES, V60, P2387, DOI 10.1002/mnfr.201600048
   Zhao WH, 2018, MOL CARCINOGEN, V57, P193, DOI 10.1002/mc.22746
   Zhao WH, 2015, J CHROMATOGR B, V990, P111, DOI 10.1016/j.jchromb.2015.03.024
   Zhou BH, 2016, FOOD CHEM TOXICOL, V97, P375, DOI 10.1016/j.fct.2016.10.005
   Zhou Y, 2016, NUTRIENTS, V8, DOI 10.3390/nu8080515
   Zhou Yujuan, 2018, Oncotarget, V9, P33403, DOI 10.18632/oncotarget.23607
NR 140
TC 7
Z9 7
U1 5
U2 12
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2296-861X
J9 FRONT NUTR
JI Front. Nutr.
PD JUN 7
PY 2021
VL 8
AR 647582
DI 10.3389/fnut.2021.647582
PG 15
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA SV3OS
UT WOS:000663732400001
PM 34164422
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Li, X
   Xia, L
   Ouyang, XH
   Suyila, Q
   Su, LY
   Su, XL
AF Li, Xian
   Xia, Long
   Ouyang, Xiaohui
   Suyila, Qimuge
   Su, Liya
   Su, Xiulan
TI Bioactive Peptides Sensitize Cells to Anticancer Effects of Oxaliplatin
   in Human Colorectal Cancer Xenografts in Nude Mice
SO PROTEIN AND PEPTIDE LETTERS
LA English
DT Article
DE Anticancer peptide activity; oxaliplatin; colorectal cancer; nude mouse
   xenograft; bioactive peptides apoptosis; tumors
ID CHEMOTHERAPY; APOPTOSIS; AUTOPHAGY; GROWTH; DEATH
AB Background: Despite new agent development and short-term benefits in patients with Colorectal Cancer (CRC), metastatic CRC cure rates have not improved due to high rates of oxaliplatin resistance and toxicity. There is an urgent need for effective tools to prevent and treat CRC and reduce morbidity and mortality of CRC patients. Exploring the effects of bioactive peptides on the antitumor to CRC was of vital importance to the clinical application.
   Objective: This study aimed to investigate the therapeutic impact of Anticancer Bioactive Peptides (ACBP) on anticancer effect of oxaliplatin (LOHP) in human colorectal cancer xenografts models in nude mice.
   Methods: HCT-116 cells were cultured in vitro via CCK-8 assays and the absorbance was measured at 450 nm. Apoptosis and cell cycle were assessed by Flow Cytometry (FCM) in vitro. HCT-1 16 human colorectal cancer cells inoculated subcutaneously in nude mice of treatment with PBS (GG), ACBP, LOHP, ACBP+LOHP (A+L) in vivo. The quality of life was assessed by dietary amount of nude mice, the weight of nude mice, inhibition rates, tumor weight and tumor volume. Immunohistochemistry and RT-qPCR method was conducted to determine the levels of apoptosis regulating proteins/genes in transplanted tumors.
   Results: ACBP induced substantial reductions in viable cell numbers and apoptosis of HCT116 cells in combined with LOHP in vitro. Compared with the control GG group, ACBP combined low dose oxaliplatin (U) group demonstrated significantly different tumor volume, the rate of apoptosis, the expression levels of Cyt-C, caspase-3,8,9 proteins and corresponding RNAs (P<0.05). The expression of pro-apoptotic proteins in the cytoplasm around the nucleus was significantly enhanced by ACBP. Short term intermittent use of ACBP alone indicted a certain inhibitory effect on tumor growth, and improve the quality of life of tumor bearing nude mice.
   Conclusion: ACBP significantly increased the anti-cancer responses of low dose oxaliplatin (L-LOHP), thus, significantly improving the quality of life of tumor-bearing nude mice.
C1 [Li, Xian; Xia, Long; Ouyang, Xiaohui; Suyila, Qimuge; Su, Liya; Su, Xiulan] Inner Mongolia Med Univ, Affiliated Hosp, Clin Med Res Ctr, Hohhot 010050, Inner Mongolia, Peoples R China.
RP Su, XL (corresponding author), Inner Mongolia Med Univ, Affiliated Hosp, Clin Med Res Ctr, Hohhot 010050, Inner Mongolia, Peoples R China.
EM xlsu@hotmail.com
RI 苏, 丽/AAM-5834-2021
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81660468, 81860541]; Natural Science
   Foundation of Inner Mongolia Autonomous region [2017BS0812]; General
   project of Clinical Medical Research Center, Affiliated Hospital of
   Inner Mongolia Medical University, China [NYFY YB044]
FX This study was financed by the National Natural Science Foundation of
   China (81660468 and 81860541), Natural Science Foundation of Inner
   Mongolia Autonomous region (2017BS0812) and General project of Clinical
   Medical Research Center, Affiliated Hospital of Inner Mongolia Medical
   University, China (NYFY YB044).
CR Bhat ZI, 2019, GENE, V682, P25, DOI 10.1016/j.gene.2018.10.010
   Chang YT, 2011, EUR J CLIN INVEST, V41, P84, DOI 10.1111/j.1365-2362.2010.02383.x
   Chen W, 2010, CHIN J CANCER, V26, P48, DOI DOI 10.3978/J.ISSN.1000-9604.2014.0
   Jian You-Sin, 2017, Int J Nanomedicine, V12, P2315, DOI 10.2147/IJN.S120847
   Jin ZY, 2005, CANCER BIOL THER, V4, P139, DOI 10.4161/cbt.4.2.1508
   Kelly C, 2007, SURG ONCOL, V16, P65, DOI 10.1016/j.suronc.2007.04.006
   Kim EJ, 2010, BMC GASTROENTEROL, V10, DOI 10.1186/1471-230X-10-96
   Li J, 2010, EUR J CANCER, V46, P1900, DOI 10.1016/j.ejca.2010.02.021
   Li X, 2017, ONCOL REP, V38, P129, DOI 10.3892/or.2017.5674
   Longley DB, 2006, BBA-REV CANCER, V1766, P184, DOI 10.1016/j.bbcan.2006.08.001
   Marino G, 2014, NAT REV MOL CELL BIO, V15, P81, DOI 10.1038/nrm3735
   Marx A, 2014, J THORAC ONCOL, V9, P596, DOI 10.1097/JTO.0000000000000154
   Mustapha N, 2016, J CELL BIOCHEM, V117, P1262, DOI 10.1002/jcb.25416
   Nishimura J, 2015, EUR J CANCER, V51, P1274, DOI 10.1016/j.ejca.2015.03.024
   Nosher JL, 2015, J GASTROINTEST ONCOL, V6, P224, DOI 10.3978/j.issn.2078-6891.2014.065
   Shimizu S, 2014, INT J MOL SCI, V15, P3145, DOI 10.3390/ijms15023145
   Stacul F, 2007, RADIOL MED, V112, P751, DOI 10.1007/s11547-007-0178-9
   Su LY, 2010, ONCOL REP, V23, P3, DOI 10.3892/or_00000599
   Su XL, 2014, CELL BIOSCI, V4, DOI 10.1186/2045-3701-4-7
   Xing ZW, 2016, CELL BIOSCI, V6, DOI 10.1186/s13578-016-0112-8
   Yu L, 2014, J CELL BIOCHEM, V115, P697, DOI 10.1002/jcb.24711
   Zhu YL, 2014, INDIAN J CANCER, V51, P113, DOI 10.4103/0019-509X.154101
NR 22
TC 5
Z9 5
U1 2
U2 13
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 0929-8665
EI 1875-5305
J9 PROTEIN PEPTIDE LETT
JI Protein Pept. Lett.
PY 2019
VL 26
IS 7
BP 512
EP 522
DI 10.2174/0929866526666190405124955
PG 11
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA IK5UG
UT WOS:000476649800006
PM 30950338
DA 2022-04-25
ER

PT J
AU Lai, K
   Killingsworth, MC
   Lee, CS
AF Lai, K.
   Killingsworth, M. C.
   Lee, C. S.
TI Gene of the month: PIK3CA
SO JOURNAL OF CLINICAL PATHOLOGY
LA English
DT Article
ID COLORECTAL-CANCER; ONCOGENIC MUTATIONS; HIGH-FREQUENCY; PTEN LOSS; HEAD;
   NECK; INHIBITOR; CORRELATE; NVP-BYL719; CARCINOMA
AB PIK3CA encodes the p110 alpha catalytic subunit of phosphatidylinositol 3-kinase (PI3K) which through its role in the PI3K/Akt pathway is important for the regulation of important cellular functions such as proliferation, metabolism and protein synthesis, angiogenesis and apoptosis. Mutations in PIK3CA are known to be involved in a wide range of human cancers and mutant PIK3CA is thought to act as an oncogene. The specific PIK3CA inhibitor, NVP-BYL719, has displayed promising results in cancer therapy and is currently under clinical trials. Furthermore, PI3K regulates autophagy, a cellular process that recycles proteins and organelles through lysosomal degradation and has recently been recognised as an attractive therapeutic target due to its pro-and anti-cancer properties. Several studies have attempted to investigate the effects of combining the inhibition of both PI3K and autophagy in cancer therapy, and an in vivo model has demonstrated that the combined use of a concomitant PI3K and autophagy inhibitor induced apoptosis in glioma cells.
C1 [Lai, K.; Lee, C. S.] Ingham Inst Appl Med Res, Sydney, NSW, Australia.
   [Lai, K.; Killingsworth, M. C.; Lee, C. S.] Univ Western Sydney, Sch Med, Discipline Pathol & Mol Med, Liverpool, NSW 2170, Australia.
   [Lai, K.; Killingsworth, M. C.; Lee, C. S.] Univ Western Sydney, Sch Med, Res Grp, Liverpool, NSW 2170, Australia.
   [Lai, K.] Univ Sydney, Dept Pathol, Sydney, NSW 2006, Australia.
   [Lai, K.; Killingsworth, M. C.] Liverpool Hosp, Electron Microscopy Lab, Sydney, NSW, Australia.
   [Lai, K.; Killingsworth, M. C.; Lee, C. S.] Liverpool Hosp, Dept Anat Pathol, Sydney, NSW, Australia.
   [Lee, C. S.] Univ Sydney, Bosch Inst, Canc Pathol, Sydney, NSW 2006, Australia.
RP Lai, K (corresponding author), Univ Western Sydney, Sch Med, Discipline Pathol & Mol Med, Liverpool, NSW 2170, Australia.
EM ken.lai@uws.edu.au
RI ravegnini, gloria/K-1330-2016; Killingsworth, Murray/O-3736-2019;
   Killingsworth, Murray C/G-5908-2015
OI ravegnini, gloria/0000-0002-7774-402X; Killingsworth,
   Murray/0000-0002-6125-1183; Lee, C. Soon/0000-0003-1058-5826
CR [Anonymous], 2013, PHAS 1B TRIAL BGJ398
   [Anonymous], 2012, PHAS IB 2 STUD BYL71
   [Anonymous], 2011, PHAS IB STUD MEK162
   Bader AG, 2005, NAT REV CANCER, V5, P921, DOI 10.1038/nrc1753
   Barault L, 2008, INT J CANCER, V122, P2255, DOI 10.1002/ijc.23388
   Bol V, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/696028
   Boyault S, 2012, BREAST CANCER RES TR, V132, P29, DOI 10.1007/s10549-011-1518-y
   Buttitta F, 2006, J PATHOL, V208, P350, DOI 10.1002/path.1908
   Campbell IG, 2004, CANCER RES, V64, P7678, DOI 10.1158/0008-5472.CAN-04-2933
   Chandarlapaty S, 2012, CLIN CANCER RES, V18, P6784, DOI 10.1158/1078-0432.CCR-12-1785
   Chang YS, 2014, ORAL SURG ORAL MED O, V118, P110
   Cizkova M, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3113
   De Roock W, 2010, LANCET ONCOL, V11, P753, DOI 10.1016/S1470-2045(10)70130-3
   DHAND R, 1994, EMBO J, V13, P522, DOI 10.1002/j.1460-2075.1994.tb06290.x
   Esteva FJ, 2010, AM J PATHOL, V177, P1647, DOI 10.2353/ajpath.2010.090885
   Falasca M, 2012, BIOCHEM J, V443, P587, DOI 10.1042/BJ20120008
   Fan QW, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2001017
   Fenic I, 2007, ONCOL REP, V18, P253
   Fritsch C, 2014, MOL CANCER THER, V13, P1117, DOI 10.1158/1535-7163.MCT-13-0865
   Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481
   Furet P, 2013, BIOORG MED CHEM LETT, V23, P3741, DOI 10.1016/j.bmcl.2013.05.007
   He YJ, 2009, CLIN CANCER RES, V15, P6956, DOI 10.1158/1078-0432.CCR-09-1165
   Kalinsky K, 2009, CLIN CANCER RES, V15, P5049, DOI 10.1158/1078-0432.CCR-09-0632
   Kang S, 2006, P NATL ACAD SCI USA, V103, P1289, DOI 10.1073/pnas.0510772103
   Kostakis GC, 2010, ORAL SURG ORAL MED O, V109, pE53, DOI 10.1016/j.tripleo.2010.01.015
   Lai K, 2014, J CLIN PATHOL, V67, P854, DOI 10.1136/jclinpath-2014-202529
   Liao XY, 2012, NEW ENGL J MED, V367, P1596, DOI 10.1056/NEJMoa1207756
   Liao XY, 2012, CLIN CANCER RES, V18, P2257, DOI 10.1158/1078-0432.CCR-11-2410
   Lievre A, 2010, ONCOGENE, V29, P3033, DOI 10.1038/onc.2010.89
   Loi S, 2013, JNCI-J NATL CANCER I, V105, P960, DOI 10.1093/jnci/djt121
   Maira SM, 2008, MOL CANCER THER, V7, P1851, DOI 10.1158/1535-7163.MCT-08-0017
   Mao C, 2012, ANN ONCOL, V23, P1518, DOI 10.1093/annonc/mdr464
   Maruyama N, 2007, CLIN CANCER RES, V13, P408, DOI 10.1158/1078-0432.CCR-06-0267
   Murugan AK, 2008, INT J ONCOL, V32, P101
   Murugan AK, 2013, CANCER LETT, V338, P193, DOI 10.1016/j.canlet.2013.04.005
   O'Farrell F, 2013, FEBS J, V280, P6322, DOI 10.1111/febs.12486
   Perez-Tenorio G, 2007, CLIN CANCER RES, V13, P3577, DOI 10.1158/1078-0432.CCR-06-1609
   Phillips WA, 1998, CANCER, V83, P41, DOI 10.1002/(SICI)1097-0142(19980701)83:1<41::AID-CNCR6>3.0.CO;2-H
   Psyrri Amanda, 2013, Am Soc Clin Oncol Educ Book, P246, DOI 10.1200/EdBook_AM.2013.33.246
   Qiu WL, 2008, INT J CANCER, V122, P1189, DOI 10.1002/ijc.23217
   Qiu WL, 2006, CLIN CANCER RES, V12, P1441, DOI 10.1158/1078-0432.CCR-05-2173
   Razis E, 2011, BREAST CANCER RES TR, V128, P447, DOI 10.1007/s10549-011-1572-5
   Saal LH, 2005, CANCER RES, V65, P2554, DOI 10.1158/0008-5472-CAN-04-3913
   Samuels Y, 2004, CELL CYCLE, V3, P1221, DOI 10.4161/cc.3.10.1164
   Seiwert TY, 2015, CLIN CANCER RES, V21, P632, DOI 10.1158/1078-0432.CCR-13-3310
   Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038/5042
   Stein RC, 2001, ENDOCR-RELAT CANCER, V8, P237, DOI 10.1677/erc.0.0080237
   Sun WY, 2014, ANN NY ACAD SCI, V1333, P33, DOI 10.1111/nyas.12599
   VOLINIA S, 1994, GENOMICS, V24, P472, DOI 10.1006/geno.1994.1655
   Wang LP, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-248
   Whitehall VLJ, 2012, INT J CANCER, V131, P813, DOI 10.1002/ijc.26440
   Young NR, 2013, MOL ONCOL, V7, P359, DOI 10.1016/j.molonc.2012.11.001
   Zhang Y, 2014, NEOPLASMA, V61, P461, DOI 10.4149/neo_2014_057
   Zhao L, 2008, ONCOGENE, V27, P5486, DOI 10.1038/onc.2008.244
NR 54
TC 34
Z9 36
U1 1
U2 12
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0021-9746
EI 1472-4146
J9 J CLIN PATHOL
JI J. Clin. Pathol.
PD APR
PY 2015
VL 68
IS 4
BP 253
EP 257
DI 10.1136/jclinpath-2015-202885
PG 5
WC Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology
GA CD6XG
UT WOS:000351233100001
PM 25688137
DA 2022-04-25
ER

PT J
AU O'Connell, CE
   Vassilev, A
AF O'Connell, Constandina E.
   Vassilev, Alex
TI Combined Inhibition of p38MAPK and PIKfyve Synergistically Disrupts
   Autophagy to Selectively Target Cancer Cells
SO CANCER RESEARCH
LA English
DT Article
ID P38 MAP KINASE; ACTIVATION; THERAPY; DRUG; COMBINATION; P38-ALPHA;
   PATHWAYS; STRESS
AB In nutrient-poor conditions, autophagy buffers metabolic stress and counteracts the effects of chemotherapy and radiation on cancer cells, which depend on autophagy for survival. However, clinical trials targeting autophagy have failed to produce successful anticancer treatments using currently available inhibitors. Recent studies have shown that PIKfyve kinase inhibitors disrupt lysosome function in autophagy and can selectively kill certain cancer cells. Analysis of biochemical changes caused by PIKfyve inhibition revealed that resistant cells contain significantly higher levels of cellular p38MAPK protein and phosphorylation. Expression of the lysosomal protein, lysosomal-associated membrane protein 2, carrying phosphomimetic mutations of the p38MAPK phosphorylation sites prevented all effects caused by PIKfyve inhibition-induced lysosome dysfunction. Thus, the activation of p38MAPK in response to PIKfyve inhibition revealed a novel compensatory role in maintaining lysosome function in autophagy. The functional cooperation between the cellular PIKfyve and p38MAPK pathways in regulating lysosome homeostasis was especially important in cancer cells. Combined inhibition of PIKfyve and p38MAPK activities synergistically blocked autophagy-mediated protein degradation, prevented cathepsin maturation, and markedly reduced the viability of multiple cancer cell types without affecting the viability of normal cells. Furthermore, combined PIKfyve and p38MAPK inhibitors synergistically reduced tumor growth in mice bearing xenografts of human colorectal adenocarcinoma, suggesting a novel way to target cancer cells by prolonged inhibition of autophagy using lower drug concentrations.
   Significance: This study demonstrates that PIKfyve and p38MAPK cooperate to regulate lysosome homeostasis and their combined inhibition synergistically blocks autophagy to reduce cancer cell viability in vitro and in vivo.
C1 [O'Connell, Constandina E.; Vassilev, Alex] NICHHD, NIH, Bethesda, MD 20892 USA.
RP Vassilev, A (corresponding author), NICHHD, NIH, Bethesda, MD 20892 USA.
EM vassilev@nih.gov
FU Eunice Kennedy Shriver National Institute of Child Health and Human
   Development intramural research program [ZIA HD000506, ZIA HD000507]
FX The authors thank Dr. Elaine Jordan for providing training and expertise
   with the xenograft studies. This work was supported by the Eunice
   Kennedy Shriver National Institute of Child Health and Human Development
   intramural research program (ZIA HD000506 and ZIA HD000507).
CR Altman BJ, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a008763
   Amaravadi RK, 2007, J CLIN INVEST, V117, P326, DOI 10.1172/JCI28833
   Bain J, 2007, BIOCHEM J, V408, P297, DOI 10.1042/BJ20070797
   Balla T, 2013, PHYSIOL REV, V93, P1019, DOI 10.1152/physrev.00028.2012
   Bhowmick NA, 2001, J BIOL CHEM, V276, P46707, DOI 10.1074/jbc.M106176200
   Chou TC, 2010, CANCER RES, V70, P440, DOI 10.1158/0008-5472.CAN-09-1947
   Choy CH, 2018, J CELL SCI, V131, DOI 10.1242/jcs.213587
   Chude CI, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18061279
   Corre I, 2017, ONCOTARGET, V8, P55684, DOI 10.18632/oncotarget.18264
   Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001
   Eastman A, 2017, ONCOTARGET, V8, P8854, DOI 10.18632/oncotarget.12673
   Fitzgerald JB, 2006, NAT CHEM BIOL, V2, P458, DOI 10.1038/nchembio817
   Gayle S, 2017, BLOOD, V129, P1768, DOI 10.1182/blood-2016-09-736892
   Gonzalez-Polo RA, 2005, J CELL SCI, V118, P3091, DOI 10.1242/jcs.02447
   Grossi V, 2014, WORLD J GASTROENTERO, V20, P9744, DOI 10.3748/wjg.v20.i29.9744
   He CC, 2009, ANNU REV GENET, V43, P67, DOI 10.1146/annurev-genet-102808-114910
   Hou JZ, 2019, ONCOL REP, V41, P1971, DOI 10.3892/or.2018.6928
   Hu YB, 2015, TRANSL NEURODEGENER, V4, DOI 10.1186/s40035-015-0041-1
   Inwald EC, 2013, BREAST CANCER RES TR, V139, P539, DOI 10.1007/s10549-013-2560-8
   Karantza-Wadsworth V, 2007, GENE DEV, V21, P1621, DOI 10.1101/gad.1565707
   Kimmelman AC, 2017, CELL METAB, V25, P1037, DOI 10.1016/j.cmet.2017.04.004
   Klionsky DJ, 2016, AUTOPHAGY, V12, P1, DOI 10.1080/15548627.2015.1100356
   Koeberle SC, 2012, NAT CHEM BIOL, V8, P141, DOI 10.1038/nchembio.761
   LeGolvan MP, 2010, J SURG ONCOL, V102, P898, DOI 10.1002/jso.21817
   Li WM, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01609-x
   Lu YY, 2014, AUTOPHAGY, V10, P1895, DOI 10.4161/auto.32200
   Lv ZM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022806
   Manic G, 2014, MOL CELL ONCOL, V1, DOI 10.4161/mco.29911
   Menon MB, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023054
   Miwatashi S, 2005, J MED CHEM, V48, P5966, DOI 10.1021/jm050165o
   Mizushima N, 2011, CELL, V147, P728, DOI 10.1016/j.cell.2011.10.026
   Mullen P, 2004, METH MOLEC MED, V88, P247
   Olson OC, 2015, NAT REV CANCER, V15, P712, DOI 10.1038/nrc4027
   Patnaik A, 2016, CLIN CANCER RES, V22, P1095, DOI 10.1158/1078-0432.CCR-15-1718
   Puri PL, 2000, GENE DEV, V14, P574
   Ranjan A, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17122068
   Sano O, 2016, FEBS LETT, V590, P1576, DOI 10.1002/1873-3468.12195
   Sbrissa D, 2012, AM J PHYSIOL-CELL PH, V303, pC436, DOI 10.1152/ajpcell.00105.2012
   Sharma G, 2019, AUTOPHAGY, V15, P1694, DOI 10.1080/15548627.2019.1586257
   Shibutani ST, 2014, CELL RES, V24, P58, DOI 10.1038/cr.2013.159
   Suarez-Cuervo C, 2004, CLIN EXP METASTAS, V21, P525, DOI 10.1007/s10585-004-3503-x
   Sui XB, 2014, CANCER LETT, V344, P174, DOI 10.1016/j.canlet.2013.11.019
   Vassilev A, 2001, GENE DEV, V15, P1229, DOI 10.1101/gad.888601
   Vassilev A, 2016, ONCOTARGET, V7, P34956, DOI 10.18632/oncotarget.9008
   Wagner EF, 2009, NAT REV CANCER, V9, P537, DOI 10.1038/nrc2694
   Zaidi N, 2008, BIOCHEM BIOPH RES CO, V376, P5, DOI 10.1016/j.bbrc.2008.08.099
NR 46
TC 2
Z9 2
U1 7
U2 9
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD JUN 1
PY 2021
VL 81
IS 11
BP 2903
EP 2917
DI 10.1158/0008-5472.CAN-20-3371
PG 15
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA SO9ML
UT WOS:000659297500012
PM 33685990
OA Bronze, Green Accepted
DA 2022-04-25
ER

PT J
AU Bader, S
   Wilmers, J
   Ontikatze, T
   Ritter, V
   Jendrossek, V
   Rudner, J
AF Bader, Sina
   Wilmers, Julia
   Ontikatze, Teona
   Ritter, Violetta
   Jendrossek, Verena
   Rudner, Justine
TI Loss of pro-apoptotic Bax and Bak increases resistance to
   dihydroartemisinin-mediated cytotoxicity in normoxia but not in hypoxia
   in HCT116 colorectal cancer cells
SO FREE RADICAL BIOLOGY AND MEDICINE
LA English
DT Article
DE Hypoxia; Therapy resistance; Dihydroartemisinin; Reactive oxygen
   species; Lipid peroxidation; Apoptosis; Glutathione
ID MECHANISMS; ACTIVATION; ARTESUNATE; AUTOPHAGY; ARTEMISININ; EXPRESSION;
   OXIDATION; EXPOSURE; THERAPY; STRESS
AB Tumor hypoxia is a major biological factor that drives resistance to chemotherapy and radiotherapy. We previously demonstrated that the pro-oxidative drug dihydroartemisinin (DHA) efficiently targeted normoxic and hypoxic cancer cells. Although well studied in normoxia, the mechanism behind DHA-mediated cytotoxicity in hypoxia is insufficiently explored. Here, we analyzed the effect of DHA in HCT116 wild type (wt) cells and in HCT116 Bax-/-Baksh cells with a defective intrinsic apoptosis pathway. Normoxic HCT116 wt cells underwent apoptosis shortly after treatment with DHA. Autophagy-associated cell death contributes to short-term cytotoxicity of DHA in normoxia. These cells switched to an apoptosis- and autophagy-independent cell death after treatment with DHA in hypoxia and displayed similar long-term survival in response to DHA in normoxia and hypoxia. In HCT116 Bax- /-Baksh cells, DHA induced cell cycle arrest shortly after treatment irrespective of oxygen levels. Later, HCT116 Bax-/-Baksh cells induced a delayed cell death after treatment with DHA in hypoxia followed by return to normoxia, while treatment with DHA in normoxia was hardly toxic. We identified lower glutathione levels in hypoxic HCT116 cells which correlated with higher lipid peroxidation after treatment with DHA. Moreover, insufficient expression of Bax/Bak counteracted hypoxiamediated downregulation of mitochondrial function, thereby adding to DHA-induced ROS production and lipid peroxidation in hypoxia. In summary, DHA-mediated cytotoxicity in normoxia depended on Bax/Bak expression, while cytotoxicity after treatment with DHA in hypoxia was regulated independently of Bax/Bak in HCT116 colorectal cancer cells.
C1 [Bader, Sina; Wilmers, Julia; Ontikatze, Teona; Ritter, Violetta; Jendrossek, Verena; Rudner, Justine] Univ Duisburg Essen, Univ Hosp Essen, Inst Cell Biol Canc Res, Essen, Germany.
RP Rudner, J (corresponding author), Univ Hosp Essen, Dept Mol Cell Biol, Inst Cell Biol Tumor Res, Virchowstr 173, D-45122 Essen, Germany.
EM justine.rudner@uk-essen.de
RI Rudner, Justine/ABD-1397-2021; Jendrossek, Verena/ABD-2190-2021
OI Rudner, Justine/0000-0002-5067-755X
FU Deutsche Krebshilfe/Mil-dred Scheel StiftungDeutsche Krebshilfe [110344,
   70112711]; DFG Research Training GroupGerman Research Foundation (DFG)
   [GRK1739/2]
FX This work was supported by grants of the Deutsche Krebshilfe/Mil-dred
   Scheel Stiftung (No.110344 to VJ and No. 70112711 to JR and VJ) as well
   as the DFG Research Training Group (GRK1739/2 to VJ) .
CR Adams JM, 2018, CELL DEATH DIFFER, V25, P27, DOI 10.1038/cdd.2017.161
   Azadmanesh J, 2018, ANTIOXIDANTS-BASEL, V7, DOI 10.3390/antiox7020025
   Bader S, 2021, FREE RADICAL BIO MED, V168, P44, DOI 10.1016/j.freeradbiomed.2021.03.024
   Bhutia SK, 2013, ADV CANCER RES, V118, P61, DOI 10.1016/B978-0-12-407173-5.00003-0
   Bodur C, 2012, J CELL PHYSIOL, V227, P3556, DOI 10.1002/jcp.24057
   Boohaker RJ, 2011, AM J PHYSIOL-CELL PH, V300, pC1466, DOI 10.1152/ajpcell.00325.2010
   Bystrom LM, 2015, FREE RADICAL BIO MED, V79, P337, DOI 10.1016/j.freeradbiomed.2014.04.035
   Calbet JAL, 2020, REDOX BIOL, V35, DOI 10.1016/j.redox.2020.101478
   Czabotar PE, 2014, NAT REV MOL CELL BIO, V15, P49, DOI 10.1038/nrm3722
   D'Alessandro S, 2011, BIOCHEM PHARMACOL, V82, P476, DOI 10.1016/j.bcp.2011.06.002
   D'Errico I, 2011, CELL CYCLE, V10, P2937, DOI 10.4161/cc.10.17.16791
   Dixon SJ, 2012, CELL, V149, P1060, DOI 10.1016/j.cell.2012.03.042
   dos Santos SL, 2018, ANTIOXIDANTS-BASEL, V7, DOI 10.3390/antiox7120191
   Eling Nils, 2015, Oncoscience, V2, P517
   Eng KE, 2010, AUTOPHAGY, V6, P634, DOI 10.4161/auto.6.5.12112
   Fanello C, 2021, ANTIMICROB AGENTS CH, V65, DOI 10.1128/AAC.02223-20
   Galluzzi L, 2018, CELL DEATH DIFFER, V25, P486, DOI 10.1038/s41418-017-0012-4
   Hockel M, 1999, CANCER RES, V59, P4525
   Horsman MR, 2012, NAT REV CLIN ONCOL, V9, P674, DOI 10.1038/nrclinonc.2012.171
   Huang XJ, 2007, J PHARM PHARMACOL, V59, P849, DOI 10.1211/jpp.59.6.0011
   Jelinek A, 2018, FREE RADICAL BIO MED, V117, P45, DOI 10.1016/j.freeradbiomed.2018.01.019
   Kang YP, 2021, CELL METAB, V33, P174, DOI 10.1016/j.cmet.2020.12.007
   Kumar A, 2015, FUTURE MED CHEM, V7, P1535, DOI 10.4155/fmc.15.88
   Leo C, 2007, CLIN CANCER RES, V13, P1149, DOI 10.1158/1078-0432.CCR-06-2371
   Li ML, 2010, BIOCHEM PHARMACOL, V79, P122, DOI 10.1016/j.bcp.2009.08.011
   Luo WB, 2019, ADV EXP MED BIOL, V1136, P1, DOI 10.1007/978-3-030-12734-3_1
   Mailloux RJ, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/antiox9060472
   Mari M, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/antiox9100909
   Matschke J, 2016, ANTIOXID REDOX SIGN, V25, P89, DOI 10.1089/ars.2015.6589
   Matschke J, 2016, RADIAT ONCOL, V11, DOI 10.1186/s13014-016-0647-1
   Meshnick SR, 2002, INT J PARASITOL, V32, P1655, DOI 10.1016/S0020-7519(02)00194-7
   Mukhopadhyay S, 2014, APOPTOSIS, V19, P555, DOI 10.1007/s10495-014-0967-2
   Murphy MP, 2009, BIOCHEM J, V417, P1, DOI 10.1042/BJ20081386
   Murray J, 2014, ANTICANCER RES, V34, P7055
   Musaogullari A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21218113
   Nguyen T, 2005, J BIOL CHEM, V280, P32485, DOI 10.1074/jbc.M503074200
   Ontikatze T, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00116
   Pfeiffer A, 2017, FREE RADICAL BIO MED, V112, P350, DOI 10.1016/j.freeradbiomed.2017.08.007
   Radhakrishnan P, 2016, CANCER RES, V76, P2219, DOI 10.1158/0008-5472.CAN-15-1474
   Saxena K, 2019, BIOMOLECULES, V9, DOI 10.3390/biom9080339
   Sun C, 2017, BBA-MOL CELL RES, V1864, P1285, DOI 10.1016/j.bbamcr.2017.04.014
   Tacchini L, 1999, J BIOL CHEM, V274, P24142, DOI 10.1074/jbc.274.34.24142
   Tsuda K, 2018, BIOL PHARM BULL, V41, P555, DOI 10.1248/bpb.b17-00855
   Tyurina YY, 2006, MOL PHARMACOL, V70, P706, DOI 10.1124/mol.106.022731
   Vandewynckel YP, 2014, EUR J GASTROEN HEPAT, V26, P861, DOI 10.1097/MEG.0000000000000066
   Vaupel P, 2020, ADV EXP MED BIOL, V1232, P169, DOI 10.1007/978-3-030-34461-0_21
   Weinmann M, 2004, FASEB J, V18, P1906, DOI 10.1096/fj.04-1918fje
   Xu CC, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.529881
   Yang ND, 2014, J BIOL CHEM, V289, P33425, DOI 10.1074/jbc.M114.564567
   Zalachoras I, 2020, NEUROSCI BIOBEHAV R, V114, P134, DOI 10.1016/j.neubiorev.2020.03.015
   Zhang B, 2017, MOL MED REP, V16, P597, DOI 10.3892/mmr.2017.6633
   Zhang Y., J EXP BIOL, V224
NR 52
TC 0
Z9 0
U1 1
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0891-5849
EI 1873-4596
J9 FREE RADICAL BIO MED
JI Free Radic. Biol. Med.
PD OCT
PY 2021
VL 174
BP 157
EP 170
DI 10.1016/j.freeradbiomed.2021.08.012
EA AUG 2021
PG 14
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA UL2WO
UT WOS:000692517600004
PM 34403740
DA 2022-04-25
ER

PT J
AU Silva-Pavez, E
   Villar, P
   Trigo, C
   Caamano, E
   Niechi, I
   Perez, P
   Munoz, JP
   Aguayo, F
   Burzio, VA
   Varas-Godoy, M
   Castro, AF
   Colombo, MI
   Tapia, JC
AF Silva-Pavez, Eduardo
   Villar, Paulina
   Trigo, Cesar
   Caamano, Esteban
   Niechi, Ignacio
   Perez, Pablo
   Munoz, Juan P.
   Aguayo, Francisco
   Burzio, Veronica A.
   Varas-Godoy, Manuel
   Castro, Ariel F.
   Colombo, Maria, I
   Tapia, Julio C.
TI CK2 inhibition with silmitasertib promotes methuosis-like cell death
   associated to catastrophic massive vacuolization of colorectal cancer
   cells
SO CELL DEATH & DISEASE
LA English
DT Article
ID PROTEIN-KINASE CK2; MTOR-SIGNALING PATHWAY; MAMMALIAN TARGET;
   DOWN-REGULATION; INDUCED APOPTOSIS; AUTOPHAGY; EXPRESSION; RAPAMYCIN;
   GROWTH; VIABILITY
AB Protein kinase CK2 is a highly conserved and constitutively active Ser/Thr-kinase that phosphorylates a large number of substrates, resulting in increased cell proliferation and survival. A known target of CK2 is Akt, a player in the PI3K/Akt/ mTORC1 signaling pathway, which is aberrantly activated in 32% of colorectal cancer (CRC) patients. On the other hand, mTORC1 plays an important role in the regulation of protein synthesis, cell growth, and autophagy. Some studies suggest that CK2 regulates mTORC1 in several cancers. The most recently developed CK2 inhibitor, silmitasertib (formerly CX-4945), has been tested in phase I/II trials for cholangiocarcinoma and multiple myeloma. This drug has been shown to induce autophagy and enhance apoptosis in pancreatic cancer cells and to promote apoptosis in nonsmall cell lung cancer cells. Nevertheless, it has not been tested in studies for CRC patients. We show in this work that inhibition of CK2 with silmitasertib decreases in vitro tumorigenesis of CRC cells in response to G2/M arrest, which correlates with mTORC1 inhibition and formation of large cytoplasmic vacuoles. Notably, molecular markers indicate that these vacuoles derive from massive macropinocytosis. Altogether, these findings suggest that an aberrantly elevated expression/activity of CK2 may play a key role in CRC, promoting cell viability and proliferation in untreated cells, however, its inhibition with silmitasertib promotes methuosis-like cell death associated to massive catastrophic vacuolization, accounting for decreased tumorigenicity at later times. These characteristics of silmitasertib support a potential therapeutic use in CRC patients and probably other CK2-dependent cancers.
C1 [Silva-Pavez, Eduardo; Villar, Paulina; Trigo, Cesar; Caamano, Esteban; Niechi, Ignacio; Perez, Pablo; Munoz, Juan P.; Aguayo, Francisco; Tapia, Julio C.] Univ Chile, Fac Med, Dept Oncol Basico Clin, Santiago, Chile.
   [Burzio, Veronica A.] Univ Andres Bello, Fdn Ciencia & Vida, Andes Biotechnol SpA, Fac Ciencias Vida, Santiago, Chile.
   [Varas-Godoy, Manuel] Univ Los Andes, Fac Med, Ctr Invest Biomed, Santiago, Chile.
   [Castro, Ariel F.] Univ Concepcion, Dept Bioquim & Biol Mol, Fac Ciencias Biol, Lab Transducc Senales & Canc, Concepcion, Chile.
   [Colombo, Maria, I] Univ Nacl Cuyo, CONICET, Fac Ciencias Med, Inst Histol & Embriol,Lab Biol Celular & Mol, Mendoza, Argentina.
   [Niechi, Ignacio] Univ Austral Chile, Fac Ciencias, Lab Patol Mol, Inst Bioquim & Microbiol, Valdivia, Chile.
RP Tapia, JC (corresponding author), Univ Chile, Fac Med, Dept Oncol Basico Clin, Santiago, Chile.
EM jtapia@med.uchile.cl
RI Pineda, Julio Tapia/AAW-8949-2020
OI Pineda, Julio Tapia/0000-0003-1678-2708; Niechi,
   Ignacio/0000-0003-1857-8698; Varas-Godoy, Manuel/0000-0001-5857-4793
FU CONICYT-FONDECYT-ChileComision Nacional de Investigacion Cientifica y
   Tecnologica (CONICYT)CONICYT FONDECYT [1140345, 1161219, 11150624,
   1160731, 1160889]; Universidad Nacional de Cuyo [SeCTyP 06/J432];
   Agencia Nacional de Investigacion Cientifica y Tecnologica, Argentina
   [PICT2013-0305]; CONICYT-FONDAP-Chile grant [15130011]
FX We thank Felix Urra, Hernan Huerta, and Barbara Pesce (Universidad de
   Chile), Diego A. Rodriguez (St. Jude Children's Research Hospital), as
   well as Milagros Lopez de Armentia (Universidad Nacional de Cuyo) for
   their valuable technical support in some cytometry, soft-agar,
   necroptosis and microscopy analysis. This work was supported by
   CONICYT-FONDECYT-Chile grants #1140345 (to V.A.B.), #1161219 (to F.A.),
   #11150624 (to M.V.G.), #1160731 (to A.F.C.) and #1160889 (to J.C.T.);
   CONICYT-FONDAP-Chile grant #15130011 (to F.A.); SeCTyP 06/J432 grant
   from Universidad Nacional de Cuyo and PICT2013-0305 grant from Agencia
   Nacional de Investigacion Cientifica y Tecnologica, Argentina (to
   M.I.C.).
CR Ahmed D, 2013, ONCOGENESIS, V2, DOI 10.1038/oncsis.2013.35
   Bliesath J, 2012, CANCER LETT, V322, P113, DOI 10.1016/j.canlet.2012.02.032
   Brady Owen A, 2016, Small GTPases, V7, P197
   Campos T, 2016, MOL CARCINOGEN, V55, P220, DOI 10.1002/mc.22272
   Chowdhury S, 2013, J SURG RES, V184, P755, DOI 10.1016/j.jss.2013.03.035
   Coker-Gurkan A, 2014, EXP CELL RES, V328, P87, DOI 10.1016/j.yexcr.2014.07.022
   Cuyas E, 2014, METHODS MOL BIOL, V1170, P113, DOI 10.1007/978-1-4939-0888-2_7
   Deming DA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060709
   Di Maira G, 2005, CELL DEATH DIFFER, V12, P668, DOI 10.1038/sj.cdd.4401604
   Dibble CC, 2015, TRENDS CELL BIOL, V25, P545, DOI 10.1016/j.tcb.2015.06.002
   Dobashi Y, 2011, INT J CLIN EXP PATHO, V4, P476
   Dunlop EA, 2014, SEMIN CELL DEV BIOL, V36, P121, DOI 10.1016/j.semcdb.2014.08.006
   Fan B, 2016, MOL MED REP, V13, P3771, DOI 10.3892/mmr.2016.5011
   Francipane MG, 2014, ONCOTARGET, V5, P49, DOI 10.18632/oncotarget.1548
   Fujishita T, 2008, P NATL ACAD SCI USA, V105, P13544, DOI 10.1073/pnas.0800041105
   Girardi C, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/185736
   Gray GK, 2014, ONCOTARGET, V5, P6484, DOI 10.18632/oncotarget.2248
   Guerra B, 2006, INT J ONCOL, V28, P685
   Hwang DW, 2017, PANCREAS, V46, P575, DOI 10.1097/MPA.0000000000000780
   Johnson SM, 2010, J AM COLL SURGEONS, V210, P767, DOI 10.1016/j.jamcollsurg.2009.12.008
   Jung CH, 2010, FEBS LETT, V584, P1287, DOI 10.1016/j.febslet.2010.01.017
   Kim KW, 2006, J BIOL CHEM, V281, P36883, DOI 10.1074/jbc.M607094200
   Klionsky DJ, 2016, AUTOPHAGY, V12, P1, DOI 10.1080/15548627.2015.1100356
   Kreutzer JN, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-440
   Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017
   Ligresti G, 2009, CELL CYCLE, V8, P1352, DOI 10.4161/cc.8.9.8255
   Lin KY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017193
   Lin KY, 2010, ANN SURG ONCOL, V17, P1695, DOI 10.1245/s10434-010-0911-9
   Ma ZB, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0174037
   Maltese WA, 2015, FRONT PHYSIOL, V6, DOI 10.3389/fphys.2015.00038
   Maltese WA, 2014, AM J PATHOL, V184, P1630, DOI 10.1016/j.ajpath.2014.02.028
   Marquez RT, 2012, AM J CANCER RES, V2, P214
   Mathew R, 2007, NAT REV CANCER, V7, P961, DOI 10.1038/nrc2254
   Matsumoto G, 2011, MOL CELL, V44, P279, DOI 10.1016/j.molcel.2011.07.039
   Menon S, 2014, CELL, V156, P771, DOI 10.1016/j.cell.2013.11.049
   Moschetta M, 2014, BRIT J PHARMACOL, V171, P3801, DOI 10.1111/bph.12749
   Niechi I, 2015, ONCOTARGET, V6, P42749, DOI 10.18632/oncotarget.5722
   Olsen BB, 2012, INT J ONCOL, V41, P1967, DOI 10.3892/ijo.2012.1635
   Overmeyer JH, 2008, MOL CANCER RES, V6, P965, DOI 10.1158/1541-7786.MCR-07-2036
   Overmeyer JH, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-69
   Pinna LA, 2009, CELL MOL LIFE SCI, V66, P1797, DOI 10.1007/s00018-009-9148-9
   Polivka J, 2014, PHARMACOL THERAPEUT, V142, P164, DOI 10.1016/j.pharmthera.2013.12.004
   Ponce DP, 2011, MOL CELL BIOCHEM, V356, P127, DOI 10.1007/s11010-011-0965-4
   Ponce DP, 2011, J CELL PHYSIOL, V226, P1953, DOI 10.1002/jcp.22527
   Populo H, 2012, INT J MOL SCI, V13, P1886, DOI 10.3390/ijms13021886
   Ramirez-Valle F, 2010, MOL CELL BIOL, V30, P3151, DOI 10.1128/MCB.00322-09
   Recouvreux MV, 2017, FRONT ENDOCRINOL, V8, DOI 10.3389/fendo.2017.00261
   Russell RC, 2014, CELL RES, V24, P42, DOI 10.1038/cr.2013.166
   Ruzzene M, 2010, BBA-PROTEINS PROTEOM, V1804, P499, DOI 10.1016/j.bbapap.2009.07.018
   Sander P, 2017, ONCOTARGET, V8, P35124, DOI 10.18632/oncotarget.16703
   Saxton RA, 2017, CELL, V168, P960, DOI [10.1016/j.cell.2017.02.004, 10.1016/j.cell.2017.03.035]
   Scaffidi P, 2002, NATURE, V418, P191, DOI 10.1038/nature00858
   So KS, 2015, ANTICANCER RES, V35, P1537
   St-Denis NA, 2009, CELL MOL LIFE SCI, V66, P1817, DOI 10.1007/s00018-009-9150-2
   Tapia JC, 2006, P NATL ACAD SCI USA, V103, P15079, DOI 10.1073/pnas.0606845103
   Wang LJ, 2016, TUMOR BIOL, V37, P11743, DOI 10.1007/s13277-016-5018-x
   Wang PN, 2017, ONCOTARGET, V8, P34352, DOI 10.18632/oncotarget.16128
   Yang ZL, 2015, CLIN RES HEPATOL GAS, V39, P98, DOI 10.1016/j.clinre.2014.06.014
   Yefi R, 2011, J CELL BIOCHEM, V112, P3167, DOI 10.1002/jcb.23247
   Yu CC, 2014, ANTICANCER RES, V34, P2927
   Zheng Y, 2013, CLIN CANCER RES, V19, P6484, DOI 10.1158/1078-0432.CCR-13-0265
   Zhou BP, 2000, J BIOL CHEM, V275, P8027, DOI 10.1074/jbc.275.11.8027
NR 62
TC 25
Z9 26
U1 3
U2 26
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-4889
J9 CELL DEATH DIS
JI Cell Death Dis.
PD JAN 25
PY 2019
VL 10
AR 73
DI 10.1038/s41419-019-1306-x
PG 13
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA HJ2SI
UT WOS:000457019800016
PM 30683840
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Wu, L
   Yang, LL
AF Wu, Lei
   Yang, Lili
TI The function and mechanism of HMGB1 in lung cancer and its potential
   therapeutic implications
SO ONCOLOGY LETTERS
LA English
DT Review
DE high-mobility group protein B1; lung cancer; proliferation; function
ID GLYCATION END-PRODUCTS; GROUP BOX-1 PROTEIN; BRONCHIAL EPITHELIAL-CELLS;
   TOLL-LIKE RECEPTORS; BACTERIAL CPG-DNA; HEPATOCELLULAR-CARCINOMA;
   INFLAMMATORY RESPONSES; ADENOCARCINOMA CELLS; REGULATES AUTOPHAGY;
   SODIUM-SALICYLATE
AB As a non-histone chromatin-associated protein, high-mobility group box-1 (HMGB1) performs a pivotal function in various human diseases, including autoimmune diseases, neurodegenerative diseases and cancer. Overexpression of HMGB1 has been demonstrated in numerous types of cancer, including breast cancer, colorectal cancer, lung cancer and hepatocellular carcinoma. However, the underlying mechanism of HMGB1 function in lung cancer remains to be elucidated. The present study aimed to analyze, and summarize the role and mechanism of HMGB1 in lung cancer by retrieving available literature regarding HMGB1 in association with lung cancer. It provides comprehensive information on the association of HMGB1 with the carcinogenesis and progression of lung cancer, and discusses the molecular mechanism of these processes. HMGB1 may induce tumorigenesis, metastasis and chemotherapy resistance in lung cancer. Overall, it is evident that HMGB1 serves an important role in the development and progression of lung cancer, and this review warrants further investigation into HMGB1 as a novel target for cancer therapy.
C1 [Wu, Lei; Yang, Lili] Tianjin Med Univ, Tianjin Canc Inst & Hosp, Dept Immunol, Huanhuxi Rd, Tianjin 300060, Peoples R China.
   [Wu, Lei; Yang, Lili] Tianjin Med Univ, Natl Clin Res Ctr Canc, Tianjin Canc Inst & Hosp, Tianjin 300060, Peoples R China.
   [Wu, Lei; Yang, Lili] Tianjin Med Univ, Key Lab Canc Immunol & Biotherapy, Tianjin Canc Inst & Hosp, Tianjin 300060, Peoples R China.
RP Yang, LL (corresponding author), Tianjin Med Univ, Tianjin Canc Inst & Hosp, Dept Immunol, Huanhuxi Rd, Tianjin 300060, Peoples R China.
EM yanglili@tjmuch.com
FU National Key Technology RD ProgramNational Key Technology R&D Program
   [2015BAI12B12]; Key Projects of Tianjin Health Industry [15KG145];
   National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81572265, 31500736]
FX The present study was supported by the National Key Technology R&D
   Program (grant no. 2015BAI12B12), Key Projects of Tianjin Health
   Industry (grant no. 15KG145) and the National Natural Science Foundation
   of China (grant no. 81572265 and 31500736).
CR Ahmad-Nejad P, 2002, EUR J IMMUNOL, V32, P1958, DOI 10.1002/1521-4141(200207)32:7<1958::AID-IMMU1958>3.0.CO;2-U
   Amann R, 2002, EUR J PHARMACOL, V447, P1, DOI 10.1016/S0014-2999(02)01828-9
   Andersson U, 2014, J INTERN MED, V276, P420, DOI 10.1111/joim.12309
   Aranda F, 2014, ONCOIMMUNOLOGY, V3, DOI 10.4161/21624011.2014.955685
   Beaulieu LM, 2011, BLOOD, V117, P5963, DOI 10.1182/blood-2010-09-304949
   Bianchi ME, 2009, J LEUKOCYTE BIOL, V86, P573, DOI 10.1189/jlb.1008585
   Bin Goh WW, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-35
   BRETT J, 1993, AM J PATHOL, V143, P1699
   Chen RC, 2014, MOL CELL BIOCHEM, V390, P271, DOI 10.1007/s11010-014-1978-6
   Conti L, 2013, FASEB J, V27, P4731, DOI 10.1096/fj.13-230201
   Copetti T, 2009, MOL CELL BIOL, V29, P2594, DOI 10.1128/MCB.01396-08
   Dasu MR, 2010, DIABETES CARE, V33, P861, DOI 10.2337/dc09-1799
   Gribar SC, 2008, MOL MED, V14, P645, DOI 10.2119/2008-00035.Gribar
   Gunasekaran MK, 2016, ADIPOCYTE, V5, P384, DOI 10.1080/21623945.2016.1245818
   Guo XH, 2015, INT IMMUNOPHARMACOL, V29, P454, DOI 10.1016/j.intimp.2015.10.015
   Hacker H, 2000, J EXP MED, V192, P595, DOI 10.1084/jem.192.4.595
   Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123
   HORI O, 1995, J BIOL CHEM, V270, P25752, DOI 10.1074/jbc.270.43.25752
   Ivanov S, 2007, BLOOD, V110, P1970, DOI 10.1182/blood-2006-09-044776
   Jakubowska K, 2015, ADV EXP MED BIOL, V852, P49, DOI 10.1007/5584_2015_115
   Kang R, 2011, CELL DEATH DIFFER, V18, P571, DOI 10.1038/cdd.2010.191
   Kang R, 2010, CELL DEATH DIFFER, V17, P666, DOI 10.1038/cdd.2009.149
   Kang R, 2011, ANTIOXID REDOX SIGN, V15, P2175, DOI 10.1089/ars.2010.3378
   Kang R, 2010, AUTOPHAGY, V6, P1209, DOI 10.4161/auto.6.8.13651
   Katsuoka F, 1997, BIOCHEM BIOPH RES CO, V238, P512, DOI 10.1006/bbrc.1997.7263
   Kawada M, 2010, J ANTIBIOT, V63, P237, DOI 10.1038/ja.2010.28
   Kelland L, 2007, NAT REV CANCER, V7, P573, DOI 10.1038/nrc2167
   Khan N, 2015, CANCER LETT, V359, P155, DOI 10.1016/j.canlet.2015.01.038
   Kim J, 2011, AM J NEPHROL, V33, P524, DOI 10.1159/000327992
   Krynetskaia NF, 2009, MOL CANCER THER, V8, P864, DOI 10.1158/1535-7163.MCT-08-0695
   Kumagai Yutaro, 2008, Journal of Infection and Chemotherapy, V14, P86, DOI 10.1007/s10156-008-0596-1
   Latz E, 2004, NAT IMMUNOL, V5, P190, DOI 10.1038/ni1028
   Lee SA, 2014, YONSEI MED J, V55, P1165, DOI 10.3349/ymj.2014.55.5.1165
   Liang Y, 2015, MOL CELL BIOCHEM, V405, P63, DOI 10.1007/s11010-015-2396-0
   Lim SC, 2008, ONCOL REP, V19, P1165
   Lin E, 2009, CARDIOVASC THER, V27, P117, DOI 10.1111/j.1755-5922.2009.00077.x
   Liu PL, 2010, AM J RESP CELL MOL, V43, P530, DOI 10.1165/rcmb.2009-0269OC
   Liu Y, 2016, ONCOL LETT, V12, P4181, DOI 10.3892/ol.2016.5198
   Livesey KM, 2012, CANCER RES, V72, P1996, DOI 10.1158/0008-5472.CAN-11-2291
   Lotze MT, 2007, IMMUNOL REV, V220, P60, DOI 10.1111/j.1600-065X.2007.00579.x
   Musumeci D, 2014, PHARMACOL THERAPEUT, V141, P347, DOI 10.1016/j.pharmthera.2013.11.001
   Nogueira-Machado JA, 2012, RECENT PATENTS ENDOC, V6, P201, DOI 10.2174/187221412802481784
   Ohmori H, 2011, EXPERT OPIN THER TAR, V15, P183, DOI 10.1517/14728222.2011.546785
   Pan BZ, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-165
   Park JS, 2006, AM J PHYSIOL-CELL PH, V290, pC917, DOI 10.1152/ajpcell.00401.2005
   Park JS, 2004, J BIOL CHEM, V279, P7370, DOI 10.1074/jbc.M306793200
   Ren T, 2007, CANCER BIOL THER, V6, P1704, DOI 10.4161/cbt.6.11.4826
   Riuzzi F, 2006, J BIOL CHEM, V281, P8242, DOI 10.1074/jbc.M509436200
   Rouhiainen Ari, 2013, Methods Mol Biol, V963, P239, DOI 10.1007/978-1-62703-230-8_15
   de Cos JS, 2009, LUNG CANCER, V63, P140, DOI 10.1016/j.lungcan.2008.04.013
   Schraml P, 1997, CANCER RES, V57, P3669
   Shang GH, 2009, RESP MED, V103, P1949, DOI 10.1016/j.rmed.2009.05.019
   Shen XK, 2009, ONCOL REP, V22, P535, DOI 10.3892/or_00000468
   Singh B, 2016, EUR J IMMUNOL, V46, P2388, DOI 10.1002/eji.201646386
   Sirois CM, 2013, J EXP MED, V210, P2447, DOI 10.1084/jem.20120201
   Spira A, 2004, NEW ENGL J MED, V350, P379, DOI 10.1056/NEJMra035536
   Stordal B, 2007, IUBMB LIFE, V59, P696, DOI 10.1080/15216540701636287
   Su ZL, 2015, IMMUNOBIOLOGY, V220, P539, DOI 10.1016/j.imbio.2014.12.009
   Sun KK, 2013, MOL MED REP, V7, P1678, DOI 10.3892/mmr.2013.1362
   Sun XF, 2014, AUTOPHAGY, V10, P1873, DOI 10.4161/auto.32184
   Taguchi A, 2000, NATURE, V405, P354, DOI 10.1038/35012626
   Tang DL, 2012, IMMUNOL REV, V249, P158, DOI 10.1111/j.1600-065X.2012.01146.x
   Tang DL, 2010, J CELL BIOL, V190, P881, DOI 10.1083/jcb.200911078
   Tian J, 2007, NAT IMMUNOL, V8, P487, DOI 10.1038/ni1457
   Ulloa L, 2002, P NATL ACAD SCI USA, V99, P12351, DOI 10.1073/pnas.192222999
   Venereau E, 2016, PHARMACOL RES, V111, P534, DOI 10.1016/j.phrs.2016.06.031
   Wang CH, 2012, CANCER BIOL THER, V13, P727, DOI 10.4161/cbt.20555
   Wang Haichao, 2008, Expert Reviews in Molecular Medicine, V10, P1, DOI 10.1017/S1462399408000884
   Wang HM, 2015, ONCOL LETT, V10, P51, DOI 10.3892/ol.2015.3200
   Wang JL, 2014, ASIAN PAC J CANCER P, V15, P4865, DOI 10.7314/APJCP.2014.15.12.4865
   Wang Y, 2014, CLIN EXP PHARMACOL P, V41, P408, DOI 10.1111/1440-1681.12232
   Wei F, 2016, ONCOTARGET, V7, P40106, DOI 10.18632/oncotarget.9496
   Wood SL, 2015, CANCER TREAT REV, V41, P361, DOI 10.1016/j.ctrv.2015.02.008
   Wu XJ, 2013, MOL CELL BIOCHEM, V380, P249, DOI 10.1007/s11010-013-1680-0
   Xia QS, 2016, ONCOTARGETS THER, V9, P3917, DOI 10.2147/OTT.S104409
   Xiao P, 2015, INT J CLIN EXP PATHO, V8, P10800
   Xu L, 2009, BIOCHEM BIOPH RES CO, V382, P571, DOI 10.1016/j.bbrc.2009.03.072
   Yanai H, 2009, NATURE, V462, P99, DOI 10.1038/nature08512
   Yang YL, 2014, TUMOR BIOL, V35, P2905, DOI 10.1007/s13277-013-1493-5
   Yao SH, 2015, BIOMED PHARMACOTHER, V70, P72, DOI 10.1016/j.biopha.2015.01.013
   Yaser AM, 2012, INT J MOL SCI, V13, P5982, DOI 10.3390/ijms13055982
   Ye X, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004070
   Yu LX, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6256
   Yu Y, 2015, FRONT PHYSIOL, V6, DOI 10.3389/fphys.2015.00093
   Zhang CL, 2013, ACTA BIOCH BIOPH SIN, V45, P1055, DOI 10.1093/abbs/gmt109
   Zhang H, 2018, MOL MED REP, V17, P2915, DOI 10.3892/mmr.2017.8216
   Zhang RG, 2015, TUMOR BIOL, V36, P8585, DOI 10.1007/s13277-015-3617-6
   Zhang XH, 2013, WSPOLCZESNA ONKOL, V17, P350, DOI 10.5114/wo.2013.35291
   Zhou RR, 2014, CELL ADHES MIGR, V8, P493, DOI 10.4161/19336918.2014.969139
   Zhu JH, 2016, BIOCHEM BIOPH RES CO, V480, P522, DOI 10.1016/j.bbrc.2016.10.052
NR 90
TC 39
Z9 40
U1 4
U2 9
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792-1074
EI 1792-1082
J9 ONCOL LETT
JI Oncol. Lett.
PD MAY
PY 2018
VL 15
IS 5
BP 6799
EP 6805
DI 10.3892/ol.2018.8215
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA GF3DN
UT WOS:000431825900094
PM 29725415
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Lizarraga-Verdugo, E
   Ruiz-Garcia, E
   Lopez-Camarillo, C
   Bermudez, M
   Avendano-Felix, M
   Ramos-Payan, R
   Romero-Quintana, G
   Ayala-Ham, A
   Villegas-Mercado, C
   Perez-Plasencia, C
   Aguilar-Medina, M
AF Lizarraga-Verdugo, Erik
   Ruiz-Garcia, Erika
   Lopez-Camarillo, Cesar
   Bermudez, Mercedes
   Avendano-Felix, Mariana
   Ramos-Payan, Rosalio
   Romero-Quintana, Geovanni
   Ayala-Ham, Alfredo
   Villegas-Mercado, Carlos
   Perez-Plasencia, Carlos
   Aguilar-Medina, Maribel
TI Cell Survival Is Regulated via SOX9/BCL2L1 Axis in HCT-116 Colorectal
   Cancer Cell Line
SO JOURNAL OF ONCOLOGY
LA English
DT Article
ID BCL-2 PROTEIN FAMILY; X-L; SOX9; EXPRESSION; GENE; METASTASIS;
   AUTOPHAGY; DIFFERENTIATION; INHIBITION; ACTIVATION
AB Colorectal cancer (CRC) is one of the most frequent types of malignancies and one of the major causes of cancer-related death worldwide. Sex-determining region Y (SRY)-box 9 protein (SOX9) is a member of the SOX family of transcription factors which are involved in the regulation of differentiation and development. Recently, several reports suggest an important role of SOX9 in tumorigenesis since its overexpression correlates with tumor progression and poor outcome in several types of cancer; however, its role in CRC is not clear until now. Therefore, in this work, we searched for novel SOX9-regulated genes involved in cell survival of CRC. We silenced SOX9 in the poorly differentiated HCT-116 cell line, using a specific siRNA, to identify differential expressed genes by DNA microarrays and analyzed the role or candidate genes in apoptosis and autophagy. Transcriptome analysis showed that diverse cellular pathways, associated with CRC carcinogenesis such as Wnt/beta-catenin, MAPK, TGF-beta, and mTOR, were modulated after SOX9 silencing. Interestingly, we found that SOX9 silencing promotes downregulation of BCL2L1 and overexpression of CASP3, proteins related to apoptosis, which was further confirmed in SW-480, a moderated-differentiated cell line, but not in HT-29, well-differentiated cell line. Moreover, inhibition of BCL2L1 by ABT-737 (BH3 mimetic) in SOX9-silenced HCT-116 cells resulted in an increased apoptosis percentage. However, downregulation of BCL2L1 was not enough to induce autophagy. This is the first report, suggesting that cell survival in poorly and moderated-differentiated CRC cells lines is regulated by SOX9/BCL2L1 axis, but not in well-differentiated cell lines.
C1 [Lizarraga-Verdugo, Erik; Bermudez, Mercedes; Avendano-Felix, Mariana; Ramos-Payan, Rosalio; Romero-Quintana, Geovanni; Aguilar-Medina, Maribel] Univ Autonoma Sinaloa, Fac Ciencias Quim Biol, Culiacan, Sinaloa, Mexico.
   [Ruiz-Garcia, Erika; Perez-Plasencia, Carlos] Inst Nacl Cancerol, Mexico City, DF, Mexico.
   [Lopez-Camarillo, Cesar] Univ Autonoma Ciudad Mexico, Posgrad Ciencias Genom, Mexico City, DF, Mexico.
   [Ayala-Ham, Alfredo; Villegas-Mercado, Carlos] Univ Autonoma Sinaloa, Fac Odontol, Culiacan, Sinaloa, Mexico.
RP Aguilar-Medina, M (corresponding author), Univ Autonoma Sinaloa, Fac Ciencias Quim Biol, Culiacan, Sinaloa, Mexico.
EM eriklizarraga.fcqb@uas.edu.mx; betzabe100@yahoo.com.mx;
   genomicas@yahoo.com.mx; bermudezcm@uas.edu.mx;
   mariana_melisa25@hotmail.com; rosaliorp@uas.edu.mx;
   geovanniromero@uas.edu.mx; endoalfredo@uas.edu.mx;
   carlosvillegas@uas.edu.mx; carlos.pplas@gmail.com;
   maribelaguilar@uas.edu.mx
RI Lopez-Camarillo, Cesar/I-1946-2019
OI Lopez-Camarillo, Cesar/0000-0002-9417-2609; Villegas-Mercado,
   Carlos/0000-0001-5729-4677; Ruiz-Garcia, Erika/0000-0002-0446-123X;
   Perez-Plasencia, Carlos/0000-0002-8593-8211; Ramos-Payan,
   Rosalio/0000-0001-7500-7571
FU Consejo Nacional de Ciencia y Tecnologia CONACYTConsejo Nacional de
   Ciencia y Tecnologia (CONACyT) [290311]
FX The authors acknowledge Consejo Nacional de Ciencia y Tecnologia CONACYT
   for Mariana Avendano-Felix (575985) and Erik Lizarraga-Verdugo (304939)
   fellowships. The authors acknowledge Consejo Nacional de Ciencia y
   Tecnologia CONACYT (grant 290311) for funding.
CR Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322
   Bastide P, 2007, J CELL BIOL, V178, P635, DOI 10.1083/jcb.200704152
   BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x
   BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N
   Boroughs LK, 2015, NAT CELL BIOL, V17, P351, DOI 10.1038/ncb3124
   Carrasco-Garcia E, 2016, SCI REP-UK, V6, DOI 10.1038/srep32350
   Chen H, 2017, CLIN CANCER RES, V23, P5176, DOI 10.1158/1078-0432.CCR-17-0177
   Chen YB, 2016, ONCOTARGET, V7, P76508, DOI 10.18632/oncotarget.12894
   Cronin KA, 2018, CANCER-AM CANCER SOC, V124, P2785, DOI 10.1002/cncr.31551
   Derwinger K, 2010, ACTA ONCOL, V49, P57, DOI 10.3109/02841860903334411
   Domenici G, 2019, ONCOGENE, V38, P3151, DOI 10.1038/s41388-018-0656-7
   Fodde R, 2002, EUR J CANCER, V38, P867, DOI 10.1016/S0959-8049(02)00040-0
   FOSTER JW, 1994, NATURE, V372, P525, DOI 10.1038/372525a0
   Francis Jeffrey C, 2018, Oncotarget, V9, P7604, DOI 10.18632/oncotarget.24123
   Fullgrabe J, 2014, NAT REV MOL CELL BIO, V15, P65, DOI 10.1038/nrm3716
   Genecards, 2020, BCL2L1 GEN
   Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320
   Grimm D, 2020, SEMIN CANCER BIOL, V67, P122, DOI 10.1016/j.semcancer.2019.03.004
   Guicciardi ME, 2009, FASEB J, V23, P1625, DOI 10.1096/fj.08-111005
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Hariharan N, 2010, CIRC RES, V107, P1470, DOI 10.1161/CIRCRESAHA.110.227371
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923
   Huang JQ, 2019, J TRANSL MED, V17, DOI 10.1186/s12967-019-1895-2
   Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249
   Jo A, 2014, GENES DIS, V1, P149, DOI 10.1016/j.gendis.2014.09.004
   Larsimont JC, 2015, CELL STEM CELL, V17, P60, DOI 10.1016/j.stem.2015.05.008
   Liu HW, 2015, CELL BIOCHEM BIOPHYS, V73, P205, DOI 10.1007/s12013-015-0647-z
   Liu LH, 2016, CELL DEATH DISCOV, V2, DOI 10.1038/cddiscovery.2016.66
   Liu PF, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0180620
   Lu BJ, 2008, AM J CLIN PATHOL, V130, P897, DOI 10.1309/AJCPW1W8GJBQGCNI
   Maiuri MC, 2007, EMBO J, V26, P2527, DOI 10.1038/sj.emboj.7601689
   Marshman E, 2001, J PATHOL, V195, P285
   Mei Y, 2016, PROTEIN SCI, V25, P1767, DOI 10.1002/pro.2984
   Mizushima N, 2004, MOL BIOL CELL, V15, P1101, DOI 10.1091/mbc.E03-09-0704
   Montorsi L, 2016, ONCOTARGET, V7, P59144, DOI 10.18632/oncotarget.10828
   Nagasaka A, 2010, CELL DEATH DIFFER, V17, P931, DOI 10.1038/cdd.2009.186
   O'Neill BT, 2019, DIABETES, V68, P556, DOI 10.2337/db18-0416
   Ogino S, 2010, J NATL CANCER I, V102, P365, DOI 10.1093/jnci/djq031
   Oltersdorf T, 2005, NATURE, V435, P677, DOI 10.1038/nature03579
   Paoli P, 2013, BBA-MOL CELL RES, V1833, P3481, DOI 10.1016/j.bbamcr.2013.06.026
   Pryczynicz A, 2014, WORLD J GASTROENTERO, V20, P1305, DOI 10.3748/wjg.v20.i5.1305
   Pu X, 2017, APOPTOSIS, V22, P357, DOI 10.1007/s10495-016-1323-5
   Shen LL, 2018, ONCOGENE, V37, P1759, DOI 10.1038/s41388-017-0118-7
   Sinha S, 2008, ONCOGENE, V27, pS137, DOI 10.1038/onc.2009.51
   Song G, 2005, J CELL MOL MED, V9, P59, DOI 10.1111/j.1582-4934.2005.tb00337.x
   Su ZY, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0321-5
   Sun Y, 2006, CANCER DETECT PREV, V30, P168, DOI 10.1016/j.cdp.2006.02.004
   Tang ZF, 2017, NUCLEIC ACIDS RES, V45, pW98, DOI 10.1093/nar/gkx247
   Topol LL, 2009, J BIOL CHEM, V284, P3323, DOI 10.1074/jbc.M808048200
   VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901
   Vogler Meike, 2014, Adv Med, V2014, P943648, DOI 10.1155/2014/943648
   Wan YP, 2017, ONCOL RES TREAT, V40, P15, DOI 10.1159/000455145
   Yagi R, 2005, J BIOL CHEM, V280, P30517, DOI 10.1074/jbc.M502751200
   Youle RJ, 2008, NAT REV MOL CELL BIO, V9, P47, DOI 10.1038/nrm2308
   Yu XH, 2014, ONCOTARGET, V5, P9039, DOI 10.18632/oncotarget.1996
   Yuan XD, 2018, BRIT J CANCER, V119, P1358, DOI 10.1038/s41416-018-0338-9
   Yun CW, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113466
   Zhang HC, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0397-y
NR 59
TC 2
Z9 2
U1 0
U2 0
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1687-8450
EI 1687-8469
J9 J ONCOL
JI J. Oncol.
PD APR 29
PY 2020
VL 2020
AR 5701527
DI 10.1155/2020/5701527
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA LN9TJ
UT WOS:000533273200002
PM 32411238
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Lee, HY
   Son, SW
   Moeng, S
   Choi, SY
   Park, JK
AF Lee, Han Yeoung
   Son, Seung Wan
   Moeng, Sokviseth
   Choi, Soo Young
   Park, Jong Kook
TI The Role of Noncoding RNAs in the Regulation of Anoikis and
   Anchorage-Independent Growth in Cancer
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Review
DE anoikis; anchorage-independent growth; metastasis; apoptosis; noncoding
   RNA; microRNA; long noncoding RNA; cancer
ID EPITHELIAL-MESENCHYMAL TRANSITION; HEPATOCELLULAR-CARCINOMA CELLS;
   SUPPRESSES TUMOR-METASTASIS; FOCAL ADHESION KINASE; ADENOMATOUS
   POLYPOSIS-COLI; ACUTE MYELOID-LEUKEMIA; BREAST-CANCER; UP-REGULATION;
   COLORECTAL-CANCER; LUNG-CANCER
AB Cancer is a global health concern, and the prognosis of patients with cancer is associated with metastasis. Multistep processes are involved in cancer metastasis. Accumulating evidence has shown that cancer cells acquire the capacity of anoikis resistance and anchorage-independent cell growth, which are critical prerequisite features of metastatic cancer cells. Multiple cellular factors and events, such as apoptosis, survival factors, cell cycle, EMT, stemness, autophagy, and integrins influence the anoikis resistance and anchorage-independent cell growth in cancer. Noncoding RNAs (ncRNAs), such as microRNAs (miRNAs) and long noncoding RNAs (lncRNAs), are dysregulated in cancer. They regulate cellular signaling pathways and events, eventually contributing to cancer aggressiveness. This review presents the role of miRNAs and lncRNAs in modulating anoikis resistance and anchorage-independent cell growth. We also discuss the feasibility of ncRNA-based therapy and the natural features of ncRNAs that need to be contemplated for more beneficial therapeutic strategies against cancer.
C1 [Lee, Han Yeoung; Son, Seung Wan; Moeng, Sokviseth; Choi, Soo Young; Park, Jong Kook] Hallym Univ, Dept Biomed Sci, Chunchon 24252, South Korea.
   [Lee, Han Yeoung; Son, Seung Wan; Moeng, Sokviseth; Choi, Soo Young; Park, Jong Kook] Hallym Univ, Res Inst Biosci & Biotechnol, Chunchon 24252, South Korea.
RP Park, JK (corresponding author), Hallym Univ, Dept Biomed Sci, Chunchon 24252, South Korea.
EM gksdudsd@gmail.com; miyanae@naver.com; sokvisethmoeng@yahoo.com;
   sychoi@hallym.ac.kr; jkp555@hallym.ac.kr
OI Park, Jong Kook/0000-0002-3946-5687
FU National Research Foundation of Korea (NRF) - Ministry of Education
   [2017R1D1A3B03035662, 2019R1A6A1A11036849]; National Research Foundation
   of Korea (NRF) - Korea government (MSIT) [2019R1A2C1089710]
FX This work was supported by a grant from the Basic Science Research
   Program through the National Research Foundation of Korea (NRF) funded
   by the Ministry of Education (2017R1D1A3B03035662) (J.K.P.) and
   (2019R1A6A1A11036849) (S.Y.C.); and the National Research Foundation of
   Korea (NRF) grant funded by the Korea government (MSIT)
   (2019R1A2C1089710) (J.K.P.).
CR Agosta C, 2018, INT J CANCER, V143, P944, DOI 10.1002/ijc.31363
   Al-Khalaf HH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021111
   Alanko J, 2016, CELL CYCLE, V15, P605, DOI 10.1080/15384101.2015.1130576
   Alfano D, 2006, J BIOL CHEM, V281, P17758, DOI 10.1074/jbc.M601812200
   An YF, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2308-4
   Arnold J, 2020, EXP MOL PATHOL, V112, DOI 10.1016/j.yexmp.2019.104348
   Bae SJ, 2017, ELIFE, V6, DOI [10.7554/eLife.30278.001, 10.7554/eLife.30278]
   Berezovskaya O, 2005, CANCER RES, V65, P2378, DOI 10.1158/0008-5472.CAN-04-2649
   Bersani F, 2016, CANCER RES, V76, P6095, DOI 10.1158/0008-5472.CAN-16-0709
   Bharambe HS, 2019, ACTA NEUROPATHOL COM, V7, DOI 10.1186/s40478-019-0697-3
   Botti G, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20092279
   Braconi C, 2011, ONCOGENE, V30, P4750, DOI 10.1038/onc.2011.193
   Cantile M, 2020, CANCERS, V12, DOI 10.3390/cancers12051197
   Carabet LA, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20010120
   Carrasco-Garcia E, 2016, SCI REP-UK, V6, DOI 10.1038/srep32350
   Catalano M, 2020, J EXTRACELL VESICLES, V9, DOI 10.1080/20013078.2019.1703244
   Chang L, 2017, CLIN TRANSL ONCOL, V19, P695, DOI 10.1007/s12094-016-1582-1
   Chao HC, 2019, CARCINOGENESIS, V40, P1341, DOI 10.1093/carcin/bgz039
   Chaturvedi A, 2014, MOL BIOL CELL, V25, P2695, DOI 10.1091/mbc.E14-01-0007
   Chen JL, 2017, MOL CANCER RES, V15, P26, DOI 10.1158/1541-7786.MCR-16-0200-T
   Chen JQ, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-63279-y
   Chen M, 2020, DIGEST DIS SCI, V65, P2442, DOI 10.1007/s10620-019-05916-9
   Chen QG, 2019, CANCER CELL INT, V19, DOI 10.1186/s12935-019-0782-5
   Chen QN, 2017, ONCOTARGET, V8, P1925, DOI 10.18632/oncotarget.12461
   Chen TW, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-53699-w
   Chen WR, 2019, EXP THER MED, V17, P4100, DOI 10.3892/etm.2019.7436
   Chen ZZ, 2020, J CANCER, V11, P1383, DOI 10.7150/jca.32552
   Cheng L, 2018, MODERN PATHOL, V31, P24, DOI 10.1038/modpathol.2017.104
   Chunhacha P, 2012, AM J PHYSIOL-CELL PH, V302, pC1284, DOI 10.1152/ajpcell.00318.2011
   Collins NL, 2005, MOL CELL BIOL, V25, P5282, DOI 10.1128/MCB.25.12.5282-5291.2005
   Corcoran C, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-71
   Corcoran C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050999
   Cristobal I, 2019, J CLIN MED, V8, DOI 10.3390/jcm8030346
   Cui YX, 2017, BRIT J CANCER, V117, P89, DOI 10.1038/bjc.2017.156
   Cully M, 2005, CANCER RES, V65, P10363, DOI 10.1158/0008-5472.CAN-05-1633
   D'Amato NC, 2015, CANCER RES, V75, P4651, DOI 10.1158/0008-5472.CAN-15-2011
   Dai WY, 2018, ONCOTARGETS THER, V11, P5103, DOI 10.2147/OTT.S169809
   Dan J, 2018, BIOMED PHARMACOTHER, V99, P931, DOI 10.1016/j.biopha.2018.01.164
   Datar I, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0204387
   DeLigio JT, 2017, J BIOL CHEM, V292, P17909, DOI 10.1074/jbc.M117.810127
   Deng W, 2019, EXP BIOL MED, V244, P953, DOI 10.1177/1535370219860207
   Deng WT, 2015, J CELL SCI, V128, P1123, DOI 10.1242/jcs.162164
   Deng YC, 2003, INT J CANCER, V106, P342, DOI 10.1002/ijc.11228
   Derouet Mathieu Francois, 2018, Oncotarget, V9, P15198, DOI 10.18632/oncotarget.24613
   Di Mauro C, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-10062-1
   Ding SM, 2018, CANCER BIOMARK, V22, P217, DOI 10.3233/CBM-170777
   Dong GY, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-1033-8
   Dong JX, 2007, CELL, V130, P1120, DOI 10.1016/j.cell.2007.07.019
   Dong L, 2018, SIGNAL TRANSDUCT TAR, V3, DOI 10.1038/s41392-018-0025-6
   Dong PX, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1306-9
   Donnarumma E, 2017, ONCOTARGET, V8, P19592, DOI 10.18632/oncotarget.14752
   Douma S, 2004, NATURE, V430, P1034, DOI 10.1038/nature02765
   Du MJ, 2017, BIOCHEM BIOPH RES CO, V482, P582, DOI 10.1016/j.bbrc.2016.11.077
   Duan ZQ, 2018, MOL CELL BIOCHEM, V448, P165, DOI 10.1007/s11010-018-3323-y
   Duxbury MS, 2004, SURGERY, V135, P555, DOI 10.1016/j.surg.2003.10.017
   Elbadawy M, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20092340
   Endo H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077070
   Feng M, 2011, ONCOGENE, V30, P2242, DOI 10.1038/onc.2010.602
   Fleisig HB, 2012, ONCOGENE, V31, P954, DOI 10.1038/onc.2011.292
   Franzetti GA, 2017, ONCOGENE, V36, P3505, DOI 10.1038/onc.2016.498
   FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619
   Fu XT, 2018, CANCER LETT, V412, P108, DOI 10.1016/j.canlet.2017.10.012
   Gan L, 2009, CELL DEATH DIFFER, V16, P1408, DOI 10.1038/cdd.2009.86
   Gao W, 2017, J CANCER, V8, P2356, DOI 10.7150/jca.19470
   Gao ZR, 2019, ONCOL REP, V41, P235, DOI 10.3892/or.2018.6827
   Guadamillas MC, 2011, J CELL SCI, V124, P3189, DOI 10.1242/jcs.072165
   Guan HY, 2018, ONCOTARGETS THER, V11, P4893, DOI 10.2147/OTT.S170293
   Guo B, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170620
   Guo ST, 2017, ONCOGENESIS, V6, DOI 10.1038/oncsis.2017.37
   Guo XD, 2020, ACTA BIOCH BIOPH SIN, V52, P1148, DOI 10.1093/abbs/gmaa102
   Hamidi Hellyeh, 2018, Nat Rev Cancer, V18, P533, DOI 10.1038/s41568-018-0038-z
   Han F, 2015, ONCOGENE, V34, P4391, DOI 10.1038/onc.2014.370
   Han F, 2015, INT J CLIN EXP PATHO, V8, P8937
   Hannen R, 2018, FEBS LETT, V592, P2023, DOI 10.1002/1873-3468.13084
   Hata T, 2017, INT J ONCOL, V50, P487, DOI 10.3892/ijo.2016.3813
   He P, 2018, INT J ONCOL, V52, P1305, DOI 10.3892/ijo.2018.4284
   He RQ, 2015, INT J CLIN EXP PATHO, V8, P15632
   Heinen CD, 2002, GASTROENTEROLOGY, V123, P751, DOI 10.1053/gast.2002.35382
   Hirata H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051056
   Hollern DP, 2014, MOL CELL BIOL, V34, P3229, DOI 10.1128/MCB.00737-14
   Huang C, 2017, J HEMATOL ONCOL, V10, DOI 10.1186/s13045-016-0376-9
   Hung PS, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177346
   Hyun TS, 2004, J BIOL CHEM, V279, P14294, DOI 10.1074/jbc.M312645200
   Ikematsu N, 1999, ONCOGENE, V18, P7432, DOI 10.1038/sj.onc.1203193
   Ishii S, 2017, ONCOTARGET, V8, P74567, DOI 10.18632/oncotarget.20209
   Jandrey EHF, 2019, NPJ BREAST CANCER, V5, DOI 10.1038/s41523-019-0106-x
   Jia B, 2018, EXP THER MED, V15, P2569, DOI 10.3892/etm.2018.5716
   Jiang GS, 2018, CARCINOGENESIS, V39, P482, DOI 10.1093/carcin/bgy015
   Jiang GS, 2017, MOL CANCER THER, V16, P924, DOI 10.1158/1535-7163.MCT-16-0631
   Jiang WL, 2018, J CELL MOL MED, V22, P1864, DOI 10.1111/jcmm.13470
   Jin XL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125515
   Jin YX, 2019, CELL BIOSCI, V9, DOI 10.1186/s13578-019-0338-3
   Jo MJ, 2010, CANCER RES, V70, P8948, DOI 10.1158/0008-5472.CAN-10-1936
   Johnson RM, 2015, J BIOL CHEM, V290, P25717, DOI 10.1074/jbc.M115.671206
   Jolly MK, 2019, MOL CANCER RES, V17, P1391, DOI 10.1158/1541-7786.MCR-18-0763
   Jones DZ, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4258-0
   Kang J, 2013, FASEB J, V27, P2807, DOI 10.1096/fj.12-220897
   Kawada M, 1998, JPN J CANCER RES, V89, P110, DOI 10.1111/j.1349-7006.1998.tb00537.x
   Khurana N, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20092066
   Kim MJ, 2014, MOL CELLS, V37, P759, DOI 10.14348/molcells.2014.0232
   Kim SY, 2016, J CELL BIOCHEM, V117, P2289, DOI 10.1002/jcb.25527
   Kim YJ, 2019, CANCER CELL INT, V19, DOI 10.1186/s12935-019-0892-0
   Kim Yong-Nyun, 2012, Int J Cell Biol, V2012, P306879, DOI 10.1155/2012/306879
   Kim YJ, 2020, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.01574
   Kochetkova M, 2009, CELL DEATH DIFFER, V16, P664, DOI 10.1038/cdd.2008.190
   Kong FY, 2019, GUT, V68, P950, DOI 10.1136/gutjnl-2018-316627
   Kozak J, 2019, MOL CELL BIOCHEM, V459, P21, DOI 10.1007/s11010-019-03547-2
   Krstic M, 2019, J PATHOL, V248, P191, DOI 10.1002/path.5245
   Kumar A, 2018, MOL ONCOL, V12, P1596, DOI 10.1002/1878-0261.12360
   Kwon JJ, 2016, ONCOTARGET, V7, P71635, DOI 10.18632/oncotarget.11928
   Lai A, 1999, ONCOGENE, V18, P2091, DOI 10.1038/sj.onc.1202520
   Lai XN, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21041193
   Larsimont JC, 2015, CELL STEM CELL, V17, P60, DOI 10.1016/j.stem.2015.05.008
   Lauzier A, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-47659-7
   Le Clorennec C, 2019, CELL COMMUN SIGNAL, V17, DOI 10.1186/s12964-019-0413-8
   Lee HY, 2019, MOL CANCER RES, V17, P544, DOI 10.1158/1541-7786.MCR-18-0630
   Lee YJ, 2020, BIOCHEM BIOPH RES CO, V522, P270, DOI 10.1016/j.bbrc.2019.11.104
   Leung Z, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1402-x
   Li G, 2017, BIOMED PHARMACOTHER, V96, P1170, DOI 10.1016/j.biopha.2017.11.105
   Li JW, 2020, ONCOL REP, V43, P1516, DOI 10.3892/or.2020.7517
   Li L, 2020, J CANCER, V11, P6277, DOI 10.7150/jca.44037
   Li MY, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0284-8
   Li M, 2020, MOL THER-ONCOLYTICS, V18, P70, DOI 10.1016/j.omto.2020.06.002
   Li SL, 2017, J CANCER, V8, P3480, DOI 10.7150/jca.21241
   Li S, 2020, BIOMED PHARMACOTHER, V125, DOI 10.1016/j.biopha.2020.109889
   Li SF, 2018, GENES DIS, V5, P27, DOI 10.1016/j.gendis.2017.11.003
   Li X, 2018, MOL CELL BIOL, V38, DOI 10.1128/MCB.00273-18
   Li YM, 2004, CANCER CELL, V6, P459, DOI 10.1016/j.ccr.2004.09.027
   Li YC, 2015, ONCOTARGETS THER, V8, DOI 10.2147/OTT.S89459
   Li ZH, 2018, ONCOGENE, V37, P3822, DOI 10.1038/s41388-018-0237-9
   Li ZQ, 2016, BIOMED PHARMACOTHER, V83, P508, DOI 10.1016/j.biopha.2016.07.010
   Liang Y, 2020, GASTRIC CANCER, V23, P212, DOI 10.1007/s10120-019-01002-1
   Liao YB, 2016, GYNECOL ONCOL, V143, P655, DOI 10.1016/j.ygyno.2016.09.010
   Lin CC, 2015, ONCOGENESIS, V4, DOI 10.1038/oncsis.2015.8
   Lin Y, 2017, BIOMED PHARMACOTHER, V95, P497, DOI 10.1016/j.biopha.2017.08.052
   Lin YX, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0760-3
   Liu B, 2019, EXP THER MED, V18, P4747, DOI 10.3892/etm.2019.8120
   Liu DD, 2020, CANCER CONTROL, V27, DOI 10.1177/1073274819897977
   Liu H, 2014, CELL SIGNAL, V26, P2710, DOI 10.1016/j.cellsig.2014.08.010
   Liu H, 2012, NAT CELL BIOL, V14, P567, DOI 10.1038/ncb2491
   Liu LH, 2019, INT J ONCOL, V54, P929, DOI 10.3892/ijo.2019.4695
   Liu L, 2020, MOL THER, V28, P2177, DOI 10.1016/j.ymthe.2020.06.024
   Liu XL, 2019, MOL THER-ONCOLYTICS, V15, P248, DOI 10.1016/j.omto.2019.10.008
   Liu XL, 2019, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00207
   Liu YK, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.61
   Liu YD, 2017, J BIOL CHEM, V292, P3186, DOI 10.1074/jbc.M116.751685
   Liu Y, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4255-3
   Liu ZH, 2015, INT J CLIN EXP MED, V8, P3490
   Liu ZL, 2013, MOL CELL BIOCHEM, V372, P35, DOI 10.1007/s11010-012-1443-3
   Lo HW, 2007, CANCER RES, V67, P9066, DOI 10.1158/0008-5472.CAN-07-0575
   Lu Y, 2016, ONCOTARGETS THER, V9, P3077, DOI 10.2147/OTT.S102658
   Ma FF, 2020, BIOMED PHARMACOTHER, V125, DOI 10.1016/j.biopha.2020.109905
   Ma L, 2007, NATURE, V449, P682, DOI 10.1038/nature06174
   Madsen CD, 2007, J CELL BIOL, V177, P927, DOI 10.1083/jcb.200612058
   Mahmood N, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00024
   Mahoney MG, 2002, ONCOGENE, V21, P2161, DOI 10.1038/sj.onc.1205277
   Mailleux AA, 2007, DEV CELL, V12, P221, DOI 10.1016/j.devcel.2006.12.003
   Mak CSL, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0582-2
   Malagobadan S, 2020, CANCER BIOL MED, V17, P101, DOI 10.20892/j.issn.2095-3941.2019.0010
   Massoumi R, 2006, CELL, V125, P665, DOI 10.1016/j.cell.2006.03.041
   Matsuyama R, 2016, CANCER SCI, V107, P28, DOI 10.1111/cas.12834
   Melino G, 2011, CELL DEATH DIFFER, V18, P1487, DOI 10.1038/cdd.2011.81
   Meltzer S, 2019, TRANSL ONCOL, V12, P1038, DOI 10.1016/j.tranon.2019.04.014
   Moeng S, 2020, BIOMEDICINES, V8, DOI 10.3390/biomedicines8080267
   Moore C, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0178028
   Murai S, 2017, ONCOGENESIS, V6, DOI 10.1038/oncsis.2017.34
   Muys BR, 2019, CANCER RES, V79, P3294, DOI 10.1158/0008-5472.CAN-19-0490
   Muzumdar MD, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00942-5
   Nawaz Muhammad, 2017, Stem Cell Investig, V4, P83, DOI 10.21037/sci.2017.10.04
   Ni SJ, 2018, ONCOTARGETS THER, V11, P3835, DOI 10.2147/OTT.S172887
   Oh E, 2016, BBA-MOL CELL RES, V1863, P1071, DOI 10.1016/j.bbamcr.2016.03.010
   Okuda H, 2013, CANCER RES, V73, P1434, DOI 10.1158/0008-5472.CAN-12-2037
   Okugawa Y, 2014, CARCINOGENESIS, V35, P2731, DOI 10.1093/carcin/bgu200
   Orford K, 1999, J CELL BIOL, V146, P855, DOI 10.1083/jcb.146.4.855
   Pan Y, 2019, ACTA BIOCH BIOPH SIN, V51, P807, DOI 10.1093/abbs/gmz066
   Park JK, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19041206
   Pedini F, 2019, MOL ONCOL, V13, P1836, DOI 10.1002/1878-0261.12506
   Peres J, 2017, CANCER LETT, V405, P111, DOI 10.1016/j.canlet.2017.07.018
   Puthalakath H, 2001, SCIENCE, V293, P1829, DOI 10.1126/science.1062257
   Qi XT, 2019, ACTA PHARMACOL SIN, V40, P546, DOI 10.1038/s41401-018-0050-6
   Qin YR, 2011, CLIN CANCER RES, V17, P46, DOI 10.1158/1078-0432.CCR-10-1155
   Qiu HJ, 2016, ONCOL LETT, V12, P2301, DOI 10.3892/ol.2016.5002
   Rao XF, 2019, ONCOTARGETS THER, V12, P11241, DOI 10.2147/OTT.S220621
   Rice MA, 2016, ONCOGENE, V35, P4752, DOI 10.1038/onc.2016.6
   Rogers TJ, 2019, MOL CANCER RES, V17, P30, DOI 10.1158/1541-7786.MCR-18-0246
   Sa KD, 2018, BIOCHEM BIOPH RES CO, V501, P758, DOI 10.1016/j.bbrc.2018.05.062
   Samantarrai D, 2017, EXP CELL RES, V357, P33, DOI 10.1016/j.yexcr.2017.04.017
   Sandoval-Borquez A, 2017, CLIN EPIGENETICS, V9, DOI 10.1186/s13148-017-0413-8
   Schaller J, 2020, CANCERS, V12, DOI 10.3390/cancers12113385
   Schwarzenbacher D, 2019, BREAST CANCER RES, V21, DOI 10.1186/s13058-019-1104-5
   Sen N, 2014, CANCER METAST REV, V33, P879, DOI 10.1007/s10555-014-9515-3
   Seo HA, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9010029
   Shao C, 2020, REDOX BIOL, V36, DOI 10.1016/j.redox.2020.101685
   Shen HX, 2017, CELL DEATH DIFFER, V24, P1253, DOI 10.1038/cdd.2017.63
   Shen HX, 2015, J CELL BIOCHEM, V116, P1563, DOI 10.1002/jcb.25110
   Shen XF, 2020, ONCOTARGETS THER, V13, P3265, DOI 10.2147/OTT.S220306
   Shi HS, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0840-1
   Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522
   Shu ZB, 2016, WORLD J SURG ONCOL, V14, DOI 10.1186/s12957-016-0984-4
   Singh A, 2020, NEOPLASIA, V22, P497, DOI 10.1016/j.neo.2020.08.002
   Son SW, 2020, MOLECULES, V25, DOI 10.3390/molecules25204701
   Spano D, 2010, MOL MED, V16, P102, DOI 10.2119/molmed.2009.00119
   Stepp MW, 2018, MOL CARCINOGEN, V57, P549, DOI 10.1002/mc.22779
   Stokes JB, 2011, MOL CANCER THER, V10, P2135, DOI 10.1158/1535-7163.MCT-11-0261
   Su XH, 2010, NATURE, V467, P986, DOI 10.1038/nature09459
   Subauste MC, 2004, J CELL BIOL, V165, P371, DOI 10.1083/jcb.200308011
   Sun MX, 2020, DOSE-RESPONSE, V18, DOI 10.1177/1559325820918450
   Sun Q, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1841-5
   Sun T, 2020, ONCOTARGETS THER, V13, P2957, DOI 10.2147/OTT.S232839
   Talukdar S, 2018, P NATL ACAD SCI USA, V115, P5768, DOI 10.1073/pnas.1721650115
   Tan C, 2016, MOL CARCINOGEN, V55, P397, DOI 10.1002/mc.22290
   Tanaka K, 2016, INT J ONCOL, V48, P1135, DOI 10.3892/ijo.2016.3317
   Tang YB, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0813-4
   Tawinwung S, 2015, ANTICANCER RES, V35, P4789
   Terashima M, 2017, J BIOL CHEM, V292, P82, DOI 10.1074/jbc.M116.750950
   Tiang JM, 2015, CANCER MED-US, V4, P565, DOI 10.1002/cam4.415
   Tordjman J, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-5771-5
   Wan WC, 2019, BIOMED PHARMACOTHER, V118, DOI [10.1016/j.biopha.2019.10911, 10.1016/j.biopha.2019.109111]
   Wang C, 2018, BIOMED PHARMACOTHER, V105, P1054, DOI 10.1016/j.biopha.2018.05.157
   Wang H, 2020, GENE, V722, DOI 10.1016/j.gene.2019.144076
   Wang HB, 2019, NAT CHEM BIOL, V15, P42, DOI 10.1038/s41589-018-0161-x
   Wang H, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-5951-3
   Wang LL, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0193560
   Wang SL, 2019, CANCER CELL INT, V19, DOI 10.1186/s12935-019-0808-z
   Wang XC, 2009, MOL CANCER RES, V7, P12, DOI 10.1158/1541-7786.MCR-08-0092
   Wang XF, 2018, CANCER RES, V78, P4586, DOI 10.1158/0008-5472.CAN-17-3841
   Wang XM, 2019, ARTIF CELL NANOMED B, V47, P2265, DOI 10.1080/21691401.2019.1623229
   Wang X, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10633
   Wang Y, 2016, ONCOGENE, V35, P4080, DOI 10.1038/onc.2015.470
   Wang Y, 2019, ONCOL LETT, V17, P2356, DOI 10.3892/ol.2018.9880
   Wang YA, 2017, DNA CELL BIOL, V36, P991, DOI 10.1089/dna.2017.3829
   Wang Y, 2008, MOL BIOL CELL, V19, P4076, DOI 10.1091/mbc.E07-12-1296
   Wang Y, 2016, ONCOTARGET, V7, P24383, DOI 10.18632/oncotarget.8328
   Wang Z, 2020, AGING-US, V12, P1867, DOI 10.18632/aging.102719
   Wei F, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0694-8
   Wei JL, 2016, PROTEIN CELL, V7, P305, DOI 10.1007/s13238-016-0255-8
   Wei YQ, 2019, EUR REV MED PHARMACO, V23, P7314, DOI 10.26355/eurrev_201909_18837
   Woods NT, 2007, CANCER RES, V67, P10744, DOI 10.1158/0008-5472.CAN-07-3148
   Wu JH, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-21708-z
   Wu Y, 2019, J ONCOL, V2019, DOI 10.1155/2019/8607859
   Xia KK, 2015, BIOMED PHARMACOTHER, V70, P158, DOI 10.1016/j.biopha.2015.01.001
   Xian QJ, 2020, DOSE-RESPONSE, V18, DOI 10.1177/1559325820928687
   Xiao L, 2011, J BIOL CHEM, V286, P7788, DOI 10.1074/jbc.M110.173468
   Xin H, 2018, BIOMED PHARMACOTHER, V107, P1548, DOI 10.1016/j.biopha.2018.08.144
   Xu ZH, 2014, MOL CARCINOGEN, V53, P917, DOI 10.1002/mc.22059
   Yan F, 2018, MOL MED REP, V17, P4237, DOI 10.3892/mmr.2018.8381
   Yan M, 2004, P NATL ACAD SCI USA, V101, P17468, DOI 10.1073/pnas.0406142101
   Yan Z, 1998, P NATL ACAD SCI USA, V95, P3603, DOI 10.1073/pnas.95.7.3603
   Yang F, 2006, CELL SIGNAL, V18, P679, DOI 10.1016/j.cellsig.2005.06.015
   Yang HL, 2017, ONCOTARGETS THER, V10, P579, DOI 10.2147/OTT.S115791
   Yang KG, 2018, INT J CANCER, V142, P2323, DOI 10.1002/ijc.31248
   Yang Z, 2019, AUTOPHAGY, V15, P668, DOI 10.1080/15548627.2018.1539590
   Yao SH, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-1059-y
   Ye P, 2018, BIOMED PHARMACOTHER, V101, P219, DOI 10.1016/j.biopha.2018.02.066
   Ye Y, 2017, ONCOTARGET, V8, P94834, DOI 10.18632/oncotarget.22014
   Yi H, 2017, ONCOGENE, V36, P3477, DOI 10.1038/onc.2016.499
   Yin J, 2017, MOL MED REP, V16, P6764, DOI 10.3892/mmr.2017.7481
   Yin SP, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0183578
   Yin Y, 2014, CLIN CANCER RES, V20, P6187, DOI 10.1158/1078-0432.CCR-14-1030
   Ying XY, 2016, CELL PHYSIOL BIOCHEM, V39, P501, DOI 10.1159/000445642
   Yoshimura H, 2018, LAB INVEST, V98, P814, DOI 10.1038/s41374-018-0048-1
   Yu FX, 2013, GENE DEV, V27, P355, DOI 10.1101/gad.210773.112
   Yuan XN, 2017, ONCOL REP, V38, P1733, DOI 10.3892/or.2017.5788
   Zhai YQ, 2017, INT J CLIN EXP PATHO, V10, P10989
   Zhang J, 2020, J CANCER, V11, P3199, DOI 10.7150/jca.33273
   Zhang J, 2019, CANCER CELL INT, V19, DOI 10.1186/s12935-019-0893-z
   Zhang LH, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-290
   Zhang L, 2015, APPL BIOCHEM BIOTECH, V176, P33, DOI 10.1007/s12010-015-1505-6
   Zhang PF, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2015.324
   Zhang QQ, 2018, J CELL BIOCHEM, V119, P4447, DOI 10.1002/jcb.26537
   Zhang QY, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1127-x
   Zhang SL, 2017, ONCOL LETT, V14, P5018, DOI 10.3892/ol.2017.6745
   Zhang X, 2015, ONCOTARGET, V6, P2277, DOI 10.18632/oncotarget.2956
   Zhang XP, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20225573
   Zhang Y, 2018, CANCER BIOL THER, V19, P230, DOI 10.1080/15384047.2017.1416939
   Zhang YZ, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0796-y
   Zhang Y, 2014, SCI REP-UK, V4, DOI 10.1038/srep06248
   Zhao B, 2012, GENE DEV, V26, P54, DOI 10.1101/gad.173435.111
   Zhao MY, 2018, CURR MED SCI, V38, P245, DOI 10.1007/s11596-018-1872-7
   Zhao N, 2016, SCI REP-UK, V6, DOI 10.1038/srep23091
   Zheng JY, 2005, WORLD J GASTROENTERO, V11, P7072, DOI 10.3748/wjg.v11.i45.7072
   Zheng QD, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0305-7
   Zheng ZM, 2017, MED SCI MONITOR, V23, P1277, DOI 10.12659/MSM.900092
   Zhong WB, 2015, J BIOL CHEM, V290, P8876, DOI 10.1074/jbc.M114.610188
   Zhou M, 2014, CELL IMMUNOL, V292, P65, DOI 10.1016/j.cellimm.2014.09.004
   Zhu GN, 2020, J INVEST DERMATOL, V140, P666, DOI 10.1016/j.jid.2019.07.720
   Zhu JF, 2018, CANCER CELL INT, V18, DOI 10.1186/s12935-018-0684-y
   Zhu WJ, 2020, CANCER MANAG RES, V12, P3013, DOI 10.2147/CMAR.S237752
   Zhu ZL, 2018, CELL PHYSIOL BIOCHEM, V46, P238, DOI 10.1159/000488426
   Zhuang ZH, 2020, THERANOSTICS, V10, P1433, DOI 10.7150/thno.38507
   Zou ZW, 2016, ONCOTARGET, V7, P61741, DOI 10.18632/oncotarget.11437
   Zouq NK, 2009, J CELL SCI, V122, P357, DOI 10.1242/jcs.030478
NR 292
TC 5
Z9 5
U1 6
U2 8
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD JAN
PY 2021
VL 22
IS 2
AR 627
DI 10.3390/ijms22020627
PG 34
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA PX4HT
UT WOS:000611318400001
PM 33435156
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Glibo, M
   Serman, A
   Karin-Kujundzic, V
   Vlatkovic, IB
   Miskovic, B
   Vranic, S
   Serman, L
AF Glibo, Mislav
   Serman, Alan
   Karin-Kujundzic, Valentina
   Vlatkovic, Ivanka Bekavac
   Miskovic, Berivoj
   Vranic, Semir
   Serman, Ljiljana
TI The role of glycogen synthase kinase 3 (GSK3) in cancer with emphasis on
   ovarian cancer development and progression: A comprehensive review
SO BOSNIAN JOURNAL OF BASIC MEDICAL SCIENCES
LA English
DT Review
DE GSK3; ovarian cancer; therapeutic target
ID FACTOR-KAPPA-B; WNT-SIGNALING PATHWAY; CELL-CYCLE ARREST; URSOLIC ACID;
   E-CADHERIN; MESENCHYMAL TRANSITION; 3-BETA INHIBITORS; BETA-CATENIN;
   COLORECTAL-CANCER; INDUCED APOPTOSIS
AB Glycogen synthase kinase 3 (GSK3) is a monomeric serine-threonine kinase discovered in 1980 in a rat skeletal muscle. It has been involved in various cellular processes including embryogenesis, immune response, inflammation, apoptosis, autophagy, wound healing, neurodegeneration, and carcinogenesis. GSK3 exists in two different isoforms, GSK3 alpha, and GSK3 beta, both containing seven antiparallel beta-plates, a short linking part and an alpha helix, but coded by different genes and variously expressed in human tissues. In the current review, we comprehensively appraise the current literature on the role of GSK3 in various cancers with emphasis on ovarian carcinoma. Our findings indicate that the role of GSK3 in ovarian cancer development cannot be decisively determined as the currently available data support both prooncogenic and tumor-suppressive effects. Likewise, the clinical impact of GSK3 expression on ovarian cancer patients and its potential therapeutic implications are also limited. Further studies are needed to fully elucidate the pathophysiological and clinical implications of GSK3 activity in ovarian cancer.
C1 [Glibo, Mislav; Karin-Kujundzic, Valentina; Serman, Ljiljana] Univ Zagreb, Sch Med, Dept Biol, Zagreb, Croatia.
   [Serman, Alan; Karin-Kujundzic, Valentina; Vlatkovic, Ivanka Bekavac; Miskovic, Berivoj; Serman, Ljiljana] Univ Zagreb, Ctr Excellence Reprod & Regenerat Med, Sch Med, Zagreb, Croatia.
   [Serman, Alan; Vlatkovic, Ivanka Bekavac; Miskovic, Berivoj] Univ Zagreb, Sch Med, Dept Obstet & Gynecol, Zagreb, Croatia.
   [Serman, Alan; Vlatkovic, Ivanka Bekavac; Miskovic, Berivoj] Clin Hosp Sveti Duh, Clin Obstet & Gynecol, Sveti Duh 64, Zagreb 10000, Croatia.
   [Vranic, Semir] Qatar Univ, Coll Med, QU Hlth, Doha, Qatar.
RP Serman, A (corresponding author), Clin Hosp Sveti Duh, Clin Obstet & Gynecol, Sveti Duh 64, Zagreb 10000, Croatia.
EM sermana@mef.hr
RI Vranic, Semir/I-6823-2019
OI Vranic, Semir/0000-0001-9743-7265
FU European Union through the Europe Regional Development Fund, Operational
   Programme Competitiveness and Cohesion [KK.01.1.1.01.0008]
FX This publication was co-financed by the European Union through the
   Europe Regional Development Fund, Operational Programme Competitiveness
   and Cohesion, under grant agreement No. KK.01.1.1.01.0008, Reproductive
   and Regenerative Medicine - Exploring New Platforms and Potentials.
CR Acikgoz E, 2019, SPECTROCHIM ACTA A, V209, P150, DOI 10.1016/j.saa.2018.10.036
   Andersson D, 2003, ANTICANCER RES, V23, P3317
   Arafa ESA, 2009, CANCER RES, V69, P8910, DOI 10.1158/0008-5472.CAN-09-1543
   Auersperg N, 1999, P NATL ACAD SCI USA, V96, P6249, DOI 10.1073/pnas.96.11.6249
   Azoulay-Alfaguter I, 2015, ONCOGENE, V34, P4613, DOI 10.1038/onc.2014.390
   Azoulay-Alfaguter I, 2011, J BIOL CHEM, V286, P13470, DOI 10.1074/jbc.M110.127969
   Bennecib M, 2000, FEBS LETT, V485, P87, DOI 10.1016/S0014-5793(00)02203-1
   Beurel E, 2015, PHARMACOL THERAPEUT, V148, P114, DOI 10.1016/j.pharmthera.2014.11.016
   Blechschmidt K, 2008, BRIT J CANCER, V98, P489, DOI 10.1038/sj.bjc.6604115
   Burkhalter RJ, 2011, J BIOL CHEM, V286, P23467, DOI 10.1074/jbc.M110.199539
   Busino L, 2012, NAT CELL BIOL, V14, P375, DOI 10.1038/ncb2463
   Buss H, 2004, J BIOL CHEM, V279, P49571, DOI 10.1074/jbc.C400442200
   Cai GQ, 2007, INT J ONCOL, V31, P657
   Cao H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031502
   Cao Q, 2006, CELL RES, V16, P671, DOI 10.1038/sj.cr.7310078
   Cassavaugh JM, 2011, J CELL BIOCHEM, V112, P3882, DOI 10.1002/jcb.23321
   Chen LH, 2019, CELL ONCOL, V42, P679, DOI 10.1007/s13402-019-00455-x
   Chen S, 2016, DRUG DES DEV THER, V10, P1225, DOI 10.2147/DDDT.S102506
   Choi KC, 2001, MOL CELL ENDOCRINOL, V174, P99, DOI 10.1016/S0303-7207(00)00447-0
   Cianfrocca R, 2010, CAN J PHYSIOL PHARM, V88, P796, DOI 10.1139/Y10-052
   Cohen P, 2001, NAT REV MOL CELL BIO, V2, P769, DOI 10.1038/35096075
   Cole A, 2004, BIOCHEM J, V377, P249, DOI 10.1042/BJ20031259
   Cormier Kevin W, 2017, F1000Res, V6, DOI 10.12688/f1000research.10557.1
   Dastjerdi FV, 2012, CELL BIOL INT, V36, P967, DOI 10.1042/CBI20110541
   Do TV, 2008, ENDOCRINOLOGY, V149, P3809, DOI 10.1210/en.2007-1584
   Doble BW, 2007, CELLS TISSUES ORGANS, V185, P73, DOI 10.1159/000101306
   Domoto T, 2016, CANCER SCI, V107, P1363, DOI 10.1111/cas.13028
   Dupont J, 2003, BIOL REPROD, V68, P1877, DOI 10.1095/biolreprod.102.012005
   Espinosa L, 2003, J BIOL CHEM, V278, P32227, DOI 10.1074/jbc.M304001200
   Foltz DR, 2002, CURR BIOL, V12, P1006, DOI 10.1016/S0960-9822(02)00888-6
   Force USPST, GUID CLIN PREV SERV, DOI [10.1016/b978-1-4557-0658-7.00018-9., DOI 10.1016/B978-1-4557-0658-7.00018-9.]
   Forde JE, 2007, CELL MOL LIFE SCI, V64, P1930, DOI 10.1007/s00018-007-7045-7
   Fu YF, 2014, ONCOTARGETS THER, V7, P1159, DOI 10.2147/OTT.S62158
   Fu YF, 2011, INT J GYNECOL CANCER, V21, P439, DOI 10.1097/IGC.0b013e31820d7366
   Fujimoto H, 2009, INT J CANCER, V125, P1276, DOI 10.1002/ijc.24378
   Gao Y, 2017, EUR J MED CHEM, V135, P370, DOI 10.1016/j.ejmech.2017.04.039
   Garcea G, 2007, CURR CANCER DRUG TAR, V7, P209, DOI 10.2174/156800907780618266
   Gatenby RA, 2003, CANCER RES, V63, P3847
   Gillitzer R, 2001, J LEUKOCYTE BIOL, V69, P513
   Giovannini C, 2013, ONCOTARGET, V4, P1618, DOI 10.18632/oncotarget.1221
   Goc A, 2014, ONCOTARGET, V5, P775, DOI 10.18632/oncotarget.1770
   Goodyear A, 2010, J IMMUNOL, V184, P1445, DOI 10.4049/jimmunol.0900411
   Grimes CA, 2001, PROG NEUROBIOL, V65, P391, DOI 10.1016/S0301-0082(01)00011-9
   Guo R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066330
   Guo X, 2008, GENE DEV, V22, P106, DOI 10.1101/gad.1590908
   Gwak H, 2017, MOL CARCINOGEN, V56, P349, DOI 10.1002/mc.22498
   Gwak H, 2016, CANCER LETT, V371, P347, DOI 10.1016/j.canlet.2015.11.032
   Han XZ, 2012, BIOCHEM BIOPH RES CO, V423, P282, DOI 10.1016/j.bbrc.2012.05.111
   Hilliard TS, 2011, ANTI-CANCER DRUG, V22, P978, DOI 10.1097/CAD.0b013e32834ac8fc
   Hu C, 2016, ONCOL REP, V35, P2027, DOI 10.3892/or.2016.4591
   Imai T, 2004, HUM PATHOL, V35, P1469, DOI 10.1016/j.humpath.2004.09.014
   Jacobs Keith M, 2012, Int J Cell Biol, V2012, P930710, DOI 10.1155/2012/930710
   Kassi E, 2009, CANCER INVEST, V27, P723, DOI 10.1080/07357900802672712
   Kim BR, 2016, ONCOL REP, V35, P1041, DOI 10.3892/or.2015.4408
   Kitano A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055289
   Kopan R, 1996, CURR OPIN NEUROBIOL, V6, P594, DOI 10.1016/S0959-4388(96)80090-0
   Kotliarova S, 2008, CANCER RES, V68, P6643, DOI 10.1158/0008-5472.CAN-08-0850
   Kumar S, 2013, CANCER-AM CANCER SOC, V119, P555, DOI 10.1002/cncr.27706
   Tovar CFL, 2016, ADV CLIN EXP MED, V25, P1139, DOI 10.17219/acem/63752
   Li CJ, 2016, CELL PHYSIOL BIOCHEM, V39, P1098, DOI 10.1159/000447818
   Li N, 2019, ONCOL LETT, V17, P2631, DOI 10.3892/ol.2019.9923
   Li S, 2017, CELL MOL IMMUNOL, V14, P621, DOI 10.1038/cmi.2015.106
   Li XH, 2007, BIOL PSYCHIAT, V61, P216, DOI 10.1016/j.biopsych.2006.02.027
   Linseman DA, 2004, J NEUROSCI, V24, P9993, DOI 10.1523/JNEUROSCI.2057-04.2004
   Liu HY, 2019, J OVARIAN RES, V12, DOI 10.1186/s13048-019-0532-2
   Liu L, 2011, CANCER RES, V71, P3972, DOI 10.1158/0008-5472.CAN-10-3852
   Liu Y, 2018, ONCOGENE, V37, P768, DOI 10.1038/onc.2017.370
   Loberg RD, 2002, J BIOL CHEM, V277, P41667, DOI 10.1074/jbc.M206405200
   Lu JJ, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/6253280
   Ma C, 2007, CANCER RES, V67, P7756, DOI 10.1158/0008-5472.CAN-06-4665
   Macheda ML, 2005, J CELL PHYSIOL, V202, P654, DOI 10.1002/jcp.20166
   Majidi A, 2020, GYNECOL ONCOL, V157, P678, DOI 10.1016/j.ygyno.2020.03.028
   Mancinelli R, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/4629495
   Manu KA, 2008, INT IMMUNOPHARMACOL, V8, P974, DOI 10.1016/j.intimp.2008.02.013
   Marchetti A, 2008, CELL SIGNAL, V20, P2113, DOI 10.1016/j.cellsig.2008.08.002
   Masamha CP, 2009, CANCER RES, V69, P6565, DOI 10.1158/0008-5472.CAN-09-0913
   McCubrey JA, 2016, BBA-MOL CELL RES, V1863, P2942, DOI 10.1016/j.bbamcr.2016.09.004
   McCubrey JA, 2014, ONCOTARGET, V5, P2881, DOI 10.18632/oncotarget.2037
   Mishra R, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0300-x
   Mishra R, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-144
   Mitra T, 2017, CELL PHYSIOL BIOCHEM, V41, P1336, DOI 10.1159/000464436
   Nagini S, 2019, SEMIN CANCER BIOL, V56, P25, DOI 10.1016/j.semcancer.2017.12.010
   Naruse K, 1996, GENOMICS, V34, P236, DOI 10.1006/geno.1996.0274
   Ng SS, 2009, J BIOL CHEM, V284, P35308, DOI 10.1074/jbc.M109.078261
   Nicolaou KA, 2012, BIOCHEM BIOPH RES CO, V425, P76, DOI 10.1016/j.bbrc.2012.07.053
   Novetsky AP, 2013, INT J GYNECOL CANCER, V23, P361, DOI 10.1097/IGC.0b013e31827cfecb
   Organisation for Economic Co-operation and Development, 2018, UN E HLTH GLANC
   Ougolkov AV, 2005, CANCER RES, V65, P2076, DOI 10.1158/0008-5472.CAN-04-3642
   Ozretic P, 2017, INT J ONCOL, V51, P1869, DOI 10.3892/ijo.2017.4156
   Pal K, 2014, MOL CANCER THER, V13, P285, DOI 10.1158/1535-7163.MCT-13-0681
   Pan Y, 2006, MOL CELL BIOL, V26, P3365, DOI 10.1128/MCB.26.9.3365-3377.2006
   Pangas SA, 2000, TRENDS ENDOCRIN MET, V11, P309, DOI 10.1016/S1043-2760(00)00294-0
   Patel P, 2017, CURR TOP DEV BIOL, V123, P277, DOI 10.1016/bs.ctdb.2016.11.011
   Pernicova I, 2014, NAT REV ENDOCRINOL, V10, P143, DOI 10.1038/nrendo.2013.256
   Qiu HJ, 2016, BIOMED PHARMACOTHER, V82, P117, DOI 10.1016/j.biopha.2016.04.052
   Rask K, 2003, BRIT J CANCER, V89, P1298, DOI 10.1038/sj.bjc.6601265
   Rauf A, 2018, CRIT REV FOOD SCI, V58, P1428, DOI 10.1080/10408398.2016.1263597
   Rosano L, 2005, CANCER RES, V65, P11649, DOI 10.1158/0008-5472.CAN-05-2123
   Ryves WJ, 2001, BIOCHEM BIOPH RES CO, V280, P720, DOI 10.1006/bbrc.2000.4169
   Sagae S, 1999, JPN J CANCER RES, V90, P510, DOI 10.1111/j.1349-7006.1999.tb00777.x
   Sanchez JF, 2003, MOL CELL BIOL, V23, P4649, DOI 10.1128/MCB.23.13.4649-4662.2003
   Sayas CL, 2006, MOL BIOL CELL, V17, P1834, DOI 10.1091/mbc.E05-07-0688
   Sekerija M, 2017, CROATIAN NATL CANC R, V42, P2020
   Shakoori A, 2005, BIOCHEM BIOPH RES CO, V334, P1365, DOI 10.1016/j.bbrc.2005.07.041
   Shanmugam MK, 2011, INT J CANCER, V129, P1552, DOI 10.1002/ijc.26120
   Shin K, 2016, ADV CLIN EXP MED, V25, P513, DOI 10.17219/acem/62540
   Simonelli C, 2013, J CLIN ONCOL, V31
   Skoda AM, 2018, BOSNIAN J BASIC MED, V18, P8, DOI 10.17305/bjbms.2018.2756
   Soler AP, 1997, HUM PATHOL, V28, P734, DOI 10.1016/S0046-8177(97)90184-2
   Song MQ, 2019, CANCER RES, V79, P1019, DOI 10.1158/0008-5472.CAN-18-2738
   Song YH, 2012, BIOL PHARM BULL, V35, P1022, DOI 10.1248/bpb.b110660
   Stavridi ES, 2004, GENE DEV, V18, P241, DOI 10.1101/gad.1181704
   Taira N, 2012, J CLIN INVEST, V122, P859, DOI 10.1172/JCI60818
   Takada Y, 2004, J BIOL CHEM, V279, P39541, DOI 10.1074/jbc.M403449200
   Takenaka K, 2007, BIOCHEM BIOPH RES CO, V353, P501, DOI 10.1016/j.bbrc.2006.12.058
   Thompson TB, 2004, MOL CELL ENDOCRINOL, V225, P9, DOI 10.1016/j.mce.2004.02.007
   Thornton TM, 2008, SCIENCE, V320, P667, DOI 10.1126/science.1156037
   Thotala DK, 2012, CELL DEATH DIFFER, V19, P387, DOI 10.1038/cdd.2011.94
   Thotala DK, 2010, INT J RADIAT ONCOL, V76, P557, DOI 10.1016/j.ijrobp.2009.09.024
   Trnski D, 2015, BBA-MOL BASIS DIS, V1852, P2574, DOI 10.1016/j.bbadis.2015.09.005
   Turenne GA, 2001, BMC CELL BIOL, V2, DOI 10.1186/1471-2121-2-12
   Usongo M, 2013, DEV DYNAM, V242, P291, DOI 10.1002/dvdy.23919
   Vergara D, 2012, MOL BIOSYST, V8, P1078, DOI 10.1039/c2mb05486h
   Nguyen VHL, 2019, J OVARIAN RES, V12, DOI 10.1186/s13048-019-0596-z
   Wang BL, 2000, CELL, V100, P423, DOI 10.1016/S0092-8674(00)80678-9
   Watcharasit P, 2002, P NATL ACAD SCI USA, V99, P7951, DOI 10.1073/pnas.122062299
   Welcker M, 2003, MOL CELL, V12, P381, DOI 10.1016/S1097-2765(03)00287-9
   Woodgett J R, 2001, Sci STKE, V2001, pre12, DOI 10.1126/stke.2001.100.re12
   Wu Feng-Lan, 2019, Shengli Xuebao, V71, P415, DOI 10.13294/j.aps.2019.0039
   Wu G, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004926
   Wulfkuhle JD, 2003, PROTEOMICS, V3, P2085, DOI 10.1002/pmic.200300591
   Yu AS, 2016, TUMOR BIOL, V37, P4857, DOI 10.1007/s13277-015-4344-8
   Yu PN, 2014, INT J CANCER, V134, P542, DOI 10.1002/ijc.28399
   Yun SH, 2020, ANTICANCER RES, V40, P653, DOI 10.21873/anticanres.13995
   Zeng X, 2005, NATURE, V438, P873, DOI 10.1038/nature04185
   Zhang K, 2015, CELL PROLIFERAT, V48, P249, DOI 10.1111/cpr.12161
   Zhang MH, 2017, ONCOTARGET, V8, P31347, DOI 10.18632/oncotarget.15532
   Zheng HC, 2007, ANTICANCER RES, V27, P3561
   Zheng L, 2018, MOL BIOL CELL, V29, P389, DOI 10.1091/mbc.E17-07-0474
   Zhou FF, 2011, MOL BIOL CELL, V22, P3533, DOI 10.1091/mbc.E11-06-0483
NR 140
TC 6
Z9 6
U1 2
U2 4
PU ASSOC BASIC MEDICAL SCI FEDERATION BOSNIA & HERZEGOVINA SARAJEVO
PI CEKALUSA
PA UNIV SARAJEVO, MEDICAL FAC, CEKALUSA, SARAJEVO 90, BOSNIA & HERCEG
SN 1512-8601
EI 1840-4812
J9 BOSNIAN J BASIC MED
JI Bosnian J. Basic Med. Sci.
PY 2021
VL 21
IS 1
BP 5
EP 18
DI 10.17305/bjbms.2020.5036
PG 14
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA PU0CO
UT WOS:000608975800002
PM 32767962
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Kim, J
   Kim, D
   Jung, H
   Lee, J
   Hong, VS
AF Kim, Jeongeun
   Kim, Donghee
   Jung, Hyunho
   Lee, Jinho
   Hong, Victor Sukbong
TI Identification and Kinetic Characterization of Serum- and
   Glucocorticoid-Regulated Kinase Inhibitors Using a Fluorescence
   Polarization-Based Assay
SO SLAS DISCOVERY
LA English
DT Article
DE serum; and glucocorticoid-regulated kinase; SGK inhibitor;
   kinase-focused library; thiazolidine-2; 4-dione; molecular modeling
AB The serum- and glucocorticoid-regulated kinase (SGK) family consists of three isoforms (SGK1, SGK2, and SGK3) that have been implicated in the regulation of tumor growth, metastasis, autophagy, and epithelial ion transport. SGK1 and SGK3 play essential roles in protein kinase B (AKT or PKB)-independent phosphoinositide 3-kinases (PI3K)-mediated tumorigenesis, as evidenced by the significantly elevated expression levels of SGK1 and SGK3 in many cancers, including prostate cancer, colorectal carcinoma, estrogen-dependent breast cancer, and glioblastoma. Therefore, SGK is a potential target for anticancer therapy. A small kinase-focused library comprising 160 compounds was screened against SGK1 using a fluorescence polarization-based kinase assay that yielded a Z'-factor of 0.82. Among the 39 compounds obtained as initial hits in a primary screen, 12 compounds contained the thiazolidine-2,4-dione scaffold. The inhibitory mechanisms of the most potent hit, KMU010402, were further investigated using kinetic analyses, followed by determination of the inhibition constants for SGK1, SGK2, and SGK3. Molecular modeling was used to propose a potential binding mode of KMU010402 to SGK1.
C1 [Kim, Jeongeun; Kim, Donghee; Jung, Hyunho; Lee, Jinho; Hong, Victor Sukbong] Keimyung Univ, Dept Chem, Coll Nat Sci, Daegu, South Korea.
RP Lee, J; Hong, VS (corresponding author), Keimyung Univ, Dept Chem, 1095 Dalgubeoldaero, Daegu 42601, South Korea.
EM jinho@kmu.ac.kr; victorh@kmu.ac.kr
CR Arakawa T, 2007, BIOPHYS CHEM, V131, P62, DOI 10.1016/j.bpc.2007.09.004
   Castel P, 2016, CANCER CELL, V30, P229, DOI 10.1016/j.ccell.2016.06.004
   Chang F, 2003, LEUKEMIA, V17, P590, DOI 10.1038/sj.leu.2402824
   CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0
   Gagliardi PA, 2012, NEOPLASIA, V14, P719, DOI 10.1593/neo.12856
   Gong GQ, 2018, ACTA PHARMACOL SIN, V39, P1902, DOI 10.1038/s41401-018-0087-6
   Greenawalt EJ, 2019, MOL CANCER RES, V17, P289, DOI 10.1158/1541-7786.MCR-18-0364
   Hong F, 2008, MOL CELL, V30, P701, DOI 10.1016/j.molcel.2008.04.027
   Huw LY, 2013, ONCOGENESIS, V2, DOI 10.1038/oncsis.2013.46
   Janku F, 2018, NAT REV CLIN ONCOL, V15, P273, DOI 10.1038/nrclinonc.2018.28
   Jiang NN, 2020, MOL BIOL REP, V47, P4587, DOI 10.1007/s11033-020-05435-1
   Kobayashi T, 1999, BIOCHEM J, V344, P189, DOI 10.1042/0264-6021:3440189
   Lee S, 2016, ASSAY DRUG DEV TECHN, V14, P50, DOI 10.1089/adt.2015.685
   Liu WW, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0743-1
   Nakanishi Y, 2016, CANCER RES, V76, P1193, DOI 10.1158/0008-5472.CAN-15-2201
   Roskoski R, 2020, PHARMACOL RES, V152, DOI 10.1016/j.phrs.2019.104609
   Sanner MF, 1999, J MOL GRAPH MODEL, V17, P57
   Sharlow ER, 2008, NAT PROTOC, V3, P1350, DOI 10.1038/nprot.2008.111
   Sherk AB, 2008, CANCER RES, V68, P7475, DOI 10.1158/0008-5472.CAN-08-1047
   Sommer EM, 2013, BIOCHEM J, V452, P499, DOI 10.1042/BJ20130342
   Sportsman JR, 2004, ASSAY DRUG DEV TECHN, V2, P205, DOI 10.1089/154065804323056549
   Sportsman R, 2006, DRUG DISCOV SER, V5, P85
   Tessier M, 2006, J BIOL CHEM, V281, P23978, DOI 10.1074/jbc.M604333200
   Truhlar DG, 2007, J COMPUT CHEM, V28, P73, DOI 10.1002/jcc.20529
   Vasudevan KM, 2009, CANCER CELL, V16, P21, DOI 10.1016/j.ccr.2009.04.012
   Wang YZ, 2014, MOL ENDOCRINOL, V28, P935, DOI 10.1210/me.2013-1339
   Wang YZ, 2011, MOL ENDOCRINOL, V25, P72, DOI 10.1210/me.2010-0294
   Zhao B, 2007, PROTEIN SCI, V16, P2761, DOI 10.1110/ps.073161707
   Zhu RZ, 2020, THER ADV MED ONCOL, V12, DOI 10.1177/1758835920940946
NR 29
TC 1
Z9 1
U1 1
U2 4
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 2472-5552
EI 2472-5560
J9 SLAS DISCOV
JI SLAS Discov.
PD JUN
PY 2021
VL 26
IS 5
BP 655
EP 662
AR 24725552211002465
DI 10.1177/24725552211002465
EA MAR 2021
PG 8
WC Biochemical Research Methods; Biotechnology & Applied Microbiology;
   Chemistry, Analytical
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Chemistry
GA SF2XG
UT WOS:000635765800001
PM 33783250
DA 2022-04-25
ER

PT J
AU Wu, C
   Tang, ZY
   Chen, HY
   Zhang, J
   Zhao, C
AF Wu, C.
   Tang, Z-Y
   Chen, H-Y
   Zhang, J.
   Zhao, C.
TI High-expression of lncRNA CEBPA-AS1 promotes liver cancer progression
SO EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES
LA English
DT Article
DE LncRNAs; CEBPA-AS1; Liver cancer; EMT; Invasion
ID LONG NONCODING RNA; EPITHELIAL-MESENCHYMAL TRANSITION;
   HEPATOCELLULAR-CARCINOMA; COLORECTAL-CANCER; EMT; METASTASIS; PROGNOSIS;
   AUTOPHAGY; CELLS; ATB
AB OBJECTIVE: Long non-coding RNAs (lncRNAs) have been confirmed to play important roles in the progression of different cancers. The aim of this study was to detect the expression level of lncRNA CEBPA-AS1 in liver cancer and to study its influence on cell proliferation, invasion and prognosis.
   PATIENTS AND METHODS: Quantitative Real Time-Polymerase Chain Reaction (qRT-PCR), MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) assay, transwell assay, Western blot, Kaplan-Meier survival curve and Cox regression were used to evaluate lncRNA CEBPA-AS1 expression, cell proliferation, invasion, epithelial-mesenchymal transition (EMT)-related molecules expression and prognosis, respectively.
   RESULTS: The expression of lncRNA CEB-PA-AS1 increased significantly in liver cancer tissues (p<0.05). Meanwhile, CEBPA-AS1 expression was associated with tumor size, portal vein tumor thrombus and invasion and metastasis (p<0.05). In vitro experiments indicated that downregulation of lncRNA CEBPA-AS1 could effectively reduce cell proliferation, invasion and EMT process.
   CONCLUSIONS: LncRNA CEBPA-AS1 acts as an oncogene in liver cancer, which may be a novel biomarker in liver cancer progression.
C1 [Wu, C.] Sun Yat Sen Univ, Dept Intervent, Affiliated Hosp 3, Guangzhou, Guangdong, Peoples R China.
   [Tang, Z-Y] Peoples Hosp Guangxi Zhuang Autonomous Reg, Dept Hepatobiliary Surg, Nanning, Peoples R China.
   [Chen, H-Y] Southern Med Univ, Liver Tumor Ctr, Nanfang Hosp, Guangzhou, Guangdong, Peoples R China.
   [Zhang, J.] Sun Yat Sen Univ, Dept Hepat Surg, Affiliated Hosp 3, Guangzhou, Guangdong, Peoples R China.
   [Zhao, C.] Guangxi Med Univ, Dept Invas Technol, Canc Hosp, Nanning, Peoples R China.
RP Zhang, J (corresponding author), Sun Yat Sen Univ, Dept Hepat Surg, Affiliated Hosp 3, Guangzhou, Guangdong, Peoples R China.; Zhao, C (corresponding author), Guangxi Med Univ, Dept Invas Technol, Canc Hosp, Nanning, Peoples R China.
EM zhangjian629@sina.com; 710519137@qq.com
FU Free Application Project of Guangdong Provincial Natural Science
   Foundation [2018A0303130050]
FX Free Application Project of Guangdong Provincial Natural Science
   Foundation (2018A0303130050).
CR Battistelli C, 2017, ONCOGENE, V36, P942, DOI 10.1038/onc.2016.260
   Block TM, 2003, ONCOGENE, V22, P5093, DOI 10.1038/sj.onc.1206557
   But DYK, 2008, WORLD J GASTROENTERO, V14, P1652, DOI 10.3748/wjg.14.1652
   Cao H, 2015, PATHOL RES PRACT, V211, P557, DOI 10.1016/j.prp.2015.05.010
   Che DH, 2017, MOL IMMUNOL, V90, P197, DOI 10.1016/j.molimm.2017.06.018
   Chen HW, 2013, MOL CARCINOGEN, V52, P647, DOI 10.1002/mc.21904
   Feng JT, 2006, ONCOGENE, V25, P3810, DOI 10.1038/sj.onc.1209551
   Fu XM, 2017, EUR REV MED PHARMACO, V21, P3239
   Gasri-Plotnitsky L, 2017, ONCOTARGET, V8, P23775, DOI 10.18632/oncotarget.15864
   Guo Y, 2018, CANCER BIOL THER, V19, P205, DOI 10.1080/15384047.2017.1416276
   Harries LW, 2012, BIOCHEM SOC T, V40, P902, DOI 10.1042/BST20120020
   He H, 2012, DIAGN MOL PATHOL, V21, P143, DOI 10.1097/PDM.0b013e318249fd8b
   He R, 2017, BIOMED PHARMACOTHER, V95, P331, DOI 10.1016/j.biopha.2017.08.057
   Huang ZQ, 2018, CELL PHYSIOL BIOCHEM, V46, P1341, DOI 10.1159/000489149
   Jiang N, 2018, CLIN CHIM ACTA, V486, P26, DOI 10.1016/j.cca.2018.07.026
   Ke D, 2017, ONCOTARGET, V8, P21516, DOI 10.18632/oncotarget.15628
   Li GL, 2016, PURINERG SIGNAL, V12, P479, DOI 10.1007/s11302-016-9513-8
   Li XM, 2016, ONCOTARGET, V7, P23197, DOI 10.18632/oncotarget.8099
   Liu Y, 2018, BBA-MOL BASIS DIS, V1864, P420, DOI 10.1016/j.bbadis.2017.11.003
   Ning XF, 2019, ONCOL RES, V27, P399, DOI 10.3727/096504018X15179675206495
   Pan Q, 2017, CANCER LETT, V392, P26, DOI 10.1016/j.canlet.2017.01.039
   Taylor DH, 2015, MOL REPROD DEV, V82, P932, DOI 10.1002/mrd.22581
   Wang TT, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3701-y
   Xu H, 2018, CANCER LETT, V412, P69, DOI 10.1016/j.canlet.2017.09.030
   Yang SC, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0700-1
   Zemmour D, 2017, P NATL ACAD SCI USA, V114, pE3472, DOI 10.1073/pnas.1700946114
   Zhang QQ, 2018, J CELL BIOCHEM, V119, P4447, DOI 10.1002/jcb.26537
   Zhang W, 2018, BIOCHIMIE, V144, P21, DOI 10.1016/j.biochi.2017.10.002
NR 28
TC 5
Z9 5
U1 0
U2 4
PU VERDUCI PUBLISHER
PI ROME
PA VIA GREGORIO VII, ROME, 186-00165, ITALY
SN 1128-3602
J9 EUR REV MED PHARMACO
JI Eur. Rev. Med. Pharmacol. Sci.
PY 2019
VL 23
IS 19
BP 8295
EP 8302
DI 10.26355/eurrev_201910_19140
PG 8
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA JH3RG
UT WOS:000492684500014
PM 31646559
DA 2022-04-25
ER

PT J
AU Yu, S
   Wang, LJ
   Cao, ZX
   Gong, DY
   Liang, QY
   Chen, HT
   Fu, HZ
   Wang, WW
   Tang, X
   Xie, ZH
   He, Y
   Peng, C
   Li, YZ
AF Yu, Si
   Wang, Lijiao
   Cao, Zhixing
   Gong, Daoyin
   Liang, Qianyi
   Chen, Hanting
   Fu, Huizhu
   Wang, Wenwen
   Tang, Xue
   Xie, Zihao
   He, Yang
   Peng, Cheng
   Li, Yuzhi
TI Anticancer effect of Polyphyllin in colorectal cancer cells through
   ROS-dependent autophagy and G2/M arrest mechanisms
SO NATURAL PRODUCT RESEARCH
LA English
DT Article
DE Polyphyllin; autophagy; ROS; G2/M arrest
ID PARIS-POLYPHYLLA; APOPTOSIS
AB Polyphyllin is a steroidal saponin isolated from the rhizoma of Paris polyphylla. In the present study, we aimed to investigate the anticancer effects of polyphyllin in colorectal cancer and to elucidate the potential underlying molecular mechanisms. Using, CCK8 assay, flow cytometry, laser confocal microscope analysis and western blot, the anticancer effects of the polyphyllin were analysed in colorectal cells. Our results indicate that polyphyllin significantly decreased cell viability of HCT 116 cells and induced autophagy. Furthermore, we found that polyphyllin induced autophagy in an ROS-dependent cell death and not related with PI3K/AKT/mTOR pathway. We also provide evidence that excessive ROS triggered by polyphyllin could induce G2/M phase arrest via regulating cycle proteins expression of cell cycle regulators, such as p21 and cyclinB1. In conclusion, polyphyllin exhibit anticancer effect through ROS-dependent autophagy and induces G2/M arrest in colorectal cancer.
   [GRAPHICS]
   .
C1 [Yu, Si; Wang, Lijiao; Cao, Zhixing; Gong, Daoyin; Chen, Hanting; Tang, Xue; Xie, Zihao; Peng, Cheng; Li, Yuzhi] Chengdu Univ Tradit Chinese Med, Coll Pharm, Chengdu, Sichuan, Peoples R China.
   [Yu, Si; Wang, Lijiao; Cao, Zhixing; Gong, Daoyin; Chen, Hanting; Tang, Xue; Xie, Zihao; Peng, Cheng; Li, Yuzhi] Minist Educ Key Lab Standardizat Chinese Herbal M, Chengdu, Sichuan, Peoples R China.
   [Yu, Si; Wang, Lijiao; Cao, Zhixing; Gong, Daoyin; Chen, Hanting; Tang, Xue; Xie, Zihao; Peng, Cheng; Li, Yuzhi] Chinese Med Resources Sichuan Province, Key Lab Breeding Base Co Founded Sichuan Prov & M, Key Lab Systemat Res Dev & Utilizat, Chengdu, Sichuan, Peoples R China.
   [Liang, Qianyi; Fu, Huizhu; Wang, Wenwen; He, Yang] Chengdu Univ Tradit Chinese Med, Sch Med Technol, Chengdu, Sichuan, Peoples R China.
RP Peng, C; Li, YZ (corresponding author), Chengdu Univ Tradit Chinese Med, Coll Pharm, Chengdu, Sichuan, Peoples R China.; Peng, C; Li, YZ (corresponding author), Minist Educ Key Lab Standardizat Chinese Herbal M, Chengdu, Sichuan, Peoples R China.; Peng, C; Li, YZ (corresponding author), Chinese Med Resources Sichuan Province, Key Lab Breeding Base Co Founded Sichuan Prov & M, Key Lab Systemat Res Dev & Utilizat, Chengdu, Sichuan, Peoples R China.
EM pengchengchengdu@126.com; liyuzhi5654@163.com
CR Arnold M, 2016, GUT
   Blokhina O, 2010, PLANT PHYSIOL BIOCH, V48, P359, DOI 10.1016/j.plaphy.2010.01.007
   Chang JL, 2015, J ETHNOPHARMACOL, V170, P117, DOI 10.1016/j.jep.2015.05.006
   Gu LH, 2013, J TRADIT CHIN MED, V33, P325, DOI 10.1016/S0254-6272(13)60174-0
   He L, 2011, BIOCHEM BIOPH RES CO, V409, P489, DOI 10.1016/j.bbrc.2011.05.032
   Huo YA, 2009, EXP EYE RES, V89, P876, DOI 10.1016/j.exer.2009.07.012
   Jing SS, 2017, NAT PROD RES, V31, P660, DOI 10.1080/14786419.2016.1219861
   Ling Y, 2015, NAT PROD RES, V29, P1798, DOI 10.1080/14786419.2015.1007137
   Liu B, 2012, CELL DEATH DIS, V4, p[e892, e892]
   Liu J, 2015, BIOCHEM BIOPH RES CO, V463, P262, DOI 10.1016/j.bbrc.2015.05.042
   Nagesh R, 2017, GENE REP, V6, P103, DOI 10.1016/j.genrep.2016.12.008
   Prasad S, 2017, CANCER LETT, V387, P95, DOI 10.1016/j.canlet.2016.03.042
   Shi YM, 2015, PHYTOMEDICINE, V22, P1139, DOI 10.1016/j.phymed.2015.08.014
   Sun ZL, 2017, BIOMED PHARMACOTHER, V85, P303, DOI 10.1016/j.biopha.2016.11.030
   Torre LA, 2016, CANCER EPIDEM BIOMAR, V25, P16, DOI 10.1158/1055-9965.EPI-15-0578
   Tsujimoto Y, 2005, CELL DEATH DIFFER, V12, P1528, DOI 10.1038/sj.cdd.4401777
   Xu CL, 2014, FITOTERAPIA, V99, P292, DOI 10.1016/j.fitote.2014.10.010
NR 17
TC 11
Z9 15
U1 5
U2 31
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1478-6419
EI 1478-6427
J9 NAT PROD RES
JI Nat. Prod. Res.
PY 2018
VL 32
IS 12
BP 1489
EP 1492
DI 10.1080/14786419.2017.1353512
PG 4
WC Chemistry, Applied; Chemistry, Medicinal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry; Pharmacology & Pharmacy
GA GD9WN
UT WOS:000430863800023
PM 28714320
DA 2022-04-25
ER

PT J
AU Yu, TC
   Guo, FF
   Yu, YN
   Sun, TT
   Ma, D
   Han, JX
   Qian, Y
   Kryczek, I
   Sun, DF
   Nagarsheth, N
   Chen, YX
   Chen, HY
   Hong, J
   Zou, WP
   Fang, JY
AF Yu, TaChung
   Guo, Fangfang
   Yu, Yanan
   Sun, Tiantian
   Ma, Dan
   Han, Jixuan
   Qian, Yun
   Kryczek, Ilona
   Sun, Danfeng
   Nagarsheth, Nisha
   Chen, Yingxuan
   Chen, Haoyan
   Hong, Jie
   Zou, Weiping
   Fang, Jing-Yuan
TI Fusobacterium nucleatum Promotes Chemoresistance to Colorectal Cancer by
   Modulating Autophagy
SO CELL
LA English
DT Article
ID RESISTANCE; CELLS; COMMENSAL; OXALIPLATIN; SENSITIVITY; STATISTICS;
   MECHANISMS; MICROBIOTA; EXPRESSION; CETUXIMAB
AB Gut microbiota are linked to chronic inflammation and carcinogenesis. Chemotherapy failure is the major cause of recurrence and poor prognosis in colorectal cancer patients. Here, we investigated the contribution of gut microbiota to chemoresistance in patients with colorectal cancer. We found that Fusobacterium (F.) nucleatum was abundant in colorectal cancer tissues in patients with recurrence post chemotherapy, and was associated with patient clinicopathological characterisitcs. Furthermore, our bioinformatic and functional studies demonstrated that F. nucleatum promoted colorectal cancer resistance to chemotherapy. Mechanistically, F. nucleatum targeted TLR4 and MYD88 innate immune signaling and specific microRNAs to activate the autophagy pathway and alter colorectal cancer chemotherapeutic response. Thus, F. nucleatum orchestrates a molecular network of the Toll-like receptor, microRNAs, and autophagy to clinically, biologically, and mechanistically control colorectal cancer chemoresistance. Measuring and targeting F. nucleatum and its associated pathway will yield valuable insight into clinical management and may ameliorate colorectal cancer patient outcomes.
C1 [Yu, TaChung; Guo, Fangfang; Yu, Yanan; Sun, Tiantian; Ma, Dan; Han, Jixuan; Qian, Yun; Sun, Danfeng; Chen, Yingxuan; Chen, Haoyan; Hong, Jie; Fang, Jing-Yuan] Shanghai Jiao Tong Univ, State Key Lab Oncogenes & Related Genes,Shanghai, Key Lab Gastroenterol & Hepatol,Shanghai Canc Ins, Minist Hlth,Div Gastroenterol & Hepatol,Renji Hos, 145 Middle Shandong Rd, Shanghai 200001, Peoples R China.
   [Kryczek, Ilona; Sun, Danfeng; Nagarsheth, Nisha; Zou, Weiping] Univ Michigan, Ctr Comprehens Canc, Grad Programs Immunol & Canc Biol, Dept Surg,Sch Med, Ann Arbor, MI 48109 USA.
RP Chen, YX; Chen, HY; Hong, J; Fang, JY (corresponding author), Shanghai Jiao Tong Univ, State Key Lab Oncogenes & Related Genes,Shanghai, Key Lab Gastroenterol & Hepatol,Shanghai Canc Ins, Minist Hlth,Div Gastroenterol & Hepatol,Renji Hos, 145 Middle Shandong Rd, Shanghai 200001, Peoples R China.; Zou, WP (corresponding author), Univ Michigan, Ctr Comprehens Canc, Grad Programs Immunol & Canc Biol, Dept Surg,Sch Med, Ann Arbor, MI 48109 USA.
EM yingxuanchen71@126.com; haoyanchen@shsmu.edu.cn; jiehong97@shsmu.edu.cn;
   wzou@med.umich.edu; jingyuanfang@sjtu.edu.cn
OI Nagarsheth, Nisha/0000-0002-9508-1530; fang,
   jingyuan/0000-0003-2282-0248
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81421001, 81320108024, 81530072, 81522008,
   31371273, 31371420, 81572303, 81001070]; National Key Technology RD
   ProgramNational Key Technology R&D Program [2014BAI09B05]; Program for
   Professor of Special Appointment at Shanghai Institutions of Higher
   Learning [201268, QD2015003]; Shanghai Municipal Education
   Commission-Gaofeng Clinical Medicine Grant [20152512, 20161309];
   Chenxing Project of Shanghai Jiao-Tong University; National Cancer
   InstituteUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)
   [CA211016]; NATIONAL CANCER INSTITUTEUnited States Department of Health
   & Human ServicesNational Institutes of Health (NIH) - USANIH National
   Cancer Institute (NCI) [R01CA190176, R01CA211016] Funding Source: NIH
   RePORTER
FX This project was supported in part by grants from the National Natural
   Science Foundation of China (81421001, 81320108024, 81530072, 81522008
   31371273, 31371420, 81572303, and 81001070), the National Key Technology
   R&D Program (2014BAI09B05), the Program for Professor of Special
   Appointment (Eastern Scholar No. 201268 and 2015 Youth Eastern Scholar
   NO. QD2015003) at Shanghai Institutions of Higher Learning, the Shanghai
   Municipal Education Commission-Gaofeng Clinical Medicine Grant (no.
   20152512, 20161309), the Chenxing Project of Shanghai Jiao-Tong
   University (H. Chen and J. Hong), and the National Cancer Institute
   (CA211016, W.Z). We thank Dr. Ming Zhong for collecting colocretal
   cancer tissues and patient information for this work. We thank Dr.
   Tingting Yan for graphic abstract conception.
CR Abed J, 2016, CELL HOST MICROBE, V20, P215, DOI 10.1016/j.chom.2016.07.006
   Abreu MT, 2014, GASTROENTEROLOGY, V146, P1534, DOI 10.1053/j.gastro.2014.01.001
   Anders S, 2013, NAT PROTOC, V8, P1765, DOI 10.1038/nprot.2013.099
   Arthur JC, 2012, SCIENCE, V338, P120, DOI 10.1126/science.1224820
   Bardelli A, 2010, J CLIN ONCOL, V28, P1254, DOI 10.1200/JCO.2009.24.6116
   Bertotti A, 2015, CLIN CANCER RES, V21, P3377, DOI 10.1158/1078-0432.CCR-14-0848
   Cartwright TH, 2012, CLIN COLORECTAL CANC, V11, P155, DOI 10.1016/j.clcc.2011.11.001
   Castellarin M, 2012, GENOME RES, V22, P299, DOI 10.1101/gr.126516.111
   Chen HM, 2013, AM J CLIN NUTR, V97, P1044, DOI 10.3945/ajcn.112.046607
   Dahan L, 2009, BRIT J PHARMACOL, V158, P610, DOI 10.1111/j.1476-5381.2009.00341.x
   Dallas NA, 2009, CANCER RES, V69, P1951, DOI 10.1158/0008-5472.CAN-08-2023
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI 10.1056/NEJMra072067
   Garrett WS, 2015, SCIENCE, V348, P80, DOI 10.1126/science.aaa4972
   Hanzelmann S, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-7
   Nguyen HTT, 2014, GASTROENTEROLOGY, V146, P508, DOI 10.1053/j.gastro.2013.10.021
   Iida N, 2013, SCIENCE, V342, P967, DOI 10.1126/science.1240527
   Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006
   Jeong H, 2007, INT J SYST EVOL MICR, V57, P1784, DOI 10.1099/ijs.0.63283-0
   Kelland L, 2007, NAT REV CANCER, V7, P573, DOI 10.1038/nrc2167
   Kim D, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-4-r36
   Kostic AD, 2012, GENOME RES, V22, P292, DOI 10.1101/gr.126573.111
   Krek A, 2005, NAT GENET, V37, P495, DOI 10.1038/ng1536
   Linardou H, 2008, LANCET ONCOL, V9, P962, DOI 10.1016/S1470-2045(08)70206-7
   Liu HQ, 2007, J IMMUNOL, V179, P2501, DOI 10.4049/jimmunol.179.4.2501
   Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8
   Mima K, 2016, GUT, V65, P1973, DOI 10.1136/gutjnl-2015-310101
   Moutinho C, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/djt322
   Rhee KJ, 2009, INFECT IMMUN, V77, P1708, DOI 10.1128/IAI.00814-08
   Rubinstein MR, 2013, CELL HOST MICROBE, V14, P195, DOI 10.1016/j.chom.2013.07.012
   Schirmer M, 2016, CELL, V167, P1125, DOI 10.1016/j.cell.2016.10.020
   Schwabe RF, 2013, NAT REV CANCER, V13, P800, DOI 10.1038/nrc3610
   Segata N, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-6-r60
   Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166
   Sivan A, 2015, SCIENCE, V350, P1084, DOI 10.1126/science.aac4255
   Song JR, 2009, AUTOPHAGY, V5, P1131, DOI 10.4161/auto.5.8.9996
   Sun TT, 2015, INT J CANCER, V136, P1053, DOI 10.1002/ijc.29061
   Van Geelen CMM, 2004, DRUG RESIST UPDATE, V7, P345, DOI 10.1016/j.drup.2004.11.002
   Vetizou M, 2015, SCIENCE, V350, P1079, DOI 10.1126/science.aad1329
   Viaud S, 2013, SCIENCE, V342, P971, DOI 10.1126/science.1240537
   Walko CM, 2005, CLIN THER, V27, P23, DOI 10.1016/j.clinthera.2005.01.005
   Wang WM, 2016, CELL, V165, P1092, DOI 10.1016/j.cell.2016.04.009
   Weichert W, 2008, CLIN CANCER RES, V14, P1669, DOI 10.1158/1078-0432.CCR-07-0990
   Xiong H, 2012, J BIOL CHEM, V287, P5819, DOI 10.1074/jbc.M111.295964
   Yu YN, 2015, ONCOTARGET, V6, P32013, DOI 10.18632/oncotarget.5166
   Zhou CH, 2012, AUTOPHAGY, V8, P1215, DOI 10.4161/auto.20284
   Zitvogel L, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.3010473
   Zou WP, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad7118
NR 47
TC 674
Z9 719
U1 51
U2 364
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 0092-8674
EI 1097-4172
J9 CELL
JI Cell
PD JUL 27
PY 2017
VL 170
IS 3
BP 548
EP +
DI 10.1016/j.cell.2017.07.008
PG 32
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA FB9ME
UT WOS:000406462400013
PM 28753429
OA Green Accepted, Bronze
HC Y
HP N
DA 2022-04-25
ER

PT J
AU Nazim, UMD
   Moon, JH
   Lee, YJ
   Seol, JW
   Kim, YJ
   Park, SY
AF Nazim, Uddin M. D.
   Moon, Ji-Hong
   Lee, You-Jin
   Seol, Jae-Won
   Kim, Yong Ju
   Park, Sang-Youel
TI Glipizide sensitizes lung cancer cells to TRAIL-induced apoptosis via
   Akt/mTOR/autophagy pathways
SO ONCOTARGET
LA English
DT Article
DE glipizide; autophagy; TRAIL; apoptosis; lung cancer cells
ID DIABETES-MELLITUS; COLORECTAL-CANCER; AUTOPHAGY FLUX; RECEPTOR; DEATH;
   RISK; MECHANISMS; LIGAND; GROWTH; INHIBITION
AB The combination of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) with subsidiary agents is a promising anticancer strategy to conquer TRAIL resistance in malignant cells. Glipizide is a second-generation oral hypoglycemic medicine for the cure of type II diabetes because of its capability to selectively stimulate insulin secretion from beta-cells. In this study, we revealed that glipizide could trigger TRAIL-mediated apoptotic cell death in human lung adenocarcinoma cells. Pretreatment with glipizide downregulation of p-Akt and p-mTOR in different concentrations. In addition, LC3-II and p-Akt was suppressed in the presence of LY294002, a well-known inhibitor of P13K. Treatment with glipizide commenced in a slight increase in conversion rate of LC3-I to LC3-II and significantly decreased p62 expression levels in a dose-dependent manner. This indicates that glipizide encouraged autophagy flux activation in human lung cancer cells. Inhibition of autophagy flux applying a specific inhibitor and genetically modified ATG5 siRNA enclosed glipizide-mediated enhancing effect of TRAIL. These data demonstrate that inhibition of Akt/mTOR by glipizide sensitizes TRAIL-induced tumor cell death through activating autophagy flux and also suggest that glipizide may be a combination therapeutic target with TRAIL protein in TRAIL-resistant cancer cells.
C1 [Nazim, Uddin M. D.; Moon, Ji-Hong; Lee, You-Jin; Seol, Jae-Won; Park, Sang-Youel] Chonbuk Natl Univ, Biosafety Res Inst, Coll Vet Med, Iksan 54596, Jeonbuk, South Korea.
   [Kim, Yong Ju] Chonbuk Natl Univ, Dept Herbal Med Resources, Coll Environm & Bioresources, Iksan 54596, Jeonbuk, South Korea.
RP Park, SY (corresponding author), Chonbuk Natl Univ, Biosafety Res Inst, Coll Vet Med, Iksan 54596, Jeonbuk, South Korea.
EM sypark@chonbuk.ac.kr
RI Park, Sang-Youel/D-5966-2012
OI Park, Sang-Youel/0000-0003-0575-6045
FU National Research Foundation of Korea (NRF) - Korean government (MISP)
   [2016R1A2B2009293]
FX This study was supported by a grant from the National Research
   Foundation of Korea (NRF), funded by the Korean government (MISP)
   (2016R1A2B2009293).
CR Aggarwal BB, 2003, NAT REV IMMUNOL, V3, P745, DOI 10.1038/nri1184
   Baehrecke EH, 2005, NAT REV MOL CELL BIO, V6, P505, DOI 10.1038/nrm1666
   Bhardwaj A, 2003, J CLIN IMMUNOL, V23, P317, DOI 10.1023/A:1025319031417
   Davila JA, 2005, GUT, V54, P533, DOI 10.1136/gut.2004.052167
   De A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072748
   Densmore Charles L., 2006, Current Drug Delivery, V3, P55, DOI 10.2174/156720106775197547
   Feng YH, 2011, J CELL MOL MED, V15, P825, DOI 10.1111/j.1582-4934.2010.01083.x
   Gonzalvez F, 2010, ONCOGENE, V29, P4752, DOI 10.1038/onc.2010.221
   Hao WH, 2014, PEERJ, V2, DOI 10.7717/peerj.555
   Huxley R, 2005, BRIT J CANCER, V92, P2076, DOI 10.1038/sj.bjc.6602619
   Ikezoe T, 2007, LEUKEMIA RES, V31, P673, DOI 10.1016/j.leukres.2006.08.001
   Inoue M, 2006, ARCH INTERN MED, V166, P1871, DOI 10.1001/archinte.166.17.1871
   Jiang PD, 2014, CELL RES, V24, P69, DOI 10.1038/cr.2013.161
   Jin CY, 2011, MOL NUTR FOOD RES, V55, P300, DOI 10.1002/mnfr.201000024
   Johnstone RW, 2008, NAT REV CANCER, V8, P782, DOI 10.1038/nrc2465
   Kim H, 2006, CANCER RES, V66, P1740, DOI 10.1158/0008-5472.CAN-05-1568
   Klionsky DJ, 2007, NAT REV MOL CELL BIO, V8, P931, DOI 10.1038/nrm2245
   Kourtis N, 2009, CELL DEATH DIFFER, V16, P21, DOI 10.1038/cdd.2008.120
   Law BYK, 2014, SCI REP-UK, V4, DOI 10.1038/srep05510
   LeBlanc H, 2002, NAT MED, V8, P274, DOI 10.1038/nm0302-274
   Lee JH, 2015, ONCOTARGET, V6, P9701, DOI 10.18632/oncotarget.3832
   Levy JMM, 2011, PHARMACOL THERAPEUT, V131, P130, DOI 10.1016/j.pharmthera.2011.03.009
   Lum JJ, 2005, CELL, V120, P237, DOI 10.1016/j.cell.2004.11.046
   Ma BBY, 2013, INVEST NEW DRUG, V31, P567, DOI 10.1007/s10637-012-9896-5
   Ma BBY, 2010, INVEST NEW DRUG, V28, P413, DOI 10.1007/s10637-009-9269-x
   Meijer AJ, 2004, INT J BIOCHEM CELL B, V36, P2445, DOI 10.1016/j.biocel.2004.02.002
   Mizuno CS, 2008, CURR MED CHEM, V15, P61
   Nazim UMD, 2016, ONCOTARGET, V7, P23468, DOI 10.18632/oncotarget.8048
   Nazim UM, 2015, ONCOL REP, V33, P2331, DOI 10.3892/or.2015.3869
   Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111
   Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687
   Riddle MC, 1999, AM FAM PHYSICIAN, V60, P2613
   Rodriguez C, 2005, AM J EPIDEMIOL, V161, P147, DOI 10.1093/aje/kwh334
   Rousseau MC, 2006, INT J CANCER, V118, P2105, DOI 10.1002/ijc.21600
   Seow A, 2006, JNCI-J NATL CANCER I, V98, P135, DOI 10.1093/jnci/djj015
   Shankar S, 2004, DRUG RESIST UPDATE, V7, P139, DOI 10.1016/j.drup.2004.03.002
   Shimizu S, 2004, NAT CELL BIOL, V6, P1221, DOI 10.1038/ncb1192
   Skyler JS, 2004, J MED CHEM, V47, P4113, DOI 10.1021/jm0306273
   Srivastava RK, 2001, NEOPLASIA, V3, P535, DOI 10.1038/sj.neo.7900203
   Van Geelen CMM, 2004, DRUG RESIST UPDATE, V7, P345, DOI 10.1016/j.drup.2004.11.002
   Walczak H, 1997, EMBO J, V16, P5386, DOI 10.1093/emboj/16.17.5386
   Wang CG, 2006, P NATL ACAD SCI USA, V103, P11567, DOI 10.1073/pnas.0603363103
   Xie CM, 2011, FREE RADICAL BIO MED, V51, P1365, DOI 10.1016/j.freeradbiomed.2011.06.016
   Xie XQ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055096
   Yang XL, 2010, DIABETES RES CLIN PR, V90, P343, DOI 10.1016/j.diabres.2010.08.022
   Yang XL, 2013, BIORESEARCH OPEN ACC, V2, P258, DOI 10.1089/biores.2013.0014
   Yang ZF, 2010, CURR OPIN CELL BIOL, V22, P124, DOI 10.1016/j.ceb.2009.11.014
   Zhang T, 2014, ANTI-CANCER DRUG, V25, P887, DOI 10.1097/CAD.0000000000000116
NR 48
TC 6
Z9 8
U1 0
U2 2
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD NOV 21
PY 2017
VL 8
IS 59
BP 100021
EP 100033
DI 10.18632/oncotarget.21754
PG 13
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA FS1TR
UT WOS:000419561600072
PM 29245957
OA Green Submitted, gold, Green Published
DA 2022-04-25
ER

PT J
AU Fu, R
   Ding, Y
   Luo, J
   Huang, KM
   Tang, XJ
   Li, DS
   Guo, SW
AF Fu, Rui
   Ding, Yan
   Luo, Jie
   Huang, Kuan Ming
   Tang, Xiang Jun
   Li, Dong Sheng
   Guo, Shi Wen
TI Ten-eleven translocation 1 regulates methylation of autophagy-related
   genes in human glioma
SO NEUROREPORT
LA English
DT Article
DE autophagy; glioma; 5-hydroxymethylcytosine; 5-methylcytosine; ten-eleven
   translocation 1
ID MALIGNANT GLIOMAS; SIGNALING PATHWAY; COLORECTAL-CANCER; THERAPY; TET1;
   5-HYDROXYMETHYLCYTOSINE; CHALLENGES; CELLS
AB Ten-eleven translocation 1 catalyzes the conversion of 5-methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC), which plays an important role in epigenetics and is related to the malignant biological behavior of tumors. However, its regulatory role in glioma remains unclear. In this study, the levels of 5mC and 5hmC were detected using immunohistochemistry, dot-blot, hMeDIP-chip, and western blot in glioma tissues and normal brain tissues, whereas 5hmC differentially enriched genes were determined and further validated. The level of 5hmC in gliomas was decreased, whereas 5mC was increased. 5hmC highly enriched 10 functional protein-coding genes and 10 signaling pathways were identified using hMeGIP-chip in glioma tissues. Two autophagy-related genes, ATG13 and DNA damage-regulated autophagy modulator protein 1, with low enrichment of 5hmC in glioma tissues were verified in the promoter region, and hMeGIP-PCR further confirmed this result in U251 cells. Immunohistochemistry further confirmed that autophagy level in glioma tissues was lower than that of normal controls, and negatively correlated with WHO grade. This study indicates that ten-eleven translocation 1 may be involved in the development and progression of glioma through demethylation regulating a variety of cellular functions and signaling pathways, and autophagy is one of the regulatory mechanisms.
C1 [Fu, Rui; Luo, Jie; Huang, Kuan Ming; Tang, Xiang Jun] Xi An Jiao Tong Univ, Hlth Sci Ctr, Affiliated Taihe Hosp, Dept Neurosurg, Xian, Shaanxi, Peoples R China.
   [Ding, Yan; Li, Dong Sheng] Hubei Univ Med, Taihe Hosp, Hubei Key Lab Embryon Stem Cell Res, Shiyan, Hubei, Peoples R China.
   [Guo, Shi Wen] Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Neurosurg, Xian 710061, Shanxi, Peoples R China.
RP Guo, SW (corresponding author), Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Neurosurg, Xian 710061, Shanxi, Peoples R China.
EM gsw1962@126.com
OI /0000-0002-4916-8125
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81602297]; Science and Technology Department
   of Hubei Province [2016CFB11, 2017CFB562]
FX This work was supported by the National Natural Science Foundation of
   China (grant number 81602297); and the Science and Technology Department
   of Hubei Province (grant numbers 2016CFB11 and 2017CFB562).
CR Ahsan S, 2014, ACTA NEUROPATHOL COM, V2, DOI 10.1186/2051-5960-2-59
   Alers S, 2014, AUTOPHAGY, V10, P944, DOI 10.4161/auto.28987
   Bian EB, 2014, J NEURO-ONCOL, V116, P429, DOI 10.1007/s11060-013-1328-7
   Coulter JB, 2013, J BIOL CHEM, V288, P28792, DOI 10.1074/jbc.M113.491365
   Crighton D, 2007, AUTOPHAGY, V3, P72, DOI 10.4161/auto.3438
   Davis F G, 2001, Expert Rev Anticancer Ther, V1, P395, DOI 10.1586/14737140.1.3.395
   Drabsch Y, 2012, CANCER METAST REV, V31, P553, DOI 10.1007/s10555-012-9375-7
   Frosina G, 2015, CRIT REV ONCOL HEMAT, V96, P257, DOI 10.1016/j.critrevonc.2015.05.013
   Fu R, 2017, BIOSCIENCE REP, V37, P1
   Guan JJ, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2014.546
   Guishard AF, 2018, J CLIN NEUROSCI, V47, P28, DOI 10.1016/j.jocn.2017.10.001
   Hadjipanayis CG, 2009, J MOL MED, V87, P363, DOI 10.1007/s00109-009-0440-9
   Hou LC, 2017, MED SCI MONITOR, V23, P5130, DOI 10.12659/MSM.904492
   Ichimura N, 2015, CANCER PREV RES, V8, P702, DOI 10.1158/1940-6207.CAPR-14-0306
   Jeschke J, 2016, CURR OPIN GENET DEV, V36, P16, DOI 10.1016/j.gde.2016.01.004
   Kraus TFJ, 2012, INT J CANCER, V131, P1577, DOI 10.1002/ijc.27429
   Lian H, 2016, ONCOTARGET, V7, P64512, DOI 10.18632/oncotarget.11412
   Louis DN, 2007, ACTA NEUROPATHOL, V114, P97, DOI 10.1007/s00401-007-0243-4
   Muller T, 2012, AM J PATHOL, V181, P675, DOI 10.1016/j.ajpath.2012.04.017
   Neri F, 2015, ONCOGENE, V34, P4168, DOI 10.1038/onc.2014.356
   Rajesh Y, 2017, ACTA PHARMACOL SIN, V38, P591, DOI 10.1038/aps.2016.167
   Sahoo SS, 2017, ONCOTARGET, V8, P71400, DOI 10.18632/oncotarget.18069
   Selim KA, 2017, DISEASES, V26, P5
   Wallot-Hieke  N., 2017, AUTOPHAGY, P1
   Wang HX, 2015, NEOPLASIA, V17, P239, DOI 10.1016/j.neo.2015.02.002
   Wang X, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0683-9
NR 26
TC 4
Z9 4
U1 2
U2 10
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0959-4965
EI 1473-558X
J9 NEUROREPORT
JI Neuroreport
PD JUN 13
PY 2018
VL 29
IS 9
BP 731
EP 738
DI 10.1097/WNR.0000000000001024
PG 8
WC Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA GH0MM
UT WOS:000433096700006
PM 29659445
DA 2022-04-25
ER

PT J
AU Zabirnyk, O
   Liu, W
   Khalil, S
   Sharma, A
   Phang, JM
AF Zabirnyk, Olga
   Liu, Wei
   Khalil, Shadi
   Sharma, Anit
   Phang, James M.
TI Oxidized low-density lipoproteins upregulate proline oxidase to initiate
   ROS-dependent autophagy
SO CARCINOGENESIS
LA English
DT Article
ID ACTIVATED-RECEPTOR-GAMMA; OXIDATIVE STRESS; COLORECTAL-CANCER; LIGAND
   ACTIVATION; TUMOR-SUPPRESSOR; APOPTOSIS; CELLS; EXPRESSION; INDUCTION;
   7-KETOCHOLESTEROL
AB Epidemiological studies showed that high levels of oxidized low-density lipoproteins (oxLDLs) are associated with increased cancer risk. We examined the direct effect of physiologic concentrations oxLDL on cancer cells. OxLDLs were cytotoxic and activate both apoptosis and autophagy. OxLDLs have ligands for peroxisome proliferator-activated receptor gamma and upregulated proline oxidase (POX) through this nuclear receptor. We identified 7-ketocholesterol (7KC) as a main component responsible for the latter. To elucidate the role of POX in oxLDL-mediated cytotoxicity, we knocked down POX via small interfering RNA and found that this (i) further reduced viability of cancer cells treated with oxLDL; (ii) decreased oxLDL-associated reactive oxygen species generation; (iii) decreased autophagy measured via beclin-1 protein level and light-chain 3 protein (LC3)-I into LC3-II conversion. Using POX-expressing cell model, we established that single POX overexpression was sufficient to activate autophagy. Thus, it led to autophagosomes accumulation and increased conversion of LC3-I into LC3-II. Moreover, beclin-1 gene expression was directly dependent on POX catalytic activity, namely the generation of POX-dependent superoxide. We conclude that POX is critical in the cellular response to the noxious effects of oxLDL by activating protective autophagy.
C1 [Zabirnyk, Olga] NCI, Metab & Canc Susceptibil Sect, Comparat Carcinogenesis Lab, Ctr Canc Res,NIH, Frederick, MD 21702 USA.
RP Zabirnyk, O (corresponding author), NCI, Metab & Canc Susceptibil Sect, Comparat Carcinogenesis Lab, Ctr Canc Res,NIH, Bldg 538,Room 144, Frederick, MD 21702 USA.
EM olga_zabirnyk@yahoo.com; phangj@mail.nih.gov
RI liu, wei/E-7340-2012
FU National Institutes of Health; National Cancer Institute; Center for
   Cancer ResearchUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Cancer
   Institute (NCI); NATIONAL CANCER INSTITUTEUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Cancer Institute (NCI) [ZIABC010744, ZIABC010743] Funding
   Source: NIH RePORTER
FX Intramural Research Program of the National Institutes of Health;
   National Cancer Institute; Center for Cancer Research.
CR Beachy PA, 2004, NATURE, V432, P324, DOI 10.1038/nature03100
   Brito PM, 2009, ATHEROSCLEROSIS, V205, P126, DOI 10.1016/j.atherosclerosis.2008.11.011
   Brown AJ, 1999, ATHEROSCLEROSIS, V142, P1, DOI 10.1016/S0021-9150(98)00196-8
   Cao Y, 2007, CELL RES, V17, P839, DOI 10.1038/cr.2007.78
   Chen CY, 2007, LIFE SCI, V80, P2469, DOI 10.1016/j.lfs.2007.04.007
   Chen HW, 2008, CARDIOLOGY, V110, P252, DOI 10.1159/000112409
   Chen Y, 2009, CELL DEATH DIFFER, V16, P1040, DOI 10.1038/cdd.2009.49
   Cheng JZ, 2007, ENDOCRINOLOGY, V148, P2085, DOI 10.1210/en.2006-1709
   Couillard C, 2005, J CLIN ENDOCR METAB, V90, P6454, DOI 10.1210/jc.2004-2438
   Delimaris L, 2007, CLIN BIOCHEM, V40, P1129, DOI 10.1016/j.clinbiochem.2007.06.007
   Donald SP, 2001, CANCER RES, V61, P1810
   Duerrschmidt N, 2006, ENDOCRINOLOGY, V147, P3851, DOI 10.1210/en.2006-0088
   ESTERBAUER H, 1990, MUTAT RES, V238, P223, DOI 10.1016/0165-1110(90)90014-3
   Furukawa S, 2004, J CLIN INVEST, V114, P1752, DOI [10.1172/JCI21625, 10.1172/JCI20042162S]
   Heinloth A, 2000, J AM SOC NEPHROL, V11, P1819, DOI 10.1681/ASN.V11101819
   Ishigaki Y, 2008, CIRCULATION, V118, P75, DOI 10.1161/CIRCULATIONAHA.107.745174
   Karantza-Wadsworth V, 2007, GENE DEV, V21, P1621, DOI 10.1101/gad.1565707
   Kim KY, 2007, MOL PHARMACOL, V72, P674, DOI 10.1124/mol.107.035584
   Klionsky DJ, 2008, AUTOPHAGY, V4, P151, DOI 10.4161/auto.5338
   Klionsky DJ, 2007, NAT REV MOL CELL BIO, V8, P931, DOI 10.1038/nrm2245
   Kroemer G, 2009, CELL DEATH DIFFER, V16, P3, DOI 10.1038/cdd.2008.150
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257
   Liu Y, 2006, ONCOGENE, V25, P5640, DOI 10.1038/sj.onc.1209564
   Liu YM, 2005, CARCINOGENESIS, V26, P1335, DOI 10.1093/carcin/bgi083
   Liu YM, 2009, CANCER RES, V69, P6414, DOI 10.1158/0008-5472.CAN-09-1223
   Martinet W, 2004, ARTERIOSCL THROM VAS, V24, P2296, DOI 10.1161/01.ATV.0000146266.65820.a1
   Mathew R, 2007, NAT REV CANCER, V7, P961, DOI 10.1038/nrc2254
   Maxwell SA, 2003, J BIOL CHEM, V278, P9784, DOI 10.1074/jbc.M210012200
   Maziere C, 2000, BIOCHEM BIOPH RES CO, V276, P718, DOI 10.1006/bbrc.2000.3528
   Mueller E, 2000, P NATL ACAD SCI USA, V97, P10990, DOI 10.1073/pnas.180329197
   Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3
   Nicklin P, 2009, CELL, V136, P521, DOI 10.1016/j.cell.2008.11.044
   Overholtzer M, 2007, CELL, V131, P966, DOI 10.1016/j.cell.2007.10.040
   Pandhare J, 2006, J BIOL CHEM, V281, P2044, DOI 10.1074/jbc.M507867200
   Pandhare J, 2009, J CELL BIOCHEM, V107, P759, DOI 10.1002/jcb.22174
   Phang JM, 2008, AMINO ACIDS, V35, P681, DOI 10.1007/s00726-008-0063-4
   Phang JM, 2008, PPAR RES, V2008, DOI 10.1155/2008/542694
   PHANG JM, 1978, FED PROC, V37, P1480
   Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525
   Raijmakers MTM, 2004, ACTA OBSTET GYN SCAN, V83, P1173, DOI 10.1111/j.0001-6349.2004.00539.x
   Rao ML, 1999, ANN NY ACAD SCI, V893, P379, DOI 10.1111/j.1749-6632.1999.tb07860.x
   Ross JS, 2001, ANN NY ACAD SCI, V947, P271
   Sasaki H, 2007, METABOLISM, V56, P357, DOI 10.1016/j.metabol.2006.10.017
   Seleverstov O, 2009, METHOD ENZYMOL, V452, P277, DOI 10.1016/S0076-6879(08)03618-5
   Sukhanov S, 2003, BIOCHEM BIOPH RES CO, V306, P443, DOI 10.1016/S0006-291X(03)00990-2
   Suzuki K, 2004, CANCER EPIDEM BIOMAR, V13, P1781
   SZWEDA LI, 1993, J BIOL CHEM, V268, P3342
   White TA, 2007, J BIOL CHEM, V282, P14316, DOI 10.1074/jbc.M700912200
   Zabirnyk O, 2007, AUTOPHAGY, V3, P278, DOI 10.4161/auto.3916
   Zettler ME, 2004, ARTERIOSCL THROM VAS, V24, P727, DOI 10.1161/01.ATV.0000120373.95552.aa
   Zettler ME, 2003, AM J PHYSIOL-HEART C, V284, pH644, DOI 10.1152/ajpheart.00494.2001
NR 52
TC 58
Z9 67
U1 0
U2 9
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0143-3334
EI 1460-2180
J9 CARCINOGENESIS
JI Carcinogenesis
PD MAR
PY 2010
VL 31
IS 3
BP 446
EP 454
DI 10.1093/carcin/bgp299
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 564VE
UT WOS:000275245200017
PM 19942609
OA Green Submitted, hybrid, Green Published
DA 2022-04-25
ER

PT J
AU Zhang, ZR
   Zhang, MX
   Liu, H
   Yin, W
AF Zhang, Zhirui
   Zhang, Mengxiao
   Liu, Hao
   Yin, Wu
TI AZD9291 promotes autophagy and inhibits PI3K/Akt pathway in NSCLC cancer
   cells
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Article
DE autophagy; AZD9291; epidermal growth factor receptor (EGFR);
   phosphoinositide-3 kinase/protein kinase B (PI3K/Akt)
ID RECEPTOR-TYROSINE KINASE; COLORECTAL-CANCER; EGFR; OSIMERTINIB;
   RESISTANCE; MUTATION; MECHANISMS; T790M; DEATH; INDUCTION
AB AZD9291, a third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), is highly selective against EGFR T790M-mutant non-small cell lung cancer (NSCLC). On investigating the growth inhibitory effects of AZD9291 on NSCLC and the underlying mechanism, we found that AZD9291 can trigger autophagy-mediated cell death in both A549 and H1975 cells by increasing the expression of phosphatidylethanolamine-modified microtubule-associated protein light-chain 3 (LC3) and decreasing the expression of p62. In the presence of the autophagy inhibitor chloroquine, the AZD9291-induced increase in LC3 level was further augmented. AZD9291 decreased the levels of phosphoinositide-3 kinase (PI3K), protein kinase B (Akt), and phosphorylated Akt. AZD9291-induced cell death was enhanced by Akt knockdown, and the levels of both EGFR and phosphorylated EGFR were decreased by AZD9291. AZD9291 was also found to significantly suppress the tumor growth in H1975 xenograft nude mice. Thus, AZD9291 was found to induce autophagy, decrease in EGFR levels, and show a strong inhibitory effect on NSCLC both in vitro and in vivo. Furthermore, the PI3K/Akt signaling pathway was found to play a critical role in AZD9291-induced cell death.
C1 [Zhang, Zhirui; Yin, Wu] Nanjing Univ, Coll Life Sci, State Key Lab Pharmaceut Biotechnol, Nanjing, Jiangsu, Peoples R China.
   [Zhang, Zhirui; Zhang, Mengxiao; Liu, Hao] Bengbu Med Coll, Fac Pharm, 2600 Donghai Rd, Bengbu 233000, Anhui, Peoples R China.
RP Liu, H (corresponding author), Bengbu Med Coll, Fac Pharm, 2600 Donghai Rd, Bengbu 233000, Anhui, Peoples R China.; Yin, W (corresponding author), Nanjing Univ, Coll Life Sci, SKLPB, LBMP, Xianlin Campus,163 Xianlin Rd, Nanjing 210046, Jiangsu, Peoples R China.
EM liuhao6886@foxmail.com; wyin@nju.edu.cn
FU Education Department of Anhui Natural Science Research Project China
   [KJ2018A0238]; Key development project of Jiangsu Province [BE2017712];
   Open Project Program of Jiangsu Key Laboratory for Pharmacology and
   Safety Evaluation of Chinese Materia Medica [JKLPSE201509]; Six talent
   peaks project in Jiangsu Province [YY-012]; Natural Science Fund of
   ChinaNational Natural Science Foundation of China (NSFC) [91540119,
   81473293, 81673462, 31071250]; Fundamental Research Funds for the
   Central UniversitiesFundamental Research Funds for the Central
   Universities; Priority Academic Program Development of Jiangsu Higher
   Education Institutions
FX Education Department of Anhui Natural Science Research Project China,
   Grant/Award Number: KJ2018A0238; Key development project of Jiangsu
   Province, Grant/Award Number: BE2017712; The Open Project Program of
   Jiangsu Key Laboratory for Pharmacology and Safety Evaluation of Chinese
   Materia Medica, Grant/Award Number: JKLPSE201509; Six talent peaks
   project in Jiangsu Province to Y.W., Grant/Award Number: YY-012; Natural
   Science Fund of China, Grant/Award Numbers: 91540119, 81473293,
   81673462, 31071250; Fundamental Research Funds for the Central
   Universities; Project of the Priority Academic Program Development of
   Jiangsu Higher Education Institutions
CR Ballard P, 2016, CLIN CANCER RES, V22, P5130, DOI 10.1158/1078-0432.CCR-16-0399
   Berg M, 2012, DISCOV MED, V14, P207
   Bersanelli M, 2016, J THORAC ONCOL, V11, pE121, DOI 10.1016/j.jtho.2016.05.019
   Cappuzzo F, 2007, J THORAC ONCOL, V2, P423, DOI 10.1097/01.JTO.0000268676.79872.9b
   Chang CY, 2014, EXP CELL RES, V327, P102, DOI 10.1016/j.yexcr.2014.05.011
   Chen Chien-Wei, 2017, J Thorac Oncol, V12, pe72, DOI 10.1016/j.jtho.2017.02.005
   Chong DL, 2017, ANTI-CANCER DRUG, V28, P831, DOI 10.1097/CAD.0000000000000517
   Cross DAE, 2014, CANCER DISCOV, V4, P1046, DOI 10.1158/2159-8290.CD-14-0337
   Dizon DS, 2016, J CLIN ONCOL, V34, P987, DOI 10.1200/JCO.2015.65.8427
   Dragowska WH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076503
   Goeckenjan G, 2011, Pneumologie, V65, P39, DOI 10.1055/s-0030-1256562
   Gottschling S, 2012, CANCER GENOM PROTEOM, V9, P275
   Greig SL, 2016, DRUGS, V76, P263, DOI 10.1007/s40265-015-0533-4
   Han WD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018691
   Henson ES, 2006, CELL SIGNAL, V18, P2089, DOI 10.1016/j.cellsig.2006.05.015
   Janne PA, 2015, NEW ENGL J MED, V372, P1689, DOI 10.1056/NEJMoa1411817
   Jiang T, 2014, TRANSL LUNG CANCER R, V3, P370, DOI 10.3978/j.issn.2218-6751.2014.08.02
   Jiang XM, 2017, ACTA PHARMACOL SIN, V38, P1512, DOI 10.1038/aps.2017.123
   Kimura S, 2007, AUTOPHAGY, V3, P452, DOI 10.4161/auto.4451
   Klionsky DJ, 2016, AUTOPHAGY, V12, P1, DOI 10.1080/15548627.2015.1100356
   Li YY, 2013, LUNG CANCER, V81, P354, DOI 10.1016/j.lungcan.2013.05.012
   Melosky B, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00244
   Minari R, 2016, TRANSL LUNG CANCER R, V5, P695, DOI 10.21037/tlcr.2016.12.02
   Ohashi K, 2013, J CLIN ONCOL, V31, P1070, DOI 10.1200/JCO.2012.43.3912
   Prabhu VV, 2017, J ENVIRON PATHOL TOX, V36, P151, DOI 10.1615/JEnvironPatholToxicolOncol.2017018341
   Remon J, 2017, CLIN LUNG CANCER, V18, P583, DOI 10.1016/j.cllc.2017.02.005
   Sacco PC, 2014, FRONT BIOSCI-LANDMRK, V19, P259, DOI 10.2741/4205
   Schuurbiers OCJ, 2009, J THORAC ONCOL, V4, P761, DOI 10.1097/JTO.0b013e3181a1084f
   Sequist LV, 2006, J THORAC ONCOL, V1, P740
   Shigematsu H, 2005, JNCI-J NATL CANCER I, V97, P339, DOI 10.1093/jnci/dji055
   So KS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114000
   Soejima K, 2017, EXPERT REV CLIN PHAR, V10, P31, DOI 10.1080/17512433.2017.1265446
   Sugita S, 2015, BIOCHEM BIOPH RES CO, V461, P28, DOI 10.1016/j.bbrc.2015.03.162
   Sui XB, 2014, MOL CLIN ONCOL, V2, P8, DOI 10.3892/mco.2013.187
   Sullivan I, 2016, THER ADV RESPIR DIS, V10, P549, DOI 10.1177/1753465816670498
   Sun YM, 2015, J BIOENERG BIOMEMBR, V47, P319, DOI 10.1007/s10863-015-9612-1
   Tang ZH, 2017, TOXICOL APPL PHARM, V321, P18, DOI 10.1016/j.taap.2017.02.017
   Thress KS, 2015, NAT MED, V21, P560, DOI 10.1038/nm.3854
   Wang L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088291
   Wang SH, 2016, J HEMATOL ONCOL, V9, DOI 10.1186/s13045-016-0268-z
   Ward RA, 2013, J MED CHEM, V56, P7025, DOI 10.1021/jm400822z
   Wei YJ, 2013, CELL, V154, P1269, DOI 10.1016/j.cell.2013.08.015
   Yarden Y, 2007, CELL, V131, DOI 10.1016/j.cell.2007.11.013
   Zhang ML, 2017, J BIOMED NANOTECHNOL, V13, P458, DOI 10.1166/jbn.2017.2358
   Zhang ZR, 2016, J EXP CLIN CANC RES, V35, DOI 10.1186/s13046-016-0428-6
   Zhang ZX, 2017, J BIOENERG BIOMEMBR, V49, P265, DOI 10.1007/s10863-017-9714-z
NR 46
TC 17
Z9 20
U1 0
U2 27
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0730-2312
EI 1097-4644
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD JAN
PY 2019
VL 120
IS 1
BP 756
EP 767
DI 10.1002/jcb.27434
PG 12
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA HB1XP
UT WOS:000450823500068
PM 30145802
DA 2022-04-25
ER

PT J
AU Gao, S
   Zhao, ZY
   Wu, R
   Wu, LN
   Tian, X
   Zhang, ZY
AF Gao, Song
   Zhao, Zhiying
   Wu, Rong
   Wu, Lina
   Tian, Xin
   Zhang, Zhenyong
TI MiR-146b inhibits autophagy in prostate cancer by targeting the
   PTEN/Akt/mTOR signaling pathway
SO AGING-US
LA English
DT Article
DE prostate cancer; microRNA-146b; PTEN; autophagy; AKT/m-TOR signaling
   pathway
ID PI3K/AKT/MTOR PATHWAY; CELL-PROLIFERATION; COLORECTAL-CANCER;
   LUNG-CANCER; APOPTOSIS; METASTASIS; MICRORNAS; SUPPRESSION; RESISTANCE;
   CARCINOMA
AB Prostate cancer (PCa) is considered as a common visceral cancer in males and the sixth major cause of cancer-related deaths in males worldwide. Significant diagnostic and therapeutic advances have been made in the past decades. However, an improved understanding of their molecular mechanism is still needed. In the present research, we first detected the expression of miR-146b by quantitative real-time PCR (qRT-PCR) and found that miR-146b expression was increased in PCa. Subsequently, we found that miR-146b play an important role in the viability and proliferation capacity of PCa cells functionally. To explore the mechanism, we performed western blot to examine the autophagy-related markers, and found that miR-146b may promote autophagy in PCa cells via activation of PTEN/AKT/mTOR signaling pathway. Furthermore, we performed the dual luciferase reporter assay to clarify the relationship between miR-146b and PTEN. In conclusion, this study demonstrated that miR-146b inhibited autophagy in PCa by targeting the PTEN/Akt/mTOR signaling pathway, and it could be a potential candidate for application in the treatment of PCa.
C1 [Gao, Song; Wu, Rong; Wu, Lina; Tian, Xin; Zhang, Zhenyong] China Med Univ, Shengjing Hosp, Dept Clin Oncol 2, Shenyang 110022, Liaoning, Peoples R China.
   [Zhao, Zhiying] Northeastern Univ, Sch Comp Sci & Engn, Shenyang 110004, Liaoning, Peoples R China.
RP Zhang, ZY (corresponding author), China Med Univ, Shengjing Hosp, Dept Clin Oncol 2, Shenyang 110022, Liaoning, Peoples R China.
EM zhangzy@sj-hospital.org
CR Armstrong CM, 2017, PROSTATE, V77, P1020, DOI 10.1002/pros.23358
   Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002
   Bitting RL, 2013, ENDOCR-RELAT CANCER, V20, pR83, DOI 10.1530/ERC-12-0394
   Calle AS, 2018, CANCER SCI, V109, P2093, DOI 10.1111/cas.13642
   Chen CX, 2018, BRAZ J MED BIOL RES, V51, DOI [10.1590/1414-431X20187080, 10.1590/1414-431x20187080]
   Chen R, 2018, J CELL MOL MED, V22, P1855, DOI 10.1111/jcmm.13469
   Chen SS, 2015, CELL PHYSIOL BIOCHEM, V35, P997, DOI 10.1159/000369755
   De Amicis F, 2014, J CELL MOL MED, V18, P2252, DOI 10.1111/jcmm.12363
   Deng XZ, 2015, CELL PHYSIOL BIOCHEM, V35, P71, DOI 10.1159/000369676
   Fort RS, 2018, EXP HEMATOL ONCOL, V7, DOI 10.1186/s40164-018-0102-0
   Fu Q, 2018, BIOMED PHARMACOTHER, V97, P120, DOI 10.1016/j.biopha.2017.10.115
   Garzon R, 2009, ANNU REV MED, V60, P167, DOI 10.1146/annurev.med.59.053006.104707
   Han F, 2018, J CELL BIOCHEM, V119, P1604, DOI 10.1002/jcb.26320
   Hu XX, 2018, J CANCER, V9, P2603, DOI 10.7150/jca.24918
   Huang EY, 2018, J CELL MOL MED, V22, P3661, DOI 10.1111/jcmm.13649
   Huang ZQ, 2017, J CELL MOL MED, V21, P467, DOI 10.1111/jcmm.12990
   Irimie AI, 2015, ONCOTARGETS THER, V8, P461, DOI 10.2147/OTT.S78358
   Kanzawa T, 2003, CANCER RES, V63, P2103
   Lapierre LR, 2015, AUTOPHAGY, V11, P867, DOI 10.1080/15548627.2015.1034410
   Li JL, 2018, GENE, V665, P26, DOI 10.1016/j.gene.2018.04.086
   Li W, 2018, NEUROSCI LETT, V675, P83, DOI 10.1016/j.neulet.2018.03.041
   Liao HQ, 2015, ONCOL LETT, V10, P2055, DOI 10.3892/ol.2015.3551
   Liu WW, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0743-1
   Livesey KM, 2009, CURR OPIN INVEST DR, V10, P1269
   Luo CL, 2016, BIOMED PHARMACOTHER, V82, P595, DOI 10.1016/j.biopha.2016.05.029
   Ma JF, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/4780612
   Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639
   Mraz M, 2009, BIOCHEM BIOPH RES CO, V390, P1, DOI 10.1016/j.bbrc.2009.09.061
   Pei GQ, 2018, CELL PHYSIOL BIOCHEM, V46, P847, DOI 10.1159/000488742
   Ramalinga M, 2015, ONCOTARGET, V6, P34446, DOI 10.18632/oncotarget.5920
   Sharma K, 2014, EXCLI J, V13, P178
   Shi ZJ, 2018, J CELL BIOCHEM, V119, P5813, DOI 10.1002/jcb.26768
   Shi ZJ, 2018, J CELL MOL MED, V22, P2055, DOI 10.1111/jcmm.13515
   Shi ZJ, 2017, INT J NEUROSCI, V127, P1104, DOI 10.1080/00207454.2017.1323208
   Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387
   Sohn EJ, 2018, CANCER CELL INT, V18, DOI 10.1186/s12935-017-0500-0
   Takayama KI, 2017, CANCERS, V9, pE102
   Vera-Ramirez L, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04070-6
   Wang Q, 2018, EXP THER MED, V15, P3028, DOI 10.3892/etm.2018.5792
   Wu SJ, 2018, ONCOTARGETS THER, V11, P2593, DOI 10.2147/OTT.S157707
   Xu S, 2017, BIOMED PHARMACOTHER, V96, P634, DOI 10.1016/j.biopha.2017.10.037
   Yang CL, 2018, CELL PHYSIOL BIOCHEM, V46, P93, DOI 10.1159/000488412
   Yang JL, 2018, BIOMED PHARMACOTHER, V103, P699, DOI 10.1016/j.biopha.2018.04.072
   Yang ZNJ, 2011, MOL CANCER THER, V10, P1533, DOI 10.1158/1535-7163.MCT-11-0047
   Yu X, 2018, ONCOTARGETS THER, V11, P1833, DOI 10.2147/OTT.S155716
   Yu X, 2016, J CELL MOL MED, V20, P10, DOI 10.1111/jcmm.12650
   Zhao N, 2019, J CELL BIOCHEM, V120, P12070, DOI 10.1002/jcb.26417
   Zhu YZ, 2017, AM J CANCER RES, V7, P1136
NR 48
TC 25
Z9 27
U1 1
U2 16
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
SN 1945-4589
J9 AGING-US
JI Aging-US
PD AUG
PY 2018
VL 10
IS 8
BP 2113
EP 2121
DI 10.18632/aging.101534
PG 9
WC Cell Biology; Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Geriatrics & Gerontology
GA GS1RN
UT WOS:000443308900026
PM 30153654
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Liu, JZ
   Hu, YL
   Feng, Y
   Guo, YB
   Li, YF
   Yang, JL
   Mao, QS
   Xue, WJ
AF Liu, Jia-Zhou
   Hu, Yi-Lin
   Feng, Ying
   Guo, Yi-Bing
   Li, Yi-Fei
   Yang, Jun-Ling
   Mao, Qin-Sheng
   Xue, Wan-Jiang
TI Rafoxanide promotes apoptosis and autophagy of gastric cancer cells by
   suppressing PI3K /Akt/mTOR pathway
SO EXPERIMENTAL CELL RESEARCH
LA English
DT Article
DE Rafoxanide; Gastric cancer; PI3K; Apoptosis; Autophagy
ID IMMATURE FASCIOLA-HEPATICA; DOUBLE-EDGED-SWORD; POOR-PROGNOSIS; DEATH;
   INHIBITION; ACTIVATION; EXPRESSION; RESISTANCE; CLOSANTEL; STRESS
AB Rafoxanide is commonly used as anti-helminthic medicine in veterinary medicine, a main compound of salicylanilide. Previous studies have reported that rafoxanide, as an inhibitor of BRAF V600E mutant protein, inhibits the growth of colorectal cancer, multiple myeloma, and skin cancer. However, its therapeutic effect on gastric cancer (GC) and the potential mechanism has not been investigated. Here, we have found that rafoxanide inhibited the proliferation of GC cells in vitro, arrested the cell cycle in the G0/G1 phase, and promoted apoptosis and autophagy in GC cells. Treatment with specific autophagy inhibitor 3-methyladenine drastically inhibited the apoptotic cell death effect by suppressing the switch from autophagy to apoptosis. Mechanistically, we found that rafoxanide inhibited the growth of GC cells in vitro by inhibiting the activity of the PI3K/Akt/mTOR signaling pathway. This process induced autophagy, which essentially resulted in the apoptosis of GC cells. Results from subcutaneous implanted tumor models in nude mice also indicated that rafoxanide inhibited the growth of GC cells in vivo. Taken together, our findings revealed that rafoxanide inhibited the growth of GC cells both in vitro and vivo, indicating a potential drug candidate for the treatment of GC.
C1 [Liu, Jia-Zhou; Hu, Yi-Lin; Feng, Ying; Mao, Qin-Sheng; Xue, Wan-Jiang] Nantong Univ, Affiliated Hosp, Dept Gastrointestinal Surg, 20 Xisi St, Nantong 226001, Peoples R China.
   [Liu, Jia-Zhou; Hu, Yi-Lin; Feng, Ying; Guo, Yi-Bing; Yang, Jun-Ling; Xue, Wan-Jiang] Nantong Univ, Affiliated Hosp, Res Ctr Clin Med, 20 Xisi St, Nantong 226001, Peoples R China.
   [Li, Yi-Fei] Nantong Univ, Affiliated Hosp, Dept Pathol, 20 Xisi St, Nantong 226001, Peoples R China.
RP Mao, QS; Xue, WJ (corresponding author), Nantong Univ, Affiliated Hosp, Dept Gastrointestinal Surg, 20 Xisi St, Nantong 226001, Peoples R China.
EM tdfymaoqsh@sina.com; xuewanjiang@ntu.edu.cn
OI Guo, Yibing/0000-0001-9723-0678
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81672409]; China Postdoctoral Science
   FoundationChina Postdoctoral Science Foundation [2016M590489,
   2017T100393]; Postdoctoral Science Foundation of Jiangsu ProvinceChina
   Postdoctoral Science Foundation [1601101C]; Jiangsu Provincial Medical
   Youth Talent [QNRC2016700]; Scientific and Technological Innovation and
   Demonstration Project of Nantong City [MS32016018, M512017001-6,
   MS12017007-5, MS12017008-5]; "333 Talent" Cultivating Project of Jiangsu
   Province [BRA2018394]; Postgraduate Research & Practice Innovation
   Program of Jiangsu Province [SJCX18_0831]
FX This work was supported by the National Natural Science Foundation of
   China (No. 81672409), China Postdoctoral Science Foundation
   (2016M590489, 2017T100393), Postdoctoral Science Foundation of Jiangsu
   Province (1601101C), Jiangsu Provincial Medical Youth Talent
   (QNRC2016700), Scientific and Technological Innovation and Demonstration
   Project of Nantong City (MS32016018, M512017001-6, MS12017007-5, and
   MS12017008-5), "333 Talent" Cultivating Project of Jiangsu Province
   (BRA2018394), and Postgraduate Research & Practice Innovation Program of
   Jiangsu Province (SJCX18_0831).
CR AlAmri MA, 2017, CHEMMEDCHEM, V12, P639, DOI 10.1002/cmdc.201700077
   Apel A, 2009, INT J CANCER, V125, P991, DOI 10.1002/ijc.24500
   ARMOUR J, 1970, VET REC, V87, P213, DOI 10.1136/vr.87.7.213
   Bai T, 2017, BRIT J CANCER, V116, P1177, DOI 10.1038/bjc.2017.76
   Boya P, 2013, NAT CELL BIOL, V15, P713, DOI 10.1038/ncb2788
   Chen HY, 2011, CANCER PREV RES, V4, P973, DOI 10.1158/1940-6207.CAPR-10-0387
   Clavel M, 2017, TRENDS PLANT SCI, V22, P646, DOI 10.1016/j.tplants.2017.06.007
   Coccolini Federico, 2018, Acta Biomed, V89, P104, DOI 10.23750/abm.v89i8-S.7904
   Cui SQ, 2019, TOXICOLOGY, V426, DOI 10.1016/j.tox.2019.152267
   Domalaon R, 2019, J ANTIBIOT, V72, P605, DOI 10.1038/s41429-019-0186-8
   Emhemmed F, 2014, BIOCHEM PHARMACOL, V89, P185, DOI 10.1016/j.bcp.2014.02.020
   Ge J, 2009, DIGESTION, V80, P148, DOI 10.1159/000226089
   Grille SJ, 2003, CANCER RES, V63, P2172
   Hoves S, 2003, METHODS, V31, P127, DOI 10.1016/S1046-2023(03)00122-1
   Hu YL, 2019, EXP CELL RES, V381, P66, DOI 10.1016/j.yexcr.2019.04.030
   Jeong S, 2019, CANCERS BASEL, V11
   Jung S, 2020, AUTOPHAGY, V16, P512, DOI 10.1080/15548627.2019.1630222
   Kakeya H, 2003, BIOORG MED CHEM LETT, V13, P3743, DOI 10.1016/j.bmcl.2003.08.003
   Kinsey CG, 2019, NAT MED, V25, P861, DOI 10.1038/s41591-019-0433-3
   Lamb CA, 2013, NAT REV MOL CELL BIO, V14, P759, DOI 10.1038/nrm3696
   Laudisi F, 2019, CANCER LETT, V462, P1, DOI 10.1016/j.canlet.2019.07.014
   Lei BL, 2019, CHEMOSPHERE, V220, P362, DOI 10.1016/j.chemosphere.2018.12.122
   Li YS, 2016, SCI REP-UK, V6, DOI 10.1038/srep31074
   Liu XR, 2015, EUR REV MED PHARMACO, V19, P4068
   Marrugal-Lorenzo JA, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-37290-3
   Mirza-Aghazadeh-Attari M, 2019, J CELL PHYSIOL, V234, P17011, DOI 10.1002/jcp.28435
   Mujtaba SF, 2019, J PHOTOCH PHOTOBIO B, V196, DOI 10.1016/j.jphotobiol.2019.05.004
   Pak S, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1342-5
   Park G.B., 2019, MAR DRUGS, V17
   PRESIDENTE PJ, 1972, AM J VET RES, V33, P1603
   PRICHARD RK, 1978, PARASITOLOGY, V76, P277, DOI 10.1017/S0031182000048150
   Sarathbabu S, 2019, ANTI-CANCER AGENT ME, V19, P337, DOI 10.2174/1871520619666181127113848
   Schlosser SF, 2003, ANTIMICROB AGENTS CH, V47, P1912, DOI 10.1128/AAC.47.6.1912-1921.2003
   Schwarz RE, 2015, J GASTROINTEST SURG, V19, P782, DOI 10.1007/s11605-014-2707-x
   Shi XN, 2018, ONCOL REP, V40, P1592, DOI 10.3892/or.2018.6533
   Tharmalingam N, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-22037-x
   Vegliante R, 2016, CARCINOGENESIS, V37, P233, DOI 10.1093/carcin/bgw003
   Wang K, 2019, LIFE SCI, V233, DOI 10.1016/j.lfs.2019.116687
   Wang M, 2019, BIOMED PHARMACOTHER, V118, DOI 10.1016/j.biopha.2019.109316
   Wang WQ, 2010, MOL DIAGN THER, V14, P155, DOI 10.2165/11536340-000000000-00000
   Wang XY, 2019, J CELL MOL MED, V23, P5349, DOI 10.1111/jcmm.14413
   Wang ZM, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01450
   Xiao WQ, 2019, CANCER LETT, V444, P45, DOI 10.1016/j.canlet.2018.12.014
   Xiong JJ, 2017, EXP CELL RES, V361, P316, DOI 10.1016/j.yexcr.2017.10.033
   Ye T, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-5852-5
   YURDAKOK M, 1985, Mikrobiyoloji Bulteni, V19, P38
NR 46
TC 13
Z9 13
U1 1
U2 18
PU ELSEVIER INC
PI SAN DIEGO
PA 525 B STREET, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0014-4827
EI 1090-2422
J9 EXP CELL RES
JI Exp. Cell Res.
PD DEC 15
PY 2019
VL 385
IS 2
AR 111691
DI 10.1016/j.yexcr.2019.111691
PG 12
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA JU0XU
UT WOS:000501403300008
PM 31678170
DA 2022-04-25
ER

PT J
AU Zhao, Z
   Han, FH
   Yang, SB
   Wu, JH
   Zhan, WH
AF Zhao, Zhi
   Han, Fanghai
   Yang, Shibin
   Wu, Jianhai
   Zhan, Wenhua
TI Oxamate-mediated inhibition of lactate dehydrogenase induces protective
   autophagy in gastric cancer cells: Involvement of the Akt-mTOR signaling
   pathway
SO CANCER LETTERS
LA English
DT Article
DE Gastric cancer; Glycolysis; Lactate dehydrogenase; Oxamate; Autophagy
ID POOR-PROGNOSIS; COLORECTAL-CANCER; IN-VITRO; EXPRESSION; ASSOCIATION;
   HIF-1-ALPHA; METABOLISM; CARCINOMA; APOPTOSIS; SURVIVAL
AB Cancer cells produce a substantial amount of energy through aerobic glycolysis even in the presence of adequate oxygen. Lactate dehydrogenase (LDH), a key regulator of glycolysis, reversibly catalyzes the conversion of pyruvate to lactate. Recently, oxamate, an inhibitor of LDH, has been shown to be a promising anticancer agent. However, the detailed mechanism remains largely unclear. In this study, we demonstrate that oxamate inhibits the viability of human gastric cancer cells in a dose- and time-dependent manner. In addition, treatment with oxamate induces protective autophagy in gastric cancer cells. Moreover, autophagy inhibited by chloroquine or Beclin 1 small interfering RNA (siRNA) enhances oxamateinduced apoptosis and proliferation inhibition. Further study has shown that oxamate treatment significantly augments reactive oxygen species (ROS) production. Furthermore, cells pretreated with N-acetyl cyste(NAC), a ROS inhibitor, display significantly reduced ROS production and attenuated oxamateinduced autophagy. Finally, functional studies reveal that the Akt mTOR signaling pathway, a major negative regulator of autophagy, is inhibited by oxamate. Together, our results provide new insights regarding the biological and anti-proliferative activities of oxamate against gastric cancer, and may offer a promising therapeutic strategy for gastric cancer. (C) 2014 Elsevier Ireland Ltd. All rights reserved.
C1 [Zhao, Zhi; Han, Fanghai; Yang, Shibin; Wu, Jianhai; Zhan, Wenhua] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Gastrointestinal Surg, Guangzhou 510080, Guangdong, Peoples R China.
RP Han, FH (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 1, Dept Gastrointestinal Surg, Guangzhou 510080, Guangdong, Peoples R China.
EM FH_Han@163.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81072049]
FX This study was supported by the National Natural Science Foundation of
   China (No.81072049).
CR Altomare DA, 2004, ONCOGENE, V23, P5853, DOI 10.1038/sj.onc.1207721
   Amornphimoltham P, 2005, CANCER RES, V65, P9953, DOI 10.1158/0008-5472.CAN-05-0921
   Boya P, 2008, ONCOGENE, V27, P6434, DOI 10.1038/onc.2008.310
   Ding ZB, 2011, CLIN CANCER RES, V17, P6229, DOI 10.1158/1078-0432.CCR-11-0816
   Fiume L, 2011, PHARMACOL RES, V63, P328, DOI 10.1016/j.phrs.2010.12.005
   Fotakis G, 2006, TOXICOL LETT, V160, P171, DOI 10.1016/j.toxlet.2005.07.001
   Fujiwara S, 2013, BRIT J CANCER, V108, P170, DOI 10.1038/bjc.2012.527
   Guo JY, 2013, CELL, V155, P1216, DOI 10.1016/j.cell.2013.11.019
   Han Y, 2014, ASIAN PAC J CANCER P, V15, P4583, DOI 10.7314/APJCP.2014.15.11.4583
   Hartgrink HH, 2009, LANCET, V374, P477, DOI 10.1016/S0140-6736(09)60617-6
   Huang J, 2011, ANTIOXID REDOX SIGN, V14, P2215, DOI 10.1089/ars.2010.3554
   Jemal A, 2010, CANCER EPIDEM BIOMAR, V19, P1893, DOI 10.1158/1055-9965.EPI-10-0437
   Kolev Y, 2008, ANN SURG ONCOL, V15, P2336, DOI 10.1245/s10434-008-9955-5
   Koppenol WH, 2011, NAT REV CANCER, V11, P325, DOI 10.1038/nrc3038
   Koukourakis MI, 2003, BRIT J CANCER, V89, P877, DOI 10.1038/sj.bjc.6601205
   Koukourakis MI, 2006, J CLIN ONCOL, V24, P4301, DOI 10.1200/JCO.2006.05.9501
   Kroemer G, 2005, NAT MED, V11, P725, DOI 10.1038/nm1263
   Kroemer G, 2010, MOL CELL, V40, P280, DOI 10.1016/j.molcel.2010.09.023
   Kunz PL, 2012, J CLIN ONCOL, V30, P3507, DOI 10.1200/JCO.2011.35.8028
   Levine B, 2011, NATURE, V469, P323, DOI 10.1038/nature09782
   Li J, 2010, EUR J CANCER, V46, P1900, DOI 10.1016/j.ejca.2010.02.021
   Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009
   Marino G, 2014, NAT REV MOL CELL BIO, V15, P81, DOI 10.1038/nrm3735
   Mukhopadhyay S, 2014, APOPTOSIS, V19, P555, DOI 10.1007/s10495-014-0967-2
   Nagelkerke A, 2014, SEMIN CANC BIOL
   Rao S, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4056
   Scherz-Shouval R, 2011, TRENDS BIOCHEM SCI, V36, P30, DOI 10.1016/j.tibs.2010.07.007
   Shi Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051076
   Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166
   Sishi BJN, 2013, BIOCHEM PHARMACOL, V85, P124, DOI 10.1016/j.bcp.2012.10.005
   Strohecker AM, 2014, AUTOPHAGY, V10, P384, DOI 10.4161/auto.27320
   Thornburg JM, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2154
   Torgersen ML, 2013, BLOOD, V122, P2467, DOI 10.1182/blood-2013-05-500629
   Vernon PJ, 2013, ANTIOXID REDOX SIGN, V18, P677, DOI 10.1089/ars.2012.4810
   Wan XB, 2010, AUTOPHAGY, V6, P395, DOI 10.4161/auto.6.3.11303
   White E, 2012, NAT REV CANCER, V12, P401, DOI 10.1038/nrc3262
   Zhang YJ, 2012, CANCER LETT, V321, P45, DOI 10.1016/j.canlet.2012.03.013
   Zhao Z, 2014, EJSO-EUR J SURG ONC, V40, P1361, DOI 10.1016/j.ejso.2014.04.005
NR 38
TC 87
Z9 91
U1 5
U2 55
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0304-3835
EI 1872-7980
J9 CANCER LETT
JI Cancer Lett.
PD MAR 1
PY 2015
VL 358
IS 1
BP 17
EP 26
DI 10.1016/j.canlet.2014.11.046
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA CB3DB
UT WOS:000349507300003
PM 25524555
DA 2022-04-25
ER

PT J
AU Takhsha, FS
   Vangestel, C
   Tanc, M
   De Bruycker, S
   Berg, M
   Pintelon, I
   Stroobants, S
   De Meyer, GRY
   van der Veken, P
   Martinet, W
AF Takhsha, Farnaz Sedigheh
   Vangestel, Christel
   Tanc, Muhammet
   De Bruycker, Sven
   Berg, Maya
   Pintelon, Isabel
   Stroobants, Sigrid
   De Meyer, Guido R. Y.
   van der Veken, Pieter
   Martinet, Wim
TI ATG4B Inhibitor UAMC-2526 Potentiates the Chemotherapeutic Effect of
   Gemcitabine in a Panc02 Mouse Model of Pancreatic Ductal Adenocarcinoma
SO FRONTIERS IN ONCOLOGY
LA English
DT Article
DE pancreatic ductal adenocarcinoma; autophagy; ATG4B; UAMC-2526;
   gemcitabine; proliferation; Panc02
ID CANCER-CELLS; AUTOPHAGY; PROLIFERATION; RESISTANCE; HYPOXIA; TARGET;
   MTOR
AB Resistance against anti-cancer therapy is one of the major challenges during treatment of multiple cancers. Gemcitabine is a standard first-line chemotherapeutic drug, yet autophagy is highly activated in the hypoxic microenvironment of solid tumors and enhances the survival of tumor cells against gemcitabine chemotherapy. Recently, we showed the add-on effect of autophagy inhibitor UAMC-2526 to prevent HT-29 colorectal tumor growth in CD1(-/-) Foxn1nu mice treated with oxaliplatin. In this study, we aimed to investigate the potential beneficial effects of UAMC-2526 in a syngeneic Panc02 mouse model of pancreatic ductal adenocarcinoma (PDAC). Our data showed that UAMC-2526 combined with gemcitabine significantly reduced tumor growth as compared to the individual treatments. However, in contrast to in vitro experiments with Panc02 cells in culture, we were unable to detect autophagy inhibition by UAMC-2526 in Panc02 tumor tissue, neither via western blot analysis of autophagy markers LC3 and p62, nor by transmission electron microscopy. In vitro experiments revealed that UAMC-2526 enhances the potential of gemcitabine to inhibit Panc02 cell proliferation without obvious induction of cell death. Altogether, we conclude that although the combination treatment of UAMC-2526 with gemcitabine did not inhibit autophagy in the Panc02 mouse model, it has a beneficial effect on tumor growth inhibition.
C1 [Takhsha, Farnaz Sedigheh; De Meyer, Guido R. Y.; Martinet, Wim] Univ Antwerp, Lab Physiopharmacol, Antwerp, Belgium.
   [Vangestel, Christel; De Bruycker, Sven; Stroobants, Sigrid] Univ Antwerp, Mol Imaging Ctr Antwerp MICA, Antwerp, Belgium.
   [Vangestel, Christel; Stroobants, Sigrid] Univ Antwerp Hosp, Dept Nucl Med, Edegem, Belgium.
   [Tanc, Muhammet; van der Veken, Pieter] Univ Antwerp, Lab Med Chem, Antwerp, Belgium.
   [Tanc, Muhammet] Kings Coll London, Dept Imaging Chem & Biol, London, England.
   [De Bruycker, Sven] AP Univ Appl Sci & Arts Antwerp, Dept Sci & Technol, Antwerp, Belgium.
   [Berg, Maya; De Meyer, Guido R. Y.; van der Veken, Pieter; Martinet, Wim] Univ Antwerp, Infla Med Ctr Excellence, Antwerp, Belgium.
   [Pintelon, Isabel] Univ Antwerp, Lab Cell Biol & Histol, Antwerp, Belgium.
RP Martinet, W (corresponding author), Univ Antwerp, Lab Physiopharmacol, Antwerp, Belgium.; Martinet, W (corresponding author), Univ Antwerp, Infla Med Ctr Excellence, Antwerp, Belgium.
RI Van der Veken, Pieter/P-5819-2016
OI Van der Veken, Pieter/0000-0003-1208-3571
CR Akin D, 2014, AUTOPHAGY, V10, P2021, DOI 10.4161/auto.32229
   Andor N, 2016, NAT MED, V22, P105, DOI 10.1038/nm.3984
   Apel A, 2008, CANCER RES, V68, P1485, DOI 10.1158/0008-5472.CAN-07-0562
   Ben-Josef E, 2008, INT J CLIN ONCOL, V13, P121, DOI 10.1007/s10147-007-0763-x
   Bortnik S, 2016, ONCOTARGET, V7, P66970, DOI 10.18632/oncotarget.11408
   Chen Q, 2018, SIGNAL TRANSDUCT TAR, V3, DOI 10.1038/s41392-018-0018-5
   Chu JQ, 2018, ARCH BIOCHEM BIOPHYS, V644, P29, DOI 10.1016/j.abb.2018.03.001
   CORBETT TH, 1984, CANCER RES, V44, P717
   Cufi S, 2013, SCI REP-UK, V3, DOI 10.1038/srep02469
   Cunningham D, 2009, J CLIN ONCOL, V27, P5513, DOI 10.1200/JCO.2009.24.2446
   Donohue E, 2013, J CANCER, V4, P585, DOI 10.7150/jca.7030
   Dowling RJO, 2010, BBA-PROTEINS PROTEOM, V1804, P433, DOI 10.1016/j.bbapap.2009.12.001
   Frake RA, 2015, J CLIN INVEST, V125, P65, DOI 10.1172/JCI73944
   Fujii S, 2008, CANCER SCI, V99, P1813, DOI 10.1111/j.1349-7006.2008.00893.x
   Fukuda T, 2015, GYNECOL ONCOL, V137, P538, DOI 10.1016/j.ygyno.2015.03.053
   Garber K, 2011, J NATL CANCER I, V103, P708, DOI 10.1093/jnci/djr168
   Gerlinger M, 2010, BRIT J CANCER, V103, P1139, DOI 10.1038/sj.bjc.6605912
   Huang TZ, 2017, CANCER CELL, V32, P840, DOI 10.1016/j.ccell.2017.11.005
   Jamal-Hanjani M, 2015, CLIN CANCER RES, V21, P1258, DOI 10.1158/1078-0432.CCR-14-1429
   Jiang M, 2010, AM J PATHOL, V176, P1181, DOI 10.2353/ajpath.2010.090594
   Kamisawa T, 2016, LANCET, V388, P73, DOI 10.1016/S0140-6736(16)00141-0
   Kim YC, 2015, J CLIN INVEST, V125, P25, DOI 10.1172/JCI73939
   Kleeff J, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.22
   Koong AC, 2000, INT J RADIAT ONCOL, V48, P919, DOI 10.1016/S0360-3016(00)00803-8
   Kurdi A, 2017, BIOCHEM PHARMACOL, V138, P150, DOI 10.1016/j.bcp.2017.06.119
   Lavandero S, 2013, AUTOPHAGY, V9, P1455, DOI 10.4161/auto.25969
   Li M, 2011, J BIOL CHEM, V286, P7327, DOI 10.1074/jbc.M110.199059
   Li XF, 2014, TRANSL ONCOL, V7, P240, DOI 10.1016/j.tranon.2014.02.010
   Liu PF, 2018, THERANOSTICS, V8, P830, DOI 10.7150/thno.22012
   Maes H, 2013, TRENDS MOL MED, V19, P428, DOI 10.1016/j.molmed.2013.04.005
   Martinet W, 2014, METHOD ENZYMOL, V543, P89, DOI 10.1016/B978-0-12-801329-8.00005-2
   Nakatogawa H, 2007, CELL, V130, P165, DOI 10.1016/j.cell.2007.05.021
   Ohsumi Y, 2014, CELL RES, V24, P9, DOI 10.1038/cr.2013.169
   Perera R, 2015, NATURE, V524, P361, DOI 10.1038/nature14587
   Rabinowitz JD, 2010, SCIENCE, V330, P1344, DOI 10.1126/science.1193497
   Rosenfeld MR, 2014, AUTOPHAGY, V10, P1359, DOI 10.4161/auto.28984
   Rothe K, 2014, BLOOD, V123, P3622, DOI 10.1182/blood-2013-07-516807
   Schniewind B, 2004, INT J CANCER, V109, P182, DOI 10.1002/ijc.11679
   Sehgal A, 2003, CURR MED CHEM, V10, P749, DOI 10.2174/0929867033457764
   Selvakumaran M, 2013, CLIN CANCER RES, V19, P2995, DOI 10.1158/1078-0432.CCR-12-1542
   Seo JW, 2016, SCI REP-UK, V6, DOI 10.1038/srep37594
   Settembre C, 2014, TRENDS CELL BIOL, V24, P743, DOI 10.1016/j.tcb.2014.06.006
   Shibaji T, 2003, ANTICANCER RES, V23, P4721
   Siegel RL, 2019, CA-CANCER J CLIN, V69, P7, DOI 10.3322/caac.21551
   Singhi AD, 2019, GASTROENTEROLOGY, V156, P2024, DOI 10.1053/j.gastro.2019.01.259
   Sui X, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.350
   Tehrani Rodney, 2008, Semin Ophthalmol, V23, P201, DOI 10.1080/08820530802049962
   Vakkila J, 2004, NAT REV IMMUNOL, V4, P641, DOI 10.1038/nri1415
   Von Hoff DD, 2013, NEW ENGL J MED, V369, P1691, DOI 10.1056/NEJMoa1304369
   White E, 2015, J CLIN INVEST, V125, P42, DOI 10.1172/JCI73941
   Yang YP, 2013, ACTA PHARMACOL SIN, V34, P625, DOI 10.1038/aps.2013.5
   Yao F, 2012, MOL MED REP, V5, P84, DOI 10.3892/mmr.2011.590
   Zhang GJ, 2015, J NUCL MED, V56, P607, DOI 10.2967/jnumed.114.148254
   Zhang L, 2016, CANCER LETT, V373, P19, DOI 10.1016/j.canlet.2016.01.022
NR 54
TC 0
Z9 0
U1 6
U2 6
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2234-943X
J9 FRONT ONCOL
JI Front. Oncol.
PD NOV 18
PY 2021
VL 11
AR 750259
DI 10.3389/fonc.2021.750259
PG 14
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA XI6FG
UT WOS:000726204300001
PM 34868951
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Auger, C
   Christou, N
   Brunel, A
   Perraud, A
   Verdier, M
AF Auger, Clement
   Christou, Niki
   Brunel, Aude
   Perraud, Aurelie
   Verdier, Mireille
TI Autophagy and Extracellular Vesicles in Colorectal Cancer: Interactions
   and Common Actors?
SO CANCERS
LA English
DT Review
DE autophagy; extracellular vesicles; secretory autophagy; rab-GTPases;
   colorectal cancer
ID UNCONVENTIONAL SECRETORY PATHWAY; MULTIVESICULAR BODIES; STEM-CELLS;
   EXOSOMES; BIOGENESIS; PROTEINS; MICROVESICLES; RELEASE; FUSION;
   COMMUNICATION
AB Simple Summary
   Cancer stem cells (CSCs) are known for their ability to survive under stressful conditions. To this aim, they use autophagy to recycle their altered organelles and proteins by addressing them toward a lysosome for their degradation. CSCs can also communicate with their environment using the secretion of extracellular vesicles (EVs) which carry information, strengthening their ability to survive under such conditions. Both mechanisms are known for using common actors and have been described as implicated in colorectal cancer (CRC). However, CSCs remain difficult to target due to the lack of specific markers identified, especially in colorectal cancer. Then, the study of the crosstalk between autophagy and the secretion of EVs seems crucial regarding a better targeting of CSCs.
   Autophagy is a homeostatic process involved in the degradation of disabled proteins and organelles using lysosomes. This mechanism requires the recruitment of specialized proteins for vesicle trafficking, that may also be involved in other types of machinery such as the biogenesis and secretion of extracellular vesicles (EVs), and particularly small EVs called exosomes. Among these proteins, Rab-GTPases may operate in both pathways, thus representing an interesting avenue for further study regarding the interaction between autophagy and extracellular vesicle machinery. Both mechanisms are involved in the development of colorectal cancer (CRC), particularly in cancer stem cell (CSC) survival and communication, although they are not specific to CRC or CSCs. This highlights the importance of studying the crosstalk between autophagy and EVs biogenesis and release.
C1 [Auger, Clement; Christou, Niki; Brunel, Aude; Perraud, Aurelie; Verdier, Mireille] Univ Limoges, GEIST, Fac Med, CAPTuR,EA 3842, 2 Rue Dr Marcland, F-87025 Limoges, France.
   [Christou, Niki; Perraud, Aurelie] Limoges Univ Hosp, Endocrine Gen & Digest Surg Dept, 2 Rue Martin Luther King, F-87042 Limoges, France.
RP Christou, N (corresponding author), Univ Limoges, GEIST, Fac Med, CAPTuR,EA 3842, 2 Rue Dr Marcland, F-87025 Limoges, France.; Christou, N (corresponding author), Limoges Univ Hosp, Endocrine Gen & Digest Surg Dept, 2 Rue Martin Luther King, F-87042 Limoges, France.
EM clement.auger@unilim.fr; christou.niki19@gmail.com;
   aude.brunel@unilim.fr; aurelie.perraud@unilim.fr;
   mireille.verdier@unilim.fr
OI VERDIER, Mireille/0000-0002-8162-4856; CHRISTOU,
   Niki/0000-0003-2125-0503; Auger, Clement/0000-0001-5260-535X; Perraud,
   Aurelie/0000-0001-7882-0613
CR Adnan M, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8040337
   Al-Nedawi K, 2008, NAT CELL BIOL, V10, P619, DOI 10.1038/ncb1725
   Alers S, 2012, MOL CELL BIOL, V32, P2, DOI 10.1128/MCB.06159-11
   Ao X, 2014, CELL DEATH DIFFER, V21, P348, DOI 10.1038/cdd.2013.187
   Babst M, 2011, CURR OPIN CELL BIOL, V23, P452, DOI 10.1016/j.ceb.2011.04.008
   Bader CA, 2015, BIOL OPEN, V4, P1345, DOI 10.1242/bio.013979
   Baietti MF, 2012, NAT CELL BIOL, V14, P677, DOI 10.1038/ncb2502
   Becker A, 2016, CANCER CELL, V30, P836, DOI 10.1016/j.ccell.2016.10.009
   Beckler MD, 2013, MOL CELL PROTEOMICS, V12, P343, DOI 10.1074/mcp.M112.022806
   Bel S, 2017, SCIENCE, V357, P1047, DOI 10.1126/science.aal4677
   Blanc Lionel, 2018, Small GTPases, V9, P95, DOI 10.1080/21541248.2016.1264352
   Chen L, 2018, J CELL COMMUN SIGNAL, V12, P343, DOI 10.1007/s12079-017-0421-7
   Chen YD, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-06076-4
   Chiarugi P, 2008, BIOCHEM PHARMACOL, V76, P1352, DOI 10.1016/j.bcp.2008.07.023
   Cho JA, 2012, INT J ONCOL, V40, P130, DOI 10.3892/ijo.2011.1193
   Colombo M, 2014, ANNU REV CELL DEV BI, V30, P255, DOI 10.1146/annurev-cellbio-101512-122326
   Colombo M, 2013, J CELL SCI, V126, P5553, DOI 10.1242/jcs.128868
   Devenport SN, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8111349
   Dupont N, 2011, EMBO J, V30, P4701, DOI 10.1038/emboj.2011.398
   Ejlerskov P, 2013, J BIOL CHEM, V288, P17313, DOI 10.1074/jbc.M112.401174
   Fader CM, 2008, TRAFFIC, V9, P230, DOI 10.1111/j.1600-0854.2007.00677.x
   Fujita N, 2008, MOL BIOL CELL, V19, P4651, DOI 10.1091/mbc.E08-03-0312
   Fung C, 2008, MOL BIOL CELL, V19, P797, DOI 10.1091/mbc.E07-10-1092
   Galluzzi L, 2017, EMBO J, V36, P1811, DOI 10.15252/embj.201796697
   Galluzzi L, 2015, EMBO J, V34, P856, DOI 10.15252/embj.201490784
   Gong C, 2013, ONCOGENE, V32, P2261, DOI 10.1038/onc.2012.252
   Gross JC, 2012, NAT CELL BIOL, V14, P1036, DOI 10.1038/ncb2574
   Gudbergsson JM, 2019, J CELL COMMUN SIGNAL, V13, P443, DOI 10.1007/s12079-019-00524-8
   Guo HS, 2018, MOL CELL ONCOL, V5, DOI 10.1080/23723556.2018.1445941
   Guo HS, 2017, DEV CELL, V43, P716, DOI 10.1016/j.devcel.2017.11.018
   Gyorgy B, 2011, CELL MOL LIFE SCI, V68, P2667, DOI 10.1007/s00018-011-0689-3
   Henne WM, 2011, DEV CELL, V21, P77, DOI 10.1016/j.devcel.2011.05.015
   Henne WM, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a016766
   Hessvik NP, 2018, CELL MOL LIFE SCI, V75, P193, DOI 10.1007/s00018-017-2595-9
   Hu YL, 2012, CANCER RES, V72, P1773, DOI 10.1158/0008-5472.CAN-11-3831
   Huang Tianzhi, 2018, Critical Reviews in Oncogenesis, V23, P247, DOI 10.1615/CritRevOncog.2018027913
   Huotari J, 2011, EMBO J, V30, P3481, DOI 10.1038/emboj.2011.286
   Hurley JH, 2015, EMBO J, V34, P2398, DOI 10.15252/embj.201592484
   Itakura E, 2012, CELL, V151, P1256, DOI 10.1016/j.cell.2012.11.001
   Kenific CM, 2010, CURR OPIN CELL BIOL, V22, P241, DOI 10.1016/j.ceb.2009.10.008
   Kimura T, 2017, EMBO J, V36, P42, DOI 10.15252/embj.201695081
   Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717
   Koustas E, 2019, CANCERS, V11, DOI 10.3390/cancers11040533
   Kowal J, 2014, CURR OPIN CELL BIOL, V29, P116, DOI 10.1016/j.ceb.2014.05.004
   Kroemer G, 2010, MOL CELL, V40, P280, DOI 10.1016/j.molcel.2010.09.023
   Kumar D, 2015, ONCOTARGET, V6, P3280, DOI 10.18632/oncotarget.2462
   Lauzier A, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-47659-7
   Leidal AM, 2020, NAT CELL BIOL, V22, P187, DOI 10.1038/s41556-019-0450-y
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Levine B, 2019, CELL, V176, P11, DOI 10.1016/j.cell.2018.09.048
   Levy JMM, 2017, NAT REV CANCER, V17, P528, DOI 10.1038/nrc.2017.53
   Li J, 2013, CARCINOGENESIS, V34, P1343, DOI 10.1093/carcin/bgt063
   Lindoso Rafael Soares, 2017, Stem Cell Investig, V4, P75, DOI 10.21037/sci.2017.08.08
   Liu J, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17040531
   Lucchetti D, 2017, AM J PATHOL, V187, P1633, DOI 10.1016/j.ajpath.2017.03.015
   Lugini L, 2016, ONCOTARGET, V7, P50086, DOI 10.18632/oncotarget.10574
   Fader CM, 2009, BBA-MOL CELL RES, V1793, P1901, DOI 10.1016/j.bbamcr.2009.09.011
   Mathew R, 2007, NAT REV CANCER, V7, P961, DOI 10.1038/nrc2254
   Mathew R, 2007, GENE DEV, V21, P1367, DOI 10.1101/gad.1545107
   Mazouffre C, 2017, J CELL MOL MED, V21, P2610, DOI 10.1111/jcmm.13181
   Migneault F., 2021, MATRIX BIOL
   Mizushima N, 2007, GENE DEV, V21, P2861, DOI 10.1101/gad.1599207
   Mizushima N, 2011, ANNU REV CELL DEV BI, V27, P107, DOI 10.1146/annurev-cellbio-092910-154005
   Mokarram P, 2017, AUTOPHAGY, V13, P781, DOI 10.1080/15548627.2017.1290751
   Mowers EE, 2017, ONCOGENE, V36, P1619, DOI 10.1038/onc.2016.333
   Mowers EE, 2018, FEBS J, V285, P1751, DOI 10.1111/febs.14388
   Murrow L, 2015, NAT CELL BIOL, V17, P300, DOI 10.1038/ncb3112
   Nilsson P, 2013, CELL REP, V5, P61, DOI 10.1016/j.celrep.2013.08.042
   Onorati AV, 2018, CANCER-AM CANCER SOC, V124, P3307, DOI 10.1002/cncr.31335
   Ostrowski M, 2010, NAT CELL BIOL, V12, P19, DOI 10.1038/ncb2000
   Patel KK, 2013, EMBO J, V32, P3130, DOI 10.1038/emboj.2013.233
   Perez-Hernandez D, 2013, J BIOL CHEM, V288, P11649, DOI 10.1074/jbc.M112.445304
   Pinet S, 2016, ONCOTARGET, V7, P50349, DOI 10.18632/oncotarget.10387
   Ponpuak M, 2015, CURR OPIN CELL BIOL, V35, P106, DOI 10.1016/j.ceb.2015.04.016
   Quaglia M, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00074
   Raiborg C, 2009, NATURE, V458, P445, DOI 10.1038/nature07961
   Raposo G, 2013, J CELL BIOL, V200, P373, DOI 10.1083/jcb.201211138
   Ravanan P, 2017, LIFE SCI, V188, P53, DOI 10.1016/j.lfs.2017.08.029
   Record M, 2014, BBA-MOL CELL BIOL L, V1841, P108, DOI 10.1016/j.bbalip.2013.10.004
   Sasaki K, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-370
   Savina A, 2005, TRAFFIC, V6, P131, DOI 10.1111/j.1600-0854.2004.00257.x
   Seiwert N, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.418
   Singh SS, 2018, ONCOGENE, V37, P1142, DOI 10.1038/s41388-017-0046-6
   Skog J, 2008, NAT CELL BIOL, V10, P1470, DOI 10.1038/ncb1800
   Son SM, 2016, AUTOPHAGY, V12, P784, DOI 10.1080/15548627.2016.1159375
   Steinbichler TB, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0970-x
   Stuffers S, 2009, TRAFFIC, V10, P925, DOI 10.1111/j.1600-0854.2009.00920.x
   Sun WL, 2011, AUTOPHAGY, V7, P1035, DOI 10.4161/auto.7.9.16521
   Sung BH, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8164
   Szvicsek Z, 2019, CELL MOL LIFE SCI, V76, P2463, DOI 10.1007/s00018-019-03052-1
   Tanida I, 2004, INT J BIOCHEM CELL B, V36, P2503, DOI 10.1016/j.biocel.2004.05.009
   Tauro BJ, 2013, MOL CELL PROTEOMICS, V12, P2148, DOI 10.1074/mcp.M112.027086
   Thery Clotilde, 2011, F1000 Biol Rep, V3, P15, DOI 10.3410/B3-15
   Tkach M, 2016, CELL, V164, P1226, DOI 10.1016/j.cell.2016.01.043
   Torii S, 2016, EMBO REP, V17, P1552, DOI 10.15252/embr.201642565
   Trajkovic K, 2008, SCIENCE, V319, P1244, DOI 10.1126/science.1153124
   Uytterhoeven V, 2015, NEURON, V88, P735, DOI 10.1016/j.neuron.2015.10.012
   Villarroya-Beltri C, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13588
   Webber JP, 2015, ONCOGENE, V34, P319, DOI 10.1038/onc.2013.560
   Webber J, 2010, CANCER RES, V70, P9621, DOI 10.1158/0008-5472.CAN-10-1722
   Weidberg H, 2011, ANNU REV BIOCHEM, V80, P125, DOI 10.1146/annurev-biochem-052709-094552
   White E, 2015, CLIN CANCER RES, V21, P5037, DOI 10.1158/1078-0432.CCR-15-0490
   Wilson CM, 2014, J CELL SCI, V127, P3983, DOI 10.1242/jcs.149336
   Wolf J, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3576
   Xu J, 2018, J CELL SCI, V131, DOI 10.1242/jcs.215210
   Yang XD, 2016, ONCOTARGET, V7, P79603, DOI 10.18632/oncotarget.12873
   Yang ZNJ, 2011, MOL CANCER THER, V10, P1533, DOI 10.1158/1535-7163.MCT-11-0047
   Yu DD, 2015, CANCER SCI, V106, P959, DOI 10.1111/cas.12715
   Yun CW, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113466
   Zhang M, 2015, ELIFE, V4, DOI 10.7554/eLife.11205
NR 110
TC 3
Z9 3
U1 1
U2 4
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2072-6694
J9 CANCERS
JI Cancers
PD MAR
PY 2021
VL 13
IS 5
AR 1039
DI 10.3390/cancers13051039
PG 14
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA QV4YR
UT WOS:000627979600001
PM 33801266
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU D'Orazi, G
   Cordani, M
   Cirone, M
AF D'Orazi, Gabriella
   Cordani, Marco
   Cirone, Mara
TI Oncogenic pathways activated by pro-inflammatory cytokines promote
   mutant p53 stability: clue for novel anticancer therapies
SO CELLULAR AND MOLECULAR LIFE SCIENCES
LA English
DT Article
DE Inflammatory cytokines; Cancer; Mutant p53; Unfolded protein response;
   Oncogenic pathways; Autophagy
ID ENDOPLASMIC-RETICULUM STRESS; COLORECTAL-CANCER; PROTEIN-KINASE;
   CELL-SURVIVAL; P38 MAPK; AUTOPHAGY; MTOR; GAIN; CONTRIBUTES; INTERPLAY
AB Inflammation and cancerogenesis are strongly interconnected processes, not only because inflammation promotes DNA instability, but also because both processes are driven by pathways such as NF-kB, STAT3, mTOR and MAPKs. Interestingly, these pathways regulate the release of pro-inflammatory cytokines such as IL-6, TNF-alpha and IL-1 beta that in turn control their activation and play a crucial role in shaping immune response. The transcription factor p53 is the major tumor suppressor that is often mutated in cancer, contributing to tumor progression. In this overview, we highlight how the interplay between pro-inflammatory cytokines and pro-inflammatory/pro-oncogenic pathways, regulating and being regulated by UPR signaling and autophagy, affects the stability of mutp53 that in turn is able to control autophagy, UPR signaling, cytokine release and the activation of the same oncogenic pathways to preserve its own stability and promote tumorigenesis. Interrupting these positive feedback loops may represent a promising strategy in anticancer therapy, particularly against cancers carrying mutp53.
C1 [D'Orazi, Gabriella] IRCCS Regina Elena Natl Canc Inst, Dept Res & Adv Technol, Rome, Italy.
   [Cordani, Marco] IMDEA Nanociencia, C Faraday 9,Ciudad Univ Cantoblanco, Madrid, Spain.
   [Cirone, Mara] Sapienza Univ Rome, Dept Expt Med, Lab Affiliated Pasteur Inst Italy Fdn Cenci Bolog, Rome, Italy.
RP Cirone, M (corresponding author), Sapienza Univ Rome, Dept Expt Med, Lab Affiliated Pasteur Inst Italy Fdn Cenci Bolog, Rome, Italy.
EM mara.cirone@uniroma1.it
RI D'Orazi, Gabriella/T-2792-2019; Cordani, Marco/N-1247-2018
OI D'Orazi, Gabriella/0000-0001-6876-9105; Cordani,
   Marco/0000-0001-9342-4862; cirone, mara/0000-0002-2207-9624
FU Italian Association for Cancer Research (AIRC)Fondazione AIRC per la
   ricerca sul cancro [11377, 16742, 23040]; Istituto Pasteur Italia
   Fondazione Cenci BolognettiIstituto Pasteur Italia Fondazione Cenci
   Bolognetti
FX The research in the laboratory of GD has been supported by Grants from
   the Italian Association for Cancer Research (AIRC) (IG 2013, 11377; IG
   2015, 16742); in the laboratory of Mara Cirone by Grants from the
   Italian Association for Cancer Research (AIRC) IG 2019 23040) and by
   Istituto Pasteur Italia Fondazione Cenci Bolognetti. The funding
   agencies played no role in the concept, design, or writing of this
   study.
CR Agarwal S, 2016, MOL CANCER RES, V14, P66, DOI 10.1158/1541-7786.MCR-15-0159
   Agrawal S, 2011, J CLIN IMMUNOL, V31, P89, DOI [10.1007/s10875-010-9456-8, 10.1007/s10875-010-9507-1]
   Alexandrova EM, 2017, CELL DEATH DIFFER, V24, P3, DOI 10.1038/cdd.2016.145
   Allen Dylan, 2018, J Mol Signal, V13, P1, DOI 10.5334/1750-2187-13-1
   Appenzeller-Herzog C, 2012, TRENDS CELL BIOL, V22, P274, DOI 10.1016/j.tcb.2012.02.006
   Baldari S, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2014.591
   Bhatt AP, 2010, BLOOD, V115, P4455, DOI 10.1182/blood-2009-10-251082
   Bossi G, 2008, CELL CYCLE, V7, P1870, DOI 10.4161/cc.7.12.6161
   Bryant KL, 2019, NAT MED, V25, P628, DOI 10.1038/s41591-019-0368-8
   Chatterjee K, 2019, HELIYON, V5, DOI 10.1016/j.heliyon.2019.e02624
   Chatterjee M, 2013, HAEMATOLOGICA, V98, P1132, DOI 10.3324/haematol.2012.066175
   Choudhury S, 2013, CELL CYCLE, V12, P1022, DOI 10.4161/cc.24128
   Cirone M, 2020, AGEING RES REV, V58, DOI 10.1016/j.arr.2020.101026
   Cirone M, 2012, ONCOIMMUNOLOGY, V1, P1218, DOI 10.4161/onci.20428
   Cooks T, 2014, CARCINOGENESIS, V35, P1680, DOI 10.1093/carcin/bgu134
   Cordani M, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10030361
   Cordani M, 2017, BBA-REV CANCER, V1867, P19, DOI 10.1016/j.bbcan.2016.11.003
   Cordani M, 2016, MOL ONCOL, V10, P1008, DOI 10.1016/j.molonc.2016.04.001
   Cordani M, 2016, CANCER LETT, V376, P303, DOI 10.1016/j.canlet.2016.03.046
   D'Orazi G, 2019, CANCERS, V11, DOI 10.3390/cancers11050614
   Darling NJ, 2014, BBA-MOL CELL RES, V1843, P2150, DOI 10.1016/j.bbamcr.2014.01.009
   DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144
   Di Minin G, 2014, MOL CELL, V56, P617, DOI 10.1016/j.molcel.2014.10.013
   Dikic I, 2018, NAT REV MOL CELL BIO, V19, P349, DOI 10.1038/s41580-018-0003-4
   Dodson M, 2013, FREE RADICAL BIO MED, V63, P207, DOI 10.1016/j.freeradbiomed.2013.05.014
   Galdiero MR, 2018, CSH PERSPECT BIOL, V10, DOI 10.1101/cshperspect.a028662
   Garufi A, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.217
   Garufi A, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10030392
   Garufi A, 2016, J EXP CLIN CANC RES, V35, DOI 10.1186/s13046-016-0417-9
   Gilardini Montani MS, 2019, CANCERS, V11, DOI 10.3390/cancers11050703
   Granato M, 2019, BIOMOLECULES, V9, DOI 10.3390/biom9090482
   Granato M, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-017-0632-z
   Granato M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-13533-7
   Granato M, 2017, J NUTR BIOCHEM, V41, P124, DOI 10.1016/j.jnutbio.2016.12.011
   Granato M, 2015, CANCER LETT, V366, P191, DOI 10.1016/j.canlet.2015.07.006
   Granato M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075965
   Greten FR, 2019, IMMUNITY, V51, P27, DOI 10.1016/j.immuni.2019.06.025
   Guertin DA, 2007, CANCER CELL, V12, P9, DOI 10.1016/j.ccr.2007.05.008
   Gulhati P, 2011, CANCER RES, V71, P3246, DOI 10.1158/0008-5472.CAN-10-4058
   Gurtner A, 2010, J BIOL CHEM, V285, P14160, DOI 10.1074/jbc.M109.094813
   Kitamura T, 2009, CANCER RES, V69, P7681, DOI 10.1158/0008-5472.CAN-09-2133
   Klionsky DJ, 2012, AUTOPHAGY, V8, P445, DOI 10.4161/auto.19496
   Kochetkova EY, 2018, AGING-US, V10, P3574, DOI 10.18632/aging.101686
   Kondo Y, 2005, NAT REV CANCER, V5, P726, DOI 10.1038/nrc1692
   Lan KH, 2002, ONCOGENE, V21, P4801, DOI 10.1038/sj.onc.1205589
   Landskron G, 2014, J IMMUNOL RES, V2014, DOI 10.1155/2014/149185
   Laudisi F, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19061787
   Lavieu G, 2006, J BIOL CHEM, V281, P8518, DOI 10.1074/jbc.M506182200
   Mantovani F, 2019, CELL DEATH DIFFER, V26, P199, DOI 10.1038/s41418-018-0246-9
   Masuelli L, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2017.1356151
   Mathew R, 2007, GENE DEV, V21, P1367, DOI 10.1101/gad.1545107
   Meares GP, 2014, MOL CELL BIOL, V34, P3911, DOI 10.1128/MCB.00980-14
   Meijer AJ, 2007, AUTOPHAGY, V3, P238, DOI 10.4161/auto.3710
   Mijok V, 2016, J INNATE IMMUN, V8, P464, DOI 10.1159/000447668
   Morita M, 2013, CELL METAB, V18, P698, DOI 10.1016/j.cmet.2013.10.001
   Muller PAJ, 2014, CANCER CELL, V25, P304, DOI 10.1016/j.ccr.2014.01.021
   Pantouli E, 2005, BIOCHEM BIOPH RES CO, V329, P224, DOI 10.1016/j.bbrc.2005.01.122
   Parrales A, 2018, CELL DEATH DIFFER, V25, P460, DOI 10.1038/s41418-017-0026-y
   Powell JD, 2012, ANNU REV IMMUNOL, V30, P39, DOI 10.1146/annurev-immunol-020711-075024
   Puca R, 2008, CANCER RES, V68, P3707, DOI 10.1158/0008-5472.CAN-07-6776
   Qu XL, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00563
   Rahnamoun H, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01117-y
   Rao J, 2014, AM J TRANSPLANT, V14, P1552, DOI 10.1111/ajt.12711
   Reverendo M, 2019, FEBS J, V286, P297, DOI 10.1111/febs.14391
   Romeo MA, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.01102
   Salmond RJ, 2018, FRONT CELL DEV BIOL, V6, DOI 10.3389/fcell.2018.00122
   Santarelli R, 2019, VIROLOGY, V528, P137, DOI 10.1016/j.virol.2018.12.015
   Santarelli R, 2014, SCI REP-UK, V4, DOI 10.1038/srep04241
   Saud K, 2005, NEUROTOX RES, V8, P277, DOI 10.1007/BF03033981
   Saxton RA, 2017, CELL, V168, P960, DOI [10.1016/j.cell.2017.02.004, 10.1016/j.cell.2017.03.035]
   Schmitz ML, 2018, BIOMEDICINES, V6, DOI 10.3390/biomedicines6020058
   Schulz-Heddergott R, 2018, CANCER CELL, V34, P298, DOI 10.1016/j.ccell.2018.07.004
   Scian MJ, 2005, MOL CELL BIOL, V25, P10097, DOI 10.1128/MCB.25.22.10097-10110.2005
   Senft D, 2015, TRENDS BIOCHEM SCI, V40, P141, DOI 10.1016/j.tibs.2015.01.002
   Sicari D, 2019, ONCOGENE, V38, P6184, DOI 10.1038/s41388-019-0878-3
   Strazza M, 2020, INFLAMMATION, V43, P1201, DOI 10.1007/s10753-020-01235-8
   Trocoli A, 2011, AM J CANCER RES, V1, P629
   Ubertini V, 2015, ONCOGENE, V34, P2493, DOI 10.1038/onc.2014.191
   Verzella D, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2399-y
   Wang XM, 2006, PHYSIOLOGY, V21, P362, DOI 10.1152/physiol.00024.2006
   Weisz L, 2007, CANCER RES, V67, P2396, DOI 10.1158/0008-5472.CAN-06-2425
   Yamazaki H, 2009, J IMMUNOL, V183, P1480, DOI 10.4049/jimmunol.0900017
   Yeudall WA, 2012, CARCINOGENESIS, V33, P442, DOI 10.1093/carcin/bgr270
   Yeung YT, 2012, J NEURO-ONCOL, V109, P35, DOI 10.1007/s11060-012-0875-7
   Yu H, 2007, NAT REV IMMUNOL, V7, P41, DOI 10.1038/nri1995
   Zhang C, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3935
   Zhang KZ, 2008, NATURE, V454, P455, DOI 10.1038/nature07203
   Zhao YW, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00511
   Zhong ZY, 2016, CELL, V164, P896, DOI 10.1016/j.cell.2015.12.057
NR 89
TC 15
Z9 15
U1 2
U2 6
PU SPRINGER BASEL AG
PI BASEL
PA PICASSOPLATZ 4, BASEL, 4052, SWITZERLAND
SN 1420-682X
EI 1420-9071
J9 CELL MOL LIFE SCI
JI Cell. Mol. Life Sci.
PD MAR
PY 2021
VL 78
IS 5
BP 1853
EP 1860
DI 10.1007/s00018-020-03677-7
EA OCT 2020
PG 8
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA QX9SH
UT WOS:000579408000001
PM 33070220
OA Bronze
DA 2022-04-25
ER

PT J
AU Scherz-Shouval, R
   Weidberg, H
   Gonen, C
   Wilder, S
   Elazar, Z
   Oren, M
AF Scherz-Shouval, Ruth
   Weidberg, Hilla
   Gonen, Chagay
   Wilder, Sylvia
   Elazar, Zvulun
   Oren, Moshe
TI p53-dependent regulation of autophagy protein LC3 supports cancer cell
   survival under prolonged starvation
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE apoptosis; posttranscriptional regulation
ID WILD-TYPE P53; TUMOR SUPPRESSORS; TUMORIGENESIS; MODULATION; EXPRESSION;
   APOPTOSIS; SESTRIN2; STRESS
AB The p53 tumor suppressor is mutated in a high percentage of human tumors. However, many other tumors retain wild-type ( wt) p53 expression, raising the intriguing possibility that they actually benefit from it. Recent studies imply a role for p53 in regulation of autophagy, a catabolic pathway by which eukaryotic cells degrade and recycle macromolecules and organelles, particularly under conditions of nutrient deprivation. Here, we show that, in many cell types, p53 confers increased survival in the face of chronic starvation. We implicate regulation of autophagy in this effect. In HCT116 human colorectal cancer cells exposed to prolonged nutrient deprivation, the endogenous wt p53 posttranscriptionally down-regulates LC3, a pivotal component of the autophagic machinery. This enables reduced, yet sustainable autophagic flux. Loss of p53 impairs autophagic flux and causes excessive LC3 accumulation upon starvation, culminating in apoptosis. Thus, p53 increases cell fitness by maintaining better autophagic homeostasis, adjusting the rate of autophagy to changing circumstances. We propose that some cancer cells retain wt p53 to benefit from the resultant increased fitness under limited nutrient supply.
C1 [Scherz-Shouval, Ruth; Gonen, Chagay; Wilder, Sylvia; Oren, Moshe] Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel.
   [Weidberg, Hilla; Elazar, Zvulun] Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel.
RP Oren, M (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel.
EM moshe.oren@weizmann.ac.il
OI Oren, Moshe/0000-0003-4311-7172; scherz-shouval,
   ruth/0000-0002-4570-121X
FU Sir Charles Clore postdoctoral fellowship; National Cancer
   InstituteUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R37
   CA40099]; Robert Bosch Foundation; Israel Science FoundationIsrael
   Science Foundation; Israeli Cancer Research Foundation; M.D. Moross
   Institute for Cancer Research; Yad Abraham Center for Cancer Diagnosis
   and Therapy; NATIONAL CANCER INSTITUTEUnited States Department of Health
   & Human ServicesNational Institutes of Health (NIH) - USANIH National
   Cancer Institute (NCI) [R37CA040099] Funding Source: NIH RePORTER
FX We thank Adi Kimchi (Weizmann Institute, Rehovot, Israel) and her team
   for helpful discussions and reagents, Vera Shinder for helpful
   discussions and technical guidance, Dan Michael for sharing ideas, Gilad
   Fuchs, Gil Hornung, and Noa Levi for scientific and technical
   assistance, and Bert Vogelstein (Johns Hopkins University, Baltimore)
   and Varda Rotter (Weizmann Institute, Rehovot, Israel) for the gift of
   cell lines. R.S.-S. is recipient of the Sir Charles Clore postdoctoral
   fellowship. Z.E. is incumbent of the Harold Korda Chair of Biology; M.O.
   is incumbent of the Andere Lwoff chair in Molecular Biology. This work
   was supported in part by Grant R37 CA40099 from the National Cancer
   Institute, a grant from the Robert Bosch Foundation, the Israel Science
   Foundation and the Israeli Cancer Research Foundation (to Z.E.), and the
   M.D. Moross Institute for Cancer Research and the Yad Abraham Center for
   Cancer Diagnosis and Therapy (to M.O.). The electron microscopy studies
   were conducted at the Irving and Cherna Moskowitz Center for Nano and
   Bio-Nano Imaging at The Weizmann Institute of Science.
CR Aylon Y, 2006, GENE DEV, V20, P2687, DOI 10.1101/gad.1447006
   Bensaad K, 2009, EMBO J, V28, P3015, DOI 10.1038/emboj.2009.242
   Bjorkoy G, 2005, J CELL BIOL, V171, P603, DOI 10.1083/jcb.200507002
   Budanov AV, 2008, CELL, V134, P451, DOI 10.1016/j.cell.2008.06.028
   Corcelle EA, 2009, FEBS J, V276, P6084, DOI 10.1111/j.1742-4658.2009.07332.x
   Crighton D, 2006, CELL, V126, P121, DOI 10.1016/j.cell.2006.05.034
   Eisenberg-Lerner A, 2009, APOPTOSIS, V14, P376, DOI 10.1007/s10495-008-0307-5
   Feng ZH, 2005, P NATL ACAD SCI USA, V102, P8204, DOI 10.1073/pnas.0502857102
   Feng ZH, 2010, TRENDS CELL BIOL, V20, P427, DOI 10.1016/j.tcb.2010.03.004
   Gottlieb E, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001040
   Ichimura Y, 2000, NATURE, V408, P488, DOI 10.1038/35044114
   Jones RG, 2009, GENE DEV, V23, P537, DOI 10.1101/gad.1756509
   Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720
   Kabeya Y, 2004, J CELL SCI, V117, P2805, DOI 10.1242/jcs.01131
   Karantza-Wadsworth V, 2007, GENE DEV, V21, P1621, DOI 10.1101/gad.1565707
   Kim E, 2009, BIOCHEM PHARMACOL, V77, P11, DOI 10.1016/j.bcp.2008.08.030
   Klionsky DJ, 2008, AUTOPHAGY, V4, P849, DOI 10.4161/auto.6845
   Klionsky DJ, 2008, AUTOPHAGY, V4, P151, DOI 10.4161/auto.5338
   Kuroda M, 2005, CANCER LETT, V221, P21, DOI 10.1016/j.canlet.2004.08.006
   Lassus P, 1996, EMBO J, V15, P4566, DOI 10.1002/j.1460-2075.1996.tb00834.x
   Lee JH, 2010, SCIENCE, V327, P1223, DOI 10.1126/science.1182228
   Levine AJ, 2009, NAT REV CANCER, V9, P749, DOI 10.1038/nrc2723
   Maiuri MC, 2010, CURR OPIN CELL BIOL, V22, P181, DOI 10.1016/j.ceb.2009.12.001
   Maiuri MC, 2009, CELL CYCLE, V8, P1571, DOI 10.4161/cc.8.10.8498
   Mathew R, 2009, CELL, V137, P1062, DOI 10.1016/j.cell.2009.03.048
   Mizushima N, 2009, CURR TOP MICROBIOL, V335, P71, DOI 10.1007/978-3-642-00302-8_3
   MOSNER J, 1995, EMBO J, V14, P4442, DOI 10.1002/j.1460-2075.1995.tb00123.x
   Phelps ED, 2006, AM J PHYSIOL-CELL PH, V290, pC352, DOI 10.1152/ajpcell.00050.2005
   Sablina AA, 2005, NAT MED, V11, P1306, DOI 10.1038/nm1320
   Scherz-Shouval R, 2007, EMBO J, V26, P1749, DOI 10.1038/sj.emboj.7601623
   Shema E, 2008, GENE DEV, V22, P2664, DOI 10.1101/gad.1703008
   Tasdemir E, 2008, NAT CELL BIOL, V10, P676, DOI 10.1038/ncb1730
   Vousden KH, 2009, CELL, V137, P413, DOI 10.1016/j.cell.2009.04.037
   White E, 2010, CURR OPIN CELL BIOL, V22, P212, DOI 10.1016/j.ceb.2009.12.008
   White E, 2009, CLIN CANCER RES, V15, P5308, DOI 10.1158/1078-0432.CCR-07-5023
   Yang ZF, 2009, CURR TOP MICROBIOL, V335, P1, DOI 10.1007/978-3-642-00302-8_1
   Young ARJ, 2009, GENE DEV, V23, P798, DOI 10.1101/gad.519709
NR 37
TC 166
Z9 174
U1 0
U2 16
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD OCT 26
PY 2010
VL 107
IS 43
BP 18511
EP 18516
DI 10.1073/pnas.1006124107
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 673QG
UT WOS:000283677400053
PM 20937856
OA Green Published
DA 2022-04-25
ER

PT J
AU Xie, YC
   Liu, J
   Kang, R
   Tang, DL
AF Xie, Yangchun
   Liu, Jiao
   Kang, Rui
   Tang, Daolin
TI Mitophagy Receptors in Tumor Biology
SO FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
LA English
DT Review
DE mitophagy; cancer; cell death; autophagy; mitochondria
ID CANCER STEM-CELLS; MITOCHONDRIAL AUTOPHAGY; PINK1/PARKIN-MEDIATED
   MITOPHAGY; MOLECULAR-MECHANISMS; COLORECTAL-CANCER; DRUG-RESISTANCE;
   BNIP3; PARKIN; DEATH; NIX
AB Mitochondria are multifunctional organelles that regulate cancer biology by synthesizing macromolecules, producing energy, and regulating cell death. The understanding of mitochondrial morphology, function, biogenesis, fission and fusion kinetics, and degradation is important for the development of new anticancer strategies. Mitophagy is a type of selective autophagy that can degrade damaged mitochondria under various environmental stresses, especially oxidative damage and hypoxia. The key regulator of mitophagy is the autophagy receptor, which recognizes damaged mitochondria and allows them to enter autophagosomes by binding to MAP1LC3 or GABARAP, and then undergo lysosomal-dependent degradation. Many components of mitochondria, including mitochondrial membrane proteins (e.g., PINK1, BNIP3L, BNIP3, FUNDC1, NIPSNAP1, NIPSNAP2, BCL2L13, PHB2, and FKBP8) and lipids (e.g., cardiolipin and ceramides), act as mitophagy receptors in a context-dependent manner. Dysfunctional mitophagy not only inhibits, but also promotes, tumorigenesis. Similarly, mitophagy plays a dual role in chemotherapy, radiotherapy, and immunotherapy. In this review, we summarize the latest advances in the mechanisms of mitophagy and highlight the pathological role of mitophagy receptors in tumorigenesis and treatment.
C1 [Xie, Yangchun] Cent South Univ, Xiangya Hosp 2, Dept Oncol, Changsha, Peoples R China.
   [Liu, Jiao] Guangzhou Med Univ, Affiliated Hosp 3, Guangzhou, Peoples R China.
   [Kang, Rui; Tang, Daolin] Univ Texas Southwestern Med Ctr Dallas, Dept Surg, Dallas, TX 75390 USA.
RP Xie, YC (corresponding author), Cent South Univ, Xiangya Hosp 2, Dept Oncol, Changsha, Peoples R China.; Tang, DL (corresponding author), Univ Texas Southwestern Med Ctr Dallas, Dept Surg, Dallas, TX 75390 USA.
EM xieyangchun88@csu.edu.cn; daolin.tang@utsouthwestern.edu
RI Kang, Rui/ABD-5291-2021; Tang, Daolin/ABD-5062-2021; Tang,
   Daolin/B-2905-2010
OI Kang, Rui/0000-0003-2725-1574; Tang, Daolin/0000-0002-1903-6180; Xie,
   Yangchun/0000-0003-2571-4774
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81802476]
FX YX was supported by the National Natural Science Foundation of China
   (No. 81802476).
CR Adams JM, 2007, ONCOGENE, V26, P1324, DOI 10.1038/sj.onc.1210220
   Bacon AL, 2007, ONCOGENE, V26, P132, DOI 10.1038/sj.onc.1209761
   Bai YS, 2019, BIOCHEM BIOPH RES CO, V508, P997, DOI 10.1016/j.bbrc.2018.12.039
   Bernardini JP, 2017, ONCOGENE, V36, P1315, DOI 10.1038/onc.2016.302
   Bhujabal Z, 2017, EMBO REP, V18, P947, DOI 10.15252/embr.201643147
   Bialik S, 2018, J CELL SCI, V131, DOI 10.1242/jcs.215152
   Bock FJ, 2020, NAT REV MOL CELL BIO, V21, P85, DOI 10.1038/s41580-019-0173-8
   Brittain JM, 2012, CHANNELS, V6, P94, DOI 10.4161/chan.19415
   Carranza G, 2017, BBA-BIOMEMBRANES, V1859, P1124, DOI 10.1016/j.bbamem.2017.03.006
   Chang MH, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0905-1
   Chen G, 2014, MOL CELL, V54, P362, DOI 10.1016/j.molcel.2014.02.034
   Chen M, 2016, AUTOPHAGY, V12, P689, DOI 10.1080/15548627.2016.1151580
   Chen Y, 2008, INVEST OPHTH VIS SCI, V49, P1721, DOI 10.1167/iovs.07-1121
   Chen ZH, 2017, EMBO REP, V18, P495, DOI 10.15252/embr.201643309
   Cho DH, 2018, MOL CELLS, V41, P55, DOI 10.14348/molcells.2018.2245
   Chourasia AH, 2015, EMBO REP, V16, P1145, DOI 10.15252/embr.201540759
   Chu CT, 2013, NAT CELL BIOL, V15, P1197, DOI 10.1038/ncb2837
   Dany M, 2016, BLOOD, V128, P1944, DOI 10.1182/blood-2016-04-708750
   Dany M, 2015, BBA-MOL CELL RES, V1853, P2834, DOI 10.1016/j.bbamcr.2014.12.039
   Dikic I, 2018, NAT REV MOL CELL BIO, V19, P349, DOI 10.1038/s41580-018-0003-4
   Ding WX, 2010, J BIOL CHEM, V285, P27879, DOI 10.1074/jbc.M110.119537
   Dudek J, 2017, FRONT CELL DEV BIOL, V5, DOI 10.3389/fcell.2017.00090
   Edlich F, 2005, EMBO J, V24, P2688, DOI 10.1038/sj.emboj.7600739
   Eiyama A, 2015, CURR OPIN CELL BIOL, V33, P95, DOI 10.1016/j.ceb.2015.01.002
   Ferro F, 2020, SEMIN CELL DEV BIOL, V98, P129, DOI 10.1016/j.semcdb.2019.05.029
   Galluzzi L, 2018, CELL DEATH DIFFER, V25, P486, DOI 10.1038/s41418-017-0012-4
   Geisler S, 2010, NAT CELL BIOL, V12, P119, DOI 10.1038/ncb2012
   Gray MW, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a011403
   Harper JW, 2018, NAT REV MOL CELL BIO, V19, P93, DOI 10.1038/nrm.2017.129
   Herst PM, 2017, FRONT ENDOCRINOL, V8, DOI 10.3389/fendo.2017.00296
   Hosokawa N, 2009, MOL BIOL CELL, V20, P1981, DOI 10.1091/mbc.E08-12-1248
   Hou HL, 2017, CANCER MED-US, V6, P1871, DOI 10.1002/cam4.1112
   Hou W, 2016, AUTOPHAGY, V12, P1425, DOI 10.1080/15548627.2016.1187366
   Hui L, 2019, CLIN TRANSL ONCOL, V21, P596, DOI 10.1007/s12094-018-1958-5
   Humpton TJ, 2019, CANCER DISCOV, V9, P1268, DOI 10.1158/2159-8290.CD-18-1409
   Ianniciello A, 2018, FRONT CELL DEV BIOL, V6, DOI 10.3389/fcell.2018.00120
   Janssens S, 2014, NAT IMMUNOL, V15, P910, DOI 10.1038/ni.2991
   Jung CH, 2009, MOL BIOL CELL, V20, P1992, DOI 10.1091/mbc.E08-12-1249
   Kang R, 2011, CELL DEATH DIFFER, V18, P571, DOI 10.1038/cdd.2010.191
   Kang Rui, 2018, J Pancreatol, V1, P19
   Kang R, 2019, AUTOPHAGY, V15, P172, DOI 10.1080/15548627.2018.1526611
   Kang R, 2017, CELL RES, V27, P916, DOI 10.1038/cr.2017.51
   Kasashima K, 2006, J BIOL CHEM, V281, P36401, DOI 10.1074/jbc.M605260200
   Kataoka T, 2001, J BIOL CHEM, V276, P19548, DOI 10.1074/jbc.M010520200
   Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717
   Kounakis K, 2019, FRONT CELL DEV BIOL, V7, DOI 10.3389/fcell.2019.00185
   Koyano F, 2019, EMBO REP, V20, DOI 10.15252/embr.201947728
   Kroemer G, 2010, MOL CELL, V40, P280, DOI 10.1016/j.molcel.2010.09.023
   Kroemer G, 2008, NAT REV MOL CELL BIO, V9, P1004, DOI 10.1038/nrm2529
   Lee Y, 2011, AM J PHYSIOL-HEART C, V301, pH1924, DOI 10.1152/ajpheart.00368.2011
   Lemasters JJ, 2005, REJUV RES, V8, P3, DOI 10.1089/rej.2005.8.3
   Levine B, 2019, CELL, V176, P11, DOI 10.1016/j.cell.2018.09.048
   Levy A, 2020, P NATL ACAD SCI USA, V117, P1994, DOI 10.1073/pnas.1902788117
   Levy JMM, 2017, NAT REV CANCER, V17, P528, DOI 10.1038/nrc.2017.53
   Li CF, 2021, AUTOPHAGY, V17, P948, DOI [10.1080/15548627.2020.1739447, 10.1145/3421766.3421867]
   Li CF, 2018, DEV CELL, V46, P441, DOI 10.1016/j.devcel.2018.07.012
   Li WH, 2019, HEPATOLOGY, V69, P604, DOI 10.1002/hep.30191
   Li YJ, 2019, EMBO J, V38, DOI 10.15252/embj.201798786
   Liu J, 2020, CELL CHEM BIOL, V27, P420, DOI 10.1016/j.chembiol.2020.02.005
   Liu L, 2012, NAT CELL BIOL, V14, P177, DOI 10.1038/ncb2422
   Mancias JD, 2014, NATURE, V509, P105, DOI 10.1038/nature13148
   MARINKOVIC M, 2020, AUTOPHAGY 0425, DOI DOI 10.1007/7651_2017_14
   McEwan DG, 2011, TRENDS CELL BIOL, V21, P195, DOI 10.1016/j.tcb.2010.12.006
   Misaka T, 2018, J MOL CELL CARDIOL, V114, P93, DOI 10.1016/j.yjmcc.2017.11.004
   Montano MM, 1999, P NATL ACAD SCI USA, V96, P6947, DOI 10.1073/pnas.96.12.6947
   Montero J, 2010, BBA-BIOENERGETICS, V1797, P1217, DOI 10.1016/j.bbabio.2010.02.010
   Murai M, 2005, CLIN CANCER RES, V11, P1021
   Murakawa T, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8527
   Naik PP, 2018, CELL PROLIFERAT, V51, DOI 10.1111/cpr.12411
   Ney PA, 2015, BBA-MOL CELL RES, V1853, P2775, DOI 10.1016/j.bbamcr.2015.02.022
   Novak I, 2010, EMBO REP, V11, P45, DOI 10.1038/embor.2009.256
   O'Sullivan TE, 2015, IMMUNITY, V43, P331, DOI 10.1016/j.immuni.2015.07.012
   Okami J, 2004, CANCER RES, V64, P5338, DOI 10.1158/0008-5472.CAN-04-0089
   Okamoto T, 2006, EMBO J, V25, P5015, DOI 10.1038/sj.emboj.7601367
   Otsu K, 2015, AUTOPHAGY, V11, P1932, DOI 10.1080/15548627.2015.1084459
   Palikaras K, 2018, NAT CELL BIOL, V20, P1013, DOI 10.1038/s41556-018-0176-2
   Panigrahi DP, 2020, SEMIN CANCER BIOL, V66, P45, DOI 10.1016/j.semcancer.2019.07.015
   Paradies G, 2014, ANTIOXID REDOX SIGN, V20, P1925, DOI 10.1089/ars.2013.5280
   Park CW, 2013, AUTOPHAGY, V9, P345, DOI 10.4161/auto.23072
   Pei S, 2018, CELL STEM CELL, V23, P86, DOI 10.1016/j.stem.2018.05.021
   Pfanner N, 2019, NAT REV MOL CELL BIO, V20, P267, DOI 10.1038/s41580-018-0092-0
   Pickrell AM, 2015, NEURON, V85, P257, DOI 10.1016/j.neuron.2014.12.007
   Poulogiannis G, 2010, P NATL ACAD SCI USA, V107, P15145, DOI 10.1073/pnas.1009941107
   Praharaj PP, 2019, CELL MOL LIFE SCI, V76, P1641, DOI 10.1007/s00018-018-2990-x
   Princely Abudu Y., 2019, DEV CELL, V49, pe12
   Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167
   Sandoval H, 2008, NATURE, V454, P232, DOI 10.1038/nature07006
   Schwarten M, 2009, AUTOPHAGY, V5, P690, DOI 10.4161/auto.5.5.8494
   Schweers RL, 2007, P NATL ACAD SCI USA, V104, P19500, DOI 10.1073/pnas.0708818104
   Sentelle RD, 2012, NAT CHEM BIOL, V8, P831, DOI 10.1038/NCHEMBIO.1059
   Seroussi E, 1998, GENE, V212, P13, DOI 10.1016/S0378-1119(98)00098-5
   Shimura H, 2000, NAT GENET, V25, P302, DOI 10.1038/77060
   Shirane-Kitsuji M, 2014, INT J BIOCHEM CELL B, V51, P19, DOI 10.1016/j.biocel.2014.03.007
   Sowter HM, 2001, CANCER RES, V61, P6669
   Takeda M, 2019, CANCER RES, V79, P1426, DOI 10.1158/0008-5472.CAN-18-2192
   Tang DL, 2019, CELL RES, V29, P347, DOI 10.1038/s41422-019-0164-5
   Tang DL, 2011, CELL METAB, V13, P701, DOI 10.1016/j.cmet.2011.04.008
   Tang DL, 2010, J CELL BIOL, V190, P881, DOI 10.1083/jcb.200911078
   Tatsuta T, 2005, MOL BIOL CELL, V16, P248, DOI 10.1091/mbc.E04-09-0807
   Twig G, 2011, ANTIOXID REDOX SIGN, V14, P1939, DOI 10.1089/ars.2010.3779
   Valente EM, 2004, SCIENCE, V304, P1158, DOI 10.1126/science.1096284
   Vande Velde C, 2000, MOL CELL BIOL, V20, P5454, DOI 10.1128/MCB.20.15.5454-5468.2000
   Vara-Perez M, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8050493
   Vives-Bauza C, 2010, P NATL ACAD SCI USA, V107, P378, DOI 10.1073/pnas.0911187107
   Wang YG, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00413
   Ward RJ, 2007, ANNU REV PATHOL-MECH, V2, P175, DOI 10.1146/annurev.pathol.2.010506.091847
   Wei Y, 2017, CELL, V168, pe10
   Wild P, 2014, J CELL SCI, V127, P3, DOI 10.1242/jcs.140426
   Wong YC, 2014, P NATL ACAD SCI USA, V111, pE4439, DOI 10.1073/pnas.1405752111
   Wu WX, 2014, EMBO REP, V15, P566, DOI 10.1002/embr.201438501
   Xie Y., 2020, J PANCREATOL, V3, P154, DOI [10.1097/JP9.0000000000000054, DOI 10.1097/JP9.0000000000000054]
   Xie YC, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00431
   Xie YC, 2015, AUTOPHAGY, V11, P28, DOI 10.4161/15548627.2014.984267
   Xu SS, 2019, J MED VIROL, V91, P482, DOI 10.1002/jmv.25327
   Yan CJ, 2020, AUTOPHAGY, V16, P419, DOI 10.1080/15548627.2019.1628520
   Yan C, 2017, CANCER LETT, V388, P34, DOI 10.1016/j.canlet.2016.11.018
   Yan HZ, 2018, INT J ONCOL, V52, P367, DOI 10.3892/ijo.2017.4216
   Yang MH, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aaw2238
   Yang ZF, 2010, NAT CELL BIOL, V12, P814, DOI 10.1038/ncb0910-814
   Yin J, 2018, TOXICOL IN VITRO, V51, P1, DOI 10.1016/j.tiv.2018.05.001
   Yu Z, 2020, ACS NANO, V14, P4816, DOI 10.1021/acsnano.0c00708
   Zaffagnini G, 2016, J MOL BIOL, V428, P1714, DOI 10.1016/j.jmb.2016.02.004
   Zhang H, 2020, MED SCI MONITOR, V26, DOI 10.12659/MSM.923227
   Zhang J, 2009, CELL DEATH DIFFER, V16, P939, DOI 10.1038/cdd.2009.16
   Zhao QH, 2019, CANCER CELL INT, V19, DOI 10.1186/s12935-019-0777-2
   Zheng R, 2015, ONCOTARGET, V6, P17417, DOI 10.18632/oncotarget.4002
   Zhou BR, 2020, SEMIN CANCER BIOL, V66, P89, DOI 10.1016/j.semcancer.2019.03.002
   Zhou ZL, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-19917-7
   Zorova LD, 2018, ANAL BIOCHEM, V552, P50, DOI 10.1016/j.ab.2017.07.009
NR 129
TC 12
Z9 12
U1 6
U2 9
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2296-634X
J9 FRONT CELL DEV BIOL
JI Front. Cell. Dev. Biol.
PD NOV 11
PY 2020
VL 8
AR 594203
DI 10.3389/fcell.2020.594203
PG 11
WC Cell Biology; Developmental Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Developmental Biology
GA OV0CL
UT WOS:000591889100001
PM 33262988
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Cheng, YP
   Li, SM
   Chuang, WL
   Li, CH
   Chen, GJ
   Chang, CC
   Or, CHR
   Lin, PY
   Chang, CC
AF Cheng, Yen-Po
   Li, Shiming
   Chuang, Wan-Ling
   Li, Chia-Hsuan
   Chen, Guan-Jun
   Chang, Ching-Chin
   Or, Chi-Hung R.
   Lin, Ping-Yi
   Chang, Chia-Che
TI Blockade of STAT3 Signaling Contributes to Anticancer Effect of
   5-Acetyloxy-6,7,8,4 '-Tetra-Methoxyflavone, a Tangeretin Derivative, on
   Human Glioblastoma Multiforme Cells
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE glioblastoma multiforme; STAT3; tangeretin; 5-acetyloxy-6; 7; 8; 4
   '-tetramethoxyflavone; polymethoxyflavone; BCL-2; BCL-xL; apoptosis
ID POLYMETHOXYLATED FLAVONE; OXIDATIVE STRESS; BREAST-CANCER; IN-VITRO;
   AUTOPHAGY; TISSUE
AB Glioblastoma multiforme (GBM) is the most aggressive primary brain tumor with poor prognosis, largely due to resistance to current radiotherapy and Temozolomide chemotherapy. The constitutive activation of Signal Transducer and Activator of Transcription 3 (STAT3) is evidenced as a pivotal driver of GBM pathogenesis and therapy resistance, and hence, is a promising GBM drug target. 5-acetyloxy-6,7,8,4 '-tetramethoxyflavone (5-AcTMF) is an acetylated derivative of Tangeretin which is known to exert anticancer effects on breast, colon, lung, and multiple myeloma; however, its effect on GBM remains elusive. Herein, we reported that 5-AcTMF suppressed the viability and clonogenicity along with inducing apoptosis in multiple human GBM cell lines. Mechanistic analyses further revealed that 5-AcTMF lowered the levels of Tyrosine 705-phosphorylated STAT3 (p-STAT3), a canonical marker of STAT3 activation, but also dampened p-STAT3 upregulation elicited by Interleukin-6. Notably, ectopic expression of dominant-active STAT3 impeded 5-AcTMF-induced suppression of viability and clonogenicity plus apoptosis induction in GBM cells, confirming the prerequisite of STAT3 blockage for the inhibitory action of 5-AcTMF on GBM cell survival and growth. Additionally, 5-AcTMF impaired the activation of STAT3 upstream kinase JAK2 but also downregulated antiapoptotic BCL-2 and BCL-xL in a STAT3-dependent manner. Moreover, the overexpression of either BCL-2 or BCL-xL abrogated 5-AcTMF-mediated viability reduction and apoptosis induction in GBM cells. Collectively, we, for the first time, revealed the anticancer effect of 5-AcTMF on GBM cells, which was executed via thwarting the JAK2-STAT3-BCL-2/BCL-xL signaling axis. Our findings further implicate the therapeutic potential of 5-AcTMF for GBM treatment.
C1 [Cheng, Yen-Po] Yuanlin Changhua Christian Hosp, Dept Surg, Div Neurosurg, Changhua 50006, Taiwan.
   [Cheng, Yen-Po; Li, Chia-Hsuan; Chen, Guan-Jun; Chang, Ching-Chin; Chang, Chia-Che] Natl Chung Hsing Univ, Inst Biomed Sci, Taichung 40227, Taiwan.
   [Li, Shiming] Huanggang Normal Univ, Hubei Key Lab Proc & Applicat Catalyt Mat, Huanggang 438000, Peoples R China.
   [Li, Shiming] Rutgers State Univ, Dept Food Sci, New Brunswick, NJ 08901 USA.
   [Chuang, Wan-Ling; Lin, Ping-Yi] Changhua Christian Hosp, Transplant Med & Surg Res Ctr, Changhua 50006, Taiwan.
   [Or, Chi-Hung R.] Tungs Taichung MetroHarbor Hosp, Dept Anesthesiol, Taichung 43503, Taiwan.
   [Lin, Ping-Yi; Chang, Chia-Che] China Med Univ Hosp, Dept Med Res, Taichung 40447, Taiwan.
   [Chang, Chia-Che] Natl Chung Hsing Univ, Rong Hsing Res Ctr Translat Med, PhD Program Translat Med, Dept Life Sci,iEGG & Anim Biotechnol Res Ctr, Taichung 40227, Taiwan.
   [Chang, Chia-Che] Asia Univ, Dept Biotechnol, Taichung 41354, Taiwan.
RP Chang, CC (corresponding author), Natl Chung Hsing Univ, Inst Biomed Sci, Taichung 40227, Taiwan.; Lin, PY (corresponding author), Changhua Christian Hosp, Transplant Med & Surg Res Ctr, Changhua 50006, Taiwan.; Lin, PY; Chang, CC (corresponding author), China Med Univ Hosp, Dept Med Res, Taichung 40447, Taiwan.; Chang, CC (corresponding author), Natl Chung Hsing Univ, Rong Hsing Res Ctr Translat Med, PhD Program Translat Med, Dept Life Sci,iEGG & Anim Biotechnol Res Ctr, Taichung 40227, Taiwan.; Chang, CC (corresponding author), Asia Univ, Dept Biotechnol, Taichung 41354, Taiwan.
EM 69221@cch.org.tw; chia_che@dragon.nchu.edu.tw
OI Chang, Chia-Che/0000-0003-3509-3713
FU iEGG; Animal Biotechnology Center from The Feature Areas Research Center
   Program within Ministry of Education (MOE) in Taiwan
FX This research was financially supported by The iEGG and Animal
   Biotechnology Center from The Feature Areas Research Center Program
   within the framework of the Higher Education Sprout Project by the
   Ministry of Education (MOE) in Taiwan.
CR Braidy N, 2017, CNS NEUROL DISORD-DR, V16, P387, DOI 10.2174/1871527316666170328113309
   Brantley EC, 2008, MOL CANCER RES, V6, P675, DOI 10.1158/1541-7786.MCR-07-2180
   Chang N, 2017, MOL CELL ENDOCRINOL, V451, P53, DOI 10.1016/j.mce.2017.01.004
   Datla KP, 2001, NEUROREPORT, V12, P3871, DOI 10.1097/00001756-200112040-00053
   Davis ME, 2016, CLIN J ONCOL NURS, V20, P2, DOI 10.1188/16.CJON.S1.2-8
   Fox BM, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20081853
   Ganguly Debolina, 2018, Oncotarget, V9, P22095, DOI 10.18632/oncotarget.25188
   Han XT, 2017, ONCOTARGET, V8, P100931, DOI 10.18632/oncotarget.21753
   Jensen KV, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0189670
   Kohsaka S, 2012, MOL CANCER THER, V11, P1289, DOI 10.1158/1535-7163.MCT-11-0801
   Lai CS, 2013, ROY SOC CH, V344, P281
   Lee B, 2018, ANIM CELLS SYST, V22, P54, DOI 10.1080/19768354.2018.1426627
   Li SM, 2008, ACS SYM SER, V987, P191
   Li YR, 2016, CANCER BIOL THER, V17, P48, DOI 10.1080/15384047.2015.1108491
   Lin GS, 2014, MED ONCOL, V31, DOI 10.1007/s12032-014-0924-5
   Linder B, 2019, CANCERS, V11, DOI 10.3390/cancers11030333
   Luwor RB, 2013, J CLIN NEUROSCI, V20, P907, DOI 10.1016/j.jocn.2013.03.006
   Ma NH, 2014, J FUNCT FOODS, V11, P528, DOI 10.1016/j.jff.2014.08.009
   Masliantsev K, 2018, ONCOTARGET, V9, P3968, DOI 10.18632/oncotarget.23374
   Okuyama S, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18030489
   Ostrom QT, 2018, NEURO-ONCOLOGY, V20, P1, DOI 10.1093/neuonc/noy131
   Ouedraogo ZG, 2017, MOL NEUROBIOL, V54, P5780, DOI 10.1007/s12035-016-0103-0
   Pearson JRD, 2017, SIGNAL TRANSDUCT TAR, V2, DOI 10.1038/sigtrans.2017.40
   Periyasamy K, 2015, CANCER CHEMOTH PHARM, V75, P263, DOI 10.1007/s00280-014-2629-z
   Reardon DA, 2017, SEMIN IMMUNOPATHOL, V39, P225, DOI 10.1007/s00281-016-0616-7
   Shu ZP, 2014, INT IMMUNOPHARMACOL, V19, P275, DOI 10.1016/j.intimp.2014.01.011
   Stoyanov GS, 2018, MED ONCOL, V35, DOI 10.1007/s12032-018-1083-x
   Sundaram R, 2015, J FUNCT FOODS, V16, P315, DOI 10.1016/j.jff.2015.03.024
   Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024
   Tung Y., 2019, CURR PHARM REP, V5, P98, DOI DOI 10.1007/S40495-019-00170-Z
   Wang JH, 2014, CELL BIOCHEM BIOPHYS, V70, P1255, DOI 10.1007/s12013-014-0049-7
   Wang X., 2018, J FOOD BIOACT, V3, P76
   Wu CF, 2019, J CELL BIOCHEM, V120, P4883, DOI 10.1002/jcb.27762
   Yamamoto K, 1999, MOL CELL BIOL, V19, P8469
   Yuan G, 2014, J BIOL CHEM, V289, P10607, DOI 10.1074/jbc.M113.528760
   Zhi D, 2014, FOOD SCI HUM WELL, V3, P197, DOI [10.1080/15384047.2015.1108491, DOI 10.1080/15384047.2015.1108491, 10.1016/j.fshw.2014.12.003, DOI 10.1016/J.FSHW.2014.12.003]
NR 36
TC 8
Z9 9
U1 3
U2 6
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD JUL 1
PY 2019
VL 20
IS 13
AR 3366
DI 10.3390/ijms20133366
PG 14
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA IL1EG
UT WOS:000477041100250
PM 31323961
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Maisonneuve, C
   Tsang, DKL
   Foerster, EG
   Robert, LM
   Mukherjee, T
   Prescott, D
   Tattoli, I
   Lemire, P
   Winer, DA
   Winer, S
   Streutker, CJ
   Geddes, K
   Cadwell, K
   Ferrero, RL
   Martin, A
   Girardin, SE
   Philpott, DJ
AF Maisonneuve, Charles
   Tsang, Derek K. L.
   Foerster, Elisabeth G.
   Robert, Lukian Maxence
   Mukherjee, Tapas
   Prescott, Dave
   Tattoli, Ivan
   Lemire, Paul
   Winer, Daniel A.
   Winer, Shawn
   Streutker, Catherine J.
   Geddes, Kaoru
   Cadwell, Ken
   Ferrero, Richard L.
   Martin, Alberto
   Girardin, Stephen E.
   Philpott, Dana J.
TI Nod1 promotes colorectal carcinogenesis by regulating the
   immunosuppressive functions of tumor-infiltrating myeloid cells
SO CELL REPORTS
LA English
DT Article
ID MULTIPLE INTESTINAL NEOPLASIA; IMMUNE RECEPTOR NOD1; NF-KAPPA-B; MURAMYL
   DIPEPTIDE; SUPPRESSOR-CELLS; BACTERIAL PEPTIDOGLYCAN; ALTERNATIVE
   ACTIVATION; IMMUNOACTIVE PEPTIDES; HOST RECOGNITION; T-CELLS
AB Pioneering studies from the early 1980s suggested that bacterial peptidoglycan-derived muramyl peptides (MPs) could exert either stimulatory or immunosuppressive functions depending, in part, on chronicity of exposure. However, this Janus-faced property of MPs remains largely unexplored. Here, we demonstrate the immunosuppressive potential of Nod1, the bacterial sensor of diaminopimelic acid (DAP)-containing MPs. Using a model of self-limiting peritonitis, we show that systemic Nod1 activation promotes an autophagy-dependent reprogramming of macrophages toward an alternative phenotype. Moreover, Nod1 stimulation induces the expansion of myeloid-derived suppressor cells (MDSCs) and maintains their immunosuppressive potential via arginase-1 activity. Supporting the role of MDSCs and tumor-associated macrophages in cancer. we demonstrate that myeloid-intrinsic Nod1 expression sustains intra-tumoral arginase-1 levels to foster an immunosuppressive and tumor-permissive microenvironment during colorectal cancer (CRC) development. Our findings support the notion that bacterial products, via Nod1 detection, modulate the immunosuppressive activity of myeloid cells and fuel tumor progression in CRC.
C1 [Maisonneuve, Charles; Tsang, Derek K. L.; Foerster, Elisabeth G.; Robert, Lukian Maxence; Mukherjee, Tapas; Prescott, Dave; Tattoli, Ivan; Winer, Daniel A.; Geddes, Kaoru; Martin, Alberto; Girardin, Stephen E.; Philpott, Dana J.] Univ Toronto, Dept Immunol, Toronto, ON M5S 1A8, Canada.
   [Tattoli, Ivan; Lemire, Paul; Winer, Daniel A.; Winer, Shawn; Streutker, Catherine J.; Girardin, Stephen E.] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5S 1A8, Canada.
   [Winer, Daniel A.] Univ Toronto, Toronto Gen Hosp, Dept Pathol, Toronto, ON M5S 1A8, Canada.
   [Winer, Shawn; Streutker, Catherine J.] St Michaels Hosp, Toronto, ON M5B 1W8, Canada.
   [Cadwell, Ken] New York Grossman Univ, Kimmel Ctr Biol & Med, Grossman Sch Med, Skirball Inst, New York, NY 10016 USA.
   [Cadwell, Ken] NYU, Dept Microbiol, Grossman Sch Med, New York, NY 10016 USA.
   [Cadwell, Ken] NYU, Dept Med, Div Gastroenterol & Hepatol, Grossman Sch Med, New York, NY 10016 USA.
   [Winer, Daniel A.] Buck Inst Res Aging, Novato, CA 94945 USA.
   [Ferrero, Richard L.] Monash Univ, Dept Mol & Translat Sci, Clayton, Vic 3800, Australia.
   [Ferrero, Richard L.] Hudson Inst Med Res, Ctr Innate Immun & Infect Dis, Clayton, Vic 3168, Australia.
   [Ferrero, Richard L.] Monash Univ, Biomed Discovery Inst, Dept Microbiol, Clayton, Vic 3800, Australia.
RP Philpott, DJ (corresponding author), Univ Toronto, Dept Immunol, Toronto, ON M5S 1A8, Canada.
EM dana.philpott@utoronto.ca
RI Tattoli, Ivan/H-2600-2017
OI Tattoli, Ivan/0000-0001-7925-4609; Prescott, David/0000-0002-9798-9526;
   Foerster, Elisabeth/0000-0002-3271-0782; Cadwell,
   Ken/0000-0002-5860-0661
FU Canadian Cancer Society Research InstituteCanadian Cancer Society (CCS)
   [703185]; Canadian Institutes for Health Research (CIHR) Team
   Grant-Environments, Genes, and Chronic DiseaseCanadian Institutes of
   Health Research (CIHR) [ECD-144628]; Canada's National Microbiology
   Laboratory; National Health and Medical Research Council (NHMRC) of
   AustraliaNational Health and Medical Research Council (NHMRC) of
   Australia [APP1107930]; Victorian State Government Operational
   Infrastructure Scheme; Queen Elizabeth II/Aventis Pasteur Graduate
   Scholarship in Science and Technology
FX The authors of this paper would like to thank Dionne White and Joanna
   Warzyszynska for their expert FACS assistance and the University of
   Toronto Department of Comparative Medicine animal facility for their
   assistance. This work was supported by grants from the Canadian Cancer
   Society Research Institute (703185 to D.J.P. and A.M.); a Canadian
   Institutes for Health Research (CIHR) Team Grant-Environments, Genes,
   and Chronic Disease (ECD-144628 to D.J.P., S.E.G., and A.M.); Canada's
   National Microbiology Laboratory; the National Health and Medical
   Research Council (NHMRC) of Australia (APP1107930); and the Victorian
   State Government Operational Infrastructure Scheme. R.L.F. is an NHMRC
   Senior Research Fellow (APP1079904). C.M. was supported by the Queen
   Elizabeth II/Aventis Pasteur Graduate Scholarship in Science and
   Technology.
CR Alissafi T, 2018, J CLIN INVEST, V128, P3840, DOI 10.1172/JCI120888
   Bain CC, 2014, NAT IMMUNOL, V15, P929, DOI 10.1038/ni.2967
   Biswas SK, 2009, TRENDS IMMUNOL, V30, P475, DOI 10.1016/j.it.2009.07.009
   Ghosn EEB, 2010, P NATL ACAD SCI USA, V107, P2568, DOI 10.1073/pnas.0915000107
   Bronte V, 2003, J IMMUNOL, V170, P270, DOI 10.4049/jimmunol.170.1.270
   Bronte V, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12150
   Burns MB, 2018, PLOS GENET, V14, DOI 10.1371/journal.pgen.1007376
   Byles V, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3834
   Bystrom J, 2008, BLOOD, V112, P4117, DOI 10.1182/blood-2007-12-129767
   Castellarin M, 2012, GENOME RES, V22, P299, DOI 10.1101/gr.126516.111
   Chamaillard M, 2003, NAT IMMUNOL, V4, P702, DOI 10.1038/ni945
   Chang CP, 2013, CELL DEATH DIFFER, V20, P515, DOI 10.1038/cdd.2012.146
   Chang CP, 2013, AUTOPHAGY, V9, P619, DOI 10.4161/auto.23546
   Chen DG, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03225-9
   Chen GY, 2008, CANCER RES, V68, P10060, DOI 10.1158/0008-5472.CAN-08-2061
   Chen PW, 2013, INT REV CEL MOL BIO, V301, P1, DOI 10.1016/B978-0-12-407704-1.00001-4
   Colegio OR, 2014, NATURE, V513, P559, DOI 10.1038/nature13490
   Cortez-Retamozo V, 2012, P NATL ACAD SCI USA, V109, P2491, DOI 10.1073/pnas.1113744109
   De Schepper S, 2018, CELL, V175, P400, DOI 10.1016/j.cell.2018.07.048
   Diaz-Montero CM, 2009, CANCER IMMUNOL IMMUN, V58, P49, DOI 10.1007/s00262-008-0523-4
   Dobrovolskaia MA, 2002, MICROBES INFECT, V4, P903, DOI 10.1016/S1286-4579(02)01613-1
   Duan W, 2010, J ALLERGY CLIN IMMUN, V126, P1284, DOI 10.1016/j.jaci.2010.09.021
   Fairweather D, 2009, J AUTOIMMUN, V33, P222, DOI 10.1016/j.jaut.2009.09.012
   Fritz JH, 2007, IMMUNITY, V26, P445, DOI 10.1016/j.immuni.2007.03.009
   Gabrilovich DI, 2009, NAT REV IMMUNOL, V9, P162, DOI 10.1038/nri2506
   Geddes K, 2010, INFECT IMMUN, V78, P5107, DOI 10.1128/IAI.00759-10
   Geddes K, 2009, NAT REV DRUG DISCOV, V8, P465, DOI 10.1038/nrd2783
   Geiger R, 2016, CELL, V167, P829, DOI 10.1016/j.cell.2016.09.031
   Girardin SE, 2003, J BIOL CHEM, V278, P8869, DOI 10.1074/jbc.C200651200
   Girardin SE, 2003, J BIOL CHEM, V278, P41702, DOI 10.1074/jbc.M307198200
   Girardin SE, 2001, EMBO REP, V2, P736, DOI 10.1093/embo-reports/kve155
   Girardin SE, 2003, SCIENCE, V300, P1584, DOI 10.1126/science.1084677
   Gordon S, 2003, NAT REV IMMUNOL, V3, P23, DOI 10.1038/nri978
   Grimm WA, 2016, GUT, V65, P456, DOI 10.1136/gutjnl-2014-308735
   Guo Y, 2019, CANCER IMMUNOL IMMUN, V68, P1909, DOI 10.1007/s00262-019-02415-8
   Hadis U, 2011, IMMUNITY, V34, P237, DOI 10.1016/j.immuni.2011.01.016
   Hanahan D, 2012, CANCER CELL, V21, P309, DOI 10.1016/j.ccr.2012.02.022
   Harusato A, 2019, CANCER IMMUNOL RES, V7, P544, DOI 10.1158/2326-6066.CIR-18-0444
   Huang SCC, 2014, NAT IMMUNOL, V15, P846, DOI 10.1038/ni.2956
   Inohara N, 2003, J BIOL CHEM, V278, P5509, DOI 10.1074/jbc.C200673200
   Inohara N, 1999, J BIOL CHEM, V274, P14560, DOI 10.1074/jbc.274.21.14560
   Irving AT, 2014, CELL HOST MICROBE, V15, P623, DOI 10.1016/j.chom.2014.04.001
   Jiang HY, 2020, PROTEIN CELL, V11, P187, DOI 10.1007/s13238-019-00687-5
   Kang YH, 2016, ONCOTARGET, V7, P35577, DOI 10.18632/oncotarget.9590
   KITAURA Y, 1982, EXPERIENTIA, V38, P1101, DOI 10.1007/BF01955390
   Kobayashi KS, 2005, SCIENCE, V307, P731, DOI 10.1126/science.1104911
   Kostic AD, 2013, CELL HOST MICROBE, V14, P207, DOI 10.1016/j.chom.2013.07.007
   Kostic AD, 2012, GENOME RES, V22, P292, DOI 10.1101/gr.126573.111
   LECLERC C, 1982, EUR J IMMUNOL, V12, P249, DOI 10.1002/eji.1830120316
   Lessard AJ, 2017, CELL REP, V20, P1830, DOI 10.1016/j.celrep.2017.08.009
   Li Y, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0938-5
   Liu K, 2015, AUTOPHAGY, V11, P271, DOI 10.1080/15548627.2015.1009787
   Liu RR, 2015, ONCOTARGET, V6, P33456, DOI 10.18632/oncotarget.5587
   Lu TY, 2011, J CLIN INVEST, V121, P4015, DOI 10.1172/JCI45862
   Magalhaes JG, 2005, EMBO REP, V6, P1201, DOI 10.1038/sj.embor.7400552
   Magalhaes JG, 2011, P NATL ACAD SCI USA, V108, P14896, DOI 10.1073/pnas.1015063108
   Magalhaes JG, 2008, J IMMUNOL, V181, P7925, DOI 10.4049/jimmunol.181.11.7925
   Mamantopoulos M, 2018, GUT MICROBES, V9, P374, DOI 10.1080/19490976.2017.1421888
   McAllister SS, 2014, NAT CELL BIOL, V16, P717, DOI 10.1038/ncb3015
   McCoy AN, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053653
   Medvedev AE, 2006, J ENDOTOXIN RES, V12, P133, DOI 10.1179/096805106X102255
   MINE Y, 1983, J ANTIBIOT, V36, P1059, DOI 10.7164/antibiotics.36.1059
   MINE Y, 1983, J ANTIBIOT, V36, P1045, DOI 10.7164/antibiotics.36.1045
   Miret JJ, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0504-5
   MOSER AR, 1990, SCIENCE, V247, P322, DOI 10.1126/science.2296722
   Nagaraj S, 2007, NAT MED, V13, P828, DOI 10.1038/nm1609
   OuYang LY, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0410-7
   Pauleau AL, 2004, J IMMUNOL, V172, P7565, DOI 10.4049/jimmunol.172.12.7565
   Pedrosa L., 2019, CANCERS, V11, P861
   Prescott D, 2020, P NATL ACAD SCI USA, V117, P10946, DOI 10.1073/pnas.1912866117
   Quail DF, 2013, NAT MED, V19, P1423, DOI 10.1038/nm.3394
   Robertson SJ, 2019, CELL REP, V27, P1910, DOI 10.1016/j.celrep.2019.04.023
   Robertson SJ, 2013, GUT MICROBES, V4, P222, DOI 10.4161/gmic.24373
   Rodriguez PC, 2004, CANCER RES, V64, P5839, DOI 10.1158/0008-5472.CAN-04-0465
   Rommereim L, 2019, J IMMUNOL, V202
   Senda T, 2007, MED MOL MORPHOL, V40, P68, DOI 10.1007/s00795-006-0352-5
   Shand FHW, 2014, P NATL ACAD SCI USA, V111, P7771, DOI 10.1073/pnas.1402914111
   Shaw TN, 2018, J EXP MED, V215, P1507, DOI 10.1084/jem.20180019
   SOUVANNAVONG V, 1980, EUR J IMMUNOL, V10, P654, DOI 10.1002/eji.1830100814
   Stranks AJ, 2015, J INNATE IMMUN, V7, P375, DOI 10.1159/000370112
   SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108
   Travassos LH, 2010, NAT IMMUNOL, V11, P55, DOI 10.1038/ni.1823
   Youn JI, 2008, J IMMUNOL, V181, P5791, DOI 10.4049/jimmunol.181.8.5791
   Zhan Y, 2016, J IMMUNOL, V196, P5121, DOI 10.4049/jimmunol.1501822
   ZIDEK Z, 1983, EUR J IMMUNOL, V13, P859, DOI 10.1002/eji.1830131015
   Zigmond E, 2014, IMMUNITY, V40, P720, DOI 10.1016/j.immuni.2014.03.012
NR 86
TC 15
Z9 15
U1 0
U2 5
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 2211-1247
J9 CELL REP
JI Cell Reports
PD JAN 26
PY 2021
VL 34
IS 4
AR 108677
DI 10.1016/j.celrep.2020.108677
EA JAN 2021
PG 24
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA QA7OV
UT WOS:000613631500019
PM 33503439
OA gold
DA 2022-04-25
ER

PT J
AU Kang, Y
   Jia, YL
   Wang, QL
   Zhao, QR
   Song, M
   Ni, R
   Wang, J
AF Kang, Yan
   Jia, Yaoli
   Wang, Qilong
   Zhao, Qianru
   Song, Meng
   Ni, Ran
   Wang, Jing
TI Long Noncoding RNA KCNQ1OT1 Promotes the Progression of Non-Small Cell
   Lung Cancer via Regulating miR-204-5p/ATG3 Axis
SO ONCOTARGETS AND THERAPY
LA English
DT Article
DE KCNQ1OT1; miR-204-5p; ATG3; NSCLC
ID LNCRNA KCNQ1OT1; HEPATOCELLULAR-CARCINOMA; COLORECTAL-CANCER;
   TUMOR-SUPPRESSOR; PROLIFERATION; METASTASIS; EXPRESSION; INVASION; A549
AB Purpose: Non-small cell lung cancer (NSCLC) is the first leading cause of cancer-related death globally. Long noncoding RNA KCNQ1 overlapping transcript 1 (KCNQ1OT1) was involved in the progression of multiple cancers by sponging target miRNA. We aimed to explore the pathological mechanism of KCNQ1OT1 in NSCLC progression.
   Methods: The expression of KCNQ1OT1, miR-204-5p and autophagy-related gene 3 (ATG3) was measured by quantitative real-time polymerase chain reaction (qRT-PCR). 3-(4, 5-Dimethyl-2-thiazolyl)-2, 5-diphenyl-2-H-tetrazolium bromide (MTT) assay and flow cytometry assay were conducted for the detection of cell proliferation and apoptosis, respectively. Western blot assay was performed to examine the protein levels of B-cell lymphoma-2 (BCL-2), BCL2-Associated X (Bax), cleaved caspase-3, cleaved caspase-9 and LC3 II /LC3 I and P62. The interaction between miR-204-5p and KCNQ1OT1 or ATG3 was validated by dual-luciferase reporter system and RNA immunoprecipitation (RIP) assay. Murine xenograft assay was conducted to explore the function of KCNQ1OT1 in vivo Immunohistochemistry (IHC) staining assay was used for the analysis of ki67-positive cell percentage.
   Results: The expression of KCNQ1OT1 and ATG3 was up-regulated whereas miR-204-5p was down-regulated in NSCLC tumors and cells. MiR-204-5p was inversely con elated with KCNQ1OT1 or ATG3. In addition, KCNQ1OT1 knockdown facilitated apoptosis, inhibited autophagy and proliferation of NSCLC cells in vitro and blocked tumor growth in vivo. However, the miR-204-5p inhibitor reversed the effects. More importantly, ATG3 was a target gene of miR-204-5p and ATG3 overexpression restored the effect of miR-204-5p on NSCLC cell progression.
   Conclusion: KCNQ1OT1 promotes cell proliferation and autophagy and inhibits cell apoptosis via regulating miR-204-5p/ATG3 axis, providing a promising target for NSCLC therapy.
C1 [Kang, Yan; Wang, Qilong; Ni, Ran; Wang, Jing] Zhengzhou Univ, Affiliated Hosp 1, Dept Resp Med 2, 1 Jianshe East Rd, Zhengzhou 450052, Henan, Peoples R China.
   [Jia, Yaoli] Xuchang Cent Hosp, Dept Resp Med, Xuchang, Henan, Peoples R China.
   [Zhao, Qianru] Zhengzhou Univ, Affiliated Hosp 1, Dept Geriatr Med, Zhengzhou, Henan, Peoples R China.
   [Song, Meng] Zhengzhou Univ, Coll Publ Hlth, Dept Epidemiol & Hlth Stat, Zhengzhou, Henan, Peoples R China.
RP Ni, R; Wang, J (corresponding author), Zhengzhou Univ, Affiliated Hosp 1, Dept Resp Med 2, 1 Jianshe East Rd, Zhengzhou 450052, Henan, Peoples R China.
EM anxian218911qco@126.com; shijin199410ut@126.com
CR Ai XH, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4224-x
   Bian YZ, 2019, CANCER BIOL THER, V20, P886, DOI 10.1080/15384047.2019.1579959
   Chang RM, 2014, HEPATOLOGY, V60, P1251, DOI 10.1002/hep.27221
   Chung TKH, 2012, INT J CANCER, V130, P1036, DOI 10.1002/ijc.26060
   Cui M, 2019, J CELL BIOCH
   Dong ZW, 2019, J CELL PHYSIOL, V234, P11304, DOI 10.1002/jcp.27788
   Feng WL, 2018, CELL PHYSIOL BIOCHEM, V49, P432, DOI 10.1159/000492978
   Gao W, 2017, J CANCER, V8, P2356, DOI 10.7150/jca.19470
   Gao XR, 2018, BIOL CHEM, V399, P375, DOI 10.1515/hsz-2017-0215
   Hu HQ, 2018, BIOCHEM BIOPH RES CO, V503, P2400, DOI 10.1016/j.bbrc.2018.06.168
   Hua L, 2018, CELL BIOL INT, V42, P1240, DOI 10.1002/cbin.10995
   Imam JS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052397
   Jia H, 2019, PATHOL RES PRACT, V215, P697, DOI 10.1016/j.prp.2018.12.039
   Jiang GB, 2016, CELL BIOCHEM FUNCT, V34, P505, DOI 10.1002/cbf.3223
   Li C, 2019, J CELL PHYSL
   Li M, 2019, BIOCHIMIE, V158, P224, DOI 10.1016/j.biochi.2018.12.003
   Li N, 2018, GYNECOL ONCOL, V150, P343, DOI 10.1016/j.ygyno.2018.06.013
   Li Q, 2016, INT J MOL MED, V37, P1067, DOI 10.3892/ijmm.2016.2513
   Li YC, 2019, ONCOTARGETS THER, V12, P2649, DOI 10.2147/OTT.S188054
   Liu LY, 2015, BIOCHEM BIOPH RES CO, V457, P621, DOI 10.1016/j.bbrc.2015.01.037
   Liu TM, 2018, BIOCHEM BIOPH RES CO, V503, P1503, DOI 10.1016/j.bbrc.2018.07.070
   Luan WK, 2017, ONCOTARGETS THER, V10, P1237, DOI 10.2147/OTT.S128819
   Luan XT, 2018, J GYNECOL ONCOL, V29, DOI 10.3802/jgo.2018.29.e95
   Moravcikova E, 2017, INT J CANCER, V141, P2050, DOI 10.1002/ijc.30906
   Shao J, 2019, J CELL PHYSIOL, V234, P17269, DOI 10.1002/jcp.28344
   Sumbul AT, 2014, TUMOR BIOL, V35, P12713, DOI 10.1007/s13277-014-2596-3
   Sun HW, 2018, ARCH BIOCHEM BIOPHYS, V658, P7, DOI 10.1016/j.abb.2018.09.019
   Sun X, 2018, THORAC CANCER, V9, P523, DOI 10.1111/1759-7714.12599
   Tang QL, 2018, INT J ONCOL, V53, P1732, DOI 10.3892/ijo.2018.4493
   Wang CG, 2019, EXP MOL PATHOL, V107, P77, DOI 10.1016/j.yexmp.2019.01.012
   Wang H, 2018, ONCOL REP, V39, P247, DOI 10.3892/or.2017.6088
   Wang XJ, 2016, BIOMED PHARMACOTHER, V82, P202, DOI 10.1016/j.biopha.2016.04.060
   Wang YZ, 2018, CANCER BIOMARK, V22, P721, DOI 10.3233/CBM-181228
   Wang YX, 2018, CANCER CELL INT, V18, DOI 10.1186/s12935-018-0628-6
   Xie YD, 2019, BIOMED PHARMACOTHER, V109, P679, DOI 10.1016/j.biopha.2018.10.097
   Yin Y, 2014, CLIN CANCER RES, V20, P6187, DOI 10.1158/1078-0432.CCR-14-1030
   You JW, 2018, MED SCI MONITOR, V24, P2126, DOI 10.12659/MSM.909627
   Zhang SY, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0793-5
   Zheng L, 2019, EUR REV MED PHARMACO, V23, P6944, DOI 10.26355/eurrev_201908_18734
NR 39
TC 40
Z9 40
U1 0
U2 4
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-6930
J9 ONCOTARGETS THER
JI OncoTargets Ther.
PY 2019
VL 12
BP 10787
EP 10797
DI 10.2147/OTT.S226044
PG 11
WC Biotechnology & Applied Microbiology; Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Oncology
GA JV1NO
UT WOS:000502135400001
PM 31849486
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Gutierrez-Salmeron, M
   Garcia-Martinez, JM
   Martinez-Useros, J
   Fernandez-Acenero, MJ
   Viollet, B
   Olivier, S
   Chauhan, J
   Lucena, SR
   De la Vieja, A
   Goding, CR
   Chocarro-Calvo, A
   Garcia-Jimenez, C
AF Gutierrez-Salmeron, Maria
   Manuel Garcia-Martinez, Jose
   Martinez-Useros, Javier
   Jesus Fernandez-Acenero, Maria
   Viollet, Benoit
   Olivier, Severine
   Chauhan, Jagat
   Lucena, Silvia R.
   De la Vieja, Antonio
   Goding, Colin R.
   Chocarro-Calvo, Ana
   Garcia-Jimenez, Custodia
TI Paradoxical activation of AMPK by glucose drives selective EP300
   activity in colorectal cancer
SO PLOS BIOLOGY
LA English
DT Article
ID PROTEIN-KINASE; HISTONE ACETYLTRANSFERASE; GENE-EXPRESSION; P300
   ACETYLATION; PHOSPHORYLATION; TRANSCRIPTION; MECHANISMS; METFORMIN;
   METABOLISM; AUTOPHAGY
AB Coordination of gene expression with nutrient availability supports proliferation and homeostasis and is shaped by protein acetylation. Yet how physiological/pathological signals link acetylation to specific gene expression programs and whether such responses are cell-type-specific is unclear. AMP-activated protein kinase (AMPK) is a key energy sensor, activated by glucose limitation to resolve nutrient supply-demand imbalances, critical for diabetes and cancer. Unexpectedly, we show here that, in gastrointestinal cancer cells, glucose activates AMPK to selectively induce EP300, but not CREB-binding protein (CBP). Consequently, EP300 is redirected away from nuclear receptors that promote differentiation towards beta-catenin, a driver of proliferation and colorectal tumorigenesis. Importantly, blocking glycogen synthesis permits reactive oxygen species (ROS) accumulation and AMPK activation in response to glucose in previously nonresponsive cells. Notably, glycogen content and activity of the ROS/AMPK/EP300/beta-catenin axis are opposite in healthy versus tumor sections. Glycogen content reduction from healthy to tumor tissue may explain AMPK switching from tumor suppressor to activator during tumor evolution.
C1 [Gutierrez-Salmeron, Maria; Manuel Garcia-Martinez, Jose; Lucena, Silvia R.; Chocarro-Calvo, Ana; Garcia-Jimenez, Custodia] Univ Rey Juan Carlos, Fac Hlth Sci, Area Physiol, Madrid, Spain.
   [Martinez-Useros, Javier] Univ Hosp Fdn Jimenez Diaz UAM, OncoHlth Inst, Translat Oncol Div, Hlth Res Inst, Madrid, Spain.
   [Jesus Fernandez-Acenero, Maria] Hosp Gregorio Maranon, Dept Surg Pathol, Madrid, Spain.
   [Viollet, Benoit; Olivier, Severine] Univ Paris, Inst Cochin, INSERM, CNRS, Paris, France.
   [Chauhan, Jagat; Goding, Colin R.; Chocarro-Calvo, Ana] Univ Oxford, Ludwig Inst Canc Res, Nuffield Dept Med, Oxford, England.
   [De la Vieja, Antonio] Inst Salud Carlos III, Unidad Tumores Endocrinos UFIEC, Madrid, Spain.
   [De la Vieja, Antonio] CiberOnc, Madrid, Spain.
RP Chocarro-Calvo, A; Garcia-Jimenez, C (corresponding author), Univ Rey Juan Carlos, Fac Hlth Sci, Area Physiol, Madrid, Spain.; Chocarro-Calvo, A (corresponding author), Univ Oxford, Ludwig Inst Canc Res, Nuffield Dept Med, Oxford, England.
EM ana.chocarro@urjc.es; custodia.garcia@urjc.es
RI Chocarro-Calvo, Ana/AAM-3213-2020; García-Jiménez,
   Custodia/AAS-7744-2020; De la Vieja, Antonio/I-4774-2013; Viollet,
   Benoit/N-2397-2019; Viollet, Benoit/O-6927-2017; Lucena, Silvia
   Rocio/M-5703-2014
OI Chocarro-Calvo, Ana/0000-0003-1476-4848; García-Jiménez,
   Custodia/0000-0003-0146-4424; De la Vieja, Antonio/0000-0002-1187-1907;
   Viollet, Benoit/0000-0002-0121-0224; Viollet,
   Benoit/0000-0002-0121-0224; Garcia Martinez, Jose
   Manuel/0000-0002-6498-5174; Fernandez-Acenero/0000-0002-2439-3553;
   Gutierrez-Salmeron, Maria/0000-0002-6818-6951; Olivier,
   Severine/0000-0002-7653-2295; Lucena, Silvia Rocio/0000-0002-1803-3922
FU Spanish governmentSpanish GovernmentEuropean Commission
   [AEI,Mineco/FEDER SAF2016-79837-R, PID2019-110998RB-100, MICIU/FEDER:
   RTI2018-099343-B-100]; European UnionEuropean Commission
   [PIEF-GA-2013-626098]; EMBO Postdoctoral Long-Term Fellowship [ALTF
   800-2013]; Comunidad de Madrid: Ayudas Atraccion de TalentoComunidad de
   Madrid [2017-T1/BMD-5334]; Comunidad de MadridComunidad de Madrid
   [FEDER-PEJD-2017-POST/BMD-3906]; Ludwig Institute for Cancer Research;
   INSERMInstitut National de la Sante et de la Recherche Medicale
   (Inserm)European Commission; CNRSCentre National de la Recherche
   Scientifique (CNRS)European Commission; Universite Paris Descartes; SFD
   (Societe Francophone du Diabete); Region Ile-deFranceRegion
   Ile-de-France
FX The financial support of the Spanish government (Grant Numbers: AEI,
   Mineco/FEDER SAF2016-79837-R and PID2019-110998RB-100 to CG-J and
   MICIU/FEDER: RTI2018-099343-B-100 to
   AV)(http://www.ciencia.gob.es/portal/site/MICINN/aei) is gratefully
   acknowledged. A.C-C. was supported by a European Union Marie Curie
   FP7-PEOPLE-2013-IEF (PIEF-GA-2013-626098), EMBO Postdoctoral Long-Term
   Fellowship (ALTF 800-2013) and by Comunidad de Madrid: Ayudas Atraccion
   de Talento (2017-T1/BMD-5334);
   (https://gestiona3.madrid.org/quadrivium/convocatorias/home/talento).SR.
   L.was supported by Comunidad de Madrid/FEDER-PEJD-2017-POST/BMD-3906.
   (https://gestiona3.madrid.org/quadrivium/convocatorias/) J.C. and C.R.G.
   were supported by the Ludwig Institute for Cancer Research
   (https://www.ludwig.ox.ac.uk/).B.V.was funded by INSERM, CNRS,
   Universite Paris Descartes (http://www.idf.inserm.fr/) and SFD (Societe
   Francophone du Diabete: https://www.sfdiabete.org/) and S.O. by the
   Region Ile-deFrance. The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Abbud W, 2000, ARCH BIOCHEM BIOPHYS, V380, P347, DOI 10.1006/abbi.2000.1935
   Arif M, 2007, J PHYS CHEM B, V111, P11877, DOI 10.1021/jp0762931
   Attar N, 2017, CSH PERSPECT MED, V7, DOI 10.1101/cshperspect.a026534
   Barbachano A, 2017, VITAMIN D, P837, DOI [10.1016/B978-0-12-809963-6.00099-7, DOI 10.1016/B978-0-12-809963-6.00099-7]
   Bhanot H, 2013, BLOOD, V122, DOI 10.1182/blood.V122.21.1479.1479
   Bowers EM, 2010, CHEM BIOL, V17, P471, DOI 10.1016/j.chembiol.2010.03.006
   Brownlee M, 2001, NATURE, V414, P813, DOI 10.1038/414813a
   Bugyei-Twum A, 2014, CARDIOVASC DIABETOL, V13, DOI 10.1186/1475-2840-13-89
   Cardinaux JR, 2000, MOL CELL BIOL, V20, P1546, DOI 10.1128/MCB.20.5.1546-1552.2000
   Carling D, 2012, BIOCHEM J, V445, P11, DOI 10.1042/BJ20120546
   Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095
   Chang MY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040999
   Chen SL, 2010, AM J PHYSIOL-ENDOC M, V298, pE127, DOI 10.1152/ajpendo.00432.2009
   Chocarro-Calvo A, 2013, MOL CELL, V49, P474, DOI 10.1016/j.molcel.2012.11.022
   Choi SL, 2001, BIOCHEM BIOPH RES CO, V287, P92, DOI 10.1006/bbrc.2001.5544
   Dancy BM, 2015, CHEM REV, V115, P2419, DOI 10.1021/cr500452k
   De Luca G, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000266
   Delvecchio M, 2013, NAT STRUCT MOL BIOL, V20, P1040, DOI 10.1038/nsmb.2642
   Emerling BM, 2009, FREE RADICAL BIO MED, V46, P1386, DOI 10.1016/j.freeradbiomed.2009.02.019
   Foretz M, 2014, CELL METAB, V20, P953, DOI 10.1016/j.cmet.2014.09.018
   Gang XK, 2016, ONCOTARGET, V7, P15135, DOI 10.18632/oncotarget.7715
   Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088
   Garcia D, 2017, MOL CELL, V66, P789, DOI 10.1016/j.molcel.2017.05.032
   Garcia-Jimenez C, 2019, CELL METAB, V29, P254, DOI 10.1016/j.cmet.2018.11.018
   Garcia-Jimenez C, 2016, BRIT J CANCER, V114, P716, DOI 10.1038/bjc.2016.37
   Goransson O, 2007, J BIOL CHEM, V282, P32549, DOI 10.1074/jbc.M706536200
   Grenier A, 2018, METHODS MOL BIOL, V1732, P171, DOI 10.1007/978-1-4939-7598-3_11
   Gutierrez-Salmeron M, 2017, REV ENDOCRINOLOGIA D, V64, P109, DOI 10.1016/j.endinu.2016.10.005
   Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604
   Hardie DG, 2012, NAT REV MOL CELL BIO, V13, P251, DOI 10.1038/nrm3311
   Hardie David Grahame, 2017, F1000Res, V6, P1724, DOI 10.12688/f1000research.11960.1
   He L, 2012, J BIOL CHEM, V287, P32069, DOI 10.1074/jbc.M112.385864
   Henry RA, 2015, ACS CHEM BIOL, V10, P146, DOI 10.1021/cb500726b
   Henry RA, 2013, BIOCHEMISTRY-US, V52, P5746, DOI 10.1021/bi400684q
   Hu SC, 1999, NEURON, V22, P799, DOI 10.1016/S0896-6273(00)80738-2
   Huang WC, 2005, MOL CELL BIOL, V25, P6592, DOI 10.1128/MCB.25.15.6592-6602.2005
   Janzen NR, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113344
   Karmodiya K, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-424
   Kim Y, 2016, KIDNEY RES CLIN PRAC, V35, P69, DOI 10.1016/j.krcp.2016.02.004
   Lee IH, 2009, J BIOL CHEM, V284, P6322, DOI 10.1074/jbc.M807135200
   Li XD, 2015, CELL RES, V25, P50, DOI 10.1038/cr.2014.150
   Liberzon A, 2011, BIOINFORMATICS, V27, P1739, DOI 10.1093/bioinformatics/btr260
   Lin SC, 2018, CELL METAB, V27, P299, DOI 10.1016/j.cmet.2017.10.009
   Liou GY, 2010, FREE RADICAL RES, V44, P479, DOI 10.3109/10715761003667554
   Liu F, 2016, NAT REV CANCER, V16, P359, DOI 10.1038/nrc.2016.41
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   McBride A, 2009, CELL METAB, V9, P23, DOI 10.1016/j.cmet.2008.11.008
   Menyhart O, 2018, ROY SOC OPEN SCI, V5, DOI 10.1098/rsos.181006
   Mihaylova MM, 2011, NAT CELL BIOL, V13, P1016, DOI 10.1038/ncb2329
   Olivier S, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20205171
   Olivier S, 2018, BIOCHEM PHARMACOL, V153, P147, DOI 10.1016/j.bcp.2018.01.049
   Otto M, 2003, DIABETES OBES METAB, V5, P189, DOI 10.1046/j.1463-1326.2003.00263.x
   Parang B, 2016, METHODS MOL BIOL, V1422, P297, DOI 10.1007/978-1-4939-3603-8_26
   Pietrocola F, 2015, CELL METAB, V21, P805, DOI 10.1016/j.cmet.2015.05.014
   Rena G, 2017, DIABETOLOGIA, V60, P1577, DOI 10.1007/s00125-017-4342-z
   Riesenberg S, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9755
   Sakar Y, 2010, J PHYSIOL PHARMACOL, V61, P301
   Salt IP, 1998, BIOCHEM J, V335, P533, DOI 10.1042/bj3350533
   Suissa S, 2014, DIABETES CARE, V37, P1786, DOI 10.2337/dc14-0500
   Szerlong HJ, 2010, J BIOL CHEM, V285, P31954, DOI 10.1074/jbc.M110.148718
   Tanaka T, 2003, CANCER SCI, V94, P965, DOI 10.1111/j.1349-7006.2003.tb01386.x
   Thompson PR, 2004, NAT STRUCT MOL BIOL, V11, P308, DOI 10.1038/nsmb740
   Turunen M, 2004, BBA-BIOMEMBRANES, V1660, P171, DOI 10.1016/j.bbamem.2003.11.012
   Ushio-Fukai M, 1999, J BIOL CHEM, V274, P22699, DOI 10.1074/jbc.274.32.22699
   Vara-Ciruelos D, 2019, OPEN BIOL, V9, DOI 10.1098/rsob.190099
   Vindis C, 2001, KIDNEY INT, V59, P76, DOI 10.1046/j.1523-1755.2001.00468.x
   Wan W, 2017, MOL CELL, V68, P323, DOI 10.1016/j.molcel.2017.09.020
   Wang L, 2008, CURR OPIN STRUC BIOL, V18, P741, DOI 10.1016/j.sbi.2008.09.004
   Wang SA, 2014, BBA-MOL CELL RES, V1843, P1135, DOI 10.1016/j.bbamcr.2014.02.001
   Woods A, 2000, MOL CELL BIOL, V20, P6704, DOI 10.1128/MCB.20.18.6704-6711.2000
   Wu N, 2013, MOL CELL, V49, P1167, DOI 10.1016/j.molcel.2013.01.035
   Xiao B, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms4017
   Yang WB, 2001, J BIOL CHEM, V276, P38341, DOI 10.1074/jbc.C100316200
   Yuan LW, 2002, BBA-MOL CELL RES, V1592, P205, DOI 10.1016/S0167-4889(02)00327-0
   Yuan LW, 2000, J BIOL CHEM, V275, P40946, DOI 10.1074/jbc.M007832200
   Zadra G, 2015, MOL CANCER RES, V13, P1059, DOI 10.1158/1541-7786.MCR-15-0068
   Zmijewski JW, 2010, J BIOL CHEM, V285, P33154, DOI 10.1074/jbc.M110.143685
   Zois CE, 2016, J MOL MED, V94, P137, DOI 10.1007/s00109-015-1377-9
NR 78
TC 5
Z9 5
U1 2
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1544-9173
EI 1545-7885
J9 PLOS BIOL
JI PLoS. Biol.
PD JUN
PY 2020
VL 18
IS 6
AR e3000732
DI 10.1371/journal.pbio.3000732
PG 29
WC Biochemistry & Molecular Biology; Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics
GA MH6AU
UT WOS:000546810300001
PM 32603375
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Li, XN
   Wang, ZJ
   Ye, CX
   Zhao, BC
   Li, ZL
   Yang, Y
AF Li, Xiang-Nan
   Wang, Zhen-Jun
   Ye, Chun-Xiang
   Zhao, Bao-Cheng
   Li, Zhu-Lin
   Yang, Yong
TI RNA sequencing reveals the expression profiles of circRNA and indicates
   that circDDX17 acts as a tumor suppressor in colorectal cancer
SO JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
LA English
DT Article
DE Colorectal cancer; Circular RNAs; High-throughput sequencing;
   Bioinformatic analysis; CircDDX17; Tumor suppressor
ID CIRCULAR RNAS; PROGNOSTIC MARKER; CONFERS; AUTOPHAGY
AB BackgroundCircular RNA (circRNA) is a novel class of noncoding RNAs with functions in various pathophysiological activities. However, the expression profiles and functions of circRNAs in colorectal cancer (CRC) remain largely unknown.MethodsHigh-throughput RNA sequencing (RNA-seq) was performed to assess circRNA expression profiles in 4 paired CRC tissues, and significantly dysregulated circRNAs were validated by quantitative real-time polymerase chain reaction (qRT-PCR). Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses were performed to predict the potential functions of dysregulated circRNAs. Target miRNAs of circRNAs were predicted using miRanda software, and were further analyzed combining DIANA-miRPath v.3 platform (Reverse Search module) with KEGG pathways of COLORECTAL CANCER and MicroRNAs in cancer (Entry: map05210 and map05206). CircRNA-miRNA interaction networks were constructed using Cytoscape software. Expression levels of a significantly down-regulated circRNA, circDDX17 (hsa_circ_0002211), was detected by qRT-PCR in 60 paired CRC tissues. CircDDX17 was knockdown by siRNA, and the biological functions of circDDX17 were examined in CRC cell lines.ResultsTotally 448 differentially expressed circRNAs were identified, including 394 up-regulated and 54 down-regulated circRNAs. qRT-PCR validation confirmed the reliability of the RNA-Seq data. GO and KEGG analyses revealed that these dysregulated circRNAs were potentially implicated in CRC pathogenesis. Analyses by combining miRanda and miRPath softwares with KEGG pathways suggested that the miRNAs targeted by the top 10 dysregulated circRNAs were associated with the KEGG pathways of COLORECTAL CANCER and MicroRNAs in cancer, indicating that circRNA-miRNA interactions might play important functional roles in the initiation and progression of CRC. The results of qRT-PCR for circDDX17 in 60 paired CRC tissues showed that circDDX17 was significantly down-regulated in CRC tissues and associated with unfavorable clinicopathological parameters. In vitro experiments showed that silencing of circDDX17 promoted CRC cell proliferation, migration, invasion, and inhibited apoptosis.ConclusionsIn conclusion, we have identified numerous circRNAs that are dysregulated in CRC tissues compared with adjacent normal mucosa tissues. Bioinformatic analyses suggested that these dysregulated circRNAs might play important functional roles in CRC tumorigenesis. CircDDX17 functions as a tumor suppressor and could serve as a potential biomarker and a therapeutic target for CRC.
C1 [Li, Xiang-Nan; Wang, Zhen-Jun; Ye, Chun-Xiang; Zhao, Bao-Cheng; Li, Zhu-Lin; Yang, Yong] Capital Med Univ, Beijing Chao Yang Hosp, Dept Gen Surg, 8 Gongtinan Rd, Beijing 100020, Peoples R China.
RP Wang, ZJ (corresponding author), Capital Med Univ, Beijing Chao Yang Hosp, Dept Gen Surg, 8 Gongtinan Rd, Beijing 100020, Peoples R China.
EM Drzhenjun@163.com
OI Wang, Zhen-jun/0000-0001-6885-9354
FU National High-Tech R & D Program of China (863 Program) [2015AA033602];
   1351 Personnel Training Program of Beijing Chao-Yang Hospital Affiliated
   to Capital Medical University [CYXZ-2017-09]
FX This study was supported by the National High-Tech R & D Program of
   China (863 Program) (2015AA033602); 1351 Personnel Training Program of
   Beijing Chao-Yang Hospital Affiliated to Capital Medical University
   (CYXZ-2017-09).
CR Barrett SP, 2016, DEVELOPMENT, V143, P1838, DOI 10.1242/dev.128074
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
   Brown J, 2017, BIOINFORMATICS, V33, P3137, DOI 10.1093/bioinformatics/btx373
   Castets M, 2012, NATURE, V482, P534, DOI 10.1038/nature10708
   Chen B, 2018, THERANOSTICS, V8, P4003, DOI 10.7150/thno.24106
   Chen J, 2017, CANCER LETT, V388, P208, DOI 10.1016/j.canlet.2016.12.006
   Dai M, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-S4-S7
   Enright AJ, 2004, GENOME BIOL, V5
   Fan XY, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-015-0706-1
   Fleming NI, 2013, CANCER RES, V73, P725, DOI 10.1158/0008-5472.CAN-12-2706
   Ghosal Suman, 2013, Frontiers in Genetics, V4, P283, DOI 10.3389/fgene.2013.00283
   Glazar P, 2014, RNA, V20, P1666, DOI 10.1261/rna.043687.113
   Granados-Riveron JT, 2016, BBA-GENE REGUL MECH, V1859, P1245, DOI 10.1016/j.bbagrm.2016.07.009
   Guo JU, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0409-z
   Guo XZ, 2015, ONCOL REP, V34, P2557, DOI 10.3892/or.2015.4240
   Han B, 2018, PHARMACOL THERAPEUT, V187, P31, DOI 10.1016/j.pharmthera.2018.01.010
   Han D, 2017, HEPATOLOGY, V66, P1151, DOI 10.1002/hep.29270
   He SS, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8839
   Holdt LM, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12429
   Jeck WR, 2013, RNA, V19, P141, DOI 10.1261/rna.035667.112
   Kim D, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-4-r36
   Li ZY, 2015, NAT STRUCT MOL BIOL, V22, P256, DOI 10.1038/nsmb.2959
   Lin PL, 2014, CARCINOGENESIS, V35, P2175, DOI 10.1093/carcin/bgu110
   Liu J, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0630-y
   Mazelin L, 2004, NATURE, V431, P80, DOI 10.1038/nature02788
   Memczak S, 2013, NATURE, V495, P333, DOI 10.1038/nature11928
   Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007
   Su Gang, 2014, Curr Protoc Bioinformatics, V47, DOI 10.1002/0471250953.bi0813s47
   Valle L, 2008, SCIENCE, V321, P1361, DOI 10.1126/science.1159397
   Vlachos IS, 2015, NUCLEIC ACIDS RES, V43, pW460, DOI 10.1093/nar/gkv403
   Wang RJ, 2018, CANCER RES, V78, P4812, DOI 10.1158/0008-5472.CAN-18-0532
   Xie C, 2011, NUCLEIC ACIDS RES, V39, pW316, DOI 10.1093/nar/gkr483
   Yu YJ, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0372-7
   Zhang XO, 2014, CELL, V159, P134, DOI 10.1016/j.cell.2014.09.001
   Zhao YG, 2017, MOL CELL, V67, P974, DOI 10.1016/j.molcel.2017.08.005
   Zhong ZY, 2016, CELL, V166, P288, DOI 10.1016/j.cell.2016.05.051
NR 36
TC 116
Z9 119
U1 9
U2 27
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1756-9966
J9 J EXP CLIN CANC RES
JI J. Exp. Clin. Cancer Res.
PD DEC 27
PY 2018
VL 37
AR 325
DI 10.1186/s13046-018-1006-x
PG 14
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA HF8NM
UT WOS:000454499100002
PM 30591054
OA gold, Green Published
HC Y
HP N
DA 2022-04-25
ER

PT J
AU Koehler, BC
   Jassowicz, A
   Scherr, AL
   Lorenz, S
   Radhakrishnan, P
   Kautz, N
   Elssner, C
   Weiss, J
   Jaeger, D
   Schneider, M
   Schulze-Bergkamen, H
AF Koehler, Bruno Christian
   Jassowicz, Adam
   Scherr, Anna-Lena
   Lorenz, Stephan
   Radhakrishnan, Praveen
   Kautz, Nicole
   Elssner, Christin
   Weiss, Johanna
   Jaeger, Dirk
   Schneider, Martin
   Schulze-Bergkamen, Henning
TI Pan-Bcl-2 inhibitor Obatoclax is a potent late stage autophagy inhibitor
   in colorectal cancer cells independent of canonical autophagy signaling
SO BMC CANCER
LA English
DT Article
DE Autophagy; Colorectal cancer; Apoptosis; Autophagy related gene; LC3;
   p62 (SQSTM1); Obatoclax; Chloroquine
ID REGULATES AUTOPHAGY; THERAPEUTIC TARGET; INDUCED APOPTOSIS;
   ACRIDINE-ORANGE; BCL-2 FAMILY; BH3 MIMETICS; RESISTANCE; BECLIN-1; LC3;
   CHLOROQUINE
AB Background: Colorectal cancer is the third most common malignancy in humans and novel therapeutic approaches are urgently needed. Autophagy is an evolutionarily highly conserved cellular process by which cells collect unnecessary organelles or misfolded proteins and subsequently degrade them in vesicular structures in order to refuel cells with energy. Dysregulation of the complex autophagy signaling network has been shown to contribute to the onset and progression of cancer in various models. The Bcl-2 family of proteins comprises central regulators of apoptosis signaling and has been linked to processes involved in autophagy. The antiapoptotic members of the Bcl-2 family of proteins have been identified as promising anticancer drug targets and small molecules inhibiting those proteins are in clinical trials.
   Methods: Flow cytometry and colorimetric assays were used to assess cell growth and cell death. Long term 3D cell culture was used to assess autophagy in a tissue mimicking environment in vitro. RNA interference was applied to modulate autophagy signaling. Immunoblotting and q-RT PCR were used to investigate autophagy signaling. Immunohistochemistry and fluorescence microscopy were used to detect autophagosome formation and autophagy flux.
   Results: This study demonstrates that autophagy inhibition by obatoclax induces cell death in colorectal cancer (CRC) cells in an autophagy prone environment. Here, we demonstrate that pan-Bcl-2 inhibition by obatoclax causes a striking, late stage inhibition of autophagy in CRC cells. In contrast, ABT-737, a Mcl-1 sparing Bcl-2 inhibitor, failed to interfere with autophagy signaling. Accumulation of p62 as well as Light Chain 3 (LC3) was observed in cells treated with obatoclax. Autophagy inhibition caused by obatoclax is further augmented in stressful conditions such as starvation. Furthermore, our data demonstrate that inhibition of autophagy caused by obatoclax is independent of the essential pro-autophagy proteins Beclin-1, Atg7 and Atg12.
   Conclusions: The objective of this study was to dissect the contribution of Bcl-2 proteins to autophagy in CRC cells and to explore the potential of Bcl-2 inhibitors for autophagy modulation. Collectively, our data argue for a Beclin-1 independent autophagy inhibition by obatoclax. Based on this study, we recommend the concept of autophagy inhibition as therapeutic strategy for CRC.
C1 [Koehler, Bruno Christian; Jassowicz, Adam; Scherr, Anna-Lena; Lorenz, Stephan; Kautz, Nicole; Jaeger, Dirk; Schulze-Bergkamen, Henning] Univ Heidelberg Hosp, Dept Med Oncol, Internal Med 6, Natl Ctr Tumor Dis, Heidelberg, Germany.
   [Radhakrishnan, Praveen; Schneider, Martin] Heidelberg Univ, Dept Gen Visceral & Transplantat Surg, D-69120 Heidelberg, Germany.
   [Weiss, Johanna] Heidelberg Univ, Univ Heidelberg Hosp, Dept Clin Pharmacol & Pharmacoepidemiol, D-69120 Heidelberg, Germany.
   [Schulze-Bergkamen, Henning] Marien Hosp, Dept Internal Med 2, Wesel, Germany.
RP Koehler, BC (corresponding author), Univ Heidelberg Hosp, Dept Med Oncol, Internal Med 6, Natl Ctr Tumor Dis, Heidelberg, Germany.
EM bruno.koehler@nct-heidelberg.de
CR Bai H, 2012, ONCOGENE, V31, P4397, DOI 10.1038/onc.2011.613
   Basit F, 2013, CELL DEATH DIFFER, V20, P1161, DOI 10.1038/cdd.2013.45
   Bonapace L, 2010, J CLIN INVEST, V120, P1310, DOI 10.1172/JCI39987
   Burdelski C, 2015, CLIN CANCER RES, V21, P3471, DOI 10.1158/1078-0432.CCR-14-0620
   Choi AMK, 2013, NEW ENGL J MED, V368, P1845, DOI 10.1056/NEJMc1303158
   Cruickshanks N, 2012, MOL PHARMACOL, V81, P748, DOI 10.1124/mol.112.077586
   Drake KR, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009806
   Erlich S, 2007, AUTOPHAGY, V3, P561, DOI 10.4161/auto.4713
   Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516
   Fu LL, 2013, INT J BIOCHEM CELL B, V45, P921, DOI 10.1016/j.biocel.2013.02.007
   Fukuda T, 2015, GYNECOL ONCOL, V137, P538, DOI 10.1016/j.ygyno.2015.03.053
   Funderburk SF, 2010, TRENDS CELL BIOL, V20, P355, DOI 10.1016/j.tcb.2010.03.002
   Goldberg SB, 2012, J THORAC ONCOL, V7, P1602, DOI 10.1097/JTO.0b013e318262de4a
   Grimaldi A, 2015, CANCER BIOL THER, V16, P567, DOI 10.1080/15384047.2015.1018494
   Guo JY, 2013, CELL, V155, P1216, DOI 10.1016/j.cell.2013.11.019
   Guo SJ, 2015, AUTOPHAGY, V11, P560, DOI 10.1080/15548627.2015.1017181
   Holohan C, 2013, NAT REV CANCER, V13, P714, DOI 10.1038/nrc3599
   Hu F, 2015, J PHARMACOL SCI, V128, P27, DOI 10.1016/j.jphs.2015.04.003
   Huett A, 2010, INFLAMM BOWEL DIS, V16, P152, DOI 10.1002/ibd.20991
   Jain A, 2015, J BIOL CHEM, V290, P14945, DOI 10.1074/jbc.M115.656116
   Jiang XJ, 2015, J CLIN INVEST, V125, P47, DOI 10.1172/JCI73942
   Kadowaki M, 2009, METHOD ENZYMOL, V452, P199, DOI 10.1016/S0076-6879(08)03613-6
   Kang R, 2011, CELL DEATH DIFFER, V18, P571, DOI 10.1038/cdd.2010.191
   Kang YJ, 2011, CELL DEATH DIFFER, V18, P133, DOI 10.1038/cdd.2010.82
   Kelly PN, 2011, CELL DEATH DIFFER, V18, P1414, DOI 10.1038/cdd.2011.17
   Kimura T, 2013, CANCER RES, V73, P3, DOI 10.1158/0008-5472.CAN-12-2464
   Klionsky DJ, 2008, AUTOPHAGY, V4, P151, DOI 10.4161/auto.5338
   Koehler BC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106571
   Koehler BC, 2014, WORLD J GASTROENTERO, V20, P1923, DOI 10.3748/wjg.v20.i8.1923
   Koehler BC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076446
   Koehler BC, 2009, WORLD J GASTROENTERO, V15, P5924, DOI 10.3748/wjg.15.5924
   Komatsu M, 2010, FEBS LETT, V584, P1374, DOI 10.1016/j.febslet.2010.02.017
   Kroemer G, 2015, J CLIN INVEST, V125, P1, DOI 10.1172/JCI78652
   Lagadinou ED, 2013, CELL STEM CELL, V12, P329, DOI 10.1016/j.stem.2012.12.013
   Lai K, 2014, J CLIN PATHOL, V67, P854, DOI 10.1136/jclinpath-2014-202529
   Maiuri MC, 2007, AUTOPHAGY, V3, P374, DOI 10.4161/auto.4237
   Mani J, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1239-4
   McCoy F, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.86
   Mehrpour M, 2010, CELL RES, V20, P748, DOI 10.1038/cr.2010.82
   Millot C, 1997, J HISTOCHEM CYTOCHEM, V45, P1255, DOI 10.1177/002215549704500909
   Mizushima N, 2007, AUTOPHAGY, V3, P542, DOI 10.4161/auto.4600
   Mohamed A, 2015, FRONT ONCOL, V5, DOI [10.3389/fonc.2015.00070, 10.1158/1541-7786.MCR-06-0182]
   Moreno A, 2010, J STRUCT BIOL, V172, P261, DOI 10.1016/j.jsb.2010.06.015
   Moscat J, 2012, TRENDS BIOCHEM SCI, V37, P230, DOI 10.1016/j.tibs.2012.02.008
   Mukhopadhyay S, 2014, APOPTOSIS, V19, P555, DOI 10.1007/s10495-014-0967-2
   Nikoletopoulou V, 2013, BBA-MOL CELL RES, V1833, P3448, DOI 10.1016/j.bbamcr.2013.06.001
   Perera R, 2015, NATURE, V524, P361, DOI 10.1038/nature14587
   Pierzynska-Mach A, 2014, CYTOM PART A, V85A, P729, DOI 10.1002/cyto.a.22495
   Polager S, 2008, ONCOGENE, V27, P4860, DOI 10.1038/onc.2008.117
   Schwartz-Roberts JL, 2013, MOL CANCER THER, V12, P448, DOI 10.1158/1535-7163.MCT-12-0617
   Sharma A, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.155
   Shen Y, 2015, EXP CELL RES, V334, P207, DOI 10.1016/j.yexcr.2015.04.010
   Su J, 2015, ONCOL REP, V34, P235, DOI 10.3892/or.2015.3944
   Sui X, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.350
   Sun T, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-161
   Tang Y, 2015, AM J CANCER RES, V5, P498
   Tanida I, 2011, MICROBIOL IMMUNOL, V55, P1, DOI 10.1111/j.1348-0421.2010.00271.x
   Vela L, 2015, CURR OPIN PHARMACOL, V23, P74, DOI 10.1016/j.coph.2015.05.014
   White E, 2015, J CLIN INVEST, V125, P42, DOI 10.1172/JCI73941
   White E, 2012, NAT REV CANCER, V12, P401, DOI 10.1038/nrc3262
   Wild P, 2014, J CELL SCI, V127, P3, DOI 10.1242/jcs.140426
   Wilson CA, 2002, CELL DEATH DIFFER, V9, P1321, DOI 10.1038/sj.cdd.4401107
   Wroblewski D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0084073
   Yazbeck VY, 2014, ORAL ONCOL, V50, P120, DOI 10.1016/j.oraloncology.2013.10.013
   Zhai H, 2015, ONCOTARGET
   Zhang ZL, 2015, BIOMED PHARMACOTHER, V74, P17, DOI 10.1016/j.biopha.2015.06.003
NR 66
TC 22
Z9 22
U1 0
U2 11
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-2407
J9 BMC CANCER
JI BMC Cancer
PD NOV 19
PY 2015
VL 15
AR 919
DI 10.1186/s12885-015-1929-y
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA CW8UR
UT WOS:000365275400002
PM 26585594
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Lin, X
   Lai, XJ
   Feng, W
   Yu, XF
   Gu, Q
   Zheng, X
AF Lin, Xiao
   Lai, Xiaojing
   Feng, Wei
   Yu, Xiaofu
   Gu, Qing
   Zheng, Xiao
TI MiR-30a sensitized lung cancer against neoadjuvant chemotherapy by
   depressing autophagy
SO JAPANESE JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Article
DE NSCLC; neoadjuvant chemotherapy; miR-30a; autophagy; sensitivity;
   cisplatin; pemetrexed
ID RENAL-CELL CARCINOMA; INDUCED APOPTOSIS; COLORECTAL-CANCER; 1ST-LINE
   THERAPY; DOWN-REGULATION; INHIBITION; MICRORNA; EXPRESSION;
   CHEMORESISTANCE; GEMCITABINE
AB Objective: This study was aimed at exploring whether miR-30a enhanced sensitivity of non-small-cell lung cancer (NSCLC) cells against neoadjuvant chemotherapy through an autophagy-dependent way.
   Methods: We totally recruited 304 NSCLC patients who have underwent chemotherapy, as well as 185 NSCLC patients who did not receive chemotherapy. NSCLC cell lines (i.e. H1299 and H460) were also purchased, and they were transfected by miR-30a mimic/inhibitor. Furthermore, cisplatin (DDP)/pemetrexed (PEM) resistance of NSCLC cells was assessed utilizing MTT assay, and autophagic proteins isolated from NSCLC tissues and cells were quantitated by western blotting.
   Results: Lowly expressed miR-30a was reflective of lymph node metastasis, advanced TNM stage and poor 5-year survival among NSCLC patients treated by neoadjuvant chemotherapy (i.e. combined treatment of DDP and PEM) (P < 0.05). Moreover, DDP combined with PEM attenuated viability and proliferation, but, on the contrary, promoted autophagy of H1299 and H460 cell lines (P < 0.05). However, miR-30a undermined resistance of NSCLC cells against DDP and PEM (P < 0.05), and it suppressed DDP/PEM-induced autophagy and promoted DDP/PEM-triggered apoptosis of NSCLC cells (P < 0.05).
   Conclusions: Intentionally elevating miR-30a expression was conducive to improving NSCLC prognosis after neoadjuvant chemotherapy, for its depressing drug-caused autophagy and resistance.
C1 [Lin, Xiao; Lai, Xiaojing; Feng, Wei; Yu, Xiaofu; Gu, Qing; Zheng, Xiao] Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp, Dept Thorac Radiotherapy, 1 Banshan East Rd, Hangzhou 310022, Zhejiang, Peoples R China.
RP Zheng, X (corresponding author), Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp, Dept Thorac Radiotherapy, 1 Banshan East Rd, Hangzhou 310022, Zhejiang, Peoples R China.
EM neayozhengxiao@163.com
CR Amaravadi RK, 2007, J CLIN INVEST, V117, P326, DOI 10.1172/JCI28833
   Arndt GM, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-374
   Calvert H, 2003, SEMIN ONCOL, V30, P2, DOI 10.1053/sonc.2003.37267
   Chen N, 2009, BBA-MOL CELL RES, V1793, P1516, DOI 10.1016/j.bbamcr.2008.12.013
   Chen S, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0950-x
   Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338
   Cheng CW, 2012, BREAST CANCER RES TR, V134, P1081, DOI 10.1007/s10549-012-2034-4
   Cummins JM, 2006, P NATL ACAD SCI USA, V103, P3687, DOI 10.1073/pnas.0511155103
   Fleeman N, 2010, HEALTH TECHNOL ASSES, V14, P47, DOI [10.3310/hta14Suppl1/07, 10.3310/hta14suppl1/07]
   Heinzelmann J, 2011, WORLD J UROL, V29, P367, DOI 10.1007/s00345-010-0633-4
   Hou YJ, 2011, LAB INVEST, V91, P1146, DOI 10.1038/labinvest.2011.97
   Huang QB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067294
   Iaccarino I, 2011, CELL DEATH DIFFER, V18, P565, DOI 10.1038/cdd.2010.174
   Ichihara E, 2015, J THORAC ONCOL, V10, P486, DOI 10.1097/JTO.0000000000000434
   Katz B, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113700
   Khan SA, 2005, LANCET, V366, P1303, DOI 10.1016/S0140-6736(05)67530-7
   Kondo Y, 2005, NAT REV CANCER, V5, P726, DOI 10.1038/nrc1692
   Kumar MS, 2007, NAT GENET, V39, P673, DOI 10.1038/ng2003
   Kumarakulasinghe NB, 2015, RESPIROLOGY, V20, P370, DOI 10.1111/resp.12490
   Landi D, 2012, CANCER-AM CANCER SOC, V118, P4670, DOI 10.1002/cncr.27435
   Lebovitz CB, 2015, AUTOPHAGY, V11, P1668, DOI 10.1080/15548627.2015.1067362
   Li WF, 2016, TUMOR BIOL, V37, P5885, DOI 10.1007/s13277-015-4456-1
   Li X, 2009, CELL, V137, P273, DOI 10.1016/j.cell.2009.01.058
   Liu ZY, 2014, FEBS LETT, V588, P3089, DOI 10.1016/j.febslet.2014.06.037
   Liu ZF, 2014, J CELL MOL MED, V18, P610, DOI 10.1111/jcmm.12209
   Longo L, 2008, MOL CANCER THER, V7, P2476, DOI 10.1158/1535-7163.MCT-08-0361
   Maione Paolo, 2010, Ther Adv Med Oncol, V2, P251, DOI 10.1177/1758834010366707
   Nasrallah H, 2012, MED ONCOL, V29, P212, DOI 10.1007/s12032-010-9790-y
   O'Donovan TR, 2011, AUTOPHAGY, V7, P509, DOI 10.4161/auto.7.5.15066
   Prochnik SE, 2007, DEV GENES EVOL, V217, P73, DOI 10.1007/s00427-006-0116-1
   Richetta C, 2013, CELL MICROBIOL, V15, P368, DOI 10.1111/cmi.12043
   Sato K, 2007, CANCER RES, V67, P9677, DOI 10.1158/0008-5472.CAN-07-1462
   Scagliotti GV, 2012, J CLIN ONCOL, V30, P172, DOI 10.1200/JCO.2010.33.7089
   Shi QX, 2019, CHEMOSPHERE, V215, P710, DOI 10.1016/j.chemosphere.2018.10.019
   Siegel RL, 2018, CA-CANCER J CLIN, V68, P7, DOI 10.3322/caac.21442
   Sun WL, 2011, AUTOPHAGY, V7, P1035, DOI 10.4161/auto.7.9.16521
   Tanida I, 2005, AUTOPHAGY, V1, P84, DOI 10.4161/auto.1.2.1697
   Thatcher N, 2015, LANCET ONCOL, V16, P763, DOI 10.1016/S1470-2045(15)00021-2
   Toton E, 2014, J PHYSIOL PHARMACOL, V65, P459
   Wang CL, 2017, CELL PHYSIOL BIOCHEM, V43, P2405, DOI 10.1159/000484394
   Wang SY, 2017, J PHARMACOL SCI, V134, P197, DOI 10.1016/j.jphs.2017.07.001
   Weidberg H, 2010, EMBO J, V29, P1792, DOI 10.1038/emboj.2010.74
   Xu RD, 2016, ONCOL REP, V35, P1757, DOI 10.3892/or.2015.4497
   Yadunandam AK, 2012, INT J ONCOL, V41, P1036, DOI 10.3892/ijo.2012.1506
   Yang X, 2017, CELL PHYSIOL BIOCHEM, V43, P1126, DOI 10.1159/000481754
   Zeng LY, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-S8-S14
   Zhang HD, 2017, INT J MOL MED, V40, P1235, DOI 10.3892/ijmm.2017.3084
   Zheng B, 2015, BIOCHEM BIOPH RES CO, V459, P234, DOI 10.1016/j.bbrc.2015.02.084
   Zhong M, 2013, CELL PHYSIOL BIOCHEM, V31, P209, DOI 10.1159/000343362
   Zhu H, 2009, AUTOPHAGY, V5, P816, DOI 10.4161/auto.9064
   Zou ZY, 2016, BIOCHEM J, V473, P2131, DOI 10.1042/BCJ20160177
NR 51
TC 4
Z9 4
U1 1
U2 1
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0368-2811
EI 1465-3621
J9 JPN J CLIN ONCOL
JI Jpn. J. Clin. Oncol.
PD MAY
PY 2021
VL 51
IS 5
BP 675
EP 684
DI 10.1093/jjco/hyaa272
EA FEB 2021
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA SA4HC
UT WOS:000649258300002
PM 33537721
OA Bronze
DA 2022-04-25
ER

PT J
AU Rebecca, VW
   Nicastri, MC
   McLaughlin, N
   Fennelly, C
   McAfee, Q
   Ronghe, A
   Nofal, M
   Lim, CY
   Witze, E
   Chude, CI
   Zhang, G
   Alicea, GM
   Piao, SF
   Murugan, S
   Ojha, R
   Levi, SM
   Wei, Z
   Barber-Rotenberg, JS
   Murphy, ME
   Mills, GB
   Lu, YL
   Rabinowitz, J
   Marmorstein, R
   Liu, Q
   Liu, SJ
   Xu, XW
   Herlyn, M
   Zoncu, R
   Brady, DC
   Speicher, DW
   Winkler, JD
   Amaravadi, RK
AF Rebecca, Vito W.
   Nicastri, Michael C.
   McLaughlin, Noel
   Fennelly, Colin
   McAfee, Quentin
   Ronghe, Amruta
   Nofal, Michel
   Lim, Chun-Yan
   Witze, Eric
   Chude, Cynthia I.
   Zhang, Gao
   Alicea, Gretchen M.
   Piao, Shengfu
   Murugan, Sengottuvelan
   Ojha, Rani
   Levi, Samuel M.
   Wei, Zhi
   Barber-Rotenberg, Julie S.
   Murphy, Maureen E.
   Mills, Gordon B.
   Lu, Yiling
   Rabinowitz, Joshua
   Marmorstein, Ronen
   Liu, Qin
   Liu, Shujing
   Xu, Xiaowei
   Herlyn, Meenhard
   Zoncu, Roberto
   Brady, Donita C.
   Speicher, David W.
   Winkler, Jeffrey D.
   Amaravadi, Ravi K.
TI A Unified Approach to Targeting the Lysosome's Degradative and Growth
   Signaling Roles
SO CANCER DISCOVERY
LA English
DT Article
ID AUTOPHAGY INHIBITION; PANCREATIC ADENOCARCINOMA; MONITORING AUTOPHAGY;
   AMINO-ACIDS; CELL-DEATH; CANCER; IDENTIFICATION; METABOLISM; RESISTANCE;
   PROTEINS
AB Lysosomes serve dual roles in cancer metabolism, executing catabolic programs (i.e., autophagy and macropinocytosis) while promoting mTORC1-dependent anabolism. Antimalarial compounds such as chloroquine or quinacrine have been used as lysosomal inhibitors, but fail to inhibit mTOR signaling. Further, the molecular target of these agents has not been identified. We report a screen of novel dimeric antimalarials that identifies dimeric quinacrines (DQ) as potent anticancer compounds, which concurrently inhibit mTOR and autophagy. Central nitrogen methylation of the DQ linker enhances lysosomal localization and potency. An in situ photoaffinity pulldown identified palmitoyl-protein thioesterase 1 (PPT1) as the molecular target of DQ661. PPT1 inhibition concurrently impairs mTOR and lysosomal catabolism through the rapid accumulation of palmitoylated proteins. DQ661 inhibits the in vivo tumor growth of melanoma, pancreatic cancer, and colorectal cancer mouse models and can be safely combined with chemotherapy. Thus, lysosome-directed PPT1 inhibitors represent a new approach to concurrently targeting mTORC1 and lysosomal catabolism in cancer.
   SIGNIFICANCE: This study identifies chemical features of dimeric compounds that increase their lysosomal specificity, and a new molecular target for these compounds, reclassifying these compounds as targeted therapies. Targeting PPT1 blocks mTOR signaling in a manner distinct from catalytic inhibitors, while concurrently inhibiting autophagy, thereby providing a new strategy for cancer therapy. (C) 2017 AACR.
C1 [Rebecca, Vito W.; Fennelly, Colin; McAfee, Quentin; Chude, Cynthia I.; Piao, Shengfu; Murugan, Sengottuvelan; Ojha, Rani; Levi, Samuel M.; Amaravadi, Ravi K.] Univ Penn, Dept Med, Philadelphia, PA 19104 USA.
   [Nicastri, Michael C.; McLaughlin, Noel; Levi, Samuel M.; Winkler, Jeffrey D.] Univ Penn, Dept Chem, Philadelphia, PA 19104 USA.
   [Ronghe, Amruta; Zhang, Gao; Alicea, Gretchen M.; Murphy, Maureen E.; Liu, Qin; Herlyn, Meenhard; Speicher, David W.] Wistar Inst Anat & Biol, Mol & Cellular Oncogenesis Program, 3601 Spruce St, Philadelphia, PA 19104 USA.
   [Ronghe, Amruta; Zhang, Gao; Alicea, Gretchen M.; Murphy, Maureen E.; Liu, Qin; Herlyn, Meenhard; Speicher, David W.] Wistar Inst Anat & Biol, Melanoma Res Ctr, 3601 Spruce St, Philadelphia, PA 19104 USA.
   [Nofal, Michel; Rabinowitz, Joshua] Princeton Univ, Dept Chem & Integrat Genom, Princeton, NJ 08544 USA.
   [Lim, Chun-Yan; Zoncu, Roberto] Univ Calif Berkeley, Dept Mol & Cell Biol, 229 Stanley Hall, Berkeley, CA 94720 USA.
   [Witze, Eric; Brady, Donita C.] Univ Penn, Abramson Family Canc Res Inst, Dept Canc Biol, Philadelphia, PA 19104 USA.
   [Wei, Zhi] New Jersey Inst Technol, Dept Comp Sci, Newark, NJ 07102 USA.
   [Barber-Rotenberg, Julie S.; Marmorstein, Ronen] Univ Penn, Dept Biochem & Biophys, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA.
   [Mills, Gordon B.; Lu, Yiling] Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX 77030 USA.
   [Liu, Shujing; Xu, Xiaowei] Univ Penn, Dept Pathol, Philadelphia, PA 19104 USA.
   [Winkler, Jeffrey D.; Amaravadi, Ravi K.] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA.
RP Winkler, JD (corresponding author), Univ Penn, Dept Chem, Philadelphia, PA 19104 USA.; Amaravadi, RK (corresponding author), Univ Penn, 8th Floor BRB,421 Curie Blvd, Philadelphia, PA 19104 USA.
EM winkler@sas.upenn.edu; ravi.amaravadi@uphs.upenn.edu
RI , AndyWei/H-4415-2012; Ojha, Rani/ABF-9507-2020
OI Wei, Zhi/0000-0001-6059-4267; /0000-0002-9823-351X; Levi,
   Samuel/0000-0003-0973-3991; Mills, Gordon/0000-0002-0144-9614; Chude,
   Cynthia/0000-0002-8595-9151; Liu, Shujing/0000-0002-2958-093X; Murphy,
   Maureen/0000-0001-7644-7296
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [R01CA169134, P01 CA114046, P30
   CA016520, SPORE P50 CA174523, 1R01CA198015, CA016672, P30CA010815];
   NATIONAL CANCER INSTITUTEUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Cancer
   Institute (NCI) [P50CA093372, DP2CA195761, R01CA169134, R50CA221838,
   P50CA174523, P30CA010815, P30CA016520, R01CA139319, R01CA198015,
   P01CA114046, P30CA016672] Funding Source: NIH RePORTER; NATIONAL
   INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASESUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal
   & Skin Diseases (NIAMS) [F30AR065870] Funding Source: NIH RePORTER
FX This work was entirely supported by NIH grants R01CA169134, P01
   CA114046, P30 CA016520, SPORE P50 CA174523, 1R01CA198015, CA016672, and
   P30CA010815.
CR Aits S, 2015, AUTOPHAGY, V11, P1408, DOI 10.1080/15548627.2015.1063871
   Bagh MB, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14612
   Bar-Peled L, 2012, CELL, V150, P1196, DOI 10.1016/j.cell.2012.07.032
   Barret A, 2003, J VIROL, V77, P8462, DOI 10.1128/JVI.77.15.8462-8469.2003
   Bishop BM, 2015, ANN PHARMACOTHER, V49, P196, DOI 10.1177/1060028014561227
   Boone BA, 2015, ANN SURG ONCOL, V22, P4402, DOI 10.1245/s10434-015-4566-4
   Bowie M, 2015, WORLD J CLIN ONCOL, V6, P299, DOI 10.5306/wjco.v6.i6.299
   Carroll B, 2016, ELIFE, V5, DOI 10.7554/eLife.11058
   Cheong H, 2011, P NATL ACAD SCI USA, V108, P11121, DOI 10.1073/pnas.1107969108
   Clarke JJ, 2001, MUTAT RES-GEN TOX EN, V494, P41, DOI 10.1016/S1383-5718(01)00178-4
   Cox J, 2008, NAT BIOTECHNOL, V26, P1367, DOI 10.1038/nbt.1511
   Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001
   Egan DF, 2015, MOL CELL, V59, P285, DOI 10.1016/j.molcel.2015.05.031
   Ellegaard AM, 2016, EBIOMEDICINE, V9, P130, DOI 10.1016/j.ebiom.2016.06.013
   Goldman AR, 2016, MOL CELL PROTEOMICS, V15, P3348, DOI 10.1074/mcp.M116.062539
   JENNINGS BR, 1983, BIOPHYS STRUCT MECH, V10, P71, DOI 10.1007/BF00535543
   Jiang XJ, 2015, J CLIN INVEST, V125, P47, DOI 10.1172/JCI73942
   Kamphorst JJ, 2015, CANCER RES, V75, P544, DOI 10.1158/0008-5472.CAN-14-2211
   Keyszer G, 1999, CLIN RHEUMATOL, V18, P145, DOI 10.1007/s100670050073
   Klempner SJ, 2013, CANCER DISCOV, V3, P1345, DOI 10.1158/2159-8290.CD-13-0063
   Klionsky DJ, 2016, AUTOPHAGY, V12, P1, DOI 10.1080/15548627.2015.1100356
   Klionsky DJ, 2012, AUTOPHAGY, V8, P445, DOI 10.4161/auto.19496
   Korfel A, 2016, J CLIN ONCOL, V34, P1757, DOI 10.1200/JCO.2015.64.9897
   Krishna S, 2016, DEV CELL, V38, P536, DOI 10.1016/j.devcel.2016.08.001
   Leu JIJ, 2009, MOL CELL, V36, P15, DOI 10.1016/j.molcel.2009.09.023
   Lin CW, 2015, SCI REP-UK, V5, DOI 10.1038/srep15807
   Liu JL, 2011, CELL, V147, P223, DOI 10.1016/j.cell.2011.08.037
   Ma XH, 2014, J CLIN INVEST, V124, P1406, DOI 10.1172/JCI70454
   McAfee Q, 2012, P NATL ACAD SCI USA, V109, P8253, DOI 10.1073/pnas.1118193109
   Ni HM, 2011, AUTOPHAGY, V7, P188, DOI 10.4161/auto.7.2.14181
   Ostenfeld MS, 2008, AUTOPHAGY, V4, P487, DOI 10.4161/auto.5774
   Palm W, 2015, CELL, V162, P259, DOI 10.1016/j.cell.2015.06.017
   Perera R, 2015, NATURE, V524, P361, DOI 10.1038/nature14587
   Petersen NHT, 2013, CANCER CELL, V24, P379, DOI 10.1016/j.ccr.2013.08.003
   Potts MB, 2015, NAT CHEM BIOL, V11, P401, DOI 10.1038/nchembio.1797
   Powles T, 2016, J CLIN ONCOL, V34, P1660, DOI 10.1200/JCO.2015.64.8808
   Rangwala R, 2014, AUTOPHAGY, V10, P1391, DOI 10.4161/auto.29119
   Rebecca VW, 2014, PIGM CELL MELANOMA R, V27, P465, DOI 10.1111/pcmr.12227
   Rodrik-Outmezguine VS, 2016, NATURE, V534, P272, DOI 10.1038/nature17963
   Salas E, 2016, ONCOGENE, V35, P2913, DOI 10.1038/onc.2015.348
   Sancak Y, 2010, CELL, V141, P290, DOI 10.1016/j.cell.2010.02.024
   Sanders SS, 2015, PLOS COMPUT BIOL, V11, DOI 10.1371/journal.pcbi.1004405
   Selvakumaran M, 2013, CLIN CANCER RES, V19, P2995, DOI 10.1158/1078-0432.CCR-12-1542
   Shchors K, 2015, CANCER CELL, V28, DOI 10.1016/j.ccell.2015.08.012
   Slomnicki LP, 2016, MOL CELL PROTEOMICS, V15, P2055, DOI 10.1074/mcp.M115.051920
   Strohecker AM, 2014, CANCER DISCOV, V4, P766, DOI 10.1158/2159-8290.CD-14-0196
   Twyman-Saint Victor C, 2015, NATURE, V520, P373, DOI 10.1038/nature14292
   van Diggelen OP, 1999, MOL GENET METAB, V66, P240, DOI 10.1006/mgme.1999.2809
   Villanueva-Paz Marina, 2016, Genes Cancer, V7, P260
   Wan J, 2007, NAT PROTOC, V2, P1573, DOI 10.1038/nprot.2007.225
   Wangchuk S, 2016, MALARIA J, V15, DOI 10.1186/s12936-016-1320-8
   Wolpin BM, 2014, ONCOLOGIST, V19, P637, DOI 10.1634/theoncologist.2014-0086
   Yang A, 2014, CANCER DISCOV, V4, P905, DOI 10.1158/2159-8290.CD-14-0362
   Zhang G, 2016, J CLIN INVEST, V126, P1834, DOI 10.1172/JCI82661
   Zoncu R, 2011, SCIENCE, V334, P678, DOI 10.1126/science.1207056
NR 55
TC 97
Z9 97
U1 11
U2 32
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 2159-8274
EI 2159-8290
J9 CANCER DISCOV
JI Cancer Discov.
PD NOV
PY 2017
VL 7
IS 11
BP 1266
EP 1283
DI 10.1158/2159-8290.CD-17-0741
PG 18
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA FL5BY
UT WOS:000414247300011
PM 28899863
OA Green Accepted
DA 2022-04-25
ER

PT J
AU Zhang, ZD
   Wang, AH
   Li, H
   Zhi, H
   Lu, F
AF Zhang, Zhongde
   Wang, Aihua
   Li, Hui
   Zhi, Hui
   Lu, Feng
TI RETRACTED: STAT3-dependent TXNDC17 expression mediates Taxol resistance
   through inducing autophagy in human colorectal cancer cells (Retracted
   article. See vol. 730, 2020)
SO GENE
LA English
DT Article; Retracted Publication
DE TXNDC17; Autophagy; Taxol resistance; Colorectal cancer cell
ID THIOREDOXIN-RELATED PROTEIN; TARGETING AUTOPHAGY; GROWTH-FACTOR; 14 KDA;
   STAT3; SURVIVAL; INDUCTION; PROMOTES; TRP14
AB Taxol (paclitaxel) is one of the taxane class of anticancer drugs as a first-line chemotherapeutic agent against many cancers including colorectal cancer, breast cancer, non-small cell lung cancer, ovarian cancer and so on. It is verified to induce cytotoxicity in a concentration and time-dependent manner. Numerous novel formulations of Taxol have been remanufactured for better therapeutic effect. Though Taxol works as a common anticancer drug for a long time in clinical practice, drug resistance is a major limitation of its long-term administration. In-depth research on drug resistance is still in progress and researchers have made some achievements, however, the mechanism or key molecule related to Taxol resistance in colorectal cancer still remains to be explored. In the present study, we observed that the high expression of TXNDC17 (thioredoxin domain containing 17) was associated with Taxol resistance in colorectal cancer cells. And TXNDC17 mediated Taxol resistance was related with increased basal autophagy level. Taxol exposure induced high levels of phospho-STAT3 (Tyr 705) and TXNDC17; and increase of basal autophagy in colorectal cancer cells. TXNDC17 overexpression cells obtained Taxol resistance and a high level of autophagy, and it is not surprising that stable downregulation of TXNDC17 accordingly reversed these phenomena. Interestingly, STAT3 could similarly work as TXNDC17 in spite of slighter effect compared to TXNDC17. And it has been proved that phospho-STAT3 (Tyr 705) possesses transcriptional regulation activity through forming dimmers. Many research revealed that transcription factor STAT3 affected more than 1000 gene products, and TXNDC17 is predicted to be a target gene of STAT3 at UCSC database. For the first time, we found STAT3 could bind promoter region of TXNDC17 (-623 bp to -58 bp relative to the transcription start site (TSS)) for regulating its expression. These results suggest the possibility that TXNDC17 could play an important role in Taxol resistance via enhancing autophagy in human colorectal cancer cells. TXNDC17 may become a potential target of colorectal cancer therapeutics. (C) 2016 Elsevier B.V. All rights reserved.
C1 [Zhang, Zhongde; Wang, Aihua; Li, Hui; Zhi, Hui] Zhoukou City Cent Hosp, Dept Colorectum Anus Surg, Zhoukou 466000, Peoples R China.
   [Lu, Feng] Zhoukou City Cent Hosp, Dept Digest Syst, Zhoukou 466000, Peoples R China.
RP Lu, F (corresponding author), Renmin Rd, Zhoukou 466000, Peoples R China.
EM lufengzks@163.com
CR Basciani S, 2007, FEBS LETT, V581, P5897, DOI 10.1016/j.febslet.2007.11.069
   Bellodi C, 2009, J CLIN INVEST, V119, P1109, DOI 10.1172/JCI35660
   Brenner H, 2014, LANCET, V383, P1490, DOI 10.1016/S0140-6736(13)61649-9
   Broz DK, 2013, AUTOPHAGY, V9, P1440, DOI 10.4161/auto.25833
   Center MM, 2009, CA-CANCER J CLIN, V59, P366, DOI 10.3322/caac.20038
   Chen Z., 2015, CLIN CANC RES
   Choi AMK, 2013, NEW ENGL J MED, V368, P651, DOI [10.1056/NEJMra1205406, 10.1056/NEJMc1303158]
   Crystal AS, 2014, SCIENCE, V346, P1480, DOI 10.1126/science.1254721
   De Sousa E Melo F, 2013, NAT MED, V19, P614, DOI 10.1038/nm.3174
   Ertmer A, 2007, LEUKEMIA, V21, P936, DOI 10.1038/sj.leu.2404606
   Harris J, 2011, CYTOKINE, V56, P140, DOI 10.1016/j.cyto.2011.08.022
   Jeong W, 2004, J BIOL CHEM, V279, P3151, DOI 10.1074/jbc.M307959200
   Jeong W, 2004, J BIOL CHEM, V279, P3142, DOI 10.1074/jbc.M307932200
   Jin S, 2007, J CELL SCI, V120, P379, DOI 10.1242/jcs.03349
   Klionsky DJ, 2012, AUTOPHAGY, V8, P445, DOI 10.4161/auto.19496
   Kumar A, 2015, FUTURE MED CHEM, V7, P1535, DOI 10.4155/fmc.15.88
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Lum JJ, 2005, CELL, V120, P237, DOI 10.1016/j.cell.2004.11.046
   Niso-Santano M, 2013, AUTOPHAGY, V9, P415, DOI 10.4161/auto.22910
   O'Donovan TR, 2011, AUTOPHAGY, V7, P509, DOI 10.4161/auto.7.5.15066
   Pader I, 2014, P NATL ACAD SCI USA, V111, P6964, DOI 10.1073/pnas.1317320111
   Sadanandam A, 2013, NAT MED, V19, P619, DOI 10.1038/nm.3175
   Sankaranarayanan R, 2010, LANCET ONCOL, V11, P165, DOI 10.1016/S1470-2045(09)70335-3
   Shen SS, 2012, MOL CELL, V48, P667, DOI 10.1016/j.molcel.2012.09.013
   Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138
   Sun Y., 2015, INT J ONCOL
   Tan QX, 2015, CANCER SCI, V106, P1023, DOI 10.1111/cas.12712
   van Adrichem A.J., 2015, FEBS LETT
   You LK, 2015, AUTOPHAGY, V11, P729, DOI 10.1080/15548627.2015.1017192
   Zhang SF, 2015, AUTOPHAGY, V11, P225, DOI 10.1080/15548627.2014.998931
   Zhao J, 2016, GENE, V576, P828, DOI 10.1016/j.gene.2015.11.013
   ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422
NR 32
TC 19
Z9 20
U1 0
U2 27
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0378-1119
EI 1879-0038
J9 GENE
JI Gene
PD JUN 10
PY 2016
VL 584
IS 1
BP 75
EP 82
DI 10.1016/j.gene.2016.03.012
PG 8
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA DK0NM
UT WOS:000374609500011
PM 26976343
DA 2022-04-25
ER

PT J
AU Beyer, S
   Schwalm, S
   Pfeilschifter, J
   Huwiler, A
AF Beyer, Sandra
   Schwalm, Stephanie
   Pfeilschifter, Josef
   Huwiler, Andrea
TI Renal Mesangial Cells Isolated from Sphingosine Kinase 2 Transgenic Mice
   Show Reduced Proliferation and are More Sensitive to Stress-Induced
   Apoptosis
SO CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
LA English
DT Article
DE Mesangial cells; Proliferation; Apoptosis; Autophagy; S1P; Transgenic
   SK-2 mice
ID UNILATERAL URETERAL OBSTRUCTION; EPIDERMAL-GROWTH-FACTOR; SPHINGOLIPID
   METABOLISM; INHIBITOR ABC294640; KIDNEY FIBROSIS; BREAST-CANCER;
   COLON-CANCER; LINE MCF7; IN-VIVO; 1-PHOSPHATE
AB Background/Aims: Sphingosine 1-phosphate (S1P) is considered as a key molecule regulating various cell functions including cell growth and death. It is produced by two sphingosine kinases (SK) denoted as SK-1 and SK-2. Whereas SK-1 has been extensively studied and has been appointed a role in promoting cell growth, the function of SK-2 is controversial, and both proproliferative and pro-apoptotic functions have been suggested. In this study we investigated whether renal mesangial cells isolated from transgenic mice overexpressing the human Sphk2 gene (hSK2-tg) showed an altered cell response towards growth-inducing and apoptotic stimuli. Methods: hSK2-tg mice were generated by using a Quick KnockinR strategy. Renal mesangial cells were isolated by a differential sieving method and further cultivated in vitro. Lipids were quantified by mass spectrometry. Protein expression was determined by Western blot analysis, cell proliferation was determined by 3H-thymidine incorporation, and apoptosis was determined by a DNA fragmentation ELISA. Results: We show here that kidneys and mesangial cells from hSK2-tg mice express the hSK2 as well as the endogenous mouse mSK2. hSK2 and mSK2 predominantly resided in the cytosol of quiescent transgenic cells. However, S1P accumulated strongly in the nucleus and only minimally in the cytosol of transgenic cells. Functionally, hSK2-tg cells proliferated less than control cells under normal growth conditions and were also more sensitive towards stress-induced apoptosis. On the molecular level, this was reflected by reduced ERK and Akt/PKB activation, and upon staurosporine treatment, by a sensitized mitochondrial pathway as manifested by reduced anti-apoptotic Bcl-XL expression and increased cleavage of caspase-9, downstream caspase-3 and PARP-1. Conclusion: Altogether, these data demonstrate that SK-2 exerts an antiproliferative and apoptosissensitizing effect in renal mesangial cells which suggests that selective inhibitors of SK-2 may promote proliferation and reduce apoptosis and this may have impact on the outcome of proliferation-associated diseases such as mesangioproliferative glomerulonephritis. (C) 2018 The Author(s) Published by S. Karger AG, Basel
C1 [Beyer, Sandra; Schwalm, Stephanie; Pfeilschifter, Josef] Univ Klinikum, Pharmazentrum Frankfurt ZAFES, Frankfurt, Germany.
   [Beyer, Sandra; Schwalm, Stephanie; Pfeilschifter, Josef] Goethe Univ, Frankfurt, Germany.
   [Huwiler, Andrea] Univ Bern, Inselspital, Inst Pharmacol, INO F, CH-3010 Bern, Switzerland.
RP Huwiler, A (corresponding author), Univ Bern, Inselspital, Inst Pharmacol, INO F, CH-3010 Bern, Switzerland.
EM Huwiler@pki.unibe.ch
OI , Stephanie/0000-0002-2198-6898
FU Swiss National Science FoundationSwiss National Science Foundation
   (SNSF)European Commission [310030-153346, 310030-175561/1]; German
   Research FoundationGerman Research Foundation (DFG) [SFB1039, PF361/6-1]
FX This work was supported by the Swiss National Science Foundation
   (310030-153346 and 310030-175561/1) and the German Research Foundation
   (SFB1039; PF361/6-1). We thank Isolde Romer and Simone Albert for
   excellent technical assistance.
CR Alemany R, 2007, N-S ARCH PHARMACOL, V374, P413, DOI 10.1007/s00210-007-0132-3
   Antoon JW, 2010, ENDOCRINOLOGY, V151, P5124, DOI 10.1210/en.2010-0420
   Bajwa A, 2017, J AM SOC NEPHROL, V28, P1145, DOI 10.1681/ASN.2016030306
   Beaumatin F, 2016, ONCOTARGET, V7, P17129, DOI 10.18632/oncotarget.7938
   Beljanski V, 2011, CANCER BIOL THER, V11, P524, DOI 10.4161/cbt.11.5.14677
   Chumanevich AA, 2010, CARCINOGENESIS, V31, P1787, DOI 10.1093/carcin/bgq158
   Doll F, 2007, ENDOCR-RELAT CANCER, V14, P325, DOI 10.1677/ERC-06-0050
   Doll F, 2005, BBA-MOL CELL BIOL L, V1738, P72, DOI 10.1016/j.bbalip.2005.12.001
   Floege J, 1999, AM J PATHOL, V154, P169, DOI 10.1016/S0002-9440(10)65263-7
   French KJ, 2010, J PHARMACOL EXP THER, V333, P129, DOI 10.1124/jpet.109.163444
   French KJ, 2003, CANCER RES, V63, P5962
   Giuliano M, 2004, INT J MOL MED, V13, P565
   Hagen N, 2009, J BIOL CHEM, V284, P11346, DOI 10.1074/jbc.M807336200
   Hait NC, 2005, J BIOL CHEM, V280, P29462, DOI 10.1074/jbc.M502922200
   Hait NC, 2007, J BIOL CHEM, V282, P12058, DOI 10.1074/jbc.M609559200
   Hait NC, 2006, BBA-BIOMEMBRANES, V1758, P2016, DOI 10.1016/j.bbamem.2006.08.007
   Hofmann LP, 2008, BIOL CHEM, V389, P1399, DOI 10.1515/BC.2008.160
   HUWILER A, 1994, BRIT J PHARMACOL, V113, P1455, DOI 10.1111/j.1476-5381.1994.tb17160.x
   Huwiler A, 2008, BIOCHEM PHARMACOL, V75, P1893, DOI 10.1016/j.bcp.2007.12.018
   Huwiler A, 2006, CURR PHARM DESIGN, V12, P4625, DOI 10.2174/138161206779010422
   Huwiler A, 2006, BBA-MOL CELL BIOL L, V1761, P367, DOI 10.1016/j.bbalip.2006.02.007
   Igarashi N, 2003, J BIOL CHEM, V278, P46832, DOI 10.1074/jbc.M306577200
   Ihlefeld K, 2012, BIOCHEM J, V447, P457, DOI 10.1042/BJ20120811
   JOHNSON RJ, 1992, J EXP MED, V175, P1413, DOI 10.1084/jem.175.5.1413
   Kharel Y, 2015, J PHARMACOL EXP THER, V355, P23, DOI 10.1124/jpet.115.225862
   Klawitter S, 2007, BRIT J PHARMACOL, V150, P271, DOI 10.1038/sj.bjp.0706983
   Liang J, 2013, CANCER CELL, V23, P107, DOI 10.1016/j.ccr.2012.11.013
   Liu H, 2003, J BIOL CHEM, V278, P40330, DOI 10.1074/jbc.M304455200
   Liu K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056471
   Maceyka M, 2005, J BIOL CHEM, V280, P37118, DOI 10.1074/jbc.M502207200
   Miyajima A, 2000, KIDNEY INT, V58, P2301, DOI 10.1046/j.1523-1755.2000.00414.x
   Mizutani N, 2015, J CELL BIOCHEM, V116, P2227, DOI 10.1002/jcb.25173
   Morchang A, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0188121
   Neubauer HA, 2016, ONCOTARGET, V7, P64886, DOI 10.18632/oncotarget.11714
   Newton J, 2015, EXP CELL RES, V333, P195, DOI 10.1016/j.yexcr.2015.02.025
   Okada T, 2005, J BIOL CHEM, V280, P36318, DOI 10.1074/jbc.M504507200
   Pyne NJ, 2010, NAT REV CANCER, V10, P489, DOI 10.1038/nrc2875
   Rost S, 2002, KIDNEY INT, V62, P1659, DOI 10.1046/j.1523-1755.2002.00621.x
   Ruckhaberle E, 2008, BREAST CANCER RES TR, V112, P41, DOI 10.1007/s10549-007-9836-9
   Schmidt H, 2006, PROSTAG OTH LIPID M, V81, P162, DOI 10.1016/j.prostaglandins.2006.09.003
   Schwalm S, 2017, AM J PATHOL, V187, P2413, DOI 10.1016/j.ajpath.2017.06.017
   Schwalm S, 2015, BIOL CHEM, V396, P813, DOI 10.1515/hsz-2014-0289
   Wurstle ML, 2012, EXP CELL RES, V318, P1213, DOI 10.1016/j.yexcr.2012.02.013
   Yuan J, 2017, BMC NEPHROL, V18, DOI 10.1186/s12882-017-0708-1
   Zemann B, 2006, BLOOD, V107, P1454, DOI 10.1182/blood-2005-07-2628
NR 45
TC 2
Z9 2
U1 1
U2 3
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 1015-8987
EI 1421-9778
J9 CELL PHYSIOL BIOCHEM
JI Cell. Physiol. Biochem.
PY 2018
VL 47
IS 6
BP 2522
EP 2533
DI 10.1159/000491625
PG 12
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Physiology
GA GO6KR
UT WOS:000440152000028
PM 29991026
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Liu, HH
   Zhao, JQ
   Fu, RZ
   Zhu, CH
   Fan, DD
AF Liu, Huanhuan
   Zhao, Jiaqi
   Fu, Rongzhan
   Zhu, Chenhui
   Fan, Daidi
TI The ginsenoside Rk3 exerts anti-esophageal cancer activity in vitro and
   in vivo by mediating apoptosis and autophagy through regulation of the
   PI3K/Akt/mTOR pathway
SO PLOS ONE
LA English
DT Article
ID CELL-CYCLE ARREST; COLORECTAL-CANCER; DUAL ROLE; STATISTICS; CROSSTALK;
   ANTITUMOR; DEATH
AB The rare ginsenoside Rk3 is a bioactive component derived from ginseng and Panax notoginseng that has been proven to possess anti-lung cancer activity. However, the effect of Rk3 on human esophageal cancer has not yet been reported. In this study, we aimed to explore its anticancer curative effect and potential molecular mechanisms in the Eca109 and KYSE150 cell lines. We found that Rk3 was able to significantly repress cell proliferation and colony formation in both Eca109 and KYSE150 cells in vitro. In the KYSE150 xenograft model, Rk3 obviously inhibited tumor growth and exhibited little toxicity in organs. Moreover, Rk3 could trigger G1 phase arrest and induce apoptosis and autophagy. Interestingly, apoptosis induced by Rk3 could be partly abrogated by 3-MA (an autophagy inhibitor), implying that autophagy could enhance apoptosis. Further studies indicated that pretreatment with the Akt inhibitor GSK690693 or the mTOR inhibitor rapamycin promoted Rk3-induced apoptosis and autophagy, demonstrating that the PI3K/Akt/mTOR pathway is related to Rk3-induced apoptosis and autophagy. In conclusion, the present study is the first to clarify that Rk3 can inhibit Eca109 and KYSE150 cell proliferation through activating apoptosis and autophagy by blocking the PI3K/Akt/mTOR pathway, suggesting that Rk3 may be a promising antitumor agent for esophageal cancer. In addition, this study provides ideas and an experimental basis for further research on the anti-esophageal cancer effects of the ginsenoside Rk3 and its mechanism.
C1 [Liu, Huanhuan; Fu, Rongzhan; Zhu, Chenhui; Fan, Daidi] Northwest Univ, Sch Chem Engn, Shaanxi Key Lab Degradable Biomed Mat, Xian, Shaanxi, Peoples R China.
   [Liu, Huanhuan; Fu, Rongzhan; Zhu, Chenhui; Fan, Daidi] Northwest Univ, Sch Chem Engn, Shaanxi R&D Ctr Biomat & Fermentat Engn, Xian, Shaanxi, Peoples R China.
   [Liu, Huanhuan; Fu, Rongzhan; Zhu, Chenhui; Fan, Daidi] Northwest Univ, Res Inst, Biotech & Biomed, Xian, Shaanxi, Peoples R China.
   [Zhao, Jiaqi] Guangzhou Univ Chinese Med, Sch Pharmaceut Sci, Guangzhou, Guangdong, Peoples R China.
RP Zhu, CH; Fan, DD (corresponding author), Northwest Univ, Sch Chem Engn, Shaanxi Key Lab Degradable Biomed Mat, Xian, Shaanxi, Peoples R China.; Zhu, CH; Fan, DD (corresponding author), Northwest Univ, Sch Chem Engn, Shaanxi R&D Ctr Biomat & Fermentat Engn, Xian, Shaanxi, Peoples R China.; Zhu, CH; Fan, DD (corresponding author), Northwest Univ, Res Inst, Biotech & Biomed, Xian, Shaanxi, Peoples R China.
EM zch@nwu.edu.cn; fandaidi@nwu.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [21576222, 21576223, 21576160, 21878247,
   21838009, 21808184]; Shaanxi Key Laboratory of Degradable Biomedical
   Materials Program [16JS106, 2016SZSj-35]
FX This study was financially supported by the National Natural Science
   Foundation of China (21576222 to CZ, 21576223, 21576160, 21878247 to CZ,
   21838009 to DF, 21808184 to RF) and Shaanxi Key Laboratory of Degradable
   Biomedical Materials Program (16JS106, 2016SZSj-35 to DF). The funders
   had no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR Attele AS, 1999, BIOCHEM PHARMACOL, V58, P1685, DOI 10.1016/S0006-2952(99)00212-9
   Booth LA, 2014, CELL SIGNAL, V26, P549, DOI 10.1016/j.cellsig.2013.11.028
   Boya P, 2013, NAT CELL BIOL, V15, P713, DOI 10.1038/ncb2788
   Chaabane W, 2013, ARCH IMMUNOL THER EX, V61, P43, DOI 10.1007/s00005-012-0205-y
   Chen F, 2017, J FUNCT FOODS, V32, P382, DOI 10.1016/j.jff.2017.03.013
   Chong DL, 2017, ANTI-CANCER DRUG, V28, P831, DOI 10.1097/CAD.0000000000000517
   Cohen-Kaplan V, 2016, P NATL ACAD SCI USA, V113, pE7490, DOI 10.1073/pnas.1615455113
   Cools-Lartigue J, 2015, J GASTROINTEST SURG, V19, P964, DOI 10.1007/s11605-014-2701-3
   Duan Z, 2017, FOOD FUNCTION, V8
   Fridman JS, 2003, ONCOGENE, V22, P9030, DOI 10.1038/sj.onc.1207116
   Fu DX, 2016, DIABETOLOGIA, V59, P2251, DOI 10.1007/s00125-016-4058-5
   Fu LL, 2013, INT J BIOCHEM CELL B, V45, P921, DOI 10.1016/j.biocel.2013.02.007
   Fulda S, 2006, ONCOGENE, V25, P4798, DOI 10.1038/sj.onc.1209608
   Gao Q, 2018, CELL PROLIF
   Gao QR, 2018, CELL PROLIFERAT, V51, DOI 10.1111/cpr.12438
   Garner TP, 2017, CURR OPIN CHEM BIOL, V39, P133, DOI 10.1016/j.cbpa.2017.06.014
   Hanada T, 2007, J BIOL CHEM, V282, P37298, DOI 10.1074/jbc.C700195200
   Ivanova T, 2011, CELL CYCLE, V10, P912, DOI 10.4161/cc.10.6.14963
   Kim KY, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18051088
   Kumar D, 2014, CANCER LETT, V343, P179, DOI 10.1016/j.canlet.2013.10.003
   LI Y, 1994, ONCOGENE, V9, P2261
   Lim SH, 2013, DEVELOPMENT, V140, P3079, DOI 10.1242/dev.091744
   Liu YN, 2018, FOOD FUNCT, V9, DOI 10.1039/c8fo01122b
   Mi YS, 2016, FREE RADICAL BIO MED, V90, P230, DOI 10.1016/j.freeradbiomed.2015.11.022
   Miller KD, 2016, CA-CANCER J CLIN, V66, P271, DOI 10.3322/caac.21349
   Nordin N, 2018, APOPTOSIS, V23, P152, DOI 10.1007/s10495-018-1447-x
   Oh SJ, 2016, EXPERT OPIN INV DRUG, V25, P667, DOI 10.1517/13543784.2016.1163336
   Ohashi S, 2015, GASTROENTEROLOGY, V149, P1700, DOI 10.1053/j.gastro.2015.08.054
   Ru WW, 2015, DRUG DISCOV THER, V9, P23, DOI 10.5582/ddt.2015.01004
   Schwartz GK, 2005, J CLIN ONCOL, V23, P9408, DOI 10.1200/JCO.2005.01.5594
   Shibata Shigeru, 2002, Gan To Kagaku Ryoho, V29, P2209
   Song SL, 2017, J CELL PHYSIOL, V232, P2977, DOI 10.1002/jcp.25785
   Sun J, 2017, J CELLULAR BIOCH, V119
   Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262
   Toshimitsu H, 2004, CANCER LETT, V211, P69, DOI 10.1016/j.canlet.2004.01.038
   Wang R, 2016, SCI REP-UK, V6, DOI 10.1038/srep27071
   Wu Q, 2018, BIOCHEM PHARMACOL, V148, P64, DOI 10.1016/j.bcp.2017.12.004
   Zeng XH, 2011, FRONT ONCOL, V1, DOI 10.3389/fonc.2011.00030
   Zhang Ping, 2007, Zhonghua Zhongliu Zazhi, V29, P773
   Zhang ZW, 2017, NUTR RES, V38, P27, DOI 10.1016/j.nutres.2017.01.003
   Zheng WL, 2018, TOXINS, V10, DOI 10.3390/toxins10010024
   Zhou Y, 2018, COMMUNICATION BY GAZE INTERACTION (COGAIN 2018), DOI 10.1145/3206343.3206353
   2018, CANC LETT, V415, P73, DOI DOI 10.1016/J.CANLET.2017.11.037
NR 43
TC 27
Z9 30
U1 3
U2 13
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 15
PY 2019
VL 14
IS 5
AR e0216759
DI 10.1371/journal.pone.0216759
PG 16
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA HY2KH
UT WOS:000467949100040
PM 31091245
OA Green Published, gold, Green Submitted
DA 2022-04-25
ER

PT J
AU Li, ZX
   Wen, CM
   Li, JL
   Meng, HM
   Ji, C
   Han, ZC
   An, GL
   Yang, L
AF Li, Zixuan
   Wen, Chunmei
   Li, Jialu
   Meng, Huimin
   Ji, Cheng
   Han, Zhichao
   An, Gangli
   Yang, Lin
TI Zkscan3 gene is a potential negative regulator of plasma cell
   differentiation
SO EUROPEAN JOURNAL OF INFLAMMATION
LA English
DT Article
DE plasma cell; X-inactive-specific transcript; zkscan3
ID AUTOPHAGY
AB We previously showed that the ZKSCAN3 gene codes for a zinc-finger transcription factor that regulates the expression of important genes and plays crucial roles in the development, metastasis, and pathogenesis of rectal cancer, prostate cancer, myeloma, and so on, and in the regulation of autophagy. However, its biological functions under normal physiological conditions remain unclear. In addition, our previous studies showed that the ZKSCAN3 gene may negatively regulate B cell functions. Therefore, we constructed a zkscan3-knockout mouse model and observed that knockout mice contained a greater number of plasma cells than wild-type mice. We also found that the number of plasma cells was significantly increased in either colorectal cancer xenografts or under lipopolysaccharide-induced conditions. RNA-seq and quantitative-polymerase chain reaction assay indicated that the X-inactive-specific transcript is upregulated in B cells of zkscan3-knockout mice, which may represent a potential mechanism how zkscan3 modulates plasma cell differentiation.
C1 [Li, Zixuan; Wen, Chunmei; Li, Jialu; Meng, Huimin; Ji, Cheng; Han, Zhichao; An, Gangli; Yang, Lin] Soochow Univ, Cyrus Tang Hematol Ctr, Suzhou, Jiangsu, Peoples R China.
   [An, Gangli; Yang, Lin] Soochow Univ, Collaborat Innovat Ctr Hematol, Suzhou, Peoples R China.
   [An, Gangli; Yang, Lin] Soochow Univ, State Key Lab Radiat Med & Protect, Suzhou, Peoples R China.
   [Yang, Lin] Persongen BioTherapeut Suzhou Co Ltd, Suzhou, Peoples R China.
RP An, GL; Yang, L (corresponding author), Soochow Univ, Cyrus Tang Hematol Ctr, Suzhou, Jiangsu, Peoples R China.
EM gangli_an@suda.edu.cn; yanglin@suda.edu.cn
FU Priority Academic Program Development of Jiangsu Higher Education
   Institutions; National Natural Science Foundation of ChinaNational
   Natural Science Foundation of China (NSFC) [31471283]; National Key R&D
   Program of China [2016YFC1303403]; Collaborative Innovation Major
   Project [XYXT2015304]; Six Talent Peaks Project in Jiangsu Province
   [SWYY-CXTD-010]; Cyrus Tang Hematology Center, Soochow University,
   Suzhou, Jiangsu, PR China; Collaborative Innovation Center of
   Hematology, Soochow University, Suzhou, Jiangsu, PR China; Project of
   State Key Laboratory of Radiation Medicine and Protection, Soochow
   University, Suzhou, Jiangsu, PR China [GZN1201803]
FX The author(s) disclosed receipt of the following financial support for
   the research, authorship, and/or publication of this article: This work
   was supported by the Priority Academic Program Development of Jiangsu
   Higher Education Institutions; National Natural Science Foundation of
   China (Grant No. 31471283); National Key R&D Program of China
   (2016YFC1303403); Collaborative Innovation Major Project (Grant No.
   XYXT2015304); Six Talent Peaks Project in Jiangsu Province (No.
   SWYY-CXTD-010); the Cyrus Tang Hematology Center, Soochow University,
   Suzhou, Jiangsu, PR China; Collaborative Innovation Center of
   Hematology, Soochow University, Suzhou, Jiangsu, PR China; and the
   Project of State Key Laboratory of Radiation Medicine and Protection,
   Soochow University, Suzhou, Jiangsu, PR China (No. GZN1201803).
CR Babu E, 2015, BIOCHEM J, V469, P17, DOI 10.1042/BJ20150437
   BUTTERWOM, 1967, NATURE, V214, P1224, DOI DOI 10.1038/2141224A0
   Cenci S, 2014, MOL IMMUNOL, V62, P289, DOI 10.1016/j.molimm.2014.02.008
   Chauhan S, 2013, MOL CELL, V50, P16, DOI 10.1016/j.molcel.2013.01.024
   Chi YY, 2018, BIOCHEM BIOPH RES CO, V503, P2583, DOI 10.1016/j.bbrc.2018.07.019
   Delogu A, 2006, IMMUNITY, V24, P269, DOI 10.1016/j.immuni.2006.01.012
   Hardy RR, 2001, ANNU REV IMMUNOL, V19, P595, DOI 10.1146/annurev.immunol.19.1.595
   Imayoshi I, 2012, NEUROSCI RES, V73, P85, DOI 10.1016/j.neures.2012.02.003
   Lee S, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19102859
   Li WJ, 2015, CANCER PREV RES, V8, P487, DOI 10.1158/1940-6207.CAPR-14-0297-T
   Lin L, 2004, J EXP MED, V200, P115, DOI 10.1084/jem.20040612
   Masle-Farquhar E, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00549
   Milan E, 2016, J CLIN IMMUNOL, V36, pS18, DOI 10.1007/s10875-016-0254-9
   Mittrucker HW, 1997, SCIENCE, V275, P540, DOI 10.1126/science.275.5299.540
   Nera KP, 2006, IMMUNITY, V24, P283, DOI 10.1016/j.immuni.2006.02.003
   Nutt SL, 2011, SEMIN IMMUNOL, V23, P341, DOI 10.1016/j.smim.2011.08.010
   Ochiai K, 2006, J BIOL CHEM, V281, P38226, DOI 10.1074/jbc.M607592200
   PURTILO DT, 1979, AM J DIS CHILD, V133, P1251, DOI 10.1001/archpedi.1979.02130120043008
   Reimold AM, 2001, NATURE, V412, P300, DOI 10.1038/35085509
   Reljic R, 2000, J EXP MED, V192, P1841, DOI 10.1084/jem.192.12.1841
   Ross MT, 2005, NATURE, V434, P325, DOI 10.1038/nature03440
   Shapiro-Shelef M, 2003, IMMUNITY, V19, P607, DOI 10.1016/S1074-7613(03)00267-X
   Spolarics Z, 2007, SHOCK, V27, P597, DOI 10.1097/SHK.0b013e31802e40bd
   Syrett CM, 2017, PLOS GENET, V13, DOI 10.1371/journal.pgen.1007050
   Takeuchi T, 2002, BIOCHEM BIOPH RES CO, V293, P953, DOI 10.1016/S0006-291X(02)00321-2
   Tunyaplin C, 2004, J IMMUNOL, V173, P1158, DOI 10.4049/jimmunol.173.2.1158
   Urrutia R, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-231
   Wang JL, 2016, P NATL ACAD SCI USA, V113, pE2029, DOI 10.1073/pnas.1520113113
   Yamamoto M, 2009, GENESIS, V47, P107, DOI 10.1002/dvg.20474
   Yang L, 2011, ONCOGENE, V30, P1329, DOI 10.1038/onc.2010.515
   Yang L, 2008, CANCER RES, V68, P4321, DOI 10.1158/0008-5472.CAN-08-0407
   Yang L, 2008, J BIOL CHEM, V283, P35295, DOI 10.1074/jbc.M806965200
   Yildirim E, 2013, CELL, V152, P727, DOI 10.1016/j.cell.2013.01.034
   Zhang W, 2014, ONCOL REP, V32, P1913, DOI 10.3892/or.2014.3418
   Zhang XD, 2012, INT J BIOCHEM CELL B, V44, P1166, DOI 10.1016/j.biocel.2012.04.005
NR 35
TC 0
Z9 0
U1 1
U2 3
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1721-727X
EI 2058-7392
J9 EUR J INFLAMM
JI Eur. J. Inflamm.
PD MAY
PY 2019
VL 17
AR 2058739219850008
DI 10.1177/2058739219850008
PG 11
WC Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology
GA HZ5RK
UT WOS:000468910000001
OA gold
DA 2022-04-25
ER

PT J
AU Arun, RP
   Sivanesan, D
   Patra, B
   Varadaraj, S
   Verma, RS
AF Arun, Raj Pranap
   Sivanesan, Divya
   Patra, Bamadeb
   Varadaraj, Sudha
   Verma, Rama Shanker
TI Simulated microgravity increases polyploid giant cancer cells and
   nuclear localization of YAP
SO SCIENTIFIC REPORTS
LA English
DT Article
ID AUTOPHAGY MAINTAINS; HIPPO PATHWAY; STEM-CELLS; DIFFERENTIATION;
   EXPRESSION; MTOR; HOMEOSTASIS; RENEWAL; CD44; OCT4
AB Physical cues are vital in determining cellular fate in cancer. In vitro 3D culture do not replicate forces present in vivo. These forces including tumor interstitial fluid pressure and matrix stiffness behave as switches in differentiation and metastasis, which are intricate features of cancer stem cells (CSCs). Gravity determines the effect of these physical factors on cell fate and functions as evident from microgravity experiments on space and ground simulations. Here, we described the role of simulation of microgravity (SMG) using rotary cell culture system (RCCS) in increasing stemness in human colorectal cancer cell HCT116. We observed distinct features of cancer stem cells including CD133/CD44 dual positive cells and migration in SMG which was not altered by autophagy induction or inhibition. 3D and SMG increased autophagy, but the flux was staggered under SMG. Increased unique giant cancer cells housing complete nuclear localization of YAP were observed in SMG. This study highlights the role of microgravity in regulating stemness in CSC and importance of physical factors in determining the same.
C1 [Arun, Raj Pranap; Sivanesan, Divya; Patra, Bamadeb; Varadaraj, Sudha; Verma, Rama Shanker] Indian Inst Technol Madras, Stem Cell & Mol Biol Lab, Bhupat & Jyoti Mehta Sch Biosci, Dept Biotechnol, Madras 600036, Tamil Nadu, India.
RP Verma, RS (corresponding author), Indian Inst Technol Madras, Stem Cell & Mol Biol Lab, Bhupat & Jyoti Mehta Sch Biosci, Dept Biotechnol, Madras 600036, Tamil Nadu, India.
EM vermars@iitm.ac.in
RI Patra, Bamadeb/AAL-6915-2020; Patra, Bamadeb/F-1696-2016
OI Patra, Bamadeb/0000-0003-1309-2162; Patra, Bamadeb/0000-0003-1309-2162;
   Arun, Raj Pranap/0000-0001-5746-4728
FU Defence Research Development organizationDefence Research & Development
   Organisation (DRDO) [DLS/81/48222/LSRB-273/SHDD/2013]; Indian Institute
   of Technology Madras; Ministry of Human Resource Department, India
FX We wish to thank the Defence Research Development organization for
   supporting this work (DLS/81/48222/LSRB-273/SH&DD/2013). Raj Pranap
   Arun, Divya Sivanesan, Bamdeb Patra and Sudha Varadaraj wish to thank
   Indian Institute of Technology Madras, and Ministry of Human Resource
   Department, India for their fellowship. We thank Dr. Ganesh and Mr. M.
   Anandharasan from DSS infotech (Olympus, USA) for their support
   procuring confocal images. We thank R.S. Anand, Anna University, Chennai
   for his contribution in design of this work.
CR Alok A, 2017, J CELL SCI, V130, P1532, DOI 10.1242/jcs.198093
   Ariffin AB, 2014, CANCER RES, V74, P2655, DOI 10.1158/0008-5472.CAN-13-3696
   Arun RP, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-06416-4
   Ben-David U, 2011, NAT REV CANCER, V11, P268, DOI 10.1038/nrc3034
   Bjorkoy G, 2009, METHOD ENZYMOL, V452, P181, DOI 10.1016/S0076-6879(08)03612-4
   Brenner H, 2014, LANCET, V383, P1490, DOI 10.1016/S0140-6736(13)61649-9
   Chen JT, 2018, J PROTEOMICS, V188, P139, DOI 10.1016/j.jprot.2018.02.031
   Csibi A, 2012, NAT CELL BIOL, V14, P1244, DOI 10.1038/ncb2634
   Deng YH, 2016, NEURAL REGEN RES, V11, P1108, DOI 10.4103/1673-5374.187045
   Diaz-Carballo D, 2018, CANCER RES, V78, P2318, DOI 10.1158/0008-5472.CAN-17-1861
   Duelli D, 2007, NAT REV CANCER, V7, P968, DOI 10.1038/nrc2272
   Elsaba TMA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010714
   Friedrich J, 2009, NAT PROTOC, V4, P309, DOI 10.1038/nprot.2008.226
   Garcia-Prat L, 2016, NATURE, V529, P37, DOI 10.1038/nature16187
   Gwak JM, 2017, ONCOTARGET, V8, P36305, DOI 10.18632/oncotarget.16750
   Harvey KF, 2013, NAT REV CANCER, V13, P246, DOI 10.1038/nrc3458
   Horst D, 2008, BRIT J CANCER, V99, P1285, DOI 10.1038/sj.bjc.6604664
   Hu JKH, 2017, CELL STEM CELL, V21, P91, DOI 10.1016/j.stem.2017.03.023
   Ingram M, 1997, IN VITRO CELL DEV-AN, V33, P459
   Janmaleki M, 2016, SCI REP-UK, V6, DOI 10.1038/srep32418
   Jeong AJ, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-32965-3
   Jessup JM, 2000, IN VITRO CELL DEV-AN, V36, P367
   Jessup JM, 1997, IN VITRO CELL DEV-AN, V33, P352
   Kenific CM, 2016, J CELL SCI, V129, P3685, DOI 10.1242/jcs.188490
   Kim HB, 2018, BMB REP, V51, P119, DOI 10.5483/BMBRep.2018.51.3.018
   Kim H, 2018, BREAST CANCER RES, V20, DOI 10.1186/s13058-018-0944-8
   Kopp S, 2016, SCI REP-UK, V6, DOI 10.1038/srep26887
   Kopp S, 2015, SCI REP-UK, V5, DOI 10.1038/srep16691
   Lathia JD, 2011, CELL STEM CELL, V8, P482, DOI 10.1016/j.stem.2011.04.013
   Lee KW, 2015, CLIN CANCER RES, V21, P357, DOI 10.1158/1078-0432.CCR-14-1374
   Lee Y, 2017, CELL REP, V19, P188, DOI 10.1016/j.celrep.2017.03.030
   Lelkes PI, 1998, IN VITRO CELL DEV-AN, V34, P316
   Li H, 2015, CANCER PREV RES, V8, P1120, DOI 10.1158/1940-6207.CAPR-15-0242
   Li LQ, 2016, TUMOR BIOL, V37, P653, DOI 10.1007/s13277-015-3842-z
   Li XL, 2017, ONCOTARGET, V8, P46363, DOI 10.18632/oncotarget.18199
   Markolefa I, 2019, INT J ASTROBIOL, V18, P384, DOI 10.1017/S1473550418000277
   Mazure NM, 2010, CURR OPIN CELL BIOL, V22, P177, DOI 10.1016/j.ceb.2009.11.015
   Mo JS, 2014, EMBO REP, V15, P642, DOI 10.15252/embr.201438638
   MOOS PJ, 1994, EXP CELL RES, V213, P458, DOI 10.1006/excr.1994.1223
   Moss SC, 2010, J BIOL CHEM, V285, P11991, DOI 10.1074/jbc.M109.066621
   Nicklin P, 2009, CELL, V136, P521, DOI 10.1016/j.cell.2008.11.044
   Niu N, 2017, ONCOGENE, V36, P4887, DOI 10.1038/onc.2017.72
   Nukuda A, 2015, ONCOGENESIS, V4, DOI 10.1038/oncsis.2015.24
   Oliver L, 2012, STEM CELLS DEV, V21, P2779, DOI 10.1089/scd.2012.0124
   Pavel M, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05388-x
   Peng QH, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-017-0644-8
   Pflaumf J, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00285
   RILEY DA, 1987, MUSCLE NERVE, V10, P560, DOI 10.1002/mus.880100612
   ROKHLENKO KD, 1981, KOSM BIOL AVIAK MED+, V15, P77
   Rudin CM, 2012, NAT GENET, V44, P1111, DOI 10.1038/ng.2405
   Salemi S, 2012, CELL RES, V22, P432, DOI 10.1038/cr.2011.200
   Sambandam Y, 2014, BONE, V61, P125, DOI 10.1016/j.bone.2014.01.004
   Sandri M, 2013, INT J BIOCHEM CELL B, V45, P2121, DOI 10.1016/j.biocel.2013.04.023
   Senbanjo LT, 2017, FRONT CELL DEV BIOL, V5, DOI 10.3389/fcell.2017.00018
   Sharif T, 2017, AUTOPHAGY, V13, P264, DOI 10.1080/15548627.2016.1260808
   Tanida Isei, 2008, V445, P77, DOI 10.1007/978-1-59745-157-4_4
   Thome MP, 2016, J CELL SCI, V129, P4622, DOI 10.1242/jcs.195057
   Vidyasekar P, 2016, IN VITRO CELL DEV-AN, V52, P204, DOI 10.1007/s11626-015-9971-2
   Vidyasekar P, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135958
   Wang TT, 2019, CURR DRUG TARGETS, V20, P354, DOI 10.2174/1389450119666180626120852
   Wang Y, 2014, J BIOL CHEM, V289, P35159, DOI 10.1074/jbc.M114.600767
   Wang YJ, 2015, AM J PHYSIOL-CELL PH, V309, pC709, DOI 10.1152/ajpcell.00212.2015
   Weber GF, 1997, P ASSOC AM PHYSICIAN, V109, P1
   Wojnacki J, 2018, J BIOL CHEM, V293, P4575, DOI 10.1074/jbc.H118.002041
   Yu FX, 2015, CELL, V163, P811, DOI 10.1016/j.cell.2015.10.044
   Zanconato F, 2016, CANCER CELL, V29, P783, DOI 10.1016/j.ccell.2016.05.005
   Zha YH, 2017, EXP THER MED, V14, P199, DOI 10.3892/etm.2017.4512
   Zhang M, 2013, AM J PATHOL, V182, P565, DOI 10.1016/j.ajpath.2012.10.015
   Zhang S, 2014, ONCOGENE, V33, P116, DOI 10.1038/onc.2013.96
   Zhao H., 2009, CANCER RES, V69, P5080, DOI [10.1158/0008-5472.SABCS-09-5080, DOI 10.1158/0008-5472.SABCS-09-5080]
   Zhou JY, 2016, ONCOTARGET, V7, P7657, DOI 10.18632/oncotarget.7084
NR 71
TC 17
Z9 17
U1 2
U2 7
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD JUL 23
PY 2019
VL 9
AR 10684
DI 10.1038/s41598-019-47116-5
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA IK6SP
UT WOS:000476718900070
PM 31337825
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Li, J
   Wang, SW
   Zhang, DS
   Sun, Y
   Zhu, CY
   Fei, Q
   Hu, J
   Zhang, C
   Sun, YM
AF Li, Juan
   Wang, Shu-Wei
   Zhang, Dong-Sheng
   Sun, Ye
   Zhu, Chun-Yan
   Fei, Qiang
   Hu, Jun
   Zhang, Chuan
   Sun, Yue-Ming
TI FTY720-induced enhancement of autophagy protects cells from FTY720
   cytotoxicity in colorectal cancer
SO ONCOLOGY REPORTS
LA English
DT Article
DE FTY720; colorectal cancer; autophagy; cytoprotection; drug resistance;
   CIP2A
ID OVARIAN-CANCER; PP2A; LC3; PROLIFERATION; EXPRESSION; INHIBITOR;
   APOPTOSIS; EFFICACY; ASSAYS; CIP2A
AB FTY720, also known as fingolimod, is a widely used immunomodulator in multiple sclerosis and multiple organ transplantation. It is also an important protein phosphatase 2A (PP2A) activator. Based on this, a number of studies have recently demonstrated the cytotoxic effect of FTY720 in various cancers. Yet in colorectal cancer (CRC), the underlying mechanisms of FTY720 cytotoxicity remain less clear, especially the relationship between a drug and autophagy. We demonstrate here for the first time that FTY720 promotes the appearance of autophagic hallmarks such as autophagosome formation and light chain 3 (LC3)-II accumulation, indicating the participation of autophagy in FTY720 cytotoxicity on CRC. Moreover, inhibition of autophagy using 3-methyladenine (3-MA), a specific inhibitor of autophagy, enhanced FTY720 cytotoxicity, indicating the protective role of autophagy against the drug's own cytotoxic effect. The protective autophagy was likely affected by cancerous inhibitor of PP2A (CIP2A), an endogenous PP2A inhibitor that is closely related with poor prognosis and drug resistance. Consequently, our data not only demonstrate a new mechanism underlying the cytotoxic effect of FTY720 in CRC, but also a new strategy for CRC treatment, especially in cases resistant to conventional chemotherapies because of high CIP2A levels.
C1 [Li, Juan; Zhang, Dong-Sheng; Sun, Ye; Zhu, Chun-Yan; Fei, Qiang; Zhang, Chuan; Sun, Yue-Ming] Nanjing Med Univ, Dept Colorectal Surg, Affiliated Hosp 1, 300 Guangzhou Rd, Nanjing 210029, Jiangsu, Peoples R China.
   [Wang, Shu-Wei] Nanjing Univ Chinese Med, Dept Gen Surg, Wuxi Affiliated Hosp, Wuxi, Peoples R China.
   [Hu, Jun] First Peoples Hosp Changzhou, Dept Hepatobiliary Surg, Changzhou 214000, Jiangsu, Peoples R China.
RP Sun, YM (corresponding author), Nanjing Med Univ, Dept Colorectal Surg, Affiliated Hosp 1, 300 Guangzhou Rd, Nanjing 210029, Jiangsu, Peoples R China.
EM sym890207@163.com
FU Department of Health of the Jiangsu Province, China
FX This study was supported by a grant from the Fund of Department of
   Health of the Jiangsu Province, China.
CR Ahmed D, 2015, PHARMACOL RES PERSPE, V3, DOI 10.1002/prp2.171
   Alinari L, 2012, AUTOPHAGY, V8, P416, DOI 10.4161/auto.19050
   Barth S, 2010, J PATHOL, V221, P117, DOI 10.1002/path.2694
   Bockelman C, 2012, CANCER BIOL THER, V13, P289, DOI [10.4161/cbt.18922, 10.4161/cbt.13.5.18922]
   Brinkmann V, 2004, YONSEI MED J, V45, P991, DOI 10.3349/ymj.2004.45.6.991
   Figueroa-Aldariz MC, 2015, MOL CARCINOGEN, V54, P1430, DOI 10.1002/mc.22217
   Center MM, 2009, CA-CANCER J CLIN, V59, P366, DOI 10.3322/caac.20038
   Coles A, 2015, ANN INDIAN ACAD NEUR, V18, pS30, DOI 10.4103/0972-2327.164824
   Cristobal I, 2015, MAR DRUGS, V13, P3276, DOI 10.3390/md13063276
   Cristobal I, 2014, MOL CANCER THER, V13, P938, DOI 10.1158/1535-7163.MCT-13-0150
   de Mendoza AEH, 2015, J BIOMED NANOTECHNOL, V11, P691, DOI 10.1166/jbn.2015.1944
   Ding YY, 2014, MOL MED REP, V10, P387, DOI 10.3892/mmr.2014.2173
   Edwards BK, 2010, CANCER-AM CANCER SOC, V116, P544, DOI 10.1002/cncr.24760
   Fang YJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073528
   Gao M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105693
   Gomez VE, 2015, SEMIN CANCER BIOL, V35, P11, DOI 10.1016/j.semcancer.2015.09.011
   Hait NC, 2015, ONCOGENESIS, V4, DOI 10.1038/oncsis.2015.16
   Jin Jing, 2014, Yaoxue Xuebao, V49, P627
   Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720
   Kabeya Y, 2004, J CELL SCI, V117, P2805, DOI 10.1242/jcs.01131
   Klionsky DJ, 2012, AUTOPHAGY, V8, P445, DOI 10.4161/auto.19496
   Kovarik JM, 2004, J CLIN PHARMACOL, V44, P532, DOI 10.1177/0091270004264165
   Kroemer G, 2009, CELL DEATH DIFFER, V16, P3, DOI 10.1038/cdd.2008.150
   Liu Q, 2008, BLOOD, V111, P275, DOI 10.1182/blood-2006-10-053884
   Lu ZY, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-783
   Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239
   Mizushima N, 2007, AUTOPHAGY, V3, P542, DOI 10.4161/auto.4600
   Mizushima N, 2010, CELL, V140, P313, DOI 10.1016/j.cell.2010.01.028
   Ohama Takashi, 2015, Folia Pharmacologica Japonica, V145, P293
   Ozpolat B, 2015, CANCER MANAG RES, V7, P291, DOI 10.2147/CMAR.S34859
   Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74
   Perrotti D, 2013, LANCET ONCOL, V14, pE229, DOI 10.1016/S1470-2045(12)70558-2
   Rybaczek D, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142307
   SEGLEN PO, 1982, P NATL ACAD SCI-BIOL, V79, P1889, DOI 10.1073/pnas.79.6.1889
   Teng HW, 2012, J GASTROINTEST SURG, V16, P1037, DOI 10.1007/s11605-012-1828-3
   Van Hoof C, 2003, BBA-MOL CELL RES, V1640, P97, DOI 10.1016/S0167-4889(03)00029-6
   Yu HC, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0055705, 10.1371/journal.pone.0057111, 10.1371/journal.pone.0066447]
   Zhang N, 2010, AUTOPHAGY, V6, P1157, DOI 10.4161/auto.6.8.13614
   Zhang N, 2009, CANCER SCI, V100, P2459, DOI 10.1111/j.1349-7006.2009.01340.x
   Zhao Y, 2014, ONCOL REP, V31, P358, DOI 10.3892/or.2013.2850
NR 40
TC 9
Z9 9
U1 0
U2 5
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1021-335X
EI 1791-2431
J9 ONCOL REP
JI Oncol. Rep.
PD MAY
PY 2016
VL 35
IS 5
BP 2833
EP 2842
DI 10.3892/or.2016.4668
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA DJ3AS
UT WOS:000374077700038
PM 26985637
OA Bronze
DA 2022-04-25
ER

PT J
AU Wang, ZH
   Guo, K
   Gao, P
   Pu, QQ
   Lin, P
   Qin, SG
   Xie, N
   Hur, J
   Li, CL
   Huang, CH
   Wu, M
AF Wang, Zhihan
   Guo, Kai
   Gao, Pan
   Pu, Qinqin
   Lin, Ping
   Qin, Shugang
   Xie, Na
   Hur, Junguk
   Li, Changlong
   Huang, Canhua
   Wu, Min
TI Microbial and genetic-based framework identifies drug targets in
   inflammatory bowel disease
SO THERANOSTICS
LA English
DT Article
DE Inflammatory bowel disease; cyclic GMP-AMP synthase (cGAS); host
   transcriptome-microbiome interaction; drug repurposing; brefeldin-a
ID GMP-AMP SYNTHASE; OXIDATIVE STRESS; GUT MICROBIOTA; ACTIVATION; COLITIS;
   PATHOGENESIS; ASSOCIATION; AUTOPHAGY; IMMUNITY; PATHWAY
AB Rationale: With increasing incidence and prevalence of inflammatory bowel disease (IBD), it has become one of the major public health threats, and there is an urgent need to develop new therapeutic agents. Although the pathogenesis of IBD is still unclear, previous research has provided evidence for complex interplays between genetic, immune, microbial, and environmental factors. Here, we constructed a gene-microbiota interaction-based framework to discover IBD biomarkers and therapeutics. Methods: We identified candidate biomarkers for IBD by analyzing the publicly available transcriptomic and microbiome data from IBD cohorts. Animal models of IBD and diarrhea were established. The inflammation-correlated microbial and genetic variants in gene knockout mice were identified by 16S rRNA sequences and PCR array. We performed bioinformatic analysis of microbiome functional prediction and drug repurposing. Our validation experiments with cells and animals confirmed anti-inflammatory properties of a drug candidate. Results: We identified the DNA-sensing enzyme cyclic GMP-AMP synthase (cGAS) as a potential biomarker for IBD in both patients and murine models. cGAS knockout mice were less susceptible to DSS-induced colitis. cGAS-associated gut microbiota and host genetic factors relating to IBD pathogenesis were also identified. Using a computational drug repurposing approach, we predicted 43 candidate drugs with high potency to reverse colitis-associated gene expression and validated that brefeldin-a mitigates inflammatory response in colitis mouse model and colon cancer cell lines. Conclusions: By integrating computational screening, microbiota interference, gene knockout techniques, and in vitro and in vivo validation, we built a framework for predicting biomarkers and host-microbe interaction targets and identifying repurposing drugs for IBD, which may be tested further for clinical application. This approach may also be a tool for repurposing drugs for treating other diseases.
C1 [Wang, Zhihan; Xie, Na; Li, Changlong; Huang, Canhua] Sichuan Univ, West China Sch Basic Med Sci & Forens Med, Chengdu 610041, Sichuan, Peoples R China.
   [Wang, Zhihan; Gao, Pan; Pu, Qinqin; Lin, Ping; Qin, Shugang; Hur, Junguk; Wu, Min] Univ North Dakota, Sch Med & Hlth Sci, Dept Biomed Sci, Grand Forks, ND 58202 USA.
   [Guo, Kai] Univ Michigan, Dept Neurol, Ann Arbor, MI 48109 USA.
   [Gao, Pan] Wuhan Univ, Med Res Inst, Wuhan 430071, Peoples R China.
   [Lin, Ping] Army Med Univ, Daping Hosp, Inst Surg Res, State Key Lab Trauma Burns & Combined Injury, Chongqing 400038, Peoples R China.
   [Qin, Shugang; Huang, Canhua] Sichuan Univ, West China Hosp, State Key Lab Biotherapy, Chengdu 610041, Sichuan, Peoples R China.
   [Qin, Shugang; Huang, Canhua] Sichuan Univ, West China Hosp, Canc Ctr, Chengdu 610041, Sichuan, Peoples R China.
   [Qin, Shugang; Huang, Canhua] Collaborat Innovat Ctr Biotherapy, Chengdu 610041, Sichuan, Peoples R China.
RP Li, CL (corresponding author), Sichuan Univ, West China Sch Basic Med Sci & Forens Med, Chengdu 610041, Sichuan, Peoples R China.; Wu, M (corresponding author), Univ North Dakota, Sch Med & Hlth Sci, Dept Biomed Sci, Grand Forks, ND 58202 USA.; Huang, CH (corresponding author), Sichuan Univ, West China Hosp, State Key Lab Biotherapy, Chengdu 610041, Sichuan, Peoples R China.; Huang, CH (corresponding author), Sichuan Univ, West China Hosp, Canc Ctr, Chengdu 610041, Sichuan, Peoples R China.; Huang, CH (corresponding author), Collaborat Innovat Ctr Biotherapy, Chengdu 610041, Sichuan, Peoples R China.; Huang, CH (corresponding author), Sichuan Univ, West China Sch Basic Med Sci & Forens Med, Chengdu 610041, Sichuan, Peoples R China.
EM changlongli@scu.edu.cn; hcanhua@hotmail.com; min.wu@und.edu
OI Guo, Kai/0000-0002-4651-781X
FU National Institutes of Health (NIH)United States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USA [R01 AI138203,
   AI109317, P20 GM103442, GM113123]; National Key Research and Development
   Project [2020YFA0509400, 2020YFC2002705]; Guangdong Basic and Applied
   Basic Research Foundation [2019B030302012]; National Natural Science
   Foundation of ChinaNational Natural Science Foundation of China (NSFC)
   [81821002, 81790251]; Science and Technology Department of Sichuan
   Province [2019YJ0050]; (NIH)/NIGMSUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of General Medical Sciences (NIGMS) [P20GM113123,
   U54GM128729]; UND SMHS funds; Servier Medical Art (SMART)
FX The authors thank Charlie Rice (Rockefeller University) for kindly
   providing Cgastm1a(EUCOMM)Hmgu mice. This project was supported by the
   National Institutes of Health (NIH) grants R01 AI138203, AI109317
   grants, P20 GM103442, and GM113123 to MW, the National Key Research and
   Development Project (2020YFA0509400, 2020YFC2002705), Guangdong Basic
   and Applied Basic Research Foundation (2019B030302012), and National
   Natural Science Foundation of China (81821002 and 81790251) to CH, and
   the Science and Technology Department of Sichuan Province (No.
   2019YJ0050) to CL. The Human core, Histology core, and Imaging core at
   UND were acknowledged for the support of the work. Histological services
   were provided by the UND Histology Core Facility supported (NIH)/NIGMS
   award P20GM113123, DaCCoTA CTR NIH grant U54GM128729, and UND SMHS
   funds. Figures 1A and 5I were created by modifying illustrations
   provided by Servier Medical Art (SMART, smart.servier.com) licensed
   under a Creative Commons Attribution 3.0 Unported License and
   Vecteezy.com.
CR Aden K, 2018, J EXP MED, V215, P2868, DOI 10.1084/jem.20171029
   Adolph TE, 2013, NATURE, V503, P272, DOI 10.1038/nature12599
   An X, 2019, MOL THER-NUCL ACIDS, V14, P80, DOI 10.1016/j.omtn.2018.11.003
   Andrews S., 2010, FASTQC QUALITY CONTR
   Aytac E, 2013, TURK J GASTROENTEROL, V24, P224, DOI 10.4318/tjg.2013.0491
   Bolger AM, 2014, BIOINFORMATICS, V30, P2114, DOI 10.1093/bioinformatics/btu170
   Can G, 2015, J CROHNS COLITIS, V9, P907, DOI 10.1093/ecco-jcc/jjv114
   Chen B, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms16022
   Chen Q, 2017, NUTRIENTS, V9, DOI 10.3390/nu9121341
   Chong J, 2020, NAT PROTOC, V15, P799, DOI 10.1038/s41596-019-0264-1
   Chu HT, 2016, SCIENCE, V352, P1116, DOI 10.1126/science.aad9948
   de Lange KM, 2017, NAT GENET, V49, P256, DOI 10.1038/ng.3760
   de Souza HSP, 2017, NAT REV GASTRO HEPAT, V14, P739, DOI 10.1038/nrgastro.2017.110
   Dobbs N, 2015, CELL HOST MICROBE, V18, P157, DOI 10.1016/j.chom.2015.07.001
   el Bouhaddani S, 2016, BMC BIOINFORMATICS, V17, DOI 10.1186/s12859-015-0854-z
   Fabregat A, 2018, NUCLEIC ACIDS RES, V46, pD649, DOI [10.1093/nar/gkx1132, 10.1093/nar/gkz1031]
   Forbes JD, 2018, MICROBIOME, V6, DOI 10.1186/s40168-018-0603-4
   Franke A, 2010, NAT GENET, V42, P1118, DOI 10.1038/ng.717
   Franzosa EA, 2015, NAT REV MICROBIOL, V13, P360, DOI 10.1038/nrmicro3451
   Gao DX, 2015, P NATL ACAD SCI USA, V112, pE5699, DOI 10.1073/pnas.1516465112
   Gevers D, 2014, CELL HOST MICROBE, V15, P382, DOI 10.1016/j.chom.2014.02.005
   Guo Q, 2012, EUR J IMMUNOL, V42, P1500, DOI 10.1002/eji.201142051
   Haag SM, 2018, NATURE, V559, P269, DOI 10.1038/s41586-018-0287-8
   Haberman Y, 2014, J CLIN INVEST, V124, P3617, DOI 10.1172/JCI75436
   Hasnain SZ, 2011, J EXP MED, V208, P893, DOI 10.1084/jem.20102057
   Hernandez-Chirlaque C, 2016, J CROHNS COLITIS, V10, P1324, DOI 10.1093/ecco-jcc/jjw096
   Hong S, 2019, FASEB J, V33, P4547, DOI 10.1096/fj.201801585R
   Imhann F, 2018, GUT, V67, P108, DOI 10.1136/gutjnl-2016-312135
   Jin S, 2017, SCI REP-UK, V7, DOI 10.1038/srep43662
   Saez-Lara MJ, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/505878
   Kabat AM, 2016, ELIFE, V5, DOI 10.7554/eLife.12444
   Kaplan GG, 2015, NAT REV GASTRO HEPAT, V12, P720, DOI 10.1038/nrgastro.2015.150
   Keenan AB, 2018, CELL SYST, V6, P13, DOI 10.1016/j.cels.2017.11.001
   Kim JJ, 2012, JOVE-J VIS EXP, DOI 10.3791/3678
   Klindworth A, 2013, NUCLEIC ACIDS RES, V41, DOI 10.1093/nar/gks808
   Koleti A, 2018, NUCLEIC ACIDS RES, V46, pD558, DOI 10.1093/nar/gkx1063
   Kono M, 2018, J CROHNS COLITIS, V12, P499, DOI 10.1093/ecco-jcc/jjx170
   Lamas B, 2016, NAT MED, V22, P598, DOI 10.1038/nm.4102
   Larabi A, 2020, AUTOPHAGY, V16, P38, DOI 10.1080/15548627.2019.1635384
   Lee-Kirsch MA, 2007, NAT GENET, V39, P1065, DOI 10.1038/ng2091
   Li GP, 2013, J IMMUNOL, V191, P5359, DOI 10.4049/jimmunol.1301596
   Lichtman JS, 2016, CELL REP, V14, P1049, DOI 10.1016/j.celrep.2016.01.009
   Lin P, 2020, MOL CELL, V78, P850, DOI 10.1016/j.molcel.2020.03.033
   Lloyd-Price J, 2019, NATURE, V569, P655, DOI 10.1038/s41586-019-1237-9
   Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8
   Mabley J, 2003, EUR J PHARMACOL, V466, P323, DOI 10.1016/S0014-2999(03)01570-X
   McMurdie PJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061217
   Meddens CA, 2019, GUT, V68, P928, DOI 10.1136/gutjnl-2018-317516
   Miquel S, 2015, MBIO, V6, DOI 10.1128/mBio.00300-15
   Motwani M, 2019, NAT REV GENET, V20, P657, DOI 10.1038/s41576-019-0151-1
   Negroni A, 2012, INFLAMM BOWEL DIS, V18, P913, DOI 10.1002/ibd.21899
   Neurath MF, 2017, NAT REV GASTRO HEPAT, V14, P269, DOI 10.1038/nrgastro.2016.208
   Ohnmacht C, 2015, SCIENCE, V349, P989, DOI 10.1126/science.aac4263
   Olli KE, 2020, INFLAMM BOWEL DIS, V26, P1353, DOI 10.1093/ibd/izaa064
   Paek SM, 2018, MAR DRUGS, V16, DOI 10.3390/md16040133
   Pu QQ, 2019, PRECIS CLIN MED, V2, P166, DOI 10.1093/pcmedi/pbz019
   Pushpakom S, 2019, NAT REV DRUG DISCOV, V18, P41, DOI 10.1038/nrd.2018.168
   R Core Team, 2015, R LANG ENV STAT COMP
   Ramanan D, 2014, IMMUNITY, V41, P311, DOI 10.1016/j.immuni.2014.06.015
   Rowan F, 2010, DIS COLON RECTUM, V53, P1530, DOI 10.1007/DCR.0b013e3181f1e620
   Schirmer M, 2018, NAT MICROBIOL, V3, P337, DOI 10.1038/s41564-017-0089-z
   Schoggins JW, 2014, NATURE, V505, P691, DOI 10.1038/nature12862
   Seishima J, 2019, GENOME BIOL, V20, DOI 10.1186/s13059-019-1879-9
   Sen A, 2019, WORLD J GASTROENTERO, V25, P2846, DOI 10.3748/wjg.v25.i23.2846
   Subramanian A, 2017, CELL, V171, P1437, DOI 10.1016/j.cell.2017.10.049
   Sun LJ, 2013, SCIENCE, V339, P786, DOI 10.1126/science.1232458
   Thai JD, 2020, NUTRIENTS, V12, DOI 10.3390/nu12020581
   Wagner J, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003578
   Wood DE, 2019, GENOME BIOL, V20, DOI 10.1186/s13059-019-1891-0
   Wu M, 2003, GENE THER, V10, P1429, DOI 10.1038/sj.gt.3302009
   Wu M, 2002, ELECTROPHORESIS, V23, P2373, DOI 10.1002/1522-2683(200208)23:15<2373::AID-ELPS2373>3.0.CO;2-W
   Yamamoto T, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-42253-3
   Yan HY, 2015, INT J CLIN EXP MED, V8, P20245
   Yu Y, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0982-2
   Zhang QP, 2016, SCI REP-UK, V6, DOI 10.1038/srep27572
   Zhu QF, 2014, J IMMUNOL, V193, P4779, DOI 10.4049/jimmunol.1402051
NR 76
TC 2
Z9 2
U1 5
U2 8
PU IVYSPRING INT PUBL
PI LAKE HAVEN
PA PO BOX 4546, LAKE HAVEN, NSW 2263, AUSTRALIA
SN 1838-7640
J9 THERANOSTICS
JI Theranostics
PY 2021
VL 11
IS 15
BP 7491
EP 7506
DI 10.7150/thno.59196
PG 16
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA UJ8SC
UT WOS:000691548300004
PM 34158863
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Devkota, AK
   Tavares, CDJ
   Warthaka, M
   Abramczyk, O
   Marshall, KD
   Kaoud, TS
   Gorgulu, K
   Ozpolat, B
   Dalby, KN
AF Devkota, Ashwini K.
   Tavares, Clint D. J.
   Warthaka, Mangalika
   Abramczyk, Olga
   Marshall, Kyle D.
   Kaoud, Tamer S.
   Gorgulu, Kivanc
   Ozpolat, Bulent
   Dalby, Kevin N.
TI Investigating the Kinetic Mechanism of Inhibition of Elongation Factor 2
   Kinase by NH125: Evidence of a Common in Vitro Artifact
SO BIOCHEMISTRY
LA English
DT Article
ID DEPENDENT PROTEIN-KINASE; MALIGNANT GLIOMA-CELLS; HEAVY-CHAIN-KINASE;
   COLON-CANCER CELLS; FACTOR-II KINASE; RAT GLIAL-CELLS; PROMISCUOUS
   INHIBITORS; INDUCED AUTOPHAGY; MAMMALIAN-CELLS; PHOSPHORYLATION
AB Evidence that elongation factor 2 kinase (eEF-2K) has potential as a target for anticancer therapy and possibly for the treatment of depression is emerging. Here the steady-state kinetic mechanism of eEF-2K is presented using a peptide substrate and is shown to conform to an ordered sequential mechanism with ATP binding first. Substrate inhibition by the peptide was observed and revealed to be competitive with ATP, explaining the observed ordered mechanism. Several small molecules are reported to inhibit eEF-2K activity with the most notable being the histidine kinase inhibitor NH125, which has been used in a number of studies to characterize eEF-2K activity in cells. While NH125 was previously reported to inhibit eEF-2K in vitro with an IC50 of 60 nM, its mechanism of action was not established. Using the same kinetic assay, the ability of an authentic sample of NH125 to inhibit eEF-2K was assessed over a range of substrate and inhibitor concentrations. A typical dose-response curve for the inhibition of eEF-2K by NH125 is best fit to an IC50 of 18 +/- 0.25 mu M and a Hill coefficient of 3.7 +/- 0.14, suggesting that NH125 is a weak inhibitor of eEF-2K under the experimental conditions of a standard in vitro kinase assay. To test the possibility that NH125 is a potent inhibitor of eEF2 phosphorylation, we assessed its ability to inhibit the phosphorylation of eEF2. Under standard kinase assay conditions, NH125 exhibits a similar weak ability to inhibit the phosphorylation of eEF2 by eEF-2K. Notably, the activity of NH125 is severely abrogated by the addition of 0.1% Triton to the kinase assay through a process that can be reversed upon dilution. These studies suggest that NH125 is a nonspecific colloidal aggregator in vitro, a notion further supported by the observation that NH125 inhibits other protein kinases, such as ERK2 and TRPM7 in a manner similar to that of eEF-2K. As NH125 is reported to inhibit eEF-2K in a cellular environment, its ability to inhibit eEF2 phosphorylation was assessed in MDA-MB-231 breast cancer, A549 lung cancer, and HEK-293T cell lines using a Western blot approach. No sign of a decrease in the level of eEF2 phosphorylation was observed up to 12 h following addition of NH125 to the media. Furthermore, contrary to the previously reported literatures, NH125 induced the phosphorylation of eEF-2.
C1 [Devkota, Ashwini K.; Tavares, Clint D. J.; Dalby, Kevin N.] Univ Texas Austin, Grad Program Cell & Mol Biol, Austin, TX 78712 USA.
   [Warthaka, Mangalika; Abramczyk, Olga; Marshall, Kyle D.; Kaoud, Tamer S.; Dalby, Kevin N.] Univ Texas Austin, Coll Pharm, Div Med Chem, Austin, TX 78712 USA.
   [Kaoud, Tamer S.; Dalby, Kevin N.] Univ Texas Austin, Grad Program Pharm, Austin, TX 78712 USA.
   [Ozpolat, Bulent] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Unit 422, Houston, TX 77030 USA.
RP Dalby, KN (corresponding author), Univ Texas Austin, Grad Program Cell & Mol Biol, 107 W Dean Keaton,Biomed Engn Bldg, Austin, TX 78712 USA.
EM bozpolat@mdanderson.org; kinases@me.com
RI Kaoud, Tamer S/C-3618-2019; Dalby, Kevin N/A-1905-2013; Görgülü,
   Kıvanç/AAV-6525-2020; Gorgulu, Kivanc/M-6950-2017
OI Dalby, Kevin N/0000-0001-9272-5129; Görgülü, Kıvanç/0000-0002-1613-1422;
   Gorgulu, Kivanc/0000-0002-1613-1422; Marshall, Kyle/0000-0003-3366-1174;
   Gorgulu, Kivanc/0000-0002-0855-9939; Abramczyk,
   Olga/0000-0002-7595-3223; Kaoud, Tamer/0000-0003-1298-8725
FU Welch FoundationThe Welch Foundation [F-1390]; National Institutes of
   HealthUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [GM59802, P01GM078195]; Egyptian
   Ministry of Higher EducationScience and Technology Development Fund
   (STDF); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of General Medical Sciences (NIGMS)
   [R01GM059802, P01GM078195] Funding Source: NIH RePORTER
FX This research was supported in part by grants from the Welch Foundation
   (F-1390) to K.N.D. and the National Institutes of Health to K.N.D.
   (GM59802). A grant from the National Institutes of Health (P01GM078195)
   supported K.N.D. T.S.K. acknowledges a scholarship from the Egyptian
   Ministry of Higher Education.
CR Abramczyk O, 2011, PROTEIN EXPRES PURIF, V79, P237, DOI 10.1016/j.pep.2011.05.005
   Arora S, 2003, CANCER RES, V63, P6894
   Autry AE, 2011, NATURE, V475, P91, DOI 10.1038/nature10130
   BAGAGLIO DM, 1994, CELL GROWTH DIFFER, V5, P1403
   BAGAGLIO DM, 1993, CANCER RES, V53, P2260
   Belle R, 2011, DEV BIOL, V350, P476, DOI 10.1016/j.ydbio.2010.12.015
   Bursch W, 2000, J CELL SCI, V113, P1189
   Bursch W, 1996, CARCINOGENESIS, V17, P1595, DOI 10.1093/carcin/17.8.1595
   CARLBERG U, 1990, EUR J BIOCHEM, V191, P639, DOI 10.1111/j.1432-1033.1990.tb19169.x
   CARLBERG U, 1991, BIOCHEM BIOPH RES CO, V180, P1372, DOI 10.1016/S0006-291X(05)81347-6
   Chen ZH, 2011, J BIOL CHEM, V286, P43951, DOI 10.1074/jbc.M111.301291
   Cho SI, 2000, BBA-GEN SUBJECTS, V1475, P207, DOI 10.1016/S0304-4165(00)00061-1
   COOK PF, 1982, BIOCHEMISTRY-US, V21, P5794, DOI 10.1021/bi00266a011
   Copeland Robert A, 2005, Methods Biochem Anal, V46, P1
   Crawley SW, 2008, BBA-PROTEINS PROTEOM, V1784, P908, DOI 10.1016/j.bbapap.2008.03.001
   Ellington AA, 2006, CARCINOGENESIS, V27, P298, DOI 10.1093/carcin/bgi214
   Ellington AA, 2005, CARCINOGENESIS, V26, P159, DOI 10.1093/carcin/bgh297
   Feng BY, 2006, NAT PROTOC, V1, P550, DOI 10.1038/nprot.2006.77
   GSCHWENDT M, 1994, FEBS LETT, V338, P85, DOI 10.1016/0014-5793(94)80121-5
   Hait WN, 2006, AUTOPHAGY, V2, P294, DOI 10.4161/auto.2857
   Hait WN, 1996, FEBS LETT, V397, P55, DOI 10.1016/S0014-5793(96)01140-4
   Hoyer-Hansen M, 2005, CELL DEATH DIFFER, V12, P1297, DOI 10.1038/sj.cdd.4401651
   Ito H, 2005, INT J ONCOL, V26, P1401
   Kanzawa T, 2003, CANCER RES, V63, P2103
   Kanzawa T, 2004, CELL DEATH DIFFER, V11, P448, DOI 10.1038/sj.cdd.4401359
   Keshwani MM, 2009, J BIOL CHEM, V284, P22611, DOI 10.1074/jbc.M109.032177
   Khan AA, 2010, AM J PATHOL, V177, P481, DOI 10.2353/ajpath.2010.090836
   Kondo Y, 2005, NAT REV CANCER, V5, P726, DOI 10.1038/nrc1692
   Kondo Y, 2006, AUTOPHAGY, V2, P85, DOI 10.4161/auto.2.2.2463
   KONG CT, 1988, BIOCHEMISTRY-US, V27, P4795, DOI 10.1021/bi00413a032
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Lockman JW, 2010, BIOORG MED CHEM LETT, V20, P2283, DOI 10.1016/j.bmcl.2010.02.005
   McGovern SL, 2003, J MED CHEM, V46, P4265, DOI 10.1021/jm030266r
   McGovern SL, 2003, J MED CHEM, V46, P1478, DOI 10.1021/jm020427b
   Meijer AJ, 2004, INT J BIOCHEM CELL B, V36, P2445, DOI 10.1016/j.biocel.2004.02.002
   NAIRN AC, 1987, J BIOL CHEM, V262, P17299
   Opipari AW, 2004, CANCER RES, V64, P696, DOI 10.1158/0008-5472.CAN-03-2404
   Paglin S, 2001, CANCER RES, V61, P439
   Parmer TG, 1999, BRIT J CANCER, V79, P59, DOI 10.1038/sj.bjc.6690012
   Parmer TG, 1997, CELL GROWTH DIFFER, V8, P327
   Pavur KS, 2000, BIOCHEMISTRY-US, V39, P12216, DOI 10.1021/bi0007270
   REDPATH NT, 1993, EUR J BIOCHEM, V213, P689, DOI 10.1111/j.1432-1033.1993.tb17809.x
   Rose AJ, 2009, J PHYSIOL-LONDON, V587, P1547, DOI 10.1113/jphysiol.2008.167528
   Ryan AJ, 2003, J MED CHEM, V46, P3448, DOI 10.1021/jm0340896
   RYAZANOV A G, 1990, New Biologist, V2, P843
   Ryazanov AG, 2002, FEBS LETT, V514, P26, DOI 10.1016/S0014-5793(02)02299-8
   RYAZANOV AG, 1988, NATURE, V334, P170, DOI 10.1038/334170a0
   RYAZANOV AG, 1989, FEBS LETT, V251, P187, DOI 10.1016/0014-5793(89)81452-8
   Scarlatti F, 2004, J BIOL CHEM, V279, P18384, DOI 10.1074/jbc.M313561200
   Segel I.H., 1993, ENZYME KINETICS BEHA
   Seidler J, 2003, J MED CHEM, V46, P4477, DOI 10.1021/jm030191r
   Shao YF, 2004, P NATL ACAD SCI USA, V101, P18030, DOI 10.1073/pnas.0408345102
   SMAILOV SK, 1993, FEBS LETT, V321, P219, DOI 10.1016/0014-5793(93)80112-8
   Smith EM, 2008, EMBO J, V27, P1005, DOI 10.1038/emboj.2008.39
   Soltoff SP, 2001, J BIOL CHEM, V276, P37986
   Soltoff SP, 2007, TRENDS PHARMACOL SCI, V28, P453, DOI 10.1016/j.tips.2007.07.003
   Takeuchi H, 2005, CANCER RES, V65, P3336, DOI 10.1158/0008-5472.CAN-04-3640
   Tavares CDJ, 2012, BIOCHEMISTRY-US, V51, P2232, DOI 10.1021/bi201788e
   Waas W. F., 2003, BIOCHEMISTRY-US, V42, P2960
   Wu H, 2006, CANCER RES, V66, P3015, DOI 10.1158/0008-5472.CAN-05-1554
   Wu H, 2009, CANCER RES, V69, P2453, DOI 10.1158/0008-5472.CAN-08-2872
   Yamamoto K, 2000, BIOSCI BIOTECH BIOCH, V64, P919, DOI 10.1271/bbb.64.919
   Yamamoto K, 2001, BIOSCI BIOTECH BIOCH, V65, P2306, DOI 10.1271/bbb.65.2306
   Yao KC, 2003, J NEUROSURG, V98, P378, DOI 10.3171/jns.2003.98.2.0378
   Ye QL, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000525
NR 65
TC 45
Z9 48
U1 1
U2 13
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0006-2960
J9 BIOCHEMISTRY-US
JI Biochemistry
PD MAR 13
PY 2012
VL 51
IS 10
BP 2100
EP 2112
DI 10.1021/bi201787p
PG 13
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 907DM
UT WOS:000301398000008
PM 22352903
OA Green Accepted
DA 2022-04-25
ER

PT J
AU Jia, YF
   Yu, DF
   Huang, QH
   Zhang, XD
   Qiu, LQ
   Cao, RH
   Du, RL
   Liu, WB
AF Jia, Yifan
   Yu, Difei
   Huang, Qiuhua
   Zhang, Xiaodong
   Qiu, Liqin
   Cao, Rihui
   Du, Runlei
   Liu, Wenbin
TI Design and Synthesis of 4(1H)-quinolone Derivatives as Autophagy
   Inducing Agents by Targeting ATG5 Protein
SO LETTERS IN DRUG DESIGN & DISCOVERY
LA English
DT Article
DE Synthesis; quinolone; antiproliferative; autophagy; mechanism of action;
   ATG5 protein
ID BAX GENE-TRANSFER; BIOLOGICAL EVALUATION; QUINOLINE DERIVATIVES;
   ANTITUMOR-ACTIVITY; IN-VITRO; CANCER; P53; MUTATION; ACCUMULATION
AB Background: Quinolines have been characterized as a class of potential antitumor agents, and a large number of natural and synthetic quinolines acting as antitumor agents were reported.
   Methods: A series of 7-chloro-4(1H)-quinolone derivatives were synthesized. The antiproliferative effect of these compounds was evaluated by MTT assay against five human tumor cell lines. The mechanism of action of the selected compound 7h was also investigated.
   Results and Discussion: Most of the compounds had more potent antiproliferative activities than the lead compound 7-chloro-4(1H)-quinolone 6b. Compound 7h was found to be the most potent antiproliferative agent against human tumor cell lines. Further investigation demonstrated that compound 7h triggered ATG5-dependent autophagy of colorectal cancer cells by promoting the functions of LC3 proteins.
   Conclusion: These results were useful for designing and discovering more potent novel antitumor agents endowed with better pharmacological profiles.
C1 [Jia, Yifan] Wuhan Univ, Dept Pain Management, Renmin Hosp, Wuhan 430060, Peoples R China.
   [Liu, Wenbin] Wuhan Polytech Univ, Coll Hlth Sci & Nursing, Wuhan 430023, Peoples R China.
   [Yu, Difei; Zhang, Xiaodong; Du, Runlei] Wuhan Univ, Coll Life Sci, Hubei Key Lab Cell Homeostasis, Wuhan 430072, Peoples R China.
   [Huang, Qiuhua; Qiu, Liqin; Cao, Rihui] Sun Yat Sen Univ, Sch Chem, Guangzhou 510275, Peoples R China.
RP Liu, WB (corresponding author), Wuhan Polytech Univ, Coll Hlth Sci & Nursing, Wuhan 430023, Peoples R China.; Du, RL (corresponding author), Wuhan Univ, Coll Life Sci, Hubei Key Lab Cell Homeostasis, Wuhan 430072, Peoples R China.; Cao, RH (corresponding author), Sun Yat Sen Univ, Sch Chem, Guangzhou 510275, Peoples R China.
EM caorihui@mail.sysu.edu.cn; runleidu@whu.edu.cn; liuwenbin_1@yeah.net
FU Natural Science Foundation of Guangdong ProvinceNational Natural Science
   Foundation of Guangdong Province [S2013010012138, 2016A030313349];
   National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81872271, 31501148, 81402994]
FX This work was supported by grants from the Natural Science Foundation of
   Guangdong Province [S2013010012138 and 2016A030313349] and the National
   Natural Science Foundation of China grant [81872271, 31501148, and
   81402994].
CR Abdellatif KRA, 2017, MED CHEM RES, V26, P929, DOI 10.1007/s00044-017-1798-9
   Abouzid K, 2008, BIOORGAN MED CHEM, V16, P7543, DOI 10.1016/j.bmc.2008.07.038
   Aldred KJ, 2012, BIOCHEMISTRY-US, V51, P370, DOI 10.1021/bi2013905
   Bedri S., 2018, HUM VACCIN IMMUNOTHE
   Call JA, 2008, LANCET ONCOL, V9, P1002, DOI 10.1016/S1470-2045(08)70209-2
   Chen Q., 2005, ZHONGGUO XIN YAO ZAZ, V14, P1231
   Coll JL, 1998, HUM GENE THER, V9, P2063, DOI 10.1089/hum.1998.9.14-2063
   Haghighat P, 2000, ANTICANCER RES, V20, P1337
   Hammel P, 1999, INT J CANCER, V81, P712, DOI 10.1002/(SICI)1097-0215(19990531)81:5<712::AID-IJC7>3.0.CO;2-0
   Hardiman KM, 2018, CLIN COLON RECT SURG, V31, P147, DOI 10.1055/s-0037-1602234
   Issaka RB, 2019, PREV MED, V118, P113, DOI 10.1016/j.ypmed.2018.10.021
   Kagawa S, 2000, CANCER RES, V60, P1157
   Katsumata Kenji, 2003, Int J Clin Oncol, V8, P352, DOI 10.1007/s10147-003-0352-6
   Khelifi I, 2017, EUR J MED CHEM, V127, P1025, DOI 10.1016/j.ejmech.2016.11.012
   Kumar AR, 2015, INDIAN J CHEM B, V54, P1495
   Li K, 2016, BIOORGAN MED CHEM, V24, P1889, DOI 10.1016/j.bmc.2016.03.016
   Lopez I, 2012, GENE, V499, P81, DOI 10.1016/j.gene.2012.02.011
   Marciniec K., 2017, MOLECULES, P22
   Morling J, 2018, GUT, V67, pA196, DOI 10.1136/gutjnl-2018-BSGAbstracts.390
   Mun JG, 2019, ONCOL REP, V41, P202, DOI 10.3892/or.2018.6812
   Nasierowska-Guttmejer Anna, 2000, Pathology and Oncology Research, V6, P275
   Oh M, 2018, JNCI-J NATL CANCER I, V110, DOI 10.1093/jnci/djy148
   Pfeiffer P., 2018, EXPERT REV ANTICANCE
   PRICE CC, 1946, J AM CHEM SOC, V68, P1204, DOI 10.1021/ja01211a020
   Salahuddin, 2015, MED CHEM RES, V24, P2514, DOI 10.1007/s00044-014-1308-2
   Shroff A, 2018, AM J REPROD IMMUNOL, V80, DOI 10.1111/aji.13056
   Srivastava SK, 2007, ANTI-CANCER AGENT ME, V7, P685, DOI 10.2174/187152007784111313
   Sun J, 2013, EUR J MED CHEM, V60, P23, DOI 10.1016/j.ejmech.2012.11.039
   Wang FM, 2019, ARCH ORAL BIOL, V97, P116, DOI 10.1016/j.archoralbio.2018.10.020
   Wang L, 2015, BIOORGAN MED CHEM, V23, P4364, DOI 10.1016/j.bmc.2015.06.024
   Wang Shijia, 2018, Oncotarget, V9, P26616, DOI 10.18632/oncotarget.24299
   Wang XQ, 2017, BIOORGAN MED CHEM, V25, P886, DOI 10.1016/j.bmc.2016.12.002
   Webley KM, 2000, J PATHOL, V191, P361
   Ye JW, 2018, ONCOL LETT, V16, P2957, DOI 10.3892/ol.2018.9025
   Ye X, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02334
   Zhang ZY, 2017, EUR J MED CHEM, V140, P239, DOI 10.1016/j.ejmech.2017.09.017
   Zhang Z, 2019, ONCOL REP, V41, P619, DOI 10.3892/or.2018.6806
NR 37
TC 0
Z9 0
U1 0
U2 8
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1570-1808
EI 1875-628X
J9 LETT DRUG DES DISCOV
JI Lett. Drug Des. Discov.
PY 2020
VL 17
IS 7
BP 884
EP 890
DI 10.2174/1570180816666191122113045
PG 7
WC Chemistry, Medicinal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA MI4HM
UT WOS:000547371000007
DA 2022-04-25
ER

PT J
AU Ma, HL
   Li, YW
   Wang, XX
   Wu, H
   Qi, GH
   Li, RR
   Yang, N
   Gao, M
   Yan, S
   Yuan, CZ
   Kong, BH
AF Ma, Hanlin
   Li, Yingwei
   Wang, Xiangxiang
   Wu, Huan
   Qi, Gonghua
   Li, Rongrong
   Yang, Ning
   Gao, Min
   Yan, Shi
   Yuan, Cunzhong
   Kong, Beihua
TI PBK, targeted by EVI1, promotes metastasis and confers cisplatin
   resistance through inducing autophagy in high-grade serous ovarian
   carcinoma
SO CELL DEATH & DISEASE
LA English
DT Article
ID ORIGINATED PROTEIN-KINASE; PDZ-BINDING KINASE; PBK/TOPK EXPRESSION;
   THERAPEUTIC TARGET; CELL-PROLIFERATION; COLORECTAL-CANCER;
   PROSTATE-CANCER; TOPK; PROGNOSIS; GROWTH
AB High-grade serous ovarian carcinoma (HGSOC) is the most lethal type of gynecologic malignancy. Chemoresistance is the main reason for the poor prognosis of HGSOC. PDZ-binding kinase (PBK) promotes the malignant progression of various carcinomas. However, the roles and clinical significance of PBK in HGSOC remain unclear. Here, we reported that PBK was overexpressed in HGSOC tissues and cell lines. High PBK expression was associated with a poor prognosis, metastasis, and cisplatin resistance of HGSOC. Overexpression of PBK promoted autophagy and enhanced cisplatin resistance via the ERK/mTOR signaling pathway. Further study showed that inhibition of autophagy by chloroquine or bafilomycin A1 reversed PBK-induced cisplatin resistance. Overexpression of PBK decreased ovarian cancer responsiveness to cisplatin treatment through inducing autophagy in vivo. We also demonstrated that the PBK inhibitor OTS514 augmented the growth inhibition effect of cisplatin in vitro and in vivo. Moreover, ecotropic viral integration site-1 (EVI1) could regulate PBK expression through directly targeting the PBK promoter region. In conclusion, high PBK expression was correlated with a poor prognosis, metastasis, and cisplatin resistance through promoting autophagy in HGSOC. PBK might be a promising target for the early diagnosis and individual treatment of ovarian cancer.
C1 [Ma, Hanlin; Li, Yingwei; Wang, Xiangxiang; Wu, Huan; Qi, Gonghua; Li, Rongrong; Yang, Ning; Gao, Min; Yan, Shi; Yuan, Cunzhong; Kong, Beihua] Shandong Univ, Qilu Hosp, Dept Obstet & Gynecol, Jinan 250012, Shandong, Peoples R China.
   [Ma, Hanlin; Li, Rongrong; Yang, Ning; Gao, Min; Yan, Shi; Yuan, Cunzhong; Kong, Beihua] Shandong Univ, Qilu Hosp, Gynecol Oncol Key Lab Shandong Prov, Jinan 250012, Shandong, Peoples R China.
   [Li, Yingwei] Shandong Univ, Inst Oncol, Sch Med, Jinan 250012, Shandong, Peoples R China.
RP Kong, BH (corresponding author), Shandong Univ, Qilu Hosp, Dept Obstet & Gynecol, Jinan 250012, Shandong, Peoples R China.; Kong, BH (corresponding author), Shandong Univ, Qilu Hosp, Gynecol Oncol Key Lab Shandong Prov, Jinan 250012, Shandong, Peoples R China.
EM kongbeihuasdu@gmail.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81874107, 81572554, 81502245]; Program for
   Interdisciplinary Basic Research of Shandong University [2018JC014]
FX This work was financially supported by National Natural Science
   Foundation of China (81874107, 81572554, and 81502245) and the Program
   for Interdisciplinary Basic Research of Shandong University (2018JC014).
CR Abe Y, 2000, J BIOL CHEM, V275, P21525, DOI 10.1074/jbc.M909629199
   Abe Y, 2007, J MOL BIOL, V370, P231, DOI 10.1016/j.jmb.2007.04.067
   Alachkar H, 2015, ONCOTARGET, V6, P33410, DOI 10.18632/oncotarget.5418
   Amaravadi R, 2016, GENE DEV, V30, P1913, DOI 10.1101/gad.287524.116
   Ayllon V, 2007, ONCOGENE, V26, P3451, DOI 10.1038/sj.onc.1210142
   Brooks DJ, 1996, BRIT J CANCER, V74, P1518, DOI 10.1038/bjc.1996.583
   Brown-Clay JD, 2015, ONCOTARGET, V6, P15594, DOI 10.18632/oncotarget.3709
   Chan KK, 2018, INT J CANCER, V143, P1456, DOI 10.1002/ijc.31535
   Chang CF, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17071007
   Chen JH, 2015, INT J BIOL MACROMOL, V81, P615, DOI 10.1016/j.ijbiomac.2015.08.048
   Christie EL, 2017, ANN ONCOL, V28, P13, DOI 10.1093/annonc/mdx446
   Dikic I, 2018, NAT REV MOL CELL BIO, V19, P349, DOI 10.1038/s41580-018-0003-4
   Dougherty JD, 2005, J NEUROSCI, V25, P10773, DOI 10.1523/JNEUROSCI.3207-05.2005
   Gao T., 2018, CANC LETT, V445, P11
   Gaudet S, 2000, P NATL ACAD SCI USA, V97, P5167, DOI 10.1073/pnas.090102397
   Herbert KJ, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-1131-7
   Hinzman CP, 2018, CARCINOGENESIS, V39, P1548, DOI 10.1093/carcin/bgy114
   Hu F, 2010, ONCOGENE, V29, P5464, DOI 10.1038/onc.2010.275
   Hu F, 2013, LEUKEMIA RES, V37, P447, DOI 10.1016/j.leukres.2012.11.010
   Ichimura Y, 2000, NATURE, V408, P488, DOI 10.1038/35044114
   Ikeda Y, 2016, CLIN CANCER RES, V22, P6110, DOI 10.1158/1078-0432.CCR-16-0207
   Joel M, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0398-x
   Kato T, 2016, ONCOTARGET, V7, P17652, DOI 10.18632/oncotarget.7755
   Kim DJ, 2012, CANCER RES, V72, P3060, DOI 10.1158/0008-5472.CAN-11-3851
   Kim TW, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0658-y
   Komatsu M, 2005, J CELL BIOL, V169, P425, DOI 10.1083/jcb.200412022
   Lee HC, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.116
   Lei B, 2015, HUM PATHOL, V46, P217, DOI 10.1016/j.humpath.2014.07.026
   Li M, 2009, BMC MED GENOMICS, V2, DOI 10.1186/1755-8794-2-34
   Li Y, 2016, ONCOTARGET, V7, P6748, DOI 10.18632/oncotarget.6826
   Matsuo Y, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3010277
   Mendoza MC, 2011, TRENDS BIOCHEM SCI, V36, P320, DOI 10.1016/j.tibs.2011.03.006
   Mizushima N, 2011, ANNU REV CELL DEV BI, V27, P107, DOI 10.1146/annurev-cellbio-092910-154005
   Nandi AK, 2006, LEUKEMIA RES, V30, P437, DOI 10.1016/j.leukres.2005.08.011
   Nanjundan M, 2007, CANCER RES, V67, P3074, DOI 10.1158/0008-5472.CAN-06-2366
   O'Donovan TR, 2011, AUTOPHAGY, V7, P509, DOI 10.4161/auto.7.5.15066
   Odunsi K, 2017, ANN ONCOL, V28, P1, DOI 10.1093/annonc/mdx444
   Ohashi T, 2017, BRIT J CANCER, V116, P218, DOI 10.1038/bjc.2016.394
   Osterberg L, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-368
   Park JH, 2006, CANCER RES, V66, P9186, DOI 10.1158/0008-5472.CAN-06-1601
   Quan Chuntao, 2018, Oncotarget, V9, P7782, DOI 10.18632/oncotarget.23674
   Shih MC, 2012, ONCOGENE, V31, P2389, DOI 10.1038/onc.2011.419
   Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387
   Su L, 2010, ACS CHEM BIOL, V5, P1035, DOI 10.1021/cb100153r
   van Zyl B, 2018, ENDOCR-RELAT CANCER, V25, pR303, DOI 10.1530/ERC-17-0336
   Wang J, 2014, J BIOL CHEM, V289, P17163, DOI 10.1074/jbc.M114.558288
   Wang MY, 2016, ONCOTARGET, V7, P26604, DOI 10.18632/oncotarget.8445
   Warren AY, 2019, ONCOGENE, V38, P1136, DOI 10.1038/s41388-018-0501-z
   White E, 2012, NAT REV CANCER, V12, P401, DOI 10.1038/nrc3262
   Xi GM, 2011, CANCER LETT, V307, P141, DOI 10.1016/j.canlet.2011.03.026
   Yang YF, 2017, ONCOTARGET, V8, P47195, DOI 10.18632/oncotarget.17587
   Zhu F, 2007, GASTROENTEROLOGY, V133, P219, DOI 10.1053/j.gastro.2007.04.048
   Zlobec I, 2010, BRIT J CANCER, V102, P151, DOI 10.1038/sj.bjc.6605452
   Zou J, 2017, BIOCHEM BIOPH RES CO, V488, P247, DOI 10.1016/j.bbrc.2017.03.162
   Zou ZY, 2012, J BIOL CHEM, V287, P4148, DOI 10.1074/jbc.M111.307405
NR 55
TC 25
Z9 25
U1 6
U2 7
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-4889
J9 CELL DEATH DIS
JI Cell Death Dis.
PD FEB 18
PY 2019
VL 10
AR 166
DI 10.1038/s41419-019-1415-6
PG 15
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA HN8NU
UT WOS:000460452900004
PM 30778048
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Oliveira, CSF
   Pereira, H
   Alves, S
   Castro, L
   Baltazar, F
   Chaves, SR
   Preto, A
   Corte-Real, M
AF Oliveira, C. S. F.
   Pereira, H.
   Alves, S.
   Castro, L.
   Baltazar, F.
   Chaves, S. R.
   Preto, A.
   Corte-Real, M.
TI Cathepsin D protects colorectal cancer cells from acetate-induced
   apoptosis through autophagy-independent degradation of damaged
   mitochondria
SO CELL DEATH & DISEASE
LA English
DT Article
ID CHAIN FATTY-ACIDS; LYSOSOMAL MEMBRANE PERMEABILIZATION; CARCINOMA CELLS;
   DEATH; PROPIONIBACTERIA; PROGRESSION; EXPRESSION; MACHINERY; NECROSIS;
   THERAPY
AB Acetate is a short-chain fatty acid secreted by Propionibacteria from the human intestine, known to induce mitochondrial apoptotic death in colorectal cancer (CRC) cells. We previously established that acetate also induces lysosome membrane permeabilization in CRC cells, associated with release of the lysosomal protease cathepsin D (CatD), which has a well-established role in the mitochondrial apoptotic cascade. Unexpectedly, we showed that CatD has an antiapoptotic role in this process, as pepstatin A (a CatD inhibitor) increased acetate-induced apoptosis. These results mimicked our previous data in the yeast system showing that acetic acid activates a mitochondria-dependent apoptosis process associated with vacuolar membrane permeabilization and release of the vacuolar protease Pep4p, ortholog of mammalian CatD. Indeed, this protease was required for cell survival in a manner dependent on its catalytic activity and for efficient mitochondrial degradation independently of autophagy. In this study, we therefore assessed the role of CatD in acetate-induced mitochondrial alterations. We found that, similar to acetic acid in yeast, acetate-induced apoptosis is not associated with autophagy induction in CRC cells. Moreover, inhibition of CatD with small interfering RNA or pepstatin A enhanced apoptosis associated with higher mitochondrial dysfunction and increased mitochondrial mass. This effect seems to be specific, as inhibition of CatB and CatL with E-64d had no effect, nor were these proteases significantly released to the cytosol during acetate-induced apoptosis. Using yeast cells, we further show that the role of Pep4p in mitochondrial degradation depends on its protease activity and is complemented by CatD, indicating that this mechanism is conserved. In summary, the clues provided by the yeast model unveiled a novel CatD function in the degradation of damaged mitochondria when autophagy is impaired, which protects CRC cells from acetate-induced apoptosis. CatD inhibitors could therefore enhance acetate-mediated cancer cell death, presenting a novel strategy for prevention or therapy of CRC.
C1 [Oliveira, C. S. F.; Pereira, H.; Alves, S.; Castro, L.; Chaves, S. R.; Preto, A.; Corte-Real, M.] Univ Minho, Dept Biol, CBMA Ctr Mol & Environm Biol, P-4710057 Braga, Portugal.
   [Oliveira, C. S. F.] Univ Porto, ICBAS Inst Biomed Sci Abel Salazar, P-4100 Oporto, Portugal.
   [Baltazar, F.] Univ Minho, Sch Hlth Sci, Life & Hlth Sci Res Inst ICVS, P-4710057 Braga, Portugal.
   [Baltazar, F.] ICVS 3Bs PT Govt Associate Lab, Braga, Portugal.
RP Corte-Real, M (corresponding author), Univ Minho, Dept Biol, Ctr Mol & Environm Biol, Campus Gualtar, P-4710057 Braga, Portugal.
EM mcortereal@bio.uminho.pt
RI Alves, Sara/U-5006-2019; Corte-Real, Manuela/B-6328-2013; F,
   Baltazar/A-8720-2010; Alves, Sara/L-3253-2015; Chaves, Susana
   R/H-8786-2013; Preto, Ana/H-8112-2012
OI Corte-Real, Manuela/0000-0002-1423-1331; F,
   Baltazar/0000-0002-1770-4544; Alves, Sara/0000-0003-0404-5954; Chaves,
   Susana R/0000-0002-6004-9872; Preto, Ana/0000-0002-7302-0630; Castro,
   Lisandra/0000-0003-3048-933X; Ferro Oliveira, Claudia
   Suellen/0000-0002-0113-9528; Pereira, Helena/0000-0002-0104-8714
FU FEDER through POFC - COMPETE; Fundacao para a Ciencia e
   TecnologiaPortuguese Foundation for Science and TechnologyEuropean
   Commission [PEst-OE/BIA/UI4050/2014, FCTANR/BEX-BCM/0175/2012,
   SFRH/BD/77449/2011, SFRH/BD/73139/2010, SFRH/BD/93589/2013,
   SFRH/BPD/89980/2012]
FX We thank Frank Madeo (University of Graz) for plasmids pESC, pESC-PEP4
   and pESC-DPM, and Elisabete Fernandes (University of Minho) for the
   pESC-CTSD construct. This work was supported by FEDER through POFC -
   COMPETE and by Fundacao para a Ciencia e Tecnologia through projects
   PEst-OE/BIA/UI4050/2014 and FCTANR/BEX-BCM/0175/2012, as well as
   fellowships to CSF Oliveira (SFRH/BD/77449/2011), H Pereira
   (SFRH/BD/73139/2010), L Castro (SFRH/BD/93589/2013) and S Chaves
   (SFRH/BPD/89980/2012).
CR Altobelli E, 2014, PREV MED, V62, P132, DOI 10.1016/j.ypmed.2014.02.010
   Carmona-Gutierrez D, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.43
   Comalada M, 2006, J CANCER RES CLIN, V132, P487, DOI 10.1007/s00432-006-0092-x
   Goncalves P, 2013, CURR DRUG METAB, V14, P994
   Groth-Pedersen L, 2013, CANCER LETT, V332, P265, DOI 10.1016/j.canlet.2010.05.021
   Hah YS, 2012, CANCER LETT, V323, P208, DOI 10.1016/j.canlet.2012.04.012
   Handy DE, 2012, ANTIOXID REDOX SIGN, V16, P1323, DOI 10.1089/ars.2011.4123
   Iwase T, 2013, SCI REP-UK, V3, DOI 10.1038/srep03081
   Jan G, 2002, CELL DEATH DIFFER, V9, P179, DOI 10.1038/sj.cdd.4400935
   Janku F, 2011, NAT REV CLIN ONCOL, V8, P528, DOI 10.1038/nrclinonc.2011.71
   Kirana Chandra, 2012, Int J Proteomics, V2012, P245819, DOI 10.1155/2012/245819
   Klionsky DJ, 2005, J CELL SCI, V118, P7, DOI 10.1242/jcs.01620
   Lan A, 2007, APOPTOSIS, V12, P573, DOI 10.1007/s10495-006-0010-3
   Macfarlane GT, 2008, J APPL MICROBIOL, V104, P305, DOI 10.1111/j.1365-2672.2007.03520.x
   Margaryan NV, 2010, CANCER BIOL THER, V10, DOI 10.4161/cbt.10.5.12534
   Marques C, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.29
   Mathew R, 2007, NAT REV CANCER, V7, P961, DOI 10.1038/nrc2254
   Maynadier M, 2013, J CONTROL RELEASE, V171, P251, DOI 10.1016/j.jconrel.2013.07.017
   Mehrpour M, 2010, CELL RES, V20, P748, DOI 10.1038/cr.2010.82
   Oberle C, 2010, CELL DEATH DIFFER, V17, P1167, DOI 10.1038/cdd.2009.214
   Okamoto K, 1998, J CELL BIOL, V142, P613, DOI 10.1083/jcb.142.3.613
   Pereira C, 2010, MOL MICROBIOL, V76, P1398, DOI 10.1111/j.1365-2958.2010.07122.x
   Pereira H, 2013, FEBS LETT, V587, P200, DOI 10.1016/j.febslet.2012.11.025
   Repnik U, 2012, BBA-PROTEINS PROTEOM, V1824, P22, DOI 10.1016/j.bbapap.2011.08.016
   Sagulenko V, 2008, CARCINOGENESIS, V29, P1869, DOI 10.1093/carcin/bgn147
   Szajda SD, 2008, HEPATO-GASTROENTEROL, V55, P388
   Talieri M, 2004, CANCER LETT, V205, P97, DOI 10.1016/j.canlet.2003.09.033
   Tang Y, 2011, CELL DEATH DIFFER, V18, P602, DOI 10.1038/cdd.2010.117
   Tang Y, 2011, AUTOPHAGY, V7, P235, DOI 10.4161/auto.7.2.14277
   Troy AM, 2004, EUR J CANCER, V40, P1610, DOI 10.1016/j.ejca.2004.03.011
   Xie ZP, 2007, NAT CELL BIOL, V9, P1102, DOI 10.1038/ncb1007-1102
   Yamamoto A, 1998, CELL STRUCT FUNCT, V23, P33, DOI 10.1247/csf.23.33
   Zeng HW, 2014, WORLD J GASTRO ONCOL, V6, P41, DOI 10.4251/wjgo.v6.i2.41
   Zhu YM, 2011, CANCER LETT, V309, P119, DOI 10.1016/j.canlet.2011.06.004
NR 34
TC 38
Z9 38
U1 1
U2 12
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-4889
J9 CELL DEATH DIS
JI Cell Death Dis.
PD JUN
PY 2015
VL 6
AR e1788
DI 10.1038/cddis.2015.157
PG 11
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA CM2MO
UT WOS:000357514700014
PM 26086961
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Liu, D
   Meng, X
   Wu, DL
   Qiu, ZD
   Luo, HM
AF Liu, Da
   Meng, Xue
   Wu, Donglu
   Qiu, Zhidong
   Luo, Haoming
TI A Natural Isoquinoline Alkaloid With Antitumor Activity: Studies of the
   Biological Activities of Berberine
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Review
DE berberine; biological activities; antitumor; autophagy; epigenetic
   effects
ID INDUCED NEUROPATHIC PAIN; HUMAN GASTRIC-CARCINOMA; CELL-CYCLE ARREST;
   CANCER-CELLS; TRANSPOSABLE ELEMENTS; INDUCED APOPTOSIS; COPTIDIS
   RHIZOMA; DNA METHYLATION; GENE-EXPRESSION; MITOCHONDRIAL PATHWAY
AB Coptis, a traditional medicinal plant, has been used widely in the field of traditional Chinese medicine for many years. More recently, the chemical composition and bioactivity of Coptis have been studied worldwide. Berberine is a main component of Rhizoma Coptidis. Modern medicine has confirmed that berberine has pharmacological activities, such as anti-inflammatory, analgesic, antimicrobial, hypolipidemic, and blood pressure-lowering effects. Importantly, the active ingredient of berberine has clear inhibitory effects on various cancers, including colorectal cancer, lung cancer, ovarian cancer, prostate cancer, liver cancer, and cervical cancer. Cancer, ranked as one of the world's five major incurable diseases by WHO, is a serious threat to the quality of human life. Here, we try to outline how berberine exerts antitumor effects through the regulation of different molecular pathways. In addition, the berberine-mediated regulation of epigenetic mechanisms that may be associated with the prevention of malignant tumors is described. Thus, this review provides a theoretical basis for the biological functions of berberine and its further use in the clinical treatment of cancer.
C1 [Liu, Da; Meng, Xue; Wu, Donglu; Qiu, Zhidong; Luo, Haoming] Changchun Univ Chinese Med, Dept Pharm, Changchun, Jilin, Peoples R China.
   [Liu, Da; Meng, Xue; Wu, Donglu; Qiu, Zhidong; Luo, Haoming] Changchun Univ Chinese Med, Key Lab Effect Components Tradit Chinese Med, Changchun, Jilin, Peoples R China.
RP Qiu, ZD; Luo, HM (corresponding author), Changchun Univ Chinese Med, Dept Pharm, Changchun, Jilin, Peoples R China.; Qiu, ZD; Luo, HM (corresponding author), Changchun Univ Chinese Med, Key Lab Effect Components Tradit Chinese Med, Changchun, Jilin, Peoples R China.
EM Qiuzd@ccucm.edu.cn; luo.haoming@163.com
RI Luo, Haoming/AAF-5322-2019
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81803680]; Jilin Province Science and
   Technology Development Project in China [20170307031, YY20180520050JH]
FX This work was supported by the National Natural Science Foundation of
   China (Grant No. 81803680). Jilin Province Science and Technology
   Development Project in China (Grant Nos. 20170307031 and
   YY20180520050JH).
CR Agnarelli A, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-28952-3
   Asadi R, 2018, GENE, V676, P189, DOI 10.1016/j.gene.2018.07.034
   Balestrieri E, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.01448
   Bennetzen JL, 2014, ANNU REV PLANT BIOL, V65, P505, DOI 10.1146/annurev-arplant-050213-035811
   Bhat AV, 2018, ANTIOXID REDOX SIGN, V29, P1273, DOI 10.1089/ars.2017.7158
   Biswas S, 2018, EUR J PHARMACOL, V837, P8, DOI 10.1016/j.ejphar.2018.08.021
   Blandino G, 2014, FEBS LETT, V588, P2639, DOI 10.1016/j.febslet.2014.03.033
   Booth AK, 2015, ADV EXP MED BIOL, V846, P37, DOI 10.1007/978-3-319-12114-7_2
   Chidambaram A, 2012, J NEUROSURG, V116, P843, DOI 10.3171/2011.11.JNS111455
   Cicero AFG, 2016, ADV EXP MED BIOL, V928, P27, DOI 10.1007/978-3-319-41334-1_2
   Coward WR, 2014, FASEB J, V28, P3183, DOI 10.1096/fj.13-241760
   Crawford B, 2018, HUM MOL GENET, V27, P2840, DOI 10.1093/hmg/ddy199
   Delgado-Cruzata L, 2015, J NUTR, V145, P783, DOI 10.3945/jn.114.202853
   Dkhil MA, 2015, PARASITOL RES, V114, P1581, DOI 10.1007/s00436-015-4344-z
   Du J, 2017, ANTICANCER RES, V37, P6141, DOI 10.21873/anticanres.12063
   Dupont C, 2009, SEMIN REPROD MED, V27, P351, DOI 10.1055/s-0029-1237423
   Foroutan F, 2019, J HEART LUNG TRANSPL, V38, P260, DOI 10.1016/j.healun.2018.12.007
   Foroutan T, 2018, CELL J, V19, P654, DOI 10.22074/cellj.2018.4393
   Georgoff PE, 2018, J TRAUMA ACUTE CARE, V84, P642, DOI 10.1097/TA.0000000000001763
   Gu L, 2015, NAT GENET, V47, P22, DOI 10.1038/ng.3165
   Guo N, 2014, MOL MED REP, V10, P3132, DOI 10.3892/mmr.2014.2608
   Halicka HD, 2017, APOPTOSIS, V22, P229, DOI 10.1007/s10495-016-1315-5
   Hamsa TP, 2011, J ENVIRON PATHOL TOX, V30, P123, DOI 10.1615/JEnvironPatholToxicolOncol.v30.i2.40
   Hao DC, 2017, CURR GENOMICS, V18, P39, DOI 10.2174/1389202917666160803151752
   Hashiguchi Y, 2018, J CELL PHYSIOL, V233, P6565, DOI 10.1002/jcp.26267
   He XY, 2010, J CANCER RES CLIN, V136, P1023, DOI 10.1007/s00432-009-0747-5
   Hoen DR, 2015, MOL BIOL EVOL, V32, P1487, DOI 10.1093/molbev/msv042
   Honda H, 2006, J BIOL CHEM, V281, P21433, DOI 10.1074/jbc.M603767200
   Hu HY, 2013, ACTA PHARMACOL SIN, V34, P157, DOI 10.1038/aps.2012.161
   Huang C, 2017, ONCOL REP, V37, P1637, DOI 10.3892/or.2017.5379
   Huang SX, 2018, NEUROCHEM RES, V43, P1814, DOI 10.1007/s11064-018-2597-5
   Huang YZ, 2018, ONCOL REP, V40, P1525, DOI 10.3892/or.2018.6552
   Huang ZH, 2015, MOL MED REP, V11, P2125, DOI 10.3892/mmr.2014.2929
   Hur JM, 2009, J CELL BIOCHEM, V107, P955, DOI 10.1002/jcb.22198
   Iizuka N, 2000, CANCER LETT, V148, P19, DOI 10.1016/S0304-3835(99)00264-5
   Imenshahidi M, 2016, PHYTOTHER RES, V30, P1745, DOI 10.1002/ptr.5693
   Jiang L, 2018, BIOMED PHARMACOTHER, V107, P24, DOI 10.1016/j.biopha.2018.07.142
   Jin YL, 2017, EUR J PHARMACOL, V794, P106, DOI 10.1016/j.ejphar.2016.11.037
   Kalaiarasi A, 2016, J AGR FOOD CHEM, V64, P9542, DOI 10.1021/acs.jafc.6b04453
   Kalinkova L, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4783-x
   Katona BW, 2014, CANCER BIOL THER, V15, P1677, DOI 10.4161/15384047.2014.972776
   Khalil I, 2016, AM J TROP MED HYG, V95, P1319, DOI 10.4269/ajtmh.16-0339
   Kong W., 2004, NAT MED, V7, P464, DOI [10.1016/S1567-5688(06)81865-9, DOI 10.1016/S1567-5688(06)81865-9]
   Kumar A, 2015, EUR J PHARMACOL, V761, P288, DOI 10.1016/j.ejphar.2015.05.068
   Lee C, 2018, J NANOSCI NANOTECHNO, V18, P6339, DOI 10.1166/jnn.2018.15657
   Li BH, 2018, CANCER RES, V78, P3938, DOI 10.1158/0008-5472.CAN-17-3801
   Li CH, 2014, ASIAN PAC J CANCER P, V15, P1851, DOI 10.7314/APJCP.2014.15.4.1851
   Li J, 2018, ONCOL LETT, V15, P7409, DOI 10.3892/ol.2018.8249
   Li L, 2017, BIOMED PHARMACOTHER, V95, P1225, DOI 10.1016/j.biopha.2017.09.010
   Li LY, 2016, INT J MOL MED, V37, P851, DOI 10.3892/ijmm.2016.2455
   Li NN, 2018, J BIOMED NANOTECHNOL, V14, P2162, DOI 10.1166/jbn.2018.2656
   Li WY, 2018, NUCLEIC ACIDS RES, V46, DOI 10.1093/nar/gky423
   Liu HC, 2018, PLANT J, V95, P401, DOI 10.1111/tpj.13958
   Liu L, 2018, J PHARMACOL SCI, V137, P5, DOI 10.1016/j.jphs.2017.12.001
   Liu L, 2017, EXP THER MED, V14, P6125, DOI 10.3892/etm.2017.5316
   Lu W, 2015, MOL MED REP, V11, P3920, DOI 10.3892/mmr.2014.3139
   Ma CY, 2008, J FOOD SCI, V73, pH127, DOI 10.1111/j.1750-3841.2008.00837.x
   Ma WN, 2017, PHYTOTHER RES, V31, P1392, DOI 10.1002/ptr.5866
   Meng FC, 2018, CHIN MED-UK, V13, DOI 10.1186/s13020-018-0171-3
   Meng MJ, 2017, ONCOTARGET, V8, P76385, DOI 10.18632/oncotarget.20059
   Mirhadi E., 2018, BIOMED CHROMATOGR BM, V1060, pe4279, DOI [10.1002/bmc.4279, DOI 10.1002/BMC.4279]
   Mistry BM, 2017, ANTI-CANCER AGENT ME, V17, P1652, DOI 10.2174/1871520617666170710180549
   Mittal A, 2014, PHYTOMEDICINE, V21, P340, DOI 10.1016/j.phymed.2013.09.002
   Munir I, 2000, BIOL REPROD, V63, P933, DOI 10.1095/biolreprod63.3.933
   Murthy KNC, 2012, FOOD CHEM, V132, P27, DOI 10.1016/j.foodchem.2011.10.014
   Nardi I, 2018, INT J CANCER, V143, P2470, DOI 10.1002/ijc.31756
   Naveen CR, 2016, PHYTOMEDICINE, V23, P736, DOI 10.1016/j.phymed.2016.03.013
   Neag MA, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00557
   Oliver KR, 2013, GENOME BIOL EVOL, V5, P1886, DOI 10.1093/gbe/evt141
   Pandey A, 2015, NUTR CANCER, V67, P1293, DOI 10.1080/01635581.2015.1085581
   Peng PL, 2008, INT J RADIAT ONCOL, V70, P529, DOI 10.1016/j.ijrobp.2007.08.034
   Puneet, 2018, PATHOL ONCOL RES, V24, P757, DOI 10.1007/s12253-018-0410-z
   Qi HW, 2014, J TRANSL MED, V12, DOI 10.1186/1479-5876-12-22
   Qing YW, 2014, CELL BIOL INT, V38, P563, DOI 10.1002/cbin.10206
   Rahnamoun H, 2018, NAT STRUCT MOL BIOL, V25, P687, DOI 10.1038/s41594-018-0102-0
   Rayan NA, 2016, SEMIN CELL DEV BIOL, V57, P51, DOI 10.1016/j.semcdb.2016.05.004
   Riaz SK, 2016, W INDIAN MED J, V65, P337, DOI 10.7727/wimj.2014.297
   Sahebi M, 2018, GENE, V665, P155, DOI 10.1016/j.gene.2018.04.050
   Salimian N, 2018, GENE, V674, P25, DOI 10.1016/j.gene.2018.06.061
   Sanna L, 2018, J CELL PHYSIOL, V233, P6508, DOI 10.1002/jcp.26545
   Sengupta D, 2017, APOPTOSIS, V22, P1362, DOI 10.1007/s10495-017-1407-x
   Sengupta D, 2014, BBA-GEN SUBJECTS, V1840, P219, DOI 10.1016/j.bbagen.2013.08.020
   Shang A, 2019, BEHAV BRAIN RES, V356, P453, DOI 10.1016/j.bbr.2018.05.036
   Shi HL, 2013, LIFE SCI, V93, P830, DOI 10.1016/j.lfs.2013.09.010
   Shi YW, 2017, ONCOL LETT, V13, P4402, DOI 10.3892/ol.2017.6025
   Signorelli C, 2017, EPIDEMIOL INFECT, V145, P1962, DOI [10.1017/S0950268817000747, 10.1017/s0950268817000747]
   Siveen KS, 2011, CAN J PHYSIOL PHARM, V89, P691, DOI [10.1139/Y11-067, 10.1139/y11-067]
   STEVENS MS, 1984, BIOCHEM BIOPH RES CO, V119, P132, DOI 10.1016/0006-291X(84)91628-0
   Su YH, 2015, BBA-MOL CELL RES, V1853, P2261, DOI 10.1016/j.bbamcr.2015.05.012
   Sun WB, 2017, NEUROSCI LETT, V646, P68, DOI 10.1016/j.neulet.2016.12.047
   Tabeshpour J, 2017, IRAN J BASIC MED SCI, V20, P557, DOI 10.22038/IJBMS.2017.8682
   Tang J, 2009, J ETHNOPHARMACOL, V126, P5, DOI 10.1016/j.jep.2009.08.009
   Tao YW, 2015, ANTI-CANCER AGENT ME, V15, P258, DOI 10.2174/1871520614666140825112255
   Tong NN, 2012, ONCOL LETT, V3, P1263, DOI 10.3892/ol.2012.644
   van de Waterbeemd B, 2013, J PROTEOME RES, V12, P1898, DOI 10.1021/pr301208g
   Viegas S, 2017, ARH HIG RADA TOKSIKO, V68, P287, DOI 10.1515/aiht-2017-68-3005
   Vijayaraghavalu S, 2013, MOL PHARMACEUT, V10, P337, DOI 10.1021/mp3004622
   Walker DK, 2017, ASIA-PAC J ONCOL NUR, V4, P209, DOI 10.4103/apjon.apjon_31_17
   Wang J, 2017, ONCOL REP, V37, P2425, DOI 10.3892/or.2017.5499
   Wang N, 2015, J ETHNOPHARMACOL, V176, P35, DOI 10.1016/j.jep.2015.10.028
   Wang N, 2015, INTEGR CANCER THER, V14, P75, DOI 10.1177/1534735414550036
   Wang SY, 2018, CANCER LETT, V439, P78, DOI 10.1016/j.canlet.2018.09.026
   Wang-Johanning F, 2008, CANCER RES, V68, P5869, DOI 10.1158/0008-5472.CAN-07-6838
   Wen CJ, 2016, MOL MED REP, V14, P2250, DOI 10.3892/mmr.2016.5490
   Wong KY, 2015, EPIGENOMICS-UK, V7, P985, DOI 10.2217/epi.15.57
   Wu YQ, 2012, INFLAMMATION, V35, P1184, DOI 10.1007/s10753-011-9427-0
   Xu ZF, 2017, AGING DIS, V8, P760, DOI 10.14336/AD.2016.0620
   Xue M, 2013, INT J NANOMED, V8, P4677, DOI 10.2147/IJN.S51262
   Yakata Y, 2007, INT J ONCOL, V30, P437
   Yamada K, 2015, LIVER INT, V35, P1773, DOI 10.1111/liv.12755
   Yan L, 2001, J MAMMARY GLAND BIOL, V6, P183, DOI 10.1023/A:1011308707512
   Yan XT, 2018, J CELL PHYSIOL, V233, P4815, DOI 10.1002/jcp.26284
   Yang ML, 2016, TUMORI, V102, P135, DOI 10.5301/tj.5000411
   Zhang JY, 2017, MOLECULES, V22, DOI 10.3390/molecules22091412
   Zhang JY, 2016, AM J CANCER RES, V6, P819
   Zhang JY, 2015, MOLECULES, V20, P11524, DOI 10.3390/molecules200611524
   Zhang JY, 2013, J AGR FOOD CHEM, V61, P2188, DOI 10.1021/jf305263r
   Zhang JY, 2017, ANTI-CANCER AGENT ME, V17, P1374, DOI 10.2174/1871520617666170419120044
   Zhang JZ, 2015, INT J MOL MED, V36, P1433, DOI 10.3892/ijmm.2015.2342
   Zhang L, 2018, BIOMED PHARMACOTHER, V107, P424, DOI 10.1016/j.biopha.2018.07.155
   Zhang L, 2017, MOL MED REP, V15, P1195, DOI 10.3892/mmr.2017.6144
   Zhang SX, 2018, MOL GENET GENOMICS, V293, P1035, DOI 10.1007/s00438-018-1436-3
   Zhang XZ, 2014, J MED FOOD, V17, P955, DOI 10.1089/jmf.2013.2967
   Zhao Y, 2014, J INTERCULT ETHNOPHA, V3, P68, DOI 10.5455/jice.20140123040224
   Zhao YW, 2016, ONCOL REP, V36, P567, DOI 10.3892/or.2016.4785
   Zheng F, 2018, J CELL MOL MED, V22, P600, DOI 10.1111/jcmm.13347
   Zhu T, 2015, AM J CHINESE MED, V43, P1487, DOI 10.1142/S0192415X15500846
NR 127
TC 53
Z9 58
U1 11
U2 44
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1663-9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD FEB 14
PY 2019
VL 10
AR 9
DI 10.3389/fphar.2019.00009
PG 12
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA HL4KO
UT WOS:000458687800001
PM 30837865
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Han, XR
   Zhang, X
   Wang, Q
   Wang, L
   Yu, SW
AF Han, Xinru
   Zhang, Xiang
   Wang, Qian
   Wang, Lu
   Yu, Shuwen
TI Antitumor potential of Hedyotis diffusa Willd: A systematic review of
   bioactive constituents and underlying molecular mechanisms
SO BIOMEDICINE & PHARMACOTHERAPY
LA English
DT Review
DE Hedyotis diffusa Willd; Antitumor activity; Apoptosis; Proliferation;
   Cell cycle termination; Anti-inflammation
ID CELL-CYCLE ARREST; NF-KAPPA-B; COLORECTAL-CANCER CELLS; IN-VITRO;
   PROTOCATECHUIC ACID; INHIBITS PROLIFERATION; LIQUID-CHROMATOGRAPHY;
   EXTRACELLULAR-MATRIX; SIGNALING PATHWAY; CARCINOMA-CELLS
AB Cancer is a major cause of death in the world. Chemotherapy can extend the life of cancer patients to some extent, but the quality of life is reduced. Therefore, the quest for more efficient and less toxic medication strategies is still at the forefront of current research. Hedyotis diffusa Willd (HDW), a Chinese herb medicine, has received great attention in the past two decades and has been well documented in clinics for antitumor activity in a variety of human cancers. This review discussed a total of 58 different kinds of active antitumor components isolated from HDW, including iridoids, flavonoids, flavonol glycosides, anthraquinones, phenolic acids, and their derivatives, sterols, and volatile oils. Their antitumor activities include inhibition of tumor cell proliferation, induction of tumor cell apoptosis and tumor angiogenesis, regulation of the host immune response, anti-inflammatory and antioxidant, and protective autophagy. Besides, we provide up-to-date and systematic evidence for HDW antitumor activities and the possible underlying molecular mechanisms and reference for further development of novel drugs and dosage formulation in control of human cancers.
C1 [Han, Xinru; Zhang, Xiang; Wang, Qian; Wang, Lu; Yu, Shuwen] Shandong First Med Univ, Dept Pharm, Cent Hosp, Jinan 250013, Shandong, Peoples R China.
RP Wang, L; Yu, SW (corresponding author), Shandong First Med Univ, Dept Pharm, Cent Hosp, Jinan 250013, Shandong, Peoples R China.
EM lulucc@163.com; yaoxuebu2020@163.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81803570]; China Postdoctoral Science
   FoundationChina Postdoctoral Science Foundation [2019M652411];
   Postdoctoral Innovation Project of Shandong Province [201902044]; Jinan
   Science and Technology Bureau [201907111]
FX This work was supported by the National Natural Science Foundation of
   China (81803570), China Postdoctoral Science Foundation (2019M652411),
   the Postdoctoral Innovation Project of Shandong Province (201902044),
   and the Jinan Science and Technology Bureau (201907111).
CR Ahmed H, 2016, PHARM BIOL, V54, P2119, DOI 10.3109/13880209.2016.1146778
   Alberts W.P., 2008, MOL BIOL CELL, P1115
   Pham A, 2012, BIOCHEM BIOPH RES CO, V427, P415, DOI 10.1016/j.bbrc.2012.09.080
   Apoptosis I., 2003, MOL IMAGING BIOL, P2
   Araujo JR, 2011, NUTR RES, V31, P77, DOI 10.1016/j.nutres.2011.01.006
   Babich H, 2002, PHARMACOL TOXICOL, V91, P245, DOI 10.1034/j.1600-0773.2002.910505.x
   Bai LL, 2020, BIOFACTORS, V46, P637, DOI 10.1002/biof.1629
   Beavon IRG, 2000, EUR J CANCER, V36, P1607, DOI 10.1016/S0959-8049(00)00158-1
   Bonnans C, 2014, NAT REV MOL CELL BIO, V15, P786, DOI 10.1038/nrm3904
   Braun DE, 2013, CRYST GROWTH DES, V13, P19, DOI 10.1021/cg301506x
   Breier A, 2013, ANTI-CANCER AGENT ME, V13, P159, DOI 10.2174/187152013804487380
   Bullwinkel J, 2006, J CELL PHYSIOL, V206, P624, DOI 10.1002/jcp.20494
   Chan YH, 2020, CHEM-BIOL INTERACT, V315, DOI 10.1016/j.cbi.2019.108911
   Chao TH, 2014, J ETHNOPHARMACOL, V155, P702, DOI 10.1016/j.jep.2014.06.012
   Chen J, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01013
   Chen YC, 2016, MOLECULES, V21, DOI 10.3390/molecules21020153
   Chen YN, 2019, J ETHNOPHARMACOL, V232, P11, DOI 10.1016/j.jep.2018.12.003
   Chen YL, 2016, EXP THER MED, V11, P1116, DOI 10.3892/etm.2015.2963
   Cheng YY, 2018, J FOOD DRUG ANAL, V26, pS88, DOI 10.1016/j.jfda.2018.01.003
   Chiang CH, 2019, ANTICANCER RES, V39, P3641, DOI 10.21873/anticanres.13512
   Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322
   Cui BB, 2012, CELL BIOCHEM BIOPHYS, V62, P47, DOI 10.1007/s12013-011-9257-6
   Das U, 2019, FREE RADICAL RES, V53, P944, DOI 10.1080/10715762.2019.1655559
   Degryse B, 2011, CURR PHARM DESIGN, V17, P1872, DOI 10.2174/138161211796718161
   Dong HW, 2019, ARCH TOXICOL, V93, P2993, DOI 10.1007/s00204-019-02550-2
   Duan LJ, 2019, ANTI-CANCER DRUG, V30, P812, DOI 10.1097/CAD.0000000000000777
   Elansary HO, 2018, BMC COMPLEM ALTERN M, V18, DOI 10.1186/s12906-018-2262-1
   Farias M.R., 2019, INT J MOL SCIE, V20, P1, DOI 10.3390/ijms20123177
   Feng JY, 2017, ONCOL LETT, V14, P8197, DOI 10.3892/ol.2017.7244
   Ferrara N, 2005, NATURE, V438, P967, DOI 10.1038/nature04483
   Fu J, 2019, TALANTA, V192, P248, DOI 10.1016/j.talanta.2018.09.053
   Furuya N., 2004, AUTOPHAGY LANDES BIO
   Galderisi U, 2003, ONCOGENE, V22, P5208, DOI 10.1038/sj.onc.1206558
   Gao C, 2019, J BUON, V24, P1964
   Gao F, 2019, J CELL BIOCHEM, V120, P9264, DOI 10.1002/jcb.28202
   Gao P, 2019, BIOSCI TRENDS, V13, P160, DOI 10.5582/bst.2018.01293
   Gao XX, 2020, J PHARMACEUT BIOMED, V177, DOI 10.1016/j.jpba.2019.06.029
   Goldstein JC, 2000, NAT CELL BIOL, V2, P156, DOI 10.1038/35004029
   Guo MX, 2014, J SEP SCI, V37, P2844, DOI 10.1002/jssc.201400339
   Hara A, 2016, ARCH BIOCHEM BIOPHYS, V609, P69, DOI 10.1016/j.abb.2016.09.010
   Hassan SB, 2010, ANTICANCER RES, V30, P1911
   He JY, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19072027
   He JY, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19020457
   Heavey S, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-19688-1
   Hehlgans T, 2005, IMMUNOLOGY, V115, P1, DOI 10.1111/j.1365-2567.2005.02143.x
   Hu EP, 2015, INT J CLIN EXP MED, V8, P4059
   Huang GH, 2014, ONCOL REP, V31, P2377, DOI 10.3892/or.2014.3099
   Huang Y., 2001, ACTA CHIN MED, V16, P38
   Huo JY, 2020, INT J BIOL MACROMOL, V155, P1553, DOI 10.1016/j.ijbiomac.2019.11.132
   Imran M, 2020, PHYTOTHER RES, V34, P1812, DOI 10.1002/ptr.6647
   Jiang JP, 2017, J ETHNOPHARMACOL, V196, P253, DOI 10.1016/j.jep.2016.12.012
   Kayouka M, 2020, CHEM-BIOL INTERACT, V315, DOI 10.1016/j.cbi.2019.108892
   Khusro A, 2018, MICROB PATHOGENESIS, V125, P96, DOI 10.1016/j.micpath.2018.09.003
   Kim DH, 2019, ANTICANCER RES, V39, P6685, DOI 10.21873/anticanres.13883
   Kim GH, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20194767
   Kim SH, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20194709
   Kowalczyk A, 2017, ADV CLIN EXP MED, V26, P1143, DOI 10.17219/acem/41978
   Kuo HC, 2006, TOXICOL APPL PHARM, V210, P55, DOI 10.1016/j.taap.2005.06.020
   Lai ZJ, 2017, MOL MED REP, V16, P7752, DOI 10.3892/mmr.2017.7500
   Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758
   Lawrence JA, 2020, BIOORGAN MED CHEM, V28, DOI 10.1016/j.bmc.2019.115229
   Lee CH, 2017, CURR DRUG TARGETS, V18, P756, DOI 10.2174/1389450117666160401125213
   Lee G, 2018, EVID-BASED COMPL ALT, V2018, DOI 10.1155/2018/3412074
   Li DX, 2015, ANAL BIOANAL CHEM, V407, P231, DOI 10.1007/s00216-014-8057-4
   Li HQ, 2015, BIOCHEM SYST ECOL, V62, P173, DOI 10.1016/j.bse.2015.06.028
   Li NX, 2020, CHIN MED-UK, V15, DOI 10.1186/s13020-020-00301-5
   Li QY, 2018, MOL MED REP, V17, P358, DOI 10.3892/mmr.2017.7903
   Li R, 2018, J BUON, V23, P1420
   Li S., 1999, COMPENDIUM MAT MED
   Li XJ, 2019, EVID-BASED COMPL ALT, V2019, DOI 10.1155/2019/1856294
   Li Yunhe, 2016, Horticultural Plant Journal, V2, P1, DOI 10.1016/j.hpj.2016.02.008
   Lin HH, 2007, INT J CANCER, V120, P2306, DOI 10.1002/ijc.22571
   Lin JM, 2013, INT J ONCOL, V42, P651, DOI 10.3892/ijo.2012.1753
   Lin JM, 2011, MOL MED REP, V4, P1283, DOI 10.3892/mmr.2011.577
   Lin MH, 2012, EXP THER MED, V4, P307, DOI 10.3892/etm.2012.599
   Ling BB, 2016, DRUG DES DEV THER, V10, P3563, DOI 10.2147/DDDT.S119214
   Liu CL, 2002, FOOD CHEM TOXICOL, V40, P635, DOI 10.1016/S0278-6915(02)00002-9
   Liu J, 2004, CHEM J CHINESE U, V25, P1
   Liu K, 2006, J CHROMATOGR B, V831, P303, DOI 10.1016/j.jchromb.2005.12.018
   Liu ST, 2018, CLIN GENITOURIN CANC, V16, pE269, DOI 10.1016/j.clgc.2017.10.011
   Liu Z, 2010, TOXICOL IN VITRO, V24, P142, DOI 10.1016/j.tiv.2009.08.002
   Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9
   Loizzo MR, 2008, CELL PROLIFERAT, V41, P1002, DOI 10.1111/j.1365-2184.2008.00561.x
   Lu QX, 2016, MOLECULES, V21, DOI 10.3390/molecules21091234
   Luqmani YA, 2005, MED PRIN PRACT, V14, P35, DOI 10.1159/000086183
   Ma CJ, 2019, BIOMED PHARMACOTHER, V117, DOI 10.1016/j.biopha.2019.109167
   Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205
   Marquez N.S., 2017, MED ONCOL, V34, P1, DOI [10.1007/s12032-017-0969-3., DOI 10.1007/S12032-017-0969-3.]
   Meng FX, 2018, PROCEEDINGS OF THE ACADEMIC FORUM ON RESEARCH INTO SOCIAL MENTALITY AND SOCIAL PSYCHOLOGICAL SERVICES UNDER THE NEW ERA, P23
   Meng QX, 2013, J ETHNOPHARMACOL, V148, P229, DOI 10.1016/j.jep.2013.04.014
   Mizushima N, 2011, CELL, V147, P728, DOI 10.1016/j.cell.2011.10.026
   Mo HB, 1999, J NUTR, V129, P804, DOI 10.1093/jn/129.4.804
   Pandey P, 2019, ENDOCR METAB IMMUNE, V19, P826, DOI 10.2174/1871530319666190206124120
   Park SH, 2017, AM J CHINESE MED, V45, P757, DOI 10.1142/S0192415X17500409
   Peng DH, 2020, BIOMED PHARMACOTHER, V125, DOI 10.1016/j.biopha.2020.109984
   Pradhan N, 2019, FOOD CHEM TOXICOL, V130, P161, DOI 10.1016/j.fct.2019.05.016
   Qiu JM, 2016, INT IMMUNOPHARMACOL, V31, P109, DOI 10.1016/j.intimp.2015.12.013
   Qiu JX, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21010131
   Rajagopal C, 2018, PHARMACOL RES, V130, P273, DOI 10.1016/j.phrs.2017.12.034
   Raphael J, 2018, EUR J CANCER, V91, P38, DOI 10.1016/j.ejca.2017.12.010
   Ruan BF, 2018, CHEM BIODIVERS, V15, DOI 10.1002/cbdv.201700504
   Semaming Y, 2015, EVID-BASED COMPL ALT, V2015, DOI 10.1155/2015/593902
   Shacter E, 2002, ONCOLOGY-NY, V16, P217
   Shao JH, 2019, NAT PROD RES, V33, P1612, DOI 10.1080/14786419.2018.1428593
   Sharma SH, 2019, EUR J CANCER PREV, V28, P472, DOI 10.1097/CEJ.0000000000000496
   Sheela DL, 2019, HUM EXP TOXICOL, V38, P753, DOI 10.1177/0960327119839185
   Sheng L, 2019, J ETHNOPHARMACOL, V236, P129, DOI 10.1016/j.jep.2019.03.005
   Shi Y, 2008, BIOL PHARM BULL, V31, P1075, DOI 10.1248/bpb.31.1075
   [斯建勇 SI Jianyong], 2006, [天然产物研究与开发, Natural Product R & D], V18, P942
   Son YO, 2017, J MED FOOD, V20, P1011, DOI 10.1089/jmf.2017.3943
   Su X, 2019, BIOMED PHARMACOTHER, V109, P969, DOI 10.1016/j.biopha.2018.10.162
   Sui H, 2012, J INT MED RES, V40, P426, DOI 10.1177/147323001204000204
   Sun C, 2019, PHYTOMEDICINE, V61, DOI 10.1016/j.phymed.2019.152848
   Sun GD, 2016, ONCOL LETT, V11, P3875, DOI 10.3892/ol.2016.4431
   Tang LL, 2013, BIOMED PHARMACOTHER, V67, P179, DOI 10.1016/j.biopha.2012.10.003
   Theocharis AD, 2016, ADV DRUG DELIVER REV, V97, P4, DOI 10.1016/j.addr.2015.11.001
   Tian Q, 2019, J BUON, V24, P997
   Tsai CL, 2018, ANTICANCER RES, V38, P2057, DOI 10.21873/anticanres.12445
   Uddin SJ, 2012, PHARM BIOL, V50, P1276, DOI 10.3109/13880209.2012.673628
   Utispan Kusumawadee, 2020, Asian Pac J Cancer Prev, V21, P363, DOI 10.31557/APJCP.2020.21.2.363
   Vlahopoulos S, 2014, CURR DRUG TARGETS, V15, P843
   Wajant H, 2002, SCIENCE, V296, P1635, DOI 10.1126/science.1071553
   Wang CF, 2017, MOLECULES, V22, DOI 10.3390/molecules22122101
   Wang CF, 2018, FITOTERAPIA, V124, P152, DOI 10.1016/j.fitote.2017.11.004
   Wang JH, 2011, ARCH MED RES, V42, P577, DOI 10.1016/j.arcmed.2011.11.003
   Wang L, 2019, FOOD CHEM TOXICOL, V124, P239, DOI 10.1016/j.fct.2018.12.001
   Wang N, 2013, ARCH PHARM RES, V36, P752, DOI 10.1007/s12272-013-0096-4
   Wang R.J., 2019, MAR DRUGS, V17, P1
   Wang XD, 2019, J BUON, V24, P1686
   Wang XC, 2017, ONCOL REP, V37, P3046, DOI 10.3892/or.2017.5508
   Wang XX, 2019, CHEM-BIOL INTERACT, V310, DOI 10.1016/j.cbi.2019.108759
   Wang XN, 2019, BIOMED PHARMACOTHER, V117, DOI 10.1016/j.biopha.2019.109086
   Wu CQ, 2017, GENE, V637, P124, DOI 10.1016/j.gene.2017.09.041
   Wu ZJ, 2013, J CHROMATOGR B, V923, P54, DOI 10.1016/j.jchromb.2013.01.032
   Xie ZF, 2018, PHYTOTHER RES, V32, P2256, DOI 10.1002/ptr.6163
   Xu GH, 2010, BIOORG MED CHEM LETT, V20, P513, DOI 10.1016/j.bmcl.2009.11.109
   Xu Y, 2018, EVID-BASED COMPL ALT, V2018, DOI 10.1155/2018/3593408
   Yan XC, 2020, J AGR FOOD CHEM, V68, P3742, DOI 10.1021/acs.jafc.0c00280
   Yang S., 2012, CHIN J EXP TRADIT ME, V18, P2, DOI [10.13422/j.cnki.syfjx.2012.09.075., DOI 10.13422/J.CNKI.SYFJX.2012.09.075]
   Yang SY, 2019, BMC COMPLEM ALTERN M, V19, DOI 10.1186/s12906-019-2551-3
   Yin MC, 2009, J AGR FOOD CHEM, V57, P6468, DOI 10.1021/jf9004466
   Ying M, 2018, ACS APPL MATER INTER, V10, P19473, DOI 10.1021/acsami.8b05235
   Yoon CS, 2014, INT IMMUNOPHARMACOL, V23, P568, DOI 10.1016/j.intimp.2014.10.006
   Yue GGL, 2015, SCI REP-UK, V5, DOI 10.1038/srep11149
   Zhang G, 2019, MED SCI MONITOR, V25, P7853, DOI 10.12659/MSM.916246
   Zhang J, 2019, MED SCI MONITOR, V25, P6846, DOI 10.12659/MSM.916740
   Zhang PY, 2015, CELL BIOCHEM BIOPHYS, V72, P783, DOI 10.1007/s12013-015-0532-9
   Zhang Q., 2015, SHANGHAI J TRADIT CH, V53, P1689, DOI [10.1017/CBO9781107415324.004, DOI 10.1017/CBO9781107415324.004]
   Zhang X, 2018, FITOTERAPIA, V125, P147, DOI 10.1016/j.fitote.2018.01.005
   Zhang YT, 2018, FOOD FUNCT, V9, P6518, DOI 10.1039/c8fo02079e
   Zhao CC, 2006, NAT PROD RES, V20, P981, DOI 10.1080/14786410600921532
   Zheng CP, 2019, MOL BIOL REP, V46, P3857, DOI 10.1007/s11033-019-04828-1
   Zhu XF, 2017, INT J ONCOL, V50, P835, DOI 10.3892/ijo.2017.3873
   Zingue S, 2020, J ETHNOPHARMACOL, V247, DOI 10.1016/j.jep.2019.112251
   刘志刚, 2005, [中药新药与临床药理, Traditional Chinese Drug Research and Clinical Plarmacology], V16, P132
   王丽, 2003, [中药材, Journal of Chinese Medicinal Materials], V26, P563
NR 156
TC 3
Z9 3
U1 3
U2 7
PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY-LES-MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE
SN 0753-3322
EI 1950-6007
J9 BIOMED PHARMACOTHER
JI Biomed. Pharmacother.
PD OCT
PY 2020
VL 130
AR 110735
DI 10.1016/j.biopha.2020.110735
PG 12
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA OH6JX
UT WOS:000582697900131
PM 34321173
OA gold
DA 2022-04-25
ER

PT J
AU Vacchelli, E
   Semeraro, M
   Enot, DP
   Chaba, K
   Colame, VP
   Dartigues, P
   Perier, A
   Villa, I
   Rusakiewicz, S
   Gronnier, C
   Goere, D
   Mariette, C
   Zitvogel, L
   Kroemer, G
AF Vacchelli, Erika
   Semeraro, Michaela
   Enot, David P.
   Chaba, Kariman
   Colame, Vichnou Poirier
   Dartigues, Peggy
   Perier, Aurelie
   Villa, Irene
   Rusakiewicz, Sylvie
   Gronnier, Caroline
   Goere, Diane
   Mariette, Christophe
   Zitvogel, Laurence
   Kroemer, Guido
TI Negative prognostic impact of regulatory T cell infiltration in
   surgically resected esophageal cancer post-radiochemotherapy
SO ONCOTARGET
LA English
DT Article
DE immunogenic cell death; autophagy; ATG16L1; pattern recognition
   receptor; apoptosis
ID TUMOR MICROENVIRONMENT; CHEMOTHERAPY; EXPRESSION; CHEMORADIOTHERAPY;
   ASSOCIATION; LYMPHOCYTES; REGRESSION; MECHANISM; EFFICACY
AB Ever accumulating evidence indicates that the long-term effects of radiotherapy and chemotherapy largely depend on the induction (or restoration) of an anticancer immune response. Here, we investigated this paradigm in the context of esophageal carcinomas treated by neo-adjuvant radiochemotherapy, in a cohort encompassing 196 patients. We found that the density of the FOXP3(+) regulatory T cell (Treg) infiltrate present in the residual tumor (or its scar) correlated with the pathological response (the less Tregs the more pronounced was the histological response) and predicted cancer-specific survival. In contrast, there was no significant clinical impact of the frequency of CD8(+) cytotoxic T cells. At difference with breast or colorectal cancer, a loss-of-function allele of toll like receptor 4 (TLR4) improved cancer-specific survival of patients with esophageal cancer. While a loss-of-function allele of purinergic receptor P2X, ligand-gated ion channel, 7 (P2RX7) failed to affect cancer-specific survival, its presence did correlate with an increase in Treg infiltration. Altogether, these results corroborate the notion that the immunosurveillance seals the fate of patients with esophageal carcinomas treated with conventional radiochemotherapy.
C1 [Vacchelli, Erika; Semeraro, Michaela; Enot, David P.; Chaba, Kariman; Colame, Vichnou Poirier; Perier, Aurelie; Rusakiewicz, Sylvie; Goere, Diane; Zitvogel, Laurence; Kroemer, Guido] Gustave Roussy Canc Campus, Villejuif, France.
   [Vacchelli, Erika; Enot, David P.; Chaba, Kariman; Kroemer, Guido] INSERM, U1138, Paris, France.
   [Vacchelli, Erika; Enot, David P.; Chaba, Kariman; Kroemer, Guido] Ctr Rech Cordeliers, Equipe Labellisee Ligue Natl Canc 11, Paris, France.
   [Vacchelli, Erika; Chaba, Kariman; Kroemer, Guido] Univ Paris 05, Sorbonne Paris Cite, Paris, France.
   [Vacchelli, Erika; Kroemer, Guido] Univ Paris 06, Paris, France.
   [Semeraro, Michaela; Colame, Vichnou Poirier; Perier, Aurelie; Rusakiewicz, Sylvie; Zitvogel, Laurence] INSERM, U1015, Villejuif, France.
   [Semeraro, Michaela; Colame, Vichnou Poirier; Perier, Aurelie; Rusakiewicz, Sylvie; Zitvogel, Laurence] Ctr Clin Invest Biotherapies Canc CICBT 1428, Villejuif, France.
   [Enot, David P.; Kroemer, Guido] Gustave Roussy Canc Campus, Metabol & Cell Biol Platforms, Villejuif, France.
   [Dartigues, Peggy] Gustave Roussy Canc Campus, Dept Pathol, Villejuif, France.
   [Villa, Irene] Gustave Roussy Canc Campus, Dept Pathol, Digital Pathol, Villejuif, France.
   [Gronnier, Caroline; Mariette, Christophe] Claude Huriez Univ Hosp, Dept Digest & Oncol Surg, Lille, France.
   [Gronnier, Caroline; Mariette, Christophe] North France Univ, Lille, France.
   [Goere, Diane] Gustave Roussy Canc Campus, Dept Surg Oncol, Villejuif, France.
   [Zitvogel, Laurence] Univ Paris 11, Fac Med, Le Kremlin Bicetre, France.
   [Kroemer, Guido] Hop Europeen Georges Pompidou, AP HP, Pole Biol, Paris, France.
RP Kroemer, G (corresponding author), Gustave Roussy Canc Campus, Villejuif, France.
EM laurence.zitvogel@gustaveroussy.fr; kroemer@orange.fr
RI KROEMER, Guido/B-4263-2013; Vacchelli, Erika/E-5212-2018; Kroemer,
   Guido/AAY-9859-2020
OI KROEMER, Guido/0000-0002-9334-4405; Vacchelli,
   Erika/0000-0001-8010-0594; , GOERE/0000-0001-6306-2354
FU Ligue National contre le Cancer (Equipe labelisees); Agence National de
   la Recherche (ANR) - Projets blancsFrench National Research Agency
   (ANR); ANRFrench National Research Agency (ANR); Association pour la
   recherche sur le cancer (ARC)Fondation ARC pour la Recherche sur le
   Cancer; Canceropole Ile-de-FranceRegion Ile-de-France; Institut National
   du Cancer (INCa)Institut National du Cancer (INCA) France; Fondation
   Bettencourt-Schueller; Fondation de FranceFondation de France; Fondation
   pour la Recherche Medicale (FRM)Fondation pour la Recherche Medicale;
   European Commission (ArtForce)European CommissionEuropean Commission
   Joint Research Centre; European Research Council (ERC)European Research
   Council (ERC); LabEx Immuno-Oncology; SIRIC Stratified Oncology Cell DNA
   Repair and Tumor Immune Elimination (SOCRATE); SIRIC Cancer Research and
   Personalized Medicine (CARPEM); Paris Alliance of Cancer Research
   Institutes (PACRI)
FX G.K. and L.Z. are supported by the Ligue National contre le Cancer
   (Equipe labelisees); Agence National de la Recherche (ANR) - Projets
   blancs; ANR under the frame of E-Rare-2, the ERA-Net for Research on
   Rare Diseases; Association pour la recherche sur le cancer (ARC);
   Canceropole Ile-de-France; Institut National du Cancer (INCa); Fondation
   Bettencourt-Schueller; Fondation de France; Fondation pour la Recherche
   Medicale (FRM); the European Commission (ArtForce); the European
   Research Council (ERC); the LabEx Immuno-Oncology; the SIRIC Stratified
   Oncology Cell DNA Repair and Tumor Immune Elimination (SOCRATE); the
   SIRIC Cancer Research and Personalized Medicine (CARPEM); and the Paris
   Alliance of Cancer Research Institutes (PACRI).
CR Apetoh L, 2007, NAT MED, V13, P1050, DOI 10.1038/nm1622
   Ashida A, 2006, INT J ONCOL, V28, P1345
   Chen LJ, 2011, CANCER IMMUNOL IMMUN, V60, P1047, DOI 10.1007/s00262-011-1017-3
   Cho Y, 2003, CANCER RES, V63, P1555
   Denkert C, 2014, J CLIN ONCOL
   Denkert C, 2010, J CLIN ONCOL, V28, P105, DOI 10.1200/JCO.2009.23.7370
   Dutta S, 2012, BRIT J CANCER, V106, P702, DOI 10.1038/bjc.2011.610
   Gabitass RF, 2011, CANCER IMMUNOL IMMUN, V60, P1419, DOI 10.1007/s00262-011-1028-0
   Galluzzi L, 2012, NAT REV DRUG DISCOV, V11, P215, DOI 10.1038/nrd3626
   Ghiringhelli F, 2009, NAT MED, V15, P1170, DOI 10.1038/nm.2028
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Heinze G, 2006, STAT MED, V25, P4216, DOI 10.1002/sim.2687
   Hofman P., 2015, CANC RES
   Hothorn T, 2003, COMPUT STAT DATA AN, V43, P121
   Huang C, 2011, IMMUNOL INVEST, V40, P400, DOI 10.3109/08820139.2011.555489
   Ichihara F, 2003, CLIN CANCER RES, V9, P4404
   Issa-Nummer Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079775
   Izawa S, 2013, CANCER IMMUNOL IMMUN, V62, P161, DOI 10.1007/s00262-012-1327-0
   Kono K, 2006, CANCER IMMUNOL IMMUN, V55, P1064, DOI 10.1007/s00262-005-0092-8
   Ladoire S, 2011, J PATHOL, V224, P389, DOI 10.1002/path.2866
   Liu Q, 2009, SCAND J GASTROENTERO, V44, P960, DOI 10.1080/00365520902998679
   Loi S, 2013, J CLIN ONCOL, V31, P860, DOI 10.1200/JCO.2011.41.0902
   Lv L, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018219
   MANDARD AM, 1994, CANCER, V73, P2680, DOI 10.1002/1097-0142(19940601)73:11<2680::AID-CNCR2820731105>3.0.CO;2-C
   Maruyama T, 2010, DIS ESOPHAGUS, V23, P422, DOI 10.1111/j.1442-2050.2009.01029.x
   Rao S, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4056
   Schreiber RD, 2011, SCIENCE, V331, P1565, DOI 10.1126/science.1203486
   Schumacher K, 2001, CANCER RES, V61, P3932
   Senovilla L, 2012, SCIENCE, V337, P1678, DOI 10.1126/science.1224922
   Sistigu A, 2014, NAT MED, V20, P1301, DOI 10.1038/nm.3708
   Team RDC, 2014, R LANG ENV STAT COMP
   Tesniere A, 2010, ONCOGENE, V29, P482, DOI 10.1038/onc.2009.356
   Tsuchikawa T, 2011, CLIN EXP IMMUNOL, V164, P50, DOI 10.1111/j.1365-2249.2010.04311.x
   Tsuchikawa T, 2012, ANN SURG ONCOL, V19, P1713, DOI 10.1245/s10434-011-1906-x
   Vacchelli E, 2012, ONCOIMMUNOLOGY, V1, P271, DOI 10.4161/onci.18684
   Wang G, 2013, HEPATO-GASTROENTEROL, V60, P704, DOI 10.5754/hge12953
   Wang GC, 2012, HEPATO-GASTROENTEROL, V59, P2186, DOI 10.5754/hge11961
   Xue L, 2010, DIS ESOPHAGUS, V23, P340, DOI 10.1111/j.1442-2050.2009.01013.x
   Zhu XM, 2011, CYTOKINE, V54, P296, DOI 10.1016/j.cyto.2011.02.017
   Zingg U, 2010, EJSO-EUR J SURG ONC, V36, P670, DOI 10.1016/j.ejso.2010.05.012
   Zitvogel L, 2013, IMMUNITY, V39, P74, DOI 10.1016/j.immuni.2013.06.014
   Zitvogel L, 2011, NAT REV CLIN ONCOL, V8, P151, DOI 10.1038/nrclinonc.2010.223
NR 42
TC 41
Z9 46
U1 0
U2 9
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD AUG 28
PY 2015
VL 6
IS 25
BP 20840
EP 20850
DI 10.18632/oncotarget.4428
PG 11
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA CQ9XO
UT WOS:000360969200014
PM 26369701
OA Green Submitted, gold, Green Published
DA 2022-04-25
ER

PT J
AU Wang, ZY
   Song, D
   Huang, P
AF Wang, Ziyao
   Song, Dan
   Huang, Ping
TI MicroRNA-340 inhibits tumor cell proliferation, migration and invasion,
   and induces apoptosis in hepatocellular carcinoma
SO MOLECULAR MEDICINE REPORTS
LA English
DT Article
DE microRNA-340; hepatocellular carcinoma; proliferation; apoptosis;
   migration; invasion; S-phase kinase-associated protein 2
ID CANCER CELLS; COLORECTAL-CANCER; METASTASIS; EXPRESSION; PROGRESSION;
   AUTOPHAGY; PATHWAY
AB MicroRNAs (miRs) are short RNAs that serve a role in the origination and progression of hepatocellular carcinoma (HCC). miR-340 has been identified to be a novel tumor suppressor. The present study investigated the antitumor function of miR-340 in HCC. In the present study, it was detected that miR-340 was significantly decreased in HCC cancer tissues and human HCC cell lines using reverse transcription-quantitative polymerase chain reaction analysis. Cell Counting kit-8 and apoptosis assays demonstrated that miR-340 reduced cell proliferation and induced cellular apoptosis in HCC cell lines. A Transwell invasion assay demonstrated that miR-340 suppressed the migration and invasion of HCC cell lines. In addition, S-phase kinase-associated protein 2 (SKP2), which may be repressed by miR-340 in HCC cell lines, was identified to be a potential target of miR-340. The results of the present study revealed that miR-340 serves a tumor suppressor role by influencing the proliferation, apoptosis, migration and invasion of HCC cell lines, which may be explained by the downregulation of SKP2 by miR-340.
C1 [Wang, Ziyao; Song, Dan; Huang, Ping] Chongqing Med Univ, Affiliated Hosp 1, Dept Hepatobiliary Surg, Natl Key Clin Dept, 1 Youyi Rd, Chongqing 400000, Peoples R China.
RP Huang, P (corresponding author), Chongqing Med Univ, Affiliated Hosp 1, Dept Hepatobiliary Surg, Natl Key Clin Dept, 1 Youyi Rd, Chongqing 400000, Peoples R China.
EM huangpchina@sina.com
CR Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5
   Cai HQ, 2014, INT J MOL SCI, V15, P560, DOI 10.3390/ijms15010560
   Callegari Elisa, 2013, Onco Targets Ther, V6, P1167, DOI 10.2147/OTT.S36161
   Fernandez S, 2015, ONCOGENE, V34, P3240, DOI 10.1038/onc.2014.267
   de Cedron MG, 2016, J LIPID RES, V57, P193, DOI 10.1194/jlr.R061812
   Hou LK, 2016, ONCOTARGET, V7, P26016, DOI 10.18632/oncotarget.8421
   Huang DQ, 2015, ONCOTARGET, V6, P9257, DOI 10.18632/oncotarget.3288
   Huang K, 2016, ONCOL REP, V35, P887, DOI 10.3892/or.2015.4458
   Huang X, 2013, EMBO J, V32, P2204, DOI 10.1038/emboj.2013.133
   Lee SW, 2015, MOL CELL, V57, P1022, DOI 10.1016/j.molcel.2015.01.015
   Li PQ, 2016, CELL PHYSIOL BIOCHEM, V38, P1915, DOI 10.1159/000445553
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   McGlynn KA, 2015, CLIN LIVER DIS, V19, P223, DOI 10.1016/j.cld.2015.01.001
   Mohammadi-Yeganeh S, 2016, TUMOR BIOL, V37, P8993, DOI 10.1007/s13277-015-4513-9
   Negrini M, 2007, J CELL SCI, V120, P1833, DOI 10.1242/jcs.03450
   Peschansky VJ, 2014, EPIGENETICS-US, V9, P3, DOI 10.4161/epi.27473
   Strong AMP, 2014, ARCH BIOCHEM BIOPHYS, V563, P118, DOI 10.1016/j.abb.2014.07.012
   Sun Y, 2012, ONCOL REP, V28, P1346, DOI 10.3892/or.2012.1958
   Szabo G, 2013, NAT REV GASTRO HEPAT, V10, P542, DOI 10.1038/nrgastro.2013.87
   Takeyama H, 2014, MOL CANCER THER, V13, P976, DOI 10.1158/1535-7163.MCT-13-0571
   Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262
   Wei PT, 2016, DNA CELL BIOL, V35, P33, DOI 10.1089/dna.2015.3021
   Wu SY, 2016, WORLD J GASTROENTERO, V22, P176, DOI 10.3748/wjg.v22.i1.176
   Xu P, 2016, J ORAL MAXIL SURG, V74, P844, DOI 10.1016/j.joms.2015.09.038
   Yu WF, 2016, GENE, V577, P193, DOI 10.1016/j.gene.2015.11.045
   Zhang JS, 2012, CANCER METAST REV, V31, P653, DOI 10.1007/s10555-012-9368-6
   Zhang XY, 2009, HEPATOLOGY, V50, P490, DOI 10.1002/hep.23008
   Zucman-Rossi J, 2015, GASTROENTEROLOGY, V149, P1226, DOI 10.1053/j.gastro.2015.05.061
NR 28
TC 8
Z9 8
U1 0
U2 3
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1791-2997
EI 1791-3004
J9 MOL MED REP
JI Mol. Med. Rep.
PD NOV
PY 2017
VL 16
IS 5
BP 7649
EP 7656
DI 10.3892/mmr.2017.7583
PG 8
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Research & Experimental Medicine
GA FM0ZU
UT WOS:000414698900248
PM 28944918
OA Bronze
DA 2022-04-25
ER

PT J
AU Samdal, H
   Sandmoe, MA
   Olsen, LC
   Jarallah, EAH
   Hoiem, TS
   Schonberg, SA
   Pettersen, CHH
AF Samdal, Helle
   Sandmoe, Malin A.
   Olsen, Lene C.
   Jarallah, Elaf A. H.
   Hoiem, Therese S.
   Schonberg, Svanhild A.
   Pettersen, Caroline H. H.
TI Basal level of autophagy and MAP1LC3B-II as potential biomarkers for
   DHA-induced cytotoxicity in colorectal cancer cells
SO FEBS JOURNAL
LA English
DT Article
DE autophagy; colorectal cancer; docosahexaenoic acid; MAP1LC3B; omega-3
ID OXIDATIVE STRESS; P53 MUTATIONS; MUTANT P53; ER STRESS; EXPRESSION;
   INHIBITION; APOPTOSIS; THERAPY; GROWTH; DEATH
AB The omega-3 fatty acid docosahexaenoic acid (DHA) is known as an anticancer agent. Colorectal cancer (CRC) cells exhibit different sensitivity toward DHA, but the mechanisms involved are still unclear. Gene expression profiling of 10 CRC cell lines demonstrated a correlation between the level of DHA sensitivity and different biological stress responses, such as endoplasmic reticulum (ER) stress, oxidative stress, and autophagy. The basal level of autophagy and MAP1LC3B-II protein correlated with DHA sensitivity in the cell lines studied. DHA induced oxidative stress, ER stress, and autophagy in DHA-sensitive DLD-1 cells, while the less sensitive LS411N cells were affected to a much lesser extent. Co-treatment with DHA and the autophagy inducer rapamycin reduced DHA sensitivity in DLD-1 and HCT-8 cells, while co-treatment with DHA and the autophagy inhibitors chloroquine and 3-methyladenine increased the DHA sensitivity in LS411N and LS513 cells. Differentially expressed genes correlating with DHA sensitivity and the level of autophagy demonstrated an overlap in biological pathways involved. Results indicate the basal level of autophagy and MAP1LC3B-II protein as potential biomarkers for DHA sensitivity in CRC cells.
   DatabasesProtocol and data for gene expression experiments have been submitted to ArrayExpress with accession number E-MTAB-5750.
C1 [Samdal, Helle; Sandmoe, Malin A.; Olsen, Lene C.; Jarallah, Elaf A. H.; Hoiem, Therese S.; Schonberg, Svanhild A.; Pettersen, Caroline H. H.] Norwegian Univ Sci & Technol, Dept Clin & Mol Med, NTNU, Fac Med & Hlth Sci, Trondheim, Norway.
   [Olsen, Lene C.] Norwegian Univ Sci & Technol, Bioinformat Core Facil BioCore, NTNU, Trondheim, Norway.
   [Pettersen, Caroline H. H.] Trondheim Reg & Univ Hosp, Dept Surg, St Olavs Hosp, Trondheim, Norway.
RP Pettersen, CHH (corresponding author), Norwegian Univ Sci & Technol, Dept Clin & Mol Med, Fac Med & Hlth Sci, Labs Enteret 5th Floor East, N-7006 Trondheim, Norway.
EM caroline.h.pettersen@ntnu.no
OI Olsen, Lene Christin/0000-0002-5869-4952; Pettersen,
   Caroline/0000-0003-0658-0061
FU Joint Research Committee between St. Olavs Hospital; Faculty of Medicine
   and Health Sciences, NTNU (FFU); Faculty of Medicine and Health
   Sciences, NTNU; Cancer Research Fund at St. Olavs Hospital; Central
   Norway Regional Health Authority; Research Council of Norway through
   "Smaforsk' grant
FX We appreciate the technical assistance by Grete Klippenvag Pettersen and
   Almaz Nigatu Tesfahun. Gene expression analysis was performed at the
   Genomics Core Facility, Norwegian University of Science and Technology
   (NTNU). This work was supported by grants from the Joint Research
   Committee between St. Olavs Hospital and the Faculty of Medicine and
   Health Sciences, NTNU (FFU), The Faculty of Medicine and Health
   Sciences, NTNU, the Cancer Research Fund at St. Olavs Hospital, the
   Central Norway Regional Health Authority and the Research Council of
   Norway through "Smaforsk' grant.
CR Adams O, 2016, ONCOTARGET, V7, P39241, DOI 10.18632/oncotarget.9649
   [Anonymous], 2016, SOMATIC MUTATIONS MU
   [Anonymous], 2015, CANCER
   Avivar-Valderas A, 2011, MOL CELL BIOL, V31, P3616, DOI 10.1128/MCB.05164-11
   B'chir W, 2013, NUCLEIC ACIDS RES, V41, P7683, DOI 10.1093/nar/gkt563
   Bathen TF, 2008, ANTICANCER RES, V28, P3717
   Bjorkoy G, 2005, J CELL BIOL, V171, P603, DOI 10.1083/jcb.200507002
   Burada F, 2015, WORLD J GASTRO ONCOL, V7, P271, DOI 10.4251/wjgo.v7.i11.271
   Chiu LCM, 1999, CANCER LETT, V145, P17, DOI 10.1016/S0304-3835(99)00224-4
   D'Eliseo D, 2016, J CLIN MED, V5, DOI 10.3390/jcm5020015
   Farooqi AA, 2015, TUMOR BIOL, V36, P5743, DOI 10.1007/s13277-015-3797-0
   Gautier L, 2004, BIOINFORMATICS, V20, P307, DOI 10.1093/bioinformatics/btg405
   Gonzalez-Polo RA, 2016, PROG INFLAMM RES SER, P3, DOI 10.1007/978-3-319-30079-5_1
   Green DR, 2009, NATURE, V458, P1127, DOI 10.1038/nature07986
   Greene D, 2017, BIOINFORMATICS, V33, P1104, DOI 10.1093/bioinformatics/btw763
   HARDMAN WE, 2004, J NUTR, V3427, P3430
   Huang A, 2014, CANCER BIOL THER, V15, P297, DOI 10.4161/cbt.27308
   Jakobsen CH, 2008, J LIPID RES, V49, P2089, DOI 10.1194/jlr.M700389-JLR200
   Jing K, 2011, AUTOPHAGY, V7, P1348, DOI 10.4161/auto.7.11.16658
   Kaneko R, 2007, J BIOL CHEM, V282, P19273, DOI 10.1074/jbc.M610350200
   Kania E, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/352794
   Kim N, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/239764
   Kontos CK, 2010, BRIT J CANCER, V102, P1384, DOI 10.1038/sj.bjc.6605654
   Kroemer G, 2010, MOL CELL, V40, P280, DOI 10.1016/j.molcel.2010.09.023
   Lee Ja Young, 2017, Clin Nutr Res, V6, P147, DOI 10.7762/cnr.2017.6.3.147
   Li J, 2010, EUR J CANCER, V46, P1900, DOI 10.1016/j.ejca.2010.02.021
   Liu Y, 2006, P NATL ACAD SCI USA, V103, P976, DOI 10.1073/pnas.0510146103
   Luo X, 2012, GENE DEV, V26, P417, DOI 10.1101/gad.183509.111
   Maga G, 2003, J CELL SCI, V116, P3051, DOI 10.1242/jcs.00653
   Medico E, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8002
   Miyoshi N, 2009, BRIT J CANCER, V101, P1664, DOI 10.1038/sj.bjc.6605361
   Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639
   Mizushima N, 2010, CELL, V140, P313, DOI 10.1016/j.cell.2010.01.028
   Mokarram P, 2017, AUTOPHAGY, V13, P781, DOI 10.1080/15548627.2017.1290751
   Muller PAJ, 2014, CANCER CELL, V25, P304, DOI 10.1016/j.ccr.2014.01.021
   Muller PAJ, 2013, NAT CELL BIOL, V15, P2, DOI 10.1038/ncb2641
   Nabavi SF, 2015, CANCER METAST REV, V34, P359, DOI 10.1007/s10555-015-9572-2
   Niklaus M, 2017, ONCOTARGET, V8, P54604, DOI 10.18632/oncotarget.17554
   Pankiv S, 2007, J BIOL CHEM, V282, P24131, DOI 10.1074/jbc.M702824200
   Pettersen K, 2016, FREE RADICAL BIO MED, V90, P158, DOI 10.1016/j.freeradbiomed.2015.11.018
   Rashid HO, 2015, AUTOPHAGY, V11, P1956, DOI 10.1080/15548627.2015.1091141
   Raskov H, 2014, WORLD J GASTROENTERO, V20, P18151, DOI 10.3748/wjg.v20.i48.18151
   Reimand J, 2007, NUCLEIC ACIDS RES, V35, pW193, DOI 10.1093/nar/gkm226
   Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007
   Sadanandam A, 2013, NAT MED, V19, P619, DOI 10.1038/nm.3175
   Selvakumaran M, 2013, CLIN CANCER RES, V19, P2995, DOI 10.1158/1078-0432.CCR-12-1542
   Shin S, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/568671
   Skender B, 2012, BIOMED PAP, V156, P186, DOI 10.5507/bp.2012.093
   Sui XB, 2011, AUTOPHAGY, V7, P565, DOI 10.4161/auto.7.6.14073
   Tan SF, 2016, INT J MOL MED, V37, P1030, DOI 10.3892/ijmm.2016.2492
   Tang JJ, 2015, CANCER LETT, V363, P101, DOI 10.1016/j.canlet.2015.04.014
   Tasdemir E, 2008, NAT CELL BIOL, V10, P676, DOI 10.1038/ncb1730
   Tsimberidou A. M., 2009, WORLD, DOI 10.1200/JC0.2009.23.6018
   Xiong HY, 2010, CANCER LETT, V288, P68, DOI 10.1016/j.canlet.2009.06.039
   Xu GR, 2017, GENE, V604, P33, DOI 10.1016/j.gene.2016.12.016
   Xu J, 2011, NAT CHEM BIOL, V7, P285, DOI 10.1038/nchembio.546
   Yusof AS, 2012, ASIAN PAC J CANCER P, V13, P4713, DOI 10.7314/APJCP.2012.13.9.4713
   Zand H, 2007, MOL CELL BIOCHEM, V304, P71, DOI 10.1007/s11010-007-9487-5
NR 58
TC 5
Z9 5
U1 0
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1742-464X
EI 1742-4658
J9 FEBS J
JI FEBS J.
PD JUL
PY 2018
VL 285
IS 13
BP 2446
EP 2467
DI 10.1111/febs.14488
PG 22
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA GM1QS
UT WOS:000437845500007
PM 29723445
OA Green Submitted, Bronze
DA 2022-04-25
ER

PT J
AU Guo, GF
   Jiang, WQ
   Zhang, B
   Cai, YC
   Xu, RH
   Chen, XX
   Wang, F
   Xia, LP
AF Guo, Gui-Fang
   Jiang, Wen-Qi
   Zhang, Bei
   Cai, Yu-Chen
   Xu, Rui-Hua
   Chen, Xu-Xian
   Wang, Fang
   Xia, Liang-Ping
TI Autophagy-related proteins Beclin-1 and LC3 predict cetuximab efficacy
   in advanced colorectal cancer
SO WORLD JOURNAL OF GASTROENTEROLOGY
LA English
DT Article
DE Beclin-1; Cetuximab; Colorectal neoplasms; Drug therapy; LC3
ID MULTICENTER RANDOMIZED-TRIAL; 1ST-LINE TREATMENT; FLUOROURACIL;
   EXPRESSION; MUTATIONS; CELLS; GENE; EGFR; KRAS; CHEMOTHERAPY
AB AIM: To investigate the utility of Beclin-1 and LC3, two autophagy-related proteins, in predicting the cetuximab efficacy in advanced colorectal cancer (ACRC).
   METHODS: The data of 85 patients with ACRC treated at the Sun Yat-sen University Cancer Center from March 1, 2005 to December 31, 2008 were studied, including 45 cases treated with cetuximab-containing chemotherapy and 40 cases treated with non-cetuximab-containing chemotherapy. Beclin-1 and LC3 expression was evaluated by immunohistochemistry, and KRAS status was evaluated by polymerase chain reaction.
   RESULTS: Beclin-1 and LC3 expression in ACRC was significantly correlated (r = 0.44, P < 0.01); however, LC3 was more highly expressed in cancerous tissues than in normal tissues (Z = -2.63, P < 0.01). In the cetuximab-containing chemotherapy group, patients with low LC3 expression had higher objective response rates (ORRs) than those with high LC3 expression (52.9% vs 17.9%, P = 0.01), and patients with low Beclin-1 expression had a longer median progression-free survival (PFS) than their counterparts with higher Beclin-1 expression (9.0 mo vs 3.0 mo, P = 0.01). However, neither of these predictive relationships was detected in the group treated with non-cetuximab-containing chemotherapy. Patients with wild-type KRAS had higher ORRs (42.3% vs 9.1%, P = 0.049) and disease control rates (DCRs) (73.1% vs 36.4%, P = 0.035), and longer median PFS (5.5 mo vs 2.5 mo, P = 0.02) than those with mutant KRAS in the cetuximab-containing chemotherapy group. Neither Beclin-1 (P = 0.52) nor LC3 (P = 0.32) expression was significantly correlated with KRAS status.
   CONCLUSION: Patients with low Beclin-1 expression had a longer PFS than those with high Beclin-1 expression, and patients with low LC3 expression had a higher ORR in ACRC patients treated with cetuximab-containing chemotherapy. (C) 2011 Baishideng. All rights reserved.
C1 [Guo, Gui-Fang; Jiang, Wen-Qi; Zhang, Bei; Cai, Yu-Chen; Xu, Rui-Hua; Chen, Xu-Xian; Wang, Fang; Xia, Liang-Ping] Sun Yat Sen Univ, State Key Lab Oncol, Ctr Canc, Guangzhou 510060, Guangdong, Peoples R China.
   [Guo, Gui-Fang; Zhang, Bei; Chen, Xu-Xian; Wang, Fang; Xia, Liang-Ping] Sun Yat Sen Univ, VIP Reg, Ctr Canc, Guangzhou 510060, Guangdong, Peoples R China.
   [Jiang, Wen-Qi; Xu, Rui-Hua] Sun Yat Sen Univ, Dept Med Oncol, Ctr Canc, Guangzhou 510060, Guangdong, Peoples R China.
RP Xia, LP (corresponding author), Sun Yat Sen Univ, State Key Lab Oncol, Ctr Canc, 651 E Dongfeng Rd, Guangzhou 510060, Guangdong, Peoples R China.
EM xialiangping@163.com
RI Xu, Rui-Hua/AAW-4766-2021
OI Xu, Rui-Hua/0000-0001-9771-8534
FU Science and Technology Planning Project of Guangdong Province, China
   [2010B031600317]; Administration of Traditional Chinese Medicine of
   Guangdong Province, China [20111169]; National Natural Science
   Foundation of ChinaNational Natural Science Foundation of China (NSFC)
   [81071872]
FX Supported by Grants from Science and Technology Planning Project of
   Guangdong Province, China, No. 2010B031600317; Administration of
   Traditional Chinese Medicine of Guangdong Province, China, No. 20111169;
   National Natural Science Foundation of China, No. 81071872
CR Ahn CH, 2007, APMIS, V115, P1344, DOI 10.1111/j.1600-0463.2007.00858.x
   Allegra CJ, 2009, J CLIN ONCOL, V27, P2091, DOI 10.1200/JCO.2009.21.9170
   Bokemeyer C, 2009, J CLIN ONCOL, V27, P663, DOI 10.1200/JCO.2008.20.8397
   Cuervo AM, 2004, TRENDS CELL BIOL, V14, P70, DOI 10.1016/j.tcb.2003.12.002
   Douillard JY, 2000, LANCET, V355, P1041, DOI 10.1016/S0140-6736(00)02034-1
   Eberhard DA, 2008, J CLIN ONCOL, V26, P983, DOI 10.1200/JCO.2007.12.9858
   Giacchetti S, 2000, J CLIN ONCOL, V18, P136, DOI 10.1200/JCO.2000.18.1.136
   Giannopoulou E, 2009, ANTICANCER RES, V29, P5077
   Guo GF, 2010, MED ONCOL       1117
   Guo Gui-fang, 2010, Zhonghua Zhong Liu Za Zhi, V32, P777
   Guo Gui-Fang, 2009, Ai Zheng, V28, P1317
   Jaeger PA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011102
   Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717
   Klionsky DJ, 2003, DEV CELL, V5, P539, DOI 10.1016/S1534-5807(03)00296-X
   Lee JW, 2007, APMIS, V115, P750, DOI 10.1111/j.1600-0463.2007.apm_640.x
   Li XQ, 2010, AUTOPHAGY, V6, P1066, DOI 10.4161/auto.6.8.13366
   Li XQ, 2010, CANCER RES, V70, P5942, DOI 10.1158/0008-5472.CAN-10-0157
   Li ZD, 2008, PROG BIOCHEM BIOPHYS, V35, P1282
   Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257
   Martinet W, 2006, J HISTOCHEM CYTOCHEM, V54, P85, DOI 10.1369/jhc.5A6743.2005
   Mizushima N, 2004, INT J BIOCHEM CELL B, V36, P2491, DOI 10.1016/j.biocel.2004.02.005
   Rocken C, 2008, Pathologe, V29 Suppl 2, P200, DOI 10.1007/s00292-008-1041-z
   Sato K, 2007, CANCER RES, V67, P9677, DOI 10.1158/0008-5472.CAN-07-1462
   Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993
   Tatsumi K, 2008, J MOL DIAGN, V10, P520, DOI 10.2353/jmoldx.2008.080024
   Theodoropoulos GE, 2009, ANTICANCER RES, V29, P785
   Van Cutsem E, 2009, EJC SUPPL, V7, P345, DOI 10.1016/S1359-6349(09)71172-3
   Van Cutsem E, 2009, NEW ENGL J MED, V360, P1408, DOI 10.1056/NEJMoa0805019
   Weihua Z, 2008, CANCER CELL, V13, P385, DOI 10.1016/j.ccr.2008.03.015
   Yoshioka A, 2008, INT J ONCOL, V33, P461, DOI 10.3892/ijo_00000028
NR 30
TC 58
Z9 61
U1 1
U2 15
PU BAISHIDENG PUBLISHING GROUP INC
PI PLEASANTON
PA 8226 REGENCY DR, PLEASANTON, CA 94588 USA
SN 1007-9327
EI 2219-2840
J9 WORLD J GASTROENTERO
JI World J. Gastroenterol.
PD NOV 21
PY 2011
VL 17
IS 43
BP 4779
EP 4786
DI 10.3748/wjg.v17.i43.4779
PG 8
WC Gastroenterology & Hepatology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Gastroenterology & Hepatology
GA 861FG
UT WOS:000298004000005
PM 22147978
OA hybrid, Green Published, Green Submitted
DA 2022-04-25
ER

PT J
AU Zheng, HC
   Gong, BC
   Zhao, S
AF Zheng, Hua-Chuan
   Gong, Bao-Cheng
   Zhao, Shuang
TI The meta and bioinformatics analysis of GRP78 expression in gastric
   cancer
SO ONCOTARGET
LA English
DT Article
DE GRP78; gastric cancer; meta analysis; bioinformatics analysis
ID CELL-SURFACE GRP78; ER STRESS; COLORECTAL-CANCER; BREAST-CANCER;
   HEPATOCELLULAR-CARCINOMA; POOR-PROGNOSIS; PROTEIN GRP78; UP-REGULATION;
   TUMOR-GROWTH; METASTASIS
AB GRP78 is a molecular chaperone located in endoplasmic reticulum, and induces folding and assembly of newly-synthesized proteins, proteasome degradation of aberrant proteins, and translocation of secretory proteins, autophagy, and epithelialmesenchymal transition. We performed a systematic meta-and bioinformatics analysis through multiple online databases up to March 14, 2017. It was found that up-regulated GRP78 expression in gastric cancer, compared with normal mucosa at both protein and mRNA levels (p < 0.05). GRP78 expression was positively correlated with depth of invasion, TNM staging and dedifferentiation of gastric cancer (p < 0.05), while its mRNA expression was negatively correlated with depth of invasion, histological grading and dedifferentiation (p < 0.05). A positive association between GRP78 expression and unfavorable overall survival was found in patients with gastric cancer (p < 0.005). A higher GRP78 mRNA expression was positively correlated with overall and progression-free survival rates of all cancer patients, even stratified by aggressive parameters, or as an independent factor (p < 0.05). These findings indicated that GRP78 expression might be employed as a potential marker to indicate gastric carcinogenesis and subsequent progression, even prognosis.
C1 [Zheng, Hua-Chuan] China Med Univ, Dept Expt Oncol, Shengjing Hosp, Shenyang 110004, Liaoning, Peoples R China.
   China Med Univ, Anim Ctr, Shengjing Hosp, Shenyang 110004, Liaoning, Peoples R China.
RP Zheng, HC (corresponding author), China Med Univ, Dept Expt Oncol, Shengjing Hosp, Shenyang 110004, Liaoning, Peoples R China.
EM zheng_huachuan@hotmail.com
FU Liaoning BaiQianWan Program; Award for Liaoning Distinguished Professor;
   Key Scientific and Technological Project of Liaoning Province
   [2015408001]; National Natural Scientific Foundation of ChinaNational
   Natural Science Foundation of China (NSFC) [81472544, 81672700]
FX This study was supported by Liaoning BaiQianWan Program, Award for
   Liaoning Distinguished Professor, a Key Scientific and Technological
   Project of Liaoning Province (2015408001) and National Natural
   Scientific Foundation of China (81472544; 81672700).
CR Chang YJ, 2015, TUMOR BIOL, V36, P1859, DOI 10.1007/s13277-014-2788-x
   Chen WT, 2014, ONCOGENE, V33, P4997, DOI 10.1038/onc.2013.437
   Ciortea R, 2016, REV MED CHILE, V144, P1577, DOI 10.4067/S0034-98872016001200009
   Cook KL, 2016, CANCER RES, V76, P5657, DOI 10.1158/0008-5472.CAN-15-2616
   Daneshmand S, 2007, HUM PATHOL, V38, P1547, DOI 10.1016/j.humpath.2007.03.014
   Dong DZ, 2011, CANCER RES, V71, P2848, DOI 10.1158/0008-5472.CAN-10-3151
   Fu R, 2014, ASIAN PAC J CANCER P, V15, P7245, DOI 10.7314/APJCP.2014.15.17.7245
   Fu WJ, 2010, UROLOGY, V75, P603, DOI 10.1016/j.urology.2009.05.007
   [付政祺 Fu Zhengqi], 2014, [中国病理生理杂志, Chinese Journal of Pathophysiology], V30, P625
   Ge JJ, 2016, MED J COMMUN, V30, P556
   Gu YJ, 2015, ONCOTARGET, V6, P33658, DOI 10.18632/oncotarget.5603
   He ZX, 2015, MED SCI J CENT S CHI, V43, P21
   Hu YW, 2016, CHIN J CLIN ONCOL, V21, P609
   Kaira K, 2016, NEOPLASMA, V63, P588, DOI 10.4149/neo_2016_412
   Kaira K, 2016, HEAD NECK-J SCI SPEC, V38, P1539, DOI 10.1002/hed.24471
   Kelber JA, 2009, ONCOGENE, V28, P2324, DOI 10.1038/onc.2009.97
   Lee AS, 2017, SCI REP-UK, V7, DOI 10.1038/srep40919
   Lee HY, 2015, CANCER RES TREAT, V47, P804, DOI 10.4143/crt.2014.121
   Li B, 2013, ONCOL REP, V30, P2119, DOI 10.3892/or.2013.2710
   Li LN, 2014, CHIN J GASTROENTEROL, V23, P1138
   Li ZW, 2016, SCI REP-UK, V6, DOI 10.1038/srep30406
   Li ZW, 2015, CELL SIGNAL, V27, P1237, DOI 10.1016/j.cellsig.2015.02.030
   Li ZW, 2013, INT J BIOCHEM CELL B, V45, P987, DOI 10.1016/j.biocel.2013.02.002
   Liu R, 2013, CLIN CANCER RES, V19, P6802, DOI 10.1158/1078-0432.CCR-13-1106
   Ma X, 2015, DIS MARKERS, V2015
   Malek MAYA, 2015, ONCOTARGET, V6, P3098
   Niu ZY, 2015, SCI REP-UK, V5, DOI 10.1038/srep16067
   [彭春雷 Peng Chunlei], 2013, [中国癌症杂志, China Oncology], V23, P885
   Peng YA, 2013, BIOCHEM BIOPH RES CO, V440, P558, DOI 10.1016/j.bbrc.2013.09.108
   Raiter A, 2014, INT J BIOL MARKER, V29, pE431, DOI 10.5301/jbm.5000086
   Ren Peng, 2017, Onco Targets Ther, V10, P617, DOI 10.2147/OTT.S123494
   Roller C, 2013, FRONT PHARMACOL, V4, DOI 10.3389/fphar.2013.00010
   Shimizu A, 2017, PATHOL ONCOL RES, V23, P111, DOI 10.1007/s12253-016-0099-9
   Shuda M, 2003, J HEPATOL, V38, P605, DOI 10.1016/S0168-8278(03)00029-1
   Soudry E, 2017, ANN DIAGN PATHOL, V26, P52, DOI 10.1016/j.anndiagpath.2016.11.003
   Thornton M, 2013, INT J CANCER, V133, P1408, DOI 10.1002/ijc.28137
   Wang Q, 2005, CANCER DETECT PREV, V29, P544, DOI 10.1016/j.cdp.2005.09.010
   Wang YY, 2017, EXP CELL RES, V351, P24, DOI 10.1016/j.yexcr.2016.12.017
   Wei H, 2014, J CAP MED U, V35, P501
   Winder T, 2011, ANN ONCOL, V22, P2431, DOI 10.1093/annonc/mdq771
   Xie J, 2016, BIOCHEM BIOPH RES CO, V474, P612, DOI 10.1016/j.bbrc.2016.03.002
   [许福源 Xu Fuyuan], 2010, [第三军医大学学报, Acta Academiae Medicinae Militaris Tertiae], V32, P688
   Yang L, 2014, EXP MOL PATHOL, V96, P235, DOI 10.1016/j.yexmp.2014.02.011
   Yao XL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125634
   Zhang J, 2006, CLIN EXP METASTAS, V23, P401, DOI 10.1007/s10585-006-9051-9
   Zhang LJ, 2009, CANCER LETT, V274, P40, DOI 10.1016/j.canlet.2008.08.030
   Zhang LH, 2011, BRAIN RES, V1371, P23, DOI 10.1016/j.brainres.2010.11.063
   Zhang LH, 2010, J CELL BIOCHEM, V110, P1299, DOI 10.1002/jcb.22679
   Zhang XC, 2015, ONCOL LETT, V9, P1181, DOI 10.3892/ol.2014.2831
   [张新晨 ZHANG Xinchen], 2005, [中华实验外科杂志, Chinese Journal of Experimental Surgery], V22, P1483
   Zhang XX, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/917296
   Zhang Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080071
   Zhao GH, 2015, DIGEST DIS SCI, V60, P2690, DOI 10.1007/s10620-015-3689-6
   Zhao S, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1401-z
   Zheng HC, 2008, HUM PATHOL, V39, P1042, DOI 10.1016/j.humpath.2007.11.009
NR 55
TC 5
Z9 5
U1 0
U2 5
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD SEP 22
PY 2017
VL 8
IS 42
BP 73017
EP 73028
DI 10.18632/oncotarget.20318
PG 12
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA FH9DW
UT WOS:000411509400133
PM 29069845
OA gold, Green Published, Green Submitted
DA 2022-04-25
ER

PT J
AU Zhang, J
   Gao, SH
   Zhang, YD
   Yi, HX
   Xu, MX
   Xu, JL
   Liu, H
   Ding, ZC
   He, HB
   Wang, HM
   Hao, Z
   Sun, LK
   Liu, Y
   Wei, F
AF Zhang, Jian
   Gao, Shuohui
   Zhang, Yandong
   Yi, Huixin
   Xu, Mengxian
   Xu, Jialun
   HuanLiu
   Ding, Zhichen
   He, Hongbin
   Wang, Hongmei
   Hao, Zhuo
   Sun, Liankun
   Liu, Yan
   Wei, Feng
TI MiR-216a-5p inhibits tumorigenesis in Pancreatic Cancer by targeting
   TPT1/mTORC1 and is mediated by LINC01133
SO INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES
LA English
DT Article
DE LINC01133; pancreatic cancer; miR-216a-5p; TPT1; tumor progression
ID TRANSLATIONALLY-CONTROLLED 1; TUMOR PROTEIN; HEPATOCELLULAR-CARCINOMA;
   CELL-PROLIFERATION; COLORECTAL-CANCER; PROGRESSION; METASTASIS;
   STATISTICS; ACTIVATION; INVASION
AB MiR-216a-5p has opposite effects on tumorigenesis and progression in the context of different tumors, acting as either a tumor suppressor or an oncogene. However, the expression and function of miR-216a-5p in pancreatic cancer (PC) is not well characterized.
   In this study, we found miR-216a-5p was significantly downregulated in PC tissues and cell lines, which showed a negative correlation with peripancreatic lymph, perineural invasion and TNM stage of PCs patients. We made use of functional assays to reveal that miR-216a-5p inhibited growth and migration of PC cells in vitro and in vivo. Then, by employing the bioinformatics analysis and luciferase reporter assay, we demonstrated TPT1 was a potential target of miR-216a-5p, which contributes to tumor malignance by mediating mTORC1 pathway-associated autophagy. Furthermore, bioinformatics analysis and RNA pulldown confirmed that miR-216a-5p was mediated by LINC01133, which sponge miR-216a-5p, as a competing endogenous RNA (ceRNA). Collectively, our study revealed an important role of LINC01133/miR-216a-5p/TPT1 axis in the genesis and progression of PCs, which provides potential biomarkers for clinical diagnosis and therapy of PCs.
C1 [Zhang, Jian; Zhang, Yandong; HuanLiu; Ding, Zhichen; Wei, Feng] Jilin Univ, Dept Hepatobiliary & Pancreas Surg, Hosp 1, Changchun, Peoples R China.
   [Yi, Huixin; Xu, Mengxian; Hao, Zhuo; Liu, Yan] Acad Mil Med Sci, Inst Mil Vet Med, Genet Engn Lab PLA, Changchun, Peoples R China.
   [Gao, Shuohui] Jilin Univ, Dept Gastrointestinal Colorectal Surg, China Japan Union Hosp, Changchun, Peoples R China.
   [Sun, Liankun] Jilin Univ, Coll Basic Med Sci, Dept Pathophysiol, Changchun, Peoples R China.
   [Xu, Jialun] Jilin Univ, Key Lab Zoonosis Res, Coll Vet Med, Minist Educ, Changchun, Peoples R China.
   [He, Hongbin; Wang, Hongmei] Shandong Normal Univ, Coll Life Sci, Ruminant Dis Res Ctr, Jinan, Peoples R China.
RP Wei, F (corresponding author), Jilin Univ, Hosp 1, Changchun, Peoples R China.; Liu, Y (corresponding author), Acad Mil Med Sci, Changchun, Peoples R China.
EM liu820512@163.com; wei_feng@jlu.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81972273, 31972720, 81772291]; Science &
   Technology Department of Jilin Province [20190701008GH, 20160101053JC];
   China Postdoctoral Science FoundationChina Postdoctoral Science
   Foundation [2018T110253]; Bethune B Project of Jilin University
   [450060521279]
FX The work was supported by grants from the National Natural Science
   Foundation of China (Nos. 81972273 to Feng Wei, 31972720 for Yan Liu,
   81772291 to Shuohui Gao), the Science & Technology Department of Jilin
   Province (Nos. 20190701008GH and 20160101053JC), the China Postdoctoral
   Science Foundation (No. 2018T110253), and the Bethune B Project of Jilin
   University (No. 450060521279).
CR Amson R, 2012, NAT MED, V18, P91, DOI 10.1038/nm.2546
   Bae SY, 2017, AUTOPHAGY, V13, P820, DOI 10.1080/15548627.2017.1287650
   Bai JG, 2019, J CELL BIOCHEM, V120, P10310, DOI 10.1002/jcb.28315
   Chen PJ, 2018, EXP THER MED, V15, P4039, DOI 10.3892/etm.2018.5881
   Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338
   Chen WM, 2013, CELL CYCLE, V12, P2321, DOI 10.4161/cc.25404
   Du J, 2017, ONCOTARGET, V8
   Du Q, 2019, J CLIN ENDOCR METAB, V104, P2419, DOI 10.1210/jc.2018-01851
   Foroughi K, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19123881
   Ge XL, 2019, ONCOGENE, V38, P3061, DOI 10.1038/s41388-018-0645-x
   Huang CS, 2018, CANCER LETT, V421, P63, DOI 10.1016/j.canlet.2018.02.020
   Jung J, 2011, ONCOGENE, V30, P2264, DOI 10.1038/onc.2010.604
   Kong JL, 2018, J SURG ONCOL, V118, P1326, DOI 10.1002/jso.25278
   Kong JL, 2016, CANCER LETT, V380, P476, DOI 10.1016/j.canlet.2016.07.015
   Li RZ, 2019, BIOCHEM BIOPH RES CO, V508, P1259, DOI 10.1016/j.bbrc.2018.12.053
   Li YR, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0882-5
   Liang LL, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0382-7
   Lo WY, 2012, J PROTEOMICS, V77, P154, DOI 10.1016/j.jprot.2012.07.039
   Sakai S, 2019, CANCER RES, V79, P2821, DOI 10.1158/0008-5472.CAN-18-3210
   Siegel RL, 2020, CA-CANCER J CLIN, V70, P7, DOI 10.3322/caac.21590
   Tao WY, 2019, BIOSCIENCE REP, V39, DOI 10.1042/BSR20181618
   Wu WM, 2019, CANCER SCI, V110, P1587, DOI 10.1111/cas.14009
   Yang B, 2018, BIOSCIENCE REPORTS, V38
   Yang XZ, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0874-1
   Yonemori K, 2017, ONCOTARGET, V8, P70097, DOI 10.18632/oncotarget.19591
   Zang CS, 2016, ONCOTARGET, V7, P11696, DOI 10.18632/oncotarget.7077
   Zhang F, 2013, MOL CANCER RES, V11, P1508, DOI 10.1158/1541-7786.MCR-13-0389
   Zhang Y, 2019, EUR REV MED PHARMACO, V23, P2469, DOI 10.26355/eurrev_201903_17394
   Zheng YF, 2019, J CELL BIOCHEM, V120, P4172, DOI 10.1002/jcb.27704
   Zhou Y, 2007, J BIOL CHEM, V282, P24731, DOI 10.1074/jbc.M702029200
NR 30
TC 9
Z9 10
U1 1
U2 2
PU IVYSPRING INT PUBL
PI LAKE HAVEN
PA PO BOX 4546, LAKE HAVEN, NSW 2263, AUSTRALIA
SN 1449-2288
J9 INT J BIOL SCI
JI Int. J. Biol. Sci.
PY 2020
VL 16
IS 14
BP 2612
EP 2627
DI 10.7150/ijbs.46822
PG 16
WC Biochemistry & Molecular Biology; Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics
GA MT6VW
UT WOS:000555111400010
PM 32792860
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Liu, HY
   Zhang, HS
   Liu, MY
   Li, HM
   Wang, XY
   Wang, M
AF Liu, Hui-Yun
   Zhang, Hong-Sheng
   Liu, Min-Yao
   Li, Hong-Ming
   Wang, Xin-Yu
   Wang, Miao
TI GLS1 depletion inhibited colorectal cancer proliferation and migration
   via redox/Nrf2/autophagy-dependent pathway
SO ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS
LA English
DT Article
DE GLS1; Redox; Autophagy; Colorectal cancer
ID GLUTAMINE-METABOLISM; AUTOPHAGY; ROS
AB Cancer cells can metabolize glutamine to replenish TCA cycle intermediates for cell survival. Glutaminase (GLS1) is over-expressed in multiple cancers, including colorectal cancer (CRC). However, the role of GLS1 in colorectal cancer development has not yet fully elucidated. In this study, we found that GLS1 levels were significantly increased in CRC cells. Knockdown of GLS1 by shRNAs as well as GLS1 inhibitor BPTES decreased DLD1 and SW480 cell proliferation, colony formation and migration. Knockdown of GLS1 as well as BPTES induced reactive oxygen species (ROS) production, down-regulation of GSH/GSSG ratio, an decrease in Nrf2 protein expression and an increase in cytoplasmic Nrf2 protein expression in DLD1 and SW480 cells. Furthermore, Knockdown of GLS1 as well as BPTES inhibited autophagy pathway, antioxidant NAC and Nrf2 activator could reversed inhibition of GLS1-mediated an decrease in autophagic flux in DLD1 and SW480 cells. Depletion of GLS1-induced inhibition of DLD1 and SW480 CRC cell proliferation, colony formation and migration was reversed by autophagy inducer rapamycin. These results suggest that targeting GLS1 might be a new potential therapeutic target for the treatment of CRC.
C1 [Liu, Hui-Yun; Zhang, Hong-Sheng; Liu, Min-Yao; Li, Hong-Ming; Wang, Xin-Yu; Wang, Miao] Beijing Univ Technol, Fac Environm & Life, Pingleyuan 100, Beijing 100124, Peoples R China.
RP Zhang, HS (corresponding author), Beijing Univ Technol, Fac Environm & Life, Pingleyuan 100, Beijing 100124, Peoples R China.
EM zhanghs@bjut.edu.cn
FU Beijing Natural Science FoundationBeijing Natural Science Foundation
   [7192014]; Open Project of Key Laboratory of Genomics and Precision
   Medicine, Chinese Academy of Sciences; National Laboratory of
   Biomacromolecules [2017kf02]; practical training plan for the cross
   training of high level talents in Beijing Universities [2017271];
   Beijing International Science and Technology Cooperation Base of
   Antivirus Drug
FX This study was supported by Beijing Natural Science Foundation (No.
   7192014) ; the Open Project of Key Laboratory of Genomics and Precision
   Medicine, Chinese Academy of Sciences; the National Laboratory of
   Biomacromolecules (No. 2017kf02) ; the practical training plan for the
   cross training of high level talents in Beijing Universities (No.
   2017271) ; Beijing International Science and Technology Cooperation Base
   of Antivirus Drug. We would like to thank Li Yan (Research Center for
   EcoEnvironmental Sciences, Chinese Academy of Sciences) and XiaoYan
   Zhang (Beijing Normal University) for helping confocal fluorescent
   microscope of GFPLC3.
CR Altman BJ, 2016, NAT REV CANCER, V16, P619, DOI 10.1038/nrc.2016.71
   Bott AJ, 2019, CANCERS, V11, DOI 10.3390/cancers11060770
   Cai J, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1814-8
   Choi YK, 2018, BIOMOL THER, V26, P19, DOI 10.4062/biomolther.2017.178
   Harris IS, 2020, TRENDS CELL BIOL, V30, P440, DOI 10.1016/j.tcb.2020.03.002
   Hayes JD, 2020, CANCER CELL, V38, P167, DOI 10.1016/j.ccell.2020.06.001
   Huang X, 2019, AUTOPHAGY, V15, P1258, DOI 10.1080/15548627.2019.1580105
   Katt WP, 2017, FUTURE MED CHEM, V9, P223, DOI 10.4155/fmc-2016-0190
   Kodama M, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15136-9
   Lee P, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-14374-1
   Levy JMM, 2017, NAT REV CANCER, V17, P528, DOI 10.1038/nrc.2017.53
   Li BH, 2019, EBIOMEDICINE, V39, P239, DOI 10.1016/j.ebiom.2018.11.063
   Masisi BK, 2020, HISTOPATHOLOGY, V76, P498, DOI 10.1111/his.14014
   Mates JM, 2019, CANCER LETT, V467, P29, DOI 10.1016/j.canlet.2019.09.011
   Mattiuzzi C, 2019, ANN TRANSL MED, V7, DOI 10.21037/atm.2019.07.91
   Ren L, 2020, CANCER METAB, V8, DOI 10.1186/s40170-020-0209-8
   Sotthibundhu A, 2016, STEM CELL RES THER, V7, DOI 10.1186/s13287-016-0425-x
   Sun HL, 2020, ARCH BIOCHEM BIOPHYS, V685, DOI 10.1016/j.abb.2020.108349
   Turano M, 2019, CANCERS, V11, DOI 10.3390/cancers11121932
   Vander Heiden MG, 2017, CELL, V168, DOI 10.1016/j.cell.2016.12.039
   Vurusaner B, 2012, FREE RADICAL BIO MED, V52, P7, DOI 10.1016/j.freeradbiomed.2011.09.035
   Wende AR, 2016, FREE RADICAL BIO MED, V100, P94, DOI 10.1016/j.freeradbiomed.2016.05.022
   Yang LF, 2017, ANNU REV BIOMED ENG, V19, P163, DOI 10.1146/annurev-bioeng-071516-044546
   Yu Y, 2018, J MOL MED, V96, P777, DOI 10.1007/s00109-018-1659-0
   Yuan LQ, 2015, ENDOCR-RELAT CANCER, V22, P577, DOI 10.1530/ERC-15-0192
   Zhang HS, 2020, LIFE SCI, V241, DOI 10.1016/j.lfs.2019.117114
   Zhang HS, 2019, J CELL MOL MED, V23, P3451, DOI 10.1111/jcmm.14241
   Zhang HS, 2018, INT J BIOCHEM CELL B, V95, P85, DOI 10.1016/j.biocel.2017.12.016
   Zhang J, 2017, EMBO J, V36, P1302, DOI 10.15252/embj.201696151
   Zhang X, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0993-y
NR 30
TC 2
Z9 2
U1 4
U2 13
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0003-9861
EI 1096-0384
J9 ARCH BIOCHEM BIOPHYS
JI Arch. Biochem. Biophys.
PD SEP 15
PY 2021
VL 708
AR 108964
DI 10.1016/j.abb.2021.108964
EA JUN 2021
PG 9
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA TE4RM
UT WOS:000669998500014
PM 34119480
DA 2022-04-25
ER

PT J
AU Zhang, ZZ
   Ju, FY
   Chen, F
   Wu, HY
   Chen, JY
   Zhong, J
   Shao, LM
   Zheng, S
   Wang, LJ
   Xue, M
AF Zhang, Zizhen
   Ju, Fangyu
   Chen, Fei
   Wu, Haoyue
   Chen, Jingyu
   Zhong, Jing
   Shao, Liming
   Zheng, Sheng
   Wang, Liangjing
   Xue, Meng
TI GDC-0326 Enhances the Effects of 5-Fu in Colorectal Cancer Cells by
   Inducing Necroptotic Death
SO ONCOTARGETS AND THERAPY
LA English
DT Article
DE GDC-0326; 5-fluorouracil; colorectal cancer; combination therapy
ID DRUG-COMBINATION; AUTOPHAGY; NVP-BYL719; EXPRESSION; APOPTOSIS
AB Aim: Chemoresistance to 5-fluorouracil (5-Fu) is common in colorectal cancer (CRC). Programmed necrosis (necroptosis) is an alternative form of programmed cell death regulated by receptor-interacting protein kinase (RIPK) 1 and 3, assumed as a novel target of cancer therapy. In this study, we aimed to explore whether a novel small molecular agent GDC-0326 could facilitate the effect of 5-Fu through necroptosis.
   Main Methods: Cell Counting Kit-8 (CCK-8) assay and colony formation were performed to confirm the function of GDC-0326 in CRC cells. Western blot and immunofluorescence were conducted to measure the altered expressions of RIPK1/RIPK3 induced by GDC-0326. Subcutaneous tumor models were used to evaluate the chemotherapeutic effects and concomitant side effects of GDC-0326 in vivo.
   Key Findings: We found that GDC-0326 effectively suppressed the growth of CRC cells in a dose-dependent manner. The induction of necroptosis by GDC-0326 was correlated with the modulation of RIPK1 and RIPK3. Necrostatin-1 and GSK-872, inhibitors of RIPK1 and RIPK3, respectively, could rescue the cell death induced by GDC-0326. In addition, in vitro and in vivo studies showed that 5-Fu plus GDC-0326 evinced a better antitumor efficacy by suppressing tumor growth and increasing tumor necrosis with no increased toxicity.
   Significance: This study demonstrates that GDC-0326 plus 5-Fu has augmented antitumor efficacy and acceptable safety, which might be a promising therapeutic strategy for CRC patients in the future.
C1 [Zhang, Zizhen; Ju, Fangyu; Chen, Fei; Chen, Jingyu; Zhong, Jing; Shao, Liming; Zheng, Sheng; Wang, Liangjing; Xue, Meng] Zhejiang Univ, Dept Gastroenterol, Affiliated Hosp 2, Sch Med, Hangzhou 310020, Peoples R China.
   [Zhang, Zizhen; Ju, Fangyu; Chen, Fei; Chen, Jingyu; Zhong, Jing; Shao, Liming; Zheng, Sheng; Wang, Liangjing; Xue, Meng] Zhejiang Univ, Inst Gastroenterol, Hangzhou 310000, Peoples R China.
   [Zhang, Zizhen; Ju, Fangyu; Chen, Fei; Chen, Jingyu; Zhong, Jing; Shao, Liming; Zheng, Sheng; Wang, Liangjing; Xue, Meng] Zhejiang Univ, Canc Ctr, Hangzhou 310000, Peoples R China.
   [Wu, Haoyue] Zhejiang Univ, Inst Genet, Sch Med, Hangzhou 310012, Peoples R China.
   [Wu, Haoyue] Zhejiang Univ, Dept Genet, Sch Med, Hangzhou 310012, Peoples R China.
RP Wang, LJ; Xue, M (corresponding author), Zhejiang Univ, Dept Gastroenterol, Affiliated Hosp 2, Sch Med, Hangzhou 310020, Peoples R China.; Wang, LJ; Xue, M (corresponding author), Zhejiang Univ, Inst Gastroenterol, Hangzhou 310000, Peoples R China.; Wang, LJ; Xue, M (corresponding author), Zhejiang Univ, Canc Ctr, Hangzhou 310000, Peoples R China.
EM wangljzju@zju.edu.cn; xuemeng@zju.edu.cn
RI Zhang, Zizhen/AAA-1539-2022
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81802348]; Zhejiang Provincial Natural
   Science FoundationNatural Science Foundation of Zhejiang Province
   [LY18H160009, LY16H160031]
FX This work was supported by the National Natural Science Foundation of
   China (grant nos. 82073229 and 81702308), Zhejiang Provincial Natural
   Science Foundation (grant nos. LY18H160009 and LY16H160031), and the
   National Natural Science Foundation of China (grant no. 81802348).
CR Ashton JC, 2015, CANCER RES, V75, P2400, DOI 10.1158/0008-5472.CAN-14-3763
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
   Chen CY, 2017, AM J TRANSL RES, V9, P5507
   Chou TC, 2010, CANCER RES, V70, P440, DOI 10.1158/0008-5472.CAN-09-1947
   Christofferson DE, 2010, CURR OPIN CELL BIOL, V22, P263, DOI 10.1016/j.ceb.2009.12.003
   Ding Z, 2019, PHARMACEUTICS, V11, DOI 10.3390/pharmaceutics11070328
   Dittrich L, 2021, J CLIN MED, V10, DOI 10.3390/jcm10010072
   Feng Y, 2018, NANOSCALE RES LETT, V13, DOI 10.1186/s11671-018-2716-x
   Fletcher JI, 2010, NAT REV CANCER, V10, P147, DOI 10.1038/nrc2789
   Fritsch C, 2014, MOL CANCER THER, V13, P1117, DOI 10.1158/1535-7163.MCT-13-0865
   Furet P, 2013, BIOORG MED CHEM LETT, V23, P3741, DOI 10.1016/j.bmcl.2013.05.007
   Gao JW, 2018, ONCOL REP, V40, P1971, DOI 10.3892/or.2018.6634
   Heffron TP, 2016, J MED CHEM, V59, P985, DOI 10.1021/acs.jmedchem.5b01483
   Ji MY, 2018, AM J CANCER RES, V8, P2402
   Kroemer G, 2009, CELL DEATH DIFFER, V16, P3, DOI 10.1038/cdd.2008.150
   Li YM, 2019, HEPATOLOGY, V70, P1564, DOI 10.1002/hep.30676
   Linkermann A, 2014, NEW ENGL J MED, V370, P455, DOI 10.1056/NEJMra1310050
   Liu F, 2020, CANCER MED-US, V9, P1079, DOI 10.1002/cam4.2746
   Lu XH, 2020, INT J BIOL SCI, V16, P1427, DOI 10.7150/ijbs.42962
   McNamara CR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056576
   Mishra SK, 2019, BBA-MOL CELL BIOL L, V1864, P158, DOI 10.1016/j.bbalip.2018.11.002
   Scheiblecker L, 2020, PHARMACEUTICALS-BASE, V13, DOI 10.3390/ph13120418
   Sinzger M, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-38907-x
   Soler A, 2016, CLIN CANCER RES, V22, P5805, DOI 10.1158/1078-0432.CCR-15-3051
   Tigu AB, 2020, MOLECULES, V25, DOI 10.3390/molecules25081947
   Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839
   Wang JH, 2020, CANCERS, V12, DOI 10.3390/cancers12113171
   Wang WC, 2016, BIOCHEM PHARMACOL, V121, P8, DOI 10.1016/j.bcp.2016.09.024
   Wosikowski K, 1997, CLIN CANCER RES, V3, P2405
   Xin Y, 2016, CANCER LETT, V379, P24, DOI 10.1016/j.canlet.2016.05.023
   Zhang J, 2011, GASTROENTEROLOGY, V141, P50, DOI 10.1053/j.gastro.2011.05.010
   Zhang L, 2015, TOXICOL LETT, V236, P43, DOI 10.1016/j.toxlet.2015.04.015
   Zhang YH, 2020, PHARMACOL RES, V155, DOI 10.1016/j.phrs.2020.104717
   Zhang ZB, 2020, NATURE, V579, P415, DOI 10.1038/s41586-020-2071-9
   Zheng W, 2018, BIOMED PHARMACOTHER, V106, P175, DOI 10.1016/j.biopha.2018.06.111
   Zhu YH, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-03164-8
NR 36
TC 0
Z9 0
U1 1
U2 3
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-6930
J9 ONCOTARGETS THER
JI OncoTargets Ther.
PY 2021
VL 14
BP 2519
EP 2530
DI 10.2147/OTT.S302334
PG 12
WC Biotechnology & Applied Microbiology; Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Oncology
GA RM7LT
UT WOS:000639841200001
PM 33880032
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Zhu, JL
   Cai, YS
   Xu, K
   Ren, XY
   Sun, J
   Lu, SM
   Chen, JH
   Xu, P
AF Zhu, Jialin
   Cai, Yongsong
   Xu, Ke
   Ren, Xiaoyu
   Sun, Jian
   Lu, Shemin
   Chen, Jinghong
   Xu, Peng
TI Beclin1 overexpression suppresses tumor cell proliferation and survival
   via an autophagy-dependent pathway in human synovial sarcoma cells
SO ONCOLOGY REPORTS
LA English
DT Article
DE Beclin1; proliferation; autophagy; apoptosis; synovial sarcoma
ID CANCER CELLS; OVARIAN-CANCER; BREAST-CANCER; PI3K/AKT/MTOR PATHWAY;
   COLORECTAL-CANCER; SIGNALING PATHWAY; MULTIPLE-MYELOMA; DOWN-REGULATION;
   APOPTOSIS; EXPRESSION
AB Beclin1 is an important autophagy-related protein, which is involved in both autophagy and apoptosis. In recent years, the antitumor effect of Beclin1 has received increased attention. In the present study, we established a stable Beclin1-overexpressing cell line with SW982 human synovial sarcoma cells. We found that Beclin1 overexpression decreased the cell viability, inhibited proliferation and induced apoptosis in SW982 cells. The expression levels of Bcl-2 and PCNA were decreased, while the levels of cleaved-caspase-3 and cleaved-PARP were increased. Beclin1 is closely related with autophagy, thus the autophagy-related markers LC3 and p62 were detected by western blot analysis, and transmission electron microscopy was used to observe autophagosomes. The results showed that the expression level of LC3II was increased and that of p62 was decreased. Moreover, many double membrane-enclosed autophagosomes were found in cells with Beclinl overexpression, which indicated that the autophagic activity was enhanced. To explore the effect of autophagy on the viability of SW982 cells, Atg5 was knocked down using siRNA to inhibit the autophagic activity. We found that autophagy contributed to the decrease in cell viability. Knockdown of Atg5 increased the viability and decreased the apoptotic rate of SW982 cells with Beclinl overexpression. The expression level of Bcl-2 was increased, while the expression levels of cleaved-caspase-3 and cleaved-PARP were decreased. We also found that the Akt/Bcl-2/caspase-9 pathway was involved. The phosphorylation of AKT was positively correlated with cell viability. The cleavage of caspase-9 was increased by Beclin1 overexpression and decreased by inhibition of autophagy. Altogether, our results suggested that both autophagy and apoptosis contributed to the antitumor effect of Beclin1 in SW982 cells.
C1 [Zhu, Jialin; Cai, Yongsong; Xu, Ke; Ren, Xiaoyu; Xu, Peng] Xi An Jiao Tong Univ, Hlth Sci Ctr, Xian Hong Hui Hosp, Dept Joint Surg, 555 Friendship East St, Xian 710054, Shaanxi, Peoples R China.
   [Sun, Jian; Lu, Shemin] Xi An Jiao Tong Univ, Hlth Sci Ctr, Dept Genet & Mol Biol, Xian 710061, Shaanxi, Peoples R China.
   [Chen, Jinghong] Xi An Jiao Tong Univ, Hlth Sci Ctr, Inst Endem Dis,Sch Publ Hlth, Key Lab Trace Elements & Endem Dis,Natl Hlth & Fa, Xian 710061, Shaanxi, Peoples R China.
RP Xu, P (corresponding author), Xi An Jiao Tong Univ, Hlth Sci Ctr, Xian Hong Hui Hosp, Dept Joint Surg, 555 Friendship East St, Xian 710054, Shaanxi, Peoples R China.
EM sousou369@163.com
RI Lu, Shemin/AAI-6479-2021; Lu, Shemin/M-3350-2018
OI Lu, Shemin/0000-0002-5535-8320; Lu, Shemin/0000-0001-8250-850X
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81271948, 81601877, 81171742]
FX The present study was supported by the National Natural Science
   Foundation of China (grant nos. 81271948, 81601877 and 81171742).
CR Al-Shenawy HA, 2016, APMIS, V124, P229, DOI 10.1111/apm.12498
   Bai HM, 2015, ONCOTARGET, V6, P25520, DOI 10.18632/oncotarget.4550
   Baspinar S, 2014, PATHOL RES PRACT, V210, P412, DOI 10.1016/j.prp.2014.02.008
   Cai MB, 2014, INT J MOL SCI, V15, P5292, DOI 10.3390/ijms15045292
   Cai YS, 2016, SCI REP-UK, V6, DOI 10.1038/srep37845
   Chen ZH, 2013, DIGEST DIS SCI, V58, P2887, DOI 10.1007/s10620-013-2732-8
   Chen ZY, 2016, TUMOR BIOL, V37, P4083, DOI 10.1007/s13277-015-4190-8
   Correa RJM, 2015, J OVARIAN RES, V8, DOI 10.1186/s13048-015-0182-y
   De Amicis F, 2016, ONCOTARGET, V7, P57955, DOI 10.18632/oncotarget.10799
   De Amicis F, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0403-4
   El Beaino M, 2016, J SURG ONCOL, V114, P490, DOI 10.1002/jso.24306
   Elgendy M, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6637
   Fukui M, 2015, PLANTA MED, V81, P838, DOI 10.1055/s-0035-1546132
   Galluzzi L, 2015, EMBO J, V34, P856, DOI 10.15252/embj.201490784
   Garbar C, 2015, INT J CLIN EXP PATHO, V8, P4344
   Hu YF, 2015, ONCOTARGETS THER, V8, DOI 10.2147/OTT.S86844
   Huang X, 2014, ONCOL REP, V31, P1761, DOI 10.3892/or.2014.3015
   Jiang N, 2015, GASTROENTEROLOGY, V148, pS1012, DOI [10.1016/S0016-5085(15)33456-9, DOI 10.1016/S0016-5085(15)33456-9]
   Ju LL, 2016, EUR REV MED PHARMACO, V20, P1993
   Jung G, 2015, ACTA HAEMATOL-BASEL, V134, P17, DOI 10.1159/000368848
   Jung YY, 2016, EXPERT OPIN THER TAR, V20, P167, DOI 10.1517/14728222.2016.1085971
   Katagiri H, 2015, INT J ONCOL, V47, P2037, DOI 10.3892/ijo.2015.3191
   Lamy L, 2013, CANCER CELL, V23, P435, DOI 10.1016/j.ccr.2013.02.017
   Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1
   Li WL, 2016, EXP THER MED, V11, P1259, DOI 10.3892/etm.2016.3054
   Li YC, 2014, CANCER LETT, V344, P239, DOI 10.1016/j.canlet.2013.11.001
   Lian J, 2011, CELL DEATH DIFFER, V18, P60, DOI 10.1038/cdd.2010.74
   Liang XH, 1998, J VIROL, V72, P8586, DOI 10.1128/JVI.72.11.8586-8596.1998
   Liu C, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-622
   Liu LS, 2017, J ALZHEIMERS DIS, V57, P723, DOI 10.3233/JAD-161136
   Liu Y, 2015, CELL DEATH DIFFER, V22, P367, DOI 10.1038/cdd.2014.143
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Loncarevic-Vasiljkovic N, 2016, NEUROCHEM INT, V96, P69, DOI 10.1016/j.neuint.2016.02.017
   Lu Y, 2016, MOL MED REP, V14, P4747, DOI 10.3892/mmr.2016.5834
   Ma K, 2016, ONCOL REP, V36, P1807, DOI 10.3892/or.2016.5003
   Oberstein A, 2007, J BIOL CHEM, V282, P13123, DOI 10.1074/jbc.M700492200
   Park JM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100819
   Rohatgi RA, 2015, ONCOGENE, V34, P5352, DOI 10.1038/onc.2014.454
   Rohatgi RA, 2016, MOL CELL ONCOL, V3, DOI 10.1080/23723556.2015.1030539
   Shimizu S, 2014, INT J MOL SCI, V15, P3145, DOI 10.3390/ijms15023145
   Song SS, 2016, AM J PHYSIOL-CELL PH, V310, pC99, DOI 10.1152/ajpcell.00092.2015
   Song X, 2016, ONCOTARGET, V7, P75790, DOI 10.18632/oncotarget.12414
   Sun CC, 2015, ONCOTARGET, V6, P25533, DOI 10.18632/oncotarget.4575
   Tai WT, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.18
   Wang WY, 2016, MOL MED REP, V14, P355, DOI 10.3892/mmr.2016.5219
   Wang YF, 2017, AM J CHINESE MED, V45, P123, DOI 10.1142/S0192415X17500094
   Wen YF, 2014, CELL REP, V7, P488, DOI 10.1016/j.celrep.2014.03.009
   Wong VKW, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.217
   Wu SH, 2015, INT J CLIN EXP PATHO, V8, P3882
   Xu K, 2015, ARTHRITIS RES THER, V17, DOI 10.1186/s13075-015-0892-y
   Yaser S, 2014, MED ONCOL, V31, DOI 10.1007/s12032-014-0958-8
   Ying HC, 2015, ONCOL LETT, V9, P1759, DOI 10.3892/ol.2015.2950
   Yu FS, 2016, ENVIRON TOXICOL, V31, P395, DOI 10.1002/tox.22053
   Yu KN, 2013, TOXICOL IN VITRO, V27, P1187, DOI 10.1016/j.tiv.2013.02.010
   Zhao ZQ, 2016, ONCOL LETT, V12, P63, DOI 10.3892/ol.2016.4606
NR 55
TC 18
Z9 20
U1 2
U2 15
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1021-335X
EI 1791-2431
J9 ONCOL REP
JI Oncol. Rep.
PD OCT
PY 2018
VL 40
IS 4
BP 1927
EP 1936
DI 10.3892/or.2018.6599
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA GR8JZ
UT WOS:000442971200010
PM 30066884
OA Green Submitted, Green Published, hybrid
DA 2022-04-25
ER

PT J
AU Wang, SS
   Du, H
   Sun, PS
AF Wang, Sisi
   Du, Hui
   Sun, Peisen
TI Long Noncoding RNA NEAT1 Contributes to the Tumorigenesis of Colorectal
   Cancer Through Regulating SLC38A1 Expression by Sponging miR-138
SO CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS
LA English
DT Article
DE colorectal cancer; miR-138; NEAT1
ID CELL-PROLIFERATION; PROMOTES; MIGRATION; TRANSPORTERS; PROGRESSION;
   PROGNOSIS; APOPTOSIS
AB Background: Colorectal cancer (CRC), a malignant tumor, has become a highly relevant social problem. Nuclear paraspeckle assembly transcript 1 (NEAT1) was reported as an oncogenic long noncoding RNA in diverse tumors, including CRC. Nevertheless, the mechanism of NEAT1 in CRC remains unknown.
   Materials and Methods: The expression levels of NEAT1 and solute carrier family 38 member 1 (SLC38A1) in CRC tissues and cells were detected by real-time quantitative polymerase chain reaction. The protein levels of p62, microtubule-associated protein light (LC3-I), LC3-II, and SLC38A1 were examined by Western blot assay. Cell proliferation, apoptosis, and invasion were measured by 3-(4, 5-dimethyl-2-thiazolyl)-2, 5-diphenyl-2-H-tetrazolium bromide (MTT), and flow cytometry and transwell assays, respectively. The interaction between miR-138 and NEAT1 or SLC38A1 was predicted by StarBase or TargetScan, and verified by the dual-luciferase reporter assay. The effect of NEAT1 on tumor growth was determined in CRC mice model.
   Results: The expression of NEAT1 and SLC38A1 was upregulated in CRC tissues and cells. NEAT1 knockdown or SLC38A1 downregulation restrained cell proliferation and invasion, and accelerated cell apoptosis and autophagy of CRC cells. NEAT1 acted as a sponge of miR-138 to regulate SLC38A1 expression. Furthermore, NEAT1 deficiency suppressed tumor growth in vivo.
   Conclusion: These studies disclosed that NEAT1 knockdown inhibited CRC progression by miR-138/SLC38A1 axis, providing an underlying target for CRC treatment.
C1 [Wang, Sisi; Du, Hui] Qingdao Municipal Hosp, Blood Purificat Ctr, Qingdao, Peoples R China.
   [Sun, Peisen] Qingdao Municipal Hosp, Hlth Management Ctr, Qingdao, Peoples R China.
RP Sun, PS (corresponding author), Qingdao Municipal Hosp, Hlth Management Ctr, 1 Jiaozhou Rd, Shibei Dist, Shandong, Peoples R China.
EM hlitwz@163.com
CR Albers A, 2001, PFLUG ARCH EUR J PHY, V443, P92, DOI 10.1007/s004240100663
   Arnold M, 2017, GUT, V66, P683, DOI 10.1136/gutjnl-2015-310912
   Bai XX, 2017, CELL PHYSIOL BIOCHEM, V43, P757, DOI 10.1159/000481559
   Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002
   Bian ZH, 2018, CLIN CANCER RES, V24, P4808, DOI 10.1158/1078-0432.CCR-17-2967
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
   Broer A, 2016, J BIOL CHEM, V291, P13194, DOI 10.1074/jbc.M115.700534
   Bror S, 2014, PFLUG ARCH EUR J PHY, V466, P155, DOI 10.1007/s00424-013-1393-y
   Chai YQ, 2016, CANCER MED-US, V5, P1588, DOI 10.1002/cam4.710
   Diao LY, 2018, ONCOTARGETS THER, V11, P2797, DOI 10.2147/OTT.S165147
   He C, 2019, BIOSCIENCE REP, V39, DOI 10.1042/BSR20181465
   Huarte M, 2015, NAT MED, V21, P1253, DOI 10.1038/nm.3981
   Jiang P, 2019, ONCOL LETT, V18, P2109, DOI 10.3892/ol.2019.10524
   Li Y, 2017, DIS MARKERS, V2017, DOI 10.1155/2017/5314649
   Liu JW, 2019, DIGEST DIS SCI, V64, P1868, DOI 10.1007/s10620-019-05506-9
   Long LM, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-275
   Luo Y, 2019, CANCER LETT, V440, P11, DOI 10.1016/j.canlet.2018.10.002
   Mackenzie B, 2004, PFLUG ARCH EUR J PHY, V447, P784, DOI 10.1007/s00424-003-1117-9
   Nyhan MJ, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2123-6
   Peng W, 2017, PATHOL ONCOL RES, V23, P651, DOI 10.1007/s12253-016-0172-4
   Pritchard CC, 2011, GUT, V60, P116, DOI 10.1136/gut.2009.206250
   Shan YJ, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0759-7
   Si YR, 2019, CELL MOL BIOL LETT, V24, DOI 10.1186/s11658-019-0175-8
   Wang K, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-343
   Wang R, 2016, J CANCER RES CLIN, V142, P2291, DOI 10.1007/s00432-016-2238-9
   Wu GZ, 2018, ARTIF CELL NANOMED B, V46, P579, DOI 10.1080/21691401.2018.1464459
   Xie J, 2014, BMC GASTROENTEROL, V14, DOI 10.1186/1471-230X-14-70
   Xie J, 2013, CHINESE J CANCER RES, V25, P514, DOI 10.3978/j.issn.1000-9604.2013.09.03
   Xu WB, 2017, BIOMED PHARMACOTHER, V95, P1112, DOI 10.1016/j.biopha.2017.09.019
   Yang QQ, 2017, INT J ONCOL, V50, P1801, DOI 10.3892/ijo.2017.3941
   Yu HM, 2019, CELL PROLIFERAT, V52, DOI 10.1111/cpr.12526
   Zhang JL, 2018, PATHOL ONCOL RES, V24, P109, DOI 10.1007/s12253-017-0233-3
   Zhang M, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-018-0656-7
   Zhao L, 2018, J CELL PHYSIOL, V233, P4044, DOI 10.1002/jcp.26072
   Zhong F, 2018, ACTA BIOCH BIOPH SIN, V50, P1190, DOI 10.1093/abbs/gmy130
   Zhou FF, 2017, J HUAZHONG U SCI-MED, V37, P30, DOI 10.1007/s11596-017-1690-3
NR 36
TC 3
Z9 3
U1 0
U2 2
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1084-9785
EI 1557-8852
J9 CANCER BIOTHER RADIO
JI Cancer Biother. Radiopharm.
PD NOV 1
PY 2021
VL 36
IS 9
BP 793
EP 802
DI 10.1089/cbr.2020.3608
EA JUL 2020
PG 10
WC Oncology; Medicine, Research & Experimental; Pharmacology & Pharmacy;
   Radiology, Nuclear Medicine & Medical Imaging
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Research & Experimental Medicine; Pharmacology & Pharmacy;
   Radiology, Nuclear Medicine & Medical Imaging
GA XK8JL
UT WOS:000586245200001
PM 32700988
DA 2022-04-25
ER

PT J
AU Jiang, Y
   Wang, XQ
   Hu, DD
AF Jiang, Ying
   Wang, Xiaoqin
   Hu, Daode
TI Furanodienone induces G0/G1 arrest and causes apoptosis via the
   ROS/MAPKs-mediated caspase-dependent pathway in human colorectal cancer
   cells: a study in vitro and in vivo
SO CELL DEATH & DISEASE
LA English
DT Article
ID OXIDATIVE STRESS; REACTIVE OXYGEN; SIGNALING PATHWAY; UP-REGULATION;
   NITRIC-OXIDE; MITOCHONDRIA; ACTIVATION; AUTOPHAGY; TARGET; CYCLE
AB Furanodienone, a major bioactive constituents of sesquiterpene derived from Rhizoma Curcumae, has been proven to possess the potent anticancer efficacy on human breast cancer cells. Here, we investigated the cytotoxicity of furanodienone on human colorectal carcinoma cell lines in vitro and in vivo, as well as its underlying molecular mechanisms in the induction of apoptosis. In this study, we found that furanodienone significantly inhibited proliferation of RKO and HT-29 cells, induced mitochondrial dysfunction characterized by collapse of mitochondrial transmembrane potential and reduction of ATP level, and promoted the production of reactive oxygen species (ROS) that functions upstream of caspase-dependent apoptosis. The antioxidant N-acetyl cysteine, a ROS scavenger, abolished this apoptosis induced by furanodienone. In addition, furanodienone elevated the expression of p-p38, p-JNK, but decreased p-ERK, as a result of the produced ROS. The specific inhibitors U0126, SP600125 and SB202190 attenuated the expression of MAPKs, and regulated the expression of cleaved caspase-8, - 9 and - 3. Furthermore, the potential inhibitory effect of furanodienone on CRC cells was also corroborated in mouse xenograft model. In conclusion, the results demonstrated that furanodienone-triggered ROS plays a pivotal role in apoptosis as an upstream molecule-modulating activity of caspases in mitochondrial pathway via stimulating MAPKs signaling pathway. Our finding may provide a novel candidate for development of antitumor drugs targeting on colorectal cancer.
C1 [Jiang, Ying; Wang, Xiaoqin; Hu, Daode] Shanghai Jiao Tong Univ, Sch Med, Shanghai Gen Hosp, Dept Clin Pharmacol, 100 Haining Rd, Shanghai 200080, Hongkou, Peoples R China.
RP Hu, DD (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Shanghai Gen Hosp, Dept Clin Pharmacol, 100 Haining Rd, Shanghai 200080, Hongkou, Peoples R China.
EM shanghaiyao@sina.com
FU Shanghai Committee of Science and TechnologyShanghai Science &
   Technology Committee [16401901400]; Health Bureau of Shanghai, China
   [2011ZJ021]; State Key Laboratory of Clinical Pharmacology Department of
   Shanghai General Hospital, Shanghai, China
FX We gratefully acknowledge the financial support of the Shanghai
   Committee of Science and Technology (16401901400), the Health Bureau of
   Shanghai, China (2011ZJ021) and the State Key Laboratory of Clinical
   Pharmacology Department of Shanghai General Hospital, Shanghai, China.
CR Basu A, 2006, FRONT BIOSCI-LANDMRK, V11, P1508, DOI 10.2741/1900
   Breitschopf K, 2000, MOL CELL BIOL, V20, P1886, DOI 10.1128/MCB.20.5.1886-1896.2000
   Burwell LS, 2008, ANTIOXID REDOX SIGN, V10, P579, DOI 10.1089/ars.2007.1845
   Cen J, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/7053451
   Chen WQ, 2014, CHINESE J CANCER RES, V26, P48, DOI 10.3978/j.issn.1000-9604.2014.01.08
   Cheng GL, 2013, TOXICOL IN VITRO, V27, P1082, DOI 10.1016/j.tiv.2013.02.005
   Degterev A, 2003, ONCOGENE, V22, P8543, DOI 10.1038/sj.onc.1207107
   Deng CH, 2004, J CHROMATOGR A, V1059, P149, DOI 10.1016/j.chroma.2004.10.005
   DeSantis CE, 2014, CA-CANCER J CLIN, V64, P252, DOI 10.3322/caac.21235
   Gao D, 2016, J CHROMATOGR B, V1014, P17, DOI 10.1016/j.jchromb.2016.01.003
   Guo CX, 2016, INT J NANOMED, V11, P5257, DOI 10.2147/IJN.S112030
   Guo CX, 2015, INT J NANOMED, V10, P1463, DOI 10.2147/IJN.S76114
   Hsiao PC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105342
   Huang GM, 2015, WORLD J GASTROENTERO, V21, P6194, DOI 10.3748/wjg.v21.i20.6194
   Huang HL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098943
   Junttila MR, 2008, FASEB J, V22, P954, DOI 10.1096/fj.06-7859rev
   KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33
   Kim EH, 2016, MOL CANCER THER, V15, P2620, DOI 10.1158/1535-7163.MCT-16-0332
   Kiraz Y, 2016, TUMOR BIOL, V37, P8471, DOI 10.1007/s13277-016-5035-9
   Li CL, 2014, ASIAN PAC J CANCER P, V15, P10407, DOI 10.7314/APJCP.2014.15.23.10407
   Li HY, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2014.543
   Li HG, 2014, ATHEROSCLEROSIS, V237, P208, DOI 10.1016/j.atherosclerosis.2014.09.001
   Li YJ, 2013, OXID MED CELL LONGEV, V2013, DOI 10.1155/2013/323607
   Li YW, 2011, CANCER CHEMOTH PHARM, V68, P1315, DOI 10.1007/s00280-011-1624-x
   Li YW, 2011, J CELL BIOCHEM, V112, P217, DOI 10.1002/jcb.22922
   Li ZR, 2013, MOL VIS, V19, P1656
   Ma EL, 2008, CANCER LETT, V271, P158, DOI 10.1016/j.canlet.2008.06.008
   Maillet A, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.185
   Makabe H, 2006, NAT PROD RES, V20, P680, DOI 10.1080/14786410500462900
   Marvibaigi M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0158942
   Moghadamtousi SZ, 2014, SCI WORLD J, DOI 10.1155/2014/768323
   Novak B, 2003, BIOCHEM SOC T, V31, P1526
   Rouhollahi E, 2015, BMC COMPLEM ALTERN M, V15, DOI 10.1186/s12906-015-0534-6
   Saleh AM, 2015, CELL PHYSIOL BIOCHEM, V35, P1943, DOI 10.1159/000374003
   Sankpal UT, 2016, ONCOTARGET, V7, P3186, DOI 10.18632/oncotarget.6553
   Schroeter H, 2003, BIOCHEM J, V372, P359, DOI 10.1042/BJ20030201
   Shen HM, 2006, FREE RADICAL BIO MED, V40, P928, DOI 10.1016/j.freeradbiomed.2005.10.056
   Shukla S, 2014, FREE RADICAL BIO MED, V76, P185, DOI 10.1016/j.freeradbiomed.2014.07.039
   Siegel RL, 2016, CA-CANCER J CLIN, V66, P7, DOI 10.3322/caac.21332
   Tamm I, 2001, LANCET ONCOL, V2, P33, DOI 10.1016/S1470-2045(00)00193-5
   Trachootham D, 2008, ANTIOXID REDOX SIGN, V10, P1343, DOI 10.1089/ars.2007.1957
   Vermeulen K, 2003, CELL PROLIFERAT, V36, P131, DOI 10.1046/j.1365-2184.2003.00266.x
   Wang XQ, 2017, PREP BIOCHEM BIOTECH, V47, P19, DOI 10.1080/10826068.2016.1155061
   Wang XQ, 2016, CHEM CENT J, V10, DOI 10.1186/s13065-016-0177-9
   Wu JH, 2016, ONCOTARGET, V7, P49834, DOI 10.18632/oncotarget.10486
   Wu WR, 2016, ONCOTARGET, V7, P52095, DOI 10.18632/oncotarget.10603
   Xu WS, 2014, AM J CHINESE MED, V42, P243, DOI 10.1142/S0192415X14500165
   Yan LJ, 2014, REDOX BIOL, V2, P165, DOI 10.1016/j.redox.2014.01.002
   Zhang QF, 2017, ONCOTARGET, V8, P71138, DOI 10.18632/oncotarget.11424
   Zhao DD, 2012, TOXICOL IN VITRO, V26, P595, DOI 10.1016/j.tiv.2012.02.004
   Zimmermann KC, 2001, PHARMACOL THERAPEUT, V92, P57, DOI 10.1016/S0163-7258(01)00159-0
NR 51
TC 39
Z9 43
U1 0
U2 7
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-4889
J9 CELL DEATH DIS
JI Cell Death Dis.
PD MAY
PY 2017
VL 8
AR e2815
DI 10.1038/cddis.2017.220
PG 14
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA EW0QG
UT WOS:000402195700068
PM 28542135
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Huang, SB
   Yang, ZNJ
   Yu, CR
   Sinicrope, FA
AF Huang, Shengbing
   Yang, Zhineng J.
   Yu, Chunrong
   Sinicrope, Frank A.
TI Inhibition of mTOR Kinase by AZD8055 Can Antagonize Chemotherapy-induced
   Cell Death through Autophagy Induction and Down-regulation of
   p62/Sequestosome 1
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID PANCREATIC-CANCER CELLS; MAMMALIAN TARGET; COLORECTAL-CANCER; APOPTOSIS;
   PHOSPHORYLATION; ACTIVATION; GROWTH; TUMORIGENESIS; DEGRADATION;
   CASPASE-8
AB AZD8055 is an ATP-competitive inhibitor of mammalian target of rapamycin (mTOR) that forms two multiprotein complexes, mTORC1 and mTORC2, and negatively regulates autophagy. We demonstrate that AZD8055 stimulates and potentiates chemotherapy-mediated autophagy, as shown by LC3I-II conversion and down-regulation of the ubiquitin-binding protein p62/sequestosome 1. AZD8055-induced autophagy was pro-survival as shown by its ability to attenuate cell death and DNA damage (p-H2AX), and to enhance clonogenic survival by cytotoxic chemotherapy. Autophagy inhibition by siRNA against Beclin 1 or LC3B, or by chloroquine, partially reversed the cytoprotective effect of AZD8055 that was independent of cell cycle inhibition. The pro-survival role of autophagy was confirmed using ectopic expression of Beclin 1 that conferred cytoprotection. To determine whether autophagy-mediated down-regulation of p62/sequestosome 1 contributes to its pro-survival role, we generated p62 knockdown cells using shRNA that showed protection from chemotherapy-induced cell death and DNA damage. We also overexpressed wild-type (wt) p62 that promoted chemotherapy-induced cell death, whereas mutated p62 at functional domains (PB1, UBA) failed to do so. The ability of ectopic wt p62 to promote cell death was blocked by AZD8055. AZD8055 was shown to inhibit phosphorylation of the autophagy-initiating kinase ULK1 at Ser(757) and inhibited known targets of mTORC1 (p-mTOR Ser(2448), p70S6K, p-S6, p4EBP1) and mTORC2 (p-mTOR Ser(2481), p-AKT Ser(473)). Knockdown of mTOR, but not Raptor or Rictor, reduced p-ULK1 at Ser(757) and enhanced chemotherapy-induced autophagy that resulted in a similar cytoprotective effect as shown for AZD8055. In conclusion, AZD8055 inhibits mTOR kinase and ULK1 phosphorylation to induce autophagy whose pro-survival effect is due, in part, to down-regulation of p62.
C1 [Sinicrope, Frank A.] Mayo Clin, Rochester, MN 55905 USA.
   Mayo Canc Ctr, Rochester, MN 55905 USA.
RP Sinicrope, FA (corresponding author), Mayo Clin, 200 1st St SW, Rochester, MN 55905 USA.
EM sinicrope.frank@mayo.edu
FU NCI, National Institutes of HealthUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Cancer Institute (NCI) [1 K05 CA142885-01]; Mayo Cancer Center
   [CA15083]; NATIONAL CANCER INSTITUTEUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Cancer Institute (NCI) [P30CA015083, K05CA142885] Funding Source: NIH
   RePORTER
FX This work was supported, in whole or in part, by NCI, National
   Institutes of Health Grant 1 K05 CA142885-01 (Senior Scientist Award, to
   F. A. S.), and the Mayo Cancer Center core Grant CA15083.
CR Bjorkoy G, 2005, J CELL BIOL, V171, P603, DOI 10.1083/jcb.200507002
   BLOMMAART EFC, 1995, J BIOL CHEM, V270, P2320, DOI 10.1074/jbc.270.5.2320
   Carayol N, 2010, P NATL ACAD SCI USA, V107, P12469, DOI 10.1073/pnas.1005114107
   Chang YY, 2009, BIOCHEM SOC T, V37, P232, DOI 10.1042/BST0370232
   Chresta CM, 2010, CANCER RES, V70, P288, DOI 10.1158/0008-5472.CAN-09-1751
   Copp J, 2009, CANCER RES, V69, P1821, DOI 10.1158/0008-5472.CAN-08-3014
   Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001
   Donaldson KM, 2003, P NATL ACAD SCI USA, V100, P8892, DOI 10.1073/pnas.1530212100
   Guertin DA, 2007, CANCER CELL, V12, P9, DOI 10.1016/j.ccr.2007.05.008
   Gulhati P, 2011, CANCER RES, V71, P3246, DOI 10.1158/0008-5472.CAN-10-4058
   Gulhati P, 2009, CLIN CANCER RES, V15, P7207, DOI 10.1158/1078-0432.CCR-09-1249
   Hosokawa N, 2009, AUTOPHAGY, V5, P973, DOI 10.4161/auto.5.7.9296
   Huang SB, 2008, CANCER RES, V68, P2944, DOI 10.1158/0008-5472.CAN-07-2508
   Huang SB, 2010, MOL CANCER THER, V9, P742, DOI 10.1158/1535-7163.MCT-09-1004
   Huang SB, 2010, AUTOPHAGY, V6, P256, DOI 10.4161/auto.6.2.11124
   Jin ZY, 2009, CELL, V137, P721, DOI 10.1016/j.cell.2009.03.015
   Jung CH, 2010, FEBS LETT, V584, P1287, DOI 10.1016/j.febslet.2010.01.017
   Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720
   Kim J, 2011, NAT CELL BIOL, V13, P132, DOI 10.1038/ncb2152
   Komatsu M, 2007, CELL, V131, P1149, DOI 10.1016/j.cell.2007.10.035
   Kroemer G, 2008, NAT REV MOL CELL BIO, V9, P1004, DOI 10.1038/nrm2529
   Lee CH, 2007, EMBO J, V26, P4812, DOI 10.1038/sj.emboj.7601900
   Lee CH, 2007, ANNU REV PHARMACOL, V47, P443, DOI 10.1146/annurev.pharmtox.47.120505.105359
   Lindsley JE, 2004, COMP BIOCHEM PHYS B, V139, P543, DOI 10.1016/j.cbpc.2004.06.014
   Long XM, 2007, J BIOL CHEM, V282, P18542, DOI 10.1074/jbc.M610736200
   Meric-Bernstam F, 2009, J CLIN ONCOL, V27, P2278, DOI 10.1200/JCO.2008.20.0766
   O'Reilly KE, 2006, CANCER RES, V66, P1500, DOI 10.1158/0008-5472.CAN-05-2925
   Pan JA, 2011, MOL CELL BIOL, V31, P3158, DOI 10.1128/MCB.05460-11
   Pankiv S, 2007, J BIOL CHEM, V282, P24131, DOI 10.1074/jbc.M702824200
   Pattingre S, 2008, BIOCHIMIE, V90, P313, DOI 10.1016/j.biochi.2007.08.014
   POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9
   Proud CG, 2009, BIOCHEM SOC T, V37, P227, DOI 10.1042/BST0370227
   Ronellenfitsch MW, 2009, BRAIN, V132, P1509, DOI 10.1093/brain/awp093
   Sanz L, 2000, EMBO J, V19, P1576, DOI 10.1093/emboj/19.7.1576
   Sarbassov DD, 2006, MOL CELL, V22, P159, DOI 10.1016/j.molcel.2006.03.029
   Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148
   Shaw RJ, 2004, P NATL ACAD SCI USA, V101, P3329, DOI 10.1073/pnas.0308061100
   Sudarsanam S, 2010, CURR OPIN DRUG DISC, V13, P31
   TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8
   White E, 2009, CLIN CANCER RES, V15, P5308, DOI 10.1158/1078-0432.CCR-07-5023
   Wilkes Gail, 2003, Clin J Oncol Nurs, V7, P353
NR 41
TC 52
Z9 53
U1 2
U2 11
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD NOV 18
PY 2011
VL 286
IS 46
BP 40002
EP 40012
DI 10.1074/jbc.M111.297432
PG 11
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 846TI
UT WOS:000296925700033
PM 21949121
OA hybrid, Green Published
DA 2022-04-25
ER

PT J
AU Kobayashi, Y
   Kashima, H
   Rahmanto, YS
   Banno, K
   Yu, Y
   Matoba, Y
   Watanabe, K
   Iijima, M
   Takeda, T
   Kunitomi, H
   Iida, M
   Adachi, M
   Nakamura, K
   Tsuji, K
   Masuda, K
   Nomura, H
   Tominaga, E
   Aoki, D
AF Kobayashi, Yusuke
   Kashima, Hiroyasu
   Rahmanto, Yohan Suryo
   Banno, Kouji
   Yu, Yu
   Matoba, Yusuke
   Watanabe, Keiko
   Iijima, Moito
   Takeda, Takashi
   Kunitomi, Haruko
   Iida, Miho
   Adachi, Masataka
   Nakamura, Kanako
   Tsuji, Kosuke
   Masuda, Kenta
   Nomura, Hiroyuki
   Tominaga, Eiichiro
   Aoki, Daisuke
TI Drug repositioning of mevalonate pathway inhibitors as antitumor agents
   for ovarian cancer
SO ONCOTARGET
LA English
DT Article
DE ovarian cancer; drug repositioning; statin; bisphosphonate; mevalonate
   pathway
ID TUBAL INTRAEPITHELIAL CARCINOMA; METABOLIC REQUIREMENTS;
   CELL-PROLIFERATION; COLORECTAL-CANCER; STATIN USE; GLUTATHIONE; MODEL;
   APOPTOSIS; SURVIVAL; RISK
AB Drug repositioning is an alternative strategy redirecting existing drugs for new disease. We have previously reported an antitumor effect of statins, antidyslipidemic drugs, on ovarian cancer in vitro and in vivo. In this study, we investigated the antitumor effects of other mevalonate pathway inhibitors and the mechanism of the antitumor effect from a metabolic perspective.
   The effects of inhibitors of the mevalonate pathway on tumor cell growth were evaluated in vitro. Bisphosphonates that inhibit this pathway are commonly used as antiosteoporotic drugs, and antitumor effects of the bisphosphonate were examined in vitro and in vivo. Metabolites in SKOV3 ovarian cancer cells were analyzed before and after lovastatin treatment, using capillary electrophoresis-mass spectrometry.
   All mevalonate pathway inhibitors showed concentration-dependent inhibitory effects on tumor cell growth. Particularly marked effects were obtained with inhibitors of farnesyltransferase and geranylgeranyltransferase. The bisphosphonate was also shown to have an antitumor effect in vivo. The expression of autophagy marker LC3A/3B was increased in cells after treatment. In metabolomics analysis, lovastatin treatment increased the metabolites involved in the tricarboxylic acid cycle while reducing the metabolites associated with glycolysis. Also it decreased glutathione and resulted to work with chemotherapeutic agents synergistically.
   Inhibition at any point in the mevalonate pathway, and especially of farnesyl pyrophosphate and geranylgeranyl pyrophosphate, suppresses growth of ovarian cancer cells. Inhibition of this pathway may induce autophagy, cause a shift to activation of the tricarboxylic acid cycle and enhance susceptibility to chemotherapy. Drug repositioning targeting mevalonate pathway for ovarian cancer deserves consideration for clinical application.
C1 [Kobayashi, Yusuke; Banno, Kouji; Matoba, Yusuke; Watanabe, Keiko; Iijima, Moito; Takeda, Takashi; Kunitomi, Haruko; Iida, Miho; Adachi, Masataka; Nakamura, Kanako; Tsuji, Kosuke; Masuda, Kenta; Nomura, Hiroyuki; Tominaga, Eiichiro; Aoki, Daisuke] Keio Univ, Dept Obstet & Gynecol, Sch Med, Tokyo, Japan.
   [Kobayashi, Yusuke; Kashima, Hiroyasu; Rahmanto, Yohan Suryo; Yu, Yu] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA.
   [Kashima, Hiroyasu] Shinshu Univ, Sch Med, Dept Obstet & Gynecol, Nagano, Japan.
   [Yu, Yu] Curtin Univ, Curtin Hlth Innovat Res Inst, Sch Pharm, Perth, WA, Australia.
RP Kobayashi, Y (corresponding author), Keio Univ, Dept Obstet & Gynecol, Sch Med, Tokyo, Japan.; Kobayashi, Y (corresponding author), Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA.
EM kobax@a2.keio.jp
RI Suryo Rahmanto, Yohan/K-8043-2018; Adachi, Masataka/M-3477-2015; Takeda,
   Takashi/AAB-1391-2019; Yu, Yu/AAD-7947-2019; Adachi,
   Masataka/T-7247-2019; Kobayashi, Yusuke/M-5174-2019
OI Suryo Rahmanto, Yohan/0000-0003-1453-7872; Adachi,
   Masataka/0000-0003-2974-8795; Takeda, Takashi/0000-0001-6686-5742; Yu,
   Yu/0000-0002-0209-0586; Adachi, Masataka/0000-0003-2974-8795; Kobayashi,
   Yusuke/0000-0002-4503-2845
FU KAKENHI (Japan Society for the Promotion of Science)Ministry of
   Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan
   Society for the Promotion of ScienceGrants-in-Aid for Scientific
   Research (KAKENHI) [16K20205]; Translational Research Network Program
   from Ministry of Education, Culture, Sports, Science and Technology
   (MEXT); Japan Society of Gynecologic OncologyMinistry of Education,
   Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for
   the Promotion of Science; Uehara Memorial FoundationUehara Memorial
   Foundation; Kanzawa Medical Research FoundationKanzawa Medical Research
   Foundation; Kobayashi Foundation for Cancer ResearchKobayashi Foundation
   for Cancer Research; Keio University Medical Science Fund
FX This works was supported by KAKENHI (Japan Society for the Promotion of
   Science, Grant-in-aid; 16K20205), Translational Research Network Program
   from Ministry of Education, Culture, Sports, Science and Technology
   (MEXT), Japan Society of Gynecologic Oncology, the Uehara Memorial
   Foundation, Kanzawa Medical Research Foundation, Kobayashi Foundation
   for Cancer Research, and Keio University Medical Science Fund.
CR Baigent C, 2005, LANCET, V366, P1267, DOI 10.1016/S0140-6736(05)67394-1
   Bhattarai D, 2016, CURR TOP MED CHEM, V16, P2156, DOI 10.2174/1568026616666160216153618
   Cardwell CR, 2014, J CLIN ONCOL, V32, P3177, DOI 10.1200/JCO.2013.54.4569
   Chou TC, 2010, CANCER RES, V70, P440, DOI 10.1158/0008-5472.CAN-09-1947
   Circu ML, 2008, FREE RADICAL RES, V42, P689, DOI 10.1080/10715760802317663
   Deshmukh A, 2016, MOL CANCER, V15, DOI 10.1186/s12943-016-0555-x
   Desideri E, 2012, AUTOPHAGY, V8, P1769, DOI 10.4161/auto.22037
   Feingold KR., 2000, ENDOTEXT
   Gamcsik MP, 2012, BIOMARKERS, V17, P671, DOI 10.3109/1354750X.2012.715672
   Greenaway JB, 2016, ONCOTARGET, V7, P47343, DOI 10.18632/oncotarget.10121
   Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809
   Hilgendorf KI, 2013, GENE DEV, V27, P1003, DOI 10.1101/gad.211326.112
   Kami K, 2013, METABOLOMICS, V9, P444, DOI 10.1007/s11306-012-0452-2
   Kim D, 2015, NATURE, V520, P363, DOI 10.1038/nature14363
   Kobayashi Y, 2015, CLIN CANCER RES, V21, P4652, DOI 10.1158/1078-0432.CCR-14-3368
   Kuhn E, 2012, AM J SURG PATHOL, V36, P1826, DOI 10.1097/PAS.0b013e31825ec07a
   Kurman RJ, 2016, AM J PATHOL, V186, P733, DOI 10.1016/j.ajpath.2015.11.011
   Lunt SY, 2011, ANNU REV CELL DEV BI, V27, P441, DOI 10.1146/annurev-cellbio-092910-154237
   Miyoshi I, 2002, MOL REPROD DEV, V63, P168, DOI 10.1002/mrd.10175
   Nielsen SF, 2012, NEW ENGL J MED, V367, P1792, DOI 10.1056/NEJMoa1201735
   Poynter JN, 2005, NEW ENGL J MED, V352, P2184, DOI 10.1056/NEJMoa043792
   Prat J, 2014, INT J GYNECOL OBSTET, V124, P1, DOI 10.1016/j.ijgo.2013.10.001
   Sakamoto A, 2015, CANCER RES, V75, P1445, DOI 10.1158/0008-5472.CAN-14-1560
   Sherman-Baust CA, 2014, J PATHOL, V233, P228, DOI 10.1002/path.4353
   Stine JE, 2016, ONCOTARGET, V7, P946, DOI 10.18632/oncotarget.5834
   Swanson KM, 2006, CURR CANCER DRUG TAR, V6, P15, DOI 10.2174/156800906775471743
   Takebayashi S, 2015, AGING CELL, V14, P689, DOI 10.1111/acel.12351
   Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262
   Trachootham D, 2009, NAT REV DRUG DISCOV, V8, P579, DOI 10.1038/nrd2803
   Ullah N, 2016, CURR CANCER DRUG TAR, V16, P563, DOI 10.2174/1568009616666151203224603
   Vazquez A, 2016, J CELL SCI, V129, P3367, DOI 10.1242/jcs.181016
   Villalba M, 2013, INT J BIOCHEM CELL B, V45, P106, DOI 10.1016/j.biocel.2012.04.024
   WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309
   Ward PS, 2012, CANCER CELL, V21, P297, DOI 10.1016/j.ccr.2012.02.014
   Yu O, 2014, J CLIN ONCOL, V32, P5, DOI 10.1200/JCO.2013.49.4757
NR 35
TC 33
Z9 34
U1 1
U2 11
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD SEP 22
PY 2017
VL 8
IS 42
BP 72147
EP 72156
DI 10.18632/oncotarget.20046
PG 10
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA FH9DW
UT WOS:000411509400063
PM 29069775
OA gold, Green Published, Green Submitted
DA 2022-04-25
ER

PT J
AU Goulielmaki, M
   Assimomytis, N
   Rozanc, J
   Taki, E
   Christodoulou, I
   Alexopoulos, LG
   Zoumpourlis, V
   Pintzas, A
   Papahatjis, D
AF Goulielmaki, Maria
   Assimomytis, Nikos
   Rozanc, Jan
   Taki, Eleni
   Christodoulou, Ioannis
   Alexopoulos, Leonidas G.
   Zoumpourlis, Vassilis
   Pintzas, Alexandros
   Papahatjis, Demetris
TI DPS-2: A Novel Dual MEK/ERK and PI3K/AKT pathway Inhibitor with Powerful
   Ex Vivo and In Vivo Anticancer Properties
SO TRANSLATIONAL ONCOLOGY
LA English
DT Article
ID METASTATIC COLORECTAL-CANCER; ESTROGEN-RECEPTOR MODULATORS; MEK
   INHIBITORS; COMBINED BRAF; DOUBLE-BLIND; ERK PATHWAY; OPEN-LABEL;
   KINASE; KRAS; RAF
AB Development of novel bioactive compounds against KRAS and/or BRAF mutant colorectal cancer (CRC) is currently an urgent need in oncology. In addition, single or multitarget kinase inhibitors against MEK/ERK and PI3K/AKT pathways are of potential therapeutic advantage. A new compound based on the benzothiophene nucleus was synthesized, based on previous important outcomes on other pharmaceutical preparations, to be tested as potential anticancer agent. Treatments by 2-5 mu M DPS-2 of several CRC and melanoma cell lines bearing either BRAF or KRAS mutations have shown a remarkable effect on cell viability in 2D and 3D cultures. More detailed analysis has shown that DPS-2 can kill cancer cells by apoptosis, reducing at the same time their autophagy properties. After testing activities of several signaling pathways, the compound was found to have a dual inhibition of two major proliferative/survival pathways, MEK/ERK and PI3K/AKT, in both CRC and melanoma, thus providing a mechanistic evidence for its potent anticancer activity. Antitumor activity of DPS-2 was further validated in vivo, as DPS-2 treatment of mouse xenografts of Colo-205 colorectal cancer cells remarkably reduced their tumor formation properties. Our findings suggest that DPS-2 has significant anti-KRAS/ anti-BRAF mutant CRC activity in preclinical models, potentially providing a novel treatment strategy for these difficult-to-treat tumors, which needs to be further exploited.
C1 [Goulielmaki, Maria; Assimomytis, Nikos; Taki, Eleni; Christodoulou, Ioannis; Zoumpourlis, Vassilis; Pintzas, Alexandros; Papahatjis, Demetris] Natl Hellen Res Fdn, Athens 11636, Greece.
   [Rozanc, Jan; Alexopoulos, Leonidas G.] TEPA Lefkippos Demokritos, 15343 Ag Paraskevi, Athens, Greece.
   [Alexopoulos, Leonidas G.] Natl Tech Univ Athens, Sch Mech Engn, Zografos 15780, Greece.
   [Rozanc, Jan] Univ Luxembourg, Life Sci Res Unit, Belvaux, Luxembourg.
RP Papahatjis, D (corresponding author), Vas Konstantinou 48, Athens 11635, Greece.
EM dpapah@eie.gr
RI Alexopoulos, Leonidas/AAN-1148-2021
OI Rozanc, Jan/0000-0003-4283-6087; ASSIMOMYTIS, NIKOS/0000-0003-3589-9995;
   Alexopoulos, Leonidas G/0000-0003-0425-166X
FU European Regional Development Fund of the European Union under the O.P.
   Competitiveness, Entrepreneurship and Innovation NSRF 2007-2013;
   European Regional Development Fund of the European Union under Regional
   Operational Program of Attica (STHENOS project within GSRT'S KRIPIS)
   [MIS 447985]; EU Horizon 2020-Mel-Plex [642295]; Hellenic Foundation for
   Research and Innovation (HFRI) [2400]; General Secretariat for Research
   and Technology (GSRT)Greek Ministry of Development-GSRT [2400]; project
   "STHENOS-b'' - Operational Programme "Competitiveness, Entrepreneurship
   and Innovation" (NSRF 2014-2020) [MIS 5002398]; EU (European Regional
   Development Fund)
FX This work was supported by Greece and the European Regional Development
   Fund of the European Union under the O.P. Competitiveness,
   Entrepreneurship and Innovation NSRF 2007-2013 and the Regional
   Operational Program of Attica (STHENOS project MIS 447985 within GSRT'S
   KRIPIS) and the grant EU Horizon 2020-Mel-Plex (grant no. 642295). The
   salary of the Phd candidate M.G. was supported by the Hellenic
   Foundation for Research and Innovation (HFRI) and the General
   Secretariat for Research and Technology (GSRT) under the HFRI PhD
   Fellowship grant (GA no. 2400). We also acknowledge support of this work
   by the project "STHENOS-b'' (MIS 5002398), which is funded by the
   Operational Programme "Competitiveness, Entrepreneurship and Innovation"
   (NSRF 2014-2020) and cofinanced by Greece and the EU (European Regional
   Development Fund).
CR Algazi AP, 2014, J CLIN ONCOL, V32, DOI 10.1200/jco.2014.32.15_suppl.9101
   Ascierto PA, 2016, LANCET ONCOL, V17, P1248, DOI 10.1016/S1470-2045(16)30122-X
   Bollag G, 2010, NATURE, V467, P596, DOI 10.1038/nature09454
   Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782
   Cheng H, 2010, PROG CARDIOVASC DIS, V53, P114, DOI 10.1016/j.pcad.2010.06.006
   Christodoulou I, 2013, STEM CELLS INT, V2013, DOI 10.1155/2013/246134
   Cohen MH, 2007, ONCOLOGIST, V12, P356, DOI 10.1634/theoncologist.12-3-356
   Colussi D, 2013, INT J MOL SCI, V14, P16365, DOI 10.3390/ijms140816365
   Corcoran RB, 2015, J CLIN ONCOL, V33, P4023, DOI 10.1200/JCO.2015.63.2471
   Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766
   Douillard JY, 2010, J CLIN ONCOL, V28, P4697, DOI 10.1200/JCO.2009.27.4860
   Goulielmaki M, 2016, ONCOTARGET, V7, P9188, DOI 10.18632/oncotarget.6942
   Halaban R, 2010, PIGM CELL MELANOMA R, V23, P190, DOI 10.1111/j.1755-148X.2010.00685.x
   Halilovic E, 2010, CANCER RES, V70, P6804, DOI 10.1158/0008-5472.CAN-10-0409
   Hatzivassiliou G, 2012, MOL CANCER THER, V11, P1143, DOI 10.1158/1535-7163.MCT-11-1010
   Hatzivassiliou G, 2010, NATURE, V464, P431, DOI 10.1038/nature08833
   Hoshino R, 1999, ONCOGENE, V18, P813, DOI 10.1038/sj.onc.1202367
   JONES CD, 1984, J MED CHEM, V27, P1057, DOI 10.1021/jm00374a021
   Keri RS, 2017, EUR J MED CHEM, V138, P1002, DOI 10.1016/j.ejmech.2017.07.038
   Do K, 2015, INVEST NEW DRUG, V33, P720, DOI 10.1007/s10637-015-0212-z
   Kopetz S, 2010, J CLIN ONCOL S, V28
   Liu TJ, 2009, MOL CANCER THER, V8, P2204, DOI 10.1158/1535-7163.MCT-09-0160
   Maes H, 2013, TRENDS MOL MED, V19, P428, DOI 10.1016/j.molmed.2013.04.005
   Malich G, 1997, TOXICOLOGY, V124, P179, DOI 10.1016/S0300-483X(97)00151-0
   Martinez-Garcia M, 2012, CLIN CANCER RES, V18, P4806, DOI 10.1158/1078-0432.CCR-12-0742
   Montagut C, 2009, CANCER LETT, V283, P125, DOI 10.1016/j.canlet.2009.01.022
   Niculescu-Duvaz D, 2013, BIOORGAN MED CHEM, V21, P1284, DOI 10.1016/j.bmc.2012.12.035
   Overk CR, 2007, CHEMMEDCHEM, V2, P1520, DOI 10.1002/cmdc.200700104
   Planchard D, 2017, LANCET ONCOL, V18, P1307, DOI 10.1016/S1470-2045(17)30679-4
   Prahallad A, 2012, NATURE, V483, P100, DOI 10.1038/nature10868
   Price TJ, 2014, LANCET ONCOL, V15, P569, DOI 10.1016/S1470-2045(14)70118-4
   Roux PP, 2007, J BIOL CHEM, V282, P14056, DOI 10.1074/jbc.M700906200
   Services NTPUSDoHaH, 2006, NIH PUBL
   Shimizu T, 2012, CLIN CANCER RES, V18, P2316, DOI 10.1158/1078-0432.CCR-11-2381
   Shukla SJ, 2010, DRUG DISCOV TODAY, V15, P997, DOI 10.1016/j.drudis.2010.07.007
   Solmi R, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-227
   Tabernero J, 2016, J CLIN ONCOL, V34, DOI 10.1200/JCO.2016.34.15_suppl.3544
   Tabernero J, 2014, J CLIN ONCOL, V32, DOI 10.1200/jco.2014.32.15_suppl.3518
   Tabernero J, 2015, LANCET ONCOL, V16, P499, DOI 10.1016/S1470-2045(15)70127-0
   Templeton IE, 2015, CURR OPIN PHARMACOL, V23, P61, DOI 10.1016/j.coph.2015.05.012
   Temraz S, 2015, INT J MOL SCI, V16, P22976, DOI 10.3390/ijms160922976
   Thorstensen L, 2005, NEOPLASIA, V7, P99, DOI 10.1593/neo.04448
   Tolcher AW, 2018, MOL CANCER THER, V17, P3, DOI 10.1158/1535-7163.MCT-17-0349
   Tripathi S, 2016, CANCER INFORM, V15, P1, DOI 10.4137/CIN.S34506
   Tsai J, 2008, P NATL ACAD SCI USA, V105, P3041, DOI 10.1073/pnas.0711741105
   Wallace OB, 2003, CURR TOP MED CHEM, V3, P1663, DOI 10.2174/1568026033451727
   Walther A, 2009, NAT REV CANCER, V9, P489, DOI 10.1038/nrc2645
   Wee S, 2009, CANCER RES, V69, P4286, DOI 10.1158/0008-5472.CAN-08-4765
   Yaeger R, 2015, CLIN CANCER RES, V21, P1313, DOI 10.1158/1078-0432.CCR-14-2779
   Yang H, 2012, CANCER RES, V72, P779, DOI 10.1158/0008-5472.CAN-11-2941
   Yu PF, 2015, TUMOR BIOL, V36, P2143, DOI 10.1007/s13277-014-2824-x
   Zimmer L, 2014, CLIN CANCER RES, V20, P4251, DOI 10.1158/1078-0432.CCR-14-0341
NR 52
TC 9
Z9 9
U1 1
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1936-5233
J9 TRANSL ONCOL
JI Transl. Oncol.
PD JUL
PY 2019
VL 12
IS 7
BP 932
EP 950
DI 10.1016/j.tranon.2019.04.005
PG 19
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA IB2SL
UT WOS:000470118900008
PM 31096110
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Huang, YH
   Lei, J
   Yi, GH
   Huang, FY
   Li, YN
   Wang, CC
   Sun, Y
   Dai, HF
   Tan, GH
AF Huang, Yong-Hao
   Lei, Jing
   Yi, Guo-Hui
   Huang, Feng-Ying
   Li, Yue-Nan
   Wang, Cai-Chun
   Sun, Yan
   Dai, Hao-Fu
   Tan, Guang-Hong
TI Coroglaucigenin induces senescence and autophagy in colorectal cancer
   cells
SO CELL PROLIFERATION
LA English
DT Article
ID CARDIAC-GLYCOSIDES; NATURAL-PRODUCTS; CELLULAR SENESCENCE; DRUG
   DISCOVERY; EVOLVING ROLE; THERAPY; CYCLE; CDK4; NEUROBLASTOMA;
   INHIBITION
AB Objectives: Coroglaucigenin (CGN), a natural product isolated from Calotropis gigantean by our research group, has been identified as a potential anti-cancer agent. However, the molecular mechanisms involved remain poorly understood.
   Materials and methods: Cell viability and cell proliferation were detected by MTT and BrdU assays. Flow cytometry, SA-beta-gal assay, western blotting and immunofluorescence were performed to determine CGN-induced apoptosis, senescence and autophagy. Western blotting, siRNA transfection and coimmunoprecipitation were carried out to investigate the mechanisms of CGN-induced senescence and autophagy. The anti-tumour activities of combination therapy with CGN and chloroquine were observed in mice tumour models.
   Results: We demonstrated that CGN inhibits the proliferation of colorectal cancer cells both in vitro and in vivo. We showed that the inhibition of cell proliferation by CGN is independent of apoptosis, but is associated with cell-cycle arrest and senescence in colorectal cancer cells. Notably, CGN induces protective autophagy that attenuates CGN-mediated cell proliferation. Functional studies revealed that CGN disrupts the association of Hsp90 with both CDK4 and Akt, leading to CDK4 degradation and Akt dephosphorylation, eventually resulting in senescence and autophagy, respectively. Combination therapy with CGN and chloroquine resulted in enhanced anti-tumour effects in vivo.
   Conclusions: Our results demonstrate that CGN induces senescence and autophagy in colorectal cancer cells and indicate that combining it with an autophagy inhibitor may be a novel strategy suitable for CGN-mediated anti-cancer therapy.
C1 [Huang, Yong-Hao; Lei, Jing; Yi, Guo-Hui; Huang, Feng-Ying; Li, Yue-Nan; Wang, Cai-Chun; Sun, Yan; Tan, Guang-Hong] Hainan Med Coll, Key Lab Trop Dis & Translat Med, Minist Educ, Haikou, Hainan, Peoples R China.
   [Huang, Yong-Hao; Lei, Jing; Yi, Guo-Hui; Huang, Feng-Ying; Li, Yue-Nan; Wang, Cai-Chun; Sun, Yan; Tan, Guang-Hong] Hainan Med Coll, Hainan Prov Key Lab Trop Med, Haikou, Hainan, Peoples R China.
   [Dai, Hao-Fu] Chinese Acad Trop Agr Sci, Inst Trop Biosci & Biotechnol, Haikou, Hainan, Peoples R China.
   [Yi, Guo-Hui] Hainan Med Coll, Publ Res Lab, Haikou, Hainan, Peoples R China.
RP Sun, Y; Tan, GH (corresponding author), Hainan Med Coll, Key Lab Trop Dis & Translat Med, Minist Educ, Haikou, Hainan, Peoples R China.; Sun, Y; Tan, GH (corresponding author), Hainan Med Coll, Hainan Prov Key Lab Trop Med, Haikou, Hainan, Peoples R China.; Dai, HF (corresponding author), Chinese Acad Trop Agr Sci, Inst Trop Biosci & Biotechnol, Haikou, Hainan, Peoples R China.
EM 18712798207@163.com; daihaofu@itbb.org.cn; tanhoho@163.com
OI Tan, Guang-Hong/0000-0002-6406-0331
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC)
FX National Natural Science Foundation of China
CR Acosta JC, 2012, TRENDS CELL BIOL, V22, P211, DOI 10.1016/j.tcb.2011.11.006
   Anders L, 2011, CANCER CELL, V20, P620, DOI 10.1016/j.ccr.2011.10.001
   Campaner S, 2010, NAT CELL BIOL, V12, P54, DOI 10.1038/ncb2004
   Cerella C, 2013, MITOCHONDRION, V13, P225, DOI 10.1016/j.mito.2012.06.003
   Collado M, 2010, NAT REV CANCER, V10, P51, DOI 10.1038/nrc2772
   Elgendy M, 2011, MOL CELL, V42, P23, DOI 10.1016/j.molcel.2011.02.009
   Garcia-Prat L, 2016, NATURE, V529, P37, DOI 10.1038/nature16187
   Gewirtz DA, 2014, CANCER RES, V74, P647, DOI 10.1158/0008-5472.CAN-13-2966
   Gheorghiade M, 2006, CIRCULATION, V113, P2556, DOI 10.1161/CIRCULATIONAHA.105.560110
   Gordaliza M, 2007, CLIN TRANSL ONCOL, V9, P767, DOI 10.1007/s12094-007-0138-9
   Green DR, 2014, CELL, V157, P65, DOI 10.1016/j.cell.2014.02.049
   He CC, 2009, ANNU REV GENET, V43, P67, DOI 10.1146/annurev-genet-102808-114910
   Janku F, 2011, NAT REV CLIN ONCOL, V8, P528, DOI 10.1038/nrclinonc.2011.71
   Jiang SH, 2017, NATURE, V544, P460, DOI 10.1038/nature22032
   Jung CH, 2010, FEBS LETT, V584, P1287, DOI 10.1016/j.febslet.2010.01.017
   Kang C, 2016, AUTOPHAGY, V12, P898, DOI 10.1080/15548627.2015.1121361
   Koehn FE, 2005, NAT REV DRUG DISCOV, V4, P206, DOI 10.1038/nrd1657
   Kroemer G, 2010, MOL CELL, V40, P280, DOI 10.1016/j.molcel.2010.09.023
   Lee YJ, 2014, NATURE, V510, P547, DOI 10.1038/nature13267
   Liu DH, 2011, BIOL PHARM BULL, V34, P1072, DOI 10.1248/bpb.34.1072
   Liu R, 2014, AUTOPHAGY, V10, P1241, DOI 10.4161/auto.28912
   Lorenz OR, 2014, MOL CELL, V53, P941, DOI 10.1016/j.molcel.2014.02.003
   Mahalingam D, 2009, BRIT J CANCER, V100, P1523, DOI 10.1038/sj.bjc.6605066
   Malumbres M, 2009, NAT REV CANCER, V9, P153, DOI 10.1038/nrc2602
   Maoyuan W, 2008, MODERN PHARM RES, V1, P4
   Marino G, 2014, NAT REV MOL CELL BIO, V15, P81, DOI 10.1038/nrm3735
   McConkey DJ, 2000, CANCER RES, V60, P3807
   Mishra BB, 2011, EUR J MED CHEM, V46, P4769, DOI 10.1016/j.ejmech.2011.07.057
   Molenaar JJ, 2008, CANCER RES, V68, P2599, DOI 10.1158/0008-5472.CAN-07-5032
   Newman RA, 2008, MOL INTERV, V8, P36, DOI 10.1124/mi.8.1.8
   Otto T, 2017, NAT REV CANCER, V17, P93, DOI 10.1038/nrc.2016.138
   Prassas I, 2008, NAT REV DRUG DISCOV, V7, P926, DOI 10.1038/nrd2682
   Puyol M, 2010, CANCER CELL, V18, P63, DOI 10.1016/j.ccr.2010.05.025
   Rader J, 2013, CLIN CANCER RES, V19, P6173, DOI 10.1158/1078-0432.CCR-13-1675
   Roninson IB, 2003, CANCER RES, V63, P2705
   Sherr CJ, 2016, CANCER DISCOV, V6, P353, DOI 10.1158/2159-8290.CD-15-0894
   Shi LS, 2010, J NAT PROD, V73, P1214, DOI 10.1021/np9005212
   Sun M, 2017, ONCOTARGET, V8, P32807, DOI 10.18632/oncotarget.16454
   Tian LM, 2011, EXP DERMATOL, V20, P836, DOI 10.1111/j.1600-0625.2011.01324.x
   VanArsdale T, 2015, CLIN CANCER RES, V21, P2905, DOI 10.1158/1078-0432.CCR-14-0816
   Wu CH, 2007, P NATL ACAD SCI USA, V104, P13028, DOI 10.1073/pnas.0701953104
   Yang PM, 2010, CANCER RES, V70, P7699, DOI 10.1158/0008-5472.CAN-10-1626
   Young ARJ, 2009, GENE DEV, V23, P798, DOI 10.1101/gad.519709
   Yu QY, 2006, CANCER CELL, V9, P23, DOI 10.1016/j.ccr.2005.12.012
   Zhang H, 2004, J MOL MED, V82, P488, DOI 10.1007/s00109-004-0549-9
   Zhang HL, 2016, TRENDS MOL MED, V22, P671, DOI 10.1016/j.molmed.2016.06.001
   Zou XH, 2002, GENE DEV, V16, P2923, DOI 10.1101/gad.1033002
NR 47
TC 8
Z9 8
U1 1
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0960-7722
EI 1365-2184
J9 CELL PROLIFERAT
JI Cell Prolif.
PD AUG
PY 2018
VL 51
IS 4
AR e12451
DI 10.1111/cpr.12451
PG 11
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA GO3UR
UT WOS:000439922800007
PM 29484762
OA Green Published
DA 2022-04-25
ER

PT J
AU Cao, X
   Yang, M
   Wei, RC
   Zeng, Y
   Gu, JF
   Huang, WD
   Yang, DQ
   Li, HL
   Ding, M
   Wei, N
   Zhang, KJ
   Xu, B
   Liu, XR
   Qian, QJ
   Liu, XY
AF Cao, X.
   Yang, M.
   Wei, R-C
   Zeng, Y.
   Gu, J-F
   Huang, W-D
   Yang, D-Q
   Li, H-L
   Ding, M.
   Wei, N.
   Zhang, K-J
   Xu, B.
   Liu, X-R
   Qian, Q-J
   Liu, X-Y
TI Cancer targeting Gene-Viro-Therapy of liver carcinoma by dual-regulated
   oncolytic adenovirus armed with TRAIL gene
SO GENE THERAPY
LA English
DT Article
DE cancer targeting Gene-Viro-Therapy; dual-regulated oncolytic adenovirus;
   tumor necrosis factor-related apoptosis-inducing ligand; autophagy;
   apoptosis
ID HUMAN HEPATOCELLULAR-CARCINOMA; PROGRAMMED CELL-DEATH;
   ANTITUMOR-ACTIVITY; ALPHA-FETOPROTEIN; TUMOR-CELLS; COLORECTAL-CANCER;
   SURVIVIN PROMOTER; MALIGNANT GLIOMA; HUMAN HEPATOMA; SV40 ENHANCER
AB Liver cancer is a common and aggressive malignancy, but available treatment approaches remain suboptimal. Cancer targeting Gene-Viro-Therapy (CTGVT) has shown excellent anti-tumor effects in a preclinical study. CTGVT takes advantage of both gene therapy and virotherapy by incorporating an anti-tumor gene into an oncolytic virus vector. Potent anti-tumor activity is achieved by virus replication and exogenous expression of the anti-tumor gene. A dual-regulated oncolytic adenoviral vector designated Ad.AFP.E1A.E1B (Delta 55) (Ad.AFP.D55 for short thereafter) was constructed by replacing the native viral E1A promoter with the simian virus 40 enhancer/alpha-fetoprotein (AFP) composite promoter (AFPep) based on an E1B-55K-deleted construct, ZD55. Ad.AFP.D55 showed specific replication and cytotoxicity in AFP-positive hepatoma cells. It also showed enhanced safety in normal cells when compared with the mono-regulated vector ZD55. To improve the anti-hepatoma activities of the virus, the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene was introduced into Ad.AFP.D55. Ad.AFP.D55-TRAIL exhibited remarkable anti-tumor activities in vitro and in vivo. Treatment with Ad.AFP.D55-TRAIL can induce both autophagy owing to the Ad.AFP.D55 vector and caspase-dependent apoptosis owing to the TRAIL protein. Therefore, Ad.AFP.D55-TRAIL could be a potential anti-hepatoma agent with anti-tumor activities due to AFP-specific replication and TRAIL-induced apoptosis. Gene Therapy (2011) 18, 765-777; doi:10.1038/gt.2011.16; published online 17 March 2011
C1 [Cao, X.; Gu, J-F; Huang, W-D; Yang, D-Q; Li, H-L; Ding, M.; Wei, N.; Zhang, K-J; Liu, X-R; Liu, X-Y] Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, Mol Cell Biol Lab, Shanghai 200031, Peoples R China.
   [Yang, M.] NCI, HIV & AIDS Malignancy Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.
   [Wei, R-C] Guangxi Normal Univ, Sch Life Sci, Guilin, Peoples R China.
   [Zeng, Y.] Chinese Acad Sci, Inst Pasteur Shanghai, Mol Virol Lab, Shanghai 200031, Peoples R China.
   [Li, H-L] Southwestern Univ, Chongqing Engn Res Ctr Floriculture, Dept Hort & Garden, Chongqing, Peoples R China.
   [Xu, B.] Tongji Univ, Sch Med, Shanghai Peoples Hosp 10, Dept Gen Surg, Shanghai 200092, Peoples R China.
   [Qian, Q-J; Liu, X-Y] Zhejiang Sci Tech Univ, Xinyuan Inst Med & Biotechnol, Hangzhou, Zhejiang, Peoples R China.
   [Qian, Q-J] Second Mil Med Univ, Eastern Hepatobiliary Surg Hosp, Lab Gene & Virus Therapy, Shanghai, Peoples R China.
RP Liu, XY (corresponding author), Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, Mol Cell Biol Lab, 320 Yueyang Rd, Shanghai 200031, Peoples R China.
EM xyliu@sibs.ac.cn
FU National Nature Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [30623003]; Science and Technology Commission
   of Shanghai MunicipalityScience & Technology Commission of Shanghai
   Municipality (STCSM) [06DZ22032]; National Basic Research Program of
   China (973 Program)National Basic Research Program of China [2004
   CB51804]; Hi-Tech Research Development Program of China (863
   Program)National High Technology Research and Development Program of
   China [2007AA 021006]; Chinese Academy of ScienceChinese Academy of
   Sciences [KSCX2-YW-R -09, R-04]; Zhejiang Sci-Tech UniversityZhejiang
   University of Science & Technology [0616033]
FX We are grateful to Professor Mu-Jun Zhao for providing the EGFP-LC3
   plasmid, Professor Hong-Bin Ji for providing the BEAS-2B cell line,
   Professor You-Cheng Xu for critical reading the manuscript, Dr Han Di
   for help with the molecular cloning and Ms Lan-Ying Sun for help with
   the cell culture. This study was supported by grants from the National
   Nature Science Foundation of China (No. 30623003), the Science and
   Technology Commission of Shanghai Municipality (No. 06DZ22032), the
   National Basic Research Program of China (973 Program) (No. 2004
   CB51804), the Hi-Tech Research Development Program of China (863
   Program) (No. 2007AA 021006), the Key Project of the Chinese Academy of
   Science (No. KSCX2-YW-R -09, R-04) and the Zhejiang Sci-Tech University
   Grant 0616033.
CR Abou El Hassan MAI, 2004, J VIROL, V78, P12243, DOI 10.1128/JVI.78.22.12243-12251.2004
   Baehrecke EH, 2002, NAT REV MOL CELL BIO, V3, P779, DOI 10.1038/nrm931
   Berry DL, 2008, AUTOPHAGY, V4, P359, DOI 10.4161/auto.5575
   Bischoff JR, 1996, SCIENCE, V274, P373, DOI 10.1126/science.274.5286.373
   Camper S A, 1991, Biotechnology, V16, P81
   Debnath J, 2005, AUTOPHAGY, V1, P66, DOI 10.4161/auto.1.2.1738
   Han J, 2008, J BIOL CHEM, V283, P19665, DOI 10.1074/jbc.M710169200
   Herrero-Martin G, 2009, EMBO J, V28, P677, DOI 10.1038/emboj.2009.8
   HERRMANN M, 1994, NUCLEIC ACIDS RES, V22, P5506, DOI 10.1093/nar/22.24.5506
   Hu BL, 2004, BIOCHEM BIOPH RES CO, V325, P1153, DOI 10.1016/j.bbrc.2004.10.154
   Ito H, 2006, JNCI-J NATL CANCER I, V98, P625, DOI 10.1093/jnci/djj161
   Jiang H, 2007, J NATL CANCER I, V99, P1410, DOI 10.1093/jnci/djm102
   Jiang H, 2008, AUTOPHAGY, V4, P118, DOI 10.4161/auto.5260
   Johnstone RW, 2008, NAT REV CANCER, V8, P782, DOI 10.1038/nrc2465
   Kagawa S, 2001, CANCER RES, V61, P3330
   Kim J, 2002, CANCER LETT, V180, P23, DOI 10.1016/S0304-3835(02)00017-4
   Kusaba M, 2007, J HEPATOL, V47, P546, DOI 10.1016/j.jhep.2007.04.017
   Lee JW, 2002, NEOPLASIA, V4, P312, DOI 10.1038/sj.neo.7900245
   Liu XY, 2006, CELL RES, V16, P25, DOI 10.1038/sj.cr.7310005
   Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239
   Mills KR, 2004, P NATL ACAD SCI USA, V101, P3438, DOI 10.1073/pnas.0400443101
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4
   NAKABAYASHI H, 1991, MOL CELL BIOL, V11, P5885, DOI 10.1128/MCB.11.12.5885
   Niwa Y, 2005, ONCOGENE, V24, P6406, DOI 10.1038/sj.onc.1208788
   O'Shea CC, 2004, CANCER CELL, V6, P611, DOI 10.1016/j.ccr.2004.11.012
   Ohguchi S, 1998, HEPATOLOGY, V27, P599, DOI 10.1002/hep.510270239
   ONDEK B, 1987, EMBO J, V6, P1017, DOI 10.1002/j.1460-2075.1987.tb04854.x
   Park KJ, 2007, CANCER RES, V67, P7327, DOI 10.1158/0008-5472.CAN-06-4766
   Parkin DM, 2001, INT J CANCER, V94, P153, DOI 10.1002/ijc.1440
   Pei ZF, 2004, HEPATOLOGY, V39, P1371, DOI 10.1002/hep.20203
   Puntel M, 2006, HUM GENE THER, V17, P531, DOI 10.1089/hum.2006.17.531
   Qiu SB, 2004, J INTERF CYTOK RES, V24, P219, DOI 10.1089/107999004323034097
   Seol JY, 2003, CANCER GENE THER, V10, P540, DOI 10.1038/sj.cgt.7700597
   Shao RP, 2005, MOL CANCER RES, V3, P219
   Takahashi M, 2002, MOL THER, V5, P627, DOI 10.1006/mthe.2002.0589
   Tamaoki T, 2000, ADV EXP MED BIOL, V465, P47
   Ulasov IV, 2009, BRIT J CANCER, V100, P1154, DOI 10.1038/sj.bjc.6604969
   Ulasov IV, 2009, INT J ONCOL, V34, P729, DOI 10.3892/ijo_00000199
   WASYLYK B, 1984, NUCLEIC ACIDS RES, V12, P5589, DOI 10.1093/nar/12.14.5589
   Wei N, 2009, BIOCHEM BIOPH RES CO, V388, P234, DOI 10.1016/j.bbrc.2009.07.142
   Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8
   Yang M, 2008, HUM GENE THER, V19, P343, DOI 10.1089/hum.2007.0137
   Zhang KJ, 2009, HUM GENE THER, V20, P818, DOI 10.1089/hum.2008.205
   Zhang YH, 2006, CANCER RES, V66, P4291, DOI 10.1158/0008-5472.CAN-05-1834
   Zhang ZL, 2003, CELL RES, V13, P481, DOI 10.1038/sj.cr.7290191
   Zhao L, 2006, CANCER GENE THER, V13, P1011, DOI 10.1038/sj.cgt.7700969
   Zou WG, 2004, ONCOGENE, V23, P457, DOI 10.1038/sj.onc.1207033
NR 47
TC 31
Z9 39
U1 2
U2 14
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0969-7128
EI 1476-5462
J9 GENE THER
JI Gene Ther.
PD AUG
PY 2011
VL 18
IS 8
BP 765
EP 777
DI 10.1038/gt.2011.16
PG 13
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Genetics & Heredity; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Genetics & Heredity; Research & Experimental Medicine
GA 806CE
UT WOS:000293779500003
PM 21412282
OA Bronze
DA 2022-04-25
ER

PT J
AU Zhang, J
   Yang, SZ
   Xu, B
   Wang, T
   Zheng, Y
   Liu, F
   Ren, FG
   Jiang, J
   Shi, HT
   Zou, BC
   Lu, XL
   Lu, SM
   Dong, L
AF Zhang, Jing
   Yang, Suzhen
   Xu, Bing
   Wang, Ting
   Zheng, Ying
   Liu, Fei
   Ren, Fenggang
   Jiang, Jiong
   Shi, Haitao
   Zou, Baicang
   Lu, Xiaolan
   Lu, Shemin
   Dong, Lei
TI p62 functions as an oncogene in colorectal cancer through inhibiting
   apoptosis and promoting cell proliferation by interacting with the
   vitamin D receptor
SO CELL PROLIFERATION
LA English
DT Article
DE apoptosis; colorectal cancer; proliferation; SQSTM1; p62; vitamin D
   receptor
ID DOWN-REGULATION; ACTIVATION; CARCINOGENESIS; CROSSROADS; CARCINOMA;
   AUTOPHAGY; PROTECTS; SYSTEM; CYCLE
AB Objectives The role of p62 in cancer is controversial. Evidence has shown that p62 is upregulated in different cancers and promotes tumour growth, such as in liver cancer and lung cancer. However, a recent study showed that the downregulation of p62 in hepatic stellate cells (HSCs) promotes hepatocellular carcinoma (HCC) development. How p62 is regulated in colorectal cancer (CRC) remains largely unknown. In this study, we aimed to investigate the roles and molecular mechanisms of p62 in CRC. Materials and Methods The expression levels of p62 in CRC tissues and adjacent non-tumour tissues were determined by immunohistochemistry (IHC). Stable p62-overexpression HCT116 cells and p62-knockdown SW480 cells were established with lentiviral vectors. The role of p62 in CRC was investigated in in vitro and in vivo functional studies. The relationship between p62 and the vitamin D receptor (VDR) was investigated by coimmunoprecipitation (Co-IP) assays. Results p62 was significantly upregulated in CRC, and a high p62 level was an independent risk factor for a poor prognosis in CRC patients. p62 promoted CRC migration and invasion by inhibiting apoptosis and promoting cell proliferation in vitro, and p62 aggravated tumour growth and metastasis in vivo. Co-IP assays indicated that p62 interacts with the VDR and may target the NRF2-NQO1 axis. Conclusions Our study suggested that p62 functions as an oncogene in CRC through inhibiting apoptosis and promoting cell proliferation by interacting with the VDR.
C1 [Zhang, Jing; Yang, Suzhen; Wang, Ting; Zheng, Ying; Jiang, Jiong; Shi, Haitao; Zou, Baicang; Dong, Lei] Xi An Jiao Tong Univ, Affiliated Hosp 2, Dept Digest Dis & Gastrointestinal Motil Res Room, Xian, Shaanxi, Peoples R China.
   [Xu, Bing] Xi An Jiao Tong Univ, Dept Digest Dis & Gastrointestinal Motil Res Room, Xian, Shaanxi, Peoples R China.
   [Liu, Fei] Xi An Jiao Tong Univ, Coll Stomatol, Clin Res Ctr Shanxi Prov Dent & Maxillofacial Dis, Xian, Shaanxi, Peoples R China.
   [Ren, Fenggang] Xi An Jiao Tong Univ, Natl Local Joint Engn Res Ctr Precis Surg & Regen, Xian, Shaanxi, Peoples R China.
   [Lu, Xiaolan] Shanghai Pudong Hosp, Fudan Affiliated Pudong Med Ctr, Dept Digest Dis, Shanghai, Peoples R China.
   [Lu, Shemin] Xi An Jiao Tong Univ, Hlth Sci Ctr, Sch Basic Med Sci, Dept Biochem & Mol Biol, Xian, Shaanxi, Peoples R China.
RP Dong, L (corresponding author), Xi An Jiao Tong Univ, Affiliated Hosp 2, Dept Digest Dis & Gastrointestinal Motil Res Room, Xian, Shaanxi, Peoples R China.; Lu, SM (corresponding author), Xi An Jiao Tong Univ, Hlth Sci Ctr, Sch Basic Med Sci, Dept Biochem & Mol Biol, Xian, Shaanxi, Peoples R China.
EM lushemin@xjtu.edu.cn; dong556@126.com
RI Lu, Shemin/AAI-6479-2021; Ren, Fenggang/A-1942-2015; Lu,
   Shemin/M-3350-2018
OI Lu, Shemin/0000-0002-5535-8320; Ren, Fenggang/0000-0002-9239-9279; Lu,
   Shemin/0000-0001-8250-850X
FU Central government guide the development of local science and technology
   special funds [2016ZY-HM-01]; National Natural Science Foundation of
   ChinaNational Natural Science Foundation of China (NSFC) [81801310]; Key
   research and development program of shanxi province [2017SF-100,
   2018ZDXMSF-055]; Shanxi provincial science & technology plan project
   [2016KTZDSF02-02]
FX Central government guide the development of local science and technology
   special funds, Grant/Award Number: 2016ZY-HM-01; National Natural
   Science Foundation of China, Grant/Award Number: 81801310; Key research
   and development program of shanxi province, Grant/Award Number:
   2017SF-100 and 2018ZDXMSF-055; Shanxi provincial science & technology
   plan project, Grant/Award Number: 2016KTZDSF02-02
CR Aleem E, 2004, CELL CYCLE, V3, P35
   Arnold M, 2017, GUT, V66, P683, DOI 10.1136/gutjnl-2015-310912
   Merchan BB, 2017, J STEROID BIOCHEM, V167, P203, DOI 10.1016/j.jsbmb.2016.11.020
   Bendris N, 2015, CELL CYCLE, V14, P1786, DOI 10.1080/15384101.2014.998085
   Binefa G, 2014, WORLD J GASTROENTERO, V20, P6786, DOI 10.3748/wjg.v20.i22.6786
   Bressenot A, 2009, J HISTOCHEM CYTOCHEM, V57, P289, DOI 10.1369/jhc.2008.952044
   Chandel N, 2012, AM J PHYSIOL-CELL PH, V303, pC607, DOI 10.1152/ajpcell.00076.2012
   Duran A, 2008, CANCER CELL, V13, P343, DOI 10.1016/j.ccr.2008.02.001
   Duran A, 2016, CANCER CELL, V30, P595, DOI 10.1016/j.ccell.2016.09.004
   Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213
   Ferrer-Mayorga G, 2017, GUT, V66, P1449, DOI 10.1136/gutjnl-2015-310977
   Galluzzi L, 2014, CELL, V159, P1263, DOI 10.1016/j.cell.2014.11.006
   Gearhart J, 2007, NEW ENGL J MED, V357, P1469, DOI 10.1056/NEJMp078126
   Grant WB, 2006, ANTICANCER RES, V26, P2687
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9
   Inami Y, 2011, J CELL BIOL, V193, P275, DOI 10.1083/jcb.201102031
   Kaur J, 2015, NAT REV MOL CELL BIO, V16, P461, DOI 10.1038/nrm4024
   Lamkanfi M, 2010, INT J BIOCHEM CELL B, V42, P21, DOI 10.1016/j.biocel.2009.09.013
   Lee LR, 2013, CANCER PREV RES, V6, P731, DOI 10.1158/1940-6207.CAPR-12-0493
   Majewski K, 2018, J BIOL REG HOMEOS AG, V32, P321
   Matthews D, 2010, J STEROID BIOCHEM, V121, P362, DOI 10.1016/j.jsbmb.2010.03.061
   Moan J, 2008, P NATL ACAD SCI USA, V105, P668, DOI 10.1073/pnas.0710615105
   Moscat J, 2009, CELL, V137, P1001, DOI 10.1016/j.cell.2009.05.023
   Murray A, 2017, ENDOCR-RELAT CANCER, V24, P181, DOI 10.1530/ERC-16-0463
   Nakai K, 2014, AM J HYPERTENS, V27, P586, DOI 10.1093/ajh/hpt160
   Nakayama S, 2017, CANCER MED-US, V6, P1264, DOI 10.1002/cam4.1093
   Plum LA, 2010, NAT REV DRUG DISCOV, V9, P941, DOI 10.1038/nrd3318
   Prentice A, 2008, NUTR REV, V66, pS153, DOI 10.1111/j.1753-4887.2008.00100.x
   Riachy R, 2006, APOPTOSIS, V11, P151, DOI 10.1007/s10495-006-3558-z
   Shen JL, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/9091879
   Soung YH, 2003, ONCOGENE, V22, P8048, DOI 10.1038/sj.onc.1206727
   Umemura A, 2016, CANCER CELL, V29, P935, DOI 10.1016/j.ccell.2016.04.006
   Wei Z, 2018, CELL, V173, P1135, DOI 10.1016/j.cell.2018.04.013
   Yamamoto M, 2018, PHYSIOL REV, V98, P1169, DOI 10.1152/physrev.00023.2017
   Yao TB, 2015, ANTIOXID REDOX SIGN, V22, P633, DOI 10.1089/ars.2014.5887
   Ye CF, 2018, J BIOL REG HOMEOS AG, V32, P497
   Zhang C, 2016, LIVER INT, V36, P68, DOI 10.1111/liv.12888
   Zhang YB, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.77
   Zheng Y, 2017, BONE RES, V5, DOI 10.1038/boneres.2017.23
NR 39
TC 12
Z9 15
U1 3
U2 11
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0960-7722
EI 1365-2184
J9 CELL PROLIFERAT
JI Cell Prolif.
PD MAY
PY 2019
VL 52
IS 3
AR e12585
DI 10.1111/cpr.12585
PG 13
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA IA0TW
UT WOS:000469271700021
PM 30793399
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Lachenmayer, A
   Toffanin, S
   Cabellos, L
   Alsinet, C
   Hoshida, Y
   Villanueva, A
   Minguez, B
   Tsai, HW
   Ward, SC
   Thung, S
   Friedman, SL
   Llovet, JM
AF Lachenmayer, Anja
   Toffanin, Sara
   Cabellos, Laia
   Alsinet, Clara
   Hoshida, Yujin
   Villanueva, Augusto
   Minguez, Beatriz
   Tsai, Hung-Wen
   Ward, Stephen C.
   Thung, Swan
   Friedman, Scott L.
   Llovet, Josep M.
TI Combination therapy for hepatocellular carcinoma: Additive preclinical
   efficacy of the HDAC inhibitor panobinostat with sorafenib
SO JOURNAL OF HEPATOLOGY
LA English
DT Article
DE Hepatocellular carcinoma; Liver cancer; Histone modification; Signaling
   pathways; Molecular therapies
ID HISTONE DEACETYLASE INHIBITORS; TARGETED THERAPIES; COLORECTAL-CANCER;
   LBH589; EXPRESSION; SIGNATURE; AUTOPHAGY; RELAPSE; MODELS; GROWTH
AB Background & Aims: Hepatocellular carcinoma (HCC) is a heterogeneous cancer in which sorafenib is the only approved systemic therapy. Histone deacetylases (HDAC) are commonly dysregulated in cancer and therefore represent promising targets for therapies, however their role in HCC pathogenesis is still unknown. We analyzed the expression of 11 HDACs in human HCCs and assessed the efficacy of the pan-HDAC inhibitor panobinostat alone and in combination with sorafenib in preclinical models of liver cancer.
   Methods: Gene expression and copy number changes were analyzed in a cohort of 334 human HCCs, while the effects of panobinostat and sorafenib were evaluated in three liver cancer cell lines and a murine xenograft model.
   Results: Aberrant HDAC expression was identified and validated in 91 and 243 HCCs, respectively. Upregulation of HDAC3 and HDAC5 mRNAs was significantly correlated with DNA copy number gains. Inhibiting HDACs with panobinostat led to strong anti-tumoral effects in vitro and vivo, enhanced by the addition of sorafenib. Cell viability and proliferation declined, while apoptosis and autophagy increased. Panobinostat increased histone H3 and HSP90 acetylation, downregulated BIRC5 (survivin) and upregulated CDH1. Combination therapy with panobinostat and sorafenib significantly decreased vessel density, and most significantly decreased tumor volume and increased survival in HCC xenografts.
   Conclusions: Aberrant expression of several HDACs and copy number gains of HDAC3 and HDAC5 occur in HCC. Treatment with panobinostat combined with sorafenib demonstrated the highest preclinical efficacy in HCC models, providing the rationale for clinical studies with this novel combination. (C) 2012 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
C1 [Lachenmayer, Anja; Toffanin, Sara; Cabellos, Laia; Alsinet, Clara; Minguez, Beatriz; Tsai, Hung-Wen; Ward, Stephen C.; Thung, Swan; Friedman, Scott L.; Llovet, Josep M.] Mt Sinai Sch Med, Div Liver Dis, Mt Sinai Liver Canc Program, Div Liver Dis,Dept Med,Tisch Canc Inst,Dept Patho, New York, NY 10029 USA.
   [Lachenmayer, Anja] Univ Hosp Dusseldorf, Dept Gen Visceral & Pediat Surg, Dusseldorf, Germany.
   [Toffanin, Sara] Natl Canc Inst, Dept Surg & Expt Oncol, Hepatooncol Grp, I-20133 Milan, Italy.
   [Alsinet, Clara; Villanueva, Augusto; Llovet, Josep M.] Univ Barcelona, CIBERehd, IDIBAPS, Barcelona Clin Liver Canc Grp BCLC,Translat Res L, Catalonia, Spain.
   [Alsinet, Clara; Villanueva, Augusto; Llovet, Josep M.] Univ Barcelona, CIBERehd, IDIBAPS, Liver Unit,Hosp Clin, Catalonia, Spain.
   [Hoshida, Yujin] Broad Inst Harvard & MIT, Canc Program, Cambridge, MA USA.
   [Llovet, Josep M.] Inst Catalana Recerca & Estudis Avancats, Barcelona, Catalonia, Spain.
RP Llovet, JM (corresponding author), Mt Sinai Sch Med, Div Liver Dis, Mt Sinai Liver Canc Program, Div Liver Dis,Dept Med,Tisch Canc Inst,Dept Patho, Box 1123,1425 Madison Ave,Room 11-70, New York, NY 10029 USA.
EM Josep.Llovet@mssm.edu
RI Augusto, Villanueva/F-9378-2012; Llovet, Josep M/ABB-6264-2021;
   Cabellos, Laia/L-4629-2017; Hoshida, Yujin/R-7513-2019; Llovet, Josep
   M/D-4340-2014; Ward, Stephen/C-5222-2013; Mínguez, Beatriz/N-4456-2014
OI Augusto, Villanueva/0000-0003-3585-3727; Llovet, Josep
   M/0000-0003-0547-2667; Llovet, Josep M/0000-0003-0547-2667; Mínguez,
   Beatriz/0000-0002-7276-9666
FU Bayer Pharmaceutical; NIH Institutes of HealthUnited States Department
   of Health & Human ServicesNational Institutes of Health (NIH) - USA
   [1RO1DK37340, 1RO1DK56621]; US National Institutes of Diabetes and
   Digestive and Kidney DiseasesUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Diabetes & Digestive & Kidney Diseases (NIDDK) [1R01DK076986-01];
   European CommissionEuropean CommissionEuropean Commission Joint Research
   Centre [259744]; Samuel Waxman Cancer Research Foundation; Spanish
   National Health InstituteSpanish Government [SAF-2010-16055]; Landon
   Foundation-American Association for Cancer Research; German Research
   Foundation (DFG)German Research Foundation (DFG); National Cancer
   Institute, Milan, ItalyUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Cancer
   Institute (NCI); Instituto de Salud Carlos IIIInstituto de Salud Carlos
   IIIEuropean Commission; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND
   KIDNEY DISEASESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Diabetes & Digestive & Kidney Diseases (NIDDK) [R01DK056621,
   R01DK037340, R01DK076986] Funding Source: NIH RePORTER; ICREAICREA
   Funding Source: Custom
FX Prof. Llovet has a Consultancy Agreement and received research support
   from Bayer Pharmaceutical. The other authors have no conflict of
   interest to declare.; The underlying research reported in this study was
   funded by the NIH Institutes of Health.; Josep M Llovet is supported by
   grants from the US National Institutes of Diabetes and Digestive and
   Kidney Diseases (1R01DK076986-01), the European Commission's Framework
   Programme 7 (HEPTROMIC, proposal No. 259744), the Samuel Waxman Cancer
   Research Foundation and the Spanish National Health Institute
   (SAF-2010-16055). The study was supported by the Landon
   Foundation-American Association for Cancer Research Innovator Award for
   International Collaboration in Cancer Research. Scott Friedman has
   grants from the National Institutes of Health (1RO1DK37340,
   1RO1DK56621). Anja Lachenmayer was supported by a fellowship from the
   German Research Foundation (DFG) and Sara Toffanin received a fellowship
   from National Cancer Institute, Milan, Italy. Clara Alsinet is supported
   by a grant from the Instituto de Salud Carlos III.
CR Abbas T, 2009, NAT REV CANCER, V9, P400, DOI 10.1038/nrc2657
   Atadja P, 2009, CANCER LETT, V280, P233, DOI 10.1016/j.canlet.2009.02.019
   Bolden JE, 2006, NAT REV DRUG DISCOV, V5, P769, DOI 10.1038/nrd2133
   Boumber Y, 2011, ONCOLOGY-NY, V25, P220
   Chiang DY, 2008, CANCER RES, V68, P6779, DOI 10.1158/0008-5472.CAN-08-0742
   Di Fazio P, 2010, CELL ONCOL, V32, P285, DOI 10.3233/CLO-2010-0511
   Dickinson M, 2009, BRIT J HAEMATOL, V147, P97, DOI 10.1111/j.1365-2141.2009.07837.x
   El-Serag HB, 2007, GASTROENTEROLOGY, V132, P2557, DOI 10.1053/j.gastro.2007.04.061
   Ellis L, 2009, BLOOD, V114, P380, DOI 10.1182/blood-2008-10-182758
   Finn RS, 2011, J CLIN ONCOL S, V29
   Geng L, 2006, CANCER RES, V66, P11298, DOI 10.1158/0008-5472.CAN-06-0049
   Hui LJ, 2008, J CLIN INVEST, V118, P3943, DOI 10.1172/JCI37156
   Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]
   LaBonte MJ, 2011, CANCER RES, V71, P3635, DOI 10.1158/0008-5472.CAN-10-2430
   Liu YL, 2010, AUTOPHAGY, V6, P1057, DOI 10.4161/auto.6.8.13365
   Llovet JM, 2003, LANCET, V362, P1907, DOI 10.1016/S0140-6736(03)14964-1
   Llovet JM, 2008, HEPATOLOGY, V48, P1312, DOI 10.1002/hep.22506
   Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857
   Llovet JM, 2006, GASTROENTEROLOGY, V131, P1758, DOI 10.1053/j.gastro.2006.09.014
   Llovet JM, 2008, JNCI-J NATL CANCER I, V100, P698, DOI 10.1093/jnci/djn134
   Lu YS, 2007, HEPATOLOGY, V46, P1119, DOI 10.1002/hep.21804
   Mahalingam D, 2010, CLIN CANCER RES, V16, P141, DOI 10.1158/1078-0432.CCR-09-1385
   Maiso P, 2009, LEUKEMIA, V23, P2265, DOI 10.1038/leu.2009.182
   Marks PA, 2001, NAT REV CANCER, V1, P194, DOI 10.1038/35106079
   Nagai T, 2011, MOL CANCER THER, V10, P169, DOI 10.1158/1535-7163.MCT-10-0544
   Portela A, 2010, NAT BIOTECHNOL, V28, P1057, DOI 10.1038/nbt.1685
   Prince HM, 2009, FUTURE ONCOL, V5, P601, DOI [10.2217/fon.09.36, 10.2217/FON.09.36]
   Prince HM, 2009, CLIN CANCER RES, V15, P3958, DOI 10.1158/1078-0432.CCR-08-2785
   Qian DZ, 2006, CLIN CANCER RES, V12, P634, DOI 10.1158/1078-0432.CCR-05-1132
   Rabinowitz JD, 2010, SCIENCE, V330, P1344, DOI 10.1126/science.1193497
   Roessler S, 2010, CANCER RES, V70, P10202, DOI 10.1158/0008-5472.CAN-10-2607
   Toffanin S, 2011, GASTROENTEROLOGY, V140, P1618, DOI 10.1053/j.gastro.2011.02.009
   Villanueva A, 2011, GASTROENTEROLOGY, V140, P1410, DOI 10.1053/j.gastro.2011.03.006
   Villanueva A, 2008, GASTROENTEROLOGY, V135, P1972, DOI 10.1053/j.gastro.2008.08.008
   von Burstin J, 2009, GASTROENTEROLOGY, V137, P361, DOI 10.1053/j.gastro.2009.04.004
   Weichert W, 2008, BRIT J CANCER, V98, P604, DOI 10.1038/sj.bjc.6604199
   Weichert W, 2008, CLIN CANCER RES, V14, P1669, DOI 10.1158/1078-0432.CCR-07-0990
   Weichert W, 2008, LANCET ONCOL, V9, P139, DOI 10.1016/S1470-2045(08)70004-4
   Witt O, 2009, CANCER LETT, V280, P123, DOI 10.1016/j.canlet.2009.02.038
   Wu LM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014460
   Wurmbach E, 2007, HEPATOLOGY, V45, P938, DOI 10.1002/hep.21622
NR 41
TC 146
Z9 150
U1 1
U2 43
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0168-8278
EI 1600-0641
J9 J HEPATOL
JI J. Hepatol.
PD JUN
PY 2012
VL 56
IS 6
BP 1343
EP 1350
DI 10.1016/j.jhep.2012.01.009
PG 8
WC Gastroenterology & Hepatology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Gastroenterology & Hepatology
GA 948OK
UT WOS:000304512300021
PM 22322234
OA Green Accepted
DA 2022-04-25
ER

PT J
AU Chang, CT
   Hseu, YC
   Thiyagarajan, V
   Huang, HC
   Hsu, LS
   Huang, PJ
   Liu, JY
   Liao, JW
   Yang, HL
AF Chang, Chia-Ting
   Hseu, You-Cheng
   Thiyagarajan, Varadharajan
   Huang, Hui-Chi
   Hsu, Li-Sung
   Huang, Pei-Jane
   Liu, Jer-Yuh
   Liao, Jiunn-Wang
   Yang, Hsin-Ling
TI Antrodia salmonea induces G(2) cell-cycle arrest in human
   triple-negative breast cancer (MDA-MB-231) cells and suppresses tumor
   growth in athyrnic nude mice
SO JOURNAL OF ETHNOPHARMACOLOGY
LA English
DT Article
DE Antrodia salmonea; Breast cancer; MDA-MB-231cells; G(2) cell-cycle
   arrest; Apoptosis; Autophagy
ID LEUKEMIA HL-60 CELLS; IN-VITRO; HEPATOCELLULAR-CARCINOMA;
   SELECTIVE-INHIBITION; MEDICINAL MUSHROOM; COLORECTAL-CANCER; COX-2
   INHIBITORS; DOWN-REGULATION; PHASE ARREST; APOPTOSIS
AB Ethnopharmacological relevance: Antrodia salmonea (AS), is a well-known folk medicinal mushroom in Taiwan, has been reported to exhibit anti-oxidant, anti-angiogenic, and anti-inflammatory effects.
   Materials and methods: In the present study, we examined the effects of AS on cell-cycle arrest in vitro in MDA-MB-231 cells and on tumor regression in vivo using an athymic nude mice model.
   Results: AS (0-200 mu g/mL) treatment significantly induced G(2) cell-cycle arrest in MDA-MB-231 cells by reducing the levels of cyclin B1, cyclin A, cyclin E, and CDC2 proteins. In addition, N-acetylcysteine (NAC) pretreatment prevented AS induced G(2) cell-cycle arrest, indicating that ROS accumulation and subsequent cell cycle arrest might be a major mechanism of AS-induced cytotoxicity. Further, AS treatment decreased COX-2 expression and induced PARP cleavage was significantly reversed by NAC pretreatment in MDA-MB-231 cells. The in vivo study results revealed that AS treatment was effective in terms of delaying the tumor incidence and reducing the tumor growth in MDA-MB-231-xenografted nude mice. TUNEL assay, immunohistochemical staining and Western blotting confirmed that AS significantly modulated the xenografted tumor progression as demonstrated by induction of apoptosis, autophagy, and cell-cycle arrest.
   Conclusion: Our data strongly suggest that Antrodia salmonea could be an anti-cancer agent for human breast cancer.
C1 [Chang, Chia-Ting; Yang, Hsin-Ling] China Med Univ, Coll Biopharmaceut & Food Sci, Inst Nutr, 91 Hsueh Shih Rd, Taichung 40402, Taiwan.
   [Hseu, You-Cheng; Thiyagarajan, Varadharajan] China Med Univ, Coll Biopharmaceut & Food Sci, Dept Cosmeceut, Cosmeceut, Taichung 40402, Taiwan.
   [Hseu, You-Cheng; Huang, Pei-Jane] Asia Univ, Dept Hlth & Nutr Biotechnol, Taichung 41354, Taiwan.
   [Huang, Hui-Chi] China Med Univ, Sch Chinese Pharmaceut Sci & Chinese Med Resource, Coll Biopharmaceut & Food Sci, Taichung 40402, Taiwan.
   [Hsu, Li-Sung] Chung Shan Med Univ, Inst Biochem & Biotechnol, Taichung 40402, Taiwan.
   [Liu, Jer-Yuh] China Med Univ, Grad Inst Canc Biol, Taichung 40402, Taiwan.
   [Liao, Jiunn-Wang] Natl Chung Hsing Univ, Grad Inst Vet Pathol, Taichung 402, Taiwan.
RP Yang, HL (corresponding author), China Med Univ, Coll Biopharmaceut & Food Sci, Inst Nutr, 91 Hsueh Shih Rd, Taichung 40402, Taiwan.
EM hlyang@mail.cmu.edu.tw
OI Liao, Jiunn-Wang/0000-0001-7374-1203
FU Ministry of Science and TechnologyMinistry of Education, Culture,
   Sports, Science and Technology, Japan (MEXT)
   [MOST-104-2320-B-039-040-MY3, MOST-103-2320-B-039-038-MY3,
   NSC-103-2622-B-039-001-CC2, CMU103-ASIA-12, CMU 103-ASIA-09]; Asia
   University; China Medical University, TaiwanChina Medical University
FX This work was supported by the grants MOST-104-2320-B-039-040-MY3,
   MOST-103-2320-B-039-038-MY3, NSC-103-2622-B-039-001-CC2, CMU103-ASIA-12,
   and CMU 103-ASIA-09 from the Ministry of Science and Technology, Asia
   University, and China Medical University, Taiwan.
CR Ahmad N, 2001, CLIN CANCER RES, V7, P1466
   Arun B, 2004, SEMIN ONCOL, V31, P22, DOI 10.1053/j.seminoncol.2004.03.042
   BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812
   Bocca C, 2014, EXPERT OPIN THER TAR, V18, P121, DOI 10.1517/14728222.2014.860447
   Centelles Josep J, 2012, ISRN Oncol, V2012, P139268, DOI 10.5402/2012/139268
   Chen CY, 2016, PLANTA MED, V82, P244, DOI 10.1055/s-0035-1558141
   Chen YK, 2015, J NUTR BIOCHEM, V26, P484, DOI 10.1016/j.jnutbio.2014.12.003
   Chiang SS, 2015, INT J MED MUSHROOMS, V17, P21, DOI 10.1615/IntJMedMushrooms.v17.i1.30
   Chien RC, 2015, INT J MED MUSHROOMS, V17, P567, DOI 10.1615/IntJMedMushrooms.v17.i6.70
   Cleator S, 2007, LANCET ONCOL, V8, P235, DOI 10.1016/S1470-2045(07)70074-8
   Davies G, 2002, ANN ONCOL, V13, P669, DOI 10.1093/annonc/mdf125
   Ferrandez A, 2003, CURR PHARM DESIGN, V9, P2229, DOI 10.2174/1381612033454036
   Fosslien E, 2000, CRIT REV CL LAB SCI, V37, P431, DOI 10.1080/10408360091174286
   Gopinathan L, 2011, RESULTS PROBL CELL D, V53, P365, DOI 10.1007/978-3-642-19065-0_16
   Hseu YC, 2008, FOOD CHEM TOXICOL, V46, P2680, DOI 10.1016/j.fct.2008.04.036
   Hseu YC, 2016, ONCOTARGET, V7, P22409, DOI 10.18632/oncotarget.7983
   Hseu YC, 2014, J ETHNOPHARMACOL, V153, P499, DOI 10.1016/j.jep.2014.03.012
   Hseu YC, 2014, FOOD CHEM TOXICOL, V66, P150, DOI 10.1016/j.fct.2014.01.035
   Hseu YC, 2012, J AGR FOOD CHEM, V60, P2385, DOI 10.1021/jf205053r
   Hseu YC, 2011, EVID-BASED COMPL ALT, V2011, DOI 10.1093/ecam/nep142
   Hsueh CT, 2000, CANCER CHEMOTH PHARM, V45, P389, DOI 10.1007/s002800051007
   Huang GJ, 2012, FOOD CHEM TOXICOL, V50, P1485, DOI 10.1016/j.fct.2012.01.041
   Kern MA, 2006, CANCER RES, V66, P7059, DOI 10.1158/0008-5472.CAN-06-0325
   Ko Eun-Yi, 2015, J Cancer Prev, V20, P223, DOI 10.15430/JCP.2015.20.4.223
   Liou GY, 2010, FREE RADICAL RES, V44, P479, DOI 10.3109/10715761003667554
   Liu CH, 2001, J BIOL CHEM, V276, P18563, DOI 10.1074/jbc.M010787200
   Liu XH, 1996, CANCER RES, V56, P5125
   Liu Y, 2013, SCI REP-UK, V3, DOI 10.1038/srep03098
   Ly JD, 2003, APOPTOSIS, V8, P115, DOI 10.1023/A:1022945107762
   MILAS L, 1995, EUR J CANCER, V31A, P1580, DOI 10.1016/0959-8049(95)00327-F
   Pan M. H., 2002, TANGERETIN INDUCES C
   Park SH, 2012, TOXICOL LETT, V212, P252, DOI 10.1016/j.toxlet.2012.06.007
   PRICE JE, 1990, CANCER RES, V50, P717
   Ramsay RG, 2003, INT J IMMUNOPATH PH, V16, P59
   Sarkar FH, 2007, MINI-REV MED CHEM, V7, P599
   Shah SP, 2012, NATURE, V486, P395, DOI 10.1038/nature10933
   Shen CC, 2006, PLANTA MED, V72, P199, DOI 10.1055/s-2005-916175
   Shen CC, 2008, J CHIN CHEM SOC-TAIP, V55, P854, DOI 10.1002/jccs.200800127
   Shen CC, 2007, PLANTA MED, V73, P1208, DOI 10.1055/s-2007-981591
   Shukla S, 2014, APOPTOSIS, V19, P883, DOI 10.1007/s10495-014-0971-6
   Simon HU, 2000, APOPTOSIS, V5, P415, DOI 10.1023/A:1009616228304
   Subbaramaiah K, 2000, J BIOL CHEM, V275, P14838, DOI 10.1074/jbc.275.20.14838
   Takahashi A, 1999, CIRC RES, V84, P543, DOI 10.1161/01.RES.84.5.543
   Tan W, 2011, CHIN MED-UK, V6, DOI 10.1186/1749-8546-6-27
   Tang JL, 2008, LANCET, V372, P1938, DOI 10.1016/S0140-6736(08)61354-9
   Tao L, 2014, TOXICOL LETT, V228, P1, DOI 10.1016/j.toxlet.2014.04.002
   Thiyagarajan V, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0141285
   Thiyagarajan V, 2013, BBA-GEN SUBJECTS, V1830, P4091, DOI 10.1016/j.bbagen.2013.04.027
   Tsai Z., 1985, USE EFFECT GANODERMA, P116
   Wang DZ, 2004, SEMIN ONCOL, V31, P64, DOI 10.1053/j.seminoncol.2004.01.008
   Watson J, 2013, OPEN BIOL, V3, DOI 10.1098/rsob.120144
   Yang HL, 2014, FOOD FUNCT, V5, P2278, DOI [10.1039/c4fo00423j, 10.1039/C4FO00423J]
   Yang, 2005, P 4 GEN ASS HLTH FOO
   Yang HL, 2014, J ETHNOPHARMACOL, V151, P394, DOI 10.1016/j.jep.2013.10.052
   Yao M, 2004, BRIT J CANCER, V90, P712, DOI 10.1038/sj.bjc.6601489
   Zhang ZY, 2013, MAR DRUGS, V11, P81, DOI 10.3390/md11010081
   Zhang ZY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027441
NR 57
TC 11
Z9 11
U1 0
U2 18
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0378-8741
J9 J ETHNOPHARMACOL
JI J. Ethnopharmacol.
PD JAN 20
PY 2017
VL 196
BP 9
EP 19
DI 10.1016/j.jep.2016.12.018
PG 11
WC Plant Sciences; Chemistry, Medicinal; Integrative & Complementary
   Medicine; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary
   Medicine
GA EJ9ER
UT WOS:000393529900002
PM 27986611
DA 2022-04-25
ER

PT J
AU Tezcan, G
   Garanina, EE
   Zhuravleva, MN
   Hamza, S
   Rizvanov, AA
   Khaiboullina, SF
AF Tezcan, Gulcin
   Garanina, Ekaterina E.
   Zhuravleva, Margarita N.
   Hamza, Shaimaa
   Rizvanov, Albert A.
   Khaiboullina, Svetlana F.
TI Rab GTPase Mediating Regulation of NALP3 in Colorectal Cancer
SO MOLECULES
LA English
DT Article
DE colorectal cancer; NALP3; inflammasome signalling; vesicle trafficking
   pathway; Rab GTPase
ID NF-KAPPA-B; INFLAMMASOME ACTIVATION; PROTEIN SECRETION; NLRP3;
   PROGRESSION; MECHANISM; AUTOPHAGY; COLITIS; IDENTIFICATION; MACROPHAGES
AB The NALP3 inflammasome signaling contributes to inflammation within tumor tissues. This inflammation may be promoted by the vesicle trafficking of inflammasome components and cytokines. Rab5, Rab7 and Rab11 regulate vesicle trafficking. However, the role of these proteins in the regulation of inflammasomes remains largely unknown. To elucidate the role of these Rab proteins in inflammasome regulation, HCT-116, a colorectal cancer (CRC) cell line expressing pDsRed-Rab5 wild type (WT), pDsRed-Rab5 dominant-negative (DN), pDsRed-Rab7 WT, pDsRed-Rab7 DN, pDsRed-Rab11 WT and pDsRed-Rab11 DN were treated with lipopolysaccharide (LPS)/nigericin. Inflammasome activation was analyzed by measuring the mRNA expression of NLRP3, Pro-CASP1, RAB39A and Pro-IL-1 beta, conducting immunofluorescence imaging and western blotting of caspase-1 and analysing the secretion levels of IL-1 beta using enzyme-linked immunosorbent assay (ELISA). The effects of Rabs on cytokine release were evaluated using MILLIPLEX MAP Human Cytokine/Chemokine Magnetic Bead Panel-Premixed 41 Plex. The findings showed that LPS/nigericin-treated cells expressing Rab5-WT indicated increased NALP3 expression and secretion of the IL-1 beta as compared to Rab5-DN cells. Caspase-1 was localized in the nucleus and cytosol of Rab5-WT cells but was localized in the cytosol in Rab5-DN cells. There were no any effects of Rab7 and Rab11 expression on the regulation of inflammasomes. Our results suggest that Rab5 may be a potential target for the regulation of NALP3 in the treatment of the CRC inflammation.
C1 [Tezcan, Gulcin; Garanina, Ekaterina E.; Zhuravleva, Margarita N.; Hamza, Shaimaa; Rizvanov, Albert A.; Khaiboullina, Svetlana F.] Kazan Fed Univ, Inst Fundamental Med & Biol, Kazan 420008, Russia.
   [Tezcan, Gulcin] Bursa Uludag Univ, Dept Fundamental Sci, Fac Dent, TR-16240 Bursa, Turkey.
   [Khaiboullina, Svetlana F.] Univ Nevada, Dept Microbiol & Immunol, Reno, NV 89557 USA.
RP Khaiboullina, SF (corresponding author), Kazan Fed Univ, Inst Fundamental Med & Biol, Kazan 420008, Russia.; Khaiboullina, SF (corresponding author), Univ Nevada, Dept Microbiol & Immunol, Reno, NV 89557 USA.
EM gulcintezcan@gmail.com; kathryn.cherenkova@gmail.com;
   k.i.t.t.1807@gmail.com; shaimaa.hamza@mail.ru; rizvanov@gmail.com;
   sv.khaiboullina@gmail.com
RI Hamza, Shaimaa/AAE-4652-2022; Rizvanov, Albert/H-4486-2013; Tezcan,
   Gulcin/AAH-3843-2020; Zhuravleva, Margarita N/M-3926-2016
OI Rizvanov, Albert/0000-0002-9427-5739; Zhuravleva, Margarita
   N/0000-0001-8592-5325; Hamza, Shaimaa/0000-0002-5012-4760; Tezcan,
   Gulcin/0000-0002-5956-8755
FU RFBRRussian Foundation for Basic Research (RFBR) [18-34-01000]; Russian
   Government Program of Competitive Growth of Kazan Federal University;
   Ministry of Education and Science of Russian FederationMinistry of
   Education and Science, Russian Federation [0671-2020-0058]
FX The reported study was funded by RFBR Grant #18-34-01000. This research
   was supported by the Russian Government Program of Competitive Growth of
   Kazan Federal University. A.A. Rizvanov was supported by the state
   assignment no. 0671-2020-0058 of the Ministry of Education and Science
   of Russian Federation. The study was partially accomplished in the
   Centre of the National Technology Initiative at the M.M. Shemyakin-Yu.A.
   Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of
   Sciences.
CR Afonina IS, 2017, NAT IMMUNOL, V18, P861, DOI 10.1038/ni.3772
   Ahechu P, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02918
   Aliper AM, 2014, CANCER MED-US, V3, P737, DOI 10.1002/cam4.239
   Allen IC, 2010, J EXP MED, V207, P1045, DOI 10.1084/jem.20100050
   Babicki S, 2016, NUCLEIC ACIDS RES, V44, pW147, DOI 10.1093/nar/gkw419
   Balkwill F, 2006, CANCER METAST REV, V25, P409, DOI 10.1007/s10555-006-9005-3
   Baroja-Mazo A, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-42298-4
   Bauernfeind FG, 2009, J IMMUNOL, V183, P787, DOI 10.4049/jimmunol.0901363
   Becker CE, 2016, J BIOL CHEM, V291, P24800, DOI 10.1074/jbc.A109.046102
   Brody H, 2015, NATURE, V521, pS1, DOI 10.1038/521S1a
   Conroy MJ, 2020, ADV EXP MED BIOL, V1231, P1, DOI 10.1007/978-3-030-36667-4_1
   Cotlet M, 2001, P NATL ACAD SCI USA, V98, P14398, DOI 10.1073/pnas.251532698
   Cypryk W, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02188
   Cypryk W, 2014, J PROTEOME RES, V13, P2468, DOI 10.1021/pr4012552
   da Silva SD, 2015, ONCOTARGET, V6, P21950, DOI 10.18632/oncotarget.4277
   Dinarello CA, 2002, CLIN EXP RHEUMATOL, V20, pS1
   Du QM, 2016, BIOCHEM PHARMACOL, V105, P42, DOI 10.1016/j.bcp.2016.02.017
   Franchi L, 2009, NAT IMMUNOL, V10, P241, DOI 10.1038/ni.1703
   Goody RS, 2017, BIOL CHEM, V398, P565, DOI 10.1515/hsz-2016-0274
   Grivennikov SI, 2013, SEMIN IMMUNOPATHOL, V35, P229, DOI 10.1007/s00281-012-0352-6
   Grosshans BL, 2006, P NATL ACAD SCI USA, V103, P11821, DOI 10.1073/pnas.0601617103
   Guo WJ, 2014, AUTOPHAGY, V10, P972, DOI 10.4161/auto.28374
   Hao CF, 2018, MINERVA ENDOCRINOL, V43, P253, DOI 10.23736/S0391-1977.17.02721-3
   Harris J, 2017, MOL IMMUNOL, V86, P10, DOI 10.1016/j.molimm.2017.02.013
   He Y, 2016, TRENDS BIOCHEM SCI, V41, P1012, DOI 10.1016/j.tibs.2016.09.002
   Hegedus K, 2016, MOL BIOL CELL, V27, P3132, DOI 10.1091/mbc.E16-03-0205
   Huber S, 2012, NATURE, V491, P259, DOI 10.1038/nature11535
   Hulsmans M, 2013, CARDIOVASC RES, V100, P7, DOI 10.1093/cvr/cvt161
   Huotari J, 2011, EMBO J, V30, P3481, DOI 10.1038/emboj.2011.286
   Husebye H, 2020, J IMMUNOL, V204
   Kesavardhana S, 2017, INT IMMUNOL, V29, P201, DOI 10.1093/intimm/dxx018
   Knodler A, 2010, P NATL ACAD SCI USA, V107, P6346, DOI 10.1073/pnas.1002401107
   Kumar AP, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0198632
   Langemeyer L, 2018, TRENDS CELL BIOL, V28, P957, DOI 10.1016/j.tcb.2018.06.007
   Lee DJ, 2015, J INVEST DERMATOL, V135, P2012, DOI 10.1038/jid.2015.119
   Lee J, 2012, J BIOL CHEM, V287, P4033, DOI 10.1074/jbc.M111.280065
   Lee S, 2006, NAT STRUCT MOL BIOL, V13, P264, DOI 10.1038/nsmb1064
   Li Guangpu, 2015, Methods Mol Biol, V1298, P1, DOI 10.1007/978-1-4939-2569-8_1
   Lin Y, 2018, AM J GASTROENTEROL, V113, pS130
   Lissner D, 2011, THESCIENTIFICWORLDJO, V11, P1536, DOI 10.1100/tsw.2011.139
   Lorey MB, 2017, MOL CELL PROTEOMICS, V16, pS187, DOI 10.1074/mcp.M116.064840
   Maksimow M, 2002, CYTOMETRY, V47, P243, DOI 10.1002/cyto.10079
   Mariathasan S, 2006, NATURE, V440, P228, DOI 10.1038/nature04515
   Martinon F, 2006, NATURE, V440, P237, DOI 10.1038/nature04516
   Mattera R, 2006, J BIOL CHEM, V281, P6874, DOI 10.1074/jbc.M509939200
   Pandey A, 2019, YALE J BIOL MED, V92, P481
   Pandya UM, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20020408
   Perera AP, 2018, MAMM GENOME, V29, P817, DOI 10.1007/s00335-018-9783-2
   PERREGAUX D, 1992, J IMMUNOL, V149, P1294
   Poteryaev D, 2010, CELL, V141, P497, DOI 10.1016/j.cell.2010.03.011
   Rink J, 2005, CELL, V122, P735, DOI 10.1016/j.cell.2005.06.043
   Rio D.C., 2010, COLD SPRING HARB PRO, V2010, DOI [10.1101/ pdb.prot5439, DOI 10.1101/PDB.PROT5439, 10.1101/pdb.prot5439]
   Rohrle N, 2020, ADV EXP MED BIOL, V1231, P79, DOI 10.1007/978-3-030-36667-4_8
   Saitoh T, 2008, NATURE, V456, P264, DOI 10.1038/nature07383
   Saitoh T, 2016, J ALLERGY CLIN IMMUN, V138, P28, DOI 10.1016/j.jaci.2016.05.009
   Sasaki T, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/546318
   Seto S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083324
   Sharma DK, 2003, J BIOL CHEM, V278, P7564, DOI 10.1074/jbc.M210457200
   Shi CS, 2012, NAT IMMUNOL, V13, P255, DOI 10.1038/ni.2215
   Shi JJ, 2014, NATURE, V514, P187, DOI 10.1038/nature13683
   Siegmund B, 2001, P NATL ACAD SCI USA, V98, P13249, DOI 10.1073/pnas.231473998
   Stenmark H, 2009, NAT REV MOL CELL BIO, V10, P513, DOI 10.1038/nrm2728
   Strack RL, 2009, BMC BIOTECHNOL, V9, DOI 10.1186/1472-6750-9-32
   Strowig T, 2012, NATURE, V481, P278, DOI 10.1038/nature10759
   Swanson KV, 2019, NAT REV IMMUNOL, V19, P477, DOI 10.1038/s41577-019-0165-0
   Takahashi S, 2012, J CELL SCI, V125, P4049, DOI 10.1242/jcs.102913
   Taniguchi K, 2014, SEMIN IMMUNOL, V26, P54, DOI 10.1016/j.smim.2014.01.001
   Tezcan G, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00451
   Tudela JG, 2015, J CELL SCI, V128, P3068, DOI 10.1242/jcs.170092
   Ungerback J, 2012, CARCINOGENESIS, V33, P2126, DOI 10.1093/carcin/bgs256
   Valimaki E, 2016, J IMMUNOL, V197, P3315, DOI 10.4049/jimmunol.1501840
   Valimaki E, 2013, MOL CELL PROTEOMICS, V12, P749, DOI 10.1074/mcp.M112.024661
   van Hezel ME, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18061285
   Wandinger-Ness A, 2014, CSH PERSPECT BIOL, V6, DOI 10.1101/cshperspect.a022616
   Wang H, 2016, EXP CELL RES, V342, P184, DOI 10.1016/j.yexcr.2016.03.009
   Wang LQ, 2016, J HEMATOL ONCOL, V9, DOI 10.1186/s13045-016-0351-5
   Wang SM, 2019, J NEUROINFLAMM, V16, DOI 10.1186/s12974-019-1535-z
   Wang X, 2008, ACTA PHARMACOL SIN, V29, P1275, DOI 10.1111/j.1745-7254.2008.00889.x
   Xing Y, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.206
   Yang Y, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1413-8
   Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055
NR 81
TC 4
Z9 4
U1 0
U2 2
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1420-3049
J9 MOLECULES
JI Molecules
PD OCT
PY 2020
VL 25
IS 20
AR 4834
DI 10.3390/molecules25204834
PG 20
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA OL7ZW
UT WOS:000585553900001
PM 33092247
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Aly, RGO
   El-Enbaawy, MIH
   Abd El-Rahman, SS
   Ata, NS
AF Aly, Rasha G. O.
   El-Enbaawy, Mona I. H.
   Abd El-Rahman, Sahar S.
   Ata, Nagwa S.
TI Antineoplastic activity of Salmonella Typhimurium outer membrane
   nanovesicles
SO EXPERIMENTAL CELL RESEARCH
LA English
DT Article
DE Bacterial outer membrane vesicles; Salmonella, antitumor; Apoptosis;
   Autophagy; Angiogenesis
ID ENDOTHELIAL GROWTH-FACTOR; DOWN-REGULATION; VESICLES; CANCER; CELLS;
   MODELS; INDUCE; CHEMOTHERAPY; EXPRESSION; AUTOPHAGY
AB Nano-sized Gram-negative bacterial outer membrane vesicles possess unique structural and immunostimulatory effects that could be exploited to regress tumors by alerting the host immune system and reversing the immunosuppressive tumor microenvironment. The current study was conducted to investigate the antitumor activity of the outer membrane vesicles (ST-OMVs) of Salmonella Typhimurium ATCC 14028, in vitro in human colorectal carcinoma (HTC116), breast cancer (MCF-7), and hepatocellular carcinoma (HepG2) cell lines and in vivo in Ehrlich solid carcinoma-bearing mice model either as a mono-immunotherapy or as an adjuvant to a commonly used conventional chemotherapy. In addition, we investigated the safety of ST-OMVs. Adult Swiss albino female mice with transplanted Ehrlich solid carcinoma were treated with either ST-OMVs, paclitaxel or a combination of both. Tumor volume, growth inhibition rate, quantitative RT-PCR of Bax and VEGF genes expression, histopathology and immune-expression of caspase-3, Beclin-1, CD49b and Ki-67 were all analyzed. Our results showed that ST-OMVs significantly decreased tumor volume, significantly increased tumor growth inhibition rate, upregulated the immunohistochemical expression of caspase-3, Beclin-1, and CD49b (enhanced recruitment of NK cells). Furthermore, ST-OMVs down-regulated the expression of Ki-67, increased Bax gene expression and decreased VEGF gene expression as detected by qRT-PCR analysis. Histologically, ST-OMVs promoted apoptosis, decreased tumor invasion and mitotic activities. Moreover, ST-OMVs showed a remarkable cytotoxic activity in various investigated in vitro cancer cell lines. Our findings demonstrate potential antitumor activity of ST-OMVs that might be used as a promising safe antitumor immunotherapy or an adjuvant to conventional chemotherapeutic drugs, resolving some of their problems.
C1 [Aly, Rasha G. O.] Directorate Vet Med, Luxor, Egypt.
   [El-Enbaawy, Mona I. H.] Fac Vet Med, Dept Microbiol, Cairo, Egypt.
   [Abd El-Rahman, Sahar S.] Fac Vet Med, Dept Pathol, Cairo, Egypt.
   [Ata, Nagwa S.] Natl Res Ctr, Dept Microbiol, Cairo, Egypt.
RP Abd El-Rahman, SS (corresponding author), Fac Vet Med, Dept Pathol, Cairo, Egypt.
EM saharsamirmah@cu.edu.eg
OI Abd El-Rahman, Sahar S/0000-0001-8638-1737
CR ABDULAMIR AS, 2013, CANC THER, V8, P10
   Alaniz RC, 2007, J IMMUNOL, V179, P7692, DOI 10.4049/jimmunol.179.11.7692
   Arruebo Manuel, 2011, Cancers (Basel), V3, P3279, DOI 10.3390/cancers3033279
   Bancroft J.D., 2008, THEORY PRACTICE HIST
   Barbuti AM, 2015, CANCERS, V7, P2360, DOI 10.3390/cancers7040897
   Bincoletto C, 2005, INT IMMUNOPHARMACOL, V5, P679, DOI 10.1016/j.intimp.2004.11.015
   Bitto NJ, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18061287
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
   Buchser WJ, 2012, CANCER RES, V72, P2970, DOI 10.1158/0008-5472.CAN-11-3396
   Cespedes M V, 2006, Clin Transl Oncol, V8, P318
   Chang WW, 2014, INT J MOL SCI, V15, P14546, DOI 10.3390/ijms150814546
   Durrett R, 2013, NOT AMS, V60, P304, DOI [DOI 10.1090/noti953, 10.1090/noti953, DOI 10.1090/NOTI953]
   El-Bahy AA., 2012, ADV CANC RES TREAT, V125978, DOI [10.5171/2012.125978, DOI 10.5171/2012.125978]
   Ellis TN, 2010, MICROBIOL MOL BIOL R, V74, P81, DOI 10.1128/MMBR.00031-09
   Ferrara N, 2004, ONCOLOGIST, V9, P2, DOI 10.1634/theoncologist.9-suppl_1-2
   Glas R, 2000, J EXP MED, V191, P129, DOI 10.1084/jem.191.1.129
   Harmey JH, 2002, BIOESSAYS, V24, P280, DOI 10.1002/bies.10043
   Hiroshima Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134324
   Hiroshima Y, 2013, CELL CYCLE, V12, P2774, DOI 10.4161/cc.25872
   HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661
   Huang ST, 2018, INT J ONCOL, V53, P1105, DOI 10.3892/ijo.2018.4449
   Jang SC, 2015, SMALL, V11, P456, DOI 10.1002/smll.201401803
   Kim OY, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00729-8
   Kinouchi Shinichiro, 2003, Yonago Acta Medica, V46, P109
   Kiraz Y, 2016, TUMOR BIOL, V37, P8471, DOI 10.1007/s13277-016-5035-9
   Lau TM, 1999, MOL HUM REPROD, V5, P57, DOI 10.1093/molehr/5.1.57
   Lee CH, 2014, GENE THER, V21, P309, DOI 10.1038/gt.2013.86
   Lee JC, 2012, FEMS MICROBIOL LETT, V331, P17, DOI 10.1111/j.1574-6968.2012.02549.x
   Lee WH, 2015, EXP MOL MED, V47, DOI 10.1038/emm.2015.59
   Liu Q, 2016, SCI REP-UK, V6, DOI 10.1038/srep34776
   Liu ZP, 2015, AM J CANCER RES, V5, P792
   Maeda H, 2013, ADV DRUG DELIVER REV, V65, P71, DOI 10.1016/j.addr.2012.10.002
   Moorthi C, 2011, J PHARM PHARM SCI, V14, P67, DOI 10.18433/J30C7D
   Navale AM, 2013, INT J PHARM SCI RES, V4, P19, DOI 10.13040/IJPSR.0975-8232.4(1).19-28
   O'Donoghue EJ, 2016, CELL MICROBIOL, V18, P1508, DOI 10.1111/cmi.12655
   Ozaslan M, 2011, AFR J BIOTECHNOL, V10, P2375
   Park KS, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011334
   Parker H, 2010, INFECT IMMUN, V78, P5054, DOI 10.1128/IAI.00299-10
   Peng J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112744
   Repetto G, 2008, NAT PROTOC, V3, P1125, DOI 10.1038/nprot.2008.75
   Rosenberg SA, 2002, J IMMUNOTHER, V25, P218, DOI 10.1097/00002371-200205000-00004
   Scholzen T, 2000, J CELL PHYSIOL, V182, P311, DOI 10.1002/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9
   Seidel UJE, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00076
   Shi CS, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000751
   Sisto F, 2003, INFECT IMMUN, V71, P465, DOI 10.1128/IAI.71.1.465-473.2003
   Sorensen EW, 2010, J IMMUNOL, V184, P1858, DOI 10.4049/jimmunol.0903210
   Stathis A., 2012, ESMO HDB CLIN PHARM
   Talmadge JE, 2007, AM J PATHOL, V170, P793, DOI 10.2353/ajpath.2007.060929
   Thay B, 2014, INFECT IMMUN, V82, P4034, DOI 10.1128/IAI.01980-14
   Tu DG, 2016, ONCOTARGET, V7, P37513, DOI 10.18632/oncotarget.7038
   Wang H, 2001, CLIN CANCER RES, V7, P3613
   Yuan JS, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-85
   Zhu LY, 2019, CELL MOL BIOL LETT, V24, DOI 10.1186/s11658-019-0164-y
   Zuberi A, 2016, ILAR J, V57, P178, DOI 10.1093/ilar/ilw021
NR 54
TC 4
Z9 4
U1 1
U2 8
PU ELSEVIER INC
PI SAN DIEGO
PA 525 B STREET, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0014-4827
EI 1090-2422
J9 EXP CELL RES
JI Exp. Cell Res.
PD FEB 1
PY 2021
VL 399
IS 1
AR 112423
DI 10.1016/j.yexcr.2020.112423
PG 11
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA PT7RR
UT WOS:000608809600004
PM 33338480
DA 2022-04-25
ER

PT J
AU Awi, NJ
   Yap, HY
   Armon, S
   Low, JSH
   Peh, KB
   Peh, SC
   Lee, CS
   Teow, SY
AF Awi, Noel Jacques
   Yap, Hooi-Yeen
   Armon, Subasri
   Low, John Seng-Hooi
   Peh, Kaik-Boo
   Peh, Suat-Cheng
   Lee, C. Soon
   Teow, Sin-Yeang
TI Association between autophagy and KRAS mutation with clinicopathological
   variables in colorectal cancer patients
SO MALAYSIAN JOURNAL OF PATHOLOGY
LA English
DT Article
DE Autophagy proteins; KRAS mutation; prognosis; Malaysian; Indonesian;
   LC3A; LC3B; p62; colorectal cancer
ID KIRSTEN RAS MUTATIONS; POOR-PROGNOSIS; BIOMARKERS; CELLS
AB Autophagy is a host defensive mechanism responsible for eliminating harmful cellular components through lysosomal degradation. Autophagy has been known to either promote or suppress various cancers including colorectal cancer (CRC). KRAS mutation serves as an important predictive marker for epidermal growth factor receptor (EGFR)-targeted therapies in CRC. However, the relationship between autophagy and KRAS mutation in CRC is not well-studied. In this single-centre study, 92 formalin-fixed paraffin-embedded (PIPE) tissues of CRC patients (42 Malaysian Chinese and 50 Indonesian) were collected and KRAS mutational status was determined by quantitative PCR (qPCR) (n=92) while the expression of autophagy effector (p62, LC3A and LC3B) was examined by immunohistochemistry (II-IC) (n=48). The outcomes of each were then associated with the clinicopathological variables (n=48). Our findings demonstrated that the female CRC patients have a higher tendency in developing KRAS mutation in the Malaysian Chinese population (p<0.05). Expression of autophagy effector LC3A was highly associated with the tumour grade in CRC (p<0.001) but not with other clinicopathological parameters. Lastly, the survival analysis did not yield a statistically significant outcome. Overall, this small cohort study concluded that KRAS mutation and autophagy effectors are not good prognostic markers for CRC patients.
C1 [Awi, Noel Jacques; Yap, Hooi-Yeen; Peh, Suat-Cheng; Teow, Sin-Yeang] Sunway Univ, Dept Med Sci, Sch Med & Life Sci, Jalan Univ, Subang Jaya 47500, Selangor Darul, Malaysia.
   [Armon, Subasri] Hosp Kuala Lumpur, Pathol Dept, Jalan Pahang, Kuala Lumpur 50586, Malaysia.
   [Low, John Seng-Hooi; Peh, Suat-Cheng] Sunway Med Ctr, Jalan Lagoon Selatan, Subang Jaya 47500, Selangor Darul, Malaysia.
   [Peh, Kaik-Boo] Mahkota Med Ctr, Jalan Merdeka, Melaka 75000, Malaysia.
   [Lee, C. Soon] Western Sydney Univ, Sch Med, Discipline Pathol, Sydney, NSW, Australia.
RP Teow, SY (corresponding author), Sunway Univ, Subang Jaya 47500, Selangor Darul, Malaysia.
EM ronaldt@sunway.edu.my
RI Teow, Sin-Yeang/J-2253-2019
OI Teow, Sin-Yeang/0000-0002-3824-0224
FU Sunway University [GRTIN-RSF-SHMS-DMS-03-2020]; National Cancer Council
   Malaysia (MAKNA) Cancer Research Award [EXT-SIDS-SIHD-MAKNA-2017-01];
   Sunway Medical Centre Research Funds [SRC/002/2017/FR, SRC/003/2017/FR];
   Sunway University Postgraduate Degree by Research Scholarship
FX This work was funded by Sunway University Internal Research Grant 2020
   (GRTIN-RSF-SHMS-DMS-03-2020) , National Cancer Council Malaysia (MAKNA)
   Cancer Research Award (CRA) 2016 (EXT-SIDS-SIHD-MAKNA-2017-01) , and
   Sunway Medical Centre Research Funds (SRC/002/2017/FR and
   SRC/003/2017/FR) . Noel Jacques Awi and Hooi-Yeen Yap are recipients of
   Sunway University Postgraduate Degree by Research Scholarship.
CR Alves S, 2015, ONCOTARGET, V6, P30787, DOI 10.18632/oncotarget.5021
   Andreyev HJN, 2001, BRIT J CANCER, V85, P692, DOI 10.1054/bjoc.2001.1964
   Andreyev HJN, 1998, J NATL CANCER I, V90, P675, DOI 10.1093/jnci/90.9.675
   Arrington AK, 2012, INT J MOL SCI, V13, P12153, DOI 10.3390/ijms131012153
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
   Cercek A, 2017, CLIN CANCER RES, V23, P4753, DOI 10.1158/1078-0432.CCR-17-0400
   Imamura Y, 2012, CLIN CANCER RES, V18, P4753, DOI 10.1158/1078-0432.CCR-11-3210
   Keum N, 2019, NAT REV GASTRO HEPAT, V16, P713, DOI 10.1038/s41575-019-0189-8
   Khan K, 2019, CRIT REV ONCOL HEMAT, V143, P153, DOI 10.1016/j.critrevonc.2019.09.001
   Kim HS, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2141-4
   Kim J, 2017, NEOPLASIA, V19, P805, DOI 10.1016/j.neo.2017.07.003
   Koukourakis MI, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137675
   Li WH, 2019, INT J CLIN EXP PATHO, V12, P957
   Lievre A, 2017, BRIT J CANCER, V117, P1819, DOI 10.1038/bjc.2017.353
   Mizushima N, 2007, AUTOPHAGY, V3, P542, DOI 10.4161/auto.4600
   Mo SB, 2019, CARCINOGENESIS, V40, P861, DOI 10.1093/carcin/bgz031
   Nakayama S, 2017, CANCER MED-US, V6, P1264, DOI 10.1002/cam4.1093
   Niklaus M, 2017, ONCOTARGET, V8, P54604, DOI 10.18632/oncotarget.17554
   Pang SW, 2020, DIAGNOSTICS, V10, DOI 10.3390/diagnostics10010009
   Pang SW, 2018, CELL CULTURE, P75
   Porru M, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0719-1
   Rimbert J, 2018, MODERN PATHOL, V31, P517, DOI 10.1038/modpathol.2017.119
   Sato K, 2007, CANCER RES, V67, P9677, DOI 10.1158/0008-5472.CAN-07-1462
   Schmitz KJ, 2016, WORLD J SURG ONCOL, V14, DOI 10.1186/s12957-016-0946-x
   Sepulveda AR, 2017, J CLIN ONCOL, V35, P1453, DOI 10.1200/JCO.2016.71.9807
   Smeby J, 2018, ANN ONCOL, V29, P1227, DOI 10.1093/annonc/mdy085
   Yang QW, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00487
   Zheng Hai-yang, 2012, Cancer Biology Medicine, V9, P105, DOI 10.3969/j.issn.2095-3941.2012.02.004
   Zhu LH, 2018, J CANCER, V9, P4072, DOI 10.7150/jca.26399
NR 29
TC 0
Z9 0
U1 2
U2 3
PU MALAYSIAN JOURNAL PATHOLOGY
PI KUALA LUMPUR
PA UNIV MALAYSIA, FAC MEDICINE, DEPT PATHOLOGY, KUALA LUMPUR, 59100,
   MALAYSIA
SN 0126-8635
J9 MALAYS J PATHOL
JI Malay. J. Pathol.
PD AUG
PY 2021
VL 43
IS 2
BP 269
EP 279
PG 11
WC Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology
GA UJ7SV
UT WOS:000691482100007
PM 34448791
DA 2022-04-25
ER

PT J
AU Nakamura, Y
   Arakawa, H
AF Nakamura, Yasuyuki
   Arakawa, Hirofumi
TI Discovery of Mieap-regulated mitochondrial quality control as a new
   function of tumor suppressor p53
SO CANCER SCIENCE
LA English
DT Review
DE Autophagy; cancer metabolism; mitochondrial quality control; reactive
   oxygen species; tumor suppressor p53
ID CELL-CYCLE CHECKPOINT; P53-DEPENDENT APOPTOSIS; SV40-TRANSFORMED CELLS;
   CANCER-CELLS; P53-INDUCIBLE REGULATOR; CANDIDATE MEDIATOR; POTENTIAL
   MEDIATOR; COLORECTAL-CANCER; OXIDATIVE STRESS; COMPLEX-III
AB The tumor suppressor p53 gene is frequently mutated in human cancers, and the p53 protein suppresses cancer. However, the mechanism behind the p53-mediated tumor suppression is still unclear. Recently, the mitochondria-eating protein (Mieap) was identified as a p53-inducible protein. Mieap induces the accumulation of lysosomal proteins within mitochondria (Mieap-induced accumulation of lysosome-like organelles within mitochondria, or MALM) in response to mitochondrial damage, and eliminates the oxidized mitochondrial proteins to repair unhealthy mitochondria. Furthermore, Mieap also induces vacuole-like structures (Mieap-induced vacuole, or MIV) to eat and degrade unhealthy mitochondria. Therefore, Mieap controls mitochondrial quality by repairing or eliminating unhealthy mitochondria by MALM or MIV, respectively. This mechanism is not mediated by canonical autophagy. Mieap-deficient Apc(Min/+) mice show strikingly high rates of intestinal tumor development as well as advanced-grade adenomas and adenocarcinomas. The p53/Mieap/BCL2 interacting protein 3 mitochondrial quality control pathway is frequently inactivated in human colorectal cancers. Defects in Mieap-regulated mitochondrial quality control lead to accumulation of unhealthy mitochondria in cancer cells. Cancer-specific unhealthy mitochondria could contribute to cancer development and aggressiveness through mitochondrial reactive oxygen species and altered metabolism. Mieap-regulated mitochondrial quality control is a newly discovered function of p53 that plays a critical role in tumor suppression.
C1 [Nakamura, Yasuyuki; Arakawa, Hirofumi] Natl Canc Ctr, Res Inst, Div Canc Biol, Tokyo, Japan.
RP Arakawa, H (corresponding author), Natl Canc Ctr, Res Inst, Div Canc Biol, Chuo Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan.
EM harakawa@ncc.go.jp
RI Arakawa, Hirofumi/L-3459-2013
OI Arakawa, Hirofumi/0000-0001-6077-0638
FU AMEDJapan Agency for Medical Research and Development (AMED)
   [15ck0106006h0002]; KAKENHIMinistry of Education, Culture, Sports,
   Science and Technology, Japan (MEXT)Japan Society for the Promotion of
   ScienceGrants-in-Aid for Scientific Research (KAKENHI) [22501021,
   23659178, 24240117, 25430124, 25670169]
FX AMED, (Grant/Award Number: '15ck0106006h0002') KAKENHI, (Grant/Award
   Number: '22501021','23659178','24240117','25430124','25670169')
CR Adimoolam S, 2002, P NATL ACAD SCI USA, V99, P12985, DOI 10.1073/pnas.202485699
   Arakawa H, 2004, NAT REV CANCER, V4, P978, DOI 10.1038/nrc1504
   BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x
   Beloribi-Djefaflia S, 2016, ONCOGENESIS, V5, DOI 10.1038/oncsis.2015.49
   Bensaad K, 2006, CELL, V126, P107, DOI 10.1016/j.cell.2006.05.036
   Berkers CR, 2013, CELL METAB, V18, P617, DOI 10.1016/j.cmet.2013.06.019
   Bieging KT, 2014, NAT REV CANCER, V14, P359, DOI 10.1038/nrc3711
   Bourdon A, 2007, NAT GENET, V39, P776, DOI 10.1038/ng2040
   Cannito S, 2008, CARCINOGENESIS, V29, P2267, DOI 10.1093/carcin/bgn216
   DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539
   DeBerardinis RJ, 2008, CELL METAB, V7, P11, DOI 10.1016/j.cmet.2007.10.002
   DELEO AB, 1979, P NATL ACAD SCI USA, V76, P2420, DOI 10.1073/pnas.76.5.2420
   ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P
   Fodde R, 2001, NAT REV CANCER, V1, P55, DOI 10.1038/35094067
   Fodde R, 2001, TRENDS MOL MED, V7, P369, DOI 10.1016/S1471-4914(01)02050-0
   Futamura M, 2007, CANCER RES, V67, P1451, DOI 10.1158/0008-5472.CAN-06-2485
   Giannoni E, 2012, ANTIOXID REDOX SIGN, V16, P1248, DOI 10.1089/ars.2011.4280
   Guzy RD, 2005, CELL METAB, V1, P401, DOI 10.1016/j.cmet.2005.05.001
   He SS, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8839
   Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7
   Hirayama A, 2009, CANCER RES, V69, P4918, DOI 10.1158/0008-5472.CAN-08-4806
   HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840
   Humpton TJ, 2016, CSH PERSPECT MED, V6, DOI 10.1101/cshperspect.a026146
   Iiizumi M, 2002, CANCER RES, V62, P1246
   Itakura E, 2008, MOL BIOL CELL, V19, P5360, DOI 10.1091/mbc.E08-01-0080
   Kamino H, 2016, ONCOGENESIS, V5, DOI 10.1038/oncsis.2015.43
   KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2
   Kawajiri S, 2010, FEBS LETT, V584, P1073, DOI 10.1016/j.febslet.2010.02.016
   Kim I, 2007, ARCH BIOCHEM BIOPHYS, V462, P245, DOI 10.1016/j.abb.2007.03.034
   Kitamura N, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016060
   Klimova T, 2008, CELL DEATH DIFFER, V15, P660, DOI 10.1038/sj.cdd.4402307
   KRESS M, 1979, J VIROL, V31, P472, DOI 10.1128/JVI.31.2.472-483.1979
   LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0
   Li TY, 2012, CELL, V149, P1269, DOI 10.1016/j.cell.2012.04.026
   Liang CY, 2008, NAT CELL BIOL, V10, P776, DOI 10.1038/ncb1740
   Liang C, 2006, NAT CELL BIOL, V8, P688, DOI 10.1038/ncb1426
   Lin X, 2008, P NATL ACAD SCI USA, V105, P174, DOI 10.1073/pnas.0706585104
   LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9
   Matoba S, 2006, SCIENCE, V312, P1650, DOI 10.1126/science.1126863
   Matsuda N, 2010, J CELL BIOL, V189, P211, DOI 10.1083/jcb.200910140
   MELERO JA, 1979, VIROLOGY, V93, P466, DOI 10.1016/0042-6822(79)90250-2
   Menendez D, 2009, NAT REV CANCER, V9, P724, DOI 10.1038/nrc2730
   Miyamoto T, 2012, SCI REP-UK, V2, DOI 10.1038/srep00379
   Miyamoto Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016054
   Miyamoto Y, 2010, INT J ONCOL, V36, P1253, DOI 10.3892/ijo_00000609
   MIYASHITA T, 1995, CELL, V80, P293
   Mizushima N, 2007, GENE DEV, V21, P2861, DOI 10.1101/gad.1599207
   Nakamura Y, 2004, CANCER SCI, V95, P7, DOI 10.1111/j.1349-7006.2004.tb03163.x
   Nakamura Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030767
   Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3
   Narendra D, 2008, J CELL BIOL, V183, P795, DOI 10.1083/jcb.200809125
   Narendra DP, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000298
   Nelson KK, 2004, FREE RADICAL BIO MED, V37, P768, DOI 10.1016/j.freeradbiomed.2004.06.008
   Nishimori H, 1997, ONCOGENE, V15, P2145, DOI 10.1038/sj.onc.1201542
   Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053
   Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8
   Ohki R, 2000, J BIOL CHEM, V275, P22627, DOI 10.1074/jbc.C000235200
   Okamura S, 2001, MOL CELL, V8, P85, DOI 10.1016/S1097-2765(01)00284-2
   Radisky DC, 2005, NATURE, V436, P123, DOI 10.1038/nature03688
   Schieber M, 2014, CURR BIOL, V24, pR453, DOI 10.1016/j.cub.2014.03.034
   SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x
   SMITH AE, 1979, CELL, V18, P335, DOI 10.1016/0092-8674(79)90053-9
   Suzuki S, 2010, P NATL ACAD SCI USA, V107, P7461, DOI 10.1073/pnas.1002459107
   Tanaka H, 2000, NATURE, V404, P42, DOI 10.1038/35003506
   Tanikawa C, 2003, NAT CELL BIOL, V5, P216, DOI 10.1038/ncb943
   Tsuneki M, 2015, SCI REP-UK, V5, DOI 10.1038/srep12472
   Valente LJ, 2013, CELL REP, V3, P1339, DOI 10.1016/j.celrep.2013.04.012
   Vande Velde C, 2000, MOL CELL BIOL, V20, P5454, DOI 10.1128/MCB.20.15.5454-5468.2000
   Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675
   Weinberg F, 2010, P NATL ACAD SCI USA, V107, P8788, DOI 10.1073/pnas.1003428107
   Weinberg F, 2009, CELL MOL LIFE SCI, V66, P3663, DOI 10.1007/s00018-009-0099-y
   Yang M, 2016, NAT REV CANCER, V16, P650, DOI 10.1038/nrc.2016.81
   Yoon KA, 2004, J HUM GENET, V49, P134, DOI 10.1007/s10038-003-0122-3
   Youle RJ, 2011, NAT REV MOL CELL BIO, V12, P9, DOI 10.1038/nrm3028
   Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1
   Zhang J, 2009, CELL DEATH DIFFER, V16, P939, DOI 10.1038/cdd.2009.16
NR 76
TC 20
Z9 20
U1 2
U2 10
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1349-7006
J9 CANCER SCI
JI Cancer Sci.
PD MAY
PY 2017
VL 108
IS 5
BP 809
EP 817
DI 10.1111/cas.13208
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA EW2AH
UT WOS:000402298000001
PM 28222492
OA hybrid, Green Published
DA 2022-04-25
ER

PT J
AU Saito, K
   Iizuka, Y
   Ohta, S
   Takahashi, S
   Nakamura, K
   Saya, H
   Yoshida, K
   Kawakami, Y
   Toda, M
AF Saito, Katsuya
   Iizuka, Yukihiko
   Ohta, Shigeki
   Takahashi, Satoshi
   Nakamura, Kenta
   Saya, Hideyuki
   Yoshida, Kazunari
   Kawakami, Yutaka
   Toda, Masahiro
TI Functional analysis of a novel glioma antigen, EFTUD1
SO NEURO-ONCOLOGY
LA English
DT Article
DE autophagy; EFTUD1; glioma; ribosome biogenesis; SEREX
ID SHWACHMAN-DIAMOND-SYNDROME; PROGRAMMED CELL-DEATH; MTOR INHIBITOR
   RAD001; 60S RIBOSOMAL-SUBUNIT; BREAST-CANCER CELLS; P53-DEPENDENT
   APOPTOSIS; COLORECTAL-CANCER; TUMOR PROGRESSION; INDUCED AUTOPHAGY;
   SYNDROME PROTEIN
AB Background. A cDNA library made from 2 glioma cell lines, U87MG and T98G, was screened by serological identification of antigens by recombinant cDNA expression (SEREX) using serum from a glioblastoma patient. Elongation factor Tu GTP binding domain containing protein 1 (EFTUD1), which is required for ribosome biogenesis, was identified. A cancer microarray database showed overexpression of EFTUD1 in gliomas, suggesting that EFTUD1 is a candidate molecular target for gliomas.
   Methods. EFTUD1 expression in glioma cell lines and glioma tissue was assessed by Western blot, quantitative PCR, and immunohistochemistry. The effect on ribosome biogenesis, cell growth, cell cycle, and induction of apoptosis and autophagy in glioma cells during the downregulation of EFTUD1 was investigated. To reveal the role of autophagy, the autophagy-blocker, chloroquine (CQ), was used in glioma cells downregulating EFTUD1. The effect of combining CQ with EFTUD1 inhibition in glioma cells was analyzed.
   Results. EFTUD1 expression in glioma cell lines and tissue was higher than in normal brain tissue. Downregulating EFTUD1 induced G1 cell-cycle arrest and apoptosis, leading to reduced glioma cell proliferation. The mechanism underlying this antitumor effect was impaired ribosome biogenesis via EFTUD1 inhibition. Additionally, protective autophagy was induced by glioma cells as an adaptive response to EFTUD1 inhibition. The antitumor effect induced by the combined treatment was significantly higher than that of either EFTUD1 inhibition or CQ alone.
   Conclusion. These results suggest that EFTUD1 represents a novel therapeutic target and that the combination of EFTUD1 inhibition with autophagy blockade may be effective in the treatment of gliomas.
C1 [Saito, Katsuya; Takahashi, Satoshi; Yoshida, Kazunari; Toda, Masahiro] Keio Univ, Sch Med, Dept Neurosurg, Tokyo 1608582, Japan.
   [Iizuka, Yukihiko; Ohta, Shigeki; Toda, Masahiro] Keio Univ, Sch Med, Neuroimmunol Res Grp, Tokyo 1608582, Japan.
   [Ohta, Shigeki] Keio Univ, Sch Med, Dept Physiol, Tokyo 1608582, Japan.
   [Nakamura, Kenta; Kawakami, Yutaka] Keio Univ, Sch Med, Inst Adv Med Res, Div Cellular Signaling, Tokyo 1608582, Japan.
   [Saya, Hideyuki] Keio Univ, Sch Med, Inst Adv Med Res, Div Gene Regulat, Tokyo 1608582, Japan.
RP Toda, M (corresponding author), Keio Univ, Sch Med, Dept Neurosurg, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.
EM todam@z2.keio.jp
RI Ohta, Shigeki/Y-4455-2019; Takahashi, Satoshi/V-7869-2019; nakamura,
   asuka/S-7235-2016; Kawakami, Yutaka/E-7429-2013; Saya,
   Hideyuki/J-4325-2013
OI Ohta, Shigeki/0000-0003-2994-4278; Takahashi,
   Satoshi/0000-0002-0168-1261; Kawakami, Yutaka/0000-0003-4836-2855; Saya,
   Hideyuki/0000-0001-6610-1902
FU Japan Society for the Promotion of ScienceMinistry of Education,
   Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for
   the Promotion of Science [22390283]
FX This research was supported by Japan Society for the Promotion of
   Science Grants-in-Aid for Scientific Research (B), Grant number
   22390283.
CR Arima Y, 2005, J BIOL CHEM, V280, P19166, DOI 10.1074/jbc.M410691200
   Belin S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007147
   Beuvink I, 2005, CELL, V120, P747, DOI 10.1016/j.cell.2004.12.040
   Boya P, 2005, MOL CELL BIOL, V25, P1025, DOI 10.1128/MCB.25.3.1025-1040.2005
   Bursch W, 2001, CELL DEATH DIFFER, V8, P569, DOI 10.1038/sj.cdd.4400852
   Ceci M, 2003, NATURE, V426, P579, DOI 10.1038/nature02160
   Chakraborty A, 2011, WIRES RNA, V2, P507, DOI 10.1002/wrna.73
   Corcelle EA, 2009, FEBS J, V276, P6084, DOI 10.1111/j.1742-4658.2009.07332.x
   Deisenroth C, 2010, ONCOGENE, V29, P4253, DOI 10.1038/onc.2010.189
   Donati G, 2012, CANCER RES, V72, P1602, DOI 10.1158/0008-5472.CAN-11-3992
   Donati G, 2011, J CELL SCI, V124, P3017, DOI 10.1242/jcs.086074
   Drygin D, 2011, CANCER RES, V71, P1418, DOI 10.1158/0008-5472.CAN-10-1728
   Drygin D, 2009, CANCER RES, V69, P7653, DOI 10.1158/0008-5472.CAN-09-1304
   Enzenmuller S, 2013, ANTI-CANCER DRUG, V24, P14, DOI 10.1097/CAD.0b013e32835a36db
   Fan QW, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2001017
   Fan QW, 2011, AUTOPHAGY, V7, P536, DOI 10.4161/auto.7.5.14779
   Finch AJ, 2011, GENE DEV, V25, P917, DOI 10.1101/gad.623011
   Forgber M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005199
   French PJ, 2005, CANCER RES, V65, P11335, DOI 10.1158/0008-5472.CAN-05-1886
   Ganapathi KA, 2007, BLOOD, V110, P1458, DOI 10.1182/blood-2007-02-075184
   Gandin V, 2008, NATURE, V455, P684, DOI 10.1038/nature07267
   Graindorge JS, 2005, J MOL BIOL, V352, P355, DOI 10.1016/j.jmb.2005.07.037
   Hait WN, 2006, CLIN CANCER RES, V12, P1961, DOI 10.1158/1078-0432.CCR-06-0011
   Hu YL, 2012, CANCER RES, V72, P4294, DOI 10.1158/0008-5472.CAN-12-1076
   Hu YL, 2012, CANCER RES, V72, P1773, DOI 10.1158/0008-5472.CAN-11-3831
   Humbert M, 2013, BIOCHEM BIOPH RES CO, V431, P264, DOI 10.1016/j.bbrc.2012.12.120
   Kagaya A, 2011, PROTEOME SCI, V9, DOI 10.1186/1477-5956-9-31
   Kim EL, 2010, NEURO-ONCOLOGY, V12, P389, DOI 10.1093/neuonc/nop046
   Klionsky DJ, 2012, AUTOPHAGY, V8, P445, DOI 10.4161/auto.19496
   Kondo Y, 2005, NAT REV CANCER, V5, P726, DOI 10.1038/nrc1692
   Lai MD, 2007, CURR GENOMICS, V8, P43
   Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1
   Li J, 2009, CANCER SCI, V100, P2255, DOI 10.1111/j.1349-7006.2009.01325.x
   Lin JF, 2013, CARCINOGENESIS, V34, P406, DOI 10.1093/carcin/bgs359
   Lindstrom MS, 2008, J BIOL CHEM, V283, P15568, DOI 10.1074/jbc.M801151200
   Lo KY, 2010, MOL CELL, V39, P196, DOI 10.1016/j.molcel.2010.06.018
   Loehberg CR, 2012, BIOCHEM PHARMACOL, V83, P480, DOI 10.1016/j.bcp.2011.11.022
   Lomonaco SL, 2011, NEURO-ONCOLOGY, V13, P857, DOI 10.1093/neuonc/nor073
   Menne TF, 2007, NAT GENET, V39, P486, DOI 10.1038/ng1994
   Miles AK, 2007, PROSTATE, V67, P274, DOI 10.1002/pros.20520
   Miluzio A, 2011, CANCER CELL, V19, P765, DOI 10.1016/j.ccr.2011.04.018
   Miluzio A, 2009, EMBO REP, V10, P459, DOI 10.1038/embor.2009.70
   Mizushima N, 2007, AUTOPHAGY, V3, P542, DOI 10.4161/auto.4600
   Montanaro L, 2008, AM J PATHOL, V173, P301, DOI 10.2353/ajpath.2008.070752
   Morgado-Palacin L, 2012, CELL CYCLE, V11, P503, DOI 10.4161/cc.11.3.19002
   Palumbo S, 2013, J CELL PHYSIOL, V228, P1, DOI 10.1002/jcp.24118
   Panse VG, 2010, TRENDS BIOCHEM SCI, V35, P260, DOI 10.1016/j.tibs.2010.01.001
   Reggiori F, 2002, EUKARYOT CELL, V1, P11, DOI 10.1128/EC.01.1.11-21.2002
   Rosso P, 2004, HEAD NECK-J SCI SPEC, V26, P408, DOI 10.1002/hed.10401
   Ruggero D, 2003, NAT REV CANCER, V3, P179, DOI 10.1038/nrc1015
   Rujkijyanont P, 2008, HAEMATOLOGICA, V93, P363, DOI 10.3324/haematol.11579
   Sanvito F, 1999, J CELL BIOL, V144, P823, DOI 10.1083/jcb.144.5.823
   Sanvito F, 2000, CANCER RES, V60, P510
   Seitz C, 2013, INT J CANCER, V132, P2682, DOI 10.1002/ijc.27935
   Sezgin G, 2013, PEDIATR BLOOD CANCER, V60, P281, DOI 10.1002/pbc.24300
   Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330
   Sun LX, 2006, CANCER CELL, V9, P287, DOI 10.1016/j.ccr.2006.03.003
   Suzuki A, 2012, CANCER SCI, V103, P632, DOI 10.1111/j.1349-7006.2012.02219.x
   Takahashi S, 2012, J NEURO-ONCOL, V106, P519, DOI 10.1007/s11060-011-0706-2
   Tsujimoto Y, 2005, CELL DEATH DIFFER, V12, P1528, DOI 10.1038/sj.cdd.4401777
   Ueda R, 2004, ONCOGENE, V23, P1420, DOI 10.1038/sj.onc.1207252
   Wong CC, 2011, BLOOD, V118, P4305, DOI 10.1182/blood-2011-06-353938
   Wu H, 2006, CANCER RES, V66, P3015, DOI 10.1158/0008-5472.CAN-05-1554
   Wu WKK, 2012, ONCOGENE, V31, P939, DOI 10.1038/onc.2011.295
   Yang ZNJ, 2011, MOL CANCER THER, V10, P1533, DOI 10.1158/1535-7163.MCT-11-0047
   Yang ZNJ, 2011, CANCER BIOL THER, V11, P169, DOI 10.4161/cbt.11.2.14663
   Yazbeck VY, 2008, EXP HEMATOL, V36, P443, DOI 10.1016/j.exphem.2007.12.008
   Zois CE, 2009, AUTOPHAGY, V5, P442, DOI 10.4161/auto.5.4.7667
NR 68
TC 6
Z9 7
U1 0
U2 7
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1522-8517
EI 1523-5866
J9 NEURO-ONCOLOGY
JI Neuro-Oncology
PD DEC
PY 2014
VL 16
IS 12
BP 1618
EP 1629
DI 10.1093/neuonc/nou132
PG 12
WC Oncology; Clinical Neurology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Neurosciences & Neurology
GA CA0JK
UT WOS:000348604000008
PM 25015090
OA Green Published, Bronze
DA 2022-04-25
ER

PT J
AU Liu, L
   Wang, HJ
   Meng, T
   Lei, C
   Yang, XH
   Wang, QS
   Jin, B
   Zhu, JF
AF Liu, Lin
   Wang, Hai-Jiang
   Meng, Tao
   Lei, Cheng
   Yang, Xin-Hui
   Wang, Qi-San
   Jin, Bo
   Zhu, Jin-Feng
TI lncRNA GAS5 Inhibits Cell Migration and Invasion and Promotes Autophagy
   by Targeting miR-222-3p via the GAS5/PTEN-Signaling Pathway in CRC
SO MOLECULAR THERAPY-NUCLEIC ACIDS
LA English
DT Article
ID COLORECTAL-CANCER; EXPRESSION; MICRORNA
AB Colorectal cancer (CRC) is a frequently occurring lethal disorder with heterogeneous outcomes and drug responses. Recent studies have demonstrated that long non-coding RNAs (lncRNAs) play a critical role in carcinogenesis. Hence, the aim of this study was to investigate the role of lncRNA growth arrest-specific 5 (GAS5) in CRC cells via mediation of the microRNA-222-3p (miR-222-3p)/GAS5/phosphatase and tensin homolog (PTEN)-signaling pathway. HCT116 and SW480 cells were collected and treated with small interfering (si)-lncRNA GAS5, overexpressing (oe)-lncRNA GAS5, miR222- 3p mimic, miR-222-3p inhibitor, or si-lncRNA GAS5 + miR-222-3p mimic. The miR-222-3p level and mRNA and protein levels of GAS5, Beclin1, light-chain 3B (LC3B), PTEN, and Akt were detected. Besides, cell migration, invasion, and apoptosis as well as acidic vesicular organelles (AVOs) were examined respectively. Xenografts in nude mice were also performed to detect tumorigenesis in vivo. Results suggested that the downregulation of lncRNA GAS5 decreased the expressions of Beclin1, LC3B, and PTEN. When treated with oe-lncRNA GAS5 or miR-222-3p inhibitor, HCT116 and SW480 cells exhibited suppressed invasion and migration abilities and increased apoptotic cells and autophagosome and AVO activities. Moreover, overexpression of GAS5 inhibited the tumorigenesis of CRC cells in vivo. Taken together, lncRNA GAS5 upregulated the expression of PTEN by functioning as a competing endogenous RNA (ceRNA) of miR-222-3p, thus inhibiting CRC cell migration and invasion and promoting cell autophagy.
C1 [Liu, Lin; Wang, Hai-Jiang; Meng, Tao; Lei, Cheng; Yang, Xin-Hui; Wang, Qi-San; Jin, Bo; Zhu, Jin-Feng] Xinjiang Med Univ, Dept Abdomen Surg, Canc Hosp, 789 Suzhou East St, Urumqi 830011, Xinjiang Uygur, Peoples R China.
RP Liu, L (corresponding author), Xinjiang Med Univ, Dept Abdomen Surg, Canc Hosp, 789 Suzhou East St, Urumqi 830011, Xinjiang Uygur, Peoples R China.
EM 13899843593@163.com
CR Bian DH, 2017, AM J TRANSL RES, V9, P1509
   Burada F, 2015, WORLD J GASTRO ONCOL, V7, P271, DOI 10.4251/wjgo.v7.i11.271
   Chen G, 2013, NUCLEIC ACIDS RES, V41, pD983, DOI 10.1093/nar/gks1099
   Dhar S, 2015, BBA-MOL CELL RES, V1853, P265, DOI 10.1016/j.bbamcr.2014.11.004
   Dziki Lukasz, 2015, Pol Przegl Chir, V87, P459, DOI 10.1515/pjs-2015-0088
   Gao HL, 2017, CANCER CELL INT, V17, DOI 10.1186/s12935-017-0447-1
   Guo C, 2015, J BIOMED SCI, V22, DOI 10.1186/s12929-015-0213-4
   Han Y, 2014, ASIAN PAC J CANCER P, V15, P4583, DOI 10.7314/APJCP.2014.15.11.4583
   Iman M, 2016, RECENT PAT ANTI-CANC, V11, P434, DOI 10.2174/1574892811999160628114857
   Khoshinani HM, 2017, JPN J RADIOL, V35, P664, DOI 10.1007/s11604-017-0679-y
   Krell J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098561
   Kuo TY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031587
   Li J, 2018, CANCER CELL INT, V18, DOI 10.1186/s12935-017-0478-7
   Liu BY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087563
   Liu SH, 2014, GASTROENTEROLOGY, V147, P847, DOI 10.1053/j.gastro.2014.06.006
   Pickard MR, 2015, GENES-BASEL, V6, P484, DOI 10.3390/genes6030484
   Rossi Marianna Nicoletta, 2014, Int J Cell Biol, V2014, P473857, DOI 10.1155/2014/473857
   Saito Y, 2003, GENE THER, V10, P1961, DOI 10.1038/sj.gt.3302100
   Sawai H, 2008, BMC GASTROENTEROL, V8, DOI 10.1186/1471-230X-8-56
   Shi YG, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122679
   Sun XW, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0164590
   Thomas J, 2015, INT J MOL SCI, V16, P28063, DOI 10.3390/ijms161226080
   Tokarz P, 2012, ACTA BIOCHIM POL, V59, P467
   Wu SH, 2015, INT J CLIN EXP PATHO, V8, P3882
   Xu J, 2017, J ECON ENTOMOL, V110, P683, DOI 10.1093/jee/tow297
   Yang Y, 2017, ONCOL LETT, V13, P3151, DOI 10.3892/ol.2017.5841
   Yin DD, 2014, MED ONCOL, V31, DOI 10.1007/s12032-014-0253-8
   Yuan SJ, 2017, HUM GENE THER, V28, P690, DOI 10.1089/hum.2017.041
   Zhao XH, 2015, MOL THER, V23, P1899, DOI 10.1038/mt.2015.170
NR 29
TC 68
Z9 70
U1 3
U2 6
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 2162-2531
J9 MOL THER-NUCL ACIDS
JI Mol. Ther.-Nucl. Acids
PD SEP 6
PY 2019
VL 17
BP 644
EP 656
DI 10.1016/j.omtn.2019.06.009
PG 13
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA JA6XF
UT WOS:000487984400057
PM 31400607
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Hsieh, YY
   Lo, HL
   Yang, PM
AF Hsieh, Yao-Yu
   Lo, Hsiang-Ling
   Yang, Pei-Ming
TI EZH2 inhibitors transcriptionally upregulate cytotoxic autophagy and
   cytoprotective unfolded protein response in human colorectal cancer
   cells
SO AMERICAN JOURNAL OF CANCER RESEARCH
LA English
DT Article
DE Autophagy; colorectal cancer; ER stress; EZH2; unfolded protein response
ID ENDOPLASMIC-RETICULUM STRESS; METHYLTRANSFERASE EZH2; BREAST-CANCER; ER
   STRESS; GENE; DEATH; PHOSPHORYLATION; EXPRESSION; APOPTOSIS; LYMPHOMA
AB Enhancer of zeste homolog 2 (EZH2) has been emerged as novel anticancer target. Various EZH2 small-molecule inhibitors have been developed in recent years. A major class of EZH2 inhibitors are S-adenosyl-L-methionine (SAM)-competitive inhibitors, such as EPZ005687, EI1, GSK126, UNC1999 and GSK343. Autophagy, a physiological process of self-digestion, is involved in the turnover of proteins or intracellular organelles. It can serve as cytoprotective or cytotoxic function in cancer. Our previous study has found that UNC1999 and GSK343 are potent autophagy inducers. In this study, the underlying molecular mechanisms were further investigated. Our results showed that UNC1999 and GSK343 transcriptionally upregulated autophagy of human colorectal cancer (CRC) cells through inducing LC3B gene expression. Besides, UNC1999/GSK343-induced autophagy was partially dependent on ATG7 but independent to EZH2 inhibition. Microarray and PCR array analyses identified that UNC1999 and GSK343 also induced endoplasmic reticulum (ER) stress and unfolded protein response (UPR). UNC1999/GSK343-induced ER stress/UPR contributed to the survival of cancer cells, which was opposite to UNC1999/GSK343-induced autophagy that promoted cell death.
C1 [Hsieh, Yao-Yu; Lo, Hsiang-Ling; Yang, Pei-Ming] Taipei Med Univ, Coll Med Sci & Technol, PhD Program Canc Biol & Drug Discovery, Taipei, Taiwan.
   [Hsieh, Yao-Yu; Lo, Hsiang-Ling; Yang, Pei-Ming] Acad Sinica, Taipei, Taiwan.
   [Hsieh, Yao-Yu] Taipei Meidcal Univ, Shuang Ho Hosp, Div Hematol & Oncol, New Taipei, Taiwan.
   [Lo, Hsiang-Ling; Yang, Pei-Ming] Taipei Med Univ, Grad Inst Canc Biol & Drug Discovery, Coll Med Sci & Technol, 250 Wu Hsing St, Taipei 11031, Taiwan.
RP Yang, PM (corresponding author), Taipei Med Univ, Grad Inst Canc Biol & Drug Discovery, Coll Med Sci & Technol, 250 Wu Hsing St, Taipei 11031, Taiwan.
EM yangpm@tmu.edu.tw
RI Yang, Pei-Ming/G-3763-2014
OI Yang, Pei-Ming/0000-0002-4004-2518
FU Ministry of Science and TechnologyMinistry of Education, Culture,
   Sports, Science and Technology, Japan (MEXT) [MOST103-2311-B-038-003,
   MOST104-2320-B-038-005]; Taipei Medical University-Shuang Ho Hospital
   [103TMU-SHH-02, 104TMU-SHH-03]; Research team of prevention and therapy
   of colorectal cancer in Taipei Medical University [TMU-T104-01];
   Comprehensive Cancer Center of Taipei Medical University fund by the
   Health and welfare surcharge of tobacco products
   [MOHW105-TDU-B-212-134001]
FX This work was supported by the Ministry of Science and Technology
   (MOST103-2311-B-038-003 and MOST104-2320-B-038-005); Taipei Medical
   University-Shuang Ho Hospital (103TMU-SHH-02 and 104TMU-SHH-03);
   Research team of prevention and therapy of colorectal cancer in Taipei
   Medical University (TMU-T104-01); and Comprehensive Cancer Center of
   Taipei Medical University fund by the Health and welfare surcharge of
   tobacco products (MOHW105-TDU-B-212-134001).
CR Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225
   Chen SN, 2010, BBA-REV CANCER, V1806, P220, DOI 10.1016/j.bbcan.2010.07.003
   Cheong H, 2011, P NATL ACAD SCI USA, V108, P11121, DOI 10.1073/pnas.1107969108
   CLARKE PGH, 1990, ANAT EMBRYOL, V181, P195, DOI 10.1007/bf00174615
   Codogno P, 2012, NAT REV MOL CELL BIO, V13, P7, DOI 10.1038/nrm3249
   Croonquist PA, 2005, ONCOGENE, V24, P6269, DOI 10.1038/sj.onc.1208771
   de Narvajas AAM, 2013, MOL CELL BIOL, V33, P3983, DOI 10.1128/MCB.00813-13
   Du KY, 2003, SCIENCE, V300, P1574, DOI 10.1126/science.1079817
   Dupont N, 2013, CURR PATHOBIOL REP, V1, P263, DOI [10.1007/s40139-013-0030-y, DOI 10.1007/S40139-013-0030-Y]
   Egan DF, 2011, SCIENCE, V331, P456, DOI 10.1126/science.1196371
   Fullgrabe J, 2014, NAT REV MOL CELL BIO, V15, P65, DOI 10.1038/nrm3716
   Fullgrabe J, 2013, AUTOPHAGY, V9, P1621, DOI 10.4161/auto.25803
   Fullgrabe J, 2013, NATURE, V500, P468, DOI 10.1038/nature12313
   Hardie DG, 1998, ANNU REV BIOCHEM, V67, P821, DOI 10.1146/annurev.biochem.67.1.821
   Hoyer-Hansen M, 2007, CELL DEATH DIFFER, V14, P1576, DOI 10.1038/sj.cdd.4402200
   Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2
   Kamada Y, 2000, J CELL BIOL, V150, P1507, DOI 10.1083/jcb.150.6.1507
   Kihara A, 2001, EMBO REP, V2, P330, DOI 10.1093/embo-reports/kve061
   Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100
   Klionsky DJ, 2016, AUTOPHAGY, V12, P1, DOI 10.1080/15548627.2015.1100356
   Knutson SK, 2012, NAT CHEM BIOL, V8, P890, DOI [10.1038/NCHEMBIO.1084, 10.1038/nchembio.1084]
   Konze KD, 2013, ACS CHEM BIOL, V8, P1324, DOI [10.1021/cb400133J, 10.1021/cb400133j]
   Larsen KE, 2002, HISTOL HISTOPATHOL, V17, P897, DOI 10.14670/HH-17.897
   Levine B, 2007, NAT REV IMMUNOL, V7, P767, DOI 10.1038/nri2161
   Levine B, 2007, NATURE, V446, P745, DOI 10.1038/446745a
   Li J, 2008, CELL DEATH DIFFER, V15, P1460, DOI 10.1038/cdd.2008.81
   Liberzon A, 2015, CELL SYST, V1, P417, DOI 10.1016/j.cels.2015.12.004
   Liu TP, 2015, ANTI-CANCER DRUG, V26, P139, DOI 10.1097/CAD.0000000000000166
   Mathew R, 2007, NAT REV CANCER, V7, P961, DOI 10.1038/nrc2254
   McCabe MT, 2012, NATURE, V492, P108, DOI 10.1038/nature11606
   Meijer AJ, 2004, BIOCHEM BIOPH RES CO, V313, P397, DOI 10.1016/j.bbrc.2003.07.012
   Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639
   Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180
   Nishida Y, 2009, NATURE, V461, P654, DOI 10.1038/nature08455
   Nishino Ichizo, 2003, Curr Neurol Neurosci Rep, V3, P64, DOI 10.1007/s11910-003-0040-y
   Ohoka N, 2005, EMBO J, V24, P1243, DOI 10.1038/sj.emboj.7600596
   Petiot A, 2000, J BIOL CHEM, V275, P992, DOI 10.1074/jbc.275.2.992
   Qi W, 2012, P NATL ACAD SCI USA, V109, P21360, DOI 10.1073/pnas.1210371110
   Raaphorst FM, 2003, NEOPLASIA, V5, P481, DOI 10.1016/S1476-5586(03)80032-5
   Rouschop KMA, 2010, J CLIN INVEST, V120, P127, DOI 10.1172/JCI40027
   Sarkar S, 2005, J CELL BIOL, V170, P1101, DOI 10.1083/jcb.200504035
   Scarlatti F, 2008, CELL DEATH DIFFER, V15, P1318, DOI 10.1038/cdd.2008.51
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Tabas I, 2011, NAT CELL BIOL, V13, P184, DOI 10.1038/ncb0311-184
   Tan JZ, 2014, ACTA PHARMACOL SIN, V35, P161, DOI 10.1038/aps.2013.161
   Tan J, 2007, GENE DEV, V21, P1050, DOI 10.1101/gad.1524107
   Tanida I, 2004, INT J BIOCHEM CELL B, V36, P2503, DOI 10.1016/j.biocel.2004.05.009
   Todd DJ, 2008, NAT REV IMMUNOL, V8, P663, DOI 10.1038/nri2359
   Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075
   Verma SK, 2012, ACS MED CHEM LETT, V3, P1091, DOI 10.1021/ml3003346
   Wei FZ, 2015, AUTOPHAGY, V11, P2309, DOI 10.1080/15548627.2015.1117734
   Wu J, 2006, CELL DEATH DIFFER, V13, P374, DOI 10.1038/sj.cdd.4401840
   Xu CY, 2005, J CLIN INVEST, V115, P2656, DOI 10.1172/JCI26373
NR 53
TC 24
Z9 26
U1 0
U2 7
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 2156-6976
J9 AM J CANCER RES
JI Am. J. Cancer Res.
PY 2016
VL 6
IS 8
BP 1661
EP 1680
PG 20
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA DW0YQ
UT WOS:000383369900007
PM 27648357
DA 2022-04-25
ER

PT J
AU Newton, IP
   Kenneth, NS
   Appleton, PL
   Nathke, I
   Rocha, S
AF Newton, Ian P.
   Kenneth, Niall S.
   Appleton, Paul L.
   Naethke, Inke
   Rocha, Sonia
TI Adenomatous Polyposis Coli and Hypoxia-inducible Factor-1 alpha Have an
   Antagonistic Connection
SO MOLECULAR BIOLOGY OF THE CELL
LA English
DT Article
ID NF-KAPPA-B; BETA-CATENIN; TUMOR-SUPPRESSOR; CANCER-CELLS; RESPONSIVE
   ELEMENT; COLORECTAL-CANCER; GENE-EXPRESSION; APC; AUTOPHAGY; PATHWAY
AB The tumor suppressor adenomatous polyposis coli (APC) is mutated in the majority of colorectal cancers and is best known for its role as a scaffold in a Wnt-regulated protein complex that determines the availability of beta-catenin. Another common feature of solid tumors is the presence of hypoxia as indicated by the up-regulation of hypoxia-inducible factors (HIFs) such as HIF-1 alpha. Here, we demonstrate a novel link between APC and hypoxia and show that APC and HIF-1 alpha antagonize each other. Hypoxia results in reduced levels of APC mRNA and protein via a HIF-1 alpha-dependent mechanism. HIF-1 alpha represses the APC gene via a functional hypoxia-responsive element on the APC promoter. In contrast, APC-mediated repression of HIF-1 alpha requires wild-type APC, low levels of beta-catenin, and nuclear factor-kappa B activity. These results reveal down-regulation of APC as a new mechanism that contributes to the survival advantage induced by hypoxia and also show that loss of APC mutations produces a survival advantage by mimicking hypoxic conditions.
C1 [Kenneth, Niall S.; Rocha, Sonia] Univ Dundee, Coll Life Sci, Wellcome Trust Ctr Gene Regulat & Express, Dundee DD1 5EH, Scotland.
   [Newton, Ian P.; Appleton, Paul L.; Naethke, Inke] Univ Dundee, Coll Life Sci, Div Cell & Dev Biol, Dundee DD1 5EH, Scotland.
RP Rocha, S (corresponding author), Univ Dundee, Coll Life Sci, Wellcome Trust Ctr Gene Regulat & Express, Dundee DD1 5EH, Scotland.
EM s.rocha@dundee.ac.uk
OI Nathke, Inke/0000-0003-2420-4385; KENNETH, NIALL/0000-0001-8528-1021;
   Rocha, Sonia/0000-0002-2413-4981
FU Cancer Research UKCancer Research UK; Association for International
   Cancer Research; Research Council UKUK Research & Innovation (UKRI);
   University of Dundee; MRCUK Research & Innovation (UKRI)Medical Research
   Council UK (MRC) [G0601098] Funding Source: UKRI; Cancer Research
   UKCancer Research UK [11243] Funding Source: researchfish; Medical
   Research CouncilUK Research & Innovation (UKRI)Medical Research Council
   UK (MRC)European Commission [G0601098] Funding Source: researchfish
FX We thank Prof. T. Waldman for providing the IIA beta cells and Dr. O.
   Sansom for providing the APC-Cre mouse tissue. This study was mainly
   funded by a Cancer Research UK program grant (to I.P.N., P. L. A., and
   I.S.N.) and Association for International Cancer Research project grant
   (to N.S.K.). S. R. is funded by a Research Council UK fellowship,
   University of Dundee, with additional support from a Medical Research
   Council New Investigator Research Grant.
CR Anderson LA, 2003, MOL CELL BIOL, V23, P721, DOI 10.1128/MCB.23.2.721-732.2003
   Bardos JI, 2005, BBA-REV CANCER, V1755, P107, DOI 10.1016/j.bbcan.2005.05.001
   Bardos JI, 2004, MOL CELL BIOL, V24, P2905, DOI 10.1128/MCB.24.7.2905-2914.2004
   Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7
   Brabletz T, 2001, P NATL ACAD SCI USA, V98, P10356, DOI 10.1073/pnas.171610498
   Bruegge K, 2007, CURR MED CHEM, V14, P1853
   Damalas A, 2001, EMBO J, V20, P4912, DOI 10.1093/emboj/20.17.4912
   Dang DT, 2006, CANCER RES, V66, P1684, DOI 10.1158/0008-5472.CAN-05-2887
   Deng J, 2004, MOL CARCINOGEN, V39, P139, DOI 10.1002/mc.10169
   Deng JO, 2002, CANCER CELL, V2, P323, DOI 10.1016/S1535-6108(02)00154-X
   Dikovskaya D, 2007, J CELL BIOL, V176, P183, DOI 10.1083/jcb.200610099
   Du Q, 2009, CANCER RES, V69, P3764, DOI 10.1158/0008-5472.CAN-09-0014
   Fandrey J, 2006, CARDIOVASC RES, V71, P642, DOI 10.1016/j.cardiores.2006.05.005
   Fearnhead NS, 2001, HUM MOL GENET, V10, P721, DOI 10.1093/hmg/10.7.721
   Furlan D, 2008, HUM PATHOL, V39, P1483, DOI 10.1016/j.humpath.2008.02.013
   GARCIA JA, 2006, SCI STKE, pPE25
   Gorlach Agnes, 2008, Biochem J, V412, pe17, DOI 10.1042/BJ20080920
   ICHII S, 1993, ONCOGENE, V8, P2399
   Kaidi A, 2007, NAT CELL BIOL, V9, P210, DOI 10.1038/ncb1534
   Kenneth NS, 2009, J BIOL CHEM, V284, P4123, DOI 10.1074/jbc.M808491200
   Kenneth NS, 2008, BIOCHEM J, V414, P19, DOI 10.1042/BJ20081055
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Li ZY, 2005, CANCER RES, V65, P5195, DOI 10.1158/0008-5472.CAN-04-4609
   Lim JH, 2008, CANCER RES, V68, P5177, DOI 10.1158/0008-5472.CAN-07-6234
   Liu J, 2001, MOL CELL, V7, P927, DOI 10.1016/S1097-2765(01)00241-6
   LIU X, 2010, PHARM RES
   McCartney BM, 2008, CURR OPIN CELL BIOL, V20, P186, DOI 10.1016/j.ceb.2008.02.001
   Menrad H, 2010, HEPATOLOGY, V51, P2183, DOI 10.1002/hep.23597
   Metzen E, 2005, BIOCHEM J, V387, P711, DOI 10.1042/BJ20041736
   Morselli E, 2009, BBA-MOL CELL RES, V1793, P1524, DOI 10.1016/j.bbamcr.2009.01.006
   Nathke IS, 1996, J CELL BIOL, V134, P165, DOI 10.1083/jcb.134.1.165
   Perkins ND, 2006, CELL DEATH DIFFER, V13, P759, DOI 10.1038/sj.cdd.4401838
   Pescador N, 2005, BIOCHEM J, V390, P189, DOI 10.1042/BJ20042121
   Phelps RA, 2009, CELL, V137, P623, DOI 10.1016/j.cell.2009.02.037
   POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0
   Rajaganeshan R, 2008, INT J COLORECTAL DIS, V23, P1049, DOI 10.1007/s00384-008-0497-x
   Rius J, 2008, NATURE, V453, P807, DOI 10.1038/nature06905
   Rocha S, 2005, EMBO J, V24, P1157, DOI 10.1038/sj.emboj.7600608
   Sansom OJ, 2004, GENE DEV, V18, P1385, DOI 10.1101/gad.287404
   Schumm K, 2006, EMBO J, V25, P4820, DOI 10.1038/sj.emboj.7601343
   Taylor CT, 2007, J MOL MED, V85, P1295, DOI 10.1007/s00109-007-0277-z
   van Uden P, 2008, BIOCHEM J, V412, P477, DOI 10.1042/BJ20080476
   Wilkinson S, 2009, AUTOPHAGY, V5, P1068, DOI 10.4161/auto.5.7.9821
   Yu L, 2008, AUTOPHAGY, V4, P567, DOI 10.4161/auto.5902
   Zhang HF, 2008, J BIOL CHEM, V283, P10892, DOI 10.1074/jbc.M800102200
NR 45
TC 41
Z9 41
U1 0
U2 1
PU AMER SOC CELL BIOLOGY
PI BETHESDA
PA 8120 WOODMONT AVE, STE 750, BETHESDA, MD 20814-2755 USA
SN 1059-1524
EI 1939-4586
J9 MOL BIOL CELL
JI Mol. Biol. Cell
PD NOV 1
PY 2010
VL 21
IS 21
BP 3630
EP 3638
DI 10.1091/mbc.E10-04-0312
PG 9
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA 672KR
UT WOS:000283582400002
PM 20844082
OA Green Published, Green Submitted
DA 2022-04-25
ER

PT J
AU Hu, YL
   Yin, Y
   Liu, HY
   Feng, YY
   Bian, ZH
   Zhou, LY
   Zhang, JW
   Fei, BJ
   Wang, YG
   Huang, ZH
AF Hu, Ya-Ling
   Yin, Yuan
   Liu, He-Yong
   Feng, Yu-Yang
   Bian, Ze-Hua
   Zhou, Le-Yuan
   Zhang, Ji-Wei
   Fei, Bo-Jian
   Wang, Yu-Gang
   Huang, Zhao-Hui
TI Glucose deprivation induces chemoresistance in colorectal cancer cells
   by increasing ATF4 expression
SO WORLD JOURNAL OF GASTROENTEROLOGY
LA English
DT Article
DE Glucose deprivation; ATF4; Oxaliplatin; 5-Fluorouracil; Chemoresistance
ID UNFOLDED PROTEIN RESPONSE; MULTIDRUG-RESISTANCE; CARCINOMA-CELLS;
   AUTOPHAGY; APOPTOSIS; SURVIVAL; HYPOXIA; PATHWAY; PERK/ATF4/LAMP3-ARM;
   SENSITIVITY
AB AIM: To investigate the role of activating transcription factor 4 (ATF4) in glucose deprivation (GD) induced colorectal cancer (CRC) drug resistance and the mechanism involved.
   METHODS: Chemosensitivity and apoptosis were measured under the GD condition. Inhibition of ATF4 using short hairpin RNA in CRC cells under the GD condition and in ATF4-overexpressing CRC cells was performed to identify the role of ATF4 in the GD induced chemoresistance. Quantitative real-time RTPCR and Western blot were used to detect the mRNA and protein expression of drug resistance gene 1 (MDR1), respectively.
   RESULTS: GD protected CRC cells from drug-induced apoptosis (oxaliplatin and 5-fluorouracil) and induced the expression of ATF4, a key gene of the unfolded protein response. Depletion of ATF4 in CRC cells under the GD condition can induce apoptosis and drug resensitization. Similarly, inhibition of ATF4 in the ATF4-overexpressing CRC cells reintroduced therapeutic sensitivity and apoptosis. In addition, increased MDR1 expression was observed in GD-treated CRC cells.
   CONCLUSION: These data indicate that GD promotes chemoresistance in CRC cells through up-regulating ATF4 expression.
C1 [Hu, Ya-Ling; Yin, Yuan; Liu, He-Yong; Feng, Yu-Yang; Bian, Ze-Hua; Zhou, Le-Yuan; Zhang, Ji-Wei; Fei, Bo-Jian; Huang, Zhao-Hui] Jiangnan Univ, Affiliated Hosp, Wuxi Oncol Inst, 200 Huihe Rd, Wuxi 214062, Jiangsu, Peoples R China.
   [Wang, Yu-Gang] Univ Michigan, Sch Dent, Dept Biol & Mat Sci, Ann Arbor, MI 48109 USA.
RP Huang, ZH (corresponding author), Jiangnan Univ, Affiliated Hosp, Wuxi Oncol Inst, 200 Huihe Rd, Wuxi 214062, Jiangsu, Peoples R China.
EM hzhwxsy@126.com
RI Huang, Zhaohui/S-9410-2019; Yin, Yuan/AAG-1707-2020
OI Huang, Zhaohui/0000-0002-0117-9976; 
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81000867, 81272299, 81301784, 81301920];
   Natural Science Foundation of Jiangsu ProvinceNatural Science Foundation
   of Jiangsu Province [BK20150004, BK20151108]; Fundamental Research Funds
   for the Central UniversitiesFundamental Research Funds for the Central
   Universities [NOJUSRP51619B]; Medical Key Professionals Program of
   Jiangsu Province [RC2011031]; "333" Talents Project of Jiangsu Province;
   Hospital Management Center of Wuxi [YGZXM1524]
FX Supported by National Natural Science Foundation of China, No. 81000867,
   No. 81272299, No. 81301784 and No. 81301920; Natural Science Foundation
   of Jiangsu Province, No. BK20150004 and No. BK20151108; the Fundamental
   Research Funds for the Central Universities, No. NOJUSRP51619B; Medical
   Key Professionals Program of Jiangsu Province, No. RC2011031; "333"
   Talents Project of Jiangsu Province, and Hospital Management Center of
   Wuxi, No. YGZXM1524.
CR Alekshun MN, 2007, CELL, V128, P1037, DOI 10.1016/j.cell.2007.03.004
   Ameri K, 2015, CELL REP, V10, P891, DOI 10.1016/j.celrep.2015.01.020
   Chen F, 2014, PROTEIN CELL, V5, P816, DOI 10.1007/s13238-014-0097-1
   Dey S, 2015, J CLIN INVEST, V125, P2592, DOI 10.1172/JCI78031
   Fan CF, 2014, TUMOR BIOL, V35, P765, DOI 10.1007/s13277-013-1104-5
   Goldenberg-Cohen N, 2012, APOPTOSIS, V17, P278, DOI 10.1007/s10495-011-0678-x
   Hecht JR, 2015, CANCER MANAG RES, V7, P165, DOI 10.2147/CMAR.S61408
   Igarashi T, 2007, ONCOGENE, V26, P4749, DOI 10.1038/sj.onc.1210289
   Jiang Q, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.200
   Ledoux S, 2003, CANCER RES, V63, P7284
   Lee SH, 2013, J NUTR BIOCHEM, V24, P664, DOI 10.1016/j.jnutbio.2012.03.016
   Mathews EH, 2014, NUTRITION, V30, P218, DOI 10.1016/j.nut.2013.07.024
   Milani M, 2009, CANCER RES, V69, P4415, DOI 10.1158/0008-5472.CAN-08-2839
   Nagelkerke A, 2015, HEAD NECK-J SCI SPEC, V37, P896, DOI 10.1002/hed.23693
   Nagelkerke A, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3373
   Nishimoto A, 2014, INT J ONCOL, V44, P2077, DOI 10.3892/ijo.2014.2367
   Notte A, 2015, INT J BIOCHEM CELL B, V62, P1, DOI 10.1016/j.biocel.2015.02.010
   Ord T, 2015, BBA-MOL CELL RES, V1853, P2492, DOI 10.1016/j.bbamcr.2015.06.006
   Redzic ZB, 2015, INT J STROKE, V10, P407, DOI 10.1111/ijs.12197
   Rzymski T, 2009, CELL CYCLE, V8, P3838, DOI 10.4161/cc.8.23.10086
   Singleton DC, 2012, EXPERT OPIN THER TAR, V16, P1189, DOI 10.1517/14728222.2012.728207
   Walter F, 2015, CELL DEATH DIFFER, V22, P1502, DOI 10.1038/cdd.2014.241
   Wang YG, 2013, NEOPLASIA, V15, P989, DOI 10.1593/neo.13262
   Wang YG, 2012, CANCER RES, V72, P5396, DOI 10.1158/0008-5472.CAN-12-0474
   Ye P, 2014, MOL CELL BIOL, V34, P3421, DOI 10.1128/MCB.00221-14
   Yin Y, 2014, CLIN CANCER RES, V20, P6187, DOI 10.1158/1078-0432.CCR-14-1030
   Zang Y, 2012, AUTOPHAGY, V8, P1873, DOI 10.4161/auto.22185
   Zhang ZH, 2012, CANCER BIOL THER, V13, P435, DOI 10.4161/cbt.19295
   Zhu HW, 2014, CANCER LETT, V354, P142, DOI 10.1016/j.canlet.2014.07.044
   Zhu HW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031431
NR 30
TC 12
Z9 13
U1 2
U2 14
PU BAISHIDENG PUBLISHING GROUP INC
PI PLEASANTON
PA 8226 REGENCY DR, PLEASANTON, CA 94588 USA
SN 1007-9327
EI 2219-2840
J9 WORLD J GASTROENTERO
JI World J. Gastroenterol.
PD JUL 21
PY 2016
VL 22
IS 27
BP 6235
EP 6245
DI 10.3748/wjg.v22.i27.6235
PG 11
WC Gastroenterology & Hepatology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Gastroenterology & Hepatology
GA DS4RV
UT WOS:000380769700012
PM 27468213
OA hybrid, Green Published
DA 2022-04-25
ER

PT J
AU Fu, XJ
   Zhao, WW
   Li, KK
   Zhou, JY
   Chen, XH
AF Fu, Xiaojing
   Zhao, Wenwen
   Li, Kangkang
   Zhou, Jingyi
   Chen, Xuehong
TI Cryptotanshinone Inhibits the Growth of HCT116 Colorectal Cancer Cells
   Through Endoplasmic Reticulum Stress-Mediated Autophagy
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE cryptotanshinone; colorectal cancer; apoptosis; autophagy; endoplasmic
   reticulum stress
ID UNFOLDED-PROTEIN-RESPONSE; INDUCED-APOPTOSIS; PATHWAY; DEATH; ACID
AB Among cancers, colorectal cancer (CRC) has one of the highest annual incidence and death rates. Considering severe adverse reactions associated with classical chemotherapy medications, traditional Chinese medicines have become potential drug candidates. In the current study, the effects of cryptotanshinone (CPT), a major component of Salvia miltiorrhiza Bunge (Danshen) on CRC and underlying mechanism were explored. First of all, data from in vitro experiments and in vivo zebrafish models indicated that CPT selectively inhibited the growth and proliferation of HCT116 and SW620 cells while had little effect on SW480 cells. Secondly, both ER stress and autophagy were associated with CRC viability regulation. Interestingly, ER stress inhibitor and autophagy inhibitor merely alleviated cytotoxic effects on HCT116 cells in response to CPT stimulation, while have little effect on SW620 cells. The significance of apoptosis, autophagy and ER stress were verified by clinical data from CRC patients. In summary, the current study has revealed the anti-cancer effects of CPT in CRC by activating autophagy signaling mediated by ER stress. CPT is a promising drug candidate for CRC treatment.
C1 [Fu, Xiaojing; Zhao, Wenwen; Li, Kangkang; Zhou, Jingyi; Chen, Xuehong] Qingdao Univ, Sch Basic Med, Qingdao, Peoples R China.
   [Zhao, Wenwen] Univ Macau, Inst Chinese Med Sci, State Key Lab Qual Res Chinese Med, Macau, Peoples R China.
RP Chen, XH (corresponding author), Qingdao Univ, Sch Basic Med, Qingdao, Peoples R China.
EM chen-xuehong@163.com
OI chen, xuehong/0000-0003-0102-4023
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81803766]; Key Research and Discovery
   Program of Shandong Province [2019GSF107072]; Natural Science Foundation
   of Shandong ProvinceNatural Science Foundation of Shandong Province
   [ZR2018BH036]; China Postdoctoral Science FoundationChina Postdoctoral
   Science Foundation [2019M652336]; Shandong Key Research and Development
   Program Project [2018GSF118124]; Qingdao Postdoctoral Application
   Research Project
FX This study was supported by the National Natural Science Foundation of
   China (81803766), the Key Research and Discovery Program of Shandong
   Province (2019GSF107072), the Natural Science Foundation of Shandong
   Province (ZR2018BH036) China Postdoctoral Science Foundation
   (2019M652336), and the Qingdao Postdoctoral Application Research Project
   and Shandong Key Research and Development Program Project
   (2018GSF118124).
CR Alper P, 2021, BIOORGAN MED CHEM, V30, DOI 10.1016/j.bmc.2020.115963
   Bhardwaj M, 2020, SEMIN CANCER BIOL, V66, P116, DOI 10.1016/j.semcancer.2019.11.007
   Bravo-San Pedro JM, 2015, AUTOPHAGY, V11, P452, DOI 10.1080/15548627.2015.1017191
   Cai YE, 2016, INT J NANOMED, V11, P121, DOI 10.2147/IJN.S84035
   Chen LL, 2020, J ETHNOPHARMACOL, V260, DOI 10.1016/j.jep.2020.113066
   Chen XP, 2014, MED RES REV, V34, P768, DOI 10.1002/med.21304
   Denton D, 2019, CELL DEATH DIFFER, V26, P605, DOI 10.1038/s41418-018-0252-y
   Ding X, 2016, ANAL CHEM, V88, P12081, DOI 10.1021/acs.analchem.6b02709
   Fang JP, 2021, BIOCHEM BIOPH RES CO, V552, P183, DOI 10.1016/j.bbrc.2021.02.147
   Ferri KF, 2001, NAT CELL BIOL, V3, pE255, DOI 10.1038/ncb1101-e255
   Gomez-Diaz C, 2019, SEMIN CELL DEV BIOL, V93, P125, DOI 10.1016/j.semcdb.2018.09.004
   Grasso S, 2016, EUR J MED CHEM, V122, P611, DOI 10.1016/j.ejmech.2016.06.043
   He Y, 2021, INT J BIOL MACROMOL, V167, P182, DOI 10.1016/j.ijbiomac.2020.11.168
   Huang CF, 2021, TOXICOLOGY, V455, DOI 10.1016/j.tox.2021.152764
   Jhou AJ, 2021, BIOCHEM PHARMACOL, V184, DOI 10.1016/j.bcp.2020.114403
   Kang JH, 2019, BIOMOL THER, V27, P34, DOI 10.4062/biomolther.2018.140
   Kang R, 2011, CELL DEATH DIFFER, V18, P571, DOI 10.1038/cdd.2010.191
   Li HY, 2021, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.592109
   Li XX, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419-021-03605-y
   Liu HB, 2021, PHARMACOL RES, V164, DOI 10.1016/j.phrs.2020.105384
   Lu M, 2014, SCIENCE, V345, P98, DOI 10.1126/science.1254312
   Luo Y, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.01264
   Maranhao SS, 2020, BIOORG MED CHEM LETT, V30, DOI 10.1016/j.bmcl.2019.126851
   Miller KD, 2020, CA-CANCER J CLIN, V70, P443, DOI 10.3322/caac.21637
   Mokarram P, 2019, AUTOPHAGY, V15, P2039, DOI 10.1080/15548627.2019.1606638
   Mowers EE, 2018, FEBS J, V285, P1751, DOI 10.1111/febs.14388
   Munoz-Guardiola P, 2021, AUTOPHAGY, V17, P1349, DOI 10.1080/15548627.2020.1761651
   Nagappan A, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0174591
   Noguchi M, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2724-5
   Park IJ, 2014, APOPTOSIS, V19, P615, DOI 10.1007/s10495-013-0929-0
   Prasad V, 2021, FEMS MICROBIOL REV, V45, DOI 10.1093/femsre/fuab016
   Qi PF, 2019, INT J BIOL SCI, V15, P1072, DOI 10.7150/ijbs.31277
   Rah B, 2015, AUTOPHAGY, V11, P314, DOI 10.1080/15548627.2015.1017182
   Roessler S, 2010, CANCER RES, V70, P10202, DOI 10.1158/0008-5472.CAN-10-2607
   Rouschop KMA, 2010, J CLIN INVEST, V120, P127, DOI 10.1172/JCI40027
   Schleicher SM, 2010, DRUG RESIST UPDATE, V13, P79, DOI 10.1016/j.drup.2010.04.002
   Siegel RL, 2020, CA-CANCER J CLIN, V70, P145, DOI 10.3322/caac.21601
   Siegel RL, 2020, CA-CANCER J CLIN, V70, P7, DOI 10.3322/caac.21590
   Sun C, 2020, PHARMACOL RES, V160, DOI 10.1016/j.phrs.2020.105193
   van Anken E, 2021, TRENDS CELL BIOL, V31, P529, DOI 10.1016/j.tcb.2021.02.004
   Walter P, 2011, SCIENCE, V334, P1081, DOI 10.1126/science.1209038
   Wang H, 2020, PHARMACOL RES, V153, DOI 10.1016/j.phrs.2020.104661
   Wang L, 2021, PHARMACOL RES, V163, DOI 10.1016/j.phrs.2020.105232
   Wang M, 2016, NATURE, V529, P326, DOI 10.1038/nature17041
   Wang YL, 2022, ACTA PHARMACOL SIN, V43, P10, DOI 10.1038/s41401-021-00629-0
   Wang YY, 2018, ONCOL RES, V26, P889, DOI 10.3727/096504017X15009419625178
   Wu CZ, 2020, ADV SCI, V7, DOI 10.1002/advs.202002747
   Xia D, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.347
   Xia YQ, 2021, THERANOSTICS, V11, P4335, DOI 10.7150/thno.52077
   Xie QQ, 2020, TRANSL ONCOL, V13, DOI 10.1016/j.tranon.2020.100871
   Xu DF, 2012, CANCER LETT, V316, P11, DOI 10.1016/j.canlet.2011.10.006
   Xu ZY, 2017, CHEM-BIOL INTERACT, V273, P48, DOI 10.1016/j.cbi.2017.06.003
   Yang YF, 2018, CANCER MED-US, V7, P4610, DOI 10.1002/cam4.1691
   Zhao MM, 2021, OXID MED CELL LONGEV, V2021, DOI 10.1155/2021/5472605
   Zhao WW, 2021, ANTIOXID REDOX SIGN, V34, P351, DOI 10.1089/ars.2019.7796
   Zhao WW, 2019, FOOD FUNCT, V10, P7142, DOI 10.1039/c9fo01891c
   Zheng HY, 2020, TOXICOL APPL PHARM, V409, DOI 10.1016/j.taap.2020.115271
NR 57
TC 0
Z9 0
U1 8
U2 9
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1663-9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD JUN 17
PY 2021
VL 12
AR 653232
DI 10.3389/fphar.2021.653232
PG 12
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA TC5HA
UT WOS:000668668700001
PM 34220498
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Fu, R
   Yang, P
   Li, ZW
   Liu, W
   Amin, S
   Li, ZY
AF Fu, Rong
   Yang, Peng
   Li, Zongwei
   Liu, Wen
   Amin, Sajid
   Li, Zhuoyu
TI Avenanthramide A triggers potent ROS-mediated anti-tumor effects in
   colorectal cancer by directly targeting DDX3
SO CELL DEATH & DISEASE
LA English
DT Article
ID CELL-DEATH; OAT; METABOLISM; MODULATION; AUTOPHAGY; ACIDITY; STRESS
AB Colorectal cancer (CRC) is a common malignant gastrointestinal tumor with high mortality worldwide. Drug resistance and cytotoxicity to normal cells are the main causes of chemotherapeutic treatment failure in CRC. Therefore, extracting the bioactive compounds from natural products with anti-carcinogenic activity and minimal side-effects is a promising strategy against CRC. The present study aims to evaluate the anti-carcinogenic properties of avenanthramides (AVNs) extracted from oats bran and clarify the underlying molecular mechanisms. We demonstrated that AVNs treatment suppressed mitochondrial bioenergetic generation, resulting in mitochondrial swelling and increased reactive oxygen species (ROS) production. Further study indicated that AVNs treatment significantly reduced DDX3 expression, an oncogenic RNA helicase highly expressed in human CRC tissues. DDX3 overexpression reversed the ROS-mediated CRC apoptosis induced by AVNs. Of note, we identified Avenanthramide A (AVN A) as the effective ingredient in AVNs extracts. AVN A blocked the ATPase activity of DDX3 and induced its degradation by directly binding to the Arg287 and Arg294 residues in DDX3. In conclusion, these innovative findings highlight that AVNs extracts, in particular its bioactive compound AVN A may crack the current hurdles in the way of CRC treatment.
C1 [Fu, Rong; Yang, Peng; Liu, Wen; Amin, Sajid; Li, Zhuoyu] Shanxi Univ, Inst Biotechnol, Key Lab Chem Biol & Mol Engn, Natl Minist Educ, Taiyuan 030006, Shanxi, Peoples R China.
   [Fu, Rong; Yang, Peng] Shanxi Univ, Inst Biomed Sci, Taiyuan 030006, Shanxi, Peoples R China.
   [Li, Zongwei] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Ctr Canc Immunol Res, Houston, TX 77030 USA.
   [Li, Zhuoyu] Shanxi Univ, Sch Life Sci, Taiyuan 030006, Shanxi, Peoples R China.
RP Li, ZY (corresponding author), Shanxi Univ, Inst Biotechnol, Key Lab Chem Biol & Mol Engn, Natl Minist Educ, Taiyuan 030006, Shanxi, Peoples R China.; Li, ZY (corresponding author), Shanxi Univ, Inst Biomed Sci, Taiyuan 030006, Shanxi, Peoples R China.
EM lzy@sxu.edu.cn
RI Li, Zongwei/AAM-4135-2021; Amin, Sajid/AAW-6491-2020
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [31800657, 31770382]; "1331 Project" Key
   Innovation Center and Team of Shanxi Province; Shanxi Province Science
   Foundation for Key Projects [201801D111001]; Shanxi Province Science
   Foundation for Youths [201601D021107]; Scientific and Technological
   Innovation Programs of Higher Education Institutions in Shanxi [2016121]
FX This work was supported by the National Natural Science Foundation of
   China (No. 31800657 and 31770382), "1331 Project" Key Innovation Center
   and Team of Shanxi Province (Prof. Zhuoyu Li), Shanxi Province Science
   Foundation for Key Projects (No. 201801D111001), Shanxi Province Science
   Foundation for Youths (No. 201601D021107), Scientific and Technological
   Innovation Programs of Higher Education Institutions in Shanxi (No.
   2016121). We are grateful to the product specialists, Rui Zhang and
   Jiawei Wu from GE Healthcare for their technical assistance in
   Recognition and recovery of DDX3-bound ingredients and SPR affinity
   analysis. We also acknowledge to Dr. Jinping Jia and Prof. Jianbin Chao
   from Scientific Instrument Center of Shanxi University for their
   assistance on HPLC/MS and 1H NMR.
CR Ariumi Y, 2014, FRONT GENET, V5, DOI 10.3389/fgene.2014.00423
   Bhola PD, 2016, MOL CELL, V61, P695, DOI 10.1016/j.molcel.2016.02.019
   Bol GM, 2015, EMBO MOL MED, V7, P648, DOI 10.15252/emmm.201404368
   Bol GM, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0461-7
   Brenner H, 2014, LANCET, V383, P1490, DOI 10.1016/S0140-6736(13)61649-9
   Chen LD, 2018, ANAL CHEM, V90, P8936, DOI 10.1021/acs.analchem.8b01103
   Chikara S, 2018, CANCER LETT, V413, P122, DOI 10.1016/j.canlet.2017.11.002
   Cui L, 2017, ANAL CHEM, V89, P11737, DOI 10.1021/acs.analchem.7b03232
   Dehnel N, 2017, CURR OPIN PHARMACOL, V35, P12, DOI 10.1016/j.coph.2017.04.007
   Ding GB, 2018, ACS APPL MATER INTER, V10, P5227, DOI 10.1021/acsami.7b17454
   Fu JS, 2015, MOL NUTR FOOD RES, V59, P2471, DOI 10.1002/mnfr.201500250
   He TY, 2016, SCI REP-UK, V6, DOI 10.1038/srep21483
   Hitayezu R, 2015, J CEREAL SCI, V63, P35, DOI 10.1016/j.jcs.2015.02.005
   Huang R, 2017, CANCER LETT, V390, P1, DOI 10.1016/j.canlet.2016.12.038
   Hussain SS, 2016, SEMIN CANCER BIOL, V40-41, P233, DOI 10.1016/j.semcancer.2016.06.002
   Ishihara A, 2014, BIOSCI BIOTECH BIOCH, V78, P1975, DOI 10.1080/09168451.2014.946390
   Klemm F, 2015, TRENDS CELL BIOL, V25, P198, DOI 10.1016/j.tcb.2014.11.006
   Meydani M, 2009, NUTR REV, V67, P731, DOI 10.1111/j.1753-4887.2009.00256.x
   Nakazawa MS, 2016, NAT REV CANCER, V16, P663, DOI 10.1038/nrc.2016.84
   Plitzko B, 2017, J BIOL CHEM, V292, P21102, DOI 10.1074/jbc.M116.774836
   Sabharwal SS, 2014, NAT REV CANCER, V14, P709, DOI 10.1038/nrc3803
   Samal SK, 2015, SCI REP-UK, V5, DOI 10.1038/srep09982
   Scarpa ES, 2018, EUR J NUTR, V57, P1381, DOI 10.1007/s00394-017-1418-y
   Shanmugam MK, 2016, SEMIN CANCER BIOL, V40-41, P35, DOI 10.1016/j.semcancer.2016.03.005
   Shrotriya S, 2015, MOL CARCINOGEN, V54, P1734, DOI 10.1002/mc.22246
   Stevens JF, 2018, ANTIOXID REDOX SIGN, V29, P1589, DOI 10.1089/ars.2017.7404
   Taylor S, 2015, DRUG RESIST UPDATE, V23, P69, DOI 10.1016/j.drup.2015.08.004
   van Voss MRH, 2018, ONCOGENE, V37, P63, DOI 10.1038/onc.2017.308
   Weinberg SE, 2015, NAT CHEM BIOL, V11, P9, DOI 10.1038/nchembio.1712
   Wilky BA, 2016, ONCOGENE, V35, P2574, DOI 10.1038/onc.2015.336
   Wu DW, 2017, THERANOSTICS, V7, P1114, DOI 10.7150/thno.18175
   Wu DW, 2016, ONCOTARGET, V7, P22687, DOI 10.18632/oncotarget.8143
   Yang P, 2018, FOOD FUNCT, V9, DOI [10.1039/C8FO01161C, 10.1039/c8fo01161c]
   Yang P, 2014, CELL SIGNAL, V26, P1853, DOI 10.1016/j.cellsig.2014.03.020
   Yu X, 2018, J FOOD SCI, V83, P844, DOI 10.1111/1750-3841.14074
   Zhang L, 2017, CHEM SCI, V8, P2687, DOI 10.1039/c6sc05368h
NR 36
TC 15
Z9 16
U1 3
U2 14
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-4889
J9 CELL DEATH DIS
JI Cell Death Dis.
PD AUG 7
PY 2019
VL 10
AR 593
DI 10.1038/s41419-019-1825-5
PG 14
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA IO3LH
UT WOS:000479281300003
PM 31391454
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Zhao, YY
   Wang, LF
   Wang, YS
   Dong, SY
   Yang, SJ
   Guan, YF
   Wu, X
AF Zhao, Yanyan
   Wang, Lufang
   Wang, Yanshi
   Dong, Siyu
   Yang, Shaojie
   Guan, Yifu
   Wu, Xin
TI Astragaloside IV inhibits cell proliferation in vulvar squamous cell
   carcinoma through the TGF-beta/Smad signaling pathway
SO DERMATOLOGIC THERAPY
LA English
DT Article
DE apoptosis; Astragaloside IV; autophagy; proliferation; TGF-beta; Smad
   pathway; vulvar squamous cell carcinoma
ID COLORECTAL-CANCER; CHINESE MEDICINE; DOWN-REGULATION; APOPTOSIS; LINES;
   G1
AB Objective To explore the inhibition of the proliferation of vulvar squamous cell carcinoma (VSCC) by astragaloside IV. Methods MTT examined the cell proliferation of VSCC. Flow cytometry analyzed cell cycle and apoptosis. Western blot assay detected the expression of some relevant proteins. Results AS-IV reduced the proliferation of SW962 cells in a concentration- and time-dependent manner, induced cell-cycle arresting in G0/G1 phase, as demonstrated by the up-regulation of P53 and P21 expression, and the down-regulation of cyclin D1 expression. AS-IV enhanced the expression of Bax and cleaved-caspase 3, and suppressed Bcl-2 and Bcl-xl expression, which resulted in apoptosis increased. Furthermore, the expression of Beclin-1 and LC3-B was upregulated and that of P62 was downregulated, which suggested that AS-IV could increase the incidence of autophagy in SW962 cells. After inhibiting autophagy by 3-methyladenine (3-MA), cell apoptosis decreased upon AS-IV treatment. Similarly, TGF-beta 1 stimulated SW962 cells, cell proliferation enhanced, and the expression of TGF-beta RII and Smad4 was decreased. Furthermore, the expression of proteins that promote apoptosis and autophagy decreased. After AS-IV treatment, the expression levels of the above proteins exhibited the opposite effect. Conclusion AS-IV inhibits cell proliferation and induces apoptosis and autophagy through the TGF-beta/Smad signaling pathway in VSCC.
C1 [Zhao, Yanyan; Wang, Lufang; Wang, Yanshi; Dong, Siyu; Yang, Shaojie; Wu, Xin] China Med Univ, Dept Gynecol, Affiliated Hosp 1, Shenyang 110001, Liaoning, Peoples R China.
   [Guan, Yifu] China Med Univ, Dept Biochem & Mol Biol, Shenyang, Liaoning, Peoples R China.
RP Wu, X (corresponding author), China Med Univ, Dept Gynecol, Affiliated Hosp 1, Shenyang 110001, Liaoning, Peoples R China.
EM xinwu.1964@aliyun.com
OI Zhao, yanyan/0000-0002-6940-2206
CR Bertoli C, 2013, NAT REV MOL CELL BIO, V14, P518, DOI 10.1038/nrm3629
   Canavan TP, 2002, AM FAM PHYSICIAN, V66, P1269
   Fei ZW, 2016, J CLIN BIOCHEM NUTR, V58, P105, DOI 10.3164/jcbn.15-64
   Hill-Daniel Jamie, 2015, FP Essent, V438, P31
   Ikushima H, 2010, NAT REV CANCER, V10, P415, DOI 10.1038/nrc2853
   Jiang K, 2017, INT IMMUNOPHARMACOL, V42, P195, DOI 10.1016/j.intimp.2016.10.001
   Kaminska B., 2016, ACTA BIOCHIM POL, V52, P329
   Kao ST, 2001, LIFE SCI, V69, P1485, DOI 10.1016/S0024-3205(01)01226-7
   Li B, 2017, BIOCHEM BIOPH RES CO, V491, P98, DOI 10.1016/j.bbrc.2017.07.052
   Li FL, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/956107
   Li M, 2017, NEUROSCI LETT, V639, P114, DOI 10.1016/j.neulet.2016.12.046
   Lin SC, 2016, INT J BIOCHEM CELL B, V71, P24, DOI 10.1016/j.biocel.2015.12.003
   Luo XC, 2016, INT IMMUNOPHARMACOL, V35, P22, DOI 10.1016/j.intimp.2016.03.020
   Ma YH, 2015, INT J MOL MED, V35, P1667, DOI 10.3892/ijmm.2015.2188
   Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239
   Maiuri MC, 2007, EMBO J, V26, P2527, DOI 10.1038/sj.emboj.7601689
   Martelossi C. G. C., 2016, EUR CYTOKINE NETW, V27, P81
   Ren S, 2013, J TRADIT CHIN MED, V33, P413, DOI 10.1016/S0254-6272(13)60189-2
   Schiemann WP, 2007, EXPERT REV ANTICANC, V7, P609, DOI 10.1586/14737140.7.5.609
   SCHMIDT W, 1992, GEBURTSH FRAUENHEILK, V52, P462, DOI 10.1055/s-2007-1023789
   Song Y, 2011, PHYTOTHER RES, V25, P909, DOI 10.1002/ptr.3354
   Wang LF, 2018, MOL MED REP, V17, P4299, DOI 10.3892/mmr.2018.8455
   Wang SX, 2018, BIOMED PHARMACOTHER, V102, P1037, DOI 10.1016/j.biopha.2018.03.127
   Wang Y., 2016, SHANXI MED J, V45, P627
   Wu ZM, 2018, CANCER MED-US, V7, P1546, DOI 10.1002/cam4.1419
   Xia QM, 2014, J CANCER RES THER, V10, P1, DOI 10.4103/0973-1482.139741
   Xie T, 2016, ONCOL RES, V24, P447, DOI 10.3727/096504016X14685034103590
   Yuan W, 2008, PLANTA MED, V74, P1259, DOI 10.1055/s-2008-1081290
   Zhou XJ, 2017, INT IMMUNOPHARMACOL, V42, P18, DOI 10.1016/j.intimp.2016.11.006
   Zhu JH, 2018, PHYTOTHER RES, V32, P1289, DOI 10.1002/ptr.6057
NR 30
TC 5
Z9 6
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1396-0296
EI 1529-8019
J9 DERMATOL THER
JI Dermatol. Ther.
PD JUL-AUG
PY 2019
VL 32
IS 4
AR e12802
DI 10.1111/dth.12802
PG 7
WC Dermatology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Dermatology
GA IP7SN
UT WOS:000480248400054
PM 30536730
DA 2022-04-25
ER

PT J
AU Hwang, WC
   Kim, MK
   Song, JH
   Choi, KY
   Min, DS
AF Hwang, Won Chan
   Kim, Mi Kyoung
   Song, Ju Hyun
   Choi, Kang-Yell
   Min, Do Sik
TI Inhibition of phospholipase D2 induces autophagy in colorectal cancer
   cells
SO EXPERIMENTAL AND MOLECULAR MEDICINE
LA English
DT Article
ID MAMMALIAN AUTOPHAGY; BREAST-CANCER; MTOR; EXPRESSION; ISOFORM; HOMOLOG;
   PROTEIN; GROWTH; LC3; PLD
AB Autophagy is a conserved lysosomal self-digestion process used for the breakdown of long-lived proteins and damaged organelles, and it is associated with a number of pathological processes, including cancer. Phospholipase D (PLD) isozymes are dysregulated in various cancers. Recently, we reported that PLD1 is a new regulator of autophagy and is a potential target for cancer therapy. Here, we investigated whether PLD2 is involved in the regulation of autophagy. A PLD2-specific inhibitor and siRNA directed against PLD2 were used to treat HT29 and HCT116 colorectal cancer cells, and both inhibition and genetic knockdown of PLD2 in these cells significantly induced autophagy, as demonstrated by the visualization of light chain 3 (LC3) puncta and autophagic vacuoles as well as by determining the LC3-II protein level. Furthermore, PLD2 inhibition promoted autophagic flux via the canonical Atg5-, Atg7- and AMPK-Ulk1-mediated pathways. Taken together, these results suggest that PLD2 might have a role in autophagy and that its inhibition might provide a new therapeutic basis for targeting autophagy.
C1 [Hwang, Won Chan; Kim, Mi Kyoung; Song, Ju Hyun; Min, Do Sik] Pusan Natl Univ, Dept Mol Biol, Coll Nat Sci, Pusan 609735, South Korea.
   [Choi, Kang-Yell; Min, Do Sik] Yonsei Univ, Translat Res Ctr Prot Funct Control, Seoul 120749, South Korea.
   [Choi, Kang-Yell] Yonsei Univ, Dept Biotechnol, Coll Life Sci & Biotechnol, Seoul 120749, South Korea.
RP Min, DS (corresponding author), Pusan Natl Univ, Dept Mol Biol, Coll Nat Sci, 30 Jangjeon Dong, Pusan 609735, South Korea.
EM minds@pusan.ac.kr
FU National Research Foundation of Korea (NRF) - Korean government
   (MEST)Ministry of Education, Science and Technology, Republic of
   KoreaNational Research Foundation of KoreaKorean Government
   [2012002009]; Translational Research Center for Protein Function Control
   Grant [NSF 2009-0092960]
FX This study was supported by a National Research Foundation of Korea
   (NRF) grant funded by the Korean government (MEST; No. 2012002009) and a
   Translational Research Center for Protein Function Control Grant (NSF
   2009-0092960). We thank Dr G Velasco (Complutense University), M Komatsu
   (Tokyo Metropolitan Institute of Medical Science) and M Kundu (St Jude
   Children's Hospital) for materials.
CR Bruntz RC, 2014, J BIOL CHEM, V289, P600, DOI 10.1074/jbc.M113.532978
   Bursch W, 1996, CARCINOGENESIS, V17, P1595, DOI 10.1093/carcin/17.8.1595
   Chen Q, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2003257
   Colley WC, 1997, CURR BIOL, V7, P191, DOI 10.1016/S0960-9822(97)70090-3
   Crighton D, 2006, CELL, V126, P121, DOI 10.1016/j.cell.2006.05.034
   Cuzick J, 2011, LANCET ONCOL, V12, P496, DOI 10.1016/S1470-2045(11)70030-4
   Dall'Armi C, 2010, NAT COMMUN, V1, DOI 10.1038/ncomms1144
   Efeyan A, 2010, CURR OPIN CELL BIOL, V22, P169, DOI 10.1016/j.ceb.2009.10.007
   Faivre S, 2006, NAT REV DRUG DISCOV, V5, P671, DOI 10.1038/nrd2062
   Foster DA, 2007, CANCER RES, V67, P1, DOI 10.1158/0008-5472.CAN-06-3016
   HAMMOND SM, 1995, J BIOL CHEM, V270, P29640
   Henkels KM, 2013, ONCOGENE, V32, P5551, DOI 10.1038/onc.2013.207
   Hosokawa N, 2007, FEBS LETT, V581, P2623, DOI 10.1016/j.febslet.2006.04.008
   Jang YH, 2014, CELL DEATH DIFFER, V21, P533, DOI 10.1038/cdd.2013.174
   Janku F, 2011, NAT REV CLIN ONCOL, V8, P528, DOI 10.1038/nrclinonc.2011.71
   Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720
   Kang DW, 2014, J BIOL CHEM, V289, P22575, DOI 10.1074/jbc.R114.569822
   Kim J, 2006, CANCER RES, V66, P784, DOI 10.1158/0008-5472.CAN-05-1316
   Kim J, 2011, NAT CELL BIOL, V13, P132, DOI 10.1038/ncb2152
   Kimura S, 2007, AUTOPHAGY, V3, P452, DOI 10.4161/auto.4451
   Komatsu M, 2005, J CELL BIOL, V169, P425, DOI 10.1083/jcb.200412022
   Kuma A, 2010, SEMIN CELL DEV BIOL, V21, P683, DOI 10.1016/j.semcdb.2010.03.002
   Meley D, 2006, J BIOL CHEM, V281, P34870, DOI 10.1074/jbc.M605488200
   Mizushima N, 2004, INT J BIOCHEM CELL B, V36, P2491, DOI 10.1016/j.biocel.2004.02.005
   Mizushima N, 2010, CELL, V140, P313, DOI 10.1016/j.cell.2010.01.028
   Ravikumar B, 2010, PHYSIOL REV, V90, P1383, DOI 10.1152/physrev.00030.2009
   Saito M, 2007, ONCOL REP, V18, P1329
   Sarkar S, 2007, NAT CHEM BIOL, V3, P331, DOI 10.1038/nchembio883
   Scott SA, 2009, NAT CHEM BIOL, V5, P108, DOI 10.1038/nchembio.140
   Sun YT, 2008, CELL CYCLE, V7, P3118, DOI 10.4161/cc.7.20.6881
   Tanida I, 2005, AUTOPHAGY, V1, P84, DOI 10.4161/auto.1.2.1697
   Tasdemir E, 2008, NAT CELL BIOL, V10, P676, DOI 10.1038/ncb1730
   Yang ZF, 2010, NAT CELL BIOL, V12, P814, DOI 10.1038/ncb0910-814
NR 33
TC 12
Z9 13
U1 0
U2 6
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 1226-3613
EI 2092-6413
J9 EXP MOL MED
JI Exp. Mol. Med.
PD DEC
PY 2014
VL 46
AR e124
DI 10.1038/emm.2014.74
PG 8
WC Biochemistry & Molecular Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Research & Experimental Medicine
GA AZ2KY
UT WOS:000348063700001
PM 25475140
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Fiorito, S
   Flahaut, E
   Rapino, S
   Paolucci, F
   Andreola, F
   Moroni, N
   Pittaluga, E
   Zonfrillo, M
   Valenti, G
   Mastrofrancesco, A
   Groppi, F
   Sabbioni, E
   Bakalis, E
   Zerbetto, F
   Serafino, A
AF Fiorito, Silvana
   Flahaut, Emmanuel
   Rapino, Stefania
   Paolucci, Francesco
   Andreola, Federica
   Moroni, Noemi
   Pittaluga, Eugenia
   Zonfrillo, Manuela
   Valenti, Giovanni
   Mastrofrancesco, Arianna
   Groppi, Flavia
   Sabbioni, Enrico
   Bakalis, Evangelos
   Zerbetto, Francesco
   Serafino, Annalucia
TI Redox active Double Wall Carbon Nanotubes show intrinsic
   anti-proliferative effects and modulate autophagy in cancer cells
SO CARBON
LA English
DT Article
ID METALLIC IMPURITIES; NEURONAL GROWTH; INTERFACING NEURONS; CCVD
   SYNTHESIS; APOPTOSIS; ELECTROCHEMISTRY; ELECTRODES; OXIDATION;
   STIMULATION; HYPOXIA
AB In Double-Walled-Carbon-Nanotubes (DWCNTs) the outer shell screens the inner one from the external environment. As a consequence, the electronic properties of the smaller tube are enhanced and DWCNTs have therefore been advocated for a number of uses. In their raw form they may contain small metallic clusters, left over from the catalytic process, that can give them a redox activity characterized by redox potentials in the range of one hundred millivolts and able to affect biological systems. Indeed, we find that redox active raw-DWCNTs inhibit rat colorectal cancer cell proliferation by blocking cells in the G2 phase through ROS generation by tumor cells. We show that raw-DWCNTs could also modulate autophagy in tumor cells through induction of intracellular acidification. To the best of our knowledge, this is the first time that DWCNTs have been found to inhibit proliferation and modulate autophagy in cancer cells. Our work further supports previous studies that provided promising results on the possibility of future applications of Carbon Nanotubes (CNTs) in nanomedicine. (C) 2014 Elsevier Ltd. All rights reserved.
C1 [Fiorito, Silvana] Univ Roma La Sapienza, Dipartimento Med Clin, I-00185 Rome, Italy.
   [Flahaut, Emmanuel] Univ Toulouse 3, CNRS CIRIMAT, F-31062 Toulouse, France.
   [Rapino, Stefania; Paolucci, Francesco; Valenti, Giovanni; Bakalis, Evangelos; Zerbetto, Francesco] Univ Bologna, Dipartimento Chim G Ciamician, I-40126 Bologna, Italy.
   [Fiorito, Silvana; Andreola, Federica; Moroni, Noemi; Pittaluga, Eugenia; Zonfrillo, Manuela; Serafino, Annalucia] CNR, Inst Translat Pharmacol, I-00133 Rome, Italy.
   [Mastrofrancesco, Arianna] IRCCS, San Gallicano Dermatol Inst, Rome, Italy.
   [Groppi, Flavia] Univ Milan, Segrate, MI, Italy.
   [Groppi, Flavia] Ist Nazl Fis Nucl, Lab Radiochim LASA, Segrate, MI, Italy.
   [Sabbioni, Enrico] CeSI, Fdn Univ G DAnnunzio, Chieti, Italy.
RP Fiorito, S (corresponding author), Univ Roma La Sapienza, Dipartimento Med Clin, Viale Univ 37, I-00185 Rome, Italy.
EM silvana.fiorito@uniroma1.it
RI FLAHAUT, Emmanuel/B-7964-2009; Zerbetto, Francesco/D-2503-2014;
   Zonfrillo, Manuela/A-3172-2016; Paolucci, Francesco/A-8708-2008;
   Serafino, Annalucia/AAC-1719-2019; Mastrofrancesco, Arianna/K-2433-2018;
   Bakalis, Evangelos/AAY-4577-2020; Valenti, Giovanni/M-5876-2017; Groppi,
   Flavia/S-4052-2019
OI FLAHAUT, Emmanuel/0000-0001-8344-6902; Zerbetto,
   Francesco/0000-0002-2419-057X; Zonfrillo, Manuela/0000-0001-6457-2380;
   Paolucci, Francesco/0000-0003-4614-8740; Serafino,
   Annalucia/0000-0002-1142-4752; Mastrofrancesco,
   Arianna/0000-0003-1231-3832; Valenti, Giovanni/0000-0002-6223-2072;
   Groppi, Flavia/0000-0002-8987-8375; Bakalis,
   Evangelos/0000-0002-0036-7887
CR Ambrosi A, 2010, CHEM-EUR J, V16, P1786, DOI 10.1002/chem.200902534
   Bottini M, 2006, TOXICOL LETT, V160, P121, DOI 10.1016/j.toxlet.2005.06.020
   Chen Y, 2008, CELL DEATH DIFFER, V15, P171, DOI 10.1038/sj.cdd.4402233
   Chen Y, 2009, CELL DEATH DIFFER, V16, P1040, DOI 10.1038/cdd.2009.49
   Chiche J, 2010, J CELL MOL MED, V14, P771, DOI 10.1111/j.1582-4934.2009.00994.x
   Comes F, 2007, CELL DEATH DIFFER, V14, P693, DOI 10.1038/sj.cdd.4402076
   Cui DX, 2005, TOXICOL LETT, V155, P73, DOI 10.1016/j.toxlet.2004.08.015
   De Nicola M, 2007, J PHYS-CONDENS MAT, V19, DOI 10.1088/0953-8984/19/39/395013
   Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001
   Fabbro A, 2011, PROG BRAIN RES, V194, P241, DOI 10.1016/B978-0-444-53815-4.00003-0
   Fiorito S, 2009, CARBON, V47, P2789, DOI 10.1016/j.carbon.2009.06.023
   Firestone R.B., 1999, TABLE ISOTOPES
   Flahaut E, 2003, CHEM COMMUN, P1442, DOI 10.1039/b301514a
   Gatenby RA, 2004, NAT REV CANCER, V4, P891, DOI 10.1038/nrc1478
   Gatenby RA, 2008, NAT REV CANCER, V8, P56, DOI 10.1038/nrc2255
   Guo L, 2007, CHEM MATER, V19, P3472, DOI 10.1021/cm062691p
   Hanson HH, 2010, J BIOL CHEM, V285, P20982, DOI 10.1074/jbc.M109.092031
   Hu H, 2004, NANO LETT, V4, P507, DOI 10.1021/nl035193d
   Hu H, 2005, J PHYS CHEM B, V109, P4285, DOI 10.1021/jp0441137
   Huang J, 2011, ANTIOXID REDOX SIGN, V14, P2215, DOI 10.1089/ars.2010.3554
   Huber V, 2010, J TRANSL MED, V15, P8
   JACKSON JD, 1975, CLASSICAL ELECTRODYN, P116
   Keefer EW, 2008, NAT NANOTECHNOL, V3, P434, DOI 10.1038/nnano.2008.174
   Kill IR, 1996, J CELL SCI, V109, P1253
   Klionsky DJ, 2012, AUTOPHAGY, V8, P445, DOI 10.4161/auto.19496
   Koyama S, 2009, CARBON, V47, P1365, DOI 10.1016/j.carbon.2009.01.028
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lovat V, 2005, NANO LETT, V5, P1107, DOI 10.1021/nl050637m
   Lukanov P, 2011, ADV FUNCT MATER, V21, P3583, DOI 10.1002/adfm.201100364
   Mattson MP, 2000, J MOL NEUROSCI, V14, P175, DOI 10.1385/JMN:14:3:175
   Mazzatenta A, 2007, J NEUROSCI, V27, P6931, DOI 10.1523/JNEUROSCI.1051-07.2007
   McKenzie JL, 2004, BIOMATERIALS, V25, P1309, DOI 10.1016/j.biomaterials.2003.08.006
   Miller JR, 1999, ONCOGENE, V18, P7860, DOI 10.1038/sj.onc.1203245
   Musameh M, 2002, ELECTROCHEM COMMUN, V4, P743, DOI 10.1016/S1388-2481(02)00451-4
   Nam CW, 2011, ARCH PHARM RES, V34, P661, DOI 10.1007/s12272-011-0417-4
   Nugent JM, 2001, NANO LETT, V1, P87, DOI 10.1021/nl005521z
   Osswald S, 2005, CHEM PHYS LETT, V402, P422, DOI 10.1016/j.cplett.2004.12.066
   Pumera M, 2009, J PHYS CHEM C, V113, P4401, DOI 10.1021/jp900069e
   Ravikumar B, 2010, PHYSIOL REV, V90, P1383, DOI 10.1152/physrev.00030.2009
   Rodriguez-Fernandez L, 2012, ACS NANO, V6, P6614, DOI 10.1021/nn302222m
   Rofstad EK, 2006, CANCER RES, V66, P6699, DOI 10.1158/0008-5472.CAN-06-0983
   Scherz-Shouval R, 2007, EMBO J, V26, P1749, DOI 10.1038/sj.emboj.7601623
   Seichepine F, 2012, NANOTECHNOLOGY, V23, DOI 10.1088/0957-4484/23/9/095303
   Serafino A, 2012, NANOMED-NANOTECHNOL, V8, P299, DOI 10.1016/j.nano.2011.06.018
   Stuart EJE, 2010, J PHYS CHEM C, V114, P21296, DOI 10.1021/jp108819s
   Supronowicz PR, 2002, J BIOMED MATER RES, V59, P499, DOI 10.1002/jbm.10015
   Teng X, 2011, AUTOPHAGY, V7, P1316
   Valko M, 2007, INT J BIOCHEM CELL B, V39, P44, DOI 10.1016/j.biocel.2006.07.001
   Wang JX, 2002, ANAL CHEM, V74, P1993, DOI 10.1021/ac010978u
   Wang JX, 2002, ELECTROANAL, V14, P225, DOI 10.1002/1521-4109(200202)14:3<225::AID-ELAN225>3.0.CO;2-I
   Wang ZH, 2002, ANALYST, V127, P653, DOI 10.1039/b201060g
   Wong CH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009996
   Zhang HY, 2009, TOXICOL SCI, V110, P376, DOI 10.1093/toxsci/kfp101
NR 53
TC 5
Z9 5
U1 1
U2 53
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0008-6223
EI 1873-3891
J9 CARBON
JI Carbon
PD NOV
PY 2014
VL 78
BP 589
EP 600
DI 10.1016/j.carbon.2014.07.046
PG 12
WC Chemistry, Physical; Materials Science, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry; Materials Science
GA AO6LP
UT WOS:000341463900061
OA Green Published, Green Accepted
DA 2022-04-25
ER

PT J
AU Li, DT
   Wang, PP
   Luo, YH
   Zhao, MY
   Chen, F
AF Li, Daotong
   Wang, Pengpu
   Luo, Yinghua
   Zhao, Mengyao
   Chen, Fang
TI Health benefits of anthocyanins and molecular mechanisms: Update from
   recent decade
SO CRITICAL REVIEWS IN FOOD SCIENCE AND NUTRITION
LA English
DT Review
DE Anthocyanins; benefits; mechanism; anti-cancer activity;
   anti-inflammation activity; neuroprotective activity
ID E-DEFICIENT MICE; SPINAL-CORD-INJURY; RICH EXTRACT; IN-VITRO;
   ENDOTHELIAL-CELLS; COLON-CANCER; HEPATOCELLULAR-CARCINOMA;
   CARDIOVASCULAR-DISEASE; MART. FRUIT; MOUSE MODEL
AB Anthocyanins are one of the most widespread families of natural pigments in the plant kingdom. Their health beneficial effects have been documented in many in vivo and in vitro studies. This review summarizes the most recent literature regarding the health benefits of anthocyanins and their molecular mechanisms. It appears that several signaling pathways, including mitogen- activated protein kinase, nuclear factor B-k, AMP- activated protein kinase, and Wnt/ beta- catenin, as well as some crucial cellular processes, such as cell cycle, apoptosis, autophagy, and biochemical metabolism, are involved in these beneficial effects and may provide potential therapeutic targets and strategies for the improvement of a wide range of diseases in future. In addition, specific anthocyanin metabolites contributing to the observed in vivo biological activities, structure- activity relationships as well as additive and synergistic efficacy of anthocyanins are also discussed.
   Abbreviations: ABCA1: ATP- binding cassette transporter A1; ABCG1: ATP- binding cassette transporter G1; ACC: acetyl- CoA carboxylase; ACO: acyl- CoA oxidase; AD: Alzheimer's disease; AIF: apoptosis- inducing factor; AMPK: AMPactivated protein kinase; AP- 1: activator protein- 1; aP2: adipocyte fatty acid binding protein; apo E-/-: apolipoprotein E- deficient; APP: amyloid precursor protein; Atg5: autophagy- related gene 5; ATGL: adipose triglyceride lipase; ATP: adenosine triphosphate; Ab: amyloid- beta peptide; C/ EBP delta: CCAAT/ enhancer- binding protein; COX- 2: cyclooxygenase- 2; CPT1A: carnitine palmitoyltransferase- 1A; CRP: C- reactive protein; eIF2 alpha: eukaryotic initiation factor 2asubunit; Endo G: endonuclease G; ERK: extracellular signal-regulated kinase; FFAs: free fatty acids; FoxO1: forkhead box O1; G6Pase: glucose-6-phosphatase; GFAT: glutamine: fructose 6-phosphate aminotransferase; Glut2: glucose transporter 2; Glut4: glucose transporter 4; GSK3b: glycogen synthase kinase 3 beta; HBP: hexosamine biosynthetic pathway; IL: interleukin; iNOS: inducible nitric oxide synthase; JNK: c-Jun N-terminal kinase; LPL: lipoprotein lipaseand; LPS: lipopolysaccharide; MAPK: mitogen-activated protein kinase; MMP: matrix metalloproteinase; mtGPAT1: mitochondrial acyl-CoA: glycerol-sn-3-phosphate acyltransferase 1; mTOR: mammalian target of rapamycin; NF-kB: nuclear factor kB; NO: nitric oxide; OGD: oxygen-glucose deprivation; oxLDL: oxidative modification of low-density lipoprotein; PARP: poly ADP-ribose polymerase; PCA: protocatechuic acid; PD: Parkinson's disease; PEPCK: phosphoenol pyruvate carboxykinase; PGE(2): prostaglandin E2; PhIP: 2-amino-1-methyl-6-phenylimidazo [ 4,5-b] pyridine; PKCz: protein kinase C z; PPAR gamma: peroxisome proliferator-activated receptor gamma; Pt: petunidin; RCT: reverse cholesterol transport; ROS: reactive oxygen species; RR-ARFs: anthocyanin-rich fractions from red raspberries; SCI: spinal cord injury; SGLT1: sodium-dependent glucose transporter 1; STAT3: signal transducers and activators of transcription 3; TG: triglycerides; TNF: tumor necrosis factor; TRAFs: tumor necrosis factor receptor-associated factors; UCP2: uncoupling protein 2; UDP-GlcNAc: UDP-N-acetylglucosamine production
C1 [Li, Daotong; Wang, Pengpu; Zhao, Mengyao; Chen, Fang] China Agr Univ, Natl Engn Res Ctr Fruit & Vegetable Proc, Key Lab Fruits & Vegetables Proc, Coll Food Sci & Nutr Engn,Minist Agr, Beijing, Peoples R China.
   [Li, Daotong; Wang, Pengpu; Zhao, Mengyao; Chen, Fang] China Agr Univ, Engn Res Ctr Fruits & Vegetables Proc, Minist Educ, Beijing, Peoples R China.
   [Luo, Yinghua] Univ Maryland, Dept Nutr & Food Sci, College Pk, MD 20742 USA.
RP Chen, F (corresponding author), China Agr Univ, Coll Food Sci & Nutr Engn, 17,East Qinghua Rd, Beijing 100083, Peoples R China.
EM chenfangch@sina.com
OI Zhao, Mengyao/0000-0002-5038-8504
FU Program for New Century Excellent Talents in University (NCET)Program
   for New Century Excellent Talents in University (NCET) [12-0520];
   National Basic Research Program of China (973 Program)National Basic
   Research Program of China [2012CB720805]; National Natural Science
   Foundation of China (NSFC)National Natural Science Foundation of China
   (NSFC) [81102152]; National Science & Technology Support Plan of the
   Chinese Ministry of EducationMinistry of Education, China [2011BAD39B00]
FX This work was supported by Program for New Century Excellent Talents in
   University (NCET) No. 12-0520, the National Basic Research Program of
   China (973 Program) No. 2012CB720805, and the National Natural Science
   Foundation of China (NSFC) No. 81102152, and the National Science &
   Technology Support Plan of the Chinese Ministry of Education No.
   2011BAD39B00.
CR Afaq F, 2005, INT J CANCER, V113, P423, DOI 10.1002/ijc.20587
   Akiyama S, 2012, BIOFACTORS, V38, P226, DOI 10.1002/biof.1008
   Alzaid F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078932
   Andersen O. M., 2001, ANTHOCYANINS
   Andersen O. M., 2006, FLAVONOIDS CHEM BIOC
   Aqil F, 2012, NUTR CANCER, V64, P428, DOI 10.1080/01635581.2012.657766
   Hassimotto NMA, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/146716
   Barrios J, 2010, J AGR FOOD CHEM, V58, P2100, DOI 10.1021/jf9041497
   Bishayee A, 2011, J NUTR BIOCHEM, V22, P1035, DOI 10.1016/j.jnutbio.2010.09.001
   Bishayee A, 2010, NAT PROD COMMUN, V5, P1613
   Bobe G, 2006, J AGR FOOD CHEM, V54, P9322, DOI 10.1021/jf0612169
   Bunea A, 2013, PHYTOCHEMISTRY, V95, P436, DOI 10.1016/j.phytochem.2013.06.018
   Cassidy A, 2013, CIRCULATION, V127, P188, DOI 10.1161/CIRCULATIONAHA.112.122408
   Chang H, 2010, NUTR CANCER, V62, P1128, DOI 10.1080/01635581.2010.494821
   Dai J, 2009, FOOD CHEM TOXICOL, V47, P837, DOI 10.1016/j.fct.2009.01.016
   de Pascual-Teresa S, 2014, ARCH BIOCHEM BIOPHYS, V559, P68, DOI 10.1016/j.abb.2014.04.012
   de Pascual-Teresa Sonia, 2008, Phytochemistry Reviews, V7, P281, DOI 10.1007/s11101-007-9074-0
   Devi PS, 2011, INT J BREAST CANCER, V2011, DOI 10.4061/2011/891481
   Edirisinghe I, 2011, BRIT J NUTR, V106, P913, DOI 10.1017/S0007114511001176
   Fernandes I, 2014, J FUNCT FOODS, V7, P54, DOI 10.1016/j.jff.2013.05.010
   Filipiak K, 2014, FOOD FUNCT, V5, P381, DOI 10.1039/c3fo60465a
   Forester SC, 2014, MOL CARCINOGEN, V53, P432, DOI 10.1002/mc.21974
   Ghosh D, 2007, ASIA PAC J CLIN NUTR, V16, P200
   Graf D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066690
   Guo HH, 2007, PLANT FOOD HUM NUTR, V62, P1, DOI 10.1007/s11130-006-0031-7
   Guo HH, 2012, FOOD CHEM TOXICOL, V50, P3040, DOI 10.1016/j.fct.2012.06.015
   Guo HH, 2011, J LIPID RES, V52, P908, DOI 10.1194/jlr.M013375
   Hagiwara A, 2001, CANCER LETT, V171, P17, DOI 10.1016/S0304-3835(01)00510-9
   He JA, 2010, ANNU REV FOOD SCI T, V1, P163, DOI 10.1146/annurev.food.080708.100754
   Hou DX, 2005, BIOCHEM PHARMACOL, V70, P417, DOI 10.1016/j.bcp.2005.05.003
   Hung TC, 2014, EVID-BASED COMPL ALT, V2014, DOI 10.1155/2014/450592
   Hwa KS, 2011, PHYTOTHER RES, V25, P1415, DOI 10.1002/ptr.3421
   Jang H, 2010, J AGR FOOD CHEM, V58, P12686, DOI 10.1021/jf102688g
   Jing P, 2008, J AGR FOOD CHEM, V56, P9391, DOI 10.1021/jf8005917
   Jurgonski A, 2013, NUTRITION, V29, P898, DOI 10.1016/j.nut.2012.11.006
   Kao ES, 2009, CHEM-BIOL INTERACT, V179, P212, DOI 10.1016/j.cbi.2009.01.009
   Kay CD, 2006, NUTR RES REV, V19, P137, DOI 10.1079/NRR2005116
   Kim KT, 2011, J KOREAN NEUROSURG S, V49, P205, DOI 10.3340/jkns.2011.49.4.205
   Kim YK, 2012, BIOMOL THER, V20, P68, DOI 10.4062/biomolther.2012.20.1.068
   Kocic B, 2011, J BUON, V16, P602
   Koide T, 1996, CANCER BIOTHER RADIO, V11, P273, DOI 10.1089/cbr.1996.11.273
   Koide T, 1997, CANCER BIOTHER RADIO, V12, P277, DOI 10.1089/cbr.1997.12.277
   Konczak-Islam I, 2003, J AGR FOOD CHEM, V51, P5916, DOI 10.1021/jf030066o
   Lala G, 2006, NUTR CANCER, V54, P84, DOI 10.1207/s15327914nc5401_10
   Li GL, 2013, J ACAD NUTR DIET, V113, P786, DOI 10.1016/j.jand.2013.01.018
   Li L, 2014, SCI REP-UK, V4, DOI 10.1038/srep06234
   Lim S, 2013, MOL NUTR FOOD RES, V57, P1908, DOI 10.1002/mnfr.201300040
   Liu LK, 2008, J FOOD SCI, V73, pH113, DOI 10.1111/j.1750-3841.2008.00801.x
   Liu Y, 2014, AM J PHYSIOL-ENDOC M, V306, pE975, DOI 10.1152/ajpendo.00699.2013
   Longo L, 2008, MOL CANCER THER, V7, P2476, DOI 10.1158/1535-7163.MCT-08-0361
   Lu XL, 2014, FOOD FUNCT, V5, P2892, DOI 10.1039/c4fo00391h
   Malik M, 2003, NUTR CANCER, V46, P186, DOI 10.1207/S15327914NC4602_12
   Mauray A, 2012, NUTR METAB CARDIOVAS, V22, P72, DOI 10.1016/j.numecd.2010.04.011
   Mauray A, 2010, GENES NUTR, V5, P343, DOI 10.1007/s12263-010-0171-0
   Mazza G., 1993, ANTHOCYANINS FRUITS
   McGhie TK, 2007, MOL NUTR FOOD RES, V51, P702, DOI 10.1002/mnfr.200700092
   Min JY, 2011, NEUROSCI LETT, V500, P157, DOI 10.1016/j.neulet.2011.05.048
   Mink PJ, 2007, AM J CLIN NUTR, V85, P895, DOI 10.1093/ajcn/85.3.895
   Miyake S, 2012, LAB INVEST, V92, P102, DOI 10.1038/labinvest.2011.132
   Mpiana PT, 2010, BLOOD TRANSFUS-ITALY, V8, P248, DOI [10.2450/2009.0120-09, 10.2450/2009.0120.09]
   Muraki I, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f5001
   NHANES, 2001, NAT HLTH NUTR EX SUR
   Paixao J, 2011, APOPTOSIS, V16, P976, DOI 10.1007/s10495-011-0632-y
   Park SY, 2014, BMC COMPLEM ALTERN M, V14, DOI 10.1186/1472-6882-14-109
   Peiffer DS, 2014, CANCER PREV RES, V7, P574, DOI 10.1158/1940-6207.CAPR-14-0003
   Poulose SM, 2012, J AGR FOOD CHEM, V60, P1084, DOI 10.1021/jf203989k
   Reddivari L, 2007, CARCINOGENESIS, V28, P2227, DOI 10.1093/carcin/bgm117
   RIMM EB, 1991, LANCET, V338, P464, DOI 10.1016/0140-6736(91)90542-W
   Rugina D, 2012, J MED FOOD, V15, P700, DOI 10.1089/jmf.2011.0246
   Samuels TL, 2013, ANN OTO RHINOL LARYN, V122, P632, DOI 10.1177/000348941312201006
   Shih PH, 2010, J NUTR BIOCHEM, V21, P598, DOI 10.1016/j.jnutbio.2009.03.008
   Singletary KW, 2007, J MED FOOD, V10, P244, DOI 10.1089/jmf.2006.258
   Sohn DW, 2014, UROLOGY, V84, P1112, DOI 10.1016/j.urology.2014.06.026
   Srivastava A, 2007, J AGR FOOD CHEM, V55, P3180, DOI 10.1021/jf062915o
   Strathearn KE, 2014, BRAIN RES, V1555, P60, DOI 10.1016/j.brainres.2014.01.047
   Takikawa M, 2010, J NUTR, V140, P527, DOI 10.3945/jn.109.118216
   Tall JM, 2004, BEHAV BRAIN RES, V153, P181, DOI 10.1016/j.bbr.2003.11.011
   Taverniti V, 2014, J AGR FOOD CHEM, V62, P8346, DOI 10.1021/jf502180j
   Tsai TC, 2014, J AGR FOOD CHEM, V62, P1572, DOI 10.1021/jf405235j
   Tsuda T, 2002, J NUTR SCI VITAMINOL, V48, P305, DOI 10.3177/jnsv.48.305
   Tsuda T, 2004, BIOCHEM BIOPH RES CO, V316, P149, DOI 10.1016/j.bbrc.2004.02.031
   Vepsalainen S, 2013, J NUTR BIOCHEM, V24, P360, DOI 10.1016/j.jnutbio.2012.07.006
   Wallace TC, 2011, ADV NUTR, V2, P1, DOI 10.3945/an.110.000042
   Wang CC, 2013, DIABETES-METAB RES, V29, P398, DOI 10.1002/dmrr.2406
   Wang DL, 2012, CIRC RES, V111, P967, DOI [10.1161/CIRCRESAHA.112.266502, 10.1161/circresaha.112.266502]
   Wang J, 2012, NEUROCHEM RES, V37, P2814, DOI 10.1007/s11064-012-0883-1
   Wang LS, 2008, CANCER LETT, V269, P281, DOI 10.1016/j.canlet.2008.05.020
   Welch CR, 2008, CURR ANAL CHEM, V4, P75, DOI 10.2174/157341108784587795
   Wu T, 2013, FOOD FUNCT, V4, P1654, DOI 10.1039/c3fo60251f
   Wu XL, 2006, J AGR FOOD CHEM, V54, P4069, DOI 10.1021/jf060300l
   Xia M, 2007, ARTERIOSCL THROM VAS, V27, P519, DOI 10.1161/01.ATV.0000254672.04573.2d
   Xia M, 2009, ATHEROSCLEROSIS, V202, P41, DOI 10.1016/j.atherosclerosis.2008.04.005
   Xia XD, 2006, J NUTR, V136, P2220, DOI 10.1093/jn/136.8.2220
   Xiao JB, 2015, CURR MED CHEM, V22, P23
   Ye JL, 2010, NEUROCHEM RES, V35, P357, DOI 10.1007/s11064-009-0063-0
   Yoon B. I., 2013, CHIN J INTEGR MED, V14
   You J, 2010, THERIOGENOLOGY, V74, P777, DOI 10.1016/j.theriogenology.2010.04.002
   Youdim KA, 2004, FREE RADICAL BIO MED, V37, P1683, DOI 10.1016/j.freeradbiomed.2004.08.002
   Zapolska-Downar D, 2008, ANN NUTR METAB, V53, P283, DOI 10.1159/000191290
   Zhao C, 2004, J AGR FOOD CHEM, V52, P6122, DOI 10.1021/jf049517a
   Zhu Y, 2013, NUTR METAB CARDIOVAS, V23, P843, DOI 10.1016/j.numecd.2012.06.005
   Zhu YN, 2011, CLIN CHEM, V57, P1524, DOI 10.1373/clinchem.2011.167361
NR 102
TC 203
Z9 212
U1 48
U2 288
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1040-8398
EI 1549-7852
J9 CRIT REV FOOD SCI
JI Crit. Rev. Food Sci. Nutr.
PY 2017
VL 57
IS 8
BP 1729
EP 1741
DI 10.1080/10408398.2015.1030064
PG 13
WC Food Science & Technology; Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Food Science & Technology; Nutrition & Dietetics
GA EO6BU
UT WOS:000396777500017
PM 26192537
OA hybrid
HC Y
HP N
DA 2022-04-25
ER

PT J
AU Abate, M
   Festa, A
   Falco, M
   Lombardi, A
   Luce, A
   Grimaldi, A
   Zappavigna, S
   Sperlongano, P
   Irace, C
   Caraglia, M
   Misso, G
AF Abate, Marianna
   Festa, Agostino
   Falco, Michela
   Lombardi, Angela
   Luce, Amalia
   Grimaldi, Anna
   Zappavigna, Silvia
   Sperlongano, Pasquale
   Irace, Carlo
   Caraglia, Michele
   Misso, Gabriella
TI Mitochondria as playmakers of apoptosis, autophagy and senescence
SO SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY
LA English
DT Review
DE Mitochondrion; Metabolism; Apoptosis; Autophagy; Senescence; Cancer
ID CYTOCHROME-C RELEASE; TUMOR-SUPPRESSOR GENE; BCL-2 FAMILY PROTEINS;
   BREAST-CANCER CELLS; I-LIKE RECEPTORS; OXIDATIVE STRESS; CELLULAR
   SENESCENCE; COLORECTAL-CANCER; OUTER-MEMBRANE; DNA-DAMAGE
AB Mitochondria are the key energy-producing organelles and cellular source of reactive species. They are responsible for managing cell life and death by a balanced homeostasis passing through a network of structures, regulated principally via fission and fusion. Herein we discuss about the most advanced findings considering mitochondria as dynamic biophysical systems playing compelling roles in the regulation of energy metabolism in both physiologic and pathologic processes controlling cell death and survival. Precisely, we focus on the mitochondrial commitment to the onset, maintenance and counteraction of apoptosis, autophagy and senescence in the bioenergetic reprogramming of cancer cells. In this context, looking for a pharmacological manipulation of cell death processes as a successful route for future targeted therapies, there is major biotechnological challenge in underlining the location, function and molecular mechanism of mitochondrial proteins. Based on the critical role of mitochondrial functions for cellular health, a better knowledge of the main molecular players in mitochondria disfunction could be decisive for the therapeutical control of degenerative diseases, including cancer.
C1 [Abate, Marianna; Festa, Agostino; Falco, Michela; Lombardi, Angela; Luce, Amalia; Grimaldi, Anna; Zappavigna, Silvia; Caraglia, Michele; Misso, Gabriella] Univ Campania Luigi Vanvitelli, Dept Precis Med, I-80138 Naples, Italy.
   [Sperlongano, Pasquale] Univ Campania Luigi Vanvitelli, Sch Med, Unit Gen & Geriatr Surg, I-80137 Naples, Italy.
   [Irace, Carlo] Univ Naples Federico II, Sch Med, Dept Pharm, Via Domenico Montesano 49, I-80131 Naples, Italy.
   [Caraglia, Michele] Biogem, IRGS, Via Camporeale, I-83031 Avellino, Italy.
RP Caraglia, M; Misso, G (corresponding author), Univ Campania Luigi Vanvitelli, Dept Precis Med, I-80138 Naples, Italy.; Irace, C (corresponding author), Univ Naples Federico II, Sch Med, Dept Pharm, Via Domenico Montesano 49, I-80131 Naples, Italy.
EM carlo.irace@unina.it; michele.caraglia@unicampania.it;
   gabriella.misso@unicampania.it
RI ABATE, MARIANNA/AAG-4679-2019; Caraglia, Michele/AAK-4569-2020
OI Caraglia, Michele/0000-0003-2408-6091; ABATE,
   MARIANNA/0000-0002-2297-3706; Falco, Michela/0000-0003-4513-8639; Misso,
   Gabriella/0000-0002-7787-2531; LOMBARDI, ANGELA/0000-0001-5421-9970;
   Luce, Amalia/0000-0003-0372-6870
CR Acin-Perez R, 2008, MOL CELL, V32, P529, DOI 10.1016/j.molcel.2008.10.021
   Adams JM, 2018, CELL DEATH DIFFER, V25, P27, DOI 10.1038/cdd.2017.161
   Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322
   Aguilar V, 2010, EMBO MOL MED, V2, P338, DOI 10.1002/emmm.201000089
   Ahmad T, 2015, FASEB J, V29, P2912, DOI 10.1096/fj.14-268276
   Alavi M.V., 2019, INT J CANC
   Alberghina L, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.513
   Aouacheria A, 2015, TRENDS BIOCHEM SCI, V40, P736, DOI 10.1016/j.tibs.2015.09.007
   Baeissa H, 2017, ONCOTARGET, V8, P21290, DOI 10.18632/oncotarget.15514
   Barman J, 2018, CURR PHARM BIOTECHNO, V19, P644, DOI 10.2174/1389201019666180821093239
   Bell EL, 2011, ONCOGENE, V30, P2986, DOI 10.1038/onc.2011.37
   Bellot G, 2009, MOL CELL BIOL, V29, P2570, DOI 10.1128/MCB.00166-09
   Ben-Porath I, 2005, INT J BIOCHEM CELL B, V37, P961, DOI 10.1016/j.biocel.2004.10.013
   Benard G, 2008, ANTIOXID REDOX SIGN, V10, P1313, DOI 10.1089/ars.2007.2000
   Berkers CR, 2013, CELL METAB, V18, P617, DOI 10.1016/j.cmet.2013.06.019
   Bhat P, 2018, BIOCHEM PHARMACOL, V147, P170, DOI 10.1016/j.bcp.2017.11.021
   Bhatti JS, 2017, BBA-MOL BASIS DIS, V1863, P1066, DOI 10.1016/j.bbadis.2016.11.010
   Bjelakovic G, 2007, JNCI-J NATL CANCER I, V99, P742, DOI 10.1093/jnci/djk211
   Boland ML, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00292
   Bosc C, 2017, CELL METAB, V26, P705, DOI 10.1016/j.cmet.2017.10.013
   Brahmbhatt H, 2015, CLIN CANCER RES, V21, P2671, DOI 10.1158/1078-0432.CCR-14-0959
   Brentnall M, 2013, BMC CELL BIOL, V14, DOI 10.1186/1471-2121-14-32
   Bruick RK, 2000, P NATL ACAD SCI USA, V97, P9082, DOI 10.1073/pnas.97.16.9082
   Buart S, 2017, ONCOTARGET, V8, P108786, DOI 10.18632/oncotarget.22150
   Burke PJ, 2017, TRENDS CANCER, V3, P857, DOI 10.1016/j.trecan.2017.10.006
   Burkhart D, 2008, NAT REV, V8, P1, DOI DOI 10.1038/NRC2399
   Burrell RA, 2013, NATURE, V494, P492, DOI 10.1038/nature11935
   Burton TR, 2006, INT J CANCER, V118, P1660, DOI 10.1002/ijc.21547
   Cairns RA, 2011, NAT REV CANCER, V11, P85, DOI 10.1038/nrc2981
   Campbell KJ, 2018, OPEN BIOL, V8, DOI 10.1098/rsob.180002
   Campisi J, 2007, NAT REV MOL CELL BIO, V8, P729, DOI 10.1038/nrm2233
   Cesari R, 2003, P NATL ACAD SCI USA, V100, P5956, DOI 10.1073/pnas.0931262100
   Chan N, 2017, CLIN CANCER RES, V23, P666, DOI 10.1158/1078-0432.CCR-16-1326
   CHANCE B, 1955, J BIOL CHEM, V217, P383
   Chen G, 1997, J EXP MED, V186, P1975, DOI 10.1084/jem.186.12.1975
   Chen HZ, 2009, NAT REV CANCER, V9, P785, DOI 10.1038/nrc2696
   Cheng G, 2012, CANCER RES, V72, P2634, DOI 10.1158/0008-5472.CAN-11-3928
   Cheung ECC, 2007, APOPTOSIS, V12, P979, DOI 10.1007/s10495-007-0745-5
   Chourasia AH, 2015, AUTOPHAGY, V11, P1937, DOI 10.1080/15548627.2015.1085136
   Cipolat S, 2006, CELL, V126, P163, DOI 10.1016/j.cell.2006.06.021
   Cleland MM, 2011, MITOCHONDRIAL DYNAMICS AND NEURODEGENERATION, P109, DOI 10.1007/978-94-007-1291-1_4
   Cloonan SM, 2013, CURR OPIN MICROBIOL, V16, P327, DOI 10.1016/j.mib.2013.05.005
   Cogliati S, 2016, TRENDS BIOCHEM SCI, V41, P261, DOI 10.1016/j.tibs.2016.01.001
   Cogliati S, 2013, CELL, V155, P160, DOI 10.1016/j.cell.2013.08.032
   Coppe JP, 2010, ANNU REV PATHOL-MECH, V5, P99, DOI 10.1146/annurev-pathol-121808-102144
   Correia-Melo Clara, 2014, Longev Healthspan, V3, P1, DOI 10.1186/2046-2395-3-1
   Cory S, 2016, TRENDS CANCER, V2, P443, DOI 10.1016/j.trecan.2016.07.001
   Cosentino K, 2017, TRENDS CELL BIOL, V27, P266, DOI 10.1016/j.tcb.2016.11.004
   Costantino M, 2009, AMINO ACIDS, V36, P161, DOI 10.1007/s00726-008-0032-y
   CROSS CE, 1987, ANN INTERN MED, V107, P526, DOI 10.7326/0003-4819-107-4-526
   Cui M, 2010, J BIOL CHEM, V285, P11740, DOI 10.1074/jbc.M109.066662
   de Brito OM, 2008, NATURE, V456, P605, DOI 10.1038/nature07534
   De Nicola GM, 2011, NATURE, V475, P106, DOI 10.1038/nature10189
   Deas E, 2011, HUM MOL GENET, V20, P867, DOI 10.1093/hmg/ddq526
   Delbridge ARD, 2015, CELL DEATH DIFFER, V22, P1071, DOI 10.1038/cdd.2015.50
   Delbridge ARD, 2016, NAT REV CANCER, V16, P99, DOI 10.1038/nrc.2015.17
   Dewson G, 2009, J CELL SCI, V122, P2801, DOI 10.1242/jcs.038166
   DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567
   Ding CM, 2018, CELL PROLIFERAT, V51, DOI 10.1111/cpr.12464
   Ding WX, 2010, J BIOL CHEM, V285, P27879, DOI 10.1074/jbc.M110.119537
   Diwan A, 2007, P NATL ACAD SCI USA, V104, P6794, DOI 10.1073/pnas.0610666104
   Edlich F, 2018, BIOCHEM BIOPH RES CO, V500, P26, DOI 10.1016/j.bbrc.2017.06.190
   Efimova EV, 2010, CANCER RES, V70, P6277, DOI 10.1158/0008-5472.CAN-09-4224
   El-Hattab AW, 2017, MOL GENET METAB, V122, P1, DOI 10.1016/j.ymgme.2017.09.009
   Engelman JA, 2008, NAT MED, V14, P1351, DOI 10.1038/nm.1890
   Estaquier J, 2012, ADV EXP MED BIOL, V942, P157, DOI 10.1007/978-94-007-2869-1_7
   Fan J, 2014, NATURE, V510, P298, DOI 10.1038/nature13236
   Feng X, 2011, EMBO J, V30, P3397, DOI 10.1038/emboj.2011.248
   Ferecatu I, 2009, BMC CELL BIOL, V10, DOI 10.1186/1471-2121-10-50
   Fesik SW, 2005, NAT REV CANCER, V5, P876, DOI 10.1038/nrc1736
   Finley LWS, 2011, CANCER CELL, V19, P416, DOI 10.1016/j.ccr.2011.02.014
   Flynn MG, 2019, AGING DIS, V10, P147, DOI 10.14336/AD.2018.0326
   Fogal V, 2010, MOL CELL BIOL, V30, P1303, DOI 10.1128/MCB.01101-09
   Friedman JR, 2015, ELIFE, V4, DOI 10.7554/eLife.07739
   Gaglio D, 2011, MOL SYST BIOL, V7, DOI 10.1038/msb.2011.56
   Glab JA, 2017, INT REV CEL MOL BIO, V328, P163, DOI 10.1016/bs.ircmb.2016.08.005
   Glasauer A, 2014, J CLIN INVEST, V124, P117, DOI 10.1172/JCI71714
   Goldsmith J, 2014, METHOD ENZYMOL, V542, P25, DOI 10.1016/B978-0-12-416618-9.00002-9
   Gong JN, 2016, BLOOD, V128, P1834, DOI 10.1182/blood-2016-03-704908
   Gorbunova V, 2002, J BIOL CHEM, V277, P38540, DOI 10.1074/jbc.M202671200
   Gottlieb E, 2003, CELL DEATH DIFFER, V10, P709, DOI 10.1038/sj.cdd.4401231
   Grosse L, 2016, EMBO J, V35, P402, DOI 10.15252/embj.201592789
   Guo CY, 2013, NEURAL REGEN RES, V8, P2003, DOI 10.3969/j.issn.1673-5374.2013.21.009
   Guo JY, 2011, GENE DEV, V25, P460, DOI 10.1101/gad.2016311
   Guo K, 2001, CELL DEATH DIFFER, V8, P367, DOI 10.1038/sj.cdd.4400810
   Habersetzer J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075429
   HACKENBROCK CR, 1966, J CELL BIOL, V30, P269, DOI 10.1083/jcb.30.2.269
   Halazonetis TD, 2008, SCIENCE, V319, P1352, DOI 10.1126/science.1140735
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Harris IS, 2014, ONCOGENE, V33, P1047, DOI 10.1038/onc.2013.24
   Hassan M, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/150845
   He JM, 2017, J CANCER, V8, P1187, DOI 10.7150/jca.18171
   He LM, 2017, CELL MOL LIFE SCI, V74, P2395, DOI 10.1007/s00018-017-2477-1
   Head B, 2009, J CELL BIOL, V187, P959, DOI 10.1083/jcb.200906083
   Hekimi S, 2011, TRENDS CELL BIOL, V21, P569, DOI 10.1016/j.tcb.2011.06.008
   Herranz N, 2018, J CLIN INVEST, V128, P1238, DOI 10.1172/JCI95148
   Hilgendorf KI, 2013, GENE DEV, V27, P1003, DOI 10.1101/gad.211326.112
   Hori YS, 2015, J NEURO-ONCOL, V122, P11, DOI 10.1007/s11060-014-1686-9
   Hsieh MCF, 2008, J BIOL CHEM, V283, P27410, DOI 10.1074/jbc.M802418200
   Hsu CC, 2016, EXP BIOL MED, V241, P1281, DOI 10.1177/1535370216641787
   Huttemann M, 2007, BBA-MOL CELL RES, V1773, P1701, DOI 10.1016/j.bbamcr.2007.10.001
   Irace C, 2017, SCI REP-UK, V7, DOI 10.1038/srep45236
   Jacobs JL, 2013, J MOL BIOL, V425, P5009, DOI 10.1016/j.jmb.2013.10.007
   Jacobs JJL, 2000, NAT GENET, V26, P291, DOI 10.1038/81583
   Jain RK, 2002, NAT REV CANCER, V2, P266, DOI 10.1038/nrc778
   Jakobs S, 2014, CURR OPIN CHEM BIOL, V20, P9, DOI 10.1016/j.cbpa.2014.03.019
   Janeway KA, 2011, P NATL ACAD SCI USA, V108, P314, DOI 10.1073/pnas.1009199108
   Jans DC, 2013, P NATL ACAD SCI USA, V110, P8936, DOI 10.1073/pnas.1301820110
   Jayashankar V, 2016, CURR OPIN CELL BIOL, V38, P45, DOI 10.1016/j.ceb.2016.02.006
   Jiang P, 2013, NATURE, V493, P689, DOI 10.1038/nature11776
   Jiang X, 2014, P NATL ACAD SCI USA, V111, P14782, DOI 10.1073/pnas.1417253111
   Jin HS, 2017, IMMUNE NETW, V17, P77, DOI 10.4110/in.2017.17.2.77
   Jones RG, 2005, MOL CELL, V18, P283, DOI 10.1016/j.molcel.2005.03.027
   Jornayvaz FR, 2010, ESSAYS BIOCHEM, V47, P69, DOI [10.1042/BSE0470069, 10.1042/bse0470069]
   Jourdain A, 2009, INT J BIOCHEM CELL B, V41, P1884, DOI 10.1016/j.biocel.2009.05.001
   Kalkavan H, 2018, CELL DEATH DIFFER, V25, P46, DOI 10.1038/cdd.2017.179
   Kaminskyy VO, 2012, AUTOPHAGY, V8, P1032, DOI 10.4161/auto.20123
   Karbowski M, 2010, ADV EXP MED BIOL, V687, P131
   Kasahara A, 2014, TRENDS CELL BIOL, V24, P761, DOI 10.1016/j.tcb.2014.08.005
   Kasumba DM, 2019, TRENDS PHARMACOL SCI, V40, P116, DOI 10.1016/j.tips.2018.12.003
   Kawauchi K, 2008, NAT CELL BIOL, V10, P611, DOI 10.1038/ncb1724
   Kilic-Eren M, 2013, CANCER CELL INT, V13, DOI 10.1186/1475-2867-13-36
   Kim S, 2013, SPRINGERPLUS, V2, DOI 10.1186/2193-1801-2-299
   Kim Y, 2008, BIOCHEM BIOPH RES CO, V377, P975, DOI 10.1016/j.bbrc.2008.10.104
   Klotz LO, 2015, REDOX BIOL, V6, P51, DOI 10.1016/j.redox.2015.06.019
   Knight T, 2019, BIOCHEM PHARMACOL, V162, P250, DOI 10.1016/j.bcp.2019.01.015
   Koop EA, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-175
   Koppenol WH, 2011, NAT REV CANCER, V11, P325, DOI 10.1038/nrc3038
   Korolchuk VI, 2017, EBIOMEDICINE, V21, P7, DOI 10.1016/j.ebiom.2017.03.020
   Koshiba T, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001147
   Krock Bryan L, 2011, Genes Cancer, V2, P1117, DOI 10.1177/1947601911423654
   Kubl DA, 2007, BIOCHEM J, V405, P407, DOI 10.1042/BJ20070319
   Kuilman T, 2008, CELL, V133, P1019, DOI 10.1016/j.cell.2008.03.039
   Kulikov AV, 2017, BIOCHEM BIOPH RES CO, V482, P432, DOI 10.1016/j.bbrc.2016.10.088
   Kuo SJ, 2010, CANCER GENET CYTOGEN, V201, P94, DOI 10.1016/j.cancergencyto.2010.05.013
   Kvansakul M, 2015, APOPTOSIS, V20, P136, DOI 10.1007/s10495-014-1051-7
   LaBiche R A, 1992, In Vivo, V6, P317
   Lamb R, 2015, ONCOTARGET, V6, P4569, DOI 10.18632/oncotarget.3174
   Lane N, 2010, NATURE, V467, P929, DOI 10.1038/nature09486
   Lazarou M, 2012, DEV CELL, V22, P320, DOI 10.1016/j.devcel.2011.12.014
   Le A, 2012, CELL METAB, V15, P110, DOI 10.1016/j.cmet.2011.12.009
   Lee HC, 2004, MUTAT RES-FUND MOL M, V547, P71, DOI 10.1016/j.mrfmmm.2003.12.011
   Lee HC, 2014, WORLD J GASTROENTERO, V20, P3950, DOI 10.3748/wjg.v20.i14.3950
   Lee KS, 2013, GENE DEV, V27, P2642, DOI 10.1101/gad.225169.113
   Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1
   Lewis CA, 2014, MOL CELL, V55, P253, DOI 10.1016/j.molcel.2014.05.008
   Li K, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18020404
   Li Y, 2017, ONCOTARGET, V8, P63208, DOI 10.18632/oncotarget.18736
   Lievre A, 2005, J CLIN ONCOL, V23, P3517, DOI 10.1200/JCO.2005.07.044
   Luo C, 2016, TRENDS CANCER, V2, P619, DOI 10.1016/j.trecan.2016.09.006
   Ma SB, 2014, CELL DEATH DIFFER, V21, P1925, DOI 10.1038/cdd.2014.119
   Macher-Goeppinger S, 2017, TRANSL ONCOL, V10, P869, DOI 10.1016/j.tranon.2017.08.008
   MacVicar T, 2016, J CELL SCI, V129, P2297, DOI 10.1242/jcs.159186
   Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239
   Malty RH, 2015, J PROTEOME RES, V14, P5, DOI 10.1021/pr500813f
   Martin-Rufian M, 2014, J MOL MED, V92, P277, DOI 10.1007/s00109-013-1105-2
   Mates JM, 2009, INT J BIOCHEM CELL B, V41, P2051, DOI 10.1016/j.biocel.2009.03.003
   Matsuyama S, 2000, NAT CELL BIOL, V2, P318, DOI 10.1038/35014006
   Matsuyama W, 2003, HUM MUTAT, V21, P441, DOI 10.1002/humu.10196
   Maya-Mendoza A, 2015, MOL ONCOL, V9, P601, DOI 10.1016/j.molonc.2014.11.001
   MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8
   Mehta MM, 2017, NAT REV IMMUNOL, V17, P608, DOI 10.1038/nri.2017.66
   Merino D, 2018, CANCER CELL, V34, P879, DOI 10.1016/j.ccell.2018.11.004
   Minelli A, 2009, BBA-REV CANCER, V1795, P83, DOI 10.1016/j.bbcan.2008.11.001
   Misso G, 2013, J CELL PHYSIOL, V228, P130, DOI 10.1002/jcp.24112
   MITCHELL P, 1961, NATURE, V191, P144, DOI 10.1038/191144a0
   Morris LGT, 2010, ONCOGENE, V29, P3453, DOI 10.1038/onc.2010.127
   Mucaj V, 2012, INT J HEMATOL, V95, P464, DOI 10.1007/s12185-012-1070-5
   Muenst S, 2016, J INTERN MED, V279, P541, DOI 10.1111/joim.12470
   Murphy MP, 2018, NAT REV DRUG DISCOV
   Narendra DP, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000298
   Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X
   Nazarewicz RR, 2013, ANTIOXID REDOX SIGN, V19, P344, DOI 10.1089/ars.2013.5185
   Nelyudova A, 2007, CELL CYCLE, V6, P2171, DOI 10.4161/cc.6.17.4610
   Neuzil J, 2013, MITOCHONDRION, V13, P199, DOI 10.1016/j.mito.2012.07.112
   Nicolay BN, 2013, GENE DEV, V27, P182, DOI 10.1101/gad.206227.112
   Nilsson R, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4128
   Noviello C, 1996, CLIN CANCER RES, V2, P1601
   Ong SB, 2017, CARDIOVASC DRUG THER, V31, P87, DOI 10.1007/s10557-016-6710-1
   Opferman JT, 2018, CELL DEATH DIFFER, V25, P37, DOI 10.1038/cdd.2017.170
   Otera H, 2012, INT J CELL BIOL, DOI DOI 10.1155/2012/821676
   Otera H, 2016, J CELL BIOL, V212, P531, DOI 10.1083/jcb.201508099
   Paik JY, 2014, J CLIN ONCOL, V32, pE10, DOI 10.1200/JCO.2012.47.2647
   Park HK, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-431
   Passos JF, 2010, MOL SYST BIOL, V6, DOI 10.1038/msb.2010.5
   Patten DA, 2014, EMBO J, V33, P2676, DOI 10.15252/embj.201488349
   Paumard P, 2002, EMBO J, V21, P221, DOI 10.1093/emboj/21.3.221
   Pedersen P L, 1978, Prog Exp Tumor Res, V22, P190
   Pekarsky Y, 2018, CELL DEATH DIFFER, V25, P21, DOI 10.1038/cdd.2017.159
   Pendin D, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00102
   Pentimalli F., 2018, GENES IMMUN
   Perkins GA, 2016, CELL DEATH BIOL DIS, P85, DOI 10.1007/978-1-4939-3612-0_5
   Picchio MC, 2004, CLIN CANCER RES, V10, P2720, DOI 10.1158/1078-0432.CCR-03-0086
   Polyakov VY, 2003, BIOCHEMISTRY-MOSCOW+, V68, P838, DOI 10.1023/A:1025738712958
   Poulogiannis G, 2010, P NATL ACAD SCI USA, V107, P15145, DOI 10.1073/pnas.1009941107
   Poyton RO, 2009, TRENDS ENDOCRIN MET, V20, P332, DOI 10.1016/j.tem.2009.04.001
   Pyakurel A, 2015, MOL CELL, V58, P244, DOI 10.1016/j.molcel.2015.02.021
   Qu XZ, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173712
   Quintana-Cabrera R, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05655-x
   Ralph SJ, 2006, RECENT PAT ANTI-CANC, V1, P327, DOI 10.2174/157489206778776952
   Raschella G., 2018, GENES IMMUN
   Renault TT, 2013, INT J BIOCHEM CELL B, V45, P64, DOI 10.1016/j.biocel.2012.09.022
   Reynolds MR, 2014, ONCOGENE, V33, P556, DOI 10.1038/onc.2012.635
   Rieger B, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4103
   Rigoulet M, 2011, ANTIOXID REDOX SIGN, V14, P459, DOI 10.1089/ars.2010.3363
   Salminen A, 2012, AGEING RES REV, V11, P230, DOI 10.1016/j.arr.2011.12.005
   Santidrian AF, 2013, J CLIN INVEST, V123, P1068, DOI 10.1172/JCI64264
   Scatena C, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00452
   Schafer B, 2009, MOL BIOL CELL, V20, P2276, DOI 10.1091/mbc.E08-10-1056
   Scherz-Shouval R, 2011, TRENDS BIOCHEM SCI, V36, P30, DOI 10.1016/j.tibs.2010.07.007
   Schwartzenberg-Bar-Yoseph F, 2004, CANCER RES, V64, P2627, DOI 10.1158/0008-5472.CAN-03-0846
   Sciacovelli M, 2013, CELL METAB, V17, P988, DOI 10.1016/j.cmet.2013.04.019
   Scorrano L, 2002, DEV CELL, V2, P55, DOI 10.1016/S1534-5807(01)00116-2
   Selak MA, 2005, CANCER CELL, V7, P77, DOI 10.1016/j.ccr.2004.11.022
   Seluanov A, 2001, MOL CELL BIOL, V21, P1552, DOI 10.1128/MCB.21.5.1552-1564.2001
   Semenza GL, 2010, ONCOGENE, V29, P625, DOI 10.1038/onc.2009.441
   Semenza GL, 2012, TRENDS PHARMACOL SCI, V33, P207, DOI 10.1016/j.tips.2012.01.005
   Shah SP, 2012, NATURE, V486, P395, DOI 10.1038/nature10933
   Shimizu S, 2004, NAT CELL BIOL, V6, P1221, DOI 10.1038/ncb1192
   Sikora Ewa, 2018, Postepy Biochem, V64, P110, DOI 10.18388/pb.2018_120
   Singh R, 2019, NAT REV MOL CELL BIO, V20, P175, DOI 10.1038/s41580-018-0089-8
   Sirangelo I, 2009, J CELL PHYSIOL, V221, P412, DOI 10.1002/jcp.21871
   Soderquist RS, 2016, MOL CANCER THER, V15, P2011, DOI 10.1158/1535-7163.MCT-16-0031
   Suen DF, 2010, P NATL ACAD SCI USA, V107, P11835, DOI 10.1073/pnas.0914569107
   Suzuki M, 2000, CELL, V103, P645, DOI 10.1016/S0092-8674(00)00167-7
   Tait SWG, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a008706
   Tait SWG, 2010, DEV CELL, V18, P802, DOI [10.1016/j.devcel.2010.03.014, 10.1016/j.devce1.2010.03.014]
   Tal MC, 2011, IMMUNOL REV, V243, P215, DOI 10.1111/j.1600-065X.2011.01038.x
   Tan CC, 2014, NEUROBIOL AGING, V35, P941, DOI 10.1016/j.neurobiolaging.2013.11.019
   Thornburg J.M., 2010, BREAST CANCER RES, V10, pR84
   Todt F, 2015, EMBO J, V34, P67, DOI 10.15252/embj.201488806
   Trachootham D, 2006, CANCER CELL, V10, P241, DOI 10.1016/j.ccr.2006.08.009
   Trotta AP, 2017, CELL MOL LIFE SCI, V74, P1999, DOI 10.1007/s00018-016-2451-3
   Tseng LM, 2006, GENE CHROMOSOME CANC, V45, P629, DOI 10.1002/gcc.20326
   Urra FA, 2016, CURR PHARM DESIGN, V22, P5998, DOI 10.2174/1381612822666160719122626
   Vakiani E, 2012, J CLIN ONCOL, V30, P2956, DOI 10.1200/JCO.2011.38.2994
   van der Bliek AM, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a011072
   van Deursen JM, 2014, NATURE, V509, P439, DOI 10.1038/nature13193
   Vande Velde C, 2000, MOL CELL BIOL, V20, P5454, DOI 10.1128/MCB.20.15.5454-5468.2000
   Varanita T, 2015, CELL METAB, V21, P834, DOI 10.1016/j.cmet.2015.05.007
   VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0
   Vazquez F, 2013, CANCER CELL, V23, P287, DOI 10.1016/j.ccr.2012.11.020
   Veeriah S, 2010, NAT GENET, V42, P77, DOI 10.1038/ng.491
   Vinay DS, 2015, SEMIN CANCER BIOL, V35, pS185, DOI 10.1016/j.semcancer.2015.03.004
   Vurusaner B, 2012, FREE RADICAL BIO MED, V52, P7, DOI 10.1016/j.freeradbiomed.2011.09.035
   Vyas S, 2016, CELL, V166, P555, DOI 10.1016/j.cell.2016.07.002
   Wai T, 2016, TRENDS ENDOCRIN MET, V27, P105, DOI 10.1016/j.tem.2015.12.001
   Walensky LD, 2011, TRENDS BIOCHEM SCI, V36, P642, DOI 10.1016/j.tibs.2011.08.009
   Wallace DC, 2012, NAT REV CANCER, V12, P685, DOI 10.1038/nrc3365
   Wang JB, 2010, CANCER CELL, V18, P207, DOI 10.1016/j.ccr.2010.08.009
   Wang SJ, 2014, CURR OPIN ONCOL, V26, P78, DOI 10.1097/CCO.0000000000000024
   WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309
   Warburg O, 1927, J GEN PHYSIOL, V8, P519, DOI 10.1085/jgp.8.6.519
   Ward PS, 2012, CANCER CELL, V21, P297, DOI 10.1016/j.ccr.2012.02.014
   Waterhouse NJ, 2001, J CELL BIOL, V153, P319, DOI 10.1083/jcb.153.2.319
   Weerts MJA, 2019, DRUG DISCOV TODAY
   Weinberg F, 2010, P NATL ACAD SCI USA, V107, P8788, DOI 10.1073/pnas.1003428107
   Weinberg SE, 2015, NAT CHEM BIOL, V11, P9, DOI 10.1038/nchembio.1712
   WEINHOUSE S, 1951, CANCER RES, V11, P845
   WENNER CE, 1952, CANCER RES, V12, P44
   Westermann B, 2008, J BIOL CHEM, V283, P13501, DOI 10.1074/jbc.R800011200
   Wiley CD, 2016, CELL METAB, V23, P303, DOI 10.1016/j.cmet.2015.11.011
   Wilkens V, 2013, J CELL SCI, V126, P103, DOI 10.1242/jcs.108852
   Willis SN, 2007, SCIENCE, V315, P856, DOI 10.1126/science.1133289
   Willis SN, 2005, GENE DEV, V19, P1294, DOI 10.1101/gad.1304105
   Wong WWL, 2008, IUBMB LIFE, V60, P390, DOI 10.1002/iub.51
   Wu B, 2015, CURR OPIN VIROL, V12, P91, DOI 10.1016/j.coviro.2015.04.004
   Wu CR, 2018, EXPERT OPIN THER PAT, V28, P823, DOI 10.1080/13543776.2018.1530759
   Wu YB, 2017, TRANSL RES, V190, P51, DOI 10.1016/j.trsl.2017.08.004
   Xiang WG, 2018, ONCOTARGETS THER, V11, P7301, DOI 10.2147/OTT.S146228
   Xie LL, 2018, CANCER SCI, V109, P3686, DOI 10.1111/cas.13830
   Xu ZJ, 2016, FRONT PHARMACOL, V7, DOI 10.3389/fphar.2016.00473
   Yamaguchi R, 2008, MOL CELL, V31, P557, DOI 10.1016/j.molcel.2008.07.010
   Yamaguchi R, 2019, PHARMACOL THERAPEUT, V195, P13, DOI 10.1016/j.pharmthera.2018.10.009
   Yamaguchi R, 2009, BBA-BIOENERGETICS, V1787, P963, DOI 10.1016/j.bbabio.2009.02.005
   Yamano K, 2013, AUTOPHAGY, V9, P1758, DOI 10.4161/auto.24633
   Yan H, 2009, NEW ENGL J MED, V360, P765, DOI 10.1056/NEJMoa0808710
   Yang LF, 2017, ANNU REV BIOMED ENG, V19, P163, DOI 10.1146/annurev-bioeng-071516-044546
   Yang PY, 2010, NAT IMMUNOL, V11, P487, DOI 10.1038/ni.1876
   Yang Y, 2010, CANCER GENET CYTOGEN, V196, P45, DOI 10.1016/j.cancergencyto.2009.08.018
   Ye JB, 2014, CANCER DISCOV, V4, P1406, DOI 10.1158/2159-8290.CD-14-0250
   Yoshii SR, 2011, J BIOL CHEM, V286, P19630, DOI 10.1074/jbc.M110.209338
   Zhang MZ, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-02825-7
   Zhao J, 2013, ONCOGENE, V32, P4814, DOI 10.1038/onc.2012.494
   Zhou C, 2008, P NATL ACAD SCI USA, V105, P12022, DOI 10.1073/pnas.0802814105
   Zhou J, 2015, AUTOPHAGY, V11, P1259, DOI 10.1080/15548627.2015.1056970
   Zhou LY, 2008, J CELL SCI, V121, P2186, DOI 10.1242/jcs.024703
   Zhu ZJ, 2015, CANCER PREV RES, V8, P518, DOI 10.1158/1940-6207.CAPR-14-0121
   Ziegler DV, 2015, AGING CELL, V14, P1, DOI 10.1111/acel.12287
NR 289
TC 98
Z9 105
U1 42
U2 209
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 1084-9521
EI 1096-3634
J9 SEMIN CELL DEV BIOL
JI Semin. Cell Dev. Biol.
PD FEB
PY 2020
VL 98
SI SI
BP 139
EP 153
DI 10.1016/j.semcdb.2019.05.022
PG 15
WC Cell Biology; Developmental Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Developmental Biology
GA KD5XE
UT WOS:000507938200016
PM 31154010
HC Y
HP N
DA 2022-04-25
ER

PT J
AU Jing, Z
   Sui, XB
   Yao, JL
   Xie, JS
   Jiang, LM
   Zhou, YB
   Pan, HM
   Han, WD
AF Jing, Zhao
   Sui, Xinbing
   Yao, Junlin
   Xie, Jiansheng
   Jiang, Liming
   Zhou, Yubin
   Pan, Hongming
   Han, Weidong
TI SKF-96365 activates cytoprotective autophagy to delay apoptosis in
   colorectal cancer cells through inhibition of the calcium/CaMKII
   gamma/AKT-mediated pathway
SO CANCER LETTERS
LA English
DT Article
DE SKF-96365; Autophagy; Apoptosis; Colorectal cancer; CaMKII
ID OPERATED CA2+ ENTRY; KINASE II-GAMMA; CYTOCHROME-C; THERAPEUTIC TARGET;
   CRITICAL REGULATOR; BREAST-CANCER; AKT/MTOR; RELEASE; STIM1;
   MITOCHONDRIA
AB Store-operated Ca2+ entry (SOCE) inhibitors are emerging as an attractive new generation of anti-cancer drugs. Here, we report that SKF-96365, an SOCE inhibitor, exhibits potent anti-neoplastic activity by inducing cell-cycle arrest and apoptosis in colorectal cancer cells. In the meantime, SKF-96365 also induces cytoprotective autophagy to delay apoptosis by preventing the release of cytochrome c (cyt c) from the mitochondria into the cytoplasm. Mechanistically, SKF-96365 treatment inhibited the calcium/calmodulin-dependent protein kinase Il gamma(CaMKIl gamma)/AKT signaling cascade in vitro and in vivo. Overexpression of CaMKII gamma or ART abolished the effects of SKF-96365 on cancer cells, suggesting a critical role of the CaMKII gamma/AKT signaling pathway in SFK-96365-induced biological effects. Moreover, Hydroxychloroquine (HCQ), an FDA-approved drug used to inhibit autophagy, could significantly augment the anti-cancer effect of SFK-96365 in a mouse xenograft model. To our best knowledge, this is the first report to demonstrate that calcium/CaMKII gamma/AKT signaling can regulate apoptosis and autophagy simultaneously in cancer cells, and the combination of the SOCE inhibitor SKF-96365 with autophagy inhibitors represents a promising strategy for treating patients with colorectal cancer. (C) 2016 Elsevier Ireland Ltd. All rights reserved.
C1 [Jing, Zhao; Sui, Xinbing; Yao, Junlin; Jiang, Liming; Pan, Hongming; Han, Weidong] Zhejiang Univ, Coll Med, Dept Med Oncol, Sir Run Run Shaw Hosp, Hangzhou 310003, Zhejiang, Peoples R China.
   [Xie, Jiansheng; Pan, Hongming; Han, Weidong] Zhejiang Univ, Sch Med, Biomed Res Ctr, Sir Run Run Shaw Hosp, Hangzhou 310003, Zhejiang, Peoples R China.
   [Zhou, Yubin] Texas A&M Univ, Hlth Sci Ctr, Ctr Translat Canc Res, Inst Biosci & Technol, Houston, TX 77030 USA.
RP Pan, HM; Han, WD (corresponding author), Zhejiang Univ, Coll Med, Dept Med Oncol, Sir Run Run Shaw Hosp, Hangzhou 310003, Zhejiang, Peoples R China.; Pan, HM; Han, WD (corresponding author), Zhejiang Univ, Sch Med, Biomed Res Ctr, Sir Run Run Shaw Hosp, Hangzhou 310003, Zhejiang, Peoples R China.
EM hongmingpan@gmail.com; hanwd@zju.edu.cn
RI Zhou, Yubin/D-4748-2011
OI Zhou, Yubin/0000-0001-7962-0517
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81272593, 81572592, 81372621, 81572361];
   Zhejiang Medicines and Health Platform Program [2014ZDA012]; National
   Health and Family Planning Commission Fund [2015112271]; Zhejiang
   Province Preeminence Youth Fund [LR16H160001]; NATIONAL INSTITUTE OF
   GENERAL MEDICAL SCIENCESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of General Medical Sciences (NIGMS) [R01GM112003] Funding Source: NIH
   RePORTER
FX This work was supported by the National Natural Science Foundation of
   China (81272593, 81572592), the Zhejiang Medicines and Health Platform
   Program (2014ZDA012), and the National Health and Family Planning
   Commission Fund (2015112271) to H. Pan, the National Natural Science
   Foundation of China (81372621, 81572361), and Zhejiang Province
   Preeminence Youth Fund (LR16H160001) to W. Han.
CR Balasubramaniam SL, 2015, J BIOL CHEM, V290, P12463, DOI 10.1074/jbc.M114.629519
   Booth LA, 2014, CELL SIGNAL, V26, P549, DOI 10.1016/j.cellsig.2013.11.028
   Cai R, 2009, INT J CANCER, V125, P2281, DOI 10.1002/ijc.24551
   Chai SJ, 2015, ONCOTARGET, V6, P16069, DOI 10.18632/oncotarget.3866
   Chai SJ, 2014, CANCER LETT, V344, P119, DOI 10.1016/j.canlet.2013.10.022
   Elmore SP, 2001, FASEB J, V15, P2286, DOI 10.1096/fj.01-0206fje
   Elmore SP, 2004, ARCH BIOCHEM BIOPHYS, V422, P145, DOI 10.1016/j.abb.2003.12.031
   Fahrenholtz CD, 2014, ONCOTARGET, V5, P9007, DOI 10.18632/oncotarget.2346
   Fedida-Metula S, 2012, CARCINOGENESIS, V33, P740, DOI 10.1093/carcin/bgs021
   Feldman B, 2010, CELL CALCIUM, V47, P525, DOI 10.1016/j.ceca.2010.05.002
   Gu Y, 2012, BLOOD, V120, P4829, DOI 10.1182/blood-2012-06-434894
   Guthrie H. David, 2008, V477, P89, DOI 10.1007/978-1-60327-517-0_8
   Jiang X, 2014, P NATL ACAD SCI USA, V111, P14782, DOI 10.1073/pnas.1417253111
   Johnson EA, 2008, LUNG CANCER, V60, P200, DOI 10.1016/j.lungcan.2007.10.003
   Kim SJ, 2014, P NATL ACAD SCI USA, V111, P6413, DOI 10.1073/pnas.1321114111
   Kohn EC, 1996, CANCER RES, V56, P569
   Leung YM, 1999, JPN J PHARMACOL, V81, P253, DOI 10.1254/jjp.81.253
   Li JP, 2015, DRUG DES DEV THER, V9, P1627, DOI 10.2147/DDDT.S75378
   Liu KH, 2015, ONCOTARGET, V6, P5088, DOI 10.18632/oncotarget.3243
   Meng ZP, 2013, MOL CANCER THER, V12, P2067, DOI 10.1158/1535-7163.MCT-13-0314
   MROSS K, 1993, ANN ONCOL, V4, P45, DOI 10.1093/oxfordjournals.annonc.a058356
   Ogawa A, 2012, AM J PHYSIOL-CELL PH, V302, pC405, DOI 10.1152/ajpcell.00337.2011
   Quinsay MN, 2010, J MOL CELL CARDIOL, V48, P1146, DOI 10.1016/j.yjmcc.2009.12.004
   Schmidt S, 2014, ONCOTARGET, V5, P4799, DOI 10.18632/oncotarget.2035
   Selvaraj S, 2016, MOL CARCINOGEN, V55, P818, DOI 10.1002/mc.22324
   Si JT, 2008, CANCER RES, V68, P3733, DOI 10.1158/0008-5472.CAN-07-2509
   Song P, 2015, ONCOTARGET, V6, P3861, DOI 10.18632/oncotarget.2869
   Stathopulos PB, 2008, CELL, V135, P110, DOI 10.1016/j.cell.2008.08.006
   Stathopulos PB, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3963
   Sui X, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.350
   Sui XB, 2014, CANCER LETT, V344, P174, DOI 10.1016/j.canlet.2013.11.019
   Viola G, 2012, BIOCHEM PHARMACOL, V83, P16, DOI 10.1016/j.bcp.2011.09.017
   Wang F, 2015, INT J IMMUNOPATH PH, V28, P362, DOI 10.1177/0394632015598849
   Wang JY, 2015, ONCOGENE, V34, P4358, DOI 10.1038/onc.2014.366
   Wu Y, 2014, MOL MED REP, V10, P3021, DOI 10.3892/mmr.2014.2665
   Zhang D, 2007, CELL DEATH DIFFER, V14, P703, DOI 10.1038/sj.cdd.4402072
   Zhang J, 2015, BIO-MED MATER ENG, V26, pS2259, DOI 10.3233/BME-151532
   Zhang Y, 2010, EUR J PHARMACOL, V647, P126, DOI 10.1016/j.ejphar.2010.08.010
   Zhang Z, 2015, ONCOGENE, V34, P4808, DOI 10.1038/onc.2014.404
   Zhu H, 2014, ONCOTARGET, V5, P3455, DOI 10.18632/oncotarget.1903
   Zou WY, 2012, CELL PHYSIOL BIOCHEM, V30, P221, DOI 10.1159/000339059
NR 41
TC 48
Z9 48
U1 1
U2 46
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0304-3835
EI 1872-7980
J9 CANCER LETT
JI Cancer Lett.
PD MAR 28
PY 2016
VL 372
IS 2
BP 226
EP 238
DI 10.1016/j.canlet.2016.01.006
PG 13
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA DE8RN
UT WOS:000370904500010
PM 26803057
OA Green Accepted
DA 2022-04-25
ER

PT J
AU Wei, JC
   Yang, P
   Li, WL
   Hei, F
   Zeng, SQ
   Zhang, T
   Zhong, JB
   Huang, D
   Chen, ZP
   Wang, CX
   Chen, HC
   Hu, H
   Cao, J
AF Wei, Jianchang
   Yang, Ping
   Li, Wanglin
   Hei, Feng
   Zeng, Shanqi
   Zhang, Tong
   Zhong, Junbin
   Huang, Di
   Chen, Zhuanpeng
   Wang, Chengxing
   Chen, Huacui
   Hu, He
   Cao, Jie
TI Gambogic acid potentiates the chemosensitivity of colorectal cancer
   cells to 5-fluorouracil by inhibiting proliferation and inducing
   apoptosis
SO EXPERIMENTAL AND THERAPEUTIC MEDICINE
LA English
DT Article; Proceedings Paper
CT 2nd Workshop on Paediatric Virology
CY OCT 08, 2016
CL Athens, GREECE
DE gambogic acid; 5-fluorouracil; colorectal cancer; chemosensitivity;
   apoptosis
ID THYMIDYLATE SYNTHASE; SURVIVIN EXPRESSION; IN-VITRO; P53; LEUCOVORIN;
   CARCINOMA; MODULATION; AUTOPHAGY; LYMPHOMA; PATHWAY
AB Chemotherapy using 5-fluorouracil (5-FU) for colorectal cancer (CRC) has low specificity and response rates, leading to severe side effects. Gambogic acid (GA), a traditional Chinese medicine, has multi-targeted anticancer effects, including growth inhibition and apoptosis induction. However, it is unclear whether a combination of 5-FU and GA has synergistic anticancer effects in CRC cells. In this study, SW480 and HCT116 human CRC cells and human intestinal epithelial cells (IECs) were treated with different concentrations of 5-FU, GA or 5-FU+GA. A Cell Counting kit-8 assay was conducted to quantify cell proliferation. The combination index (CI) was calculated and the median-effect principle was applied to analyze the interaction between 5-FU and GA. Flow cytometry was used to determine the percentage of cells undergoing apoptosis. Reverse transcription-quantitative polymerase chain reaction and western blotting were applied to measure P53, survivin and thymidylate synthase (TS) mRNA and protein levels. It was found that 5-FU+GA more pronouncedly inhibited cell growth and induced apoptosis, compared with either monotherapy. CI values <1 indicated the synergistic effects of the drugs. 5-FU+GA further decreased P53, survivin and TS mRNA and protein levels in the two CRC cell lines compared with single drugs, whereas increased P53 protein levels were observed in HCT116 cells. Moreover, 5-FU+GA did not increase cytotoxicity to IECs. These results demonstrate that GA enhances the anticancer effects of 5-FU on CRC cells. Combined treatment with 5-FU and GA is effective and safe for CRC cells, and may become a promising chemotherapy treatment.
C1 [Wei, Jianchang; Yang, Ping; Li, Wanglin; Hei, Feng; Zeng, Shanqi; Zhang, Tong; Zhong, Junbin; Huang, Di; Chen, Zhuanpeng; Wang, Chengxing; Chen, Huacui; Hu, He; Cao, Jie] Guangzhou Med Univ, Guangzhou Peoples Hosp 1, Dept Gen Surg, Guangzhou Digest Dis Ctr, 1 Panfu Rd, Guangzhou 510180, Guangdong, Peoples R China.
   [Wang, Chengxing] Sun Yat Sen Univ, Dept Gastrointestinal Surg, Affiliated Jiangmen Hosp, Jiangmen 529000, Guangdong, Peoples R China.
RP Cao, J (corresponding author), Guangzhou Med Univ, Guangzhou Peoples Hosp 1, Dept Gen Surg, Guangzhou Digest Dis Ctr, 1 Panfu Rd, Guangzhou 510180, Guangdong, Peoples R China.
EM czhongt@126.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81272556]
FX This study was supported by a grant from the National Natural Science
   Foundation of China (grant no. 81272556). The authors thank MedSci
   (Shanghai, China) for English editing.
CR Akgul O, 2014, WORLD J GASTROENTERO, V20, P6113, DOI 10.3748/wjg.v20.i20.6113
   Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917
   Andre T, 1999, EUR J CANCER, V35, P1343, DOI 10.1016/S0959-8049(99)00150-1
   Andre T, 2013, CURR COLORECT CANC R, V9, P261, DOI 10.1007/s11888-013-0181-6
   Chen WQ, 2015, CHINESE J CANCER RES, V27, P2, DOI 10.3978/j.issn.1000-9604.2015.01.06
   Chou TC, 2010, CANCER RES, V70, P440, DOI 10.1158/0008-5472.CAN-09-1947
   de Gramont A, 2000, J CLIN ONCOL, V18, P2938, DOI 10.1200/JCO.2000.18.16.2938
   Duan DZ, 2014, FREE RADICAL BIO MED, V69, P15, DOI 10.1016/j.freeradbiomed.2013.12.027
   Freed-Pastor WA, 2012, GENE DEV, V26, P1268, DOI 10.1101/gad.190678.112
   Gustavsson B, 2015, CLIN COLORECTAL CANC, V14, P1, DOI 10.1016/j.clcc.2014.11.002
   Iacopetta B, 2003, HUM MUTAT, V21, P271, DOI 10.1002/humu.10175
   Kandoth C, 2013, NATURE, V502, P333, DOI 10.1038/nature12634
   Kim SA, 2015, ARCH PHARM RES, V38, P239, DOI 10.1007/s12272-014-0528-9
   Lee MR, 2015, BIOCHEM BIOPH RES CO, V463, P229, DOI 10.1016/j.bbrc.2015.05.031
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lu N, 2013, EUR J PHARM SCI, V49, P220, DOI 10.1016/j.ejps.2013.02.018
   Muller PAJ, 2013, NAT CELL BIOL, V15, P2, DOI 10.1038/ncb2641
   Nakamura A, 2014, GASTRIC CANCER, V17, P188, DOI 10.1007/s10120-013-0249-7
   Noordhuis P, 2004, ANN ONCOL, V15, P1025, DOI 10.1093/annonc/mdh264
   Qi Q, 2008, J ETHNOPHARMACOL, V117, P433, DOI 10.1016/j.jep.2008.02.027
   Qi Q, 2015, MOL CARCINOGEN, V54, pE13, DOI 10.1002/mc.22138
   Rahman L, 2004, CANCER CELL, V5, P341, DOI 10.1016/S1535-6108(04)00080-7
   Rochette PJ, 2005, J MOL BIOL, V352, P44, DOI 10.1016/j.jmb.2005.06.033
   Sarela AI, 2000, GUT, V46, P645, DOI 10.1136/gut.46.5.645
   Su JJ, 2014, BIOL PHARM BULL, V37, P1259, DOI 10.1248/bpb.b13-00972
   Subbarayan PR, 2010, ANTICANCER RES, V30, P1157
   Sun Z, 2015, CLIN TRANSL ONCOL, V17, P876, DOI 10.1007/s12094-015-1318-7
   Suzuki R, 2014, ANTICANCER RES, V34, P4685
   Takayama T, 2006, J GASTROENTEROL, V41, P185, DOI 10.1007/s00535-006-1801-6
   Thirion P, 2004, J CLIN ONCOL, V23, P1337
   Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262
   Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675
   Vousden KH, 2009, CELL, V137, P413, DOI 10.1016/j.cell.2009.04.037
   Wang J, 2009, TOXICOLOGY, V256, P135, DOI 10.1016/j.tox.2008.11.014
   Wang SP, 2015, CHEM-BIOL INTERACT, V235, P76, DOI 10.1016/j.cbi.2015.03.017
   Xu JY, 2013, CHINESE J CANCER RES, V25, P183, DOI 10.3978/j.issn.1000-9604.2013.02.06
   Yang WL, 2012, J SURG ONCOL, V106, P680, DOI 10.1002/jso.23184
   Zhao W, 2011, ONCOL REP, V25, P1289, DOI 10.3892/or.2011.1189
NR 38
TC 5
Z9 5
U1 4
U2 18
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792-0981
EI 1792-1015
J9 EXP THER MED
JI Exp. Ther. Med.
PD FEB
PY 2017
VL 13
IS 2
BP 662
EP 668
DI 10.3892/etm.2017.4021
PG 7
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)
SC Research & Experimental Medicine
GA EL9GH
UT WOS:000394927900047
PM 28352348
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Wang, Z
   Chen, Q
   Li, B
   Xie, JM
   Yang, XD
   Zhao, K
   Wu, Y
   Ye, ZY
   Chen, ZR
   Qin, ZH
   Xing, CG
AF Wang, Zhong
   Chen, Qiang
   Li, Bin
   Xie, Jia-ming
   Yang, Xiao-dong
   Zhao, Kui
   Wu, Yong
   Ye, Zhen-yu
   Chen, Zheng-rong
   Qin, Zheng-hong
   Xing, Chun-gen
TI Escin-induced DNA damage promotes escin-induced apoptosis in human
   colorectal cancer cells via p62 regulation of the ATM/gamma H2AX pathway
SO ACTA PHARMACOLOGICA SINICA
LA English
DT Article
DE escin, p62, DNA damage, ATM/gamma H2AX pathway; apoptosis, colorectal
   cancer; HCT116 cells; HCT8 cells
ID FACTOR-KAPPA-B; BETA-ESCIN; MULTIDRUG-RESISTANCE; IN-VITRO; LUNG
   ADENOCARCINOMA; P62/SEQUESTOSOME 1; DRUG-RESISTANCE; TUMOR-CELLS;
   AUTOPHAGY; PROLIFERATION
AB Escin, a triterpene saponin isolated from horse chestnut seed, has been used to treat encephaledema, tissue swelling and chronic venous insufficiency. Recent studies show that escin induces cell cycle arrest, tumor proliferation inhibition and tumor cell apoptosis. But the relationship between escin-induced DNA damage and cell apoptosis in tumor cells remains unclear. In this study, we investigated whether and how escin-induced DNA damage contributed to escin-induced apoptosis in human colorectal cancer cells. Escin (5-80 mu g/mL) dose-dependently inhibited the cell viability and colony formation in HCT116 and HCT8 cells. Escin treatment induced DNA damage, leading to p-ATM and gamma H2AX upregulation. Meanwhile, escin treatment increased the expression of p62, an adaptor protein, which played a crucial role in controlling cell survival and tumorigenesis, and had a protective effect against escininduced DNA damage: knockdown of p62 apparently enhanced escin-induced DNA damage, whereas overexpression of p62 reduced escin-induced DNA damage. In addition, escin treatment induced concentration- and time-dependent apoptosis. Similarly, knockdown of p62 significantly increased escin-induced apoptosis in vitro and produced an escin-like antitumor effect in vivo. Overexpression of p62 decreased the rate of apoptosis. Further studies revealed that the functions of p62 in escin-induced DNA damage were associated with escin-induced apoptosis, and p62 knockdown combined with the ATM inhibitor KU55933 augmented escin-induced DNA damage and further increased escin-induced apoptosis. In conclusion, our results demonstrate that p62 regulates ATM/gamma H2AX pathway-mediated escin-induced DNA damage and apoptosis.
C1 [Wang, Zhong; Chen, Qiang; Xie, Jia-ming; Yang, Xiao-dong; Zhao, Kui; Wu, Yong; Ye, Zhen-yu; Chen, Zheng-rong; Xing, Chun-gen] Soochow Univ, Affiliated Hosp 2, Dept Gen Surg, Suzhou 215007, Peoples R China.
   [Li, Bin] First Peoples Hosp Wu Jiang, Dept Gen Surg, Suzhou 215200, Peoples R China.
   [Qin, Zheng-hong] Soochow Univ, Coll Pharmaceut Sci, Dept Pharmacol, Suzhou 215123, Peoples R China.
   [Qin, Zheng-hong] Soochow Univ, Lab Aging & Nervous Dis, Jiangsu Key Lab Translat Res & Therapy Neuropsych, Jiangsu Key Lab Prevent & Translat Med Geriatr Di, Suzhou 215123, Peoples R China.
RP Xing, CG (corresponding author), Soochow Univ, Affiliated Hosp 2, Dept Gen Surg, Suzhou 215007, Peoples R China.; Qin, ZH (corresponding author), Soochow Univ, Coll Pharmaceut Sci, Dept Pharmacol, Suzhou 215123, Peoples R China.; Qin, ZH (corresponding author), Soochow Univ, Lab Aging & Nervous Dis, Jiangsu Key Lab Translat Res & Therapy Neuropsych, Jiangsu Key Lab Prevent & Translat Med Geriatr Di, Suzhou 215123, Peoples R China.
EM qinzhenhong@suda.edu.cn; xingcgchn@163.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81672970]; Natural Science Foundation of
   Jiangsu ProvinceNatural Science Foundation of Jiangsu Province
   [BK20160338]; Suzhou Key Medical Center [LCZX201505]; Projects of Suzhou
   Technology Bureau [SS201753, SYS201552, SZS201618]; Second Affiliated
   Hospital of Soochow University Preponderant Clinic Discipline Group
   Project Funding; Invigorating Health Care through Science, Technology
   and Education (Jiangsu Provincial Medical Youth Talent) [QNRC2016249];
   Graduate Student Scientific Research Innovation Projects of Jiangsu
   Province [KYCX17_1999]; National Natural Science Youth Foundation of
   ChinaNational Natural Science Foundation of China (NSFC) [81602613]
FX This work was partially supported by the National Natural Science
   Foundation of China (No 81672970), the Natural Science Foundation of
   Jiangsu Province (No BK20160338), and supported by Suzhou Key Medical
   Center (No LCZX201505), the Projects of Suzhou Technology Bureau (No
   SS201753, SYS201552, SZS201618), the Second Affiliated Hospital of
   Soochow University Preponderant Clinic Discipline Group Project Funding,
   the Project of Invigorating Health Care through Science, Technology and
   Education (Jiangsu Provincial Medical Youth Talent, QNRC2016249) and
   Graduate Student Scientific Research Innovation Projects of Jiangsu
   Province (No KYCX17_1999), National Natural Science Youth Foundation of
   China (No 81602613).
CR Bonner WM, 2008, NAT REV CANCER, V8, P957, DOI 10.1038/nrc2523
   Burma S, 2001, J BIOL CHEM, V276, P42462, DOI 10.1074/jbc.C100466200
   Chipuk JE, 2006, CELL DEATH DIFFER, V13, P994, DOI 10.1038/sj.cdd.4401908
   Ciftci GA, 2015, CYTOTECHNOLOGY, V67, P893, DOI 10.1007/s10616-015-9877-6
   Diehm C, 1996, LANCET, V347, P292, DOI 10.1016/S0140-6736(96)90467-5
   Duran A, 2008, CANCER CELL, V13, P343, DOI 10.1016/j.ccr.2008.02.001
   Fletcher JI, 2016, DRUG RESIST UPDATE, V26, P1, DOI 10.1016/j.drup.2016.03.001
   Fojo T, 2003, ONCOGENE, V22, P7512, DOI 10.1038/sj.onc.1206951
   Gilardini Montani MS, 2013, J EXP CLIN CANC RES, V32, DOI 10.1186/1756-9966-32-95
   Guney G, 2013, PHYTOTHER RES, V27, P900, DOI 10.1002/ptr.4804
   Guo DK, 2015, NEUROSCI BULL, V31, P469, DOI 10.1007/s12264-015-1543-7
   Harford-Wright E, 2016, ONCOTARGET, V7, P66865, DOI 10.18632/oncotarget.11784
   Harikumar KB, 2010, MOL PHARMACOL, V77, P818, DOI 10.1124/mol.109.062760
   Holohan C, 2013, NAT REV CANCER, V13, P714, DOI 10.1038/nrc3599
   Huang GL, 2015, WORLD J GASTROENTERO, V21, P1148, DOI 10.3748/wjg.v21.i4.1148
   Inoue D, 2012, CANCER SCI, V103, P760, DOI 10.1111/j.1349-7006.2012.02216.x
   Lage H, 2008, CELL MOL LIFE SCI, V65, P3145, DOI 10.1007/s00018-008-8111-5
   Luo X, 2012, GENE DEV, V26, P417, DOI 10.1101/gad.183509.111
   Mathew R, 2009, CELL, V137, P1062, DOI 10.1016/j.cell.2009.03.048
   Ming ZJ, 2010, PHYTOMEDICINE, V17, P575, DOI 10.1016/j.phymed.2009.12.009
   Mojzisova G, 2016, ACTA BIOCHIM POL, V63, P79, DOI 10.18388/abp.2015_1013
   Moscat J, 2009, CELL, V137, P1001, DOI 10.1016/j.cell.2009.05.023
   Nakayama S, 2017, CANCER MED-US, V6, P1264, DOI 10.1002/cam4.1093
   Niu YP, 2008, LEUKEMIA LYMPHOMA, V49, P1384, DOI 10.1080/10428190802090151
   Patiolla JMR, 2006, MOL CANCER THER, V5, P1459, DOI 10.1158/1535-7163.MCT-05-0495
   Patlolla JMR, 2013, CANCER PREV RES, V6, P1140, DOI 10.1158/1940-6207.CAPR-13-0216
   Pittler MH, 2012, COCHRANE DB SYST REV, V11, DOI DOI 10.1002/14651858.CD003230.PUB423152216
   Ren F, 2016, BBA-REV CANCER, V1866, P266, DOI 10.1016/j.bbcan.2016.10.001
   Ren F, 2014, MOL CELL BIOCHEM, V385, P95, DOI 10.1007/s11010-013-1818-0
   Rimmon A, 2013, BIOCHEM RES INT, V2013, DOI 10.1155/2013/251752
   Rolland P, 2007, ENDOCR-RELAT CANCER, V14, P73, DOI 10.1677/erc.1.01312
   Roos WP, 2006, TRENDS MOL MED, V12, P440, DOI 10.1016/j.molmed.2006.07.007
   Shen DY, 2011, PHYTOTHER RES, V25, P1519, DOI 10.1002/ptr.3435
   Siegel R, 2014, CA-CANCER J CLIN, V64, P104, DOI 10.3322/caac.21220
   Siegel RL, 2017, CA-CANCER J CLIN, V67, P177, DOI 10.3322/caac.21395
   Tan SML, 2010, J PHARMACOL EXP THER, V334, P285, DOI 10.1124/jpet.110.165498
   Thompson HGR, 2003, ONCOGENE, V22, P2322, DOI 10.1038/sj.onc.1206325
   Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262
   Wang YN, 2016, MOL CELL, V63, P34, DOI 10.1016/j.molcel.2016.05.027
   Wang YW, 2012, J CANCER RES CLIN, V138, P785, DOI 10.1007/s00432-012-1152-z
   Weston VJ, 2010, BLOOD, V116, P4578, DOI 10.1182/blood-2010-01-265769
   Williamson CT, 2010, MOL CANCER THER, V9, P347, DOI 10.1158/1535-7163.MCT-09-0872
   Wu Q, 2014, CANCER LETT, V347, P159, DOI 10.1016/j.canlet.2014.03.013
   Xu LZ, 2017, ONCOGENE, V36, P304, DOI 10.1038/onc.2016.202
   Yu H, 2011, EUR J CANCER, V47, P1585, DOI 10.1016/j.ejca.2011.01.019
   Yuan SY, 2017, ONCOL REP, V37, P1002, DOI 10.3892/or.2017.5348
   Zhang ZZ, 2011, PHYTOTHER RES, V25, P1747, DOI 10.1002/ptr.3457
NR 47
TC 9
Z9 9
U1 2
U2 13
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1671-4083
EI 1745-7254
J9 ACTA PHARMACOL SIN
JI Acta Pharmacol. Sin.
PD OCT
PY 2018
VL 39
IS 10
BP 1645
EP 1660
DI 10.1038/aps.2017.192
PG 16
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry; Pharmacology & Pharmacy
GA GY2RU
UT WOS:000448391500010
PM 29849127
OA Bronze, Green Published
DA 2022-04-25
ER

PT J
AU Wang, Y
   Zhang, JY
   Zheng, S
AF Wang, Yong
   Zhang, Jingyu
   Zheng, Shuang
TI The role of XBP-1-mediated unfolded protein response in colorectal
   cancer progression-a regulatory mechanism associated with
   lncRNA-miRNA-mRNA network
SO CANCER CELL INTERNATIONAL
LA English
DT Article
DE Colorectal cancer; XBP-1; Endoplasmic reticulum stress; KCNQ1OT1; XIST
ID ENDOPLASMIC-RETICULUM; XBP-1; STRESS; APOPTOSIS; AUTOPHAGY; XBP1S
AB Background We aim to identify the expression and analyze the molecular action of dysregulated lncRNA-miRNA mediated by XBP-1 in colorectal cancer (CRC). Methods Here, we identified XBP-1-mediated dysregulated lncRNAs and miRNAs in CRC by bioinformatics analysis. The expression level of lncRNAs and miRNA was measured using quantitative real time PCR, and the expression of XBP-1, as well as apoptosis-related proteins, were detected by western blot. CCK-8 and TUNEL assays were performed to determine cell proliferation and apoptosis, respectively. Luciferase reporter assay was conducted to verify the binding relationship among lncRNA-miRNA-XBP-1. BALB/c nude mice were inoculated subcutaneously with HCT116 cells to establish tumor-bearing mice model. Histological analysis was carried out by HE staining and immunohistochemical staining. Results Six downregulated lncRNAs (SLFNL1-AS1, KCNQ1OT1, NEAT1, XIST, AC016876.2, AC026362.1), four dysregulated miRNAs (miR-500a-3p, miR-370-3p, miR-2467-3p, miR-512-3p) and upregulated XBP-1 were identified in CRC cell lines. Gain- and loss-of-function experiments showed that overexpression of KCNQ1OT1/XIST promoted cell proliferation and suppressed cell apoptosis. In addition, overexpression of KCNQ1OT1/XIST partly abolished the inhibitory effects of XBP-1u knockdown or tunicamycin, an activator of endoplasmic reticulum stress, on CRC cell viability loss and apoptosis. Furthermore, KCNQ1OT1/XIST aggravated tumor growth in vivo by regulating endoplasmic reticulum stress and cell apoptosis. Conclusions This study has constructed lncRNA-miRNA-mRNA networks based on XBP-1 in CRC, and disclosed the regulatory mechanism of action, providing a set of pivotal biomarkers for future molecular investigation and targeted treatment of CRC.
C1 [Wang, Yong] Nanjing Med Univ, Dept Colorectal Surg, Affiliated Hosp 1, Nanjing 210029, Jiangsu, Peoples R China.
   [Zhang, Jingyu] Second Peoples Hosp Lianyungang, Dept Gastrointestinal Oncol, Lianyungang 200023, Jiangsu, Peoples R China.
   [Zheng, Shuang] Wenzhou Med Univ, Taizhou Peoples Hosp 1, Dept Gen Surg, Huangyan Hosp, 218 Hengjie Rd, Taizhou City 318020, Zhejiang, Peoples R China.
RP Zheng, S (corresponding author), Wenzhou Med Univ, Taizhou Peoples Hosp 1, Dept Gen Surg, Huangyan Hosp, 218 Hengjie Rd, Taizhou City 318020, Zhejiang, Peoples R China.
EM zszheng2021@163.com
OI , Shuang/0000-0003-0393-0505
CR Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
   Chen XX, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0962-6
   Cheng CS, 2018, MED SCI MONITOR, V24, P6331, DOI 10.12659/MSM.908400
   Cheng Y, 2019, DIS MARKERS, V2019, DOI 10.1155/2019/7636757
   Day LW, 2015, GUT LIVER, V9, P143, DOI 10.5009/gnl14302
   Dewal MB, 2015, CHEM BIOL, V22, P1301, DOI 10.1016/j.chembiol.2015.09.006
   Dong XH, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00160
   Fearnhead NS, 2002, BRIT MED BULL, V64, P27, DOI 10.1093/bmb/64.1.27
   Feldman DE, 2005, MOL CANCER RES, V3, P597, DOI 10.1158/1541-7786.MCR-05-0221
   Gao ZZ, 2019, TECHNOL CANCER RES T, V18, DOI 10.1177/1533033819853237
   Hetz C, 2012, NAT REV MOL CELL BIO, V13, P89, DOI 10.1038/nrm3270
   Hsu SK, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20102518
   Huang C, 2017, SCI ADV, V3, DOI 10.1126/sciadv.1701383
   Huang C, 2020, ONCOL REP, V44, P449, DOI 10.3892/or.2020.7639
   Ji H, 2019, BIOCHEM BIOPH RES CO, V508, P203, DOI 10.1016/j.bbrc.2018.11.112
   Koong AC, 2006, CANCER BIOL THER, V5, P756, DOI 10.4161/cbt.5.7.2973
   Lee AH, 2003, MOL CELL BIOL, V23, P7448, DOI 10.1128/MCB.23.21.7448-7459.2003
   Leung-Hagesteijn C, 2013, CANCER CELL, V24, P289, DOI 10.1016/j.ccr.2013.08.009
   Li Y, 2020, INFLAMMATION, V43, P2264, DOI 10.1007/s10753-020-01295-w
   Li ZC, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-018-1012-z
   Lin LJ, 2020, DRUG DES DEV THER, V14, P1127, DOI 10.2147/DDDT.S238124
   Liu Y, 2017, APOPTOSIS, V22, P544, DOI 10.1007/s10495-016-1334-2
   Luo B, 2013, ONCOGENE, V32, P805, DOI 10.1038/onc.2012.130
   Ma ZQ, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08547-0
   Mhaidat NM, 2015, J CHEMOTHERAPY, V27, P167, DOI 10.1179/1973947815Y.0000000006
   Papaioannou A, 2018, CURR TOP MICROBIOL, V414, P159, DOI 10.1007/82_2017_36
   Tirosh B, 2006, J BIOL CHEM, V281, P5852, DOI 10.1074/jbc.M509061200
   Wang LY, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20225758
   Wang M, 2016, NATURE, V529, P326, DOI 10.1038/nature17041
   Wu SD, 2018, BIOCHEM BIOPH RES CO, V500, P530, DOI 10.1016/j.bbrc.2018.04.033
   Xiao HQ, 2020, J CELL PHYSIOL, V235, P2881, DOI 10.1002/jcp.29193
   Xu M, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-018-0690-5
   Yang L, 2020, J CELL PHYSIOL, DOI 10.1002/jcp.29484
   Zhao Y, 2013, CELL RES, V23, P491, DOI 10.1038/cr.2013.2
   Zhuang M, 2019, EBIOMEDICINE, V41, P286, DOI 10.1016/j.ebiom.2018.12.049
NR 35
TC 1
Z9 1
U1 0
U2 0
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1475-2867
J9 CANCER CELL INT
JI Cancer Cell Int.
PD SEP 14
PY 2021
VL 21
IS 1
AR 488
DI 10.1186/s12935-021-02167-5
PG 14
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA UQ1RI
UT WOS:000695847800001
PM 34521445
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Sun, HZ
   Wang, RR
   Liu, Y
   Mei, HT
   Liu, XN
   Peng, ZH
AF Sun, Hongze
   Wang, Rangrang
   Liu, Yuan
   Mei, Haitao
   Liu, Xueni
   Peng, Zhihai
TI USP11 induce resistance to 5-Fluorouracil in Colorectal Cancer through
   activating autophagy by stabilizing VCP
SO JOURNAL OF CANCER
LA English
DT Article
DE USP11; VCP; colorectal cancer; 5-fluorouracil; chemotherapy resistance
ID SENSITIVITY; PROMOTES; SURVIVAL; THERAPY; VCP/P97; CELLS; CHEMOTHERAPY;
   MECHANISMS; APOPTOSIS; P53
AB Chemotherapy plays an important role in the treatment of patients with colorectal cancer (CRC). However, the resistance to chemotherapy severely affects the prognosis of CRC patients and the mechanisms are still poorly understood. Our study investigated the role of ubiquitin-specific protease 11 (USP11) in CRC chemotherapy and found that USP11 could induce resistance to 5-fluorouracil by activating autophagy. A series of in vitro and in vivo experiments revealed that USP11 promoted autophagy through AMPK/Akt/mTOR pathway via stabilizing valosin-containing protein (VCP). Overall, our study demonstrated that USP11 might be valuable to predict the chemotherapeutic sensitivity and improve the prognosis of CRC patients.
C1 [Sun, Hongze; Wang, Rangrang; Liu, Yuan; Mei, Haitao; Liu, Xueni; Peng, Zhihai] Shanghai Jiao Tong Univ, Sch Med, Shanghai Gen Hosp, Dept Gen Surg, Shanghai, Peoples R China.
   [Sun, Hongze] Shandong Univ, Qilu Hosp, Dept Gen Surg, Jinan, Peoples R China.
   [Peng, Zhihai] Xiamen Univ, Sch Med, Xiangan Hosp, Dept Gen Surg, Xiamen, Peoples R China.
RP Liu, XN; Peng, ZH (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Shanghai Gen Hosp, Dept Gen Surg, Shanghai, Peoples R China.; Peng, ZH (corresponding author), Xiamen Univ, Sch Med, Xiangan Hosp, Dept Gen Surg, Xiamen, Peoples R China.
EM 016543lxn@shgh.cn; pengzhihai1958@163.com
OI Liu, Yuan/0000-0001-6227-024X
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81530044, 81802343, 81972216]; Shanghai
   three-year action plan to promote clinical skills and clinical
   innovation capacity of municipal hospitals [16CR2008A]; Technology Major
   Project of China [2017ZX10203206]
FX This project was supported by the National Natural Science Foundation of
   China (81530044, 81802343, 81972216), Shanghai three-year action plan to
   promote clinical skills and clinical innovation capacity of municipal
   hospitals (No.16CR2008A) and Technology Major Project of China Grants
   (2017ZX10203206).
CR Amaravadi R, 2016, GENE DEV, V30, P1913, DOI 10.1101/gad.287524.116
   Bayraktar S, 2013, CANCER J, V19, P10, DOI 10.1097/PPO.0b013e3182801b3a
   Codogno P, 2005, CELL DEATH DIFFER, V12, P1509, DOI 10.1038/sj.cdd.4401751
   de la Cruz-Morcillo MA, 2012, ONCOGENE, V31, P1073, DOI 10.1038/onc.2011.321
   Dekker E, 2019, LANCET, V394, P1467, DOI 10.1016/S0140-6736(19)32319-0
   Furuta S, 2004, ONCOGENE, V23, P3898, DOI 10.1038/sj.onc.1207539
   Galluzzi L, 2015, EMBO J, V34, P856, DOI 10.15252/embj.201490784
   He CC, 2009, ANNU REV GENET, V43, P67, DOI 10.1146/annurev-genet-102808-114910
   Iwashita H, 2018, FEBS LETT, V592, P559, DOI 10.1002/1873-3468.12979
   Johnson AE, 2015, ELIFE, V4, DOI 10.7554/eLife.07366
   Kocaturk NM, 2019, EUR J PHARM SCI, V134, P116, DOI 10.1016/j.ejps.2019.04.011
   Lee EW, 2015, CELL DEATH DIFFER, V22, P1463, DOI 10.1038/cdd.2014.234
   Levy JMM, 2017, NAT REV CANCER, V17, P528, DOI 10.1038/nrc.2017.53
   Li J, 2009, ANN SURG ONCOL, V16, P761, DOI 10.1245/s10434-008-0260-0
   Liu JL, 2011, CELL, V147, P223, DOI 10.1016/j.cell.2011.08.037
   Longley DB, 2003, NAT REV CANCER, V3, P330, DOI 10.1038/nrc1074
   Marquez J, 2013, INT J CANCER, V133, P2113, DOI 10.1002/ijc.28232
   Meyer H, 2012, NAT CELL BIOL, V14, P117, DOI 10.1038/ncb2407
   Mocellin S, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006875.pub3
   MOERTEL CG, 1994, NEW ENGL J MED, V330, P1136
   O'Donovan TR, 2011, AUTOPHAGY, V7, P509, DOI 10.4161/auto.7.5.15066
   Ou JJ, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08902-x
   Papadopoulos C, 2017, EMBO J, V36, P135, DOI 10.15252/embj.201695148
   Pattingre S, 2003, J BIOL CHEM, V278, P16667, DOI 10.1074/jbc.M210998200
   Peng H, 2020, AUTOPHAGY, V16, P698, DOI 10.1080/15548627.2019.1635381
   Punt CJA, 2017, NAT REV CLIN ONCOL, V14, P235, DOI 10.1038/nrclinonc.2016.171
   Sasaki K, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-370
   Siegel RL, 2016, CA-CANCER J CLIN, V66, P7, DOI 10.3322/caac.21332
   Sun HZ, 2019, EBIOMEDICINE, V48, P236, DOI 10.1016/j.ebiom.2019.08.061
   Nguyen TV, 2017, P NATL ACAD SCI USA, V114, P3565, DOI 10.1073/pnas.1700949114
   Tresse E, 2010, AUTOPHAGY, V6, P217, DOI 10.4161/auto.6.2.11014
   Van Cutsem E, 2019, J CLIN ONCOL, V37, P1460, DOI 10.1200/JCO.18.02459
   van den Boom J, 2018, MOL CELL, V69, P182, DOI 10.1016/j.molcel.2017.10.028
   Venook AP, 2017, JAMA-J AM MED ASSOC, V317, P2392, DOI 10.1001/jama.2017.7105
   Violette S, 2002, INT J CANCER, V98, P498, DOI 10.1002/ijc.10146
   Vodenkova S, 2020, PHARMACOL THERAPEUT, V206, DOI 10.1016/j.pharmthera.2019.107447
   Wang B, 2019, MOL CELL, V74, P742, DOI 10.1016/j.molcel.2019.03.027
   Wang YQ, 2015, AUTOPHAGY, V11, P595, DOI 10.1080/15548627.2015.1034408
   Wei MF, 2014, AUTOPHAGY, V10, P1179, DOI 10.4161/auto.28679
   White E, 2009, CLIN CANCER RES, V15, P5308, DOI 10.1158/1078-0432.CCR-07-5023
   Yang Y, 2020, CELL DEATH DIFFER, V27, P858, DOI 10.1038/s41418-019-0480-9
   Yang ZF, 2010, CURR OPIN CELL BIOL, V22, P124, DOI 10.1016/j.ceb.2009.11.014
   Zhang HH, 2015, CANCER LETT, V356, P781, DOI 10.1016/j.canlet.2014.10.029
   Zhou Z, 2017, EBIOMEDICINE, V15, P48, DOI 10.1016/j.ebiom.2016.12.014
NR 44
TC 3
Z9 3
U1 4
U2 4
PU IVYSPRING INT PUBL
PI LAKE HAVEN
PA PO BOX 4546, LAKE HAVEN, NSW 2263, AUSTRALIA
SN 1837-9664
J9 J CANCER
JI J. Cancer
PY 2021
VL 12
IS 8
BP 2317
EP 2325
DI 10.7150/jca.52158
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA QP9EF
UT WOS:000624131100015
PM 33758608
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Zhang, D
   Zhou, Q
   Huang, DD
   He, L
   Zhang, H
   Hu, B
   Peng, H
   Ren, DL
AF Zhang, Di
   Zhou, Qian
   Huang, Dandan
   He, Lu
   Zhang, Heng
   Hu, Bang
   Peng, Hui
   Ren, Donglin
TI ROS/JNK/c-Jun axis is involved in oridonin-induced caspase-dependent
   apoptosis in human colorectal cancer cells
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Oridonin; Colorectal cancer; Apoptosis; Caspase; Reactive oxygen
   species; c-Jun N-Terminal kinase
ID DRUG-RESISTANCE; EFFECTIVELY REVERSES; REACTIVE OXYGEN; INHIBITION;
   INDUCTION; ACTIVATION; AUTOPHAGY; PATHWAYS; SURVIVAL; STRESS
AB Colorectal cancer (CRC) is one of the most common malignant neoplasms with high mortality worldwide. Oridonin, a diterpenoid isolated from the Chinese medicinal herb Rabdosia rubescens, has been proved to have anticancer effect on various types of cancer cells. However, the detailed mechanisms of oridonin in CRC cells remain unclear and if oridonin can overcome 5-FU resistance have not been investigated yet. In this study, we investigated the anticancer effect of oridonin in both 5-FU sensitive and resistant CRC cells and illuminated the underlying mechanisms. We showed that oridonin induced proliferation inhibition and caspase-dependent apoptosis in both 5-FU sensitive and resistant CRC cells. Oridonin induced reactive oxygen species (ROS) accumulation in both 5-FU sensitive and resistant CRC cells, which resulted in cell apoptosis as oridonin-induced apoptosis was almost abolished when cells were co-treated with the ROS scavenger N-acetyl-L-cysteine (NAC). Moreover, we found that oridonin induced CRC cell apoptosis via the c-Jun N-terminal kinase (JNK)/c-Jun pathway as oridonin activated JNK/c-Jun pathway and the JNK inhibitor SP600125 restored oridonin-induced apoptosis in CRC cells. Interestingly, when CRC cells were co-treated with NAC, the activation of JNK/c-Jun pathway induced by oridonin was nearly reversed, indicating that oridonin induced JNK/c-Jun pathway activation through the accumulation of ROS. Taken together, these data reveal that oridonin induces apoptosis through the ROS/JNK/c-Jun axis in both 5-FU sensitive and resistant CRC cells, suggesting that oridonin could be a potential agent for CRC treatment. (C) 2019 Elsevier Inc. All rights reserved.
C1 [Zhang, Di; Zhou, Qian; Huang, Dandan; Zhang, Heng; Hu, Bang; Peng, Hui; Ren, Donglin] Sun Yat Sen Univ, Affiliated Hosp 6, Dept Gastrointestinal Surg, Guangzhou, Guangdong, Peoples R China.
   [Zhang, Di; Zhou, Qian; Huang, Dandan; He, Lu; Zhang, Heng; Hu, Bang; Peng, Hui; Ren, Donglin] Sun Yat Sen Univ, Affiliated Hosp 6, Guangdong Inst Gastroenterol, Guangdong Prov Key Lab Colorectal & Pelv Floor Di, Guangzhou, Guangdong, Peoples R China.
   [He, Lu] Sun Yat Sen Univ, Affiliated Hosp 6, Dept Neurol, Guangzhou, Guangdong, Peoples R China.
RP Ren, DL (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 6, Guangzhou, Guangdong, Peoples R China.
EM rendl111@163.com
FU Science and Technology Program of Guangdong [Z20150108201706156];
   Natural Science Foundation of GuangdongNational Natural Science
   Foundation of Guangdong Province [2015A030313165]
FX This study was supported by the Science and Technology Program of
   Guangdong (Z20150108201706156) and the Natural Science Foundation of
   Guangdong (2015A030313165).
CR Biagi JJ, 2011, JAMA-J AM MED ASSOC, V305, P2335, DOI 10.1001/jama.2011.749
   Bu HQ, 2014, ONCOL REP, V31, P975, DOI 10.3892/or.2013.2888
   Cai DT, 2013, MOL CELL BIOCHEM, V379, P161, DOI 10.1007/s11010-013-1638-2
   Cao SJ, 2016, INT J ONCOL, V49, P2075, DOI 10.3892/ijo.2016.3696
   Cheng Y, 2009, AUTOPHAGY, V5, P430, DOI 10.4161/auto.5.3.7896
   Colucci G, 2005, J CLIN ONCOL, V23, P4866, DOI 10.1200/JCO.2005.07.113
   Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210
   Galadari S, 2017, FREE RADICAL BIO MED, V104, P144, DOI 10.1016/j.freeradbiomed.2017.01.004
   Gao FH, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-610
   He ZW, 2017, ONCOL LETT, V14, P2499, DOI 10.3892/ol.2017.6421
   Huang HL, 2014, CURR PHARM DESIGN, V20, P6543, DOI 10.2174/1381612820666140826153203
   Huang J, 2005, ACTA MED OKAYAMA, V59, P261
   Kang N, 2010, CANCER LETT, V294, P147, DOI 10.1016/j.canlet.2010.01.032
   Krens SFG, 2006, FEBS LETT, V580, P4984, DOI 10.1016/j.febslet.2006.08.025
   Lamkanfi M, 2007, CELL DEATH DIFFER, V14, P44, DOI 10.1038/sj.cdd.4402047
   Liu Z, 2012, CELL PROLIFERAT, V45, P499, DOI 10.1111/j.1365-2184.2012.00849.x
   Longley DB, 2006, BBA-REV CANCER, V1766, P184, DOI 10.1016/j.bbcan.2006.08.001
   Lu Y, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0031-6
   Ma SH, 2016, MOL MED REP, V13, P3342, DOI 10.3892/mmr.2016.4897
   Ma YC, 2016, ONCOTARGET, V7, P86211, DOI 10.18632/oncotarget.13367
   Roux PP, 2004, MICROBIOL MOL BIOL R, V68, P320, DOI 10.1128/MMBR.68.2.320-344.2004
   Shen HM, 2006, FREE RADICAL BIO MED, V40, P928, DOI 10.1016/j.freeradbiomed.2005.10.056
   Wen CY, 2016, CANCER LETT, V383, P295, DOI 10.1016/j.canlet.2016.09.007
   Wen CY, 2015, INT J ONCOL, V47, P1663, DOI 10.3892/ijo.2015.3166
   Xiao XL, 2016, INT J ONCOL, V48, P2608, DOI 10.3892/ijo.2016.3488
   Yao Z, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.35
   Zhang Y, 2017, SAUDI J BIOL SCI, V24, P678, DOI 10.1016/j.sjbs.2017.01.042
   Zhen T, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003562
   Zhou GB, 2007, CELL RES, V17, P274, DOI 10.1038/cr.2007.21
NR 29
TC 18
Z9 21
U1 0
U2 19
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD JUN 4
PY 2019
VL 513
IS 3
BP 594
EP 601
DI 10.1016/j.bbrc.2019.04.011
PG 8
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA HY6RW
UT WOS:000468258400010
PM 30981511
DA 2022-04-25
ER

PT J
AU Gholizadeh, M
   Doustvandi, MA
   Mohammadnejad, F
   Shadbad, MA
   Tajalli, H
   Brunetti, O
   Argentiero, A
   Silvestris, N
   Baradaran, B
AF Gholizadeh, Mahsa
   Doustvandi, Mohammad Amin
   Mohammadnejad, Fateme
   Shadbad, Mahdi Abdoli
   Tajalli, Habib
   Brunetti, Oronzo
   Argentiero, Antonella
   Silvestris, Nicola
   Baradaran, Behzad
TI Photodynamic Therapy with Zinc Phthalocyanine Inhibits the Stemness and
   Development of Colorectal Cancer: Time to Overcome the Challenging
   Barriers?
SO MOLECULES
LA English
DT Article
DE photodynamic therapy; zinc phthalocyanine; cancer stem cell; colorectal
   cancer; stemness; prognosis; metastasis
ID CELLS; PHOTOSENSITIZER; APOPTOSIS
AB Photodynamic therapy (PDT) is a light-based cancer therapy approach that has shown promising results in treating various malignancies. Growing evidence indicates that cancer stem cells (CSCs) are implicated in tumor recurrence, metastasis, and cancer therapy resistance in colorectal cancer (CRC); thus, targeting these cells can ameliorate the prognosis of affected patients. Based on our bioinformatics results, SOX2 overexpression is significantly associated with inferior disease-specific survival and worsened the progression-free interval of CRC patients. Our results demonstrate that zinc phthalocyanine (ZnPc)-PDT with 12 J/cm(2) or 24 J/cm(2) irradiation can substantially decrease tumor migration via downregulating MMP9 and ROCK1 and inhibit the clonogenicity of SW480 cells via downregulating CD44 and SOX2. Despite inhibiting clonogenicity, ZnPc-PDT with 12 J/cm(2) irradiation fails to downregulate CD44 expression in SW480 cells. Our results indicate that ZnPc-PDT with 12 J/cm(2) or 24 J/cm(2) irradiation can substantially reduce the cell viability of SW480 cells and stimulate autophagy in the tumoral cells. Moreover, our results show that ZnPc-PDT with 12 J/cm(2) or 24 J/cm(2) irradiation can substantially arrest the cell cycle at the sub-G1 level, stimulate the intrinsic apoptosis pathway via upregulating caspase-3 and caspase-9 and downregulating Bcl-2. Indeed, our bioinformatics results show considerable interactions between the studied CSC-related genes with the studied migration- and apoptosis-related genes. Collectively, the current study highlights the potential role of ZnPc-PDT in inhibiting stemness and CRC development, which can ameliorate the prognosis of CRC patients.
C1 [Gholizadeh, Mahsa; Doustvandi, Mohammad Amin; Mohammadnejad, Fateme; Shadbad, Mahdi Abdoli; Baradaran, Behzad] Tabriz Univ Med Sci, Immunol Res Ctr, Tabriz 5166614731, Iran.
   [Shadbad, Mahdi Abdoli] Tabriz Univ Med Sci, Student Res Comm, Tabriz 5166614731, Iran.
   [Tajalli, Habib] Islamic Azad Univ, Biophoton Res Ctr, Tabriz Branch, Tabriz 5157944533, Iran.
   [Tajalli, Habib] Univ Tabriz, Res Inst Appl Phys & Astron, Tabriz 5166616471, Iran.
   [Brunetti, Oronzo; Argentiero, Antonella; Silvestris, Nicola] Ist Nazl Tumori IRCCS, Ist Tumori BariGiovanni Paolo II, I-70124 Bari, Italy.
   [Silvestris, Nicola] Univ Bari Aldo Moro, Sch Med, Dept Biomed Sci & Human Oncol, I-70124 Bari, Italy.
   [Baradaran, Behzad] Tabriz Univ Med Sci, Neurosci Res Ctr, Tabriz 5166614731, Iran.
RP Baradaran, B (corresponding author), Tabriz Univ Med Sci, Immunol Res Ctr, Tabriz 5166614731, Iran.; Silvestris, N (corresponding author), Ist Nazl Tumori IRCCS, Ist Tumori BariGiovanni Paolo II, I-70124 Bari, Italy.; Silvestris, N (corresponding author), Univ Bari Aldo Moro, Sch Med, Dept Biomed Sci & Human Oncol, I-70124 Bari, Italy.; Baradaran, B (corresponding author), Tabriz Univ Med Sci, Neurosci Res Ctr, Tabriz 5166614731, Iran.
EM Gmahsa42@gmail.com; m.amin.dostvandi@gmail.com;
   fatememohamadnejad@gmail.com; abdoli.med99@gmail.com;
   habibtajalli@yahoo.com; dr.oronzo.brunetti1983@gmail.com;
   argentieroantonella@gmail.com; n.silvestris@oncologico.bari.it;
   baradaranb@tbzmed.ac.ir
RI Baradaran, Behzad/AAQ-5177-2020; Abdoli Shadbad, Mahdi/AAR-2537-2021
OI Baradaran, Behzad/0000-0002-8642-6795; Abdoli Shadbad,
   Mahdi/0000-0003-4865-8779; doustvandi, mohammad
   amin/0000-0002-3655-2515; Mohammadnejad, Fateme/0000-0002-4107-9689
FU Apulian Regional Project "Medicina di Precisione"Regione Puglia
FX This research was funded by the Apulian Regional Project "Medicina di
   Precisione" to N.S.
CR Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
   Cho SH, 2012, INT J ONCOL, V41, P211, DOI 10.3892/ijo.2012.1453
   Derakhshani A, 2021, MOLECULES, V26, DOI 10.3390/molecules26082278
   Dolmans DEJGJ, 2003, NAT REV CANCER, V3, P380, DOI 10.1038/nrc1071
   Dougherty TJ, 1998, JNCI-J NATL CANCER I, V90, P889, DOI 10.1093/jnci/90.12.889
   Doustvandi MA, 2019, PHOTODIAGN PHOTODYN, V28, P88, DOI 10.1016/j.pdpdt.2019.08.027
   Doustvandi MA, 2017, J PHOTOCH PHOTOBIO B, V176, P62, DOI 10.1016/j.jphotobiol.2017.09.020
   Han X, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041335
   Hodgkinson Natasha, 2017, Tumour Biol, V39, p1010428317734691, DOI 10.1177/1010428317734691
   Huang LF, 2018, EUR J MED CHEM, V151, P294, DOI 10.1016/j.ejmech.2018.03.077
   Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]
   Keyal U, 2018, J BIOPHOTONICS, V11, DOI 10.1002/jbio.201800114
   Kuzyniak W, 2017, INT J ONCOL, V50, P953, DOI 10.3892/ijo.2017.3854
   Lotfinejad P, 2021, BIOMED PHARMACOTHER, V138, DOI 10.1016/j.biopha.2021.111436
   Lundberg IV, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2509-5
   Mornex F, 2006, INT J RADIAT ONCOL, V66, P1152, DOI 10.1016/j.ijrobp.2006.06.015
   Mulsow J, 2011, BRIT J SURG, V98, P1785, DOI 10.1002/bjs.7653
   Najafzadeh B, 2021, J CELL PHYSIOL, V236, P2443, DOI 10.1002/jcp.30063
   Navaeipour F, 2016, J PHOTOCH PHOTOBIO B, V161, P456, DOI 10.1016/j.jphotobiol.2016.06.017
   Novak D, 2020, SEMIN CANCER BIOL, V67, P74, DOI 10.1016/j.semcancer.2019.08.007
   Parizadeh SM, 2019, INT J BIOCHEM CELL B, V110, P75, DOI 10.1016/j.biocel.2019.02.010
   Park YS, 2012, ONCOL REP, V27, P339, DOI 10.3892/or.2011.1532
   Schmidt J, 2018, INT J MOL MED, V42, P534, DOI 10.3892/ijmm.2018.3620
   Sekhejane PR, 2014, INT J PHOTOENERGY, V2014, DOI 10.1155/2014/383027
   Takeda K, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-36251-0
   Vahidian F, 2020, MOL BIOL REP, V47, P9541, DOI 10.1007/s11033-020-05952-z
   Wahab SMR, 2017, CLIN COLORECTAL CANC, V16, P93, DOI 10.1016/j.clcc.2017.01.011
   Wang ZP, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00309
   Xue EY, 2019, RSC ADV, V9, P20652, DOI 10.1039/c9ra03911b
   Yaghobi Z, 2021, EUR J PHARMACOL, V903, DOI 10.1016/j.ejphar.2021.174147
   Yu W, 2018, NANOMED-NANOTECHNOL, V14, P1099, DOI 10.1016/j.nano.2018.02.005
   Yu XN, 2020, ACS APPL MATER INTER, V12, P17193, DOI 10.1021/acsami.0c00375
   Zhang SZ, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-00242-3
   Zhang XH, 2020, PATHOL RES PRACT, V216, DOI 10.1016/j.prp.2019.152769
   Zheng JH, 2017, ONCOTARGET, V8, P98635, DOI 10.18632/oncotarget.21709
   Zhou ZJ, 2016, CHEM SOC REV, V45, P6597, DOI 10.1039/c6cs00271d
NR 36
TC 0
Z9 0
U1 7
U2 7
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1420-3049
J9 MOLECULES
JI Molecules
PD NOV
PY 2021
VL 26
IS 22
AR 6877
DI 10.3390/molecules26226877
PG 15
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA XK2YX
UT WOS:000727338300001
PM 34833970
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Zheng, S
   Zhong, YF
   Tan, DM
   Xu, Y
   Chen, HX
   Wang, D
AF Zheng, Sheng
   Zhong, Yong-Fu
   Tan, De-Ming
   Xu, Yue
   Chen, Huai-Xiang
   Wang, Dan
TI miR-183-5p enhances the radioresistance of colorectal cancer by directly
   targeting ATG5
SO JOURNAL OF BIOSCIENCES
LA English
DT Review
DE ATG5; colorectal cancer; miR-183-5p; radiosensitivity
ID BREAST-CANCER; CELL-PROLIFERATION; MAMMALIAN TARGET; AUTOPHAGY;
   RADIOSENSITIVITY; INHIBITION; EXPRESSION; MICRORNAS; APOPTOSIS; ONCOGENE
AB Radioresistance is a material obstacle for effective treatment of colorectal cancer (CRC). Thus, the discovery of a novel biomarker for determining the CRC radiosensitivity is necessary. Recent studies have confirmed that miR-183-3p regulates cell phenotypes and tumor growth in various cancers. However, the role and mechanism of this micro-ribonucleic acid in CRC radiosensitivity remains unclear. Here, the abundances of miR-183-5p and ATG5 mRNA were detected by a real-time quantitative reverse transcription polymerase chain reaction. Kaplan-Meier survival analysis was carried out to explore the correlation between miR-183-5p and patient prognosis. Cell viability was evaluated by the MTT assay. Survival fraction analysis through colony formation was performed to assess the cell radiation response. Bioinformatic, luciferase and western blot assays were employed to verify the targeted interaction between miR-183-5p and ATG5. The results showed that an elevated abundance of miR-183-5p and a reduced ATG5 level in CRC were associated with the poor prognosis. The knockdown of miR-183-5p enhanced the sensitivity of CRC cells to radiation, inflected by the decreased cell viability and survival fraction. Mechanically, ATG5 was targeted by miR-183-5p. The addition of ATG5 conferred the radiosensitivity of the CRC cells, which was revered by miR-183-5p restoration. Furthermore, miR-183-5p knockdown hindered the tumor growth by repressing ATG5 in vivo after radiation treatment. In summary, the output data indicated that miR-183-5p heightened the radiation response of the CRC cells by targeting ATG5, promising a novel therapeutic target for CRC patients with radioresistance.
C1 [Zheng, Sheng; Zhong, Yong-Fu; Tan, De-Ming; Xu, Yue; Chen, Huai-Xiang] Chongqing Three Gorges Cent Hosp, Dept Emergency Surg, Chongqing 404000, Peoples R China.
   [Wang, Dan] Chongqing Three Gorges Med Coll, Dept Publ Hlth & Management, Chongqing 404120, Peoples R China.
RP Wang, D (corresponding author), Chongqing Three Gorges Med Coll, Dept Publ Hlth & Management, Chongqing 404120, Peoples R China.
EM xiaobaihau57@sina.com
CR An J, 2007, ONCOGENE, V26, P652, DOI 10.1038/sj.onc.1209830
   Arora H, 2011, EXP MOL MED, V43, P298, DOI 10.3858/emm.2011.43.5.031
   Baerga R, 2009, AUTOPHAGY, V5, P1118, DOI 10.4161/auto.5.8.9991
   Banasiak D, 1999, RADIAT ONCOL INVESTI, V7, P77, DOI 10.1002/(SICI)1520-6823(1999)7:2<77::AID-ROI3>3.0.CO;2-M
   Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002
   Bi DP, 2016, ONCOL REP, V35, P2873, DOI 10.3892/or.2016.4631
   Cao C, 2006, CANCER RES, V66, P10040, DOI 10.1158/0008-5472.CAN-06-0802
   Cheng Y, 2016, REPROD BIOL, V16, P225, DOI 10.1016/j.repbio.2016.07.002
   Falzone L, 2018, AGING-US, V10, P1000, DOI 10.18632/aging.101444
   Fan HY, 2018, BIOMED PHARMACOTHER, V97, P1554, DOI 10.1016/j.biopha.2017.11.050
   FARNIOK KE, 1994, CANCER-AM CANCER SOC, V74, P2154, DOI 10.1002/1097-0142(19941001)74:7+<2154::AID-CNCR2820741725>3.0.CO;2-G
   Gao WY, 2019, ARCH BIOCHEM BIOPHYS, V665, P69, DOI 10.1016/j.abb.2018.01.013
   He RQ, 2018, ONCOL REP, V40, P83, DOI 10.3892/or.2018.6429
   Hu JL, 2018, ONCOGENESIS, V7, DOI 10.1038/s41389-018-0028-8
   Iorio MV, 2012, CARCINOGENESIS, V33, P1126, DOI 10.1093/carcin/bgs140
   Kim KW, 2006, J BIOL CHEM, V281, P36883, DOI 10.1074/jbc.M607094200
   Kurrey NK, 2009, STEM CELLS, V27, P2059, DOI 10.1002/stem.154
   Li F, 2010, BBA-REV CANCER, V1805, P167, DOI 10.1016/j.bbcan.2010.01.002
   Lu YY, 2015, BIOMED PHARMACOTHER, V70, P151, DOI 10.1016/j.biopha.2015.01.016
   Mo N, 2014, ONCOL REP, V32, P1905, DOI 10.3892/or.2014.3427
   Pedroza-Torres A, 2014, MOLECULES, V19, P6263, DOI 10.3390/molecules19056263
   Sarver AL, 2010, CANCER RES, V70, P9570, DOI 10.1158/0008-5472.CAN-10-2074
   Siegel RL, 2017, CA-CANCER J CLIN, V67, P177, DOI 10.3322/caac.21395
   Sun QQ, 2015, INT J CANCER, V136, P1003, DOI 10.1002/ijc.29065
   Sun Y, 2015, INT J ONCOL, V46, P750, DOI 10.3892/ijo.2014.2745
   Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262
   Toulany M, 2005, RADIOTHER ONCOL, V76, P143, DOI 10.1016/j.radonc.2005.06.024
   Ueno K, 2013, BRIT J CANCER, V108, P1659, DOI 10.1038/bjc.2013.125
   Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103
   Wang XJ, 2016, EUR REV MED PHARMACO, V20, P2020
   Wang XF, 2016, ONCOTARGETS THER, V9, P1159, DOI 10.2147/OTT.S100427
   Xu F, 2014, CLIN TRANSL ONCOL, V16, P980, DOI 10.1007/s12094-014-1183-9
   Yan H, 2013, PHARMACOLOGY, V92, P167, DOI 10.1159/000354585
   Yousefi S, 2006, NAT CELL BIOL, V8, P1124, DOI 10.1038/ncb1482
   Yuan DW, 2015, CANCER BIOL THER, V16, P268, DOI 10.1080/15384047.2014.1002327
   Yuan Y, 2018, INT J MOL MED, V42, P3562, DOI 10.3892/ijmm.2018.3871
   Zhang XL, 2015, ONCOL REP, V34, P1557, DOI 10.3892/or.2015.4078
   Zhang YQ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120884
   Zhao ZJ, 2008, CELL HOST MICROBE, V4, P458, DOI 10.1016/j.chom.2008.10.003
   Zheng L, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0592-z
   Zhou ZR, 2017, ACTA PHARMACOL SIN, V38, P513, DOI 10.1038/aps.2016.136
NR 41
TC 19
Z9 19
U1 1
U2 6
PU INDIAN ACAD SCIENCES
PI BANGALORE
PA C V RAMAN AVENUE, SADASHIVANAGAR, P B #8005, BANGALORE 560 080, INDIA
SN 0250-5991
EI 0973-7138
J9 J BIOSCIENCES
JI J. Biosci.
PD SEP
PY 2019
VL 44
IS 4
AR 92
DI 10.1007/s12038-019-9918-y
PG 11
WC Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Life Sciences & Biomedicine - Other Topics
GA IN7WF
UT WOS:000478891800009
PM 31502570
DA 2022-04-25
ER

PT J
AU Peng, H
   Zheng, J
   Su, Q
   Feng, XY
   Peng, MS
   Gong, L
   Wu, H
   Pan, X
AF Peng, Hong
   Zheng, Jie
   Su, Qiang
   Feng, Xueya
   Peng, Mingsha
   Gong, Lei
   Wu, Hong
   Pan, Xue
TI VPS53 Suppresses Malignant Properties in Colorectal Cancer by Inducing
   the Autophagy Signaling Pathway
SO ONCOTARGETS AND THERAPY
LA English
DT Article
DE colorectal cancer; VPS53; autophagy; cell migration; cell invasion
ID STATISTICS; REGULATOR; CELLS
AB Background: Many studies found that VPS53, one of the subunits of the golgi-associated retrograde protein (GARP) complexes, was aberrantly expressed in human diseases.
   Aim: This study investigated the functions and molecular mechanisms of VPS53 in colorectal cancer (CRC).
   Methods: Expression and correlation of Beclin 1 and VPS53 were analyzed by RT-qPCR and Pearson's correlation in CRC tissues, and VPS53 expression was also determined in CRC cells. The changes of proliferation, migration, invasion, apoptosis, and autophagy of CRC cells were examined by a succession of functional experiments including CCK-8, flow cytometry, transwell assay, and electron microscopy. The levels of autophagy related proteins were evaluated by Western blotting analysis.
   Results: RT-qPCR results found that VPS53 was downregulated in CRC tissues and cells, and Beclin 1 expression was also decreased in CRC tissues. There was a positive correlation between VPS53 and Beclin 1. Functional results showed that overexpression of VPS53 could suppress proliferation, migration, and invasion, and accelerate apoptosis and autophagy of CRC cells. Also, VPS53 could upregulate Beclin 1 and LC3BII, suggesting the inductive effect of VPS53 on CRC cell autophagy. Furthermore, it was found that the autophagy inhibitor (Inhb) could attenuate the inhibition of VPS53 on CRC progression.
   Conclusion: VPS53 repressed CRC progression by regulating the autophagy signaling pathway, suggesting that VPS53 might be a promising therapeutic target for CRC.
C1 [Peng, Hong; Feng, Xueya; Peng, Mingsha; Wu, Hong] Nanchong Cent Hosp, Clin Med Coll 2, North Sichuan Med Coll, Dept Anorectal Surg, Nanchong 637000, Sichuan, Peoples R China.
   [Zheng, Jie] Southwest Med Univ, Dept Anesthesiol, Affiliated Tradit Chinese Med Hosp, Luzhou 646000, Sichuan, Peoples R China.
   [Su, Qiang] Nanchong Cent Hosp, Nanchong Key Lab Individualized Drug Therapy Nanc, North Sichuan Med Coll, Dept Pharm,Clin Med Coll 2, Nanchong 637000, Sichuan, Peoples R China.
   [Gong, Lei] Nanchong Cent Hosp, Clin Med Coll 2, North Sichuan Med Coll, Dept Gastrointestinal Surg, Nanchong 637000, Sichuan, Peoples R China.
   [Pan, Xue] Chongqing Med Univ, Sci Res Dept, Affiliated Hosp 1, 1 Youyi Rd, Chongqing 400016, Peoples R China.
RP Pan, X (corresponding author), Chongqing Med Univ, Sci Res Dept, Affiliated Hosp 1, 1 Youyi Rd, Chongqing 400016, Peoples R China.
EM panxue89012705@163.com
FU North Sichuan Medical College City school cooperation program
   [18SXHZ0364, 18SXHZ0408, 19SXHZ0297]; Science and Technology Research
   Project of Sichuan Province [2017JY0116]; School Grade Research Key
   Project of North Sichuan Medical College [CBY18-A-ZD13]; Basic
   Scientific and Technological Strategic Cooperation of Nanchong Municipal
   Schools [NSMC20170311]
FX This work was supported by North Sichuan Medical College City school
   cooperation program (18SXHZ0364, 18SXHZ0408, 19SXHZ0297); Science and
   Technology Research Project of Sichuan Province (2017JY0116); School
   Grade Research Key Project of North Sichuan Medical College
   (CBY18-A-ZD13), and Basic Scientific and Technological Strategic
   Cooperation of Nanchong Municipal Schools (NSMC20170311).
CR Amaravadi R, 2016, GENE DEV, V30, P1913, DOI 10.1101/gad.287524.116
   Aparicio IM, 2016, ANIMAL, V10, P1182, DOI 10.1017/S1751731116000240
   Arnold M, 2017, GUT, V66, P683, DOI 10.1136/gutjnl-2015-310912
   Best JT, 2019, CURR OPIN CELL BIOL, V59, P8, DOI 10.1016/j.ceb.2019.02.004
   Bravo-San Pedro JM, 2017, CIRC RES, V120, P1812, DOI 10.1161/CIRCRESAHA.117.311082
   Chen C, 2018, ANTI-CANCER DRUG, V29, P1, DOI 10.1097/CAD.0000000000000572
   Dikic I, 2018, NAT REV MOL CELL BIO, V19, P349, DOI 10.1038/s41580-018-0003-4
   Dulai PS, 2016, CANCER PREV RES, V9, P887, DOI 10.1158/1940-6207.CAPR-16-0124
   Fu LL, 2013, INT J BIOCHEM CELL B, V45, P921, DOI 10.1016/j.biocel.2013.02.007
   Gan Y, 2008, CANCER GENE THER, V15, P808, DOI 10.1038/cgt.2008.52
   Goh Chee Leng, 2014, Recent Results Cancer Res, V202, P9, DOI 10.1007/978-3-642-45195-9_2
   Guo F, 2018, BRAIN PATHOL, V28, P3, DOI 10.1111/bpa.12545
   Hausman-Kedem M, 2019, NEUROGENETICS, V19
   Kim TE, 2002, INT J CANCER, V97, P780, DOI 10.1002/ijc.10124
   Kuemmel D, 2008, CURR PROTEIN PEPT SC, V9, P197, DOI 10.2174/138920308783955252
   Lampada A, 2017, CELL DEATH DIFFER, V24, P1045, DOI 10.1038/cdd.2017.41
   Li HJ, 2016, ONCOTARGET, V7, P57866, DOI 10.18632/oncotarget.11077
   Liu L, 2019, MOL THER-NUCL ACIDS, V17, P644, DOI 10.1016/j.omtn.2019.06.009
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Mokarram P, 2017, AUTOPHAGY, V13, P781, DOI 10.1080/15548627.2017.1290751
   Nakao M, 2011, ONCOL REP, V25, P1603, DOI 10.3892/or.2011.1246
   Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74
   Qi L, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/2769140
   QJ W, 2010, TRENDS CELL BIOL, V20, P355, DOI [10.1016/j.tcb.2010.03.002, DOI 10.1016/J.TCB.2010.03.002]
   Rebbeck TR, 2017, SEMIN RADIAT ONCOL, V27, P3, DOI 10.1016/j.semradonc.2016.08.002
   Roncucci L, 2015, EUR J INTERN MED, V26, P752, DOI 10.1016/j.ejim.2015.08.019
   Saltz LB, 2015, HEMATOL ONCOL CLIN N, V29, pIX, DOI 10.1016/j.hoc.2014.10.012
   Shao LN, 2016, MOL MED REP, V13, P2661, DOI 10.3892/mmr.2016.4820
   Shi L, 2017, PATHOL RES PRACT, V213, P1344, DOI 10.1016/j.prp.2017.09.024
   Siegel RL, 2017, CA-CANCER J CLIN, V67, P177, DOI 10.3322/caac.21395
   Smith M, 2017, ESSAYS BIOCHEM, V61, P625, DOI 10.1042/EBC20170092
   Svestka Tomislav, 2016, Cas Lek Cesk, V155, P27
   Vasan N, 2010, P NATL ACAD SCI USA, V107, P14176, DOI 10.1073/pnas.1009419107
   Xu WN, 2018, J APPL GENET, V59, P345, DOI 10.1007/s13353-018-0451-8
   Yan Y, 2017, FREE RADICAL BIO MED, V109, P108, DOI 10.1016/j.freeradbiomed.2016.12.003
   Yu TC, 2017, CELL, V170, P548, DOI 10.1016/j.cell.2017.07.008
   Zhang WD, 2018, ACS APPL NANO MATER, V1, P5865, DOI 10.1021/acsanm.8b01452
NR 37
TC 0
Z9 0
U1 1
U2 2
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-6930
J9 ONCOTARGETS THER
JI OncoTargets Ther.
PY 2020
VL 13
BP 10667
EP 10675
DI 10.2147/OTT.S254823
PG 9
WC Biotechnology & Applied Microbiology; Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Oncology
GA OD2DO
UT WOS:000579664100004
PM 33116643
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Kong, FH
   Zou, H
   Liu, X
   He, J
   Zheng, YW
   Xiong, L
   Miao, XY
AF Kong, Fanhua
   Zou, Heng
   Liu, Xi
   He, Jun
   Zheng, Yanwen
   Xiong, Li
   Miao, Xiongying
TI miR-7112-3p targets PERK to regulate the endoplasmic reticulum stress
   pathway and apoptosis induced by photodynamic therapy in colorectal
   cancer CX-1 cells
SO PHOTODIAGNOSIS AND PHOTODYNAMIC THERAPY
LA English
DT Article
DE Colorectal cancer; miR-7112-3p; Photodynamic therapy; Endoplasmic
   reticulum stress; PERK; Apoptosis
ID ER STRESS; SINOPORPHYRIN SODIUM; AUTOPHAGY; EXPRESSION; SENSITIZER;
   HYPERICIN; MICRORNAS; DEATH; PDT
AB Background: Colorectal cancer (CRC) is the third most common malignant tumor worldwide. Photodynamic therapy (PDT) is an emerging modality for the treatment of solid tumors. Sinoporphyrin sodium (DVDMS) is a new photosensitizer with good therapeutic killing effects on cancer cells. Recent findings have shown that microRNAs play important roles in many biological processes. However, the functions of microRNAs in DVDMS-induced PDT remain largely unclear.
   Materials and Methods: Proteins involved in endoplasmic reticulum (ER) stress and apoptosis of CX-1 cells treated with DVDMS-PDT were examined by Western blotting and cell viability assays. 15 candidate miRNAs targeting RNA-dependent protein kinase-like ER kinase (PERK) were screened and verified using the TargetScan, miRWalk and miRDB databases. The downstream pathways of candidate miRNAs with high scores were studied by cell transfection, qRT-PCR, Western blotting and dual-luciferase reporter assays. The subcellular location of DVDMS was confirmed by laser confocal microscopy.
   Results: DVDMS-PDT induced apoptosis via elevated ER stress and activation of the PERK/ATF4/CHOP/caspase cascade pathway in CX-1 cells. The endoplasmic reticulum was involved in the subcellular accumulation of DVDMS in CX-1 cells. Dual-luciferase reporting experiment confirmed that a direct crosslinking between miR-7112-3p and PERK. In addition, miR-7112-3p was highly expressed in CRC tissues compared with peripheral tissues.
   Conclusion: Our work showed that miR-7112-3p directly targeted PERK and further regulated PERK/ATF4/CHOP/caspase cascade pathway, resulting in enhanced apoptosis in CX-1 cells treated with DVDMS-PDT.
C1 [Kong, Fanhua; Zou, Heng; Liu, Xi; He, Jun; Zheng, Yanwen; Xiong, Li; Miao, Xiongying] Cent South Univ, Xiangya Hosp 2, Dept Gen Surg, Changsha, Hunan, Peoples R China.
RP Xiong, L; Miao, XY (corresponding author), Cent South Univ, Xiangya Hosp 2, Dept Gen Surg, Changsha, Hunan, Peoples R China.
EM lixionghn@csu.edu.cn; miaoxiongying3016@csu.edu.cn
FU National Natural Science FoundationNational Natural Science Foundation
   of China (NSFC) [81773293, 31660266]; Natural Science Foundation of
   Hunan ProvinceNatural Science Foundation of Hunan Province
   [2015JJ4083,2018JJ3758,2019JJ50874]; Hunan provincial key research and
   development program [2017DK2011, 2017WK2060, 2015GK3117]; Hunan
   provincial traditional Chinese medicine research project [201869,
   201951]
FX This study was supported by the National Natural Science Foundation
   (81773293, 31660266), Natural Science Foundation of Hunan Province
   (2015JJ4083,2018JJ3758,2019JJ50874), Hunan provincial key research and
   development program (2017DK2011, 2017WK2060, 2015GK3117), Hunan
   provincial traditional Chinese medicine research project (201869,
   201951).
CR Agostinis P, 2002, INT J BIOCHEM CELL B, V34, P221, DOI 10.1016/S1357-2725(01)00126-1
   [Anonymous], 2019, CANC TODAY
   Araki Kazutaka, 2012, Cold Spring Harb Perspect Biol, V4, pa015438, DOI 10.1101/cshperspect.a015438
   Chen J, 2018, ONCOTARGETS THER, V11, P4315, DOI 10.2147/OTT.S163366
   Chilakamarthi U, 2017, CHEM REC, V17, P775, DOI 10.1002/tcr.201600121
   Clarke HJ, 2014, CANCER CELL, V25, P563, DOI 10.1016/j.ccr.2014.03.015
   El-Daly SM, 2017, EUR J MED CHEM, V142, P550, DOI 10.1016/j.ejmech.2017.10.011
   Fiandalo M. V., 2012, Experimental Oncology, V34, P165
   Garg AD, 2014, PHOTOCH PHOTOBIO SCI, V13, P474, DOI 10.1039/c3pp50333j
   Gomes-da-Silva LC, 2018, EMBO J, V37, DOI 10.15252/embj.201798354
   Gong J, 2017, J ZHEJIANG UNIV-SC B, V18, P1, DOI 10.1631/jzus.B1600043
   Guo QZ, 2016, MOL MED REP, V14, P544, DOI 10.3892/mmr.2016.5248
   Hammond SM, 2015, ADV DRUG DELIVER REV, V87, P3, DOI 10.1016/j.addr.2015.05.001
   Hu JM, 2014, PHOTOCHEM PHOTOBIOL, V90, P1404, DOI 10.1111/php.12333
   Iwakawa HO, 2015, TRENDS CELL BIOL, V25, P651, DOI 10.1016/j.tcb.2015.07.011
   Kaneko M, 2017, BIOL PHARM BULL, V40, P1337, DOI 10.1248/bpb.b17-00342
   Kawczyk-Krupka A, 2016, PHOTODIAGN PHOTODYN, V13, P158, DOI 10.1016/j.pdpdt.2015.07.175
   Kim YK, 2016, P NATL ACAD SCI USA, V113, pE1881, DOI 10.1073/pnas.1602532113
   Kuipers EJ, 2015, NAT REV DIS PRIMERS, V1, DOI 10.1038/nrdp.2015.65
   Kushibiki T, 2010, J BIOPHOTONICS, V3, P368, DOI 10.1002/jbio.200900082
   Lan MH, 2019, ADV HEALTHC MATER, V8, DOI 10.1002/adhm.201900132
   Lee JM, 2015, ONCOTARGET, V6, P3918, DOI 10.18632/oncotarget.2928
   LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y
   Li DH, 2015, ONCOTARGETS THER, V8, P703, DOI 10.2147/OTT.S76370
   Li KT, 2016, CANCER MED-US, V5, P3186, DOI 10.1002/cam4.895
   Lin N, 2015, PHOTOCH PHOTOBIO SCI, V14, P815, DOI 10.1039/c4pp00463a
   Lin SC, 2017, INT J BIOCHEM CELL B, V87, P54, DOI 10.1016/j.biocel.2017.04.001
   Moon S, 2017, ONCOTARGET, V8, P35184, DOI 10.18632/oncotarget.17059
   Mulsow J, 2011, BRIT J SURG, V98, P1785, DOI 10.1002/bjs.7653
   Onyoh Elias F, 2019, Curr Gastroenterol Rep, V21, P36, DOI 10.1007/s11894-019-0703-8
   Rozpedek W, 2016, CURR MOL MED, V16, P533, DOI 10.2174/1566524016666160523143937
   Rumba Roberts, 2018, Acta Med Litu, V25, P185, DOI 10.6001/actamedica.v25i4.3929
   Sano R, 2013, BBA-MOL CELL RES, V1833, P3460, DOI 10.1016/j.bbamcr.2013.06.028
   Schroder M, 2005, MUTAT RES-FUND MOL M, V569, P29, DOI 10.1016/j.mrfmmm.2004.06.056
   Siegel RL, 2017, CA-CANCER J CLIN, V67, P177, DOI 10.3322/caac.21395
   Tameire F, 2015, SEMIN CANCER BIOL, V33, P3, DOI 10.1016/j.semcancer.2015.04.002
   Tang XJ, 2019, BIOCHIMIE, V163, P58, DOI 10.1016/j.biochi.2019.05.010
   Treiber T, 2019, NAT REV MOL CELL BIO, V20, P5, DOI 10.1038/s41580-018-0059-1
   Verfaillie T, 2012, CELL DEATH DIFFER, V19, P1880, DOI 10.1038/cdd.2012.74
   Verfaillie T, 2013, BIOCHEM BIOPH RES CO, V438, P500, DOI 10.1016/j.bbrc.2013.07.107
   Vickers AJ, 2011, CA-CANCER J CLIN, V61, P315, DOI 10.3322/caac.20118
   Wang HP, 2014, INT J NANOMED, V9, P3077, DOI 10.2147/IJN.S59302
   Wang KP, 2018, PHOTODIAGN PHOTODYN, V24, P349, DOI 10.1016/j.pdpdt.2018.10.020
   Wang XB, 2015, THERANOSTICS, V5, P772, DOI 10.7150/thno.10853
   Wong MCS, 2019, INTEST RES, V17, P317, DOI 10.5217/ir.2019.00021
   Wu RWK, 2013, J PHOTOCH PHOTOBIO B, V127, P114, DOI 10.1016/j.jphotobiol.2013.07.020
   Xu GL, 2016, MOL ENDOCRINOL, V30, P917, DOI 10.1210/me.2016-1056
   Xu L, 2019, J INORG BIOCHEM, V191, P126, DOI 10.1016/j.jinorgbio.2018.11.015
   Yano S, 2011, J PHOTOCH PHOTOBIO C, V12, P46, DOI 10.1016/j.jphotochemrev.2011.06.001
   Yuan B, 2019, DALTON T, V48, P6408, DOI 10.1039/c9dt01072f
   Zhang SQ, 2019, WORLD J CLIN CASES, V7, P798, DOI 10.12998/wjcc.v7.i6.798
   Zhu B, 2019, INT J BIOL SCI, V15, P12, DOI 10.7150/ijbs.27156
   Zhu J, 2018, CANCER MED-US, V7, P1908, DOI 10.1002/cam4.1418
NR 53
TC 15
Z9 16
U1 2
U2 15
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1572-1000
EI 1873-1597
J9 PHOTODIAGN PHOTODYN
JI Photodiagnosis Photodyn. Ther.
PD MAR
PY 2020
VL 29
AR 101663
DI 10.1016/j.pdpdt.2020.101663
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA LG2HV
UT WOS:000527929400048
PM 31945549
OA hybrid
DA 2022-04-25
ER

PT J
AU Park, SY
   Lee, SJ
   Cho, HJ
   Kim, JT
   Yoon, HR
   Lee, KH
   Kim, BY
   Lee, Y
   Lee, HG
AF Park, Sang Yoon
   Lee, Seon-Jin
   Cho, Hee Jun
   Kim, Jong-Tae
   Yoon, Hyang Ran
   Lee, Kyung Ho
   Kim, Bo Yeon
   Lee, Younghee
   Lee, Hee Gu
TI Epsilon-Globin HBE1 Enhances Radiotherapy Resistance by Down-Regulating
   BCL11A in Colorectal Cancer Cells
SO CANCERS
LA English
DT Article
DE ER stress; HBE1; BCL11A; JNK; radioresistant; oxidative stress; cell
   cycle arrest
ID DNA-DAMAGE RESPONSE; RADIATION-INDUCED AUTOPHAGY; STRAND BREAK REPAIR;
   IONIZING-RADIATION; STRESS; HEMOGLOBIN; APOPTOSIS; GENE; EXPRESSION;
   CONTRIBUTES
AB Resistance to radiotherapy is considered an important obstacle in the treatment of colorectal cancer. However, the mechanisms that enable tumor cells to tolerate the effects of radiation remain unclear. Moreover, radiotherapy causes accumulated mutations in transcription factors, which can lead to changes in gene expression and radiosensitivity. This phenomenon reduces the effectiveness of radiation therapy towards cancer cells. In the present study, radiation-resistant (RR) cancer cells were established by sequential radiation exposure, and hemoglobin subunit epsilon 1 (HBE1) was identified as a candidate radiation resistance-associated protein based on RNA-sequencing analysis. Then, compared to radiosensitive (RS) cell lines, the overexpression of HBE1 in RR cell lines was used to measure various forms of radiation-induced cellular damage. Consequently, HBE1-overexpressing cell lines were found to exhibit decreased radiation-induced intracellular reactive oxygen species (ROS) production and cell mortality. Conversely, HBE1 deficiency in RR cell lines increased intracellular ROS production, G2/M arrest, and apoptosis, and decreased clonogenic survival rate. These effects were reversed by the ROS scavenger N-acetyl cysteine. Moreover, HBE1 overexpression was found to attenuate radiation-induced endoplasmic reticulum stress and apoptosis via an inositol-requiring enzyme 1(IRE1)Jun amino-terminal kinase (JNK) signaling pathway. In addition, increased HBE1 expression induced by gamma-irradiation in RS cells attenuated expression of the transcriptional regulator BCL11A, whereas its depletion in RR cells increased BCL11A expression. Collectively, these observations indicate that the expression of HBE1 during radiotherapy might potentiate the survival of radiation-exposed colorectal cancer cells.
C1 [Park, Sang Yoon; Cho, Hee Jun; Kim, Jong-Tae; Yoon, Hyang Ran; Lee, Kyung Ho; Kim, Bo Yeon; Lee, Hee Gu] Korea Res Inst Biosci & Biotechnol, Immunotherapy Convergence Res Ctr, Daejeon 34141, South Korea.
   [Park, Sang Yoon; Lee, Younghee] Chungbuk Natl Univ, Coll Nat Sci, Dept Biochem, Cheongju 28644, South Korea.
   [Lee, Seon-Jin] Korea Res Inst Biosci & Biotechnol, Environm Dis Res Ctr, Daejeon 34141, South Korea.
   [Lee, Seon-Jin; Lee, Hee Gu] Univ Sci & Technol, Dept Biomol Sci, Daejeon 34141, South Korea.
RP Lee, HG (corresponding author), Korea Res Inst Biosci & Biotechnol, Immunotherapy Convergence Res Ctr, Daejeon 34141, South Korea.; Lee, HG (corresponding author), Univ Sci & Technol, Dept Biomol Sci, Daejeon 34141, South Korea.
EM psy478@kribb.re.kr; sjlee@kribb.re.kr; hjcho@kribb.re.kr;
   kjtdna@naver.com; yhr1205@kribb.re.kr; leekh@kribb.re.kr;
   bykim@kribb.re.kr; yh14177@chungbuk.ac.kr; hglee@kribb.re.kr
RI Lee, Seon-Jin/AAJ-8258-2020
OI Lee, Seon-Jin/0000-0001-7214-7536
FU R&D Convergence Program of the National Research Council of Science &
   Technology (NST) of the Republic of Korea [CAP-16-03-KRIBB]; National
   Research Foundation (NRF) - Korea government [2017R1A2B2005629]
FX This work was supported by the R&D Convergence Program (CAP-16-03-KRIBB)
   of the National Research Council of Science & Technology (NST) of the
   Republic of Korea and supported by the National Research Foundation
   (NRF) grant funded by the Korea government (No. 2017R1A2B2005629).
CR Arjmandi MK, 2016, REP PRACT ONCOL RADI, V21, P141, DOI [10.1016/j.rpor.2015.17.009, 10.1016/j.rpor.2015.12.009]
   Azzam EI, 2012, CANCER LETT, V327, P48, DOI 10.1016/j.canlet.2011.12.012
   Begg AC, 2011, NAT REV CANCER, V11, P239, DOI 10.1038/nrc3007
   Blanpain C, 2011, CELL STEM CELL, V8, P16, DOI 10.1016/j.stem.2010.12.012
   Borek C, 2004, J NUTR, V134, p3207S, DOI 10.1093/jn/134.11.3207S
   Borges HL, 2008, CELL RES, V18, P17, DOI 10.1038/cr.2007.110
   Chan KSK, 2012, FASEB J, V26, P1736, DOI 10.1096/fj.11-199356
   Chen L, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.193
   Chong WC, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18040771
   Chui DHK, 2003, BLOOD, V101, P791, DOI 10.1182/blood-2002-07-1975
   Deng XM, 2001, J BIOL CHEM, V276, P23681, DOI 10.1074/jbc.M100279200
   Fernet M, 2010, DNA REPAIR, V9, P48, DOI 10.1016/j.dnarep.2009.10.006
   Folkesson J, 2005, J CLIN ONCOL, V23, P5644, DOI 10.1200/JCO.2005.08.144
   Gao YJ, 2013, BIOMED REP, V1, P47, DOI 10.3892/br.2012.9
   Grundmann O, 2009, J DENT RES, V88, P894, DOI 10.1177/0022034509343143
   Habibullah G, 2018, ASIA-PAC J ONCOL NUR, V5, P184, DOI 10.4103/apjon.apjon_70_17
   Hafner MF, 2016, VISC MED, V32, P172, DOI 10.1159/000446486
   He ZN, 2002, P NATL ACAD SCI USA, V99, P10635, DOI 10.1073/pnas.162269099
   Hellweg CE, 2016, FRONT ONCOL, V6, DOI 10.3389/fonc.2016.00061
   Hur W, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18122749
   Jo GH, 2015, CANCER RES TREAT, V47, P221, DOI 10.4143/crt.2013.159
   Kamimura D, 2008, J IMMUNOL, V181, P5433, DOI 10.4049/jimmunol.181.8.5433
   Kamimura K, 2007, ONCOGENE, V26, P5840, DOI 10.1038/sj.onc.1210388
   Kang MA, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2011.134
   Kato H, 2012, CELL DEATH DIFFER, V19, P310, DOI 10.1038/cdd.2011.98
   Kavanagh JN, 2013, ANTIOXID REDOX SIGN, V18, P2458, DOI 10.1089/ars.2012.5151
   Kesari S, 2011, FUTURE ONCOL, V7, P1335, DOI [10.2217/fon.11.111, 10.2217/FON.11.111]
   Kim KW, 2010, ONCOGENE, V29, P3241, DOI 10.1038/onc.2010.74
   Korennykh AV, 2009, NATURE, V457, P687, DOI 10.1038/nature07661
   Lamson D W, 1999, Altern Med Rev, V4, P304
   Liu PT, 2003, NAT IMMUNOL, V4, P525, DOI 10.1038/ni925
   Lomax ME, 2013, CLIN ONCOL-UK, V25, P578, DOI 10.1016/j.clon.2013.06.007
   Maier P, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17010102
   Miccio A, 2010, MOL CELL BIOL, V30, P3460, DOI 10.1128/MCB.00001-10
   Nakarai C, 2015, CLIN EXP MED, V15, P333, DOI 10.1007/s10238-014-0298-1
   Nishi H, 2008, J AM SOC NEPHROL, V19, P1500, DOI 10.1681/ASN.2007101085
   Onda M, 2005, BRIT J CANCER, V92, P2216, DOI 10.1038/sj.bjc.6602634
   Pateras IS, 2015, PHARMACOL THERAPEUT, V154, P36, DOI 10.1016/j.pharmthera.2015.06.011
   Prasanna PGS, 2012, TRANSL CANCER RES, V1, P35, DOI 10.3978/j.issn.2218-676X.2012.05.05
   Psatha N, 2018, MOL THER-METH CLIN D, V10, P313, DOI 10.1016/j.omtm.2018.08.003
   Rahmanian N, 2016, J BIOMED SCI, V23, DOI 10.1186/s12929-016-0306-8
   RAICH N, 1995, EMBO J, V14, P801, DOI 10.1002/j.1460-2075.1995.tb07058.x
   Rupon JW, 2011, BLOOD CELL MOL DIS, V46, P212, DOI 10.1016/j.bcmd.2011.01.001
   Saha D, 2014, INT J INFLAMM, V2014, DOI 10.1155/2014/803237
   Satterwhite E, 2001, BLOOD, V98, P3413, DOI 10.1182/blood.V98.12.3413
   Shimura T, 2016, CELL CYCLE, V15, P1099, DOI 10.1080/15384101.2016.1156276
   Tabas I, 2011, NAT CELL BIOL, V13, P184, DOI 10.1038/ncb0311-184
   Tanabe O, 2002, EMBO J, V21, P3434, DOI 10.1093/emboj/cdf340
   Thyagarajan A, 2018, INTEGR CANCER THER, V17, P210, DOI 10.1177/1534735416681639
   Tufanli O, 2017, P NATL ACAD SCI USA, V114, pE1395, DOI 10.1073/pnas.1621188114
   Wang YD, 2016, HAEMATOLOGICA, V101, DOI 10.3324/haematol.2015.139980
   Willers H, 2004, BRIT J CANCER, V90, P1297, DOI 10.1038/sj.bjc.6601729
   Wozniak A, 2012, OXID MED CELL LONGEV, V2012, DOI 10.1155/2012/789870
   Wu QB, 2018, MOL CLIN ONCOL, V8, P523, DOI 10.3892/mco.2018.1578
   Yamamori T, 2013, FEBS LETT, V587, P3348, DOI 10.1016/j.febslet.2013.08.030
   Yamamori T, 2012, FREE RADICAL BIO MED, V53, P260, DOI 10.1016/j.freeradbiomed.2012.04.033
   Yi ZH, 2006, PLOS GENET, V2, P129, DOI 10.1371/journal.pgen.0020014
   Zheng Y, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14344
NR 58
TC 6
Z9 6
U1 1
U2 2
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 2072-6694
J9 CANCERS
JI Cancers
PD APR
PY 2019
VL 11
IS 4
AR 498
DI 10.3390/cancers11040498
PG 17
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA HY0BE
UT WOS:000467773400066
PM 30965648
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Shao, BZ
   Yao, Y
   Li, JP
   Chai, NL
   Linghu, EQ
AF Shao, Bo-Zong
   Yao, Yi
   Li, Jin-Ping
   Chai, Ning-Li
   Linghu, En-Qiang
TI The Role of Neutrophil Extracellular Traps in Cancer
SO FRONTIERS IN ONCOLOGY
LA English
DT Review
DE neutrophil extracellular trap; cancer; neutrophil; immunity;
   inflammation
ID PROCOAGULANT ACTIVITY; EPITHELIAL-CELLS; BLOOD-CELLS; AUTOPHAGY;
   NETOSIS; TUMOR; RECEPTOR; RELEASE; GROWTH; MICE
AB Neutrophils are vital components of innate and adaptive immunity. It is widely acknowledged that in various pathological conditions, neutrophils are activated and release condensed DNA strands, triggering the formation of neutrophil extracellular traps (NETs). NETs have been shown to be effective in fighting against microbial infections and modulating the pathogenesis and progression of diseases, including malignant tumors. This review describes the current knowledge on the biological characteristics of NETs. Additionally, the mechanisms of NETs in cancer are discussed, including the involvement of signaling pathways and the crosstalk between other cancer-related mechanisms, including inflammasomes and autophagy. Finally, based on previous and current studies, the roles of NET formation and the potential therapeutic targets and strategies related to NETs in several well-studied types of cancers, including breast, lung, colorectal, pancreatic, blood, neurological, and cutaneous cancers, are separately reviewed and discussed.
C1 [Shao, Bo-Zong; Yao, Yi; Li, Jin-Ping; Chai, Ning-Li; Linghu, En-Qiang] Gen Hosp Chinese Peoples Liberat Army, Dept Gastroenterol, Beijing, Peoples R China.
RP Chai, NL; Linghu, EQ (corresponding author), Gen Hosp Chinese Peoples Liberat Army, Dept Gastroenterol, Beijing, Peoples R China.
EM csxlily@163.com; linghuenqiang@vip.sina.com
FU Ministry of Science and Technology of the Peoples Republic of
   ChinaMinistry of Science and Technology, China [2016YFC1303600]; General
   Hospital of the Chinese Peoples Liberation Army [2018ZD-006, 2018MS-012]
FX Funding This work was supported by a grant from Ministry of Science and
   Technology of the Peoples Republic of China (No. 2016YFC1303600) and
   grants from General Hospital of the Chinese Peoples Liberation Army (No.
   2018ZD-006 and 2018MS-012).
CR Acuff HB, 2006, CANCER RES, V66, P259, DOI 10.1158/0008-5472.CAN-05-2502
   Albrengues J, 2018, SCIENCE, V361, P1353, DOI 10.1126/science.aao4227
   Allen EA, 2020, CELL DEATH DIFFER, V27, P903, DOI 10.1038/s41418-020-0497-0
   Almeida VH, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8070716
   An ZJ, 2019, CELL CYCLE, V18, P2928, DOI 10.1080/15384101.2019.1662678
   Andzinski L, 2016, INT J CANCER, V138, P1982, DOI 10.1002/ijc.29945
   Arpinati L, 2020, CANCER IMMUNOL IMMUN, V69, P199, DOI 10.1007/s00262-019-02474-x
   Arroyo R, 2019, COMMUN BIOL, V2, DOI 10.1038/s42003-019-0662-5
   Balachandran AA, 2020, CANCERS, V12, DOI 10.3390/cancers12092534
   Bian YC, 2020, INT J BIOL MACROMOL, V162, P107, DOI 10.1016/j.ijbiomac.2020.06.054
   Bianchi M, 2009, BLOOD, V114, P2619, DOI 10.1182/blood-2009-05-221606
   Blenman KRM, 2019, PIGM CELL MELANOMA R, V32, P448, DOI 10.1111/pcmr.12769
   Boeltz S, 2019, CELL DEATH DIFFER, V26, P395, DOI 10.1038/s41418-018-0261-x
   Bonaventura A, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9010231
   Boone BA, 2015, CANCER GENE THER, V22, P326, DOI 10.1038/cgt.2015.21
   Boone BA, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4584-2
   Branzk N, 2014, NAT IMMUNOL, V15, P1017, DOI 10.1038/ni.2987
   Brenner H, 2014, LANCET, V383, P1490, DOI 10.1016/S0140-6736(13)61649-9
   Brinkmann V, 2004, SCIENCE, V303, P1532, DOI 10.1126/science.1092385
   Brinkmann V, 2018, J INNATE IMMUN, V10, P414, DOI 10.1159/000489829
   Brinkmann V, 2012, J CELL BIOL, V198, P773, DOI 10.1083/jcb.201203170
   Campello E, 2019, BRIT J CANCER, V121, P359, DOI 10.1038/s41416-019-0510-x
   Cao XY, 2019, TUMORI J, V105, P456, DOI 10.1177/0300891619868007
   Chang NTC, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00138
   Chowdhury CS, 2014, ARTHRITIS RES THER, V16, DOI 10.1186/ar4579
   Clark SR, 2007, NAT MED, V13, P463, DOI 10.1038/nm1565
   Colon DF, 2019, CRIT CARE, V23, DOI 10.1186/s13054-019-2407-8
   Cox LE, 2020, BMC ANESTHESIOL, V20, DOI 10.1186/s12871-019-0911-7
   Craver BM, 2020, BLOOD ADV, V4, P312, DOI 10.1182/bloodadvances.2019000967
   Dekker E, 2019, LANCET, V394, P1467, DOI 10.1016/S0140-6736(19)32319-0
   Demers M, 2012, P NATL ACAD SCI USA, V109, P13076, DOI 10.1073/pnas.1200419109
   DeSouza-Vieira T, 2016, J LEUKOCYTE BIOL, V100, P801, DOI 10.1189/jlb.4A0615-261RR
   Diaz-Godinez C, 2018, FRONT CELL INFECT MI, V8, DOI 10.3389/fcimb.2018.00184
   Dinallo V, 2019, J CROHNS COLITIS, V13, P772, DOI 10.1093/ecco-jcc/jjy215
   Doring Y, 2020, CIRC RES, V126, P1228, DOI 10.1161/CIRCRESAHA.120.315931
   Douda DN, 2015, P NATL ACAD SCI USA, V112, P2817, DOI 10.1073/pnas.1414055112
   Ducroux C, 2018, STROKE, V49, P754, DOI 10.1161/STROKEAHA.117.019896
   Elssner A, 2004, J IMMUNOL, V172, P4987, DOI 10.4049/jimmunol.172.8.4987
   Ershaid N, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12370-8
   Evavold CL, 2019, IMMUNITY, V51, P609, DOI 10.1016/j.immuni.2019.08.005
   Fagerhol MK, 2020, SCAND J IMMUNOL, V91, DOI 10.1111/sji.12870
   Folco EJ, 2018, ARTERIOSCL THROM VAS, V38, P1901, DOI 10.1161/ATVBAHA.118.311150
   Fonseca Z, 2018, FRONT CELL INFECT MI, V8, DOI 10.3389/fcimb.2018.00226
   Fousert E, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9040915
   Fu YY, 2020, CANCERS, V12, DOI 10.3390/cancers12061523
   Galkina SI, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21020586
   Galluzzi L, 2018, CELL DEATH DIFFER, V25, P486, DOI 10.1038/s41418-017-0012-4
   Gao HL, 2020, BIOL CHEM, V401, P367, DOI 10.1515/hsz-2019-0219
   Glick D, 2010, J PATHOL, V221, P3, DOI 10.1002/path.2697
   Gomes T, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02088
   Gonzalez-Aparicio M, 2019, J IMMUNOL RES, V2019, DOI 10.1155/2019/6252138
   Gottlieb Y, 2018, PATHOL INT, V68, P517, DOI 10.1111/pin.12715
   Granger V, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02824
   Gregoire M, 2015, ONCOTARGET, V6, P16471, DOI 10.18632/oncotarget.4106
   Gregory AD, 2012, J BIOL CHEM, V287, P35341, DOI 10.1074/jbc.M112.385617
   Guo BC, 2016, SCI REP-UK, V6, DOI 10.1038/srep36107
   Gupta AK, 2010, FEBS LETT, V584, P3193, DOI 10.1016/j.febslet.2010.06.006
   Hamam HJ, 2019, BIOMOLECULES, V9, DOI 10.3390/biom9010032
   Harbeck N, 2017, LANCET, V389, P1134, DOI [10.1016/s0140-6736(16)31891-8, 10.1016/S0140-6736(16)31891-8]
   He R, 2020, PHARMACOL RES, V158, DOI 10.1016/j.phrs.2020.104857
   He Y, 2016, NATURE, V530, P354, DOI 10.1038/nature16959
   Hilscher MB, 2019, GASTROENTEROLOGY, V157, P193, DOI 10.1053/j.gastro.2019.03.013
   Hirsch FR, 2017, LANCET, V389, P299, DOI 10.1016/S0140-6736(16)30958-8
   Hisada Y, 2020, HAEMATOLOGICA, V105, P218, DOI 10.3324/haematol.2019.217083
   Houghton AM, 2010, NAT MED, V16, P219, DOI 10.1038/nm.2084
   Hu QY, 2019, ARTHRITIS RES THER, V21, DOI 10.1186/s13075-018-1800-z
   Huang CF, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-017-0589-y
   Ireland AS, 2020, IMMUNITY, V52, P729, DOI 10.1016/j.immuni.2020.04.009
   Jiang H, 2020, J BUON, V25, P1070
   Jin W, 2021, J CELL MOL MED, V25, P5443, DOI 10.1111/jcmm.16555
   Jin W, 2019, ANN SURG ONCOL, V26, P635, DOI 10.1245/s10434-018-6941-4
   Jorch SK, 2017, NAT MED, V23, P279, DOI 10.1038/nm.4294
   Jorgensen I, 2016, EUR J IMMUNOL, V46, P2761, DOI 10.1002/eji.201646647
   Josefs T, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.134796
   Jung HS, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0216055
   Kamisawa T, 2016, LANCET, V388, P73, DOI 10.1016/S0140-6736(16)00141-0
   Kaplan MJ, 2012, J IMMUNOL, V189, P2689, DOI 10.4049/jimmunol.1201719
   Karki R, 2017, CANCER IMMUNOL RES, V5, P94, DOI 10.1158/2326-6066.CIR-16-0269
   Ke P, 2017, CNS NEUROSCI THER, V23, P875, DOI 10.1111/cns.12758
   Kennedy A, 2017, LANCET ONCOL, V18, P1577, DOI 10.1016/S1470-2045(17)30849-5
   Kenny EF, 2017, ELIFE, V6, DOI [10.7554/eLife.24437, 10.7554/elife.24437]
   Klionsky DJ, 2012, AUTOPHAGY, V8, P445, DOI 10.4161/auto.19496
   Kubiritova Z, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20153662
   Lachowicz-Scroggins ME, 2019, AM J RESP CRIT CARE, V199, P1076, DOI 10.1164/rccm.201810-1869OC
   Laridan E, 2019, SEMIN THROMB HEMOST, V45, P86, DOI 10.1055/s-0038-1677040
   Lee KH, 2017, AUTOIMMUN REV, V16, P1160, DOI 10.1016/j.autrev.2017.09.012
   Li M, 2020, MOL CANCER THER, V19, P1530, DOI 10.1158/1535-7163.MCT-19-1020
   Li T, 2020, J CROHNS COLITIS, V14, P240, DOI 10.1093/ecco-jcc/jjz132
   Li Y, 2019, INT J ONCOL, V55, P69, DOI 10.3892/ijo.2019.4808
   Li ZB, 2019, J TRANSL MED, V17, DOI 10.1186/s12967-019-1838-y
   Lin CF, 2016, J INTERF CYTOK RES, V36, P100, DOI 10.1089/jir.2015.0011
   Linares MA, 2015, PRIMARY CARE, V42, P645, DOI 10.1016/j.pop.2015.07.006
   Liu D, 2019, CLIN SCI, V133, P565, DOI 10.1042/CS20180600
   Liu YF, 2019, BIOSCI TRENDS, V13, P469, DOI 10.5582/bst.2019.01326
   Louis DN, 2016, ACTA NEUROPATHOL, V131, P803, DOI 10.1007/s00401-016-1545-1
   Ma R, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.186
   Manda-Handzlik A, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8121477
   Mansour A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21041391
   Marone G, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.02103
   Martins-Cardoso K, 2020, CANCERS, V12, DOI 10.3390/cancers12061542
   Masuda S, 2016, CLIN CHIM ACTA, V459, P89, DOI 10.1016/j.cca.2016.05.029
   Mayadas TN, 2014, ANNU REV PATHOL-MECH, V9, P181, DOI 10.1146/annurev-pathol-020712-164023
   Mesa MA, 2013, AUTOIMMUN DIS, V2013, DOI 10.1155/2013/651497
   Mestas J, 2004, J IMMUNOL, V172, P2731, DOI 10.4049/jimmunol.172.5.2731
   Meyer-Hoffert U, 2011, CURR OPIN HEMATOL, V18, P19, DOI 10.1097/MOH.0b013e32834115d1
   Mussbacher M, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00085
   Onorati AV, 2018, CANCER-AM CANCER SOC, V124, P3307, DOI 10.1002/cncr.31335
   Pabinger I, 2014, HEMATOL-AM SOC HEMAT, P410, DOI 10.1182/asheducation-2014.1.410
   Papayannopoulos V, 2018, NAT REV IMMUNOL, V18, P134, DOI 10.1038/nri.2017.105
   Park J, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aag1711
   Paryzhak S, 2018, AUTOIMMUNITY, V51, P297, DOI 10.1080/08916934.2018.1514390
   Parzych KR, 2014, ANTIOXID REDOX SIGN, V20, P460, DOI 10.1089/ars.2013.5371
   Presta M, 2017, PHARMACOL THERAPEUT, V179, P171, DOI 10.1016/j.pharmthera.2017.05.013
   Rabadi M, 2016, AM J PHYSIOL-RENAL, V311, pF437, DOI 10.1152/ajprenal.00254.2016
   Rada B, 2019, METHODS MOL BIOL, V1982, P517, DOI 10.1007/978-1-4939-9424-3_31
   Rathinam VAK, 2016, CELL, V165, P792, DOI 10.1016/j.cell.2016.03.046
   Raup-Konsavage WM, 2018, KIDNEY INT, V93, P365, DOI 10.1016/j.kint.2017.08.014
   Ravanan P, 2017, LIFE SCI, V188, P53, DOI 10.1016/j.lfs.2017.08.029
   Ravindran M, 2019, BIOMOLECULES, V9, DOI 10.3390/biom9080365
   Rayes RF, 2020, J IMMUNOL, V204, P2285, DOI 10.4049/jimmunol.1900240
   Rayes RF, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.128008
   Richardson JJR, 2017, INT J INFLAMM, V2017, DOI 10.1155/2017/4915062
   Risnik D, 2020, LEUKEMIA LYMPHOMA, V61, P2409, DOI 10.1080/10428194.2020.1753043
   Rosales C, 2020, J LEUKOCYTE BIOL, V108, P377, DOI 10.1002/JLB.4MIR0220-574RR
   Scandolara TB, 2020, IMMUNOL LETT, V221, P33, DOI 10.1016/j.imlet.2020.02.011
   Schedel F, 2020, PIGM CELL MELANOMA R, V33, P63, DOI 10.1111/pcmr.12818
   Schlesinger M, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-018-0669-2
   Schroder K, 2010, CELL, V140, P821, DOI 10.1016/j.cell.2010.01.040
   Shang AQ, 2020, CELL COMMUN SIGNAL, V18, DOI 10.1186/s12964-020-0517-1
   Shao BZ, 2019, INFLAMMATION, V42, P1666, DOI 10.1007/s10753-019-01027-9
   Shao BZ, 2019, INFLAMMATION, V42, P1147, DOI 10.1007/s10753-019-01008-y
   Shao BZ, 2018, FRONT MOL NEUROSCI, V11, DOI 10.3389/fnmol.2018.00320
   Shao BZ, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00553
   Shao BZ, 2016, ACTA PHARMACOL SIN, V37, P150, DOI 10.1038/aps.2015.87
   Shao BZ, 2015, FRONT PHARMACOL, V6, DOI 10.3389/fphar.2015.00262
   Shao BZ, 2014, CNS NEUROSCI THER, V20, P1021, DOI 10.1111/cns.12349
   Shi L, 2020, MOL CANCER RES, V18, P735, DOI 10.1158/1541-7786.MCR-19-0018
   Skendros P, 2018, FRONT CELL DEV BIOL, V6, DOI 10.3389/fcell.2018.00109
   Sollberger G, 2018, SCI IMMUNOL, V3, DOI 10.1126/sciimmunol.aar6689
   Sollberger G, 2018, DEV CELL, V44, P542, DOI 10.1016/j.devcel.2018.01.019
   Sorensen OE, 2016, J CLIN INVEST, V126, P1612, DOI 10.1172/JCI84538
   Sorensen OE, 2014, J CLIN INVEST, V124, P4539, DOI 10.1172/JCI76009
   Stoiber D, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9040855
   Takesue S, 2020, INT J ONCOL, V56, P596, DOI 10.3892/ijo.2019.4951
   Tall AR, 2019, J LIPID RES, V60, P721, DOI 10.1194/jlr.S091280
   Teijeira A, 2020, IMMUNITY, V52, P856, DOI 10.1016/j.immuni.2020.03.001
   Thalin C, 2019, ARTERIOSCL THROM VAS, V39, P1724, DOI 10.1161/ATVBAHA.119.312463
   Thalin C, 2016, THROMB RES, V139, P56, DOI 10.1016/j.thromres.2016.01.009
   Triner D, 2019, GASTROENTEROLOGY, V156, P1467, DOI 10.1053/j.gastro.2018.12.003
   Tsourouktsoglou TD, 2020, CELL REP, V31, DOI 10.1016/j.celrep.2020.107602
   Urban CF, 2019, SEMIN CELL DEV BIOL, V89, P47, DOI 10.1016/j.semcdb.2018.03.020
   Van Gorp H, 2019, EMBO REP, V20, DOI 10.15252/embr.201847575
   Van HT, 2018, CELL CYCLE, V17, P2399, DOI 10.1080/15384101.2018.1542899
   Van Noorden R, 2016, NATURE, V538, P18, DOI 10.1038/nature.2016.20721
   Wang H, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4403-9
   Wang P, 2018, PROG NEUROBIOL, V163, P98, DOI 10.1016/j.pneurobio.2018.01.001
   Wang SC, 2018, ENVIRON POLLUT, V243, P282, DOI 10.1016/j.envpol.2018.08.070
   Wang SL, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1634-x
   Wang SL, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00693
   Wang YP, 2020, MEDIAT INFLAMM, V2020, DOI 10.1155/2020/2720369
   Warnatsch A, 2015, SCIENCE, V349, P316, DOI 10.1126/science.aaa8064
   Wei ZK, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01003
   White PC, 2016, J DENT RES, V95, P26, DOI 10.1177/0022034515609097
   Wolach O, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aan8292
   Yang H, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00302
   Yang LB, 2020, NATURE, V583, P133, DOI 10.1038/s41586-020-2394-6
   Yang LY, 2020, J HEMATOL ONCOL, V13, DOI 10.1186/s13045-019-0836-0
   Yang LY, 2020, J CANCER, V11, P4384, DOI 10.7150/jca.44215
   Yazdani HO, 2019, CANCER RES, V79, P5626, DOI 10.1158/0008-5472.CAN-19-0800
   Yim WWY, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0141-7
   Yin K, 2019, ECOTOX ENVIRON SAFE, V173, P225, DOI 10.1016/j.ecoenv.2019.02.033
   Yipp BG, 2012, NAT MED, V18, P1386, DOI 10.1038/nm.2847
   Yu MX, 2020, THROMB RES, V188, P5, DOI 10.1016/j.thromres.2020.01.025
   Yun CW, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113466
   Zha CJ, 2020, CANCER BIOL MED, V17, P154, DOI 10.20892/j.issn.2095-3941.2019.0353
   Zhang Y, 2019, THROMB RES, V180, P87, DOI 10.1016/j.thromres.2019.06.005
   Zhou JW, 2019, ONCOL LETT, V18, P181, DOI 10.3892/ol.2019.10290
NR 177
TC 1
Z9 1
U1 18
U2 20
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2234-943X
J9 FRONT ONCOL
JI Front. Oncol.
PD AUG 12
PY 2021
VL 11
DI 10.3389/fonc.2021.714357
PG 13
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA UN1NY
UT WOS:000693790100001
PM 34476216
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Kinsey, CG
   Camolotto, SA
   Boespflug, AM
   Guillen, KP
   Foth, M
   Truong, A
   Schuman, SS
   Shea, JE
   Seipp, MT
   Yap, JT
   Burrell, LD
   Lum, DH
   Whisenant, JR
   Gilcrease, GW
   Cavalieri, CC
   Rehbein, KM
   Cutler, SL
   Affolter, KE
   Welm, AL
   Welm, BE
   Scaife, CL
   Snyder, EL
   McMahon, M
AF Kinsey, Conan G.
   Camolotto, Soledad A.
   Boespflug, Amelie M.
   Guillen, Katrin P.
   Foth, Mona
   Truong, Amanda
   Schuman, Sophia S.
   Shea, Jill E.
   Seipp, Michael T.
   Yap, Jeffrey T.
   Burrell, Lance D.
   Lum, David H.
   Whisenant, Jonathan R.
   Gilcrease, G. Weldon, III
   Cavalieri, Courtney C.
   Rehbein, Kaitrin M.
   Cutler, Stephanie L.
   Affolter, Kajsa E.
   Welm, Alana L.
   Welm, Bryan E.
   Scaife, Courtney L.
   Snyder, Eric L.
   McMahon, Martin
TI Protective autophagy elicited by RAF -> MEK -> ERK inhibition suggests a
   treatment strategy for RAS-driven cancers
SO NATURE MEDICINE
LA English
DT Article
ID GROWTH; CELLS; BRAF; PHOSPHORYLATION; GEMCITABINE; COMBINATION;
   TRAMETINIB; RESISTANCE; PLATFORM; PROTEIN
AB Pancreatic ductal adenocarcinoma (PDA) was responsible for similar to 44,000 deaths in the United States in 2018 and is the epitome of a recalcitrant cancer driven by a pharmacologically intractable oncoprotein, KRAS(1-4). Downstream of KRAS, the RAF. MEK. ERK signaling pathway plays a central role in pancreatic carcinogenesis(5). However, paradoxically, inhibition of this pathway has provided no clinical benefit to patients with PDA(6). Here we show that inhibition of KRAS -> RAF -> MEK -> ERK signaling elicits autophagy, a process of cellular recycling that protects PDA cells from the cytotoxic effects of KRAS pathway inhibition. Mechanistically, inhibition of MEK1/2 leads to activation of the LKB1 -> AMPK -> ULK1 signaling axis, a key regulator of autophagy. Furthermore, combined inhibition of MEK1/2 plus autophagy displays synergistic anti-proliferative effects against PDA cell lines in vitro and promotes regression of xenografted patient-derived PDA tumors in mice. The observed effect of combination trametinib plus chloroquine was not restricted to PDA as other tumors, including patient-derived xenografts (PDX) of NRAS-mutated melanoma and BRAF-mutated colorectal cancer displayed similar responses. Finally, treatment of a patient with PDA with the combination of trametinib plus hydroxychloroquine resulted in a partial, but nonetheless striking disease response. These data suggest that this combination therapy may represent a novel strategy to target RAS-driven cancers.
C1 [Kinsey, Conan G.; Camolotto, Soledad A.; Boespflug, Amelie M.; Guillen, Katrin P.; Foth, Mona; Truong, Amanda; Schuman, Sophia S.; Yap, Jeffrey T.; Burrell, Lance D.; Lum, David H.; Whisenant, Jonathan R.; Gilcrease, G. Weldon, III; Cavalieri, Courtney C.; Rehbein, Kaitrin M.; Cutler, Stephanie L.; Affolter, Kajsa E.; Welm, Alana L.; Welm, Bryan E.; Scaife, Courtney L.; Snyder, Eric L.; McMahon, Martin] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84112 USA.
   [Kinsey, Conan G.; Whisenant, Jonathan R.; Gilcrease, G. Weldon, III] Univ Utah, Sch Med, Dept Internal Med, Div Oncol, Salt Lake City, UT USA.
   [Boespflug, Amelie M.] Ctr Hosp Lyon Sud, Dept Dermatol, Pierre Benite, France.
   [Boespflug, Amelie M.] Claude Bernard Lyon 1 Univ, Canc Res Ctr Lyon, INSERM 1052, CNRS 5286, Villeurbanne, France.
   [Shea, Jill E.; Seipp, Michael T.; Welm, Bryan E.; Scaife, Courtney L.] Univ Utah, Sch Med, Dept Surg, Salt Lake City, UT USA.
   [Yap, Jeffrey T.] Univ Utah, Sch Med, Dept Radiol & Imaging Serv, Salt Lake City, UT USA.
   [Cavalieri, Courtney C.] Univ Utah, Huntsman Canc Inst, Dept Pharm Serv, Salt Lake City, UT USA.
   [Affolter, Kajsa E.; Snyder, Eric L.] Univ Utah, Sch Med, Dept Pathol, Salt Lake City, UT USA.
   [Welm, Alana L.] Univ Utah, Sch Med, Dept Oncol Sci, Salt Lake City, UT USA.
   [McMahon, Martin] Univ Utah, Sch Med, Dept Dermatol, Salt Lake City, UT 84132 USA.
RP McMahon, M (corresponding author), Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84112 USA.; McMahon, M (corresponding author), Univ Utah, Sch Med, Dept Dermatol, Salt Lake City, UT 84132 USA.
EM martin.mcmahon@hci.utah.edu
RI Foth, Mona/AAU-5336-2021
OI Boespflug, Amelie/0000-0002-2656-5144; Foth, Mona/0000-0001-6507-8114;
   Yap, Jeffrey/0000-0001-5306-2860; Shea, Jill/0000-0002-8644-7772
FU National Cancer InstituteUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Cancer
   Institute (NCI) [R01-CA176839, R01-CA131261, P30-CA042014]; Pancreatic
   Cancer Collective; Melanoma Research Alliance; Five for the Fight;
   Huntsman Cancer Foundation; Career Award for Medical Scientists from the
   Burroughs Wellcome FundBurroughs Wellcome Fund; V Scholar Award;
   NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [R01CA212415]; National Cancer
   InstituteUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Cancer Institute (NCI);
   DoDUnited States Department of Defense [U54CA224076, W81XWH1410417];
   Fondation pour la Recherche MedicaleFondation pour la Recherche Medicale
   [FDM20150633361]; Societe Francaise de Dermatologie; NATIONAL CANCER
   INSTITUTEUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)
   [R01CA176839, F30CA235964, R01CA131261, P30CA042014, U54CA224076,
   R01CA212415] Funding Source: NIH RePORTER
FX We dedicate this work to the memory of our patient and his family, whose
   courage continues to inspire us to further improve the diagnosis and
   treatment of pancreatic cancer. We thank the members of the McMahon Lab
   for their support, advice, guidance, comments and discussions during the
   course of this work. Additionally we thank I. Garrido-Laguna (HCI/Univ.
   of Utah), M. Tempero, E. Collisson and F. McCormick (U.C. San
   Francisco), E. White (Rutgers University), D. Tuveson (Cold Spring
   Harbor), and K. Olive (Columbia) for advice and guidance, J.
   Mulcahy-Levy and A. Thorburn (U.C. Denver) for inspiration, advice,
   guidance and reagents, H. Land (University of Rochester Medical Center)
   and K. Shokat (UCSF) for providing reagents, NCI Patient-Derived Models
   Repository for supplying the NCI-516677 NRAS-mutated melanoma PDX, K.
   Owings, D. Lum and the HCI Preclinical Research Resource for assistance
   with tumor xenografts and drug treatments and M. Silvis for assistance
   with drug dosing. C.K. & M.M. wish to acknowledge the collegiality of K.
   Bryant and C. Der (University of North Carolina, Chapel Hill) for
   ongoing discussions and for sharing data in advance of publication. M.
   M. acknowledges financial support from the National Cancer Institute
   (R01-CA176839, R01-CA131261 & P30-CA042014), the Pancreatic Cancer
   Collective, Melanoma Research Alliance, Five for the Fight, and the
   Huntsman Cancer Foundation. E.L.S. was supported in part by a Career
   Award for Medical Scientists from the Burroughs Wellcome Fund, a V
   Scholar Award, the Huntsman Cancer Foundation, and the NIH
   (R01CA212415). B.E.W. acknowledges support from the National Cancer
   Institute and DoD (U54CA224076 and W81XWH1410417). A.L.W. acknowledges
   support from the Huntsman Cancer Foundation. C.G.K acknowledges support
   from the Huntsman Cancer Foundation. A.M.B. acknowledges support from
   Fondation pour la Recherche Medicale (FDM20150633361) and Societe
   Francaise de Dermatologie.
CR Awasthi N, 2013, CARCINOGENESIS, V34, P2361, DOI 10.1093/carcin/bgt227
   Ben-Zvi I, 2012, CLIN REV ALLERG IMMU, V42, P145, DOI 10.1007/s12016-010-8243-x
   Boya P, 2003, ONCOGENE, V22, P3927, DOI 10.1038/sj.onc.1206622
   Bryant KL, 2019, NAT MED, V25, P628, DOI 10.1038/s41591-019-0368-8
   Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095
   Chou TC, 2010, CANCER RES, V70, P440, DOI 10.1158/0008-5472.CAN-09-1947
   Collisson EA, 2012, CANCER DISCOV, V2, P685, DOI 10.1158/2159-8290.CD-11-0347
   Di Veroli GY, 2016, BIOINFORMATICS, V32, P2866, DOI 10.1093/bioinformatics/btw230
   Egan DF, 2015, MOL CELL, V59, P285, DOI 10.1016/j.molcel.2015.05.031
   Egan DF, 2011, SCIENCE, V331, P456, DOI 10.1126/science.1196371
   Eng CH, 2016, P NATL ACAD SCI USA, V113, P182, DOI 10.1073/pnas.1515617113
   Fujita N, 2008, MOL BIOL CELL, V19, P4651, DOI 10.1091/mbc.E08-03-0312
   Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088
   Gilmartin AG, 2011, CLIN CANCER RES, V17, P989, DOI 10.1158/1078-0432.CCR-10-2200
   Gump JM, 2014, AUTOPHAGY, V10, P1327, DOI 10.4161/auto.29394
   Honda A, 2016, ACS MED CHEM LETT, V7, P72, DOI 10.1021/acsmedchemlett.5b00335
   Infante JR, 2014, EUR J CANCER, V50, P2072, DOI 10.1016/j.ejca.2014.04.024
   Kim J, 2011, NAT CELL BIOL, V13, P132, DOI 10.1038/ncb2152
   Kim KB, 2013, J CLIN ONCOL, V31, P482, DOI 10.1200/JCO.2012.43.5966
   Kimura S, 2007, AUTOPHAGY, V3, P452, DOI 10.4161/auto.4451
   Klionsky DJ, 2016, AUTOPHAGY, V12, P1, DOI 10.1080/15548627.2015.1100356
   Levy JMM, 2017, NAT REV CANCER, V17, P528, DOI 10.1038/nrc.2017.53
   Levy JMM, 2017, ELIFE, V6, DOI 10.7554/eLife.19671
   Levy JMM, 2014, CANCER DISCOV, V4, P773, DOI 10.1158/2159-8290.CD-14-0049
   Li DH, 2004, LANCET, V363, P1049, DOI 10.1016/S0140-6736(04)15841-8
   Lito P, 2016, SCIENCE, V351, P604, DOI 10.1126/science.aad6204
   Ma XH, 2014, J CLIN INVEST, V124, P1406, DOI 10.1172/JCI70454
   Mihaylova MM, 2011, NAT CELL BIOL, V13, P1016, DOI 10.1038/ncb2329
   Morris EJ, 2013, CANCER DISCOV, V3, P742, DOI 10.1158/2159-8290.CD-13-0070
   Patricelli MP, 2016, CANCER DISCOV, V6, P316, DOI 10.1158/2159-8290.CD-15-1105
   Poillet-Perez L, 2018, NATURE, V563, P569, DOI 10.1038/s41586-018-0697-7
   Rice KD, 2012, ACS MED CHEM LETT, V3, P416, DOI 10.1021/ml300049d
   Ronan B, 2014, NAT CHEM BIOL, V10, P1013, DOI 10.1038/nchembio.1681
   Rosenfeldt MT, 2013, NATURE, V504, P296, DOI 10.1038/nature12865
   Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387
   Sousa CM, 2016, NATURE, V536, P479, DOI 10.1038/nature19084
   Vessoni AT, 2016, FREE RADICAL BIO MED, V90, P91, DOI 10.1016/j.freeradbiomed.2015.11.008
   White NJ, 1996, NEW ENGL J MED, V335, P800, DOI 10.1056/NEJM199609123351107
   Yang AN, 2018, CANCER DISCOV, V8, P276, DOI 10.1158/2159-8290.CD-17-0952
   Young NP, 2011, CANCER RES, V71, P4040, DOI 10.1158/0008-5472.CAN-10-4563
   Zheng B, 2009, MOL CELL, V33, P237, DOI 10.1016/j.molcel.2008.12.026
NR 41
TC 253
Z9 260
U1 11
U2 119
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1078-8956
EI 1546-170X
J9 NAT MED
JI Nat. Med.
PD APR
PY 2019
VL 25
IS 4
BP 620
EP +
DI 10.1038/s41591-019-0367-9
PG 17
WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research &
   Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental
   Medicine
GA HR7OA
UT WOS:000463342800024
PM 30833748
OA Green Accepted
HC Y
HP N
DA 2022-04-25
ER

PT J
AU Liu, L
   Ren, WH
   Chen, KS
AF Liu, Liru
   Ren, Weihua
   Chen, Kuisheng
TI MiR-34a Promotes Apoptosis and Inhibits Autophagy by Targeting HMGB1 in
   Acute Myeloid Leukemia Cells
SO CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
LA English
DT Article
DE miR-34a; HMGB1; Apoptosis; Autophagy; Acute myeloid leukemia
ID COLORECTAL-CANCER; GENE-EXPRESSION; MICRORNAS; GROWTH; P53;
   PROLIFERATION; MACROPHAGES; INDUCTION; INCREASES; SURVIVAL
AB Background: MiR-34a is identified as a tumor suppressor gene and involved in acute myeloid leukemia (AML) development. However, the regulatory mechanism of miR-34a in AML is unclear. Methods: The expression of miR-34a and HMGB1 in HL-60, THP-1 and HS-5 cells were detected by qRT-PCR and western blot. Lipofectamine 2000 was used to transfect with miR34a mimics, miR-34a inhibitor, si-HMGB1, pcDNA 3.1-HMGB1, and corresponding controls. The apoptosis and autophagy of transfected AML cells were assessed by flow cytometry and western blot, respectively. Bioinformatics software and dual luciferase reporter assay were applied to predict and verify the target of miR-34a. The effects of miR-34a mimics or si-HMGB1 on chemotherapy-induced autophagy were further explored in HL-60 cells treated with all-trans retinoic acid (ATRA) along with lysosomal protease inhibitors E64d and pepstatin A. Results: MiR-34a was lower expressed and HMGB1 mRNA and proteins were both higher expressed in HL-60 and THP-1 cells compared with that in HS-5 cells. Higher expression levels of MiR-34 and lower expression levels of HMGB1 both significantly promoted apoptosis and inhibited autophagy in HL-60 and THP-1 cells. Dual luciferase reporter system confirmed that HMGB1 was a potential target of miR-34a. Moreover, overexpression of HMGB1 dramatically reversed the promotion of apoptosis and inhibition of autophagy mediated by higher expression level of miR-34a. Higher expression level of miR-34a and lower expression level of HMGB1 both inhibited chemotherapy-induced autophagy by stimulating the LC3 conversion. Conclusion: MiR-34a promoted cell apoptosis and inhibited autophagy by targeting HMGB1. Therefore, miR-34a may be a potential promising molecular target for AML therapy. (C) 2017 The Author(s). Published by S. Karger AG, Basel.
C1 [Liu, Liru; Ren, Weihua] Zhengzhou Univ, Luoyang Cent Hosp, Dept Clin Lab, 288 Zhongzhou Rd, Xigong Dist 471000, Luoyang, Peoples R China.
   [Chen, Kuisheng] Zhengzhou Univ, Affiliated Hosp 1, Dept Pathol, Zhengzhou, Peoples R China.
RP Liu, L (corresponding author), Zhengzhou Univ, Luoyang Cent Hosp, Dept Clin Lab, 288 Zhongzhou Rd, Xigong Dist 471000, Luoyang, Peoples R China.
EM klirucb@163.com
CR Aakula A, 2016, EUR UROL, V69, P1120, DOI 10.1016/j.eururo.2015.09.019
   Adams BD, 2016, CANCER RES, V76, P927, DOI 10.1158/0008-5472.CAN-15-2321
   Agostini M, 2014, ONCOTARGET, V5, P872, DOI 10.18632/oncotarget.1825
   Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5
   Chandrasekaran KS, 2016, TUMOR BIOL, V37, P13155, DOI 10.1007/s13277-016-5261-1
   Chang TC, 2007, MOL CELL, V26, P745, DOI 10.1016/j.molcel.2007.05.010
   Chen X, 2015, MOL MED REP, V12, P4462, DOI 10.3892/mmr.2015.3928
   Cheng YJ, 2015, CELL PHYSIOL BIOCHEM, V36, P1577, DOI 10.1159/000430320
   Chiu CF, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17081337
   Farh KKH, 2005, SCIENCE, V310, P1817, DOI 10.1126/science.1121158
   Favreau AJ, 2016, EXP HEMATOL ONCOL, V5, DOI 10.1186/s40164-016-0033-6
   Han ZY, 2015, ONCOTARGET, V6, P13149, DOI 10.18632/oncotarget.3693
   Huang KB, 2015, MOL MED REP, V12, P7830, DOI 10.3892/mmr.2015.4455
   Huber R, 2016, SCI REP-UK, V6, DOI 10.1038/srep29914
   Ichimura A, 2010, MOL PHARMACOL, V77, P1016, DOI 10.1124/mol.109.063321
   JIANG HP, 1994, ONCOGENE, V9, P3397
   Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035
   Li GD, 2016, ADV MATER SCI ENG, V2016, DOI 10.1155/2016/8530574
   Liu L, 2011, LEUKEMIA, V25, P23, DOI 10.1038/leu.2010.225
   Lou GH, 2015, CELL PHYSIOL BIOCHEM, V35, P2192, DOI 10.1159/000374024
   Lu F, 2014, INT J ONCOL, V45, P383, DOI 10.3892/ijo.2014.2390
   Mehta A, 2015, IMMUNITY, V42, P1021, DOI 10.1016/j.immuni.2015.05.017
   Ofran Y, 2014, ACTA HAEMATOL-BASEL, V132, P292, DOI 10.1159/000360200
   Piletic K, 2016, ARCH TOXICOL, V90, P2405, DOI 10.1007/s00204-016-1815-7
   Raver-Shapira N, 2007, MOL CELL, V26, P731, DOI 10.1016/j.molcel.2007.05.017
   Rucker FG, 2013, LEUKEMIA, V27, P353, DOI 10.1038/leu.2012.208
   Samuel N, 2016, ONCOTARGET, V7, P49611, DOI 10.18632/oncotarget.10417
   Sengsayadeth S, 2015, HAEMATOLOGICA, V100, P859, DOI 10.3324/haematol.2015.123331
   Song CS, 2017, BIOCHEM BIOPH RES CO, V482, P22, DOI 10.1016/j.bbrc.2016.11.037
   SUGIMOTO K, 1992, BLOOD, V79, P2378, DOI 10.1182/blood.V79.9.2378.2378
   Suren D, 2014, MED SCI MONITOR, V20, P530, DOI 10.12659/MSM.890531
   Thiebes KP, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8718
   Traore K, 2005, LEUKEMIA RES, V29, P863, DOI 10.1016/j.leukres.2004.12.011
   Wang JC, 2015, CELL PHYSIOL BIOCHEM, V35, P767, DOI 10.1159/000369736
   Wang X, 2015, CELL SIGNAL, V27, P443, DOI 10.1016/j.cellsig.2014.12.003
   WOLF D, 1985, P NATL ACAD SCI USA, V82, P790, DOI 10.1073/pnas.82.3.790
   Xu Y, 2015, INT J CLIN EXP MED, V8, P6446
   Yang DQ, 2017, INT J LAB HEMATOL, V39, P42, DOI 10.1111/ijlh.12566
   Yu Yan, 2008, Ai Zheng, V27, P929
   Zauli G, 2011, CLIN CANCER RES, V17, P2712, DOI 10.1158/1078-0432.CCR-10-3244
   Zhao XD, 2015, J CELL BIOL, V210, P613, DOI 10.1083/jcb.201501073
NR 42
TC 75
Z9 80
U1 0
U2 9
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 1015-8987
EI 1421-9778
J9 CELL PHYSIOL BIOCHEM
JI Cell. Physiol. Biochem.
PY 2017
VL 41
IS 5
BP 1981
EP 1992
DI 10.1159/000475277
PG 12
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Physiology
GA EY7LW
UT WOS:000404173800021
PM 28478444
OA gold
DA 2022-04-25
ER

PT J
AU Wang, Y
   Lu, JH
   Wu, QN
   Jin, Y
   Wang, DS
   Chen, YX
   Liu, J
   Luo, XJ
   Meng, Q
   Pu, HY
   Wang, YN
   Hu, PS
   Liu, ZX
   Zeng, ZL
   Zhao, Q
   Deng, R
   Zhu, XF
   Ju, HQ
   Xu, RH
AF Wang, Yun
   Lu, Jia-Huan
   Wu, Qi-Nian
   Jin, Ying
   Wang, De-Shen
   Chen, Yan-Xing
   Liu, Jia
   Luo, Xiao-Jing
   Meng, Qi
   Pu, Heng-Ying
   Wang, Ying-Nan
   Hu, Pei-Shan
   Liu, Ze-Xian
   Zeng, Zhao-Lei
   Zhao, Qi
   Deng, Rong
   Zhu, Xiao-Feng
   Ju, Huai-Qiang
   Xu, Rui-Hua
TI LncRNA LINRIS stabilizes IGF2BP2 and promotes the aerobic glycolysis in
   colorectal cancer
SO MOLECULAR CANCER
LA English
DT Article
DE Autophagy; CRC; IGF2BP2; LINRIS; MYC
ID LONG NONCODING RNA; MESSENGER-RNA; DNA METHYLATION; NUCLEAR-RNA; GROWTH;
   CELLS; GENE; MYC; METASTASIS; ACTIVATION
AB Background Long noncoding RNAs (lncRNAs) play nonnegligible roles in the epigenetic regulation of cancer cells. This study aimed to identify a specific lncRNA that promotes the colorectal cancer (CRC) progression and could be a potential therapeutic target. Methods We screened highly expressed lncRNAs in human CRC samples compared with their matched adjacent normal tissues. The proteins that interact with LINRIS (Long Intergenic Noncoding RNA for IGF2BP2 Stability) were confirmed by RNA pull-down and RNA immunoprecipitation (RIP) assays. The proliferation and metabolic alteration of CRC cells with LINRIS inhibited were tested in vitro and in vivo. Results LINRIS was upregulated in CRC tissues from patients with poor overall survival (OS), and LINRIS inhibition led to the impaired CRC cell line growth. Moreover, knockdown of LINRIS resulted in a decreased level of insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2), a newly found N-6-methyladenosine (m(6)A) 'reader'. LINRIS blocked K139 ubiquitination of IGF2BP2, maintaining its stability. This process prevented the degradation of IGF2BP2 through the autophagy-lysosome pathway (ALP). Therefore, knockdown of LINRIS attenuated the downstream effects of IGF2BP2, especially MYC-mediated glycolysis in CRC cells. In addition, the transcription of LINRIS could be inhibited by GATA3 in CRC cells. In vivo experiments showed that the inhibition of LINRIS suppressed the proliferation of tumors in orthotopic models and in patient-derived xenograft (PDX) models. Conclusion LINRIS is an independent prognostic biomarker for CRC. The LINRIS-IGF2BP2-MYC axis promotes the progression of CRC and is a promising therapeutic target.
C1 [Wang, Yun; Lu, Jia-Huan; Wu, Qi-Nian; Jin, Ying; Wang, De-Shen; Chen, Yan-Xing; Liu, Jia; Luo, Xiao-Jing; Meng, Qi; Pu, Heng-Ying; Wang, Ying-Nan; Hu, Pei-Shan; Liu, Ze-Xian; Zeng, Zhao-Lei; Zhao, Qi; Deng, Rong; Zhu, Xiao-Feng; Ju, Huai-Qiang; Xu, Rui-Hua] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Canc Ctr, Guangzhou, Guangdong, Peoples R China.
   [Wang, Yun; Jin, Ying; Wang, De-Shen; Chen, Yan-Xing; Liu, Jia; Luo, Xiao-Jing; Meng, Qi; Xu, Rui-Hua] Sun Yat Sen Univ, Dept Med Oncol, Canc Ctr, Guangzhou, Guangdong, Peoples R China.
   [Lu, Jia-Huan] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Anat & Cellular Pathol, State Key Lab Translat Oncol, Hong Kong, Peoples R China.
   [Wu, Qi-Nian] Sun Yat Sen Univ, Dept Pathol, Canc Ctr, Guangzhou, Guangdong, Peoples R China.
   [Ju, Huai-Qiang; Xu, Rui-Hua] Chinese Acad Med Sci, Precis Diag & Treatment Gastrointestinal Canc, Guangzhou, Guangdong, Peoples R China.
RP Ju, HQ; Xu, RH (corresponding author), Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Canc Ctr, Guangzhou, Guangdong, Peoples R China.; Xu, RH (corresponding author), Sun Yat Sen Univ, Dept Med Oncol, Canc Ctr, Guangzhou, Guangdong, Peoples R China.; Ju, HQ; Xu, RH (corresponding author), Chinese Acad Med Sci, Precis Diag & Treatment Gastrointestinal Canc, Guangzhou, Guangdong, Peoples R China.
EM juhq@sysucc.org.cn; xurh@sysucc.org.cn
RI Liu, Zexian/D-1153-2011; Zhao, Qi/X-7899-2019; Xu, Rui-Hua/AAW-4766-2021
OI Liu, Zexian/0000-0001-9698-0610; Zhao, Qi/0000-0002-8683-6145; Luo,
   Xiao-jing/0000-0001-9440-9189
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81930065, 81871951, 81802438]; Natural
   Science Foundation of Guangdong ProvinceNational Natural Science
   Foundation of Guangdong Province [2014A030312015]; Science and
   Technology Program of Guangdong [2019B020227002]; Science and Technology
   Program of Guangzhou [201904020046, 201803040019, 201704020228]; CAMS
   Innovation Fund for Medical Sciences [2019-I2M-5-036]; Pearl River S&T
   Nova Program of Guangzhou [201806010002]
FX This research was supported by National Natural Science Foundation of
   China (81930065, 81871951, 81802438); Natural Science Foundation of
   Guangdong Province (2014A030312015); Science and Technology Program of
   Guangdong (2019B020227002); Science and Technology Program of Guangzhou
   (201904020046, 201803040019, 201704020228); CAMS Innovation Fund for
   Medical Sciences (2019-I2M-5-036) and Pearl River S&T Nova Program of
   Guangzhou (201806010002).
CR Bell JL, 2013, CELL MOL LIFE SCI, V70, P2657, DOI 10.1007/s00018-012-1186-z
   Bertucci F, 2019, NATURE, V569, P560, DOI 10.1038/s41586-019-1056-z
   Cabili MN, 2011, GENE DEV, V25, P1915, DOI 10.1101/gad.17446611
   Cai Q, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1016-0
   Carpenter S, 2013, SCIENCE, V341, P789, DOI 10.1126/science.1240925
   Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635
   Du H, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12626
   Flavahan WA, 2017, SCIENCE, V357, DOI 10.1126/science.aal2380
   Gogvadze V, 2010, MOL ASPECTS MED, V31, P60, DOI 10.1016/j.mam.2009.12.004
   Goncalves MD, 2018, CELL METAB, V28, P3, DOI 10.1016/j.cmet.2018.06.017
   Gruber AR, 2015, METHODS MOL BIOL, V1269, P307, DOI 10.1007/978-1-4939-2291-8_19
   Guffanti G, 2013, PSYCHONEUROENDOCRINO, V38, P3029, DOI 10.1016/j.psyneuen.2013.08.014
   Gupta RA, 2010, NATURE, V464, P1071, DOI 10.1038/nature08975
   Hansen TB, 2013, NATURE, V495, P384, DOI 10.1038/nature11993
   Hsieh AL, 2015, SEMIN CELL DEV BIOL, V43, P11, DOI 10.1016/j.semcdb.2015.08.003
   Hu XW, 2014, CANCER CELL, V26, P344, DOI 10.1016/j.ccr.2014.07.009
   Hu YR, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0743-3
   Huang HL, 2018, NAT CELL BIOL, V20, P285, DOI 10.1038/s41556-018-0045-z
   Ji CH, 2017, MOL CELLS, V40, P441, DOI 10.14348/molcells.2017.0115
   Jia GF, 2011, NAT CHEM BIOL, V7, P885, DOI [10.1038/NCHEMBIO.687, 10.1038/nchembio.687]
   Jiao L, 2018, AUTOPHAGY, V14, P671, DOI 10.1080/15548627.2017.1381804
   Ju HQ, 2019, JNCI-J NATL CANCER I, V111, P584, DOI 10.1093/jnci/djy160
   Ju HQ, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14437
   Law JA, 2010, NAT REV GENET, V11, P204, DOI 10.1038/nrg2719
   Lee S, 2016, CELL, V164, P69, DOI 10.1016/j.cell.2015.12.017
   Li B, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-323
   Li S, 2018, REDOX BIOL, V18, P246, DOI 10.1016/j.redox.2018.07.017
   Li W, 2014, GASTROENTEROLOGY, V146, P1714, DOI 10.1053/j.gastro.2014.03.002
   Li Y, 2014, GASTROENTEROLOGY, V146, P1701, DOI 10.1053/j.gastro.2014.02.029
   Li Z, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04006-0
   Liao YJ, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.66
   Liberti MV, 2016, TRENDS BIOCHEM SCI, V41, P211, DOI 10.1016/j.tibs.2015.12.001
   Lin AF, 2016, NAT CELL BIOL, V18, P213, DOI 10.1038/ncb3295
   Lin MC, 2017, ONCOGENE, V36, P4380, DOI 10.1038/onc.2017.196
   Liu JZ, 2014, NAT CHEM BIOL, V10, P93, DOI 10.1038/nchembio.1432
   Liu ZX, 2014, NUCLEIC ACIDS RES, V42, pD531, DOI 10.1093/nar/gkt1093
   Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8
   Madrigal-Matute J, 2016, GASTROENTEROLOGY, V150, P328, DOI 10.1053/j.gastro.2015.09.042
   Mizushima N, 2011, CELL, V147, P728, DOI 10.1016/j.cell.2011.10.026
   Mohammad HP, 2019, NAT MED, V25, P403, DOI 10.1038/s41591-019-0376-8
   Noubissi FK, 2006, NATURE, V441, P898, DOI 10.1038/nature04839
   Peng ZX, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0812-2
   Rupaimoole R, 2015, CELL REP, V13, P2395, DOI 10.1016/j.celrep.2015.11.047
   Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993
   Sidibe A, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02610-0
   Siegel RL, 2019, CA-CANCER J CLIN, V69, P7, DOI 10.3322/caac.21551
   Tateishi K, 2016, CLIN CANCER RES, V22, P4452, DOI 10.1158/1078-0432.CCR-15-2274
   Wang X, 2014, NATURE, V505, P117, DOI 10.1038/nature12730
   Wang YN, 2018, ONCOGENE, V37, P6025, DOI 10.1038/s41388-018-0384-z
   Wilson CL, 2017, ADV DRUG DELIVER REV, V121, P124, DOI 10.1016/j.addr.2017.10.011
   Xiao W, 2016, MOL CELL, V61, P507, DOI 10.1016/j.molcel.2016.01.012
   Xu RH, 2005, CANCER RES, V65, P613
   Yamamoto T, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4480
   Yu WQ, 2008, NATURE, V451, P202, DOI 10.1038/nature06468
   Zheng J, 2016, NAT GENET, V48, P747, DOI 10.1038/ng.3568
   Zheng R S, 2019, Zhonghua Zhong Liu Za Zhi, V41, P19, DOI 10.3760/cma.j.issn.0253-3766.2019.01.005
NR 56
TC 127
Z9 131
U1 11
U2 25
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1476-4598
J9 MOL CANCER
JI Mol. Cancer
PD DEC 2
PY 2019
VL 18
IS 1
AR 174
DI 10.1186/s12943-019-1105-0
PG 18
WC Biochemistry & Molecular Biology; Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology
GA JT1RQ
UT WOS:000500775500001
PM 31791342
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Wang, YG
   Liu, HH
   Cao, YT
   Zhang, LL
   Huang, F
   Yi, C
AF Wang, Yigang
   Liu, Hui-Hui
   Cao, Yu-Ting
   Zhang, Lei-Lei
   Huang, Fang
   Yi, Cong
TI The Role of Mitochondrial Dynamics and Mitophagy in Carcinogenesis,
   Metastasis and Therapy
SO FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
LA English
DT Review
DE mitochondria; mitochondrial dynamics; mitophagy; carcinogenesis; therapy
ID HYPOXIA-INDUCED AUTOPHAGY; CELL-DEATH; BREAST-CANCER; DEPENDENT
   MITOPHAGY; COLORECTAL-CANCER; MAMMALIAN HOMOLOG; SIGNALING PATHWAY;
   TUMOR PROGRESSION; DRUG-RESISTANCE; PARKIN ISOFORMS
AB Mitochondria are key cellular organelles and play vital roles in energy metabolism, apoptosis regulation and cellular homeostasis. Mitochondrial dynamics refers to the varying balance between mitochondrial fission and mitochondrial fusion that plays an important part in maintaining mitochondrial homeostasis and quality. Mitochondrial malfunction is involved in aging, metabolic disease, neurodegenerative disorders, and cancers. Mitophagy, a selective autophagy of mitochondria, can efficiently degrade, remove and recycle the malfunctioning or damaged mitochondria, and is crucial for quality control. In past decades, numerous studies have identified a series of factors that regulate mitophagy and are also involved in carcinogenesis, cancer cell migration and death. Therefore, it has become critically important to analyze signal pathways that regulate mitophagy to identify potential therapeutic targets. Here, we review recent progresses in mitochondrial dynamics, the mechanisms of mitophagy regulation, and the implications for understanding carcinogenesis, metastasis, treatment, and drug resistance.
C1 [Wang, Yigang; Liu, Hui-Hui; Cao, Yu-Ting; Zhang, Lei-Lei] Zhejiang Sci Tech Univ, Xinyuan Inst Med & Biotechnol, Sch Life Sci & Med, Hangzhou, Peoples R China.
   [Huang, Fang] Zhejiang Prov Peoples Hosp, Peoples Hosp, Dept Pathol, Hangzhou Med Coll, Hangzhou, Peoples R China.
   [Yi, Cong] Zhejiang Univ, Sch Med, Dept Biochem Hepatobiliary & Pancreat Surg, Affiliated Hosp 1, Hangzhou, Peoples R China.
RP Huang, F (corresponding author), Zhejiang Prov Peoples Hosp, Peoples Hosp, Dept Pathol, Hangzhou Med Coll, Hangzhou, Peoples R China.; Yi, C (corresponding author), Zhejiang Univ, Sch Med, Dept Biochem Hepatobiliary & Pancreat Surg, Affiliated Hosp 1, Hangzhou, Peoples R China.
EM huangfang0794@163.com; yiconglab@zju.edu.cn
FU Zhejiang Provincial Natural Science FoundationNatural Science Foundation
   of Zhejiang Province [LY18C070002]; National Natural Science Foundation
   of ChinaNational Natural Science Foundation of China (NSFC) [81803069,
   91754107, 31771528]; Zhejiang Medical and Health Science and Technology
   project [2019337459]; Grant for 521 talent project of ZSTU
FX This work was supported by the Zhejiang Provincial Natural Science
   Foundation (No. LY18C070002), the National Natural Science Foundation of
   China (No. 81803069), Zhejiang Medical and Health Science and Technology
   project (No. 2019337459) and the Grant for 521 talent project of ZSTU to
   YW, and National Natural Science Foundation of China (Nos. 91754107 and
   31771528) to CY.
CR Abeliovich H, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3789
   Araki K, 2019, COMMUN BIOL, V2, DOI 10.1038/s42003-018-0246-9
   Ashrafi G, 2013, CELL DEATH DIFFER, V20, P31, DOI 10.1038/cdd.2012.81
   Basit F, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.133
   Bensinger SJ, 2012, SEMIN CELL DEV BIOL, V23, P352, DOI 10.1016/j.semcdb.2012.02.003
   Bernardini JP, 2017, ONCOGENE, V36, P1315, DOI 10.1038/onc.2016.302
   Bhujabal Z, 2017, EMBO REP, V18, P947, DOI 10.15252/embr.201643147
   Bingol B, 2014, NATURE, V510, P370, DOI 10.1038/nature13418
   Boyle KA, 2018, J BIOL CHEM, V293, P14891, DOI 10.1074/jbc.RA117.001469
   Burrell RA, 2013, NATURE, V494, P492, DOI 10.1038/nature11935
   Cao ST, 2019, FOOD FUNCT, V10, P344, DOI 10.1039/c8fo02091d
   Cao YL, 2017, NATURE, V542, P372, DOI 10.1038/nature21077
   Cassidy-Stone A, 2008, DEV CELL, V14, P193, DOI 10.1016/j.devcel.2007.11.019
   Chan DC, 2006, ANNU REV CELL DEV BI, V22, P79, DOI 10.1146/annurev.cellbio.22.010305.104638
   Chan DC, 2020, ANNU REV PATHOL-MECH, V15, P235, DOI 10.1146/annurev-pathmechdis-012419-032711
   Chan DC, 2012, ANNU REV GENET, V46, P265, DOI 10.1146/annurev-genet-110410-132529
   Chan NC, 2011, HUM MOL GENET, V20, P1726, DOI 10.1093/hmg/ddr048
   Chang CR, 2010, ANN NY ACAD SCI, V1201, P34, DOI 10.1111/j.1749-6632.2010.05629.x
   Chang HW, 2019, ONCOGENE, V38, P3729, DOI 10.1038/s41388-019-0697-6
   Chang JY, 2017, BBA-BIOENERGETICS, V1858, P633, DOI 10.1016/j.bbabio.2016.12.008
   Chang SH, 2015, CHEMOTHERAPY, V61, P304, DOI 10.1159/000445044
   Chen DS, 2017, NATURE, V541, P321, DOI 10.1038/nature21349
   Chen G, 2014, MOL CELL, V54, P362, DOI 10.1016/j.molcel.2014.02.034
   Chen L, 2017, J CANCER, V8, P3733, DOI 10.7150/jca.20814
   Chen ZW, 2015, CANCER BIOMARK, V15, P467, DOI 10.3233/CBM-150474
   Chen ZH, 2017, EMBO REP, V18, P495, DOI 10.15252/embr.201643309
   Chourasia AH, 2015, EMBO REP, V16, P1145, DOI 10.15252/embr.201540759
   Chourasia AH, 2015, CANCER METAB, V3, DOI 10.1186/s40170-015-0130-8
   Chowdhury SR, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.77
   Cipolat S, 2004, P NATL ACAD SCI USA, V101, P15927, DOI 10.1073/pnas.0407043101
   D'Amico AG, 2015, TUMOR BIOL, V36, P5133, DOI 10.1007/s13277-015-3166-z
   Dany M, 2016, BLOOD, V128, P1944, DOI 10.1182/blood-2016-04-708750
   Deng Y, 2017, RESP RES, V18, DOI 10.1186/s12931-017-0536-7
   Diwan A, 2007, P NATL ACAD SCI USA, V104, P6794, DOI 10.1073/pnas.0610666104
   Farrand L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074008
   Farre JC, 2009, CURR OPIN CELL BIOL, V21, P522, DOI 10.1016/j.ceb.2009.04.015
   Fei PW, 2004, CANCER CELL, V6, P597, DOI 10.1016/j.ccr.2004.10.012
   Fimia GM, 2007, NATURE, V447, P1121, DOI 10.1038/nature05925
   Fujiwara M, 2008, ONCOGENE, V27, P6002, DOI 10.1038/onc.2008.199
   Giampazolias E, 2016, FEBS J, V283, P803, DOI 10.1111/febs.13603
   Giatromanolaki A, 2008, J CLIN PATHOL, V61, P217, DOI 10.1136/jcp.2007.046680
   Guo JY, 2013, GENE DEV, V27, P1447, DOI 10.1101/gad.219642.113
   Gustafsson AB, 2011, PEDIATR CARDIOL, V32, P267, DOI 10.1007/s00246-010-9876-5
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Hirota Yuko, 2012, Int J Cell Biol, V2012, P354914, DOI 10.1155/2012/354914
   Hockenbery DM, 2010, ENVIRON MOL MUTAGEN, V51, P476, DOI 10.1002/em.20552
   Hou HL, 2017, CANCER MED-US, V6, P1871, DOI 10.1002/cam4.1112
   Huang QC, 2017, CANCER LETT, V403, P108, DOI 10.1016/j.canlet.2017.05.034
   Hui L, 2019, CLIN TRANSL ONCOL, V21, P596, DOI 10.1007/s12094-018-1958-5
   Humpton TJ, 2019, CANCER DISCOV, V9, P1268, DOI 10.1158/2159-8290.CD-18-1409
   Ingerman E, 2005, J CELL BIOL, V170, P1021, DOI 10.1083/jcb.200506078
   Ji WK, 2015, ELIFE, V4, DOI [10.7554/eLife.11553.001, 10.7554/eLife.11553]
   Jung J, 2019, CANCER RES, V79, P5218, DOI 10.1158/0008-5472.CAN-19-0198
   Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720
   Kanki T, 2011, ANTIOXID REDOX SIGN, V14, P1989, DOI 10.1089/ars.2010.3762
   Kanki T, 2009, DEV CELL, V17, P98, DOI 10.1016/j.devcel.2009.06.014
   Kim EH, 2007, CANCER RES, V67, P6314, DOI 10.1158/0008-5472.CAN-06-4217
   Kitada T, 1998, NATURE, V392, P605, DOI 10.1038/33416
   Kondapalli C, 2012, OPEN BIOL, V2, DOI 10.1098/rsob.120080
   Kondo-Okamoto N, 2012, J BIOL CHEM, V287, P10631, DOI 10.1074/jbc.M111.299917
   Lazarou M, 2015, NATURE, V524, P309, DOI 10.1038/nature14893
   Lee YS, 2018, CANCER LETT, V433, P156, DOI 10.1016/j.canlet.2018.07.007
   Leo C, 2006, INT J GYNECOL CANCER, V16, P1314, DOI 10.1111/j.1525-1438.2006.00394.x
   Li WH, 2019, HEPATOLOGY, V69, P604, DOI 10.1002/hep.30191
   Li Y, 2007, J BIOL CHEM, V282, P35803, DOI 10.1074/jbc.M705231200
   Liu L, 2012, NAT CELL BIOL, V14, P177, DOI 10.1038/ncb2422
   Liu LH, 2018, BIOMED PHARMACOTHER, V106, P333, DOI 10.1016/j.biopha.2018.06.128
   Loson OC, 2013, MOL BIOL CELL, V24, P659, DOI 10.1091/mbc.E12-10-0721
   Lu HQ, 2013, AUTOPHAGY, V9, P1720, DOI 10.4161/auto.26550
   Maes H, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.94
   Mammucari C, 2007, CELL METAB, V6, P458, DOI 10.1016/j.cmet.2007.11.001
   Maugeri G, 2015, INT J ONCOL, V47, P1282, DOI 10.3892/ijo.2015.3105
   Meyer N, 2018, AUTOPHAGY, V14, P1693, DOI 10.1080/15548627.2018.1476812
   Mishra P, 2016, J CELL BIOL, V212, P379, DOI 10.1083/jcb.201511036
   Murakawa T, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8527
   Naik PP, 2018, CELL PROLIFERAT, V51, DOI 10.1111/cpr.12411
   Ni HM, 2015, REDOX BIOL, V4, P6, DOI 10.1016/j.redox.2014.11.006
   Novak I, 2010, EMBO REP, V11, P45, DOI 10.1038/embor.2009.256
   Okami J, 2004, CANCER RES, V64, P5338, DOI 10.1158/0008-5472.CAN-04-0089
   Okamoto K, 2009, DEV CELL, V17, P87, DOI 10.1016/j.devcel.2009.06.013
   Otsu K, 2015, AUTOPHAGY, V11, P1932, DOI 10.1080/15548627.2015.1084459
   Oun R, 2018, DALTON T, V47, P7848, DOI 10.1039/c8dt90088d
   Panda PK, 2018, BBA-MOL CELL RES, V1865, P480, DOI 10.1016/j.bbamcr.2017.12.002
   Panigrahi DP, 2020, SEMIN CANCER BIOL, V66, P45, DOI 10.1016/j.semcancer.2019.07.015
   Pernas L, 2016, ANNU REV PHYSIOL, V78, P505, DOI 10.1146/annurev-physiol-021115-105011
   Porporato PE, 2018, CELL RES, V28, P265, DOI 10.1038/cr.2017.155
   Poulogiannis G, 2010, P NATL ACAD SCI USA, V107, P15145, DOI 10.1073/pnas.1009941107
   Rao S, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4056
   Ray R, 2000, J BIOL CHEM, V275, P1439, DOI 10.1074/jbc.275.2.1439
   Rehman J, 2012, FASEB J, V26, P2175, DOI 10.1096/fj.11-196543
   Rosenfeldt MT, 2013, NATURE, V504, P296, DOI 10.1038/nature12865
   Sandoval H, 2008, NATURE, V454, P232, DOI 10.1038/nature07006
   Schubert AF, 2017, NATURE, V552, P51, DOI 10.1038/nature24645
   Sekine S, 2018, BMC BIOL, V16, DOI 10.1186/s12915-017-0470-7
   Senft D, 2016, CURR OPIN CELL BIOL, V39, P43, DOI 10.1016/j.ceb.2016.02.001
   Sentelle RD, 2012, NAT CHEM BIOL, V8, P831, DOI 10.1038/NCHEMBIO.1059
   Shi C, 2018, REDOX BIOL, V14, P59, DOI 10.1016/j.redox.2017.08.013
   Shi RY, 2014, CNS NEUROSCI THER, V20, P1045, DOI 10.1111/cns.12325
   Sowter HM, 2003, J PATHOL, V201, P573, DOI 10.1002/path.1486
   Sowter HM, 2001, CANCER RES, V61, P6669
   Strappazzon F, 2015, CELL DEATH DIFFER, V22, P419, DOI 10.1038/cdd.2014.139
   Su YC, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148408
   Subarsky P, 2003, CLIN EXP METASTAS, V20, P237, DOI 10.1023/A:1022939318102
   Sun XD, 2013, CELL CYCLE, V12, P1133, DOI 10.4161/cc.24215
   Taguchi N, 2007, J BIOL CHEM, V282, P11521, DOI 10.1074/jbc.M607279200
   Tan EY, 2007, CLIN CANCER RES, V13, P467, DOI 10.1158/1078-0432.CCR-06-1466
   Tay SP, 2010, J BIOL CHEM, V285, P29231, DOI 10.1074/jbc.M110.108241
   Tilokani L, 2018, ESSAYS BIOCHEM, V62, P341, DOI 10.1042/EBC20170104
   Vasquez-Trincado C, 2016, J PHYSIOL-LONDON, V594, P509, DOI 10.1113/JP271301
   Veeriah S, 2010, NAT GENET, V42, P77, DOI 10.1038/ng.491
   Villa E, 2017, CELL REP, V20, P2846, DOI 10.1016/j.celrep.2017.08.087
   Vyas S, 2016, CELL, V166, P555, DOI 10.1016/j.cell.2016.07.002
   Wai T, 2016, TRENDS ENDOCRIN MET, V27, P105, DOI 10.1016/j.tem.2015.12.001
   Wallace DC, 2012, NAT REV CANCER, V12, P685, DOI 10.1038/nrc3365
   Wan YY, 2014, ONCOL REP, V32, P619, DOI 10.3892/or.2014.3235
   Wang F, 2004, GENE CHROMOSOME CANC, V40, P85, DOI 10.1002/gcc.20020
   Wang JN, 2015, MOL ONCOL, V9, P488, DOI 10.1016/j.molonc.2014.10.002
   Wang WJ, 2014, NAT CHEM BIOL, V10, P133, DOI [10.1038/NCHEMBIO.1406, 10.1038/nchembio.1406]
   Wei YJ, 2017, CELL, V168, P224, DOI 10.1016/j.cell.2016.11.042
   Wu HW, 2015, MOL MED REP, V12, P6467, DOI 10.3892/mmr.2015.4255
   Wu HM, 2015, SCI REP-UK, V5, DOI 10.1038/srep12291
   Xie Q, 2015, NAT NEUROSCI, V18, P501, DOI 10.1038/nn.3960
   Yamashita K, 2017, ANN SURG ONCOL, V24, P4025, DOI 10.1245/s10434-017-6096-8
   Yan C, 2017, CANCER LETT, V388, P34, DOI 10.1016/j.canlet.2016.11.018
   Yang Z, 2017, ONCOTARGET, V8, P80981, DOI 10.18632/oncotarget.20941
   Yao N, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1470-z
   Youle RJ, 2011, NAT REV MOL CELL BIO, V12, P9, DOI 10.1038/nrm3028
   Zhang C, 2011, P NATL ACAD SCI USA, V108, P16259, DOI 10.1073/pnas.1113884108
   Zhang X, 2015, SCI REP-UK, V5, DOI [10.1038/srep09803, 10.1038/srep09940]
   Zhang YF, 2019, NAT IMMUNOL, V20, P433, DOI 10.1038/s41590-019-0324-2
   Zhao J, 2013, ONCOGENE, V32, P4814, DOI 10.1038/onc.2012.494
   Zhou J, 2015, AUTOPHAGY, V11, P1259, DOI 10.1080/15548627.2015.1056970
   Zhu YX, 2020, BIOMATERIALS, V232, DOI 10.1016/j.biomaterials.2019.119668
   Zhu YY, 2013, J BIOL CHEM, V288, P1099, DOI 10.1074/jbc.M112.399345
NR 134
TC 28
Z9 28
U1 5
U2 12
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2296-634X
J9 FRONT CELL DEV BIOL
JI Front. Cell. Dev. Biol.
PD JUN 10
PY 2020
VL 8
AR 413
DI 10.3389/fcell.2020.00413
PG 12
WC Cell Biology; Developmental Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Developmental Biology
GA MD3QA
UT WOS:000543884500001
PM 32587855
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Bobak, Y
   Kurlishchuk, Y
   Vynnytska-Myronovska, B
   Grydzuk, O
   Shuvayeva, G
   Redowicz, MJ
   Kunz-Schughart, LA
   Stasyk, O
AF Bobak, Yaroslav
   Kurlishchuk, Yuliya
   Vynnytska-Myronovska, Bozhena
   Grydzuk, Olesia
   Shuvayeva, Galyna
   Redowicz, Maria J.
   Kunz-Schughart, Leoni A.
   Stasyk, Oleh
TI Arginine deprivation induces endoplasmic reticulum stress in human solid
   cancer cells
SO INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
LA English
DT Article
DE Arginine deprivation; ER stress; Canavanine; Metabolic anticancer
   therapy
ID UNFOLDED PROTEIN RESPONSE; ER STRESS; DEGRADING ENZYMES; IN-VITRO; ACID;
   APOPTOSIS; MECHANISMS; ORGANIZATION; AUTOPHAGY; PATHWAY
AB Deprivation for the single amino acid arginine is a rapidly developing metabolic anticancer therapy, which allows growth control in a number of highly malignant tumors. Here we report that one of the responses of human solid cancer cells to arginine starvation is the induction of prolonged endoplasmic reticulum (ER) stress and activation of the unfolded protein response (UPR). Systematic study of two colorectal carcinoma HCT-116 and HT29, glioblastoma U251 MG and ovarian carcinoma SKOV3 cell lines revealed, however, that the ER stress triggered by the absence of arginine does not result in massive apoptosis despite a profound upregulation of the proapoptotic gene CHOP. Instead, Akt- and MAPK-dependent pathways were activated which may counteract proapoptotic signaling. Treatment with DMSO as a disaggregating agent or with cycloheximide to block protein synthesis reduced ER stress evoked by arginine deprivation. On the other hand, ER stress and apoptosis induction in arginine-starved cells could be critically augmented by the arginine analog of plant origin canavanine, but not by the classic ER stress inducer tunicamycin. Our data suggest that canavanine treatment applied under the lack of arginine may enhance the efficacy of arginine deprivation -based anticancer therapy. (C) 2015 Elsevier Ltd. All rights reserved.
C1 [Bobak, Yaroslav; Kurlishchuk, Yuliya; Vynnytska-Myronovska, Bozhena; Grydzuk, Olesia; Shuvayeva, Galyna; Stasyk, Oleh] Natl Acad Sci Ukraine, Inst Cell Biol, Dept Cell Signaling, Drahomanov Str 14-16, UA-79005 Lvov, Ukraine.
   [Kurlishchuk, Yuliya; Vynnytska-Myronovska, Bozhena; Kunz-Schughart, Leoni A.] Fac Med, OncoRay Natl Ctr Radiat Res Oncol, Fetscherstr 74, D-01307 Dresden, Germany.
   [Kurlishchuk, Yuliya; Vynnytska-Myronovska, Bozhena; Kunz-Schughart, Leoni A.] Univ Hosp Carl Gustav Carus, TU Dresden & Helmholtz Zentrum Dresden Rossendorf, Inst Radiooncol, Fetscherstr 74, D-01307 Dresden, Germany.
   [Redowicz, Maria J.] Polish Acad Sci, Nencki Inst Expt Biol, Lab Mol Basis Cell Motil, Pasteur Str 3, PL-02093 Warsaw, Poland.
   [Kunz-Schughart, Leoni A.] Dept Oncol, Old Rd,Campus Res Bldg,Roosevelt Dr, Oxford OX3 7DQ, England.
   [Vynnytska-Myronovska, Bozhena] Univ Saarland, Clin Urol & Pediat Urol, Kirrberger Str, D-66421 Homburg, Germany.
RP Stasyk, O (corresponding author), Natl Acad Sci Ukraine, Inst Cell Biol, Dept Cell Signaling, Drahomanov Str 14-16, UA-79005 Lvov, Ukraine.
EM bobakyaroslav@gmail.com; kurlishchukyuliya@gmail.com;
   b.vynnytskamyronovska@gmail.com; olesia.hr@gmail.com;
   galinash1977@mail.ru; jolanta@nencki.gov.pl;
   leoni.kunz-schughart@oncoray.de; stasyk@cellbiol.lviv.ua
RI Stasyk, Oleh/E-9496-2019; Shuvayeva, Galyna Yu/F-3863-2019; Bobak,
   Yaroslav P/F-4864-2019; Redowicz, Maria Jolanta/R-4083-2016; Redowicz,
   Maria Jolanta/AAM-8020-2020; Shuvayeva, Galyna/AAP-9669-2020
OI Stasyk, Oleh/0000-0001-8135-6102; Shuvayeva, Galyna
   Yu/0000-0001-7803-3900; Bobak, Yaroslav P/0000-0003-3399-1392; Redowicz,
   Maria Jolanta/0000-0001-5834-471X; Shuvayeva,
   Galyna/0000-0001-7803-3900; Kunz-Schughart, Leoni/0000-0003-3912-6594
FU Polish Ministry of Science and Higher EducationMinistry of Science and
   Higher Education, Poland [N303 3182 39]; statutory funds to the Nencki
   Institute; West-Ukrainian BioMedical Research Center; German Academic
   Exchange Service (DAAD)Deutscher Akademischer Austausch Dienst (DAAD)
FX The work has been supported by Polish Ministry of Science and Higher
   Education: grant N303 3182 39 to MJR, and the statutory funds to the
   Nencki Institute. YK and BVM were supported with fellowships granted by
   the West-Ukrainian BioMedical Research Center and the German Academic
   Exchange Service (DAAD).
CR Agrawal V, 2012, EXPERT OPIN BIOL TH, V12, P53, DOI 10.1517/14712598.2012.636349
   [Anonymous], [No title captured]
   Ascierto PA, 2005, J CLIN ONCOL, V23, P7660, DOI 10.1200/JCO.2005.02.0933
   B'chir W, 2014, CELL SIGNAL, V26, P1385, DOI 10.1016/j.cellsig.2014.03.009
   Baumann O, 2001, INT REV CYTOL, V205, P149, DOI 10.1016/S0074-7696(01)05004-5
   Bobak YP, 2010, CELL BIOL INT, V34, P1085, DOI 10.1042/CBI20100451
   Chambers JE, 2014, AM J PHYSIOL-CELL PH, V307, pC657, DOI 10.1152/ajpcell.00183.2014
   Changou CA, 2014, P NATL ACAD SCI USA, V111, P14147, DOI 10.1073/pnas.1404171111
   Garcia-Navas R, 2012, AUTOPHAGY, V8, P1557, DOI 10.4161/auto.21315
   Glazer ES, 2010, J CLIN ONCOL, V28, P2220, DOI 10.1200/JCO.2009.26.7765
   Gorman AM, 2012, PHARMACOL THERAPEUT, V134, P306, DOI 10.1016/j.pharmthera.2012.02.003
   Harding HP, 2000, MOL CELL, V5, P897, DOI 10.1016/S1097-2765(00)80330-5
   Healy SJM, 2009, EUR J PHARMACOL, V625, P234, DOI 10.1016/j.ejphar.2009.06.064
   Hetz C, 2013, NAT REV DRUG DISCOV, V12, P703, DOI 10.1038/nrd3976
   Hwang SJ, 2011, BIOTECHNOL PROGR, V27, P587, DOI 10.1002/btpr.579
   Jousse C, 1999, FEBS LETT, V448, P211, DOI 10.1016/S0014-5793(99)00373-7
   Kandala PK, 2012, ONCOTARGET, V3, P435
   Kolb PS, 2015, INT J BIOCHEM CELL B, V61, P45, DOI 10.1016/j.biocel.2015.01.015
   Lu Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073866
   Ma YJ, 2004, NAT REV CANCER, V4, P966, DOI 10.1038/nrc1505
   Morris SM, 2004, J NUTR, V134, p2765S, DOI 10.1093/jn/134.10.2765S
   Morris SM, 2004, J NUTR, V134, p2743S, DOI 10.1093/jn/134.10.2743S
   Morrow K, 2013, LEUKEMIA, V27, P569, DOI 10.1038/leu.2012.247
   Novoa I, 2001, J CELL BIOL, V153, P1011, DOI 10.1083/jcb.153.5.1011
   Ohoka N, 2005, EMBO J, V24, P1243, DOI 10.1038/sj.emboj.7600596
   Oslowski CM, 2011, METHOD ENZYMOL, V490, P71, DOI 10.1016/B978-0-12-385114-7.00004-0
   Oyadomari S, 2004, CELL DEATH DIFFER, V11, P381, DOI 10.1038/sj.cdd.4401373
   Pavlyk I, 2015, AMINO ACIDS, V47, P199, DOI 10.1007/s00726-014-1857-1
   Phillips MM, 2013, CANCER RES TREAT, V45, P251, DOI 10.4143/crt.2013.45.4.251
   Puthalakath H, 2007, CELL, V129, P1337, DOI 10.1016/j.cell.2007.04.027
   Putt KS, 2005, CHEMBIOCHEM, V6, P53, DOI 10.1002/cbic.200400330
   ROSENTHAL GA, 1989, J BIOL CHEM, V264, P13693
   Savaraj N, 2010, CURR MOL MED, V10, P405, DOI 10.2174/156652410791316995
   Shuvayeva G, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/505041
   Stasyk OV, 2015, CELL BIOL INT, V39, P246, DOI 10.1002/cbin.10383
   Tabas I, 2011, NAT CELL BIOL, V13, P184, DOI 10.1038/ncb0311-184
   Vynnytska BO, 2011, ANTI-CANCER DRUG, V22, P148, DOI 10.1097/CAD.0b013e32833e0334
   Vynnytska-Myronovska B, 2013, AMINO ACIDS, V45, P1221, DOI 10.1007/s00726-013-1586-x
   Vynnytska-Myronovska B, 2012, INT J CANCER, V130, P2164, DOI 10.1002/ijc.26221
   Wang Z, 2014, APPL MICROBIOL BIOT, V98, P641, DOI 10.1007/s00253-013-4870-5
   Yadav Raj Kumar, 2014, J Cancer Prev, V19, P75, DOI 10.15430/JCP.2014.19.2.75
   Yau T, 2013, INVEST NEW DRUG, V31, P99, DOI 10.1007/s10637-012-9807-9
   Zhang PC, 2002, MOL CELL BIOL, V22, P6681, DOI 10.1128/MCB.22.19.6681-6688.2002
NR 43
TC 24
Z9 25
U1 1
U2 15
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1357-2725
EI 1878-5875
J9 INT J BIOCHEM CELL B
JI Int. J. Biochem. Cell Biol.
PD JAN
PY 2016
VL 70
BP 29
EP 38
DI 10.1016/j.biocel.2015.10.027
PG 10
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA DB9WX
UT WOS:000368869500004
PM 26546743
DA 2022-04-25
ER

PT J
AU Wang, SH
   Chong, ZZ
   Shang, YC
   Maiese, K
AF Wang, Shaohui
   Chong, Zhao Zhong
   Shang, Yan Chen
   Maiese, Kenneth
TI WISP1 (CCN4) Autoregulates its Expression and Nuclear Trafficking of
   beta-Catenin during Oxidant Stress with Limited Effects upon Neuronal
   Autophagy
SO CURRENT NEUROVASCULAR RESEARCH
LA English
DT Article
DE Akt1; apoptosis; autophagy; beta-catenin; Beclin 1; CCN4; glycogen
   synthase kinase-3 beta; LC3; neurons; oxidative stress; p62; WISP; Wnt1
ID SIGNALING PATHWAY PROTEIN-1; INDUCED SECRETED PROTEIN-1; HUMAN
   COLORECTAL-CANCER; MICROGLIAL ACTIVATION; CELL-SURVIVAL; VASCULAR
   INTEGRITY; GENE-EXPRESSION; WNT PATHWAY; CROSS-TALK; KAPPA-B
AB Wnt1 inducible signaling pathway protein 1 (WISP1/CCN4) is a CCN family member more broadly identified with development and tumorigenesis. However, recent studies have shed new light and enthusiasm on WISP1 as a novel target directed against toxic cell degeneration. Here we show WISP1 prevents apoptotic degeneration in primary neurons during oxidant stress through the activation of protein kinase B (Akt1), the post-translational maintenance of beta-catenin integrity that is consistent with inhibition of glycogen synthase kinase-3 beta (GSK-3 beta), and the subcellular trafficking of beta-catenin to foster its translocation to the nucleus. Interestingly, WISP1 autoregulates its expression through the promotion of beta-catenin activity and may employ beta-catenin to have a limited control over autophagy, but neuronal injury during oxidant stress as a result of autophagy appears portioned to a small population of neurons without significant impact upon overall cell survival. New strategies that target WISP1, its autoregulation, and the pathways responsible for neuronal cell injury may bring forth new insight for the treatment of neurodegenerative disorders.
C1 [Maiese, Kenneth] New Jersey Hlth Sci Univ, Ctr Canc, Lab Cellular & Mol Signaling, Newark, NJ 07101 USA.
   [Maiese, Kenneth] New Jersey Hlth Sci Univ, Canc Inst New Jersey, Newark, NJ 07101 USA.
RP Maiese, K (corresponding author), New Jersey Hlth Sci Univ, Ctr Canc, Lab Cellular & Mol Signaling, F 1220,205 S Orange Ave, Newark, NJ 07101 USA.
EM wntin75@yahoo.com
RI Wang, Shaohui/G-7247-2012
FU American Diabetes AssociationAmerican Diabetes Association; American
   Heart Association (National)American Heart Association; Bugher
   FoundationAmerican Heart Association; LEARN Foundation; NIH NIEHSUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Environmental Health
   Sciences (NIEHS); NIH NIAUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   on Aging (NIA); NIH NINDSUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Neurological Disorders & Stroke (NINDS); NIH ARRAUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USA; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Neurological Disorders &
   Stroke (NINDS) [R01NS053946] Funding Source: NIH RePORTER
FX This research was supported by the following grants to Kenneth Maiese:
   American Diabetes Association, American Heart Association (National),
   Bugher Foundation Award, LEARN Foundation Award, NIH NIEHS, NIH NIA, NIH
   NINDS, and NIH ARRA.
CR Adachi K, 2007, STEM CELLS, V25, P2827, DOI 10.1634/stemcells.2007-0177
   Al Sweidi S, 2012, J NEUROENDOCRINOL, V24, P48, DOI 10.1111/j.1365-2826.2011.02193.x
   Balan V, 2008, J BIOL CHEM, V283, P27810, DOI 10.1074/jbc.M804681200
   Baryawno N, 2010, CANCER RES, V70, P266, DOI 10.1158/0008-5472.CAN-09-0578
   Berschneider B, 2011, INT J BIOCHEM CELL B, V43, P306, DOI 10.1016/j.biocel.2010.11.013
   Case N, 2008, J BIOL CHEM, V283, P29196, DOI 10.1074/jbc.M801907200
   Chattopadhyay M, 2009, BRAIN, V132, P879, DOI 10.1093/brain/awp014
   Chong ZZ, 2007, BRIT J PHARMACOL, V150, P839, DOI 10.1038/sj.bjp.0707161
   Chong ZZ, 2007, CELL SIGNAL, V19, P1150, DOI 10.1016/j.cellsig.2006.12.009
   Chong ZZ, 2007, INT J MOL MED, V19, P263
   Chong ZZ, 2006, CURR NEUROVASC RES, V3, P107, DOI 10.2174/156720206776875830
   Chong ZZ, 2012, EXPERT OPIN THER TAR, V16, P167, DOI 10.1517/14728222.2012.648926
   Chong ZZ, 2011, CURR NEUROVASC RES, V8, P103
   Chong ZZ, 2010, OXID MED CELL LONGEV, V3, P153, DOI 10.4161/oxim.3.2.11758
   Chong ZZ, 2005, CURR NEUROVASC RES, V2, P387, DOI 10.2174/156720205774962683
   Chong ZZ, 2005, CURR NEUROVASC RES, V2, P197, DOI 10.2174/1567202054368317
   Chong ZZ, 2005, HISTOL HISTOPATHOL, V20, P299, DOI 10.14670/HH-20.299
   Chong ZZ, 2004, J CEREBR BLOOD F MET, V24, P728, DOI 10.1097/01.WCB.0000122746.72175.0E
   Chong ZZ, 2003, CELL MOL NEUROBIOL, V23, P561, DOI 10.1023/A:1025158314016
   Chong ZZ, 2003, BRIT J PHARMACOL, V138, P1107, DOI 10.1038/sj.bjp.0705161
   Chong ZZ, 2003, J CEREBR BLOOD F MET, V23, P320, DOI 10.1097/01.WCB.0000050061.57184.AE
   Chong ZZ, 2002, CIRCULATION, V106, P2973, DOI 10.1161/01.CIR.0000039103.58920.1F
   Chonga ZZ, 2004, EXP CELL RES, V296, P196, DOI 10.1016/j.yexcr.2004.01.021
   Chugh P, 2007, J MOL BIOL, V366, P67, DOI 10.1016/j.jmb.2006.11.011
   Colston JT, 2007, AM J PHYSIOL-HEART C, V293, pH1839, DOI 10.1152/ajpheart.00428.2007
   Davies SR, 2010, INT J ONCOL, V36, P1129, DOI 10.3892/ijo_00000595
   French DM, 2004, AM J PATHOL, V165, P855, DOI 10.1016/S0002-9440(10)63348-2
   Ghanevati M, 2005, J MOL NEUROSCI, V25, P79, DOI 10.1385/JMN:25:1:079
   He BA, 2005, ONCOGENE, V24, P3054, DOI 10.1038/sj.onc.1208511
   Heise RL, 2011, J BIOL CHEM, V286, P17435, DOI 10.1074/jbc.M110.137273
   Hosokawa N, 2009, MOL BIOL CELL, V20, P1981, DOI 10.1091/mbc.E08-12-1248
   Hou CH, 2011, BIOCHEM PHARMACOL, V81, P1286, DOI 10.1016/j.bcp.2011.03.016
   Hou JL, 2011, CURR NEUROVASC RES, V8, P220, DOI 10.2174/156720211796558069
   Hou JL, 2010, MOL CELL ENDOCRINOL, V321, P194, DOI 10.1016/j.mce.2010.02.037
   Hou JL, 2010, CURR NEUROVASC RES, V7, P95, DOI 10.2174/156720210791184899
   Kawamoto EM, 2012, BRAZ J MED BIOL RES, V45, P58, DOI 10.1590/S0100-879X2011007500157
   Koh SH, 2009, STEM CELLS DEV, V18, P411, DOI 10.1089/scd.2008.0040
   Kohara H, 2011, BIOMATERIALS, V32, P5726, DOI 10.1016/j.biomaterials.2011.04.035
   Komandirov MA, 2011, J MOL NEUROSCI, V45, P229, DOI 10.1007/s12031-011-9499-1
   L'Episcopo F, 2011, NEUROBIOL DIS, V41, P508, DOI 10.1016/j.nbd.2010.10.023
   L'Episcopo F, 2012, J NEUROSCI, V32, P2062, DOI 10.1523/JNEUROSCI.5259-11.2012
   Lee HN, 2010, NEUROCHEM RES, V35, P114, DOI 10.1007/s11064-009-0036-3
   Li F, 2006, HISTOL HISTOPATHOL, V21, P103, DOI 10.14670/HH-21.103
   Li F, 2006, CURR NEUROVASC RES, V3, P187, DOI 10.2174/156720206778018758
   Lin SH, 2000, J CEREBR BLOOD F MET, V20, P1380, DOI 10.1097/00004647-200009000-00013
   Liu JQ, 2012, J DERMATOL SCI, V65, P38, DOI 10.1016/j.jdermsci.2011.09.012
   Liu YL, 2011, CURR CANCER DRUG TAR, V11, P1098, DOI 10.2174/156800911798073041
   Maiese K, 2011, ROM J MORPHOL EMBRYO, V52, P1173
   Maiese K, 2005, JAMA-J AM MED ASSOC, V293, P90, DOI 10.1001/jama.293.1.90
   Maiese K, 2008, PHARMACOL THERAPEUT, V118, P58, DOI 10.1016/j.pharmthera.2008.01.004
   Maiese K, 2007, CURR MED CHEM, V14, P1729
   Maiese K, 2009, MED RES REV, V29, P395, DOI 10.1002/med.20139
   Mannell HK, 2012, CARDIOVASC RES, V93, P111, DOI 10.1093/cvr/cvr265
   Marchand A, 2011, AGING CELL, V10, P220, DOI 10.1111/j.1474-9726.2010.00661.x
   Fernandez-Martos CM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027000
   Nagai Y, 2011, ANTICANCER RES, V31, P991
   Nguyen TMB, 2009, J CELL MOL MED, V13, P3687, DOI 10.1111/j.1582-4934.2009.00722.x
   Pennica D, 1998, P NATL ACAD SCI USA, V95, P14717, DOI 10.1073/pnas.95.25.14717
   Pineda D, 2012, GLIA, V60, P526, DOI 10.1002/glia.22284
   Price RM, 2004, J AM COLL SURGEONS, V199, P411, DOI 10.1016/j.jamcollsurg.2004.04.023
   Qin AP, 2010, AUTOPHAGY, V6, P738, DOI 10.4161/auto.6.6.12573
   Reddy VS, 2011, J CELL PHYSIOL, V226, P3303, DOI 10.1002/jcp.22676
   Seibenhener ML, 2004, MOL CELL BIOL, V24, P8055, DOI 10.1128/MCB.24.18.8055-8068.2004
   Shahjee HM, 2010, J EXP CLIN CANC RES, V29, DOI 10.1186/1756-9966-29-160
   Shang YC, 2012, AGING-US, V4, P187, DOI 10.18632/aging.100440
   Shang YC, 2011, CURR NEUROVASC RES, V8, P270
   Shang YC, 2009, CURR NEUROVASC RES, V6, P223, DOI 10.2174/156720209789630302
   Shang YC, 2009, CURR NEUROVASC RES, V6, P20, DOI 10.2174/156720209787466064
   Shanmugam P, 2011, J MOL CELL CARDIOL, V50, P928, DOI 10.1016/j.yjmcc.2011.02.012
   Shen JF, 2010, INVEST OPHTH VIS SCI, V51, P35, DOI 10.1167/iovs.09-3544
   Su F, 2002, GENE DEV, V16, P46, DOI 10.1101/gad.942902
   Su KH, 2011, J CELL PHYSIOL, V226, P3330, DOI 10.1002/jcp.22678
   Toba H, 2009, EUR J PHARMACOL, V612, P106, DOI 10.1016/j.ejphar.2009.03.065
   Toku AE, 2011, COMPUT BIOL CHEM, V35, P282, DOI 10.1016/j.compbiolchem.2011.07.002
   Venkatachalam K, 2009, J BIOL CHEM, V284, P14414, DOI 10.1074/jbc.M809757200
   Venkatesan B, 2010, CELL SIGNAL, V22, P809, DOI 10.1016/j.cellsig.2010.01.005
   VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241
   Wang SH, 2012, CURR NEUROVASC RES, V9, P20, DOI 10.2174/156720212799297137
   Wang XH, 2010, ONCOL REP, V24, P1093, DOI 10.3892/or_00000960
   Wang YS, 2012, AM J TRANSL RES, V4, P44
   Wymann MP, 1996, MOL CELL BIOL, V16, P1722
   Xin XY, 2011, CAN J NEUROL SCI, V38, P631, DOI 10.1017/S031716710001218X
   Xu LF, 2000, GENE DEV, V14, P585
   Yeger H, 2007, J CELL COMMUN SIGNAL, V1, P159, DOI 10.1007/s12079-008-0022-6
   You ZB, 2002, J CELL BIOL, V157, P429, DOI 10.1083/jcb.200201110
   Zeng KW, 2011, EUR J PHARMACOL, V672, P45, DOI 10.1016/j.ejphar.2011.09.177
   Zhang FJ, 2012, J PHARM PHARMACOL, V64, P120, DOI 10.1111/j.2042-7158.2011.01382.x
   Zhou XP, 2011, IMMUNOPHARM IMMUNOT, V33, P594, DOI 10.3109/08923973.2010.549135
NR 88
TC 23
Z9 26
U1 0
U2 3
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1567-2026
EI 1875-5739
J9 CURR NEUROVASC RES
JI Curr. Neurovasc. Res.
PD MAY
PY 2012
VL 9
IS 2
BP 91
EP 101
DI 10.2174/156720212800410858
PG 11
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 934UR
UT WOS:000303472700003
PM 22475393
OA Green Accepted
DA 2022-04-25
ER

PT J
AU Wang, LH
   Li, MM
   Sha, BB
   Hu, XY
   Sun, YX
   Zhu, MD
   Xu, Y
   Li, PP
   Wang, YT
   Guo, YN
   Li, JF
   Shi, JX
   Li, P
   Hu, T
   Chen, P
AF Wang, Longhao
   Li, Miaomiao
   Sha, Beibei
   Hu, Xuanyu
   Sun, Yaxin
   Zhu, Mingda
   Xu, Yan
   Li, Pingping
   Wang, Yating
   Guo, Yanyan
   Li, Jiangfeng
   Shi, Jianxiang
   Li, Pei
   Hu, Tao
   Chen, Ping
TI Inhibition of deubiquitination by PR-619 induces apoptosis and autophagy
   via ubi-protein aggregation-activated ER stress in oesophageal squamous
   cell carcinoma
SO CELL PROLIFERATION
LA English
DT Article
DE apoptosis; autophagy; ER stress; oesophageal squamous cell carcinoma;
   PR&#8208; 619
ID SMALL-MOLECULE INHIBITOR; ENDOPLASMIC-RETICULUM STRESS;
   COLORECTAL-CANCER; MULTIPLE-MYELOMA; OVARIAN-CANCER; ENZYME USP14;
   CAMKK-BETA; EXPRESSION; AMPK; PROLIFERATION
AB Objectives Targeting the deubiquitinases (DUBs) has become a promising avenue for anti-cancer drug development. However, the effect and mechanism of pan-DUB inhibitor, PR-619, on oesophageal squamous cell carcinoma (ESCC) cells remain to be investigated.
   Materials and Methods The effect of PR-619 on ESCC cell growth and cell cycle was evaluated by CCK-8 and PI staining. Annexin V-FITC/PI double staining was performed to detect apoptosis. LC3 immunofluorescence and acridine orange staining were applied to examine autophagy. Intercellular Ca2+ concentration was monitored by Fluo-3AM fluorescence. The accumulation of ubi-proteins and the expression of the endoplasmic reticulum (ER) stress-related protein and CaMKK beta-AMPK signalling were determined by immunoblotting.
   Results PR-619 could inhibit ESCC cell growth and induce G2/M cell cycle arrest by downregulating cyclin B1 and upregulating p21. Meanwhile, PR-619 led to the accumulation of ubiquitylated proteins, induced ER stress and triggered apoptosis by the ATF4-Noxa axis. Moreover, the ER stress increased cytoplasmic Ca2+ and then stimulated autophagy through Ca2+-CaMKK beta-AMPK signalling pathway. Ubiquitin E1 inhibitor, PYR-41, could reduce the accumulation of ubi-proteins and alleviate ER stress, G2/M cell cycle arrest, apoptosis and autophagy in PR-619-treated ESCC cells. Furthermore, blocking autophagy by chloroquine or bafilomycin A1 enhanced the cell growth inhibition effect and apoptosis induced by PR-619.
   Conclusions Our findings reveal an unrecognized mechanism for the cytotoxic effects of general DUBs inhibitor (PR-619) and imply that targeting DUBs may be a potential anti-ESCC strategy.
C1 [Wang, Longhao; Li, Miaomiao; Sha, Beibei; Hu, Xuanyu; Sun, Yaxin; Zhu, Mingda; Xu, Yan; Li, Pingping; Wang, Yating; Guo, Yanyan; Li, Jiangfeng; Li, Pei; Hu, Tao; Chen, Ping] Zhengzhou Univ, Acad Med Sci, Sch Basic Med Sci, Zhengzhou, Peoples R China.
   [Shi, Jianxiang] Zhengzhou Univ, Henan Inst Med & Pharmaceut Sci, Precis Med Ctr, Zhengzhou, Peoples R China.
   [Shi, Jianxiang] Zhengzhou Univ, BGI Coll, Zhengzhou, Peoples R China.
   [Chen, Ping] Zhengzhou Univ, Henan Key Lab Precis Clin Pharm, Affiliated Hosp 1, Zhengzhou, Peoples R China.
RP Hu, T; Chen, P (corresponding author), Zhengzhou Univ, Sch Basic Med Sci, Zhengzhou 450001, Peoples R China.
EM hnhutao@zzu.edu.cn; zzdx_chenping@zzu.edu.cn
FU Program for Innovation Research Team (in Science and Technology) in
   University of Henan Province [20IRTSTHN026]; National Natural Science
   Foundation Grant of ChinaNational Natural Science Foundation of China
   (NSFC) [81672421]; Program for Science&Technology Innovation Talents in
   Universities of Henan Province [18HASTIT046]; Outstanding Young Talent
   Research Fund of Zhengzhou University [51999223, 32210449]; Henan Key
   Laboratory of Precision Clinical Pharmacy
FX Program for Innovation Research Team (in Science and Technology) in
   University of Henan Province, Grant/Award Number: 20IRTSTHN026; National
   Natural Science Foundation Grant of China, Grant/Award Number: 81672421;
   Program for Science&Technology Innovation Talents in Universities of
   Henan Province, Grant/Award Number: 18HASTIT046; Outstanding Young
   Talent Research Fund of Zhengzhou University, Grant/Award Number:
   51999223 and 32210449; Open Program of Henan Key Laboratory of Precision
   Clinical Pharmacy
CR Albert MC, 2014, MOL CELL ONCOL, V1, DOI 10.4161/mco.29906
   Altun M, 2011, CHEM BIOL, V18, P1401, DOI 10.1016/j.chembiol.2011.08.018
   An T, 2017, BIOCHEM PHARMACOL, V131, P29, DOI 10.1016/j.bcp.2017.02.011
   Boutros R, 2007, NAT REV CANCER, V7, P495, DOI 10.1038/nrc2169
   Cai JY, 2017, ONCOTARGET, V8, P63232, DOI 10.18632/oncotarget.18774
   Chauhan D, 2012, CANCER CELL, V22, P345, DOI 10.1016/j.ccr.2012.08.007
   Chen P, 2016, CLIN CANCER RES, V22, P4145, DOI 10.1158/1078-0432.CCR-15-2254
   Chen P, 2015, ONCOTARGET, V6, P9002, DOI 10.18632/oncotarget.3282
   Cheng CD, 2013, ONCOL REP, V29, P1730, DOI 10.3892/or.2013.2342
   Cheng J, 2019, BBA-REV CANCER, V1872, DOI 10.1016/j.bbcan.2019.188312
   Coughlin K, 2014, CLIN CANCER RES, V20, P3174, DOI 10.1158/1078-0432.CCR-13-2658
   Crowder RN, 2016, J BIOL CHEM, V291, P5960, DOI 10.1074/jbc.M115.713545
   D'Arcy P, 2011, NAT MED, V17, P1636, DOI 10.1038/nm.2536
   Deshmukh RR, 2015, BREAST CANCER RES TR, V153, P79, DOI 10.1007/s10549-015-3512-2
   Ding X, 2010, JNCI-J NATL CANCER I, V102, P1052, DOI 10.1093/jnci/djq217
   Farshi P, 2015, EXPERT OPIN THER PAT, V25, P1191, DOI 10.1517/13543776.2015.1056737
   Fischle W, 2005, NATURE, V438, P1116, DOI 10.1038/nature04219
   He YT, 2019, CHINESE J CANCER RES, V31, P426, DOI 10.21147/j.issn.1000-9604.2019.03.04
   Hou YS, 2015, MOL CELL BIOL, V35, P2740, DOI 10.1128/MCB.00285-15
   Hoyer-Hansen M, 2007, MOL CELL, V25, P193, DOI 10.1016/j.molcel.2006.12.009
   Hu T, 2019, MOL CARCINOGEN, V58, P42, DOI 10.1002/mc.22905
   Iurlaro R, 2016, FEBS J, V283, P2640, DOI 10.1111/febs.13598
   Jacomin AC, 2018, CELLS-BASEL, V7, DOI 10.3390/cells7080112
   Jayasooriya RGPT, 2018, FOOD CHEM TOXICOL, V121, P648, DOI 10.1016/j.fct.2018.09.057
   Jiang SN, 2015, CELL SIGNAL, V27, P1186, DOI 10.1016/j.cellsig.2015.02.024
   Kuo KL, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8101268
   Lee BSL, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00489
   Lee G, 2016, BIOCHEM BIOPH RES CO, V470, P181, DOI 10.1016/j.bbrc.2016.01.021
   Lim KH, 2013, CURR PHARM DESIGN, V19, P4039, DOI 10.2174/1381612811319220013
   Lin S, 2018, ONCOL LETT, V15, P2583, DOI 10.3892/ol.2017.7616
   Lin ZH, 2015, CELL DISCOV, V1, DOI 10.1038/celldisc.2015.28
   Ling SB, 2012, CELL MOL BIOL, V58, P1803, DOI 10.1170/213
   Liu B, 2019, PATHOL RES PRACT, V215, DOI 10.1016/j.prp.2019.152592
   Ma M, 2016, ONCOTARGETS THER, V9, P1559, DOI 10.2147/OTT.S100050
   Min H, 2014, CANCER CHEMOTH PHARM, V74, P167, DOI 10.1007/s00280-014-2451-7
   Monda JK, 2018, OPEN BIOL, V8, DOI 10.1098/rsob.180095
   Nacarelli T, 2019, NAT CELL BIOL, V21, P397, DOI 10.1038/s41556-019-0287-4
   Oh YT, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08424-w
   Poondla N, 2019, BMB REP, V52, P181, DOI 10.5483/BMBRep.2019.52.3.048
   Sarcar B, 2011, MOL CANCER THER, V10, P2405, DOI 10.1158/1535-7163.MCT-11-0469
   Seiberlich V, 2013, CELL BIOCHEM BIOPHYS, V67, P149, DOI 10.1007/s12013-013-9622-8
   Seiberlich V, 2012, BBA-MOL CELL RES, V1823, P2057, DOI 10.1016/j.bbamcr.2012.04.011
   Setz C, 2017, VIRUSES-BASEL, V9, DOI 10.3390/v9080222
   Sha B, 2019, APOPTOSIS, V24, P826, DOI 10.1007/s10495-019-01561-9
   Shinji S, 2006, ONCOL REP, V15, P539
   Siegel RL, 2019, CA-CANCER J CLIN, V69, P7, DOI 10.3322/caac.21551
   Soji K, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0202409
   Thome MP, 2016, J CELL SCI, V129, P4622, DOI 10.1242/jcs.195057
   Tian Z, 2014, BLOOD, V123, P706, DOI 10.1182/blood-2013-05-500033
   Wang HB, 2019, BIOCHEM BIOPH RES CO, V517, P477, DOI 10.1016/j.bbrc.2019.07.100
   Wang MY, 2017, CELL PHYSIOL BIOCHEM, V43, P1755, DOI 10.1159/000484062
   Wang YY, 2015, MED ONCOL, V32, DOI 10.1007/s12032-014-0379-8
   Wong VKW, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.217
   Wu N, 2013, INT J MOL SCI, V14, P10749, DOI 10.3390/ijms140610749
   Xi HB, 2013, BIOCHEM PHARMACOL, V85, P1463, DOI 10.1016/j.bcp.2013.02.037
   Yi YJ, 2015, REPROD FERT DEVELOP, V27, P1154, DOI 10.1071/RD14012
   Young MJ, 2019, J BIOMED SCI, V26, DOI 10.1186/s12929-019-0522-0
   Yuan T, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01080
   Zhang BH, 2017, THORAC CANCER, V8, P344, DOI 10.1111/1759-7714.12453
   Zhang L, 2016, TOHOKU J EXP MED, V239, P165, DOI 10.1620/tjem.239.165
NR 60
TC 6
Z9 6
U1 7
U2 11
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0960-7722
EI 1365-2184
J9 CELL PROLIFERAT
JI Cell Prolif.
PD JAN
PY 2021
VL 54
IS 1
AR e12919
DI 10.1111/cpr.12919
EA OCT 2020
PG 17
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA PS9LS
UT WOS:000582979200001
PM 33129231
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Pan, SJ
   Hong, F
   Li, LT
   Guo, Y
   Qiao, XX
   Zhang, J
   Xu, PF
   Zhai, YG
AF Pan, Shijia
   Hong, Fan
   Li, Letong
   Guo, Yuan
   Qiao, Xiaoxiao
   Zhang, Jia
   Xu, Pengfei
   Zhai, Yonggong
TI Melatonin Attenuates Dextran Sodium Sulfate Induced Colitis in Obese
   Mice
SO PHARMACEUTICALS
LA English
DT Article
DE melatonin; obesity; colitis; lipolysis; autophagy
ID INFLAMMATORY-BOWEL-DISEASE; DIET-INDUCED OBESITY; OXIDATIVE STRESS;
   EPITHELIAL-CELLS; ANTIOXIDANT DEFENSES; COLORECTAL-CANCER;
   CROHNS-DISEASE; ADIPOSE-TISSUE; PPAR-GAMMA; TNF-ALPHA
AB Epidemiological studies have indicated that obesity is an independent risk factor for colitis and that a high-fat diet (HFD) increases the deterioration of colitis-related indicators in mice. Melatonin has multiple anti-inflammatory effects, including inhibiting tumor growth and regulating immune defense. However, the mechanism of its activity in ameliorating obesity-promoted colitis is still unclear. This study explored the possibility that melatonin has beneficial functions in HFD-induced dextran sodium sulfate (DSS)-induced colitis in mice. Here, we revealed that HFD-promoted obesity accelerated DSS-induced colitis, while melatonin intervention improved colitis. Melatonin significantly alleviated inflammation by increasing anti-inflammatory cytokine release and reducing the levels of proinflammatory cytokines in HFD- and DSS-treated mice. Furthermore, melatonin expressed antioxidant activities and reversed intestinal barrier integrity, resulting in improved colitis in DSS-treated obese mice. We also found that melatonin could reduce the ability of inflammatory cells to utilize fatty acids and decrease the growth-promoting effect of lipids by inhibiting autophagy. Taken together, our study indicates that the inhibitory effect of melatonin on autophagy weakens the lipid-mediated prosurvival advantage, which suggests that melatonin-targeted autophagy may provide an opportunity to prevent colitis in obese individuals.
C1 [Pan, Shijia; Hong, Fan; Li, Letong; Guo, Yuan; Qiao, Xiaoxiao; Zhang, Jia; Xu, Pengfei; Zhai, Yonggong] Beijing Normal Univ, Coll Life Sci, Beijing Key Lab Gene Resource & Mol Dev, Beijing 100875, Peoples R China.
   [Pan, Shijia; Hong, Fan; Li, Letong; Guo, Yuan; Qiao, Xiaoxiao; Zhang, Jia; Zhai, Yonggong] Beijing Normal Univ, Coll Life Sci, State Educ Minist, Key Lab Cell Proliferat & Regulat Biol, Beijing 100875, Peoples R China.
   [Xu, Pengfei] Univ Pittsburgh, Ctr Pharmacogenet, Pittsburgh, PA 15261 USA.
   [Xu, Pengfei] Univ Pittsburgh, Dept Pharmaceut Sci, Pittsburgh, PA 15261 USA.
RP Xu, PF; Zhai, YG (corresponding author), Beijing Normal Univ, Coll Life Sci, Beijing Key Lab Gene Resource & Mol Dev, Beijing 100875, Peoples R China.; Zhai, YG (corresponding author), Beijing Normal Univ, Coll Life Sci, State Educ Minist, Key Lab Cell Proliferat & Regulat Biol, Beijing 100875, Peoples R China.; Xu, PF (corresponding author), Univ Pittsburgh, Ctr Pharmacogenet, Pittsburgh, PA 15261 USA.; Xu, PF (corresponding author), Univ Pittsburgh, Dept Pharmaceut Sci, Pittsburgh, PA 15261 USA.
EM 201931200003@mail.bnu.edu.cn; hongfanky@126.com;
   201921200016@mail.bnu.edu.cn; gy5326@126.com;
   201921200023@mail.bnu.edu.cn; 202021200029@mail.bnu.edu.cn;
   PEX9@pitt.edu; ygzhai@bnu.edu.cn
OI Xu, Pengfei/0000-0001-6854-6040
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [31571164, 82070901]; BNU Interdisciplinary
   Research Foundation for First-Year Doctoral Candidates [BNUXKJC1924]
FX This research was funded by the National Natural Science Foundation of
   China (NO. 31571164 and NO. 82070901). This research was also supported
   by the BNU Interdisciplinary Research Foundation for First-Year Doctoral
   Candidates (Grant NO. BNUXKJC1924).
CR Agus A, 2018, CELL HOST MICROBE, V23, P716, DOI 10.1016/j.chom.2018.05.003
   Akcan A, 2008, WORLD J GASTROENTERO, V14, P918, DOI 10.3748/wjg.14.918
   Alzoghaibi MA, 2013, WORLD J GASTROENTERO, V19, P6540, DOI 10.3748/wjg.v19.i39.6540
   Aouichat S, 2021, PHARMACEUTICALS-BASE, V14, DOI 10.3390/ph14030232
   Azad MB, 2009, ANTIOXID REDOX SIGN, V11, P777, DOI 10.1089/ARS.2008.2270
   Barollo M, 2011, WORLD J GASTROENTERO, V17, P4099, DOI 10.3748/wjg.v17.i36.4099
   Bibi S, 2017, NUTRIENTS, V9, DOI 10.3390/nu9050509
   Bilski J, 2019, BIOMOLECULES, V9, DOI 10.3390/biom9120780
   Bilski J, 2019, NUTRIENTS, V11, DOI 10.3390/nu11051127
   Blain A, 2002, CLIN NUTR, V21, P51, DOI 10.1054/clnu.2001.0503
   Borniquel S, 2012, J NUTR, V142, P2135, DOI 10.3945/jn.112.163931
   Braun K, 2018, J EXP BIOL, V221, DOI 10.1242/jeb.165381
   Bubenik GA, 2002, DIGEST DIS SCI, V47, P2336, DOI 10.1023/A:1020107915919
   BUBENIK GA, 1980, HORM RES, V12, P313, DOI 10.1159/000179137
   BUFFINTON GD, 1995, FREE RADICAL BIO MED, V19, P911, DOI 10.1016/0891-5849(95)94362-H
   Caradonna L, 2000, J ENDOTOXIN RES, V6, P205, DOI 10.1177/09680519000060030101
   Carrillo-Vico A, 2013, INT J MOL SCI, V14, P8638, DOI 10.3390/ijms14048638
   Cetinkaya A, 2006, DIGEST DIS SCI, V51, P488, DOI 10.1007/s10620-006-3160-9
   Chamanara M, 2019, INFLAMMOPHARMACOLOGY, V27, P361, DOI 10.1007/s10787-018-0523-8
   Chao YC, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22115649
   Chen DM, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10081158
   Cheng L, 2016, INT IMMUNOPHARMACOL, V40, P1, DOI 10.1016/j.intimp.2016.08.018
   Chojnacki C, 2011, J PHYSIOL PHARMACOL, V62, P327
   COOPER HS, 1993, LAB INVEST, V69, P238
   Crespo I, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050407
   Cuellar-Nunez ML, 2021, FOOD RES INT, V144, DOI 10.1016/j.foodres.2021.110318
   Ding XM, 2018, LAB INVEST, V98, P462, DOI 10.1038/s41374-017-0005-4
   Ehrlich AC, 2017, EXPERT REV ANTICANC, V17, P247, DOI 10.1080/14737140.2017.1283987
   Esteban-Zubero E, 2017, LIFE SCI, V170, P72, DOI 10.1016/j.lfs.2016.11.031
   Galluzzi L, 2014, CELL, V159, P1263, DOI 10.1016/j.cell.2014.11.006
   Gao T, 2019, J PINEAL RES, V67, DOI 10.1111/jpi.12574
   Harper JW, 2016, WORLD J GASTROENTERO, V22, P7868, DOI 10.3748/wjg.v22.i35.7868
   Hong F, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9020489
   Iwamoto M, 1996, J PATHOL, V180, P152
   Jiang Y, 2021, BIOMOLECULES, V11, DOI 10.3390/biom11070968
   Jimenez-Aranda A, 2013, J PINEAL RES, V55, P416, DOI 10.1111/jpi.12089
   Kaczmarek-Szczepanska B, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22115658
   Kaplan GG, 2017, GASTROENTEROLOGY, V152, P313, DOI 10.1053/j.gastro.2016.10.020
   Khaldoun SA, 2014, MOL BIOL CELL, V25, P118, DOI 10.1091/mbc.E13-06-0324
   Kim SW, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-59314-7
   Koch TR, 2000, DIGEST DIS SCI, V45, P1814, DOI 10.1023/A:1005517824877
   Kostic AD, 2014, GASTROENTEROLOGY, V146, P1489, DOI 10.1053/j.gastro.2014.02.009
   Kreuter R, 2019, BBA-MOL BASIS DIS, V1865, P63, DOI 10.1016/j.bbadis.2018.10.020
   Lalanne S, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22031490
   Levine B, 2011, NATURE, V469, P323, DOI 10.1038/nature09782
   Li X, 2020, INFLAMMATION, V43, P1884, DOI 10.1007/s10753-020-01261-6
   LihBrody L, 1996, DIGEST DIS SCI, V41, P2078, DOI 10.1007/BF02093613
   Lin NY, 2013, AUTOPHAGY, V9, P1253, DOI 10.4161/auto.25467
   Liu K, 2013, CELL DEATH DIFFER, V20, P3, DOI 10.1038/cdd.2012.63
   Liu KQ, 2019, J LIPID RES, V60, P767, DOI [10.1194/jlr.M087619, 10.1194/jlr.m087619]
   Liu XW, 2019, INT IMMUNOPHARMACOL, V73, P108, DOI 10.1016/j.intimp.2019.05.005
   Losurdo G, 2020, WORLD J GASTROENTERO, V26, P7528, DOI 10.3748/wjg.v26.i47.7528
   Luzardo-Ocampo I, 2020, FOOD RES INT, V132, DOI 10.1016/j.foodres.2020.109097
   Lv WJ, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/1241894
   Ma N, 2020, MED RES REV, V40, P606, DOI 10.1002/med.21628
   Mahdavi NS, 2019, RES PHARM SCI, V14, P391, DOI 10.4103/1735-5362.268199
   Mahler M, 1998, AM J PHYSIOL-GASTR L, V274, pG544, DOI 10.1152/ajpgi.1998.274.3.G544
   Mathew R, 2011, COLD SH Q B, V76, P389, DOI 10.1101/sqb.2012.76.011015
   Mazzon E, 2006, J PINEAL RES, V41, P363, DOI 10.1111/j.1600-079X.2006.00378.x
   Mhalhel K, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21249597
   Moore MN, 2007, AQUAT TOXICOL, V84, P80, DOI 10.1016/j.aquatox.2007.06.007
   Muzes G, 2012, WORLD J GASTROENTERO, V18, P5848, DOI 10.3748/wjg.v18.i41.5848
   Nduhirabandi F, 2016, J PINEAL RES, V60, P39, DOI 10.1111/jpi.12286
   Perez CCN, 2006, PHARMACOL RES, V54, P345, DOI 10.1016/j.phrs.2006.07.001
   Ostrycharz E, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21249667
   Owczarek D, 2016, WORLD J GASTROENTERO, V22, P895, DOI 10.3748/wjg.v22.i3.895
   Paik J, 2013, J NUTR, V143, P1240, DOI 10.3945/jn.113.174615
   Park JH, 2020, J PINEAL RES, V68, DOI 10.1111/jpi.12623
   Peterson LW, 2014, NAT REV IMMUNOL, V14, P141, DOI 10.1038/nri3608
   Peyrin-Biroulet L, 2007, GUT, V56, P577, DOI 10.1136/gut.2005.082925
   Ranjbaran Z, 2007, INFLAMM RES, V56, P51, DOI 10.1007/s00011-006-6067-1
   Ranjbaran Z, 2007, J GASTROEN HEPATOL, V22, P1748, DOI 10.1111/j.1440-1746.2006.04820.x
   Ren WK, 2018, J PINEAL RES, V64, DOI 10.1111/jpi.12448
   Ren WK, 2017, J PINEAL RES, V62, DOI 10.1111/jpi.12394
   Rocha R, 2009, BRIT J NUTR, V101, P676, DOI 10.1017/S0007114508032224
   Roy J, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22136841
   Rozich JJ, 2020, AM J GASTROENTEROL, V115, P832, DOI 10.14309/ajg.0000000000000608
   RUGTVEIT J, 1994, GUT, V35, P669, DOI 10.1136/gut.35.5.669
   Ryu V, 2018, PHYSIOL BEHAV, V190, P11, DOI 10.1016/j.physbeh.2017.07.011
   Salim SY, 2011, INFLAMM BOWEL DIS, V17, P362, DOI 10.1002/ibd.21403
   Sartor RB, 2008, GASTROENTEROLOGY, V134, P577, DOI 10.1053/j.gastro.2007.11.059
   Satyanarayanan SK, 2018, CURR PHARM DESIGN, V24, P2549, DOI 10.2174/1381612824666180803112304
   Scherz-Shouval R, 2019, EMBO J, V38, DOI 10.15252/embj.2019101812
   Schicho R, 2011, INFLAMM BOWEL DIS, V17, P1651, DOI 10.1002/ibd.21538
   Schwanke RC, 2013, MOL NUTR FOOD RES, V57, P1938, DOI 10.1002/mnfr.201300134
   Seril DN, 2003, CARCINOGENESIS, V24, P353, DOI 10.1093/carcin/24.3.353
   Silvestri C, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.585096
   Singh MK, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10091243
   Singh R, 2009, NATURE, V458, P1131, DOI 10.1038/nature07976
   Sotak M, 2006, J PINEAL RES, V41, P183, DOI 10.1111/j.1600-079X.2006.00355.x
   Strater J, 1997, GASTROENTEROLOGY, V113, P160, DOI 10.1016/S0016-5085(97)70091-X
   Teixeira LG, 2011, LIPIDS HEALTH DIS, V10, DOI 10.1186/1476-511X-10-204
   Tilg H, 2006, NAT REV IMMUNOL, V6, P772, DOI 10.1038/nri1937
   Truter D, 2018, ACTA HISTOCHEM, V120, P347, DOI 10.1016/j.acthis.2018.03.006
   Tsvetkova AS, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22010328
   van der Logt EMJ, 2013, J NUTR BIOCHEM, V24, P1159, DOI 10.1016/j.jnutbio.2012.09.001
   Wang B, 2020, GENOM PROTEOM BIOINF, V18, P708, DOI 10.1016/j.gpb.2020.06.013
   White E, 2012, NAT REV CANCER, V12, P401, DOI 10.1038/nrc3262
   Wild GE, 2007, WORLD J GASTROENTERO, V13, P1, DOI 10.3748/wjg.v13.i1.1
   Wu HH, 2009, J BIOMED SCI, V16, DOI 10.1186/1423-0127-16-19
   Xu PF, 2021, GASTROENTEROLOGY, V161, P271, DOI 10.1053/j.gastro.2021.03.048
   Xu PF, 2017, BBA-GEN SUBJECTS, V1861, P2690, DOI 10.1016/j.bbagen.2017.07.013
   Xu PF, 2017, J PINEAL RES, V62, DOI 10.1111/jpi.12399
   Xu PF, 2017, EBIOMEDICINE, V16, P251, DOI 10.1016/j.ebiom.2017.01.019
   Ye PF, 2020, CANCERS, V12, DOI 10.3390/cancers12061408
   Zeng M, 2013, BIOCHEM BIOPH RES CO, V436, P180, DOI 10.1016/j.bbrc.2013.05.070
   Zhang H, 2021, J HAZARD MATER, V407, DOI 10.1016/j.jhazmat.2020.124489
   Zhu D, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/2607679
NR 108
TC 0
Z9 0
U1 14
U2 16
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1424-8247
J9 PHARMACEUTICALS-BASE
JI Pharmaceuticals
PD AUG
PY 2021
VL 14
IS 8
AR 822
DI 10.3390/ph14080822
PG 19
WC Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA UH6BI
UT WOS:000690013400001
PM 34451919
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU He, J
   Chen, YP
   Cai, L
   Li, ZL
   Guo, XQ
AF He, Jing
   Chen, Yuanping
   Cai, Lu
   Li, Zelei
   Guo, Xiaoqing
TI UBAP2L silencing inhibits cell proliferation and G2/M phase transition
   in breast cancer
SO BREAST CANCER
LA English
DT Article
DE Breast cancer; CDK1; Cell proliferation; Cyclin B1; G2/M phase; UBAP2L
ID UBIQUITIN-PROTEASOME SYSTEM; PROTEIN 2-LIKE; CARCINOMA CELLS;
   DOWN-REGULATION; GROWTH; AUTOPHAGY; THERAPY
AB Ubiquitin-associated protein 2-like (UBAP2L) contains a ubiquitin-associated domain near its N-terminus, which has been demonstrated to be overexpressed in multiple tumors, including hepatocellular carcinoma and colorectal carcinoma but its role has not been well studied in breast cancer. Thus, this study was designed to evaluate whether UBAP2L can serve as a potential molecular target for breast cancer therapy.
   The expression of UBAP2L was determined in breast cancer tissues and cell lines by Western blotting and Oncomine database mining. Then the expression of UBAP2L was silenced using RNA interference and the effects of UBAP2L knockdown on breast cancer cell proliferation and cell cycle progression by MTT and colony formation assay, and Flow cytometry, respectively.
   We found the expression of UBAP2L was significantly up-regulated in breast cancer tissues and cell lines. Knockdown of UBAP2L suppressed cell proliferation, impaired colony formation ability and induced cell cycle arrest at G2/M phase. At molecular levels, knockdown of UBAP2L increased p21 expression, but decreased the expression of CDK1 and Cyclin B1 in breast cancer cells.
   Our findings suggest that UBAP2L plays an important role in breast cancer cell proliferation and might serve as a potential target for breast cancer treatment.
C1 [He, Jing; Chen, Yuanping; Cai, Lu; Li, Zelei; Guo, Xiaoqing] Nanchang Univ, Dept Oncol, Affiliated Ganzhou Hosp, 17 Hongqi Ave, Ganzhou 341000, Jiangxi, Peoples R China.
RP Guo, XQ (corresponding author), Nanchang Univ, Dept Oncol, Affiliated Ganzhou Hosp, 17 Hongqi Ave, Ganzhou 341000, Jiangxi, Peoples R China.
EM guoxiaoQ_0102@126.com
CR Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100
   Baumgartner R, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003598
   Bordeleau ME, 2014, BLOOD, V124, P2362, DOI 10.1182/blood-2014-01-548651
   Chai R, 2016, TUMOR BIOL, V37, P13225, DOI 10.1007/s13277-016-5159-y
   Ciechanover A, 2003, NEURON, V40, P427, DOI 10.1016/S0896-6273(03)00606-8
   Ford D, 1998, AM J HUM GENET, V62, P676, DOI 10.1086/301749
   Huang WW, 2013, INT J ONCOL, V42, P2069, DOI 10.3892/ijo.2013.1909
   Lee MJ, 2013, PROG NEUROBIOL, V105, P49, DOI 10.1016/j.pneurobio.2013.03.001
   Li D, 2014, ONCOL REP, V32, P1578, DOI 10.3892/or.2014.3360
   Liao YJ, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.66
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Ma XJ, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2222
   Maeda M, 2016, FASEB J, V30, P312, DOI 10.1096/fj.14-268987
   Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016
   Prat A, 2015, BREAST, V24, pS26, DOI 10.1016/j.breast.2015.07.008
   Rousseau D, 1999, ONCOGENE, V18, P4313, DOI 10.1038/sj.onc.1202686
   Siegel R, 2014, CA-CANCER J CLIN, V64, P104, DOI 10.3322/caac.21220
   Stockler M, 2000, CANCER TREAT REV, V26, P151, DOI 10.1053/ctrv.1999.0161
   Wilde IB, 2011, J PROTEOME RES, V10, P1062, DOI 10.1021/pr1008543
   Yang YL, 2009, CANCER SCI, V100, P24, DOI 10.1111/j.1349-7006.2008.01013.x
   Ye T, 2017, CELL PHYSIOL BIOCHEM, V41, P1584, DOI 10.1159/000470824
   Zhao B, 2015, INT J MOL MED, V36, P1012, DOI 10.3892/ijmm.2015.2323
   Zhao HJ, 2004, MOL BIOL CELL, V15, P2523, DOI 10.1091/mbc.E03-11-0786
NR 23
TC 15
Z9 15
U1 0
U2 6
PU SPRINGER JAPAN KK
PI TOKYO
PA CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065,
   JAPAN
SN 1340-6868
EI 1880-4233
J9 BREAST CANCER-TOKYO
JI Breast Cancer
PD MAR
PY 2018
VL 25
IS 2
BP 224
EP 232
DI 10.1007/s12282-017-0820-x
PG 9
WC Oncology; Obstetrics & Gynecology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Obstetrics & Gynecology
GA FW8AJ
UT WOS:000425549100013
PM 29196913
OA hybrid, Green Published
DA 2022-04-25
ER

PT J
AU Lee, CS
   Lee, LC
   Yuan, TL
   Chakka, S
   Fellmann, C
   Lowe, SW
   Caplen, NJ
   McCormick, F
   Luo, J
AF Lee, Chih-Shia
   Lee, Liam C.
   Yuan, Tina L.
   Chakka, Sirisha
   Fellmann, Christof
   Lowe, Scott W.
   Caplen, Natasha J.
   McCormick, Frank
   Luo, Ji
TI MAP kinase and autophagy pathways cooperate to maintain RAS mutant
   cancer cell survival
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE KRAS; RAF; MAPK; autophagy; siRNA
ID INHIBITOR TRAMETINIB GSK1120212; SYNTHETIC LETHAL INTERACTIONS; IB
   DOSE-ESCALATION; LUNG-CANCER; K-RAS; C-RAF; TUMOR PROGRESSION; CYCLE
   ARREST; MOUSE MODEL; PHASE-I
AB Oncogenic mutations in the small GTPase KRAS are frequently found in human cancers, and, currently, there are no effective targeted therapies for these tumors. Using a combinatorial siRNA approach, we analyzed a panel of KRAS mutant colorectal and pancreatic cancer cell lines for their dependency on 28 gene nodes that represent canonical RAS effector pathways and selected stress response pathways. We found that RAF node knockdown best differentiated KRAS mutant and KRAS WT cancer cells, suggesting RAF kinases are key oncoeffectors for KRAS addiction. By analyzing all 376 pairwise combination of these gene nodes, we found that cotargeting the RAF, RAC, and autophagy pathways can improve the capture of KRAS dependency better than targeting RAF alone. In particular, codepletion of the oncoeffector kinases BRAF and CRAF, together with the autophagy E1 ligase ATG7, gives the best therapeutic window between KRAS mutant cells and normal, untransformed cells. Distinct patterns of RAS effector dependency were observed across KRAS mutant cell lines, indicative of heterogeneous utilization of effector and stress response pathways in supporting KRAS addiction. Our findings revealed previously unappreciated complexity in the signaling network downstream of the KRAS oncogene and suggest rational target combinations for more effective therapeutic intervention.
C1 [Lee, Chih-Shia; Lee, Liam C.; Luo, Ji] NCI, Lab Canc Biol & Genet, Ctr Canc Res, Bethesda, MD 20892 USA.
   [Yuan, Tina L.; McCormick, Frank] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94158 USA.
   [Chakka, Sirisha; Caplen, Natasha J.] NCI, Genet Branch, Ctr Canc Res, Bethesda, MD 20892 USA.
   [Fellmann, Christof; Lowe, Scott W.] Cold Spring Harbor Lab, POB 100, Cold Spring Harbor, NY 11724 USA.
   [Lowe, Scott W.] Mem Sloan Kettering Canc Ctr, Howard Hughes Med Inst, New York, NY 10065 USA.
   [Lowe, Scott W.] Mem Sloan Kettering Canc Ctr, Dept Canc Biol & Genet, New York, NY 10065 USA.
   [McCormick, Frank] Leidos Biomed Res, Frederick Natl Lab Canc Res, Canc Res Technol Program, Frederick, MD 21702 USA.
   [Lee, Liam C.] Loxo Oncol, Med Affairs, Stamford, CT 06901 USA.
   [Yuan, Tina L.] Novartis Inst Biomed Res, Oncol Translat Res, Cambridge, MA 02139 USA.
   [Chakka, Sirisha] NIH, Natl Ctr Adv Translat Sci, Rockville, MD 20850 USA.
   [Fellmann, Christof] Gladstone Inst, Inst Data Sci & Biotechnol, San Francisco, CA 94158 USA.
RP Luo, J (corresponding author), NCI, Lab Canc Biol & Genet, Ctr Canc Res, Bethesda, MD 20892 USA.; McCormick, F (corresponding author), Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94158 USA.; McCormick, F (corresponding author), Leidos Biomed Res, Frederick Natl Lab Canc Res, Canc Res Technol Program, Frederick, MD 21702 USA.
EM frank.mccormick@ucsf.edu; ji.luo@nih.gov
RI Caplen, Natasha J/H-2768-2016
OI Caplen, Natasha J/0000-0002-0001-9460; Fellmann,
   Christof/0000-0002-9545-5723
FU NCI Intramural Grant [ZIA BC 011437]; NCI Director's Innovation Award;
   NATIONAL CANCER INSTITUTEUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Cancer
   Institute (NCI) [ZIABC011437] Funding Source: NIH RePORTER
FX We thank Drs. Eric Batchelor, Jayne Stommel, and Rosandra Kaplan for
   their constructive suggestions, and the Flow Cytometry Core Facility of
   the Center for Cancer Research at the National Cancer Institute (NCI)
   for the technical support. This work was supported by NCI Intramural
   Grant ZIA BC 011437 (to J.L.) and by an NCI Director's Innovation Award
   (to C.-S.L.).
CR Alagesan B, 2015, CLIN CANCER RES, V21, P396, DOI 10.1158/1078-0432.CCR-14-1591
   Barbie DA, 2009, NATURE, V462, P108, DOI 10.1038/nature08460
   Bedard PL, 2015, CLIN CANCER RES, V21, P730, DOI 10.1158/1078-0432.CCR-14-1814
   Benitah SA, 2005, SCIENCE, V309, P933, DOI 10.1126/science.1113579
   Berti DA, 2017, METHODS MOL BIOL, V1487, P175, DOI 10.1007/978-1-4939-6424-6_13
   Blasco RB, 2011, CANCER CELL, V19, P652, DOI 10.1016/j.ccr.2011.04.002
   Blumenschein GR, 2015, ANN ONCOL, V26, P894, DOI 10.1093/annonc/mdv072
   BOTTORFF D, 1995, MOL CELL BIOL, V15, P5113
   Brachmann SA, 2005, MOL CELL BIOL, V25, P2593, DOI 10.1128/MCB.25.7.2593-2606.2005
   Buehler E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051942
   Chen J, 2001, P NATL ACAD SCI USA, V98, P7783, DOI 10.1073/pnas.141224398
   Chien YC, 2006, CELL, V127, P157, DOI 10.1016/j.cell.2006.08.034
   Corcoran RB, 2013, CANCER CELL, V23, P121, DOI 10.1016/j.ccr.2012.11.007
   Cox AD, 2014, NAT REV DRUG DISCOV, V13, P828, DOI 10.1038/nrd4389
   Dorard C, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15262
   Drosten M, 2010, EMBO J, V29, P1091, DOI 10.1038/emboj.2010.7
   Emery CM, 2009, P NATL ACAD SCI USA, V106, P20411, DOI 10.1073/pnas.0905833106
   Eng CH, 2016, P NATL ACAD SCI USA, V113, P182, DOI 10.1073/pnas.1515617113
   Engelman JA, 2008, NAT MED, V14, P1351, DOI 10.1038/nm.1890
   Fellmann C, 2011, MOL CELL, V41, P733, DOI 10.1016/j.molcel.2011.02.008
   Freeman AK, 2013, MOL CELL, V49, P751, DOI 10.1016/j.molcel.2012.12.018
   Garimella SV, 2014, BREAST CANCER RES, V16, DOI 10.1186/bcr3645
   Grilley-Olson JE, 2016, INVEST NEW DRUG, V34, P740, DOI 10.1007/s10637-016-0377-0
   Guo JY, 2016, GENE DEV, V30, P1704, DOI 10.1101/gad.283416.116
   Guo JY, 2013, AUTOPHAGY, V9, P1636, DOI 10.4161/auto.26123
   Guo JY, 2011, GENE DEV, V25, P460, DOI 10.1101/gad.2016311
   Haigis KM, 2008, NAT GENET, V40, P600, DOI 10.1038/ng.115
   He XY, 2017, NAT CHEM BIOL, V13, P1164, DOI [10.1038/NCHEMBIO.2463, 10.1038/nchembio.2463]
   Heid I, 2011, GASTROENTEROLOGY, V141, P719, DOI 10.1053/j.gastro.2011.04.043
   Herrera R, 1998, EXP CELL RES, V238, P407, DOI 10.1006/excr.1997.3847
   Huser M, 2001, EMBO J, V20, P1940, DOI 10.1093/emboj/20.8.1940
   Janne PA, 2017, JAMA-J AM MED ASSOC, V317, P1844, DOI 10.1001/jama.2017.3438
   Karreth FA, 2011, CANCER DISCOV, V1, P128, DOI 10.1158/2159-8290.CD-10-0044
   Karsli-Uzunbas G, 2014, CANCER DISCOV, V4, P914, DOI 10.1158/2159-8290.CD-14-0363
   Do K, 2015, INVEST NEW DRUG, V33, P720, DOI 10.1007/s10637-015-0212-z
   Kim HS, 2013, CELL, V155, P552, DOI 10.1016/j.cell.2013.09.041
   Kimmelman AC, 2017, CELL METAB, V25, P1037, DOI 10.1016/j.cmet.2017.04.004
   Kissil JL, 2007, CANCER RES, V67, P8089, DOI 10.1158/0008-5472.CAN-07-2300
   Lito P, 2016, SCIENCE, V351, P604, DOI 10.1126/science.aad6204
   Luo J, 2009, CELL, V137, P835, DOI 10.1016/j.cell.2009.05.006
   Luo J, 2009, CELL, V136, P823, DOI 10.1016/j.cell.2009.02.024
   Malone CF, 2014, CANCER DISCOV, V4, P1062, DOI 10.1158/2159-8290.CD-14-0159
   Martin TD, 2017, CELL REP, V20, P427, DOI 10.1016/j.celrep.2017.06.061
   McDonald ER, 2017, CELL, V170, P577, DOI 10.1016/j.cell.2017.07.005
   Montalvo SK, 2017, FUTURE ONCOL, V13, P263, DOI 10.2217/fon-2016-0363
   Nishiguchi GA, 2017, J MED CHEM, V60, P4869, DOI 10.1021/acs.jmedchem.6b01862
   O'Neill E, 2004, SCIENCE, V306, P2267, DOI 10.1126/science.1103233
   Patricelli MP, 2016, CANCER DISCOV, V6, P316, DOI 10.1158/2159-8290.CD-15-1105
   Peschard P, 2012, CURR BIOL, V22, P2063, DOI 10.1016/j.cub.2012.09.013
   Piazzolla D, 2005, J CELL BIOL, V171, P1013, DOI 10.1083/jcb.200504137
   Pumiglia KM, 1997, P NATL ACAD SCI USA, V94, P448, DOI 10.1073/pnas.94.2.448
   Pylayeva-Gupta Y, 2011, NAT REV CANCER, V11, P761, DOI 10.1038/nrc3106
   Sanclemente M, 2018, CANCER CELL, V33, P217, DOI 10.1016/j.ccell.2017.12.014
   Sarthy AV, 2007, MOL CANCER THER, V6, P269, DOI 10.1158/1535-7163.MCT-06-0560
   Scholl FA, 2007, DEV CELL, V12, P615, DOI 10.1016/j.devcel.2007.03.009
   Shao WL, 2018, CANCER RES, V78, P1537, DOI 10.1158/0008-5472.CAN-17-2033
   Shimizu T, 2012, CLIN CANCER RES, V18, P2316, DOI 10.1158/1078-0432.CCR-11-2381
   Smith JL, 2016, CELL BIOSCI, V6, DOI 10.1186/s13578-016-0122-6
   Soucy TA, 2009, NATURE, V458, P732, DOI 10.1038/nature07884
   Stephen AG, 2014, CANCER CELL, V25, P272, DOI 10.1016/j.ccr.2014.02.017
   Tolcher AW, 2015, CANCER CHEMOTH PHARM, V75, P183, DOI 10.1007/s00280-014-2615-5
   Tsherniak A, 2017, CELL, V170, P564, DOI 10.1016/j.cell.2017.06.010
   Wainberg ZA, 2017, TARGET ONCOL, V12, P775, DOI 10.1007/s11523-017-0530-5
   Wang T, 2017, CELL, V168, P890, DOI 10.1016/j.cell.2017.01.013
   Weng MT, 2012, P NATL ACAD SCI USA, V109, pE3659, DOI 10.1073/pnas.1207673110
   Wojnowski L, 2000, MECH DEVELOP, V91, P97, DOI 10.1016/S0925-4773(99)00276-2
   Xie XQ, 2015, CANCER DISCOV, V5, P410, DOI 10.1158/2159-8290.CD-14-1473
   Xiong Y, 2017, ACS MED CHEM LETT, V8, P61, DOI 10.1021/acsmedchemlett.6b00373
   Yang A, 2014, CANCER DISCOV, V4, P905, DOI 10.1158/2159-8290.CD-14-0362
   Yuan TL, 2018, CELL REP, V22, P1889, DOI 10.1016/j.celrep.2018.01.051
   Yuan TL, 2014, CANCER DISCOV, V4, P1182, DOI 10.1158/2159-8290.CD-13-0900
   Yun JY, 2009, SCIENCE, V325, P1555, DOI 10.1126/science.1174229
NR 72
TC 56
Z9 56
U1 2
U2 11
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD MAR 5
PY 2019
VL 116
IS 10
BP 4508
EP 4517
DI 10.1073/pnas.1817494116
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA HN5RI
UT WOS:000460242100085
PM 30709910
OA Bronze, Green Published
DA 2022-04-25
ER

PT J
AU Tan, J
   Wang, HL
   Yang, J
   Liu, QQ
   Li, CM
   Wang, YQ
   Fu, LN
   Gao, QY
   Chen, YX
   Fang, JY
AF Tan, Juan
   Wang, Hao-Lian
   Yang, Jie
   Liu, Qian-Qian
   Li, Chun-Min
   Wang, Yun-Qian
   Fu, Lin-Na
   Gao, Qin-Yan
   Chen, Ying-Xuan
   Fang, Jing-Yuan
TI JMJD2B-induced amino acid alterations enhance the survival of colorectal
   cancer cells under glucose-deprivation via autophagy
SO THERANOSTICS
LA English
DT Article
DE JMJD2B; CRC; amino acids metabolism; autophagy; LC3B
ID HISTONE DEMETHYLASE JMJD2B; DNA-DAMAGE RESPONSE; EPIGENETIC REGULATION;
   NUTRIENT DEPRIVATION; PROTEIN-SYNTHESIS; CYCLE ARREST; IN-VITRO;
   PROLIFERATION; APOPTOSIS; MELANOMA
AB Rationale: Post-translational modifications have emerged as vital players in alterations to tumor metabolism, including amino acid metabolic reprogramming. Jumonji domain-containing protein 2B (JMJD2B) enhances colorectal cancer (CRC) cell survival upon glucose deficiency. In the present study, we hypothesized that JMJD2B affects tumor cell amino acid metabolism in CRC and consequently promotes survival of CRC cells upon glucose deprivation.
   Methods: Non-target metabolic profiling was used to evaluate the roles of JMJD2B in CRC cell metabolism under glucose starvation. The roles of amino acid alterations induced by JMJD2B on CRC cell survival were determined by cell viability, immunoblotting, and clonogenic assays, and flow cytometry. The underlying mechanisms by which JMJD2B affected CRC cell metabolism were assessed using immunofluorescence staining, chromatin immunoprecipitation assays, electron microscopy in CRC cell lines, and using xenograft models. The correlation between JMJD2B and LC3B expression in human CRC specimens was assessed using immunohistochemistry.
   Results: Profound metabolic reprogramming was detected in JMJD2B knockdown CRC cells under glucose deficiency, especially those involving amino acid metabolites. Silencing of JMJD2B reduced the levels of certain amino acids that were induced by glucose deficiency. Among these amino acids, asparagine (Asn), phenylalanine (Phe), and histidine (His) promoted CRC cell survival under glucose starvation when JMJD2B was knocked down. Mechanistically, downregulation of JMJD2B inhibited autophagy in CRC cells through epigenetic regulation of microtubule associated protein 1 light chain 3 beta (LC3B), and subsequently decreased intracellular amino acid (Asn, Phe, His) levels under glucose deprivation, thus suppressing the survival of CRC cells. Using a nude mouse xenograft model, we verified that inhibiting JMJD2B could decrease the levels of amino acids (Asn, Phe, His). In addition, the inhibitory effects of JMJD2B-knockdown on tumor growth and amino acids level were rescued by overexpression of LC3B. Furthermore, we observed that the high expression of LC3B was more likely detected in tissuses with high expression of JMJD2B (P < 0.001) in 60 human CRC tissues.
   Conclusion: These results indicated that JMJD2B sustained the intracellular amino acids derived from autophagy in CRC cells upon glucose deficiency, partly through epigenetic regulation of LC3B, thus driving the malignancy of CRC.
C1 [Tan, Juan; Wang, Hao-Lian; Liu, Qian-Qian; Li, Chun-Min; Wang, Yun-Qian; Fu, Lin-Na; Gao, Qin-Yan; Chen, Ying-Xuan; Fang, Jing-Yuan] Shanghai Jiao Tong Univ, State Key Lab Oncogenes & Related Genes, Key Lab Gastroenterol & Hepatol,Minist Hlth, Renji Hosp,Sch Med,Div Gastroenterol & Hepatol, 145 Middle Shandong Rd, Shanghai 200001, Peoples R China.
   [Tan, Juan; Wang, Hao-Lian; Liu, Qian-Qian; Li, Chun-Min; Wang, Yun-Qian; Fu, Lin-Na; Gao, Qin-Yan; Chen, Ying-Xuan; Fang, Jing-Yuan] Shanghai Inst Digest Dis, 145 Middle Shandong Rd, Shanghai 200001, Peoples R China.
   [Yang, Jie] Shanghai Jiao Tong Univ, Educ Minist Cell Differentiat & Apoptosis, Dept Biochem & Mol Cell Biol, Sch Med,Inst Med Sci,Key Lab, 280 South Chongqing Rd, Shanghai 200025, Peoples R China.
RP Chen, YX (corresponding author), 145 Middle Shandong Rd, Shanghai 200001, Peoples R China.
EM yingxuanchen71@sjtu.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81772506, 81530072]; Shanghai Shenkang
   Center [SHDC12018121]
FX This study was supported by the National Natural Science Foundation of
   China (No. 81772506, 81530072), the funds from Shanghai Shenkang Center
   (SHDC12018121).
CR Bergers G, 2003, NAT REV CANCER, V3, P401, DOI 10.1038/nrc1093
   Berry WL, 2013, CANCER RES, V73, P2936, DOI 10.1158/0008-5472.CAN-12-4300
   Black JC, 2013, BIOPOLYMERS, V99, P127, DOI 10.1002/bip.22136
   Bray F, 2018, CA CANC J CLIN
   Chen L, 2014, BRIT J CANCER, V110, P1014, DOI 10.1038/bjc.2013.808
   Danecka MK, 2015, J MED GENET, V52, P175, DOI 10.1136/jmedgenet-2014-102621
   de Narvajas AAM, 2013, MOL CELL BIOL, V33, P3983, DOI 10.1128/MCB.00813-13
   Duan L, 2019, J BIOL CHEM, V294, P9186, DOI 10.1074/jbc.RA118.007122
   Ezaki J, 2011, AUTOPHAGY, V7, P727, DOI 10.4161/auto.7.7.15371
   Fu LN, 2018, ONCOGENE, V37, P389, DOI 10.1038/onc.2017.345
   Fu LN, 2012, CARCINOGENESIS, V33, P1664, DOI 10.1093/carcin/bgs217
   Fu YM, 2008, J CELL PHYSIOL, V217, P184, DOI 10.1002/jcp.21490
   Fu YM, 2007, J NUTR, V137, p1591S, DOI 10.1093/jn/137.6.1591S
   Fu YM, 2006, J CELL PHYSIOL, V209, P522, DOI 10.1002/jcp.20766
   Fu YM, 2010, J CELL PHYSIOL, V224, P491, DOI 10.1002/jcp.22148
   Fu YM, 1997, NUTR CANCER, V29, P104, DOI 10.1080/01635589709514610
   Fu YM, 1999, CANCER RES, V59, P758
   Fu YM, 2004, CLIN EXP METASTAS, V21, P587
   Fu YM, 2003, NUTR CANCER, V45, P60, DOI 10.1207/S15327914NC4501_8
   Fukumura D, 2007, MICROVASC RES, V74, P72, DOI 10.1016/j.mvr.2007.05.003
   Fullgrabe J, 2014, NAT REV MOL CELL BIO, V15, P65, DOI 10.1038/nrm3716
   Garufi A, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.163
   Jain M, 2012, SCIENCE, V336, P1040, DOI 10.1126/science.1218595
   Jiang Y, 2017, THERANOSTICS, V7, P1036, DOI 10.7150/thno.18005
   Kim JG, 2012, BBA-GENE REGUL MECH, V1819, P1200, DOI 10.1016/j.bbagrm.2012.10.001
   Kim TD, 2016, J CLIN INVEST, V126, P706, DOI 10.1172/JCI78132
   Knott SRV, 2018, NATURE, V554, P378, DOI 10.1038/nature25465
   Krall AS, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11457
   Kuma A, 2004, NATURE, V432, P1032, DOI 10.1038/nature03029
   Le A, 2012, CELL METAB, V15, P110, DOI 10.1016/j.cmet.2011.12.009
   Leung-Pineda V, 2004, BIOCHEM J, V379, P79, DOI 10.1042/BJ20031383
   Li WJ, 2011, BIOCHEM BIOPH RES CO, V416, P372, DOI 10.1016/j.bbrc.2011.11.045
   Liu YX, 2013, GUT, V62, P571, DOI 10.1136/gutjnl-2011-301059
   Martin C, 2005, NAT REV MOL CELL BIO, V6, P838, DOI 10.1038/nrm1761
   Mizushima N, 2007, GENE DEV, V21, P2861, DOI 10.1101/gad.1599207
   MORTIMORE GE, 1987, ANNU REV NUTR, V7, P539, DOI 10.1146/annurev.nu.07.070187.002543
   Onodera J, 2005, J BIOL CHEM, V280, P31582, DOI 10.1074/jbc.M506736200
   Palorini R, 2016, PLOS GENET, V12, DOI 10.1371/journal.pgen.1005931
   Perera R, 2015, NATURE, V524, P361, DOI 10.1038/nature14587
   Reitman ZJ, 2011, P NATL ACAD SCI USA, V108, P3270, DOI 10.1073/pnas.1019393108
   Ren AS, 2015, BIOCHEM BIOPH RES CO, V459, P10, DOI 10.1016/j.bbrc.2015.01.068
   Schubert U, 2000, NATURE, V404, P770, DOI 10.1038/35008096
   Shin HJR, 2016, NATURE, V534, P553, DOI 10.1038/nature18014
   Sun LC, 2015, CELL RES, V25, P429, DOI 10.1038/cr.2015.33
   Toyokawa G, 2011, CANCER PREV RES, V4, P2051, DOI 10.1158/1940-6207.CAPR-11-0290
   Tredan O, 2007, J NATL CANCER I, V99, P1441, DOI 10.1093/jnci/djm135
   Tsun ZY, 2015, SEMIN CELL DEV BIOL, V43, P22, DOI 10.1016/j.semcdb.2015.08.002
   Vabulas RM, 2005, SCIENCE, V310, P1960, DOI 10.1126/science.1121925
   Wang HJ, 2014, P NATL ACAD SCI USA, V111, P279, DOI 10.1073/pnas.1311249111
   Wang XJ, 2013, AUTOPHAGY, V9, P1500, DOI 10.4161/auto.25573
   Wen L, 2012, ACTA PHARMACOL SIN, V33, P109, DOI 10.1038/aps.2011.145
   Yeon A, 2018, THERANOSTICS, V8, P4520, DOI 10.7150/thno.25130
   Young LC, 2013, J BIOL CHEM, V288, P21376, DOI 10.1074/jbc.M113.491514
   Yu B, 2015, CIRC-CARDIOVASC GENE, V8, P351, DOI 10.1161/CIRCGENETICS.114.000697
   Yu TC, 2017, CELL, V170, P548, DOI 10.1016/j.cell.2017.07.008
   Yu X, 2015, MOL BIOSYST, V11, P1867, DOI 10.1039/c5mb00166h
NR 56
TC 3
Z9 4
U1 4
U2 9
PU IVYSPRING INT PUBL
PI LAKE HAVEN
PA PO BOX 4546, LAKE HAVEN, NSW 2263, AUSTRALIA
SN 1838-7640
J9 THERANOSTICS
JI Theranostics
PY 2020
VL 10
IS 13
BP 5763
EP 5777
DI 10.7150/thno.38087
PG 15
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA LK1IF
UT WOS:000530611900008
PM 32483417
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Zheng, XR
   Wei, JL
   Li, WJ
   Li, XL
   Wang, WY
   Guo, JB
   Fu, ZX
AF Zheng, Xiangru
   Wei, Jinlai
   Li, Wenjun
   Li, Xiaoli
   Wang, Wuyi
   Guo, Jinbao
   Fu, Zhongxue
TI PRDX2 removal inhibits the cell cycle and autophagy in colorectal cancer
   cells
SO AGING-US
LA English
DT Article
DE colorectal cancer; cell-cycle; autophagy; P38 pathway
ID PEROXIREDOXIN 2; SIGNALING PATHWAYS; MAPK; PROGRESSION; STATISTICS;
   SURVIVAL; GROWTH; CHINA; PI3K
AB Colorectal cancer (CRC) is a prevalent worldwide disease in which the antioxidant enzyme peroxiredoxin 2 (PRDX2) plays an important role. To investigate the molecular mechanism of PRDX2 in CRC, we performed bioinformatics analysis of The Cancer Genome Atlas (TCGA) datasets and Gene Expression Omnibus (GEO) DataSets (accession no. GSE81429). Our results suggest that PRDX2 is associated with cell-cycle progression and autophagy activated by the P38 MAPK/FOXO signaling pathway. Using a short-hairpin RNA vector, we verified that PRDX2 is essential for CRC cell proliferation and S-phase progression. Immunostaining, electron microscopy and western blotting assays verified the effect of PRDX2 knockdown on autophagy flux and p38 activation. The P38 activator dehydrocorydaline chloride partially rescued the effects of sh-PRDX2 on the expression of proteins related to cell-cycle progression and autophagy. We verified the correlation between PRDX2 expression and the expression of an array of cell-cycle and autophagy-related genes using data from an independent set of 222 CRC patient samples. A mouse xenoplast model was consistent with in vitro results. Our results suggest that PRDX2 promotes CRC cell-cycle progression via activation of the p38 MAPK pathway.
C1 [Zheng, Xiangru; Wei, Jinlai; Wang, Wuyi; Fu, Zhongxue] Chongqing Med Univ, Dept Gastrointestinal Surg, Affiliated Hosp 1, Chongqing, Peoples R China.
   [Li, Wenjun] Chongqing Med Univ, Dept Pharm, Affiliated Hosp 3, Chongqing, Peoples R China.
   [Li, Xiaoli] Chongqing Med Univ, Coll Pharm, Chongqing, Peoples R China.
   [Guo, Jinbao] Chongqing Med Univ, Dept Thorac Surg, Affiliated Hosp 1, Chongqing, Peoples R China.
RP Fu, ZX (corresponding author), Chongqing Med Univ, Dept Gastrointestinal Surg, Affiliated Hosp 1, Chongqing, Peoples R China.
EM fzx@hospital.cqmu.edu.cn
OI Zheng, Xiangru/0000-0003-1170-943X; Fu, Zhongxue/0000-0003-2765-3469
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81572319]; Chongqing Municipal Education
   Commission [KJ1702021]; Chongqing Science and Technology
   CommissionNatural Science Foundation Project of CQ CSTC
   [cstc2017jcyjAX0127]; Key Project of Prevention and Control of Priority
   Diseases in Chongqing [2019ZX003]
FX National Natural Science Foundation of China: 81572319, Chongqing
   Municipal Education Commission: KJ1702021, Chongqing Science and
   Technology Commission: cstc2017jcyjAX0127, Key Project of Prevention and
   Control of Priority Diseases in Chongqing: 2019ZX003.
CR Avitabile D, 2014, INT J BIOCHEM CELL B, V53, P24, DOI 10.1016/j.biocel.2014.04.024
   Borah N, 2017, INT J ONCOL, V51, P1685, DOI 10.3892/ijo.2017.4157
   Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095
   Chandrashekar DS, 2017, NEOPLASIA, V19, P649, DOI 10.1016/j.neo.2017.05.002
   CHEN JJ, 2013, BIOMED RES INT, V2013, DOI DOI 10.1155/2013/901578
   Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338
   D'Arcy MS, 2019, CELL BIOL INT, V43, P582, DOI 10.1002/cbin.11137
   Fang JY, 2005, LANCET ONCOL, V6, P322, DOI 10.1016/S1470-2045(05)70168-6
   Federti E, 2017, FREE RADICAL BIO MED, V112, P376, DOI 10.1016/j.freeradbiomed.2017.08.004
   Fernandes MS, 2018, ADV EXP MED BIOL, V1110, P35, DOI 10.1007/978-3-030-02771-1_4
   Ji DB, 2013, CARCINOGENESIS, V34, P1265, DOI 10.1093/carcin/bgt056
   Kang DH, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00054-0
   Kondo Y, 2005, NAT REV CANCER, V5, P726, DOI 10.1038/nrc1692
   Kuipers EJ, 2015, NAT REV DIS PRIMERS, V1, DOI 10.1038/nrdp.2015.65
   Lim W, 2017, J CELL PHYSIOL, V232, P1428, DOI 10.1002/jcp.25637
   Lu WD, 2014, CANCER LETT, V343, P190, DOI 10.1016/j.canlet.2013.10.002
   Luo WJ, 2013, BIOINFORMATICS, V29, P1830, DOI 10.1093/bioinformatics/btt285
   Lv ZB, 2017, J TRANSL MED, V15, DOI 10.1186/s12967-017-1357-7
   Mardis ER, 2012, CURR OPIN GENET DEV, V22, P245, DOI 10.1016/j.gde.2012.03.005
   Matte A, 2019, CURR OPIN HEMATOL, V26, P145, DOI 10.1097/MOH.0000000000000495
   Meldrum Cliff, 2011, Clin Biochem Rev, V32, P177
   Miller KD, 2016, CA-CANCER J CLIN, V66, P271, DOI 10.3322/caac.21349
   Mizushima N, 2007, GENE DEV, V21, P2861, DOI 10.1101/gad.1599207
   Montenegro MF, 2015, ONCOGENE, V34, P135, DOI 10.1038/onc.2013.605
   Nagelkerke A, 2015, SEMIN CANCER BIOL, V31, P99, DOI 10.1016/j.semcancer.2014.06.001
   Pawlik TM, 2004, INT J RADIAT ONCOL, V59, P928, DOI 10.1016/j.ijrobp.2004.03.005
   Peng LL, 2017, ONCOTARGET, V8, P15057, DOI 10.18632/oncotarget.14801
   Roux PP, 2004, MICROBIOL MOL BIOL R, V68, P320, DOI 10.1128/MMBR.68.2.320-344.2004
   Sebolt-Leopold JS, 2004, NAT REV CANCER, V4, P937, DOI 10.1038/nrc1503
   Slobodnyuk K, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1607-0
   Taupin D, 1999, GASTROENTEROLOGY, V116, P1072, DOI 10.1016/S0016-5085(99)70010-7
   Uhlen M, 2017, SCIENCE, V357, P660, DOI 10.1126/science.aan2507
   Wang LM, 2017, ENVIRON POLLUT, V228, P287, DOI 10.1016/j.envpol.2017.03.083
   Wang R, 2016, ONCOTARGET, V7, P86816, DOI 10.18632/oncotarget.13559
   Webber JL, 2010, EMBO J, V29, P27, DOI 10.1038/emboj.2009.321
   Xu JF, 2017, ACTA POLYM SIN, P37, DOI 10.11777/j.issn1000-3304.2017.16262
   Yu GY, 2019, ECOTOX ENVIRON SAFE, V181, P89, DOI 10.1016/j.ecoenv.2019.05.086
NR 37
TC 4
Z9 4
U1 2
U2 12
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
SN 1945-4589
J9 AGING-US
JI Aging-US
PD AUG 31
PY 2020
VL 12
IS 16
BP 16390
EP 16409
DI 10.18632/aging.103690
PG 20
WC Cell Biology; Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Geriatrics & Gerontology
GA NM2AA
UT WOS:000567903700014
PM 32692719
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Colangelo, T
   Polcaro, G
   Ziccardi, P
   Muccillo, L
   Galgani, M
   Pucci, B
   Milone, MR
   Budillon, A
   Santopaolo, M
   Mazzoccoli, G
   Matarese, G
   Sabatino, L
   Colantuoni, V
AF Colangelo, T.
   Polcaro, G.
   Ziccardi, P.
   Muccillo, L.
   Galgani, M.
   Pucci, B.
   Milone, M. Rita
   Budillon, A.
   Santopaolo, M.
   Mazzoccoli, G.
   Matarese, G.
   Sabatino, L.
   Colantuoni, V.
TI The miR-27a-calreticulin axis affects drug-induced immunogenic cell
   death in human colorectal cancer cells
SO CELL DEATH & DISEASE
LA English
DT Article
ID CALRETICULIN EXPOSURE; ATP SECRETION; AUTOPHAGY; DAMPS; MECHANISMS;
   MICRORNAS; PROMOTES; PATHWAY; GROWTH
AB Immunogenic cell death (ICD) evoked by chemotherapeutic agents implies emission of selected damage-associated molecular patterns (DAMP) such as cell surface exposure of calreticulin, secretion of ATP and HMGB1. We sought to verify whether miR-27a is implicated in ICD, having demonstrated that it directly targets calreticulin. To this goal, we exposed colorectal cancer cell lines, genetically modified to express high or low miR-27a levels, to two bona fide ICD inducers (mitoxantrone and oxaliplatin). Low miR-27a-expressing cells displayed more ecto-calreticulin on the cell surface and increased ATP and HMGB1 secretion than high miR-27a-expressing ones in time-course experiments upon drug exposure. A calreticulin target protector counteracted the miR-27a effects while specific siRNAs mimicked them, confirming the results reported. In addition, miR-27a negatively influenced the PERK-mediated route and the late PI3K-dependent secretory step of the unfolded protein response to endoplasmic reticulum stress, suggesting that miR-27a modulates the entire ICD program. Interestingly, upon chemotherapeutic exposure, low miR-27a levels associated with an earlier and stronger induction of apoptosis and with morphological and molecular features of autophagy. Remarkably, in ex vivo setting, under the same chemotherapeutic induction, the conditioned media from high miR-27a-expressing cells impeded dendritic cell maturation while increased the secretion of specific cytokines (interleukin (IL)-4, IL-6, IL-8) and negatively influenced CD4(+) T-cell interferon. production and proliferation, all markers of a tumor immunoevasion strategy. In conclusion, we provide the first evidence that miR-27a impairs the cell response to drug-induced ICD through the regulatory axis with calreticulin.
C1 [Colangelo, T.; Polcaro, G.; Ziccardi, P.; Muccillo, L.; Sabatino, L.; Colantuoni, V.] Univ Sannio, Dept Sci & Technol, Via PortArsa 11, I-82100 Benevento, Italy.
   [Galgani, M.; Matarese, G.] CNR, IEOS, I-80131 Naples, Italy.
   [Pucci, B.; Milone, M. Rita; Budillon, A.] Ist Nazl Tumori Fdn G Pascale IRCCS, Ctr Ric Oncol Mercogliano, I-83013 Mercogliano, AV, Italy.
   [Santopaolo, M.; Matarese, G.] Univ Naples Federico II, Dipartimento Med Mol & Biotecnol Med, I-80131 Naples, Italy.
   [Mazzoccoli, G.] IRCCS Casa Sollievo Sofferenza, Div Internal Med, I-71013 San Giovanni Rotondo, FG, Italy.
   [Mazzoccoli, G.] IRCCS Casa Sollievo Sofferenza, Chronobiol Unit, I-71013 San Giovanni Rotondo, FG, Italy.
RP Colantuoni, V (corresponding author), Univ Sannio, Dept Sci & Technol, Via PortArsa 11, I-82100 Benevento, Italy.
EM colantuoni@unisannio.it
RI Pucci, Biagio/AAS-7502-2021; Polcaro, Giovanna/AAC-1810-2019; Matarese,
   Giuseppe/AAO-4077-2021; Mazzoccoli, Gianluigi/H-2447-2016; pucci,
   biagio/AAA-9268-2020; Galgani, Mario/AAC-3298-2022; Budillon,
   Alfredo/K-4763-2016; Colangelo, Tommaso/B-6119-2017
OI Polcaro, Giovanna/0000-0002-2329-3200; Matarese,
   Giuseppe/0000-0001-9429-0616; Mazzoccoli, Gianluigi/0000-0003-3535-7635;
   pucci, biagio/0000-0003-4502-1748; Budillon,
   Alfredo/0000-0002-6330-6053; Colangelo, Tommaso/0000-0002-6927-403X;
   Galgani, Mario/0000-0001-8414-1676
FU AIL (Associazione italiana per lo studio dei linfomi e plasmacitomi);
   Fondazione Italiana Sclerosi Multipla (FISM)Fondazione Italiana Sclerosi
   Multipla (FISM) [2012/R/11]; EU Ideas Programme; ERC-StG
   'menTORingTregs' [310496]; FIRB MERIT Grant [RBNE08HWLZ_015]; CNR
   Medicina Personalizzata Grant; Juvenile Diabetes Research Foundation
   (JDRF)Juvenile Diabetes Research Foundation [1-PNF-2015-115-5-B]; PhD
   Program in Medicina Molecolare e Biotecnologie Mediche, Universita degli
   Studi di Napoli 'Federico ll'
FX This work was partially supported by a grant from AIL (Associazione
   italiana per lo studio dei linfomi e plasmacitomi) to VC, by grants from
   the Fondazione Italiana Sclerosi Multipla (FISM) n. 2012/R/11, EU Ideas
   Programme, ERC-StG 'menTORingTregs' n. 310496, FIRB MERIT Grant n.
   RBNE08HWLZ_015, and a CNR Medicina Personalizzata Grant to GM and by a
   grant from Juvenile Diabetes Research Foundation (JDRF) n.
   1-PNF-2015-115-5-B to MG. MS is supported by the PhD Program in Medicina
   Molecolare e Biotecnologie Mediche, Universita degli Studi di Napoli
   'Federico ll'. We are grateful to Prof Marco E Bianchi for generous gift
   of reagents, critical reading of the manuscript and discussion. We would
   like to thank Mariarosaria Montagna (DBBBM) for technical assistance.
CR Ali TH, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6639
   Bianchi ME, 2014, CELL DEATH DIFFER, V21, P1, DOI 10.1038/cdd.2013.147
   Cekaite L, 2016, ONCOTARGET, V7, P6476, DOI 10.18632/oncotarget.6390
   Colangelo T, 2016, CELL DEATH DIS IN PR
   Colangelo T, 2013, NEOPLASIA, V15, P1204, DOI 10.1593/neo.13998
   Di Leva G, 2014, ANNU REV PATHOL-MECH, V9, P287, DOI 10.1146/annurev-pathol-012513-104715
   Dudek AM, 2013, CYTOKINE GROWTH F R, V24, P319, DOI 10.1016/j.cytogfr.2013.01.005
   Francipane MG, 2008, CANCER RES, V68, P4022, DOI 10.1158/0008-5472.CAN-07-6874
   Galgani M, 2004, J BIOL CHEM, V279, P32507, DOI 10.1074/jbc.M403355200
   Garg AD, 2014, CELL DEATH DIFFER, V21, P26, DOI 10.1038/cdd.2013.48
   Garg AD, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00588
   Garg AD, 2015, ONCOTARGET, V6, P26841, DOI 10.18632/oncotarget.4754
   Garg AD, 2012, EMBO J, V31, P1062, DOI 10.1038/emboj.2011.497
   Guo YQ, 2012, CANCER TREAT REV, V38, P904, DOI 10.1016/j.ctrv.2012.04.007
   Hayes J, 2014, TRENDS MOL MED, V20, P460, DOI 10.1016/j.molmed.2014.06.005
   Hou W, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.493
   Inoue H, 2014, CELL DEATH DIFFER, V21, P39, DOI 10.1038/cdd.2013.84
   Jahid S, 2012, CANCER DISCOV, V2, P540, DOI 10.1158/2159-8290.CD-11-0267
   Kepp O, 2013, CYTOKINE GROWTH F R, V24, P311, DOI 10.1016/j.cytogfr.2013.05.001
   Kroemer G, 2013, ANNU REV IMMUNOL, V31, P51, DOI 10.1146/annurev-immunol-032712-100008
   Krysko DV, 2012, NAT REV CANCER, V12, P860, DOI 10.1038/nrc3380
   Krysko O, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.156
   Lee YS, 2012, BRIT J CANCER, V106, P1833, DOI 10.1038/bjc.2012.177
   Marino G, 2014, NAT REV MOL CELL BIO, V15, P81, DOI 10.1038/nrm3735
   Martins I, 2014, CELL DEATH DIFFER, V21, P79, DOI 10.1038/cdd.2013.75
   Masci AM, 2003, J LEUKOCYTE BIOL, V74, P1117, DOI 10.1189/jlb.0503239
   Mellman I, 2011, NATURE, V480, P480, DOI 10.1038/nature10673
   Michaud M, 2011, SCIENCE, V334, P1573, DOI 10.1126/science.1208347
   Obeid M, 2007, IMMUNOL REV, V220, P22, DOI 10.1111/j.1600-065X.2007.00567.x
   Obeid M, 2007, NAT MED, V13, P54, DOI 10.1038/nm1523
   Ohsumi Y, 2014, CELL RES, V24, P9, DOI 10.1038/cr.2013.169
   Panaretakis T, 2008, CELL DEATH DIFFER, V15, P1499, DOI 10.1038/cdd.2008.67
   Panaretakis T, 2009, EMBO J, V28, P578, DOI 10.1038/emboj.2009.1
   Peng RQ, 2010, WORLD J GASTROENTERO, V16, P2428, DOI 10.3748/wjg.v16.i19.2428
   Raghavan M, 2013, TRENDS IMMUNOL, V34, P13, DOI 10.1016/j.it.2012.08.002
   Tesniere A, 2008, CELL DEATH DIFFER, V15, P3, DOI 10.1038/sj.cdd.4402269
   Verfaillie T, 2012, CELL DEATH DIFFER, V19, P1880, DOI 10.1038/cdd.2012.74
   Wang WA, 2012, INT J BIOCHEM CELL B, V44, P842, DOI 10.1016/j.biocel.2012.02.009
   Yazid S, 2009, BIOCHEM PHARMACOL, V77, P1814, DOI 10.1016/j.bcp.2009.03.010
   Zhang ZP, 2011, CANCER GENET-NY, V204, P486, DOI 10.1016/j.cancergen.2011.07.004
NR 40
TC 42
Z9 44
U1 2
U2 25
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-4889
J9 CELL DEATH DIS
JI Cell Death Dis.
PD FEB
PY 2016
VL 7
AR e2108
DI 10.1038/cddis.2016.29
PG 11
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA DG5FU
UT WOS:000372102400013
PM 26913599
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Gallot, YS
   Durieux, AC
   Castells, J
   Desgeorges, MM
   Vernus, B
   Plantureux, L
   Remond, D
   Jahnke, VE
   Lefai, E
   Dardevet, D
   Nemoz, G
   Schaeffer, L
   Bonnieu, A
   Freyssenet, DG
AF Gallot, Yann S.
   Durieux, Anne-Cecile
   Castells, Josiane
   Desgeorges, Marine M.
   Vernus, Barbara
   Plantureux, Lea
   Remond, Didier
   Jahnke, Vanessa E.
   Lefai, Etienne
   Dardevet, Dominique
   Nemoz, Georges
   Schaeffer, Laurent
   Bonnieu, Anne
   Freyssenet, Damien G.
TI Myostatin Gene Inactivation Prevents Skeletal Muscle Wasting in Cancer
SO CANCER RESEARCH
LA English
DT Article
ID INHIBIN-DEFICIENT MICE; FOXO TRANSCRIPTION FACTORS; CACHEXIA-LIKE
   SYNDROME; ACTRIIB ANTAGONISM; TUMOR PROGRESSION; II RECEPTORS; IN-VIVO;
   ATROPHY; ACTIVIN; MASS
AB Cachexia is a muscle-wasting syndrome that contributes significantly to morbidity and mortality of many patients with advanced cancers. However, little is understood about how the severe loss of skeletal muscle characterizing this condition occurs. In the current study, we tested the hypothesis that the muscle protein myostatin is involved in mediating the pathogenesis of cachexia-induced muscle wasting in tumor-bearing mice. Myostatin gene inactivation prevented the severe loss of skeletal muscle mass induced in mice engrafted with Lewis lung carcinoma (LLC) cells or in Apc(Min/+) mice, an established model of colorectal cancer and cachexia. Mechanistically, myostatin loss attenuated the activation of muscle fiber proteolytic pathways by inhibiting the expression of atrophy-related genes, MuRF1 and MAFbx/Atrogin-1, along with autophagy-related genes. Notably, myostatin loss also impeded the growth of LLC tumors, the number and the size of intestinal polyps in Apc(Min/+) mice, thus strongly increasing survival in both models. Gene expression analysis in the LLC model showed this phenotype to be associated with reduced expression of genes involved in tumor metabolism, activin signaling, and apoptosis. Taken together, our results reveal an essential role for myostatin in the pathogenesis of cancer cachexia and link this condition to tumor growth, with implications for furthering understanding of cancer as a systemic disease. (C)2014 AACR.
C1 [Gallot, Yann S.; Durieux, Anne-Cecile; Castells, Josiane; Desgeorges, Marine M.; Plantureux, Lea; Jahnke, Vanessa E.; Freyssenet, Damien G.] Univ Lyon, Lab Physiol Exercice, St Etienne, France.
   [Vernus, Barbara; Bonnieu, Anne] INRA, UMR Dynam Musculaire & Metab 866, F-34060 Montpellier, France.
   [Remond, Didier; Dardevet, Dominique] INRA, UMR 1019, Unite Nutr Humaine, Clermont Ferrand, France.
   [Lefai, Etienne; Nemoz, Georges] Univ Lyon, CarMeN Lab, INRA USC1235, INSERM U1060, Oullins, France.
   [Schaeffer, Laurent] Ecole Normale Super Lyon, Lab Biol Mol Cellule, CNRS UMR 5239, F-69364 Lyon, France.
RP Freyssenet, DG (corresponding author), Fac Med, Lab Physiol Exercice, 15 Rue Ambroise Pare, F-42023 St Etienne 2, France.
EM damien.freyssenet@univ-st-etienne.fr
RI Lefai, Etienne/E-9615-2019; Lefai, Etienne/L-7961-2019; Gallot, Yann
   Simon/ABC-1826-2021; Bonnieu, Anne/ABA-7182-2020
OI Lefai, Etienne/0000-0002-3042-7801; Lefai, Etienne/0000-0002-3042-7801;
   Gallot, Yann Simon/0000-0003-4447-1448; schaeffer,
   laurent/0000-0001-6600-503X; Dardevet, Dominique/0000-0001-7320-9970;
   Remond, Didier/0000-0003-4430-0067
FU Ligue Contre le CancerLigue nationale contre le cancer; Institut
   National du Cancer (INCa)Institut National du Cancer (INCA) France
FX This work was supported by grants from the Ligue Contre le Cancer and
   the Institut National du Cancer (INCa).
CR Amirouche A, 2009, ENDOCRINOLOGY, V150, P286, DOI 10.1210/en.2008-0959
   Antsiferova M, 2012, J CELL SCI, V125, P3929, DOI 10.1242/jcs.094789
   ARGILES JM, 1991, J BIOL CHEM, V266, P2978
   Baltgalvis KA, 2008, AM J PHYSIOL-REG I, V294, pR393, DOI 10.1152/ajpregu.00716.2007
   Berthon P, 2007, PFLUG ARCH EUR J PHY, V454, P625, DOI 10.1007/s00424-007-0230-6
   Bodine SC, 2001, NAT CELL BIOL, V3, P1014, DOI 10.1038/ncb1101-1014
   Bonetto A, 2009, CURR CANCER DRUG TAR, V9, P608, DOI 10.2174/156800909789057015
   Busquets S, 2012, J CACHEXIA SARCOPENI, V3, P37, DOI 10.1007/s13539-011-0049-z
   Cai DS, 2004, CELL, V119, P285, DOI 10.1016/j.cell.2004.09.027
   Chen JL, 2014, FASEB J, V28, P1711, DOI 10.1096/fj.13-245894
   Chicheportiche Y, 1997, J BIOL CHEM, V272, P32401, DOI 10.1074/jbc.272.51.32401
   Cipriano SC, 2000, ENDOCRINOLOGY, V141, P2319, DOI 10.1210/en.141.7.2319
   Coerver KA, 1996, MOL ENDOCRINOL, V10, P534, DOI 10.1210/me.10.5.534
   Costelli P, 2008, EUR J CLIN INVEST, V38, P531, DOI 10.1111/j.1365-2362.2008.01970.x
   Durieux AC, 2007, ENDOCRINOLOGY, V148, P3140, DOI 10.1210/en.2006-1500
   Fearon K, 2011, LANCET ONCOL, V12, P489, DOI 10.1016/S1470-2045(10)70218-7
   Grobet L, 2003, GENESIS, V35, P227, DOI 10.1002/gene.10188
   GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0
   Han HQ, 2013, INT J BIOCHEM CELL B, V45, P2333, DOI 10.1016/j.biocel.2013.05.019
   Hu-Lowe DD, 2011, CANCER RES, V71, P1362, DOI 10.1158/0008-5472.CAN-10-1451
   Klimek MEB, 2010, BIOCHEM BIOPH RES CO, V391, P1548, DOI 10.1016/j.bbrc.2009.12.123
   Klionsky DJ, 2012, AUTOPHAGY, V8, P445, DOI 10.4161/auto.19496
   Kumar TR, 1999, MOL ENDOCRINOL, V13, P851, DOI 10.1210/me.13.6.851
   Lach-Trifilieff E, 2014, MOL CELL BIOL, V34, P606, DOI 10.1128/MCB.01307-13
   Lee SJ, 2005, P NATL ACAD SCI USA, V102, P18117, DOI 10.1073/pnas.0505996102
   Li QL, 2007, MOL HUM REPROD, V13, P675, DOI 10.1093/molehr/gam055
   Liu CM, 2008, GENE THER, V15, P155, DOI 10.1038/sj.gt.3303016
   Lokireddy S, 2011, AM J PHYSIOL-CELL PH, V301, pC1316, DOI 10.1152/ajpcell.00114.2011
   Macheda ML, 2005, J CELL PHYSIOL, V202, P654, DOI 10.1002/jcp.20166
   Mammucari C, 2007, CELL METAB, V6, P458, DOI 10.1016/j.cmet.2007.11.001
   MATZUK MM, 1994, P NATL ACAD SCI USA, V91, P8817, DOI 10.1073/pnas.91.19.8817
   McPherron AC, 1997, NATURE, V387, P83, DOI 10.1038/387083a0
   Mittal A, 2010, J CELL BIOL, V188, P833, DOI 10.1083/jcb.200909117
   MOSER AR, 1990, SCIENCE, V247, P322, DOI 10.1126/science.2296722
   Paul PK, 2010, J CELL BIOL, V191, P1395, DOI 10.1083/jcb.201006098
   Rapisarda A, 2012, ADV CANCER RES, V114, P237, DOI 10.1016/B978-0-12-386503-8.00006-5
   Rommel C, 2001, NAT CELL BIOL, V3, P1009, DOI 10.1038/ncb1101-1009
   Sandri M, 2004, CELL, V117, P399, DOI 10.1016/S0092-8674(04)00400-3
   Sartori R, 2013, NAT GENET, V45, P1309, DOI 10.1038/ng.2772
   Semenza GL, 2004, PHYSIOLOGY, V19, P176, DOI 10.1152/physiol.00001.2004
   Souza TA, 2008, MOL ENDOCRINOL, V22, P2689, DOI 10.1210/me.2008-0290
   Stitt TN, 2004, MOL CELL, V14, P395, DOI 10.1016/S1097-2765(04)00211-4
   Tisdale MJ, 2010, CURR OPIN GASTROEN, V26, P146, DOI 10.1097/MOG.0b013e3283347e77
   Tisdale MJ, 2009, PHYSIOL REV, V89, P381, DOI 10.1152/physrev.00016.2008
   Tisdale MJ, 2002, NAT REV CANCER, V2, P862, DOI 10.1038/nrc927
   Winbanks CE, 2013, J CELL BIOL, V203, P345, DOI 10.1083/jcb.201211134
   Zhao J, 2007, CELL METAB, V6, P472, DOI 10.1016/j.cmet.2007.11.004
   Zhou XL, 2010, CELL, V142, P531, DOI 10.1016/j.cell.2010.07.011
   Zimmers TA, 2002, SCIENCE, V296, P1486, DOI 10.1126/science.1069525
NR 49
TC 55
Z9 58
U1 0
U2 24
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD DEC 15
PY 2014
VL 74
IS 24
BP 7344
EP 7356
DI 10.1158/0008-5472.CAN-14-0057
PG 13
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA AW6FC
UT WOS:000346363900020
PM 25336187
OA Bronze
DA 2022-04-25
ER

PT J
AU Liu, YQ
   Chen, XJ
   Chen, XL
   Liu, JQ
   Gu, H
   Fan, RT
   Ge, H
AF Liu, Yingqiang
   Chen, Xijuan
   Chen, Xiling
   Liu, Junqi
   Gu, Hao
   Fan, Ruitai
   Ge, Hong
TI Long non-coding RNA HOTAIR knockdown enhances radiosensitivity through
   regulating microRNA-93/ATG12 axis in colorectal cancer
SO CELL DEATH & DISEASE
LA English
DT Article
ID AUTOPHAGY; RESISTANCE; MICRORNAS; ROLES; CERNA; CELLS
AB Colorectal cancer (CRC) is a global healthcare problem. Radioresistance is a huge setback for CRC radiotherapy. In this text, the roles and molecular mechanisms of long non-coding RNA HOTAIR in CRC tumorigenesis and radioresistance were further investigated. ATG12 mRNA, HOTAIR, and microRNA-93 (miR-93) levels were measured by quantitative reverse transcription polymerase chain reaction (RT-qPCR) assay. Protein levels of LC3 I, LC3 II, p62, ATG12, cleaved caspase 3, Bax, and Bcl-2 were detected by western blotting assay in cells and were examined by immunohistochemistry (IHC) assay in tissues. Cell survival fractions, viability, and apoptotic rates were determined by clonogenic survival assay, CCK-8 assay, and flow cytometry analysis, respectively. The relationships of HOTAIR, miR-93, and ATG12 were tested by bioinformatics analysis and luciferase reporter assay. Mouse xenograft tumor models were established to investigate the influence of HOTAIR knockdown on CRC radioresistance in vivo. We found that HOTAIR expression was markedly upregulated in plasma from CRC patients after radiotherapy and CRC cells after irradiation. HOTAIR knockdown, miR-93 overexpression, or ATG12 silencing weakened cell viability, induced cell apoptosis, inhibited cell autophagy, and enhanced cell radiosensitivity in CRC. HOTAIR exerted its functions by downregulating miR-93. Moreover, HOTAIR functioned as a molecular sponge of miR-93 to regulate ATG12 expression. ATG12 protein expression was markedly upregulated and associated with miR-93 and HOTAIR expression in CRC tissues. Furthermore, HOTAIR knockdown enhanced radiosensitivity of CRC xenograft tumors by regulating miR-93/ATG12 axis. In conclusion, HOTAIR knockdown potentiated radiosensitivity through regulating miR-93/ATG12 axis in CRC, further elucidating the roles and molecular basis of HOTAIR in CRC radioresistance.
C1 [Liu, Yingqiang] Zhengzhou Univ, Affiliated Tumor Hosp, Dept Gen Surg, Zhengzhou, Henan, Peoples R China.
   [Chen, Xijuan; Ge, Hong] Zhengzhou Univ, Affiliated Tumor Hosp, Dept Radiat Oncol, Zhengzhou, Henan, Peoples R China.
   [Chen, Xiling] Zhengzhou Univ, Affiliated Hosp 2, Dept Geriatr Med, Zhengzhou, Henan, Peoples R China.
   [Liu, Junqi; Gu, Hao; Fan, Ruitai] Zhengzhou Univ, Affiliated Hosp 1, Dept Radiat Oncol, Zhengzhou, Henan, Peoples R China.
RP Ge, H (corresponding author), Zhengzhou Univ, Affiliated Tumor Hosp, Dept Radiat Oncol, Zhengzhou, Henan, Peoples R China.
EM nihaoma22189@sina.com
OI Liu, Junqi/0000-0002-6015-1033
FU Subsidized Project of Henan Medical Science and Technology Research
   Program [201304060]
FX This work was supported by the Subsidized Project of Henan Medical
   Science and Technology Research Program (Grant Number 201304060).
CR Abdeahad H, 2019, J CELL PHYSIOL, V234, P10926, DOI 10.1002/jcp.27918
   Bao X, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.31
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
   Brenner H, 2014, LANCET, V383, P1490, DOI 10.1016/S0140-6736(13)61649-9
   Cai B, 2014, NEOPLASMA, V61, P379, DOI 10.4149/neo_2014_075
   Cui HJ, 2017, DIGEST DIS SCI, V62, P1995, DOI 10.1007/s10620-017-4579-x
   Fanale D, 2016, ADV EXP MED BIOL, V937, P207, DOI 10.1007/978-3-319-42059-2_11
   Greither T, 2017, ONCOL REP, V38, P1268, DOI 10.3892/or.2017.5764
   Gupta SK, 2016, J MOL CELL CARDIOL, V95, P26, DOI 10.1016/j.yjmcc.2015.11.012
   Hajjari M, 2015, CANCER BIOL MED, V12, P1, DOI 10.7497/j.issn.2095-3941.2015.0006
   Hu JL, 2018, ONCOGENESIS, V7, DOI 10.1038/s41389-018-0028-8
   Kaihui L, 2012, THESIS
   Kang M, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18020321
   Kogo R, 2011, CANCER RES, V71, P6320, DOI 10.1158/0008-5472.CAN-11-1021
   Kuipers EJ, 2015, NAT REV DIS PRIMERS, V1, DOI 10.1038/nrdp.2015.65
   Li J, 2015, TUMOR BIOL, V36, P3611, DOI 10.1007/s13277-014-2998-2
   Lin K, 2018, DIGEST DIS SCI, V63, P2320, DOI 10.1007/s10620-018-5127-z
   Lu XY, 2018, ONCOL RES, V26, P473, DOI 10.3727/096504017X15105708598531
   Pawlowska E, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18112317
   Prensner JR, 2011, CANCER DISCOV, V1, P391, DOI 10.1158/2159-8290.CD-11-0209
   Qi XL, 2015, J MED GENET, V52, P710, DOI 10.1136/jmedgenet-2015-103334
   Sun MY, 2017, BIOTECHNOL LETT, V39, P1477, DOI 10.1007/s10529-017-2392-4
   Tan DM, 2018, MOL MED REP, V17, P6319, DOI 10.3892/mmr.2018.8645
   Tan WQ, 2014, WORLD J GASTROENTERO, V20, P5962, DOI 10.3748/wjg.v20.i20.5962
   Tang QC, 2015, TUMOR BIOL, V36, P1701, DOI 10.1007/s13277-014-2771-6
   Tay Y, 2014, NATURE, V505, P344, DOI 10.1038/nature12986
   Tutar L, 2014, CURR PHARM BIOTECHNO, V15, P430, DOI 10.2174/1389201015666140519095304
   Wang J, 2015, INT J MOL SCI, V16, P19886, DOI 10.3390/ijms160819886
   Wei H, 2019, GENE, V687, P9, DOI 10.1016/j.gene.2018.11.008
   Wu CL, 2018, CANCER MANAG RES, V10, P5261, DOI 10.2147/CMAR.S174066
   Wu QB, 2018, MOL CLIN ONCOL, V8, P523, DOI 10.3892/mco.2018.1578
   Xiang Y, 2017, EXP CELL RES, V357, P135, DOI 10.1016/j.yexcr.2017.05.007
   Xue M, 2017, METHODS MOL BIOL, V1617, P1, DOI 10.1007/978-1-4939-7046-9_1
   Yang IP, 2012, CARCINOGENESIS, V33, P1522, DOI 10.1093/carcin/bgs166
   Yang L, 2016, MOL BIOSYST, V12, P2605, DOI 10.1039/c6mb00114a
   Yang XD, 2016, ONCOL REP, V35, P479, DOI 10.3892/or.2015.4397
   Yang Y, 2018, BIOCHEM BIOPH RES CO, V497, P1003, DOI 10.1016/j.bbrc.2018.02.141
   Yoo BC, 2017, EPMA J, V8, P61, DOI 10.1007/s13167-017-0082-x
   Zhou Y, 2017, ONCOL LETT, V13, P1143, DOI 10.3892/ol.2017.5587
NR 39
TC 36
Z9 37
U1 2
U2 5
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-4889
J9 CELL DEATH DIS
JI Cell Death Dis.
PD MAR 6
PY 2020
VL 11
IS 3
AR 175
DI 10.1038/s41419-020-2268-8
PG 14
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA KT8JV
UT WOS:000519258800003
PM 32144238
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Vangestel, C
   Van de Wiele, C
   Mees, G
   Mertens, K
   Staelens, S
   Reutelingsperger, C
   Pauwels, P
   Van Damme, N
   Peeters, M
AF Vangestel, Christel
   Van de Wiele, Christophe
   Mees, Gilles
   Mertens, Koen
   Staelens, Steven
   Reutelingsperger, Chris
   Pauwels, Patrick
   Van Damme, Nancy
   Peeters, Marc
TI Single-Photon Emission Computed Tomographic Imaging of the Early Time
   Course of Therapy-Induced Cell Death Using Technetium 99m Tricarbonyl
   His-Annexin A5 in a Colorectal Cancer Xenograft Model
SO MOLECULAR IMAGING
LA English
DT Article
ID APOPTOTIC TUMOR RESPONSE; IN-VIVO DETECTION; IONIZING-RADIATION; V
   SCINTIGRAPHY; CHEMOTHERAPY; PHOSPHATIDYLSERINE; AUTOPHAGY; PANITUMUMAB;
   INCREASES; EFFICACY
AB As apoptosis occurs over an interval of time after administration of apoptosis-inducing therapy in tumors, the changes in technetium 99m (Tc-99m)-tricarbonyl (CO)(3) His-annexin A5 (His-ann A5) accumulation over time were examined. Colo205-bearing mice were divided into six treatment groups: (1) control, (2) 5-fluorouracil (5-FU; 250 mg/kg), (3) irinotecan (100 mg/kg), (4) oxaliplatin (30 mg/kg), (5) bevacizumab (5 mg/kg), and (6) panitumumab (6 mg/kg). (99)mTc-(CO)(3) His-ann A5 was injected 4, 8, 12, 24, and 48 hours posttreatment, and micro-single-photon emission computed tomography was performed. Immunostaining of caspase-3 (apoptosis), survivin (antiapoptosis), and LC3-II (autophagy marker) was also performed. Different dynamics of (99)mTc-(CO)(3) His-ann A5 uptake were observed in this colorectal cancer xenograft model, in response to a single dose of three different chemotherapeutics (5-FU, irinotecan, and oxaliplatin). Bevacizumab-treated mice showed no increased uptake of the radiotracer, and a peak of (99)mTc-(CO)(3) HisannA5 uptake in panitumumab-treated mice was observed 24 hours posttreatment, as confirmed by caspase-3 immunostaining. For irinotecan-, oxaliplatin-, and bevacizumab-treated tumors, a significant correlation was established between the radiotracer uptake and caspase-3 immunostaining (r = .8, p < .05; r = .9, p < .001; r = .9, p < .001, respectively). For 5-FU- and panitumumab-treated mice, the correlation coefficients were r = .7 (p = .18) and r = .7 (p = .19), respectively. Optimal timing of annexin A5 imaging after the start of different treatments in the Colo205 model was determined.
C1 [Vangestel, Christel] Ghent Univ Hosp, Dept Gastroenterol, B-9000 Ghent, Belgium.
   Ghent Univ Hosp, Dept Nucl Med & Radiol, B-9000 Ghent, Belgium.
   Ghent Univ Hosp, Dept Pathol, B-9000 Ghent, Belgium.
   Univ Groningen, Univ Med Ctr Groningen, Dept Nucl Med & Mol Imaging, Groningen, Netherlands.
   Ghent Univ IBBT, Fac Engn, Dept Med Signal, Ghent, Belgium.
   Ghent Univ IBBT, Fac Engn, Image Proc Grp, Ghent, Belgium.
   Univ Maastricht, Cardiovasc Res Inst, Dept Biochem, Maastricht, Netherlands.
RP Vangestel, C (corresponding author), Ghent Univ Hosp, Dept Gastroenterol, Pintelaan 185, B-9000 Ghent, Belgium.
EM christel.vangestel@uza.be
RI Peeters, Marc/C-5525-2013; Staelens, Steven/D-8385-2017
OI Peeters, Marc/0000-0003-4969-2303; Staelens, Steven/0000-0003-3376-0519
FU European Union through a Euregional PACT II grant from the Interreg IV
   program of Grensregio Vlaanderen-Nederland [IVA-VLANED-1.20]
FX Part of this work was financially supported by the European Union
   through a Euregional PACT II grant from the Interreg IV program of
   Grensregio Vlaanderen-Nederland (IVA-VLANED-1.20).
CR Altieri Dario C, 2003, Prog Cell Cycle Res, V5, P447
   Amado RG, 2008, J CLIN ONCOL, V26, P1626, DOI 10.1200/JCO.2007.14.7116
   Angell H., 2008, BIOSCI HORIZ, V1, P85, DOI [10.1093/biohorizons/hzn012, DOI 10.1093/BIOHORIZONS/HZN012]
   Blankenberg F, 2002, CLIN CANCER RES, V8, P2757
   Blankenberg FG, 1999, J NUCL MED, V40, P184
   Blankenberg FG, 2008, J NUCL MED, V49, p81S, DOI 10.2967/jnumed.107.045898
   Brink M, 2003, CARCINOGENESIS, V24, P703, DOI 10.1093/carcin/bgg009
   Brouckaert G, 2004, MOL BIOL CELL, V15, P1089, DOI 10.1091/mbc.E03-09-0668
   Capdevila J, 2009, CANCER TREAT REV, V35, P354, DOI 10.1016/j.ctrv.2009.02.001
   de Bruin EC, 2008, CANCER TREAT REV, V34, P737, DOI 10.1016/j.ctrv.2008.07.001
   Eom YW, 2005, ONCOGENE, V24, P4765, DOI 10.1038/sj.onc.1208627
   Epstein RJ, 2007, CANCER METAST REV, V26, P443, DOI 10.1007/s10555-007-9071-1
   Gerl R, 2005, CARCINOGENESIS, V26, P263, DOI 10.1093/carcin/bgh283
   Giannopoulou E, 2009, ANTICANCER RES, V29, P5077
   Kartachova M, 2004, RADIOTHER ONCOL, V72, P333, DOI 10.1016/j.radonc.2004.07.008
   Kartachova M, 2007, J CLIN ONCOL, V25, P2534, DOI 10.1200/JCO.2006.10.1337
   Kartachova MS, 2008, NUCL MED COMMUN, V29, P39, DOI 10.1097/MNM.0b013e3282f1bc22
   Kawasaki H, 1998, CANCER RES, V58, P5071
   Kondo Y, 2005, NAT REV CANCER, V5, P726, DOI 10.1038/nrc1692
   Leist M, 2001, NAT REV MOL CELL BIO, V2, P589, DOI 10.1038/35085008
   Mandl Stefanie J, 2004, Mol Imaging, V3, P1, DOI 10.1162/153535004773861679
   McGee MC, 2010, INT J RADIAT ONCOL, V76, P1537, DOI 10.1016/j.ijrobp.2009.12.010
   Mizushima N, 2004, INT J BIOCHEM CELL B, V36, P2491, DOI 10.1016/j.biocel.2004.02.005
   Mochizuki T, 2003, J NUCL MED, V44, P92
   Myers AL, 2010, J PEDIATR SURG, V45, P1080, DOI 10.1016/j.jpedsurg.2010.02.068
   Ohtsuki K, 1999, EUR J NUCL MED, V26, P1251, DOI 10.1007/s002590050580
   Rottey S, 2006, J NUCL MED, V47, P1813
   Tait F, 1994, THROMB RES, V75, P491, DOI [10.1016/0049-3848(94)90224-0., DOI 10.1016/0049-3848(94)90224-0]
   Takei T, 2004, J NUCL MED, V45, P2083
   Vand de Wiele C, 2003, J CLIN ONCOL, V21, P3483, DOI 10.1200/JCO.2003.12.096
   Vangestel C, 2010, NUCL MED BIOL, V37, P965, DOI 10.1016/j.nucmedbio.2010.06.007
   Wild R, 2006, MOL CANCER THER, V5, P104, DOI 10.1158/1535-7163.MCT-05-0259
   Yoshioka A, 2008, INT J ONCOL, V33, P461, DOI 10.3892/ijo_00000028
   Zhang HY, 2009, CLIN EXP MED, V9, P207, DOI 10.1007/s10238-009-0031-7
   Zwaal RFA, 2005, CELL MOL LIFE SCI, V62, P971, DOI 10.1007/s00018-005-4527-3
NR 35
TC 18
Z9 20
U1 0
U2 17
PU B C DECKER INC
PI HAMILTON
PA 69 JOHN STREET SOUTH, STE 310, HAMILTON, ONTARIO L8N 2B9, CANADA
SN 1535-3508
J9 MOL IMAGING
JI Mol. Imaging
PD MAR-APR
PY 2012
VL 11
IS 2
BP 135
EP 147
DI 10.2310/7290.2011.00034
PG 13
WC Biochemical Research Methods; Radiology, Nuclear Medicine & Medical
   Imaging
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Radiology, Nuclear Medicine & Medical
   Imaging
GA 990QO
UT WOS:000307645900005
PM 22469241
OA gold
DA 2022-04-25
ER

PT J
AU Huang, Z
   Liu, J
   Luo, L
   Sheng, P
   Wang, B
   Zhang, J
   Peng, SS
AF Huang, Zhi
   Liu, Jie
   Luo, Liang
   Sheng, Pan
   Wang, Biao
   Zhang, Jun
   Peng, Sha-sha
TI Genome-Wide Identification of a Novel Autophagy-Related Signature for
   Colorectal Cancer
SO DOSE-RESPONSE
LA English
DT Article
DE colorectal cancer; autophagy-related genes; prognostic signature; RNA
   sequencing
ID NEUREGULIN-1 NRG1; PROLIFERATION; EXPRESSION; PROGRESSION; METASTASIS;
   RECURRENCE; SURVIVAL; INVASION; ISOFORM; THERAPY
AB Background: Plenty of evidence has suggested that autophagy plays a crucial role in the biological processes of cancers. This study aimed to screen autophagy-related genes (ARGs) and establish a novel a scoring system for colorectal cancer (CRC). Methods: Autophagy-related genes sequencing data and the corresponding clinical data of CRC in The Cancer Genome Atlas were used as training data set. The GSE39582 data set from the Gene Expression Omnibus was used as validation set. An autophagy-related signature was developed in training set using univariate Cox analysis followed by stepwise multivariate Cox analysis and assessed in the validation set. Then we analyzed the function and pathways of ARGs using Gene Ontology and Kyoto Encyclopedia of Genes and Genomes (KEGG) database. Finally, a prognostic nomogram combining the autophagy-related risk score and clinicopathological characteristics was developed according to multivariate Cox analysis. Results: After univariate and multivariate analysis, 3 ARGs were used to construct autophagy-related signature. The KEGG pathway analyses showed several significantly enriched oncological signatures, such as p53 signaling pathway, apoptosis, human cytomegalovirus infection, platinum drug resistance, necroptosis, and ErbB signaling pathway. Patients were divided into high- and low-risk groups, and patients with high risk had significantly shorter overall survival (OS) than low-risk patients in both training set and validation set. Furthermore, the nomogram for predicting 3- and 5-year OS was established based on autophagy-based risk score and clinicopathologic factors. The area under the curve and calibration curves indicated that the nomogram showed well accuracy of prediction. Conclusions: Our proposed autophagy-based signature has important prognostic value and may provide a promising tool for the development of personalized therapy.
C1 [Huang, Zhi; Liu, Jie; Luo, Liang; Sheng, Pan; Wang, Biao; Zhang, Jun] Dazhou Cent Hosp, Dept Gen Surg, Dazhou, Sichuan, Peoples R China.
   [Peng, Sha-sha] Hubei Polytech Univ, Huangshi Cent Hosp, Dept Hepatobiliary & Pancreat Surg, Edong Healthcare Grp, 141 Tianjin Rd, Huangshi 435000, Hubei, Peoples R China.
   [Peng, Sha-sha] Wuhan Univ Sci & Technol, Hubei Prov Key Lab Occupat Hazard Identificat & C, 141 Tianjin Rd, Wuhan 435000, Hubei, Peoples R China.
RP Peng, SS (corresponding author), Hubei Polytech Univ, Huangshi Cent Hosp, Dept Hepatobiliary & Pancreat Surg, Edong Healthcare Grp, 141 Tianjin Rd, Huangshi 435000, Hubei, Peoples R China.; Peng, SS (corresponding author), Wuhan Univ Sci & Technol, Hubei Prov Key Lab Occupat Hazard Identificat & C, 141 Tianjin Rd, Wuhan 435000, Hubei, Peoples R China.
EM drpengss@126.com
FU Health commission of Hubei Province Scientific Research Project
   [WJ2019H160]
FX The author(s) disclosed receipt of the following financial support for
   the research, authorship, and/or publication of this article: This work
   was supported by Health commission of Hubei Province Scientific Research
   Project (WJ2019H160).
CR Amin MB, 2017, CA-CANCER J CLIN, V67, P93, DOI 10.3322/caac.21388
   Bai BJ, 2016, ONCOTARGET, V7, P76735, DOI 10.18632/oncotarget.12523
   Balachandran VP, 2015, LANCET ONCOL, V16, pE173, DOI 10.1016/S1470-2045(14)71116-7
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
   Chen XX, 2018, AGING-US, V10, P3421, DOI 10.18632/aging.101656
   Chen XX, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0962-6
   De Boeck A, 2013, GUT, V62, P550, DOI 10.1136/gutjnl-2011-301393
   Dong D, 2019, ANN ONCOL, V30, P431, DOI 10.1093/annonc/mdz001
   Fu JF, 2019, PEERJ, V7, DOI 10.7717/peerj.6350
   Fu YY, 2019, AUTOPHAGY, V15, P295, DOI 10.1080/15548627.2018.1517073
   Jehn CF, 2014, EUR J CANCER, V50, P1269, DOI 10.1016/j.ejca.2014.01.005
   Kohonen-Corish MRJ, 2014, INT J CANCER, V134, P2820, DOI 10.1002/ijc.28619
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Li JQ, 2018, J SURG ONCOL, V118, P1034, DOI 10.1002/jso.25213
   Liu XH, 2011, J NEUROSCI, V31, P8491, DOI 10.1523/JNEUROSCI.5317-10.2011
   Ludmir EB, 2017, CANCER-AM CANCER SOC, V123, P1497, DOI 10.1002/cncr.30600
   Mesange P, 2018, CLIN CANCER RES, V24, P2548, DOI 10.1158/1078-0432.CCR-17-3187
   Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639
   Moody L, 2019, CANCERS, V11, DOI 10.3390/cancers11081111
   Pan HD, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00643
   Peak TC, 2019, BJU INT, V123, P1005, DOI 10.1111/bju.14652
   Pole JCM, 2006, ONCOGENE, V25, P5693, DOI 10.1038/sj.onc.1209570
   Qiu YY, 2016, CELL PROLIFERAT, V49, P69, DOI 10.1111/cpr.12237
   Roxburgh CSD, 2012, CANCER TREAT REV, V38, P451, DOI 10.1016/j.ctrv.2011.09.001
   Russo A, 2005, J CLIN ONCOL, V23, P7518, DOI 10.1200/JCO.2005.00.471
   Steinthorsdottir V, 2004, GENE, V342, P97, DOI 10.1016/j.gene.2004.07.029
   Takahashi N, 2016, BRIT J CANCER, V114, P1003, DOI 10.1038/bjc.2016.74
   Tan W, 2007, J BIOL CHEM, V282, P24343, DOI 10.1074/jbc.M702953200
   Teo WH, 2017, INT J ONCOL, V51, P1415, DOI 10.3892/ijo.2017.4135
   Tournigand C, 2015, LANCET ONCOL, V16, P1493, DOI 10.1016/S1470-2045(15)00216-8
   Toyota M, 1999, SEMIN CANCER BIOL, V9, P349, DOI 10.1006/scbi.1999.0135
   Van Cutsem E, 2006, EUR J CANCER, V42, P2212, DOI 10.1016/j.ejca.2006.04.012
   Wade M, 2013, NAT REV CANCER, V13, P83, DOI 10.1038/nrc3430
   Wang CB, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00076
   Wang D, 2019, J TRANSL MED, V17, DOI 10.1186/s12967-019-2008-y
   Wang JY, 2017, BIOMED PHARMACOTHER, V93, P1047, DOI 10.1016/j.biopha.2017.07.030
   Wang M, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-1187-4
   Weidberg H, 2011, ANNU REV BIOCHEM, V80, P125, DOI 10.1146/annurev-biochem-052709-094552
   Wolbers M, 2009, EPIDEMIOLOGY, V20, P555, DOI 10.1097/EDE.0b013e3181a39056
   Xing X, 2013, BRIT J CANCER, V108, P2542, DOI 10.1038/bjc.2013.251
   Yang XH, 2018, CANCER MANAG RES, V10, P5839, DOI 10.2147/CMAR.S161990
   Yu CR, 2019, BIOSCIENCE REP, V39, DOI 10.1042/BSR20181781
   Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118
   Zhao CL, 2019, CANCER MED-US, V8, P200, DOI 10.1002/cam4.1932
   Zhao WJ, 2013, FOLIA HISTOCHEM CYTO, V51, P38, DOI 10.5603/FHC.2013.006
   Zhou L, 2019, FASEB J, V33, P5520, DOI 10.1096/fj.201801983R
NR 46
TC 13
Z9 13
U1 0
U2 2
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1559-3258
J9 DOSE-RESPONSE
JI Dose-Response
PD OCT
PY 2019
VL 17
IS 4
AR 1559325819894179
DI 10.1177/1559325819894179
PG 11
WC Pharmacology & Pharmacy; Radiology, Nuclear Medicine & Medical Imaging;
   Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy; Radiology, Nuclear Medicine & Medical Imaging;
   Toxicology
GA JV4WY
UT WOS:000502367300001
PM 31853237
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Wanigasooriya, K
   Tyler, R
   Barros-Silva, JD
   Sinha, Y
   Ismail, T
   Beggs, AD
AF Wanigasooriya, Kasun
   Tyler, Robert
   Barros-Silva, Joao D.
   Sinha, Yashashwi
   Ismail, Tariq
   Beggs, Andrew D.
TI Radiosensitising Cancer Using Phosphatidylinositol-3-Kinase (PI3K),
   Protein Kinase B (AKT) or Mammalian Target of Rapamycin (mTOR)
   Inhibitors
SO CANCERS
LA English
DT Review
DE radiosensitiser; chemoradiotherapy; PI3K; AKT; mTOR inhibitors; rectal
   cancer; prostate cancer; glioblastoma multiforme; head and neck cancer;
   non-small cell lung cancer
ID DUAL PI3K/MTOR INHIBITOR; SQUAMOUS-CELL CARCINOMA; ESTRO-SIOG
   GUIDELINES; PHASE-I TRIAL; PROSTATE-CANCER; 3-KINASE/MAMMALIAN TARGET;
   RADIATION-THERAPY; LUNG-CANCER; DNA-REPAIR; NEOADJUVANT TREATMENT
AB Radiotherapy is routinely used as a neoadjuvant, adjuvant or palliative treatment in various cancers. There is significant variation in clinical response to radiotherapy with or without traditional chemotherapy. Patients with a good response to radiotherapy demonstrate better clinical outcomes universally across different cancers. The PI3K/AKT/mTOR pathway upregulation has been linked to radiotherapy resistance. We reviewed the current literature exploring the role of inhibiting targets along this pathway, in enhancing radiotherapy response. We identified several studies using in vitro cancer cell lines, in vivo tumour xenografts and a few Phase I/II clinical trials. Most of the current evidence in this area comes from glioblastoma multiforme, non-small cell lung cancer, head and neck cancer, colorectal cancer, and prostate cancer. The biological basis for radiosensitivity following pathway inhibition was through inhibited DNA double strand break repair, inhibited cell proliferation, enhanced apoptosis and autophagy as well as tumour microenvironment changes. Dual PI3K/mTOR inhibition consistently demonstrated radiosensitisation of all types of cancer cells. Single pathway component inhibitors and other inhibitor combinations yielded variable outcomes especially within early clinical trials. There is ample evidence from preclinical studies to suggest that direct pharmacological inhibition of the PI3K/AKT/mTOR pathway components can radiosensitise different types of cancer cells. We recommend that future in vitro and in vivo research in this field should focus on dual PI3K/mTOR inhibitors. Early clinical trials are needed to assess the feasibility and efficacy of these dual inhibitors in combination with radiotherapy in brain, lung, head and neck, breast, prostate and rectal cancer patients.
C1 [Wanigasooriya, Kasun; Barros-Silva, Joao D.; Sinha, Yashashwi; Beggs, Andrew D.] Univ Birmingham, Inst Canc & Genom Sci, Coll Med & Dent Sci, Birmingham B15 2TT, W Midlands, England.
   [Wanigasooriya, Kasun; Tyler, Robert; Sinha, Yashashwi; Ismail, Tariq; Beggs, Andrew D.] Univ Hosp Birmingham NHS Fdn Trust, New Queen Elizabeth Hosp, Birmingham B15 2TH, W Midlands, England.
RP Wanigasooriya, K (corresponding author), Univ Birmingham, Inst Canc & Genom Sci, Coll Med & Dent Sci, Birmingham B15 2TT, W Midlands, England.; Wanigasooriya, K (corresponding author), Univ Hosp Birmingham NHS Fdn Trust, New Queen Elizabeth Hosp, Birmingham B15 2TH, W Midlands, England.
EM k.s.wanigasooriya@bham.ac.uk; r.tyler.2@bham.ac.uk; j.silva@bham.ac.uk;
   yashsinha1991@gmail.com; tariq.ismail@uhb.nhs.uk; a.beggs@bham.ac.uk
RI Beggs, Andrew/A-6912-2013
OI Beggs, Andrew/0000-0003-0784-2967; Wanigasooriya,
   Kasun/0000-0002-3683-1864; Barros Silva, Joao Diogo/0000-0002-6648-0217
FU Cancer Research UK, Advanced Clinician Scientist Award [C31641/A23923];
   MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC)
   [MR/M009157/1] Funding Source: UKRI
FX Cancer Research UK, Advanced Clinician Scientist Award (ref
   C31641/A23923).
CR Assad DX, 2018, PATHOL RES PRACT, V214, P259, DOI 10.1016/j.prp.2017.10.019
   Azria D, 2013, J CLIN ONCOL, V31, DOI 10.1200/jco.2013.31.6_suppl.150
   Barker HE, 2015, NAT REV CANCER, V15, P409, DOI 10.1038/nrc3958
   Bolla M, 2010, LANCET ONCOL, V11, P1066, DOI 10.1016/S1470-2045(10)70223-0
   Bozec A, 2011, ORAL ONCOL, V47, P340, DOI 10.1016/j.oraloncology.2011.02.020
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
   Brunn GJ, 1996, EMBO J, V15, P5256, DOI 10.1002/j.1460-2075.1996.tb00911.x
   Buijsen J, 2015, RADIOTHER ONCOL, V116, P214, DOI 10.1016/j.radonc.2015.07.039
   Burris HA, 2013, CANCER CHEMOTH PHARM, V71, P829, DOI 10.1007/s00280-012-2043-3
   Cerniglia GJ, 2012, MOL PHARMACOL, V82, P1230, DOI 10.1124/mol.112.080408
   Chalhoub N, 2009, ANNU REV PATHOL-MECH, V4, P127, DOI 10.1146/annurev.pathol.4.110807.092311
   Chang L, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.415
   Chen YH, 2019, CANCERS, V11, DOI 10.3390/cancers11081204
   Chen YH, 2015, CANCER LETT, V357, P582, DOI 10.1016/j.canlet.2014.12.015
   Chinnaiyan P, 2018, NEURO-ONCOLOGY, V20, P666, DOI 10.1093/neuonc/nox209
   Choi EJ, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-17
   Choi YJ, 2014, ONCOGENE, V33, P1890, DOI 10.1038/onc.2013.137
   Cornford P, 2017, EUR UROL, V71, P630, DOI 10.1016/j.eururo.2016.08.002
   Cuneo KC, 2015, PHARMACOL THERAPEUT, V154, P67, DOI 10.1016/j.pharmthera.2015.07.002
   D'Amico AV, 2003, J UROLOGY, V169, P1320, DOI 10.1097/01.ju.0000049200.30192.d1
   De Felice F, 2018, NEOPLASIA, V20, P227, DOI 10.1016/j.neo.2018.01.002
   de Melo AC, 2016, CANCER CHEMOTH PHARM, V78, P101, DOI 10.1007/s00280-016-3064-0
   del Alcazar CRG, 2014, CLIN CANCER RES, V20, P1235, DOI 10.1158/1078-0432.CCR-13-1607
   Detti B, 2016, J CHEMOTHERAPY, V28, P432, DOI 10.1080/1120009X.2016.1173869
   Deutsch E, 2015, ANN ONCOL, V26, P1223, DOI 10.1093/annonc/mdv105
   Diaz R, 2009, BRIT J CANCER, V100, P932, DOI 10.1038/sj.bjc.6604938
   Djuzenova CS, 2016, ONCOTARGET, V7, P38191, DOI 10.18632/oncotarget.9501
   Dumont RA, 2013, J NUCL MED, V54, P762, DOI 10.2967/jnumed.112.112169
   Edden Y, 2012, COLORECTAL DIS, V14, P555, DOI 10.1111/j.1463-1318.2011.02697.x
   Engelman JA, 2006, NAT REV GENET, V7, P606, DOI 10.1038/nrg1879
   Eshleman JS, 2002, CANCER RES, V62, P7291
   Fatehi D, 2018, PATHOL RES PRACT, V214, P889, DOI 10.1016/j.prp.2018.04.001
   Fokas E, 2012, RADIAT ONCOL, V7, DOI 10.1186/1748-717X-7-48
   Fokas E, 2012, CANCER RES, V72, P239, DOI 10.1158/0008-5472.CAN-11-2263
   Ganesh K, 2019, NAT MED, V25, P1607, DOI 10.1038/s41591-019-0584-2
   Gelsomino F, 2017, CLIN COLORECTAL CANC, V16, P410, DOI 10.1016/j.clcc.2017.03.011
   Golden E.B., 2015, SEMINARRAD ONCOLOG
   Gollins S, 2017, COLORECTAL DIS, V19, P37, DOI 10.1111/codi.13705
   Harrington KJ, 2011, BRIT J CANCER, V105, P628, DOI 10.1038/bjc.2011.240
   Hoendervangers S, 2018, EJSO-EUR J SURG ONC, V44, P1013, DOI 10.1016/j.ejso.2018.03.014
   Holler M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154745
   Junker K, 1997, J CANCER RES CLIN, V123, P469
   Kao GD, 2007, J BIOL CHEM, V282, P21206, DOI 10.1074/jbc.M703042200
   Kazda T, 2018, RADIOL ONCOL, V52, P121, DOI 10.2478/raon-2018-0023
   Kim EJ, 2013, J CELL BIOCHEM, V114, P1248, DOI 10.1002/jcb.24465
   Kim IA, 2005, CANCER RES, V65, P7902, DOI 10.1158/0008-5472.CAN-05-0513
   Kim KW, 2008, AUTOPHAGY, V4, P659, DOI 10.4161/auto.6058
   Kim Kwang Woon, 2014, Genes Cancer, V5, P293
   Konstantinidou G, 2009, CANCER RES, V69, P7644, DOI 10.1158/0008-5472.CAN-09-0823
   Kuger S, 2014, BREAST CANCER-BASIC, V8, P39, DOI 10.4137/BCBCR.S13693
   Kuger S, 2013, TRANSL ONCOL, V6, P169, DOI 10.1593/tlo.12364
   Laplante M, 2009, J CELL SCI, V122, P3589, DOI 10.1242/jcs.051011
   Leiker AJ, 2015, CLIN CANCER RES, V21, P2792, DOI 10.1158/1078-0432.CCR-14-3279
   Li HF, 2009, RADIAT ONCOL, V4, DOI 10.1186/1748-717X-4-43
   Liu Q, 2014, NEURO-ONCOLOGY, V16, P1313, DOI 10.1093/neuonc/nou058
   Liu TX, 2015, MOL CANCER THER, V14, P429, DOI 10.1158/1535-7163.MCT-14-0548
   Liu WL, 2014, ONCOTARGET, V5, P3662, DOI 10.18632/oncotarget.1978
   Lockney NA, 2017, CLIN TRANSL RAD ONCO, V7, P91, DOI 10.1016/j.ctro.2017.11.002
   Lukas J, 2013, SCIENCE, V339, P652, DOI 10.1126/science.1234602
   Ma DJ, 2015, NEURO-ONCOLOGY, V17, P1261, DOI 10.1093/neuonc/nou328
   Ma L, 2005, CELL, V121, P179, DOI 10.1016/j.cell.2005.02.031
   Maas M, 2010, LANCET ONCOL, V11, P835, DOI 10.1016/S1470-2045(10)70172-8
   Manegold PC, 2008, CLIN CANCER RES, V14, P892, DOI 10.1158/1078-0432.CCR-07-0955
   Manning BD, 2017, CELL, V169, P381, DOI 10.1016/j.cell.2017.04.001
   Marur S., 2016, MAYO CLIN P
   Mauceri HJ, 2012, ONCOL REP, V27, P1625, DOI 10.3892/or.2012.1666
   Miyasaka A, 2015, GYNECOL ONCOL, V138, P174, DOI 10.1016/j.ygyno.2015.04.015
   Mottet N, 2017, EUR UROL, V71, P618, DOI 10.1016/j.eururo.2016.08.003
   Movsas B., 2016, CANCER, V13, P515
   Mukherjee B, 2012, NEOPLASIA, V14, P34, DOI 10.1593/neo.111512
   Murphy JD, 2009, CLIN CANCER RES, V15, P589, DOI 10.1158/1078-0432.CCR-08-1019
   Nakamura JL, 2005, J NEURO-ONCOL, V71, P215, DOI 10.1007/s11060-004-1718-y
   Narayan V, 2017, INT J RADIAT ONCOL, V97, P355, DOI 10.1016/j.ijrobp.2016.10.013
   Osaki M, 2004, APOPTOSIS, V9, P667, DOI 10.1023/B:APPT.0000045801.15585.dd
   Pajonk F, 2010, STEM CELLS, V28, P639, DOI 10.1002/stem.318
   Panier S, 2013, NAT REV MOL CELL BIO, V14, P661, DOI 10.1038/nrm3659
   Park JH, 2017, ONCOTARGET, V8, P112893, DOI 10.18632/oncotarget.22850
   Pigott KH, 1996, RADIOTHER ONCOL, V40, P45, DOI 10.1016/0167-8140(96)01730-6
   Pitroda SP, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008291
   Porta C, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00064
   Potiron VA, 2013, RADIOTHER ONCOL, V106, P138, DOI 10.1016/j.radonc.2012.11.014
   Prevo R, 2008, CANCER RES, V68, P5915, DOI 10.1158/0008-5472.CAN-08-0757
   Qiao Q, 2013, J PHARMACOL SCI, V121, P247, DOI 10.1254/jphs.12149FP
   Qiao XY, 2003, LUNG CANCER-J IASLC, V41, P1, DOI 10.1016/S0169-5002(03)00152-1
   Rodel C, 2005, J CLIN ONCOL, V23, P8688, DOI 10.1200/JCO.2005.02.1329
   RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0
   Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474
   Rybinski B, 2016, ONCOTARGET, V7, P72322, DOI 10.18632/oncotarget.11875
   Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148
   Sarkaria JN, 2011, INT J RADIAT ONCOL, V81, P468, DOI 10.1016/j.ijrobp.2010.05.064
   Shaw RJ, 2006, NATURE, V441, P424, DOI 10.1038/nature04869
   Shi F, 2018, ONCOTARGET, V9, P706, DOI 10.18632/oncotarget.23091
   Shinohara ET, 2005, ONCOGENE, V24, P5414, DOI 10.1038/sj.onc.1208715
   Spiotto M, 2016, SCI IMMUNOL, V1, DOI 10.1126/sciimmunol.aag1266
   Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330
   Suarez J, 2008, COLORECTAL DIS, V10, P563, DOI 10.1111/j.1463-1318.2007.01424.x
   Thies S, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00262
   Toulany M, 2013, TRANSL CANCER RES, V2, P190, DOI 10.3978/j.issn.2218-676X.2013.04.09
   Van der Jeught K, 2018, WORLD J GASTROENTERO, V24, P3834, DOI 10.3748/wjg.v24.i34.3834
   van der Valk MJM, 2018, LANCET, V391, P2537, DOI 10.1016/S0140-6736(18)31078-X
   Vansteenkiste J, 2013, ANN ONCOL, V24, P89, DOI 10.1093/annonc/mdt241
   Vignard J, 2013, RADIOTHER ONCOL, V108, P362, DOI 10.1016/j.radonc.2013.06.013
   Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839
   Wang M, 2017, CANCER RES, V77, P2018, DOI 10.1158/0008-5472.CAN-16-0808
   Wang WJ, 2013, ACTA PHARMACOL SIN, V34, P681, DOI 10.1038/aps.2013.22
   Wen PY, 2015, NEURO-ONCOLOGY, V17, P1275, DOI 10.1093/neuonc/nov083
   Wise-Draper TM, 2017, TARGET ONCOL, V12, P323, DOI 10.1007/s11523-017-0482-9
   World Health Organisation, 2014, HEAD NECK CANC
   Young MR, 2016, PROSTATE CANCER: SCIENCE AND CLINICAL PRACTICE, 2ND EDITION, P413, DOI 10.1016/B978-0-12-800077-9.00045-1
   Yu CC, 2017, ONCOTARGET, V8, P68641, DOI 10.18632/oncotarget.19817
   Zhang HY, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-38585-9
   Zhu WJ, 2013, CANCER BIOTHER RADIO, V28, P665, DOI 10.1089/cbr.2012.1443
NR 112
TC 25
Z9 25
U1 2
U2 6
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2072-6694
J9 CANCERS
JI Cancers
PD MAY
PY 2020
VL 12
IS 5
AR 1278
DI 10.3390/cancers12051278
PG 29
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA LW6HT
UT WOS:000539246000219
PM 32443649
OA gold, Green Published, Green Submitted
DA 2022-04-25
ER

PT J
AU Draz, H
   Goldberg, A
   Guns, EST
   Fazli, L
   Safe, S
   Sanderson, J
AF Draz, Hossam
   Goldberg, Alexander A.
   Guns, Emma S. Tomlinson
   Fazli, Ladan
   Safe, Stephen
   Sanderson, J. Thomas
TI Autophagy inhibition improves the chemotherapeutic efficacy of
   cruciferous vegetable-derived diindolymethane in a murine prostate
   cancer xenograft model
SO INVESTIGATIONAL NEW DRUGS
LA English
DT Article
DE Prostate cancer; PC-3; CD-1 nude mice; Autophagy; Diindolylmethane;
   Ring-DIMs
ID IN-VIVO; 3,3'-DIINDOLYLMETHANE DIM; COLORECTAL-CANCER; CELLS; INDUCTION;
   APOPTOSIS; SURVIVAL; VITRO
AB Prostate cancer is the second leading cause of cancer-related deaths in men in North America and there is an urgent need for development of more effective therapeutic treatments against this disease. We have recently shown that diindolylmethane (DIM) and several of its halogenated derivatives (ring-DIMs) induce death and protective autophagy in human prostate cancer cells. However, the in vivo efficacy of ring-DIMs and the use of autophagy inhibitors as adjuvant therapy have not yet been studied in vivo. The objective of this study was to determine these effects on tumor growth in nude CD-1 mice bearing bioluminescent androgen-independent PC-3 human prostate cancer cells. We found that chloroquine (CQ) significantly sensitized PC-3 cells to death in the presence of sub-toxic concentrations of DIM or 4,4'-Br2DIM in vitro. Moreover, a combination of DIM (10 mg/kg) and CQ (60 mg/kg), 3x per week, significantly decreased PC-3 tumor growth in vivo after 3 and 4 weeks of treatment. Furthermore, 4,4'-Br2DIM at 10 mg/kg (3x per week) significantly inhibited tumour growth after 4 weeks of treatment. Tissues microarray analysis showed that DIM alone or combined with CQ induced apoptosis marker TUNEL; the combination also significantly inhibited the cell proliferation marker Ki67. In conclusion, we have confirmed that DIM and 4,4'-Br2DIM are effective agents against prostate cancer in vivo and shown that inhibition of autophagy with CQ enhances the anticancer efficacy of DIM. Our results suggest that including selective autophagy inhibitors as adjuvants may improve the efficacy of existing and novel drug therapies against prostate cancer.
C1 [Draz, Hossam; Goldberg, Alexander A.; Sanderson, J. Thomas] INRS Inst Armand Frappier, 531 Blvd Prairies, Laval, PQ H7V 1B7, Canada.
   [Draz, Hossam] Natl Res Ctr, Dept Biochem, Cairo, Egypt.
   [Guns, Emma S. Tomlinson; Fazli, Ladan] Univ British Columbia, Vancouver Prostate Ctr, Vancouver, BC, Canada.
   [Safe, Stephen] Texas A&M Univ, Vet Physiol & Pharmacol, College Stn, TX USA.
RP Sanderson, J (corresponding author), INRS Inst Armand Frappier, 531 Blvd Prairies, Laval, PQ H7V 1B7, Canada.
EM thomas.sanderson@iaf.inrs.ca
RI ; Sanderson, Thomas/H-7272-2015
OI , Alexander/0000-0002-7471-8598; Sanderson, Thomas/0000-0002-3190-2811
FU Canadian Institutes of Health Research (CIHR)Canadian Institutes of
   Health Research (CIHR) [MOP-115019]; Fonds de Recherche du Quebec -
   Sante (FRQS)Fonds de la Recherche en Sante du Quebec
FX This work was supported by an operating grant from the Canadian
   Institutes of Health Research (CIHR grant no. MOP-115019) to Thomas
   Sanderson and Emma Guns. Hossam Draz received a scholarship from the
   Fonds de Recherche du Quebec - Sante (FRQS).
CR Banerjee S, 2011, MUTAT RES-REV MUTAT, V728, P47, DOI 10.1016/j.mrrev.2011.06.001
   Blackadar CB, 2016, WORLD J CLIN ONCOL, V7, P54, DOI 10.5306/wjco.v7.i1.54
   Chen D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047186
   Chen N, 2009, BBA-MOL CELL RES, V1793, P1516, DOI 10.1016/j.bbamcr.2008.12.013
   Chen SN, 2010, BBA-REV CANCER, V1806, P220, DOI 10.1016/j.bbcan.2010.07.003
   Chen Y, 2008, CURR OPIN PHARMACOL, V8, P440, DOI 10.1016/j.coph.2008.07.005
   Cho HJ, 2011, MOL CARCINOGEN, V50, P100, DOI 10.1002/mc.20698
   DEKRUIF CA, 1991, CHEM-BIOL INTERACT, V80, P303, DOI 10.1016/0009-2797(91)90090-T
   Draz H, 2017, CELL SIGNAL, V40, P172, DOI 10.1016/j.cellsig.2017.09.006
   Fares F, 2010, EUR J CANCER PREV, V19, P199, DOI 10.1097/CEJ.0b013e328333fbce
   Goldberg AA, 2014, INVEST NEW DRUG, V32, P25, DOI 10.1007/s10637-013-9979-y
   Goldberg Alexander A, 2015, Genes Cancer, V6, P265
   Kim MK, 2009, P NUTR SOC, V68, P103, DOI 10.1017/S0029665108008884
   Le HT, 2003, J BIOL CHEM, V278, P21136, DOI 10.1074/jbc.M300588200
   Levy JMM, 2017, NAT REV CANCER, V17, P528, DOI 10.1038/nrc.2017.53
   Lorin S, 2013, SEMIN CANCER BIOL, V23, P361, DOI 10.1016/j.semcancer.2013.06.007
   Muilenburg D, 2014, ANTICANCER RES, V34, P631
   Nachshon-Kedmi M, 2004, PROSTATE, V61, P153, DOI 10.1002/pros.20092
   Parzych KR, 2014, ANTIOXID REDOX SIGN, V20, P460, DOI 10.1089/ars.2013.5371
   Siegel RL, 2016, CA-CANCER J CLIN, V66, P7, DOI 10.3322/caac.21332
   Singh-Gupta V, 2012, CANCER LETT, V318, P86, DOI 10.1016/j.canlet.2011.12.006
   Vyas AR, 2013, CANCER RES, V73, P5985, DOI 10.1158/0008-5472.CAN-13-0755
   White E, 2015, J CLIN INVEST, V125, P42, DOI 10.1172/JCI73941
   Wu TY, 2013, AAPS J, V15, P864, DOI 10.1208/s12248-013-9493-3
   Yang SY, 2011, ANN SURG ONCOL, V18, pS239, DOI 10.1245/s10434-011-1789-x
   Zhang XB, 2017, ONCOL REP, V38, P569, DOI 10.3892/or.2017.5693
   Zheng N, 2015, J PHARMACOL SCI, V128, P97, DOI 10.1016/j.jphs.2015.05.001
   Zhou HY, 2016, CANCER BIOMARK, V17, P1, DOI 10.3233/CBM-160613
NR 28
TC 5
Z9 5
U1 0
U2 6
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0167-6997
EI 1573-0646
J9 INVEST NEW DRUG
JI Invest. New Drugs
PD AUG
PY 2018
VL 36
IS 4
BP 718
EP 725
DI 10.1007/s10637-018-0595-8
PG 8
WC Oncology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Pharmacology & Pharmacy
GA GO5CD
UT WOS:000440034600023
PM 29607466
DA 2022-04-25
ER

PT J
AU Biddle, A
   Gammon, L
   Liang, X
   Costea, DE
   Mackenzie, IC
AF Biddle, Adrian
   Gammon, Luke
   Liang, Xiao
   Costea, Daniela Elena
   Mackenzie, Ian C.
TI Phenotypic Plasticity Determines Cancer Stem Cell Therapeutic Resistance
   in Oral Squamous Cell Carcinoma
SO EBIOMEDICINE
LA English
DT Article
DE Cancer; Stem cell; CSC; EMT; Plasticity; Therapy; Resistance
ID EPITHELIAL-MESENCHYMAL TRANSITION; LARGE GENE LISTS; BREAST-CANCER;
   COLORECTAL-CANCER; RETINOIC ACID; TUMOR-GROWTH; METASTASIS;
   CHEMOTHERAPY; LINES; CD24
AB Cancer stem cells (CSCs) drive tumour spread and therapeutic resistance, and can undergo epithelial-to-mesenchymal transition (EMT) and mesenchymal-to-epithelial transition (MET) to switch between epithelial and post-EMT sub-populations. Examining oral squamous cell carcinoma (OSCC), we now show that increased phenotypic plasticity, the ability to undergo EMT/MET, underlies increased CSC therapeutic resistance within both the epithelial and post-EMT sub-populations. The post-EMT CSCs that possess plasticity exhibit particularly enhanced therapeutic resistance and are defined by a CD44(high)EpCAM(low)/-CD24(+) cell surface marker profile. Treatment with TGF beta and retinoic acid (RA) enabled enrichment of this sub-population for therapeutic testing, through which the endoplasmic reticulum(ER) stressor and autophagy inhibitor Thapsigargin was shown to selectively target these cells. Demonstration of the link between phenotypic plasticity and therapeutic resistance, and development of an in vitro method for enrichment of a highly resistant CSC sub-population, provides an opportunity for the development of improved chemotherapeutic agents that can eliminate CSCs. (C) 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
C1 [Biddle, Adrian; Gammon, Luke; Mackenzie, Ian C.] Queen Mary Univ London, Barts & London Sch Med & Dent, Blizard Inst, London, England.
   [Liang, Xiao; Costea, Daniela Elena] Univ Bergen, Dept Clin Med, Gade Lab Pathol, N-5020 Bergen, Norway.
RP Biddle, A (corresponding author), Blizard Inst, Ctr Cell Biol & Cutaneous Res, 4 Newark St, London E1 2AT, England.
EM a.biddle@qmul.ac.uk
RI Costea, Daniela Elena/AAB-9705-2020
OI Liang, Kristina Xiao/0000-0002-3586-4218; Biddle,
   Adrian/0000-0003-4371-9720; Costea, Daniela-Elena/0000-0001-7673-0358
FU National Centre for the Replacement [NC/L00061X/1, NC/K500495/1,
   G0900799/1] Funding Source: researchfish; National Centre for the
   Replacement, Refinement and Reduction of Animals in ResearchUK Research
   & Innovation (UKRI)National Centre for the Replacement, Refinement &
   Reduction of Animals in Research (NC3Rs) [G0900799/1, NC/K500495/1,
   NC/L00061X/1] Funding Source: Medline
CR Aigner S, 1997, BLOOD, V89, P3385, DOI 10.1182/blood.V89.9.3385
   Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100
   Azzam DJ, 2013, EMBO MOL MED, V5, P1502, DOI 10.1002/emmm.201302558
   Biddle A, 2011, CANCER RES, V71, P5317, DOI 10.1158/0008-5472.CAN-11-1059
   Brabletz T, 2012, CANCER CELL, V22, P699, DOI 10.1016/j.ccr.2012.11.009
   Bretz N, 2012, CLIN EXP METASTAS, V29, P27, DOI 10.1007/s10585-011-9426-4
   Buchberger A, 2010, MOL CELL, V40, P238, DOI 10.1016/j.molcel.2010.10.001
   Chaffer CL, 2006, CANCER RES, V66, P11271, DOI 10.1158/0008-5472.CAN-06-2044
   Chaffer CL, 2013, CELL, V154, P61, DOI 10.1016/j.cell.2013.06.005
   Charafe-Jauffret E, 2010, CLIN CANCER RES, V16, P45, DOI 10.1158/1078-0432.CCR-09-1630
   Chen F, 2007, DEVELOPMENT, V134, P2969, DOI 10.1242/dev.006221
   Clarke Michael F, 2006, Cancer Res, V66, P9339, DOI 10.1158/0008-5472.CAN-06-3126
   da Silva SD, 2012, FRONT PHARMACOL, V3, DOI 10.3389/fphar.2012.00149
   Driessens G, 2012, NATURE, V488, P527, DOI 10.1038/nature11344
   Drygin D, 2011, CANCER RES, V71, P1418, DOI 10.1158/0008-5472.CAN-10-1728
   Ganley IG, 2011, MOL CELL, V42, P731, DOI 10.1016/j.molcel.2011.04.024
   Gjerdrum C, 2010, P NATL ACAD SCI USA, V107, P1124, DOI 10.1073/pnas.0909333107
   Goldman A, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7139
   Gupta PB, 2009, CELL, V138, P645, DOI 10.1016/j.cell.2009.06.034
   Hay ED, 2005, DEV DYNAM, V233, P706, DOI 10.1002/dvdy.20345
   Hermann PC, 2007, CELL STEM CELL, V1, P313, DOI 10.1016/j.stem.2007.06.002
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923
   Jensen DH, 2015, J PATHOL, V236, P505, DOI 10.1002/path.4550
   Ke XS, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-669
   Kreso A, 2013, SCIENCE, V339, P543, DOI 10.1126/science.1227670
   Kristiansen G, 2004, J MOL HISTOL, V35, P255
   Kroemer G, 2010, MOL CELL, V40, P280, DOI 10.1016/j.molcel.2010.09.023
   Lau AN, 2014, EMBO J, V33, P468, DOI 10.1002/embj.201386082
   Li XX, 2008, J NATL CANCER I, V100, P672, DOI 10.1093/jnci/djn123
   Lim J, 2014, ARCH BIOCHEM BIOPHYS, V558, P120, DOI 10.1016/j.abb.2014.06.022
   Liu SL, 2014, STEM CELL REP, V2, P78, DOI 10.1016/j.stemcr.2013.11.009
   Locke M, 2005, CANCER RES, V65, P8944, DOI 10.1158/0008-5472.CAN-05-0931
   Martinsson H, 2005, EXP DERMATOL, V14, P161, DOI 10.1111/j.0906-6705.2005.00239.x
   Metallo CM, 2008, STEM CELLS, V26, P372, DOI 10.1634/stemcells.2007-0501
   Ocana OH, 2012, CANCER CELL, V22, P709, DOI 10.1016/j.ccr.2012.10.012
   Prince ME, 2007, P NATL ACAD SCI USA, V104, P973, DOI 10.1073/pnas.0610117104
   Sarrio D, 2012, STEM CELLS, V30, P292, DOI 10.1002/stem.791
   Sharma SV, 2010, CELL, V141, P69, DOI 10.1016/j.cell.2010.02.027
   Torre LA, 2015, CA CANC J CLIN
   Tsai JH, 2012, CANCER CELL, V22, P725, DOI 10.1016/j.ccr.2012.09.022
   Xu CY, 2005, J CLIN INVEST, V115, P2656, DOI 10.1172/JCI26373
   Yamamoto A, 1998, CELL STRUCT FUNCT, V23, P33, DOI 10.1247/csf.23.33
   Yang MH, 2008, NAT CELL BIOL, V10, P295, DOI 10.1038/ncb1691
   Yeung TM, 2010, P NATL ACAD SCI USA, V107, P3722, DOI 10.1073/pnas.0915135107
NR 45
TC 70
Z9 75
U1 0
U2 8
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 2352-3964
J9 EBIOMEDICINE
JI EBioMedicine
PD FEB
PY 2016
VL 4
BP 138
EP 145
DI 10.1016/j.ebiom.2016.01.007
PG 8
WC Medicine, General & Internal; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine; Research & Experimental Medicine
GA DE7HL
UT WOS:000370806400024
PM 26981578
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Jo, YK
   Park, NY
   Shin, JH
   Jo, DS
   Bae, JE
   Choi, ES
   Maeng, S
   Jeon, HB
   Roh, SA
   Chang, JW
   Kim, JC
   Cho, DH
AF Jo, Yoon Kyung
   Park, Na Yeon
   Shin, Ji Hyun
   Jo, Doo Sin
   Bae, Ji-Eun
   Choi, Eun Sun
   Maeng, Sungho
   Jeon, Hong Bae
   Roh, Seon Ae
   Chang, Jong Wook
   Kim, Jin Cheon
   Cho, Dong-Hyung
TI Up-regulation of UVRAG by HDAC1 Inhibition Attenuates 5FU-induced Cell
   Death in HCT116 Colorectal Cancer Cells
SO ANTICANCER RESEARCH
LA English
DT Article
DE UVRAG; HDAC1; epigenetics; 5FU; colorectal cancer
ID TRANSCRIPTIONAL REGULATION; HISTONE DEACETYLASES; DUAL ROLE; AUTOPHAGY;
   GENE; MECHANISMS; APOPTOSIS; MUTATION; THERAPY
AB The ultraviolent irradiation resistance-associated gene (UVRAG), a component of the Beclin 1/autophagy-related 6 complex, regulates the autophagy initiation step and functions in the DNA-damage response. UVRAG is frequently mutated in various cancer types, and mutations of UVRAG increase sensitivity to chemotherapy by impairing DNA-damage repair. In this study, we addressed the epigenetic regulation of UVRAG in colorectal cancer cells. UVRAG expression was increased in cells treated with histone deacetylase (HDAC) inhibitors, such as valproic acid and suberoylanilide hydroxamic acid. Down-regulation of HDAC1 enhanced UVRAG expression in colorectal cancer cells. In addition, both chemical and genetic inhibition of HDAC1 reduced the activation of caspase-3 and cytotoxicity in 5-fluorouracil (5FU)-treated cancer cells. In contrast, UVRAG overexpression inhibited caspase activation and cell death in 5FU-treated cells. Taken together, our findings suggest that up-regulation of UVRAG by HDAC1 inhibition potentiates DNA-damage-mediated cell death in colorectal cancer cells.
C1 [Jo, Yoon Kyung; Park, Na Yeon; Shin, Ji Hyun; Jo, Doo Sin; Bae, Ji-Eun; Choi, Eun Sun; Maeng, Sungho; Cho, Dong-Hyung] Kyung Hee Univ, Grad Sch East West Med Sci, Dept Gerontol, Seoul, South Korea.
   [Jeon, Hong Bae] MEDIPOST Corp, Biomed Res Inst, Seongnam, South Korea.
   [Roh, Seon Ae; Kim, Jin Cheon] Asan Med Ctr, Asan Inst Life Sci, Seoul, South Korea.
   [Chang, Jong Wook] Samsung Med Ctr, Stem Cell & Regenerat Med Inst, Seoul, South Korea.
   [Kim, Jin Cheon] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Surg, Seoul, South Korea.
RP Kim, JC (corresponding author), Univ Ulsan, Coll Med, Asan Med Ctr 88, Dept Surg, Olymp Ro 43 Gil, Seoul 05505, South Korea.; Cho, DH (corresponding author), Kyung Hee Univ, Grad Sch East West Med Sci, 1732 Deogyeong Daero, Yongin 17014, Gyeonggi Do, South Korea.
EM jckim@amc.seoul.kr; dhcho@khu.ac.kr
RI Maeng, Sungho/N-2905-2018
OI Maeng, Sungho/0000-0002-9347-7902
FU National Research Foundation, Ministry of Science, ICT and Future
   Planning, Republic of Korea [NRF-2017R1A2B4005501, 2016R1E1A1A02919844]
FX This study was supported by grants from the National Research Foundation
   NRF-2017R1A2B4005501 and 2016R1E1A1A02919844), Ministry of Science, ICT
   and Future Planning, Republic of Korea
CR Boland CR, 2010, GASTROENTEROLOGY, V138, P2073, DOI [10.1053/j.gastro.2009.12.064, 10.1053/j.gastro.2010.04.024]
   Choi AMK, 2013, NEW ENGL J MED, V368, P651, DOI [10.1056/NEJMra1205406, 10.1056/NEJMc1303158]
   De Ruijter AJM, 2003, BIOCHEM J, V370, P737, DOI 10.1042/BJ20021321
   Falkenberg KJ, 2014, NAT REV DRUG DISCOV, V13, P673, DOI 10.1038/nrd4360
   Fullgrabe J, 2016, J CELL SCI, V129, P3059, DOI 10.1242/jcs.188920
   He SS, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8839
   Huangfu LT, 2016, ONCOTARGET, V7, P4735, DOI 10.18632/oncotarget.6732
   Kaur J, 2015, NAT REV MOL CELL BIO, V16, P461, DOI 10.1038/nrm4024
   Kim MS, 2008, HUM PATHOL, V39, P1059, DOI 10.1016/j.humpath.2007.11.013
   Kim Y, 2015, AUTOPHAGY, V11, P796, DOI 10.1080/15548627.2015.1035503
   Klionsky DJ, 2016, AUTOPHAGY, V12, P1, DOI 10.1080/15548627.2015.1100356
   Knaevelsrud H, 2010, AUTOPHAGY, V6, P863, DOI 10.4161/auto.6.7.13033
   Lee JM, 2014, NATURE, V516, P112, DOI 10.1038/nature13961
   Li ZM, 2014, INT J BIOL SCI, V10, P757, DOI 10.7150/ijbs.9067
   Liang CY, 2007, AUTOPHAGY, V3, P69, DOI 10.4161/auto.3437
   Liang C, 2006, NAT CELL BIOL, V8, P688, DOI 10.1038/ncb1426
   Mottamal M, 2015, MOLECULES, V20, P3898, DOI 10.3390/molecules20033898
   Santoro F, 2013, BLOOD, V121, P3459, DOI 10.1182/blood-2012-10-461988
   Seok S, 2014, NATURE, V516, P108, DOI 10.1038/nature13949
   Shin HJR, 2016, NATURE, V534, P553, DOI 10.1038/nature18014
   Shin HJ, 2016, ONCOTARGET, V7, P39796
   Wilson AJ, 2006, J BIOL CHEM, V281, P13548, DOI 10.1074/jbc.M510023200
   Witt O, 2009, CANCER LETT, V280, P123, DOI 10.1016/j.canlet.2009.02.038
   Xie YX, 2015, AUTOPHAGY, V11, P1934, DOI 10.1080/15548627.2015.1084460
   Yang W, 2013, EXP CELL RES, V319, P122, DOI 10.1016/j.yexcr.2012.11.014
   Yang YF, 2016, MOL CELL, V62, P507, DOI 10.1016/j.molcel.2016.04.014
   Yin XC, 2011, EMBO REP, V12, P727, DOI 10.1038/embor.2011.79
   Zhao Z, 2012, AUTOPHAGY, V8, P1392, DOI 10.4161/auto.21035
   Zhao Z, 2012, DEV CELL, V22, P1001, DOI 10.1016/j.devcel.2011.12.027
NR 29
TC 15
Z9 16
U1 1
U2 9
PU INT INST ANTICANCER RESEARCH
PI ATHENS
PA EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22,
   ATHENS 19014, GREECE
SN 0250-7005
EI 1791-7530
J9 ANTICANCER RES
JI Anticancer Res.
PD JAN
PY 2018
VL 38
IS 1
BP 271
EP 277
DI 10.21873/anticanres.12218
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA FR5TW
UT WOS:000419130100035
PM 29277783
OA Bronze
DA 2022-04-25
ER

PT J
AU Long, HD
   Ma, YS
   Yang, HQ
   Xue, SB
   Liu, JB
   Yu, F
   Lv, ZW
   Li, JY
   Xie, RT
   Chang, ZY
   Lu, GX
   Xie, WT
   Fu, D
   Pang, LJ
AF Long, Hui-Deng
   Ma, Yu-Shui
   Yang, Hui-Qiong
   Xue, Shao-Bo
   Liu, Ji-Bin
   Yu, Fei
   Lv, Zhong-Wei
   Li, Ji-Yu
   Xie, Ru-Ting
   Chang, Zheng-Yan
   Lu, Gai-Xia
   Xie, Wen-Ting
   Fu, Da
   Pang, Li-Juan
TI Reduced hsa-miR-124-3p levels are associated with the poor survival of
   patients with hepatocellular carcinoma
SO MOLECULAR BIOLOGY REPORTS
LA English
DT Article
DE Hsa-miR-124-3p expression; HCC; OS; GEO; Biomarker
ID CANCER STEM-CELLS; COLORECTAL-CANCER; PROLIFERATION; MICRORNA-124A;
   MIR-124A; IDENTIFICATION; GLIOBLASTOMA; METASTASIS; AUTOPHAGY; ALTERS
AB Hsa-MicroRNA-124a-3p (hsa-miR-124-3p) is involved in tumor progression in certain malignant tumors. However, its function and clinical implication in hepatocellular carcinoma (HCC) have not yet been illustrated. In this study, we explored the expression and prognostic value of hsa-miR-124-3p in patients with HCC. Hsa-miR-124-3p expression in HCC was analyzed in silico, which was subsequently confirmed by quantitative PCR in 155 HCC biopsy samples. Overall survival (OS) and disease-free survival in HCC patients was evaluated by Kaplan-Meier survival analysis, and univariate and multivariate Cox proportional hazard models were used. The in silico results demonstrated that hsa-miR-124-3p was reduced in cell lines and tissues of HCC, and hsa-miR-124-3p expression was lower in HCC tumor samples than in normal liver tissues. Moreover, a decrease in hsa-miR-124-3p expression was closely correlated with tumor diameter (ae<yen> 5 cm) and number of lesions (multiple). Lower hsa-miR-124-3p expression was shown to be correlated with a shorter OS and poor prognosis in HCC. Our findings demonstrate that hsa-miR-124-3p might be a potential target for the diagnosis and prognosis of HCC.
C1 [Long, Hui-Deng; Pang, Li-Juan] Shihezi Univ, Sch Med, Affiliated Hosp 1, Dept Pathol, Shihezi 832003, Xinjiang, Peoples R China.
   [Ma, Yu-Shui] East China Normal Univ, Coll Chem & Mol Engn, Shanghai Engn Res Ctr Mol Therapeut & New Drug De, Shanghai 200062, Peoples R China.
   [Ma, Yu-Shui; Yu, Fei; Lv, Zhong-Wei; Lu, Gai-Xia; Xie, Wen-Ting; Fu, Da] Tongji Univ, Sch Med, Shanghai Peoples Hosp 10, Dept Nucl Med, Shanghai 200072, Peoples R China.
   [Yang, Hui-Qiong; Xie, Ru-Ting; Chang, Zheng-Yan] Tongji Univ, Sch Med, Shanghai Peoples Hosp 10, Dept Pathol, Shanghai 200072, Peoples R China.
   [Xue, Shao-Bo; Li, Ji-Yu; Fu, Da] Tongji Univ, Sch Med, Shanghai Peoples Hosp 10, Cent Lab Med Res, Shanghai 200072, Peoples R China.
   [Liu, Ji-Bin] Nantong Tumor Hosp, Inst Canc, Nantong 226631, Peoples R China.
RP Pang, LJ (corresponding author), Shihezi Univ, Sch Med, Affiliated Hosp 1, Dept Pathol, Shihezi 832003, Xinjiang, Peoples R China.; Fu, D (corresponding author), Tongji Univ, Sch Med, Shanghai Peoples Hosp 10, Dept Nucl Med, Shanghai 200072, Peoples R China.; Fu, D (corresponding author), Tongji Univ, Sch Med, Shanghai Peoples Hosp 10, Cent Lab Med Res, Shanghai 200072, Peoples R China.
EM fu800da900@126.com; ocean123456@163.com
RI Sui, Yanwei/AAH-9928-2021
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81560053, 81772932, 81201535, 81302065,
   81472202, 81301993]; Youth Science and Technology Innovation Leading
   Talents Project of Corps [2017CB004]; Fundamental Research Funds for the
   Central UniversitiesFundamental Research Funds for the Central
   Universities [22120170212, 22120170117]; Shanghai Natural Science
   FoundationNatural Science Foundation of Shanghai [12ZR1436000]; Shanghai
   Municipal Commission of Health and Family Planning [201540228]; peak of
   six personnel Foundation in Jiangsu Province [WSW-009]; fifth phase of
   333 talents Engineering Science and Technology Project of Jiangsu
   Province [BRA2017205]
FX This study was supported partly by grants from the National Natural
   Science Foundation of China (81560053, 81772932, 81201535, 81302065,
   81472202 and 81301993), the Youth Science and Technology Innovation
   Leading Talents Project of Corps (2017CB004), The Fundamental Research
   Funds for the Central Universities (22120170212 and 22120170117),
   Shanghai Natural Science Foundation (12ZR1436000), Shanghai Municipal
   Commission of Health and Family Planning (201540228), The peak of six
   personnel Foundation in Jiangsu Province (WSW-009) and The fifth phase
   of 333 talents Engineering Science and Technology Project of Jiangsu
   Province (BRA2017205).
CR Ben Gacem R, 2014, TUMOR BIOL, V35, P4047, DOI 10.1007/s13277-013-1530-4
   Chen XY, 2013, INVEST OPHTH VIS SCI, V54, P2248, DOI 10.1167/iovs.12-10977
   Chen XR, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0787-2
   Cheng LC, 2009, NAT NEUROSCI, V12, P399, DOI 10.1038/nn.2294
   Deng GR, 2011, ONCOL LETT, V2, P175, DOI 10.3892/ol.2010.222
   Dong Z, 2017, BIOCHEM BIOPH RES CO, V483, P630, DOI 10.1016/j.bbrc.2016.12.091
   Du XX, 2017, TOXICOL LETT, V280, P195, DOI 10.1016/j.toxlet.2017.08.082
   Fowler A, 2011, EUR J CANCER, V47, P953, DOI 10.1016/j.ejca.2010.11.026
   Fu D, 2009, J CELL BIOCHEM, V107, P686, DOI 10.1002/jcb.22163
   Fu XT, 2018, CANCER LETT, V412, P108, DOI 10.1016/j.canlet.2017.10.012
   Hou LK, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170431
   Huang Q, 2017, JPN J CLIN ONCOL, V47, P590, DOI 10.1093/jjco/hyw188
   Jazirehi Ali R, 2013, Epigenomics, V5, P251
   Kawano S, 2011, ANN RHEUM DIS, V70, pI88, DOI 10.1136/ard.2010.138669
   Kynast KL, 2013, PAIN, V154, P368, DOI 10.1016/j.pain.2012.11.010
   Liang Z, 2017, ONCOTARGET, V8, P47389, DOI 10.18632/oncotarget.17650
   Liu LL, 2011, STEM CELLS DEV, V20, P2023, DOI 10.1089/scd.2011.0012
   Luo P, 2017, MOL MED REP, V16, P238, DOI 10.3892/mmr.2017.6595
   Lv HW, 2018, CANCER LETT, V418, P51, DOI 10.1016/j.canlet.2018.01.001
   Ma YS, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0890-1
   Ma YS, 2017, ONCOTARGET, V8, P11896, DOI 10.18632/oncotarget.14435
   Rajasethupathy P, 2009, NEURON, V63, P803, DOI 10.1016/j.neuron.2009.05.029
   Shah R, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153691
   Wang XF, 2013, CANCER EPIDEMIOL, V37, P60, DOI 10.1016/j.canep.2012.07.007
   Wang Y, 2012, J CELL MOL MED, V16, P425, DOI 10.1111/j.1582-4934.2011.01437.x
   Wu SD, 2012, CANCER TREAT REV, V38, P218, DOI 10.1016/j.ctrv.2011.06.010
   Xie RT, 2018, ONCOL LETT, V15, P4571, DOI 10.3892/ol.2018.7892
   Yang HQ, 2018, ONCOL LETT, V15, P4097, DOI 10.3892/ol.2018.7879
   Yu JY, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13884
   Yuan HR, 2017, J CLIN INVEST, V127, P3381, DOI 10.1172/JCI94292
   Yuan JY, 2017, BIOCHEM BIOPH RES CO, V483, P578, DOI 10.1016/j.bbrc.2016.12.102
   Zhao JJ, 2010, BLOOD, V115, P2630, DOI 10.1182/blood-2009-09-243147
NR 32
TC 29
Z9 30
U1 1
U2 8
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0301-4851
EI 1573-4978
J9 MOL BIOL REP
JI Mol. Biol. Rep.
PD DEC
PY 2018
VL 45
IS 6
BP 2615
EP 2623
DI 10.1007/s11033-018-4431-1
PG 9
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA HD5BS
UT WOS:000452543200102
PM 30341691
DA 2022-04-25
ER

PT J
AU Ji, E
   Lee, H
   Ahn, S
   Jung, M
   Lee, SH
   Lee, JH
   Lee, EK
AF Ji, Eunbyul
   Lee, Heejin
   Ahn, Sojin
   Jung, Myeongwoo
   Lee, Sung Hak
   Lee, Jeong-Hwa
   Lee, Eun Kyung
TI Heterogeneous nuclear ribonucleoprotein A1 promotes the expression of
   autophagy-related protein 6 in human colorectal cancer
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Heterogeneous nuclear ribonucleoprotein A1; Autophagy-related gene 6;
   Colorectal cancer; Post-transcriptional regulation
ID RNA-BINDING PROTEIN; BECLIN 1; POOR-PROGNOSIS; GENE; PHOSPHORYLATION;
   TRANSCRIPTION; MECHANISM; PATTERNS; SWITCH; CELLS
AB Autophagy, a lysosomal self-degradative process of cellular components, is essential for cellular homeostasis to response cellular stress and is tightly controlled by autophagy-related genes (ATGs). Autophagy-related gene 6 (ATG6, also known as Beclin-1 in human) is an essential factor regulating autophagy and apoptosis. RNA binding proteins (RBPs) regulate gene expression at the post-transcriptional level and their differential expression is linked to the pathogenesis of several human diseases. Here, we demonstrate the role of heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1) as a novel factor regulating ATG6 expression. hnRNPA1 associates with the 3' untranslated region (3'UTR) of ATG6 mRNA and promotes its expression without significant changes at the mRNA level. Knockdown of hnRNPA1 decreases ATG6 expression, which is enhanced by the overexpression of hnRNPA1. Also, we show augmented expression of both hnRNPA1 and ATG6 in the colorectal cancer (CRC) tissues obtained from patients and demonstrate a positive correlation of their expression in CRC tissues. Our results suggest the potential role of hnRNPA1-mediated ATG6 regulation in the pathogenesis of CRC. (C) 2019 Elsevier Inc. All rights reserved.
C1 [Ji, Eunbyul; Lee, Heejin; Ahn, Sojin; Jung, Myeongwoo; Lee, Jeong-Hwa; Lee, Eun Kyung] Catholic Univ, Korea Coll Med, Dept Biochem, Seoul 06591, South Korea.
   [Lee, Jeong-Hwa; Lee, Eun Kyung] Catholic Univ, Korea Coll Med, Inst Aging & Metab Dis, Seoul 06591, South Korea.
   [Lee, Sung Hak] Catholic Univ, Korea Coll Med, Dept Hosp Pathol, Seoul 06591, South Korea.
RP Lee, EK (corresponding author), 222 Banpodae Ro, Seoul 06591, South Korea.
EM leeek@catholic.ac.kr
OI Lee, Eun Kyung/0000-0003-4207-2080
FU National Research Foundation of Korea - Korea governmentNational
   Research Foundation of KoreaKorean Government [2017R1A2B2009381,
   2017R1A2B2005508]
FX This work is supported by the National Research Foundation of Korea
   grant funded by the Korea government (2017R1A2B2009381 and
   2017R1A2B2005508).
CR Abrahamsen H, 2012, FEBS LETT, V586, P1584, DOI 10.1016/j.febslet.2012.04.046
   Ahn CH, 2007, APMIS, V115, P1344, DOI 10.1111/j.1600-0463.2007.00858.x
   Botti-Millet J, 2016, AM J PHYSIOL-CELL PH, V311, pC351, DOI 10.1152/ajpcell.00129.2016
   Bruun GH, 2016, BMC BIOL, V14, DOI 10.1186/s12915-016-0279-9
   Burada F, 2015, WORLD J GASTRO ONCOL, V7, P271, DOI 10.4251/wjgo.v7.i11.271
   Buxade M, 2005, IMMUNITY, V23, P177, DOI 10.1016/j.immuni.2005.06.009
   Chen M, 2010, CANCER RES, V70, P8977, DOI 10.1158/0008-5472.CAN-10-2513
   Copetti T, 2009, MOL CELL BIOL, V29, P2594, DOI 10.1128/MCB.01396-08
   David CJ, 2010, NATURE, V463, P364, DOI 10.1038/nature08697
   Feng YC, 2015, TRENDS CELL BIOL, V25, P354, DOI 10.1016/j.tcb.2015.02.002
   Glick D, 2010, J PATHOL, V221, P3, DOI 10.1002/path.2697
   Glisovic T, 2008, FEBS LETT, V582, P1977, DOI 10.1016/j.febslet.2008.03.004
   Gong C, 2013, ONCOGENE, V32, P2261, DOI 10.1038/onc.2012.252
   Guo GF, 2011, WORLD J GASTROENTERO, V17, P4779, DOI 10.3748/wjg.v17.i43.4779
   Gurkar AU, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3189
   Hope NR, 2011, HUM PATHOL, V42, P393, DOI 10.1016/j.humpath.2010.08.006
   Hu GW, 2015, NAT CELL BIOL, V17, P930, DOI 10.1038/ncb3189
   Iervolino A, 2002, MOL CELL BIOL, V22, P2255, DOI 10.1128/MCB.22.7.2255-2266.2002
   Ji E, 2019, MOL CELL BIOL, V39, DOI 10.1128/MCB.00508-18
   Kang R, 2011, CELL DEATH DIFFER, V18, P571, DOI 10.1038/cdd.2010.191
   Kim C, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/2062384
   Kim C, 2014, J BIOL CHEM, V289, P112, DOI 10.1074/jbc.M113.474700
   Koukourakis MI, 2010, BRIT J CANCER, V103, P1209, DOI 10.1038/sj.bjc.6605904
   Lee EK, 2012, MOL CELL, V45, P826, DOI 10.1016/j.molcel.2012.01.016
   Levine B, 2007, NATURE, V446, P745, DOI 10.1038/446745a
   Lewis SM, 2007, MOL BIOL CELL, V18, P1302, DOI 10.1091/mbc.E06-06-0515
   Li DD, 2009, ONCOGENE, V28, P886, DOI 10.1038/onc.2008.441
   Lin H, 2014, MOL PHARMACOL, V85, P682, DOI 10.1124/mol.113.090092
   Ma YL, 2009, J PROTEOME RES, V8, P4525, DOI 10.1021/pr900365e
   Masuda K., 2018, DIVERSE ROLES RNA BI, pe1520
   Mukaka MM, 2012, MALAWI MED J, V24, P69
   Murrow L, 2013, ANNU REV PATHOL-MECH, V8, P105, DOI 10.1146/annurev-pathol-020712-163918
   Nicotra G, 2010, MODERN PATHOL, V23, P937, DOI 10.1038/modpathol.2010.80
   Noda NN, 2015, ANNU REV BIOPHYS, V44, P101, DOI 10.1146/annurev-biophys-060414-034248
   Otsuka Kurataka, 2018, Oncotarget, V9, P24718, DOI 10.18632/oncotarget.25339
   Palanisamy K, 2019, J CELL PHYSIOL, V234, P7448, DOI 10.1002/jcp.27502
   Park SJ, 2015, BBA-GENE REGUL MECH, V1849, P1423, DOI 10.1016/j.bbagrm.2015.10.017
   Pino I, 2003, LUNG CANCER-J IASLC, V41, P131, DOI 10.1016/S0169-5002(03)00193-4
   Roy R., 2017, EMERGING ROLES HNRNP, P8
   Sahni S, 2014, J CLIN PATHOL, V67, P656, DOI 10.1136/jclinpath-2014-202356
   Shi CS, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000751
   Shi YJ, 2008, CANCER RES, V68, P10215, DOI 10.1158/0008-5472.CAN-08-1066
   Wang B, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010409
   White E, 2012, NAT REV CANCER, V12, P401, DOI 10.1038/nrc3262
   Wirawan E, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2009.16
   Yao DH, 2016, CELL PROLIFERAT, V49, P541, DOI 10.1111/cpr.12277
   Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100
   Zalckvar E, 2009, EMBO REP, V10, P285, DOI 10.1038/embor.2008.246
   Zhang MY, 2014, INT J MOL SCI, V15, P14372, DOI 10.3390/ijms150814372
   Zhou BG, 2016, IUBMB LIFE, V68, P201, DOI 10.1002/iub.1474
   Zhou WH, 2012, AUTOPHAGY, V8, P389, DOI 10.4161/auto.18641
   Zhou ZJ, 2013, INT J CANCER, V132, P1080, DOI 10.1002/ijc.27742
   2013, ONCOGENE, V32, P2261, DOI DOI 10.1038/ONC.2012.252
   2017, J NEUROONCOL, V133, P247, DOI DOI 10.1007/S11060-017-2438-4
NR 54
TC 6
Z9 6
U1 1
U2 3
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD MAY 21
PY 2019
VL 513
IS 1
BP 255
EP 260
DI 10.1016/j.bbrc.2019.03.179
PG 6
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA HY6RL
UT WOS:000468257300038
PM 30954215
DA 2022-04-25
ER

PT J
AU Li, X
   Hu, ZH
   Shi, HR
   Wang, C
   Lei, J
   Cheng, Y
AF Li, Xia
   Hu, Zhenhua
   Shi, Huirong
   Wang, Cong
   Lei, Jia
   Cheng, Yan
TI Inhibition of VEGFA Increases the Sensitivity of Ovarian Cancer Cells to
   Chemotherapy by Suppressing VEGFA-Mediated Autophagy
SO ONCOTARGETS AND THERAPY
LA English
DT Article
DE ovarian cancer; VEGFA; chemotherapy; autophagy
ID COLORECTAL-CANCER; 1ST-LINE CHEMOTHERAPY; DOWN-REGULATION; ANGIOGENESIS;
   EXPRESSION; PROLIFERATION; PROGRESSION; RESISTANT; APOPTOSIS; MIGRATION
AB Background: Ovarian cancer (OvCa) is the leading cause of death of gynecological malignancies worldwide. Vascular endothelial growth factor A (VEGFA), the most potent angiogenic factor, is responsible for tumor growth and angiogenesis, but its role in OvCa chemotherapy resistance remains unclear.
   Methods: RT-PCR and Western blot were used to detect VEGFA expression in tumor cells and normal ovarian surface epithelial cells. Gene Ontology (GO) enrichment analysis was used to analyze GO terms correlated with VEGFA. In in vitro experiments, we knockdown VEGFA in tumor cells and detected the tumor cell viability and apoptosis after chemotherapy drug treatment by MTT assay and flow cytometry. Western blot was used to detect autophagy and apoptosis related proteins.
   Results: We proved that VEGFA was highly expressed in tumor cells comparted with normal ovarian surface epithelial cells, and enriched GO analysis of VEGFA showed that VEGFA was involved in anti-apoptotic process. Further in vitro experiments confirmed that expression of VEGFA was correlated with chemotherapy resistance and this effect was mediated by autophagy. Meanwhile tumor cells treated with chemotherapy drugs also promoted the expression of VEGFA. Knockdown VEGFA inhibited autophagy of tumor cells and thus potents the killing efficiency in DDP resistant tumor cells and this effect could be reversed by the addition of recombinant VEGFA.
   Conclusion: Taken together, our study demonstrates that VEGFA is involved in antiapoptosis of tumor cells to chemotherapy, killing partly through autophagy, indicating that VEGFA may serve as a potential target to improve chemotherapy treatment.
C1 [Li, Xia; Wang, Cong; Lei, Jia; Cheng, Yan] Zhengzhou Univ, Affiliated Hosp 1, Gynecol Oncol Radiotherapy Ward, Zhengzhou, Henan, Peoples R China.
   [Hu, Zhenhua; Shi, Huirong] Zhengzhou Univ, Dept Gynecol & Obstet, Affiliated Hosp 1, Zhengzhou, Henan, Peoples R China.
RP Cheng, Y (corresponding author), Zhengzhou Univ, Affiliated Hosp 1, Zhengzhou, Henan, Peoples R China.
EM djzdyfy@163.com
FU Basic and Advanced Technology Research Foundation from Science and
   Technology Department of Henan Province [172102310008]
FX This work was supported by the Basic and Advanced Technology Research
   Foundation from Science and Technology Department of Henan Province
   (Grant No.172102310008).
CR Aktas SH, 2017, TURK J MED SCI, V47, P399, DOI 10.3906/sag-1509-80
   Baba H, 2015, ONCOTARGET, V6, P34004, DOI 10.18632/oncotarget.5227
   Balasubramaniam S, 2017, CLIN CANCER RES, V23, P7165, DOI 10.1158/1078-0432.CCR-17-1337
   Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003
   Bookman MA, 2012, CLIN OBSTET GYNECOL, V55, P96, DOI 10.1097/GRF.0b013e31824b45da
   Borst P, 2008, CELL CYCLE, V7, P1353, DOI 10.4161/cc.7.10.5930
   Braicu EI, 2014, ANTICANCER RES, V34, P385
   Chen BH, 2014, TUMOR BIOL, V35, P11587, DOI 10.1007/s13277-014-2463-2
   Dikic I, 2010, CANCER RES, V70, P3431, DOI 10.1158/0008-5472.CAN-09-4027
   Eoh KJ, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3476-1
   Fahmy K, 2016, INT J CANCER, V138, P652, DOI 10.1002/ijc.29820
   Fleming ND, 2017, GYNECOL ONCOL, V147, P41, DOI 10.1016/j.ygyno.2017.07.137
   Gong Q, 2013, PHOTONIC CRYSTALS: PRINCIPLES AND APPLICATIONS, P1
   Guo XL, 2012, CANCER LETT, V320, P171, DOI 10.1016/j.canlet.2012.03.002
   Jang K, 2017, EMBO MOL MED, V9, P304, DOI 10.15252/emmm.201606840
   Lawicki S, 2013, J OVARIAN RES, V6, DOI 10.1186/1757-2215-6-45
   Liang B, 2012, RADIAT ONCOL, V7, DOI 10.1186/1748-717X-7-213
   Liu BB, 2019, J CELL BIOCHEM, V120, P507, DOI 10.1002/jcb.27406
   Lu WL, 2016, TUMOR BIOL, V37, P15783, DOI 10.1007/s13277-016-5374-6
   Ma X, 2015, UROL ONCOL-SEMIN ORI, V33, DOI 10.1016/j.urolonc.2015.01.003
   Pchejetski D, 2016, J CANCER RES CLIN, V142, P1659, DOI 10.1007/s00432-015-2064-5
   Ramakrishnan R, 2012, CANCER RES, V72, P5483, DOI 10.1158/0008-5472.CAN-12-2236
   Ren XL, 2016, J CANCER RES CLIN, V142, P581, DOI 10.1007/s00432-015-2053-8
   Ropolo A, 2012, PANCREATOLOGY, V12, P1, DOI 10.1016/j.pan.2011.11.003
   Takahashi N, 2016, BRIT J CANCER, V114, P1003, DOI 10.1038/bjc.2016.74
   Tang ZF, 2017, NUCLEIC ACIDS RES, V45, pW98, DOI 10.1093/nar/gkx247
   Wang W, 2014, ONCOL REP, V32, P2127, DOI 10.3892/or.2014.3439
   Weckman A, 2015, ENDOCR-RELAT CANCER, V22, pR205, DOI 10.1530/ERC-15-0042
   Yan JJ, 2015, ONCOTARGET, V6, P29527, DOI 10.18632/oncotarget.5012
   Yan XY, 2020, CANCER CELL INT, V20, DOI 10.1186/s12935-020-01196-w
   Yang ZNJ, 2011, MOL CANCER THER, V10, P1533, DOI 10.1158/1535-7163.MCT-11-0047
   Yao P, 2013, PLOS BIOL, V11, DOI 10.1371/journal.pbio.1001635
   Yu H, 2011, EUR J CANCER, V47, P1585, DOI 10.1016/j.ejca.2011.01.019
   Zeng CY, 2017, J CANCER, V8, P786, DOI 10.7150/jca.17712
   Zeng FC, 2016, ONCOTARGETS THER, V9, P2131, DOI 10.2147/OTT.S98002
   Zhang WB, 2015, CELL PHYSIOL BIOCHEM, V37, P1123, DOI 10.1159/000430237
   Zhang X, 2020, AM J TRANSL RES, V12, P2052
   Zhu S, 2013, AUTOPHAGY, V9, P317, DOI 10.4161/auto.22923
NR 38
TC 10
Z9 11
U1 3
U2 5
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-6930
J9 ONCOTARGETS THER
JI OncoTargets Ther.
PY 2020
VL 13
BP 8161
EP 8171
DI 10.2147/OTT.S250392
PG 11
WC Biotechnology & Applied Microbiology; Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Oncology
GA OH7BY
UT WOS:000582750600001
PM 32884298
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Abu el Maaty, MA
   Strassburger, W
   Qaiser, T
   Dabiri, Y
   Wolfl, S
AF Abu el Maaty, Mohamed A.
   Strassburger, Wendy
   Qaiser, Tooba
   Dabiri, Yasamin
   Woelfl, Stefan
TI Differences in p53 status significantly influence the cellular response
   and cell survival to 1,25-dihydroxyvitamin D3-metformin cotreatment in
   colorectal cancer cells
SO MOLECULAR CARCINOGENESIS
LA English
DT Article
DE 1,25-dihydroxyvitamin D3; AMPK; metformin; p53
ID VITAMIN-D; DIRECT TARGET; METFORMIN; APOPTOSIS; AUTOPHAGY; FAMILY; AMPK;
   FAK
AB Mutations in the tumor suppressor p53 are highly prevalent in cancers and are known to influence the sensitivity of cells to various chemotherapeutics including the anti-cancer candidates 1,25-dihydrovitamin D3 [1,25D3] and metformin. Previous studies have demonstrated additive/synergistic anti-cancer effects of the 1,25D3-metformin combination in different models, however, the influence of p53 status on the efficacy of this regimen has not been investigated. The CRC colorectal cancer (CRC) cell lines HCT116 wild-type (wt), HCT116 p53-/-, and HT-29 (mutant; R273H) were employed, covering three different p53 variations. Synergistic effects of the combination were confirmed in all cell lines using MTT assay. Detailed evaluation of the combination's effects was performed, including on-line measurements of cellular metabolism (glycolysis/respiration) using a biosensor chip system, analyses of mitochondrial activity (membrane potential and ATP/ROS production), mRNA expression analysis of WNT/-catenin pathway players, and a comprehensive proteomic screen using immunoblotting and ELISA microarrays. AMPK signaling was found to be more strongly induced in response to all treatments in HCT116wt cells compared to other cell lines, an observation that was coupled to a stronger accumulation of intracellular ROS in response to metformin/combination, and finally an induction in autophagy, depicted by an increase in LC3II:LC3I ratio in combination-treated cells compared to mono-treatments. An induction in apoptotic signaling was observed in the other cell lines in response to the combination, illustrated by a decrease in expression of pro-survival Bcl2 family members. P53 status impacts cellular responses to the combination but does not hamper its anti-proliferative synergy.
C1 [Abu el Maaty, Mohamed A.; Strassburger, Wendy; Qaiser, Tooba; Dabiri, Yasamin; Woelfl, Stefan] Heidelberg Univ, Inst Pharm & Mol Biotechnol, Neuenheimer Feld 364, D-69120 Heidelberg, Germany.
RP Wolfl, S (corresponding author), Heidelberg Univ, Inst Pharm & Mol Biotechnol, Neuenheimer Feld 364, D-69120 Heidelberg, Germany.
EM wolfl@uni-hd.de
OI Abu el Maaty, Mohamed/0000-0002-8760-6376
FU Bundesinstitut fur Risikobewertung [FKZ1329-468]; Deutscher Akademischer
   Austausch Dienst KairoDeutscher Akademischer Austausch Dienst (DAAD)
FX Bundesinstitut fur Risikobewertung, Grant number: FKZ1329-468; Deutscher
   Akademischer Austausch Dienst Kairo
CR Alborzinia H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019714
   Alrefai D, 2017, NUTRIENTS, V9, DOI 10.3390/nu9101112
   Araujo J, 2010, CANCER TREAT REV, V36, P492, DOI 10.1016/j.ctrv.2010.02.015
   Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497
   Buzzai M, 2007, CANCER RES, V67, P6745, DOI 10.1158/0008-5472.CAN-06-4447
   Cardaci S, 2012, J CELL SCI, V125, P2115, DOI 10.1242/jcs.095216
   Chou TC, 2010, CANCER RES, V70, P440, DOI 10.1158/0008-5472.CAN-09-1947
   FAN SJ, 1995, CANCER RES, V55, P1649
   Feldman D, 2014, NAT REV CANCER, V14, P342, DOI 10.1038/nrc3691
   Filomeni G, 2015, CELL DEATH DIFFER, V22, P377, DOI 10.1038/cdd.2014.150
   Gao CX, 2015, ELIFE, V4, DOI 10.7554/eLife.10072
   Guo LS, 2015, PHARMAZIE, V70, P117, DOI 10.1691/ph.2015.4535
   Hirata E, 2015, CANCER CELL, V27, P574, DOI 10.1016/j.ccell.2015.03.008
   Holenya P, 2012, J IMMUNOL METHODS, V380, P10, DOI 10.1016/j.jim.2012.03.006
   Holenya P, 2011, PROTEOMICS, V11, P2129, DOI 10.1002/pmic.201000690
   Hoyer-Hansen M, 2010, TRENDS MOL MED, V16, P295, DOI 10.1016/j.molmed.2010.04.005
   Jones RG, 2005, MOL CELL, V18, P283, DOI 10.1016/j.molcel.2005.03.027
   Kim J, 2011, NAT CELL BIOL, V13, P132, DOI 10.1038/ncb2152
   Kim NH, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001744
   Kommagani R, 2007, J BIOL CHEM, V282, P29847, DOI 10.1074/jbc.M703641200
   Kwan HT, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053597
   Lane D, 2010, COLD SPRING HARB PER, V2
   Larriba Maria Jesus, 2013, Cancers (Basel), V5, P1242, DOI 10.3390/cancers5041242
   Levine B, 2008, AUTOPHAGY, V4, P600, DOI 10.4161/auto.6260
   Li HX, 2015, CLIN EXP PHARMACOL P, V42, P711, DOI 10.1111/1440-1681.12409
   Li W, 2015, CANCER PREV RES, V8, P139, DOI 10.1158/1940-6207.CAPR-14-0128
   LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7
   Lu HB, 2013, MOL CANCER THER, V12, P2864, DOI 10.1158/1535-7163.MCT-13-0233
   Maiuri MC, 2010, CURR OPIN CELL BIOL, V22, P181, DOI 10.1016/j.ceb.2009.12.001
   Markowitz SD, 2009, NEW ENGL J MED, V361, P2449, DOI 10.1056/NEJMra0804588
   Maruyama R, 2006, CANCER RES, V66, P4574, DOI 10.1158/0008-5472.CAN-05-2562
   Morales DR, 2015, ANNU REV MED, V66, P17, DOI 10.1146/annurev-med-062613-093128
   Muller PAJ, 2014, CANCER CELL, V25, P304, DOI 10.1016/j.ccr.2014.01.021
   Nave BT, 1999, BIOCHEM J, V344, P427, DOI 10.1042/0264-6021:3440427
   Queiroz EAIF, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098207
   Ryan ZC, 2016, J BIOL CHEM, V291, P1514, DOI 10.1074/jbc.M115.684399
   Saleem A, 2009, PHYSIOL GENOMICS, V37, P58, DOI 10.1152/physiolgenomics.90346.2008
   Stambolsky P, 2010, CANCER CELL, V17, P273, DOI 10.1016/j.ccr.2009.11.025
   Sulzmaier FJ, 2014, NAT REV CANCER, V14, P598, DOI 10.1038/nrc3792
   Tanida Isei, 2008, V445, P77, DOI 10.1007/978-1-59745-157-4_4
   White E, 2015, J CLIN INVEST, V125, P42, DOI 10.1172/JCI73941
   Zaanan A, 2010, ANN ONCOL, V21, P772, DOI 10.1093/annonc/mdp383
   Zhang JL, 2014, PHARMACOL THERAPEUT, V142, P154, DOI 10.1016/j.pharmthera.2013.12.003
   Zhao JX, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.199372
   Zheng W, 2013, J STEROID BIOCHEM, V138, P79, DOI 10.1016/j.jsbmb.2013.03.012
NR 45
TC 18
Z9 18
U1 0
U2 15
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0899-1987
EI 1098-2744
J9 MOL CARCINOGEN
JI Mol. Carcinog.
PD NOV
PY 2017
VL 56
IS 11
BP 2486
EP 2498
DI 10.1002/mc.22696
PG 13
WC Biochemistry & Molecular Biology; Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology
GA FJ2NK
UT WOS:000412565500012
PM 28618116
DA 2022-04-25
ER

PT J
AU Tang, CT
   Yang, J
   Liu, ZD
   Chen, YX
   Zeng, CY
AF Tang, Chao-Tao
   Yang, Jing
   Liu, Zi-De
   Chen, Youxiang
   Zeng, Chunyan
TI Taraxasterol acetate targets RNF31 to inhibit RNF31/p53 axis-driven cell
   proliferation in colorectal cancer
SO CELL DEATH DISCOVERY
LA English
DT Article
ID PHARMACOLOGY-BASED IDENTIFICATION; LINEAR UBIQUITINATION; MICE;
   INFLAMMATION; RESPONSES
AB Colorectal cancer (CRC) is the third most common cancer worldwide. Several studies have suggested that taraxasterol acetate (TA) can inhibit the growth of tumor cells. However, to date, it remains unclear how TA inhibits cell growth and how RNF31 functions as an oncogene. We examined the expression of RNF31 in CRC tissue samples via immunohistochemistry and elucidated the function of RNF31 in CRC cells by constructing a cell model with RNF31 depletion. A cycloheximide (CHX)-chase analysis and immunofluorescence assays were conducted to demonstrate that TA can promote RNF31 degradation by activating autophagy. We used the PharmMapper website to predict targets of TA and identified RNF31. CHX-chase experiments showed that TA could facilitate RNF31 degradation, which was inhibited by the administration of chloroquine. Immunofluorescence assays showed that RNF31 protein was colocalized with LC3I/II and p62, suggesting that TA promoted RNF31 degradation by activating autophagy. We also found that CRC patients with RNF31 overexpression had poorer survival than those with low RNF31 expression. The results of the CHX-chase experiment showed that depletion of RNF31 alleviated p53 degradation, which was inhibited by MG132. A series of co-immunoprecipitation (Co-IP) assays revealed that RNF31 interacts with p53 and promotes p53 ubiquitination and degradation. A Co-IP assay performed with a truncated RNF31 plasmid showed that the PUB domain interacts with p53. Moreover, the PUB domain is the key structure in the induction of p53 ubiquitination. Our findings reveal a key role of RNF31 in CRC cell growth and indicate a mechanism through which TA inhibits cell growth.
C1 [Tang, Chao-Tao; Yang, Jing; Liu, Zi-De; Chen, Youxiang; Zeng, Chunyan] Nanchang Univ, Affiliated Hosp 1, Dept Gastroenterol, Nanchang, Jiangxi, Peoples R China.
RP Chen, YX; Zeng, CY (corresponding author), Nanchang Univ, Affiliated Hosp 1, Dept Gastroenterol, Nanchang, Jiangxi, Peoples R China.
EM chenyx102@ncu.edu.cn; zengcy896@ncu.edu.cn
FU Foundation of Jiangxi provincial department of Science and Technology
   [20201ZDG02007]; National Natural Science Foundation of ChinaNational
   Natural Science Foundation of China (NSFC) [81660404, 82060448,
   81560398]; Special fund for innovation of Postgraduates in Jiangxi
   Province [YC2020-B058]
FX The Foundation of Jiangxi provincial department of Science and
   Technology (Grant No. 20201ZDG02007, PI: Y.X.C.); This study was
   supported by grants from the National Natural Science Foundation of
   China (Grant No. 81660404 and 82060448, PI: C.Y.Z.); the National
   Natural Science Foundation of China (Grant No. 81560398, PI: Y.X.C.).
   Special fund for innovation of Postgraduates in Jiangxi Province
   (YC2020-B058).
CR Arnold M, 2017, GUT, V66, P683, DOI 10.1136/gutjnl-2015-310912
   Bao TH, 2018, J MOL MED, V96, P661, DOI 10.1007/s00109-018-1652-7
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
   Che L, 2019, EXP THER MED, V18, P1745, DOI 10.3892/etm.2019.7736
   Chen JF, 2019, INT IMMUNOPHARMACOL, V70, P274, DOI 10.1016/j.intimp.2019.02.029
   Chen W, 2020, INT J IMMUNOPATH PH, V34, DOI 10.1177/2058738420933107
   Chen W, 2019, INT IMMUNOPHARMACOL, V71, P259, DOI 10.1016/j.intimp.2019.03.042
   Chu YY, 2021, AUTOPHAGY, V17, P1684, DOI [10.1080/15548627.2020.1781393, 10.6084/m9.figshare.12851372.v3]
   Dekker E, 2019, LANCET, V394, P1467, DOI 10.1016/S0140-6736(19)32319-0
   Dong SH, 2018, FUTURE ONCOL, V14, P1307, DOI 10.2217/fon-2017-0439
   Fu YY, 2020, CANCERS, V12, DOI 10.3390/cancers12061523
   Gerlach B, 2011, NATURE, V471, P591, DOI 10.1038/nature09816
   Guo J, 2015, BIOCHEM BIOPH RES CO, V464, P1302, DOI 10.1016/j.bbrc.2015.07.127
   Hostager BS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023061
   Kakiuchi N, 2020, NATURE, V577, P260, DOI 10.1038/s41586-019-1856-1
   Kathiria AS, 2012, CANCER RES, V72, P5778, DOI 10.1158/0008-5472.CAN-12-0603
   Laukoetter MG, 2011, J GASTROINTEST SURG, V15, P576, DOI 10.1007/s11605-010-1402-9
   Liang Q, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1143-x
   Noad J, 2017, NAT MICROBIOL, V2, DOI 10.1038/nmicrobiol.2017.63
   Qiu P, 2018, ONCOL LETT, V15, P789, DOI 10.3892/ol.2017.7431
   Risques RA, 2011, CANCER RES, V71, P1669, DOI 10.1158/0008-5472.CAN-10-1966
   Sang R, 2019, ARTIF CELL NANOMED B, V47, P3929, DOI 10.1080/21691401.2019.1671433
   Sasaki Y, 2013, EMBO J, V32, P2463, DOI 10.1038/emboj.2013.184
   Tang CT, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00554
   Taraborrelli L, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06155-8
   Wang P, 2020, SEMIN CANCER BIOL, V67, P131, DOI 10.1016/j.semcancer.2020.05.002
   Wu YH, 2018, SIGNAL TRANSDUCT TAR, V3, DOI 10.1038/s41392-018-0031-8
   Yu K, 2020, MED SCI MONITOR, V26, DOI 10.12659/MSM.919360
   Zhang XM, 2012, J ETHNOPHARMACOL, V141, P206, DOI 10.1016/j.jep.2012.02.020
   Zhu FX, 2018, J BIOL CHEM, V293, P20099, DOI 10.1074/jbc.RA118.005802
   Zhu J, 2019, ONCOGENE, V38, P299, DOI 10.1038/s41388-018-0502-y
   Zhu J, 2016, ONCOGENE, V35, P1955, DOI 10.1038/onc.2015.260
   Zhu J, 2014, ONCOGENE, V33, P4340, DOI 10.1038/onc.2013.573
NR 33
TC 1
Z9 1
U1 2
U2 3
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
EI 2058-7716
J9 CELL DEATH DISCOV
JI Cell Death Discov.
PD APR 6
PY 2021
VL 7
IS 1
AR 66
DI 10.1038/s41420-021-00449-5
PG 13
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA WN1BU
UT WOS:000711511200003
PM 33824292
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Sueda, T
   Sakai, D
   Kawamoto, K
   Konno, M
   Nishida, N
   Koseki, J
   Colvin, H
   Takahashi, H
   Haraguchi, N
   Nishimura, J
   Hata, T
   Takemasa, I
   Mizushima, T
   Yamamoto, H
   Satoh, T
   Doki, Y
   Mori, M
   Ishii, H
AF Sueda, Toshinori
   Sakai, Daisuke
   Kawamoto, Koichi
   Konno, Masamitsu
   Nishida, Naohiro
   Koseki, Jun
   Colvin, Hugh
   Takahashi, Hidekazu
   Haraguchi, Naotsugu
   Nishimura, Junichi
   Hata, Taishi
   Takemasa, Ichiro
   Mizushima, Tsunekazu
   Yamamoto, Hirofumi
   Satoh, Taroh
   Doki, Yuichiro
   Mori, Masaki
   Ishii, Hideshi
TI BRAF(V600E) inhibition stimulates AMP-activated protein kinase-mediated
   autophagy in colorectal cancer cells
SO SCIENTIFIC REPORTS
LA English
DT Article
ID ENERGY SENSOR; BRAF; PHOSPHORYLATION; RESISTANCE; PATHWAY; NUTRIENT;
   GROWTH; TARGET; LKB1
AB Although BRAF(V600E) mutation is associated with adverse clinical outcomes in patients with colorectal cancer (CRC), response and resistance mechanisms for therapeutic BRAF(V600E) inhibitors remains poorly understood. In the present study, we demonstrate that selective BRAF(V600E) inhibition activates AMP-activated protein kinase (AMPK), which induces autophagy as a mechanism of therapeutic resistance in human cancers. The present data show AMPK-dependent cytoprotective roles of autophagy under conditions of therapeutic BRAF(V600E) inhibition, and AMPK was negatively correlated with BRAF(V600E) dependent activation of MEK-ERK-RSK signaling and positively correlated with unc-51-like kinase 1 (ULK1), a key initiator of autophagy. Furthermore, selective BRAF(V600E) inhibition and concomitant suppression of autophagy led to the induction of apoptosis. Taken together, present experiments indicate that AMPK plays a role in the survival of BRAF(V600E) CRC cells by selective inhibition and suggest that the control of autophagy contributes to overcome the chemoresistance of BRAF(V600E) CRC cells.
C1 [Sueda, Toshinori; Sakai, Daisuke; Konno, Masamitsu; Nishida, Naohiro; Colvin, Hugh; Satoh, Taroh; Doki, Yuichiro; Mori, Masaki; Ishii, Hideshi] Osaka Univ, Grad Sch Med, Dept Frontier Sci Canc & Chemotherapy, Suita, Osaka 5650871, Japan.
   [Sueda, Toshinori; Kawamoto, Koichi; Colvin, Hugh; Takahashi, Hidekazu; Haraguchi, Naotsugu; Nishimura, Junichi; Hata, Taishi; Takemasa, Ichiro; Mizushima, Tsunekazu; Doki, Yuichiro; Mori, Masaki] Osaka Univ, Grad Sch Med, Dept Gastrointestinal Surg, Suita, Osaka 5650871, Japan.
   [Koseki, Jun; Colvin, Hugh; Doki, Yuichiro; Mori, Masaki; Ishii, Hideshi] Osaka Univ, Grad Sch Med, Dept Canc Profiling Discovery, Suita, Osaka 5650871, Japan.
   [Yamamoto, Hirofumi] Osaka Univ, Grad Sch Med & Hlth Sci, Dept Mol Pathol, Suita, Osaka 5650871, Japan.
RP Mori, M (corresponding author), Osaka Univ, Grad Sch Med, Dept Frontier Sci Canc & Chemotherapy, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.
EM mmori@gesurg.med.osaka-u.ac.jp; hishii@gesurg.med.osaka-u.ac.jp
RI Satoh, Taroh/AAF-5193-2021; Satoh, Taroh/AAF-7913-2020; Koseki,
   Jun/ABH-7420-2020; Ishii, Hideshi/AAV-5317-2020
OI Satoh, Taroh/0000-0002-4615-2638; 
FU Ministry of Education, Culture, Sports, Science, and TechnologyMinistry
   of Education, Culture, Sports, Science and Technology, Japan (MEXT);
   P-DIRECT; Ministry of Health, Labour and WelfareMinistry of Health,
   Labour and Welfare, Japan; Taiho Pharmaceutical Co., Ltd.; Evidence
   Based Medical (EBM) Research Center, Chugai Co., Ltd.; Yakult Honsha
   Co., Ltd.
FX We thank the members of our laboratories for their helpful discussions.
   In particular, we thank H. Yoshimori, M. Hamasaki, and the members of
   The Yoshimori Lab of the Department of Genetics, Osaka University
   Graduate school of Medicine. This work was partly supported by
   Grants-in-Aid for Scientific Research from the Ministry of Education,
   Culture, Sports, Science, and Technology; P-DIRECT; Ministry of Health,
   Labour and Welfare. Partial support was received as institutional
   endowments from Taiho Pharmaceutical Co., Ltd., the Evidence Based
   Medical (EBM) Research Center, Chugai Co., Ltd., and Yakult Honsha Co.,
   Ltd. No funding bodies were involved in data collection or analysis, the
   decision to publish, or preparation of the manuscript.
CR Amaravadi RK, 2011, CLIN CANCER RES, V17, P654, DOI 10.1158/1078-0432.CCR-10-2634
   Boussemart L, 2014, NATURE, V513, P105, DOI 10.1038/nature13572
   Chen SN, 2010, BBA-REV CANCER, V1806, P220, DOI 10.1016/j.bbcan.2010.07.003
   CHOU TC, 1981, EUR J BIOCHEM, V115, P207, DOI 10.1111/j.1432-1033.1981.tb06218.x
   CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4
   Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766
   Egan DF, 2011, SCIENCE, V331, P456, DOI 10.1126/science.1196371
   Esteve-Puig R, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004771
   Flaherty KT, 2010, NEW ENGL J MED, V363, P809, DOI 10.1056/NEJMoa1002011
   Ganley IG, 2009, J BIOL CHEM, V284, P12297, DOI 10.1074/jbc.M900573200
   Hardie DG, 2007, NAT REV MOL CELL BIO, V8, P774, DOI 10.1038/nrm2249
   Hardie DG, 2012, NAT REV MOL CELL BIO, V13, P251, DOI 10.1038/nrm3311
   Hardie DG, 2011, GENE DEV, V25, P1895, DOI 10.1101/gad.17420111
   Hardie DG, 2011, EMBO J, V30, P634, DOI 10.1038/emboj.2011.12
   Hardie DG, 2004, J CELL SCI, V117, P5479, DOI 10.1242/jcs.01540
   Hoyer-Hansen M, 2008, AUTOPHAGY, V4, P574, DOI 10.4161/auto.5921
   Hutchins G, 2011, J CLIN ONCOL, V29, P1261, DOI 10.1200/JCO.2010.30.1366
   Kim J, 2011, NAT CELL BIOL, V13, P132, DOI 10.1038/ncb2152
   Kopetz S, 2009, J CLIN ONCOL, V27, P3677, DOI 10.1200/JCO.2008.20.5278
   Lee JH, 2010, INT J TISSUE REGEN, V1, P1, DOI DOI 10.1371/J0URNAL.P0NE.0015394
   Levine B, 2006, AUTOPHAGY, V2, P65, DOI 10.4161/auto.2.2.2457
   Lito P, 2013, NAT MED, V19, P1401, DOI 10.1038/nm.3392
   Ma XH, 2014, J CLIN INVEST, V124, P1406, DOI 10.1172/JCI70454
   Mathew R, 2007, NAT REV CANCER, V7, P961, DOI 10.1038/nrc2254
   Mizushima N, 2010, CURR OPIN CELL BIOL, V22, P132, DOI 10.1016/j.ceb.2009.12.004
   Mizushima N, 2010, CELL, V140, P313, DOI 10.1016/j.cell.2010.01.028
   Montagut C, 2009, CANCER LETT, V283, P125, DOI 10.1016/j.canlet.2009.01.022
   Sapkota GP, 2001, J BIOL CHEM, V276, P19469, DOI 10.1074/jbc.M009953200
   Shang LB, 2011, P NATL ACAD SCI USA, V108, P4788, DOI 10.1073/pnas.1100844108
   Xie XQ, 2015, CANCER DISCOV, V5, P410, DOI 10.1158/2159-8290.CD-14-1473
   Zheng B, 2009, MOL CELL, V33, P237, DOI 10.1016/j.molcel.2008.12.026
   Zheng LY, 2013, CLIN CANCER RES, V19, P5372, DOI 10.1158/1078-0432.CCR-13-0203
NR 32
TC 24
Z9 24
U1 0
U2 3
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD JAN 11
PY 2016
VL 6
AR 18949
DI 10.1038/srep18949
PG 14
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA DA9JW
UT WOS:000368125900001
PM 26750638
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Lee, NR
   Meng, RY
   Rah, SY
   Jin, H
   Ray, N
   Kim, SH
   Park, BH
   Kim, SM
AF Lee, Na-Ri
   Meng, Ruo Yu
   Rah, So-Young
   Jin, Hua
   Ray, Navin
   Kim, Seong-Hun
   Park, Byung Hyun
   Kim, Soo Mi
TI Reactive Oxygen Species-Mediated Autophagy by Ursolic Acid Inhibits
   Growth and Metastasis of Esophageal Cancer Cells
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE ursolic acid; esophageal squamous cell carcinoma; anticancer; autophagy;
   reactive oxygen species; cell death
ID COLORECTAL-CANCER; INDUCED APOPTOSIS; ACTIVATION; DEATH; PATHWAY; AKT;
   PROLIFERATION; PROMOTES; SUPPRESSION; METABOLISM
AB Ursolic acid (UA) possesses various pharmacological activities, such as antitumorigenic and anti-inflammatory effects. In the present study, we investigated the mechanisms underlying the effects of UA against esophageal squamous cell carcinoma (ESCC) (TE-8 cells and TE-12 cells). The cell viability assay showed that UA decreased the viability of ESCC in a dose-dependent manner. In the soft agar colony formation assay, the colony numbers and size were reduced in a dose-dependent manner after UA treatment. UA caused the accumulation of vacuoles and LC3 puncta, a marker of autophagosome, in a dose-dependent manner. Autophagy induction was confirmed by measuring the expression levels of LC3 and p62 protein in ESCC cells. UA increased LC3-II protein levels and decreased p62 levels in ESCC cells. When autophagy was hampered using 3-methyladenine (3-MA), the effect of UA on cell viability was reversed. UA also significantly inhibited protein kinase B (Akt) activation and increased p-Akt expression in a dose-dependent manner in ESCC cells. Accumulated LC3 puncta by UA was reversed after wortmannin treatment. LC3-II protein levels were also decreased after treatment with Akt inhibitor and wortmannin. Moreover, UA treatment increased cellular reactive oxygen species (ROS) levels in ESCC in a time- and dose-dependent manner. Diphenyleneiodonium (an ROS production inhibitor) blocked the ROS and UA induced accumulation of LC3-II levels in ESCC cells, suggesting that UA-induced cell death and autophagy are mediated by ROS. Therefore, our data indicate that UA inhibits the growth of ESCC cells by inducing ROS-dependent autophagy.
C1 [Lee, Na-Ri] Jeonbuk Natl Univ, Div Hematol & Oncol, Med Sch, Jeonju 54907, South Korea.
   [Lee, Na-Ri; Kim, Seong-Hun] Jeonbuk Natl Univ, Dept Internal Med, Med Sch, Jeonju 54907, South Korea.
   [Lee, Na-Ri] Jeonbuk Natl Univ, Res Inst Clin Med, Biomed Res Inst, Med Sch, Jeonju 54907, South Korea.
   [Meng, Ruo Yu; Ray, Navin; Kim, Soo Mi] Jeonbuk Natl Univ, Dept Physiol, Med Sch, Jeonju 54907, South Korea.
   [Meng, Ruo Yu; Ray, Navin; Kim, Soo Mi] Jeonbuk Natl Univ, Inst Med Sci, Med Sch, Jeonju 54907, South Korea.
   [Rah, So-Young; Park, Byung Hyun] Jeonbuk Natl Univ, Dept Biochem, Med Sch, Jeonju 54907, South Korea.
   [Jin, Hua] Tsinghua Univ, Sch Pharmaceut Sci, Beijing 100084, Peoples R China.
RP Kim, SM (corresponding author), Jeonbuk Natl Univ, Dept Physiol, Med Sch, Jeonju 54907, South Korea.; Kim, SM (corresponding author), Jeonbuk Natl Univ, Inst Med Sci, Med Sch, Jeonju 54907, South Korea.
EM nariflower@jbnu.ac.kr; kathymeng1216@gmail.com; syrah1004@hanmail.net;
   jinhuaxy@126.com; navin.ray@gmail.com; shkimgi@jbnu.ac.kr;
   bhpark@jbnu.ac.kr; soomikim@jbnu.ac.kr
OI Rah, So-Young/0000-0002-0255-1960
FU Basic Science Research Program [2018R1D1A1B07048569]; Medical Research
   Center Program through the National Research Foundation - Korean
   government (MSIP) [NRF-2017R1A5A2015061]; Chonbuk National University in
   2019
FX This paper was supported by research funds for newly appointed
   professors of Chonbuk National University in 2019, by the Basic Science
   Research Program (2018R1D1A1B07048569), and by grants from the Medical
   Research Center Program (NRF-2017R1A5A2015061) through the National
   Research Foundation, which is funded by the Korean government (MSIP).
CR Blommaart EFC, 1997, EUR J BIOCHEM, V243, P240, DOI 10.1111/j.1432-1033.1997.0240a.x
   Cai QY, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317695015
   Chaffer CL, 2011, SCIENCE, V331, P1559, DOI 10.1126/science.1203543
   Chang CD, 2016, ANTICANCER RES, V36, P5097, DOI 10.21873/anticanres.11079
   Che Y, 2017, TOXICOL LETT, V280, P106, DOI 10.1016/j.toxlet.2017.08.005
   Chen Z, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0795-3
   Chuang WL, 2016, MOLECULES, V21, DOI 10.3390/molecules21040460
   Dewaele M, 2010, AUTOPHAGY, V6, P838, DOI 10.4161/auto.6.7.12113
   Ding H, 2017, NEUROCHEM RES, V42, P337, DOI 10.1007/s11064-016-2077-8
   Doherty J, 2018, NAT CELL BIOL, V20, P1110, DOI 10.1038/s41556-018-0201-5
   Enzinger PC, 2003, NEW ENGL J MED, V349, P2241, DOI 10.1056/NEJMra035010
   Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210
   Fukuzawa K, 1999, CANCER LETT, V144, P145, DOI 10.1016/S0304-3835(99)00223-2
   Gai WT, 2016, ONCOL LETT, V12, P2880, DOI 10.3892/ol.2016.5015
   Galluzzi L, 2018, CELL DEATH DIFFER, V25, P486, DOI 10.1038/s41418-017-0012-4
   Galluzzi L, 2017, EMBO J, V36, P1811, DOI 10.15252/embj.201796697
   Grishchuk Y, 2011, AUTOPHAGY, V7, P1115, DOI 10.4161/auto.7.10.16608
   Gu W, 2017, BIOORG MED CHEM LETT, V27, P4128, DOI 10.1016/j.bmcl.2017.07.033
   Huang QX, 2016, PHARM BIOL, V54, P3189, DOI 10.1080/13880209.2016.1214742
   Jager S, 2009, MOLECULES, V14, P2016, DOI 10.3390/molecules14062016
   Jiang QX, 2016, MOL CELL BIOCHEM, V420, P171, DOI 10.1007/s11010-016-2787-x
   Kamangar F, 2006, J CLIN ONCOL, V24, P2137, DOI 10.1200/JCO.2005.05.2308
   Kikuchi H, 2018, ANN THORAC CARDIOVAS, V24, P219, DOI 10.5761/atcs.ed.18-00126
   Kim S, 2016, SCI REPORTS, V6, P1, DOI DOI 10.1038/s41598-016-0001-8
   Laussmann MA, 2011, CELL DEATH DIFFER, V18, P1584, DOI 10.1038/cdd.2011.27
   Leem SH, 2015, INT J ONCOL, V47, P918, DOI 10.3892/ijo.2015.3089
   Leng SL, 2013, INT J CANCER, V133, P2781, DOI 10.1002/ijc.28301
   Lewinska A, 2017, APOPTOSIS, V22, P800, DOI 10.1007/s10495-017-1353-7
   Li S, 2019, J SURG ONCOL, V120, P831, DOI 10.1002/jso.25656
   Li XJ, 2013, INT J ONCOL, V43, P1992, DOI 10.3892/ijo.2013.2121
   Li XJ, 2013, ONCOL REP, V30, P2419, DOI 10.3892/or.2013.2717
   LI Y, 2016, ONCOTARGET, V8, P1058, DOI DOI 10.18632/oncotarget.13717
   Lin Z, 2016, SCI REP-UK, V6, DOI 10.1038/srep33358
   Liu TS, 2017, INT J ONCOL, V51, P555, DOI 10.3892/ijo.2017.4035
   Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009
   Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639
   N'Diaye EN, 2009, EMBO REP, V10, P173, DOI 10.1038/embor.2008.238
   Napoletano F, 2019, TRENDS CELL BIOL, V29, P323, DOI 10.1016/j.tcb.2018.12.007
   Peng JS, 2019, SURG ONCOL CLIN N AM, V28, P177, DOI 10.1016/j.soc.2018.11.009
   Prasad S, 2012, CLIN CANCER RES, V18, P4942, DOI 10.1158/1078-0432.CCR-11-2805
   Rautou PE, 2010, J HEPATOL, V53, P1123, DOI 10.1016/j.jhep.2010.07.006
   Robey RB, 2009, SEMIN CANCER BIOL, V19, P25, DOI 10.1016/j.semcancer.2008.11.010
   Scherz-Shouval R, 2011, TRENDS BIOCHEM SCI, V36, P30, DOI 10.1016/j.tibs.2010.07.007
   Secretan B, 2009, LANCET ONCOL, V10, P1033, DOI 10.1016/S1470-2045(09)70326-2
   Sever R, 2015, CSH PERSPECT MED, V5, DOI 10.1101/cshperspect.a006098
   Shanmugam MK, 2013, BIOCHEM PHARMACOL, V85, P1579, DOI 10.1016/j.bcp.2013.03.006
   Shanmugam MK, 2012, CANCER LETT, V320, P158, DOI 10.1016/j.canlet.2012.02.037
   Shen SY, 2014, CHEM-BIOL INTERACT, V218, P28, DOI 10.1016/j.cbi.2014.04.017
   Sheng HM, 2011, NAT PROD REP, V28, P543, DOI 10.1039/c0np00059k
   Siewert JR, 2005, CHIRURG, V76, P1033, DOI 10.1007/s00104-005-1096-9
   Siewert JR, 2001, ANN SURG, V234, P360, DOI 10.1097/00000658-200109000-00010
   Stein HJ, 2005, ANN SURG, V242, P566, DOI 10.1097/01.sla.0000184211.75970.85
   Tang Q, 2016, ONCOTARGET, V7, P73114, DOI 10.18632/oncotarget.12232
   Taniguchi S, 2002, PHYTOCHEMISTRY, V59, P315, DOI 10.1016/S0031-9422(01)00455-1
   Togashi Y, 2014, ONCOTARGET, V5, P2962, DOI 10.18632/oncotarget.1561
   Toker A, 2006, CANCER RES, V66, P3963, DOI 10.1158/0008-5472.CAN-06-0743
   Verhoeven DTH, 1996, CANCER EPIDEM BIOMAR, V5, P733
   Visser E, 2017, ONCOTARGET, V8, P5566, DOI 10.18632/oncotarget.13328
   Wang ML, 2017, MAT SCI ENG C-MATER, V71, P1231, DOI 10.1016/j.msec.2016.11.014
   Wang WJ, 2016, ONCOL REP, V36, P428, DOI 10.3892/or.2016.4813
   Wu YT, 2009, AUTOPHAGY, V5, P824, DOI 10.4161/auto.9099
   Xavier CPR, 2013, J NUTR BIOCHEM, V24, P706, DOI 10.1016/j.jnutbio.2012.04.004
   Yadav RK, 2015, AUTOPHAGY, V11, P1760, DOI 10.1080/15548627.2015.1082021
   Yang LJ, 2016, J EXP CLIN CANC RES, V35, DOI 10.1186/s13046-016-0330-2
   Yang YB, 2015, J GASTROEN HEPATOL, V30, P609, DOI 10.1111/jgh.12723
   Ye S, 2014, INT J ONCOL, V44, P2153, DOI 10.3892/ijo.2014.2374
   Zhao C, 2013, AUTOPHAGY, V9, P196, DOI 10.4161/auto.22805
   Zhao L., 2019, PARKINSONS DIS, V2019, P1, DOI DOI 10.1155/2019/2526314
   Zhao Y, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0648-1
   Zheng K, 2016, AUTOPHAGY, V12, P1593, DOI 10.1080/15548627.2016.1192751
   Zhong F, 2016, AM J CANCER RES, V6, P226
NR 71
TC 4
Z9 4
U1 2
U2 5
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD DEC
PY 2020
VL 21
IS 24
AR 9409
DI 10.3390/ijms21249409
PG 16
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA PL8TB
UT WOS:000603385900001
PM 33321911
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Huang, S
   Zhao, SM
   Shan, LH
   Zhou, XL
AF Huang Shuai
   Zhao Shuang-Mei
   Shan Lian-Hai
   Zhou Xian-Li
TI Antitumor activity of nervosine VII, and the crosstalk between apoptosis
   and autophagy in HCT116 human colorectal cancer cells
SO CHINESE JOURNAL OF NATURAL MEDICINES
LA English
DT Article
DE Liparis nervosa; Pyrrolizidine alkaloids; Nervosine VII; Autophagy;
   Apoptosis; HCT116 cells
ID NERVOGENIC ACID-DERIVATIVES; PYRROLIZIDINE ALKALOIDS; MODULATION;
   PATHWAYS
AB Nervosine VII is one of the known saturated pyrrolizidine alkaloids isolated from the plant of Liparis nervosa. This is first study to investigate the antitumor activity of nervosine VII in vitro, and the results indicated that nervosine VII induced autophagy and apoptosis in HCT116 human colorectal cancer cells. Mechanistic studies showed that nervosine VII-induced apoptosis was associated with the intrinsic pathway by the activation of caspase-9, -3 and -7. Autophagy induced by nervosine VII was characteristic with the regulation of autophagic markers including the increase of LC3-II and beclin 1 proteins, and the decrease of p62 protein. Nervosine VII simultaneously induced autophagy and apoptosis by activated MAPKs signaling pathway including JNK, ERK1/2 and p38, suppressing the p53 signaling pathway.
C1 [Huang Shuai; Zhao Shuang-Mei; Shan Lian-Hai; Zhou Xian-Li] Southwest Jiaotong Univ, Sch Life Sci & Engn, Chengdu 610031, Peoples R China.
RP Huang, S; Zhou, XL (corresponding author), Southwest Jiaotong Univ, Sch Life Sci & Engn, Chengdu 610031, Peoples R China.
EM shuaih@swjtu.edu.cn; zhouxl@swjtu.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81402803]
FX This work was supported by the National Natural Science Foundation of
   China (No. 81402803).
CR Amaravadi RK, 2007, J CLIN INVEST, V117, P326, DOI 10.1172/JCI28833
   BUSH LP, 1993, AGR ECOSYST ENVIRON, V44, P81, DOI 10.1016/0167-8809(93)90040-V
   Castells E, 2014, PHYTOCHEMISTRY, V108, P137, DOI 10.1016/j.phytochem.2014.09.006
   Chen L, 2013, PHYTOCHEMISTRY, V93, P154
   Debatin KM, 2004, CANCER IMMUNOL IMMUN, V53, P153, DOI 10.1007/s00262-003-0474-8
   Editorial Committee of the Flora of China of Chinese Academy of Science, 1999, FLORA CHINA, V18, P71
   Feng ZH, 2005, P NATL ACAD SCI USA, V102, P8204, DOI 10.1073/pnas.0502857102
   Hartmann T, 1999, PLANTA, V207, P483, DOI 10.1007/s004250050508
   Hua YX, 1999, CHINESE HERBAL, V12, P997
   Huang S, 2016, CHINESE CHEM LETT, V27, P757, DOI 10.1016/j.cclet.2016.01.003
   Huang S, 2013, CHINESE CHEM LETT, V24, P734, DOI 10.1016/j.cclet.2013.04.043
   Huang S, 2013, PHYTOCHEMISTRY, V93, P154, DOI 10.1016/j.phytochem.2013.03.009
   Huang S, 2013, PLANTA MED, V79, P281, DOI 10.1055/s-0032-1328109
   Kim WK, 2016, J NAT PROD, V79, P1097, DOI 10.1021/acs.jnatprod.6b00006
   Liu XJ, 2017, PHYTOCHEMISTRY, V138, P93, DOI 10.1016/j.phytochem.2017.02.027
   Pliyev BK, 2012, APOPTOSIS, V17, P1050, DOI 10.1007/s10495-012-0738-x
   Siciliano T, 2005, PHYTOCHEMISTRY, V66, P1593, DOI 10.1016/j.phytochem.2005.05.002
   Sun YJ, 2013, FOOD CHEM TOXICOL, V51, P53, DOI 10.1016/j.fct.2012.09.012
   Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312
   Wang G, 2017, BIOORG CHEM, V72, P64, DOI 10.1016/j.bioorg.2017.03.011
   White E, 2009, CLIN CANCER RES, V15, P5308, DOI 10.1158/1078-0432.CCR-07-5023
   Xu MY, 2014, J NAT PROD, V77, P370, DOI 10.1021/np401022g
   Zhang L, 2015, FITOTERAPIA, V103, P46, DOI 10.1016/j.fitote.2015.03.010
NR 23
TC 3
Z9 3
U1 0
U2 6
PU CHINESE JOURNAL NATURAL MEDICINES
PI NANJING
PA 24, TONGJIA XIANG, NANJING, 210009, PEOPLES R CHINA
SN 2095-6975
EI 1875-5364
J9 CHIN J NAT MEDICINES
JI Chin. J. Nat. Med.
PD FEB
PY 2020
VL 18
IS 2
BP 81
EP 89
DI 10.1016/S1875-5364(20)30009-1
PG 9
WC Integrative & Complementary Medicine; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Integrative & Complementary Medicine; Pharmacology & Pharmacy
GA KU3CI
UT WOS:000519585300001
PM 32172951
DA 2022-04-25
ER

PT J
AU Chang, CL
   Chen, KH
   Sung, PH
   Chiang, JY
   Huang, CR
   Chen, HH
   Yip, HK
AF Chang, Chia-Lo
   Chen, Kuan-Hung
   Sung, Pei-Hsun
   Chiang, John Y.
   Huang, Chi-Ruei
   Chen, Hong-Hwa
   Yip, Hon-Kan
TI Combined high energy of extracorporeal shock wave and 5-FU effectively
   suppressed the proliferation and growth of tongue squamous cell
   carcinoma
SO BIOMEDICINE & PHARMACOTHERAPY
LA English
DT Article
DE Cancer cells; Tumor growth; Extracorporeal shock wave; Anti-cancer drug
ID HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY; INDUCED CHRONIC CYSTITIS;
   PERITONEAL CARCINOMATOSIS; CANCER STATISTICS; THERAPY; CYTOREDUCTION;
   PATHWAY; ISCHEMIA; COLON
AB Background: We tested the hypothesis that extracorporeal shock wave (ECSW)-assisted 5-FU therapy effectively suppressed human tongue squamous carcinoma cell line SAS (i.e., SAS cells) proliferation and tumor growth.
   Methods and results: In vitro study showed that as compared with lower ECSW energy (<= 0.12 mJ/mm(2)), higher ECSW energy (>= 0.25-035 mJ/mm(2)) significantly suppressed the SAS cell proliferation and upregulated tumor cell apoptosis/DNA-damage/oxidative-stress, whereas combined higher ECSW energy (0.35 mJ/mm(2)) and 5-FU (20uM) further significantly altered the expressions of these parameters (all p < 0.001). Adult male nude mice (NM) (n = 36) were equally categorized into group 1 (2.0 x 10(5) SAS cells were implanted into NM back), group 2 [SAS in NM back + stepwise-increased ECSW energy (from 0.05/0.1/0.3/to 0.5 mJ/mm(2))/500 impulses which applied to the tumor at days 9/12/15/21], group 3 (SAS in NM back + 5-FU/i.p./7 mg/kg/every 3-day) and group 4 (SAS in NM back + ECSW + 5-FU) and tumors were removed from each animal by day-28. The result showed that tumor volume and tumor weight were significantly progressively reduced from group 1 to group 4 (all p < 0.0001). The protein expressions of apoptotic (mitochondrial-Bax/cleaved-caspase3/cleaved-PARP/cyclophyllin-D), autophagic (ratio of LC3B-II/LC3B-I) and oxidative-stress (NOX-1/NOX-2) biomarkers displayed an opposite pattern of tumor mass among the groups, whereas the cell-stress signaling (p-PI3K/p-Akt/p-m-TOR, and ASK1/MKK4/MKK7/p38/p-JNK/p-c-JUN), MAP kinase family members (RAS/cRAF/KRAS/BRAF/p-ERK1/2), tumor protein (p53) and cellular levels of angiogenesis/DNA-damage (alpha-SMA+/VEGF+/gamma-H2AX+) exhibited an identical pattern of tumor mass among the groups (all p < 0.0001).
   Conclusion: Combined high-energy ECSW and 5-FU offers an additional benefit for suppressing the cancer cell proliferation and tumor growth.
C1 [Chang, Chia-Lo; Chen, Hong-Hwa] Kaohsiung Chang Gung Mem Hosp, Dept Surg, Div Colorectal Surg, Kaohsiung, Taiwan.
   [Chang, Chia-Lo; Chen, Kuan-Hung; Sung, Pei-Hsun; Huang, Chi-Ruei; Chen, Hong-Hwa; Yip, Hon-Kan] Chang Gung Univ, Coll Med, 123 Dapi Rd, Kaohsiung 83301, Taiwan.
   [Chen, Kuan-Hung] Kaohsiung Chang Gung Mem Hosp, Dept Anesthesiol, Kaohsiung, Taiwan.
   [Sung, Pei-Hsun; Huang, Chi-Ruei; Yip, Hon-Kan] Kaohsiung Chang Gung Mem Hosp, Dept Internal Med, Div Cardiol, 123 Dapi Rd, Kaohsiung 83301, Taiwan.
   [Chiang, John Y.] Natl Sun Yat Sen Univ, Dept Comp Sci & Engn, Kaohsiung 80424, Taiwan.
   [Sung, Pei-Hsun; Yip, Hon-Kan] Kaohsiung Chang Gung Mem Hosp, Inst Translat Res Biomed, Kaohsiung 83301, Taiwan.
   [Sung, Pei-Hsun; Yip, Hon-Kan] Kaohsiung Chang Gung Mem Hosp, Ctr Shockwave Med & Tissue Engn, Kaohsiung 83301, Taiwan.
   [Yip, Hon-Kan] China Med Univ Hosp, China Med Univ, Dept Med Res, Taichung 40402, Taiwan.
   [Yip, Hon-Kan] Asia Univ, Dept Nursing, Taichung 41354, Taiwan.
   [Yip, Hon-Kan] Xiamen Chang Gung Hosp, Div Cardiol, Dept Internal Med, Xiamen 361028, Fujian, Peoples R China.
RP Chen, HH; Yip, HK (corresponding author), Chang Gung Univ, Coll Med, 123 Dapi Rd, Kaohsiung 83301, Taiwan.; Yip, HK (corresponding author), Kaohsiung Chang Gung Mem Hosp, Dept Internal Med, Div Cardiol, 123 Dapi Rd, Kaohsiung 83301, Taiwan.
EM ma2561@adm.cgmh.org.tw; han.gung@msa.hinet.net
OI Sung, Pei-Hsun/0000-0002-1989-9752
FU Chang Gung Memorial Hospital, Chang Gung UniversityChang Gung Memorial
   Hospital [CRRPG8J0121(1/3), CRRPG8J0122(2/3), CRRPG8J0123(3/3)]
FX This study was supported by a program grant from Chang Gung Memorial
   Hospital, Chang Gung University [Grant number: CRRPG8J0121(1/3),
   CRRPG8J0122(2/3), CRRPG8J0123(3/3)].
CR Chen YT, 2020, AM J TRANSL RES, V12, P999
   Chen YT, 2019, J PINEAL RES, V66, DOI 10.1111/jpi.12536
   Chen YT, 2018, AM J TRANSL RES, V10, P1036
   Delaloge S, 2017, LANCET ONCOL, V18, P1293, DOI 10.1016/S1470-2045(17)30514-4
   Fu M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024342
   Hilger RA, 2002, ONKOLOGIE, V25, P511, DOI 10.1159/000068621
   Huang TH, 2016, MOL MED, V22, P850, DOI 10.2119/molmed.2016.00108
   Lee FY, 2017, AM J TRANSL RES, V9, P1603
   Lin KC, 2018, MEDIAT INFLAMM, V2018, DOI 10.1155/2018/5425346
   LoRusso PM, 2016, J CLIN ONCOL, V34, P3803, DOI 10.1200/JCO.2014.59.0018
   Lu T, 2019, CANCER MANAG RES, V11, P943, DOI 10.2147/CMAR.S187317
   Ma FY, 2014, AM J PHYSIOL-RENAL, V307, pF1263, DOI 10.1152/ajprenal.00211.2014
   Meloche S, 2007, ONCOGENE, V26, P3227, DOI 10.1038/sj.onc.1210414
   Nadler A, 2015, CLIN COLON RECT SURG, V28, P234, DOI 10.1055/s-0035-1564431
   Naghavi M, 2017, LANCET, V390, P1151, DOI 10.1016/S0140-6736(17)32152-9
   Nishida T, 2004, CIRCULATION, V110, P3055, DOI 10.1161/01.CIR.0000148849.51177.97
   Noguti J, 2012, CANCER GENOM PROTEOM, V9, P329
   Ogden JA, 2001, CLIN ORTHOP RELAT R, P8
   Ogier JM, 2020, J MOL MED, V98, P335, DOI 10.1007/s00109-020-01878-y
   Ramalingam SS, 2011, CA-CANCER J CLIN, V61, P91, DOI 10.3322/caac.20102
   Rawla P, 2019, GASTROENTEROL REV, V14, P89, DOI 10.5114/pg.2018.81072
   Rompe JD, 2003, AM J SPORT MED, V31, P268, DOI 10.1177/03635465030310021901
   Rompe JD, 2001, CLIN ORTHOP RELAT R, P72
   Sheu JJ, 2017, ONCOTARGET, V8, P54747, DOI 10.18632/oncotarget.18287
   Siegel R, 2014, CA-CANCER J CLIN, V64, P104, DOI 10.3322/caac.21220
   Sundling KE, 2016, CANCER TREAT RES, V168, P309, DOI 10.1007/978-3-319-34244-3_15
   Sung PH, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/7518920
   Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262
   Vaira M, 2010, IN VIVO, V24, P79
   Verwaal VJ, 2008, ANN SURG ONCOL, V15, P2426, DOI 10.1245/s10434-008-9966-2
   Wang L, 2008, AM J SPORT MED, V36, P340, DOI 10.1177/0363546507307402
   Yang CH, 2019, NEUROCHEM RES, V44, P796, DOI 10.1007/s11064-018-02713-0
   Yeh KH, 2012, CRIT CARE MED, V40, P169, DOI 10.1097/CCM.0b013e31822d74d0
   Yin TC, 2019, VASC PHARMACOL, V113, P57, DOI 10.1016/j.vph.2018.12.003
   Yuen CM, 2015, AM J TRANSL RES, V7, P976
NR 35
TC 0
Z9 0
U1 1
U2 2
PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY-LES-MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE
SN 0753-3322
EI 1950-6007
J9 BIOMED PHARMACOTHER
JI Biomed. Pharmacother.
PD OCT
PY 2021
VL 142
AR 112036
DI 10.1016/j.biopha.2021.112036
EA AUG 2021
PG 13
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA UR6ZH
UT WOS:000696894400004
PM 34411913
OA gold
DA 2022-04-25
ER

PT J
AU Wu, WB
   Dong, JY
   Gou, H
   Geng, RM
   Yang, XL
   Chen, D
   Xiang, B
   Zhang, ZK
   Ren, SC
   Chen, LH
   Liu, J
AF Wu, Wenbing
   Dong, Jingying
   Gou, Hui
   Geng, Ruiman
   Yang, Xiaolong
   Chen, Dan
   Xiang, Bing
   Zhang, Zhengkun
   Ren, Sichong
   Chen, Lihong
   Liu, Ji
TI EGCG synergizes the therapeutic effect of irinotecan through enhanced
   DNA damage in human colorectal cancer cells
SO JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
LA English
DT Article
DE apoptosis; autophagy; colorectal cancer; DNA damage; EGCG; irinotecan
ID GREEN TEA; EPIGALLOCATECHIN-3-GALLATE EGCG; AUTOPHAGY; DEATH; APOPTOSIS;
   ATM; INACTIVATION; CONSTITUENT
AB Irinotecan is a kind of alkaloid with antitumour activity, but its low solubility and high toxicity limit its application. Epigallocatechin-3-gallate (EGCG) is one of the main bioactive components in tea. The epidemiological investigation and animal and cell experiments show that EGCG has a preventive and therapeutic effect on many kinds of tumours. Here, colorectal cancer cells RKO and HCT116 were employed, and the CCK8 proliferation test was used to screen the appropriate concentration of EGCG and irinotecan, and the effects of single and/or combined drugs on migration, invasion, DNA damage, cell cycle and autophagy of tumour cells were investigated. The results showed that EGCG combined with irinotecan (0.5 mu mol L-) not only had a stronger inhibitory effect on tumour cells than EGCG or irinotecan alone but also prevented tumour cell migration and invasion. EGCG alone did not cause DNA damage in colorectal cancer cells, but its combination with irinotecan could induce S or G2 phase arrest by inhibiting topoisomerase I to cause more extensive DNA damage. EGCG also induced apoptosis by promoting autophagy with irinotecan synergistically. These results indicated that EGCG in combination with irinotecan could be a promising strategy for colorectal cancer.
C1 [Wu, Wenbing; Dong, Jingying; Geng, Ruiman; Yang, Xiaolong; Chen, Dan; Xiang, Bing; Zhang, Zhengkun; Chen, Lihong; Liu, Ji] Sichuan Univ, Sch Basic Med Sci & Forens Med, Dept Biochem & Mol Biol, Chengdu, Peoples R China.
   [Wu, Wenbing] Southwest Med Univ, Sch Basic Med Sci, Dept Biochem & Mol Biol, Luzhou, Peoples R China.
   [Gou, Hui] Southwest Med Univ, Dept Pharm, Affiliated Hosp, Luzhou, Peoples R China.
   [Ren, Sichong] Sichuan Acad Tradit Chinese Med, State Key Lab Qual Evaluat Tradit Chinese Med, Chengdu, Peoples R China.
RP Chen, LH; Liu, J (corresponding author), Sichuan Univ, West China Sch Basic Med Sci & Forens Med, Dept Biochem & Mol Biol, Chengdu 610041, Peoples R China.
EM chenlih_bioch@126.com; liuji6103@163.com
OI wenbing, wu/0000-0002-8132-5100; Xiang, Bin/0000-0002-9261-8347; Geng,
   Ruiman/0000-0002-9253-9171
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81803967]
FX National Natural Science Foundation of China, Grant/Award Number:
   81803967
CR Abe O, 2018, EUR J CLIN PHARMACOL, V74, P775, DOI 10.1007/s00228-018-2436-2
   Abedin MJ, 2007, CELL DEATH DIFFER, V14, P500, DOI 10.1038/sj.cdd.4402039
   Alexander A, 2010, AUTOPHAGY, V6, P672, DOI 10.4161/auto.6.5.12509
   Alshatwi AA, 2016, CHEM-BIOL INTERACT, V247, P1, DOI 10.1016/j.cbi.2016.01.012
   Berger SJ, 2001, BIOCHEM BIOPH RES CO, V288, P101, DOI 10.1006/bbrc.2001.5736
   Bhat KPL, 2002, ANN NY ACAD SCI, V957, P210, DOI 10.1111/j.1749-6632.2002.tb02918.x
   Blackford AN, 2017, MOL CELL, V66, P801, DOI 10.1016/j.molcel.2017.05.015
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
   Brewer JR, 2016, GYNECOL ONCOL, V140, P176, DOI 10.1016/j.ygyno.2015.11.011
   Calgarotto AK, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-21516-5
   Campbell JM, 2017, PHARMACOGENOMICS J, V17, P21, DOI 10.1038/tpj.2016.58
   Filippini T, 2020, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005004.pub3
   Fujiki H, 2018, MOL CELLS, V41, P73, DOI 10.14348/molcells.2018.2227
   Guole L., 2019, CHINESE GEN PRACTICE, V22, P4031
   Haller DG, 2005, J CLIN ONCOL, V23, P8671, DOI 10.1200/JCO.2004.00.5686
   HSIANG YH, 1985, J BIOL CHEM, V260, P4873
   Inoue M, 1998, CANCER CAUSE CONTROL, V9, P209, DOI 10.1023/A:1008890529261
   Kang KB, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-66
   Katayama M, 2007, CELL DEATH DIFFER, V14, P548, DOI 10.1038/sj.cdd.4402030
   Lecumberri E, 2013, CLIN NUTR, V32, P894, DOI 10.1016/j.clnu.2013.03.008
   Lu LDY, 2013, SCI REP-UK, V3, DOI 10.1038/srep03169
   Masuda M, 2001, CLIN CANCER RES, V7, P4220
   Meschini S, 2008, AUTOPHAGY, V4, P1020, DOI 10.4161/auto.6952
   Rieber M, 2008, CANCER BIOL THER, V7, P1561, DOI 10.4161/cbt.7.10.6540
   Shunichiro K., 2013, CANCER CELL INT, V13, P1
   Singh BN, 2011, BIOCHEM PHARMACOL, V82, P1807, DOI 10.1016/j.bcp.2011.07.093
   Smith GCM, 1999, MOL CELL BIOL, V19, P6076
   Song X, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.463
   Staker BL, 2002, P NATL ACAD SCI USA, V99, P15387, DOI 10.1073/pnas.242259599
   Stearns ME, 2011, TRANSL ONCOL, V4, P147, DOI 10.1593/tlo.10286
   Takacs-Vellai K, 2005, CURR BIOL, V15, P1513, DOI 10.1016/j.cub.2005.07.035
   Wang JZ, 2006, AM J PHYSIOL-RENAL, V291, pF1300, DOI 10.1152/ajprenal.00509.2005
   Wenzel ES, 2018, IN VIVO, V32, P1, DOI 10.21873/invivo.11197
   Yang CS., 2006, CANCER RES, V66, P1150
   Zhang FL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081815
   [朱虹 ZHU Hong], 2007, [生命科学, Chinese Bulletin of Life Sciences], V19, P139
NR 36
TC 2
Z9 2
U1 4
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1582-1838
EI 1582-4934
J9 J CELL MOL MED
JI J. Cell. Mol. Med.
PD AUG
PY 2021
VL 25
IS 16
BP 7913
EP 7921
DI 10.1111/jcmm.16718
EA JUN 2021
PG 9
WC Cell Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA TZ1DR
UT WOS:000661840800001
PM 34132471
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Zhao, DY
   Sun, XZ
   Long, SD
   Yao, SK
AF Zhao, Dongyan
   Sun, Xizhen
   Long, Sidan
   Yao, Shukun
TI An autophagy-related long non-coding RNA signature for patients with
   colorectal cancer
SO PHYSIOLOGY INTERNATIONAL
LA English
DT Article
DE autophagy; long non-coding RNA; prognostic signature; colorectal cancer;
   TCGA
ID GROWTH
AB Aim: Long non-coding RNAs (lncRNAs) have been identified to regulate cancers by controlling the process of autophagy and by mediating the post-transcriptional and transcriptional regulation of autophagy-related genes. This study aimed to investigate the potential prognostic role of autophagy-associated lncRNAs in colorectal cancer (CRC) patients. Methods: LncRNA expression profiles and the corresponding clinical information of CRC patients were collected from The Cancer Genome Atlas (TCGA) database. Based on the TCGA dataset, autophagy-related lncRNAs were identified by Pearson correlation test. Univariate Cox regression analysis and the least absolute shrinkage and selection operator analysis (LASSO) Cox regression model were performed to construct the prognostic gene signature. Gene set enrichment analysis (GSEA) was used to further clarify the underlying molecular mechanisms. Results: We obtained 210 autophagy-related genes from the whole dataset and found 1187 lncRNAs that were correlated with the autophagy-related genes. Using Univariate and LASSO Cox regression analyses, eight lncRNAs were screened to establish an eight-lncRNA signature, based on which patients were divided into the low-risk and high-risk group. Patients' overall survival was found to be significantly worse in the high-risk group compared to that in the low-risk group (log-rank p = 2.731E-06). ROC analysis showed that this signature had better prognostic accuracy than TNM stage, as indicated by the area under the curve. Furthermore, GSEA demonstrated that this signature was involved in many cancer-related pathways, including TGF-beta p53, mTOR and WNT signaling pathway. Conclusions: Our study constructed a novel signature from eight autophagy-related lncRNAs to predict the overall survival of CRC, which could assistant clinicians in making individualized treatment.
C1 [Zhao, Dongyan; Sun, Xizhen; Yao, Shukun] Peking Union Med Coll & Chinese Acad Med Sci, Grad Sch, Beijing 100730, Peoples R China.
   [Long, Sidan] Beijing Univ Chinese Med, Beijing 100029, Peoples R China.
   [Yao, Shukun] China Japan Friendship Hosp, Dept Gastroenterol, 2nd Yinghua East Rd, Beijing 100029, Peoples R China.
RP Yao, SK (corresponding author), China Japan Friendship Hosp, Dept Gastroenterol, 2nd Yinghua East Rd, Beijing 100029, Peoples R China.
EM shukunyao@126.com
FU National Key Development Plan for Precision Medicine Research
   [2017YFC0910002]
FX The authors thank the TCGA project for providing invaluable datasets for
   statistical analyses. This work was supported by the National Key
   Development Plan for Precision Medicine Research (2017YFC0910002).
CR Amaravadi RK, 2011, CLIN CANCER RES, V17, P654, DOI 10.1158/1078-0432.CCR-10-2634
   Arnold M, 2017, GUT, V66, P683, DOI 10.1136/gutjnl-2015-310912
   Broz DK, 2013, GENE DEV, V27, P1016, DOI 10.1101/gad.212282.112
   Devenport SN, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8111349
   Fan YF, 2020, BIOSCIENCE REP, V40, DOI 10.1042/BSR20193309
   Filfan M, 2017, ROM J MORPHOL EMBRYO, V58, P27
   Guinney J, 2015, NAT MED, V21, P1350, DOI 10.1038/nm.3967
   Janku F, 2011, NAT REV CLIN ONCOL, V8, P384, DOI 10.1038/nrclinonc.2011.82
   Johansson I, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3116
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Li D, 2019, IN VITRO CELL DEV-AN, V55, P577, DOI 10.1007/s11626-019-00376-x
   Li J, 2017, DNA CELL BIOL, V36, P1117, DOI 10.1089/dna.2017.3888
   Li XY, 2019, AGING-US, V11, P5646, DOI 10.18632/aging.102149
   Li Y, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00139
   Liu LK, 2020, J ORAL PATHOL MED, V49, P243, DOI 10.1111/jop.12989
   Liu PF, 2014, AUTOPHAGY, V10, P1454, DOI 10.4161/auto.29556
   Markle B, 2010, CANCER METAST REV, V29, P395, DOI 10.1007/s10555-010-9234-3
   Marmol I, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18010197
   Morris KV, 2014, NAT REV GENET, V15, P423, DOI 10.1038/nrg3722
   Mowers EE, 2017, ONCOGENE, V36, P1619, DOI 10.1038/onc.2016.333
   Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252
   Newton PT, 2019, BIOCHEM J, V476, P779, DOI 10.1042/BCJ20190020
   Niklaus M, 2017, ONCOTARGET, V8, P54604, DOI 10.18632/oncotarget.17554
   Roychowdhury A, 2020, GENOMICS, V112, P961, DOI 10.1016/j.ygeno.2019.06.012
   Ruan ZH, 2019, ONCOL LETT, V18, P1107, DOI 10.3892/ol.2019.10435
   Saxton RA, 2017, CELL, V168, P960, DOI [10.1016/j.cell.2017.02.004, 10.1016/j.cell.2017.03.035]
   Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Sui X, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.350
   Tasdemir E, 2008, NAT CELL BIOL, V10, P676, DOI 10.1038/ncb1730
   Wang Y, 2019, BIOMED PHARMACOTHER, V111, P1297, DOI 10.1016/j.biopha.2018.12.134
   Weiser MR, 2011, J CLIN ONCOL, V29, P4796, DOI 10.1200/JCO.2011.36.5080
   Yu H, 2015, J THORAC ONCOL, V10, P645, DOI 10.1097/JTO.0000000000000470
   Zhang J, 2017, AUTOPHAGY, V13, P1004, DOI 10.1080/15548627.2017.1312041
   Zheng YS, 2019, J CELL BIOCHEM, V120, P3922, DOI 10.1002/jcb.27676
   Zhu Z, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20030728
NR 36
TC 0
Z9 0
U1 0
U2 1
PU AKADEMIAI KIADO ZRT
PI BUDAPEST
PA BUDAFOKI UT 187-189-A-3, H-1117 BUDAPEST, HUNGARY
SN 2498-602X
J9 PHYSIOL INT
JI Physiol. Int.
PD JUN
PY 2021
VL 108
IS 2
BP 202
EP 220
DI 10.1556/2060.2021.00125
PG 19
WC Physiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Physiology
GA TZ0QL
UT WOS:000684181000004
PM 34224393
OA Green Accepted
DA 2022-04-25
ER

PT J
AU Wu, XL
   Feng, XF
   Zhao, XQ
   Ma, FT
   Liu, N
   Guo, HM
   Li, CN
   Du, H
   Zhang, BX
AF Wu, Xiaoli
   Feng, Xuefeng
   Zhao, Xiaoqing
   Ma, Futian
   Liu, Na
   Guo, Hongming
   Li, Chaonan
   Du, Huan
   Zhang, Baoxi
TI Role of Beclin-1-Mediated Autophagy in the Survival of Pediatric
   Leukemia Cells
SO CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
LA English
DT Article
DE Pediatric leukemia (PL); Oxidative stress; Autophagy; Apoptosis;
   Beclin-1; miR-93
ID ACUTE MYELOID-LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA;
   BONE-MARROW-TRANSPLANTATION; INHIBITS TUMOR-GROWTH; PATHWAY IN-VITRO;
   CANCER-CELLS; COLORECTAL-CANCER; INDUCED APOPTOSIS; GASTRIC-CANCER;
   BREAST-CANCER
AB Background/Aims: Acute and chronic leukemia are severe malignant cancers worldwide, and can occur in pediatric patients. Since bone marrow cell transplantation is seriously limited by the availability of the immune-paired donor sources, the therapy for pediatric leukemia (PL) remains challenging. Autophagy is essential for the regulation of cell survival in the harsh environment. However, the role of autophagy in the survival of PL cells under the oxidative stress, e.g. chemotherapy, remain ill-defined. In the current study, we addressed these questions. Methods: We analyzed the effects of oxidative stress on the cell viability of PL cells in vitro, using a CCK-8 assay. We analyzed the effects of oxidative stress on the apoptosis and autophagy of PL cells. We analyzed the levels of Beclin-1 and microRNA-93 (miR-93) in PL cells. Prediction of binding between miR-93 and 3'-UTR of Beclin-1 mRNA was performed by a bioinformatics algorithm and confirmed by a dual luciferase reporter assay. The relationship between levels of miR-93 and patients' survival was analyzed in PL patients. Results: We found that oxidative stress dose-dependently increased autophagy in PL cells. While low-level oxidative stress did not increase apoptosis, high-level oxidative stress increased apoptosis, seemingly from failure of autophagy-mediated cell survival. High-level oxidative stress appeared to suppress the protein levels of an autophagy protein Beclin-1 in PL cells, possibly through induction of miR-93, which inhibited the translation of Beclin-1 mRNA via 3'-UTR binding. Conclusion: Beclin-1-mediated autophagy plays a key role in the survival of PL cells against oxidative stress. Induction of miR-93 may increase the sensitivity of PL cells to oxidative stress during chemotherapy to improve therapeutic outcome. (C) 2016 The Author(s) Published by S. Karger AG, Basel
C1 [Wu, Xiaoli; Zhao, Xiaoqing; Ma, Futian; Liu, Na; Guo, Hongming; Li, Chaonan; Du, Huan; Zhang, Baoxi] Hebei Med Univ, Hosp 2, Dept Pediat Hematol Oncol, 215 Heping West Rd, Shijiazhuang 050000, Peoples R China.
   [Feng, Xuefeng] Hebei Med Univ, Hosp 2, Dept Hematol, Shijiazhuang, Peoples R China.
RP Zhang, BX (corresponding author), Hebei Med Univ, Hosp 2, Dept Pediat Hematol Oncol, 215 Heping West Rd, Shijiazhuang 050000, Peoples R China.
EM zbx_238@yeah.net
FU Science and Technology Department of Hebei Province [152777206]
FX This work is supported by Science and Technology Department of Hebei
   Province (NO: 152777206).
CR Ahmed AA, 2007, CANCER CELL, V12, P514, DOI 10.1016/j.ccr.2007.11.014
   Arakawa Y, 2014, PEDIATR INT, V56, P647, DOI 10.1111/ped.12424
   Arico M, 2008, CANCER-AM CANCER SOC, V113, P515, DOI 10.1002/cncr.23587
   Chang M, 2000, LEUKEMIA, V14, P1201, DOI 10.1038/sj.leu.2401832
   Chen J, 2015, AM J TRANSL RES, V7, P1510
   Chen YC, 2015, AM J TRANSL RES, V7, P1574
   Cheng YJ, 2015, CELL PHYSIOL BIOCHEM, V36, P1163, DOI 10.1159/000430287
   Coronnello C, 2013, NUCLEIC ACIDS RES, V41, pW159, DOI 10.1093/nar/gkt379
   Di Leva G, 2013, CURR OPIN GENET DEV, V23, P3, DOI 10.1016/j.gde.2013.01.004
   Green DR, 2014, CELL, V157, P65, DOI 10.1016/j.cell.2014.02.049
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Li CG, 2015, CELL PHYSIOL BIOCHEM, V35, P1303, DOI 10.1159/000373952
   Li DH, 2014, TUMOR BIOL, V35, P8201, DOI 10.1007/s13277-014-2099-2
   Li X, 2014, CELL PHYSIOL BIOCHEM, V34, P1227, DOI 10.1159/000366334
   Liang HH, 2013, CELL PHYSIOL BIOCHEM, V32, P1818, DOI 10.1159/000356615
   Liu G, 2014, TUMOR BIOL, V35, P9801, DOI 10.1007/s13277-014-2273-6
   Liu J, 2013, CELL PHYSIOL BIOCHEM, V32, P1213, DOI 10.1159/000354520
   Lu ZM, 2014, TUMOR BIOL, V35, P2941, DOI 10.1007/s13277-013-1378-7
   Ma JX, 2014, TUMOR BIOL, V35, P8439, DOI 10.1007/s13277-014-1873-5
   Mei Q, 2014, CANCER SCI, V105, P755, DOI 10.1111/cas.12436
   Nandi SS, 2015, AM J TRANSL RES, V7, P683
   Ohta K, 2015, ONCOTARGET, V6, P3211, DOI 10.18632/oncotarget.3085
   Pereira DM, 2013, DRUG DISCOV TODAY, V18, P282, DOI 10.1016/j.drudis.2012.10.002
   Pusztai L, 2007, ANN ONCOL, V18, P15, DOI 10.1093/annonc/mdm534
   Rouzier R, 2005, P NATL ACAD SCI USA, V102, P8315, DOI 10.1073/pnas.0408974102
   Saleh AM, 2015, CELL PHYSIOL BIOCHEM, V35, P1958, DOI 10.1159/000374004
   Shaw PJ, 2010, BLOOD, V116, P4007, DOI 10.1182/blood-2010-01-261958
   Shin D, 2015, CELL PHYSIOL BIOCHEM, V36, P1151, DOI 10.1159/000430286
   Swanton C, 2007, CANCER CELL, V11, P498, DOI 10.1016/j.ccr.2007.04.011
   Tang QC, 2015, TUMOR BIOL, V36, P1701, DOI 10.1007/s13277-014-2771-6
   Wang F, 2014, TUMOR BIOL, V35, P8653, DOI 10.1007/s13277-014-2131-6
   Wang XM, 2015, CELL PHYSIOL BIOCHEM, V37, P1914, DOI 10.1159/000438552
   Wang YP, 2014, CELL PHYSIOL BIOCHEM, V34, P325, DOI 10.1159/000363002
   Whitehurst AW, 2007, NATURE, V446, P815, DOI 10.1038/nature05697
   Wu XJ, 2013, TUMOR BIOL, V34, P463, DOI 10.1007/s13277-012-0571-4
   Wu X, 2014, CELL PHYSIOL BIOCHEM, V34, P506, DOI 10.1159/000363018
   Xiao XY, 2015, INT J ONCOL, V46, P161, DOI 10.3892/ijo.2014.2704
   Xiao ZG, 2013, EUR J GASTROEN HEPAT, V25, P296, DOI 10.1097/MEG.0b013e32835c077a
   Xie M, 2014, CELL PHYSIOL BIOCHEM, V33, P1475, DOI 10.1159/000358712
   Xiong Y, 2014, CELL PHYSIOL BIOCHEM, V34, P1863, DOI 10.1159/000366385
   Yang IP, 2012, CARCINOGENESIS, V33, P1522, DOI 10.1093/carcin/bgs166
   Yun M, 2015, CELL PHYSIOL BIOCHEM, V35, P1821, DOI 10.1159/000373993
   Zhang T, 2015, CELL PHYSIOL BIOCHEM, V37, P1421, DOI 10.1159/000438511
   Zhang T, 2015, CELL PHYSIOL BIOCHEM, V37, P1369, DOI 10.1159/000430402
   Zhao SM, 2014, CELL PHYSIOL BIOCHEM, V33, P78, DOI 10.1159/000356651
   Zhu YX, 2014, CELL PHYSIOL BIOCHEM, V33, P933, DOI 10.1159/000358665
NR 46
TC 19
Z9 21
U1 0
U2 3
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 1015-8987
EI 1421-9778
J9 CELL PHYSIOL BIOCHEM
JI Cell. Physiol. Biochem.
PY 2016
VL 39
IS 5
BP 1827
EP 1836
DI 10.1159/000447882
PG 10
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Physiology
GA EC9ZT
UT WOS:000388503500015
PM 27744427
OA gold
DA 2022-04-25
ER

PT J
AU Jiffry, J
   Thavornwatanayong, T
   Rao, D
   Fogel, EJ
   Saytoo, D
   Nahata, R
   Guzik, H
   Chaudhary, I
   Augustine, T
   Goel, S
   Maitra, R
AF Jiffry, Jeeshan
   Thavornwatanayong, Thongthai
   Rao, Devika
   Fogel, Elisha J.
   Saytoo, Durvanand
   Nahata, Rishika
   Guzik, Hillary
   Chaudhary, Imran
   Augustine, Titto
   Goel, Sanjay
   Maitra, Radhashree
TI Oncolytic Reovirus (pelareorep) Induces Autophagy in KRAS-mutated
   Colorectal Cancer
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID DOUBLE-EDGED-SWORD; BECLIN 1; APOPTOSIS; EXPRESSION; MUTATIONS; NECROSIS
AB Purpose: To explore the effects of pelareorep on autophagy in multiple models of colorectal cancer, including patient-derived peripheral blood mononuclear cells (PBMCs).
   Experimental Design: HCT116 [KRAS mutant (mut)] and Hke3 [KRAS wild-type (WT)] cells were treated with pelareorep (multiplicity of infection, 5) and harvested at 6 and 9 hours. LC3 A/B expression was determined by immunofluorescence and flow cytometry; five autophagic proteins were analyzed by Western blotting. The expression of 88 autophagy genes was determined by qRT-PCR. Syngeneic mouse models, CT26/Balb-C (KRAS mut) and MC38/C57B6 (KRAS WT), were developed and treated with pelareorep (10 x 10(6) plaque-forming unit/day) intraperitoneally. Protein and RNA were extracted from harvested tumor tissues. PBMCs from five experimental and three control patients were sampled at 0 (pre) and 48 hours, and on days 8 and 15. The gene expression normalized to "pre" was determined using 2(-Delta Delta Ct) method.
   Results: Pelareorep induced significant upregulation of LC3 A/B in HCT116 as compared with Hke3 cells by immunofluorescence (3.24 x and 8.67 x), flow cytometry (2.37 x and 2.58 x), and autophagosome formation (2.02 x and 1.57 x), at 6 and 9 hours, respectively; all P < 0.05. Western blot analysis showed an increase in LC3 A/B (2.38 x and 6.82 x) and Beclin1 ( 1.17 x and 1.24 x) at 6 and 9 hours, ATG5 (2.4 x) and P-62 (1.52 x) at 6 hours, and VPS-34 (1.39 x) at 9 hours (all P < 0.05). Induction of 13 transcripts in cell lines (>4 x; 6 and 9 hours; P < 0.05), 12 transcripts in CT26 (qRT-PCR), and 14 transcripts in human PBMCs (P < 0.05) was observed. LC3 A/B, RICTOR, and RASD1 expression was upregulated in all three model systems.
   Conclusions: Pelareorep hijacks host autophagic machinery in KRAS-mut conditions to augment its propagation and preferential oncolysis of the cancer cells.
C1 [Jiffry, Jeeshan; Thavornwatanayong, Thongthai; Saytoo, Durvanand; Nahata, Rishika; Guzik, Hillary; Augustine, Titto; Goel, Sanjay; Maitra, Radhashree] Albert Einstein Coll Med, Bronx, NY 10467 USA.
   [Rao, Devika; Chaudhary, Imran; Goel, Sanjay; Maitra, Radhashree] Montefiore Med Ctr, 1695 Eastchester Rd, Bronx, NY 10461 USA.
   [Fogel, Elisha J.; Maitra, Radhashree] Yeshiva Univ, Dept Biol, New York, NY 10033 USA.
RP Goel, S (corresponding author), Montefiore Med Ctr, 1695 Eastchester Rd, Bronx, NY 10461 USA.; Maitra, R (corresponding author), Yeshiva Univ, 500 West 185th St,BH 1404, New York, NY 10033 USA.
EM sgoel@montefiore.org; radhashree.maitra@yu.edu
RI Rao, Devika/AAZ-5201-2020
OI GOEL, SANJAY/0000-0002-2798-7568; Fogel, Elisha/0000-0002-0190-6934;
   Augustine, Titto/0000-0002-0539-864X
FU NIH/AG1R21 NIH grantUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [AG 1R21AG058027-01];
   Yeshiva University [2A4108]; NCIUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Cancer Institute (NCI) [P30CA013330]
FX S. Goel was supported by NIH/AG1R21 NIH grant AG 1R21AG058027-01. R.
   Maitra was supported by Yeshiva University startup fund 2A4108. We
   gratefully acknowledge the Genomic Facility, Flow Cytometry Core
   Facility, and the Analytical Imaging Facility of Albert Einstein College
   of Medicine (Bronx, NY) along with the NCI cancer center support grant
   (P30CA013330), which partially supports all morphometric work conducted
   with 3D Histech P250 High Capacity Slide Scanner SIG #1S10OD019961-01 of
   the shared facilities. We also thankfully acknowledge Prof. Xingxing
   Zang (Department of Microbiology and Immunology, Albert Einstein College
   of Medicine, Bronx, NY) for kind gift of two transplantable (syngeneic)
   models of murine tumor cell lines, CT26 and MC38. The costs of
   publication of this article were defrayed in part by the payment of page
   charges. This article must therefore be hereby marked advertisement in
   accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
CR Ahmad L, 2018, FRONT CELL DEV BIOL, V6, DOI 10.3389/fcell.2018.00155
   Amaravadi RK, 2011, CLIN CANCER RES, V17, P654, DOI 10.1158/1078-0432.CCR-10-2634
   Apel A, 2009, INT J CANCER, V125, P991, DOI 10.1002/ijc.24500
   Beau I, 2011, INT J BIOCHEM CELL B, V43, P460, DOI 10.1016/j.biocel.2011.01.006
   Chen N, 2010, FEBS LETT, V584, P1427, DOI 10.1016/j.febslet.2009.12.034
   Choi Y, 2018, NAT REV MICROBIOL, V16, P340, DOI 10.1038/s41579-018-0003-6
   Cianfanelli V, 2015, J CELL SCI, V128, P2003, DOI 10.1242/jcs.168153
   Goel S, 2020, MOL CANCER THER, V19, P1148, DOI 10.1158/1535-7163.MCT-19-1117
   Gollamudi R, 2010, INVEST NEW DRUG, V28, P641, DOI 10.1007/s10637-009-9279-8
   Gozuacik D, 2007, CURR TOP DEV BIOL, V78, P217, DOI 10.1016/S0070-2153(06)78006-1
   Grimm WA, 2016, GUT, V65, P456, DOI 10.1136/gutjnl-2014-308735
   Hagan GN, 2008, MOL CELL BIOL, V28, P4215, DOI 10.1128/MCB.00867-07
   Han CB, 2012, CANCER INVEST, V30, P741, DOI 10.3109/07357907.2012.732159
   Jebali A, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0794-0
   Kang R, 2011, CELL DEATH DIFFER, V18, P571, DOI 10.1038/cdd.2010.191
   Kemp V, 2017, VIRUSES-BASEL, V9, DOI 10.3390/v9100266
   Kim DH, 2003, MOL CELL, V11, P895, DOI 10.1016/S1097-2765(03)00114-X
   Lee HR, 2012, FRONT MICROBIOL, V3, DOI 10.3389/fmicb.2012.00044
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lo Re AE, 2012, J BIOL CHEM, V287, P25325, DOI 10.1074/jbc.M112.370809
   Maitra R, 2014, ONCOTARGET, V5, P2807, DOI 10.18632/oncotarget.1921
   Maitra R, 2012, MOL CANCER RES, V10, P1514, DOI 10.1158/1541-7786.MCR-12-0157
   Marinkovic M, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/8023821
   Marino G, 2014, NAT REV MOL CELL BIO, V15, P81, DOI 10.1038/nrm3735
   Mills KR, 2004, P NATL ACAD SCI USA, V101, P3438, DOI 10.1073/pnas.0400443101
   Mizushima N, 2007, AUTOPHAGY, V3, P542, DOI 10.4161/auto.4600
   Nikoletopoulou V, 2013, BBA-MOL CELL RES, V1833, P3448, DOI 10.1016/j.bbamcr.2013.06.001
   Pan BF, 2015, ACTA PHARMACOL SIN, V36, P1480, DOI 10.1038/aps.2015.119
   Paquette M, 2018, CANCERS, V10, DOI 10.3390/cancers10010018
   Parakrama R, 2020, BMC CANCER, V20, DOI 10.1186/s12885-020-07038-2
   Peeters M, 2015, EUR J CANCER, V51, P1704, DOI 10.1016/j.ejca.2015.05.017
   Piao H, 2017, SCI REP-UK, V7, DOI 10.1038/srep39887
   Rouschop KMA, 2009, CURR MOL MED, V9, P417, DOI 10.2174/156652409788167131
   Ruder Dennis, 2018, Oncotarget, V9, P33995, DOI 10.18632/oncotarget.26129
   Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148
   Schmitz KJ, 2016, WORLD J SURG ONCOL, V14, DOI 10.1186/s12957-016-0946-x
   Sun QM, 2008, P NATL ACAD SCI USA, V105, P19211, DOI 10.1073/pnas.0810452105
   Szklarczyk D, 2019, NUCLEIC ACIDS RES, V47, pD607, DOI 10.1093/nar/gky1131
   Vaidyanathan G, 2004, ONCOGENE, V23, P5858, DOI 10.1038/sj.onc.1207774
   Wan G, 2014, AUTOPHAGY, V10, P70, DOI 10.4161/auto.26534
   White E, 2009, CLIN CANCER RES, V15, P5308, DOI 10.1158/1078-0432.CCR-07-5023
   Wie J, 2015, CHANNELS, V9, P186, DOI 10.1080/19336950.2015.1058454
   Yang WQ, 2004, CLIN CANCER RES, V10, P8561, DOI 10.1158/1078-0432.CCR-04-0940
   Yang YP, 2013, ACTA PHARMACOL SIN, V34, P625, DOI 10.1038/aps.2013.5
   Ye X, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02334
   Yin ZY, 2016, MICROB CELL, V3, P457, DOI 10.15698/mic2016.12.546
NR 46
TC 7
Z9 7
U1 1
U2 8
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
EI 1557-3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD FEB 1
PY 2021
VL 27
IS 3
BP 865
EP 876
DI 10.1158/1078-0432.CCR-20-2385
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA QG1CK
UT WOS:000617323900021
PM 33168658
OA Green Accepted
DA 2022-04-25
ER

PT J
AU Gu, W
   Wan, DW
   Qian, QY
   Yi, B
   He, ZL
   Gu, YL
   Wang, L
   He, SB
AF Gu, Wen
   Wan, Daiwei
   Qian, Qinyi
   Yi, Bin
   He, Zhilong
   Gu, Yilin
   Wang, Liang
   He, Songbing
TI Ambra1 Is an Essential Regulator of Autophagy and Apoptosis in SW620
   Cells: Pro-Survival Role of Ambra1
SO PLOS ONE
LA English
DT Article
ID CALPAIN-MEDIATED CLEAVAGE; COLORECTAL-CANCER CELLS;
   MOLECULAR-MECHANISMS; MONITORING AUTOPHAGY; BECLIN-1; INHIBITION;
   EXPRESSION; THERAPY; PROTEIN
AB Recent research has revealed a role for Ambra1, an autophagy-related gene-related (ATG) protein, in the autophagic pro-survival response, and Ambra1 has been shown to regulate Beclin1 and Beclin1-dependent autophagy in embryonic stem cells. However, whether Ambra1 plays an important role in the autophagy pathway in colorectal cancer cells is unknown. In this study, we hypothesized that Ambra1 is an important regulator of autophagy and apoptosis in CRC cell lines. To test this hypothesis, we confirmed autophagic activity in serum-starved SW620 CRC cells by assessing endogenous microtubule-associated protein 1 light chain 3 (LC3) localization, the presence of autophagosomes (transmission electron microscopy) and LC3 protein levels (Western blotting). Ambra1 expression was detected by Western blot in SW620 cells treated with staurosporine or etoposide. Calpain and caspase inhibitors were employed to verify whether calpains and caspases were responsible for Ambra1 cleavage. To examine the role of Ambra1 in apoptosis, Ambra1 knockdown cells were treated with staurosporine and etoposide. Cell apoptosis and viability were measured by annexin-V and PI staining and MTT assays. We determined that serum deprivation-induced autophagy was associated with Ambra1 upregulation in colorectal cancer cell lines. Ambra1 expression decreased during staurosporine- or etoposide-induced apoptosis. Calpains and caspases may be responsible for Ambra1 degradation. When Ambra1 expression was reduced by siRNA, SW620 cells were more sensitive to staurosporine-or etoposide-induced apoptosis. In addition, starvation-induced autophagy decreased. Finally, Co-immunoprecipitation of Ambra1 and Beclin1 demonstrated that Ambra1 and Beclin1 interact in serum-starved or rapamycin-treated SW620 cells, suggesting that Ambra1 regulates autophagy in CRC cells by interacting with Beclin1. In conclusion, Ambra1 is a crucial regulator of autophagy and apoptosis in CRC cells that maintains the balance between autophagy and apoptosis.
C1 [Gu, Wen; Yi, Bin; Wang, Liang; He, Songbing] Soochow Univ, Affiliated Hosp 1, Dept Gen Surg, Suzhou, Peoples R China.
   [Wan, Daiwei] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Hepatobiliary Surg, Guangzhou 510275, Guangdong, Peoples R China.
   [He, Songbing] Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Hlth Sci, Shanghai, Peoples R China.
   [He, Songbing] Chinese Acad Sci, Shanghai Inst Biol Sci, Shanghai Inst Immunol, Shanghai, Peoples R China.
   [He, Songbing] Shanghai Jiao Tong Univ, Sch Med, Shanghai 200030, Peoples R China.
   [Qian, Qinyi] Changshu 2 Peoples Hosp, Dept Ultrasonog, Changshu, Peoples R China.
   [Gu, Yilin] Soochow Univ, Affiliated Hosp 1, Dept Operating Rooms, Suzhou, Peoples R China.
   [He, Zhilong] Soochow Univ, Affiliated Hosp 1, Dept Gastroenterol, Suzhou, Peoples R China.
   [He, Songbing] Washington Univ, Sch Med, St Louis, MO USA.
RP Wang, L (corresponding author), Soochow Univ, Affiliated Hosp 1, Dept Gen Surg, Suzhou, Peoples R China.
EM wangliangsuda@163.com; hesongbing1979@163.com
FU Nature Science Foundation of P.R. China [81201905]; China Postdoctoral
   Science FoundationChina Postdoctoral Science Foundation [2013M540374];
   Shanghai Postdoctoral Scientific Program of P.R. China [13R21415200];
   Nature Science Research Grants of the University of Jiangsu Province of
   P.R. China [12KJB320009]; Research Project of the Science and Technology
   Bureau of Suzhou City of P.R. China [SYS201220]; Government Overseas
   Scholarship from the Department of Education of Jiangsu Province
FX This work was supported by the Project of the Nature Science Foundation
   of P.R. China (81201905), the China Postdoctoral Science Foundation
   (2013M540374), the Shanghai Postdoctoral Scientific Program of P.R.
   China (13R21415200), Nature Science Research Grants of the University of
   Jiangsu Province of P.R. China (12KJB320009), and the Research Project
   of the Science and Technology Bureau of Suzhou City of P.R. China
   (SYS201220), and sponsored by a Government Overseas Scholarship from the
   Department of Education of Jiangsu Province. The funders had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Ahn CH, 2007, APMIS, V115, P1344, DOI 10.1111/j.1600-0463.2007.00858.x
   Cecconi F, 2008, CELL DEATH DIFFER, V15, P1170, DOI 10.1038/cdd.2008.64
   Cui JZ, 2013, BBA-REV CANCER, V1836, P15, DOI 10.1016/j.bbcan.2013.02.003
   Fan YJ, 2013, CHIN J CANCER, V32, P121, DOI 10.5732/cjc.012.10106
   Fimia GM, 2007, NATURE, V447, P1121, DOI 10.1038/nature05925
   Fimia GM, 2011, AUTOPHAGY, V7, P115, DOI 10.4161/auto.7.1.14071
   Grothey A, 2005, J CLIN ONCOL, V23, P9441, DOI 10.1200/JCO.2005.04.4792
   Holt SV, 2011, TOXICOL PATHOL, V39, P516, DOI 10.1177/0192623310396903
   Jaboin JJ, 2009, METHOD ENZYMOL, V453, P287, DOI 10.1016/S0076-6879(08)04014-7
   Jain K, 2013, AM J CANCER RES, V3, P251
   Kang R, 2011, CELL DEATH DIFFER, V18, P571, DOI 10.1038/cdd.2010.191
   Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1
   Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257
   Lotze MT, 2013, CANCER J, V19, P341, DOI 10.1097/PPO.0b013e31829da0d6
   Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239
   Mathew R, 2011, CURR OPIN GENET DEV, V21, P113, DOI 10.1016/j.gde.2010.12.008
   Mizushima N, 2004, INT J BIOCHEM CELL B, V36, P2491, DOI 10.1016/j.biocel.2004.02.005
   Mizushima N, 2009, METHOD ENZYMOL, V452, P13, DOI 10.1016/S0076-6879(08)03602-1
   Ohsumi Y, 2001, NAT REV MOL CELL BIO, V2, P211, DOI 10.1038/35056522
   Pagliarini V, 2012, CELL DEATH DIFFER, V19, P1495, DOI 10.1038/cdd.2012.27
   Pandey S, 2012, ASIAN PAC J CANCER P, V13, P4867, DOI 10.7314/APJCP.2012.13.10.4867
   Rohn TT, 2011, NEUROBIOL DIS, V43, P68, DOI 10.1016/j.nbd.2010.11.003
   Russo R, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.29
   Sato K, 2007, CANCER RES, V67, P9677, DOI 10.1158/0008-5472.CAN-07-1462
   Strappazzon F, 2011, EMBO J, V30, P1195, DOI 10.1038/emboj.2011.49
   Troiani T, 2013, CURR MED CHEM
   Wang S, 1999, MOL BRAIN RES, V70, P167, DOI 10.1016/S0169-328X(99)00145-X
   Wei YJ, 2008, MOL CELL, V30, P678, DOI 10.1016/j.molcel.2008.06.001
   Wirawan E, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2009.16
   Wu SB, 2013, BIOCHEM BIOPH RES CO, V434, P898, DOI 10.1016/j.bbrc.2013.04.053
   Xu HD, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063232
   Yousefi S, 2006, NAT CELL BIOL, V8, P1124, DOI 10.1038/ncb1482
   Zheng Hai-yang, 2012, Cancer Biology Medicine, V9, P105, DOI 10.3969/j.issn.2095-3941.2012.02.004
NR 33
TC 24
Z9 26
U1 3
U2 20
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 26
PY 2014
VL 9
IS 2
AR e90151
DI 10.1371/journal.pone.0090151
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA AC3BC
UT WOS:000332389000136
PM 24587252
OA Green Published, Green Submitted, gold
DA 2022-04-25
ER

PT J
AU Kaliszczak, M
   van Hechanova, E
   Li, YQ
   Alsadah, H
   Parzych, K
   Auner, HW
   Aboagye, EO
AF Kaliszczak, Maciej
   van Hechanova, Erich
   Li, Yunqing
   Alsadah, Hibah
   Parzych, Katarzyna
   Auner, Holger W.
   Aboagye, Eric O.
TI The HDAC6 inhibitor C1A modulates autophagy substrates in diverse cancer
   cells and induces cell death
SO BRITISH JOURNAL OF CANCER
LA English
DT Article
ID HISTONE DEACETYLASE 6; REGULATES AGGRESOME FORMATION; KINASE INHIBITOR;
   ANTITUMOR-ACTIVITY; N-MYC; COMBINATION; BORTEZOMIB; MECHANISMS; PROTEIN;
   DRUG
AB BACKGROUND: Cytosolic deacetylase histone deacetylase 6 (HDAC6) is involved in the autophagy degradation pathway of malformed proteins, an important survival mechanism in cancer cells. We evaluated modulation of autophagy-related proteins and cell death by the HDAC6-selective inhibitor C1A.
   METHODS: Autophagy substrates (light chain-3 (LC-3) and p62 proteins) and endoplasmic reticulum (ER) stress phenotype were determined. Caspase-3/7 activation and cellular proliferation assays were used to assess consequences of autophagy modulation.
   RESULTS: C1A potently resolved autophagy substrates induced by 3-methyladenine and chloroquine. The mechanism of autophagy inhibition by HDAC6 genetic knockout or C1A treatment was consistent with abrogation of autophagosome-lysosome fusion, and decrease of Myc protein. CIA alone or combined with the proteasome inhibitor, bortezomib, enhanced cell death in malignant cells, demonstrating the complementary roles of the proteasome and autophagy pathways for clearing malformed proteins. Myc-positive neuroblastoma, KRAS-positive colorectal cancer and multiple myeloma cells showed marked cell growth inhibition in response to HDAC6 inhibitors. Finally, growth of neuroblastoma xenografts was arrested in vivo by single agent C1A, while combination with bortezomib slowed the growth of colorectal cancer xenografts.
   CONCLUSIONS: C1A resolves autophagy substrates in malignant cells and induces cell death, warranting its use for in vivo preclinical autophagy research.
C1 [Kaliszczak, Maciej; van Hechanova, Erich; Li, Yunqing; Aboagye, Eric O.] Imperial Coll London, Hammersmith Hosp, Canc Imaging Ctr, Dept Surg & Canc, Du Cane Rd, London W12 0NN, England.
   [Alsadah, Hibah; Parzych, Katarzyna; Auner, Holger W.] Imperial Coll London, Hammersmith Hosp, Dept Med, Canc Cell Prot Metab Grp, Du Cane Rd, London W12 0NN, England.
   [Kaliszczak, Maciej] Biogen, Preclin Imaging & Pharmacol, 125 Broadway St, Cambridge, MA 02142 USA.
   [van Hechanova, Erich] UCL, UCL Great Ormond St Inst Child Hlth, Dev Biol Birth Defects Sect, 30 Guilford St, London WC1N 1EH, England.
RP Aboagye, EO (corresponding author), Imperial Coll London, Hammersmith Hosp, Canc Imaging Ctr, Dept Surg & Canc, Du Cane Rd, London W12 0NN, England.
EM eric.aboagye@imperial.ac.uk
OI Auner, Holger/0000-0003-4040-0642; ABOAGYE, Eric/0000-0003-2276-6771
FU Cancer Research UKCancer Research UK [C2536/A10337] Funding Source:
   Medline; Cancer Research UK (CRUK)Cancer Research UK [C2536/A16584]
   Funding Source: Medline
CR Auner HW, 2015, BRIT J HAEMATOL, V168, P14, DOI 10.1111/bjh.13172
   BARONE MV, 1995, NATURE, V378, P509, DOI 10.1038/378509a0
   Belounis A, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2906-9
   Blake RA, 2000, MOL CELL BIOL, V20, P9018, DOI 10.1128/MCB.20.23.9018-9027.2000
   Boone BA, 2015, ANN SURG ONCOL, V22, P4402, DOI 10.1245/s10434-015-4566-4
   Chesler L, 2008, NEOPLASIA, V10, P1268, DOI 10.1593/neo.08778
   Chesler L, 2006, CANCER RES, V66, P8139, DOI 10.1158/0008-5472.CAN-05-2769
   Dimopoulos M, 2013, LANCET ONCOL, V14, P1129, DOI 10.1016/S1470-2045(13)70398-X
   Dolman MEM, 2015, CLIN CANCER RES, V21, P5100, DOI 10.1158/1078-0432.CCR-15-0313
   Dong LH, 2013, J HEMATOL ONCOL, V6, DOI 10.1186/1756-8722-6-53
   Furstoss O, 2002, EMBO J, V21, P514, DOI 10.1093/emboj/21.4.514
   Ganley IG, 2011, MOL CELL, V42, P731, DOI 10.1016/j.molcel.2011.04.024
   Gillet JP, 2011, P NATL ACAD SCI USA, V108, P18708, DOI 10.1073/pnas.1111840108
   Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653
   Graves JA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037699
   He CC, 2009, ANNU REV GENET, V43, P67, DOI 10.1146/annurev-genet-102808-114910
   Hideshima T, 2005, P NATL ACAD SCI USA, V102, P8567, DOI 10.1073/pnas.0503221102
   Hideshima T, 2016, P NATL ACAD SCI USA, V113, P13162, DOI 10.1073/pnas.1608067113
   Huang R, 2011, FASEB J, V25, P4138, DOI 10.1096/fj.11-185033
   Iwata A, 2005, J BIOL CHEM, V280, P40282, DOI 10.1074/jbc.M508786200
   Kaliszczak M, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.180
   Kaliszczak M, 2013, BRIT J CANCER, V109, P2356, DOI 10.1038/bjc.2013.584
   Kaliszczak M, 2013, BRIT J CANCER, V108, P342, DOI 10.1038/bjc.2012.576
   Kaliszczak M, 2010, AAPS J, V12, P617, DOI 10.1208/s12248-010-9225-x
   Kamada Y, 2003, CURR TOP MICROBIOL, V279, P73
   Kawaguchi Y, 2003, CELL, V115, P727, DOI 10.1016/S0092-8674(03)00939-5
   Krypuy M, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-295
   Lambert LA, 2008, CANCER RES, V68, P7966, DOI 10.1158/0008-5472.CAN-08-1333
   Lee JH, 2013, P NATL ACAD SCI USA, V110, P15704, DOI 10.1073/pnas.1313893110
   Luscher B, 2012, EUR J CELL BIOL, V91, P506, DOI 10.1016/j.ejcb.2011.07.005
   Lutz W, 1996, ONCOGENE, V13, P803
   Lwin T, 2013, J CLIN INVEST, V123, P4612, DOI 10.1172/JCI64210
   Mathew R, 2007, NAT REV CANCER, V7, P961, DOI 10.1038/nrc2254
   Mizushima N, 2010, CELL, V140, P313, DOI 10.1016/j.cell.2010.01.028
   Nakaso K, 2004, BRAIN RES, V1012, P42, DOI 10.1016/j.brainres.2004.03.029
   Nawrocki ST, 2008, BLOOD, V112, P2917, DOI 10.1182/blood-2007-12-130823
   Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746
   Ouyang H, 2012, J BIOL CHEM, V287, P2317, DOI 10.1074/jbc.M111.273730
   Parzych K, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.373
   Pitts TM, 2009, MOL CANCER THER, V8, P342, DOI 10.1158/1535-7163.MCT-08-0534
   Poklepovic A, 2014, AUTOPHAGY, V10, P1478, DOI 10.4161/auto.29428
   Rosenfeld MR, 2014, AUTOPHAGY, V10, P1359, DOI 10.4161/auto.28984
   Santo L, 2012, BLOOD, V119, P2579, DOI 10.1182/blood-2011-10-387365
   SCHWAB M, 1985, NATURE, V316, P160, DOI 10.1038/316160a0
   Simi L, 2008, AM J CLIN PATHOL, V130, P247, DOI 10.1309/LWDY1AXHXUULNVHQ
   Sui X, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.350
   Verfaillie T., 2010, INT J CELL BIOL, V2010, DOI [10.1155/2010/93050920145727, DOI 10.1155/2010/930509]
   Vichai V, 2006, NAT PROTOC, V1, P1112, DOI 10.1038/nprot.2006.179
   Vogl DT, 2017, CLIN CANCER RES, V23, P3307, DOI 10.1158/1078-0432.CCR-16-2526
   Watanabe Y, 2011, J CELL SCI, V124, P2692, DOI 10.1242/jcs.081232
   White E, 2012, NAT REV CANCER, V12, P401, DOI 10.1038/nrc3262
   Workman P, 2010, BRIT J CANCER, V102, P1555, DOI 10.1038/sj.bjc.6605642
   Wu YY, 2013, AUTOPHAGY, V9, P595, DOI 10.4161/auto.23641
   Yao Tso-Pang, 2010, Genes Cancer, V1, P779
   Zhang XJ, 2013, ACTA PHARMACOL SIN, V34, P595, DOI 10.1038/aps.2012.184
NR 55
TC 33
Z9 34
U1 0
U2 6
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0007-0920
EI 1532-1827
J9 BRIT J CANCER
JI Br. J. Cancer
PD NOV 13
PY 2018
VL 119
IS 10
BP 1278
EP 1287
DI 10.1038/s41416-018-0232-5
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA HA8TK
UT WOS:000450566200013
PM 30318510
OA Green Published, hybrid
DA 2022-04-25
ER

PT J
AU Gong, J
   Lin, YY
   Zhang, HQ
   Liu, CQ
   Cheng, Z
   Yang, XW
   Zhang, JM
   Xiao, YY
   Sang, N
   Qian, XY
   Wang, L
   Cen, XB
   Du, X
   Zhao, YL
AF Gong, Jin
   Lin, Yiyun
   Zhang, Huaqin
   Liu, Chunqi
   Cheng, Zhong
   Yang, Xiaowei
   Zhang, Jiamei
   Xiao, Yuanyuan
   Sang, Na
   Qian, Xinying
   Wang, Liang
   Cen, Xiaobo
   Du, Xiao
   Zhao, Yinglan
TI Reprogramming of lipid metabolism in cancer-associated fibroblasts
   potentiates migration of colorectal cancer cells
SO CELL DEATH & DISEASE
LA English
DT Article
ID TUMOR-STROMA; FATTY-ACIDS; GROWTH; METASTASIS; INHIBITION; APOPTOSIS;
   AUTOPHAGY; INVASION; BINDING; MARKER
AB Metabolic interaction between cancer-associated fibroblasts (CAFs) and colorectal cancer (CRC) cells plays a major role in CRC progression. However, little is known about lipid alternations in CAFs and how these metabolic reprogramming affect CRC cells metastasis. Here, we uncover CAFs conditioned medium (CM) promote the migration of CRC cells compared with normal fibroblasts CM. CAFs undergo a lipidomic reprogramming, and accumulate more fatty acids and phospholipids. CAFs CM after protein deprivation still increase the CRC cells migration, which suggests small molecular metabolites in CAFs CM are responsible for CRC cells migration. Then, we confirm that CRC cells take up the lipids metabolites that are secreted from CAFs. Fatty acids synthase (FASN), a crucial enzyme in fatty acids synthesis, is significantly increased in CAFs. CAF-induced CRC cell migration is abolished by knockdown of FASN by siRNA or reducing the uptake of fatty acids by CRC cells by sulfo-N-succinimidyloleate sodium in vitro and CD36 monoclonal antibody in vivo. To conclude, our results provide a new insight into the mechanism of CRC metastasis and suggest FASN of CAFs or CD36 of CRC cells may be potential targets for anti-metastasis treatment in the future.
C1 [Gong, Jin; Lin, Yiyun; Zhang, Huaqin; Liu, Chunqi; Yang, Xiaowei; Sang, Na; Qian, Xinying; Zhao, Yinglan] Sichuan Univ, West China Hosp, State Key Lab Biotherapy & Canc Ctr, Chengdu 610041, Peoples R China.
   [Gong, Jin; Lin, Yiyun; Zhang, Huaqin; Liu, Chunqi; Yang, Xiaowei; Zhang, Jiamei; Xiao, Yuanyuan; Sang, Na; Qian, Xinying; Wang, Liang; Cen, Xiaobo; Zhao, Yinglan] Collaborat Innovat Ctr Biotherapy, Chengdu 610041, Peoples R China.
   [Cheng, Zhong; Du, Xiao] Sichuan Univ, West China Hosp, Dept Gastrointestinal Surg, Chengdu 610041, Peoples R China.
   [Zhang, Jiamei; Xiao, Yuanyuan; Wang, Liang; Cen, Xiaobo] Sichuan Univ, Natl Chengdu Ctr Safety Evaluat Drugs, West China Hosp, State Key Lab Biotherapy, Chengdu 610041, Peoples R China.
   [Du, Xiao] Ya An Peoples Hosp, Dept Gen Surg, Yaan 625000, Peoples R China.
RP Zhao, YL (corresponding author), Sichuan Univ, West China Hosp, State Key Lab Biotherapy & Canc Ctr, Chengdu 610041, Peoples R China.; Zhao, YL (corresponding author), Collaborat Innovat Ctr Biotherapy, Chengdu 610041, Peoples R China.; Du, X (corresponding author), Sichuan Univ, West China Hosp, Dept Gastrointestinal Surg, Chengdu 610041, Peoples R China.; Du, X (corresponding author), Ya An Peoples Hosp, Dept Gen Surg, Yaan 625000, Peoples R China.
EM Duxiao_home@163.com; zhaoyinglan@scu.edu.cn
OI Lin, Yiyun/0000-0002-9277-3048
FU Project of the National keypoint research and invention program of China
   Ministry of Science and Technology [MOST-2016YFC1303200]; National ST
   Major project [2018ZX09201018]; National Natural Science Foundation of
   ChinaNational Natural Science Foundation of China (NSFC) [81773198]
FX This work was supported by Project of the National keypoint research and
   invention program of China Ministry of Science and Technology
   (MOST-2016YFC1303200) and National S&T Major project (2018ZX09201018),
   National Natural Science Foundation of China (81773198).
CR ABUMRAD NA, 1993, J BIOL CHEM, V268, P17665
   Alwarawrah Y, 2016, CELL CHEM BIOL, V23, P678, DOI 10.1016/j.chembiol.2016.04.011
   Auciello FR, 2019, CANCER DISCOV, V9, P617, DOI 10.1158/2159-8290.CD-18-1212
   Beloribi-Djefaflia S, 2016, ONCOGENESIS, V5, DOI 10.1038/oncsis.2015.49
   Bu L, 2019, ONCOGENE, V38, P4887, DOI 10.1038/s41388-019-0765-y
   Chaudhri VK, 2013, MOL CANCER RES, V11, P579, DOI 10.1158/1541-7786.MCR-12-0437-T
   Fiaschi T, 2013, CELL CYCLE, V12, P1791, DOI 10.4161/cc.24902
   Fiaschi T, 2012, CANCER RES, V72, P5130, DOI 10.1158/0008-5472.CAN-12-1949
   Franco OE, 2010, SEMIN CELL DEV BIOL, V21, P33, DOI 10.1016/j.semcdb.2009.10.010
   Gong JJ, 2017, INT J ONCOL, V50, P883, DOI 10.3892/ijo.2017.3867
   Greenhough A, 2009, CARCINOGENESIS, V30, P377, DOI 10.1093/carcin/bgp014
   Guido C, 2012, CELL CYCLE, V11, P3019, DOI 10.4161/cc.21384
   Hua W, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127507
   Huang CF, 2015, INT J MOL SCI, V16, P924, DOI 10.3390/ijms16010924
   Keren K, 2011, EUR BIOPHYS J BIOPHY, V40, P1013, DOI 10.1007/s00249-011-0741-0
   Ko YH, 2011, CANCER BIOL THER, V12, P1085, DOI 10.4161/cbt.12.12.18671
   Kuda O, 2013, J BIOL CHEM, V288, P15547, DOI 10.1074/jbc.M113.473298
   Lee JS, 2009, BIOL PHARM BULL, V32, P1427, DOI 10.1248/bpb.32.1427
   Li JJ, 2017, CELL STEM CELL, V20, P303, DOI 10.1016/j.stem.2016.11.004
   Luo XJ, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0646-3
   Nath A, 2016, SCI REP-UK, V6, DOI 10.1038/srep18669
   Nicholls HT, 2011, DIABETES, V60, P1100, DOI 10.2337/db10-1353
   Nieman KM, 2011, NAT MED, V17, P1498, DOI 10.1038/nm.2492
   Papaevangelou E, 2018, INT J CANCER, V143, P992, DOI 10.1002/ijc.31392
   Pascual G, 2017, NATURE, V541, P41, DOI 10.1038/nature20791
   Pavlides S, 2009, CELL CYCLE, V8, P3984, DOI 10.4161/cc.8.23.10238
   Rabinowitz JD, 2010, SCIENCE, V330, P1344, DOI 10.1126/science.1193497
   Sepra J., 2018, TUMOUR BIOL, P1, DOI [10.1177/1010428318756203, DOI 10.1177/1010428318756203]
   Shiga K, 2015, CANCERS, V7, P2443, DOI 10.3390/cancers7040902
   Siegel RL, 2019, CA-CANCER J CLIN, V69, P7, DOI 10.3322/caac.21551
   Sousa CM, 2016, NATURE, V536, P479, DOI 10.1038/nature19084
   Stuelten CH, 2005, J CELL SCI, V118, P2143, DOI 10.1242/jcs.02334
   Stulnig TM, 1998, J CELL BIOL, V143, P637, DOI 10.1083/jcb.143.3.637
   Sun XC, 2018, SIGNAL TRANSDUCT TAR, V3, DOI 10.1038/s41392-018-0011-z
   Tabe Y, 2017, CANCER RES, V77, P1453, DOI 10.1158/0008-5472.CAN-16-1645
   Tanaka M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-13438-5
   Tao LL, 2017, ONCOL LETT, V14, P2611, DOI 10.3892/ol.2017.6497
   Todaro M, 2014, CELL STEM CELL, V14, P342, DOI 10.1016/j.stem.2014.01.009
   Visentin B, 2006, CANCER CELL, V9, P225, DOI 10.1016/j.ccr.2006.02.023
   Wu DJ, 2017, SEMIN CELL DEV BIOL, V64, P125, DOI 10.1016/j.semcdb.2016.11.003
   Wu MH, 2011, CLIN CANCER RES, V17, P1306, DOI 10.1158/1078-0432.CCR-10-1824
   Zhang DX, 2015, CELL REP, V10, P1335, DOI 10.1016/j.celrep.2015.02.006
NR 42
TC 37
Z9 38
U1 7
U2 12
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-4889
J9 CELL DEATH DIS
JI Cell Death Dis.
PD APR 23
PY 2020
VL 11
IS 4
DI 10.1038/s41419-020-2434-z
PG 15
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA LJ6KX
UT WOS:000530273000005
PM 32327627
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Bao, YJ
   Tang, JY
   Qian, Y
   Sun, TT
   Chen, HM
   Chen, ZF
   Sun, DF
   Zhong, M
   Chen, HY
   Hong, J
   Chen, YX
   Fang, JY
AF Bao, Yujie
   Tang, Jiayin
   Qian, Yun
   Sun, Tiantian
   Chen, Huimin
   Chen, Zhaofei
   Sun, Danfeng
   Zhong, Ming
   Chen, Haoyan
   Hong, Jie
   Chen, Yingxuan
   Fang, Jing-Yuan
TI Long noncoding RNA BFAL1 mediates enterotoxigenic Bacteroides
   fragilis-related carcinogenesis in colorectal cancer via the RHEB/mTOR
   pathway
SO CELL DEATH & DISEASE
LA English
DT Article
ID MICROBIOTA; AUTOPHAGY; DIFFERENTIATION; EXPRESSION; NETWORK; GROWTH;
   CELLS
AB Long noncoding RNAs (lncRNAs) contribute to many steps in carcinogenesis and often serve as biomarkers or therapeutic targets for tumor diagnosis and therapy. Although the role of lncRNAs in tumor formation is becoming clear, whether lncRNAs mediate gut microbiota-induced colorectal cancer (CRC) is largely unknown. Enterotoxigenic Bacteroides fragilis (ETBF) is a well-known tumor-inducing bacterium in the human gut; however, its tumorigenic effect remains to be explored. In the present study, we revealed the mechanism by which a lncRNA participates in gut bacteria-induced carcinogenesis: Bacteroides fragilis-associated lncRNA1 (BFAL1) in CRC tissues mediates ETBF carcinogenesis. BFAL1 was highly expressed in CRC tissues compared with that in adjacent normal tissues. In vitro, BFAL1 was upregulated in ETBF-treated CRC cells. Mechanistically, ETBF promoted tumor growth via BFAL1 by activating the Ras homolog, which is the MTORC1 binding/mammalian target of the rapamycin (RHEB/mTOR) pathway. Furthermore, BFAL1 regulated RHEB expression by competitively sponging microRNAs miR-155-5p and miR-200a-3p. Clinically, both high expression of BFAL1 and high abundance of ETBF in CRC tissues predicted poor outcomes for patients with CRC. Thus, BFAL1 is a mediator of ETBF-induced carcinogenesis and may be a potential therapeutic target for ETBF-induced CRC.
C1 [Bao, Yujie; Tang, Jiayin; Qian, Yun; Sun, Tiantian; Chen, Huimin; Chen, Zhaofei; Sun, Danfeng; Chen, Haoyan; Hong, Jie; Chen, Yingxuan; Fang, Jing-Yuan] Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, State Key Lab Oncogenes & Related Genes, 145 Middle Shandong Rd, Shanghai 200001, Peoples R China.
   [Bao, Yujie; Tang, Jiayin; Qian, Yun; Sun, Tiantian; Chen, Huimin; Chen, Zhaofei; Sun, Danfeng; Chen, Haoyan; Hong, Jie; Chen, Yingxuan; Fang, Jing-Yuan] Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Key Lab Gastroenterol & Hepatol,Minist Hlth, 145 Middle Shandong Rd, Shanghai 200001, Peoples R China.
   [Bao, Yujie; Tang, Jiayin; Qian, Yun; Sun, Tiantian; Chen, Huimin; Chen, Zhaofei; Sun, Danfeng; Chen, Haoyan; Hong, Jie; Chen, Yingxuan; Fang, Jing-Yuan] Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Div Gastroenterol & Hepatol, 145 Middle Shandong Rd, Shanghai 200001, Peoples R China.
   [Bao, Yujie; Tang, Jiayin; Qian, Yun; Sun, Tiantian; Chen, Huimin; Chen, Zhaofei; Sun, Danfeng; Chen, Haoyan; Hong, Jie; Chen, Yingxuan; Fang, Jing-Yuan] Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Shanghai Inst Digest Dis, 145 Middle Shandong Rd, Shanghai 200001, Peoples R China.
   [Bao, Yujie] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 9, Sch Med, Dept Infect Dis, 639 Zhizhaoju Rd, Shanghai 200001, Peoples R China.
   [Tang, Jiayin; Zhong, Ming] Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Dept Gastrointestinal Surg, Shanghai 200001, Peoples R China.
RP Fang, JY (corresponding author), Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, State Key Lab Oncogenes & Related Genes, 145 Middle Shandong Rd, Shanghai 200001, Peoples R China.; Fang, JY (corresponding author), Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Key Lab Gastroenterol & Hepatol,Minist Hlth, 145 Middle Shandong Rd, Shanghai 200001, Peoples R China.; Fang, JY (corresponding author), Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Div Gastroenterol & Hepatol, 145 Middle Shandong Rd, Shanghai 200001, Peoples R China.; Fang, JY (corresponding author), Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Shanghai Inst Digest Dis, 145 Middle Shandong Rd, Shanghai 200001, Peoples R China.
EM jingyuanfang@sjtu.edu.cn
RI Tang, Jiayin/AAJ-5473-2021
OI Tang, Jiayin/0000-0002-2510-6448
FU Division of Gastroenterology and Hepatology, Renji Hospital, School of
   Medicine; Shanghai Jiao Tong University; National Natural Science
   Foundation of ChinaNational Natural Science Foundation of China (NSFC)
   [81421001, 81530072, 81871901, 81874159, 81790632]
FX This work was supported by the Division of Gastroenterology and
   Hepatology, Renji Hospital, School of Medicine, and Shanghai Jiao Tong
   University. This study was financially supported by the National Natural
   Science Foundation of China (Grant Nos. 81421001, 81530072, 81871901,
   81874159, and 81790632).
CR Antunes ENF, 2002, ANAEROBE, V8, P17, DOI 10.1006/anae.2002.0410
   Bullman S, 2017, SCIENCE, V358, P1443, DOI 10.1126/science.aal5240
   Bultman SJ, 2014, CELL HOST MICROBE, V16, P143, DOI 10.1016/j.chom.2014.07.011
   Caballero-Garrido E, 2015, J NEUROSCI, V35, P12446, DOI 10.1523/JNEUROSCI.1641-15.2015
   Cesana M, 2011, CELL, V147, P358, DOI 10.1016/j.cell.2011.09.028
   Chen M, 2011, DRUG DISCOV TODAY, V16, P1007, DOI 10.1016/j.drudis.2011.09.008
   Chung Liam, 2018, CELL HOST MICROBE, V23, P1
   Feil R, 2012, NAT REV GENET, V13, P97, DOI 10.1038/nrg3142
   Guo W, 2016, INT J OBESITY, V40, P1222, DOI 10.1038/ijo.2016.60
   Nguyen HTT, 2014, GASTROENTEROLOGY, V146, P508, DOI 10.1053/j.gastro.2013.10.021
   Hyum C. R., 2011, J IMMUNOL, V187, P1931
   Jan K., 2016, NUCLEIC ACIDS RES, V34, P451
   Kim SG, 2013, MOL CELLS, V35, P463, DOI 10.1007/s10059-013-0138-2
   Kretz M, 2013, NATURE, V493, P231, DOI 10.1038/nature11661
   Kun Z., 2011, NAT COMMUN, V8, P144
   Labianca R, 2010, CRIT REV ONCOL HEMAT, V74, P106, DOI 10.1016/j.critrevonc.2010.01.010
   Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035
   Liang LX, 2015, SCI REP-UK, V5, DOI 10.1038/srep11763
   Long X, 2005, CURR BIOL, V15, P702, DOI 10.1016/j.cub.2005.02.053
   Lv JL, 2017, CELL PHYSIOL BIOCHEM, V43, P1436, DOI 10.1159/000481875
   Marchese FP, 2017, GENOME BIOL, V18, DOI 10.1186/s13059-017-1348-2
   Nicholson JK, 2012, SCIENCE, V336, P1262, DOI 10.1126/science.1223813
   Pantosti A, 1997, J CLIN MICROBIOL, V35, P2482, DOI 10.1128/JCM.35.10.2482-2486.1997
   Paul B, 2015, CLIN EPIGENETICS, V7, DOI 10.1186/s13148-015-0144-7
   Peloquin JM, 2013, ANAEROBE, V24, P102, DOI 10.1016/j.anaerobe.2013.04.006
   Prensner JR, 2011, CANCER DISCOV, V1, P391, DOI 10.1158/2159-8290.CD-11-0209
   Qian K, 2018, INT J ONCOL, V53, P1083, DOI 10.3892/ijo.2018.4443
   Qin YF, 2018, J BIOCHEM, V163, P105, DOI 10.1093/jb/mvx080
   Quan HY, 2018, CELL PHYSIOL BIOCHEM, V46, P401, DOI 10.1159/000488474
   Quinn JJ, 2016, NAT REV GENET, V17, P47, DOI 10.1038/nrg.2015.10
   Sears CL, 2014, J CLIN INVEST, V124, P4166, DOI 10.1172/JCI72334
   Sears CL, 2014, CELL HOST MICROBE, V15, P317, DOI 10.1016/j.chom.2014.02.007
   Shields CED, 2016, J INFECT DIS, V214, P122, DOI 10.1093/infdis/jiw069
   Siegel R, 2014, CA-CANCER J CLIN, V64, P104, DOI 10.3322/caac.21220
   Smith RA, 2010, CA-CANCER J CLIN, V60, P99, DOI 10.3322/caac.20063
   TaChung Y., 2017, CELL, V170, P548
   Terzic J, 2010, GASTROENTEROLOGY, V138, P2101, DOI 10.1053/j.gastro.2010.01.058
   Toprak NU, 2006, CLIN MICROBIOL INFEC, V12, P782, DOI 10.1111/j.1469-0691.2006.01494.x
   Vetizou M, 2015, SCIENCE, V350, P1079, DOI 10.1126/science.aad1329
   Viaud S, 2013, SCIENCE, V342, P971, DOI 10.1126/science.1240537
   Wang JY, 2018, MOL CELL BIOL, V38, DOI 10.1128/MCB.00010-18
   Wang XW, 2014, WORLD J GASTROENTERO, V20, P4178, DOI 10.3748/wjg.v20.i15.4178
   Wang YH, 2017, CELL PHYSIOL BIOCHEM, V42, P2481, DOI 10.1159/000480211
   Wu SG, 2002, INFECT IMMUN, V70, P2463, DOI 10.1128/IAI.70.5.2463-2471.2002
   Wu XJ, 2017, NAT REV GENET, V18, P517, DOI 10.1038/nrg.2017.33
   Xing GP, 2016, MED SCI MONITOR, V22, DOI 10.12659/MSM.898980
   Yang F, 2011, HEPATOLOGY, V54, P1679, DOI 10.1002/hep.24563
   Yoon JH, 2013, J MOL BIOL, V425, P3723, DOI 10.1016/j.jmb.2012.11.024
   Yuan J. H., 2014, CANCER CELL, V25, P1
   Zhu H, 2018, BIOMED PHARMACOTHER, V105, P789, DOI 10.1016/j.biopha.2018.05.053
NR 50
TC 32
Z9 33
U1 3
U2 14
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-4889
J9 CELL DEATH DIS
JI Cell Death Dis.
PD SEP 12
PY 2019
VL 10
AR 675
DI 10.1038/s41419-019-1925-2
PG 14
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA JB8TZ
UT WOS:000488851300002
PM 31515468
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Qi, JJ
   Zhou, NN
   Li, LY
   Mo, SY
   Zhou, YD
   Deng, Y
   Chen, T
   Shan, CL
   Chen, Q
   Lu, B
AF Qi, Jianjun
   Zhou, Ningning
   Li, Liyi
   Mo, Shouyong
   Zhou, Yidan
   Deng, Yao
   Chen, Ting
   Shan, Changliang
   Chen, Qin
   Lu, Bin
TI Ciclopirox activates PERK-dependent endoplasmic reticulum stress to
   drive cell death in colorectal cancer
SO CELL DEATH & DISEASE
LA English
DT Article
ID UNFOLDED PROTEIN RESPONSE; FUNGICIDE CICLOPIROX; ER; AUTOPHAGY
AB Ciclopirox (CPX) modulates multiple cellular pathways involved in the growth of a variety of tumor cell types. However, the effects of CPX on colorectal cancer (CRC) and the underlying mechanisms for its antitumor activity remain unclear. Herein, we report that CPX exhibited strong antitumorigenic properties in CRC by inducing cell cycle arrest, repressing cell migration, and invasion by affecting N-cadherin, Snail, E-cadherin, MMP-2, and MMP-9 expression, and disruption of cellular bioenergetics contributed to CPX-associated inhibition of cell growth, migration, and invasion. Interestingly, CPX-induced reactive oxygen species (ROS) production and impaired mitochondrial respiration, whereas the capacity of glycolysis was increased. CPX (20mg/kg, intraperitoneally) substantially inhibited CRC xenograft growth in vivo. Mechanistic studies revealed that the antitumor activity of CPX relies on apoptosis induced by ROS-mediated endoplasmic reticulum (ER) stress in both 5-FU-sensitive and -resistant CRC cells. Our data reveal a novel mechanism for CPX through the disruption of cellular bioenergetics and activating protein kinase RNA-like endoplasmic reticulum kinase (PERK)-dependent ER stress to drive cell death and overcome drug resistance in CRC, indicating that CPX could potentially be a novel chemotherapeutic for the treatment of CRC.
C1 [Qi, Jianjun; Zhou, Ningning; Zhou, Yidan; Deng, Yao; Chen, Ting; Lu, Bin] Wenzhou Med Univ, Sch Lab Med & Life Sci, Prot Qual Control & Dis Lab, Wenzhou 325035, Zhejiang, Peoples R China.
   [Qi, Jianjun; Chen, Qin] Wenzhou Med Univ, Dept Intens Care, Affiliated Hosp 1, Wenzhou 325000, Zhejiang, Peoples R China.
   [Li, Liyi] Wenzhou Med Univ, Dept Surg, Affiliated Hosp 2, Wenzhou 325000, Zhejiang, Peoples R China.
   [Mo, Shouyong] Wenzhou Med Univ, Dept Lab Med, Affiliated Hosp 5, Lishui 32300, Zhejiang, Peoples R China.
   [Shan, Changliang] Nankai Univ, Coll Pharm, State Key Lab Med Chem Biol, Tianjin 300350, Peoples R China.
   [Shan, Changliang; Chen, Qin; Lu, Bin] Nankai Univ, Tianjin Key Lab Mol Drug Res, Tianjin 300350, Peoples R China.
RP Lu, B (corresponding author), Wenzhou Med Univ, Sch Lab Med & Life Sci, Prot Qual Control & Dis Lab, Wenzhou 325035, Zhejiang, Peoples R China.; Chen, Q (corresponding author), Wenzhou Med Univ, Dept Intens Care, Affiliated Hosp 1, Wenzhou 325000, Zhejiang, Peoples R China.
EM chenqin@wmu.edu.cn; lubmito@wmu.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [31570772, 31771534]; Key Discipline of
   Zhejiang Province in Medical Technology (First Class, Category A)
FX The authors thank Prof. Michael B. Mathews (Rutgers New Jersey Medical
   School) and Prof. Jianhong Zhu (Wenzhou Medical University) for the
   critical reading and editing of the paper. This research was supported
   by the National Natural Science Foundation of China (31570772 and
   31771534 to B.L.), and the Key Discipline of Zhejiang Province in
   Medical Technology (First Class, Category A).
CR Ameri K, 2008, INT J BIOCHEM CELL B, V40, P14, DOI 10.1016/j.biocel.2007.01.020
   Birsoy K, 2014, NATURE, V508, P108, DOI 10.1038/nature13110
   Boyce M, 2005, SCIENCE, V307, P935, DOI 10.1126/science.1101902
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
   Buondonno I, 2019, CELL MOL LIFE SCI, V76, P609, DOI 10.1007/s00018-018-2967-9
   Chen WQ, 2018, CHINESE J CANCER RES, V30, P1, DOI 10.21147/j.issn.1000-9604.2018.01.01
   Clarke HJ, 2014, CANCER CELL, V25, P563, DOI 10.1016/j.ccr.2014.03.015
   Clement PM, 2012, INT J CANCER, V100, P491
   Eberhard Y, 2009, BLOOD, V114, P3064, DOI 10.1182/blood-2009-03-209965
   Gallo A, 2016, ANNU REV CELL DEV BI, V32, P279, DOI 10.1146/annurev-cellbio-111315-125024
   Gerl R, 2005, CARCINOGENESIS, V26, P263, DOI 10.1093/carcin/bgh283
   Gupta AK, 2006, INT J DERMATOL, V45, P66, DOI 10.1111/j.1365-4632.2004.02331.x
   Halperin L, 2014, IUBMB LIFE, V66, P318, DOI 10.1002/iub.1272
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Harding HP, 2000, MOL CELL, V5, P897, DOI 10.1016/S1097-2765(00)80330-5
   Hetz C, 2018, MOL CELL, V69, P169, DOI 10.1016/j.molcel.2017.06.017
   Hetz C, 2012, NAT REV MOL CELL BIO, V13, P89, DOI 10.1038/nrm3270
   Huang YM, 2019, BIOMOLECULES, V9, DOI 10.3390/biom9110688
   Jose C, 2011, BBA-BIOENERGETICS, V1807, P552, DOI 10.1016/j.bbabio.2010.10.012
   JUE SG, 1985, DRUGS, V29, P330, DOI 10.2165/00003495-198529040-00002
   Jurikova M, 2016, ACTA HISTOCHEM, V118, P544, DOI 10.1016/j.acthis.2016.05.002
   Lan LH, 2018, CANCER LETT, V432, P132, DOI 10.1016/j.canlet.2018.06.012
   Liberti MV, 2016, TRENDS BIOCHEM SCI, V41, P211, DOI 10.1016/j.tibs.2015.12.001
   Liu HC, 2020, BIOMED PHARMACOTHER, V125, DOI 10.1016/j.biopha.2020.110005
   Lochhead P, 2013, CLIN GASTROENTEROL H, V11, P109, DOI 10.1016/j.cgh.2012.08.037
   Luo Y, 2011, ONCOGENE, V30, P2098, DOI 10.1038/onc.2010.590
   Malhotra JD, 2007, ANTIOXID REDOX SIGN, V9, P2277, DOI 10.1089/ars.2007.1782
   Minden MD, 2014, AM J HEMATOL, V89, P363, DOI 10.1002/ajh.23640
   Oka OBV, 2015, BIOCHEM J, V469, P279, DOI 10.1042/BJ20141423
   Perri ER, 2016, FRONT CELL DEV BIOL, V3, DOI 10.3389/fcell.2015.00080
   Radisky ES, 2010, J MAMMARY GLAND BIOL, V15, P201, DOI 10.1007/s10911-010-9177-x
   Rao RV, 2004, CELL DEATH DIFFER, V11, P372, DOI 10.1038/sj.cdd.4401378
   Rao RV, 2004, CURR OPIN CELL BIOL, V16, P653, DOI 10.1016/j.ceb.2004.09.012
   REITZER LJ, 1979, J BIOL CHEM, V254, P2669
   Rodriguez-Enriquez S, 2010, INT J BIOCHEM CELL B, V42, P1744, DOI 10.1016/j.biocel.2010.07.010
   Rutkowski DT, 2004, TRENDS CELL BIOL, V14, P20, DOI 10.1016/j.tcb.2003.11.001
   Scheau C, 2019, ANAL CELL PATHOL, V2019, DOI 10.1155/2019/9423907
   Shen T, 2016, CURR PHARM DESIGN, V22, P4443, DOI 10.2174/1381612822666160530151209
   van Galen P, 2014, NATURE, V510, P268, DOI 10.1038/nature13228
   Walczak A, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/5729710
   Wallace DC, 2012, NAT REV CANCER, V12, P685, DOI 10.1038/nrc3365
   Wang Y, 2019, CANCER LETT, V449, P263, DOI 10.1016/j.canlet.2019.01.034
   Woehlbier U, 2011, TRENDS BIOCHEM SCI, V36, P329, DOI 10.1016/j.tibs.2011.03.001
   Wu JR, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161509
   Yang J, 2017, CANCER RES, V77, P4626, DOI [10.1158/0008-5472.can-16-0826, 10.1158/0008-5472.CAN-16-0826]
   Zhang XN, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4295
   Zhou HY, 2016, BIOCHEM PHARMACOL, V116, P39, DOI 10.1016/j.bcp.2016.07.005
   Zhou HY, 2014, ONCOTARGET, V5, P10140, DOI 10.18632/oncotarget.2471
   Zhou HY, 2010, INT J CANCER, V127, P2467, DOI 10.1002/ijc.25255
   Zhou J, 2019, THERANOSTICS, V9, P5577, DOI 10.7150/thno.34663
NR 50
TC 12
Z9 12
U1 4
U2 6
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 2041-4889
J9 CELL DEATH DIS
JI Cell Death Dis.
PD JUL 27
PY 2020
VL 11
IS 7
AR 582
DI 10.1038/s41419-020-02779-1
PG 16
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA MV9XZ
UT WOS:000556702900001
PM 32719342
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Maiese, K
AF Maiese, Kenneth
TI Moving to the Rhythm with Clock (Circadian) Genes, Autophagy, mTOR, and
   SIRT1 in Degenerative Disease and Cancer
SO CURRENT NEUROVASCULAR RESEARCH
LA English
DT Review
DE Aging; aging-related disorders; Alzheimer's disease; AMP activated
   protein kinase (AMPK); angiogenesis; apoptosis; autophagy; BMAL1;
   cardiovascular disease; beta-catenin; circadian rhythm; CLOCK; clock
   genes; Cryptochrome; diabetes mellitus; hamartin (tuberous sclerosis
   1)/tuberin (tuberous sclerosis 2) (TSC1/TSC2); Huntington's disease;
   mechanistic target of rapamycin (mTOR); mTOR Complex 1 (mTORC1); mTOR
   Complex 2 (mTORC2); metabolism; nerve growth factor; nicotinamide;
   nicotinamide adenine dinucleotide (NAD(+)); Parkinson's disease; period
   (PER); oxidative stress; programmed cell death; REV-ERB alpha; ROR
   alpha; RORE; shift work; silent mating type information regulation 2
   homolog 1 (Saccharomyces cerevisiae) (SIRT1); sirtuin; space travel;
   stem cells; suprachiasmatic nucleus; wingless; Wnt
ID CATENIN SIGNALING PATHWAY; MAMMALIAN TARGET; ALZHEIMERS-DISEASE;
   STEM-CELLS; CARDIOVASCULAR-DISEASE; NEURODEGENERATIVE DISEASES;
   THERAPEUTIC STRATEGIES; INDUCED NEUROTOXICITY; CALORIC RESTRICTION;
   MECHANISTIC TARGET
AB Background: The mammalian circadian clock and its associated clock genes are increasingly been recognized as critical components for a number of physiological and disease processes that extend beyond hormone release, thermal regulation, and sleep-wake cycles. New evidence suggests that clinical behavior disruptions that involve prolonged shift work and even space travel may negatively impact circadian rhythm and lead to multi-system disease.
   Methods: In light of the significant role circadian rhythm can hold over the body's normal physiology as well as disease processes, we examined and discussed the impact circadian rhythm and clock genes hold over lifespan, neurodegenerative disorders, and tumorigenesis.
   Results: In experimental models, lifespan is significantly reduced with the introduction of arrhythmic mutants and leads to an increase in oxidative stress exposure. Interestingly, patients with Alzheimer's disease and Parkinson's disease may suffer disease onset or progression as a result of alterations in the DNA methylation of clock genes as well as prolonged pharmacological treatment for these disorders that may lead to impairment of circadian rhythm function. Tumorigenesis also can occur with the loss of a maintained circadian rhythm and lead to an increased risk for nasopharyngeal carcinoma, breast cancer, and metastatic colorectal cancer. Interestingly, the circadian clock system relies upon the regulation of the critical pathways of autophagy, the mechanistic target of rapamycin (mTOR), AMP activated protein kinase (AMPK), and silent mating type information regulation 2 homolog 1 (Saccharomyces cerevisiae) (SIRT1) as well as proliferative mechanisms that involve the wingless pathway of Wnt/beta-catenin pathway to foster cell survival during injury and block tumor cell growth.
   Conclusion: Future targeting of the pathways of autophagy, mTOR, SIRT1, and Wnt that control mammalian circadian rhythm may hold the key for the development of novel and effective therapies against aging-related disorders, neurodegenerative disease, and tumorigenesis.
C1 [Maiese, Kenneth] Cellular & Mol Signaling, Newark, NJ 07101 USA.
RP Maiese, K (corresponding author), Cellular & Mol Signaling, Newark, NJ 07101 USA.
EM wntin75@yahoo.com
FU American Diabetes AssociationAmerican Diabetes Association; American
   Heart AssociationAmerican Heart Association; NIH NIEHSUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Environmental Health Sciences (NIEHS);
   NIH NIAUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute on Aging (NIA);
   NIH NINDSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Neurological
   Disorders & Stroke (NINDS); NIH ARRAUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USA; NATIONAL
   INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department
   of Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Neurological Disorders & Stroke (NINDS)
   [R01NS053946] Funding Source: NIH RePORTER
FX This research was supported by the following grants to Kenneth Maiese:
   American Diabetes Association, American Heart Association, NIH NIEHS,
   NIH NIA, NIH NINDS, and NIH ARRA.
CR [Anonymous], 2015, CANC RES, V75
   Arunachalam G, 2016, J PHARMACOL EXP THER, V356, P314, DOI 10.1124/jpet.115.226894
   Beker MC, 2017, MOL NEUROBIOL, DOI [10.1007/s12035-017-0524-4, DOI 10.1007/S12035-017-0524-4.]
   Bellanti F, 2017, J ALZHEIMERS DIS, V59, P615, DOI 10.3233/JAD-160942
   Bellet MM, 2016, J BIOL CHEM, V291, P23318, DOI 10.1074/jbc.M116.737114
   Bondy S, 2010, OXIDATIVE STRESS APP
   Bruckbauer A, 2017, AM J CARDIOVASC DIS, V7, P33
   Bunney BG, 2015, MOL PSYCHIATR, V20, P48, DOI 10.1038/mp.2014.138
   Charles S, 2017, PHARMACOL RES, V119, P1, DOI 10.1016/j.phrs.2017.01.022
   Chen B, 2017, ONCOL LETT, V13, P423, DOI 10.3892/ol.2016.5430
   Chen C, 2017, MOLECULES, V22
   Chen L, 2016, J NEUROIMMUNOL, V299, P164, DOI 10.1016/j.jneuroim.2016.09.008
   Chen X, 2015, J FORMOS MED ASSOC, V114, P430, DOI 10.1016/j.jfma.2015.01.007
   Chen X, 2015, SCI REP-UK, V5, DOI 10.1038/srep12115
   Chong ZZ, 2007, CURR NEUROVASC RES, V4, P194
   Chong ZZ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045456
   Chong ZZ, 2012, PROG NEUROBIOL, V99, P128, DOI 10.1016/j.pneurobio.2012.08.001
   Chong ZZ, 2012, CARDIOVASC DIABETOL, V11, DOI 10.1186/1475-2840-11-45
   Chong ZZ, 2011, TRENDS CARDIOVAS MED, V21, P151, DOI 10.1016/j.tcm.2012.04.005
   Chong ZZ, 2012, EXPERT OPIN THER TAR, V16, P167, DOI 10.1517/14728222.2012.648926
   Chong ZZ, 2012, FUTUR CARDIOL, V8, P89, DOI [10.2217/fca.11.76, 10.2217/FCA.11.76]
   Chong ZZ, 2010, OXID MED CELL LONGEV, V3, P374, DOI 10.4161/oxim.3.6.14787
   Crespo MC, 2017, BIOFACTORS, DOI [10.1002/biof.1356, DOI 10.1002/BIOF.1356.]
   Crino PB, 2016, NAT REV NEUROL, V12, P379, DOI 10.1038/nrneurol.2016.81
   Cronin P, 2017, ALZHEIMERS DEMENT, V13, P689, DOI 10.1016/j.jalz.2016.10.003
   Cui L, 2017, TOXICOL LETT, V275, P28, DOI 10.1016/j.toxlet.2017.04.018
   D'Onofrio N, 2015, BBA-MOL BASIS DIS, V1852, P1311, DOI 10.1016/j.bbadis.2015.03.001
   Di Rosa M, 2016, CURR NEUROPHARMACOL, V14, P810, DOI 10.2174/1570159X14666160321122900
   Dijkstra AA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128651
   Dong W, 2016, AGING CLIN EXP RES, V28, P303, DOI 10.1007/s40520-015-0398-0
   Duan P, 2016, TOXICOLOGY, V341, P28, DOI 10.1016/j.tox.2016.01.004
   Duan WZ, 2013, FRONT AGING NEUROSCI, V5, DOI 10.3389/fnagi.2013.00036
   Fang MZ, 2017, ONCOTARGET, V8, P32752, DOI 10.18632/oncotarget.15678
   Geng C, 2017, SCI CHINA LIFE SCI, DOI [10.1007/s11427-016-9027-6, DOI 10.1007/S11427-016-9027-6.]
   Gulhati P, 2011, CANCER RES, V71, P3246, DOI 10.1158/0008-5472.CAN-10-4058
   Guo P, 2016, MOL MED REPORT, V13
   Gurlo T, 2016, MOL ENDOCRINOL, V30, P446, DOI 10.1210/me.2015-1255
   Hardeland R, 2017, J PINEAL RES, V62, DOI 10.1111/jpi.12377
   He Y, 2016, CHRONOBIOL INT, V33, P553, DOI 10.3109/07420528.2015.1137581
   Hood S, 2017, FRONT AGING NEUROSCI, V9, DOI 10.3389/fnagi.2017.00170
   Hughes MA, 2017, J MUSCLE RES CELL M, DOI [10.1007/s10974-017-9473-9, DOI 10.1007/S10974-017-9473-9.]
   Hung CH, 2015, MOL NUTR FOOD RES, V59, P1905, DOI 10.1002/mnfr.201500144
   Hwang ES, 2017, CELL MOL LIFE SCI
   Hyrskyluoto A, 2012, EXP CELL RES
   Jenwitheesuk A, 2014, INT J MOL SCI, V15, P16848, DOI 10.3390/ijms150916848
   Jia SQ, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317699755
   Jin X, 2014, MOL NUTR FOOD RES, V58, P1941, DOI 10.1002/mnfr.201400161
   Joeng KS, 2017, J CLIN INVEST, V127, P2678, DOI 10.1172/JCI92617
   Karthik GM, 2015, CANCER LETT, V367, P76, DOI 10.1016/j.canlet.2015.07.017
   Klionsky DJ, 2016, AUTOPHAGY, V12, P1, DOI 10.1080/15548627.2015.1100356
   Lamoke F, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139664
   Lee JS, 2015, NEURO-ONCOLOGY, V17, P95, DOI 10.1093/neuonc/nou145
   Lee JH, 2015, NEURON, V85, P303, DOI 10.1016/j.neuron.2014.12.019
   Li L, 2017, CNS DRUGS, V31, P535, DOI 10.1007/s40263-017-0431-2
   Li SY, 2017, CHINESE MED J-PEKING, V130, P1085, DOI 10.4103/0366-6999.204920
   Li WY, 2016, ARCH VIROL, V161, P621, DOI 10.1007/s00705-015-2712-8
   Lin FW, 2013, CELL BIOCHEM FUNCT, V31, P166, DOI 10.1002/cbf.2871
   Lin L, 2014, ONCOL REP, V32, P2831, DOI 10.3892/or.2014.3521
   Lin Z, 2017, J CELL MOL MED, DOI [10.1111/jcmm.13224, DOI 10.1111/JCMM.13224.]
   Lipina C, 2016, TRENDS ENDOCRINOL ME
   Liu SL, 2017, CANCER LETT, V402, P117, DOI 10.1016/j.canlet.2017.05.022
   Ma JR, 2012, J ORTHOP RES, V30, P144, DOI 10.1002/jor.21497
   Ma LN, 2015, BRAIN RES BULL, V116, P67, DOI 10.1016/j.brainresbull.2015.06.004
   Ma LQ, 2016, PATHOL RES PRACT, V212, P310, DOI 10.1016/j.prp.2016.02.001
   Maiese K, 2011, ROM J MORPHOL EMBRYO, V52, P1173
   Maiese K., 2016, MOL MED MTOR TRANSLA
   Maiese K, 2008, PHARMACOL THERAPEUT, V118, P58, DOI 10.1016/j.pharmthera.2008.01.004
   Maiese K, 2017, CURR NEUROVASC RES, V14, P184, DOI 10.2174/1567202614666170313105337
   Maiese K, 2017, CURR NEUROVASC RES, V14, P1, DOI 10.2174/1567202614999161206161215
   Maiese Kenneth, 2016, J Transl Sci, V2, P327
   Maiese Kenneth, 2016, J Transl Sci, V2, P185
   Maiese K, 2016, BRIT J CLIN PHARMACO, V82, P1245, DOI 10.1111/bcp.12804
   Maiese Kenneth, 2016, J Transl Sci, V1, P83
   Maiese Kenneth, 2016, J Transl Sci, V2, P241
   Maiese K, 2016, CURR NEUROVASC RES, V13, P329, DOI 10.2174/1567202613666160729164900
   Maiese Kenneth, 2015, J Transl Sci, V1, P55
   Maiese K, 2016, NEURAL REGEN RES, V11, P372, DOI 10.4103/1673-5374.179032
   Maiese K, 2015, CURR NEUROVASC RES, V12, P404, DOI 10.2174/1567202612666150807112524
   Maiese K, 2015, WORLD J STEM CELLS, V7, P999, DOI 10.4252/wjsc.v7.i7.999
   Maiese K, 2015, ANAL CELL PATHOL, V2015, DOI 10.1155/2015/569392
   Maiese K, 2015, OXID MED CELL LONGEV, V2015, DOI 10.1155/2015/875961
   Maiese K, 2015, CURR NEUROVASC RES, V12, P173, DOI 10.2174/1567202612666150305110929
   Maiese K, 2015, WORLD J STEM CELLS, V7, P235, DOI 10.4252/wjsc.v7.i2.235
   Maiese K, 2015, WORLD J DIABETES, V6, P217, DOI 10.4239/wjd.v6.i2.217
   Maiese K, 2014, ANN MED, V46, P587, DOI 10.3109/07853890.2014.941921
   Maiese K, 2014, CURR NEUROVASC RES, V11, P378, DOI 10.2174/1567202611666140912115107
   Maiese K, 2014, NEURAL REGEN RES, V9, P1413, DOI 10.4103/1673-5374.139453
   Maiese K, 2013, TRENDS MOL MED, V19, P51, DOI 10.1016/j.molmed.2012.11.001
   Maiese K, 2013, EXPERT OPIN DRUG DIS, V8, P35, DOI 10.1517/17460441.2013.736485
   Maiese K, 2012, INT J MOL SCI, V13, P13830, DOI 10.3390/ijms131113830
   Maiese K, 2012, EXPERT OPIN THER TAR, V16, P1203, DOI 10.1517/14728222.2012.719499
   Malla R, 2015, BIOCHEM BIOPH RES CO, V463, P161, DOI 10.1016/j.bbrc.2015.05.041
   Martin A, 2015, IMMUNOL RES, V61, P187, DOI 10.1007/s12026-014-8557-5
   Mazzoccoli G, 2014, EXP GERONTOL, V50, P137, DOI 10.1016/j.exger.2013.10.014
   Milisav I, 2017, APOPTOSIS, V22, P265, DOI 10.1007/s10495-016-1317-3
   Min JJ, 2014, SCI REP-UK, V4, DOI 10.1038/srep05555
   Moors TE, 2017, MOL NEURODEGENER, V12, DOI 10.1186/s13024-017-0154-3
   Murphy KE, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18061168
   Ortiz-Masia D, 2014, MUCOSAL IMMUNOL, V7, P929, DOI 10.1038/mi.2013.108
   Ou X, 2014, STEM CELLS, V32, P1183, DOI 10.1002/stem.1641
   Park JA, 2017, J VET SCI, V18, P11, DOI 10.4142/jvs.2017.18.1.11
   Park YS, 2017, ENVIRON TOXICOL, V32, P109, DOI 10.1002/tox.22216
   Patel SA, 2014, ANTIOXID REDOX SIGN, V20, P2997, DOI 10.1089/ars.2013.5671
   Poulose N, 2015, BBA-MOL BASIS DIS, V1852, P2442, DOI 10.1016/j.bbadis.2015.08.017
   Qi ZT, 2016, J NUTR BIOCHEM, V36, P31, DOI 10.1016/j.jnutbio.2016.07.005
   Bellozi PMQ, 2016, SCI REP-UK, V6, DOI 10.1038/srep25226
   Ramalinga M, 2015, ONCOTARGET, V6, P34446, DOI 10.18632/oncotarget.5920
   Rami A, 2017, CURR NEUROVASC RES, V14, P207, DOI 10.2174/1567202614666170619083239
   Ratliff EP, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132768
   White CR, 2017, ADV EXP MED BIOL, V982, P407, DOI 10.1007/978-3-319-55330-6_22
   Saboori S, 2016, NUTR METAB CARDIOVAS, V26, P489, DOI 10.1016/j.numecd.2015.11.013
   Sasazawa Y, 2015, J BIOL CHEM, V290, P6168, DOI 10.1074/jbc.M114.606293
   Shah N, 2014, CELL BIOCHEM FUNCT, V32, P309, DOI 10.1002/cbf.3027
   Shang YC, 2012, CURR NEUROVASC RES, V9, P239
   Shao Y, 2016, DIABETES-METAB RES, V32, P534, DOI 10.1002/dmrr.2788
   Sun TJ, 2014, EUR REV MED PHARMACO, V18, P2460
   Tasioudi KE, 2015, APMIS, V123, P639, DOI 10.1111/apm.12398
   Tourette C, 2014, J BIOL CHEM, V289, P6709, DOI 10.1074/jbc.M113.523696
   Tsai HC, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.421
   Vaccaro A, 2017, PLOS GENET, V13, DOI 10.1371/journal.pgen.1006507
   Vaiserman AM, 2016, AGEING RES REV, V31, P9, DOI 10.1016/j.arr.2016.08.004
   Vikram A, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12565
   Wang L, 2013, DIABETES, V62, P4122, DOI 10.2337/db13-0518
   Wang YP, 2017, INT J ONCOL, V50, P2191, DOI 10.3892/ijo.2017.3987
   Wegrzyn LR, 2017, AM J EPIDEMIOL, DOI [10.1093/aje/kwx140, DOI 10.1093/AJE/KWX140.]
   Wu XR, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00315
   Xydous M, 2014, BBA-GENE REGUL MECH, V1839, P866, DOI 10.1016/j.bbagrm.2014.07.011
   Yang CM, 2017, ONCOTARGETS THER, V10, P711, DOI 10.2147/OTT.S117933
   Zhang C, 2017, SCI REP-UK, V7, DOI 10.1038/srep41082
   Zhang ZH, 2017, J NEUROSCI, V37, P2449, DOI 10.1523/JNEUROSCI.3229-16.2017
   Zhou Q, 2016, SCI REP-UK, V6, DOI 10.1038/srep32206
   Ziebarth AJ, 2013, CLIN CANCER RES, V19, P170, DOI 10.1158/1078-0432.CCR-12-1045
   Zoncu R, 2011, NAT REV MOL CELL BIO, V12, P21, DOI 10.1038/nrm3025
NR 133
TC 63
Z9 67
U1 3
U2 44
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1567-2026
EI 1875-5739
J9 CURR NEUROVASC RES
JI Curr. Neurovasc. Res.
PY 2017
VL 14
IS 3
BP 299
EP 304
DI 10.2174/1567202614666170718092010
PG 6
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA FF1MP
UT WOS:000408663900013
PM 28721811
OA Green Accepted
DA 2022-04-25
ER

PT J
AU Espinoza, JA
   Zisi, A
   Kanellis, DC
   Carreras-Puigvert, J
   Henriksson, M
   Huhn, D
   Watanabe, K
   Helleday, T
   Lindstrom, MS
   Bartek, J
AF Espinoza, Jaime A.
   Zisi, Asimina
   Kanellis, Dimitris C.
   Carreras-Puigvert, Jordi
   Henriksson, Martin
   Huhn, Daniela
   Watanabe, Kenji
   Helleday, Thomas
   Lindstrom, Mikael S.
   Bartek, Jiri
TI The antimalarial drug amodiaquine stabilizes p53 through ribosome
   biogenesis stress, independently of its autophagy-inhibitory activity
SO CELL DEATH AND DIFFERENTIATION
LA English
DT Article
ID RNA-POLYMERASE-I; TRANSCRIPTION; CANCER; ACTIVATION; NUCLEOLUS; CELLS;
   CHLOROQUINE; METABOLISM; INITIATION; COMPLEX
AB Pharmacological inhibition of ribosome biogenesis is a promising avenue for cancer therapy. Herein, we report a novel activity of the FDA-approved antimalarial drug amodiaquine which inhibits rRNA transcription, a rate-limiting step for ribosome biogenesis, in a dose-dependent manner. Amodiaquine triggers degradation of the catalytic subunit of RNA polymerase I (Pol I), with ensuing RPL5/RPL11-dependent stabilization of p53. Pol I shutdown occurs in the absence of DNA damage and without the subsequent ATM-dependent inhibition of rRNA transcription. RNAseq analysis revealed mechanistic similarities of amodiaquine with BMH-21, the first-in-class Pol I inhibitor, and with chloroquine, the antimalarial analog of amodiaquine, with well-established autophagy-inhibitory activity. Interestingly, autophagy inhibition caused by amodiaquine is not involved in the inhibition of rRNA transcription, suggesting two independent anticancer mechanisms. In vitro, amodiaquine is more efficient than chloroquine in restraining the proliferation of human cell lines derived from colorectal carcinomas, a cancer type with predicted susceptibility to ribosome biogenesis stress. Taken together, our data reveal an unsuspected activity of a drug approved and used in the clinics for over 30 years, and provide rationale for repurposing amodiaquine in cancer therapy.
C1 [Espinoza, Jaime A.; Zisi, Asimina; Kanellis, Dimitris C.; Carreras-Puigvert, Jordi; Huhn, Daniela; Lindstrom, Mikael S.; Bartek, Jiri] Karolinska Inst, Dept Med Biochem & Biophys, Div Genome Biol, Sci Life Lab, S-17121 Stockholm, Sweden.
   [Henriksson, Martin; Helleday, Thomas] Karolinska Inst, Dept Oncol Pathol, Sci Life Lab, S-17176 Stockholm, Sweden.
   [Watanabe, Kenji; Bartek, Jiri] Danish Canc Soc, Res Ctr, DK-2100 Copenhagen, Denmark.
   [Helleday, Thomas] Univ Sheffield, Dept Oncol & Metab, Weston Pk Canc Ctr, Sheffield S10 2RX, S Yorkshire, England.
RP Lindstrom, MS; Bartek, J (corresponding author), Karolinska Inst, Dept Med Biochem & Biophys, Div Genome Biol, Sci Life Lab, S-17121 Stockholm, Sweden.; Bartek, J (corresponding author), Danish Canc Soc, Res Ctr, DK-2100 Copenhagen, Denmark.
EM mikael.lindstrom@ki.se; jb@cancer.dk
RI Carreras-Puigvert, Jordi/AAN-3020-2021; Zisi, Asimina P/Q-5796-2017;
   Lindström, Mikael S/AAA-1451-2019
OI Zisi, Asimina P/0000-0002-4253-0275; Lindström, Mikael
   S/0000-0003-1148-8497; Kanellis, Dimitrios/0000-0001-8690-2010;
   Espinoza, Jaime/0000-0002-0731-2715
CR Bindea G, 2009, BIOINFORMATICS, V25, P1091, DOI 10.1093/bioinformatics/btp101
   Boulon S, 2010, MOL CELL, V40, P216, DOI 10.1016/j.molcel.2010.09.024
   Bruno PM, 2017, NAT MED, V23, P461, DOI 10.1038/nm.4291
   Burger K, 2010, J BIOL CHEM, V285, P12416, DOI 10.1074/jbc.M109.074211
   Bywater MJ, 2012, CANCER CELL, V22, P51, DOI 10.1016/j.ccr.2012.05.019
   Calo E, 2015, NATURE, V518, P249, DOI 10.1038/nature13923
   Carpenter AE, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-10-r100
   Colis L, 2014, ONCOTARGET, V5, P4361, DOI 10.18632/oncotarget.2020
   Cornelison R, 2017, CLIN CANCER RES, V23, P6529, DOI 10.1158/1078-0432.CCR-17-0282
   Daniely Y, 2000, J CELL BIOL, V149, P799, DOI 10.1083/jcb.149.4.799
   Derenzini M, 2009, HISTOPATHOLOGY, V54, P753, DOI 10.1111/j.1365-2559.2008.03168.x
   Drygin D, 2010, ANNU REV PHARMACOL, V50, P131, DOI 10.1146/annurev.pharmtox.010909.105844
   Floutsakou I, 2013, GENOME RES, V23, P2003, DOI 10.1101/gr.157941.113
   Gallagher LE, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.416
   Harding SM, 2015, CELL REP, V13, P251, DOI 10.1016/j.celrep.2015.08.085
   Hein N, 2017, BLOOD, V129, P2882, DOI 10.1182/blood-2016-05-718171
   Herdman C, 2017, PLOS GENET, V13, DOI 10.1371/journal.pgen.1006899
   Hetz C, 2018, MOL CELL, V69, P169, DOI 10.1016/j.molcel.2017.06.017
   Horn HF, 2008, ONCOGENE, V27, P5774, DOI 10.1038/onc.2008.189
   King MA, 2016, ONCOGENE, V35, P4518, DOI 10.1038/onc.2015.511
   Kruhlak M, 2007, NATURE, V447, P730, DOI 10.1038/nature05842
   Kwon I, 2014, SCIENCE, V345, P1139, DOI 10.1126/science.1254917
   Lamb J, 2006, SCIENCE, V313, P1929, DOI 10.1126/science.1132939
   Larsen DH, 2014, NAT CELL BIOL, V16, P792, DOI 10.1038/ncb3007
   Lawrence MG, 2018, EUR UROL, V74, P562, DOI 10.1016/j.eururo.2018.06.020
   Li XQ, 2002, J PHARMACOL EXP THER, V300, P399, DOI 10.1124/jpet.300.2.399
   Lindstrom MS, 2018, ONCOGENE, V37, P2351, DOI 10.1038/s41388-017-0121-z
   Lobach AR, 2014, CHEM RES TOXICOL, V27, P699, DOI 10.1021/tx500019u
   Lyu YL, 2007, CANCER RES, V67, P8839, DOI 10.1158/0008-5472.CAN-07-1649
   Maes H, 2014, CANCER CELL, V26, P190, DOI 10.1016/j.ccr.2014.06.025
   MAGGS JL, 1988, BIOCHEM PHARMACOL, V37, P303, DOI 10.1016/0006-2952(88)90733-2
   Mauthe M, 2018, AUTOPHAGY, V14, P1435, DOI 10.1080/15548627.2018.1474314
   Mayer C, 2004, GENE DEV, V18, P423, DOI 10.1101/gad.285504
   McAfee Q, 2012, P NATL ACAD SCI USA, V109, P8253, DOI 10.1073/pnas.1118193109
   Morgado-Palacin L, 2014, CARCINOGENESIS, V35, P2822, DOI 10.1093/carcin/bgu220
   Pasquier B, 2016, CELL MOL LIFE SCI, V73, P985, DOI 10.1007/s00018-015-2104-y
   Pelletier J, 2018, NAT REV CANCER, V18, P51, DOI 10.1038/nrc.2017.104
   Peltonen K, 2014, MOL CANCER THER, V13, P2537, DOI 10.1158/1535-7163.MCT-14-0256
   Peltonen K, 2014, CANCER CELL, V25, P77, DOI 10.1016/j.ccr.2013.12.009
   Peltonen K, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012996
   PERRY RP, 1970, J CELL PHYSIOL, V76, P127, DOI 10.1002/jcp.1040760202
   Poortinga G, 2015, ONCOGENE, V34, P403, DOI 10.1038/onc.2014.13
   Pushpakom S, 2019, NAT REV DRUG DISCOV, V18, P41, DOI 10.1038/nrd.2018.168
   Qiao SX, 2013, AUTOPHAGY, V9, P2087, DOI 10.4161/auto.26506
   Quin J, 2016, ONCOTARGET, V7, P49800, DOI 10.18632/oncotarget.10452
   Shimizu S, 2009, ARCH TOXICOL, V83, P701, DOI 10.1007/s00204-009-0436-9
   Skrott Z, 2017, NATURE, V552, P194, DOI 10.1038/nature25016
   Sohn TA, 2002, CARCINOGENESIS, V23, P949, DOI 10.1093/carcin/23.6.949
   Trere D, 2000, MICRON, V31, P127, DOI 10.1016/S0968-4328(99)00069-4
   Tse WC, 2004, ACCOUNTS CHEM RES, V37, P61, DOI 10.1021/ar030113y
   Verbaanderd C, 2017, ECANCERMEDICALSCIENC, V11, DOI 10.3332/ecancer.2017.781
   Walsky RL, 2005, J CLIN PHARMACOL, V45, P68, DOI 10.1177/0091270004270642
   Wang M, 2017, PLOS GENET, V13, DOI 10.1371/journal.pgen.1006994
   Westerink WMA, 2007, TOXICOL IN VITRO, V21, P1581, DOI 10.1016/j.tiv.2007.05.014
   White NJ, 1996, LANCET, V348, P1184, DOI 10.1016/S0140-6736(05)65475-X
   World Health Organization, 2015, GUID TREATM MAL
   Xu H, 2017, NAT COMMUN, V8, P5321743
   Zhang WJ, 2002, DRUG METAB DISPOS, V30, P314, DOI 10.1124/dmd.30.3.314
   Zhang YJ, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00388
   Zhang YJ, 2017, BRIT J CLIN PHARMACO, V83, P572, DOI 10.1111/bcp.13148
   Zhao J, 2003, MOL CELL, V11, P405, DOI 10.1016/S1097-2765(03)00036-4
NR 61
TC 18
Z9 18
U1 1
U2 8
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 1350-9047
EI 1476-5403
J9 CELL DEATH DIFFER
JI Cell Death Differ.
PD FEB
PY 2020
VL 27
IS 2
BP 773
EP 789
DI 10.1038/s41418-019-0387-5
PG 17
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA KH8YO
UT WOS:000510936500025
PM 31285544
OA Green Published, hybrid, Green Accepted
DA 2022-04-25
ER

PT J
AU Cho, HS
   Han, TS
   Hur, K
   Ban, HS
AF Cho, Hyun-Soo
   Han, Tae-Su
   Hur, Keun
   Ban, Hyun Seung
TI The Roles of Hypoxia-Inducible Factors and Non-Coding RNAs in
   Gastrointestinal Cancer
SO GENES
LA English
DT Review
DE hypoxia; non-coding RNA; microRNA; hypoxia-inducible factor;
   gastrointestinal cancer
ID GASTRIC-CANCER; COLORECTAL-CANCER; INDUCED AUTOPHAGY;
   CELL-PROLIFERATION; PROMOTES; METASTASIS; EXPRESSION; INVASION;
   HIF-1-ALPHA; OVEREXPRESSION
AB Hypoxia-inducible factors (HIFs) are transcription factors that play central roles in cellular responses against hypoxia. In most cancers, HIFs are closely associated with tumorigenesis by regulating cell survival, angiogenesis, metastasis, and adaptation to the hypoxic tumor microenvironment. Recently, non-coding RNAs (ncRNAs) have been reported to play critical roles in the hypoxic response in various cancers. Here, we review the roles of hypoxia-response ncRNAs in gastrointestinal cancer, with a particular focus on microRNAs and long ncRNAs, and discuss the functional relationships and regulatory mechanisms between HIFs and ncRNAs.
C1 [Cho, Hyun-Soo; Han, Tae-Su; Ban, Hyun Seung] Korea Res Inst Biosci & Biotechnol, Daejeon 34141, South Korea.
   [Hur, Keun] Kyungpook Natl Univ, Sch Med, Dept Biochem & Cell Biol, Daegu 41944, South Korea.
RP Ban, HS (corresponding author), Korea Res Inst Biosci & Biotechnol, Daejeon 34141, South Korea.; Hur, K (corresponding author), Kyungpook Natl Univ, Sch Med, Dept Biochem & Cell Biol, Daegu 41944, South Korea.
EM chohs@kribb.re.kr; tshan@kribb.re.kr; KeunHur@knu.ac.kr;
   banhs@kribb.re.kr
RI ; Ban, Hyun Seung/F-9526-2014
OI cho, Hyun-soo/0000-0002-8242-9390; Ban, Hyun Seung/0000-0002-2698-6037;
   Hur, Keun/0000-0002-6944-2718
FU National Research Foundation of Korea (NRF) - Ministry of Science and
   ICT [NRF-2017R1C1B2012268, 2018M3A9H3023077, 2019R1A2C1083892,
   2019R1I1A2A01060951]; KRIBB Research Initiative Program
FX This study supported by grants from the National Research Foundation of
   Korea (NRF) funded by the Ministry of Science and ICT
   (NRF-2017R1C1B2012268, 2018M3A9H3023077, 2019R1A2C1083892,
   2019R1I1A2A01060951) and the KRIBB Research Initiative Program.
CR Ayers D, 2017, GENES-BASEL, V8, DOI 10.3390/genes8030095
   Ayremlou N, 2015, CANCER BIOMARK, V15, P851, DOI 10.3233/CBM-150529
   Barsoum IB, 2014, CANCER RES, V74, P665, DOI 10.1158/0008-5472.CAN-13-0992
   Bartonicek N, 2016, MOL CANCER, V15, DOI 10.1186/s12943-016-0530-6
   Bhan A, 2017, GENE, V629, P16, DOI 10.1016/j.gene.2017.07.069
   Bhan A, 2017, CANCER RES, V77, P3965, DOI 10.1158/0008-5472.CAN-16-2634
   Chen J, 2016, ANN ONCOL, V27, P409, DOI 10.1093/annonc/mdv615
   Chen KC, 2015, ONCOTARGET, V6, P24105, DOI 10.18632/oncotarget.4152
   Chen T, 2014, CANCER BIOL THER, V15, P516, DOI 10.4161/cbt.28017
   Choudhry H, 2015, ONCOGENE, V34, P4482, DOI 10.1038/onc.2014.378
   Courtney KD, 2018, J CLIN ONCOL, V36, P867, DOI 10.1200/JCO.2017.74.2627
   Couvelard A, 2008, CLIN CANCER RES, V14, P6634, DOI 10.1158/1078-0432.CCR-07-5258
   Denko NC, 2008, NAT REV CANCER, V8, P705, DOI 10.1038/nrc2468
   DiGiacomo JW, 2019, ADV EXP MED BIOL, V1136, P141, DOI 10.1007/978-3-030-12734-3_10
   Fallah J, 2019, CURR ONCOL REP, V21, DOI 10.1007/s11912-019-0752-z
   Ge XX, 2016, ONCOTARGET, V7, P24466, DOI 10.18632/oncotarget.8228
   Ha M, 2014, NAT REV MOL CELL BIO, V15, P509, DOI 10.1038/nrm3838
   He C, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0603-1
   He WS, 2012, ONCOL RES, V20, P251, DOI 10.3727/096504013X13589503483012
   Hirose K, 1996, MOL CELL BIOL, V16, P1706
   Huang T, 2017, BIOMED PHARMACOTHER, V88, P302, DOI 10.1016/j.biopha.2017.01.049
   Iyer MK, 2015, NAT GENET, V47, P199, DOI 10.1038/ng.3192
   Jin FF, 2019, CANCER LETT, V440, P211, DOI 10.1016/j.canlet.2018.10.025
   LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y
   Lee Y, 2004, EMBO J, V23, P4051, DOI 10.1038/sj.emboj.7600385
   Li YK, 2015, SCI REP-UK, V5, DOI 10.1038/srep11000
   Liu CJ, 2010, CANCER RES, V70, P1635, DOI 10.1158/0008-5472.CAN-09-2291
   Liu L, 2016, ONCOGENESIS, V5, DOI 10.1038/oncsis.2016.35
   Liu L, 2016, FRONT PHYSIOL, V7, DOI 10.3389/fphys.2016.00420
   Liu XQ, 2018, CANCER SCI, V109, P988, DOI 10.1111/cas.13519
   MacFarlane LA, 2010, CURR GENOMICS, V11, P537, DOI 10.2174/138920210793175895
   Majmundar AJ, 2010, MOL CELL, V40, P294, DOI 10.1016/j.molcel.2010.09.022
   Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459
   Messai Y, 2016, EUR UROL, V70, P623, DOI 10.1016/j.eururo.2015.11.029
   Nakagawa Y, 2019, CANCER SCI, V110, P2540, DOI 10.1111/cas.14090
   Noman MZ, 2014, J EXP MED, V211, P781, DOI 10.1084/jem.20131916
   Petrova V, 2018, ONCOGENESIS, V7, DOI 10.1038/s41389-017-0011-9
   Rankin EB, 2008, CELL DEATH DIFFER, V15, P678, DOI 10.1038/cdd.2008.21
   Reinhart BJ, 2000, NATURE, V403, P901, DOI 10.1038/35002607
   Ribas A, 2018, SCIENCE, V359, P1350, DOI 10.1126/science.aar4060
   Ruf M, 2016, INT J CANCER, V139, P396, DOI 10.1002/ijc.30077
   Sabry D, 2019, MOL CELL BIOCHEM, V454, P177, DOI 10.1007/s11010-018-3462-1
   Schito L, 2016, TRENDS CANCER, V2, P758, DOI 10.1016/j.trecan.2016.10.016
   Schmitt AM, 2016, CANCER CELL, V29, P452, DOI 10.1016/j.ccell.2016.03.010
   SEMENZA GL, 1991, P NATL ACAD SCI USA, V88, P5680, DOI 10.1073/pnas.88.13.5680
   Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187
   Seo AN, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0223608
   Seok JK, 2014, NUCLEIC ACIDS RES, V42, P8062, DOI 10.1093/nar/gku515
   Serocki M, 2018, ANGIOGENESIS, V21, P183, DOI 10.1007/s10456-018-9600-2
   Shang YY, 2017, EXP CELL RES, V360, P243, DOI 10.1016/j.yexcr.2017.09.014
   Sitarz R, 2018, CANCER MANAG RES, V10, P239, DOI 10.2147/CMAR.S149619
   Sun Y, 2015, INT J ONCOL, V46, P750, DOI 10.3892/ijo.2014.2745
   Wallace EM, 2016, CANCER RES, V76, P5491, DOI 10.1158/0008-5472.CAN-16-0473
   Wang CJ, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-616
   WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510
   Wang KC, 2011, MOL CELL, V43, P904, DOI 10.1016/j.molcel.2011.08.018
   Wang QS, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18122540
   Wang YF, 2014, NEOPLASIA, V16, P1094, DOI 10.1016/j.neo.2014.10.008
   Wei SC, 2018, CANCER DISCOV, V8, P1069, DOI 10.1158/2159-8290.CD-18-0367
   Wilson WR, 2011, NAT REV CANCER, V11, P393, DOI 10.1038/nrc3064
   Wu FX, 2019, ONCOTARGETS THER, V12, P657, DOI 10.2147/OTT.S175521
   Wu FB, 2015, EXP THER MED, V10, P717, DOI 10.3892/etm.2015.2546
   Xia Y, 2018, ONCOTARGETS THER, V11, P3003, DOI 10.2147/OTT.S158206
   Xu K, 2019, MOL THER, V27, P1810, DOI 10.1016/j.ymthe.2019.05.017
   Xu Q, 2012, NUCLEIC ACIDS RES, V40, P761, DOI 10.1093/nar/gkr730
   Xu R, 2019, J MED CHEM, V62, P6876, DOI 10.1021/acs.jmedchem.9b00719
   Xue G, 2015, ONCOGENE, V34, P1393, DOI 10.1038/onc.2014.82
   Yamakuchi M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020291
   Yamakuchi M, 2010, P NATL ACAD SCI USA, V107, P6334, DOI 10.1073/pnas.0911082107
   Yang LQ, 2018, CANCER LETT, V414, P44, DOI 10.1016/j.canlet.2017.11.007
   Yang W, 2014, EXP CELL RES, V326, P22, DOI 10.1016/j.yexcr.2014.05.022
   Yang W, 2012, EXP CELL RES, V318, P944, DOI 10.1016/j.yexcr.2012.02.010
   Yang Z, 2015, INT J CLIN EXP MED, V8, P19954
   Yang ZC, 2018, EXP CELL RES, V368, P194, DOI 10.1016/j.yexcr.2018.04.030
   Ye H, 2015, DIAGN PATHOL, V10, DOI 10.1186/s13000-015-0260-x
   Yu PF, 2015, MED HYPOTHESES, V84, P209, DOI 10.1016/j.mehy.2014.12.024
   Yu Y., 2019, DRUG DISCOV TODAY, V10
   Zhang C, 2016, J MOL MED, V94, P401, DOI 10.1007/s00109-015-1350-7
   Zhang H, 2014, ONCOGENE, V33, P387, DOI 10.1038/onc.2012.574
   Zhang HF, 2008, P NATL ACAD SCI USA, V105, P19579, DOI 10.1073/pnas.0809763105
   Zhang J, 2019, CLIN TRANSL ONCOL, V21, P1142, DOI 10.1007/s12094-019-02035-9
   Zhang R, 2016, ONCOL LETT, V12, P1233, DOI 10.3892/ol.2016.4770
   Zhang W, 2018, BIOCHIMIE, V144, P21, DOI 10.1016/j.biochi.2017.10.002
   Zhang XW, 2015, BIOCHEM BIOPH RES CO, V462, P227, DOI 10.1016/j.bbrc.2015.04.121
   Zhao Q, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132746
   Zhong H, 1999, CANCER RES, V59, P5830
   Zhou Y, 2019, J CELL PHYSIOL, V234, P17876, DOI 10.1002/jcp.28418
NR 87
TC 7
Z9 7
U1 1
U2 1
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2073-4425
J9 GENES-BASEL
JI Genes
PD DEC
PY 2019
VL 10
IS 12
AR 1008
DI 10.3390/genes10121008
PG 13
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA KC7GS
UT WOS:000507342400061
PM 31817259
OA gold, Green Published
DA 2022-04-25
ER

EF